[Senate Hearing 116-39]
[From the U.S. Government Publishing Office]
S. Hrg. 116-39
DRUG PRICING IN AMERICA:
A PRESCRIPTION FOR CHANGE, PART II
=======================================================================
HEARING
before the
COMMITTEE ON FINANCE
UNITED STATES SENATE
ONE HUNDRED SIXTEENTH CONGRESS
FIRST SESSION
__________
FEBRUARY 26, 2019
__________
[GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT]
Printed for the use of the Committee on Finance
________
U.S. GOVERNMENT PUBLISHING OFFICE
37-143 PDF WASHINGTON: 2019
COMMITTEE ON FINANCE
CHUCK GRASSLEY, Iowa, Chairman
MIKE CRAPO, Idaho RON WYDEN, Oregon
PAT ROBERTS, Kansas DEBBIE STABENOW, Michigan
MICHAEL B. ENZI, Wyoming MARIA CANTWELL, Washington
JOHN CORNYN, Texas ROBERT MENENDEZ, New Jersey
JOHN THUNE, South Dakota THOMAS R. CARPER, Delaware
RICHARD BURR, North Carolina BENJAMIN L. CARDIN, Maryland
JOHNNY ISAKSON, Georgia SHERROD BROWN, Ohio
ROB PORTMAN, Ohio MICHAEL F. BENNET, Colorado
PATRICK J. TOOMEY, Pennsylvania ROBERT P. CASEY, Jr., Pennsylvania
TIM SCOTT, South Carolina MARK R. WARNER, Virginia
BILL CASSIDY, Louisiana SHELDON WHITEHOUSE, Rhode Island
JAMES LANKFORD, Oklahoma MAGGIE HASSAN, New Hampshire
STEVE DAINES, Montana CATHERINE CORTEZ MASTO, Nevada
TODD YOUNG, Indiana
Kolan Davis, Staff Director and Chief Counsel
Joshua Sheinkman, Democratic Staff Director
(ii)
C O N T E N T S
----------
OPENING STATEMENTS
Page
Grassley, Hon. Chuck, a U.S. Senator from Iowa, chairman,
Committee on Finance........................................... 1
Wyden, Hon. Ron, a U.S. Senator from Oregon...................... 3
WITNESSES
Gonzalez, Richard A., chairman and chief executive officer,
AbbVie Inc., North Chicago, IL................................. 6
Soriot, Pascal, chief executive officer, AstraZeneca, Wilmington,
DE............................................................. 8
Caforio, Giovanni, M.D., chairman of the board and chief
executive officer, Bristol-Myers Squibb Company, New York, NY.. 9
Taubert, Jennifer, executive vice president, worldwide chairman,
Janssen Pharmaceuticals, Johnson & Johnson, New Brunswick, NJ.. 11
Frazier, Kenneth C., chairman and chief executive officer, Merck
and Company, Inc., Kenilworth, NJ.............................. 12
Bourla, Albert, DVM, Ph.D., chief executive officer, Pfizer, New
York, NY....................................................... 14
Brandicourt, Olivier, M.D., chief executive officer, Sanofi,
Bridgewater, NJ................................................ 15
ALPHABETICAL LISTING AND APPENDIX MATERIAL
Bourla, Albert, DVM, Ph.D.:
Testimony.................................................... 14
Prepared statement........................................... 63
Responses to questions from committee members................ 66
Brandicourt, Olivier, M.D.:
Testimony.................................................... 15
Prepared statement........................................... 134
Responses to questions from committee members................ 144
Caforio, Giovanni, M.D.:
Testimony.................................................... 9
Prepared statement........................................... 474
Responses to questions from committee members................ 475
Frazier, Kenneth C.:
Testimony.................................................... 12
Prepared statement........................................... 495
Responses to questions from committee members................ 497
Gonzalez, Richard A.:
Testimony.................................................... 6
Prepared statement........................................... 527
Responses to questions from committee members................ 528
Grassley, Hon. Chuck:
Opening statement............................................ 1
Prepared statement........................................... 704
Soriot, Pascal:
Testimony.................................................... 8
Prepared statement........................................... 705
Responses to questions from committee members................ 713
Taubert, Jennifer:
Testimony.................................................... 11
Prepared statement........................................... 839
Responses to questions from committee members................ 845
Thune, Hon. John:
Submission, 340B Health...................................... 1,053
Wyden, Hon. Ron:
Opening statement............................................ 3
Prepared statement........................................... 1,054
Communications
AARP............................................................. 1,057
American Society of Health-System Pharmacists.................... 1,058
Coalition for Affordable Prescription Drugs...................... 1,062
George, Linda.................................................... 1,064
Huszagh, Robin K................................................. 1,065
Interfaith Center on Corporate Responsibility.................... 1,066
National Association of Free and Charitable Clinics.............. 1,070
National Business Group on Health................................ 1,072
National Coordinating Committee for Multiemployer Plans.......... 1,076
Oxfam America.................................................... 1,078
Patients for Affordable Drugs Now................................ 1,080
Pharmaceutical Care Management Association....................... 1,084
Raffle, Debra L.................................................. 1,089
Ricci, Laura T................................................... 1,091
Rowland, Rhonda.................................................. 1,099
DRUG PRICING IN AMERICA:
A PRESCRIPTION FOR CHANGE, PART II
----------
TUESDAY, FEBRUARY 26, 2019
U.S. Senate,
Committee on Finance,
Washington, DC.
The hearing was convened, pursuant to notice, at 10:15
a.m., in room SD-215, Dirksen Senate Office Building, Hon.
Chuck Grassley (chairman of the committee) presiding.
Present: Senators Roberts, Enzi, Cornyn, Thune, Isakson,
Portman, Toomey, Scott, Cassidy, Lankford, Daines, Young,
Wyden, Stabenow, Cantwell, Menendez, Carper, Cardin, Brown,
Bennet, Casey, Whitehouse, Hassan, and Cortez Masto.
Also present: Republican staff: Chris Allen, Senior Advisor
for Benefits and Exempt Organizations; Brett Baker, Health
Policy Advisor; Stuart Portman, Health Care Policy Advisor;
Karen Summar, Chief Health Policy Advisor; and Jeff Wrase,
Deputy Chief of Staff and Chief Economist. Democratic staff:
Michael Evans, General Counsel; Peter Gartrell, Investigator;
Matt Kazan, Senior Health Policy Advisor; Kristen Lunde,
Winston Fellow; and Joshua Sheinkman, Staff Director.
OPENING STATEMENT OF HON. CHUCK GRASSLEY, A U.S. SENATOR FROM
IOWA, CHAIRMAN, COMMITTEE ON FINANCE
The Chairman. I want to welcome and to thank our witnesses
for being here. We know that you put a lot of hard work into
it, and staffs and the Senators have done the same thing.
The information that these witnesses will share will help
inform the committee as it addresses the issues of high
prescription drug prices. America has a problem with the high
cost of prescription medicines.
Whether it is about EpiPen, insulin, or other
prescriptions, in the thousands of letters that I have
received, Iowans have made clear that high drug prices are
hurting. I have heard from people about skipping doses of their
prescription drugs to make them last until the next paycheck.
Of course, I am not a doctor, but rationing one medicine
does not sound like the safe prescription for health and
wellness that Americans want. Others have told me about leaving
their prescription on the pharmacy counter because it costs too
much.
There is no question that researchers and doctors have
developed treatments and cures for diseases where there were
once no such cures or treatments. And such innovations take
time and money. I think all of us at this table--and most
people who are not at this table--if they study at all the
pharmaceutical industry and the FDA process, they know it takes
time and money. But we are all trying to understand the sticker
shock that many drugs generate, especially when some of these
drugs have been around for a long, long time.
There is a balance then between incentivizing innovation
and keeping prices affordable for consumers and taxpayers. And
the taxpayers are involved, because the Federal Government is a
great purchaser of drugs through a lot of health programs.
Like all systems, things can get out of balance. The good
news is that we are here to discuss solutions. And we thank all
of you for cooperating with us in that effort today.
In fact, we are here today thanks to a system of checks and
balances that is within our Constitution. Congress has a
constitutional responsibility to be a meaningful check on the
spending of taxpayers' money. That responsibility includes not
just holding hearings, but also holding the private sector and
the government accountable through oversight, just like a
doctor. That doctor has to properly diagnose a disease before
it can be treated. Congress needs to understand what is going
on in the drug pricing supply chain in order to respond in a
measured and effective way.
As part of that fact-finding, as of the last Friday Ranking
Member Wyden and I launched an inquiry into the high cost of
insulin. This hearing is not about scapegoating any one group
regarding high drug costs. That is why we are holding a series
of bipartisan hearings on this issue.
Without a doubt, drug pricing is a complex issue. But I
think we should also be asking whether or not it is too complex
or whether it should be so complex. We cannot allow anyone to
hide behind the current complexities to shield the true cost of
drugs. And we should not turn a blind eye to industry practices
that thwart laws and regulations designed to promote
competition and generic drug entries into the marketplace.
Health and Human Services Secretary Alex Azar, FDA
Commissioner Scott Gottlieb, and the Federal Trade Commission
have identified a number of tactics that undermine competition,
like withholding samples, pay-for-delay, product hopping, and
rebate bundling. And that just names a few. While these
agencies are taking enforcement action or looking at regulatory
changes, we here in Congress are exploring legislative options
to deter companies from engaging in these practices that keep
drug prices high for patients.
Today we expect open, honest answers from the
pharmaceutical industry to figure out how we got where we are
today and to see what ideas they have to make things better.
One of the first things that we need to talk about is
pretty simple: list price. Now you folks are probably going to
tell us it is not that simple. Secretary Azar has said that
pharmaceutical companies believe that the list price is
meaningless. In fact, some of your testimony today will echo
that.
However, for a patient taking a drug that has no
competition, the list price then becomes very meaningful. For
seniors on Part D or paying coinsurance as a percentage of list
price, then for that person, list price is very meaningful. For
people who have high-
deductible plans and pay thousands of dollars towards the list
price, then for those people, the list price is very
meaningful.
For pharmacy benefit managers, providing drugs with a high
list price can be more attractive than providing a less
expensive drug. Therefore, for the taxpayers then, the list
price becomes very meaningful.
We have all seen the finger-pointing. Every link in the
supply chain has gotten skilled at that finger-pointing. But
like most Americans, I at least--I think like most members of
Congress--am sick and tired of the blame game.
It is time then for solutions. One way or another, we are
going to get some clarity. The American people deserve straight
answers and real solutions.
On that note, I want to remind each of our witnesses that
it is a crime under title 18, section 101 to provide false
testimony to Congress. I thank you all for coming.
[The prepared statement of Chairman Grassley appears in the
appendix.]
The Chairman. Senator Wyden?
OPENING STATEMENT OF HON. RON WYDEN,
A U.S. SENATOR FROM OREGON
Senator Wyden. Thank you very much, Mr. Chairman.
And I just want to note, at the outset, our focus on
bipartisanship. We began that with our effort to go after price
gouging with hepatitis C. Recently we have gone after
manufacturers ripping off Medicaid. You noted our investigation
to look at insulin prices that just soar and soar and soar some
more. So I just very much appreciate the fact that we are
tackling this in a bipartisan way.
Colleagues, prescription drugs did not become outrageously
expensive by accident. It is not the result of a system too
complicated for Americans to understand. Drug prices are
astronomically high because that is where pharmaceutical
companies and their investors want them. The brakes have come
off pharmaceutical pricing, and American families are hurtling
along in the passenger seat terrified about what comes next.
Today the committee is going to hear about uplifting
stories and miracle cures. Yet it is morally repugnant when
patients cannot afford those miracles. It is morally repugnant
when ailing patients are forced to choose between filling the
next prescription or putting food on the table because they
cannot afford both. It is morally repugnant when patients are
forced to skip doses.
Pharma executives, all of you who are here today, are here
because the way you have been doing business is unacceptable.
Ten companies accounted for half of all the profits in the
health-care sector last year. Nine of them were drug
manufacturers. All but one of today's witnesses represent
companies on this list.
Drugmakers behave as if the patients and the taxpayers are
unlocked ATMs full of cash to be extracted, and their
shareholders are the customers whom they value above anybody
else. So I am going to go through a short list of examples
starting with AbbVie, which manufactures the top-selling
prescription drug in America, the arthritis medication Humira.
Over 6 years, the company doubled the price of a 12-month
supply from $19,000 to $38,000. Can the patients opt for a less
expensive alternative? They cannot, because AbbVie protects the
exclusivity of Humira like Gollum with his ring--thick cobwebs
of patents and legal tricks and shadowy deals with other
drugmakers. All of them are in place to keep the cash flowing.
Now I also want to address some very troubling information
we just got from AbbVie's proxy statement. It is a document
every publicly traded company has to file with the SEC. Page 37
shows that in 2017, a portion of CEO Richard Gonzalez's multi-
million-dollar bonus was directly tied to sales of Humira. It
appears the same incentive was in place in 2015 and 2016. In
fact, the committee's review shows that all of AbbVie's top
executives have the same arrangement.
Mr. Gonzalez is welcome to respond, but the implication
ought to be clear. From top down, AbbVie's leadership had
reason to keep pushing prices and sales up.
Now Pfizer, that company gets first prize for the emptiest
pricing gesture in 2018. After stern Trump tweets, Pfizer said
it would temporarily freeze the prices. But once the President
got his flashy headlines, his gaze went elsewhere. Pfizer's
former CEO told investors it was back to normal, another round
of price hikes in 2019, including the pain medication Lyrica.
Lyrica has increased 163 percent in price since 2012. Just one
drug allowed Pfizer to pull in $4.5 billion in 2017.
Merck gets second prize for emptiest pricing gesture of
2018. They made sweet-sounding promises after coming under
criticism, but they cut prices for drugs that essentially
produce no revenue for the company. Left untouched were the
cash cows Keytruda and Januvia, which account for more than a
quarter of the company's revenue. It is like promising car
shoppers a great deal, except the only discounted model on the
lot is an Edsel.
Sanofi--this is a company wringing more and more cash out
of people with an incurable disease. In 2010, a vial of this
insulin cost less than $100. In 2018, it cost nearly $300. The
company raised prices again in 2019. Considering the landmark
breakthrough on insulin came early in the roaring 20s, nothing
could justify this sudden price hike a century later. Diabetics
who cannot afford the cost now self-ration and endanger their
lives. But you know what? Investors are happy.
AstraZeneca--a lesson in saying the quiet part out loud. In
an interview earlier, the CEO complained that his $12-million
salary made him the lowest-paid CEO in the whole industry, and
he said it was annoying to some extent. His company, meanwhile,
continues to raise the price of Symbicort, its $3-billion
asthma drug. For some asthmatics, being able to breathe costs
hundreds of dollars a month.
And Johnson & Johnson gets the record today for flip-
flopping. This January 7th at the JP Morgan Health Conference,
the CEO said the pharmaceutical industry needs self-policing on
prices. That sounded good, but 3 days later the company hiked
the prices of hundreds of its drugs, including drugs that
account for billions in Medicare spending.
And finally, there is Bristol-Myers Squibb. In 2017, the
company spent roughly $11 billion on dividends, stock buybacks,
marketing, sales, and administrative costs that roughly triple
the amount spent on R&D.
Now I am going to close by saying that I want us to compare
these concrete examples of two-faced scheming and profiteering
with the central arguments that we are going to get this
morning. The central argument from pharma is basically, the
fault is always somebody else's. The health plans are at fault,
the pharmaceutical benefit managers are at fault, regulators
are at fault. What we know for certain is the history that
pharma CEOs always say somebody else is at fault.
We are also going to hear that the list price does not
matter, that the true costs are just so complicated. But
companies do not set and raise list prices for fun. Those
prices are directly tied to the amount patients pay out-of-
pocket at pharmacy windows from sea to shining sea. They are
directly tied to what taxpayers spend on health-care programs.
Then drugmakers point the finger at middlemen, the pharmacy
benefit managers. I have said for years these pharmacy managers
are wasteful and secretive, and take their cut without proving
their worth to anybody. They are going to have their day before
the committee too. But those pharmacy managers do not set list
prices. The manufacturers do.
And by the way, the manufacturers do not offer rebates for
nearly 40 percent of Part D brand-name drugs. Those prices are
going up. That is on the drug companies, not on the pharmacy
managers.
We are also going to hear that any changes in business as
usual hurt research and development. A quick look at company
finances shows that that is a fable. Revenue generated from
American patients alone dwarfs what they spend on R&D
worldwide.
Drugmakers spend as much, if not more, on those
exhilarating TV ads and office-to-office salesmen as they spend
on research and development. And if lower prices would diminish
R&D, why don't costly dividends? Why don't stock buybacks? Is
the stock price more important than inventing that next miracle
cure? Even if you buy the specious argument that a drug's list
price at launch is driven by research costs, what could justify
arbitrary price increases year after year, long after the
research and development spending is done?
Finally, we are going to hear about how patients can get
coupons. But if this was so generous, why can't drug companies
just lower prices across the board? I believe it is just more
slick branding, branding that allows companies to keep the
status quo cash cow rolling along.
I will close with this. I was there when seven big tobacco
CEOs testified in a committee room just like this one. They
lied that day. This committee, the chairman and I, expect
better than that this morning.
Your profits are outsized compared to others in the
industry. You get a massive portion of your revenue from
American taxpayers, and you bear none of the consequences of
these skyrocketing prices. It is long past time to drop the
excuses and take concrete action to make medicine in America
more affordable.
Thank you, Mr. Chairman.
[The prepared statement of Senator Wyden appears in the
appendix.]
The Chairman. Now I will introduce our seven witnesses, but
once again, thank you for participating in this very important
hearing on a very important topic. We are grateful for your
participation and cooperation with our committee.
The first witness is Richard Gonzalez, chairman and chief
executive officer of AbbVie, Incorporated. Then we will hear
from Pascal Soriot, DVM, executive director and chief executive
officer of AstraZeneca. Then we will hear from Giovanni
Caforio, M.D., chairman of the board and chief executive
officer, Bristol-Myers Squibb; then Jennifer Taubert, executive
vice president and worldwide chairman of pharmaceuticals for
Johnson & Johnson; Kenneth C. Frazier, chairman and chief
executive officer of Merck and Company; Albert Bourla, DVM,
Ph.D., chief executive officer of Pfizer; and Dr. Olivier
Brandicourt, M.D., chief executive officer of Sanofi.
We welcome all of you, and we will start in that direction.
And you have been given 5 minutes. I do not gavel you down at
the end of 5 minutes, but I wish when the red light would come
on, you would start to summarize, if you have not finished.
So we will start with Mr. Gonzalez.
STATEMENT OF RICHARD A. GONZALEZ, CHAIRMAN AND CHIEF EXECUTIVE
OFFICER, ABBVIE INC., NORTH CHICAGO, IL
Mr. Gonzalez. Thank you, Chairman Grassley, Ranking Member
Wyden, and members of the committee.
I am Richard Gonzalez, and I am the chief executive officer
of AbbVie, a company dedicated to developing new innovative
medicines for some of health care's most challenging diseases,
such as cancer, Alzheimer's, viral infections, and autoimmune
diseases.
Since our inception in 2013, AbbVie has invested
approximately $50 billion in pursuit of that goal. However,
because we were tackling some of medicine's most challenging
problems, solutions do not come easily, nor without significant
risks.
Where we have succeeded, we have been able to provide cures
for fatal diseases like hepatitis C and significantly alter the
disease progression for certain cancers, lessening the burden
of illness on patients and on the health-care system. This is
what the 30,000 employees of AbbVie are dedicated to doing.
We agree that access to life-saving medicines is a critical
issue, and we look forward to sharing our perspectives with
you. There is no one solution to this complex issue, but AbbVie
is committed to working with the committee and others on how we
can better partner in your efforts to address pharmaceutical
pricing and access. AbbVie and the rest of our industry must
play a role in solving these issues and be prepared to work
together with the insurance industry, the administration, and
you to find a better path for American patients.
My remarks today will focus on one aspect of this inquiry,
the Medicare Part D benefit design, which, even after
pharmaceutical list prices are lowered, still contributes to
making innovative therapies cost-prohibitive for many Medicare
patients.
In general, the Medicare Part D program has worked well.
Its market-based structure and utilization of formularies
encourages competitive price discounts that have yielded
significant savings to the government since the Part D benefit
went into place back in 2006. However, despite these cost
savings, Part D patient out-of-pocket costs have significantly
increased. Some would blame that solely on high drug prices,
and we agree that price should be part of the discussion. But
it is also important to acknowledge that science has enabled us
to advance the standard of care far beyond what was possible
when the Part D benefit was originally designed.
Many of today's specialty medicines offer significant
advancements in treating or curing serious chronic or life-
threatening conditions and save significant amounts of money
for the health-care system by decreasing overall health-care
costs. Yet these therapies are also costly.
Due to the structure of the Part D benefit design, patients
are charged out-of-pocket costs on a medicine's list price,
which does not reflect the market-based rebates or discounts
that Medicare receives. We are encouraged by the proposed rule
that would reflect manufacturer's discounts in patient's Part D
out-of-pocket payments. This is an important step in the right
direction, but we believe more must still be done to help Part
D patients.
Let me give you a recent real-world example that
demonstrates the challenge with the current Part D benefit
design, and why the focus solely on list price does not fully
address the access challenges. An uninsured hepatitis C
infection leads to downstream medical costs for surgery,
chemotherapy, and radiation for patients who progress to
needing a liver transplant or having liver cancer. Today we can
cure hepatitis C with drugs. This cure is highly cost-effective
for the overall health-care system.
In 2017, AbbVie launched Mavyret, a highly effective cure
for HCV. At the time, the list prices for the competitive
alternatives were as high as $94,500 for the most commonly
prescribed treatment duration. We launched Mavyret at a list
price that was 72 percent lower. But even though we cut the
list price of an HCV cure--for most patients by 72 percent--
Medicare Part D patients' out-of-pocket obligations are still
too high for many patients to access this medicine.
We believe it is important that discussions about access
and affordability include a focus on how to alleviate Medicare
Part D out-of-pocket burdens above and beyond just lowering
list price. We are prepared to step up and discuss how
companies like ours can shoulder more of the burden of the
patient out-of-pocket expense as we do in other areas.
We believe AbbVie, the rest of the pharmaceutical industry,
and the insurance providers should come together with the
administration and you to work towards solutions that make
life-changing medicines more affordable to Part D patients. I
can assure you AbbVie is committed to doing its part, and we
look forward to working with you.
Thank you.
[The prepared statement of Mr. Gonzalez appears in the
appendix.]
The Chairman. Mr. Soriot?
STATEMENT OF PASCAL SORIOT, CHIEF EXECUTIVE OFFICER,
ASTRAZENECA, WILMINGTON, DE
Mr. Soriot. Chairman Grassley, Ranking Member Wyden, and
members of the committee, good morning. I appreciate the
invitation to address concerns regarding the pricing of
medicines in the United States.
My name is Pascal Soriot, and I am the CEO of AstraZeneca.
Our company is dedicated to science and innovation. And in
2018, we invested nearly $6 billion in research and
development, 28 percent of our product sales, which is well
above the industry average.
In the past 2 years, our commitment to R&D has resulted in
18 significant FDA approvals and 5 breakthrough designations.
However, I know that these statistics are meaningless unless
patients can actually afford our medicines and those medicines
reduce overall health-care costs.
I am here to discuss how we can work with other
stakeholders to take specific actions that address pricing
concerns. My first proposal is that we move away from the
current rebate system while continuing to work with payers and
PBMs to ensure robust negotiations.
The current system is built on high list prices coupled
with rebates. This is not sustainable, and all of us have a
role to play. For example, the estimates for 2018 show that
across our medicines, our average rebate is nearly 50 percent
of our gross revenues in the U.S. Despite this, in recent years
in our primary care portfolio, we have seen flat to declining
net effective prices for most of our medicines. As a company
dependent upon government action for eliminating rebates in
commercial and in Part D, we are prepared to reduce our list
prices by an equivalent amount of rebates, less the appropriate
market-based fees, to those in the supply chain. This will
actually reduce overall costs not only for patients, but also
for the government.
My second proposal is that if a change of the current
system is not possible, a portion of discounts and rebates
could be used to create out-of-pocket caps for Medicare
patients. This approach is used successfully in some other
countries. Actually, it gives patients greater certainty in
their out-of-pocket cost.
Third, I believe that value-based agreements have the
potential to transform how medicines are priced and reimbursed
in the U.S. In our own value-based agreements, the price of a
medicine is directly linked to the value it provides to
patients, to payers, and to the health-care system.
For example, last month we announced an agreement for
University of Pittsburgh Medical Center Medicare patients who
are prescribed Brilinta. This innovative contract directly
reduces the cost for patients, and it ties price to clinical
value, basing our payments on patient outcome. These types of
agreements can be especially effective for medicines where
there is limited competition. As an example, for one of our
oral oncology medicines we agreed to reimburse a large payer
for discontinued use because patients did not respond to
treatment. And we have reimbursed the payer under those
agreements 20 percent of the time.
To that end, I appreciate the support of Senator Warner and
Senator Cassidy for value-based agreements, as demonstrated by
their request for input on the Patient Affordability, Value,
and Efficiency, the PAVE Act.
My fourth proposal is that we must encourage biosimilars
and eliminate policy and commercial barriers to their greater
use. Biologics are actually making very important contributions
to medicine, and I believe a vigorous biosimilar market would
reduce costs like generics do for small molecules. In fact,
biosimilars have gained up to 85 percent market share in the 5
largest countries in Europe, and the average biosimilar
discount is between 40 and 80 percent.
In closing, I would like to emphasize my strong commitment
to addressing the concerns raised by the committee. I believe
that we can work together to find solutions that continue to
allow manufacturers to innovate, while creating a more
efficient and more affordable system.
There are no easy answers, it is very clear, but we want to
be a constructive partner. Thank you, and I look forward to the
discussion.
[The prepared statement of Mr. Soriot appears in the
appendix.]
The Chairman. Dr. Caforio?
STATEMENT OF GIOVANNI CAFORIO, M.D., CHAIRMAN OF THE BOARD AND
CHIEF EXECUTIVE OFFICER, BRISTOL-MEYERS SQUIBB COMPANY, NEW
YORK, NY
Dr. Caforio. Chairman Grassley, Ranking Member Wyden, and
members of the committee, good morning, and thank you for the
opportunity to be here today on behalf of the 24,000 employees
of Bristol-Myers Squibb. I look forward to working together to
align incentives to ensure all Americans have access to the
medicines they need.
I am a physician. I joined the pharmaceutical industry 30
years ago because of the impact companies like ours have on
patients.
We should all be proud that American companies lead our
industry. Our researchers have contributed to the development
of medicines that have reduced mortality from cardiovascular
disease, helped transform HIV/AIDS into a chronic disease, and
are now making significant progress with the treatment of
cancer.
Just 10 years ago, the idea of harnessing the immune system
to treat cancer was viewed with great skepticism. But our
researchers saw the promise of that approach and ignited an era
of scientific innovation that has changed survival expectations
in multiple tumors. Prior to the availability of immuno-
oncology treatments, only 25 percent of patients diagnosed with
metastatic melanoma were alive after 1 year. Today, thanks to
immuno-oncology therapies, that number has increased to 74
percent.
The potential of this approach has also been seen in lung
cancer, kidney cancer, and many other difficult-to-treat
tumors. These patients now have a chance for quality and long-
term survival.
But not all patients respond to current immunotherapies.
And so we must do more. We recently opened a new facility
dedicated to investigating what we call immuno-oncology
resistance. And we continuously seek external innovation to
augment our pipeline. In fact, in this context, we recently
announced our plans to acquire Celgene. Our goal is to bring
together the drive and dedication of two science-driven
companies to do even more for patients.
As a physician, I do recognize that medicines are only
helpful if patients and health-care systems can afford them. We
share the committee's concern with escalating health-care costs
and believe that our responsibility extends to ensuring that
patients have access to and can afford our medicines. For this
reason, the average net pricing across our U.S. portfolio of
medicines increased by 5 percent or less year-over-year for the
last 5 years. Importantly, it did not increase at all in 2018.
And we expect that it will not increase in 2019.
Despite this fact, we do recognize that patients' out-of-
pocket costs continue to increase. We believe it is possible to
work together to realign incentives to ensure patients can
afford medicines without stifling scientific innovation. So
what are the solutions? We are supportive of the proposed rule
aimed at reforming the rebate system with a focus on what is
best for patients.
We need to ensure more generics are available whenever
permissible under our system. We support value-based purchasing
arrangements that tie payments to value. These models can
reduce costs, improve access and patient adherence, and
contribute to better outcomes.
We applaud efforts by Health and Human Services and this
committee in all of these areas. We do believe the U.S. should
not adopt policies that stifle innovation in other countries.
Outside of the U.S., reimbursement of new medicines often takes
more than 2 years. For example, nearly 4 years ago our Opdivo
and Yervoy regimen was first approved to treat metastatic
melanoma in the U.S. Today, 6 of the 16 countries included in
the international price index proposal still do not provide
reimbursement for this combination, which is the standard of
care for the treatment of this cancer. This is why we do not
support the proposed international price index model for
Medicare Part B drugs.
I would like to leave you with a few thoughts. First, we
recognize the need for change. We are witnessing a historic era
in biomedical innovation. American research-based companies are
leading the way to help patients whose diseases cannot be
adequately treated with today's medicines. But we must ensure
that patients have affordable access to new innovations. And we
should work on policies that support and reward access and
these investments. I look forward to working together to
implement real change that broadens access to innovative
medicines for patients.
In closing, on behalf of my colleagues at Bristol-Myers
Squibb and the patients we serve, my sincere thanks for your
time and attention today.
The Chairman. Thank you very much.
[The prepared statement of Dr. Caforio appears in the
appendix.]
The Chairman. Now, Ms. Taubert?
STATEMENT OF JENNIFER TAUBERT, EXECUTIVE VICE PRESIDENT,
WORLDWIDE CHAIRMAN, JANSSEN PHARMACEUTICALS, JOHNSON & JOHNSON,
NEW BRUNSWICK, NJ
Ms. Taubert. Chairman Grassley, Ranking Member Wyden,
members of the committee, thank you for the opportunity to be
here today. I am Jennifer Taubert, and I lead the Janssen
Pharmaceutical Companies of Johnson & Johnson. We focus on
discovering and developing transformational medicines for some
of the world's most challenging diseases, including multiple
myeloma, prostate cancer, HIV, schizophrenia, and Crohn's
disease, among others.
Like many of you, I know what it is like when a loved one
faces serious illness. My own mother died of lung cancer while
in her 40s, and at that time there was very little that could
be done for her. I have committed my career to bringing
families hope: hope for years of life, for the chance to be
there for a daughter's wedding or for a grandson's birth.
Janssen invested $8.4 billion in research and development
last year in the search for medical breakthroughs, making us
one of the world's top R&D investors in any industry. In fact,
our investment in R&D last year was 86 percent more than we
spent on sales and marketing. And this substantial investment
is changing lives. It has helped turn HIV from a death sentence
to a manageable disease. Our targeted cancer medicines have
helped patients with some of the most deadly cancers live
longer, in some cases for many years.
Medicines not only help patients and families. They also
help lower overall health-care costs by keeping people well,
preventing the need for expensive procedures and
hospitalizations. But medicines cannot make a difference if the
patients who need them cannot afford them. We understand the
concerns about the cost of health care.
Our approach recognizes our responsibility to patients
today and patients tomorrow. Patients today need access to our
medicines. Patients tomorrow count on us to deliver cures and
treatments for the most challenging diseases. When we price our
medicines, we balance the value to patients, the importance of
affordable access, and the importance of developing future
breakthroughs. The list price is a starting point that is
reduced by required discounts to government programs and
rebates to payers so they will grant patients access to our
medicines.
Last year our discounts and rebates amounted to $21 billion
and our net price decreased 6.8 percent. Unfortunately, while
our overall price decreased for the past 2 years, patients have
seen their out-of-pocket costs go up. One reason is increased
enrollment in health plans that require patients to pay more
for their prescriptions. As one recent analysis shows, patients
are required to pay 13 percent of overall pharmaceutical costs,
versus only 3 percent of hospital costs, even though medicine
can help keep patients out of the hospital.
Above all, we need an American solution to this American
challenge. We must ensure that today's medicines are
affordable, while at the same time preserving the innovation
that has delivered so much and promises even more. We must
maintain the hallmarks that make American health care
remarkable: access to innovative therapies, personal choice,
and doctors and patients making decisions based on what is
right for each individual.
At Janssen, we are committed to being a part of the
solution. We believe open dialogue is essential. That is why in
2016, we began issuing the Janssen Transparency Report, sharing
information about how we invest our resources, price our
medicines, and help people access them. And we recently
announced our plan to include list price and potential patient
out-of-pocket costs in our direct-to-consumer TV advertising.
In the same spirit of open dialogue, we have consistently
brought forward ideas and perspectives to both Congress and the
administration to fix what is not working while preserving what
is.
We have included more details in our submitted testimony,
but I want to touch on a few points today. First, while
Medicare Part D is working for many seniors and has been
effective in containing costs, we believe an out-of-pocket cap
is a needed protection.
Second, in Medicare Part B, we have proposed options that
would allow Medicare to continue to achieve negotiated savings
through market competition while reducing costs.
And third, we support rebate reforms that ensure patients
benefit from the negotiated rebates and discounts--$150 billion
in total in 2017 alone--and as a result, have patients see
lower out-of-pocket costs at the pharmacy.
We are on the verge of extraordinary progress that could
change our lives and the lives of our children and
grandchildren. At Janssen, we are committed to bringing that
promise to life.
Thank you very much.
The Chairman. Thank you.
[The prepared statement of Ms. Taubert appears in the
appendix.]
The Chairman. Mr. Frazier?
STATEMENT OF KENNETH C. FRAZIER, CHAIRMAN AND CHIEF EXECUTIVE
OFFICER, MERCK AND COMPANY, INC., KENILWORTH, NJ
Mr. Frazier. Mr. Chairman, Ranking Member Wyden, and
members of the committee, thank you for the opportunity to
appear here today.
Merck's mission is to save and improve lives around the
world by bringing forward breakthrough medicines and vaccines.
Research is at the core of Merck. Last year we invested $10
billion in R&D, 23 percent of product sales. And we have
invested nearly $70 billion over the past decade.
Over the last 5 years, we have also made capital
investments of over $5 billion in the United States, and we
plan to invest more than $9 billion more over the next few
years to increase manufacturing capacity and to open two new
research centers in the United States.
We go where the science leads us, which means we do not
focus only on diseases in wealthier countries. For example, we
are proud to have deployed 70,000 doses of our experimental
Ebola vaccine in the Congo, working in partnership with the
United States government. The goal is to save lives even where
no viable commercial opportunity exists. We do all this to
serve patients.
We fully understand that U.S. patients are having a harder
and harder time affording the medicines they need. While
medicine costs are growing at the slowest rate in years, our
patients are too often being asked to pay more out of pocket. I
am here to suggest some ways that together we can address this
problem. First, we want to be clear that our industry has a
duty to be responsible in our pricing practices and to
contribute to solutions that address patient affordability.
Merck has a history of responsible pricing. We publish
information about our prices, and the rebates and discounts we
provide to payers. Last year we pledged that we will not
increase our average net prices across our portfolio by more
than the rate of inflation annually
Second, we must ensure that patients get the benefit of
these large rebates and discounts. The incentives in the
current system are badly misaligned with the growing gap
between list and net prices, creating incentives to favor
products with higher list prices. This misalignment hurts
patients because their cost sharing is often based on the list
price of a drug. We urge you to support action to ensure that
patients benefit from these discounts.
Third, we can significantly reduce drug spending for
patients in the health-care system by ensuring that we have a
viable biosimilars market in the United States. We urge
Congress to encourage and support greater biosimilar
utilization.
Fourth, we believe that prices can better align with a
drug's value, when manufacturers and payers are able to
negotiate innovative contracts that base payment on a drug's
benefit. We need to move to this type of system, but there
remain major regulatory and operational obstacles to such
value-based arrangements, which we urge Congress to address. We
agree that manufacturers should be rewarded based on the value
that our therapies deliver.
Fifth, we support efforts to encourage generic competition.
A version of Chairman Grassley's CREATES Act and similar
policies could make needed reforms to encourage generic
competition and ensure there is no inappropriate gaming of the
system. We also support eliminating coupons in cases where
brand name generic competition exists.
Finally, we would like to work with the committee to find
ways to end price gouging by some who excessively increase off-
patent drug prices where there is no competition. These high
prices hurt patients, and they do not create incentives for
research. These changes could bring real relief to today's
patients while preserving the incentives to invest in
tomorrow's breakthroughs. Decades of research investment are
now yielding life-changing discoveries. If we damage the
biomedical ecosystem that thrives on these investments, we will
surely limit what can be achieved for patients and society.
The single most important thing we do at Merck is to
persist in making large and risky investments in R&D that allow
our thousands of researchers to sit at their lab benches to try
to create something transformative despite the overwhelming
odds that their efforts will not succeed, since more than 9 out
of 10 compounds fail.
I would like to end on a brief personal note. My mother
died when I was a child, and my siblings and I were raised by
my father. He was a giant in my life, and I was devastated when
Alzheimer's took him away from us.
Last year, after spending many years and over $1 billion,
Merck had to end development of a promising Alzheimer's therapy
because it did not work. Yet we continue on, seeking better
approaches, and I truly believe that Merck or one of the other
companies at this table will find a medicine that will avoid
the pain of seeing a loved one taken away from them in this
way.
This vital work depends on having a U.S. market that is
free, competitive, and predictable. We must work together to
solve the affordability challenges of today's patients without
jeopardizing the hopes of those waiting for tomorrow's cures.
The changes I have discussed today have the potential to vastly
improve the market while lessening the financial hardships many
people face.
I am here to pledge Merck's cooperation with you in
creating such changes. Thank you very much.
The Chairman. Thank you, Mr. Frazier.
[The prepared statement of Mr. Frazier appears in the
appendix.]
The Chairman. Now, Dr. Bourla?
STATEMENT OF ALBERT BOURLA, DVM, Ph.D.,
CHIEF EXECUTIVE OFFICER, PFIZER, NEW YORK, NY
Dr. Bourla. Good morning. Chairman Grassley, Ranking Member
Wyden, and members of the committee, thank you for the
invitation. My name is Albert Bourla. I have been with Pfizer
26 years and just last month became its chief executive
officer.
I have to say that today I am particularly humbled to take
part in such an important policy discussion within the United
States Senate. When I immigrated into the United States 18
years ago, I could never have imagined such an honor.
In that frightening moment when you hear that you or a
loved one has been diagnosed with a serious disease, one
question comes to mind: is there a treatment available? The
answer to this question will change your life. Happily the
answer, increasingly, is ``yes.''
New breakthroughs are coming quickly to treat many
difficult and devastating diseases. But these breakthroughs
will not do anyone any good if patients cannot afford them. And
unfortunately, the horribly misaligned incentives within our
health-care system often make medicines unaffordable for
American patients. We need to fix this. Today, we would like to
propose four ideas to drive meaningful savings for patients.
The first idea is passing all rebates to patients. Pfizer
supports a system in which transparent up-front discounts
directly benefit patients, rather than the system where rebates
are swallowed up by the supply chain. In the current system,
for example, none of the approximately $12 billion that Pfizer
paid in rebates, in 2018, found its way to American patients.
If the proposed rule to share rebates with consumers at the
point of sale is finalized, we estimate that seniors taking
Pfizer medicines could save hundreds of dollars a year, on
average.
The second idea is less volume, less pay. Imagine a system
where Pfizer gets paid based on the number of heart attacks we
prevent, rather than on the number of pills we sell. In such a
system, if our medicines do not produce good results, we should
be paid less. And if they do, we should be paid more.
Such value-based payment arrangements, if done correctly,
can align the interests of patients, insurance companies, and
biopharmaceutical companies around one shared goal, ensuring
positive health outcomes for patients. I understand that
several members of this committee are working on legislation to
pave the way for these types of arrangements. And we applaud
this effort.
The third idea is around capping seniors' out-of-pocket
medicine costs. Patients are increasingly being required to
take on a disproportionately higher share of their medicines'
costs. Today patients pay on average 14 percent of the cost of
their medicines, but they pay only 3 percent of the cost
associated with hospital stays, for example. This is forcing
patients to forego taking needed medications or to limit their
doses. This is bad, not only for patients, but also for overall
system costs. Patients who do not take their medicines often
end up in the hospital, costing much more to the system. An
important first step is capping out-of-pocket costs seniors
experience in the medical drug program.
And the fourth idea is to knock down barriers to lower-cost
biosimilars. Others have spoken about it. Adverse incentives
that favor higher-cost biologics are keeping biosimilars from
reaching patients. In many cases, insurance companies declined
to include lower-cost biosimilars in their formularies because
they would risk losing the rebates from covering higher-cost
medicines. I cannot think of a more concerning example of a
broken system, and we need to do something about it.
In closing, Pfizer is all about breakthroughs that change
patients' lives. This is why our more than 90,000 colleagues,
many of whom work in laboratories and manufacturing plants in
States represented by members of this committee, come to work
every day. And it is why we are here today, to work with you
and all stakeholders to find ways to ensure that we can
continue to discover medicines that can change patients' lives.
The Chairman. Thank you.
[The prepared statement of Dr. Bourla appears in the
appendix.]
The Chairman. Now to Dr. Brandicourt.
STATEMENT OF OLIVIER BRANDICOURT, M.D., CHIEF EXECUTIVE
OFFICER, SANOFI, BRIDGEWATER, NJ
Dr. Brandicourt. Chairman Grassley, Ranking Member Wyden,
and members of the committee, thank you for the opportunity to
appear before the Senate Committee on Finance to discuss
pharmaceutical pricing, affordability, and patient access. I am
Olivier Brandicourt, the chief executive officer of Sanofi. I
understand the anger about rising out-of-pocket costs for many
medicines, including insulins.
I appreciate the confusion as to why patient costs continue
to rise, even when the amount that PBMs and health plans pay
declines. This situation is unacceptable and unsustainable for
too many patients. My goal today is to have an honest
discussion about how the system works, and how it can be
improved. As you may know, 2 years ago Sanofi announced our
progressive and industry-leading principles.
First, we made a pledge to keep price increases at or below
the U.S. national health expenditure projected growth rates.
Second, we committed to providing a clear rationale for pricing
when we launch new medicines. And third, we have increased
transparency by providing each year information about our list
and net prices across all of our medicines.
In 2018, the average aggregate least-price increase across
all Sanofi medicines in the U.S. was 4.6 percent, while the
average aggregate net price--that is the price actually paid to
Sanofi--declined by 8 percent. So declining average aggregate
net price in 2018 represents a third consecutive year in which
the amount paid by payers across all of our medicines went
down.
I feel a special obligation to address the pressing issues
around access and affordability of our insulins. Insulin is a
clear example of the growing gap between list and net prices.
Since 2012, the net price of Sanofi insulins has declined 25
percent. Yet patient out-of-pocket costs have continued to
rise. If you take Lantus, for instance, our most prescribed
insulin, the net price has fallen by 30 percent since 2012. Yet
over the same period, average out-of-pocket costs have risen
approximately 60 percent for patients with commercial insurance
and Medicare. It is my belief that declining net prices should
result in lower out-of-pocket costs for patients. But clearly,
this is not always the case.
Addressing these prices alone will not be sufficient to
solve the problem of patients' out-of-pocket costs. As we look
for solutions, we must have protections for patients and link
responsible pricing to both access and affordability. Every
actor in the system has a role to play, and Sanofi takes this
call to action seriously. There are different ways to
accomplish these goals, and Sanofi could support options that
align to our core principles. First, changes to the drug
pricing and reimbursement system must be holistic, factoring in
all actors in the system. And the majority of benefits should
accrue to patients.
And second, to maintain a strong environment for innovation
in the United States, the government should not directly
control the price of medicines, either through Federal
Government price controls, or worse, outsourcing price
decisions to other countries.
To ensure that responsible pricing translates to better
access and affordability for patients, Sanofi supports the
policy solutions outlined in my written testimony, including
several policies introduced by members of this committee, such
as the CREATES Act, the C-THRU Act, and the SPIKE Act.
So thank you for the invitation to speak with you today,
and I look forward to answering your questions.
The Chairman. I thank all of you for your testimony.
[The prepared statement of Dr. Brandicourt appears in the
appendix.]
The Chairman. And I think I heard from each of you that you
are willing to work with us and people in the administration to
find solutions to these problems. I welcome that sort of
cooperation and just implore you that that cooperation will
have to go on weeks beyond this hearing, because we would not
expect to get all the information we need just at this hearing.
Now, we will go to questioning. Do not start my clock yet.
I have not asked my questions yet. [Laughter.]
Before I ask questions, if I could have--obviously, we have
a very important meeting here. We have seven witnesses. We have
24 or 25 members of this committee.
I think I am fairly liberal in letting people ask
questions. But I want to repeat something I have said before,
and that is that if you will take your 5 minutes, and if there
are a few seconds left, you ask a question then--hopefully, it
is a short question at that point, and hopefully there is a
short answer at that point.
What irritates me about that process is when somebody
thinks they can have back and forth for 3 or 4 minutes after
you ask your last question. So I am asking you, if you would
please be tolerant towards people who abide by the 5 minutes,
to be respectful of that so that everybody gets a chance to ask
questions.
Now my 5 minutes starts. [Laughter.]
I want to thank those of you who are here who said you
would be supportive of legislation that I have been backing for
a long period of time: CREATES, which is sponsored by Senator
Leahy and this Senator, and Pay-for-Delay by Senator Klobuchar
and this Senator. So those are bipartisan bills.
One other bipartisan bill that you probably do not know
about yet--it was introduced by Senator Wyden and me a couple
weeks ago--is called the Right Rebate Act, which would close a
loophole that was exploited by Mylan in the EpiPen case.
So leading to my questions, starting off, Ranking Member
Wyden and I have been working--before I became chairman of this
committee again, we investigated a lot about Gilead's pricing
decisions for hepatitis C drugs. During that investigation, we
acquired a document that listed some factors that Gilead
considered when it priced those drugs.
Those factors included the risk of ``public outcry'' or
``the likelihood of a letter from Congress'' or the
``likelihood of a congressional hearing.'' So taking off from
that point, here is a very simple question to answer, I think.
So I want a ``yes'' or ``no'' from each of you.
When your company prices its drugs, do you consider the
risk of negative public opinion in the pricing of that drug? We
will start with AbbVie.
Mr. Gonzalez. Senator----
The Chairman. Can you answer ``yes'' or ``no''?
Mr. Gonzalez. Yes, we do.
The Chairman. Yes, you do. Okay.
What about AstraZeneca?
Mr. Soriot. Yes, we do, Senator. Amongst other factors, of
course, but we do.
The Chairman. Okay.
What about Bristol-Myers?
Dr. Caforio. Yes, we do, Senator, among many factors.
The Chairman. Okay.
Johnson & Johnson?
Ms. Taubert. Yes, we do, Senator, as well as affordable
access to the medicines for the patients.
The Chairman. Okay.
What about Merck?
Mr. Frazier. Yes, we do, among other factors.
The Chairman. Okay.
And what about Pfizer?
Dr. Bourla. Yes, we do, among other factors.
The Chairman. And what about Sanofi?
Dr. Brandicourt. Yes, we do, among other factors.
The Chairman. Okay. Thank you.
Another ``yes'' or ``no'' question: when determining list
price, do you consider the likelihood of a congressional
inquiry? Let's start with AbbVie.
Mr. Gonzalez. No, we do not.
The Chairman. What about AstraZeneca?
Mr. Soriot. No, we do not, Senator.
The Chairman. What about Bristol-Myers?
Dr. Caforio. No, Senator, we do not.
The Chairman. And what about Johnson & Johnson?
Ms. Taubert. No, Senator, we do not.
The Chairman. Okay; and Merck?
Mr. Frazier. Not explicitly.
I would say we do care what the public thinks.
The Chairman. Okay.
And what about Pfizer?
Dr. Bourla. No, we do not think----
The Chairman. Okay. What about Sanofi?
Dr. Brandicourt. Same, Senator; we do not.
The Chairman. Okay.
Then I would have another ``yes'' or ``no'' question. When
your company prices its drugs, do you take into account the
fact that a key player is the Federal Government?
Let us start with AbbVie.
Mr. Gonzalez. We evaluate all the channels when we make
determinations on price and affordability.
The Chairman. Okay.
So that obviously would include the Federal Government.
Mr. Gonzalez. Correct.
The Chairman. AstraZeneca?
Mr. Soriot. Yes, we use the same approach, and of course
the Federal Government is a very key aspect of our
deliberations.
The Chairman. Okay.
Bristol-Myers?
Dr. Caforio. Yes, Senator, because the Federal Government
is a large part of our----
The Chairman. Okay.
Johnson & Johnson?
Ms. Taubert. Yes, we take into account the value to
patients, the health-care system, and society, and the
government is a key part of that.
The Chairman. Okay.
And Merck?
Mr. Frazier. Yes.
The Chairman. Okay.
And Pfizer?
Dr. Bourla. Absolutely.
The Chairman. And then Sanofi?
Dr. Brandicourt. Yes.
The Chairman. Okay.
My last question. ``Yes'' or ``no'': some of you have
voiced support for the recent rebate rule proposed by the
administration. Should the administration finalize this rule,
will you commit to lowering your drug prices?
Mr. Gonzalez. Mr. Chairman, we are supportive of the rule.
We would like to see it in its final form, obviously, to make a
final decision. But we are supportive of taking the discount to
the patient at the point of sale.
The Chairman. Okay.
AstraZeneca?
Mr. Soriot. The same for us, Senator. I would go one step
further: if the rebates were removed from the commercial sector
as well, we would definitely reduce our list prices.
The Chairman. Okay.
And Bristol-Myers?
Dr. Caforio. We have the same position, sir.
The Chairman. Okay.
And Johnson & Johnson?
Ms. Taubert. Yes, we are supportive, and that definitely
would be my goal. We would just need to see the final
legislation, provided that there are not additional fees that
are added into the system to compensate for the rebates.
The Chairman. Okay.
Merck?
Mr. Frazier. I would expect that our prices would go down
if we change the system, again, on the commercial side as well
as the Medicare side.
The Chairman. Okay.
Pfizer?
Dr. Bourla. It is our very clear intention that we will not
keep a single dollar from these rebates. We will try to move
every single penny to the patients. And we think if this goes
also to the commercial plans, that would be even better for
more patients.
The Chairman. Okay.
Sanofi?
Dr. Brandicourt. Lowering list price has to be linked to
better access and affordability at the counter for the
patients.
The Chairman. Okay.
I want fellow colleagues to know that I stopped at 5
minutes and 26 seconds.
Senator Wyden?
Senator Wyden. Thank you, Mr. Chairman.
Let me start, if I could, with you, Mr. Bourla, on this
list price question. And I want to see if we can do a couple of
``yes'' or ``no'' questions.
Is it correct that your company, and nobody else, sets the
starting price for all drugs sold by Pfizer? That is a ``yes''
or ``no.''
Dr. Bourla. It is a negotiation with PBMs, and they are
very powerful.
Senator Wyden. But you still get to set the list price?
Dr. Bourla. Yes, but we set----
Senator Wyden. Okay.
Dr. Bourla [continuing]. The list price and the rebates
based on----
Senator Wyden. Is it correct when a hypothetical patient--
let us call her Mrs. Jones--goes to pay for her drug at the
pharmacy counter, her coinsurance is based on the price of the
drug you set?
Dr. Bourla. It is correct in many cases.
Senator Wyden. Okay.
I just want you all to know that the number one reason
consumers are getting hammered is because these list prices--
and you have the last word with respect to where they are--are
unaffordable. And the high prices are tied to what the consumer
pays at the pharmacy counter. And all this other stuff you talk
about--the rebates and the discounts and the coupons--all this
other stuff is window dressing, all of it. And the fact is on
Part D, 40 percent of the drugs do not even have a rebate.
So I want it understood--particularly, because I have asked
you, Dr. Bourla--I think you and others in the industry are
stonewalling on the key issue, which is actually lowering list
prices. And reducing those list prices is the easiest way for
American consumers to pay less at the pharmacy counter.
Now, Mr. Gonzalez, I want to ask you some questions
relating to the international pricing situation. Drug prices
are much higher in the United States than in other developed
countries, on average 40 percent higher. In 2017, AbbVie made
$9.9 billion in revenue outside the United States.
So my first question to you is, do you make a profit on the
drugs that you sell in Germany or in France?
Mr. Gonzalez. Yes, we do.
Senator Wyden. So if you do, and you have said that that is
the case, if you can turn a profit in a country with
dramatically lower prices, you can do the same thing in the
United States. How is that not gouging the American consumer
with high prices, even though you are giving other people in
Western industrialized countries a better deal?
Mr. Gonzalez. Senator, it is a great question. And the
reality is--and I do not think it is just unique to AbbVie--
that prices vary dramatically around the world. There is no
question, at least in AbbVie's business for the most part, the
U.S. has some of the highest prices in the world.
That is not universally true. The government has some
relatively low prices in comparison. But I think the
fundamental issue is this: our system is built around a variety
of pricing around the world, but that overall system supports
our R&D model.
If a market the size of the United States were to collapse
to the lower end of that pricing model, then I can just tell
you AbbVie would not be able to invest the level of R&D that it
invests today. So that is the reality.
Senator Wyden. Well, I think time is short.
As I noted in my opening statement, global R&D spending is
far less than the revenue you make in America. American
patients bring in more than enough revenue to cover your R&D
costs.
I mean, I am going to have town meetings in a few days at
home, and people will say, ``Ron, this is ridiculous that we
are getting gouged when people around the world are getting a
better deal.'' And what you have told me today is: (a) they are
getting a better deal and you can make a profit; and (b) it is
somehow tied to research and development. And the fact is that
research and development is less than the revenue that you are
making in this country, and that is why people are so angry.
And I would also like to note that a Humira biosimilar was
launched in Europe last year, and due to AbbVie's anti-
competitive behavior in the United States, that same biosimilar
will not be available here until 2023. You have a double
standard. You are willing to sit by and hose the American
consumer and give the breaks to people overseas.
So I am going to wrap up and stick to the chairman's time
limit by asking you for a response in writing. So that we can
better understand the situation for the drugs you sell in other
countries, I would like to know, for the drugs you sell in
other Western industrialized countries--just the Western
industrialized countries--does your company make or lose money?
Can you get that to me in writing within 10 days?
Mr. Gonzalez. I can give it to you right now.
Senator Wyden. Okay.
Mr. Gonzalez. We make money in any country that we sell in
unless we choose to donate the product into those countries.
And we do that in certain countries that cannot afford it, but
not the Western----
Senator Wyden. I would like it in writing.
Mr. Gonzalez. Okay.
One thing I would like to point out that I do not think is
totally accurate that you described, at least for AbbVie, is we
spend $5.2 billion dollars in R&D. We make $5.6 billion dollars
in earnings.
So our R&D is almost equivalent to what our earnings are.
Senator Wyden. Well----
The Chairman. I am going to----
Senator Wyden. We will continue that.
The Chairman. I am going to list four names at a time.
Roberts will be next, and then Stabenow, and then Enzi, and
then Cantwell. So if you are irritated about how you might be
on this list, take it out with one of your colleagues on the
committee, because I am reading it just the way the staff gave
it to me.
So, Senator Roberts?
Senator Roberts. Thank you, Mr. Chairman. I will try to be
timely.
This whole situation reminds me of when Mark Twain, i.e.,
Samuel Clemens, went to Missouri--that was his first mistake--
and made some remarks to a small town. The mayor afterwards
said, ``Well now, we have the tar and the feathers and a rail.
We would like to ride you out of town on a rail.'' He said,
``If it was not for the honor of it, I'd just as soon not do
that.''
And I think in some ways that is where you are sitting
right now. I worry about the cost. I worry about the access. I
worry about the value. I worry about the fact that when I go--I
did just last night, and all of a sudden I found out that the
prescription I had cost twice as much. I still have not quite
figured that out. I do not know which one of you to blame.
But at any rate, I worry about HHS. I worry about CMS. I
worry about the Federal Government taking over with regards to
the decisions that you make. I also worry about what the
distinguished Senator from Oregon described as a terrified
public, and certainly we do not want any liars.
I want to ask you one simple question. Staff has arranged
about seven good questions. I will submit them for the record.
Under the banner of certainty and predictability, what
keeps you up at night? In other words, if in fact we invited
you back and you could come back--well, let me put it another
way. What would happen if you ran into some things that were
unprecedented and you would not be here? We would not have the
Magnificent Seven, if in fact that's why we won a ``W.''
What I want to know is, what is the thing that keeps you up
at night, so you could be a viable company now and down the
road to achieve what we all want in terms of access and cost?
And I am going to start with Dr. Brandicourt, because I want to
go from right to left for a change.
Dr. Brandicourt. Thank you, Senator. What keeps me up at
night is ensuring that I have a pipeline of new products which
is innovative enough to alleviate, you know, some of the
disease burdens in the countries where we are. So it is making
our company meaningful and delivering what we are supposed to
do best.
Senator Roberts. Thank you.
Dr. Bourla. Mr. Senator, the reason we exist is to bring
breakthroughs that change patients' lives. And this is what
keeps me up, and this is the reason why our employees come to
work. This is the reason why our investors invest in us.
If our pipeline will not deliver on the promise--and this
is very challenging, because you are dealing with very
difficult diseases to crack--then we will not be able to
fulfill our promise to society and will not be able to fulfill
our promise to investors.
Senator Roberts. Mr. Frazier, thank you for your five-point
plan. What say you?
Mr. Frazier. I would say, Senator, the thing that keeps me
most up at night is the concern that we will not have a viable,
predictable market that will allow people to continue to put
the very large amounts of money at risk for a long period of
time in an attempt to find solutions to some of the hardest
problems, like Alzheimer's, that have evaded solutions.
And what really concerns me is when we do not treat these
issues as systemic issues and the public thinks that they have
to have outrageous solutions to the problem where, in the
future, we will not get these drugs.
So I would hope that we could talk about these things
systemically and try to come up with the kinds of solutions
that will, in fact, make patients have access to medicines
today while allowing tomorrow's breakthroughs to happen. Thank
you.
Senator Roberts. Thank you.
Ms. Taubert?
Ms. Taubert. Senator, the easy diseases have largely been
solved. It gets harder and harder as we go after new treatments
and new cures for ever more challenging diseases.
So from our perspective, what keeps me up at night is that
investment in innovation and the ability to continue to invest
to be able to go after the cures and the diseases that we
really want to solve.
Senator Roberts. Thank you.
Dr. Caforio?
Dr. Caforio. Mr. Senator, I am a physician, as I said
earlier. What keeps me up at night is our patients who still do
not have an opportunity for their cancer to be treated. And as
a result of that, I am really focused on, first, continuing to
invest in R&D together with the 7,000 scientists at Bristol-
Myers Squibb, and also making sure that every patient who needs
one of our medicines has access to it.
Senator Roberts. Mr. Soriot?
Mr. Soriot. Senator, two things, actually. One is making
sure we have the best science, the best scientists, and an
environment that stimulates their innovation. The second is
really to come up with ways to demonstrate the value of our
products. I believe that medicines are actually part of the
solution, not part of the problem. And it is sad that we are
talking about those difficulties patients are facing.
In the last 15 years, the mortality for cardiovascular
disease has declined by 35 percent. Most of this is due to good
treatments for hypertension, cholesterol. And in fact, it is
cost-effective. We keep patients out of the hospital.
So the one thing that really keeps me up at night is, how
do we demonstrate the value we bring, and how do we reduce
overall health-care costs?
Senator Roberts. Mr. Gonzalez, I am out of time.
The Chairman. No, he can answer. You asked your question.
Go ahead.
Senator Roberts. Thank you for being so liberal.
[Laughter.]
Mr. Gonzalez. Thank you, Senator.
There are two things that keep me up at night. The first is
we, like many around this table, are working on some of the
toughest diseases that are out there, which takes on tremendous
amount of risk--I am sure you heard that many, many times.
But the reality is, when we work on these diseases, like
Alzheimer's as an example, when someone comes up with a
beneficial treatment for Alzheimer's, it is going to change the
lives of patients, families, and it is going to reduce
dramatically health-care costs. But not necessarily the cost of
medicine.
The cost of medicine is going to go up. The cost of nursing
homes is going to go down. And systems have a very difficult
time trying to measure that benefit, but the reality is, when
you are working in these areas with these kind of intractable
diseases, that is the ultimate payback that the system has to
be able to evaluate.
Senator Roberts. Thank you.
The Chairman. Senator Stabenow?
Senator Stabenow. Thank you very much, Mr. Chairman and
Ranking Member.
Thank you for being here. I will tell you what keeps people
in Michigan up late at night. It is the cost of life-saving
medicine for themselves, their children, their parents. And so
that is why it is important that we are here, and I am glad we
are talking about research, because I would like to step back a
moment and talk about who basically is funding research, and I
hope you will say ``thank you'' to the American taxpayer,
because American families fund the National Institutes of
Health.
A recent report found that NIH-funded research contributed
to every single one of the 210 new drugs approved by the FDA
from 2010 to 2016, and that American taxpayers contributed more
than $200 billion in grants--$200 billion in grants to your
companies and others. Grants, not loans; grants to develop
these drugs.
That is about 200,000 years of accumulated research. And I
support that, because the basic research is something that I
believe we all need to share in. At the same time, when you
then go from there and are doing R&D, you can write that off
your taxes, so American taxpayers subsidize you again.
Now, according to the most recent SEC filings, the seven
companies--all of you here today--have spent about $80 billion
on selling, marketing, and administrative expenses last year,
which was $22 billion more than you spent on R&D.
So let us just be clear on this: American taxpayers, we are
happy to help you be able to develop these drugs, but I can
tell you, people in Michigan just feel that the bargain ought
to be that they ought to be able to afford the medicine after
they have helped to develop it.
Between 2006 and 2015, the largest 25 drug companies
enjoyed an average annual profit of between 15 and 20 percent.
Most other large Fortune 500 companies saw between 4 and 9
percent.
I know the auto industry would love to get the kind of
profits that you have. But the reality is that, if people do
not buy a car, they do not buy furniture, their life is not
threatened. If they cannot buy your product, it may be. So that
is why this is so important today.
And, Mr. Gonzales, I want to specifically start with you,
because Humira is the world's best-selling drug. It treats
arthritis, Crohn's disease as we know, also ulcerative colitis.
And you introduced the drug in 2003, and in 2017 it generated
$18.4 billion in revenue. And if Humira was its own company, it
would be among the Fortune 500 companies all by itself.
So let us talk about this, because the average person on
Medicare is earning $26,000 a year. The price of your drug
started high and has gone higher, to a point now where it is as
much as $50,000 a year.
So, Mr. Gonzales, your primary patent expired in the U.S.
in 2016. Is that correct?
Mr. Gonzalez. That is correct.
Senator Stabenow. And you have more than a hundred other
kinds of patents for processes and techniques and so on. In
fact, according to a report, ``Broad U.S. Humira Patent
Estate,'' some of the patents go up to 2034, which gives you
about 31 years of patent protection. That is a pretty good deal
on this successful drug.
When we look at what is happening around--well, let me
first ask this. Has the drug itself gotten any better with all
the new patents?
Mr. Gonzalez. I think as you look at the evolution of the
patent portfolio that is around Humira, it is important to keep
in perspective that that patent portfolio evolved as we
discovered and learned new things about Humira, in particular,
as we discovered that this particular molecule could be
utilized across a large number of different disease states.
Senator Stabenow. And I am going to, unfortunately, in the
interest of time--I appreciate that and would want to follow up
in writing, but as I understand it, the chemical formula is the
same. And so it is a question of how we use the patent system.
But to look at, in Europe, when your patents expired in the
fall of 2018 and biosimilars came out on the market, your
prices there were already lower than in the U.S., but now you
are offering, I understand, up to 80 percent discounts to be
able to continue to compete in Europe. Why do you not--with all
of the support from American taxpayers on this drug, why do you
not offer the same low price to American families?
Mr. Gonzalez. Because Humira plays a very important role in
AbbVie's overall funding of R&D. And I think it is
fundamentally underpinned by the fact that if you look at these
inventions that we have created, that were patented, as I said,
they included a number of different diseases for which Humira
was effective, and they evolved over time.
We think we have struck a reasonable balance. We have now
licensed seven biosimilar players to the entire portfolio. So
they can use that portfolio to go out and copy Humira. We have
given licenses to them, and they will all enter the market in
2023.
The earliest patent to expire in that portfolio is June of
2022. So, literally seven biosimilars will come within a year.
Senator Stabenow. Mr. Gonzales, I know my time is up. Let
me just say, I think that you charge more here because you can.
And American taxpayers are subsidizing all of you to be able to
have incredibly high profits, the fastest-growing part of the
health-care system. And I think the people in Michigan and
across the country deserve better. They need to be able to
afford the medicine and not have to go to another country to
get it.
The Chairman. Senator Cantwell?
Senator Cantwell. Thank you, Mr. Chairman.
I wanted to get feedback on the market-type mechanisms and
whether they would drive down costs to purchasers and to
consumers. So concepts like allowing States to negotiate on
behalf of a population for health-care plans, like the basic
health plan in New York--do they drive down cost?
[No response.]
Senator Cantwell. No one wants to take that on?
Mr. Frazier. Thank you, Senator. I did not know who the
question was addressed to.
I think first of all, it is important to recognize that
there is no single market for drugs in this country. So for
example----
Senator Cantwell. We are on limited time, and I appreciate
the chairman's great efforts. No, I am just trying to get
``yes'' and ``no'' answers whether these concepts drive down
costs--whether you believe they do. If it is a hard question to
answer, it just tells me something about how willing you are
going to be to help us with this problem.
So my point is this. States negotiating on drug prices on
behalf of a group of citizens, does it drive down prices for
consumers in your opinion, ``yes'' or ``no''?
Mr. Frazier. I would have to say, depending on the system,
it could very well do that. But I think it will do that at the
expense of a system, for example, our Medicare system that has
come in at 50 percent of what it was projected to be.
I want to come back to an issue that was raised at the
beginning about the affordability, if you will just allow me. A
significant issue in our system is that patients pay 13 percent
against the list price for drugs when they pay 3 percent
against a lower negotiated price for other medical services.
I think the primary issue in our country now is out-of-
pocket costs--13 percent is much higher than 3 percent. And if
we were designing a system, we would never design a system that
actually taxes the sicker people to pay for the healthy people.
Senator Cantwell. Okay.
I am asking a really basic question. Like the VA's ability
to negotiate on drug prices, do you think that States having
that same ability drives down price?
Mr. Frazier. I would say that the VA would get a lower
price and the States would get a lower price if you are willing
to go into an environment where that could be imposed by
States.
Senator Cantwell. Well, or the Federal Government. But in
one example--which I think you are familiar with, because I do
think you are involved with hepatitis C drugs--Washington's
Medicaid program is continuing to think about a Netflix model
where you buy the best, the lowest per-unit costs, and cover
more people. Do you think that model works in driving down
costs to consumers?
Mr. Frazier. I think that could work to drive down cost to
consumers, no question, as long as you have the State
``negotiating.'' I would object to the word. Very frequently,
when we deal with governments outside the United States, people
use the word ``negotiations.'' Those prices are imposed.
Senator Cantwell. Well, someone who is negotiating on
behalf of the patients they are trying to cover negotiates with
you or other drug companies on whether they are going to meet
that discount. They are using market forces of bundling up and
leverage. I call it a Costco model. If you buy in bulk, you get
a discount. We are clearly doing it with the VA.
The question debated here is whether we should spread that
out to cover more Federal programs, which is what is being done
in Canada, and whether we should use those same market forces
in allowing States to negotiate, at least for the working poor
in this country, a better deal than they can get because they
work for employers that do not cover them.
So I think if you guys cannot even agree that these basic
market functions that allow people to buy in bulk and get a
discount are good ideas for consumers, then I do not think you
are going to come up with anything we are going to agree on
here, because these are market functions, basic market
functions.
Does anybody else want to add whether they believe in these
market functions?
Mr. Gonzalez. Yes, Senator. I would just illustrate one
point.
I think your point is a valid one for the overall system
costs, but I think what Mr. Frazier was describing is a
critical issue.
There are two affordability issues here. There is the
affordability to the system, and there is the affordability to
the patient. Both have challenges, but the affordability to
patients now has really gotten out of hand.
I will give you an example, my HCV example. We cut the
price by 72 percent, the list price by 72 percent. The out-of-
pocket cost in Medicare is $3,250. The same patient who could
not afford the out-of-pocket cost at $7,000, unfortunately
cannot afford $3,250.
Senator Cantwell. Well, I will tell you what is absurd is
the fact that you got a $6.3-billion tax break in the last tax
bill and you cannot even say that you are for basic market
functions like giving people discounts when they are bundled
and you get volume.
So I guess we will have a tough time coming to something--
but I know people here are going to want basic market functions
to drive down costs for consumers.
Thank you, Mr. Chairman.
The Chairman. Senator Cornyn?
Senator Cornyn. Thank you, Mr. Chairman.
Mr. Gonzalez, I want to focus on Humira. Obviously it
generates about $18 billion of revenue for your company each
year. Is that right?
Mr. Gonzalez. That is correct.
Senator Cornyn. Please understand that I get it. We want to
make sure that we maintain the most innovative pharmaceutical
drug companies in the world, because we want to provide
lifesaving cures for our people. And I get the idea that that
is the purpose of the patent system, which is to protect the
exclusivity of that drug that you have sunk a lot of money into
the research and development for. And I support our patent
system. I think it is very important.
But what I do not understand is, according to my
information here, Humira has 247 patents. And some of those
patents do not expire until 2034. As Senator Stabenow pointed
out, Humira first was sold to patients in 2003.
So is it your company's position that it should have an
exclusive monopoly on that medication for 31 years?
Mr. Gonzalez. Senator, no, it is not. It is essentially
that the patents cover innovations that we created. And I think
one of the things that has been lost here is, it does not
matter how many patents you have--and those are applications
that you described, not actual patents. But there is a large
portfolio of patents. It has 136 patents, and together----
Senator Cornyn. So you have 247 patent applications, but
you have 61 patents? How many patents do you----
Mr. Gonzalez. No. I am sorry. A hundred and thirty-six
patents.
Senator Cornyn. A hundred and thirty six patents on one
drug?
Mr. Gonzalez. But well, remember, Humira is like 9
different drugs or 10 different drugs. So----
Senator Cornyn. I thought you said to Senator Stabenow it
was the same molecule.
Mr. Gonzalez. It is the same molecule, but it treats
different conditions. And if you look at that patent
portfolio----
Senator Cornyn. So you use the same molecule to treat
different conditions, and you can get a patent on that
treatment?
Mr. Gonzalez. Certainly. Now, an example of one of the
areas that got a significant number of patents is inflammatory
bowel disease. After we developed it for RA, we realized that
Humira might work in that area. That was an area that was
under-treated. Most drugs had failed.
We did 20 clinical trials to determine how to make Humira
work in those patients. And we were issued a large number of
patents for the discovery work that we did in that area.
But in the end, the number of patents is not something that
protects a product. If a competitor wants to make a generic
version of a product--there are patents everywhere. The
question is, does the invention stop the biosimilar player from
making the product? If the invention does not, the patent is
meaningless. If the invention and----
Senator Cornyn. The patent gives you an exclusive right to
produce a drug.
Mr. Gonzalez. No, we do not block any biosimilars.
Biosimilars can make the product----
Senator Cornyn. No, no. Maybe you misunderstood. A patent,
during its term, gives you exclusive rights to produce a drug.
Correct?
Mr. Gonzalez. No.
Senator Cornyn. No?
Mr. Gonzalez. No. The composition-of-matter patent would
give you exclusive rights to produce the drug. But the patents
that are covered in this portfolio are for individual
innovations that were created. And in many cases, when we go
into an area, there are always patents. The first thing you do
is, you look to see, can I design around those patents?
If ultimately you determine you cannot design around those
patents, then you go to the player who has the patent and you
negotiate a license. And we have now given license to virtually
every single biosimilar player--with the exception of one--and
we have done it literally 10 years before the last patent
expires in that portfolio.
So we have tried to strike what we think is a reasonable
balance. I realize it may not be popular, but I think it is a
reasonable balance. Those----
Senator Cornyn. But what I am concerned about is--as I told
you at the outset, I support drug companies covering a profit,
based on their R&D and their development of innovative drugs.
But at some point, that patent has to end, that exclusivity has
to end so that the patients get access to those drugs at a much
cheaper cost.
It is true that you, your company, blocked Amgen for a
number of years from seeking to produce a Humira biosimilar or
equivalent; correct?
Mr. Gonzalez. Amgen has a license in the United States
right now to be able to produce----
Senator Cornyn. But you blocked them for 5 years, right?
Mr. Gonzalez. No, we did not block them.
Senator Cornyn. You sued them.
Mr. Gonzalez. They came to us, and they wanted access to
the portfolio that we had. And we licensed them.
Senator Cornyn. Did you sue them?
Mr. Gonzalez. We did, yes.
Senator Cornyn. And you entered into an agreement with them
that accommodated both your needs and their needs, I assume.
Mr. Gonzalez. We licensed them a patent portfolio. They pay
us a royalty on the patent portfolio when they come to market,
and that is essentially just like any other license.
Senator Wyden. Mr. Chairman, I do not want to interrupt.
Senator Cornyn is dead right, and that is exactly the same
point I was going to make.
Senator Cornyn. Mr. Chairman, could I just make a
suggestion that----
The Chairman. Go ahead.
Senator Cornyn. I know this topic is within the
jurisdiction of the Finance Committee, but those of us like you
and me who are also on the Judiciary Committee, which has
jurisdiction over the patent system, I think this is an area
that we need to look into through our Judiciary Committee
authorities as well.
The Chairman. Why don't you take that up with Senator
Graham, and I will make sure that I back you up on it.
Senator Cornyn. I will look forward to your back-up.
The Chairman. And let me know what your conversation
produces.
Senator Cornyn. Thank you.
The Chairman. The next four would be Menendez, Thune,
Carper, and Isakson.
Senator Menendez?
Senator Menendez. Thank you, Mr. Chairman.
Let me say a few words before asking some questions. To the
New Jersey companies here today, thank you for coming. I am
proud our State is at the forefront of innovation.
But even in New Jersey, where the pharmaceutical industry
and related fields like medical research employ hundreds of
thousands of people, the overwhelming majority of the more than
9 million New Jerseyans believe drug prices are too high. And
so I think we all have to be responsive to that challenge
collectively.
Americans everywhere reject the notion that reducing
prescription drug costs means reducing innovation. They are
uniting around this issue. And it is not a Democratic or
Republican priority. It is bipartisan. Maybe it is for
political reasons, but President Trump is talking more and more
about executive action.
A Republican chairman of the Finance Committee, Senator
Grassley, has convened this hearing today, the second of two on
prescription drugs. And reducing prescription drug prices has
become a focal point of virtually every Democratic presidential
campaign.
So consider it a friendly warning from someone who believes
in the hope that you provide patients in need of new cures and
treatments: it is time to be proactive, because if you do not
make the meaningful action to reduce prescription drug prices,
policymakers are inevitably going to do it for you. So I just
hope you will take that to heart.
Let me ask you, many corporations--not just pharmaceutical
ones--received a huge windfall from the Trump tax bill. Your
companies spent well over $40 billion buying back your own
stock in the past year. Going down the row, can you just give
me the ballpark number? Did any of you use your tax breaks to
lower the costs of any of your prescription drugs?
Mr. Gonzalez. We did not use our tax break to lower the
cost of prescription drugs. We used it for other aspects of
trying to stimulate the economy and invest further in the
United States.
Senator Menendez. No, you did not use it to lower the cost.
Mr. Soriot. Senator, the tax break for us, being based in
the UK, had a very marginal impact on our profitability. So I
think the question is----
Senator Menendez. The question is--it is a simple ``yes''
or ``no.'' Whatever the tax break was, did you use any part of
it to lower the cost of prescription drugs?
Mr. Soriot. Well, the cost of our prescription drugs on the
net basis has been declining for many years now. Senator Wyden
took----
Senator Menendez. I am sorry to interrupt you, Mr. Soriot.
It is a simple question. Did you use any part of the tax break
that you got to lower the cost of your prescription drugs?
Mr. Soriot. In a roundabout way, yes, we did, because the
minimal tax benefit we got helped us sustain our profitability
at the same time as our prices were declining.
Senator Menendez. Dr. Caforio?
Dr. Caforio. We did not.
Ms. Taubert. Hello, Senator. It provided us the opportunity
to invest an incremental $30 billion in R&D and capital
investments in the U.S. over the next 4 years. We think that
that is the best way for us to be able to deliver for patients.
Senator Menendez. Mr. Frazier?
Mr. Frazier. Senator, our effective tax rate went up from
19.1 to 19.8 percent.
Dr. Bourla. We did use this tax break to do many things,
among them reduce our prices. Prices in 2018, for the first
time since I remember, went down at Pfizer.
Dr. Brandicourt. As a French company headquartered in
Paris, we did not get much from the tax break. On the GAAP
basis, we lowered our global tax rate by 1.5 percent.
Senator Menendez. All right.
Now, in November 2017, FDA Commissioner Scott Gottlieb
called on pharmaceutical companies to ``end the shenanigans
when it comes to the ability of potential competitors to
purchase branded doses at full market price.'' He stated, ``I
see this clearly, for example, in steps branded companies
sometimes take to make it hard, or altogether impossible, for
generic firms to get access to the doses of the branded
companies needed in order to complete bioequivalence studies
that the FDA requires for a generic approval.''
I have co-sponsored legislation called CREATES that ends
the gamesmanship by certain companies, where they prevent
generic manufacturers from accessing the necessary samples they
need to develop generics. Last year the FDA published its first
list of medicines that generic companies have had trouble
accessing. That list includes more than 170 complaints covering
50 medicines.
So can you go down the line and tell me, ``yes'' or ``no,''
does your company in any way restrict access to, or block the
purchase of samples at full market price?
Mr. Gonzalez. No, we do not.
Mr. Soriot. No, we do not.
Dr. Caforio. We do not. We support the current version of
the CREATES Act.
Ms. Taubert. No, we do not.
Mr. Frazier. No, we do not.
Dr. Bourla. No, we do not, and we support CREATES.
Dr. Brandicourt. No, we do not, and we support CREATES too.
Senator Menendez. I have other questions. I am going to
submit them for the record. Thank you.
The Chairman. Thank you.
Senator Carper?
Senator Carper. Thanks to each of you for joining us today.
My wife lost her mother when she was 11 years old. My wife said
it put a hole in her heart. She has never gotten over it. My
own mother, her mother, and her grandmother, by the time they
were 80, they did not know who they were, or where they were,
or who we were.
For all of us this is personal, and it is political, and it
is economic. When we have a hearing of this nature, one of the
things I like to do with disparate witnesses like these--you
are all from the same industry, but you have different views,
come from different parts of the world. But I am going to, in a
minute, give you--what I am looking for is consensus. What I
think we are looking for is consensus agreement on what is the
right thing to do to make sure that what we are producing is
effective and affordable for us, for the government, for our
constituents.
I am going to give you three items and ask you to tell us
what you think. If we do nothing else, those three items, we
can all agree on those. Okay, and I will give them to you right
now.
The first is eliminating rebates to PBMs. That is the first
one: eliminating rebates to PBMs. The second is value-based
arrangements. And the third is increasing transparency
industry-wide on how you set your prices--increasing
transparency industry-wide on how you set your prices.
If you would like to take a moment--and we would just start
with you, Mr. Gonzalez. We will just start with this question
first and see if we have time to get it done. I hope we do,
those three.
Mr. Gonzalez. I would say that we clearly support providing
the discount at the patient level, so eliminating rebates,
essentially.
We absolutely support value-based pricing, because that is
the business we are in and the kinds of diseases we are trying
to treat and cure.
And we absolutely support transparency. And I would say
transparency even more broadly across the entire system,
including everyone that is in the supply chain. And that would
also include where government rebates are, such as the 340B
program. We would support total transparency across that.
Senator Carper. Thank you. I would ask each of our other
witnesses to also keep your responses short.
Mr. Soriot?
Mr. Soriot. Senator, I would give the same responses. We
support all three items.
I would go one step beyond, which is if the rebates--as I
said earlier--were to be removed from Part D and the commercial
sector, we would actually reduce our list prices by the
rebates' amount, less the fees that are probably single-digit
type fees to be paid to wholesalers and other stakeholders in
the system.
Since you talked about a disease that is very common and
becoming more common and a tragedy for people who suffer from
it, Senator, I would just like to say that, as Mr. Frazier said
a bit earlier, his company spent a billion dollars on
developing a drug for Alzheimer's. Our company together with
Lilly, we spent $900 million to try to develop an Alzheimer's
drug that failed.
And that is a really good reminder of the risks that we
take as an industry. We spent $900 million, many years of work,
and at the end of the day, nothing.
Senator Carper. Thank you.
Dr. Caforio?
Dr. Caforio. Yes, Senator. First of all, I am very sorry--
--
Senator Carper. Please be very brief.
Dr. Caforio. I would say that not only do we support all
three elements that you mentioned, but I do believe those three
elements together with the continued effort to develop a
generic and biosimilar market would mean significant change,
and would clearly alleviate the concerns that patients have
today.
Senator Carper. Great. Thank you, sir.
Ms. Taubert?
Ms. Taubert. Senator, first of all, I am very sorry for
your wife's family and also for your family. It underscores----
Senator Carper. While I said that, everybody in this room
could probably point to similar experiences. All of us have had
them.
Ms. Taubert. Absolutely.
Senator Carper. Thank you.
Ms. Taubert. We are very supportive of all three elements
that you outlined. So the elimination of----
Senator Carper. That is all I need.
Ms. Taubert. Perfect.
Senator Carper. Thank you.
Mr. Frazier?
Mr. Frazier. We too support all three.
Senator Carper. Thank you.
Dr. Bourla. Senator, all three elements are
transformational for our industry, will disrupt it. However, we
do agree that these are the three things that need to be done,
and also I believe that they will have significant, meaningful
results if we do them.
Senator Carper. Thank you, sir.
Dr. Brandicourt. We strongly support the three, Senator,
but we want to keep in mind at the end of the chain, the
patient has to benefit. So if rebates are removed, it has to be
to the benefit of patients.
Senator Carper. Good. Thanks.
Mr. Chairman, I am going to do a follow-up question in
writing, asking your responses, your reaction to what is going
on in Germany on this front--what do you like about it, what
concerns you might have about it. But that is a different
question, but it relates to this discussion.
Thank you.
The Chairman. Before Senator Thune goes, can I ask Dr.
Caforio, did you say you support the CREATES Act as well?
Dr. Caforio. I did, Chairman Grassley.
The Chairman. Thank you. As sponsor of that, I appreciate
that very much.
Dr. Caforio. Thanks for your work in that area.
The Chairman. Senator Thune?
Senator Thune. Thank you, Mr. Chairman.
I would like to ask unanimous consent to insert for the
record a one-page document from 340B Health that shows that
manufacturer discounts account for less than 2 percent of the
total drug market.
The Chairman. Without objection, so ordered.
[The document appears in the appendix on p. 1,053.]
Senator Thune. Thank you.
Each of you has referenced the recently proposed rebate
rule, which outlined several different scenarios of how drug
companies and others would react, as well as the impact on Part
D premiums.
Mr. Frazier and Dr. Bourla, if the rule were finalized,
could you please discuss how you would set list price and how
your negotiations would work with others in the supply chain?
Mr. Frazier. Okay, assuming that--as I said when I answered
the question before, assuming that we do change the systems on
the commercial side and the Medicare side so that no one
company faces a disadvantage, we would be lowering list prices.
We have been asked to lower list prices. We have lowered
list prices in the past and found that it creates a financial
disadvantage for the company, and it does not get us more
volume because of the incentives in the system. So if we change
all the incentives at one time, then list prices can come down.
Senator Thune. Dr. Bourla?
Dr. Bourla. Fifty percent of the American people are in
commercial plans, and these rebate rules apply to Medicare. If
the rules apply to all, definitely the list price will go down.
But also, during the Medicare-only application, we pledge
and we commit that every single dollar will go to the patients.
As the chairman said, the list price is not irrelevant. It
is very relevant for a lot of people, because they have to pay
list price during the deductible period. However, if the rebate
rule is applied, then it becomes irrelevant because the
patients will not be paying the list price at the purchase
point. And this is a significant win.
What I want to say is that, even if we do not move it to
commercial, which I overwhelmingly support, I think it is a
significant win for the American people if we do it even in
Medicare only.
Senator Thune. So Medicare-only would be an improvement,
but you pointed out in your testimony the challenges associated
with the bifurcated market with respect to rebate reform. So
how would manufacturers respond if the rebate rule were
finalized for government programs? I mean, what does that mean
for the commercial market?
Dr. Bourla. Senator, as I said before, all these proposals
we are discussing, including eliminating the rebate rule, are
transformational and will disrupt the way we do business. I do
not know exactly how the system will evolve, and I really do
not favor a bifurcated system. I would like to have a
transparent, single system across both parts. So we need to see
how the whole thing will evolve.
Senator Thune. Okay.
You have each expressed support, and this was alluded to
earlier by Senator Carper, for paying for value as well as the
value your medicines bring to the health-care system. I am a
believer in value-based insurance design as a way to lower the
overall health-care costs, and I have worked on legislation to
advance this principle.
As we drive toward paying for value, how do we make sure
that you as drug manufacturers still have the incentives to
keep your prices low and that we are not just shifting money
around in the system?
Dr. Bourla. I think by definition that a value-based
arrangement will align the incentives, not only of us, but
those of the insurance companies, around one common goal: the
good for the patient, clinical outcomes, measurable clinical
outcomes for the patient and the health-care system.
In this case, if we fail to produce drugs through our
research efforts that will have meaningful clinical benefits
for the patients, yes, we will not be paid. And this system
also will ensure the medicines that do not add value will be
paid much much less. So to create space for medicines that do
create value is the best way of aligning the incentives of
everyone around the interest of the patients.
Senator Thune. Does anybody else want to react to that?
Mr. Soriot. Yes, Senator, if you allow me.
We have an example that I quoted before. We have a product
that is used for the treatment of patients who have experienced
a heart attack.
If you experience a heart attack, when you are discharged
from the hospital, your chance of getting a second heart attack
is pretty high. So we contracted with an organization and
committed to reducing the percentage of patients who have a
second heart attack.
In return, the University of Pittsburgh Medical Center, for
these Medicare patients, committed to ask these patients to pay
a very low co-pay to make sure they were complying with their
treatment. And that actually delivers value to the system,
because patients are kept healthy. Of course, good for them,
but also they do not go back to the hospital. This is how we
deliver value.
Senator Thune. Okay. Thanks.
Mr. Gonzalez. Senator, I would just add one point. I think
your point is a valid one. Look, an innovative pharmaceutical
cannot capture 100 percent of the value that it saves. It has
to capture less than that.
And I think the way that will evolve the best is if there
is strong market competition. I remember back in HCV, if you
look at the health economic data around that drug, it would
have suggested that you could justify a price well north of
$100,000 per patient. And the prices were relatively close to
that when there was one player in the market. Today prices have
gravitated down to about $25,000-$26,000 per patient.
It is the market force that created that, the market
competition of more than one player being in that market and
competing on an active basis. We were obviously part of that
competition that drove those prices in that direction.
So I do not think it is realistic to assume that a
pharmaceutical, just because it can save $150,000, as an
example, that it can charge $150,000. It has to charge less
than that so that the overall system can benefit from the value
of that medicine. But it has to be able to charge a price that
is reasonable enough to be able to achieve and continue to fund
the programs going forward.
The Chairman. Senator Isakson, and then Senator Cardin.
Senator Isakson. Thank you, Mr. Chairman.
I thank all of you for being here. This is a terrific
hearing, and we are going to have a lot of hearings on this
subject. I told my staff a couple of weeks ago, I said, ``You
know, I have been a solid supporter of the pharmaceutical
industry all my career,'' and I have, and I appreciate all that
you do.
I go to work every day because of levodopa. I would not be
able to be here today if it was not for the pharmaceutical
industry, and I have Parkinson's disease. But I can function
every day and do my job because of that, and I appreciate it
every day.
My first chief of staff called me Sunday night from
Children's Hospital in Atlanta to say his youngest son had just
been diagnosed with juvenile diabetes. His first child, a
daughter, had juvenile diabetes 12 years ago. But the thing he
said was, ``At least I know that you can live a normal, happy
life because of insulin and because of pharmaceutical care.''
So I am not softening you up, but I am softening you up,
because those are good stories that we cannot forget. And that
is the value of innovation and research development, and we
appreciate it.
However, when you cannot explain it and you are elected to
the U.S. Senate--and I appreciate your comment about how
honored you are to be in the U.S. Senate, Dr. Bourla--but the
fact of the matter is, when I cannot explain it, it is tough.
And I cannot explain the cost increases I have seen a lot of
recently.
One medicine I take--I take eight a day--one of the ones I
take every day went up. When I went to get my new prescription
in January, it was $90 more than it was at the end of last
year.
I just said, ``How can that be?'' And the guy said this and
that and the other. But he said, ``Let me call you back.'' He
said, ``I will call you in the next hour and see if I cannot
find a better price.''
In an hour's time he had four prices for the same
pharmaceutical. If I did not use insurance, it was one price.
If I used cash, it was another price. If I took discounts, it
was another price. If you had coupons, it was another price.
I do not remember the name of all of them, but I know it
was very complicated, and it reminded me of my business. When I
sold real estate, the price of a mortgage was not just the
interest rate that you paid and the sticker price, but you take
the effect of discount points and rebates and other things that
go into the annual percentage rate return of the product, and
that is what you are doing with discounts and with rebates, I
assume. And it is going into the cost and ultimately into your
product, which caused me to ask this question: who sets the
discount and who sets the rebate?
Pardon my finger. We will start with you, Mr. Gonzalez.
Mr. Gonzalez. Thank you, Senator.
I think the best way to illustrate what you are describing
is to give you an example.
Senator Isakson. A short example, please.
Mr. Gonzalez. Okay.
Humira--we raised the price in 2019 6.2 percent. The actual
fall-through to the company, the realized increase in 2019,
will be .9 percent. So the part in between there is rebates
that have gone up and channel mix, primarily. But it does give
you some idea of the massive change that can occur between list
and realized price.
We raised the price to try to offset inflation, merit
increases that we give our employees, and increases in R&D----
Senator Isakson. So you set the discount or the rebate?
Mr. Gonzalez. Well, we negotiate with payers. So managed
care----
Senator Isakson. You are a supplier, though. So you
negotiate with the PBMs and those people? Is that right?
Mr. Gonzalez. Correct, and they negotiate aggressively.
Senator Isakson. Is that pretty much true, everybody, that
they are the major component between the end retail consumer
price and the origin of the product?
Mr. Gonzalez. Yes, Senator.
Senator Isakson. Well, that seems like some place we ought
to focus, because that is where the distorted numbers come in.
Johnson & Johnson--and I'm sorry. Janssen, is that right?
Is that the subsidiary?
Ms. Taubert. Yes, Janssen; correct.
Senator Isakson. In your testimony you talk about your
average list price of 8.1 percent up, but an average net price
change of only 4.6 percent. So, while your gross went up 8.6,
your net went down 4.6 in the same pricing period.
How does that happen? How does it not go up on the bottom?
Ms. Taubert. Yes, and in fact in 2018, our net price
actually declined 8.6 percent, so even more than that. So the
intermediaries in the system are very very effective
negotiators.
Senator Isakson. Tell me who the intermediaries are.
Ms. Taubert. Those would be the PBMs and the insurers.
Senator Isakson. And the insurance companies?
Ms. Taubert. Right, and they set the formularies for
patients.
Senator Isakson. And they are not the same, because they
are two different people?
Ms. Taubert. Yes, correct.
And so what they do----
Senator Isakson. Excuse me for interrupting Ms. Taubert. I
want to make sure I get all of this in. And I apologize. You
are a nice lady, and I am being ugly to do that. But I am
sorry.
Ms. Taubert. I am fine.
Senator Isakson. All right. We have the PBMs and we have
the insurance companies.
Ms. Taubert. Yes.
Senator Isakson. Is there anybody else between the
wholesale price by the manufacturer at the beginning and the
retail price it is sold for at the end, at the drugstore? Is
there anybody else that contributes to the cost, other than the
discount and the rebate?
Dr. Brandicourt. Several actors, Senator, in the supply
chain are rewarded on the listing price: wholesalers
themselves, and----
Senator Isakson. Is that a consumption bonus? Is that a
sales bonus? They are rewarded for doing what?
Dr. Brandicourt. Well, to be a wholesaler and distribute
our products. What we need to do in order to realign the
incentive is to get rid of the reward being based on a listing
price.
Senator Isakson. I have to stop, because the chairman is
mean and he will cut me off the next time.
So I will end by saying this. You answered my question, but
it does point out that the one person who is not benefiting
from the rebates, not benefiting from the cost negotiation, is
the customer. And we are here for the customer today. We
represent them. So we have to get to the bottom of this so we
can have something we can explain, and they can experience.
I apologize, Mr. Chairman.
The Chairman. I let the Senator go because he was echoing
my beliefs.
Go ahead, Senator Cardin.
Senator Cardin. Thank you, Mr. Chairman. And let me thank
all of our witnesses. I also want to say how proud I am of the
results of the pharmaceutical industry and the discoveries that
you have made, innovations that you have brought to market, the
impact you have had on quality of life and on cost, overall
cost of health care, by the discoveries that you have been able
to advance.
The challenge that we all have is, why should Americans be
shouldering the lion's share of the cost and burden of research
and development and bringing new drugs to market? You talk
about burden-sharing, you talk about the fact that there should
be a fair allocation on the global market--and by the way, also
within our domestic market, we know that a lot of people are
being denied access to these innovative drugs because of the
pricing mechanisms within the United States.
So let me try to drill down on those points. Really, am I
defending an administration policy? So let me break with my
normal tradition and talk about the international pricing
mechanism that the Trump administration is proposing that would
set target prices or international pricing indexes over a 5-
year period for Part B drugs pinned to the price in comparable
industrial nations, phasing it in over a period of time and
allowing a cushion for even higher prices in the United States.
So if, in fact, these drugs are already priced
competitively, that should not be a problem. But as I
understand it, there are so many drugs that we pay, American
consumers pay, a lot more for than consumers in other
industrial nations. So why not move towards a process in which
American consumers share a similar price as consumers in other
industrial nations in the world, particularly on the Part B
program? I think it could also be extended to Part D.
The only explanation I have heard is that in some
countries, it takes a little bit longer to get new drugs
admitted. We are not talking about new drugs. We are talking
here about drugs that already have an existing price mechanism.
Or do you support it?
Dr. Caforio. Senator, thanks for your question.
I did mention this in my opening remarks. So I am happy to
elaborate further. I think it is a very important point.
So we take the perspective that we should always start from
patient access to medicines.
Senator Cardin. I am going to try to drill down, because I
only have 2 minutes.
Dr. Caforio. Thank you.
Senator Cardin. So what is wrong with a model of comparing
U.S. prices to prices in other industrial nations?
Dr. Caforio. So 55 percent of new cancer medicines that are
available to American patients are not reimbursed in at least--
--
Senator Cardin. We are talking about where there is a
market price in another country, because if there is no target
price, there is no price to compare it to. So there has to be a
price in another country. So we are talking about drugs that
are commonly available.
Dr. Caforio. I believe, Senator, many of the most recently
introduced drugs are not available in----
Senator Cardin. Then that would not apply. If I understand,
it only deals with prices where there is a target price that
already exists. If the drug is not on the market, it is not
going to have a target price. But if the drug is on the market,
you have a target price, and as I understand it, that would
bring down the cost here in the United States.
Dr. Caforio. I believe, Senator, it would be very important
for us to be thinking about policies that continue to reward
innovation.
We do need your support to make sure that----
Senator Cardin. So you are basically saying we overpay on
available drugs so that you can make more profit from the
American consumer to underwrite R&D which benefits the global
community. That is basically, as I understand that point--to me
that is a disconnect in the pricing mechanism.
I want to ask, Ms. Taubert, you are the one who mentioned
the advantages of the free market in negotiations under Part D.
So let me just change the equation. Suppose you were on the
other side of the table. Why not allow the Health Secretary to
combine the entire Medicare market in order to negotiate a
larger market share to bring down costs for Medicare?
Ms. Taubert. Yes, so we really believe that open
competition and a free market are the right way to go for
patients.
Senator Cardin. But isn't market share that you can offer,
as a person seeking the cost, a driver for bringing down costs?
Ms. Taubert. So the PBMs and the insurers are
extraordinarily effective negotiators. And they do negotiate
now on behalf of Part D members quite aggressively.
In fact, I mentioned our $21 billion----
Senator Cardin. And my question is, is it not true that the
larger the market share, the better the price you are going to
get?
Ms. Taubert. The larger the market share, the better the
price? It depends on a number of factors, including the number
of competitors and the companies that are bidding to try to
get----
Senator Cardin. If you control more of the market, isn't
that going to bring down your price? I learned that in
Economics 101.
The Chairman. Answer the question, and then we will go to
Senator Hassan.
Ms. Taubert. Yes; I am not sure I understand the last piece
of that question.
Senator Cardin. With a larger consumer base on a drug,
because you represent all the Medicare market, are you not in a
stronger negotiating position? Yes, you are.
Ms. Taubert. I think conceptually you could be. I would say
that the PBMs and insurers are pretty darn effective right now.
The Chairman. Senator Hassan?
Senator Hassan. Well, thank you, Mr. Chairman. And I want
to thank you and Ranking Member Wyden for this hearing today.
I want to thank all of the witnesses for being here today
as well. A couple of observations; one is that breakthroughs
are not breakthroughs if people cannot afford the medicine that
produces the breakthrough.
Secondly, as you have all mentioned the importance of a
viable and predictable system, it has to be a viable and
predictable system for patients. And right now it is so
convoluted and so non-transparent that my constituents cannot
figure out what the price of their medication is going to be
day to day. And despite a wonderful staff, I feel like I need a
Ph.D. in prescription drug pricing to understand how the heck
this industry works. And that should not be the way we proceed
in this country to get these breakthroughs to people.
But I want to talk about a slightly different aspect of
your industry right now. We have been talking about drug
pricing, which is one part of how drug companies make money.
The other part is how you maximize sales.
So, Ms. Taubert, I would like to focus on how your company
maximizes sales for a particular class of drugs--opioids. Can
you define for me please, Ms. Taubert, what pseudo-addiction
is?
Ms. Taubert. I am sorry. I am not sure. I am not familiar
with that term.
Senator Hassan. Let me fill you in, then. Pseudo-addiction
is an unproven and dubious concept that asserts that certain
patients present signs of addiction because they were
prescribed insufficient doses of opioids. Those peddling this
pseudo-addiction concept say that instead of providing
addiction treatment when somebody shows the signs of addiction,
the doctor should increase their opioid doses. Even one of the
original doctors who pushed this theory now admits it was ``an
excuse to give patients more drugs.''
He has told us that Janssen promoted this made-up concept
of pseudo-addiction on a website that it approved and funded
that was called ``Let's Talk Pain.'' Since then, your company
has repeatedly said that your action ``in the marketing and
promotion of our opioid pain medicines was appropriate and
responsible.'' So, Ms. Taubert, how can you possibly claim that
promoting the theory of pseudo-addiction--the doctor should
prescribe more opioids to patients showing signs of addiction--
was appropriate and responsible?
Ms. Taubert. Senator, thank you so much for that question.
Abuse and addiction, particularly opioid abuse and addiction,
are very serious public health concerns, and we recognize the
impact on the American public.
Senator Hassan. So then the question is--and again like
everybody else, I have only a few minutes here. The question
is, looking back at what your company did promoting pseudo-
addiction--an unproven theory that was just used to maximize
sales of a deadly drug--why is that something that you are
calling appropriate and responsible?
Ms. Taubert. So, I am sorry. I am not familiar with the
term.
What I can say is, on behalf of our company, opioids
represent less than 1 percent of our product.
Senator Hassan. All right, let me stop you right there,
because my constituents do not care about the percentage. They
care about the behavior to maximize sales in an industry.
Do you know how many Americans died from drug overdoses in
2017?
Ms. Taubert. Far too many.
Senator Hassan. It was 70,237. In 1 year, more Americans
died from drug overdoses than died fighting the entire war in
Vietnam. And the vast majority of those overdose deaths, about
50,000, were from opioids.
My constituents are dying. Nearly 500 people in New
Hampshire died from overdoses last year. And nearly 500 the
year before that. And companies like Janssen and Purdue Pharma
fueled this epidemic, employing deceptive and truly
unconscionable marketing tactics despite the known risks so you
could sell more drugs to maximize your profits.
And now you are refusing to take responsibility for your
company's role in this crisis. So one more time, do you truly
think that Janssen's opioid marketing practices were
appropriate and responsible, or will you finally take
responsibility for your company's role in helping create this
crisis that is killing more than 100 Americans every day?
Ms. Taubert. Everything that I have seen leads me to
conclusively believe that everything that we have done with our
products, when we promoted opioid products, which we stopped
marketing a long time ago, was very appropriate and
responsible.
However, that being said, we do believe that we have a
leadership position to take in helping with this. And so we are
doing a number of things in terms of mothers and babies, and
physician and patient education to help----
Senator Hassan. So let me--again----
[Simultaneous speech.]
Ms. Taubert. We recognize we all play a part in trying to
help this, because we realize that----
Senator Hassan. Our time is done, but right now it is hard
for me to take the industry's goal here as promoting good
health seriously when its behavior to maximize sales of opioids
created an epidemic.
The Chairman. Senator Lankford?
Senator Lankford. Thank you, Mr. Chairman.
Thank you all for being here. And there are people alive in
the United States, around the world right now, because of your
companies and the work they have done with R&D along with the
National Institutes of Health. And I fully acknowledge that,
and I am grateful to the people who are researching and working
right now, who are not watching this hearing because their face
is in a microscope actually going through things to be able to
research today and what they are doing.
With that said--it is all of us who acknowledge that. We
are trying to figure out the issue on drug pricing, because
people in my State, whether they are on insulin or whether on
Parkinson's drugs, or whether my own family or other people in
my neighborhood, it is a very significant issue for them to try
to figure out how to be able to manage this. So we have to get
to the bottom of how we manage this.
All of you have mentioned that the rebate issue has been a
problem and that insurance companies and PBMs are very
effective negotiators. Part of the challenge of this is, health
insurance companies pay their PBM based on the quality of their
negotiation skills, cutting a price off the list price. And so,
if a list price is higher and a rebate is higher, that also
gives preference to them. So the difficulty is, as you raise
list price and the rebate gets larger, the insurance company
gives that preference, making it harder for biosimilars. Am I
tracking this correctly?
So the challenge that we have with this is, how do we
figure out how to break this down? Because we have insurance
companies, PBMs, your companies that are creating the list
prices, and then the biosimilars trying to be able to get into
this.
So, Mr. Frazier, you mentioned this, in particular about
biosimilars and the difficulty of trying to be able to break
into the market. Would you identify why it is hard for
biosimilars to get into the market, which are inherently less
expensive?
Mr. Frazier. I would make two suggestions very quickly,
because I know you only have a little bit of time here. One is,
I think we have to educate physicians and other health-care
providers about the value of biosimilars. I think, secondly, it
would be very helpful if we could relieve patients of their
obligation to pay copays for the cheaper biosimilars.
Those would be two specific recommendations that I would
make.
Senator Lankford. Thank you. I appreciate that. For the
Part B drugs, those physicians are paid a percentage of the
drug costs. So a biosimilar, when it comes into the market in
the Part B world, is, on its own, less attractive to a
physician because a physician gets a higher percentage amount
prescribing the more expensive drug, which then feeds down to
the patient and the taxpayers, right?
Mr. Frazier. That is correct.
Senator Lankford. How do we break that chain?
Mr. Frazier. I think that we--there are many ways that we
would have to look at it. I do not have a specific suggestion
here.
I do think educating physicians is important here, and I
think relieving patients, but we also have to look at the
incentives.
Dr. Bourla. Maybe I can----
Senator Lankford. Dr. Bourla, please jump in, because you
had mentioned this in your testimony as well.
Dr. Bourla. I did, Senator, and thank you for giving me the
opportunity.
Let me give you a statistic that I think will present the
magnitude of the problem. Here in the U.S., the penetration of
biosimilars is much lower than in other places, but it is
disproportional to different parts of the U.S. health-care
system.
For example, in open systems, systems where the decision-
maker is a PBM, one biosimilar or two has a market of 5 percent
in the U.S. In closed systems, in systems like Kaiser, for
example, with their integrated health-care systems--where the
one who decides has the whole cost of the health-care system in
its interest--we have 73 percent. Five percent versus 73
percent for the same product.
I agree with what Mr. Frazier said, that we need to create
incentives, but I would add also that we need to break this
rebate trap that creates significant disincentives for
providers, and the health-care system, and insurance companies.
Senator Lankford. Does anybody else want to jump in on
that?
Dr. Brandicourt. I can give you an example, Senator.
The insulin market has a reputation of not being very
competitive. In fact, it is, and we have biosimilars which have
reached the market and have grabbed a very significant market
share.
We believe that when insulin will not be treated as a drug,
but will be considered a biologic and can be submitted to
biosimilar regulation in 2020, the biosimilar market share and
penetration will be even higher.
Senator Lankford. Thank you.
My State, in particular, is working very hard on our
Medicaid side, working on value-based pricing. I know that is
something that several of you have mentioned before. It is the
grand challenge of not pricing a drug based on the fact that it
would be more expensive to do surgery and so we want to be
slightly under the cost of surgery.
We do have to be able to break through that model. Of
course surgery would be more expensive than most of our
treatments, but I think there is a benefit that we continue to
experiment with if the drug is effective and we have a reducing
price on it. And we can get a chance to be able to work through
that, as we have done in our State.
Mr. Frazier. We would support that.
Senator Lankford. Well, we will continue to be able to work
through other creative mechanisms. At the end, we cannot just
have the taxpayer pay more and the consumer pay less, because
that is really the consumer still paying. It just moves it to
another spot.
Mr. Chairman, thank you.
The Chairman. Senator Cassidy?
Senator Cassidy. First, think of innovation. As a doctor, I
have seen cures for hepatitis C and therapies to control HIV,
other inflammatory conditions, cancers that 30 years ago, when
I graduated from medical school, were either death sentences or
were a ticket to a lifetime of morbidity and complications. So
I thank you for that. But I also say that some of my patients
could not afford the medicine. And for them, it is as if the
innovation never took place. And that is one concern.
Secondly, another concern is, I think in some cases we do
not have value. Now, Ms. Taubert, you suggested that PBMs are
very effective negotiators. One drug that I want to bring up is
Duexis, which is a combination of over-the-counter generic
ibuprofen and Pepcid. Now, if I were to take this--and this is
not the cheapest I could find it--in the doses that are used
for Duexis, it would cost me 200 bucks a month. But it lists at
over $2,400 to $2,600 a month.
Now, that does not seem like very good negotiations on
behalf of the PBM. And if the taxpayer is paying that money for
something which over the counter is 200 bucks a month, and we
are paying $2,600 a month, it is almost as if the taxpayer has
``stupid'' written on their face, which they should not. That
is unfair.
This is not your medicine, but I use it to make the point
that, right now, Medicare has a very limited ability to
negotiate based on marginal value. And I think that is one of
the fundamental problems in this.
So that said, all things considered, since Medicare does
have this very low ability, Ms. Taubert, do you think that
Medicare should have the ability--if the PBM's negotiation does
not work--should Medicare have the ability to negotiate based
on value?
Ms. Taubert. So we are very supportive of the notion of
value-based contracting and results and----
Senator Cassidy. This is a little bit different though,
because we have been describing, on value-based contracting, is
the cancer cured or not, is the hepatitis C cured or not? This
is, my gosh, you are taking two generic medicines and charging
ten times what they would cost over the counter.
Ms. Taubert. Yes, and I agree that that example does not
make any sense.
Senator Cassidy. So is it reasonable then to ask that
Medicare would have the ability to make some sort of judgment
based upon relative value of a therapy?
Ms. Taubert. I think, as we have talked about, if the PBMs
are very effective in negotiating, we do not know that the
government would be as effective in negotiating as the
professional negotiators.
Senator Cassidy. We do not know. I agree with that, but on
the other hand it does--I have limited time. I do not mean to
be rude. I do apologize. But there is this kind of shining
example of where the PBM is not an effective negotiator. Yes,
sir, Mr. Frazier?
Mr. Frazier. I think this is where Chairman Grassley's
opening statements about transparency come in. I think one of
the keys of transparency is, it empowers patients and it
empowers other payers to actually make informed choices about
which of those two medicines makes sense.
Senator Cassidy. Now, let me ask, because someone brought
up the fact that Humira is now sold at an 80-percent discount
in Denmark. And there is a Bernstein analysis which states that
AbbVie still makes a profit because marginal cost in
manufacturing is only about 5 percent of the manufacturing.
So would this same entity have the ability to look not just
at value, but at comparable drugs and at that which would bring
value, because clearly biosimilars have had a much greater
penetration in Europe, and the United States continues to pay
top dollar for the same class of drugs. Something is
fundamentally broken in our system when the Danes get an 80-
percent discount and we do not.
Yes, sir?
Mr. Frazier. I think we have to look at the way in which
generic penetration happens outside the biosimilars market.
When a drug goes off-patent----
Senator Cassidy. Well, hang on, Mr. Frazier. I am sorry. I
just get limited time, and I am going to hold you on that.
Okay, I do not mean to--one of the things I have heard is that,
if there is some limit on that profit, it may have a negative
impact upon R&D. I think that has been a message here.
But, Dr. Brandicourt, France has a committee on
transparency which evaluates the relative added clinical
benefit of a new drug. Price is then negotiated based upon that
added benefit as well as other drugs in the market.
Is it safe to say that your company has found that it still
pays to innovate and to do R&D in France and to offer them
access to the best cutting-edge drugs?
Dr. Brandicourt. As a global company, we do have R&D in
France. However, I would not use the French system as the
benchmark of a good system.
Senator Cassidy. But they do have access to these--I have
limited time. I am sorry. They do have access to these drugs?
Dr. Brandicourt. Well, that is a very good point. Some
drugs are not put on the market because you do not get to the
right pricing and therefore the right----
Senator Cassidy. But if I am--I will finish with this. I do
not mean to be rude. I apologize.
In the international pricing index, we may quibble about
the details, but if the U.S. would be paying 1.3 times a market
basket of developed countries--a Germany, a France, a Canada,
not smaller countries--we would still be paying more than they,
but it would still have some relationship to reasonableness.
And right now, it seems as if Medicare--in the absence of the
ability to judge value--is almost a price taker when it should
not be, as the largest purchaser.
Dr. Brandicourt. You would ask countries where there is no
negotiation, where prices are imposed, to set up your U.S.
pricing. And I do not think that would be good policy.
Senator Cassidy. It is imposed now, but it is imposed from
the other side.
The Chairman. Of the people who are still here, Bennet
would be next, and then Whitehouse, and then Cortez Masto.
Go ahead, Senator Bennet.
Senator Bennet. Thank you, Mr. Chairman. Thank you so much
for holding this hearing.
There is not a town hall in Colorado where I do not hear
how expensive drugs are forcing people to choose between life-
saving treatments or food and utilities. In our last hearing
here, we heard from a mother whose son ate once a day in order
to ration his insulin, because the full cost of the monthly
treatment was $1,700. I do not think anybody here understands
how that could be the case, but it is the case.
And there has been a lot said here today about the
important research and development that is going on in this
country. And I, for one--and I know others share this view--
want to keep that in the United States. Having said that, I am
trying to understand how Federal spending goes into
prescription drug development, distribution, treatment, and
pricing and yet Americans cannot afford their medications.
The estimates of annual spending on prescription drugs
range from $320 to $480 billion a year. The fact that we cannot
even get a more precise number than that tells you something
right off the bat, but those numbers include almost $100
billion in Medicare Part D spending never paid for. Of that,
$25 billion is in Medicare Part B. Medicaid spends almost $60
billion on prescription drugs. This is what the taxpayer spends
every year on prescription drugs.
DoD and VA spending is about $11 billion. That number alone
dwarfs the R&D budgets of some of your companies. Over 6
years--slightly different point--but over 6 years between 2010
and 2016, more than $100 billion was spent in NIH funding
toward research that contributed to drug patents. Between $1
and $2 billion is claimed annually through the orphan tax
credit for drugs that treat rare diseases. Another $1 billion
is annually claimed through the research and development tax
credit. About $12 billion dollars is claimed annually through
the direct-to-consumer advertising tax credit.
I would ask you guys if I missed anything, but I think that
is a pretty complete list of what we have. Yet notwithstanding
that almost $500 billion, half a trillion dollars--by the way
Medicare, you know, to spend all that money in Medicare, we are
spending $2 for every dollar we are collecting. That delta is
largely because of drug prices in the unfunded part of Medicare
Part D.
And here is what Coloradans have recently reported. In a
recent survey on high drug prices, 22 percent did not fill a
prescription, and 20 percent reported cutting pills in half or
skipping doses.
Seventy-four percent believe drug companies are charging too
much money, and 91 percent believe the government should
authorize the Attorney General to take legal action to prevent
price gouging or unfair prescription drug price hikes--over 90
percent.
And that does not necessarily give you their legal
judgment, but that is how keenly they are feeling the problem.
And 90 percent believe the government should require drug
companies to provide advance notice of price increases and
information to justify those increases.
So, I would ask all of you, or anybody who would care to
answer, this question: how do we explain to our constituents on
the one hand that we have this massive outlay of Federal funds,
it is their taxpayer funds, and the on the other hand, the
drugs they are buying are not affordable?
And I realize there are all kinds of layers to this. I
accept that. You know, there are the higher co-pays that you
guys mentioned earlier from the insurance companies. That is a
huge issue too.
But I think that in a world where opacity or opaqueness has
been, from the public's point of view, a business model for
everybody in health care, whether it is the Federal Government
or drug companies or insurance companies or doctors, nobody
knows what anything actually costs. Nobody knows what anything
will pay.
My question, I guess, is, how do we better align the
incentives here so that that huge outlay of money every year
comes with affordable drugs at the end of the process?
Mr. Gonzalez, thank you.
Mr. Gonzalez. Senator, I can just tell you there is
probably not anybody at this table who does not agree not a
single American should go without drugs that they need. And I
can tell you, that is the case at AbbVie.
We do a lot of things to try to provide drugs for patients
who cannot afford them. But there are certain patients whom we
are unable to do that for based on the laws and the
regulations, and in particular, most of Medicare Part D falls
into that situation.
And so I believe fundamentally we have to do two things.
There are substantial discounts or rebates that are going into
this system. Take Humira as an example. In the United States,
there are rebates or discounts on that product that range from
87 percent down to 26 percent. Okay, and it is the Federal
Government that gets the highest form of discount or rebate on
Humira, even though it represents a relatively small percentage
of the volume, less than 20 percent of the overall volume.
Now that does not mean that we could not do more. But what
we are asking is, we do believe that there is a situation now
where the co-pays for patients are such that it is extremely
difficult for them to afford it. And what we are asking for
is--``we,'' meaning AbbVie and I am sure others here, would
like to do more. There is more we can do to help patients
afford their medicines, but we have to eliminate some barriers
that are blocking that.
Today we give away to 81,000 patients free drugs; half of
those are Humira. Of those Humira patients, half of them are
Medicare Part D. They are patients who make less than 500
percent of poverty, so they make less than $128,000 per year
for a family of four.
Those patients we can provide free drug for. Anybody above
that, we cannot. It is considered an inducement.
And when you look at the copay for a drug like Humira,
commercial patients, Medicaid patients, the low-income subsidy
patients in Medicare, pay less than $100 per year of copay for
Humira. A standard Part D patient pays $5,500. They make
$26,000, so they cannot afford it.
Senator Bennet. I apologize. I know I am out of time. Thank
you.
The Chairman. Senator Whitehouse?
Senator Bennet. Could I, Sheldon, just make one point,
which is, I think what we ought to be doing is figuring out how
people do not have to cut their prescription drugs in half, and
that would be a worthy goal for this committee and the people
on this panel.
The Chairman. Senator Whitehouse?
Senator Whitehouse. I would like to ask about a particular
segment of the pharmaceutical market. Chairman Grassley opened
his remarks by talking about patients taking a drug that has no
competition as being a cause for concern.
Mr. Frazier, your testimony included the statement that
price gouging by those who jack up the prices of off-patent
drugs that have no competition is a problem. Let me ask if
there is anyone on this panel who disagrees, who disagrees that
there are de facto off-patent monopolies now in the
pharmaceutical market? Does anybody disagree with that as a
fact?
Mr. Frazier. I do not disagree.
Senator Whitehouse. In fact it is true.
Mr. Frazier. There are.
Senator Whitehouse. There are.
Mr. Frazier. That is what I was saying.
Senator Whitehouse. And indeed, is it also not true that
sometimes these off-patent monopolies are used to impose
monopoly pricing?
Mr. Frazier. It is true, and I think the most egregious
examples that we have seen recently have been exactly in that
situation.
Senator Whitehouse. Does anybody disagree with that?
Everybody agrees.
Now are there, among those entities that are in that
category with off-patent monopolies that are extracting
monopoly pricing by virtue of that, entrants who are not even
really in the pharmaceutical industry?
Mr. Frazier. Absolutely there are.
Senator Whitehouse. They invest nothing in R&D.
Mr. Frazier. Exactly.
Senator Whitehouse. They do not even come from the
pharmaceutical industry.
Mr. Frazier. Yes.
Senator Whitehouse. They are more or less corporate raiders
who have bought something in order to jack up prices and take
advantage of monopoly rents. Correct?
Mr. Frazier. There are many people like that.
Senator Whitehouse. There are many people like that. Does
anybody disagree that that is a feature right now within the
pharmaceutical market? Everybody agrees?
Dr. Bourla. And I would add also, Senator, that they are
not allowed to be part of the Pharma Association.
Senator Whitehouse. So here is the problem: it is not
difficult, in my view as a lawyer of many years and a
prosecutor of many years, to prove the existence of a monopoly.
We have been proving the existence of de facto monopolies in
courtrooms and in regulatory proceedings for decades.
So we can identify where these monopolies exist, even if
you let all the ties go to the runner so that, wherever there
is a real question, you throw that one out. There still would
remain a significant population of entities where it is beyond
dispute that they are pricing based on monopoly power. And as I
look around, there is no place to address that. There is no
organization in the Federal Government that is taking an
interest in that, and it is the scandal, I view, of the
pharmaceutical industry. And you guys take a hit for it.
Here is the problem: when we try to do anything about that,
the people you pay to lobby us here in Congress come out and
say, ``Nope, we cannot do anything like that. That might look
like price control.'' We are not interested in taking any look
at this monopoly problem in your industry. I should not even
say it is in your industry, because I think a lot of these
people are raiders into your industry who are not really part
of your industry. They do not really develop drugs.
I see a lot of head-nodding here. So help us solve at least
that problem. You know, there are lots of other problems that
we are going to have to look through with your pricing. Help us
solve at least that problem. Turn off your lawyers and your
lobbyists as antagonists when we try to solve that problem.
Mr. Frazier. We will. Senator----
Senator Whitehouse. In fact, switch them on and say, let us
figure out how we deal with these modern monopolists who are
not even really in the pharmaceutical industry.
Mr. Frazier. I could not agree more. These people are at
best tone-deaf, at worse abusive.
I would also point out that there are companies here--I
know, for example, my company. There is a very important cancer
drug called TICE BCG. It was an invention of Merck. It has been
off-patent for many many years. It is an incredibly essential
drug for bladder cancer patients.
A number of companies that were making it went out of the
business. And so now we have had to double supply. Over the
last nearly 12 years the cost of that drug has increased by
$16. That is not how we make money at Merck. We make money at
Merck by inventing new drugs that did not exist before.
It is those people, I think, that contributed to the
villainizing of an industry. The public cannot distinguish
those people from the research-based companies.
Senator Whitehouse. You all say that here. There is a lot
of head-nodding here. There is a lot of agreement here.
When your lobbyists come, everybody is in and they are not
going to let anybody lose in all of this. We have to at least
cut off these people.
Mr. Frazier. Thank you for telling me that, because I never
knew that our lobbyists were opposed to that.
Senator Whitehouse. We have no support for working against
these monopoly raiders.
Dr. Brandicourt. Well, Senators, the message is very clear.
And we are going to take that very seriously as a task.
The Chairman. Senator Brown came back. So you will go ahead
of the Senator from Nevada.
Go ahead.
Senator Brown. Thank you, Mr. Chairman. Thank you for doing
this hearing.
Thank you all for joining us. I want to thank Senator
Hassan for her questions on opioids. Eleven people a day die in
my State from opioid addiction, and there is a responsibility
shared more widely than we sometimes say.
I so appreciated Chairman Grassley's ``yes'' or ``no''
questions, and I appreciated the seven of you going along with
his ``yes'' or ``no.'' And I would like to ask a series of
``yes'' or ``no'' questions, and please keep it to ``yes'' or
``no.'' They really are ``yes'' or ``no'' questions.
Mr. Gonzales, let's start with you. Is it true that the
pharmaceutical industry benefits from U.S. taxpayer-funded
research? ``Yes'' or ``no''?
Mr. Gonzalez. It is, yes.
Senator Brown. Across, each of you.
Mr. Soriot. Yes.
Dr. Caforio. Yes.
Ms. Taubert. Yes.
Mr. Frazier. Yes.
Dr. Bourla. Yes.
Dr. Brandicourt. Yes.
Senator Brown. Okay. Thank you.
Is it true that no other nation invests more taxpayer
dollars in basic research that directly and indirectly benefits
the industry?
Mr. Gonzalez. Yes.
Mr. Soriot. Yes.
Dr. Caforio. Yes.
Ms. Taubert. Yes.
Mr. Frazier. Yes.
Dr. Bourla. I am not sure I understood the question.
Senator Brown. Is it true that no other nation on earth
invests more taxpayer dollars in basic research?
Dr. Bourla. Yes.
Dr. Brandicourt. Is it proportional to GDP, Senator?
Senator Brown. I am not asking that, but that is close
enough. Thank you.
Is it true that the U.S. Government allows drug companies
the longest period of exclusivity on biologics?
Mr. Gonzalez?
Mr. Gonzalez. I believe that is true.
Mr. Soriot. I believe that is true.
Dr. Caforio. I believe that is true.
Ms. Taubert. Yes.
Mr. Frazier. Yes.
Dr. Bourla. Yes.
Dr. Brandicourt. Yes.
Senator Brown. We know Medicare limits prices with doctors
and hospitals. Is it true that Medicare cannot negotiate to
lower prices with drug companies?
Mr. Gonzalez. That is true directly.
Mr. Soriot. Yes.
Dr. Caforio. Yes.
Ms. Taubert. Yes; other agents work on their behalf to
negotiate, but they do not negotiate directly.
Mr. Frazier. Yes, they cannot negotiate directly.
Dr. Bourla. Yes.
Dr. Brandicourt. Yes.
Senator Brown. Thank you.
Is it true U.S. taxpayers subsidize pharmaceutical
advertising and marketing activities through the tax code's
business expense deduction?
Mr. Gonzalez?
Mr. Gonzalez. Yes.
Mr. Soriot. Yes.
Dr. Caforio. Yes.
Ms. Taubert. Yes.
Mr. Frazier. Yes, no different from any other advertising,
but yes.
Dr. Bourla. Yes.
Dr. Brandicourt. Yes.
Senator Brown. Thank you.
We note the United States is the world's largest market for
pharmaceuticals. Is it true that we pay the highest--in the
overwhelming number of cases, is it true that we pay the
highest drug prices in the world?
Mr. Gonzalez?
Mr. Gonzalez. The average government price would--that
would not be the case.
Senator Brown. No, that we as Americans individually pay
the highest drug prices in the world?
Mr. Gonzalez. As an average, that would be true.
Mr. Soriot. I am not sure that it would be true, Senator,
because the generic prices are some of the lowest in the world,
and government prices, for many of our drugs even before patent
expiry, are sometimes as low as Europe or lower.
So on average, probably it is true, but there are many many
different kinds of----
Senator Brown. I know there are exceptions. I am looking
for an average.
Dr. Caforio?
Dr. Caforio. Yes, on average I would say.
Senator Brown. Ms. Taubert?
Ms. Taubert. I would say that the list prices are higher,
but the net price in the United States is more comparable to
much of the pricing outside the U.S.
Senator Brown. Mr. Frazier?
Mr. Frazier. Yes, outside Medicaid and other things, yes.
Senator Brown. Okay.
Dr. Bourla. Nine out of 10 products in the U.S. are
generics. So the pricing of the generic products is much lower
in the U.S. than other countries.
Senator Brown. Yes, but generics----
Dr. Bourla. But you are right about branded----
Senator Brown. Do not confuse generic numbers of drugs sold
with cost in the aggregate? Your answer?
Dr. Bourla. But nine out of 10, I am telling you--you are
right that in the innovation, the prices outside the U.S. in
many cases are much higher.
Dr. Brandicourt. So I would agree with that: patented
drugs, yes, generics, no.
Senator Brown. Okay. Thank you. Last question.
Is it true that drug manufacturers set the--what Ms.
Taubert talked about--list prices? Is it true that you, the
drug manufacturers, set those list prices?
Mr. Gonzalez. That is correct.
Mr. Soriot. That is correct, but of course, there is a
negotiation that takes place with PBMs and insurers about the
price and the rebate level.
Senator Brown. Dr. Caforio?
Dr. Caforio. It is true for list price, but the delta
between list and net price is the highest in the U.S.
Senator Brown. Ms. Taubert?
Ms. Taubert. Correct. Yes, we set the list price.
Senator Brown. Mr. Frazier?
Mr. Frazier. Yes, we set list price.
Senator Brown. Dr. Bourla?
Dr. Bourla. Actually, I would not agree that we set the
list price. It is the result of a major negotiation. And I have
to say that the problem in the U.S. health-care system it is
that everything is geared around list price, a lot of
incentives, which creates a hydraulic effect for the list
prices to go down.
I would be very happy to have much less list prices and the
same net.
Senator Brown. Dr. Brandicourt?
Dr. Brandicourt. Ultimately, we set the listing price.
Senator Brown. Okay. Thank you.
So taxpayers subsidize your research, subsidize your
marketing, and you continue to raise drug list prices on them.
The median income of a person on Medicare is $26,000 a year,
while the average annual cost for a single specialty medication
was more than $52,000 in 2015. Americans cannot afford to pay
for prescription drugs that cost more money than they make in a
year. We cannot continue to give big pharma the blank check
that you have had to pay for high-priced prescription drugs.
But I guess it is not surprising that big drug companies
take all the taxpayer money they can. What is so troubling is
that this Congress continues, because of the lobbyists that
Senator Whitehouse talked about and other pressures, that this
Congress continues to allow you to do so.
Thank you for answers.
The Chairman. The Senator from Nevada.
Senator Cortez Masto. Thank you for being here. Thank you,
Mr. Chairman and Ranking Member, for this important hearing,
one of four.
Let me follow up on Senator Brown's line of questioning. Do
any of you invest more in R&D than you spend on marketing and
administration? If we could start ``yes'' or ``no'' to the
right here.
Dr. Brandicourt. No.
Dr. Bourla. No.
Mr. Frazier. Spend more on R&D versus marketing?
Senator Cortez Masto. More in R&D than you spend on
marketing and administration. Do you invest more in R&D than
you do on marketing?
Mr. Frazier. On marketing, but not if you include general
administration, facilities, and all of that stuff. But yes,
more than marketing.
Senator Cortez Masto. Okay.
Dr. Bourla. I would correct my answer also if it is only
marketing. Yes, we spend more on R&D.
Senator Cortez Masto. Let us just do marketing.
Dr. Brandicourt [indicating agreement with Dr. Bourla].
Ms. Taubert. Yes, we spend 86 percent more on R&D than we
do on sales and marketing.
Senator Cortez Masto. Okay.
Dr. Caforio. Yes, we do more on R&D.
Mr. Soriot. Same, more than marketing, but excluding
administrative costs.
Mr. Gonzalez. Significantly more in R&D than sales and
marketing.
Senator Cortez Masto. But if you included administration
with the marketing, that would be the reverse. Is that correct?
Mr. Gonzalez. That is correct.
Senator Cortez Masto. Yes from the rest of you?
Mr. Frazier. It is about tied at Merck.
Senator Cortez Masto. Okay.
So let me just ask this question. Apart from New Zealand,
nowhere else in the world will you see drug ads on television--
and I have asked this question for some of you. My
understanding is--the answer that I have been given is that you
maintain that television ads are a critical public health tool
that helps patients identify their symptoms and seek treatment.
Would you all agree with that? Is that a ``yes''? ``No''?
Why do we have television ads when it----
Dr. Brandicourt. Yes, you are right.
Senator Cortez Masto. Is that why? Is that a ``yes''?
Dr. Brandicourt. Yes.
Dr. Bourla. Yes.
Mr. Frazier. Yes.
Ms. Taubert. Yes.
Dr. Caforio. Yes.
Mr. Soriot. Yes.
Mr. Gonzalez. Yes.
Senator Cortez Masto. Okay. So if you maintain that
television ads are a critical public health tool, then how can
that be if our health outcomes are not significantly better
than in those countries where it is outlawed?
Dr. Bourla. Thank you, and you are raising a very good
point.
I think that the health-care outcomes and life expectancy--
there are a lot of factors that influence them. For example,
exercise, diet, lifestyle, and I feel that our Nation needs to
improve a lot in many of these cases. But I can assure you,
Senator, that if you get cancer or another serious disease, you
want to be treated in this country.
Senator Cortez Masto. Okay.
Dr. Bourla. There is no comparison.
Senator Cortez Masto. All right. So let me jump back then
to this discussion on authorized generics. And I am trying to
understand this, I think, along with all of my colleagues, to
address how we reduce the cost and get the drugs in the hands
of the people who need them--where the R&D came in, where they
were created--for individuals who actually need the drugs.
I want to ask about the concept of authorized generics.
Those, as you know, are the drugs that are identical to the
brand, manufactured by the brand, but marketed without the
brand on its label.
Yet the companies, my understanding is, keep selling the
higher-cost brand drug to consumers who, according to press
reports, do not realize that the same product from the same
company is available at a better price.
All of you manufacture authorized generics to maintain your
market share once your patent expires. Is that true?
Dr. Brandicourt. No.
Senator Cortez Masto. That is not true?
Dr. Bourla. We do have authorized generics.
Dr. Brandicourt. We do have authorized generics, but do not
do it with the goal that you just highlighted.
Senator Cortez Masto. So you do have authorized generics?
Do all of you have authorized generics?
Mr. Frazier. For some brands.
Senator Cortez Masto. Okay.
Ms. Taubert. Very selectively.
Dr. Caforio. Very selectively.
Mr. Soriot. We do not.
Senator Cortez Masto. You do not?
Mr. Gonzalez. I do not believe we do.
Senator Cortez Masto. You do not have authorized generics?
So for those of you who have authorized generics, explain to
me, if you do have those, why do you continue selling the
brand?
Mr. Frazier. Okay, so in our case when we have had
authorized generics, we have allowed a third-party to bring a
generic product to market. The issue that you are really
getting to, again, is the issue that Senator Cassidy talked
about, which is transparency.
At the end of the day, if patients really understood what
their options were, they would not make these choices. But we
have an opaque system, which is something that I think we have
to change. We have to empower patients to be able to choose the
cheapest medication. And Merck strongly supports generics.
What I said in my introduction is, we will never use
coupons when there is a generic.
Senator Cortez Masto. What are you doing to empower the
patients? What are you doing to empower the patients to
understand that the generics are out there?
Mr. Frazier. It is very hard. We do not connect with the
patients in all those situations. That is why there is
legislation saying, for example, that pharmacists must tell
patients at the counter what the cheapest alternative is for
them at the counter. We do not----
Senator Cortez Masto. So you rely on others to tell----
Mr. Frazier. Yes. We do not meet them at the counter,
Senator.
Senator Cortez Masto. Okay. Let me ask one final question,
because I am running out of time here. I want to get a sense
from all of you what types of policies you could support. I
have heard some of those, but let me ask you this. Democrats
have proposed to require manufacturers to submit advanced
justification for price hikes that outpace inflation and make
that information public.
Given that many of you have already committed to tapering
price hikes, is this something you could support, ``yes'' or
``no''?
Dr. Brandicourt. We can support such legislation, yes.
Dr. Bourla. Yes.
Senator Cortez Masto. Thank you.
Dr. Caforio. Yes.
Ms. Taubert. We are very supportive of increased pricing
transparency. Advance notification can cause problems in the
supply chain and could cause outages for certain States. So we
are very supportive of the notion of transparency. Advance
notification can be problematic.
Senator Cortez Masto. Okay.
Dr. Caforio. We disclose our price increases.
Senator Cortez Masto. Okay.
Mr. Soriot. We support it.
Mr. Gonzalez. We support it, but we would like to see
consistency. As you probably know, California has that right
now, but if we had a consistent standard that we operated with,
that would certainly be helpful.
Senator Cortez Masto. Thank you. Thank you very much.
The Chairman. Senator Daines?
Senator Daines. It is very clear from what is going on
today that there are ultimately not any silver bullets to cure
the high cost of prescription drugs. I am pleased that we can
have this discussion. My hope is that we can truly find some
ways to incentivize the system here to deliver a lower price,
ultimately, for the consumer as well as incentivizing
innovation.
As manufacturers, you are responsible for setting this list
price, this ethereal list price. But the more I hear what is
going on here today, I am convinced we probably should call
this the asking price. I am sure ``list price'' is a bit of a
misnomer, because after hearing all about coupons, rebates,
discounts, the pricing volatility--yes, I spent 13 years at
Procter and Gamble, and once upon a time we drove a business
with a lot of coupons, with rebates, pricing incentives. It was
a very elastic pricing model. Oftentimes, we had a high-margin
business. There is elasticity in the pricing, and you are an
example of that.
I spent 12 years in the cloud computing business after
that. The margins were even higher. We saw great volatility in
pricing and elasticity in pricing. We eventually, years ago of
course, went to the everyday low price, EDLP, model. It, again,
may or may not apply to Pharma. But it was just trying to take
out all of that in between the manufacturer and the consumer
nonsense that was going on, that was lacking transparency.
And ultimately, I think the consumer was not winning in
that equation, because the prices--they were not seeing really
the true everyday low price. There are a lot of perverse
incentives in the system today, as best I can tell. So my
question is, who pays list price?
Dr. Brandicourt. Unfortunately, the patient at the end, at
the pharmacy counter, is probably one of the few paying the
list price.
Mr. Frazier. There is a small percentage of people who have
no insurance who could actually be charged the list price.
Senator Daines. So the people who can afford it the least,
arguably, are paying list price.
Mr. Frazier. Senator, that to me is what I meant by saying,
in some ways the reimbursement system here is regressive. The
people who can least afford it are paying the most.
Senator Daines. Do you think that that is a good system?
Mr. Frazier. I do not. I can tell you that is, to me, the
biggest problem that we have as a country, that we now have a
system where the poorest and the sickest are subsidizing
others.
Senator Daines. Okay. So with insurance companies that now
own the PBMs and the supply chain from the time you list the
price until the consumer eventually gets it, is it fair to say
the list price is really a starting point for, then, a
negotiation?
Mr. Frazier. Yes.
Senator Daines. Does anybody disagree with that premise?
Ms. Taubert. No.
Senator Daines. So what are some of the incentives? And
maybe we will start with Mr. Frazier. What are the incentives
that contribute to high list prices that are being paid by
those who can afford them least?
Mr. Frazier. The real answer, Senator, is, if you went back
a few years ago when we negotiated to get our drugs on
formulary, our goal was to have the lowest copay for patients.
Today the goal is to pay into the supply chain the biggest
rebate. And so that actually puts the patient at a
disadvantage, since they are the only ones who are paying a
portion of the list price. The list price is actually working
against the patient.
Senator Daines. So why do we have a system today where you
all are setting--I will just say very very high list prices,
which is our starting point for negotiation? Why?
Dr. Brandicourt. Senator, we are trying to get formulary
position with those high list prices, high rebates. It is a
preferred position. Unfortunately, the preferred position does
not automatically ensure affordability at the end of the day.
Mr. Frazier. And, Senator, if you bring a product to the
market with a low list price in this system, you get punished
financially and you get no uptake, because everyone in the
supply chain makes money as a result of a higher list price.
Senator Daines. Chairman Grassley, if I could just ask a
follow-up question here. And that is, the GAO report said that
generics might fall 20 percent for each new generic entrant
into the market.
I appreciate the chairman's efforts here with the CREATES
Act. It is going to crack down on some of these bad actors who
block or delay competing generic drugs from entering the
market. I have co-sponsored the bill, and I think that will
help us provide better access to low-cost generics.
Here is my question: has your company ever withheld samples
from generic manufacturers?
Dr. Brandicourt. No.
Dr. Bourla. No.
Mr. Frazier. No.
Ms. Taubert. No.
Dr. Caforio. No.
Mr. Soriot. No.
Mr. Gonzalez. No.
Senator Daines. Right. Do you believe the CREATES Act would
be a positive step forward, ensuring generics enter the market
in a timely fashion? I would love to poll the team here.
Mr. Frazier. I said in my testimony, legislation like the
CREATES Act would be positive in that regard.
Dr. Bourla. Yes.
Dr. Brandicourt. Yes.
Dr. Caforio. Yes.
Mr. Soriot. Yes.
Mr. Gonzalez. We are supportive.
Ms. Taubert. We are supportive of efforts to make sure that
there are no abuses of that sample system.
Senator Daines. All right; I am out a time now. Thank you.
The Chairman. Senator Young?
Senator Young. Thank you, Mr. Chairman.
I want to move to the issue of Medicaid best price. In the
Trump administration's blueprint, they suggest that because
drug manufacturers have to give Medicaid the best price drugs,
there is no incentive to offer deeper discounts to other
payers, both government and commercial, than what is already
offered under the Medicaid drug rebate program.
So first of all, I would ask each of you, is the Trump
administration's assessment accurate?
Mr. Gonzalez. In concept, I would say I understand the
concept. In other words, if you have best price, you obviously
have to be conscious of where that price is going, because it
is going to be compared against that.
I would tell you in practice, because of the negotiation
that occurs in the formula around Medicaid, I do not believe
that that is actually, today, resulting in higher prices in the
Medicare program.
Senator Young. You have anticipated my follow-up question.
So I appreciate that.
So the best price requirement does not encourage
manufacturers to increase initial prices? You have thoughts on
that?
Mr. Gonzalez. I would say it does not necessarily encourage
you to set a higher list price. I think what happens with list
price is this negotiation you have heard of, going forward,
where you are looking for a certain amount of impact to fall
through, but the rebates and the other aspects of the value
chain in between absorb a large chunk of that, which drives
list prices, increases up higher.
Senator Young. Okay. Others?
Mr. Frazier. I think where best price really is an issue
is, again, it is a barrier to the kind of value-based pricing
that we want to have within the marketplace, where if, for
example, a drug did not work, you might reimburse that payer
for that unit, where that becomes a problem for value-based
pricing.
Dr. Brandicourt. Another example, Senator, is when you want
to put on the market a second NDC, like we did recently where
it had a much lower list price, then the best price potentially
becomes a problem because it is calculated with the other
version, the higher list price version, which has stayed on the
market. So that is something to pay attention to.
Senator Young. What changes, if any--if I could pivot a
bit--would you suggest making to the program?
Dr. Caforio. Senator, I believe that flexibility with
value-based arrangements is really important, because I think
we have all expressed a strong support for a system where we
are paid based on the clinical results that our medicines
produce in patients and having greater flexibility to do that.
It would be very, very important. It would be very valuable
for patients. It would reduce health-care costs overall.
Senator Young. General agreement?
Ms. Taubert. Yes, we agree.
Mr. Frazier. Yes.
Senator Young. Okay.
So would you be willing to work with the administration on
a different model, one you regard as more optimal?
Ms. Taubert. Absolutely.
Senator Young. Very good. Thank you.
With respect to reducing drug prices and the subsidies that
U.S. payers provide with respect to research and development to
much of the rest of the wealthy world, the President and the
administration have gone so far as to issue proposals, like the
international pricing index, which we all are familiar with, to
bring down prescription drug prices.
So with the increased scrutiny of the industry and of the
drug supply chain as a whole in the U.S., have any of your
companies re-evaluated your business strategy in foreign
countries?
Mr. Frazier. That is a common question that we get asked.
And the answer to that question is, we do everything in our
power to ensure that there is less freeloading by governments
outside the United States. But the reality of the world is, the
greatest opportunity we have is to walk away.
And that is really challenging when you have the kinds of
essential medicines that make a big difference to people's
lives. And frankly, they know that. They know that they can
establish a price, and that ultimately what we have is an
option to walk away, leaving patients behind.
I would also make the point that has been made several
times here, that in the course of negotiating for
reimbursement, often those countries take a very deliberate
approach, such that these medicines are available many years
later than they are here.
So they not only negotiate on a low price, but they
actually provide very few of these medicines early on to their
populations. If you look at, for example, lung cancer, where in
this country now, there is data showing that certain medicines
can reduce the risk of death by 50 percent in newly diagnosed
lung cancer patients, compare that to the UK, where people die
regularly of lung cancer because they do not have these
medicines.
Mr. Soriot. Senator, I think it is important to keep in
mind that all these investments, number one, create a lot of
very good jobs in the U.S. and economic value that really
benefits the country. And second, they allow patients to get
access to important new medicines much, much, much earlier than
in Europe, for instance, sometimes 3, 4 years before.
And I share Mr. Frazier's comment here. I have many
examples that I could share where medicines that save lives are
available here. We are still waiting in Europe.
The Chairman. Just three more questions. One from--if some
of you want to answer yet, I did not mean to interrupt you. Go
ahead.
Mr. Gonzalez. The only thing I would add is, if we could
develop a model where, as in the early days of HIV when
countries ultimately shared the burden, knowing that you would
have to provide HIV treatments at a very low cost in certain
countries, there was a tiered pricing system that came through
where, yes, the U.S. paid the highest price, but the Europeans
paid a fairly significant price for very important specialty
medicines. If we could negotiate through trade or other
mechanisms, we would be able to get a more balanced sharing of
the investment that is made, not keeping all of that burden on
the U.S., because the U.S. does bear the bulk of the burden of
innovation in our business. That is absolutely true.
Senator Young. So that is a really interesting idea. If you
or your team are aware of any academic paper you might bring to
my attention----
The Chairman. Okay. That is the end.
Senator Young. Thank you, Mr. Chairman.
The Chairman. Yes.
Now we have three questions, one from Senator Wyden, then
Senator Cassidy, then me. And then that will be it.
Senator Wyden. Thank you very much, Mr. Chairman.
This is going to be one question and then a very brief
closer. And the question is for you, Mr. Gonzalez.
I have the company's proxy statement here. And financial
disclosures show that you were paid $22.6 million in 2017, and
that included a $4.3-million bonus. That is what I want to look
at.
On page 37 in this proxy statement, it says your bonus was
tied to the financial performance of Humira. And it seems that
was the case in 2015 and 2016. That strikes me as problematic,
since AbbVie reported that the higher prices in the U.S. were
responsible for increasing sales of Humira.
Would you make a smaller bonus if you dropped the price of
Humira?
Mr. Gonzalez. Humira was one element of a set of financial
factors that were evaluated as part of my compensation. It is
obviously a very significant product for us. So it is clear
that it would be a part of that evaluation.
Senator Wyden. I would like that in writing. It looks to me
like you would be making a smaller bonus if you dropped the
price of Humira. I would like that in writing within 10 days.
My last point--Mr. Chairman, I appreciate being able to do
this for a closer--is that I have heard a lot of happy talk
this morning, things like, well, if you get rid of rebates,
drug prices are going to go down. But what people are taking
away from this hearing is--I have seen it said and reported--
well, no firm commitments have been made to lower list prices.
So I am just going to tell you what I would like in writing
is, I would like an answer in writing to the question, if
rebates go away, will you support a black letter law that
requires that you reduce list prices by the amount of the
rebate?
I am going to get that to you right away. I would like an
answer within 10 days, because that is right at the heart of
this issue, and after the ``happy talk'' is over, that is what
is really going to help people at pharmacy counters from sea to
shining sea.
Thank you, Mr. Chairman.
The Chairman. Senator Cassidy?
Senator Cassidy. Thank you, Mr. Chairman.
Thank you, again. This has been incredibly provocative. And
if there is a tension here, the tension is, how do we support
innovation, but at the same time make it that the patient can
afford that innovation?
Mr. Frazier, you may have guessed that--it seems like we
have a mirror image, in my mind. Either the plans impose a
price or the government imposes a price. But either way, the
side having it imposed upon them is not very wild about that.
And you just mentioned to Todd Young that you can walk
away. If France offers you too low a price, you just walk away
from France. The UK does not have a deal right now. But in some
areas, Medicare cannot walk away. So it is back to that mirror
image. And you started to say something and I was out of time.
But my question is, in the six protected classes--and if there
is a new drug, like Sovaldi was at the beginning, right now the
commercials can walk away, the commercials can delay, but
Medicare cannot.
So help me resolve this. How do we give the patient, the
taxpayer, the same sort of tools that--and by the way, CBO says
unless you can walk away, negotiations will not lower prices.
Mr. Frazier. So my point was, for all practical purposes,
we cannot walk away from our European colleagues, even though
they give us low prices, because we think it would be immoral
to leave those patients----
Senator Cassidy. Now some of your colleagues have, because
there are drugs not yet available in the UK.
Mr. Frazier. Well, the problem with the UK is that they
delay. Just like they can set the price, they delay when they
put the drug on the market. It is the UK's delay, it is not our
delay. So I want to clarify that point.
But coming back to your six protected classes, those
protected classes are there because many, many sick vulnerable
people need medicines in those classes. And we believe that
there are ways of lowering the prices, stimulating innovation,
without violating the compact that was around those six
protected classes, because patients are particularly needing
those medicines.
Senator Cassidy. Well, we will have to leave it there, but
I am not sure that is--you know, that seems almost status quo.
And status quo is kind of not working.
But again, thank you all very much, and I thank you again
for your innovation.
Dr. Bourla. I would add, Senator, I believe the
administration should try, through trade agreements, to protect
the American innovation, because by and large the
pharmaceutical innovation is happening in this country. And
right now, I think rightly, these price control mechanisms are
for multiple well-developed countries. It is in reality free-
riding on American innovation.
Senator Cassidy. Okay.
Well, thank you.
The Chairman. My last question is very general, but I would
like to know if there are any policies affecting Medicaid or
Medicare that are in your control to change? In other words,
from the company level, is there anything in your control that
you could change on Medicare or Medicaid?
I will start with you on my right here.
Dr. Brandicourt. I do not think we can change directly any
policy, Senator, on Medicare or Medicaid. We can talk about
different solutions, but I do not think we can change. We have
no power to change.
The Chairman. But if you lowered your list price, it would
help. That is one thing you could do.
Dr. Brandicourt. If we were able to lower our list price,
that would certainly help, again, the patient at the end, at
the pharmacy, to have a copay which they could afford.
However, we could not do that independently of a major
reform because we would lose formulary placement if we were
doing that in isolation, and especially in very competitive
areas where you do have, you know, brands and generics. And
again, I am referring to the insulin market, which has become
extremely, extremely competitive. That would not work.
The Chairman. Do you have anything?
Dr. Bourla. Mr. Chairman, I think the most impactful thing
I can do right now it is to make the pledge that, as leader of
this company, Pfizer, I would be taking very seriously the
responsible pricing of our products. This is something that we
have already started.
Pricing at Pfizer in the past was growing in the mid-single
digits, even more in some cases. This is not something that we
continued doing. Pricing at Pfizer went down last year, went
down this year.
And when I spoke to our investors, not to the Senate, to
our investors, I made it very clear that pricing will not be a
growth driver for this company now or in the years to come. Why
do I think this is the most important? Because I think the tone
is set from the top.
The Chairman. Mr. Frazier?
Mr. Frazier. Senator, I understand the dissatisfaction with
our industry. I understand why patients are frustrated, because
they need these medicines and they cannot afford them.
I would pledge to do everything that we could, but I would
urge you to recognize that the system itself is complex, and it
is interdependent. And no one company can unilaterally lower
list prices without running into financial and operating
disadvantages that make it impossible to do that. But if we
bring all the parties together around the table with the goal
of doing what is best for the patient, I think we can come up
with a system that works for all Americans.
Thank you for giving us the time today.
The Chairman. I did not mean to--for the rest of you,
before you answer, I did not mean to say list price. I just
said, well, that is kind of obvious. Yes, I did not want to
concentrate just on that.
Ms. Taubert?
Ms. Taubert. We really want to be a part of the solution,
and we want patients to be able to access and pay for the
medicines that they so desperately need. So we do strongly
advocate for rebate reforms that would allow us to lower our
list prices that would then end up helping patients get access.
The Chairman. Dr. Caforio?
Dr. Caforio. Mr. Chairman, I would echo. Our perspective is
that it starts with a very responsible and thoughtful approach
to pricing and price increases. That is what Bristol-Myers
Squibb does.
The second point that I would like to make is that, today
we have discussed a number of very concrete policies, from
addressing the issue of rebates to value-based pricing to
supporting the development of a generic and biosimilar market.
And you have my commitment that our company is looking forward
to working with this committee and the administration to make
sure that many of those policies can be enacted, because they
would make a very big difference for our patients.
The Chairman. Mr. Soriot?
Mr. Soriot. Senator, we actually cannot influence policy.
What we can do is, indeed, apply reasonable pricing and also
continue pushing for value-based pricing. But I would like to
make a general comment, which is that hopefully--you know,
hopefully my colleagues will share this. This view is that I
really do not think we are blaming anybody in the system. In
his introduction, Senator Wyden thought that we were placing
the blame on PBMs and others. I really do not think we are
doing this.
I think what it is is that we are in a system that used to
be fit for purpose and really drove enormous savings over the
last few years but is no longer fit for purpose. And it is one
of those situations where nobody in the system can do anything,
can fix it by themselves. The government has to step up and
change the rules, and those rebates have to go.
The Chairman. Mr. Gonzalez?
Mr. Gonzalez. I think I would agree with many of the points
that were already raised. We as an industry have to continue to
do everything we can to be responsible about pricing in both
how we set pricing and price increases over time. I think we
have seen a positive trend in that area. But ultimately, the
final fixes here to realign the system appropriately would
require legislative-type changes.
The only other thing I would say is, as I mentioned a
moment ago, we are absolutely committed that no patient goes
without medicine of ours that they need. And we have an
extensive patient assistance program, but we are talking about
how we more broadly ensure all patients understand they can get
that support from us if they cannot afford their medicines.
The Chairman. I want to inform all members of the committee
that I will set a deadline of March 12th if you have questions
you want to submit to the panel for answers in writing. And
then for you folks, after you get those questions, I hope you
can get back to us very quickly.
And so, all of the people besides the witnesses who have
attended either here or off-site for this hearing, I thank you
for your interest in this issue. And I want to once again thank
our witnesses for being here today and sharing your knowledge
and expertise. And I indicated that this is the start of a
dialogue I hope to have with you so that we can correct some of
these things that have been pointed out at this committee
meeting that we think need to be corrected.
Thank you all very much.
Meeting adjourned.
[Whereupon, at 1:25 p.m., the hearing was concluded.]
A P P E N D I X
Additional Material Submitted for the Record
----------
Prepared Statement of Albert Bourla, DVM, Ph.D.,
Chief Executive Officer, Pfizer
Chairman Grassley, Ranking Member Wyden, and members of the
committee, thank you for the opportunity to speak with you today. My
name is Albert Bourla. I have been with Pfizer for 26 years, and just
last month had the honor of becoming its chief executive officer.
Today, I am pleased to take part in such an important policy
discussion within the United States Senate. Pfizer shares an important
goal with this committee: to ensure that America remains the leader
when it comes to innovative medicines, and that our citizens have
affordable access to these modern miracles when they need them.
In that frightening moment when you hear that you or a loved one
has been diagnosed with a serious disease, one question comes to mind:
``Is there a cure or treatment available?'' The answer can change your
life. And happily, the answer to that question increasingly is ``yes.''
Breakthrough medicines are coming quickly across a wide range of
conditions. Most of them are discovered here, by the American
Biopharmaceutical Industry, which is the crown jewel of innovation. Let
me share a few examples. In 2015, Pfizer launched a life-changing new
treatment for metastatic breast cancer that can delay the progression
of the disease two times longer than previous treatments. Thanks to our
meningitis B vaccine, parents can send their teens to college confident
in the knowledge that being vaccinated helps protect them in the event
of an outbreak on campus. In 2018, we brought 4 new cancer treatments
to the market to treat varying forms of breast cancer, lung cancer and
leukemia. And we are currently working on a non-opioid alternative with
the potential to address the serious unmet needs of the more than 27
million Americans living with osteoarthritis and the more than 33
million suffering chronic low back pain.
But all of these breakthroughs won't do anyone any good if patients
can't afford them.
That's why at Pfizer we are so committed to our purpose:
breakthroughs that change patients' lives. Pfizer's more than 90,000
colleagues around the world come to work every day focused not only on
creating breakthrough medicines, but also on making sure those
medicines get into the hands of the patients who need them.
To create solutions that make medicines affordable for patients and
our entire health-care system, I believe that all players in the
industry must come together and play a part. Whether it's hospitals or
providers, pharmacy benefit managers or insurance companies, or
biopharmaceutical companies, we all have a role to play. The series of
hearings being held by Congress can be a catalyst for this much-
needed collaboration.
There are two indisputable truths that make this the exact right
moment for change:
1. Medicines alleviate human suffering and reduce overall
system costs.
2. The horribly misaligned incentives within our health-care
system often prevent medicines from getting into the hands of
patients.
Our health-care system is broken, and we need to fix it. The system
needs to be simpler and more transparent. It needs to incentivize
innovation while simultaneously ensuring access. Simply put, it needs
to put patients--and their health--first.
How will we know when the health-care system is fixed? When
patients feel real relief at the pharmacy counter--the kind of relief
that means cost will no longer be a determining factor in whether
someone picks up, and adheres to, their prescription. Too often,
Americans are forced to choose between buying a medication that will
improve, extend or save their lives or paying their bills. Too often,
they fill their prescriptions, but take less than the prescribed dose
in an effort to save money. Too often, lower-cost, FDA-approved generic
and biosimilar alternatives are not made available to patients who
desperately need them.
We must take bold actions to ensure these scenarios do not play out
time and time again across America.
Pfizer intends to be a productive participant in this policy making
and has come to the table with solutions. As such, we would like to
propose four ideas to drive meaningful reductions in costs for
patients.
passing all rebates to patients
Today's current drug rebate system is good for two things: driving
up both drug list prices and consumer out-of-pocket costs. In fact, in
2018, the average net price of Pfizer's medicines in the United States
declined 1 percent. However, I am certain that patients using our
medicines had a very different experience at the pharmacy counter since
their costs in the current system are more closely related to the list
price than the net price. This is impactful when patients pay a
coinsurance or are in the deductible phase of their benefits coverage.
In these instances, patients are being asked to pay an average of 10
percent to 20 percent or more out of their own pockets for many Pfizer
products.
There are two reasons for this disconnect: changes in benefit
designs are pushing more and more of the medicines' cost to the pockets
of the patients, and none of the close to $12 billion of rebates that
Pfizer paid in 2018 found their way to American patients. As long as
rebates serve as profit drivers, we will continue to see a major
disconnect between list prices and prices people pay at the counter.
Pfizer supports reforms that would create a system in which
transparent, up-front discounts benefit patients at the pharmacy
counter, rather than a system driven by rebates that are swallowed up
by companies in the supply chain.
The way to alleviate sticker shock at the pharmacy counter is by
changing the incentives in the supply chain so that more of the $150
billion in negotiated rebates and discounts actually reach patients.
This can be accomplished by applying the discounts paid by the
pharmaceutical manufacturer to the price actually paid by patients at
the pharmacy. In 2019, Pfizer expects to pay billions in rebates to
ensure patients with pharmacy benefits coverage in Medicare Part D and
patients in commercial plans have access to our medicines. If the
proposed rule to share rebates with consumers at the point of sale is
finalized, we estimate that seniors taking Pfizer medicines could save
$270 on average per year, and up to $574 per year for certain Pfizer
medicines, through lower cost sharing--and that would outweigh any
premium increases.
Research also shows that sharing discounts at the pharmacy counter
could reduce total health-care spending, and that reductions in overall
out-of-pocket costs would outweigh any premium increases.
We realize that the transition away from rebates toward a point-of-
sale discount model will result in a lowering of our net prices.
Despite this potential negative financial impact, we support efforts to
eliminate rebates because we believe the new model will be good for
patients.
Importantly, we believe any reform should apply to all market
segments as this will also lead to further reduction in list prices. A
bifurcated market in which we eliminate rebates in government programs
but maintain rebates for commercial plans will make it difficult for
manufacturers to reduce list prices because it applies to all markets.
We will work with other leaders in the healthcare sector to advance
these reforms, and we're committed to lowering list prices if the
rebate rule applies to the commercial market.
less value, less pay
Pfizer supports the move to value-based health care and is prepared
to stand behind the benefits that our medicines deliver to patients and
to the United States health-care system.
Medical science is advancing so rapidly that payment models simply
haven't been able to keep up. That's why Pfizer is focusing not only on
scientific innovation, but also on commercial innovations that will
allow us to get breakthrough medicines into the hands of patients,
while simultaneously holding all participants in the system--including
Pfizer--accountable for the health outcomes they help produce.
This will require a fundamental shift in the way we think about the
value that medicines deliver and how all participants in the system are
reimbursed with regard to that value. It will also require the
evolution of insurance designs to advance value-based insurance plans
that removebarriers to high-value treatments.
Imagine a system in which hospitals are rewarded for keeping
patients from being readmitted; where physicians get paid more to
prevent disease than they do to simply treat it; and where companies
like Pfizer get paid based on the number of strokes we prevent or the
number of cancer patients who go into full remission, rather than the
number of pills we sell.
In such a system, if our medicines do not produce results, we would
be paid less. And if they do produce results, we would be paid more. If
done correctly, these arrangements--focused on the appropriate
therapeutic areas--can align the interests of patients, health plans
and biopharmaceutical companies around one shared goal: ensuring
positive health outcomes for the patient.
To make this a reality, we need Congress's help to remove the
roadblocks in the current system for the good of patients. I understand
several members of this committee are drafting a legislative effort to
pave the way for broader adoption of outcomes-based arrangements, and
we applaud these efforts.
capping seniors' out-of-pocket medicine costs
Patients are increasingly being required to take on a bigger share
of their medicines' costs, and that is particularly true when it comes
to innovative and expensive treatments. Today, patients are made to pay
on average 14 percent of the cost of their medicines, but only 3
percent of the costs associated with hospital stays.
This is forcing patients to forgo taking needed medications, to cut
their pills in half, or to limit their doses in ways that are not
medically prescribed. In fact, there is evidence that at least a
quarter of new Medicare Part D prescriptions are abandoned at the
pharmacy counter if beneficiaries are asked to pay $50 or more, which
unfortunately is often the case. This number can exceed 50 percent for
new prescriptions.
This is bad not only for patients, but also for overall health-care
system cost. Patients who do not take their medications often end up in
the hospital, costing the health-care system much more. This needs to
be fixed.
Excessive cost-sharing is one of the greatest barriers to patient
adherence and leads to more frequent discontinuation of therapy. While
spending on medicines has been growing at a slower rate than in prior
years, the number of patients with high deductible plans and high co-
insurance are growing rapidly. Since 2009, enrollment in high
deductible plans has grown 250 percent, and since 2010 the number of
patients exposed to high specialty tiers has grown 60 percent. In fact,
I've heard from several members of this committee that their
constituents--or they themselves--have recently gone to the pharmacy
counter only to be shocked by an excessively high co-pay. That's why
the time is now to review cost-sharing burdens in the Medicare
prescription drug program and to take steps to ensure seniors don't
have to make the difficult decision of forgoing their needed
prescription.
We commit to working with the committee on meaningful policy
solutions that remove the burdens seniors face in paying for their
medicines, and we believe an important first step is capping the out-
of-pocket costs seniors experience in the Medicare drug program.
knocking down barriers to lower-cost biosimilars
Medicines are the only segment of the health-care system with a
built-in cost containment mechanism. When a medicine's patent expires,
lower-cost generics are made available, often at just 5 percent of the
cost of the original branded product.
This system is working well for generic drugs. In fact, nine out of
10 drugs sold in the U.S. today are lower-cost generics. However, the
system is not yet working in the biologics space where the adoption of
biosimilars is facing resistance.
Establishing a robust biosimilars market can help to lower the
overall health-care costs in the United States, and Pfizer is committed
to bringing these more affordable treatment options to patients. That's
why we must incentivize the use of biosimilars, which can be as much as
40 percent less expensive than the branded biologic for Medicare
patients.
Unfortunately, adverse incentives that favor higher-cost originator
biologics are keeping biosimilars from reaching patients. In many
cases, payers decline to include lower-cost biosimilars or generics in
their formularies because they would risk losing the rebates they can
get by covering higher-cost medicines. I can't think of a more
concerning example of a broken U.S. healthcare system that is directly
impacting the pocketbooks of Americans.
We have also witnessed exclusionary contracting or misleading
marketing practices that mischaracterize important elements of
biosimilar criteria. This creates doubt and confusion among patients,
and it must end. Interestingly, the rebate reform I referenced earlier
would go a long way toward removing the perverse incentives that lead
to such exclusionary contracts.
At Pfizer, we believe there are several solutions that could help
patients and providers share savings associated with biosimilars and
reduce costs to the Medicare program. Let me touch on two:
A Shared Savings Biosimilars Model: Congress could direct
the CMS Innovation Center (CMMI) to test a biosimilar ``shared
savings'' approach in which Medicare savings associated with
prescribing a biosimilar, as compared to a reference
biological, would be shared with providers.
Reduced Patient Cost Sharing for Biosimilars: CMS could
provide reduced or zero-dollar cost sharing for biosimilars for
patients for a certain period.
closing
In 2018, we estimate \1\ that Pfizer vaccines protected more than
65 million babies and elderly patients; our medicines helped reduce the
risk of heart attack or stroke for more than 48 million cardiovascular
patients; and oncologists used our therapies to treat more than 1.2
million people battling cancer.
---------------------------------------------------------------------------
\1\ Patient counts are estimates derived from multiple data
sources.
Overall more than 784 million people around the world used a Pfizer
medicine or vaccine to improve their health and, in many cases, save
---------------------------------------------------------------------------
their lives.
These are staggering and humbling numbers. More important, they
represent real people; real people who rely on our innovations. They
also serve as a reminder that we--like our industry peers--are among
the biggest contributors of good to humanity.
This is why we come to work every day. It's why the researchers in
our labs in California, Connecticut, Massachusetts and New York work
day-in and day-out to perfect a formula. It's why our manufacturing
colleagues in Georgia, Kansas, Michigan, Missouri, North Carolina,
Ohio, Pennsylvania and Wisconsin--many of whom are represented by
members of this committee--work to ensure the reliable supply and
highest standards of quality of our products.
And it's why we are here today to work with our peers, other
participants in the healthcare system, and Congress to find ways to
ensure the patients who need our medicines can access them so our
industry's breakthroughs can continue to change patients' lives.
______
Questions Submitted for the Record to Albert Bourla, DVM, Ph.D.
Questions Submitted by Hon. Chuck Grassley
Question. At the hearing, you testified that Pfizer does not
withhold samples from generic manufacturers in order to block generic
versions of your drug from entering the market. You also expressed your
support for the ``Creating and Restoring Equal Access to Equivalent
Samples Act,'' also known as the CREATES Act.
However, the FDA has a list on its website which identifies
reference listed drug (RLD) access inquiries where brand manufacturers
may have prevented generic companies from obtaining samples of products
necessary to support FDA approval. Pfizer is on this FDA list. This
would appear to contradict your testimony at the hearing that Pfizer
has not withheld samples of their products to delay generic
competition.
Could you please explain in detail why Pfizer is on the FDA
list?
Could you please explain in detail the discrepancy between
your testimony and the FDA list?
Has Pfizer ever blocked access to samples?
Answer. As a patient-focused company and leading manufacturer of
innovative, generic, and biosimilar medicines, Pfizer supports
innovation and a strong, competitive marketplace. Consistent with these
values, Pfizer does not block generic manufacturers from purchasing our
products, and it has never been our policy to do so. Generic
manufacturers are treated the same as any other customer seeking to
purchase our products. Pfizer is not aware of any current, unfulfilled
requests from a generic manufacturer to purchase a Pfizer product.
Generic manufacturers seeking to purchase Pfizer products should
request the product from Pfizer's authorized distributors or, if the
product is not available at a distributor, from Pfizer directly, the
same as any other Pfizer customers. Pfizer's website includes a list of
our authorized distributors, from which customers (including generic
companies) may purchase most Pfizer products (see https://www.
pfizer.com/products/medicine-distributors). For products that are not
available via our authorized distributors and that are not in extreme
drug shortage or unavailable due to a recall, customers can contact
Pfizer's Customer Service center at 1-800-TRY-FIRST (1-800-879-3477) to
purchase product directly from Pfizer. The telephone number for
Pfizer's Customer Service center is also included on our website at
https://www.pfizer.com/contact. Pfizer makes its products available for
sale to appropriately licensed entities at Pfizer's listed price and on
Pfizer's standard terms of sale. We do not have any agreements with
authorized distributors that block the sale of Pfizer's products to
generic manufacturers.
Regarding the FDA List (the List), while Pfizer supports FDA's (the
agency) goal of providing transparency, Pfizer is concerned that the
List lacks certain key information and context and, as currently
presented, may create the misleading impression that all products on
the List are the result of bad faith attempts to block generic
manufacturer access to samples. The appearance of a product on the FDA
List means only that a generic manufacturer informed the agency at some
point in time that it was having difficulty purchasing the listed
product. FDA's own disclaimer states that the agency has not
independently investigated or confirmed whether a generic manufacturer
actually made a request to purchase product, and to whom.\1\ The FDA
List also lacks several important pieces of information that would
enable a New Drug Application (NDA) holder to investigate its
appearance on the List. The List does not include: (1) which generic
manufacturer made the request; (2) when and to whom the generic
manufacturer made the request (e.g., to a wholesaler or directly to the
NDA holder); (3) whether the generic manufacturer that made the inquiry
was thereafter able to obtain product; and (4) any reason(s) why a
generic manufacturer may not have been able to obtain product (e.g., a
recall). Finally, Pfizer notes that FDA does not currently inform an
NDA holder in real time when a generic manufacturer notifies the agency
that it is having difficulty obtaining product. Had the agency informed
Pfizer at the time it received the inquiries noted on the FDA List,
Pfizer could have then undertaken its own efforts to resolve the issue.
Pfizer communicated its concerns about the FDA List to the agency in
May 2018. For your information we have included Pfizer's letter to FDA
on this topic and the agency's response (see Exhibits 1 and 2 in the
Appendix).
---------------------------------------------------------------------------
\1\ (https://www.fda.gov/Drugs/DevelopmentApprovalProcess/
HowDrugsareDevelopedandAp
proved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/
ucm607738.htm).
There are three new drug applications owned by Pfizer on the FDA
List: Embeda (NDA 022321), Tikosyn (NDA 020931) and Hemabate (NDA
017989). Embeda offers a good example of the List's shortcomings.
Pfizer acquired King Pharmaceuticals (the previous NDA holder of
Embeda) in March 2011, and two weeks later determined that Embeda
needed to be recalled from the U.S. market due to stability issues.
After diligently addressing the issues that led to the recall, Pfizer
relaunched Embeda to the U.S. market in January 2015, and it is
available for purchase via Pfizer's authorized distributors. However,
one consequence of the recall was that Embeda was not available in the
U.S. market for almost 4 years which may explain why a generic
manufacturer had a problem obtaining it during those years. The FDA
List does not specify when the generic manufacturer's inquiry regarding
Embeda was made nor does the FDA List indicate that several generic
applications for Embeda had been submitted to FDA in 2010 (which means
that before the recall, several generic manufacturers were successfully
able to purchase Embeda, conduct the necessary testing, and file
Abbreviated New Drug Applications (ANDAs)). Pfizer has not identified
any recent inquiries from generic manufacturers seeking to purchase
---------------------------------------------------------------------------
Embeda that have not been fulfilled.
The circumstances around Tikosyn also illustrate the List's
shortcomings. Pfizer was able to identify a single inquiry made by a
generic manufacturer directly to Pfizer to purchase Tikosyn in 2014. At
that time, Tikosyn was subject to an FDA imposed Risk Evaluation and
Mitigation Strategies (REMS) with Elements to Assure Safe Use
(``ETASU'') that restricted distribution, so Pfizer responded by asking
the manufacturer to obtain written confirmation from the FDA that
Pfizer's provision of the product to the generic manufacturer would not
be considered a violation of its REMS. The generic manufacturer did not
contact Pfizer further, and Pfizer never received any written
correspondence from the agency. FDA subsequently removed the REMS for
Tikosyn in 2016, and multiple generic versions of Tikosyn are now
approved, the first generic approval occurring in June 2016. This
context is not reflected in FDA's List.
Finally, with respect to Hemabate, this product was previously
subject to certain restrictions on distribution (i.e., it was sold only
to customers with medical and surgical intensive care centers) to
ensure its safe and appropriate use. This distribution approach was
established by the previous NDA holder (Pharmacia) and it continued
following Pfizer's acquisition of Pharmacia in 2003. Pfizer
discontinued this approach in early 2018 after determining that it was
no longer necessary, and this product is now available through our
authorized distributors. During the time when Hemabate was under
restricted distribution, it was not available at Pfizer's authorized
distributors, but had a generic manufacturer approached Pfizer's
Customer Service center directly, we would have been able to address
the inquiry. Pfizer's Customer Service was not able to identify any
specific requests from a generic manufacturer to purchase Hemabate that
have not been fulfilled.
We hope that this information explains the apparent discrepancy
between Mr. Bourla's testimony and the appearance of these Pfizer
products on the FDA List, and demonstrates Pfizer's diligence on these
issues and commitment to a competitive marketplace.
Question. The Department of Health and Human Services' proposed
rule, ``Fraud and Abuse; Removal of Safe Harbor Protection for Rebates
Involving Prescription Pharmaceuticals and Creation of New Safe Harbor
Protection for Certain Point-of-Sale Reductions in Price on
Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager
Service Fees,'' envisions that drug manufacturers will offer up-front
discounts rather than the back-end rebates that are now commonly
provided. Some observers argue that a 1996 court case called into
question whether manufacturers could offer up-front discounts,
resulting in today's rebate-based system. I've heard differing opinions
as to whether the issues related to the initial court case are still
relevant. If the HHS proposed rule is finalized, can you assure the
committee that your company will offer up-front discounts? If not, why?
Answer. Yes, if finalized, price concessions negotiated with
intermediaries, including Pharmacy Benefit Managers (PBMs) and plan
sponsors, will be provided as discounts that will be applied at the
point of sale. These discounts will lower patient out-of-pocket costs
since the net price will be used to determine the cost to the patient
when they are in the deductible, co-insurance, and coverage gap phases
of their benefits.
Question. Please describe how you expect your company to respond to
the HHS proposed rule to eliminate safe harbor protection for back-end
rebates in Medicare Part D that is referenced above if it is finalized.
Assuming you are confident that antitrust laws do not prevent your
company from offering up-front discounts, specifically, do you envision
that your company lowers the list price of a drug to the current after-
rebate net price, offer discounts equal to the current rebate amount,
or a combination of both?
Answer. If finalized, the rule will result in lower out-of-pocket
patient costs at the pharmacy counter and help address the perverse
incentives in the system that have been contributing to higher list
prices for medicines. We realize that the transition away from rebates
toward a point-of-sale discount model will result in a lowering of our
net prices. Despite this potential negative financial impact, we
support efforts to eliminate rebates because we believe the new model
will be good for patients.
As currently written, the proposed rule only applies to the
Medicare and Medicaid managed care segments of the market. It will be
important to have any rebate reform apply to both government programs
and the commercial market as that will also lead to a lowering of list
prices as well. A bifurcated market will make it more challenging for
manufacturers to reduce list price since the commercial market covers
more than 50 percent of Americans with insurance and represents over
half of the business for most manufacturers.
If the proposed rule is modified to apply to all market segments,
we would evaluate the best options to arrive at a net price that
ensures patients have access to our medicines. Decisions would be made
on a product by product basis given that each therapeutic class has its
own set of competitive and access dynamics. As such, we expect to use
both list price reductions and up-front discounts to achieve these
lower net prices. To ensure these benefits reach patients, it will be
important for Congress to ensure that plans do not create new barriers
or restrictions that hinder patient access and undermine the spirit of
the rule.
Question. To what extent are the back-end rebates your company
currently offers contingent on the amount of market share realized for
your drugs as a result of Part D plan formulary placement and other
techniques?
Answer. Pfizer's contracts with Part D Health Plans and PBMs
negotiating on their behalf do not make rebates contingent on market
share.
Question. Please provide a breakdown of percentage of sales that go
to each payer (including Medicare, Medicaid, private pay, other) and a
similar percentage by volume of the total number of each drug compared
to total volume. Please provide this data for the most recent year
available.
Answer. Pfizer's prescription pharmaceutical products are sold
principally to wholesalers, and therefore the Company does not have
sufficient visibility into wholesaler distribution at the channel level
to provide responses as requested. We welcome the opportunity to
discuss with your committee staff the confidential information
requested and what we maintain in the ordinary course of business.
Question. Do your companies hire consultants or lobbyists to
promote products at State Medicaid Pharmacy and Therapeutics
Committees?
Answer. No.
Question. To whom do you disclose advocacy activities surrounding
State Medicaid programs, if at all?
Answer. Pfizer is committed to the principle of transparency--the
disclosure of activities reflecting participation in efforts of public
interest. These activities include such areas as funding for
educational activities, the status of Pfizer's U.S. pharmaceutical
post-marketing commitments, Pfizer's pipeline of experimental
medicines, the registration and reporting of results of clinical
trials, political contributions in the United States and payments to
U.S. health care professionals. The information we report includes
grants to support independent medical education, support for
fellowship, scholarship and visiting professorship programs, grants to
patient organizations, medical and scientific associations, and
academic or other medical centers, charitable contributions, health
care-related support to civic organizations and health care-related
non-promotional sponsorships to organizations. For descriptions of
types of support, please visit https://www.pfizer.com/purpose/
independent-grants/transparency-in-grants. Any Medicaid specific
advocacy funding we provide would be captured in these reports.
Question. Please describe how the costs of programs are accounted
for within your company's financial statements. Please also describe
the types of market information, such as prescribing and use patterns,
that your company collects from different types of patient assistance
programs and patient hub services.
Answer. Pfizer's patient assistance program is a charitable free
drug program that provides commercially available Pfizer medicines free
of charge to financially eligible uninsured and underinsured patients.
Separate from the Pfizer patient assistance program, Pfizer also offers
patient support programs, which are limited access reimbursement
support offerings to patients to assist with obtaining access to and
coverage of a prescribed Pfizer medicine.
The product and administrative costs for the patient assistance
program are charged against Pfizer's Selling, General and
Administrative Expenses line in the income statement.
Pfizer gathers data in the course of providing free drugs to
patients via the patient assistance program. We can bucket data
collection in several ways:
(1) Transactional data--Utilized to determine patient
eligibility to receive free access to a physician-prescribed
therapy.
(2) Operational data--The operational data is utilized to
provide free access to medicines to the eligible patient and
the following is reported at an aggregated level: (i) program
utilization trends; (ii) application processing trends; (iii)
patient coverage trends; (iv) channel utilization (distribution
versus pharmacy); (v) fulfillment and order processing days;
and (vi) call metrics.
Pfizer gathers the following two categories of data when providing
patient support programs:
(1) Transactional--Utilized to assist in accessing prescribed
therapy and to determine insurance coverage for the patient.
This information contains data such as the outcome of a
benefits investigation, information to determine the financial
need and eligibility for patient support, and disposition of
the patient case (i.e., sent to a specialty pharmacy for
fulfillment, sent to Pfizer patient assistance program, triaged
to other financial options, or rejected/denied).
(2) Operational--These fields could include primary and
secondary payers, out-of-pocket costs borne by the patient,
turnaround time to obtain insurance approval, prior
authorization requirements, number of cases requiring appeals,
and other data elements on access dynamics. In addition to
these elements, Pfizer will collect relevant adverse events as
required by Pfizer drug safety.
Question. Please provide a list of all contributions since January
1, 2014, that your company has made to any tax exempt organizations
working on issues related to drugs within your product lines, including
but not limited to patient groups, disease awareness groups, medical or
professional societies, universities or hospitals, industry
associations or leagues. For each contribution, please provide the name
of the organization that received the donation, the date the donation
was made, the amount of the donation, and a description of the purpose
of the contribution (i.e., was the contribution for the general fund, a
specific purpose to a specific program, or continuing medical
education). Please also note whether the contribution was unrestricted
or restricted; if it was restricted, please explain all restrictions.
Finally, if your company maintains a foundation or other separate
charitable arm, please provide the name of all such entities, and list
all donations made from that entity or entities.
Answer. Information about Pfizer's charitable giving is listed on
Pfizer.com. Please see the annual reports dating back to 2008 available
at https://www.pfizer.
com/purpose/independent-grants/transparency-in-grants, which include
the recipient name, the contribution amount and the annual quarter in
which it was made, and a description of the relevant program or
project. This data is updated each quarter. Data from Q4 2018 is
currently being analyzed and will be available at the end of March
2019. The annual reports include various funding types and recipient
types. However, in collating this data, Pfizer does not characterize
the organizations as working on issues related to drugs within product
lines, or contributions as restricted or unrestricted. Consequently,
the requested data is not available in that format.
Note that information regarding charitable contributions from the
Pfizer Foundation is not included in these reports, so Pfizer has
included a Pfizer Foundation Grant Summary as Exhibit 3. The Pfizer
Foundation has been working to expand health-care access to people
around the world for nearly 65 years. The impact of this work is
significant and far-reaching, helping underserved individuals from
diverse backgrounds in remote corners of the globe. Through the Pfizer
Foundation's global health strategy, we provide grant and investment
funding to support organizations and social entrepreneurs in an effort
to improve health care delivery in low-and middle-income countries and
increase access to health care for underserved communities.
Question. Pay for delay agreements cost consumers and taxpayers
billions in higher drug costs every year. The FTC has gone after drug
companies that enter into these settlements where the brand pays the
generic company to keep its lower cost alternative off the market. I'm
the lead Republican sponsor of S. 64, the ``Preserve Access to
Affordable Generics and Biosimilars Act,'' which would help put an end
to these deals.
Do you agree that these pay-off agreements keep drug costs high for
patients because they delay competition?
Answer. Pfizer wants to work with you on this issue because we
agree that gaming the patent system is unacceptable. The company's
patent settlements do not involve ``pay for delay.'' On the contrary,
when Pfizer settles patent litigation with generic firms, it does so on
terms that generally enable entry of generic competition earlier than
the expiration of its patents and that do not involve unlawful reverse
payments. Pfizer's patent settlements thus involve lawful compromises
that accelerate patient access to lower cost generics relative to the
expiration of its patents.
Question. Has your company ever entered into these kinds of
settlements with a generic company?
Answer. No. On the contrary, when Pfizer settles patent litigation
with generic firms, it does so on terms that generally enable entry of
generic competition earlier than the expiration of its patents and that
do not involve unlawful reverse payments. Pfizer's patent settlements
thus involve lawful compromises that appropriately resolve patent
disputes and accelerate patient access to lower cost generics relative
to the expiration of its patents. While Pfizer has been the target of
plaintiff lawyer driven class action lawsuits challenging certain of
its settlements with generic companies, we believe these lawsuits are
without merit and are vigorously asserting the pro-competitive nature
of these settlements in court.
Question. Do you support the pay for delay bill?
Answer. Pfizer agrees that gaming the patent system is
unacceptable. We hope to work with you on legislation that prohibits
anticompetitive patent settlements that is prospective, clearly defines
violations and what is deemed to be an improper settlement and does not
presume all patent settlement agreements are per se illegal and
anticompetitive. Laws or actions to restrict certain kinds of
pharmaceutical patent settlements could prevent some pro-consumer
settlements that bring generics to market prior to patent expiration--
patent settlements often include an agreement that enables generics to
enter the market earlier than the date of patent expiration, speeding
patient access to more affordable generic options.
rebate traps/walls
Question. I'm increasingly concerned about the effect of so-called
``rebate traps'' or ``rebate walls'' on patients' access to quality,
lower cost medicine. I understand there is ongoing litigation
challenging these practices as anti-competitive.
Does your company engage in the bundling of rebates over multiple
products? If so, why? And what benefit does the consumer gain from
that?
Answer. Pfizer does currently bundle rebates over multiple
products. Pfizer does offer bundling arrangements to obtain formulary
positions that allow patients to access our medicines that otherwise
might be restricted.
Question. Does your company view these practices as anticompetitive
or harmful to patients' access to quality, lower cost medicine?
Answer. Pfizer does not believe bundling is inherently
anticompetitive and in certain circumstances can be procompetitive.
However, Pfizer does not tie bundled rebates to blocking lower cost
competitive agents and believes that when a firm with monopoly power
uses such practices to block lower cost alternatives the conduct is
anticompetitive.
Question. If a policy were adopted to eliminate rebates, or to
require that rebate savings be passed on to the consumer, would that in
and of itself solve the issue of rebate ``traps'' and ``walls''? And
would consumers benefit from such a policy?
Answer. A policy that moves rebates to discounts would not in and
of itself eliminate the ability of a market leader to block a lower
priced medicine. In both Medicare and commercial, the Health Plan is
still responsible for the majority of the drug cost and would therefore
receive the majority of the discount. The Health Plan or PBM would
still need to transition patients from the higher priced market leader
to the lower priced product in order to realize the savings from the
discount. Based on internal analysis, Pfizer expects that moving from a
rebate to a discount model will weaken a market leader's ability to
restrict other less expensive products, but it would not eliminate the
possibility.
drug pricing
Question. When setting the list price of a drug, does your company
consider regulatory costs or compliance? If so, how specifically do
those factors affect the list price of a drug? Please provide at least
one specific example, if applicable, from your current product
portfolio.
Answer. The Food and Drug Administration is the primary regulatory
body for the pharmaceutical industry and is largely focused on the
safety, quality, and efficacy of medicines. The price of a new medicine
is most directly influenced by the value that the medicine may bring to
patients and society. Inherent in the value any product Pfizer brings
to the market are the quality, safety, delivery, efficacy, and
reliability of our medicines. These regulatory and compliance factors
are part of the underlying investments to identify a product's value
and are amongst the many factors we consider when we determine a launch
price or make a decision to change a price.
Question. When setting the list price of a drug, does your company
consider the risk of liability or litigation? If so, how specifically
do those factors affect the list price of a drug? Please provide at
least one specific example, if applicable, from your current product
portfolio.
Answer. Liability and litigation are not primary considerations
when setting the list price of a medicine; the value that a product may
bring to patients and society is the most important factor considered.
______
Questions Submitted by Hon. Pat Roberts
Question. What role do you see value-based agreements (VBAs)
playing in the effort to reduce prescription drug costs? What potential
do these arrangements have to find the ``sweet spot'' between
controlling costs to patients and encouraging innovation of new drugs?
Answer. Value-based agreements (VBA) provide a framework for
manufacturers to be compensated based on a product's value to patients
and the overall health-care system. Although there are different
constructs for VBAs, the basic premise is that the net price for a
product will ultimately be derived based on an agreed upon performance
metric (e.g., clinical, financial, adherence, etc.). Therefore, VBAs
can play a role in reducing prescription drug costs by ensuring that
net prices are linked to value.
As we shift to a system that rewards value, manufacturers will be
incentivized to focus research and development (R&D) investments in
disease areas where there are unmet needs, to focus on best in class or
first in class medicines, and to design trials that provide the
necessary evidence to demonstrate the value of a medicine beyond the
regulatory standards of safety and efficacy to include the evidence to
support reimbursement. If manufacturers deliver medicines of value, the
system will reward the manufacturer which encourages innovation of new
drugs.
Question. How can VBAs help lower what patients pay out-of-pocket?
Answer. Value-based agreements (VBA) provide a framework for
manufacturers to be compensated based on a product's value to patients
and the overall health-care system. There are many different types of
VBAs including those based on clinical and/or financial performance
metrics for a product. Based on the outcomes achieved, payers use this
information to inform how they cover products. Products that perform
better should be covered in a more favorable manner which often
includes lower out-of-pockets costs for patients which is a benefit to
patients in the near term. In the long term, patients can also benefit
from other savings either directly, (e.g., reducing spending on other
medications, lowering medical costs from reduced hospitalizations,
doctor's visits, etc.), or indirectly through lower premiums based on
reductions in total cost of care.
Question. Can Congress do more to allow for and encourage the use
of VBAs?
Answer. VBAs are in the very early stages of development in the
United States. Many payers and manufacturers have tested different
concepts, but to date VBAs have not achieved scale. There are multiple
reasons why VBAs represent a small fraction of manufacturer/payer
contracts (e.g., access to data, difficult and costly to administer,
etc.). There are certain aspects of the current U.S. regulatory
landscape that are perceived by many as not only complicating VBA
implementation but in some cases limiting their rapid uptake.
Stakeholders have frequently identified two key regulatory hurdles as
limiting the expanded adoption of VBAs: (i) the Anti-Kickback Statute
and (ii) the Medicaid Best Price calculation requirement. While these
regulations serve important roles within the current volume-based
reimbursement system they do not contemplate innovative value-based
arrangements which have resulted in a lack of clarity on how to account
for these under the current regulatory framework. Ultimately, an
expansion of VBAs will require reforms to existing regulations that
enable more flexibility in designing VBAs.
______
Questions Submitted by Hon. Michael B. Enzi
Question. More than 10 years ago, I worked on a bipartisan basis
with my good friends Ted Kennedy and Orrin Hatch to develop a
biosimilars approval pathway. One of the difficult things was
accounting for the differences between biosimilars and generics. I have
said before that if a drug was a three-bedroom, two-bath home, a
biologic would be a skyscraper. The size and complexity of the items
are just that different. I understand that it is much harder to build a
skyscraper without blueprints than a house. Even though the science has
come a long way since then, there aren't as many biosimilars on the
market as we might have hoped. Do you think the incentives in the law
appropriately account for the differences between biosimilars and
generics?
Answer. The Biologics Price Competition and Innovation Act (BPCIA)
created an abbreviated pathway for the licensure of biosimilars,
including interchangeable biologic products, and created the framework
biosimilar applicants and reference product sponsors use to resolve
patent disputes. There are currently seven biosimilars on the market in
the United States, and there are a number of biosimilars currently in
development. The FDA has approved a total of 18 biosimilars to date.
Nevertheless, the success of the BPCIA lies in the increased use of
these products, which will provide savings to both the patient and the
taxpayer.
To date, there have been two key policies that have helped support
the biosimilars marketplace: 340B pass-through status for biosimilars
and the separate billing/J code policy for biosimilars.
The separate billing/J code policy for biosimilars has aided in the
prompt reimbursement of biosimilars for physicians, which is critical
in supporting uptake of biosimilars. The separate billing/J code also
provides Congress and CMS with transparency on the average sales price
of the biosimilar versus the reference biologic. Below is a table
outlining the latest Medicare published average sales prices for the
reference biologic Remicade and both of the biosimilars on the market
for Remicade, Pfizer's Inflectra and Merck's Renflexis.\2\ It is
important to note that the average sales price (ASP) for both
biosimilars is lower than the ASP of the reference biologic. Yet, the
market share of the Inflectra biosimilar remains at 6 percent in open
systems (which excludes the VA and Kaiser, which are closed systems
where the insurer is the payer, the prescriber and the provider).
---------------------------------------------------------------------------
\2\ https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-
Drugs/McrPartBDrugAvg
SalesPrice/2019ASPFiles.html.
------------------------------------------------------------------------
Q4 2018 CMS Q1 2019 CMS Q2 2019 CMS
HCPCS Code ASP ASP ASP
------------------------------------------------------------------------
Remicade (reference J1745 $743.71 $723.10 $677.60
biologic)
------------------------------------------------------------------------
Inflectra Q5103 $569.01 $529.37 $502.72
(biosimilar)
------------------------------------------------------------------------
Renflexis Q5104 $599.20 $575.64 $552.00
(biosimilar)
------------------------------------------------------------------------
The 340B pass-through policy for biosimilars has been another
positive policy to support uptake of biosimilars in 340B hospitals. The
340B pass-through policy provides a temporary ``level playing field''
for the biosimilar and the reference biologic. Under the reimbursement
model of ASP + x%, providers are incentivized to use a higher cost
product to drive a higher ``+ x%'' reimbursement. As in the case of
biosimilars, when the biosimilar has a lower ASP the reimbursement is
lower to the health-care provider/340B hospital. The pass-through
policy provides temporary reimbursement parity for lower cost
biosimilars. This policy has encouraged 340B hospitals to adopt
biosimilars and gain experience and confidence in using them.
Despite these current policies, other adverse incentives that favor
higher-cost originator biologics are keeping biosimilars from reaching
patients. In many cases, payers decline to include lower-cost
biosimilars or generics in their formularies because they would risk
losing the rebates they could receive by covering higher-cost
medicines.
Question. I know there are proposals to essentially pay more for
biosimilars to make them more attractive, but that is not exactly what
we were intending when we wrote the law. Can you talk about adverse
incentives in the market and any barriers to market penetration that we
might address to help improve patient access to these lower cost
products?
Answer. Ninety percent of the medicines Americans take are generics
and competition from these drugs keeps prices low in most cases. The
biologics market, where some of the most expensive drugs exist, needs
similar competition. The market today has already seen demonstrated
savings as high as 40 percent relative to the branded product. In
Europe, biosimilars have obtained a market share of over 60 percent on
some products. However, in the United States, our biosimilar,
Inflectra, has captured only 6 percent, despite the fact that its
average selling price (ASP) is more than 25 percent lower than the
originator product. With more competition, Pfizer hopes even further
savings can be realized. We believe some of the adverse incentives and
barriers to market penetration include:
1. The Rebate Trap: Brand-name biologic companies are using
maneuvers to block biosimilar competition such as higher
rebates and exclusionary contracts.
2. Misinformation: We believe that some physician and patient-
directed materials created by brand companies mischaracterize
biosimilars, creating doubt and confusion about the safety and
efficacy of biosimilars. As defined by statute, an approved
biosimilar must be highly similar to and have no clinically
meaningful differences from the reference product and must have
the same mechanism of action (to the extent the mechanism(s) of
action of the reference product are known) as the reference
product. Thus, by definition, biosimilars are safe and
efficacious treatments relative to the reference product and
must work in the same way as the reference product. Any
information disseminated by reference product sponsors to
suggest or imply otherwise should be promptly addressed by the
FDA.
3. Need for incentives: Legislative ideas to promote
biosimilar uptake could include a shared savings biosimilar
model; reduced patient cost sharing for biosimilars.
Although the biosimilar market in the United States is still
relatively new, Pfizer's experience has been that
anticompetitive conduct by brand-name biologic manufacturers,
combined with the lack of policy measures to support
appropriate uptake of biosimilars, have contributed to a slow
uptake. Therefore, we encourage you to consider measures to
help incentivize the use of biosimilars, which can
substantially lower Medicare costs with demonstrated savings to
date as high as nearly 40 percent relative to the branded
biologic.
In addition to stopping anticompetitive behavior (either
through government enforcement or in the courts through private
litigation), some key policy initiatives we believe will
support the uptake of biosimilars in the United States include:
Waiver of Part B Patient Coinsurance for Biosimilars for a
certain period of time. CMS should waive Part B patient
coinsurance amounts for biosimilars. Cost-sharing changes could
be applied at the Healthcare Common Procedure Coding System
(HCPCS) level. This would not change the overall payment for a
biosimilar; however, it would change the beneficiary's payment
percentage.
CMS should pursue a CMMI model designed to increase access
to biosimilars, including a ``shared savings'' model whereby
Medicare savings associated with prescribing a biosimilar, as
compared to a reference biological, would be shared with
providers.
CMS should maintain the current biosimilar pass-through
status as this provides biosimilars with a ``level playing
field'' with their higher priced reference biologic
competitors.
CMS should create payment incentives for plans by
contracting with a measure developer for a biosimilar use
measure for the STARS program, which would correct other
adverse incentives for biosimilar uptake for Medicare Advantage
plans.
______
Questions Submitted by Hon. John Cornyn
Question. We continue to hear that rebates negotiated off of the
list price of a drug are both good and bad.
Pharmacy benefit managers and plans have argued that rebates are
used to lower premiums across the board and that it is the best way to
seek a price concession on otherwise expensive drugs.
Your industry argues that these payers are insisting on higher
rebates that can only be achieved by raising list prices.
But patients often lose under this system, with out of pocket costs
being tied to list price. Insulin patients appear to be routinely
impacted by this perversity in the system.
Please explain to the committee how your company would reduce list
prices if rebates were no longer a part of the equation?
Answer. If finalized, the rule would result in lower out-of-pocket
patient costs at the pharmacy counter and help address the perverse
incentives in the system that have been contributing to higher list
prices for medicines.
In 2019, Pfizer expects to pay billions of dollars in rebates to
ensure patients with pharmacy benefits coverage in Medicare Part D and
patients in commercial plans have access to our medicines. If the
proposed rule to share rebates with consumers at the point of sale is
finalized, we estimate that seniors taking Pfizer medicines could save
$270 on average per year, and up to $574 per year for certain Pfizer
medicines, through lower cost sharing--and that would outweigh any
premium increases.
As currently written, the proposed rule only applies to the
Medicare and Medicaid managed care segments of the market. It will be
important to have rebate reform changes apply to both government
programs and the commercial market. A bifurcated market will make it
more challenging for manufacturers to reduce list price since the
commercial market covers more than 50 percent of Americans with
insurance and represents over half of the business for most
manufacturers.
If the proposed reform is modified to apply to all market segments,
we would evaluate the best options to arrive at a net price that
ensures patients have access to our medicines. Decisions would be made
on a product by product basis given that each therapeutic class has its
own set of competitive and access dynamics.
Question. What assurance can you provide that you would in fact
lower your prices?
Answer. If the rule is finalized consistent with the aforementioned
concerns, Pfizer is confident patients will benefit from savings of any
price concessions at the point of sale.
Question. What actions should be taken to ensure that patients are
actually seeing the benefits of lower out of pocket costs?
Answer. We strongly support ensuring that patients receive the
benefit of rebates at the pharmacy counter and look forward to working
with Congress and HHS on this issue. We encourage Congress to ensure
that plans do not impose new barriers or restrictions to access that
undermine the spirit of the rule and prevent patients from benefiting
from the savings.
Question. If rebates are driving high list prices for drugs as drug
manufacturers' claim, why do you think that Part B drugs, which have no
PBM rebates, are also seeing significant price increases? Whose fault
is that?
There are rebates involved with infusion medicines (Medicare Part B
drugs), and Pfizer is willing to engage with your staff in general
terms to explain the relationship and negotiations between
manufacturers and payers such as insurers and PBMs for drugs in this
space.
Pfizer also believes there are other ways to reform the Part B
payment system to move away from incentivizing the use of more costly
drugs. One solution we support for reforming Part B is a Competitive
Acquisition Program (CAP) to allow vendors to deliver and bill Medicare
for drugs, starting in a few cities. We believe this will inject
competition into the program.
Biosimilars are another solution. Pfizer is fully committed to the
goals set by Congress to bring new biosimilars to market, ensuring that
patients have access to a wide range of treatment options at a
competitive, affordable price. The market today has already seen
demonstrated savings as high as 40 percent relative to the branded
product. With more competition, we hope even further savings can be
realized.
rebate traps
Question. Pfizer's biosimilar to Janssen's Remicade has struggled
to gain market share, despite being priced at a significant discount to
the biologic.
Please explain the market challenges you are seeing with this
product. How does the practice of drug companies ``bundling'' the
prices of product portfolios and rebates associated with these drugs
limit competition and access to lower-cost biosimilars?
Answer. As more fully laid out in Exhibit 4, the primary barrier to
Inflectra's uptake is an anticompetitive contracting scheme that
targets both the payer (i.e., insurer) channel and the health-care
provider (i.e., hospitals, clinics and doctors) channel. The
centerpiece of the scheme is the ``rebate trap'' that uses pricing
penalties (i.e., the loss of significant rebates) to coerce insurers to
enter into exclusive deals that cover Remicade while effectively
blocking Inflectra from coverage. Multi-
product bundling is just one aspect of the conduct. Despite bringing a
lower-cost version of Remicade to market, this biosimilar has captured
less than 10 percent of the market.
Question. Do you attribute this to exclusionary contracts or
``paying for position'' to keep your product off formularies? Please
explain this practice and how it keeps lower-cost drugs out of the
hands of patients.
Answer. Pfizer attributes low uptake to an anticompetitive
contracting scheme as described above in response to Question 1.
This is particularly concerning not only because of the direct
impact regarding the health-care system's spend, but also because it
could become the playbook by which innovator biologics thwart entry by
biosimilars in the future. This could inhibit significant competition
to biologics going forward and act as a disincentive for companies to
invest in developing biosimilars.
______
Questions Submitted by Hon. Steve Daines
Question. As an advocate for improving Montanans' access to low-
cost medications, I've been a champion of the Creating and Restoring
Equal Access to Equivalent Samples (CREATES) Act, which would combat
anticompetitive practices used by some brand-name pharmaceutical
companies to block or delay competing generic drugs from entering the
market.
During the hearing when I asked if your company had ever withheld
samples from generic manufacturers, you answered emphatically no. Yet,
according to the Food and Drug Administration (FDA), generic drug
makers have made inquiries with the agency claiming they were unable to
access samples provided by Pfizer and AstraZeneca that are needed to
conduct studies to produce low-cost generic drugs.
Do you agree that denying generic drug manufacturers access to
samples keeps drug costs high for patients due to lack of competition?
Has your company refused to sell samples or placed any barriers in
the way of generic drug makers acquiring samples?
Are you aware of any outstanding requests for samples?
How does your company work to prevent abuses in the sample system?
Answer. As a patient-focused company and leading manufacturer of
innovative, generic, and biosimilar medicines, Pfizer supports
innovation and a strong, competitive marketplace. Consistent with these
values, Pfizer does not block generic manufacturers from purchasing our
products, and it has never been our policy to do so. Generic
manufacturers are treated the same as any other customer seeking to
purchase our products. Pfizer is not aware of any current, unfulfilled
requests from a generic manufacturer to purchase a Pfizer product.
Generic manufacturers seeking to purchase Pfizer products should
request the product from Pfizer's authorized distributors or, if the
product is not available at a distributor, from Pfizer directly, the
same as any other Pfizer customers. Pfizer's website includes a list of
our authorized distributors, from which customers (including generic
companies) may purchase most Pfizer products (see https://www.
pfizer.com/products/medicine-distributors). For products that are not
available via our authorized distributors and that are not in extreme
drug shortage or unavailable due to a recall, customers can contact
Pfizer's Customer Service center at 1-800-TRY-FIRST (1-800-879-3477) to
purchase product directly from Pfizer. The telephone number for
Pfizer's Customer Service center is also included on our website at
https://www.pfizer.com/contact. Pfizer makes its products available for
sale to appropriately licensed entities at Pfizer's listed price and on
Pfizer's standard terms of sale. We do not have any agreements with
authorized distributors that block the sale of Pfizer's products to
generic manufacturers.
Regarding the FDA List (the List), while Pfizer supports FDA's (the
agency) goal of providing transparency, Pfizer is concerned that the
List lacks certain key information and context and, as currently
presented, may create the misleading impression that all products on
the List are the result of bad faith attempts to block generic
manufacturer access to samples. The appearance of a product on the FDA
List means only that a generic manufacturer informed the agency at some
point in time that it was having difficulty purchasing the listed
product. FDA's own disclaimer states that the agency has not
independently investigated or confirmed whether a generic manufacturer
actually made a request to purchase product, and to whom.\3\ The FDA
List also lacks several important pieces of information that would
enable a New Drug Application (NDA) holder to investigate its
appearance on the List. The List does not include: (1) which generic
manufacturer made the request; (2) when and to whom the generic
manufacturer made the request (e.g., to a wholesaler, directly to the
NDA holder); (3) whether the generic manufacturer that made the inquiry
was thereafter able to obtain product; and (4) any reason(s) why a
generic manufacturer may not have been able to obtain product (e.g., a
recall). Finally, Pfizer notes that FDA does not currently inform an
NDA holder in real time when a generic manufacturer notifies the agency
that it is having difficulty obtaining product. Had the agency informed
Pfizer at the time it received the inquiries noted on the FDA List,
Pfizer could have then undertaken its own efforts to resolve the issue.
Pfizer communicated its concerns about the FDA List to the agency in
May 2018. For your information we have included Pfizer's letter to FDA
on this topic and the agency's response (see Exhibits 1 and 2 in the
Appendix).
---------------------------------------------------------------------------
\3\ (https://www.fda.gov/Drugs/DevelopmentApprovalProcess/
HowDrugsareDevelopedandAp
proved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/
ucm607738.htm).
There are three new drug applications owned by Pfizer on the FDA
List: Embeda (NDA 022321), Tikosyn (NDA 020931) and Hemabate (NDA
017989). Embeda offers a good example of the List's shortcomings.
Pfizer acquired King Pharmaceuticals (the previous NDA holder of
Embeda) in March 2011, and two weeks later determined that Embeda
needed to be recalled from the U.S. market due to stability issues.
After diligently addressing the issues that led to the recall, Pfizer
relaunched Embeda to the U.S. market in January 2015, and it is
available for purchase via Pfizer's authorized distributors. However,
one consequence of the recall, was that Embeda was not available in the
U.S. market for almost 4 years which may explain why a generic
manufacturer had a problem obtaining it during those years. The FDA
List does not specify when the generic manufacturer's inquiry regarding
Embeda was made nor does the FDA List indicate that several generic
applications for Embeda had been submitted to FDA in 2010 (which means
that before the recall, several generic manufacturers were successfully
able to purchase Embeda, conduct the necessary testing, and file
Abbreviated New Drug Applications (ANDAs)). Pfizer has not identified
any recent inquiries from generic manufacturers seeking to purchase
---------------------------------------------------------------------------
Embeda that have not been fulfilled.
The circumstances around Tikosyn also illustrate the List's
shortcomings. Pfizer was able to identify a single inquiry made by a
generic manufacturer directly to Pfizer to purchase Tikosyn in 2014. At
that time, Tikosyn was subject to an FDA imposed Risk Evaluation and
Mitigation Strategies (REMS) with Elements to Assure Safe Use
(``ETASU'') that restricted distribution, so Pfizer responded by asking
the manufacturer to obtain written confirmation from the FDA that
Pfizer's provision of the product to the generic manufacturer would not
be considered a violation of its REMS. The generic manufacturer did not
contact Pfizer further, and Pfizer never received any written
correspondence from the agency. FDA subsequently removed the REMS for
Tikosyn in 2016, and multiple generic versions of Tikosyn are now
approved, the first generic approval occurring in June 2016. This
context is not reflected in FDA's List.
Finally, with respect to Hemabate, this product was previously
subject to certain restrictions on distribution (i.e., it was sold only
to customers with medical and surgical intensive care centers) to
ensure its safe and appropriate use. This distribution approach was
established by the previous NDA holder (Pharmacia) and it continued
following Pfizer's acquisition of Pharmacia in 2003. Pfizer
discontinued this approach in early 2018 after determining that it was
no longer necessary, and this product is now available through our
authorized distributors. During the time when Hemabate was under
restricted distribution, it was not available at Pfizer's authorized
distributors, but had a generic manufacturer approached Pfizer's
Customer Service center directly, we would have been able to address
the inquiry. Pfizer's Customer Service was not able to identify any
specific requests from a generic manufacturer to purchase Hemabate that
have not been fulfilled.
We hope that this information explains the apparent discrepancy
between Mr. Bourla's testimony and the appearance of these Pfizer
products on the FDA List, and demonstrates Pfizer's diligence on these
issues and commitment to a competitive marketplace.
______
Questions Submitted by Hon. Todd Young
re-evaluating business strategies in foreign countries
Question. Since taking office, President Trump has made reducing
drug prices one of his highest priorities--and has repeatedly spoken
about his frustration with the U.S. subsidizing the costs of
pharmaceuticals for the rest of the world. He has gone so far as to
issue proposals, like the International Pricing Index (IPI) Model, in
an attempt to bring down prescription drug prices.
With the increased scrutiny of the industry and of the drug supply
chain as a whole in the United States, have any of your companies re-
evaluated your business strategy in foreign countries?
Answer. Pfizer's purpose is breakthroughs that change patients'
lives; all aspects of Pfizer's business model are infused with this
purpose. It is Pfizer's priority to make our medicines and vaccines
available and accessible to all patients who need them, regardless of
where they live.
Proposals to implement international reference pricing for the U.S.
market would have far-reaching consequences to patient access,
innovation and our business strategies both in the United States and in
foreign countries.
If the United States were to implement the proposed International
Price Indexing (IPI) model, we believe that a change of this scale
could be very disruptive, challenging our ability to reach patients
both inside and outside of the United States in a timely manner while
fulfilling commitments to our shareholders and further investing in
R&D.
Question. If not, then why?
Answer. Pfizer agrees that more must be done to address foreign
pricing differentials. We want to continue to work with policymakers on
solutions to ensure other countries appropriately recognize the value
of innovation. Pfizer supports the concept of ``shared value for
innovation'' because it promotes global fairness. This means that all
nations recognize the importance and benefits of medicines to patients
and society and the significant investments required to develop them,
and that all patients should benefit, no matter where they live.
If foreign countries were to increase their support for shared
value for innovation, American patients would benefit based on
increased innovation, drug launches, competition and more access to new
medicines.
Question. If a proposal, like IPI, were implemented, would it force
your companies to potentially ``walk away from the negotiating table
when other countries demand low prices subsidized by America's
seniors,'' as HHS Senior Advisor for Drug Pricing Reform John O'Brien
has said?
Answer. While the IPI could lead to potential situations in which a
company would ``walk away'' as noted by John O'Brien, pricing is not
the only determinant of reimbursement negotiations in foreign
countries, many of which employ access controls, restricting patients'
ability to receive new innovative medicines.
We have concerns with the IPI model. The use of reference pricing
is strongly associated with market and patient access delays in
countries that have adopted reference pricing, among other cost-
containment mechanisms. Pfizer works with governments and health
systems around the world to support patients' access to the medicines
they need. We strongly believe that flexibility in our ability to set
global prices improves access to medicines.
Question. What are some of your ideas on how we can ensure
Americans aren't shouldering the full cost of pharmaceuticals?
Answer. Pfizer believes that developed countries have an important
role to play in supporting global innovation ecosystems. As such, we
would encourage the United States Government to continue to elevate the
innovation agenda in multilateral discussions, with an emphasis on
rewarding innovation in health-care delivery, science policy and
pharmaceutical breakthroughs (e.g., through the G7). U.S. trade
negotiations, such as those with Japan, also provide important
opportunities for the United States to secure robust commitments that
ensure countries protect intellectual property, provide fair market
access for U.S. companies, and appropriately recognize the value of
innovation.
Pfizer also believes that there are other ways to reform the Part B
payment system to move away from incentivizing the use of more costly
drugs. One solution we support for reforming Part B is a Competitive
Acquisition Program (CAP) to allow vendors to deliver and bill Medicare
for drugs, starting in a few cities. We believe this will inject
competition into the program.
Biosimilars are another solution. Pfizer is fully committed to the
goals set by Congress to bring new biosimilars to market, ensuring that
patients have access to a wide range of treatment options at a
competitive, affordable price. The market today has already seen
demonstrated savings as high as 40 percent relative to the branded
product. With more competition, Pfizer hopes even further savings can
be realized.
foreign countries' pricing and reimbursement
Question. President Trump and Secretary Azar have both repeatedly
described their frustrations with ``foreign freeloading'' of U.S. drugs
in the last year.
``When foreign governments extort unreasonably low prices from U.S.
drug makers, Americans have to pay more to subsidize the enormous cost
of research and development. . . . It's unfair and it's ridiculous, and
it's not going to happen any longer.''
Do you agree that because of foreign countries' pricing and
reimbursement systems, U.S. patients and innovators are shouldering the
burden for financing medical advances?
Answer. Pfizer agrees that more must be done to address foreign
pricing differentials. Wealthy countries should reimburse innovative
medicines based on fair value. As stated above, ``foreign free-
loading'' has a significant impact on the U.S. biopharmaceutical
industry's investments in continued innovation. If the United States
secures agreements that ensure countries protect intellectual property,
provide fair market access for U.S. companies, and appropriately
recognize the value of innovation, this will help ensure U.S. patients
continue to have access to innovative medicines.
Question. How do foreign countries' pricing and reimbursement
systems affect our prescription drug costs?
Answer. The U.S. health-care system offers patients more choice and
faster availability of innovative medicines. While government-run
health systems aim to provide care to their people, they are often
challenged to provide fast and easy access to the latest innovations.
These governments often have to make choices between paying for health
care and other government priorities.
The United States allows companies and providers to set prices that
reflect the benefits to patients and societies. This includes ensuring
that health-care professionals and patients have choices for
individualized care, that there is competition among companies, and
that their expectations for access to the latest medical advances are
met.
Some developed countries rely on price controls and other
government regulations to set the prices of health care, including
medicines. This may result in some lower prices but can also result in
restrictions on who is eligible to receive a covered medicine. A recent
op-ed in The Wall Street Journal pointed out that of the 45 new drugs
that FDA approved in 2015, all were covered by Medicare in the United
States in 2017, but only 19 in France, 13 in Canada and 11 in
Australia.\4\
---------------------------------------------------------------------------
\4\ https://www.wsj.com/articles/how-to-reduce-prescription-drug-
prices-first-do-no-harm-1155
0100537.
However, prices are not always higher in the United States. Nine
out of ten drugs that patients pick up at the pharmacy are generics,
and these drugs are less expensive than they are in Europe, Japan,
China or many countries around the world. The U.S. system is the most
---------------------------------------------------------------------------
efficient system for delivering lower-cost generics to patients.
Pfizer supports the concept of ``shared value for innovation''
because it promotes global fairness. This means that all nations
recognize the importance and benefits of medicines to patients and
society and the significant investments required to develop them, and
that all patients should benefit, no matter where they live.
If foreign countries were to increase their support for shared
value for innovation, American patients would benefit based on
increased innovation, drug launches, competition and more access to new
medicines.
Question. Are foreign governments taking note of the concerns being
raised by the Trump administration and have they responded in any way?
Answer. Pfizer believes that other governments are indeed taking
note of the administration's focus on health-care spending.
Question. Has there been any noticeable change in any of our trade
agreements since these concerns have been raised by the Trump
administration?
Answer. The Trump administration recently signed the U.S.-Mexico-
Canada Agreement (USMCA), which includes important commitments that
will help companies like Pfizer continue to innovate to bring new
therapies to patients. For example, the agreement includes a commitment
to provide 10 years of regulatory data protection for biologics. This
commitment had not been included in any trade agreement negotiated
prior to USMCA and is an important achievement. The Trump
administration is also pursuing new bilateral trade negotiations with
Japan, the EU, and the UK; because the negotiations have not yet
concluded, however, it is premature to comment on how those agreements
may compare to other U.S. trade deals.
medicaid closed formulary proposals
Question. In an attempt to bring down drug costs, various States
have been exploring whether to exclude certain drugs from its Medicaid
program. For example, the State of Massachusetts' recently asked CMS
for permission to create a closed formulary where the State Medicaid
program would pick at least one drug per therapeutic class. CMS denied
their waiver request citing violation of Federal law, but this proposal
does bring up important questions on how to contain drug prices in
State Medicaid programs.
If the principles of the Medicare Part D program--including the
necessary patient protections--were applied to State Medicaid programs,
do you think it lower drugs costs while ensuring access to patients?
Answer. Pfizer supports efforts to ensure patients have access to
medicines. Studies suggest that allowing more choice of medications has
positive results for patients: lowering the chances of drug
interactions and adverse events and increasing the efficacy of
treatment.\5\ Years of research have also shown that limiting
formularies correlates to poor medication adherence outcomes.\6\
Studies featuring Medicaid recipients with severe health conditions
indicate that in many instances, these restrictions can result in
negative health outcomes and other outcomes (such as increased
incarceration rates) without generating program savings or other
intended benefits (and sometimes increasing overall State costs).\7\
---------------------------------------------------------------------------
\5\ See, e.g., DiMasi, ``Competitiveness in follow-on drug R&D: a
race or imitation?'', 10 Nat. Rev. Discov. 23-27 (Jan. 2011); Turner
et. al, ``Parsing Interindividual Drug Variability: An Emerging Role
for Systems Pharmacology,'' Wiley Interdiscip. Rev. Syst. Biol. Med.
221-41 (2015); Mullins et. al, ``Persistence, Switching, and
Discontinuation Rates Among Patients Receiving Sertraline, Paroxetine,
and Citalopram,'' 25 Pharmacotherapy 660-67 (2005).
\6\ See, e.g., Happe et. al, ``A Systematic Literature Review
Assessing the Directional Impact of Managed Care Formulary Restrictions
on Medication Adherence, Clinical Outcomes, Economic Outcomes, and
Health Care Resource Utilization,'' 20 Manag. Care Spec. Pharm. 677-84
(2014).
\7\ See, e.g., U.S.C. Schaffer, ``Medicaid Access Restrictions on
Psychiatric Drugs: Penny-Wise or Pound Foolish?'', (Feb. 2015), http://
healthpolicy.usc.edu/documents/USC%20Issue%20Brief
%20No.%202%20Final.pdf (indicating increased incarceration rates
associated with certain access restrictions); Lu, et. al, ``Unintended
Impacts of a Medicaid Prior Authorization Policy on Access to
Medications for Bipolar Illness,'' 48 Medical Care 4 (Jan. 2010)
(finding that while a prior authorization policy in Maine Medicaid was
associated with a marked decrease in rates of initiation of bipolar
treatments associated with reduction in initiation of nonpreferred
agents, the policy had no discernable impact on rates of switching
therapy among patients currently on treatment); Farley, et al.,
``Retrospective Assessment of Medicaid Step-Therapy Prior Authorization
Policy for Atypical Antipsychotic Medications,'' 30 Clinical
Therapeutics 1524 (April 2008) (showing, for a group of Medicaid
patients with schizophrenia who were subject to a prior authorization
policy for atypical antipsychotic medications, significant increases in
per member per month outpatient expenditures far exceeded the
associated savings in atypical antipsychotic expenditures).
---------------------------------------------------------------------------
medicaid ``best price''
Question. In the Trump administration's Blueprint, they suggested
that because drug manufactures have to give Medicaid the ``best price''
on drugs, there is no incentive to offer deeper discounts to other
payers--both government and commercial--than what is already offered
under the Medicaid Drug Rebate Program.
Does the Medicaid ``best price'' requirement encourage
manufacturers to increase initial prices?
Answer. Medicaid Best Price is not a factor in setting our launch
prices.
Question. What, if any, changes would you suggest we make to the
program?
Answer. Pfizer encourages HHS to consider how to address the
challenges that Medicaid Best Price poses for value-based agreement
(VBAs). Specifically, we recommend that:
To allow for innovative approaches and risk sharing, a poor
outcome should not set a new price for Medicaid. This would
allow manufacturers to share more risk with commercial health
plans.
Approaches to reporting VBAs should be as simple as
possible. This would help avoid creating operational challenges
for companies that may prevent development of innovative
approaches.
Manufacturers should continue to have flexibility to make
reasonable assumptions in their price reporting, so that
reporting approaches can evolve to reflect changes in the
dynamic market and contracting environment.
outcomes-based contracts
Question. In almost all of your testimonies, you highlight your
support of outcomes-based contracts and how we need to be shifting our
system toward that approach.
How will these contracts lower drug costs for patients in both the
near term and long-term?
Answer. Value-based agreements (VBA) provide a framework for paying
for medicines based on their value to patients and the overall health-
care system. There are many different types of VBAs including those
based on clinical and/or financial performance metrics for a product.
Based on the outcomes achieved, payers use this information to inform
how they cover products. Products that perform better should be covered
in a more favorable manner which often includes lower out-of-pockets
costs for patients which is a benefit to patients in the near term. In
the long term, patients can also benefit from other savings either
directly, (e.g., reducing spending on other medications, lowering
medical costs from reduced hospitalizations, doctor's visits, etc.), or
indirectly through lower premiums based on reductions in total cost of
care.
Question. How will they lower overall health-care costs for our
Federal programs?
Answer. VBAs can be implemented in Federal programs so that the
benefits described above can accrue to the Federal programs.
Question. What have the preliminary results looked like so far?
Answer. VBAs are in the very early stages of development in the
United States. Many payers and manufacturers have tested different
concepts but to date, VBAs have not achieved scale. There are multiple
reasons why VBAs represent a small fraction of manufacturer/payer
contracts (e.g., access to data, difficult and costly to administer,
etc.). There are certain aspects of the current U.S. regulatory
landscape that are perceived by many as not only complicating VBA
implementation but in some cases limiting their rapid uptake.
Stakeholders have frequently identified two key regulatory hurdles as
limiting the expanded adoption of VBAs: (i) the Anti-Kickback Statute
and (ii) the Medicaid Best Price calculation requirement. While these
regulations serve important roles within the current volume-based
reimbursement system they do not contemplate innovative value-based
arrangements which has resulted in a lack of clarity on how to account
for these under the current regulatory framework. Ultimately, an
expansion of VBAs will require reforms to existing regulations that
enable more flexibility in designing VBAs.
transparency/point of sale
Question. In almost all of your testimonies, you express your
support for the Trump administration's proposal to allow manufacturers
to provide PBMs up-front discounts that are passed onto patients at the
point of sale.
Do you feel like this proposal will make the transactions within
the drug supply chain more transparent?
Answer. Pfizer acknowledges that providing discounts pursuant to
the safe harbor for point-of-sale price discounts will enhance
transparency of net pricing strategies and potentially drive downward
pressure on net prices. Nonetheless, Pfizer believes that the proposed
safe harbors are good for patients and lay the groundwork for the
systemic change needed to create a simpler, more cost effective, and
more transparent U.S. health-care system, and we are fully committed to
operating in this new system. We are concerned, however, that plans and
PBMs could impose new formulary restrictions and utilization barriers
to make up for lost rebates that undermine the spirit of the rule and
create new access challenges to patients. For patients to receive the
benefits of the rule, we urge policymakers to ensure that no new access
barriers are created as a way to compensate for lost rebate.
Question. If so, would this transparency bring down drug costs--
overall and for specialty drugs?
Answer. Only through such transparency can Pfizer and other
industry players ensure that discounts and other price reductions
directly benefit the patient, which is a critical factor driving
Pfizer's support for the Proposed Rule.
the relationship between wholesalers and manufacturers
Question. When talking about the pharmaceutical supply chain, a lot
of focus has been placed on the Pharmacy Benefit Manager. But there's
another side of the equation that I'd like to ask about: how do
wholesalers negotiate pricing with manufacturers?
Answer. Wholesalers pay list price for our products. They may
receive prompt pay discounts, which would reduce their net price.
Wholesalers also can earn bona fide service fees based on performing
services that are important to pharmaceutical manufacturers.
Question. What impact does this have on drug costs?
Answer. These discounts and fees are relatively consistent across
products and do not significantly impact drug costs.
Question. What incentives or disincentives do they have to contain
price increases?
Answer. As a result of the competitive nature of their business,
wholesalers do have an incentive to contain price increases.
______
Questions Submitted by Hon. Ron Wyden
proposed rebate rule
Question. As has been done in many other settings, drug
manufacturers said during the hearing that one reason list prices for
drugs are high is that pharmaceutical benefit managers (PBMs) demand
larger and larger rebates in order for the drug to receive favorable
placement on a formulary. You and your colleagues who testified during
the hearing stated if the administration's proposal on changes to the
anti-kickback safe harbor for pharmaceutical rebates took effect, your
company would likely lower list price.
Like many Oregonians, I am skeptical drug manufacturers would
voluntarily lower their prices. Therefore, would you support
legislation that would (1) make similar changes the administration has
put forward related to Part D and Medicaid managed care, (2) change the
rebate system in a similar way to the proposal for the commercial
market, and (3) require drug makers to lower the list price of their
drugs equal to the amount of rebates provided today?
Answer. Pfizer would support legislation that reforms the current
system of rebating to one in which payers are required to use
manufacturer provided discounts to ensure that the patient gets the
benefit of the discount at the point of sale. We support this reform
across all segments of the market where private sector negotiations
result in lower net prices including Medicare Part D, Medicaid managed
care and the commercial markets.
We realize that the transition away from rebates toward a point-of-
sale discount model will result in a lowering of our net prices.
Despite this potential negative financial impact, we support efforts to
eliminate rebates because we believe the new model will be good for
patients.
As currently written, the proposed rule only applies to the
Medicare and Medicaid managed care segments of the market. It will be
important to have any rebate reform apply to both government programs
and the commercial market as that will also lead to a lowering of list
prices as well. A bifurcated market will make it more challenging for
manufacturers to reduce list price since the commercial market covers
more than 50 percent of Americans with insurance and represents over
half of the business for most manufacturers.
If the proposed rule is modified to apply to all market segments,
we would evaluate the best options to arrive at a net price that
ensures patients have access to our medicines. Decisions would be made
on a product by product basis given that each therapeutic class has its
own set of competitive and access dynamics. To ensure these benefits
reach patients, it will be important for policymakers to ensure that
plans do not create new barriers or restrictions that hinder patient
access and undermine the spirit of the rule.
medicaid drug rebate program
Question. The Medicaid Drug Rebate Program (MDRP) requires
manufacturers to provide a basic rebate and an additional inflationary
rebate for both brand and generic drugs. The inflationary rebate is an
increasingly substantial part of total rebates due in large part to
large increases in drug prices that exceed inflation. Under current
law, this inflationary rebate is capped at 100 percent of Average
Manufacturer Price (AMP). This is the case even when manufacturers
continue to raise their prices well above inflation.
Please provide a list of all of your pharmaceutical products that
have reached the Medicaid AMP rebate cap in any of the 20 quarters from
January 1, 2014 through December 31, 2018.
For each drug listed in response to question 1, please also provide
a list of which quarters and years each drug hit the cap.
Answer. Given the highly confidential nature of the information
requested, we would need to discuss the scope of this request with your
staff.
medicaid drug rebate program compliance
Question. I am concerned about recent reports and legal settlements
surrounding drug manufacturers' failure to comply fully with the
requirements of the MDRP. For example, an analysis by the U.S.
Department of Health and Human Services Office of Inspector General
found that between 2012 and 2016 taxpayers may have overpaid by as much
as $1.3 billion for 10 potentially misclassified drugs. That is why I
introduced the Right Rebate Act with Chairman Grassley to prevent drug
manufacturers from manipulating Medicaid to increase their profits.
However, I continued to be concerned about oversight and manufacturer
compliance with the requirements of the Medicaid Drug Rebate Program.
Accordingly, please describe the following: your company's current
compliance plan and procedures used to ensure compliance with the
requirements of the Medicaid Drug Rebate Program including internal
audits or other checks you use to identify compliance vulnerabilities;
any past or ongoing issues of non-compliance; any corrective actions
taken to address identified problems or issues of non-compliance with
the MDRP and how such steps were communicated to the Centers for
Medicare and Medicaid Services; and any steps taken to improve
compliance and ensure that all Medicaid drug rebates owed to the
Federal Government and the States are paid in full.
Answer. It is Pfizer's policy to comply with all legislation,
regulations, provisions, requirements, terms and conditions of the
MDRP.
In order for its outpatient drugs to be covered by the Medicaid
program, a manufacturer must enter into a national rebate agreement
with the Secretary of HHS. This agreement generally requires
manufacturers to offer Medicaid agencies the mandated discounts for
covered prescription drugs. Pfizer is responsible for calculating and
reporting to the Federal Government on a monthly and quarterly basis
various metrics for each of Pfizer's products and, ultimately, for
paying corresponding rebates based on Medicaid recipients' purchases of
the company's covered drugs. In return for these rebates, State
Medicaid agencies must pay for all of the drug company's covered drugs
(with certain limited exceptions). If the price of the manufacturer's
drug rises faster than the inflation rate, States may require an
additional rebate. Pfizer and/or its predecessor entities have signed a
Rebate Agreement with HHS for all Pfizer labeler codes and Pfizer
remains vigilant of its obligations under the Medicaid Drug Rebate
Program.
The Company has robust policies and procedures to ensure compliance
with government price calculations, certification and reporting under
MDRP including Pfizer's certification, reporting, payment obligations,
records retention and audit obligations. The Company's policies and
procedures are also meant to impart to Pfizer employees an
understanding of the government pricing metrics calculated under the
MDRP. Consistent with Pfizer's policies and procedures and available
CMS guidance, if Pfizer becomes aware of any instances of non-
compliance with the MDRP, Pfizer reports and/or communicates with CMS.
Based on our current information and belief, Pfizer complies with CMS
regulations and interacts with CMS to take corrective action as
instructed.
bonus payments tied to specific drugs
Question. I am concerned by the potential for employee financial
incentives to encourage high launch prices and price increases for
prescription drugs.
Is your salary, bonus, or other compensation tied to sales or
revenue targets of a single product your company sells? Has it ever
been? If yes, please state the product or products to which your
salary, bonus or other compensation was tied.
Answer. No. Dr. Bourla's salary, bonus, or other compensation is
not nor has ever been tied to the sales or revenue targets of a single
product.
Question. Is your salary, bonus, or other compensation tied to
either revenue or net income of the company as a whole? Has it ever
been? If yes, please explain what assumptions about price increases are
used when the compensation committee sets revenue or net income goals.
Does the compensation committee provide any guidance to executives in
regards to the amount of revenue that the company will generate from
price increases versus volume growth?
Answer. Dr. Bourla, along with over approximately 48,000 other
colleagues, participates in Pfizer's annual bonus plan, Pfizer's Global
Performance Plan (GPP), which is funded annually based on Pfizer's
performance measured against three financial metrics: revenue, adjusted
earnings per share and cash flow from operations and has been since
2008.
Therefore, any annual bonuses through Pfizer's GPP, determined by
the Compensation Committee of the Board of Directors and ratified by
the independent members of the Board, is in part based on company
revenue and net income as adjusted earnings per share is derived from
net income. In determining Dr. Bourla's bonus, the Compensation
Committee also takes into account other factors such as his individual
performance against his annual performance objectives and overall
company performance (e.g., pipeline). Neither Dr. Bourla's salary nor
other compensation is tied to revenue or net income of the company as a
whole.
In setting the corporate financial goals for compensation purposes,
the Compensation Committee uses the company's annual budget as the
starting point and it is adjusted accordingly based on the final
business plan discussion which accounts for various factors, including
access, rebates, losses of exclusivity and expected price adjustments.
The Compensation Committee does not provide any guidance with
regard to the amount of revenue that the company will generate from
price increases versus volume growth.
net prices
Question. In your testimony, you stated, ``In 2018, the average net
price of Pfizer's medicines in the United States declined 1 percent.''
Please describe how the company's year-over-year aggregate net price is
calculated.
Answer. The Net Sales Price impact versus the Prior Year reflects
the year-over-year change in average net selling price (calculated as
net sales / units) multiplied by the current year's units. This
calculation is performed at a product NDC level, and then aggregated up
to the product and then the total business level.
The company's aggregate year-over-year impact of price on growth is
the summation of the sales price impact versus prior year from all
products in dollars, divided by the prior year's total net revenues. In
2018, the year-over-year impact on price on growth for the U.S.
pharmaceutical business was negative 1 percent.
Question. How many products are included in the calculation of the
average net price change? What was the median net price change?
Answer. For 2018, there are a total of 399 products included in the
U.S. portfolio; median net price impact on growth is negative 4
percent.
Question. Is net price weighted? If so, how? For example, in
determining the aggregate net price does the company assign different
weights to different products based on volume or other factors? Are
``on patent'' and ``off patent'' drugs weighted identically? Are other
statistical weights used or are all products treated equally?
Answer. Aggregate change in net price is weighted based on product
volume (units) and mix. All products--both ``on patent'' and ``off
patent''--are treated identically.
Question. Does the figure that you provided during your testimony
account for U.S. prices, international prices, or both? Generally
speaking, when your company reports net price changes, does it
differentiate between U.S. and international prices?
Answer. The figure of negative 1 percent price impact on growth
provided during the testimony is for the United States. Generally
speaking, when we respond to inquiries on the impact of price on
growth, we have responded on a global basis, a U.S. only basis, or
both, dictated by how the inquiry is posed.
Question. Please list the five drugs your company sold in the U.S.
that had the greatest year-over-year net price increase in 2018, noting
the increase for each drug by dollar figure and percentage.
Answer. The following products had the greatest positive impact of
sales price on growth in the United States in 2018: Prevnar, Lyrica,
Chantix, Pristiq, Relpax.
Question. Please list the five drugs your company sold in the U.S.
that had the lowest year-over-year net price increase (and/or the
greatest decrease) in 2018, noting the increase (or decrease) for each
drug by dollar figure and percentage.
Answer. The following products had the greatest negative impact of
sales price on growth in the United States in 2018: Xeljanz, Viagra,
Inflectra, Ibrance, Celebrex.
Question. For 2018, what was the average net price change in the
U.S. market for (1) drugs with no competition, (2) drugs with only
branded competition, and (3) drugs with generic competition?
Answer. The 2018 impact of price on growth from branded products in
the United States was 2 percent. 2018 impact of price on growth from
remainder of portfolio (excluding Branded Products) in the United
States was negative 5 percent.
Question.Pfizer has lost exclusivity for several products in recent
years, including Viagra, Zyvox, Relpax, Tygacil, and Pristiq. For each
of these products, please provide the percentage and dollar change in
the average net price from (1) the last full year in which Pfizer
maintained product exclusivity to the (2) first full year in which
generic competition was present in the market.
Answer. Pfizer has lost exclusivity on several products in recent
years, including: 2014: Detrol, Rapamune, Celebrex; 2015: Zyvox; 2016:
Relpax, Tygacil; and 2017: Viagra, Pristiq.
In all but one case, the net price impact of the branded products
listed above was negative the year after exclusivity was lost,
reflecting market dynamics and the competitive environment.
______
Questions Submitted by Hon. Robert Menendez
Question. During the hearing, when I asked whether your company
engaged in tactics to delay generic production of your products, you
answered ``no''. However, Pfizer appears on the FDA's list of companies
who have access complaints against them. Can you explain the
discrepancy between your answer and the FDA list? The FDA list can be
found here: https://www.fda.gov/Drugs/DevelopmentApproval
Process/HowDrugsareDevelopedandApproved/ApprovalApplications/
Abbreviated
NewDrugApplicationANDAGenerics/ucm607738.htm.
Answer. As a patient-focused company and leading manufacturer of
innovative, generic, and biosimilar medicines, Pfizer supports
innovation and a strong, competitive marketplace. Consistent with these
values, Pfizer does not block generic manufacturers from purchasing our
products, and it has never been our policy to do so. Generic
manufacturers are treated the same as any other customer seeking to
purchase our products. Pfizer is not aware of any current, unfulfilled
requests from a generic manufacturer to purchase a Pfizer product.
Generic manufacturers seeking to purchase Pfizer products should
request the product from Pfizer's authorized distributors or, if the
product is not available at a distributor, from Pfizer directly, the
same as any other Pfizer customers. Pfizer's website includes a list of
our authorized distributors, from which customers (including generic
companies) may purchase most Pfizer products (see https://www.
pfizer.com/products/medicine-distributors). For products that are not
available via our authorized distributors and that are not in extreme
drug shortage or unavailable due to a recall, customers can contact
Pfizer's Customer Service center at 1-800-TRY-FIRST (1-800-879-3477) to
purchase product directly from Pfizer. The telephone number for
Pfizer's Customer Service center is also included on our website at
https://www.pfizer.com/contact. Pfizer makes its products available for
sale to appropriately licensed entities at Pfizer's listed price and on
Pfizer's standard terms of sale. We do not have any agreements with
authorized distributors that block the sale of Pfizer's products to
generic manufacturers.
Regarding the FDA List (the List), while Pfizer supports FDA's (the
agency) goal of providing transparency, Pfizer is concerned that the
List lacks certain key information and context and, as currently
presented, may create the misleading impression that all products on
the List are the result of bad faith attempts to block generic
manufacturer access to samples. The appearance of a product on the FDA
List means only that a generic manufacturer informed the agency at some
point in time that it was having difficulty purchasing the listed
product. FDA's own disclaimer states that the agency has not
independently investigated or confirmed whether a generic manufacturer
actually made a request to purchase product, and to whom.\8\ The FDA
List also lacks several important pieces of information that would
enable a New Drug Application (NDA) holder to investigate its
appearance on the List. The List does not include: (1) which generic
manufacturer made the request; (2) when and to whom the generic
manufacturer made the request (e.g., to a wholesaler, directly to the
NDA holder); (3) whether the generic manufacturer that made the inquiry
was thereafter able to obtain product; and (4) any reason(s) why a
generic manufacturer may not have been able to obtain product (e.g., a
recall). Finally, Pfizer notes that FDA does not currently inform an
NDA holder in real time when a generic manufacturer notifies the agency
that it is having difficulty obtaining product. Had the agency informed
Pfizer at the time it received the inquiries noted on the FDA List,
Pfizer could have then undertaken its own efforts to resolve the issue.
Pfizer communicated its concerns about the FDA List to the agency in
May 2018. For your information we have included Pfizer's letter to FDA
on this topic and the agency's response (see Exhibits 1 and 2 in the
Appendix).
---------------------------------------------------------------------------
\8\ (https://www.fda.gov/Drugs/DevelopmentApprovalProcess/
HowDrugsareDevelopedandAp
proved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/
ucm607738.htm).
There are three new drug applications owned by Pfizer on the FDA
List: Embeda (NDA 022321), Tikosyn (NDA 020931) and Hemabate (NDA
017989). Embeda offers a good example of the List's shortcomings.
Pfizer acquired King Pharmaceuticals (the previous NDA holder of
Embeda) in March 2011, and two weeks later determined that Embeda
needed to be recalled from the U.S. market due to stability issues.
After diligently addressing the issues that led to the recall, Pfizer
relaunched Embeda to the U.S. market in January 2015, and it is
available for purchase via Pfizer's authorized distributors. However,
as a consequence of the recall, Embeda was not available in the U.S.
market for almost 4 years which may explain why a generic manufacturer
had a problem obtaining it during those years. The FDA List does not
specify when the generic manufacturer's inquiry regarding Embeda was
made nor does the FDA List indicate that several generic applications
for Embeda had been submitted to FDA in 2010 (which means that before
the recall, several generic manufacturers were successfully able to
purchase Embeda, conduct the necessary testing, and file Abbreviated
New Drug Applications (ANDAs)). Pfizer has not identified any recent
inquiries from generic manufacturers seeking to purchase Embeda that
---------------------------------------------------------------------------
have not been fulfilled.
The circumstances around Tikosyn also illustrate the List's
shortcomings. Pfizer was able to identify a single inquiry made by a
generic manufacturer directly to Pfizer to purchase Tikosyn in 2014. At
that time, Tikosyn was subject to an FDA imposed Risk Evaluation and
Mitigation Strategies (REMS) with Elements to Assure Safe Use
(``ETASU'') that restricted distribution, so Pfizer responded by asking
the manufacturer to obtain written confirmation from the FDA that
Pfizer's provision of the product to the generic manufacturer would not
be considered a violation of its REMS. The generic manufacturer did not
contact Pfizer further, and Pfizer never received any written
correspondence from the agency. FDA subsequently removed the REMS for
Tikosyn in 2016, and multiple generic versions of Tikosyn are now
approved, the first generic approval occurring in June 2016. This
context is not reflected in FDA's List.
Finally, with respect to Hemabate, this product was previously
subject to certain restrictions on distribution (i.e., it was sold only
to customers with medical and surgical intensive care centers) to
ensure its safe and appropriate use. This distribution approach was
established by the previous NDA holder (Pharmacia) and it continued
following Pfizer's acquisition of Pharmacia in 2003. Pfizer
discontinued this approach in early 2018 after determining that it was
no longer necessary, and this product is now available through our
authorized distributors. During the time when Hemabate was under
restricted distribution, it was not available at Pfizer's authorized
distributors, but had a generic manufacturer approached Pfizer's
Customer Service center directly, we would have been able to address
the inquiry. Pfizer's Customer Service was not able to identify any
specific requests from a generic manufacturer to purchase Hemabate that
have not been fulfilled.
We hope that this information explains the apparent discrepancy
between Mr. Bourla's testimony and the appearance of these Pfizer
products on the FDA List, and demonstrates Pfizer's diligence on these
issues and commitment to a competitive marketplace.
Question. When new products enter the market, do drug companies set
high initial rebates and then provide deep rebates in order to gain
access to insurance plan's formularies?
Answer. Launch pricing is driven by a multitude of factors, the
most important being the medicine's impact on patients and their
health. We also may consider other factors like the medicine's
potential to reduce other health-care costs, such as hospital stays;
the availability of other treatments and generic options; affordability
for patients, insurers and governments; and investments to maintain the
quality, safety, delivery, and reliability of our medicines.
Given the consolidation that has taken place in the U.S. market,
the vast majority of retail prescriptions are managed by a few large
PBMs. Pharmaceutical manufacturers must successfully negotiate with
these PBMs to gain access to their formularies or risk having their
products disadvantaged or even excluded from coverage.
The system has evolved in a manner where rebates play a significant
role in how the PBM business is transacted and in the decisions
regarding product placement on formularies. PBMs often win or lose
business on the basis of rebate guarantees and are therefore
incentivized to favor products with high list prices and deep rebates
assuming comparable safety and efficacy. Because the PBMs have enormous
leverage and depend on rebates to attract and retain clients, many
manufacturers will enter the market with higher list prices and deeper
rebates in order to ensure patients have access to their medicines.
Question. If CMS finalizes the rebate rule, do you anticipate
future products entering the market with significantly lower initial
list prices?
Answer. Launch pricing will be driven by product value and
competitive intensity of the specific therapeutic category.
Importantly, if finalized, the rule could result in lower out-of-pocket
patient costs at the pharmacy counter and help address the perverse
incentives in the system that have been contributing to higher list
prices for medicines.
______
Questions Submitted by Hon. Thomas R. Carper
Question. What are your recommendations for lowering prices for the
40 percent of drugs that do not offer rebates in Medicare Part D? In
the health insurance plans that you offer your employees, do you ask
your insurers to pass through the full manufacturer rebates to the
beneficiaries?
Answer. It is unclear if the 40 percent of drugs that do not offer
rebates in Medicare Part D are brand medicines or generics. However,
Pfizer pledges to bring more affordable treatment options to the
market. Our mid-to late-stage pipeline contains five biosimilar
candidates expected to launch in the next 2 to 3 years. Ninety percent
of medicines Americans take are generics, and competition from these
drugs keeps prices low in most cases. We need to bring similar
competition to the biologics market, where some of the most expensive
drugs exist. The market today has already seen demonstrated savings as
high as 40 percent relative to the branded product. With more
competition, we hope even further savings can be realized.
Pfizer's plan design is generous and corresponding employee cost
sharing for prescription drugs is already very limited--in fact, for
many products, Pfizer employees experience no cost sharing at all.
Given this, the terms of contract with our PBM for our employee
benefits does not include a requirement to pass on rebates to Pfizer
employees at the point of sale.
Question. The systems for pricing and distributing drugs are opaque
and difficult to understand. What are your recommendations for
increasing transparency in how your companies set the list prices for
drugs, and for improving transparency in the supply chain for
prescription drugs? Would you support Federal standards for
transparency in setting the list prices for drugs?
Answer. Pfizer supports system-wide price transparency that is
thoughtful, purpose-driven, and that can result in improved patient
care, an enhanced understanding of the comparative value of all medical
services, and a more patient-centered use of health-care resources.
We would be interested in exploring with the committee ways to
ensure transparency across the health care system, including hospitals,
plans, PBMs, etc., so that we can make informed judgments about the
root of cost inflators in the system. We are also committed to ensuring
that patients, health-care professionals and payers understand our
commitment to pricing our medicines responsibly.
Regarding a Federal transparency standard, we believe that an
appropriately crafted, balanced piece of Federal legislation that
applies to all stakeholders in the health care system and preempts
future State laws could be beneficial for patients. However, Pfizer
believes that mandating disclosure of research and development,
manufacturing, or marketing costs to assess the value of medicines is
inconsistent with purpose-driven transparency.
Question. In nearly every sector of the health-care industry,
Medicare, Medicaid, employers, and insurers are moving away from fee-
for-service payments to reimbursements based on value and performance.
Prescription drugs and medical devices were the glaring exceptions to
this trend until recently. How many of your drugs are included in
value-based contracts and how many patients are benefiting from them?
Answer. Patient outcomes should determine our reimbursement and
Pfizer pledges that we will aggressively pursue value-based
arrangements. We should not be rewarded for treatments that do not
work.
Currently, Pfizer has value-based contracts for twelve drugs in our
portfolio.
The agreements are in place with commercial and Medicare payers
with millions of covered lives. In addition, Pfizer has a multi-product
innovative agreement that has been offered to the majority of States
for the Medicaid program, but currently only a small number of States
compromising less than five million lives have taken or are actively
considering the offer.
Question. How do these value-based contracts work to lower drug
prices for both patients and taxpayers?
Answer. Value-based agreements (VBA) provide a framework for
manufacturers to be compensated based on a product's value to patients
and the overall health-care system. There are many different types of
VBAs but the optimal structure of a VBA includes clinical and/or
financial performance metrics for a product. Based on the outcomes
achieved, payers use this information to inform how they cover
products. Products that perform better should be covered in a more
favorable manner which often includes lower out-of-pockets costs for
patients which is a benefit to patients in the near term. In the long
term, patients can also benefit from other savings either directly,
(e.g., reducing spending on other medications, lowering medical costs
from reduced hospitalizations, doctor's visits, etc.), or indirectly
through lower premiums based on reductions in total cost of care.
VBAs can be implemented in Federal and State programs so that the
benefits described above can accrue to the Federal programs thereby
benefitting taxpayers.
Question. Last year, Senator Portman and I did an investigation on
the pricing of an opioid overdose reversal drug called EVZIO,
manufactured by Kaleo. Kaleo increased the price of EVZIO from $575 in
2014 to $4,100 in 2017. We found that the best price Medicare was able
to get for EVZIO, about $4,000, was much higher than the price other
Federal programs and private insurers were able to get. It seemed that
Kaleo was able to get this higher price of $4,000 from Medicare by
helping doctors fill out paperwork showing that the drug was medically
necessary, even though there are cheaper alternatives on the market. As
a result of the investigation, Kaleo announced it will bring a generic
version of the drug to market at only $168 per pack. Are any of your
companies providing medical necessity paperwork to doctors in order to
get your drugs covered by Medicare?
Answer. Consistent with industry practice, Pfizer provides a sample
statement of medical necessity and appeals letters through our patient
support programs for patients, their caregivers and prescribing
physicians to help guide these individuals in gaining access to certain
Pfizer medicines after a physician has determined that a Pfizer product
is right for a patient and a prescription has been written. These
sample letters are generally PDF documents that describe the type of
information payers require to approve access/coverage of a particular
medication based upon the payers' formulary requirements, such as step
therapy (therapeutic agents that must be tried first), proof of
diagnosis or other common utilization management techniques that payers
determine. Pfizer does not customize these letters, and patients,
caregivers and physicians are advised that they are responsible for the
accuracy of the information that they submit to the payer to obtain
coverage and/or reimbursement. Sample letters are available from
Pfizer's third-party call centers which specialize in product access
triage with payers, field based reimbursement specialists and Pfizer
product websites. Pfizer sales representatives do not provide this
information to physicians.
Question. In 2017, the Rand Corporation estimated that biosimilar
drugs, which are competitors to complex, biologic drugs, could save the
United States more than $50 billion over the next decade. Some of you
have also argued that increasing the use of biosimilar drugs would help
lower drugs costs for consumers and taxpayers. What is delaying the
uptake of biosimilar drugs in the United States? What policies do you
recommend to increase the development of biosimilar drugs?
Answer. Pfizer believes that some of the adverse incentives and
barriers to market penetration include:
1. The Rebate Trap: Brand-name biologic companies are using
maneuvers to block biosimilar competition such as higher
rebates and exclusionary contracts.
2. Misinformation: Some physician and patient-directed
materials created by brand companies mischaracterize
biosimilars, creating doubt and confusion about the safety and
efficacy of biosimilars. As defined by statute, an approved
biosimilar must be highly similar to and have no clinically
meaningful differences from the reference product and must have
the same mechanism of action (to the extent the mechanism(s) of
action of the reference product are known) as the reference
product; thus, by definition, biosimilars are safe and
efficacious treatments relative to the reference product and
must work in the same way as the reference product. Any
information disseminated by reference product sponsors to
suggest or imply otherwise should be promptly addressed by FDA.
3. Need for incentives: Legislative ideas to promote
biosimilar uptake could include a shared savings biosimilar
model; reduced patient cost sharing for biosimilars. More
detail is provided below.
Although the biosimilars market in the United States is still
relatively new, our experience has been that anticompetitive conduct by
brand-name biologic manufacturers, combined with the lack of policy
measures to support appropriate uptake of biosimilars, have contributed
to a slow uptake. Therefore, we encourage you to consider measures to
help incentivize the use of biosimilars, which can substantially lower
Medicare costs with demonstrated savings to date as high as nearly 40
percent relative to the branded biologic.
Some key policy initiatives we believe will support the uptake of
biosimilars in the United States are the following:
Waiver of Part B Patient Coinsurance for Biosimilars for a
certain period of time:
CMS should waive Part B patient coinsurance
amounts for biosimilars. Cost-sharing changes could be applied
at the HCPCS level. This would not change the overall payment
for a biosimilar; however, it would change the beneficiary's
payment percentage.
CMS should pursue a CMMI model designed to increase access
to biosimilars, including a ``shared savings'' model whereby
Medicare savings associated with prescribing a biosimilar, as
compared to a reference biological, would be shared with
providers.
CMS should maintain the current biosimilar pass-through
status as this provides biosimilars with a ``level playing
field'' with their higher priced reference biologic
competitors.
CMS should create payment incentives for plans by
contracting with a measure developer for a biosimilar use
measure for the STARS program, which would correct other
adverse incentives for biosimilar uptake for Medicare Advantage
plans.
______
Questions Submitted by Hon. Benjamin L. Cardin
Question. The United States is one of the only countries in the
world to allow prescription drug manufacturers to advertise directly to
consumers through magazines, billboards, radio, and television
commercials. While I will not argue that it is beneficial to educate
consumers about an unfamiliar disease and encourage them to seek
medical help, most commercials from all of your companies recommend
asking about a specific brand name drug, not a medical condition.
Furthermore, even if your advertisements follow all FDA rules and list
medication side effects, they also almost always list these while a
smiling, apparently healthy person is walking on a beach.
Researchers say that this type of imagery, combined with viewing
hours of drug commercials each month, leads consumers to underestimate
the risks associated with medications. For the past decade, studies
have shown that aggressive direct-to-consumer advertising is associated
with rising drug prices and an increase in inappropriate drug
prescriptions.
Since researchers have concluded that consumers are
misunderstanding the benefits and risks described in your ads, what
further policies could help you and your colleagues ensure that you are
educating patients in a clear manner?
Answer. Pfizer wants patients to have access to our drugs and part
of this is making sure patients have the information they need. Pfizer
believes that direct-to-
consumer (DTC) advertising should be, first and foremost, a tool
through which we can provide patients with useful information to inform
them about their medical conditions, and the potential benefits and
risks of available treatment options so they can have a discussion with
their doctors and take an active role in managing their health.
The Office of Prescription Drug Promotion at the FDA, which has
responsibility for reviewing prescription drug advertising and
promotional labeling to ensure that the information contained in them
is not false or misleading, studies advertising so that regulations are
grounded in evidence on how best to ensure ads are accurate, balanced
and not misleading. The FDA's website describes in detail the many ways
that its Office of Prescription Drug Promotion ensures that DTC
advertising is not misleading.\9\
---------------------------------------------------------------------------
\9\ https://www.fda.gov/aboutfda/centersoffices/
officeofmedicalproductsandtobacco/cder/ucm
090142.htm.
DTC advertising is of significant educational importance to
patients, especially as the provision of health care becomes more
patient-centric. Over the last 2 decades, consumer research sponsored
by the industry and the FDA has underscored that clear, relevant
communication allows DTC advertising, when executed thoughtfully, to
have a positive impact on public health. For example, in 2004, a study
by FDA found that ``DTC ads help patients have better discussions with
their physicians and provide greater awareness of treatments. The study
demonstrated that when a patient asked about a specific drug, 88
percent of the time they had the condition that the drug treated. And
80 percent of physicians believed their patients understood what
---------------------------------------------------------------------------
condition the advertised drug treats.''
More recently, according to a 2017 survey, conducted by Princeton
Survey Research Associates International on behalf of PhRMA, Americans
overwhelmingly reported that DTC advertisements help inform people
about new treatments (88 percent), alert people to symptoms that are
related to a medical condition they may already have (81 percent), and
allow people to be more involved in their health care (79 percent).\10\
Similarly, a research survey published in 2017 with 4,481 U.S. adults
and sponsored by a working group of pharmaceutical companies has shown
DTC advertising conveys useful information.\11\ DTC ads raise awareness
about medications and effectively communicate potential risks and
benefits, but they also increase concern about potential side effects.
---------------------------------------------------------------------------
\10\ 2017 Direct to Consumer Advertising Survey Results, presented
by Princeton Survey Research Associates International, prepared for
PhRMA, https://www.phrma.org/report/2017-direct-to-consumer-
advertising-survey-results.
\11\ DIA, Therapeutic and Regulatory Science, https://
journals.sagepub.com/doi/abs/10.1177/2168479017708226iii, https://
www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProducts
andTobacco/CDER/ucm090276.htm#Completed.
Pfizer believes that PhRMA, individual companies, academics and FDA
should continue to study DTC advertising to ensure that pharmaceutical
consumer communications are achieving their intended goals to educate,
inform information-seeking consumers and facilitate better discussions
with health-care professionals.
pharmaceutical companies continue to raise prices
Question. As you are well aware, high prescription drug prices are
the number one concern for Americans and their families. According to
the Organization for Economic Cooperation and Development, the average
American spends around $1,208 annually on prescription drugs. There
have been several instances where brand name or even generic drugs that
have been on the market for years continue to increase in price.
One of the most well-known examples is Mylan's increase of the
price of EpiPen from less than $100 in 2007 to more than $600 in 2016.
Another example, is the ever-increasing price of insulin. Sanofi
increased the price of a vial of Lantus from $88.20 in 2007 to $307.20
in 2017. And those are just a small sample of price increases.
Why don't we see price decreases for drugs that have been on the
market for years without new formulations or added benefit?
Answer. There are a number of reasons that the price of medicines
can change over time. While these reasons often include more obvious
changes such as discovery of new indications and new formulations, they
can also include less obvious changes such as improvements in the
manufacturing and supply chain and market-based factors.
Pfizer has reduced the price of many of our older off-patent
medicines in the United States, and we are committed to bringing more
affordable treatment options to the market to induce competition,
including generic and biosimilar medicines. Competition is the best way
to promote affordable access to quality, safe and effective medicines;
competition means more and better medicines, more options for patients,
and more affordable drugs.
pay for delay
Question. Pay for delay is a tactic that more and more branded drug
manufacturers have been using to stifle competition from lower-cost
generic manufacturers. This allows you to sidestep competition by
offering patent settlements that pay generic companies not to bring
lower-cost alternatives to market.
These ``pay-for-delay'' patent settlements benefit both brand-name
pharmaceutical companies by helping them avoid costly patent litigation
and general manufacturers by rewarding them a hefty sum to delay
entering the market with a cheaper drug alternative. However, these
deals do not benefit consumers. According to an FTC study, these
anticompetitive deals cost consumers and taxpayers $3.5 billion in
higher drug costs every year.
Does your company partake in pay-for-delay settlements?
Answer. No. On the contrary, when Pfizer settles patent litigation
with generic firms, we do so on terms that generally enable entry of
generic competition earlier than the expiration of its patents and that
do not involve unlawful reverse payments. Pfizer's patent settlements
thus involve lawful compromises that appropriately resolve patent
disputes and accelerate patient access to lower cost generics relative
to the expiration of its patents. While Pfizer has been the target of
plaintiff lawyer driven class action lawsuits challenging certain of
its settlements with generic companies, we believe these lawsuits are
without merit and are vigorously asserting the pro-competitive nature
of these settlements in court.
Question. Why would a pharmaceutical company enter into a pay-for-
delay agreement?
Answer. Pfizer does not enter into these types of settlements and
cannot speculate on why others might.
Question. Do you think these agreements stifle competition and
prevent generic alternatives to your branded medications?
Answer. Pfizer's patent settlements do not ``stifle competition''
or ``prevent generic alternatives.'' On the contrary, when Pfizer
settles patent litigation with generic firms, it does so on terms that
generally enable entry of generic competition earlier than the
expiration of its patents and that do not involve unlawful reverse
payments. Pfizer's patent settlements thus involve lawful compromises
that accelerate patient access to lower cost generics relative to the
expiration of its patents.
drug rebate rule
Question. In January, the Department of Health and Human Services'
(HHS) Office of Inspector General (OIG) promulgated a new regulation to
remove regulatory safe harbor protections under the Anti-Kickback
Statute (AKS) for rebates on prescription drugs rebates paid by
manufactures to PBMs under Medicare Part D and for Medicaid managed
care organizations (MCOs). The OIG proposal attempts to ban most
rebates by eliminating their regulatory protections.
The rule is predicted to increase net drug costs in its early
years. The CMS actuaries estimate it would cost $196 billion over 10
years. Despite this high price tag, the beneficiary benefits are
limited. The proposed rule notes that under the CMS Actuary's analysis,
the majority of beneficiaries would see an increase in their total out-
of-pocket payments and premium costs; reductions in total cost sharing
will exceed total premium increases.
I wanted to ask a question about the administration's rebate rule,
which I understand that many of the drug manufacturers, and your main
trade association, strongly support. According to an analysis of the
rule by the Office of Actuaries at CMS, drug manufacturers are likely
to initially retain 15 percent of the current rebates as higher net
drug prices.
Given that estimate, can you provide the committee with any
assurances that prices will not increase under this proposed rule?
Answer. If finalized, the rule could result in lower out-of-pocket
patient costs at the pharmacy counter and help address the perverse
incentives in the system that have been contributing to higher list
prices for medicines. In 2019, Pfizer expects to pay billions of
dollars in rebates to ensure patients with pharmacy benefits coverage
in Medicare Part D and patients in commercial plans have access to our
medicines. If the proposed rule to share rebates with consumers at the
point of sale is finalized, we estimate that seniors taking Pfizer
medicines could save $270 on average per year, and up to $574 per year
for certain Pfizer medicines, through lower cost sharing.
Importantly, we believe any reform should apply to all market
segments as this could also lead to further reduction in list prices. A
bifurcated market in which we eliminate rebates in government programs
but maintain rebates for commercial plans will make it difficult for
manufacturers to reduce list prices because a single list price applies
to all markets.
______
Questions Submitted by Hon. Sherrod Brown
Question. According to an article recently published in the Journal
of the American Medical Association, medical marketers spent nearly $30
billion dollars in 2016, up from $17 billion in 1997. Direct-to-
Consumer (DTC) advertising had the biggest percentage increase: from
$2.1 billion, or 11.9 percent of all medical marketing, in 1997 to $9.6
billion, or 32 percent of total spending, in 2016.
Can each of you please provide what your ratio of spending on sales
and marketing to research and development is today?
Answer. In order to fulfill Pfizer's mission to create breakthrough
medicines that change patients' lives, we invest in several areas to
ensure an innovative pipeline, top-quality manufacturing, and education
of patients and physicians to ensure they have the information they
need to make knowledgeable decisions about patient care.
In 2018, Pfizer spent approximately $6.9 billion on direct sales
and marketing and approximately $8 billion on research and development
globally.
biosimilars/rebate traps
Question. In many of your testimonies, you mention that encouraging
the development of generics and biosimilars will help bring down the
cost of drugs. However, while 17 biosimilars are now approved in the
US, only 7 are actually on the market and available to patients. There
are growing concerns about rebate traps, which are ways of gaming the
system to ensure a biosimilar is not able to enter the market.
Dr. Bourla, in your testimony, you said: ``Adverse incentives that
favor higher cost originator biologics are keeping biosimilars from
reaching patients. In many cases, payers decline to include lower cost
biosimilars or generics in their formularies because they would risk
losing the rebates they can get by covering higher cost medicines.''
Your company has filed lawsuits challenging rebate traps as antitrust
violations. What do you think should be done about these rebate
practices?
Answer. Anticompetitive conduct should be stopped through
government enforcement of the antitrust laws and in the courts. Brand-
name biologic companies should not be permitted to abuse the rebate
system to effectively block lower-cost biosimilars from coverage
For more details, see Pfizer's Exhibit 4 attached.
price-gouging
Question. Sanofi, as I understand it, has made a pledge to the
public to limit its price increases to the national health expenditures
growth projection.
Would your company commit to a cap on annual price increases as
part of your PhRMA membership criteria?
Answer. We are unable to answer this question as it requires
analysis under the antitrust laws.
Question. What policies would you propose to help ensure lower
launch prices for new drugs?
Answer. At Pfizer, we are committed to our purpose: breakthroughs
that change patients' lives. Pfizer's more than 90,000 colleagues
around the world come to work every day focused not only on creating
breakthrough medicines, but also on making sure those medicines get
into the hands of the patients who need them.
The launch prices for our medicines reflect the value that they
bring to patients and society. The relationship between the price of a
medicine and a patient's out-of-pocket cost is not always clear. Out-
of-pocket costs continue to rise due to insurance designs that place a
disproportionate burden on consumers who use medicines than other
interventions. Consumers on average pay 15 percent of medicine costs
but only 2 percent of hospitalization and other health-care costs. We
encourage Congress to continue its efforts to understand the complexity
of the pricing and reimbursement system in the United States, and to
identify ways in which patient out-of-pocket expenditures can be
reduced.
transparency
Question. In many of your testimonies, you mentioned that the
current system of pharmacy benefit manager (PBM) back-end rebates do
not rarely results in a scenario where the PBM passes on savings to
consumers at the point of sale (POS). The administration recently
proposed a rule to eliminate the anti-kickback statute safe harbor
protections for these drug rebates.
Do you agree that greater transparency should be required to
understand how manufacturers and PBMs are negotiating prices and
rebates to ensure that savings are passed down to beneficiaries?
Answer. Pfizer is committed to working toward greater transparency
along the supply chain, so patients can better understand what they are
paying for and why. We believe pricing transparency policies should
seek to inform consumers about the costs of health-care items and
services across the industry and should promote a definition of value
that considers impact to health and costs over time and across all
industry stakeholders.
Pfizer believes that the proposed safe harbors lay the groundwork
for the systemic change needed to create a simpler, more cost
effective, and more transparent U.S. health-care system, and we are
committed to operating in this new system.
Question. Senator Thune asked if this administration rule would
lead you to lowering list prices. Both of you answered that you would
be likely to lower your prices. However, if this rule were finalized
tomorrow as proposed, would any of your companies be required to lower
the list price of any of your drugs?
Answer. As long as rebate reform extends to both the commercial
market and government programs, there could be a reduction in list
prices. The commercial market covers more than 50 percent of Americans
with insurance, and the safe harbor will not affect it at all. However,
in Medicare, the rebate rule will make list prices less relevant
because the entire rebate will be converted to a point of sale discount
so that patient out-of-pocket costs, when they are in the deductible,
coinsurance, and coverage gap phases of the benefit, will be based off
the lower net price. If we ensure that rebates paid out to commercial
plans find their way to patients, the patients will see savings of
hundreds of dollars.
pbms
Question. An Axios article from March 7, 2019 highlights the fact
that, while ``pharmaceutical companies put a lot of the blame for high
drug prices on pharmacy benefit managers,'' many large pharmaceutical
companies ``rely on PBMs to manage their own health-care benefits.''
In your role as an employer, does your company contract with a
pharmaceutical benefit manager (PBM) to administer the prescription
drug benefits for your employees and negotiate lower drug costs on your
behalf?
Answer. Yes, we contract with a PBM to administer our prescription
drug benefits and we work with them to establish criteria for
negotiating lower drug costs on our employees' behalf.
Question. For those of you who do use a PBM to help manage the
prescription drug benefit for your employees, how do you utilize the
rebates your PBM negotiates to lower health-care costs or drug costs
for your employee plans, and what does your company do with that
savings? Specifically, do the savings go toward lowering premiums?
Answer. Pfizer's medical and prescription drug coverage is generous
in terms of what we subsidize as an employer; therefore we work to
ensure that our employees benefit from our investment in our workforce
and any savings in the form of affordable plan premiums and
substantially lower cost sharing responsibilities for prescription
drugs.
Question. For those of you who do use a PBM to help manage the
prescription drug benefit for your employees, does your PBM offer
point-of-sale rebates to your employees?
Answer. Pfizer's plan design is generous and corresponding employee
cost sharing responsibility for prescription drugs is already very
limited--in fact, for many products, Pfizer employees experience no
cost sharing at all. Given this, the terms of contract with our PBM for
our employee benefits does not include a requirement to pass on rebates
to Pfizer employees at the point of sale.
______
Questions Submitted by Hon. Sheldon Whitehouse
Question. Please describe any policy changes you support that would
result in your company lowering the list prices of its drugs.
Answer. Pfizer would support legislation that reforms the current
system of rebating to one in which payers are required to use
manufacturer provided discounts to ensure that the patient gets the
benefit of the discount at the point of sale. We support this reform
across all segments of the market where private sector negotiations
result in lower net prices including Medicare Part D, Medicaid managed
care and the commercial markets. It is important to understand that
even if rebates are prohibited, manufacturers will still negotiate
discounts with plans consistent with safe harbors in exchange for
formulary access, though those discounts will be reflected in lowered
drug prices at the pharmacy counter rather than retrospective payments
benefitting plans or their PBM instead of the beneficiaries who are
underwriting premiums for others.
To ensure these benefits reach patients, it will be important for
Congress and the administration to ensure that plans do not create new
barriers or restrictions that hinder patient access and undermine the
spirit of the rule.
Question. How much does your company's research and development
portfolio rely on taxpayer-funded research conducted by the National
Institutes of Health (NIH)?
Answer. The biopharmaceutical industry is one of the most research-
intensive industries in the United States. In 2017, NIH had a budget of
$39.2 billion, only a fraction of which, $3.2 billion, was dedicated to
drug discovery. The industry invested over $90 billion in R&D--almost
30 times more. For Pfizer alone, we invested approximately $8 billion
in R&D last year.
NIH's strength is its focus on important basic scientific research
and the industry does derive important insights from basic scientific
research conducted by NIH-funded researchers and scientists worldwide.
There is, however, a large gap between understanding basic scientific
principles and the discovery, development, and delivery of medicines to
patients. For example, the initial NIH-funded basic science discovery
of cell division and cell signaling proteins in yeast led researchers
to identify similar proteins in humans. This early research later
informed the thinking of Pfizer scientists and helped pave the way for
the discovery and development of targeted cancer drugs like
palbociclib, a new treatment for breast cancer.
The discovery of cell division in yeast is a long way from
discovering and developing a drug that prevents cancer tumors from
growing. As stated above, the government plays a role in advancing
basic science such as identifying cellular pathways underlying disease.
However, the ability to translate knowledge about biological processes
into a medicine or vaccine, with appropriate drug-like properties and a
clinically meaningful benefit, remains the primary function of the
biopharmaceutical industry. The drug discovery and development process
involves harnessing existing knowledge of underlying disease biology to
chart and execute a research agenda that often encompasses ten to 15
years of discovery research, preclinical testing, clinical development
(for dosing, safety, and efficacy) and pharmaceutical science to ensure
the quality of the compound to be delivered. Disciplines like medicinal
chemistry, process and formulation chemistry and formulation, drug
metabolism, pharmacokinetics and safety sciences are practiced at a
scale and expertise in the biopharmaceutical industry that extends well
beyond government and academic research endeavors to deliver life-
savings therapies for patients.
Question. How many of your company's products are based, at least
in part, on NIH research, and how many are the result of research
funded solely by your company?
Answer. We have not identified readily available information in
response to this request that is maintained in the ordinary course of
business. We would need to discuss the scope and terms of this question
with your staff to respond appropriately.
Question. In each of the last 5 years, how much has your company
spent on research and development versus the advertising and marketing
of your products?
Answer. In order to fulfill Pfizer's mission to create breakthrough
medicines that change patients' lives, we invest in several areas to
ensure an innovative pipeline, top-quality manufacturing, and education
of patients and physicians to ensure they have the information they
need to make knowledgeable decisions about patient care.
Over the last 5 years, Pfizer spent approximately $34 billion on
advertising and marketing and approximately $40 billion on R&D
globally. Advertising and marketing expenses include advertising,
promotion and field selling.
Question. During the hearing, you mentioned that your company would
be likely to lower the list prices of its drugs if the recent proposal
by the Trump administration to change the current system of rebates was
extended to the private market.
If the policy was extended to the private market, how large would
the list price reductions be relative to the size of the rebates your
company is currently providing?
Answer. The size of any list price reductions relative to the size
of rebates Pfizer is currently providing would depend on all components
of the final rule and how the point of sale discount model that
replaces rebates will function.
Question. How will this proposal affect how your company sets the
list prices for new drug products?
Answer. At Pfizer, we are committed to our purpose: breakthroughs
that change patients' lives. Pfizer's more than 90,000 colleagues
around the world come to work every day focused not only on creating
breakthrough medicines, but also on making sure those medicines get
into the hands of the patients who need them.
Launch pricing is driven by a multitude of factors, the most
important being the medicine's impact on patients and their health. We
also may consider other factors like the medicine's potential to reduce
other health-care costs, such as hospital stays; the availability of
other treatments and generic options; affordability for patients,
insurers and governments; and investments to maintain the quality,
safety, delivery and reliability of our medicines.
Question. If the proposal is finalized and not extended to the
private market, will your company make any list price reductions? If
so, how large would the reductions be relative to the size of the
rebates your company is currently providing?
Answer. Because there is no specific requirement for plans and PBMs
to shift away from negotiating contracted rebates in the commercial
market, it is possible that a bifurcated market, with the same perverse
incentives and the same mechanism to drive list prices higher, will
result. If reform does extend to the commercial marketplace, it could
result in lowering of list prices. However, we cannot speculate on the
amounts until we see the specifics of the rule and the changes that are
made to the supply chain.
______
Question Submitted by Hon. Maggie Hassan
Question. In June of 2018, the Medicaid and CHIP Payment and Access
Commission (MACPAC) unanimously recommended under Recommendation 1.1 in
their annual report to Congress that Congress remove the statutory
requirement that manufacturers blend the average manufacturer price
(AMP) of a brand drug and its authorized generic.\12\
---------------------------------------------------------------------------
\12\ MACPAC: ``Improving Operations of the Medicaid Drug Rebate
Program,'' https://www.macpac.gov/wp-content/uploads/2018/06/Improving-
Operations-of-the-Medicaid-Drug-Rebate-Program.pdf.
This requirement created an unintended loophole. Rather than use
the price of the authorized generic, drug companies can sell its
authorized generic to a corporate subsidiary at an artificially lower
price, and use that lower price to bring down the AMP, which in turn
---------------------------------------------------------------------------
lowers the rebate obligation.
Does your company engage in this practice? Has your company ever
engaged in this practice in the past?
Answer. Pfizer has a number of Authorized Generics (AGs)
arrangements, both with affiliates and non-affiliates. CMS's Medicaid
Covered Outpatient Drugs Final Rule, 81 Fed. Reg. 5170 (Feb. 1, 2016)
(the ``Final Rule'') included an extensive discussion of when a primary
manufacturer should include or exclude sales of AGs to secondary
manufacturers in its average manufacturer price (AMP). Pfizer has
developed reasonable assumptions that it believes are consistent with
the guidance CMS set forth in the Final Rule for purposes of
determining when to include or exclude sales of AGs in its AMP
calculation. Pfizer disclosed its assumptions with respect to its
approach both in written correspondence and in an onsite meeting with
CMS representatives. In addition, Pfizer disclosed its assumptions to
the OIG in response to a January 2018 survey.
______
Questions Submitted by Hon. Catherine Cortez Masto
Question. According to public filings, in 2015 Pfizer collected
U.S. revenues that were more than double the amount you invested in
R&D. Is this still true--do you collect more in revenue in the U.S.
alone than you invest in R&D?
Answer. The biopharmaceutical industry is one of the most research-
intensive industries in the United States In 2017, NIH had a budget of
$39.2 billion, only a fraction of which, $3.2 billion, was dedicated to
drug discovery. The industry invested over $90 billion in R&D--almost
30 times more. For Pfizer alone, we invested approximately $8 billion
in R&D last year.
Pfizer's number one priority is always the care of our patients,
and we are proud of the investments Pfizer makes to insure we continue
to bring new, innovative cures to patients. These responsibilities
require investments in R&D, manufacturing and other areas to accomplish
our mission of creating breakthrough medicines that change people's
lives.
In 2018, Pfizer spent approximately $20 billion on global R&D and
manufacturing. This includes investing in state-of-the-art labs so we
can attract the finest scientists in the world and continuing to invest
in innovative, high-tech manufacturing to ensure the high quality of
our products. Pfizer's revenues in the United States in 2018 totaled
approximately $25 billion.
Question. As a portion of your revenue, for what percentage of the
drugs in your portfolio do you offer no rebates? Based on the drugs in
your pipeline, do you foresee that portion growing? For those drugs is
your list price equal to your net price?
Answer. Approximately one third of Pfizer's revenue comes from
products that are not Medicare Part D eligible. This product group
includes generics, vaccines, and physician administered products. Of
the remaining two thirds of our revenue, 92 percent comes from products
that offer Medicare Part D or commercial rebates. The remaining 8
percent is from products that have lost patent exclusivity, have
generic alternatives, and offer no rebates. It is not possible to
determine at this time whether that portion will increase because
rebating on future products will be based on numerous factors,
including product value and the competitive intensity of the
therapeutic area. For products that do not rebate, there are additional
deductions from sales such as prompt payment fees and distribution
service fees resulting in the net price being lower than list price.
Question. Do you invest more in R&D than you generate in U.S. sales
revenue? Please include specific figures.
Answer. The biopharmaceutical industry is one of the most research-
intensive industries in the United States In 2017, NIH had a budget of
$39.2 billion, only a fraction of which, $3.2 billion, was dedicated to
drug discovery. The industry invested over $90 billion in R&D--almost
30 times more. For Pfizer alone, we invested approximately $8 billion
in R&D last year.
Pfizer's number one priority is always the care of our patients,
and we are proud of the investments Pfizer makes to insure we continue
to bring new, innovative cures to patients. These responsibilities
require investments in R&D, manufacturing and other areas to accomplish
our mission of creating breakthrough medicines that change people's
lives.
In 2018, Pfizer's revenues in the United States totaled
approximately $25 billion and Pfizer spent approximately $20 billion on
global R&D and manufacturing. This includes investing in state-of-the-
art labs so we can attract the finest scientists in the world and
continuing to invest in innovative, high-tech manufacturing to ensure
the high quality of our products.
Question. Do you invest more in R&D than you spend on marketing and
administration? What company functions do you consider to be included
in administration? Please include specific figures.
Answer. In order to fulfill Pfizer's mission to create breakthrough
medicines that change patients' lives, we invest in several areas to
ensure an innovative pipeline, top-quality manufacturing, and education
of patients and physicians to ensure they have the information they
need to make knowledgeable decisions about patient care.
In 2018, Pfizer spent approximately $14 billion on selling,
informational and administrative expenses and approximately $8 billion
on R&D. Selling, informational and administrative costs are expensed as
incurred. Among other things, these expenses include the internal and
external costs of marketing, advertising, shipping and handling,
information technology and legal defense.
Question. Do you invest more in R&D than you spend on marketing and
sales? What company functions do you consider to be included in sales?
Please include specific figures.
Answer. In order to fulfill Pfizer's mission to create breakthrough
medicines that change patients' lives, we invest in several areas to
ensure an innovative pipeline, top-quality manufacturing, and education
of patients and physicians to ensure they have the information they
need to make knowledgeable decisions about patient care.
In 2018, Pfizer spent approximately $6.9 billion on direct sales &
marketing and approximately $8 billion on R&D globally. Direct sales
and marketing expenses include, among other things: direct promotion or
sale of the company's products.
Question. Why do you advertise for the drugs you manufacture? What
factors do you consider in choosing which drugs you advertise?
Answer. Pfizer believes that direct-to-consumer (DTC) advertising
should be, first and foremost, a tool through which we can provide
patients with useful information about their medical conditions, the
availability of treatments and the potential benefits and risks of
available treatment options so they can have a discussion with their
doctors and take an active role in managing their health. Research has
confirmed that this communication channel delivers on this goal.\13\
---------------------------------------------------------------------------
\13\ See 2017 Direct to Consumer Advertising Survey Results,
presented by Princeton Survey Research Associates International,
prepared for PhRMA, https://www.phrma.org/report/2017-direct-to-
consumer-advertising-survey-results; DIA, Therapeutic and Regulatory
Science, https://journals.sagepub.com/doi/abs/10.1177/2168479017708226;
https://www.fda.gov/AboutFDA/CentersOffices/
OfficeofMedicalProductsandTobacco/CDER/ucm090276.htm#Completed.
We may consider several factors when making decisions about our
consumer communications. Some of these may include the information
needs of patients who might benefit from one of our medicines and/or
the extent to which a health condition is un- and under-diagnosed and
---------------------------------------------------------------------------
treated.
______
Pfizer Inc.
500 Arcola Rd.
Collegeville, PA 19426
Tel: 484-865-8937 Fax: 484-865-0090
www.pfizer.com
Peter Honig, M.D., M.P.H.
Senior Vice President
Worldwide Safety and Regulatory
May 30, 2018
Scott Gottlieb, M.D.
Commissioner
Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
[email protected]
Re: Reference Listed Drug (RLD) Access Inquiries Website and NDA
022321 for Embeda (morphine sulfate; naltrexone hydrochloride)
Extended-
Release Capsules; NDA 017989 for Hemabate (carboprost tromethamine)
Injection; and NDA 020931 for Tikosyn (dofetilide) Capsules
Dear Dr. Gottlieb:
We write in reference to the newly posted page on the FDA website
entitled ``Reference Listed Drug (RLD) Access Inquiries.'' \1\ We note
that several new drug applications (NDAs) owned by Pfizer Inc. or
wholly-owned subsidiaries of Pfizer (collectively, ``Pfizer'') are
included in the list published on this site (``List''):
---------------------------------------------------------------------------
\1\ https://www.fda.gov/Drugs/DevelopmentApprovalProcess/
HowDrugsareDevelopedandAp
proved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/
ucm607738.htm.
1. Embeda (morphine sulfate; naltrexone hydrochloride), NDA
022321;
2. Hemabate (carboprost tromethamine), NDA 01 7989; and
3. Tikosyn (dofetilide), NDA 020931.
We write to the Agency for several reasons. First, we wish to inform
the Agency about Pfizer's internal practice for handling drug
purchasing inquiries from prospective generic applicants, as well as
provide some context for why the Agency may have received inquiries
about these particular products, and Pfizer's diligence in addressing
these issues. We believe that this information demonstrates Pfizer's
commitment to supporting innovation and a competitive marketplace.
Second, we wish to provide our suggestions on additional, non-
confidential information to add to the List in order to provide context
critical to understanding the List and its value. Additionally, we wish
to express our concerns that the Agency's announcement surrounding the
new webpage and how the information is currently presented implies that
the companies listed have engaged in ``gaming'' or anti-competitive
behavior, which is untrue with respect to Pfizer, and not supported by
the facts currently included in the List.
Pfizer was surprised and disappointed to discover that FDA had been
informed by prospective generic applicants that they had difficulty
obtaining some of our products to conduct the testing necessary to
support submission of an abbreviated new drug application (ANDA).
However, we note that the Agency included a disclaimer on the webpage
stating that ``[w]e note that FDA has not independently investigated or
confirmed the access limitations described in the inquiries received.''
\2\ As discussed in more detail below, without having any additional
information about these inquiries, Pfizer is unable to confirm whether
those inquiries were made to Pfizer, and if so, whether they were
handled in accordance with Pfizer's practice to make its drug products
available to applicants for purchase.
---------------------------------------------------------------------------
\2\ https://www.fda.gov/Drugs/DevelopmentApprovalProcess/
HowDrugsareDevelopedandAp
proved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/
ucm607738.htm.
Following publication of the List, Pfizer conducted internal due
diligence to identify whether Pfizer was contacted by prospective
generic applicants for the listed products, and whether Pfizer was able
to provide those customers with the requested drug product. By way of
background, our standard approach is to ensure that drug product is
available to licensed generic manufacturers at the listed price and on
Pfizer's standard terms of sale.\3\ The vast majority of Pfizer's
products are available through traditional wholesale channels (i.e.,
available through one or more of Pfizer's authorized distributors). If
Pfizer receives an inquiry about a product that is available at
wholesale, Pfizer will refer a prospective buyer to a publicly
available list of its authorized distributors, and indicate that the
prospective buyer should obtain product from an authorized distributor
on that list. For the limited number of products that are not available
at wholesale, requests made to Pfizer by a generic manufacturer wishing
to purchase drug samples should be fulfilled in accordance with
Pfizer's standard practice. If such requests involve a product with a
REMS that restricts distribution, Pfizer's position is that a Safety
Determination Letter (SDL) needs to be provided prior to sale. Pfizer
developed an internal process to handle such requests in early 2015,
upon realizing that such requests come into Pfizer via multiple
departments and colleagues.
---------------------------------------------------------------------------
\3\ If a drug product is in critical short supply, Pfizer will ship
products to fulfill orders for dispensing to patients before fulfilling
orders for product for testing.
---------------------------------------------------------------------------
Tikosyn
The List indicated that the Agency had received four inquiries
regarding Tikosyn. To the best of its knowledge, Pfizer is aware of
only one request for Tikosyn from a prospective generic applicant. At
the time of that request, Tikosyn was approved with a REMS with
elements to assure safe use (ETASU) that restricted distribution. When
contacted by the applicant, Pfizer requested that the applicant provide
us with written confirmation from the Agency that Pfizer's sale of the
product to the applicant would not be considered a violation of our
REMS. The applicant did not contact Pfizer further and Pfizer never
received any written correspondence from the Agency. The Agency removed
the REMS in 2016, and Pfizer notes that the Access Inquiries Webpage
indicates that FDA never issued any SDLs for this drug product.
We note despite the inquiries submitted to the Agency identified in the
List, ANDAs have been submitted and approved for the drug product.
There are three approved ANDAs for the drug product, with the first
approved on June 6, 2016,\4\ and two additional ANDAs approved in
2018.\5\ Additionally, the Agency's paragraph IV certification list
indicates that the first ANDA containing a paragraph IV certification
was submitted on May 1, 2014, when the REMS was still in place.\6\ This
additional information indicates that applicants were able to obtain
product, submit ANDAs, and obtain approval from the approval even while
the REMS was in place.
---------------------------------------------------------------------------
\4\ ANDA 207058, see https://www.accessdata.fda.gov/scripts/cder/
ob/results_product.cfm?Ap
pl_Type=A&Appl_No=207058, accessed May 23, 2018.
\5\ ANDA 208625, see https://www.accessdata.fda.gov/scripts/cder/
ob/results_product.cfm?Ap
pl_Type=A&Appl_No=208625, accessed May 23, 2018; ANDA 207746, see
https://www.
accessdata.fda.gov/scripts/cder/ob/
results_product.cfm?Appl_Type=A&Appl_No=207746, accessed May 23, 2018.
\6\ See https://www.fda.gov/downloads/Drugs/
DevelopmentApprovalProcess/HowDrugsareDe
velopedandApproved/ApprovalApplications/
AbbreviatedNewDrugApplicationANDAGenerics/UC
M293268.pdf.
As the REMS has been removed by the Agency, Pfizer now makes Tikosyn
available at wholesale through its authorized distributors.
Embeda
The List indicated that the Agency received one inquiry regarding
Embeda. We note that despite the inquiry submitted to the Agency, ANDAs
containing a paragraph IV certification were submitted to the Agency
for Embeda from May 3, 2010, through May 28, 2010, covering five of the
six approved strengths of Embeda.\7\ Pfizer acquired King
Pharmaceuticals (and with it, Ernbeda) on March 1, 2011. Two weeks
later, Pfizer recalled Embeda from the market due to stability issues
with the product. Pfizer spent the next several years diligently
addressing the issues that led to the recall, and Pfizer was able to
re-launch the product in January 2015. However, as a result of these
issues, from March 2011 through January 2015, there was no Embeda
product available for sale in the U.S. market.
---------------------------------------------------------------------------
\7\ See https://www.fda.gov/downloads/Drugs/
DevelopmentApprovalProcess/HowDrugsareDe
velopedandApproved/ApprovalApplications/
AbbreviatedNewDrugApplicationANDAGenerics/UC
M293268.pdf.
Pfizer was not able to identify any request from a generic applicant to
purchase Embeda. Embeda is now available at wholesale through Pfizer's
authorized distributors.
Hemabate
Finally, the List indicated that FDA had received one inquiry for
Hemabate, an older drug owned by Pharmacia and Upjohn Co., which was
acquired by Pfizer in 2003. Pharmacia, and later Pfizer, limited
Hemabate distribution to customers with medical and surgical intensive
care facilities to help ensure the drug product was used in accordance
with the product's labeling. While this limited distribution may have
prevented a prospective generic applicant from acquiring the drug
product from a wholesaler, it would not have prevented an applicant
from contacting Pfizer directly to buy the drug product. Pfizer ceased
the limited distribution of Hemabate to ensure patients and healthcare
professionals had appropriate access to the drug product. The product
is now available at wholesale through Pfizer's authorized distributors
since January 2018. Pfizer was not able to identify any request from a
generic applicant to purchase Hemabate.
Proposed Revisions to the List
We encourage the Agency, in accordance with its goal ``[t]o help
address this issue and to provide transparency regarding these
inquiries,'' \8\ to add further information to the List. The
information Pfizer suggests the Agency include will provide critical
context to help clarify to the stakeholders involved, i.e., the
American public, the United States Government, and industry, whether an
NDA bolder may be preventing generic applicants from obtaining the drug
products necessary to support submission of an ANDA Without this
information, stakeholders may come away with the false impression that
every company on the List has impeded access, as demonstrated by the
news coverage of the List and FDA's statements.\9\
---------------------------------------------------------------------------
\8\ https://www.fda.gov/Drugs/DevelopmentApprovalProcess/
HowDrugsareDevelopedandAp
proved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/
ucm607738.htm.
\9\ See, e.g., Sara Koblitz, FDA's Version of the Scarlet Letter,
FDA Law Blog (May 23, 2018), http://www.fdalawblog.net/2018/05/fdas-
version-of-the-scarlett-letter/; Sheila Kaplan, ``F.D.A. Names and
Shames Drug Makers to Encourage Generic Competition,'' The New York
Times (May 17, 2018), https://www.nytimes.com/2018/05/17/health/drug-
prices-generics-fda.html; Sy Mukherjee, ``The FDA Is Naming and Shaming
Companies Accused of Blocking Cheap Generic Drugs,'' Fortune (May 17,
2018), http://fortune.com/2018/05/17/fda-database-generic-drug-delays/.
---------------------------------------------------------------------------
We recommend that the List include:
The date the inquiry was made to FDA, and if furnished by the
prospective generic applicant, the date(s) the applicant attempted to
acquire the drug product and failed;
If available, whether the prospective generic applicant directly
approached the NDA holder or manufacturer , and was unable to obtain
product that way;
The identity of the NDA holder at the time the inquiry was made;
Whether there are approved generic products for the drug
product, and when those were approved;
Whether and when an applicant submitted an ANDA with paragraph
IV certification; and
Whether a particular inquiry for a product with a REMS with
ETASU restricting distribution included a protocol, and whether the
Agency issued an SDL relating to that inquiry.
While the Agency includes a disclaimer on the Access Inquiries Webpage
that it has not investigated or confirmed the access limitations
described in the inquiries it received,\10\ the Agency's statements,
both on its website and in public statements, strongly suggest that the
Agency endorses the claim that access to biosamples was blocked for all
products on the list. In reality, however, the only certain fact about
the inquiries on the List is that a prospective applicant complained to
FDA that it was unable to obtain the drug product. Neither Pfizer nor
the FDA knows whether that is in fact the case, or, if it is, whether
there are reasons the applicant did not obtain product that are not the
result of ``gaming'' or anti-competitive tactics by NDA holders. For
example, the drug may not be available due to a drug shortage, recall
(as in the case of Embeda), or because the generic applicant did not
actually try all avenues to obtain the drug product, such as contacting
the NOA holder or manufacturer directly.
---------------------------------------------------------------------------
\10\ https://www.fda.gov/Drugs/DevelopmentApprovalProcess/
HowDrugsareDevelopedandAp
proved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/
ucm607738.
htm.
Including this additional information in the List will shed light on
the reasons the generic applicant may have been w1able to obtain the
drug product, as well as indicate whether generic applicants were able
to obtain the drug product, despite the inquiries received by FDA. For
example, knowing the dates the inquiries were made could indicate
whether the requests came during a time when the drug product was not
being marketed, as in a recall situation, or when a REMS with ETASU
that restricted distribution was in place that may have triggered the
need for a review of the prospective generic applicant's protocol. And,
knowing those dates will help industry perform its own due diligence to
identify whether a request for drug product was inappropriately denied.
Likewise, noting whether the prospective generic applicant stated
whether it contacted the NDA holder or manufacturer will indicate
whether the applicant reached out to a party that could provide the
drug product, and will assist a company in determining whether its
policy on providing drug product, such as Pfizer's, was appropriately
---------------------------------------------------------------------------
followed.
Additionally, providing the identity of the NDA holder at the time of
the inquiry will help clarify whether the company that currently owns
the NDA could potentially be responsible for the failure to provide
drug product, or whether that failure, if any, could be attributable to
the prior holder of the NDA. For example, without knowing when the
inquiry was made or who the NDA holder was at the time of the inquiry,
Pfizer cannot tell for two of its products on the List (Embeda and
Hemabate) whether those inquiries came before or after Pfizer's
acquisition of the companies that originally owned those
products.Accordingly, Pfizer cannot adequately respond to allegations
that it may have inappropriately restricted access to its drug
products.
Including the dates of generic entry would also demonstrate to
stakeholders whether generic competition was impeded, or if in fact,
one or more generic applicants were able to obtain the product needed
in order to obtain approval from the Agency. While we recognize that
the Agency may be unable to identify who made the inquiry to FDA, even
if that applicant has an ANDA approved later, to the extent that
information can be provided, it would demonstrate whether a particular
generic applicant was blocked from obtaining product.
Additionally, providing more information related to products with REMS
that restrict distribution, e.g., whether an applicant has submitted a
protocol to the Agency, and whether a particular inquiry on the List
correlates to the issuance of an SOL, will also indicate whether the
generic applicant who made the inquiry provided its protocol to the
Agency, and whether the Agency determined that the protocol contained
safety protections comparable to the REMS. Currently, there is no
indication as to whether an applicant who complained about not having
access to such drug product took appropriate steps to facilitate its
access to the product when there was such a REMS in place for the drug
product.
Finally, we also note that the Agency does not inform an NOA holder in
real time when an applicant has had difficulty obtaining product. Given
Pfizer's policy to provide drug product when requested, if the Agency
had informed Pfizer that it had received such an inquiry on a specific
date, Pfizer could have then undertaken its own efforts to resolve the
issue.
We appreciate the Agency's consideration of the issues raised in this
letter, and reiterate our commitment to competition and innovation in
the biopharmaceutical industry.
Sincerely,
Peter Honig, M.D., M.P.H.
Senior Vice President, Worldwide Safety and Regulatory
cc: Janel Woodcock, M.D., Janet [email protected]
Theresa Toigo, [email protected]
Kathleen Uhl, M.D., [email protected]
Maryll Toufanian, [email protected]
______
U.S. Food and Drug Administration (FDA)
July 19, 2018
Peter Honig , M.D., M.P.H.
Senior Vice President, Worldwide Safety and Regulatory
Pfizer Inc.
Email: [email protected]
Dear Dr. Honig:
Thank you for your letter of May 30, 2018, regarding FDA's Reference
Listed Drug (RLD) Access Inquiries webpage. Your letter informs FDA
about Pfizer's internal practice for handling inquiries about samples
from prospective generic applicants, provides suggestions about
additional information to add to the RLD Access Inquiries webpage, and
expresses concern about the Agency's announcement surrounding the
webpage (Letter at 1-2). The Commissioner referred your letter to the
Center for Drug Evaluation and Research (CDER) for response.
1. Pfizer's internal practice for handling drug purchasing
inquiries from prospective generic applicants
Your letter provides a synopsis of Pfizer's internal practices for
handling the inquiries that it receives related to RLD access to its
products and the circumstances surrounding the Pfizer products that
appear on the RLD Access Inquiries webpage (Letter at 2-3). We
appreciate the insight provided by Pfizer on its internal processes. As
you are aware, inclusion on the list of products on the RLD Access
Inquiries webpage signifies that FDA has received an RLD access inquiry
related to limited distribution of the product. As we state on the
webpage, FDA has not independently investigated or confirmed the access
limitations as described in the inquiries received.
You also state that FDA ``does not inform an NDA holder in real time
when an applicant has had difficulty obtaining product'' and that ``if
[FDA] had informed Pfizer that it had received such an inquiry on a
specific date, Pfizer could have then undertaken its own efforts to
resolve the issue.'' As the webpage explains (and as also described in
the draft guidance for industry How to Obtain a Letter from FDA Stating
that Bioequivalence Study Protocols Contain Safety Protections
Comparable to Applicable REMS for RLD (How to Obtain a Letter
Guidance)), FDA does notify certain RLD sponsors, after the prospective
generic applicant has provided appropriate disclosure authorization to
the Agency. However, to the extent that Pfizer has a process for
prospective generic applicants to obtain samples, we encourage Pfizer
to consider making that process public to help ensure both that
interested developers know what process to use, and that Pfizer has
access to as much information as possible about any access issues.
2. Suggestions for additional information Pfizer believes FDA
should add to the RLD Access Inquiries webpage
Your letter also contains a list of six points of information Pfizer
recommends be added to the RLD Access web page (Letter at 4):
1. The date the inquiry was made to FDA, and (if furnished
by the prospective generic applicant), the date(s) the
applicant attempted to acquire the product and failed;
2. If available, whether the prospective generic applicant
directly approached the NDA bolder or manufacturer, and was
unable to obtain product that way;
3. The identity of the NDA holder at the time the inquiry
was made;
4. Whether there are approved generic products for the drug
product, and when those were approved;
5. Whether and when an applicant submitted an ANDA with a
paragraph IV certification; and
6. Whether a particular inquiry for a product with a REMS
with ETASU impacting distribution included a protocol, and
whether the Agency issued a Safety Determination Letter (SDL)
relating to that inquiry.
We note that two of these items (``[t]he identity of the NDA holder at
the time the inquiry was made,'' and ``whether the Agency issued a
[Safety Determination Letter] relating to [an] inquiry'') are already
included on the RLD Access Inquiries webpage. The webpage identifies
the RLD sponsor associated with each inquiry, and clarifies that this
is the RLD sponsor that was listed in the Approved Drug Products with
Therapeutic Equivalence Evaluations (the Orange Book) at the time FDA
received the inquiry (see footnote on the chart of inquiries). The web
page also identifies whether FDA issued a Safety Determination Letter
in connection with a particular RLD access inquiry (and explains that
receipt of such a letter is preceded by FDA' s review of bioequivalence
study protocols to assess whether they contain safety protections
comparable to those in the applicable REMS for the RLD).
Two of the other points of information (``[w]hether there are approved
generic products for the drug product, and when those were approved''
and ``[w]hether an applicant submitted an ANDA with a paragraph IV
certification'') are already publicly available on FDA's website (via
the Orange Book or Drugs@FDA and the Paragraph IV Certifications List,
respectively).\1\ For the remaining points of information, to the
extent FDA has access to the information you describe, we will take
your feedback (along with feedback from other stakeholders) into
account as we consider whether any changes to the RLD Access Inquiries
webpage should be made in order to best address and improve
transparency about this topic.
---------------------------------------------------------------------------
\1\ See http://www.accessdata.fda.gov/scripts/cder/ob/index.cfm,
http://www.accessdata.fda.
gov/scripts/cder/daf/index.cfm and https://www.fda.gov/downloads/Drugs/
DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/
ApprovalApplications/Abbre
viatedNewDrugApplicationANDAGenerics/UCM293268.pdf, respectively.
3. Concerns relating to the Agency's announcement surrounding the
---------------------------------------------------------------------------
RLD Access Inquiries webpage
Your letter also indicates that FDA's presentation of information about
this topic ``strongly suggest that the Agency endorses the claim that
access to biosamples was blocked for all products on the list'' (Letter
at 4). As you note, however, the RLD Access webpage makes clear that
FDA has not independently investigated or confirmed the access
limitations described in the inquiries the Agency received. The webpage
is one effort under the FDA's Drug Competition Action Plan to provide
transparency about the potential impact of this important issue. If
generic companies are unable to purchase the samples they need to
support their applications, this slows down, or entirely impedes, the
generic drug development process--leading to delays in bringing
affordable generic alternatives to patients in need. FDA is committed
to advancing policies to help bring more competition to the
prescription drug market, and we will continue to consider how we can
best advance this goal, including whether any changes to the RLD Access
Inquiries webpage should be made. We appreciate your feedback on this
issue.
Thank you again for contacting us.
Sincerely,
Janet Woodcock, M.D.
Director
Center for Drug Evaluation and Research
______
PFIZER FOUNDATION GRANT SUMMARY
2015-2018
TOTAL: $45,877,000
GLOBAL HEALTH PROGRAMMING
NOTE: This report includes information for recipient both U.S. and ex-
U.S. recipient organizations. Certain Pfizer Foundation grants to non-
U.S. grantees are facilitated through U.S.-based donor-advised funds
that specialize in vetting and processing grants to non-U.S. grant
recipients.
IMPROVING HEALTHCARE DELIVERY AND LOCAL INNOVATION
------------------------------------------------------------------------
DATE BOARD
APPROVED PARTNER DESCRIPTION AMOUNT
------------------------------------------------------------------------
November 2015 Swasth Global Health Innovation $1,500,000
Foundation, Grants support
Afya Research, organizations that are
Jacaranda advancing innovative
Heath, health models in low
Northstar and middle income
Alliance, countries. The goal of
Penda Health, this portfolio is to
World Health improve healthcare
Partners, delivery for
Clinicas del underserved populations
Azucar, and support local
Saluno, APOPO, innovation in key
Ayzh, Last countries: India,
Mile Health, Kenya, Mozambique,
LifeNet Mexico, Tanzania,
International, India, Liberia, Uganda,
One Family Rwanda, and South
Health, Africa. The grants
Operation ASHA support projects that
and Sevamob align to the
Foundation's 4
strategic elements:
primary healthcare
delivery, women and
children's health,
health technologies for
low resource settings
and innovative
financing mechanisms.
The Foundation
supported $100,000
grants to fifteen
organizations in 10
countries.
------------------------------------------------------------------------
December 2016 Swasth SECOND CYCLE: The 2,000,000
Foundation, Foundation supported
Afya Research, $100,000 grants to
Jacaranda twenty organizations in
Heath, 10 countries.
Northstar
Alliance,
Penda Health,
World Health
Partners,
Clinicas del
Azucar,
Saluno, Ayzh,
Last Mile
Health,
LifeNet
International,
One Family
Health,
Operation ASHA
and Sevamob,
Purple Source,
Unjani,
AccuHealth,
Bive, Salud
Cercana,
2020MicroClini
c
------------------------------------------------------------------------
March 2018 Swasth THIRD CYCLE: The 2,000,000
Foundation, Foundation supported
Afya Research, $100,000 grants to
Jacaranda twenty organizations in
Heath, 12 countries.
Northstar
Alliance,
World Health
Partners,
Clinicas del
Azucar,
Saluno, Ayzh,
Last Mile
Health,
LifeNet
International,
One Family
Health,
Operation ASHA
and Sevamob,
Purple Source,
Unjani, Bive,
2020MicroClini
c, MUSO,
Possible, UE
Life Sciences
------------------------------------------------------------------------
March 2018 Acumen The Foundation provided 500,000
catalytic funding to
Acumen America, an
early-stage
philanthropic venture
fund that invests in
companies that are
improving the lives of
low-income Americans
and advancing
innovative solutions to
issues of poverty in
America. Through this
grant, Acumen will grow
its portfolio of health
investments that
transform services for
the poor in the US,
including programs that
will increase access to
care, including
lowering the financial
and time burden of
health and wellness on
low-income individuals,
improve quality of care
to make care more
effective, and improve
patient experience of
care to drive patient
engagement & adherence.
Portfolio companies
include approaches to
use technology to
address and reduce
health disparities for
underserved and
multicultural
populations.
------------------------------------------------------------------------
IMPACT INVESTING CATALYTIC GRANTS
------------------------------------------------------------------------
DATE BOARD
APPROVED PARTNER DESCRIPTION AMOUNT
------------------------------------------------------------------------
July 2015 PharmAccess The Foundation provided $1,500,000
a grant to support the
development and roll
out of PharmAccess'
innovative healthcare
financing, funding
which will help scale
PharmAccess's mobile
health (mHealth)
wallet, a mobile health
payment platform linked
to M-Pesa in Kenya. The
goal of the
Foundation's grant is
to support user roll-
out of the platform and
increase the number of
people who use the
platform, demonstrating
its usability and
collecting data. The
Foundation's grant will
target 100,000 low
income, urban mothers
who will be enrolled
and receive a financial
subsidy through the
mHealth wallet to pay
for healthcare services
and products for their
children under 5 years
old.
------------------------------------------------------------------------
July 2015 PATH The Foundation provided 350,000
a grant to support the
expansion of PATH's
Global Health
Innovation Hub in South
Africa, in partnership
with the South Africa
Medical Research
Council. The Hub's
mission is to
accelerate access to
the most promising
technology innovations
by building the
capacity of local
innovators to develop,
manufacture, and deploy
global health
technologies for
vulnerable groups,
leveraging PATH's
expertise and network
in global health and
product development.
The grant will support
activities to build and
accelerate local
innovations and
identify and prioritize
local technologies that
can deliver global
health impact.
------------------------------------------------------------------------
July 2015 UNITUS The Foundation provided 650,000
a grant to support the
expansion of
`StartHealth,' a health
technology jump-starter
designed to accelerate
the pace of development
of bottom of the
pyramid focused health-
tech startups in India.
------------------------------------------------------------------------
July 2015 Global The Foundation provided 500,000
Partnerships a grant to this impact
investment fund, which
focuses on providing
products and services
using market based
approaches in Latin
America. This includes
efforts to pilot and
validate high potential
health modes for last
mile and underserved
populations, with a
focus on woman and
children.
------------------------------------------------------------------------
SUPPORT INNOVATIVE APPROACHES TO ENHANCING NON-COMUNICABLE DISEASE CARE
------------------------------------------------------------------------
DATE BOARD
APPROVED PARTNER DESCRIPTION AMOUNT
------------------------------------------------------------------------
November 2015 FHI360 The Foundation provided a $1,000,000
grant to support the
``Suc Khoe Doi Dao''
project that will
establish a community-
based, integrated NCD
prevention and control
program in Vietnam.
------------------------------------------------------------------------
November 2015 George This partnership will 1,000,000
Institute of pilot implementation of a
Global Health novel primary care
platform to support
communities and
healthcare providers in
the prevention and
management of NCDs in
Indonesia and India.
------------------------------------------------------------------------
April 2016 PATH As part of Pfizer 500,000
Foundation's work to
advance oncology care,
the Foundation provided
support to PATH in Peru
to reduce the growing
burden of illness and
death from breast cancer
for underserved
populations through early
detection linked to
service and treatment.
------------------------------------------------------------------------
April 2016 Susan G Komen As part of Pfizer 500,000
Breast Cancer Foundation's work to
Foundation advance oncology care,
the Foundation provided
support to Susan G Komen
Breast Cancer Foundation
in Northeast Brazil to
integrate breast cancer
patient support, early
detection and timely/
quality diagnosis into
existing primary care
services with the goal of
improving health access
and delivery for
underserved women.
------------------------------------------------------------------------
April 2016 Partners in As part of Pfizer 500,000
Health Foundation's work to
advance oncology care,
the Foundation provided
support to Partners in
Health to increase
accessibility of
treatment for breast
cancer for underserved
patients and document and
disseminate lessons
learned to inform cancer
care in Rwanda.
------------------------------------------------------------------------
April 2016 Indiana As part of Pfizer 500,000
University Foundation's work to
Center for advance oncology care,
Global Health the Foundation partnered
with AMPATH, through the
Indiana University Center
for Global Health, to
improve breast cancer
services for underserved
women in Kenya including
screening, early
diagnosis, treatment and
palliative and
survivorship care.
------------------------------------------------------------------------
April 2017 FHI360 The Foundation provided 300,000
additional funding of the
``Abundant Health''
project to support
routine prevention,
screening and management
of hypertension and
diabetes care in five
commune health stations
in Tan Phu district in Ho
Chi Minh City, Vietnam.
------------------------------------------------------------------------
April 2017 PATH The Foundation provided 350,000
additional funding of the
``Community Based Program
for Breast Health''
project in Peru.
------------------------------------------------------------------------
August 2018 FHI360 The Foundation provided 437,000
additional funding/phase
two of the ``Abundant
Health'' project to
support routine
prevention, screening and
management of
hypertension (HTN) and
diabetes (DM) care at the
community level.
------------------------------------------------------------------------
August 2018 PATH The Foundation provided 230,000
additional funding of the
``Community Based Program
for Breast Health''
project in Peru.
------------------------------------------------------------------------
August 2018 Indiana The Foundation provided 250,000
University additional funding to
Center for AMPATH, through the
Global Health Indiana University Center
for Global Health, to
improve breast cancer
services for underserved
women in Kenya including
screening, early
diagnosis, treatment and
palliative and
survivorship care.
------------------------------------------------------------------------
August 2018 George The Foundation additional 150,000
Washington funding to help improve
American health outcomes and
Cancer reduce health disparities
Institute for African-American,
Latina and LGBT women.
------------------------------------------------------------------------
PROVIDING CRITICAL SUPPORT FOR PRESSING U.S. PUBLIC HEALTH NEEDS
------------------------------------------------------------------------
DATE BOARD
APPROVED PARTNER DESCRIPTION AMOUNT
------------------------------------------------------------------------
April 2016 American As part of Pfizer $1,000,000
Cancer Foundation's work to
Society advance oncology care,
the Foundation partnered
with the American Cancer
Society in Los Angeles,
California and Hamptons
Roads, Virginia to
develop a patient
navigation model that
links community health
advisors with federally-
qualified health center
(FQHC) screening and in-
hospital navigation.
------------------------------------------------------------------------
April 2016 George As part of Pfizer 1,000,000
Washington Foundation's work to
American advance oncology care,
Cancer the Foundation provided
Institute support to George
Washington University
Cancer Institute to help
improve health outcomes
and reduce health
disparities for African-
America, Latina and LGBT
women.
------------------------------------------------------------------------
December 2017 West Virginia The Foundation provided a 500,000
Department of grant to support opioid
Health and addiction prevention and
Human education programming in
Resources West Virginia.
------------------------------------------------------------------------
December 2017 New Hampshire The Foundation provided a 500,000
Department of grant to support opioid
Education addiction prevention and
education programming in
New Hampshire.
------------------------------------------------------------------------
December 2017 Office of Drug The Foundation provided a 500,000
Control grant to support opioid
Policy addiction prevention and
education programming in
Kentucky.
------------------------------------------------------------------------
December 2017 New Mexico The Foundation provided a 500,000
Department of grant to support opioid
Health addiction prevention and
education programming in
New Mexico.
------------------------------------------------------------------------
December 2017 Utah The Foundation provided a 500,000
Department of grant to support opioid
Health addiction prevention and
education programming in
Utah.
------------------------------------------------------------------------
December 2017 Commonwealth The Foundation provided a 500,000
of grant to support opioid
Massachusetts addiction prevention and
Department of education programming in
Public Health Massachusetts.
------------------------------------------------------------------------
December 2017 Rhode Island The Foundation provided a 500,000
Department of grant to support opioid
Health addiction prevention and
education programming in
Rhode Island.
------------------------------------------------------------------------
December 2017 Foundation for The Foundation provided a 500,000
Appalachian grant to support opioid
Ohio addiction prevention and
education programming in
Ohio.
------------------------------------------------------------------------
December 2017 Department of The Foundation provided a 500,000
Public Health grant to support opioid
addiction prevention and
education programming in
CT.
------------------------------------------------------------------------
December 2017 Delaware The Foundation provided a 500,000
Health and grant to support opioid
Social addiction prevention and
Services education programming in
Delaware.
------------------------------------------------------------------------
ADDRESSING KEY BARRIERS FOR WOMEN AND CHILDREN
------------------------------------------------------------------------
DATE BOARD
APPROVED PARTNER DESCRIPTION AMOUNT
------------------------------------------------------------------------
July 2015 Save the The Foundation provided a $500,000
Children grant to support a pilot
program offering an
integrated approach to
delivering immunization
and family planning
services. The grant
supported development of
materials and tools for
healthcare workers to
engage women on family
planning services,
including formal
evaluation.
------------------------------------------------------------------------
November 2015 CARE The Foundation provided a 1,000,000
grant to support
increased access to
family planning and
immunization in Benin by
integrating both services
into comprehensive
delivery and
strengthening of clinical
skills and outreach.
------------------------------------------------------------------------
November 2015 FHI360 The Foundation provided a 1,000,000
grant to support to
develop a global
monitoring and evaluation
framework to assess task
shifting in the delivery
of family planning
products and demonstrate
the effectiveness and
safety of using Community
Health Workers to
administer products.
------------------------------------------------------------------------
November 2015 IRC The Foundation provided a 1,200,000
grant to support
increased access to
family planning and
immunization in Ethiopia
and Uganda by integrating
both services into
comprehensive delivery
and male engagement. The
project focused on last
mile and hard to reach
communities.
------------------------------------------------------------------------
November 2015 PSI The Foundation provided a 1,000,000
grant to support
increased access to and
demand for contraception
and reproductive health
services in Uganda for
women and adolescent
girls
------------------------------------------------------------------------
November 2015 U.S. Fund for The Foundation provided a 1,000,000
UNICEF grant to support
expanding national mobile
health platforms that
improve immunization
coverage and delivery in
Indonesia, Laos and
Uganda in partnership
with MOH.
------------------------------------------------------------------------
November 2015 World Vision The Foundation provided a 1,000,000
grant to support
increased access to
family planning and
immunization in Kenya by
integrating both services
into comprehensive
delivery, community
mobilization and male
engagement.
------------------------------------------------------------------------
August 2016 World Vision The Foundation partnered 1,000,000
with World Vision in
Zimbabwe to identify gaps
in immunization coverage
for children, adolescents
and adults and support
efforts to develop a life
course approach to
immunization with the
Ministry of Health. The
focus of the project was
to increase access to and
use of basic childhood
immunizations for
children from birth to
age 5, and HPV
immunization for girls as
well as maternal
immunizations for
pregnant women. In
addition World Vision
worked with the Ministry
of Health to address
adult immunization needs,
barriers and gaps in
community service.
Activities included
training village health
workers, health facility
staff and community and
faith leaders to educate
and mobilize their
communities around
immunization and promote
vaccination. This project
also supported the
development of a national
life course approach.
------------------------------------------------------------------------
August 2016 U.S. Fund for The Foundation provided a 1,000,000
UNICEF grant to help UNICEF
improve immunization
coverage in urban
underserved communities
in Asia (Cambodia,
Myanmar, Mongolia and the
Philippines), and to
support UNICEF in
conducting operational
research to assess the
feasibility of using
current newborn
immunization delivery
programs to support life
course immunization
strategies and reach
female populations with
additional immunizations
and reproductive health
services. A centerpiece
of this work is
supporting the roll out
of technology platforms
that track immunization
coverage and population
registries.
------------------------------------------------------------------------
August 2016 UN FOUNDATION The Foundation partnered 1,000,000
with the UN Foundation's
Shot@Life program to
pilot a life course
immunization approach
with a focus on rubella.
Activities include the
development of culturally
specific local
communication materials
on the importance of
vaccination and answering
concerns parents may have
about immunization and
life-long impacts, as
well as an integrated
marketing program
featuring social media,
digital assets and a U.S.-
based media campaign.
------------------------------------------------------------------------
April 2017 IRC The Foundation provided 800,000
additional funding to
existing programs in
Uganda and Ethiopia to
advance integrated
immunization and family
planning program.
------------------------------------------------------------------------
April 2017 Save the The Foundation provided 250,000
Children additional funding to
existing programs in
Malawi to advance
integrated immunization
and family planning
program.
------------------------------------------------------------------------
July 2017 CARE The Foundation provided 250,000
additional funding to an
existing program in Benin
to advance integrated
immunization and family
planning program.
------------------------------------------------------------------------
July 2017 World Vision The Foundation provided 300,000
additional funding to an
existing program in Kenya
focused on integrated
immunization and family
planning.
------------------------------------------------------------------------
March 2018 CARE The Foundation provided 1,000,000
additional funding to
support work in Benin,
where mortality of
mothers and children is
high. The project works
in 20 public health
clinics to increase the
uptake of two live saving
interventions, childhood
vaccinations and family
planning, through
integration of the two
services. The project
addresses two main
challenges at the same
time: a weak healthcare
system and sociocultural
barriers in the
community, which both
need to be overcome for
women and children to
have access to quality
health services.
------------------------------------------------------------------------
March 2018 IRC The Foundation provided 1,500,000
additional funding to
permit the IRC to expand
their work with health
partners in Ethiopia and
Uganda to increase the
use of immunization and
family planning by
reaching women with
information and services
at a critical time--the
12 months following
birth.
------------------------------------------------------------------------
March 2018 Save the The Foundation provided 1,000,000
Children additional funding to an
existing program in
Malawi to advance
integrated immunization
and family planning
program with Save the
Children.
------------------------------------------------------------------------
March 2018 World Vision The Foundation provided 1,000,000
funding for the second
phase of this project,
Increasing Use of Family
Planning (FP) and
Immunization Services in
Kenya.
------------------------------------------------------------------------
DISASTER RELIEF RESPONSE
------------------------------------------------------------------------
DATE BOARD
APPROVED PARTNER DESCRIPTION AMOUNT
------------------------------------------------------------------------
April 2015 American Red Cross Cyclone Pam $10,000
------------------------------------------------------------------------
June 2016 American Red Cross West Virginia 25,000
relief efforts
------------------------------------------------------------------------
June 2016 American Red Cross Ecuador Earthquake 75,000
------------------------------------------------------------------------
June 2016 International Ecuador Earthquake 75,000
Medical Corp.
------------------------------------------------------------------------
Sept-Oct 2016 American Red Cross West Virginia 25,000
relief efforts
------------------------------------------------------------------------
Sept-Oct 2016 American Red Cross Ecuador Earthquake 75,000
------------------------------------------------------------------------
Sept-Oct 2016 International Ecuador Earthquake 75,000
Medical Corp.
------------------------------------------------------------------------
Sept-Oct 2016 American Red Cross Louisiana flooding 25,000
------------------------------------------------------------------------
Sept-Oct 2016 Direct Relief Louisiana flooding 25,000
International
------------------------------------------------------------------------
Sept-Oct 2016 One SC Fund Hurricane Matthew 50,000
in SC
------------------------------------------------------------------------
Sept-Oct 2016 Direct Relief Hurricane Matthew 50,000
International in the US
------------------------------------------------------------------------
Sept-Oct 2016 Project Hope Hurricane Matthew 50,000
in Haiti
------------------------------------------------------------------------
Sept-Oct 2016 World Vision Hurricane Matthew 50,000
in Haiti
------------------------------------------------------------------------
Sept-Oct 2016 PSI Zika virus relief 100,000
efforts
------------------------------------------------------------------------
Sept-Oct 2016 The CDC Foundation Zika virus relief 500,000
efforts
------------------------------------------------------------------------
Sept-Oct 2016 The CDC Foundation Zika virus relief 500,000
efforts
------------------------------------------------------------------------
Sept-Oct 2016 PAHO Foundation Zika virus relief 1,000,000
efforts
------------------------------------------------------------------------
Sept-Oct 2016 Florida State Dept Zika virus relief 1,000,000
of Health efforts
------------------------------------------------------------------------
Sept-Oct 2016 Texas Dept of Zika virus relief 1,000,000
Health efforts
------------------------------------------------------------------------
December 2016 American Red Cross Louisiana flooding 25,000
------------------------------------------------------------------------
December 2016 Pinebelt Foundation Mississippi 25,000
flooding
------------------------------------------------------------------------
December 2016 American Red Cross Peru and Colombia 100,000
mudslide
------------------------------------------------------------------------
December 2016 UNICEF Peru and Colombia 100,000
mudslide
------------------------------------------------------------------------
Sept-Oct 2017 Americares Hurricane Harvey-- 125,000
TX and LA
------------------------------------------------------------------------
Sept-Oct 2017 World Vision Hurricane Harvey-- 125,000
TX and LA
------------------------------------------------------------------------
Sept-Oct 2017 American Red Cross Hurricane Harvey-- 250,000
TX and LA
------------------------------------------------------------------------
Sept-Oct 2017 One America Appeal Hurricane Irma--TX 500,000
and FL
------------------------------------------------------------------------
Sept-Oct 2017 American Red Cross Hurricane Irma-- 400,000
Puerto Rico/U.S.
Virgin Islands
------------------------------------------------------------------------
Sept-Oct 2017 IFRC Hurricane Irma-- 100,000
Caribbean
------------------------------------------------------------------------
Sept-Oct 2017 American Red Cross Hurricane Maria-- 250,000
Puerto Rico
------------------------------------------------------------------------
Sept-Oct 2017 American Red Cross Mexico Earthquake 250,000
------------------------------------------------------------------------
Sept-Oct 2017 UNICEF Mexico Earthquake 250,000
------------------------------------------------------------------------
Sept-Oct 2018 American Red Cross California 50,000
Wildfires
------------------------------------------------------------------------
Sept-Oct 2018 United Way of North Hurricane Florence 100,000
Carolina
------------------------------------------------------------------------
Sept-Oct 2018 Central Carolina Hurricane Florence 100,000
Community
Foundation
------------------------------------------------------------------------
Sept-Oct 2018 International Hurricane Florence 200,000
Medical Corp.
------------------------------------------------------------------------
Sept-Oct 2018 American Red Cross Hurricane Florence 100,000
------------------------------------------------------------------------
Sept-Oct 2018 International Hurricane Michael 100,000
Medical Corp.
------------------------------------------------------------------------
Sept-Oct 2018 Florida Disaster Hurricane Michael 100,000
Fund
------------------------------------------------------------------------
Sept-Oct 2018 Save the Children Indonesia Tsunami 100,000
------------------------------------------------------------------------
Sept-Oct 2018 Direct Relief Indonesia Tsunami 100,000
International
------------------------------------------------------------------------
Sept-Oct 2018 World Vision Indonesia Tsunami 100,000
------------------------------------------------------------------------
Sept-Oct 2018 Physicians for a California 100,000
Healthy California Wildfires
------------------------------------------------------------------------
______
UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF PENNSYLVANIA
PFIZER INC., Plaintiff, Case No.
v. JURY TRIAL DEMANDED
JOHNSON & JOHNSON and JANSSEN
BIOTECH, INC., Defendants.
COMPLAINT
For its Complaint, plaintiff Pfizer Inc. (``Pfizer'') alleges
against defendants Johnson & Johnson and Janssen Biotech, Inc.
(collectively, ``J&J''), as follows:
PRELIMINARY STATEMENT
1. It is accepted national policy to promote price competition
among pharmaceutical manufacturers after an originator firm's patent
protection has expired. This policy extends to biologics, a unique
category of medications that are derived from living organisms. As one
lawmaker put it when adopting applicable legislation, such competition
``is good for patient safety, consumer choice . . . and the healthcare
system at large.'' This case is about J&J's efforts to suppress that
competition and deprive society of those benefits by, among other
things, imposing a web of exclusionary contracts on both health
insurers and healthcare providers (e.g., hospitals and clinics) to
maintain its stranglehold in respect of an important biologic, brand
named Remicade, also known by its generic name, infliximab.
2. For many patients suffering from chronic diseases such as
rheumatoid arthritis, plaque psoriasis, and Crohn's disease, the best--
and sometimes the only--option for treatment is infusion therapy with
infliximab. As these conditions are chronic in nature, patients often
require long-term treatment and multiple infusions per year.
3. J&J owned patents protecting infliximab and has been amply
rewarded for its invention: Between 1998 and 2016, Remicade was the
only infliximab product on the market. This position allowed Remicade
to become J&J's best-selling drug by far, generating about $4.8 billion
in U.S. sales in 2016 alone. In fact, Remicade is among the best
selling drugs in the world. For most uses, at list price Remicade sells
for about $4,000 per infused dose and about $26,000 for a full year of
treatment. When Pfizer introduced its competing biologic Inflectra
(infliximab-dyyb) in 2016, J&J deployed improper exclusionary tactics
to maintain the dominance of its flagship product.
4. Inflectra received marketing approval under the Biologics Price
Competition and Innovation Act (``BPCIA''). Congress recognized the
growing importance of biologics, as well as the growing costs
associated with them, and passed the BPCIA in 2010. The purpose of the
BPCIA, as its name suggests, is to foster meaningful price competition
for long-entrenched branded biologic products--with the ultimate goal
of lowering healthcare costs. To facilitate price competition, the
BPCIA provides an abbreviated FDA approval pathway for ``biosimilar''
versions of branded biologic drugs. Biosimilars are products that the
FDA has determined to have ``no clinically meaningful differences''
from the already approved biologic (sometimes referred to as the
``reference listed drug'' or ``RLD'') in terms of safety, purity, and
potency. Although the BPCIA was enacted in 2010, FDA procedures for
implementing the Act did not become effective until a few years later,
and biosimilars are only recently beginning to come onto the market,
with the first biosimilar approval in 2015.
5. On April 5, 2016, Inflectra received FDA approval as the first
biosimilar to Remicade. Pfizer began shipping Inflectra in November
2016 and set its initial list price, often referred to as the wholesale
acquisition cost (or ``WAC''), at 15 percent below the then-current WAC
of Remicade.\1\
---------------------------------------------------------------------------
\1\ WAC is the manufacturer's published list price to wholesalers
or direct purchasers, not including prompt pay or other discounts,
rebates, or reductions in price.
6. The threat from Inflectra did not go unnoticed by J&J. Within
weeks of Inflectra's launch, J&J began to deploy what it publicly has
termed its ``Biosimilar Readiness Plan.'' The core features of the plan
are exclusionary contracts that foreclose Pfizer's access to an
overwhelming share of consumers, coupled with anticompetitive bundling
and coercive rebate policies designed to block both insurers from
reimbursing, and hospitals and clinics from purchasing, Inflectra or
---------------------------------------------------------------------------
other biosimilars of Remicade despite their lower pricing.
7. J&J's actions with respect to Remicade exclude competition at
multiple levels:
8. Exclusive contracts with insurance company payers. Insurer
decisions regarding reimbursement policies have a dramatic impact on
which infliximab product will be stocked by healthcare providers such
as hospitals and clinics. Because providers administer infliximab on
site (it is an infusion product), they must use their own funds to
stock the product, purchasing it for later use and relying upon
subsequent reimbursement from insurers to recoup their expenses. Given
the cost of biologic drugs generally, and Remicade in particular, there
is almost no chance that providers will pay for a product that is not
widely covered by insurers for fear of stocking a product that will not
be reimbursed after the provider administers it to a patient, as even a
single unreimbursed dose may cost the provider in excess of $4,000.
Recognizing this, J&J has induced insurers to enter into
contracts that require an explicit commitment not to cover Inflectra at
all or to do so only in the rarest of circumstances--in effect, to make
Remicade the only covered infliximab. As a direct result of these
exclusive dealing contractual commitments, Inflectra is either not
listed on the insurance company's medical policy--a published listing
of the drugs approved for reimbursement under the insurer's medical
benefit--or is designated reimbursable only in so-called ``fail first''
cases. The ``fail first'' exception, which requires that Remicade has
been tried by and failed with respect to a given patient before a
biosimilar infliximab can be reimbursed, is medically inappropriate and
illusory in practice. If Remicade, which is an infliximab product, does
not work for a patient, a physician would turn to a non-infliximab
drug, not to Inflectra, which also is an infliximab product and has no
clinically meaningful differences from Remicade. The spurious nature of
J&J's ``fail first'' restriction is illustrated by the fact that in
early 2017, before J&J's contracts took hold, the major insurers listed
Inflectra at parity with Remicade--indicating that they saw no medical
reason to favor one over the other.
J&J's ``fail first'' contractual restrictions therefore have the
same practical effect as pure exclusive contracts: both operate to
exclude Inflectra from qualifying for reimbursement under the insurers'
plans; both prevent the insurer from freely reimbursing for Inflectra
or another biosimilar without breaching the contracts; and both
foreclose Inflectra from competing for patients covered by those plans.
J&J has entered into such contracts with all or nearly all national
health insurance companies. These ``biosimilar-exclusion'' contracts,
on their own, have foreclosed Inflectra's ability to vie for at least
70 percent of commercially insured patients in the United States,
including a significant number of commercially insured patients who
reside in the Philadelphia area. But the foreclosure effects of those
insurer contracts go well beyond the immediate impact on patients
covered by the affected plans, as discussed below.
9. Exclusionary rebates and bundling arrangements with insurance
company payers. A key to J&J's ability to coerce insurers into
accepting its exclusionary commitments is its denial of rebates to
insurers that decline J&J's exclusivity commitments, thereby imposing a
substantial financial penalty. In effect, J&J says to insurers, ``If
you want to receive attractive rebates on Remicade for all your
existing Remicade patients''--rebates which, for some insurers, run
into the tens of millions of dollars annually--``you must agree to not
reimburse for Inflectra, or to do so in the most limited of
circumstances.'' In short, insurers that decline J&J's offer face a
substantial financial penalty, and those that accept receive a payoff
(multimillion dollar rebate payments) in return for their commitment to
exclude biosimilars.
J&J's threatened financial penalty is effective because there is
a substantial base of patients across the country who are already
controlling their diseases with Remicade and thus are unlikely to
switch to a lower-priced biosimilar once available. Although
biosimilars have no clinically meaningful differences in safety,
purity, and potency from the biologic originator, they are not
substitutable without the prescriber's approval (unlike generics for
non-biologic drugs approved under the Hatch-Waxman structure, which are
substitutable without a new prescription). And, although the FDA's
approval permits physicians to switch from the originator to the
biosimilar, and Pfizer believes they should consider doing so in
appropriate circumstances, as a practical matter, existing-patient
Remicade demand is economically incontestable, that is, not a realistic
candidate for biosimilar firms to compete for. As the head of J&J's
pharmaceuticals business told investors, ``the 70 percent of patients
who are [already] stable on Remicade are highly unlikely to switch.''
\2\ J&J bundles this economically ``incontestable'' demand for Remicade
with the portion of demand that is ``contestable'' for biosimilar
firms-- new patients starting therapy with infliximab--by threatening
to deny rebates on all Remicade prescriptions if any infliximab
biosimilar prescriptions are reimbursed, effectively meaning insurers
would have to forfeit their rebates and pay J&J's ever increasing price
for the incontestable patients.
---------------------------------------------------------------------------
\2\ Johnson & Johnson, Q3 2016 Results Earnings Call Transcript
(Oct. 14, 2016), available at https://seekingalpha.com/search/
transcripts?term=johnson+%26+Johnson+biosimilar.
J&J also bundles rebates on multiple different products, such
that insurers that refuse to grant exclusivity to Remicade would be
forced to pay higher prices and/or forego enhanced portfolio rebates.
The net effect of these anticompetitive bundling practices is that the
insurers subject to them have no real choice but to agree to J&J's
exclusivity conditions. Insurers have made it clear to Pfizerthat its
net cost for Inflectrawould need to be low enough to offset the loss of
J&J rebates. Pfizer and other biosimilar firms cannot feasibly make up
the difference for the J&J rebates (on the existing Remicade patient
base) that insurers would lose if they declined J&J's conditions.
Insurers have stated a desire to support biosimilars--and the lower
per-unit prices they bring--but realistically cannot do so without
incurring a substantial financial penalty imposed by J&J and thus
potentially placing themselves at a disadvantage relative to insurers
---------------------------------------------------------------------------
accepting J&J's rebates.
10. J&J-engineered coverage restrictions impact provider purchasing
behavior and thus magnify foreclosure. The foreclosure created by J&J's
exclusionary insurer-level contracts goes well beyond the patients
covered by these health insurers: Inflectra's coverage status has a
spillover effect on the purchasing decisions of healthcare providers
(as noted, the clinics, hospitals, and other institutions that purchase
and administer infliximab) as well as the prescribing decisions of
physicians affiliatedtherewith. Given the widespread gaps in
Inflectra's insurance coverage--engineered by J&J--providers have
overwhelmingly chosen to stock only Remicade (which is essentially
universally covered given its long tenure and dominant position) rather
than deal with the risk of possible denials of coverage for Inflectra.
Thus, providers have declined to purchase Inflectra across the board,
even for patients covered by insurance plans that do cover the product.
To take one example, even though Inflectra is covered by Medicare and
other government programs, providers have been unwilling to stock
Inflectra even for potential use with such government-insured patients.
As a result, not only is the federal government forced to continue
reimbursing for Remicade, the more expensive product, but the effective
foreclosure of biosimilars is expanded well beyond the 70 percent of
commercially insured patients directly foreclosed by J&J's insurer
contracts. Indeed, as of September 1, 2017, about 90 percent of
healthcare provider accounts using infliximab had purchased no
Inflectra at all. J&J has stoked providers' reluctance to purchase
Inflectra by touting with providers the very lack of coverage for
Inflectra created by J&J's own exclusionary contracts.
11. Exclusionary rebates and bundling arrangements with healthcare
providers. Beyond the spillover impact described above, J&J has also
extended its practices of multi-product bundling and bundling of
contestable and incontestable demand in contracts with healthcare
providers.
12. J&J's exclusionary plan has been remarkably effective at
stifling competition: Today, almost no national commercial health
insurer provides coverage for Inflectra (except under the spurious
``fail first'' scenario), and the vast bulk of healthcare provider
accounts using infliximab (approximately 90 percent) have not purchased
Inflectra at all. Despite some coverage by regional and government
plans, Inflectra has secured less than 4 percent of total infliximab
unit sales in the U.S. as of September 1, 2017.
13. The harm to Pfizer and to competition as a whole--and,
ultimately, to consumers, businesses, and the U.S. government, who bear
the brunt of rising healthcare costs nationwide--is manifest. In
response to a new entrant offering lower prices for a product deemed to
have ``no clinically meaningful differences'' from the incumbent's
brand, basic economics would predict that market-wide prices would
fall. Instead, the opposite has occurred. Since the time the FDA
approved Inflectra and J&J implemented its publicly-stated plan to
block biosimilars like Inflectra, J&J has raised the list price of
Remicade by close to 9 percent and increased the amount the U.S.
government reimburses for Remicade by more than $190 per infused dose.
J&J's list price increases are not overcome by increased rebates and
discounts: Remicade's ``average selling price'' (``ASP'')--which by
federal law is an average of a drug's pricing after taking into account
discounts, rebates, and other price concessions--actually has increased
since Inflectra's entry. As of September 2017, Remicade's ASP was more
than 10 percent higher than Inflectra's ASP. Pfizer has offered to
guarantee clients that Inflectra would be less expensive unit-for-unit
than Remicade during a contract term. Despite Inflectra's lower per-
unit prices, and J&J's escalating prices, Remicade has not lost any
substantial volume or share of sales to Inflectra, even though FDA
determined there to be no clinically meaningful differences between the
two products.
14. In July, J&J extolled the success of its scheme, noting that it
had not ``seen much of an impact'' from Inflectra's entrance, and that
J&J is ``especially well-
prepared to manage through the Remicade biosimilars.'' \3\ J&J also
said it was confident that it could fend off even subsequent biosimilar
entrants this year because of its exclusionary contracts: ``[W]e have
our contracting in place with all the managed care organizations [e.g.,
health insurers].'' \4\ The net result is that patients (along with
healthcare providers and the U.S. Government) have fewer choices and
pay more than they should.
---------------------------------------------------------------------------
\3\ Johnson & Johnson, Q2 2017 Results Earnings Call Transcript
(July 18, 2017), available at https://seekingalpha.com/search/
transcripts?term=johnson+$26+Johnson+biosimilar.
\4\ Id.
15. Major stakeholders at every level of the healthcare marketplace
---------------------------------------------------------------------------
are suffering as a result of J&J's competition-reducing actions:
Most importantly, consumers suffer in the form of artificially
inflated prices (including higher coinsurance payments, insurance
premiums, and taxes), as well as reduced choice.
Government programs, including Medicare--and ultimately
taxpayers--suffer by having to pay artificially higher prices for the
vast majority of their infliximab utilization.
Pfizer, of course, suffers loss of sales, investment, and
reputation as a result of J&J's success in securing commitments to
disadvantage Inflectra.
16. Pfizer brings this action under the antitrust laws of the
United States to challenge J&J's anticompetitive conduct. If J&J's
conduct is allowed to continue, its ``Biosimilar Readiness Plan'' will
become the playbook for biologic originator firms seeking to preserve
their dominance in the face of biosimilar competition--thus subverting
the competition-enhancing objectives of the BPCIA.
17. Allegations relating to Pfizer's conduct are based on personal
knowledge; other allegations are based on Pfizer's research, publicly
available sources, feedback from customers, and information and belief.
THE PARTIES
18. Plaintiff Pfizer is a corporation organized and existing under
the laws of Delaware. Pfizer's principal place of business in the
United States is located at 235 East 42nd Street, New York, New York
10017. Pfizer is a research-based international pharmaceutical company
which researches, develops, manufactures, and sells pharmaceutical
products across the spectrum, from branded innovator products to
generics and over-the-counter medications. Pfizer is also committed to
developing biosimilar medications to bring competition, lower prices,
and choice to patients.
19. Pfizer has commercialized Inflectra, a biosimilar to J&J's
Remicade, through its partnership with Celltrion, the holder of the
drug product's Biologics License Application. The FDA approved
Inflectraas a biosimilar to Remicade on April 5, 2016.
20. Defendant Johnson & Johnson is a corporation organized and
existing under the laws of New Jersey. Johnson & Johnson's principal
place of business in the United States is located at One J&J Plaza, New
Brunswick, New Jersey 08933. Johnson & Johnson is an international
pharmaceutical company--one of the largest in the world--and was the
sole supplier of infliximab, marketed as Remicade, between 1998 and
2016, when Inflectra came to market.
21. Defendant Janssen Biotech, Inc. (``Janssen'') is a wholly owned
subsidiary of Johnson & Johnson. Janssen is a corporation organized and
existing under the laws of Pennsylvania. Janssen's corporate
headquarters are located at 800 Ridgeview Drive, Horsham, Pennsylvania
19044. Janssen co-owns or has licenses to the Remicade patents and
performs the marketing for Remicade in the United States.
JURISDICTION, VENUE, AND INTERSTATE COMMERCE
22. This action arises under the antitrust laws of the United
States, including Section 1 of the Sherman Act, 15 U.S.C. Sec. 1,
Section 2 of the Sherman Act, 15 U.S.C. Sec. 2, Section 3 of the
Clayton Act, 15 U.S.C. Sec. 14, and Sections 4 and 16 of the Clayton
Act, 15 U.S.C. Sec. Sec. 15 and 26.
23. Subject matter jurisdiction is founded on 28 U.S.C.
Sec. Sec. 1331 and 1337(a).
24. Johnson & Johnson may be found, transacts business, and is
subject to personal jurisdiction in this judicial district.
25. Janssen maybe found, transacts business, and is subject to
personal jurisdiction in this judicial district.
26. The violations of law alleged in this Complaint took place, in
part, in this judicial district and have injured Pfizer in this
district. Venue is therefore appropriate in the Eastern District of
Pennsylvania under Section 12 of the Clayton Act, 15 U.S.C. Sec. 22,
and under 28 U.S.C. Sec. Sec. 1391(b) and (c).
27. The creation, marketing, sale, and distribution of Remicade and
Inflectra, and the actions complained of in this Complaint, occur in
and substantially affect interstate commerce.
FACTUAL AND REGULATORY BACKGROUND
A. Biologics
28. Biologics are treatments derived from living systems such as
microorganisms or plant or animal cells. As the FDA explains:
``Biological products include a wide range of products such as
vaccines, blood and blood components, allergenics, somatic cells, gene
therapy, tissues, and recombinant therapeutic proteins. Biologics can
be composed of sugars, proteins, or nucleic acids or complex
combinations of these substances, or maybe living entities such as
cells and tissues. Biologics are isolated from a variety of natural
sources--human, animal, or microorganism--and may be produced by
biotechnology methods and other cutting-edge technologies. Gene-based
and cellular biologics, for example, often are at the forefront of
biomedical research, and may be used to treat a variety of medical
conditions for which no other treatments are available.'' \5\ In
contrast to most drugs, which are chemically synthesized and whose
structure is known, most biologics are complex mixtures that are not
easily identified or characterized.\6\
---------------------------------------------------------------------------
\5\ See U.S. Food & Drug Administration, What Are ``Biologics''
Questions and Answers, https://www.fda.gov/aboutfda/centersoffices/
officeofmedicalproductsandtobacco/cber/ucm133077.htm (last visited
Sept. 18, 2017).
\6\ Id.
B. Congress Enacts the Biologics Price Competition and
---------------------------------------------------------------------------
Innovation Act to Spur Price Competition for Biologic Medications
29. Congress has made clear that competition in pharmaceuticals is
to be encouraged, and, to that end, in 1984 enacted the Hatch-Waxman
Act (``Hatch-Waxman''), which established an abbreviated pathway for
approval of generic counterparts to non-biologic branded drug products.
Before Hatch-Waxman, a generic applicant had to conduct the same kinds
of safety and efficacy studies (including large clinical trials and the
like) as the originating drug manufacturer. Such a process, which can
cost hundreds of millions of dollars and take years to complete, was
prohibitive for would-be generic entrants and led to the near absence
of generic competition to branded drug products. Hatch-Waxman
eliminated this hurdle; it allowed generic firms to rely upon the
originator's safety and efficacy studies. Generic applicants need only
show that their products use the same active pharmaceutical ingredient
as the originator, and that their products are bioequivalent (e.g.,
that the generic product's uptake into the body is equivalent to the
branded drug). A principal goal of Hatch-Waxman was to trigger price
competition with originator products, many of which had enjoyed
longstanding exclusivity. That goal has been achieved: According to the
FDA, the competition spurred by Hatch-Waxman has saved more than $1.6
trillion for patients and the healthcare system.\7\
---------------------------------------------------------------------------
\7\ See Kathleen ``Cook'' Uhl, 2016: A Record-Setting Year for
Generic Drugs, U.S. Food & Drug Administration (Feb. 24, 2017),
available at https://blogs.fda.gov/fdavoice/index.php/2017/02/2016-a-
record-setting-year-for-generic-drugs/ (noting that ``2016 was a
record-setting year for FDA's generic drug program,'' and that ``[o]ver
the last 10 years, generic drugs have saved the U.S. healthcare system
about $1.68 trillion'').
30. However, for a number of reasons, biologic products generally
are not covered by the Hatch-Waxman procedures. Nevertheless, given the
success of Hatch-
Waxman in spurring competition for non-biologic medicines, Congress and
nearly all stakeholders in the healthcare system have recognized the
great desirability of having an analogous system for biologics.\8\
---------------------------------------------------------------------------
\8\ See U.S. Food & Drug Administration, Implementation of the
Biologics Price Competition and Innovation Act of 2009 (Feb. 12, 2016),
available at https://www.fda.gov/drugs/
guidancecomplianceregulatoryinformation/ucm215089.htm (``The goal of
the BPCI Act is similar, in concept, to that of the Drug Price
Competition and Patent Term Restoration Act of 1984 (a.k.a. the `Hatch-
Waxman Act') which created abbreviated pathways for the approval of
drug products under Federal Food, Drug, and Cosmetic Act (FFD&C
Act).'').
31. In 2009, Congress addressed the need for competition in the
biologics marketplace by introducing the BPCIA, which was signed into
law in 2010. The Act furthers the ``FDA's longstanding policy of
permitting appropriate reliance on what is already known about a drug,
thereby saving time and resources and avoiding unnecessary duplication
of . . . testing.'' \9\
---------------------------------------------------------------------------
\9\ U.S. Food & Drug Administration, Implementation of the
Biologics Competition and Innovation Act of 2009, https://www.fda.gov/
Drugs/GuidanceComplianceRegulatoryInformation/ucm215089.htm (last
visited Sept. 18, 2017).
32. A principal purpose of the Act--as reflected in its very name
(i.e., the Biologics Price Competition and Innovation Act)--was to spur
---------------------------------------------------------------------------
price competition in biologic drug products:
``We have to find a way to introduce competition into [the
biosimilar] market,'' including balancing ``giving incentives
for development of new products but bringing about the benefits
of competition in the marketplace.'' (Hon. Henry Waxman, United
States Representative from California)
``Legislation to facilitate the development of biosimilars
should promote competition and lower prices[.]'' (Hon. Anna G.
Eshoo, United States Representative from California)
``We want to foster a robust biosimilar market.'' (Hon. Joe
Barton, United States Representative from Texas)
``[C]ompetition [from biosimilars] is good for patient
safety, consumer choice, and drive[s] savings for consumers and
the healthcare system at large.'' (Hon. Gene Green, United
States Representative from Texas)
33. The BPCIA provides an abbreviated regulatory approval pathway
for the introduction of biosimilars. A biosimilar applicant may rely on
the clinical studies of the reference listed drug if it can show: (a)
that the proposed biosimilar is ``highly similar to the [originator
product, or RLD] notwithstanding minor differences in clinically
inactive components''; and (b) that ``there are no clinically
meaningful differences between the [proposed biosimilar] and the [RLD]
in terms of safety, purity, and potency'' (42 U.S.C. Sec. 262(i)(2)).
34. Although biosimilars have no clinically meaningful differences
in safety, purity, and potency from the RLD, they are not automatically
substitutable with the RLD (unlike Hatch-Waxman generics). Thus, if a
doctor prescribes the RLD, a pharmacist cannot substitute a biosimilar
unless that product has been designated as interchangeable by FDA and
the relevant state law permits substitution of interchangeable
biologics.\10\ This allows originator firms to retain the bulk of their
existing patient bases, which typically is not possible for a branded
firm to do when a Hatch-Waxman generic enters (because state
substitution laws permit prescriptions for the brand to be
automatically substituted with the Hatch-Waxman generic by the
pharmacist without the need for physician intervention). This
difference enables biologic originator firms to leverage their
monopolies over existing patients to extract anticompetitive
commitments from insurers and providers.
---------------------------------------------------------------------------
\10\ The BPCIA does provide for an ``interchangeable'' designation,
but FDA published draft guidelines for establishing interchangeability
only this year. U.S. Food and Drug Administration, Considerations in
Demonstrating Interchangeability With a Reference Product (Draft
Guidance) (Jan. 17, 2017). And while Pfizer believes that Inflectra can
be safely and effectively substituted for Remicade (indeed, studies
have shown that switching patients can be done safely and effectively,
and Pfizer has supported and/or taken part in some of these studies),
it will be years before Inflectra or any other biologic receives a
formal ``interchangeability'' designation from FDA in the United
States. Nonetheless, neither the BPCIA nor FDA contemplates that
biosimilars should be prevented from competing in themarketplace--i.e.,
that consumers should be denied access to them--until they are
designated interchangeable.
---------------------------------------------------------------------------
C. Infliximab
35. Infliximab is a tumor necrosis factor (``TNF'')-inhibiting
biologic drug used to treat a range of immune-mediated diseases,
including Crohn's disease, ulcerative colitis, rheumatoid arthritis,
psoriatic arthritis, ankylosingspondylitis, and plaque psoriasis.
36. As a biologic, infliximab is not synthesized in a laboratory,
but rather derived from a living organism. Infliximab is a chimeric
IgG1k monoclonal antibody (composed of human constant and murine
variable regions) specific for human tumor necrosis factor-alpha.
Infliximab is produced by a recombinant cell line cultured by
continuous perfusion and is purified by a series of steps that includes
measures to inactivate and remove viruses.
37. Infliximab is an infusion therapy, meaning it is administered
intravenously. Thus, infliximab patients must (in most cases) visit
clinics, hospitals, or other medical facilities to receive the therapy
from healthcare professionals. As a result, patients rarely purchase
infliximab themselves at retail pharmacies. Instead, infusion centers,
clinics, and hospitals purchase infliximab, and after administration,
seek reimbursement from the patient's insurer or a government payer
(e.g., Medicare). Infliximab is an important medicine that has provided
life-changing benefits to millions of patients.
D. J&J's Remicade
38. J&J introduced the first infliximab product in the United
States in 1998, under the brand name Remicade.
39. Remicade is widely used: An estimated 475,000 patients in the
U.S. receive at least one dose of Remicade annually. This fact,
combined with the cost (approximately $4,000 per infused dose at list
price), makes administering Remicade a major expense item for insurers
and healthcare providers.
40. J&J's list price increases for Remicade and other pricing
actions have resulted in consistent increases in Remicade's ASP. J&J
has increased the price of Remicade without experiencing a loss of
sales to other therapies. Instead, Remicade sales have increased
steadily since it was introduced. Indeed, J&J has been able to continue
raising the price of Remicade notwithstanding the arrival of Inflectra.
41. Since 1998, J&J has made billions of dollars in profit on
Remicade.
E. Pfizer's Inflectra
42. Beginning in 2008, Celltrion undertook to develop a biosimilar
to Remicade and move it through the intensive FDA review process. The
Biologics License Application for Inflectra was filed with FDA in 2014.
After rigorous scientific review, FDA approved infliximab-dyybon April
5, 2016. In the FDA news release announcing its approval of Inflectra,
the director of FDA's Center for Drug Evaluation and Research
reiterated that approval as a biosimilar reflects a determination of
``no clinically meaningful differences'' from the originator, and
stated that ``[p]atients and the health care community can be confident
that biosimilar products are high quality and meet the agency's
rigorous scientific standards.'' \11\
---------------------------------------------------------------------------
\11\ See U.S. Food and Drug Administration, FDA Approves Inflectra,
A Biosimilar to Remicade (Apr. 5, 2016), https://www.fda.gov/
newsevents/newsroom/pressannouncements/ucm494227.
htm.
43. J&J claimed patent protection over Remicade--as noted, making
it the sole provider of infliximab for nearly two decades--and thus
Pfizer and Celltrion were forced to defend against J&J's patent suit in
parallel with FDA's regulatory review of the Inflectra application. On
August 17, 2016, J&J's patent covering the infliximab antibody was
ruled invalid by the United States District Court for the District of
Massachusetts, a ruling which confirmed that J&J had no valid right to
exclude Pfizer (or other potential biosimilar entrants). The Court held
that the antibodies covered by J&J's Remicade patent had been disclosed
and claimed in an earlier patent.\12\ Just a few months after the
district court ruling, the U.S. Patent and Trademark Office issued a
final decision in a re-examination of the same patent, holding that the
patent was invalid.\13\
---------------------------------------------------------------------------
\12\ Janelle Lawrence, J&J Remicade Patent Found Invalid in U.S.
Victory for Pfizer, Bloomberg (Aug. 17, 2016), https://
www.bloomberg.com/news/articles/2016-08-17/j-j-patent-on-remicade-
expiring-in-2018-invalid-judge-rules.
\13\ Id.
44. After overcoming these hurdles, and after a 180-day notice
period required by the BPCIA, Pfizer began selling Inflectra in
---------------------------------------------------------------------------
November 2016.
45. Inflectra is approved for all the same indications as Remicade,
except pediatric ulcerative colitis, as to which J&J continues to enjoy
an FDA-granted period of exclusivity because of the indication's status
as an ``orphan'' indication (established on proof that the number of
people affected by the disease or condition for which the drug is to be
developed is fewer than 200,000 persons), which is scheduled to end in
2018. On that date, Inflectra will be eligible to seek approval for
pediatric ulcerative colitis. In any event, this indication accounted
for less than 5 percent of overall infliximab utilization in 2016.
46. Pfizer introduced Inflectra with a list price 15 percent lower
than Remicade's, and, in negotiations with insurers and providers,
offered substantial additional pricing concessions in the form of
discounts and/or rebates that in some instances were more than 40
percent below Inflectra's list price. The goal and effect was to offer
Inflectra for less than J&J was offering Remicade; indeed, for many
customers, Pfizer committed to ensure that Inflectra would have a lower
net per-unit price than Remicade.
47. Given that it was charging a lower price for Inflectra than J&J
was charging for Remicade, Pfizer was optimistic that it would have an
opportunity to compete, to secure a reasonable share of the business,
particularly for new patients, and to bring the benefits of price
competition to consumers, providers, insurers, and the U.S. government.
However, due to J&J's exclusionary conduct, competition has been
foreclosed. J&J maintains its monopoly and has continued to capture
over 96 percent of infliximab sales even while maintaining prices far
above competitive levels.
F. The Importance of Insurance Coverage for Infliximab
48. Most patients who are prescribed Remicade have some form of
insurance coverage or qualify for patient assistance. The sources of
insurance coverage are (a) private insurance, accounting for about 60
percent of patients nationally, and (b) government insurance programs
(principally Medicare and Medicaid), accounting for the remaining 40
percent. Insurance coverage and reimbursement are therefore key to the
adoption of the product by patients and healthcare providers alike. If
a product as expensive as Remicade is not widely reimbursed, it will
not be significantly utilized.
49. Because Remicade is not dispensed in a retail pharmacy but
rather administered intravenously in a clinic or other institutional
setting, it generally is not included under the ``pharmacy benefit'' of
most health plans. In the pharmacy benefit setting, physicians
prescribe a drug and the patient procures the medication him or herself
at the pharmacy, paying for it with a combination of insurance coverage
(either private or government-sponsored) and out-of-pocket payment
(usually, a co-pay). In the pharmacy benefit context, neither the
prescribing physician nor the institution with which the physician is
affiliated bears financial risk with respect to the drug selected,
i.e., the drug is not purchased and stocked in advance by providers at
their own cost. The pharmacy buys the drug, dispenses it, and is
reimbursed.
50. In contrast, ``medical benefit'' products such as Remicade are
administered at a clinic or other healthcare provider site, and the
provider itself first purchases the drug product for use in the
infusion treatment of patients, and then later seeks reimbursement for
the drug from a third party payer (a practice commonly referred to as
``buy and bill''). When a treatment is administered, the provider must
secure payment for the service, including the cost of the product
dispensed (which the provider had to pay up front with its own funds).
In this context, the provider has a strong interest in utilizing drugs
that are widely covered by insurance, particularly by the major
national commercial health insurers and significant regional insurers
active in its area. If a drug product is not widely covered, such that
there is a risk that coverage might be denied, and providers thus would
be burdened with a potential financial loss for what they paid for the
product, providers are much less likely to purchase that product--a
response that is in line with the providers' economic interests (to be
reimbursed).
51. Many of the facilities administering infusion services of the
type at issue here are physician-owned. Thus, the physicians themselves
have both prescribing authority and a strong financial incentive to
avoid products that are not widely covered.
52. Commercial insurers typically publish medical policies
enumerating the drug products they will cover under the medical benefit
and the terms under which they will do so. For example, medical
policies may exclude drugs from coverage, or they may dictate
restrictions on use. Drug manufacturers compete, usually with rebates
or other price concessions, to obtain coverage under insurer medical
policies and to have either fewer restrictions on reimbursement than
their competitors--or, at a minimum, to achieve ``parity'' whereby the
competing products have the same restrictions on reimbursement and the
patient and/or doctor can choose between them. Securing at least parity
placement is critical, especially for new products seeking to gain
traction in the marketplace, and particularly with large insurers,
which have tens of millions of covered patients.
G. The Importance of Access at the Provider Level
53. As discussed above, providers (hospitals, clinics, etc.) are
the market actors that actually purchase infliximab for use with their
infusion services for patients. J&J's agreements and conduct have the
effect of foreclosing this essential source of distribution.
54. Providers do not want to risk being unable to secure
reimbursement for any drug used to treat a patient after having already
paid for the product. Because it can be costly to monitor coverage
status across myriad insurers and implement procedures to match product
use to a patient's coverage, gaps in reimbursement policies give ``buy
and bill'' provider accounts reasons to stock only products with
universal (or near-universal) coverage. Here, due to J&J's
anticompetitive contracts at the insurer level, J&J has succeeded in
preventing biosimilar competitors from achieving the same status.
J&J'S EXCLUSIONARY SCHEME
55. Not content with its nearly 2 full decades of exclusivity with
Remicade, and the billions of dollars of profits that such exclusivity
enabled, J&J hatched a multifaceted scheme to ensure that biosimilars
would never become viable competitors--a scheme embodied, at least in
part, in its ``Biosimilar Readiness Plan.'' J&J revealed the existence
of the plan, and at least some specifics thereof, during a recent
investor call and presentation.\14\ And a J&J consultant bragged at a
recent health conference that his firm helped design the plan to
realize J&J's goal of ensuring that biosimilars never gain a foothold.
---------------------------------------------------------------------------
\14\ Johnson & Johnson, Q3 2016 Results Earnings Call Transcript
(Oct. 14, 2016), available at https://seekingalpha.com/search/
transcripts?term=johnson+%26+Johnson+biosimilar.
56. J&J's conduct has not gone unnoticed in the industry. For
example, an analyst at a prominent securities firm (Bernstein Research)
recently summarized key aspects of J&J's scheme, observing that J&J
has: (a) ``negotiated with [insurers]'' and set up ``exclusive
contracts . . . in nearly half the market,'' thereby making providers
unwilling to purchase Inflectra; (b) ``offered up deeper discounts to
large independent infusion centers [i.e., major providers], which are
more economically sensitive''; and (c) ``bundled several drugs and
medical devices [together] for larger hospitals.'' \15\ The analyst
also noted that a key to J&J's strategy was the ``long `tail' of
[patients] remaining on the brand'' \16\--the incontestable demand--
which gives J&J leverage to extract commitments from insurers not to
cover Inflectra.\17\ Another industry observer, commenting on the
Bernstein survey, noted that J&J's ``fail first'' requirements with
insurers ``force hospitals and clinics to buy Remicade.'' The observer
also noted that:
---------------------------------------------------------------------------
\15\ Aaron Gal, Biosimilars: So, Why Has Remicade Biosimilar Not
Gotten Much Traction in the U.S., Bernstein Research, at 1 (July 20,
2017).
\16\ Id.
\17\ While the Bernstein survey suggests that Pfizer has offered
only a `` `low single digit' discount off of the ASP'' of Inflectra,
that is not accurate. As set forth herein, Pfizer has offered Inflectra
at a significantdiscount (to list price as well as ASP), but continues
to be foreclosed by J&J's anticompetitive contracts. J&J, meanwhile,
has raised the price of Remicade since Inflectra's entry. The Bernstein
survey also speculates that with the entry of a third biosimilar in
mid-2019, ``we would likely [sic] see one of the biosimilars crossing
the Rubicon and offering the required discounts.'' Gal, supra note 15,
at 1. However, as set forth herein, J&J's exclusive contracts and
bundling practices foreclose all new biosimilar entrants, including
Pfizer, from competing with Remicade on price and, if not stopped, will
allow J&J to continue to maintain the monopoly power it currently
exercises with Remicade.
J&J has had yet another advantage--an ability and willingness
to bundle different medicines as part of a package deal. By
offering discounts and rebates for several drugs, J&J can
secure contracts and crowd out rivals. And discounts are also
appealing to physicians who run their own infusion centers.\18\
---------------------------------------------------------------------------
\18\ Ed Silverman, J&J Now Has Two Competitors for A Pricey
Blockbuster. Will That Finally Drive Down Prices?, Stat News (July 25,
2017), https://www.statnews.com/pharmalot/2017/07/25/merck-samsung-
biosimilar-pfizer-johnson/.
---------------------------------------------------------------------------
57. J&J's scheme is set forth in more detail below:
A. J&J Bars Access to Insurer Reimbursement Through Improper
Exclusive Contracts and Anticompetitive Bundling Practices
1. J&J's Exclusive Contracts with Health Insurers
58. A centerpiece of J&J's strategy to block competition from
biosimilars has been to secure contractual commitments from commercial
insurance companies to exclude biosimilars from coverage under their
plans, making Remicade the exclusive infliximab available to patients
covered by those plans. Such contractual commitments have taken various
forms. Some insurers have entered into contracts with J&J that required
them simply to exclude biosimilars from their medical policies and/or
drug formularies altogether. Other J&J contracts have imposed a
spurious requirement that the biosimilar could be reimbursed only after
a patient first tried and failed on Remicade (the ``fail first''
requirement), which virtually ensures that the biosimilar will never be
prescribed and never be reimbursed. If a patient fails on Remicade, it
would defy sound medical judgment for a physician to switch to the
therapeutically equivalent biosimilar, which works in exactly the same
way, rather than another therapy, to which a patient may potentially
respond differently.\19\ Regardless of their specific form, these
contracts all had the same effect--to exclude biosimilars from coverage
and (as one analyst recently confirmed) grant an ``exclusive'' to
Remicade.\20\
---------------------------------------------------------------------------
\19\ The notion that attempting treatment with a biosimilar after
its reference listed drug has first failed would defy medical judgment
recently has been reinforced in the European League Against Rheumatism
rheumatoid arthritis management recommendations. In those
recommendations, ``[t]he Task Force reiterated its position that if a
TNF-inhibitor fails, another TNF-inhibitor--but not a biosimilar of the
same molecule!--can be as effective as changing the mode of action.''
Smolen, J.S., et al., EULAR Recommendations for the Management of
Rheumatoid Arthritis with Synthetic and Biological Disease-Modifying
Antirheumatic Drugs: 2016 Update, Annals of the Rheumatic Diseases
2017:0:1-18 (Mar. 6, 2017).
\20\ Gal, supra note 15, at 1.
59. J&J has induced most major health insurers, covering at least
70 percent of commercially insured patients in the United States, to
adopt these improper contractual exclusivity restrictions and to impose
outright bans on Inflectra's coverage or so-called ``fail first''
requirements. These insurers include (in decreasing order of patients
---------------------------------------------------------------------------
covered):
National insurers:
(a) UnitedHealthcare: UnitedHealthcare adopted the ``fail first''
requirement. United Healthcare has approximately 30.6 million covered
commercial medical patients across all 50 states.
(b) Anthem: Anthem excluded Inflectra from coverage altogether.
Anthem has approximately 30.4 million covered commercial medical
patients concentrated in 14 states.
(c) Aetna: Aetna adopted a complex set of indication specific
conditions which operate in practice as ``fail first'' requirements.
Aetna has approximately 17.9 million covered commercial medical
patients in all or nearly all states and territories in the United
States.
(d) Cigna: Cigna adopted the ``fail first'' requirement. Cigna has
approximately 13 million covered commercial medical patients across all
50 states.
Regional insurers:
(a) HealthNet (Centene): HealthNet adopted a complex set of
indication specific conditions which operate in practice as ``fail
first'' requirements. HealthNet (as part of its acquisition by Centene)
has approximately 12 million covered commercial medical patients
concentrated in 28 states.
(b) CareFirst/Blue Cross Blue Shield: CareFirst adopted the ``fail
first'' requirement. Indeed, CareFirst agreed with J&J that Inflectra
would be non-preferred, meaning it cannot be reimbursed unless there
are ``clinical circumstances that would exclude the use of . . .
preferred products,'' including Remicade. CareFirst has approximately
3.2 million covered commercial medical patients principally found in
Maryland, Virginia, and the District of Columbia.
(c) Blue Cross Blue Shield of North Carolina: BCBS of North
Carolina adopted the ``fail first'' requirement. BCBS of North Carolina
has approximately 2.7 million covered commercial medical patients
concentrated in North Carolina.
(d) Blue Cross Blue Shield of Tennessee: BCBS of Tennessee adopted
the ``fail first'' requirement. BCBS of Tennessee has approximately 1.6
million covered commercial medical patients concentrated in Tennessee.
(e) Blue Cross Blue Shield of Louisiana: BCBS of Louisiana adopted
the ``fail first'' requirement. BCBS of Louisiana has approximately 1.6
million covered commercial medical patients principally concentrated in
Louisiana.
(f) Excellus Blue Cross Blue Shield: Excellus BCBS adopted the
``fail first'' requirement. Excellus has approximately 1.2 million
covered commercial medical patients concentrated in New York.
(g) Independence Blue Cross: Independence Blue Cross adopted the
``fail first'' requirement. Independence Blue Cross is the leading
health insurer in Philadelphia.
These contracts alone affect approximately 114 million covered
commercial medical patients of the over approximately 214 million
patients covered by commercial medical insurance in the United States.
Pfizer has reason to believe there are more.
60. While exclusive contracts can--in certain circumstances--be
perfectly appropriate, the exclusivity provisions described in
Paragraphs 8, 9, and 58 serve no legitimate or procompetitive purpose
and were not earned through simple price competition. After Inflectra's
FDA approval in April 2016, and before J&J implemented its exclusionary
contracts, health insurers undertook reviews to determine whether there
was a medical reason not to reimburse Inflectra or to disfavor it
relative to other therapies. Following these reviews, several major
health insurance companies--including at least Aetna, Anthem, and
UnitedHealthcare-- classified Inflectra at parity with Remicade. This
confirmed that there was no medical reason justifying a restrictive
reimbursement policy toward Inflectra. It also meant that, for the time
being, Inflectra would be reimbursed without restriction. As a result,
the stage was set for Inflectra to begin competing head-to-head with
Remicade on a level playing field--and for patients to begin receiving
the benefits of greater choice and lower prices.
61. But this initial state of affairs was short lived. As a result
of J&J's anticompetitive conduct, insurers began to reverse course and
restrict coverage of Inflectra.
62. For example, in October 2016, UnitedHealthcare, the nation's
largest health insurer, with over 30 million covered commercial medical
patients, published an update to its medical and site of care policies
classifying Inflectra at parity with Remicade for the approved
indications (with an effective date of November 1, 2016). This meant
that, for UnitedHealthcare, Inflectra would be reimbursed freely and
would not be disfavored relative to Remicade. Just weeks later,
however, UnitedHealthcare reversed course. UnitedHealthcare classified
Remicade as its ``preferred'' product, and instructed that Inflectra
would be eligible for reimbursement only in circumstances so limited as
to be practically non-existent. Under UnitedHealthcare's new policy,
Inflectra could be reimbursed only where the following conditions are
met: (a) the patient must show a minimal clinical response, or an
intolerance or adverse reaction, to Remicade; (b) the physician must
attest that Inflectra would not lead to the same adverse responses; and
(c) the patient must show no loss of favorable response in established
maintenance therapy with Remicade, and must not have developed
neutralizing antibodies to any infliximab biosimilar product that has
made the therapy less effective. As a practical matter, this meant that
Inflectra would not be reimbursed for UnitedHealthcare's more than 30
million commercial medical members, and that Remicade would be the
exclusive infliximab with UnitedHealthcare--despite the lack of any
medical basis for denying those members access to a lower-priced
alternative to Remicade.
63. UnitedHealthcare's reversal, of course, did not happen by
chance. J&J induced UnitedHealthcare to enter into an exclusive deal by
threatening to penalize UnitedHealthcare with the loss of significant
rebates unless UnitedHealthcare agreed to deny coverage of Inflectra.
64. J&J has employed the same approach to secure exclusive deals
with most or all of the major insurers identified above. In most cases
these coercive biosimilar-exclusion contracts were the only
economically viable option for insurers--as adopting any alternative
would require the insurer to incur a substantial penalty (i.e.,
foregone rebates to existing Remicade patients) that could not be
offset by the per-unit cost savings available on the number of patients
likely to use the biosimilar, at least in the near term.
2. J&J's Bundling Tactics with Health Insurers
65. J&J's threatened penalties are effective because they leverage
the large base of existing patients already stabilized on Remicade.
Given that J&J has offered the only infliximab option in the United
States for nearly two decades, its base of existing Remicade patients
is substantial, amounting to hundreds of thousands of patients across
the country. And, in part driven by J&J's marketing efforts to secure
this outcome, existing Remicade patients are likely to stay on
Remicade. Thus, the demand for Remicade associated with this existing
base of patients is, as a practical and economic matter, incontestable.
This is so despite the fact that switching is within the scope of FDA's
approval for use of biosimilars and thus appropriate when medically
directed--something Pfizer discusses with clients. The situation is
different for new patients who may be candidates for infliximab. In
light of this, Pfizer has focused, among other things, on competing for
a substantial share of new patient starts (the ``contestable'' demand)
by pricing Inflectra competitively with both insurers and providers on
a unit-for-unit basis. The fact that Inflectra's ASP is lower than
Remicade's underscores the cost savings it offers.
66. By threatening to withhold attractive rebates on all Remicade
prescriptions-- including those for existing patients as well as new
ones--unless an insurer agrees to exclusivity, J&J is able to leverage
the incontestable demand for Remicade to exclude competition for the
contestable demand, i.e., it bundles the contestable and incontestable
demand. Even if Pfizer offers a significantly lower price for Inflectra
unit-for-unit, as it has done, insurers will agree to J&J's exclusive
deals to avoid losing rebates on the substantial base of existing
Remicade patients who are not likely to switch to Inflectra despite the
presence of the lower-priced biosimilar. A recent article by two Yale
Medical School professors in the Journal of the American Medical
Association illustrates how the kind of leverage J&J has over existing,
stable Remicade patients allows it to extract commitments to exclude
the biosimilar:
If a biosimilar manufacturer intends to upend the preferred
position of the brand by offering a substantial price discount
to the [insurer], the branded manufacturer can respond by
withdrawing the rebate on the [branded] biologic, creating a
``rebate trap.'' For any patient continuing the [branded]
biologic, a payer's cost for that patient will double once the
rebate is withdrawn. . . . Even in [an] optimistic scenario, in
which the price of the biosimilar is 60 percent less than the
price of the brand after rebates and discounts, if the payer is
only able to convert 50 percent of its patient users to the
biosimilar [because existing patients will tend to stay on the
original branded product], the rebate trap ensures that payer
total costs actually increase relative to costs prior to
biosimilar availability.
* * *
To avoid the rebate trap, any strategy to reduce spending on
biologics through adoption of biosimilars requires a near-
complete switch of patient users from the branded biologic to
the biosimilar. However, for many chronic diseases, the
proportion of patients new to a given biological therapy is
less than 20 percent of the total patients taking that drug in
a given year. The remainder represents a stable base of
patients whose disease is well-maintained while they are using
current therapy and thus are unlikely to switch [to the
biosimilar].\21\
---------------------------------------------------------------------------
\21\ Aaron Hakim and Joseph S. Ross, ``Obstacles to the Adoption of
Biosimilars for Chronic Diseases,'' Journal of the American Medical
Association (May 1, 2017), available at http://jamanetwork.com/
journals/jama/article-abstract/2625049 (emphasis added).
67. J&J has further insulated its contracts with insurers from
competition by bundling rebates for Remicade with rebates on other
products in return for commitments not to cover Inflectra. J&J made it
no secret that it would leverage other products as part of its
``Biosimilar Readiness Plan.'' As J&J's Worldwide Chair for
Pharmaceuticals made clear on a recent earnings call, ``We are fully
prepared to execute our focused biosimilar readiness plan,'' including
``developing innovative contracts . . . [to] utilize the full breadth
of our portfolio.'' \22\ The ``full breadth of [J&J's] portfolio''
includes several drugs for which Pfizer does not offer any directly
competing alternative. These include drugs such as Simponi (used for
rheumatoid arthritis, psoriatic arthritis, ankylosingspondylitis, and
ulcerative colitis), Simponi Aria (used for rheumatoid arthritis), and
Stelara (used for plaque psoriasis, psoriatic arthritis, and Crohn's
disease). These products are widely used, with Simponi/Simponi Aria
generating for J&J approximately $1.7 billion in 2016 and Stelara
generating for J&J approximately $3.2 billion in 2016. J&J has
threatened insurers with the loss of rebates on these other drugs, as
well as Remicade, if they do not agree to exclude Inflectra from
coverage.
---------------------------------------------------------------------------
\22\ Johnson & Johnson, Q3 2016 Results Earnings Call Transcript
(Oct. 14, 2016), available at https://seekingalpha.com/search/
transcripts?term=johnson+%26+Johnson+biosimilar.
68. J&J's multi-product bundling, along with its bundling of
contestable demand (i.e., new patients) and incontestable demand (i.e.,
existing Remicade patients), have amplified the anticompetitive effects
of J&J's exclusive contracts, and made the exclusivity provided by
those contracts even more durable. Insurers have made it clear to
Pfizer that its net cost for Inflectra would need to be low enough to
offset the loss of J&J rebates. But, because of the combined effect of
these bundles, Pfizer cannot offset the financial penalties that J&J
threatens to impose on insurers who do not agree to exclusivity. As a
result, Pfizer is economically prohibited from competing for coverage
by the major insurers--even when their exclusive contracts with J&J
expire. J&J can use the same bundling strategies to ensure continuation
---------------------------------------------------------------------------
of the exclusionary pattern.
B. J&J's Improper Insurer-Level Contracts Deter Hospitals
and Clinics from Purchasing Inflectra, Thus Amplifying Foreclosure
69. Providers are unwilling to stock a drug product where there is
significant uncertainty about whether it will be reimbursed by health
insurers; because they administer infliximab onsite, providers must
expend funds for the product in the first instance, then seek
reimbursement after providing treatment. The provider has theoretical
recourse against the patient where coverage is denied, but the prospect
of securing payment in full from the patient is bleak, especially for
drugs as costly as Remicade. As a result, where a significant portion
of a provider's patients are insured by plans that have agreed to
exclude Inflectra--pursuant to the types of contracts described above--
the provider is unlikely to offer Inflectra for any of its patients, to
avoid being caught with no reimbursement.
70. As a recent article in Bloomberg stated:
Ascension Health, a nearly 23,000-bed nonprofit hospital system
based in St. Louis, spends $55 million a year on Remicade, more
than any other drug. Using Inflectra, part of a new class of
medicines called biosimilars, would save it at least $10
million annually, according to Ascension's chief pharmacist,
Roy Guharoy. He met with Pfizer and planned to integrate
Inflectra into care more often until learning that insurers
preferred to stay with Remicade. ``This we did not expect,''
Guharoy said. ``If the insurance companies force us to use the
branded product, of course our hands are tied.'' \23\
---------------------------------------------------------------------------
\23\ Jared S. Hopkins, What's Harder Than Making Copycat Biotech
Drugs? Selling Them, Bloomberg (Aug. 15, 2017).
In short, provider purchases are driven by the coverage stated by
---------------------------------------------------------------------------
commercial insurers.
71. Having created reimbursement concerns through its exclusionary
contracts with health insurers, J&J touts the excluded status of
Inflectra in its marketing communications, knowing that doing so will
discourage providers from stocking the new biosimilar. As this brochure
shows, J&J markets the ``fail first'' requirement as a selling point
despite the fact that such a provision is medically inappropriate and
despite FDA's determination that there are no clinically meaningful
differences between the two products. Thus the brochure touts that
Remicade is ``Preferred Over Inflectra . . . Inflectra requires trial
and failure on Remicade prior to [Inflectra] utilization.''
[GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT]
72. Given the widespread gaps in Inflectra's insurance coverage--
caused by J&J--providers using infliximab have overwhelmingly chosen to
stock only Remicade (which is essentially universally covered given its
long tenure and dominant position) rather than deal with the risk of
possible denials of coverage for Inflectra. Thus, providers have
declined to purchase Inflectra across the board, even for patients
covered by commercial or government insurance plans that do cover the
product. The effective foreclosure of biosimilars thereby is expanded
well beyond the 70 percent of commercially insured patients directly
foreclosed by J&J's insurer contracts. Indeed, as of September 1, 2017,
about 90 percent of healthcare provider accounts using infliximab had
purchased no Inflectra at all.
C. J&J Has Further Barred Access Through Exclusionary
Contracts with Providers
73. To further amplify Inflectra's foreclosure--even beyond the
population of patients covered by insurance plans that have agreed to
J&J's exclusivity terms, and the spillover effect on providers
discussed above--J&J has imposed exclusionary contracts on providers
themselves (e.g., clinics, hospitals, etc.).
74. After Inflectra's introduction, J&J began offering certain
large providers additional rebates and/or discounts on Remicade, but
only if the provider committed to buy Remicade for nearly all of its
infliximab needs. To be eligible for rebates, J&J required providers to
maintain purchase levels for Remicade at very close to the levels of
the year before Inflectra's launch--when Remicade was the only
infliximab option. With about 30 percent of prescriptions in any year
representing new patients (and a certain percentage of existing
patients exiting therapy each year), this condition also requires
providers to use Remicade for new patients if they wish to secure
payment from J&J, thus bundling contestable and incontestable demand
for Remicade. Like its insurer-level contracts, these contracts as a
practical matter make Remicade the exclusive infliximab with the
participating providers.
75. J&J has also used multi-product bundling in its provider-level
contracts. As one analyst reported, ``J&J bundled several drugs and
medical devices for larger hospitals, making Inflectra less
economical.'' \24\ Conditioning rebates linked to other J&J products
upon a promise not to do business with Inflectra only exacerbates the
exclusionary nature of J&J's contracts.
---------------------------------------------------------------------------
\24\ Gal, supra note 15, at 1.
76. Pfizer was and is prepared to negotiate with providers to make
Inflectra the lower-priced infliximab option on a per-unit basis, and
has even offered to guarantee that Inflectra would be less expensive
unit-for-unit than Remicade. But as with insurer contracts, to secure
the right to deal freely as to Inflectra (i.e., principally as to new
patients), the providers would lose significant J&J rebates on their
---------------------------------------------------------------------------
existing Remicade patient bases.
77. For Pfizer to make up the J&J rebates/discounts that insurers
and providers would lose on their existing Remicade patients, Pfizer
would have to price Inflectra below its own average variable cost. This
is because the lost J&J rebates/discounts are based on the much larger
base of existing Remicade patients, whereas Pfizer would be serving a
much smaller group of new patients, at least in the near term.
78. When the total amount of discounts and rebates that J&J offers
to insurers and providers under the contracts described herein,
including multi-product bundle contracts, is attributed to the portion
of Remicade sales that is contestable by a biosimilar like Inflectra,
J&J is pricing Remicade below its own average variable cost. As a
result, biosimilar competition to Remicade is foreclosed.
79. The combined effect of J&J's multifaceted exclusionary scheme
has been to foreclose Inflectra from approximately 90 percent of the
provider account distribution channel essential to connecting Inflectra
with patients of any kind.
J&J HAS MONOPOLY POWER IN THE RELEVANT MARKETS
80. Monopoly power is the ability of a single seller to raise
prices above the competitive price level without losing significant
business.
81. For years before Inflectra's entry, J&J's ASP for Remicade
increased, yet Remicade did not lose business. Between 2007 and 2017,
Remicade's ASP increased more than 62 percent. Despite Remicade's price
hikes, unit sales of Remicade have actually grown 15 percent during the
period from 2012 to 2016.
82. Inflectra's introduction has done nothing to erode Remicade's
monopoly power: Since Inflectra was launched, Remicade's ASP has
continued to increase without impacting Remicade's market position. Ten
months after Inflectra was introduced, Remicade still accounts for over
96 percent of all infliximab sales. Indeed, J&J has confirmed that
``biosimilar competition'' has had ``very little impact'' on
Remicade.\25\
---------------------------------------------------------------------------
\25\ Johnson & Johnson, Q1 2017 Results Earnings Call Transcript
(Apr. 18, 2017), available at https://seekingalpha.com/search/
transcripts?term=johnson+%26+Johnson+biosimilar.
83. As noted, infliximab is an infusion-administered TNF-inhibiting
immunosuppressant with FDA approved indications for rheumatoid
arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative
colitis, Crohn's disease, and plaque psoriasis (together, the
---------------------------------------------------------------------------
``Relevant Indications'').
84. The broadest appropriate relevant product market is infusion-
administered drugs whose approved labeling from the FDA (a) encompasses
one or more of the Relevant Indications, and (b) is without restriction
for the applicable Relevant Indication, that is to say, the labeling
does not specify that the drug may be used for the applicable Relevant
Indication only after the patient has not responded to another therapy
(the ``Relevant Product Market'').\26\ Remicade enjoys a share of over
60 percent in the Relevant Product Market, nearly the same share it had
before Inflectra entered.
---------------------------------------------------------------------------
\26\ For example, the FDA approved Rituxan for the treatment of
moderate to severe active rheumatoid arthritis in adults only after
treatment with at least one other TNF antagonist has been used and did
not work well enough.
85. The following infusion-administered therapies have been
---------------------------------------------------------------------------
approved as unrestricted therapies for the Relevant Indications:
Rheumatoid Arthritis:
Remicade (infliximab) (J&J) (TNF-
inhibitingimmuno-suppressant)
Simponi Aria (golimumab) (J&J) (TNF-
inhibiting immuno-suppressant)
Inflectra (infliximab) (Pfizer) (TNF-
inhibitingimmuno-suppressant)
Renflexis (infliximab) (Merck) (TNF-
inhibitingimmuno-suppressant)
Orencia IV (abatacept) (Bristol-Myers Squibb)
(synthetic recombinant DNA technology immune-suppressant)
Actemra IV (tocilizumab) (Roche)
(interleukin-6 blocker) (IL-6 blocker)
Psoriatic Arthritis:
Remicade (infliximab) (J&J) (TNF-
inhibitingimmuno-suppressant)
Stelara IV (ustekinumab) (J&J) (human
interleukin-12 and -23 antagonist)
Inflectra (infliximab) (Pfizer) (TNF-
inhibitingimmuno-suppressant)
Renflexis (infliximab) (Merck) (TNF-
inhibitingimmuno-suppressant)
Orencia IV (abatacept) (Bristol-Myers Squibb)
(synthetic recombinant DNA technology immuno-suppressant)
Ankylosing Spondylitis:
Remicade (infliximab) (J&J) (TNF-
inhibitingimmuno-suppressant)
Inflectra (infliximab) (Pfizer) (TNF-
inhibitingimmuno-suppressant)
Renflexis (infliximab) (Merck) (TNF-
inhibitingimmuno-suppressant)
Plaque Psoriasis:
Remicade (infliximab) (J&J) (TNF-
inhibitingimmuno-suppressant)
Stelara IV (ustekinumab)(J&J) (human
interleukin-12 and -23 antagonist)
Inflectra (infliximab) (Pfizer) (TNF-
inhibitingimmuno-suppressant)
Renflexis (infliximab) (Merck) (TNF-
inhibitingimmuno-suppressant)
Crohn's Disease:
Remicade (infliximab) (J&J) (TNF-
inhibitingimmuno-suppressant)
Stelara IV (ustekinumab) (J&J) (human
interleukin-12 and -23 antagonist)
Inflectra (infliximab) (Pfizer) (TNF-
inhibitingimmuno-suppressant)
Renflexis (infliximab) (Merck) (TNF-
inhibitingimmuno-suppressant)
Entyvio (vedolizumab) (Takeda) (integrin
receptor antagonist monoclonal antibody)
Ulcerative Colitis:
Remicade (infliximab) (J&J) (TNF-
inhibitingimmuno-suppressant)
Inflectra (infliximab) (Pfizer) (TNF-
inhibitingimmuno-suppressant)
Renflexis (infliximab) (Merck) (TNF-
inhibitingimmuno-suppressant)
Entyvio (vedolizumab) (Takeda) (integrin
receptor antagonist monoclonal antibody)
These infusion therapies are referred to collectively as the ``Relevant
Products.''
86. Certain non-infusion drugs are also indicated to treat the
Relevant Indications. None of those drugs, however, is a reasonable
substitute for the infusion-
administered products. None significantly constrains the prices J&J is
able to charge for Remicade.
87. The non-infusion products approved for the Relevant Indications
include oral medications (e.g., Xeljanz) and self-injectables (e.g.,
Humira, Enbrel). These products are patient-administered. Infusion
drugs, by contrast, must be delivered by healthcare professionals in a
clinical setting (e.g., hospitals or infusion centers) during infusion
sessions that take upwards of two hours.
88. Physicians are not likely to switch from prescribing their
patients infliximab to prescribing those non-infusion products in
response to a small but significant non-transitory change in the price
of infliximab.
89. Not only are the infusion and non-infusion treatments different
kinds of therapies, but they are most often sold to different buyers,
on different contracts, and are distributed by different means:
Infliximab is, as described above, sold primarily to
hospitals and clinics and is almost never stocked by retail
pharmacies (only rarely being stocked by certain specialty
pharmacies). After administering the infusion treatments to
their patients, the hospitals and clinics seek reimbursement
from the patients' insurers or government payers.
By contrast, non-infusion drugs such as Xeljanz, Humira, and
Enbrel are primarily sold to and distributed in the pharmacy
channels. Physicians who prescribe these non-infusion drugs
generally do not administer the treatments and do not bear
financial risk with respect to the drug selected.
Non-infusion drugs are also typically covered by insurance
through a pharmacy benefit plan. These are products that
insured patients obtain using their ``pharmacy'' cards. Such
drugs are put out for bid periodically by insurers and/or
pharmacybenefit managers. The bidding process generally does
not even include infusion and other therapies not stocked in a
retail pharmacy.
By contrast, infusion therapies generally are treated as
part of the basic medical coverage provided by health insurers.
Infusion therapies are thus generally put out for bid
separately from self-administered therapies.
90. Beyond the medical reasons physicians may have for prescribing
an infusion therapy as opposed to a non-infusion therapy, patients
exhibit strong preferences for one form of therapy over another.
Patients with active lifestyles often prefer self-administered
treatments. Infusion therapy, on the other hand, is often preferred by
patients with needle aversions, or by patients who prefer to have their
treatments administered by medical professionals.
91. In addition, infusion and non-infusion therapies are offered at
very different price points: On an annual basis, Enbrel and Humira
(which are self-administered therapies) at list price are at least
twice as expensive as Remicade (which is an infusion therapy) for
patients stabilized on them.
92. Because of these various factors, a small but significant non-
transitory increase in price of infusion therapies would not have a
meaningful impact on the demand for non-infusion therapies, and vice-
versa.
93. As noted, the Relevant Product Market includes certain segments
that qualify themselves as Relevant Markets, in which J&J also
possesses monopolypower. For example:
94. Specific-use product markets. Specific-use product markets are
predicated on infusion-administered therapies for the Relevant
Indications. A small but significant nontransitory increase in price
for an infusion product in each of these specific-use product markets
would not cause substitution to non-infusion medicines approved for the
same indication. In each category, Remicade has been the dominant
infusion-administered therapy. The categories are as follows:
Infusion-administered therapies for Crohn's disease.
Remicade accounts for over 70 percent of prescriptions to
patients of infusion-based drugs indicated for Crohn's disease.
Infusion-administered therapies for rheumatoid arthritis.
Remicade accounts for nearly 55 percent of prescriptions to
patients of infusion-based drugs indicated for rheumatoid
arthritis. When combined with the share of its product Simponi
Aria, J&J commands an aggregate of nearly 65 percent of
prescriptions to patients in this category.
Infusion-administered therapies for ulcerative colitis.
Remicade accounts for nearly 70 percent of prescriptions to
patients of infusion-based drugs indicated for ulcerative
colitis.
Infusion-administered therapies for psoriatic arthritis.
Remicade accounts for over 95 percent of prescriptions to
patients of infusion-based drugs indicated for psoriatic
arthritis.
Infusion-administered therapies for ankylosing spondylitis.
Remicade accounts for over 95 percent of prescriptions to
patients of infusion-based drugs indicated for ankylosing
spondylitis.
Infusion-administered therapies for plaque psoriasis.
Remicade accounts for over 95 percent of prescriptions to
patients of infusion-based drugs for plaque psoriasis.
95. Clinic-based product market. The Relevant Product Market
encompasses a submarket consisting of sales of the Relevant Products to
non-hospital clinics (including freestanding clinics and physician
offices with infusion chairs) that administer infusion therapies to
patients. Such a submarket is properly treated as a relevant submarket
among other reasons because J&J is able to price discriminate between
hospitals and non-hospital clinics. The U.S. antitrust enforcement
agencies and economists recognize that relevant antitrust product
markets can be based on categories of customers against whom sellers
can exercise price discrimination, i.e., differential pricing.\27\ Non-
hospital clinics are subject to successful price discrimination by J&J.
J&J can and does identify and target clinics for differential pricing.
There are significant differences in the rebates and discounts J&J
makes available to non-hospital clinics as compared to hospital
customers. Moreover, a small but significant non-transitory increase in
the price of Remicade or other Relevant Products will not induce
infusion clinics to switch to self-administered therapies. A very
substantial percentage of provider accounts that purchase infliximab
are non-hospital clinics.
---------------------------------------------------------------------------
\27\ See, e.g., U.S. Department of Justice and Federal Trade
Commission Horizontal Merger Guidelines (2010), Sec. 3.
96. Product markets for new and existing patients. As described
above, J&J has a substantial base of existing Remicade patients, the
substantial majority of whom are not likely to switch to another
therapy, even a biosimilar, if they have achieved relief with
Remicade--even in response to a small but significant non-
transitory increase in price for Remicade. By contrast, for new
patients who are candidates for infusion-administered therapies for the
Relevant Indications, Inflectra is a reasonable substitute for
Remicade. Thus, there is a distinct product market for sales of
Relevant Products to new patients in need of infusion-administered
therapies for the Relevant Indications. There is also a distinct
product market for patients already stabilized on Remicade--a market
dominated by Remicade. As described above, J&J's scheme has bundled its
control over the latter market (for patients stabilized on Remicade) to
thwart competition in the former market (for new patients in need of
---------------------------------------------------------------------------
infusion therapy).
97. Infliximab product market. After discovery, the data may also
support an infliximab-only product market. Among other things, J&J has
been able to raise prices for Remicade consistently without losing
significant sales to other branded drug products. Both J&J and Pfizer
consider Remicade and Inflectra to be particularly close substitutes.
For example, J&J's marketing materials focus on comparisons of price
and clinical effectiveness between Remicade and infliximab biosimilars,
and do not reference any other therapies, and its ``Biosimilar
Readiness Plan'' similarly ignores other therapies, focusing instead on
the unique competitive threat posed by biosimilars. Inflectra's
marketing materials likewise focus on Remicade, not on other therapies.
98. Barriers to entry. Substantial barriers to entry exist to
developing other infusion-administered drug therapies for the Relevant
Indications generally, and infusion-administered TNF inhibitors
specifically. The development of a new therapy requires tens if not
hundreds of millions of dollars and substantial risk, as any new
product must survive years of research and development, clinical
trials, and FDA approval. If left unchecked, J&J's conduct will serve
as an additional barrier to entry, as potential new entrants will
recognize that they will be unable to break J&J's ``rebate trap'' and
thus to profitably enter the Relevant Markets--and consequently will
not invest the resources necessary to develop biosimilars.
99. While a second biosimilar to Remicade has been approved--called
Renflexis, sponsored by Merck and Samsung--the sponsoring firms had to
overcome just the kind of substantial burdens noted above, and began
the effort long before J&J commenced its scheme to exclude biosimilar
competition. J&J itself has expressed confidence in maintaining its
Remicade dominance despite the potential entry of Renflexisbased on its
exclusionary contracting strategy. Pfizer has received marketplace
feedback that Renflexis will face the same access challenges from J&J's
scheme as Inflectra.
100. J&J's scheme--including coercive contracts bundling the
incontestable demand (existing patients) with contestable demand (new
patients), and promoting the results of its exclusionary insurer-level
contracts to create uncertainty about Inflectra among providers--has
led directly, with J&J's active encouragement, to nearly all provider
accounts that use infliximab declining to purchase Inflectra at all.
Even if some portion of a provider's patient base may be covered,
providers are unwilling to risk using Inflectra only to ultimately be
denied coverage. A single denied claim can cost a provider in excess of
$4,000, whereas the typical provider savings in product acquisition
cost for a covered Inflectra claim is $200-300. Because Remicade is
nearly universally covered, providers have taken the ``safe'' option
and stocked Remicade over Inflectra, thus increasing the already-
substantial foreclosure caused by J&J's exclusionary contracts. Thus,
as a practical matter, J&J's scheme has foreclosed Inflectra from
approximately 90 percent of provider accounts using infliximab, the
essential channel of distribution for infliximab. And, as noted, in
terms of sales, Remicade continues to control over 96 percent of
infliximab unit sales.
101. Geographic market. The relevant geographic market for the
Relevant Markets alleged herein is the United States of America and its
possessions and territories, as these products are marketed and sold on
a national basis.
J&J's CONDUCT HAS STIFLED COMPETITION IN THE RELEVANT MARKETS, THEREBY
MAINTAINING AND ENHANCING ITS MONOPOLY POWER AND INJURING PFIZER
102. J&J's scheme has led to the near total foreclosure of
Inflectra with patients across the country. First, its exclusionary
contracts with health insurers alone--including with most of the
largest health insurers in the country--have foreclosed Pfizer's
ability to compete for at least 70 percent of patients covered by
commercial health insurance plans in the United States. Second, J&J's
exclusionary contracts with certain providers have foreclosed Pfizer's
ability to compete even for patients covered by plans that do provide
reimbursement for Inflectra. And, as discussed, the reimbursement
challenges (created by J&J) have led most provider accounts to decline
to purchase Inflectra at all, with approximately 90 percent of provider
accounts that use infliximab across the country not stocking Inflectra
at all. As of September 2017, J&J maintained over 96 percent share of
infliximab unit sales in the U.S.
103. Despite vigorous efforts to compete--including offering
guarantees that Inflectra would be less expensive unit-for-unit than
Remicade--Pfizer has been foreclosed from gaining a competitive
foothold as a direct result of J&J's scheme. In the absence of
Remicade's exclusionary practices, Inflectra's growth in the Relevant
Markets would be substantially greater than it has been, and would be
substantially larger in the future. J&J's conduct has deprived Pfizer
of (a) past profits; (b) future profits; and (c) the value of invested
capital from unrealized efforts to enter and expand in the Relevant
Markets. Further, Pfizer's current and prospective customer
relationships and goodwill have been, and will continue to be,
impaired. J&J's conduct, if allowed to continue, will also dampen the
incentives of Pfizer and other biosimilar developers to invest the
substantial resources needed to bring biosimilars to the market. Thus,
the aims of the BPCIA will have been thwarted.
104. J&J's activities have not only harmed Pfizer, they have caused
substantial harm to the competitive process as well as to government
payers and to consumers, who have been deprived of the principal
benefits of competition--more choices and lower prices. The
anticompetitive effects of J&J's conduct are evident in its pricing of
Remicade since Inflectra's entry. Despite the fact that Pfizer has
offered substantial discounts and a lower ASP to compete for business
with insurers and healthcare providers, J&J has been able to increase
the price of Remicade without losing any significant share or volume of
sales to Pfizer (or any other competitor). J&J's prices for Remicade
have been increasing by every measure. J&J has increased Remicade list
prices twice since FDA approval of Inflectra. These increases alone
raised Remicade's list price nearly 9 percent. Remicade's actual ASP
(which, as noted above, is net of discounts, rebates, and other price
concessions) has also increased since Inflectra's entry-- negating any
claim that J&J's rebates qualify as meaningful price competition.
105. There is no efficiency or cost-reducing justification for
J&J's coercive and exclusionary insurer- or provider-level contract
terms. J&J has not achieved improved production costs, or economies of
scale or scope through its contracting strategies. J&J also has
achieved no improvements in the Remicade treatment through its
contracting strategies.
106. If J&J's conduct is not prohibited, it will be adopted by
other originator biologics firms aiming to preserve their dominant
positions. As the first major biosimilar approval, this case will be a
bellwether for the success of Congress's biosimilars initiative, as
embodied in the BPCIA.
CLAIMS FOR RELIEF
FIRST CLAIM FOR RELIEF
Violation of 15 U.S.C. Sec. 2
Monopolization of All Relevant Markets
107. Pfizer repeats and realleges Paragraphs 1 through 106 as set
forth herein.
108. J&J has monopolized the Relevant Markets in violation of
Section 2 of the Sherman Act.
109. J&J has monopoly power in the Relevant Markets.
110. Through the scheme described above, and other conduct likely
to be revealed in discovery, J&J has willfully and unlawfully
maintained and enhanced its monopoly power in violation of Section 2 of
the Sherman Act. J&J's scheme constitutes exclusionary conduct within
the meaning of Section 2 of the Sherman Act.
111. J&J's scheme has stifled competition in the Relevant Markets
and thwarted Congress's purpose in enacting the BPCIA.
112. Among other things, given that (a) J&J imposed explicit
conditions that insurers and providers eliminate (or almost completely
curtail) their dealings with infliximab biosimilars, and (b) J&J's ASP
for Remicade has actually increased since the biosimilar entered, J&J's
pricing is not the clearly predominant means by which competition has
been foreclosed in the Relevant Markets.
113. Even if price were deemed to be the clearly predominant means
by which competition has been foreclosed, when the total amount of
discounts and rebates that J&J offers to insurers and providers under
the contracts described herein, including multi-product bundle
contracts, is attributed to the portion of Remicade sales that is
contestable by a biosimilar like Inflectra, J&J is pricing Remicade
below its own average variable cost.
114. As a result of J&J's conduct, and the harm to competition
caused by that conduct, Pfizer has suffered substantial and continuing
injuries.
SECOND CLAIM FOR RELIEF
Violation of 15 U.S.C. Sec. 2
Attempted Monopolization of All Relevant Markets
115. Pfizer repeats and realleges Paragraphs 1 through 114 as set
forth herein.
116. J&J has attempted to monopolize the Relevant Markets in
violation of Section 2 of the Sherman Act.
117. J&J is violating Section 2 of the Sherman Act by attempting to
implement the anticompetitive scheme set forth above with the specific
intent to monopolize the Relevant Markets. J&J's scheme constitutes
exclusionary conduct within the meaning of Section 2 of the Sherman
Act.
118. There is a dangerous probability that J&J will succeed in
monopolizing the Relevant Markets through its anticompetitive scheme.
119. J&J's scheme has stifled competition in the Relevant Markets and
thwarted Congress's purpose in enacting the BPCIA.
120. Among other things, given that (a) J&J imposed explicit
conditions that insurers and providers eliminate (or almost completely
curtail) their dealings with infliximab biosimilars, and (b) J&J's ASP
for Remicade has actually increased since the biosimilar entered, J&J's
pricing is not the clearly predominant means by which competition is
dangerously likely to be foreclosed in the Relevant Markets.
121. Even if price were deemed to be the clearly predominant means
by which competition is dangerously likely to be foreclosed, when the
total amount of discounts and rebates that J&J offers to insurers and
providers under the contracts described herein, including multi-product
bundle contracts, is attributed to the portion of Remicade sales that
is contestable by a biosimilar like Inflectra, J&J is pricing Remicade
below its own average variable cost.
122. As a result of J&J's conduct, and the harm to competition
caused by that conduct, Pfizer has suffered substantial and continuing
injuries.
THIRD CLAIM FOR RELIEF
Violation of 15 U.S.C. Sec. 14
Sale on Condition to Exclude Inflectra and Other Infliximab Biosimilars
or Impose a Fail First Requirement and to Force Use of Remicade in All
Relevant Markets
123. Pfizer repeats and realleges Paragraphs 1 through 122 as set
forth herein.
124. J&J has entered into agreements with insurers (which reimburse
Remicade) and providers (which purchase Remicade), whereby it has
conditioned the availability of discounts, rebates, and/or other price
concessions on insurers and/or providers eliminating or drastically
curtailing their dealings with Inflectra (or any other infliximab
biosimilar).
125. J&J's agreements function as exclusive agreements, what are
for all practical purposes sole-source agreements, the effect of which
is to foreclose substantially competition from rivals, such as Pfizer,
in the sale of the infliximab to medical providers, in violation of
Section 3 of the Clayton Act.
126. The essence of the J&J-insurer contracts is to pay the
insurers to exclude biosimilar alternatives from their prescription
drug or medical benefits coverage, whereby the insurers either deny
coverage altogether or restrict coverage to only the rarest of
circumstances. The insurers, as the payers for the treatment, have the
ability to exclude selected drugs from coverage and as a result,
patients and providers do not have a practical ability to choose
Inflectra or other infliximab biosimilars over Remicade where coverage
is not available. Moreover, because insurers wield power over providers
with the ability to grant or withhold coverage for treatment, and
because providers are risk-averse when it comes to buying and stocking
medications such as infliximab, the providers are effectively compelled
to stock Remicade exclusively.
127. The intent and effect of the insurers' performance of these
contracts is to cause providers to forgo alternatives and to drive all
treatment sales to J&J. The result of the J&J insurer contracts thus is
the amplification of foreclosure, such that Inflectra and other
biosimilars are denied access to approximately 90 percent of provider
accounts and foreclosed from competition in the Relevant Markets.
128. Because providers and insurers are the gateway for the
distribution and sale of the Relevant Products, there are no viable
alternative means of distribution or sale and substantial foreclosure
exists. Biosimilar competitors to J&J have no practical alternative
means of selling infliximab to patients.
129. These de facto exclusive arrangements are in effect durable
long-term agreements because the incentives J&J has exploited are not
likely to change. So long as J&J's contracts remain in place,
biosimilars will not be able to dent J&J's base of existing patients,
and the incentives underlying J&J's contracts will remain. No insurer
can practically walk away from and not continue to perform under the
J&J agreement due to the above-discussed penalties.
130. The effect of each such agreement is and has been to
substantially lessen competition in the Relevant Markets. The aggregate
impact of such agreements is and has been to substantially lessen
competition or tend to create a monopoly in the Relevant Markets.
131. By imposing such conditional contracts, J&J is directly and
proximately foreclosing Pfizer and other competitors from a substantial
portion of the Relevant Markets.
132. J&J's conduct has had anticompetitive effects in the Relevant
Markets, including, without limitation, the effects described above in
Paragraphs 102 through 106.
133. As a result of J&J's conduct, and the harm to competition
caused by that conduct, Pfizer has suffered substantial and continuing
injuries.
FOURTH CLAIM FOR RELIEF
Violation of 15 U.S.C. Sec. 1
Agreements in Restraint of Trade in All Relevant Markets
134. Pfizer repeats and realleges Paragraphs 1 through 133 as set
forth herein.
135. J&J has entered into agreements with insurers and providers of
Remicade with the purpose and effect of unreasonably restraining trade
and commerce in the Relevant Markets.
136. J&J's solicitation and enforcement of the exclusionary
contracts described above constitute unlawful agreements, contracts,
and concerted activity that unreasonably restrain trade in the Relevant
Markets in violation of Section 1 of the Sherman Act.
137. J&J's conduct has had anticompetitive effects in the Relevant
Markets, including, without limitation, the effects described above in
Paragraphs 102 through 106.
138. Among other things, given that (a) J&J imposed explicit
conditions that insurers and providers eliminate (or almost completely
curtail) their dealings with infliximab biosimilars, and (b) J&J's ASP
for Remicade has actually increased since the biosimilar entered, J&J's
pricing is not the clearly predominant means by which competition has
been foreclosed in the Relevant Markets.
139. Even if price were deemed to be the clearly predominant means
by which competition has been foreclosed, when the total amount of
discounts and rebates that J&J offers to insurers and providers under
the contracts described herein, including multi-product bundle
contracts, is attributed to the portion of Remicade sales that is
contestable by a biosimilar like Inflectra, J&J is pricing Remicade
below its own average variable cost.
140. As a result of J&J's conduct, and the harm to competition
caused by that conduct, Pfizer has suffered substantial and continuing
injuries.
PRAYER FOR RELIEF
141. WHEREFORE, Pfizer respectfully prays that the Court enter
judgment against J&J and in favor of Pfizer, as follows:
a. Awarding Pfizer money damages, trebled pursuant to
law, in an amount in excess of $150,000.00 (exclusive of
interest and costs);
b. Awarding Pfizer the costs of the lawsuit, including
its reasonable attorneys' fees and court costs;
c. Declaring J&J's conduct unlawful and in violation of
the above-
referenced statutes;
d. Entering appropriate preliminary and permanent
injunctive relief barring J&J from continuing to undertake its
anticompetitive scheme, including its exclusionary contracts;
and
e. Ordering such other and further relief as the Court
may deem just, proper, and equitable.
JURY TRIAL DEMANDED
142. Pfizer demands a trial by jury for all issues triable by
jury.
Dated: September 20, 2017 . Respectfully submitted,
Philadelphia, PA
Robert Fiebach, Esq. (PA 02812)
Peter M. Ryan, Esq. (PA 81816)
Cozen O' Connor
One Liberty Place
1650 Market Street, Suite 2800
Philadelphia, PA 19103
Tel: +1 215 665 4166
Fax: +1 215 665 2013
[email protected]
[email protected]
Robert A. Milne, Esq. (Pro Hac Vice
forthcoming)
Michael J. Gallagher, Esq. (Pro Hac
Vice forthcoming)
Bryan D. Gant, Esq. (Pro Hac Vice
forthcoming)
White & Case LLP
1221 Avenue of the Americas
New York, NY 10025-1095
Tel: (212) 819-8200
Fax: (212) 354-8113
[email protected]
[email protected]
[email protected]
Elliott E. Dionisio, Esq. (Pro Hac
Vice forthcoming)
White & Case LLP
555 S. Flower Street, Suite 2700
Los Angeles, CA 90071 2433
Tel: (213) 620-7700
Fax: (213) 452-2329
[email protected]
Counsel for Pfizer Inc.
______
Prepared Statement of Olivier Brandicourt, M.D.,
Chief Executive Officer, Sanofi
Chairman Grassley, Ranking Member Wyden, and members of the
committee, thank you for the opportunity to appear before the Senate
Committee on Finance to discuss pharmaceutical pricing, affordability,
and patient access in the United States. I am Dr. Olivier Brandicourt,
the chief executive officer of Sanofi.
At Sanofi, we work passionately every day to understand and address
the health care needs of patients around the world. We are dedicated to
solving patients' most serious health challenges in numerous
therapeutic areas, including diabetes, cardiovascular disease,
immunology, oncology, multiple sclerosis (MS), rare diseases, and rare
blood disorders. We are also devoted to preventing diseases through the
research, development, and delivery of vaccines. And we contribute to
improving the health of people around the world through our broad
portfolio of consumer health products.
Sanofi's U.S. subsidiaries have a rich history in the United States
dating back over 100 years. We currently employ more than 13,000
professionals across the United States in a broad range of critical
roles, including business operations, research and development, and
manufacturing, with our most significant presence in Massachusetts,
where we are the largest employer in the life sciences industry, and
major centers of operation in New Jersey, Pennsylvania, and Tennessee.
Last year, Sanofi spent almost $7 billion on research and
development, an increase of approximately 7 percent from 2017, which
reflects our commitment to bringing better therapies to patients.
Sanofi plans to maintain this level of R&D investment through 2021, and
our R&D pipeline now contains 81 projects, including 33 new molecular
entities in clinical development, and 35 projects that are in Phase III
or have been submitted to regulatory authorities. This investment means
that Sanofi potentially will seek approval for nine new medications in
the next three years, primarily in therapeutic areas where Sanofi sees
the greatest nexus between our expertise and patient need: diabetes,
vaccines, oncology, immunology, rare diseases, and rare blood
disorders.
Our work in R&D includes more than a dozen compounds for the
treatment of various kinds of cancers, and we are employing cutting-
edge approaches in an effort to make significant advances for patients.
Our research includes potential treatments to help the body's own
immune system fight cancer, and antibody drug conjugates that we
believe can deliver cytotoxic drugs to tumors while sparing normal
tissue. Earlier this month, we announced successful results with one
such candidate in a mid-stage trial in lung cancer, and we intend to
initiate a pivotal study later this year.
i. rising costs for patients
While the research and development landscape has fundamentally
changed, the landscape in which patients access medications has also
fundamentally changed, and not for the better. Affordability of
medicines is a real and growing challenge for too many Americans. We
understand the anger of patients who cannot afford the medicines they
or their loved ones need due to rising out-of-pocket drug costs.
There is no single root cause to the problem of rising patient out-
of-pocket costs, and in order to develop meaningful solutions for
patients, it is critical to take a comprehensive look at what is
driving rising costs for patients. Given the number of factors that
contribute to determining out-of-pocket costs for patients, every part
of the supply chain, including manufacturers, has a role to play in
solving this problem.
We want everyone--including patients, providers, payers, pharmacy
benefit managers (PBMs), policy makers, and regulators--to understand
why we set prices as we do, and to reaffirm our commitment to our core
principles of access, affordability and innovation. An important
component of pricing includes the intersection between the list prices
of our medicines, the net prices we actually receive after accounting
for all rebates and other discounts, and out-of-pocket costs.
While list prices often receive the most attention, they reflect
the initial price we set for our medicines. They are not the amount
Sanofi receives nor the prices typically paid by government and
commercial insurers, employers, or PBMs. Under the current system,
players within the supply chain--including PBMs, plans, wholesalers,
distributors, and group purchasing organizations--receive either
rebates and/or fees based on a percentage of the list price. Their
economic incentives are therefore directly linked to the list price.
And as long as the net price grows at a predictable rate, the greater
the list price, the greater the economic returns for many players in
the supply chain. Manufacturers, in turn, must account for anticipated
rebates and other discounts when setting their list price.
Thus, list price is the starting point for negotiations with
payers, and it is often the basis for patient out-of-pocket costs. But
focusing solely on the list price does not tell the whole story. In the
current system, manufacturers pay significant rebates as a percentage
of the list price to both government and private payers, as well as
other intermediaries, in an effort to improve access for patients. In
2018, 55 percent of Sanofi's gross sales were given back to payers as
rebates, including $4.5 billion in mandatory rebates to government
payers and $7.3 billion in discretionary rebates. As described later in
my testimony, due to these rebates, the average aggregate net price of
our products, including our insulin products, actually has declined
over the last number of years.
Sanofi provides rebates to PBMs and health plans to improve patient
access to, and affordability for, Sanofi medicines. We want these
rebates, which lower net prices, to benefit patients. Unfortunately,
under the current system, savings from rebates are not consistently
passed through to patients in the form of lower deductibles, co-
payments or coinsurance amounts.
For some patients, out-of-pocket costs are calculated based on a
medicine's list price. However, based on variability in plan design,
the list price alone does not explain patients' increasing
affordability issues.
Sanofi and Sanofi Genzyme U.S. Gross to Net 2018 Breakdown *
[GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT]
------------------------------------------------------------------------
-------------------------------------------------------------------------
* Below are the summarized categories (by type) for various
transactions:
Mandatory Rebates: Medicaid, VA-DOD, Tricare, 340B, Medicare Coverage
Gap
Discretionary Rebates: Commercial, Medicare, Managed Medicaid, Medicaid
Supplemental, GPO, Institutional Discounts
Government Purchasing Organization (GPO) Fees & Coupons: Fees paid for
administration of Sanofi's agreements with Group Purchasing
Organizations on behalf of their members and various copay assistance
programs
DPA Fees: Performance based fees earned by wholesalers for providing
complete sales information and maintaining targeting inventory rates
Cash Discounts: Trade discounts offered to wholesalers for prompt
payment of invoices
Sales Returns: Netted with Clawback, Other Corrections/Credit Memos
------------------------------------------------------------------------
For instance, in some cases, affordability issues are the result of
changes in health plan designs, such as the increase in the number of
high deductible health plans. Among those with private health
insurance, enrollment in high deductible health plans (HDHPs) has
generally increased since 2010. The design of these plans generally
requires patients to pay the full list price of medicines during the
deductible phase of the program, rather than the negotiated drug price
available when the insurance portion kicks in.
[GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT]
In other cases, affordability issues are caused by changes in
insurance design which increasingly ask patients to pay higher cost-
sharing for their medicines, even when the price of those medicines has
stayed relatively flat or has declined for the health plan. For
example, as noted later in my testimony, the average net price of
Lantus, our most prescribed insulin, has declined by over 30 percent
since 2012, while the average out-of-pocket burden for patients with
commercial insurance and Medicare has increased by approximately 60
percent over that same period. In this case, not only are discounts
apparently not being passed on to patients, but patients are in fact
being asked to pay more when PBMs and health plans are paying less for
the medicine. This situation defies logic and should not happen.
Increasing out-of-pocket costs also can result from changes to
prescription drug formularies, which have a significant impact on the
amount of out-of-pocket costs a patient will be asked to pay. A recent
opinion piece in The New York Times \1\ powerfully highlights how
changes to prescription drug formularies not only can create confusion
and frustration for providers and patients, but also ultimately
increase costs for patients when the medicines they need are not
covered on a formulary's preferred tier.
---------------------------------------------------------------------------
\1\ See https://www.nytimes.com/2019/01/18/opinion/cost-insurance-
diabetes-insulin.html.
The impact of the role each of these factors plays in out-of-pocket
costs for any individual patient is highly variable, thus compounding
the complexity of this issue. Out-of-pocket costs for a medicine for
any particular patient depend on a number of factors in addition to
list price, including: (1) what portion, if any, of a manufacturer's
rebates a PBM or payer passes through to the patient, (2) the benefit
design of the patient's health plan, and (3) the level of reimbursement
negotiated between the patient's plan and the particular pharmacy. Each
of these factors varies significantly among plans and pharmacies--even
within the same health insurance company or PBM receiving the same
---------------------------------------------------------------------------
manufacturer rebate--creating confusion and frustration for patients.
Given the complexity in the system and number of factors that
impact out-of-
pocket costs, every part of the health-care system has an obligation to
work to solve this problem. I am grateful that this Committee--and
others--are taking a holistic approach to collecting information both
on what is causing the problem for patients, and also on solutions to
address patient access and affordability without undermining the
incentives and rewards for scientific risk-taking and discovery that
are the hallmark of the United States ecosystem and economy.
I am here today to share Sanofi's story, the actions we have taken
to improve patient access and affordability, and our ideas about what
more can be done.
ii. sanofi actions to improve patient access and affordability
As a global health-care leader, Sanofi has a long-standing
commitment to promoting health-care systems and policies that make our
treatments accessible and affordable to patients in need. We believe we
can play an important role in the development of constructive solutions
that will benefit both patients and the health-care system as a whole.
I will address some of our ongoing initiatives and recommendations for
solutions in my testimony.
Sanofi's ultimate goal, detailed below, is to encourage a
transition to a value-
driven health-care system that provides incentives for continued
improvements in patient care while increasing access and affordability.
Given the complexities of the current system, changes must be
approached thoughtfully, with a focus on establishing processes that
will both enable affordable access to treatment and protect innovation
in an era of potentially transformative scientific advancements.
Sanofi is--and will continue to be--an industry leader in helping
to address this challenge. While many factors, including decisions
affecting patient out-of-pocket spending and insurance coverage, are
influenced or controlled by others in the health-care system, including
other manufacturers, we recognize that there are actions we can take to
help improve access and affordability for patients. For our part, we
recognize that we must price our medicines transparently and according
to their value, while at the same time contributing to broader
solutions that improve patient outcomes and the financial
sustainability of the U.S. health-care system.
Policy changes are required across the entire health care system.
But we are not waiting for systemic change to arrive before taking
action. Sanofi has adopted a variety of approaches to work within the
current system to improve access and affordability for patients.
Whether it has been launching new medicines in multiple sclerosis and
rheumatoid arthritis at disruptively low prices, limiting price
increases to an external benchmark of overall medical spending, or
lowering the net price of a medicine, Sanofi has approached the
challenge of access and affordability not with words, but with actions.
iii. sanofi pricing principles and actions
Two years ago, Sanofi announced our progressive and industry-
leading pricing principles to help stakeholders understand our pricing
decisions and to advance a more informed discussion of issues related
to the pricing of medicines.\2\
---------------------------------------------------------------------------
\2\ See https://www.sanofi.us/-/media/Project/One-Sanofi-Web/
Websites/North-America/Sanofi-US/Home/corporateresponsibility/
Prescription_Medicine_Pricing_2019.pdf.
These principles include a pledge to keep annual list price
increases at or below the projected U.S. National Health Expenditure
(NHE) growth rate, an estimate of medical spending calculated by the
Centers for Medicare and Medicaid Services (CMS) and often used as a
measure of healthcare inflation. These principles apply to all of our
prescription medicines if a pricing decision results in more than a $15
annual increase in the price of the medication. In addition, we
committed to making both our average aggregate list and net price
changes across our portfolio transparent to help illustrate how revenue
accrues to Sanofi versus other parts of the pharmaceutical supply
---------------------------------------------------------------------------
chain.
In 2018, all of our price increases were consistent with our
policy, as are all pricing actions we have taken in 2019. Across our
entire portfolio of medicines, the average aggregate list price
increase was 4.6 percent while the average aggregate net price--that
is, the actual price paid to Sanofi--declined by 8.0 percent.
The declining average aggregate net price in 2018 represents the
third consecutive year the amount that health plans and PBMs pay Sanofi
for our medicines has declined.
U.S. Portfolio Annual Average Aggregate Price Changes *
------------------------------------------------------------------------
Average Aggregate List Average Aggregate Net
Year Price Price
------------------------------------------------------------------------
2016 4.0% Increase 2.1% Decrease
------------------------------------------------------------------------
2017 1.6% Increase 8.4% Decrease
------------------------------------------------------------------------
2018 4.6% Increase 8.0% Decrease
------------------------------------------------------------------------
* Average aggregate across Sanofi's prescription product portfolio.
Specific to insulin, the average aggregate net price across all
Sanofi insulin products has declined over the past four years. For our
entire insulin portfolio, the average net price is 25 percent lower
today than it was in 2012.\3\
---------------------------------------------------------------------------
\3\ Based on internal review of pricing actions and payer
contracting.
[GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT]
In addition to our pledge to limit price increases in the U.S.,
Sanofi's pricing policy includes a commitment to transparency in how we
price new medicines coming to the market for the first time. When we
set the price of a new medicine, we hold ourselves to a rigorous and
structured process that includes consultation with external
---------------------------------------------------------------------------
stakeholders and considers four factors:
(1) A holistic assessment of value, including (a) clinical
value and outcomes, or the benefit the medicine delivers to
patients, and how well it works compared to a standard of care;
(b) economic value, or how the medicine reduces the need--and
therefore costs--of other health care interventions; and (c)
social value, or how the medicine contributes to quality of
life and productivity. Our assessments rely on a range of
internal and external methodologies, including health
technology assessment (HTA) approaches and other analyses that
help define or quantify value and include patient perspectives
and priorities.
(2) Similar treatment options available or anticipated at the
time of launch in order to understand the competitive landscape
within the disease areas in which the medicine may be used.
(3) Affordability, including the steps we must take to promote
access for patients and contribute to a more sustainable system
for payers and health-care delivery systems.
(4) Unique factors specific to the medicine at the time of
launch. For example, we may need to support ongoing clinical
trials to provide additional critical information on the value
of the product (e.g., longer-term outcomes studies), implement
important regulatory commitments, or develop sophisticated
patient support tools that improve care management and help
decrease the total cost of care.
Using this approach, Sanofi has launched a number of highly
innovative products at prices well below the competition, some even
before our principles were officially adopted.
In 2012, Sanofi launched Aubagio ', a medicine
used to treat relapsing forms of MS, at a list price more than
25 percent below the other approved oral MS medication on the
market at the time.
In 2017, we launched Kevzara ', a second line
medication used to treat certain types of rheumatoid arthritis
(RA), at a list price 30 percent below other leading treatments
for RA. After completing a head to head study against the
market-leading anti-TNF, Kevzara was found superior in RA
patients.
In 2017, we launched Dupixent ', the first drug
of its kind for moderate to severe atopic dermatitis,
specifically within the cost-effectiveness range provided by
the Institute for Clinical and Economic Review (ICER) of
$37,000, compelling the Chief Medical Officer for a leading PBM
to say ``this is how pricing should work.'' While we have
concerns about ICER's methodology in many of their drug
reviews, our willingness to work with ICER is further
demonstration to our commitment to price our medicines based on
the value they provide with consideration of input from a
third-party analysis.
In 2018, we launched Admelog ' at the lowest list
price of any mealtime insulin.
In February 2019, Sanofi and Regeneron announced that
Praluent ' will be made available at a new reduced
U.S. list price. Beginning in early March, new U.S. National
Drug Code (NDC) option will be available at approximately 60
percent less than the original list price for the drug. This
action follows our earlier announcement in March 2018, when
Sanofi and Regeneron committed to lowering the U.S. net price
for payers in return for reducing burdensome access barriers
for appropriate patients.\4\ Sanofi and Regeneron took the
additional step of announcing a new NDC to further assist
patients, particularly in Part D, who still face cost-sharing
linked to the list price, and who were thus not helped by the
earlier net price reduction. With the new lower-priced
Praluent, most Medicare Part D patients are expected to save as
much as $345 per month, depending on their insurance plan.
---------------------------------------------------------------------------
\4\ See http://www.news.sanofi.us/2018-03-10-Sanofi-and-Regeneron-
announce-plans-to-make-Praluent-R-more-accessible-and-affordable-for-
patients-with-the-greatest-health-risk-and-unmet-need.
With the right incentives in the system, our approach to setting
launch prices for these new medicines would have had the effect of
ensuring affordable access for patients. Unfortunately, because of the
way the U.S. health care system is currently constructed, our
experience has shown that pricing medicines at lower list prices has
failed to result in adequate access or affordability for most patients.
For instance, since Dupixent was launched, rebates have been required
in most cases to secure access for patients. Despite the responsible
list price and subsequent rebates, 8 commercial and 2 Medicaid plans
nevertheless implemented a step edit requiring patients to try
immunosuppressant therapy first before using Dupixent. They implemented
this step edit notwithstanding the fact that immunosuppressant therapy
is not FDA approved for use in atopic dermatitis and is referenced as a
worst-case scenario for patients in practice guidelines due to its
questionable benefit-risk profile.
iv. sanofi's insulin products: a case study
We feel a special obligation to address the pressing issues around
access and affordability of insulin products. In my time as CEO, Sanofi
has made a concerted effort to improve both system sustainability and
patient affordability in our approach to our portfolio of insulin
products, which includes six different products to meet individualized
patient needs. And it is important to note the evolution and innovation
of insulin, as we are often asked if anything has changed in the last
100 years that warrants pricing action.
Sanofi's groundbreaking discovery of insulin glargine, and its
development of a novel pre-filled disposable injection pen to deliver
insulin glargine, have profoundly improved the lives of millions of
patients living with diabetes in the United States and worldwide.
Sanofi's insulin glargine drug products are sold under the trade names
Lantus ', Lantus SoloSTAR ', Toujeo SoloSTAR
', and Toujeo Max SoloSTAR ', each of which
represents a significant leap forward in the treatment of diabetes.
Sanofi has been awarded patents for its innovative technologies on each
of these products.
These novel drug products began with Sanofi's discovery of insulin
glargine. Despite having ``insulin'' in its name, Sanofi's insulin
glargine is markedly different from prior insulin products, which had a
relatively short duration of action and required patients to inject
themselves multiple times a day and wake up at night for injections in
order to control blood glucose levels. Each injection of prior insulin
products caused a sharp spike in the patient's insulin levels, which
could cause symptoms of low blood sugar ranging from shakiness and
confusion to, in the extreme, coma or death. Injections also had to be
timed before every meal, disrupting patient's lives, sleep times, and
ability to eat with friends and family. As such, the consistent goals
of insulin therapy over the last century have included reducing the
frequency of insulin administration and flattening the post-
administration peak of insulin in the bloodstream. Prior attempts to
achieve these goals included cumbersome mechanical pumps that had to be
worn on the body for constant infusion, and NPH insulin, which had an
intermediate duration of action but still caused a pronounced peak in
insulin levels.
Glargine changed all of that. Sanofi scientists, in a remarkable
feat of protein engineering, succeeded in fundamentally altering the
human insulin molecule at the amino acid level, changing its
pharmacological characteristics to give patients a steady release of
insulin with just a single daily administration. Unlike anything that
came before it, glargine forms tiny solid crystals upon injection that
dissipate over time to provide a flatter, stable, long-lasting effect
that mimics the flat profile of insulin release from a healthy pancreas
and reduces the risks caused by low blood sugar. The once-daily
administration of glargine also proved a significant boon to patient
lifestyles.
Insulin is also an excellent example of list prices not reflecting
the actual prices paid by insurance companies, and out-of-pocket costs
that continue to rise despite lower net prices. The net price of our
insulin product Lantus ', for example, has fallen over 30
percent since 2012; yet, over this same period, average out-of-pocket
costs for patients with commercial insurance and Medicare--before the
benefit of any Sanofi financial assistance program--has risen 60
percent.
v. sanofi's financial assistance programs
Our commitment to affordability for patients extends beyond
responsible launch pricing, limited price increases, and transparency.
We offer a suite of traditional and innovative patient assistance
programs to enable appropriate patient access and to help patients
afford the Sanofi medicines prescribed to them. We publicize our
programs in a number of ways to ensure patients and providers are aware
of our offerings, including through advertising online, on television,
as well as in provider office settings and at pharmacies.
As noted previously in my testimony, rising out-of-pocket costs for
patients is a complex problem with many causes. In some cases, access
issues are linked to lack of insurance. But having insurance is no
longer a guarantee of affordable care, and Sanofi believes it is also
critical to address the needs of patients who may be exposed to
excessive cost-sharing based on insurance plan design or other
deficiencies in the system.
Because patient situations are different, we have carefully
tailored our assistance programs for insulin products to meet a variety
of patient needs:
Commercially insured patients qualify for our co-pay
assistance program, which reduces the financial burden for
insulin products. Through this program, over 90 percent of
participating commercially insured patients pay either $10 or
$0 per month for their Sanofi-manufactured insulin products.
Last year, our co-pay assistance programs for commercially
insured patients provided more than 400,000 eligible patients
with $342 million in patient savings.
For diabetes patients who do not qualify for one of our co-
pay assistance programs, we created the Insulins ValYOU Savings
Program in 2018. The purpose of this program is to provide
relief for those patients who currently pay high variable
retail prices for insulin and do not qualify for other
assistance programs. Through this program, eligible individuals
can access all Sanofi insulins for $99 per 10 mL vial or $149
for a pack of SoloStar pens, approximately a one-month supply
of insulin,\5\ at a discount of up to 60 percent discount below
the list price, resulting in potential savings of up to $3,000
per year. There are no income requirements and the program is
available at U.S. pharmacies. Last year (its first year), the
program resulted in $6.2 million in patient savings.
---------------------------------------------------------------------------
\5\ Patients with type 1 diabetes require insulin replacement with
both long-acting (basal) and mealtime (bolus) insulin. An average adult
with type 1 diabetes who weighs 70 kg (155 pounds) should be taking
anywhere from 0.5-1.0 u/kg/day--depending upon activity levels, and
meal choices. Using the higher daily dose of 1.0 u/kg/day, this patient
would need a total of 70 units/day of insulin, of which approximately
half should be mealtime (bolus) insulin and half should be long-acting
(basal) insulin. For this average patient, one vial of long-acting
(basal) and one vial of mealtime (bolus) insulin could provide a
monthly supple of insulin.
Many patients with type 2 diabetes require long-acting (basal)
insulin only. Our internal data shows the average daily dose is
approximately 45 units per day, resulting in a monthly requirement of
1350 units of long-acting (basal) insulin per month. Lantus SoloSTAR
' pack contains 1500 units of insulin (5 pens x 300 units
per pen) and Toujeo SoloSTAR ' pack contains 1350 units of
insulin (3 pens x 450 units per pen). For the average patient with type
2 diabetes, the ValYOU Savings Program would meet the monthly insulin
requirement with one payment of $149. Patients on lower doses of Lantus
may opt for the 10ml vial, which would meet the monthly insulin
requirement with one payment of $99.
For eligible low-income patients, Sanofi offers many of our
medicines, including our insulin products, at no charge through
its Sanofi Patient Connection patient assistance program. We
are proud that, in 2018, more than 93,000 patients participated
in the Sanofi Patient Connection program, receiving free
---------------------------------------------------------------------------
medicine valued at $508 million.
While Sanofi alone cannot eliminate the issue of patient
affordability, no matter how comprehensive or innovative our patient
assistance programs, we believe that our efforts can make a meaningful
difference for many patients. We are committed to maintaining these
programs and raising awareness of these options to the patients who
need them.
vi. policy proposals
Over the past few years, we have led by example and made decisions
to help improve access and affordability for patients. I am here today
to tell you that I know our actions, while well-intentioned, have not
been enough. I hope we can all agree on market-based policy solutions
that will incentivize a high-value, sustainable health-care system that
improves the affordability of innovative medicines in the U.S.
Based on our experience, targeting list price controls alone will
not be sufficient to address patient access and affordability. That is
why the solution to drug pricing must include protections for patients,
tying responsible pricing to both access and affordability for
patients.
There are obviously a variety of ways to accomplish this, and
Sanofi could support any number of options that align to our core
principles:
(1) The U.S. should continue to maintain a strong ecosystem
for innovation. As such, any policy proposals should strictly
avoid directly and artificially controlling the price of
medicines, either through price controls set by the Federal
Government, or worse, outsourcing that decision to foreign
governments. Policy proposals that we believe would
fundamentally undermine the unique innovation ecosystem of the
United States include reference pricing, importation, or price
controls set by CMS. Based on our experience, these approaches
may be effective at controlling budgets for central payers but
come at a steep cost for patients--namely limiting access to
innovative treatments. Additionally, given that the U.S. is the
world's leader in science and innovation--and the jobs that
come with it--these approaches pose additional risks to the
U.S. economy and future scientific discovery. Finally, and most
importantly, given the differences between systems, these
approaches may do little to improve access and affordability
for patients.
As we have experienced, within the current system,
declining prices for payers or new treatments priced at
responsibly lower list prices are no guarantee that those
actions will translate to affordability or access for patients.
(2) Changes to the pricing system must be holistic, and the
majority of benefits should accrue to patients. As noted
previously, simply enacting price controls--either set by a
State, Federal, or foreign government--will not solve the
problem of access and affordability for patients. We believe
system incentives need to change to encourage smaller list
price increases, or even list price reductions, by requiring
health plans to cover those medicines that meet these standards
at an affordable co-pay level and only allow access
restrictions consistent with the label and accepted evidence-
based best clinical practice.
If policies are enacted that solely target the list price
of medicines without these common-sense patient protections,
our shared goal of lowering drug costs--for both government and
patients while maintaining the engine of innovation in the
United States to bring new innovative medicines to patients
will not be fully achieved. To appropriately accomplish this
objective, Sanofi is willing to trade price for access and
affordability and share accountability for offsetting the
financial impact on the Medicare programs.
Sanofi supports and recommends several policy solutions to
incentivize responsible pricing behavior. To ensure that these
changes do not create a windfall for manufacturers or health
plans and PBMs, Sanofi recommends applying these policies only
to medicines that satisfy certain limits on price increases.
This approach will shift the current incentives in the system
to reward ``good'' behavior in a manner that truly helps
patients. Several of the solutions outlined below are also
priorities for Chairman Grassley, Ranking Member Wyden and
other members of this committee and I look forward to the
opportunity to work with you on advancing these and other
policy initiatives:
First, reducing out-of-pocket costs for patients is our top
priority. As we have experienced, limiting list price of
medicines alone is not sufficient to fully solve this problem.
Sanofi has identified a number of ways to effectively reduce
out-of-pocket costs for consumers and broadly supports
tradeoffs between price and access to help patients, including:
Implementation of the Anti-Kickback Safe Harbor rebate
proposed rule in a manner that directly lowers out-of-pocket
costs for patients without creating loopholes that would
undermine the proposed rule's intent.
Requiring a portion of the discounts and rebates paid by
manufacturers to reduce costs for patients at the pharmacy
counter.
Changing government price reporting rules and the Anti-
Kickback statute in a manner that would promote value-based
contracting.
Implementing an annual out-of-pocket cap for Medicare
beneficiaries.
Allowing manufacturers to offer co-pay assistance to
Medicare beneficiaries.
Changing or clarifying government price reporting rules
to make it easier to reduce list prices on medicines that have
been on the market for a long time--namely by (1) making clear
that the government pricing metrics for the new, lower list
price drug do not have to be averaged with the metrics for
older, higher list price drug and (2) permitting a company to
treat the new lower price drug as a new product for purposes of
Medicaid rebate calculations, which will help to link the
rebate liability for the new drug to the new drug's lower price
as opposed to the higher price for the old drug.
Second, Sanofi supports policies that cultivate a highly
competitive free market system and rewards the type of
entrepreneurial risk-taking necessary to the discovery and
development of life-saving new medicines. A key element of that
system is a strong and predictable intellectual property
system. However, after a reasonable period of time--which I
believe is already reflected in U.S. law--generic and
biosimilar medicines should quickly enter the market to offer
long-term access at lower costs. To help accomplish these
goals, Sanofi supports:
Legislation that promotes competition, such as the
CREATES Act, and prohibitions on ``reverse payment''
agreements. While some changes may be needed to avoid
unintended consequences, we support moving forward with
policies that limit manufacturers' ability to unfairly avoid
competition. At Sanofi, we make product supply available to
generic and biosimilar manufacturers developing data necessary
for FDA applications for their products. We do this in a timely
manner and on reasonable terms.
Increased system-wide transparency, which would improve
competition across health care by making relevant information
available to patients and policymakers. Providing more
information about what is driving costs in the system and how
money is flowing through the system will allow for increased
competition and better-informed decision making. Policies like
the SPIKE Act, which appropriately include a threshold for
reporting to incentivize responsible pricing behavior and the
C-THRU Act, are potential approaches.
vii. conclusion
I look forward to having a productive conversation about the
complexities of the current prescription drug pricing system and
proposals to improve affordable patient access to high quality,
innovative medications to drive optimal health outcomes.
Thank you for the invitation to speak with you today and I look
forward to working with you.
______
Questions Submitted for the Record to Olivier Brandicourt, M.D.
Questions Submitted by Hon. Chuck Grassley
Question. The Department of Health and Human Services' proposed
rule, ``Fraud and Abuse; Removal of Safe Harbor Protection for Rebates
Involving Prescription Pharmaceuticals and Creation of New Safe Harbor
Protection for Certain Point-of-Sale Reductions in Price on
Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager
Service Fees,'' envisions that drug manufacturers will offer up-front
discounts rather than the back-end rebates that are now commonly
provided. Some observers argue that a 1996 court case called into
question whether manufacturers could offer up-front discounts,
resulting in today's rebate-based system. I've heard differing opinions
as to whether the issues related to the initial court case are still
relevant. If the HHS proposed rule is finalized, can you assure the
committee that your company will offer up-front discounts? If not, why?
Answer. As the question notes, one of the practical implications of
the Proposed Rule is to incentivize a shift from back-end rebate
payments to up-front discounts that are passed through at the point-of-
service to the patient (at least in part). We understand that some in
the health care industry have raised concerns that the nation's
antitrust laws, specifically the Robinson-Patman Act, and long-running
antitrust litigation involving drug manufacturers, wholesalers, and
pharmacies could prevent or reduce discounting under a pricing
structure without rebates. But, the Robinson-Patman Act focuses on
price discrimination--involving any dimension of price--and it does not
distinguish between up-front discounts and rebates. In addition, the
referenced litigation, In re Brand Name Prescription Drugs Antitrust
Litigation, did not result in any change in the ability of a
prescription drug manufacturer to offer an up-front discount.
Consequently, because Sanofi's view is that the antitrust laws apply
equally to up-front discounts and back-end rebates, we do not believe
that they present any impediment to offering up-front discounts to
patients at the point of sale. Sanofi is committed to working with
other stakeholders to lower patient out-of-pocket costs, and the
company will carefully review any final rule issued by HHS regarding
the Anti-Kickback Statute and its safe harbor regulations--with the
goal of providing point-of-sale discounts to patients in a compliant
manner to help lower patient out-of-pocket costs.
Question. Please describe how you expect your company to respond to
the HHS proposed rule to eliminate safe harbor protection for back-end
rebates in Medicare Part D that is referenced above if it is finalized.
Assuming you are confident that antitrust laws do not prevent your
company from offering up-front discounts, specifically, do you envision
that your company lowers the list price of a drug to the current after-
rebate net price, offer discounts equal to the current rebate amount,
or a combination of both?
Answer. Sanofi is committed to working with other stakeholders to
lower patient out-of-pocket costs, and the company will carefully
review any final rule issued by HHS regarding the Anti-Kickback Statute
and its safe harbor regulations--with the goal of providing point-of-
sale discounts to patients in a compliant manner to help lower patient
out-of-pocket costs.
With respect to list price, if (1) the proposed changes to the
anti-kickback statute safe harbors were codified, and (2) Congress
implemented similar changes to the commercial insurance market, Sanofi
would lower the list prices of its prescription medications for
products in competitive categories for which there is currently a
material difference between list price and net price on the assumption
that patient access and affordability would be improved. Sanofi also
supports policy changes that would de-link other payments in the
pharmaceutical supply chain from list price.
We support extending the intent behind the anti-kickback statute
safe harbor proposed rule to the commercial market so that incentives
are aligned across the marketplace. Together, we believe these changes
would facilitate Sanofi's ability to lower our list prices. However, we
recommend a step-wise approach, implementing changes to the commercial
market after the safe harbor rule is implemented on January 1, 2020.
Such an approach would provide an opportunity for stakeholders and the
government to identify unintended consequences, and address them, prior
to extending these policies to the commercial market.
We want to ensure that the new system achieves its goal of
improving affordability for patients. For instance, CMS should monitor
and evaluate how the new system affects formulary access, utilization
management, and patient cost-sharing, particularly with respect to
medicines with a lower list price. We also have concerns that changes
to the rebate system may lead to new fees, which simply require
manufacturers to pay previous rebate values in new ways, rather than
creating savings for patients.
Without a better understanding of how these policy changes
ultimately would affect the competitive marketplace, patient access,
and affordability, we are unable to quantify the amount of up-front
discounts or any potential list price reduction.
Question. To what extent are the back-end rebates your company
currently offers contingent on the amount of market share realized for
your drugs as a result of Part D plan formulary placement and other
techniques?
Answer. Sanofi negotiates rebates with PBMs and Part D plans to
secure better formulary position for our products, which in turn
provides the best possible access and cost sharing for the majority of
Medicare Part D beneficiaries. When evaluating what level of rebates to
offer, Sanofi considers the potential business impact of such
arrangements.
Question. Please provide a breakdown of percentage of sales that go
to each payer (including Medicare, Medicaid, private pay, other) and a
similar percentage by volume of the total number of each drug compared
to total volume. Please provide this data for the most recent year
available.
Primary Care Products
Percentage of Sales by Payer Channel \1\
----------------------------------------------------------------------------------------------------------------
Channel
----------------------------------------------------------------------------------------------------------------
FSS Others
Product Commercial Medicare Medicaid Tricare 340B \2\ Institutional \3\
----------------------------------------------------------------------------------------------------------------
Lantus 25% 36% 10% 0% 5% 19% 4%
----------------------------------------------------------------------------------------------------------------
Toujeo 47% 39% 7% 0% 4% 2% 0%
----------------------------------------------------------------------------------------------------------------
Soliqua 100/33 77% 15% 3% 0% 3% 1% 0%
----------------------------------------------------------------------------------------------------------------
Apidra 16% 1% 66% 0% 8% 7% 2%
----------------------------------------------------------------------------------------------------------------
Admelog 0% 0% 91% 0% 9% 0% 0%
----------------------------------------------------------------------------------------------------------------
Multaq 24% 57% 2% 0% 3% 12% 2%
----------------------------------------------------------------------------------------------------------------
Praluent 22% 32% 1% 0% 2% 5% 38%
----------------------------------------------------------------------------------------------------------------
\1\ Based on gross sales.
\2\ This category includes the VA, DOD, and other purchases through Sanofi US's Federal Supply Schedule (FSS).
\3\ This category includes Hospital/GPO, Long-Term Care, Outpatient, and Staff Model.
Percentage by Volume by Payer Channel
----------------------------------------------------------------------------------------------------------------
Channel
----------------------------------------------------------------------------------------------------------------
Product Commercial Medicare Medicaid Tricare 340B FSS Others Institutional
----------------------------------------------------------------------------------------------------------------
Lantus 25% 36% 10% 0% 5% 19% 4%
----------------------------------------------------------------------------------------------------------------
Toujeo 47% 39% 7% 0% 4% 2% 0%
----------------------------------------------------------------------------------------------------------------
Soliqua 100/33 77% 15% 3% 0% 3% 1% 0%
----------------------------------------------------------------------------------------------------------------
Apidra 16% 1% 67% 0% 7% 7% 2%
----------------------------------------------------------------------------------------------------------------
Admelog 0% 0% 91% 0% 9% 0% 0%
----------------------------------------------------------------------------------------------------------------
Multaq 24% 57% 2% 0% 3% 12% 2%
----------------------------------------------------------------------------------------------------------------
Praluent 22% 32% 1% 0% 2% 5% 38%
----------------------------------------------------------------------------------------------------------------
Specialty Care Products
Percentage of Sales by Payer Channel \4\
----------------------------------------------------------------------------------------------------------------
Channel
----------------------------------------------------------------------------------------------------------------
Commercial/ Medicaid/VA / Non-Contracted
Product Managed Care Medicare DOD/Tricare PHS/340B Sales
----------------------------------------------------------------------------------------------------------------
Cerdelga 0% 12% 6% 4% 78%
----------------------------------------------------------------------------------------------------------------
Cerezyme 0% 15% 15% 22% 48%
----------------------------------------------------------------------------------------------------------------
Aldurazyme 0% 6% 29% 23% 42%
----------------------------------------------------------------------------------------------------------------
Fabrazyme 0% 13% 10% 26% 51%
----------------------------------------------------------------------------------------------------------------
Myozyme 0% 18% 15% 31% 36%
----------------------------------------------------------------------------------------------------------------
Thyrogen 0% 4% 5% 25% 66%
----------------------------------------------------------------------------------------------------------------
Caprelsa 0% 6% 10% 0% 84%
----------------------------------------------------------------------------------------------------------------
Aubagio 47% 33% 11% 2% 7%
----------------------------------------------------------------------------------------------------------------
Lemtrada 0% 35% 10% 41% 14%
----------------------------------------------------------------------------------------------------------------
Kevzara 69% 15% 4% 3% 9%
----------------------------------------------------------------------------------------------------------------
Dupixent 75% 9% 6% 3% 7%
----------------------------------------------------------------------------------------------------------------
Eloctate 0% 5% 33% 37% 25%
----------------------------------------------------------------------------------------------------------------
Alprolix 0% 5% 27% 39% 29%
----------------------------------------------------------------------------------------------------------------
Jevtana 0% 70% 1% 30% 0%
----------------------------------------------------------------------------------------------------------------
Zaltrap 0% 0% 0% 0% 100%
----------------------------------------------------------------------------------------------------------------
Elitek 0% 15% 1% 7% 77%
----------------------------------------------------------------------------------------------------------------
Mozobil 0% 25% 6% 45% 24%
----------------------------------------------------------------------------------------------------------------
Thymoglobulin 0% 0% 0% 4% 96%
----------------------------------------------------------------------------------------------------------------
\4\ The data used to derive this information is contracted sales data. Because many of these products are
purchased through non-contracted sales, Sanofi has a limited view regarding through which channels these
products are purchased. Percentage by volume by channel results in similar percentages to percentage by sales
so a separate chart is not provided.
Question. Do your companies hire consultants or lobbyists to
promote products at State Medicaid Pharmacy and Therapeutics
Committees? To whom do you disclose advocacy activities surrounding
State Medicaid programs, if at all?
Answer. Sanofi does not hire external consultants or lobbyists to
advocate for coverage of our products at State Medicaid Pharmacy and
Therapeutics Committees. Sanofi employees do attend State Medicaid
Pharmacy and Therapeutics Committees meetings. Relevant advocacy
activities to support Medicaid access and coverage of our medicines, if
any, are disclosed to States in accordance with individual State laws.
Question. Please describe how the costs of patient assistance
programs are accounted for within your company's financial statements.
Please also describe the types of market information, such as
prescribing and use patterns, that your company collects from different
types of patient assistance programs and patient hub services.
Answer. Within Sanofi's financial statements, Sanofi includes the
administrative costs of the company's co-pay assistance programs, other
point-of-sale programs, and free drug patient assistance program
(Sanofi Patient Connection) in the ``Selling and general expenses''
line item. For co-pay assistance and other point-of-sale programs,
Sanofi records the pharmacy reimbursement amount paid by the company as
a reduction in sales. Sanofi records free product provided through
Sanofi Patient Connection within ``Cost of Sales.'' Sanofi Care North
America, the 501(c)(3) operating foundation that donates free product
to Sanofi Patient Connect, records the free goods as a ``Contribution''
when received from Sanofi and as a ``Donation'' when donated to Sanofi
Patient Connection.
With regard to market information associated with its patient
assistance programs and hub services, Sanofi generally collects data
that aids in the efficient administration and operation of these
programs. For example, the vendors operating Sanofi Patient Connection
and the hubs collect information provided by patients on enrollment
forms, including patient and provider demographic information, patient
insurance information, patient diagnosis, and prescription information
necessary to evaluate patient program eligibility and/or administer the
program. (Sanofi does not itself receive patient protected health
information except in very limited circumstances, such as when a
patient reaches out to Sanofi directly when they do not agree with
their patient assistance eligibility determination or when Sanofi
monitors vendor calls for compliance with company policies and
procedures.) With respect to Sanofi Patient Connection, Sanofi does not
use this information for purposes other than administering the patient
assistance program. With respect to hub services, in addition to using
this information to administer hub programs, Sanofi may use this data
to develop market and business insights.
With respect to Sanofi's point-of-sale patient assistance programs,
Sanofi also receives anonymized program utilization data, including
information about patient out-of-pocket costs, the average amounts that
Sanofi reimburses pharmacies through the program, abandonment rates,
dispensing pharmacies, and the prescribers writing the prescriptions
associated with program utilization. This information is used to
administer the program. Sanofi may also use this data to develop market
and business insights.
Question. Please provide a list of all contributions since January
1, 2014, that your company has made to any tax exempt organizations
working on issues related to drugs within your product lines, including
but not limited to patient groups, disease awareness groups, medical or
professional societies, universities or hospitals, industry
associations or leagues. For each contribution, please provide the name
of the organization that received the donation, the date the donation
was made, the amount of the donation, and a description of the purpose
of the contribution (i.e., was the contribution for the general fund, a
specific purpose to a specific program, or continuing medical
education). Please also note whether the contribution was unrestricted
or restricted; if it was restricted, please explain all restrictions.
Finally, if your company maintains a foundation or other separate
charitable arm, please provide the name of all such entities, and list
all donations made from that entity or entities.
Answer. In the attached documents, we have provided information for
the period January 1, 2015 through December 31, 2018 regarding payments
made by Sanofi US to tax-exempt organizations.\5\ The information is
provided in a number of documents consistent with how Sanofi maintains
this information. In some cases, this information may be over-inclusive
and include non-tax exempt organizations (e.g., contributions for
independent medical education into both non-profit and other entities).
The information includes contributions and sponsorships to various tax-
exempt health-care-oriented organizations, including patient groups.
The information also includes contributions made for independent
medical education grants, and to teaching hospitals for investigator-
sponsored trials and for physician fellowship payments. On March 8,
2018, Sanofi acquired Bioverativ, Inc., a biopharmaceutical company
focused on therapies for hemophilia and other rare blood disorders. The
attached documents also describe the monetary contributions to tax
exempt organizations made by Bioverativ since March 8, 2018.
---------------------------------------------------------------------------
\5\ These contributions may not relate to particular drug products.
Sanofi US supports programs and initiatives of external, independent,
not-for-profit organizations that align with Sanofi US's corporate
vision and values. These organizations are generally healthcare-
oriented and focus on one or more therapeutic areas in which Sanofi US
is actively involved. The attached information focuses on Sanofi US
entities that manufacture and sell drug products and does not include
entities that manufacturer and sell consumer health products or
vaccines. Contribution information prior to 2015 is archived in
databases and systems that Sanofi does not currently maintain and which
are not easily accessible. The information available does not
distinguish between restricted and unrestricted grants.
With respect to any foundations or charitable arms of Sanofi, from
January 1, 2014 through the end of 2017, Sanofi maintained an entity
called Sanofi Foundation of North America, a 501(c)(3) nonprofit
operating foundation that was closed at the end of 2017. Donations made
from that entity are included in the attachments described above.
Currently, Sanofi maintains an entity called Sanofi Cares North
America, which is a 501(c)(3) nonprofit operating foundation that makes
donations of Sanofi products free of charge to eligible financially-
needy uninsured and underinsured patients through a program known as
the Sanofi Patient Connection. Sanofi Cares North America also donates
product to five non-governmental organization partners for the purpose
of emergency disaster relief--Americares, DirectRelief, Heart to Heart
International, MAP International, and Project Hope, and to
approximately one hundred summer camps with 501(c)(3) status for
---------------------------------------------------------------------------
children with diabetes.
Question. Pay for delay agreements cost consumers and taxpayers
billions in higher drug costs every year. The FTC has gone after drug
companies that enter into these settlements where the brand pays the
generic company to keep its lower cost alternative off the market. I'm
the lead Republican sponsor of S. 64, the ``Preserve Access to
Affordable Generics and Biosimilars Act,'' which would help put an end
to these deals.
Do you agree that these pay-off agreements keep drug costs high for
patients because they delay competition?
Answer. With respect to patent litigation, Sanofi believes it is
inappropriate to presume that any settlement of patent litigations
related to pharmaceutical products is anticompetitive. Patent
settlements are often the most efficient and effective way to resolve
disputes regarding patented drugs, and they often lead to the earliest
appropriate entry of generic products into the market, which benefits
patients. In fact, settlements permit entry of a generic alternative
into the market earlier than expiration of the relevant branded
product's patent. Each patent litigation and potential settlement
presents unique factors and must be considered individually and in
light of the relevant circumstances.
Question. Has your company ever entered into these kinds of
settlements with a generic company?
Answer. No, Sanofi does not enter into ``pay for delay'' or
``reverse payment'' agreements that prohibit generic drug or biosimilar
development after the expiration of a patent. Sanofi has reached
settlements in patent infringement cases, and these agreements have
allowed the generic company to commercialize its product before the
expiration of the branded product's patent(s).
Question. Do you support the pay for delay bill?
Answer. We support the intent behind this legislation to promote
competition, including prohibitions on ``reverse payment'' agreements.
However, we have significant concerns with the way that this bill is
drafted, and therefore we do not support this particular legislation.
We believe that it is inappropriate to make settlements of patent
litigations presumptively illegal or to classify such settlements as
anticompetitive. Such settlements can be the most efficient and
effective way to resolve legitimate disputes regarding patented drugs,
and they often lead to the earliest appropriate entry of generic
products into the market, which in turn benefits patients. As stated
above, each patent litigation and potential settlement presents unique
factors and must be considered individually and in light of the
relevant circumstances.
Additionally, we have concerns that this bill could apply
retroactively to agreements entered into after June 17, 2013. For
clarity and certainty in the marketplace, any new legislation governing
the settlement of patent litigation should apply prospectively only.
rebate traps/walls
Question. I'm increasingly concerned about the effect of so-called
``rebate traps'' or ``rebate walls'' on patients' access to quality,
lower cost medicine. I understand there is ongoing litigation
challenging these practices as anti-competitive.
Does your company engage in the bundling of rebates over multiple
products? If so, why? And what benefit does the consumer gain from
that?
Answer. Sanofi offers discounts in bundled sales arrangements only
in limited circumstances. For example, Sanofi may offer bundled
discounts on its products Toujeo' and Lantus' to
ensure that both products attain a formulary position that benefits
patients. This is especially important because the products may serve
patients with different medical needs.
Question. Does your company view these practices as anticompetitive
or harmful to patients' access to quality, lower cost medicine?
Answer. Sanofi prioritizes patient access to medications at a
reasonable cost. Sanofi's arrangements with individual PBMs or insurers
promote this goal by maintaining stability of supply at affordable
prices. In competitive drug markets, Sanofi may enter into arrangements
with particular PBMs or insurers that permit Sanofi to further reduce
its prices on one or more medications in exchange for greater certainty
regarding the amount of those medications it will sell over a specified
term. These arrangements promote patient access to quality, affordable
medications, are procompetitive, and comply with the antitrust laws.
Moreover, in competitive drug markets Sanofi's ability to ensure
patient access to affordable medications is affected both by PBMs and
insurers (who may have considerable negotiating leverage over
manufacturers) and by other manufacturers (who may respond to
competition from Sanofi in a variety of ways). While some manufacturers
may respond by building ``rebate walls'' or ``rebate traps'' around
their products, Sanofi shares the Committee's concern about practices
that are harmful to patients' access to quality, affordable medication.
Question. If a policy were adopted to eliminate rebates, or to
require that rebate savings be passed on to the consumer, would that in
and of itself solve the issue of rebate ``traps'' and ``walls''? And
would consumers benefit from such a policy?
Answer. The elimination of safe harbor protection for rebates would
remove incentives for manufacturers to attempt to influence formulary
placement through such discounts. It is also possible that competitive
products would be launched at lower list prices and more readily
incorporated into formularies on the basis of their clinical benefits
in a world without rebates. This would benefit the system overall,
including consumers.
drug pricing
Question. When setting the list price of a drug, does your company
consider regulatory costs or compliance? If so, how specifically do
those factors affect the list price of a drug? Please provide at least
one specific example, if applicable, from your current product
portfolio.
Answer. The primary factors that Sanofi considers in setting list
price include the value of the product, the competitive environment,
patient affordability and access, investment in further product
development or needs to reinvest in R&D more generally. In certain
limited cases, Sanofi also will consider regulatory costs when setting
the list price of a product. These factors may be considered, for
example, where ongoing clinical trials are needed for a particular
therapy or when the FDA mandates a Risk Evaluation and Mitigation
Strategy (``REMS'') for a product--such as with Sanofi's drug
Lemtrada. Sanofi does not, however, consider our routine and ongoing
regulatory compliance efforts within the cost of our products. Rather,
those efforts are considered part of Sanofi's operating costs.
Question. When setting the list price of a drug, does your company
consider the risk of liability or litigation? If so, how specifically
do those factors affect the list price of a drug? Please provide at
least one specific example, if applicable, from your current product
portfolio.
Answer. When conducting its pricing analysis for a new drug, Sanofi
does not specifically consider the risk of liability or litigation
associated with such product.
______
Questions Submitted by Hon. Pat Roberts
Question. What role do you see Value Based Arrangements (VBAs)
playing in the effort to reduce prescription drug costs? What potential
do these arrangements have to find the ``sweet spot'' between
controlling costs to patients and encouraging innovation of new drugs?
How can VBAs help lower what patients pay out-of-pocket?
Can Congress do more to allow for and encourage the use of VBAs?
Answer. Sanofi believes that encouraging an environment that is
supportive of value-based arrangements would help promote drug
affordability, increase patient access to medicines, and improve
patient adherence and outcomes. Although there are different types of
these agreements, value-based contracts generally tie prices and
payments to the value of a particular prescription drug product--while
potentially reducing patient out-of-pocket costs and providing patients
with better access to the most innovative drug products. A manufacturer
could, for example, condition payment for a product on its success in
meeting a predefined clinical outcome, and this type of arrangement
could make drugs more affordable and lower healthcare costs throughout
the system.
Facilitating value-based arrangements also could encourage new drug
innovation, control costs for such new products, and recognize the full
value of complex and personalized treatments. Nevertheless, despite the
promise of these arrangements, industry stakeholders--including
manufacturers and payers--need better legal and regulatory clarity. For
example, we support the creation of a safe harbor from Anti-Kickback
Statute liability to protect value-based agreements. We also are
supportive of any legislation that would facilitate value-based
arrangements and protect them from legal enforcement, such as the
Patient Affordability, Value, and Efficiency Act (PAVE Act).
______
Questions Submitted by Hon. John Cornyn
Question. We continue to hear that rebates negotiated off of the
list price of a drug are both good and bad.
Pharmacy benefit managers and plans have argued that rebates are
used to lower premiums across the board and that it is the best way to
seek a price concession on otherwise expensive drugs.
Your industry argues that these payers are insisting on higher
rebates that can only be achieved by raising list prices.
But patients often lose under this system, with out of pocket costs
being tied to list price. Insulin patients appear to be routinely
impacted by this perversity in the system.
Please explain to the committee how your company would reduce list
prices if rebates were no longer a part of the equation?
What assurance can you provide that you would in fact lower your
prices?
What actions should be taken to ensure that patients are actually
seeing the benefits of lower out of pocket costs?
Answer. If (1) the proposed changes to the anti-kickback statute
safe harbors were codified, and (2) Congress implemented similar
changes to the commercial insurance market, Sanofi would lower the list
prices of its prescription medications for products in competitive
categories for which there is currently a material difference between
list price and net price on the assumption that patient access and
affordability would be improved. Sanofi also supports policy changes
that would de-link other payments in the pharmaceutical supply chain
from list price.
We support extending the intent behind the anti-kickback statute
safe harbor proposed rule to the commercial market so that incentives
are aligned across the marketplace. Together, we believe these changes
would facilitate Sanofi's ability to lower its list prices. However, we
recommend a step-wise approach, implementing changes to the commercial
market after the safe harbor rule is implemented on January 1, 2020.
Such an approach would provide an opportunity for stakeholders and the
government to identify unintended consequences, and address them, prior
to extending these policies to the commercial market.
We want to ensure that the new system achieves its goal of
improving affordability for patients. For instance, CMS should monitor
and evaluate how the new system affects formulary access, utilization
management, and patient cost-sharing, particularly with respect to
medicines with a lower list price. We also have concerns that changes
to the rebate system may lead to new fees, which simply require
manufacturers to pay previous rebate values in new ways, rather than
creating savings for patients.
Without a better understanding of how these policy changes
ultimately would affect the competitive marketplace, patient access,
and affordability, we are unable to quantify the amount of any
potential list price reduction.
With respect to actions that should be taken to ensure patients are
seeing the benefit of lower out-of-costs, we support legislation that
would incentivize manufacturers to lower list prices by connecting
better patient access and affordability to such pricing actions.
Question. If rebates are driving high list prices for drugs as drug
manufacturers' claim, why do you think that Part B drugs, which have no
PBM rebates, are also seeing significant price increases? Whose fault
is that?
Answer. Sanofi considers a variety of factors when setting or
raising its list prices. These factors include the value of the
product, the competitive environment, patient affordability and access,
investment in further product development or needs to reinvest in R&D
more generally. Within this framework, any list price increase is made
consistent with our pricing principles, including our commitment to
limit the total annual increase to a level at or below the NHE
projected growth rate, as estimated by CMS.
Although we agree that one factor in price increases across the
industry may be the increased demand for rebates at the PBM and health
plan level, that is not the only factor. In fact, Sanofi believes that
reducing incentives for high prices throughout the supply chain by
delinking payments from list price would have a meaningful impact on
price and patient costs. This is true, for example, with group
purchasing organizations (GPOs) that negotiate pricing for Part B
providers. As with PBMs, these GPOs negotiate rebates and
administrative fees that are linked to the list price of the product.
These structures thus create the same misalignment of interests as in
the PBM setting. It is important to note, as well, that the current
average sales price (ASP)-based system for Medicare Part B works to
moderate price growth because reimbursement reflects the weighted
average of discounts given to providers, payers, and other commercial
purchasers. This means that the Medicare program and its beneficiaries
benefit from the discounts health plans and providers negotiate on
these drugs. Due to this market-based competition, ASP reimbursement
rates often are substantially lower than list prices.
biosimilar competition/insulin
Question. Biosimilars have been much anticipated as a solution to
the drug pricing crisis. In particular, the FDA is moving to make
insulin a biologic that would be subject to biosimilar competition in
the future.
But we are hearing from all of you that the biosimilar market
doesn't work and the benefit of these cheaper but equally effective
alternatives are really not available to U.S. patients.
Can a biosimilar version of insulin be part of the solution for
diabetes patients?
If so, what changes need to be made to the system so that patients
and the taxpayer can realize the benefit of biosimilars? (Merck gave up
on pursuing a biosimilar to Sanofi's Lantus.) \6\
---------------------------------------------------------------------------
\6\ https://www.fiercepharma.com/pharma/merck-ditches-biosimilar-
lantus-but-will-ease-path-for-mylan-s-rival-insulin-product.
Answer. Sanofi believes that biosimilars currently--and will
continue to--result in increased competition. In fact, this type of
competition has grown among insulin manufacturers in recent years, and
we expect that it will continue to lower prices for patients with
diabetes. For example, in 2016, Eli Lilly introduced a follow-on
biologic to Sanofi's drug Lantus. Additionally, in 2018, Sanofi
introduced Admelog, a follow-on biologic of Humalog, at a list price
that was 15% lower than the reference product. Mylan also is developing
a second follow-on insulin glargine that references Lantus, and Sanofi
is developing a biosimilar insulin aspart, a rapid-acting insulin,
which we expect to introduce in 2021. Sanofi expects that the already
highly competitive diabetes drug market will become increasingly robust
over time--including with the anticipated introduction of
---------------------------------------------------------------------------
interchangeable biosimilar basal and rapid acting insulins.
There are changes already in place that will help patients and
taxpayers realize the benefit of biosimilars. Specifically, in March
2020, certain biologics that are currently regulated as drugs,
including long acting insulins, will be regulated as biologics and
therefore will be subject to the existing biosimilars pathway. We
expect the change in insulin regulation to spur the continued
development of substitutable or interchangeable insulin products, and
to increase competition in this space generally.
______
Questions Submitted by Hon. Todd Young
re-evaluating business strategies in foreign countries
Question. Since taking office, President Trump has made reducing
drug prices one of his highest priorities--and has repeatedly spoken
about his frustration with the U.S. subsidizing the costs of
pharmaceuticals for the rest of the world. He has gone so far as to
issue proposals, like the International Pricing Index (IPI) Model, in
an attempt to bring down prescription drug prices.
With the increased scrutiny of the industry and of the drug supply
chain as a whole in the United States, have any of your companies re-
evaluated your business strategy in foreign countries? If not, then
why?
Answer. No, Sanofi has not reevaluated its business strategy in
foreign countries. Other countries have implemented systems, such as
price controls or reference price regimes, to directly and artificially
regulate the price of medicines. In our experience, there is not an
opportunity for Sanofi to negotiate prices with these foreign
government payers. Sanofi's only choice is to accept the government-
mandated price, or to not sell the pharmaceutical in that country,
which not only hurts a company financially, but more importantly harms
patients.
We note that, although these systems may be effective at
controlling budgets for central payers, they come at a steep cost for
patients, including severe access restrictions and rationing. For
instance, one analysis of the report released to justify the
International Pricing Index found that 96 percent of new cancer
medicines are available in the U.S. compared to 71 percent in the
United Kingdom and 65 percent in France.\7\
---------------------------------------------------------------------------
\7\ http://phrma-docs.phrma.org/download.cfm?objectid=0C19E240-
19C7-11E9-87D20050569A4
B6C.
As a Sanofi specific example, Dupixent is the first drug to be
approved for moderate to severe atopic dermatitis (eczema) in the US.
FDA granted Breakthrough Therapy designation to Dupixent as preliminary
clinical evidence indicated that ``the drug may demonstrate substantial
improvement over available therapy on clinically significant
endpoint(s).'' Dupixent was approved by FDA in March 2017 under
Priority Review, which means that FDA's goal is to take action on this
application within 6 months (compared to 10 months under standard
review). Within 24 hours of FDA approval, Sanofi shipped orders for
Dupixent to be made available to U.S. patients. In contrast, Health
Canada approved Dupixent in November 2017. However, Dupixent is still
---------------------------------------------------------------------------
not publicly reimbursed in Canada.
Question. If a proposal, like IPI, were implemented, would it force
your companies to potentially ``walk away from the negotiating table
when other countries demand low prices subsidized by America's
seniors,'' as HHS Senior Advisor for Drug Pricing Reform John O'Brien
has said?
Answer. In our experience, there is not an opportunity for
manufacturers to negotiate with a government. Sanofi's only choice is
to accept the government-mandated price, or to not sell the product in
that country, which, as noted above, not only hurts Sanofi financially,
but more importantly harms patients.
Question. What are some of your ideas on how we can ensure
Americans aren't shouldering the full cost of pharmaceuticals?
Answer. While we understand the concern that Americans are
shouldering more than their fair share of the cost of innovation in the
pharmaceutical sector, the list price discrepancy between the U.S. and
other countries is due, in primary part, to the different health care
systems. Because Sanofi pays significant rebates to payers and PBMs,
the difference between the price in other developed countries and the
net price in the U.S. is not nearly as large.
Sanofi's top priority is reducing out-of-pocket costs for patients.
We believe that there need to be reforms to the current system to
better align incentives, including market-based approaches to pricing
that promote competition and ensure patients have affordable and
sustainable access to innovative medicines. Currently, payers and PBMs
inconsistently pass through the growing savings that they receive from
increased negotiated rebates. Accordingly, despite increasing rebates
and lower net prices, out-of-pocket costs for many patients have
continued to grow. Sanofi supports policies that pass PBM and payer
rebate savings to patients at the pharmacy counter through lower copays
and coinsurance. Sanofi would also support policies that would
incentivize responsible pricing by tying smaller list price increases,
or even list price reductions, to both access and affordability for
patients.
foreign countries' pricing and reimbursement
Question. President Trump and Secretary Azar have both repeatedly
described their frustrations with ``foreign freeloading'' of U.S. drugs
in the last year.
``When foreign governments extort unreasonably low prices from U.S.
drug makers, Americans have to pay more to subsidize the enormous cost
of research and development. . . . It's unfair and it's ridiculous, and
it's not going to happen any longer.''
Do you agree that because of foreign countries' pricing and
reimbursement systems, U.S. patients and innovators are shouldering the
burden for financing medical advances?
Answer. It is true that the U.S. is the main engine in
pharmaceutical and biotechnology innovation in the world. Although
U.S.-based manufacturers manage clinical trials globally, there are
substantially more research and development dollars invested in the
U.S. than in any other country. To illustrate, in 2015, PhRMA member
companies spent over $47 billion in domestic R&D and only $12 billion
in R&D abroad. For Sanofi, in 2018, we spent nearly $7 billion on R&D
globally--a substantial portion of which in the U.S.--and we expect
that our annual R&D spend will be consistent through 2021. These
investments in research, in turn, create significant and important job
opportunities in the United States.
However, it is important to note that while other countries'
pricing and reimbursement systems may help to contain costs in those
countries, they come at a steep cost for patients, including severe
access restrictions and rationing. For instance, one analysis of the
report released to justify the International Pricing Index found that
96 percent of new cancer medicines are available in the U.S. compared
to 71 percent in the United Kingdom and 65 percent in France.\8\
Moreover, the list price discrepancy between the U.S. and other
countries is due, in part, to the different health-care systems.
Because Sanofi pays significant rebates to payers and PBMs, the
difference between the price in other developed countries and the net
price in the U.S. is not nearly as large.
---------------------------------------------------------------------------
\8\ http://phrma-docs.phrma.org/download.cfm?objectid=0C19E240-
19C7-11E9-87D20050569A4
B6C.
Question. How do foreign countries' pricing and reimbursement
---------------------------------------------------------------------------
systems affect our prescription drug costs?
Answer. Pricing and reimbursement systems in other countries do not
affect how Sanofi prices its medicines in the United States. Consistent
with our pricing principles, when Sanofi sets the price of a new
medicine in the U.S., we hold ourselves to a rigorous and structured
process that includes consultation with external stakeholders. In our
view, an objective measure of a new product's value considers the
benefit to patients, compared to a standard of care; the reduced need--
and therefore costs--of other health-care interventions; and any
increase in quality of life and productivity. We believe our pricing
reflects these factors. We also consider factors such as the
affordability for patients and any unique factors specific to the
medicine, like the need to support ongoing clinical trials, implement
important regulatory commitments, or develop sophisticated patient
support tools that improve care management and help decrease the total
cost of care. Additionally, under our pricing principles, we have
pledged to limit price increases at or below the National Health
Expenditure (NHE), which is the projected annual health-care spending
growth rate as estimated by CMS.
Question. Are foreign governments taking note of the concerns being
raised by the Trump administration and have they responded in any way?
Answer. Sanofi is not aware of any responses by foreign governments
to U.S. drug pricing policy proposals advanced by the Trump
administration.
Question. Has there been any noticeable change in any of our trade
agreements since these concerns have been raised by the Trump
administration?
Answer. Sanofi is not aware of any such changes.
medicaid closed formulary proposals
Question. In an attempt to bring down drug costs, various States
have been exploring whether to exclude certain drugs from their
Medicaid program. For example, the State of Massachusetts recently
asked CMS for permission to create a closed formulary where the State
Medicaid program would pick at least one drug per therapeutic class.
CMS denied their waiver request citing violation of Federal law, but
this proposal does bring up important questions on how to contain drug
prices in State Medicaid programs.
If the principles of the Medicare Part D program--including the
necessary patient protections--were applied to State Medicaid programs,
do you think it would lower drugs costs while ensuring access to
patients?
Answer. The Part D program encourages strong competition in the
marketplace, including by providing beneficiaries with choice of
different plans and encouraging drug manufacturers to compete for
formulary position to support broad access to their medicines (in part
by securing lower cost-sharing obligations for patients in preferred
formulary tiers). By contrast, State Medicaid programs are obligated,
as a condition of a manufacturer's participation in the Medicaid Drug
Rebate Program, to cover company's products (subject to certain narrow
exceptions). Consequently, although we believe that increased
competition in the Medicaid program could help to lower drug prices,
including if Medicaid implemented certain of the Part D program's
principles, it is not immediately clear how these changes would further
enhance patient access.
medicaid ``best price''
Question. In the Trump administration's Blueprint, they suggested
that because drug manufactures have to give Medicaid the ``best price''
on drugs, there is no incentive to offer deeper discounts to other
payers--both government and commercial--than what is already offered
under the Medicaid Drug Rebate Program.
Does the Medicaid ``best price'' requirement encourage
manufacturers to increase initial prices?
Answer. The Medicaid Rebate Act, and CMS's corresponding rules,
require drug manufacturers to pay rebates to the State Medicaid
Programs for units of drug dispensed to their beneficiaries. Medicaid
``Best Price'' generally is defined as the lowest price offered to
commercial purchasers in the United States, and it is one of two key
metrics used for setting the level of rebates that manufacturers must
pay to each state Medicaid program for Medicaid beneficiary
utilization. Best Price does not, therefore, reflect a price point at
which manufacturers sell products to Medicaid, and Sanofi does not view
the Medicaid Best Price requirements as encouraging manufacturers to
set higher initial prices. However, Medicaid Best Price considerations
are a factor in assessing whether to offer higher rebate amounts to our
commercial (Best Price-eligible) customers.
Question. What, if any, changes would you suggest we make to the
program?
Answer. With regard to the Medicaid Drug Rebate Program and the
determination of Best Price, the Trump administration's Pricing
Blueprint highlights the impediments that exist under current rules
with regard to value-based discounting arrangements. Sanofi would like
to pursue more innovative product discounting strategies--including
arrangements in which we would stand behind the value or outcomes that
our products provide to patients and to the healthcare system
generally. But, current Medicaid rebate calculation rules regarding
bundled discount arrangements, and the manner in which manufacturers
must account for discounts that are incurred over long periods of time,
present significant obstacles to adopting these arrangements. If the
rules for the Medicaid Drug Rebate Program were amended to permit
manufacturers to exclude certain appropriately-structured value-based
discounts from their Best Price calculation, it is likely that Sanofi
could adopt more innovative value-based discount contracts, and that
these arrangements in turn could result in significant savings for
patients and the system.
outcomes-based contracts
Question. In almost all of your testimonies, you highlight your
support of outcomes-based contracts and how we need to be shifting our
system toward that approach.
How will these contracts lower drug costs for patients in both the
near term and long-term?
How will they lower overall health-care costs for our Federal
programs?
What have the preliminary results looked like so far?
Answer. Sanofi believes that encouraging an environment that is
supportive of value-based arrangements would help promote drug
affordability, increase patient access to medicines, and improve
patient adherence and outcomes. Specifically, value-based arrangements
tie prices and payments to value while reducing patient out-of-pocket
costs and providing patients with better access to the most innovative
drug products. For example, value-based arrangements can be premised
upon the effectiveness of a manufacturer's product, which may help to
secure payer coverage for new and innovative therapies. Where payment
to a manufacturer is conditioned on the value or clinical outcomes of a
product, value-based arrangements also may help to improve patient
cost-sharing challenges. Additionally, value-based arrangements could
encourage new drug innovation while controlling costs for such new
products by aligning the price of the drug to the value the drug brings
to the patient.
Recently, Sanofi has executed value-based contracts related to
Soliqua 100/33, Praluent, and Kevzara. These arrangements are in their
nascent stages, and we do not have sufficient information to assess the
results.
Despite the promise of these and similar arrangements, Sanofi
strongly believes that better legal and regulatory clarity would
facilitate greater proliferation of value-based contracts. For example,
we support the creation of a safe harbor from Anti-Kickback Statute
liability to expressly protect value-based agreements. We also are
supportive of legislation that would remove Best Price-barriers to
value-based contracts, such as the Patient Affordability, Value, and
Efficiency Act (PAVE Act).
transparency/point of sale
Question. In almost all of your testimonies, you express your
support for the Trump Administration's proposal to allow manufacturers
to provide PBMs up-front discounts that are passed onto patients at the
point-of-sale.
Do you feel like this proposal will make the transactions within
the drug supply chain more transparent?
If so, would this transparency bring down drug costs--overall and
for specialty drugs?
Answer. Because the proposed rule would require manufacturer
discounts to be provided at the pharmacy counter, the proposal will
facilitate increased transparency with respect to the arrangements
between manufacturers and PBMs, and with respect to the discounts
manufacturers offer on their medicines. We believe such increased
transparency would result in lower patient costs.
However, Sanofi believes that HHS's proposal does not go far enough
in creating the kind of systemic change needed to create a more
transparent drug supply chain throughout the entire U.S. health-care
system. We believe that increased, system-wide transparency, that
appropriately protects competitively sensitive information, would
improve competition by making relevant information available to
patients and policymakers. Providing more information about what is
driving costs in the system, and taking steps to curtail misaligned
incentives related to the flow of money through the system, for
instance through legislation like the C-THRU Act, would allow for
increased competition and better-informed decision making.
the relationship between wholesalers and manufacturers
Question. When talking about the pharmaceutical supply chain, a lot
of focus has been placed on the Pharmacy Benefit Manager. But there's
another side of the equation that I'd like to ask about.
How do wholesalers negotiate pricing with manufacturers?
What impact does this have on drug costs?
What incentives or disincentives do they have to contain price
increases?
Answer. Wholesalers do not typically negotiate pricing with
manufacturers. Wholesalers are merchant-middlemen in the supply chain,
and they generally facilitate the efficient distribution of drugs and
biologicals to end customers (such as pharmacies or clinics). While
Sanofi may offer a prompt pay discount to wholesalers, wholesalers
generally purchase product at Wholesale Acquisition Cost (i.e., list
price) and they facilitate the acquisition of products by end
purchases--frequently at prices that are negotiated between Sanofi and
the end purchaser. If wholesalers sell to end purchasers at a loss
based on the negotiated price, wholesalers will issue a ``chargeback''
to the manufacturer for the difference. In addition, Sanofi pays
service fees to wholesalers to operationalize this distribution and
chargeback process, and those fees typically are based on a percent of
WAC. As with fees paid to PBMs, Sanofi's view is that flat pricing for
wholesaler administrative services could exert downward pressure on
drug prices by delinking list price from fee payments.
______
Questions Submitted by Hon. Ron Wyden
proposed rebate rule
Question. As has been done in many other settings, drug
manufacturers said during the hearing that one reason list prices for
drugs are high is that pharmaceutical benefit managers (PBMs) demand
larger and larger rebates in order for the drug to receive favorable
placement on a formulary. You and your colleagues who testified during
the hearing stated if the administration's proposal on changes to the
anti-kickback safe harbor for pharmaceutical rebates took effect, your
company would likely lower list price.
Like many Oregonians, I am skeptical drug manufacturers would
voluntarily lower their prices. Therefore, would you support
legislation that would (1) make similar changes the administration has
put forward related to Part D and Medicaid managed care, (2) change the
rebate system in a similar way to the proposal for the commercial
market, and (3) require drug makers to lower the list price of their
drugs equal to the amount of rebates provided today?
Answer. If (1) the proposed changes to the anti-kickback statute
safe harbors were codified, and (2) Congress implemented similar
changes to the commercial insurance market, Sanofi would lower the list
prices of its prescription medications for products in competitive
categories for which there is currently a material difference between
list price and net price on the assumption that patient access and
affordability would be improved. Sanofi also supports policy changes
that would de-link other payments in the pharmaceutical supply chain
from list price.
We support extending the intent behind the anti-kickback statute
safe harbor proposed rule to the commercial market so that incentives
are aligned across the marketplace. Together, we believe these changes
would facilitate Sanofi's ability to lower our list prices. However, we
recommend a step-wise approach, implementing changes to the commercial
market after the safe harbor rule is implemented on January 1, 2020.
Such an approach would provide an opportunity for stakeholders and the
government to identify unintended consequences, and address them, prior
to extending these policies to the commercial market.
We want to ensure that the new system achieves its goal of
improving affordability for patients. For instance, CMS should monitor
and evaluate how the new system affects formulary access, utilization
management, and patient cost-sharing, particularly with respect to
medicines with a lower list price. We also have concerns that changes
to the rebate system may lead to new fees, which simply require
manufacturers to pay previous rebate values in new ways, rather than
creating savings for patients.
Without a better understanding of how these policy changes
ultimately would affect the competitive marketplace, patient access,
and affordability, we are unable to quantify the amount of any
potential list price reduction.
We support legislation that would incentivize manufacturers to
lower list prices by connecting better patient access and affordability
to such pricing actions. The U.S. market-based approach to drug pricing
has been successful in reducing net prices, but in the current system,
that value is not being passed on to patients. We expect that the
reforms we note above would address that issue while preserving a
market-based approach that promotes competition and ensures patients
have affordable and sustainable access to innovative medicines.
medicaid drug rebate program
Question. The Medicaid Drug Rebate Program (MDRP) requires
manufacturers to provide a basic rebate and an additional inflationary
rebate for both brand and generic drugs. The inflationary rebate is an
increasingly substantial part of total rebates due in large part to
large increases in drug prices that exceed inflation. Under current
law, this inflationary rebate is capped at 100 percent of Average
Manufacturer Price (AMP). This is the case even when manufacturers
continue to raise their prices well above inflation.
Please provide a list of all of your pharmaceutical products that
have reached the Medicaid AMP rebate cap in any of the 20 quarters from
January 1, 2014 through December 31, 2018.
For each drug listed in response to question 1, please also provide
a list of which quarters and years each drug hit the cap.
Answer. Sanofi takes steps to ensure that it complies with all
applicable laws related to the Medicaid Drug Rebate Program, including
that it is paying rebates to the state Medicaid programs in accordance
with law. Sanofi sells NDCs in 29 product families for which it pays
Medicaid rebates at 100 percent of AMP. Respectfully, Sanofi's view is
that the detailed information requested by this question is
confidential and proprietary. We would be happy to work with the
Committee to provide this information in a way that mitigates against
competitive harms that could arise from public disclosure of this
information.
medicaid drug rebate program compliance
Question. I am concerned about recent reports and legal settlements
surrounding drug manufacturers' failure to comply fully with the
requirements of the MDRP. For example, an analysis by the U.S.
Department of Health and Human Services Office of Inspector General
found that between 2012 and 2016 taxpayers may have overpaid by as much
as $1.3 billion for 10 potentially misclassified drugs. That is why I
introduced the Right Rebate Act with Chairman Grassley to prevent drug
manufacturers from manipulating Medicaid to increase their profits.
However, I continued to be concerned about oversight and manufacturer
compliance with the requirements of the Medicaid Drug Rebate Program.
Accordingly, please describe the following:
Your company's current compliance plan and procedures used to
ensure compliance with the requirements of the Medicaid Drug Rebate
Program including internal audits or other checks you use to identify
compliance vulnerabilities.
Answer. Sanofi takes steps to ensure that it complies with all
applicable laws related to its participation in the Medicaid Drug
Rebate Program (MDRP). These steps include, for example, documenting
Medicaid rebate calculation methodologies, processes, and reasonable
assumptions as appropriate. Sanofi's government price reporting
personnel also hold weekly meetings with the Sanofi legal department,
including with support from outside counsel as needed, to ensure that
compliance questions are discussed and addressed in a timely manner.
Sanofi's MDRP compliance is tested through several audits, including
biannual Sarbanes-Oxley Act audits, biannual external audits,
conversations with an external consultant government pricing advisory
team, and annual calculation audits of Average Manufacturer Price and
Best Price.
Question. Any past or ongoing issues of non-compliance.
Answer. Given the complexity of the MDRP and applicable law and
guidance, Sanofi routinely reviews its calculation methodologies and
reasonable assumptions. In the normal course of business, questions may
arise as to specific Sanofi compliance processes for the MDRP. When
such questions arise, Sanofi takes prompt steps to engage with CMS
about appropriate next steps, including a restatement of any of the
components of the Medicaid rebate calculation if needed. Such
restatements are administrative in nature and expressly contemplated by
the CMS regulations.
Question. Any corrective actions taken to address identified
problems or issues of noncompliance with the MDRP and how such steps
were communicated to the Centers for Medicare & Medicaid Services.
Answer. As noted above, in the event that Sanofi identifies any
compliance questions that it believes warrant review by CMS, Sanofi
promptly engages with CMS. This may occur, for example, in the event of
statutory or regulatory changes, or if CMS releases new sub-regulatory
guidance.
Question. Any steps taken to improve compliance and ensure that all
Medicaid drug rebates owed to the federal government and the states are
paid in full.
Answer. Sanofi's government price reporting team routinely works
with in-house and outside counsel regarding compliance with the
Medicaid Drug Rebate Act and CMS rules. As part of this continuing
compliance, the company assesses its calculation processes and
reasonable assumptions for purposes of calculating Average Manufacturer
Price, Best Price, and Unit Rebate Amount. In certain cases, moreover,
Sanofi engages directly with CMS to seek the agency's view of Sanofi's
reasonable assumptions or compliance processes. In any instance in
which Sanofi would determine that the State Medicaid Programs were
underpaid rebates, Sanofi would engage with CMS to determine the
appropriate way forward, including restating pricing metrics and paying
additional rebates to the States.
bonus payments tied to specific drugs
Question. I am concerned by the potential for employee financial
incentives to encourage high launch prices and price increases for
prescription drugs.
Is your salary, bonus or other compensation tied to sales or
revenue targets of a single product your company sells? Has it ever
been? If yes, please state the product or products to which your
salary, bonus or other compensation was tied.
Is your salary, bonus or other compensation tied to either revenue
or net income of the company as a whole? Has it ever been? If yes,
please explain what assumptions about price increases are used when the
compensation committee sets revenue or net income goals. Does the
compensation committee provide any guidance to executives in regards to
the amount of revenue that the company will generate from price
increases versus volume growth?
Answer. The Sanofi board of directors, acting on the recommendation
of the Compensation Committee, sets the compensation for the chief
executive officer (CEO). That compensation structure includes fixed
compensation, variable compensation, options, performance shares, and
benefits in kind.
Sanofi's overall compensation policy is designed to motivate and
reward performance by ensuring that a significant portion of
compensation is contingent on the attainment of financial, operational,
and extra-financial criteria aligned with the corporate interest and
with the creation of shareholder value. Therefore, in 2017 (the most
current year in which public information is available), as Sanofi's
CEO, Dr. Brandicourt was eligible for up to 250 percent of his target
fixed compensation in variable compensation. Several factors are
considered in determining his variable compensation; 40 percent is
based on financial indicators, and 60 percent is based on specific
individual objectives, including external growth, product launches,
operational transformation, organization and staff relations, and new
product pipeline.
Dr. Brandicourt's compensation package also includes equity-based
compensation, which is medium-term and aims to align the interests of
the CEO with those of the shareholders and other stakeholders. In 2017,
he received a set number of options to subscribe for shares, based on
performance conditions measured over a 3-year period, as well as
performance shares based on business net income, return on assets, and
total shareholder return.
net prices
Question. In your testimony, you stated, ``we have increased
transparency by providing, each year, information about our list and
net prices across all of our medicines,'' and that ``in 2018, the
average aggregate list price increase across all Sanofi medicines in
the U.S. was 4.6 percent . . . the price actually paid to Sanofi,
declined by 8 percent. So declining average aggregate net price in
[2018] represents the third consecutive year in which the amount paid
by payers across all of our medicines went down.'' Please describe how
the company's year-over-year aggregate net price is calculated. Please
also specifically address the following questions.
Answer. Sanofi calculates the aggregate net price as follows: Brand
net sales are divided by common units for the appropriate period. This
amount--``net price per unit''--is then compared to the prior period.
This amount establishes any increase or decrease for the brand for the
period being calculated. Once this is done for all brands, the
increase/decrease is weighted by gross sales (i.e., volume) to show the
aggregate net price impacts for Sanofi's portfolio of medicines.
Question. How many products are included in the calculation of the
average net price change? What was the median net price change?
Answer. This analysis is done on 79 separate products, covering 76
brands. Some brands have multiple product forms with different prices;
Sanofi separates these product forms when calculating average net
price.
The median net price change in 2018 was zero percent across all
products. Removing products with no net price change, the median net
price change in 2018 is -1.0%. This calculation is not weighted by
gross sales.
Question. Is net price weighted? If so, how? For example, in
determining the aggregate net price does the company assign different
weights to different products based on volume or other factors? Are
``on patent'' and ``off patent'' drugs weighted identically? Are other
statistical weights used or are all products treated equally?
Answer. All products are weighted by gross sales (i.e., volume),
irrespective of whether Sanofi has any current patents related to the
product. No other statistical weights were used.
Question. Does the figure that you provided during your testimony
account for U.S. prices, international prices, or both? Generally
speaking, when your company reports net price changes, does it
differentiate between U.S. and international prices?
Answer. The data Dr. Brandicourt provided regarding average
aggregate list price and average aggregate net price accounted for U.S.
prices. Sanofi's annual pricing report \9\ and related reporting on net
price consider U.S. prices only.
---------------------------------------------------------------------------
\9\ https://mediaroom.sanofi.com/-/media/Project/One-Sanofi-Web/
Websites/Global/Sanofi-COM/mediaroom/pdf/2019/
Prescription_Medicine_Pricing_2019.pdf.
Question. Please list the five drugs your company sold in the U.S.
that had the greatest year-over-year net price increase in 2018, noting
the increase for each drug by dollar figure and percentage. Please list
the five drugs your company sold in the U.S. that had the lowest year-
over-year net price increase (and/or the greatest decrease) in 2018,
noting the increase (or decrease) for each drug by dollar figure and
---------------------------------------------------------------------------
percentage.
Products with Greatest Average Net Price Increases in 2018 \10\
------------------------------------------------------------------------
YOY Percentage YOY U.S. Dollar
Product Change Change by Unit
------------------------------------------------------------------------
Renvela \11\ 40% $1.00
------------------------------------------------------------------------
Imovax \12\ 15% 30.10
------------------------------------------------------------------------
Caprelsa \13\ 12% 1,536.60
------------------------------------------------------------------------
Hectorol \14\ 11% 0.03
------------------------------------------------------------------------
Zaltrap \15\ 9% 0.60
------------------------------------------------------------------------
\10\ We have excluded products that were discontinued/divested in 2018,
have no sales in 2018, or if the reason for net price increase was due
to changes in prior accounting estimates or assumptions (as opposed to
changes in rebates and discounts).
\11\ Sanofi did not take any list price increases on Renvela in 2018.
The net price increase is due to (1) changes in prior accounting
estimates/assumptions, and (2) increasing use of generics in class,
resulting in (i) change in the mix of business, and (ii) a reduction
in rebate payments.
\12\ Sanofi took a 5-percent list price increase on Imovax in 2018.
\13\ Sanofi took a 5-percent list price increase on Caprelsa in 2018.
\14\ Sanofi reduced the list price of Hectorol by 47 percent in October
2018. The net price increase was due to a reduction in rebate
payments.
\15\ Sanofi did not take any list price increases on Zeltrap in 2018.
Products with Greatest Average Net Price Decreases in 2018 \16\
------------------------------------------------------------------------
YOY Percentage YOY U.S. Dollar
Product Change Change by Unit
------------------------------------------------------------------------
Renvela AG -74% -1.57
------------------------------------------------------------------------
Zolpidem CR -68% -0.26
------------------------------------------------------------------------
Leflunomide -63% -0.59
------------------------------------------------------------------------
Clolar -48% -894.26
------------------------------------------------------------------------
Priftin -26% -0.54
------------------------------------------------------------------------
\16\ We have excluded products that were discontinued/divested, have no
sales in 2018, or if the reason for net price decline was due to
changes in prior accounting estimates or assumptions (as opposed to
changes in rebates and discounts).
Question. For 2018, what was the average net price change in the
U.S. market for (1) drugs with no competition, (2) drugs with only
branded competition, and (3) drugs with generic competition?
Answer. (1) Drugs with no competition:\17\ 0.0%.
---------------------------------------------------------------------------
\17\ We define a product as having no competition if there are no
other products in the therapeutic class.
(2) Drugs with only branded competition:\18\ -2.1%.
---------------------------------------------------------------------------
\18\ We define a product as having only branded competition if
there is no generic, follow-on biologic, or biosimilar product in the
therapeutic class.
(3) Drugs with AB-rated generic/follow-on biologic/biosimilar
---------------------------------------------------------------------------
competition: -13.5%.
Question. In its most recent pricing report, Sanofi states that it
``increased the price of 35 of our 76 prescription medicines'' in the
United States. This statement appears to be in regards to list price.
How many of these medicines had their net price increase?
Answer. Seventeen of the 35 prescription medicines with list price
increases also had average net price increases.
Question. In its most recent pricing report, Sanofi states that
``in 2018, 55 percent of our gross sales were given back to payers as
rebates, including $4.5 billion in mandatory rebates to government
payers and $7.3 billion in discretionary rebates.'' For each product,
please disclose the gross sales and the amount of rebates paid.
Answer. Product-level rebate information is confidential and
proprietary information for competitive reasons and falls within the
definition of ``trade secret'' under the Trade Secrets Act, 18 U.S.C.
Sec. 1905, Exemption 4 of the Freedom of Information Act, 5 U.S.C.
Sec. 552(b)(4), and the Defend Trade Secrets Act of 2016, 18 U.S.C.
Sec. 1836. Public disclosure of this information would cause
significant harm to Sanofi and Sanofi's customers, and competitors
would gain unfair competitive advantage if they were to obtain this
information through public disclosure.
We note that congressional and executive agencies have historically
expressed concern that disclosure of such information could inhibit
competition. For example, in 2007 when then-chairman Waxman asked
several Medicare Part D prescription drug plans (``PDPs'') to submit to
the House Oversight and Government Reform Committee information on the
negotiated price discounts, rebates and other price concessions that
they obtained from drug manufacturers, the CBO issued a report
concluding that public disclosure of that information could reduce the
rebates that PDPs received and thus raise Medicare costs.\19\
Specifically, the CBO found that the disclosure of rebate data could
cause the variation in rebates among purchasers to decline. Because
PDPs generally secure rebates that are somewhat larger than the average
rebates observed in commercial health plans, the disclosure of Part D
rebates to competitors could create pressure to reduce those rebate
amounts, which in turn could increase costs for the Medicare program
and, on average, the costs for Medicare beneficiaries.\20\
Specifically, the CBO found that the disclosure of rebate data could
cause the variation in rebates among purchasers to decline. Second, CBO
concluded that disclosure of rebates could facilitate tacit collusion
among the manufacturers of competing brand-name drugs, reducing the
rebates to PDPs and thus increasing net drug prices.\21\ Similarly, the
Federal Trade Commission (``FTC'') has cited concerns regarding the
anti-competitive effects of disclosing net pricing and other price-
sensitive information. In the context of the healthcare industry
generally, the FTC noted:
---------------------------------------------------------------------------
\19\ CBO, Letter to the Hon. Joe Barton and the Hon. Jim McCrery
(March 12, 2007), available at https://www.cbo.gov/system/
files?file=2018-10/03-12-drug-rebates.pdf; see also CBO, ``Increasing
Transparency in the Pricing of Health Care Services and
Pharmaceuticals'' (June 5, 2008), available at https://www.cbo.gov/
sites/default/files/110th-congress-2007-2008/reports/06-05-
pricetransparency.pdf.
\20\ Id., at 3.
\21\ Id., at 4.
[Price transparency] can actually harm competition and
consumers. Some types of information are not particularly
useful to consumers, but are of great interest to competitors.
We are especially concerned when information disclosures allow
competitors to figure out what their rivals are charging, which
dampens each competitor's incentive to offer a low price, or
increases the likelihood that they can coordinate on higher
prices.\22\
---------------------------------------------------------------------------
\22\ FTC, Office of Policy Planning, ``Price Transparency or TMI?''
(July 2, 2015), available at https://www.ftc.gov/news-events/blogs/
competition-matters/2015/07/price-transparency-or-tmi.
Moreover, in describing its concerns about a New York state bill
that would have required pharmacy benefit managers (``PBMs'') to
disclose their rebate arrangements with drug manufacturers, the FTC
explained that disclosure of this information could ``facilitate
collusion, raise prices, and harm the patients the Bill is supposed to
protect.'' \23\ The FTC further explained that, without knowledge of
such competitor rebate information:
---------------------------------------------------------------------------
\23\ FTC, Office of Policy Planning, Bureau of Competition and
Bureau of Economics, Letter to Hon. James L. Seward re: New York Senate
Bill 58, at 5 (March 31, 2009), available at https://www.ftc.gov/sites/
default/files/documents/advocacy--documents/ftc-staff-comment-
honorable-james-l.seward-concerning-new-york-senate-bill-58-pharmacy-
benefit-managers-pbms/v090006newyorkpbm.pdf.
[M]anufacturers have powerful incentives to bid aggressively
for formulary position, because preferential formulary
treatment may yield increased sales. Unprotected disclosures
thus may raise the price that New York consumers pay for
pharmaceutical coverage by undermining competition among
pharmaceutical companies for preferred formulary treatment.\24\
---------------------------------------------------------------------------
\24\ Id. See, also, FTC, Office of Policy Planning, Bureau of
Competition, and Bureau of Economics, to Assemblyman Greg Aghazarian
re: California Assembly Bill No. 1960 (September 7, 2004) (concluding
that, if manufacturers learn the exact amount of the rebates offered by
their competitors through required PBM disclosures, then tacit
collusion among manufacturers is more feasible, which may lead to
higher prices for PBM services and drugs), available at https://
www.ftc.gov/sites/default/files/documents/advocacy_documents/ftc-
comment-hon.greg-aghazarian-concerning-ca.b.1960-requiring-pharmacy-
benefit-managers-make-disclosures-purchasers-and-prospective-
purchasers/v040027.pdf.
For these reasons, in public settings, we have provided rebate
information at an aggregate level only, to prevent reverse engineering
by competitors to learn our net pricing information for specific
products. We would be happy to work with the committee to provide this
information in a way that mitigates against competitive harms that
---------------------------------------------------------------------------
could arise from public disclosure of this information.
______
Questions Submitted by Hon. Robert Menendez
Question. When new products enter the market, do drug companies set
high initial prices and then provide deep rebates in order to gain
access to insurance plan's formularies?
Answer. We can only speak for Sanofi. Consistent with our pricing
principles, when Sanofi sets the price of a new medicine, we hold
ourselves to a transparent, rigorous, and structured process that
includes consultation with external stakeholders. In our view, an
objective measure of a new product's value considers the benefit to
patients, compared to a standard of care; the reduced need--and
therefore costs--of other health care interventions; and any increase
in quality of life and productivity. We believe our pricing reflects
these factors. We also consider factors such as the affordability for
patients and any unique factors specific to the medicine, like the need
to support ongoing clinical trials, implement important regulatory
commitments, or develop sophisticated patient support tools that
improve care management and help decrease the total cost of care.
Additionally, under our pricing principles, we limit annual list price
increases to the National Health Expenditure, which is CMS's projected
annual health-care spending growth rate. Since we established our
pricing principles in 2017, all price increases for our insulin
products have been at or below NHE.
Sanofi offers rebates to health plans and PBMs in order to help
secure and maintain favorable formulary positions. Our aim in these
negotiations is to establish affordable access to patients. Currently,
however, payers and PBMs inconsistently pass through to patients the
growing savings they receive from increased negotiated rebates and
discounts. Accordingly, despite increasing rebates and lower net
prices, out-of-pocket costs for many patients have continued to grow.
Sanofi supports policies that would pass through PBM rebate savings to
patients at the pharmacy counter in the form of lower cost-sharing.
Question. If CMS finalizes the rebate rule, do you anticipate
future products entering the market with significantly lower initial
list prices?
Answer. We can only speak for Sanofi. If (1) the proposed changes
to the anti-kickback statute safe harbors were codified, and (2)
Congress implemented similar changes to the commercial insurance
market, Sanofi would lower the list prices of its prescription
medications for products in competitive categories for which there is
currently a material difference between list price and net price on the
assumption that patient access and affordability would be improved.
Sanofi also supports policy changes that would de-link other payments
in the pharmaceutical supply chain from list price.
We support extending the intent behind the anti-kickback statute
safe harbor proposed rule to the commercial market so that incentives
are aligned across the marketplace. Together, we believe these changes
would facilitate Sanofi's ability to lower our list prices. However, we
recommend a step-wise approach, implementing changes to the commercial
market after the safe harbor rule is implemented on January 1, 2020.
Such an approach would provide an opportunity for stakeholders and the
government to identify unintended consequences, and address them, prior
to extending these policies to the commercial market.
We want to ensure that the new system achieves its goal of
improving affordability for patients. For instance, CMS should monitor
and evaluate how the new system affects formulary access, utilization
management, and patient cost-sharing, particularly with respect to
medicines with a lower list price. We also have concerns that changes
to the rebate system may lead to new fees, which would simply require
manufacturers to pay previous rebate values in new ways, rather than
creating savings for patients.
Without a better understanding of how these policy changes
ultimately would affect the competitive marketplace, patient access,
and affordability, we are unable to quantify the amount of any
potential list price reduction. When setting the price of a new
medicine, Sanofi's decision making will continue to be guided by our
pricing principles framework, which are discussed in Part 1 of this
response.
______
Questions Submitted by Hon. Thomas R. Carper
Question. What are your recommendations for lowering prices for the
40 percent of drugs that do not offer rebates in Medicare Part D? In
the health insurance plans that you offer your employees, do you ask
your insurers to pass through the full manufacturer rebates to the
beneficiaries?
Answer. To address prices of drugs that are not subject to rebates
in Medicare Part D, Sanofi supports policies that would incentivize
responsible pricing by tying smaller list price increases, or even list
price reductions, to both access and affordability for patients. Sanofi
also believes that value-based discounting arrangements could drive
down the price of prescription drugs in all contexts, regardless of the
existence of rebates, including for Medicare Part D. Sanofi favors
reforms in applicable statutes and regulations to permit manufacturers
and payers to adopt these arrangements more broadly than is the case
today.
The Sanofi medical plan is self-insured; as such, the company pays
the majority (approximately 80 percent) of the health-care claims that
are incurred by our employees and their dependents. Sanofi does not,
therefore, pass rebates through to members. Importantly, the Sanofi PPO
medical/Rx plan, which covers 90 percent of our employees who elect
medical coverage, maintains very low member cost-sharing for
prescriptions. For example, members incur no cost ($0 co-pays) for
Sanofi and partner prescription drugs. For non-Sanofi prescriptions,
the out-ofpocket expense varies for generic ($15/prescription),
preferred brand ($25/prescription) and non-
preferred brand ($40/prescription).
Question. The systems for pricing and distributing drugs are opaque
and difficult to understand. What are your recommendations for
increasing transparency in how your companies set the list prices for
drugs, and for improving transparency in the supply chain for
prescription drugs? Would you support federal standards for
transparency in setting the list prices for drugs?
Answer. Sanofi supports increased system-wide transparency, which
would improve competition by making relevant information available to
patients and policymakers. Two years ago, Sanofi announced our
progressive and industry-leading pricing principles to help
stakeholders understand our pricing decisions and to advance a more
informed discussion of issues related to the pricing of medicines.\25\
---------------------------------------------------------------------------
\25\ https://mediaroom.sanofi.com/en/articles/2017/sanofi-pricing-
principles-for-the-u-s/.
Sanofi's pricing policy includes a commitment to transparency in
how we price new medicines coming to the market for the first time.
When Sanofi sets the price of a new medicine, we hold ourselves to a
transparent, rigorous, and structured process that includes
consultation with external stakeholders. In our view, an objective
measure of a new product's value considers the benefit to patients,
compared to a standard of care; the reduced need--and therefore costs--
of other health care interventions; and any increase in quality of life
and productivity. We believe our pricing reflects these factors. We
also consider factors such as the affordability for patients and any
unique factors specific to the medicine, like the need to support
ongoing clinical trials, implement important regulatory commitments, or
develop sophisticated patient support tools that improve care
---------------------------------------------------------------------------
management and help decrease the total cost of care.
Tied to our pledge to keep annual list price increases at or below
the projected U.S. National Health Expenditure growth rate, Sanofi has
committed to providing its rationale should Sanofi increase any list
price above the NHE growth rate, highlighting clinical value, real
world evidence, regulatory change, new data, or other circumstances
that support our decision. Sanofi also has committed to disclose
annually our aggregate U.S. gross and net price changes from the prior
calendar year. These data may help illustrate how pricing changes
accrue to manufacturers versus others in the value chain, highlighting
our discrete role in the broader U.S. health care system.
We support Federal standards for transparency in the rationale for
price increases above a certain threshold, provided that there are
appropriate guardrails. Sanofi believes that increased transparency
should accomplish three goals:
(1) Preempt similar state laws, as was done with the Sunshine
Act, to create a consistent reporting process.
(2) Ensure information that if released publically could be
anti-competitive is kept confidential.
(3) Take a holistic approach to transparency, such as
requiring PBMs to disclose when the net price of a medicine has
declined and whether the increased rebates are used to lower
costs for patients or for other reasons.
We would be willing to work with this Committee on appropriate
policy solutions.
Question. In nearly every sector of the health-care industry,
Medicare, Medicaid, employers, and insurers are moving away from fee-
for-service payments to reimbursements based on value and performance.
Prescription drugs and medical devices were the glaring exceptions to
this trend until recently. How many of your drugs are included in
value-based contracts and how many patients are benefiting from them?
How do these value-based contracts work to lower drug prices for both
patients and taxpayers?
Answer. At this time, Sanofi has entered into value-based
arrangements involving three Sanofi products: Soliqua 100/33, Praluent,
and Kevzara. At present, we are not able to identify the specific
number of patients who benefit from these arrangements.
Sanofi believes that encouraging an environment that is supportive
of value-based arrangements would help promote drug affordability,
increase patient access to medicines, and improve patient adherence and
outcomes. Specifically, although there are different types of these
agreements, value-based contracts generally tie prices and payments to
the value of a particular prescription drug product--while potentially
reducing patient out-of-pocket costs and providing patients with better
access to the most innovative drug products. A manufacturer could, for
example, condition payment for a product on its success in meeting a
predefined clinical outcome, and this type of arrangement could make
drugs more affordable and lower costs throughout the system.
Question. Last year, Senator Portman and I did an investigation on
the pricing of an opioid overdose reversal drug called EVZIO,
manufactured by Kaleo. Kaleo increased the price of EVZIO from $575 in
2014 to $4,100 in 2017. We found that the best price Medicare was able
to get for EVZIO, about $4,000, was much higher than the price other
Federal programs and private insurers were able to get. It seemed that
Kaleo was able to get this higher price of $4,000 from Medicare by
helping doctors fill out paperwork showing that the drug was medically
necessary, even though there are cheaper alternatives on the market. As
a result of the investigation, Kaleo announced it will bring a generic
version of the drug to market at only $168 per pack. Are any of your
companies providing medical necessity paperwork to doctors in order to
get your drugs covered by Medicare?
Answer. No. Sanofi does not provide patient-specific clinical or
medical necessity information to physicians in furtherance of the
Medicare coverage of any of Sanofi's products for particular patients.
Consistent with guidance from the Department of Health and Human
Services Office of Inspector General (OIG), Sanofi typically provides
physicians with a copy of an applicable blank prior authorization form,
or in some cases, the form with only the physician's demographic
information filled out, along with separate instructions for filling
out the form. Also, in keeping with OIG guidance, Sanofi provides
physicians with template appeals letter for instances in which a
physician needs to appeal non-coverage for a Sanofi product. These
template letters do not include any patient medical information, and
instead are provided only as a guide for physicians to describe the
reasons that the patient requires his or her prescribed Sanofi
product.\26\ Similarly, Sanofi provides physicians with template
letters of medical necessity, which do not offer medical information on
specific patients. Instead, these documents provide a general framework
pursuant to which physicians may prepare their own, patient-specific
letters of medical necessity.\27\ These measures comply with the OIG
guidance in that they provide ``limited support'' in connection with a
purchase or prescribing decision for a Sanofi product.
---------------------------------------------------------------------------
\26\ See, e.g., https://www.visitspconline.com/servlet/
servlet.FileDownload?file=00P3600000Q1T
boEAF.
\27\ See, e.g., https://www.visitspconline.com/servlet/
servlet.FileDownload?file=00P3600000Q1T
byEAF.
Question. In 2017, the Rand Corporation estimated that biosimilar
drugs, which are competitors to complex, biologic drugs, could save the
United States more than $50 billion over the next decade. Some of you
have also argued that increasing the use of biosimilar drugs would help
lower drugs costs for consumers and taxpayers. What is delaying the
uptake of biosimilar drugs in the United States? What policies do you
---------------------------------------------------------------------------
recommend to increase the development of biosimilar drugs?
Answer. Sanofi supports the entry of biosimilar medicines in the
market after a reasonable period of time after the innovator biologic
is developed, which we believe is already reflected in U.S. law. There
are changes already in place that will help patients and taxpayers
realize the benefit of biosimilars. Specifically, in March 2020,
certain biologics that are currently regulated as drugs, including long
acting insulins, will be regulated as biologics and therefore will be
subject to the existing biosimilars pathway. We expect the change in
regulation to spur the continued development of substitutable or
interchangeable products, and to increase competition in this space
generally. Further, we believe that as health-care providers become
more familiar with biosimilars, the uptake of biosimilar drugs will
increase. Findings from a recent review show that there is an overall
lack of biosimilar familiarity among U.S. and European health-care
providers, leading to low prescribing comfort as well as safety and
efficacy concerns.\28\ The study concludes that, to realize the full
cost-saving potential of biosimilar medicines, clinician-directed
biosimilar education is necessary to address the gaps in biosimilar
knowledge, facilitate prescribing changes, and ultimately increase
biosimilar use.
---------------------------------------------------------------------------
\28\ See ``Factors Affecting Health Care Provider Knowledge and
Acceptance of Biosimilar Medicines: A Systematic Review,'' 25 J.
Managed Care & Specialty Pharm. 102-112 (Jan. 2019), available at
https://www.jmcp.org/doi/10.18553/jmcp.2019.25.1.102.
______
Questions Submitted by Hon. Benjamin L. Cardin
Question. The United States is one of the only countries in the
world to allow prescription drug manufacturers to advertise directly to
consumers through magazines, billboards, radio, and television
commercials. While I will not argue that it is beneficial to educate
consumers about an unfamiliar disease and encourage them to seek
medical help, most commercials from all of your companies recommend
asking about a specific brand name drug, not a medical condition.
Furthermore, even if your advertisements follow all FDA rules and list
medication side effects, they also almost always list these while a
smiling, apparently healthy person is walking on a beach.
Researchers say that this type of imagery, combined with viewing
hours of drug commercials each month, leads consumers to underestimate
the risks associated with medications. For the past decade, studies
have shown that aggressive direct-toconsumer advertising is associated
with rising drug prices and an increase in inappropriate drug
prescriptions.
Since researchers have concluded that consumers are
misunderstanding the benefits and risks described in your ads, what
further policies could help you and your colleagues ensure that you are
educating patients in a clear manner?
Answer. Sanofi believes DTC advertisements can play an important
role in both raising awareness about a disease and educating patients
about their treatment options. The benefits of DTC advertisements are
reflected in the results of a recent survey conducted by Princeton
Survey Research Associates International, which found that DTC
advertisements often prompt conversations about alternatives such as
generics or lifestyle changes, and prompt positive behaviors, such as
information-seeking and medicine adherence.\29\
---------------------------------------------------------------------------
\29\ https://www.phrma.org/report/2017-direct-to-consumer-
advertising-survey-results.
When DTC advertisements solely discuss a particular disease or
condition without mentioning or alluding to a specific drug, FDA
considers the advertisements disease awareness communications. Disease
awareness communications are not considered promotional labeling or
advertising, and thus such communications are not subject to the
requirements of the Federal, Food, Drug and Cosmetic Act (FDCA) or FDA
regulations. In contrast, DTC advertisements that make claims about a
drug are subject to requirements governing disclosure of risk and other
information, including a statutory requirement to include a brief
summary relating to side effects, contraindications, and effectiveness.
FDA's prescription drug advertising regulations distinguish between
print and broadcast advertisements, which require a ``brief summary''
for print advertisements and what is referred to as a ``major
statement'' of risks for broadcast advertisements. FDA regulations also
set forth additional requirements for information to be included in
both print and broadcast advertisements. Certain broadcast
advertisements, including the initial television advertisement for a
prescription drug and all television advertisements for prescription
drugs subject to a Risk Evaluation Mitigation Strategy with elements to
assure safe use, are subject to pre-dissemination review by FDA. Even
where a television advertisement is not subject to mandatory review,
sponsors may elect to voluntarily submit the advertisement to FDA for
---------------------------------------------------------------------------
advisory review.
While the time-limited nature of broadcast DTC advertisements can
present challenges in ensuring a drug advertisement presents all
information required by the FDCA and FDA regulations in a manner easily
digestible to a consumer, or even HCP, audience, Sanofi strives to
disseminate balanced DTC advertisements that clearly and effectively
communicate a product's benefits and risks. To that end, prior to
airing any DTC television advertisement, Sanofi submits each
advertisement to FDA for pre-dissemination review and incorporates
FDA's comments, even when such review is not required for the
advertisement in question. To further the objective of ensuring that
DTC advertisements educate consumers about potential treatment options
in a non-misleading manner, we believe industry would benefit from a
regulatory framework that allows for greater flexibility in the risk
and other information required to be included in broadcast
advertisements, including, for example, the flexibility to focus on
select significant risks in the advertisement itself while directing
consumers to a website for a more fulsome discussion of a product's
risks. FDA has acknowledged that its regulations provide ``only limited
flexibility'' for risk disclosure in broadcast advertisements. Thus,
allowing for greater flexibility in content control in DTC
advertisements would likely require amending existing FDA regulations,
as well as potentially the underlying statutory provisions governing
the information required to be disclosed in advertisements.
pharmaceutical companies continue to raise prices
Question. As you are well aware, high prescription drug prices are
the number one concern for Americans and their families. According to
the Organization for Economic Cooperation and Development, the average
American spends around $1,208 annually on prescription drugs. There
have been several instances where brand name or even generic drugs that
have been on the market for years continue to increase in price.
One of the most well-known examples is Mylan's increase of the
price of EpiPen from less than $100 in 2007 to more than $600 in 2016.
Another example, is the ever-increasing price of insulin. Sanofi
increased the price of a vial of Lantus from $88.20 in 2007 to $307.20
in 2017. And those are just a small sample of price increases.
Why don't we see price decreases for drugs that have been on the
market for years without new formulations or added benefit?
Answer. Current regulations, including price reporting
requirements, create uncertainty about the implications of lowering a
list price. We are working with CMS on alternatives that could enable
us to put lower list price versions of our products on the market.
Until such system changes are implemented, we are working to improve
the affordability of our products for those who are uninsured or
underinsured through our many patient support programs.
It is important to note, as well, that revenues from existing
therapies are used to fund future R&D across therapeutic areas.
Sanofi's R&D strategy is to allocate resources to priority therapeutic
areas based both on scientific opportunity and unmet medical need,
leveraging multiple therapeutic modalities and accelerating early
development. Our R&D pipeline currently contains 81 projects, including
33 new molecular entities in clinical development, and 35 projects are
in Phase III or have been submitted to regulatory authorities. From
2008 to 2017, Sanofi invested over $55 billion dollars globally in R&D.
Last year we invested almost $7 billion globally, or approximately 24%
of our gross profits, in our research and development activities. We
expect to continue to spend around the same on R&D in the coming years.
pay for delay
Question. Pay for delay is a tactic that more and more branded drug
manufacturers have been using to stifle competition from lower-cost
generic manufacturers. This allows you to sidestep competition by
offering patent settlements that pay generic companies not to bring
lower-cost alternatives to market.
These ``pay-for-delay'' patent settlements benefit both brand-name
pharmaceutical companies by helping them avoid costly patent litigation
and general manufacturers by rewarding them a hefty sum to delay
entering the market with a cheaper drug alternative. However, these
deals do not benefit consumers. According to an FTC study, these
anticompetitive deals cost consumers and taxpayers $3.5 billion in
higher drug costs every year.
Does your company partake in pay-for-delay settlements?
Answer. No, Sanofi does not enter into ``pay for delay'' agreements
that prohibit generic drug or biosimilar development after the
expiration of a patent. Sanofi has reached settlements in patent
infringement cases, and these agreements have allowed the generic
company to commercialize its product before the expiration of the
applicable patent covering Sanofi's innovator product.
Question. Why would a pharmaceutical company enter into a pay-for
delay agreement?
Answer. We can only speak for Sanofi, and we do not enter into
``pay-for-delay'' settlement agreements.
Question. Do you think these agreements stifle competition and
prevent generic alternatives to your branded medications?
Answer. With respect to patent litigation, generally, Sanofi
believes it is inappropriate to presume that any settlement of patent
litigations related to pharmaceutical products is anticompetitive. Such
settlements are often the most efficient and effective way to resolve
disputes regarding patented drugs. Additionally, they often lead to the
earliest appropriate entry of generic products into the market thereby
benefiting patients--earlier than expiration of the relevant patents.
Each patent litigation and potential settlement presents unique factors
and must be considered individually and in light of the relevant
circumstances.
drug rebate rule
Question. In January, the Department of Health and Human Services'
(HHS) Office of Inspector General (OIG) promulgated a new regulation to
remove regulatory safe harbor protections under the Anti-Kickback
Statute (AKS) for rebates on prescription drugs rebates paid by
manufactures to PBMs under Medicare Part D and for Medicaid managed
care organizations (MCOs). The OIG proposal attempts to ban most
rebates by eliminating their regulatory protections.
The rule is predicted to increase net drug costs in its early
years. The CMS actuaries estimate it would cost $196 billion over 10
years. Despite this high price tag, the beneficiary benefits are
limited. The proposed rule notes that under the CMS Actuary's analysis,
the majority of beneficiaries would see an increase in their total out-
of-pocket payments and premium costs; reductions in total cost sharing
will exceed total premium increases.
I wanted to ask a question about the administration's rebate rule,
which I understand that many of the drug manufacturers, and your main
trade association, strongly support. According to an analysis of the
rule by the Office of Actuaries at CMS, drug manufacturers are likely
to initially retain 15 percent of the current rebates as higher net
drug prices.
Given that estimate, can you provide the committee with any
assurances that prices will not increase under this proposed rule?
Answer. At this time, it is difficult to predict the effect of the
administration's proposed rule. It is our expectation that it will
result in lower out-of-pocket costs for patients by protecting only
manufacturer rebates to Medicare Part D and Medicaid MCO plans and
their PBMs that are reflected in the point-of-sale price. Without a
better understanding of how these policy changes ultimately would
affect the competitive marketplace, patient access, and affordability,
however, we are unable to provide assurances regarding how prices might
change.
We want to ensure that the new system achieves its goal of
improving affordability for patients. For instance, CMS should monitor
and evaluate how the new system affects formulary access, utilization
management, and patient cost-sharing, particularly with respect to
medicines with a lower list price. We also have concerns that changes
to the rebate system may lead to new fees, which simply require
manufacturers to pay previous rebate values in new ways, rather than
creating savings for patients.
______
Questions Submitted by Hon. Sherrod Brown
Question. According to an article recently published in the Journal
of the American Medical Association, medical marketers spent nearly $30
billion dollars in 2016, up from $17 billion in 1997. Direct-to-
Consumer (DTC) advertising had the biggest percentage increase: from
$2.1 billion, or 11.9% of all medical marketing, in 1997 to $9.6
billion, or 32% of total spending, in 2016.
Can each of you please provide what your ratio of spending on sales
and marketing to research and development is today?
Answer. In 2018, Sanofi's global ratio of spending on sales and
marketing \30\ to research and development was approximately 117
percent.
---------------------------------------------------------------------------
\30\ ``Sales and marketing'' includes, but is not limited to: sales
force, promotion, and marketing management.
---------------------------------------------------------------------------
price-gouging
Question. Sanofi, as I understand it, has made a pledge to the
public to limit its price increases to the national health expenditures
growth projection.
As the chair of the board of directors at PhRMA would you support
membership requirements that would cap annual price increases for drugs
sold as part of Medicare, similar to what Sanofi has pledged?
Given that PhRMA members are considering creating higher standards
for themselves, would you support an industry-wide standard on annual
price increases that applies to all pharmaceutical corporations,
whether or not they are members of PhRMA?
Answer. Dr. Brandicourt appeared before the committee on behalf of
Sanofi; we cannot speak on behalf of PhRMA or any other company. We
note that pricing discussions among PhRMA members, or pharmaceutical
manufacturers more generally, could implicate federal antitrust laws
and therefore would be inappropriate.
Two years ago, Sanofi announced our progressive and industry-
leading pricing principles, which include a pledge to keep annual list
price increases at or below the projected U.S. National Health
Expenditure (NHE) growth rate, as calculated by CMS. In 2018, all of
Sanofi's price increases across its medicines were consistent with
those pricing principles, as are all pricing actions taken in 2019.
Question. What policies would you propose to help ensure lower
launch prices for new drugs?
Answer. For Sanofi, the key requirement for any policy solution is
that it should result in improved access and lower prescription out-of-
pocket drug costs for patients, while maintaining incentives for
innovations. To reform the current misaligned incentives in the current
system, Sanofi supports de-linking payments to PBMs, payers and others
in the supply chain from the list price. Additionally, we support
policies that would incentivize lower launch prices, smaller list price
increases, or even list price reductions, by requiring health plans to
cover those medicines at an affordable co-pay level and only allow
access restrictions consistent with the label and accepted best
clinical practice.
transparency
Question. In many of your testimonies, you mentioned that the
current system of pharmacy benefit manager (PBM) back-end rebates do
not rarely results in a scenario where the PBM passes on savings to
consumers at the point of sale (POS). The Administration recently
proposed a rule to eliminate the anti-kickback statute safe harbor
protections for these drug rebates.
Do you agree that greater transparency should be required to
understand how manufacturers and PBMs are negotiating prices and
rebates to ensure that savings are passed down to beneficiaries?
Answer. Yes. Sanofi supports policies, such as those proposed in
the C-THRU Act, that would encourage or require PBMs and payers to be
transparent regarding how they use manufacturer rebates and pass
through manufacturer rebates to patient at point of sale in the form of
lower out-of-pocket costs.
As part of our pricing principles, Sanofi voluntarily discloses
annually our aggregate U.S. gross and net price changes from the prior
calendar year. These data help illustrate how pricing changes accrue to
manufacturers versus others in the value chain, highlighting our
discrete role in the broader U.S. health care system.
pbms
Question. An Axios article from March 7, 2019 highlights the fact
that, while ``pharmaceutical companies put a lot of the blame for high
drug prices on pharmacy benefit managers,'' many large pharmaceutical
companies ``rely on PBMs to manage their own health-care benefits.''
In your role as an employer, does your company contract with a
pharmaceutical benefit manager (PBM) to administer the prescription
drug benefits for your employees and negotiate lower drug costs on your
behalf?
Answer. Yes, we do.
Question. For those of you who do use a PBM to help manage the
prescription drug benefit for your employees, how do you utilize the
rebates your PBM negotiates to lower health-care costs or drug costs
for your employee plans and what does your company do with that
savings? Specifically, do the savings go toward lowing premiums?
Answer. The Sanofi medical plan is self-insured; as such, the
company pays the majority (approximately 80 percent) of the health-care
claims that are incurred by our employees and their dependents.
Therefore, Sanofi uses rebates to defray the overall cost of its health
plan, which allows us to keep plan costs stable for all participants.
We offer our employees generous healthcare coverage and have been
able to keep the deductibles of our PPO, which covers 90% of our
employees who elect medical coverage, at $200 for single coverage and
$400 for family coverage over the past few years. With respect to our
PPO prescription drug benefit, members incur no cost ($0 co-pays) for
Sanofi and partner prescription drugs. For non-Sanofi prescriptions,
the out-of-pocket expense varies for generic ($15/prescription),
preferred brand ($25/prescription) and non-preferred brand ($40/
prescription). The Sanofi plan's actuarial value is around 90%, which
puts it at the ``platinum'' level.
Question. For those of you who do use a PBM to help manage the
prescription drug benefit for your employees, does your PBM offer
point-of-sale rebates to your employees?
Answer. Yes, our PBM does offer point-of-sale rebates, however only
around 8 percent of its clients currently are enrolled in point-of-sale
rebates.
______
Questions Submitted by Hon. Sheldon Whitehouse
Question. Please describe any policy changes you support that would
result in your company lowering the list prices of its drugs.
Answer. For Sanofi, the key requirement for any policy solution is
that it should result in improved access and lower prescription out-of-
pocket drug costs for patients, while maintaining incentives for
innovations. To reform the current misaligned incentives in the current
system, Sanofi supports de-linking payments to PBMs, payers and others
in the supply chain from the list price. Additionally, we support
policies that would incentivize lower launch prices, smaller list price
increases, or even list price reductions, by requiring health plans to
cover those medicines at an affordable co-pay level and only allow
access restrictions consistent with the label and accepted best
clinical practice.
Sanofi also supports the intent behind legislation like the SPIKE
Act, which would impose price transparency requirements on companies
that increase the list price of a particular drug over a certain
threshold. We believe that increased transparency should accomplish
three goals: (1) preempt similar state laws, as was done with the
Sunshine Act, to create a consistent reporting process; (2) ensure
information that if released publically could be anti-competitive is
kept confidential; and (3) take a holistic approach to transparency,
such as requiring PBMs to disclose when the net price of a medicine has
declined and whether the increased rebates are used to lower costs for
patients or for other reasons.
Question. How much does your company's research and development
portfolio rely on taxpayer-funded research conducted by the National
Institutes of Health (NIH)? How many of your company's products are
based, at least in part, on NIH research, and how many are the result
of research funded solely by your company?
Answer. In identifying targets for new drugs, Sanofi relies on
global science, which often includes NIH-funded research. Sanofi has
collaborated with NIH on various research and development (R&D)
initiatives on projects related to HIV,
Epstein-Barr virus, influenza, and respiratory syncytial virus.
While there is no question that NIH plays a vital role in basic
research and early discovery, the majority of Sanofi's current
portfolio of products in the pre-development to development phases do
not rely on NIH funding. Sanofi reinvests a significant portion of its
revenue into the R&D of new or improved medicines and vaccines. Last
year, Sanofi globally spent almost $7 billion on R&D globally, an
increase of approximately 7 percent from 2017, which reflects our
commitment to bringing better therapies to patients. Sanofi plans to
maintain this level of R&D investment through 2021, and our R&D
pipeline now contains 81 projects, including 33 new molecular entities
in clinical development, and 35 projects that are in Phase III or have
been submitted to regulatory authorities. This investment means that
Sanofi potentially will seek approval for nine new medications in the
next three years, primarily in therapeutic areas where Sanofi sees the
greatest nexus between our expertise and patient need: diabetes,
vaccines, oncology, immunology, rare diseases, and rare blood
disorders.
Question. In each of the last 5 years, how much has your company
spent on research and development versus the advertising and marketing
of your products?
Answer.
------------------------------------------------------------------------
Research and Advertising and
USD \31\ Development Marketing \32\
------------------------------------------------------------------------
2018 $6,954,920,000 $4,519,400,000
------------------------------------------------------------------------
2017 $6,238,080,000 $3,764,280,000
------------------------------------------------------------------------
2016 $5,689,200,000 $3,006,300,000
------------------------------------------------------------------------
2015 $5,590,200,000 $2,773,100,000
------------------------------------------------------------------------
2014 $6,160,440,000 $2,673,000,000
------------------------------------------------------------------------
\31\ Sanofi reports its financials in Euros. All financial figures
reported in this document have been converted from Euros into U.S.
dollars. These are Sanofi global financial figures.
\32\ Includes global spending on ``promotion'' and ``marketing
management.''
Question. During the hearing, you mentioned that your company would
be likely to lower the list prices of its drugs if the recent proposal
by the Trump administration to change the current system of rebates was
extended to the private market.
If the policy was extended to the private market, how large would
the list price reductions be relative to the size of the rebates your
company is currently providing?
Answer. If (1) the proposed changes to the anti-kickback statute
safe harbors were codified, and (2) Congress implemented similar
changes to the commercial insurance market, Sanofi would lower the list
prices of its prescription medications for products in competitive
categories for which there is currently a material difference between
list price and net price on the assumption that patient access and
affordability would be improved. Sanofi also supports policy changes
that would de-link other payments in the pharmaceutical supply chain
from list price.
We support extending the intent behind the anti-kickback statute
safe harbor proposed rule to the commercial market so that incentives
are aligned across the marketplace. Together, we believe these changes
would facilitate Sanofi's ability to lower its list prices. However, we
recommend a step-wise approach, implementing changes to the commercial
market after the safe harbor rule is implemented on January 1, 2020.
Such an approach would provide an opportunity for stakeholders and the
government to identify unintended consequences, and address them, prior
to extending these policies to the commercial market.
We want to ensure that the new system achieves its goal of
improving affordability for patients. For instance, CMS should monitor
and evaluate how the new system affects formulary access, utilization
management, and patient cost-sharing, particularly with respect to
medicines with a lower list price. We also have concerns that changes
to the rebate system may lead to new fees, which simply require
manufacturers to pay previous rebate values in new ways, rather than
creating savings for patients.
Without a better understanding of how these policy changes
ultimately would affect the competitive marketplace, patient access,
and affordability, we are unable to quantify the amount of any
potential list price reduction.
Question. How will this proposal affect how your company sets the
list prices for new drug products?
Answer. When setting the price of a new medicine, Sanofi's decision
making will continue to be guided by our pricing principles framework.
When Sanofi sets the price of a new medicine in the U.S., we hold
ourselves to a rigorous and structured process that includes
consultation with external stakeholders. In our view, an objective
measure of a new product's value considers the benefit to patients,
compared to a standard of care; the reduced need--and therefore costs--
of other health-care interventions; and any increase in quality of life
and productivity. We believe our pricing reflects these factors. We
also consider factors such as the affordability for patients and any
unique factors specific to the medicine, like the need to support
ongoing clinical trials, implement important regulatory commitments, or
develop sophisticated patient support tools that improve care
management and help decrease the total cost of care.
To the extent reform of the anti-kickback statute safe harbors
results in changes in the competitive marketplace, patient access, and
affordability, the rule is likely to affect our pricing of new
medicines.
Question. If the proposal is finalized and not extended to the
private market, will your company make any list price reductions? If
so, how large would the reductions be relative to the size of the
rebates your company is currently providing?
Answer. Sanofi is committed to working with other stakeholders to
lower patient out-of-pocket costs, and the company will carefully
review any final rule issued by HHS regarding the Anti-Kickback Statute
and its safe harbor regulations--with the goal of providing point-of-
sale discounts to patients, in accordance with law, to lower their out-
of-pocket costs.
Without addressing the currently misaligned incentives across all
payer channels, it is unclear the extent to which Sanofi would be able
to lower list prices. We would need a better understanding of how the
rule ultimately would affect the competitive marketplace, patient
access, and affordability in both the government and commercial
insurance markets in order to quantify the amount of any potential list
price reduction.
______
Question Submitted by Hon. Maggie Hassan
Question. In June of 2018, the Medicaid and CHIP Payment and Access
Commission (MACPAC) unanimously recommended under Recommendation 1.1 in
their annual report to Congress that Congress remove the statutory
requirement that manufacturers blend the average manufacturer price
(AMP) of a brand drug and its authorized generic.\33\
---------------------------------------------------------------------------
\33\ MACPAC, ``Improving Operations of the Medicaid Drug Rebate
Program,'' https://www.macpac.gov/wp-content/uploads/2018/06/Improving-
Operations-of-the-Medicaid-Drug-Rebate-Program.pdf.
This requirement created an unintended loophole. Rather than use
the price of the authorized generic, drug companies can sell its
authorized generic to a corporate subsidiary at an artificially lower
price, and use that lower price to bring down the AMP, which in turn
---------------------------------------------------------------------------
lowers the rebate obligation.
Does your company engage in this practice? Has your company ever
engaged in this practice in the past?
Answer. Sanofi currently markets authorized generic versions of
certain of its products, through corporate affiliates, under separate
National Drug Codes (``NDC''). Sanofi's general approach for these
products has been that if two products share the same drug, dosage
form, and strength, and both are sold by the same corporate entity or
Sanofi business unit, then their sales are blended for the calculation
of AMP and Best Price.
______
Questions Submitted by Hon. Catherine Cortez Masto
Question. In October you were asked by a reporter whether you would
lower the price of insulin if point-of-sale rebates were enacted. Your
response was, ``We realize that some medicines remain economically out
of reach for some patients. We take this issue seriously and will
continue to seek innovative solutions to help make insulins more
affordable for patients.'' Please answer that question more
specifically: will you lower your list price in response to the rebate
rule?
Answer. If (1) the proposed changes to the anti-kickback statute
safe harbors were codified, and (2) Congress implemented similar
changes to the commercial insurance market, Sanofi would lower the list
prices of its prescription medications for products in competitive
categories for which there is currently a material difference between
list price and net price on the assumption that patient access and
affordability would be improved. Sanofi also supports policy changes
that would de-link other payments in the pharmaceutical supply chain
from list price.
We support extending the intent behind the anti-kickback statute
safe harbor proposed rule to the commercial market so that incentives
are aligned across the marketplace. Together, we believe these changes
would facilitate Sanofi's ability to lower its list prices. However, we
recommend a step-wise approach, implementing changes to the commercial
market after the safe harbor rule is implemented on January 1, 2020.
Such an approach would provide an opportunity for stakeholders and the
government to identify unintended consequences, and address them, prior
to extending these policies to the commercial market.
We want to ensure that the new system achieves its goal of
improving affordability for patients. For instance, CMS should monitor
and evaluate how the new system affects formulary access, utilization
management, and patient cost-sharing, particularly with respect to
medicines with a lower list price. We also have concerns that changes
to the rebate system may lead to new fees, which simply require
manufacturers to pay previous rebate values in new ways, rather than
creating savings for patients.
Without a better understanding of how these policy changes
ultimately would affect the competitive marketplace, patient access,
and affordability, we are unable to quantify the amount of any
potential list price reduction.
Question. As a portion of your revenue, for what percentage of the
drugs in your portfolio do you offer no rebates? Based on the drugs in
your pipeline, do you foresee that portion growing? For those drugs is
your list price equal to your net price?
Answer. When considering rebates paid by Sanofi in any form,
including those that are government-mandated, Sanofi offers rebates on
all of its products at some point in the distribution channel. We do
not expect that this will change based on the company's pipeline.
Question. Do you invest more in R&D than you generate in U.S. sales
revenue? Please include specific figures.
Answer. In 2018, Sanofi spent $6,954,920,000 globally on R&D, a 7-
percent increase over 2017 and approximately 24 percent of its global
gross profits. In 2018, Sanofi's U.S. net sales were $13,617,200,000.
Answer. Do you invest more in R&D than you spend on marketing and
administration? What company functions do you consider to be included
in administration? Please include specific figures.
Answer. Yes. In 2018, Sanofi spent $6,954,920,000 globally on R&D,
and $6,921, 880,000 globally on marketing and administration.
``Administration'' includes, but is not limited to: finance, human
resources, external affairs, legal, business services, business
development, and internal audit.
Question. Do you invest more in R&D than you spend on marketing and
sales? What company functions do you consider to be included in sales?
Please include specific figures.
Answer. In 2018, Sanofi spent $6,954,920,000 globally on R&D, and
$8,154,980,000 globally on marketing and sales. The primary function
included in ``sales'' is the sales force.
Question. Why do you advertise for the drugs you manufacture? What
factors do you consider in choosing which drugs you advertise?
Answer. Sanofi believes that advertising is an important tool to
inform and educate the public about its medicines, while raising
general awareness of diseases that are frequently surrounded by stigma.
We are committed to ensuring that our advertisements provide accurate,
accessible, and useful health information to patients and consumers.
Our communications are designed to educate patients and consumers about
serious health conditions and the availability of treatments, and to
encourage them to seek guidance from their healthcare professionals
about appropriate treatment. We consider a variety of factors in
determining whether and how to advertise a product, including patient
needs and the unique aspects of an individual product or disease state.
______
Independent Medical Education Grants
1st Jan 2015-30th June 2015
Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education
activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and
consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged.
Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.
----------------------------------------------------------------------------------------------------------------
Funding Amount
Recipient Name(s) \1\ Activity Title \2\
----------------------------------------------------------------------------------------------------------------
Academic CME, LLC Postgraduate Incorporating Advancements in Monoclonal Antibody $298,600.04
Institute for Medicine Therapeutics into Patient Management Strategies Collaboration \3\
within Dyslipidemia
Academy of Managed Care Pharmacy The unmet needs of multiple sclerosis, and the $6,500
principles and current evidence in the use of DMTs
Admin of the Tulane Educational Fund 7th Annual Tulane Symposium on Thyroid And Parathyroid $10,000.00
on behalf of TUHSC CCE Diseases Collaboration \3\
AKH Inc. Advancing Knowledge and American Society for Preventive Cardiology: Annual $10,000.00
Healthcare Cardiovascular Disease Prevention Conference
American Academy of Physician AAPA Conference 2015--Neurology Track $5,000.00
Assistants
American Academy of Physician AAPA Conference 2015--Endocrinology Track $5,000.00
Assistants
American Academy of Physician AAPA Conference 2015--Nephrology Track $3,500.00
Assistants
American Association of Clinical Georgia-AACE 2015 Annual Meeting $7,500.00
Endocrinologists
American Association of Clinical Lipids Sessions at Endocrine University: Disease $5,000.00
Endocrinologists Management and Technology Skills for Endocrinology
Fellows In Training
American Association of Clinical Southern States--AACE 2015 Annual Meeting $7,500.00
Endocrinologists
American Association of Clinical Diabetes Sessions At Endocrine University: Disease $25,000.00
Endocrinologists Management and Technology for Endocrinology Fellows
in Training
American Association of Clinical AACE 24th Annual Scientific & Clinical Congress $47,350.00
Endocrinologists (Thyroid Sessions)
American Association of Clinical AACE 24th Annual Scientific & Clinical Congress $47,350.00
Endocrinologists (Diabetes Session)
American Association of Clinical Diabetes Sessions at AACE 24th Annual Scientific And $47,350.00
Endocrinologists Clinical Congress
American Association of Clinical Mid Atlantic Chapter of The American Association of $7,500.00
Endocrinologists Clinical Endocrinologists 13th Annual Meeting &
Symposium
American Association of Clinical Mid Atlantic Chapter of the American Association of $7,500.00
Endocrinologists Clinical Endocrinologists 13th Annual Meeting 7
Symposium
American Association of Clinical California Chapter of The American Association of $20,000.00
Endocrinologists Clinical Endocrinologists Presents: Hot Topics in
Diabetes and Endocrinology for Primary Care
American Association of Clinical LDL-C Reduction in the High-Risk Patient: How Low $261,057.00
Endocrinologists Medtelligence, LLC Should We Go? Collaboration \3\
Association of Diabetes Educators Diabetes Education and People with Diabetes: Partners $15,000.00
in the Winners Circle, New York American State
Regional Conference
American Association of Diabetes AADE 2015--Rumor has It? Demystifying the Use of Basal $321,895.00
Educators Insulin in Type 2 Diabetes Management
American College of Cardiology ACC Rise and Shine Series: Just The Facts--An $55,000.00
Foundation Objective Overview of PCSK9 Inhibitors Collaboration \3\
American College of Cardiology Lipid Management Today: Unanswered Questions and $125,000.00
Foundation Med-IQ, LLC Unquestioned Answers Collaboration \3\
American College of Surgeons American 36th Annual Meeting of the American Association of $5,000.00
Association of Endocrine Surgeons Endocrine Surgeons
American Diabetes Association 2015 Professional Educator Conference $5,000.00
American Diabetes Association ADA Inside: The Intelligent Use of Insulin Inspiring $387,602.00
System Improvement with Diabetes Education
American Diabetes Association Diabetes is Primary $166,545.00
American Health Resources, Inc. Focus on the Patient with Diabetes: Managing Co- $6,000.00
Morbidities and Improving Outcomes
American Health Resources, Inc. Identification and Resolution of Injection Technique $12,600.00
Barriers in Patients with Diabetes
American Nephrology Nurses' The Questions, Myths, and Facts Regarding the $160,000.00
Association Rockpointe Corporation Management Of CKD-MBD
American Neurological Association 2015 American Neurological Association 140th Annual $25,000.00
Meeting
American Society of Nephrology ASN Highlights 2015 $15,000.00
American Society of Nephrology AST/ASN Transplant Nephrology Core Curriculum $15,000.00
Ann & Robert H. Lurie Children's Lysosomal Storage Disease Training Program for Genetic $75,000.00
Hospital of Chicago Counselors
Annenberg Center for Health Sciences Diabetes Monitor Conference Coverage (ADA 2015) $50,000.00
at Eisenhower
Association of Black Cardiologists, Lipid Management and Cardiovascular Risk Reduction: $380,000.00
Inc. National Association for The Evolving Treatment Paradigm Collaboration \3\
Continuing Education
Association of Family Practice Chronic Kidney Disease $4,000.00
Physician Assistants
Association of Family Practice Joint Injection $6,100.00
Physician Assistants
Association of Family Practice Diabetes--What Do I Prescribe After Metformin? $3,150.00
Physician Assistants
Baylor University Medical Center dba New Treatment Paradigms for Castrate Resistant $15,330.00
A. Webb Roberts Center CancerNet, Prostate Cancer
LLC
Baylor University Medical Center dba New Treatment Paradigms for Castrate Resistant $15,330.00
A. Webb Roberts Center CancerNet, Prostate Cancer
LLC
BIDDM Beth Israel Deaconess Medical Center Renal Division $5,500.00
Grand Rounds and Renal Biology Conference Series
Board of Regents of the University of 18th Annual Primary Care Update $6,000.00
Oklahoma Health Science
Brigham and Women's Hospital Workshop Kidney Disease Screening And Awareness Program (KDSAP) $29,000.00
New Chapters Training Workshop
California Academy of Family The Family Medicine Clinical Forum $20,000.00
Physicians
Cardiovascular Institute of Sarasota 11th Annual Cardiovascular Symposium Cardiology Update $10,000.00
Foundation for Education Florida 2015: Time to Focus on Early Cardiovascular Disease Collaboration \3\
Medical Association Prevention
Children Health and Research Fellowship in Inherited Metabolic Disorders and $75,000.00
Foundation, Inc. Lysosomal Storage Disorders
Children's Hospital of Philadelphia Genetic Counselor Fellowship in lysosomal storage $75,000.00
Foundation disorders
Cincinnati Children's Hospital Genetic Counseling Fellowship in the Lysosomal Storage $74,987.00
Medical Center Disorders
Cleveland Clinic Educational Nephrology Update2015 $10,000.00
Foundation
Cleveland Clinic Educational Diabetes and Thyroid Update--A Multidisciplinary $10,000.00
Foundation Symposium on Diabetes and Thyroid Diseases
Cleveland Clinic Educational 2015 Diabetes Day 20th Annual Symposium: Diabetes $10,000.00
Foundation Through The Ages
Cleveland Clinic Educational 18th Annual Intensive Review of Endocrinology and $20,000.00
Foundation Metabolism
Cleveland Clinic Educational Mellen Center Update In Multiple Sclerosis $5,000.00
Foundation
Colorado Foundation for Medical Care 3rd Annual Convention of The Cardio Renal Society of $30,000.00
Cardio Renal Society of America America
CME Outfitters, LLC Risky Business: Understanding and Attenuating Risk $207,090.00
Associated with Disease-Modifying Therapy in
Relapsing-Remitting Multiple Sclerosis
Consortium of Multiple Sclerosis Expert Debates in Multiple Sclerosis: Opposing Views $125,000.00
Centers in Management
Consortium of Multiple Sclerosis PatientGPS TM: Clinical Paths to Explore Treatment $100,000.00
Centers Options and Individualize Therapy in Multiple
Sclerosis
Consortium of Multiple Sclerosis A Practical Guide to Rehabilitation in MS (an AIMS $190,765.00
Centers Primer)
Creative Educational Concepts, Inc. Achieving Equilibrium in Diabetes with GLP-1 Receptor $142,875.00
Agonists: Avoiding Hypoglycemia When Treating
Postprandial Hyperglycemia
Duke University Residency in Medical Genetics $70,853.52
Educational Concepts Group, LLC Advances in The Management Of GU Cancers: Highlights $22,000.00
From the 2015 Genitourinary Cancers Symposium
Educational Review Systems National Effective Management of Gaucher Disease? A Primer for $35,000.00
Home Infusion Association Home and Specialty Infusion Clinicians
Emory Genetics Laboratory Multidisciplinary Extramural LSD Educational Talks on $24,200.00
Lysosomal Storage Diseases
Emory Genetics Laboratory The Paul M. Fernhoff Genetic Counseling Fellowship in $75,000.00
the Lysosomal Storage Disorders
Emory University Emory Latino Diabetes Education Program $241,455.00
Endometriosis Association Inc. Adhesion Awareness for Doctors and Patients: $54,591.48
Communicating the Significance of Adhesion Disease
Fabry Support & Information Group Eyes On Fabry-Illinois College of Optometry--Chicago $2,550.00
Fabry Support & Information Group Eyes on Fabry Southern College of Optometry Memphis, $2,500.00
TN
Florida Academy of Physician The Good, the Bad, and the Latrogenic: Renal $9,000.00
Assistants Medication Dosing?
Foundation for Care Management Diabetes Mellitus: Detecting and Treating Type I & II $50,000.00
Patients in a Type II Global Epidemic
Glens Falls Association for the Blind Interesting Cases - Lessons Learned the Hard Way $23,352.24
Horizon CME, Inc. PCSK9 Inhibitors: Where Do They Fit in The Treatment $163,300.00
of Dyslipidemia? Collaboration \3\
Hospital for Special Surgery Neurological Directions 2015: Update in Neuromuscular $5,000.00
Medicine
Humboldt-Del Norte Consortium for Multiple Sclerosis $4,100.00
Continuing Medical Education
Icahn School of Medicine at Mount Multiple Sclerosis and its Mimics $1,920.00
Sinai
Imedex, LLC Unraveling The Complexities of Treating Metastatic $198,856.00
Colorectal Cancer with Anti-Angiogenesis Agents Collaboration \3\
Across Multiple Lines of Therapy
Institute for Medical and Nursing New Developments in Insulin Therapy: Expert Answers To $222,519.33
Education Your Clinical Questions--A Regional Meeting Series
Johns Hopkins University The 11th Annual Johns Hopkins Multiple Sclerosis $210,000.00
Symposium Series
Johns Hopkins University Advanced The Future of Lipid Management: New Perspectives & $174,400.00
Studies in Medicine Targets For LOWERING LDL-C
Johns Hopkins University Medical Innovations in Prandial Glucose Control for Patients $133,000.00
Logix, LLC with Type 2 Diabetes
Kidneys for Life Fund Raising for 4th Update on Fabry Nephropathy; Manchester UK, June 1- $75,000.00
MINT 2, 2015
Joslin Diabetes Center, Inc. Complementary Treatments To Enhance Insulin Efficacy: $392,463.00
Integrated Learning Partners, LLC Theory And Strategies
Letters & Sciences University of MS Leadership Summit 2015-2016 $205,000.00
North Texas Health Science Center at
Fort Worth
Medical Education Resources CMEology, Shifting the Treatment Paradigm for Multiple $100,000.00
LLC Sclerosis: Advances in Pathophysiology and Emergence
of Novel Disease Modifying Therapies
Medical Education Resources Tarsus Best of the Cardiometabolic Health Congress: Regional $80,000.00
Cardio Inc. dba Health Science Media Conference Series and Virtual Highlights Activity
with Extended Distribution on Medscape Education
Medical Education Resources Tarsus Best of the Cardiometabolic Health Congress: Regional $65,000.00
Cardio Inc. dba Health Science Media Conference Series and Virtual Highlights Activity
with Extended Distribution on Medscape Education
Medical Education Resources Tarsus Novel Therapies for LDL-C Lowering in the Fight $250,000.00
Cardio Inc. dba Health Science Media Against Residual ASCVD Risk
Medical Learning Institute, Inc. Understanding the Evolution of MS Care: Optimizing $43,186.00
Therapeutic Decision Making
Medical University of South Carolina 10th Annual Symposium on the Nephrology Update for $2,500.00
Primary Care and Hospital Medicine
Med-IQ, LLC The Top 10 Challenges in Managing High Risk Prostate $192,276.00
Cancer
Med-IQ, LLC Advancing the Management of Gaucher's Disease $200,957.00
Med-IQ, LLC The Evolving Therapeutic Landscape In Gaucher's $147,963.00
Disease
Med-IQ, LLC The Evolution of Science, Medicine and Patient $315,090.00
Centered Care in CKD-MBD
Med-IQ, LLC Medical Insiders: Emerging Science for the Management $100,000.00
of Metastatic Castration-Resistant Prostate Cancer
Med-IQ, LLC Moving Beyond the Guidelines in the Management of $135,207.00
Castration-Resistant Prostate Cancer
Med-IQ, LLC New Horizons In Dyslipidemia Management: An $121,862.00
Interactive Digital Publication Collaboration \3\
Med-IQ, LLC Taking Control of Your New and Emerging Insulins: The Top 10 Things You Need $568,909.00
Diabetes to Know About Biosimilars and Other Novel Insulins on
the Therapeutic Horizon
Med-IQ, LLC Taking Control of Your Practical Strategies to Address Postprandial $722,362.00
Diabetes Hyperglycemia in Type 1 and Type 2 Diabetes: An Collaboration \3\
Important Aspect of Overall Diabetes Care
Med-IQ, LLC Taking Control of Your Making the Connection: Advancing Clinical Care and $200,000.00
Diabetes Improving Adherence for Patients with Diabetes
Medscape, LLC Advances in Ultra Rapid-Acting Insulin $732,600.00
Medscape, LLC A Balancing Act in CKD-MBD: Managing Hyperphosphatemia $377,300.00
and Cardiovascular Disease
Medscape, LLC Anti-Vegf Therapy in Metastatic Colorectal Cancer: $99,000.00
Where Are We and What Do We Know? Collaboration \3\
Medscape, LLC The Future of Basal Insulin: Improving Patient $200,000.00
Outcomes by Addressing Unmet Needs
Medscape, LLC Combination Therapy in The Modern T2D Era $170,000.00
Medscape, LLC Long-Term Efficacy and Safety of Phosphate Binders for $209,500.00
Hyperphosphatemia in CKD-MBD
Medscape, LLC Comprehensive Management of CKD-MBD: Hands-on Case $192,000.00
Studies
Medscape, LLC An Update on LDL-C Management: Current Guidelines, $450,000.00
Treatment, and Future Recommendations
Medscape, LLC Highlights on Multiple Sclerosis Management From AAN $100,000.00
2015
Michigan Council of Nurse Update in Arthritis Medication: Clearing Up the $1,600.00
Practitioners Confusion Michigan Council of Nurse Practitioners
Annual Conference
Michigan State Medical Society 2015 Diabetes and Lipid Updates $5,000.00
Minnesota Optometric Association Eyes on Fabry Minnesota Optometric Association's $5,100.00
Fabry Support & Information Group Metro Society
Montefiore Medical Center Multiple Sclerosis: Exploring Treatment Options and $85,000.00
Individualizing Therapy
National Association of Managed Care Individualizing Treatment Strategies to Improve $57,000.00
Physicians, Inc. Patient Outcomes in the Management of Type 2 Diabetes
(T2DM)
National Committee for Quality Strategies for Success As A Patient-Centered Medical $100,000.00
Assurance (NCQA) Med-IQ, LLC Home--Diabetes
National Committee for Quality Strategies for Success As A Patient-Centered Medical $250,000.00
Assurance (NCQA) Med-IQ, LLC Home--Dyslipidemia Collaboration \3\
National Comprehensive Cancer NCCN 20th Annual Conference General Session: Advancing $50,000.00
Network, Inc. the Standard of Cancer CareTM
National Kidney Foundation Getting Ahead of Metabolic and Mineral Disturbances in $350,850.00
the Management of CKD-MBD: A Focus on Management
Strategies
National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) $10,000.00
2015
National Kidney Foundation, Inc. 24th Annual Fellows Research Forum $5,000.00
National Kidney Foundation, Inc. Charlotte Patient Empowerment Workshop $3,500.00
National Lipid Association Lipid Academy Course Series of 3 $15,000.00
National Lipid Association Masters in Lipidology Course Series of 3 $15,000.00
National Lipid Association National Lipid Association's 2015 Scientific Meeting $55,000.00
Series
National Lipid Association National Lipid Association's 2015 Scientific Meeting $70,000.00
Series Collaboration \3\
National Lipid Association 2015 National Lipid Association's Masters in $30,000.00
Lipidology and Lipid Academy Course Series Collaboration \3\
National Lipid Association Continuing Dyslipidemia: New Challenges and Emerging Options in $248,160.00
Education Alliance, LLC Lowering CVD RISK Collaboration \3\
National Tay-Sachs & Allied Diseases NTSAD Science Symposium & Workshop For Researchers & $10,000.00
Association, Inc. Healthcare Professionals
Nebraska Academy of Physician Renal Medication Dosing: The Good, the Bad and the $4,000.00
Assistants Latrogenic
New Jersey Academy of Family The Future of Basal Insulin: Improving Patient $399,550.00
Physicians Medscape, LLC Outcomes by Addressing Unmet Needs
New Mexico Optometric Association Genetics, Gene Therapy and Stem Cell Therapy in Eye $2,500.00
Inc. Care--The Future is Here
North American Center for Continuing (CRS 2015) Therapeutic Advances in $310,100.00
Medical Education, LLC Horizon CME, Hypercholesterolemia: Examining the Role of PCSK-9 Collaboration \3\
Inc. Inhibitors in Addressing Unmet Needs
North American Center for Continuing Overcoming Systemic Barriers To Optimized $274,805.00
Medical Education, LLC Horizon CME, Hematopoeitic Stem Cell Transplants
Inc.
Nurse Practitioner Alternatives Caring for the Patient 2015 $118,400.00
International Organization of
Multiple Sclerosis Nurses
Oakstone Publishing, LLC PeerVoice When Statins Are Not Enough: State of the Science in $256,350.00
America Limited Targeting Residual CV Risk Collaboration \3\
Ohio State University Neuromuscular Fellowship Program $75,000.00
Penn State University Antidote 15th Annual Diabetes Symposium $18,000.00
Education Company
Penn State University PeerView Peerview Inplay: ``A Game-Based Approach to Patient- $199,300.00
Institute for Medical Education, Centered Hypercholesterolemia Management'' Collaboration \3\
Inc.
Penn State University PeerView Peerview Video In session, ``Approved Disease- $139,375.00
Institute for Medical Education, Modifying Therapies For Multiple Sclerosis
Inc. Management: What Can We Learn From Recently Presented
Data?''
Penn State University PeerView Peerview Select-A-Scenario Live, ``Applying The Latest $74,210.00
Institute for Medical Education, Evidence To Guide Treatment Decision-Making in CRPC:
Inc. Real Cases, Difficult Choices--You Make the Call''
Pharmacy Times Office of Continuing Overcoming Challenges and Optimizing Insulin Therapy $216,040.00
Professional Education in Type 2 Diabetes
Pharmacy Times Office of Continuing A Guide to Optimizing Insulin Therapy in Type 2 $175,730.00
Professional Education Diabetes in the Managed Care Setting: Guidelines, New
and Emerging Insulin Analogs, and Challenges in
Management a Satellite Symposium at the 2015 AMCP
Annual Meeting
Pharmacy Times Office of Continuing Overcoming Challenges of Insulin Therapy in Type 2 $128,495.00
Professional Education Diabetes: Exploring Emerging Options
Physicians' Education Resource, LLC 8th Annual Interdisciplinary Prostate Cancer Congress $15,000.00
and Other Genitourinary Malignancies
Postgraduate Institute for Medicine C- New Frontiers and Treatment Advances for Atopic $350,000.00
MEducation Resources, LLC Dermatitis: Focus on the Role of Established and Collaboration \3\
Evolving Biologic Therapies for Patients with
Moderate-to-Severe and Treatment-Resistant Atopic
Dermatitis
Postgraduate Institute for Medicine 20th Anniversary Scottsdale Prostate Cancer Symposium $15,000.00
Diversified Conference Management,
Inc.
Postgraduate Institute for Medicine Differentiating Therapeutic Approaches for Relapsing $50,000.00
Enquiring Minds LLC Multiple Sclerosis
Primary Care Education Consortium Managing Postprandial Hyperglycemia in Type 2 $230,465.30
Diabetes: Combining Basal Insulin and Glucagon-Like
Peptide-1 Receptor Agonists
Primary Care Education Consortium Strategies for Intensifying Insulin Management in Type $275,955.15
2 Diabetes
PRIME Education Inc. (PRIME) Shifting Paradigms in Lipid Management $215,850.00
Collaboration \3\
PRIME Education Inc. (PRIME) New Therapies and Evidence for Patient-Centered $205,000.00
Hypercholesterolemia Care--Evolving Roles for Collaboration \3\
Pharmacists
PRIME Education Inc. (PRIME) Evidence-Based Decisions and a Mock P&T: The Role of $161,020.00
New LDL-C Reduction Therapy
Pri-Med Institute, LLC (d/b/a pmiCME) Optimizing Insulin Therapy for Patients with Type 2 $805,275.00
Diabetes: Existing Challenges and New Opportunities
for Improved Care
Pri-Med Institute, LLC (d/b/a pmiCME) Evolving Insulin Therapy: Optimizing Care Through $812,950.00
Horizon CME, Inc. Proper Selection & Use
Pri-Med Institute, LLC (d/b/a pmiCME) Combining GLP-1 Receptor Agonists With Basal Insulin: $797,090.00
Horizon CME, Inc. Realizing the Potential in Type 2 Diabetes
ProCE, Inc. Safe Use of Concentrated Insulin: Helping Patients to $87,575.00
Get It Right
Purdue University Medikinetics LLC Addressing Postprandial Glucose Excursions in Type 2 $363,648.00
Diabetes with Inhaled Insulin
Purdue University PeerView Institute Peerview Video Inexchange, ``Contemporary Multiple $38,000.00
for Medical Education, Inc. Sclerosis Management: Identifying and Overcoming
Challenges in the Managed Care Setting''
Regents of the University of 5th Annual UC Irvine Health Neuromuscular Colloquium $20,000.00
California
Regents of the University of Colorado Practical Ways to Achieve Targets in Diabetes Care $200,000.00
Regents of the University of Colorado Aspen Lung Conference Asthma 2015: Mechanisms to $5,000.00
Personalized Medicine/Thomas Petty Aspen Lung Collaboration \3\
Conference
Regents of the University of Pharmacotherapy of Inherited Metabolic Diseases PharmD $75,000.00
Minnesota Post-Doctoral Fellowship
Regents of the University of Transplant Immunosuppression 2015: Improving Outcomes $50,000.00
Minnesota
Research To Practice Data + Perspectives: Clinical Investigators Review Key $100,000.00
Publications And Current Cases in Advanced Prostate
Cancer? An Independent Satellite Symposium (ISS)
Series Held as Ancillary Events During The 2015
Genitourinary Cancers Symposium
Rush University Medical Center Rush University Medical Center Thyroid Cancer $20,000.00
Symposium
Saint Joseph's Regional Medical Chronic Kidney Disease for the Excellent Internist $2,700.00
Center
Saint Louis University School of Role of Inflammation in Neurologic & Psychiatric $5,850.00
Medicine Diseases: Implications for Clinical Practice
Scripps Health Type 2 DM-Emerging Therapeutic Trends in OADS and $330,257.00
Insulin Combinations 2015: ADA Symposium
Scripps Health Scripps' 35th Annual Conference: Clinical Hematology $15,000.00
and Oncology 2015
Scripps Health Advanced Therapeutic Interventions to Optimize Obesity $50,000.00
and DM Care
Scripps Health Emerging Therapeutic Trends to Optimize Diabetes Care $50,000.00
Society for Urologic Nurses and Expert Perspectives in Advanced Prostate Cancer: $30,000.00
Associates (SUNA) Plexus Practical Issues And Considerations for Nurses
Communications
Southeastern Regional Genetics Lysosomal Storage Disease Workgroup Meeting $2,000.00
Groups, Inc. (SERGG)
Southern Alliance for Physician Comprehensive Management of Thyroid and Parathyroid $8,500.00
Specialties CME Diseases
St. Dominic-Jackson Memorial Hospital Managing the Diabetes Spectrum in the Pediatric and $10,000.00
Adult Populations: Pre-Diabetes, Type 1 and Type 2
Stony Brook University Hands on Cadaver Training in Colon And Rectal Diseases $5,000.00
Robotics, Laparoscopy, Endoscopy, Abdominal Wall
Reconstruction
Swedish Medical Center Foundation Thyroid Cancer and Parathyroid Disease - A Practical $8,000.00
Approach
Texas Academy of Family Physicians Management of Chronic Kidney Disease in Primary Care $3,000.00
At The 2015 C. Frank Webber Lectureship
The Board of Trustees of the Fabry Nephrology Fellowship $75,000.00
University of Alabama for the
University of Alabama at Birmingham
The Board of Trustees of the UA for Mini-Symposium on Fabry Disease: Prospects for $17,536.00
the UA at Birmingham Improved Care
The Children's Mercy Hospital 12th Annual Great Plains Pediatric and Adult Endocrine $3,000.00
Symposium
The Endocrine Society Overcoming Barriers in Diabetes Management with $512,978.00
Individualized Treatment Strategies
The Endocrine Society PCSK9 Inhibition--A Revolution in Cholesterol Therapy $272,029.00
Collaboration \3\
The Endocrine Society Endo 2015 Thyroid Cancer Sessions $73,000.00
Collaboration \3\
The Endocrine Society Endo 2015 Diabetes Sessions $50,000.00
The Endocrine Society Maximizing Benefits of Incretin-Based Therapy in Type $135,056.00
2 Diabetes
The Endocrine Society American Diabetes Masters Series 2015--Solving The Puzzle: $235,867.00
Association of Diabetes Educators Current Approaches to Providing Quality T2DM Care
The France Foundation American Diabetes: Making the Right Choice in a Sea of $121,080.00
Academy of Physician Assistants Treatment Options
The France Foundation MS Clinical Dialogs: A Peer Discussion on Optimal $76,547.00
Treatment (Phase 2)
The Medical College of Wisconsin, The Eighth Annual Diabetes Symposium of Wisconsin $5,000.00
Inc.
The Ohio State University, Endocrine Update 2015 $10,000.00
The University of Texas MD Anderson 6th Current Concepts in the Management of Thyroid & $20,000.00
Cancer Center Parathyroid Neoplasms
The University of Texas Southwestern 37th Annual Carrell-Krusen Neuromuscular Symposium $20,000.00
Medical Center at Dallas
The University of Texas Southwestern Neuromuscular Medicine Fellowship $74,100.00
Medical Center at Dallas
The University of Toledo Outcomes of Myeloma: The Optimizing Sequenxe of $3,000.00
Treatments Including Transplant
Trustees of Columbia University in Renal Biopsy in Medical Diseases of the Kidneys $3,500.00
the City of New York
UC Regents Diabetes Update and Advances In Endocrinology And $7,500.00
Metabolism
UC Regents LSD Genetic Counseling Fellowship $75,000.00
Ultimate Medical Academy, LLC dba Cutting Edge Of Transplantation 2015 $30,000.00
Global Education Group American
Society of Transplantation
University of California Irvine Genetic Neuromuscular Diseases Fellowship $75,000.00
University of California, San Diego 34th Annual Advanced Nephrology: Nephrology for the $10,000.00
Consultant
University of California, San Diego 20th International Conference on Advances in Critical $5,000.00
CRRT Inc. Care Nephrology--AKI & CRRT 2015
University of Cincinnati CORE Medical Navigating the Evolving Therapeutic Landscape in $65,500.00
Education, LLC. Advanced Prostate Cancer
University of Cincinnati Paradigm Multidisciplinary Approach to Charting a Treatment $94,650.00
Medical Communications, LLC Course for Men with Metastatic Castration-Resistant
Prostate Cancer
University of Cincinnati Paradigm Advancing Treatment Strategies in Metastatic $95,000.00
Medical Communications, LLC Castration-Resistant Prostate Cancer: The Urologist's
Role
University of Florida Pediatric Neuromuscular Fellowship $75,000.00
University of Florida Foundation Southern Salt, Water, and Kidney Club 56th Annual $5,000.00
Scientific Meeting
University of Kansas Endowment Neuromuscular Review Course Series 2015 $60,000.00
Association
University of Massachusetts Medical MS Practice Update: Managing Walking Impairment, $30,000.00
School Neurogenic Bladder, Bowel and Sexual Dysfunction in
Multiple Sclerosis
University of Massachusetts Medical Understanding and Applying New Advances in Basal $303,080.00
School C-MEducation Resources, LLC Insulin Therapy
University of Massachusetts Medical The IQ&A Interactive Diabetes Intelligence Zone: Focus $152,000.00
School C-MEducation Resources, LLC on Inhaled Insulin, Combination Regimens, and
Postprandial Hyperglycemia
University of Massachusetts Medical Novel Mechanisms and Advancing Therapeutic Paradigms $336,000.00
School C-MEducation Resources, LLC for Optimizing LDL--Focused Management and Collaboration \3\
Cardioprotection in the Diabetic Patient
University of Massachusetts Medical New Frontiers and Treatment Advances for Atopic $366,000.00
School C-MEducation Resources, LLC Dermatitis: Focus on the Role of Established and Collaboration \3\
Evolving Biologic Therapies for Patients with
Moderate-to-Severe and Treatment-Resistant Atopic
Dermatitis
University of Massachusetts Medical New Frontiers and Treatment Advances in Rheumatoid $345,000.00
School C-MEducation Resources, LLC Arthritis: Focus on Mechanisms of Action, Cytokine- Collaboration \3\
Mediated Inflammation and the Evidence for Safe and
Effective Therapy for RA Through Inhibition of the IL-
6 Cytokine and Other Signaling Systems
University of Massachusetts Medical Novel Mechanisms and Advancing Therapeutic Paradigms $465,900.00
School C-MEducation Resources, LLC for Optimizing LDL-Focused Management of Primary and Collaboration \3\
Familial Hypercholesterolemia
University of Massachusetts Medical Understanding and Applying New Advances in Basal $971,000.00
School C-M Education Resources, LLC Insulin Therapy
University of Massachusetts Medical New Frontiers and Emerging Treatment Paradigms for $347,000.00
School C-MEducation Resources, LLC Optimizing LDL-Targeted Cardiovascular Risk Reduction Collaboration \3\
University of Miami Pediatric Nephrology Seminar XLII and Renal Pathology $10,000.00
Course
University of Pittsburgh Seventh Annual Multidisciplinary Thyroid Cancer $3,250.00
Symposium: Integrating the New ATA Guidelines into
Clinical Practice
University of Rochester, School of 2015 Society for Investigative Dermatology Annual $10,000.00
Medicine and Dentistry Society of Meeting Collaboration \3\
Investigative Dermatology
University of Southern California 37th Thyroid Symposium 2015: Practical Solutions To $10,000.00
Complex Clinical Problems
University of the Pacific Horizon Basal Insulin Therapy in the Treatment of Insulin $223,275.00
CME, Inc. Resistant Type 2 Diabetes: The Role of the Pharmacist
in Ensuring Their Safe and Effective Use
University of Virginia The 39th Annual Fitz-Hugh Symposium: Contemporary $10,000.00
Management and Cutting Edge Advances in
Otolaryngology--Head & Neck Surgery (Special Emphasis
on Laryngology and Head & Neck Endocrine Surgery)
USF Health Professions Conferencing 12th Annual Rocky Mountain Metabolic Syndrome $5,000.00
Corporation CEConsultants, LLC Symposium
VHA Inc. Treating Elevated LDL-C: Beyond Statins $85,000.00
Collaboration \3\
Wellmont Health System 13th Annual Diabetes Symposium $4,000.00
Yale University Diabetes 2015 $50,000.00
Yale University 2015 New England Thyroid Club Program $10,000.00
----------------------------------------------------------------------------------------------------------------
\1\ Applicant names are provided by the requestor. If applicants apply as a group for a single educational
activity; all applicants may be not be identified above. The Company funds other educational activities
(including fellowships and non-physician and patient education); all of which do not appear on this report,
but appear on other reports on this site.
\2\ ``Funding Amount'' is the amount that the Company funded during Q3, 2015 identified above based upon an
agreement. Recipients are required to return any unused funds. Information on unused funds returned by the
applicant on activities are not reported. ``Funding Amount'' does not include funds that may have been
provided by other affiliated Sanofi Company Entities (e.g., Sanofi Pasteur).
\3\ Collaboration (Shared) Funding--is the full amount of a grant funded under an agreement with Regeneron, some
or all of which may be shared between the collaborating entities.
Independent Medical Education Grants
1st Jul 2015-30th Sep 2015
Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education
activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and
consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged.
Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.
----------------------------------------------------------------------------------------------------------------
Funding Amount
Recipient Name(s) \1\ Activity Title ($) \2\
----------------------------------------------------------------------------------------------------------------
Academic CME, LLC APPLYING ADVANCED TREATMENT STRATEGIES WITHIN 326,430
RHEUMATOID ARTHRITIS Collaboration \3\
AKH Inc. Advancing Knowledge and FLORIDA SOCIETY OF RHEUMATOLOGY 2015 ANNUAL CME 5,000
Healthcare Florida Society of CONFERENCE
Rheumatology
American Academy of Continuing TRANSLATING CLINICAL DATA INTO NEPHROLOGY PRACTICE IN 149,800
Medical Education, Inc. THE MANAGEMENT OF HYPERPHOSPHATEMIA
American Association of Clinical HEARTLAND-AACE 6TH ANNUAL MEETING 7,500
Endocrinologists
American Association of Clinical ILLINOIS CHAPTER OF THE AMERICAN ASSOCIATION OF 5,000
Endocrinologists CLINICAL ENDOCRINOLOGISTS 5TH ANNUAL METING
American Association of Diabetes INHALED INSULIN A BREATH OF FRESH AIR FOR THE 62,800
Educators Horizon CME, Inc. TREATMENT OF DIABETES
American Diabetes Association 30TH ANNUAL CLINICAL CONFERENCE ON DIABETES: BEYOND 25,000
THE NUMBERS
American Diabetes Association DIABETES AND ENDOCRINE DISORDERS FOR THE GENERALIST 5,000
AND SPECIALIST
American Diabetes Association TRANSITIONS OF CARE THROUGH THE DIABETES LIFESPAN 5,000
American Society of Nephrology ASN BOARD REVIEW COURSE AND UPDATE 15,000
American Society of Nephrology CALCIUM OR NO CALCIUM: THAT IS THE QUESTION 125,825
American Urological Association ESTABLISHING AN ADVANCED PROSTATE CANCER CLINIC: A 60,000
Education & Research, Inc. PRACTICAL GUIDE FOR THE UROLOGY CLINIC
Association of Family Practice JOINT ASPIRATION/INJECTION WORKSHOP 5,300
Physician Assistants
Cardiovascular Society of Buffalo and UNDERSTANDIJG FABRY DISEASE FROM A CARDIAC PERSPECTIVE 7,000
Western NY SUNY AT BUFFALO CME
OFFICE
Cleveland Clinic Educational CURRENT AND FUTURE THERAPEUTIC OPTIONS TARGETING 80,000
Foundation RESIDUAL CVD RISK: EMERGING THERAPIES FOR THE Collaboration \3\
TREATMENT OF DYSLIPIDEMIA
CME Outfitters, LLC RISKY BUSINESS: UNDERSTANDING AND ATTENUATING RISK 207,090
ASSOCIATED WITH DISEASE-MODIFYING THERAPY IN
RELAPSING-REMITTING MULTIPLE SCLEROSIS
Consortium of Multiple Sclerosis EXPERT DEBATES IN MULTIPLE SCLEROSIS: OPPOSING VIEWS 125,000
Centers Nurse Practitioner IN MANAGEMENT
Alternatives
Consortium of Multiple Sclerosis PATIENTGPS?: CLINICAL PATHS TO EXPLORE TREATMENT 100,000
Centers Nurse Practitioner OPTIONS AND INDIVIDUALIZE THERAPY IN MULTIPLE
Alternatives SCLEROSIS
Dignity Health MandatoryCE LLC 2ND ANNUAL NEW MEXICO REGIONAL DIABETES SYMPOSIUM 45,000
FORE 2015 ORTHOPAEDICS FOR THE PRIMARY CARE PRACTITIONER & 4,000
REHABILITATION THERAPIST
Humboldt-Del Norte Consortium for MULTIPLE SCLEROSIS 4,100
Continuing Medical Education
Icahn School of Medicine at Mount MULTIPLE SCLEROSIS AND ITS MIMICS 1,920
Sinai
Icahn School of Medicine at Mount ADVANCES IN PEDIATRIC FOOD ALLERGY 15,000
Sinai
Institute for the Advancement of LEARNER-DIRECTED CME: WHAT DO PRIMARY CARE PROVIDERS 49,500
Human Behavior Answers in CME, Inc. NEED TO KNOW ABOUT THE LATEST ADVANCES IN THE
TREATMENT HYPERCHOLESTEROLEMIA
Johns Hopkins University Advanced THE 11TH ANNUAL JOHNS HOPKINS MULTIPLE SCLEROSIS 210,000
Studies in Medicine SYMPOSIUM SERIES
Johns Hopkins University Advanced COMPREHENSIVE CARE FOR PATIENTS WITH GAUCHER DISEASE: 195,100
Studies in Medicine EMERGING CONCEPTS FOR IMPROVED OUTCOMES
Johns Hopkins University Medical MANAGEMENT OF PERSISTENT HYPERGLYCEMIA IN TYPE 2 81,750
Logix, LLC DIABETES: BEYOND STARTING DOSES OF BASAL INSULIN
Medical Education Resources Tarsus THE EVOLUTION OF INSULIN THERAPY: NEW DEVELOPMENTS IN 100,000
Cardio Inc. dba Health Science Media TREATMENT, TECHNOLOGY, AND METHODS OF ADMINISTRATION
Medical Learning Institute, Inc. PEERVIEW INREVIEW, RISING TO THE CHALLENGE: FOSTERING 100,000
PeerView Institute for Medical EFFECTIVE PATIENTPROVIDER COMMUNICATION THROUGHOUT
Education, Inc. THE COURSE OF POMPE DISEASE
Medical University of South Carolina 1ST ANNUAL NEPHROLOGY TRANSPLANT SYMPOSIUM FOR 2,500
NEPHROLOGISTS, PRIMARY CARE AND HOSPITALISTS
Med-IQ, LLC TARGETING MODERATE-TO-SEVERE ATOPIC DERMATITIS: 99,896
EVOLVING TREATMENT STRATEGIES TO ADDRESS A KEY UNMET Collaboration \3\
MEDICAL NEED
Med-IQ, LLC CASE SIMULATIONS IN TUMOR LYSIS SYNDROME: AGGRESSIVE 100,000
PROPHYLAXIS STRATEGIES TO PREVENT ADVERSE PATIENT
OUTCOMES
Med-IQ, LLC UPDATE FOR CLINICIANS: THE POTENTIAL OF IL-6 104,578
INHIBITORS TO REVOLUTIONIZE RHEUMATOID ARTHRITIS Collaboration \3\
TREATMENT
Medscape, LLC A PRACTICAL GUIDE TO THE PREVENTION OF SURGICAL 160,000
ADHESIONS
Medscape, LLC IDENTIFYING AND ADDRESSING INADEQUATELY MANAGED 138,500
OSTEOARTHRITIS PAIN
Medscape, LLC GLP-1 RECEPTOR AGONISTS IN T2D MANAGEMENT: THE MODERN 105,100
INJECTABLE
Missouri Academy of Physician THE GOOD, THE BAD, AND THE IATROGENIC? 3,500
Assistants
Missouri Academy of Physician JOINT INJECTIONS 5,000
Assistants
Montefiore Medical Center PlatformQ A COMPREHENSIVE PERSPECTIVE ON INSULIN REPLACEMENT FOR 100,000
Health Education, LLC TYPE 2 DIABETES
Montefiore Medical Center PlatformQ MULTIPLE SCLEROSIS: EXPLORING TREATMENT OPTIONS AND 85,000
Health Education, LLC INDIVIDUALIZING THERAPY
National Association of Managed Care ADVANCES IN THE MANAGEMENT OF MULTIPLE SCLEROSIS: A 57,000
Physicians, Inc. CLOSER LOOK AT NOVEL THERAPIES
National Association of Managed Care INDIVIDUALIZING TREATMENT STRATEGIES FOR EFFECTIVE A1C 57,000
Physicians, Inc. REDUCTION AND IMPROVED OUTCOMES IN TYPE 2 DIABETES
National Jewish Health California CSAAI 23RD ANNUAL EDUCATIONAL MEETING 10,000
Society of Allergy, Asthma and Collaboration \3\
Immunology
National Kidney Foundation, Inc. GREENSBORO PATIENT EMPOWERMENT WORKSHOP 3,500
National Kidney Foundation, Inc. CHRONIC KIDNEY DISEASE & THE PRIMARY CARE 25,000
PRACTITIONER: EARLY SCREENING AND PREVENTION FOR THE
AT-RISK PATIENT
National Kidney Foundation, Inc. 11TH ANNUAL JOINT MEETING OF THE UPSTATE AND WESTERN 5,000
NEW YORK COUNCILS ON RENAL NUTRITION
National Medical Association NEW TYPE 2 DIABETES GUIDELINES AND THE TREND TOWARD 100,000
NEWER PHARMACOLOGICAL TREATMENT
North American Center for Continuing IMPLEMENTING BEST PRACTICES FOR TUMOR LYSIS SYNDROME 100,000
Medical Education, LLC Horizon CME,
Inc.
Not-For-Profit Hospital Corporation CHRONIC KIDNEY DISEASE: STATE OF THE ART 2015 1,900
Pennsylvania Academy of Family PA ACADEMY OF FAMILY PHYSICIANS FOUNDATION A1C 150,000
Physicians Foundation CHALLENGE
Pennsylvania Society of Physician THYROID MASSES 8,400
Assistants
Pharmacy Times Office of Continuing CONVENIENT CARE OPPORTUNITIES TO OPTIMIZING INSULIN 48,689
Professional Education THERAPY IN TREATMENT OF TYPE 2 DIABETES
Pharmacy Times Office of Continuing AJPB QUALITY FORUM: IMPLEMENTATION OF QUALITY MEASURES 50,000
Professional Education PQA, Inc. TO IMPROVE OUTCOMES IN DYSLIPIDEMIA Collaboration \3\
Pharmacy Times Office of Continuing AJPB QUALITY FORUM: AIMING FOR A FIVE-STAR RATING IN 50,000
Professional Education PQA, Inc. DIABETES CARE: MANAGED CARE PLANS AND COMMUNITY
PHARMACIST COLLABORATION
Postgraduate Healthcare Education, ADDRESSING HYPOGLYCEMIA IN TYPE 2 DIABETES MELLITUS: 30,000
LLC Medical Logix, LLC THE PHARMACISTS ROLE IN OPTIMIZING PATIENT OUTCOMES
Postgraduate Institute for Medicine C- NOVEL MECHANISMS AND ADVANCING THERAPEUTIC PARADIGMS 379,000
MEducation Resources, LLC FOR OPTIMIZING LDL-FOCUSED MANAGEMENT AND Collaboration \3\
CARDIOPROTECTION IN THE DIABETIC PATIENT
Postgraduate Institute for Medicine C- THE IQ&A INTERACTIVE CARDIOVASCULAR INTELLIGENCE ZONE: 238,100
MEducation Resources, LLC NEW FRONTIERS IN LDL-TARGETED CV RISK REDUCTION Collaboration \3\
Preventive Cardiovascular Nurses 2015 FALL LEARNING SERIES 35,000
Association
PRIME Education Inc. (PRIME) CASE-BASED DEBATES ABOUT UTILITY OF PCSK9 INHIBITORS 123,000
IN PATIENT POPULATIONS FOR LIPID REDUCTION Collaboration \3\
PRIME Education Inc. (PRIME) INTERNATIONAL INSIGHTS ON TREATMENT ADVANCES FOR 166,077
RHEUMATOID ARTHRITIS Collaboration \3\
PRIME Education Inc. (PRIME) NEW CHALLENGES IN THE PREVENTION AND MANAGEMENT OF 78,810
TUMOR LYSIS SYNDROME IN PATIENTS WITH CHRONIC
LYMPHOCYTIC LEUKEMIA
Pri-Med Institute, LLC (d/b/a pmiCME) DYSLIPIDEMIA IN PRIMARY CARE: NEW GUIDELINE 250,000
Horizon CME, Inc. RECOMMENDATIONS AND TREATMENT OPTIONS Collaboration \3\
ProCE, Inc. Institute for Safe CONCENTRATED INSULIN: SAFE USE IN THE HOSPITAL AND 102,233
Medication Practices TRANSITIONS OF CARE
Projects In Knowledge, Inc. MULTIPLE SCLEROSIS @ POINT OF CARE 200,000
Regents of the University of Colorado RENAL DISEASE & ELECTROLYTE DISORDERS COURSE 3,000
Regents of the University of Colorado PEDIATRIC AND ADULT DIFFERENTIATED THYROID CANCER, ARE 75,000
American Thyroid Association THEY DIFFERENT?
Regents, University of California THIRD ANNUAL UCLA REVIEW OF CLINICAL NEUROLOGY 15,000
Rush University Medical Center Plexus DEVELOPING AN INTEGRATIVE APPROACH TO METASTATIC 65,000
Communications PROSTATE CANCER: MAKING IT PERSONAL TO IMPROVE
CLINICAL OUTCOMES
Rutgers, The State University of New 8TH ANNUAL PERSPECTIVES IN RHEUMATIC DISEASES, 10,000
Jersey Global Academy for Medical PRESENTED BY RHEUMATOLOGY NEWS, INTERNAL MEDICINE Collaboration \3\
Education, LLC NEWS, FAMILY PRACTICE NEWS
South Dakota Academy of Physician DIABETIC MANAGEMENT 3,500
Assistants
Tennessee Academy of Physician FALLFEST 2015-RENAL DISEASE 2,500
Assistants
Texas A&M University System Health 11TH ANNUAL DIABETES CONFERENCE 10,000
Science Center Coastal Be
The Boston Home CARING FOR THE PATIENT WITH ADVANCED MULTIPLE 10,000
SCLEROSIS
The Endocrine Society UPDATE IN BASAL INSULINS: YOUR QUESTIONS ANSWERED 129,040
The Endocrine Society 2015 CLINICAL ENDOCRINOLOGY UPDATE 25,000
The Endocrine Society 2015 CLINICAL ENDOCRINOLOGY UPDATE 25,000
The France Foundation MS CLINICAL DIALOGS: A PEER DISCUSSION ON OPTIMAL 76,547
TREATMENT (PHASE 2)
The France Foundation National A MULTI-DISCIPLINARY APPROACH TO LIMB-GIRDLE MUSCLE 240,794
Society of Genetic Counselors WEAKNESS DYSTROPHY AND RELATED CONDITIONS MANAGEMENT
The Medical College of Wisconsin, INTERACTIVE UPDATES IN USE OF STEM CELL MOBILIZATION 120,000
Inc. Carden Jennings Publishing Co., FOR THE TREATMENT OF BLOOD RELATED CANCERS
Ltd.
Ultimate Medical Academy, LLC dba IMPROVING OUTCOMES IN RHEUMATOID ARTHRITIS: TREATING 162,588
Global Education Group Integritas TO TARGET, IL-6-DIRECTED THERAPIES, AND EVOLVING Collaboration \3\
Communications, LLC MANAGEMENT ALGORITHMS
UMA MLG, LLC THE CHANGING LANDSCAPE OF DYSLIPIDEMIA TREATMENT 198,900
Collaboration \3\
UMA MLG, LLC A 3-DIMENSIONAL VIEW INTO THE ROLE OF GLP1 IN TYPE-2 30,000
DIABETES: EXPLORING EVIDENCE-BASED GUIDELINES AS
PATIENT-CENTERED THERAPY
University of California, San Diego PROMOTING BEHAVIOR CHANGE IN DIABETES: A SKILL 50,000
Behavioral Diabetes Institute BUILDING PROGRAM FOR HEALTH CARE PROFESSIONALS A
University of Cincinnati Global THE KNEE COURSE 2015 19,500
Academy for Medical Education, LLC
University of Virginia Renal RENAL PHYSICIANS ASSOCIATION 2015 ADVANCED 12,500
Physicians Association PRACTITIONER CONFERENCE
----------------------------------------------------------------------------------------------------------------
\1\ Applicant names are provided by the requestor. If applicants apply as a group for a single educational
activity; all applicants may be not be identified above. The Company funds other educational activities
(including fellowships and non-physician and patient education); all of which do not appear on this report,
but appear on other reports on this site.
\2\ ``Funding Amount'' is the amount that the Company funded during Q3, 2015 identified above based upon an
agreement. Recipients are required to return any unused funds. Information on unused funds returned by the
applicant on activities are not reported. ``Funding Amount'' does not include funds that may have been
provided by other affiliated Sanofi Company Entities (e.g., Sanofi Pasteur).
\3\ Collaboration (Shared) Funding--is the full amount of a grant funded under an agreement with Regeneron, some
or all of which may be shared between the collaborating entities.
Independent Medical Education Grants
1st Oct 2015-31st Dec 2015
Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education
activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and
consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged.
Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.
----------------------------------------------------------------------------------------------------------------
Funding Amount
Recipient Name(s) \1\ Activity Title ($) \2\
----------------------------------------------------------------------------------------------------------------
American Academy of Physician 2015 ADULT HOSPITAL MEDICINE BOOT CAMP 2,500
Assistants
American Association of Clinical NEW ENGLAND CHAPTER OF AACE 7TH ANNUAL MEETING 5,000
Endocrinologists
American Association of Clinical DIABETES DAY FOR PRIMARY CARE CLINICIANS EDUCATIONAL 50,000
Endocrinologists SERIES
American Neurological Association 2015 AMERICAN NEUROLOGICAL ASSOCIATION 140TH ANNUAL 25,000
MEETING
ANNA Chapter 125, 126, and 133 ANNA NJ COLLABORATIVE 2015 3,000
Annenberg Center for Health Sciences INITIATING AND ADVANCING MULTIPLE SCLEROSIS THERAPIES: 125,000
at Eisenhower Postgraduate Institute IMPROVING PATIENT CARE AND HEALTH OUTCOMES
for Medicine
Baylor University Medical Center dba FOLLOWING THE EVIDENCE A PRACTICAL, CASE BASED 45,975
A. Webb Roberts Center MedNet, LLC APPROACH TO PERSONALIZED TREATMENT OPTIONS FOR
MULTIPLE SCLEROSIS
California Optometric Association 2015 MONTEREY SYMPOSIUM 7,416
Cedars-Sinai Medical Center 5TH ANNUAL SYMPOSIUM ON LYSOSOMAL STORAGE DISORDERS 26,010
Consortium of Multiple Sclerosis 4TH CONFERENCE OF THE INTERNATIONAL MS COGNITION 56,280
Centers Nurse Practitioner SOCIETY IN COLLABORATION WITH THE CONSORTIUM OF
Alternatives MULTIPLE SCLEROSIS CENTERS
Harris County Optometric Society EYES ON FABRY HARRIS COUNTY OPTOMETRIC SOCIETY 7,000
Fabry Support & Information Group
Horizon CME, Inc. STRATEGIES FOR SELECTION AND OPTIMAL SEQUENCING OF 85,000
CURRENT TREATMENT OPTIONS FOR METASTATIC CASTRATION-
RESISTANT PROSTATE CANCER
Icahn School of Medicine at Mount 3RD NY MASTERS COURSE IN ENDOCRINOLOGY AND ENDOCRINE 15,000
Sinai SURGERY
Indiana Academy of Physician THE GOOD, THE BAD AND THE IATROGENIC (RENAL MEDICATION 3,250
Assistants DOSING)
Letters & Sciences ADVANCES IN MS RESEARCH & PRACTICE 2015 ANNUAL 70,000
CONFERENCE
Medical Education Resources Tarsus 2015 CMHC SYMPOSIUM: NOVEL THERAPIES FOR LDL-C 40,000
Cardio Inc. dba Health Science Media LOWERING IN THE FIGHT AGAINST RESIDUAL ASCVD RISK
Medical Learning Institute, Inc. PEERVIEW IN EXCHANGE, ESTABLISHING BEST PRACTICES FOR 140,325
PeerView Institute for Medical THE PERSONALIZED CARE OF PATIENTS WITH MULTIPLE
Education, Inc. SCLEROSIS: A TIMELY DISCUSSION AMONG ADVANCED
PRACTICE CLINICIANS?
Medical Learning Institute, Inc. PEERVIEW VIDEO IN SESSION, CLINICAL HIGHLIGHTS FROM 134,450
PeerView Institute for Medical BARCELONA: AN UP-TO-DATE REVIEW OF NEW DATA ON
Education, Inc. APPROVED DISEASE-MODIFYING THERAPIES FOR MULTIPLE
SCLEROSIS MANAGEMENT?
Medical Learning Institute, Inc. 2016 ACMG--PEERVIEW LIVE, ENSURING THE RAPID 239,950
PeerView Institute for Medical IDENTIFICATION AND INDIVIDUALIZED MANAGEMENT OF
Education, Inc. GAUCHER DISEASE TYPE 1: KEY PRINCIPLES AND STRATEGIES
Med-IQ, LLC NEW THERAPIES FOR GAUCHER'S DISEASE: TALK TO YOUR 147,396
PHARMACIST
Med-IQ, LLC EARLIER RECOGNITION AND TREATMENT OF GAUCHER'S DISEASE 135,728
IN HEMATOLOGY CLINICS
Med-IQ, LLC RECOGNIZING THE UNLIKELY: IMPROVING IDENTIFICATION AND 246,977
CARE OF FABRY DISEASE
Michigan State Medical Society CARDIOVASCULAR DISEASE IN PATIENTS WITH RENAL DISEASE 2,500
National Jewish Health 38TH ANNUAL PULMONARY AND ALLERGY UPDATE 10,000
Collaboration \3\
National Jewish Health Western WSAAI 54TH ANNUAL SCIENTIFIC SESSION 10,000
Society of Allergy, Asthma and Collaboration \3\
Immunology (WSAAI)
National Kidney Foundation, Inc. NATIONAL KIDNEY FOUNDATION'S 47TH ANNUAL MEDICAL 2,500
SYMPOSIUM
National Multiple Sclerosis Society Research Symposium 2015: MS Research Discoveries: 3,000
New York Chapter Wellness and Treatments for Living Your Best Life
Pennsylvania Society of Physician RENAL MEDICATION DOSING: THE GOOD, THE BAD, AND THE 4,000
Assistants IATROGENIC
PESI, Inc. Metabolic Endocrine 13TH ANNUAL WORLD CONGRESS ON INSULIN RESISTANCE, 15,000
Education Foundation DIABETES AND CARDIOVASCULAR DISEASE--WCIRDC Collaboration \3\
Postgraduate Institute for Medicine FAILURE IS NOT AN OPTION: SELECTING OPTIMAL STEM CELL 205,195
AXIS Medical Education, Inc. MOBILIZATION STRATEGIES FOR MULTIPLE MYELOMA AND NON-
HODGKIN LYMPHOMA
Postgraduate Institute for Medicine 1,800 SECONDS? IN DIABETES MANAGEMENT WITH A GLP-1 75,000
Catamount Medical Education, LLC RECEPTOR AGONIST AND BASAL INSULIN
Projects In Knowledge, Inc. MedPage CLINICAL CONTEXT: MULTIPLE SCLEROSIS 131,000
Today, LLC
Rutgers, The State University of New THE FOURTH EVIDENCE-BASED PEDIATRIC UPDATE SYMPOSIUM 5,000
Jersey
Rutgers, The State University of New SKIN DISEASE EDUCATION FOUNDATION'S 16TH ANNUAL LAS 5,000
Jersey Global Academy for Medical VEGAS DERMATOLOGY SEMINAR, FEATURING THE 12TH ANNUAL Collaboration \3\
Education, LLC PSORIASIS FORUM
Society of Nuclear Medicine SNMMI 2015-2016 THYROID IMAGING AND THERAPY 108,730
EDUCATIONAL OUTREACH FOR REFING PHYSICIANS AND
IMAGING PHYSICIANS
Swedish Medical Center Foundation FIFTH ANNUAL INTENSIVE UPDATE IN NEUROLOGY 10,000
Swedish Medical Center Foundation DIABETES MANAGEMENT UPDATE 2015 8,000
The Board of Trustees of the UA for SPECIAL NEPHROLOGY RESEARCH AND TRAINING CENTER 15,000
the UA at Birmingham SYMPOSIUM--11/9/15
The University of Texas Southwestern NEUROTHERAPEUTICS UPDATE 5,000
Medical Center at Dallas
Tufts University School of Medicine IMPROVING CARE FOR HEART FAILURE PATIENTS: AN UPDATE 5,000
FOR HEALTHCARE PROVIDERS - THE 8TH ANNUAL NEW ENGLAND
HEART FAILURE AND TRANSPLANT NETWORK CONFERENCE
University of Massachusetts Medical NEW FRONTIERS AND EMERGING TREATMENT PARADIGMS FOR 347,000
School C-MEducation Resources, LLC OPTIMIZING LDLTARGETED CARDIOVASCULAR RISK REDUCTION Collaboration \3\
University of Massachusetts Medical THE IQ&A INTERACTIVE RHEUMATOID ARTHRITIS INTELLIGENCE 189,000
School C-MEducation Resources, LLC ZONE: FOCUS ON THE EVIDENCE BASIS FOR RA MANAGEMENT Collaboration \3\
THROUGH INHIBITION OF THE IL-6 CYTOKINE AND OTHER
FOUNDATION SIGNALING SYSTEMS
University of Massachusetts Medical NEW FRONTIERS AND TREATMENT ADVANCES FOR ATOPIC 360,000
School C-MEducation Resources, LLC DERMATITIS: FOCUS ON THE ROLE OF ESTABLISHED AND Collaboration \3\
EVOLVING BIOLOGIC THERAPIES FOR PEDIATRIC AND ADULT
PATIENTS WITH MODERATE-TO-SEVERE AND TREATMENT-
RESISTANT ATOPIC DERMATITIS
University of Texas Health Science AMDA INTERNATIONAL PATIENT AND SCIENTIFIC CONFERENCE-- 60,000
Center at San Antonio Acid Maltase PAST, PRESENT, FUTURE
Deficiency Association, Inc.
Vindico Medical Education, LLC IN SEARCH OF THE GUIDING LIGHT: RE-VISITING THE USE OF 372,524
ORAL AND HIGHEFFICACY THERAPIES IN A MODERN ERA OF
MULTIPLE SCLEROSIS TREATMENT
----------------------------------------------------------------------------------------------------------------
\1\ Applicant names are provided by the requestor. If applicants apply as a group for a single educational
activity; all applicants may be not be identified above. The Company funds other educational activities
(including fellowships and non-physician and patient education); all of which do not appear on this report,
but appear on other reports on this site.
\2\ ``Funding Amount'' is the amount that the Company funded during Q4, 2015 identified above based upon an
agreement. Recipients are required to return any unused funds. Information on unused funds returned by the
applicant on activities are not reported. ``Funding Amount'' does not include funds that may have been
provided by other affiliated Sanofi Company Entities (e.g., Sanofi Pasteur).
\3\ Collaboration (Shared) Funding--is the full amount of a grant funded under an agreement with Regeneron, some
or all of which may be shared between the collaborating entities.
Independent Medical Education Grants
1st Jan 2016-31th Mar 2016
Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education
activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and
consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged.
Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.
----------------------------------------------------------------------------------------------------------------
Funding Amount
Recipient Name(s) \1\ Activity Title ($) \2\
----------------------------------------------------------------------------------------------------------------
Admin of the Tulane Educa Fund on 8TH ANNUAL TULANE SYMPOSIUM ON THYROID AND PARATHYROID 7,500
behalf of TUHSC CCE DISEASES
AKH Inc Advancing Knowledge and 2016 SOUTH BEACH SYMPOSIUM: CLINICAL DERMATOLOGY 5,000
Healthcare SYMPOSIUM Collaboration \3\
AKH Inc Advancing Knowledge and NOVEL MECHANISMS AND ADVANCING THERAPEUTIC PARADIGMS 336,000
Healthcare C-MEducation Resources, FOR OPTIMIZING LDLFOCUSED MANAGEMENT AND CV RISK Collaboration \3\
LLC REDUCTION IN THE DIABETIC PATIENT
American Academy of Continuing INCREASING ACCESS TO KIDNEY TRANSPLANTATION: NOVEL 104,000
Medical Education, Inc. Spire STRATEGIES TO EXPAND LIVING DONATION
Learning
American Association of Clinical THYROID SESSIONS AT ENDOCRINE UNIVERSITYr: DISEASE 30,000
Endocrinologists MANAGEMENT & TECHNOLOGY SKILLS FOR ENDOCRINOLOGY
FELLOWS IN TRAINING
American Association of Clinical NEVADA AACE THYROID CANCER SYMPOSIUM 5,000
Endocrinologists
American Association of Clinical LDL-C REDUCTION IN THE PATIENT WITH DIABETES: HOW LOW 267,758
Endocrinologists Medtelligence, LLC SHOULD WE GO AND HOW SHOULD WE GET THERE? Collaboration\3\
American College of Cardiology DYSLIPIDEMIA COMBO-THERAPY: A FRAMEWORK FOR CLINICAL 75,000
Foundation DECISION-MAKING Collaboration\3\
American College of Rheumatology 2016 ACR RHEUMATOLOGY COURSES 150,000
Collaboration \3\
American Health Resources, Inc. EXAMINING THE ROLE OF PCSK9 INHIBITORS IN DYSLIPIDEMIA 4,200
MANAGEMENT Collaboration \3\
American Kidney Fund AMERICAN KIDNEY FUND 2016 CLINICAL SCIENTIST IN 75,000
NEPHROLOGY PROGRAM
American Society of Transplant ASTS 16TH ANNUAL STATE OF THE ART WINTER SYMPOSIUM: 50,000
Surgeons LIMITED SUPPLY, INCREASING DEMAND: EXPANDING ORGAN
DONATION
Annenberg Center for Health Sciences EXPERTS IN RESIDENCE: BRIDGING THE GAP FROM KNOWLEDGE 110,000
at Eisenhower TO PRACTICE IN CASTRATION-RESISTANT PROSTATE CANCER
Association of Black Cardiologists, EVOLVING STRATEGIES FOR CARDIOVASCULAR RISK REDUCTION: 350,000
Inc. National Association for BEYOND STATIN THERAPY Collaboration \3\
Continuing Education
Cardiovascular Center of Sarasota 12TH ANNUAL CARDIOVASCULAR SYMPOSIUM CARDIOLOGY UPDATE 5,000
Foundation for Research and Florida 2016: FROM INTERVENTION TO PREVENTION TIME TO FOCUS Collaboration \3\
Medical Association ON EARLY CARDIOVASCULAR HEALTH
Cardio Renal Society of America 4th ANNUAL CARDIO-RENAL METABOLIC CONFERENCE 6,000
CME Outfitters, LLC IMPLEMENTING PERSONALIZED ACTION PLANS FOR PATIENTS 99,867.5
WITH ATOPIC DERMATITIS Collaboration \3\
Consortium of Multiple Sclerosis CLINICIAN-PATIENT SHARED DECISION MAKING IN MS: AN 100,860
Centers Nurse Practitioner ESSENTIAL STEP TOWARD BETTER OUTCOMES
Alternatives
Emory University EVALUATION OF THE LGMD DIAGNOSTIC TESTING PROGRAM: 5,850
PROGRAM UPDATES, OPPORTUNITIES AND FUTURE WORK
Forefront Collaborative National CURRENT CONTROVERSIES IN DYSLIPIDEMIA MANAGEMENT: A 85,000
Lipid Association POINT-COUNTERPOINT DISCUSSION Collaboration \3\
Medical Learning Institute, Inc. UNDERSTANDING THE EVOLUTION OF MS CARE: OPTIMIZING 43,186
THERAPEUTIC DECISION MAKING
Medical Learning Institute, Inc. PEERVIEW INCLINIC, ``MAXIMIZING CARE FOR INDIVIDUALS 145,000
PeerView Institute for Medical WITH MULTIPLE SCLEROSIS: THE ROLE OF
Education, Inc. INTERPROFESSIONAL EDUCATION''
Medical Learning Institute, Inc. PEERVIEW LIVE, "DISRUPTING DISEASE WORSENING IN 296,820
PeerView Institute for Medical PATIENTS WITH MS: HOW CAN WE HARNESS THE FULL
Education, Inc POTENTIAL OF AVAILABLE DISEASE-MODIFYING
Med-IQ, LLC WHEN INSULIN ALONE ISN'T THE ANSWER: A FOCUSED LOOK AT 257,768
COMBINING BASAL INSULIN AND GLP-1 RECEPTOR AGONISTS
Med-IQ, LLC HOW EARLY IS EARLY? WHEN TO START ERT AND OTHER 160,522
CONSIDERATIONS FOR OPTIMIZING TREATMENT OF FABRY
DISEASE
National Association of Managed Care EFFECTIVE A1C REDUCTION IN TYPE 2 DIABETES: A CLOSER 75,000
Physicians, Inc. LOOK AT COMBINATION INSULIN THERAPY
National Kidney Foundation, Inc. CKD-MBD: STATE-OF-THE-ART CONSIDERATIONS FOR OPTIMAL 253,850
University of Illinois at Chicago OUTCOMES
National Lipid Association NATIONAL LIPID ASSOCIATION 2016 MASTERS IN LIPIDOLOGY 20,000
COURSE SERIES Collaboration \3\
National Lipid Association NATIONAL LIPID ASSOCIATION 2016 LIPID ACADEMY COURSE 20,000
SERIES Collaboration \3\
Nebraska Academy of Physician JOINT INJECTION WORKSHOP 5,100
Assistants
Nevada System of Higher Education 2016 WINTER CLINICAL DERMATOLOGY CONFERENCE--HAWAII 50,000
Foundation for Research and Collaboration \3\
Education in Dermatology
North American Center for Continuing MEETING THE UNMET NEEDS OF PATIENTS WITH 415,000
Medical Education, LLC Horizon CME, HYPERCHOLESTEROLEMIA: A FOCUS ON PCSK9 INHIBITORS Collaboration \3\
Inc.
NYU School of Medicine SEMINAR IN ADVANCED RHEUMATOLOGY 20,000
Collaboration \3\
NYU School of Medicine 41ST ANNUAL COMPREHENSIVE REVIEW OF PHYSICAL MEDICINE 5,000
AND REHABILITATION
Pharmacy Times Office of Continuing COST-EFFECTIVENESS OF DISEASE-MODIFYING THERAPIES IN 89,160
Professional Education MULTIPLE SCLEROSIS: A MANAGED CARE PERSPECTIVE
Pharmacy Times Office of Continuing INNOVATION AND CLINICAL ADVANCES IN ACHIEVING GLYCEMIC 240,728
Professional Education CONTROL: EVALUATING THE EFFICACY OF COMPLIMENTARY
AGENTS
Pharmacy Times Office of Continuing THE ROLE OF THE PHARMACIST IN ACHIEVING TIGHT GLYCEMIC 53,346
Professional Education CONTROL IN TYPE 2 DIABETES: PROMOTING PATIENT SELF-
MONITORING AND AGGRESSIVE TREATMENT
Physicians' Education Resource, LLC 2016 NEW YORK GUTM: 9TH ANNUAL INTERDISCIPLINARY 75,000
PROSTATE CANCER CONGRES
Postgraduate Healthcare Education, OPTIMIZED APPROACHES TO INSULIN THERAPY AND GLUCOSE 301,000
LLC CONTROL IN TYPE 2 DIABETES
Postgraduate Institute for Medicine C- NEW THERAPEUTIC ADVANCES AND PRACTICAL STRATEGIES FOR 309,500
MEducation Resources, LLC COMPLEMENTARY BASAL INSULIN PLUS INCRETIN SYSTEM-
TARGETED THERAPY TO OPTIMIZE GLUCOSE CONTROL
Postgraduate Institute for Medicine C- NEW THERAPEUTIC ADVANCES AND PRACTICAL STRATEGIES FOR 331,000
MEducation Resources, LLC COMPLEMENTARY BASAL INSULIN PLUS INCRETIN SYSTEM-
TARGETED THERAPY IN COMPLEX PATIENTS WITH
Primary Care Education Consortium COMBINING A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST 309,985
WITH BASAL INSULIN: THE WHY AND HOW
PRIME Education Inc (PRIME) NEW TREATMENT GUIDELINES, EVIDENCE, AND AGENTS IN 249,505
RHEUMATOID ARTHRITIS Collaboration \3\
Pri-Med Institute, LLC (d/b/a pmiCME) HOW TO SELECT AND INITIATE INSULIN THERAPY IN THE TYPE 998,500
Horizon CME, Inc. 2 DIABETES PATIENT
Pri-Med Institute, LLC (d/b/a pmiCME) GLP-1 RECEPTOR AGONISTS AND BASAL INSULIN COMBINATION: 977,000
Horizon CME, Inc. AN COMPLEMENTARY STRATEGY FOR TYPE 2 DIABETES
TREATMENT INTENSIFICATION
Projects In Knowledge, Inc. MEDIMAGE CASES: MULTIPLE SCLEROSIS 125,000
Rhode Island Hospital, CME ENDOCRINE GRAND ROUNDS 10,000
Rutgers, The State University of New SKIN DISEASE EDUCATION FOUNDATION'S 40TH ANNUAL HAWAII 10,000
Jersey Global Academy for Medical DERMATOLOGY SEMINAR Collaboration \3\
Education, LLC
ScientiaCME, LLC Specialty Pharma PROSTATE CANCER: ADVANCES IN PATIENT MANAGEMENT & 14,875
Education Center TREATMENT OPTIONS
Scripps Health SCRIPPS WHITTIER DIABETES INSTITUTE'S PROJECT DULCE 50,000
The Endocrine Society Advanced THE EFFECTIVE USE OF INSULIN IN TYPE 2 DIABETES: A 329,613
Studies in Medicine FOCUS ON TREATMENT ADVANCES
The Endocrine Society Institute for DIABETES MASTERS SERIES 2016: INITIATING THE 237,055.5
Medical and Nursing Education CONVERSATION: SHARING PERSPECTIVES ON ADVANCES IN
T2DM TREATMENT TO IMPROVE PATIENT-CENTERED CARE
The Endocrine Society Scripps Health NEW COMPLEMENTARY INSULIN COMBINATIONS TO ACHIEVE 361,515
HBA1C TARGETS: 2016 ENDOCRINE SOCIETY ANNUAL
CONVENTION SATELLITE SYMPOSIUM
The Massachusetts General Hospital CLINICAL ENDOCRINOLOGY 2016 5,000
The Medical College of Wisconsin, NEW TITORY FOR THE UROLOGIST: OPTIMAL MONITORING AND 150,000
Inc. Paradigm Medical TREATMENT SELECTION FOR MCRPC
Communications, LLC
The Medical College of Wisconsin, OPTIMIZING STEM CELL MOBILIZATION STRATEGIES TO 299,980
Inc. PeerView Institute for Medical ENHANCE SUCCESS OF AUTOLOGOUS HEMATOPOIETIC STEM CELL
Education, Inc. TRANSPLANTATION
The Vitamin D Workshop Inc. THE 19TH WORKSHOP ON VITAMIN D 5,000
Trustees of Boston University PCE DIRECTED LEARNING ECOURSE: A MULTIMODAL APPROACH 152,105
Continuing Education Alliance, LLC TO MANAGING KNEE OSTEOARTHRITIS
Trustees of the University of 2016 THYROID MASTER CLASS: MANAGEMENT OF ADVANCED 10,000
Pennsylvania/CME (PROGRESSIVE MEDULLARY AND RAI-REFRACTORY
DIFFERENTIATED) THYROID CANCER AND UPDATE IN THYROID/
PARATHYROID ULTRASOUND IMAGING
University of Cincinnati PeerView PEERVIEW INREVIEW, ``ACHIEVING RAPID CONTROL OF 68,700
Institute for Medical Education, DISEASE ACTIVITY IN PATIENTS WITH MULTIPLE SCLEROSIS:
Inc. THE INCREASINGLY IMPORTANT ROLE OF DISEASEMODIFYING''
University of Massachusetts Medical THE PHYSIOLOGIC BASIS FOR OPTIMIZING GLYCEMIC CONTROL 331,000
School C-MEducation Resources, LLC WITH BASAL INSULIN IN COMPLEX PATIENTS WITH DIABETES
University of Massachusetts Medical THE FOUNDATIONAL ROLE AND PHYSIOLOGIC BASIS FOR 305,600
School C-MEducation Resources, LLC OPTIMIZING GLYCEMIC CONTROL WITH LONG-ACTING
INSULINS: FOCUS ON THE SAFETY-EFFICACY PROFILES OF
NEW
University of Massachusetts Medical NEW FRONTIERS AND CLINICAL ADVANCES IN IMMUNOTHERAPY 389,000
School C-MEducation Resources, LLC FOR ASTHMA: FOCUS ON BIOLOGICS-BASED MANAGEMENT OF Collaboration \3\
MODERATE-TO-SEVERE ASTHMA IN PATIENTS
University of Virginia RENAL PHYSICIANS ASSOCIATION 2016 ANNUAL MEETING 25,000
University of Virginia RENAL PHYSICIANS ASSOCIATION ADVANCED PRACTITIONER 7,500
CONFERENCE
Yale University Research To Practice CURRENT STRATEGIES AND ONGOING RESEARCH IN THE 80,000
MANAGEMENT OF ADVANCED PROSTATE CANCER--AN
INDEPENDENT SATELLITE SYMPOSIUM (ISS) HELD AS AN
----------------------------------------------------------------------------------------------------------------
\1\ Applicant names are provided by the requestor. If applicants apply as a group for a single educational
activity; all applicants may be not be identified above. The Company funds other educational activities
(including fellowships and non-physician and patient education); all of which do not appear on this report,
but appear on other reports on this site.
\2\ ``Funding Amount'' is the amount that the Company funded during Q1, 2016 identified above based upon an
agreement. Recipients are required to return any unused funds. Information on unused funds returned by the
applicant on activities are not reported. ``Funding Amount'' does not include funds that may have been
provided by other affiliated Sanofi Company Entities (e.g., Sanofi Pasteur).
\3\ Collaboration (Shared) Funding--is the full amount of a grant funded under an agreement with Regeneron, some
or all of which may be shared between the collaborating entities.
Independent Medical Education Grants
1st Apr 2016-30th Jun 2016
Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education
activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and
consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged.
Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.
----------------------------------------------------------------------------------------------------------------
Funding Amount
Recipient Name(s) \1\ Activity Title ($) \2\
----------------------------------------------------------------------------------------------------------------
Academic CME, LLC STRATEGIES FOR IMPROVING OUTCOMES IN PATIENTS WITH 20,000
MULTIPLE SCLEROSIS
AKH Inc., Advancing Knowledge and NOVEL MECHANISMS AND ADVANCING THERAPEUTIC PARADIGMS 350,000
Healthcare C-MEducation Resources, FOR OPTIMIZING REAL WORLD MANAGEMENT OF Collaboration \3\
LLC HYPERCHOLESTEROLEMIA: APPLYING LDLTARGETED THERAPIES
FOR CV RISK REDUCTION TO THE FRONT LINES OF
CARDIOVASCULAR, DIABETES, AND INTERNAL MEDICINE
PRACTICE
AKH Inc Advancing Knowledge and NAVIGATING THE COMPLEX MAZE OF LDL-LOWERING THERAPIES: 378,700
Healthcare C-MEducation Resources, A REAL WORLD ROADMAP FOR THE CARDIOVASCULAR Collaboration \3\
LLC SPECIALIST
American Academy of Physician AAPA CONFERENCE 2016--ENDOCRINOLOGY TRACK 12,500
Assistants
American Academy of Physician AAPA CONFERENCE 2016--NEPHROLOGY TRACK 6,000
Assistants
American Academy of Physician AAPA CONFERENCE 2016--ORTHOPAEDICS TRACK 7,500
Assistants
American Association of Clinical AACE 25TH ANNUAL MEETING AND CLINICAL CONGRESS-- 5,0000
Endocrinologists DIABETES SESSIONS
American Association of Clinical CALIFORNIA CHAPTER OF THE AMERICAN ASSOCIATION OF 20,000
Endocrinologists CLINICAL ENDOCRINOLOGISTS PRESENTS: HOT TOPICS IN
DIABETES AND ENDOCRINOLOGY FOR PRIMARY CARE 2016
American Association of Diabetes AADE 2016: DOES THE SHOE FIT? MATCHING THE RIGHT 321,194
Educators Institute for Medical and INSULIN COMBINATION TO INDIVIDUAL PATIENTS WITH T2DM
Nursing Education
American Association of Nurse SECONDARY PREVENTION OF ASCVD: NOVEL THERAPIES TO 75,000
Practitioners (AANP) Medical IMPROVE OUTCOMES IN PATIENTS WITH Collaboration \3\
Communications Media, Inc. HYPERCHOLESTEROLEMIA
American College of Allergy, Asthma & EAC 2016 - UPDATE IN ALLERGY, ASTHMA & IMMUNOLOGY 10,000
Immunology Eastern Allergy Collaboration \3\
Conference
American Diabetes Association DIABETES IS PRIMARY 133,595
American Diabetes Association 31ST ANNUAL CLINICAL CONFERENCE ON DIABETES 32,000
American Society of Gene Therapy ASGCT 19TH ANNUAL MEETING 26,000
American Society of Health-System THE CHANGING LANDSCAPE OF HYPERCHOLESTEROLEMIA: THE 117,215
Pharmacists EMERGING ROLE OF NON-STATIN THERAPIES Collaboration \3\
American Thoracic Society ATS 2016 INTERNATIONAL CONFERENCE--SELECTED SESSIONS 20,178
IN ASTHMA Collaboration \3\
Baylor University Medical Center dba UPDATE ON GLP-1 RECEPTOR AGONISTS IN THE MANAGEMENT OF 20,000
A. Webb Roberts Center MedNet, LLC TYPE 2 DIABETES MELLITUS
Carolinas Healthcare System/Charlotte 30TH ANNUAL MEETING OF THE GLOMERULAR DISEASE 3,000
AHEC COLLABORATIVE NETWORK
Children's Hospital Corporation BOSTON CHILDREN'S HOSPITAL, DIVISION OF NEPHROLOGY 5,500
WEEKLY SEMINAR SERIES
Consortium of Multiple Sclerosis 2016 SCIENCE OF MS MANAGEMENT 69,225
Centers Nurse Practitioner
Alternatives
Foundation of the Consortium of MS 2016 MS MENTORSHIP FORUM 25,000
Centers
Horizon CME, Inc. GLP-1 RECEPTOR AGONISTS: AN ALTERNATIVE TO PRANDIAL 265,190
INSULIN
Horizon CME, Inc. ACHIEVING LDL GOALS IN PATIENTS WITH 187,395
HYPERCHOLESTEROLEMIA: APPLYING PCSK9 INHIBITORS IN Collaboration \3\
PRACTICE
Horizon CME, Inc. CURRENT THERAPIES FOR PROSTATE CANCER 24,000
Johns Hopkins University Medical PATIENT-CENTERED CARE IN ADVANCED PROSTATE CANCER 60,000
Communications Media, Inc.
Johns Hopkins University Medical MULTIPLE SCLEROSIS IN THE AGE OF ENHANCED THERAPEUTIC 100,000
Logix, LLC OPTIONS
Johns Hopkins University Medscape, REAL-LIFE SCENARIOS: SIMULATION IN MCRPC 50,000
LLC
Medical Education Resources Tarsus PATIENT-FOCUSED LDL-C MANAGEMENT AND RISK REDUCTION IN 200,000
Cardio Inc. dba Cardiometabolic CLINICAL PRACTICE: THE UTILITY OF PCSK9 INHIBITORS Collaboration \3\
Health Congress
Med-IQ, LLC RECENT UPDATES IN CKD-MBD: MERGING SCIENCE AND PATIENT- 84,883
CENTERED CARE
Med-IQ, LLC Taking Control of Your PRACTICAL STRATEGIES FOR ADVANCING INSULIN THERAPY: 995,246.5
Diabetes FROM TIMELY INITIATION AND APPROPRIATE TITRATION OF
BASAL INSULIN TO ADDRESSING POST PRANDIAL GLUCOSE
CONTROL
Medscape, LLC KEY CONCEPTS IN CKD-MBD: ESSENTIALS FOR IMPROVING 199,500
OUTCOMES
Medscape, LLC ADVANCES IN BASAL INSULIN 829,075
Medscape, LLC CME-TV: INDIVIDUALIZING T2D INSULIN THERAPY UTILZIING 816,000
COMPLIMENTARY MECHANISMS OF ACTION
Medscape, LLC CASE CONSIDERATIONS: HOW TO REDUCE CV RISK IN 225,100
DYSLIPIDEMIA? Collaboration \3\
Medscape, LLC 2016 UPDATE: CLINICAL ADVANCEMENTS IN MODERATE TO 640,000
SEVERE ATOPIC DERMATITIS Collaboration \3\
Medscape, LLC WHAT DO WE KNOW ABOUT LDL-C?: A 2016 UPDATE 242,190
Collaboration\3\
Medscape, LLC A PATIENT JOURNEY THROUGH STATIN INTOLERANCE: WHAT 249,215
HAVE WE LEARNED? Collaboration \3\
Medscape, LLC AN ENDOCRINOLOGY CLINIC IN DYSLIPIDEMIA: SOLVING 237,915
CHALLENGING CASES Collaboration \3\
Medscape, LLC RHEUMATOID ARTHRITIS: FOUNDATIONS IN PATHOPHYSIOLOGY, 249,825
TARGETS, AND TREATMENT Collaboration \3\
Medscape, LLC WATERSHEDS IN RHEUMATOID ARTHRITIS: A CONCISE GUIDE TO 99,500
MAJOR CONFERENCES IN 2016 Collaboration \3\
Michigan State Medical Society DIABETES AND LIPID UPDATES 5,000
MidEastern Chapter of the Society of 46TH ANNUAL SPRING MEETING AND EXHIBITION OF THE 7,500
Nuclear Medicine MIDEASTERN CHAPTER OF THE SOCIETY OF NUCLEAR MEDICINE
AND MOLECULAR IMAGING
Missouri Academy of Physician DIABETES UPDATE FOR THE PRIMARY CARE PROVIDER 5,000
Assistants
Montefiore Medical Center PlatformQ EVOLVING TREATMENT PARADIGMS IN METASTATIC CASTRATION- 75,000
Health Education, LLC RESISTANT PROSTATE CANCER
National Association of Managed Care BEST PRACTICES IN THE TREATMENT AND MANAGEMENT OF 57,000
Physicians, Inc. RELAPSING MULTIPLE SCLEROSIS
National Association of Managed Care ADVANCES IN LDL-C REDUCTION: A STRATEGIC LOOK AT THE 25,000
Physicians, Inc. EFFECTIVENESS OF PCSK9 INHIBITORS Collaboration \3\
National Comprehensive Cancer NCCN 2016 ONCOLOGY CASE MANAGER AND MEDICAL DIRECTOR 25,000
Network, Inc. PROGRAM
National Comprehensive Cancer 2016-2017 MONTHLY ONCOLOGY TUMOR BOARDS: A 25,000
Network, Inc. MULTIDISCIPLINARY APPROACH TO INDIVIDUALIZED PATIENT
CARE
National Jewish Health EVALUATION AND TREATMENT OF SEVERE ASTHMA: THE ROLE OF 94,011.5
BIOLOGIC AND DIRECTED THERAPIES Collaboration \3\
National Jewish Health Prova ATOPIC DERMATITIS: DEFINING ITS PATHOGENESIS, 224,850
Education, Inc. TARGETING ITS TREATMENT Collaboration \3\
National Kidney Foundation, Inc. PATHOGENESIS AND MANAGEMENT OF FABRY DISEASE 166,485
National MS Society Greater New NEW HAMPSHIRE LIVING WELL WITH MS CONFERENCE 1,500
England Chapter
National Lipid Association TRANSLATION OF THE LDL RECEPTOR: A NATIONAL LIPID 125,000
ASSOCIATION CORE CURRICULUM INTENSIVE PROGRAM Collaboration \3\
New Jersey Academy of Family MANAGING T2DM IN SPECIAL POPULATIONS 6,000
Physicians
North American Center for Continuing GRAND ROUNDS IN CARDIOLOGY: PCSK9 INHIBITORS WITHIN 499,838
Medical Education, LLC THE TARGETED TREATMENT APPROACH TO Collaboration \3\
HYPERCHOLESTEROLEMIA
Nurse Practitioner Alternatives IMPROVING CARE IN MULTIPLE SCLEROSIS: A NURSING 100,000
International Organization of PERSPECTIVE
Multiple Sclerosis Nurses
Nurse Practitioner Alternatives MULTIPLE SCLEROSIS 2016: WHAT NURSES NEED TO KNOW 57,900
International Organization of
Multiple Sclerosis Nurses
Nurse Practitioner Alternatives 2016 MS COUNSELING POINTS:HIGHLIGHTING THE ROLE OF 35,625
International Organization of NURSES IN MULTIDISCIPLINARY MANAGEMENT OF MS
Multiple Sclerosis Nurses
Oakstone Publishing, LLC PeerVoice ADVANCEMENTS IN CARE FOR PATIENTS WITH 29,725
America Limited HYPERCHOLESTEROLEMIA AND RESIDUAL CV RISK: EMERGING Collaboration \3\
DATA, EVOLVING STRATEGIES
Oregon Health & Science University ON THE HORIZON: UPDATES IN MULTIPLE SCLEROSIS 9,930
Foundation
Penn State University i3 Health GUIDELINE UPDATES AND EVOLVING CLINICAL PARADIGMS IN 23,500
DIFFERENTIATED THYROID CANCER
Penn State University PeerView PEERVIEW SELECT-A-SCENARIO LIVE: TRANSFORMING PROSTATE 120,510
Institute for Medical Education, CANCER CARE IN A RAPIDLY EVOLVING TREATMENT LANDSCAPE
Inc.
Penn State University PeerView PEERVIEW SELECT-A-SCENARIO LIVE: ``CRITICAL 150,000
Institute for Medical Education, DISCUSSIONS IN PROSTATE CANCER: HOW TO SELECT AND
Inc. SEQUENCE THERAPIES THROUGHOUT THE DISEASE CONTINUUM''
Pharmacy Times Office of Continuing ACHIEVING GLYCEMIC CONTROL: PROMOTING PATIENT SELF- 57,000
Professional Education MONITORING AND EXPLORING INNOVATIVE TREATMENT
STRATEGIES IN THE CONVENIENT CARE SETTING
Pharmacy Times Office of Continuing MANAGING HYPERLIPIDEMIA: A NEW CHARGE FOR SPECIALTY 32,000
Professional Education PHARMACY WITH THE ADVENT OF PCSK9 INHIBITORS Collaboration \3\
Pharmacy Times Office of Continuing OPTIMIZING TREATMENT REGIMENS FOR MS: THE PHARMACIST?S 35,000
Professional Education ROLE IN ADVANCING PATIENT CARE
Pharmacy Times Office of Continuing MANAGING ATOPIC DERMATITIS: A PHARMACIST'S OPPORTUNITY 86,450
Professional Education TO INTERVENE Collaboration \3\
Physicians' Education Resource, LLC CANCER SUMMARIES AND COMMENTARIE: UPDATE FROM CHICAGO: 40,000
ADVANCES IN THE TREATMENT OF GENITOURINARY CANCERS
Pna Centers For Neurological Research RRNMF COURSE ON POMPE'S DISEASE RECOGNITION AND 25,000
THERAPY
Postgraduate Healthcare Education, THE CHANGING LANDSCAPE IN THE TREATMENT OF RHEUMATOID 52,500
LLC ARTHRITIS: AN UPDATE FOR PHARMACISTS Collaboration \3\
Postgraduate Institute for Medicine C- IQ&A INTERACTIVE DIABETES INTELLIGENCE ZONE: GLYCEMIC 191,000
MEducation Resources, LLC REGULATION THROUGH COMBINATION THERAPY--FOCUS ON
SAFETY, CONVENIENCE, METABOLIC EFFECTS, HA1C CONTROL,
AND EFFICACY OF COMBINATION BASAL INSULIN-GLP-1 RA
REGIMENS FOR FPG AND PPG CONTROL
Postgraduate Institute for Medicine WHY AREN'T THEY TAKING THEIR MEDS? PATIENT-CENTERED 33,000
Enquiring Minds LLC APPROACHES TO NON-ADHERENCE IN MS
Primary Care Education Consortium REMOVING THE COMPLEXITY AND CONCERNS OF INSULIN 78,595
MANAGEMENT IN TYPE 2 DIABETES, 4-HOUR WORKSHOPS TO BE
HELD DURING THE METABOLIC AND ENDOCRINE DISEASE
SUMMITS 2016
PRIME Education Inc (PRIME) PRACTICAL SKILLS IN MEDICATION MANAGEMENT WITH NEWER 415,000
CHOLESTEROL THERAPIES: CAN WE ACHIEVE PATIENT AND Collaboration \3\
MANAGED CARE HOMEOSTASIS?
PRIME Education Inc (PRIME) GME-CME ADVANCED PRACTICE SEMINAR IN MULTIPLE 150,329
SCLEROSIS: FOCUSED TRAINING FOR EFFECTIVE
INDIVIDUALIZED TREATMENT DECISION-MAKING
PRIME Education Inc (PRIME) RHEUMATOLOGY HOUSE CALLS--ENGAGING PATIENTS AND 172,845
PROVIDERS IN RHEUMATOID ARTHRITIS COLLABORATIVE Collaboration \3\
LEARNING
PRIME Education Inc (PRIME) NEW TARGETS IN THE THERAPEUTIC LANDSCAPE FOR ADULTS 291,095
WITH ATOPIC DERMATITIS Collaboration \3\
Pri-Med Institute, LLC (d/b/a pmiCME) OSTEOARTHRITIS OF THE KNEE: A MULTI-MODAL APPROACH TO 160,000
PAIN MANAGEMENT
Pri-Med Institute, LLC (d/b/a pmiCME) HOW LOW DO YOU GO? CLINICAL UPDATES IN LOW-DENSITY 490,479
LIPOPROTEINCHOLESTEROL MANAGEMENT Collaboration \3\
Purdue University Focus Medical 2016 ARTHROS CITY ROUNDS SERIES 10,000
Communications, LLC Collaboration \3\
Research Foundation of SUNY MEASURING QUALITY OF LIFE (QOL) IN ESRD 5,000
Research To Practice YEAR IN REVIEW--A FOUR-PART MULTI-TUMOR REGIONAL CME 60,000
SYMPOSIA SERIES FOCUSED ON THE APPLICATION OF
EMERGING RESEARCH INFORMATION TO THE CARE OF PATIENTS
WITH COMMON CANCERS: GENITOURINARY CANCERS MODULE
San Francisco Neurological Society CALIFORNIA NEUROLOGY SOCIETY - UPDATES IN NEUROLOGY 3,000
Association of California 2016
Neurologists Foundation
Scripps Health ANNUAL NEW APPROACHES TO OPTIMIZE REAL-WORLD DIABETES 50,000
CARE: SPRING CONFERENCE
Society for Urologic Nurses and COMPETENCE IN ADVANCED PROSTATE CANCER REGIONAL ONS 30,000
Associates (SUNA) CHAPTER NURSING FORUMS. DEVELOPING STRATEGIES FOR
SEQUENCING AND COMBINING THERAPIES: NURSING
CONSIDERATIONS FOR IMPLEMENTING A TAILORED TREATMENT
APPROACH
Society of Nuclear Medicine 61ST ANNUAL MEETING OF THE SOUTHWESTERN CHAPTER, SNMMI 2,000
Southwestern Chapter of the Society
of Nuclear Medicine
Swedish Medical Center Foundation SIXTH ANNUAL INTENSIVE UPDATE IN NEUROLOGY 3,000
Texas A&M University System Health 12TH ANNUAL DIABETES CONFERENCE: 'DIABETES HEAD TO 10,000
Science Center Coastal Be TOE'
The Endocrine Society ENDO 2016 GENYZME THYROID SESSIONS 100,000
The Omnia-Prova Education MANAGEMENT OF RA: GLOBAL OUTLOOK AND LATIN AMERICAN 311,067
Collaborative, Inc. Prova Education, IMPLICATIONS Collaboration \3\
Inc.
Trustees of Boston University KEYS TO ACHIEVING OPTIMAL GLUCOSE CONTROL: EARLY 375,000
Continuing Education Alliance, LLC INSULIN INITIATION AND CONTROL OF POSTPRANDIAL
GLUCOSE
Trustees of Boston University IMPLEMENTING NEW THERAPIES FOR REFRACTORY 350,000
Continuing Education Alliance, LLC DYSLIPIDEMIA: PRACTICAL CONSIDERATIONS FOR CLINICAL Collaboration \3\
PRACTICE
Ultimate Medical Academy, LLC dba IMPROVING OUTCOMES IN SEVERE ASTHMA: A NEW ERA IN 185,333
Global Education Group Integritas PRECISION MEDICINE Collaboration \3\
Communications, LLC
UMA MLG, LLC COMPREHENSIVE DYSLIPIDEMIA MANAGEMENT: A VIRTUAL 249,825
REALITY TOUR BEYOND STATIN MONOTHERAPY Collaboration\3\
University of Chicago Intelligent INSIDE DYSLIPIDEMIA MANAGEMENT: IMPROVING RISK 285,734
Medical Decisions, Inc. ASSESSMENT, REFERRALS AND LIPID GOAL ATTAINMENT FOR Collaboration \3\
HIGH-RISK CV PATIENTS INSPIRING SYSTEM IMPROVEMENT
WITH DATA-DRIVEN EDUCATION
University of Cincinnati Advances in MAUIDERM NP+PA SUMMER 2016 25,000
Cosmetic and Medical Dermatology Collaboration \3\
University of Kansas Endowment NEUROMUSCULAR REVIEW COURSE SERIES 2016 15,000
Association
University of Massachusetts Medical PIVOTAL TREATMENT ADVANCES IN BIOLOGIC THERAPY FOR 376,000
School C-MEducation Resources, LLC ATOPIC DERMATITIS (AD): FOCUS ON THE Collaboration \3\
IMMUNOPATHOBIOLOGY OF AD AND ROLE OF EVOLVING
BIOLOGIC THERAPIES FOR OPTIMIZING OUTCOMES IN
PATIENTS WITH MODERATE-TO-SEVERE AND TREATMENT-
RESISTANT AD
University of Rochester Society of 2016 SOCIETY FOR INVESTIGATIVE DERMATOLOGY ANNUAL 50,000
Investigative Dermatology MEETING Collaboration \3\
University of Southern California VAN DER MEULEN SYMPOSIUM: MULTIPLE SCLEROSIS UPDATE 20,000
University of Tennessee Advanced ONCOLOGY PHARMACY CONSULTS: UPDATES ON THE MANAGEMENT 45,000
Studies in Medicine OF PROSTATE CANCER
University of Texas Health Science AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) 2016 3,500
Center at San Antonio REVIEW
University of Vermont and State NEW ENGLAND THYROID CONFERENCE 10,000
Agricultural College
USF Health Professions Conferencing 13TH ANNUAL ROCKY MOUNTAIN METABOLIC SYNDROME 5,000
Corporation CEConsultants, LLC SYMPOSIUM
Wellmont Health System 14TH ANNUAL DIABETES SYMPOSIUM 4,000
Yale University INAUGURAL 1-95 INFILTRATIVE CARDIOMYOPATHY CONFERENCE 5,000
----------------------------------------------------------------------------------------------------------------
\1\ Applicant names are provided by the requestor. If applicants apply as a group for a single educational
activity; all applicants may be not be identified above. The Company funds other educational activities
(including fellowships and non-physician and patient education); all of which do not appear on this report,
but appear on other reports on this site.
\2\ ``Funding Amount'' is the amount that the Company funded during Q2, 2016 identified above based upon an
agreement. Recipients are required to return any unused funds. Information on unused funds returned by the
applicant on activities are not reported. ``Funding Amount'' does not include funds that may have been
provided by other affiliated Sanofi Company Entities (e.g., Sanofi Pasteur).
\3\ Collaboration (Shared) Funding--is the full amount of a grant funded under an agreement with Regeneron, some
or all of which may be shared between the collaborating entities.
Independent Medical Education Grants
1st July 2016-30th Sep 2016
Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education
activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and
consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged.
Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.
----------------------------------------------------------------------------------------------------------------
Funding Amount
Recipient Name(s) \1\ Activity Title ($) \2\
----------------------------------------------------------------------------------------------------------------
American Association of Clinical ORR-AACE 18TH ANNUAL MEETING 5,000
Endocrinologists
American Association of Clinical MID ATLANTIC-AACE 14TH ANNUAL MEETING 2,500
Endocrinologists
American Association of Clinical TEXAS-AACE ANNUAL MEETING & TEXAS ENDOCRINE SURGICAL 5,000
Endocrinologists SYMPOSIUM
American Association of Clinical NEVADA AACE ENDOCRINOLOGY FOR THE NON ENDOCRINOLOGISTS 5,000
Endocrinologists AND ANNUAL MEETING
American Association of Clinical NEVADA-AACE ENDOCRINOLOGY FOR THE NON ENDOCRINOLOGISTS 7,500
Endocrinologists AND ANNUAL MEETING
American Association of Nurse BEST PRACTICES IN ACHIEVING OPTIMAL A1C TARGETS AND 141,980
Practitioners (AANP) POST PRANDIAL GLYCEMIC CONTROL
American Diabetes Association 14TH ANNUAL PROFESSIONAL EDUCATION SYMPOSIUM, AN 10,000
AFTERNOON WITH DIABETES EXPERTS: DIABETES DISTRESS,
PHYSICAL ACTIVITY, MEDICATIONS, AND UPDATES TO THE
STANDARDS
American Health Resources, Inc. EXAMINING NEW OPTIONS IN THE MANAGEMENT OF INSULIN 4,600
RESISTANT TYPE 2 DIABETES: A FOCUS ON BASAL INSULIN
THERAPY
American Society for Blood and Marrow 2017 ASBMT/SANOFI NEW INVESTIGATOR AWARD 65,000
Transplantation
Antidote Education Company MANAGING DIABETES IN OLDER POPULATIONS 50,000
California Academy of Physician MANAGEMENT OF OSTEOARTHRITIS IN THE PRIMARY SETTING 4,000
Assistants
California Academy of Physician 2016 ANNUAL MEETING OF THE CALIFORNIA ACADEMY OF 4,000
Assistants PHYSICIAN ASSISTANTS (CAPA): UPDATES IN TYPE 2
DIABETES CARE
Cardiovascular Research Foundation BEST MANAGEMENT FOR COMPLEX PATIENTS WITH COMPLEX 58,100
DISEASE: THE NEXT FRONTIER BEYOND REVASCULARIZATION
Consortium of Multiple Sclerosis 2016 CMSC ANNUAL MEETING SCIENTIFIC PROGRAM 25,000
Centers Nurse Practitioner
Alternatives
Consortium of Multiple Sclerosis MS AT THE CUTTING EDGE: A 5-PART WEBINAR SERIES 56,700
Centers Nurse Practitioner
Alternatives
Dignity Health MandatoryCE LLC 5TH ANNUAL ARIZONA DIABETES SYMPOSIUM 50,000
Dignity Health MandatoryCE LLC 2016 ARKANSAS DIABETES SYMPOSIUM: FOCUS ON PREVENTION, 35,000
CURRENT TREATMENTS, AND COMORBIDITIES
Elsevier Office of Continuing Medical ECTRIMS 2016: OPTIMALLY MANAGING PATIENTS WITH 85,000
Education Academic CME, LLC MULTIPLE SCLEROSIS THROUGH INDIVIDUALIZED TREATMENT
OPTIONS
Emory University 9TH WORLD CONGRESS ON PREVENTION OF DIABETES AND ITS 50,000
COMPLICATIONS
Florida Academy of Physician EVALUATING KIDNEY DISEASE: KIDNEY KASES 5,000
Assistants
Florida Academy of Physician JOINT INJECTIONS 5,500
Assistants
Foundation for Orthopaedic Research ORTHOPAEDICS FOR THE PRIMARY CARE PRACTITIONER & 5,000
and Education, Inc. REHABILITATION THERAPIST
Horizon CME, Inc. GLP-1 RECEPTOR AGONIST AND BASAL INSULIN: AN EMERGING 53,253
STANDARD FOR TYPE DIABETES TREATMENT
Horizon CME, Inc. ULTRALONG-ACTING BASAL INSULINS: WHERE DO THEY FIT? 53,253
Integritas Communications, LLC CLINICAL UPDATES IN THE MANAGEMENT OF SEVERE ASTHMA: 5,000
Ultimate Medical Academy, LLC dba NEW STRATEGIES TO INDIVIDUALIZE LONG-TERM CARE Collaboration \3\
Global Education Group
LeBonheur Children's Hospital BACK TO SCHOOL DIABETES CONFERENCE 3,828
Medical Education Resources Tarsus COMBINING GLP-1RAS WITH INSULIN TO IMPROVE GLUCOSE 159,650
Cardio Inc. dba Cardiometabolic CONTROL
Health Congress
Medical Learning Institute, Inc. PEERVIEW VIDEO INSESSION AT AAN 2016, ``STAYING 131,530
PeerView Institute for Medical CURRENT WITH THE LATEST UPDATES ON APPROVED DISEASE-
Education, Inc. MODIFYING THERAPIES FOR MULTIPLE SCLEROSIS
MANAGEMENT: CLINICAL HIGHLIGHTS FROM VANCOUVER''
Med-IQ, LLC SEQUENCING TREATMENT FOR METASTATIC CASTRATION- 158,565
RESISTANT PROSTATE CANCER: HOW TO MATCH PATIENTS TO
THE RIGHT THERAPY
Med-IQ, LLC THE EVOLVING THERAPEUTIC LANDSCAPE FOR MODERATE-TO- 88,759
SEVERE ATOPIC DERMATITIS Collaboration \3\
National Association for Continuing POSTPRANDIAL HYPERGLYCEMIA AND GLP-1 RECEPTOR 150,000
Education AGONISTS: EFFECTIVE STRATEGIES TO ACHIEVE GOALS
National Association of Managed Care NEW PERSPECTIVES AND EMERGING TREATMENT PARADIGMS IN 57,000
Physicians, Inc. THE MANAGEMENT OF RELAPSING MULTIPLE SCLEROSIS
National Association of Managed Care CLINICAL ADVANCES IN ATOPIC DERMATITIS: NOVEL 57,000
Physicians, Inc. THERAPIES FOR IMPROVED PATIENT OUTCOMES
National Association of Managed Care IMPROVING PATIENT OUTCOMES WITH INDIVIDUALIZED THERAPY 57,000
Physicians, Inc. IN THE MANAGEMENT OF TYPE 2 DIABETES
National Kidney Foundation, Inc. 25TH ANNUAL FELLOWS RESEARCH FORUM 3,500
National Kidney Foundation, Inc. CHRONIC KIDNEY DISEASE-MINERAL BONE DISORDER: 149,420
University of Illinois at Chicago IMPLICATIONS FOR CARDIAC OUTCOMES
National Medical Association STRATEGIES TO ACHIEVE BETTER CLINICAL OUTCOMES IN TYPE 200,000
2 DIABETES AND ITS THERAPEUTIC COMPLICATIONS
Penn State University Antidote 16TH ANNUAL DIABETES SYMPOSIUM 15,000
Education Company
Penn State University Medical STRATEGIES FOR IMPROVING OUTCOMES IN PATIENTS WITH MS 15,000
Communications Media, Inc.
Pennsylvania Society of Physician NEW TREATMENT OPTIONS IN DIABETES MELLITUS 8,000
Assistants
Potomac Center for Medical Education EXPANDING DMD TREATMENT OPTIONS FOR PATIENTS WITH MS 205,000
Rockpointe Corporation
Primary Care Network, Inc. PlatformQ THE EVOLUTION OF BASAL INSULINS: ONE SMALL STEP OR A 100,000
Health Education, LLC GIANT LEAP?
Projects In Knowledge MedPage Today, NEUROLOGY MASTERY IN MULTIPLE SCLEROSIS 120,000
LLC
Regents of the University of 6TH ANNUAL UC IRVINE HEALTH NEUROMUSCULAR COLLOQUIUM 20,000
California
Regents of the University of Colorado PRACTICAL WAYS TO ACHIEVE TARGETS IN DIABETES CARE 200,000
Regents, University of California THE 4TH ANNUAL UCLA DIABETES SYMPOSIUM 10,000
Scripps Health ANNUAL NEW APPROACHES TO OPTIMIZE REAL-WORLD DIABETES 70,000
CARE: FALL CONFERENCE AND ENDURING MATERIALS
The Board of Trustees of the UA for SPECIAL NEPHROLOGY RESEARCH AND TRAINING CENTER 15,000
the UA at Birmingham SYMPOSIUM--11/9/15
The Medical College of Wisconsin, 2016 ASBMT CLINICAL RESEARCH TRAINING COURSE 25,000
Inc. American Society for Blood and
Marrow Transplantation
University of California, San Diego-- PROMOTING BEHAVIOR CHANGE IN DIABETES: A SKILL 50,000
Behavioral Diabetes Institute BUILDING PROGRAM FOR HEALTH CARE PROFESSIONALS
University of California, San Diego ADDRESSING THE NATURAL HISTORY OF TYPE 2 DIABETES: 142,899
Taking Control of Your Diabetes PRACTICAL APPROACHES TO CONTROLLING FASTING AND POST-
PRANDIAL GLUCOSE LEVELS
University of Cincinnati Global HE METABOLIC & ENDOCRINE DISEASE SUMMIT (MEDS) 2016 25,000
Academy for Medical Education, LLC T
----------------------------------------------------------------------------------------------------------------
\1\ Applicant names are provided by the requestor. If applicants apply as a group for a single educational
activity; all applicants may be not be identified above. The Company funds other educational activities
(including fellowships and non-physician and patient education); all of which do not appear on this report,
but appear on other reports on this site.
\2\ ``Funding Amount'' is the amount that the Company funded during Q3, 2016 identified above based upon an
agreement. Recipients are required to return any unused funds. Information on unused funds returned by the
applicant on activities are not reported. ``Funding Amount'' does not include funds that may have been
provided by other affiliated Sanofi Company Entities (e.g., Sanofi Pasteur).
\3\ Collaboration (Shared) Funding--is the full amount of a grant funded under an agreement with Regeneron, some
or all of which may be shared between the collaborating entities.
Independent Medical Education Grants
1st Oct 2016-31th Dec 2016
Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education
activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and
consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged.
Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.
----------------------------------------------------------------------------------------------------------------
Funding Amount
Recipient Name(s) \1\ Activity Title ($) \2\
----------------------------------------------------------------------------------------------------------------
American Academy of Pas 2016 ADULT HOSPITAL MEDICINE BOOT CAMP 5,000
American Association of Clinical CALIFORNIA CHAPTER OF THE AMERICAN ASSOCIATION OF 5,000
Endocrinologists CLINICAL ENDOCRINOLOGISTS (CA AACE) 16TH ANNUAL
MEETING & SYMPOSIUM
American Association of Clinical DIABETES DAY FOR PRIMARY CARE CLINICIANS ADVANCES IN 75,000
Endocrinologists DIABETES CARE
American College of Allergy, Asthma & PLENARY SESSION: MODERN THERAPIES FOR ALLERGIC SKIN 35,000
Immunology DISEASES Collaboration \3\
American Health Resources, Inc. NEW COMPLEMENTARY COMBINATION THERAPY FOR DIABETES: 21,800
FIXED DOSE BASAL INSULINS AND GLP-1 RECEPTOR AGONISTS
American Nephrology Nurses' IMPROVING PATIENT OUTCOMES IN CKD-MBD: INDIVIDUALIZED 139,250
Association MANAGEMENT AND ENHANCED PATIENT ENGAGEMENT
American Society of Nephrology CKD-MBD GUIDELINES: A CRITICAL APPRAISAL OF RECENT 181,790
STUDIES
American Society of Transplantation AST FELLOWS SYMPOSIUM ON TRANSPLANTATION (2016) 35,000
American Thyroid Association, Inc. 3RD ANNUAL E. CHESTER RIDGWAY TRAINEE CONFERENCE 25,000
University of Colorado School of
Medicine
American Thyroid Association, Inc. 86TH ANNUAL MEETING OF THE AMERICAN THYROID 50,000
University of Colorado School of ASSOCIATION
Medicine
American Urological Association ADVANCEMENTS IN UROLOGY 2017, AN AUA/JUA SYMPOSIUM 15,000
American Urological Association ADVANCED PROSTATE CANCER: MANAGING THE SPECTRUM OF THE 60,000
Education & Research, Inc. DISEASE
Annenberg Center for Health Sciences EXPERTPERSPECTIVES: SHIFTING PARADIGMS, EMERGING 224,355
at Eisenhower TREATMENTS IN MODERATE TO SEVERE ATOPIC DERMATITIS Collaboration \3\
Annenberg Center for Health Sciences DEVELOPMENT OF SPANISH LANGUAGE VERSION OF: ANIMATED 75,000
at Eisenhower Postgraduate Institute MULTIPLE SCLEROSIS (MS) PATIENT AN ANIMATED PATIENTS
for Medicine Prime Medic GUIDE TO MS/ANIMADAS DE ESCLEROSIS MULTIPLE (EM)
PACIENTE GUIA DEL PACIENTES ANIMADA A EM
Augusta University NEUROLOGY FOR THE NON-NEUROLOGIST 5,000
AXIS Medical Education, Inc. AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION AND 74,580
MOBILIZATION IN MULTIPLE MYELOMA: CURRENT DEBATE AND
DEVELOPMENTS
Baylor Scott & White Health Baylor 3RD ANNUAL SYMPOSIUM ON INDIVIDUALIZED NOVEL DISEASE- 40,000
University Medical Center dba A. MODIFYING TREATMENT OPTIONS FOR MULTIPLE SCLEROSIS
Webb Roberts Center MedNet, LLC
Baylor Scott & White Health MedNet EMERGING BIOLOGICAL THERAPIES FOR ATOPIC DERMATITIS IN 35,000
CHILDREN AND ADULTS Collaboration \3\
California Optometric Association FABRY DISEASE--OPHTHALMIC MANIFESTATIONS AND RECENT 9,650
ADVANCES
Cleveland Clinic Educational MULTIPLE SCLEROSIS CASE-BASED ONLINE MONOGRAPH 25,000
Foundation
Clinical Care Options, LLC NEW DIRECTIONS IN GU CANCERS: HIGHLIGHTS FROM THE 2017 25,000
Postgraduate Institute for Medicine GENITOURINARY CANCERS SYMPOSIUM
C-MEducation Resources, LLC AKH Inc NEW FRONTIERS AND PIVOTAL CLINICAL ADVANCES IN 297,000
Advancing Knowledge and Healthcare PATHOIMMUNOBIOLOGY OF ATOPIC DERMATITIS: THE Collaboration \3\
TRANSLATIONAL PATH IN ATOPIC DERMATITIS AND
IMPLICATIONS FOR DERMATOLOGY PRACTICE
Consortium of Multiple Sclerosis ADDRESSING COMORBIDITIES IN THE DIAGNOSIS AND 85,000
Centers Nurse Practitioner MANAGEMENT OF PATIENTS WITH MULTIPLE SCLEROSIS: A
Alternatives RESOURCE GUIDE FOR CLINICIANS
Consortium of Multiple Sclerosis CLINICAL CONSULT: CASES AND COMPREHENSIVE CARE IN MS 115,200
Centers Nurse Practitioner
Alternatives
Consortium of Multiple Sclerosis MONITORING AND FOLLOW-UP IN MULTIPLE SCLEROSIS 60,725
Centers Nurse Practitioner COMPREHENSIVE CARE
Alternatives
Continuing Education Alliance, LLC TARGETED THERAPIES IN MODERATE TO SEVERE ATOPIC 92,550
Board of Regents for University of DERMATITIS: EMERGING OPTIONS Collaboration \3\
Nebraska
Creative Educational Concepts, Inc. ADVANCED PROSTATE CANCER: SEARCHING FOR OPTIMAL 15,000
THERAPY SEQUENCE AND ASSESSING EMERGING TREATMENT
OPTIONS
Delaware Academy of Physician MULTIPLE SCLEROSIS 2,200
Assistants Inc.
Elsevier Office of Continuing Medical CLINICAL ADVANCES IN RHEUMATOID ARTHRITIS: A FOCUS ON 350,000
Education Advanced Studies in IMPROVING PATIENT OUTCOMES
Medicine
Elsevier Office of Continuing Medical SPOTLIGHT ON FABRY DISEASE: DIAGNOSIS, GENOTYPE- 200,000
Education Excerpta Medica PHENOTYPE CORRELATION, AND MULTIDISCIPLINARY PATIENT
CARE
Elsevier Office of Continuing Medical ESMO2016: A THERAPEUTIC UPDATE ON THE MANAGEMENT OF 90,000
Education Excerpta Medica BV PATIENTS WITH PROSTATE CANCER
Excel Continuing Education MULTIPLE SCLEROSIS: MANAGING THE DISEASE, ITS SYMPTOMS 7,000
AND QUALITY OF LIFE (PART OF THE SOUTH FLORIDA
NEUROLOGY SYMPOSIUM: IMPROVING PATIENT OUTCOMES)
Excel Continuing Education NEW DIRECTIONS IN THE MANAGEMENT OF POMPE DISEASE 64,120
Florida Academy of Physician MULTIPLE SCLEROSIS 5,000
Assistants Inc.
Foundation of the Consortium of MS 2016-2017 ROBERT LISAK, MD MEDICAL STUDENT RESEARCH 8,000
Centers SCHOLARSHIP
Global Academy for Medical Education SKIN DISEASE EDUCATION FOUNDATION'S 17TH ANNUAL LAS 25,000
Postgraduate Institute for Medicine VEGAS DERMATOLOGY SEMINAR FEATURING THE 13TH ANNUAL Collaboration \3\
Rutgers, the State University PSORIASIS FORUM
Global Academy for Medical Education 16TH ANNUAL CARIBBEAN DERMATOLOGY SYMPOSIUM 20,000
Rutgers Biomedical and Health Collaboration \3\
Sciences
Global Academy for Medical Education SKIN DISEASE EDUCATION FOUNDATION'S 41ST ANNUAL HAWAII 50,000
University of Louisville Research DERMATOLOGY SEMINAR Collaboration \3\
Foundation
Haymarket Medical Education BASAL INSULIN PLUS GLP-1 RAS: THERAPEUTIC SYNERGIES TO 146,788
OPTIMIZE PATIENT OUTCOMES: 4 VIDEO ``HOUSE CALLS''
DISCUSSIONS AMONG EXPERTS
Illinois Academy of Physician JOINT INJECTABLES 4,000
Assistants
Illinois Academy of Physician CHRONIC KIDNEY DISEASE 5,000
Assistants
Indiana Academy of Physician ``WHAT IS CHRONIC KIDNEY DISEASE (CKD) AND END STAGE 6,500
Assistants RENAL DISEASE (ESRD)?''
Indiana Neurological Society Indiana DEMYELINATING DISEASES: WHAT TO DO WHEN THE INSULATION 5,000
State Medical Association BEGINS TO FRAY
Integritas Communications Global LOOKING BENEATH THE SURFACE IN ATOPIC DERMATITIS: 361,807
Education Group TARGETING IMMUNE DYSREGULATION AND DELIVERING Collaboration \3\
COMPREHENSIVE CARE
Integritas Communications, LLC UMA ATOPIC DERMATITIS: NEW PERSPECTIVES ON MANAGING A 267,480
Education, Inc. dba Global Education CHRONIC INFLAMMATORY DISEASE Collaboration \3\
Group
Integritas Communications, LLC UMA CLINICAL ADVANCES IN ATOPIC DERMATITIS: EXPERT 202,218
Education, Inc. dba Global Education INSIGHTS INTO NEW AND EMERGING THERAPIES Collaboration \3\
Group
Integritas Communications, LLC UMA CLINICAL UPDATES IN RHEUMATOID ARTHRITIS: NEW 249,900
Education, Inc. dba Global Education STRATEGIES TO TARGET REMISSION AND INDIVIDUALIZE Collaboration \3\
Group COMPREHENSIVE CARE
International Eczema Council PSORIASIS AND ATOPIC DERMATITIS: TWO DISEASES OR ONE 100,000
International Psoriasis Council SPECTRUM? Collaboration \3\
International Organization of MS NP CONNECTIONS: THE ROLE OF THE NURSE PRACTITIONER IN 75,000
Nurses Nurse Practitioner MULTIPLE SCLEROSIS CARE
Alternatives
Kentucky Academy of Physician JOINT INJECTION WORKSHOP 5,000
Assistants
Medical Learning Institute Inc. PVI PEERVIEW LIVE AT CMSC 2017, GUIDING PATIENTS THROUGH 345,810
Peerview Institute for Medical THE RISKS AND BENEFITS OF DISEASE-MODIFYING THERAPY:
Education Inc. PATIENT STORIES OF SHARED DECISION-MAKING THROUGHOUT
THE COURSE OF MULTIPLE SCLEROSIS
Medical Learning Institute Inc. PVI PEERVIEW LIVE AT ACMG 2017 STRENGTHENING THE GENETICS- 219,430
Peerview Institute for Medical HEMATOLOGY PARTNERSHIP TO SHORTEN THE PATH TO
Education Inc. DIAGNOSIS & TREATMENT OF GAUCHER DISEASE TYPE 1: A
PATIENT STORY
Medical Learning Institute Inc. PVI, PEERVIEW VIDEO INPLAY NOVEL OPTIONS AND PATIENT 169,480
PeerView for Medical Education Inc. PERSPECTIVES IN RHEUMATOID ARTHRITIS: INDIVIDUALIZING Collaboration \3\
CARE FOR THERAPEUTIC SUCCESS
Medical Learning Institute Inc. PVI, PEERVIEW VIDEO INREVIEW: ASSESSING THE COMPARATIVE 60,000
PeerView Institute for Medical EFFECTIVENESS OF DISEASE-MODIFYING THERAPIES: WHAT
Education CAN BE LEARNED FROM HEAD-TO-HEAD CLINICAL TRIALS AND
RECENT NUMBER-NEEDED-TO-TREAT ANALYSES?
Medical Learning Institute, Inc. PEERVIEW IN REVIEW, ``DELAYING DISABILITY PROGRESSION 106,800
PeerView Institute for Medical IN THE MULTIPLE SCLEROSIS PATIENT: WHAT CAN WE LEARN
Education, Inc. FROM AVAILABLE DATA ON APPROVED DISEASE-MODIFYING
THERAPY?''
Medical Learning Institute, Inc. PEERVIEW TALKS: HIGHLY EFFECTIVE DISEASE-MODIFYING 65,000
PeerView Institute for Medical THERAPIES FOR MULTIPLE SCLEROSIS: WHEN AND IN WHOM
Education, Inc. SHOULD THEY BE USED?
Medical Learning Institute, Inc. NEW DEVELOPMENTS IN THE TREATMENT OF ATOPIC 156,480
PeerView Institute for Medical DERMATITIS: CLINICAL HIGHLIGHTS FROM VIENNA Collaboration \3\
Education, Inc.
Med-IQ, LLC DIFFERENTIATING GAUCHER DISEASE FROM OTHER HEMATOLOGIC 290,043
CONDITIONS: EVERY DAY COUNTS
Med-IQ, LLC LYSOSOMAL STORAGE DISEASES: NEWBORN SCREENING UPDATES 261,483
AND IMPLICATIONS FOR LONG-TERM CARE
Med-IQ, LLC FABRY DISEASE : WHEN TO TREAT 100,000
Michigan State Medical Society CARING FOR PATIENTS WITH A FOCUS ON THE KIDNEYS 5,000
MS Views And News Inc. 2016 NEUROLOGICAL ASPECTS OF MS AND BEYOND--SYMPOSIUM 17,500
MSWorld Inc. 2016 MSWORLD-HOSTED TALKS SERIES 35,000
National Association of Managed Care NEW HORIZONS IN THE TREATMENT AND MANAGEMENT OF 70,000
Physicians, Inc. MULTIPLE SCLEROSIS: BEST PRACTICES FOR IMPROVED
PATIENT OUTCOMES
National Association of Managed Care NEW HORIZONS IN THE TREATMENT AND MANAGEMENT OF ATOPIC 90,000
Physicians, Inc. DERMATITIS (AD): HOW NOVEL THERAPIES ARE CHANGING THE Collaboration \3\
TREATMENT PARADIGM
National Jewish Health THE 39TH ANNUAL NATIONAL JEWISH HEALTH PULMONARY & 20,000
ALLERGY UPDATE Collaboration \3\
National Kidney Foundation 12TH ANNUAL JOINT MEETING OF THE UPSTATE AND WESTERN 7,500
NEW YORK COUNCILS ON RENAL NUTRITION
National Kidney Foundation STRATEGIES TO IMPROVE PATIENT OUTCOMES IN CKD-MBD 243,260
MANAGEMENT
Neurologic Disease Foundation 21ST FALL MS SEMINAR--OPTIMIZING MANAGEMENT OF MS 5,995
New England Section American 85TH ANNUAL MEETING NEW ENGLAND SECTION OF THE 10,000
Urological Assn American Urological AMERICAN UROLOGICAL ASSOCIATION
Association Education and Research,
Inc.
Not-For-Profit Hospital Corporation THYROID CANCER MANAGEMENT? AN OVERVIEW AND UPDATE OF 2,750
NEW TREATMENT OPTIONS
Not-For-Profit Hospital Corporation END STAGE RENAL DISEASE FOR THE NON-NEPHROLOGIST 1,910
PeerVoice America Limited Oakstone EMERGING PARADIGMS IN ATOPIC DERMATITIS: TARGETING THE 492,850
Publishing, LLC. UNDERLYING PATHOLOGY Collaboration \3\
Penn State College of Medicine CASES FROM THE COMMUNITY: CLINICAL INVESTIGATORS 80,000
Research To Practice PROVIDE THEIR PERSPECTIVES ON EMERGING RESEARCH AND
ACTUAL PATIENTS WITH ADVANCED PROSTATE CANCER]AN
INDEPENDENT SATELLITE SYMPOSIUM (ISS) HELD AS A
PREMIUM ANCILLARY EVENT DURING THE 2017 GENITOURINARY
CANCERS SYMPOSIUM
Penn State University PENN STATE HERSHEY CANCER INSTITUTE: CONTEMPORARY 3,500
TOPICS IN THYROID CANCER
Pennsylvania Society of Physician MULTIPLE SCLEROSIS: A PRIMARY CARE PERSPECTIVE 4,500
Assistants
Pharmacy Times Continuing Education AN AMERICAN JOURNAL OF MANAGED CARE SYMPOSIUM: 92,358
APPLYING MANAGED CARE STRATEGIES TO THE ADVANCING
LANDSCAPE OF MULTIPLE SCLEROSIS
Pharmacy Times Office of Continuing MANAGING ATOPIC DERMATITIS: A PHARMACIST'S OPPORTUNITY 23,200
Professional Education TO INTERVENE Collaboration \3\
Postgraduate Institute for Medicine BEST PRACTICES FOR MANAGING ADVERSE EVENTS ASSOCIATED 40,000
Clinical Care Options, LLC WITH NOVEL THERAPIES FOR PATIENTS WITH HEMATOLOGIC
MALIGNANCIES
Potomac Center for Medical Education NOVEL INSIGHTS IN ATOPIC DERMATITIS: PATHWAYS, 469,900
Rockpointe Corporation BIOMARKERS, AND PHENOTYPES FOR A TARGETED APPROACH
President and Fellows of Harvard DIABETES AND CARDIOMETABOLIC SYNDROME IN PRIMARY CARE 10,000
College Beth Israel Deaconess
Department of Medicine
President and Fellows of Harvard 18TH BIENNIAL HARVARD UROLOGIC CANCER COURSE 50,000
College Dana Farber Cancer Institute
President and Fellows of Harvard SURGERY OF THE THYROID AND PARATHYROID GLANDS 10,000
College Massachusetts Eye and Ear
Infirmary Depart of Otolaryngology
PRIME Education Inc. (PRIME) ADVANCING OUR UNDERSTANDING OF THE IMMUNOLOGY AND 289,785
TREATMENT CONSIDERATIONS IN ATOPIC DERMATITIS
ProCE, Inc. Wild Iris Medical EVOLUTION OF MULTIPLE SCLEROSIS MANAGEMENT: PHARMACY'S 119,975
Education, Inc. ROLE
Purdue University CiME LLC APPLYING EVIDENCE BASED MANAGEMENT STRATEGIES FOR 62,792
PATIENTS WITH MS: AN EDUCATIONAL DATA CONTINUUM
Regents, University of California FOURTH ANNUAL UCLA REVIEW OF CLINICAL NEUROLOGY 5,000
Rheumatology Nurses Society American RHEUMATOLOGY NURSES SOCIETY 2016 ANNUAL CONFERENCE 25,000
Academy of Continuing Medical
Education, Inc.
RMEI Postgraduate Institute for A LEARNING PATHWAY IN ATOPIC DERMATITIS: ACHIEVING 989,750
Medicine SUCCESS IN ASSESSMENT AND MANAGEMENT TO IMPROVE Collaboration \3\
PATIENT OUTCOMES
RMEI The Omnia-Prova Education TARGETING THE CYTOKINE PATHWAY IN RA MANAGEMENT: 199,610
Collaborative (TOPEC) IMPLICATIONS FOR NOVEL AND EMERGING IL-6 AGENTS Collaboration \3\
Robert Michael Educational Institute, THE FUTURE OF ASTHMA MANAGEMENT: PRECISION THERAPY 212,340
LLC WITH EMERGING CYTOKINE INHIBITORS Collaboration \3\
Sanford Medical Center Fargo 2016 SANFORD HEALTH NEPHROLOGY, DIALYSIS, TRANSPLANT 3,000
SYMPOSIUM
Sidney Kimmel Medical College at 5TH ANNUAL DIABETES SYMPOSIUM: NEW ADVANCES & TRENDS 10,000
Thomas Jefferson University
Society of Urologic Nurses and EMERGING PRACTICE PATTERNS FOR THE UROLOGY NURSE IN 50,000
Associates Plexus Communications MANAGING PATIENTS WITH ADVANCED PROSTATE CANCER:
CHALLENGES AND BEST PRACTICES WITH SYSTEMIC THERAPY
Southern Alliance for Physician 40TH ANNUAL SOUTHEASTERN CONSORTIUM FOR DERMATOLOGY 10,000
Specialties CME UPDATES IN PSORIASIS AND INFLAMMATORY DISORDERS Collaboration \3\
Southern Salt, Water, and Kidney Club 57TH ANNUAL SCIENTIFIC MEETING 2,500
The Medical College of Wisconsin, 25TH ANNUAL PERSPECTIVES IN UROLOGY: POINT 15,000
Inc. Carden Jennings Publishing Co., COUNTERPOINT (PCP 25)
Ltd.
Trustees of Boston University 2016 PCE ONCOLOGY SYMPOSIA SERIES FOR ADVANCED 150,000
Continuing Education Alliance PRACTICE PROVIDERS SPECIALIZED IN ONCOLOGY: CHOOSING
INITIAL THERAPY FOR METASTATIC PROSTATE CANCER: A NEW
DIRECTION
Trustees of Boston University PRACTICING CLINICIANS EXCHANGE (PCE) 2016 PRIMARY CARE 50,000
Continuing Education Alliance, LLC SYMPOSIA SERIES 3 FOR NURSE PRACTITIONERS & PHYSICIAN Collaboration \3\
ASSISTANTS: RHEUMATOID ARTHRITIS: TREATING TO TARGET
IN PRIMARY CARE
UMA Education, Inc. dba Global SCRATCHING BENEATH THE SURFACE OF ATOPIC DERMATITIS 25,000
Education Group Collaboration \3\
UMA Education, Inc. dba Global METASTATIC PROSTATE CANCER: CURRENT TRENDS AND FUTURE 53,000
Education Group Applied Clinical LANDSCAPE
Education
UMA MLG, LLC MANAGING MODERATE-TO-SEVERE ATOPIC DERMATITIS IN 169,430
ADULTS: PATHOLOGY-BASED, TARGETED THERAPIES Collaboration \3\
University of Cincinnati INNOVATIVE TECHNIQUES: THE KNEE COURSE 2016 5,000
University of Cincinnati CORE Medical PRACTICE CHANGING ADVANCES: EXPANDING THE ATOPIC 112,825
Education, LLC DERMATITIS ARMAMENTARIUM Collaboration\3\
University of Cincinnati CORE Medical TYPE 2 DIABETES: MASTERING COMBINATION THERAPIES TO 42,825
Education, LLC INDIVIDUALIZE AND OPTIMIZE OUTCOMES
University of Cincinnati Robert TAILORING APPROACHES TO MANAGEMENT IN PATIENTS WITH 247,170
Michael Educational Institute, LLC RHEUMATOID ARTHRITIS: WHAT'S NEW? Collaboration \3\
University of Nevada, Reno School of 2016 FALL CLINICAL DERMATOLOGY CONFERENCE 125,000
Medicine Foundation for Research and Collaboration \3\
Education in Dermatology
University of Tennessee Advanced LYSIS CRISIS: PHARMACIST'S ROLE AND RESPONSIBILITY IN 70,000
Studies in Medicine THE MANAGEMENT OF TUMOR LYSIS SYNDROME
University of Vermont and State NORTHERN NEW ENGLAND NEUROLOGICAL SOCIETY ANNUAL 5,000
Agricultural College MEETING
WebMD Global LLC 2016 CLINICAL COURSE ON NEW DEVELOPMENTS IN ATOPIC 144,200
DERMATITIS Collaboration \3\
World Allergy Organization WAO INTERNATIONAL SCIENTIFIC CONFERENCE 2016 30,000
Collaboration \3\
----------------------------------------------------------------------------------------------------------------
\1\ Applicant names are provided by the requestor. If applicants apply as a group for a single educational
activity; all applicants may be not be identified above. The Company funds other educational activities
(including fellowships and non-physician and patient education); all of which do not appear on this report,
but appear on other reports on this site.
\2\ ``Funding Amount'' is the amount that the Company funded during Q4, 2016 identified above based upon an
agreement. Recipients are required to return any unused funds. Information on unused funds returned by the
applicant on activities are not reported. ``Funding Amount'' does not include funds that may have been
provided by other affiliated Sanofi Company Entities (e.g., Sanofi Pasteur).
\3\ Collaboration (Shared) Funding--is the full amount of a grant funded under an agreement with Regeneron, some
or all of which may be shared between the collaborating entities.
Independent Medical Education Grants
1st Jan 2017-31th Mar 2017
Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education
activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and
consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged.
Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.
----------------------------------------------------------------------------------------------------------------
Funding Amount
Recipient Name(s) \1\ Activity Title ($) \2\
----------------------------------------------------------------------------------------------------------------
AcademicCME, LLC. Applying Newer Biologic Therapies to Improve Outcomes 324,370.00
in Patients with Atopic Dermatitis Collaboration \3\
Academy for Continued Healthcare Current and Emerging Approaches to Customize Prostate 50,000.00
Learning Cancer Treatment: an eNewsletter Series
Academy of Managed Care Pharmacy Management of Rare and Orphan Diseases for Improved 34,500.00
(AMCP) Patient and Payer Outcomes
Advanced Studies in Medicine Elsevier Hawaii Dermatology Seminar: A Therapeutic Update on 131,590.00
Office of Continuing Medical the Management of Patients with Atopic Dermatitis Collaboration \3\
Education
Advancing Knowledge in Healthcare Overcoming the Clinical Challenges of Basal Insulin 167,340.00
Medtelligence Usage in Type 2 Diabetes
American Academy of PAs AAPA 2017--Rheumatology Track 5,000.00
Collaboration \3\
American Association of Clinical Using Insulin When, Where, and How It's Needed: Type 2 204,570.00
Endocrinologists Diabetes Treatment in the Modern Age
American Association of Clinical AACE 2017--Treatment Advances for Challenging Patients 329,620.00
Endocrinologists ASiM with Type 2 Diabetes: The Role of Emerging Insulin
Combinations
American Association of Clinical Endocrine University--Thyroid Sessions 10,000.00
Endocrinologists
American Association of Diabetes Improving Adherence with New Fixed-Dose Insulin 864,525.00
Educators Medscape Combination Therapy
American College of Cardiology Recent Trends in Combination Therapy: Managing 50,000.00
Foundation Cholesterol Even in the Most Resistant Collaboration \3\
American College of Medical Genetics Genzyme/ACMG Foundation Clinical Genetics Fellowships 75,000.00
Foundation in Medical Biochemical Genetics
American College of Rheumatology 2017 ACR Rheumatology Courses 150,000.00
Collaboration \3\
American Society of Transplantation 2017 AST Cutting Edge of Transplantation: One 38,000.00
Transplant for Life, Many Pathways to Success
American Urological Association 2017 CRPC Live Forum for Urology Residents and Fellows 60,000.00
American Urological Association 2017 AUA Annual Meeting: Highlights in Advanced 75,000.00
Prostate Cancer
Annenberg Center for Health Sciences Chronic Kidney Disease-Mineral and Bone Disorder- 67,905.00
at Eisenhower Translating Evidence Into Practice
Annenberg Center for Health Sciences Expert Discussions: Recent Advances in Metastatic 100,000.00
at Eisenhower Clinical Care Options, Prostate Cancer Treatment
LLC
Annenberg Center for Health Sciences Dana Farber Master Class for Oncologists-- 25,000.00
at Eisenhower Genitourinary Cancers Track
AXIS Medical Education Integrating Shared Decision Making and Guideline 40,000.00
Recommendations for Prostate Cancer Treatment
AXIS Medical Education ReachMD Advancing Interdisciplinary Care in Prostate Cancer: 143,090.00
Clinical Updates for Urology and Oncology Healthcare
Professionals
Boston University School of Medicine-- PCE Series 2: Decision Points--Considerations for 399,897.00
Office of CME Continung Education Using New Complementary GLP-1 Receptor Agonist-
Alliance, LLC Institute for Medical Insulin Combinations in Patients with T2DM
and Nursing Education, Inc.
Boston University School of Medicine PCE 2017 Primary Care Symposia Series 3: Joint 100,000.00
Practicing Clinicians Exchange Management: The Role of Primary Care in Rheumatoid Collaboration \3\
Arthritis
Catamount Medical Education, LLC MS4: Sequencing, Switching, Escalation, and Symptom 150,000.00
Postgraduate Institute for Medicine Management
Cedars-Sinai Medical Center 6th Annual Symposium on Lysosomal Storage Disorders 15,000.00
Children's Hospital of Philadelphia Genetic Counselor Fellowship in Lysosomal Storage 75,000.00
Foundation Disorders
Conquer Cancer Foundation of the 2017 Genitourinary (GU) Cancers Symposium: Translating 28,000.00
American Society of Clinical Research to Value-Based and Patient-Centric Care
Oncology American Society of
Clinical Oncology, Inc.
Consortium of Multiple Sclerosis The Science of MS Management: 2017 70,775.00
Centers Nurse Practitioner
Alternatives
Consortium of Multiple Sclerosis Advances In Multiple Sclerosis (AIMS) 2016: A 360 125,000.00
Centers Nurse Practitioner Approach to Translating Data into Optimal Practice
Alternatives The France Foundation
Duke University Fellowship in Medical Biochemical Genetics 75,000.00
Elesevier Office of Continuing Clinical Issues in Severe Asthma: Consensus and 271,605.00
Education Integritas Communications Controversies on the Road to Precision Medicine Collaboration \3\
Elsevier Office of Continuing Medical Perspectives from the American Academy of Dermatology 131,590.00
Education ASiM 2017 Meeting: Clinical Strategies and Scientific Collaboration3
Advances in Atopic Dermatitis
Emory Genetics Laboratory Paul M. Fernhoff Genetic Counselor Fellowship in 75,000.00
Lysosomal Storage Diseases
Endocrine Society ENDO 2017 Thyroid Sessions 75,000.00
Enquiring Minds, LLC Postgraduate Multiple Sclerosis in Pediatric Patients: Expert 60,000.00
Institute for Medicine Guidance on Overcoming Challenges in Diagnosis and
Treatment
Evolve Medical Education, LLC From Symptom Control to Target Treatment: The Shifting 201,325.00
Paradigm of Atopic Dermatitis Collaboration \3\
Excerpta Medica BV Elsevier Office of 2017 Genitourinary Cancers Symposium: A Therapeutic 65,795.00
Continuing Medical Education Update on the Management of Patients with Prostate
Cancer
Foundation of the Consortium of MS 2017 FCMSC Medical Resident Annual Meeting (CMSC) 24,700.00
Centers Scientific Scholarships
Foundation of the Consortium of MS 2017-2018 Medical Student Research Scholarships 34,000.00
Centers
Haymarket Medical Education Physiologic Approaches to Optimizing Glycemic Control: 309,519.00
A Pecha Kucha-Inspired CME Symposium on Long-Acting
Insulins
Horizon CME Fixed-Ratio GLP-1RA and Basal Insulin Formulations: 182,100.00
How and When to Use Them?
Horizon CME GLP-1 RA and Basal Insulin Combinations: New Options 212,645.00
for Treatment Intensification
Integrity Continuing Education, Inc. Overcoming Barriers to the Early Recognition and 149,000.00
Diagnosis of Rheumatoid Arthritis in Real-World Collaboration \3\
Practice: Strategies to Expedite Treatment to
Remission
Integrity Continuing Education, Inc. 2017 AAFP State Society CME Meetings and Publication 198,500.00
in Action Enduring Material Initiative--Evaluating Collaboration \3\
Newer Targeted Therapies for Patients with Rheumatoid
Arthritis: Addressing Unmet Needs in the Primary Care
Practice
International Psoriasis Council Evolving Perspectives on Psoriasis and Atopic 100,000.00
Dermatitis: Are They Two Diseases or One Spectrum? Collaboration \3\
Lysosomal and Rare Disorders Research Genetic, Rare and Immune Disorders Symposium (GRIDS) 30,000.00
and Treatment Center Professional 2016
Education Services Group
Med Learning Group Actionable Pathologic Targets in Rheumatoid Arthritis: 169,700.00
Modifying the Dysregulation of the Immune Response to Collaboration \3\
Self to Optimize Patient Outcomes
Medical Learning Institute Inc. PVI ``Insights Into the Pathophysiology of Atopic 290,600.00
Peerview Institute for Medical Dermatitis: Setting the Stage for Novel Treatment Collaboration \3\
Education Inc. Options''
Medical Learning Institute Inc. PVI ``Addressing Unmet Needs in Rheumatoid Arthritis 156,730.00
Peerview Institute for Medical Through Novel Treatment Options and Enhanced Collaboration \3\
Education Inc. Physician-Patient Collaboration''
Medical Learning Institute Inc. PVI, PeerView Video in Exchange, ``Establishing a 98,750.00
PeerView Institute for Medical Therapeutic Alliance in the Management of Multiple
Education Sclerosis: How Can We Better Align Treatment
Preferences and Goals among Patients and
Practitioners?''
Med-IQ, LLC Newborn Screening for Lysosomal Storage Disorders: 197,866.00
Recent Progress and Unanswered Questions
Med-IQ, LLC Medical Insiders: Targeting IL-6 Signaling in the 125,000.00
Treatment of Rheumatoid Arthritis Collaboration3
Med-IQ, LLC Tumor Lysis Syndrome in a Rapidly Evolving Treatment 142,099.00
Landscape
Med-IQ, LLC Insulin Intensification with GLP-1 Receptor Agonists: 251,110.00
Clinical Evidence and Real World Perspectives
Med-IQ, LLC Viewpoints on Atopic Dermatitis: How Emerging 169,995.00
Treatments May Change the Management of Moderate to Collaboration \3\
Severe Disease
Medscape Osteoarthritis of the Knee: A Patient-Simulation 250,000.00
Approach to Assessment and Management
Medscape LLC Managing Patients With Rheumatoid Arthritis in the 250,000.00
Virtual Clinic Setting Collaboration \3\
Medscape LLC A Lipid Clinic in Action: How Would You Treat? 225,000.00
Collaboration \3\
Medscape LLC Close Concerns Improving Outcomes in Diabetes: Glucose Monitoring, 75,000.00
Adherence, and Individualized Treatment
Medscape, LLC Autologous Stem Cell Transplantation in Multiple 182,500.00
Myeloma: Who, When, and How?
Mount Sinai School of Medicine International Center for Fabry Disease 150,000.00
MS Cure Fund, Inc. 1st Quarter 2017 Multiple Sclerosis Lifestyle 19,750.00
Management Patient Education Programs
National Association of Managed Care Managing Castration-Resistant Prostate Cancer: 45,000.00
Physicians Understanding the Therapeutic Landscape
National Association of Managed Care What's New in the Evolving Treatment Landscape for 57,000.00
Physicians, Inc. Moderate-to-Severe Atopic Dermatitis (AD) Collaboration \3\
National Jewish Health Personalized Medicine in Severe Asthma: Applying 120,044.00
Emerging Data and Treatments to Everyday Clinical Collaboration \3\
Practice
National Jewish Health Western WSAAI 55th Annual Scientific Session 15,000.00
Society of Allergy, Asthma and Collaboration \3\
Immunology (WSAAI)
National Lipid Association Robert Navigating the Challenges of Prescribing PCSK9 249,835.00
Michael Educational Institute (RMEI) Inhibitors in Persistent Elevated LDL-C Collaboration \3\
National Society of Genetic New Lysosomal Storage Disease Healthcare Advocate 28,000.00
Counselors (NSGC) Emory University Workshop
New York University--Langone School Department of Neurology, Division of Neurogenetics 75,000.00
of Medicine
North American Center for Continuing Fixed-Ratio GLP-1 RA and Basal Insulin Combinations: A 173,365.00
Medical Education Horizon CME Complementary Approach to Treatment Intensification
Norton Healthcare Foundation Celebrating MS Innovations 2017 10,000.00
NYU Post-Graduate Medical School NYU Seminar In Advanced Rheumatology 10,000.00
Collaboration \3\
Organ Donation and Transplantation 2017 National Donor Management Summit 5,000.00
Alliance
Penn State College of Medicine MCM Evolving Standards of Care in Metastatic Prostate 138,400.00
Education Cancer
Penn State College of Medicine PVI ``PeerView Master Class and Practicum Live--Urologists 150,000.00
Peerview Institute for Medical at the Intersection of Evidence-Based and Patient-
Education Inc. Centric Prostate Cancer Care: Practical Guidance for
Everyday Practice''
Penn State College of Medicine, MCM Rheumatoid Arthritis: Improving Quality of Care 100,000.00
Education Collaboration \3\
Pharmacy Times Continuing Education Managing Diabetes with Insulin/ GLP-1 Receptor Agonist 251,500.00
Combinations: A Clinical Discussion of Safety and
Efficacy Data
Pharmacy Times Continuing Education Information for Pharmacists: Counseling on 36,000.00
Dermatologic Conditions Collaboration \3\
Pharmacy Times Continuing Education Advances in the Treatment of Moderate to Severe Atopic 59,867.00
Dermatitis: Practice and Management Essentials for Collaboration \3\
Specialty Pharmacists
Pharmacy Times Continuing Education Medical Crossfirer: Value-Based Diabetes: Managing 187,400.00
Costs Yet Improving Outcomes
Pharmacy Times Continuing Education Treatment Advances in Diabetes: Evaluating the Safety 68,000.00
and Efficacy of Insulin/GLP-1 Receptor Agonist
Combinations
Pharmacy Times Continuing Education Atopic Dermatitis: Focusing on the Patient Care 74,000.00
Strategy in the Managed Care Setting Collaboration \3\
Ponce Medical School Foundation, Inc. The Role of the Primary Care Providers with Chronic 10,000.00
Kidney Disease Patients.
Postgraduate Healthcare Education, Working Together Against Clinical Inertia: Using 126,075.00
LLC Combination Injectable Therapies in Type 2 Diabetes
Postgraduate Institute for Medicine Best Practice Roadmaps and Clinical Rationale for Use 968,000.00
CMEducation Resources of Complementary Insulin plus GLP-1 Receptor Agonist
Combination Therapy To Optimize PAN-Glycemic HA1c
Target Goal Attainment in T2D: The Physiologic and
Mechanistic Basis for New Basal Insulin plus Short-
Acting GLP-1 RA Fixed-Ratio, Combination Formulations
for Controlling FPG and Postprandial Hyperglycemia
(PPG): Optimizing Glucose Control and Reducing Risks
of Hypoglycemia and Weight Gain
Postgraduate Institute for Medicine Best Practice Roadmaps and Clinical Rationale for Use 319,000.00
CMEducation Resources of Complementary Insulin plus GLP-1 Receptor Agonist
Combination Therapy To Optimize PAN-Glycemic HA1c
Target Goal Attainment in T2D: The Physiologic and
Mechanistic Basis for New Basal Insulin plus Short-
Acting GLP-1 RA Fixed-Ratio, Combination Formulations
for Controlling FPG and Postprandial Hyperglycemia
(PPG): Optimizing Glucose Control and Reducing Risks
of Hypoglycemia and Weight Gain
Postgraduate Institute for Medicine New Fixed-Ratio Combination Insulin Regimens for 341,000.00
CMEducation Resources Optimizing Comprehensive Glycemic Management In
Challenging Patients with T2D: The Rationale,
Evidence, and Mechanistic Basis for Fixed Ratio,
Complementary Insulin plus GLP-1 RA Combinations for
Achieving FPG and PPG Target Goals-Focus on Pan-
Glycemic Control While Mitigating Risks of
Hypoglycemia and Weight Gain
Practicing Clinicians Exchange Practicing Clinicians Exchange (PCE) Directed Learning 138,800.00
Continuing Education Alliance eCourse: Updates on the Management of Knee
Osteoarthritis in Primary Care: The Role of
Viscosupplementation
President and Fellows of Harvard New England Thyroid Club 1,500.00
College acting through Harvard
Medical School Depart. of Contin Edu
Beth Israel Deaconess Medical Center
President and Fellows of Harvard Clinical Endocrinology 2017 5,000.00
College acting through the Harvard
Medical School Department of Con The
Massachusetts General Hospital
PRIME Education, LLC GME-CME Today Advanced Practice in Multiple Sclerosis: 92,938.00
Focused Training for Effective Individualized
Treatment Decision-Making
PRIME Education, LLC Implications of Cardiovascular Outcomes Trials on 228,145.00
Lipid-Lowering Therapies Collaboration \3\
PRIME Education, LLC Applying Evidence and Lessons Learned in the 295,270.00
Management of Moderate-to-Severe Atopic Dermatitis Collaboration \3\
Pri-Med Institute, LLC Horizon CME Practical Strategies to Using Novel GLP-1 RA and Basal 972,120.00
Insulin Combinations in Clinical Practice
Pri-Med Institute, LLC Horizon CME Integrating Newer Basal Insulins in Primary Care: A 956,499.91
Case-based Review
Projects In Knowledge @Point of Care Rheumatologic Diseases @Point of Care 150,000.00
Collaboration \3\
Projects In Knowledge @Point of Care Multiple Sclerosis @Point of Care 133,225.00
Prostate Cancer Foundation MARS2 Retreat (Mission: Androgen Receptor Splice 10,000.00
Variant)
PVI Peerview Institute for Medical PeerView Video inSession, ``Examining the Clinical 66,240.00
Education Inc. Medical Learning Implications of Late-Breaking Data on Approved and
Institute Inc. Emerging Disease Modifying Therapies for Multiple
Sclerosis Management: What Are the Key Learnings From
Boston?''
Regents of the University of 5th Annual UC San Diego Essentials and Advances in 5,000.00
California Apheresis
Regents of the University of Transplant Immunosuppression 2017: Achieving Long-Term 35,000.00
Minnesota Success
Research To Practice What Urologists Want to Know: Addressing Current 85,000.00
Questions and Controversies in the Management of
Early and Advanced Prostate Cancer--An Independent
Satellite Symposium (ISS) Held in Conjunction with
the 2017 American Urological Association (AUA) Annual
Meeting
Rocky Mountain MS Center MS 101 2017 Programs 10,000.00
Rush University Medical Center Plexus Realizing Improved Outcomes in Advanced Prostate 80,000.00
Communications Cancer through Evolving Research and Emerging
Treatment Paradigms: Challenges and Opportunities
Rush University Medical Center Plexus VHA Oncology Clinical Forums: ``Current Treatment 100,000.00
Communications Strategies for Advanced Prostate Cancer: Sequencing
Therapies and Incorporating Novel Approaches''
Society for Inherited Metabolic 2016 North American Metabolic Academy 20,000.00
Disorders
St. Joseph's Regional Medical Center Introduction to Clinical Transplantation; Renal 1,500.00
Transplantation--An Overview
The France Foundation State Chapter Meetings: A Physiological Approach to 357,120.00
Combination Therapies: Improving Glycemic Control in
T2DM
The France Foundation A Bright Outlook on New and Emerging RA Management 145,330.00
Options: What Would You Do? Collaboration \3\
The France Foundation Calibre Famous People with Diabetes: A Case Study Exploring 552,210.00
Institute for Quality Medical the Use of New and Emerging Basal Insulins
Education
The Medical College of Wisconsin, 27th International Prostate Cancer Update 20,000.00
Inc. Carden Jennings Publishing Co.,
Ltd.
The Medical College of Wisconsin, Optimizing Stem Cell Mobilization for Autologous 223,000.00
Inc. Carden Jennings Publishing Co., Transplantation in Myeloma
Ltd.
The National Multiple Sclerosis The Living Well with MS Conference (North Florida) 3,500.00
Society, North Florida Chapter
The Trustees of the University of Lysosomal Storage Disease Fellowship 75,000.00
Pennsylvania
The University of Chicago 22nd Annual University of Chicago Developmental 5,000.00
Therapeutics Symposium
The University of Texas MD Anderson 7th Current Concepts in the Management of Thyroid & 25,000.00
Cancer Center Parathyroid Neoplasms
Tufts Medical Center Hypertrophic Cardiomyopathy--A Contemporary and 20,000.00
Treatable Disease: Diagnosis, Heart Failure
Management, and Prevention of Sudden Death
UC Irvine University of California, Irvine Lysosomal Storage 56,857.68
Diseases Patient and Family Educational Grant
UCI Office of Continuing Medical Nephrology Grand Rounds 2,000.00
Education University of California
Irvine
UMA Education Inc., dba Global Optimizing Outcomes in Atopic Dermatitis 106,250.00
Education Group, Physicians' Collaboration \3\
Education Resource
University of Alabama at Birmingham 2017 Fabry Fellowship 75,000.00
UMA Education, Inc.: dba Global Going Deeper on Atopic Dermatitis: Pathophysiology to 239,640.92
Education Integritas Communications the Management of Moderate-to-Severe Disease Collaboration \3\
University of Arkansas for Medical Tackling Type 2 Diabetes at the Community Level: A 90,000.00
Sciences MedIQ Focused QI Initiative to Overcome Local Challenges to
Patient Health
University of Cincinnati Advances in MauiDerm 2017 45,000.00
Cosmetic and Medical Dermatology Collaboration \3\
University of Kansas Medical Center/ Neuromuscular Review Course 2017 20,000.00
Kansas Endowment Association
University of Kansas School of Neuromuscular Medicine Fellowship 75,000.00
Medicine
University of Massachusetts Medical The Physiologic and Mechanistic Rationale for 341,000.00
School CMEducation Resources Achieving HA1c Target Goals with Basal Insulin In
Vulnerable Patients with Type 2 Diabetes: Focus on
the Safety-Efficacy Equation, Patient Selection,
Switching, Dosing and Physiologic, PK/PD Profiles of
Long-Acting Basal Insulin Formulations
University of Massachusetts Medical The iQ&A Case-By-Case interactive Diabetes 178,000.00
School CMEducation Resources Intelligence Zone: Practical, Real World Strategies
for Deploying Fixed-Ratio Insulin Combinations in T2D-
National Experts in Diabetes Focus on Patient
Identification, Dose Titration, Pan-Glycemic (FPG and
PPG) Control, Mechanistic Complementarity, and
Optimizing the Safety-Weight-Efficacy Equation in
Patients with Diabetes
University of Massachusetts Medical The iQ&A Case-By-Case Interactive Diabetes 178,000.00
School CMEducation Resources Intelligence Zone: Focus on Practical Aspects of
Using Physiologic, Long-Acting Basal Insulin to
Optimize Glycemic Management in T2D
University of Rochester School of 2017 Society for Investigative Dermatology Annual 50,000.00
Medicine and Dentistry Society for Meeting Collaboration \3\
Investigative Dermatology
University of Massachusetts Medical The iQ&A Case-By-Case Interactive Diabetes 178,000.00
School CMEducation Resources Intelligence Zone: Focus on Practical Aspects of
Using Physiologic, Long-Acting Basal Insulin to
Optimize Glycemic Management in T2D
University of Rochester School of 2017 Society for Investigative Dermatology Annual 50,000.00
Medicine and Dentistry Society for Meeting Collaboration3
Investigative Dermatology
University of Vermont and State The 28th Annual Eastern Winter Dermatology Conference Collaboration \3\
Agricultural Colle 10,000.00
UT Southwestern Medical Center 39th Annual Carrell-Krusen Neuromuscular Symposium 5,000.00
Collaboration \3\
World Allergy Organization Collaboration on Severe Asthma (COSA) 35,000.00
Collaboration \3\
----------------------------------------------------------------------------------------------------------------
\1\ Applicant names are provided by the requestor. If applicants apply as a group for a single educational
activity; all applicants may be not be identified above. The Company funds other educational activities
(including fellowships and non-physician and patient education); all of which do not appear on this report,
but appear on other reports on this site.
\2\ ``Funding Amount'' is the amount that the Company funded during Q1, 2017 identified above based upon an
agreement. Recipients are required to return any unused funds. Information on unused funds returned by the
applicant on activities are not reported. ``Funding Amount'' does not include funds that may have been
provided by other affiliated Sanofi Company Entities (e.g., Sanofi Pasteur).
\3\ Collaboration (Shared) Funding--is the full amount of a grant funded under an agreement with Regeneron, some
or all of which may be shared between the collaborating entities.
Independent Medical Education Grants
1st April 2017-30th June 2017
Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education
activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and
consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged.
Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.
----------------------------------------------------------------------------------------------------------------
Funding Amount
Recipient Name(s) \1\ Activity Title ($) \2\
----------------------------------------------------------------------------------------------------------------
AKH Inc., Advancing Knowledge in A Multidisciplinary Approach to the Treatment of 149,125.00
Healthcare Center of Excellence Prostate Cancer: Providing Therapies that Improve
Media, LLC--An affiliate of The Lynx Overall Survival and Quality of Life
Group
AKH Inc., Advancing Knowledge in Endocrine Nurses Society Symposium 2017 Thyroid 5,000.00
Healthcare Endocrine Nurses Society Sessions
American Academy of Dermatology The The Future is Finally Here--Targets of the New Atopic 75,000.00
France Foundation Dermatitis Drugs Collaboration \3\
American Academy of PAs AAPA 2017--Orthopaedics Track 10,000.00
American Association of Clinical Current Landscape in Medullary Thyroid Cancer: Updates 198,425.00
Endocrinologists for Clinicians
American Association of Clinical Georgia-AACE April Dinner Program: New Developments in 3,276.00
Endocrinologists Thyroid Cancer
American College of Allergy, Asthma & EAC 2017 Update in Allergy, Asthma & Immunology 10,000.00
Immunology Eastern Allergy Collaboration \3\
Conference
American College of Allergy, Asthma & Society of Allergy, Asthma & Immunology CSAAI 2017 A 10,000.00
Immunology; California Midsummer Night's Wheeze
American College of Medical Genetics Genzyme/ACMG Foundation Clinical Genetics Fellowships 75,000.00
Foundation in Biochemical Genetics
American Society of Clinical Oncology 2017 ASCO Annual Meeting Genitourinary Cancer 28,000.00
Oncology, Inc. Conquer Cancer Tracks Bundle--Prostate and Nonprostate
Foundation of the American Society
of Clinical
American Thoracic Society ATS 2017 International Conference--Selected Sessions 20,000.00
in Asthma Collaboration \3\
Ann & Robert H. Lurie Children's Lysosomal Storage Disease Training Program for Genetic 75,000.00
Hospital of Chicago Counselors
Med Learning Group Novel Formulations of Basal Insulins for Patients with 249,050.00
Diabetes: A New Opportunity to Optimize Outcomes
Med Learning Group A Virtual Reality View of Biologic Agents: Targeted 375,000.00
Therapies for the Management of Moderate-to-Severe Collaboration \3\
Atopic Dermatitis in Adults
Medical Learning Institute Inc. PVI Enhancing Autologous Hematopoietic Stem Cell 108,050.00
Peerview Institute for Medical Transplantation Through Individualized Stem Cell
Education Inc. Mobilization Strategies
Medical Learning Institute Inc. PVI PeerView Video in Session ``New Developments in 154,980.00
Peerview Institute for Medical Inflammatory Dermatologic and Respiratory Diseases: Collaboration \3\
Education Inc. Clinical Highlights From Helsinki''
Medscape LLC Basal Insulin in Today's Clinical Practice 500,000.00
Environment: Improving Use for Better Patient
Outcomes
Medscape LLC Clinical Advances in Atopic Dermatitis 950,000.00
Collaboration \3\
Medscape LLC A Medscape Studio Series on Modern Approaches for 125,000.00
Optimizing Care in MS
Michigan State Medical Society Rheumatology Update 5,000.00
Collaboration \3\
MSWorld Inc. Comprehensive Proposal for 2017 MS World Conference 50,000.00
Coverage
MSWorld Inc. 2017 ``MSWorld Talks'' Series 55,000.00
Muscular Dystrophy Association MDA Care Center Open House at Nemours Children's 500.00
Hospital
National Association of Managed Care Individualizing Treatment in the Management of Type 2 57,000.00
Physicians, Inc. Diabetes: Novel Therapies for Improved Patient
Outcomes
National Comprehensive Cancer Network Prostate Cancer Patient Management Simulator 35,000.00
National Lipid Association Vindico Back to the Future: Clinical Experience with and 50,000.00
Medical Education Access to Lipid-Lowering Agents of the Past, Present, Collaboration \3\
and Future--A National Lipid Association Expert
Discussion and Town Hall
National Medical Association Endocrinology, Diabetes, and Metabolism Symposium 250,000.00
Current and Emerging Interventions: Saving Lives and
Limbs by Improving Diabetes Care
National Medical Association MODERN ERA DIAGNOSIS, TREATMENT AND MANAGEMENT OF 15,000.00
PATIENTS WITH PROSTATE CANCER
National Multiple Sclerosis Society National MS Society Monthly Email Newsletter 75,000.00
National Society for Cutaneous 2017 Real World Dermatology for Residents 40,000.00
Medicine Collaboration \3\
OhioHealth OhioHealth Multiple Sclerosis Symposium 5,000.00
Oncology Nursing Society 42nd ONS Annual Congress and two Oncology Updates 25,000.00
Regional Programs
Oregon Health & Science University 7th International Symposium on Gait & Balance in 13,108.00
Multiple Sclerosis: Neuroplasticity and
Rehabilitation in MS
Palm Beach County Medical Society Managing Thyroid Disease for the Primary Care Provider 5,000.00
Services Palm Beach Diabetes &
Endocrine Specialists, P.A.
Penn State College of Medicine i3 Selecting Optimal Therapeutic Strategies for Patients 50,000.00
Health With Differentiated and Medullary Thyroid Cancer
Penn State College of Medicine PVI ``Science and Stories: Making the Most of the Complex 146,030.00
PPerview Institute for Medical Treatment Landscape in Prostate Cancer''
Education Inc.
Pharmacy Times Continuing Education Reaching Out: A Pharmacist's Curriculum to Optimize 251,240.00
Insulin Therapy Through Patient Engagement and
Management
Postgraduate Healthcare Education, How Specialty Pharmacists Can Enhance Patient-Driven 58,000.00
LLC Postgraduate Institute for Care in Multiple Sclerosis
Medicine
Postgraduate Healthcare Education, Providing Relief to Patients with Atopic Dermatitis: 137,250.00
LLC Postgraduate Institute for How Pharmacists Can Help Collaboration \3\
Medicine
Potomac Center for Medical Education MULTIPLE SCLEROSIS CARE IN THE HOSPITAL SETTING: Novel 75,000.00
Rockpointe Corporation Neuroimaging Techniques, Individualized Treatment
Strategies, and Management of Comorbidities
Practicing Clinicians Exchange Boston New and Emerging Strategies in T2DM Using Basal 375,000.00
University School of Medicine Insulin
PRIME Education, LLC Advances in Psoriatic Diseases and Atopic Dermatitis 150,000.00
for Clinicians in Federal and Public Healthcare Collaboration \3\
Settings
PRIME Education, LLC When Statin Therapy Isn't Enough 192,435.00
Collaboration \3\
ProCE Inc. Atopic Dermatitis: A Specialty Pharmacy 360-Degree 42,250.00
View of the Patient Collaboration \3\
Projects In Knowledge MedImages Cases: Multiple Sclerosis 125,000.00
Purdue University MCM Education Managing Type 2 Diabetes: The Role of Insulin 175,000.00
Regents of the University of Colorado Practical Ways to Achieve Targets in Diabetes Care 150,000.00
Regents of the University of Pharmacotherapy of Inherited Metabolic Diseases Post- 75,000.00
Minnesota Doctoral PharmD Fellowship
Society for Translational Oncology Conference Perspectives: Lessons Learned 40,000.00
St. Vincent Neuroscience Institute, MS: A Personal Approach 3,000.00
St. Vincent Hospital, Indianapolis
The University of Chicago MCM Evolving Paradigms for Insulin Therapy of Type 2 150,000.00
Education Diabetes
Tisch Multiple Sclerosis Research Tisch MS Research Center 20th Annual MS Patient 50,000.00
Center of New York Symposium
UMA Education Inc., dba Global Coalition United for Better Eczema Care (CUBE-C) 320,000.00
Education Group FactoRx Health Collaboration \3\
Advocacy Partners National Eczema
Association Med Ed Consulting
UMA Education Inc., dba Global R.A.P.I.D.--Rheumatoid Arthritis: A Primary Care 150,000.00
Education Group FactoRx MedEd Initiative for Improved Diagnosis and Outcomes Collaboration \3\
Consulting Improve CME, LLC Indegene
UMA Education Inc., dba Global The Role of Concentrated Insulins and Insulin 127,500.00
Education Group Physicians' Combinations in Overcoming Insulin Resistance and
Education Resource Improving Adherence A Patient Centered
Multidisciplinary Approach
UMA Education Inc., dba Global Medical Crossfirer: Advances in Atopic Dermatitis: A 157,000.00
Education Group Physicians' Multidisciplinary, Patient-Centered Approach to
Education Resources Addressing Unmet Therapeutic Needs
UMA Education Inc., dba Global Effective Management of Atopic Dermatitis: New 99,585.00
Education Group Physicians' Approaches to Guiding Everyday Practice Collaboration \3\
Education Resources
UMA Education Inc., dba Global Getting Beneath the Surface in Atopic Dermatitis: A 164,330.00
Education Group Physicians' Patient-Centered Approach to Optimize Outcomes Collaboration \3\
Education Resources
UMA Education, Inc. dba Global Best Practices: Efficient and Cost Effective 155,884.00
Education Group Tarsus Cardio Inc. Management of the Authorization Process Collaboration \3\
dba Cardiometabolic Health Congress
----------------------------------------------------------------------------------------------------------------
\1\ Applicant names are provided by the requestor. If applicants apply as a group for a single educational
activity; all applicants may be not be identified above. The Company funds other educational activities
(including fellowships and non-physician and patient education); all of which do not appear on this report,
but appear on other reports on this site.
\2\ ``Funding Amount'' is the amount that the Company funded during Q2, 2017 identified above based upon an
agreement. Recipients are required to return any unused funds. Information on unused funds returned by the
applicant on activities are not reported. ``Funding Amount'' does not include funds that may have been
provided by other affiliated Sanofi Company Entities (e.g., Sanofi Pasteur).
\3\ Collaboration (Shared) Funding--is the full amount of a grant funded under an agreement with Regeneron, some
or all of which may be shared between the collaborating entities.
Independent Medical Education Grants
1st July 2017--30th Sep 2017
Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education
activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and
consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged.
Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.
----------------------------------------------------------------------------------------------------------------
Funding Amount
Recipient Name(s) \1\ Activity Title ($) \2\
----------------------------------------------------------------------------------------------------------------
American Academy of PAs 2017 Adult Hospital Medicine Boot Camp 5,490.00
American Association of Clinical Current Landscape in Medullary Thyroid Cancer: Updates 147,769.00
Endocrinologists for Clinicians
American Association of Clinical Illinois-AACE 7th Annual Meeting 5,000.00
Endocrinologists
American Association of Clinical New Jersey Chapter of the American Association of 5,000.00
Endocrinologists Clinical Endocrinologists
American College of Allergy, Asthma & Thursday Morning Session: Atopic Dermatitis Yardstick 40,000.00
Immunology Collaboration \3\
American College of Medical Genetics Genzyme ACMG Foundation Clinical Genetics Fellowships 75,000.00
Foundation in Biochemical Genetics
American Society of Transplant 11th Annual Surgical Fellows Symposium 44,500.00
Surgeons
American Society of Transplantation 2017 Fellows Symposium on Transplantation 40,000.00
American Urological Association Practical Management of Metastatic Prostate Cancer: 75,000.00
Guidelines and Beyond
Ann & Robert H. Lurie Children's Lysosomal Storage Disease Training Program for Genetic 75,000.00
Hospital of Chicago Counselors
Ascendant Limited Albert Einstein The Team-based Approach to Diagnosing and Managing 134,868.75
College of Medicine and Montefiore African American Patients with MS: A Quality
Medical Center, Center for CME Improvement Curriculum
Carden Jennings Publishing Co., Ltd. 27th International Prostate Cancer Update 20,000.00
The Medical College of Wisconsin,
Inc.
Cleveland Clinic Educational Pitfalls in Diagnosis of Multiple Sclerosis 25,000.00
Foundation
Clinical and Patient Educators Oncology Emergency Essentials: Addressing Tumor Lysis 117,394.90
Association Syndrome in Your Practice
Carden Jennings Publishing Co., Ltd. 27th International Prostate Cancer Update 20,000.00
The Medical College of Wisconsin,
Inc.
Cleveland Clinic Educational Pitfalls in Diagnosis of Multiple Sclerosis 25,000.00
Foundation
CMEducation Resources Postgraduate Optimizing Insulin-Based Glycemic Control in Type 2 500,000.00
Institute for Medicine Diabetes: The Foundational Role and Physiologic
Rationale for Long-Acting Insulin: An Evidence-Based
Roadmap for Clinical Success-Focus on the Safety-
Efficacy and PK/PD Profiles of New Long-Acting
Physiologic Insulin Formulations
Connecticut Pharmacists Association Current and Emerging Therapies in Multiple Sclerosis 10,000.00
Continuing Education Alliance PCE Interactive eCourse Series: New Pathways in Atopic 149,534.00
Practicing Clinicians Exchange Dermatitis: Novel Therapies for Optimizing Outcomes Collaboration \3\
Dignity Health MandatoryCE 2017 Arkansas Diabetes Symposium: Focus on Treatment 25,000.00
Advances, Nutrition Therapy, Obesity and Metabolic
Syndrome
DKBmed The Johns Hopkins University The Johns Hopkins University School of Medicine 120,000.00
School of Medicine eDiabetes Review Volume 3
Duke University Duke Solid Organ Transplant Summit 30,000.00
E&S MedEd Group, Inc. American Zeroing In on A1C Targets: Pinpointing the Optimal 284,660.00
Association of Diabetes Educators Basal Insulin Strategy in Every Patient with Type 2
Diabetes
Elsevier Office of Continuing Evolving Treatment Paradigms for Rheumatoid Arthritis: 75,000.00
Education Integritas Communications Translating Comprehensive Patient Evaluations Into Collaboration \3\
Personalized Therapy
Elsevier Office of Continuing Medical MS Paris 2017: Clinical Updates on Disease Modifying 161,920.00
Education AcademicCME Therapies to Improve Outcomes for Patients with
Multiple Sclerosis
Enquiring Minds, LLC Postgraduate Are My Patients Taking Their Meds as Prescribed? 106,205.00
Institute for Medicine Addressing Suboptimal Therapeutic Response Among
Patients with MS
Euforea IVZW European Summit on the Prevention and Self-Management 10,676.50
of Airway Diseases
Excel Continuing Education Expanding Horizons in ASMD/Niemann-Pick Disease 68,175.00
Focus Medical Communications, LLC 2017 International Coalition of Rheumatology Education 100,000.00
Siyemi Learning Providers Initiative
Foundation for Orthopaedic Research & 2017 Orthopaedics for the Primary Care Practitioner & 5,000.00
Education (FORE) Rehabilitation
Global Academy Medical Education Innovative Techniquesr: The Knee, Hip and Shoulder 25,000.00
University of Cincinnati Course
Haymarket Medical Education Haymarket Race to Remission: Timely Diagnosis and Early, 273,823.00
Media/MIMS Intensive Treatment in Rheumatoid Arthritis Care: A Collaboration \3\
Patient-Centered Global Curriculum Aligning With the
Spirit of World Arthritis Day
Indiana Academy of Physician ``Multiple sclerosis 2017--Update on diagnostic 5,000.00
Assistants criteria, clinical descriptors, and treatments''
International Niemann-Pick Disease Support for the development and management of the 117,706.45
Registry International Niemann Pick Disease Registry
Kentucky Academy of Physician Joint Injection Workshop 5,000.00
Assistants
Letters & Sciences Advances in Multiple Sclerosis Research & Practice, 69,000.00
Annual CNE Conference Hosted by Columbia University,
MS Clinical Care and Research Center
Mattel Children's Hospital UCLA Post Doc Fellowship 63,000.00
Med Learning Group Pathologic Targets in Rheumatoid Arthritis: Modifying 288,350.00
the Immune Response to Optimize Patient Outcomes Collaboration3
Med Learning Group A 3-Dimensional View of Recent Advances in 353,460.00
Personalized Treatment for the Management of Collaboration \3\
Uncontrolled Asthma
Med-IQ, LLC Clinical and Translational Insights in Pompe Disease: 189,407.00
Disease Pathology, Patient Identification, and
Treatment
Medscape LLC CME LIVE: A Late-Breaking Update on PCSK9 Inhibitors 500,000.00
and Cardiovascular Outcomes Collaboration \3\
Medscape LLC Advances in Rheumatoid Arthritis 2017: What's the 99,500.00
Conference Buzz? Collaboration \3\
MedStar Georgetown University 4th Annual Current Issues in the Care of Dialysis and 10,000.00
Hospital Transplant Patients
Montefiore Medical Center MRCME, LLC PCSK9 Inhibitor Therapy for Dyslipidemia: Implications 399,845.00
of Outcome Trial Results and a Look to the Future Collaboration\3\
MS Views and News The 2017 Multiple Sclerosis Symposium of South Florida- 20,000.00
The Neurological Aspects of MS and Beyond Collaboration \3\
National Association for Continuing Utilizing Concentrated Insulins: A New Strategy for 260,000.00
Education the Insulin Resistant Patient
National Association of Managed Care New Targets in the Therapeutic Landscape for Moderate- 57,000.00
Physicians, Inc. to-Severe Atopic Dermatitis (AD): What Does Managed Collaboration \3\
Care Need to Know?
National Gaucher Foundation, Inc. Medical Diagnostic/Testing Program 150,000.00
Collaboration \3\
National Multiple Sclerosis Society Life-Changing Breakthroughs: African American 10,000.00
Education Conference
National Organization for Rare NORD Continuing Medical Education 80,000.00
Disorders University of
Massachusetts Medical School
Oregon Health & Science University 17th Annual Pacific Northwest Prostate Cancer 20,000.00
Conference
Penn State College of Medicine MCM Contemporary Management of Type 2 Diabetes 166,694.00
Education
Penn State College of Medicine PVI PeerView In Session, ``Analyzing the Latest Evidence 151,480.00
Peerview Institute for Medical in Atopic Dermatitis: Clinical Updates From Geneva'' Collaboration \3\
Education Inc.
Pennsylvania Society of Physician ``Joint Injections'' 5,500.00
Assistants Collaboration \3\
Pharmacy Times Continuing Education Advances in Insulin and Insulin Combination Therapies: 68,300.00
Opportunities for Convenient Care Providers to
Improve Patient Outcomes
PlatformQ Health Education, LLC From Novice to Expert: A Series in Multiple Sclerosis 100,000.00
Consortium of Multiple Sclerosis Management
Centers Nurse Practitioner
Alternatives
Postgraduate Healthcare Education, Understanding the Mechanisms of DMARD Therapy in 53,500.00
LLC Postgraduate Institute for Patients with Rheumatoid Arthritis Collaboration \3\
Medicine
Postgraduate Institute for Medicine The Importance of Early Diagnosis and Timely Access to 349,850.00
Global Academy for Medical Education Treatment of RA Collaboration \3\
Postgraduate Institute for Medicine Defining Personalized Care Plans in Metastatic 60,000.00
i3 Health Castration-Resistant Prostate Cancer
Postgraduate Institute for Medicine Managing Multiple Sclerosis: Current Treatment and 150,000.00
Impact Education, LLC Care Management Strategies for Managed Care
PRIME Education, LLC Scaling-Up Shared Decision-Making in Multiple 162,382.50
Sclerosis Treatment
Projects in Knowledge The Art & Science of Multiple Sclerosis Management 175,000.00
Projects in Knowledge @Point of Care Atopic Dermatitis @Point of Care 200,000.00
Collaboration \3\
Regents of the University of Michigan Pompe Disease Patient Educational Booklet 2,777.00
Collaboration \3\
Regents University of California Los Educational Seminars for Patients, Families, and 20,000.00
Angeles Friends 2017-2018
Research To Practice Year in Review--A Four-Part Multi-tumor Regional CME 40,000.00
Symposia Series Focused on the Application of
Emerging Research Information to the Care of Patients
with Common Cancers: Genitourinary Cancers Module
Rheumatology Nurses Society RNS 2017 Annual Conference 25,000.00
Collaboration \3\
RMEI Postgraduate Institute for Achieving Success in RA Assessment and Management: A 349,547.00
Medicine Learner Pathway to Improve Patient Outcomes Collaboration \3\
Suffolk Academy of Medicine Long The Long Island Allergy & Asthma Society 24th Annual 10,000.00
Island Allergy & Asthma Society Scientific Meeting Collaboration \3\
Suffolk Academy of Medicine Long The Long Island Allergy & Asthma Society 24th Annual 10,000.00
Island Allergy & Asthma Society Scientific Meeting Collaboration3
The Regents of UC/Office of Cont Med UCLA Review of Clinical Neurology 2,500.00
Educ
Tufts University School of Medicine Severe Asthma: Inspiring Change 216,712.50
DKBmed Collaboration \3\
UMA Education, Inc. dba Global Closing the Gap Created by Clinical Inertia: New 207,845.00
Education Group Tarsus Cardio Inc. Strategies for T2DM Treatment
dba Cardiometabolic Health Congress
Universitatsmedizin Rostock, Albrecht- Recent advances in rare diseases: Gaucher disease as a 25,000.00
Kossel-Institute for model (RARD 2017)
Neuroregeneration (AKos)
University of Louisville Research 10th Annual Perspectives in Rheumatic Diseases 12,500.00
Foundation Global Academy for presented by Rheumatology News, Internal Medicine Collaboration \3\
Medical Education, LLC Postgraduate News & Family Practice News
Institute for Medicine
University of Nevada, Reno School of 2017 Fall Clinical Dermatology Conference 125,000.00
Medicine Foundation for Research and
Education in Dermatology
Vindico Medical Education, LLC When Severe Asthma is Out of Control: Examining 137,340.00
Phenotypic Approaches to Treatment Collaboration \3\
Yale New Haven Hospital New and Emerging Multiple Sclerosis Therapies 15,000.00
Yale School of Medicine The Yale-Cambridge Transplantation Symposium: Donor 20,000.00
Decision-Making in an Era of Advanced Medical
Complexity
----------------------------------------------------------------------------------------------------------------
\1\ Applicant names are provided by the requestor. If applicants apply as a group for a single educational
activity; all applicants may be not be identified above. The Company funds other educational activities
(including fellowships and non-physician and patient education); all of which do not appear on this report,
but appear on other reports on this site.
\2\ ``Funding Amount'' is the amount that the Company funded during Q3, 2017 identified above based upon an
agreement. Recipients are required to return any unused funds. Information on unused funds returned by the
applicant on activities are not reported. ``Funding Amount'' does not include funds that may have been
provided by other affiliated Sanofi Company Entities (e.g., Sanofi Pasteur).
\3\ Collaboration (Shared) Funding--is the full amount of a grant funded under an agreement with Regeneron, some
or all of which may be shared between the collaborating entities.
Independent Medical Education Grants
1st Oct 2017-31th Dec 2017
Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education
activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and
consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged.
Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.
----------------------------------------------------------------------------------------------------------------
Funding Amount
Recipient Name(s) \1\ Activity Title ($) \2\
----------------------------------------------------------------------------------------------------------------
AcademicCME, LLC. Applying Individualized Therapeutic Strategies of 98,000.00
Switching and Sequencing to Improve Outcomes for
Patients with Multiple Sclerosis: The Right Treatment
at the Right Time for the Right Patient
Albert Einstein College of Medicine/ Atopic Dermatitis (Eczema) Challenges: Recognition and 108,682.50
Montefiore Medical Center M2 Assessment in Primary Care Collaboration \3\
Communications
American Association of Clinical New Jersey-AACE January Dinner Program: Treatment of 2,591.00
Endocrinologists Advanced Thyroid Cancer
American Association of Clinical Minnesota/Midwest Chapter of the American Association 5,000.00
Endocrinologists of Clinical Endocrinologists 8th Annual Meeting
American College of Allergy, Asthma & Biologics in Atopic Dermatitis Workshop 25,320.00
Immunology
American College of Allergy, Asthma & WSAAI 2018: 56th Annual Scientific Session 20,000.00
Immunology Western Society of Collaboration \3\
Allergy, Asthma & Immunology
Annenberg Center for Health Sciences 10th Annual Linda Morgante MS Nurse Leadership Program 35,000.00
at Eisenhower Academy for Continued
Healthcare Learning (ACHL)
Association pulmonaire du Quebec Biennale de l'Espace francophone de la pneumologie 12,150.00
Boston University School of Medicine Management of Knee Osteoarthritis in Primary Care: The 200,000.00
Practicing Clinicians Exchange Case for Viscosupplementation
Continuing Education Alliance LLC
California Optometric Association 2017 Monterey Symposium 10,400.00
Cedars-Sinai Medical Center 7th Annual Symposium on Lysosomal Storage Disorders 15,000.00
Children's Hospital of Philadelphia Lysosomal Storage Disease (LSD) Fellowship 75,000.00
Foundation
Cleveland Clinic--Lou Ruvo Center for Advancing Therapeutics for Multiple Sclerosis 5,000.00
Brain Health
Cleveland Clinic Center for Clinical Updates on Fabry Disease: Diagnosis Through 159,750.00
Continuing Medical Education Treatment
Medscape LLC
Cleveland Clinic Educational Medical Dermatology Therapy Update: Autoimmune 10,000.00
Foundation Diseases, Chronic Inflammatory and Advanced
Malignancies
Cleveland Clinic Educational 6th Annual Basic & Clinical Immunology for the Busy 25,000.00
Foundation Clinician
CME Outfitters, LLC Peeking Beneath the Surface of Atopic Dermatitis: 200,000.00
Testing Your Skills from Pathogenesis to Treatment
Division of Medical Genetics and Better Outcomes of Lysosomal Diseases (BOLD) 75,000.00
Genomic Medicine Fellowship
Elsevier Office of Continuing Medical THE LSD DEBATE: OPTIMIZING DIAGNOSIS AND FUTURE 248,465.00
Education Excerpta Medica BV MANAGEMENT
Elsevier Office of Continuing Medical Clinical Issues in Severe Asthma: Debates and 628,867.00
Education Integritas Communications Discussions About Personalizing Patient Management
Elsevier Office of Continuing Medical Clinical Issues in Atopic Dermatitis: Discussions and 784,641.50
Education Integritas Communications Debates on Managing Moderate-to-Severe Disease Collaboration \3\
Emory University The Paul M. Fernhoff Genetic Counseling Fellowship in 75,000.00
the Lysosomal Storage and Other Genetic Disorders
EUFOREA IVZW European Rhinology Research Forum 18,000.00
European Respiratory Society ERS Satellites 72,000.00
European Society for Dermatological 47th ESDR Meeting 2017 44,400.00
Research
Excel Continuing Education Responding to the Challenge of Pompe Disease 100,165.00
(satellite symposium at 2018 World Congress)
George Washington University (GW) American Contact Dermatitis Society-Frontiers in 10,000.00
Office of Continuing Education in Dermatitis 2017 Collaboration \3\
the Health Profession (CEHP)
American Contact Dermatitis Society
Global Education Group Integritas Clinical Issues in Atopic Dermatitis: Discussions and 177,074.00
Communications Debates on Managing Moderate-to-Severe Disease Collaboration \3\
Icahn School of Medicine at Mount 4th NY Masters Course in Endocrinology and Endocrine 10,000.00
Sinai Surgery Collaboration \3\
Icahn School of Medicine at Mount 20th Annual Mount Sinai Winter Symposium ``Advances in 20,000.00
Sinai Medical & Surgical Dermatology''
Indiana Academy of Physician ``Anterior Knee Pain and Osteoarthritis'' 5,000.00
Assistants
Institute for Medical and Nursing MEDS 2018: Going Flat-Out for Glycemic Control: The 381,055.00
Education, Inc. Role of New Basal Insulins in Patient-Centered T2DM
Management
Institute for Medical and Nursing MEDS 2018: Rationale, Recognition, and 354,830.00
Education, Inc. Recommendations: Expert Perspectives on Combining
Basal Insulin and GLP-1 RAs to Intensify Treatment of
T2DM
Kidney Disease Improving Global KDIGO Controversies Conference on Glomerular Diseases 25,000.00
Outcomes (KDIGO)
Med Learning Group Recognizing the Connection: A View into the Parallels 225,000.00
between Asthma and Nasal Polyps
Medical Education Resources, Inc. Basic concepts in eczema diagnosis and management 20,000.00
Dermveda Inc.
Medical Learning Institute Inc. PVI, PeerView ``Ascertaining the Potential Clinical 80,000.00
Peerview Institute for Medical Implications of The Latest Data on Approved and
Education Inc. Emerging Disease Modifying Therapies for Multiple
Sclerosis Management: A Recap from Paris''
Medical Learning Institute Inc. PVI, PeerView in Session, ``Exploring the Latest Data in 74,490.00
PeerView Institute for Medical the Treatment of Uncontrolled Persistent Asthma: Collaboration \3\
Education, Inc. Clinical Highlights from San Diego''
Medical Learning Institute PVI, PeerView Talks, ``A Patient-Centered Approach to the 153,580.00
PeerView Institute for Medical Diagnosis and Treatment of Atopic Dermatitis in Collaboration \3\
Education Adults: An Expert's Story''
Med-IQ, LLC Pragmatic Approaches to Improving Insulin Introduction 254,623.00
and Integration in T2DM:Patient Simulations For
Frontline Providers
Med-IQ, LLC Addressing Bone Manifestations of GD: The Latest 382,736.00
Evidence in Evaluation and Treatment
Medscape LLC Updates and Perspectives in Diabetic Dyslipidemia: 246,500.00
2017 in Review Collaboration \3\
Medscape LLC Addressing Disease Burden in Asthma and Comorbidities: 400,000.00
From Pathophysiology to Targeted Treatments
Medstar Georgetown University Multiple Sclerosis Patient Education Day 7,500.00
Hospital
Mount Sinai School of Medicine The Icahn School of Medicine at Mount Sinai NP 75,000.00
Fellowship Program in Lysosomal Storage Disease
National Association For Continuing Atopic Dermatitis: New Insights, New Therapies 150,000.00
Education
National Committee for Quality A Patient-Centered Approach to Severe Asthma 232,325.00
Assurance NACCME, LLC Management: Embracing Diversity and Improving Collaboration \3\
Outcomes with Emerging Therapies
NCCN Foundation NCCN Guidelines for Patients: Prostate Cancer 25,000.00
Nurse Practitioner Alternatives Advances In Multiple Sclerosis (AIMS) Primer: Third 59,150.00
Consortium of Multiple Sclerosis Edition
Centers
Nurse Practitioner Alternatives 1,800 SecondsTM in MS Management: An Online 92,000.00
Consortium of Multiple Sclerosis Educational Series for MS Clinicians
Centers
Oakstone Publishing, LLC PeerVoice A New Treatment Paradigm in Atopic Dermatitis: Expert 268,700.00
America Limited Insights on Incorporating Biologic Therapy Among
Available Options
Oakstone Publishing, LLC PeerVoice Optimizing Systemic Therapy for Atopic Dermatitis: 268,700.00
America Limited Practical Strategies to Ensure Patient Safety
Oregon Health and Science University Annual OHSU Colloquium on Neuromuscular Disorders 5,000.00
PEERVOICE AMERICA LIMITED Oakstone ``Practical Strategies for Managing Inadequate 193,250.00
Publishing, LLC Responders to Atopic Dermatitis Treatment'' Collaboration \3\
Penn State College of Medicine Beyond the Guidelines: Investigator Perspectives on 100,000.00
Research To Practice Current Clinical Issues and Ongoing Research in the
Management of Advanced Prostate Cancer
PESG Lysosomal And Rare Disorders GRIDS2017: A workshop on immune aspects of Lysosomal 55,000.00
Research And Treatment Center Inc. Storage Disorders: From pathology to therapy
Pharmacy Times Continuing Education A Specialty Pharmacy Update on PCSK9 Inhibitor Therapy 10,000.00
for Hypercholesterolemia Collaboration \3\
Pharmacy Times Continuing Education An American Journal of Managed Care Webinar: 75,255.00
Evaluating Novel Therapies for Atopic Dermatitis
Physician's Education Resource, LLC Provider and Caregiver Connection--Getting Beneath the 167,850.00
Surface: Addressing Patient Concerns In Moderate to
Severe Atopic Dermatitis
Postgraduate Institute for Medicine Early Detection and New Approaches to the Management 150,000.00
Catamount Medical Education, LLC of Atopic Dermatitis in the Family Medicine Setting Collaboration3
Postgraduate Institute for Medicine The Role of Specialty Pharmacy and the Challenge of 150,000.00
Impact Education, LLC Managing Moderate-to-Severe Atopic Dermatitis Collaboration \3\
Postgraduate Institute for Medicine The Management of Atopic Dermatitis: Entering a New 200,000.00
Impact Education, LLC Paradigm
Postgraduate Institute for Medicine Rheumatoid Arthritis Management Strategies: New 150,000.00
Impact Education, LLC Insights for Managed Care
Postgraduate Institute for Medicine The Learning Pathway in Atopic Dermatitis: Optimizing 382,947.00
Robert Michael Educational Institute Management Approaches in Patients with Moderate-to- Collaboration \3\
LLC Severe Disease
Potomac Center for Medical Education Targeting Improved Outcomes In Atopic Dermatitis: 449,955.00
Rockpointe Corporation Strategies for Achieving Personalized Treatment Goals Collaboration \3\
Potomac Center for Medical Education Achieving New Treatment Goals In Multiple Sclerosis: 176,000.00
Rockpointe Corporation Nurse Strategies for Initial Treatment Selection and
Practitioner Alternatives Patient Engagement
PRIME Education, LLC Aligning Managed Care Decision-Making with the Latest 272,543.00
Evidence for Targeted Asthma Treatment
PRIME Education, LLC Navigating the Intersection of Uncontrolled Asthma and 354,188.00
Related Comorbidities: Implications of Novel
Mechanisms of Action for Managed Care
PRIME Education, LLC Advancing Specialty Pharmacy Decision-Making to 242,011.00
Optimize Therapy Selection and Access in Uncontrolled
and Severe Asthma
PRIME Education, LLC Solving the Problem of Choice in Treatment Decisions 182,535.00
for Patients with Rheumatoid Arthritis: Evidence-
Based, Guideline-Directed, and Patient-Centered
Strategies
Pri-Med Institute, LLC Viscosupplementation for Osteoarthritis of the Knee: 149,499.92
Who, When, and How?
Projects In Knowledge Asthma--Practical Applications from ATS 2018: A Video 50,000.00
Roundtable
Rutgers, The State University of New Cognitive Dysfunction and Fatigue in Multiple 3,011.00
Jersey Sclerosis
Sidney Kimmel Medical College at Thyroid Cancer 2017: New Advances in Diagnosis & 10,000.00
Thomas Jefferson Treatment
Society for Inherited Metabolic 2017 North American Metabolic Academy 20,000.00
Disorders
St. Joseph's Regional Medical Center Multiple Sclerosis: A Changing Landscape 1,300.00
The France Foundation Achieving Better Control of Severe Asthma: New 262,700.00
Understandings in Asthma Pathophysiology and Targeted
Therapies
The France Foundation Are You Ready? Recent Effective Atopic Dermatitis 240,720.00
Therapy Considerations
The Regents of the University of Post Doc Fellowship 63,000.00
California--UCLA Division of
Nephrology
UC Regents Genetic Neuromuscular Diseases Fellowship 75,000.00
UMA Education, Inc. dba Global Beyond the Flare: A Practical Overview of the Newest 25,000.00
Education Group Tarsus Cardio dba Concepts in Atopic Dermatitis Pathogenesis and Collaboration \3\
South Beach Symposium Treatment
UMA Education, Inc. dba Global 2018 Masters of Pediatric Dermatology Symposium 20,000.00
Education Group Tarsus Cardio Inc., Collaboration \3\
dba South Beach Symposium
University Neurology, Inc. The 2017 New York State Multiple Sclerosis Consortium 5,000.00
(NYSMSC) Annual Professional Research and Education
Meeting
University of Alabama at Birmingham 2017 Fabry Fellowship 73,714.12
University of California, San Diego Challenges in Pompe 4,800.00
San Diego Neurology Society
University of Colorado School of 87th Annual Meeting of the American Thyroid 50,000.00
Medicine American Thyroid Association
Association
University of Louisville School of Visiting Professor and Endocrine Grand Rounds 3,320.00
Medicine
University of Louisville Global Skin Disease Education Foundation's 18th Annual Las 25,000.00
Academy for Medical Education Vegas Dermatology Seminar featuring the 14th Annual Collaboration \3\
Postgraduate Institute for Medicine Psoriasis Forum
University of Louisville Postgraduate 17th Annual Caribbean Dermatology Symposium 50,000.00
Institute of Medicine Global Academy Collaboration \3\
for Medical Education
University of Louisville Postgraduate Skin Disease Education Foundation's 42nd Annual Hawaii 50,000.00
Institute of Medicine Global Academy Dermatology Seminar Collaboration \3\
for Medical Education
University of Massachusetts Medical New Frontiers and Pivotal Investigation-Based Advances 369,000.00
School CMEducation Resources in the Pathoimmunobiology and Management of Atopic Collaboration \3\
Dermatitis
Vindico Medical Education, LLC Shutting Down MS: New Insights on Induction, 196,378.58
Escalation, Oral Agents, and Monitoring
WEBMD Global Advancing the Care of Patients With Atopic Dermatitis- 301,000.00
International Perspectives for OUS MDS: An Initiative
developed in partnership with the University of
Sheffield Medical School, Dermatology Research
----------------------------------------------------------------------------------------------------------------
\1\ Applicant names are provided by the requestor. If applicants apply as a group for a single educational
activity; all applicants may be not be identified above. The Company funds other educational activities
(including fellowships and non-physician and patient education); all of which do not appear on this report,
but appear on other reports on this site.
\2\ ``Funding Amount'' is the amount that the Company funded during Q4, 2017 identified above based upon an
agreement. Recipients are required to return any unused funds. Information on unused funds returned by the
applicant on activities are not reported. ``Funding Amount'' does not include funds that may have been
provided by other affiliated Sanofi Company Entities (e.g., Sanofi Pasteur).
\3\ Collaboration (Shared) Funding--is the full amount of a grant funded under an agreement with Regeneron, some
or all of which may be shared between the collaborating entities.
Organization Name Amount
Acid Maltase Deficiency Association INC. $5,000.00
Allergy & Asthma Network Mothers of Asthmatics, INC $50,000.00
Allergy & Asthma Network Mothers of Asthmatics, INC. $117,000.00
Allergy & Asthma Network Mothers of Asthmatics, INC. $25,000.00
Allergy & Asthma Network Mothers of Asthmatics, INC. $25,000.00
Allergy & Asthma Network Mothers of Asthmatics, INC. $25,000.00
Allergy & Asthma Network Mothers of Asthmatics, INC. $25,000.00
Allergy & Asthma Network Mothers of Asthmatics, INC. $60,000.00
Allergy & Asthma Network Mothers of Asthmatics, INC. $75,000.00
Alliance for the Adoption of Innovations in Medicine $50,000.00
American Association Of Kidney Patients Inc. $362,293.31
American Association Of Kidney Patients Inc. $10,000.00
American College of Allergy, Asthma & Immunology $6,000.00
American College of Allergy, Asthma & Immunology $30,000.00
American College of Allergy, Asthma & Immunology $70,000.00
American College of Allergy, Asthma & Immunology $100,000.00
American College of Allergy, Asthma & Immunology $60,000.00
American College of Allergy, Asthma & Immunology $55,000.00
American College of Allergy, Asthma & Immunology $95,000.00
American College of Allergy, Asthma & Immunology $165,000.00
American College of Allergy, Asthma & Immunology $35,000.00
American College of Allergy, Asthma & Immunology $30,000.00
American College of Allergy, Asthma & Immunology $150,000.00
American College of Allergy, Asthma & Immunology $175,000.00
American Kidney Fund Inc. $40,000.00
American Kidney Fund Inc. $10,000.00
APFED (American Partnership for Eosinophilic $15,000.00
Disorders)
Arthritis Foundation $100,000.00
Arthritis Foundation $25,000.00
Arthritis Foundation $25,000.00
Arthritis Foundation $3,500.00
Arthritis Foundation $1,250.00
Arthritis Foundation $5,000.00
Arthritis Foundation $10,000.00
Arthritis Foundation $3,500.00
Arthritis Foundation $250,000.00
Arthritis Foundation $250,000.00
Arthritis Foundation $30,000.00
Arthritis Foundation $100,000.00
Arthritis Foundation $100,000.00
Arthritis Foundation Inc. $2,500.00
Arthritis Foundation of NENY $5,000.00
Association For Glycogen Storage Disease $3,000.00
Asthma and Allergy Foundation of America $150,000.00
Asthma and Allergy Foundation of America $24,200.00
Asthma and Allergy Foundation of America $50,000.00
Asthma and Allergy Foundation of America $75,000.00
Asthma and Allergy Foundation of America $100,000.00
Asthma and Allergy Foundation of America, New England $20,000.00
Chapter
Aubrey Rose Foundation $25,000.00
Barbara Ann Karmanos Cancer Institute $10,000.00
Be The Match Foundation $40,000.00
Berkshire Resource Project $1,500.00
Berkshire Resource Project $1,500.00
Beyond the Diagnosis $10,000.00
Can Do Multiple Sclerosis $8,000.00
Can Do Multiple Sclerosis $40,000.00
Can Do Multiple Sclerosis $26,000.00
Can Do Multiple Sclerosis $10,000.00
Can Do Multiple Sclerosis $10,000.00
Can Do Multiple Sclerosis $20,000.00
Can Do Multiple Sclerosis $20,000.00
Can Do Multiple Sclerosis $30,000.00
Can Do Multiple Sclerosis $40,000.00
Can Do Multiple Sclerosis $70,000.00
Can Do Multiple Sclerosis $30,000.00
Community Oncology Alliance $75,000.00
CrowdCare Foundation $45,000.00
Cure GM1 Incorporated $5,000.00
Cure GM1 Incorporated $5,000.00
Cystic Fibrosis Foundation $10,000.00
EveryLife Foundation for Rare Diseases $10,000.00
EveryLife Foundation for Rare Diseases $30,000.00
EveryLife Foundation for Rare Diseases $5,000.00
EveryLife Foundation for Rare Diseases $30,000.00
EveryLife Foundation for Rare Diseases $15,000.00
EveryLife Foundation for Rare Diseases $25,000.00
EveryLife Foundation for Rare Diseases $20,000.00
Fabry Support & Information Group $22,000.00
Fabry Support & Information Group $1,500.00
Fabry Support & Information Group $50,000.00
Fabry Support & Information Group $30,000.00
Fabry Support & Information Group $100,000.00
Florida Hemophilia Association $3,000.00
Foundation Fighting Blindness Inc. $5,000.00
Fundacion de Esclerosis Multiple de Puerto Rico $15,000.00
Global Alliance for Patient Access $115,000.00
Global Alliance for Patient Access $30,000.00
Global Healthy Living Foundation, Inc. $100,000.00
Global Healthy Living Foundation, Inc. $50,000.00
Global Parents for Eczema Research, a project of $47,438.00
Heluna Health
Great Lakes Hemophilia Foundation Inc. $2,500.00
Hemophilia Foundation of Northern California $5,000.00
Hemophilia of Iowa $1,500.00
Hemophilia of Iowa $1,000.00
Hemophilia of North Carolina $5,000.00
Hermansky-Pudlak Syndrome Network $24,935.00
Holy Name Health Care MS Center $2,500.00
Holy Name Health Care MS Center $2,500.00
Hope for Hemophilia $15,000.00
Hope for Hemophilia $15,000.00
International Myeloma Foundation $75,000.00
International Myeloma Foundation $50,000.00
International Myeloma Foundation $75,000.00
International Society For Mannosidosis & Related $30,000.00
Disease Inc.
Kessler Foundation $5,000.00
Leukemia & Lymphoma Society--MA Chapter $20,000.00
Light of Life Foundation $5,000.00
Little Miss Hannah Foundation $1,000.00
Lone Star Chapter of the National Hemophilia $15,000.00
Foundation
Lymphoma Research Foundation $20,000.00
March of Dimes Foundation $10,000.00
March of Dimes Foundation $15,000.00
Mercy Foundation $20,000.00
Mid America MS Achievement Center $5,000.00
Mid America MS Achievement Center $5,000.00
MLD Foundation $12,000.00
MLD Foundation $12,000.00
MS Bright Spots of Hope $2,500.00
MS Cure Fund $3,000.00
MS Cure Fund $5,250.00
MS Cure Fund $2,500.00
MS Dream Center--RI, Inc. $3,000.00
MS HOPE FOR A CURE INC. $10,000.00
MS Views and News $25,000.00
MS Views and News $50,000.00
MS Views and News $30,000.00
MS Views and News $30,000.00
MS Views and News $10,000.00
MS Views and News $40,000.00
MS Views and News $25,000.00
MSWorld, Inc. $4,000.00
Multiple Myeloma Cure Seeker Society $5,000.00
Multiple Sclerosis Association of America $200,000.00
Multiple Sclerosis Association of America $30,000.00
Multiple Sclerosis Association of America $25,000.00
Multiple Sclerosis Association of America $50,000.00
Multiple Sclerosis Association of America $50,000.00
Multiple Sclerosis Association of America $46,031.00
Multiple Sclerosis Center of Georgia $10,000.00
Multiple Sclerosis Center of Georgia $7,000.00
Multiple Sclerosis Foundation $30,000.00
Multiple Sclerosis Foundation $20,000.00
Multiple Sclerosis Foundation $50,000.00
Multiple Sclerosis Resources of Central New York, Inc. $7,500.00
Muscular Dystrophy Association $20,000.00
Muscular Dystrophy Association $430,000.00
National Bone Marrow Transplant Link $3,000.00
National Eczema Association $100,000.00
National Eczema Association $85,000.00
National Eczema Association $100,000.00
National Eczema Association $75,000.00
National Eczema Association $100,000.00
National Fabry Disease Foundation $100,000.00
National Fabry Disease Foundation $100,000.00
National Fabry Disease Foundation $40,000.00
National Gaucher Foundation $1,500,000.00
National Gaucher Foundation $650,000.00
National Gaucher Foundation $200,000.00
National Gaucher Foundation $1,900,000.00
National Hemophilia Foundation $37,500.00
National Hemophilia Foundation $100,000.00
National Hemophilia Foundation $9,479.00
National Kidney Foundation $3,700.00
National Kidney Foundation $10,000.00
National Kidney Foundation $10,000.00
National MPS Society $500.00
National MPS Society $20,000.00
National MPS Society $100,000.00
National MS Society $5,000.00
National Multiple Sclerosis Society $780,000.00
National Multiple Sclerosis Society $65,000.00
National Multiple Sclerosis Society $15,000.00
National Multiple Sclerosis Society $2,500.00
National Multiple Sclerosis Society $15,000.00
National Multiple Sclerosis Society $750,000.00
National Multiple Sclerosis Society $150,000.00
National Multiple Sclerosis Society New York City $2,500.00
Chapter
National Multiple Sclerosis Society New York City $1,100.00
Chapter
National Multiple Sclerosis Society New York City $15,000.00
Chapter
National Multiple Sclerosis Society New York City $122,100.00
Chapter
National Multiple Sclerosis Society New York City $5,000.00
Chapter
National Multiple Sclerosis Society New York City $1,250.00
Chapter
National Multiple Sclerosis Society New York City $300.00
Chapter
National Multiple Sclerosis Society New York City $1,000.00
Chapter
National Multiple Sclerosis Society New York City $5,000.00
Chapter
National Multiple Sclerosis Society New York City $5,000.00
Chapter
National Niemann-Pick Disease Foundation $40,000.00
National Organization for Rare Disorders, Inc. $50,000.00
National Organization for Rare Disorders, Inc. $5,000.00
National Organization for Rare Disorders, Inc. $25,000.00
National Organization for Rare Disorders, Inc. $100,000.00
National Organization for Rare Disorders, Inc. $75,000.00
National Organization for Rare Disorders, Inc. $50,000.00
National Tay-Sachs & Allied Diseases Association, Inc. $20,000.00
National Tay-Sachs & Allied Diseases Association, Inc. $10,000.00
National Tay-Sachs & Allied Diseases Association, Inc. $10,000.00
New England Hemophilia Association $5,000.00
New England Hemophilia Association $10,000.00
New England Hemophilia Association $2,500.00
New England Hemophilia Association $7,500.00
Next Step Fund Inc. $10,000.00
OhioHealth Corporation $25,000.00
Osteogenesis Imperfecta Foundation $5,000.00
Patient Access Network Foundation $300,000.00
Patient Empowerment Network $20,000.00
Patient Empowerment Network $20,000.00
Patient Services, Inc. $662,500.00
Patient Services, Inc. $2,381,250.00
Patient Services, Inc. $4,797,500.00
Patient Services, Inc. $1,418,750.00
Patient Services, Inc. $1,365,000.00
PKD Foundation $50,000.00
PKD Foundation $20,000.00
PKD Foundation $25,000.00
Prostate Cancer Foundation $300,000.00
Prostate Health Education Network Inc. $20,000.00
Quinn Madeleine Inc. $5,000.00
Rare Disease United Foundation $15,000.00
Rare New England, INC. $4,000.00
Rare New England, INC. $4,000.00
Rare New England, INC. $4,000.00
Rocky Mountain Multiple Sclerosis Center $2,500.00
Rocky Mountain Multiple Sclerosis Center $5,000.00
Rocky Mountain Multiple Sclerosis Center $5,000.00
Rocky Mountain Multiple Sclerosis Center $2,500.00
Rocky Mountain Multiple Sclerosis Center $3,000.00
Sofia Sees Hope $22,000.00
Swiss Hemophilia Society (Schweizerische Hemophilie $2,600.00
Gesellschaft)
The Assistance Fund, Inc. $10,000,000.00
The Leukemia & Lymphoma Society Eastern PA Chapter $10,000.00
ThyCa: Thyroid Cancer Survivors' Association, Inc. $5,000.00
ThyCa: Thyroid Cancer Survivors' Association, Inc. $3,000.00
ThyCa: Thyroid Cancer Survivors' Association, Inc. $5,000.00
ThyCa: Thyroid Cancer Survivors' Association, Inc. $10,000.00
Tisch Multiple Sclerosis Research Center of New York, $15,000.00
Inc.
Tisch Multiple Sclerosis Research Center of New York, $2,500.00
Inc.
Transplant Life Foundation $12,000.00
Tri-State Multiple Sclerosis Association $2,500.00
United Pompe Foundation $50,000.00
United Pompe Foundation $42,500.00
United Pompe Foundation $30,000.00
United States Bone and Joint Initiative, NFP $80,000.00
United States Bone and Joint Initiative, NFP $30,000.00
United States Bone and Joint Initiative, NFP $25,000.00
University of Minnesota Foundation $5,000.00
Us TOO International $2,500.00
Us TOO International $30,000.00
Wylder Nation Foundation $5,000.00
Wylder Nation Foundation $15,000.00
Program/Event
PCMA of Texas's Pull Telehealth 2018 Patient Awareness
for Pompe Program
Understanding Severe 2018 USAsthma Summit Corporate Council 2018
Asthma Program
2018 Allergy & Asthma 2018 Asthma Bloggers Understanding Severe
Awareness Day Conference Asthma Guide
Webinars on Medical Education Education Project
Dermatological
Conditions in the
Workplace
Eczema Online Program Patient Awareness Patient Awareness
Program Program
Fellow-in-Training Severe Atopic 2018 Corporate Council
Travel Scholarships Dermatitis Toolkit Membership
Program
Biologics Education Severe Asthma Allergist Webinar Education
Program and Patient Education Program
Severe Asthma Patient Practice Management Educational Tools for
Education Center: Expansion and Allergists and
Enhancement Patient Education
Campaign
Patient Education Proposal Request in Annual Patient
Program Support of 360 Degrees Education Conference
of Care
Patient Voice Access Arthritis Foundation 2018 Arthritis
Project Patient Engagement at Foundation Conference
ACR of Champions
2018 Bone Bash Silver Ball Fundraiser Evening of Honors
Fundraiser Fundraiser
Freedom of Movement San Francisco Bone Bash 2018 Jingle Bell Run
Fundraiser Fundraiser
Walk to Cure Arthritis Arthritis Industry Patient Awareness
Forum (AIF) Program
Patient Education and 2018 Bone Bash Albany Commitment to a
Awareness Program Fundraiser Cure Fundraiser
Annual GSD Conference Patient Education Patient Access Program
Program
My Life With AD AAFA's Patient Support My Kids' Life With
Center Asthma
Be Smart and Breathe Medical Resources for 8th Annual Prostate
Easy Patient Education Children: An Cancer Symposium
Invaluable Database
Be The Match 2018 Patient Education and Patient Education
National Walk+Run Awareness Program Program
Series
Operating Support Patient Awareness 2019 SKI for MS
Program
2019 JUMPSTART Program 2018 MS Global Patient 9th Annual Can Do
Exhibits Programs Month
2018 Young 2018 JUMPSTART Program 2018 Online Programs
Professionals Program Exhibition Sponsorship
2018 CAN DO Program 2018 JUMPSTART Program 2018 Can Do On Demand
2018 COA Corporate Patient Awareness 2nd GM1 Research
Sponsorship Program Symposium
TORCH award donation Fundraiser event Patient Awareness
Program
RareVoice Awards Rare Disease Scientific RARE on the Road
Workshop Leadership Series
Patient Awareness Rare Disease Week Community Congress
Program Sponsorship
FSIG Patient Meetings 2018 Fun Run/Walk 2018 FSIG Expert Fabry
Conference
Patient Assistance Operating Support 35th Annual Florida
Program Bleeding Disorders
Conference
Boston VisionWalk Managing MS: A European RA patient
multidisciplinary online program
approach
European Alliance for Patient Education and 50-State Network
Patient Access RA Awareness Program Patient Advocacy
Stakeholders Workshop
Assessing and 2018 Wisconsin Bleeding BLeaders
Communicating the Disorders Conference
Impact of AD on
Patients and Families
Annual Meeting Teen Program Family Education
Sponsorship Program
Research Program 2018 MS Awards 21st Annual Spring
Reception Fling for MS
Superhero Run/Walk-- 2018 Superhero Hope Run/ Long Term Care
Covington Walk--Wichita Survivors Initiative
2018 IMF Patient IMF 9th Annual 6th Glycoproteinoses
Patient and Family International Myeloma International
Seminars and Regional Working Group Summit Conference--Atlanta--
Community Workshops USA
Kessler Foundation's Light The Night Boston Light of Life
2018 Stroll 'N Roll Foundation 2018
Walk Patient Activities
3rd Annual Vegas Cares Texas Bleeding Research Program
About Rare Kids 5K Disorders Conference
2018
Fundraising Event Boston March for Babies Multiple Sclerosis
Achievement Center
Wellness Education
programs
Eat Bid Laugh 7 Program Race to Nowhere 2018 RUSP Roundtable
Program
RUSP Roundtable Program MS Bright Spots Evening 6th ANNUAL MS ADAPTIVE
of Hope SKI DAY--THRIVING
BEYOND MS!
Relapse Management and MS ALPINE ADVENTURES Exhibit Sponsorship
Rehabilitation Program 2018 ADAPTIVE SKI DAY
2018 MS Hope Day Patient Education and Patient Education and
Awareness Program Awareness Program
Patient Education and Patient Education and 2018 Champions
Awareness Program Awareness Program Tackling MS Awards
Dinner
Patient Education and Patient Education and 2018 ``MSWorld Talks''
Awareness Program Awareness Program Cleveland Clinic:
Display Table
2018 Defeat Multiple Patient Assistance A Better Understanding
Myeloma Run/Walk Program of MS within the
Hispanic Community
Patient Education and 2018 Multiple Sclerosis MS Awareness Month
Awareness Program Summit: A Community 2018
Conference and
Exposition
2018 Needs Assessment MS Fest for Patients Health, Hope & Hops
MS Focus' Homecare MS Focus' Assistive National MS Education
Assistance Grant Technology Program and Awareness Month
Program 2018
2018 Mission Steps Walk Congress Sponsorship Community Education
and MS Awareness Days and Engagement
Support
Resource Guide of Eczema Awareness Month- The Face of Atopic
Helpful Organizations Unhide Eczema Campaign Dermatitis in America
Eczema Expo '18 Atopic Dermatitis Teen Educational Webcasts
Commitment Campaign for Patients &
Caregivers
Operating Support 2018 Fabry Community Community support
Support and Education programs
programs
Patient Assistance Patient Education and Patient Education and
Program Awareness Program Awareness Program
Patient Assistance NHF 2018 Bleeding UNITE for Bleeding
Program Disorders Conference Disorders National
Walk 2018
NHF Bleeding Disorders Congress Sponsorship New York City Kidney
Conference 2018 Walk
The Big Ask The Big In-Kind Donation National MPS Society
Give National Run Program
2018--15th Bike MS: City to Shore National sponsorship
International Ride of Walk MS and local
Symposium on MPS and sponsorship of select
Related Diseases Bike MS events
MS Breakthroughs 2018 National MS Women on the Move--
Program Society Leadership Pittsburgh
Conference
Everyday Matters: National MS Society Fellowship Program
Living Your Best Life National Event
with MS Sponsorship
Knoxville Fall Crush 40th Annual Ambassadors Mood Changes In MS
Fundraiser
Alliance Industry Forum On the Move Luncheon-- Women on the Move
2018 New Orleans Luncheon and Fashion
Show--Cincinnati
Women On the Move-- 2018 On the Move On The Move Luncheon-
Washington, D.C. Luncheon--St Louis Houston
2017 On The Move Patient Education and Patient Assistance
Luncheon--Dallas TXH Awareness Program Program
Running for Rare 2018 Corporate Council Patient Education and
Membership--Corporate Awareness Program
Product Member
2018 Rare Diseases and 2018 Rare Impact Awards Imagine & Believe
Orphan Product Program
Breakthrough Summit
Voices of 40th Annual Family Congress Sponsorship
Determination, An Conference
Evening to Benefit
NTSAD
Family Camp Massachusetts Advocacy New England Hemophilia
Days Association 9th
Annual Walk
Face Forward OhioHealth Multiple Conference Sponsorship
Campference and Year- Sclerosis Wellness
Round Programming for Program
Youth With Rare
Genetic Disorders
Patient Assistance Multiple Myeloma 2018 Myeloma Patient
Program Community Meetings Cafe
Patient Assistance Patient Assistance Patient Assistance
Program Program Program
Patient Assistance Patient Assistance Walk for PKD
Program Program
2018 Boston Walk for 2018 PKD Connect 25th Annual Scientific
PKD National Conference Retreat
PHEN Rally Against TORCH award donation Beyond the Diagnosis
Prostate Cancer
Rare New England Inc. RNE Honors Rare Disease Patient Education and
Day Speakers Series Awareness Program
2019
2018 RMMSC Annual 2018 MS4MS (Multiple Rocky Mountain MS
Fundraiser Summits for MS) Center's Spring
Education Summit
2018 Conversations on 2018 Webinar Series LCA and IRD Community
MS Outreach and
Education
70th NHF Bleeding Patient Assistance LLS Light The Night
Disorders Conference Program Events
Website Update Project Congress Sponsorship 21st International
Thyroid Cancer
Survivors' Conference
Patient Education and Patient Education and 2018 Future Without MS
Awareness Program Awareness Program Fundraiser
Donate Life Transplant Autumn Walks Fiscal Year 2018
Games
Patient Meeting Patient Meeting Experts in Arthritis
Program
Access Program Corporate Sponsorship Marrow on the Move
14th Annual SEA Blue Us TOO Prostate Cancer TORCH award donation
Prostate Cancer Walk & Regional Educational
Run Symposiums
5th Annual Living Like
a Warrior Gala
Independent Medical Education Grants
1st Jan 2018-31th Mar 2018
Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education
activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and
consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged.
Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.
----------------------------------------------------------------------------------------------------------------
Funding Amount
Recipient Name(s) \1\ Activity Title ($) \2\
----------------------------------------------------------------------------------------------------------------
University of Kansas Continuing 2017 Muscle Study Group Scientific annual Meeting-- 25,000
Education & Professional Development Neuromuscular Therapeutics: Bench to Bedside and
Beyond
National Jewish Health PVI Peerview PeerView inPlay and inClinic: ``Optimizing Asthma 209,000
institute for Medical Education Inc. Control Through Accurate Identification, Evidence-
Based Management and Targeted Therapeutic Options''
Aventura Hospital Miami Thyroid Oncology Symposium 10,000
AcademicCME, LLC. ASCO GU 2018: A Clinical Analysis of Optimal 82,300
Therapeutics to Improve Outcomes in Patients with
Prostate Cancer
The Medical College of Wisconsin, PeerView Live at BMT 2018, ``Integrated Myeloma 88,555
Inc. PVI, PeerView Institute for Management & Enhanced Patient Outcomes: The
Medical Education, Inc. Conjunction of Novel Therapeutic Platforms,
Innovative Agents, and Stem Cell Transplant''
American Society of Transplant 18th Annual State of the Art Winter Symposium The 75,000
Surgeons Future Is Now: Saving More Lives Through
Transplantation
The Medical College of Wisconsin, Optimal Use of Stem Cell Mobilization in Patients with 305,000
Inc. Carden Jennings Publishing Multiple Myeloma and Non-Hodgkin's Lymphoma
Medical Learning Institute PVI, PeerView inReview, ``Assessing the Potential Impact of 104,250
PeerView Institute for Medical New Consensus Recommendations and Ongoing Clinical
Learning Trials of Emerging Therapies on the Diagnosis and
Treatment of Acid Sphingolmyelinase Deficiency''
National Society of Genetic New Lysosomal Storage Disease Healthcare Advocate 42,637
Counselors (NSGC) Workshop 2018
American Society of Clinical 2018 Genitourinary (GU) Cancers Symposium: Translating 30,000
Oncology, Inc. Conquer Cancer Evidence to Multidisciplinary Care
Foundation of the American Society
of Clinical Oncology
American Association of Clinical Advances in Medical & Surgical Management of Thyroid 15,000
Endocrinologists Cancer
ScientiaCME LLC Atopic Dermatitis (AD): Best Practices, Barriers to 19,100
Care, and Emerging Therapies in Medication Management
Potomac Center for Medical Education Risk-Benefit Analysis and Personalized Treatment in 100,000
Rockpointe Corporation Multiple Sclerosis: Basing Treatment Goals on the
Latest Evidence
Elsevier Office of Continuing Medical Moving from Treating Atopic Dermatitis Symptoms to 165,000
Education ASiM CE, LLC Treating Underlying Pathology
University of Cincinnati Advances in MauiDerm 2018 50,000
Cosmetics and Medical Dermatology
Postgraduate Institute for Medicine The Rheumatoid Arthritis Vital Education Initiative: 264,800
New Horizons in Therapeutic Options (RAVE: New
Horizons)
American Society for Blood and Marrow American Society for Blood and Marrow Transplantation 65,000
Transplantation New Investigator Award
UT Southwestern Medical Center 40th Annual Carrell-Krusen Neuromuscular Symposium 5,000
Regents of the University of 6th Annual UC San Diego Essentials and Advances in 5,000
California Apheresis
Physicians' Education Resource Multiple Sclerosis: A Treatment Paradigm Shift when 85,100
Time is Brain
Physicians' Education Resource, LLC 2018 New York GUTTM: 11th Annual Interdisciplinary 50,000
(PER) Prostate Cancer Congress
National Comprehensive Cancer Network NCCN 23rd Annual Conference: Improving the Quality, 25,000
Effectiveness, and Efficiency of Cancer CareTM
UNTHSC Overcoming Persistent Barriers to Effective Management 72,500
of Atopic Dermatitis
Cleveland Clinic Educational 2018 Nephrology Update 10,000
Foundation
Medical Learning Institute, Inc. PVI, PeerView in Session, ``New Developments in Allergic 168,730
PeerView Institute for Medical and Inflammatory Diseases: Clinical Updates From San
Education, Inc. Diego and Orlando''
Penn State College of Medicine PVI, Science and Stories: Navigating the Prostate Cancer 90,000
PeerView Institute for Medical Landscape: Urologists at the Intersection of Emerging
Education Inc. Evidence and Patient Centric Care
UMA Education Inc., dba Global Cutting Edge of Transplantation 2018: Breaking through 40,000
Education Group American Society of Regulatory Barriers to Unleash Transplant Innovation
Transplantation to Success
American College of Rheumatology 2018 ACR Rheumatology Courses 75,000
PRIME Education, LLC Global Perspectives on Current and Emerging Biologic 151,341
Therapies for Rheumatoid Arthritis
The Medical College of Wisconsin, The 28th Annual International Prostate Cancer Update 10,000
Inc. Carden Jennings Publishing Co., (IPCU 28)
Ltd.
NYU Post-Graduate Medical School NYU Langone Seminar in Advanced Rheumatology 20,000
AcademicCME, LLC. Individualizing Treatment Plans to Reduce Disease 75,000
Activity in Patients with Rheumatoid Arthritis
Physicians' Education Resource, LLC Medical Crossfire: Personalizing Care for Multiple 75,000
(PER) Myeloma Patients: Current and Future Sequencing
Strategies
American College of Surgeons The changing face of thyroid cancer management for 40,900
surgeons: real-life applications of the new ATA
guidelines
Penn State College of Medicine PVI, PeerView Live at ASCO 2018: ``How I Think, How I 75,000
PeerView Institute for Medical Treat: A Personal Look at Innovative Therapy and
Education, Inc. Meeting Patient Needs in Multiple Myeloma''
UMA Education Inc., LLC dba: Global Evolving Management Strategies for Moderate-to-Severe 346,647
Education Group (GLOBAL) Atopic Dermatitis: Looking Beyond Barriers to
Optimized Therapy
Physicians' Education Resource, LLC Advances InT Supportive Care: An Onco-Nurses Guide to 50,000
(PER) Managing Cancer Treatment-Related Toxicities
National Association of Managed Care Exploring the Challenges of Severe Asthma: 45,000
Physicians Implementing Personalized Treatment Plans for
Improved Patient Outcomes
National Association for Continuing Conversations in Dermatology The Evolving Paradigm in 59,000
Education Atopic Dermatitis: Integrating Evolving Treatments to
Improve Outcomes
Eastern Virginia Medical School Multiple Sclerosis Symposium 2018 5,000
University of Kansas Medical Center Neuromuscular Review Course 25,000
American Academy of Pas Medical Moving Toward Improved Outcomes in MS: How PAs Can 50,000
Logix, LLC Make a Difference
Med-IQ, LLC Preventing Tumor Lysis Syndrome: Risk Assessment and 75,000
Appropriate Prophylaxis
Cleveland Clinic Educational Cleveland Clinic Neurological Institute Summit 2018: 50,000
Foundation MS Treatment Strategies
Johns Hopkins University School of 14th Annual Advances in the Diagnosis and Treatment of 30,000
Medicine the Rheumatic Diseases
National Association of Managed Care Implementing Newer Biologic Therapies to Improve 57,000
Physicians Economic and Clinical Outcomes in Patients with
Moderate to Severe Atopic Dermatitis
Annenberg Center for Health Sciences Master Class for Oncologists 30,000
at Eisenhower Dana Farber Cancer
Institute
Elsevier Office of Continuing Medical Rising to the Challenge: Diagnosis and Optimal 124,000
Education ASiM CE LLC Dannemiller Management of Atopic Dermatitis in the Primary Care
Setting
National Association of Managed Care Novel Treatment Advances and Approaches in Rheumatoid 45,000
Physicians Arthritis: Personalizing Therapy for Improved
Clinical and Economic Outcomes
National Kidney Foundation Managing the Life-Long Impact of Fabry Disease 265,995
Annenberg Center for Health Sciences Optimal Treatment sequencing in Metastatic Castration- 65,000
at Eisenhower PlatformQ Health Resistant Prostat Cancer: Expert Analysis through
Education, LLC Case Studies
Michael J Fox Foundation MDS-PAS Movement Disorders School for Neurology 20,000
Residents
Penn State College of Medicine PVI, Science and Stories at ASCO 2018: Making an Impact in 100,000
PeerView Institute for Medical Prostate Cancer--Using Expert Experience and Evidence
Education, Inc. to Personalize the Complex Treatment Landscape
Purdue University Clinical Care Advancing Care in Prostate Cancer: Aligning Your 80,000
Options, LLC Practice With Rapidly Evolving Standards of Care
Throughout the Disease Continuum
Continuing Education Alliance 2018 PCE Oncology Symposia Series Segment: Sequencing 125,000
Therapy in Patients with Castration-Resistant
Prostate Cancer
University of Chicago At the Forefront of Hepatology 5,000
National Association of Managed Care The Value of Personalized Treatment Sequencing for 45,000
Physicians Castration-Resistant Prostate Cancer
Vindico Medical Education, LLC Immunology Bootcamp 100,000
American Urological Association 2018 Evidence-based Clinical Management of Advanced 100,000
and Castration-Resistant Prostate Cancer
International Transplant Nurses European Transplant Nursing Symposium 10,000
Society
UMA Education Inc., dba Global R.A.P.I.D.--Rheumatoid Arthritis: A Primary Care 200,000
Education Group FACTORx MedEd Initiative for Improved Diagnosis and Outcomes
Consulting Improve CME, LLC NACE Pri-
Med Indegene, Inc.
Postgraduate Institute for Medicine The Learning Pathway in Atopic Dermatitis: Maximizing 362,310
Positive Outcomes for Your Patients
American Urological Association AUA 2018 Highlights in Advanced and Castration- 80,000
Resistant Prostate Cancer
PESI Inc. 15th Annual World Congress on Insulin Resistance, 50,000
Diabetes & Cardiovascular Disease
Horizon CME Improving the Quality of Care in Patients with 237,900
Diabetes through a Simulated QI Experience
Joslin Diabetes Center Long-acting Insulins in Treatment of Type 2 Diabetes: 324,500
Aligning Provider and Patient Perspectives to Address
Therapeutic Barriers
Boston University School of Medicine Balancing Glycemic Control and Hypoglycemia in T2DM: 435,000
Practicing Clinicians Exchange (PCE) the Role of long-acting Basal Insulin Analogues
Physicians' Education Resource Physiologic Insulin Replacement: Practical Strategies 105,650
for Insulin Initiation and Titration of Long-Acting
Insulins
University of Massachusetts Medical The Foundational role of Physiologic, long-acting 341,000
School CMEducation Resources Basal Insulin: Optimizing the safety-efficacy
equation in vulnerable patients with T2D
Postgraduate Institute for Medicine Targeting diabetic patients for Physiologic, long- 496,200
CMEducation Resources acting Basal Insulin therapy--A best practice roadmap
to clinical success
The Endocrine Society Institute for Diabetes Masters Series 2018: Getting to the heart of 249,885
Medical and Nursing Education, Inc. the matter: Multidisciplinary perspectives on patient-
centered care in T2DM
American Association of Diabetes Leveraging CDEs to Improve Individualized Management 1,024,440
Educators of T2D: Focus on Injectable Therapies
Pharmacy Times Continuing Education An American Journal of Managed Care Medical Crossfire: 202,150
Evaluating New Generation Basal Insulin Therapy
American Association of Nurse The I's Have It: Improving Insulin Initiation Inertia 358,557
Practitioners A Nurse Practitioner-Led Quality Initiative
Pri-Med Institute, LLC Newer Long-acting Insulins: A Physiologic Approach to 721,504
Glucose Control
National Association for Continuing Clinical Updates for NPs and PAs: 2018--Advances in 244,585
Education Insulin Therapy: Another Step Closer to a More
Physiological Strategy
Institute for Medical and Nursing AAFP 2018: Building Basal Knowledge: Establishing a 374,867
Education, Inc. Solid Foundation for Using New Options in Basal
Insulin for T2DM
NACCME, LLC Incorporating Long-Acting Insulin Therapy into the 180,565
Physiologic Approach to Diabetes Management
Postgraduate Institute for Medicine Multi-Mechanistic, Insulin-Based Approaches for 347,000
CMEducation Resources Achieving HA1c/PPG Targets and Optimizing Safety in
Challenging Patients with T2D
Pharmacy Times Continuing Education Emerging Strategies for the Safe and Effective 81,303
Treatment of Uncontrolled Diabetes: The Application
of Fixed Ratio Combination Insulin/GLP-1 RA Options
Boston University School of Medicine Type 2 Diabetes: New Treatment Combinations for Early 870,000
Practicing Clinicians Exchange and Aggressive Glucose Control
Postgraduate Institute for Medicine Complementary insulin-based approaches for achieving 935,000
CMEducation Resources HA1c/PPG targets and optimizing safety in patients
with T2D: A best practice roadmap
American Academy of PAs Achieving Quality Measures in T2DM: Addressing 199,600
Clinical Inertia and Patient Needs with Complementary
Insulin-Based Therapies
National Association for Continuing Clinical Updates for NPs and PAs: 2018--Combination 244,585
Education Basal Insulin and GLP-1 RA Therapy: A Physiologic
Approach to Diabetes Care
North Carolina Academy of Family Ready, set, action: An intervention to combat clinical 372,477
Physicians Med-IQ, LLC inertia and reduce prolonged hyperglycemia in T2DM
Pharmacy Times Continuing Education The Advent of Insulin/GLP-1 RA Fixed-Ratio Agents for 129,020
Uncontrolled Diabetes: Moving Past the Barriers of
Clinical Inertia
Pri-Med Institute, LLC Treatment Intensification in T2DM: A Pathophysiologic 721,504
Approach to Combining GLP-1 Receptor Agonists with
Basal Insulin
American Association of Clinical Endocrine University: Lipids Module 4,000
Endocrinologists
Elsevier Office of Continuing Medical Raising the Bar by Lowering the Target: Integrating 419,083
Education Integritas Communications PCSK9 Inhibitors into Hypercholesterolemia Management
University of Tennessee College of Breaking Barriers to Diabetes Control with GLP-1RA/ 165,000
Pharmacy Insulin Combination Agents: Opportunities for the
Community Pharmacist
American Association of Nurse Advances in Diabetes Management: Titratable Fixed- 235,873
Practitioners Ratio Combination Therapy and its Role in T2DM
Treatment
University of California, San Diego Comparing and Contrasting Basal Insulin Strategies in 481,775
Type 1 and Type 2 Diabetes
University of Massachusetts Medical The Mechanistic and Therapeutic Rationale for Dual 342,750
School CMEducation Resources SGLT1/2 Inhibition in Adults with Type 1 Diabetes Collaboration \4\
American Association of Clinical AACE 2018--Reflecting on the Data Pool: Emerging Roles 357,151
Endocrinologists Institute for for SGLT1 and SGLT2 Inhibition in T1DM Collaboration \4\
Medical and Nursing Education, Inc.
American Association of Diabetes Reducing Glycemic Variability in Type 1 Diabetes: An 333,715
Educators E&S MedEd Group, Inc. Exploration of Non-Insulin Treatment Options Collaboration \4\
Medscape LLC Maximizing Medical Management of Knee Osteoarthritis: 174,500
Use of Injectable Therapy
Oakstone Publishing, LLC. PeerVoice Reducing Cardiovascular Risk in Patients With 374,288
America Limited Dyslipidemia: What Do We Know Now? (And What Should Collaboration \3\
We Do About It?)
Pharmacy Times Continuing Education Managing Hypercholesterolemia: Clinical Updates for 85,201
Specialty Pharmacists on PCSK9 Inhibitor Therapy Collaboration \3\
Postgraduate Institute for Medicine The Landmark Evidence and Clinical Rationale for PCSK9 486,800
CMEducation Resources Inhibition in the diabetic patient Collaboration \3\
Preventive Cardiovascular Nurses 2018 PCNA Dyslipidemia Campaign 60,000
Association Collaboration \3\
Oakstone Publishing, LLC. PeerVoice Modern Management of Lipid-Related Cardiovascular Risk 375,000
America Limited in Patients With Dyslipidemia Collaboration \3\
UMA Education, Inc. dba Global Mastering the Prior Authorization Process to Meet 275,000
Education Group Patient Needs Collaboration \3\
----------------------------------------------------------------------------------------------------------------
\1\ Applicant names are provided by the requestor. If applicants apply as a group for a single educational
activity; all applicants may be not be identified above. The Company funds other educational activities
(including fellowships and non-physician and patient education); all of which do not appear on this report,
but appear on other reports on this site.
\2\ ``Funding Amount'' is the amount that the Company funded during Q1, 2018 identified above based upon an
agreement. Recipients are required to return any unused funds. Information on unused funds returned by the
applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided
by other affiliated Sanofi Company Entities (e.g., Sanofi Pasteur).
\3\ Collaboration (Shared) Funding--is the full amount of a grant funded under an agreement with Regeneron, some
or all of which may be shared between the collaborating entities.
\4\ Collaboration (Shared) Funding--is the full amount of a grant funded under an agreement with Lexicon, some
or all of which may be shared between the collaborating entities.
Independent Medical Education Grants
1st April 2018-30th June 2018
Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education
activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and
consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged.
Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.
----------------------------------------------------------------------------------------------------------------
Funding Amount
Recipient Name(s) \1\ Activity Title ($) \2\
----------------------------------------------------------------------------------------------------------------
Med-IQ, Inc. Getting Social About Multiple Sclerosis: Tools for 75,000
Newly Diagnosed Patients and Their Care Teams
National Association of Managed Care Building a Better Understanding in Asthma Management: 57,000
Physicians Best Practices for Treatment and Control
Excel Continuing Education Exploring the Genetics and Management of Fabry Disease 69,720
The Trustees of Columbia University The Columbia Renal Biopsy Course 5,000
in the City of New York
Rheumatology Nurses Society Medscape Updates in RA, PsA, and Biosimilars: A Pipeline View 50,000
Education for the Clinical Nurse
University of Illinois at Chicago Illinois Transplant Pharmacists Association Symposium 8,000
College of Pharmacy
Rush University Medical Center Plexus Northern California Genitourinary Malignancy 10,000
Communications Symposium: Translating Clinical Advancements to
Practical Patient Care
Medscape, LLC Managing Multiple Myeloma: What's Next? 116,000
University of Louisville Research 11th Annual Perspectives in Rheumatic Diseases, 30,000
Foundation Inc. Global Academy for presented by Rheumatology News, Internal Medicine
Medical Education Postgraduate News, Family Practice News
Institute for Medicine
AKH Inc, Advancing Knowledge in Focusing on the Patient Voice: Utilizing Components of 100,000
Healthcare 47-Consultants in Medical a Patient Coach Module Contextually within Patient-
Education Centric CME Activities
University of Colorado Denver Forty-fifth annual Renal Disease and Electrolyte 5,000
Disorders Course
Annenberg Center for Health Sciences Advancing Knowledge to Practice: Optimizing Severe 200,000
at Eisenhower Asthma Care in the Age of Biologics
USF Health i3 Health Challenges and Opportunities in Metastatic Castration- 90,000
Resistant Prostate Cancer: A CME/CE/CPE-Certified VA/
DoD Meeting Series
Projects In Knowledge @Point of Care Multiple Sclerosis @Point of Care 75,000
New Jersey Academy of Family Ascertaining the Role of the Primary Care Clinician in 5,000
Physicians the Recognition and Management of Patients With
Multiple Sclerosis in the Modern Era
Med Learning Group Pathology-Based, Targeted Therapies--Managing Moderate- 124,745
to-Severe Atopic Dermatitis in Adults
Annenberg Center for Health Sciences 2018 SUNA Advanced Prostate Cancer Grant 30,000
at Eisenhower Prostate Cancer
Education Council
Consortium of Multiple Sclerosis Immune Dysfunction in Multiple Sclerosis: Modern 75,000
Centers Catamount Medical Education Considerations in Treatment and Management
Dallas County Optometric Society Eyes on Fabry Dallas County Optometric Society 9,266
Fabry Support & Information Group
Association of Reproductive Health Snap, Crackle and Pop: Provider Education and Targeted 52,000
Professionals Training to Improve the Diagnosis and Therapeutic
Management of Rheumatoid Arthritis in Female Patients
AcademicCME Improving Individualized Outcomes in Asthma with 45,000
Evidence-based Treatment Strategies
Integrity Continuing Education, Inc. 2018 Asthma State Society CME Meetings and BioDigital 319,350
Human On-demand Simulation Activity--Improving Severe
Asthma Control through Comprehensive Patient
Assessment and Tailored Treatment Selection
UMA MLG, LLC Targeted Therapies for the Management of Moderate-to- 249,975
Severe Atopic Dermatitis in Adults--Animated
Whiteboard View
Society for Investigative Dermatology Neuro-Immunology of Skin Symposia 75,000
Penn State College of Medicine PVI, PeerView Live: ``Unraveling the Complex Treatment 60,000
PeerView Institute for Medical Landscape for Prostate Cancer: Guidance for
Education, Inc. Delivering Evidence-Based, Patient-Centered Care''
Medscape, LLC Minimizing the Effects of TLS and CRS in Patients with 74,000
Hematologic Malignances
Excel Continuing Education Unraveling the Genetics and Management of MPS 1 55,565
Hereditary Disease Foundation Hereditary Disease Foundation's ``Milton Wexler 10,000
Celebration of Life'' Symposium of international
Huntington's disease researchers
Medscape LLC Targeted Therapies for the Management of Severe 261,500
Asthma: Surveying an Evolving Landscape
Seattle Children's Hospital PLUGS Summit 2018: Clinical Laboratory Stewardship: 8,000
Where Patient Safety and Financial Responsibility
Meet
University of Cincinnati Global Skin Disease Education Foundation's 14th Women's & 10,000
Academy for Medical Education Pediatric Dermatology Seminar
Postgraduate Institute for Medicine
Physicians' Education Resource, LLC 2018 ASH Symposium: ``D'' is for Diagnosis: Solving 250,000
(PER) the Mystery of Rare Hematologic Disorders
Boston University School of Medicine, Practical Approach to Electromyography and 7,500
CME Neuromuscular Disorders Conference
Specialty Pharma Education Center Renal Transplantation: Overview of Advances in 49,750
Clinical Understandings, Guidelines, and Treatment &
Management Strategies
University of California Irvine 8th Annual UC Irvine Neuromuscular Colloquium 20,000
Physicians' Education Resource, LLC Oncology BriefingsTM: Current Perspectives on 50,000
(PER) Preventing and Managing Tumor Lysis Syndrome
UMA Education Inc., dba Global Nursing Management of Treatment-Related Side Effects 120,000
Education Group MCM Education in Metastatic Prostate Cancer
UMA Education Inc., dba Global A Quality Improvement (QI) Educational Pilot on 107,155
Education Group Q Synthesis, LLC Enhancing Prostate Cancer Management in Urology
Practice
Med Learning Group Evolving Therapeutic Options for Moderate-to-Severe 274,785
Asthma: A Comprehensive 3-Dimensional Study
University of Cincinnati 2018 International Rare Lung Diseases Research 10,000
Conference
Consortium of Multiple Sclerosis Therapeutic Decision-Making for Disease Modification 49,288
Centers Inc. Delaware Media Group in MS: 2018 Update
Excel Continuing Education Unraveling a Therapeutic Conundrum: ASMD Niemann Pick 106,790
Disease
University of Cincinnati Advances in MauiDerm NP+PA Summer 2018 25,000
Cosmetic and Medical Dermatology
American Thoracic Society ATS 2018 International Conference - Selected Sessions 20,000
in Asthma
Creighton University Physicians Skin of Color Seminar Series 2018 (SOCSS 2018) 15,000
Continuing Education, Corporation
UMA MLG, LLC Treating a Chronic Autoimmune Inflammatory Disease: 214,500
Targeting Pathophysiologic Cytokines in the
Management of Rheumatoid Arthritis--Animated
Whiteboard View
Tarrant County Organization Society Eyes on Fabry Tarrant County Optometric Society 7,998
Fabry Support & Information Group
University of Nevada, Reno School of 2018 Real World Dermatology for PAs and NPs 25,000
Medicine Dermatology University LLC
American Society of Clinical 2018 ASCO Annual Meeting Genitourinary Cancer Tracks 40,000
Oncology, Inc. Conquer Cancer Bundle (Prostate and Nonprostate)
Foundation of the American Society
of Clinical Oncology
Postgraduate Institute for Medicine Clinical Care Team Exchange: The Role of New Biologics 425,170
for Optimal RA Management
PRIME Education, LLC Driving Practice Change in Systems-Based Care of 344,805
Patients with Atopic Dermatitis
The Medical College of Wisconsin, The 23rd Annual Southwest Prostate Cancer Symposium 5,000
Inc. Carden Jennings Publishing Co., (SPCS 23)
Ltd
St. Joseph's Regional Medical Center Acute Rejection of the Allograft--New Concepts and Old 1,810
MS Cure Fund, Inc. 2018 Q1 Lifestyle Management Patient Education 20,000
Programs for individuals diagnosed with multiple
sclerosis, and their support team.
Alaska Regional Hospital Wheezin', Sneezin' & Itchin' in Alaska 5,000
American Academy of PAs AAPA 2018--Rheumatology Track 5,000
Postgraduate Institute for Medicine The Specialty Pharmacy Review BoardTM--Examining 235,000
Impact Education, LLC Emerging Biologics for Difficult-to-treat or Severe
Asthma
National Association of Managed Care Individualizing Therapy in the Management of Relapsing 45,000
Physicians Multiple Sclerosis: Expert Switching and Sequencing
Strategies
Consortium of Multiple Sclerosis Nursing Care in Multiple Sclerosis: Evidence-Based 75,000
Centers Inc. International Practice
Organization of MS Nurses
The Annenberg Center for Health How I Treat Advanced Prostate Cancer: Making Sense of 100,000
Sciences at Eisenhower prIME the Ever-Increasing Options
Oncology, LLC
Elsevier Office of Continuing Medical Clinical Issues in Atopic Dermatitis: Discussions and 784,642
Education Integritas Communications Debates on Managing Moderate-to-Severe Disease
Horizon CME, Inc. How to Select and Start Insulin in Patients with Type 59,925
2 Diabetes: A Hands-on Workshop
National Assocation For Continuing Getting Comfortable with Insulin: New Approaches to 355,396
Education Getting Patients Safely to Target
Medscape LLC Improving Use of Basal Insulin for Better Diabetes 800,000
Outcomes
Pri-Med Institute, LLC (d/b/a pmiCME) The Southern Diabetes Initiative: Individualizing Care 400,000
in the 21st Century
Elsevier Office of Continuing Medical Emerging Strategies for Achieving Glycemic Control in 179,950
Education Adults with Type 1 Diabetes Collaboration \4\
The France Foundation When Insulin Isn't Enough: Exploring Dual SGLT1 and 153,900
SGLT2 Inhibition in T1DM Collaboration \4\
NACCME, LLC. Integrating Emerging Evidence in Adjunctive Therapies 432,535
Into Team-Based Management Strategies in Type 1 Collaboration \4\
Diabetes
Med-IQ, LLC Evolving Evidence in Type 1 Diabetes Management: 238,281
Evaluating the Role of SGLT Inhibition Collaboration \4\
UMA Education Inc., dba Global Type 1 Diabetes: New and Emerging Therapeutic 511,628
Education Group Strategies to Address Unmet Needs Collaboration \4\
Haymarket Medical Education GLP-1 Receptor Agonists: Injecting More Confidence in 49,950
Achieving Glycemic Control for Patients With T2DM The
my CME Town Wall: A Live Clinical Forum for Multiple
Viewpoints on a Virtual Stage
Medscape LLC Novel Treatments for T1D 499,000
Collaboration \4\
Med-IQ, Inc. Initiating Insulin in Patients Who Fear Needles: Using 297,385
Evolving Basal Insulins to Improve Adoption
National Association of Managed Care The Role of PCSK9 Inhibitors in Lowering LDL-C in 95,000
Physicians Patients with Dyslipidemia: What Managed Care Needs Collaboration \3\
to Know
Allina Health Minneapolis Heart PCSK9 Inhibitors--Science, Selection and Access 5,000
Institute Foundation Collaboration \3\
Medscape LLC PCSK9 Inhibitors and Cardiovascular Outcomes: ACC 2018 237,125
Data You Cannot Afford to Miss Collaboration \3\
Postgraduate Institute for Medicine The Landmark trial-based evidence and rationale for 398,000
CMEducation Resources, LLC PCSK9 inhibition to prevent and treat Atherosclerotic Collaboration \3\
Cardiovascular Disease (ASCVD)
National Lipid Association Horizon PCSK9 Inhibitors in Practice: Real-World Challenges 261,335
CME, Inc. and Solutions Collaboration \3\
National Lipid Association The New Era of Preventive Cardiology: Applying PCSK9 153,000
Inhibitor Therapeutics to Prevent Heart Attack and Collaboration \3\
Stroke
Postgraduate Institute for Medicine New Evidence-Based, Therapeutic Strategies for 397,000
CMEducation Resources, LLC applying CV outcome and trialbased evidence for PCSK9 Collaboration \3\
inhibition to the front lines of CAD Prevention and
Treatment
Med Learning Group A Virtual Reality Tour of Nonstatin LDL-C-lowering 573,725
Agents that Decrease Cardiovascular Risk for Patients Collaboration \3\
with Persistent Hypercholesterolemia
Potomac Center for Medical Education Role of Interventional Cardiologists in Secondary 198,450
Prevention of Myocardial Infarction: Redefining Collaboration \3\
Clinical Practice
North American Center for Continuing Cardiology Grand Rounds: Overcoming Access Barriers 476,838
Medical Education, LLC and Practice Challenges to PCSK9 Inhibitor Collaboration \3\
Implementation
PRIME Education, LLC Applying the Latest Cardiovascular Outcomes Trial 146,740
Evidence to PCSK9 Inhibitor Decision-Making in Lipid Collaboration \3\
Management
Pri-Med Institute, LLC (d/b/a pmiCME) Translating Evidence to Practice: Improving Outcomes 575,150
Horizon CME, Inc. in Patients with ASCVD with PCSK9 Inhibitors Collaboration \3\
Med Learning Group A Virtual Reality In Practice View: Maximizing 174,400
Clinical Benefit Through Optimal LDL-C Reductions in Collaboration \3\
Patients With Atherosclerotic Disease
Physicians' Education Resource 2018 New York Multidisciplinary Cardio-Endo-Renal 35,000
Collaborative: Access to PCSK9i: Updates on Collaboration \3\
Guidelines, Emerging Cardiovascular Benefits and
Overcoming Barriers to Access
PRIME Education, LLC Integrating Evidence from the Latest Cardiovascular 459,799
Outcomes Data into Managed Care Decision-Making in Collaboration \3\
Lipid Management
The Academy for Continued Healthcare Improving Outcomes and Expanding Opportunities for the 180,420
Learning Treatment of Hyperlipidemia Collaboration \3\
----------------------------------------------------------------------------------------------------------------
\1\ Applicant names are provided by the requestor. If applicants apply as a group for a single educational
activity; all applicants may be not be identified above. The Company funds other educational activities
(including fellowships and non-physician and patient education); all of which do not appea r on this report,
but appear on other reports on this site.
\2\ ``Funding Amount'' is the amount that the Company funded during Q2, 2018 identified above based upon an
agreement. Recipients are required to return any unused funds. Information on unused funds returned by the
applicant on activities are not reported. ``Funding Amount'' does not include funds that may have been
provided by other affiliated Sanofi Company Entities (e.g., Sanofi Pasteur).
\3\ Collaboration (Shared) Funding--is the full amount of a grant funded under an agreement with Regeneron, some
or all of which may be shared between the collaborating entities.
\4\ Collaboration (Shared) Funding--is the full amount of a grant funded under an agreement with Lexicon, some
or all of which may be shared between the collaborating entities.
Independent Medical Education Grants
1st July 2018-30th Sept 2018
Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education
activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and
consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged.
Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.
----------------------------------------------------------------------------------------------------------------
Funding Amount
Recipient Name(s) \1\ Activity Title ($) \2\
----------------------------------------------------------------------------------------------------------------
Integrity Continuing Education, Inc. Advancing Diagnosis and Management of Atopic 318,450
Dermatitis in Children and Adolescents--
Practitioner's Edge State Society Meeting Series,
CaseScribe On-demand Activity, and Mobile Coach
Platform
Penn State College of Medicine PVI, PeerView inSession, ``An Expert Analysis of New Data 76,740
PeerView Institute for Medical for Uncontrolled Persistent Asthma Treatments:
Education, Inc. Clinical Updates From Paris''
Medscape LLC Advances in Severe Asthma Management: Conference 219,500
Highlights and Perspectives
PRIME Education, LLC 4th Annual Regional Meetings for Providers in Federal 188,000
and Public Healthcare Sectors: Interprofessional
Education on Psoriatic Diseases, Atopic Dermatitis,
and Rheumatoid Arthritis
Medscape LLC Guide to Atopic Dermatitis: Clinical Pearls for 198,400
Dermatologists and Allergists
MediCom Worldwide, Inc. 2018 ASH Meeting on Hematologic Malignancies: The Art 25,000
and Science of Relapsed/Refractory Multiple Myeloma:
A Practical Guide to Complex Therapeutic Choices
Medscape LLC The Pediatrician's Role in Atopic Dermatitis 458,225
Integrity Continuing Education, Inc. Strategies to Provide Individualized Treatment in 360,900
Moderate-to-Severe Atopic Dermatitis--Practitioner's
Edge State Society Meeting Series and Publication in
Action On-demand Activity
Regents of the University of Frontiers in Autosomal Dominant Polycystic Kidney 10,000
California Disease (ADPKD)
National Association of Managed Care Optimizing Clinical and Economic Outcomes in the 57,000
Physicians Management of Moderate to Severe Atopic Dermatitis:
Taking a Closer Look at the Role of Biologic
Therapies
National Jewish Health Catamount What is Multiple Myeloma? A Game-Based Learning 75,000
Medical Education, LLC Experience on Novel Treatment Strategies for
MultipleMyeloma
Medical Learning Institute, Inc. PVI, PeerView inVision, Expert Insights on Available and 122,250
PeerView Institute for Medical Emerging Therapies for the Management Pompe Disease
Education, Inc.
ScientiaCME LLC Treatment strategies in Fabry disease 17,800
UMA MLG, LLC Utilizing the Molecular/Physiologic Phenotype to 289,400
Direct Asthma Therapy: A Comprehensive Infographic
View
CME Outfitters, LLC Atopic Dermatitis: You Can't Improve What You Don't 279,850
Measure
The University of Kansas Medical The Changing Landscape of Neuromuscular Disease: The 40,000
Center--Continuing Medical Education Future is Here
Oakstone Publishing, LLC. Getting Under the Skin with Targeted Therapy to 170,000
Improve Atopic Dermatitis Management
University of Cincinnati Global 14th Annual Coastal Dermatology Symposium 10,000
Academy for Medical Education
Postgraduate Institute For Medicine
MediCom Worldwide, Inc. 2018 Meeting Highlights of the 4th International 12,500
Conference on Multiple Myeloma
National Comprehensive Cancer Network NCCN 13th Annual Congress: Hematologic MalignanciesTM 25,000
Boston Children's Hospital/Division Metabolism Conference Series 10,000
of Genetics and Genomics
Postgraduate Institute for Medicine Incorporating New Agents into the Management of Atopic 375,400
PlatformQ Health Education, LLC Dermatitis
Asthma and Allergy Foundation of
America
Purdue University MCM Education Improving the Management of Severe Asthma in Patients 125,000
with Type 2 Inflammation
Cedars-Sinai 8th Annual Symposium on Lysosomal Storage Disorders 20,000
AMERICAN UROLOGICAL ASSOCIATION Use of Novel Hormonal Agents and Systemic Therapy in 50,000
Advanced Prostate Cancer
Med Learning Group In Pursuit of Clinical Remission: Optimizing the 249,850
Pharmacologic Management of Rheumatoid Arthritis
Physicians' Education Resource, LLC Cancer Summaries and CommentariesT: Report from San 50,000
(PER) Diego on Advancements in Multiple Myeloma
Physicians' Education Resource, LLC 2019 ASCO GU Symposium: Prostate Cancer Tumor Board: 100,000
(PER) Integration of Recent Data Sets Across Lines of Care
University of Pittsburgh 2018 Pittsburgh International Lung Conference-- 10,000
Pulmonary Medicine: Basic Biology and Novel Therapies
American College of Chest Phys Update on Moderate-to-Severe Asthma for Specialists: 500,000
Conference Coverage from CHEST 2018
American Academy of Physician 10th Annual Allergy, Asthma & ENT CME Conference 5,000
Assistants in Allergy, Asthma &
Immunology
Oakstone Publishing, LLC Answers in Strategies for Success in Rheumatoid Arthritis 170,000
CME Inc. Treatment: Integrating the Patient Voice
American College of Allergy, Asthma & An interactive Case Discussion of a Young Adult with 40,000
Immunology Severe Atopic Dermatitis: Insights from the Expert
UT Southwestern Medical Center Treatment Approaches and Therapies for Highly Active 83,350
Medical Logix, LLC Multiple Sclerosis: Implementing Updated MS
Guidelines
National Association of Managed Care Implementing Personalized Therapeutic Strategies of 45,000
Physicians Switching and Sequencing to Improve Patient Outcomes
in the Management of Multiple Sclerosis
Projects In Knowledge MedImage Cases: Multiple Sclerosis 75,000
American Society of Transplant 12 Annual Surgical Fellows Symposium 110,000
Surgeons
Medscape LLC Management Challenges in Rheumatoid Arthritis: A 250,000
Virtual Simulation Approach
Michael J. Fox Foundation For MDS-PAS Movement Disorders School for Neurology 20,000
Parkinson's Research Residents
Society for Inherited Metabolic 2018 North American Metabolic Academy 25,000
Disorders
Duke University 2018 Duke Solid Organ Transplant Summit 15,000
American Society of Nephrology Fabry Disease for the Nephrologist: Present and Future 125,000
University of Minnesota
American College of Allergy, Asthma & Thursday Morning Session: Biologic Therapies in Your 77,875
Immunology Practice
Physicians' Education Resourcer Advances inTM Therapies for Patients with Multiple 60,000
(PER) Myeloma: More Options. More Decisions. Better
Outcomes
Oakstone Publishing, LLC Answers in Making the Case for Stepping Up Therapy for Atopic 185,000
CME Inc. Dermatitis
Oakstone Publishing, LLC Answers in Assessing the Impact of AD: Physical and Beyond 170,000
CME Inc.
Postgraduate Institute for Medicine Recognizing and Managing Suboptimal Therapeutic 35,000
Enquiring Minds, LLC Response in MS: Expert Guidance on Challenging Cases
JPatible JPatible Jewish Genetic Screening and Couple 77,500
Compatibility Matching Program
Illinois Academy of Physician Multiple Sclerosis 6,500
Assistants
American Society for Reconstructive Vascularized Composite Tissue Allografts: What it 30,152
Transplantation Takes to Succeed
Massachusetts Association of ``Multiple Sclerosis'' 4,800
Physician Assistants
i3 Health Castration-Resistant Prostate Cancer: Implementing New 86,975
Data and Evolving Standards
Mayo Clinic College of Medicine and International Myeloma Society Educational Workshop 50,000
Science SPARGO Inc. on behalf of the
International Myeloma Society
UCSF Office of CME UCSF TRANSPLANT 2018: Pioneering Advances in 5,000
Transplantation
The University of Texas MD Anderson Emerging Therapeutic Strategies for Relapsed and 50,000
Cancer Center ASiM CE, LLC Refractory Multiple Myeloma: Highlights from ASH 2018
Regents of the University of Colorado 88th Annual Meeting of the American Thyroid 75,000
American Thyroid Association Association and the 2018 Annual Ridgway Trainee
Conference
National Assocation For Continuing Matching Pathogenesis and Treatment in Atopic 92,800
Education Dermatitis: The Evolving Science
The Medical College of Wisconsin PVI, PeerView Live at the 2019 TCT Meetings--``Innovative 119,477
PeerView Institute for Medical Therapies and Concepts in Transplant-Eligible
Education Patients With Myeloma: Advancing Toward More
Effective Care Across Treatment Settings''
Physicians' Education Resource, LLC Medical Crossfire: How Can We Best Leverage the Use 50,000
(PER) of MRD to Optimize Outcomes in the Management of
Hematologic Malignances?
Postgraduate Healthcare Education, Identification and Management of Atopic Dermatitis: 154,500
LLC Postgraduate Institute for Applying Advances to Improve Outcomes A PHE/Power-Pak
Medicine (PIM) Initiative Program 2: Treatment and Emerging
Therapies in Moderate-to-Severe Atopic Dermatitis
Physicians' Education Resource, LLC Optimizing Outcomes Through Stem Cell Mobilization: 300,000
(PER) The Medical College of Applying Evidence to Patients with Multiple Myeloma
Wisconsin, Inc. and Non-Hodgkin's Lymphoma
Continuing Education Alliance PCE Directed Learning eCourse plus eMinders and 148,275
Reinforcements: Changing Pathways in Moderate to
Severe Atopic Dermatitis
American Academy of CME, Inc. Reversing the Trend in Living Kidney Donation: 122,875
Improving Risk Assessment and Increasing Access
Postgraduate Institute for Medicine Applying Precision Medicine in Severe and Difficult-to- 322,100
Treat Asthma.
Penn State College of Medicine Consensus or Controversy? Clinical Investigators 95,000
Research To Practice Provide Perspectives on the Current and Future
Management of Patients with Prostate Cancer--An
Independent Satellite Symposium (ISS) Held as a
Premium Ancillary Educational Event During the 2019
Genitourinary Cancers Symposium
Excel Continuing Education Newborn Screening for Rare Disorders: Focusing on 77,575
Pompe Disease and Gaucher Disease
Excel Continuing Education ``Multiple Sclerosis: Treating and Managing Symptoms'' 5,000
Medical Learning Institute, Inc. PVI, PeerView inSession, Taking Stock of Late-Breaking Data 50,000
PeerView Institute for Medical on Disease-Modifying Therapies for the Treatment of
Education, Inc. Multiple Sclerosis: What Are the Key Learnings from
Berlin?
UMA MLG, LLC A 3D View: Moderate-to-Severe Atopic Dermatitis in the 425,000
Pediatric Population: Long-term Treatment and Managed
Care Issues
Postgraduate Institute for Medicine A Learning Pathway for Clinicians in Multiple 50,000
RMEI Sclerosis: Practical Strategies for Early Diagnosis
and Informed Management
Postgraduate Institute for Medical Atopic Dermatitis: A Specialist Perspective on 300,000
Education Global Academy for Medical Diagnosis and Management Across the Age Spectrum
Education
American Academy of CME, Inc Crucial Conversations in Rare & Orphan Disease: 36,000
Challenges of Diagnosing Rare Diseases: A Focus on
Gaucher Disease
Consortium of Multiple Sclerosis Improving Multiple Sclerosis Care: Integrating Patient- 60,000
Centers PlatformQ Health Education, Provider Perspectives
LLC
Postgraduate Healthcare Education The Pharmacist's Role in Managing Disease-Modifying 30,000
Spire Learning Therapies in Adults With Multiple Sclerosis
Integrity Continuing Education, Inc. Improving Diagnosis and Treatment of Atopic Dermatitis 299,800
through Collaborative Primary & Specialist Care--
Practitioner's Edge State Society Meeting Series and
CME Audit and Feedback Practice Assessment
Regents of the University of Colorado Practical Ways to Achieve Targets in Diabetes Care 25,000
(ATDC) Collaboration \4\
Regents of the University of Colorado Practical Ways to Achieve Targets in Diabetes Care 50,000
(ATDC)
Regents of the University of Colorado Practical Ways to Achieve Targets in Diabetes Care 75,000
(ATDC)
Horizon CME, Inc. Can We Do It Better: Improving Outcomes in the 165,100
Management of Patients with Atrial Fibrillation
Integrity Continuing Education, Inc. 2019 AAFP State Society CME Meetings, Hands-on 160,000
Workshop And BioDigital Human On-demand Simulation
Activity: Overcoming Barriers to Initiating or
Intensifying Insulin Therapy: Best Practices for the
Family Physician
NACCME, LLC. Cardiology Grand Rounds: Diagnostic and 221,710
Pharmacotherapeutic Strategies for the Individualized
Management of Atrial Fibrillation
University of Cincinnati New Developments in Type 2 Diabetes Treatment to 275,000
Decrease the Risk of Hypoglycemia
Medscape LLC Lipid Clinic Considerations: What Would You Do? A Live 447,220
Patient Simulation Collaboration \3\
PRIME Education, LLC Patients, Payers, Providers Opine: When to Treat with 445,879
PCSK9s Collaboration \3\
Boston University School of Medicine 2018 PCE Series 3 Live and Enduring Home Study with 225,000
Practicing Clinicians Exchange (PCE) Eminders and Reinforcement Activities--Evolution of Collaboration \3\
Dyslipidemia Management: The Expanding Role of PCSK9
Inhibitors
Association of Black Cardiologists, Managing Lipids and Cardiovascular Risk: Using the 250,000
Inc. Data to Optimize Care Collaboration \3\
Pharmacy Times Continuing Education An American Journal of Managed Care (AJMC) Payor and 51,850
Specialty Pharmacy Forum: Discussing Clinical Updates Collaboration \3\
and Outcomes Data for PCSK9 Inhibitors
Med-IQ, Inc. Exploring Treatment Intensification in Type 2 250,050
Diabetes: Focus on the Provider-Patient Collaborative
UMA MLG, LLC An In Practice View: Moving Beyond Statins To Decrease 178,150
Cardiovascular Events in Patients With Collaboration \3\
Atherosclerotic Disease
Oakstone Publishing, LLC Answers in Putting Cardiovascular Outcomes Data Into Context: How 170,000
CME Inc. Will the Latest Information on PCSK9 Inhibitors Collaboration \3\
Change Practice?
----------------------------------------------------------------------------------------------------------------
\1\ Applicant names are provided by the requestor. If applicants apply as a group for a single educational
activity; all applicants may be not be identified above. The Company funds other educational activities
(including fellowships and non-physician and patient education); all of which do not appear on this report,
but appear on other reports on this site.
\2\ ``Funding Amount'' is the amount that the Company funded during Q3, 2018 identified above based upon an
agreement. Recipients are required to return any unused funds. Information on unused funds returned by the
applicant on activities are not reported. ``Funding Amount'' does not include funds that may have been
provided by other affiliated Sanofi Company Entities (e.g., Sanofi Pasteur).
\3\ Collaboration (Shared) Funding--is the full amount of a grant funded under an agreement with Regeneron, some
or all of which may be shared between the collaborating entities.
\4\ Collaboration (Shared) Funding--is the full amount of a grant funded under an agreement with Lexicon, some
or all of which may be shared between the collaborating entities.
Independent Medical Education Grants
1st Oct 2018--31st Dec 2018
Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education
activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and
consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged.
Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.
----------------------------------------------------------------------------------------------------------------
Funding Amount
Recipient Name(s) \1\ Activity Title ($) \2\
----------------------------------------------------------------------------------------------------------------
NACCME, LLC Horizon CME Clinical and Cost Considerations for Value-Based 74,875
Multiple Sclerosis Care
AKH, Inc. Catalyst Medical Education, Improving Care for Patients with Pompe Disease: A Look 239,740
LLC at Emerging Therapies and Multidisciplinary
Management Strategies
Medical Education Resources Impact Managing Clinical and Cost Outcomes in Multiple 75,000
Education, LLC Sclerosis: Expert Insights
i3 Health Current Trends in the Management of Castration- 47,530
Resistant Prostate Cancer
Oakstone Publishing, LLC Answers in A Breath of Fresh Air: Exploring Pathophysiology and 340,000
CME Inc. Novel Therapeutic Options to Improve Outcomes in
Moderate-to-Severe Asthma
ANA NY, ISONG 2018 ISONG Congress--Building Connections to Genomic 2,500
Health
Affinity CE/PESG LDRTC Genetic Rare and Immune Disorders Symposium-GRIDS 2018 50,000
GRIDS 2018 title: Late and Attenuated Presentations
of Lysosomal Storage Disorders
UMA MLG, LLC A Virtual Reality Experience--Pediatric Atopic 230,950
Dermatitis: Treatment and Management
UMA MLG, LLC A Virtual Reality View--Long-term Management of Atopic 449,550
Dermatitis: New and Emerging Targeted Systemic
Therapies
UMA Education, Inc. dba Global Clinical Issues in Atopic Dermatitis: Discussions and 168,203
Education Group Integritas Debates on Improving Outcomes for Moderate-to Severe
Communications Disease
National Kidney Foundation Evidence-Based New Insights on the Management of Fabry 145,000
Disease
UMA Education Inc., dba Global Looking Ahead: Optimizing Management Strategies in 393,362
Education Group Integritas Moderate-to-Severe Atopic Dermatitis
Communications
Postgraduate Healthcare Education, Type 1 Gaucher Disease: Optimizing Treatment and 63,950
LLC Postgraduate Institute for Management Approaches
Medicine (PIM)
The France Foundation Severe Asthma Science: Endotypes and Precision 292,680
Medicine Presidential Case Studies
UMA Education, Inc dba Global Clearing the Air in Severe Asthma Management: 549,981
Education Group Integritas Improving Patient Outcomes Through Shared Clinical
Communications Decision Making
AKH Inc. Advancing Knowledge in Masters of Pediatric Dermatology 20,000
Healthcare Tarsus Cardio dba South
Beach Symposium
PRIME Education, LLC Atopic Dermatitis Across the Life Cycle: Taking the 199,700
Long View on Diagnostic, Treatment, and Management
Strategies
PRIME Education, LLC Linking Patients, Providers, and Payers in Coordinated 316,500
Approaches to Severe Asthma Treatment
AKH Inc., Advancing Knowledge in 17th Annual South Beach Symposium 20,000
Healthcare Tarsus Cardio
PRIME Education, LLC Stepping Up Managed Care and Specialty Pharmacy 499,075
Decision-Making to Support Integration of New
Evidence and Mechanisms in Asthma Treatment
Academy of Managed Care Pharmacy AMCP Specialty Connect--Focus on Gene Therapy 35,000
(AMCP)
UMA MLG, LLC The Unique Role of the Community Pharmacist in the 199,550
Management of Moderate-to-Severe Atopic Dermatitis in
the Pediatric Population
Rush University Medical Center Plexus Applying the Latest Clinical Data and Emerging 60,000
Communications Therapeutic Approaches in the Management of Prostate
Cancer Throughout the Disease Spectrum
Purdue University College of Pharmacy PeerView Live, ``Unraveling the Complexities of 109,387
PVI, PeerView Institute for Medical Prostate Cancer Management: Focus on Therapeutic
Education, Inc. Decisions for Early Stage Disease and the
Implications for Later Stage Disease''
Rush University Medical Center Plexus Community Uro-Oncology Forums: Understanding the 80,000
Communications Disease Continuum and Navigating the Evolving
Treatment Paradigms in Prostate Cancer
American Health Resources, LLC Updates in Myeloma Therapeutics: Bone Health, 8,000
Smoldering Disease, and CAR-T Cells
Siyemi Learning Action Eczema: Global Atopic Dermatitis Educational 383,320
Resource Center
ScientiaCME Genetic Disorders: Updates from The 15th Annual World 17,800
Symposium
NERGG, Inc. NERGG 2018 Annual Meeting 6,000
UMA MLG, LLC The CATALYST Initiative--A 3D View--Targeting 348,275
Inflammatory Cytokines: Addressing Articular and
Systemic Pathology in Patients with Moderate-to-
Severe Rheumatoid Arthritis
University of Nevada, Reno School of 2018 Fall Clinical Dermatology Conferencer and Beyond: 150,000
Medicine Foundation for Research and Practical Approaches to Patient Management--Focus on
Education in Dermatology Atopic Dermatitis
Trustees of Boston University Talem Talem ACO Summit Series--Atopic Dermatitis: Improving 198,555
Health, LLC Outcomes Through a Patient-Centered Approach
Cleveland Clinic Educational 7th Annual Basic & Clinical Immunology for the Busy 15,000
Foundation Clinician
University of Nebraska Medical Center Rural Health Summit Series: Updates in Atopic 201,343
The Board of Regents of the Dermatitis for the Rural Primary Care Physician
University of Nebraska dba the
University of Nebraska Medical
Center
International Eczema Council Atopic Dermatitis Phenotypes and Biomarkers 11,500
Excel Continuing Education Fabry Disease: Role of the Genetic Counselor in an 81,900
Ever-Changing Landscape; The Role of the Genetic
Counselor in Pompe Disease
Specialty Pharma Education Center Advancing Care in Prostate Cancer: Clinical 49,750
Understandings & Evolving Treatment and Management
Approaches
Massachusetts Eye And Ear Infirmary, Surgery of the Thyroid and Parathyroid Glands 15,000
Department of Otolaryngology
President and Fellows of Harvard
College
Rush University Medical Center Plexus VHA UroOncology Clinical Forums ``Advancing Strategies 90,000
Communications in Prostate Cancer: Individualizing Treatment Plans
Based on the Rapidly Evolving Landscape and Disease
Continuum''
Physicians' Education Resource, LLC ``D'' is for Diagnosis: Solving the Mystery of 100,000
(PER) Lysosomal Storage Disorders
Muscular Dystrophy Association Medical Education Tactics for the Physician and Care 211,525
Center Community: Hot Topics in NMD Webcast and MDA
Speaker Slides
Med-IQ, Inc. Bridging the Gap Between Research and Clinical 245,887
Advances in Gaucher Disease Type 3
Medical Education Resources, Inc. Managing Multiple Sclerosis: A Guide for Specialty 75,000
Impact Education, LLC Pharmacy Professionals
Med Learning Group A Multiple Sclerosis Virtual Reality Experience: 50,000
Reaching Diagnosis, Delivering Treatment, and Setting
Goals for Long-Term Success
Integrity Continuing Education, Inc. 2019 AAFP State Society CME Meetings and BioDigital 299,000
Human On-demand Simulation Activity--Ensuring Early
Diagnosis and Targeting Treatment to Remission in
Patients with Rheumatoid Arthritis: Recommendations
for Primary Care Clinicians
Yale School of Medicine 2019 Update: What's New in the Field of Multiple 15,000
Sclerosis
Annenberg Center for Health Sciences 11th Annual Linda Morgante MS Nurse Leadership Program 45,000
at Eisenhower Academy for Continued
Healthcare Learning
Physicians' Education Resource, LLC 2019 ACTRIMS: An Interactive, Case-Based Discussion: 212,000
(PER) Interpreting the Therapeutic Landscape in Multiple
Sclerosis
The Medical College of Wisconsin, 29th Annual International Prostate Cancer Update (IPCU 15,000
Inc. Carden Jennings Publishing Co., 29)
Ltd.
UMA MLG, LLC In Pursuit of the Best Outcomes in Rheumatoid 194,680
Arthritis: Inhibiting Inflammatory Pathology
NJ State Society of Physician Focus on the Future 21,000
Assistants College of Saint
Elizabeth
Postgraduate Institute for Medicine Lysomal Storage Disorders--Common Presetations of 99,885
Enquiring Minds, LLC Uncommon Diseases: Expert Guidance on Early
Identification and Therapeutic Optimization
Greenwood Genetic Center Spring 2019 and Spring 2020 educational program: 82,003
Enhancing genetic understanding of lysosomal storage
diseases for practicing Physician Assistants (PA) and
PA students
ThinkGenetic Foundation Closing the Genetics Gap: A Lecture for Healthcare 9,320
Advocates on Lysosomal Storage Diseases Designed to
Increase Access to Genetics Services in Medically
Underserved Parishes of Louisiana
National Association for Continuing Conversations in Primary Care 2019 Live Virtual 64,000
Education Symposium Series Individualizing Asthma Care:
Addressing Type 2 Inflammation
Excel Continuing Education Newborn Screening for Fabry Disease: What 86,735
Neonatologists and Pediatricians Needs to Know
Excel Continuing Education Exploring the Genetic Counselor's Role in Gaucher 42,330
Disease (satellite symposium at NSGC)
Mayo Clinic Arizona Mayo Clinic 2019 Multiple Sclerosis & Autoimmune 7,500
Neurology Update
UT Southwestern Medical Center 41st Annual Carrell Krusen Neuromuscular Symposium 5,000
Medscape LLC Improving Appropriate Use of PCSK9 Inhibitors in 736,125
Interventional Cardiology: Patient-Centered Care Collaboration \3\
Perspectives Post-MI
Postgraduate Institute for Medicine The iQ&A Case-by-Case, PCSK9 Cardiovascular Medicine 488,000
Intelligence zone: from trials to treatment-How Do Collaboration \3\
Recent Guidelines and CV Outcome Trials Help Identify
High Risk Patients (Elevated LDL-C, Recent ACS,
Advanced ASCVD, PCI, Statin Intolerance and
Resistance, and Diabetes) Who Are Optimal Candidates
for PCSK9 Inhibitor-Mediated Therapy
----------------------------------------------------------------------------------------------------------------
\1\ Applicant names are provided by the requestor. If applicants apply as a group for a single educational
activity; all applicants may be not be identified above. The Company funds other educational activities
(including fellowships and non-physician and patient education); all of which do not appear on this report,
but appear on other reports on this site.
\2\ ``Funding Amount'' is the amount that the Company funded during Q4, 2018 identified above based upon an
agreement. Recipients are required to return any unused funds. Information on unused funds returned by the
applicant on activities are not reported. ``Funding Amount'' does not include funds that may have been
provided by other affiliated Sanofi Company Entities (e.g., Sanofi Pasteur).
\3\ Collaboration (Shared) Funding--is the full amount of a grant funded under an agreement with Regeneron, some
or all of which may be shared between the collaborating entities.
\4\ Collaboration (Shared) Funding--is the full amount of a grant funded under an agreement with Lexicon, some
or all of which may be shared between the collaborating entities.
Organization Name
------------------------------------------------------------------------
------------------------------------------------------------------------
Hawaii Chapter--National Hemophilia The Coalition for Hemophilia B
Foundation
Hemophilia of North Carolina Virginia Hemophilia Foundation
Hemophilia Foundation of Greater West Virginia Chapter National
Florida Hemophilia Foundation
The Coalition for Hemophilia B Brandywine Valley Hemophilia
Annual Reqests Foundation
Arizona Hemophilia Association Hemophilia Association of the
Capital Area
Central California Hemophilia National Hemophilia Foundation,
Foundation Colorado Chapter
Hemophilia Foundation of Arkansas, Hemophilia Foundation of Northern
Inc. California
United Hemophilia Foundation, Inc. Lone Star Chapter of the National
Hemophilia Foundation
Lone Star Chapter of the National Mississippi Hemophilia Foundation
Hemophilia Foundation
Lone Star Chapter of the National Lone Star Chapter of the National
Hemophilia Foundation Hemophilia Foundation
Utah Hemophilia Foundation Hemophilia Association of the
Capital Area
Florida Hemophilia Association Great Lakes Hemophilia Foundation
Bleeding Disorders Alliance Gateway Hemophilia Association
Illinois
Arizona Hemophilia Association Tennessee Hemophilia and Bleeding
Disorders Foundation
Hemophilia Foundation of Northern Nebraska Chapter of the National
California Hemophilia Foundation
Hemophilia Association of the Northern Ohio Hemophilia Foundation
Capital Area
Hemophilia Foundation of Southern Hemophilia Foundation of Southern
California California
Hemophilia Alliance of Maine Bleeding Disorders Association of
Northeastern New York, Inc.
Connecticut Hemophilia Society, Idaho Chapter of the National
Inc. Hemophilia Foundation
Hemophilia Foundation of Minnesota/ Hemophilia Foundation of Michigan
Dakotas
Oklahoma Hemophilia Foundation Hemophilia and Bleeding Disorders
of Alabama, Inc.
Cooley's Anemia Foundation Oklahoma Hemophilia Foundation
Louisiana Hemophilia Foundation Gateway Hemophilia Association
Virginia Hemophilia Foundation Virginia Hemophilia Foundation
Utah Hemophilia Foundation Alaska Hemophilia Association
Nevada Chapter of the National Utah Hemophilia Foundation
Hemophilia Foundation
Alaska Hemophilia Association Hemophilia of South Carolina
Hemophilia Foundation of Oregon Tennessee Hemophilia and Bleeding
Disorders Foundation
Tennessee Hemophilia and Bleeding Hemophilia Foundation of Greater
Disorders Foundation Florida
Hemophilia of Indiana, Inc. Hemophilia Foundation of Maryland,
Inc.
Hemophilia Foundation of Maryland Northern Ohio Hemophilia Foundation
Inc.
National Hemophilia Foundation, National Hemophilia Foundation,
Colorado Chapter Colorado Chapter
New England Hemophilia Association Hemophilia Foundation of Arkansas,
Inc.
New England Hemophilia Association New York City Hemophilia Chapter
Hemophilia Foundation of WNY, INC. The Coalition for Hemophilia B
Woman's Retreat
Arizona Hemophilia Association Hemophilia Foundation of Greater
Florida
The Bleeding Disorder Foundation of National Hemophilia Foundation
Washington
The Hemophilia Association of New Great Lakes Hemophilia Foundation
Jersey
The Hemophilia Association of New Texas Central Hemophilia
Jersey Association
National Hemophilia Foundation, Hemophilia Association of San Diego
Colorado Chapter County
Kentucky Hemophilia Foundation Kentucky Hemophilia Foundation
(KHF) (KHF)
Kentucky Hemophilia Foundation Central California Hemophilia
(KHF) Foundation
West Virginia Chapter of the Foundation for Sickle Cell Disease
National Hemophilia Foundation Research
Federation of American Societies Gateway Hemophilia Association
for Experimental Biology
Great Lakes Hemophilia Foundation Hemophilia Foundation of Southern
California
United Hemophilia Foundation, Inc. Florida Hemophilia Association
Hemophilia Foundation of Southern Nevada Chapter of the National
California Hemophilia Foundation
Nevada Chapter of the National Hemophilia of North Carolina
Hemophilia Foundation
Hemophilia of North Carolina Hemophilia of Indiana, Inc.
Hemophilia of Indiana, Inc. Hemophilia of Indiana, Inc.
Hemophilia Association of San Diego Hawaii Chapter--National Hemophilia
County Foundation
Oklahoma Hemophilia Foundation Disabled Adventure Outfitters
National Hemophilia Foundation, Hawaii Chapter--NHF
Colorado Chapter
Rocky Mountain Hemophilia & Rocky Mountain Hemophilia &
Bleeding Disorders Association Bleeding Disorders Association
Virginia Hemophilia Foundation Hemophilia Association of the
Capital Area
Hemophilia Association of the The Western Pennsylvania Chapter of
Capital Area the National Hemophilia Foundation
Lone Star Chapter of the National Central Ohio Chapter, NHF
Hemophilia Foundation
Bleeding Disorders Alliance Central California Hemophilia
Illinois Foundation
Hemophilia Alliance of Maine New England Hemophilia Asssociation
Alaska Hemophilia Association FAMOHIO, Inc.
FOUNDATION HOPE AND LIFE USA CORP. National Hemophilia Foundation
Midwest Hemophilia Association Great Lakes Hemophilia Foundation
Hemophilia Foundation of WNY, INC. Utah Hemophilia Foundation
Hope for Hemophilia Hope for Hemophilia
West Virginia Chapter of the Hemophilia of Iowa, Inc.
National Hemophilia Foundation
New York City Hemophilia Chapter New England Hemophilia Association
Association of Pediatric Hematology SISTERS AND CAREGIVERS BLEEDING
Oncology Nurses DISORDER NETWORK, INC DBA BLOOD B
National Hemophilia Foundation, Colorado Chapter, National
Colorado Chapter Hemophilia Foundation
American Society of Hematology Hemophilia Association of the
Southern Tier, Inc.
Mississippi Hemophilia Foundation New York City Hemophilia Chapter
Comprehensive Health Education New England Hemophilia Association
Services
Northern Ohio Hemophilia Foundation Hemophilia Association of the
Capital Area
Global Genes Mary M. Gooley Hemophilia Center,
Inc.
Midwest Hemophilia Association Hemophilia of South Carolina
Arizona Hemophilia Association Sickle Cell Disease Association of
America, Inc.
Hemostasis and Thrombosis Research Greater Boston Sickle Cell Disease
Society, Inc. Association, Inc.
Bleeding Disorders Alliance Hope for Hemophilia
Illinois
Central Ohio Chapter National New York City Hemophilia Chapter
Hemophilia Foundation
New York City Hemophilia Chapter The Hemophilia Association of New
Jersey
Arizona Hemophilia Association Nebraska Chapter of the National
Hemophilia Foundation
Nevada Chapter of the National Sickle Cell Disease Association of
Hemophilia Foundation America, Michigan Chapter
Hemophilia of South Carolina Hemophilia of Iowa, Inc.
Empowering Women with Bleeding and Tennessee Hemophilia and Bleeding
Clotting Disorders (Global Blood Disorders Foundation
Disorder Foundation)
Hemophilia Foundation of Oregon The Hemophilia Association of New
Jersey
Hemophilia Foundation of Arkansas, Connecticut Hemophilia Society,
Inc. Inc.
Bleeding Disorders Advocacy Network National Hemophilia Foundation,
West Virginia Chapter
New England Hemophilia Association Western Pennsylvania Chapter of the
National Hemophilia Foundation
Virginia Hemophilia Foundation Hemophilia Foundation of Greater
Florida
Hemophilia Foundation of Greater National Hemophilia Foundation,
Florida West Virginia Chapter
Idaho Chapter of the National Tri-State Bleeding Disorder
Hemophilia Foundation Foundation
Northwest Ohio Hemophilia New York City Hemophilia Chapter
Foundation
Hemophilia Association of the Hemophilia Foundation of Southern
Capital Area California
Hemophilia of North Carolina Oklahoma Hemophilia Foundation
Bleeding Disorders Association of Louisiana Hemophilia Foundation
Northeastern New York, Inc.
Eastern Pennsylvania Chapter of the Sangre De Oro, Inc.
National Hemophilia Foundation
National Hemophilia Foundation Midwest Hemophilia Association
United Hemophilia Foundation, Inc. Texas Central Hemophilia
Association
Hemophilia Foundation of Northern Central Ohio Chapter, NHF
California
The Bleeding Disorder Foundation of Nebraska Chapter of the National
Washington Hemophilia Foundation
The Coalition for Hemophilia B Northern Ohio Hemophilia Foundation
West Virginia Chapter of the Hemophilia and Bleeding Disorders
National Hemophilia Foundation of Alabama, Inc.
Academia Medica del Sur, Inc. Hemophilia Association of New York,
Inc.
Texas Central Hemophilia New York City Hemophilia Chapter
Association
Tri-State Bleeding Disorder Hemophilia Alliance of Maine
Foundation
Nevada Chapter of the National FOUNDATION HOPE AND LIFE USA CORP.
Hemophilia Foundation
Central California Hemophilia American Society of Gene & Cell
Foundation Therapy
The Coalition for Hemophilia B Virginia Hemophilia Foundation
Nevada Chapter of the National Hemophilia Association of the
Hemophilia Foundation Capital Area
Hemophilia Council of California Hemophilia Foundation of Maryland,
Inc.
Tri-State Bleeding Disorder Hemophilia Foundation of Southern
Foundation California
United Hemophilia Foundation, Inc. The Bleeding Disorder Foundation of
Washington
The Bleeding Disorder Foundation of Rocky Mountain Hemophilia &
Washington Bleeding Disorders Association
New England Hemophilia Association Arizona Hemophilia Association
Hemophilia Foundation of Maryland Western Pennsylvania Chapter of the
National Hemophilia Foundation
Western Pennsylvania Chapter of the Hemophilia Foundation of Arkansas,
National Hemophilia Foundation Inc.
Virginia Hemophilia Foundation Virginia Hemophilia Foundation
Hemophilia Foundation of Southern Hemophilia Council of California
California
Hemophilia Foundation of Maryland, The Western Pennsylvania Chapter of
Inc. the National Hemophilia Foundation
New England Hemophilia Association Arizona Hemophilia Association
Hawaii Chapter--National Hemophilia Hawaii Chapter--National Hemophilia
Foundation Foundation
Hemophilia Foundation of Southern Arizona Hemophilia Association
California
Hemophilia of North Carolina Virginia Hemophilia Foundation
Connecticut Hemophilia Society, Idaho Chapter of the National
Inc. Hemophilia Foundation
Hemophilia Association of New Bleeding Disorders Alliance of
Jersey North Dakota
Hemophilia Foundation of Oregon
------------------------------------------------------------------------
------------------------------------------------------------------------
Payment amount
Project name (in (USD)) Payment date
------------------------------------------------------------------------
Industry Symposium $7,500.00 3/13/2018
------------------------------------------------------------------------
The Coalition for Hemophilia B 12th $20,000.00 3/14/2018
Annual Symposium
------------------------------------------------------------------------
2018 HNC Walks in Charlotte & Raleigh $7,500.00 3/14/2018
------------------------------------------------------------------------
Family Weekend $2,500.00 3/16/2018
------------------------------------------------------------------------
Gainesville Clot Trot $2,500.00 3/17/2018
------------------------------------------------------------------------
WVNHF Men's and Women's Day $3,000.00 3/20/2018
------------------------------------------------------------------------
The Coalition for Hemophilia B 2018 $8,000.00 3/20/2018
Annual Sponsorship Run
------------------------------------------------------------------------
Big Red Run 2018 $1,500.00 3/20/2018
------------------------------------------------------------------------
FAME Phoenix and Tucson $3,000.00 3/20/2018
------------------------------------------------------------------------
Infusion Classes $1,000.00 3/20/2018
------------------------------------------------------------------------
World Hemophilia Day $1,000.00 3/22/2018
------------------------------------------------------------------------
Educations Days 2018 $5,000.00 3/22/2018
------------------------------------------------------------------------
Northwest Arkansas Educational Day $1,500.00 3/22/2018
------------------------------------------------------------------------
World Hemophilia Day $2,500.00 3/23/2018
------------------------------------------------------------------------
Annual Meeting & Family Education $3,000.00 3/26/2018
Dinner
------------------------------------------------------------------------
Hill Country Family Education Day $1,000.00 3/26/2018
------------------------------------------------------------------------
Southeast Texas Family Education Day $1,000.00 3/26/2018
------------------------------------------------------------------------
Men's Retreat $2,500.00 3/26/2018
------------------------------------------------------------------------
Texas Bleeding Disorders Conference $6,000.00 3/27/2018
Exhibit
------------------------------------------------------------------------
Texas Bleeding Disorders Conference $50,000.00 3/27/2018
------------------------------------------------------------------------
Women and Bleeding Disorders $1,500.00 3/27/2018
Conference
------------------------------------------------------------------------
Family Education Day $2,500.00 3/27/2018
------------------------------------------------------------------------
8th Annual Walk in the Jungle $5,000.00 3/27/2018
------------------------------------------------------------------------
Family Camp $1,000.00 3/28/2018
------------------------------------------------------------------------
BDAI 2018 Statewide Family Education $2,500.00 3/28/2018
Weekend & World
------------------------------------------------------------------------
2018 Bleeding Disorder Walk $1,000.00 3/28/2018
------------------------------------------------------------------------
Camp HONOR $1,000.00 3/29/2018
------------------------------------------------------------------------
Be A Factor 5 k $500.00 3/29/2018
------------------------------------------------------------------------
Unite for Bleeding Disorders Health $2,500.00 3/30/2018
Fair
------------------------------------------------------------------------
Family Education Weekend $3,000.00 3/30/2018
------------------------------------------------------------------------
Family Education Weekend $2,000.00 4/3/2018
------------------------------------------------------------------------
Spring Wellness Program $1,500.00 4/4/2018
------------------------------------------------------------------------
Teen Leadership Summit $1,000.00 4/4/2018
------------------------------------------------------------------------
Family Information Day $5,000.00 4/4/2018
------------------------------------------------------------------------
Annual Meeting $5,000.00 4/5/2018
------------------------------------------------------------------------
Unite for Bleeding Disorders Walk $2,500.00 4/5/2018
------------------------------------------------------------------------
Spring Social $1,500.00 4/5/2018
------------------------------------------------------------------------
Victory for Women $2,800.00 4/5/2018
------------------------------------------------------------------------
HFMD Annual Members Meeting $1,500.00 4/6/2018
------------------------------------------------------------------------
HFM's 2018 National Conference for $100,000.00 4/6/2018
Women with Bleeding Disorders
------------------------------------------------------------------------
OHF Camp Independence $4,000.00 4/9/2018
------------------------------------------------------------------------
Camp Clot Not $2,500.00 4/9/2018
------------------------------------------------------------------------
2018 CAF Care Walk $7,500.00 4/9/2018
------------------------------------------------------------------------
2018 ``Unite for Bleeding Disorders'' $2,500.00 4/9/2018
Health Fair and Walk
------------------------------------------------------------------------
2018 Camp Globeclotters $2,500.00 4/9/2018
------------------------------------------------------------------------
2018 Camp Notaclotamongus $1,250.00 4/10/2018
------------------------------------------------------------------------
Teen/Young Adult Program $15,000.00 4/10/2018
------------------------------------------------------------------------
Annual State Educational Meeting $3,500.00 4/10/2018
------------------------------------------------------------------------
Website ad and direct mailing $4,000.00 4/11/2018
------------------------------------------------------------------------
Youth Leadership Weekend 2018 $500.00 4/11/2018
------------------------------------------------------------------------
Camp Independent Firefly $1,000.00 4/11/2018
------------------------------------------------------------------------
Utah Hemophilia Foundation's Family $2,000.00 4/11/2018
Resource Fair
------------------------------------------------------------------------
Camp Frozen Chozen $3,500.00 4/11/2018
------------------------------------------------------------------------
HELLO- State Annual Meeting and $2,500.00 4/16/2018
Educational Conference
------------------------------------------------------------------------
2018 Oregon Unite for Bleeding $2,500.00 4/16/2018
Disorders Walk
------------------------------------------------------------------------
2018 Race for Ian $500.00 4/17/2018
------------------------------------------------------------------------
2018 48th Annual Meeting $3,000.00 4/17/2018
------------------------------------------------------------------------
17th Annual Family Education Program $2,800.00 4/19/2018
------------------------------------------------------------------------
Camp Brave Eagle $1,500.00 4/19/2018
------------------------------------------------------------------------
Race to Stop the Bleeding $4,000.00 4/19/2018
------------------------------------------------------------------------
HFM Family Educational Dinner and $4,000.00 4/19/2018
Display Night
------------------------------------------------------------------------
Gears for Good Charity Bike Ride $1,000.00 4/19/2018
------------------------------------------------------------------------
Colorado Family Camp 2018 $1,500.00 4/20/2018
------------------------------------------------------------------------
Spanish Program: Greeley $1,000.00 4/20/2018
------------------------------------------------------------------------
Family Camp $5,000.00 4/20/2018
------------------------------------------------------------------------
Eighth Annual Center for Bleeding $1,500.00 4/20/2018
Disorders Conference
------------------------------------------------------------------------
9th Annual Walk $10,000.00 4/20/2018
------------------------------------------------------------------------
NYC Unite for Bleeding Disorders Walk $5,000.00 4/20/2018
2018
------------------------------------------------------------------------
New Patient Summer Social $1,000.00 4/20/2018
------------------------------------------------------------------------
The Coalition for Hemophilia B Fall $72,500.00 4/20/2018
Woman's Retreat
------------------------------------------------------------------------
Community Education Days $7,500.00 4/20/2018
------------------------------------------------------------------------
Tampa Superhero Walk For Bleeding $2,500.00 4/20/2018
Disorders
------------------------------------------------------------------------
Western Washington Spring Education $1,500.00 4/20/2018
Day
------------------------------------------------------------------------
2018 New Jersey Hemophilia Walk $4,000.00 4/23/2018
------------------------------------------------------------------------
7th Annual Hemophilia Awareness Walk $2,500.00 4/30/2018
------------------------------------------------------------------------
2018 Wisconsin Bleeding Disorders $4,000.00 5/1/2018
Conference
------------------------------------------------------------------------
Hemophilia Association Annual Meeting $5,000.00 5/15/2018
------------------------------------------------------------------------
2018 TexCen Annual Meeting and Summer $3,000.00 5/20/2018
Education Day
------------------------------------------------------------------------
Social Factor: Colorado Spring $1,000.00 5/21/2018
------------------------------------------------------------------------
2018 Industry Symposium $3,500.00 5/22/2018
------------------------------------------------------------------------
2018 Kentucky Unite for Bleeding $2,500.00 6/5/2018
Disorders Walk
------------------------------------------------------------------------
2018 Annual Education Meeting $1,750.00 6/5/2018
------------------------------------------------------------------------
2018 KHF Camp Discovery--Summer Camp $2,000.00 6/5/2018
Program for Children and Teens
------------------------------------------------------------------------
Unite for Bleeding Disorders Walk $1,000.00 6/7/2018
------------------------------------------------------------------------
WVNHF Industry Symposium $3,000.00 6/7/2018
------------------------------------------------------------------------
12th Annual Sickle Cell Disease $5,000.00 6/11/2018
Research and Educational
------------------------------------------------------------------------
FASEB Conference on ``Genome $2,000.00 6/13/2018
Engineering: Cutting-Edge
------------------------------------------------------------------------
2018 Family Education Weekend $2,000.00 6/14/2018
------------------------------------------------------------------------
Camp Klotty Pine 2018 $1,000.00 6/14/2018
------------------------------------------------------------------------
Camp Blood Brothers and Sisters $2,000.00 6/17/2018
------------------------------------------------------------------------
Family Education Conference $5,000.00 6/17/2018
------------------------------------------------------------------------
35th Annual Florida Bleeding Disorders $6,000.00 6/17/2018
Conference (Formerly known as the
``Family Education Symposium'')
------------------------------------------------------------------------
Familia de Sangre $50,000.00 6/18/2018
------------------------------------------------------------------------
Northern Nevada Family Education Day $1,500.00 6/18/2018
------------------------------------------------------------------------
Unite For Bleeding Disorders $1,000.00 6/18/2018
------------------------------------------------------------------------
Union Latina (Latin Union) Educational $2,500.00 6/18/2018
Retreat
------------------------------------------------------------------------
Men's Educational Retreat $1,500.00 6/18/2018
------------------------------------------------------------------------
2018 Hemophilia of Indiana Annual $4,000.00 6/19/2018
Meeting
------------------------------------------------------------------------
2018 Unite For Bleeding Disorders Walk $3,500.00 6/19/2018
------------------------------------------------------------------------
Doug Thompson Teen Leadership Camp $1,500.00 6/19/2018
------------------------------------------------------------------------
2018 Teen Camp $2,000.00 6/20/2018
------------------------------------------------------------------------
Hawaii Teen Summit $7,500.00 6/20/2018
------------------------------------------------------------------------
OHF Annual Meeting 2018 $3,500.00 6/20/2018
------------------------------------------------------------------------
Teen Adventure Camp $2,500.00 6/20/2018
------------------------------------------------------------------------
Mile High Summer Camp 2018 $1,000.00 6/20/2018
------------------------------------------------------------------------
Koko Ohana Family Camp $2,500.00 6/20/2018
------------------------------------------------------------------------
RMHBDA Walk for Bleeding Disorders $1,500.00 6/21/2018
------------------------------------------------------------------------
RMHBDA BIG SKY FAMILY CAMP $1,000.00 6/21/2018
------------------------------------------------------------------------
Camp Youngblood--Summer Camp $1,000.00 6/21/2018
------------------------------------------------------------------------
Summer Camp $1,000.00 6/21/2018
------------------------------------------------------------------------
HACA Fall Festival and Walk $7,500.00 6/21/2018
------------------------------------------------------------------------
Western Pennsylvania Walk, Run, and $2,000.00 6/21/2018
Cornhole Tournament
------------------------------------------------------------------------
Unite for Bleeding Disorders Walk $3,000.00 6/22/2018
------------------------------------------------------------------------
COC-New Patient Orientstion $1,750.00 6/22/2018
------------------------------------------------------------------------
BDAI 2018 Unite Walk for Bleeding $2,500.00 6/25/2018
Disorders Sponsorship
------------------------------------------------------------------------
Family Education Day $5,500.00 6/26/2018
------------------------------------------------------------------------
Hike4HAM $2,500.00 6/27/2018
------------------------------------------------------------------------
Women's Retreat $2,000.00 6/27/2018
------------------------------------------------------------------------
Alaska Bleeding Disorder Walk--Exhibit $1,750.00 6/27/2018
------------------------------------------------------------------------
FAMOHIO Annual Meeting and Educational $12,500.00 6/27/2018
Symposium
------------------------------------------------------------------------
Back to School Educational Event $2,500.00 6/28/2018
------------------------------------------------------------------------
NHF 2018 Bleeding Disorders Conference $237,000.00 6/29/2018
Sponsorships
------------------------------------------------------------------------
MHA UNITE for Bleeding Disorders Walk- $2,500.00 7/2/2018
a-Thon
------------------------------------------------------------------------
2018 Wisconsin Unite for Bleeding $5,000.00 7/2/2018
Disorders Walk
------------------------------------------------------------------------
``In my Blood'' Bleeding Disorders $2,000.00 7/2/2018
Awareness Walk
------------------------------------------------------------------------
Camp Valor 2018 $6,000.00 7/2/2018
------------------------------------------------------------------------
Superhero Run/Walk--Covington, LA $5,000.00 7/3/2018
------------------------------------------------------------------------
Superhero HOPE Run/Walk--Wichita, KS $5,000.00 7/3/2018
------------------------------------------------------------------------
WVNHF Family Camp $3,000.00 7/5/2018
------------------------------------------------------------------------
Annual Meeting $1,500.00 7/5/2018
------------------------------------------------------------------------
Kids Day Camp $7,000.00 7/6/2018
------------------------------------------------------------------------
BLeaders Teen Retreat $5,000.00 7/15/2018
------------------------------------------------------------------------
BITS AND PIECES OF Pediatric $1,000.00 7/16/2018
Hematology, Oncology & BM
------------------------------------------------------------------------
BBBDN Back to School Educating for $5,000.00 7/16/2018
Success
------------------------------------------------------------------------
Western Slope Social Factor $1,000.00 7/17/2018
------------------------------------------------------------------------
Colorado Unite for Bleeding Disorders $1,500.00 7/17/2018
Walk
------------------------------------------------------------------------
ASH Corporate Friends $35,000.00 7/17/2018
------------------------------------------------------------------------
Annual BDAST 2018 Hike Fundraiser $3,000.00 7/17/2018
------------------------------------------------------------------------
Family Retreat $4,000.00 7/17/2018
------------------------------------------------------------------------
NYCHC 2018 Women's Retreat $10,000.00 7/23/2018
------------------------------------------------------------------------
National LadyBugs Womens Summit $50,000.00 8/2/2018
------------------------------------------------------------------------
Hispanic Heritage Symposium $3,500.00 8/2/2018
------------------------------------------------------------------------
UNITE for Bleeding Disorders Walk $2,500.00 8/2/2018
------------------------------------------------------------------------
Women's Retreat $2,000.00 8/2/2018
------------------------------------------------------------------------
2018 Patient Advocacy Summit $33,000.00 8/7/2018
------------------------------------------------------------------------
2018 Finger Lakes Triathlon $5,000.00 8/7/2018
------------------------------------------------------------------------
MHA Family Education Weekend-- $2,000.00 8/8/2018
Connecting the Bleeding
------------------------------------------------------------------------
Educational Family Camp and Adult $3,000.00 8/10/2018
Retreat
------------------------------------------------------------------------
NACCHO 2019 $180,000.00 8/13/2018
------------------------------------------------------------------------
46th Annual SCDAA National Convention $25,000.00 8/14/2018
------------------------------------------------------------------------
HTRS Corporate Colleague--Sustaining $10,000.00 8/16/2018
Member
------------------------------------------------------------------------
Walk for Sickle Cell Disease $5,000.00 8/20/2018
------------------------------------------------------------------------
Community Liaison Project $5,000.00 8/22/2018
------------------------------------------------------------------------
2018 HOPE Conference $15,000.00 8/23/2018
------------------------------------------------------------------------
Unite for Bleeding Disorders 5K $2,500.00 8/28/2018
------------------------------------------------------------------------
TORCH Teen Retreat $7,000.00 8/29/2018
------------------------------------------------------------------------
Bilingual Back to School Event $5,000.00 8/29/2018
------------------------------------------------------------------------
Hemophilia Association of New Jersey $2,500.00 8/29/2018
(HANJ) Fall Education
------------------------------------------------------------------------
Annual Statewide Meeting $10,000.00 8/29/2018
------------------------------------------------------------------------
Unite for Bleeding Disorder Walk $1,000.00 9/4/2018
------------------------------------------------------------------------
Fall Fam Jam $1,000.00 9/5/2018
------------------------------------------------------------------------
Sickle CELLebration $3,000.00 9/5/2018
------------------------------------------------------------------------
The Turkey Trot 5k Walk for Hemophilia $2,500.00 9/6/2018
and Bleeding Disorders
------------------------------------------------------------------------
Unite for Bleeding Disorder Walk $1,500.00 9/6/2018
------------------------------------------------------------------------
Empowering Women with Bleeding and $3,500.00 9/7/2018
Clotting Disorders
------------------------------------------------------------------------
Blazin for Bleeders 5k/walk $1,000.00 9/7/2018
------------------------------------------------------------------------
2018 HFO Insurance Forum $3,000.00 9/7/2018
------------------------------------------------------------------------
2018 PACT Workshop $15,000.00 9/8/2018
------------------------------------------------------------------------
2018 Family Retreat/Annual Meeting $3,500.00 9/10/2018
------------------------------------------------------------------------
Annual Meeting $1,500.00 9/10/2018
------------------------------------------------------------------------
2018 BDAN Fall Family Retreat $2,500.00 9/10/2018
------------------------------------------------------------------------
Spokes Men for Bleeders $500.00 9/11/2018
------------------------------------------------------------------------
Fall Fest $5,000.00 9/11/2018
------------------------------------------------------------------------
WPCNHF'S Erie Educational Event $2,000.00 9/11/2018
------------------------------------------------------------------------
Unite for Bleeding Disorders Walk $5,000.00 9/11/2018
------------------------------------------------------------------------
Orlando Creepy Crawl 5K and Vampire $3,000.00 9/11/2018
Mile
------------------------------------------------------------------------
Jacksonville Creepy Crawl 5K and $3,000.00 9/11/2018
Vampire Mile
------------------------------------------------------------------------
Unite for Bleeding Disorders--Annual $2,500.00 9/17/2018
Walk
------------------------------------------------------------------------
Unite for Bleeding Disorders Walk $1,000.00 9/17/2018
------------------------------------------------------------------------
TSBDF Annual Meeting $1,500.00 9/17/2018
------------------------------------------------------------------------
Unite for Bleeding Disorders Walk $1,000.00 9/17/2018
------------------------------------------------------------------------
Latino Retreat $10,000.00 9/17/2018
------------------------------------------------------------------------
Spanish-Language Education Event $1,500.00 9/17/2018
------------------------------------------------------------------------
Inaugural Health Fair $2,500.00 9/18/2018
------------------------------------------------------------------------
2018 Adult Retreat $1,500.00 9/19/2018
------------------------------------------------------------------------
OHF Family Education Retreat $1,000.00 9/20/2018
------------------------------------------------------------------------
Annual Meeting $2,000.00 9/21/2018
------------------------------------------------------------------------
42nd Annual Meeting and Educational $5,500.00 9/26/2018
Symposium
------------------------------------------------------------------------
Trick or Trot Family Walk $3,000.00 9/26/2018
------------------------------------------------------------------------
Patient and Family Education Weekend $2,500.00 10/5/2018
------------------------------------------------------------------------
2018 Bleeding Disorders Conference $35,000.00 10/8/2018
Final Night Event
------------------------------------------------------------------------
Wichita Education Day $1,500.00 10/9/2018
------------------------------------------------------------------------
Winter Education Meeting and Holiday $3,500.00 10/9/2018
Festival
------------------------------------------------------------------------
8th Annual Unite for Bleeding $2,500.00 10/9/2018
Disorders Walk and Fun Race
------------------------------------------------------------------------
Family Education Day $2,500.00 10/11/2018
------------------------------------------------------------------------
COC-Education Retreat $3,250.00 10/11/2018
------------------------------------------------------------------------
Eastern Washington Annual Meeting 2018 $1,500.00 10/11/2018
------------------------------------------------------------------------
Nebraska Industry Symposium $5,000.00 10/16/2018
------------------------------------------------------------------------
The Coalition for Hemophilia B $3,000.00 10/16/2018
Meetings on the Road
------------------------------------------------------------------------
NOHF Annual Education Meeting $5,500.00 10/16/2018
------------------------------------------------------------------------
Annual Meeting $3,000.00 10/17/2018
------------------------------------------------------------------------
Camp Harvest $6,000.00 10/18/2018
------------------------------------------------------------------------
Issues and Challenges in the $2,500.00 10/22/2018
Management of Hemophilia
------------------------------------------------------------------------
Steven Margolies, MD Family $6,000.00 10/22/2018
Educational Conference
------------------------------------------------------------------------
2018 TexCen Chapter Winter Education $3,000.00 11/1/2018
Day
------------------------------------------------------------------------
NYCHC Annual Education Day $7,500.00 11/2/2018
------------------------------------------------------------------------
TSBDF Education Dinner $2,000.00 11/5/2018
------------------------------------------------------------------------
Winterfest $1,500.00 11/6/2018
------------------------------------------------------------------------
Annual Family Conference $2,250.00 11/19/2018
------------------------------------------------------------------------
Holiday Educational Program $2,000.00 12/6/2018
------------------------------------------------------------------------
College and Career Fair $1,500.00 12/11/2018
------------------------------------------------------------------------
ASGCT Patient Education Videos $5,000.00 12/13/2018
------------------------------------------------------------------------
The Coalition for Hemophilia B Patient $10,000.00 12/18/2018
Survey
------------------------------------------------------------------------
Advocacy Training $2,500.00 12/18/2018
------------------------------------------------------------------------
Grassroots Advocacy Project $5,000.00 12/19/2018
------------------------------------------------------------------------
State Advocacy Training $500.00 1/3/2019
------------------------------------------------------------------------
Annual Silver-level Corporate $15,000.00 1/4/2019
Sponsorship
------------------------------------------------------------------------
Annual Meeting and Family Educational $10,000.00 1/7/2019
Dinner
------------------------------------------------------------------------
TSBDF Winter Program-Journey Around $1,500.00 1/7/2019
the World
------------------------------------------------------------------------
4th Annual Industry Forum $5,000.00 1/11/2019
------------------------------------------------------------------------
Advocacy Education and Training $5,000.00 1/15/2019
Seminar
------------------------------------------------------------------------
Latino Group Weekend 2019 $1,500.00 1/16/2019
------------------------------------------------------------------------
Winter Education Day 2019 $1,500.00 1/16/2019
------------------------------------------------------------------------
RMHBDA EDUCATION WEEKEND AND ANNUAL $2,000.00 1/16/2019
MEETING
------------------------------------------------------------------------
New England Hemophilia Association $1,500.00 1/16/2019
Winter Camp
------------------------------------------------------------------------
Purpose Driven Leadership Program $2,500.00 1/16/2019
------------------------------------------------------------------------
Maryland Advocacy Days $5,000.00 1/21/2019
------------------------------------------------------------------------
WPCNHF's New Parent Network $4,000.00 1/21/2019
------------------------------------------------------------------------
WPCNHF's Semi-Annual Education Weekend $5,000.00 1/21/2019
------------------------------------------------------------------------
Men In Action/Infusing Love Group's $1,500.00 1/21/2019
Valentine Event
------------------------------------------------------------------------
Medial Symposium $5,000.00 1/21/2019
------------------------------------------------------------------------
Women's Retreat $5,000.00 1/21/2019
------------------------------------------------------------------------
emPOWERment Forum $2,500.00 1/22/2019
------------------------------------------------------------------------
2018 Corporate Program Sponsorship-- $1,875.00 2/4/2019
Silver
------------------------------------------------------------------------
Four Bioverativ Branded Educational $1,250.00 2/4/2019
Dinners
------------------------------------------------------------------------
WPCNHF's New Parent Network $1,000.00 2/4/2019
------------------------------------------------------------------------
Consumer Medical Symposium $3,000.00 2/12/2019
------------------------------------------------------------------------
Zoo Walk 2019 $4,000.00 2/12/2019
------------------------------------------------------------------------
Hawaii Future Leaders $2,500.00 2/13/2019
------------------------------------------------------------------------
Hawaii Ohana Education Weekend 2019 $7,500.00 2/13/2019
------------------------------------------------------------------------
Women's Retreat $3,500.00 2/13/2019
------------------------------------------------------------------------
Bleeding Disorder Awareness Kick Off $1,500.00 2/13/2019
------------------------------------------------------------------------
2019 Annual Meeting $2,000.00 2/13/2019
------------------------------------------------------------------------
Teen--Young Adult Program $15,000.00 2/13/2019
------------------------------------------------------------------------
15th Annual CHS Alpine Walk $2,000.00 2/20/2019
------------------------------------------------------------------------
Victory for Women $2,800.00 3/7/2019
------------------------------------------------------------------------
Winter Membership Gathering $5,000.00 3/7/2019
------------------------------------------------------------------------
2019 Annual Meeting $3,000.00 3/13/2019
------------------------------------------------------------------------
YETI--Youth Effectively Transitioning $5,000.00 3/18/2019
to Independence
------------------------------------------------------------------------
2015 SANOFI US
------------------------------------------------------------------------
Legal Name Project Title Payment Amount
------------------------------------------------------------------------
A R M S Inc. Homecoming & Project Little $5,000.00
Soldier
Academy of Managed Improving patient outcomes and $45,000.00
Care Pharmacy management of hyperlipidem
ACS Organic Chemistry Graduate Research Symposium $1,000.00
Division
AHIP Foundation Executive Leadership Program $55,000.00
Alabama Kidney 2015 Huntsville Kidney Walk $1,000.00
Foundation
Alabama Kidney 2015 Birmingham Kidney Walk $1,000.00
Foundation
Alabama Kidney Dothan Kidney Walk $1,000.00
Foundation
Albany American Saratoga Springs Tour de Cure $5,000.00
Diabetes Association
ALL IN TOGETHER All in Together Campaign: $37,500.00
CAMPAIGN INC. Advancing and Empowering Women
Allergy & Asthma US Anaphylaxis Summit $30,000.00
Network Mothers of
Asthmatics
Allergy & Asthma AAP Anaphylaxis Champions $100,000.00
Network Mothers of Program
Asthmatics
Allergy & Asthma Allergy & Asthma Day Capitol $50,000.00
Network Mothers of Hill 2015
Asthmatics
Alliance For A Alliance for a Healthier $25,000.00
Healthier Generation Generation
Inc.
Alliance for Aging 2015 Aging in Motion Coalition $15,000.00
Research
Amerian Diabetes American Diabetes Association $2,500.00
Association Diabetes Health and Wellness
Expo
American Academy of American Academy of Pediatrics $35,000.00
Pediatrics-Key Cards Key Card Sponsorship
AMERICAN ASSOCIATION 2015 AACR Annual Meeting MICR $10,000.00
FOR CANCER RESEARCH Networking and Resource Center
AMERICAN ASSOCIATION 2015 AACR Network Hubs $25,000.00
FOR CANCER RESEARCH Sponsorship
American Cancer ACS CAN Seattle Research $2,500.00
Society Breakfast and ACS CAN advocacy
activities
American Cancer ACS CAN CA Research Events and $5,000.00
Society ACS CAN advocacy activities
American Cancer ACS CAN's advocacy activities $1,500.00
Society in Arkansas and nationwide
American Cancer ACS CAN Virginia Research $1,000.00
Society Breakfast and advocacy
activities
American Cancer ACS CAN's advocacy activities $1,000.00
Society in Louisiana and nationwide
American Cancer ACS CAN Mississippi Health $1,000.00
Society Forum and ACS CAN advocacy
activities
American Cancer ACS CAN Iowa Research Event and $2,000.00
Society ACS CAN advocacy activities
American Cancer 2015 Minnesota Policy Breakfast $1,000.00
Society and ACS CAN advocacy
activities
American Cancer 2015 Oklahoma Policy Forums $750.00
Society
American Cancer 2015 Pennsylvania Advocacy $1,000.00
Society Event
American Cancer 2015 Maryland Advocacy $1,000.00
Society Breakfast
American Cancer Gemson Awards $2,500.00
Society
American Cancer Nationwide Hope Lodge $25,000.00
Society Inc. Partnership
American Chemical Division of Medicinal Chemistry $2,500.00
Society Division of Program 250th ACS national me
Medicinal Chemistry
American College of American College of Allergy, $53,000.00
Allergy, Asthma & Asthma & Immunology FIT Bowl
Immunology-FIT Bowl
American College of 2015 Patient Engagement $25,000.00
Cardiology Pavilion
American College of Sanofi/Regeneron Meeting $10,412.60
Cardiology
American College of Moving to the Quadruple Aim: $280,369.00
Physicians, Inc. ACP Quality Connect: Diabetes
American Diabetes Step Out: Walk to Stop Diabetes $5,000.00
Assocation
American Diabetes Central Iowa Tour de Cure $5,000.00
Association
American Diabetes Tour de Cure Southeast $1,500.00
Association Wisconsin (Grafton)
American Diabetes Tour de Cure Madison $1,500.00
Association
American Diabetes 2015 American Diabetes $2,000.00
Association Association--WI Gala
American Diabetes Father of the Year/Camp Sugar $2,000.00
Association Falls
American Diabetes Father of the Year Awards $5,000.00
Association
American Diabetes Stop Diabetes Through Advocacy $2,000.00
Association Workshop
American Diabetes Boston Step Out Walk to STOP $5,000.00
Association Diabetes
American Diabetes Central MA Step Out Walk to $5,000.00
Association STOP Diabetes
American Diabetes 2015 Kiss a Pig Gala $2,500.00
Association
American Diabetes 2015 Rochester Tour de Cure $2,500.00
Association
American Diabetes Step Out: Walk to Stop Diabetes $5,000.00
Association
American Diabetes Portland Father of the Year $2,500.00
Association Awards Dinner
American Diabetes Jim Hansen, MD Memorial $3,500.00
Association Symposium Series
American Diabetes St. Louis Tour de Cure $500.00
Association
American Diabetes Diabetes Awareness and $50,000.00
Association Intervention--via Step Out:
Walk to St
American Diabetes 2015 World Diabetes Day $5,000.00
Association
American Diabetes 75th Anniversary & Awards $50,000.00
Association Celebration
American Diabetes Step Out Walk to STOP Diabetes $2,500.00
Association
American Diabetes American Diabetes Expo--Exhibit/ $57,000.00
Association Expo- Speaker/Booth Signage/Program
Exhibit/Speaker/
BoothSignage/Program
AMERICAN DIABETES Diabetes Hospitality Days: Stop $75,000.00
ASSOCIATION INC. Diabetes In Boston
AMERICAN DIABETES 2015 Pathways to Stop Diabetes $2,500,000.00
ASSOCIATION INC.
AMERICAN DIABETES Step Out: Walk to Stop Diabetes $5,000.00
ASSOCIATION INC.
AMERICAN DIABETES Step Out: Walk to Stop Diabetes $2,500.00
ASSOCIATION INC.
AMERICAN DIABETES Father of the Year Awards Gala $5,000.00
ASSOCIATION INC.
American Diabetes 2015 Tour de Cure $5,000.00
Association, Indiana
Indiana
American Diabetes ADA Indiana's Josiah Kirby $15,000.00
Association, Indiana Lilly Sr. Distinguished
Service Award
American Diabetes Father of the Year Gala $5,000.00
Associaton
American Heart AMERICAN HEART ASSOCIATION-- $75,000.00
Association MOBILE APP
American Heart 2015 Walking Challenge $100,000.00
Association
American Heart American Heart Association $50,000.00
Association Advertising Space (Key Cards)
American Heart 2015 Heart Innovation Forum $15,000.00
Association
American National Red 2015-2016 General Blood $25,000.00
Cross Services Support and High
School Sc
American Pharmacists Emerging Insulins $79,000.00
Association
American Society for Second Regional Bone Marrow $12,700.00
Blood and Marrow Transplant conference for
Transplantation Nurses
American Society of 2015 ASN Abstract CD $80,000.00
Nephrology Sponsorship
American Society of 2015 Sponsorship Opportunities $50,000.00
Transplantation
Americares Foundation US Disaster Assistance $10,000.00
Inc.
America's Health CMO Roundtable $45,000.00
Insurance Plans
APhA Foundation Primary Care and Patient $249,550.00
Empowerment through Diabetes
Patie
Arizona Diabetes Diabetes: A Prescription for $5,000.00
Foundation Care
Arrow Lake Foundation Arrow Lake Foundation $50,000.00
Activities Plan
Arthritis Foundation Research Update Events $10,000.00
Northeast Region,
Inc.
Arthritis Foundation Advocacy Program and Advocacy $15,000.00
Northeast Region, Training Series
Inc.
Association for IQ/AAALAC International Global $5,000.00
Assessment and 3Rs Awards
Accreditation of
Laboratory Animal Ca
Association of 32 National Oncology Conference $50,000.00
Community Cancer
Centers
Association of 2015 Membership Dues $6,250.00
Corporate
Contributions
Professionals
Asthma & Allergy Advocacy Day $1,000.00
Foundation of
America, St. Louis
Chapter
Asthma & Allergy Allertrain Master Trainer $1,500.00
Foundation of Program
America, St. Louis
Chapter
Asthma and Allergy 2015 KFA Anaphylaxis Patient $33,000.00
Foundation of America Education
Asthma and Allergy 2015 Anaphylaxis Awareness $250,000.00
Foundation of America Campaign
ASTS Foundation ASTS Program Support $75,000.00
Autoimmune Advocacy Living with Autoimmunity--3 $2,500.00
Alliance separate events
Bay Area Association Help! I Just Learned I have $1,200.00
of Kidney Patients Chronic Kidney Disease! What
do I do?
Bay Area Bioscience CALBIO 2015 $10,000.00
Association
Baylor Health Care STEEEP Academy Lectureship $135,000.00
System Foundation Series
Be The Match Quick Reference Guidelines-- $90,000.00
Foundation Transplant Consultation and
Post-Transplant
BHCAG FOUNDATION MNBTE Recognition Event $5,000.00
Bill, Hillary, and Program Support--CHMI $100,000.00
Chelsea Clinton
Foundation
Bill, Hilary, and National Health Transformation $50,000.00
Chelsea Clinton
Foundation
Biocom Global Life Science Partnering $10,000.00
Conference
BIONJ INC. Bio NJ Sponsorship event $10,000.00
BIONJ INC. BIONJ INC. BioPartnering $3,000.00
BIONJ INC. CEO Summit $7,500.00
Blood and Marrow Survivorship Symposium Pre-Plan $5,000.00
Transplant
Information Network
Blood and Marrow Ask the Multiple Myeloma Expert $7,500.00
Transplant
Information Network
Blood and Marrow Transplant 101: An introduction $7,500.00
Transplant to hematopoietic cell
Information Network transplant
Blood and Marrow Caregiver 101: The Role of $7,500.00
Transplant Caregiver in Support of Bone
Information Network Marrow
Blood and Marrow Enhancing the Power of Peer $7,500.00
Transplant Support
Information Network
Blood and Marrow BMT InfoNet Web Site Redesign-- $75,000.00
Transplant Phase 1
Information Network
Bringing Hope Home General Operating Support $10,000.00
Inc.
Buffalo American Buffalo Niagara Tour de Cure $5,000.00
Diabetes Association
Cambridgeport 2015 Summer Programs at $5,000.00
Neighborhood Magazine Beach Park
Association, Inc.
Camp Nejeda Foundation Helping Children with type 1 $20,000.00
diabetes live happier,
healthier lives
Cancer Resource Boston Prostate Cancer Walk Run $5,000.00
Foundation
Cancer Support Celebration of Hope: A Free, $5,000.00
Community Greater Full-Day, Educational and
Philadelphia Inspirational
Cardio Renal Society Path to Wellness National Pilot $100,000.00
of America
Center for Healthcare Diversity, Inclusion, & Life $9,500.00
Innovation Sciences Symposium
Central New Jersey Leaders of Tomorrow (LOT) $10,000.00
Chapter Of The Program
National Black Mba
Association
CEO Roundtable On Project Data Sphere initiative $1,000,000.00
Cancer, Inc.
Chicago Hispanic Vive tu Vida/Get Up! Get $1,000.00
Health Coalition Moving! Health and Wellness
Fair
Children with Diabetes Platinum Sponsorship--Children $75,000.00
With Diabetes--Friends for
Life
Children with Diabetes Gold Level sponsorship of the $100,000.00
Children with Diabetes Friends
for Life
Childrens Inn At NIH Sanofi US Legacy Endowment Fund $1,000,000.00
Inc. at The Children's Inn at NIH
Children's Medical Food Allergy Camp $5,000.00
Center Foundation
Chordoma Foundation New York Regional Chordoma $2,500.00
Community Conference
Chris4Life Colon 5th Annual Blue Hope Bash $3,000.00
Cancer Foundation
Christ the King Prep Corporate Work Study Program $57,000.00
Cleveland Clinic Advances in Organ $134,276.00
Transplantation--Annual
Fellows Conference
CNY American Diabetes 2015 CNY Tour de Cure $4,000.00
Association
Coastal Area Health Community Health Worker Core $25,000.00
Education Center Inc. Consensus (C3) Project
Colon Cancer Alliance Blue Star Concert $1,000.00
Committee Encouraging 2015 Membership Dues $15,000.00
Corporate
Philanthropy
Community Oncology 2015 Community Oncology Payer $25,000.00
Alliance Exchange Summit III Oncology
Conquer Cancer Fdn Of Conquer Cancer Foundation $50,000.00
The American Society General Mission Support
Of Clinical Oncology
Council on Foundations 2015 Membership Dues $15,000.00
CT Coalition for Organ Premier Charity of the Hartford $1,500.00
and Tissue Donation, Marathon
dba, Donate Life
Connect
Dallas Fort Worth DFWBGH 11th Annual Benefits $5,000.00
Business Group on Forum
Health
DaVita Village Trust 2015 Tour DaVita $2,500.00
Deirdre O Brien Child Clinical Counseling Program $10,000.00
Advocacy Center Inc.
Diabetes Care and DCE NewsFlash and 2 e-Blasts $21,500.00
Education with the
Academy of Nutrition
and Diete
Diabetes Education and 2015 Industry Partners Advisory $15,000.00
Camping Association Council (IPAC)
Diabetes Foundation Dancing for Diabetes Awards $10,000.00
Inc. Dinner
Diabetes Hands Online Community for People $12,500.00
Foundation with Diabetes
Diabetes Hands DHF--Hero Sponsorship $25,000.00
Foundation
DiabetesSisters 2015 DiabetesSisters' PODS $20,000.00
Meetup Program
Diplomacy Matters Spotlighting Humanitarian $2,500.00
Institute Innovation & Patents for
Humanity
Direct Relief Auvi-Q epinephrine injections $75,000.00
for students throughout
California
Direct Relief U.S. Hurricane/All Hazards $10,000.00
preparedness Program
Employers Health Employer Health 2015 Annual $6,500.00
Coalition, Inc. Symposium
Epilepsy Foundation of Parent Advocacy toolkit $8,000.00
NC
Federal Circuit Bar Global Series: 2015 Shanghai $10,000.00
Association Conference
Charitable and
Educational Fund
Federation of Clinical FOCIS 2015 Annual Meeting $14,500.00
Immunology Societies
Fight Colorectal Patient Resource Guide for $5,000.00
Cancer Stage III and IV
Finger Lakes American 2015 Finger Lakes Tour de Cure $4,000.00
Diabetes Association
Florida Health Care Seeking Value in Cancer Care $5,000.00
Coalition
Florida Health Care Health Care Purchasers as $7,500.00
Coalition Consumers: Smart Shopping for
Health Care
Food Allergy & FAACT Education Programs $150,000.00
Anaphylaxis
Connection Team
Food Allergy Research FARE National Food Allergy $25,000.00
Education Conference
Food Allergy Research FARE Teen Summit $25,000.00
Education
Food Allergy Research THE FOOD ALLERGY BALL $25,000.00
Education
Food Allergy Research FAREWalk for Food Allergies $200,000.00
Education
Food Bank of Somerset Back Pack Program $5,000.00
County Inc.
Foundation for FBR Educational Programs--Bench $10,000.00
Biomedical Research to Bedside, Social Ambassadors
Foundation For Prader Multiple Projects $1,000.00
Willi Research
Fundacion Centro Diabetes Summer Camp 2015 $10,000.00
Pediatrico de
Diabetes
Fundacion Centro XIV Gala $3,500.00
Pediatrico de
Diabetes
Fundacion Centro 8th World Diabetes Month $5,000.00
Pediatrico de Celebration
Diabetes
Garden State Equality Teach and Affirm Students in $2,500.00
Education Fund Inc. New Jersey
Global Healthy Living Managed Care Organization $24,000.00
Foundation Education (Overview)
Gordon Research Gordon Research Atherosclerosis $20,000.00
Conference Meeting
Governors Books From Tennessee's Imagination Library $2,500.00
Birth Foundation Program
Greater New England Economic Development $4,000.00
Minority Supplier
Development Council
Health Action Council Annual Conference $4,200.00
Healthcare Woman of the Year $18,150.00
Businesswomen's
Association
HEART OF FLORIDA SP 2014 United Way Campaign $2,269.50
UNITED WAY Payout
Heart To Heart US Crisis Readiness & Response $10,000.00
International Inc.
Idaho Immunization Immunization Summit $2,000.00
Coalition
Illinois Diabetes Illinois Diabetes Caucus $3,500.00
Caucus Foundation Foundation
Illinois Business Day & Annual Lunch $1,000.00
Manufacturers' Sponsorships
Association
International Chinese 2015 International Chinese $2,000.00
Statistical Statistical Association (ICSA)/
Association Graybi
International Eczema International Eczema Council $100,000.00
Council
International Isotope Sponsorship of 12th $3,250.00
Society, Inc. International Symposium on the
Synthesis
International Myeloma 9th Annual Comedy Celebration $5,000.00
Foundation benefiting the Peter Boyle
Research Fund
International Myeloma 6th Annual International $35,000.00
Foundation Myeloma Working Group Summit
International Myeloma Patient Programs 2015 $100,000.00
Foundation
International Society RSG DREAM Conference $10,000.00
for Computational
Biology
International Society 25th ISHC Congress $1,000.00
of Heterocyclic
Chemistry
International Society ACoP6 $5,000.00
of Pharmacometrics
JDRF Imagine Gala $100,000.00
JDRF JDRF One Walk Philadelphia and $2,500.00
Bucks County
JDRF JDRF One Walk $7,500.00
JDRF JDRF Central AR One Walk $2,500.00
JDRF--Eastern PA JDRF One Walk Moosic, Poconos, $2,500.00
Chapter Lehigh Valley and Berks County
JDRF Greater Dallas JDRF One Walk, Dallas $2,500.00
JDRF International JDRF One Walk Boston 2015 $10,000.00
JDRF International JDRF OneWalk $5,000.00
JDRF International JDRF Research Updates $2,000.00
Jefferson University Quality and Safety Leadership $100,000.00
(School of Population Series
Health)
Jefferson University Supporting Patient Access to $79,700.00
(School of Population Diabetes Care: Follow-on to
Health) Janua
Jersey Battered Womens Vocational Development Program $5,000.00
Service
Joslin Diabetes A Taste of Ginger $25,000.00
Center, Inc.
Joslin Diabetes National Diabetes Month/High $50,000.00
Center, Inc. Hopes Gala
Juvenile Diabetes Rock the Cure $1,000.00
Research Foundation
Kean University 2015 Group Summer Scholars $15,000.00
Foundation Inc. Research Program
Keystone Symposia on Cancer Immunotherapy: Immunity $25,000.00
Molecular and and Immunosuppression Meds
Cellular Biology
Kidney Health Alliance Share Your Spare 5k for Get $750.00
of KY Healthy Get Transplanted
Kids Corporation li Kids Corp General Operating $10,000.00
Lagrant Foundation Internship Program $25,000.00
Large Urological Group LUGPA Annual Meeting Gold Level $85,000.00
Practice Association Membership
LUGPA
Leukemia & Lymphoma Man & Woman of the Year $3,500.00
Society
Living Well Cancer General Operating Support $2,500.00
Resource Center
MA Conference for MA Conference for Women $20,000.00
Women Inc.
Map International United States Disaster Relief $10,000.00
March of Dimes Supporting NICU Babies and $86,000.00
Foundation Families
Maryland Health Care Specialty Rx Forum $7,500.00
Coalition DBA
MidAtlantic Business
Group on Health Care
Massachusetts Annual Conference. Payment $2,000.00
Association of Health Reform--Three Years Later
Plans
MedStar Washington MedStar Washington Medical $3,000.00
Hospital Center Center--Current Issues in the
Care
Mended Hearts Patient Advocacy Network $100,000.00
Mended Hearts 2015 Mended Hearts National $50,000.00
Education and Training
Conference
Michigan Biosciences MichBio Conference Description $1,500.00
Industry Association
Mid Atlantic Lifespan, Senior Care Providers $4,000.00
Inc. Roundtables With Local
Hospitals
Midland Adult Services Midland Meals on Wheels $10,000.00
Inc. Employment Training Program
Migrant Clinicians Health Champions: Reducing $500.00
Network Disease to Improve Health
Milken Institute The Research Acceleration and $10,000.00
Innovation Network (TRAIN)
Milken Institute 2015 Milken Institute $1,000,000.00
Conference Sponsorships &
Engagement
Minnesota Society of MSHP Corporate Sponsorship $6,000.00
Health-System
Pharmacists
MIT 13th US-Japan Symposium on Drug $7,000.00
Delivery Systems
MIT 14th Annual Koch Institute $5,000.00
Summer Symposium ``CANCER
COMMITTEE''
MIT $100K Competition MIT $100K Competition $25,000.00
Multiple Myeloma Advances in Minimal Residual $25,000.00
Research Foundation Disease Testing in Myeloma
Multiple Myeloma Advances in Minimal Residual $25,000.00
Research Foundation Disease Testing in Myeloma
NATIONAL ACADEMY OF Forum on Drug Discovery, $85,000.00
SCIENCES Development and Translation
National Alliance of 11th Annual Meeting $5,000.00
State Prostate Cancer
Coalitions
National Arbor Day Chippewa National Forest tree $4,138.00
Foundation planting
National Association Childhood Obesity $10,000.00
for the Advancement
of Colored People
National Committee for NCQA's 25th Anniversary $10,000.00
Quality Assurance
(``NCQA'')
National Consumers Health Policies for Better $5,000.00
League Outcomes and Balanced Budgets
National Eczema The Decade of Eczema: Roadmap $200,000.00
Association to Advocacy
National Forum for 13th Annual Meeting of the $25,000.00
Heart Disease and National Forum for Heart
Stroke Prevention Disease and Stoke Prevention
Inc.
National Foundation TB Trials Consortium $671,292.00
For The Ctrs For
Disease Contr &
Prevention Inc.
National Health Voluntary Health Leadership $20,000.00
Council Conference
National Health Policy Development Fund $70,000.00
Council
National Kidney Patient Empowerment Workshop $2,000.00
Foundation
National Kidney Kansas City Kidney Walk $1,000.00
Foundation
National Kidney Wichita Kidney Walk $250.00
Foundation
National Kidney 2015 Boston Kidney Walk $15,000.00
Foundation
National Kidney Champion of Hope Tribute Dinner $1,000.00
Foundation of
Michigan
National Kidney Gift of Life Gala $1,500.00
Foundation of West
Tennessee
National Kidney NKF of West Tennessee Wolf Mash $250.00
Foundation of West Dash 5K
Tennessee
National Kidney 2015 New York City Kidney Walk $25,000.00
Foundation, Inc.
National Kidney NKF Cares 2015 $25,000.00
Foundation, Inc.
National Kidney NKF Peers 2015 $25,000.00
Foundation, Inc.
National Kidney Eight Annual Mid-Atlantic First $5,000.00
Foundation, Inc. Year Renal Fellowship
Symposium
National Kidney 7th Annual Central New Jersey $1,000.00
Foundation, Inc. Kidney Walk
National Kidney Philadelphia Kidney Walk $500.00
Foundation, Inc.
National Kidney Chester County Kidney Walk $500.00
Foundation, Inc.
National Kidney Wilmington Kidney Walk $500.00
Foundation, Inc.
National Kidney Pittsburgh Kidney Walk $500.00
Foundation, Inc.
National Kidney Northeast Ohio Kidney Walk $1,000.00
Foundation, Inc.
Serving Ohio
National Kidney 2015 Patient Symposium $1,000.00
Foundation, Inc.
Serving Ohio
National Patient NPAF Policy Consortium $20,000.00
Advocate Foundation
National Press Training Journalists on $40,000.00
Foundation Advances in Biologics and
Biosimilars
National TB 2015 National TB Conference: $500.00
Controllers Sponsorship Request
Association
National Transitions National Transition of Care $250,000.00
of Care Coalition Coalition
NBCH Hypoglycemia Action Brief $17,500.00
NBCH Annual Conference $3,500.00
NBCH ASCVD Action Brief $17,500.00
NCOMS NC Oncology Management Society $5,000.00
NEHI New Policy: Better Use of $25,000.00
Medicines in Diabetes
Neuropathy Action 9th Annual ``Neuropathy Action $2,500.00
Foundation Awareness Day''
New Jersey Hall of Mobile Museum $2,500.00
Fame
New Jersey Public NJPHA Sponsorship $5,000.00
Health Association
New York Stem Cell NYSCF 10th Annual Translational $2,000.00
Foundation, Inc. Stem Cell Research Conference
NJ SEEDS College Scholars Program $10,000.00
North Coast Health Celebration of Caring $2,500.00
Northeast Business eValue8 - Health Plan $9,000.00
Group on Health Performance Review
Northeast Business Specialty Pharmacy Conference $5,000.00
Group on Health
Northeastern Section German Exchange Program $2,000.00
of the American
Chemical Society
NSHMBA Foundation NSHMBA New Jersey Annual $5,000.00
Partnership
Oklahoma Center for The transformation of $3,500.00
Healthcare Healthcare
Improvement
Opportunity Through Arizona Pavilion at BIO 2015 $1,000.00
Entrepreneurship
Foundation
Organization for OFII Annual Dinner $15,000.00
International
Investment
Partnership For 2016 Membership Dues $19,000.00
Quality Medical
Donations
Patient Advocate Prostate and CRC Co-Pay Relief $550,000.00
Foundation Fund
PATIENT EMPOWERMENT The Latest News on Advanced $20,000.00
NETWORK Prostate Cancer Research and
Treatment
PCMA 2015 sPCMA Business Forum $60,000.00
Sponsorship
PCMA 2015 Annual Meeting $75,000.00
Presidential Sponsorship
Pediatric Cancer NHL 2015 Pediatric Sponsorship $10,000.00
Research Foundation
Pennsylvania CBO Dinner $5,000.00
Biotechnology
Association
Perimeter Bicycling 2015 El Tour de Tucson $15,000.00
Association of
America, Inc.
Pharmaceutical PhRMA Foundation Grants and $100,000.00
Research and Fellowships
Manufacturers of
America Foundation
Premier Cares Premier Cares Foundation $1,500.00
Foundation Prostate Cancer Walk
Preventive Cholesterol Patient Education $100,000.00
Cardiovascular Nurses
Association
PRIDE PRIDE Conference $6,000.00
Project Hope The Responding to the Nepal $10,000.00
People To People Earthquake
Health Foundation
Inc.
Prostate Cancer 22nd Annual Scientific Retreat $300,000.00
Foundation
Raritan Valley Galileo Scholarships: Providing $17,500.00
Community College Access to STEM Education
Foundation
Raritan Valley Preparing for the Next $10,000.00
Community College Generation Science Standards
Foundation
Regents of the V-BID Summit 2015: A Decade of $40,000.00
University of Transforming the Health Care
Michigan
Renal Support Network KidneyTalk Podcast $1,000.00
Renal Support Network Live & Give Newsletter $1,500.00
Renal Support Network CKD Patient Education Meetin $1,500.00
Renal Support Network 13th Annual Patient Essay $1,000.00
Contest
Resource Center of Transitional Housing Program $5,000.00
Somerset Inc.
Rutgers University Vets 4 Warriors $10,000.00
Foundation
RVCC Foundation STEM Education: Equity Issues $10,000.00
and Workforce Pipeline
RVCC Foundation College Campus Experience Day $3,000.00
for STEM High School Students
Sage Bionetworks 2015 Paris Assembly $15,000.00
Sanofi US Matching Sanofi US Matching Gifts--Q2 $277,628.31
Gifts--2015 2015
Sanofi US Matching Sanofi US Matching Gifts--Q1 $427,531.29
Gifts--2015 2015
SARSEF-SOUTHERN The Future of Biomedical $5,000.00
ARIZONA RESEARCH Research
SCIENCE AND
ENGINEERING
Scripps Translational The Future of Genomic Medicine $10,000.00
Science Institute VIII
Society of Toxicologic 2015 ACVP/ASVCP/STP Combined $2,500.00
Pathology Annual Meeting
Society of Toxicology Society of Toxicology Annual $10,000.00
Meeting
Somerset County SCBP 2015 program of work $20,000.00
Business Partnership
Somerset Medical Fun 'N Fit $25,000.00
Center Foundation
Inc.
Somerset Medical EMS Program $5,000.00
Center Foundation
Inc.
Somerset Medical El Poder Sobre La Diabetes $10,000.00
Center Foundation
Inc.
South Dakota Diabetes Virtual Nurse Model: School $5,100.00
Coalition Project
St. Louis Children's Food Allergy Management and $75,000.00
Hospital Foundation Education
Stop Hunger Now Inc. Stop Hunger Now Program $10,000.00
Expansion to New York City
Metro
Stowe Weekend of Hope Stowe Weekend of Hope $5,000.00
T. Leroy Jefferson 2015 Community Health Fair $2,500.00
Medical Society
Taking Control of Your The 9th Annual Diabetes Forum $10,000.00
Diabetes
Tennessee Kidney 2015 Gift of Life Walk/5K $2,000.00
Foundation
Tennessee Kidney Spring Soiree 2015 $2,500.00
Foundation
Teratology Society Teratology Society 55th Annual $1,500.00
Meeting
The American Major Symposia--Roots and $10,000.00
Association of Mechanisms of Human Autoimmun
Immunologists, Inc.
The American College ACVP/ASVCP/STP Combined Annual $6,000.00
of Veterinary Meeting
Pathologists
The American Fallen Portrait Sponsorship $25,000.00
Soldiers Project Inc.
The American Kidney A Pairing for Prevention 2015 $5,000.00
Fund, Inc.
The American Kidney The Hope Affair 2015 $50,000.00
Fund, Inc.
The American Kidney 9th Annual New York Spring $1,500.00
Fund, Inc. Event
The Bus Stops Here Hall Of Fame Induction for $35,000.00
Foundation Jerome Bettis
The Center For Great Adult Women's Program $10,000.00
Expectations Inc.
The Childrens Health Medical Home Initiative $665,000.00
Fund
The Cleveland Clinic A Celebration of Survivorship $5,000.00
Foundation-BMT An Educational Symposium for
Cleveland Clinic BM
Sponsorship
The Council of State Bowhay Institute for $5,000.00
Government, Ltd. Legislative Leadership
Development
The Diabetes Coalition Giving Diabetes the Blues $2,500.00
of Mississippi/
Mississippi Rural
Health Association
The FH Foundation CASCADE FH Registry $500,000.00
The Flood Sisters 7th Annual Love.Give.Life. $2,000.00
Kidney Foundation of Fashion Show/Gala
America
The Friends of Matheny Matheny Center of Medicine and $5,000.00
Dentistry
The Life Raft Group Research Team Meeting $5,000.00
The Salvation Army Healthy Food Pantry Program $5,000.00
The University of First Annual Immuno-Oncology in $25,000.00
Texas Foundation, Myeloma 2015 Workshop
Inc.
Trustees of Boston Boston University's 15th Annual $1,500.00
University CMD Symposium on Molecular
Discovery
Trustees of the Research Training in $20,000.00
University of Pharmacoepidemiology
Pennsylvania
Tufts Medical Center CEVR Database Subscription $35,000.00
TULANE CANCER CENTER NOLA Bluedoo Party/Walk/Run $1,000.00
Tuskegee Human And Donation for Public Education $5,000.00
Civil Rights
Multicultural Center
UCSF Cancer Center (c/ 2015 HDFCCC Symposium: $5,000.00
o UCSF Foundation) Breakthroughs in Cancer
Immunotherapy
United Network for Transplant Living Program $25,000.00
Organ Sharing
United States Soccer Soccer for Success--Paterson, $10,000.00
Federation Foundation NJ
Inc.
United Way of Greater Merial--Duluth 2014 United Way $23,984.25
Atlanta Campaign
United Way of Hall 2014 United Way Campaign Match-- $2,841.50
County Inc. Merial Select
United Way of SP 2014 United Way Campaign $7,221.00
Lackawanna and Wayne Payout
Counties
United Way of Sanofi Pasteur 2014 United Way $521.00
Massachusetts Bay Campaign Payout
Inc.
United Way of Monroe SP 2014 United Way Campaign $56,881.53
County Match
United Way of 2014 United Way Campaign-- $5,000.00
Northeast Georgia Merial Athens
United Way of Northern Caregivers Coalition $100,000.00
New Jersey
Unitio Inc. T1D Education Event Series $45,000.00
Univeristy of Arizona Alternative Muscle Club $2,700.00
Foundation for the meeting
benefit of Univeristy
of Arizona
University of Arizona Support for the Undergraduate $3,000.00
Foundation Biology Research Program
Conference
University of Arizona Applied Biosciences GIDP Merit $5,000.00
Foundation Scholarship
University of Arizona Keep Engaging Youth in Science $6,400.00
Foundation (KEYS) High School Summer
Internships
University of UCSF Diabetes Center 15th $5,000.00
California, San Anniversary Symposium
Francsico Foundation
University of Florida New Developments in Clinical $1,000.00
Foundation, Inc. Pharmacy and Clinical
Pharmacology
UNIVERSITY OF MARYLAND M-Cersi Conference on Patient $10,000.00
BALTIMORE FOUNDATION Focused Drug Development
INC.
University of North Pharmacoepidemiology Program $20,000.00
Carolina at Chapel Donation
Hill
University of Southern USC/UCLA/UCSF Tri-Institutional $3,000.00
California Retreat
University of Southern National Unity 2015 Conference: $5,000.00
Mississippi Community Health Workers
Foundation
US China Health Summit 5th US-China Health Summit at $70,000.00
Inc. Harvard University
Us TOO International Us TOO 25th Anniversary $10,000.00
Educational Symposium & Gala
Celebration
Vision y Compromiso 13th Annual Promotoras and $10,000.00
Community Health Workers
Conference
Washington Legal 2015 General Operating Support $25,000.00
Foundation
Washington Policy WPC's 2015 Annual Dinner $3,500.00
Center
Wellness Community of School-Based Support Groups $15,000.00
Central New Jersey
Winter Urologic Forum Winter Urologic Forum (WUF) $15,000.00
(WUF) Symposia Timeslot
WomenHeart: The WomenHeart Science & Leadership $50,000.00
National Coalition Symposium
for Women with Heart
Disease
WomenHeart: The National Science & Policy $25,000.00
National Coalition Summit on Women's Heart Health
for Women with Heart
Disease
Women's Venture Fund Highest Leaf Awards $15,000.00
YMCA of Greater Boston YMCA's Diabetes Prevention $5,000.00
Program
ZERO--The End of ZERO Prostate Cancer Run/Walk $1,500.00
Prostate Cancer Delaware
------------------------------------------------------------------------
Payments made by Sanofi US (2016)
------------------------------------------------------------------------
Legal Name Payment Amount Project Title
------------------------------------------------------------------------
AMERICAN DIABETES $48,070 American Diabetes Association
ASSOCIATION EXPOS EXPO
------------------------------------------------------------------------
American Society of $35,000 AMERICAN ASSOCIATION FOR CANCER
Transplant Surgeons RESEARCH--Networking Hub
------------------------------------------------------------------------
American Society of $35,000 American Society of Transplant
Transplant Surgeons Surgeons--Bronze Level Support
------------------------------------------------------------------------
Taking Control of Your $200,000 Taking Control of Your
Diabetes Diabetes--Gold Sponsorship
------------------------------------------------------------------------
Children with Diabetes $35,000 2016 Children with Diabetes
(CWD) Sponsorship
------------------------------------------------------------------------
MedStar Washington $3,000 MedStar Washington Hospital
Medical Center Center--Current Issues in the
Care of Dialysis and
Transplant Patient
------------------------------------------------------------------------
Joslin Diabetes $25,000 A Taste of Ginger
Center, Inc.
------------------------------------------------------------------------
Massachusetts General $5,000 Collaborative Novel-Novel
Hospital Combination Therapies Workshop
------------------------------------------------------------------------
Greater New England $7,000 Economic Development
Minority Supplier
------------------------------------------------------------------------
Healthy Capital $2,500 Diabetes Community Resource
District Initative Guide
------------------------------------------------------------------------
American Diabetes $2,500 Get Moving Challenge
Association
------------------------------------------------------------------------
American Diabetes $2,500 Tour de Cure
Association
------------------------------------------------------------------------
American Diabetes $2,500 2016 Step Out: Walk to Stop
Association Diabetes
------------------------------------------------------------------------
AMERICAN DIABETES $2,500 Father of the Year Awards Gala
ASSOCIATION INC.
------------------------------------------------------------------------
Buffalo American $2,500 2016 Buffalo Niagara Tour de
Diabetes Association Cure
------------------------------------------------------------------------
CNY American Diabetes $2,500 2016 Tour de Cure
Association
------------------------------------------------------------------------
Albany American $2,500 Saratoga Springs Tour de Cure
Diabetes Association
------------------------------------------------------------------------
American Diabetes $2,500 Tour de Cure Michigan
Association
------------------------------------------------------------------------
American Diabetes $2,000 2016 Finger Lakes Tour de Cure
Association Inc.
------------------------------------------------------------------------
American Diabetes $10,000 2016 High Risk Community
Association Initiatives for Southwest
Florida
------------------------------------------------------------------------
American Diabetes $2,500 Charlotte Step Out: Walk to
Association Stop Diabetes
------------------------------------------------------------------------
American Diabetes $2,500 Tour de Cure Hawaii
Association
------------------------------------------------------------------------
American Diabetes $2,500 Step Out: Walk to Stop Diabetes
Association Upstate, SC
------------------------------------------------------------------------
American Diabetes $2,500 American Diabetes Association's
Association Boston Step Out Walk to STOP
Diabetes
------------------------------------------------------------------------
American Diabetes $2,500 American Diabetes Association's
Association Connecticut Step Out Walk to
STOP Diabetes
------------------------------------------------------------------------
American Diabetes $2,500 American Diabetes Association's
Association Central Massachusetts Step Out
Walk to STOP Diabetes
------------------------------------------------------------------------
American Diabetes $2,500 2016 New Orleans Father of the
Association Year
------------------------------------------------------------------------
American Diabetes $2,500 2016 Indiana Tour de Cure
Association, Indiana
------------------------------------------------------------------------
AMERICAN DIABETES $75,000 Diabetes Hospitality Days: Stop
ASSOCIATION INC Diabetes in New Orleans
------------------------------------------------------------------------
National Kidney $25,000 NKF Patient Programs 2016
Foundation, Inc.
------------------------------------------------------------------------
Asthma and Allergy $100,000 AAFA Patient Education and
Foundation of America Outreach
------------------------------------------------------------------------
Asthma and Allergy $10,000 KFA Strides for Safe Kids Mall
Foundation of America Walk and Expo
------------------------------------------------------------------------
Asthma and Allergy $15,000 KFA Patient Education and
Foundation of America Outreach
------------------------------------------------------------------------
Northeast Business $20,000 eValue8--Health Plan
Group on Health Performance Review
------------------------------------------------------------------------
Food Allergy Research $100,000 FOOD ALLERGY 101 Online
Education Training Component and School
Action Campaign Grassroots
Advocacy
------------------------------------------------------------------------
American Heart $2,000 Peoria Heart and Stroke Ball
Association | and Peoria and Bloomington
American Stroke Heart Walk
Association
------------------------------------------------------------------------
American Heart $15,000 2016 Heart Innovation Forum
Association
------------------------------------------------------------------------
American Heart $2,000 Springfield Heart Ball
Association |
American Stroke
Association
------------------------------------------------------------------------
ATS Foundation Inc $25,000 Eighth Annual ATS Foundation
Research Program Benefit
------------------------------------------------------------------------
BHCAG FOUNDATION $2,500 Employer Leadership Summit
------------------------------------------------------------------------
National Alliance of $5,000 11th Annual Meeting
State Prostate Cancer
Coalitions
------------------------------------------------------------------------
New York Stem Cell $2,000 The NYSCF Conference
Foundation, Inc.
------------------------------------------------------------------------
Opportunity Through $1,000 Arizona Pavilion at BIO 2016
Entrepreneurship
Foundation
------------------------------------------------------------------------
Somerset Health Care $1,000 Healthier Somerset
Foundation
------------------------------------------------------------------------
Diabetes Foundation $10,000 25th Anniversary Awards Dinner
Inc. & Talent Competition
------------------------------------------------------------------------
JDRF $2,500 One Walk Philadelphia
------------------------------------------------------------------------
JDRF $2,500 JDRF One Promise Gala
Allentown--Passport to a Cure
------------------------------------------------------------------------
JDRF $2,500 Rockin' Docs for Diabetes Cure
------------------------------------------------------------------------
JDRF $2,500 2016 JDRF Poconos One Walk
------------------------------------------------------------------------
JDRF $12,000 JDRF One Promise Gala
Philadelphia
------------------------------------------------------------------------
JDRF $2,500 2016 JDRF Moosic One Walk
------------------------------------------------------------------------
JDRF $2,500 2016 JDRF Reading One Walk
------------------------------------------------------------------------
JDRF $2,500 One Walk Newtown
------------------------------------------------------------------------
JDRF $2,500 2016 JDRF Lehigh Valley One
Walk
------------------------------------------------------------------------
JDRF $2,500 ACE For A Cure
------------------------------------------------------------------------
JDRF Central PA $2,500 JDRF One Walk--Lancaster
Chapter
------------------------------------------------------------------------
JDRF New York City $15,000 44th Annual Promise Ball
Chapter
------------------------------------------------------------------------
JDRF International $2,500 34th Annual Boston Gala
------------------------------------------------------------------------
JDRF INTERNATIONAL $50,000 2016 TypeOneNation Summits
------------------------------------------------------------------------
JDRF INTERNATIONAL $50,000 2016 JDRF Government Day
------------------------------------------------------------------------
JDRF Greater Dallas $2,500 JDRF One Walk, Dallas
------------------------------------------------------------------------
Juvenile Diabetes $2,500 Rock the Cure
Research Foundation
------------------------------------------------------------------------
JDRF $10,000 JDRF Imagine Gala
------------------------------------------------------------------------
National Comprehensive $10,000 Emerging Issues in Oncology--An
Cancer Network NCCN Roundtable Discussion
------------------------------------------------------------------------
American Society for $2,500 ASN Annual Meeting
Neurochemistry
------------------------------------------------------------------------
American Orthopaedic $50,000 Early Osteoarthritis/Prevention
Society for Sports of Disease Progression
Medicine
------------------------------------------------------------------------
Diabetes Foundation of $2,000 LIVE-A-BETES: Learning To Live
Mississippi Well With Diabetes
------------------------------------------------------------------------
Renal Physicians $10,000 RPA Kidney Quality Improvement
Association Registry
------------------------------------------------------------------------
New York & New Jersey $8,000 Annual Sponsorship
Minority Supplier
Development Council
------------------------------------------------------------------------
Gordon Research $3,000 2016 Gordon Research Conference
Conference (GRC) entitled Autophagy in
Stress, Development, and
Disease: From the basics to
therapeutic targets
------------------------------------------------------------------------
Gordon Research $2,000 Drug Carriers in Medicine and
Conference Biology
------------------------------------------------------------------------
Gordon Research $10,000 Gordon Research Conference
Conference Antibody Biology & Engineering
March 2016
------------------------------------------------------------------------
PATIENT EMPOWERMENT $20,000 2016 Town Meeting for Advanced
NETWORK Prostate Cancer Patients
------------------------------------------------------------------------
PATIENT EMPOWERMENT $25,000 Online Advanced Prostate News
NETWORK Coverage for Patients
------------------------------------------------------------------------
Bioscience Association $1,500 WV Bioscience Summit 2016
of WV
------------------------------------------------------------------------
Arthritis Foundation $2,000 Sponsorship for Arthritis
Foundation Crystal Ball
------------------------------------------------------------------------
National Transitions $125,000 NTOCC
of Care Coalition
------------------------------------------------------------------------
American Medical $50,000 AMSSM Foundation Research Grant
Society for Sports Awards
Medicine Foundation,
Inc.
------------------------------------------------------------------------
Biocom $10,000 Global Life Science Partnering
Conference
------------------------------------------------------------------------
Biocom $10,000 Global Life Science Partnering
Conference
------------------------------------------------------------------------
Taking Control of Your $200,000 Taking Control Of Your Diabetes
Diabetes Conferences and Health Fairs
------------------------------------------------------------------------
Prescription Drug $1,000 Legislative Reception and
Assistance Foundation Celebration of Access
------------------------------------------------------------------------
The Cleveland Clinic $95,275 Advances in Organ
Foundation Transplantation--Annual
Fellows Conference
------------------------------------------------------------------------
Employers Health $6,500 Employer Health 2016 Annual
Coalition, Inc. Symposium
------------------------------------------------------------------------
Respiratory Health $750 Lung Health Education
Association
------------------------------------------------------------------------
Us TOO International $15,000 Prostate Cancer News You Can
Use
------------------------------------------------------------------------
Us TOO International $5,000 Prostate Cancer Educational
Webinar
------------------------------------------------------------------------
Us TOO International $5,000 Us TOO Prostate Cancer Business
Leadership Council
------------------------------------------------------------------------
Blood and Marrow $25,000 Celebrating a Second Chance at
Transplant Life 2016 Survivorship
Information Network Symposium
------------------------------------------------------------------------
Blood and Marrow $7,500 2016 BMT InfoNet Transplant
Transplant Webinar Series
Information Network
------------------------------------------------------------------------
PCMA $80,000 2016 sPCMA Business Forum
------------------------------------------------------------------------
PCMA $95,000 2016 Annual Meeting
Presidential Sponsorship
------------------------------------------------------------------------
Regents of the $40,000 V-BID Summit 2016
University of
Michigan
------------------------------------------------------------------------
Minnesota Society of $6,000 MSHP 2016 Corporate Business
Health-System Partnership Program
Pharmacists
------------------------------------------------------------------------
Be The Match $25,000 National Sponsorship for Be The
Foundation Match Walk+Run
------------------------------------------------------------------------
Mid-America Coalition $5,000 4th Annual Workforce &
on Health Care Community Well-Being Forum
------------------------------------------------------------------------
Global Virus Network, $10,000 8th International Global Virus
Inc. Network Meeting
------------------------------------------------------------------------
CrowdCare Foundation, $10,000 Muscles for Myeloma
Inc.
------------------------------------------------------------------------
PRIDE $6,000 PRIDE Conference
------------------------------------------------------------------------
The diaTribe $100,000 d16 Executive Forum
Foundation
------------------------------------------------------------------------
US China Health Summit $70,000 5th US-China Health Summit at
Inc. Harvard University
------------------------------------------------------------------------
Greater Philadelphia $5,000 GPBCH 2016 Annual Conference
Business Coalition on
Health
------------------------------------------------------------------------
Food Allergy & $100,000 FAACT Education Programs
Anaphylaxis
Connection Team
------------------------------------------------------------------------
Deep South Cancer $5,000 2016 Cycliad Charity Bicycle
Foundation Ride
------------------------------------------------------------------------
California Life $2,500 CLSA Life Sciences Academy
Sciences Association
------------------------------------------------------------------------
Globalization of $3,500 GPEN2016
Pharmaceutics
Education Network,
Inc.
------------------------------------------------------------------------
American Association $20,000 Public Policy Forum 2016
of Diabetes Educators
------------------------------------------------------------------------
Federation of American $5,000 FASEB conference on Muscle
Societies for Satellite Cells and
Experimental Biology Regeneration
(FASEB)
------------------------------------------------------------------------
Teratology Society $1,500 Teratology Society 56th Annual
Meeting
------------------------------------------------------------------------
Biotechnology $145,000 BIO International Convention
Innovation
Organization
------------------------------------------------------------------------
Biotechnology $40,000 BIO Europe Spring and BIO
Innovation Europe International
Organization Partnering Conference
------------------------------------------------------------------------
Maryland Black Caucus $2,000 Maryland Black Caucus
Foundation, Inc. Foundation, Inc.
------------------------------------------------------------------------
American Cancer $25,083 2016 ACS CAN Fundraising Events
Society Cancer Action and ACS CAN advocacy
Network activities
------------------------------------------------------------------------
Mid Atlantic Lifespan, $4,000 Senior Care Providers
Inc. Roundtables With Local
Hospitals
------------------------------------------------------------------------
ACS Organic Chemistry $1,500 ACS-DOC Graduate Research
Division Symposium
------------------------------------------------------------------------
Society of Toxicology $10,000 Society of Toxicology Annual
Meeting
------------------------------------------------------------------------
NATIONAL ACADEMY OF $50,000 Forum on Neuroscience and
SCIENCES Nervous System Disorders
------------------------------------------------------------------------
NATIONAL ACADEMY OF $85,000 Forum on Drug Discovery,
SCIENCES Development and Translation
------------------------------------------------------------------------
Allergy & Asthma $100,000 AAP Asthma, Allergy &
Network Mothers of Anaphylaxis Champion Program
Asthmatics
------------------------------------------------------------------------
Virginia Bio $1,500 Legislative Reception
------------------------------------------------------------------------
AMGA Foundation Inc $200,000 Together 2 Goal
------------------------------------------------------------------------
International Society $70,000 World Kidney Day 2016
of Nephrology
------------------------------------------------------------------------
Florida Health Care $7,500 ``The Health Care Revolution:
Coalition Building the Health Rosetta''
------------------------------------------------------------------------
Florida Caucus of $2,000 Scholarship
Black State
Legislators
------------------------------------------------------------------------
Fundacion Centro $15,000 Diabetes Summer Camp 2016
Pediatrico de
Diabetes
------------------------------------------------------------------------
American Drug $15,000 American Drug Utilization
Utilization Review Review Symposium
Society
------------------------------------------------------------------------
The University of $25,000 Second Annual Immuno-Oncology
Texas Foundation, and Myeloma Workshop
Inc.
------------------------------------------------------------------------
El Paso Diabetes $2,500 2016 Diabetes Walk/Run
Association, Inc.
------------------------------------------------------------------------
National TB $2,500 Using the Stories and Voices of
Controllers TB Survivors for Patient
Association Education, Building a
Supportive Community, and
Advocacy
------------------------------------------------------------------------
French American $1,000 FACS XVI
Chemical Society
------------------------------------------------------------------------
Texas Tech Foundation, $286,000 Community Health Worker (CHW)
Inc. Core Consensus Project 2016:
Increasing Stakeholder
Engagement and Endorsement,
Defining CHW Roles and Skills
in Clinical and Community
Settings, and CHW Skill
Assessment Approaches and
Tools
------------------------------------------------------------------------
Houston Business $6,000 The Employer's Specialty
Coalition on Health Pharmaceutical Dilemma--
Challenges & Opportunities
------------------------------------------------------------------------
UNM Comprehensive $1,000 Hoops4Hope
Cancer Center
------------------------------------------------------------------------
University of Utah $50,000 Western Atrial Fibrillation
Symposium
------------------------------------------------------------------------
WithinReach $5,000 Improving Health Access and
Immunization Policy
------------------------------------------------------------------------
NASPA $5,000 NASPA Leadership Conference
Awareness Walk
------------------------------------------------------------------------
National Eczema $300,000 Roadmap to Advocacy
Association
------------------------------------------------------------------------
American Society on $5,000 2016 Aging in America
Aging Conference
------------------------------------------------------------------------
Milken Institute $500,000 2016 Milken Institute
Conference Engagement
------------------------------------------------------------------------
International Myeloma $100,000 IMF Patient Programs 2016
Foundation
------------------------------------------------------------------------
International Myeloma $5,000 IMF 10th Annual Comedy
Foundation Celebration benefitting the
Peter Boyle Research
Foundation
------------------------------------------------------------------------
International Myeloma $35,000 7th Annual Internaltional
Foundation Myeloma Working Group Summit
------------------------------------------------------------------------
California Center for $2,500 Pre-diabetes Epidemic in
Public Health California--What Now?
Advocacy
------------------------------------------------------------------------
Out & Equal $25,000 2016 Out & Equal Workplace
Summit
------------------------------------------------------------------------
GLBTQ Legal Advocates $3,000 GLAD 2016 Summer Party
& Defenders
------------------------------------------------------------------------
Gay Men's Health $5,000 AIDS Walk New York
Crisis, Inc
------------------------------------------------------------------------
The Children's Aid $25,000 The Children's Aid Society 5th
Society Annual KTP Gala
------------------------------------------------------------------------
Jersey Battered $7,000 JBWS Grand Tastings XXII
Women's Service, Inc.
------------------------------------------------------------------------
Community Hope, Inc. $10,000 2016 Silver Corporate Partner
------------------------------------------------------------------------
RESOURCES USA INC $7,500 French Talks
------------------------------------------------------------------------
Court Appointed $1,000 Night of a Thousand Stars Gala
Special Advocates of
Mercer County, Inc.
------------------------------------------------------------------------
Machestic Dragons $5,000 10th Annual ``Paddle for Pink''
Community Dragon Boat Festival
------------------------------------------------------------------------
American Lebanese $10,000 St. Jude Gourmet Gala
Syrian Associated
Charities, Inc.
------------------------------------------------------------------------
National Kidney $1,000 Champion of Hope Tribute Dinner
Foundation of
Michigan
------------------------------------------------------------------------
National Congressional $25,000 Gold Membership
Award Foundation
------------------------------------------------------------------------
Research!America $25,000 20th Annual Advocacy Awards
Dinner
------------------------------------------------------------------------
Society for Women's $10,000 2016 SWHR Annual Gala Dinner
Health Research
------------------------------------------------------------------------
American Cancer $2,500 Relay For Life of Bridgewater
Society Cancer Action
Network
------------------------------------------------------------------------
University of Arizona $3,000 Sponsorship of the 28th Annual
Foundation Undergraduate Biology Research
Program Conference
------------------------------------------------------------------------
Diabetes Hands $37,500 Online Community for People
Foundation with Diabetes
------------------------------------------------------------------------
Boston University $2,500 Boston University School of
School of Public Public Health 40th Anniversary
Health Gala
------------------------------------------------------------------------
Pro Bono Partnership $10,000 Pro Bono Partnership 2016 Gala
------------------------------------------------------------------------
Christ The King $5,000 8th Annual President's Gala
Preparatory School of
Newark NJ Corp.
------------------------------------------------------------------------
Children's Health Fund $25,000 2016 Annual Benefit
------------------------------------------------------------------------
The Children's Aid $25,000 The Children's Aid Society's
Society Keeping the Promise Benefit
------------------------------------------------------------------------
The American Heart $5,000 Heart & Stroke Ball
Association
------------------------------------------------------------------------
Good Grief Inc. $2,500 2016 Great Pumpkin Ball
------------------------------------------------------------------------
United Way of Northern $500 Pathways for Caregivers 2016
New Jersey Reprint
------------------------------------------------------------------------
Easterseals New Jersey $1,350 46th Annual Raritan Valley
Workshop Dinner Dance
------------------------------------------------------------------------
Safe+Sound Somerset $10,000 Soaring to New Heights
------------------------------------------------------------------------
Deirdre O'Brien Child $2,000 Gala Sponsorship
Advocacy Center Inc.
------------------------------------------------------------------------
The Center For Great $5,000 2016 Gift of Hope Gala
Expectations Inc
------------------------------------------------------------------------
Somerset County $500 Second Annual Workplace Health
Business Partnership & Wellness Expo 2016
------------------------------------------------------------------------
RESOURCES USA INC. $5,000 Bastille Day 2016
------------------------------------------------------------------------
RESOURCES USA INC $5,000 Bastille Day events
------------------------------------------------------------------------
CANCER SUPPORT $5,000 Inspiring Hope
COMMUNITY CENTRAL NEW
JERSEY
------------------------------------------------------------------------
Auxiliary of the $5,000 57th Annual Auxiliary Autumn
Robert Wood Johnson Ball
University Hospital
------------------------------------------------------------------------
Pocono Mountains $6,000 Pocono Mountains Community
Community Challenge Fundraiser
Fund
------------------------------------------------------------------------
The American Kidney $50,000 2016 The Hope Affair
Fund, Inc.
------------------------------------------------------------------------
Partnership for a $4,500 PHA Fit to Celebrate Gala
Healthier America
Inc.
------------------------------------------------------------------------
American Society of $75,000 2017 Corporate Sponsor
Transplant Surgeons
Foundation
------------------------------------------------------------------------
Vision y Compromiso $5,000 Hacia Una Vida y Sana, the 13th
Annual Promotoras and
Community Health Workers
Conference
------------------------------------------------------------------------
Turn 2 Foundation Inc. $15,000 Turn 2 Foundation 20th Annual
Dinner
------------------------------------------------------------------------
AAALAC International $5,000 IQ/AAALAC International Global
3Rs Award Program
------------------------------------------------------------------------
Asthma & Allergy $1,000 Fall 2016 AAFA-STL Printed
Foundation of Newsletter
America, St. Louis
Chapter
------------------------------------------------------------------------
Autoimmune Advocacy $2,500 A Grapevine Grows
Alliance
------------------------------------------------------------------------
Operation Warrior $7,500 Warrior Wishes 2016 Army/Navy
Wishes Foundation Game
------------------------------------------------------------------------
Washington Legal $30,000 2016 General Operating Support
Foundation
------------------------------------------------------------------------
Maryland Black Caucus $2,500 Legislative Weekend
Foundation, Inc.
------------------------------------------------------------------------
Research!America $10,000 National Health Research Forum
------------------------------------------------------------------------
Friends of Cancer $25,000 Friends of Cancer Research 20th
Research Anniversary Cancer Leadership
Awards Dinner
------------------------------------------------------------------------
Project Hope The $10,000 2016 Project HOPE Gala
People To People
Health Foundation
Inc.
------------------------------------------------------------------------
The Virginia Public $700 Lighten Up, It's Just Politics
Access Project
------------------------------------------------------------------------
AMGA Foundation Inc. $10,000 AMGA Foundation 50th
Anniversary Gala
------------------------------------------------------------------------
CEO Roundtable on $500,000 Project Data Sphere initiative
Cancer
------------------------------------------------------------------------
Conference of Western $5,000 CWAG 2016 Winter Dinner
Attorneys General Sponsorship
------------------------------------------------------------------------
Western Governors' $10,000 WGA Annual Contribution
Foundation
------------------------------------------------------------------------
Colon Cancer Alliance $3,500 2016 Blue Hope Bash
------------------------------------------------------------------------
American Statistical $9,500 Breiamn Award
Association
------------------------------------------------------------------------
Washington Policy $4,000 2016 Annual Dinner
Center
------------------------------------------------------------------------
NEHI (Network for $75,000 Health Care Without Walls
Excellence in Health
Innovation)
------------------------------------------------------------------------
Cheshire Health $1,000 Cheshire Stepping Out for
Foundation Diabetes Walk
------------------------------------------------------------------------
Massachusetts General $5,000 The Role of Tumor
Hospital Microenvironment: a 40-year
Journey
------------------------------------------------------------------------
Massachusetts General $5,000 Massachusetts General Hospital
Hospital Immunology Seminar Series
------------------------------------------------------------------------
YMCA of Greater Boston $10,000 YMCA's Diabetes Prevention
Program
------------------------------------------------------------------------
MIT 100K $25,000 MIT 100K Entrepreneurship
Entrepreneurship Competition
Competition
------------------------------------------------------------------------
Joslin Diabetes $10,000 High Hopes Gala
Center, Inc.
------------------------------------------------------------------------
Joslin Diabetes $2,500 Ritmos de salud (healthy
Center, Inc. rhythms)
------------------------------------------------------------------------
Multi Regional $50,000 Multi Regional Clinical Trials
Clinical Trials Center of Brigham and Women's
Center of Brigham and Hospital and Harvard
Women's Hospital and
Harvard
------------------------------------------------------------------------
Foundation for $12,500 Animal Research Communications
Biomedical Research Campaign
------------------------------------------------------------------------
Foundation for $20,000 Public Education to Advance
Biomedical Research Understanding of Animal
Research
------------------------------------------------------------------------
Massachusetts Society $2,500 The MSMR Annual Meeting of
for Medical Research, Members
Inc.
------------------------------------------------------------------------
Children's Hospital $10,000 PCMM Retreat
Corporation
------------------------------------------------------------------------
Foundation for $5,000 Scientific Symposium in honor
Neurologic Diseases, Vijay K. Kuchroo
Inc.
------------------------------------------------------------------------
Lake Norman Community $1,000 Sunset and Sandals
Health Clinic
------------------------------------------------------------------------
Multiple Myeloma $50,000 Multiple Myeloma Educational
Research Foundation Programming
------------------------------------------------------------------------
American Diabetes $2,500 CNY Diabetes Community Forum
Association Inc.
------------------------------------------------------------------------
American Diabetes $5,000 Community Awareness Training
Association
------------------------------------------------------------------------
American Diabetes $2,500 Step Out Walk to Stop Diabetes--
Association Phoenix
------------------------------------------------------------------------
American Diabetes $2,500 2016 Kiss a Pig Gala
Association
------------------------------------------------------------------------
American Diabetes $2,500 American Diabetes Association's
Association Connecticut Tour de Cure
------------------------------------------------------------------------
American Diabetes $5,000 American Diabetes Association
Association New England Classic Multi-Day
Tour de Cure
------------------------------------------------------------------------
American Diabetes $2,500 American Diabetes Association's
Association Kennebunks Tour de Cure
------------------------------------------------------------------------
American Diabetes $2,500 American Diabetes Association's
Association Ocean State Tour de Cure
------------------------------------------------------------------------
American Diabetes $2,500 American Diabetes Association's
Association North Shore Tour de Cure
------------------------------------------------------------------------
American Diabetes $10,000 ADA Indiana's Josiah Kirby
Association, Indiana Lilly Sr. Distinguished
Service Award Gala
------------------------------------------------------------------------
American Diabetes $2,500 2016 Father of the Year Awards
Association Dinner
------------------------------------------------------------------------
American Diabetes $50,000 Diabetes Awareness and
Association Intervention--via Step Out:
Walk to Stop Diabetes, the Red
Rider/Red Strider Program and
the Annual Diabetes Conference
in NJ
------------------------------------------------------------------------
American Diabetes $2,500 2016 World Diabetes Day Summit
Association
------------------------------------------------------------------------
American Diabetes $20,000 Unmasking Diabetes Gala &
Association Awards
------------------------------------------------------------------------
American Diabetes $2,500 Step Out Walk to Stop Diabetes
Association of the Triangle
------------------------------------------------------------------------
American Diabetes $2,500 Tour De Cure + Step Out: Walk
Association to Stop Diabetes
------------------------------------------------------------------------
American Diabetes $2,500 Father of the Year Awards
Association
------------------------------------------------------------------------
National Health $100,000 The Patient Perspective on the
Council Value of Treatments
------------------------------------------------------------------------
National Health $95,000 Health Technology Assessments
Council and Value: The Patient
Perspective
------------------------------------------------------------------------
National Kidney $50,000 2016 New York City Kidney Walk
Foundation, Inc. and Patient Journeys
------------------------------------------------------------------------
National Kidney $15,000 2016 Boston Kidney Walk
Foundation
------------------------------------------------------------------------
Organization for $15,000 2016 OFII Annual Dinner
International
Investment
------------------------------------------------------------------------
Healthcare $8,850 HBA Woman of the Year Elite
Businesswomen's Table
Association
------------------------------------------------------------------------
United States Bone and $20,000 Burden of Musculoskeletal
Joint Initiative, NFP Diseases in the United States
(BMUS) Report
------------------------------------------------------------------------
United States Bone and $80,000 Experts in Arthritis (EIA)
Joint Initiative, NFP
------------------------------------------------------------------------
American College of $150,000 LDL Address the Risk Think Tank
Cardiology
------------------------------------------------------------------------
The Leukemia & $2,500 Lowcountry Light The Night Walk
Lymphoma Society
------------------------------------------------------------------------
The Leukemia & $16,000 Light The Night Sponsorship
Lymphoma Society
------------------------------------------------------------------------
THE LEUKEMIA & $50,000 Band Against Cancer: The Sarah
LYMPHOMA SOCIETY Cannon Tour
------------------------------------------------------------------------
Moses E. Cheeks Slam $2,500 Moses E. Cheeks Slam Dunk for
Dunk for Diabetes Diabetes Basketball Camp
------------------------------------------------------------------------
American Foundation $25,000 2016 Get in Rhythm. Stay in
for Women's Health Rhythm. Atrial Fibrillation
(dbaStopAfib.org) Patient Conference
------------------------------------------------------------------------
National Alliance of $5,000 Advanced Prostate Cancer
State Prostate Cancer Laminate
Coalitions
------------------------------------------------------------------------
National Alliance of $5,000 12th Annual Meeting of the
State Prostate Cancer National Alliance of State
Coalitions Prostate Cancer Coalitions
------------------------------------------------------------------------
Colorectal Cancer $10,000 Guide in the Fight for Late
Coalition Inc Stage CRC Patients
------------------------------------------------------------------------
Myotonic Dystrophy $3,000 MDF Annual Conference
Foundation
------------------------------------------------------------------------
New Jersey Association $1,000 3Rs Sharing Conference V
for Biomedical
Research, Inc.
------------------------------------------------------------------------
Academy of Managed $15,000 AMCP 2016 Partnership Forum:
Care Pharmacy Enabling the Exchange of
Clinical and Economic Data Pre-
FDA Approval
------------------------------------------------------------------------
Academy of Managed $18,000 AMCP Oncology Management
Care Pharmacy Partnership Forum
------------------------------------------------------------------------
BIONJ INC. $10,000 Annual Dinner
------------------------------------------------------------------------
Community Oncology $15,000 Oncology Care Model Filming
Alliance
------------------------------------------------------------------------
Community Oncology $7,500 Community Oncology Alliance CMS
Alliance Oncology Care Model Payer
Session
------------------------------------------------------------------------
Community Oncology $25,000 2016 Community Oncology Payer
Alliance Exchange Summit V Oncology
Payment Reform
------------------------------------------------------------------------
JDRF International $2,500 JDRF One Walk 2016
------------------------------------------------------------------------
JDRF $5,000 JDRF One Walk Pittsburgh
------------------------------------------------------------------------
JDRF $5,000 JDRF One Walk Westmoreland
------------------------------------------------------------------------
Juvenile Diabetes $2,500 JDRF One Walk Rochester
Research Foundation
------------------------------------------------------------------------
Juvenile Diabetes $2,500 JDRF One Walk Southern Tier
Research Foundation
------------------------------------------------------------------------
JDRF NENY $2,500 JDRF Saratoga One Walk
------------------------------------------------------------------------
JDRF--Western New York $2,500 JDRF Buffalo One Walk
Chapter
------------------------------------------------------------------------
JDRF International $2,500 JDRF One Walk Boston 2016
------------------------------------------------------------------------
American Society of $10,000 Mambo for Myeloma ASH
Hematology Sponsorship
------------------------------------------------------------------------
The American Kidney $5,000 2016 A Pairing For Prevention
Fund, Inc.
------------------------------------------------------------------------
The American Kidney $75,000 New To Dialysis Campaign
Fund, Inc.
------------------------------------------------------------------------
THE TRANSPLANTATION $50,000 TTS Transplantation Leadership
SOCIETY Series
------------------------------------------------------------------------
PROMIS Health $10,000 PROMIS: Measuring Health
Organization (PHO) Outcomes Around the World
------------------------------------------------------------------------
The Foundation for $5,000 International Research
Peripheral Neuropathy Symposium/Advances in
Neuropathy--Emerging Therapies
------------------------------------------------------------------------
PQA, Inc. $5,000 PQA Leadership Summit 2016
------------------------------------------------------------------------
PQA, Inc. $25,000 PQA Insulin Adherence Committee
------------------------------------------------------------------------
MMORE: Multiple $5,000 MoveMMORE Seattle 2016
Myeloma Opportunities
for Research &
Education
------------------------------------------------------------------------
International Society $5,000 ACoP7 meeting
of Pharmacometrics
------------------------------------------------------------------------
The Galien Foundation $15,000 The Galien Forum
------------------------------------------------------------------------
MassChallenge, Inc. $4,000 2016 MC Awards
------------------------------------------------------------------------
MassChallenge, Inc. $40,000 MassChallenge
------------------------------------------------------------------------
Alliance for $5,000 Cell & Gene Meeting on the Mesa
Regenerative Medicine
------------------------------------------------------------------------
Oklahoma Center for $3,000 Transformation of Healthcare:
Healthcare CPC Learning Session
Improvement
------------------------------------------------------------------------
Health Literacy $225,000 The Blue Ribbon Online
Missouri Clearinghouse of Kidney
Transplantation and Living
Donation Resources (BROC)
------------------------------------------------------------------------
Health Literacy $50,000 My Transplant Coach Application
Missouri Development Project
------------------------------------------------------------------------
Center for Medical $40,000 GPC--Real World Evidence
Technology Policy
------------------------------------------------------------------------
Center for Healthcare $7,500 2016 Diversity, Inclusion, &
Innovation Life Sciences Symposium
------------------------------------------------------------------------
BIO Ventures for $10,000 2016 BIO International
Global Health (BVGH) Convention Africa Pavilion
------------------------------------------------------------------------
National Transitions $50,000 NTOCC Mission Support
of Care Coalition
------------------------------------------------------------------------
The American College $6,000 2016 ACVP/ASVCP Concurrent
of Veterinary Annual Meeting
Pathologists
------------------------------------------------------------------------
South Dakota Diabetes $1,000 Third Annual Sweet Success
Coalition Extravaganza
------------------------------------------------------------------------
T. Leroy Jefferson $2,000 2016 Community Health Fair:
Medical Society Healthy Children for a Healthy
Future
------------------------------------------------------------------------
North Coast Health $1,000 Celebration of Caring 2016
------------------------------------------------------------------------
Academy of Nutrition $18,000 DCE On the Cutting Edge
and Dietetics on newsletter
behalf of Diabetes
Care and Education
------------------------------------------------------------------------
America's Health $55,000 Executive Leadership Program
Insurance Plans
------------------------------------------------------------------------
American Liver $2,500 Diabetes and NASH Webinar
Foundation
------------------------------------------------------------------------
Us TOO International $2,500 12th Annual SEA Blue Chicago
Prostate Cancer Walk & Run
------------------------------------------------------------------------
Blood and Marrow $2,500 BMT InfoNet Resource Directory
Transplant update and reprint
Information Network
------------------------------------------------------------------------
Chicago Hispanic $1,000 10th Annual Vive tu Vida/Get
Health Coalition Up! Get Moving! Health and
Wellness Fair
------------------------------------------------------------------------
The Council of State $5,000 Bowhay Institute
Government, Ltd.
------------------------------------------------------------------------
National Bone Marrow $5,000 Update, Edit and Transplant
Transplant Link Survivors' Guide for Bone
Marrow, Stem Cell and Cord
Blood Transplant
------------------------------------------------------------------------
International Society $8,000 Corporate Membership
for Application
Pharmacoepidemiology
------------------------------------------------------------------------
Be The Match $90,000 Quick Reference Guidelines--
Foundation Transplant Consultation and
Post-Transplant Care
------------------------------------------------------------------------
American Society of $10,000 Meet the Faculty Networking
Transplantation Session @ 2016 AST Fellows
Symposium on Transplantation
------------------------------------------------------------------------
Iowa Pharmacy $10,000 2016 Leadership in Pharmacy
Association advocacy program
Foundation
------------------------------------------------------------------------
Mid-America Coalition $4,000 Type 2 Diabetes in Kansas City:
on Health Care A Collaborative Approach
------------------------------------------------------------------------
St. Louis Children's $50,000 Food Allergy Management and
Hospital Foundation Education (FAME)
------------------------------------------------------------------------
Missouri Biotechnology $1,000 BIO Benchmarking Program
Association
------------------------------------------------------------------------
Metabolic Endocrine $25,000 14th Annual World Congress on
Education Foundation Insulin Resistance Diabetes
and Cardiovascular Disease
(WCIRDC)
------------------------------------------------------------------------
The diaTribe $5,000 10th Annual Diabetes Forum
Foundation
------------------------------------------------------------------------
Greater Philadelphia $1,000 GPBCH Annual Wellness Summit
Business Coalition on
Health
------------------------------------------------------------------------
Project Access of $500 Diabetic Walk
Howard County
------------------------------------------------------------------------
National Diabetes $14,000 Access to Insulin Patient
Volunteer Leadership Advocacy Study
Council
------------------------------------------------------------------------
Keystone for $5,000 Foundation2016 Conference
Incubating Innovation
in Life sciences
Network (KiiLN)
------------------------------------------------------------------------
ALL IN TOGETHER $25,000 All In Together Campaign Women
CAMPAIGN INC in Healthcare Policy Forum
------------------------------------------------------------------------
Washington Health $6,600 2016 Alliance Membership
Alliance
------------------------------------------------------------------------
IIT Association of $2,500 2016 PanIIT Leadership
Greater New England Conference
------------------------------------------------------------------------
California Life $7,500 2016 Life Sciences Academy
Sciences Association
------------------------------------------------------------------------
The Kansas Chamber $884 Corporate Membership
------------------------------------------------------------------------
Delaware Diabetes $2,500 Delaware Diabetes Coalition
Coalition 2016 EXPO
------------------------------------------------------------------------
American Legislative $10,000 Life Sciences Academy
Exchange Council
------------------------------------------------------------------------
Biotechnology $10,000 ODTC White Paper
Innovation
Organization
------------------------------------------------------------------------
Biotechnology $20,000 State Policy Maker Round Tables
Innovation on Value of Biopharmaceutical
Organization (BIO) Industry
------------------------------------------------------------------------
American Association $50,000 Sustaining Sponsorship
of Pharmaceutical
Scientists
------------------------------------------------------------------------
Society for Women's $10,000 National Conference on Women's
Health Research Health Research--Diabetes/
Metabolism
------------------------------------------------------------------------
International $33,000 IPEC-Americas 2016 Membership
Pharmaceutical Dues
Excipients Council of
the Americas (IPEC-
Americas)
------------------------------------------------------------------------
FSH Society $2,500 FSHD Connect Conference
------------------------------------------------------------------------
International Society $10,000 RECOMB/ISCB Conference on
for Computational Regulatory and Systems
Biology, Inc. Genomics with DREAM Challenges
------------------------------------------------------------------------
WomenHeart: The $25,000 Access NOW! Campaign
National Coalition
for Women with Heart
Disease
------------------------------------------------------------------------
Springboard 2000 $15,000 Health Innovation Hub
Enterprises, Inc.
------------------------------------------------------------------------
American Cancer $1,000 2016 ACS CAN Michigan Forum and
Society Cancer Action ACS CAN advocacy activities
Network nationwide
------------------------------------------------------------------------
APhA Foundation $168,870 Consensus Consortium on Patient
Self-Management Credentialing
(PSMC) and Value-Based Health
Benefit Design Considerations
in Patient-Centered, Team-
Based Care
------------------------------------------------------------------------
Society of Toxicology $2,500 The Use of Cardiomyocytes for
the Assessment of
Proarrhythmic Risk
------------------------------------------------------------------------
Camp Holiday Trails $2,500 Family Diabetes Camp and Summer
Camperships
------------------------------------------------------------------------
Women In Government $5,000 2016 Healthcare Summit Diabetes
Foundation, Inc. Programming
------------------------------------------------------------------------
Women In Government $20,000 Diabetes Campaign--Phase II
Foundation, Inc.
------------------------------------------------------------------------
Patient Advocate $35,000 Understanding What Patients
Foundation Value and What and Matters to
Them During Their Treatment:
The Prostate Cancer Research
Program (PCRP)
------------------------------------------------------------------------
Organ Donation and $4,500 National Critical Issues Forum
Transplantation
Alliance
------------------------------------------------------------------------
Arthritis Foundation, $40,000 ICER Survey
Inc.
------------------------------------------------------------------------
Georgia Life Sciences $1,500 Georgia Life Sciences Coalition
Coalition
------------------------------------------------------------------------
International Cytokine $15,000 4TH ANNUAL MEETING OF THE
and Interferon INTERNATIONAL CYTOKINE AND
Society Inc. INTERFERON SOCIETY (ICIS)
------------------------------------------------------------------------
American Association $25,000 AACE Diabetes Resource Center,
of Clinical 2016-17
Endocrinologists
------------------------------------------------------------------------
ZERO--The End of $5,000 ZERO Prostate Cancer Community
Prostate Cancer Advocacy Events
------------------------------------------------------------------------
The Diabetes Coalition $2,500 Giving Diabetes the Blues
of Mississippi/
Mississippi Rural
Health Association
------------------------------------------------------------------------
University of Southern $5,000 National Unity 2016 Conference:
Mississippi Community Health Workers -
Foundation Social Change Agents Advancing
Health Equity and Improving
Outcomes
------------------------------------------------------------------------
NBCH $25,000 High Value Health: Making the
Dream a Reality
------------------------------------------------------------------------
Fundacion Centro $5,000 World Diabetes Month
Pediatrico de Celebration 2016
Diabetes
------------------------------------------------------------------------
Fundacion Centro $3,500 XV Annual Gala Dinner
Pediatrico de
Diabetes
------------------------------------------------------------------------
TULANE CANCER CENTER $1,000 NOLA Bluedoo Run/Walk
------------------------------------------------------------------------
NCSL Foundation for $7,500 NCSL LegisBrief Sponsorship
State Legislatures
------------------------------------------------------------------------
Arizona Diabetes $2,500 Arizona Diabetes Foundation
Foundation
------------------------------------------------------------------------
Federation of Clinical $10,000 FOCIS 2016 Annual Meeting
Immunology Societies
------------------------------------------------------------------------
Society of Dermatology $30,000 SDPA 14th Annual Fall
Physician Assistants Dermatology Conference
------------------------------------------------------------------------
Colon Cancer Alliance $10,000 2016 Live Your Best Life mCRC
Patient Symposium
------------------------------------------------------------------------
National Eczema $100,000 Leaders in Eczema Forum Series
Association
------------------------------------------------------------------------
Congress of California $1,500 Script Your Future Senior
Seniors Education and Leader Education
Research Fund
------------------------------------------------------------------------
Association of Black $20,000 Improving Access to Innovative
Cardiologists Therapies in High-Risk
Populations
------------------------------------------------------------------------
Lymphoma Research $3,000 Understanding Transplantation
Foundation and Lymphoma Patient Guide
------------------------------------------------------------------------
Prostate Cancer $250,000 23rd Annual Scientific Retreat
Foundation
------------------------------------------------------------------------
$8,708,932
Product Donations made
by Sanofi US to the
Sanofi Foundation for
North America *
(estimate)
$343,602,000
------------------------------------------------------------------------
Donations made by the Sanofi Foundation for North America
------------------------------------------------------------------------
Legal Name Payment Amount Project Title
------------------------------------------------------------------------
Trustees of Boston $125,000 National CHW Association
University
------------------------------------------------------------------------
Tufts Center for the $12,500 Assessing the Use of Real World
Study of Drug Evidence to Support Regulated
Development Medical Research and Post-
Marketing Safety Monitoring
------------------------------------------------------------------------
Cambridge Arts Council $5,000 2016 Summer Programs for
Fund Magazine Beach Park
------------------------------------------------------------------------
Americares $25,000 Disaster Relief--Hurricane
Matthew
------------------------------------------------------------------------
Americares $5,000 AmeriCares Airlift Benefit
------------------------------------------------------------------------
Americares $25,000 Ecuador Earthquake Response
------------------------------------------------------------------------
Americares $10,000 U.S. Disaster Assistance
------------------------------------------------------------------------
Christ The King $59,000 Corporate Work Study Program
Preparatory School of
Newark NJ Corp
------------------------------------------------------------------------
NAACP $10,000 Childhood Obesity
------------------------------------------------------------------------
AMERICAN DIABETES $2,500,000 Pathway to Stop Diabetes
ASSOCIATION INC
------------------------------------------------------------------------
National Kidney $5,000 New Jersey Kidney Transplant
Foundation, Inc. Workshop
------------------------------------------------------------------------
March of Dimes $86,000 Supporting NICU Babies and
Foundation Families
------------------------------------------------------------------------
Heritage of Pride, $2,899 NYC Pride March
Inc.
------------------------------------------------------------------------
Children's Health Fund $5,000 Baton Rouge--Emergency Response
------------------------------------------------------------------------
The Salvation Army $10,000 Healthy Food Pantry Program
------------------------------------------------------------------------
Columbia Univeristy $100,000 Project on Non-Communicable
Mailman School of Diseases
Public Health
------------------------------------------------------------------------
THE LEUKEMIA & $19,640 Fiscal Year 2017 Myeloma
LYMPHOMA SOCIETY Patient Education
------------------------------------------------------------------------
Stop Hunger Now Inc. $10,000 Stop Hunger Now Disaster Ready
Response
------------------------------------------------------------------------
Garden State Equality $5,000 Pledge and Protect LGBT Seniors
Education Fund Inc.
------------------------------------------------------------------------
Camp Nejeda Foundation $10,000 Camp Nejeda: Helping Kids with
Type 1 Diabetes Live Happier,
Healthier Lives
------------------------------------------------------------------------
Matheny School and $10,000 Matheny Center of Medicine and
Hospital Inc. Dentistry
------------------------------------------------------------------------
United Way of Northern $100,000 Caregivers Coalition
New Jersey
------------------------------------------------------------------------
Jersey Battered $5,000 Community Counseling Services
Women's Service, Inc.
------------------------------------------------------------------------
Food Bank of Somerset $10,000 Back Pack Program
County Inc.
------------------------------------------------------------------------
Community Hope, Inc. $25,000 Residential Recovery Programs
for Homeless Veterans and
Disabled Individuals
------------------------------------------------------------------------
Hyacinth Foundation, A $15,000 Hyacinth Psychosocial Support
New Jersey Non-profit Services
Corporation
------------------------------------------------------------------------
Kean University $15,000 2016 Group Summer Scholars
Foundation Inc Research Program
------------------------------------------------------------------------
Visiting Nurse $10,000 Hospice Care and Adult Day Club
Association of Services
Somerset Hills
------------------------------------------------------------------------
NJ SEEDS $10,000 Young Scholars Program--Health
Sessions
------------------------------------------------------------------------
Somerset Health Care $30,000 Fun n' Fit
Foundation
------------------------------------------------------------------------
Somerset Health Care $5,000 Quality CPR Saves Lives
Foundation
------------------------------------------------------------------------
Somerset Health Care $10,000 El poder
Foundation
------------------------------------------------------------------------
Deirdre O'Brien Child $10,000 Clinical Counseling
Advocacy Center Inc
------------------------------------------------------------------------
Midland Adult Services $10,000 Midland Helping Hands
Inc Employment Training Program
and Midland Meals on Wheels
Employment Training Program
------------------------------------------------------------------------
The Center For Great $10,000 Adult Women & their Children
Expectations Inc.
------------------------------------------------------------------------
Dress For Success $10,000 Dress for Success Morris County
Morris County Inc. Transforming Lives Gala
------------------------------------------------------------------------
Dress For Success $10,000 FOUNDATIONS OF SUCCESS
Morris County Inc. WORKSHOPS
------------------------------------------------------------------------
The Partnership for $10,000 Community of Practice
Quality Medical
Donations
------------------------------------------------------------------------
Raritan Valley $3,000 College Campus Experience Day
Community College for STEM High School Students
Foundation
------------------------------------------------------------------------
Raritan Valley $10,000 Preparing for the Next
Community College Generation Science Standards
Foundation
------------------------------------------------------------------------
Raritan Valley $7,500 Galileo Scholarships: Expanding
Community College Access to STEM Education
Foundation
------------------------------------------------------------------------
Rutgers University $10,000 Vets4Warriors
Foundation
------------------------------------------------------------------------
The American Fallen $15,000 Portrait Sponsorship
Soldiers Project Inc.
------------------------------------------------------------------------
Strengthen Orlando d/b/ $5,000 OneOrlando Fund
a OneOrlando Fund
------------------------------------------------------------------------
Alliance For A $25,000 America's Healthiest Schools
Healthier Generation
Inc.
------------------------------------------------------------------------
Diabetes Scholars $10,000 Diabetes Scholars Foundation
Foundation College Scholarships
------------------------------------------------------------------------
Map International $10,000 US Disaster Relief
------------------------------------------------------------------------
Head and Neck Cancer $1,000 Research on Xerostomia in HNC
Alliance patients
------------------------------------------------------------------------
United States Soccer $10,000 Soccer for Success--Camden
Federation Foundation
Inc.
------------------------------------------------------------------------
Camp Quality USA dba $10,000 Camp Quality NJ
Camp Quality NJ
------------------------------------------------------------------------
Operation Warrior $5,000 Warrior Wishes 2016 Mission
Wishes Foundation
------------------------------------------------------------------------
National Transitions $25,000 NTOCC Program Support
of Care Foundation
------------------------------------------------------------------------
Sheltered Yoga $5,000 Sheltered Yoga Curriculum and
Programming
------------------------------------------------------------------------
Dare to Dream Ranch $1,000 The Dare to Dream Ranch
------------------------------------------------------------------------
Provention Health $106,790 LDL Management Forum
Foundation Inc.
------------------------------------------------------------------------
Heart To Heart $50,000 Hurricane Matthew Response
International Inc.
------------------------------------------------------------------------
Heart To Heart $5,000 Louisiana Flood Reponse
International Inc.
------------------------------------------------------------------------
Heart To Heart $10,000 U.S. Disaster Relief
International Inc.
------------------------------------------------------------------------
American Society for $1,265 General Operating Support
Blood and Marrow
Transplantation
------------------------------------------------------------------------
Pharmaceutical $270,000 PhRMA Foundation Grants &
Research and Fellowships
Manufacturers of
America Foundation
------------------------------------------------------------------------
Georgetown University $100,000 Health Promotion and Chronic
Illness: An Educational
Approach
------------------------------------------------------------------------
Patient Advocate $550,000 Metastatic Prostate &
Foundation Metastatic CRC Fund
------------------------------------------------------------------------
University of North $20,000 Pharmacoepidemiology Program
Carolina at Chapel
Hill
------------------------------------------------------------------------
United Way of Greater $23,226 2016 Merial United Way Campaign
Atlanta Sanofi Foundation Match
------------------------------------------------------------------------
United Way of Greater $24,000 Merial 2016 UW Campaign Match
Atlanta
------------------------------------------------------------------------
UNITED WAY OF $5,000 Merial 2016 UW Campaign Match
NORTHEAST GEORGIA
INC.
------------------------------------------------------------------------
UNITED WAY OF $5,000 Merial Athens 2015 UW Campaign
NORTHEAST GEORGIA INC Match
------------------------------------------------------------------------
UNITED WAY OF HALL $4,000 2016 Merial United Way Campaign
COUNTY INC. Sanofi Foundation Match
------------------------------------------------------------------------
UNITED WAY OF HALL $3,615 2015 Merial United Way Campaign
COUNTY INC.
------------------------------------------------------------------------
University of Arizona $5,000 Applied Biosciences Graduate
Foundation for the Interdisciplinary Programs
benefit of GIDP Merit Scholarship
------------------------------------------------------------------------
Direct Relief $25,000 Hurricane Matthew Response in
Haiti
------------------------------------------------------------------------
Direct Relief $5,000 Louisiana Flood Response
------------------------------------------------------------------------
Cancer Support $8,000 Bringing Multiple Myeloma
Community Journey Partners to the Cancer
Support Community
------------------------------------------------------------------------
Partners in Research $25,000 Sanofi Biogenius Canada
Canada
------------------------------------------------------------------------
Sanofi US Matching $116,524 Sanofi US Matching Gifts--Q4
Gifts--2015 (December) 2015 Match
------------------------------------------------------------------------
Tufts Medical Center $35,000 CEVR Database Subscription
------------------------------------------------------------------------
Multiple Myeloma $19,640 Mambo for Myeloma
Research Foundation
------------------------------------------------------------------------
Children's Health Fund $25,000 Flint Emergency Response & Long
Term Need
------------------------------------------------------------------------
Children's Health Fund $665,000 Medical Home Initiative
------------------------------------------------------------------------
Volunteers of America $5,000 Agape House
Delaware Valley
------------------------------------------------------------------------
Cancer Support $15,000 School-Based Support Groups
Community Central New
Jersey
------------------------------------------------------------------------
Trustees of the $20,000 Research Training in
University of Pharmacoepidemiology
Pennsylvania
------------------------------------------------------------------------
Foundation Fighting $100,000 Supporting Research to Find
Blindness Preventions, Treatments and
Cures for Retinal Diseases
------------------------------------------------------------------------
Raritan Valley $15,000 Galileo Scholarships: Providing
Community College Access to STEM Education
Foundation
------------------------------------------------------------------------
Raritan Valley $10,000 Preparing for the Next
Community College Generation Science Standards
Foundation
------------------------------------------------------------------------
Arbor Day Foundation $5,305 Trees in Celebration-Green
Printing Initiative
------------------------------------------------------------------------
Rutgers University $125,000 Health Outcomes, Policy, and
Foundation Economics
------------------------------------------------------------------------
Arrow Lake Foundation $146,722 General Mission Support
------------------------------------------------------------------------
Bill, Hillary, and $50,000 National Health Transformation
Chelsea Clinton
Foundation
------------------------------------------------------------------------
Regents of the $25,000 V-BID
University of
Michigan
------------------------------------------------------------------------
The Medical College of $1,265 CIBMTR General Operating
Wisconsin, Inc. Support
------------------------------------------------------------------------
ALL IN TOGETHER $37,500 All in Together Campaign:
CAMPAIGN INC. Advancing and Empowering Women
Leaders
------------------------------------------------------------------------
Childrens Inn at NIH $500,000 Sanofi US Legacy Endowment Fund
Inc. at The Children's Inn at NIH
------------------------------------------------------------------------
Kids Corporation II $10,000 Kids Corp General Operating
------------------------------------------------------------------------
American Cancer $25,000 Nationwide Hope Lodge
Society Cancer Action Partnership
Network
------------------------------------------------------------------------
Boy Scouts of America, $1,000 STEM Scouts, BSA
Catalina Council
------------------------------------------------------------------------
Kino Learning Center $2,000 STEM Funding
Inc.
------------------------------------------------------------------------
SARSEF-SOUTHERN $5,000 Finding the Next Generation of
ARIZONA RESEARCH STEM Researchers
SCIENCE AND
ENGINEERING
FOUNDATION
------------------------------------------------------------------------
International Myeloma $19,640 International Myeloma
Foundation Foundation Mission Support
------------------------------------------------------------------------
International Myeloma $2,000 MMJP Donation to Support the
Foundation International Myeloma
Foundation
------------------------------------------------------------------------
$6,715,031
Total 2016 Sanofi $352,310,932
US
------------------------------------------------------------------------
Payments made by Sanofi US (2017)
------------------------------------------------------------------------
Legal Name Payment Amount Project Title
------------------------------------------------------------------------
AAALAC International $2,500.00 IQ Consortium/AAALAC
International Global 3Rs
Awards Program
------------------------------------------------------------------------
Academy of Managed $30,000.00 2017 AMCP Partnership Forums
Care Pharmacy
------------------------------------------------------------------------
Academy of Nutrition $18,000.00 DCE On the Cutting Edge
and Dietetics on newsletter
behalf of Diabetes
Care and Education
------------------------------------------------------------------------
ALL IN TOGETHER $25,000.00 National Women's Leadership
CAMPAIGN INC. Initiative
------------------------------------------------------------------------
Alliance for Patient $150,000.00 Keep My Rx Campaign
Access
------------------------------------------------------------------------
Alliance for the $50,000.00 Webinars on Nonmedical
Adoption of Switching of Diabetes
Innovations in Patients
Medicine (Aimed
Alliance)
------------------------------------------------------------------------
Alliance for the $42,000.00 Campaign to End Nonmedical
Adoption of Switching of Diabetes
Innovations in Patients
Medicine (Aimed
Alliance)
------------------------------------------------------------------------
American Academy of $250,000.00 Practice Management Center
Dermatology Inc
------------------------------------------------------------------------
American Association $25,000.00 AACE 26th Annual Scientific &
of Clinical Clinical Congress General
Endocrinologists Support
------------------------------------------------------------------------
American Association $150,035.00 AACE Multi-Site Proposal to
of Clinical Extend the
Endocrinologists Transculturalization of
Diabetes Care
------------------------------------------------------------------------
American Association $75,000.00 AADE Access and Affordability
of Diabetes Forum
Educators
------------------------------------------------------------------------
American Association $20,000.00 2017 Public Policy Forum
of Diabetes
Educators
------------------------------------------------------------------------
American Cancer $2,500.00 RUN FOR DAD
Society
------------------------------------------------------------------------
American Cancer $10,000.00 ACS CAN State Government
Society Cancer Relations Director Training
Action Network and Advocacy Activities
Nationwide
------------------------------------------------------------------------
American Cancer $25,000.00 2017 ACS CAN Fundraising
Society Cancer Events and ACS CAN advocacy
Action Network activities
------------------------------------------------------------------------
American Cancer $2,500.00 Relay For Life of Bridgewater
Society Inc.
------------------------------------------------------------------------
American Chemical $3,000.00 Division of Medicinal
Society Division of Chemistry Program 253rd ACS
Medicinal Chemistry national meeting
------------------------------------------------------------------------
American Chemical $2,500.00 ACS MEDI-EFMC Frontiers in
Society Division of Medicinal Chemistry 2017
Medicinal Chemistry
------------------------------------------------------------------------
American Chemical $3,000.00 Division of Medicinal
Society Division of Chemistry Program 254th ACS
Medicinal Chemistry National Meeting
------------------------------------------------------------------------
American College of $100,000.00 Heart House Roundtable:
Cardiology Effective Prior Authorization
Foundation
------------------------------------------------------------------------
American College of $100,000.00 ACC's 2017 LDL: Address the
Cardiology Risk Think Tank
Foundation
------------------------------------------------------------------------
American College of $20,000.00 Donald C. Jones Leadership and
Endocrinology Endocrine Excellence Award
------------------------------------------------------------------------
American College of $2,000.00 Expand the body of knowledge
Laboratory Animal in the fields of laboratory
Medicine animal science and medicine
------------------------------------------------------------------------
American College of $1,500.00 2017 ACT Corporate Membership
Toxicology
------------------------------------------------------------------------
American Diabetes $2,500.00 Tour de Cure Hawaii--Hele On
Association Hawaii
------------------------------------------------------------------------
American Diabetes $2,500.00 American Diabetes Month--
Association Malama Ohana
------------------------------------------------------------------------
American Diabetes $2,500.00 2017 RVA Tour de Cure &
Association Fitness Walk
------------------------------------------------------------------------
AMERICAN DIABETES $2,000,000.00 Pathway to Stop Diabetes
ASSOCIATION INC.
------------------------------------------------------------------------
American Drug $20,000.00 American Drug Utilization
Utilization Review Review Symposium
Society
------------------------------------------------------------------------
American Foundation $25,000.00 2017 Get in Rhythm. Stay in
for Women's Health Rhythm. Atrial Fibrillation
(dba StopAfib.org) Patient Conference
------------------------------------------------------------------------
American Friends of $15,000.00 Scholarship Fundraising Event--
Toulouse School of Toulouse School of Economics
Economics Inc Gala Event
------------------------------------------------------------------------
American Heart $25,000.00 2017 National Health Tech &
Association Innovation Forum
------------------------------------------------------------------------
American Heart $30,000.00 Boston Heart & Stroke Ball
Association Sponsor
------------------------------------------------------------------------
American Heart $15,000.00 Heart Innovation Forum
Association Inc
------------------------------------------------------------------------
American Medical $50,000.00 AMSSM Research Grant Awards
Society for Sports Program
Medicine Foundation,
Inc.
------------------------------------------------------------------------
American Medical $25,000.00 Multi-Site CRN OA Grant with
Society for Sports Shark Tank competition
Medicine Foundation,
Inc.
------------------------------------------------------------------------
American Orthopaedic $55,000.00 Early Osteoarthritis and
Society for Sports Prevention of OA Progression
Medicine
------------------------------------------------------------------------
American Pharmacists $75,000.00 Osteoarthritis Pharmacist-
Association Patient Companion Guide
------------------------------------------------------------------------
American Pharmacists $80,000.00 Osteoarthritis Pharmacist Quiz
Association Platform
------------------------------------------------------------------------
American Society for $10,000.00 4th Annual ASBMT Fall Clinical
Blood and Marrow Education Conference
Transplantation
------------------------------------------------------------------------
American Society for $2,500.00 ASN Annual Meeting
Neurochemistry
------------------------------------------------------------------------
American Society for $1,500.00 Myelin Satellite Meeting
Neurochemistry
------------------------------------------------------------------------
American Society for $70,000.00 2017 Town Hall Presentation
Preventive Series
Cardiology
------------------------------------------------------------------------
American Society of $35,000.00 Kidney Week 2017--Sponsorships
Nephrology
------------------------------------------------------------------------
American Society of $75,000.00 2018 Corporate Sponsor
Transplant Surgeons
Foundation
------------------------------------------------------------------------
American Statistical $1,000.00 ASA Princeton-Trenton chapter
Association of 2017 Spring Symposium
Princeton-Trenton
Chapter
------------------------------------------------------------------------
Americans for Medical $7,500.00 Raising Voices, Saving Lives
Progress Educational
Foundation
------------------------------------------------------------------------
Americares $12,000.00 Air Lift Benefit Sponsorship
2017
------------------------------------------------------------------------
Americares $70,000.00 Sanofi Solar Power Puerto Rico
Concept
------------------------------------------------------------------------
AMGA Foundation Inc $175,000.00 Together 2 Goal diabetes
campaign
------------------------------------------------------------------------
Amigos Together For $5,000.00 Domino Night Gala for After
Kids, Inc. d/b/a School Program, Nurturing
Amigos For Kids Parent Program and Blue
Ribbon Campaign
------------------------------------------------------------------------
Arizona Diabetes $3,000.00 Diabetes: A Prescription for
Foundation Care
------------------------------------------------------------------------
Arkansas Pharmacy $1,000.00 Immunization Summit
Foundation
------------------------------------------------------------------------
Arthritis Foundation $1,200.00 2017 Delaware Bone Bash
------------------------------------------------------------------------
Asian American Legal $10,000.00 2017 Justice in Action Awards
Defense and Gala
Education Fund
------------------------------------------------------------------------
Association of $7,500.00 Sponsorship of Health
American Medical Workforce Research Conference
Colleges
------------------------------------------------------------------------
Association of Black $25,000.00 Improving Healthcare Access
Cardiologists for Minority and High Risk
Population Gala Dinner
------------------------------------------------------------------------
Association of Black $100,000.00 ABC Advocacy Training Program
Cardiologists
------------------------------------------------------------------------
Association of $5,000.00 AUTM 2017 Annual Meeting
University Sponsorship
Technology Managers
Inc.
------------------------------------------------------------------------
Asthma & Allergy $1,000.00 Asthma Coalition Meeting
Foundation of
America, St. Louis
Chapter
------------------------------------------------------------------------
Austin Black $2,500.00 Austin Black Physicians
Physicians Association Scholarship
Association Fundraiser
------------------------------------------------------------------------
Autoimmune Advocacy $2,500.00 Living with Autoimmunity
Alliance
------------------------------------------------------------------------
Be The Match $37,500.00 Be The Match Walk+Run National
Foundation Sponsorship
------------------------------------------------------------------------
Biocom $10,000.00 Global Life Science Partnering
Conference
------------------------------------------------------------------------
BIONJ INC. $10,000.00 2017 Annual Dinner Meeting
------------------------------------------------------------------------
BIONJ INC. $2,500.00 2017 bioNJ BioPartnering
Conference
------------------------------------------------------------------------
Biotechnology $195,000.00 2017 BIO International
Innovation Convention Sponsorship
Organization
------------------------------------------------------------------------
Biotechnology $25,000.00 2017 BIO Europe Spring
Innovation Sponsorship
Organization
------------------------------------------------------------------------
Biotechnology $25,000.00 2017 BIO Europe Sponsorship--
Innovation November
Organization
------------------------------------------------------------------------
Biotechnology $10,000.00 2017 BIO Patient and Health
Innovation Advocacy Summit
Organization
------------------------------------------------------------------------
Biotechnology $57,500.00 2018 BIO International
Innovation Convention
Organization
------------------------------------------------------------------------
Blood and Marrow $25,000.00 Celebrating a Second Chance at
Transplant Life 2017 Survivorship
Information Network Symposium
------------------------------------------------------------------------
Brigham and Women's $2,000.00 PKD symposium
Hospital
------------------------------------------------------------------------
Cancer Support $8,000.00 Bringing Multiple Myeloma
Community Journey Partners to the
Cancer Support Community
------------------------------------------------------------------------
CANCER SUPPORT $5,000.00 2017 Wings of Hope
COMMUNITY CENTRAL
NEW JERSEY
------------------------------------------------------------------------
CANCER SUPPORT $2,500.00 Inspiring Hope Advocate
COMMUNITY CENTRAL Sponsorship
NEW JERSEY
------------------------------------------------------------------------
CASSS $2,500.00 6th International Symposium on
Higher Order Structure of
Protein Therapeutics (HOS
2017)
------------------------------------------------------------------------
CASSS $2,500.00 WCBP 2017: 21st Symposium on
the Interface of Regulatory
and Analytical Sciences for
Biotechnology Health Products
------------------------------------------------------------------------
CASSS $2,500.00 Advances in the Biotechnology
& Pharmaceutical Industries:
19th Symposium on the
Practical Applications for
the Analysis of Proteins,
Nucleotides and Small
Molecules
------------------------------------------------------------------------
CASSS $2,500.00 14th Symposium on the
Practical Application of Mass
Spectrometry in the
Biotechnology Industry
------------------------------------------------------------------------
CASSS $2,500.00 Analytical Technologies in the
Biopharmaceutical Industry
(AT Europe 2017)
------------------------------------------------------------------------
CASSS $2,500.00 Bioassays 2017
------------------------------------------------------------------------
Catalyst Inc. $13,500.00 Catalyst International Women's
Day Gala Dinner
------------------------------------------------------------------------
Chicago Hispanic $500.00 Vive tu Vida!Get up! Get
Health Coalition moving! Health and Wellness
Fair
------------------------------------------------------------------------
Children's Health $30,000.00 Children's Health Fund 2017
Fund Annual Benefit
------------------------------------------------------------------------
Children's Health $665,000.00 Medical Home Initiative
Fund
------------------------------------------------------------------------
Children's Health $665,000.00 Medical Home Initiative
Fund
------------------------------------------------------------------------
Children's Hospital $10,000.00 2017 PCMM Scientific Retreat
Corporation
------------------------------------------------------------------------
Children's Hospital $500.00 Boston Postdoctoral
Corporation Association Symposium on
Careers and Collaboration in
Science
------------------------------------------------------------------------
Christ the King $5,000.00 Annual President's Gala
Preparatory School
of Newark NJ Corp
------------------------------------------------------------------------
CISCRP $25,000.00 AWARE for All: Clinical
Research Education Day
------------------------------------------------------------------------
CISCRP $160,000.00 AWARE for All Campaign
------------------------------------------------------------------------
Coalition for $5,000.00 Health RX: Building
Affordable Health Affordability & Access event
Coverage sponsorship
------------------------------------------------------------------------
Coastal Volunteers in $1,000.00 Care & Management of Diabetic
Medicine Patients
------------------------------------------------------------------------
Cold Spring Harbor $15,000.00 Cold Spring Harbor Laboratory
Laboratory Corporate Sponsor Program
2017
------------------------------------------------------------------------
College Diabetes $55,000.00 CDN Political Advocacy for
Network Inc. Young Adults Guide
------------------------------------------------------------------------
College Diabetes $20,000.00 2017 Corporate Membership
Network Inc.
------------------------------------------------------------------------
Colorado Business $7,000.00 Corporate Membership
Group on Health
------------------------------------------------------------------------
Community Health $2,500.00 ``Patient-Centered and
Coalition, Inc. Population Health for Us''
------------------------------------------------------------------------
Community Health Task $500.00 2017 World Diabetes Day 5th
Force, Inc. Annual BridgeWalk for
Diabetes Awareness and Care
------------------------------------------------------------------------
Community Hope, Inc. $4,800.00 Veterans Pre-Holiday Dinner
and Gift Cards
------------------------------------------------------------------------
Community Hope, Inc. $10,000.00 2017 Corporate Partner Program
------------------------------------------------------------------------
Community Oncology $25,000.00 2017 Payer Exchange Summit VII
Alliance
------------------------------------------------------------------------
Conference of Western $5,000.00 CWAG 2017 Chair Initiative
Attorneys General Sponsorship
------------------------------------------------------------------------
Congress of $2,500.00 Adherence Outreach and
California Seniors Education with Seniors =
Education and Script your Future
Research Fund
------------------------------------------------------------------------
Council for the $60,000.00 10th World Conference of
Advancement of Science Journalists
Science Writing,
Inc.
------------------------------------------------------------------------
CrowdCare Foundation, $20,000.00 Muscles for Myeloma
Inc.
------------------------------------------------------------------------
CSweetener $25,000.00 CSweetener Mentoring Program
------------------------------------------------------------------------
Deep South Cancer $5,000.00 Cycliad 2017
Foundation
------------------------------------------------------------------------
Deirdre O'Brien Child $5,000.00 21st Annual Gala Solicitation
Advocacy Center Inc.
------------------------------------------------------------------------
Diabetes Foundation $1,000.00 Tastings & Tapas Fundraiser
Inc.
------------------------------------------------------------------------
Diabetes Foundation $2,500.00 Live-A-Betes: Living Well with
of Mississippi Diabetes
------------------------------------------------------------------------
Diversity Alliance $5,500.00 DA4S East Coast 2017
for Science, Inc.
------------------------------------------------------------------------
Diversity Alliance $3,500.00 DA4S West Coast 2017
for Science, Inc.
------------------------------------------------------------------------
Donate Life America $26,025.00 Mission Support
------------------------------------------------------------------------
Donate Life Northwest $10,000.00 Part II. Removing Barriers
through Knowledge: An
Educational Series for
Providers of Dialysis and
ESRD Patients
------------------------------------------------------------------------
Dress For Success $15,000.00 Transforming Lives Celebration
Northern New Jersey--
10 Counties, Inc.
------------------------------------------------------------------------
Employers Health $7,500.00 2017 Employers Health
Coalition, Inc. Innovations in Employee
Benefits Conference
------------------------------------------------------------------------
Endocrine Society $150,000.00 Hypoglycemia Quality
Improvement Program
------------------------------------------------------------------------
Families of SMA DBA $5,000.00 2017 Annual SMA Conference
Cure SMA
------------------------------------------------------------------------
Federal Circuit Bar $2,500.00 Major Regional Program--Boston
Association
Charitable and
Educational Fund
------------------------------------------------------------------------
Federation of $2,000.00 FASEB SRC on the Biology of
American Societies Cilia and Flagella
for Experimental
Biology (FASEB)
------------------------------------------------------------------------
Federation of $25,000.00 FOCIS 2017 Annual Meeting
Clinical Immunology
Societies
------------------------------------------------------------------------
Florida Health Care $5,000.00 FLHCC 24th Annual National
Coalition Conference: Getting to Better
Care and Improved Outcomes
------------------------------------------------------------------------
Florida International $170,000.00 Expert Workshop State of the
University Art Pertussis Prevention and
Foundation Inc. Control in Latin America and
the Caribbean
------------------------------------------------------------------------
Florida International $60,000.00 LATIN AMERICAN AND CARIBBEAN
University DIABETES NETWORK: A FRAMEWORK
Foundation Inc FOR ACTION
------------------------------------------------------------------------
Florida International $60,000.00 Assesment of acellular
University vaccination programs in
Foundation Inc. Mexico, Costa Rica and Panama
------------------------------------------------------------------------
Florida International $25,000.00 Develop Guidelines for
University Antimicrobial Stewardship For
Foundation Inc. Latin America and Caribbean
region
------------------------------------------------------------------------
Florida International $62,000.00 REVIEW OF NATIONAL
University IMMUNIZATION CALENDARS OF THE
Foundation Inc. EXPANDED PROGRAM OF
IMMUNIZATION (EPI) IN
COUNTRIES OF LATIN AMERICA
AND THE CARIBBEAN.
PRELIMINARY OBSERVATIONS ON
FINANCIAL AND FUNDING
MECHANISMS OF THE NATIONAL
IMMUNIZATION PROGRAMS.
------------------------------------------------------------------------
Food Allergy Research $50,000.00 FARE Patient Registry
& Education, Inc.
------------------------------------------------------------------------
Foundation Fighting $100,000.00 Research to Overcome Retinal
Blindness Degenerative Diseases
------------------------------------------------------------------------
Foundation for $7,500.00 ANIMAL RESEARCH HELPS ANIMALS
Biomedical Research CAMPAIGN
------------------------------------------------------------------------
Foundation of the $20,000.00 Foundation of the National
National Lipid Lipid Association Young
Association Investigator Abstract Award
Program
------------------------------------------------------------------------
French-American $2,500.00 FACC Corporate Membership
Chamber of Commerce
in the United
States, Inc.--New
York Chapter
------------------------------------------------------------------------
Friends of Cancer $25,000.00 Exploring New Biomarkers for
Research Immunology
------------------------------------------------------------------------
Friends of Cancer $50,000.00 2017 Mission Support
Research
------------------------------------------------------------------------
George Washington $130,000.00 The George Washington
University University Forum on Arbovirus
Infections
------------------------------------------------------------------------
GLBTQ Legal Advocates $3,000.00 18th Annual Spirit of Justice
& Defenders Award Dinner
------------------------------------------------------------------------
Good Grief Inc. $7,500.00 2017 Golf ``Fore'' the Kids
------------------------------------------------------------------------
Good Grief Inc. $5,000.00 Great Pumpkin Ball Sponsorship
------------------------------------------------------------------------
Gordon Research $10,000.00 GRC: Pancreatic Diseases
Conference ``Exocrine and Endocrine
Pancreas: Molecules to
Human''
------------------------------------------------------------------------
Gordon Research $1,000.00 High Throughput Chemistry and
Conference Chemical Biology GRC
------------------------------------------------------------------------
Gordon Research $2,500.00 The Enduring Potential of
Conference Heterocycles as Synthetic
Targets, Cellular Probes, and
Drug Candidates
------------------------------------------------------------------------
Gordon Research $2,000.00 2017 Gordon Research
Conference Conference on Natural
Products & Bioactive
Compounds
------------------------------------------------------------------------
Gordon Research $3,000.00 2017 Gordon Research
Conference Conference on Medicinal
Chemistry
------------------------------------------------------------------------
Gordon Research $3,000.00 Gordon Research Conference and
Conference Seminar on ``Lysosomal
Diseases''
------------------------------------------------------------------------
Gordon Research $5,000.00 Gordon Research Conference
Conference (GRC) entitled ``Neuroimmune
communication in health and
disease''
------------------------------------------------------------------------
Gordon Research $5,000.00 2018 Biology of Spirochetes
Conference Gordon Research Conference
and Gordon Research Seminar
------------------------------------------------------------------------
Greater Detroit Area $7,000.00 2017 GDAHC Membership Dues
Health Council, Inc.
------------------------------------------------------------------------
Greater New England $4,000.00 Economic Development
Minority Supplier Sponsorship opportunities
Development Council
------------------------------------------------------------------------
Health Action Council $4,500.00 Health Action Council Annual
Ohio Event Sponsorship
------------------------------------------------------------------------
HealthCare 21 $25,000.00 Data Impact: Evaluating the
Business Coalition Impact of Formulary Exclusion
on Pharmacy Data
------------------------------------------------------------------------
Healthcare $3,000.00 2017 Woman of the Year event
Businesswomen's
Association
------------------------------------------------------------------------
Healthcare $10,000.00 2017 HBA Woman of the Year
Businesswomen's event sponsorship
Association
------------------------------------------------------------------------
Heart To Heart $15,000.00 25th Anniversary Gala
International Inc.
------------------------------------------------------------------------
Heart To Heart $8,500.00 Rutgers Fellows Volunteer
International Inc. Service Trip
------------------------------------------------------------------------
Hereditary Disease $2,000.00 2017 Celebration of Discovery
Foundation Symposium and Gala
------------------------------------------------------------------------
Horton's Kids, Inc. $15,000.00 Home Runs for Horton's Kids:
Comprehensive Programming for
At-Risk Children
------------------------------------------------------------------------
Hunterdon Medical $5,000.00 2017 Crystal Ball Sponsorship
Center Foundation
------------------------------------------------------------------------
Hyacinth Foundation A $1,000.00 Hyacinth Gala & Silent Auction
New Jersey Nonprofit
Corporation
------------------------------------------------------------------------
Hyacinth Foundation A $2,500.00 Hyacinth Gala & Silent Auction
New Jersey Nonprofit
Corporation
------------------------------------------------------------------------
Icahn School of $5,000.00 ISMMS-Sanofi Quantitative
Medicine at Mount Systems Pharmacology
Sinai Symposium
------------------------------------------------------------------------
ILSI Health and $99,074.00 2017 HESI Membership and
Environmental Health Committee Assessments
Institute
------------------------------------------------------------------------
Institute for Cancer $10,000.00 2017 In Vino Vita Sponsorship
Research dba The Request
Research Institute
of Fox Chase Cancer
Center
------------------------------------------------------------------------
Institute for Safe $1,000.00 20th Annual ISMP Cheers Awards
Medication Practices
------------------------------------------------------------------------
International $5,000.00 NIH Oxford-Cambridge 2017
Biomedical Research Global Doctoral Partnerships
Alliance Annual Workshop
------------------------------------------------------------------------
International $5,000.00 NIH Oxford-Cambridge 2016
Biomedical Research Global Doctoral Partnerships
Alliance Annual Workshop
------------------------------------------------------------------------
International Myeloma $50,000.00 8th International Myeloma
Foundation Working Group (IMWG) Summit,
Madrid, Spain
------------------------------------------------------------------------
International Myeloma $50,000.00 2017 IMF Patient Programs
Foundation
------------------------------------------------------------------------
International Myeloma $50,000.00 International Myeloma
Foundation Foundation 2017 Asian Myeloma
Network (AMN) Summit
------------------------------------------------------------------------
Iowa Pharmacy $10,000.00 2017 Leadership Pharmacy
Association leadership training program
Foundation
------------------------------------------------------------------------
JDRF $2,500.00 2017 One Walk Allentown
------------------------------------------------------------------------
JDRF $2,500.00 2017 One Walk Bucks County
------------------------------------------------------------------------
JDRF $2,500.00 2017 One Walk Reading
------------------------------------------------------------------------
JDRF $2,500.00 JDRF Passport to a Cure Gala
------------------------------------------------------------------------
JDRF $2,500.00 Rockin' Docs for Diabetes Cure
------------------------------------------------------------------------
JDRF $2,500.00 2017 One Walk Stroudsburg
------------------------------------------------------------------------
JDRF $2,500.00 2017 One Walk Moosic
------------------------------------------------------------------------
JDRF $2,500.00 2017 One Walk Philadelphia
------------------------------------------------------------------------
JDRF $1,500.00 2017 JDRF One Walk Maine
------------------------------------------------------------------------
JDRF $5,000.00 2017 Triangle Eastern NC
OneWalk
------------------------------------------------------------------------
JDRF $10,000.00 2017 Triangle Eastern NC Hope
Gala
------------------------------------------------------------------------
JDRF $5,000.00 JDRF One Promise Gala
Philadelphia
------------------------------------------------------------------------
JDRF $5,000.00 JDRF One Walk Westmoreland
------------------------------------------------------------------------
JDRF $2,500.00 JDRF One Walk
------------------------------------------------------------------------
JDRF $5,000.00 25th Anniversary JDRF Promise
Gala
------------------------------------------------------------------------
JDRF $2,500.00 JDRF TypeOneNation Summit
------------------------------------------------------------------------
JDRF $5,000.00 JDRF Imagine Gala
------------------------------------------------------------------------
JDRF--Western New $3,000.00 Journey to A Cure Gala
York Chapter
------------------------------------------------------------------------
JDRF--Western New $2,500.00 Buffalo JDRF One Walk 2017
York Chapter
------------------------------------------------------------------------
JDRF--Western New $5,000.00 Journey to a Cure Gala
York Chapter
------------------------------------------------------------------------
JDRF Greater Dallas $2,500.00 JDRF One Walk, Dallas
------------------------------------------------------------------------
JDRF International $2,500.00 JDRF One Walk 2017
------------------------------------------------------------------------
JDRF International $5,000.00 JDRF 35th Annual Boston Gala
------------------------------------------------------------------------
JDRF INTERNATIONAL $50,000.00 2017 JDRF Government Day
------------------------------------------------------------------------
JDRF International $5,000.00 2017 JDRF One Walk Las Vegas
------------------------------------------------------------------------
JDRF NENY $2,500.00 JDRF Saratoga One Walk
------------------------------------------------------------------------
JDRF NENY $2,500.00 JDRF Albany One Walk
------------------------------------------------------------------------
JDRF New York City $10,000.00 45th annual Promise Ball
Chapter
------------------------------------------------------------------------
Jersey Battered $14,000.00 Grand Tastings XXIII
Women's Service,
Inc.
------------------------------------------------------------------------
Joslin Diabetes $10,000.00 2017 High Hopes Gala
Center, Inc.
------------------------------------------------------------------------
Joslin Diabetes $10,000.00 A Taste of Ginger
Center, Inc.
------------------------------------------------------------------------
Junior Achievement of $5,000.00 Empowering NJ Students for
New Jersey, Inc. Success
------------------------------------------------------------------------
Juvenile Diabetes $5,000.00 2018 Hope for a Cure Gala
Research Foundation
------------------------------------------------------------------------
Juvenile Diabetes $2,500.00 2017 JDRF One Walk Southern
Research Foundation Tier
------------------------------------------------------------------------
Juvenile Diabetes $2,500.00 2017 Hope for a Cure Gala
Research Foundation
------------------------------------------------------------------------
Juvenile Diabetes $2,500.00 JDRF One Walk Rochester
Research Foundation
------------------------------------------------------------------------
Juvenile Diabetes $2,500.00 2017 Rock the Cure
Research Foundation
------------------------------------------------------------------------
Juvenile Diabetes $2,500.00 One Walk, Yonkers
Research Foundation
International
------------------------------------------------------------------------
Keystone Symposia on $50,000.00 Keystone Symposia Directors'
Molecular and Fund
Cellular Biology
------------------------------------------------------------------------
Keystone Symposia on $25,000.00 Keystone Symposia Directors'
Molecular and Fund
Cellular Biology
------------------------------------------------------------------------
Lake Norman Community $2,500.00 Sunset and Sandals
Health Clinic
------------------------------------------------------------------------
Lymphoma Research $2,000.00 10th Annual Love to Find a
Foundation Cure Dinner
------------------------------------------------------------------------
Machestic Dragons $5,000.00 2017 Machestic Dragons ``
`Paddle for Pink' Community
Dragon Boat Festival''
------------------------------------------------------------------------
Machestic Dragons $500.00 2017 Machestic Dragons ``
`Paddle for Pink' Community
Dragon Boat Festival''
------------------------------------------------------------------------
Map International $10,000.00 Bill Foege Event Sponsorship
------------------------------------------------------------------------
March of Dimes $2,500.00 Signature Chefs--Seattle
Foundation
------------------------------------------------------------------------
Massachusetts General $1,500.00 18th Annual Paul S. Russell
Hospital--Transplant Lecture in Transplantation
Center
------------------------------------------------------------------------
Massachusetts $5,000.00 Immune Engineering Symposium
Institute of 2017
Technology
------------------------------------------------------------------------
Massachusetts $5,000.00 Immune Engineering Symposium
Institute of 2017
Technology
------------------------------------------------------------------------
Massachusetts $5,000.00 Koch Institute Summer
Institute of Symposium 2017
Technology
------------------------------------------------------------------------
Massachusetts Society $1,000.00 MSMR Annual Meeting of Members
for Medical
Research, Inc.
------------------------------------------------------------------------
MassChallenge, Inc. $50,000.00 PULSE@MassChallenge 2018
Sanofi Gold Sponsorship
------------------------------------------------------------------------
Medical Foundation of $10,000.00 Osteoarthritis Action Alliance
North Carolina Inc (OAAA) Community mini-grant
Program
------------------------------------------------------------------------
Men's Health Network $25,000.00 Men's Health Month Sponsorship
------------------------------------------------------------------------
Mercy Health $2,500.00 Stick it to Diabetes
Foundation Joplin
------------------------------------------------------------------------
Mercy Health $2,500.00 Mercy Gala of Hope
Foundation--Springfi
eld
------------------------------------------------------------------------
Metabolic Endocrine $25,000.00 15th Annual World Congress on
Education Foundation Insulin Resistance Diabetes
and Cardiovascular Disease
WCIRDC
------------------------------------------------------------------------
Metabolic Endocrine $100,000.00 1st Annual Congress--Heart in
Education Foundation Diabetes (HiD)
------------------------------------------------------------------------
Metabolic Endocrine $25,000.00 15th Annual World Congress on
Education Foundation Insulin Resistance Diabetes
and Cardiovascular Disease--
WCIRDC = Request 2
------------------------------------------------------------------------
Mid-America Coalition $5,000.00 5th Annual Workforce &
on Health Care Community Well-Being Forum
------------------------------------------------------------------------
Middle Atlantic $1,000.00 Bradford award/student career
Reproduction and event
Teratology
Association (MARTA)
------------------------------------------------------------------------
Moses E. Cheeks Slam $2,500.00 Chicago Camp Slam Dunk for
Dunk for Diabetes Diabetes
------------------------------------------------------------------------
Multiple Myeloma $20,000.00 Stem Cell Care Package Program
Research Foundation and Re Birthday Program
------------------------------------------------------------------------
Multiple Myeloma $20,000.00 Multiple Myeloma Patient
Research Foundation Summits
------------------------------------------------------------------------
Myotonic Dystrophy $3,000.00 2017 MDF Conference
Foundation Sponsorship
------------------------------------------------------------------------
NASPA $5,000.00 OA Mobility Discussion and
Event
------------------------------------------------------------------------
NATIONAL ACADEMY OF $50,000.00 Forum on Neuroscience and
SCIENCES Nervous System Disorders
------------------------------------------------------------------------
NATIONAL ACADEMY OF $85,000.00 Forum on Drug Discovery,
SCIENCES Development and Translation
------------------------------------------------------------------------
National Alliance of $17,000.00 Supporting Employers to
Healthcare Purchaser Effectively Manage Rheumatoid
Coalitions Arthritis Action Brief
------------------------------------------------------------------------
National Alliance of $2,000.00 13th Annual Meeting of NASPCC
State Prostate
Cancer Coalitions
------------------------------------------------------------------------
National Bone Marrow $5,000.00 PEER SUPPORT FOR BONE MARROW,
Transplant Link STEM CELL TRANSPLANT
COMMUNITY
------------------------------------------------------------------------
National Bone Marrow $2,500.00 Resource Directory
Transplant Link
------------------------------------------------------------------------
National Committee $10,000.00 NCQA's Quality Talks 2017
for Quality
Assurance
(``NCQA''')
------------------------------------------------------------------------
National $10,000.00 NCCN 12th Annual Congress:
Comprehensive Cancer Hematologic Malignancies
Network Patient Advocacy Pavilion
------------------------------------------------------------------------
National Eczema $50,000.00 National Eczema Association's
Association Grassroots Advocacy Program
------------------------------------------------------------------------
National Forum for $25,000.00 National Forum Cholesterol
Heart Disease and Initiative (Phase 3)
Stroke Prevention
Inc.
------------------------------------------------------------------------
National Forum for $25,000.00 National Forum Value & Access
Heart Disease and Initiative
Stroke Prevention
Inc.
------------------------------------------------------------------------
National Health $130,000.00 Patient Perspective on the
Council Value of Treatments
------------------------------------------------------------------------
National Hispanic $5,000.00 Diabetes and Renal Disease
Medical Association among Latino Patients
Conference
------------------------------------------------------------------------
National Kidney $1,000.00 2017 Champion of Hope Tribute
Foundation of Dinner
Michigan
------------------------------------------------------------------------
National Kidney $50,000.00 Connecting Diabetes,
Foundation, Inc. Cardiovascular Disease, and
Kidney Disease `` Patient
Awareness Campaign
------------------------------------------------------------------------
National Lipid $30,000.00 Expansion of Discovering the
Association Barriers to Access of PCSK9
Inhibitors: an NLA Assessment
------------------------------------------------------------------------
National Minority $25,000.00 Diabetes Working Group: Vision
Quality Forum 20/20
------------------------------------------------------------------------
National TB $5,000.00 Sponsorship for the 2017
Controllers National TB Conference:
Association Poster Discussion
------------------------------------------------------------------------
NCSL Foundation for $7,500.00 NCSL LegisBrief Sponsorship
State Legislatures
------------------------------------------------------------------------
New England $5,000.00 New England Immunology
Immunology Conference
Conference, Inc.
------------------------------------------------------------------------
New Jersey Public $500.00 New Jersey Public Health
Health Association Association 2017 Annual
Conference
------------------------------------------------------------------------
New Jersey Society of $5,000.00 Sponsorship/Membership
Oncology Managers
------------------------------------------------------------------------
New York & New Jersey $10,000.00 Annual Event Sponsorship
Minority Supplier
Development Council
------------------------------------------------------------------------
NewYorkBIO $8,000.00 NewYorkBIO 2017 Annual
Conference
------------------------------------------------------------------------
NJ AIDS Services $2,500.00 New Jersey AIDS Walk
------------------------------------------------------------------------
North Eastern Section $2,000.00 6th Advances in Chemical
Of American Chemical Sciences
Society
------------------------------------------------------------------------
NorthCrest Medical $2,500.00 NorthCrest Gala
Center Foundation
------------------------------------------------------------------------
Northeast Business $20,000.00 eValue8--Health Plan
Group on Health Performance Assessment
------------------------------------------------------------------------
NYU School of $5,000.00 The Skirball Institute 18th
Medicine, an Symposium Honoring Dan
administrative unit Littman, MD
of New York
University
------------------------------------------------------------------------
Ohio Chamber of $1,250.00 2017 Salt Fork Policy
Commerce Conference
------------------------------------------------------------------------
Operation Jersey $500.00 Gala of Giving II
Cares
------------------------------------------------------------------------
Operation Warrior $10,000.00 2017 Army Navy Game
Wishes Foundation
------------------------------------------------------------------------
Oregon State $7,500.00 OSU College of Pharmacy,
University Pharmacy Partners Program
Foundation
------------------------------------------------------------------------
Organization for $15,000.00 2017 OFII Annual Dinner
International
Investment
------------------------------------------------------------------------
Out & Equal $25,000.00 2017 Workplace Summit
------------------------------------------------------------------------
Patient Advocate $5,000.00 16th Annual A Promise of Hope
Foundation Affair
------------------------------------------------------------------------
Patient Advocate $250,000.00 Patient Advocate Foundation Co-
Foundation Pay Relief Program Oncology
Donation
------------------------------------------------------------------------
PATIENT EMPOWERMENT $25,000.00 Virtual Town Meeting for
NETWORK Advanced Prostate Cancer
Patients
------------------------------------------------------------------------
Patient Services Inc. $5,000.00 PSI Advocacy Day and
Congressional Reception
------------------------------------------------------------------------
PCMA $80,000.00 2017 sPCMA Business Forum
Sponsorship, Presidential
------------------------------------------------------------------------
PCMA $95,000.00 2017 Annual Meeting
Presidential Sponsorship
------------------------------------------------------------------------
Pharmaceutical $270,000.00 PhRMA Foundation Grants &
Research and Fellowships
Manufacturers of
America Foundation
------------------------------------------------------------------------
PQA, Inc. $7,500.00 PQA 2017 Leadership Summit:
Connecting the Dots to
Enhance Patient Care
------------------------------------------------------------------------
PQA, Inc $100,000.00 An Accelerated Strategy for
Advancing an Insulin
Adherence/Persistence Quality
Measure
------------------------------------------------------------------------
Preventive $50,000.00 Access to Innovative Medicine
Cardiovascular Campaign
Nurses Association
------------------------------------------------------------------------
Pro Bono Partnership $15,000.00 Pro Bono Partnership 2017 Gala
------------------------------------------------------------------------
Project Hope The $10,000.00 2017 Gala--Project HOPE: A
People To People Voice for Global Health
Health Foundation
Inc.
------------------------------------------------------------------------
Prostate Cancer $10,000.00 Chemotherapy Patient Education
Education Council
------------------------------------------------------------------------
Prostate Cancer $25,000.00 Interactive Patient Education
Education Council Programs
------------------------------------------------------------------------
Prostate Cancer $300,000.00 24th Annual Scientific Retreat
Foundation
------------------------------------------------------------------------
Public Health $5,000.00 Building Health Equity in
Advocates Diabetes Prevention and
Treatment Conference
------------------------------------------------------------------------
Raritan Valley $3,000.00 College Campus Experience
Community College Sessions for STEM High School
Foundation Students
------------------------------------------------------------------------
Raritan Valley $10,000.00 Preparing for the Next
Community College Generation Science Standards--
Foundation District Partnership Program
------------------------------------------------------------------------
Raritan Valley $125,000.00 Sanofi Nursing Simulation Lab:
Community College Preparing Nursing Students to
Foundation Meet the Community's Health
Care Needs
------------------------------------------------------------------------
Raritan Valley $25,000.00 Galileo Scholarships:
Community College Providing Access to STEM
Foundation Education
------------------------------------------------------------------------
Raritan Valley $46,100.00 Sanofi US Corporate Mentor
Community College Program at RVCC
Foundation
------------------------------------------------------------------------
Raritan Valley $3,250.00 An Evening of Elegance for
Community College Education
Foundation
------------------------------------------------------------------------
Raritan Valley $10,000.00 Preparing for the Next
Community College Generation Science Standards
Foundation
------------------------------------------------------------------------
Raritan Valley $15,000.00 Galileo Scholarships:
Community College Providing Access to STEM
Foundation Education
------------------------------------------------------------------------
Regents University of $10,000.00 March Kidney Fair, March 26,
California Los 2017
Angeles
------------------------------------------------------------------------
Research!America $10,000.00 National Health Research Forum
------------------------------------------------------------------------
Research!America $25,000.00 Advocacy Awards Dinner
------------------------------------------------------------------------
RESOURCES USA INC $10,000.00 Bastille Day 2017--Washington
DC--Celebrates the Franco-
American relationship
------------------------------------------------------------------------
RESOURCES USA INC. $5,000.00 Bastille Day 2017--Boston
------------------------------------------------------------------------
Rutgers University $20,000.00 The Sanofi US Scholarship for
Foundation Veterans in the Rutgers
Business School Executive
Education Program
------------------------------------------------------------------------
Rutgers University $5,000.00 Andrew Giovanni Woman in
Foundation Neuroscience Endowed Travel
Scholarship
------------------------------------------------------------------------
SDHB Pheo-Para $9,900.00 SDHB Pheo-Para Coalition Gala
Coalition, Inc.
------------------------------------------------------------------------
Seeding Labs $2,000.00 Positively Instrumental: 2017
Instrumental Access Launch &
Donor Recognition Event
------------------------------------------------------------------------
Society for $25,000.00 Trainee Professional
Neuroscience Development Awards at
Neuroscience 2017
------------------------------------------------------------------------
Society of Toxicology $10,000.00 Society of Toxicology (SOT)
Annual Meeting
------------------------------------------------------------------------
SOME INC. $5,000.00 2017 SOME Gala
------------------------------------------------------------------------
Somerset Alliance for $1,000.00 NJ Smart Workplace Recognition
the Future d.b.a Breakfast
RideWise
------------------------------------------------------------------------
Somerset Health Care $2,500.00 Healthier Somerset
Foundation
------------------------------------------------------------------------
Springboard 2000 $25,000.00 Health Innovation Hub 2017
Enterprises, Inc.
------------------------------------------------------------------------
State University of $2,500.00 Wellstone Family Conference
Iowa Foundation 2017
------------------------------------------------------------------------
T1 Today, Inc., dba $29,625.00 Round Table on Impact of Non-
Children with Medical Switching of Insulin
Diabetes
------------------------------------------------------------------------
T1 Today, Inc., dba $48,500.00 Forced Non-Medical Switching
Children with Awareness--November 2017
Diabetes
------------------------------------------------------------------------
T1 Today, Inc., dba $20,000.00 Friends for Life Orlando
Children with Supporting Sponsorship
Diabetes
------------------------------------------------------------------------
T1 Today, Inc., dba $49,500.00 Round Table on Impact of Non-
Children with Medical Switching of Insulin--
Diabetes San Diego
------------------------------------------------------------------------
Taking Control of $25,000.00 Educating Patients and Their
Your Diabetes Caregivers About The Role Of
Treatments In Diabetes
Management
------------------------------------------------------------------------
Taking Control of $60,000.00 Taking Control Of Your
Your Diabetes Diabetes 2017
------------------------------------------------------------------------
Taking Control of $20,000.00 ONE: The Ultimate Conference &
Your Diabetes Retreat for Adult Type 1's
------------------------------------------------------------------------
TBA Foundation $15,000.00 Pat's Myeloma Survival School
------------------------------------------------------------------------
Teratology Society $1,500.00 Teratology Society 57th Annual
Meeting
------------------------------------------------------------------------
THE ALBERT B SABIN $300,000.00 Arbovirus Surveillance
VACCINE INSTITUTE Strengthening Phase II
INC.
------------------------------------------------------------------------
The American Fallen $5,700.00 2018 Portrait Donation
Soldiers Project Inc
------------------------------------------------------------------------
The American Heart $25,000.00 American Heart Association
Association Multicultural Initiatives
------------------------------------------------------------------------
The American Heart $50,000.00 Go Red for Women; Health
Association Education Symposium
------------------------------------------------------------------------
The American Heart $25,000.00 Heart and Stroke Ball Campaign
Association 2017
------------------------------------------------------------------------
The American Kidney $50,000.00 The Hope Affair 2017--Imagine
Fund, Inc. the Possibilities
------------------------------------------------------------------------
The American Kidney $5,000.00 2017 A Pairing For Prevention
Fund, Inc.
------------------------------------------------------------------------
The American Kidney $20,000.00 The Hope Affair Sponsorship
Fund, Inc.
------------------------------------------------------------------------
THE BIOBREAK $5,000.00 BioBreak Industry Sponsorship
ORGANIZATION INC.
------------------------------------------------------------------------
The Broad Institute, $2,000.00 Glom-NExT3 Symposium
Inc.
------------------------------------------------------------------------
The Center For Great $5,000.00 2017 Gift of Hope Gala
Expectations Inc.
------------------------------------------------------------------------
The Children's Aid $25,000.00 Children's Aid Keeping the
Society Promise Benefit
------------------------------------------------------------------------
The Children's $2,000.00 2017 Conference on Clinical
Hospital of Trial Readiness in the
Philadelphia Leukodystrophies
------------------------------------------------------------------------
The Children's $2,000.00 2017 Conference on Clinical
Hospital of Trial Readiness in the
Philadelphia Leukodystrophies
------------------------------------------------------------------------
The Children's Inn at $10,000.00 An Evening for Hope
NIH, Inc.
------------------------------------------------------------------------
The Council of State $5,000.00 Bowhay Institute for
Government, Ltd. Legislative Leadership
Development
------------------------------------------------------------------------
The Diabetes $2,500.00 Giving Diabetes the Blues
Coalition of
Mississippi/
Mississippi Rural
Health Association
------------------------------------------------------------------------
The diaTribe $50,000.00 Consensus Conference Glycemic
Foundation Outcomes Beyond A1C
------------------------------------------------------------------------
The diaTribe $20,000.00 11th Annual Diabetes Forum
Foundation
------------------------------------------------------------------------
The diaTribe $90,000.00 Follow Up for d17: Executive
Foundation Innovation Lab in Diabetes
and Prediabetes
------------------------------------------------------------------------
The Economic Alliance $2,500.00 EAM Health Purchaser Forum
for Michigan
------------------------------------------------------------------------
The FH Foundation $250,000.00 The CASCADE FHTM Registry
------------------------------------------------------------------------
The FH Foundation $100,000.00 Advocates for Awareness
------------------------------------------------------------------------
The FH Foundation $75,000.00 2017 FH Global Summit
------------------------------------------------------------------------
The Galien Foundation $15,000.00 PRIX GALIEN USA GALIEN FORUM
------------------------------------------------------------------------
The Health $5,000.00 Inspire Sponsorship
Collaborative
------------------------------------------------------------------------
THE LEUKEMIA & $50,000.00 Blood and Marrow Stem Cell
LYMPHOMA SOCIETY Transplantation Booklet and
Guide
------------------------------------------------------------------------
The Medical College $10,000.00 2017 BMT Tandem Meetings--
of Wisconsin, Inc. Administrative Directors
Reception
------------------------------------------------------------------------
The Mended Hearts, $25,000.00 Patient Advocacy Network (PAN)
Inc. Training
------------------------------------------------------------------------
The Mended Hearts, $10,000.00 National Education & Training
Inc. Conference
------------------------------------------------------------------------
The Mesothelioma $2,000.00 Sponsorship--Clinical Trial
Applied Research Awareness
Foundation
------------------------------------------------------------------------
The New York Academy $5,000.00 Challenge 2030: Tomorrow's
of Science innovators tackle today's
grand challenges
------------------------------------------------------------------------
The Ohio State $25,000.00 Pharmacy Patient Counseling
University Education
Foundation
------------------------------------------------------------------------
The Ohio State $1,000.00 Pharmathon 5k
University
Foundation
------------------------------------------------------------------------
The Partnership for $5,000.00 PQMD London Educational Forum
Quality Medical
Donations
------------------------------------------------------------------------
The Pennsylvania $150,000.00 SARP SUPPLEMENTAL FUNDING
State University AGREEMENT
------------------------------------------------------------------------
THE TRANSPLANTATION $7,500.00 The 14th Congress of the
SOCIETY International
Xenotransplantation
Association
------------------------------------------------------------------------
THE TRANSPLANTATION $15,000.00 9th Congress of the
SOCIETY International Pediatric
Transplant
------------------------------------------------------------------------
The Virginia Public $700.00 Lighten Up, It's Just Politics
Access Project
------------------------------------------------------------------------
The World Orphan Fund $500.00 2017 Annual Wisconsin Gala
Inc.
------------------------------------------------------------------------
Thomas Jefferson $65,000.00 Population Health Leadership
University Series (formerly Quality and
Safety Leadership Series)
------------------------------------------------------------------------
Thomas Jefferson $100,000.00 Quality and Safety Leadership
University Series
------------------------------------------------------------------------
Tree Canada $14,089.00 Operation ReLeaf Fort McMurray
------------------------------------------------------------------------
Trustees of Boston $65,000.00 National Association of
University Community Health Workers
Communications and
Organizational Development
Project
------------------------------------------------------------------------
Trustees of Boston $1,000.00 Boston University's 16th
University Annual CMD Symposium on
Molecular Discovery: From
Chemical Synthesis to
Biological Applications
------------------------------------------------------------------------
Trustees of Boston $20,000.00 iHEA's 12th World Congress in
University Health Economics
------------------------------------------------------------------------
Trustees of $5,000.00 Translational Retinal Research
University of & Therapies 2017 Symposium
Pennsylvania
------------------------------------------------------------------------
Tufts Center for the $30,000.00 Tufts CSDD 2017 Sponsorship
Study of Drug
Development c/o
Trustees of Tufts
College
------------------------------------------------------------------------
TULANE CANCER CENTER $2,500.00 NOLA Bluedoo 2017
------------------------------------------------------------------------
University of Florida $5,000.00 11th Annual Clinical Pharmacy
Foundation and Pharmacology Symposium
------------------------------------------------------------------------
University of $5,000.00 UMN John S. Najarian Lecture &
Minnesota Foundation 50 Years of Pancreas
Symposium
------------------------------------------------------------------------
University of New $1,000.00 2017 Hoops4Hope Legislative
Mexico Foundation = Basketball Game
Hoops for Hope
------------------------------------------------------------------------
University of North $20,000.00 Pharmacoepidemiology Program
Carolina at Chapel
Hill
------------------------------------------------------------------------
University of $10,000.00 Unity 2017 Conference
Southern Mississippi
Foundation
------------------------------------------------------------------------
University of Texas $50,000.00 Third Annual International
Foundation-UT Austin Immuno-Therapy in Myeloma
Scientific Workshop
------------------------------------------------------------------------
University of Utah $50,000.00 2017 Western Atrial
Fibrillation Symposium
------------------------------------------------------------------------
Us TOO International $15,000.00 Prostate Cancer Support Group
Meeting Webcast
------------------------------------------------------------------------
Us TOO International $20,000.00 Prostate Cancer News You Can
Use
------------------------------------------------------------------------
Virginia Bio $3,000.00 Women Building Bio--the XX
Factor
------------------------------------------------------------------------
Virginia Quality $1,000.00 VQHN Eighteenth Annual Wrap Up
Healthcare Network Event
------------------------------------------------------------------------
Vision y Compromiso $10,000.00 Vision y Compromiso's 15th
Annual Conference for
Promotoras and CHWs,
``Resiliency: Our Strength in
Times of Change''
------------------------------------------------------------------------
Waltham West Suburban $6,000.00 Waltham West Suburban Chamber
Chamber of Commerce, of Commerce Sponsorship
Inc. Opportunities
------------------------------------------------------------------------
Washington Legal $30,000.00 2017 General Operating Support
Foundation
------------------------------------------------------------------------
Washington Policy $3,500.00 2017 Annual Dinner
Center
------------------------------------------------------------------------
Western Governors' $10,000.00 2017-2018 Bi-annual
Foundation Conferences
------------------------------------------------------------------------
Women In Government $5,000.00 2017 Healthcare Summit--
Foundation, Inc. Inspiration Station
------------------------------------------------------------------------
Women In Government $65,000.00 2017 Healthcare Summit--
Foundation, Inc. Diabetes PSAs
------------------------------------------------------------------------
WomenHeart: The $25,000.00 2017 Wenger Awards
National Coalition
for Women with Heart
Disease
------------------------------------------------------------------------
WomenHeart: The $45,000.00 Access NOW! Key Opinion
National Coalition Leaders Thought Workshop &
for Women with Heart Congressional Briefing
Disease
------------------------------------------------------------------------
Wyoming Congressional $5,000.00 WY Congressional Award
Award Council Council's Spring Awards
ceremony
------------------------------------------------------------------------
ZERO--The End of $8,000.00 Chemotherapy and Immunotherapy
Prostate Cancer Sequencing in Prostate Cancer
Webinar
------------------------------------------------------------------------
$13,245,248.00
------------------------------------------------------------------------
Product Donations $594,228,133
made by Sanofi US to
the Sanofi
Foundation for North
Americaestimate as
of March 2018)
------------------------------------------------------------------------
Donations made by the Sanofi Foundation for North America
------------------------------------------------------------------------
Legal Name Payment Amount Project Title
------------------------------------------------------------------------
American Cancer $5,000.00 Hope Lodge of Framingham
Society Inc. Operating Support
------------------------------------------------------------------------
American Cancer $25,000.00 Nationwide American Cancer
Society Inc. Society Hope Lodge
------------------------------------------------------------------------
American National Red $25,000.00 2017-2018 American Red Cross
Cross Biomedical Services
------------------------------------------------------------------------
American Recreational $3,200.00 Project Homecoming
Military Services
------------------------------------------------------------------------
American Red Cross $10,000.00 Disaster Relief & Home Fire
Preparedness Campaign
------------------------------------------------------------------------
American Red Cross $177,422.00 Disaster Relief--special
employee match
------------------------------------------------------------------------
American Society of $5,000.00 Daniel R. Salomon Frontiers in
Transplantation Transplantation Endowment
(FITE)
------------------------------------------------------------------------
Americares $50,000.00 Hurricane Maria Response
------------------------------------------------------------------------
Americares $100,000.00 Hurricane Harvey Response
------------------------------------------------------------------------
Americares $10,000.00 U.S. Disaster Assistance
------------------------------------------------------------------------
Camp Nejeda Foundation $5,000.00 Camp Nejeda Campership Program
------------------------------------------------------------------------
Camp Nejeda Foundation $10,000.00 Camp Nejeda: Helping Kids with
Type 1 Diabetes Live Happier,
Healthier Lives
------------------------------------------------------------------------
Camp Quality USA dba $10,000.00 Camp Quality USA dba Camp
Camp Quality NJ Quality NJ
------------------------------------------------------------------------
CANCER SUPPORT $15,000.00 Teens Connect School Based
COMMUNITY CENTRAL NEW Support Groups
JERSEY
------------------------------------------------------------------------
Children's Health Fund $30,000.00 Asthma Video
------------------------------------------------------------------------
Children's Health Fund $665,000.00 Medical Home Initiative
------------------------------------------------------------------------
Children's Health Fund $665,000.00 Medical Home Initiative
------------------------------------------------------------------------
Christ the King $59,000.00 Christ the King Corporate Work
Preparatory School of Study Program
Newark NJ Corp.
------------------------------------------------------------------------
Christopher & Dana $5,000.00 Reeve Patient Care & Cures--NJ
Reeve Foundation
------------------------------------------------------------------------
Coastal Bend Food Bank $1,000.00 Diabetes Hands On
------------------------------------------------------------------------
Deirdre O'Brien Child $10,000.00 Advocacy Program for Child
Advocacy Center Inc. Victims of Abuse and/or
Neglect
------------------------------------------------------------------------
Direct Relief $100,000.00 Hurricane Harvey Response
------------------------------------------------------------------------
Direct Relief $50,000.00 Responding to Hurricane Maria
in Puerto Rico
------------------------------------------------------------------------
Direct Relief $10,000.00 Emergency Prep Programs
------------------------------------------------------------------------
Dress For Success $5,000.00 General Operating Expenses
Northern New Jersey--
10 Counties, Inc.
------------------------------------------------------------------------
Food Bank of Somerset $12,500.00 Back Pack Program
County Inc.
------------------------------------------------------------------------
Heart To Heart $25,000.00 Hurricane Relief Maria
International Inc.
------------------------------------------------------------------------
Heart To Heart $10,000.00 US Crisis Relief
International Inc.
------------------------------------------------------------------------
Heart To Heart $25,000.00 Hurricane Harvey Response
International Inc.
------------------------------------------------------------------------
Hyacinth Foundation A $10,000.00 General Support-Sanofi in Our
New Jersey Nonprofit Communities, Celebrating
Corporation Diversity
------------------------------------------------------------------------
Hyacinth Foundation A $10,000.00 General Support
New Jersey Nonprofit
Corporation
------------------------------------------------------------------------
International Myeloma $18,950.00 International Myeloma
Foundation Foundation Mission Support
------------------------------------------------------------------------
Jersey Battered $5,000.00 General Operating
Women's Service, Inc.
------------------------------------------------------------------------
Kids Corporation II $10,000.00 Kids Corp General Operating
------------------------------------------------------------------------
Map International $10,000.00 MAP's Domestic Medicine Program
------------------------------------------------------------------------
March of Dimes $86,000.00 Supporting NICU Babies and
Foundation Family's
------------------------------------------------------------------------
Matheny School and $5,000.00 Matheny Center for Medicine and
Hospital Inc. Dentistry
------------------------------------------------------------------------
Matheny School and $5,000.00 Matheny School STEM Program
Hospital Inc.
------------------------------------------------------------------------
Midland Adult Services $5,000.00 Midland Helping Hands & Midland
Inc. Meals on Wheels Employment
Training Programs
------------------------------------------------------------------------
Multiple Myeloma $18,950.00 Mambo for Myeloma
Research Foundation
------------------------------------------------------------------------
NJ SEEDS $10,000.00 Young Scholars Program--Health
Sessions
------------------------------------------------------------------------
NJ Sharing Network $5,000.00 Multicultural Outreach
Foundation Initiative
------------------------------------------------------------------------
Partners in Research $25,000.00 Sanofi Biogenius Canada
Canada
------------------------------------------------------------------------
PATIENT EMPOWERMENT $25,000.00 ASCO, AUA Coverage for Advanced
NETWORK Prostate Cancer Patients
------------------------------------------------------------------------
Rise Against Hunger $7,500.00 Rise Against Hunger Disaster
Ready Response Program
------------------------------------------------------------------------
Rutgers University $10,000.00 Vets4Warriors
Foundation
------------------------------------------------------------------------
Safe + Sound Somerset $10,000.00 Residential Children's Program
------------------------------------------------------------------------
Sheltered Yoga $5,000.00 Sheltered Yoga NJ Programming
------------------------------------------------------------------------
Somerset County YMCA $6,000.00 Somerville YMCA/Annual Campaign
------------------------------------------------------------------------
Somerset Health Care $5,000.00 Quality CPR Saves Lives
Foundation
------------------------------------------------------------------------
Somerset Health Care $10,000.00 El poder
Foundation
------------------------------------------------------------------------
Somerset Health Care $10,000.00 El poder
Foundation
------------------------------------------------------------------------
Somerset Health Care $18,560.00 1st Healthcare Conference for
Foundation the LGBT Community
------------------------------------------------------------------------
Somerset Health Care $5,000.00 Quality CPR Saves Lives
Foundation
------------------------------------------------------------------------
The Center For Great $10,000.00 Adult Women & their Children
Expectations Inc.
------------------------------------------------------------------------
The Center For Great $10,000.00 Adult Women & their Children
Expectations Inc.
------------------------------------------------------------------------
The Children's Inn at $500,000.00 Sanofi US Legacy Endowment Fund
NIH, Inc. at The Children's Inn at NIH
Sanofi US Legacy Endowment
Fund at The Children's Inn at
NIH
------------------------------------------------------------------------
The Children's Inn at $500,000.00 Sanofi US Legacy Endowment Fund
NIH, Inc. at The Children's Inn at NIH
------------------------------------------------------------------------
The Children's Inn at $500,000.00 Sanofi US Legacy Endowment Fund
NIH, Inc. at The Children's Inn at NIH
------------------------------------------------------------------------
THE LEUKEMIA & $18,950.00 Fiscal Year 2017 Myeloma
LYMPHOMA SOCIETY Patient Education
------------------------------------------------------------------------
The Partnership for $5,000.00 General Support for PQMD
Quality Medical
Donations
------------------------------------------------------------------------
The Salvation Army $10,000.00 Healthy Food Pantry Program
------------------------------------------------------------------------
Trustees of University $20,000.00 Research Training in
of Pennsylvania Pharmacoepidemiology
------------------------------------------------------------------------
Tyler Clementi $5,000.00 New Jersey Programs
Foundation Inc
------------------------------------------------------------------------
United Way of Monroe $59,069.70 SP 2017 UW Campaign Match
County
------------------------------------------------------------------------
United Way of Northern $75,000.00 Caregivers Coalition
New Jersey
------------------------------------------------------------------------
Visiting Nurse $10,000.00 General Operating
Association of
Somerset Hills
------------------------------------------------------------------------
$3,682,101.70
------------------------------------------------------------------------
Grand Total $16,927,350
------------------------------------------------------------------------
Sponsorships and Charitable Donations
1st Jan 2015-31st Dec 2015
Sanofi US and its affiliate Genzyme Corporation are committed to
supporting sponsorships for specific activities and initiatives of
healthcare organizations and institutions, independent medical or
professional societies, trade organizations and organized patient groups
to improve patient care and provide information to the medical and/or
patient communities. The goal of our charitable giving approach is to
fund general operational support for patient/disease organizations, or
program support for community-based organizations. Sanofi US and Genzyme
Corporation are part of the Sanofi Group, a global pharmaceutical
company.
Applicant names are provided by the requestor. If applicants apply as a
group for a single activity; all applicants may be not be identified
above. ``Funding Amount'' is the amount that the Company funded during
2015 identified above. ``Funding Amount'' does not include funds that
may have been provided by other affiliated Sanofi Company Entities
(e.g., Sanofi Pasteur).
Recipient Name(s) Activity Title Funding Amount
Acacia In Kenya Volunteer Match $1,000.00
Acacia In Kenya Volunteer Match $1,000.00
Accelerated Cure MS Discovery: The Podcast of $102,400.00
Project the MS Discovery Forum
Accelerated Cure Data Visualizations in $89,400.00
Project Multiple Sclerosis
Acid Maltase Deficiency AMDA Patient Education $35,000.00
Association Inc. Programs
Acid Maltase Deficiency The 2015 AMDA/IPA $20,000.00
Association Inc. International Pompe Patient
and Scientific Conference
Acid Maltase Deficiency AMDA Patient Education $12,000.00
Association Inc. Programs
Acid Maltase Deficiency Pull for Pompe Event $3,000.00
Association Inc.
ALD Connect Inc. ALD Connect Meeting $4,000.00
Alport Syndrome 2015 International Workshop $2,500.00
Foundation, Inc. on Alport Syndrome
American Academy of 2015 Palatucci Advocacy $50,000.00
Neurology Institute Leadership Forum
American Academy of Fellows Scholarship Program $20,000.00
Neurology Institute
American Academy of Residents Scholarship Program $20,000.00
Neurology Institute
American Academy of 2014-2015 Emerging Leaders $17,500.00
Neurology Institute Forum
American Academy of Brain Health Fair $10,000.00
Neurology Institute
American Association of 2015 Pan-American Scientific $50,000.00
Clinical Symposia on Clinical
Endocrinologists Endocrinology in Latin
America
American Autoimmune and 50 Cents for 50 Million $5,000.00
Related Diseases Campaign AND Fight For
Association Immunity Comedy Show
American Chemical ACS BIOT 2015 Annual Meeting $5,000.00
Society Merck And Co
Inc.
American College of Summer Genetics Scholars $75,000.00
Medical Genetics Program
Foundation
American Physiological Experimental Biology 2015 $3,000.00
Society
American Red Cross of Women Who Care, A Leadership $5,000.00
Massachusetts Breakfast
American Society of ASGCT 18th Annual Meeting $5,000.00
Gene Therapy
American Society of ASN Kidney Week 2015 $30,000.00
Nephrology Exhibitor Spotlight
Andrew's Buddies FightSMA Annual Research $3,000.00
Corporation dba Conference 2015
FightSMA
ANERA (American Near ANERA (American Near East $5,000.00
East Refugee Aid) Refugee Aid) Annual Dinner
Ann & Robert H. Lurie MPS Patient and Family $2,000.00
Children's Hospital of Conference
Chicago
Arizona Kidney 16th Annual Southwest $6,000.00
Foundation Nephrology Conference
Ashland Fire Department Community Support for Ashland $40,000.00
Association Fire Department Association
Assistance Fund Inc. Multiple Sclerosis Disease $5,300,000.00
Patient Assistance Fund
Program
Assistance Fund Inc. Multiple Sclerosis Disease $500,000.00
Patient Assistance Fund
Program
Association For Annual Conference; Family $6,000.00
Glycogen Storage Assistance; The Ray
Disease
Beauty Bus Foundation 6th Annual Beauty Drive for $3,000.00
Patients and Caregivers
Berkshire Resource 2015 Annual Gala $5,000.00
Project, Inc.
Big Brothers Big Big Brothers Big Sisters $10,000.00
Sisters of Central Central Mass/Metrowest
Mass Metrowest Inc. (BBBSCM) STEM Institute
Biomedical Science Evening of Hope: To support $75,000.00
Careers Program underrepresented minority
students/fellows interested
in science
Biomedical Science Hope Scholarship 2015-2016 $7,500.00
Careers Program
Boston Health Care For Life Essentials Community $25,000.00
The Homeless Program Support Program
Inc.
Boston Plan For Boston Teacher Residency: A $15,000.00
Excellence in the High-Quality Pipeline for
Public Schools Boston Public Schools' STEM
Foundation Teachers
Boston Private Industry 2015 Corporate Contribution's $15,000.00
Council Campaign
Boston Private Industry Volunteer Match $1,000.00
Council
Bottom Line Boston STEM Success Program $15,000.00
Boys and Girls Clubs of Staffing & Transportation for $25,000.00
MetroWest Increased Membership at
BGCMW's Framingham Clubhouse
Boys and Girls Clubs of 2015 Bids for Kids Auction & $10,000.00
MetroWest Gala
Boys and Girls Clubs of Volunteer Match $4,000.00
MetroWest
Boys and Girls Clubs of The 2015 Great Pumpkin Glow $5,000.00
Middlesex County Inc.
Breakthrough Greater Full STEAM (Science $10,000.00
Boston Technology, Engineering,
Arts, and Math) Ahead
Program
Cambridge Family & 2015 Circle of Friends Gala & $5,000.00
Children's Service Auction
Cambridge School Volunteer Match $1,000.00
Volunteers, Inc.
Camp Korey Metabolic Disorders Family $5,000.00
Weekend
Can Do Multiple 2015 TAKE CHARGE Program $55,000.00
Sclerosis
Can Do Multiple Can Do Program $50,000.00
Sclerosis
Can Do Multiple 2015 JUMPSTART Program $50,000.00
Sclerosis
Can Do Multiple Can Do 2015 Online $40,000.00
Sclerosis Programming
Can Do Multiple Vertical Express for Can Do $25,000.00
Sclerosis MS Events
Canavan Foundation Jewish Genetic Disease $4,500.00
Leadership Database
Expansion Project
Case Management Society CMSA 25th Annual Conference & $14,000.00
of America Expo
Case Management Society CMSA 25th Annual Conference & $4,800.00
of America Expo (Booth)
Case Management Society Case Management Society of $1,000.00
of New England New England's 26th Annual
Conference and Exhibitor
Expo
CASSS--An International CMC Strategy Forums $2,500.00
Separation Science
Society
Charcot-Marie-Tooth CMTA's Boston Patient/Family $5,000.00
Association Conference
Charcot-Marie-Tooth CMTA's Boston Patient/Family $2,000.00
Association Conference
Children's Hospital Global Pediatric Innovation $20,000.00
Boston Summit + Awards 2015
Children's Hospital La Gala de Milagros para $5,000.00
Corporation Ninos
Church Hillers Inc. Volunteer Match $1,000.00
City Sprouts, Inc. After School Ecology Clubs $7,000.00
Colon Cancer Coalition Volunteer Match $2,000.00
Community Boating, Inc. Universal Access Program $15,000.00
2015--Patient Assistance
Program
Community Farms Fresh Food Access Program $12,000.00
Outreach
Community Rowing, Inc. Let's Row Boston $15,000.00
Community Servings, Pie in the Sky $10,000.00
Inc.
Consortium of Multiple 29th Annual Meeting of the $52,000.00
Sclerosis Centers Consortium of Multiple
Sclerosis Centers Breakfast
Council on Renal Patient Empowerment Workshop $1,000.00
Nutrition of Western
PA
Courage to Make a Courage: Living life without $1,000.00
Difference Inc. limit patient videos
Cradles to Crayons Inc. Ready for School and Backpack- $20,000.00
a-Thon
Cystic Fibrosis Uncork the Cure Event $10,000.00
Foundation
DEAF, Inc.-- Deaf-Accessible Medical Case $10,000.00
Developmental Management and Health
Evaluation and Education
Adjustment Facilities,
Inc.
Deliver The Dream Inc. Community Champions Awards $2,500.00
Department of Neurology Shop to Stop Multiple $10,000.00
Multiple Sclerosis Sclerosis
Center of Excellence
Dimock Community Health Building the Road to $150,000.00
Center Recovery--Expanding and
Renovating Acute Treatment
Services
DISARM Education FUND, Combating Rare Diseases and $20,000.00
INC. Raising Awareness in the
Developing World
East End House Inc. Generating and Evaluating New $20,000.00
Adventures in Science After
School (GENASAS)
East End House Inc. Volunteer Match $2,000.00
Emory Genetics LSDC Patient Meetings $27,390.00
Laboratory
Engineering Conferences Integrated Continuous $10,000.00
International Biomanufacturing II
Conference
EveryLife Foundation Rare Voice Awards Gala $20,000.00
for Rare Diseases
EveryLife Foundation EveryLife Foundation Annual $10,000.00
for Rare Diseases Rare Disease Scientific
Workshop: Patient Engagement
in the Clinical Development
Process
Fabry Support & FSIG Expert Fabry Conference $50,000.00
Information Group 2015
Fabry Support & FSIG Patient Assistance Fund $40,000.00
Information Group
Fabry Support & FSIG Patient Assistance Fund $40,000.00
Information Group
Fabry Support & Rapid Assistance Funds-- $30,000.00
Information Group Patient Assistance Program
Fabry Support & FSIG Newsletter $12,000.00
Information Group
Fabry Support & 2015 FSIG Fabry Fun Run/Walk $1,500.00
Information Group & FSIG Fabry Get Together
Meeting
Family Promise Keep the Promise: An evening $2,500.00
Metrowest Inc. of food tasting to benefit
families that are homeless
Foundation of the 2016 CMSC Annual Meeting-- $414,000.00
Consortium of Multiple Celebrating 30 Years of MS
Sclerosis Centers Care
Foundation of the FCMSC 2015-2016 Pilot $44,000.00
Consortium of Multiple Research Grant Award in
Sclerosis Centers Multiple Sclerosis
Foundation of the NARCOMS Now Patient Quarterly $33,358.00
Consortium of Multiple Magazine
Sclerosis Centers
Foundation of the 2015-2016 FCMSC Medical $22,000.00
Consortium of Multiple Resident Annual Meeting
Sclerosis Centers Scientific Scholarships
Foundation of the 2015-2016 Workforce of the $22,000.00
Consortium of Multiple Future: Medical Student
Sclerosis Centers Scholarships
Framingham Townwide PTO Volunteer Match $1,000.00
Council
Franciscan Children's Adaptive Sports Program for $10,000.00
Hospital and Children with Disabilities
Rehabilitation Center
Friends of Hopkinton Community Support for general $4,000.00
SPEAC operating
Friends of Resiliency Academic Support component of $10,000.00
for Life Inc. Resiliency for Life (RFL)
Friends of Resiliency Volunteer Match $1,000.00
for Life Inc.
Friends of the Community Support for Friends $16,000.00
Hopkinton Seniors group to raise funds for
nutrition programs
FSH Society, Inc. FSH Society $2,000.00
Facioscapulohumeral Muscular
Dystrophy [FSHD] 2015
International Research
Consortium & Research
Planning Meetings
Fundacion de Esclerosis MS Community Educational $20,000.00
Multiple de Puerto Conferences
Rico
Fundacion de Esclerosis Abrazarte a la vida Patient $2,500.00
Multiple de Puerto Fundraising Event
Rico
Gateway Area Chapter Community Walk MS 2015 $5,000.00
Gateway Area Chapter Women on the Move Luncheon $2,500.00
2015
Generation Citizen Inc. Generation Citizen Spring $5,000.00
2015 Civics Day
Georgia Chapter of the Non-AAP industry/foundation $3,500.00
American Academy of symposium
Pediatrics
Girl Scouts of Eastern Girls Building Self-esteem $10,000.00
Massachusetts Inc.
Global Genes 4th Annual RARE Tribute to $25,000.00
Champions Event
Global Genes Global Genes RARE Patient $25,000.00
Advocacy Summit
Global Genes Global Genes Corporate $15,000.00
Alliance Program
Global Genes Give RARE Disease Giving Day $10,000.00
Global Genes Pixar's The Good Dinosaur-- $10,000.00
Exclusive Screening &
Fundraiser
Global Genes Tribute to Champions-- $7,460.00
Expression of Hope Art
Exhibit
Global Genes RARE Toolkit & Educational $5,000.00
Podcast Programs
Gordon Research Lysosomal Diseases Gordon $5,000.00
Conferences Research Conference and
Gordon Research Seminar
Gordon Research 2015 CAG Repeat Disorders $2,000.00
Conferences Gordon Research Conference
Greater Boston Chamber Chamber's 2015 Annual Meeting $10,000.00
of Commerce
Habitat For Humanity Holliston Build Project $15,000.00
Metrowest--Greater
Worcester Inc.
Habitat For Humanity Volunteer Match $2,000.00
Metrowest--Greater
Worcester Inc.
Health Care For All Ethnic Media and Grassroots $10,000.00
Inc. Outreach to Improve Health
Coverage Access in
Framingham
Health Technology HTAI Annual Meeting 2015 $20,000.00
Assessment
International
Hearts & Noses Hospital Ongoing Hospital Clown Visits $15,000.00
Clown Troupe Inc. to Ill and Disabled Children
in Greater Boston
Holy Name Health Care 18th Annual Spring Fashion $15,000.00
Foundation Inc. Fling for MS
Horizons for Homeless 17th Annual Women's Breakfast $3,500.00
Children
Huntington Study Group HSG 2015: Building Our Future $1,500.00
Ltd.
Huntington's Disease Huntington's Disease Society $2,500.00
Society of America of America 30th Annual
Convention
Icahn School of 13th Annual Gala in Support $25,000.00
Medicine at Mount of the Corinne Goldsmith
Sinai Dickinson Center for
Multiple Sclerosis at Mount
Sinai
Icahn School of 13th Annual Gala in Support $12,000.00
Medicine at Mount of the Corinne Goldsmith
Sinai Dickinson Center for
Multiple Sclerosis at Mount
Sinai
International 2015 MS Perspectives $75,000.00
Organization of Publication
Multiple Sclerosis
Nurses
International 2015 Annual Meeting IOMSN $30,000.00
Organization of Dinner
Multiple Sclerosis
Nurses
International Society Glycoproteinoses: Fourth $5,000.00
For Mannosidosis & International Conference on
Related Disease Inc. Advances in Pathogenesis and
Therapy
International Society 31st International Conference $2,000.00
For on Pharmacoepidemiology
Pharmacoepidemiology
International Society ISN Forefronts $3,500.00
of Nephrology ``Immunomodulation of Cardio-
Renal Function--A focus on
cardio-renal pathophysiology
and immunity'' (Oct 22-25,
2015, Shenzhen, China)
Italian Home For City Lights Gala $5,000.00
Children Inc.
Japan Society of Boston 2015 Japan Society of Boston $5,000.00
Annual Dinner
Jewish Federation of Expanding Footprint of Jewish $10,000.00
southern New Jersey Genetic Disease Awareness in
South Jersey
Jewish Genetic Disease Jewish Genetic Disease $5,000.00
Consortium (JGDC) Consortium Screening
Awareness Program
Jewish Genetic Diseases PHOENIX--Our Heritage and our $980.00
Center of Greater Health--Ashkenazi Jewish
Phoenix Genetics Disease and the
Founder Effect
Jewish Genetic Diseases TUCSON--Our Heritage and our $950.00
Center of Greater Health--Ashkenazi Jewish
Phoenix Genetic Disease and the
Founder Effect
Joseph M. Smith JMSCHS's Prenatal Program $15,000.00
Community Health
Center, Inc.
Kidney Foundation of 24th Annual Wine Affair Event $1,000.00
Northwest Ohio for Disease Awareness
Kidney Foundation of Kilometers for Kidneys $500.00
Northwest Ohio
Light of Life Light of Life Foundation 2015 $25,000.00
Foundation Patient Support Activities
Light of Life Light of Life Foundation $20,000.00
Foundation Patient Awareness Program
Light of Life Light of Life Foundation $1,000.00
Foundation Night of Comedy Fundraiser
Little Brothers/Friends Medical Escort/Transport and $7,500.00
of the Elderly Prescription Escort Patient
Assistance Program
Little Miss Hannah Little Miss Hannah Foundation $8,000.00
Foundation General Operating Support
Little Miss Hannah Little Miss Hannah's Rainbows $1,000.00
Foundation in the Wind Festival
Lysosomal and Rare Towards a patient-centered $10,000.00
Disorders Research and disease registry; Connecting
Treatment Center Inc. the patches for Gaucher
Disease
March of Dimes March for Babies $15,000.00
March of Dimes Black Ties for Babies Gala $10,000.00
March of Dimes Volunteer Match $2,000.00
March of Dimes Volunteer Match $1,000.00
March of Dimes Volunteer Match $1,000.00
Margaret Fuller Scholarships for Port/Area IV $15,000.00
Neighborhood House Youth to Attend Summer Camp
at Margaret Fuller House
Mass Insight Education College Success Program $15,000.00
and Research Institute
Inc.
Massachusetts Bay STEM Mentor Program $26,500.00
Community College
Foundation
Massachusetts Patient Advocacy Summit--Live $10,000.00
Biotechnology Council & Breathe: Building a
Patient Centered Biotech
Massachusetts BioTeach Life Sciences $50,000.00
Biotechnology Student Program
Education Foundation
Inc.
Massachusetts Institute Cambridge Science Festival $5,000.00
of Technology
Massachusetts Outdoor DFW Plymouth Red-bellied $5,000.00
Heritage Foundation Cooter Head-starting Program
Inc.
Massachusetts Outdoor Volunteer Match $1,000.00
Heritage Foundation
Inc.
Massachusetts State Massachusetts State Science & $50,000.00
Science and Engineering Fair
Engineering Fair, Inc.
Mercy Foundation Mercy Multiple Sclerosis (MS) $20,000.00
Achievement Center Wellness
Programs
Metrowest Free Medical Chronic Disease Patient $10,000.00
Program Inc. Assistance Program
Mid America MS The Race to Nowhere 2015 $5,000.00
Achievement Center
Mid America MS The Race to Nowhere 2015 $2,500.00
Achievement Center
Mid America MS Eat Bid Laugh Event $2,500.00
Achievement Center benefiting the Mid-America
Multiple Sclerosis
Achievement Center (MSAC) in
Kansas City
Milwaukee Synagogue for Gaucher Disease Education $5,000.00
Russian Jews Program
MLD Foundation RUSP Roundtable $4,000.00
MS Cure Fund Women Thriving With MS $125,000.00
MS Cure Fund Risks & Benefits Program $103,700.00
MS Cure Fund Resource Information Database $12,360.00
Conversion and Website
Integration
MS Cure Fund MS Cure Newsletter $10,000.00
MS Cure Fund Lifestyle Management Programs $8,250.00
Fall 2015
MS Hope for a Cure Inc. 2015 MS Cycle for a Cure--A $5,000.00
Ride for Research (6 event
sites)
MS Views and News Inc. 2015--MS Symposium SERIES-- $64,491.00
``The Neurological Aspects
of MS''
MS Views and News Inc. Empowering MS Communities in $46,000.00
America's Heartland series--
2
MS Views and News Inc. BRING IT ON!--``Everything $27,835.00
You Want to Know about MS''
a Q&A program
MS Views and News Inc. Empowering MS Communities in $22,000.00
America's Hearthland series
MS Views and News Inc. Women's Health Issues with $16,924.75
Multiple Sclerosis
MS Views and News Inc. New and Emerging Therapies $15,925.00
plus Invisible Symptoms of
MS
MS Views and News Inc. New and Emerging Treatment $14,750.00
Options plus Invisible
Symptoms of MS--Chicago
MS Views and News Inc. BRING IT ON!--Everything you $12,295.00
want to Know about MS--Q&A
MS Views and News Inc. Women's Health with Multiple $9,582.00
Sclerosis
MS Views and News Inc. Men's Health Issues with $9,178.50
Multiple Sclerosis
MS Views and News Inc. 2015 Renewal of Annual $7,900.00
Display Sponsorship
MS Views and News Inc. MS Views and News--5th Annual $3,000.00
Bowlathon Fundraiser to
Benefit MS Education and
Stem Cell Research
MSWorld, Inc. 2015 MSWorld Conference $20,000.00
Coverage
MSWorld, Inc. 2015 MSWorld ``Wellness $20,000.00
Unleashed Program''
Multiple Sclerosis Crossfire: The Science and $436,320.00
Association of America Emotion of Risk
Multiple Sclerosis MSAA MRI Patient Assistance $350,000.00
Association of America Fund
Multiple Sclerosis Hot Topics in Multiple $217,941.00
Association of America Sclerosis: An Interactive
Series of MS Patient
Education Programs
Multiple Sclerosis Swim for MS In Person Program $58,985.00
Association of America Pilot Series
Multiple Sclerosis MSAA's 2015 Improving Lives $15,000.00
Association of America Benefit
Multiple Sclerosis MS Festival Program $10,000.00
Center of Georgia
Multiple Sclerosis Health, Hope & Hops Program $7,000.00
Center of Georgia
Multiple Sclerosis Foundation's Assistive $50,000.00
Foundation Technology Program
Multiple Sclerosis Support Group News quarterly $27,300.00
Foundation informational newsletter
Multiple Sclerosis African Americans with MS-- $20,000.00
Foundation The Medical, Cultural and
Psychological Differences
Multiple Sclerosis Resource Website $117,367.00
International Communications Support
Federation Foundation
Inc.
Multiple Sclerosis Middle East Patient Awareness $78,245.00
International Program
Federation Foundation
Inc.
Multiple Sclerosis Arab Region Patient Awareness $60,117.00
International Program
Federation Foundation
Inc.
Multiple Sclerosis World MS Day 2015 Campaign $46,947.00
International
Federation Foundation
Inc.
Multiple Sclerosis Latin America Resource $41,950.00
International Analysis Project
Federation Foundation
Inc.
Multiple Sclerosis Global Patient Awareness $39,122.00
International Program
Federation Foundation
Inc.
Multiple Sclerosis MSQLP's 9th Annual Walk 'n $1,500.00
Quality of Life Roll Fundraiser
Project Corporation
Multiple Sclerosis 2015 Mission Steps Wak & MS $8,000.00
Resources of Central Awareness Day
New York, Inc.
Muscular Dystrophy Muscle Walk 2015 $1,000.00
Association--Lake
Mary, FL
Muscular Dystrophy 2015 MDA Muscle Summit $8,000.00
Association--Alameda,
CA
Muscular Dystrophy MDA Newsletter $2,000.00
Association--Albany,
NY
Muscular Dystrophy 2015 MDA Research Seminar $2,000.00
Association--Albany,
NY
Muscular Dystrophy New Mexico MDA Muscle Walk $1,000.00
Association--Albuquerq
ue, NM
Muscular Dystrophy 2015 MDA Muscle Summit $8,000.00
Association--Allentown
, PA
Muscular Dystrophy Muscle Walk Greater Lehigh $1,000.00
Association--Allentown Valley
, PA
Muscular Dystrophy 17th Annual Black and Blue $5,000.00
Association--Ark Ball
Valley, Richmond, VA
Muscular Dystrophy Muscle Walk Greater Fort $1,000.00
Association--Ark Wayne
Valley, Richmond, VA
Muscular Dystrophy Muscle Walk Ft Myers, FL $1,000.00
Association--Ark
Valley, Richmond, VA
Muscular Dystrophy Muscle Walk Pittsburgh $1,000.00
Association--Ark
Valley, Richmond, VA
Muscular Dystrophy Muscle Walk Springfield, MO $1,000.00
Association--Ark
Valley, Richmond, VA
Muscular Dystrophy Muscle Walk Richmond, VA $1,000.00
Association--Ark
Valley, Richmond, VA
Muscular Dystrophy Muscle Walk Central Texas $1,000.00
Association--Austin,
TX
Muscular Dystrophy 2015 Muscular Dystrophy $1,000.00
Association--Billings, Summer Camp of Montana
MT
Muscular Dystrophy Muscle Walk Montana $1,000.00
Association--Billings,
MT
Muscular Dystrophy MDA Health Patient Care $1,000.00
Association - Services Program
Birmingham, AL
Muscular Dystrophy MDA Idaho Summer Camp $1,000.00
Association--Boise, ID
Muscular Dystrophy MDA Superhero Muscle Walk and $1,000.00
Association--Boise, ID 5k Fun Run
Muscular Dystrophy Muscle Walk of Chattanooga $2,500.00
Association--Brentwood
, TN
Muscular Dystrophy Muscle Walk of Nashville $1,000.00
Association--Brentwood
, TN
Muscular Dystrophy 2015 Nashville Muscle Team $1,000.00
Association--Brentwood Gala
, TN
Muscular Dystrophy Muscle Walk of Nashville $1,000.00
Association--Brentwood
, TN
Muscular Dystrophy Muscle Walk of Greater $1,000.00
Association--Brookfiel Milwaukee
d, WI
Muscular Dystrophy Muscle Walk of Greater $1,000.00
Association--Brookfiel Madison
d, WI
Muscular Dystrophy Muscle Walk 2015 $1,000.00
Association--Broomall,
PA
Muscular Dystrophy Muscle Walk Quad Cities $1,000.00
Association--Cedar
Rapids, IA
Muscular Dystrophy Muscle Walk Des Moines $1,000.00
Association--Cedar
Rapids, IA
Muscular Dystrophy Muscle Walk Iowa City $1,000.00
Association--Cedar
Rapids, IA
Muscular Dystrophy Muscle Walk Iowa City $1,000.00
Association--Cedar
Rapids, IA
Muscular Dystrophy Muscle Walk Waterloo $1,000.00
Association--Cedar
Rapids, IA
Muscular Dystrophy Muscle Walk Des Moines $1,000.00
Association--Cedar
Rapids, IA
Muscular Dystrophy Mucscle Walk Morgantown $1,000.00
Association--Charlesto
n, WV
Muscular Dystrophy Muscle Walk 2015 $1,000.00
Association--Charlotte
, NC
Muscular Dystrophy MDA--LGMD Genetic Testing $700,000.00
Association--Chicago, Program
IL
Muscular Dystrophy MDA Pompe Testing Program $60,000.00
Association--Chicago,
IL
Muscular Dystrophy 2015 Muscle Summit $8,000.00
Association--Chicago,
IL
Muscular Dystrophy MDA Illinois Muscle Summit $8,000.00
Association--Chicago,
IL
Muscular Dystrophy Muscular Dystrophy $2,000.00
Association--Chicago, Association, Third Quarter
IL Newsletter
Muscular Dystrophy Muscle Walk 2015 $1,000.00
Association--Chicago,
IL
Muscular Dystrophy MDA-ALS Muscle Walk $1,000.00
Association--Chicago,
IL
Muscular Dystrophy 2015 Southern Ohio Muscular $1,000.00
Association--Cincinnat Dystrophy Association Summer
i, OH Camp
Muscular Dystrophy Muscle Walk of Greater $1,000.00
Association--Cincinnat Cincinnati
i, OH
Muscular Dystrophy Muscle Walk of Greater $1,000.00
Association--Cleveland Cleveland
, OH
Muscular Dystrophy MDA Winter Newsletter $2,500.00
Association--Columbia,
SC
Muscular Dystrophy Road Map to Independence for $2,000.00
Association--Columbia, Young Adults Resource
SC Program
Muscular Dystrophy MDA Fall Newsletter $2,000.00
Association--Columbia,
SC
Muscular Dystrophy Muscle Walk $1,000.00
Association--Columbia,
SC
Muscular Dystrophy Muscle Walk of Denver $1,000.00
Association--Denver,
CO
Muscular Dystrophy Muscle Walk of Chicagoland & $2,000.00
Association--Downers Muscle Walk of Rockford
Grove, IL
Muscular Dystrophy Muscle Walk 2015 $1,000.00
Association--El Paso,
TX
Muscular Dystrophy Muscle Walk Greater Mishawaka $1,000.00
Association--Fort
Wayne, IN
Muscular Dystrophy Muscle Walk of Greater $1,000.00
Association--Fort Mishawaka
Wayne, IN
Muscular Dystrophy Muscle Walk Western Colorado $1,000.00
Association--Grand
Junction, CO
Muscular Dystrophy Partners in Progress: an MDA $5,000.00
Association--Green Muscle Symposium
Bay, WI
Muscular Dystrophy Muscle Walk of Green Bay $1,000.00
Association--Green
Bay, WI
Muscular Dystrophy Muscle Walk 2015 $1,000.00
Association--Greenvill
e, SC
Muscular Dystrophy Limb-Girdle Muscular $10,000.00
Association--Harrisbur Dystrophy Education Program,
g, PA First Quarter, 2015
Muscular Dystrophy 2015 Central PA MDA Muscle $8,000.00
Association--Harrisbur Summit
g, PA
Muscular Dystrophy Muscle Walk Central PA $1,000.00
Association--Harrisbur
g, PA
Muscular Dystrophy Muscle Walk Hawaii $1,500.00
Association--Honolulu,
HI
Muscular Dystrophy Muscle Walk Houston $1,000.00
Association--Houston,
TX
Muscular Dystrophy Patient and Family Healthcare $2,000.00
Association--Jacksonvi Newsletter
lle, FL
Muscular Dystrophy Muscle Walk 2015 $1,000.00
Association--Knoxville
, TN
Muscular Dystrophy Muscle Walk $1,000.00
Association--Knoxville
, TN
Muscular Dystrophy Family Engagement Events $1,000.00
Association--Knoxville
, TN
Muscular Dystrophy Muscle Walk $1,000.00
Association--Las
Vegas, NV
Muscular Dystrophy Muscle Walk of Little Rock $1,000.00
Association--Little
Rock, AR
Muscular Dystrophy MDA Summer Camp $5,000.00
Association--Los
Angeles, CA
Muscular Dystrophy Muscle Walk Louisville $1,000.00
Association--Louisvill
e, KY
Muscular Dystrophy Muscle Walk $1,000.00
Association--Louisvill
e, KY
Muscular Dystrophy MDA Conference $1,500.00
Association--Mancheste
r, NH
Muscular Dystrophy Muscle Walk St Louis $1,000.00
Association--Maryland
Heights, MO
Muscular Dystrophy 2015 Central New Jersey MDA $8,000.00
Association--Maywood, Muscle Summit
NJ
Muscular Dystrophy 2nd Quarter/4th Quarter Print $2,000.00
Association--Maywood, Newsletters 2015
NJ
Muscular Dystrophy Muscle Walk $1,000.00
Association--Memphis,
TN
Muscular Dystrophy Muscle Walk 2015 $1,000.00
Association--Metairie,
LA
Muscular Dystrophy Muscle Walk Baton Rouge $1,000.00
Association--Metairie,
LA
Muscular Dystrophy MDA South Alabama Chapter $2,000.00
Association--Montgomer Quarterly Family Newsletter
y, AL
Muscular Dystrophy Muscular Dystrophy $2,000.00
Association--New Association 2015 2nd Quarter
Haven, CT Newsletter
Muscular Dystrophy Muscle Walk Metro NY $1,000.00
Association--New York,
NY
Muscular Dystrophy Muscular Dystrophy $2,000.00
Association--North Association 1st Quarter 2015
Haven, CT Newsletter
Muscular Dystrophy 18th Annual MDA Black and $2,000.00
Association--North Blue Ball
Haven, CT
Muscular Dystrophy Muscular Dystrophy $1,500.00
Association--North Association 2015 3rd Quarter
Haven, CT Newsletter
Muscular Dystrophy 2015 Mohegan Sun Southern New $1,000.00
Association--North England MDA Muscle Walk
Haven, CT
Muscular Dystrophy Muscle Walk of Greater $1,000.00
Association--Okemos, Lansing Area
MI
Muscular Dystrophy Muscle Walk $1,000.00
Association--Okemos,
MI
Muscular Dystrophy Muscle Walk 2015 $1,000.00
Association--Omaha, NE
Muscular Dystrophy Muscle Walk Medford $1,000.00
Association--Portland,
OR
Muscular Dystrophy Muscle Walk $1,000.00
Association--Portland,
OR
Muscular Dystrophy Muscle Walk Raleigh $1,000.00
Association--Raleigh,
NC
Muscular Dystrophy Muscle Walk 2015 $1,000.00
Association--Reston,
VA
Muscular Dystrophy Fall 2015 Newsletter $1,200.00
Association--Rochester
, NY
Muscular Dystrophy Muscle Walk 2015 $1,000.00
Association--Salt Lake
City, UT
Muscular Dystrophy Muscle Walk Salt Lake City $1,000.00
Association--Salt Lake
City, UT
Muscular Dystrophy Muscle Walk San Antonio & 5K $1,000.00
Association--San Fun Run
Antonio, TX
Muscular Dystrophy Muscle Walk Twin Cities $1,500.00
Association--Shrevepor
t, LA
Muscular Dystrophy Patient Newsletter $1,500.00
Association--Southfiel
d, MI
Muscular Dystrophy MDA Summer Camp 2015 $1,000.00
Association--Spokane,
WA
Muscular Dystrophy Muscle Walk Spokane $1,000.00
Association--Spokane,
WA
Muscular Dystrophy MDA Summer Camp 2015 $1,000.00
Association--St
Petersburg, FL
Muscular Dystrophy MDA Summer Camp 2015 $1,000.00
Association--St
Petersburg, FL
Muscular Dystrophy Muscle Walk Tampa Bay $1,000.00
Association--St
Petersburg, FL
Muscular Dystrophy MDA Muscle Walk--Exhibit $1,000.00
Association--Tempe, AZ Booth for Patient Education
Muscular Dystrophy MDA Muscle Walk Tucson-- $1,000.00
Association--Tempe, AZ Exhibit Booth for Patient
Education
Muscular Dystrophy Muscle Walk of Baltimore $1,000.00
Association--Towson,
MD
Muscular Dystrophy Muscle Walk Ark-La-Tex $1,000.00
Association--Tucson,
AZ
Muscular Dystrophy Muscle Walk Central New $1,000.00
Association--Tucson, Jersey
AZ
Muscular Dystrophy MDA 4th Quarter Newsletter $2,000.00
Association--Warwick,
RI
Muscular Dystrophy Newsletter-CAMP $2,000.00
Association--Westborou
gh, MA
Muscular Dystrophy Volunteer Match $1,000.00
Association--Westborou
gh, MA
Muscular Dystrophy Quarterly Newsletter $3,000.00
Association--Westbrook
, ME
Muscular Dystrophy Pompe Support Dinner $2,000.00
Association--Westbrook
, ME
Muscular Dystrophy Pompe Awareness and Education $1,500.00
Association--Westbrook Day
, ME
Muscular Dystrophy Pompe Awareness and $1,000.00
Association--Westbrook EducationDay
, ME
Muscular Dystrophy Limb-Girdle Support Group $1,000.00
Association--Westbrook
, ME
Muscular Dystrophy Muscle Walk Maine $1,000.00
Association--Westbrook
, ME
Muscular Dystrophy 2015 MDA Muscle Walk and $2,000.00
Association--Wilmingto Educational Symposium
n, NC
Muscular Dystrophy Muscle Walk of Greenville and $1,500.00
Association--Wilmingto Patient Educational
n, NC Symposium
Muscular Dystrophy Muscle Walk of Central Ohio $1,000.00
Association--Worthingt
on, OH
Muscular Dystrophy Muscle Walk $1,000.00
Association--Worthingt
on, OH
Muscular Dystrophy Muscle Walk $1,000.00
Association--Westborou
gh, MA
Museum of Science Genzyme/Museum of Science $66,980.00
Teacher Sabbatical Program
2014
Museum of Science The Science Behind the Stars $10,000.00
Event
National Fabry Disease 2015 NFDF Education and $45,000.00
Foundation Community Patient Assistance
Program
National Fabry Disease 2015 NFDF Core Patient $40,000.00
Foundation Assistance Program
National Fabry Disease 2015 NFDF Core Patient $40,000.00
Foundation Assistance Program
National Fabry Disease 2015 Fabry Family Camp and $25,000.00
Foundation Annual Educational
Conference
National Fabry Disease 2015 Fabry Family Camp and $25,000.00
Foundation Annual Educational
Conference
National Fabry Disease 2015 Fabry Family Camp and $25,000.00
Foundation Annual Educational
Conference
National Fabry Disease 2015 Fabry Educational $14,000.00
Foundation Meetings
National Fabry Disease 2015 Fabry Emergency $10,000.00
Foundation Assistance and Ancillary
Expense Support
National Fabry Disease 2015 Fabry Emergency $10,000.00
Foundation Assistance and Ancillary
Expense Support
National Fabry Disease 2015 Family Patient $5,000.00
Foundation Assistance Program
National Fabry Disease 2015 Family Patient $5,000.00
Foundation Assistance Program
National Family RareCaregivers.org: Caring $10,000.00
Caregivers Association for Rare Disease Caregivers
DBA Caregiver Action
Network
National Family Creating the Voice: A $5,000.00
Caregivers Association Celebration of Family
DBA Caregiver Action Caregiving Event
Network
National Gaucher CARE Program--Patient $1,250,000.00
Foundation Assistance Program
National Gaucher NGF Education, Awareness and $400,000.00
Foundation Resources Program for
Patients
National Gaucher 2015 National Gaucher $25,000.00
Foundation Conference
National Kidney Louisville Kidney Walk $1,000.00
Foundation Inc.
National Kidney Great Chefs of the West Gala $200.00
Foundation Inc.
National Kidney Evansville Kidney Walk $500.00
Foundation of Indiana
National Kidney Northwest Kidney Walk $500.00
Foundation of Indiana
National Kidney Northeast Indiana Kidney Walk $500.00
Foundation of Indiana
National Kidney 2015 Mardi Gras Kidney Ball $1,000.00
Foundation of Michigan
National MPS Society National MPS Society 29th $20,000.00
Annual Family Conference
National MPS Society National MPS Society 29th $15,000.00
Annual Family Conference
National MPS Society National MPS Society 5K Walk/ $10,000.00
Run
National Multiple Southern New York Chapter's $100,000.00
Sclerosis Society--New Walk MS 2015
York, NY
National Multiple Chapter Women Against MS $1,000.00
Sclerosis Society-- Luncheon
Arizona
National Multiple Spring Fling/Fall Ball $10,000.00
Sclerosis Society--New Socialization Programs for
York, NY People with MS
National Multiple Moving Forward: An $3,000.00
Sclerosis Society--New Educational Program for
York, NY Those Newly Diagnosed with
Multiple Sclerosis
National Multiple The National Multiple $2,500.00
Sclerosis Society-- Sclerosis Society, Alabama--
Alabama-Mississippi Mississippi Chapter's MS
Chapter Dinner of Champions
National Multiple MS Symposium $1,000.00
Sclerosis Society--
Alabama-Mississippi
Chapter
National Multiple Arizona Chapter's Walk MS $10,000.00
Sclerosis Society-- 2015
Arizona Chapter
National Multiple Women Against MS Luncheon-- $2,500.00
Sclerosis Society-- Patient Wellness Program
Brentwood, TN
National Multiple Newly Diagnosed with MS $1,150.00
Sclerosis Society-- Meeting
Brentwood, TN
National Multiple Women's Day Out: Health, $450.00
Sclerosis Society-- Beauty, Wellness and MS
Brentwood, TN
National Multiple Central Virginia Chapter's $15,000.00
Sclerosis Society-- Walk MS 2015
Central Virginia
Chapter
National Multiple Women on the Move Luncheon $2,500.00
Sclerosis Society--
Central Virginia
Chapter
National Multiple Mind and Body Wellness $1,000.00
Sclerosis Society-- Educational Symposium
Central Virginia
Chapter
National Multiple Colorado-Wyoming Chapter's $15,000.00
Sclerosis Society-- Walk MS 2015
Colorado-Wyoming
Chapter
National Multiple I Ride with MS at Bike MS $10,000.00
Sclerosis Society-- Colorado Event
Colorado-Wyoming
Chapter
National Multiple 2015 SH & Patient Support $8,610.00
Sclerosis Society-- Groups
Colorado-Wyoming
Chapter
National Multiple Optimal Health with MS-- $8,350.00
Sclerosis Society-- Integrating Lifestyle,
Colorado-Wyoming Alternative & Conventional
Chapter Medicine
National Multiple Fitness as a Lifestyle 2015-- $4,710.00
Sclerosis Society-- Patient Wellness Program
Colorado-Wyoming
Chapter
National Multiple National MS Society $25,000.00
Sclerosis Society-- Scholarship Program
Denver, CO
National Multiple Navigator Patient Resource $15,000.00
Sclerosis Society-- Program
Gateway Area Chapter
MS
National Multiple Walk MS 2015 $5,000.00
Sclerosis Society--
Gateway Area Chapter
National Multiple Walk MS $50,000.00
Sclerosis Society--
Greater Illinois
Chapter
National Multiple MuckFest MS Chicago Race $15,000.00
Sclerosis Society--
Greater Illinois
Chapter
National Multiple 7th Annual Women on the Move $7,000.00
Sclerosis Society-- Luncheon
Greater Illinois
Chapter
National Multiple Walk MS Boston $25,000.00
Sclerosis Society--
Greater New England
Chapter
National Multiple Muckfest MS Boston $25,000.00
Sclerosis Society--
Greater New England
Chapter
National Multiple Bike MS Ride the Vineyard $10,000.00
Sclerosis Society--
Greater New England
Chapter
National Multiple National MS Walks Worcester $2,000.00
Sclerosis Society-- and Boston
Greater New England
Chapter
National Multiple Maine Living Well with MS $1,500.00
Sclerosis Society-- Program
Greater New England
Chapter
National Multiple Vermont Living Well with MS $1,250.00
Sclerosis Society-- Conference
Greater New England
Chapter
National Multiple Hidden Symptoms of MS $1,250.00
Sclerosis Society-- Conference
Greater New England
Chapter
National Multiple New Hampshire Spring $1,250.00
Sclerosis Society-- Education Conference
Greater New England
Chapter
National Multiple Rhode Island Living Well with $1,250.00
Sclerosis Society-- MS Spring Conference
Greater New England
Chapter
National Multiple Connecticut Walk MS 2015 $2,500.00
Sclerosis Society--
Hartford, CT
National Multiple National MS Society South $20,000.00
Sclerosis Society-- Central Region BP 150 Bike
Houston, TX Race Event
National Multiple North Texas Walk MS 2015 $18,000.00
Sclerosis Society--
Houston, TX
National Multiple Tulsa & Central, OK Walk MS $10,000.00
Sclerosis Society-- 2015
Houston, TX
National Multiple San Antonio MS Walk 2015 $10,000.00
Sclerosis Society--
Houston, TX
National Multiple 2015 Oklahoma Leadership $10,000.00
Sclerosis Society-- Events
Houston, TX
National Multiple Lydia Emily Project $10,000.00
Sclerosis Society-- supporting BP 150 Bike Race
Houston, TX Event
National Multiple North Texas Bike MS 2015 $7,500.00
Sclerosis Society--
Houston, TX
National Multiple On The Move Luncheon program $5,000.00
Sclerosis Society-- to raise funds and awareness
Houston, TX for Multiple Sclerosis
National Multiple I Ride With MS Oklahoma Bike $5,000.00
Sclerosis Society-- Event
Houston, TX
National Multiple Louisiana--New Orleans, $3,500.00
Sclerosis Society-- Shreveport, and Baton Rouge
Houston, TX Walk MS 2015
National Multiple Bike MS Event--Midland $3,000.00
Sclerosis Society--
Houston, TX
National Multiple On The Move Luncheon Baton $2,500.00
Sclerosis Society-- Rouge
Houston, TX
National Multiple Ohio Buckeye Chapter's Walk $5,000.00
Sclerosis Society-- MS 2015
Independence, OH
National Multiple North Florida Walk MS 2015 $7,500.00
Sclerosis Society--
Jacksonville, FL
National Multiple MS On the Move Luncheon $2,500.00
Sclerosis Society--
Jacksonville, FL
National Multiple MS On the Move Luncheon $1,000.00
Sclerosis Society--
Jacksonville, FL
National Multiple MS Awareness Mural $10,000.00
Sclerosis Society--
Kentucky-Southeast
Indiana Chapter
National Multiple Walk MS Kentucky $10,000.00
Sclerosis Society--
Kentucky-Southeast
Indiana Chapter
National Multiple Moving Mountains For MS: 2015 $7,500.00
Sclerosis Society-- Family Weekend Retreat
Kentucky-Southeast
Indiana Chapter
National Multiple Crystal Boots & Silver Spurs $5,000.00
Sclerosis Society-- Fundraising Event
Kentucky-Southeast
Indiana Chapter
National Multiple Best of Louisville 2015 $3,000.00
Sclerosis Society-- Patient Resources Event
Kentucky-Southeast
Indiana Chapter
National Multiple Women on the Move--Patient $1,000.00
Sclerosis Society-- Awareness Program
Kentucky-Southeast
Indiana Chapter
National Multiple Long Island Walk MS 2015 $5,000.00
Sclerosis Society--
Long Island Chapter
National Multiple 10th Annual Spring into $3,000.00
Sclerosis Society-- Awareness Luncheon
Long Island Chapter
National Multiple Southern California & Nevada $25,000.00
Sclerosis Society--Los Chapter's Walk MS 2015
Angeles, CA
National Multiple 40th Annual Dinner of $5,000.00
Sclerosis Society--Los Champions
Angeles, CA
National Multiple Program on Fueling Impact in $4,000.00
Sclerosis Society--Los MS Research
Angeles, CA
National Multiple Lydia Emily ``Make Your Mark $2,500.00
Sclerosis Society--Los on MS'' Mural Project that
Angeles, CA will provide hope to the
local MS community and
greatly increase public
awareness of MS
National Multiple Dinner of Champions Northern $2,500.00
Sclerosis Society--Los Nevada
Angeles, CA
National Multiple Maryland Walk MS 2015 $7,500.00
Sclerosis Society--
Maryland Chapter
National Multiple Walk MS 2015 $5,000.00
Sclerosis Society--MI
Chapter
National Multiple The 37th Annual Ambassadors $25,000.00
Sclerosis Society-- Ball
National Capital
Chapter
National Multiple National Capital Chapter's $10,000.00
Sclerosis Society-- Walk MS 2015
National Capital
Chapter
National Multiple National Capital Chapter's $5,000.00
Sclerosis Society-- Walk MS 2015
National Capital
Chapter
National Multiple 11th Annual Women On The Move $5,000.00
Sclerosis Society-- Luncheon
National Capital
Chapter
National Multiple Bike MS Ride the Vine Event $5,000.00
Sclerosis Society--
National Capital
Chapter
National Multiple A Day for Men Living with MS $1,500.00
Sclerosis Society-- Program
National Capital
Chapter
National Multiple Bike MS 'I Ride with MS' $600,000.00
Sclerosis Society--New Program
York, NY
National Multiple The International Progressive $100,000.00
Sclerosis Society--New MS Alliance 2015
York, NY
National Multiple National MS Society E- $75,000.00
Sclerosis Society--New Communications Program
York, NY
National Multiple North American Education $35,000.00
Sclerosis Society--New Program for people with MS
York, NY and their families
National Multiple Knowledge is Power 2015 at $35,000.00
Sclerosis Society--New Home Educational series
York, NY
National Multiple MS Navigator: Information $25,000.00
Sclerosis Society--New Program
York, NY
National Multiple National MS Society $25,000.00
Sclerosis Society--New educational video
York, NY programming for people with
MS and their families
through ``MS Learn Online''
National Multiple 2015 National MS Society, $15,000.00
Sclerosis Society--New Southern NY Chapter
York, NY Scholarship Program
National Multiple 2015 Women on the Move $12,000.00
Sclerosis Society--New Program
York, NY
National Multiple 2015 Gala/Dinner of Champions $12,000.00
Sclerosis Society--New
York, NY
National Multiple Research Symposium 2015: MS $3,000.00
Sclerosis Society--New Research Discoveries:
York, NY Wellness and Treatments for
Living Your Best Life
National Multiple Medical Student Clinical $1,500.00
Sclerosis Society--New Summer Fellowship
York, NY
National Multiple MS Awareness and Education $15,000.00
Sclerosis Society--NJ Newsletter
Metro Chapter
National Multiple New Jersey Metro Chapter's $10,000.00
Sclerosis Society--NJ Walk MS 2015
Metro Chapter
National Multiple Northern California Chapter's $25,000.00
Sclerosis Society-- Walk MS 2015
Northern California
National Multiple Chapter DuskBuster 5k Race $2,500.00
Sclerosis Society-- Event
Northern California
National Multiple Ohio Valley Chapter's Walk MS $10,000.00
Sclerosis Society-- 2015
Ohio Valley Chapter
National Multiple Women on the Move Luncheon $2,500.00
Sclerosis Society-- and Fashion Show
Ohio Valley Chapter
National Multiple Lydia Emily ``Make Your Mark $33,554.00
Sclerosis Society-- on MS'' Mural Project that
Oregon Chapter will provide hope to the
local MS community and
greatly increase public
awareness of MS
National Multiple Oregon Chapter's Walk MS 2015 $10,000.00
Sclerosis Society--
Oregon Chapter
National Multiple Bike MS 2015: Willamette $5,000.00
Sclerosis Society-- Valley
Oregon Chapter
National Multiple Gala MS 2015 $5,000.00
Sclerosis Society--
Oregon Chapter
National Multiple Relationship Matters--Spring $5,000.00
Sclerosis Society-- 2015
Oregon Chapter
National Multiple Greater Delaware Valley and $7,500.00
Sclerosis Society-- Delaware Chapter's Walk MS
Philadelphia, PA 2015
National Multiple Women Against MS Luncheon-- $2,500.00
Sclerosis Society-- Patient Wellness Program
Philadelphia, PA
National Multiple Pennsylvania Keystone $25,000.00
Sclerosis Society-- Chapter's Walk MS Champaign
Pittsburgh, PA (to include 23 Walk Events)
National Multiple Walk MS 2015 $10,000.00
Sclerosis Society--
Rochester, NY
National Multiple 2015 National MS Society, $7,000.00
Sclerosis Society-- Upstate NY Chapter
Rochester, NY Scholarship Program
National Multiple Bike MS Event $5,000.00
Sclerosis Society--
Rochester, NY
National Multiple 2015 MS Research Nights $5,000.00
Sclerosis Society--
Rochester, NY
National Multiple Champions On the Move $3,000.00
Sclerosis Society-- Luncheon
Rochester, NY
National Multiple 8th Annual Hudson Valley $3,000.00
Sclerosis Society-- Multiple Sclerosis Symposium
Rochester, NY
National Multiple 2015 Health and Wellness Fair $2,000.00
Sclerosis Society--
Rochester, NY
National Multiple Everyday Matters: Living Your $2,000.00
Sclerosis Society-- Best Life with MS Program
Rochester, NY
National Multiple On the Move Luncheon program $1,500.00
Sclerosis Society-- to raise funds and awareness
Rochester, NY for Multiple Sclerosis
National Multiple MS Service Day--Patient $1,000.00
Sclerosis Society-- Assistance Program
Rochester, NY
National Multiple Free From Falls--Patient $750.00
Sclerosis Society-- Wellness Program
Rochester, NY
National Multiple Utah-Southern Idaho Walk MS $15,000.00
Sclerosis Society-- 2015
Salt Lake City, UT
National Multiple Women on the Move Luncheon $2,500.00
Sclerosis Society-- and Fashion Show 2015
Salt Lake City, UT
National Multiple Walk MS San Diego $15,000.00
Sclerosis Society--San
Diego, CA
National Multiple 28th Annual MS Dinner Charity $10,000.00
Sclerosis Society--San Auction
Diego, CA
National Multiple MS Dinner Auction Hawaii $5,000.00
Sclerosis Society--San
Diego, CA
National Multiple UC Irvine Lunch & Learn $4,000.00
Sclerosis Society--San Symposium
Diego, CA
National Multiple Challenge Walk MS $2,500.00
Sclerosis Society--San
Diego, CA
National Multiple South Florida Chapter's Walk $25,000.00
Sclerosis Society-- MS 2015
South Florida Chapter
National Multiple MS Gala Luncheon 2015 $10,000.00
Sclerosis Society--
South Florida Chapter
National Multiple Festival Hispano 2015-- $4,000.00
Sclerosis Society-- Patient Awareness Program
South Florida Chapter
National Multiple Mind, Body & Soul--ESTERO $1,500.00
Sclerosis Society-- Event
South Florida Chapter
National Multiple Mind, Body & Soul--Boca Raton $1,500.00
Sclerosis Society-- Event
South Florida Chapter
National Multiple Walk MS: North Dakota Walks, $5,500.00
Sclerosis Society-- South Dakota Walks, and Twin
Upper Midwest Chapter Cities Challenge Walk
National Multiple Upper Midwest Chapter's Walk $5,000.00
Sclerosis Society-- MS 2015
Upper Midwest Chapter
National Multiple Taste of Generosity Gala $2,500.00
Sclerosis Society-- Dinner
Upper Midwest Chapter
National Multiple St. Cloud MS Walk 2015 $1,000.00
Sclerosis Society--
Upper Midwest Chapter
National Multiple Wisconsin Chapter's Walks MS $10,000.00
Sclerosis Society-- 2015 (to include 20 Walk
Wisconsin Chapter Events)
National Multiple Georgia Chapter's Walk MS $5,000.00
Sclerosis Society-- 2015
Georgia Chapter
National Multiple Bike MS Cape Cod Getaway, the $50,000.00
Sclerosis Society-- largest MS ride in New
Greater New England England
Chapter
National Multiple MileStones 2015 Program Ad $5,000.00
Sclerosis Society-
Greater New England
Chapter
National Multiple Greater Northwest Chapter's $25,000.00
Sclerosis Society- Walk MS Events
Greater Northwest
Chapter
National Multiple Bike MS Race Event: I Ride $10,000.00
Sclerosis Society- with MS
Greater Northwest
Chapter
National Multiple Mood & Cognition in MS: What $8,230.00
Sclerosis Society- you can do--Patient Wellness
Greater Northwest Program
Chapter
National Multiple Northwest Chapter's Dinner of $2,500.00
Sclerosis Society- Champions Gala
Greater Northwest
Chapter
National Multiple Indiana Chapter's Walk MS $8,500.00
Sclerosis Society 2015
Indiana State Chapter
National Multiple Society's Financial Patient $5,000.00
Sclerosis Society Assistance Program
Indiana State Chapter
National Multiple MS Navigator: Information $5,000.00
Sclerosis Society Program
Indiana State Chapter
National Multiple 39th Annual Dinner of $5,000.00
Sclerosis Society--Los Champions
Angeles, CA
National Multiple Everyday Matters Patient $909.00
Sclerosis Society-- Wellness Program
Upstate New York
Chapter
National Niemann-Pick Hope is on the Horizon Family $30,000.00
Disease Foundation Patient Services Program
National Organization Portraits of Courage 2015 $50,000.00
for Rare Disorders
National Organization Volunteer Match $9,000.00
for Rare Disorders
National Organization Rare Disease Day Relay $6,000.00
for Rare Disorders
National Organization NORD's Rare Diseases and $50,000.00
for Rare Disorders, Orphan Products Breakthrough
Inc. Summit
National Tay-Sachs & Imagine & Believe 2015 Event $10,000.00
Allied Diseases
Association, Inc.
National Tay-Sachs & 37th Annual Family Conference $5,000.00
Allied Diseases
Association, Inc.
National Tay-Sachs & Raising Awareness of $1,200.00
Allied Diseases Ashkenazi Jewish Genetic
Association, Inc. Diseases through the
Forward's annual genetics
issue
Nebraska Kidney Patient & Family Education $500.00
Association Day
Neurologic Disease MS: Today and Tomorrow $5,995.00
Foundation Caregiver Wellness Program
Neurologic Disease Newly Diagnosed MS Patient $4,995.00
Foundation Educational Series 2015
Neuropathy Action 9th Annual Neuropathy Action $2,500.00
Foundation Awareness Day
New England Healthcare The Nick Littlefield Health $25,000.00
Institute Policy Fellowship
New England Healthcare Innovators in Health Awards $25,000.00
Institute
Next Step Fund Inc. Expansion of year-round $10,000.00
programming in Song.Studio
and the Media Lab for youth
with rare genetic disorders
Norton Healthcare 2015 Neuro Expo $10,000.00
Foundation, Inc.
OhioHealth Corporation OhioHealth Multiple Sclerosis $20,000.00
Patient Education Program
Oligonucleotide 11th Annual Meeting of the $2,500.00
Therapeutic Society Oligonucleotide Therapeutics
Society
Operation Warm Inc. Community support for Boston $15,000.00
Warmth in Winter
Oregon Health & Science At the Frontier & Beyond: MS $8,850.00
University 2015
Oregon Health & Science On the Horizon: Updates in $8,700.00
University Multiple Sclerosis
Our Space Inc. Volunteer Match $1,000.00
Partners Healthcare World Medical Innovation $50,000.00
System, Inc. Forum--Neurosciences
Patient Access Network Patient Assistance Program $260,000.00
Foundation for Homozygous Familial
Hypercholesterolemia (HoFH)
Patients
Patient Access Network Patient Assistance Program $125,000.00
Foundation for Patients with Thyroid
Cancer
Patient Access Network Patient Assistance Program $50,000.00
Foundation for Homozygous Familial
Hypercholesterolemia (HoFH)
Patients
Patient Access Network Patient Assistance Program $50,000.00
Foundation for Homozygous Familial
Hypercholesterolemia (HoFH)
Patients
Patient Services Inc. Fabry Financial Patient $3,150,000.00
Assistance Program
Patient Services Inc. Pompe Patient Assistance $237,422.00
Program
Patient Services Inc. Pompe Patient Assistance $237,422.00
Program
Patient Services Inc. MPS1 Patient Assistance $212,778.00
Program
Patient Services Inc. Patient Assistance Program $212,378.00
for Gauchers Disease
Peer Health Exchange Peer Health Exchange: $5,000.00
Inc. Empowering Boston Youth to
Make Healthy Decisions
Perkins School for the Perkins eLearning: Accessible $20,000.00
Blind Science Education
Pharmacy Quality Development of Quality $75,000.00
Alliance Measurement Strategy for
Multiple Sclerosis Program
Phillips Brooks House Put on a Helmet! $5,755.76
Association
Incorporated
Portland VA Research PDX Patient Workshop $4,000.00
Foundation Inc.
Pro Player Foundation Flavors of Austin hosted by $5,000.00
Earl Campbell
Project Eden Inc. Volunteer Match $1,000.00
Race--Run Against Super Sunday 5K Sponsorship $10,000.00
Cancer Events
Race to Erase MS 22nd Annual Race to Erase MS $60,000.00
Resolve Community Volunteer Match $1,000.00
Counseling Center,
Inc.
Rhode Island Rare World Rare Disease Dar Art $5,000.00
Disease Foundation Exhibit 2015
Rhode Island Rare Beyond the Diagnosis Art $2,500.00
Disease Foundation Exhibit
Rocky Mountain Multiple Rocky Mountain MS Center $5,000.00
Sclerosis Center Annual Gala
Room to Grow Clinical Community Support $5,000.00
Program
S S Cosmas & Damian 88th Annual East Cambridge $2,500.00
Society Inc. Festival
Samaritans of Greater Community Support for Youth $25,000.00
Boston Suicide Prevention Program
Science Club For Girls Campus Chapters Supporting K- $10,000.00
Inc. 12 Science Clubs
Science From Scientists 69th Annual Boston Citywide $10,000.00
Inc. Science Fair
Seattle Children's MPS Family Day 2015 $6,000.00
Hospital Foundation
Special Olympics Bio-Ball 2015 $2,000.00
Massachusetts Inc.
Stop Hunger Now, Inc. Meal Packaging Event--Take $3,044.08
Our Sons & Daughters to Work
Day
Student Clubs of HBS, 12th Annual Healthcare $1,500.00
Inc. Conference at Harvard
Business School
Temple University Genzyme Allston/Brighton $5,000.00
Biotechnology College
Scholarship
Terrapinn Inc. World Orphan Drug Congress $50,000.00
USA 2015
Texas Neurological TNS 18th Annual Winter $5,000.00
Society Conference
THANC Foundation, Inc. A Starry Night to benefit the $5,000.00
THANC (Thyroid, Head and
Neck Cancer) Foundation
honoring R. Michael Tuttle,
MD
THANC Foundation, Inc. A Starry Night to benefit the $5,000.00
THANC (Thyroid, Head and
Neck Cancer) Foundation
honoring R. Michael Tuttle,
MD
The Boston Home, Inc. B.Fit! Day Wellness Program $18,000.00
The Boston Home, Inc. iPads Communication System $12,000.00
for Wheelchair Users--
Patient Assistance Program
The Boston Home, Inc. The Boston Home Art Program $10,000.00
The Boston Home, Inc. Volunteer Match $1,000.00
The Community Art Community Teen Media Program $10,000.00
Center
The Familial FH Patient Speakers Bureau $25,000.00
Hypercholesterolemia Program
Foundation
The Familial Homozygous Familial $20,000.00
Hypercholesterolemia Hypercholesterolemia (HoFH)
Foundation Community Program
The FH Foundation 2015 FH Global Summit $25,000.00
The Forsyth Institute The ForsythKids School Oral $10,000.00
Health Program: Expansion to
serve Homeless Youth in
Cambridge
The Friends of the Community Support of The $4,000.00
Hopkinton Public Friends of the Hopkinton
Library Public Library
The Life Sciences Leadership Mid-Term Funding $50,000.00
Foundation for Educational Programs
The McCourt Foundation MS Educational Update Program $20,000.00
The McCourt Foundation McCourt Foundation Gala & $15,000.00
Auction
The McCourt Foundation Tour de South Shore Bike $10,000.00
Event
The McCourt Foundation The Immune System and The $5,000.00
Brain With a Focus on MS
The National Cancer Gaucher's Disease Relief $5,000.00
Coalition, Inc. Patient Assistance Program
The Oak Clinic 2015 Diamond Run for MS $5,000.00
The Posse Foundation Community Support for Posse $20,000.00
Boston's Students Program
Thompson Island Outward Connections--STEM learning to $10,000.00
Bound Education Center empower urban youth
Inc.
Thyca Thyroid Cancer 18th International Thyroid $30,000.00
Survivors Association Cancer Survivors' Conference
Inc.
Thyca Thyroid Cancer Informational Resource $7,875.00
Survivors Association Support for ``After the
Inc. Diagnosis, Medullary Thyroid
Cancer Memoirs'' to all
ThyCa Support Group
Tisch Multiple 18th Annual Patient Symposium $30,000.00
Sclerosis Research
Center of New York,
Inc.
Tisch Multiple Healing MS Patient Newsletter $15,000.00
Sclerosis Research
Center of New York,
Inc.
Trustees of Boston Genzyme Youth Science & $5,050.00
University Engineering Workshop
Scholarships for U-Design
Program at Boston University
Trustees of Boston Genzyme Allston/Brighton $2,000.00
University Biotechnology College
Scholarship
Trustees of Boston Genzyme Allston/Brighton $2,000.00
University Biotechnology College
Scholarship
Trustees of Tufts Genzyme Allston/Brighton $5,000.00
College Biotechnology College
Scholarship
Tutoring Plus of Science & Math Enrichment $5,000.00
Cambridge, Inc. Programs
Tutoring Plus of Volunteer Match $1,000.00
Cambridge, Inc.
United Pompe Foundation Pompe Community Support $46,500.00
Programs
United Pompe Foundation Duke Late Onset Pompe Patient $20,000.00
Meeting
United Way of Tri Volunteer Match $1,000.00
County Inc.
University of Florida 8th International Conference $2,000.00
on Unstable Microsatellites
and Human Disease
University of Massachusetts STEM Summit $10,000.00
Massachusetts 2015: Promising Practices,
Proven Results
University of Student Success Program for $200,000.00
Massachusetts UMass Boston, College of
Foundation Inc. Science and Mathematics
University of Southern Genzyme Allston/Brighton $5,000.00
California Biotechnology College
Scholarship
Urban Kidney Alliance, Prescription Medication $500.00
Inc. Assistance Program (PMAP)
Veterans Inc. Volunteer Match $1,000.00
Visiting Nurse Heroes in Health Care Gala $10,000.00
Association of Boston
& Affiliates
Weill Medical College Talk MS Program $10,000.00
of Cornell University
West County MS Center 10th Annual Trivia and $7,500.00
Auction
West End House Boys and Volunteer Match $1,000.00
Girls Club
WGBH WGBH Pledge Night $12,000.00
Whitehead Institute for Whitehead Institute's 2015 $10,000.00
Biomedical Research CampBio Program
Whitehead Institute for Whitehead Institute's 2016 $10,000.00
Biomedical Research CampBio Program
Women's Lunch Place Community Support for Meals $35,000.00
Program
Worcester County Food Volunteer Match $1,000.00
Bank Inc.
Worcester Polytechnic Genzyme Allston/Brighton $1,000.00
Institute Biotechnology College
Scholarship
WriteBoston STEM Teacher Excellence: $10,000.00
Powered By Genzyme
Wylder Nation 2nd Annual Living Like a $10,000.00
Foundation Warrior Gala
YMCA of Greater Boston Oak Square YMCA--Summer Day $15,000.00
Camp Scholarship
Sponsorships and Charitable Donations
1st Jan 2016-31st Dec 2016
Sanofi US and its affiliate Genzyme Corporation are committed to
supporting sponsorships for specific activities and initiatives of
healthcare organizations and institutions, independent medical or
professional societies, trade organizations and organized patient groups
to improve patient care and provide information to the medical and/or
patient communities. The goal of our charitable giving approach is to
fund general operational support for patient/disease organizations, or
program support for community-based organizations. Sanofi US and Genzyme
Corporation are part of the Sanofi Group, a global pharmaceutical
company.
Applicant names are provided by the requestor. If applicants apply as a
group for a single activity; all applicants may be not be identified
above. ``Funding Amount'' is the amount that the Company funded during
2015 identified above. ``Funding Amount'' does not include funds that
may have been provided by other affiliated Sanofi Company Entities
(e.g., Sanofi Pasteur).
Recipient Name(s) Activity Title Funding Amount
Acid Maltase Deficiency General Operating Support $48,000.00
Association Inc.
ACTRIMS Congress Sponsorships $30,000.00
Allston Brighton Feastworthy: Pilot Prepared $15,000.00
Community Development Meals Delivery Program
Corporation
American Academy of Congress Sponsorships $482,897.00
Neurology Institute
American Academy of Palatucci Advocacy Leadership $50,000.00
Neurology Institute Forum
American Academy of Brain Health Fair $7,500.00
Neurology Institute
American Academy of Fellows Scholarship Fund $20,000.00
Neurology Institute
American Academy of Residents Scholarship Fund $20,000.00
Neurology Institute
American Academy of Emerging Leaders Program $20,000.00
Neurology Institute
American Association of Congress Sponsorships $4,300.00
Clinical
Endocrinologists
American Association of Fabry Family Member Testing $164,970.00
Kidney Patients and Education Project
American Autoimmune and 50 Cents for 50 Million $5,000.00
Related Diseases Laughs Campaign
Association
American Brain Patient Advocacy Organization $5,000.00
Coalition Membership Sponsorship
American Cancer Society Volunteer Match $1,000.00
American Cancer Society Volunteer Match $11,000.00
American Chemical Recovery of Biological $5,000.00
Society Merck and Co Products XVII Conference
Inc.
American Chemical Biochemical Technology ACS $5,000.00
Society Merck and Co National Meeting
Inc.
American College of Congress Sponsorships $50,875.00
Medical Genetics and
Genomics
American Red Cross of American Red Cross Blood $5,000.00
Massachusetts Services
American Red Cross of American Red Cross of $5,000.00
Massachusetts Massachusetts Women Who Care
Breakfast
American Thyroid Congress Sponsorships $3,000.00
Association
American Thyroid Congress Sponsorships $15,000.00
Association
ANERA (American Near ANERA Annual Dinner $5,000.00
East Refugee Aid)
Angel's Hands Family Assistance Program $5,000.00
Foundation
Ann & Robert H. Lurie MPS Patient and Family $2,000.00
Children's Hospital of Conference
Chicago
Arthritis Foundation Orange County & Inland Empire $2,500.00
Jingle Bell Run
Assistance Fund Inc. Patient Assistance Program $7,750,000.00
for MS
Association For Annual Conference; Family $6,000.00
Glycogen Storage Assistance; The Ray
Disease (newsletter)
Association For Annual Conference; Family $6,000.00
Glycogen Storage Assistance; The Ray
Disease (newsletter)
Barth Syndrome Barth Syndrome Foundation $2,000.00
Foundation Conference
Batten Disease Support NCL Congress Boston $5,000.00
And Research
Association
Berkshire Resource 8th Annual GALA Fundraiser $5,000.00
Project
Berkshire Resource When IWalk - An MS Story $8,000.00
Project
Big Brothers Big MySTEM--Mentoring Youth in $10,000.00
Sisters Of Central Science, Technology,
Mass Metrowest Inc. Engineering, and Mathematics
Biomedical Science Hope Scholarship $7,500.00
Careers Program
Biomedical Science Evening of Hope $75,000.00
Careers Program
Biotechnology BIO Patient and Health $10,000.00
Innovation Advocacy Summit
Organization
Boston Area Rape Crisis Community Program $25,000.00
Center
Boston Area Rape Crisis Advocacy Program $25,000.00
Center
Boston College Trustees Allston Brighton College $2,000.00
Scholarship
Boston College Trustees Allston Brighton College $4,000.00
Scholarship
Boston Educational Boston Public Schools Science $10,000.00
Development Fair
Foundation, Inc.
Boston Health Care For Life Essentials for Homeless $35,000.00
The Homeless Program Patients
Inc.
Boston Health Care For Volunteer Match $1,000.00
The Homeless Program
Inc.
Boston Health Care For General Operating Support $10,000.00
The Homeless Program
Inc.
Boston Partners in Power Lunch Program $6,000.00
Education, Inc.
Boston Private Industry Corporate Contributions $15,000.00
Council Campaign
Boston Private Industry Volunteer Match $1,000.00
Council
Bottom Line Boston STEM Success Program $15,000.00
Bottom Line Volunteer Match $1,000.00
Boys and Girls Clubs of Staffing & Transportation for $25,000.00
MetroWest Membership at BGCMW's
Framingham Clubhouse
Boys and Girls Clubs of Volunteer Match $1,000.00
MetroWest
Boys and Girls Clubs of Volunteer Match $4,000.00
MetroWest
Boys and Girls Clubs of Volunteer Match $1,000.00
MetroWest
Boys and Girls Clubs of Bids for Kids Auction & Gala $10,000.00
MetroWest
Boys and Girls Clubs Of Great Pumpkin Glow $6,000.00
Middlesex County Inc.
BPE Boston Teacher Residency: $15,000.00
Putting Students at the
Center of STEM Teacher
Training
Breakthrough Greater Full STEAM Ahead Program With $10,000.00
Boston Low-Income Students
Brian J. Honan Brian Honan 5K Road Race $2,500.00
Charitable Fund
California Association Congress Sponsorships $1,500.00
of Physician Groups
(CAPG)
California Association Congress Sponsorships $1,000.00
of Physician Groups
(CAPG)
California District Congress Sponsorships $3,000.00
American Academy of
Pediatrics
California Pharmacists Congress Sponsorships $1,500.00
Association
Educational Foundation
Cambridge Chamber of Women in Business Programming $4,350.00
Commerce Series Sponsor
Cambridge Health Volunteer Match $1,000.00
Alliance Foundation
Inc.
Cambridge School Volunteer Match $1,000.00
Volunteers, Inc.
Cambridge School Volunteer Match $15,825.00
Volunteers, Inc.
Cambridge School Volunteer Match $13,755.00
Volunteers, Inc.
Cambridge School Community Program $11,000.00
Volunteers, Inc.
Cambridge School Community Program $11,000.00
Volunteers, Inc.
Camp Korey Metabolic Disorders Family $5,000.00
Weekend Camp
Can Do Multiple JUMPSTART Programs $60,000.00
Sclerosis
Can Do Multiple Annual Autumn Benefit for Can $5,000.00
Sclerosis Do Multiple Sclerosis
Can Do Multiple Vertical Express for Can Do $30,000.00
Sclerosis MS
Can Do Multiple Annual Autumn Benefit $10,000.00
Sclerosis
Can Do Multiple CAN DO Program $60,000.00
Sclerosis
Can Do Multiple TAKE CHARGETM Program $37,500.00
Sclerosis
Case Management Society CMSA 26th Annual Conference & $4,650.00
of America Expo
Case Management Society Congress Sponsorships $14,000.00
of America
Case Management Society Congress Sponsorships $5,500.00
of America
Case Management Society New Frontiers of $1,050.00
of New England Technological Advancement
Program
Case Management Society Corporate Sponsorship of $1,250.00
of New England CMSNE
Case Management Society Creativity, Inspiration & $1,000.00
of New England Collaboration: Building
Blocks of Successful
Leadership
CASSS--An International WCBP--20th Symposium $7,500.00
Separation Science
Society
Charles River Community Mom & Baby Program $15,000.00
Health
Charles River Volunteer Match $1,000.00
Conservancy
Charles River Volunteer Match $4,000.00
Conservancy
Chelsea Jewish Nursing ALS & MS Walk for Living $2,500.00
Home Foundation, Inc.
Childrens Gaucher Gaucher Related Research Fund $75,000.00
Research Fund
Children's Hospital La Gala de Milagros para $5,000.00
Boston Ninos
Children's Hospital Volunteer Match $1,000.00
Boston
Children's Hospital of Lysosomal Day at The $16,370.33
Philadelphia Philadelphia Zoo
Foundation
Chronic Disease Fund, Medullary Thyroid Cancer $300,000.00
Inc DBA Good Days from Patient Assistance Program
CDF
Chronic Disease Fund, Medullary Thyroid Cancer $150,000.00
Inc DBA Good Days from Patient Assistance Program
CDF
Church Hillers Inc. Volunteer Match $1,000.00
Cincinnati Children's Meeting for Patients with $5,000.00
Hospital Medical Fabry Disease
Center
Citizen Schools Expanding STEM Learning at $15,000.00
Boston Schools
Citizen Schools Deepening the Impact of STEM $15,000.00
Education
City Sprouts, Inc. CitySprouts Middle School $8,000.00
Program in Cambridge
City Sprouts, Inc. CitySprouts Middle School $8,000.00
Program
Cleveland Clinic Multiple Sclerosis (MS) $10,125.00
Foundation Promoting Wellness and
Healthy Lifestyle
Community Boating, Inc. Universal Access Program 2016 $15,000.00
Community Farms Fresh Food Access Program $15,000.00
Outreach
Community Living and The Giving Tree Campaign $6,500.00
Support Services, Inc.
Community Rowing, Inc. Let's Row Boston $10,000.00
Community Servings, Pie in the Sky $10,000.00
Inc.
Consortium of MS Congress Sponsorships $5,000.00
Centers
Courageous Parents Patient Education and $7,000.00
Network Awareness Program
Cradles To Crayons Inc. Ready for School $20,000.00
Cradles To Crayons Inc. General Operating Support $10,000.00
Cradles To Crayons Inc. Volunteer Match $1,000.00
Cystic Fibrosis Volunteer Match $4,000.00
Foundation
Cystic Fibrosis Uncork the Cure $10,000.00
Foundation
Damon Runyon Cancer General Operating Support $5,000.00
Research Foundation
DEAF, Inc.-- Community Program $10,000.00
Developmental
Evaluation and
Adjustment Facilities,
Inc.
Dimock Community Health 29th Annual Steppin' Out for $25,000.00
Center The Dimock Center
Dimock Realty Building the Road to Recovery $50,000.00
Corporation Campaign
Direct Relief Patient Assistance Fund for $10,000.00
International Rare Diseases
Direct Relief Patient Assistance Fund for $5,000.00
International Rare Diseases
DPC Education Center Fabry Disease Newsletter $25,000.00
Support
Duke University Patient Assistance Program $400,000.00
Duke University Hospitals Patient Assistance $224,000.00
Program
East End House Inc. Generating and Evaluating New $20,000.00
Adventures in Science After
School (GENASAS)
East End House Inc. Generating and Evaluating New $20,000.00
Adventures in Science After
School (GENASAS)
Engineering Conferences Cell Culture Engineering XV $10,000.00
International Conference
EveryLife Foundation Community Congress $15,000.00
for Rare Diseases
EveryLife Foundation Rare Disease Advocacy Program $20,000.00
for Rare Diseases
EveryLife Foundation Rare Voice Awards $15,000.00
for Rare Diseases
EveryLife Foundation Patient Education and $5,000.00
for Rare Diseases Awareness Program
EveryLife Foundation Community Congress $5,000.00
for Rare Diseases
Fabry Support & Fabry Support &Information $30,000.00
Information Group Group Patient Assistance
Fund Program
Fabry Support & Fabry Support & Information $100,000.00
Information Group Group General Operating
Support
Fabry Support & Fun Run/Walk St. Louis, MO $1,500.00
Information Group
Fabry Support & FSIG Expert Fabry Conference $50,000.00
Information Group
Families of SMA Annual SMA Conference $10,000.00
Family Promise Keep the Promise, Food $2,500.00
Metrowest Inc. Program for the Homeless
Florida Society of Congress Sponsorships $15,000.00
Rheumatology
Food For Free Community Program $1,000.00
Committee, Inc.
Foundation Fighting Volunteer Match $2,000.00
Blindness Inc.
Framingham Townwide Pto Volunteer Match $1,000.00
Council
Franciscan Hospital For Adaptive Sports Program $10,000.00
Children Inc.
Friends of Resiliency Community Program $10,000.00
for Life Inc.
Friends of Resiliency Volunteer Match $1,000.00
for Life Inc.
Generation Citizen Inc. Spring and Fall Civics Day $5,000.00
Genetic Alliance Inc. Industry Program $20,000.00
Girl Scouts of Eastern Girls Building Self-eSTeEM $10,000.00
Massachusetts Inc.
Girl Scouts of Eastern Volunteer Match $1,000.00
Massachusetts Inc.
Girl Scouts of Eastern Volunteer Match $1,000.00
Massachusetts Inc.
Global Genes RARE Tribute To Champions of $25,000.00
Hope
Global Genes RARE Webinars & RARE Toolkits $30,000.00
Global Genes Patient Assistance Program $20,000.00
Global Genes RARE Patient Advocacy Summit $25,000.00
Gordon Research Barriers of the Central $2,000.00
Conferences Nervous System Gordon
Research Conference
Greater Boston Chamber Annual Meeting $10,000.00
of Commerce
Habitat For Humanity Home Build for Four Low- $20,000.00
Metrowest--Greater Income Families Program
Worcester Inc.
Habitat For Humanity Volunteer Match $1,000.00
Metrowest--Greater
Worcester Inc.
Habitat For Humanity Volunteer Match $1,500.00
Metrowest--Greater
Worcester Inc.
Habitat For Humanity Volunteer Match $2,000.00
Metrowest--Greater
Worcester Inc.
Habitat For Humanity High Heels and Hard Hats $7,500.00
Metrowest - Greater Auction and Gala
Worcester Inc.
Harvard College Allston Brighton College $2,000.00
Scholarship
Health Care For All Public Education Campaign to $15,000.00
Inc. Improve Access to Health
Care in Framingham
Health Resources In The Leaders through $20,000.00
Action Inc. Education, Action and Hope
(LEAH) Project
Health Resources in The Leaders through $20,000.00
Action Inc. Education, Action, and Hope
(LEAH) Project
Hearts & Noses Hospital Hospital Clown Visits to Ill $15,000.00
Clown Troupe Inc. and Disabled Children in
Greater Boston
Hereditary Disease Milton Wexler Celebration of $5,000.00
Foundation Life Symposium
Holy Name Health Care MS Awards Reception $2,500.00
Foundation Inc.
Holy Name Health Care 19th Annual spring Fling to $5,000.00
Foundation Inc. benefit MS
Holy Name Health Care MS Awards Reception $5,000.00
Foundation Inc.
Horizons for Homeless 18th Annual Women's Breakfast $5,000.00
Children
Huntington's Disease Patient Education and $5,000.00
Society of America Awareness Program
Huntington's Disease Huntington's Disease Society $2,000.00
Society of America of America 31st Annual
Convention
International Institute Patient Navigation Services $10,000.00
of New England for Refugees in Boston
International Institute Golden Door Award Gala $10,000.00
of New England
International Stress--You Can't Avoid It, $10,000.00
Organization of But You Can Manage It!
Multiple Sclerosis
Nurses
International Annual Meeting IOMSN Dinner $30,000.00
Organization of
Multiple Sclerosis
Nurses
International MS Perspectives $75,000.00
Organization of
Multiple Sclerosis
Nurses
Italian Home For Annual Gala $5,000.00
Children Inc.
Jewish Family Service Patient Navigator Program $15,000.00
of Metrowest Inc.
Jewish Family Service Patient Navigator Program $15,000.00
of Metrowest Inc.
Jewish Genetic Disease Community and Rabbinic $500.00
Consortium (JGDC) Education for Jewish Genetic
Diseases
Just-A-Start St. Patrick's Fund $5,000.00
Corporation
Just-A-Start Biomedical Careers Program $22,950.00
Corporation
LGMD2D Foundation Patient Assistance Program $650,000.00
LGMD2D Foundation Patient Assistance Program $600,000.00
Light of Life Light of Life Foundation $40,000.00
Foundation Program
Little Brothers/Friends Community Program $7,500.00
of the Elderly
Louisiana Association Congress Sponsorships $5,285.00
of Health Plans
MagellanRx Management Congress Sponsorships $5,000.00
Manchaug Pond Volunteer Match $1,000.00
Association
March of Dimes Volunteer Match $2,000.00
March of Dimes Black Ties for Babies $10,000.00
March of Dimes March for Babies $15,000.00
Margaret Fuller Please Help a Crumbling $20,000.00
Neighborhood House Community Resource
Margaret Fuller Margaret Fuller Kids Summer $15,000.00
Neighborhood House Explorations Program
Mass Insight Education Advanced Placement (AP) $15,000.00
and Research Institute Science, Technology,
Inc. Engineering, and Math (STEM)
and English Program
Massachusetts Bay STEM Mentor Program (SMP) $37,000.00
Community College
Foundation
Massachusetts Congress Sponsorships $25,000.00
Biotechnology Council
Massachusetts Patient Advocacy Summit $10,000.00
Biotechnology Council
Massachusetts MassBio Annual Meeting $10,000.00
Biotechnology Council
Massachusetts 2016 MassBio Policy $5,000.00
Biotechnology Council Leadership Breakfast
Massachusetts Volunteer Match $1,000.00
Biotechnology
Education Foundation
Inc.
Massachusetts BioTeach $50,000.00
Biotechnology
Education Foundation
Inc.
Massachusetts Volunteer Match $1,000.00
Biotechnology
Education Foundation
Inc.
Massachusetts Champions for Biotechnology $2,500.00
Biotechnology Education Program
Education Foundation
Inc.
Massachusetts Black Massachusetts Black Women $5,000.00
Women Attorneys Attorneys 35th Anniversary
Foundation Inc. Celebration
Massachusetts College Next Generation of Women $10,000.00
of Pharmacy and Health Leaders in STEM
Sciences
Massachusetts Institute Cambridge Science Festival $5,000.00
of Technology
Massachusetts Outdoor Volunteer Match $1,000.00
Heritage Foundation
Inc.
Massachusetts State Massachusetts State Science & $50,000.00
Science and Engineering Fair
Engineering Fair, Inc.
Mattel Children's Educational Seminars for $59,000.00
Hospital UCLA Patients with Fabry Disease
Mercy Foundation Multiple Sclerosis $25,000.00
Achievement Center Wellness
Education Programs
Metrowest Free Medical Expanding Access to Women's $10,000.00
Program Inc. Health Care and Health
Education in Framingham
Miami Childrens Health Education and Outreach $5,000.00
System Foundation Inc. Activities of Jewish Genetic
and Pan-Ethnic Diseases
Mid America MS The Race to Nowhere $5,000.00
Achievement Center
Mid America MS Your MS Depression Toolkit $8,210.00
Achievement Center
Mint For Mounts Inc. Volunteer Match $1,000.00
MITS Inc. STEM Professional Development $20,000.00
Institutes for teachers
MITS Inc. Professional Development $20,000.00
Institutes for teachers
MS Cure Fund Women Thriving with MS--How $125,000.00
to be a partner, a mother, a
woman--FIRST
MS Cure Fund Lifestyle Management Programs $13,500.00
Spring
MS Cure Fund eNewsletter $24,000.00
MS Cure Fund Patient Education and $22,580.00
Awareness Program
MS Hope for a Cure Inc. MS Hope Day $10,000.00
MS Views and News Inc. Wheelchairs for Charity $6,000.00
MS Views and News Inc. Effective Communication $19,775.00
Program
MS Views and News Inc. Champions Tackling MS Awards $5,000.00
Dinner Gala
MS Views and News Inc. Congress Sponsorships $7,900.00
MS Views and News Inc. MS Views and News 6th Annual $3,500.00
Bowlathon Fundraiser
MS Views and News Inc. Patient Education and $10,406.75
Awareness Program
MS Views and News Inc. The Evolution of MS Care-- $14,200.00
Making Impacts on Health and
Wellness
MS Views And News Inc. Patient Education and $26,910.75
Awareness Program
MSWorld, Inc. MSWorld Conference Coverage $12,000.00
Multiple Sclerosis Patient Assistance Program $125,000.00
Association of America
Multiple Sclerosis MSAA Cooling Equipment $15,000.00
Association of America Distribution Program
Multiple Sclerosis Patient Assistance Program $50,000.00
Association of America
Multiple Sclerosis Navigating MS Program $75,000.00
Association of America
Multiple Sclerosis ``MS Health and Wellness'' $20,000.00
Association of America Program
Multiple Sclerosis Patient Education and $105,000.00
Association of America Awareness Program
Multiple Sclerosis MSAA's Improving Lives $10,000.00
Association of America Benefit
Multiple Sclerosis MSAA Annual Healthcare $24,887.00
Association of America Advisory Council Summit
Multiple Sclerosis Patient Education and $17,409.50
Association of America Awareness Program
Multiple Sclerosis MS Fest $10,000.00
Center of Georgia
Multiple Sclerosis Health, Hope & Hops $7,000.00
Center of Georgia
Multiple Sclerosis Health, Hope & Hops $7,000.00
Center of Georgia
Multiple Sclerosis Multiple Sclerosis $50,000.00
Foundation Foundation's Assistive
Technology Program
Multiple Sclerosis EmpowerSource Support Group $28,000.00
Foundation Newsletter
Multiple Sclerosis Chapter Meetings Support $7,000.00
Foundation
Multiple Sclerosis National March MS Education $40,000.00
Foundation and Awareness Monthr 2016
Multiple Sclerosis MS Dinner of Hope $1,500.00
Resources of Central
New York, Inc.
Multiple Sclerosis Mission Steps Walk & MS $8,000.00
Resources of Central Awareness Day
New York, Inc.
Muscular Dystrophy MDA Summer Camp $3,500.00
Association
Muscular Dystrophy Volunteer Match $1,000.00
Association
Muscular Dystrophy Care Services Program $1,500.00
Association
Muscular Dystrophy Live Unlimited Program $30,000.00
Association
Muscular Dystrophy Patient Assistance Program $700,000.00
Association
Muscular Dystrophy MDA MuscleWalk Fresno $1,000.00
Association
Muscular Dystrophy Muscular Dystrophy $2,000.00
Association Association, Second Quarter
Newsletter
Muscular Dystrophy Muscular Dystrophy $2,000.00
Association Association 2nd Quarter
Newsletter
Muscular Dystrophy Quarterly Newsletter $5,000.00
Association
Muscular Dystrophy Kids Art Auction $1,500.00
Association
Muscular Dystrophy Patient Assistance Program $2,000.00
Association
Muscular Dystrophy Patient, Provider and Family $2,000.00
Association Healthcare Newsletter
Muscular Dystrophy Muscular Dystrophy $2,500.00
Association Association of Montana
Summer Camp
Muscular Dystrophy MDA Summer Camp $2,500.00
Association
Muscular Dystrophy MDA Summer Camp $2,500.00
Association
Muscular Dystrophy Newsletter $2,500.00
Association
Muscular Dystrophy Muscular Dystrophy $2,000.00
Association Association Quarter
Newsletter
Muscular Dystrophy Patient Education and $1,000.00
Association Awareness Program
Muscular Dystrophy MDA Black N Blue comedy event $2,500.00
Association
Muscular Dystrophy MDA MuscleWalk Dayton $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk Albany $1,000.00
Association
Muscular Dystrophy MDA Wisconsin Muscle Summit $8,000.00
Association
Muscular Dystrophy MDA MuscleWalk MA $1,000.00
Association
Muscular Dystrophy MDA Central Texas MuscleWalk $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk of Greater $1,000.00
Association Cincinnati
Muscular Dystrophy MDA MuscleWalk MN $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk of Green Bay $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk Knoxville $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk Omaha $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk Jacksonville $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk Hawaii $1,000.00
Association
Muscular Dystrophy Passport to a Cure Program $1,500.00
Association
Muscular Dystrophy MDA MuscleWalk St. George $1,000.00
Association Utah
Muscular Dystrophy MDA MuscleWalk Miami $1,000.00
Association
Muscular Dystrophy MDA Muscle Team $3,000.00
Association
Muscular Dystrophy 3rd and 4th Quarter $3,000.00
Association Newsletter
Muscular Dystrophy MDA of Maine MuscleWalk $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk Kansas City $1,000.00
Association
Muscular Dystrophy Fourth Quarter Newsletter $2,000.00
Association
Muscular Dystrophy MDA MuscleWalk Northwest $1,000.00
Association Indiana
Muscular Dystrophy MDA MuscleWalk Tucson $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk Houston $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk of Metro NY $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk NH $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk of Raleigh $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk of Northwest $1,000.00
Association Arkansas
Muscular Dystrophy 3rd Quarter Newsletter $3,000.00
Association
Muscular Dystrophy MDA MuscleWalk of Columbia $1,000.00
Association
Muscular Dystrophy 3rd Quarter Newsletter $5,000.00
Association
Muscular Dystrophy MDA MuscleWalk of Greater $1,000.00
Association Madison
Muscular Dystrophy MDA MuscleWalk FL $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk Amarillo $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk of Manasota $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk MO $1,000.00
Association
Muscular Dystrophy Northern California Muscle $8,000.00
Association Summit
Muscular Dystrophy MDA MuscleWalk of Palm Beach $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk FL $500.00
Association
Muscular Dystrophy MDA MuscleWalk WA $1,000.00
Association
Muscular Dystrophy 2nd Annual Nashville Muscle $1,000.00
Association Team Gala
Muscular Dystrophy MDA MuscleWalk Hartford/New $1,000.00
Association Haven
Muscular Dystrophy MDA MuscleWalk of Colorado $1,000.00
Association Springs
Muscular Dystrophy MDA MuscleWalk of San Diego $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk Tri-Cities $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk Chattanooga $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk Greater Lehigh $1,000.00
Association Valley
Muscular Dystrophy MDA MuscleWalk Midland $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk Lubbock $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk Orlando $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk South Alabama $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk of Peoria $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk of Greater $1,000.00
Association Baton Rouge
Muscular Dystrophy MDA MuscleWalk of Greater New $1,000.00
Association Orleans
Muscular Dystrophy MDA MuscleWalk of Central New $1,000.00
Association Jersey
Muscular Dystrophy MDA MuscleWalk Central $1,000.00
Association Illinois
Muscular Dystrophy MDA MuscleWalk of Omaha $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk of Little Rock $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk of Baltimore $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk of Jackson $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk Spokane $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk CA $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk of Rockford $1,000.00
Association
Muscular Dystrophy MDA Summer Newsletter $1,500.00
Association
Muscular Dystrophy MDA MuscleWalk of Greater $1,000.00
Association Tulsa
Muscular Dystrophy MDA MuscleWalk of Chicagoland $1,000.00
Association & Rockford
Muscular Dystrophy MDA MuscleWalk Pittsburgh $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk of San Antonio $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk of Tampa Bay $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk Jacksonville $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk of Greater $1,000.00
Association Fort Wayne
Muscular Dystrophy MDA MuscleWalk Salt Lake City $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk Warwick RI $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk Portland OR $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk Eugene $1,000.00
Association
Muscular Dystrophy MuscleWalk: Portland $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk of St. Louis $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk of Greater $1,000.00
Association Indianapolis
Muscular Dystrophy MDA Muscle Walk of Wichita $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk of Greater $1,000.00
Association Cleveland
Muscular Dystrophy MDA MuscleWalk of $1,000.00
Association Springfield, MO
Muscular Dystrophy MDA MuscleWalk Missoula $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk Montana $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk Twin Cities $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk Charleston $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk of Greater $1,000.00
Association Milwaukee
Muscular Dystrophy MDA MuscleWalk of Los Angeles $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk LA $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk of Iowa City $1,000.00
Association
Muscular Dystrophy Northeast PA Muscle Summit $4,000.00
Association
Muscular Dystrophy MDA MuscleWalk of Waterloo $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk of Des Moines $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk of the Quad $1,000.00
Association Cities
Muscular Dystrophy MDA MuscleWalk of Denver $1,000.00
Association
Muscular Dystrophy MDA MuscleWalk Western $1,000.00
Association Colorado
Muscular Dystrophy MDA MuscleWalk VA $1,000.00
Association
Museum of Science Science Teacher Sabbatical $66,980.00
Program
Museum of Science Stars of STEM $10,000.00
National Fabry Disease Volunteer Match $1,000.00
Foundation
National Fabry Disease Philadelphia Fabry Family $2,200.00
Foundation Meeting
National Fabry Disease Family Assistance Program $10,000.00
Foundation
National Fabry Disease Conference and Camp Part 2 $70,000.00
Foundation
National Fabry Disease NFDF 2016 Fabry Family $15,000.00
Foundation Educational Meetings
National Fabry Disease Urgent and Unmet Needs $40,000.00
Foundation Program
National Fabry Disease NFDF Core Program $50,000.00
Foundation
National Fabry Disease Fabry Conference and Camp $50,000.00
Foundation
National Fabry Disease NFDF Core Program $50,000.00
Foundation
National Fabry Disease Volunteer Match $7,000.00
Foundation
National Gaucher Patient Assistance CARE $1,200,000.00
Foundation, Inc. Program
National Gaucher Patient Assistance Program $400,000.00
Foundation, Inc.
National Gaucher Optimal Health Initiative & $225,000.00
Foundation, Inc. Education/Awareness
National Kidney South Bend Indiana Kidney $2,500.00
Foundation Program
National Kidney Nutrition Program for Chronic $1,000.00
Foundation Kidney Disease, Diabetes and
Hypertension
National Kidney Indianapolis Kidney Health $1,500.00
Foundation Awareness Program
National Kidney Kidney Health Awareness $1,500.00
Foundation Program
National Kidney Evansville Kidney Health $1,500.00
Foundation Awareness Program
National Kidney Kidney Health Awareness $1,500.00
Foundation Program
National Kidney Patient Education and $77,000.00
Foundation Awareness Program
National Kidney NKF Clinical Bulletin on $95,775.00
Foundation Fabry Disease
National MPS Society Family Support Programs $30,000.00
National MPS Society Symposium funding $4,000.00
National MPS Society National MPS Society $24,000.00
Conferences
National MPS Society National MPS Society $24,000.00
Conferences
National MPS Society Congress Sponsorships $50,000.00
National MPS Society National Run--National MPS $10,000.00
Society
National Multiple Volunteer Match $4,000.00
Sclerosis Society
National Multiple National MS Society $15,000.00
Sclerosis Society Nationwide Connection
Programs
National Multiple Everyday Matters: Living Your $25,000.00
Sclerosis Society Best Life with MS
National Multiple Volunteer Match $25,000.00
Sclerosis Society
National Multiple Information Resource Center $25,000.00
Sclerosis Society
National Multiple North American Education $35,000.00
Sclerosis Society Program
National Multiple Knowledge is Power $35,000.00
Sclerosis Society
National Multiple Volunteer Match $9,000.00
Sclerosis Society
National Multiple MS Care Management Program $5,000.00
Sclerosis Society
National Multiple Free From Falls $1,000.00
Sclerosis Society
National Multiple MS Service Day $3,000.00
Sclerosis Society
National Multiple Day at the Bay $3,500.00
Sclerosis Society
National Multiple MS Exercise/Wellness Program $5,000.00
Sclerosis Society
National Multiple Scholarship Program $10,000.00
Sclerosis Society
National Multiple 41st annual Dinner of $2,500.00
Sclerosis Society Champions
National Multiple Bike MS: I Ride with MS $5,000.00
Sclerosis Society Greater NW
National Multiple Bike MS Cape Cod Getaway $50,000.00
Sclerosis Society
National Multiple National MS Society E- $75,000.00
Sclerosis Society Communications Program
National Multiple Muckfest MS Boston $25,000.00
Sclerosis Society
National Multiple Dinner of Champions Seattle $10,000.00
Sclerosis Society
National Multiple Bike MS Ride the Vineyard $10,000.00
Sclerosis Society
National Multiple Walk MS Walks MT $5,000.00
Sclerosis Society
National Multiple Walk MS Southern California & $25,000.00
Sclerosis Society Nevada
National Multiple MS Walks Pacific $10,000.00
Sclerosis Society
National Multiple Walk MS Boston $25,000.00
Sclerosis Society
National Multiple Fast Forward Research $75,000.00
Sclerosis Society Showcase Meeting
National Multiple Bike MS ``I Ride With MS'' NY $350,000.00
Sclerosis Society
National Multiple Walk MS Phoenix $5,000.00
Sclerosis Society
National Multiple National MS Society Tykeson $10,000.00
Sclerosis Society Fellows Conference
National Multiple National MS Society $50,000.00
Sclerosis Society Leadership Conference
National Multiple Bike MS Coastal Challenge Los $10,000.00
Sclerosis Society Angeles
National Multiple Dinner of Champions Las Vegas $2,500.00
Sclerosis Society
National Multiple Are You What You Eat?: $5,000.00
Sclerosis Society Studying Diet and
Supplements in Multiple
Sclerosis
National Multiple National MS Society $15,000.00
Sclerosis Society Leadership Conference
National Multiple Live Fully, LiveWell: $15,000.00
Sclerosis Society Discover Your Personal Path
to Living Your Best Life
with MS
National Multiple Chicago Symposium $5,000.00
Sclerosis Society
National Multiple MS Walks Greater Houston Area $10,000.00
Sclerosis Society
National Multiple Moving Forward: Annual $5,000.00
Sclerosis Society Meeting and Resource Fair
National Multiple Bike MS NYC $6,000.00
Sclerosis Society
National Multiple Dallas On The Move Luncheon $5,000.00
Sclerosis Society
National Multiple MuckFest MS $3,000.00
Sclerosis Society
National Multiple Gala MS $2,500.00
Sclerosis Society
National Multiple Bike MS: City to Shore Ride $5,000.00
Sclerosis Society
National Multiple Crystal Boots & Silver Spurs $2,400.00
Sclerosis Society
National Multiple Bike MS--Northern California $5,000.00
Sclerosis Society
National Multiple MS Auction Hawaii $3,500.00
Sclerosis Society
National Multiple Orange Country MS Research $2,500.00
Sclerosis Society Symposium
National Multiple MS Walks Central Texas $2,500.00
Sclerosis Society
National Multiple Ambassadors Ball $25,000.00
Sclerosis Society
National Multiple Weekend Escape VA $5,000.00
Sclerosis Society
National Multiple Cooling Shirts Gel Packs $4,500.00
Sclerosis Society
National Multiple Bike MS Willamette Valley $5,000.00
Sclerosis Society
National Multiple Smarty Pants Trivia Night $2,500.00
Sclerosis Society
National Multiple Spellbound on the Farm $1,500.00
Sclerosis Society
National Multiple Bike MS $5,000.00
Sclerosis Society
National Multiple MS On the Move Luncheon $2,500.00
Sclerosis Society
National Multiple Women Against MS (WAMS) $5,000.00
Sclerosis Society Luncheon PA
National Multiple Walk MS Jones Beach $5,000.00
Sclerosis Society
National Multiple On The Move Luncheon New $5,000.00
Sclerosis Society Orleans
National Multiple Women on the Move Luncheon $6,000.00
Sclerosis Society
National Multiple Walk MS PA $5,000.00
Sclerosis Society
National Multiple Women on the Move Program $2,500.00
Sclerosis Society
National Multiple Walk MS Greater Illinois $50,000.00
Sclerosis Society
National Multiple Walk MS Knoxville $750.00
Sclerosis Society
National Multiple Walk MS Michigan Chapter $5,000.00
Sclerosis Society
National Multiple Walk MS Rochester NY $2,500.00
Sclerosis Society
National Multiple Walk MS Denver $20,000.00
Sclerosis Society
National Multiple MS Walks Minnesota, Dakotas $15,500.00
Sclerosis Society
National Multiple Women on the Move Luncheon MO $5,000.00
Sclerosis Society
National Multiple Walk MS Clarksville $750.00
Sclerosis Society
National Multiple MS Walk Indiana $12,000.00
Sclerosis Society
National Multiple MS Walks Iowa $2,500.00
Sclerosis Society
National Multiple Walk MS Wisconsin $10,000.00
Sclerosis Society
National Multiple 20th Anniversary: Books for a $20,000.00
Sclerosis Society Better Life Awards
National Multiple MS Walks PA $10,000.00
Sclerosis Society
National Multiple Walk MS Chattanooga $750.00
Sclerosis Society
National Multiple Walk MS NJ $10,000.00
Sclerosis Society
National Multiple Walk MS MO $5,000.00
Sclerosis Society
National Multiple Walk MS Northern California $25,000.00
Sclerosis Society
National Multiple MS Walks Utah & Southern $20,000.00
Sclerosis Society Idaho
National Multiple Walk MS CT $2,500.00
Sclerosis Society
National Multiple Walk MS OR $10,000.00
Sclerosis Society
National Multiple Walk MS Middle Tennessee $750.00
Sclerosis Society
National Multiple Walk MS Kentucky $10,000.00
Sclerosis Society
National Multiple Walk MS NY $100,000.00
Sclerosis Society
National Multiple Walk MS OH $5,000.00
Sclerosis Society
National Multiple Walk MS Jacksonville $7,500.00
Sclerosis Society
National Multiple Walk MS Arkansas $3,000.00
Sclerosis Society
National Multiple Walk MS New Mexico $2,500.00
Sclerosis Society
National Multiple Walk MS Oklahoma $10,000.00
Sclerosis Society
National Multiple Walk MS Washington DC $10,000.00
Sclerosis Society
National Multiple Walk MS Cincinnati $10,000.00
Sclerosis Society
National Multiple Walk MS Memphis $750.00
Sclerosis Society
National Multiple Walk MS Louisiana $5,000.00
Sclerosis Society
National Multiple Walk MS San Diego $20,000.00
Sclerosis Society
National Multiple Women on the Move Louisville $1,000.00
Sclerosis Society
National Multiple On The Move Luncheon--Houston $5,000.00
Sclerosis Society
National Multiple Walk MS Atlanta $5,000.00
Sclerosis Society
National Multiple Walk MS San Antonio $10,000.00
Sclerosis Society
National Multiple On the Move Luncheon $3,000.00
Sclerosis Society
National Multiple Runway for MS--Fashion Show $2,500.00
Sclerosis Society Luncheon
National Multiple Michigan Chapter's Annual $2,500.00
Sclerosis Society Meeting & Recognition
Breakfast
National Multiple MS Walks Arizona $24,000.00
Sclerosis Society
National Multiple Walk MS Alabama Mississippi $7,500.00
Sclerosis Society
National Multiple On The Move Luncheon--Baton $2,500.00
Sclerosis Society Rouge
National Multiple Walk MS Ft. Lauderdale $15,000.00
Sclerosis Society
National Multiple Women Against MS Luncheon TN $2,500.00
Sclerosis Society
National Multiple Health Issues in Multiple $9,000.00
Sclerosis Society Sclerosis Hawaii
National Multiple 6th Annual Festival Hispano $4,000.00
Sclerosis Society
National Multiple MS Gala Luncheon $5,000.00
Sclerosis Society
National Multiple New Jersey Metro Chapter $10,000.00
Sclerosis Society Volunteer Program
National Multiple Annual Meeting and Education $8,500.00
Sclerosis Society Conferences
National Multiple MuckFest MS Houston $2,500.00
Sclerosis Society
National Multiple Women Against MS Luncheon $3,000.00
Sclerosis Society (WAMS)
National Multiple Fall Crush Nashville $2,500.00
Sclerosis Society
National Multiple Walk MS Houston $20,000.00
Sclerosis Society
National Multiple FallCrush Nashville $2,500.00
Sclerosis Society
National Multiple Symposium Educational $7,500.00
Sclerosis Society Programs
National Multiple MuckFest MS $5,000.00
Sclerosis Society
National Multiple Team Finish MS at the $3,000.00
Sclerosis Society Hartford Marathon
National Multiple Bike MS Louisiana $5,000.00
Sclerosis Society
National Multiple Bike MS: City to Shore Ride $5,000.00
Sclerosis Society PA
National Multiple San Antonio Bike MS $10,000.00
Sclerosis Society
National Multiple New Hampshire Living Well $1,500.00
Sclerosis Society with MS Conference
National Multiple Chapter Annual Meeting and $5,000.00
Sclerosis Society Education Program:
Contemporary Issues in MS
National Multiple Moving Mountains for MS-- $10,000.00
Sclerosis Society Family Weekend Retreat
National Multiple Relationship Matters $5,000.00
Sclerosis Society
National Multiple MOVING FORWARD $1,500.00
Sclerosis Society
National Multiple Men with MS Elevation $10,000.00
Sclerosis Society Conference
National Multiple Children's Hope for $3,800.00
Sclerosis Society Understanding Multiple
Sclerosis
National Multiple MS Research Nights $5,000.00
Sclerosis Society
National Multiple Day of Discovery $7,500.00
Sclerosis Society
National Niemann-Pick Volunteer Match $1,000.00
Disease Foundation
National Niemann-Pick Staying Strong as we $50,000.00
Disease Foundation Persevere in our Quest for a
Cure
National Organization Volunteer Match $9,000.00
for Rare Disorders,
Inc.
National Organization Volunteer Match $6,000.00
for Rare Disorders,
Inc.
National Organization Running For Rare $5,000.00
for Rare Disorders,
Inc.
National Organization NORD's Rare Diseases and $50,000.00
for Rare Disorders, Orphan Products Breakthrough
Inc. Summit
National Organization Rare Impact Awards $50,000.00
for Rare Disorders,
Inc.
National Tay-Sachs & Raising Awareness of $1,100.00
Allied Diseases Ashkenazi Jewish Genetic
Association, Inc. Diseases
National Tay-Sachs & Expand Family Support Through $5,000.00
Allied Diseases Technology
Association, Inc.
National Tay-Sachs & Imagine & Believe $10,000.00
Allied Diseases
Association, Inc.
National Tay-Sachs & 38th Annual Family Conference $5,000.00
Allied Diseases
Association, Inc.
NCCN Foundation NCCN Guidelines for Patients: $25,000.00
Thyroid Cancer
NEHI The Nick Littlefield Health $25,000.00
Policy Fellowship
NEHI Innovators in Health Awards $25,000.00
Nephcure Foundation 11th International Podocyte $3,000.00
Conference
Neurologic Disease 21st Fall MS Seminar-- $5,995.00
Foundation Optimizing Management of MS
Neuropathy Action General Patient Advocacy and $2,500.00
Foundation Organizational Support
Next Step Fund Inc. FaceForward Campference and $10,000.00
general operating support
North American Vascular 19th International Vascular $10,000.00
Biology Organization Biology Meeting
Inc.
North Shore Community Volunteer Match $1,000.00
Health Inc.
Northeast Business Congress Sponsorships $5,000.00
group on Health
Northeastern University Allston Brighton College $2,000.00
Scholarship
Northwest Animal Rights Volunteer Match $1,000.00
Network
Northwest Animal Rights Volunteer Match $1,000.00
Network
Norton Healthcare Moonlight & Moonshine Gala $5,000.00
Foundation, Inc.
Norton Healthcare Neuroscience Expo $10,000.00
Foundation, Inc.
Norton Healthcare 1-N-3 Gala $5,000.00
Foundation, Inc.
Operation Warm Inc. Boston Warmth in Winter $18,000.00
OptumHealth Education Congress Sponsorships $7,500.00
Oregon Health & Science On the Horizon: Updates in $9,930.00
University Foundation Multiple Sclerosis
Pan Massachusetts Volunteer Match $11,000.00
Challenge
Pan Massachusetts Volunteer Match $11,000.00
Challenge
Patient Access Network Patient Assistance Program $100,000.00
Foundation for Thyroid Cancer
Patient Access Network Patient Assistance Program $100,000.00
Foundation for Thyroid Cancer
Patient Access Network Patient Assistance Fund for $100,000.00
Foundation Thyroid Cancer
Patient Access Network Patient Assistance Program $50,000.00
Foundation for Thyroid Cancer
Patient Access Network Patient Assistance Program $50,000.00
Foundation for Homozygous Familial
Hypercholesterolemia
Patient Access Network Patient Assistance Program $125,000.00
Foundation for Homozygous Familial
Hypercholesterolemia
Patient Services Inc. Patient Assistance Program $4,440,000.00
for Fabry, Pompe, MPS1, and
Gaucher Disease
Patient Services Inc. Patient Assistance Program $2,000,000.00
Patient Services Inc. Patient Assistance Program $6,500,000.00
Peer Health Exchange Peer Health Exchange: $5,000.00
Inc. Empowering Boston Youth to
Make Healthy Decisions
Perkins School for the Perkins eLearning: Enhancing $20,000.00
Blind Accessible Science Education
Phillips Brooks House Community Program $5,000.00
Association
Incorporated
Phoenix Children's MPS patient meeting $1,200.00
Hospital Foundation
Portland VA Research PDX Patient Workshops $3,150.00
Foundation Inc.
President and Fellows Community Program $20,000.00
of Harvard College
President and Fellows Patient Assistance Program $50,000.00
of Harvard College
Pro Player Foundation Flavors of Austin $5,000.00
Pro Player Foundation Flavors of Austin $5,000.00
Project Eden Inc. Volunteer Match $1,000.00
Project Just Because, 211 Domestic Abuse/Emergency $10,000.00
Inc. Program & Keep A Family Warm
Program
Race to Erase MS Race to Erase MS--MS Forum $10,000.00
Race to Erase MS 23rd Annual Race to Erase MS $50,000.00
Read to a Child, Inc. Community Program $5,000.00
Read to a Child, Inc. Community Program $2,500.00
Resolve Community Volunteer Match $1,000.00
Counseling Center,
Inc.
Restore Volunteer Match $1,000.00
Rocky Mountain Multiple KADEP (King Adult Day $5,000.00
Sclerosis Center Enrichment Program) Annual
Winter Community Gathering
Rocky Mountain Multiple Rocky Mountain MS Center $10,000.00
Sclerosis Center Annual Gala
Rocky Mountain Multiple MS4MS Event $5,000.00
Sclerosis Center
Rocky Mountain Multiple KADEP Annual Holiday $5,000.00
Sclerosis Center Celebration
Rocky Mountain Multiple Webinar Series $5,000.00
Sclerosis Center
Room to Grow Community Program $5,000.00
Runkle School Extended Volunteer Match $1,000.00
Day Program Inc.
S S Cosmas & Damian Community Program $2,500.00
Society Inc.
Saint Francis Hospital International Symposium: The $50,000.00
and Medical Center Multiple Sclerosis Brain--
Foundation Bridging the Gap
Salute the Ribbon Meet, Greet n' Eat Luncheon $1,000.00
Incorporated ``Opening Doors for Health
Care Access to Cancer Care''
Samaritans Inc. Community Program $25,000.00
Science Club For Girls Community Program $10,000.00
Inc.
Science Club For Girls Catalyst Awards $10,000.00
Inc.
Science From Scientists STEM enrichment program for $25,000.00
Inc. Boston Public Schools
Science From Scientists In-School Module-Based (ISMB) $20,000.00
Inc. STEM enrichment program
Science From Scientists 70th Annual Boston Citywide $10,000.00
Inc. Science Fair
Sharp Rees-Stealy Congress Sponsorships $5,000.00
Medical Group Sharp
Healthcare
Society for Inherited North American Metabolic $20,000.00
Metabolic Disorders Academy
Society of Nuclear SNMMI Patient Education Day $5,000.00
Medicine and Molecular
Imaging
Special Olympics Bio-Ball $2,500.00
Massachusetts Inc.
St. Francis House Community Program $10,000.00
Stop Hunger Now, Inc. Volunteer Match $2,944.08
Strongwater Farm Riding group for individuals $7,500.00
Therapeutic Equestrian living with MS
Center
Temple Beth Sholom [The Patient Education and $6,200.00
Tribe] Awareness Program
Temple University Allston Brighton College $2,000.00
Scholarship
The Boston Home, Inc. Volunteer Match $1,000.00
The Boston Home, Inc. The Boston Home iPad InstaAid $12,000.00
Program Expansion
The Boston Home, Inc. The Boston Home Arts Program $10,000.00
The Boston Home, Inc. The Boston Home B.Fit $18,000.00
Wellness Program
The Boston Home, Inc. The Boston Home Resident $10,000.00
Family Picnic
The Boston Home, Inc. Finding Your Voice $5,000.00
The Community Art Teen Media Program $15,000.00
Center
The Discovery Museums Genzyme Discovery Science $15,000.00
The Discovery Museums Discovery Science Program $15,000.00
The Forsyth Institute Community Program $10,000.00
The Greater Boston Food Volunteer Match $2,000.00
Bank Inc.
The Greater Boston Food General Operating Support $10,000.00
Bank Inc.
The Greater Boston Food Volunteer Match $1,000.00
Bank Inc.
The Jewish Community Our Heritage and Our Health-- $1,250.00
Center of Greater Ashkenazi Jewish Genetic
Kansas City Disease and the Founder
Effect
The Jewish P.O.C.E.T. Greater Chicago Jewish $3,240.00
Festival
The Leukemia & Lymphoma Light The Night Walk $6,500.00
Society Inc.
The Life Sciences Leadership Mid-Term Funding $50,000.00
Foundation for Educational Programs
The McCourt Foundation Tour de South Shore $10,000.00
The McCourt Foundation McCourt Gala $20,000.00
The McCourt Foundation McCourt Foundation MS $20,000.00
Educational Update
The Oak Clinic Oak Clinic Acorn Run $3,500.00
The Oak Clinic Diamond Run $5,000.00
The Posse Foundation Community Program $25,000.00
The Possible Project The Possible Project's $10,000.00
Powering Possibilities
Annual Gala
The Salvation Army Volunteer Match $2,000.00
Thompson Island Outward Community Program $10,000.00
Bound Education Center
Inc.
Thompson Island Outward Islands Expedition Gala $5,000.00
Bound Education Center
Inc.
Thompson Island Outward Thompson Island 4K Trail Run $5,000.00
Bound Education Center
Inc.
ThyCa: Thyroid Cancer Patient Education and $15,000.00
Survivors' Awareness Program
Association, Inc.
ThyCa: Thyroid Cancer 19th International Thyroid $35,000.00
Survivors' Cancer Survivors' Conference
Association, Inc.
Tisch Multiple Tisch MS Research Center $15,000.00
Sclerosis Research Newsletter
Center of New York,
Inc.
Tisch Multiple Future Without MS Gala $5,000.00
Sclerosis Research
Center of New York,
Inc.
Tisch Multiple Future Without MS Gala $15,000.00
Sclerosis Research
Center of New York,
Inc.
Tisch Multiple Tisch MS Research Center 19th $25,000.00
Sclerosis Research Annual MS Patient Symposium
Center of New York,
Inc.
Triangle, Inc. Volunteer Match $1,000.00
Triangle, Inc. Triangle's 45th Annual Spring $5,000.00
Gala
Tri-State Multiple Evansville Autumn Walk $2,500.00
Sclerosis Association
Tri-State Multiple Owensboro Autumn Walk $2,500.00
Sclerosis Association
Tri-State Multiple Evening of Excellence $2,000.00
Sclerosis Association
Tri-State Multiple Tri-State Multiple Sclerosis $4,500.00
Sclerosis Association Association Autumn Walks
Tutoring Plus of STEAM Enrichment Programs $7,500.00
Cambridge, Inc.
Tutoring Plus of Community Program $5,000.00
Cambridge, Inc.
U C San Diego UCSD Regional MS Expositions $50,000.00
Foundation
United Network for Congress Sponsorship $7,800.00
Organ Sharing
United Pompe Foundation Duke Late Onset Pompe Patient $19,000.00
Meeting
United Pompe Foundation Pompe Patient Meeting $19,000.00
United Pompe Foundation General Operating Support $50,000.00
United Rheumatology Congress Sponsorship $60,000.00
United Way of Tri Volunteer Match $1,000.00
County Inc.
United Way of Tri Volunteer Match $1,000.00
County Inc.
United Way of Tri Volunteer Match $1,000.00
County Inc.
United Way of Tri Volunteer Match $2,000.00
County Inc.
University of Student Success Program, $200,000.00
Massachusetts UMass Boston, College of
Foundation Inc. Science and Mathematics
University of Massachusetts STEM Summit $5,000.00
Massachusetts
Foundation Inc.
University of Southern Allston Brighton College $4,000.00
California Scholarship
Visiting Nurse Heroes in Health Care Gala $10,000.00
Association of Boston
& Affiliates
VNA Care Hospice Inc. Community Program $5,000.00
VNA Care Hospice Inc. Community Program $5,000.00
Wentworth Institute of Allston Brighton College $2,000.00
Technology Scholarship
West End House Boys and Volunteer Match $1,000.00
Girls Club
West End House Boys and Community Program $25,000.00
Girls Club
West End House Boys and Community Program $25,000.00
Girls Club
WGBH Pledge Night Sponsorship $12,000.00
Whitehead Institute for Whitehead Institute's CampBio $10,000.00
Biomedical Research Program
Women's Lunch Place Meals Program $35,000.00
Women's Lunch Place General Operating Support $10,000.00
Women's Lunch Place Community Program $10,000.00
World Unity Inc. Volunteer Match $1,000.00
WriteBoston Community Program $10,000.00
Wylder Nation Patient Education and $15,000.00
Foundation Awareness Program
Wylder Nation 3rd Annual Living Like a $15,000.00
Foundation Warrior Gala
YMCA of Greater Boston Oak Square YMCA--Summer Day $15,000.00
Camp Scholarships
ziMS Foundation ziMS STRIKE DOWN MS Event $5,000.00
Sponsorships and Charitable Donations
1st Jan 2017-31st Dec 2017
Sanofi US and its affiliate Genzyme Corporation are committed to
supporting sponsorships for specific activities and initiatives of
healthcare organizations and institutions, independent medical or
professional societies, trade organizations and organized patient groups
to improve patient care and provide information to the medical and/or
patient communities. The goal of our charitable giving approach is to
fund general operational support for patient/disease organizations, or
program support for community-based organizations. Sanofi US and Genzyme
Corporation are part of the Sanofi Group, a global pharmaceutical
company.
Applicant names are provided by the requestor. If applicants apply as a
group for a single activity; all applicants may be not be identified
above. ``Funding Amount'' is the amount that the Company funded during
2017 identified above. ``Funding Amount'' does not include funds that
may have been provided by other affiliated Sanofi Company Entities
(e.g., Sanofi Pasteur).
Recipient Name(s) Activity Title Funding Amount
American Academy of Congress Sponsorship $35,317.50
Neurology
Academy of Managed Care Congress Sponsorship $1,000.00
Pharmacy A New Jersey
Nonprofit Corporation
Academy of Managed Care Congress Sponsorship $26,500.00
Pharmacy A New Jersey
Nonprofit Corporation
Accelerated Cure 2017 Leadership Summit $15,000.00
Project
Acid Maltase Deficiency Annual Fundraiser $3,000.00
Association Inc.
Acid Maltase Deficiency General Operating Support $50,000.00
Association, Inc.
Alabama Kidney Patient Education Conferences $2,500.00
Foundation
Allergy & Asthma Understanding Atopic $75,000.00
Network Mothers of Dermatitis Guide
Asthmatics, Inc.
Allergy & Asthma Patient Activation $200,000.00
Network Mothers of Measurement Study
Asthmatics, Inc.
Allergy & Asthma GlobalSkin Conference $3,000.00
Network Mothers of
Asthmatics, Inc.
Allergy & Asthma Severe Asthma Awareness $150,000.00
Network Mothers of Campaign
Asthmatics, Inc.
Allergy & Asthma Project Access Initiative $25,000.00
Network Mothers of
Asthmatics, Inc.
Allergy & Asthma Allergy & Asthma Awareness $25,000.00
Network Mothers of Day
Asthmatics, Inc.
Allergy & Asthma Allergy & Asthma Network $25,000.00
Network Mothers of Corporate Council 2017
Asthmatics, Inc.
Alliance for Patient 2018 Membership $100,000.00
Access
Allston Village Main Taste of Allston Event $1,000.00
Streets, Inc.
American Academy of Patient AccessDerm Program $250,000.00
Dermatology
American Academy of President's Summit on $5,000.00
Dermatology Diversity in Dermatology
American Academy of Congress Sponsorship $17,800.00
Neurology
American Academy of Congress Sponsorship $432,935.00
Neurology
American Academy of Emerging Leaders Program $20,000.00
Neurology Institute
American Academy of Women Leading in Neurology $20,000.00
Neurology Institute Program
American Academy of Clinical Research Training $50,000.00
Neurology Institute Scholarship in Multiple
Sclerosis
American Academy of Palatucci Advocacy Leadership $50,000.00
Neurology Institute Forum
American Academy of Residents Scholarship Fund $20,000.00
Neurology Institute
American Academy of Fellows Scholarship Fund $20,000.00
Neurology Institute
American Academy of Brain Health Fair $10,000.00
Neurology Institute
American Academy of Neurology Annual Meeting 2017 $208,632.90
Neurology Institute
American Academy of Transforming Leaders Program $20,000.00
Neurology Institute
American Association AAAS 2017 Annual Meeting-- $25,000.00
For The Advancement of Family Science Days
Science
American Association of Congress Sponsorship $4,300.00
Clinical
Endocrinologists
American Association of Congress Sponsorship $18,500.00
Endocrine Surgeons
American Association of Congress Sponsorship $67,600.00
Neuromuscular &
Electrodiagnostic
Medicine
American Brain Membership $20,000.00
Coalition
American Cancer Society 25th Making Strides Against $1,000.00
Breast Cancer Walk
American Cancer Society Bicycles Battling Cancer 2017 $11,000.00
American Cancer Society Bicycles Battling Cancer 2016 $11,000.00
American Cancer Society 10th Annual ACS CAN New $10,000.00
Cancer Action Network England Research Breakfast
American College of Shared Decision Making $125,000.00
Allergy, Asthma & Toolkit for Severe Atopic
Immunology Dermatitis
American College of Severe Pediatric Asthma $60,000.00
Allergy, Asthma & Shared Decision Making
Immunology Toolkit
American College of Shared Decision Making $125,000.00
Allergy, Asthma & Toolkit for Severe Pediatric
Immunology Asthma
American College of Practice Management Center $240,000.00
Allergy, Asthma &
Immunology
American College of Patient Education Brochure $31,000.00
Allergy, Asthma &
Immunology
American College of Atopic Dermatitis Yardstick $145,000.00
Allergy, Asthma & Educational Manuscript
Immunology
American College of Membership $60,000.00
Chest Physicians
American College of Congress Sponsorship $2,000.00
Rheumatology
American Lung Membership $20,000.00
Association
American Lung Asthma Care Coverage Project $75,000.00
Association
American Optometric Congress Sponsorship $3,150.00
Association
American Red Cross of Women Who Care Leadership $5,000.00
Massachusetts Breakfast
American Society of ASCO Annual Meeting $118,000.00
Clinical Oncology
American Society of 59th Annual ASH Convention $224,300.00
Hematology
American Society of Congress Sponsorship $56,600.00
Hematology
American Society of Congress Sponsorship $3,300.00
Human Genetics
American Society of Congress Sponsorship $35,000.00
Nephrology
American Society of Congress Sponsorship $20,950.00
Nephrology
American Society of Congress Sponsorship $40,000.00
Nephrology
American Society of Congress Sponsorship $35,000.00
Transplant Surgeons
American Society of Congress Sponsorship $6,000.00
Transplant Surgeons
American Society of Congress Sponsorship $35,000.00
Transplantation
American Society of Congress Sponsorship $35,000.00
Transplantation
American Thoracic Corporate Membership Program $50,000.00
Society
American Thyroid Congress Sponsorship $11,950.00
Association
American Thyroid Congress Sponsorship $18,000.00
Association
American Transplant Congress Sponsorship $45,000.00
Congress
Americas Committee for Congress Sponsorship $15,000.00
Treatment and Research
in Multiple Sclerosis,
Inc.
ANERA (American Near Annual Dinner $5,000.00
East Refugee Aid)
Ann & Robert H. Lurie MPS Patient and Family Day $2,500.00
Children's Hospital of
Chicago
Arizona Myeloma Network Cancer Patient & Caregivers $3,250.00
Outreach & Seminar Series
Arthritis Foundation-- 37th Annual Silver Ball Gala $1,250.00
St. Louis, MO
Arthritis Foundation-- Arthritis Industry Forum $25,000.00
Atlanta, GA
Arthritis Foundation-- Casino Night Gala $2,500.00
St. Paul, MN
Arthritis Foundation-- Patient Engagement Program $25,000.00
Atlanta, GA
Arthritis Foundation-- Taste of the Town Gala $5,000.00
Hawaii Chapter
Arthritis Foundation-- Freedom of Movement Gala $5,000.00
Chicago, IL
Arthritis Foundation-- Houston Bone Bash Gala $10,000.00
Houston, TX
Arthritis Foundation-- PREOP Training and Engagement $250,000.00
Atlanta, GA Initiative
Arthritis Foundation-- Walk to Cure Arthritis and $250,000.00
Atlanta, GA Jingle Bell Run
Arthritis Foundation-- Walk to Cure Arthritis $3,500.00
Green Bay, WI
Arthritis Foundation-- Walk to Cure Arthritis $5,000.00
Sacramento, CA
Arthritis Foundation-- Walk to Cure Arthritis $2,500.00
Irvine, CA
Arthritis Foundation-- Walk to Cure Arthritis $1,000.00
St. Paul, MN
Arthritis Foundation-- Ambassador Program $125,000.00
Atlanta, GA
Arthritis Foundation-- Advocacy Summit $25,000.00
Atlanta, GA
Arthritis Foundation-- Walk to Cure Arthritis $5,000.00
Boston, MA
Arthritis Foundation-- Walk to Cure Arthritis $5,000.00
Los Angeles, CA
Arthritis Foundation-- Patient Voice Accumulator $50,000.00
Atlanta, GA Project
Arthritis Foundation-- 51st Annual Knowles Lecture $7,500.00
Northern California
Arthritis Foundation-- Walk to Cure Arthritis $1,000.00
Hawaii Chapter
Arthritis Foundation-- Walk to Cure Arthritis $2,500.00
Chicago, IL
Arthritis Foundation-- Walk to Cure Arthritis $2,500.00
New England Chapter
Arthritis Foundation-- Walk to Cure Arthritis $2,500.00
New England Chapter
Arthritis Foundation-- Evening of Honors Event $5,000.00
New Jersey Chapter
ASCO Congress Sponsorship $5,495.00
Asembia Specialty Asembia Specialty Pharmacy $20,000.00
Pharmacy Summit LLC Summit
Assistance Fund Inc Patient Assistance Program $10,000,000.00
for MS
Association For Annual Conference $7,000.00
Glycogen Storage
Disease
Association of 41st Annual APHON Conference $6,850.00
Pediatric Hematology/
Oncology Nurses
Association of VA 13th Annual AVAHO Meeting $10,000.00
Hematology/Oncology
Asthma and Allergy Strengthening the Asthma $200,000.00
Foundation of America Community
Asthma and Allergy Asthma Capitals Report $125,000.00
Foundation of America
Asthma and Allergy Supporting Patients and $110,000.00
Foundation of America Families Program
Asthma and Allergy Research Project $200,000.00
Foundation of America
Asthma and Allergy Research Project $120,000.00
Foundation of America
Barbara Ann Karmanos Seventh Annual Prostate $7,500.00
Cancer Institute Cancer Advocacy Symposium
Bendcare National Meeting $10,310.00
Bendcare Educational Conferences $92,790.00
Berkshire Resource People Living with MS that $4,000.00
Project have Impaired Vision Program
Berkshire Resource Functional Ability Skills for $3,500.00
Project Everyday Living With
Multiple Sclerosis
Berkshire Resource 9th Annual Gala ``Let's Kiss $5,000.00
Project MS Goodbye''
Berkshire Resource Coping With The Emotional $4,000.00
Project Aspects of MS Program
Big Brothers Big MySTEM Program $15,000.00
Sisters of Central
Mass Metrowest Inc.
Biomedical Science Evening of Hope 2017 $100,000.00
Careers Program
Biomedical Science Hope Scholarship 2017-2018 $7,500.00
Careers Program
Blue Cross Blue Shield Blues National Summit $15,975.00
Association
Boston Business Boston Business Journal $5,500.00
Journal, Inc. Corporate Citizenship Awards
Boston Health Care For Charitable Contribution--Life $35,000.00
The Homeless Program, Essentials for Homeless
Inc. Patients
Boston Partners in Power Lunch Program $6,000.00
Education, Inc.
Boston Private Industry 2017 Corporate Contributions $15,000.00
Council Campaign
Boston Private Industry Volunteer Match $1,000.00
Council
Bottom Line Boston STEM Success Program $15,000.00
Boys & Girls Clubs of Fall Flashback Festival $5,000.00
Medford and Somerville
Inc.
Boys and Girls Clubs of Volunteer Match $2,000.00
MetroWest
Boys and Girls Clubs of Volunteer Match $1,000.00
MetroWest
Boys and Girls Clubs of Bids for Kids Auction & Gala $10,000.00
MetroWest
Boys and Girls Clubs of Membership $25,000.00
MetroWest
Boys and Girls Clubs of Volunteer Match $2,000.00
MetroWest
BPE Boston Teacher Residency: $15,000.00
Innovative STEM Educators
Program
Breakthrough Greater Full STEAM Ahead Program $15,000.00
Boston
Breakthrough Greater Full STEAM Ahead Program $10,000.00
Boston
California Life CLSA Life Sciences Academy $8,000.00
Sciences Association
California rheumatology Annual Meeting $50,000.00
Alliance
Cambridge Chamber of Lead Sponsorship $7,500.00
Commerce
Cambridge Health Volunteer Match $1,000.00
Alliance Foundation,
Inc.
Cambridge School Volunteer Match $1,000.00
Volunteers, Inc.
Cambridgeport 2017 Summer Programs for $5,000.00
Neighborhood Magazine Beach Park Support
Association, Inc.
Can Do Multiple 2018 SKI for MS $40,000.00
Sclerosis
Can Do Multiple 2017 MS Global $10,000.00
Sclerosis
Can Do Multiple 2017 TAKE CHARGE Program $40,000.00
Sclerosis
Can Do Multiple 8th Annual Can Do Day $10,000.00
Sclerosis
Can Do Multiple 2017 CAN DO Programs $50,000.00
Sclerosis
Can Do Multiple Can Do On Demand Program $60,000.00
Sclerosis
Can Do Multiple 2017 TAKE CHARGE and $16,500.00
Sclerosis JUMPSTART Programs
Can Do Multiple 2017 JUMPSTART Programs $80,000.00
Sclerosis
Can Do Multiple 2017 Ski for MS $30,000.00
Sclerosis
Can Do Multiple 2017 Online Programs $45,000.00
Sclerosis
Can Do Multiple Can Do MS eNews: Your Best $5,000.00
Sclerosis Life Update
Case Management Society Annual Corporate Partnership $5,500.00
of America
Case Management Society CMSA 2017 Conference $14,000.00
of America
Case Management Society CMSA 27th Annual Conference & $1,725.00
of America Expo
Case Management Society Focus on the Future--Keeping $1,050.00
of New England a Keen Eye on Tomorrow
Program
Case Management Society Corporate Sponsorship $1,250.00
of New England
Case Management Society Case Management Society of $1,000.00
of New England New England Conference
Charles River Community Mom and Baby Program $15,000.00
Health
CheckOrphan Rare Disease Page Sponsorship $40,000.00
Chicago Rheumatism Congress Sponsorship $4,500.00
Society
Childrens Gaucher Research Grant $75,000.00
Research Fund
Children's Hospital Milagros para Ninos 2017 Gala $5,000.00
Corporation
Chronic Disease Fund, Patient Assistance Program $350,000.00
Inc. DBA Good Days
from CDF
Cincinnati Children's Congress Sponsorship $10,000.00
Hospital Medical
Center
Cleveland Clinic Congress Sponsorship $15,000.00
Educational Institute
Cleveland Clinic 5th Annual Basic & Clinical $3,500.00
Educational Institute Immunology for the Busy
Clinician
Clevleand Clinic Scott Hamilton and Friends $5,000.00
Ice Show and Gala
Coalition of State CSRO State Society Key $37,500.00
Rheumatology Legislator Education Program
Organizations
Coalition of State Coalition of State $100,000.00
Rheumatology Rheumatology Organizations
Organizations Support
Community Boating, Inc. Universal Access Program 2017 $15,000.00
Community Farms Fresh Food Access $15,000.00
Outreach
Community Farms Volunteer Match $1,000.00
Outreach
Community Oncology Congress Sponsorship $33,000.00
Alliance
Community Servings, 25th Anniversary Pie in the $10,000.00
Inc. Sky Fundraiser
Consortium of Multiple North American Registry for $200,000.00
Sclerosis Centers Care and Research in
Multiple Sclerosis Support
Consortium of Multiple 2017 CMSC Annual Meeting $100,000.00
Sclerosis Centers
Courageous Parents Empowering parents and $26,250.00
Network caregivers of children with
MPS, Gaucher, Nieman-Pick
Cradles to Crayons Ready for School Program $20,000.00
Support
Cradles to Crayons Volunteer Match $2,000.00
Cure GM1 Incorporated TORCH Award $5,000.00
Cure Sanfilippo TORCH Award $5,000.00
Foundation
Cystic Fibrosis Uncork the Cure $15,000.00
Foundation
Cystic Fibrosis Massachusetts CF Cycle for $4,000.00
Foundation Life Fundraiser
DEAF, Inc.-- Deaf-Accessible Medical Case $10,000.00
Developmental Management and Access to
Evaluation and Health Program
Adjustment Facilities,
Inc.
Department of Congress Sponsorship $5,878.75
Pediatrics, Tufts
Medical Center
Dimock Community Volunteer Match $1,000.00
Foundation Inc.
Dimock Community 30th Anniversary Steppin' Out $100,000.00
Foundation Inc. for The Dimock Center
DPC Education Center Fabry Disease Education $27,500.00
Program
Eastern Allergy Congress Sponsorship $39,000.00
Conference
Emerald Necklace 14th Anniversary Party in the $6,500.00
Conservancy, Inc. Park
Emory University JScreen Jewish Genetic $216,089.00
Disease Education Initiative
Endocrine Society Congress Sponsorship $24,500.00
EveryLife Foundation 2017 RareVoice Awards $30,000.00
for Rare Diseases
EveryLife Foundation Emerging Technologies for $15,000.00
for Rare Diseases Rare Diseases: Clinical &
Regulatory Case Studies and
Approval Pathways
EveryLife Foundation Rare on the Road Leadership $30,000.00
for Rare Diseases Tour
EveryLife Foundation TORCH Award Donations $5,000.00
for Rare Diseases
Fabry Support & FSIG Fun Run/Walk $1,500.00
Information Group
Fabry Support & General Operating Support $100,000.00
Information Group
Fabry Support & FSIG Annual Family Conference $1,000.00
Information Group
Fabry Support & 2017 FSIG Expert Fabry $50,000.00
Information Group Conference
Family Promise Fundraising Event $2,500.00
Metrowest, Inc.
Florida Society of Congress Sponsorship $35,000.00
Rheumatology
Food For Free A Nutrition Program for $5,000.00
Committee, Inc. Seniors and People with
Disabilities
Foundation of the Newsletter Support $6,500.00
Consortium of MS
Centers
Foundation of the Annual Meeting $5,450.00
Consortium of MS
Centers
Foundation of the Research Grant $42,000.00
Consortium of MS
Centers
Foundation of the Multiple Sclerosis Workforce $32,000.00
Consortium of MS of the Future 2018:Medical
Centers Student Research
Scholarships
Foundation of the NARCOMS NOW Patient Quarterly $33,583.00
Consortium of MS Magazine
Centers
Foundation of the Congress Sponsorship $432,000.00
Consortium of MS
Centers
Framingham Townwide Pto Volunteer Match $1,000.00
Council
Franciscan Hospital For Adaptive Sports Program $15,000.00
Children, Inc.
Friends of Children Celebrating Fatherhood Brunch $2,500.00
Trust Fund, Inc.
Friends of Resiliency Resiliency's Academic Support $10,000.00
For Life, Inc.
Fundacion de Esclerosis Hurricane Relief $3,334.00
Multiple de Puerto
Rico
Generation Citizen, Massachusetts Spring 2017 $6,000.00
Inc. Civics Day
Genetic Alliance, Inc. 30th Anniversary Conference $30,000.00
and Celebration
Genetic Alliance, Inc. 30th Anniversary Conference $30,000.00
and Celebration
Genetic Disease Fabry disease (dbFGP) Support $100,000.00
Foundation
Georgia Chapter of the Georgia AAP: Pediatrics on $5,000.00
American Academy of the Parkway
Pediatrics
Georgia Society of Congress Sponsorship $2,000.00
Rheumatology
Georgia Society of Congress Sponsorship $8,000.00
Rheumatology
Girl Scouts of Eastern Girls Building Self-eSTeEM $15,000.00
Massachusetts Inc. Program
Global Academy For Congress Sponsorship $55,000.00
Medical Education,
Inc.
Global Alliance for Membership $50,000.00
Patient Access
Global Genes RARE Tribute to Champions of $25,000.00
Hope
Global Genes RARE Patient Advocacy Summit $25,000.00
Global Genes Membership $25,000.00
Greater Boston Chamber 2017 Annual Meeting $10,000.00
of Commerce
Habitat For Humanity High Heels and Hard Hats $10,000.00
Metrowest--Greater Auction and Gala
Worcester, Inc.
Habitat For Humanity Home Renovation Build Support $20,000.00
Metrowest--Greater
Worcester, Inc.
Hadassah Greater Our Heritage and Our Health-- $900.00
Detroit Jewish Genetic Disorders and
Founder Effect Program
Health Care For All, Public Education Campaign $15,000.00
Inc.
Health Literacy Media MTC Educational Program $50,000.00
Hearts & Noses Hospital Ongoing Bedside Hospital $15,000.00
Clown Troupe, Inc. Clown Visits Program
Hematology Oncology Congress Sponsorship $7,500.00
Managers of New York,
Inc.
Holy Name Health Care 2017 MS Awards Reception $2,500.00
MS Center
Holy Name Medical 20th Annual Spring Fling to $2,500.00
Center Benefit MS
Hope and Comfort, Inc. Hope and Comfort Program $5,000.00
Support
Horizons for Homeless 19th Annual Women's Breakfast $5,000.00
Children
Houston Food Bank Volunteer Match $1,000.00
Imedex, LLC Congress Sponsorship $94,778.35
International Institute Healthcare Navigation for $15,000.00
of New England Refugees Program
International Institute 2017 Golden Door Award Gala $10,000.00
of New England
International Institute Transport Costs for Bicycles $100.00
of New England for Refugee Families
International 20th Anniversary IOMSN Dinner $30,000.00
Organization of
Multiple Sclerosis
Nurses
International 2017 MS Perspectives Digital $40,000.00
Organization of Magazine
Multiple Sclerosis
Nurses
International Society 5th Glycoproteinoses $16,650.00
For Mannosidosis & International Conference
Related Disease Inc.
Jewish Genetic Disease General Operating Support $5,000.00
Consortium
Knect365 US, Inc. Battle of the Biotech Bands $5,000.00
Fundraiser
Kometa Serbian Volunteer Match $1,000.00
Childrens Program Inc.
Life Science Cares, Life Science Cares Impact $10,000.00
Inc. Breakfast
Light of Life Light of Life Foundation 2017 $40,000.00
Foundation Activities
Little Brothers/Friends Medical Escort/Transportation $7,500.00
of the Elderly Program
Little Miss Hannah Vegas Cares About Rare Kids $5,000.00
Foundation 5K
Little Miss Hannah Vegas Cares About Rare Kids $2,500.00
Foundation 5K
LUGPA LUGPA Annual Meeting $10,000.00
Lycee International De ISB Benefit Gala $8,000.00
Boston International
School of Boston Inc.
MagellanRx Management Congress Sponsorship $7,500.00
March of Dimes Volunteer Match $2,000.00
Foundation
March of Dimes Boston March for Babies $25,000.00
Foundation Fundraiser
March of Dimes Volunteer Match $1,000.00
Foundation
Margaret Fuller Youth Development Programs $15,000.00
Neighborhood House
Mass Insight Education STEM and English Program $15,000.00
and Research Institute
Inc.
Massachusetts Bay STEM Mentor Program $40,000.00
Community College
Foundation
Massachusetts Patient Advocacy Summit $10,000.00
Biotechnology Council
Massachusetts Congress Sponsorship $25,000.00
Biotechnology Council
Massachusetts MassBio Annual Meeting $10,000.00
Biotechnology Council
Massachusetts Rare Disease Day 2017 $1,000.00
Biotechnology Council
Massachusetts 2017 Champions for $3,500.00
Biotechnology Biotechnology Awards
Education Foundation,
Inc.
Massachusetts BioTeach Program $50,000.00
Biotechnology
Education Foundation,
Inc.
Massachusetts Life Sciences Workforce 2017, $3,500.00
Biotechnology 2nd Annual Conference
Education Foundation,
Inc.
Massachusetts College Sanofi Genzyme Biotchnology $7,000.00
of Pharmacy and Health College Scholarship
Sciences
Massachusetts State Advancing Science & Health $50,000.00
Science and Education Programs
Engineering Fair, Inc.
Mayo Clinic Congress Sponsorship $2,000.00
MedImpact Healthcare Congress Sponsorship $8,000.00
Systems, Inc.
MetroWest Chamber of Board of Directors Luncheon $250.00
Commerce
Metrowest Free Medical Access to Women's Health Care $15,000.00
Program Inc. for the Uninsured
Mid America MS Eat Bid Laugh 6 Event $10,000.00
Achievement Center
Mid America MS Race to Nowhere 19 $5,000.00
Achievement Center
Milwaukee Synagogue for Education Program $5,000.00
Russian Jews:
Congregation Moshiach
Now Inc.
Milwaukee Synagogue for Education Program $5,000.00
Russian Jews:
Congregation Moshiach
Now Inc.
MS Bright Spots of Hope MS Evening of Hope $2,500.00
MS Cure Fund Patient Education Programs $25,000.00
MS Cure Fund Late Summer Education $25,000.00
Programs
MS Cure Fund Lifestyle Management Programs $15,000.00
Spring 2017
MS Cure Fund 2017 Spring MS Health Fair $1,500.00
MS HOPE FOR A CURE INC. 2017 MS Hope Day $10,000.00
MS Views And News Inc. MS Neuro TV $35,000.00
MS Views And News Inc. Living Beyond MS--Effective $20,000.00
Communication with Your
Healthcare Team
MS Views And News Inc. The Compass To Care Program $73,550.00
MS Views And News Inc. 2017 Display Sponsorship $10,000.00
request
MS Views And News Inc. Educational Programs $23,825.00
MS Views And News Inc. Educational Programs $25,000.00
MS Views And News Inc. 2nd Annual Champions Tackling $10,000.00
MS Awards Dinner Gala
MS Views And News Inc. MS Views and News 2017 $1,000.00
Bowlathon
Multiple Myeloma Cure Defeat Multiple Myeloma run/ $5,000.00
Seeker Society walk
Multiple Sclerosis Navigating MS: Optimizing $73,125.00
Association of America
Multiple Sclerosis MSAA MRI Access Fund $125,000.00
Association of America
Multiple Sclerosis MSAA Improving Lives Benefit $2,500.00
Association of America 2017
Multiple Sclerosis Educational Programs $60,000.00
Association of America
Multiple Sclerosis Understanding MS Progression $39,000.00
Association of America
Multiple Sclerosis MS Fest $10,000.00
Center of Georgia
Multiple Sclerosis Health, Hope & Hops $7,000.00
Center of Georgia
Multiple Sclerosis MS Focus' EmpowerSource $35,000.00
Foundation Newsleter
Multiple Sclerosis Mind & Mobility $5,000.00
Foundation
Multiple Sclerosis Homecare Assistance Grant $20,000.00
Foundation Program
Multiple Sclerosis Assistive Technology Program $30,000.00
Foundation
Multiple Sclerosis 2017 National MS Education $30,000.00
Foundation and Awareness Month
Multiple Sclerosis 30th Anniversary Gala $5,000.00
Foundation ``Bourbon & Blues''
Multiple Sclerosis 2017 Mission Steps Walks & MS $8,000.00
Resources of Central Awareness Days
New York, Inc.
Multiple Sclerosis MS Awareness Expo $1,000.00
Society of Colorado
Springs, Inc.
Muscular Dystrophy Muscle Walk $1,000.00
Association--Pittsburg
h, PA
Muscular Dystrophy Muscle Walk $1,000.00
Association--Denver,
CO
Muscular Dystrophy 5th Annual Muscle Summit $6,000.00
Association--Harrisbur
g, PA
Muscular Dystrophy MDA Muscle Summit $8,000.00
Association--Broomall,
PA
Muscular Dystrophy Muscle Walk $1,000.00
Association--Shrevepor
t, LA
Muscular Dystrophy Muscle Walk $1,000.00
Association--Deerfield
Beach, FL
Muscular Dystrophy Muscle Walk $1,000.00
Association--Tallahass
ee, FL
Muscular Dystrophy Muscle Walk $1,000.00
Association--Grand
Rapids, MI
Muscular Dystrophy Muscle Walk $1,000.00
Association--Fort
Wayne, IN
Muscular Dystrophy Muscle Walk $1,000.00
Association--Metairie,
LA
Muscular Dystrophy Muscle Walk $1,000.00
Association--Deerfield
Beach, FL
Muscular Dystrophy Muscle Walk $1,000.00
Association--Los
Angeles, CA
Muscular Dystrophy Muscle Walk $1,000.00
Association--Shrevepor
t, LA
Muscular Dystrophy Muscle Walk $1,000.00
Association--Harrisbur
g, PA
Muscular Dystrophy Muscle Walk $1,000.00
Association--Allentown
, PA
Muscular Dystrophy Muscle Walk $2,000.00
Association--Urbana,
IL
Muscular Dystrophy Muscle Walk $1,000.00
Association--Billings,
MT
Muscular Dystrophy Muscle Walk $1,000.00
Association--San
Diego, CA
Muscular Dystrophy Muscle Walk $1,000.00
Association--Cincinnat
i, OH
Muscular Dystrophy Muscle Walk $1,000.00
Association--Portland,
MA
Muscular Dystrophy Muscle Walk $1,000.00
Association--Spokane,
WA
Muscular Dystrophy Muscle Walk $1,000.00
Association--Salt Lake
City, UT
Muscular Dystrophy Muscle Walk $1,000.00
Association--Louisvill
e, KY
Muscular Dystrophy Muscle Walk $1,000.00
Association--Wilmingto
n, NC
Muscular Dystrophy Muscle Walk $1,000.00
Association--Worthingt
on, OH
Muscular Dystrophy Muscle Walk $1,000.00
Association--Dallas,
TX
Muscular Dystrophy Muscle Walk $1,000.00
Association--Albany,
NY
Muscular Dystrophy Muscle Walk $1,000.00
Association--Chicago,
IL
Muscular Dystrophy Muscle Walk $1,000.00
Association--Greensbor
o, NC
Muscular Dystrophy Muscle Walk $1,000.00
Association--Columbus,
OH
Muscular Dystrophy Muscle Walk $1,000.00
Association--Albany,
NY
Muscular Dystrophy Muscle Walk $1,000.00
Association--Cincinnat
i, OH
Muscular Dystrophy Muscle Walk $1,000.00
Association--Portland,
OR
Muscular Dystrophy Muscular Dystrophy Summer $2,000.00
Association--North Camp Program
Haven, CT
Muscular Dystrophy Montana Muscular Dystrophy $2,000.00
Association--Billings, Association Summer Camp 2017
MT
Muscular Dystrophy MDA Limb Girdle Muscular $900,000.00
Association--Chicago, Dystrophy (LGMD) Genetic
IL Testing Program
Muscular Dystrophy 2017 Summer Camp $2,500.00
Association--Spokane,
WA
Muscular Dystrophy Muscle Walk $1,000.00
Association--Okemos,
MI
Muscular Dystrophy 2017 MDA Summer Camp of $2,500.00
Association--Tulsa, OK Oklahoma
Muscular Dystrophy National Education and Impact $400,000.00
Association - Chicago, Partner
IL
Muscular Dystrophy MDA Summer Newsletter $2,000.00
Association--Columbia,
SC
Muscular Dystrophy 2017 MDA Summer Camp $2,500.00
Association--Cincinnat
i, OH
Muscular Dystrophy MDA Summer Camp $5,000.00
Association--Mountlake
Terrace, WA
Muscular Dystrophy MDA Summer Camp $5,000.00
Association--Denver,
CO
Muscular Dystrophy 2017 MDA Summer Camp $2,500.00
Association--Shrevepor
t, LA
Muscular Dystrophy 2017 MDA Summer Camp $8,000.00
Association--Dallas,
TX
Muscular Dystrophy MDA Summer Camp $2,500.00
Association--Bolingbro
ok, IL
Muscular Dystrophy Muscle Walk $1,000.00
Association--Denver,
CO
Muscular Dystrophy Muscle Walk $1,000.00
Association--Denver,
CO
Muscular Dystrophy Muscle Walk $1,000.00
Association--North
Haven, CT
Muscular Dystrophy Muscle Walk $1,000.00
Association--Maywood,
NJ
Muscular Dystrophy Muscle Walk $1,000.00
Association--Indianapo
lis, IN
Muscular Dystrophy Muscle Walk $1,000.00
Association--Urbana,
IL
Muscular Dystrophy Muscle Walk $1,000.00
Association--Louisvill
e, KY
Muscular Dystrophy Muscle Walk $1,000.00
Association--Chicago,
IL
Muscular Dystrophy Muscle Walk $1,000.00
Association--Edina, MN
Muscular Dystrophy Muscle Walk $1,000.00
Association--Metairie,
LA
Muscular Dystrophy Muscle Walk $1,000.00
Association--Reston,
VA
Muscular Dystrophy Muscle Walk $1,000.00
Association--Little
Rock, AR
Muscular Dystrophy Muscle Walk $1,000.00
Association--Springfie
ld, MO
Muscular Dystrophy Muscle Walk $1,000.00
Association--Cedar
Rapids, IA
Muscular Dystrophy Muscle Walk $1,000.00
Association--Fort
Myers, FL
Muscular Dystrophy Muscle Walk $1,000.00
Association--Bolingbro
ok, IL
Muscular Dystrophy Muscle Walk $1,000.00
Association--Green
Bay, WI
Muscular Dystrophy Muscle Walk $1,000.00
Association--Edina, MN
Muscular Dystrophy Muscle Walk $1,000.00
Association--Dallas,
TX
Muscular Dystrophy Quarterly Newsletter $3,000.00
Association--Westbrook
, ME
Muscular Dystrophy TORCH Award $5,000.00
Association--Midland,
TX
Muscular Dystrophy Muscle Walk $1,000.00
Association--St.
Petersburg, FL
Muscular Dystrophy 2017 MDA Muscle Walk of $1,000.00
Association--Jacksonvi Jacksonville
lle, FL
Muscular Dystrophy Muscle Walk $1,000.00
Association--Charlotte
, NC
Muscular Dystrophy Muscle Walk $1,000.00
Association--Towson,
MD
Muscular Dystrophy Muscle Walk $1,500.00
Association--Cedar
Rapids, IA
Muscular Dystrophy Muscle Walk & Fire Truck Pull $1,000.00
Association--Austin,
TX
Muscular Dystrophy Muscle Walk $1,500.00
Association--Sacrament
o, CA
Muscular Dystrophy Muscle Walk $1,000.00
Association--Cedar
Rapids, IA
Muscular Dystrophy Muscle Walk $1,000.00
Association--Fort
Wayne, IN
Muscular Dystrophy Muscle Walk $1,000.00
Association--Birmingha
m, AL
Muscular Dystrophy Muscle Walk $1,000.00
Association--Edina, MN
Muscular Dystrophy Muscle Walk $1,000.00
Association--Salt Lake
City, UT
Muscular Dystrophy Muscle Walk $1,000.00
Association--Lafayette
, LA
Muscular Dystrophy Spring Newsletter $1,500.00
Association--Columbia,
SC
Muscular Dystrophy Muscle Walk $1,000.00
Association--Memphis,
TN
Muscular Dystrophy Muscle Walk $1,000.00
Association--Allentown
, PA
Muscular Dystrophy Muscle Walk $1,000.00
Association--Cedar
Rapids, IA
Muscular Dystrophy Muscle Walk $1,000.00
Association--Lafayette
, LA
Muscular Dystrophy Muscle Walk $1,000.00
Association--Maryland
Heights, MO
Muscular Dystrophy 1st Quarter Newsletter $1,000.00
Association--North
Haven, CT
Muscular Dystrophy Second Quarter Newsletter $1,500.00
Association--Chicago,
IL
Muscular Dystrophy Muscle Walk $1,000.00
Association--Cleveland
, OH
Muscular Dystrophy Muscle Walk $1,000.00
Association--Oklahoma
City, OK
Muscular Dystrophy Muscle Walk $1,000.00
Association--Wilmingto
n, NC
Muscular Dystrophy Muscle Walk $1,000.00
Association--San
Antonio, TX
Muscular Dystrophy Muscle Walk $1,000.00
Association--Scottsdal
e, AZ
Muscular Dystrophy Muscle Walk $1,000.00
Association--Montgomer
y, AL
Muscular Dystrophy First Quarter Newsletter $2,500.00
Association--Chicago,
IL
Muscular Dystrophy 4th Quarter Newsletter $1,500.00
Association--North
Haven, CT
Muscular Dystrophy Muscle Walk $1,000.00
Association--El Paso,
TX
Muscular Dystrophy Summer Camp 2017 $8,000.00
Association--Cypress,
CA
Muscular Dystrophy 1st Quarter Newsletter $3,000.00
Association--North
Haven, CT
Muscular Dystrophy Kids Art Auction $2,000.00
Association--Lake
Mary, FL
Muscular Dystrophy Muscle Walk $2,000.00
Association--Westborou
gh, MA
Muscular Dystrophy Muscle Walk $1,000.00
Association--Westborou
gh, MA
Muscular Dystrophy Muscle Walk $1,000.00
Association--Brentwood
, TN
Muscular Dystrophy Muscle Walk $1,000.00
Association--Lake
Mary, FL
Muscular Dystrophy Muscle Walk $1,000.00
Association--Brookfiel
d, WI
Muscular Dystrophy Muscle Walk $1,000.00
Association--Wichita,
KS
Muscular Dystrophy MA and RI Newsletters $10,000.00
Association--Westborou
gh, MA
Museum of Fine Arts Membership $20,000.00
Museum of Science Sanofi Genzyme Teacher $66,980.00
Sabbatical Program 2017-2018
Museum of Science Stars of STEM 2017 $10,000.00
National Bone Marrow Caregiver Webinar Series $2,500.00
Transplant Link
National Comprehensive Membership $210,000.00
Cancer Network
National Eczema Be Well, Mind + Body, Eczema $100,000.00
Association Awareness Month Campaign
National Eczema NEA Educational Webcast for $15,000.00
Association Patients & Caregivers
National Eczema Leaders in Eczema Forum $100,000.00
Association Series
National Eczema Health Care Provider $85,000.00
Association Engagement Program
National Eczema Patient Engagement Program $150,000.00
Association
National Eczema Ambassadors Program $100,000.00
Association
National Fabry Disease Fabry Family Conference $6,500.00
Foundation
National Fabry Disease 2017 Urgent and Unmet Needs $40,000.00
Foundation Program
National Fabry Disease 2017 Annual Educational $50,000.00
Foundation Conference and Fabry Family
Camp
National Fabry Disease Annual Conference $70,000.00
Foundation
National Fabry Disease 2018 NFDF Core Program Grant $100,000.00
Foundation
National Fabry Disease Fabry Family Meeting $3,000.00
Foundation
National Fabry Disease Family Meeting $5,000.00
Foundation
National Fabry Disease 2017 Family Assistance $10,000.00
Foundation Program
National Gaucher CARE Programs $800,000.00
Foundation
National Gaucher Optimal Health Initiative & $900,000.00
Foundation Education and Awareness
National Gaucher CARE Programs $1,500,000.00
Foundation
National Gaucher Optimal Health Initiative & $400,000.00
Foundation Education and Awareness
National Kidney Kidney Walk $25,000.00
Foundation
National Kidney Spring Clinical Meeting $3,500.00
Foundation
National Kidney Kidney Health Risk Assessment $1,500.00
Foundation of Indiana Program
National Kidney Kidney Health Risk Assessment $1,500.00
Foundation of Indiana Program
National Kidney Kidney Health Risk Assessment $1,500.00
Foundation of Indiana Program
National Kidney Kidney Health Risk Assessment $1,500.00
Foundation of Indiana Program
National Kidney Kidney Walk $1,000.00
Foundation of Michigan
National Kidney 31st Annual Gift of Life Gala $2,500.00
Foundation of Eastern
Missouri, Metro East
National MPS Society 2018 International MPS $100,000.00
Symposium
National MPS Society National MPS Society Gala $134.00
Silent Auction
National MPS Society National MPS Society Family $7,500.00
Conference Scholarships
National MPS Society 31st Annual Family Conference $35,000.00
National MPS Society National MPS Society 2017 Run/ $20,000.00
Walk Program
National Multiple Free From Falls $1,150.00
Sclerosis Society--
Southern California &
Nevada Chapter
National Multiple Champions on the Move $5,000.00
Sclerosis Society--
Upstate New York
Chapter
National Multiple Spellbound In the Vineyard $2,500.00
Sclerosis Society--
Upstate New York
Chapter
National Multiple 2016 Annual Meeting $2,500.00
Sclerosis Society--
Greater Delaware
Valley Chapter
National Multiple Women on the Move Luncheon $2,500.00
Sclerosis Society--
Greater Illinois
Chapter
National Multiple Life-Changing Breakthroughs: $65,000.00
Sclerosis Society-- MS Society Impact Series
Colorado-Wyoming
Chapter
National Multiple Leadership Conference 2017 $15,000.00
Sclerosis Society--
Colorado-Wyoming
Chapter
National Multiple The Tykeson Fellows $15,000.00
Sclerosis Society-- Conference
Colorado-Wyoming
Chapter
National Multiple Moving Mountains for MS: $10,000.00
Sclerosis Society-- Family Weekend Retreat
Kentucky-Southeast
Indiana Chapter
National Multiple Crystal Boots and Silver $3,000.00
Sclerosis Society-- Spurs
Kentucky-Southeast
Indiana Chapter
National Multiple Nationwide MS Navigator $50,000.00
Sclerosis Society-- Services
Colorado-Wyoming
Chapter
National Multiple On the Move Luncheon $2,500.00
Sclerosis Society--
Gateway Area Chapter
National Multiple Walk MS--Lanyard Sponsorship $10,000.00
Sclerosis Society--New
Jersey Metro Chapter
National Multiple On the Move Luncheon $2,500.00
Sclerosis Society--
South Central Chapter
National Multiple Annual Meeting & Day of $7,500.00
Sclerosis Society--Mid Discovery
Florida Chapter
National Multiple Volunteer Program $10,000.00
Sclerosis Society--New
Jersey Metro Chapter
National Multiple Fall Crush Knoxville $2,500.00
Sclerosis Society--Mid
South Chapter
National Multiple Fall Crush Knoxville $2,500.00
Sclerosis Society--Mid
South Chapter
National Multiple Women Against MS Luncheon $3,000.00
Sclerosis Society--New
York City Chapter
National Multiple Challenge Walk MS $5,000.00
Sclerosis Society--New
York City Chapter
National Multiple On the Move Baltimore $3,500.00
Sclerosis Society--New
York City Chapter
National Multiple Ambassadors Ball $10,000.00
Sclerosis Society--New
York City Chapter
National Multiple Hispanic Outreach Initiative $10,000.00
Sclerosis Society--New
York City Chapter
National Multiple MS Scholarship Program $15,000.00
Sclerosis Society--New
York City Chapter
National Multiple 2017 Weekend Escape $5,000.00
Sclerosis Society--New
York City Chapter
National Multiple 2017 Dinner of Champions $2,500.00
Sclerosis Society--
Reno Chapter
National Multiple Everyday Matters: Living Your $20,000.00
Sclerosis Society--New Best Life with MS
York City Chapter
National Multiple International Progressive MS $122,249.00
Sclerosis Society--New Alliance Industry Forum
York City Chapter
National Multiple 2017 On The Move Luncheon $2,500.00
Sclerosis Society--New
York City Chapter
National Multiple Books for a Better Life $20,000.00
Sclerosis Society--New Awards
York City Chapter
National Multiple Women on the Move Luncheon $6,000.00
Sclerosis Society--New
York City Chapter
National Multiple National ``Living with MS'' $600,000.00
Sclerosis Society--New Event
York City Chapter
National Multiple Walk MS 2017 $25,000.00
Sclerosis Society--
South Florida Chapter
National Multiple Festival Hispano $1,500.00
Sclerosis Society--
South Florida Chapter
National Multiple MS Gala Luncheon 2017 $2,500.00
Sclerosis Society--
South Florida Chapter
National Multiple MS Walk West Virginia $7,500.00
Sclerosis Society--
Central Virginia
Chapter
National Multiple Patient Assistance Program $5,000.00
Sclerosis Society--
Indiana State Chapter
National Multiple Walk MS $5,000.00
Sclerosis Society--
Long Island Chapter
National Multiple Women on the Move Luncheon & $1,250.00
Sclerosis Society-- Fashion Show
Ohio Valley Chapter
National Multiple 2017 MS Neurology Dinner $5,000.00
Slcerosis Society--
Pacific South Coast
Chapter
National Multiple Challenge Walk MS $2,500.00
Slcerosis Society--
Pacific South Coast
Chapter
National Niemann-Pick Reinvention of The National $75,000.00
Disease Foundation Niemann Pick Disease
Foundation (NNPDF)
National Organization Rare Disease Day Fundraiser $10,000.00
for Rare Disorders
National Organization 2017 Rare Diseases and Orphan $50,000.00
for Rare Disorders, Product Breakthrough Summit
Inc.
National Organization Running for Rare $5,000.00
for Rare Disorders,
Inc.
National Organization 2017 Corporate Council $25,000.00
for Rare Disorders,
Inc.
National Organization 2017 Rare Impact Awards $50,000.00
for Rare Disorders,
Inc.
National Organization Undiagnosed Diseases Network $5,000.00
for Rare Disorders, Fund
Inc.
National Organization Orphan Drug Act Advocacy $75,000.00
for Rare Disorders,
Inc.
National Parkinson Moving Day--Boston 2016 $1,000.00
Foundation
National Society of 36th Annual Education $2,800.00
Genetic Counselors Conference
National Tay-Sachs & Imagine & Believe $20,000.00
Allied Diseases
Association, Inc.
National Tay-Sachs & Raising Awareness of $1,100.00
Allied Diseases Ashkenazi Jewish Genetic
Association, Inc. Diseases
National Tay-Sachs & 39th Annual Family Conference $10,000.00
Allied Diseases
Association, Inc.
National Tay-Sachs & Family Support Resource Video $5,000.00
Allied Diseases Series and Podcasts
Association, Inc.
NEHI NEHI's Innovators in Health $25,000.00
Awards
NEHI The Nick Littlefield Health $25,000.00
Policy Fellowship
Neuroscience Centers of How to Improve Physical and $6,640.00
Florida Foundation, Psychological Health Program
Inc.
Neuroscience Centers of Maintaining Intimacy with $3,895.72
Florida Foundation, Multiple Sclerosis
Inc.
Next Step Fund, Inc. Summer Campference Program $10,000.00
Northeastern University Biotchnology College $1,000.00
Scholarship
Northern California Congress Sponsorship $10,000.00
Rheumatology Society
Northern New England Congress Sponsorship $2,000.00
Clinical Oncology
Society
Operation Warm, Inc. Boston Coat Program $20,000.00
Operation Warrior Wounded Military Event $798.00
Wishes
Pan Massachusetts Pan Mass Challenge $11,000.00
Challenge
Patient Access Network Patient Assistance Program $460,000.00
Foundation
Patient Access Network Patient Assistance Program $200,000.00
Foundation
Patient Services, Inc. Patient Assistance Program $481,250.00
Patient Services, Inc. Patient Assistance Program $2,902,500.00
Patient Services, Inc. Patient Assistance Program $237,500.00
Patient Services, Inc. Patient Assistance Program $818,750.00
Patient Services, Inc. Patient Assistance Program $650,000.00
Patient Services, Inc. Patient Assistance Program $5,960,000.00
PCMA Pharmaceutical Congress Sponsorship $60,000.00
Care Management
Association
Pediatric Endocinology Congress Sponsorship $6,200.00
Nursey Society
Pediatric Endocrine Congress Sponsorship $27,500.00
Society
Peer Health Exchange, Peer Health Exchange Program $5,000.00
Inc.
Pennsylvania Congress Sponsorship $10,000.00
Rheumatology Society
Perkins School for the Enhancing Accessible Science $20,000.00
Blind and Technology Education
eLearning Program
Philadelphia Rheumatism 5th Annual Ralph Schumacher $2,250.00
Society Lecture
Phillips Brooks House Bridges Workshop $3,000.00
Association
Incorporated
President and Fellows The Family Van Health Clinic $50,000.00
of Harvard College
Pro Player Foundation Flavors of Austin Fundraiser $5,000.00
Project HOPE Project Hope Gala $10,000.00
Project Just Because, 211 Domestic Abuse/Emergency $10,000.00
Inc. Program & Keep A Family Warm
Program
Prostate Cancer Academy Proscate Cancer Academy 2017 $7,500.00
Race to Erase MS 24th Annual Race to Erase MS $15,000.00
Race to Erase MS Race to Erase MS $10,000.00
Radiological Society of 103rd Scientific Assembly and $3,500.00
North America Annual Meeting
Rare Disease United 14th Annual World Symposium-- $20,000.00
Foundation Lysosomal Diseases
Rare Genomics Institute Patient Advoacy Leadership $25,000.00
Awards and Rare Disease
Patient Advocate Teaching
Modules
Rare New England, Inc. Improving Health Care $3,000.00
Experiences in the Rare
Disease Community
Read to a Child, Inc. Read to a Child's Lunchtime $5,000.00
Reading Program
Resolve Community Volunteer Match $1,000.00
Counseling Center,
Inc.
Rheumatology Congress Sponsorship $2,000.00
Association of IOWA
Rheumatology Congress Sponsorship $20,000.00
Association of
Minnesota and the
Dakotas
Rheumatology Congress Sponsorship $10,000.00
Association of Nevada
Rheumatology Nurses Immunology Webinar $50,000.00
Society
Rheumatology Nurses 10th Rheumatology Nurses $3,443.91
Society Society Annual Conference
Rise Against Hunger Volunteer Match $2,944.08
Rise Against Hunger Volunteer Match $2,944.08
Rocky Mountain Multiple MS4MS Fundraising Program $5,000.00
Sclerosis Center
Rocky Mountain Multiple 2017 Webinar Program Series $5,000.00
Sclerosis Center
Rocky Mountain Multiple 2016 Fall Education Summit $5,000.00
Sclerosis Center
Samaritans, Inc. Youth Suicide Prevention $25,000.00
Services
Saunders Health 2017 Night of Lights $2,500.00
Services Foundation
Saunders Health 2016 Night of Lights $1,000.00
Services Foundation
Save One Life, Inc. Panel Discussion Donation $250.00
Scholarship America, TORCH Awards Program $11,600.00
Inc.
Scholarship America, Scholarship Program $39,900.00
Inc.
Science Club For Girls, 10th Annual Catalyst Awards $10,000.00
Inc.
Science Club For Girls, STEMinistas Program Expansion $10,000.00
Inc.
Society of Nuclear Congress Sponsorship $1,250.00
Medicine and Molecular
Imaging
Society of Nuclear Congress Sponsorship $2,200.00
Medicine and Molecular
Imaging
Society of Nuclear Congress Sponsorship $7,790.00
Medicine and Molecular
Imaging
Society of Nuclear Congress Sponsorship $1,800.00
Medicine and Molecular
Imaging
Special Olympics Bio-Ball 2017 $2,500.00
Massachusetts Inc.
Sportsmen's Tennis & Academic Enrichment Program $12,500.00
Enrichment Center
St. Francis House Triage and Coordinated Care $10,000.00
for the Poor and Homeless
Population
St. Mary's Center for Women@Work Plus Program $15,000.00
Women and Children
State of Texas Congress Sponsorships $20,000.00
Association of
Rheumatologists
Temple Beth Sholom [The Jewish Genetic Disease $7,000.00
Tribe] Awareness Screening
The American Congress Sponsorship $20,000.00
Association of
Clinical
Endocrinologists
(AACE)
The American Society of Congress Sponsorship $10,000.00
Hematology
The Boston Home, Inc. The Boston Home Arts Program $5,000.00
The Boston Home, Inc. Socialization & Wellness $9,000.00
Program
The Boston Home, Inc. Resident & Family 2017 Event $10,000.00
Series
The Boston Home, Inc. 135 Anniversary Event $10,000.00
The Community Art Teen Media Program $15,000.00
Center
The Community Art General Operating Support $10,000.00
Center
The Forsyth Institute Mobile Dental Program Service $10,000.00
The Greater Boston Food Volunteer Match $1,000.00
Bank, Inc.
The Leukemia & Lymphoma Light The Night Event $10,000.00
Society Eastern PA
Chapter
The Leukemia & Lymphoma Light The Night Event $20,000.00
Society, Inc.
The MAGIC Foundation 23rd Annual Convention $5,000.00
The McCourt Foundation Tour de South Shore--Bike/ $7,500.00
Walk
The McCourt Foundation MS Educational Program Update $20,000.00
The Menkes Foundation The Rare Disease Film $3,000.00
Festival
The MS Center of St 12th Annual Trivia and $15,000.00
Louis Auction Benefit
The Oak Clinic Wellness Thursday Nutrition $21,000.00
for MS Seminars
The Oak Clinic 2017 Oak Clinic Acorn Run $3,500.00
The Oak Clinic 2017 Diamond Run for MS $5,000.00
The Oak Clinic Wellness Wednesday Nutrition $14,000.00
for MS Seminars
The Posse Foundation STEM Posse Program $25,000.00
The Possible Project Powering Possibilities Gala $10,000.00
The Regents of the Rare Disease Symposium $10,000.00
University of
California, San
Francisco
The University of Texas Congress Sponsorship $10,000.00
MD Anderson Cancer
Center
Thompson Island Outward Connections--Science $15,000.00
Bound Education Education for Boston Public
Center, Inc. School Students
Thompson Island Outward Thompson Island 4K Trail Run $5,000.00
Bound Education
Center, Inc.
ThyCa: Thyroid Cancer Production and Distribution $15,000.00
Survivors' of Educational Handbooks and
Association, Inc. Materials
ThyCa: Thyroid Cancer 20th International Thyroid $35,000.00
Survivors' Cancer Survivors' Conference
Association, Inc.
Tisch Multiple 2017 Future Without MS Gala $10,000.00
Sclerosis Research
Center of New York,
Inc.
Tisch Multiple Healing MS: Online Newsletter $8,000.00
Sclerosis Research
Center of New York,
Inc.
Tri-State Multiple Owensboro Autumn Walk $2,500.00
Sclerosis Association
Tri-State Multiple Evansville Autumn Walk $2,500.00
Sclerosis Association
Tutoring Plus of STEAM Enrichment Programs $7,500.00
Cambridge, Inc.
UMASS Dartmouth Allston Brighton College $2,000.00
Scholarship
United Arizona Congress Sponsorship $45,000.00
Rheumatology Alliance
United Network For Congress Sponsorship $8,400.00
Organ Sharing
United Pompe Foundation Reception and Early Onset $30,000.00
Pompe Patient Meeting
United Pompe Foundation Reception and Early Onset $45,000.00
Pompe Patient Meeting
United Pompe Foundation General Operating Support $50,000.00
United Rheumatology Congress Sponsorship $130,000.00
United Rheumatology Congress Sponsorship $140,000.00
United States Bone and General Program Support $46,250.00
Joint Initiative, NFP
United States Bone and The Burden of Musculoskeletal $25,000.00
Joint Initiative, NFP Diseases in the United
States
United States Bone and Membership $20,000.00
Joint Initiative, NFP
United States Bone and Patient Education Programs $80,000.00
Joint Initiative, NFP
University Hospitals 40th Anniversary Bone Marrow $5,000.00
Health System, Inc. Transplant Celebration
University Neurology, 2017 NYSMSC Annual Meeting $5,000.00
Inc.
University of Sanofi Genzyme Biotchnology $3,000.00
Connecticut Foundation College Scholarship
University of Student Success Program $200,000.00
Massachusetts
Foundation, Inc.
University of Sanofi Genzyme Biotchnology $4,000.00
Massachusetts: Lowell College Scholarship
University of Miami Sanofi Genzyme Biotchnology $1,000.00
College Scholarship
University of Congress Sponsorship $23,500.00
Minnesota--Department
of Surgery
University of New Sanofi Genzyme Biotchnology $4,000.00
Hampshire College Scholarship
University of Congress Sponsorship $2,500.00
Pennsylvania
Us TOO International 13th Annual SEA Blue Prostate $5,000.00
Cancer Walk & Run
VCU Hume-Lee Transplant Congress Sponsorship $1,000.00
Center
Visiting Nurse Heroes in Health Care Gala $10,000.00
Association of Boston
& Affiliates
VZW Sint-Aloysius Oud Volunteer Match $2,000.00
Scouts Geel
Washington University Washington University Fellows $1,500.00
in St. Louis; Siteman Program
Cancer Center
Wentworth Institute of Sanofi Genzyme Biotchnology $500.00
Technology College Scholarship
West End House Boys and Volunteer Match $1,000.00
Girls Club
WGBH Educational WGBH Pledge Night Event $12,000.00
Foundation
Whitehead Institute for Expedition: Bio 2018 Program $10,000.00
Biomedical Research
Wisconsin Rheumatology Congress Sponsorship $10,000.00
Association
Women's Lunch Place 2017 Spaghetti Dinner $10,000.00
Women's Lunch Place Healthy Meals Program $35,000.00
WORLD Symposium Congress Sponsorship $40,000.00
WORLD Symposium Congress Sponsorship $600.00
WORLD Symposium Congress Sponsorship $1,200.00
WORLD Symposium Congress Sponsorship $25,000.00
WORLD Symposium Congress Sponsorship $63,000.00
WORLD Symposium Congress Sponsorship $210,000.00
WORLD Symposium Congress Sponsorship $160,000.00
WORLD Symposium Congress Sponsorship $5,000.00
WriteBoston Chelsea and WriteBoston $18,000.00
Educational Programs
Wylder Nation 4th Annual Living Like a $15,000.00
Foundation Warrior Gala
YMCA of Greater Boston Summer Day Camp Scholarships $15,000.00
for Low-Income Youth
Young Men's Christian MS One Step Program $15,000.00
Association of
Montclair, NJ
ziMS Foundation 8th Annual UVA MS Event $5,000.00
ziMS Foundation 7th Annual UVA MS Event $5,000.00
Sponsorships, Charitable Donations, Memberships and Fellowships
1st Jan 2018-31st Dec 2018
Sanofi US and its affiliate Genzyme Corporation are committed to
supporting sponsorships for specific activities and initiatives of
healthcare organizations and institutions, independent medical or
professional societies, trade organizations and organized patient groups
to improve patient care and provide information to the medical and/or
patient communities. The goal of our charitable giving approach is to
fund general operational support for patient/disease organizations, or
program support for community-based organizations. Sanofi US and Genzyme
Corporation are part of the Sanofi Group, a global pharmaceutical
company.
Applicant names are provided by the requestor. If applicants apply as a
group for a single activity; all applicants may be not be identified
above. ``Funding Amount'' is the amount that the Company funded during
2018 identified above. ``Funding Amount'' does not include funds that
may have been provided by other affiliated Sanofi Company Entities
(e.g., Sanofi Pasteur).
------------------------------------------------------------------------
Recipient Name(s) Activity Title Funding Amount
------------------------------------------------------------------------
495 MetroWest Membership $10,000.00
Partnership
------------------------------------------------------------------------
ACMG Congress Sponsorship $33,000.00
------------------------------------------------------------------------
ACMG Congress Sponsorship $7,600.00
------------------------------------------------------------------------
ACMG Congress Sponsorship $500.00
------------------------------------------------------------------------
ACMG Congress Sponsorship $4,500.00
------------------------------------------------------------------------
ACTRIMS Congress Sponsorship $42,500.00
------------------------------------------------------------------------
Alabama Cancer Congress Membership $4,000.00
------------------------------------------------------------------------
Alliance for Membership $100,000.00
Regenerative Medicine
------------------------------------------------------------------------
Allston Village Main Community Event $1,000.00
Streets Inc.
------------------------------------------------------------------------
American Academy of DataDerm Program $350,000.00
Dermatology
------------------------------------------------------------------------
American Academy of Quality Innovation Center $50,000.00
Dermatology (QIC) Program
------------------------------------------------------------------------
American Academy of AccessDerm Program $250,000.00
Dermatology
------------------------------------------------------------------------
American Academy of 2019 President's Fundraiser $275,000.00
Dermatology
------------------------------------------------------------------------
American Academy of Practice Management Center $100,000.00
Dermatology Program
------------------------------------------------------------------------
American Academy of 2018 President's Fundraiser $275,000.00
Dermatology
------------------------------------------------------------------------
American Academy of Congress Sponsorship $1,000.00
Neurology Institute
------------------------------------------------------------------------
American Academy of Congress Sponsorship $500.00
Neurology Institute
------------------------------------------------------------------------
American Academy of Congress Sponsorship $500.00
Neurology Institute
------------------------------------------------------------------------
American Academy of Congress Sponsorship $15,000.00
Neurology Institute
------------------------------------------------------------------------
American Academy of Congress Sponsorship $81,000.00
Neurology Institute
------------------------------------------------------------------------
American Academy of Congress Sponsorship $598,935.00
Neurology Institute
------------------------------------------------------------------------
American Academy of Women Leading in Neurology $20,000.00
Neurology Institute Program
------------------------------------------------------------------------
American Academy of Transforming Leaders Program $25,000.00
Neurology Institute
------------------------------------------------------------------------
American Academy of Palatucci Advocacy Leadership $30,000.00
Neurology Institute Forum
------------------------------------------------------------------------
American Academy of 2018 Industry Roundtable $50,000.00
Neurology Institute
------------------------------------------------------------------------
American Academy of Diversity Leadership Program $30,000.00
Neurology Institute
------------------------------------------------------------------------
American Association Congress Sponsorship $26,500.00
for Pediatric
Ophthalmology &
Strabismus
------------------------------------------------------------------------
American Association of Congress Sponsorship $100.00
Clinical
Endocrinologists
------------------------------------------------------------------------
American Association of Congress Sponsorship $50,000.00
Neuromuscular &
Electrodiagnostic
Medicine
------------------------------------------------------------------------
American Association of Congress Sponsorship $2,100.00
Neuromuscular &
Electrodiagnostic
Medicine
------------------------------------------------------------------------
American Association of Congress Sponsorship $990.00
Neuromuscular &
Electrodiagnostic
Medicine
------------------------------------------------------------------------
American City Business Corporate Citizenship Awards $5,500.00
Journals, Inc. 2018
------------------------------------------------------------------------
American College of Industry Advisory Council $60,000.00
Chest Physicians 2018
------------------------------------------------------------------------
American College of Congress Sponsorship $7,600.00
Medical Genetics and
Genomics
------------------------------------------------------------------------
American College of Congress Sponsorship $17,500.00
Medical Genetics and
Genomics
------------------------------------------------------------------------
American College of Congress Sponsorship $10,000.00
Medical Genetics and
Genomics
------------------------------------------------------------------------
American College of Fellowship Program $75,000.00
Medical Genetics
Foundation
------------------------------------------------------------------------
American College of Fellowship Program $75,000.00
Medical Genetics
Foundation
------------------------------------------------------------------------
American College of Congress Sponsorship $10,000.00
Rheumatology
------------------------------------------------------------------------
American College of Congress Sponsorship $15,000.00
Rheumatology
------------------------------------------------------------------------
American Society for Conference Sponsorship $10,000.00
Blood and Marrow
Transplant
------------------------------------------------------------------------
American Society for Sarah Cannon Blood Cancer $10,000.00
Blood and Marrow Network Event
Transplant
------------------------------------------------------------------------
American Society for ASBMT Website Sponsorship $15,000.00
Blood and Marrow
Transplant
------------------------------------------------------------------------
American Society of Congress Sponsorship $118,000.00
Clinical Oncology
------------------------------------------------------------------------
American Society of Congress Sponsorship $358,750.00
Clinical Oncology
------------------------------------------------------------------------
American Society of Congress Sponsorship $285,500.00
Hematology
------------------------------------------------------------------------
American Society of Congress Sponsorship $75,000.00
Hematology
------------------------------------------------------------------------
American Society of Congress Sponsorship $3,000.00
Human Genetics
------------------------------------------------------------------------
American Society of Congress Sponsorship $5,000.00
Nephrology
------------------------------------------------------------------------
American Society of Congress Sponsorship $3,600.00
Nephrology
------------------------------------------------------------------------
American Society of Congress Sponsorship $25,000.00
Transplant Surgeons
------------------------------------------------------------------------
American Society of Congress Sponsorship $36,750.00
Transplant Surgeons
------------------------------------------------------------------------
American Thoracic ATS 2018 Corporate Member $50,000.00
Society Program
------------------------------------------------------------------------
American Thyroid Congress Sponsorship $5,000.00
Association
------------------------------------------------------------------------
American Transplant Congress Sponsorship $153,000.00
Congress
------------------------------------------------------------------------
Americas Committee for Congress Sponsorship $42,500.00
Treatment and Research
in Multiple Sclerosis,
Inc.
------------------------------------------------------------------------
Americas Committee for Congress Sponsorship $12,480.00
Treatment and Research
in Multiple Sclerosis,
Inc.
------------------------------------------------------------------------
Americas Committee for Congress Sponsorship $19,000.00
Treatment and Research
in Multiple Sclerosis,
Inc.
------------------------------------------------------------------------
America's Physician Congress Sponsorship $4,500.00
Groups
------------------------------------------------------------------------
ANERA (American Near Anera 50th Anniversary $10,000.00
East Refugee Aid) Fundraiser
------------------------------------------------------------------------
Ann & Robert H. Lurie MPS Patient and Family Day $2,500.00
Children's Hospital of
Chicago
------------------------------------------------------------------------
Ann & Robert H. Lurie Fellowship Program $75,000.00
Children's Hospital of
Chicago
------------------------------------------------------------------------
Ann & Robert H. Lurie Fellowship Program $75,000.00
Children's Hospital of
Chicago
------------------------------------------------------------------------
Arthritis Foundation Congress Sponsorship $7,500.00
Northern California
Office
------------------------------------------------------------------------
Arts & Business Council Battle of the Biotech Bands $5,250.00
of Greater Boston,
Inc.
------------------------------------------------------------------------
ASCO Exhibits Congress Sponsorship $5,495.00
Management
------------------------------------------------------------------------
ASCO Exhibits Congress Sponsorship $18,990.00
Management
------------------------------------------------------------------------
Asembia Specialty Congress Sponsorship $20,000.00
Pharmacy Summit LLC
------------------------------------------------------------------------
Asembia Specialty Congress Sponsorship $20,000.00
Pharmacy Summit LLC
------------------------------------------------------------------------
Asembia Specialty Congress Sponsorship $20,000.00
Pharmacy Summit LLC
------------------------------------------------------------------------
ASN Congress Sponsorship $7,200.00
------------------------------------------------------------------------
ASN Congress Sponsorship $72,500.00
------------------------------------------------------------------------
ASPHO Congress Sponsorship $3,000.00
------------------------------------------------------------------------
Association of Managed Congress Sponsorship $20,000.00
Care Pharmacy (AMCP)
------------------------------------------------------------------------
Association of Northern Membership $1,200.00
California Oncologists
------------------------------------------------------------------------
Association of VA Congress Sponsorship $10,000.00
Hematology/Oncology
------------------------------------------------------------------------
Association of Women in AWIR 2018 Corporate Program $75,000.00
Rheumatology
------------------------------------------------------------------------
Bendcare Congress Sponsorship $180,000.00
------------------------------------------------------------------------
Bendcare Congress Sponsorship $165,000.00
------------------------------------------------------------------------
Big Brothers Big Mentoring Youth in Science $15,000.00
Sisters of Central Technology Engineering and
Mass Metrowest Inc. Math (MySTEM)
------------------------------------------------------------------------
Biomedical Science Evening of Hope 2018 $75,000.00
Careers Program
------------------------------------------------------------------------
Biomedical Science Hope Scholarship 2018-2019 $7,500.00
Careers Program
------------------------------------------------------------------------
Bleeding Disorders Patient Education Program $7,000.00
Alliance Illinois
------------------------------------------------------------------------
Blue Cross Blue Shield Congress Sponsorship $17,500.00
Association
------------------------------------------------------------------------
Boston Area Rape Crisis Medical Advocacy Program $30,000.00
Center
------------------------------------------------------------------------
Boston Area Rape Crisis Medical Advocacy (MedAd) $30,000.00
Center Program
------------------------------------------------------------------------
Boston Children's Fellowship Program $75,000.00
Hospital Corporation
------------------------------------------------------------------------
Boston College Membership $10,000.00
------------------------------------------------------------------------
Boston Educational Boston Public Schools Science $10,000.00
Development Fair
Foundation, Inc.
------------------------------------------------------------------------
Boston Health Care For Life Essentials Fund $35,000.00
The Homeless Program
Inc.
------------------------------------------------------------------------
Boston Partners in Power Lunch, 2017-2018 $6,000.00
Education, Inc.
------------------------------------------------------------------------
Boston Plan for Boston Teacher Residency: $15,000.00
Excellence in The Building a Diverse Pipeline
Public Schools of STEM Educators for BPS
Foundation
------------------------------------------------------------------------
Boston Private Industry 2018 Corporate Contributions $15,000.00
Council Campaign
------------------------------------------------------------------------
Boston University Congress Sponsorship $1,500.00
Continuing Medical
Education
------------------------------------------------------------------------
Bottom Line Boston STEM Success Program $15,000.00
------------------------------------------------------------------------
Boys and Girls Clubs of 2018 Bids for Kids Auction & $10,000.00
MetroWest fundraising event
------------------------------------------------------------------------
Boys and Girls Clubs of Operating Support $25,000.00
MetroWest
------------------------------------------------------------------------
Breakthrough Greater Full STEAM Ahead Support $15,000.00
Boston
------------------------------------------------------------------------
California Dermatology Congress Sponsorship $15,000.00
Physician Assistant
Society
------------------------------------------------------------------------
California Rheumatology Congress Sponsorship $50,000.00
Alliance
------------------------------------------------------------------------
Cambridge Chamber of Membership $7,250.00
Commerce
------------------------------------------------------------------------
Cambridge Chamber of 2018 Visionary Awards $3,250.00
Commerce
------------------------------------------------------------------------
Cambridge Chamber of Community support program $7,500.00
Commerce
------------------------------------------------------------------------
Cambridge School Fundraiser for Cambridge $10,000.00
Volunteers, Inc. Schools
------------------------------------------------------------------------
Cambridge School Fundraiser for Cambridge $10,000.00
Volunteers, Inc. Schools
------------------------------------------------------------------------
Cambridge School Reading Buddies--Fletcher $16,818.00
Volunteers, Inc. Maynard Academy Support
------------------------------------------------------------------------
Cambridge School Reading Buddies--Fletcher $16,423.00
Volunteers, Inc. Maynard Academy Support
------------------------------------------------------------------------
Cancer Research CRI's Webinar Series: Cancer $25,000.00
Institute Immunotherapy and You
------------------------------------------------------------------------
Case Management Society CMSA's 28th Annual Conference $1,725.00
of America & Expo
------------------------------------------------------------------------
Case Management Society CMSA's 28th Annual Conference $14,000.00
of America & Expo
------------------------------------------------------------------------
Case Management Society CMSA's 28th Annual Conference $5,500.00
of America & Expo
------------------------------------------------------------------------
Case Management Society Corporate Sponsorship of $1,250.00
of New England CMSNE
------------------------------------------------------------------------
Case Management Society Patient Education and $1,550.00
of New England Awareness Program
------------------------------------------------------------------------
Case Management Society Patient Education and $1,000.00
of New England Awareness Program
------------------------------------------------------------------------
Center for Congress Sponsorship $133,900.00
International Blood
and Marrow Transplant
Research
------------------------------------------------------------------------
CEO Roundtable on Membership $40,000.00
Cancer
------------------------------------------------------------------------
Charles River Community Mom and Baby Program $15,000.00
Health
------------------------------------------------------------------------
CheckOrphan Rare Disease Page Sponsorship $11,000.00
------------------------------------------------------------------------
Child Neurology Society Congress Sponsorship $4,250.00
------------------------------------------------------------------------
Children Health and Fellowship Program $75,000.00
Research Foundation,
Inc.
------------------------------------------------------------------------
Childrens Gaucher Research: A novel iPSC-based $75,000.00
Research Fund system to elucidate the
molecular mechanisms leading
to neuronopathic Gaucher
disease
------------------------------------------------------------------------
Children's Hospital Fellowship Program $75,000.00
Corporation
------------------------------------------------------------------------
Children's Hospital of 2019-2020 UCLA Intercampus $75,000.00
Orange County Medical Biochemical Genetics
Training Program
------------------------------------------------------------------------
Children's Hospital of Fellowship Program $75,000.00
Philadelphia
------------------------------------------------------------------------
Citizen Schools STEM Learning at Somerville's $15,000.00
East Somerville Community
School
------------------------------------------------------------------------
Citizen Schools STEM Learning for High-Need $15,000.00
Middle School Students in
Somerville
------------------------------------------------------------------------
CitySprouts, Inc. Middle School Program $8,000.00
------------------------------------------------------------------------
CitySprouts, Inc. Middle School Program $8,000.00
------------------------------------------------------------------------
Cleveland Clinic Congress Sponsorship $3,500.00
Educational Foundation
------------------------------------------------------------------------
Coalition of Hematology Membership $6,000.00
Oncology Practices
------------------------------------------------------------------------
Collegium 32nd Symposium of the $25,000.00
Internationale Collegium Internationale
Allergologicum Allergologicum
------------------------------------------------------------------------
Community Boating, Inc. Operating Support $15,000.00
------------------------------------------------------------------------
Community Farms Community Food Access $15,000.00
Outreach Programs
------------------------------------------------------------------------
Community Servings, Pie in the Sky $10,000.00
Inc.
------------------------------------------------------------------------
Community Servings, General Operating Support $30,000.00
Inc.
------------------------------------------------------------------------
Community Servings, Volunteer Match $1,000.00
Inc.
------------------------------------------------------------------------
Community Servings, Nutrition Program for $30,000.00
Inc. Individuals & Families
Affected by Multiple
Sclerosis and Other Acute
Life-Threatening Illnesses
------------------------------------------------------------------------
Consortium of Multiple Congress Sponsorship $8,000.00
Sclerosis Centers
------------------------------------------------------------------------
Consortium of Multiple Congress Sponsorship $21,000.00
Sclerosis Centers
------------------------------------------------------------------------
Consortium of Multiple Congress Sponsorship $22,200.00
Sclerosis Centers
------------------------------------------------------------------------
Consortium of Multiple Congress Sponsorship $1,200.00
Sclerosis Centers
------------------------------------------------------------------------
Consortium of Multiple Congress Sponsorship $6,000.00
Sclerosis Centers
------------------------------------------------------------------------
Consortium of Multiple Congress Sponsorship $1,500.00
Sclerosis Centers
------------------------------------------------------------------------
Consortium of Multiple North American Registry for $200,000.00
Sclerosis Centers Care and Research in
Multiple Sclerosis (NARCRMS)
2018 Support
------------------------------------------------------------------------
Cradles To Crayons Inc. Ready for School Program $20,000.00
------------------------------------------------------------------------
Critical Path Institute Transplant Therapeutics $55,000.00
Consortium
------------------------------------------------------------------------
DEAF, Inc.-- Deaf-Accessible Medical Case $10,000.00
Developmental Management Program
Evaluation and
Adjustment Facilities,
Inc.
------------------------------------------------------------------------
Deep South Cancer 2018 Magic City Cycliad $5,000.00
Foundation
------------------------------------------------------------------------
Dermatology Nurses DNA 2018 Corporate Membership $3,000.00
Association
------------------------------------------------------------------------
Dimock Community 4th Annual Road to Wellness $1,000.00
Foundation Inc. 5K Walk/Run
------------------------------------------------------------------------
Dimock Community 31st Annual Fundraiser $100,000.00
Foundation Inc.
------------------------------------------------------------------------
Duke University Fellowship Program $75,000.00
------------------------------------------------------------------------
East End House Inc. Generating and Evaluating New $20,000.00
Adventures in Science After
School (GENASAS)
------------------------------------------------------------------------
East End House Inc. Generating and Evaluating New $20,000.00
Adventures in Science After
School (GENASAS)
------------------------------------------------------------------------
Emory University Fellowship Program $75,000.00
------------------------------------------------------------------------
Emory University JScreen Jewish Genetic $100,000.00
Disease Education Initiative
------------------------------------------------------------------------
Family Promise Capital Campaign: A Place to $25,000.00
Metrowest Inc. Call Home
------------------------------------------------------------------------
Florida Society of Membership $25,000.00
Clinical Oncology
------------------------------------------------------------------------
Florida Society of Living with Prostate Cancer $3,750.00
Clinical Oncology
------------------------------------------------------------------------
Florida Society of Congress Sponsorship $35,600.00
Rheumatology
------------------------------------------------------------------------
Food For Free Home Delivery--A Nutrition $15,000.00
Committee, Inc. Program for Seniors and
People with Disabilities
------------------------------------------------------------------------
Foundation of the Multiple Sclerosis Workforce $31,225.00
Consortium of MS of the Future: Medical
Centers Student Research
Scholarships
------------------------------------------------------------------------
Foundation of the 2018 FCMSC Neurology Resident $10,000.00
Consortium of MS Annual Meeting Scientific
Centers Scholarships
------------------------------------------------------------------------
Foundation of the NARCOMS NOW 2018 $15,000.00
Consortium of MS
Centers
------------------------------------------------------------------------
Foundation of the Foundation of the Consortium $10,000.00
Consortium of MS of Multiple Sclerosis
Centers Centers 2018 Mission Support
------------------------------------------------------------------------
Framingham Townwide Pto Barbieri school holiday gift $1,000.00
Council drive
------------------------------------------------------------------------
Franciscan Hospital For Adaptive Sports Program $15,000.00
Children Inc.
------------------------------------------------------------------------
Friends of Resiliency Dropout Prevention Academic $10,000.00
for Life Inc. Services
------------------------------------------------------------------------
Generation Citizen Inc. Generation Citizen $10,000.00
Massachusetts Civics Day
------------------------------------------------------------------------
Generation Citizen Inc. Volunteer Match $1,000.00
------------------------------------------------------------------------
Georgia Dermatology of Congress Sponsorship $35,000.00
Physician Assistants
(GDPA)
------------------------------------------------------------------------
Georgia Society of Membership $6,000.00
Clinical Oncology
------------------------------------------------------------------------
Georgia Society of Congress Sponsorship $10,000.00
Dermatology and
Dermatologic Surgery
------------------------------------------------------------------------
Georgia Society of Congress Sponsorship $10,000.00
Rheumatology
------------------------------------------------------------------------
Georgia Society of Congress Sponsorship $2,100.00
Rheumatology
------------------------------------------------------------------------
Girl Scouts of Eastern Girls Building Self-eSTeEM $15,000.00
Massachusetts Inc.
------------------------------------------------------------------------
Global Academy for Congress Sponsorship $65,000.00
Medical Education,
Inc.
------------------------------------------------------------------------
Global Academy for Congress Sponsorship $40,037.50
Medical Education,
Inc.
------------------------------------------------------------------------
Global Alliance for Membership $50,000.00
Patient Access
------------------------------------------------------------------------
Global Genes In-kind donation $11,128.38
------------------------------------------------------------------------
Global Genes Access Program $25,000.00
------------------------------------------------------------------------
Global Genes 2018 Patient Advocacy Summit: $2,500.00
Advocacy Support
------------------------------------------------------------------------
Global Genes 2018 RARE Corporate Alliance $25,000.00
------------------------------------------------------------------------
Global Genes 2018 Patient Advocacy Summit $50,000.00
------------------------------------------------------------------------
Global Genes RARE Global Advocacy $10,000.00
Leadership Symposium
------------------------------------------------------------------------
Global Genes 2018 RARE Education Programs $25,000.00
------------------------------------------------------------------------
Global Genes 2018 Rare Disease Hub $5,000.00
------------------------------------------------------------------------
Global Genes 2019 Corporate Alliance $25,000.00
------------------------------------------------------------------------
Gordon Research Lysosomal storage diseases $10,000.00
Conferences Program
------------------------------------------------------------------------
Greater Boston Chamber Membership $4,000.00
of Commerce
------------------------------------------------------------------------
Greenwood Genetic Fellowship Program $74,764.00
Center Inc.
------------------------------------------------------------------------
Greenwood Genetic Fellowship Program $74,991.00
Center Inc.
------------------------------------------------------------------------
Habitat For Humanity Fundraiser Event $10,000.00
Metrowest--Greater
Worcester Inc.
------------------------------------------------------------------------
Habitat For Humanity Affordable Home Build Program $20,000.00
Metrowest--Greater
Worcester Inc.
------------------------------------------------------------------------
Habitat For Humanity of Corporate Build Day $1,500.00
North Central
Massachusetts
------------------------------------------------------------------------
Harvard Medical School Congress Sponsorship $2,500.00
Global and Continuing
Education
------------------------------------------------------------------------
Health Care For All Framingham Area Health Care $15,000.00
Inc. Access Education and
Outreach Campaign
------------------------------------------------------------------------
Health Resources in The Leaders through $25,000.00
Action Inc. Education, Action and Hope
(LEAH) Project
------------------------------------------------------------------------
Health Resources in The Leaders through $866.75
Action Inc. Education, Action and Hope
(LEAH) Project
------------------------------------------------------------------------
Hearts & Noses Hospital Ongoing Bedside Hospital $15,000.00
Clown Troupe Inc. Clown Visits to Ill and
Disabled Children in Greater
Boston
------------------------------------------------------------------------
Hemostasis and Membership $10,000.00
Thrombosis Research
Society
------------------------------------------------------------------------
Hope and Comfort Inc. Hope and Comfort: Personal $10,000.00
Hygiene Products to Low-
Income Individuals and
Families
------------------------------------------------------------------------
Horizons for Homeless STEAM Education for Young $10,000.00
Children Homeless Children
------------------------------------------------------------------------
Illinois Society of Congress Sponsorship $25,000.00
Dermatology Physicians
Assistants
------------------------------------------------------------------------
Imedex, LLC Congress Sponsorship $99,900.00
------------------------------------------------------------------------
Institute for Cancer 2018 In Vino Vita Fundraising $10,000.00
Research dba The Event
Research Institute of
Fox Chase Cancer
Center
------------------------------------------------------------------------
International Eczema Congress Sponsorship $200,000.00
Council
------------------------------------------------------------------------
International Institute 2018 Golden Door Award $10,000.00
of New England Fundraiser
------------------------------------------------------------------------
International Institute Healthcare Navigation for $15,000.00
of New England Refugees in Boston
------------------------------------------------------------------------
International Myeloma Congress Sponsorship $450,000.00
Workshop, c/o SPARGO,
Inc.
------------------------------------------------------------------------
International 2018 MS Perspectives Program $40,000.00
Organization of
Multiple Sclerosis
Nurses
------------------------------------------------------------------------
International 2018 IOMSN Mission Support $10,000.00
Organization of
Multiple Sclerosis
Nurses
------------------------------------------------------------------------
International Society Congress Sponsorship $11,799.99
on Thrombosis and
Haemostasis
------------------------------------------------------------------------
Italian Home For Volunteer Match $1,000.00
Children Inc.
------------------------------------------------------------------------
Italian Home For Comprehensive Care for $12,500.00
Children Inc. Children
------------------------------------------------------------------------
Jewish Family Service Patient Navigator/Enhanced $20,000.00
of Metrowest Inc. Medical Escort Program
------------------------------------------------------------------------
Jewish Genetic Disease JGDC Website and Social Media $5,000.00
Consortium (JGDC) Rebuild Phase Two and
Brochure Update
------------------------------------------------------------------------
Jewish Genetic Diseases Our Heritage and our Health-- $975.00
Center of Greater Ashkenazi Jewish Genetic
Phoenix Disease and the Founder
Effect
------------------------------------------------------------------------
Just-A-Start Just-A-Start Biomedical $25,000.00
Corporation Careers Program
------------------------------------------------------------------------
Just-A-Start Biomedical Careers Program (& $25,000.00
Corporation Mass Bio Membership)
------------------------------------------------------------------------
Kansas University Fellowship Program $75,000.00
Endowment Association
------------------------------------------------------------------------
Knect365 US, Inc. Selections from DISORDER the $15,000.00
Rare Disease Film Festival
at Biotech Week Boston
------------------------------------------------------------------------
Kometa Serbian Volunteer Match $1,000.00
Childrens Program Inc.
------------------------------------------------------------------------
Life Science Cares Inc. 2018 Impact Breakfast $10,000.00
------------------------------------------------------------------------
Little Brothers/Friends Medical Escort Program $5,000.00
of the Elderly
------------------------------------------------------------------------
Louisiana Association Congress Sponsorship $5,285.00
of Health Plans
------------------------------------------------------------------------
Lycee International De Fundraiser Event $10,000.00
Boston International
School of Boston Inc.
------------------------------------------------------------------------
Lysosomal and Rare Fellowship Program $75,000.00
Disorders Research and
Treatment Center Inc.
------------------------------------------------------------------------
Lysosomal and Rare Fellowship Program $75,000.00
Disorders Research and
Treatment Center Inc.
------------------------------------------------------------------------
Magellan Rx Management Congress Sponsorship $7,500.00
Inc.
------------------------------------------------------------------------
Margaret Fuller Margaret Fuller Neighborhood $15,000.00
Neighborhood House House Youth Programs
------------------------------------------------------------------------
Mass Insight Education Mass Insight's Advanced $15,000.00
and Research Institute Placement (AP) STEM &
Inc English Program
------------------------------------------------------------------------
Massachusetts Bay STEM Mentor Program (SMP) $43,000.00
Community College
Foundation
------------------------------------------------------------------------
Massachusetts Congress Sponsorship $100,000.00
Biotechnology Council
------------------------------------------------------------------------
Massachusetts Membership $30,800.00
Biotechnology Council
------------------------------------------------------------------------
Massachusetts Patient Advocacy Summit $10,000.00
Biotechnology Council
------------------------------------------------------------------------
Massachusetts Conference Sponsorship $5,000.00
Biotechnology
Education Foundation
Inc.
------------------------------------------------------------------------
Massachusetts 2018 Champions for $5,000.00
Biotechnology Biotechnology Education
Education Foundation Program
Inc.
------------------------------------------------------------------------
Massachusetts Life Sciences Workforce 2018 $5,000.00
Biotechnology
Education Foundation
Inc.
------------------------------------------------------------------------
Massachusetts MassBioEd Mission $50,000.00
Biotechnology
Education Foundation
Inc.
------------------------------------------------------------------------
Massachusetts Black 2018 Ida B. Wells Annual $5,000.00
Women Attorneys Awards Event
Foundation Inc.
------------------------------------------------------------------------
Massachusetts College Next Generation of Women $10,000.00
of Pharmacy and Health Leaders in STEM
Sciences
------------------------------------------------------------------------
Massachusetts Life Massachusetts Next Generation $50,000.00
Sciences Center Initiative (MassNextGen)
------------------------------------------------------------------------
Massachusetts State 2018 Fair Operations & Sanofi $50,000.00
Science and Genzyme Science Award
Engineering Fair, Inc.
------------------------------------------------------------------------
Medical Oncology Membership $10,000.00
Association of
Southern California,
Inc.
------------------------------------------------------------------------
MedStar Health Congress Sponsorship $2,500.00
------------------------------------------------------------------------
Metrowest Free Medical Access to Women's Health Care $15,000.00
Program Inc. Program
------------------------------------------------------------------------
Michigan Society of Membership $12,000.00
Hematology & Oncology
------------------------------------------------------------------------
Museum of Fine Arts Membership $20,000.00
------------------------------------------------------------------------
Museum of Science Sanofi Genzyme Teacher $71,520.00
Sabbatical at the Museum of
Science Cohort Year 2018/19
------------------------------------------------------------------------
National Comprehensive 2019 NCCN Global Corporate $15,000.00
Cancer Network Council Membership
------------------------------------------------------------------------
National Comprehensive NCCN 13th Annual Congress: $10,000.00
Cancer Network Hematologic MalignanciesTM:
Patient Advocacy Pavilion
------------------------------------------------------------------------
National Organization Congress Sponsorship $3,000.00
of Rheumatology
Managers
------------------------------------------------------------------------
National Organization Corporate Membership $30,000.00
of Rheumatology
Managers
------------------------------------------------------------------------
National Society of Congress Sponsorship $2,500.00
Genetic Counselors
------------------------------------------------------------------------
National Society of Congress Sponsorship $2,500.00
Genetic Counselors
------------------------------------------------------------------------
National Society of Congress Sponsorship $375.00
Genetic Counselors
------------------------------------------------------------------------
NEHI NEHI's 2018 Innovators in $10,000.00
Health Awards
------------------------------------------------------------------------
New York University-- Fellowship Program $75,000.00
Langone School of
Medicine
------------------------------------------------------------------------
NJ Sharing Network Congress Sponsorship $5,000.00
------------------------------------------------------------------------
NJ Society of Oncology Membership $5,000.00
Managers
------------------------------------------------------------------------
Nora's Home Congress Sponsorship $5,000.00
------------------------------------------------------------------------
North Carolina Oncology Membership $5,000.00
Management Society
------------------------------------------------------------------------
Northeastern University Community Student Scholarship $4,000.00
Program
------------------------------------------------------------------------
Northern California Congress Sponsorship $10,000.00
Rheumatology Society
------------------------------------------------------------------------
Norton Healthcare 2018 Neuroscience Expo $5,000.00
Foundation, Inc.
------------------------------------------------------------------------
Norton Healthcare 2018 Celebrating MS $5,000.00
Foundation, Inc. Innovations
------------------------------------------------------------------------
NSGC Congress Sponsorship $6,600.00
------------------------------------------------------------------------
Ohio Hematology Membership $5,000.00
Oncology Society
------------------------------------------------------------------------
Operation Warm Inc. 2018 Boston Coat Program $20,000.00
------------------------------------------------------------------------
Organ Donation & 2018 Corporate Sponsorship $5,000.00
Transplantation
Alliance
------------------------------------------------------------------------
Pan American League of Congress Sponsorship $131,750.00
Associations for
Rheumatology
------------------------------------------------------------------------
PCMA Pharmaceutical Congress Sponsorship $56,000.00
Care Management
Association
------------------------------------------------------------------------
PCMA Pharmaceutical Congress Sponsorship $50,000.00
Care Management
Association
------------------------------------------------------------------------
PCMA Pharmaceutical Congress Sponsorship $36,000.00
Care Management
Association
------------------------------------------------------------------------
PCMA Pharmaceutical Congress Sponsorship $50,000.00
Care Management
Association
------------------------------------------------------------------------
Peer Health Exchange Peer Health Exchange: $5,000.00
Inc. Empowering Boston's Young
People to Make Healthy
Decisions
------------------------------------------------------------------------
Pennsylvania Congress Sponsorship $10,000.00
Rheumatology Society
------------------------------------------------------------------------
Perkins School for the Technology for Success in $20,000.00
Blind STEM Learning
------------------------------------------------------------------------
Philadelphia Rheumatism Membership $1,000.00
Society
------------------------------------------------------------------------
Phillips Brooks House Bridges Food Science and $3,000.00
Association Physical Fitness Workshop
Incorporated
------------------------------------------------------------------------
Phoenix Rheumatology Congress Sponsorship $10,000.00
Association
------------------------------------------------------------------------
Phoenix Rheumatology Congress Sponsorship $30,000.00
Association
------------------------------------------------------------------------
Phoenix Rheumatology Membership $10,000.00
Association
------------------------------------------------------------------------
Premier Oncology Membership $5,000.00
Hematology Management
Society
------------------------------------------------------------------------
Premier Oncology Membership $5,000.00
Hematology Management
Society
------------------------------------------------------------------------
Premier Specialty Congress Sponsorship $15,000.00
Network
------------------------------------------------------------------------
President and Fellows The Family Van: Culturally- $50,000.00
of Harvard College Competent Care for All
------------------------------------------------------------------------
President and Fellows The Family Van: Increasing $50,000.00
of Harvard College Healthcare Access to
Everyone
------------------------------------------------------------------------
Pri-Med Institute Congress Sponsorship $66,750.00
------------------------------------------------------------------------
Pro Player Foundation Patient Education and $5,000.00
Awareness Program
------------------------------------------------------------------------
Pro Player Foundation Patient Education and $5,000.00
Awareness Program
------------------------------------------------------------------------
Project Just Because, 211 Domestic Abuse/Emergency $10,000.00
Inc. Program & Keep A Family Warm
Program
------------------------------------------------------------------------
Prostate Cancer Academy Congress Sponsorship $7,500.00
------------------------------------------------------------------------
Read to a Child, Inc. Read to a Child's Lunchtime $5,000.00
Reading Program
------------------------------------------------------------------------
Regents of the Fellowship Program $75,000.00
University of
California
------------------------------------------------------------------------
Regents of the Lysosomal Storage Diseases $57,059.40
University of Patient and Family
California Educational Grant
------------------------------------------------------------------------
Regents of the Fellowship Program $75,000.00
University of Michigan
------------------------------------------------------------------------
Regents of the Fellowship Program $75,000.00
University of
Minnesota
------------------------------------------------------------------------
Rheumatology Congress Sponsorship $7,500.00
Association of Iowa
------------------------------------------------------------------------
Rheumatology Congress Sponsorship $20,000.00
Association of Iowa
------------------------------------------------------------------------
Rheumatology Congress Sponsorship $10,000.00
Association of
Minnesota and the
Dakotas
------------------------------------------------------------------------
Rheumatology Congress Sponsorship $10,000.00
Association of Nevada
------------------------------------------------------------------------
Rheumatology Nurses Congress Sponsorship $2,000.00
Society
------------------------------------------------------------------------
Rheumatology Nurses Congress Sponsorship $45,000.00
Society
------------------------------------------------------------------------
Rheumatology Nurses Congress Sponsorship $3,655.00
Society
------------------------------------------------------------------------
Rheumatology Nurses Congress Sponsorship $33,575.00
Society
------------------------------------------------------------------------
Rheumatology Nurses Congress Sponsorship $1,700.00
Society
------------------------------------------------------------------------
Rheumatology Nurses National Advocacy Sponsorship $50,000.00
Society
------------------------------------------------------------------------
Rheumatology Nurses Speed Advocacy Session of the $7,500.00
Society RNS Advocacy Experience Day
------------------------------------------------------------------------
Rheumatology Nurses Corporate Sponsorship $50,000.00
Society
------------------------------------------------------------------------
Rhode Island Diabetes & Congress Sponsorship $750.00
Endocrine Society
------------------------------------------------------------------------
Run for Dad American Run for Dad $3,000.00
Cancer Society
------------------------------------------------------------------------
S S Cosmas & Damian 92nd Annual Feast of S.S. $2,500.00
Society Inc. Cosmas and Damian
------------------------------------------------------------------------
Samaritans, Inc. Youth Suicide Prevention $25,000.00
Services
------------------------------------------------------------------------
Scholarship America, Chart Your Own Course $32,250.00
Inc. Scholarship Program
------------------------------------------------------------------------
Scholarship America, Sanofi Genzyme TORCH Awards $11,600.00
Inc. program
------------------------------------------------------------------------
Science Club For Girls Science Clubs and Junior $10,000.00
Inc. Mentors Program
------------------------------------------------------------------------
Science From Scientists In-School Module-Based (ISMB) $30,000.00
Inc. STEM Enrichment Program for
Boston Public Schools 2017-
18
------------------------------------------------------------------------
Science From Scientists In-School Module-Based (ISMB) $30,000.00
Inc. STEM Enrichment Program for
Boston Public Schools 2018-
19
------------------------------------------------------------------------
Society for Congress Sponsorship $20,000.00
Investigative
Dermatology
------------------------------------------------------------------------
Southern Oncology Membership $5,000.00
Association of
Practices
------------------------------------------------------------------------
Southern Regional Congress Sponsorship $2,000.00
Genetics Group (SERGG)
------------------------------------------------------------------------
Special Olympics 2018 Bio-Ball $2,500.00
Massachusetts Inc.
------------------------------------------------------------------------
Special Olympics Special Olympics $7,500.00
Massachusetts Inc. Massachusetts Shrewsbury
Basketball Team to Compete
at Special Olympics World
Games in Abu Dhabi
------------------------------------------------------------------------
Sportsmen's Tennis & School to Sportsmen's Program $15,000.00
Enrichment Center
------------------------------------------------------------------------
St. Francis House Triage Program $10,000.00
------------------------------------------------------------------------
St. Mary's Center for Women@Work Plus $15,000.00
Women and Children
------------------------------------------------------------------------
State of Texas Congress Sponsorship $40,000.00
Association of
Rheumatologists
------------------------------------------------------------------------
State of Texas Congress Sponsorship $40,000.00
Association of
Rheumatologists
------------------------------------------------------------------------
The Administrators of NOLA Bluedoo Run/Walk/ $7,500.00
the Tulane Education Celebration for Prostate
Fund on behalf of Cancer Research
Tulane University
Health Sciences
Center, CCE
------------------------------------------------------------------------
The American Society of Congress Sponsorship $10,000.00
Hematology
------------------------------------------------------------------------
The American Society of Congress Sponsorship $3,150.00
Hematology
------------------------------------------------------------------------
The Boston Home, Inc. B.Fit! Socialization and $18,000.00
Wellness Day Program
------------------------------------------------------------------------
The Community Art Community Art Center Youth $15,000.00
Center Programming
------------------------------------------------------------------------
The Community Art Community Art Center School $15,000.00
Center Age Child Care and Teen
Programs
------------------------------------------------------------------------
The Discovery Museums Sanofi Genzyme Discovery $15,000.00
Science 2018
------------------------------------------------------------------------
The Discovery Museums Fundraiser Event $5,000.00
------------------------------------------------------------------------
The Discovery Museums Discovery Science: Framingham $15,000.00
and Waltham
------------------------------------------------------------------------
The Endocrine Society Congress Sponsorship $3,995.00
------------------------------------------------------------------------
The Forsyth Institute Mobile Dental Program Service $10,000.00
to the Youth on Fire Shelter
in Cambridge
------------------------------------------------------------------------
The Greater Boston Food General Operating Support $30,000.00
Bank Inc.
------------------------------------------------------------------------
The Greater Boston Food Volunteer Match $1,000.00
Bank Inc.
------------------------------------------------------------------------
The Greater Boston Food Volunteer Match $1,000.00
Bank Inc.
------------------------------------------------------------------------
The Greater Boston Food Emergency Food Distribution $30,000.00
Bank Inc. Across Eastern Massachusetts
------------------------------------------------------------------------
The Jewish P.O.C.E.T. Congress Sponsorship $2,500.00
------------------------------------------------------------------------
The Massachusetts Everyday Amazing Race $5,000.00
General Hospital
------------------------------------------------------------------------
The McCourt Foundation Educational Update $20,000.00
------------------------------------------------------------------------
The McCourt Foundation Tour de South Shore Athletic $5,000.00
Festival
------------------------------------------------------------------------
The McCourt Foundation MS Educational Update for $20,000.00
Patients, Caregivers and
Family Members
------------------------------------------------------------------------
The Oak Clinic 2018 Oak Clinic Acorn Run $4,500.00
------------------------------------------------------------------------
The Oak Clinic Oak Clinic's Marvelous $15,000.00
Monday's Wellness Programs
------------------------------------------------------------------------
The Oak Clinic 2018 Oak Clinic Diamond Run $5,000.00
------------------------------------------------------------------------
The Posse Foundation Posse Boston $25,000.00
Inc.
------------------------------------------------------------------------
The Possible Project The Possible Project 2018 $10,000.00
Event Series
------------------------------------------------------------------------
The Regents of the Fellowship Program $75,000.00
University of
California, Irvine
------------------------------------------------------------------------
The Regents of the Fellowship Program $75,000.00
University of
California, Los
Angeles
------------------------------------------------------------------------
The Salvation Army Volunteer Match $2,000.00
------------------------------------------------------------------------
The Salvation Army Volunteer Match $6,000.00
------------------------------------------------------------------------
The UCLA Foundation The UCLA Fabry Disease $2,500.00
Program
------------------------------------------------------------------------
Thompson Island Outward Connections Program $15,000.00
Bound Education Center
Inc.
------------------------------------------------------------------------
Thompson Island Outward 2018 Thompson Island 4k Trail $5,000.00
Bound Education Center Run
Inc.
------------------------------------------------------------------------
Trustees of Boston Community Student Scholarship $4,000.00
University Program
------------------------------------------------------------------------
Trustees of Boston Community Student Scholarship $825.00
University Program
------------------------------------------------------------------------
Trustees of the The 19th International $50,000.00
University of Vasculitis & ANCA Workshop
Pennsylvania
------------------------------------------------------------------------
Tutoring Plus of STEAM Programming $5,000.00
Cambridge, Inc.
------------------------------------------------------------------------
Tutoring Plus of Elementary and Middle School $12,500.00
Cambridge, Inc. Programs
------------------------------------------------------------------------
UAB Division of Fellowship Program $75,000.00
Nephrology Attn:
Jennifer Clendenin
------------------------------------------------------------------------
UConn Health Congress Sponsorship $500.00
------------------------------------------------------------------------
United Arizona Congress Sponsorship $25,000.00
Rheumatology Alliance
------------------------------------------------------------------------
United Network For Congress Sponsorship $9,100.00
Organ Sharing
------------------------------------------------------------------------
United Network For Congress Sponsorship $6,000.00
Organ Sharing
------------------------------------------------------------------------
United Network For Congress Sponsorship $8,000.00
Organ Sharing
------------------------------------------------------------------------
United Rheumatology LLC Congress Sponsorship $135,000.00
------------------------------------------------------------------------
United Way of Tri- Volunteer Match $1,000.00
County
------------------------------------------------------------------------
University of Alabama Fellowship Program $75,000.00
at Birmingham
------------------------------------------------------------------------
University of Chicago Congress Sponsorship $15,000.00
Hospitals
------------------------------------------------------------------------
University of Colorado Congress Sponsorship $20,000.00
Anschutz Medical
Campus
------------------------------------------------------------------------
University of Florida Fellowship Program $75,000.00
Foundation Inc.
------------------------------------------------------------------------
University of Florida Fellowship Program $74,900.00
Foundation Inc.
------------------------------------------------------------------------
University of Illinois Congress Sponsorship $10,000.00
at Chicago
------------------------------------------------------------------------
University of Congress Sponsorship $10,000.00
Louisville
------------------------------------------------------------------------
University of Student Success Program, $200,000.00
Massachusetts UMass Boston, College of
Foundation Inc. Science and Mathematics
------------------------------------------------------------------------
University of TORCH award donations $5,000.00
Mississippi Foundation
------------------------------------------------------------------------
Uplifting Athletes Inc. Leadership Development $38,000.00
Conference/Organizational
Support
------------------------------------------------------------------------
Uplifting Athletes Inc. 2019 Uplifting Athletes Young $20,000.00
Investigator Draft
------------------------------------------------------------------------
Uplifting Athletes Inc. Young Investigator Draft $5,000.00
------------------------------------------------------------------------
Vanderbilt University Fellowship Program $75,000.00
School of Medicine
------------------------------------------------------------------------
VNA Care Hospice Inc. Elizabeth Evarts de Rham $5,000.00
Hospice Home at Chilton
Street
------------------------------------------------------------------------
Wade Institute for Summer Professional $20,000.00
Science Education Development STEM Institutes
for teachers
------------------------------------------------------------------------
Wade Institute for Summer Professional $20,000.00
Science Education Development Institutes for
Science Teachers 2019
------------------------------------------------------------------------
Washington State Membership $5,000.00
Medical Oncology
Society
------------------------------------------------------------------------
Wentworth Institute of Community Student Scholarship $4,000.00
Technology Program
------------------------------------------------------------------------
West End House Boys and Volunteer Match $1,000.00
Girls Club
------------------------------------------------------------------------
West End House Boys and Volunteer Match $1,000.00
Girls Club
------------------------------------------------------------------------
West End House Boys and West End House Expect More $24,609.00
Girls Club Campaign: MakerZone
------------------------------------------------------------------------
West End House Boys and West End House Annual $25,000.00
Girls Club Celebration
------------------------------------------------------------------------
West End House Boys and West End House Annual $50,000.00
Girls Club Celebration
------------------------------------------------------------------------
Western States Regional Congress Sponsorship $18,000.00
Hemophilia Network
------------------------------------------------------------------------
Wheelchairs 4 Kids Let's Roll Program $10,000.00
------------------------------------------------------------------------
Whitehead Institute for Expedition: Bio 2019 $10,000.00
Biomedical Research
------------------------------------------------------------------------
Wisconsin Rheumatology Congress Sponsorship $10,000.00
Association
------------------------------------------------------------------------
Women's Dermatologic Congress Sponsorship $2,500.00
Society
------------------------------------------------------------------------
Women's Lunch Place Healthy Meals Program $45,000.00
------------------------------------------------------------------------
WORLD Symposium Congress Sponsorship $1,000.00
------------------------------------------------------------------------
WORLD Symposium Congress Sponsorship $1,000.00
------------------------------------------------------------------------
WORLD Symposium Congress Sponsorship $1,000.00
------------------------------------------------------------------------
WORLD Symposium Congress Sponsorship $67,000.00
------------------------------------------------------------------------
WORLD Symposium Congress Sponsorship $110,000.00
------------------------------------------------------------------------
WORLD Symposium Congress Sponsorship $5,000.00
------------------------------------------------------------------------
WORLD Symposium Congress Sponsorship $50,000.00
------------------------------------------------------------------------
WORLD Symposium Congress Sponsorship $60,000.00
------------------------------------------------------------------------
WORLD Symposium Congress Sponsorship $35,000.00
------------------------------------------------------------------------
WORLD Symposium Congress Sponsorship $35,000.00
------------------------------------------------------------------------
WORLD Symposium Congress Sponsorship $50,000.00
------------------------------------------------------------------------
WORLD Symposium Congress Sponsorship $50,000.00
------------------------------------------------------------------------
WORLDSymposia Congress Sponsorship $5,250.00
------------------------------------------------------------------------
WORLDSymposia Congress Sponsorship $45,000.00
------------------------------------------------------------------------
WriteBoston Aligning and Elevating $18,000.00
Literacy Instruction across
the Chelsea Public Schools
------------------------------------------------------------------------
YMCA of Greater Boston Scholarships for Low-Income $15,000.00
Allston-Brighton Children
------------------------------------------------------------------------
ziMS Foundation 2018 ZIMS Strike Down MS Bowl- $5,000.00
A-Thon
------------------------------------------------------------------------
Proposal Type Project Name Legal Name Amount
Corporate Transplantation Critical Path $55,000.00
Membership Therapeutics Institute
Membership
Corporate Corporate Endocrine Society $11,000.00
Membership Membership
Corporate Corporate Colorado Business $5,000.00
Membership Membership Group on Health
Corporate Corporate Rheumatology $200,000.00
Membership Membership Research
Foundation
Corporate Corporate National $25,000.00
Membership Membership Governors
Association
Corporate Corporate National $5,000.00
Membership Membership Conference of
Insurance
Legislato
Corporate CEVR Membership Tufts Medical $35,000.00
Membership Center
Corporate Corporate American $20,000.00
Membership Membership Association for
Cancer Research
Corporate Corporate American $20,000.00
Membership Membership Association for
Cancer Research
Corporate Corporate American $25,000.00
Membership Membership Association of
Diabetes
Educator
Corporate Corporate AMGA Foundation $15,000.00
Membership Membership Inc.
Corporate 2018 NEHI NEHI $75,000.00
Membership Membership
Corporate 2018 Corporate National Kidney $10,000.00
Membership Membership Foundation, Inc.
Corporate Corporate The Partnership $19,000.00
Membership Membership Dues for Quality
2018 Medical Donati
Corporate STOP Obesity George Washington $25,000.00
Membership Alliance University's
STOP Obes
Corporate Premium Texas Business $15,000.00
Membership Membership Group on Health
Corporate Health University of $50,000.00
Membership Organization Louisville
Corporate School of Public
Membership Health
Corporate Corporate American $20,000.00
Membership Membership Association of
Nurse
Practitioner
Corporate Corporate Georgia Chamber $750.00
Membership Membership of Commerce
Corporate Corporate American $20,000.00
Membership Membership Association of
Clinical
Endocrinol
Corporate Corporate National Business $16,500.00
Membership Membership Group on Health
Corporate PBSM Corporate National Business $15,000.00
Membership Membership Group on Health
Corporate Membership Dues Florida Chamber $2,000.00
Membership of Commerce,
Inc.
Corporate 2018 Membership Buyers Health $10,000.00
Membership Care Action
Group
Corporate Chamber of Montana Chamber $280.00
Membership Commerce Dues of Commerce
Corporate Corporate Business for $33,000.00
Membership Membership Social
Responsibility
Corporate 2018 ACCP Annual Association of $6,250.00
Membership Membership Corporate
Contributions
Pro
Corporate Corporate Society of $2,500.00
Membership Membership Toxicologic
Pathology
Corporate Corporate Healthcare $45,000.00
Membership Membership Distribution
Alliance HDA
Corporate Tufts CSDD Tufts Center for $15,000.00
Membership the Study of
Drug Developm
Corporate Affiliate Massachusetts $2,500.00
Membership Membership Dues Association of
Health Plans
Corporate Corporate National Health $32,000.00
Membership Membership Council
Corporate Corporate Illinois $2,500.00
Membership Membership Manufacturers'
Association
Corporate NASPA 2018 NASPA $5,000.00
Membership Associate Member
Dues
Corporate Corporate National LGBT $7,500.00
Membership Membership 2018 Chamber of
Commerce
Corporate Corporate National LGBT $7,500.00
Membership Membership 2018 Chamber of
Commerce
Corporate Corporate International $20,000.00
Membership Membership Society for
Medical
Publicatio
Corporate ACPA Corporate American Chronic $10,000.00
Membership Membership Pain Association
Corporate Corporate Pharmaceutical $397,832.00
Membership Membership Research and
Manufacture
Corporate Corporate Pharmaceutical -
Membership Memberhsip Research and
Manufacture
Corporate Women's Heart Tides Center $75,000.00
Membership Alliance
Mebership
Corporate Corporate College Diabetes $25,000.00
Membership Membership Network Inc.
Corporate Corp. AIM--Associated $10,000.00
Membership Industries of
Massachuset
Corporate NLGA Corporate National Lt. $10,000.00
Membership Membership Governors
Association
Corporate Corporate Ohio Chamber of $1,700.00
Membership Membership Commerce
Corporate Corporate Somerset Health $2,500.00
Membership Membership Care Foundation
Corporate Corporate Academy of $10,000.00
Membership Membership Managed Care
Pharmacy
Corporate Corporate HealthCare $5,000.00
Membership Membership Institute of NJ
Corporate DA4S Corporate Diversity $700.00
Membership Membership Alliance for
Science, Inc.
Corporate Corporate Healthcare $23,500.00
Membership Membership Businesswomen's
Association
Corporate National Quality National Quality $39,400.00
Membership Forum Membership Forum
Corporate WPEO Corporate Women President $5,000.00
Membership Membership Educational
Organization
Corporate Corporate Minnesota Society $6,000.00
Membership Membership of Health-System
Pharm
Corporate Corporate The Medical Alley $2,000.00
Membership Membership Association
Corporate 2018 Membership New York & New $6,500.00
Membership Jersey Minority
Supplier D
Corporate Corporate Pittsburgh $3,450.00
Membership Membership Business Group
on Health
Corporate GDAHC Corporate Greater Detroit $7,000.00
Membership Membership Area Health
Council, Inc.
Corporate Ruby Annual US Business $7,500.00
Membership Membership Leadership
Network
Corporate Ruby Annual US Business $7,500.00
Membership Membership Leadership
Network
Corporate 2018 Corporate Physician $20,000.00
Membership Dues Assistant
Foundation of
the Americas
Corporate 2018 Somerset Somerset County $15,000.00
Membership County Business Business
Partnership dues Partnership
Corporate Annual Membership Women in $20,000.00
Membership Government
Foundation, Inc.
Corporate CLSA Sustaining California Life $76,000.00
Membership Membership Sciences
Association
Corporate NaVOBA corporate NaVOBA--National $15,000.00
Membership membership Veteran Owned
Busines
Corporate Corporate Intellectual $26,800.00
Membership Membership Property Owners
Association
Corporate Annual Membership Michigan Primary $5,000.00
Membership Care Consortium
Corporate Annual Membership National Alliance $15,000.00
Membership of Healthcare
Purchaser
Corporate Annual Membership ISPOR $15,000.00
Membership
Corporate Corporate The Antibody $10,000.00
Membership Membership Society
Corporate Corporate Michigan $2,500.00
Membership Membership Association of
Health
Corporate Corporate Life Science $1,500.00
Membership Membership Tennessee
Corporate 2018 Corporate Association of $75,000.00
Membership Membership Community Cancer
Centers
Corporate Corporate Texas Association $5,000.00
Membership Membership of Manufacturers
Corporate Annual Membership JDRF $30,000.00
Membership International
Corporate Corporate AMDA--The Sociery $2,584.00
Membership Membership for Post-Acute
and Long
Corporate Corporate Texas Healthcare $5,000.00
Membership Membership and Bioscience
Institute
Corporate Corporate BioForward $3,000.00
Membership Membership
Corporate Annual Membership National $224,000.00
Membership Association of
Manufacturers
Corporate 2018 Business The Health $450.00
Membership Partner Collaborative
Membership
Corporate OFII 2018 Organization for $17,500.00
Membership Membership Dues International
Investment
Corporate AMA Foundation American Medical $20,000.00
Membership dues Association
Foundation
Corporate Corporate National $200,000.00
Membership Membership Dues Pharmaceutical
Council
Corporate Corporate National $200,000.00
Membership Membership Dues Pharmaceutical
Council
Corporate Corporate National $50,000.00
Membership Membership Dues Pharmaceutical
Council
Corporate Biocom Membership Biocom $15,000.00
Membership Dues
Corporate 2018 Preferred BIONJ Inc. $30,000.00
Membership Membership
Corporate 2018 Membership Healthcare $200,000.00
Membership Dues Leadership
Council
Corporate Corporate Oregon Business & $1,500.00
Membership Membership Industry
Association
Corporate Membership Dues American Society $30,000.00
Membership of
Transplantation
Corporate Patients Count Milken Institute $50,000.00
Membership Membership Dues
Corporate Membership Dues Rheumatology $200,000.00
Membership Research
Foundation
Corporate Membership Dues The Kansas $993.00
Membership Chamber
Corporate Membership Dues Lehigh Valley $1,500.00
Membership Business
Coalition on
Healthcare
Corporate 2018 BIO Biotechnology $718,851.00
Membership Membership Innovation
Organization
Corporate 2018 Membership Northeast $10,500.00
Membership Dues Business Group
on Health
Corporate Corporate Indiana Chamber $650.00
Membership Membership of Commerce
Corporate Corporate American Society $35,000.00
Membership Membership Dues of Hematology
Corporate Corporate HealthCare 21 $2,750.00
Membership Membership Business
Coalition
Corporate MichiBio Michigan $1,500.00
Membership Membership Biosciences
Industry
Association
Corporate Membership Dues Virginia Bio $2,300.00
Membership
Corporate Corporate American $50,000.00
Membership Membership Foundation for
Women's Health
Corporate PSTC Corporate Critical Path $35,000.00
Membership Membership Institute
Corporate Corporate Research!America $15,000.00
Membership Membership Dues
Corporate Membership Dues ILSI Health and $15,000.00
Membership Environmental
Health Instit
Corporate Membership Dues ILSI Health and $82,971.00
Membership Environmental
Health Instit
Corporate Membership Dues Washington Health $6,930.00
Membership Alliance
Corporate Membership Dues Employers Health $1,000.00
Membership Coalition, Inc.
Corporate Membership Dues State Legislative $35,000.00
Membership Leaders
Foundation, Inc.
Corporate Associate Alliance for $50,000.00
Membership Sustaining Patient Access
Membership Dues
Corporate 2018 NewYorkBIO NewYorkBIO $2,500.00
Membership Membership
Corporate Membership Michigan Chamber $1,950.00
Membership Renewal of Commerce
Corporate CAHF Associate CA Assn of Health $1,200.00
Membership Membership Facilities
Renewal
Corporate 2018 Memebership Alliance for a $20,000.00
Membership Stronger FDA
Corporate Industry Advisory The Foundation $25,000.00
Membership Board for Post-Acute &
Long-Term
Corporate DTA Membership Digital $75,000.00
Membership Therapeutics
Alliance
Corporate Corporate Public Affairs $12,900.00
Membership Membership Council
Renewal
Corporate 2018 IPAC Diabetes $15,000.00
Membership membership Education and
Camping
Associatio
Corporate Annual Membership Evidence for $100,000.00
Membership Health Care
Improvement d/b
Corporate Consortium for National Academy $100,000.00
Membership Value and of Sciences
Science
Membership
Corporate HRPA Membership HR Policy $15,000.00
Membership Association
Corporate CPR Membership International $10,000.00
Membership Institute for
Conflict
Preventio
Corporate Corporate American $100,000.00
Membership Membership Enterprise
Institute for
Public Policy
Corporate Annual Membership Louisiana $1,765.00
Membership Association of
Health Plans
Corporate Corporate U.S. Capitol $10,000.00
Membership Committee Historical
Membership 2018 Society
Corporate 2018 Memebership Well-Being $1,000.00
Membership Collaborative of
Ohio
Corporate 2018 Council Virginia Center $5,000.00
Membership Membership for Health
Innovation
Corporate Corporate Arkansas State $1,000.00
Membership Membership Chamber of
Commerce/AIA
Corporate Corporate International $8,000.00
Membership Membership Society for
Pharmacoepidemi
Corporate AWB Membership Association of $2,500.00
Membership Washington
Business
Corporate Membership dues Pharmaceutical -
Membership Research and
Manufacture
Corporate Annual Membership Medical $5,000.00
Membership Association of
Georgia
Corporate Annual Membership New Jersey $5,000.00
Membership Association of
Health Plans
Corporate Annual Membership CECP $15,000.00
Membership
Corporate Corporate Kentuckiana $1,500.00
Membership Membership Health
Collaborative
Corporate 2018 PQA PQA, Inc. $34,375.00
Membership Membership Dues
Corporate 2018 CIBMTR The Medical $30,000.00
Membership Corporate College of
Membership Wisconsin, Inc.
Corporate Annual Membership American $75,000.00
Membership Thrombosis and
Hemostasis
Network
Corporate Annual Membership Missouri Chamber $1,500.00
Membership of Commerce and
Indust
Corporate Annual membership Center Forward $20,000.00
Membership
Corporate PACH Associate Partnership for $125,000.00
Membership Membership the Advancement
of Cardio
Corporate HUBZone HUBZone $2,495.00
Membership Contractors Contractors
National Council National
Council, Inc.
Corporate Annual Membership Greater Las Vegas $1,499.50
Membership Chamber of
Commerce
Corporate GlobalWIN Annual Global Women's $20,000.00
Membership Support Innovation
Network
Corporate FDLI Membership Food and Drug Law $13,750.00
Membership Institute
Corporate Annual Membership Wisconsin $714.00
Membership Manufacturers
and Commerce
Corporate Annual Membership Midwest Business $8,000.00
Membership Group on Health
Corporate Corporate National $25,000.00
Membership Membership Committee for
Quality
Assurance
Corporate Affiliate Partner Central Florida $1,800.00
Membership dues Health Care
Coalition
Corporate MRCT Clinical Multi Regional $50,000.00
Membership Trials Clinical Trial
Membership Center of Brigha
Corporate MRCT Bioethics Multi Regional $25,000.00
Membership Membership Clinical Trial
Center of Brigha
Corporate MOBIO Membership Missouri $1,500.00
Membership 2018 Biotechnology
Association
Corporate Corporate National Hispanic $25,000.00
Membership Membership Health
Foundation
Corporate Annual Membership West Virginia $1,320.00
Membership Chamber of
Commerce, Inc.
Corporate Annual Membership New Jersey $3,000.00
Membership Alliance for
Action
Corporate Corporate American College $1,500.00
Membership Membership of Toxicology
Corporate 2018 Memebership National $9,960.00
Membership Association of
Chain Drug
Stores
Corporate Annual Membership Business Council $3,000.00
Membership of Alabama
Corporate Corporate US Pain $20,000.00
Membership Membership Foundation Inc.
Corporate Corporate South Carolina $3,000.00
Membership Membership Alliance of
Health Plans
Corporate Corporate The Oklahoma $2,400.00
Membership Membership State Chamber of
Commerc
Corporate Corporate American $5,000.00
Membership Membership Legislative
Exchange Council
Corporate Corporate American $12,000.00
Membership Membership Legislative
Exchange Council
Corporate Corporate American Society $20,000.00
Membership Membership of Nephrology
Corporate Corporate American Society $10,000.00
Membership Membership of Nephrology
Corporate Annual Membership Iowa $2,000.00
Membership Dues Biotechnology
Association
Corporate CHOT Annual University of $50,000.00
Membership Membership Louisville
School of Public
Health
Corporate Corporate Maryland Health $5,000.00
Membership Membership Care Coalition
DBA MidAtlantic
Corporate Corporate NCSL Foundation $12,500.00
Membership Membership for State
Legislatures
Corporate Corporate Associated $3,865.00
Membership Membership Industries of
Missouri
Corporate Annual Associate Derma Care Access $100,000.00
Membership Membership Network
Corporate Corporate Wisconsin $3,750.00
Membership Membership Collaborative
for Healthcare
Quality
Corporate Corporate Academy of $15,000.00
Membership Membership Integrative Pain
Management
Corporate Corporate Association of $3,000.00
Membership Membership Military
Surgeons of the
Unit
Corporate DPAC Corporate Diabetes Patient $25,000.00
Membership Membership Advocacy
Coalition
Corporate HISCI Membership Health Industry $5,300.00
Membership Distributors
Association
Corporate CCCC Corporate California $5,000.00
Membership Membership Chronic Care
Coalition
Corporate Corporate America's $25,000.00
Membership Membership 2018- Physician Groups
2019
Corporate Corporate Integrated $33,450.00
Membership Membership Benefits
Institute, Inc.
Corporate Corporate Integrated $7,814.00
Membership Membership Benefits
Institute, Inc.
Corporate Corporate Integrated $8,736.00
Membership Membership Benefits
Institute, Inc.
Corporate 2019 Affiliate Greater $5,000.00
Membership Membership Dues Philadelphia
Business
Coalition on
Health
Corporate Maryland Tech Maryland Tech $1,800.00
Membership Council Council
Membership
Corporate Gender Parity Healthcare $30,000.00
Membership Collaborative Businesswomen's
Membership Association
Donations Adult Day Center Visiting Nurse $10,000.00
Expanded Association of
Therapeutic Somerset Hills
Programing
Request
Donations SARP Program The Pennsylvania $150,000.00
Support State University
Donations Katy's Place The Center For $5,000.00
Child Great
Development Expectations
Center Inc.
Donations Community Operation Jersey $600.00
Outreach to Cares
Veterans
Donations Sanofi US Seattle $5,000.00
Empowering Life Children's
Photo Contest Hospital
Foundation
Donations Student Support Drexel University $5,000.00
for Drexel
Chemical and
Biological
Engineering
Donations XTL Youth Affirmations $2,500.00
Programming--Emp
owering Life
Winner
Donations COTA for CJ T-- COTA Children's $2,500.00
Empowering Life Organ Transplant
Winner Associati
Donations General Mission The Partnership $10,000.00
Support for Quality
Medical Donati
Donations Research Training Trustees of The $20,000.00
in University of
Pharmacoepidemio Pennsylvania
logy
Donations Friends of Cancer Friends of Cancer $50,000.00
Research Mission Research
Support
Donations Cooley Landing Grassroots $25,000.00
Community-Based Ecology
Baylands
Restoration
Project
Donations Green Printing Arbor Day $4,944.00
Initiative Foundation
Donations Veterans and U.S. Naval $1,000.00
Careers Academy Alumni
Association
Donations Fellowship Pharmaceutical $270,000.00
Support Research and
Manufacture
Donations General Mission United Way of $55.00
Support Northern New
Jersey
Donations 2018 Warrior Operation Warrior $10,000.00
Wishes Program Wishes
Foundation
Donations General Mission ASTS Foundation $50,000.00
Support
Donations General Operating American College $2,500.00
Support of Laboratory
Animal Medicine
Donations Meals on Wheels Midland Adult $5,000.00
Services Inc.
Donations General Operating Washington Legal $30,000.00
Support Foundation
Donations Empowering young Junior $50,000.00
people for Achievement of
success in STEM New Jersey, Inc.
careers
Donations Get Active and College Diabetes $12,000.00
Make a Network Inc.
Difference
Challenge
Donations Get Active and Junior $2,500.00
Make a Achievement USA
Difference
Challenge
Donations Get Active & Make Boys & Girls $2,500.00
a Difference Clubs of America
Challenge
Donations Residential Safe + Sound $10,000.00
Children's Somerset
Program
Donations Get Active and March of Dimes $8,000.00
Make a Foundation
Difference
Challenge
Donations Healthy Food The Salvation $10,000.00
Pantry Program Army
Donations Responding to Direct Relief $25,000.00
California
Wildfires
Donations Vets4Warrios Rutgers $2,000.00
University
Foundation
Donations MAP's Domestic Map International $10,000.00
Disaster Relief
Prepardness
Donations Midland Explores Midland Adult $5,000.00
Community Services Inc.
Program
Donations MAS Employment Midland Adult $5,000.00
Program Services Inc.
Donations Get Active and Wounded Warrior $40,000.00
Make a Project, Inc.
Difference
Challenge
Donations Advancing Students 2 $250,000.00
Authentic STEM Science
Education
Donations Success By 6 with United Way of $37,000.00
Scholarship Northern New
Support and STEM Jersey
Enhancement
Donations Get Active and National Alliance $2,500.00
Make A for Caregiving
Difference
Challenge
Donations General Operating Food Bank of $25,000.00
Support Somerset County
Inc.
Donations Corporate Work- Cristo Rey Newark $60,000.00
Study Program High School
Corp.
Donations U.S. Disaster Americares $25,000.00
Assitance
Donations LGBT Staff Somerset Health $7,000.00
Sensitivity Care Foundation
Training
Donations US Disaster Heart To Heart $25,000.00
Readiness & International
Response Inc.
Donations U.S. Emergency Direct Relief $25,000.00
Preparedness and
Response
Donations Empowering Inner Sheltered Yoga $5,000.00
City Kids
Through Yoga &
Meditation
Donations Comprehensive NJ Sharing $5,000.00
Family Support Network
Foundation
Donations NCCN Foundation NCCN Foundation $25,000.00
Patient Advocacy
Collaboration
Donations Advocacy and Deirdre O'Brien $5,000.00
Forensic Child Advocacy
Interviewing of Center Inc.
Child Victims of
Abuse
Donations Genearl Operating Camp Quality USA $10,000.00
Support dba Camp Quality
NJ
Donations General Operating Jersey Battered $5,000.00
Women's Service,
Inc.
Donations Trainee Society for $25,000.00
Professional Neuroscience
Development
Awards
Donations Project Self Family Promise of $10,000.00
Sufficiency--San Monroe County
ofi in our
Communities
Donations Americares Americares $5,000.00
Airlift Benefit
Donations Get Active and Dress for Success $2,500.00
Make a Northern New
Difference Jersey--10
Challenge
Donations Young Scholars NJ SEEDS $10,000.00
Program
Donations Vets4Warriors Rutgers $10,000.00
University
Foundation
Donations Foundations of Dress for Success $10,000.00
Success Northern New
Jersey--10
Donations US Disaster Heart To Heart $25,000.00
Relief--Hurrican International
e Michael Inc.
Donations Hurricane Michael Direct Relief $50,000.00
Response
Donations Hunterdon County Hunterdon $10,000.00
Food Back Pack Healthcare
Program Foundation
Donations General Operating Hyacinth $10,000.00
Support Foundation: A
New Jersey
Nonprofit
Donations HSF General Hispanic $5,000.00
Operating Scholarship Fund
Support
Donations Hurricane Michael Americares $25,000.00
Response
Donations General Operating Good Grief Inc. $5,000.00
Support
Donations General Operating Deirdre O'Brien $5,000.00
Support Child Advocacy
Center Inc.
Donations Valhalla's Hope Valhalla Veterans $10,000.00
Services
Donations Residential Community Hope, $25,000.00
Recovery Inc.
Programs for
Homeless
Veterans and Dis
Donations Sanofi Corporate Raritan Valley $10,000.00
Mentor Program Community
at RVCC College Foundat
Donations PRIDE Connect Hyacinth $3,500.00
Project Support Foundation: A
New Jersey
Nonprofit
Donations Trevor's Life- Trevor Project $3,500.00
Saving Programs Inc.
for LGBTQ Youth
Donations General Operating Junior $5,000.00
Support Achievement of
Northeastern
Pennsylvania
Donations Camp Nejeda: Camp Nejeda $10,000.00
Helping Kids Foundation
with type 1
diabetes live
happier
Donations Advocacy Program Deirdre O'Brien $5,000.00
for Child Child Advocacy
Victims of Abuse Center Inc.
and or Neglect
Donations California Direct Relief $100,000.00
Wildfires
Donations SP 2018 UW United Way of $86,982.00
Campaign Match Monroe County
Donations Vets4Warrios Rutgers $4,000.00
University
Foundation
Donations Support4Families: Cancer Support $15,000.00
Teens Connect Community
School-Based Central
Support Group
Donations Supporting Students 2 $25,000.00
Environmental Science
Science for High
School Students
Donations Health for Covenant House $25,000.00
Homeless Youth New Jersey Inc.
Donations Medical Home Children's Health $198,000.00
Initiative 2019 Fund
Donations Serving Local Matheny School $10,000.00
Patients With and Hospital
Disabilities Inc.
Donations Matheny School Matheny School $10,000.00
STEM program and Hospital
Inc.
Donations Support4Families: Cancer Support $5,000.00
Strengthening Community
Our Schools Central
Donations Food, Health and The Community $25,000.00
Hope: An Answer Food Bank of New
to Diabetes (FHH Jersey
Diabetes)
Donations Camp Quality USA Camp Quality USA $10,000.00
dba Camp Quality dba Camp Quality
NJ NJ
Donations General Operating Visiting Nurse $10,000.00
Support Association of
Somerset Hills
Donations Steeple Chase Somerset Health $100,000.00
Cancer Center Care Foundation
Patient
Assistance Fund
Donations General Hyacinth $10,000.00
Operational Foundation: A
Support New Jersey
Nonprofit
Donations Healthier Somerset Health $10,000.00
Somerset Care Foundation
Donations HSF STEM Summit Hispanic $50,000.00
Scholarship Fund
Donations Nights of Support Good Grief Inc. $10,000.00
Program
Donations General Operating Dress for Success $10,000.00
Support Northern New
Jersey--10
Donations Trevor's Life- Boys & Girls $10,000.00
Saving Programs Clubs of Union
for LGBTQ Youth County
Donations Camp Nejeda: Camp Nejeda $10,000.00
Education and Foundation
Empowerment for
Children
Donations Vets4Warriors Rutgers $10,000.00
University
Foundation
Donations HSF Scholarship Hispanic $50,000.00
Fund Scholarship Fund
Donations General Operating NJ SEEDS $10,000.00
Support for NJ
SEEDS
Donations Banco de Banco de $25,000.00
ALimentos de Alimentos de
Puerto Rico Puerto Rico
LOR BCCNS Patient BCCNS Alliance $25,000.00
Project
LOR Patient Patients Rising, $10,000.00
Engagement Inc.
Sponsorship
LOR Patient Education Taking Control of $40,000.00
Diabetes Your Diabetes
Conferences and
Health Fairs
LOR Biological California $15,000.00
Research Institute of
Symposium Technology
LOR Patient Skin American Cancer $200,000.00
Cancer Education Society
and Awareness
LOR Populatoin Health Thomas Jefferson $60,000.00
Leadership University
Series
LOR nPOD Annual University of $15,000.00
Meeting Florida
LOR Diabetes Scholars Diabetes Scholars $10,000.00
Foundation Foundation
College
Scholarships
LOR 2018 Annual Health Action $4,700.00
Symposium and Council
Conference
LOR Western Atrial University of $50,000.00
Fibrillation Utah
Symposium 2018
LOR Gordon Research Gordon Research $5,000.00
Conference on Conferences
Myelin
LOR Cell Culture Engineering $5,000.00
Engineering XVI Conferences
Conference International
LOR 2018 Alliance Alliance for $20,000.00
Industry Summitt Continuing
Education in the
Health Sciences
LOR Symposium on Drug Massachusetts $8,000.00
Delivery Systems Institute of
Technology
LOR 2nd Annual EPIC Children's $10,000.00
Diabetes Diabetes
Conference Foundation
LOR ASN 48th Annual American Society $2,500.00
Meeting for
Neurochemistry
LOR 2018 BIO Biotechnology $334,500.00
International Innovation
Convention Organization
LOR FOCIS 2018 Annual Federation of $25,000.00
Meeting Clinical
Immunology
Societies
LOR 2018 BIO Europe Biotechnology $22,500.00
Spring Innovation
Organization
LOR 2018 BIO Europe Biotechnology $22,500.00
Fall Innovation
Organization
LOR Annual Healthcare MIT Sloan $5,000.00
Conference Healthcare
Conference and
Club
LOR SOT 2018 Annual Society of $10,000.00
Meeting Toxicology
LOR 2018 Public American $20,000.00
Policy Forum Association of
Diabetes
Educator
LOR Annual Gala Asian American $20,000.00
Dinner Legal Defense
and Educatio
LOR JDRF Imagine Gala JDRF $10,000.00
LOR 2018 Advocacy Research!America $25,000.00
Awards Dinner
LOR JDRF Government JDRF $50,000.00
Day International
LOR Immune Tolerance Parker Institute $10,000.00
Symposium for Cancer
Immunotherapy
LOR Annual Forum on National Academy $85,000.00
Drug Discovery of Sciences
and Development
LOR Biomedical Foundation for $25,000.00
Research Program Biomedical
Research
LOR Annual Symposium CASSS $2,500.00
of Regulatory
and Analytical
Science
LOR Analytical CASSS $2,500.00
Technologies
Symposium
LOR 2018 Gordon Gordon Research $3,000.00
Research Conferences
Conference on
Medicinal
Chemistry
LOR 2018 AMSSM American Medical $50,000.00
Foundation Society for
Research Grant Sports Medicine
Award Program
LOR Patient National Health $130,000.00
Perspective Council
Program
LOR Annual Business Waltham Chamber $6,000.00
Meeting of Commerce
LOR Barriers of the Gordon Research $5,000.00
CNS Conference Conferences
LOR FARE Patient Food Allergy $50,000.00
Registry Research &
Education, Inc.
LOR Wonder Women: Center for Talent $40,000.00
Flourishing and Innovation
Thriving on the
Frontiers
LOR Early American $55,000.00
Osteoarthritis Orthopaedic
and Prevention Society for
of OA Sports Medicine
Progression
LOR Pharmacy Iowa Pharmacy $10,000.00
Leadership Association
Training Program Foundation
LOR FIU Global Health Florida $95,000.00
Conference International
University Board
of Trustees
LOR 2018 Statewide Florida Health $15,000.00
Cardiac Care Coalition
Collaborative
LOR 36 Annual JDRF JDRF $2,500.00
Boston Gala International
LOR Innovative Preventive $150,000.00
Medicine Cardiovascular
Campaign Nurses
Association
LOR Women and Heart WomenHeart: The $50,000.00
Disease Program National
Coalition for
Women With Heart
Disease
LOR Off to College College Diabetes $50,000.00
Sponsorship 2018 Network Inc.
LOR Patient Education Diabetes $2,000.00
Diabetes Foundation of
Conference Mississippi
LOR Division of ACS Division of $3,000.00
Medicinal Medicinal
Chemistry Chemistry
Program ACS
National Meeting
LOR Patient Centered National Lipid $16,060.00
Management of Association
Dyslipidemia
LOR 2018 Annual SMA Families of SMA $5,000.00
Conference DBA Cure SMA
LOR 2018 ZERO ZERO--The End of $2,000.00
Prostate Cancer Prostate Cancer
Summit
LOR DA4S West Coast Diversity $3,000.00
2018 Alliance for
Science, Inc.
LOR Economic Greater New $4,000.00
Development = England Minority
Corporate Supplier
Sponsorship Development
Renewal
LOR 2018 V-BID Regents of the $50,000.00
Summit: V-BID at University of
the Big House Michigan
LOR AUTM 2018 Annual Association of $5,000.00
Meeting University
Technology Mana
LOR 2018 Annual BIONJ Inc. $10,000.00
Dinner Meeting
LOR SOT Annual Society of $2,500.00
meeting Toxicology
LOR Forum Group on George Washington $70,000.00
Arbovirus University
Infections
LOR World Vitiligo The Umass $2,500.00
Day 2018 Memorial
Conference Foundation Inc.
LOR Men's Health Men's Health $30,000.00
Month Network
Sponsorship
LOR OSU Pharmacy Oregon State $7,500.00
Partners Program University
Foundation
LOR 2018 Global International $5,000.00
Doctoral Biomedical
Partnerships Research
Annual Workshop Alliance
LOR 2018 AAAS Annual American $25,000.00
Meeting Association for
Sponsorship the Advancement
LOR Cold Spring Cold Spring $15,000.00
Harbor Meetings Harbor
and Courses Laboratory
Program
LOR 2018 Annual Event New York & New $10,000.00
Sponsorship Jersey Minority
Supplier
Development
LOR 2018 Greater New American Diabetes $10,000.00
York Tour de Association
Cure & Wellness
Expo
LOR National Minority Make Well Known $25,000.00
Cardiovascular Foundation
Alliance
LOR OASC Annual Ohio Association $1,000.00
Conference of Senior
Centers
LOR 2018 Flu Podcast Women In $5,000.00
Campaign Government
Foundation, Inc.
LOR 25th Annual Florida Health $5,000.00
National Care Coalition
Conference
LOR State Lung Health Respiratory $500.00
Education Health
Program Association
LOR CWAG 2018 Annual Conference of $5,000.00
Meeting Western
Attorneys
General
LOR 2018 Town Hall American Society $203,900.00
Meeting Support for Preventive
Cardiology
LOR Get in Rhythm American $25,000.00
Stay in Rhythm-- Foundation for
Afib Patient Women's Health
Conference
LOR PRISMS 10th Smith- PRISMS, Inc. $2,500.00
Magenis Syndrome
Conference
LOR Guidelines for Florida $50,000.00
Antimicrobial International
Stewardship University
Foundation
LOR Latin American Florida $70,000.00
and Caribbean International
Diabetes University
Network: A Foundation
framework
LOR Assesment of Florida $60,000.00
acellular International
vaccination University
programs in Foundation
Mexico, Costa
LOR Bioorganic Gordon Research $1,000.00
Research Conferences
Conference
LOR National Trustees of $150,000.00
Community Health Boston
Workers Project University
LOR Health Innovation Springboard 2000 $25,000.00
Hub 2018 Enterprises,
Inc.
LOR Bill Foege Event Map International $10,000.00
Sponsorship
LOR SDHB Pheo-Para SDHB Pheo-Para $10,000.00
Coalition Gala Coalition, Inc.
LOR 9th International University of $2,000.00
Conference on Florida
Unstable Foundation, Inc.
Microsatellites
and Human
Disease
LOR 21st Annual HealthCare 21 $3,000.00
Health & Business
Productivity Coalition
Forum
LOR 2018 Celebrating Blood and Marrow $25,000.00
a Second Chance Transplant
at Life Information
Survivorship
Sympos
LOR Patient Education Taking Control of $40,000.00
Diabetes Your Diabetes
Conferences and
Health Fairs
LOR Patient Education Taking Control of $60,000.00
Diabetes Your Diabetes
Conferences and
Health Fairs
LOR 2018 FH Global The FH Foundation $75,000.00
Summit
LOR Chemical Biology Northeastern $1,000.00
in the Hub Section of the
Symposium American
Chemical Society
LOR 2018 Champion of National Kidney $1,000.00
Hope Tribute Foundation of
Dinner Michigan
LOR 7th International CASSS $2,500.00
Symposium on
Higher Order
Structure of
Protein
Therapeutics
LOR Bioassays 2018: CASSS $2,500.00
Scientific
Approaches &
Regulatory
Strategies
LOR A Taste of Ginger Joslin Diabetes $10,000.00
Gala Center, Inc.
LOR 2018 Annual Western $10,000.00
Meeting Governors'
Sponsorship Foundation
LOR Community Hope Community Hope, $10,000.00
Annual Dinner Inc.
LOR 8th International Florida $150,000.00
Conference on International
Global Health University
Foundation
LOR 8th International Florida $14,000.00
Conference on International
Global Health University
Foundation
LOR 2018 Machestic Machestic Dragons $5,500.00
Dragons ``Paddle
for Pink''
Community Dragon
LOR ``Visions of Diabetes $2,500.00
Hope'' Awards Foundation Inc.
Dinner
LOR Stick It to Mercy Health $2,000.00
Diabetes Foundation
Joplin
LOR 2018 FSH Society $2,000.00
International
Research
Conference
LOR Teratology Teratology $1,500.00
Society 58th Society
Annual Meeting
LOR 255th ACS ACS Division of $5,000.00
National Meeting Biochemical
and Exposition Technology
(BIOT Division)
LOR Forum on National Academy $50,000.00
Neuroscience and of Sciences
Nervous System
Disorders
LOR 2018 National ACS Division of $3,000.00
Medicinal Medicinal
Chemistry Chemistry
Symposium
LOR Giving Diabetes The Diabetes $2,500.00
the Blues Coalition of
Conference Mississippi
LOR Diabetes Care and Academy of $10,000.00
Dietetic Nutrition and
Education Dietetics
Program
LOR 2018 Heart & The American $25,000.00
Stroke Ball Heart
Association
LOR RNA Therapeutics: The Umass $10,000.00
From Base Pairs Memorial
to Bedsides Foundation Inc.
LOR 2nd Annual Heart Metabolic $100,000.00
in Diabetes--HiD Endocrine
Education
Foundation
LOR Immuno-Therapy The University of $50,000.00
Scientific Texas Foundation
Workshop
LOR Cell Culture Engineering $2,500.00
Engineering XVI Conferences
Conference International
LOR 2018 LVBCH Annual Lehigh Valley $1,000.00
Conference Business
Coalition on
Healthcare
LOR Bowhay Institute The Council of $5,000.00
State
Government, Ltd.
LOR 2018 Lysosomes Gordon Research $2,000.00
and Endocytosis Conferences
Gordon Research
Conference
LOR South Sound JDRF JDRF $1,000.00
One Walk International--N
orthwest Chapter
LOR 36th Annual JDRF $2,500.00
Nordstrom Beat
the Bridge
LOR Diabetes Under American Diabetes $1,000.00
the Dome Event Association
LOR 2018 Wenger WomenHeart: The $25,000.00
Awards Dinner National
Coalition for
Women With Heart
Disease
LOR CRI's Cancer Research $25,000.00
Immunotherapy Institute Inc.
Patient Summit
Series
LOR 2018 HBA Woman of Healthcare $15,000.00
the Year Event Businesswomen's
Association
LOR Transforming Dress for Success $15,000.00
Lives 20th year Northern New
Celebration Jersey--10
LOR Recovery of American Chemical $10,000.00
Biological Society,
Products XVIII Division of
Conference Biochemistry
LOR Friends for Life Children with $25,000.00
Orlando 2018 Diabetes
Patient
Conference
LOR 2018 Orlando Children with $10,000.00
Fellows Program Diabetes
LOR Hypoglycemia Endocrine Society $150,000.00
Quality
Improvement/
Prevention
Project
LOR 2018 Annual Henry The Henry Kunkel $2,000.00
Kunkel Society Society c/o The
Meeting Rockefeller
LOR GPEN 2018 Globalization of $1,500.00
Scientific Pharmaceutics
Meeting Education
LOR 2018 Conference Employers Health $7,500.00
Sponsorship Coalition, Inc.
LOR RVCC's 50th Raritan Valley $25,000.00
Anniversary Community
Golden Harvest College Foundat
Gala
LOR 2018 PQA Annual Healthcare $6,100.00
Meeting Businesswomen's
Association
LOR 2018 PQA Annual PQA, Inc. $12,500.00
Meeting
LOR eValue8 Project Northeast $2,500.00
Business Group
on Health
LOR Annual Good Grief Good Grief Inc. $3,500.00
Gala
LOR 8th Annual Center for $10,000.00
Diversity, Healthcare
Inclusion, & Innovation
Health Equity
Symposium
LOR Real World American Diabetes $210,000.00
Evidence Association
Generation and
Analysis
Research
Symposium
LOR From Rare to Keystone Symposia $3,000.00
Care: Discovery, on Molecular and
Modeling and Cellular
Translation of
Rare Diseases
LOR 6th Annual International $15,000.00
Meeting of the Cytokine and
International Interferon
Cytokine & Society
Interferon
LOR Diabetes and CV Icahn School of $30,000.00
Risk Factors Medicine at
Program Mount Sinai
LOR Prix Galien USA The Galien $15,000.00
Forum Foundation
LOR Learning Sessions The Health $5,000.00
Program Collaborative
LOR Horton's Kids Horton's Kids, $15,000.00
Comprehensive Inc.
Programming for
At-Risk Children
LOR Children's Health Children's Health $30,000.00
Fund 2018 Annual Fund
Benefit
LOR 60th Anniversary Project Hope The $10,000.00
Project HOPE People To People
Gala Health
LOR Structural Harvard Medical $2,500.00
Biology Meeting School
LOR PROMIS: Global Harvard Medical $2,500.00
Advances in School
Methodology and
Clinical Science
LOR 68th Annual Somerset County $2,500.00
Outstanding Business
Citizen of the Partnership
Year Awards
Dinner
LOR Annual Meeting Somerset County $2,500.00
Awards Luncheon Business
2018 Partnership
LOR Illinois Diabetes Illinois Diabetes $250.00
Caucus Caucus
Fundraiser Foundation
LOR 18th annual The Virginia $700.00
luncheon Public Access
Project
LOR Grand Tastings Jersey Battered $15,000.00
XXIV Women's Service,
Inc.
LOR d18 Executive The diaTribe $250,000.00
Innovation Lab Foundation
on Diabetes and
Prediabetes
LOR 2018 Scientific Children's $10,000.00
Program in Hospital
Cellular and Corporation
Molecular
Medicine
LOR JDRF One Walk, JDRF $2,500.00
Washington, DC
LOR WOCIP 2018-2019 Women of Color in $20,000.00
Annual Meeting Pharma
LOR WOCIP 2018-2019 Women of Color in $20,000.00
Annual Meeting Pharma
LOR Koch Institute Massachusetts $5,000.00
2018 Summer Institute of
Symposium Technology
LOR Koch Institute Massachusetts $5,000.00
2018 Summer Institute of
Symposium Technology
LOR Event Sponsorship- Discovering $10,000.00
Discovering Justice
Justice 20th
Anniversary Gala
LOR Boston Children's $3,000.00
Postdoctoral Hospital
Association Corporation
Symposium on
Careers and
Collaboration in
Science
LOR ONE: The Ultimate Taking Control of $20,000.00
Conference for Your Diabetes
Adult Type 1
LOR 2018 Gordon Gordon Research $3,000.00
Research Conferences
Conference on
Heterocycles
LOR PDAF Fundraiser Prescription Drug $1,250.00
Sponsorship Assistance
Foundation
LOR Generations Gala Adult Day Center $3,000.00
Event of Somerset
County
LOR 12th Annual The diaTribe $10,000.00
Diabetes Forum Foundation
LOR 2018 Triangle JDRF $10,000.00
Hope Glala
LOR Lecture Series The New York $25,000.00
Program Academy of
Sciences
LOR Division of ACS Division of $3,000.00
Medicinal Medicinal
Chemistry Chemistry
Program ACS
National Meeting
LOR 11th Annual Brigham and $2,000.00
Polycystic Women's Hospital
Kidney Disease
Symposium
LOR DA4S East Coast Diversity $7,500.00
2018 Alliance for
Science, Inc.
LOR The Jessica Dana Farber $5,000.00
Ingram Lecture Cancer Institute
Series
LOR The Jessica Dana Farber $5,000.00
Ingram Lecture Cancer Institute
Series
LOR Key Initiatives Prostate Cancer $30,000.00
Program Education
Council
LOR NEQCA Annual New England $5,000.00
Forum Quality Care
Alliance
LOR MMRF 2018 Myeloma Multiple Myeloma $100,000.00
Patient and Research
Caregiver Foundation
Education
Program
LOR National Forum National Forum $200,000.00
for Heart for Heart
Disease Disease and
Stroke
LOR TB Survivors for National TB $5,000.00
Patient Controllers
Education Association
LOR 9th Annual Spirit Association of $50,000.00
of the Heart Black
Awards Dinner Cardiologists
LOR Change for Women Catalyst Inc. $15,000.00
in the Workplace
Program
LOR 2018 Annual Washington Policy $3,500.00
Dinner Center
LOR National The Mended $25,000.00
Education & Hearts, Inc.
Training
Conference 2018
LOR 2018 ICSA International $3,000.00
Symposium Chinese
Statistical
Association
LOR BMT InfoNet Blood and Marrow $10,000.00
Patient Guide Transplant
Reprint Information
LOR Research on Harvard T.H. Chan $200,000.00
Health School of Public
Technology Health
Assessment
LOR DIA Inspires Drug Information $4,500.00
Award Dinner Asssociation
(DIA)
LOR Diabetes Fundacion Centro $7,000.00
Education Pediatrico de
Program for Diabetes
School Personnel
and T1D Students
LOR NCCN Guidelines NCCN Foundation $25,000.00
for Patients
guide
LOR Fall Meeting Middle Atlantic $1,000.00
Sponsorship Reproduction and
Teratolog
LOR PROMIS: Global PROMIS Health $15,000.00
Advances in Organization
Methodology and (PHO)
Clinical Science
LOR Immunization Idaho $2,500.00
Summit 2018 Immunization
Coalition
LOR Bob Langer 70th Rutgers $20,000.00
Birthday Gala University
and Symposium Foundation
LOR TMA Group Annual Texas Medical $1,200.00
Meeting Association
LOR Clinical Inertia American Diabetes $300,000.00
Campaign Association
LOR Life Sciences Life Sciences PA $250.00
Event June 2018
LOR CE in the CASSS $2,500.00
Biotechnology &
Pharmaceutical
Industries: 20th
Symposium
LOR 15th Symposium on CASSS $2,500.00
the Practical
Applications of
Mass
Spectrometry
LOR NCQA's Quality National $10,000.00
Talks 2018 Committee for
Quality
Assurance
LOR Gala of Giving Operation Jersey $3,000.00
Country Style Cares
2018
LOR Cell & Gene CASSS $5,000.00
Therapy Products
(CGTP):
Manufacturing,
Quality
LOR Newletter Funding Skin Cancer $100,000.00
Foundation
LOR Advocating for Lupus Foundation $5,000.00
Chronic Disease of America Inc.
Patients
LOR Inspiring Hope Cancer Support $2,500.00
Gala Community
Central
LOR 2018 National Lung Cancer $10,000.00
Advocacy Summit Alliance
LOR Bastille Day Resources USA $5,000.00
Boston 2018 Inc.
LOR Bastille Day Resources USA $10,000.00
Washington DC Inc.
2018
LOR The Lancet Women Icahn School of $100,000.00
and Medicine at
Cardiovascular Mount Sinai
Disease
Commission
LOR Northeast CASSS $2,500.00
Regional Forum
October 2018
LOR 2018 National Research!America $25,000.00
Health Research
Forum
LOR Promoting Nurses Preventive $25,000.00
as Leaders in Cardiovascular
Prevention Nurses
Program Association
LOR ACCC educational Association of $144,000.00
program funding Community Cancer
Centers
LOR Patient Access Alliance for $75,000.00
Collaborative Patient Access
LOR NJMLA 2018 Annual New Jersey Muslim $1,250.00
Eid Gala Lawyer
Association
LOR 2018 Biomarkers Foundation for $2,500.00
Consortium the National
meeting Institutes of
Health
LOR Pro Bono Pro Bono $25,000.00
Partnership 2018 Partnership
Gala
LOR Tour de Cure American Diabetes $2,500.00
Hawaii Association
LOR 19th Annual Patient Advocate $10,000.00
Patient Congress Foundation
LOR Patient Education ZERO--The End of $8,000.00
Webinar Funding Prostate Cancer
LOR 2018 Diabetes Joslin Diabetes $5,000.00
Coalition Center, Inc.
Conference
LOR Mary's Center Mary's Center $30,000.00
2018 Symposium
LOR 2018 Safety Safety $2,500.00
Pharmacology Pharmacology
Society Annual Society
meeting
LOR Drugs for Drugs for $50,000.00
Neglected Neglected
Diseases Diseases
initiative Initiative,
(DNDi)'s Making North American
Medical History Inc.
LOR Drugs for Drugs for $25,000.00
Neglected Neglected
Diseases Diseases
initiative Initiative North
(DNDi)'s Making American Inc.
Medical History
LOR Drugs for Drugs for $25,000.00
Neglected Neglected
Diseases Diseases
initiative Initiative North
(DNDi)'s Making American Inc.
Medical History
LOR Pharmacy Alumni The Ohio State $1,000.00
Society University
Pharmathon 5k Foundation
Sponsorship
LOR Diabetes Policy Alliance for $150,000.00
Advocacy Patient Access
Initiatives
LOR Yale Yale University $2,000.00
Immunobiology
Student
Symposium 2018
LOR ConnecT1D Family ConnecT1D $5,000.00
Camp 2018
LOR 2018 Alumni Hall Hispanic $25,000.00
of Fame Gala Scholarship Fund
Dinner
LOR JDRF One Walk JDRF $5,000.00
LOR ACS CAN National American Cancer $35,000.00
Advocacy Society Cancer
Activities Action Network
LOR American College American College $2,500.00
of Toxicology of Toxicology
39th Annual
Meeting
LOR Fall Advocacy Day ASTS Foundation $15,000.00
LOR 2018 OFII Annual Organization for $15,000.00
Dinner International
Investment
LOR 2018 Patient & Biotechnology $10,000.00
Health Advocacy Innovation
Summit Organization
LOR 2018 Indiana Tour American Diabetes $2,500.00
de Cure Association,
Indiana
LOR 2018 JDRF One JDRF $5,000.00
Walk Syracuse International
LOR 12th Annual Gala International $10,000.00
Celebration Myeloma
Foundation
LOR 14th Annual National Alliance $2,500.00
Meeting of of State
NASPCC Prostate Cancer
LOR Translational American $25,000.00
Cancer Research Association for
for Basic Cancer Research
Scientists
Workshop
LOR Boston Heart Walk American Heart $5,000.00
Association
LOR JDRF One Walk JDRF $5,000.00
2018 International
LOR Airline Benefit Americares $12,000.00
Gala
LOR Improving National Minority $125,000.00
Diabetes and Quality Forum
Cardiovasular
Disease
Management
LOR Digital Health MassChallenge, $100,000.00
Accellerator Inc.
Program
LOR Multiple Myeloma Blood and Marrow $3,750.00
Patient Survival Transplant
Guide Information
LOR 2018 ACS CAN American Cancer $25,000.00
State Events Society Cancer
Program Action Network
LOR Healthcare American College $1,000.00
Leaders of Healthcare
Educational Executives
Events
LOR 36th Annual President and $10,000.00
Retreat for the Fellows of
Harvard/MIT MD- Harvard College
PhD Program
LOR Moving the Needle Healthcare $1,000.00
on Gender Parity Businesswomen's
Association
LOR Employer's Guide Northeast $17,500.00
to Digital Business Group
Diabetes on Health
Prevention and
Management
LOR 10th Annual Prevent Cancer $5,000.00
Health Fair and Foundation
5k Walk/Run
LOR 16th Annual Gala Fundacion Centro $3,500.00
Dinner Pediatrico de
Diabetes
LOR Advancement and Cross-Company $2,500.00
Challenges Abuse Liability
Meeting Council
LOR Respiraory Alliance for $50,000.00
Therapy Access Patient Access
Working Group
LOR The Champions For Skin Cancer $25,000.00
Change Gala Foundation
LOR High Hopes Gala Joslin Diabetes $25,000.00
Center, Inc.
LOR Friends Annual Friends of Cancer $10,000.00
Cancer Research Research
Leadership
Awards
LOR Women Building Virginia Bio $3,000.00
Bio Sponsorship
LOR NACHW Trustees of $20,000.00
Organizational Boston
Launch University
Announcement
Event
LOR 2018 PQA PQA, Inc. $7,500.00
Leadership
Summit
LOR High Level Speak Up Africa d/ $25,000.00
Conference and b/a The Access
Awards Event Challenge
LOR International International $90,000.00
Myeloma Myeloma
Foundation Foundation
Patient
Initiative
Programs
LOR NCCN Innovation National $40,000.00
Pilot Program Comprehensive
Cancer Network
LOR Annual AMCP Academy of $18,000.00
meeting Managed Care
Pharmacy
LOR Solvable Problems The diaTribe $48,000.00
in Diabetes Foundation
Program
LOR NESOT Annual Society of $1,500.00
Meeting Toxicology
LOR Patient Advocacy Cancer Support $75,000.00
Kit for Multiple Community
Myeloma
LOR Patient Education National Kidney $7,500.00
Brochure Big Ask Foundation, Inc.
Big Give
LOR Patient Awareness National Hispanic $25,000.00
and Education Medical
Program for Association
Hispanic Patient
LOR Diabetes Family Fundacion Centro $5,000.00
Day Sponsorship Pediatrico de
Diabetes
LOR Annual Promise JDRF $20,000.00
Ball International
LOR Congress American Society $10,000.00
Sponsorship of Hematology
LOR Scientific Annual Lupus Research $10,000.00
Conference Alliance
LOR R3 Annual Forum Multi Regional $7,500.00
Clinical Trial
Center of
Brigham
LOR Diabetes Public Health $10,000.00
Prevention on Advocates
the Ground in
California
Sponsorship
LOR Northcrest Annual NorthCrest $2,500.00
Gala Medical Center
Foundation
LOR 19th Annual GLBTQ Legal $3,000.00
Spirit of Advocates &
Justice Award Defenders (GLAD)
Dinner
LOR AUTM Annual Association of $5,000.00
Meeting University
Technology Mana
LOR TCYOD Patient Taking Control of $75,000.00
Conferences and Your Diabetes
Health Fairs
LOR New Jersey Smart RideWise, Inc. $1,000.00
Workplace Annual
recognition
event
LOR Breakfast Women In $7,500.00
Sponsorship Government
Foundation, Inc.
LOR Patient Education Malecare $20,000.00
African American
Men with
Prostate Cancer
LOR Patient Education Malecare $15,000.00
Brochure: Simple
Cancer
LOR ONE: The Taking Control of $75,000.00
Ultimaite Your Diabetes
Conference and
Retreate for
Adults with Type
I
LOR Women in All in Together $40,000.00
Healthcare Campaign Inc.
Policy Forum
LOR Innovation Labs The diaTribe $100,000.00
on Diabetes and Foundation
Prediabetes
LOR Annual Joe Joe Andruzzi $5,000.00
Andruzzi Foundation Inc.
Foundation Gala
LOR Corporate AMGA $25,000.00
Sponsorship for
Institute for
Quality
Leadership
LOR Patient Awareness ZERO--The End of $10,000.00
and Education Prostate Cancer
Program
LOR Congress Metabolic $50,000.00
Sponsorship Endocrine
Education
Foundation
LOR 2018 Annual PCMA $95,000.00
Meeting
Sponsorship
LOR PCMA Business PCMA $80,000.00
Forum
Sponsorship
LOR Cardiovascular Association of $30,000.00
Risk Reduction Black
Project Cardiologists
LOR Corporate California Life $8,500.00
Sponsorship for Sciences
Institute for Association
Life Sciences
Academy
LOR Friends Friends of Cancer $50,000.00
ImmunoOncology Research
Programs
LOR Patient Education Prostate Cancer $20,000.00
Brochure: Education
Chemotherary in Council
Prosate Cancer
LOR 2018 Patient BIONJ Inc. $1,000.00
Advocacy Summit
Sponsorship
LOR Patient Guide Arizona Myeloma $10,000.00
Living with Network (AZMN)
Myeloma
LOR Yellow Fever Fondation Merieux $10,000.00
Symposium USA, Inc.
LOR Patient Education Blood and Marrow $40,000.00
Brochure on Transplant
Transplantation Information
LOR MBGH Sponsorship Midwest Business $20,000.00
Request Group on Health
LOR Patient Education American Academy $30,000.00
Brochure on SCC of Dermatology
Inc.
LOR HBA Woman of the Healthcare $22,250.00
Year Luncheon Businesswomen's
Association
LOR Corporate Midwest Business $30,000.00
Sponsorship Group on Health
------------------------------------------------------------------------
Date of Primary Primary Physician/Teaching
Payment Amount Purpose Nature Hospital Name (NPI)
------------------------------------------------------------------------
11/10/2015 $75,000.00 Fellowship Cash or Cash Vanderbilt
Equivalent University
Hospital
------------------------------------------------------------------------
06/15/2015 $74,987.00 Fellowship Cash or Cash Childrens Hospital
Equivalent Medical Center
------------------------------------------------------------------------
02/24/2015 $75,000.00 Fellowship Cash or Cash Langley Porter
Equivalent Psychiatric
Hospital
------------------------------------------------------------------------
08/01/2015 $75,000.00 Fellowship Cash or Cash Emory University
Equivalent Hospital
------------------------------------------------------------------------
07/01/2015 $75,000.00 Fellowship Cash or Cash Uci Medical Center
Equivalent (.)
------------------------------------------------------------------------
05/26/2015 $75,000.00 Fellowship Cash or Cash Uci Medical Center
Equivalent (.)
------------------------------------------------------------------------
04/07/2015 $43,494.57 Fellowship Cash or Cash University of
Equivalent Alabama Hospital
------------------------------------------------------------------------
05/17/2016 $75,000.00 Fellowship Cash or Cash Vanderbilt
Equivalent University
Hospitals & Cl (.)
------------------------------------------------------------------------
06/21/2016 $75,000.00 Fellowship Cash or Cash Emory University
Equivalent Hospital (.)
------------------------------------------------------------------------
03/09/2016 $77,537.90 Fellowship Cash or Cash Emory University
Equivalent Hospital (.)
------------------------------------------------------------------------
06/07/2016 $77,317.00 Fellowship Cash or Cash Ann & Robert H.
Equivalent Lurie Childrens
Hos (.)
------------------------------------------------------------------------
03/01/2016 $63,000.00 Fellowship Cash or Cash Resnick
Equivalent Neuropsychiatric
Hospital At (.)
------------------------------------------------------------------------
06/07/2016 $75,000.00 Fellowship Cash or Cash University Of
Equivalent Alabama Hospital
(.)
------------------------------------------------------------------------
06/27/2017 $75,000.00 Fellowship Cash or Cash Ann & Robert H.
Equivalent Lurie Childrens
Hos (1497018154)
------------------------------------------------------------------------
03/02/2017 $75,000.00 Fellowship Cash or Cash Hospital Of The
Equivalent Univ Of Penna
(1003946153)
------------------------------------------------------------------------
07/01/2017 $75,000.00 Fellowship Cash or Cash Cooper University
Equivalent Hospital
(1053654749)
------------------------------------------------------------------------
07/01/2017 $75,000.00 Fellowship Cash or Cash Childrens Hospital
Equivalent Medical Center
(1083665137)
------------------------------------------------------------------------
07/01/2017 $75,000.00 Fellowship Cash or Cash Uci Medical Center
Equivalent (.)
------------------------------------------------------------------------
07/01/2017 $63,000.00 Fellowship Cash or Cash Resnick
Equivalent Neuropsychiatric
Hospital At
(1124327853)
------------------------------------------------------------------------
12/12/2017 $75,000.00 Fellowship Cash or Cash Emory University
Equivalent Hospital (.)
------------------------------------------------------------------------
12/12/2017 $63,000.00 Fellowship Cash or Cash Resnick
Equivalent Neuropsychiatric
Hospital At
(1124327853)
------------------------------------------------------------------------
12/17/2017 $75,000.00 Fellowship Cash or Cash Uci Medical Center
Equivalent (.)
------------------------------------------------------------------------
12/06/2017 $75,000.00 Fellowship Cash or Cash Vanderbilt
Equivalent University Medical
Center
(1104202761)
------------------------------------------------------------------------
03/02/2017 $75,000.00 Fellowship Cash or Cash Emory University
Equivalent Hospital (.)
------------------------------------------------------------------------
03/14/2017 $73,714.12 Fellowship Cash or Cash University Of
Equivalent Alabama Hospital
(.)
------------------------------------------------------------------------
------------------------------------------------------------------------
Payment Report
Recipient Type Address Line 1 City State ZIP
------------------------------------------------------------------------
Teaching hospital 1211 MEDICAL NASHVILLE TN 37232
CENTER DRIVE
------------------------------------------------------------------------
Teaching hospital 3333 BURNET CINCINNATI OH 45229
AVENUE MLC
#4900
------------------------------------------------------------------------
Teaching hospital 405 PARNASUS SAN CA 94143
FRANCISCO
------------------------------------------------------------------------
Teaching hospital 1364 CLIFTON ATLANTA GA 30302
ROAD
------------------------------------------------------------------------
Teaching hospital 101 CITY DRIVE ORANGE CA 92868
SOUTH
------------------------------------------------------------------------
Teaching hospital 101 CITY DRIVE ORANGE CA 92868
SOUTH
------------------------------------------------------------------------
Teaching hospital 619 SOUTH 19TH BIRMINGHAM AL 35233
STREET
------------------------------------------------------------------------
Teaching hospital 1211 MEDICAL NASHVILLE TN 37232
CENTER DRIVE
------------------------------------------------------------------------
Teaching hospital 1364 CLIFTON ATLANTA GA 30302
ROAD
------------------------------------------------------------------------
Teaching hospital 1364 CLIFTON ATLANTA GA 30302
ROAD
------------------------------------------------------------------------
Teaching hospital 225 EAST CHICAGO CHICAGO IL 60611
AVENUE
------------------------------------------------------------------------
Teaching hospital 150 UCLA MEDICAL LOS ANGELES CA 90095
PLAZA
------------------------------------------------------------------------
Teaching hospital 619 SOUTH 19TH BIRMINGHAM AL 35233
STREET
------------------------------------------------------------------------
Teaching hospital 225 EAST CHICAGO CHICAGO IL 60611
AVENUE
------------------------------------------------------------------------
Teaching hospital 3400 SPRUCE PHILADELPHIA PA 19104
STREET
------------------------------------------------------------------------
Teaching hospital ONE COOPER PLAZA CAMDEN NJ 08103
------------------------------------------------------------------------
Teaching hospital 3333 BURNET CINCINNATI OH 45229
AVENUE MLC
#4900
------------------------------------------------------------------------
Teaching hospital 101 CITY DRIVE ORANGE CA 92868
SOUTH
------------------------------------------------------------------------
Teaching hospital 150 UCLA MEDICAL LOS ANGELES CA 90095
PLAZA
------------------------------------------------------------------------
Teaching hospital 1364 CLIFTON ATLANTA GA 30302
ROAD
------------------------------------------------------------------------
Teaching hospital 150 UCLA MEDICAL LOS ANGELES CA 90095
PLAZA
------------------------------------------------------------------------
Teaching hospital 101 CITY DRIVE ORANGE CA 92868
SOUTH
------------------------------------------------------------------------
Teaching hospital 1211 MEDICAL NASHVILLE TN 37232
CENTER DRIVE
------------------------------------------------------------------------
Teaching hospital 1364 CLIFTON ATLANTA GA 30302
ROAD
------------------------------------------------------------------------
Teaching hospital 619 SOUTH 19TH BIRMINGHAM AL 35233
STREET
------------------------------------------------------------------------
------------------------------------------------------------------------
Date of
Payment Amount Primary Purpose Primary Nature
------------------------------------------------------------------------
08/11/2015 $124,572.50 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
12/15/2015 $74,327.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
10/20/2015 $174,088.90 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
09/08/2015 $5,648.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
09/08/2015 $7,060.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
09/08/2015 $7,060.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
09/08/2015 $5,648.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
09/08/2015 $4,236.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
09/08/2015 $350.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
09/08/2015 $1,250.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
09/08/2015 $1,086.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
03/24/2015 $5,648.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
03/24/2015 $2,824.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
03/24/2015 $2,824.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
03/24/2015 $9,775.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
03/24/2015 $750.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
10/27/2015 $7,234.45 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
12/08/2015 $11,074.80 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
09/08/2015 $6,698.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
09/08/2015 $1,551.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
01/06/2015 $127,160.70 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
01/06/2015 $385,403.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
10/27/2015 $137,506.80 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
02/24/2015 $35,672.06 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
03/17/2015 $36,130.95 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
09/15/2015 $7,226.19 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
02/10/2015 $325,000.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
10/20/2015 $5,000.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
07/21/2015 $5,000.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
07/07/2015 $49,000.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
07/21/2015 $16,089.68 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
06/02/2015 $14,000.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
02/10/2015 $5,000.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
01/06/2015 $20,100.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
03/24/2015 $1,412.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
03/24/2015 $1,412.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
03/24/2015 $1,412.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
04/14/2015 $8,363.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
09/08/2015 $7,760.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
03/03/2015 $4,000.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
10/27/2015 $28,585.85 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
04/14/2015 $85,757.55 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
10/20/2015 $28,585.85 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
03/03/2015 $61,725.52 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
03/03/2015 $11,176.62 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
03/03/2015 $24,246.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
10/13/2015 $125,000.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
12/15/2015 $200,000.00 Investigator Fees
Sponsored Trial
------------------------------------------------------------------------
01/13/2015 $39,771.64 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
05/05/2015 $39,771.64 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
06/09/2015 $39,771.65 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
05/19/2015 $119,166.66 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
05/26/2015 $185,900.01 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
06/02/2015 $61,966.67 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
07/28/2015 $61,966.66 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
03/17/2015 $126,059.09 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
03/17/2015 $126,059.09 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
04/07/2015 $174,088.90 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
01/06/2015 $59,187.50 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
05/19/2015 $59,187.50 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
04/14/2015 $11,120.67 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
05/26/2015 $28,612.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
06/16/2015 $28,612.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
08/11/2015 $7,234.45 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
03/24/2015 $28,830.75 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
02/17/2015 $30,167.85 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
03/17/2015 $24,228.75 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
08/11/2015 $355,830.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
05/26/2015 $28,777.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
03/17/2015 $8,329.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
04/14/2015 $9,229.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
11/19/2015 $53,400.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
12/10/2015 $214,706.70 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
12/17/2015 $7,425.18 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
11/23/2015 $12,375.30 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
12/07/2015 $160,228.80 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
11/23/2015 $14,850.36 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
01/26/2016 $114,107.36 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
01/12/2016 $250,000.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
04/26/2016 $54,115.17 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
05/17/2016 $174,088.90 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
01/26/2016 $35,000.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
06/02/2016 $18,334.48 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
09/13/2016 $174,088.90 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
06/28/2016 $224,593.02 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
09/13/2016 $22,950.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
02/09/2016 $50,279.75 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
04/19/2016 $28,830.75 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
01/12/2016 $24,228.75 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
01/19/2016 $24,228.75 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
04/26/2016 $33,332.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
03/08/2016 $30,589.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
07/19/2016 $7,234.45 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
06/28/2016 $15,750.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
09/27/2016 $42,502.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
06/07/2016 $38,530.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
06/15/2016 $22,106.80 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
06/16/2016 $3,103.89 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
06/22/2016 $114,600.84 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
06/23/2016 $88,057.50 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
06/27/2016 $12,930.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
01/13/2016 $18,768.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
01/14/2016 $88,057.50 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
01/14/2016 $58,710.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
01/14/2016 $959.62 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
01/14/2016 $3,047.08 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
01/14/2016 $1,556.04 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
01/14/2016 $3,941.70 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
01/14/2016 $661.42 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
01/27/2016 $293,490.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
02/09/2016 $12,505.30 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
02/12/2016 $76,515.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
02/16/2016 $36,067.85 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
02/18/2016 $58,710.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
03/29/2016 $12,930.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
03/29/2016 $64,130.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
03/29/2016 $25,730.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
03/31/2016 $3,103.89 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
04/04/2016 $76,930.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
04/13/2016 $58,710.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
04/19/2016 $152,796.13 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
04/28/2016 $12,930.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
05/05/2016 $12,505.30 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
05/09/2016 $153,730.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
05/09/2016 $51,015.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
05/24/2016 $576,860.60 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
05/25/2016 $117,405.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
07/06/2016 $117,405.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
07/13/2016 $352,185.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
07/13/2016 $58,710.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
07/25/2016 $11,312.95 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
07/26/2016 $15,040.60 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
07/26/2016 $21,998.88 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
07/26/2016 $27,466.10 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
07/26/2016 $24,981.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
07/27/2016 $7,585.30 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
07/27/2016 $27,963.12 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
07/28/2016 $12,505.30 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
08/31/2016 $12,930.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
09/01/2016 $22,106.80 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
09/14/2016 $3,103.89 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
09/27/2016 $88,057.50 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
10/10/2016 $72,120.70 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
10/19/2016 $22,106.80 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
10/24/2016 $12,505.30 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
10/31/2016 $293,760.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
10/31/2016 $58,764.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
10/31/2016 $12,930.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
10/31/2016 $58,764.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
11/01/2016 $29,389.50 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
11/15/2016 $77,933.40 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
11/17/2016 $58,764.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
11/21/2016 $19,265.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
11/21/2016 $134,465.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
12/14/2016 $88,138.50 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
12/19/2016 $293,760.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
04/05/2016 $382.26 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
10/17/2016 $449.71 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
05/09/2016 $1,122,210.00 Investigator Fees
Sponsored Trial
------------------------------------------------------------------------
12/08/2016 $1,122,209.00 Investigator Fees
Sponsored Trial
------------------------------------------------------------------------
02/16/2016 $59,187.50 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
10/18/2016 $67,970.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
01/26/2016 $19,474.93 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
06/02/2016 $47,400.50 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
12/13/2016 $47,400.50 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
01/04/2017 $862.56 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
01/10/2017 $12,930.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
01/11/2017 $6,317.65 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
01/16/2017 $862.56 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
01/18/2017 $29,362.50 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
01/24/2017 $11,247.95 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
01/24/2017 $288.66 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
01/24/2017 $11,247.95 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
01/24/2017 $1,108.73 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
01/24/2017 $19,945.80 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
01/24/2017 $4,538.12 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
01/24/2017 $13,549.36 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
01/24/2017 $3,112.08 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
01/24/2017 $24,916.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
01/24/2017 $810.52 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
02/08/2017 $884.54 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
03/01/2017 $884.54 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
03/13/2017 $25,730.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
03/16/2017 $58,710.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
03/29/2017 $6,317.65 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
03/30/2017 $145,308.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
04/06/2017 $58,710.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
05/01/2017 $58,710.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
05/08/2017 $45,402.40 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
05/18/2017 $29,362.50 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
05/25/2017 $29,362.50 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
06/08/2017 $22,766.20 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
06/12/2017 $22,766.20 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
06/15/2017 $29,362.50 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
06/15/2017 $29,362.50 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
06/29/2017 $14,980.36 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
07/05/2017 $58,710.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
07/13/2017 $58,710.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
07/17/2017 $58,710.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
07/25/2017 $58,710.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
07/25/2017 $19,945.80 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
07/25/2017 $10,129.40 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
07/25/2017 $10,194.40 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
07/25/2017 $24,916.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
07/25/2017 $2,413.36 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
08/02/2017 $58,710.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
08/15/2017 $15,220.80 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
08/24/2017 $440,227.50 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
09/20/2017 $30,311.60 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
09/21/2017 $14,980.36 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
10/18/2017 $58,710.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
10/30/2017 $305,489.41 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
11/29/2017 $6,855.86 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
11/29/2017 $40,810.16 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
12/18/2017 $162,934.69 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
12/20/2017 $1,163,061.00 Investigator Fees
Sponsored Trial
------------------------------------------------------------------------
12/20/2017 $831,459.00 Investigator Fees
Sponsored Trial
------------------------------------------------------------------------
04/12/2017 $140,654.12 Investigator Fees
Sponsored Trial
------------------------------------------------------------------------
10/01/2017 $75,158.78 Investigator Fees
Sponsored Trial
------------------------------------------------------------------------
10/25/2017 $53,668.90 Investigator Fees
Sponsored Trial
------------------------------------------------------------------------
10/20/2017 $391,759.00 Investigator Fees
Sponsored Trial
------------------------------------------------------------------------
11/21/2017 $76,900.00 Investigator Fees
Sponsored Trial
------------------------------------------------------------------------
09/12/2017 $55,768.59 Investigator Fees
Sponsored Trial
------------------------------------------------------------------------
07/18/2017 $77,522.30 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
03/02/2017 $7,955.33 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
07/06/2017 $43,280.58 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
01/17/2017 $244,633.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
01/17/2017 $37,134.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
02/21/2017 $6,000.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
04/04/2017 $7,234.45 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
05/23/2017 $50,279.75 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
08/15/2017 $92,654.93 Investigator ...................
Sponsored Trial
Cash or Cash
Equivalent
------------------------------------------------------------------------
04/25/2017 $128,325.90 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
07/18/2017 $128,325.90 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
09/05/2017 $128,325.90 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
11/07/2017 $128,325.90 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
05/09/2017 $66,562.62 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
07/06/2017 $66,562.62 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
10/03/2017 $66,562.62 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
05/02/2017 $80,715.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
01/04/2017 $47,400.50 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
01/04/2017 $47,400.97 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
01/17/2017 $100,000.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
03/02/2017 $26,701.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
04/18/2017 $190,471.20 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
08/15/2017 $2,100.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
11/14/2017 $23,348.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
05/30/2017 $140,654.12 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
09/19/2017 $188,832.43 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
12/05/2017 $2,835.71 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
01/22/2018 $16,681.38 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
01/22/2018 $427.27 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
01/22/2018 $750.53 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
01/23/2018 $15,679.17 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
01/23/2018 $3,904.40 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
01/23/2018 $12,928.50 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
01/25/2018 $25,640.33 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
01/25/2018 $1,118.37 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
01/25/2018 $2,872.13 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
01/29/2018 $712,788.63 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
02/20/2018 $152,752.20 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
04/11/2018 $314,348.09 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
04/17/2018 $19,930.48 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
05/22/2018 $261,959.23 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
05/29/2018 $157,181.55 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
07/10/2018 $16,302.40 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
07/10/2018 $13,607.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
07/12/2018 $17,650.10 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
07/12/2018 $27,084.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
07/17/2018 $209,570.39 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
07/19/2018 $88,057.50 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
08/14/2018 $58,710.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
08/20/2018 $58,710.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
08/23/2018 $117,405.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
09/17/2018 $157,181.55 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
09/27/2018 $157,181.55 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
10/29/2018 $261,959.23 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
11/28/2018 $58,710.00 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
11/29/2018 $104,792.70 Investigator Product
Sponsored Trial
------------------------------------------------------------------------
11/26/2018 $348.48 Investigator Supplies
Sponsored Trial
------------------------------------------------------------------------
11/26/2018 $28.32 Investigator Supplies
Sponsored Trial
------------------------------------------------------------------------
04/25/2018 $67.25 Investigator Supplies
Sponsored Trial
------------------------------------------------------------------------
08/28/2018 $281.36 Investigator Supplies
Sponsored Trial
------------------------------------------------------------------------
11/27/2018 $793,755.00 Investigator Fees
Sponsored Trial
------------------------------------------------------------------------
09/24/2018 $277,130.00 Investigator Investigator Fees
Sponsored Trial
------------------------------------------------------------------------
10/19/2018 $207,848.00 Investigator Investigator Fees
Sponsored Trial
------------------------------------------------------------------------
03/20/2018 $26,125.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
01/30/2018 $76,900.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
06/12/2018 $29,796.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
02/20/2018 $178,970.30 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
01/16/2018 $244,633.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
02/06/2018 $128,325.90 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
09/06/2018 $128,325.90 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
09/06/2018 $128,325.90 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
04/19/2018 $66,562.62 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
05/15/2018 $35,581.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
05/15/2018 $30,030.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
06/19/2018 $52,087.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
07/23/2018 $31,131.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
01/30/2018 $14,223.80 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
04/03/2018 $144,601.03 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
08/02/2018 $47,500.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
08/02/2018 $148,734.45 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
03/29/2018 $238,670.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
04/05/2018 $104,418.67 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
05/10/2018 $7,939.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
11/26/2018 $14,624.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
01/09/2018 $100,000.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
01/02/2018 $53,668.90 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
01/05/2018 $391,759.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
05/08/2018 $28,610.89 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
10/29/2018 $78,100.80 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
08/21/2018 $29,796.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
11/19/2018 $103,543.60 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
11/19/2018 $97,510.18 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
12/10/2018 $48,814.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
11/19/2018 $72,000.00 Investigator Cash or Cash
Sponsored Trial Equivalent
------------------------------------------------------------------------
------------------------------------------------------------------------
Physician/
Teaching Address
Hospital Name Line 1 City State ZIP Name of Study
(NPI)
------------------------------------------------------------------------
Montefiore 111 EAST BRONX NY 10467 A roadmap for
Medical 210TH the conversion
Center STREET from sliding
scale to basal
insulin in the
long term care
setting.
------------------------------------------------------------------------
Langley Porter 405 SAN CA 94143 A Phase I Study
Psychiatric PARNASUS FRANCI of Cabazitaxel,
SCO Mitoxanthrone,
and Prednison
(CAMP) for
Patients with
Metastatic
Castration-
Resistant
Prostate Cancer
and no Prior
Chemotherapy
------------------------------------------------------------------------
Memorial 1275 YORK NEW NY 10065 An Exploratory
Hospital for AVENUE YORK Randomized
Cancer and Phase II
Allied Multicenter
Diseases Trial of
Abiraterone
Acetate with or
without
Cabazitaxel in
Treatment of
Metastatic
Castration
Resistant
Prostate Cancer
------------------------------------------------------------------------
University of 5841 SOUTH CHICAGO IL 60637 A study of the
Chicago MARYLAND effects of
Hospital AVENUE Alemtuzumab on
Surrogate
Markers of
Disease
Activity and
Repair using
Advanced MRI
measures in
Subjects with
Relapsing
Remitting
Multiple
Sclerosis.
------------------------------------------------------------------------
University of 5841 SOUTH CHICAGO IL 60637 A study of the
Chicago MARYLAND effects of
Hospital AVENUE Alemtuzumab on
Surrogate
Markers of
Disease
Activity and
Repair using
Advanced MRI
measures in
Subjects with
Relapsing
Remitting
Multiple
Sclerosis.
------------------------------------------------------------------------
University of 5841 SOUTH CHICAGO IL 60637 A study of the
Chicago MARYLAND effects of
Hospital AVENUE Alemtuzumab on
Surrogate
Markers of
Disease
Activity and
Repair using
Advanced MRI
measures in
Subjects with
Relapsing
Remitting
Multiple
Sclerosis.
------------------------------------------------------------------------
University of 5841 SOUTH CHICAGO IL 60637 A study of the
Chicago MARYLAND effects of
Hospital AVENUE Alemtuzumab on
Surrogate
Markers of
Disease
Activity and
Repair using
Advanced MRI
measures in
Subjects with
Relapsing
Remitting
Multiple
Sclerosis.
------------------------------------------------------------------------
University of 5841 SOUTH CHICAGO IL 60637 A study of the
Chicago MARYLAND effects of
Hospital AVENUE Alemtuzumab on
Surrogate
Markers of
Disease
Activity and
Repair using
Advanced MRI
measures in
Subjects with
Relapsing
Remitting
Multiple
Sclerosis.
------------------------------------------------------------------------
University of 5841 SOUTH CHICAGO IL 60637 A study of the
Chicago MARYLAND effects of
Hospital AVENUE Alemtuzumab on
Surrogate
Markers of
Disease
Activity and
Repair using
Advanced MRI
measures in
Subjects with
Relapsing
Remitting
Multiple
Sclerosis.
------------------------------------------------------------------------
University of 5841 SOUTH CHICAGO IL 60637 A study of the
Chicago MARYLAND effects of
Hospital AVENUE Alemtuzumab on
Surrogate
Markers of
Disease
Activity and
Repair using
Advanced MRI
measures in
Subjects with
Relapsing
Remitting
Multiple
Sclerosis.
------------------------------------------------------------------------
University of 5841 SOUTH CHICAGO IL 60637 A study of the
Chicago MARYLAND effects of
Hospital AVENUE Alemtuzumab on
Surrogate
Markers of
Disease
Activity and
Repair using
Advanced MRI
measures in
Subjects with
Relapsing
Remitting
Multiple
Sclerosis.
------------------------------------------------------------------------
University of 5841 SOUTH CHICAGO IL 60637 A study of the
Chicago MARYLAND effects of
Hospital AVENUE Alemtuzumab on
Surrogate
Markers of
Disease
Activity and
Repair using
Advanced MRI
measures in
Subjects with
Relapsing
Remitting
Multiple
Sclerosis.
------------------------------------------------------------------------
University of 5841 SOUTH CHICAGO IL 60637 A study of the
Chicago MARYLAND effects of
Hospital AVENUE Alemtuzumab on
Surrogate
Markers of
Disease
Activity and
Repair using
Advanced MRI
measures in
Subjects with
Relapsing
Remitting
Multiple
Sclerosis.
------------------------------------------------------------------------
University of 5841 SOUTH CHICAGO IL 60637 A study of the
Chicago MARYLAND effects of
Hospital AVENUE Alemtuzumab on
Surrogate
Markers of
Disease
Activity and
Repair using
Advanced MRI
measures in
Subjects with
Relapsing
Remitting
Multiple
Sclerosis.
------------------------------------------------------------------------
University of 5841 SOUTH CHICAGO IL 60637 A study of the
Chicago MARYLAND effects of
Hospital AVENUE Alemtuzumab on
Surrogate
Markers of
Disease
Activity and
Repair using
Advanced MRI
measures in
Subjects with
Relapsing
Remitting
Multiple
Sclerosis.
------------------------------------------------------------------------
University of 5841 SOUTH CHICAGO IL 60637 A study of the
Chicago MARYLAND effects of
Hospital AVENUE Alemtuzumab on
Surrogate
Markers of
Disease
Activity and
Repair using
Advanced MRI
measures in
Subjects with
Relapsing
Remitting
Multiple
Sclerosis.
------------------------------------------------------------------------
Keck Hospital 1500 SAN LOS CA 90033 Detection of
of USC PABLO ANGELE early end-organ
STREET S damage by
endothelial
dysfunction
with reactive
hyperemia-
digital
peripheral
arterial
tonometry in
patients with
Fabry disease
------------------------------------------------------------------------
University of 619 SOUTH BIRMING AL 35233 Improved
Alabama 19TH HAM Detection,
Hospital STREET Diagnosis, and
Management of
Fabry Disease
through Serial
Ophthalmic
Documentation
and Tear Fluid
Analysis
------------------------------------------------------------------------
University of 5841 SOUTH CHICAGO IL 60637 A study of the
Chicago MARYLAND effects of
Hospital AVENUE Alemtuzumab on
Surrogate
Markers of
Disease
Activity and
Repair using
Advanced MRI
measures in
Subjects with
Relapsing
Remitting
Multiple
Sclerosis.
------------------------------------------------------------------------
University of 5841 SOUTH CHICAGO IL 60637 A study of the
Chicago MARYLAND effects of
Hospital AVENUE Alemtuzumab on
Surrogate
Markers of
Disease
Activity and
Repair using
Advanced MRI
measures in
Subjects with
Relapsing
Remitting
Multiple
Sclerosis.
------------------------------------------------------------------------
Brigham and 75 FRANCIS BOSTON MA 02115 Effects of an
Womens STREET Intensive
Hospital Intervention on
Medication
Adherence,
Glycemic
Control, and
Readmission
Rates in
Patients with
Type 2 Diabetes
------------------------------------------------------------------------
University of 2 SEATTLE WA 98195 FLuctuation
Washington Reduction With
Insulin and GLP-
1 Added
Together (FLAT-
SUGAR)
------------------------------------------------------------------------
Beth Israel 330 BOSTON MA 02215 Simplification
Deaconess BROOKLINE of diabetes
Medical AVENUE regimen in
Center elderly
patients using
glargine
------------------------------------------------------------------------
Dana-Farber 450 BOSTON MA 02215 Phase I Study of
Cancer BROOKLINE Plerixafor
Institute AVE (AMD3100) and
Bevacizumab for
recurrent high-
grade glioma
------------------------------------------------------------------------
Dana-Farber 450 BOSTON MA 02215 Phase I/II Trial
Cancer BROOKLINE of Combination
Institute AVE AMD3100 and
Bortezomib in
Relapsed or
Relapsed/
Refractory
Multiple
Myeloma
------------------------------------------------------------------------
Dana-Farber 450 BOSTON MA 02215 Phase I/II Trial
Cancer BROOKLINE of Combination
Institute AVE AMD3100 and
Bortezomib in
Relapsed or
Relapsed/
Refractory
Multiple
Myeloma
------------------------------------------------------------------------
Dana-Farber 450 BOSTON MA 02215 Taxotere Plus
Cancer BROOKLINE Six-Month
Institute AVE Androgen
Suppression and
Radiation
Therapy vs Six-
Month Androgen
Suppression and
Radiation
Therapy for
Patients with
High-Risk
Localized or
Locally
Advanced
Prostate
Cancer: A
Randomized
Controlled
Trial
------------------------------------------------------------------------
UT MD Anderson 1515 HOUSTON TX 77030 Phase I/II Study
Cancer Center HOLCOMBE of Plerixafor
BLVD and Clofarabine
in Previously
Untreated Older
(>= 60 years)
Adult Patients
with Acute
Myelogenous
Leukemia (AML)
for Whom
Standard
Induction
Chemotherapy is
Unlikely to be
of Benefit
------------------------------------------------------------------------
UT MD Anderson 1515 HOUSTON TX 77030 G-CSF and
Cancer Center HOLCOMBE Plerixafor with
BLVD Sorafenib for
Acute
Myelogenous
Leukemia with
FLT3(ITD)
mutations
------------------------------------------------------------------------
UT MD Anderson 1515 HOUSTON TX 77030 Phase I/II Study
Cancer Center HOLCOMBE of Plerixafor
BLVD and Clofarabine
in Previously
Untreated Older
(>= 60 years)
Adult Patients
with Acute
Myelogenous
Leukemia (AML)
for Whom
Standard
Induction
Chemotherapy is
Unlikely to be
of Benefit
------------------------------------------------------------------------
UT MD Anderson 1515 HOUSTON TX 77030 G-CSF and
Cancer Center HOLCOMBE Plerixafor with
BLVD Sorafenib for
Acute
Myelogenous
Leukemia with
FLT3(ITD)
mutations
------------------------------------------------------------------------
Langley Porter 405 SAN CA 94143 A Phase III
Psychiatric PARNASUS FRANCI Trial of
Institute SCO Irinotecan/5-FU/
Leucovorin or
Oxaliplatin/5-
FU/leucovorin
with
Bevacizumab, or
Cetuximab
(C225) or with
the Combination
of Bevacizumab
and Cetuximab
for Patients
with Untreated
Metastatic
Adenocarcinoma
of the Colon or
Rectum
------------------------------------------------------------------------
U of U 50 NORTH SALT UT 84132 Phase I/II Study
Hospitals & MEDICAL LAKE of Low-Dose
Clinic DRIVE CITY Oral
Clofarabine for
the treatment
of IPSS INT-1,
INT-2 or HIGH
Myelodysplastic
Syndromes
(dysplastic
type) Patients
who have failed
Hypomethylating
Therapy
------------------------------------------------------------------------
Lehigh Valley 2100 MACK ALLENTO PA 18105 A Multicenter,
(.) BLVD. 4TH WN Randomized,
FLOOR Controlled
FINANCE Trial
Evaluating the
Safety,
Efficacy and
Cost-
Effectiveness
of Seprafilm
Adhesion
Barrier
Following
Cesarean
Section
------------------------------------------------------------------------
University of 5841 SOUTH CHICAGO IL 60637 A study of the
Chicago MARYLAND effects of
Hospital AVENUE Alemtuzumab on
Surrogate
Markers of
Disease
Activity and
Repair using
Advanced MRI
measures in
Subjects with
Relapsing
Remitting
Multiple
Sclerosis.
------------------------------------------------------------------------
University of 5841 SOUTH CHICAGO IL 60637 A study of the
Chicago MARYLAND effects of
Hospital AVENUE Alemtuzumab on
Surrogate
Markers of
Disease
Activity and
Repair using
Advanced MRI
measures in
Subjects with
Relapsing
Remitting
Multiple
Sclerosis.
------------------------------------------------------------------------
University of 5841 SOUTH CHICAGO IL 60637 A study of the
Chicago MARYLAND effects of
Hospital AVENUE Alemtuzumab on
Surrogate
Markers of
Disease
Activity and
Repair using
Advanced MRI
measures in
Subjects with
Relapsing
Remitting
Multiple
Sclerosis.
------------------------------------------------------------------------
University of 5841 SOUTH CHICAGO IL 60637 A study of the
Chicago MARYLAND effects of
Hospital AVENUE Alemtuzumab on
Surrogate
Markers of
Disease
Activity and
Repair using
Advanced MRI
measures in
Subjects with
Relapsing
Remitting
Multiple
Sclerosis.
------------------------------------------------------------------------
University of 5841 SOUTH CHICAGO IL 60637 A study of the
Chicago MARYLAND effects of
Hospital AVENUE Alemtuzumab on
Surrogate
Markers of
Disease
Activity and
Repair using
Advanced MRI
measures in
Subjects with
Relapsing
Remitting
Multiple
Sclerosis.
------------------------------------------------------------------------
Emory 1364 ATLANTA GA 30302 Do the Benefits
University CLIFTON Outweigh the
Hospital ROAD Risks?
Assessing
Patients'
Perceptions of
Newborn
Screening for
Lysosomal
Storage
Diseases
------------------------------------------------------------------------
Massachusetts FRUIT BOSTON MA 02114 Neuroimaging
General STREET Characteristics
Hospital in Fabry
Disease:
Quantitation of
CNS White
Matter Lesions
------------------------------------------------------------------------
Massachusetts FRUIT BOSTON MA 02114 Neuroimaging
General STREET Characteristics
Hospital in Fabry
Disease:
Quantitation of
CNS White
Matter Lesions
------------------------------------------------------------------------
Massachusetts FRUIT BOSTON MA 02114 Neuroimaging
General STREET Characteristics
Hospital in Fabry
Disease:
Quantitation of
CNS White
Matter Lesions
------------------------------------------------------------------------
University of 2 SEATTLE WA 98195 Podocyturia: A
Washington Non-Invasive
Biomarker of
Fabry
Nephropathy
------------------------------------------------------------------------
University of 2 SEATTLE WA 98195 Podocyturia: A
Washington Non-Invasive
Biomarker of
Fabry
Nephropathy
------------------------------------------------------------------------
University of 619 SOUTH BIRMING AL 35233 Cognitive
Alabama 19TH HAM Function
Hospital STREET Assessment in
Fabry Disease:
A Pilot
Feasibility
Study
------------------------------------------------------------------------
University of 619 SOUTH BIRMING AL 35233 Multi-center,
Alabama 19TH HAM Open-label
Hospital STREET Study of the
Safety and
Efficacy of
Control of
Proteinuria
with ACE
Inhibitors and
ARBS in
Patients with
Fabry Disease
Who Are
Receiving
Fabrazyme?: The
Fabrazyme? +
Arbs + ACE
inhibitors
Treatments
(FAACET) Study:
The FAACET
Study.
------------------------------------------------------------------------
Rochester 1425 ROCHEST NY 14621 A Study
General PORTLAND ER Evaluating
Hospital AVENUE Acute Otitis
Media and
Nasopharyngeal
Colonization
Caused by
Streptococcus
pneumoniae in
Healthy
Children
------------------------------------------------------------------------
Dana-Farber 450 BOSTON MA 02215 Randomized Phase
Cancer BROOKLINE II Study of
Institute AVE FOLFOX +/-
Aflibercept in
metastatic
esophagogastric
cancer
------------------------------------------------------------------------
Dana-Farber 450 BOSTON MA 02215 Randomized Phase
Cancer BROOKLINE II Study of
Institute AVE FOLFOX +/-
Aflibercept in
metastatic
esophagogastric
cancer
------------------------------------------------------------------------
Dana-Farber 450 BOSTON MA 02215 Randomized Phase
Cancer BROOKLINE II Study of
Institute AVE FOLFOX +/-
Aflibercept in
metastatic
esophagogastric
cancer
------------------------------------------------------------------------
UT MD Anderson 1515 HOUSTON TX 77030 A Randomized
Cancer Center HOLCOMBE Study of Once
BLVD Daily
Fludarabine-
Clofarabine vs
Fludarabine
Alone Combined
with IV
Busulfan
Followed by
Allogeneic
Hemopoietic
Stem Cell
Transplantation
for AML and MDS
------------------------------------------------------------------------
UT MD Anderson 1515 HOUSTON TX 77030 A Randomized
Cancer Center HOLCOMBE Study of Once
BLVD Daily
Fludarabine-
Clofarabine vs
Fludarabine
Alone Combined
with IV
Busulfan
Followed by
Allogeneic
Hemopoietic
Stem Cell
Transplantation
for AML and MDS
------------------------------------------------------------------------
UT MD Anderson 1515 HOUSTON TX 77030 A Randomized
Cancer Center HOLCOMBE Study of Once
BLVD Daily
Fludarabine-
Clofarabine vs
Fludarabine
Alone Combined
with IV
Busulfan
Followed by
Allogeneic
Hemopoietic
Stem Cell
Transplantation
for AML and MDS
------------------------------------------------------------------------
UT MD Anderson 1515 HOUSTON TX 77030 A Randomized
Cancer Center HOLCOMBE Study of Once
BLVD Daily
Fludarabine-
Clofarabine vs
Fludarabine
Alone Combined
with IV
Busulfan
Followed by
Allogeneic
Hemopoie
------------------------------------------------------------------------
UT MD Anderson 1515 HOUSTON TX 77030 A phase II study
Cancer Center HOLCOMBE of cabazitaxel
BLVD with or without
carboplatin in
patients with
metastatic
castration-
resistant
prostate cancer
previously
treated with
docetaxel-based
therapy.
------------------------------------------------------------------------
UT MD Anderson 1515 HOUSTON TX 77030 A phase II study
Cancer Center HOLCOMBE of cabazitaxel
BLVD with or without
carboplatin in
patients with
metastatic
castration-
resistant
prostate cancer
previously
treated with
docetaxel-based
therapy.
------------------------------------------------------------------------
Memorial 1275 YORK NEW NY 10065 An Exploratory
Hospital For AVENUE YORK Randomized
Center Phase II
Multicenter
Trial of
Abiraterone
Acetate with or
without
Cabazitaxel in
Treatment of
Metastatic
Castration
Resistant
Prostate Cancer
------------------------------------------------------------------------
Brigham And 75 FRANCIS BOSTON MA 02115 Assessment of
Womens STREET Aubagio?s
Hospital neuroprotective
effect on the
development of
T1 black holes
------------------------------------------------------------------------
Brigham And 75 FRANCIS BOSTON MA 02115 Assessment of
Womens Hosp STREET Aubagio?s
neuroprotective
effect on the
development of
T1 black holes
------------------------------------------------------------------------
Brigham And 75 FRANCIS BOSTON MA 02115 Post-partum MRI
Womens Hosp STREET Changes in
Women with
Multiple
Sclerosis.
------------------------------------------------------------------------
Brigham And 75 FRANCIS BOSTON MA 02115 Post-partum MRI
Womens Hosp STREET Changes in
Women with
Multiple
Sclerosis.
------------------------------------------------------------------------
Brigham And 75 FRANCIS BOSTON MA 02115 Post-partum MRI
Womens Hosp STREET Changes in
Women with
Multiple
Sclerosis.
------------------------------------------------------------------------
Keck Hospital 1500 SAN LOS CA 90033 Detection of
of USC PABLO ANGELE early end-organ
STREET S damage by
endothelial
dysfunction
with reactive
hyperemia-
digital
peripheral
arterial
tonometry in
patients with
Fabry Disease
------------------------------------------------------------------------
Vanderbilt 1211 NASHVIL TN 37232 Innovation in
University MEDICAL LE the timely
Hospital CENTER diagnosis and
DRIVE multidiscipinar
y treatment of
Fabry disease
------------------------------------------------------------------------
Emory 1364 ATLANTA GA 30302 A Prospective,
University CLIFTON Multicenter
Hospital ROAD Study Of Fabry
Disease
Clinical and
Biochemical
Findings in
Young Pediatric
Patients (The
MOPPET Study)
------------------------------------------------------------------------
Emory 1364 ATLANTA GA 30302 Reproductive
University CLIFTON Fitness in
Hospital ROAD Individuals
Affected by
Fabry Disease
(FIT)
------------------------------------------------------------------------
UCI Medical 101 CITY ORANGE CA 92868 Investigating
Center (.) DRIVE Pompe
SOUTH Prevalence in
NEuromuscular
Medicine
Academic
Practices
(IPANEMA Study)
------------------------------------------------------------------------
Massachusetts FRUIT BOSTON MA 02114 The Fabry Pain
General STREET Inventory:
Hospital Validation of a
New Clinical
Tool to
Comprehensively
Capture the
Fabry Pain
Experience
------------------------------------------------------------------------
University of 2 SEATTLE WA 98195 Effects of Fabry
Washington Disease on
Myelination in
the In Vivo
Adult Human
Brain
------------------------------------------------------------------------
University of 619 SOUTH BIRMING AL 35233 Improved
Alabama 19TH HAM Detection,
Hospital STREET Diagnosis, and
Management of
Fabry Disease
through Serial
Ophthalmic
Documentation
and Tear Fluid
Analysis
------------------------------------------------------------------------
Dana-Farber 450 BOSTON MA 02215 Phase II Study
Cancer BROOKLINE of Clofarabine
Institute AVE in Patients
with Recurrent
or Refractory
Langerhans Cell
Histiocytosis
------------------------------------------------------------------------
Dana-Farber 450 BOSTON MA 02215 Phase I/II Trial
Cancer BROOKLINE of Combination
Institute AVE AMD3100 and
Bortezomib in
Relapsed or
Relapsed/
Refractory
Multiple
Myeloma
------------------------------------------------------------------------
The Nebraska DEWEY OMAHA NE 68198 Leukine
Medical AVENUE AT (sargramostim)
Center 42ND for Parkinson's
disease
------------------------------------------------------------------------
Charleston 501 MORRIS CHARLES WV 25326 A Phase II Trial
Area Medical STREET TON of GM-CSF
Protein plus
Ipilimumab in
Patients with
Advanced
Melanoma (ECOG
1608)
------------------------------------------------------------------------
City of Hope 1500 EAST DUARTE CA 91010 Phase II Study
National DUARTE of Clofarabine
Medical ROAD and High-Dose
Center Melphalan
Conditioning
Prior to
Allogeneic
Heamtopoietic
Cell
Transplantation
for
Myelodysplasia
------------------------------------------------------------------------
The Christ 2139 AUBURN CINCINN OH 45219 A Phase II Trial
Hospital AVENUE ATI of GM-CSF
Protein plus
Ipilimumab in
Patients with
Advanced
Melanoma (ECOG
1608)
------------------------------------------------------------------------
Ohsu Hospital 3181 SAM PORTLAN OR 97239 A Phase I/II
and Clinics JACKSON D Trial of
(.) PARK ROAD Concurrent
Chemohormonal
Therapy Using
Enzalutamide
(MDV-3100) and
Cabazitaxel in
Patients with
Metastatic
Castration
------------------------------------------------------------------------
Memorial 1275 YORK NEW NY 10065 Creation of a
Hospital for AVENUE YORK registry of
Cancer and patients
Allied treated on
Diseases TAX3503
(101317743)
------------------------------------------------------------------------
Dana-Farber 450 BOSTON MA 02215 Phase I/II Trial
Cancer BROOKLINE of Combination
Institute (.) AVE AMD3100 and
Bortezomib in
Relapsed or
Relapsed/
Refractory
Multiple
Myeloma
------------------------------------------------------------------------
Memorial 1275 YORK NEW NY 10065 An Exploratory
Hospital for AVENUE YORK Randomized
Cancer and Phase II
Allied Multicenter
Diseases Trial of
(101317743) Abiraterone
Acetate with or
without
Cabazitaxel in
Treatment of
Metastatic
Castration
------------------------------------------------------------------------
UT MD Anderson 1515 HOUSTON TX 77030 A Randomized
Cancer Center HOLCOMBE Phase 2 study
(1083730964) BLVD to Evaluate the
Efficacy of
Rasburicase in
Patients at
Risk for TLS
During Two
Cycles of
Chemotherapy
------------------------------------------------------------------------
The Miriam 164 SUMMIT PROVIDE RI 02906 Aflibercept
Hospital (.) AVENUE NCE Maintenance for
patients with
resected or
ablated
metastatic
colorectal
cancer
------------------------------------------------------------------------
Memorial 1275 YORK NEW NY 10065 An Exploratory
Hospital for AVENUE YORK Randomized
Cancer and Phase II
Allied Multicenter
Diseases Trial of
(101317743) Abiraterone
Acetate with or
without
Cabazitaxel in
Treatment of
Metastatic
Castration
------------------------------------------------------------------------
Memorial 1275 YORK NEW NY 10065 A Multi-center
Hospital for AVENUE YORK Randomized
Cancer and Phase II Study
Allied of the Impact
Diseases of CD34+ Cell
(101317743) Dose on
Progression-
free Survival
Following High-
Dose Therapy
------------------------------------------------------------------------
Dana-Farber 450 BOSTON MA 02215 Phase I Study of
Cancer BROOKLINE Plerixafor
Institute (.) AVE (AMD3100) and
Bevacizumab for
Recurrent High-
grade Glioma
------------------------------------------------------------------------
Emory 1364 ATLANTA GA 30302 A Prospective,
University CLIFTON Multicenter
Hospital ROAD Study Of Fabry
(1073592747) Disease
Clinical and
Biochemical
Findings in
Young Pediatric
Patients (The
MOPPET Study)
------------------------------------------------------------------------
Vanderbilt 1211 NASHVIL TN 37232 Innovation in
University MEDICAL LE the timely
Hospitals & CENTER diagnosis and
Clinic (.) DRIVE multidiscipinar
y treatment of
Fabry disease
------------------------------------------------------------------------
Emory 1364 ATLANTA GA 30302 Reproductive
University CLIFTON Fitness in
Hospital ROAD Individuals
(1073592747) Affected by
Fabry Disease
(FIT)
------------------------------------------------------------------------
Emory 1364 ATLANTA GA 30302 Reproductive
University CLIFTON Fitness in
Hospital ROAD Individuals
(1073592747) Affected by
Fabry Disease
(FIT)
------------------------------------------------------------------------
Massachusetts FRUIT BOSTON MA 02114 MGH Fabry
General STREET Screening
Hospital (.) Initiative
------------------------------------------------------------------------
Emory 1364 ATLANTA GA 30302 A Comparison of
University CLIFTON Pharmacological
Hospital ROAD vs.
(1073592747) Psychological
Interventions
to Improve
Adaptive
Function in
Fabry Patients
Undergoing
Enzyme Replace
------------------------------------------------------------------------
USC Norris 1441 LOS CA 90033 Detection of
Cancer EASTLAKE ANGELE early end-organ
Hospital (.) AVE S damage by
endothelial
dysfunction
with reactive
hyperemia-
digital
peripheral
arterial
tonometry in
patients with
Fabry Disease.
------------------------------------------------------------------------
Emory 1364 ATLANTA GA 30302 Online Social
University CLIFTON Networking Use
Hospital (.) ROAD Among
Individuals
Affected with
Lysosomal
Storage
Diseases:
``Friend'' or
Foe?
------------------------------------------------------------------------
Massachusetts FRUIT BOSTON MA 02114 Characterization
General STREET and analysis of
Hospital pathophysiology
(1114196961) of the
gastrointestina
l complications
of Fabry
disease.
------------------------------------------------------------------------
Univ of MI 2301 ANN MI 48105 A Phase II Study
Hospitals & COMMONWEAL ARBOR of VEGF-Trap
Hlth Ctrs TH BLVD plus Modified
(1043488760) FOLFOX 6 in
Previously
Untreated
Patients with
Metastatic
Colorectal
Cancer
------------------------------------------------------------------------
Cleveland 9500 EUCLID CLEVELA OH 44195 A Randomized,
Clinic AVENUE ND Controlled,
Hospital (.) open-labeled
Clinical Trial
of
Thymoglobulin
Induction and
Extended Delay
of Calcineurin
Inhibitor
Therapy for
Rena
------------------------------------------------------------------------
Washington 110 IRVING WASHING DC 20010 Comparison of I-
Hospital STREET NW TON 124 and I-131
Center Radiopharmacoki
(1184638959) netics in
Patients who
have Well-
differentiated
Thyroid Cancer
and have been
Prepared with
Radioactive
Iodine 124
------------------------------------------------------------------------
OHSU Hospital 3181 SAM PORTLAN OR 97239 A Phase I/II
And Clinics JACKSON D Trial of
(.) PARK ROAD Concurrent
Chemohormonal
Therapy Using
Enzalutamide
(MDV-3100) and
Cabazitaxel in
Patients with
Metastatic
Castration
------------------------------------------------------------------------
City Of Hope 1500 EAST DUARTE CA 91010 Phase II Study
National DUARTE of Clofarabine
Medical ROAD and High-Dose
Center Melphalan
(103343529) Conditioning
Prior to
Allogeneic
Heamtopoietic
Cell
Transplantation
for
Myelodysplasia
------------------------------------------------------------------------
Massachusetts FRUIT BOSTON MA 02114 Phase II Study
General STREET of Aflibercept
Hospital (.) in Patients
with Advanced,
Progressive
Carcinoid
Tumors
------------------------------------------------------------------------
Vanderbilt 1211 NASHVIL TN 37232 Epidemiology of
University MEDICAL LE Diabetes
Hospitals & CENTER Interventions
Clinic DRIVE and
(1104202761) Complications
------------------------------------------------------------------------
City Of Hope 1500 EAST DUARTE CA 91010 Phase II Study
National DUARTE of Clofarabine
Medical ROAD and High-Dose
Center Melphalan
(103343529) Conditioning
Prior to
Allogeneic
Heamtopoietic
Cell
Transplantation
for
Myelodysplasia
------------------------------------------------------------------------
Dana-Farber 450 BOSTON MA 02215 Phase II Study
Cancer BROOKLINE of Clofarabine
Institute (.) AVE in Patients
with Recurrent
or Refractory
Langerhans Cell
Histiocytosis
------------------------------------------------------------------------
Univ Of Iowa 200 HAWKINS IOWA IA 52242 Epidemiology of
Hosp & Clinic DRIVE 1353 CITY Diabetes
(.) JCP Interventions
and
Complications
------------------------------------------------------------------------
Univ of ONE COLUMBI MO 65212 Epidemiology of
Missouri HOSPITAL A Diabetes
Health Care DRIVE Interventions
(1033499256) and
Complications
------------------------------------------------------------------------
University Of 1959 NE SEATTLE WA 98195 Epidemiology of
Washington PACIFIC ST Diabetes
Med Ctr (.) Interventions
and
Complications
------------------------------------------------------------------------
Yale-New Haven 20 YORK NEW CT 06504 Epidemiology of
Hospital (.) STREET HAVEN Diabetes
Interventions
and
Complications
------------------------------------------------------------------------
University Of 22 SOUTH BATLIMO MD 21201 Epidemiology of
Maryland Med GREENE RE Diabetes
Sys STREET Interventions
(1023304888) and
Complications
------------------------------------------------------------------------
City Of Hope 1500 EAST DUARTE CA 91010 Phase II Study
National DUARTE of Clofarabine
Medical ROAD and High-Dose
Center Melphalan
(103343529) Conditioning
Prior to
Allogeneic
Heamtopoietic
Cell
Transplantation
for
Myelodysplasia
------------------------------------------------------------------------
Charleston 501 MORRIS CHARLES WV 25326 A Phase II Trial
Area Medical STREET TON of GM-CSF
Center Inc. Protein plus
(1124248752) Ipilimumab in
Patients with
Advanced
Melanoma (ECOG
1608)
------------------------------------------------------------------------
Yale-New Haven 20 YORK NEW CT 06504 Eliglustat
Hospital STREET HAVEN Tatrate Named
(1003142225) Patient Program
------------------------------------------------------------------------
Memorial 1275 YORK NEW NY 10065 Safety and
Hospital For AVENUE YORK Efficacy Trial
Cancer And of Escalation
Allied of Plerixafor
Diseases for
(101317743) Mobilization of
CD34+
Hematopoietic
Progenitor
Cells and
Evaluation of
Globin Gene
Traits
------------------------------------------------------------------------
Dana-Farber 450 BOSTON MA 02215 Phase II Study
Cancer BROOKLINE of Clofarabine
Institute (.) AVE in Patients
with Recurrent
or Refractory
Langerhans Cell
Histiocytosis
------------------------------------------------------------------------
Massachusetts FRUIT BOSTON MA 02114 Phase II Study
General STREET of Aflibercept
Hospital (.) in Patients
with Advanced,
Progressive
Carcinoid
Tumors
------------------------------------------------------------------------
Univ Of MI 2301 ANN MI 48105 A Phase II Study
Hospitals & COMMONWEAL ARBOR of VEGF-Trap
Hlth Ctrs TH BLVD plus Modified
(1043488760) FOLFOX 6 in
Previously
Untreated
Patients with
Metastatic
Colorectal
Cancer
------------------------------------------------------------------------
University 445 LENOX BROOKLY NY 11203 A Phase II Study
Hospital Of ROAD N of VEGF-Trap
Brooklyn (.) plus Modified
FOLFOX 6 in
Previously
Untreated
Patients with
Metastatic
Colorectal
Cancer
------------------------------------------------------------------------
Washington 110 IRVING WASHING DC 20010 Comparison of I-
Hospital STREET NW TON 124 and I-131
Center Radiopharmacoki
(1184638959) netics in
Patients who
have Well-
differentiated
Thyroid Cancer
and have been
Prepared with
Radioactive
Iodine 124
------------------------------------------------------------------------
University 445 LENOX BROOKLY NY 11203 A Phase II Study
Hospital Of ROAD N of VEGF-Trap
Brooklyn (.) plus Modified
FOLFOX 6 in
Previously
Untreated
Patients with
Metastatic
Colorectal
Cancer
------------------------------------------------------------------------
Dana-Farber 450 BOSTON MA 02215 Phase II Study
Cancer BROOKLINE of Clofarabine
Institute (.) AVE in Patients
with Recurrent
or Refractory
Langerhans Cell
Histiocytosis
------------------------------------------------------------------------
OHSU Hospital 3181 SAM PORTLAN OR 97239 A Phase I/II
And Clinics JACKSON D Trial of
(.) PARK ROAD Concurrent
Chemohormonal
Therapy Using
Enzalutamide
(MDV-3100) and
Cabazitaxel in
Patients with
Metastatic
Castration
------------------------------------------------------------------------
Univ Of MI 2301 ANN MI 48105 A Phase II Study
Hospitals & COMMONWEAL ARBOR of VEGF-Trap
Hlth Ctrs TH BLVD plus Modified
(1043488760) FOLFOX 6 in
Previously
Untreated
Patients with
Metastatic
Colorectal
Cancer
------------------------------------------------------------------------
Charleston 501 MORRIS CHARLES WV 25326 A Phase II Trial
Area Medical STREET TON of GM-CSF
Center Inc. Protein plus
(1124248752) Ipilimumab in
Patients with
Advanced
Melanoma (ECOG
1608)
------------------------------------------------------------------------
Univ Of MI 2301 ANN MI 48105 A Phase II Study
Hospitals & COMMONWEAL ARBOR of VEGF-Trap
Hlth Ctrs TH BLVD plus Modified
(1043488760) FOLFOX 6 in
Previously
Untreated
Patients with
Metastatic
Colorectal
Cancer
------------------------------------------------------------------------
Yale-New Haven 20 YORK NEW CT 06504 Eliglustat
Hospital STREET HAVEN Tatrate Named
(1003142225) Patient Program
------------------------------------------------------------------------
Memorial 1275 YORK NEW NY 10065 A Multi-center
Hospital For AVENUE YORK Randomized
Cancer And Phase II Study
Allied of the Impact
Diseases of CD34+ Cell
(101317743) Dose on
Progression-
free Survival
Following High-
Dose Therapy
and Autologous
Stem-cell
Rescue
------------------------------------------------------------------------
Lucile 725 WELCH PALO CA 94304 AML08: A Phase
Packard ROAD ALTO III randomized
Childrens trial of
Hospital clofarabine
(1003929852) plus cytarabine
versus
conventional
induction
therapy and of
natural killer
cell
transplantation
------------------------------------------------------------------------
City Of Hope 1500 EAST DUARTE CA 91010 Phase II Study
National DUARTE of Clofarabine
Medical ROAD and High-Dose
Center Melphalan
(103343529) Conditioning
Prior to
Allogeneic
Heamtopoietic
Cell
Transplantation
for
Myelodysplasia
------------------------------------------------------------------------
City Of Hope 1500 EAST DUARTE CA 91010 Phase II Study
National DUARTE of Clofarabine
Medical ROAD and High-Dose
Center Melphalan
(103343529) Conditioning
Prior to
Allogeneic
Heamtopoietic
Cell
Transplantation
for
Myelodysplasia
------------------------------------------------------------------------
Texas 6621 FANNIN HOUSTON TX 77030 Phase II Study
Childrens of Clofarabine
Hospital (.) in Patients
with Recurrent
or Refractory
Langerhans Cell
Histiocytosis
------------------------------------------------------------------------
Univ Of Iowa 200 HAWKINS IOWA IA 52242 Epidemiology of
Hosp & Clinic DRIVE 1353 CITY Diabetes
(.) JCP Interventions
and
Complications
------------------------------------------------------------------------
Rainbow Babies 11100 CLEVELA OH 44106 Epidemiology of
& Childrens EUCLID ND Diabetes
Hospital AVENUE Interventions
(1013954395) and
Complications
------------------------------------------------------------------------
Univ Of ONE COLUMBI MO 65212 Epidemiology of
Missouri HOSPITAL A Diabetes
Health Care DRIVE Interventions
(1033499256) and
Complications
------------------------------------------------------------------------
University Of 1959 NE SEATTLE WA 98195 Epidemiology of
Washington PACIFIC ST Diabetes
Med Ctr (.) Interventions
and
Complications
------------------------------------------------------------------------
Yale-New Haven 20 YORK NEW CT 06504 Epidemiology of
Hospital (.) STREET HAVEN Diabetes
Interventions
and
Complications
------------------------------------------------------------------------
Mayo Clinic 1216 SECOND ROCHEST MN 55905 Epidemiology of
Hospital STREET SW ER Diabetes
Rochester (.) Interventions
and
Complications
------------------------------------------------------------------------
University Of 22 SOUTH BATLIMO MD 21201 Epidemiology of
Maryland Med GREENE RE Diabetes
Sys STREET Interventions
(1023304888) and
Complications
------------------------------------------------------------------------
Charleston 501 MORRIS CHARLES WV 25326 A Phase II Trial
Area Medical STREET TON of GM-CSF
Center Inc. Protein plus
(1124248752) Ipilimumab in
Patients with
Advanced
Melanoma (ECOG
1608)
------------------------------------------------------------------------
Massachusetts FRUIT BOSTON MA 02114 Phase II Study
General STREET of Aflibercept
Hospital (.) in Patients
with Advanced,
Progressive
Carcinoid
Tumors
------------------------------------------------------------------------
Cleveland 9500 EUCLID CLEVELA OH 44195 A Randomized,
Clinic AVENUE ND Controlled,
Hospital (.) open-labeled
Clinical Trial
of
Thymoglobulin
Induction and
Extended Delay
of Calcineurin
Inhibitor
Therapy for
Renal Failure
------------------------------------------------------------------------
Washington 110 IRVING WASHING DC 20010 Comparison of I-
Hospital STREET NW TON 124 and I-131
Center Radiopharmacoki
(1184638959) netics in
Patients who
have Well-
differentiated
Thyroid Cancer
and have been
Prepared with
Radioactive
Iodine 124
------------------------------------------------------------------------
City Of Hope 1500 EAST DUARTE CA 91010 Phase II Study
National DUARTE of Clofarabine
Medical ROAD and High-Dose
Center Melphalan
(103343529) Conditioning
Prior to
Allogeneic
Heamtopoietic
Cell
Transplantation
for
Myelodysplasia
------------------------------------------------------------------------
Memorial 1275 YORK NEW NY 10065 Safety and
Hospital For AVENUE YORK Efficacy Trial
Cancer And of Escalation
Allied of Plerixafor
Diseases for
(101317743) Mobilization of
CD34+
Hematopoietic
Progenitor
Cells and
Evaluation of
Globin Gene
Traits
------------------------------------------------------------------------
Cleveland 9500 EUCLID CLEVELA OH 44195 A Randomized,
Clinic AVENUE ND Controlled,
Hospital (.) open-labeled
Clinical Trial
of
Thymoglobulin
Induction and
Extended Delay
of Calcineurin
Inhibitor
Therapy for
Renal Failure
------------------------------------------------------------------------
Charleston 501 MORRIS CHARLES WV 25326 A Phase II Trial
Area Medical STREET TON of GM-CSF
Center Inc. Protein plus
(1124248752) Ipilimumab in
Patients with
Advanced
Melanoma (ECOG
1608)
------------------------------------------------------------------------
City Of Hope 1500 EAST DUARTE CA 91010 Phase II Study
National DUARTE of Clofarabine
Medical ROAD and High-Dose
Center Melphalan
(103343529) Conditioning
Prior to
Allogeneic
Heamtopoietic
Cell
Transplantation
for
Myelodysplasia
------------------------------------------------------------------------
Texas 6621 FANNIN HOUSTON TX 77030 Phase II Study
Childrens of Clofarabine
Hospital (.) in Patients
with Recurrent
or Refractory
Langerhans Cell
Histiocytosis
------------------------------------------------------------------------
Massachusetts FRUIT BOSTON MA 02114 Phase II Study
General STREET of Aflibercept
Hospital (.) in Patients
with Advanced,
Progressive
Carcinoid
Tumors
------------------------------------------------------------------------
Cook Childrens 901 SEVENTH FORT TX 76104 AML08: A Phase
Medical AVENUE WORTH III randomized
Center trial of
(1215907530) clofarabine
plus cytarabine
versus
conventional
induction
therapy and of
natural killer
cell
transplantation
------------------------------------------------------------------------
Texas 6621 FANNIN HOUSTON TX 77030 Phase II Study
Childrens of Clofarabine
Hospital (.) in Patients
with Recurrent
or Refractory
Langerhans Cell
Histiocytosis
------------------------------------------------------------------------
Ohsu Hospital 3181 SAM PORTLAN OR 97239 A Phase I/II
And Clinics JACKSON D Trial of
(.) PARK ROAD Concurrent
Chemohormonal
Therapy Using
Enzalutamide
(MDV-3100) and
Cabazitaxel in
Patients with
Metastatic
Castration
------------------------------------------------------------------------
Texas 6621 FANNIN HOUSTON TX 77030 Phase II Study
Childrens of Clofarabine
Hospital (.) in Patients
with Recurrent
or Refractory
Langerhans Cell
Histiocytosis
------------------------------------------------------------------------
Univ Of Mi 2301 ANN MI 48105 A Phase II Study
Hospitals & COMMONWEAL ARBOR of VEGF-Trap
Hlth Ctrs TH BLVD plus Modified
(1043488760) FOLFOX 6 in
Previously
Untreated
Patients with
Metastatic
Colorectal
Cancer
------------------------------------------------------------------------
Univ Of MI 2301 ANN MI 48105 A Phase II Study
Hospitals & COMMONWEAL ARBOR of VEGF-Trap
Hlth Ctrs TH BLVD plus Modified
(1043488760) FOLFOX 6 in
Previously
Untreated
Patients with
Metastatic
Colorectal
Cancer
------------------------------------------------------------------------
Lucile Packard 725 WELCH PALO CA 94304 AML08: A Phase
Childrens ROAD ALTO III randomized
Hospital trial of
(1003929852) clofarabine
plus cytarabine
versus
conventional
induction
therapy and of
natural killer
cell
transplantation
------------------------------------------------------------------------
City Of Hope 1500 EAST DUARTE CA 91010 Phase II Study
National DUARTE of Clofarabine
Medical ROAD and High-Dose
Center Melphalan
(103343529) Conditioning
Prior to
Allogeneic
Heamtopoietic
Cell
Transplantation
for
Myelodysplasia
------------------------------------------------------------------------
Emory 1364 ATLANTA GA 30302 Enhancing Anti-
University CLIFTON Myeloma Vaccine
Hospital ROAD Response after
(1073837167) Autologous Stem
Cell
Transplantation
------------------------------------------------------------------------
Emory 1364 ATLANTA GA 30302 MTA for :
University CLIFTON Enhancing Anti-
Hospital (.) ROAD Myeloma Vaccine
Response after
Autologous Stem
Cell Transplant
------------------------------------------------------------------------
Rochester 1425 ROCHEST NY 14621 A Study
General PORTLAND ER Evaluating
Hospital (.) AVENUE Acute Otitis
Media and
Nasopharyngeal
Colonization
Caused by
Streptococcus
pneumoniae in
Healthy
Children
------------------------------------------------------------------------
Rochester 1425 ROCHEST NY 14621 A Study
General PORTLAND ER Evaluating
Hospital (.) AVENUE Acute Otitis
Media and
Nasopharyngeal
Colonization
Caused by
Streptococcus
pneumoniae in
Healthy
Children
------------------------------------------------------------------------
Brigham And 75 FRANCIS BOSTON MA 02115 Assessment of
Womens STREET Aubagio?s
Hospital (.) neuroprotective
effect on the
development of
T1 black holes
------------------------------------------------------------------------
Brigham And 75 FRANCIS BOSTON MA 02115 miRNA profiling
Womens STREET in
Hospital Teriflunomide
(1013935550) (Aubagio)
treated
patients
------------------------------------------------------------------------
Langley Porter 405 SAN CA 94143 Long-term
Psychiatric PARNASUS FRANCI Management of
Hosptial (.) SCO ?Younger,
Active?
Patients with
Pain from Early
Knee
Osteoarthritis
with Synvisc-
One (hylan G-F
20)
------------------------------------------------------------------------
University Of 1959 NE SEATTLE WA 98195 Fluctuation
Washington PACIFIC ST Reduction With
Med Ctr (.) Insulin and GLP-
1 Added
Together (FLAT-
SUGAR)
------------------------------------------------------------------------
University Of 1959 NE SEATTLE WA 98195 Fluctuation
Washington PACIFIC ST Reduction With
Med Ctr (.) Insulin and GLP-
1 Added
Together (FLAT-
UGAR)
------------------------------------------------------------------------
Cleveland 9500 EUCLID CLEVELA OH 44195 A Randomized,
Clinic AVENUE ND Controlled,
Hospital open-labeled
(1043549397) Clinical Trial
of
Thymoglobulin
Induction and
Extended Delay
of Calcineurin
Inhibitor
Therapy for
Renal Failure
------------------------------------------------------------------------
Massachusetts FRUIT BOSTON MA 02114 Phase II Study
General STREET of Aflibercept
Hospital in Patients
(1114196961) with Advanced,
Progressive
Carcinoid
Tumors
------------------------------------------------------------------------
Charleston 501 MORRIS CHARLES WV 25326 A Phase II Trial
Area Medical STREET TON of GM-CSF
Center Inc. Protein plus
(1124248752) Ipilimumab in
Patients with
Advanced
Melanoma (ECOG
1608)
------------------------------------------------------------------------
Cleveland 9500 EUCLID CLEVELA OH 44195 A Randomized,
Clinic AVENUE ND Controlled,
Hospital open-labeled
(1043549397) Clinical Trial
of
Thymoglobulin
Induction and
Extended Delay
of Calcineurin
Inhibitor
Therapy for
Renal Failure
------------------------------------------------------------------------
Mount Sinai ONE GUSTAVE NEW NY 10029 Phase II Study
Hospital L. LEVY YORK of Clofarabine
(1003063280) PLACE in Patients
with Recurrent
or Refractory
Langerhans Cell
Histiocytosis
------------------------------------------------------------------------
Mayo Clinic 1216 SECOND ROCHEST MN 55905 Epidemiology of
Hospital STREET SW ER Diabetes
Rochester (.) Interventions
and
Complications
------------------------------------------------------------------------
Mayo Clinic 1216 SECOND ROCHEST MN 55905 Epidemiology of
Hospital STREET SW ER Diabetes
Rochester (.) Interventions
and
Complications
------------------------------------------------------------------------
University Of 200 HAWKINS IOWA IA 52242 Epidemiology of
Iowa Hosp & DRIVE 1353 CITY Diabetes
Clinics JCP Interventions
(1326474149) and
Complications
------------------------------------------------------------------------
University Of 200 HAWKINS IOWA IA 52242 Epidemiology of
Iowa Hosp & DRIVE 1353 CITY Diabetes
Clinics JCP Interventions
(1326474149) and
Complications
------------------------------------------------------------------------
Univ Of ONE COLUMBI MO 65212 Epidemiology of
Missouri HOSPITAL A Diabetes
Health Care DRIVE Interventions
(1033499256) and
Complications
------------------------------------------------------------------------
Univ Of ONE COLUMBI MO 65212 Epidemiology of
Missouri HOSPITAL A Diabetes
Health Care DRIVE Interventions
(1033499256) and
Complications
------------------------------------------------------------------------
Vanderbilt 1211 NASHVIL TN 37232 Epidemiology of
University MEDICAL LE Diabetes
Medical CENTER Interventions
Center DRIVE and
(1104202761) Complications
------------------------------------------------------------------------
Yale-New Haven 20 YORK NEW CT 06504 Epidemiology of
Hospital STREET HAVEN Diabetes
(1003142225) Interventions
and
Complications
------------------------------------------------------------------------
University Of 22 SOUTH BATLIMO MD 21201 Epidemiology of
Maryland Med GREENE RE Diabetes
Sys STREET Interventions
(1023304888) and
Complications
------------------------------------------------------------------------
University Of 22 SOUTH BATLIMO MD 21201 Epidemiology of
Maryland Med GREENE RE Diabetes
Sys STREET Interventions
(1023304888) and
Complications
------------------------------------------------------------------------
Cleveland 9500 EUCLID CLEVELA OH 44195 A Randomized,
Clinic AVENUE ND Controlled,
Hospital open-labeled
(1043549397) Clinical Trial
of
Thymoglobulin
Induction and
Extended Delay
of Calcineurin
Inhibitor
Therapy for
Renal Failure
------------------------------------------------------------------------
Cleveland 9500 EUCLID CLEVELA OH 44195 A Randomized,
Clinic AVENUE ND Controlled,
Hospital open-labeled
(1043549397) Clinical Trial
of
Thymoglobulin
Induction and
Extended Delay
of Calcineurin
Inhibitor
Therapy for
Renal Failure
------------------------------------------------------------------------
Massachusetts FRUIT BOSTON MA 02114 Phase II Study
General STREET of Aflibercept
Hospital in Patients
(1114196961) with Advanced,
Progressive
Carcinoid
Tumors
------------------------------------------------------------------------
Texas 6621 FANNIN HOUSTON TX 77030 Phase II Study
Childrens of Clofarabine
Hospital in Patients
(1013283159) with Recurrent
or Refractory
Langerhans Cell
Histiocytosis
------------------------------------------------------------------------
Charleston 501 MORRIS CHARLES WV 25326 A Phase II Trial
Area Medical STREET TON of GM-CSF
Center Inc. Protein plus
(1124248752) Ipilimumab in
Patients with
Advanced
Melanoma (ECOG
1608)
------------------------------------------------------------------------
Methodist 7700 FLOYD SAN TX 78229 A Multi-center
Hospital CURL DRIVE ANTONI Randomized
(1124074273) O Phase II Study
of the Impact
of CD34+ Cell
Dose on
Progression-
free Survival
Following High-
Dose Therapy
and Autologous
Stem-cell
Rescue
------------------------------------------------------------------------
Texas 6621 FANNIN HOUSTON TX 77030 Phase II Study
Childrens of Clofarabine
Hospital in Patients
(1013283159) with Recurrent
or Refractory
Langerhans Cell
Histiocytosis
------------------------------------------------------------------------
Massachusetts FRUIT BOSTON MA 02114 Phase II Study
General STREET of Clofarabine
Hospital in Patients
(1114196961) with Recurrent
or Refractory
Langerhans Cell
Histiocytosis
------------------------------------------------------------------------
Cleveland 9500 EUCLID CLEVELA OH 44195 A Randomized,
Clinic AVENUE ND Controlled,
Hospital open-labeled
(1013392125) Clinical Trial
of
Thymoglobulin
Induction and
Extended Delay
of Calcineurin
Inhibitor
Therapy for
Renal Failure
------------------------------------------------------------------------
Texas 6621 FANNIN HOUSTON TX 77030 Phase II Study
Childrens of Clofarabine
Hospital in Patients
(1013283159) with Recurrent
or Refractory
Langerhans Cell
Histiocytosis
------------------------------------------------------------------------
Arkansas 1 CHILDRENS LITTLE AR 72202 Phase II Study
Childrens WAY ROCK of Clofarabine
Hospital in Patients
(1134155831) with Recurrent
or Refractory
Langerhans Cell
Histiocytosis
------------------------------------------------------------------------
Cleveland 9500 EUCLID CLEVELA OH 44195 A Randomized,
Clinic AVENUE ND Controlled,
Hospital open-labeled
(1013392125) Clinical Trial
of
Thymoglobulin
Induction and
Extended Delay
of Calcineurin
Inhibitor
Therapy for
Renal Failure
------------------------------------------------------------------------
Cleveland 9500 EUCLID CLEVELA OH 44195 A Randomized,
Clinic AVENUE ND Controlled,
Hospital open-labeled
(1013392125) Clinical Trial
of
Thymoglobulin
Induction and
Extended Delay
of Calcineurin
Inhibitor
Therapy for
Renal Failure
------------------------------------------------------------------------
Texas 6621 FANNIN HOUSTON TX 77030 Phase II Study
Childrens of Clofarabine
Hospital in Patients
(1013283159) with Recurrent
or Refractory
Langerhans Cell
Histiocytosis
------------------------------------------------------------------------
Texas 6621 FANNIN HOUSTON TX 77030 Phase II Study
Childrens of Clofarabine
Hospital in Patients
(1013283159) with Recurrent
or Refractory
Langerhans Cell
Histiocytosis
------------------------------------------------------------------------
Charleston 501 MORRIS CHARLES WV 25326 A Phase II Trial
Area Medical STREET TON of GM-CSF
Center Inc. Protein plus
(1124248752) Ipilimumab in
Patients with
Advanced
Melanoma (ECOG
1608)
------------------------------------------------------------------------
Phoenix 1919 E. PHOENIX AZ 85016 Phase II Study
Childrens THOMAS of Clofarabine
Hospital ROAD in Patients
(1023475506) with Recurrent
or Refractory
Langerhans Cell
Histiocytosis
------------------------------------------------------------------------
Texas 6621 FANNIN HOUSTON TX 77030 Phase II Study
Childrens of Clofarabine
Hospital in Patients
(1013283159) with Recurrent
or Refractory
Langerhans Cell
Histiocytosis
------------------------------------------------------------------------
Texas 6621 FANNIN HOUSTON TX 77030 Phase II Study
Childrens of Clofarabine
Hospital in Patients
(1013283159) with Recurrent
or Refractory
Langerhans Cell
Histiocytosis
------------------------------------------------------------------------
Texas 6621 FANNIN HOUSTON TX 77030 Phase II Study
Childrens of Clofarabine
Hospital in Patients
(1013283159) with Recurrent
or Refractory
Langerhans Cell
Histiocytosis
------------------------------------------------------------------------
Univ Of ONE COLUMBI MO 65212 Epidemiology of
Missouri HOSPITAL A Diabetes
Health Care DRIVE Interventions
(1033499256) and
Complications
------------------------------------------------------------------------
Univ Of ONE COLUMBI MO 65212 Epidemiology of
Missouri HOSPITAL A Diabetes
Health Care DRIVE Interventions
(1033499256) and
Complications
------------------------------------------------------------------------
Yale-New Haven 20 YORK NEW CT 06504 Epidemiology of
Hospital STREET HAVEN Diabetes
(1003142225) Interventions
and
Complications
------------------------------------------------------------------------
University Of 22 SOUTH BATLIMO MD 21201 Epidemiology of
Maryland Med GREENE RE Diabetes
Sys STREET Interventions
(1023304888) and
Complications
------------------------------------------------------------------------
University Of 22 SOUTH BATLIMO MD 21201 Epidemiology of
Maryland Med GREENE RE Diabetes
Sys STREET Interventions
(1023304888) and
Complications
------------------------------------------------------------------------
Massachusetts FRUIT BOSTON MA 02114 Phase II Study
General STREET of Clofarabine
Hospital in Patients
(1114196961) with Recurrent
or Refractory
Langerhans Cell
Histiocytosis
------------------------------------------------------------------------
Cleveland 9500 EUCLID CLEVELA OH 44195 A Randomized,
Clinic AVENUE ND Controlled,
Hospital open-labeled
(1013392125) Clinical Trial
of
Thymoglobulin
Induction and
Extended Delay
of Calcineurin
Inhibitor
Therapy for
Renal Failure
------------------------------------------------------------------------
City Of Hope 1500 E. DUARTE CA 91010 Phase II Study
National DUARTE of Clofarabine
Medical Cnt ROAD and High-Dose
(1033435292) Melphalan
Conditioning
Prior to
Allogeneic
Heamtopoietic
Cell
Transplantation
for
Myelodysplasia
------------------------------------------------------------------------
Cleveland 9500 EUCLID CLEVELA OH 44195 A Randomized,
Clinic AVENUE ND Controlled,
Hospital open-labeled
(1013392125) Clinical Trial
of
Thymoglobulin
Induction and
Extended Delay
of Calcineurin
Inhibitor
Therapy for
Renal Failure
------------------------------------------------------------------------
Charleston 501 MORRIS CHARLES WV 25326 A Phase II Trial
Area Medical STREET TON of GM-CSF
Center Inc. Protein plus
(1124248752) Ipilimumab in
Patients with
Advanced
Melanoma (ECOG
1608)
------------------------------------------------------------------------
Phoenix 1919 E. PHOENIX AZ 85016 Phase II Study
Childrens THOMAS of Clofarabine
Hospital ROAD in Patients
(1023475506) with Recurrent
or Refractory
Langerhans Cell
Histiocytosis
------------------------------------------------------------------------
Mount Sinai ONE GUSTAVE NEW NY 10029 Clinical Trial
Hospital (.) L. LEVY YORK of a Rapidly
PLACE Cycling, Non-
Cross Reactive
Regimen of
Approved
Therapeutic
Agents to Treat
Prostate Cancer
------------------------------------------------------------------------
Cleveland 9500 EUCLID CLEVELA OH 44195 A Randomized,
Clinic AVENUE ND Controlled,
Hospital open-labeled
(1013392125) Clinical Trial
of
Thymoglobulin
Induction and
Extended Delay
of Calcineurin
Inhibitor
Therapy for
Renal Failure
------------------------------------------------------------------------
Cleveland 9500 EUCLID CLEVELA OH 44195 A Randomized,
Clinic AVENUE ND Controlled,
Hospital open-labeled
(1013392125) Clinical Trial
of
Thymoglobulin
Induction and
Extended Delay
of Calcineurin
Inhibitor
Therapy for
Renal Failure
------------------------------------------------------------------------
Ohsu Hospital 3181 SAM PORTLAN OR 97239 A Phase I/II
And Clinics JACKSON D Trial of
(.) PARK ROAD Concurrent
Chemohormonal
Therapy Using
Enzalutamide
(MDV-3100) and
Cabazitaxel in
Patients with
Metastatic
Castration
------------------------------------------------------------------------
Rochester 1425 ROCHEST NY 14621 A Study
General PORTLAND ER Evaluating
Hospital AVENUE Acute Otitis
(1023105376) Media and
Nasopharyngeal
Colonization
Caused by
Streptococcus
pneumoniae in
Healthy
Children
------------------------------------------------------------------------
Rochester 1425 ROCHEST NY 14621 A Study
General PORTLAND ER Evaluating
Hospital AVENUE Acute Otitis
(1023105376) Media and
Nasopharyngeal
Colonization
Caused by
Streptococcus
pneumoniae in
Healthy
Children
------------------------------------------------------------------------
Emory 1364 ATLANTA GA 30302 Glargine U300
University CLIFTON Hospital Trial:
Hospital (.) ROAD A Randomized
Controlled
Trial Comparing
Glargine U300
and Glargine
U100 for the
Inpatient and
Post-Hospital
Discharge
------------------------------------------------------------------------
Cleveland 9500 EUCLID CLEVELA OH 44195 Investigating
Clinic AVENUE ND the efficacy of
Hospital (.) Synvisc-One
(Hylan-GF 20
6ml ) as
adjunctive
therapy for
patients with
knee osteo-
arthritis or
requiring
physical
therapy
------------------------------------------------------------------------
Massachusetts FRUIT BOSTON MA 02114 Enzyme
General STREET Replacement
Hospital Therapy and
(1114196961) Podocyte
Function
------------------------------------------------------------------------
Massachusetts FRUIT BOSTON MA 02114 KINDRED--Kidney
General STREET Information
Hospital Network for
(1114196961) Disease
Research and
Education
------------------------------------------------------------------------
Tufts Medical 800 BOSTON MA 02111 The Prevalence,
Center (.) WASHINGTON Morphology,
ST Clinical Course
and Management
of Patients
with Anderson-
Fabry Disease
Identified
Among a Large
Adult
Population
------------------------------------------------------------------------
University Of 619 SOUTH BIRMING AL 35233 Teriflunomide as
Alabama 19TH HAM a disease
Hospital (.) STREET modifying anti-
inflammatory
therapy for a
severe animal
model of
chronic
inflammatory
demyelinating
polyneuropathy
------------------------------------------------------------------------
Langley Porter 405 SAN CA 94143 A Phase I Study
Psychiatric PARNASUS FRANCI of Cabazitaxel,
Hosptial SCO Mitoxanthrone,
(1417115031) and Prednisone
(CAMP) for
Patients with
Metastatic
Castration-
Resistant
Prostate Cancer
------------------------------------------------------------------------
Brigham And 75 FRANCIS BOSTON MA 02115 Post-partum MRI
Womens STREET Changes in
Hospital Women with
(1013935550) Multiple
Sclerosis.
------------------------------------------------------------------------
University Of 1959 NE SEATTLE WA 98195 Establishing an
Washington PACIFIC ST in-vitro Model
Med Ctr (.) of Fabry
Podocytopathy
------------------------------------------------------------------------
UCI Medical 101 CITY ORANGE CA 92868 Investigating
Center (.) DRIVE Pompe
SOUTH Prevalence in
NEuromuscular
Medicine
Academic
Practices
(IPANEMA Study)
------------------------------------------------------------------------
UCI Medical 101 CITY ORANGE CA 92868 Safety and
Center (.) DRIVE Effectiveness
SOUTH of Resistance
exercise
training in
late onset
Pompe disease
patients--a
pilot study
------------------------------------------------------------------------
Emory 1364 ATLANTA GA 30302 Do the Benefits
University CLIFTON Outweigh the
Hospital (.) ROAD Risks?
Assessing
Patients'
Perceptions of
Newborn
Screening for
Lysosomal
Storage
Diseases
------------------------------------------------------------------------
USC Norris 1441 LOS CA 90033 Detection of
Cancer EASTLAKE ANGELE early end-organ
Hospital AVE S damage by
(1104096577) endothelial
dysfunction
with reactive
hyperemia-
digital
peripheral
arterial
tonometry in
patients with
Fabry Disease
------------------------------------------------------------------------
Emory 1364 ATLANTA GA 30302 A Prospective,
University CLIFTON Multicenter
Hospital (.) ROAD Study Of Fabry
Disease
Clinical and
Biochemical
Findings in
Young Pediatric
Patients (The
MOPPET Study)
------------------------------------------------------------------------
University Of 1959 NE SEATTLE WA 98195 Establishing an
Washington PACIFIC ST in-vitro Model
Med Ctr (.) of Fabry
Podocytopathy
------------------------------------------------------------------------
Cleveland 9500 EUCLID CLEVELA OH 44195 A Randomized,
Clinic AVENUE ND Controlled,
Hospital open-labeled
(1013392125) Clinical Trial
of
Thymoglobulin?
Induction and
Extended Delay
of Calcineurin
Inhibitor
Therapy for
Renal
Protection
after Liver
Transplantation
A Multi-Center
Study
------------------------------------------------------------------------
Cleveland 9500 EUCLID CLEVELA OH 44195 A Randomized,
Clinic AVENUE ND Controlled,
Hospital open-labeled
(1013392125) Clinical Trial
of
Thymoglobulin?
Induction and
Extended Delay
of Calcineurin
Inhibitor
Therapy for
Renal
Protection
after Liver
Transplantation
A Multi-Center
Study
------------------------------------------------------------------------
Cleveland 9500 EUCLID CLEVELA OH 44195 A Randomized,
Clinic AVENUE ND Controlled,
Hospital open-labeled
(1013392125) Clinical Trial
of
Thymoglobulin?
Induction and
Extended Delay
of Calcineurin
Inhibitor
Therapy for
Renal
Protection
after Liver
Transplantation
A Multi-Center
Study
------------------------------------------------------------------------
Cleveland 9500 EUCLID CLEVELA OH 44195 A Randomized,
Clinic AVENUE ND Controlled,
Hospital open-labeled
(1013392125) Clinical Trial
of
Thymoglobulin?
Induction and
Extended Delay
of Calcineurin
Inhibitor
Therapy for
Renal
Protection
after Liver
Transplantation
A Multi-Center
Study
------------------------------------------------------------------------
OHSU Hospital 3181 SAM PORTLAN OR 97239 A Phase I/II
and Clinics JACKSON D Trial of
(1053454645) PARK ROAD Concurrent
Chemohormonal
Therapy Using
Enzalutamide
(MDV-3100) and
Cabazitaxel in
Patients with
Metastatic
Castration
Resistant
Prostate Cancer
------------------------------------------------------------------------
OHSU Hospital 3181 SAM PORTLAN OR 97239 A Phase I/II
and Clinics JACKSON D Trial of
(1053454645) PARK ROAD Concurrent
Chemohormonal
Therapy Using
Enzalutamide
(MDV-3100) and
Cabazitaxel in
Patients with
Metastatic
Castration
Resistant
Prostate Cancer
------------------------------------------------------------------------
OHSU Hospital 3181 SAM PORTLAN OR 97239 A Phase I/II
and Clinics JACKSON D Trial of
(1053454645) PARK ROAD Concurrent
Chemohormonal
Therapy Using
Enzalutamide
(MDV-3100) and
Cabazitaxel in
Patients with
Metastatic
Castration
Resistant
Prostate Cancer
------------------------------------------------------------------------
Mount Sinai FIRST NEW NY 10003 Gaucher
Beth Israel AVENUE AT YORK Generation--Cog
(1003052200) 16 STREET nition, Motor
Control,
Imaging and
Pathologic
Biomarkers in
GBA1 Mutation
Carriers
------------------------------------------------------------------------
University Of 1959 NE SEATTLE WA 98195 Fluctuation
Washington PACIFIC ST Reduction with
Med Ctr (.) Insulin and
GLP--1 Added
Together (FLAT-
SUGAR)
------------------------------------------------------------------------
University Of 1959 NE SEATTLE WA 98195 Fluctuation
Washington PACIFIC ST Reduction with
Med Ctr (.) Insulin and GLP-
1 Added
Together (FLAT-
SUGAR)
------------------------------------------------------------------------
Brigham And 75 FRANCIS BOSTON MA 02115 miRNA profiling
Womens STREET in
Hospital Teriflunomide
(1013935550) (Aubagio)
treated
patients
------------------------------------------------------------------------
Massachusetts FRUIT BOSTON MA 02114 Factors
General STREET influencing
Hospital patient
(1114196961) preferences for
oral versus
intravenous
(IV) enzyme
replacement
medication.
------------------------------------------------------------------------
University Of 1959 NE SEATTLE WA 98195 Localization of
Washington PACIFIC ST Globotriaosylce
Med Ctr (.) ramide (GL3)
Inclusions in
Fabry Podocytes
------------------------------------------------------------------------
Emory 1364 ATLANTA GA 30302 Online Social
University CLIFTON Networking Use
Hospital (.) ROAD Among
Individuals
Affected with
Lysosomal
Storage
Diseases:
``Friend'' or
Foe?
------------------------------------------------------------------------
University Of 619 SOUTH BIRMING AL 35233 Comparative
Alabama 19TH HAM Proteomics and
Hospital (.) STREET Lipidomics of
Exosomes
Isolated from
Serum and Urine
in Fabry
Disease
------------------------------------------------------------------------
Emory 1364 ATLANTA GA 30302 Glargine U300
University CLIFTON Hospital Trial:
Hospital (.) ROAD A Randomized
Controlled
Trial Comparing
Glargine U300
and Glargine
U100 for the
Inpatient and
Post-Hospital
Discharge
Management of
Medicine and
Surgery
Patients with
Type 2 Diabetes
------------------------------------------------------------------------
UC Davis 2315 SACRAME CA 95817 A Selective
Medical STOCKTON NTO Frontline
Center (.) BLVD Jevtana
Therapeutic
Pathway for
Castration-
Resistant
Prostate Cancer
with Integrated
Biomarkers
------------------------------------------------------------------------
Cleveland 9500 EUCLID CLEVELA OH 44195 A Study of
Clinic AVENUE ND Hematopoietic
Hospital Stem Cell
(1013392125) Supermobilizati
on in Patients
with Lymphoma
------------------------------------------------------------------------
UH Cleveland 11100 CLEVELA OH 44106 Epidemiology of
Medical EUCLID ND Diabetes
Center AVENUE Interventions
(1013954395) and
Complications
------------------------------------------------------------------------
UH Cleveland 11100 CLEVELA OH 44106 Epidemiology of
Medical EUCLID ND Diabetes
Center AVENUE Interventions
(1013954395) and
Complications
------------------------------------------------------------------------
UH Cleveland 11100 CLEVELA OH 44106 Epidemiology of
Medical EUCLID ND Diabetes
Center AVENUE Interventions
(1013954395) and
Complications
------------------------------------------------------------------------
Univ Of ONE COLUMBI MO 65212 Epidemiology of
Missouri HOSPITAL A Diabetes
Health Care DRIVE Interventions
(1033499256) and
Complications
------------------------------------------------------------------------
Univ Of ONE COLUMBI MO 65212 Epidemiology of
Missouri HOSPITAL A Diabetes
Health Care DRIVE Interventions
(1033499256) and
Complications
------------------------------------------------------------------------
Yale-New Haven 20 YORK NEW CT 06504 Epidemiology of
Hospital STREET HAVEN Diabetes
(1003142225) Interventions
and
Complications
------------------------------------------------------------------------
University Of 22 SOUTH BATLIMO MD 21201 Epidemiology of
Maryland Med GREENE RE Diabetes
Sys STREET Interventions
(1023304888) and
Complications
------------------------------------------------------------------------
University Of 22 SOUTH BATLIMO MD 21201 Epidemiology of
Maryland Med GREENE RE Diabetes
Sys STREET Interventions
(1023304888) and
Complications
------------------------------------------------------------------------
University Of 22 SOUTH BATLIMO MD 21201 Epidemiology of
Maryland Med GREENE RE Diabetes
Sys STREET Interventions
(1023304888) and
Complications
------------------------------------------------------------------------
UT MD Anderson 1515 HOUSTON TX 77030 A Dynamic
Cancer Center HOLCOMBE Allocation
(1053755272) BLVD Modular
Sequential
Trial of
Approved and
Promising
Therapies in
Men with
Metastatic
Castration-
Resistant
Prostate Cancer
------------------------------------------------------------------------
OHSU Hospital 3181 SAM PORTLAN OR 97239 A Phase I/II
And Clinics JACKSON D Trial of
(1033650353) PARK ROAD Concurrent
Chemohormonal
Therapy Using
Enzalutamide
(MDV-3100) and
Cabazitaxel in
Patients with
Metastatic
Castration
------------------------------------------------------------------------
UT MD Anderson 1515 HOUSTON TX 77030 A Dynamic
Cancer Center HOLCOMBE Allocation
(1053755272) BLVD Modular
Sequential
Trial of
Approved And
Promising
Therapies in
Men with
Metastatic
Castration-
Resistant
Prostate Cancer
------------------------------------------------------------------------
Charleston 501 MORRIS CHARLES WV 25326 A Phase II Trial
Area Medical STREET TON of GM-CSF
Center Inc. Protein plus
(1124248752) Ipilimumab in
Patients with
Advanced
Melanoma (ECOG
1608)
------------------------------------------------------------------------
UT MD Anderson 1515 HOUSTON TX 77030 A Dynamic
Cancer Center HOLCOMBE Allocation
(1053755272) BLVD Modular
Sequential
Trial of
Approved And
Promising
Therapies in
Men with
Metastatic
Castration-
Resistant
Prostate Cancer
------------------------------------------------------------------------
OHSU Hospital 3181 SAM PORTLAN OR 97239 A Phase I/II
And Clinics JACKSON D Trial of
(1033650353) PARK ROAD Concurrent
Chemohormonal
Therapy Using
Enzalutamide
(MDV-3100) and
Cabazitaxel in
Patients with
Metastatic
Castration-
Resistant
Prostate Cancer
------------------------------------------------------------------------
Univ Of ONE COLUMBI MO 65212 Epidemiology of
Missouri HOSPITAL A Diabetes
Health Care DRIVE Interventions
(1033499256) and
Complications
------------------------------------------------------------------------
Yale-New Haven 20 YORK NEW CT 06504 Epidemiology of
Hospital STREET HAVEN Diabetes
(1003142225) Interventions
and
Complications
------------------------------------------------------------------------
UH Cleveland 11100 CLEVELA OH 44106 Epidemiology of
Medical EUCLID ND Diabetes
Center AVENUE Interventions
(1013954395) and
Complications
------------------------------------------------------------------------
University Of 22 SOUTH BATLIMO MD 21201 Epidemiology of
Maryland Med GREENE RE Diabetes
Sys STREET Interventions
(1023304888) and
Complications
------------------------------------------------------------------------
OHSU Hospital 3181 SAM PORTLAN OR 97239 A Phase I/II
And Clinics JACKSON D Trial of
(1033650353) PARK ROAD Concurrent
Chemohormonal
Therapy Using
Enzalutamide
(MDV-3100) and
Cabazitaxel in
Patients with
Metastatic
Castration-
Resistant
Prostate Cancer
------------------------------------------------------------------------
Texas 6621 FANNIN HOUSTON TX 77030 Phase II Study
Childrens of Clofarabine
Hospital in Patients
(1013283159) with Recurrent
or Refractory
Langerhans Cell
Histiocytosis
------------------------------------------------------------------------
Massachusetts FRUIT BOSTON MA 02114 Phase II Study
General STREET of Clofarabine
Hospital in Patients
(1114196961) with Recurrent
or Refractory
Langerhans Cell
Histiocytosis
------------------------------------------------------------------------
Texas 6621 FANNIN HOUSTON TX 77030 Phase II Study
Childrens of Clofarabine
Hospital in Patients
(1013283159) with Recurrent
or Refractory
Langerhans Cell
Histiocytosis
------------------------------------------------------------------------
Childrens 4650 SUNSET LOS CA 90027 Phase II Study
Hospital Los BOULEVARD ANGELE of Clofarabine
Angeles S in Patients
(1003102781) with Recurrent
or Refractory
Langerhans Cell
Histiocytosis
------------------------------------------------------------------------
UT MD Anderson 1515 HOUSTON TX 77030 A Dynamic
Cancer Center HOLCOMBE Allocation
(1053755272) BLVD Modular
Sequential
Trial of
Approved and
Promising
Therapies in
Men with
Metastatic
Castration-
Resistant
Prostate Cancer
------------------------------------------------------------------------
OHSU Hospital 3181 SAM PORTLAN OR 97239 A Phase I/II
And Clinics JACKSON D Trial of
(1033650353) PARK ROAD Concurrent
Chemohormonal
Therapy Using
Enzalutamide
(MDV-3100) and
Cabazitaxel in
Patients with
Metastatic
Castration-
Resistant
Prostate Cancer
------------------------------------------------------------------------
UT MD Anderson 1515 HOUSTON TX 77030 A Dynamic
Cancer Center HOLCOMBE Allocation
(1053755272) BLVD Modular
Sequential
Trial of
Approved and
Promising
Therapies in
Men with
Metastatic
Castration-
Resistant
Prostate Cancer
------------------------------------------------------------------------
Texas 6621 FANNIN HOUSTON TX 77030 Phase II Study
Childrens of Clofarabine
Hospital in Patients
(1013283159) with Recurrent
or Refractory
Langerhans Cell
Histiocytosis
------------------------------------------------------------------------
OHSU Hospital 3181 SAM PORTLAN OR 97239 A Phase I/II
And Clinics JACKSON D Trial of
(1033650353) PARK ROAD Concurrent
Chemohormonal
Therapy Using
Enzalutamide
(MDV-3100) and
Cabazitaxel in
Patients with
Metastatic
Castration-
Resistant
Prostate Cancer
------------------------------------------------------------------------
UT MD Anderson 1515 HOUSTON TX 77030 IST-1L-
Cancer Center HOLCOMBE Smoldering
(1053755272) BLVD myeloma-PT-IV
------------------------------------------------------------------------
UT MD Anderson 1515 HOUSTON TX 77030 SAR650984--Anti-
Cancer Center HOLCOMBE CD38 naked mAb--
(1053755272) BLVD isatuximab
------------------------------------------------------------------------
UT MD Anderson 1515 HOUSTON TX 77030 IST-1L-
Cancer Center HOLCOMBE Smoldering
(1053755272) BLVD myeloma-PT-IV
------------------------------------------------------------------------
UT MD Anderson 1515 HOUSTON TX 77030 IST-1L-
Cancer Center HOLCOMBE Smoldering
(1053755272) BLVD myeloma-PT-IV
------------------------------------------------------------------------
Rochester 1425 ROCHEST NY 14617 A Study
General PORTLAND ER Evaluating
Hospital AVENUE Acute Otitis
(1023105376) Media and
Nasopharyngeal
Colonization
Caused by
Streptococcus
pneumoniae in
Healthy
Children
------------------------------------------------------------------------
KFH-Hawaii 3288 HONOLUL HI 96819 Efficacy of
(1306928254) MOANALUA U Flublok study
ROAD
------------------------------------------------------------------------
KFH-Hawaii 3288 HONOLUL HI 96819 Vaccine
(1306928254) MOANALUA U effectiveness
ROAD of Flublok 18-
64
------------------------------------------------------------------------
University of 855 WEST CHARLOT VA 22908 IRB-HSR#14386
Virginia MAIN TESVIL
Medical Cente STREET L
(.)
------------------------------------------------------------------------
Tufts Medical 800 BOSTON MA 02111 The Prevalence,
Center WASHINGTON Morphology,
(1114162013) ST Clinical Course
and Management
of Patients
with Anderson-
Fabry Disease
Identified
Among a Large
Adult
Population
------------------------------------------------------------------------
Massachusetts FRUIT BOSTON MA 02114 Characterization
General STREET and analysis of
Hospital pathophysiology
(1114196961) of the
gastrointestina
l complications
of Fabry
disease.
------------------------------------------------------------------------
Cleveland 9500 EUCLID CLEVELA OH 44195 Biomarkers of
Clinic AVENUE ND Disease
Hospital Heterogeneity
(1013392125) in Multiple
Sclerosis:
Phase II
------------------------------------------------------------------------
UCI Medical 101 THE SOUTH CA 92868 Investigating
Center (.) CITY DRIVE ORANGE Pompe
Prevalence in
NEuromuscular
Medicine
Academic
Practices
(IPANEMA Study)
------------------------------------------------------------------------
Cleveland 9500 EUCLID CLEVELA OH 44195 A Randomized,
Clinic AVENUE ND Controlled,
Hospital open-labeled
(1013392125) Clinical Trial
of
Thymoglobulin?
Induction and
Extended Delay
of Calcineurin
Inhibitor
Therapy for
Renal Failure
------------------------------------------------------------------------
Cleveland 9500 EUCLID CLEVELA OH 44195 A Randomized,
Clinic AVENUE ND Controlled,
Hospital open-labeled
(1013392125) Clinical Trial
of
Thymoglobulin?
Induction and
Extended Delay
of Calcineurin
Inhibitor
Therapy for
Renal Failure
------------------------------------------------------------------------
Cleveland 9500 EUCLID CLEVELA OH 44195 A Randomized,
Clinic AVENUE ND Controlled,
Hospital open-labeled
(1013392125) Clinical Trial
of
Thymoglobulin?
Induction and
Extended Delay
of Calcineurin
Inhibitor
Therapy for
Renal Failure
------------------------------------------------------------------------
OHSU Hospital 3181 SAM PORTLAN OR 97239 A Phase I/II
And Clinics JACKSON D Trial of
(1033650353) PARK ROAD Concurrent
Chemohormonal
Therapy Using
Enzalutamide
(MDV-3100) and
Cabazitaxel in
Patients with
Metastatic
Castration-
Resistant
Prostate Cancer
------------------------------------------------------------------------
Mount Sinai 1ST AVENUE@ NEW NY 10003 Gaucher
Beth Israel 16TH YORK Generation--Cog
(1003052200) STREET nition, Motor
Control,
Imaging and
Pathologic
Biomarkers in
GBA1 Mutation
Carriers
------------------------------------------------------------------------
Mount Sinai 1ST AVENUE@ NEW NY 10003 Gaucher
Beth Israel 16TH YORK Generation--Cog
(1003052200) STREET nition, Motor
Control,
Imaging and
Pathologic
Biomarkers in
GBA1 Mutation
Carriers
------------------------------------------------------------------------
Emory 1364 ATLANTA GA 30302 Newborn
University CLIFTON Screening XLSD
Hospital (.) ROAD Pilot Study
------------------------------------------------------------------------
University of 619 SOUTH BIRMING AL 35233 Comparative
Alabama 19TH HAM Proteomics and
Hospital (.) STREET Lipidomics of
Exosomes
Isolated from
Serum and Urine
in Fabry
Disease
------------------------------------------------------------------------
UT MD Anderson 1515 HOUSTON TX 77030 Interest of CT
Cancer Center HOLCOMBE Morphological
(1053755272) BLVD Evaluation in
Patients with
Metastatic
Colorectal
Cancer Treated
with ZIV-
Aflibercept
------------------------------------------------------------------------
Brigham And 75 FRANCIS BOSTON MA 02115 New England
Womens STREET Multiple
Hospital Sclerosis
(1013935550) Pregnancy
Registry (PREG-
MS)
------------------------------------------------------------------------
Brigham and 75 FRANCIS BOSTON MA 02115 New England
Womens STREET Multiple
Hospital Sclerosis
(1013935550) Pregnancy
Registry (PREG-
MS)
------------------------------------------------------------------------
Brigham And 75 FRANCIS BOSTON MA 02115 New England
Womens STREET Multiple
Hospital Sclerosis
(1013935550) Pregnancy
Registry (PREG-
MS)
------------------------------------------------------------------------
Univ Of Mi 2301 ANN MI 48105 Regulatory B
Hospitals & COMMONWEAL ARBOR Lymphocytes as
Hlth Ctrs TH BLVD Central
(1043488760) Mediators of
the Therapeutic
Effects of
Teriflunomide
in MS
------------------------------------------------------------------------
Univ Of Mi 2301 ANN MI 48105 Regulatory B
Hospitals & COMMONWEAL ARBOR Lymphocytes as
Hlth Ctrs TH BLVD Central
(1043488760) Mediators of
the Therapeutic
Effects of
Teriflunomide
in MS
------------------------------------------------------------------------
OHSU Hospital 3181 SAM PORTLAN OR 97239 Bright tongue
and Clinics JACKSON D sign in Pompe
(1033650353) PARK ROAD disease:
sensitivity and
specificity
------------------------------------------------------------------------
OHSU Hospital 3181 SAM PORTLAN OR 97239 Bright tongue
And Clinics JACKSON D sign in Pompe
(1033650353) PARK ROAD disease:
sensitivity and
specificity
------------------------------------------------------------------------
Brigham And 75 FRANCIS BOSTON MA 02115 miRNA profiling
Womens STREET in
Hospital Teriflunomide
(1013935550) (Aubagio)
treated
patients
------------------------------------------------------------------------
Massachusetts FRUIT BOSTON MA 02114 Enzyme
General STREET Replacement
Hospital Therapy and
(1114196961) Podocyte
Function
------------------------------------------------------------------------
Massachusetts FRUIT BOSTON MA 02114 KINDRED--Kidney
General STREET Information
Hospital Network for
(1114196961) Disease
Research and
Education
------------------------------------------------------------------------
Emory 1364 ATLANTA GA 30302 ThinkGenetic
University CLIFTON LSD: A project
Hospital (.) ROAD to identify
educational
gaps in the
informational
needs of
individuals
with Pompe,
Fabry, Gaucher,
Mucopolysacchar
ide Diseases
------------------------------------------------------------------------
Cedars-Sinai 8700 LOS CA 90048 A Pilot
Medical BEVERLY ANGELE Randomized
Center (.) BLVD. S Study to Assess
the Effect and
Safety Profile
of
Thymoglobulin?
in Primary
Cardiac
Transplant
Recipients: A
12-month,
single center
study
------------------------------------------------------------------------
Massachusetts FRUIT BOSTON MA 02114 Characterization
General STREET and analysis of
Hospital pathophysiology
(1114196961) of the
gastrointestina
l complications
of Fabry
disease.
------------------------------------------------------------------------
University Of 619 SOUTH BIRMING AL 35233 Teriflunomide as
Alabama 19TH HAM a disease
Hospital (.) STREET modifying anti-
inflammatory
therapy for a
severe animal
model of
chronic
inflammatory
demyelinating
polyneuropathy
------------------------------------------------------------------------
USC Norris 1441 LOS CA 90033 Assessing the
Cancer EASTLAKE ANGELE induction of
Hospital AVE S long-term
(1104096577) immune
regulation
following
treatment with
Lemtrada?
(Alemtuzumab).
------------------------------------------------------------------------
USC Norris 1441 LOS CA 90033 Assessing the
Cancer EASTLAKE ANGELE induction of
Hospital AVE S long-term
(1104096577) immune
regulation
following
treatment with
Lemtrada?
(Alemtuzumab).
------------------------------------------------------------------------
Emory 1364 ATLANTA GA 30302 Functional
University CLIFTON Resolution of
Hospital (.) ROAD Multi-loci
Pathogenic
Variants and
VUSs in Pompe
Disease
------------------------------------------------------------------------
Prepared Statement of Giovanni Caforio, M.D., Chairman of the Board and
Chief Executive Officer, Bristol-Myers Squibb Company
Chairman Grassley, Ranking Member Wyden, and members of the
committee, thank you for the opportunity to be here today on behalf of
the 24,000 employees at Bristol-Myers Squibb, who are working every day
to improve the lives of patients with serious diseases. I look forward
to working together to align incentives to ensure all Americans have
access to the medicines they need.
I am a physician who joined the biopharmaceutical industry 30 years
ago because of the impact companies like Bristol-Myers Squibb--and the
others represented here today--have on patients with serious diseases.
We should all be proud that American companies lead our industry.
Bristol-Myers Squibb researchers have contributed to the
development of medicines that have reduced mortality from
cardiovascular disease, helped transform HIV/AIDS into a chronic
disease, and are now making significant progress in the treatment of
cancer.
Just 10 years ago, the idea of harnessing the immune system to
treat cancer was viewed with great skepticism. But Bristol-Myers Squibb
researchers saw the promise of the approach and ignited an era of
scientific innovation that has changed survival expectations in
multiple tumor types.
Prior to the availability of Immuno-Oncology treatments, only 25
percent of patients diagnosed with metastatic melanoma survived 1 year.
Today, thanks to Immuno-Oncology therapies, this has increased to 74
percent.
The potential of this approach has also been seen in lung cancer,
kidney cancer, and many other difficult-to-treat tumors. Patients with
these diseases now have a chance for quality, long-term survival.
But not all patients respond to current immunotherapies, so we must
do more. We recently opened a new discovery facility dedicated to
investigating Immuno-
Oncology resistance, and we continuously seek external innovation to
augment our pipeline across multiple therapeutic areas. In this
context, we recently announced our plan to acquire Celgene, a natural
next step for our company. Our goal is to bring together the drive and
dedication of two science-driven organizations to do even more for
patients.
As a physician, I recognize that medicines are only helpful if
patients and health-care systems can afford them. We share the
committee's concern with escalating health-care costs and believe that
our responsibility to patients extends to ensuring they can access and
afford our medicines.
The average net pricing across our U.S. portfolio of medicines
increased by 5 percent or less per year during the last 5 years. In
2018, it did not increase and we anticipate the same in 2019.
Despite this fact, we recognize that patients' out-of-pocket costs
continue to increase. We believe it is possible to work together to
realign incentives to ensure patients can afford medicines without
stifling scientific innovation.
So what are the solutions?
We are supportive of the proposed rule aimed at reforming
the rebate system with a focus on what is best for patients.
We need to ensure more generics are available whenever
permissible under our system, and applaud Congress and the
administration's success with speeding the approval of
generics.
We support value-based purchasing arrangements that tie
payments to value. These models can reduce costs, improve
access and adherence, and contribute to better outcomes. We
applaud efforts by Health and Human Services and the Committee
to remove regulatory barriers and facilitate greater use of
these arrangements.
We do not believe the U.S. should adopt policies that stifle
innovation in other countries, which could reduce a patient's access to
new medicines. Outside of the U.S., reimbursement of new medicines can
often take more than two years. Our Opdivo and Yervoy regimen was first
approved in September 2015 to treat metastatic melanoma in the U.S.
Today, six of the 16 countries included in the International Price
Index proposal do not provide access to this combination, which is now
considered the standard of care for this cancer.
This exemplifies why Bristol-Myers Squibb does not support HHS's
proposed International Price Index Model for Medicare Part B drugs.
I would like to leave you with a few thoughts.
We are witnessing a historic era in biomedical innovation. But we
must ensure patients have affordable access to these innovations.
We recognize the need for change, and we are committed to working
with Congress to ensure every patient can benefit from today's medical
innovations.
American research-based companies are leading the next wave of
biomedical innovation to help patients whose diseases cannot be
adequately treated with today's medicines. We should work to ensure
policies that support and reward these investments.
On behalf of my colleagues at Bristol-Myers Squibb, and the
patients we serve, my sincere thanks for your time and attention today.
I look forward to working together to implement real change that
broadens access to innovative medicines for patients.
______
Questions Submitted for the Record to Giovanni Caforio, M.D.
Questions Submitted by Hon. Chuck Grassley
Question. At the hearing, you testified that Bristol-Myers Squibb
does not withhold samples from generic manufacturers in order to block
generic versions of your drug from entering the market. You also
expressed your support for the ``Creating and Restoring Equal Access to
Equivalent Samples Act,'' also known as the CREATES Act.
As you know, the FDA has a list on its website which identifies
reference listed drug (RLD) access inquiries where brand manufacturers
may have prevented generic companies from obtaining samples of products
necessary to support FDA approval. Celgene is on this FDA list.
According to your testimony, Bristol-Myers Squibb is in the process of
acquiring Celgene.
Are you aware that Celgene is on the FDA list and that Celgene had
multiple access inquiries?
Answer. Yes.
Question. Will you ensure that Bristol-Myers Squibb/Celgene will
not block access to samples once the Celgene acquisition is final?
Answer. As Dr. Caforio testified at the hearing, BMS does not
withhold samples from generic manufacturers in order to block generic
versions of the drug from entering the market. BMS believes it is
important to ensure generics are made available whenever that is
permissible under our system, and supports the administration's focus
on increasing the approval of generics. As part of that system, it is
important that generic companies perform the needed testing to ensure
product quality and patient safety. BMS cannot comment on Celgene's
practices in this area, but once the transaction closes, BMS's
practices with regard to generic samples will govern the combined
portfolio.
Question. The Department of Health and Human Services' proposed
rule, ``Fraud and Abuse; Removal of Safe Harbor Protection for Rebates
Involving Prescription Pharmaceuticals and Creation of New Safe Harbor
Protection for Certain Point-of-Sale Reductions in Price on
Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager
Service Fees,'' envisions that drug manufacturers will offer up-front
discounts rather than the back-end rebates that are now commonly
provided. Some observers argue that a 1996 court case called into
question whether manufacturers could offer up-front discounts,
resulting in today's rebate-based system. I've heard differing opinions
as to whether the issues related to the initial court case are still
relevant. If the HHS proposed rule is finalized, can you assure the
committee that your company will offer up-front discounts? If not, why?
Answer. BMS supports the HHS proposed rule to eliminate safe harbor
protection for back-end rebates under Medicare Part D and the rule's
objective to ensure that patients benefit from price reductions that
BMS provides on its drugs. As the proposed rule notes, there is
uncertainty as to the strategic behavior changes that will occur if the
rule is enacted, and therefore uncertainty as to precise mechanisms
that will be available to meet the objectives of the rule. However,
there is some risk that manufacturers would have to defend themselves
against antitrust litigation if they were to offer up-front discounts
instead of rebates if the proposed rule were finalized. In particular,
there may be risk of claims being crafted under the Robinson-Patman
Act, 15 U.S.C. Sec. 13. Any such claims would have to meet significant
substantive requirements and be subject to important statutory
defenses. Nonetheless, even if meritless, Robinson-Patman claims can be
expensive and time consuming for manufacturers to defend against.
In light of the potential for antitrust litigation, BMS recommends
that the committee consider how best to address this risk as it
considers the HHS proposal. Congress, could, for example, enact
legislation that immunizes from liability under the Robinson-Patman Act
drug manufacturers who offer up-front discounting under Medicare Part D
in accordance with the fraud and abuse safe harbor created by the HHS
rule.
Question. Please describe how you expect your company to respond to
the HHS proposed rule to eliminate safe harbor protection for back-end
rebates in Medicare Part D that is referenced above if it is finalized.
Assuming you are confident that antitrust laws do not prevent your
company from offering up-front discounts, specifically, do you envision
that your company lowers the list price of a drug to the current after-
rebate net price, offer discounts equal to the current rebate amount,
or a combination of both?
Answer. BMS supports the HHS proposed rule to eliminate safe harbor
protection for back-end rebates in Medicare Part D, and we believe it
would lead to lower out-of-pocket costs. This question rightly supposes
that the goals of the proposed rule could be achieved through lower
list prices, negotiated discounts at the point-of-sale, or some
combination of these two approaches. While it is unclear how Part D
plans and PBMs will react to the proposed rule, at this time, BMS
envisions that we would offer point-of-sale discounts to Part D plans
equivalent on average to the current contracted rebate amount and will
continue to assess the possibility of lowering list price on a product-
by-product basis. Our ability to lower list prices, however, is
constrained by the fact that the HHS proposed rule does not apply to
the commercial insurance market, where we anticipate back-end rebates
to continue for the foreseeable future.
Please also see the answer to the previous question.
Question. To what extent are the back-end rebates your company
currently offers contingent on the amount of market share realized for
your drugs as a result of Part D plan formulary placement and other
techniques?
Answer. The back-end rebates BMS currently offers pursuant to its
Medicare Part D agreements are not contingent on the amount of market
share realized for any of BMS's drugs as a result of Part D plan
formulary placement or any other performance requirement.
Question. Please provide a breakdown of percentage of sales that go
to each payer (including Medicare, Medicaid, private pay, other) and a
similar percentage by volume of the total number of each drug compared
to total volume. Please provide this data for the most recent year
available.
Answer. This information is not available publicly and is
competitively sensitive.
Question. Do your companies hire consultants or lobbyists to
promote products at State Medicaid Pharmacy and Therapeutics
Committees? To whom do you disclose advocacy activities surrounding
State Medicaid programs, if at all?
Answer. BMS does not hire consultants or lobbyists to promote its
products at State Medicaid P&T Committees. BMS complies with the
applicable lobbying laws across all 50 States, Puerto Rico, and the
District of Columbia. Many States require engagement with its Medicaid
officials to be reported. We disclose required lobbying activities to
each State in accordance with the individual State lobbying disclosure
and ethics laws.
Question. Please describe how the costs of patient assistance
programs are accounted for within your company's financial statements.
Please also describe the types of market information, such as
prescribing and use patterns that your company collects from different
types of patient assistance programs and patient hub services.
Answer. For purposes of responding to this request, BMS interprets
``patient assistance programs'' and ``patient hub services'' as BMS
programs or services supporting education, access and/or treatment
adherence for eligible patients who are prescribed a BMS medicine.
Costs associated with these programs are accounted for in our financial
statements as marketing, selling and administrative expenses or gross-
to-net sales adjustments, depending on the type of assistance offered.
Data captured through the administration of patient support
programs allows our program administrators to validate information
provided directly from patients and providers in support of the
specific program(s) for which assistance is being requested. This data
capture includes, but may not be limited to: (1) information that
supports determination of patient eligibility; (2) validation of
licensed provider/prescriber; (3) prescription related information
necessary to execute patient assistance available through program(s)
(i.e., dosage and units being prescribed/dispensed); and, (4) insurance
information.
Question. Please provide a list of all contributions since January
1, 2014, that your company has made to any tax exempt organizations
working on issues related to drugs within your product lines, including
but not limited to patient groups, disease awareness groups, medical or
professional societies, universities or hospitals, industry
associations or leagues. For each contribution, please provide the name
of the organization that received the donation, the date the donation
was made, the amount of the donation, and a description of the purpose
of the contribution (i.e., was the contribution for the general fund, a
specific purpose to a specific program, or continuing medical
education). Please also note whether the contribution was unrestricted
or restricted; if it was restricted, please explain all restrictions.
Finally, if your company maintains a foundation or other separate
charitable arm, please provide the name of all such entities, and list
all donations made from that entity or entities.
Answer. BMS refers the committee to the Corporate Giving page on
the BMS website (https://www.bms.com/about-us/responsibility/corporate-
giving.html). This page includes comprehensive information about BMS'
Corporate Giving policies and practices. It also includes comprehensive
lists of IME Grants, Charitable Donations and Corporate Giving for
calendar years 2016, 2017 and 2018. These grants are made for a variety
of appropriate purposes, not limited to issues related to drugs within
the BMS product line.
BMS supports the BMS Patient Assistance Foundation (BMSPAF), a non-
profit organization that helps patients in the United States who need
temporary help obtaining various BMS medications. In 2018, BMS donated
over $1 billion worth of BMS medicines to the BMSPAF, and the BMSPAF
provided free medicine to more than 75,000 patients.
BMS also supports the Bristol-Myers Squibb Foundation, a non-profit
organization that promotes health equity and seeks to improve the
health outcomes of populations disproportionately affected by serious
diseases by strengthening health-care worker capacity, integrating
medical care and community based support services, and mobilizing
communities to fight against disease. BMS views the activities of the
BMS Foundation as outside the scope of this question.
Question. Pay for delay agreements cost consumers and taxpayers
billions in higher drug costs every year. The FTC has gone after drug
companies that enter into these settlements where the brand pays the
generic company to keep its lower cost alternative off the market. I'm
the lead Republican sponsor of S. 64, the ``Preserve Access to
Affordable Generics and Biosimilars Act,'' which would help put an end
to these deals.
Do you agree that these pay-off agreements keep drug costs high for
patients because they delay competition?
Answer. BMS agrees that patent settlement agreements that have
substantial payments going from innovators to generics, and are solely
intended to delay competition, are anticompetitive.
Question. Has your company ever entered into these kinds of
settlements with a generic company?
Answer. BMS has not entered into patent settlements that have
substantial payments going from innovator to generics and are solely
intended to delay competition.
Question. Do you support the pay for delay bill?
Answer. In general, the ability to settle patent litigation, like
any litigation, reflects a balancing of considerations by the involved
parties and often leads to earlier generic entry than patent
expiration. The current system provides the government with the ability
to monitor and review these settlements, and has worked well.
With regard to S. 64, BMS supports the goals of the legislation but
has objections to the legislation as currently drafted. For example,
the legislation should be revised: (1) only to apply prospectively and
not retroactively to agreements already entered into; (2) eliminate the
presumption that all settlements are presumptively anticompetitive; (3)
eliminate restrictions on the arguments companies would be permitted to
advance to defend agreements; and (4) include ``exclusions'' for
certain types of agreements, such as those containing exclusive
licenses, to name a few. BMS would be happy to follow up and provide
further details to the committee.
rebate traps/walls
Question. I'm increasingly concerned about the effect of so-called
``rebate traps'' or ``rebate walls'' on patients' access to quality,
lower cost medicine. I understand there is ongoing litigation
challenging these practices as anti-competitive.
Does your company engage in the bundling of rebates over multiple
products? If so, why? And what benefit does the consumer gain from
that?
Answer. BMS does not have any Medicare Part D or any other payer
contracts with bundling of rebates.
Question. Does your company view these practices as anticompetitive
or harmful to patients' access to quality, lower cost medicine?
Answer. BMS believes that clinical treatment decisions should be
made by physicians in consultation with patients. As noted, BMS does
not have bundled payer agreements and without insight to the specific
terms of other manufacturers' bundling agreements, it is difficult to
assess the impact on patient access and healthcare costs. BMS does not
support agreements that create barriers to patients' access to quality,
lower cost medicines.
Question. If a policy were adopted to eliminate rebates, or to
require that rebate savings be passed on to the consumer, would that in
and of itself solve the issue of rebate ``traps'' and ``walls''? And
would consumers benefit from such a policy?
Answer. BMS believes that requiring PBMs and payers to pass
manufacturer rebates on to patients has the potential to lower patient
out-of-pocket costs, and therefore benefit consumers. However, it is
unclear how payers will adjust their benefit plan designs in response
to this change and whether it would completely solve the issue of
rebate ``traps'' and ``walls.'' It is possible, for example, that in
response to such changes, PBM and payer business models might evolve,
and thus we recommend implementing safeguards to protect consumers'
access to medicines.
drug pricing
Question. When setting the list price of a drug, does your company
consider regulatory costs or compliance? If so, how specifically do
those factors affect the list price of a drug? Please provide at least
one specific example, if applicable, from your current product
portfolio.
Answer. BMS does not consider these costs in setting list price.
Question. When setting the list price of a drug, does your company
consider the risk of liability or litigation? If so, how specifically
do those factors affect the list price of a drug? Please provide at
least one specific example, if applicable, from your current product
portfolio.
Answer. BMS does not consider the risk of liability or litigation
in setting list price.
______
Questions Submitted by Hon. Pat Roberts
Question. What role do you see Value Based Arrangements (VBAs)
playing in the effort to reduce prescription drug costs? What potential
do these arrangements have to find the ``sweet spot'' between
controlling costs to patients and encouraging innovation of new drugs?
Answer. Manufacturers and payers have been participating in Value
Based Agreements (VBAs) with increasing frequency. These agreements can
potentially reduce overall health-care costs by reducing costs for
medicines, and importantly, improving outcomes for patients and
reducing overall health-care costs. Although there are many types of
VBAs, and the goals and impact of these arrangements differ by specific
medicines and therapeutic areas, we believe that as the sophistication
of these payer and manufacturer arrangements increase, and the capture,
integrity and timeliness of health-care data improves, these agreements
will evolve to the ``sweet spot'' between controlling costs and
encouraging the innovation of new medicines.
Question. How can VBAs help lower what patients pay out-of-pocket?
Answer. VBAs may lower patient out-of-pocket costs where, as a
result of the VBA, the drug is placed on a preferred or lower formulary
tier. In addition, as explained above, VBAs can potentially reduce
overall healthcare costs, including patient out-of-pocket costs, by
improving outcomes for patients through the reduction or elimination of
the need for additional medicines and/or healthcare services.
Question. Can Congress do more to allow for and encourage the use
of VBAs?
Answer. Yes. Congress can do more to allow for and encourage the
use of VBAs. For example, Congress could adopt an exception to the
Anti-Kickback Statute and enact measures to avoid unintended
consequences under Medicaid price reporting.
______
Questions Submitted by Hon. John Cornyn
Question. We continue to hear that rebates negotiated off of the
list price of a drug are both good and bad. Pharmacy benefit managers
and plans have argued that rebates are used to lower premiums across
the board and that it is the best way to seek a price concession on
otherwise expensive drugs. Your industry argues that these payers are
insisting on higher rebates that can only be achieved by raising list
prices. But patients often lose under this system, with out of pocket
costs being tied to list price. Insulin patients appear to be routinely
impacted by this perversity in the system.
Please explain to the committee how your company would reduce list
prices if rebates were no longer a part of the equation?
Answer. BMS supports the HHS proposed rule to eliminate safe harbor
protection for back-end rebates in Medicare Part D, and we believe it
would lead to lower out-of-pocket costs. The goals of the proposed rule
could be achieved through lower list prices, negotiated discounts at
the point-of-sale, or some combination of these two approaches. While
it is unclear how Part D plans and PBMs will react to the proposed
rule, at this time, BMS envisions that we would offer point-of-sale
discounts to Part D plans equivalent on average to the contracted
rebate amount and will continue to assess the possibility of lowering
list prices on a product-by-product basis. BMS would likely follow a
similar approach if back-end rebates were eliminated from the
commercial insurance market.
Question. What assurance can you provide that you would in fact
lower your prices?
Answer. Please see answer to previous question.
Question. What actions should be taken to ensure that patients are
actually seeing the benefits of lower out of pocket costs?
Answer. In order to ensure that patients receive the full benefits
of manufacturer discounts, we support the proposed rule's requirement
that manufacturer discounts be passed on to patients at the point-of-
sale. In addition, we recommend implementing safeguards to protect
consumers' access to medicines, to prevent increases in patients' out-
of-pocket costs, and to ensure that patients' costs at the point-of-
sale fully reflect manufacturer discounts.
Question. If rebates are driving high list prices for drugs as drug
manufacturers' claim, why do you think that Part B drugs, which have no
PBM rebates, are also seeing significant price increases? Whose fault
is that?
Answer. The price increases for BMS Part B drugs have been largely
in line with Medical CPI. We cannot comment on the Part B price
increase practices of other manufacturers.
______
Questions Submitted by Hon. Todd Young
re-evaluating business strategies in foreign countries
Question. Since taking office, President Trump has made reducing
drug prices one of his highest priorities--and has repeatedly spoken
about his frustration with the U.S. subsidizing the costs of
pharmaceuticals for the rest of the world. He has gone so far as to
issue proposals, like the International Pricing Index (IPI) Model, in
an attempt to bring down prescription drug prices.
With the increased scrutiny of the industry and of the drug supply
chain as a whole in the United States, have any of your companies re-
evaluated your business strategy in foreign countries?
Answer. Please see answer below.
Question. If not, then why?
Answer. Please see answer below.
Question. If a proposal, like IPI, were implemented, would it force
your companies to potentially ``walk away from the negotiating table
when other countries demand low prices subsidized by America's
seniors,'' as HHS Senior Advisor for Drug Pricing Reform John O'Brien
has said?
Answer. Please see answer below.
Question. What are some of your ideas on how we can ensure
Americans aren't shouldering the full cost of pharmaceuticals?
Answer. BMS reviews its business strategies within and outside of
the U.S. on a regular basis. BMS believes that all patients deserve
access to life changing medicines. Because of these ethical
considerations, BMS would not walk away from discussions about access
to our medicines in foreign countries. We believe that the most likely
outcome of IPI is further delays in access to life extending and
innovative medicines within the referenced countries, resulting in, for
example, lower cancer survival rates.
The IPI proposal imposes price controls in the U.S. based on the
policies of foreign countries with socialized health-care systems that
often deny their citizens access to innovative medicines. Patients in
many of the countries included in the reference basket wait
significantly longer for new, life extending and innovative medicines
to reach them. Outside of the U.S., reimbursement of new medicines can
often take more than 2 years. In Greece, for example, only 8 percent of
new cancer therapies are available, and on average it requires 32
months for these products to be available to patients. In comparison,
in the U.S., 96 percent of new cancer drugs are available within 3
months of market approval. Eventually, the industry often accepts
foreign prices which do not recognize the value and cost-effectiveness
of our medicines because patients can wait no longer.
BMS is committed to working with Congress and the administration to
advance better, more effective ways to lower drug prices for patients.
As an alternative to the IPI model, finalizing the proposed rebate rule
would lower seniors' out-of-pocket costs at the pharmacy counter.
Regulatory reforms at the FDA are leading to more medicine approvals
and greater competition in the market. Value-based arrangements (VBAs)
and indication-based pricing (IBP) can reduce the payer risk of
exposure to failed outcomes, more closely associate drug costs and
value, and make prescription medicines more affordable for patients.
foreign countries' pricing and reimbursement
Question. President Trump and Secretary Azar have both repeatedly
described their frustrations with ``foreign freeloading'' of U.S. drugs
in the last year.
``When foreign governments extort unreasonably low prices from U.S.
drug makers, Americans have to pay more to subsidize the enormous cost
of research and development. . . . It's unfair and it's ridiculous, and
it's not going to happen any longer.''
Do you agree that because of foreign countries' pricing and
reimbursement systems, U.S. patients and innovators are shouldering the
burden for financing medical advances?
Answer. Please see answer below.
Question. How do foreign countries' pricing and reimbursement
systems affect our prescription drug costs?
Answer. Please see answer below.
Question. Are foreign governments taking note of the concerns being
raised by the Trump administration, and have they responded in any way?
Answer. Please see answer below.
Question. Has there been any noticeable change in any of our trade
agreements since these concerns have been raised by the Trump
administration?
Answer. Drug pricing in markets outside of the U.S. must take into
account significant differences in economic status, cultural beliefs
and values, as well as differences in the local processes for setting
prices, which vary significantly from market-to-market. Countries vary
significantly in their per capita gross domestic product (GDP), their
willingness to invest in, and provide rapid access to, health-care
innovation, their focus on a single best average treatment for a
population versus focusing on patient heterogeneity and preserving
consumer choice and provider autonomy, and their tolerance and
acceptability for optimal patient care.
The countries selected for international comparison through the IPI
model are not economically comparable with the U.S. Many of the
countries in the IPI model, most notably Greece, the Czech Republic,
and Italy, do not have comparable economies as measured in per capita
gross domestic product (GDP). The significant difference in drug costs
between the U.S. and other countries referred to by CMS in the IPI
proposal is also seen with the comparative cost of physician services,
hospital care, diagnostics, and medical devices. For example, according
to a recent report by the OECD, hospital services in the U.S. cost 150
percent more than in Japan, France, Germany, Finland and Spain; 170
percent higher than in UK, Greece, and Italy.
Through the USMCA and other trade actions, the Trump administration
has taken steps to crack down on foreign violations of U.S.
intellectual property rights. There remain, however, several practices
that undermine U.S. intellectual property and violate existing trade
deals. We need to continue to negotiate better trade deals with better
enforcement that protect American medical innovations.
medicaid closed formulary proposals
Question. In an attempt to bring down drug costs, various States
have been exploring whether to exclude certain drugs from its Medicaid
program. For example, the State of Massachusetts' recently asked CMS
for permission to create a closed formulary where the State Medicaid
program would pick at least one drug per therapeutic class. CMS denied
their waiver request citing violation of Federal law, but this proposal
does bring up important questions on how to contain drug prices in
State Medicaid programs.
If the principles of the Medicare Part D program--including the
necessary patient protections--were applied to State Medicaid programs,
do you think it lower drugs costs while ensuring access to patients?
Answer. It is unlikely that applying Part D principles to Medicaid
would lower drug costs. Medicaid is already a lower-cost channel and
patients have little to no copay obligations.
medicaid ``best price''
Question. In the Trump administration's Blueprint, they suggested
that because drug manufactures have to give Medicaid the ``best price''
on drugs, there is no incentive to offer deeper discounts to other
payers--both government and commercial--than what is already offered
under the Medicaid Drug Rebate Program.
Does the Medicaid ``best price'' requirement encourage
manufacturers to increase initial prices?
Answer. For BMS, Medicaid ``best price'' is not a consideration in
determining initial product pricing.
Question. What, if any, changes would you suggest we make to the
program?
Answer. As clarification, prices offered to Medicare Part D plans
are excluded from Medicaid ``best price,'' and therefore, manufacturers
can offer deeper discounts to Part D without impacting Medicaid best
price.
More generally, BMS recommends the creation of an exemption from
best price and AMP for select value based purchasing arrangements and
greater clarity on best price and AMP reporting on issues related to
such arrangements.
outcomes-based contracts
Question. In almost all of your testimonies, you highlight your
support of outcomes-based contracts and how we need to be shifting our
system toward that approach.
How will these contracts lower drug costs for patients in both the
near term and long-term?
Answer. The goal and design of outcome-based contracts will vary
depending on the specific drug and the therapeutic area/disease State
which is being evaluated. In general, outcome-based contracts are
designed to demonstrate the efficacy, safety, clinical superiority,
cost savings and/or improvement in overall patient health outcomes. To
the extent that outcomes-based contracts demonstrate improvement in
clinical outcomes and/or reduction in overall health-care costs and
facilitate access to appropriate medicines, patients will benefit from
improved outcomes and reduced out-of-pocket costs, and Federal health-
care programs will benefit from lower overall health-care costs.
Question. How will they lower overall health-care costs for our
Federal programs?
Answer. Please see answer to previous question.
Question. What have the preliminary results looked like so far?
Answer. Eliquis has demonstrated a better safety profile than
alternate therapies (less bleeding events) as proven through outcomes-
based contracts using real world data. Oncology patients have higher
rates of diagnostic testing done to monitor disease progression (as
recommended by guidelines), through our testing based value-based
contract.
transparency/point of sale
Question. In almost all of your testimonies, you express your
support for the Trump administration's proposal to allow manufacturers
to provide PBMs up-front discounts that are passed onto patients at the
point-of-sale.
Do you feel like this proposal will make the transactions within
the drug supply chain more transparent?
Answer. To the extent that discounts provided by manufacturers to
PBMs and payers are passed through to the patients at the point-of-
sale, transactions within the drug supply chain will be more
transparent.
Question. If so, would this transparency bring down drug costs--
overall and for specialty drugs?
Answer. In terms of bringing down drug costs, the result of passing
discounts through to patients at the point-of-sale will likely vary
depending on the individual drug. We anticipate that patients who are
prescribed high-cost, highly discounted drugs, primarily specialty
drugs, and are subject to high co-insurance costs, will experience the
greatest reduction in drug costs.
the relationship between wholesalers and manufacturers
Question. When talking about the pharmaceutical supply chain, a lot
of focus has been placed on the Pharmacy Benefit Manager. But there's
another side of the equation that I'd like to ask about.
How do wholesalers negotiate pricing with manufacturers?
Answer. Wholesalers and manufacturers negotiate distribution
service agreements that include terms and fees. The fees are typically
a percentage of list price.
Question. What impact does this have on drug costs?
Answer. It is BMS's understanding that the fees negotiated by
wholesalers and manufacturers do not have a material impact on drug
costs.
Question. What incentives or disincentives do they have to contain
price increases?
Answer. This question is best answered by wholesalers.
______
Questions Submitted by Hon. Ron Wyden
proposed rebate rule
Question. As has been done in many other settings, drug
manufacturers said during the hearing that one reason list prices for
drugs are high is that pharmaceutical benefit managers (PBMs) demand
larger and larger rebates in order for the drug to receive favorable
placement on a formulary. You and your colleagues who testified during
the hearing stated if the administration's proposal on changes to the
anti-kickback safe harbor for pharmaceutical rebates took effect, your
company would likely lower list price.
Like many Oregonians, I am skeptical drug manufacturers would
voluntarily lower their prices. Therefore, would you support
legislation that would (1) make similar changes the administration has
put forward related to Part D and Medicaid managed care, (2) change the
rebate system in a similar way to the proposal for the commercial
market, and (3) require drug makers to lower the list price of their
drugs equal to the amount of rebates provided today?
Answer. BMS supports the extension of rebate reforms to the
commercial market. However, given the significant market change in the
proposed Part D safe harbor change, we urge the committee to pursue an
implementation timeline that will allow manufacturers, PBMs, plans,
retail pharmacies, wholesalers, and other impacted parties to address
the many operational challenges for the industry. We anticipate that
the implementation of the safe harbor change in Part D will provide
important learnings, but in order to extend these changes to the
commercial market, industry will need additional lead time to do so.
Given the many payers and channels in the health-care market, an
individual drug has multiple net price points. Moreover, the goals of
the proposed rebate rule can be achieved not only through lower list
prices, but also through negotiated discounts at the point-of-sale, or
through some combination of the two approaches. We believe the goals of
the proposed rule can be best achieved by giving manufacturers the full
range of options in their negotiations with plans and PBMs.
Consequently, BMS would not support legislation that required drug
makers to lower the list price of their drugs equal to the amount of
rebates provided today.
There may be instances where a reduction in product list price is
warranted, but with or without a list price change, in order for
patients to benefit fully from the changes, regulations would need to
ensure that manufacturer discounts are passed through to patients at
the point-of-sale and that patient out-of-pocket costs are based on
product net price.
medicaid drug rebate program
Question. The Medicaid Drug Rebate Program (MDRP) requires
manufacturers to provide a basic rebate and an additional inflationary
rebate for both brand and generic drugs. The inflationary rebate is an
increasingly substantial part of total rebates due in large part to
large increases in drug prices that exceed inflation. Under current
law, this inflationary rebate is capped at 100 percent of Average
Manufacturer Price (AMP). This is the case even when manufacturers
continue to raise their prices well above inflation.
Please provide a list of all of your pharmaceutical products that
have reached the Medicaid AMP rebate cap in any of the 20 quarters from
January 1, 2014 through December 31, 2018.
Answer. Please see answer below.
Question. For each drug listed in response to question 1, please
also provide a list of which quarters and years each drug hit the cap.
Answer
------------------------------------------------------------------------
Product Quarter
------------------------------------------------------------------------
BARACLUDE TAB 0.5MG Q3 2014, Q4 2014, Q1 2015, Q2 2015, Q3
2015, Q4 2015
------------------------------------------------------------------------
BARACLUDE TAB 1MG Q3 2014, Q4 2014, Q1 2015, Q2 2015, Q3
2015, Q4 2015
------------------------------------------------------------------------
COUMADIN TAB 4MG Q1 2014, Q2 2014, Q3 2014, Q4 2014, Q1
2015, Q2 2015, Q3 2015, Q4 2015, Q1
2016, Q2 2016, Q3 2016, Q4 2016, Q1
2017, Q2 2017, Q3 2017, Q4 2017, Q1
2018, Q2 2018, Q3 2018, Q4 2018
------------------------------------------------------------------------
COUMADIN TAB 4MG (1BTLX1000) Q3 2014, Q4 2014, Q1 2015, Q2 2015
US
------------------------------------------------------------------------
COUMADIN TAB 1MG Q1 2014, Q2 2014, Q3 2014, Q4 2014, Q1
2015, Q2 2015, Q3 2015, Q4 2015, Q1
2016, Q2 2016, Q3 2016, Q4 2016, Q1
2017, Q2 2017, Q3 2017, Q4 2017, Q1
2018, Q2 2018, Q3 2018, Q4 2018
------------------------------------------------------------------------
COUMADIN TAB 2MG Q1 2014, Q2 2014, Q3 2014, Q4 2014, Q1
2015, Q2 2015, Q3 2015, Q4 2015, Q1
2016, Q2 2016, Q3 2016, Q4 2016, Q1
2017, Q2 2017, Q3 2017, Q4 2017, Q1
2018, Q2 2018, Q3 2018, Q4 2018
------------------------------------------------------------------------
COUMADIN TAB 5MG Q1 2014, Q2 2014, Q3 2014, Q4 2014, Q1
2015, Q2 2015, Q3 2015, Q4 2015, Q1
2016, Q2 2016, Q3 2016, Q4 2016, Q1
2017, Q2 2017, Q3 2017, Q4 2017, Q1
2018, Q2 2018, Q3 2018, Q4 2018
------------------------------------------------------------------------
COUMADIN TAB 7.5MG Q1 2014, Q2 2014, Q3 2014, Q4 2014, Q1
2015, Q2 2015, Q3 2015, Q4 2015, Q1
2016, Q2 2016, Q3 2016, Q4 2016, Q1
2017, Q2 2017, Q3 2017, Q4 2017, Q1
2018, Q2 2018, Q3 2018, Q4 2018
------------------------------------------------------------------------
COUMADIN TAB 10MG Q1 2014, Q2 2014, Q3 2014, Q4 2014, Q1
2015, Q2 2015, Q3 2015, Q4 2015, Q1
2016, Q2 2016, Q3 2016, Q4 2016, Q1
2017, Q2 2017, Q3 2017, Q4 2017, Q1
2018, Q2 2018, Q3 2018, Q4 2018
------------------------------------------------------------------------
COUMADIN TAB 2.5MG Q1 2014, Q2 2014, Q3 2014, Q4 2014, Q1
2015, Q2 2015, Q3 2015, Q4 2015, Q1
2016, Q2 2016, Q3 2016, Q4 2016, Q1
2017, Q2 2017, Q3 2017, Q4 2017, Q1
2018, Q2 2018, Q3 2018, Q4 2018
------------------------------------------------------------------------
COUMADIN TAB 3MG Q1 2014, Q2 2014, Q3 2014, Q4 2014, Q1
2015, Q2 2015, Q3 2015, Q4 2015, Q1
2016, Q2 2016, Q3 2016, Q4 2016, Q1
2017, Q2 2017, Q3 2017, Q4 2017, Q1
2018, Q2 2018, Q3 2018, Q4 2018
------------------------------------------------------------------------
COUMADIN TAB 6MG Q1 2014, Q2 2014, Q3 2014, Q4 2014, Q1
2015, Q2 2015, Q3 2015, Q4 2015, Q1
2016, Q2 2016, Q3 2016, Q4 2016, Q1
2017, Q2 2017, Q3 2017, Q4 2017, Q1
2018, Q2 2018, Q3 2018, Q4 2018
------------------------------------------------------------------------
COUMADIN TAB 6MG US Q1 2014, Q2 2014, Q3 2014, Q4 2014, Q1
2015
------------------------------------------------------------------------
AVAPRO TAB 75MG Q1 2014, Q2 2014, Q3 2014, Q4 2014, Q1
2015, Q2 2015, Q3 2015
------------------------------------------------------------------------
AVAPRO TAB 150MG Q1 2014, Q2 2014, Q3 2014, Q4 2014, Q1
2015, Q2 2015, Q3 2015, Q4 2015, Q1 2016
------------------------------------------------------------------------
AVAPRO TAB 300MG Q1 2014, Q2 2014, Q3 2014, Q4 2014, Q1
2015, Q2 2015, Q3 2015, Q4 2015, Q1 2016
------------------------------------------------------------------------
AVALIDE TAB 150/12.5MG Q1 2014, Q2 2014, Q3 2014, Q4 2014
------------------------------------------------------------------------
AVALIDE TAB 300/12.5MG Q1 2014, Q2 2014
------------------------------------------------------------------------
medicaid drug rebate program compliance
Question. I am concerned about recent reports and legal settlements
surrounding drug manufacturers' failure to comply fully with the
requirements of the MDRP. For example, an analysis by the U.S.
Department of Health and Human Services Office of Inspector General
found that between 2012 and 2016 taxpayers may have overpaid by as much
as $1.3 billion for 10 potentially misclassified drugs. That is why I
introduced the Right Rebate Act with Chairman Grassley to prevent drug
manufacturers from manipulating Medicaid to increase their profits.
However, I continued to be concerned about oversight and manufacturer
compliance with the requirements of the Medicaid Drug Rebate Program.
Accordingly, please describe the following:
Your company's current compliance plan and procedures used to
ensure compliance with the requirements of the Medicaid Drug Rebate
Program including internal audits or other checks you use to identify
compliance vulnerabilities.
Answer. The Company routinely assigns new employees working in the
government pricing area formal training on U.S. government pricing and
contracting. This training includes an overview of the Medicaid Program
obligations and requirements. BMS also maintains policy and procedural
documents which govern compliance relative to the Medicaid Drug Rebate
Program. In addition, BMS periodically holds informal training sessions
as part of departmental and other internal meetings, where compliance
training is provided on topics relevant to the Medicaid Drug Rebate
Program. BMS has also identified key controls related to the Medicaid
Drug Rebate Program which are independently tested as part of the
Company's Sarbanes-Oxley controls. As part of these controls, all
Medicaid pricing submissions are reviewed and approved by the
appropriate Company management. In addition, BMS Global Internal Audit
and Assurance periodically conducts internal audits of the Company's
operations, which include activities that support the Medicaid Drug
Rebate Program.
Question. Any past or ongoing issues of non-compliance.
Answer. There are no ongoing issues of non-compliance with the
Medicaid Drug Rebate Program, nor were there any within the past 5
years. (BMS interprets the question as asking for a reasonable period
in the past, and has selected 5 years).
Question. Any corrective actions taken to address identified
problems or issues of non-compliance with the MDRP and how such steps
were communicated to the Centers for Medicare and Medicaid Services.
Answer. There are no ongoing issues of non-compliance with the
Medicaid Drug Rebate Program, nor were there any within the past 5
years. (BMS interprets the question as asking for a reasonable period
in the past, and has selected 5 years).
Question. Any steps taken to improve compliance and ensure that all
Medicaid drug rebates owed to the Federal Government and the States are
paid in full.
Answer. In addition to the compliance and audit activities already
outlined, the BMS Government Pricing team conducts regular cross-
functional information sharing meetings in order to facilitate
communication within the organization, to gather all relevant pricing
and contracting information, and to provide education that is focused
on ensuring compliance with our Medicaid reporting obligations. The
Government Pricing team also conducts quarterly Medicaid Best Price
review meetings with key members of the pricing and contracting
organization and requires that leaders of key functions within the
pricing and contracting organization sign-off on quarterly Medicaid
Best Price information prior to the Company's final. Additionally, the
Company has made significant investments in the systems which are used
to support the calculation and payment of Medicaid rebates to help
ensure greater compliance, standardization and automation of our
processes. BMS also maintains a Compliance and Ethics hotline and
encourages all employees to raise potential compliance concerns so that
they can be investigated and addressed.
More specifically with regard to the payment of Medicaid drug
rebates, based on the current portfolio of active drugs, all BMS drugs
are classified as Innovator Single Source or Innovator Multiple Source
drugs which are subject to the higher basic rebate calculation. When
BMS launches a new drug that is subject to Medicaid reporting, the drug
classification is reviewed as part of the Medicaid submission approval
process.
To the extent that BMS has questions on MDRP compliance or on
interpretative approaches to MDRP price reporting, we communicate with
the Centers for Medicare and Medicaid Services.
bonus payments tied to specific drugs
Question. I am concerned by the potential for employee financial
incentives to encourage high launch prices and price increases for
prescription drugs.
Is your salary, bonus, or other compensation tied to sales or
revenue targets of a single product your company sells? Has it ever
been? If yes, please state the product or products to which your
salary, bonus or other compensation was tied.
Answer. No, Dr. Caforio's salary and bonus are not tied to sales or
revenue targets for a single product. Dr. Caforio's compensation is
tied in part to the revenue of the Company as a whole. Please see
answer below.
Question. Is your salary, bonus, or other compensation tied to
either revenue or net income of the company as a whole? Has it ever
been? If yes, please explain what assumptions about price increases are
used when the compensation committee sets revenue or net income goals.
Does the compensation committee provide any guidance to executives in
regards to the amount of revenue that the company will generate from
price increases versus volume growth?
Answer. Dr. Caforio's compensation is tied in part to the revenue
of the Company as a whole. The revenue metric is based on the overall
Company target for the applicable performance period (annual for annual
bonus and longer-term, 3 years for Performance Share Units), which
typically includes assumptions concerning both price changes and volume
growth. Over the last few years, BMS' revenue growth has been primarily
attributable to increased volume arising from increased demand for our
products rather than price increases.
Dr. Caforio's compensation is reviewed and recommended by the
Compensation and Management Development Committee, which is a committee
consisting of only independent directors, and approved by at least
three-fourths of the independent directors of our Board of Directors.
The Compensation Management and Development committee annually
completes a thoughtful and rigorous evaluation of the Company's
executive compensation program to ensure that the program is aligned
with our mission and delivers shareholder value, while not encouraging
excessive or inappropriate risk-taking by our executives. When
determining metrics and setting incentive plan targets each year and
for 3 year performance period, the committee is aware of the risks
associated with drug pricing, among other risks, and ensures our plans
do not incentivize risky behavior in order to meet targets and goals.
net prices
Question. In your testimony you stated, ``for this reason, the
average net pricing across our U.S. portfolio of medicines increased by
5 percent of the last year-over-year for the last 5 years. Importantly,
it did not increase at all in 2018 and we expect that it will not
increase in 2019.'' Please describe how the company's year-over-year
aggregate net price is calculated. Please also specifically address the
following questions.
Answer. Dr. Caforio testified that BMS's average net pricing across
the company's U.S. portfolio increased by 5 percent or less year-over-
year for the last 5 years. Please see the answer below for a
description of how year-over-year net price is calculated.
Question. How many products are included in the calculation of the
average net price change? What was the median net price change?
Answer. Approximately 20 products are included in the calculation
of the average net price change. The median net price change over the
last 5 years is 3.4% based on the following net price change per year:
2018 2017 2016 2015 2014
(0.3%) 1.6% 5.2% 3.4% 4.0%
Question. Is net price weighted? If so, how? For example, in
determining the aggregate net price does the company assign different
weights to different products based on volume or other factors? Are
``on patent'' and ``off patent'' drugs weighted identically? Are other
statistical weights used or are all products treated equally?
Answer. Net price is weighted according to the product's sales
relative to total BMS sales. Year-over-year change in Net Price =
Change in List Price + Change in effective discount rate across all
channels. Patent and off-patent drugs are treated equally in the
calculation.
Question. Does the figure that you provided during your testimony
account for U.S. prices, international prices, or both? Generally
speaking, when your company reports net price changes, does it
differentiate between U.S. and international prices?
Answer. The figure included in Dr. Caforio's testimony accounted
for U.S. prices. Yes, BMS discloses by region (i.e., U.S., Europe, Rest
of World) in our quarterly 10Q and Annual 10K filings. However, the
only net price changes specifically outlined (i.e., in percentage
terms) is for the U.S.
Question. Please list the five drugs your company sold in the U.S.
that had the greatest year-over-year net price increase in 2018, noting
the increase for each drug by dollar figure and percentage. Please list
the five drugs your company sold in the U.S. that had the lowest year-
over-year net price increase (and/or the greatest decrease) in 2018,
noting the increase (or decrease) for each drug by dollar figure and
percentage.
Answer. This question calls for information that BMS does not
disclose publicly and considers to be competitively sensitive.
Question. For 2018, what was the average net price change in the
U.S. market for (1) drugs with no competition, (2) drugs with only
branded competition, and (3) drugs with generic competition?
Answer. This questions calls for information that BMS does not
disclose publicly and considers to be competitively sensitive.
Question. You stated that average net price increased 5 percent in
2017, but did not increase in 2018, and that you do not expect it to
increase in 2019. What factors contributed to the change from 2017 to
2018? What would the net price increase have been if your company
excluded the impact of drugs like Reyataz and Sustiva, which lost
exclusivity in the United States at the end of 2017, and Daklinza,
which the company reported losing revenue on?
Answer. Dr. Caforio testified that BMS's average net pricing across
the Company's U.S. portfolio increased by 5 percent or less year-over-
year for the last 5 years. Average U.S. net price remained unchanged
from 2017 to 2018 (i.e., 0 percent net price increase from 2017 to
2018), because discounts across all channels increased at a rate higher
than list price increased. If drugs which lost exclusivity, like
Reyataz, Sustiva and Daklinza, were excluded, the net price change
would still be 0 percent.
______
Questions Submitted by Hon. Robert Menendez
Question. When new products enter the market, do drug companies set
high initial rebates and then provide deep rebates in order to gain
access to insurance plan's formularies?
Answer. BMS does not. We cannot comment on the pricing practices of
other manufacturers.
Question. If CMS finalizes the rebate rule, do you anticipate
future products entering the market with significantly lower initial
list prices?
Answer. If CMS were to finalize the rebate rule, the impact on list
prices of future products would likely differ by product depending on
such factors as the clinical profile of the product, competition,
market dynamics, and the channel into which the product is primarily
sold. As noted above, the goals of the proposed rule could be achieved
through lower list prices, negotiated discounts at the point-of-sale,
or some combination of these two approaches.
______
Questions Submitted by Hon. Thomas R. Carper
Question. What are your recommendations for lowering prices for the
40 percent of drugs that do not offer rebates in Medicare Part D?
Answer. BMS believes that market-based reforms are the best way to
lower costs and maintain the appropriate incentives for innovation. BMS
supports policies that enable payers to negotiate innovative and
flexible ways to pay for medicines, including value-based purchasing
arrangements. Additionally, we need to ensure generics are available
whenever permissible under our system. BMS notes also that even
manufacturers pay coverage gap discounts for all Part D drugs
regardless of whether a payer rebate is provided for that drug.
Question. In the health insurance plans that you offer your
employees, do you ask your insurers to pass through the full
manufacturer rebates to the beneficiaries?
Answer. Based on the contract negotiated with the PBM with which
BMS has contracted, BMS has elected to reinvest the rebates we would
otherwise have received from the PBM to reduce the per claim cost for
brand drugs across the entire population of members we cover. BMS
provides health care coverage to approximately 10,000 active employees,
4,000 retirees and 18,000 spouses and other dependents.
Under this reinvested model, those rebate dollars are applied to
reduce the negotiated rate our enrollees pay for brand drugs. This
means that the PBM charges the plan a lower negotiated rate for all
branded drugs (not just those associated with specific rebates),
benefiting a broader portion of our covered population. Since our
health plan benefit design uses a coinsurance for member cost sharing,
this lower negotiated drug cost enabled by the application of the
rebate value, reduces the coinsurance amount our members pay for their
medications at the pharmacy counter.
Question. The systems for pricing and distributing drugs are opaque
and difficult to understand. What are your recommendations for
increasing transparency in how your companies set the list prices for
drugs, and for improving transparency in the supply chain for
prescription drugs? Would you support Federal standards for
transparency in setting the list prices for drugs?
Answer. BMS intends to provide added transparency around the list
prices for its medicines. We are creating pricing pages for all of our
advertised medicine websites to include list price and additional
information on out-of-pocket costs and support programs. Any DTC TV ads
will direct patients to the site through a web link. Our plan is to
have this information available by April 15, 2019. We solicited
feedback from the patient community to ensure the resources we provide
about pricing are meaningful to patients. The research suggests
patients may misinterpret list price information in a television
advertisement without additional context.
BMS is complying with the recently enacted California drug price
transparency legislation and would like to work with the committee on
similar legislation at the Federal level, or legislation similar to the
SPIKE Act (S. 474), both of which are intended to require manufacturers
to disclose price increases above a certain threshold.
Question. In nearly every sector of the health-care industry,
Medicare, Medicaid, employers, and insurers are moving away from fee-
for-service payments to reimbursements based on value and performance.
Prescription drugs and medical devices were the glaring exceptions to
this trend until recently. How many of your drugs are included in
value-based contracts and how many patients are benefiting from them?
How do these value-based contracts work to lower drug prices for both
patients and taxpayers?
Answer. Currently, BMS has value-based contracts for two products.
Approximately 39 million patients are eligible for potential coverage
under those contracts.
The goal and design of outcome-based contracts will vary depending
on the specific drug and the therapeutic area/disease state which is
being evaluated. In general, outcome-based contracts are designed to
demonstrate the efficacy, safety, clinical superiority, cost savings
and/or improvement in overall patient health outcomes. To the extent
that outcomes-based contracts demonstrate improvement in clinical
outcomes and/or reduction in overall health-care costs, patients will
benefit from improved outcomes and reduced costs, and the Federal
programs will benefit from lower overall health-care costs.
Question. Last year, Senator Portman and I did an investigation on
the pricing of an opioid overdose reversal drug called EVZIO,
manufactured by Kaleo. Kaleo increased the price of EVZIO from $575 in
2014 to $4,100 in 2017. We found that the best price Medicare was able
to get for EVZIO, about $4,000, was much higher than the price other
Federal programs and private insurers were able to get. It seemed that
Kaleo was able to get this higher price of $4,000 from Medicare by
helping doctors fill out paperwork showing that the drug was medically
necessary, even though there are cheaper alternatives on the market. As
a result of the investigation, Kaleo announced it will bring a generic
version of the drug to market at only $168 per pack. Are any of your
companies providing medical necessity paperwork to doctors in order to
get your drugs covered by Medicare?
Answer. BMS offers patient support programs that help eligible
patients who are prescribed our medicines obtain access to those
medicines. This includes assisting patients in navigating the insurance
approval process. Consistent with longstanding OIG guidance and common
industry practices, BMS does provide the template forms required by
insurers for use in making coverage determinations, but BMS does not
provide medical necessity content. That content must be independently
provided by the prescribing health-care provider.
Question. In 2017, the Rand Corporation estimated that biosimilar
drugs, which are competitors to complex, biologic drugs, could save the
United States more than $50 billion over the next decade. Some of you
have also argued that increasing the use of biosimilar drugs would help
lower drugs costs for consumers and taxpayers. What is delaying the
uptake of biosimilar drugs in the United States? What policies do you
recommend to increase the development of biosimilar drugs?
Answer. BMS does not have a biosimilar or a branded product with
biosimilar competition, and consequently, is not in a position to offer
first-hand insight.
______
Questions Submitted by Hon. Benjamin L. Cardin
Question. The United States is one of the only countries in the
world to allow prescription drug manufacturers to advertise directly to
consumers through magazines, billboards, radio, and television
commercials. While I will not argue that it is beneficial to educate
consumers about an unfamiliar disease and encourage them to seek
medical help, most commercials from all of your companies recommend
asking about a specific brand name drug, not a medical condition.
Furthermore, even if your advertisements follow all FDA rules and list
medication side effects, they also almost always list these while a
smiling, apparently healthy person is walking on a beach.
Researchers say that this type of imagery, combined with viewing
hours of drug commercials each month, leads consumers to underestimate
the risks associated with medications. For the past decade, studies
have shown that aggressive direct-to-consumer advertising is associated
with rising drug prices and an increase in inappropriate drug
prescriptions.
Question. Since researchers have concluded that consumers are
misunderstanding the benefits and risks described in your ads, what
further policies could help you and your colleagues ensure that you are
educating patients in a clear manner?
Answer. BMS engages in DTC TV advertising selectively and only when
we think it will help educate patients. Our DTC TV advertising is
submitted to the FDA for advisory comments prior to being broadcast in
accordance with FDA guidance. BMS believes that our DTC advertising
clearly and appropriately communicates the benefits and risks of our
medicines.
BMS believes responsible DTC communications play a critical role in
educating patients and families about treatment options and encourages
them to have an informed discussion with their physician about the best
treatment for their needs. BMS would be open to considering any
additional policy proposals that further facilitate the achievement of
this goal.
pharmaceutical companies continue to raise prices
Question. As you are well aware, high prescription drug prices are
the number one concern for Americans and their families. According to
the Organization for Economic Cooperation and Development, the average
American spends around $1,208 annually on prescription drugs. There
have been several instances where brand name or even generic drugs that
have been on the market for years continue to increase in price.
One of the most well-known examples is Mylan's increase of the
price of EpiPen from less than $100 in 2007 to more than $600 in 2016.
Another example, is the ever-increasing price of insulin. Sanofi
increased the price of a vial of Lantus from $88.20 in 2007 to $307.20
in 2017. And those are just a small sample of price increases.
Why don't we see price decreases for drugs that have been on the
market for years without new formulations or added benefit?
Answer. Although list prices for a drug without new formulations or
added benefits may not decrease over time, in our experience, net
prices generally decrease over time and/or volume decreases
significantly as generics enter the market.
pay for delay
Question. Pay for delay is a tactic that more and more branded drug
manufacturers have been using to stifle competition from lower-cost
generic manufacturers. This allows you to sidestep competition by
offering patent settlements that pay generic companies not to bring
lower-cost alternatives to market.
These ``pay-for-delay'' patent settlements benefit both brand-name
pharmaceutical companies by helping them avoid costly patent litigation
and general manufacturers by rewarding them a hefty sum to delay
entering the market with a cheaper drug alternative. However, these
deals do not benefit consumers. According to an FTC study, these
anticompetitive deals cost consumers and taxpayers $3.5 billion in
higher drug costs every year.
Does your company partake in pay-for-delay settlements?
Answer. No.
Question. Why would a pharmaceutical company enter into a pay-for
delay agreement?
Answer. As stated above, BMS does not enter into any pay-for-delay
settlements. We cannot comment on the actions and motivations of other
manufacturers.
Question. Do you think these agreements stifle competition and
prevent generic alternatives to your branded medications?
Answer. BMS agrees that patent settlement agreements that have
substantial payments going from innovators to generics, and are solely
intended to delay competition, are anticompetitive. In contrast,
agreements that do not contain such substantial payments and properly
balance litigation considerations often lead to earlier generic entry
than patent expiration.
drug rebate rule
Question. In January, the Department of Health and Human Services'
(HHS) Office of Inspector General (OIG) promulgated a new regulation to
remove regulatory safe harbor protections under the Anti-Kickback
Statute (AKS) for rebates on prescription drugs rebates paid by
manufactures to PBMs under Medicare Part D and for Medicaid managed
care organizations (MCOs). The OIG proposal attempts to ban most
rebates by eliminating their regulatory protections.
The rule is predicted to increase net drug costs in its early
years. The CMS actuaries estimate it would cost $196 billion over 10
years. Despite this high price tag, the beneficiary benefits are
limited. The proposed rule notes that under the CMS Actuary's analysis,
the majority of beneficiaries would see an increase in their total out-
of-pocket payments and premium costs; reductions in total cost sharing
will exceed total premium increases.
I wanted to ask a question about the administration's rebate rule,
which I understand that many of the drug manufacturers, and your main
trade association, strongly support. According to an analysis of the
rule by the Office of Actuaries at CMS, drug manufacturers are likely
to initially retain 15 percent of the current rebates as higher net
drug prices.
Given that estimate, can you provide the committee with any
assurances that prices will not increase under this proposed rule?
Answer. BMS supports HHS's proposed rule because BMS believes it
will lower patient costs at the point-of-sale and ensure patients
realize the benefit of manufacturer discounts. We do not anticipate
that manufacturer average net prices will increase as a result of this
rule.
______
Questions Submitted by Hon. Sherrod Brown
Question. According to an article recently published in the Journal
of the American Medical Association, medical marketers spent nearly $30
billion dollars in 2016, up from $17 billion in 1997. Direct-to-
Consumer (DTC) advertising had the biggest percentage increase: from
$2.1 billion, or 11.9 percent of all medical marketing, in 1997 to $9.6
billion, or 32 percent of total spending, in 2016.
Can you please provide what your ratio of spending on sales and
marketing to research and development is today?
Answer. BMS does not disclose sales and marketing investments
separately. In 2018, BMS marketing, selling and administrative expenses
were $4.6 billion, which is inclusive of sales and marketing, and R&D
expenses were $6.3 billion. That ratio is approximately 7 to 10.
price-gouging
Question. Sanofi, as I understand it, has made a pledge to the
public to limit its price increases to the national health expenditures
growth projection.
Would your company commit to a cap on annual price increases as
part of your PhRMA membership criteria?
Answer. It is BMS's understanding that a cap on annual price
increases as part of PhRMA membership would raise significant antitrust
concerns.
Question. What policies would you propose to help ensure lower
launch prices for new drugs?
Answer. BMS does not believe that government policies should govern
launch pricing of new drugs. Payers, providers, patients, and the
marketplace should freely assess the value of new innovative therapies
relative to their improvement in outcomes and impact to total cost of
care. At BMS, we believe the prices of our medicines reflect the value
they bring to patients, healthcare providers, payers, and society as a
whole.
transparency
Question. In many of your testimonies, you mentioned that the
current system of pharmacy benefit manager (PBM) back-end rebates do
not rarely results in a scenario where the PBM passes on savings to
consumers at the point of sale (POS). The administration recently
proposed a rule to eliminate the anti-kickback statute safe harbor
protections for these drug rebates.
Do you agree that greater transparency should be required to
understand how manufacturers and PBMs are negotiating prices and
rebates to ensure that savings are passed down to beneficiaries?
Answer. Yes, BMS agrees that manufacturer's net prices should be
transparent to and passed through to beneficiaries. BMS also believes
that this transparency should be required for all entities in the
health-care market.
pbms
Question. An Axios article from March 7, 2019 highlights the fact
that, while ``pharmaceutical companies put a lot of the blame for high
drug prices on pharmacy benefit managers,'' many large pharmaceutical
companies ``rely on PBMs to manage their own health care benefits.''
In your role as an employer, does your company contract with a
pharmaceutical benefit manager (PBM) to administer the prescription
drug benefits for your employees and negotiate lower drug costs on your
behalf?
Answer. Yes.
Question. For those of you who do use a PBM to help manage the
prescription drug benefit for your employees, how do you utilize the
rebates your PBM negotiates to lower health care costs or drug costs
for your employee plans and what does your company do with that
savings? Specifically, do the savings go toward lowing premiums?
Answer. BMS uses a PBM for our self-funded Pharmacy Benefit
Program, which is part of our overall healthcare plan. The PBM offers
the option of direct point-of-sale rebates, however, based on the
contract negotiated with the PBM, BMS has elected to reinvest the
rebates we would otherwise have received from the PBM to reduce the per
claim cost for brand drugs. Under this reinvested model those rebate
dollars are applied to reduce the negotiated rate our enrollees pay for
branded drugs. This means that the PBM charges the plan a lower
negotiated rate for all branded drugs (not just those associated with
specific rebates). Since our health plan benefit design uses a
coinsurance for beneficiary cost sharing, this lower negotiated drug
cost enabled by the application of the rebate value, reduces the
coinsurance amount our members pay for their medications at the
pharmacy counter. Under this model, a greater number of participants
benefit from the value of the rebates.
Question. For those of you who do use a PBM to help manage the
prescription drug benefit for your employees, does your PBM offer
point-of-sale rebates to your employees?
Answer. Please see answer to previous question.
______
Questions Submitted by Hon. Sheldon Whitehouse
Question. Please describe any policy changes you support that would
result in your company lowering the list prices of its drugs.
Answer. BMS supports the HHS proposed rule to eliminate safe harbor
protection for back-end rebates in Medicare Part D, and we believe it
would lead to lower out-of-pocket costs. The goals of the proposed rule
could be achieved through lower list prices, negotiated discounts at
the point-of-sale, or some combination of these two approaches. While
it is unclear how Part D plans and PBMs will react to the proposed
rule, at this time, BMS envisions that we would offer point-of-sale
discounts to Part D plans equivalent to the contracted rebate amount
and will continue to assess the possibility of lowering list price on a
product-by-product basis. Our ability to lower list prices, however, is
constrained by the fact that the HHS proposed rule does not apply to
the commercial insurance market, where we anticipate back-end rebates
to continue for the foreseeable future.
Question. How much does your company's research and development
portfolio rely on taxpayer-funded research conducted by the National
Institutes of Health (NIH)? How many of your company's products are
based, at least in part, on NIH research, and how many are the result
of research funded solely by your company?
Answer. Government institutions such as NIH and NCI do critically
important basic research. However, the most significant investment
behind any molecule is the clinical development program, which is
usually when a pharmaceutical company comes into the development
process. On average it takes 10 to 15 years and about $2.5 B to bring a
medicine to patients, depending on the asset, therapeutic area, number
of indications, and other factors. This is highly dependent on the
stage of the molecule/asset when it comes to BMS. There is also
considerable risk of failure given the complexity of clinical
development. Only about 12 percent of drugs that make it to Phase 1
clinical trials result in an approved product.
Question. In each of the last 5 years, how much has your company
spent on research and development versus the advertising and marketing
of your products?
Answer. BMS does not publicly disclose specific advertising and
marketing expenditures. The figures below are for marketing, sales and
administrative expenses, which includes advertising and marketing
expenditures.
2018 spend:
Marketing, selling, and administrative expenses: $4.6 billion
Research and development expenses: $6.3 billion
2017 spend:
Marketing, selling, and administrative expenses: $4.8 billion
Research and development expenses: $6.5 billion
2016 spend:
Marketing, selling, and administrative expenses: $5.0 billion
Research and development expenses: $5.0 billion
2015 spend:
Marketing, selling, and administrative expenses: $4.8 billion
Research and development expenses: $5.9 billion
2014 spend:
Marketing, selling, and administrative expenses: $4.8 billion
Research and development expenses: $4.5 billion
Question. During the hearing, you mentioned that your company would
be likely to lower the list prices of its drugs if the recent proposal
by the Trump administration to change the current system of rebates was
extended to the private market.
If the policy was extended to the private market, how large would
the list price reductions be relative to the size of the rebates your
company is currently providing?
Answer. While it is unclear how health plans and PBMs would react
if the HHS proposed rule's policy were extended to the private market,
at this time, BMS envisions that we generally would offer point-of-sale
discounts to health plans equivalent on average to the contracted
rebate amount and would continue to assess the possibility of lowering
list price on a product-by-product basis. In the absence of list price
reductions, the policy requirement that manufacturer discounts be
passed on at the point-of-sale would accomplish the goal of reducing
patient out-of-pocket costs.
Question. How will this proposal affect how your company sets the
list prices for new drug products?
If the proposal is finalized and not extended to the private
market, will your company make any list price reductions? If so, how
large would the reductions be relative to the size of the rebates your
company is currently providing?
Answer. While it is unclear how health plans and PBMs would react
if the HHS proposed rule were finalized and not extended to the private
market, at this time, BMS envisions that we would offer point-of-sale
discounts to Part D plans equivalent on average to the contracted
rebate amount and would continue to assess the possibility of lowering
list price on a product-by-product basis. In the absence of a list
price reduction, the proposed rule's requirement that manufacturer
discounts be passed through to patients at the point-of-sale would
accomplish the goal of reducing patient out-of-pocket costs.
______
Question Submitted by Hon. Maggie Hassan
Question. In June of 2018, the Medicaid and CHIP Payment and Access
Commission (MACPAC) unanimously recommended under Recommendation 1.1 in
their annual report to Congress that Congress remove the statutory
requirement that manufacturers blend the average manufacturer price
(AMP) of a brand drug and its authorized generic.\1\
---------------------------------------------------------------------------
\1\ MACPAC, ``Improving Operations of the Medicaid Drug Rebate
Program,'' https://www.macpac.gov/wp-content/uploads/2018/06/Improving-
Operations-of-the-Medicaid-Drug-Rebate-Program.pdf.
This requirement created an unintended loophole. Rather than use
the price of the authorized generic, drug companies can sell its
authorized generic to a corporate subsidiary at an artificially lower
price, and use that lower price to bring down the AMP, which in turn
---------------------------------------------------------------------------
lowers the rebate obligation.
Does your company engage in this practice? Has your company ever
engaged in this practice in the past?
Answer. No. BMS does not have any authorized generics with its own
corporate subsidiary.
______
Questions Submitted by Hon. Catherine Cortez Masto
Question. Dr. Caforio, your company has entered a merger agreement
to acquire Celgene, which makes the cancer drug Remlivid. The price of
Remlivid was hiked nearly 20 percent in 2017, 5 percent last year, and
another 3.5 percent just last month.\2\ Remlivid was also high on a
list of brands whose manufacturers have refused to provide generic
companies with the samples they need to submit an FDA application.
Celgene refused 13 such inquiries, despite FDA's assurance that they
were safe to share.\3\, \4\ Today Remlivid stands as a
$70,000 sole source drug with no competition.\5\ You mention increasing
access to generics as a priority in your testimony. In a case were
Remlivid falls under your purview, what specific actions will you take
to promote generic competition of that drug?
---------------------------------------------------------------------------
\2\ https://www.reuters.com/article/us-celgene-results/celgene-
profit-tops-expectations-will-limit-
future-price-hikes-idUSKBN1KG1IC.
\3\ https://www.fda.gov/Drugs/DevelopmentApprovalProcess/
HowDrugsareDevelopedandApp
roved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/
ucm607738.htm
?utm_campaign=FDA%20publishes%20list%20of%20inquiries%20from%20generic%2
0drug%20
applicants%20about%20RLD%20access&utm_medium=email&utm_source=Eloqua.
\4\ https://www.npr.org/sections/health-shots/2018/05/17/571986468/
how-a-drugmaker-gamed-the-system-to-keep-generic-competition-away.
\5\ https://twitter.com/megtirrell/status/1016769284025016320.
Answer. BMS believes it is important to ensure generics are made
available whenever that is permissible under our system, and supports
the administration's focus on increasing the approval of generics. As
part of that system, it is important that generic companies perform the
---------------------------------------------------------------------------
needed testing to ensure product quality and patient safety.
Until the transaction closes, BMS and Celgene will continue to
operate as separate companies. BMS thus does not know and cannot
comment on Celgene's practices as they relate to generic manufacturers.
Once the transaction closes, BMS' practices with regard to generic
manufacturers, including the provision of samples, will govern the
combined portfolio.
Question. As a portion of your revenue, for what percentage of the
drugs in your portfolio do you offer no rebates? Based on the drugs in
your pipeline, do you foresee that portion growing? For those drugs is
your list price equal to your net price?
Answer. Although the level of rebates varies by product and
channel, BMS pays rebates for all products in our portfolio.
Question. Do you invest more in R&D than you generate in US sales
revenue? Please include specific figures.
Answer. BMS invested $6.3 billion in R&D in 2018, which includes
the discovery and development of new medicines.
U.S. sales for 2018 were $12.5 billion.
Question. Do you invest more in R&D than you spend on marketing and
administration? What company functions do you consider to be included
in administration? Please include specific figures.
Answer. BMS does not publicly disclose specific marketing and
administration expenditures. The figures below are for marketing, sales
and administrative expenses, which includes marketing and
administration expenditures.
2018 spend:
Marketing, selling, and administrative expenses: $4.6 billion
Research and development expenses: $6.3 billion
2017 spend:
Marketing, selling, and administrative expenses: $4.8 billion
Research and development expenses: $6.5 billion
2016 spend:
Marketing, selling, and administrative expenses: $5.0 billion
Research and development expenses: $5.0 billion
2015 spend:
Marketing, selling, and administrative expenses: $4.8 billion
Research and development expenses: $5.9 billion
2014 spend:
Marketing, selling, and administrative expenses: $4.8 billion
Research and development expenses: $4.5 billion
Question. Do you invest more in R&D than you spend on marketing and
sales? What company functions do you consider to be included in sales?
Please include specific figures.
Answer. BMS does not publicly disclose the functions included in
sales nor specific marketing and sales expenditures. Please see the
answer to the prior question for R&D and marketing, selling and
administrative expenses.
Question. Why do you advertise for the drugs you manufacture? What
factors do you consider in choosing which drugs you advertise?
Answer. BMS believes responsible DTC communications plays a
critical role in educating patients and families about treatment
options, and encourages them to have an informed discussion with their
physician about the best treatment for their needs. As a company, BMS
engages in DTC TV advertising selectively and only when we think it
will help educate patients. Currently BMS is engaging in DTC TV
advertising for one product (Eliquis).
______
Prepared Statement of Kenneth C. Frazier, Chairman and
Chief Executive Officer, Merck and Company, Inc.
Mr. Chairman, Senator Wyden, and members of the committee, thank
you for the opportunity to appear today. Merck's mission is to save and
improve lives around the world by bringing forward breakthrough
medicines and vaccines, and ensuring they are available and affordable
to patients who need them.
Merck is a science-based company that exists to help solve the
world's most vexing medical challenges. We have a long history of doing
this, from the development of most of the common childhood vaccines, to
bringing the first protease inhibitor to patients, turning AIDS from a
death sentence to a chronic disease, to developing the first statin,
which led to significant reductions in the negative health effects of
high cholesterol. This legacy of invention continues today.
Research is at the core of who we are and what we do. Last year,
Merck invested nearly $10 billion in research and development toward
our mission of preventing, treating, and curing disease, and since 2010
we've invested nearly $70 billion in these efforts. Our more than
12,000 researchers are focused on cancer, infectious diseases, and
Alzheimer's, as well as other major health challenges that affect large
numbers of people around the world. For our breakthrough immuno-
oncology drug Keytruda alone we have over 900 clinical trials under
way.
In pursuit of these efforts, we are also investing significantly in
infrastructure here in the United States. We have invested more than $5
billion in the last five years, and we plan to invest $9 billion more
over the next few years to increase manufacturing capacity and open two
new discovery research centers.
Our mission is to go where the science leads us, which means we
don't allocate resources only to addressing diseases in wealthy
countries; we focus our efforts on conditions that significantly impact
people living all over the world.
For instance, we are proud to have deployed 70,000 doses of our
experimental Ebola vaccine in the Democratic Republic of the Congo,
working in partnership with the Centers for Disease Control and
Prevention, the Biomedical Advanced Research and Development Authority,
and the Department of Health and Human Services. For efforts such as
this there is no commercial opportunity, but we pursue them because
these are the challenges that Merck was created to tackle.
At the end of the day we do all of this to serve patients. We
understand that patients are having a harder and harder time affording
their health care, including their prescription medicines. As a result
of robust negotiation and competition in the marketplace, medicine
costs are growing at the slowest rate in years, but the system is still
not working for patients who are too often being asked to pay more out-
of-pocket due to the complex system of pricing, distribution, and
insurance. I am here today to suggest a few ways that we can address
this problem together.
First, we want to be clear that our industry has a duty to be
responsible in our pricing practices and contribute to solutions that
address the affordability problems facing patients. We have all heard
the egregious examples of irresponsible behavior. At Merck, we have a
history of responsible pricing. To help increase transparency about our
pricing practices, we publicly disclose information about our prices in
the U.S. and the rebates and discounts we provide to payers--including
insurers, pharmacy benefit managers, and the government. Last year, we
pledged that we will not increase our average net prices for our
portfolio by more than the rate of inflation annually.
From 2010 to 2017, Merck's average net price increase across our
portfolio each year has been in the low to mid-single digits. In fact,
our average net price declined in 2017 by almost 2 percent. In 2017,
the average discount for our medicines and vaccines was more than 45
percent lower than the list price. Despite these very large discounts,
patients do not see a commensurate benefit. In fact, patient out-of-
pocket costs continue to rise, and patients are being asked to shoulder
more of their drug costs than other health-care services.
Second, we must ensure that patients get the benefit of the large
rebates and discounts that manufacturers are paying to PBMs and
insurance companies.
The incentives in the current system are badly misaligned. As a
result, the current system of drug competition that depends on rebating
is not working for patients. The growing gap between our list prices
and our net prices that results from rebating has created incentives
for supply chain entities to favor products with higher list prices.
For instance, in 2016, we introduced our hepatitis C therapy, Zepatier,
at a list price that was 42 percent below the price of the therapy that
was the standard of care. However, due to the misaligned incentives in
the supply chain that create a preference for higher priced products,
we had difficulty gaining access for patients in certain market
segments.
This kind of misalignment can have a significant negative impact on
patients because their cost-sharing is often based on the list price of
a drug, even when insurance companies and PBMs are paying a fraction of
that price. Our current system that incentivizes high list prices and
large rebates as a mechanism to keep insurance premiums low means that
sick patients are essentially subsidizing healthy patients. In this
way, our insurance system is broken. We urge you to support action to
make sure that all patients benefit from the discounts we make
available.
Third, we can significantly reduce spending on pharmaceuticals,
especially for patients, by ensuring that we have a viable market for
biosimilars in the United States. We believe, like with traditional
small molecule medicines, generic competition after a reasonable period
of exclusivity will create headroom for patients to afford the newest,
most innovative medicines. Research shows that generics and biosimilars
are expected to drive savings of $105 billion through 2022 in the
U.S.\1\
---------------------------------------------------------------------------
\1\ IQVIA Institute for Human Data Science. ``Medicine use and
spending in the U.S.: A review of 2017 and outlook to 2022.'' https://
www.iqvia.com/institute/reports/medicine-use-and-spending-in-the-us-
review-of-2017-outlook-to-2022. Published April 19, 2018. Accessed
April 2018.
However, we share the concerns expressed by FDA Commissioner
Gottlieb regarding the challenges biosimilars have experienced in
penetrating the market. Merck introduced a biosimilar to the market 18
months ago at a 35 percent discount to the originator product, yet we
have captured only a tiny fraction of the market. In general,
biosimilars competition thus far has resulted in moderation of prices,
but actual utilization of the biosimilars remains modest at best. We
fear that an environment where market entry of biosimilars brings value
to the market, but little or none of that value accrues to the
---------------------------------------------------------------------------
biosimilar, will not be sustainable.
Therefore, we urge Congress to pursue policies to encourage and
support biosimilar uptake and utilization in order to realize these
potential savings for the system and patients. These could include
reduced cost sharing in Medicare Part B.
Fourth, we believe that prices can more align with a drug's value
when manufacturers and payers are able to negotiate innovative
contracts that base payment on a drug's benefits. Manufacturers should
be rewarded based on the value that our therapies deliver. When we
developed our breakthrough immuno-oncology treatment Keytruda, we
incorporated a biomarker where clinically appropriate so that we could
identify those patients most likely to benefit, but this is not always
the case. We did this because we believe in giving the right medicine
to the right patient at the right time. This is important both for
therapeutic and economic reasons. If patients regularly take our
medicines as they are prescribed, we are prepared to stand behind their
effectiveness.
Moving to a system where we are reimbursed for the value our
medicines provide would be revolutionary. Yet there remain major
regulatory and operational obstacles to value-based payment and
contracting in the commercial and public markets, which we urge
Congress to address.
Fifth, we support efforts to encourage generic competition. A
version of Chairman Grassley's CREATES Act could make some needed
reforms to encourage generic competition, and there are likely other
policies we should consider as well to ensure there is no inappropriate
gaming of the system.
We also support the idea of eliminating the use of drug company
coupons in cases where a brand name drug now has generic competition.
This slows the use of generics and violates the spirit of the Hatch-
Waxman drug price competition law.
Finally, we would also like to work with the committee to find ways
to end the price gouging pursued by those who jack up the prices of
off-patent drugs that have no competition. These high prices hurt
patients and do not create incentives for the kind of cutting edge
research we pursue.
These six changes could bring real relief to patients while
preserving the incentives that allow us to invest billions in
developing new medicines. These are exciting times, when decades of
investment in scientific research are yielding life-changing
discoveries. But it is the investment of today that fuels the
innovations of tomorrow, and if we damage the ecosystem that drives
those investments, we'll never know what we could have achieved for the
patients we are all here to serve.
The single most important contribution that we make at Merck--to
economies, to health care, and to individual patients and their
families--is to continue making the necessary costly and long-term
investments in R&D and persuading thousands of brilliant researchers to
sit at a lab bench and try to create something transformative--despite
the overwhelming odds that their efforts will not succeed, since 9 out
of 10 compounds that even start clinical trials will fail.
The solutions to health-care spending and out-of-pocket costs for
patients must be achieved in a way that provides the balance necessary
for innovation to occur. The innovation ecosystem includes academia,
small biotechnology companies, large pharmaceutical companies,
government, and patients and providers. It is incumbent on all of us to
solve the affordability challenges of today's patients without
compromising our ability to invent for tomorrow's patients.
I'd like to end on a personal note. My mother died when I was a
child and my siblings and I were raised by my dad who worked as a
janitor in North Philadelphia. He was a giant in my life and it was
devastating when Alzheimer's took him away from me and my family.
Last year, after spending many years and over a billion dollars,
Merck had to end development of a promising new Alzheimer's therapy
because it simply didn't work. Yet we continue on, seeking better
approaches. And I truly believe Merck or one of the other companies at
this table can and will find a medicine that will ensure that no one
will have to experience the pain of seeing a loved one taken from them
in this way.
But, our success depends on having a U.S. market that is free,
competitive, and predictable. The changes I've discussed today have the
potential to vastly improve that market and help patients survive and
thrive without financial hardship. I am here to pledge our cooperation
with you for creating such changes.
Thank you.
______
Questions Submitted for the Record to Kenneth C. Frazier
Questions Submitted by Hon. Chuck Grassley
Question. At the hearing, you testified that Merck does not
withhold samples from generic manufacturers in order to block generic
versions of your drug from entering the market. You also expressed your
support for the ``Creating and Restoring Equal Access to Equivalent
Samples Act,'' also known as the CREATES Act.
However, the FDA has a list on its website which identifies
reference listed drug (RLD) access inquiries where brand manufacturers
may have prevented generic companies from obtaining samples of products
necessary to support FDA approval. Cubist Pharmaceuticals is on this
FDA list. According to news reports, Merck bought this company in 2014.
If this is accurate, this would appear to contradict your testimony at
the hearing that Merck has not withheld samples of their products to
delay generic competition.
Could you please explain in detail the discrepancy between your
testimony and the FDA list?
Has Merck ever blocked access to samples?
Answer. Merck does not block generic companies from accessing
samples. Your inquiry references FDA's website for reference listed
drugs, or RLDs, which lists inquiries the agency has received from
potential generic companies for samples of RLDs. Importantly, FDA's
website also provides the following statement in describing the various
inquiries related to the RLDs listed: ``We note that FDA has not
independently investigated or confirmed the access limitations
described in the inquiries received.''
As FDA's website details, ENTEREG (alvimopan) has a restricted
distribution requirement mandated by its FDA-approved Risk Evaluation
and Mitigation Strategy (REMS). ENTEREG is the only Merck product
subject to an FDA-approved REMS. Under this program, ENTEREG is
available only to hospitals that perform surgeries that include a bowel
resection and dispensed by pharmacies that are enrolled in the E.A.S.E.
ENTEREG REMS Program. This program is designed to ensure that ENTEREG
is used in accordance with the FDA-approved label.
Merck acquired ENTEREG from Cubist Pharmaceuticals in 2015. Since
acquiring ENTEREG, whenever Merck has received a request from a
generics company to supply ENTEREG, we have directed them to the draft
FDA Guidance which outlines how the generics company can obtain a
letter from FDA stating that their study protocols contain the
appropriate safety protections for products subject to this type of
REMS. If provided with a copy of such a letter from FDA, Merck is happy
to work with generics companies on supply arrangements. To date, we
have not received any such letters. FDA's website also details that the
agency has not issued any Safety Determination Letters for samples of
ENTEREG.
Question. The Department of Health and Human Services' proposed
rule, ``Fraud and Abuse; Removal of Safe Harbor Protection for Rebates
Involving Prescription Pharmaceuticals and Creation of New Safe Harbor
Protection for Certain Point-of-Sale Reductions in Price on
Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager
Service Fees,'' envisions that drug manufacturers will offer up-front
discounts rather than the back-end rebates that are now commonly
provided. Some observers argue that a 1996 court case called into
question whether manufacturers could offer up-front discounts,
resulting in today's rebate-based system. I've heard differing opinions
as to whether the issues related to the initial court case are still
relevant. If the HHS proposed rule is finalized, can you assure the
committee that your company will offer up-front discounts? If not, why?
Answer. Merck is aware that some in the industry have asked whether
the antitrust laws as interpreted in the In re Brand Name Prescription
Drugs Antitrust Litigation would limit the ability of manufacturers to
offer point-of-sale discounts (as opposed to rebates). But, the U.S.
antitrust laws, including the Robinson-Patman Act, apply to price
discrimination in any context (including rebates), and nothing about In
re Brand Name Prescription Drugs Antitrust Litigation changes this
fact. As a result, Merck commits that, if the OIG's Proposed Rule is
finalized, we will modify our contracts to comply with the new safe
harbors and will provide discounts in a manner consistent with the new
regulations.
Question. Please describe how you expect your company to respond to
the HHS proposed rule to eliminate safe harbor protection for back-end
rebates in Medicare Part D that is referenced above if it is finalized.
Assuming you are confident that antitrust laws do not prevent your
company from offering up-front discounts, specifically, do you envision
that your company lowers the list price of a drug to the current after-
rebate net price, offer discounts equal to the current rebate amount,
or a combination of both?
Answer. We expect that the robust negotiations that occur today
will continue in the highly competitive Part D market, and we expect to
realize the same level of net price that we do today. In fact, we
expect that there could be additional pricing pressure under the new
system, which could lead to lower net prices.
Over time, we expect that our list prices will go down if the
misaligned incentives across the system are addressed. We are currently
working with other stakeholders in the system to solve the operational
challenges that will enable these changes.
But, it is also important to note that if the rule is implemented,
Medicare beneficiaries' out-of-pocket costs will be reduced,
independent of any lowering of list prices, since their cost-sharing
will be based on the net price. Nonetheless, we believe the rebate rule
will align incentives in a way that will restrain list prices.
If this rule is implemented as written, it would only apply to our
contracts with PBMs and health plans for Medicare Part D and Managed
Medicaid. If PBMs and health plans maintain the rebate model in the
commercial market, we would still have commercial contracts based on
rebates, which would be subject to the existing constraints to lowering
list price. We also would still need a mechanism to revalue drug in the
distribution channel in a financially viable manner.
Question. To what extent are the back-end rebates your company
currently offers contingent on the amount of market share realized for
your drugs as a result of Part D plan formulary placement and other
techniques?
Answer. Our contracts typically provide rebates to Part D plans in
exchange for a specified formulary status. We are aware of only one
current agreement that makes a Part D rebate contingent on reaching a
certain market share.
Question. Please provide a breakdown of percentage of sales that go
to each payer (including Medicare, Medicaid, private pay, other) and a
similar percentage by volume of the total number of each drug compared
to total volume. Please provide this data for the most recent year
available.
Answer. The table below provides a proxy for volume by reporting
percentages based on gross sales from 2018, given that there is no
standard unit of volume measure that can be applied across our diverse
product line (e.g., tablet products, injectable products, vaccines).
------------------------------------------------------------------------
Segment Gross/Volume
------------------------------------------------------------------------
CML+Specialty Pharm 28%
------------------------------------------------------------------------
Hospital / GPO / 340B 23%
------------------------------------------------------------------------
Medicare Part D 19%
------------------------------------------------------------------------
Medicare Part B 12%
------------------------------------------------------------------------
Medicaid 12%
------------------------------------------------------------------------
Federal 6%
------------------------------------------------------------------------
Notes: CML refers to private commercial payers; Medicare Part B
also encompasses Part B products sold through Medicare
Advantage Plans; Medicaid includes fee for service and managed
Medicaid; Federal includes the VA, DoD, Coast Guard, Public
Health Service and other similar purchasers.
Question. Do your companies hire consultants or lobbyists to
promote products at State Medicaid Pharmacy and Therapeutics
Committees?
Answer. No. While Merck does contract with lobbyists who may
interact with individuals associated with State Medicaid programs, they
do not promote products at State Pharmacy and Therapeutics Committees.
Question. To whom do you disclose advocacy activities surrounding
State Medicaid programs, if at all?
Answer. Merck requires employees to adhere to State ethics law
requirements for disclosing advocacy activity. Additionally, employees
who attend Medicaid program meetings must comply with State public
meeting law requirements pertaining to their attendance and
participation.
Question. Please describe how the costs of patient assistance
programs are accounted for within your company's financial statements.
Please also describe the types of market information, such as
prescribing and use patterns, that your company collects from different
types of patient assistance programs and patient hub services.
Answer. For purposes of this question, we are interpreting
``patient assistance programs'' to include the Merck Patient Assistance
Program (Merck PAP), which provides free product to qualifying
patients, Merck donations to independent patient assistance
foundations, and Merck's patient coupon programs which help eligible
privately insured patients afford their prescribed medications. Merck
also makes available patient hub support programs to assist patients
with accessing their prescribed medications.
With respect to the company's financial statements, for Merck PAP
and Merck's donations to independent patient assistance foundations,
the costs are recorded to the ``Selling, general and administrative''
category on our Consolidated Statement of Income. The co-pay assistance
made available to patients through Merck's coupon programs is treated
as a reduction to Merck's gross sales for the applicable products and
is included in the ``Sales'' line of our Consolidated Statement of
Income. The expenses associated with administering Merck's coupon
programs are recorded in the ``Selling, general and administrative''
category on our Consolidated Statement of Income. Similarly, the
expenses associated with administering Merck's patient hub support
programs are recorded in the ``Selling, general and administrative''
category of our Consolidated Statement of Income.
Merck receives different types of market information in connection
with the different programs identified above. For market information
associated with the Merck PAP, the Merck PAP reviews data, such as
patient insurance status and household income, to determine an
individual's eligibility for PAP program enrollment. Merck PAP also
tracks the number of prescriptions associated with the PAP for
budgeting and planning purposes, but Merck PAP does not collect
information associated with the courses of therapy for individual
patients. With respect to Merck's donations to independent patient
assistance foundations Merck does not receive any market information.
Merck receives only a final report that confirms donations were
received and spent in their totality for their intended purpose.
With respect to Merck's patient coupon programs, Merck may receive
certain market information to assist it with evaluating whether its
coupons programs are functioning consistent with their intended purpose
and whether the vendor is meeting its contractual obligations. The
information also may be used to assist Merck with budgeting and
planning. For example, Merck may receive information about: the product
filled; the product dispensing date and site; the prescriber; the
number of patients enrolled in the coupon program; the number of
coupons redeemed; the patient out-of-pocket costs associated with the
use of a Merck coupon; and the benefit amount Merck pays on behalf of
privately-insured patients using a coupon.
With respect to Merck's patient hub support programs, Merck may
receive certain market information to assist it with evaluating whether
its hub support programs are functioning consistent with their intended
purpose and whether the vendor is meeting its contractual obligations.
The information also may be used to assist Merck with budgeting and
planning. For example, Merck may receive aggregate information about:
call type, frequency, and vendor response times; the number of patients
enrolled in the program; patient enrollment demographic and diagnosis
information; patient benefit investigations; insurance coverage
information for the applicable product; and pharmacy product
fulfillment information.
Merck's third-party contractors may receive additional, patient-
specific information that is not shared directly with Merck.
Question. Please provide a list of all contributions since January
1, 2014, that your company has made to any tax-exempt organizations
working on issues related to drugs within your product lines, including
but not limited to patient groups, disease awareness groups, medical or
professional societies, universities or hospitals, industry
associations or leagues. For each contribution, please provide the name
of the organization that received the donation, the date the donation
was made, the amount of the donation, and a description of the purpose
of the contribution (i.e., was the contribution for the general fund, a
specific purpose to a specific program, or continuing medical
education). Please also note whether the contribution was unrestricted
or restricted; if it was restricted, please explain all restrictions.
Finally, if your company maintains a foundation or other separate
charitable arm, please provide the name of all such entities, and list
all donations made from that entity or entities.
Answer. The information concerning our Philanthropic grants and
charitable contributions, including contributions made through the
Office of Corporate Responsibility, our company's Foundation, U.S.
Global Human Health, and the MSD for Mothers Program can be found here:
https://www.msdresponsibility.com/ethics-transparency/transparency-
disclosures/. Please note the website does not include grants or
contributions from Merck's Research Laboratories or Merck's
Manufacturing Division.
In addition, the information concerning our grants of more than
$500 provided by the company's Global Human Health division to U.S.
organizations in support of independent, accredited educational
programs for health-care professionals, as well as grants to patient
organizations and other medical education or scientific societies and
organizations in the United States, Europe, the Middle East, Africa and
Canada can also be found at the website referenced above.
Question. Pay for delay agreements cost consumers and taxpayers
billions in higher drug costs every year. The FTC has gone after drug
companies that enter into these settlements where the brand pays the
generic company to keep its lower cost alternative off the market. I'm
the lead Republican sponsor of S. 64, the Preserve Access to Affordable
Generics and Biosimilars Act, which would help put an end to these
deals.
Do you agree that these pay-off agreements keep drug costs high for
patients because they delay competition?
Answer. Patent settlement agreements challenged by the FTC as anti-
competitive, in which brands pay generic companies to stay out of the
market when it would otherwise be lawful for them to enter the market,
could delay patient access to lower cost alternatives. In contrast,
patent settlement agreements in which the brand, while not conceding
the invalidity or non-infringement of the patents, but in the face of
the uncertainties and costs associated with protracted litigation,
settles cases in a manner that allows a generic to enter the market
prior to expiry of the brand's patents could actually accelerate
patient access to lower cost alternatives. Still, brands do not enter
into such agreements lightly because they believe in the rights of
patent holders to vigorously enforce their intellectual property rights
in court. At the end of the day, these settlements do not delay entry
or cause the loss of any lawful competition because entry prior to the
expiry of these patents would be unlawful infringement unless and until
the generic manufacturers prevailed in court.
Question. Has your company ever entered into these kinds of
settlements with a generic company?
Answer. Merck has not entered into patent settlement agreements
with generic companies to delay their entry past when it would
otherwise be lawful for them to enter the market. Merck has been party
to a number of patent settlement agreements that provide for generic
market entry prior to patent expiry, including some that have provided
some level of exclusivity for a limited time. These agreements allowed
generic products to enter the market earlier than would have otherwise
been the case. The FTC has not challenged as anti-competitive any of
these types of agreements involving Merck.
Question. Do you support the pay for delay bill?
Answer. Merck does not support S. 64 in its present form. Merck
believes that the development of the law through the judicial process
is the most effective way to address the balance between antitrust law
and patent law raised by settlement agreements. S. 64 upsets the
careful balance embodied in a rule-of-reason analysis by creating a
presumption that ``anything of value'' or an ``exclusive license'' are
anticompetitive, thus denying an antitrust defendant the ability to
present and rely on countervailing evidence of pro-competitive effects,
such as the impact on competition by the entry of the generic product
before the expiration of the patent or statutory exclusivity term. As
noted by the Supreme Court in FTC v. Actavis:
Given these factors, it would be incongruous to determine
antitrust legality by measuring the settlement's
anticompetitive effects solely against patent law policy,
rather than by measuring them against procompetitive antitrust
policies as well.\1\
---------------------------------------------------------------------------
\1\ FTC v. Actavis, 570 U.S. 136, 148 (2013).
S. 64 also seeks to insulate the FTC's fact finding from judicial
review. Finally, the retroactive application of the provisions of the
bill to June 2013 is unworkable. While there had been a split between
the Circuit Courts over the proper analysis of reverse payment
settlements, the Supreme Court's opinion in Actavis in 2013 settled
that split by holding that patent settlements including those with
reverse payments were subject to a rule-of-reason analysis. That
decision did not provide hard and fast rules for the balance between
antitrust and patent principles. To impose a process that alters that
balance, and to do so retroactively, is imprudent and unfair.
rebate traps/walls
Question. I'm increasingly concerned about the effect of so-called
``rebate traps'' or ``rebate walls'' on patients' access to quality,
lower cost medicine. I understand there is ongoing litigation
challenging these practices as anti-competitive.
Does your company engage in the bundling of rebates over multiple
products? If so, why? And what benefit does the consumer gain from
that?
Answer. Merck understands this question to refer to certain
concerns about contracting practices applied to contracts between
manufacturers and PBMs or health plans. Merck offers rebates to payers
on bundles of products within certain product families (e.g., JANUVIA
and JANUMET, ASMANEX TWISTHALER and ASMANEX HFA). These bundled
discounts benefit patients by ensuring that multiple therapies are
maintained on a PBM or health plan formulary, thus ensuring wider
patient access to our medicines at lower costs to the payer. Merck also
offers discounts with respect to multiple bundled products outside of
the PBM and health plan contracts, such as in the vaccine and hospital
markets.
Question. Does your company view these practices as anticompetitive
or harmful to patients' access to quality, lower cost medicine?
Answer. No. Merck believes the rebates it offers to payers on
pharmaceutical products are procompetitive. Merck does not believe that
its rebating practices are harmful to patients.
Question. If a policy were adopted to eliminate rebates, or to
require that rebate savings be passed on to the consumer, would that in
and of itself solve the issue of rebate ``traps'' and ``walls''? And
would consumers benefit from such a policy?
Answer. Merck is very supportive of current efforts to change the
system. We believe these efforts will remove misaligned incentives
within the system, drive more transparency in the system and, most
importantly, benefit patients by lowering out-of-pocket costs. It is
difficult to predict whether these changes will solve all of the issues
seen today, but Merck is committed to working toward additional
solutions if issues remain after these changes are implemented.
drug pricing
Question. When setting the list price of a drug, does your company
consider regulatory costs or compliance? If so, how specifically do
those factors affect the list price of a drug? Please provide at least
one specific example, if applicable, from your current product
portfolio.
When setting the list price of a drug, does your company consider
the risk of liability or litigation? If so, how specifically do those
factors affect the list price of a drug? Please provide at least one
specific example, if applicable, from your current product portfolio.
Answer. In setting the list price for a drug, we do not
specifically consider the regulatory costs or compliance or the risk of
liability or litigation.
Merck approaches pricing from the perspective of value. This
approach looks at the value that a medicine provides through multiple
lenses with the goal of reflecting its benefit to patients and to
society, while at the same time paying an appropriate return on
invested capital to our investors, to ensure that we are able to
sustain R&D. While each individual situation varies based on factual
circumstances and market dynamics, generally, we consider:
Value provided to patients--to what extent does a new
medicine or vaccine establish a new standard of care that has
the potential to significantly extend and improve patient
lives?
Value provided to health-care systems--to what extent does a
new medicine or vaccine reduce the costs associated with
hospitalization and other costly complications of disease if
not appropriately (or optimally) treated?
Unmet need--does a new medicine or vaccine address a
critically unmet medical need, where few or no treatments
exist?
Access--what is the ability of various customers around the
world--including national, regional or local institutional
payers, physicians, employers and patients--to pay for our
products?
R&D sustainability--given the long-term risk and cost of
capital, can we appropriately compensate our investors to
ensure continued investment in the kind of risky and capital-
intensive research and development that will bring forward
medically important breakthroughs?
Competition--what are the costs of other treatments
currently on the market relative to the value provided by
Merck's products?
______
Questions Submitted by Hon. Pat Roberts
Question. What role do you see value-based arrangements (VBAs)
playing in the effort to reduce prescription drug costs? What potential
do these arrangements have to find the ``sweet spot'' between
controlling costs to patients and encouraging innovation of new drugs?
How can VBAs help lower what patients pay out-of-pocket?
Can Congress do more to allow for and encourage the use of VBAs?
Answer. For more than 10 years, Merck has worked with payers and
health-care providers to advance alternative pricing and contracting
arrangements, and Merck has publicly shared information about value-
based agreements (VBAs) it entered into with the payers Aetna and
Cigna. We are continuously reviewing ways in which the company may
enter into VBAs for our products, which we define as a contractual
framework aimed at achieving a mutually agreed upon value objective
that that drives greater value from health care spending. Merck is
interested, where business and customer objectives align, to implement
VBAs across the health care market, including Medicare Part D, Managed
Medicaid, and Fee-For-Service Medicaid.
By aligning payments for medicines more directly with their value
in improving meaningful health outcomes and/or reducing the need for
other health-care services (such as hospitalizations), VBAs make
pharmaceutical manufacturers accountable for the results their products
achieve in a concrete way and can help improve patients' health and
maximize the benefits of health-care spending. A recent Avalere survey
of payers found that 44 percent of payers engaged in outcomes-based
contracts experienced improvements in patient outcomes.\2\
---------------------------------------------------------------------------
\2\ Avalere Health. ``Outcomes-Based Contracts: Payer
Perspectives.'' Avalere Policy 360. July 19, 2018.
VBAs also can increase patient access to new therapies which could
ultimately improve patient outcomes. A payer that might otherwise
decline to cover a new medicine (or that would only cover the medicine
with significant utilization management restrictions or high cost
sharing) due to uncertainties about the expected percentage of its
patient population who would benefit might increase access to the
medicine if the manufacturer shared the risks of the medicine's
performance. These agreements may make medicines more accessible to
patients who will benefit from them and increase competition in
relevant therapeutic classes.\3\ Researchers have found that value-
based arrangements can improve patient access to medicines.\4\
---------------------------------------------------------------------------
\3\ Staley, L. ``A Drug's Worth: Why Federal Law Makes It Hard to
Pay for Pharmaceutical Performance.'' Boston University Law Review.
2018;98(1):303-334. (``Tying reimbursement to health outcomes presents
new opportunities for competition with rival manufacturers. . . . [A]
manufacturer that can demonstrate sustained health benefits in post-
market studies may distinguish itself from competitors.'').
\4\ See, for example, description of Entresto and Repatha contracts
in: Seely, E., and Kesselheim, A. ``Outcomes-Based Pharmaceutical
Contracts: An Answer to High U.S. Drug Spending?'' Commonwealth Fund.
Issue Brief. September 2017.
While Merck has had some experience with VBAs, these efforts have
not been as robust as they could be due to the challenges involved in
developing and implementing them. In addition to infrastructure and
data limitations, challenges include regulatory limitations such as
government pricing frameworks (e.g., Medicaid Best Price (BP) rules,
---------------------------------------------------------------------------
Medicare's Average Sales Price (ASP)) and Federal fraud and abuse laws.
Accordingly, we support opportunities that would enable greater
experimentation in the design, structure, and implementation of VBAs.
Further innovation in this space is needed to support overall sponsor
and plan learning, and to determine the range of potential benefits to
diverse health systems and beneficiaries. To fully achieve these goals,
however, the impacts of the current regulatory framework, including
government pricing requirements, the Federal Anti-Kickback Statute
(AKS), and overall environmental barriers, must be analyzed and
addressed as appropriate. Policy solutions such as the Patient
Affordability Value and Efficiency Act (PAVE), introduced by Senators
Warner and Cassidy, could provide necessary regulatory flexibility for
properly structured VBAs.
______
Questions Submitted by Hon. Michael B. Enzi
Question. More than 10 years ago, I worked on a bipartisan basis
with my good friends Ted Kennedy and Orrin Hatch to develop a
biosimilars approval pathway. One of the difficult things was
accounting for the differences between biosimilars and generics. I have
said before that if a drug was a three-bedroom, two-bath home, a
biologic would be a skyscraper. The size and complexity of the items
are just that different. I understand that it is much harder to build a
skyscraper without blueprints than a house. Even though the science has
come a long way since then, there aren't as many biosimilars on the
market as we might have hoped. Do you think the incentives in the law
appropriately account for the differences between biosimilars and
generics?
Answer. In general, biosimilars competition thus far has resulted
in moderation of prices, but actual utilization of the biosimilars
remains modest at best. We fear that an environment where market entry
of biosimilars brings value to the market, but little or none of that
value accrues to the biosimilar patient or the health-care system, will
not be sustainable.
Merck remains an advocate for rigorous biosimilarity standards
globally, and we believe that all biosimilar product applicants should
be required to demonstrate equivalence (i.e., biosimilarity) in safety
(including immunogenicity) and efficacy, and no differences in purity
and potency profiles between the originator reference product and the
biosimilar candidate. We believe the FDA has instituted such a standard
with its Totality of the Evidence approach, ``including structural and
functional characterization, nonclinical evaluation, human PK and PD
data, clinical immunogenicity data, and comparative clinical study(ies)
data.'' \5\
---------------------------------------------------------------------------
\5\ U.S. Food and Drug Administration. ``Scientific Considerations
in Demonstrating Biosimilarity to a Reference Product Guidance for
Industry.'' (Apr. 2015), https://www.fda.gov/downloads/drugs/guidances/
ucm291128.pdf.
We are urging Congress to pursue policies to encourage and support
biosimilar uptake and utilization in order to realize these potential
savings for the system and patients. These policies could include
---------------------------------------------------------------------------
reduced cost sharing in Medicare Part B.
Question. I know there are proposals to essentially pay more for
biosimilars to make them more attractive, but that is not exactly what
we were intending when we wrote the law. Can you talk about adverse
incentives in the market and any barriers to market penetration that we
might address to help improve patient access to these lower cost
products?
Answer. Merck introduced a biosimilar to the market 18 months ago
at a 35-
percent discount to the originator product, yet we have captured only a
tiny fraction of the market. Uptake of the product was limited, we
believe due to physician confusion regarding interchangeability and
extrapolation, and a lack of physician, patient, and payer incentives.
While we believe that the prescribing physician must always have the
authority to designate exactly which biological product is dispensed to
the patient, we believe there are market barriers that hamper
appropriate adoption of biosimilars. Merck encountered the following
market barriers that hampered uptake of RENFLEXIS:
We have observed cases where Medicare Advantage plans seem
to be imposing utilization management controls that require
providers to first use the reference biologic before providing
coverage for the biosimilar. This is a significant disincentive
to biosimilar uptake in that setting, and we believe is
contrary to policy objectives to promote the uptake of
biosimilars.
Some providers may be hesitant to adopt biosimilar products
due to overall confusion and the current lack of standardized
definitions of biosimilarity (including the concepts of
extrapolation and interchangeability). Currently, we lack
standardized definitions of interchangeability as it relates to
clinical significance, and concerns about the clinical
appropriateness of switching stable patients to a biosimilar
product have been contentious issues for some prescribers.
Further, prescribers may be comfortable with a single switch
(i.e., moving a stable patient from a reference product
treatment protocol to a biosimilar), but may have concerns
about switching a patient multiple times, absent the
interchangeability designation. We believe that regulatory
clarification of these terms and concepts could help mitigate
concerns for providers and support biosimilar product adoption.
We suggest the following policy changes to help encourage and
support prescriber biosimilar utilization:
Consider options to reduce or eliminate patient cost sharing
in Medicare Part B for biosimilars. While some Part B
beneficiaries are already able to reduce their 20 percent cost
sharing via supplemental coverage, we believe eliminating cost
sharing will encourage many physicians to use biosimilars for
their patients. A similar approach in Part D and in Medicaid
for small-molecule generics has driven generic utilization up
to 90 percent.\6\
---------------------------------------------------------------------------
\6\ Department of Health and Human Services. Office of Inspector
General. ``Generic Drug Utilization in the Medicare Part D Program.''
(Nov. 2007), https://oig.hhs.gov/oei/reports/oei-05-07-00130.pdf.
Create pathways for MA and Part D plans to receive bonus
payments and/or enhanced star ratings for achieving metrics
related to access to biosimilars. This will incentivize plans
to implement policies that drive additional utilization of
---------------------------------------------------------------------------
biosimilars.
Consider alternative reimbursement methodologies that adjust
the current Part B reimbursement formula. The current structure
in Part B to reimburse at ASP + 6 percent of the reference
product's ASP ensures there is no reimbursement downside to
physicians for using biosimilars. But so far, the evidence does
not suggest the current reimbursement rate sufficiently
incentivizes providers to use biosimilar products. Congress
should consider alternatives to further incentivize physician
adoption of biosimilars.
______
Questions Submitted by Hon. John Cornyn
Question. We continue to hear that rebates negotiated off of the
list price of a drug are both good and bad.
Pharmacy benefit managers and plans have argued that rebates are
used to lower premiums across the board and that it is the best way to
seek a price concession on otherwise expensive drugs.
Your industry argues that these payers are insisting on higher
rebates that can only be achieved by raising list prices.
But patients often lose under this system, with out of pocket costs
being tied to list price. Insulin patients appear to be routinely
impacted by this perversity in the system.
Please explain to the committee how your company would reduce list
prices if rebates were no longer a part of the equation?
What assurance can you provide that you would in fact lower your
prices?
What actions should be taken to ensure that patients are actually
seeing the benefits of lower out of pocket costs?
Answer. As we stated when we reduced the list price of several of
our products in July 2018, we will continue to look for opportunities
to reduce our list prices. We think the proposed rule will help create
those opportunities, but it can't happen overnight. We are currently
working with other stakeholders in the system to solve the operational
challenges that will enable these changes.
It is important to note that if the proposed rule is implemented,
Medicare beneficiaries' out-of-pocket costs will be reduced,
independent of any lowering of list prices, since their cost-sharing
will be based on the net price. Further actions to ensure patients
actually see the benefit of lower out of pocket costs might include
prohibitions on changes in benefit design by payers/PBMs that could
allow payers/PBMs to defeat the intent of delivering savings to
patients.
Question. If rebates are driving high list prices for drugs as drug
manufacturers' claim, why do you think that Part B drugs, which have no
PBM rebates, are also seeing significant price increases? Whose fault
is that?
Answer. While the misaligned incentives of Part D are partly
responsible for PBMs favoring high list prices, that is not the sole
dynamic associated with price increases. There may be unique reasons
for price increases on specific products given their individual
circumstances, including competitive dynamics and the costs of clinical
research and manufacturing improvements. In addition, while PBMs
generally do not manage Part B benefits, this does not mean that
discounts are not provided or applied on these products. Providers and
commercial health plans do receive discounts, the average of which is
passed along to patients through ASP-based reimbursement.
The 20-percent coinsurance paid by a patient is based on the ASP,
which reflects the average discounts received by providers and payers.
biosimilar competition/insulin
Question. Biosimilars have been much anticipated as a solution to
the drug pricing crisis. In particular, the FDA is moving to make
insulin a biologic that would be subject to biosimilar competition in
the future.
But we are hearing from all of you that the biosimilar market
doesn't work and the benefit of these cheaper but equally effective
alternatives are really not available to U.S. patients.
Can a biosimilar version of insulin be part of the solution for
diabetes patients?
If so, what changes need to be made to the system so that patients
and the taxpayer can realize the benefit of biosimilars? (Merck gave up
on pursuing a biosimilar to Sanofi's Lantus \7\)
---------------------------------------------------------------------------
\7\ Arlene Weintraub. ``Merck Ditches Biosimilar Lantus, But Will
That Ease the Path for Mylan's Rival Insulin Product?'' FiercePharma.
(Oct. 12, 2018), https://www.fiercepharma.com/pharma/merck-ditches-
biosimilar-lantus-but-will-ease-path-for-mylan-s-rival-insulin-product.
Answer. We believe there is potential for significant savings to
national health-care systems if high quality biosimilars--including
insulins--can be brought to the market and compete with those biologics
---------------------------------------------------------------------------
that have exhausted their intellectual property protections.
Biosimilar products are still the subject of a great deal of
confusion, particularly among providers, regarding the scientific,
regulatory, and clinical basis for extrapolation and interchangeability
decisions made by the FDA. Merck has urged the FDA to expand its work
in educating providers and other stakeholders on these topics.
Beyond that, we believe Congress should consider policy changes to
help encourage and support prescriber biosimilar utilization. In our
Blueprint comments to HHS we recommended incentives targeting patients,
health plans, and providers that we believe can move the needle in
stimulating uptake. One idea is for Congress to consider options to
reduce or eliminate patient cost sharing in Medicare Part B for
biosimilars.
As to the Lantus biosimilar, after a comprehensive assessment of
the current and future market environment for insulin glargine,
including biosimilars, which included an assessment of anticipated
pricing and cost of production, we made the business decision to
terminate our agreement on the commercialization of the Lusduna pen and
vial. There is already one other biosimilar glargine on the market and
others on the way. So, we concluded this space was, or soon will be,
adequately covered. This will allow us to allocate resources to other
products in development.
______
Questions Submitted by Hon. Todd Young
re-evaluating business strategies in foreign countries
Question. Since taking office, President Trump has made reducing
drug prices one of his highest priorities--and has repeatedly spoken
about his frustration with the U.S. subsidizing the costs of
pharmaceuticals for the rest of the world. He has gone so far as to
issue proposals, like the International Pricing Index (IPI) Model, in
an attempt to bring down prescription drug prices.
With the increased scrutiny of the industry and of the drug supply
chain as a whole in the United States, have any of your companies re-
evaluated your business strategy in foreign countries?
If not, then why?
If a proposal, like IPI, were implemented, would it force your
companies to potentially ``walk away from the negotiating table when
other countries demand low prices subsidized by America's seniors,'' as
HHS Senior Advisor for Drug Pricing Reform John O'Brien has said?
What are some of your ideas on how we can ensure Americans aren't
shouldering the full cost of pharmaceuticals?
Answer. Merck continually reevaluates its business strategies in
all markets, seeking in particular to make its vaccines and medicines
accessible to patients while realizing their full value in foreign
markets with regulatory schemes that do not recognize the full value of
these products and artificially reduce prices. Nevertheless, in most
markets there are very limited options for adjusting prices to
recognize the full value of our medicines and vaccines. One-sided and
onerous pricing and reimbursement schemes most often leave little room
for negotiation.
With regard to ``walking away from the negotiating table,'' Merck
always reserves that option. However, we recognize the serious and
negative implications on patient health and access, the company's
ultimate mission, and other possible repercussions that would result
from denying patient access to our medicines. Moreover, foreign
governments can resort to compulsory licensing, essentially seizing
patent rights, where a company refuses to market a product, which also
makes it difficult to withdraw from a foreign market.
Regarding ideas to ensure Americans aren't shouldering the full
cost of pharmaceuticals, we believe appropriate U.S. trade strategies
are a promising avenue to dealing with unreasonable foreign government
action. Positive actions in the U.S. can also reduce prices in the
U.S., including removing misaligned incentives that cause PBMs to favor
more expensive products and lead to higher out-of-pocket costs for U.S.
patients, like the administration's proposal regarding the rebate safe
harbor. One potential proposal would be to create a special USTR
negotiator specifically for drug pricing issues.
foreign countries' pricing and reimbursement
Question. President Trump and Secretary Azar have both repeatedly
described their frustrations with ``foreign freeloading'' of U.S. drugs
in the last year.
``When foreign governments extort unreasonably low prices from U.S.
drug makers, Americans have to pay more to subsidize the enormous cost
of research and development. . . . It's unfair and it's ridiculous, and
it's not going to happen any longer.''
Do you agree that because of foreign countries' pricing and
reimbursement systems, U.S. patients and innovators are shouldering the
burden for financing medical advances?
How do foreign countries' pricing and reimbursement systems affect
our prescription drug costs?
Are foreign governments taking note of the concerns being raised by
the Trump administration and have they responded in any way?
Has there been any noticeable change in any of our trade agreements
since these concerns have been raised by the Trump administration?
Answer. We agree that foreign countries' pricing and reimbursement
systems result in their not paying enough to support the
biopharmaceutical innovation from which they benefit. This causes the
U.S. to shoulder more than its fair share of financing medical
advances. These pricing and reimbursement systems do not necessarily,
however, affect prescription drug costs in the U.S. in any direct or
algorithmic fashion. Rather, Merck approaches pricing from the
perspective of value. This approach looks at the value that a medicine
provides through multiple lenses with the goal of reflecting its
benefit to patients and to society, while at the same time paying an
appropriate return on invested capital to our investors, to ensure that
we are able to sustain R&D. While each individual situation varies
based on factual circumstances and market dynamics, generally, we
consider:
Value provided to patients--to what extent does a new
medicine or vaccine establish a new standard of care that has
the potential to significantly extend and improve patient
lives?
Value provided to health-care systems--to what extent does a
new medicine or vaccine reduce the costs associated with
hospitalization and other costly complications of disease if
not appropriately (or optimally) treated?
Unmet need--does a new medicine or vaccine address a
critically unmet medical need, where few or no treatments
exist?
Access--what is the ability of various customers around the
world--including national, regional or local institutional
payers, physicians, employers and patients--to pay for our
products?
R&D sustainability--given the long-term risk and cost of
capital, can we appropriately compensate our investors to
ensure continued investment in the kind of risky and capital-
intensive research and development that will bring forward
medically important breakthroughs?
Competition--what are the costs of other treatments
currently on the market relative to the value provided by
Merck's products?
Prices in other countries often reflect different value systems and
criteria. It is important to note that all components of the health
care system, including hospital services, physician services, physician
salaries, and medical devices are considerably less expensive in
foreign countries than in the U.S. That said, we agree that foreign
countries' pricing and reimbursement systems result in their not
sufficiently supporting biopharmaceutical innovation. While foreign
governments are generally aware of concerns raised by the Trump
administration, we are not aware of any substantive response.
There has been some change in trade agreements, but more work needs
to be done. U.S. free trade agreements address discriminatory
approaches to pricing and reimbursement and ensure fair treatment for
innovative medicines through commitments established by trade partners.
Free trade agreements can help advance innovation, versus approaches
proposed by the administration such as the International Pricing Index
that have the potential to stifle investment in R&D by driving down
prices across markets.
Here are three examples:
A 2004 U.S. Department of Commerce study examining OECD
countries found that foreign price controls restrict the
ability to innovate in our sector and identified trade
agreements as a key lever. We strongly encourage the Trump
administration to update this report to reflect the impact of
continued price controls in OECD countries.
The pharmaceutical pricing and reimbursement provisions in
the U.S.-
Mexico-Canada Agreement commit governments to provide
transparency and due process protections in national
pharmaceutical reimbursement processes and decisions. This is a
step in the right direction, but more is needed to ensure that
many countries, such as Canada, appropriately recognize the
value of innovative medicines.
The Trump administration has worked to ensure adherence to
commitments in pricing and reimbursement in the Korea-U.S. Free
Trade Agreement, and direct advocacy by the U.S. has also made
an impact in Japan to mitigate some approaches.
There is clearly more work to be done in these areas, and trade
tools such as a new U.S.-Japan Free Trade Agreement, are critical.
medicaid closed formulary proposals
Question. In an attempt to bring down drug costs, various States
have been exploring whether to exclude certain drugs from its Medicaid
program. For example, the State of Massachusetts' recently asked CMS
for permission to create a closed formulary where the State Medicaid
program would pick at least one drug per therapeutic class. CMS denied
their waiver request citing violation of Federal law, but this proposal
does bring up important questions on how to contain drug prices in
State Medicaid programs.
If the principles of the Medicare Part D program--including the
necessary patient protections--were applied to State Medicaid programs,
do you think it lower drugs costs while ensuring access to patients?
Answer. There are important differences in the population covered
under Medicaid and the coverage options available that need to be
considered. Medicaid beneficiaries remain some of the sickest and most
complex populations of patients, with sometimes inconsistent
relationships with health-care providers and other complicating factors
that make accessing medical care already difficult. Many Medicaid
patients have complex diseases for which there are not always
therapeutically equivalent drugs available, so access to the specific
drug providers prescribe is crucial.
Part D is a highly competitive, successful program that has come in
at nearly half the cost that was originally projected. It also has
extremely high rates of beneficiary satisfaction--generally around 90
percent. While Part D offers multiple plan options and levels of
benefits such that patients can shop for plans that cover their
medicines at varying levels of cost-sharing, patients in Medicaid do
not have access to alternative coverage options. So, if a medicine they
need is not available, they do not have the ability to switch plans or
otherwise obtain access to the medicine.
As a result, the use of restrictive formularies is likely to result
in adverse effects on beneficiary outcomes and increased costs when
applied in Medicaid. While the patient protections that exist in Part D
may provide beneficiaries with an option to appeal formulary decisions,
it would be complicated to navigate for Medicaid patients and their
providers, who may have limited resources to take on the additional
responsibility and may take time that patients with complex conditions
may not have.
Medicaid is already receiving the best price based on the statutory
rebate and States have flexibility to exert utilization management
controls to negotiate supplemental rebates. Given this, we believe that
applying the principles of Medicare Part D in Medicaid is not likely to
result in lower drug costs without significantly impacting access.
medicaid ``best price''
Question. In the Trump administration's Blueprint, they suggested
that because drug manufactures have to give Medicaid the ``best price''
on drugs, there is no incentive to offer deeper discounts to other
payers--both government and commercial--than what is already offered
under the Medicaid Drug Rebate Program.
Does the Medicaid ``best price'' requirement encourage
manufacturers to increase initial prices?
What, if any, changes would you suggest we make to the program?
Answer. We can speak only to Merck's practices, and Merck does not
consider the Medicaid Best Price requirement when setting initial
prices. Merck approaches pricing from the perspective of value. This
approach looks at the value that a medicine provides through multiple
lenses with the goal of reflecting its benefit to patients and to
society, while at the same time paying an appropriate return on
invested capital to our investors, to ensure that we are able to
sustain R&D. While each individual situation varies based on factual
circumstances and market dynamics, generally, we consider:
Value provided to patients--to what extent does a new
medicine or vaccine establish a new standard of care that has
the potential to significantly extend and improve patient
lives?
Value provided to health-care systems--to what extent does a
new medicine or vaccine reduce the costs associated with
hospitalization and other costly complications of disease if
not appropriately (or optimally) treated?
Unmet need--does a new medicine or vaccine address a
critically unmet medical need, where few or no treatments
exist?
Access--what is the ability of various customers around the
world--including national, regional or local institutional
payers, physicians, employers and patients--to pay for our
products?
R&D sustainability--given the long-term risk and cost of
capital, can we appropriately compensate our investors to
ensure continued investment in the kind of risky and capital-
intensive research and development that will bring forward
medically-important breakthroughs?
Competition--what are the costs of other treatments
currently on the market relative to the value provided by
Merck's products?
We recognize the value that the Medicaid program provides for
patients who need it, and we do not believe the ``best price''
requirement encourages manufacturers to increase initial prices.
Merck believes that the exclusion of value-based arrangements
(VBAs) from the calculations of Best Price, Average Manufacturer Price,
and Average Sales Price would facilitate VBA implementation, which
would further align prices with the value that pharmaceutical products
bring to the market.
outcomes-based contracts
Question. In almost all of your testimonies, you highlight your
support of outcomes-based contracts and how we need to be shifting our
system toward that approach.
How will these contracts lower drug costs for patients in both the
near term and long-term?
How will they lower overall health-care costs for our Federal
programs?
What have the preliminary results looked like so far?
Answer. For more than 10 years, Merck has worked with payers and
health-care providers to advance alternative pricing and contracting
arrangements and Merck has publicly shared information about value-
based agreements (VBAs) it entered into with the payers Aetna and
Cigna. We are continuously reviewing ways in which the company may
enter into VBAs for our products, which we define as a contractual
framework aimed at achieving a mutually agreed upon value objective
that that drives greater value from health-care spending. Merck is
interested, where business and customer objectives align, to implement
VBAs across the health-care market, including Medicare Part D, Managed
Medicaid, and Fee-For-Service Medicaid.
By aligning payments for medicines more directly with their value
in improving meaningful health outcomes and/or reducing the need for
other health-care services (such as hospitalizations), VBAs make
pharmaceutical manufacturers accountable for the results their products
achieve in a concrete way and can help improve patients' health and
maximize the benefits of health-care spending. A recent Avalere survey
of payers found that 44 percent of payers engaged in outcomes-based
contracts experienced improvements in patient outcomes.\8\
---------------------------------------------------------------------------
\8\ Avalere Health. ``Outcomes-Based Contracts: Payer
Perspectives.'' Avalere Policy 360. July 19, 2018.
VBAs also can increase patient access to new therapies which could
ultimately improve patient outcomes. A payer that might otherwise
decline to cover a new medicine (or that would only cover the medicine
with significant utilization management restrictions or high cost
sharing) due to uncertainties about the expected percentage of its
patient population who would benefit might increase access to the
medicine if the manufacturer shared the risks of the medicine's
performance. These agreements may make medicines more accessible to
patients who will benefit from them and increase competition in
relevant therapeutic classes.\9\ Researchers have found that value-
based arrangements can improve patient access to medicines.\10\
---------------------------------------------------------------------------
\9\ Staley, L. ``A Drug's Worth: Why Federal Law Makes it Hard to
Pay for Pharmaceutical Performance.'' Boston University Law Review.
2018;98(1):303-334. (``Tying reimbursement to health outcomes presents
new opportunities for competition with rival manufacturers. . . . [A]
manufacturer that can demonstrate sustained health benefits in post-
market studies may distinguish itself from competitors.'').
\10\ See, for example, description of Entresto and Repatha
contracts in: Seely, E., and Kesselheim, A. ``Outcomes-Based
Pharmaceutical Contracts: An Answer to High U.S. Drug Spending?''
Commonwealth Fund. Issue Brief. September 2017.
While Merck has had some experience with VBAs, these efforts have
not been as robust as they could be due to the challenges involved in
developing and implementing them. In addition to infrastructure and
data limitations, challenges include regulatory limitations such as
government pricing frameworks (e.g., Medicaid Best Price (BP) rules,
---------------------------------------------------------------------------
Medicare's Average Sales Price (ASP)) and Federal fraud and abuse laws.
Accordingly, we support opportunities that would enable greater
experimentation in the design, structure, and implementation of VBAs.
Further innovation in this space is needed to support overall sponsor
and plan learning, and to determine the range of potential benefits to
diverse health systems and beneficiaries. To fully achieve these goals,
however, the impacts of the current regulatory framework, including
government pricing requirements, the Federal Anti-Kickback Statute
(AKS), and overall environmental barriers, must be analyzed and
addressed as appropriate. Policy solutions such as the Patient
Affordability Value and Efficiency Act (PAVE), introduced by Senators
Warner and Cassidy, could provide necessary regulatory flexibility for
properly structured VBAs.
transparency/point of sale
Question. In almost all of your testimonies, you express your
support for the Trump administration's proposal to allow manufacturers
to provide PBMs up-front discounts that are passed onto patients at the
point-of-sale.
Do you feel like this proposal will make the transactions within
the drug supply chain more transparent?
If so, would this transparency bring down drug costs--overall and
for specialty drugs?
Answer. We believe we must change the system to ensure that
patients receive the benefit of the significant rebates and discounts
that manufacturers like Merck pay to PBMs and plans. The proposed rule
is a positive step in that direction. Based on our initial assessment
of the proposal, we believe that it will remove misaligned incentives
within the system, drive more transparency in the system, and most
importantly, lower beneficiaries' out-of-pocket costs.
the relationship between wholesalers and manufacturers
Question. When talking about the pharmaceutical supply chain, a lot
of focus has been placed on the Pharmacy Benefit Manager. But there's
another side of the equation that I'd like to ask about.
How do wholesalers negotiate pricing with manufacturers?
What impact does this have on drug costs?
What incentives or disincentives do they have to contain price
increases?
Answer. There are many entities supporting the distribution and
dispensing of pharmaceutical products. Wholesalers purchase
pharmaceutical products directly from manufacturers and subsequently
sell those products to sites of care for dispensing. Downstream
customers of the wholesalers include retail and specialty pharmacies,
hospitals, clinics, and others. Those entities that purchase from the
wholesalers ultimately dispense or administer the drug to patients.
Many manufacturers typically offer a ``prompt pay'' discount to
wholesalers in exchange for timely payment of invoices (2 percent for
payment within 30 or 35 days is fairly standard in the industry).
Manufacturers also contract with wholesalers for services that
support the appropriate storage and distribution of product to
appropriate customers within the supply chain. These ``Distribution
Service Agreements'' provide wholesalers with an opportunity to earn
fees based on performance against pre-defined metrics that are part of
a set of standard services. These services include managing inventory
levels, achieving defined service levels, consolidating receipt of
inventory to a central location, and administering contract pricing and
chargebacks. Although these distribution service fees manufacturers pay
to wholesalers are commonly administered as a percent of the list
price, they are negotiated at arm's length and are based on fair market
value for the services rendered.
The terms of wholesaler agreements with their downstream customers
vary; however, in general, the prices they offer to their customers are
set relative to a product's list prices. In general, fees paid to
wholesalers by manufacturers are modest and wholesaler economics
(including both buy and sell side) are not likely to influence the
setting of a product's list price.
______
Questions Submitted by Hon. Ron Wyden
proposed rebate rule
Question. As has been done in many other settings, drug
manufacturers said during the hearing that one reason list prices for
drugs are high is that pharmaceutical benefit managers (PBMs) demand
larger and larger rebates in order for the drug to receive favorable
placement on a formulary. You and your colleagues who testified during
the hearing stated if the administration's proposal on changes to the
anti-kickback safe harbor for pharmaceutical rebates took effect, your
company would likely lower list price.
Like many Oregonians, I am skeptical drug manufacturers would
voluntarily lower their prices. Therefore, would you support
legislation that would (1) make similar changes the administration has
put forward related to Part D and Medicaid managed care, (2) change the
rebate system in a similar way to the proposal for the commercial
market, and (3) require drug makers to lower the list price of their
drugs equal to the amount of rebates provided today?
Answer. We believe we must change the system to ensure that
patients receive the benefit of the significant rebates and discounts
that manufacturers like Merck pay to PBMs and plans. The proposed rule
is a positive step in that direction. Based on our initial assessment
of the proposed rule, we believe that it will remove misaligned
incentives within the system, drive more transparency in the system,
and most importantly, lower beneficiaries' out-of-pocket costs. Merck
supports the earliest possible implementation of the proposed rule that
can be achieved without creating disruption for the beneficiaries who
rely on Medicare for their drug coverage. We are committed to working
with the PBMs and health plans and other intermediaries to make this
happen.
We do not support legislation to require manufacturers to lower
their list price equal to the amount of rebates today. First, different
purchasers receive different levels of discounts, based on
individualized negotiations and the formulary positioning of Merck's
products. So, there is not a uniform ``rebate amount'' that could
reduce the list price. Moreover, we expect that the robust negotiations
that occur today will continue in the highly competitive Part D market,
and we expect to realize the same level of net price that we do today.
In fact, we expect that there could be additional pricing pressure
under the new system, which could lead to lower net prices.
Over time, we expect that our list prices will go down if the
misaligned incentives across the system are addressed. We are currently
working with other stakeholders in the system to solve the operational
challenges that will enable these changes.
But, it is also important to note that if the rule is implemented,
Medicare beneficiaries' out-of-pocket costs will be reduced,
independent of any lowering of list prices, since their cost-sharing
will be based on the net price. Nonetheless, we believe the rebate rule
will align incentives in a way that will restrain list prices.
As we stated when we reduced the list price of several of our
products in July 2018, we have continued to look for opportunities to
reduce our list prices. We think the proposed rule would help create
those opportunities, but it can't happen overnight. All the players in
the ecosystem will need to adjust to the new model. We are actively
working to support the move to a contracting model in Part D that would
change the incentives to support lower list prices.
Lowering list prices is not an easy thing to do in our health-care
system:
One of the key challenges to lowering list prices is the
contractual arrangements that companies have with PBMs and
health plans, which are intended to ensure access to our
products. These contracts are often multi-year and are most
often written to provide a discount off of the list price,
which is paid as a rebate later.
To reduce the list price without significant financial
consequences, all of these contracts would need to be modified
to maintain the same net price. Unless the entire system
changes, one manufacturer runs the risk of being disadvantaged
and losing formulary status or being required to pay the same
percentage discount on a lower list, which could be
unsustainable.
In addition, drugs flow through a complex supply chain, from
the manufacturer, to the wholesaler, to a pharmacy or hospital
who dispenses the drug to patients. For any product but even
more so for a high volume primary care product that is flowing
through to all pharmacies and hospitals, there is not a
mechanism in place to readjust the value of the inventory being
held by all those parties.
If the proposed rule is implemented as written, it would only apply
to our contracts with PBMs and health plans for Medicare Part D and
Managed Medicaid. If PBMs and health plans maintain the rebate model in
the commercial market, we would still have commercial contracts based
on rebates, which would be subject to the existing constraints to
lowering list price. We also would still need a mechanism to revalue
drug in the distribution channel in a financially viable manner.
medicaid drug rebate program
Question. The Medicaid Drug Rebate Program (MDRP) requires
manufacturers to provide a basic rebate and an additional inflationary
rebate for both brand and generic drugs. The inflationary rebate is an
increasingly substantial part of total rebates due in large part to
large increases in drug prices that exceed inflation. Under current
law, this inflationary rebate is capped at 100 percent of Average
Manufacturer Price (AMP). This is the case even when manufacturers
continue to raise their prices well above inflation.
Please provide a list of all of your pharmaceutical products that
have reached the Medicaid AMP rebate cap in any of the 20 quarters from
January 1, 2014 through December 31, 2018.
For each drug listed in response to question 1, please also provide
a list of which quarters and years each drug hit the cap.
Answer. Merck conforms to all statutory, regulatory, and sub-
regulatory guidance regarding its participation in the Medicaid Drug
Rebate Program, including the payment of Medicaid rebates. The
information requested by this question, however, is confidential,
proprietary, and commercially and competitively sensitive. Merck would
be happy to explore other means to share this information with the
committee in a confidential fashion.
medicaid drug rebate program compliance
Question. I am concerned about recent reports and legal settlements
surrounding drug manufacturers' failure to comply fully with the
requirements of the MDRP. For example, an analysis by the U.S.
Department of Health and Human Services Office of Inspector General
found that between 2012 and 2016 taxpayers may have overpaid by as much
as $1.3 billion for 10 potentially misclassified drugs. That is why I
introduced the Right Rebate Act with Chairman Grassley to prevent drug
manufacturers from manipulating Medicaid to increase their profits.
However, I continued to be concerned about oversight and manufacturer
compliance with the requirements of the Medicaid Drug Rebate Program.
Accordingly, please describe the following:
Your company's current compliance plan and procedures used to
ensure compliance with the requirements of the Medicaid Drug Rebate
Program including internal audits or other checks you use to identify
compliance vulnerabilities.
Answer. Merck's government price reporting team--in consultation
with in-house attorneys, outside counsel, and third-party vendors as
appropriate--maintains comprehensive and detailed government price
reporting policies, procedures, and reasonable assumptions for
compliance with all price reporting programs, including the Medicaid
Drug Rebate Program (MDRP). Merck's policies are evaluated and updated,
as needed, on an annual basis by the government price report team, in-
house attorneys, and outside counsel to ensure that they are consistent
with current regulations and applicable guidance from the Centers for
Medicare and Medicaid Services (CMS). Additionally, Merck's reasonable
assumptions are evaluated and updated, as needed, on a monthly basis
for Average Manufacturer Price and on a quarterly basis for Best Price
by the government price reporting team, in-house attorneys, and outside
counsel. Merck has a long history of transparency and communication
with CMS regarding its MDRP compliance and reasonable assumptions, and
company compliance personnel regularly oversee Merck's price reporting
operations. Merck evaluates any new guidance issued by CMS to ensure
that its price reporting calculations and processes are in compliance
with the law.
Question. Any past or ongoing issues of non-compliance.
Answer. Merck maintains comprehensive and detailed reasonable
assumptions for its MDRP participation. In situations in which Merck is
uncertain about a calculation approach that is not clearly addressed in
CMS rules or guidance, the company documents its approach in
assumptions and/or discloses its intended approach to CMS.
Additionally, given the complexity of the calculations, Merck may
identify calculation mistakes or other issues that require correction.
This may happen, for example, to the extent that Merck believes that
any new CMS rules or guidance call into question a reasonable
assumption that the company has previously maintained. In such cases,
if Merck has any concern about its program compliance, it promptly
communicates with CMS to seek the agency's guidance and potentially
restate its prior MDRP reports.
Question. Any corrective actions taken to address identified
problems or issues of non-compliance with the MDRP and how such steps
were communicated to the Centers for Medicare and Medicaid Services.
Answer. As noted above, to the extent that Merck believes that any
of its existing calculation or compliance processes for MDRP
participation are not in keeping with current CMS rules or guidance,
the Company would promptly engage with the agency to identify any
necessary remedial steps and the appropriate way forward, including
filing pricing restatements.
Question. Any steps taken to improve compliance and ensure that all
Medicaid drug rebates owed to the Federal Government and the States are
paid in full.
Answer. As noted above, Merck takes its government price reporting
obligations very seriously, and the Company maintains robust, ongoing
legal and compliance oversight of its price reporting team and its
operations. As discussed above, we routinely review our policies,
procedures, and reasonable assumptions to ensure compliance with
current law. Merck also has an annual training requirement for
government price reporting compliance. If Merck were to identify any
potential noncompliance issue associated with the underpayment of
rebates to the State Medicaid Programs, Merck immediately would
identify this issue to CMS and would work with the agency to ensure the
implementation of any appropriate remedy (including restating pricing
metrics and reconciling rebate amounts with the States).
bonus payments tied to specific drugs
Question. I am concerned by the potential for employee financial
incentives to encourage high launch prices and price increases for
prescription drugs.
Is your salary, bonus, or other compensation tied to sales or
revenue targets of a single product your company sells? Has it ever
been? If yes, please state the product or products to which your
salary, bonus, or other compensation was tied.
Answer. My salary, bonus, or other compensation is not tied to
sales or revenue targets of a single product that Merck sells. In 2011,
a very small percentage of my annual bonus was tied to the net sales of
3 new products (DULERA, SIMPONI, and VICTRELIS).
Question. Is your salary, bonus, or other compensation tied to
either revenue or net income of the company as a whole? Has it ever
been? If yes, please explain what assumptions about price increases are
used when the compensation committee sets revenue or net income goals.
Does the compensation committee provide any guidance to executives in
regards to the amount of revenue that the company will generate from
price increases versus volume growth?
Answer. Yes, a portion of my annual bonus is tied to revenue and
pretax income (i.e., a variation of net income) of the company as a
whole, with each contributing 40 percent (for a total of 80 percent) to
the aggregate incentive target, and research and development
productivity constituting the other 20 percent of the target. The final
bonus that I receive is then calculated based on the company's actual
performance for those three metrics.
The Compensation and Benefits Committee of the Board sets annual
targets for revenue and pretax income based upon the company's annual
plan, as approved by the full Board of Directors.
The company's annual plan includes U.S. pricing assumptions
informed by several variables, including volume, price, and discount
rates, which for 2019 are fully consistent with our July 19, 2018
commitment to not increase net price across our product portfolio in
the U.S. by more than inflation annually.
Neither the board of directors as a whole, nor the Compensation and
Benefits Committee specifically, provides guidance to executives with
regard to the amount of revenue that the company will generate from
price increases versus volume growth.
net prices
Question. In your testimony, you stated, ``last year we pledged
that we will not increase our average net prices for our portfolio by
more than the rate of inflation annually,'' and that ``From 2010 to
2017, Merck's average net price increase across our portfolio each year
has been in the low to mid-single digits. In fact, our average net
price declined in 2017 by almost 2 percent. In 2017, the average
discount for our medicines and vaccines was more than 45 percent lower
than the list price.'' Please describe how the company's year-over-year
aggregate net price is calculated. Please also specifically address the
following questions:
Answer. Net Price Change represents the year-over-year change in
average net price, which is Wholesale Acquisition Cost (WAC) less
rebates, discounts, and returns. The annual percent change versus prior
year was calculated at a product level and weighted across the
company's U.S. Product Portfolio. U.S. Product Portfolio includes human
health pharmaceutical and vaccine products marketed by the company,
excluding partnered products. The product sales utilized in the
analysis represent 97 percent of the total U.S. Product Portfolio in
2010, increasing each year to approach 99.8 percent of coverage in
2017.
Question. How many products are included in the calculation of the
average net price change? What was the median net price change?
Answer. In 2017, 78 products were included. The median net price
change was 0 percent.
Question. Is net price weighted? If so, how? For example, in
determining the aggregate net price does the company assign different
weights to different products based on volume or other factors? Are
``on patent'' and ``off patent'' drugs weighted identically? Are other
statistical weights used or are all products treated equally?
Answer. The Net Price Change percent for each product is weighted
by its Net Sales relative to the Total Net Sales of the Product
Portfolio for the current year. On and off patent drugs are calculated
in the same fashion, and no other ``statistical weighting'' is applied.
Question. Does the figure that you provided during your testimony
account for U.S. prices, international prices, or both? Generally
speaking, when your company reports net price changes, does it
differentiate between U.S. and international prices?
Answer. Only U.S. prices are used in the report.
Question. Please list the five drugs your company sold in the U.S.
that had the greatest year-over-year net price increase in 2018, noting
the increase for each drug by dollar figure and percentage. Please list
the five drugs your company sold in the U.S. that had the lowest year-
over-year net price increase (and/or the greatest decrease) in 2018,
noting the increase (or decrease) for each drug by dollar figure and
percentage.
Answer. The product-specific information requested is competitively
sensitive and Merck therefore cannot produce it in a public setting in
which it could be accessed by competitors. However, Merck does report
similar information in an aggregated format in its annual price
transparency report, which we proactively make available on our
corporate responsibility website:
https://s3.amazonaws.com/msd18-assets/wp-content/uploads/2019/02/
281553
45/2018-US-PRICING-TRANSPARENCY-REPORT_02.2019.pdf
The report sets forth the average annual list price changes across
the Merck portfolio as well as other price related information
concerning Merck medicines and vaccines. The report shows that in 2018
the average annual list price across the Merck portfolio increased by
5.5 percent--the lowest increase since 2010--as compared with a 6.6
percent increase in 2017. In 2018, the Company's gross U.S. sales were
reduced by 44.3% as a result of rebates, discounts and returns. The
below chart reflects additional information about the price changes for
Merck products.
U.S. Product Portfolio Percent Change vs. Prior Year
----------------------------------------------------------------------------------------------------------------
2010 2011 2012 2013 2014 2015 2016 2017 2018
----------------------------------------------------------------------------------------------------------------
List Price Change (WAC) 7.4 9.5 9.2 9.6 10.5 9.8 9.6 6.6 5.5
----------------------------------------------------------------------------------------------------------------
Net Price 3.4 5.1 6.2 5.5 3.7 5.5 5.5 (1.9) 2.99
----------------------------------------------------------------------------------------------------------------
U.S. Product Portfolio
----------------------------------------------------------------------------------------------------------------
Average Discount (%) 27.3 28.9 29.9 32.1 37.0 38.2 40.9 45.1 44.3
----------------------------------------------------------------------------------------------------------------
Question. For 2018, what was the average net price change in the
U.S. market for (1) drugs with no competition, (2) drugs with only
branded competition, and (3) drugs with generic competition?
Answer. The product-specific information requested is competitively
sensitive and Merck therefore cannot produce it in a public setting in
which it could be accessed by competitors. However, Merck does report
similar information in an aggregated format in its annual price
transparency report, which we proactively make available on our
corporate responsibility website:
https://s3.amazonaws.com/msd18-assets/wp-content/uploads/2019/02/
281553
45/2018-US-PRICING-TRANSPARENCY-REPORT_02.2019.pdf
The report sets forth the average annual list price changes across
the Merck portfolio as well as other price related information
concerning Merck medicines and vaccines. The report shows that in 2018
the average annual list price across the Merck portfolio increased by
5.5 percent--the lowest increase since 2010--as compared with a 6.6-
percent increase in 2017. In 2018, the company's gross U.S. sales were
reduced by 44.3% as a result of rebates, discounts and returns. The
below chart reflects additional information about the price changes for
Merck products.
U.S. Product Portfolio Percent Change vs. Prior Year
----------------------------------------------------------------------------------------------------------------
2010 2011 2012 2013 2014 2015 2016 2017 2018
----------------------------------------------------------------------------------------------------------------
List Price Change (WAC) 7.4 9.5 9.2 9.6 10.5 9.8 9.6 6.6 5.5
----------------------------------------------------------------------------------------------------------------
Net Price 3.4 5.1 6.2 5.5 3.7 5.5 5.5 (1.9) 2.99
----------------------------------------------------------------------------------------------------------------
U.S. Product Portfolio
----------------------------------------------------------------------------------------------------------------
Average Discount (%) 27.3 28.9 29.9 32.1 37.0 38.2 40.9 45.1 44.3
----------------------------------------------------------------------------------------------------------------
Question. In Merck's most recent pricing transparency report, the
company notes that the ``the average annual net price across our
portfolio declined by 1.9 percent, reflecting specific in-year
dynamics, including the impact of loss of patent protection for three
major medicines.'' Please identify these medicines, and the net price
change for each of them on a dollar and percentage basis for 2017. What
was Merck's average net price increase/decrease in 2017 for drugs
excluding these three medications?
Answer. This information is confidential, proprietary, and
commercially sensitive. Merck's average net price increase/decrease in
2017 excluding the three drugs referred to is -0.6 percent.
Question. In Merck's pricing transparency report, the company
states that its net price is ``represents the year-over-year change in
average net price, which is WAC less rebates, discounts and returns,''
while its average discount is ``weighted . . . [and] calculated by
dividing annual rebates, discounts and returns by annual gross sales.''
Please clarify whether the company's average net price is weighted for
purposes of complying with its publically stated pledge.
Answer. Yes, the average net price is weighted.
______
Questions Submitted by Hon. Robert Menendez
Question. When new products enter the market, do drug companies set
high initial rebates and then provide deep rebates in order to gain
access to insurance plan's formularies?
Answer. Merck approaches pricing from the perspective of value.
This approach looks at the value that a medicine provides through
multiple lenses with the goal of reflecting its benefit to patients and
to society, while at the same time paying an appropriate return on
invested capital to our investors, to ensure that we are able to
sustain R&D. While each individual situation varies based on factual
circumstances and market dynamics, generally, we consider:
Value provided to patients--to what extent does a new
medicine or vaccine establish a new standard of care that has
the potential to significantly extend and improve patient
lives?
Value provided to health-care systems--to what extent does a
new medicine or vaccine reduce the costs associated with
hospitalization and other costly complications of disease if
not appropriately (or optimally) treated?
Unmet need--does a new medicine or vaccine address a
critically unmet medical need, where few or no treatments
exist?
Access--what is the ability of various customers around the
world--including national, regional or local institutional
payers, physicians, employers and patients--to pay for our
products?
R&D sustainability--given the long-term risk and cost of
capital, can we appropriately compensate our investors to
ensure continued investment in the kind of risky and capital-
intensive research and development that will bring forward
medically important breakthroughs?
Competition--what are the costs of other treatments
currently on the market relative to the value provided by
Merck's products?
When the company launched ZEPATIER into the Hepatitis C market,
Merck chose a low list price strategy, while competitors had a higher
price with significant rebates. Unfortunately, we were unable to gain
reasonable formulary status or resulting sales in certain market
segments with this strategy. Positive actions in the U.S., such as the
administration's proposal regarding the rebate safe harbor could
provide incentives for lower initial list prices in the future.
Question. If CMS finalizes the rebate rule, do you anticipate
future products entering the market with significantly lower initial
list prices?
Answer. Over time, we expect that list prices will go down if you
remove the misaligned incentives in the system. It is also important to
note that if the rule is implemented, Medicare beneficiaries' out-of-
pocket costs will be reduced--independent of any lowering of list
prices--since their cost-sharing will be based on the net price. But we
believe the rebate rule will align incentives in a way that will
restrain list prices.
If this rule is implemented as written, it would only apply to our
contracts with PBMs and health plans for Medicare Part D and Managed
Medicaid. If PBMs and health plans maintain the rebate model in the
commercial market, we would still have commercial contracts based on
rebates, which would be subject to the existing constraints to lowering
list price. We also would still need a mechanism to revalue drug in the
distribution channel in a financially viable manner.
______
Questions Submitted by Hon. Thomas R. Carper
Question. What are your recommendations for lowering prices for the
40 percent of drugs that do not offer rebates in Medicare Part D?
Answer. Assuming the 40 percent reference is correct, we believe
that the administration's rebate safe harbor proposal will lead to
lower prices even for products which currently may offer no or minimal
rebates in Medicare Part D. We believe the increasing transparency of
prices will spur heightened competition even in classes and for
products where rebating has been limited in the current system.
Similarly, the fact that price concessions will be made directly
available to patients will also create a price-reducing dynamic since
price concessions will make products more affordable to patients,
resulting potentially in greater adherence and appropriate use of
prescribed medicines, clearly benefiting patients and encouraging
manufacturers to offer price concessions. Additionally, assuming policy
changes are made to further incentivize value-based contracts, we
believe that value-based contracts can also help to restrain initial
list prices by tying those prices to the value that the products bring
to patients and the health-care system.
Question. In the health insurance plans that you offer your
employees, do you ask your insurers to pass through the full
manufacturer rebates to the beneficiaries?
Answer. Merck offers a generous health-care benefit for our 24,000
U.S. employees. There is no deductible for medications covered under
our pharmacy benefit, and employees never have to pay more than $50 for
a retail prescription for a covered medication, and in most cases pay
less. We contract with a PBM for management of the prescription drug
benefits for our employees, and the benefit does not offer point-of-
sale rebates to our employees. Merck uses savings generated by rebates
to lower overall costs for employees while ensuring low out-of-pocket
costs.
Question. The systems for pricing and distributing drugs are opaque
and difficult to understand. What are your recommendations for
increasing transparency in how your companies set the list prices for
drugs, and for improving transparency in the supply chain for
prescription drugs? Would you support Federal standards for
transparency in setting the list prices for drugs?
Answer. We are open and transparent about the factors we consider
in setting prices. Merck approaches pricing from the perspective of
value. This approach looks at the value that a medicine provides
through multiple lenses with the goal of reflecting its benefit to
patients and to society, while at the same time paying an appropriate
return on invested capital to our investors, to ensure that we are able
to sustain R&D. While each individual situation varies based on factual
circumstances and market dynamics, generally, we consider:
Value provided to patients--to what extent does a new
medicine or vaccine establish a new standard of care that has
the potential to significantly extend and improve patient
lives?
Value provided to health-care systems--to what extent does a
new medicine or vaccine reduce the costs associated with
hospitalization and other costly complications of disease if
not appropriately (or optimally) treated?
Unmet need--does a new medicine or vaccine address a
critically unmet medical need, where few or no treatments
exist?
Access--what is the ability of various customers around the
world--including national, regional or local institutional
payers, physicians, employers and patients--to pay for our
products?
R&D sustainability--given the long-term risk and cost of
capital, can we appropriately compensate our investors to
ensure continued investment in the kind of risky and capital-
intensive research and development that will bring forward
medically important breakthroughs?
Competition--what are the costs of other treatments
currently on the market relative to the value provided by
Merck's products?
Question. In nearly every sector of the health-care industry,
Medicare, Medicaid, employers, and insurers are moving away from fee-
for-service payments to reimbursements based on value and performance.
Prescription drugs and medical devices were the glaring exceptions to
this trend until recently. How many of your drugs are included in
value-based contracts and how many patients are benefiting from them?
How do these value-based contracts work to lower drug prices for both
patients and taxpayers?
Answer. Merck has been party to value-based discounting
arrangements for four of its products. It is difficult to assess
exactly how many patients have benefitted from them, however, since
that information is not in Merck's possession under the arrangements.
Merck agrees that value-based discounting strategies can benefit
patients and the Federal health care programs by ensuring that payment
aligns with the value or outcomes that a manufacturer's products bring
to the system. If, for example, a value-based agreement demonstrates
that a manufacturer's product helps patients to achieve meaningful
clinical outcomes (or even to avoid more serious illness complications
or comorbidities), the product would have demonstrated a savings to
patients and taxpayers (for example, by avoiding hospitalization or
further treatment for a particular condition). There are, however,
significant impediments under current law regarding adopting this type
of contract--including under the Anti-Kickback Statute and manufacturer
government price reporting obligations--and Merck supports legislative
or regulatory reforms to increase the proliferation of value- or
outcomes-based discounting.
Question. Last year, Senator Portman and I did an investigation on
the pricing of an opioid overdose reversal drug called EVZIO,
manufactured by Kaleo. Kaleo increased the price of EVZIO from $575 in
2014 to $4,100 in 2017. We found that the best price Medicare was able
to get for EVZIO, about $4,000, was much higher than the price other
Federal programs and private insurers were able to get. It seemed that
Kaleo was able to get this higher price of $4,000 from Medicare by
helping doctors fill out paperwork showing that the drug was medically
necessary, even though there are cheaper alternatives on the market. As
a result of the investigation, Kaleo announced it will bring a generic
version of the drug to market at only $168 per pack. Are any of your
companies providing medical necessity paperwork to doctors in order to
get your drugs covered by Medicare?
Answer. In the United States, Merck provides limited reimbursement
support for patients in connection with the purchase of certain of
Merck's products following a physician's prescribing decision (in
accordance with Department of Health and Human Services Office of
Inspector General guidance). In certain cases, this support includes
identifying--for patients and physicians--the appropriate forms and
insurance processes attendant to securing insurance coverage for our
products. But it is Merck's policy never to interfere with the
physician-patient relationship or the decision about whether to seek
insurance coverage.
Question. In 2017, the Rand Corporation estimated that biosimilar
drugs, which are competitors to complex, biologic drugs, could save the
United States more than $50 billion over the next decade. Some of you
have also argued that increasing the use of biosimilar drugs would help
lower drugs costs for consumers and taxpayers. What is delaying the
uptake of biosimilar drugs in the United States? What policies do you
recommend to increase the development of biosimilar drugs?
Answer. Merck agrees that we can significantly reduce spending on
pharmaceuticals, especially for patients, by ensuring that we have a
viable market for biosimilars in the United States. We believe, like
with traditional small molecule medicines, generic competition after a
reasonable period of exclusivity will create headroom for patients to
afford the newest, most innovative medicines. In addition to the RAND
data that you referenced, other research shows that generics and
biosimilars are expected to drive savings of $105 billion through 2022
in the U.S.\11\
---------------------------------------------------------------------------
\11\ IQVIA. ``Medicine Use and Spending in the U.S.: A Review of
2017 and Outlook to 2022.'' (Apr. 19, 2018), https://www.iqvia.com/
institute/reports/medicine-use-and-spending-in-the-us-review-of-2017-
outlook-to-2022.
We suggest the following policy changes to help encourage and
---------------------------------------------------------------------------
support prescriber biosimilar utilization:
Consider options to reduce or eliminate patient cost sharing
in Medicare Part B for biosimilars. While some Part B
beneficiaries are already able to reduce their 20 percent cost
sharing via supplemental coverage, we believe eliminating cost
sharing will encourage many physicians to use biosimilars for
their patients. A similar approach in Part D and in Medicaid
for small-molecule generics has driven generic utilization up
to 90 percent.\12\
---------------------------------------------------------------------------
\12\ Department of Health and Human Services. Office of Inspector
General. ``Generic Drug Utilization in the Medicare Part D Program.''
(Nov. 2007), https://oig.hhs.gov/oei/reports/oei-05-07-00130.pdf.
Create pathways for MA and Part D plans to receive bonus
payments and/or enhanced star ratings for achieving metrics
related to access to biosimilars. This will incentivize plans
to implement policies that drive additional utilization of
---------------------------------------------------------------------------
biosimilars.
Consider alternative reimbursement methodologies that adjust
the current Part B reimbursement formula. The current structure
in Part B to reimburse at ASP + 6 percent of the reference
product ASP ensures there is no reimbursement downside to
physicians for using biosimilars. But so far, the evidence does
not suggest the current reimbursement rate sufficiently
incentivizes providers to use biosimilar products. The
administration should consider alternatives to further
incentivize physician adoption of biosimilars.
______
Questions Submitted by Hon. Benjamin L. Cardin
Question. The United States is one of the only countries in the
world to allow prescription drug manufacturers to advertise directly to
consumers through magazines, billboards, radio, and television
commercials. While I will not argue that it is beneficial to educate
consumers about an unfamiliar disease and encourage them to seek
medical help, most commercials from all of your companies recommend
asking about a specific brand name drug, not a medical condition.
Furthermore, even if your advertisements follow all FDA rules and list
medication side effects, they also almost always list these while a
smiling, apparently healthy person is walking on a beach.
Researchers say that this type of imagery, combined with viewing
hours of drug commercials each month, leads consumers to underestimate
the risks associated with medications. For the past decade, studies
have shown that aggressive direct-to-consumer advertising is associated
with rising drug prices and an increase in inappropriate drug
prescriptions.
Since researchers have concluded that consumers are
misunderstanding the benefits and risks described in your ads, what
further policies could help you and your colleagues ensure that you are
educating patients in a clear manner?
Answer. Merck believes that direct-to-consumer (DTC) advertising
can be an important and helpful way to inform patients about diseases
that may be relevant to them and therapeutic options they may want to
discuss with their physician. Data demonstrate that DTC can have a
positive impact on patient health in terms of diagnosis, treatment, and
adherence to prescribed therapies. We recognize that DTC is one channel
amongst many to help educate patients. Print materials, telephone,
websites, and other channels are also used to provide more in-depth
information to patients. The ultimate decision to prescribe a product
for any specific patient remains with the physician following
discussion with their patient.
Merck adheres to FDA regulations and guidelines governing DTC
promotion and has a long-standing policy to voluntarily submit new DTC
broadcast advertising campaigns to FDA for pre-review. Merck also
follows the PhRMA Guiding Principles for DTC Advertisements About
Prescription Medicines. We are currently considering what additional
information we can make available to consumers to ensure that they can
make informed health care decisions.
pharmaceutical companies continue to raise prices
Question. As you are well aware, high prescription drug prices are
the number one concern for Americans and their families. According to
the Organization for Economic Cooperation and Development, the average
American spends around $1,208 annually on prescription drugs. There
have been several instances where brand name or even generic drugs that
have been on the market for years continue to increase in price.
One of the most well-known examples is Mylan's increase of the
price of EpiPen from less than $100 in 2007 to more than $600 in 2016.
Another example is the ever-increasing price of insulin. Sanofi
increased the price of a vial of Lantus from $88.20 in 2007 to $307.20
in 2017. And those are just a small sample of price increases.
Why don't we see price decreases for drugs that have been on the
market for years without new formulations or added benefit?
Answer. List prices do not generally decline largely owing to many
of the misaligned incentives that the administration's rebate safe
harbor proposal is designed to address. Specifically, rebate contracts
for commercial and Medicare Part D payers/PBMs are designed as set
percentages from the list price. Lowering list prices while maintaining
these same percentage discounts/rebates usually precludes the
commercial viability of reducing list prices.
We do in fact see price decreases for products that have been on
the market for years--extremely large ones. They occur at the time of
patent expiry, and often reduce prices by over 90 percent. This is
unlike any other part of the health care system we are aware of, where
prices drop massively after a specified period. If these massive one-
time price reductions occurred more gradually, it would be far more
obvious that prices were decreasing. Even putting this aside, net
prices on many products drop dramatically over time as competition from
new products increases. For instance, the average net price of our
anti-diabetes medicine Januvia is less today than it was when it was
launched in 2007.
pay for delay
Question. Pay for delay is a tactic that more and more branded drug
manufacturers have been using to stifle competition from lower-cost
generic manufacturers. This allows you to sidestep competition by
offering patent settlements that pay generic companies not to bring
lower-cost alternatives to market.
These ``pay-for-delay'' patent settlements benefit both brand-name
pharmaceutical companies by helping them avoid costly patent litigation
and general manufacturers by rewarding them a hefty sum to delay
entering the market with a cheaper drug alternative. However, these
deals do not benefit consumers. According to an FTC study, these
anticompetitive deals cost consumers and taxpayers $3.5 billion in
higher drug costs every year.
Does your company partake in pay-for-delay settlements?
Answer. Merck has not entered into patent settlement agreements
with generic companies to delay their entry past when it would
otherwise be lawful for them to enter the market. Merck has been party
to a number of patent settlement agreements that provide for generic
market entry prior to patent expiry, including some that have provided
some level of exclusivity for a limited time. These agreements allowed
generic products to enter the market earlier than would have otherwise
been the case. The FTC has not challenged as anti-competitive any of
these types of agreements involving Merck.
Question. Why would a pharmaceutical company enter into a pay-for-
delay agreement?
Answer. Parties enter into settlements of patent litigation for all
the same reasons parties settle other civil litigation. These include
allocation of risk in the dispute, avoidance of litigation costs, or
beneficial access to technology from cross-licensing of the litigant's
patents. Merck would be speculating as to why litigants would enter
into settlements with large unjustified reverse payments.
Question. Do you think these agreements stifle competition and
prevent generic alternatives to your branded medications?
Answer. Merck believes that the patent settlements it has made did
not stifle competition nor unlawfully prevent generic alternatives to
our patented medications.
Patent settlement agreements in which a brand settles cases in a
manner that allows a generic to enter the market prior to expiry of the
brand's patents could actually accelerate patient access to lower cost
alternatives. These settlements do not delay entry or cause the loss of
any lawful competition because entry prior to the expiry of these
patents would be unlawful infringement unless and until the generic
manufacturers prevailed in court.
Merck works within the statutory framework set by Hatch-Waxman and
BPCIA to protect its intellectual property. We believe that patent
holders have a valid right to enforce legitimate patents and that the
courts are an appropriate venue to resolve such disputes.
Our patents are a direct result of the investment we have made in
R&D. When others seek to commercialize our innovations, Merck has
engaged in litigation to enforce our patents.
Merck is a strong supporter of bringing more generics to the
market. It is important to remember that generics all started as a
branded medication. A period of patent protection is provided for all
new medicines as an incentive to research-based biopharmaceutical
companies for the costly and risky research that is undertaken to
develop them. Following the loss of patent protection, the medicines
become low-cost generics that are available for many years, often
decades into the future.
Merck is proud that more than 40 million Americans annually benefit
from our science in the form of generic medicines. Several of our
discoveries--including cholesterol-lowering, heart disease,
osteoporosis, and asthma treatments--are now widely available to a
patient as generics, including some for about $20 per year, bringing
billions of dollars in savings to consumers and the health care system.
drug rebate rule
Question. In January, the Department of Health and Human Services'
(HHS) Office of Inspector General (OIG) promulgated a new regulation to
remove regulatory safe harbor protections under the Anti-Kickback
Statute (AKS) for rebates on prescription drugs rebates paid by
manufactures to PBMs under Medicare Part D and for Medicaid managed
care organizations (MCOs). The OIG proposal attempts to ban most
rebates by eliminating their regulatory protections.
The rule is predicted to increase net drug costs in its early
years. The CMS actuaries estimate it would cost $196 billion over 10
years. Despite this high price tag, the beneficiary benefits are
limited. The proposed rule notes that under the CMS Actuary's analysis,
the majority of beneficiaries would see an increase in their total out-
of-pocket payments and premium costs; reductions in total cost sharing
will exceed total premium increases.
I wanted to ask a question about the administration's rebate rule,
which I understand that many of the drug manufacturers, and your main
trade association, strongly support. According to an analysis of the
rule by the Office of Actuaries at CMS, drug manufacturers are likely
to initially retain 15 percent of the current rebates as higher net
drug prices.
Given that estimate, can you provide the committee with any
assurances that prices will not increase under this proposed rule?
Answer. Over time, we expect that list prices will go down if the
misaligned incentives across the system are addressed. It is also
important to note that if the rule is implemented, Medicare
beneficiaries' out-of-pocket costs will be reduced, independent of any
lowering of list prices, since their cost-sharing will be based on the
net price. Nonetheless, we believe the rebate rule will align
incentives in a way that will restrain list prices.
______
Questions Submitted by Hon. Sherrod Brown
Question. According to an article recently published in the Journal
of the American Medical Association, medical marketers spent nearly $30
billion dollars in 2016, up from $17 billion in 1997. Direct-to-
Consumer (DTC) advertising had the biggest percentage increase: from
$2.1 billion, or 11.9% of all medical marketing, in 1997 to $9.6
billion, or 32% of total spending, in 2016.
Can you please provide what your ratio of spending on sales and
marketing to research and development is today?
Answer. In 2018, Merck incurred $9.8 billion in research and
development costs globally, the vast majority of which was conducted in
the U.S. Since 2010, Merck has invested nearly $70 billion in R&D to
create new medicines and vaccines that address the greatest health
challenges of our time--including antimicrobial resistance, Ebola, HIV,
and cancer--to save and improve lives around the world. In 2018, Merck
spent about $2.3 billion in the U.S. market on direct marketing and
selling expenses. This number includes all sales and marketing
expenses, including creative development of resources and headcount
related to all marketing and sales activity in the U.S. market.
price-gouging
Question. Sanofi, as I understand it, has made a pledge to the
public to limit its price increases to the national health expenditures
growth projection.
Would your company commit to a cap on annual price increases as
part of your PhRMA membership criteria?
Answer. In July 2018, Merck pledged to not increase the average net
price across our portfolio by more than inflation annually.
Question. What policies would you propose to help ensure lower
launch prices for new drugs?
Answer. Merck approaches pricing from the perspective of value.
This approach looks at the value that a medicine provides through
multiple lenses with the goal of reflecting its benefit to patients and
to society, while at the same time paying an appropriate return on
invested capital to our investors, to ensure that we are able to
sustain R&D. While each individual situation varies based on factual
circumstances and market dynamics, generally, we consider:
Value provided to patients--to what extent does a new
medicine or vaccine establish a new standard of care that has
the potential to significantly extend and improve patient
lives?
Value provided to health-care systems--to what extent does a
new medicine or vaccine reduce the costs associated with
hospitalization and other costly complications of disease if
not appropriately (or optimally) treated?
Unmet need--does a new medicine or vaccine address a
critically unmet medical need, where few or no treatments
exist?
Access--what is the ability of various customers around the
world--including national, regional or local institutional
payers, physicians, employers and patients--to pay for our
products?
R&D sustainability--given the long-term risk and cost of
capital, can we appropriately compensate our investors to
ensure continued investment in the kind of risky and capital-
intensive research and development that will bring forward
medically important breakthroughs?
Competition--what are the costs of other treatments
currently on the market relative to the value provided by
Merck's products?
We believe the proper objective should be that launch prices
appropriately reflect the true value of the medicine and are not
distorted by any misaligned incentives in Medicare Part D or any other
sector. We believe the administration's proposed rebate safe harbor,
and similar changes in commercial plans, would address the misaligned
incentives in the marketplace that favor high list prices and high
rebates in competitive markets. In addition, addressing the misaligned
incentives for the 340B program would allow for more flexibility in
list prices.
transparency
Question. In many of your testimonies, you mentioned that the
current system of pharmacy benefit manager (PBM) back-end rebates do
not rarely results in a scenario where the PBM passes on savings to
consumers at the point of sale (POS). The administration recently
proposed a rule to eliminate the anti-kickback statute safe harbor
protections for these drug rebates.
Do you agree that greater transparency should be required to
understand how manufacturers and PBMs are negotiating prices and
rebates to ensure that savings are passed down to beneficiaries?
Answer. Yes. We believe there should be greater transparency of the
financial arrangements between manufacturers and PBMs. In particular,
we believe we must change the system to ensure that patients receive
the benefit of the significant rebates and discounts that manufacturers
like Merck pay to PBMs and plans. The administration's proposed rule is
a positive step in that direction.
Based on our initial assessment of the proposed rule, we believe
that it will remove misaligned incentives within the system, drive more
transparency in the system, and most importantly, lower beneficiaries'
out-of-pocket costs.
Question. Senator Thune asked if this administration rule would
lead you to lowering list prices. Both of you answered that you would
be likely to lower your prices. However, if this rule were finalized
tomorrow as proposed, would any of your companies be required to lower
the list price of any of your drugs?
Answer. Under the proposed rule, there is no requirement to lower
list prices. However, over time, we expect that our list prices will go
down if the misaligned incentives across the system are addressed. It
is also important to note that if the rule is implemented, Medicare
beneficiaries' out-of-pocket costs will be reduced, independent of any
lowering of list prices, since their cost-sharing will be based on the
net price. Nonetheless, we believe the rebate rule will align
incentives in a way that will restrain list prices.
pbms
Question. An Axios article from March 7, 2019 highlights the fact
that, while ``pharmaceutical companies put a lot of the blame for high
drug prices on pharmacy benefit managers,'' many large pharmaceutical
companies ``rely on PBMs to manage their own health-care benefits.''
In your role as an employer, does your company contract with a
pharmaceutical benefit manager (PBM) to administer the prescription
drug benefits for your employees and negotiate lower drug costs on your
behalf?
For those of you who do use a PBM to help manage the prescription
drug benefit for your employees, how do you utilize the rebates your
PBM negotiates to lower health care costs or drug costs for your
employee plans and what does your company do with that savings?
Specifically, do the savings go toward lowing premiums?
For those of you who do use a PBM to help manage the prescription
drug benefit for your employees, does your PBM offer point-of-sale
rebates to your employees?
Answer. Merck offers a generous health care benefit for our 24,000
U.S. employees. There is no deductible for medications covered under
our pharmacy benefit, and employees never have to pay more than $50 for
a retail prescription for a covered medication, and in most cases pay
less. We contract with a PBM for management of the prescription drug
benefits for our employees, and the benefit does not offer point-of-
sale rebates to our employees. Merck uses savings generated by the PBM
on rebates to lower overall costs for employees while ensuring low out-
of-pocket costs.
______
Questions Submitted by Hon. Sheldon Whitehouse
Question. Please describe any policy changes you support that would
result in your company lowering the list prices of its drugs.
Answer. Over time, we expect that our list prices will go down if
the misaligned incentives across the system are addressed. Nonetheless,
we believe the rebate rule will align incentives in a way that will
restrain list prices.
As we stated when we reduced the list price of several of our
products in July 2018, we have continued to look for opportunities to
reduce our list prices. We think the proposed rule would help create
those opportunities, but it can't happen overnight. All of the players
in the ecosystem will need to adjust to the new model.
If the proposed rule is implemented as written, it would only apply
to our contracts with PBMs and health plans for Medicare Part D and
Managed Medicaid. If PBMs and health plans maintain the rebate model in
the commercial market, we would still have commercial contracts based
on rebates, which would be subject to the existing constraints to
lowering list price. We also would still need a mechanism to revalue
drug in the distribution channel in a financially viable manner.
Question. How much does your company's research and development
portfolio rely on taxpayer-funded research conducted by the National
Institutes of Health (NIH)? How many of your company's products are
based, at least in part, on NIH research, and how many are the result
of research funded solely by your company?
Answer. The U.S. leads the world in biomedical research thanks to a
robust biomedical ecosystem comprised of important and unique
contributions from the National Institutes of Health (NIH), academic
institutions, and the biopharmaceutical industry. Historically, the
NIH's focus has been on basic biomedical science and research
concerning public health (including in the recent budget funding for
drug and alcohol abuse prevention, reducing health-care disparities,
and other important causes). Through this basic research, NIH seeks to
understand the fundamental biological processes and leverage that
understanding to determine which processes are involved in the
development and progression of disease. There is significant basic
research that in some respects contributes to all new medicines. Most
of this is considered ``pre-competitive'' since the individual
contributions are in themselves too small or too broad to lead directly
to a new therapy, which takes considerable work to invent and develop.
Merck also conducts basic research. However, where we use
intellectual property that others have created, we are diligent in
recognizing and agreeing on terms to use that property (including
financial compensation), which may include with agencies of the U.S.
government such as NIH. After this stage of basic research, our
company's further role is to then engage in the most risky and costly
part of discovery--to invent something that's never existed in the
history of the world that will alter the targets that come from basic
research and unlock treatments and cures for disease. This invention is
then followed by extensive clinical trial programs to demonstrate
safety and effectiveness.
On occasion, we will rely on work by government agencies that is
more advanced; however, we take the same approach of respecting
intellectual property rights and agreeing on terms of use of that
property. For example, Merck, along with Instituto Butantan, has
licensed certain rights from National Institute of Allergy and
Infectious Diseases (NIAID), part of NIH, for the development of live
attenuated tetravalent vaccines (LATV).
All parts of the ecosystem are needed to continue to lead in
biomedical research: the portion of NIH's entire $33 billion budget
that it devoted to biomedical research in 2017 as well as the $70
billion the biopharmaceutical industry spent in 2017--$10 billion of
which was spent by Merck--to invent and bring to market new treatments
and cures.
Question. In each of the last 5 years, how much has your company
spent on research and development versus the advertising and marketing
of your products?
Answer. In 2018, Merck incurred $9.8 billion in research and
development costs globally, the vast majority of which was conducted in
the U.S. Since 2010, Merck has invested nearly $70 billion in R&D to
create new medicines and vaccines that address the greatest health
challenges of our time--including antimicrobial resistance, Ebola, HIV,
and cancer--to save and improve lives around the world. In 2018, Merck
spent about $2.3 billion in the U.S. on direct marketing and selling
expenses. This number includes all sales and marketing expenses,
including creative development of resources and headcount related to
all marketing and sales activity in the U.S. market.
For the remaining years, we spent the following:
In 2017, Merck invested $10.3 billion in R&D and $2.5
billion in U.S. marketing and selling expenses.
In 2016, Merck invested $10.3 billion in R&D and $2.5
billion on U.S. marketing and selling expenses.
In 2015, Merck invested $6.8 billion in R&D and $2.4 billion
on U.S. marketing and selling expenses.
In 2014, Merck invested $7.3 billion in R&D and $2 billion
on U.S. marketing and selling expenses.
Question. During the hearing, you mentioned that your company would
be likely to lower the list prices of its drugs if the recent proposal
by the Trump administration to change the current system of rebates was
extended to the private market.
If the policy was extended to the private market, how large would
the list price reductions be relative to the size of the rebates your
company is currently providing?
Answer. It is hard to predict an exact amount of list price
reduction if the rule were implemented as described. However, we
believe that removing the misaligned incentives from the system should
result in downward pressure on list prices. It is also important to
understand that different purchasers receive different levels of
discounts, based on the access provided for patients. So, there is not
a uniform ``rebate amount'' that could reduce the list price. Moreover,
we expect that the robust negotiations that occur today will continue
in the highly competitive Part D market, and we expect to realize the
same level of net price that we do today. In fact, we expect that there
could be additional pricing pressure under the new system, which could
lead to lower net prices.
Question. How will this proposal affect how your company sets the
list prices for new drug products?
Answer. Merck approaches pricing from the perspective of value.
This approach looks at the value that a medicine provides through
multiple lenses with the goal of reflecting its benefit to patients and
to society, while at the same time paying an appropriate return on
invested capital to our investors, to ensure that we are able to
sustain R&D. While each individual situation varies based on factual
circumstances and market dynamics, generally, we consider:
Value provided to patients--to what extent does a new
medicine or vaccine establish a new standard of care that has
the potential to significantly extend and improve patient
lives?
Value provided to health-care systems--to what extent does a
new medicine or vaccine reduce the costs associated with
hospitalization and other costly complications of disease if
not appropriately (or optimally) treated?
Unmet need--does a new medicine or vaccine address a
critically unmet medical need, where few or no treatments
exist?
Access--what is the ability of various customers around the
world--including national, regional or local institutional
payers, physicians, employers and patients--to pay for our
products?
R&D sustainability--given the long-term risk and cost of
capital, can we appropriately compensate our investors to
ensure continued investment in the kind of risky and capital-
intensive research and development that will bring forward
medically important breakthroughs?
Competition--what are the costs of other treatments
currently on the market relative to the value provided by
Merck's products?
We do not expect this approach to change based on the Trump
administration's proposed rule.
Question. If the proposal is finalized and not extended to the
private market, will your company make any list price reductions? If
so, how large would the reductions be relative to the size of the
rebates your company is currently providing?
Answer. We expect that the robust negotiations that occur today
will continue in the highly competitive Part D and commercial markets,
and we expect to realize the same level of net price that we do today.
In fact, we expect that there could be additional pricing pressure
under the new system, which could lead to lower net prices, but
predicting the size of any such reductions is difficult.
______
Question Submitted by Hon. Maggie Hassan
Question. In June of 2018, the Medicaid and CHIP Payment and Access
Commission (MACPAC) unanimously recommended under Recommendation 1.1 in
their annual report to Congress that Congress remove the statutory
requirement that manufacturers blend the average manufacturer price
(AMP) of a brand drug and its authorized generic.\13\
---------------------------------------------------------------------------
\13\ MACPAC. ``Improving Operations of the Medicaid Drug Rebate
Program,'' https://www.macpac.gov/wp-content/uploads/2018/06/Improving-
Operations-of-the-Medicaid-Drug-Rebate-Program.pdf.
This requirement created an unintended loophole. Rather than use
the price of the authorized generic, drug companies can sell its
authorized generic to a corporate subsidiary at an artificially lower
price and use that lower price to bring down the AMP, which in turn
---------------------------------------------------------------------------
lowers the rebate obligation.
Does your company engage in this practice? Has your company ever
engaged in this practice in the past?
Answer. No. Merck does not engage in the practice of selling
authorized products to a subsidiary and then blending the pricing data
for the products. Merck does engage with third parties who act as our
authorized generic partners. Merck has disclosed the methodology used
to account for these transactions in AMP to CMS.
______
Questions Submitted by Hon. Catherine Cortez Masto
Question. As a portion of your revenue, for what percentage of the
drugs in your portfolio do you offer no rebates? Based on the drugs in
your pipeline, do you foresee that portion growing? For those drugs is
your list price equal to your net price?
Answer. Since Merck's entire product portfolio is covered within at
least one government program that requires a mandated rebate or
discount (such as Medicaid, 340B, Federal Supply Schedule), there are
no Merck products that are not rebated or discounted. Merck also offers
voluntary rebates or discounts on many of its products. We would expect
similar rebates and discounts to be paid for our drugs in the pipeline,
barring fundamental changes in the marketplace.
Question. Do you invest more in R&D than you generate in US sales
revenue? Please include specific figures.
Answer. In 2018, Merck incurred $9.8 billion on research and
development costs globally, the vast majority of which was conducted in
the U.S. Since 2010, Merck has invested nearly $70 billion in R&D to
create new medicines and vaccines that address the greatest health
challenges of our time--including antimicrobial resistance, Ebola, HIV,
and cancer--to save and improve lives around the world. In 2018, Merck
had $18.2 billion in U.S. sales revenue.
Question. Do you invest more in R&D than you spend on marketing and
administration? What company functions do you consider to be included
in administration? Please include specific figures.
Answer. In 2018, Merck incurred $9.8 billion in research and
development costs globally, the vast majority of which was conducted in
the U.S. Since 2010, Merck has invested nearly $70 billion in R&D to
create new medicines and vaccines that address the greatest health
challenges of our time--including antimicrobial resistance, Ebola, HIV,
and cancer--to save and improve lives around the world. In 2018, Merck
spent about $10.1 billion on marketing, selling, and administration
globally ($2.6 billion of which is directly attributed to the U.S.
market). This number includes all sales and marketing expenses,
including creative development of resources and headcount related to
all marketing and sales activity, as well as administrative expenses
associated with business support functions, including information
technology, human resources, facilities, finance, legal, and others.
Question. Do you invest more in R&D than you spend on marketing and
sales? What company functions do you consider to be included in sales?
Please include specific figures.
Answer. In 2018, Merck incurred $9.8 billion on research and
development costs globally, the vast majority of which was conducted in
the U.S. Since 2010, Merck has invested nearly $70 billion in R&D to
create new medicines and vaccines that address the greatest health
challenges of our time--including antimicrobial resistance, Ebola, HIV,
and cancer--to save and improve lives around the world. In 2018, Merck
spent about $6.9 billion on direct marketing and selling expenses
globally ($2.3 billion of which is directly attributable to the U.S.
market). This number includes all sales and marketing expenses,
including creative development of resources and headcount related to
all marketing and sales activity in the U.S. market.
Question. Why do you advertise for the drugs you manufacture? What
factors do you consider in choosing which drugs you advertise?
Answer. Merck believes that direct-to-consumer (DTC) advertising
can be an important and helpful way to inform patients about diseases
that may be relevant to them and therapeutic options they may want to
discuss with their physician. Data demonstrate that DTC can have a
positive impact on patient health in terms of diagnosis, treatment, and
adherence to prescribed therapies. We recognize that DTC is one channel
amongst many to help educate patients. Print materials, telephone,
websites, and other channels are also used to provide more in-depth
information to patients. The ultimate decision to prescribe a product
for any specific patient remains with the physician following
discussion with their patient.
Merck adheres to FDA regulations and guidelines governing DTC
promotion and has a long-standing policy to voluntarily submit new DTC
broadcast advertising campaigns to FDA for pre-review. Merck also
follows the PhRMA Guiding Principles for DTC Advertisements About
Prescription Medicines. We are currently considering what additional
information we can make available to consumers to ensure that they can
make informed health care decisions.
______
Prepared Statement of Richard A. Gonzalez,
Chairman and Chief Executive Officer, AbbVie Inc.
I am Richard Gonzalez, and I am the chairman and chief executive
officer of AbbVie, a company dedicated to developing new innovative
medicines for some of healthcare's most challenging diseases, such as
cancer, Alzheimer's, viral infections, and auto-immune diseases. Since
our inception in 2013, AbbVie has invested approximately $50 billion in
pursuit of that goal. However, because we are tackling medicine's most
challenging problems, solutions do not come easily or without
significant risk. Where we have succeeded, we have been able to provide
cures for fatal diseases like hepatitis C and significantly alter the
disease progression for certain cancers, lessening the burden of
illness on patients and the health-care system. This is what the 30,000
employees of AbbVie are dedicated to doing.
We agree that access to lifesaving medicines is a critical issue
and we look forward to sharing our perspectives with you. There is no
one solution to this complex issue, but AbbVie is open to working with
the committee on how we can commit our resources to better partner in
your efforts to address pharmaceutical pricing and access. AbbVie and
the rest of our industry must play a role in solving these issues and
be prepared to work together with the insurance industry, the
administration and you to find a better path forward for American
patients.
My remarks today will focus on one aspect of this inquiry--the
Medicare Part D benefit design, which even after pharmaceutical list
prices are lowered, still contributes to making innovative therapies
cost-prohibitive for Medicare patients. In general, the Medicare Part D
program has worked well. Its market-based structure and utilization of
formularies encourages competitive price discounts that have yielded
significant savings to the government since the Part D benefit was
established in 2006. However, despite these cost savings, Part D
patients' out-of-pocket costs have significantly increased. Some would
blame that solely on high drug prices, and we agree that price should
certainly be part of the discussion. But it's also important to
acknowledge that science has enabled us to advance the standard of care
far beyond what was possible when the Part D benefit was designed.
Many of today's specialty medicines offer major advances in
treating or curing serious chronic or life-threatening conditions and
save significant amounts of money for the health-care system by
decreasing overall health-care costs, yet these therapies are also
costly. Due to the structure of the Part D benefit design, patients are
charged out-of-pocket costs on a medicine's list price which does not
reflect the
market-based rebates that Medicare receives. We are encouraged by the
proposed rule that would reflect manufacturer discounts in patients'
Part D out-of-pocket payments. This is an important step in the right
direction, but we believe more must still be done to help Part D
patients.
Let me give you a recent real-world example that demonstrates the
challenge with the current Part D benefit design and why the focus
solely on list prices does not fully address the access challenges. An
uncured hepatitis C infection leads to downstream medical costs for
surgery, chemotherapy, and radiation for patients who progress to
needing a liver transplant or having liver cancer. Today we can cure
hepatitis C with drugs. This cure is highly cost-effective for the
overall health-care system.
In 2017, AbbVie launched Mavyret, a highly effective cure for HCV.
At the time, the list prices for the competitive alternatives were as
high as $94,500 for their most commonly prescribed treatment duration.
We launched Mavyret at a list price that is 72 percent lower. But even
though we cut the list price of an HCV cure for most patients by 72
percent, Medicare Part D patients' out-of-pocket obligations are still
too high for many patients to access this medicine.
We believe it is important that discussions about access and
affordability include a focus on how to alleviate Medicare Part D out-
of-pocket burdens above and beyond just lowering list prices. We are
prepared to step up and discuss how companies like ours can shoulder
more of the burden of a patient's out-of-pocket expenses, as we do in
other areas covered by commercial insurance. Additionally, we believe
the discussion should also include the possibility of Medicare Part D
beneficiaries being able to purchase insurance (as they do in other
parts of the Medicare program) to cover more of their out-of-pocket
expenses.
We believe AbbVie, the rest of the pharmaceutical industry and
insurance providers should come together with the administration and
you to work toward solutions that make life-changing medicines more
affordable to Part D beneficiaries. I can assure you AbbVie is
committed to doing its part, and we look forward to working with you.
______
Questions Submitted for the Record to Richard A. Gonzalez \1\
---------------------------------------------------------------------------
\1\ Please note that these responses were prepared by and are from
AbbVie Inc.
---------------------------------------------------------------------------
Questions Submitted by Hon. Chuck Grassley
Question. The Department of Health and Human Services' proposed
rule, ``Fraud and Abuse; Removal of Safe Harbor Protection for Rebates
Involving Prescription Pharmaceuticals and Creation of New Safe Harbor
Protection for Certain Point-of-Sale Reductions in Price on
Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager
Service Fees,'' envisions that drug manufacturers will offer up-front
discounts rather than the back-end rebates that are now commonly
provided. Some observers argue that a 1996 court case called into
question whether manufacturers could offer up-front discounts,
resulting in today's rebate-based system. I've heard differing opinions
as to whether the issues related to the initial court case are still
relevant. If the HHS proposed rule is finalized, can you assure the
Committee that your company will offer up-front discounts? If not, why?
Please describe how you expect your company to respond to the HHS
proposed rule to eliminate safe harbor protection for back-end rebates
in Medicare Part D that is referenced above if it is finalized.
Assuming you are confident that antitrust laws do not prevent your
company from offering up-front discounts, specifically, do you envision
that your company lowers the list price of a drug to the current after-
rebate net price, offer discounts equal to the current rebate amount,
or a combination of both?
Answer. There has been significant discussion over the past several
months about proposals to eliminate rebates from Medicare Part D,
Medicaid, and the commercial market culminating in the administration's
publication of a proposed rule to ``expressly exclud[e] from safe
harbor protection under the Anti-Kickback Statute (AKS) rebates on
prescription drugs paid by manufacturers to pharmacy benefit managers
(PBMs), Part D plans, and Medicaid managed care organizations. The
proposal would create a new safe harbor protecting discounts offered to
patients at the pharmacy counter. Finally, the proposal would create
new safe harbor protection for fixed fee services arrangements between
manufacturers and PBMs.''
AbbVie is encouraged by the goals of the proposed rule to ensure
manufacturer discounts are reflected in and reduce patient cost sharing
under Part D. While we believe the rule is an important step in the
right direction, we also believe more should be done to help reduce the
out-of-pocket cost burden on Medicare Part D patients.
As for what the elimination of rebates might mean to the overall
health-care system or pharmaceutical companies, it is premature to
comment on these items until the administration's rule is finalized,
implementation timelines are solidified, and there are specific details
regarding how a new system without rebates will be structured and
function.
Question. To what extent are the back-end rebates your company
currently offers contingent on the amount of market share realized for
your drugs as a result of Part D plan formulary placement and other
techniques?
Answer. AbbVie does not have market-share based arrangements.
Question. Please provide a breakdown of percentage of sales that go
to each payer (including Medicare, Medicaid, private pay, other) and a
similar percentage by volume of the total number of each drug compared
to total volume. Please provide this data for the most recent year
available.
Answer. In 2018, on a U.S. dollars basis approximately 68 percent
of AbbVie's U.S. net sales were to commercial payers and approximately
32 percent were to government payers. AbbVie does not maintain this
information on a volume basis across all products. For Humira, AbbVie's
top product for sales, on a volume basis in the U.S. approximately 68
percent of Humira sales were to commercial payers and approximately 32
percent were to government payers. But on a U.S. dollars basis,
approximately 83 percent of Humira sales were to commercial payers and
only approximately 17 percent were to government payers.
Question. Do your companies hire consultants or lobbyists to
promote products at State Medicaid Pharmacy and Therapeutics
Committees? To whom do you disclose advocacy activities surrounding
State Medicaid programs, if at all?
Answer. AbbVie does not hire consultants or lobbyists to promote
products at State Medicaid Pharmacy and Therapeutics Committees. We
adhere to individual State's laws and regulations with respect to
advocacy disclosures.
Question. Please describe how the costs of patient assistance
programs are accounted for within your company's financial statements.
Please also describe the types of market information, such as
prescribing and use patterns, that your company collects from different
types of patient assistance programs and patient hub services.
Answer. The AbbVie Patient Assistance Program, which provides free
drug to eligible individuals, falls under the administration portion of
SG&A. AbbVie's commercial co-pay assistance costs are deducted from
gross sales.
The information that AbbVie collects through its patient support
services varies by products but may include demographic information,
diagnosis codes and prescription information, insurance information,
and claim information. AbbVie collects a more limited set of this data
through its Patient Assistance Program in order to assess patients for
eligibility and distribute medication to patients.
Question. Please provide a list of all contributions since January
1, 2014, that your company has made to any tax exempt organizations
working on issues related to drugs within your product lines, including
but not limited to patient groups, disease awareness groups, medical or
professional societies, universities or hospitals, industry
associations or leagues. for each contribution, please provide the name
of the organization that received the donation, the date the donation
was made, the amount of the donation, and a description of the purpose
of the contribution (i.e., was the contribution for the general fund, a
specific purpose to a specific program, or continuing medical
education). Please also note whether the contribution was unrestricted
or restricted; if it was restricted, please explain all restrictions.
Finally, if your company maintains a foundation or other separate
charitable arm, please provide the name of all such entities, and list
all donations made from that entity or entities.
Answer. Attached as Exhibit 1 to this response is a list of all
contributions AbbVie has made in the following categories from January
1, 2014 through December 31, 2018: (1) charitable donations to non-
profit organizations; (2) donations for patient education and disease
state diagnosis, treatment, and awareness; (3) educational grants; (4)
fellowships and scholarships; and (5) sponsorships of non-profit
organizations' events.
The AbbVie Foundation is a separate non-profit entity that makes
charitable donations and grants. Attached as Exhibit 2 is a list of all
charitable donations and grants made by The AbbVie Foundation from
January 1, 2014 through December 31, 2018.
Question. Pay-for-delay agreements cost consumers and taxpayers
billions in higher drug costs every year. The FTC has gone after drug
companies that enter into these settlements where the brand pays the
generic company to keep its lower cost alternative off the market. I'm
the lead Republican sponsor of S. 64, the ``Preserve Access to
Affordable Generics and Biosimilars Act,'' which would help put an end
to these deals.
Do you agree that these pay-off agreements keep drug costs high for
patients because they delay competition?
Has your company ever entered into these kinds of settlements with
a generic company?
Answer. ``Pay-for-delay'' is not a self-defining phrase. With
respect to the term ``pay,'' patent litigation settlements, like all
litigation settlements, involve compromise in which both sides believe
they are getting value from the resolution. There is no definition
explaining the circumstances under which that value would implicate the
term ``pay'' in ``pay-for-delay'' for purposes of these questions. And
with respect to ``delay'' virtually all patent settlements provide for
the generic competitor to enter the market before the expiration of the
patent at issue. So if the alternative resolution of a patent lawsuit
would be the innovator company continuing to enforce its patent until
expiration, then such a settlement, no matter what value is exchanged,
would actually accelerate competition, not delay it.
Question. Do you support the pay-for-delay bill?
Answer. AbbVie supports the goals of the Preserve Access to
Affordable Generics and Biosimilars Act and would likely support the
bill upon clarification that enforcement only applies to agreements
after the date of enactment.
rebate traps/walls
Question. I'm increasingly concerned about the effect of so-called
``rebate traps'' or ``rebate walls'' on patients' access to quality,
lower-cost medicine. I understand there is ongoing litigation
challenging these practices as anti-competitive.
Does your company engage in the bundling of rebates over multiple
products? If so, why? And what benefit does the consumer gain from
that?
Does your company view these practices as anticompetitive or
harmful to patients' access to quality, lower cost medicine?
Answer. Rebates are a form of price competition that results from
the aggressive negotiations that occur between health plans (and their
representative PBMs) and pharmaceutical companies to provide patients
with access to medicines and treatments that can best help patients
manage their medical conditions.
Question. If a policy were adopted to eliminate rebates, or to
require that rebate savings be passed on to the consumer, would that in
and of itself solve the issue of rebate ``traps'' and ``walls''? And
would consumers benefit from such a policy?
Answer. There has been significant discussion over the past several
months about proposals to eliminate rebates from Medicare Part D,
Medicaid, and the commercial market culminating in the administration's
publication of a proposed rule to ``expressly exclud[e] from safe
harbor protection under the Anti-Kickback Statute (AKS) rebates on
prescription drugs paid by manufacturers to pharmacy benefit managers
(PBMs), Part D plans, and Medicaid managed care organizations. The
proposal would create a new safe harbor protecting discounts offered to
patients at the pharmacy counter. Finally, the proposal would create
new safe harbor protection for fixed fee services arrangements between
manufacturers and PBMs.''
AbbVie is encouraged by the goals of the proposed rule to ensure
manufacturer discounts are reflected in and reduce patient cost sharing
under Part D. While we believe the rule is an important step in the
right direction, we also believe more should be done to help reduce the
out-of-pocket cost burden on Medicare Part D patients.
As for what the elimination of rebates might mean to the overall
health care system or pharmaceutical companies, it is premature to
comment on these items until the administration's rule is finalized,
implementation timelines are solidified, and there are specific details
regarding how a new system without rebates will be structured and
function.
drug pricing
Question. When setting the list price of a drug, does your company
consider regulatory costs or compliance? If so, how specifically do
those factors affect the list price of a drug? Please provide at least
one specific example, if applicable, from your current product
portfolio.
Answer. AbbVie does not consider regulatory costs or compliance
when considering the list price of a medicine.
Question. When setting the list price of a drug, does your company
consider the risk of liability or litigation? If so, how specifically
do those factors affect the list price of a drug? Please provide at
least one specific example, if applicable, from your current product
portfolio.
Answer. AbbVie does not consider the risk of liability or
litigation when considering the list price of a medicine.
______
Questions Submitted by Hon. Pat Roberts
Question. What role do you see value-based arrangements (VBAs)
playing in the effort to reduce prescription drug costs? What potential
do these arrangements have to find the ``sweet spot'' between
controlling costs to patients and encouraging innovation of new drugs?
How can VBAs help lower what patients pay out-of-pocket?
Can Congress do more to allow for and encourage the use of VBAs?
Answer. Value-based arrangements can be an effective and market-
based solution to managing overall health-care costs when driven by
patient outcomes. Studies have found that 38 percent of payers with
outcomes-based contracts experience improved patient outcomes and 33
percent experience plan health-care cost savings. Additionally, plans
with outcomes-based contracts have been found to have a 28 percent
lower patient co-payment. All of these factors work towards moving
payment for prescription medicines away from volume-based approaches to
value-based models in a manner that appropriately balances patient
access with the appropriate use of medications to lower overall health-
care costs.
At AbbVie, we believe all our products provide value to patients
and the larger health-care system and are interested in the
possibilities that could arise through value-based contracting. To
further foster value-based arrangements, we support the reforms
included in the Patient Affordability, Value and Efficiency (PAVE) Act,
introduced by Senators Cassidy (R-LA) and Warner (D-VA).
______
Questions Submitted by Hon. John Cornyn
Question. We continue to hear that rebates negotiated off of the
list price of a drug are both good and bad.
Pharmacy benefit managers and plans have argued that rebates are
used to lower premiums across the board and that it is the best way to
seek a price concession on otherwise expensive drugs.
Your industry argues that these payers are insisting on higher
rebates that can only be achieved by raising list prices.
But patients often lose under this system, with out of pocket costs
being tied to list price. Insulin patients appear to be routinely
impacted by this perversity in the system.
Please explain to the committee how your company would reduce list
prices if rebates were no longer a part of the equation?
What assurance can you provide that you would in fact lower your
prices?
Answer. There has been significant discussion over the past several
months about proposals to eliminate rebates from Medicare Part D,
Medicaid, and the commercial market culminating in the administration's
publication of a proposed rule to ``expressly exclud[e] from safe
harbor protection under the Anti-Kickback Statute (AKS) rebates on
prescription drugs paid by manufacturers to pharmacy benefit managers
(PBMs), Part D plans, and Medicaid managed care organizations. The
proposal would create a new safe harbor protecting discounts offered to
patients at the pharmacy counter. Finally, the proposal would create
new safe harbor protection for fixed fee services arrangements between
manufacturers and PBMs.''
AbbVie is encouraged by the goals of the proposed rule to ensure
manufacturer discounts are reflected in and reduce patient cost sharing
under Part D. While we believe the rule is an important step in the
right direction, we also believe more should be done to help reduce the
out-of-pocket cost burden on Medicare Part D patients.
As for what the elimination of rebates might mean to the overall
health care system or pharmaceutical companies, it is premature to
comment on these items until the administration's rule is finalized,
implementation timelines are solidified, and there are specific details
regarding how a new system without rebates will be structured and
function.
Question. What actions should be taken to ensure that patients are
actually seeing the benefits of lower out-of-pocket costs?
Answer. Providing discounts to the patient at the point of sale is
an effective way of ensuring that patients can see lower out-of-pocket
costs. However, this is just the start. AbbVie believes that more must
be done.
The Medicare Part D benefit design contributes to making innovative
therapies cost-prohibitive for Medicare patients because patients are
charged out-of-pocket costs based on a medicine's list price, which
does not reflect the rebates that Medicare receives.
AbbVie believes it is important to alleviate the burdens that
patients face due to Medicare Part D out-of-pocket costs. AbbVie
supports solutions like a patient out-of-pocket cap in Part D and
smoothing patient out-of-pocket payments over a full year, so patients
have some predictability with respect to their out-of-pocket costs.
In addition, AbbVie is prepared to step up and discuss how
companies like ours can shoulder more of the burden of a patient's out-
of-pocket expenses.
As policymakers consider the impact of addressing out-of-pocket
costs in Medicare Part D, questions may arise around whether it will
lead to unnecessary utilization and wasteful spending. for specialty
medicines, increased utilization should not be misunderstood as
unnecessary or wasteful. Part D plans have tools, like step therapy
requirements for patients to first try lower cost alternatives before a
specialty medicine would be covered and prior authorization
requirements before a specialty medicine would be covered, to manage
the utilization of the majority of higher cost specialty medicines.
These tools ensure patients try a less costly medication first and have
met the clinical criteria for taking the specialty drug prescribed and
serve the function that an out-of-pocket cost obligation on patients
might serve to prevent unnecessary use.
Question. If rebates are driving high list prices for drugs as drug
manufacturers' claim, why do you think that Part B drugs, which have no
PBM rebates, are also seeing significant price increases? Whose fault
is that?
Answer. Manufacturers do offer rebates on Part B products in the
commercial market. Those rebates are included in the calculation of the
Part B Average Sales Price (ASP) and are therefore reflected in the
price Medicare pays for Part B drugs. AbbVie does, however, recognize
that increased competition in Part B could lead to additional savings
and welcomes the opportunity to engage in policy discussions that seek
to increase competition in Part B.
______
Question Submitted by Hon. Michael B. Enzi
Question. The Food and Drug Administration's drug review process is
known to many as the ``gold standard'' for evaluating medical products.
I've long thought that it is critical that we maintain public
confidence in their ability to ensure that drugs are safe and
effective. There is a perception among some, however, that biosimilars
might not be as safe as their reference products. That perception can
undermine patient and provider confidence. Do you believe that when FDA
approves a biosimilar, providers can be confident that it is safe and
effective?
Answer. Consistent with the US regulatory scheme for biosimilars,
we recognize that FDA-approved biosimilars are highly similar to the
reference product with no clinically meaningful differences.
Unlike small molecule generics, however, biosimilars do not contain
the identical active ingredient as their reference products and
biosimilars are not substitutable at the pharmacy for the reference
drug absent an FDA designation of interchangeability. As FDA has
acknowledged, multiple exposures to slightly different biologics can
prime the immune system to recognize subtle differences in structural
features between products, triggering or increasing the overall immune
response. Consequently, a finding of interchangeability must be
supported by additional data demonstrating that the biosimilar is
``expected to produce the same clinical result in any given patient,''
and that there is no risk to patients associated with alternating or
switching between the biosimilar and the reference product. There is no
requirement that two biosimilars found to be interchangeable with a
single reference product must show that it is safe and effective to
switch between the two interchangeable biosimilars, even though in
practice this is likely to happen in the marketplace if biosimilars are
treated like generic drugs. Different biosimilar products each found
interchangeable with a single reference product will have subtle
structural differences from each other. Indeed, there may be more
structural differences--or different types of structural differences--
between the two biosimilar products than between either biosimilar and
the reference product. As such, without clinical data assessing the
effects of switching between two biosimilars of the same reference,
there is no evidence to scientifically justify interchangeability or
automatic substitution between them. AbbVie has raised this concern
with FDA at a 2018 Part 15 Hearing held by the agency on the subject of
biosimilarity and interchangeability.
These fundamental distinctions between small molecule and biologic
medicine regulation should not change the perception that FDA-approved
biosimilars are safe and effective, but they are central to any
understanding of the biologics market and the appropriate use of these
complex products.
______
Questions Submitted by Hon. Todd Young
re-evaluating business strategies in foreign countries
Question. Since taking office, President Trump has made reducing
drug prices one of his highest priorities--and has repeatedly spoken
about his frustration with the U.S. subsidizing the costs of
pharmaceuticals for the rest of the world. He has gone so far as to
issue proposals, like the International Pricing Index (IPI) Model, in
an attempt to bring down prescription drug prices.
With the increased scrutiny of the industry and of the drug supply
chain as a whole in the United States, have any of your companies re-
evaluated your business strategy in foreign countries?
If not, then why?
If a proposal, like IPI, were implemented, would it force your
companies to potentially ``walk away from the negotiating table when
other countries demand low prices subsidized by America's seniors,'' as
HHS Senior Advisor for Drug Pricing Reform John O'Brien has said?
Answer. The focus on U.S. versus ex-U.S. prices for pharmaceuticals
creates an erroneous impression that medicines are the major driver of
U.S. health care cost growth--ignoring that medicines account for a
small share of overall health spending. Many countries impose price
controls and restrict access to medicines in order to contain costs.
That is not the system we have here in the United States; nor should it
be. The U.S. fosters innovation and leads the world in drug discovery
and development with PhRMA members conducting nearly 80 percent of
their R&D in the United States. Importing or referencing price controls
used in other countries in the U.S. would challenge the innovation
model in a country the size of the U.S.
The U.S. relies on its competitive marketplace to manage costs,
while encouraging the development of new therapies. Because of the
ecosystem that exists in the U.S., patients enjoy access to innovative
medicines far earlier than patients in countries with centralized price
controls. Furthermore, most crosscountry comparisons focus solely on
the list prices of medicines and exclude from calculations the steep
discounts that are required in U.S. public programs such as Medicaid
and the rebates negotiated by insurers and pharmacy benefit managers in
Medicare Part D and the commercial market. In addition, these
comparisons often only include the list prices of brand-name medicines
even when lower-cost generic versions are available and widely used.
Instead of referencing price, AbbVie recommends policymakers focus
on reforms that address foreign freeloading in new trade agreements or
increasing enforcement of current agreements. We support enhancements
to trade agreements to balance share of investment costs. The United
States-Mexico-Canada Agreement (USMCA), while not yet implemented,
contains improvements in intellectual property protections as well as
provisions requiring transparency in pricing and reimbursement
mechanisms. These elements are critical to ensuring trading partners
like Mexico and Canada appropriately value innovation, allowing
innovative biopharmaceutical companies to continue bringing new
medicines to the market.
Question. What are some of your ideas on how we can ensure
Americans aren't shouldering the full cost of pharmaceuticals?
Answer. Providing discounts to the patient at the point of sale is
an effective way of ensuring that patients can see lower out-of-pocket
costs. However, this is just the start. AbbVie believes that more must
be done.
The Medicare Part D benefit design contributes to making innovative
therapies cost-prohibitive for Medicare patients because patients are
charged out-of-pocket costs based on a medicine's list price, which
does not reflect the rebates that Medicare receives.
AbbVie believes it is important to alleviate the burdens that
patients face due to Medicare Part D out-of-pocket costs. AbbVie
supports solutions like a patient out-of-pocket cap in Part D and
smoothing patient out-of-pocket payments over a full year, so patients
have some predictability with respect to their out-of-pocket costs.
In addition, AbbVie is prepared to step up and discuss how
companies like ours can shoulder more of the burden of a patient's out-
of-pocket expenses.
As policymakers consider the impact of addressing out-of-pocket
costs in Medicare Part D, questions may arise around whether it will
lead to unnecessary utilization and wasteful spending. for specialty
medicines, increased utilization should not be misunderstood as
unnecessary or wasteful. Part D plans have tools, like step therapy
requirements for patients to first try lower cost alternatives before a
specialty medicine would be covered and prior authorization
requirements before a specialty medicine would be covered, to manage
the utilization of the majority of higher cost specialty medicines.
These tools ensure patients try a less costly medication first and have
met the clinical criteria for taking the specialty drug prescribed and
serve the function that an out-of-pocket cost obligation on patients
might serve to prevent unnecessary use.
foreign countries' pricing and reimbursement
Question. President Trump and Secretary Azar have both repeatedly
described their frustrations with ``foreign freeloading'' of U.S. drugs
in the last year.
``When foreign governments extort unreasonably low prices from U.S.
drug makers, Americans have to pay more to subsidize the enormous cost
of research and development. . . . It's unfair and it's ridiculous, and
it's not going to happen any longer.''
Do you agree that because of foreign countries' pricing and
reimbursement systems, U.S. patients and innovators are shouldering the
burden for financing medical advances?
How do foreign countries' pricing and reimbursement systems affect
our prescription drug costs?
Are foreign governments taking note of the concerns being raised by
the Trump administration and have they responded in any way?
Has there been any noticeable change in any of our trade agreements
since these concerns have been raised by the Trump Administration?
Answer. The focus on U.S. versus ex-U.S. prices for pharmaceuticals
creates an erroneous impression that medicines are the major driver of
U.S. health-care cost growth--ignoring that medicines account for a
small share of overall health spending. Many countries impose price
controls and restrict access to medicines in order to contain costs.
That is not the system we have here in the United States; nor should it
be. The U.S. fosters innovation and leads the world in drug discovery
and development with PhRMA members conducting nearly 80% of their R&D
in the United States. Importing or referencing price controls used in
other countries in the U.S. would challenge the innovation model in a
country the size of the U.S.
The U.S. relies on its competitive marketplace to manage costs,
while encouraging the development of new therapies. Because of the
ecosystem that exists in the U.S., patients enjoy access to innovative
medicines far earlier than patients in countries with centralized price
controls. Furthermore, most crosscountry comparisons focus solely on
the list prices of medicines and exclude from calculations the steep
discounts that are required in U.S. public programs such as Medicaid
and the rebates negotiated by insurers and pharmacy benefit managers in
Medicare Part D and the commercial market. In addition, these
comparisons often only include the list prices of brand-name medicines
even when lower-cost generic versions are available and widely used.
Instead of referencing price, AbbVie recommends policymakers focus
on reforms that address foreign freeloading in new trade agreements or
increasing enforcement of current agreements. We support enhancements
to trade agreements to balance share of investment costs. The United
States-Mexico-Canada Agreement (USMCA), while not yet implemented,
contains improvements in intellectual property protections as well as
provisions requiring transparency in pricing and reimbursement
mechanisms. These elements are critical to ensuring trading partners
like Mexico and Canada appropriately value innovation, allowing
innovative biopharmaceutical companies to continue bringing new
medicines to the market.
medicaid closed formulary proposals
Question. In an attempt to bring down drug costs, various states
have been exploring whether to exclude certain drugs from its Medicaid
program. for example, the state of Massachusetts' recently asked CMS
for permission to create a closed formulary where the state Medicaid
program would pick at least one drug per therapeutic class. CMS denied
their waiver request citing violation of federal law, but this proposal
does bring up important questions on how to contain drug prices in
state Medicaid programs.
If the principles of the Medicare Part D program--including the
necessary patient protections--were applied to state Medicaid programs,
do you think it lower drugs costs while ensuring access to patients?
Answer. Medicaid patients currently have broad access to medicines
with nominal co-pay amounts in exchange for steep mandatory rebates
provided by manufacturers. While the question does not specify what
``principles of the Medicare Part D program'' or ``necessary patient
protections'' are proposed to be applied to State Medicaid programs,
depending on the specific details that might be proposed, exclusionary
formularies could upset this broad patient access in Medicaid without
achieving corresponding savings over the already-existing steep
mandatory rebates.
medicaid ``best price''
Question. In the Trump administration's Blueprint, they suggested
that because drug manufactures have to give Medicaid the ``best price''
on drugs, there is no incentive to offer deeper discounts to other
payers--both government and commercial--than what is already offered
under the Medicaid Drug Rebate Program.
Does the Medicaid ``best price'' requirement encourage
manufacturers to increase initial prices?
What, if any, changes would you suggest we make to the program?
Answer. AbbVie has not found that best price requirements have
created incentives in the system to increase initial prices.
outcomes-based contracts
Question. In almost all of your testimonies, you highlight your
support of outcomes-based contracts and how we need to be shifting our
system toward that approach.
How will these contracts lower drug costs for patients in both the
near term and long-term?
How will they lower overall health-care costs for our Federal
programs?
What have the preliminary results looked like so far?
Answer. Value-based arrangements can be an effective and market-
based solution to managing overall health-care costs when driven by
patient outcomes. Studies have found that 38 percent of payers with
outcomes-based contracts experience improved patient outcomes and 33
percent experience plan health-care cost savings. Additionally, plans
with outcomes-based contracts have been found to have a 28 percent
lower patient co-payment. All of these factors work towards moving
payment for prescription medicines away from volume-based approaches to
value-based models in a manner that appropriately balances patient
access with the appropriate use of medications to lower overall health-
care costs.
At AbbVie, we believe all our products provide value to patients
and the larger health care system and are interested in the
possibilities that could arise through value-based contracting. To
further foster value-based arrangements, we support the reforms
included in the Patient Affordability, Value and Efficiency (PAVE) Act,
introduced by Senators Cassidy (R-LA) and Warner (D-VA).
transparency/point of sale
Question. In almost all of your testimonies, you express your
support for the Trump Administration's proposal to allow manufacturers
to provide PBMs up-front discounts that are passed onto patients at the
point-of-sale.
Do you feel like this proposal will make the transactions within
the drug supply chain more transparent?
If so, would this transparency bring down drug costs--overall and
for specialty drugs?
Answer. There has been significant discussion over the past several
months about proposals to eliminate rebates from Medicare Part D,
Medicaid, and the commercial market culminating in the administration's
publication of a proposed rule to ``expressly exclud[e] from safe
harbor protection under the Anti-Kickback Statute (AKS) rebates on
prescription drugs paid by manufacturers to pharmacy benefit managers
(PBMs), Part D plans, and Medicaid managed care organizations. The
proposal would create a new safe harbor protecting discounts offered to
patients at the pharmacy counter. Finally, the proposal would create
new safe harbor protection for fixed fee services arrangements between
manufacturers and PBMs.''
AbbVie is encouraged by the goals of the proposed rule to ensure
manufacturer discounts are reflected in and reduce patient cost sharing
under Part D. While we believe the rule is an important step in the
right direction, we also believe more should be done to help reduce the
out-of-pocket cost burden on Medicare Part D patients.
As for what the elimination of rebates might mean to the overall
health care system or pharmaceutical companies, it is premature to
comment on these items until the Administration's rule is finalized,
implementation timelines are solidified and there are specific details
regarding how a new system without rebates will be structured and
function.
the relationship between wholesalers and manufacturers
Question. When talking about the pharmaceutical supply chain, a lot
of focus has been placed on the Pharmacy Benefit Manager. But there's
another side of the equation that I'd like to ask about.
How do wholesalers negotiate pricing with manufacturers?
What impact does this have on drug costs?
What incentives or disincentives do they have to contain price
increases?
Answer. Wholesalers provide efficiencies in the distribution of
products for manufacturers, pharmacies and providers. They track supply
needs and maintain inventory levels consistent with patient need. They
also provide manufacturers with data and information related to both
historical purchasing patterns and projected future need, allowing
manufacturers to more accurately predict future supply needed in the
market to determine production needs. Wholesalers are also a ``one-stop
shop'' for sourcing medications and in some cases provide payer
contracting efficiencies through their Pharmacy Services Administrative
Organizations. This allows pharmacies to gain access to payer networks
efficiently, without negotiating with individual payers.
Manufacturers pay bona fide fees to wholesalers cover the costs of
the services described above.
______
Questions Submitted by Hon. Ron Wyden
proposed rebate rule
Question. As has been done in many other settings, drug
manufacturers said during the hearing that one reason list prices for
drugs are high is that pharmaceutical benefit managers (PBMs) demand
larger and larger rebates in order for the drug to receive favorable
placement on a formulary. You and your colleagues who testified during
the hearing stated if the Administration's proposal on changes to the
anti-kickback safe harbor for pharmaceutical rebates took effect, your
company would likely lower list price.
Like many Oregonians, I am skeptical drug manufacturers would
voluntarily lower their prices. Therefore, would you support
legislation that would (1) make similar changes the administration has
put forward related to Part D and Medicaid managed care, (2) change the
rebate system in a similar way to the proposal for the commercial
market, and (3) require drug makers to lower the list price of their
drugs equal to the amount of rebates provided today?
Answer. There has been significant discussion over the past several
months about proposals to eliminate rebates from Medicare Part D,
Medicaid, and the commercial market culminating in the administration's
publication of a proposed rule to ``expressly exclud[e] from safe
harbor protection under the Anti-Kickback Statute (AKS) rebates on
prescription drugs paid by manufacturers to pharmacy benefit managers
(PBMs), Part D plans, and Medicaid managed care organizations. The
proposal would create a new safe harbor protecting discounts offered to
patients at the pharmacy counter. Finally, the proposal would create
new safe harbor protection for fixed fee services arrangements between
manufacturers and PBMs.''
AbbVie is encouraged by the goals of the proposed rule to ensure
manufacturer discounts are reflected in and reduce patient cost sharing
under Part D. While we believe the rule is an important step in the
right direction, we also believe more should be done to help reduce the
out-of-pocket cost burden on Medicare Part D patients.
As for what the elimination of rebates might mean to the overall
health-care system or pharmaceutical companies, it is premature to
comment on these items until the administration's rule is finalized,
implementation timelines are solidified, and there are specific details
regarding how a new system without rebates will be structured and
function.
medicaid drug rebate program
Question. The Medicaid Drug Rebate Program (MDRP) requires
manufacturers to provide a basic rebate and an additional inflationary
rebate for both brand and generic drugs. The inflationary rebate is an
increasingly substantial part of total rebates due in large part to
large increases in drug prices that exceed inflation. Under current
law, this inflationary rebate is capped at 100 percent of Average
Manufacturer Price (AMP). This is the case even when manufacturers
continue to raise their prices well above inflation.
Please provide a list of all of your pharmaceutical products that
have reached the Medicaid AMP rebate cap in any of the 20 quarters from
January 1, 2014 through December 31, 2018.
For each drug listed in response to question 1, please also provide
a list of which quarters and years each drug hit the cap.
Answer.
------------------------------------------------------------------------
PRODUCT NAME NDC 11 QTR/YEAR of AMP CAPs
------------------------------------------------------------------------
Androgel 1%, 2.5 G Unit 00051-8425-30 Q1 2015
Dose, 30'S
------------------------------------------------------------------------
Androgel 1%, 5.0 G Unit 00051-8450-30 Q1 2015
Dose, 30'S
------------------------------------------------------------------------
Androgel 1.62% 2.5Gm Unit 00051-8462-30 Q2 2017, Q1 2018-Q3 2018
Dose
------------------------------------------------------------------------
Androgel 1.62% 1.25Gm Unit 00051-8462-31 Q2 2017, Q1 2018-Q3 2018
Dose
------------------------------------------------------------------------
Androgel 1.62% Pump 00051-8462-33 Q2 2017, Q1 2018-Q3 2018
------------------------------------------------------------------------
Biaxin, Filmtab Tablets, 00074-2586-60 Q3 2016-Q4 2016
500 Mg, 60'S
------------------------------------------------------------------------
Biaxin XL, Filmtab Tab, 00074-3165-11 Q1 2014-Q4 2015
500 Mg, 10 10'S
------------------------------------------------------------------------
Biaxin XL 500Mg(1 14) 00074-3165-14 Q1 2014-Q4 2015
------------------------------------------------------------------------
Biaxin XL, Filmtab Tabs, 00074-3165-41 Q1 2014-Q4 2015
500Mg, 4 14'S
------------------------------------------------------------------------
Biaxin XL, Filmtab 00074-3165-60 Q1 2014-Q4 2015
Tablets, 500 Mg, 60'S
------------------------------------------------------------------------
Biaxin OS, 250Mg/5Ml, 00074-3188-13 Q2 2014-Q3 2014, Q1 2016-
100ML Q2 2018
------------------------------------------------------------------------
Biaxin OS 250Mg/5Ml, 50ML 00074-3188-50 Q2 2014-Q3 2014, Q1 2016-
Q2 2018
------------------------------------------------------------------------
Biaxin Filmtab Tablets, 00074-3368-60 Q1 2014, Q3 2014, Q1 2015-
250 Mg, 60'S Q3 2015
------------------------------------------------------------------------
Cardizem LA , Tablets, 120 00074-3045-30 Q1 2014-Q3 2014
Mg, 30'S
------------------------------------------------------------------------
Cardizem LA , Tablets, 120 00074-3045-90 Q1 2014-Q3 2014
Mg, 90'S
------------------------------------------------------------------------
Cardizem LA , Tablets, 180 00074-3061-30 Q1 2014
Mg, 30'S
------------------------------------------------------------------------
Cardizem LA , Tablets, 180 00074-3061-90 Q1 2014
Mg, 90'S
------------------------------------------------------------------------
Cardizem LA , Tablets, 240 00074-3062-30 Q1 2014
Mg, 30'S
------------------------------------------------------------------------
Cardizem LA , Tablets, 240 00074-3062-90 Q1 2014
Mg, 90'S
------------------------------------------------------------------------
Cardizem LA , Tablets, 300 00074-3063-30 Q1 2014
Mg, 30'S
------------------------------------------------------------------------
Cardizem LA , Tablets, 300 00074-3063-90 Q1 2014
Mg, 90'S
------------------------------------------------------------------------
Cardizem LA , Tablets, 360 00074-3064-30 Q1 2014-Q2 2014
Mg, 30'S
------------------------------------------------------------------------
Cardizem LA , Tablets, 360 00074-3064-90 Q1 2014-Q2 2014
Mg, 90'S
------------------------------------------------------------------------
Cardizem LA , Tablets, 420 00074-3069-30 Q1 2014
Mg, 30'S
------------------------------------------------------------------------
Cardizem LA, Tablets, 420 00074-3069-90 Q1 2014
Mg, 90'S
------------------------------------------------------------------------
Depacon 500Mg (100Mg/1ML) 00074-1564-10 Q1 2016, Q4 2016-Q4 2017
10 5ML SDV
------------------------------------------------------------------------
Depakene 250Mg 100Cap 00074-5681-13 Q1 2014, Q3 2014-Q4 2018
------------------------------------------------------------------------
Depakene OS 250Mg/5ML, 00074-5682-16 Q3 2014-Q4 2018
16Oz
------------------------------------------------------------------------
Depakote ER 250Mg 10 10Tab 00074-3826-11 Q1 2015, Q4 2018
------------------------------------------------------------------------
Depakote ER 250Mg 100Tab 00074-3826-13 Q1 2015, Q4 2018
------------------------------------------------------------------------
Depakote, Sprinkle 00074-6114-11 Q1 2015-Q4 2018
Capsule, 125 Mg, 10-10
------------------------------------------------------------------------
Depakote Sprinkle Capsule, 00074-6114-13 Q1 2015-Q4 2018
125Mg, 100
------------------------------------------------------------------------
Depakote 125Mg 100Tab 00074-6212-13 Q1 2014, Q3 2014-Q4 2018
------------------------------------------------------------------------
Depakote 250Mg 100Tab 00074-6214-13 Q1 2014, Q3 2014-Q4 2018
------------------------------------------------------------------------
Depakote 250Mg 500Tab 00074-6214-53 Q1 2014, Q3 2014-Q4 2018
------------------------------------------------------------------------
Depakote 500Mg 100Tab 00074-6215-13 Q1 2014, Q3 2014-Q4 2018
------------------------------------------------------------------------
Depakote 500Mg 500Tab 00074-6215-53 Q1 2014, Q3 2014-Q4 2018
------------------------------------------------------------------------
Depakote ER 500Mg 10X10Tab 00074-7126-11 Q4 2014-Q1 2015, Q1 2017-
Q3 2017, Q4 2018
------------------------------------------------------------------------
Depakote ER 500Mg 100Tab 00074-7126-13 Q4 2014-Q1 2015, Q1 2017-
Q3 2017, Q4 2018
------------------------------------------------------------------------
Depakote ER 500Mg 500Tab 00074-7126-53 Q4 2014-Q1 2015, Q1 2017-
Q3 2017, Q4 2018
------------------------------------------------------------------------
Humira 40Mg/0.8ML (2 00074-3799-02 Q2 2016-Q4 2018
Syringes)
------------------------------------------------------------------------
Humira Ped Crohns Starter 00074-3799-03 Q2 2016-Q4 2018
Pack, 40Mg
------------------------------------------------------------------------
Humira Ped Crohns Starter 00074-3799-06 Q2 2016-Q4 2018
Pack, 40Mg
------------------------------------------------------------------------
Humira 40Mg/0.8 ML (2 00074-4339-02 Q2 2016-Q4 2018
Pens)
------------------------------------------------------------------------
Humira, Crohn's, 40Mg/0.8 00074-4339-06 Q2 2016-Q4 2018
ML (6 Pens)
------------------------------------------------------------------------
Humira, Psoriasis, 40Mg/ 00074-4339-07 Q2 2016-Q4 2018
0.8ML (4 Pens)
------------------------------------------------------------------------
Humira, Single Dose 00074-6347-02 Q2 2016-Q4 2018
Syringe, 10 Mg/0.2ML
------------------------------------------------------------------------
Humira 20Mg/0.4ML (2 00074-9374-02 Q2 2016-Q4 2018
Syringes)
------------------------------------------------------------------------
K-Tab, Filmtabs, 8Meq, 00074-3058-41 Q3 2018
600Mg, 100Ct
------------------------------------------------------------------------
K-Tab, Filmtabs, 8Meq, 00074-3058-46 Q3 2018
600Mg, 1000Ct
------------------------------------------------------------------------
Marinol 2.5 Mg Capsules, 00051-0021-21 Q2 2016
60'S
------------------------------------------------------------------------
Marinol 5 Mg Capsules, 00051-0022-21 Q3 2018
60'S
------------------------------------------------------------------------
Marinol 10 Mg Capsules, 00051-0023-21 Q2 2014, Q3 2017
60'S
------------------------------------------------------------------------
Mavik, Tablets, 1 Mg, 00074-2278-13 Q4 2014, Q2 2015
100'S
------------------------------------------------------------------------
Niaspan, Tablets, 500 Mg, 00074-3074-90 Q1 2014, Q2 2015, Q1 2016-
90'S Q3 2016, Q1 2017-Q4 2018
------------------------------------------------------------------------
Niaspan, Tablets, 750 Mg, 00074-3079-90 Q1 2014, Q4 2014, Q2 2015-
90'S Q2 2016, Q4 2016-Q4 2018
------------------------------------------------------------------------
Niaspan, Tablets, 1000 Mg, 00074-3080-90 Q1 2014, Q1 2015-Q2 2015,
90'S Q1 2016-Q3 2016, Q1 2017-
Q4 2018
------------------------------------------------------------------------
Niaspan, Tablets, 500Mg, 00074-3265-90 Q4 2017-Q4 2018
90'S
------------------------------------------------------------------------
Niaspan, Tablets, 750Mg 00074-3274-90 Q1 2018-Q4 2018
90'S
------------------------------------------------------------------------
Niaspan, Tablets, 1000Mg 00074-3275-90 Q4 2017-Q4 2018
90'S
------------------------------------------------------------------------
Prometrium 100 Mg 00032-1708-01 Q2 2016-Q4 2018
Capsules, 100'S
------------------------------------------------------------------------
Prometrium 200 Mg 00032-1711-01 Q2 2016-Q4 2018
Capsules, 100'S
------------------------------------------------------------------------
Simcor 500Mg/20Mg, 90Tab 00074-3312-90 Q3 2014
------------------------------------------------------------------------
Simcor 1000Mg/20Mg, 90Tab 00074-3455-90 Q1 2014, Q3 2014
------------------------------------------------------------------------
Tarka ER 2Mg/180Mg, 100Tab 00074-3287-13 Q2 2015-Q4 2015, Q2 2016-
Q4 2016, Q2 2017-Q4
2017, Q2 2018-Q4 2018
------------------------------------------------------------------------
Tarka 1Mg/240Mg, 100Tab 00074-3288-13 Q2 2015-Q4 2015, Q2 2016-
Q4 2018
------------------------------------------------------------------------
Tarka ER 2Mg/240Mg, 100Tab 00074-3289-13 Q1 2014, Q2 2015-Q4 2015,
Q2 2016-Q4 2016, Q2 2017-
Q4 2017, Q2 2018-Q4 2018
------------------------------------------------------------------------
Tarka ER 4Mg/240Mg, 100Tab 00074-3290-13 Q1 2014, Q1 2015-Q3 2015,
Q1 2016-Q2 2016, Q4 2016-
Q2 2017, Q4 2017-Q3 2018
------------------------------------------------------------------------
Tricor, Tablets, 145Mg, 00074-3189-90 Q3 2018
90Ct Btl
------------------------------------------------------------------------
Tricor, Tablets, 48 Mg, 00074-6122-90 Q4 2014-Q1 2015
90'S
------------------------------------------------------------------------
Tricor, Tablets, 145 Mg, 00074-6123-90 Q3 2018
90'S
------------------------------------------------------------------------
Trilipix, Delayed Release 00074-3161-90 Q2 2017-Q4 2017, Q2 2018-
Cap, 45Mg 90Ct Q4 2018
------------------------------------------------------------------------
Trilipix, Delayed Release 00074-9189-90 Q3 2018-Q4 2018
Cap, 135Mg 90'S
------------------------------------------------------------------------
Trilipix, Delayed Release 00074-9642-90 Q3 2014-Q4 2014, Q2 2015-
Cap, 45Mg 90'S Q3 2015, Q1 2016, Q3
2016-Q4 2016, Q2 2017-Q4
2017, Q2 2018-Q4 2018
------------------------------------------------------------------------
Zemplar, Capsules, 2 Mcg, 00074-4314-30 Q3 2014-Q1 2015, Q3 2015-
30'S Q4 2015, Q2 2016-Q4
2016, Q2 2017, Q4 2017-
Q4 2018
------------------------------------------------------------------------
Zemplar, Capsules, 4 Mcg, 00074-4315-30 Q2 2014-Q4 2015
30'S
------------------------------------------------------------------------
Zemplar, Capsules, 1 Mcg, 00074-4317-30 Q4 2014, Q2 2015, Q4
30'S 2015, Q2 2016, Q1 2018-
Q4 2018
------------------------------------------------------------------------
medicaid drug rebate program compliance
Question. I am concerned about recent reports and legal settlements
surrounding drug manufacturers' failure to comply fully with the
requirements of the MDRP. for example, an analysis by the U.S.
Department of Health and Human Services office of Inspector General
found that between 2012 and 2016 taxpayers may have overpaid by as much
as $1.3 billion for 10 potentially misclassified drugs. That is why I
introduced the Right Rebate Act with Chairman Grassley to prevent drug
manufacturers from manipulating Medicaid to increase their profits.
However, I continued to be concerned about oversight and manufacturer
compliance with the requirements of the Medicaid Drug Rebate Program.
Accordingly, please describe the following:
Your company's current compliance plan and procedures used to
ensure compliance with the requirements of the Medicaid Drug Rebate
Program including internal audits or other checks you use to identify
compliance vulnerabilities.
Answer. AbbVie has established and maintains a comprehensive
compliance plan and procedures to ensure MDRP compliance, the core
components of which include policies and procedures relating to MDRP
issues, routine internal and external monitoring and auditing, and a
dedicated governance team to monitor and address any potential MDRP
issues.
Question. Any past or ongoing issues of non-compliance.
Answer. We are not aware of past or ongoing issues of non-
compliance with MDRP legal requirements.
Question. Any corrective actions taken to address identified
problems or issues of noncompliance with the MDRP and how such steps
were communicated to the Centers for Medicare and Medicaid Services.
Answer. We are not aware of past or ongoing issues of non-
compliance with MDRP legal requirements.
Question. Any steps taken to improve compliance and ensure that all
Medicaid drug rebates owed to the Federal Government and the States are
paid in full.
Answer. AbbVie conducts periodic reviews of its compliance plan and
updates its policies, procedures, and monitoring plans as needed to
ensure the company's continued implementation of MDRP legal
requirements.
bonus payments tied to specific drugs
Question. I am concerned by the potential for employee financial
incentives to encourage high launch prices and price increases for
prescription drugs.
Is your salary, bonus, or other compensation tied to sales or
revenue targets of a single product your company sells? Has it ever
been? If yes, please state the product or products to which your
salary, bonus or other compensation was tied.
Is your salary, bonus, or other compensation tied to either revenue
or net income of the company as a whole? Has it ever been? If yes,
please explain what assumptions about price increases are used when the
compensation committee sets revenue or net income goals. Does the
compensation committee provide any guidance to executives in regards to
the amount of revenue that the company will generate from price
increases versus volume growth?
Answer. To determine Mr. Gonzalez's 2018 annual incentive
compensation (sometimes referred to as a bonus), net revenues, income
before taxes, and Humira sales were three of several quantitative
financial metrics that were considered in addition to qualitative
factors. At most, a single quantitative financial metric had the
potential to impact up to 3 percent of Mr. Gonzalez's total
compensation, subject to additional qualitative and relative analyses.
No other compensation element, beyond the annual incentive
compensation, includes Humira sales, revenue, or net income as a
performance metric. While some specific details have differed somewhat,
the foregoing has generally been true in prior years as well.
______
Questions Submitted by Hon. Robert Menendez
Question. When new products enter the market, do drug companies set
high initial rebates and then provide deep rebates in order to gain
access to insurance plan's formularies?
Answer. Over the last 2 years, AbbVie has brought Mavyret and
Orilissa to patients. Mavyret is for the treatment of adults with
chronic hepatitis C virus (HCV) infection across all major genotypes,
and Orilissa is the first and only oral gonadotropin-releasing hormone
antagonist specifically developed for women with moderate to severe
endometriosis pain. Mavyret was introduced with a list price below
competitive alternatives and Orilissa was introduced at a list price
below the current standard of care.
Rebates are a form of price competition that results from the
aggressive negotiations that occur between health plans (and their
representative PBMs) and pharmaceutical companies to provide patients
with access to medicines and treatments that can best help patients
manage their medical conditions. Plans/PBMs create formularies to list
brand and generic medicines.
Question. If CMS finalizes the rebate rule, do you anticipate
future products entering the market with significantly lower initial
list prices?
Answer. There has been significant discussion over the past several
months about proposals to eliminate rebates from Medicare Part D,
Medicaid, and the commercial market culminating in the administration's
publication of a proposed rule to ``expressly exclud[e] from safe
harbor protection under the Anti-Kickback Statute (AKS) rebates on
prescription drugs paid by manufacturers to pharmacy benefit managers
(PBMs), Part D plans, and Medicaid managed care organizations. The
proposal would create a new safe harbor protecting discounts offered to
patients at the pharmacy counter. Finally, the proposal would create
new safe harbor protection for fixed fee services arrangements between
manufacturers and PBMs.''
AbbVie is encouraged by the goals of the proposed rule to ensure
manufacturer discounts are reflected in and reduce patient cost sharing
under Part D. While we believe the rule is an important step in the
right direction, we also believe more should be done to help reduce the
out-of-pocket cost burden on Medicare Part D patients.
As for what the elimination of rebates might mean to the overall
health care system or pharmaceutical companies, it is premature to
comment on these items until the Administration's rule is finalized,
implementation timelines are solidified and there are specific details
regarding how a new system without rebates will be structured and
function.
______
Questions Submitted by Hon. Thomas R. Carper
Question. What are your recommendations for lowering prices for the
40 percent of drugs that do not offer rebates in Medicare Part D?
Answer. A majority of the discussion about the cost of prescription
drugs has been focused on list prices. We agree that price should be
part of the discussion, however we also know that solutions targeting
list price alone are not enough. Our experience in launching a low list
price HCV medicine made it clear to AbbVie and patients that list price
reductions will not always address patient affordability and access.
Providing discounts to the patient at the point of sale is an
effective way of ensuring that patients can see lower out-of-pocket
costs. However, this is just the start. AbbVie believes that more must
be done.
The Medicare Part D benefit design contributes to making innovative
therapies cost-prohibitive for Medicare patients because patients are
charged out-of-pocket costs based on a medicine's list price, which
does not reflect the rebates that Medicare receives.
AbbVie believes it is important to alleviate the burdens that
patients face due to Medicare Part D out-of-pocket costs. AbbVie
supports solutions like a patient out-of-pocket cap in Part D and
smoothing patient out-of-pocket payments over a full year, so patients
have some predictability with respect to their out-of-pocket costs.
In addition, AbbVie is prepared to step up and discuss how
companies like ours can shoulder more of the burden of a patient's out-
of-pocket expenses.
As policymakers consider the impact of addressing out-of-pocket
costs in Medicare Part D, questions may arise around whether it will
lead to unnecessary utilization and wasteful spending. for specialty
medicines, increased utilization should not be misunderstood as
unnecessary or wasteful. Part D plans have tools, like step therapy
requirements for patients to first try lower cost alternatives before a
specialty medicine would be covered and prior authorization
requirements before a specialty medicine would be covered, to manage
the utilization of the majority of higher cost specialty medicines.
These tools ensure patients try a less costly medication first and have
met the clinical criteria for taking the specialty drug prescribed and
serve the function that an out-of-pocket cost obligation on patients
might serve to prevent unnecessary use.
Question. In the health insurance plans that you offer your
employees, do you ask your insurers to pass through the full
manufacturer rebates to the beneficiaries?
Answer. AbbVie's benefit plans are structured to ensure employees
share in the cost of their prescription drugs but are also able to
access and afford their medicines, with the goal of maximizing
prescription drug adherence.
Currently our maximum co-pays and out-of-pocket maximums ensure
patient access and allow us to utilize rebates to reduce premiums. Our
benefit includes a deductible and 25-percent co-pay for prescription
medicines that is capped at $125 for a 30-day supply. For mail order or
specialty pharmacy, there is a 20-percent co-pay that is capped at $250
for a 90-day supply. Additionally, our benefit plans include an annual
out-of-pocket maximum. Our prescription drug adherence levels are high
year over year across many disease states.
To increase transparency, members receive a receipt at retail or
via mail/specialty pharmacies that reflects their share of the
discounted price of the drug.
AbbVie has considered the impact of passing through rebates to
employees and have found a minimal impact on employee out-of-pocket
expenses for all medicines, including specialty. We have found that it
would only reduce employee spending if the rebate reduced the co-
payment obligation below $125 for drugs filled at retail or $250 for
mail order or specialty drugs.
Employees who would benefit the most in this scenario would be
those in high deductible health plans before they meet their
deductible, however it could slow the time in which they would reach
their deductible.
While we have found that providing rebates at point of sale is most
beneficial to enrollees whose benefit design does not include a maximum
co-pay and therefore may not be beneficial to AbbVie employees, we are
continuing to assess the impact in a manner that ensures we can
maintain the current employee costsharing levels in our benefit design
that drive adherence.
Question. The systems for pricing and distributing drugs are opaque
and difficult to understand. What are your recommendations for
increasing transparency in how your companies set the list prices for
drugs, and for improving transparency in the supply chain for
prescription drugs? Would you support federal standards for
transparency in setting the list prices for drugs?
Answer. AbbVie supports transparency that is accurate, timely,
comprehensive and meaningful to patients as they make better-informed
decisions about their health care. This includes broad transparency
across the entire health-care system and consistent requirements,
including for all entities in the drug supply chain, rather than a
narrow focus on one individual sector. It is also important that any
new transparency requirements are prospective and balanced with
appropriate protections for confidential, proprietary information so as
not to undermine competition in the marketplace. As Congress considers
approaches to address transparency at the Federal level, AbbVie
welcomes further discussion on this important topic.
Question. In nearly every sector of the health-care industry,
Medicare, Medicaid, employers, and insurers are moving away from fee-
for-service payments to reimbursements based on value and performance.
Prescription drugs and medical devices were the glaring exceptions to
this trend until recently. How many of your drugs are included in
valuebased contracts and how many patients are benefiting from them?
How do these valuebased contracts work to lower drug prices for both
patients and taxpayers?
Answer. Value-based arrangements can be an effective and market-
based solution to managing overall health-care costs when driven by
patient outcomes. Studies have found that 38 percent of payers with
outcomes-based contracts experience improved patient outcomes and 33
percent experience plan health-care cost savings. Additionally, plans
with outcomes-based contracts have been found to have a 28 percent
lower patient co-payment. All of these factors work towards moving
payment for prescription medicines away from volume-based approaches to
value-based models in a manner that appropriately balances patient
access with the appropriate use of medications to lower overall health-
care costs.
At AbbVie, we believe all our products provide value to patients
and the larger health care system and are interested in the
possibilities that could arise through value-based contracting. To
further foster value-based arrangements, we support the reforms
included in the Patient Affordability, Value and Efficiency (PAVE) Act,
introduced by Senators Cassidy (R-LA) and Warner (D-VA).
Question. Last year, Senator Portman and I did an investigation on
the pricing of an opioid overdose reversal drug called EVZIO,
manufactured by Kaleo. Kaleo increased the price of EVZIO from $575 in
2014 to $4,100 in 2017. We found that the best price Medicare was able
to get for EVZIO, about $4,000, was much higher than the price other
federal programs and private insurers were able to get. It seemed that
Kaleo was able to get this higher price of $4,000 from Medicare by
helping doctors fill out paperwork showing that the drug was medically
necessary, even though there are cheaper alternatives on the market. As
a result of the investigation, Kaleo announced it will bring a generic
version of the drug to market at only $168 per pack. Are any of your
companies providing medical necessity paperwork to doctors in order to
get your drugs covered by Medicare?
Answer. Unlike the scenarios raised in this question, AbbVie does
not have a practice of completing medical necessity sections on any
reimbursement forms, purporting to make medical necessity
determinations that should be made by physicians, or submitting medical
necessity forms to payors on behalf of patients or physicians.
Question. In 2017, the Rand Corporation estimated that biosimilar
drugs, which are competitors to complex, biologic drugs, could save the
United States more than $50 billion over the next decade. Some of you
have also argued that increasing the use of biosimilar drugs would help
lower drugs costs for consumers and taxpayers. What is delaying the
uptake of biosimilar drugs in the United States? What policies do you
recommend to increase the development of biosimilar drugs?
Answer. AbbVie believes that FDA's current, patient-centered and
science-based approach to the development of standards governing the
approval of biosimilars--including interchangeable biosimilars--helps
to build a sustainable biosimilar market as patients and health care
providers become more exposed to, and comfortable with, these products.
The agency's approach best ensures the approval of quality, safe, and
effective biosimilar products--products that will instill confidence
among patients and prescribers. A robust and competitive biologic
marketplace cannot survive without this stakeholder confidence and
support.
Any policies regarding the biologics market must take into
consideration the fundamental differences between small molecule
generics and biosimilars. Consequently, competition between biosimilars
and their reference products will necessarily more closely resemble
brand-to-brand competition. A key principle for encouraging appropriate
market competition for biological products, then, is ensuring a level
playing field for all biologic products. Artificially favoring either
biosimilars or innovator biologics in coverage or reimbursement creates
market inefficiencies by reducing incentives to compete on price.
Moreover, policies designed to artificially drive usage of either the
biosimilar or the reference biologic risk confusing stakeholders
regarding the clear regulatory distinctions between biosimilars and
small-molecule generics. Robust competition should therefore be driven
by an increasing number of innovator and biosimilar products competing
to treat disease at the lowest possible cost.
______
Questions Submitted by Hon. Benjamin L. Cardin
Question. The United States is one of the only countries in the
world to allow prescription drug manufacturers to advertise directly to
consumers through magazines, billboards, radio, and television
commercials. While I will not argue that it is beneficial to educate
consumers about an unfamiliar disease and encourage them to seek
medical help, most commercials from all of your companies recommend
asking about a specific brand name drug, not a medical condition.
Furthermore, even if your advertisements follow all FDA rules and list
medication side effects, they also almost always list these while a
smiling, apparently healthy person is walking on a beach.
Researchers say that this type of imagery, combined with viewing
hours of drug commercials each month, leads consumers to underestimate
the risks associated with medications. for the past decade, studies
have shown that aggressive direct-toconsumer advertising is associated
with rising drug prices and an increase in inappropriate drug
prescriptions.
Since researchers have concluded that consumers are
misunderstanding the benefits and risks described in your ads, what
further policies could help you and your colleagues ensure that you are
educating patients in a clear manner?
Answer. We believe it is unlikely that DTC advertising would lead
to an ``increase in inappropriate prescriptions'' for AbbVie's largely
specialty-product portfolio. Both commercial insurance and Part D plans
have tools, like step therapy requirements for patients to first try
lower cost alternatives before a specialty medicine would be covered
and prior authorization requirements before a specialty medicine would
be covered to manage the utilization of the majority of higher cost
specialty medicines. These tools ensure patients try a less costly
medication first and have met the clinical criteria for taking the
specialty drug prescribed.
Further, we believe that consumers understand the benefits and
risks described in AbbVie's advertisements. AbbVie goes beyond the FDA
regulations to ensure its advertising it accurate, truthful, not
misleading, and reflects an appropriate balance between the risks and
benefits of the drugs. This includes complying with PhRMA's voluntary
principles on direct to consumer advertising.\2\ Some of the key
principles addressing the issues of educating patients in a clear
manner include:
---------------------------------------------------------------------------
\2\ See http://phrmadocs.phrma.org/files/dmfile/PhRMA--Guiding--
Principles_2018.pdf.
Companies that choose to feature actors in the roles of
health-care professionals in a DTC television or print
advertisement that identifies a particular product should
acknowledge in the advertisement that actors are being used.
Likewise, if actual health-care professionals appear in such
advertisements, the advertisement should include an
acknowledgment if the health-care professional is compensated
---------------------------------------------------------------------------
for the appearance.
DTC television advertising that identifies a product by name
should clearly state the health conditions for which the
medicine is approved and the major risks associated with the
medicine being advertised.
DTC television and print advertising should be designed to
achieve a balanced presentation of both the benefits and the
risks associated with the advertised prescription medicine.
Specifically, risks and safety information, including the
substance of relevant boxed warnings, should be presented with
reasonably comparable prominence to the benefit information, in
a clear, conspicuous and neutral manner, and without
distraction from the content. In addition, DTC television
advertisements should support responsible patient education by
directing patients to health care professionals as well as to
print advertisements and/or websites where additional benefit
and risk information is available.
All DTC advertising should respect the seriousness of the
health conditions and the medicine being advertised.
AbbVie believes these are important principles that all
pharmaceutical advertisements should follow. Our approach of listening
to, and learning from, consumers, caregivers, physicians and other
health-care professionals continues to confirm our belief that
accurate, balanced and timely information about our prescription
medicines and the conditions they treat is an essential component of
our commitment to putting patient health first.
pharmaceutical companies continue to raise prices
Question. As you are well aware, high prescription drug prices are
the number one concern for Americans and their families. According to
the Organization for Economic Cooperation and Development, the average
American spends around $1,208 annually on prescription drugs. There
have been several instances where brand name or even generic drugs that
have been on the market for years continue to increase in price.
One of the most well known examples is Mylan's increase of the
price of EpiPen from less than $100 in 2007 to more than $600 in 2016.
Another example, is the everincreasing price of insulin. Sanofi
increased the price of a vial of Lantus from $88.20 in 2007 to $307.20
in 2017. And those are just a small sample of price increases.
Why don't we see price decreases for drugs that have been on the
market for years without new formulations or added benefit?
Answer. Price often does decrease for drugs that have been on the
market for years. The U.S. has a robust and well-functioning system
with fast entry of generic medicines following the expiration of patent
and market exclusivities for brand medications. When generics medicines
enter the market price reductions can be dramatic. In fact, GAO has
found that prices are typically reduced by 20 percent for each new
generic entrant to the market. From 2005 to 2013 prices of medicines
commonly used to prevent cardiovascular disease dropped 92 percent. The
daily cost of the top 10 therapeutic classes of medicines most commonly
used by Medicare Part D enrollees dropped from $1.50 to $0.77 from 2006
to 2013.
In addition to dramatic decreases in price, generic uptake is swift
in the U.S. When a generic version of a medicine becomes available for
the first time, it captures an average of three-quarters of the market
within 3 months. Some generics captures as much as 90 percent in that
same time period. Utilization is also the highest in the U.S. when
compared to uptake in other markets, such as the UK, France, Japan,
Germany, and Australia. According to the 2018 Medicare Trustees Report,
the generic utilization rate for Part D beneficiaries has steadily
increased each year, from 75 percent in 2010 to 88 percent in 2017.
Competition is also robust among branded products. From 2005 to
2011, the time only one medicine was available in its class declined
from a median of 10 years in the 1970s to close to 2 years from 2005-
2011. Half of second medicines were approved within 2.3 years and one
quarter were approved within just 4 months. These competitive forces
lead to manufacturers offering discounts. An analysis by IQVIA found
that net prices for brands continued to increase more slowly than
invoice prices from 2013 to 2016, with average price increases for
brands at 9.2 percent (down from 12 percent in 2015) and net price
growth increases at 3.5 percent. For the same year, the analysis found
that rebates, discounts, and other price concessions offset price
growth for brand medicines by 62 percent.
pay for delay
Question. Pay for delay is a tactic that more and more branded drug
manufacturers have been using to stifle competition from lower-cost
generic manufacturers. This allows you to sidestep competition by
offering patent settlements that pay generic companies not to bring
lower-cost alternatives to market.
These ``pay-for-delay'' patent settlements benefit both brand-name
pharmaceutical companies by helping them avoid costly patent litigation
and general manufacturers by rewarding them a hefty sum to delay
entering the market with a cheaper drug alternative. However, these
deals do not benefit consumers. According to an FTC study, these
anticompetitive deals cost consumers and taxpayers $3.5 billion in
higher drug costs every year.
Does your company partake in pay-for-delay settlements?
Why would a pharmaceutical company enter into a pay-for delay
agreement?
Do you think these agreements stifle competition and prevent
generic alternatives to your branded medications?
Answer. ``Pay-for-delay'' is not a self-defining phrase. With
respect to the term ``pay,'' patent litigation settlements, like all
litigation settlements, involve compromise in which both sides believe
they are getting value from the resolution. There is no definition
explaining the circumstances under which that value would implicate the
term ``pay'' in ``pay-fordelay'' for purposes of these questions. And
with respect to ``delay'' virtually all patent settlements provide for
the generic competitor to enter the market before the expiration of the
patent at issue. So if the alternative resolution of a patent lawsuit
would be the innovator company continuing to enforce its patent until
expiration, then such a settlement, no matter what value is exchanged,
would actually accelerate competition, not delay it.
drug rebate rule
Question. In January, the Department of Health and Human Services'
(HHS) office of Inspector General (OIG) promulgated a new regulation to
remove regulatory safe harbor protections under the Anti-Kickback
Statute (AKS) for rebates on prescription drugs rebates paid by
manufactures to PBMs under Medicare Part D and for Medicaid managed
care organizations (MCOs). The OIG proposal attempts to ban most
rebates by eliminating their regulatory protections.
The rule is predicted to increase net drug costs in its early
years. The CMS actuaries estimate it would cost $196 billion over 10
years. Despite this high price tag, the beneficiary benefits are
limited. The proposed rule notes that under the CMS Actuary's analysis,
the majority of beneficiaries would see an increase in their total out-
of-pocket payments and premium costs; reductions in total cost sharing
will exceed total premium increases.
I wanted to ask a question about the administration's rebate rule,
which I understand that many of the drug manufacturers, and your main
trade association, strongly support. According to an analysis of the
rule by the Office of Actuaries at CMS, drug manufacturers are likely
to initially retain 15 percent of the current rebates as higher net
drug prices.
Given that estimate, can you provide the committee with any
assurances that prices will not increase under this proposed rule?
Answer. There has been significant discussion over the past several
months about proposals to eliminate rebates from Medicare Part D,
Medicaid, and the commercial market culminating in the administration's
publication of a proposed rule to ``expressly exclude[e] from safe
harbor protection under the Anti-Kickback Statute (AKS) rebates on
prescription drugs paid by manufacturers to pharmacy benefit managers
(PBMs), Part D plans, and Medicaid managed care organizations. The
proposal would create a new safe harbor protecting discounts offered to
patients at the pharmacy counter. Finally, the proposal would create
new safe harbor protection for fixed fee services arrangements between
manufacturers and PBMs.''
AbbVie is encouraged by the goals of the proposed rule to ensure
manufacturer discounts are reflected in and reduce patient cost sharing
under Part D. While we believe the rule is an important step in the
right direction, we also believe more should be done to help reduce the
out-of-pocket cost burden on Medicare Part D patients.
As for what the elimination of rebates might mean to the overall
health care system or pharmaceutical companies, it is premature to
comment on these items until the Administration's rule is finalized,
implementation timelines are solidified and there are specific details
regarding how a new system without rebates will be structured and
function.
______
Questions Submitted by Hon. Sherrod Brown
Question. According to an article recently published in the Journal
of the American Medical Association, medical marketers spent nearly $30
billion dollars in 2016, up from $17 billion in 1997. Direct-to-
Consumer (DTC) advertising had the biggest percentage increase: from
$2.1 billion, or 11.9 percent of all medical marketing, in 1997 to $9.6
billion, or 32 percent of total spending, in 2016.
Can each of you please provide what your ratio of spending on sales
and marketing to research and development is today?
Answer. AbbVie spends more on research and development than on
global sales, marketing, and promotion costs. The global sales,
marketing, and promotion spend in 2018 across all AbbVie products was
$4.24 billion. This is less than the $5.26 billion AbbVie spent on
research and development in 2018. And AbbVie's research and development
spend does not include acquired inprocess research and development
($424 million in 2018) or money invested externally for technology,
pharmaceutical compounds, or acquisitions. for example, AbbVie acquired
Pharmacyclics for $20.8 billion in 2015 and Stemcentrx for $6.4 billion
in 2016. The acquisition of both companies enhanced AbbVie's pipeline,
research and development, and clinical programs.
price-gouging
Answer. Sanofi, as I understand it, has made a pledge to the public
to limit its price increases to the national health expenditures growth
projection.
Would your company commit to a cap on annual price increases as
part of your PhRMA membership criteria?
Answer. With respect to the question's proposed collective
agreement by PhRMA members to cap annual price increases, we note that
in 1993, PhRMA (then known as PMA, the Pharmaceutical Manufacturers
Association) sought review of such a proposal from the Antitrust
Division of the Department of Justice. The Department of Justice opined
that the proposed agreement for PhRMA members to collectively agree to
limit their price increases would be per se unlawful under federal
antitrust laws, even though the proposal was made ``in response to
concerns about controlling health care costs.'' (Oct. 1, 1993 letter
from Anne K. Bingaman, Assistant U.S. Attorney General, available at
https://www.justice.gov/atr/response-pharmaceutical-manufacturers-
associationsrequest-business-review-letter (``The PMA proposal is an
arrangement among competitors that limits individual pricing decisions
on its face. . . . An agreement among independent competitors that
interferes with free and open price competition by restraining
individual pricing decisions is a per se violation of the Sherman
Act.'').) The Department of Justice said it ``intend[ed] to bring suit
to challenge the program if PMA and its members go forward with its
proposal.'' AbbVie could not support a proposal that the Department of
Justice is on record as saying is unlawful and against which it would
file suit to block.
As for individual action, the same Department of Justice opinion
discussed above noted that, while collective agreements among
competitors raised antitrust violations, an individual company's
decision to limit its own price increases would not be problematic.
AbbVie in January 2017 became one of the first pharmaceutical companies
to commit to limiting increases of its list prices. AbbVie committed to
not more than one, single-digit price increase annually. AbbVie has
abided by that commitment.
Question. What policies would you propose to help ensure lower
launch prices for new drugs?
Answer. A majority of the discussion about the cost of prescription
drugs has been focused on list prices. We agree that price should be
part of the discussion, however we also know that solutions targeting
list price alone are not enough. Our experience in launching a low list
price HCV medicine made it clear to AbbVie and patients that list price
reductions will not always address patient affordability and access.
Providing discounts to the patient at the point of sale is an
effective way of ensuring that patients can see lower out-of-pocket
costs. However, this is just the start. AbbVie believes that more must
be done.
The Medicare Part D benefit design contributes to making innovative
therapies cost-prohibitive for Medicare patients because patients are
charged out-of-pocket costs based on a medicine's list price, which
does not reflect the rebates that Medicare receives.
AbbVie believes it is important to alleviate the burdens that
patients face due to Medicare Part D out-of-pocket costs. AbbVie
supports solutions like a patient outof-pocket cap in Part D and
smoothing patient out-of-pocket payments over a full year, so patients
have some predictability with respect to their out-of-pocket costs.
In addition, AbbVie is prepared to step up and discuss how
companies like ours can shoulder more of the burden of a patient's out-
of-pocket expenses.
As policymakers consider the impact of addressing out-of-pocket
costs in Medicare Part D, questions may arise around whether it will
lead to unnecessary utilization and wasteful spending. for specialty
medicines, increased utilization should not be misunderstood as
unnecessary or wasteful. Part D plans have tools, like step therapy
requirements for patients to first try lower cost alternatives before a
specialty medicine would be covered and prior authorization
requirements before a specialty medicine would be covered, to manage
the utilization of the majority of higher cost specialty medicines.
These tools ensure patients try a less costly medication first and have
met the clinical criteria for taking the specialty drug prescribed and
serve the function that an out-of-pocket cost obligation on patients
might serve to prevent unnecessary use.
transparency
Question. In many of your testimonies, you mentioned that the
current system of pharmacy benefit manager (PBM) back-end rebates
rarely results in a scenario where the PBM passes on savings to
consumers at the point of sale (POS). The administration recently
proposed a rule to eliminate the anti-kickback statute safe harbor
protections for these drug rebates.
Do you agree that greater transparency should be required to
understand how manufacturers and PBMs are negotiating prices and
rebates to ensure that savings are passed down to beneficiaries?
Answer. AbbVie supports price transparency across all stakeholders
that is accurate, timely, comprehensive, and meaningful to patients as
they make better-
informed decisions about their health care. This includes broad
transparency across the entire health-care system and consistent
requirements, including for all entities in the drug supply chain,
rather than a narrow focus on one individual sector. It is also
important that any new transparency requirements are prospective and
balanced with appropriate protections for confidential, proprietary
information so as not to undermine competition in the marketplace.
pbms
Question. An Axios article from March 7, 2019 highlights the fact
that, while ``pharmaceutical companies put a lot of the blame for high
drug prices on pharmacy benefit managers,'' many large pharmaceutical
companies ``rely on PBMs to manage their own health-care benefits.''
In your role as an employer, does your company contract with a
pharmaceutical benefit manager (PBM) to administer the prescription
drug benefits for your employees and negotiate lower drug costs on your
behalf?
For those of you who do use a PBM to help manage the prescription
drug benefit for your employees, how do you utilize the rebates your
PBM negotiates to lower health-care costs or drug costs for your
employee plans and what does your company do with that savings?
Specifically, do the savings go toward lowing premiums?
For those of you who do use a PBM to help manage the prescription
drug benefit for your employees, does your PBM offer point-of-sale
rebates to your employees?
Answer. AbbVie does use a PBM to manage pharmacy benefits for its
employees in the U.S. AbbVie's benefit plans are structured to ensure
employees share in the cost of their prescription drugs but are also
able to access and afford their medicines, with the goal of maximizing
prescription drug adherence.
Currently our maximum co-pays and out-of-pocket maximums ensure
patient access and allows us to utilize rebates to reduce premiums. Our
benefit includes a deductible and 25-percent co-pay for prescription
medicines that is capped per prescription at $125 for a 30-day supply.
For mail order or specialty pharmacy, there is a 20-percent co-pay that
is capped per prescription at $250 for a 90-day supply. Additionally,
our benefit plans include an annual out-of-pocket maximum. Our
prescription drug adherence levels are high year over year across many
disease states.
To increase transparency, members receive a receipt at retail or
via mail/specialty pharmacies that reflects their share of the
discounted price of the drug.
AbbVie has considered the impact of passing through rebates to
employees and have found a minimal impact on employee out-of-pocket
expenses for all medicines, including specialty. We have found that it
would only reduce employee spending if the rebate reduced the co-
payment obligation below $125 for drugs filled at retail or $250 for
mail order or specialty drugs.
Employees who would benefit the most in this scenario would be
those in high deductible health plans before they meet their
deductible, however it could slow the time in which they would reach
their deductible.
While we have found that providing rebates at point of sale is most
beneficial to enrollees whose benefit design does not include a maximum
co-pay and therefore may not be beneficial to AbbVie employees, we are
continuing to assess the impact in a manner that ensures we can
maintain the current employee cost-sharing levels in our benefit design
that drive adherence.
______
Questions Submitted by Hon. Sheldon Whitehouse
Question. Please describe any policy changes you support that would
result in your company lowering the list prices of its drugs.
Answer. A majority of the discussion about the cost of prescription
drugs has been focused on list prices. We agree that price should be
part of the discussion, however we also know that solutions targeting
list price alone are not enough. Our experience in launching a low list
price HCV medicine made it clear to AbbVie and patients that list price
reductions will not always address patient affordability and access.
Providing discounts to the patient at the point of sale is an
effective way of ensuring that patients can see lower out-of-pocket
costs. However, this is just the start. AbbVie believes that more must
be done.
The Medicare Part D benefit design contributes to making innovative
therapies cost-prohibitive for Medicare patients because patients are
charged out-of-pocket costs based on a medicine's list price, which
does not reflect the rebates that Medicare receives.
AbbVie believes it is important to alleviate the burdens that
patients face due to Medicare Part D out-of-pocket costs. AbbVie
supports solutions like a patient out-of-pocket cap in Part D and
smoothing patient out-of-pocket payments over a full year, so patients
have some predictability with respect to their out-of-pocket costs.
In addition, AbbVie is prepared to step up and discuss how
companies like ours can shoulder more of the burden of a patient's out-
of-pocket expenses.
As policymakers consider the impact of addressing out-of-pocket
costs in Medicare Part D, questions may arise around whether it will
lead to unnecessary utilization and wasteful spending. for specialty
medicines, increased utilization should not be misunderstood as
unnecessary or wasteful. Part D plans have tools, like step therapy
requirements for patients to first try lower cost alternatives before a
specialty medicine would be covered and prior authorization
requirements before a specialty medicine would be covered, to manage
the utilization of the majority of higher cost specialty medicines.
These tools ensure patients try a less costly medication first and have
met the clinical criteria for taking the specialty drug prescribed and
serve the function that an out-of-pocket cost obligation on patients
might serve to prevent unnecessary use.
Question. How much does your company's research and development
portfolio rely on taxpayer-funded research conducted by the National
Institutes of Health (NIH)? How many of your company's products are
based, at least in part, on NIH research, and how many are the result
of research funded solely by your company?
Answer. The NIH performs important basic research that helps
scientific understanding. However, AbbVie spends its own money to do
the vast majority of its drug development and clinical trial work,
relying on the more than 8,000 people in research and development to
understand complex diseases and advance medicine. for the eleven AbbVie
drugs sold in the United States that have been approved since 2000, and
the two AbbVie drugs currently under review by the FDA, only two
received funding from the NIH for drug discovery. One of those drugs,
Orilissa, was developed by Neurocrine. Neurocrine received NIH funding
for drug development prior to AbbVie's collaboration with Neurocrine.
For the second, Kaletra, AbbVie's predecessor Abbott Laboratories
received an NIH discovery grant as part of an effort by the NIH to
encourage collaborative research among pharmaceutical manufacturers and
university research centers on protease inhibitors and to explore their
potential to treat HIV, a then uncontrollable and fatal disease. This
grant contributed to the development of one of the two active
ingredients in the drug. This grant, however, represented less than 1
percent of the total funding for Kaletra, with more than 99 percent of
the funding coming from Abbott.
In addition, for AbbVie's two oncology drugs--Venclexta and
Imbruvica--AbbVie has worked cooperatively with the National Cancer
Institute to conduct certain clinical trials. To date, these
cooperative trials have not resulted in any FDA approved indications
for these drugs.
Question. In each of the last 5 years, how much has your company
spent on research and development versus the advertising and marketing
of your products?
Answer. In each of the last four years, AbbVie has spent more on
research and development than it has on sales and marketing.
----------------------------------------------------------------------------------------------------------------
2014 2015 2016 2017 2018
----------------------------------------------------------------------------------------------------------------
AbbVie Research $3.297 billion $4.285 billion $4.385 billion $5.007 billion $5.259 billion
and PDevelopment
----------------------------------------------------------------------------------------------------------------
Asset Impairments ................. ................. ................. ................. $5.070 billion
----------------------------------------------------------------------------------------------------------------
Reported Research $3.297 billion $4.285 billion $4.385 billion $5.007 billion $10.329 billion
and Development
----------------------------------------------------------------------------------------------------------------
Acquired in- $352 million $150 million $200 million $327 million $424 million
process
Presearch and
development
----------------------------------------------------------------------------------------------------------------
Global Sales and $3.652 billion $3.800 billion $3.674 billion $3.830 billion $4.239 billion
PMarketing
----------------------------------------------------------------------------------------------------------------
* Sales and marketing includes the cost of AbbVie personnel in the sales and marketing field, related overhead,
the cost to develop marketing and advertising materials, and the cost of placing advertisements.
Question. During the hearing, you mentioned that your company would
be likely to lower the list prices of its drugs if the recent proposal
by the Trump administration to change the current system of rebates was
extended to the private market.
If the policy was extended to the private market, how large would
the list price reductions be relative to the size of the rebates your
company is currently providing?
How will this proposal affect how your company sets the list prices
for new drug products?
If the proposal is finalized and not extended to the private
market, will your company make any list price reductions? If so, how
large would the reductions be relative to the size of the rebates your
company is currently providing?
Answer. There has been significant discussion over the past several
months about proposals to eliminate rebates from Medicare Part D,
Medicaid, and the commercial market culminating in the administration's
publication of a proposed rule to ``expressly exclud[e] from safe
harbor protection under the Anti-Kickback Statute (AKS) rebates on
prescription drugs paid by manufacturers to pharmacy benefit managers
(PBMs), Part D plans, and Medicaid managed care organizations. The
proposal would create a new safe harbor protecting discounts offered to
patients at the pharmacy counter. Finally, the proposal would create
new safe harbor protection for fixed fee services arrangements between
manufacturers and PBMs.''
AbbVie is encouraged by the goals of the proposed rule to ensure
manufacturer discounts are reflected in and reduce patient cost sharing
under Part D. While we believe the rule is an important step in the
right direction, we also believe more should be done to help reduce the
out-of-pocket cost burden on Medicare Part D patients.
As for what the elimination of rebates might mean to the overall
health care system or pharmaceutical companies, it is premature to
comment on these items until the administration's rule is finalized,
implementation timelines are solidified, and there are specific details
regarding how a new system without rebates will be structured and
function.
______
Question Submitted by Hon. Maggie Hassan
Question. In June of 2018, the Medicaid and CHIP Payment and Access
Commission (MACPAC) unanimously recommended under Recommendation 1.1 in
their annual report to Congress that Congress remove the statutory
requirement that manufacturers blend the average manufacturer price
(AMP) of a brand drug and its authorized generic.\3\
---------------------------------------------------------------------------
\3\ MACPAC. ``Improving Operations of the Medicaid Drug Rebate
Program,'' https://www.macpac.gov/wpcontent/uploads/2018/06/Improving-
Operations-of-the-Medicaid-Drug-Rebate-Program.pdf.
This requirement created an unintended loophole. Rather than use
the price of the authorized generic, drug companies can sell its
authorized generic to a corporate subsidiary at an artificially lower
price, and use that lower price to bring down the AMP, which in turn
---------------------------------------------------------------------------
lowers the rebate obligation.
Does your company engage in this practice? Has your company ever
engaged in this practice in the past?
Answer. AbbVie does not engage in this practice and has not engaged
in this practice in the past. AbbVie only distributes, and has only
distributed, authorized generic versions of certain of its branded
products through authorized generic distribution and/or supply
agreements with third-parties that are wholly unrelated to AbbVie,
meaning a third-party entity that is not an affiliate or subsidiary of
AbbVie or otherwise owned by, controlled by, or under common control
with, in whole or in part, AbbVie. Those agreements are negotiated by
AbbVie and the third-party at arms-length and in good faith.
______
Questions Submitted by Hon. Catherine Cortez Masto
Question. As a portion of your revenue, for what percentage of the
drugs in your portfolio do you offer no rebates? Based on the drugs in
your pipeline, do you foresee that portion growing? for those drugs is
your list price equal to your net price?
Answer. All of AbbVie's on-market medicines have some rebating/
discounting in one or multiple channels and we anticipate all of our
pipeline medicines will be similar.
Question. Do you invest more in R&D than you generate in US sales
revenue? Please include specific figures.
Answer. AbbVie spent $5.26 billion in research and development in
2018. AbbVie's research and development spend does not include acquired
in-process research and development ($424 million in 2018) or money
invested externally for technology, pharmaceutical compounds or
acquisitions. For example, AbbVie acquired Pharmacyclics for $20.8
billion in 2015 and Stemcentrx for $6.4 billion in 2016. In 2018, the
net revenues for products AbbVie sells in the United States was $21.52
billion. This includes revenues that are split with Janssen for
Imbruvica. While AbbVie's U.S net revenues are higher than its research
and development expense, AbbVie's global net income since it became an
independent company in 2013 is less than the over $50 billion it has
invested in that same time period to bring drugs to market.
Question. Do you invest more in R&D than you spend on marketing and
administration? What company functions do you consider to be included
in administration? Please include specific figures.
Answer. AbbVie spends more on research and development than on
global sales, marketing, and promotion costs. The global sales,
marketing, and promotion spend in 2018 across all AbbVie products was
$4.24 billion. This is less than the $5.26 billion AbbVie spent on
research and development in 2018. And AbbVie's research and development
spend does not include acquired inprocess research and development
($424 million in 2018) or money invested externally for technology,
pharmaceutical compounds or acquisitions. for example, AbbVie acquired
Pharmacyclics for $20.8 billion in 2015 and Stemcentrx for $6.4 billion
in 2016. However, adding the $3.16 billion spent in administration,
which includes overhead costs such as corporate human resources,
corporate finance, corporate ethics and compliance, corporate legal,
and corporate information technology, as well as other expenses such as
charitable donations, AbbVie spent a total of $7.4 billion in selling,
marketing, promotion, and administrative expenses (SG&A).
Question. Do you invest more in R&D than you spend on marketing and
sales? What company functions do you consider to be included in sales?
Please include specific figures.
Answer. AbbVie spends more on research and development than on
global sales, marketing, and promotion costs. The global sales,
marketing, and promotion spend in 2018 across all AbbVie products was
$4.24 billion. This is less than the $5.26 billion AbbVie spent on
research and development in 2018. And AbbVie's research and development
spend does not include acquired in-process research and development
($424 million in 2018) or money invested externally for technology,
pharmaceutical compounds or acquisitions. for example, AbbVie acquired
Pharmacyclics for $20.8 billion in 2015 and Stemcentrx for $6.4 billion
in 2016.
Sales and marketing includes the cost of AbbVie personnel in the
sales and marketing field, related overhead, the cost to develop
marketing and advertising materials, and the cost of placing
advertisements.
Question. Why do you advertise for the drugs you manufacture? What
factors do you consider in choosing which drugs you advertise?
Answer. Our goal in advertising is to provide those living with the
conditions that our drugs treat with the best information possible so
they can have an informed discussion with their health-care provider.
For many patients DTC ads are an important source of information about
new medicines, and advertising also plays an important role in raising
awareness of diseases, removing stigma from certain conditions, and
encouraging discussions with their health-care providers.
______
Exhibit 1
Grants Donations Report--2014
(Parentheses represent refunds of previously disclosed payments)
Updated as of 3/31/2018
------------------------------------------------------------------------
Recipient Payment Amount Purpose
------------------------------------------------------------------------
100 Black Men of Atlanta, $20,000.00 Corporate Sponsorship
Inc.
A and R Educational Group, $5,500.00 Corporate Sponsorship
LLC
A Runners Love $5,000.00 Corporate Sponsorship
Academia Medica Del $(240.57) Educational Grants
Academia Medica Del $(309.06) Educational Grants
Academia Medica Del $20,000.00 Educational Grants
Academia Medica Del $15,000.00 Educational Grants
Academia Medica Del $8,800.00 Educational Grants
Academia Medica Del $10,000.00 Educational Grants
Academia Medica Del $10,000.00 Educational Grants
Academia Medica Del $10,000.00 Educational Grants
Academia Medica Del $10,000.00 Educational Grants
Academia Medica Del $10,000.00 Educational Grants
Academia Medica Del $8,900.00 Educational Grants
Academia Medica Del $5,000.00 Educational Grants
Academia Medica Del $5,000.00 Educational Grants
Academia Medica Del $10,000.00 Educational Grants
Academia Medica Del $10,000.00 Educational Grants
Academia Medica Del $20,000.00 Educational Grants
Academia Medica Del $10,000.00 Educational Grants
Academia Medica Del $10,000.00 Educational Grants
Academia Medica Del $5,000.00 Educational Grants
Academia Medica Del $10,000.00 Educational Grants
Academia Medica Del $(1,539.53) Educational Grants
Academia Medica Del $10,000.00 Educational Grants
Academia Medica Del $15,000.00 Educational Grants
Academia Medica Del $15,000.00 Educational Grants
Academia Medica Del $15,000.00 Educational Grants
Academia Medica Del $10,000.00 Educational Grants
Academia Medica Del $5,000.00 Educational Grants
Academia Medica Del $4,000.00 Educational Grants
Academia Medica Del $10,000.00 Educational Grants
Academia Medica Del $5,000.00 Educational Grants
Academia Medica Del $5,000.00 Educational Grants
Academia Medica Del $5,000.00 Educational Grants
Academia Medica Del $10,000.00 Educational Grants
Academia Medica Del $15,000.00 Educational Grants
Academia Medica Del $10,000.00 Educational Grants
Academia Medica Del $10,000.00 Educational Grants
Academia Medica Del $10,000.00 Educational Grants
Academia Medica Del $20,000.00 Educational Grants
Academia Medica Del $15,000.00 Educational Grants
Academia Medica Del $5,000.00 Educational Grants
Academy of Managed Care $50,000.00 Corporate Sponsorship
Pharmacy
Advances in Cosmetic and $50,000.00 Corporate Sponsorship
Medical Dermatology, Inc.
Advances in Cosmetic and $50,000.00 Corporate Sponsorship
Medical Dermatology, Inc.
Advances in Cosmetic and $100,000.00 Corporate Sponsorship
Medical Dermatology, Inc.
Advances in Targeted $150,000.00 Corporate Sponsorship
Therapies
Advocate Health and $2,500.00 Educational Grants
Hospitals Corporation
AIDS Drug Assistance $2,500.00 Corporate Sponsorship
Programs Advocacy
Association
AIDS Drug Assistance $10,000.00 Educational Grants
Programs Advocacy
Association
AIDS Drug Assistance $5,000.00 Corporate Sponsorship
Programs Advocacy
Association
AIDS Foundation of Chicago $125,000.00 Charitable Donations
AIDS Foundation of Chicago $7,500.00 Charitable Donations
AIDS Project Los Angeles $5,000.00 Educational Grants
Alaska Kidney Patients $1,500.00 Patient Support
Association
Albert Einstein College of $20,000.00 Educational Grants
Medicine of Yeshiva
University
Albert Einstein College of $5,000.00 Educational Grants
Medicine of Yeshiva
University
Albert Einstein College of $10,000.00 Educational Grants
Medicine, Division of
Dermatology Attending
Association
Albert Einstein Healthcare $2,500.00 Educational Grants
Network
Albert Einstein Healthcare $6,500.00 Corporate Sponsorship
Network
Alchemy Communications $50,000.00 Corporate Sponsorship
Group, LLC
Alliance Foundation for $75,000.00 Educational Grants
Continuing Education in
the Health Professions
Alzheimer's Association $50,000.00 Corporate Sponsorship
American Academy of $(8,842.31) Educational Grants
Continuing Medical
Education, Inc.
American Academy of $25,000.00 Educational Grants
Continuing Medical
Education, Inc.
American Academy of $75,000.00 Corporate Sponsorship
Dermatology
American Academy of $50,000.00 Educational Grants
Dermatology
American Academy of $100,000.00 Corporate Sponsorship
Dermatology
American Academy of $35,000.00 Corporate Sponsorship
Dermatology
American Academy of $10,000.00 Charitable Donations
Neurology Foundation
American Academy of $45,000.00 Educational Grants
Physician Assistants
American Academy of $10,000.00 Educational Grants
Physician Assistants
American Academy of Urology $3,000.00 Educational Grants
Institute--AANI
American Association for $10,000.00 Educational Grants
Cancer Research
American Association for $10,000.00 Educational Grants
Cancer Research
American Association for $20,000.00 Charitable Donations
Laboratory Animal Science
Foundation
American Association for $500,000.00 Charitable Donations
the Study of Liver
Diseases
American Association for $7,000.00 Corporate Sponsorship
the Study of Liver
Diseases
American Association for $500,000.00 Charitable Donations
the Study of Liver
Diseases
American Association for $137,500.00 Corporate Sponsorship
the Study of Liver
Diseases
American Association of $25,000.00 Educational Grants
Clinical Endocrinologists
American Association of $25,000.00 Educational Grants
Clinical Endocrinologists
American Association of $50,000.00 Educational Grants
Kidney Patients
American Association of $10,000.00 Patient Support
Kidney Patients
American Association of $25,000.00 Corporate Sponsorship
Pharmaceutical Scientists
American Brain Tumor $10,000.00 Corporate Sponsorship
Association
American Chemical Society $1,000.00 Educational Grants
American College of $7,500.00 Educational Grants
Clinical Pharmacology
American College of $321,900.00 Corporate Sponsorship
Endocrinology
American College of $100,000.00 Corporate Sponsorship
Gastroenterology
American College of $20,000.00 Corporate Sponsorship
Gastroenterology
American College of $85,000.00 Corporate Sponsorship
Gastroenterology
American College of $25,000.00 Charitable Donations
Laboratory Animal Medicine
American College of $55,000.00 Corporate Sponsorship
Physicians Foundation
American College of $55,000.00 Corporate Sponsorship
Physicians Foundation
American College of $55,000.00 Corporate Sponsorship
Physicians Foundation
American College of $100,000.00 Corporate Sponsorship
Rheumatology
American College of $200,000.00 Fellowships and
Rheumatology Scholarships
American College of $75,000.00 Educational Grants
Rheumatology
American College of $50,000.00 Educational Grants
Rheumatology
American College of $25,000.00 Educational Grants
Rheumatology
American College of $25,000.00 Educational Grants
Rheumatology
American College of $100,000.00 Corporate Sponsorship
Rheumatology
American College of $2,000,000.00 Corporate Sponsorship
Rheumatology Research and
Education Foundation
American College of $5,000.00 Corporate Sponsorship
Veterinary Pathologists
American $303,800.00 Educational Grants
Gastroenterological
Association Institute
American $7,000.00 Corporate Sponsorship
Gastroenterological
Association Institute
American $225,000.00 Educational Grants
Gastroenterological
Association Institute
American $100,000.00 Corporate Sponsorship
Gastroenterological
Association Institute
American Health Resources $2,000.00 Educational Grants
American Kidney Fund $5,000.00 Corporate Sponsorship
American Liver Foundation $10,000.00 Charitable Donations
American Liver Foundation $10,000.00 Corporate Sponsorship
American Liver Foundation $5,000.00 Corporate Sponsorship
American Liver Foundation $10,000.00 Corporate Sponsorship
American Liver Foundation $6,000.00 Corporate Sponsorship
American Liver Foundation $2,000.00 Corporate Sponsorship
American Liver Foundation $5,000.00 Corporate Sponsorship
American Liver Foundation $5,000.00 Corporate Sponsorship
American Liver Foundation $5,000.00 Charitable Donations
American Liver Foundation $10,000.00 Corporate Sponsorship
American Liver Foundation $2,500.00 Corporate Sponsorship
American Liver Foundation $5,000.00 Corporate Sponsorship
American Liver Foundation $127,000.00 Corporate Sponsorship
American Liver Foundation $106,000.00 Corporate Sponsorship
American Liver Foundation $5,000.00 Educational Grants
American Liver Foundation $2,500.00 Corporate Sponsorship
American Medical Group $6,000.00 Corporate Sponsorship
Association
American Medical Group $6,000.00 Corporate Sponsorship
Association
American Medical Group $5,050.00 Corporate Sponsorship
Association
American Medical Group $5,050.00 Corporate Sponsorship
Association
American Medical Group $5,050.00 Corporate Sponsorship
Association
American Medical Group $5,050.00 Corporate Sponsorship
Association
American Medical Group $5,050.00 Corporate Sponsorship
Association
American Nephrology Nurses $2,500.00 Fellowships and
Association Scholarships
American Neurological $25,000.00 Educational Grants
Association
American Pancreatic $15,000.00 Charitable Donations
Association
American Pancreatic $75,000.00 Educational Grants
Association
American Pancreatic $35,000.00 Corporate Sponsorship
Association
American Parkinson Disease $2,000.00 Educational Grants
Association, Inc., Georgia
Chapter
American Physiological $2,000.00 Educational Grants
Society
American Skin Association $15,000.00 Corporate Sponsorship
American Society for $7,000.00 Corporate Sponsorship
Gastrointestinal Endoscopy
American Society for Mens $27,000.00 Corporate Sponsorship
Health, The
American Society for Mens $50,000.00 Corporate Sponsorship
Health, The
American Society for Mens $60,000.00 Corporate Sponsorship
Health, The
American Society for $23,500.00 Corporate Sponsorship
Microbiology
American Society for $23,500.00 Corporate Sponsorship
Microbiology
American Society of $5,000.00 Corporate Sponsorship
Andrology
American Society of $25,000.00 Educational Grants
Clinical Oncology
American Society of $4,500.00 Corporate Sponsorship
Clinical Rheumatologists
American Society of $15,000.00 Educational Grants
Hematology
American Society of $75,000.00 Corporate Sponsorship
Hematology
American Society of $30,000.00 Educational Grants
Nephrology
American Statistical $4,225.00 Corporate Sponsorship
Association
American Thyroid $25,000.00 Educational Grants
Association, Inc.
American Uroligical $12,300.00 Corporate Sponsorship
Association, Northeastern
Section
American Urological $20,000.00 Educational Grants
Association Education and
Research, Inc.
American Urological $70,000.00 Educational Grants
Association Education and
Research, Inc.
American Urological $75,000.00 Educational Grants
Association Education and
Research, Inc.
American Urological $50,000.00 Educational Grants
Association Education and
Research, Inc.
American Urological $30,000.00 Educational Grants
Association Education and
Research, Inc.
American Urological $10,000.00 Educational Grants
Association Education and
Research, Inc.
American Urological $10,000.00 Educational Grants
Association Education and
Research, Inc.
American Urological $25,000.00 Educational Grants
Association Education and
Research, Inc.
American Urological $10,000.00 Educational Grants
Association Education and
Research, Inc.
American Urological $25,000.00 Educational Grants
Association Education and
Research, Inc.
American Urological $70,000.00 Corporate Sponsorship
Association Foundation
American Urological $6,000.00 Corporate Sponsorship ,
Association Inc. Southeast
Section
American Urological $6,000.00 Corporate Sponsorship
Association, Inc. North
Central Section
American Urological $10,000.00 Corporate Sponsorship
Association, Inc. Western
Section
American Urological $10,000.00 Educational Grants
Association, Mid-Atlantic
Section, Education Fund,
Inc.
American Urological $10,000.00 Educational Grants
Association, New England
American Urological $1,000.00 Corporate Sponsorship
Association, New York
Section
American Urological $6,000.00 Corporate Sponsorship
Association, South Central
Section
Americas Committee for $10,000.00 Corporate Sponsorship
Treatment And Research In
Multiple Sclerosis
Anesthesia Patient Safety $25,000.00 Charitable Donations
Foundation
Angel Wings Foundation $750.00 Corporate Sponsorship
Ann & Robert H. Lurie $10,000.00 Corporate Sponsorship
Children's Hospital of
Chicago
Annenberg Center for Health $50,000.00 Educational Grants
Sciences at Eisenhower
Annenberg Center for Health $125,000.00 Educational Grants
Sciences at Eisenhower
Annenberg Center for Health $35,000.00 Educational Grants
Sciences at Eisenhower
Annenberg Center for Health $65,000.00 Educational Grants
Sciences at Eisenhower
Arthritis Foundation $20,000.00 Corporate Sponsorship
Arthritis Foundation $8,000.00 Corporate Sponsorship
Arthritis Foundation $28,500.00 Corporate Sponsorship
Arthritis Foundation $25,000.00 Corporate Sponsorship
Arthritis Foundation $5,000.00 Charitable Donations
Arthritis Foundation $5,000.00 Patient Support
Arthritis Foundation $5,000.00 Charitable Donations
Arthritis Foundation $5,000.00 Corporate Sponsorship
Central, Pennsylvania
Chapter
Arthritis Foundation New $10,000.00 Corporate Sponsorship
England
Arthritis Foundation, $225,000.00 Corporate Sponsorship
Alabama Chapter
Arthritis Foundation, $250,000.00 Corporate Sponsorship
Alabama Chapter
Arthritis Foundation, $175,000.00 Corporate Sponsorship
Alabama Chapter
Arthritis Foundation, $65,000.00 Patient Support
Alabama Chapter
Arthritis Foundation, $17,000.00 Corporate Sponsorship
Alabama Chapter
Arthritis Foundation, $2,500.00 Corporate Sponsorship
Alabama Chapter
Arthritis Foundation, $259,000.00 Corporate Sponsorship
Alabama Chapter
Arthritis Foundation, $175,000.00 Corporate Sponsorship
Alabama Chapter
Arthritis Foundation, $35,000.00 Corporate Sponsorship
Alabama Chapter
Arthritis Foundation, $250,000.00 Corporate Sponsorship
Alabama Chapter
Arthritis Foundation, Great $3,000.00 Patient Support
Lakes Region
Arthritis Foundation, Great $2,500.00 Patient Support
Lakes Region
Arthritis Foundation, Great $2,500.00 Patient Support
Lakes Region
Arthritis Foundation, Great $35,500.00 Corporate Sponsorship
Lakes Region
Arthritis Foundation, Great $20,000.00 Charitable Donations
Lakes Region
Arthritis Foundation, Great $5,000.00 Charitable Donations
Lakes Region
Arthritis Foundation, Great $12,500.00 Charitable Donations
Lakes Region
Arthritis Foundation, Great $3,000.00 Charitable Donations
Lakes Region
Arthritis Foundation, Great $2,250.00 Patient Support
Lakes Region
Arthritis Foundation, Great $2,250.00 Patient Support
Lakes Region
Arthritis Foundation, Great $3,000.00 Patient Support
Lakes Region
Arthritis Foundation, Great $2,250.00 Patient Support
Lakes Region
Arthritis Foundation, Great $2,250.00 Patient Support
Lakes Region
Arthritis Foundation, Great $1,000.00 Patient Support
Lakes Region
Arthritis Foundation, Great $35,000.00 Corporate Sponsorship
West Region
Arthritis Foundation, Great $28,000.00 Corporate Sponsorship
West Region
Arthritis Foundation, Great $10,000.00 Charitable Donations
West Region
Arthritis Foundation, $21,000.00 Corporate Sponsorship
Massachusetts Chapter
Arthritis Foundation, $1,853.94 Patient Support
Massachusetts Chapter
Arthritis Foundation, $3,000.00 Corporate Sponsorship
Massachusetts Chapter
Arthritis Foundation, $3,000.00 Corporate Sponsorship
Massachusetts Chapter
Arthritis Foundation, Mid $15,000.00 Corporate Sponsorship
Atlantic Region
Arthritis Foundation, Mid $1,500.00 Educational Grants
Atlantic Region
Arthritis Foundation, Mid $1,000.00 Patient Support
Atlantic Region
Arthritis Foundation, South $14,000.00 Corporate Sponsorship
Texas Chapter
Arthritis Foundation, South $2,500.00 Charitable Donations
Texas Chapter
Arthritis Foundation, $65,000.00 Corporate Sponsorship
Southern California
Chapter
Arthritis Foundation, $2,500.00 Charitable Donations
Southern California
Chapter
Arthritis Foundation, $2,500.00 Charitable Donations
Southern California
Chapter
Arthritis Foundation, $5,000.00 Corporate Sponsorship
Southern California
Chapter
Arthritis Foundation, $7,000.00 Corporate Sponsorship
Wisconsin Chapter
Arthritis Patient Services $10,000.00 Educational Grants
Arthritis Patient Services $25,000.00 Educational Grants
ASCO Cancer Foundation $50,000.00 Charitable Donations
ASCO Cancer Foundation $40,000.00 Fellowships and
Scholarships
ASCO Cancer Foundation $28,000.00 Educational Grants
Asociacion de Reumatologos $15,000.00 Corporate Sponsorship
de Puerto Rico
Asociacion Nacional de $4,000.00 Corporate Sponsorship
Tecnicos de Farmacia, Inc.
Asociacion Puertorriquena $1,200.00 Corporate Sponsorship
de Ayuda al Paciente de
Psoriasis
Association of Dermatology $7,500.00 Corporate Sponsorship
Administrators And
Managers
Association of Nurses in $15,000.00 Educational Grants
AIDS Care, Chicago Chapter
Association of Physicians $2,500.00 Corporate Sponsorship
of Pakistani-Descent of
North America
Balm In Gilead Inc. $75,000.00 Corporate Sponsorship
Baylor College of Medicine $5,000.00 Educational Grants
Baylor University Medical $67,716.00 Educational Grants
Center
Baylor University Medical $29,340.00 Educational Grants
Center
Beth Israel Deaconess $50,000.00 Fellowships and
Department of Medicine Scholarships
Foundation
Beth Israel Deaconess $(1,948.24) Educational Grants
Medical Center
Beth Israel Deaconess $40,000.00 Fellowships and
Medical Center Scholarships
Billings Clinic $5,000.00 Corporate Sponsorship
Bioconnections, LLC $15,000.00 Corporate Sponsorship
Biophysical Society $2,500.00 Educational Grants
Blank Children's Hospital $2,500.00 Corporate Sponsorship
Board of Regents of the $5,000.00 Educational Grants
University of Wisconsin
System
Board of Trustees of the $1,500.00 Educational Grants
University of Illinois
Board of Trustees of The $40,000.00 Fellowships and
University of Illinois, Scholarships
The
Board of Trustees of The $30,000.00 Fellowships and
University of Illinois, Scholarships
The
Boomer Esiason Foundation $1,200.00 Corporate Sponsorship
Boomer Esiason Foundation $100,000.00 Educational Grants
Boomer Esiason Foundation $75,000.00 Charitable Donations
Boomer Esiason Foundation $400,000.00 Corporate Sponsorship
Boomer Esiason Foundation $25,000.00 Corporate Sponsorship
Boomer Esiason Foundation $400,000.00 Corporate Sponsorship
Boston Society, Inc. $4,000.00 Corporate Sponsorship
Boston Society, Inc. $4,000.00 Corporate Sponsorship
Boston University School of $124,943.00 Educational Grants
Medicine
Brigham and Women's $(50,000.00) Fellowships and
Hospital, Inc. Scholarships
Brigham and Women's $50,000.00 Fellowships and
Hospital, Inc. Scholarships
California Rheumatology $30,000.00 Corporate Sponsorship
Alliance
California Separation $60,000.00 Corporate Sponsorship
Science Society
California Society of $3,000.00 Corporate Sponsorship
Health System Pharmacists
California Society of $5,000.00 Corporate Sponsorship
Health System Pharmacists
California Society of $3,000.00 Corporate Sponsorship
Health System Pharmacists
Campaign for Public Health $10,000.00 Charitable Donations
Foundation
Cancer and Leukemia Group B $20,000.00 Educational Grants
Foundation
Cancer Molecular $5,000.00 Educational Grants
Therapeutics
Case Western Reserve $25,000.00 Educational Grants
University
Cedars-Sinai Medical Center $40,000.00 Educational Grants
Cedars-Sinai Medical Center $10,000.00 Educational Grants
Cedars-Sinai Medical Center $40,000.00 Fellowships and
Scholarships
Central Florida Pharmacy $25,000.00 Educational Grants
Council, Inc.
Central Ohio Parkinson $20,000.00 Educational Grants
Society DBA National
Parkinson Foundation
Central and Southeast Ohio
Chelsea Hutchinson $2,500.00 Corporate Sponsorship
Foundation The
Children and Arthritis, $5,000.00 Charitable Donations
Inc.
Children's Digestive Health $40,000.00 Fellowships and
and Nutrition Foundation Scholarships
Children's Digestive Health $25,000.00 Educational Grants
and Nutrition Foundation
Children's Digestive Health $40,000.00 Fellowships and
and Nutrition Foundation Scholarships
Children's Digestive Health $10,000.00 Corporate Sponsorship
and Nutrition Foundation
Children's Hospital Medical $20,000.00 Corporate Sponsorship
Center
Children's Hospital Medical $40,000.00 Fellowships and
Center Scholarships
Children's Hospital Medical $20,000.00 Corporate Sponsorship
Center
Children's Oncology $5,500.00 Corporate Sponsorship
Services Inc.
Chimp Haven $50,000.00 Charitable Donations
Chris Dudley Foundation $5,000.00 Corporate Sponsorship
Chronic Liver Disease $211,000.00 Educational Grants
Foundation
Chronic Liver Disease $211,670.00 Educational Grants
Foundation
Chronic Liver Disease $1,300,000.00 Educational Grants
Foundation
Chronic Liver Disease $7,500.00 Corporate Sponsorship
Foundation
Cleveland Clinic $(1,340.00) Educational Grants
Cleveland Clinic $10,000.00 Educational Grants
Educational Foundation,
The
Cleveland Clinic $25,000.00 Educational Grants
Educational Foundation,
The
Cleveland Clinic $75,000.00 Educational Grants
Educational Foundation,
The
Cleveland Clinic $4,500.00 Educational Grants
Educational Foundation,
The
Cleveland Clinic $(2,033.31) Educational Grants
Educational Foundation,
The
Cleveland Clinic $75,000.00 Educational Grants
Educational Foundation,
The
Cleveland Clinic $15,000.00 Educational Grants
Educational Foundation,
The
Cleveland Clinic $385,000.00 Educational Grants
Educational Foundation,
The
Cleveland Clinic $132,000.00 Educational Grants
Educational Foundation,
The
Cleveland Clinic $15,000.00 Educational Grants
Educational Foundation,
The
Cleveland Clinic $5,000.00 Educational Grants
Educational Foundation,
The
Cleveland Clinic $(2,638.82) Educational Grants
Educational Foundation,
The
Cleveland Clinic $75,000.00 Educational Grants
Educational Foundation,
The
Cleveland Clinic $5,000.00 Educational Grants
Educational Foundation,
The
Cleveland Clinic Foundation $50,000.00 Fellowships and
Scholarships
Cleveland Clinic Foundation $50,000.00 Fellowships and
Scholarships
Clinical Care Options, LLC $75,000.00 Educational Grants
Clinical Care Options, LLC $150,000.00 Educational Grants
Clinical Care Options, LLC $50,000.00 Educational Grants
Clinical Care Options, LLC $25,000.00 Educational Grants
Clinical Care Options, LLC $100,000.00 Educational Grants
Clinical Care Options, LLC $209,000.00 Educational Grants
CME Incite, LLC $(175,000.00) Educational Grants
Coalition for Prevention of $5,000.00 Corporate Sponsorship
Colorectal Cancer in
Puerto Rico
Coalition on Positive $125,000.00 Patient Support
Health Empowerment
Colegio Medicos-Cirujanos $20,000.00 Educational Grants
P.R
Com & Co Sarl $3,550.00 Corporate Sponsorship
Community Health $10,000.00 Corporate Sponsorship
Community Initiatives $10,000.00 Corporate Sponsorship
Community Liver Alliance $3,000.00 Corporate Sponsorship
Community Liver Alliance $1,000.00 Corporate Sponsorship
Community Liver Alliance $5,000.00 Corporate Sponsorship
Community Liver Alliance $150,000.00 Educational Grants
Complete Conference $50,000.00 Educational Grants
Management
Complete Conference $75,000.00 Educational Grants
Management
Complete Conference $(75,000.00) Educational Grants
Management
Complete Conference $(75,000.00) Educational Grants
Management
Consortium of Multiple $25,000.00 Educational Grants
Sclerosis Centers
Continuing Educational $(703.13) Educational Grants
Alliance, LLC
Continuing Educational $362,500.00 Educational Grants
Alliance, LLC
Continuing Educational $(210.66) Educational Grants
Alliance, LLC
Continuing Educational $(258.18) Educational Grants
Alliance, LLC
Continuing Educational $(1,696.48) Educational Grants
Alliance, LLC
Continuing Medical $85,000.00 Educational Grants
Education Outfitters, LLC
Continuous Renal $10,000.00 Educational Grants
Replacement Therapies,
Inc. (CRRT)
Cornell University, Weill $5,000.00 Educational Grants
Medical College
Cornerstone Health, Inc. $(3,664.00) Educational Grants
Cornerstone Health, Inc. $200,000.00 Educational Grants
Cornerstone Health, Inc. $175,000.00 Educational Grants
Cornerstone Health, Inc. $40,000.00 Educational Grants
Cornerstone Health, Inc. $100,000.00 Educational Grants
Creighton University $2,220.00 Charitable Donations
Crohn's and Colitis $2,500.00 Corporate Sponsorship
Foundation of America
Crohn's and Colitis $22,500.00 Corporate Sponsorship
Foundation of America
Crohn's and Colitis $350,000.00 Corporate Sponsorship
Foundation of America
Crohn's and Colitis $100,000.00 Corporate Sponsorship
Foundation of America
Crohn's and Colitis $20,000.00 Corporate Sponsorship
Foundation of America
Crohn's and Colitis $9,000.00 Educational Grants
Foundation of America
Crohn's and Colitis $6,000.00 Patient Support
Foundation of America
Crohn's and Colitis $80,000.00 Corporate Sponsorship
Foundation of America
Crohn's and Colitis $9,000.00 Patient Support
Foundation of America
Crohn's and Colitis $6,200.00 Patient Support
Foundation of America
Crohn's and Colitis $4,000.00 Patient Support
Foundation of America
Crohn's and Colitis $(3,095.00) Educational Grants
Foundation of America
Crohn's and Colitis $65,000.00 Educational Grants
Foundation of America
Crohn's and Colitis $3,000.00 Educational Grants
Foundation of America
Crohn's and Colitis $10,000.00 Patient Support
Foundation of America
Crohn's and Colitis $1,000.00 Corporate Sponsorship
Foundation of America
Crohn's and Colitis $25,000.00 Charitable Donations
Foundation of America
Crohn's and Colitis $2,000.00 Corporate Sponsorship
Foundation of America
Crohn's and Colitis $100,000.00 Educational Grants
Foundation of America
Crohn's and Colitis $8,000.00 Educational Grants
Foundation of America
Crohn's and Colitis $2,000.00 Corporate Sponsorship
Foundation of America
Crohn's and Colitis $5,000.00 Corporate Sponsorship
Foundation of America
Crohn's and Colitis $2,500.00 Corporate Sponsorship
Foundation of America
Crohn's and Colitis $3,500.00 Patient Support
Foundation of America
Crohn's and Colitis $100,000.00 Fellowships and
Foundation of America Scholarships
Crohn's and Colitis $3,000.00 Patient Support
Foundation of America
Crohn's and Colitis $5,000.00 Corporate Sponsorship
Foundation of America
Crohn's and Colitis $1,500.00 Corporate Sponsorship
Foundation of America
Crohn's and Colitis $10,000.00 Educational Grants
Foundation of America
Crohn's and Colitis $65,000.00 Educational Grants
Foundation of America
Crohn's and Colitis $25,000.00 Charitable Donations
Foundation of America
Crohn's and Colitis $100,000.00 Educational Grants
Foundation of America
Curatio CME Institute $(100,000.00) Educational Grants
Cystic Fibrosis--Reaching $25,000.00 Charitable Donations
Out Foundation
Cystic Fibrosis Foundation-- $5,000.00 Corporate Sponsorship
Albany
Cystic Fibrosis Foundation-- $3,500.00 Corporate Sponsorship
Albany
Cystic Fibrosis Foundation-- $1,000.00 Corporate Sponsorship
Albany
Cystic Fibrosis Foundation-- $100,000.00 Charitable Donations
Albany
Cystic Fibrosis Foundation-- $2,000.00 Corporate Sponsorship
Albany
Cystic Fibrosis Foundation-- $5,000.00 Corporate Sponsorship
Albany
Cystic Fibrosis Foundation-- $10,000.00 Corporate Sponsorship
Albany
Cystic Fibrosis Foundation-- $4,000.00 Corporate Sponsorship
Albany
Cystic Fibrosis Foundation-- $10,000.00 Corporate Sponsorship
Albany
Cystic Fibrosis Foundation-- $2,000.00 Corporate Sponsorship
Albany
Cystic Fibrosis Foundation-- $3,000.00 Corporate Sponsorship
Albany
Cystic Fibrosis Foundation-- $1,000.00 Corporate Sponsorship
Albany
Cystic Fibrosis Foundation-- $2,500.00 Corporate Sponsorship
Albany
Cystic Fibrosis Foundation-- $1,500.00 Corporate Sponsorship
Albany
Cystic Fibrosis Foundation-- $2,500.00 Corporate Sponsorship
Albany
Cystic Fibrosis Foundation-- $2,500.00 Corporate Sponsorship
Albany
Cystic Fibrosis Foundation-- $25,000.00 Corporate Sponsorship
Albany
Cystic Fibrosis Foundation-- $1,500.00 Corporate Sponsorship
Albany
Cystic Fibrosis Foundation-- $1,500.00 Corporate Sponsorship
Albany
Cystic Fibrosis Foundation-- $1,000.00 Corporate Sponsorship
Albany
Cystic Fibrosis Foundation-- $1,000.00 Corporate Sponsorship
Albany
Cystic Fibrosis Foundation-- $15,000.00 Corporate Sponsorship
Albany
Cystic Fibrosis Research, $500.00 Corporate Sponsorship
Inc.
Cystic Fibrosis Research, $10,000.00 Educational Grants
Inc.
Cystic Fibrosis Research, $9,000.00 Patient Support
Inc.
Cystic Fibrosis Research, $5,000.00 Corporate Sponsorship
Inc.
Cystic Fibrosis Research, $5,000.00 Corporate Sponsorship
Inc.
Cystic Fibrosis Research, $15,000.00 Charitable Donations
Inc.
Cystic Fibrosis Research, $10,000.00 Corporate Sponsorship
Inc.
Dade County Medical $10,000.00 Educational Grants
Association
Dallas fort Worth Business $5,000.00 Corporate Sponsorship
Group on Health
Davis Phinney Foundation $30,000.00 Educational Grants
Davis Phinney Foundation $75,000.00 Educational Grants
Davis Phinney Foundation $15,000.00 Educational Grants
Davis Phinney Foundation $30,000.00 Educational Grants
Decatur General Hospital $2,500.00 Corporate Sponsorship
Foundation
Dermatology Education $15,000.00 Corporate Sponsorship
Foundation
Dermatology Foundation $50,000.00 Corporate Sponsorship
Diversity And Leadership $5,000.00 Corporate Sponsorship
Inc.
Duke University $6,550.00 Educational Grants
Duke University $250,000.00 Educational Grants
Duke University $150,000.00 Educational Grants
Duke University $50,000.00 Fellowships and
Scholarships
Duke University $(3,061.96) Educational Grants
Educational Review Systems $10,000.00 Educational Grants
Elizabeth Glaser Pediatric $10,000.00 Charitable Donations
AIDS Foundation
Elsevier, Inc. $70,000.00 Educational Grants
Employers Health Colition $4,000.00 Corporate Sponsorship
Inc.
Endocrine Education, Inc $25,000.00 Educational Grants
Endocrine Nurses Society $4,000.00 Corporate Sponsorship
Endocrine Society, The $25,000.00 Educational Grants
Endocrine Society, The $150,000.00 Educational Grants
Endometriosis Association $10,000.00 Charitable Donations
Engineering Conferences $1,000.00 Educational Grants
International
Enzyme Mechanisms $1,500.00 Educational Grants
Conference
Epilepsy Foundation $80,000.00 Charitable Donations
ERA-Eurocongress, Ltd. $25,000.00 Corporate Sponsorship
ERA-Eurocongress, Ltd. $15,000.00 Corporate Sponsorship
Escuela De Medicina De $10,000.00 Educational Grants
Ponce
Escuela De Medicina De $10,000.00 Educational Grants
Ponce
European Society for $250,000.00 Corporate Sponsorship
Dermatological Research
European Society for $10,000.00 Corporate Sponsorship
Medical Oncology
Excel Continuing Education $8,225.00 Educational Grants
Excellence in Rheumatology $100,000.00 Corporate Sponsorship
Education, LLC
Facing Our Risk of Cancer $25,000.00 Charitable Donations
Empowerement
Facing Our Risk of Cancer $5,000.00 Corporate Sponsorship
Empowerement (FORCE)
Federation of American $1,500.00 Educational Grants
Societies for Experimental
Biology
Federation of American $1,500.00 Educational Grants
Societies for Experimental
Biology
Federation of American $5,000.00 Corporate Sponsorship
Societies for Experimental
Biology
Federation of Clinical $20,000.00 Educational Grants
Immunology Societies
Federation of Clinical $15,000.00 Educational Grants
Immunology Societies
Federation of Clinical $20,000.00 Educational Grants
Immunology Societies
Florida Academy of $8,300.00 Educational Grants
Physician Assistants
Florida Health Care $1,500.00 Corporate Sponsorship
Coalition
Foundation for Anesthesia $20,000.00 Fellowships and
Education and Research Scholarships
Foundation for Biomedical $120,000.00 Charitable Donations
Research
Foundation for Indiana $2,220.00 Charitable Donations
University of Pennsylvania
Foundation for Indiana $2,220.00 Charitable Donations
University of Pennsylvania
Foundation for Men's $50,000.00 Corporate Sponsorship
Health, Inc
Foundation for the National $400,000.00 Corporate Sponsorship
Institutes of Health
Friends of Prentice $10,000.00 Corporate Sponsorship
Friends of the St. Louis $50,000.00 Corporate Sponsorship
University Liver Center
Fundacion Puertorriquena De $7,500.00 Educational Grants
Pacientes Con
Endometriosis
Gastrointestinal Health $150,000.00 Educational Grants
Foundation, Inc.
Gastrointestinal Health $50,000.00 Educational Grants
Foundation, Inc.
Gastrointestinal Health $75,000.00 Corporate Sponsorship
Foundation, Inc.
Gastro-Intestinal Research $15,000.00 Charitable Donations
Foundation
Gastro-Intestinal Research $1,000.00 Corporate Sponsorship
Foundation
Gastro-Intestinal Research $6,600.00 Corporate Sponsorship
Foundation
Gastro-Intestinal Research $1,500.00 Corporate Sponsorship
Foundation
Gateway for Cancer Research $6,000.00 Charitable Donations
Gay City Health Project $10,000.00 Charitable Donations
Georgia ObGyn Society $2,500.00 Corporate Sponsorship
Georgia Prostate Cancer $4,000.00 Patient Support
Coalition, The
Georgia Society of $3,000.00 Corporate Sponsorship
Dermatology and
Dermatologic Surgery
Gilda's Club Chicago $10,000.00 Charitable Donations
Gilda's Club New York City $50,000.00 Charitable Donations
Globalization of $10,000.00 Corporate Sponsorship
Pharmaceutics Education
Network
Gordon Research Conferences $1,500.00 Educational Grants
Gordon Research Conferences $1,500.00 Educational Grants
Gordon Research Conferences $1,500.00 Educational Grants
Gordon Research Conferences $1,500.00 Educational Grants
Gordon Research Conferences $1,500.00 Educational Grants
Gordon Research Conferences $1,500.00 Educational Grants
Gordon Research Conferences $1,500.00 Educational Grants
Gordon Research Conferences $1,500.00 Educational Grants
Gordon Research Conferences $1,500.00 Educational Grants
Gordon Research Conferences $1,500.00 Educational Grants
Gordon Research Conferences $2,000.00 Educational Grants
Grupo de Apoyo de Ninos y $3,000.00 Corporate Sponsorship
Adolescentes con
Reumatologia
Gynecologic Oncology Group, $25,000.00 Educational Grants
The
$7 $23,000.00 Educational Grants
Haymarket Center-Health $5,000.00 Educational Grants
Education
Haymarket Medical Education $243,190.00 Educational Grants
Health Sciences Foundation $2,500.00 Educational Grants
dba South East AHEC
Healthcare Businesswomen's $5,000.00 Corporate Sponsorship
Association, Inc.
Healthcare Financial $50,000.00 Corporate Sponsorship
Management Association
Hep C Connection $50,000.00 Educational Grants
Hep C Connection $40,000.00 Patient Support
Hep C Connection $5,000.00 Corporate Sponsorship
Hepatitis C Association $45,000.00 Educational Grants
Hepatitis C Mentor and $10,000.00 Patient Support
Support Group, The
Hepatitis Education Project $100,000.00 Charitable Donations
HIV Treaters Medical $10,000.00 Educational Grants
Association of Puerto Rico
Hope Foundation, The $10,000.00 Educational Grants
Housing Works, Inc. $10,000.00 Charitable Donations
Howard Brown Health Center $25,000.00 Corporate Sponsorship
Howard Center Inc. $10,000.00 Charitable Donations
Howard University Hospital $10,000.00 Educational Grants
Hubbard Street Dance $10,000.00 Educational Grants
Chicago
Human Growth Foundation $2,000.00 Corporate Sponsorship
IDSA Education and Research $10,000.00 Fellowships and
Foundation Scholarships
Imedex, LLC $20,000.00 Educational Grants
Imedex, LLC $75,000.00 Educational Grants
Imedex, LLC $15,000.00 Educational Grants
Imedex, LLC $25,000.00 Educational Grants
Imedex, LLC $60,000.00 Educational Grants
Impact Education, LLC $125,000.00 Educational Grants
Indiana Chamber of Commerce $2,500.00 Corporate Sponsorship
Indiana Chamber of Commerce $1,500.00 Corporate Sponsorship
Indiana University $2,500.00 Fellowships and
Scholarships
Induniv Research $2,000.00 Corporate Sponsorship
Infectious Diseases Society $35,000.00 Educational Grants
of America
Inflammatory Bowel Disease $300,000.00 Educational Grants
Support Foundation
Inflammatory Bowel Disease $50,000.00 Educational Grants
Support Foundation
Inflammatory Bowel Disease $200,000.00 Educational Grants
Support Foundation
Inflammatory Bowel Disease $200,000.00 Educational Grants
Support Foundation
Innovation Development $250,000.00 Corporate Sponsorship
Institute, Inc.
Institute for Medical and $10,000.00 Educational Grants
Nursing Education, Inc.
Integrated Benefits $35,000.00 Corporate Sponsorship
Institute, Inc.
Integrated Medical $50,000.00 Charitable Donations
Foundation
Integrated Medical $5,000.00 Corporate Sponsorship
Foundation
Integrated Medical $35,000.00 Charitable Donations
Foundation
Interfaith House $2,000.00 Charitable Donations
Intermountain Dermatology $20,000.00 Educational Grants
Society
International AIDS Society-- $100,000.00 Educational Grants
USA
International AIDS Society-- $100,000.00 Educational Grants
USA
International AIDS Society-- $75,000.00 Educational Grants
USA
International Alliance for $3,000.00 Educational Grants
Biologicals
International Association $10,000.00 Educational Grants
of Physicians in AIDS Care
International Association $25,000.00 Educational Grants
of Physicians in AIDS Care
International Chemical $2,000.00 Educational Grants
Biology Society
International Pelvic Pain $7,500.00 Educational Grants
Society
International Psoriasis $100,000.00 Corporate Sponsorship
Council, The
International Psoriasis $50,000.00 Corporate Sponsorship
Council, The
International Society for $5,000.00 Educational Grants
Antiviral Research
International Society for $10,000.00 Corporate Sponsorship
Medical Publication
Professionals
International Society for $3,000.00 Educational Grants
the Study of Xenobiotics
International Society of $50,000.00 Charitable Donations
Nephrology
International Society of $40,000.00 Charitable Donations
Nephrology
International Society of $175,000.00 Corporate Sponsorship
Nephrology
Jefferson Medical College $3,000.00 Corporate Sponsorship
at Thomas Jefferson
University
Jefferson Medical College $30,000.00 Educational Grants
at Thomas Jefferson
University
Jefferson Medical College $5,000.00 Educational Grants
at Thomas Jefferson
University
John Hopkins University $(1,706.15) Educational Grants
School of Medicine
Johns Hopkins University $225,000.00 Educational Grants
School of Medicine
Johns Hopkins University $25,000.00 Educational Grants
School of Medicine
Johns Hopkins University $(60,000.00) Educational Grants
School of Medicine
Johns Hopkins University $30,000.00 Educational Grants
School of Medicine
Johns Hopkins University $50,000.00 Fellowships and
School of Medicine Scholarships
Johns Hopkins University $95,000.00 Educational Grants
School of Medicine
Johns Hopkins University $5,000.00 Educational Grants
School of Medicine
Joint Township District $4,064.00 Patient Support
Memorial Hospital
Joint Township District $(1,508.00) Patient Support
Memorial Hospital
JWC Covenant, Inc. $35,000.00 Educational Grants
Kansas University $25,000.00 Educational Grants
Neurological Foundation
Kansas University $35,000.00 Educational Grants
Neurological Foundation
Kelsey Research Foundation $40,000.00 Fellowships and
Scholarships
Kenes International Ltd. $35,000.00 Corporate Sponsorship
Kidney Disease Improving $40,128.00 Corporate Sponsorship
Global Outcomes
KnowledgePoint360 Group, $94,785.30 Corporate Sponsorship
LLC
Laboratorio Clinico Toledo $2,460.00 Patient Support
Laboratorio Clinico Toledo $795.00 Patient Support
Laboratorio Clinico Toledo $345.00 Patient Support
Laboratorio Clinico Toledo $2,760.00 Patient Support
Laboratorio Clinico Toledo $2,145.00 Patient Support
Laboratorio Clinico Toledo $615.00 Patient Support
Laboratorio Clinico Toledo $2,160.00 Patient Support
Laboratorio Clinico Toledo $2,115.00 Patient Support
Laboratorio Clinico Toledo $1,380.00 Patient Support
Laboratorio Clinico Toledo $4,260.00 Patient Support
Laboratorio Clinico Toledo $2,070.00 Patient Support
Laboratorio Clinico Toledo $1,650.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $1,395.00 Patient Support
Laboratorio Clinico Toledo $1,380.00 Patient Support
Laboratorio Clinico Toledo $1,290.00 Patient Support
Laboratorio Clinico Toledo $1,200.00 Patient Support
Laboratorio Clinico Toledo $996.00 Patient Support
Laboratorio Clinico Toledo $825.00 Patient Support
Laboratorio Clinico Toledo $804.00 Patient Support
Laboratorio Clinico Toledo $4,455.00 Patient Support
Laboratorio Clinico Toledo $945.00 Patient Support
Laboratorio Clinico Toledo $690.00 Patient Support
Laboratorio Clinico Toledo $1,530.00 Patient Support
Laboratorio Clinico Toledo $1,335.00 Patient Support
Laboratorio Clinico Toledo $1,065.00 Patient Support
Laboratorio Clinico Toledo $975.00 Patient Support
Laboratorio Clinico Toledo $2,250.00 Patient Support
Laboratorio Clinico Toledo $2,250.00 Patient Support
Laboratorio Clinico Toledo $825.00 Patient Support
Laboratorio Clinico Toledo $720.00 Patient Support
Laboratorio Clinico Toledo $510.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $1,365.00 Patient Support
Laboratorio Clinico Toledo $1,185.00 Patient Support
Laboratorio Clinico Toledo $1,125.00 Patient Support
Laboratorio Clinico Toledo $1,110.00 Patient Support
Laboratorio Clinico Toledo $1,095.00 Patient Support
Laboratorio Clinico Toledo $855.00 Patient Support
Laboratorio Clinico Toledo $765.00 Patient Support
Laboratorio Clinico Toledo $750.00 Patient Support
Laboratorio Clinico Toledo $525.00 Patient Support
Laboratorio Clinico Toledo $1,230.00 Patient Support
Laboratorio Clinico Toledo $1,185.00 Patient Support
Laboratorio Clinico Toledo $1,110.00 Patient Support
Laboratorio Clinico Toledo $960.00 Patient Support
Laboratorio Clinico Toledo $300.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $1,230.00 Patient Support
Laboratorio Clinico Toledo $720.00 Patient Support
Laboratorio Clinico Toledo $570.00 Patient Support
Laboratorio Clinico Toledo $1,035.00 Patient Support
Laboratorio Clinico Toledo $990.00 Patient Support
Laboratorio Clinico Toledo $810.00 Patient Support
Laboratorio Clinico Toledo $705.00 Patient Support
Laboratorio Clinico Toledo $705.00 Patient Support
Laboratorio Clinico Toledo $1,095.00 Patient Support
Laboratorio Clinico Toledo $750.00 Patient Support
Laboratorio Clinico Toledo $675.00 Patient Support
Laboratorio Clinico Toledo $255.00 Patient Support
Laboratorio Clinico Toledo $1,470.00 Patient Support
Laboratorio Clinico Toledo $1,275.00 Patient Support
Laboratorio Clinico Toledo $1,230.00 Patient Support
Laboratorio Clinico Toledo $1,095.00 Patient Support
Laboratorio Clinico Toledo $900.00 Patient Support
Laboratorio Clinico Toledo $585.00 Patient Support
Laboratorio Clinico Toledo $1,890.00 Patient Support
Laboratorio Clinico Toledo $1,380.00 Patient Support
Laboratorio Clinico Toledo $1,185.00 Patient Support
Laboratorio Clinico Toledo $975.00 Patient Support
Laboratorio Clinico Toledo $2,190.00 Patient Support
Lake County Haven $5,000.00 Corporate Sponsorship
Large Urology Group 66,400.00 Corporate Sponsorship
Practice Association
Latinos Salud, Inc. $7,500.00 Charitable Donations
Legacy Counseling Center $7,500.00 Charitable Donations
Leukemia and Lymphoma $2,500.00 Educational Grants
Society, The
Leukemia Research $2,500.00 Charitable Donations
Foundation
Life Sciences Foundation $30,000.00 Charitable Donations
Life Sciences Foundation $30,000.00 Charitable Donations
Life Sciences Foundation $30,000.00 Charitable Donations
Linking Leaders, LLC $20,000.00 Corporate Sponsorship
Liver Institute and $50,000.00 Educational Grants
Foundation for Education
and Research
Living Beyond Breast Cancer $10,000.00 Corporate Sponsorship
Living Beyond Breast Cancer $5,000.00 Corporate Sponsorship
Living Beyond Breast Cancer $5,000.00 Corporate Sponsorship
Loma Linda University $1,200.00 Fellowships and
School of Medicine Scholarships
Malecare $12,000.00 Patient Support
Marsha Rivkin Center for $2,500.00 Educational Grants
Ovarian Cancer Research
Massachusetts General $25,000.00 Fellowships and
Hospital Scholarships
Massachusetts Institute of $2,220.00 Charitable Donations
Technology
Massachusetts Institute of $2,220.00 Charitable Donations
Technology
Massachusetts Institute of $5,000.00 Educational Grants
Technology
Massachusetts Prostate $5,000.00 Educational Grants
Cancer Coalition, Inc.
May We Help $3,000.00 Corporate Sponsorship
May We Help $2,500.00 Corporate Sponsorship
May We Help $2,500.00 Corporate Sponsorship
Mayo Clinic $10,000.00 Educational Grants
Medical College of $10,000.00 Educational Grants
Wisconsin
Medical College of $15,000.00 Educational Grants
Wisconsin
Medical Learning Institute $90,000.00 Educational Grants
Medical Learning Institute $(90,000.00) Educational Grants
Medical Learning Institute $75,000.00 Educational Grants
Medicinal and Bioorganic $5,000.00 Educational Grants
Chemistry Foundation, The
Medscape, LLC $250,000.00 Educational Grants
Medscape, LLC $250,000.00 Educational Grants
Medscape, LLC $100,000.00 Educational Grants
Medscape, LLC $75,000.00 Educational Grants
Medscape, LLC $740,500.00 Educational Grants
Medscape, LLC $471,000.00 Educational Grants
Medscape, LLC $37,000.00 Educational Grants
Medscape, LLC $155,000.00 Educational Grants
Medscape, LLC $150,000.00 Educational Grants
Memorial Hermann Foundation $40,000.00 Fellowships and
Scholarships
Memphis Business Group on $4,820.00 Corporate Sponsorship
Health
Mercer County Joint $2,646.00 Patient Support
Township Community
Hospital dba Mercer Health
Methodist Hospital, The $25,000.00 Corporate Sponsorship
Michael J. Fox Foundation $32,000.00 Educational Grants
Michael J. Fox Foundation $25,000.00 Corporate Sponsorship
Michael J. Fox Foundation $25,000.00 Corporate Sponsorship
Michigan Council of Nurse $1,200.00 Educational Grants
Practitioners
Michigan Institute of $5,000.00 Corporate Sponsorship
Urology
Mid Atlantic Business Group $3,000.00 Corporate Sponsorship
Health
Mid-America Coalition on $1,000.00 Corporate Sponsorship
Health Care
Miles for Cystic Fibrosis $5,000.00 Corporate Sponsorship
Mississippi Kidney $2,000.00 Educational Grants
Foundation
Missouri Hepatitis C $20,000.00 Charitable Donations
Alliance
Missouri Hepatitis C $10,000.00 Patient Support
Alliance
Montana Association of $2,000.00 Corporate Sponsorship
Health Care Purchaser
Mount Sinai School of $40,000.00 Fellowships and
Medicine Scholarships
Mount Sinai School of $240,000.00 Educational Grants
Medicine
Mount Sinai School of $10,000.00 Charitable Donations
Medicine
Mount Sinai School of $20,000.00 Educational Grants
Medicine
Mount Sinai School of $8,000.00 Educational Grants
Medicine
Mount Sinai School of $10,000.00 Educational Grants
Medicine
Movement Disorder Society, $12,000.00 Educational Grants
The
Movement Disorder Society, $234,000.00 Corporate Sponsorship
The
National Academy of $40,000.00 Educational Grants
Sciences
National Academy of $10,000.00 Charitable Donations
Sciences
National Academy of $85,000.00 Corporate Sponsorship
Sciences
National AIDS Treatment $300,000.00 Charitable Donations
Advocacy Project
National Alliance of State $100,000.00 Charitable Donations
and Territorial AIDS
Directors
National Association for $100,000.00 Educational Grants
Continuing Education
National Association of $11,500.00 Corporate Sponsorship
Chain Drug Stores, Inc.
National Association of $25,000.00 Educational Grants
Managed Care Physicians
National Association of $35,000.00 Educational Grants
Managed Care Physicians
National Association of $10,000.00 Charitable Donations
School Nurses, Inc.
National Commission on $5,000.00 Educational Grants
Correctional Health Care
National Committee for $10,000.00 Corporate Sponsorship
Quality Assurance
National Committee for $150,000.00 Educational Grants
Quality Assurance
National Committee for $10,000.00 Corporate Sponsorship
Quality Assurance
National Committee for $125,000.00 Corporate Sponsorship
Quality Assurance
National Comprehensive $10,000.00 Educational Grants
Cancer Network
National Comprehensive $(1,492.41) Educational Grants
Cancer Network
National Comprehensive $10,000.00 Educational Grants
Cancer Network
National Comprehensive $25,000.00 Charitable Donations
Cancer Network
National Comprehensive $10,000.00 Corporate Sponsorship
Cancer Network
National Foundation for the $500,000.00 Corporate Sponsorship
Centers for Disease
Control and Prevention
National Foundation for the $37,500.00 Corporate Sponsorship
Centers for Disease
Control and Prevention
National Hispanic Council $10,000.00 Charitable Donations
on Aging
National Jewish Health $151,840.00 Educational Grants
National Jewish Health $75,000.00 Educational Grants
National Kidney Foundation $500.00 Corporate Sponsorship
of Louisiana, Inc.
National Kidney Foundation $3,000.00 Patient Support
of Northeast New York
National Kidney Foundation, $5,000.00 Corporate Sponsorship
Inc.
National Kidney Foundation, $20,000.00 Educational Grants
Inc.
National Kidney Foundation, $333,333.33 Corporate Sponsorship
Inc.
National Medical $5,000.00 Corporate Sponsorship
Association
National Multiple Sclerosis $10,000.00 Corporate Sponsorship
Society
National Pancreas $6,000.00 Corporate Sponsorship
Foundation
National Pancreas $200,000.00 Educational Grants
Foundation
National Pancreas $50,000.00 Charitable Donations
Foundation
National Pancreas $65,000.00 Educational Grants
Foundation
National Parkinson $25,000.00 Corporate Sponsorship
Foundation, Inc.
National Parkinson $40,000.00 Educational Grants
Foundation, Inc.
National Parkinson $25,000.00 Educational Grants
Foundation, Inc.
National Psoriasis $125,000.00 Corporate Sponsorship
Foundation
National Psoriasis $20,000.00 Educational Grants
Foundation
National Psoriasis $500,000.00 Corporate Sponsorship
Foundation
National Psoriasis $20,000.00 Educational Grants
Foundation
National Psoriasis $2,500.00 Corporate Sponsorship
Foundation
National Psoriasis $50,000.00 Patient Support
Foundation
National Psoriasis $15,000.00 Corporate Sponsorship
Foundation
National Psoriasis $1,000.00 Corporate Sponsorship
Foundation
National Psoriasis $125,000.00 Corporate Sponsorship
Foundation
National Society for $50,000.00 Corporate Sponsorship
Cutaneous Medicine
National Society for $100,000.00 Corporate Sponsorship
Cutaneous Medicine
National Society for $100,000.00 Corporate Sponsorship
Cutaneous Medicine
NephCure Foundation $5,000.00 Patient Support
Neuro Community Foundation $2,000.00 Educational Grants
New England Baptist $5,000.00 Corporate Sponsorship
Hospital
New Jersey Association for $2,000.00 Educational Grants
Biomedical Research
New York Academy of $2,000.00 Educational Grants
Sciences
New York Academy of $5,000.00 Educational Grants
Sciences
New York Academy of $2,500.00 Educational Grants
Sciences
New York Medical College, $2,000.00 Educational Grants
office of Continuing
Medical Education
New York State Rheumatology $17,500.00 Corporate Sponsorship
Society
New York University School $5,000.00 Educational Grants
of Medicine
New York University School $40,000.00 Fellowships and
of Medicine Scholarships
New York University School $5,000.00 Educational Grants
of Medicine
New York University School $5,800.00 Educational Grants
of Medicine
New York University School $55,000.00 Educational Grants
of Medicine
New York University School $15,000.00 Educational Grants
of Medicine
New York University School $5,000.00 Educational Grants
of Medicine
Nicole Jarvis MD Parkinsons $500.00 Corporate Sponsorship
Research Foundation
NL Communications, Inc. $35,000.00 Educational Grants
NL Communications, Inc. $25,000.00 Educational Grants
NL Communications, Inc. $50,000.00 Educational Grants
No AIDS Task force $2,000.00 Educational Grants
North American Center for $252,250.00 Educational Grants
Continuing Medical
Education
North American Center for $45,000.00 Educational Grants
Continuing Medical
Education
North American Center for $124,975.00 Educational Grants
Continuing Medical
Education
North American Center for $318,000.00 Educational Grants
Continuing Medical
Education
North American Center for $95,000.00 Educational Grants
Continuing Medical
Education
North American Center for $475,000.00 Educational Grants
Continuing Medical
Education
North American Center for $200,000.00 Educational Grants
Continuing Medical
Education
North American Center for $250,000.00 Educational Grants
Continuing Medical
Education
North American Center for $99,500.00 Educational Grants
Continuing Medical
Education
North American Center for $225,000.00 Educational Grants
Continuing Medical
Education
North American Society for $20,000.00 Educational Grants
Pediatric
Gastroenterology,
Hepatology, and Nutrition
North Carolina Rheumatology $20,000.00 Corporate Sponsorship
Association
North Dakota Academy of $1,500.00 Educational Grants
Physician Assistants
Northeast Business Group on $8,000.00 Corporate Sponsorship
Health
Northwest Arthritis and $150,000.00 Educational Grants
Osteoporosis Institute
Northwest Kidney Centers $2,500.00 Corporate Sponsorship
Northwest Kidney Centers $2,500.00 Corporate Sponsorship
Northwest Urological $5,000.00 Corporate Sponsorship
Society
Northwestern Lake forest $984.00 Charitable Donations
Hospital
Northwestern University $2,220.00 Charitable Donations
Northwestern University $2,220.00 Charitable Donations
Northwestern University $40,000.00 Fellowships and
Scholarships
Northwestern University $5,000.00 Educational Grants
Northwestern University $40,000.00 Fellowships and
Scholarships
Northwestern University $50,000.00 Fellowships and
Scholarships
Northwestern University $5,000.00 Educational Grants
Northwestern University $7,500.00 Educational Grants
Ohio Association of $10,000.00 Corporate Sponsorship
Rheumatology
Ohio Gastroenterology $5,000.00 Corporate Sponsorship
Society
Oregon Health & Science $800.00 Educational Grants
University
Osteoarthritis Research $10,000.00 Educational Grants
Society International
Pacific Dermatologic $10,000.00 Corporate Sponsorship
Association
PACK Health, LLC $135,875.00 Educational Grants
Pancreas Club, The $10,000.00 Educational Grants
Pancreatic Cancer Action $2,500.00 Corporate Sponsorship
Network, Inc.
Pancreatic Cancer Action $2,500.00 Corporate Sponsorship
Network, Inc.
Pancreatic Cancer Action $5,000.00 Corporate Sponsorship
Network, Inc.
Pancreatic Cancer Action $5,000.00 Corporate Sponsorship
Network, Inc.
Pancreatic Cancer Action $5,000.00 Corporate Sponsorship
Network, Inc.
Pancreatic Cancer Action $5,000.00 Corporate Sponsorship
Network, Inc.
Pancreatic Cancer Action $5,000.00 Corporate Sponsorship
Network, Inc.
Pancreatic Cancer Action $147,600.00 Corporate Sponsorship
Network, Inc.
Pancreatic Cancer Action $5,000.00 Corporate Sponsorship
Network, Inc.
Pancreatic Cancer Action $5,000.00 Corporate Sponsorship
Network, Inc.
Pancreatic Cancer Action $5,000.00 Corporate Sponsorship
Network, Inc.
Parkinson Association of $7,500.00 Educational Grants
the Rockies
Parkinson Foundation of the $5,000.00 Educational Grants
National Capital Area
Parkinson Research $10,000.00 Educational Grants
Foundation
Parkinson Research $5,000.00 Educational Grants
Foundation
Parkinson Research $5,000.00 Educational Grants
Foundation
Parkinson Study Group $8,000.00 Educational Grants
Parkinson Support Group of $2,000.00 Educational Grants
Upstate NY dba NPF Greater
Rochester
Parkinson's Action Network $35,000.00 Corporate Sponsorship
Foundation
Parkinson's Action Network $15,000.00 Corporate Sponsorship
Foundation
Parkinson's Action Network $25,000.00 Corporate Sponsorship
Foundation
Parkinson's Disease $20,000.00 Educational Grants
Foundation
Parkinson's Disease $50,000.00 Educational Grants
Foundation
Parkinsons Resources of $5,000.00 Educational Grants
Oregon
Parkinsons Resources of $5,000.00 Educational Grants
Oregon
Parkinson's Unity Walk $150,000.00 Corporate Sponsorship
Parkinsons Voice Project $1,000.00 Corporate Sponsorship
Partners HealthCare System $40,000.00 Educational Grants
Partnership for a Drug Free $100,000.00 Charitable Donations
America
Patient Empowerment Network $20,000.00 Educational Grants
Patient Empowerment Network $15,000.00 Educational Grants
Pediatric IBD Foundation $15,000.00 Corporate Sponsorship
Peer Health Communications, $50,000.00 Educational Grants
LLC
Pennsylvania Prostate $5,000.00 Educational Grants
Cancer Coalition
Pennsylvania Society of $11,400.00 Corporate Sponsorship
Gastroenterology
Pennsylvania State $75,000.00 Educational Grants
University
Pennsylvania State $456,750.00 Educational Grants
University
Pennsylvania State $5,000.00 Educational Grants
University
Pharmaceutical Care $50,000.00 Corporate Sponsorship
Management Association
Pharmaceutical Care $75,000.00 Corporate Sponsorship
Management Association
Pharmaceutical Research and $200,000.00 Charitable Donations
Manufacturers of America
Foundation
Pharmacy Quality Alliance $15,000.00 Educational Grants
Pharmacy Quality Alliance $12,500.00 Educational Grants
Pharmacy Times office of $90,000.00 Educational Grants
Continuing Professional
Education
Pharmacy Times office of $25,000.00 Educational Grants
Continuing Professional
Education
Physicians Education $45,000.00 Educational Grants
Resource
Pittsburgh Magazine $3,500.00 Corporate Sponsorship
Postgraduate Institute for $245,035.00 Educational Grants
Medicine
Potomac Center for Medical $(550.00) Educational Grants
Education
President and Fellows of $25,000.00 Corporate Sponsorship
Harvard College
Prevent Cancer Foundation $10,000.00 Corporate Sponsorship
Primary Care Network, Inc. $142,375.00 Educational Grants
Prime Education, Inc. $100,110.00 Educational Grants
Prime Education, Inc. $148,780.00 Educational Grants
Prime Education, Inc. $482,600.00 Educational Grants
Prime Education, Inc. $138,850.00 Educational Grants
Prime Education, Inc. $(769.00) Educational Grants
Prime Education, Inc. $315,393.00 Educational Grants
Prime Oncology, Inc. $10,000.00 Educational Grants
Prime Oncology, Inc. $35,000.00 Educational Grants
Prime Oncology, Inc. $30,000.00 Educational Grants
Pri-Med Institute, LLC $77,500.00 Educational Grants
Princeton University, $50,000.00 Fellowships and
Trustees Scholarships
Project Inform, Inc. $75,000.00 Educational Grants
Project Inform, Inc. $75,000.00 Charitable Donations
Projects In Knowledge, Inc. $125,000.00 Educational Grants
Projects In Knowledge, Inc. $150,000.00 Educational Grants
Prostate Cancer Foundation $5,000.00 Corporate Sponsorship
Rodin Group
Prostate Cancer Research $25,000.00 Educational Grants
Institute
Prostate Cancer Research $10,000.00 Corporate Sponsorship
Institute
Prostate Conditions $2,500.00 Corporate Sponsorship
Education Council
Prostate Health Education $15,000.00 Patient Support
Network
Prostate Health Education $15,000.00 Educational Grants
Network
Prostate Health $5,000.00 Corporate Sponsorship
International
Puerto Rico Association of $10,000.00 Educational Grants
Gastroenterology
Puerto Rico Association of $10,000.00 Educational Grants
Gastroenterology
Purdue University $83,890.00 Educational Grants
Purdue University $400,000.00 Educational Grants
Purdue University $450,000.00 Educational Grants
Rector & Visitors of the $25,000.00 Educational Grants
University of Virginia
Regents of the University $40,000.00 Fellowships and
of California, The Scholarships
Regents of the University $5,000.00 Educational Grants
of California, The
Regents of the University $12,000.00 Corporate Sponsorship
of California, The
Regents of the University $5,000.00 Educational Grants
of California, The
Regents of the University $8,000.00 Educational Grants
of California, The
Regents of the University $10,000.00 Educational Grants
of California, The
Regents of the University $10,000.00 Corporate Sponsorship
of Michigan
Research America $25,000.00 Corporate Sponsorship
Rheumatology Alliance of $25,000.00 Corporate Sponsorship
Louisiana
Rheumatology Nurses Society $50,000.00 Educational Grants
Rheumatology Nurses Society $74,225.00 Educational Grants
Rheumatology Nurses Society $50,000.00 Educational Grants
Rheumatology Nurses Society $7,500.00 Corporate Sponsorship
Richmond University Medical $1,100.00 Educational Grants
Center
Robert Michael Educational $70,000.00 Educational Grants
Institute, LLC
Robert Michael Educational $150,000.00 Educational Grants
Institute, LLC
Rush University Medical $40,000.00 Educational Grants
Center
Rush University Medical $5,000.00 Patient Support
Center
Rush University Medical $10,000.00 Educational Grants
Center
Rutgers, The State $125,000.00 Educational Grants
University of New Jersey
Rutgers, The State $60,000.00 Educational Grants
University of New Jersey
Rutgers, The State $75,000.00 Educational Grants
University of New Jersey
Rutgers, The State $25,000.00 Educational Grants
University of New Jersey
Sacramento Valley Society $500.00 Corporate Sponsorship
of Health System
Pharmacists
Safety Pharmacology Society $2,500.00 Educational Grants
Saint Anthony Hospital $3,410.00 Patient Support
Foundation
Saint Louis University $5,000.00 Educational Grants
San Francisco AIDS $25,000.00 Corporate Sponsorship
Foundation
San Juan Bautista Medical $40,000.00 Fellowships and
Scholarships
Schneps Publications Inc. $695.00 Corporate Sponsorship
DBA Queens Courier
Scripps Health $150,000.00 Educational Grants
Sexual Medicine Society of $55,000.00 Corporate Sponsorship
North America, Inc.
Sexual Medicine Society of $225,000.00 Corporate Sponsorship
North America, Inc.
Shanti Project, Inc. $20,000.00 Educational Grants
Skin Disease Education $30,000.00 Corporate Sponsorship
Foundation
Skin Disease Education $80,000.00 Corporate Sponsorship
Foundation
Skin Disease Education $42,750.00 Corporate Sponsorship
Foundation
Skin Disease Education $46,250.00 Corporate Sponsorship
Foundation
Smart Ride, The $20,000.00 Corporate Sponsorship
Smith Wholesale Drug $9,000.00 Corporate Sponsorship
Company
Sociedad Pr Endocrinologia $(7,500.00) Educational Grants
Y Diabetologia
Sociedad Puertorriquena $1,000.00 Educational Grants
Pediatria
Society for Neuroscience $2,500.00 Educational Grants
Society for Neuroscience, $1,000.00 Educational Grants
Chicago Chapter
Society for Surgery of The $7,000.00 Corporate Sponsorship
Alimentary Tract
Society of Dermatology $20,000.00 Corporate Sponsorship
Physician Assistants
Society of Toxicologic $15,000.00 Corporate Sponsorship
Pathology
Society of Toxicology $5,000.00 Corporate Sponsorship
South Carolina Alliance of $5,000.00 Corporate Sponsorship
Health Plans
Southern California Society $5,500.00 Corporate Sponsorship
of Gastroenterologists
Southern California Society $10,000.00 Educational Grants
of Gastroenterology
Southern Illinois $3,000.00 Fellowships and
University School of Scholarships
Medicine
Spondylitis Association of $40,000.00 Patient Support
America
Spondylitis Association of $19,084.50 Educational Grants
America
St. Francis Hospital and $20,000.00 Educational Grants
Medical Center
State of Maryland $(1,308.80) Educational Grants
State of Maryland $45,000.00 Fellowships and
Scholarships
State University of Iowa $1,500.00 Educational Grants
States United for $5,000.00 Charitable Donations
Biomedical Research
Super Jake Foundation, The $25,000.00 Corporate Sponsorship
Teratology Society $1,500.00 Educational Grants
Test positive Aware Network $2,500.00 Patient Support
Test positive Aware Network $30,000.00 Corporate Sponsorship
Texas Association of Health $1,500.00 Corporate Sponsorship
Plans
Texas Urological Society $6,000.00 Corporate Sponsorship
The Endocrine Society $25,000.00 Educational Grants
The Hitchcock Foundation $25,000.00 Educational Grants
The Reginald and Dionne $5,000.00 Patient Support
Smith Foundation, Inc.
The Reginald and Dionne $5,000.00 Patient Support
Smith Foundation, Inc.
Tides Center $10,000.00 Educational Grants
Tides Center $50,000.00 Educational Grants
Tides Center $50,000.00 Educational Grants
Trinitas Regional Medical $1,800.00 Educational Grants
Center
Triple Step Toward the Cure $5,000.00 Corporate Sponsorship
Trustees of the University $69,742.00 Educational Grants
of Pennsylvania
Trustees of the University $50,000.00 Educational Grants
of Pennsylvania
Tufts Medical Center $(3,825.00) Educational Grants
Tufts Medical Center $4,000.00 Fellowships and
Scholarships
Tufts University $8,000.00 Educational Grants
Twine Clinical Consulting $158,000.00 Educational Grants
LLC
UC Regents Maxillofacial $20,000.00 Educational Grants
Prosthetics Clinic
UC Regents Maxillofacial $50,000.00 Fellowships and
Prosthetics Clinic Scholarships
UC Regents Maxillofacial $50,000.00 Fellowships and
Prosthetics Clinic Scholarships
UC Regents Maxillofacial $5,000.00 Educational Grants
Prosthetics Clinic
UC Regents Maxillofacial $20,000.00 Educational Grants
Prosthetics Clinic
Ultimate Medical Academy $90,000.00 Educational Grants
Med Learning Group, LLC
Ultimate Medical Academy $(125,000.00) Educational Grants
Med Learning Group, LLC
United States Adult Cystic $6,000.00 Educational Grants
Fibrosis Association, Inc.
United Way of Central $5,000.00 Corporate Sponsorship
Massachusetts
Universidad De Puerto Rico $40,000.00 Fellowships and
Scholarships
Universidad De Puerto Rico $6,325.00 Educational Grants
University Health Services $25,000.00 Educational Grants
at Stony Point, Inc.
University Health Services $150,111.40 Educational Grants
at Stony Point, Inc.
University Hospital of $10,000.00 Educational Grants
Brooklyn
University of Alabama at $40,000.00 Fellowships and
Birmingham Scholarships
University of California $5,000.00 Educational Grants
University of California-- $15,000.00 Corporate Sponsorship
San Francisco
University of California-- $10,000.00 Educational Grants
San Francisco
University of California-- $10,000.00 Educational Grants
San Francisco
University of California $30,000.00 Charitable Donations
Berkeley
University of California $40,000.00 Fellowships and
Irvine Scholarships
University of Chicago $60,000.00 Educational Grants
University of Chicago $28,961.64 Fellowships and
Scholarships
University of Chicago $5,000.00 Educational Grants
University of Chicago $204,525.00 Educational Grants
University of Chicago $5,000.00 Educational Grants
University of Chicago $150,000.00 Educational Grants
University of Chicago $75,000.00 Educational Grants
University of Chicago $100,000.00 Educational Grants
University of Chicago $25,000.00 Charitable Donations
Cancer Research Foundation
University of Cincinnati $100,000.00 Corporate Sponsorship
University of Cincinnati $75,000.00 Educational Grants
University of Cincinnati $100,000.00 Educational Grants
University of Cincinnati $75,000.00 Educational Grants
University of Cincinnati $100,000.00 Educational Grants
University of Cincinnati $50,000.00 Educational Grants
University of Cincinnati $2,542,080.00 Educational Grants
University of Cincinnati $50,000.00 Corporate Sponsorship
University of Cincinnati $8,000.00 Educational Grants
University of Cincinnati $10,000.00 Educational Grants
University of Connecticut $12,000.00 Fellowships and
Scholarships
University of Florida $142,709.00 Educational Grants
University of Florida $65,000.00 Educational Grants
University of Florida $50,000.00 Fellowships and
Foundation Scholarships
University of Illinois $2,220.00 Charitable Donations
Foundation
University of Illinois $2,220.00 Charitable Donations
Foundation
University of Louisville $2,220.00 Charitable Donations
Foundation
University of Louisville $150,000.00 Educational Grants
Research Foundation
University of Louisville $35,000.00 Educational Grants
Research Foundation
University of Louisville $25,000.00 Educational Grants
Research Foundation
University of Maryland $10,000.00 Educational Grants
Baltimore Foundation
University of Massachusetts $10,000.00 Charitable Donations
Medical School
University of Miami $112,000.00 Educational Grants
University of Michigan $(254.37) Educational Grants
University of Minnesota $2,220.00 Charitable Donations
University of Minnesota, $5,000.00 Educational Grants
Regents
University of Minnesota, $(160.43) Corporate Sponsorship
Regents
University of Mississippi $10,000.00 Charitable Donations
Foundation
University of Nebraska $5,000.00 Educational Grants
Medical Center
University of Nebraska $2,500.00 Educational Grants
Medical Center
University of Nebraska $15,000.00 Educational Grants
Medical Center
University of New Mexico $142,150.00 Educational Grants
Health Sciences Center,
Department of Pediatrics
Neonatology Division
University of North $50,000.00 Fellowships and
Carolina at Chapel Hill Scholarships
University of North $5,000.00 Educational Grants
Carolina at Chapel Hill
University of Notre Dame $1,000.00 Educational Grants
University of Pittsburgh $1,500.00 Fellowships and
Scholarships
University of Pittsburgh $10,000.00 Educational Grants
University of Pittsburgh $20,000.00 Educational Grants
University of Rochester $40,000.00 Fellowships and
Scholarships
University of Rochester $4,225.00 Educational Grants
University of Rochester $(1,207.00) Educational Grants
University of South Florida $150,000.00 Educational Grants
Health Professions
Conferencing Corporation
University of Southern $180,000.00 Educational Grants
California
University of Southern $1,500.00 Educational Grants
California
University of Southern $30,000.00 Educational Grants
California
University of Texas Health $25,000.00 Educational Grants
Science Center at San
Antonio
University of Texas Health $10,000.00 Educational Grants
Science Center at San
Antonio
University of Texas Health $10,000.00 Educational Grants
Science Center at San
Antonio
University of Texas M.D. $20,000.00 Educational Grants
Anderson Cancer Center
University of Texas M.D. $10,000.00 Educational Grants
Anderson Cancer Center
University of Utah $40,000.00 Fellowships and
Scholarships
University of Utah $2,200.00 Educational Grants
University of Washington $50,000.00 Fellowships and
Scholarships
University of Washington $40,000.00 Fellowships and
Scholarships
University of Wisconsin $2,220.00 Charitable Donations
Medical Foundation
University of Wisconsin $2,000.00 Educational Grants
Systems
University of Wisconsin $(500.00) Corporate Sponsorship
Systems
University of Wisconsin- $(1,857.88) Educational Grants
Madison
University of Wisconsin- $2,000.00 Educational Grants
Madison
Urological Association of $2,500.00 Educational Grants
Pennsylvania
Urology Center of Colorado $7,500.00 Corporate Sponsorship
Foundation
Us Too International $15,000.00 Educational Grants
Us Too International $5,000.00 Educational Grants
Us Too International $25,000.00 Corporate Sponsorship
Us Too International $5,000.00 Corporate Sponsorship
Us Too International $1,000.00 Corporate Sponsorship
Valley Children's Hospital $2,500.00 Patient Support
Foundation
Venice Family Clinic $10,000.00 Charitable Donations
Veritas Institute for $(50,000.00) Educational Grants
Medical Education, Inc.
Vindico Medical Education $337,509.00 Educational Grants
Virginia Commonwealth $2,100.00 Patient Support
University, School of
Medicine
Wake forest University $40,000.00 Fellowships and
Scholarships
Washington Hospital Center $10,000.00 Educational Grants
Corporation
Washington Rheumatology $30,000.00 Corporate Sponsorship
Alliance
Washington State Urology $5,000.00 Corporate Sponsorship
Society
Washington University in $2,220.00 Charitable Donations
St. Louis
Wayne State University $2,220.00 Charitable Donations
We Care in Inflammatory $50,000.00 Charitable Donations
Bowel Disease
West Penn Allegheny Health $6,000.00 Educational Grants
System, Inc.
West Penn Allegheny Health $(5,905.00) Fellowships and
System, Inc. Scholarships
West Virginia University $2,220.00 Charitable Donations
Western States Pharmacy $7,500.00 Corporate Sponsorship
Conference for Pharmacy
Residents Fellowships and
Preceptors
Why Me, Inc. $2,500.00 Charitable Donations
WINGS Program Inc. $25,000.00 Charitable Donations
Wisconsin Dairyland Chapter $2,000.00 Corporate Sponsorship
of Healthcare Information
and Management Systems
Society
Wisconsin Rheumatology $10,000.00 Corporate Sponsorship
Association
Wishes And Dreams for $1,000.00 Corporate Sponsorship
Cystic Fibrosis
Worcester Regional Research $2,500.00 Corporate Sponsorship
Bureau, Inc.
World Endometriosis $18,000.00 Corporate Sponsorship
Research Foundation
World Endometriosis Society $150,000.00 Corporate Sponsorship
World Endometriosis Society $150,000.00 Corporate Sponsorship
World Health $50,000.00 Educational Grants
Communications, Ltd.
World Parkinson Coalition $15,000.00 Educational Grants
Inc.
World Senior Games $5,250.00 Corporate Sponsorship
Yale University School of $5,000.00 Educational Grants
Medicine
Yale University School of $(10,000.00) Educational Grants
Medicine
Yale University School of $10,000.00 Educational Grants
Medicine
Young Survival Coalition $5,000.00 Corporate Sponsorship
Zero, The Project to End $7,500.00 Corporate Sponsorship
Prostate Cancer
Zero, The Project to End $210,800.00 Corporate Sponsorship
Prostate Cancer
Zero, The Project to End $15,000.00 Corporate Sponsorship
Prostate Cancer
Zero, The Project to End $2,500.00 Corporate Sponsorship
Prostate Cancer
------------------------------------------------------------------------
Grants Donations Report--2015
(Parentheses represent refunds of previously disclosed payments)
Updated as of 4/30/2018
------------------------------------------------------------------------
Recipient Payment Amount Purpose
------------------------------------------------------------------------
A Runner's Love $5,000.00 Corporate Sponsorship
Academia Medica Del Sur $12,000.00 Educational Grants
Academia Medica Del Sur $8,000.00 Educational Grants
Academia Medica Del Sur $15,000.00 Educational Grants
Academia Medica Del Sur $15,000.00 Educational Grants
Academia Medica Del Sur $10,000.00 Educational Grants
Academia Medica Del Sur $10,000.00 Educational Grants
Academia Medica Del Sur $9,000.00 Educational Grants
Academia Medica Del Sur $12,000.00 Educational Grants
Academia Medica Del Sur $14,000.00 Educational Grants
Academia Medica Del Sur $10,000.00 Educational Grants
Academia Medica Del Sur $10,000.00 Educational Grants
Academia Medica Del Sur $15,000.00 Educational Grants
Academia Medica Del Sur $5,000.00 Educational Grants
Academia Medica Del Sur $15,000.00 Educational Grants
Academia Medica Del Sur $10,000.00 Educational Grants
Academia Medica Del Sur $5,000.00 Educational Grants
Academia Medica Del Sur $7,500.00 Educational Grants
Academia Medica Del Sur $12,000.00 Educational Grants
Academia Medica Del Sur $10,000.00 Educational Grants
Academia Medica Del Sur $7,500.00 Educational Grants
Academia Medica Del Sur $10,000.00 Educational Grants
Academia Medica Del Sur $10,000.00 Educational Grants
Academia Medica Del Sur $15,000.00 Educational Grants
Academia Medica Del Sur $10,000.00 Educational Grants
Academia Medica Del Sur $12,000.00 Educational Grants
Academia Medica Del Sur $15,000.00 Educational Grants
Academia Medica Del Sur $15,000.00 Educational Grants
Academia Medica Del Sur $10,000.00 Educational Grants
Academia Medica Del Sur $10,000.00 Educational Grants
Academia Medica Del Sur $15,000.00 Educational Grants
Academia Medica Del Sur $10,000.00 Educational Grants
Academia Medica Del Sur $15,000.00 Educational Grants
Academia Medica Del Sur $10,000.00 Educational Grants
Academia Medica Del Sur $10,000.00 Educational Grants
Academia Medica Del Sur $9,000.00 Educational Grants
Academia Medica Del Sur $10,000.00 Educational Grants
Academia Medica Del Sur $15,000.00 Educational Grants
Academia Puertorriquena De $8,500.00 Corporate Sponsorship
Neurologia
Academy of Managed Care $25,000.00 Corporate Sponsorship
Pharmacy
Academy of Managed Care $75,000.00 Corporate Sponsorship
Pharmacy
Academy of Managed Care $30,000.00 Corporate Sponsorship
Pharmacy
Academy of Managed Care $25,000.00 Corporate Sponsorship
Pharmacy
Academy of Managed Care $40,000.00 Corporate Sponsorship
Pharmacy
Advances in Cosmetic and $50,000.00 Corporate Sponsorship
Medical Dermatology Inc.
Advances in Cosmetic and $50,000.00 Corporate Sponsorship
Medical Dermatology Inc.
Advances in Cosmetic and $100,000.00 Corporate Sponsorship
Medical Dermatology Inc.
Adventist Hlth System-- $15,000.00 Corporate Sponsorship
Sunbelt Inc.
Advocate Health & Hospitals $2,500.00 Educational Grants
Corporation
Aids Drug Assistance $5,000.00 Educational Grants
Programs Advocacy Asoc
AIDS Action Committee $5,000.00 Corporate Sponsorship
AIDS Foundation of Chicago $125,000.00 Charitable Donation
AIDS Foundation of Chicago $25,000.00 Corporate Sponsorship
AIDS Foundation of Chicago $10,000.00 Corporate Sponsorship
Alabama Dermatology Society $35,000.00 Corporate Sponsorship
Albany Medical Center $10,000.00 Corporate Sponsorship
Albany Medical Center $5,000.00 Educational Grants
Albert Einstein Colg of $10,000.00 Educational Grants
Medicine Div of
Dermatology Attending Asoc
Albert Einstein Colg of $85,000.00 Educational Grants
Medicine of Yeshiva Univ
Albert Einstein Med Ctr. $2,500.00 Educational Grants
Alliance for Clinical $25,000.00 Educational Grants
Trials in Oncology
Foundation
Alliance for Safe Biologic $100,000.00 Corporate Sponsorship
Medicines
Alliance Foundation for $50,000.00 Educational Grants
Continuing Education In
The Health Professions
American Academy of $75,000.00 Educational Grants
Continuing Medical
Education
American Academy of ($37,982.00) Educational Grants
Dermatology
American Academy of $75,000.00 Educational Grants
Dermatology
American Academy of $40,000.00 Charitable Donation
Dermatology
American Academy of $35,000.00 Corporate Sponsorship
Dermatology
American Academy of $40,000.00 Educational Grants
Dermatology
American Academy of $20,000.00 Corporate Sponsorship
Dermatology
American Academy of $10,000.00 Corporate Sponsorship
Dermatology
American Academy of $35,000.00 Corporate Sponsorship
Dermatology
American Academy of $200,000.00 Corporate Sponsorship
Dermatology
American Academy of Family $38,000.00 Corporate Sponsorship
Phys
American Academy of Family $38,000.00 Corporate Sponsorship
Phys
American Academy of $38,500.00 Educational Grants
Neurology Institute
American Academy of $10,000.00 Educational Grants
Neurology Institute
American Assoc for Lab $20,000.00 Charitable Donation
Animal Scnc Foundation
American Assoc for The $50,000.00 Charitable Donation
Study of Liver Diseases
American Assoc for The $500,000.00 Charitable Donation
Study of Liver Diseases
American Assoc for The $130,000.00 Corporate Sponsorship
Study of Liver Diseases
American Assoc of Phys of $15,000.00 Corporate Sponsorship
Indian Origin Arkansas
American Assoc of Phys of $10,000.00 Corporate Sponsorship
Indian Origin Arkansas
American Assoc of Phys of $5,000.00 Corporate Sponsorship
Indian Origin Arkansas
American Association for $10,000.00 Educational Grants
Cancer Research
American Association for $35,000.00 Educational Grants
Cancer Research
American Association for $10,000.00 Educational Grants
Cancer Research
American Association for $5,000.00 Educational Grants
Cancer Research
American Association for $25,000.00 Educational Grants
Cancer Research
American Association for $10,000.00 Educational Grants
Cancer Research
American Association for $25,000.00 Educational Grants
Cancer Research
American Association for $10,000.00 Educational Grants
Cancer Research
American Association for $5,000.00 Educational Grants
Laboratory Animal Science
New England Branch
American Association of $18,940.00 Educational Grants
Clinical Endocrinologists
American Association of $20,000.00 Educational Grants
Clinical Endocrinologists
American Association of $7,500.00 Educational Grants
Clinical Endocrinologists
American Association of $5,000.00 Educational Grants
Clinical Endocrinologists
American Association of $50,000.00 Corporate Sponsorship
Pharmaceutical Scientists
American Association of $3,150.00 Charitable Donation
Pharmaceutical Scientists
American Autoimmune Related $46,000.00 Corporate Sponsorship
American Autoimmune Related $10,000.00 Corporate Sponsorship
American Autoimmune Related $2,500.00 Corporate Sponsorship
American Autoimmune Related $5,000.00 Corporate Sponsorship
American Autoimmune Related $30,000.00 Corporate Sponsorship
American Brain Tumor $10,000.00 Corporate Sponsorship
Association
American Cancer Society $10,000.00 Corporate Sponsorship
American Cancer Society $2,000.00 Corporate Sponsorship
Cancer Action Network
American Cancer Society $7,000.00 Corporate Sponsorship
Cancer Action Network
American Cancer Society $5,000.00 Corporate Sponsorship
Cancer Action Network
American Cancer Society $2,500.00 Corporate Sponsorship
Cancer Action Network
American Cancer Society $1,000.00 Corporate Sponsorship
Cancer Action Network
American Cancer Society $10,000.00 Corporate Sponsorship
Cancer Action Network
American Cancer Society $2,500.00 Corporate Sponsorship
Cancer Action Network
American Cancer Society $1,000.00 Corporate Sponsorship
Cancer Action Network
American Chem Socty $2,500.00 Educational Grants
American Chem Socty $1,000.00 Educational Grants
American Chem Socty $2,500.00 Educational Grants
American Chem Socty $2,500.00 Educational Grants
American Colg of $355,000.00 Corporate Sponsorship
Endocrinology
American Colg of Lab Animal $50,000.00 Charitable Donation
Medicine
American Colg of $1,000.00 Corporate Sponsorship
Obstetricians And
Gynecologists District 1
American College of $1,000.00 Educational Grants
Clinical Pharmacology
American College of $90,000.00 Corporate Sponsorship
Gastroenterology
American College of $20,000.00 Corporate Sponsorship
Gastroenterology
American College of $25,000.00 Charitable Donation
Gastroenterology
American College of $100,000.00 Corporate Sponsorship
Gastroenterology
American College of $45,000.00 Corporate Sponsorship
Gastroenterology
American College of $90,000.00 Corporate Sponsorship
Gastroenterology
American College of $20,000.00 Corporate Sponsorship
Gastroenterology
American College of $3,000.00 Corporate Sponsorship
Healthcare Executives
Wisconsin Chapter
American College of $2,000,000.00 Corporate Sponsorship
Rheumatology
American College of $5,000.00 Corporate Sponsorship
Veterinary Pathologists
American Drug Utilization $20,000.00 Corporate Sponsorship
Review Society Adurs
American Enterprise $10,000.00 Corporate Sponsorship
Institute
American $153,517.00 Educational Grants
Gastroenterological
Association Institute
American $427,536.66 Educational Grants
Gastroenterological
Association Institute
American $25,000.00 Corporate Sponsorship
Gastroenterological
Association Institute
American $25,000.00 Corporate Sponsorship
Gastroenterological
Association Institute
American $133,200.00 Corporate Sponsorship
Gastroenterological
Association Institute
American $43,000.00 Corporate Sponsorship
Gastroenterological
Association Institute
American $25,000.00 Corporate Sponsorship
Gastroenterological
Association Institute
American Kidney Fund $5,000.00 Corporate Sponsorship
American Legion $10,000.00 Corporate Sponsorship
American Legion National $20,000.00 Corporate Sponsorship
Headquarters
American Liver Foundation $10,000.00 Corporate Sponsorship
American Liver Foundation $4,500.00 Corporate Sponsorship
American Liver Foundation $400,000.00 Corporate Sponsorship
American Liver Foundation ($10,000.00) Corporate Sponsorship
American Liver Foundation $25,000.00 Corporate Sponsorship
American Liver Foundation $5,000.00 Corporate Sponsorship
American Liver Foundation $25,000.00 Corporate Sponsorship
American Liver Foundation $5,000.00 Corporate Sponsorship
American Liver Foundation $35,000.00 Corporate Sponsorship
American Medical Group $24,700.00 Corporate Sponsorship
Association
American Neurological $25,000.00 Educational Grants
Association
American Pancreatic $75,000.00 Educational Grants
Association, Inc.
American Pancreatic $25,000.00 Corporate Sponsorship
Association, Inc.
American Pancreatic $15,000.00 Charitable Donation
Association, Inc.
American Parkinson Disease $5,350.00 Corporate Sponsorship
Association, Inc.
American Parkinson Disease $2,000.00 Corporate Sponsorship
Association, Inc.
American Parkinson Disease $15,000.00 Educational Grants
Association, Inc.
American Parkinson Disease $2,500.00 Corporate Sponsorship
Association, Inc.
American Parkinson Disease $40,000.00 Educational Grants
Association, Inc.
American Parkinson Disease $3,000.00 Corporate Sponsorship
Association, Inc.
American Parkinson Disease $500.00 Corporate Sponsorship
Association, Inc.
American Parkinson Disease $500.00 Corporate Sponsorship
Association, Inc.
American Parkinson Disease $1,000.00 Corporate Sponsorship
Association, Inc.
American Parkinson Disease $5,000.00 Corporate Sponsorship
Association, Inc.
American Parkinson Disease $1,000.00 Corporate Sponsorship
Association, Inc.
American Parkinson Disease $500.00 Corporate Sponsorship
Association, Inc.
American Parkinson Disease $1,000.00 Corporate Sponsorship
Association, Inc.
American Parkinson Disease $500.00 Corporate Sponsorship
Association, Inc.
American Parkinson Disease $1,000.00 Corporate Sponsorship
Association, Inc.
American Peptide Society $1,000.00 Educational Grants
American Pharmacists $10,000.00 Corporate Sponsorship
Association
American Society for Mens $10,000.00 Corporate Sponsorship
Health
American Society of $15,000.00 Corporate Sponsorship
Andrology
American Society of $15,000.00 Educational Grants
Clinical Oncology
American Society of $25,000.00 Educational Grants
Clinical Oncology
American Society of $15,000.00 Educational Grants
Clinical Oncology
American Society of $9,500.00 Corporate Sponsorship
Clinical Rheumatologists
American Society of Health $23,400.00 Corporate Sponsorship
System Pharmacists
American Socty of $95,000.00 Corporate Sponsorship
Hematology
American Socty of $2,550.00 Corporate Sponsorship
Hematology
American Socty of $25,000.00 Corporate Sponsorship
Hematology
American Socty of $60,000.00 Corporate Sponsorship
Hematology
American Statistical $2,500.00 Educational Grants
Association
American Thyroid $45,000.00 Educational Grants
Association, Inc.
American Uroligical Asoc $11,500.00 Corporate Sponsorship
Northeastern Section
American Urological Asoc $10,000.00 Corporate Sponsorship
Foundation
American Urological Asoc $6,000.00 Corporate Sponsorship
Inc. North Ctrl Section
American Urological Asoc $10,000.00 Corporate Sponsorship
Inc. Western Section
American Urological Asoc $1,000.00 Corporate Sponsorship
New York Section
American Urological Asoc $6,000.00 Corporate Sponsorship
South Ctrl Section
American Urological $100,000.00 Corporate Sponsorship
Association
American Urological $25,000.00 Corporate Sponsorship
Association
American Urological $37,500.00 Corporate Sponsorship
Association
American Urological $41,000.00 Corporate Sponsorship
Association
American Urological $75,000.00 Educational Grants
Association Education And
Research, Inc.
American Urological $50,000.00 Educational Grants
Association Education And
Research, Inc.
American Urological $30,000.00 Educational Grants
Association Education And
Research, Inc.
American Urological $10,000.00 Educational Grants
Association Education And
Research, Inc.
American Urological $10,000.00 Educational Grants
Association Education And
Research, Inc.
American Urological $10,000.00 Educational Grants
Association Education And
Research, Inc.
American Urological $25,000.00 Educational Grants
Association Education And
Research, Inc.
American Urological $10,000.00 Educational Grants
Association Education And
Research, Inc.
American Urological $8,000.00 Educational Grants
Association Education And
Research, Inc.
Americans for Medical $110,000.00 Charitable Donation
Progress Educational Found
Americares Foundation, Inc. $10,000.00 Corporate Sponsorship
Anesthesia Patient Safety $15,000.00 Charitable Donation
Foundation
Annenberg Center for Health $50,000.00 Educational Grants
Science
Annenberg Center for Health $140,000.00 Educational Grants
Science
Annenberg Center for Health $90,000.00 Educational Grants
Science
Annenberg Center for Health $641,628.00 Educational Grants
Science
Annenberg Center for Health $85,000.00 Educational Grants
Science
Annenberg Center for Health $75,000.00 Educational Grants
Science
Annenberg Center for Health ($5,000.00) Educational Grants
Science
Arizona United Rheum $5,000.00 Corporate Sponsorship
Alliance Aura
Arthritis Foundation, Inc. $5,000.00 Corporate Sponsorship
Arthritis Foundation, Inc. $5,000.00 Corporate Sponsorship
Arthritis Foundation, Inc. $50,000.00 Educational Grants
Arthritis Foundation, Inc. $30,000.00 Corporate Sponsorship
Arthritis Foundation, Inc. $10,000.00 Educational Grants
Arthritis Foundation, Inc. $2,500.00 Patient Support
Arthritis Foundation, Inc. $30,000.00 Corporate Sponsorship
Arthritis Foundation, Inc. $40,000.00 Patient Support
Arthritis Foundation, Inc. $20,000.00 Corporate Sponsorship
Arthritis Foundation, Inc. $12,500.00 Patient Support
Arthritis Foundation, Inc. $25,000.00 Corporate Sponsorship
Arthritis Foundation, Inc. $25,000.00 Corporate Sponsorship
Arthritis Foundation, Inc. $1,500.00 Corporate Sponsorship
Arthritis Foundation, Inc. $5,000.00 Corporate Sponsorship
Arthritis Foundation, Inc. $5,000.00 Corporate Sponsorship
Arthritis Foundation, Inc. $5,000.00 Corporate Sponsorship
Arthritis Foundation, Inc. $2,000.00 Corporate Sponsorship
Arthritis Foundation, Inc. $3,000.00 Corporate Sponsorship
Arthritis Foundation, Inc. $1,000.00 Corporate Sponsorship
Arthritis Foundation, Inc. $5,000.00 Corporate Sponsorship
Arthritis Foundation, Inc. $2,000.00 Corporate Sponsorship
Arthritis Foundation, Inc. $1,000.00 Corporate Sponsorship
Arthritis Foundation, Inc. $2,500.00 Patient Support
Arthritis Foundation, Inc. $5,000.00 Corporate Sponsorship
Arthritis Foundation, Inc. $30,000.00 Corporate Sponsorship
Arthritis Foundation, Inc. $250,000.00 Corporate Sponsorship
Arthritis Foundation, Inc. $175,000.00 Corporate Sponsorship
Arthritis Foundation, Inc. $300,000.00 Corporate Sponsorship
Arthritis Foundation, Inc. $300,000.00 Corporate Sponsorship
Arthritis Foundation, Inc. $259,000.00 Corporate Sponsorship
Arthritis Patient Services $10,000.00 Educational Grants
Arthritis Patient Services $25,000.00 Educational Grants
Asco Cancer Foundation $50,000.00 Charitable Donation
Asco Cancer Foundation $40,000.00 Fellowships or
Scholarships
Asco Cancer Foundation ($689.37) Fellowships or
Scholarships
Asociacion De Hematologia Y $5,000.00 Corporate Sponsorship
Oncologia Medica De Puerto
Rico
Asociacion De Reumatologos $22,500.00 Corporate Sponsorship
De Puerto Rico
Asociacion De Salud $2,000.00 Corporate Sponsorship
Primaria De Puerto Rico,
Inc.
Asociacion Pr De $10,000.00 Corporate Sponsorship
Gastroenterologia
Asociacion Pr De $40,000.00 Corporate Sponsorship
Gastroenterologia
Asociacion Pr De $30,000.00 Corporate Sponsorship
Gastroenterologia
Asociacion Puertorriquena $2,500.00 Corporate Sponsorship
De Ayuda Al Paciente De
Psiorasis
Asociacion Puertorriquena $15,000.00 Corporate Sponsorship
De Medicina Fisica Y
Rehabilitacion
Asociacion Puertorriquena $6,000.00 Corporate Sponsorship
De Medicina Fisica Y
Rehabilitacion
Aspen Cancer Conference, $7,500.00 Educational Grants
Inc.
Association for Assessment $5,000.00 Charitable Donation
And Accreditation of
Laboratory Animal Care
International
Association of Physician $10,000.00 Corporate Sponsorship
Assistants In Oncology
Inc.
Association of Women in $30,000.00 Corporate Sponsorship
Rheumatology
Association of Women in $30,000.00 Corporate Sponsorship
Rheumatology
At Point of Care, LLC $150,000.00 Educational Grants
Autoimmune Advocacy $2,500.00 Corporate Sponsorship
Alliance
Baehr Challenge Ltd. $2,500.00 Corporate Sponsorship
Baehr Challenge Ltd. $4,000.00 Corporate Sponsorship
Balm In Gilead Inc. $75,000.00 Corporate Sponsorship
Baylor College of Medicine $5,000.00 Educational Grants
Baylor College of Medicine $5,000.00 Corporate Sponsorship
Baylor Health Care System $40,000.00 Fellowships or
Foundation Scholarships
Baylor Univ Med Ctr. $40,000.00 Educational Grants
Beth Israel Deaconess $35,000.00 Fellowships or
Medical Center Scholarships
Beth Israel Deaconess $40,000.00 Fellowships or
Medical Center Scholarships
Beth Israel Deaconess $25,000.00 Fellowships or
Medical Center Scholarships
Beth Israel Deaconess $8,000.00 Educational Grants
Medical Center
Bioconnections LLC $125,000.00 Corporate Sponsorship
Board of Trustees of The $40,000.00 Fellowships or
University of Illinois Scholarships
Board of Trustees of The $1,500.00 Educational Grants
University of Illinois
Boomer Esiason Foundation $25,000.00 Corporate Sponsorship
Boomer Esiason Foundation $400,000.00 Corporate Sponsorship
Borland Groover Foundation $1,000.00 Corporate Sponsorship
Boston Univ School of $70,000.00 Educational Grants
Medicine
Boston Univ School of $125,000.00 Educational Grants
Medicine
Boston Univ School of $1,500.00 Educational Grants
Medicine
Boston Univ School of $5,000.00 Corporate Sponsorship
Medicine
Boston Univ School of $10,000.00 Educational Grants
Medicine
Boston University Mdcn ($3,402.40) Educational Grants
Psychtry
Brandeis University $1,250.00 Charitable Donation
Breast Friends $1,500.00 Corporate Sponsorship
Business Hlth Coalition $3,300.00 Corporate Sponsorship
Foundation
Butler University $1,250.00 Charitable Donation
California Association for $1,500.00 Corporate Sponsorship
Nurse Practitioners
California Healthcare $1,500.00 Corporate Sponsorship
Institute
California Life Sciences $5,000.00 Corporate Sponsorship
Association
California Life Sciences $1,500.00 Corporate Sponsorship
Association
California Socty of $10,000.00 Corporate Sponsorship
Dermatology & Dermatology
Surgry
Cancer Care $2,500.00 Educational Grants
Cancer Care $2,500.00 Educational Grants
Cancer Care ($2,500.00) Educational Grants
Cancer Care $25,000.00 Educational Grants
Cancer Care $25,000.00 Educational Grants
Cancer Molecular $5,000.00 Educational Grants
Therapeutics Research
Association
Capital Meeting Planning $2,000.00 Educational Grants
Inc.
Caribe Gyn, Inc. $5,000.00 Corporate Sponsorship
Casa Lake County $10,000.00 Corporate Sponsorship
Catholic Charities of The $8,500.00 Corporate Sponsorship
Archdiocese of Chicago
Cedars-Sinai Medical Center $40,000.00 Fellowships or
Scholarships
Cedars-Sinai Medical Center ($4,000.00) Educational Grants
Central Florida Pharmacy $15,000.00 Patient Support
Council
Central Savannah River Area $1,000.00 Corporate Sponsorship
Csra Parkinson Support
Group
Chicago Help Initiative $7,500.00 Charitable Donation
Childhood Arthritis And $35,000.00 Corporate Sponsorship
Rheumatology Research
Alliance Carra
Children And Arthritis, $4,500.00 Charitable Donation
Inc.
Childrens Digestive Hlth $40,000.00 Fellowships or
And Nutrition Foundation Scholarships
Childrens Digestive Hlth ($40,000.00) Fellowships or
And Nutrition Foundation Scholarships
Childrens Digestive Hlth $56,000.00 Educational Grants
And Nutrition Foundation
Childrens Digestive Hlth $10,000.00 Corporate Sponsorship
And Nutrition Foundation
Childrens Digestive Hlth $2,500.00 Corporate Sponsorship
And Nutrition Foundation
Chimp Haven, Inc. $25,000.00 Charitable Donation
Chronic Liver Disease $1,000,000.00 Educational Grants
Foundation
Chronic Liver Disease $364,315.00 Educational Grants
Foundation
Chronic Liver Disease $1,513,875.00 Educational Grants
Foundation
Chronic Liver Disease ($2,700.00) Educational Grants
Foundation
Chronic Liver Disease ($9,044.17) Educational Grants
Foundation
Chronic Liver Disease ($9,045.00) Educational Grants
Foundation
Chronic Liver Disease $27,500.00 Corporate Sponsorship
Foundation
Chronic Lymphoytic Leukemia $25,000.00 Charitable Donation
Society, Inc.
Chronic Lymphoytic Leukemia $25,000.00 Educational Grants
Society, Inc.
Chronic Lymphoytic Leukemia $10,000.00 Patient Support
Society, Inc.
Cincinnati Childrens $40,000.00 Educational Grants
Hospital
Cincinnati Childrens $22,500.00 Corporate Sponsorship
Hospital Medical Center
Pulmonary Medicine
Cleveland Clinic Foundation $3,000.00 Educational Grants
Cleveland Clinic Foundation $50,000.00 Fellowships or
Scholarships
Cleveland Clinic Foundation $40,000.00 Fellowships or
Scholarships
Cleveland Clinic Minority $5,000.00 Educational Grants
Men's Health Center
Cleveland Clnc Educational ($542.72) Educational Grants
Foundation The
Cleveland Clnc Educational $50,000.00 Educational Grants
Foundation The
Cleveland Clnc Educational $50,000.00 Educational Grants
Foundation The
Cleveland Clnc Educational ($6,109.89) Educational Grants
Foundation The
Cleveland Clnc Educational ($1,147.40) Educational Grants
Foundation The
Clinical Care Options, LLC $75,000.00 Educational Grants
Clinical Care Options, LLC $100,000.00 Educational Grants
Clinical Care Options, LLC $75,000.00 Educational Grants
Clinical Care Options, LLC $100,000.00 Educational Grants
Cll Global Research $15,000.00 Educational Grants
Foundation
Cll Global Research $25,000.00 Educational Grants
Foundation
Coalition for Prevention of $5,000.00 Corporate Sponsorship
Colorectal Cancer In
Puerto Rico
Coalition for Prevention of $3,000.00 Corporate Sponsorship
Colorectal Cancer In
Puerto Rico
Colegio De Medicos $20,000.00 Educational Grants
Cirujanos De Puerto Rico
Columbia Univ Med Ctr $1,250.00 Charitable Donation
Community Health $10,000.00 Corporate Sponsorship
Community Health $10,000.00 Corporate Sponsorship
Community Health $10,000.00 Corporate Sponsorship
Community Health And Men's $5,000.00 Patient Support
Promotion Summit
Community Initiatives $5,000.00 Corporate Sponsorship
Community Initiatives $57,000.00 Corporate Sponsorship
Community Initiatives $50,000.00 Corporate Sponsorship
Community Liver Alliance $5,000.00 Corporate Sponsorship
Complete Conference Mgmt ($916.00) Educational Grants
Connect1D $2,500.00 Corporate Sponsorship
Connecticut Academy of $1,700.00 Corporate Sponsorship
Physician Assistants
Connecticut Advocates for $500.00 Corporate Sponsorship
Parkinsons Inc.
Connecting To Cure Crohns $5,000.00 Corporate Sponsorship
And Colitis
Consortium of Multiple $25,000.00 Educational Grants
Sclerosis Centers
Continuing Education $400,000.00 Educational Grants
Alliance, LLC
Continuing Education $350,000.00 Educational Grants
Alliance, LLC
Continuing Education ($1,972.99) Educational Grants
Alliance, LLC
Continuing Education ($5,392.00) Educational Grants
Alliance, LLC
Continuing Education ($723.11) Educational Grants
Alliance, LLC
Continuing Education ($3,353.94) Educational Grants
Alliance, LLC
Continuing Education $439,195.00 Educational Grants
Alliance, LLC
Continuing Education ($1,553.15) Educational Grants
Alliance, LLC
Continuing Education ($1,523.00) Educational Grants
Alliance, LLC
Continuing Education ($567.24) Educational Grants
Alliance, LLC
Cope Coalition On Positive $20,000.00 Corporate Sponsorship
Health Empowerment
Cope Coalition On Positive $15,000.00 Corporate Sponsorship
Health Empowerment
Core Foundation $10,000.00 Corporate Sponsorship
Cornell University Weill $2,500.00 Educational Grants
Cornell Medical College
Cornell University Weill $2,500.00 Educational Grants
Cornell Medical College
Cornerstones Health Inc. $90,000.00 Educational Grants
Cornerstones Health Inc. ($20,375.00) Educational Grants
Cornerstones Health Inc. $75,000.00 Educational Grants
Crape Myrtle Festival $300.00 Corporate Sponsorship
Creighton University $7,500.00 Educational Grants
Crohn's and Colitis $400,000.00 Corporate Sponsorship
Foundation of America,
Inc.
Crohn's and Colitis $22,500.00 Corporate Sponsorship
Foundation of America,
Inc.
Crohn's and Colitis $5,000.00 Corporate Sponsorship
Foundation of America,
Inc.
Crohn's and Colitis $1,200,000.00 Educational Grants
Foundation of America,
Inc.
Crohn's and Colitis $180,000.00 Educational Grants
Foundation of America,
Inc.
Crohn's and Colitis $5,000.00 Corporate Sponsorship
Foundation of America,
Inc.
Crohn's and Colitis ($265.00) Educational Grants
Foundation of America,
Inc.
Crohn's and Colitis $50,160.00 Corporate Sponsorship
Foundation of America,
Inc.
Crohn's and Colitis $3,000.00 Corporate Sponsorship
Foundation of America,
Inc.
Crohn's and Colitis $2,500.00 Corporate Sponsorship
Foundation of America,
Inc.
Crohn's and Colitis $1,000.00 Corporate Sponsorship
Foundation of America,
Inc.
Crohn's and Colitis $25,000.00 Charitable Donation
Foundation of America,
Inc.
Crohn's and Colitis $25,000.00 Charitable Donation
Foundation of America,
Inc.
Crohn's and Colitis $90,000.00 Corporate Sponsorship
Foundation of America,
Inc.
Crohn's and Colitis $35,000.00 Educational Grants
Foundation of America,
Inc.
Crohn's and Colitis $2,500.00 Corporate Sponsorship
Foundation of America,
Inc.
Crohn's and Colitis $5,000.00 Corporate Sponsorship
Foundation of America,
Inc.
Crohn's and Colitis $1,500.00 Corporate Sponsorship
Foundation of America,
Inc.
Crohn's and Colitis $5,000.00 Corporate Sponsorship
Foundation of America,
Inc.
Crohn's and Colitis $10,000.00 Corporate Sponsorship
Foundation of America,
Inc.
Crohn's and Colitis $100,000.00 Fellowships or
Foundation of America, Scholarships
Inc.
Crohn's and Colitis $32,500.00 Corporate Sponsorship
Foundation of America,
Inc.
Crohn's and Colitis $10,000.00 Corporate Sponsorship
Foundation of America,
Inc.
Crohn's and Colitis $1,000.00 Corporate Sponsorship
Foundation of America,
Inc.
Crohn's and Colitis $1,500.00 Corporate Sponsorship
Foundation of America,
Inc.
Crohn's and Colitis $90,000.00 Corporate Sponsorship
Foundation of America,
Inc.
Crohn's and Colitis $10,000.00 Corporate Sponsorship
Foundation of America,
Inc.
Crohn's and Colitis $400,000.00 Corporate Sponsorship
Foundation of America,
Inc.
Crohn's and Colitis $22,500.00 Corporate Sponsorship
Foundation of America,
Inc.
Culinary Care $2,500.00 Corporate Sponsorship
Curatio Cme Inst ($3,261.00) Educational Grants
Curatio Cme Inst ($180.00) Educational Grants
Curatio Cme Inst ($50,000.00) Educational Grants
Curatio Cme Inst ($8,855.73) Educational Grants
Cure CF $500.00 Corporate Sponsorship
Cystic Fibrosis Foundation $10,000.00 Corporate Sponsorship
Cystic Fibrosis Foundation $5,000.00 Corporate Sponsorship
Cystic Fibrosis Foundation $2,500.00 Corporate Sponsorship
Cystic Fibrosis Foundation $3,000.00 Corporate Sponsorship
Cystic Fibrosis Foundation $1,000.00 Corporate Sponsorship
Cystic Fibrosis Foundation $1,500.00 Corporate Sponsorship
Cystic Fibrosis Foundation $3,750.00 Corporate Sponsorship
Cystic Fibrosis Foundation $500,000.00 Corporate Sponsorship
Cystic Fibrosis Foundation $2,500.00 Corporate Sponsorship
Cystic Fibrosis Foundation $100,000.00 Charitable Donation
Cystic Fibrosis Foundation $2,500.00 Corporate Sponsorship
Cystic Fibrosis Foundation $2,000.00 Corporate Sponsorship
Cystic Fibrosis Foundation $1,500.00 Corporate Sponsorship
Cystic Fibrosis Foundation $1,000.00 Corporate Sponsorship
Cystic Fibrosis Foundation $1,000.00 Corporate Sponsorship
Cystic Fibrosis Foundation $2,500.00 Corporate Sponsorship
Cystic Fibrosis Foundation $2,000.00 Corporate Sponsorship
Cystic Fibrosis Foundation $1,000.00 Corporate Sponsorship
Cystic Fibrosis Foundation $5,000.00 Corporate Sponsorship
Cystic Fibrosis Foundation $7,500.00 Corporate Sponsorship
Cystic Fibrosis Foundation $3,000.00 Corporate Sponsorship
Cystic Fibrosis Foundation $1,000.00 Corporate Sponsorship
Cystic Fibrosis Foundation $10,000.00 Corporate Sponsorship
Cystic Fibrosis Foundation $1,500.00 Corporate Sponsorship
Cystic Fibrosis Foundation $50,000.00 Corporate Sponsorship
Cystic Fibrosis Foundation $3,500.00 Corporate Sponsorship
Cystic Fibrosis Foundation $1,500.00 Corporate Sponsorship
Cystic Fibrosis Foundation $1,000.00 Corporate Sponsorship
Cystic Fibrosis Foundation $2,000.00 Corporate Sponsorship
Cystic Fibrosis Foundation $2,000.00 Corporate Sponsorship
Cystic Fibrosis Foundation $1,000.00 Corporate Sponsorship
Cystic Fibrosis Foundation $2,500.00 Corporate Sponsorship
Cystic Fibrosis Foundation $2,500.00 Corporate Sponsorship
Cystic Fibrosis Foundation $25,000.00 Corporate Sponsorship
Cystic Fibrosis Foundation $15,000.00 Corporate Sponsorship
Cystic Fibrosis Foundation $2,500.00 Corporate Sponsorship
Cystic Fibrosis Foundation $1,000.00 Corporate Sponsorship
Cystic Fibrosis Foundation $750.00 Corporate Sponsorship
Cystic Fibrosis Foundation $1,000.00 Corporate Sponsorship
Cystic Fibrosis Foundation $3,000.00 Corporate Sponsorship
Cystic Fibrosis Foundation $2,000.00 Corporate Sponsorship
Cystic Fibrosis Foundation $3,750.00 Corporate Sponsorship
Cystic Fibrosis Foundation $750,000.00 Corporate Sponsorship
Cystic Fibrosis Foundation $1,500.00 Corporate Sponsorship
Cystic Fibrosis Foundation $16,000.00 Corporate Sponsorship
Cystic Fibrosis Foundation $1,000.00 Corporate Sponsorship
Cystic Fibrosis Foundation $2,500.00 Corporate Sponsorship
Cystic Fibrosis Foundation $2,500.00 Corporate Sponsorship
Cystic Fibrosis Foundation $2,500.00 Corporate Sponsorship
Cystic Fibrosis Foundation $2,500.00 Corporate Sponsorship
Cystic Fibrosis Foundation $2,500.00 Corporate Sponsorship
Cystic Fibrosis Foundation $2,500.00 Corporate Sponsorship
Cystic Fibrosis Research $5,000.00 Corporate Sponsorship
Fund Emily's Entourage
Cystic Fibrosis Research $1,250.00 Corporate Sponsorship
Inc.
Cystic Fibrosis Research $3,000.00 Corporate Sponsorship
Inc.
Cystic Fibrosis Research $15,000.00 Corporate Sponsorship
Inc.
Cystic Fibrosis Research $10,000.00 Corporate Sponsorship
Inc.
Dallas Fort Worth Business $5,000.00 Corporate Sponsorship
Group on Health
Dava Oncology LP $95,000.00 Corporate Sponsorship
Davis Phinney Foundation $30,000.00 Educational Grants
Davis Phinney Foundation $30,000.00 Educational Grants
Davis Phinney Foundation $40,000.00 Patient Support
Dermatology Education $30,000.00 Corporate Sponsorship
Foundation
Dermatology Foundation $40,000.00 Fellowships or
Scholarships
Dermatology Foundation $135,000.00 Charitable Donation
Dermatology Foundation $50,000.00 Corporate Sponsorship
Dermatology Nurses $15,000.00 Educational Grants
Association
Dermatology Nurses $23,270.00 Corporate Sponsorship
Association
Dermatology Nurses $25,850.00 Corporate Sponsorship
Association
Desert Aids Project Inc. $2,000.00 Corporate Sponsorship
Digestive Disease Week $55,000.00 Corporate Sponsorship
Digestive Disease Week $3,500.00 Corporate Sponsorship
Digestive Health Foundation $25,000.00 Corporate Sponsorship
Duke University $40,000.00 Fellowships or
Scholarships
Duke University ($780.00) Educational Grants
Duke University Medical $10,000.00 Fellowships or
Center Scholarships
East Hawaii IPA $8,000.00 Corporate Sponsorship
Efficient Collaborative $28,100.00 Corporate Sponsorship
Retail Marketing
Eicosanoid Research $2,000.00 Educational Grants
Foundation
El Centro Regional Medical $5,000.00 Corporate Sponsorship
Center Foundation
El Centro Regional Medical $5,000.00 Corporate Sponsorship
Center Foundation
Elsevier Inc. $150,000.00 Educational Grants
Emory University $10,000.00 Corporate Sponsorship
Emory University $2,000.00 Corporate Sponsorship
Emory University $10,000.00 Corporate Sponsorship
Emory University School of $25,000.00 Educational Grants
Medicine
Employers Health Coalition $4,000.00 Corporate Sponsorship
Inc.
Endocrine Society $10,000.00 Corporate Sponsorship
Endocrine Society $15,000.00 Educational Grants
Endometriosis Foundation of $2,500.00 Corporate Sponsorship
America
Epilepsy Foundation $15,000.00 Charitable Donation
Erie Family Health Center $5,000.00 Sponsorship
Corporate
Escuela De Medicina De $8,000.00 Educational Grants
Ponce
Escuela De Medicina San $40,000.00 Fellowships or
Juan Bautista Scholarships
Evergreen Foundation of $750.00 Corporate Sponsorship
Western New York
Excellence In Rheumatology $100,000.00 Corporate Sponsorship
Education LLC
Facing Our Risk of Cancer $15,000.00 Educational Grants
Empowerement Force
Federation of American $5,000.00 Corporate Sponsorship
Societies for Experimental
Biology
Federation of American $1,500.00 Educational Grants
Societies for Experimental
Biology
Federation of American $1,500.00 Educational Grants
Societies for Experimental
Biology
Federation of American $1,500.00 Educational Grants
Societies for Experimental
Biology
Federation of American $1,500.00 Educational Grants
Societies for Experimental
Biology
Federation of Clinical $18,000.00 Educational Grants
Immunology Societies
Federation of Clinical $15,000.00 Educational Grants
Immunology Societies
Florida Health Care $10,000.00 Corporate Sponsorship
Coalition
Florida Health Care $4,500.00 Corporate Sponsorship
Coalition
Florida Society of $25,000.00 Corporate Sponsorship
Rheumatology
Focus Medical $150,000.00 Corporate Sponsorship
Communications LLC
Food Outreach $10,000.00 Corporate Sponsorship
force--Facing Our Risk of $5,000.00 Corporate Sponsorship
Cancer Emp
Foundation for Anesthesia $15,000.00 Fellowships or
Education And Research Scholarships
Foundation for Arthritis $5,500.00 Corporate Sponsorship
Treatment
Foundation for The National $10,000.00 Corporate Sponsorship
Institutes of Health
Foundation for Veterans $25,000.00 Corporate Sponsorship
Health Care
Foundation of Consortium of $8,000.00 Charitable Donation
Multiple Sclerosis Centers
Cmsc
Foundcare Inc. $2,500.00 Corporate Sponsorship
Foundcare Inc. $2,500.00 Corporate Sponsorship
Friends of Cancer Research $30,000.00 Corporate Sponsorship
Friends of Parkinsons $2,500.00 Corporate Sponsorship
Friends of Prentice $25,000.00 Charitable Donation
Fundacion De Investigacion $25,000.00 Educational Grants
Gastro Intestinal Research $50,000.00 Corporate Sponsorship
Foundation
Gastro Intestinal Research $25,000.00 Corporate Sponsorship
Foundation
Gastrointestinal And Liver $75,000.00 Educational Grants
Association of The
Americas Inc.
Gateway for Cancer Research $6,000.00 Corporate Sponsorship
General Hospital $10,000.00 Educational Grants
Corporation
Georgia Dermatology $7,500.00 Corporate Sponsorship
Physician Assistants
Georgia Dermatology $15,000.00 Corporate Sponsorship
Physician Assistants
Georgia Health Sciences $1,500.00 Educational Grants
Foundation Inc.
Georgia Prostate Cancer $5,000.00 Patient Support
Coalition
Georgia Society of $3,000.00 Corporate Sponsorship
Dermatology And
Dermatologic Surgery
Gilda's Club Chicago $25,000.00 Corporate Sponsorship
Global Academy for Medical $72,000.00 Corporate Sponsorship
Education
Global Academy for Medical $35,000.00 Corporate Sponsorship
Education
Global Academy for Medical $18,000.00 Corporate Sponsorship
Education
Global Academy for Medical $72,000.00 Corporate Sponsorship
Education
Global Academy for Medical $72,000.00 Corporate Sponsorship
Education
Global Academy for Medical $45,000.00 Corporate Sponsorship
Education
Global Alliance for Patient $30,000.00 Corporate Sponsorship
Access
Global Alliance for Patient $50,000.00 Corporate Sponsorship
Access
Global Alliance for Patient $50,000.00 Corporate Sponsorship
Access
Global Alliance for Patient $250,000.00 Educational Grants
Access
Global Healthy Living $24,000.00 Corporate Sponsorship
Foundation
Global Healthy Living $25,000.00 Corporate Sponsorship
Foundation
Gordon Research Conferences $1,500.00 Educational Grants
Gordon Research Conferences $1,500.00 Educational Grants
Gordon Research Conferences $1,500.00 Educational Grants
Gordon Research Conferences $1,500.00 Educational Grants
Gordon Research Conferences $2,000.00 Educational Grants
Gordon Research Conferences $2,500.00 Educational Grants
Gordon Research Conferences $2,000.00 Educational Grants
Gordon Research Conferences $1,500.00 Educational Grants
Gordon Research Conferences $1,500.00 Educational Grants
Gordon Research Conferences $1,500.00 Educational Grants
Gordon Research Conferences $1,500.00 Educational Grants
Gordon Research Conferences $1,000.00 Educational Grants
Gospel Heritage Foundation $10,000.00 Corporate Sponsorship
Great Lakes Chapter of The $1,000.00 Corporate Sponsorship
American Society for
Pharmacology And
Experimental Therapeutics
Group of Research And $15,000.00 Corporate Sponsorship
Assessment of Psoriasis
And Psoriatic Arthritis
Grupo De Apoyo De Ninos Y $3,000.00 Corporate Sponsorship
Adolescentes Con
Reumatologia
Gynecologic Oncology Group $25,000.00 Educational Grants
Gynecologic Oncology Group $25,000.00 Educational Grants
Heals of The South, Inc.-- $5,000.00 Charitable Donation
Hepatitis Education
Awareness And Liver
Support
Health Action Council Ohio $3,780.00 Corporate Sponsorship
Healthcare 21 Business $5,000.00 Corporate Sponsorship
Coalition
Healthcare 21 Business $5,000.00 Corporate Sponsorship
Coalition
Healthcare Financial $50,000.00 Corporate Sponsorship
Management Association
Hfma
Heather Robidoux $7,500.00 Corporate Sponsorship
Heb Grocery Company LP $10,000.00 Corporate Sponsorship
Hep C Connection $75,000.00 Patient Support
Hep C Connection $5,000.00 Corporate Sponsorship
Hepatitis Education Project $75,000.00 Charitable Donation
Hepatitis Education Project $50,000.00 Corporate Sponsorship
Herbert Kosten Pancreatic $2,000.00 Corporate Sponsorship
Cancer Charitable Fund
Hitchcock Foundation $25,000.00 Educational Grants
Hiv Treaters Med Asoc of $10,000.00 Educational Grants
Puerto Rico
HMP Communications LLC $40,000.00 Corporate Sponsorship
Honor Health Virginia G $800.00 Corporate Sponsorship
Piper Cancer Center
Hope Foundation The $20,000.00 Educational Grants
Houston Area Parkinson $2,500.00 Corporate Sponsorship
Society
Howard Brown Health Center $20,000.00 Corporate Sponsorship
Howard Hanna Children's $10,000.00 Charitable Donation
Free Care Fund
Hubbard Street Dance $10,000.00 Educational Grants
Chicago
Hughes Healthcare $177,550.00 Educational Grants
Disparities Group
Human Growth Foundation $5,000.00 Corporate Sponsorship
Human Growth Foundation $4,000.00 Corporate Sponsorship
Humboldt--Del Norte County $4,000.00 Educational Grants
Med Socty
Hyacinth Aids Foundation $5,000.00 Corporate Sponsorship
Illinois African American $10,000.00 Corporate Sponsorship
Coalition
Illinois African American $10,000.00 Corporate Sponsorship
Coalition
Imedex, LLC $40,000.00 Educational Grants
Imedex, LLC $30,000.00 Educational Grants
Imedex, LLC $40,000.00 Educational Grants
Imedex, LLC $15,000.00 Corporate Sponsorship
Imedex, LLC $50,000.00 Educational Grants
Imedex, LLC $75,000.00 Educational Grants
Indiana University $4,100.00 Fellowships or
Scholarships
Infant Welfare Society of $10,000.00 Charitable Donation
Chicago
Infectious Diseases Society $25,000.00 Charitable Donation
of America
Infectious Diseases Society $50,000.00 Educational Grants
of America
Integrated Benefits $25,000.00 Corporate Sponsorship
Institute Inc.
Integrated Benefits $25,000.00 Corporate Sponsorship
Institute Inc.
Integrated Medical $35,000.00 Charitable Donation
Foundation
Integrated Medical $2,000.00 Corporate Sponsorship
Foundation
Integrated Medical $2,000.00 Corporate Sponsorship
Foundation
Integrated Medical $1,000.00 Corporate Sponsorship
Foundation
Interfaith House $2,000.00 Charitable Donation
International Aids Socty-- $200,000.00 Educational Grants
USA
International Aids Socty-- $80,000.00 Educational Grants
USA
International Aids Socty-- $75,000.00 Educational Grants
USA
International Asoc for The $2,500.00 Corporate Sponsorship
Study of Lung Cancer IASLC
International Association $10,000.00 Educational Grants
of Providers of Aids Care
International Association $10,000.00 Educational Grants
of Providers of Aids Care
International Chinese $3,000.00 Educational Grants
Statistical Association
International Dermatology $70,000.00 Corporate Sponsorship
Outcome Measures
International Foot And $2,000.00 Corporate Sponsorship
Ankle Foundation
International League of $20,000.00 Charitable Donation
Association for
Rheumatology
International Liver $10,000.00 Educational Grants
Transplantation Society
International Liver $40,000.00 Educational Grants
Transplantation Society
International Medical Corps $5,000.00 Corporate Sponsorship
International Psoriasis $100,000.00 Corporate Sponsorship
Council
International Psoriasis $50,000.00 Corporate Sponsorship
Council
International Psoriasis $50,000.00 Corporate Sponsorship
Council
International Psoriasis $50,000.00 Corporate Sponsorship
Council
International Society for $3,000.00 Educational Grants
The Study of Xenbiotics
International Society of $2,000.00 Educational Grants
Biopharmaceutical
Statistics
International Society of $1,500.00 Educational Grants
Heterocyclic Chemistry
Iowa Pharmacy Association $5,000.00 Corporate Sponsorship
Johns Hopkins Univ School $75,000.00 Educational Grants
of Medicine
Johns Hopkins Univ School $25,000.00 Corporate Sponsorship
of Medicine
Johns Hopkins Univ School $40,000.00 Fellowships or
of Medicine Scholarships
Johns Hopkins Univ School ($5,646.02) Educational Grants
of Medicine
Johns Hopkins Univ School $46,213.00 Educational Grants
of Medicine
Johns Hopkins Univ School $50,000.00 Educational Grants
of Medicine
JWC Covenant, Inc. $20,000.00 Educational Grants
JWC Covenant, Inc. $25,000.00 Corporate Sponsorship
JWC Covenant, Inc. $2,500.00 Corporate Sponsorship
Kansas University Endowment $500.00 Corporate Sponsorship
Association
Keck Medical Center of USC $25,000.00 Educational Grants
Kelsey Research Foundation $35,000.00 Fellowships or
Scholarships
Ken Zebrowski Memorial Walk $2,000.00 Corporate Sponsorship
Kidney Disease Improving $200,000.00 Corporate Sponsorship
Global Outcomes
Laboratorio Clinico Toledo $900.00 Patient Support
Laboratorio Clinico Toledo $1,365.00 Patient Support
Laboratorio Clinico Toledo $1,200.00 Patient Support
Laboratorio Clinico Toledo $615.00 Patient Support
Laboratorio Clinico Toledo $720.00 Patient Support
Laboratorio Clinico Toledo $1,275.00 Patient Support
Laboratorio Clinico Toledo $1,365.00 Patient Support
Laboratorio Clinico Toledo $1,365.00 Patient Support
Laboratorio Clinico Toledo $2,040.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $1,365.00 Patient Support
Laboratorio Clinico Toledo $945.00 Patient Support
Laboratorio Clinico Toledo $1,320.00 Patient Support
Laboratorio Clinico Toledo $3,600.00 Patient Support
Laboratorio Clinico Toledo $1,800.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $1,245.00 Patient Support
Laboratorio Clinico Toledo $4,125.00 Patient Support
Laboratorio Clinico Toledo $2,220.00 Patient Support
Laboratorio Clinico Toledo $2,160.00 Patient Support
Laboratorio Clinico Toledo $1,605.00 Patient Support
Laboratorio Clinico Toledo $2,040.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $1,455.00 Patient Support
Laboratorio Clinico Toledo $1,650.00 Patient Support
Laboratorio Clinico Toledo $1,365.00 Patient Support
Laboratorio Clinico Toledo $360.00 Patient Support
Laboratorio Clinico Toledo $876.00 Patient Support
Laboratorio Clinico Toledo $1,110.00 Patient Support
Laboratorio Clinico Toledo $1,470.00 Patient Support
Laboratorio Clinico Toledo $2,715.00 Patient Support
Laboratorio Clinico Toledo $1,140.00 Patient Support
Laboratorio Clinico Toledo $1,770.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $1,485.00 Patient Support
Laboratorio Clinico Toledo $1,455.00 Patient Support
Laboratorio Clinico Toledo $1,335.00 Patient Support
Laboratorio Clinico Toledo $1,095.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $1,380.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $1,215.00 Patient Support
Laboratorio Clinico Toledo $975.00 Patient Support
Laboratorio Clinico Toledo $945.00 Patient Support
Laboratorio Clinico Toledo $825.00 Patient Support
Laboratorio Clinico Toledo $1,140.00 Patient Support
Laboratorio Clinico Toledo $2,730.00 Patient Support
Laboratorio Clinico Toledo $1,065.00 Patient Support
Laboratorio Clinico Toledo $990.00 Patient Support
Laboratorio Clinico Toledo $1,980.00 Patient Support
Laboratorio Clinico Toledo $2,610.00 Patient Support
Laboratorio Clinico Toledo $1,650.00 Patient Support
Laboratorio Clinico Toledo $2,190.00 Patient Support
Laboratorio Clinico Toledo $855.00 Patient Support
Laboratorio Clinico Toledo $1,785.00 Patient Support
Laboratorio Clinico Toledo $276.00 Patient Support
Laboratorio Clinico Toledo $1,680.00 Patient Support
Laboratorio Clinico Toledo $510.00 Patient Support
Laboratorio Clinico Toledo $1,200.00 Patient Support
Laboratorio Clinico Toledo $525.00 Patient Support
Laboratorio Clinico Toledo $1,335.00 Patient Support
Laboratorio Clinico Toledo $1,650.00 Patient Support
Laboratorio Clinico Toledo $630.00 Patient Support
Laboratorio Clinico Toledo $990.00 Patient Support
Laboratorio Clinico Toledo $1,020.00 Patient Support
Laboratorio Clinico Toledo $1,275.00 Patient Support
Laboratorio Clinico Toledo $1,395.00 Patient Support
Laboratorio Clinico Toledo $315.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $1,290.00 Patient Support
Laboratorio Clinico Toledo $1,275.00 Patient Support
Laboratorio Clinico Toledo $525.00 Patient Support
Laboratorio Clinico Toledo $510.00 Patient Support
Laboratorio Clinico Toledo $315.00 Patient Support
Laboratorio Clinico Toledo $1,035.00 Patient Support
Laboratorio Clinico Toledo $240.00 Patient Support
Laboratorio Clinico Toledo $1,065.00 Patient Support
Laboratorio Clinico Toledo $660.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $900.00 Patient Support
Laboratorio Clinico Toledo $900.00 Patient Support
Laboratorio Clinico Toledo $810.00 Patient Support
Laboratorio Clinico Toledo $1,020.00 Patient Support
Laboratorio Clinico Toledo $1,200.00 Patient Support
Laboratorio Clinico Toledo $3,000.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $2,400.00 Patient Support
Laboratorio Clinico Toledo $465.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $1,410.00 Patient Support
Laboratorio Clinico Toledo $825.00 Patient Support
Laboratorio Clinico Toledo $525.00 Patient Support
Laboratorio Clinico Toledo $444.00 Patient Support
Laboratorio Clinico Toledo $645.00 Patient Support
Laboratorio Clinico Toledo $1,125.00 Patient Support
Laboratorio Clinico Toledo $1,185.00 Patient Support
Laboratorio Clinico Toledo $1,320.00 Patient Support
Laboratorio Clinico Toledo $2,160.00 Patient Support
Laboratorio Clinico Toledo $1,740.00 Patient Support
Lake County Haven $10,000.00 Corporate Sponsorship
Large Urology Group $20,000.00 Corporate Sponsorship
Practice Association
Large Urology Group $15,000.00 Corporate Sponsorship
Practice Association
Large Urology Group $66,400.00 Corporate Sponsorship
Practice Association
Large Urology Group $25,000.00 Corporate Sponsorship
Practice Association
Leading Edge US LLC $125,000.00 Educational Grants
Leukemia and Lymphoma $5,000.00 Educational Grants
Society
Leukemia and Lymphoma $2,500.00 Educational Grants
Society
Leukemia and Lymphoma $15,000.00 Corporate Sponsorship
Society
Leukemia and Lymphoma $100,000.00 Corporate Sponsorship
Society
Leukemia Research $10,000.00 Corporate Sponsorship
Foundation
Leukemia Research $10,000.00 Corporate Sponsorship
Foundation
Leukemia Research $20,000.00 Corporate Sponsorship
Foundation
Leukemia Research $5,000.00 Corporate Sponsorship
Foundation
Life Sciences Foundation $30,000.00 Charitable Donation
Los Angeles Urological $8,500.00 Corporate Sponsorship
Society
Louisiana State Univ Hlth ($9,779.71) Fellowships or
Scnc Ctr Scholarships
Louisiana State Univ Hlth $1,200.00 Corporate Sponsorship
Scnc Foundation
Lupus Research Inst Inc. $50,000.00 Corporate Sponsorship
Magellan Health Services $35,000.00 Corporate Sponsorship
Main Line Health, Inc. $2,500.00 Educational Grants
Map International $25,000.00 Corporate Sponsorship
Maryland Dermatologic Socty $75,000.00 Corporate Sponsorship
Massachusetts Biotechnology $5,000.00 Corporate Sponsorship
Council
Massachusetts Institute of $1,250.00 Charitable Donation
Technology
Massachusetts Institute of $1,250.00 Charitable Donation
Technology
Massachusetts Prostate $5,000.00 Educational Grants
Cancer Coalition
Massachusetts Public Health $2,500.00 Corporate Sponsorship
Association
Massachusetts Public Health $2,500.00 Corporate Sponsorship
Association
Massachusetts Society for $5,000.00 Educational Grants
Medical Research
Max Foundation $45,000.00 Corporate Sponsorship
Medina Community Clinic $1,000.00 Corporate Sponsorship
Med-IQ, LLC $200,000.00 Educational Grants
Med-IQ, LLC $156,924.00 Educational Grants
Medscape LLC $205,000.00 Educational Grants
Medscape LLC $1,000.00 Educational Grants
Medscape LLC $175,000.00 Educational Grants
Medscape LLC $300,000.00 Educational Grants
Medscape LLC $150,000.00 Educational Grants
Medscape LLC $150,000.00 Educational Grants
Medscape LLC $50,000.00 Educational Grants
Medscape LLC $190,000.00 Educational Grants
Medscape LLC $250,000.00 Educational Grants
Medscape LLC $60,000.00 Educational Grants
Medscape LLC $50,000.00 Educational Grants
Medscape LLC $8,000.00 Educational Grants
Medscape LLC $150,000.00 Educational Grants
Memorial Hermann Foundation $35,000.00 Fellowships or
Scholarships
Memphis Business Group on $5,120.00 Corporate Sponsorship
Health
Memphis Business Group on $6,500.00 Corporate Sponsorship
Health
Men Educating Men, Inc. $20,000.00 Patient Support
Mercer County Joint Twnshp ($336.00) Educational Grants
Commty Hosp Dba Mercer
Hlth
Mercer County Joint Twnshp $3,000.00 Patient Support
Commty Hosp Dba Mercer
Hlth
Methodist Hosp The $25,000.00 Corporate Sponsorship
Mexican American $5,000.00 Corporate Sponsorship
Legislative Leadership
Foundation
Michael J Fox Foundation $69,500.00 Educational Grants
Michael J Fox Foundation $25,000.00 Corporate Sponsorship
Michael J Fox Foundation $50,000.00 Corporate Sponsorship
Michael J Fox Foundation $7,500.00 Corporate Sponsorship
Michigan Parkinson $2,000.00 Corporate Sponsorship
Foundation
Michigan Rheumatism Society $15,000.00 Corporate Sponsorship
Mid Atlantic Business Group $7,500.00 Corporate Sponsorship
Heatlh
Midwest Business Group on $1,000.00 Corporate Sponsorship
Health
Midwest Pediatric Endocrine $6,300.00 Corporate Sponsorship
Society
Military officers $10,000.00 Corporate Sponsorship
Association of America
Family Initiative
Minnesota Urological $2,500.00 Corporate Sponsorship
Society
Mississippi $1,000.00 Corporate Sponsorship
Gastroenterology Society
Mississippi $1,500.00 Corporate Sponsorship
Gastroenterology Society
Missouri Hepatitis C $25,000.00 Educational Grants
Alliance
Missouri Hepatitis C $25,000.00 Educational Grants
Alliance
Missouri Hepatitis C $25,000.00 Charitable Donation
Alliance
Montefiore Medical Center $25,000.00 Educational Grants
Montefiore Medical Center $75,000.00 Educational Grants
Montefiore Medical Center ($10,457.00) Educational Grants
Mount Sinai School of $8,000.00 Corporate Sponsorship
Medicine
Mount Sinai School of $250,000.00 Educational Grants
Medicine
Mount Sinai School of $15,000.00 Educational Grants
Medicine
Mount Sinai School of $40,000.00 Educational Grants
Medicine
Mount Sinai School of $5,000.00 Educational Grants
Medicine
Mount Sinai School of $20,000.00 Educational Grants
Medicine
Mount Sinai School of $200,000.00 Educational Grants
Medicine
Movement Disorder Socty The $172,000.00 Corporate Sponsorship
Movement Disorder Socty The $111,230.00 Educational Grants
Movement Disorder Socty The $184,500.00 Corporate Sponsorship
Multiple Myeloma Research $10,000.00 Educational Grants
Foundation
My Gut Instinct Inc. $1,500.00 Corporate Sponsorship
National Academy of $30,000.00 Corporate Sponsorship
Dermatology Nurse
Practitioners
National Academy of $30,000.00 Corporate Sponsorship
Dermatology Nurse
Practitioners
National AIDS Treatment $150,000.00 Patient Support
Advocacy Project
National AIDS Treatment $300,000.00 Charitable Donation
Advocacy Project
National Alliance of Mental $5,000.00 Corporate Sponsorship
Illness Michigan
National Alliance of Mental $2,500.00 Corporate Sponsorship
Illness Oregon
National Alliance of Mental $2,500.00 Corporate Sponsorship
Illness Washington
National Alliance of State $30,000.00 Corporate Sponsorship
And Territorial Aids
Directors
National Alliance of State $75,000.00 Charitable Donation
And Territorial Aids
Directors
National Animal Interest $20,000.00 Charitable Donation
Alliance
National Association of $25,000.00 Corporate Sponsorship
Latino Elected & Appointed
officials Educational Fund
National Black Leadership $6,000.00 Corporate Sponsorship
Commission on AIDS
National Black Leadership $5,000.00 Corporate Sponsorship
Commission on AIDS
National Black Leadership $14,000.00 Corporate Sponsorship
Commission on AIDS
National Coalition for $40,000.00 Corporate Sponsorship
Cancer
National Coalition for $2,500.00 Corporate Sponsorship
Cancer
National Comprehensive $25,000.00 Corporate Sponsorship
Cancer Network
National Comprehensive $7,196.32 Educational Grants
Cancer Network
National Comprehensive $50,000.00 Educational Grants
Cancer Network
National Comprehensive $50,000.00 Educational Grants
Cancer Network
National Comprehensive ($1,824.00) Educational Grants
Cancer Network, Inc.
National Family Caregivers $30,000.00 Corporate Sponsorship
Association
National Foundation for $25,000.00 Corporate Sponsorship
Celiac Awareness
National Hispanic Council $30,000.00 Corporate Sponsorship
on Aging
National Kidney Foundation $500.00 Corporate Sponsorship
National Minority Quality $20,000.00 Corporate Sponsorship
forum Inc.
National Minority Quality $5,000.00 Corporate Sponsorship
forum Inc
National Multiple Sclerosis $10,000.00 Corporate Sponsorship
Society
National Multiple Sclerosis $10,000.00 Corporate Sponsorship
Society
National Multiple Sclerosis $225,000.00 Corporate Sponsorship
Society
National Pancreas $5,000.00 Corporate Sponsorship
Foundation
National Pancreas $75,000.00 Charitable Donation
Foundation
National Pancreas $75,000.00 Educational Grants
Foundation
National Pancreas $6,000.00 Corporate Sponsorship
Foundation
National Pancreas $25,000.00 Corporate Sponsorship
Foundation
National Pancreas $200,000.00 Educational Grants
Foundation
National Pancreas $2,000.00 Corporate Sponsorship
Foundation
National Pancreas $1,000.00 Corporate Sponsorship
Foundation
National Pancreas $1,500.00 Corporate Sponsorship
Foundation
National Pancreas $2,500.00 Corporate Sponsorship
Foundation
National Pancreas $2,500.00 Corporate Sponsorship
Foundation
National Pancreas $2,500.00 Corporate Sponsorship
Foundation
National Pancreas $1,500.00 Corporate Sponsorship
Foundation
National Pancreas $6,000.00 Corporate Sponsorship
Foundation
National Pancreas $500.00 Corporate Sponsorship
Foundation
National Patient Advocate $65,000.00 Corporate Sponsorship
Foundation Inc.
National Psoriasis $30,000.00 Patient Support
Foundation
National Psoriasis $15,000.00 Corporate Sponsorship
Foundation
National Psoriasis $25,000.00 Corporate Sponsorship
Foundation
National Psoriasis $40,000.00 Educational Grants
Foundation
National Psoriasis $10,000.00 Corporate Sponsorship
Foundation
National Psoriasis $150,000.00 Corporate Sponsorship
Foundation
National Psoriasis $50,000.00 Corporate Sponsorship
Foundation
National Society for $50,000.00 Corporate Sponsorship
Cutaneous Medicine
National Society for $125,000.00 Corporate Sponsorship
Cutaneous Medicine
National Society for $135,000.00 Corporate Sponsorship
Cutaneous Medicine
Nationwide Childrens Hosp $7,500.00 Corporate Sponsorship
Foundation
Natl Commission On $20,000.00 Educational Grants
Correctional Hlth Care
Natl Committee for Quality $25,000.00 Corporate Sponsorship
Assurance
Natl Comprehensive Cancer $40,000.00 Charitable Donation
Ntwrk
Natl Comprehensive Cancer $25,000.00 Charitable Donation
Ntwrk
Natl Multiple Sclerosis $15,000.00 Corporate Sponsorship
Socty Greater Illinois
Chapter
Nebraska Gut Club $600.00 Corporate Sponsorship
Neuro Challenge Foundation $5,000.00 Corporate Sponsorship
Inc.
Neuropathy Action $2,500.00 Corporate Sponsorship
Foundation
New Jersey Association for $2,500.00 Educational Grants
Biomedical Research
New Mexico Parkinsons $3,000.00 Educational Grants
Disease Coalition
New York Academy of $2,500.00 Educational Grants
Sciences
New York State Rheumatology $15,000.00 Corporate Sponsorship
Society
New York Univ School of $10,000.00 Educational Grants
Medicine
New York Univ School of ($40,000.01) Fellowships or
Medicine Scholarships
New York Univ School of $10,000.00 Educational Grants
Medicine
Nicole Jarvis Md Parkinsons $1,000.00 Corporate Sponsorship
Research Foundation
Nl Communications Inc. $20,000.00 Educational Grants
Nl Communications Inc. $20,000.00 Educational Grants
Nl Communications Inc. $50,000.00 Educational Grants
Nl Communications Inc. $15,000.00 Educational Grants
North American Ctr for $350,000.00 Educational Grants
Continuing Med Education
North American Ctr for $60,000.00 Educational Grants
Continuing Med Education
North American Ctr for $200,000.00 Educational Grants
Continuing Med Education
North American Ctr for $200,000.00 Educational Grants
Continuing Med Education
North American Ctr for $375,000.00 Educational Grants
Continuing Med Education
North American Ctr for $39,500.00 Educational Grants
Continuing Med Education
North American Ctr for $88,000.00 Educational Grants
Continuing Med Education
Northeast Business Group on $1,000.00 Corporate Sponsorship
Health
Northeast Business Group on $5,000.00 Corporate Sponsorship
Health
Northwest Arthritis and $120,000.00 Educational Grants
Osteoporosis Institute
Northwest Arthritis and $30,000.00 Educational Grants
Osteoporosis Institute
Northwest Kidney Centers $2,500.00 Corporate Sponsorship
Northwest Kidney Centers $2,500.00 Corporate Sponsorship
Northwest Parkinson's $4,500.00 Educational Grants
Foundation
Northwest Parkinson's $550.00 Corporate Sponsorship
Foundation
Northwestern University $40,000.00 Fellowships or
Scholarships
Northwestern University $40,000.00 Fellowships or
Scholarships
Northwestern University $3,000.00 Educational Grants
Norton Healthcare $1,200.00 Corporate Sponsorship
Foundation
Novation LLC $25,000.00 Corporate Sponsorship
Nyu Langone Medical Center $3,000.00 Corporate Sponsorship
Ochsner Clinic Foundation $2,000.00 Corporate Sponsorship
Ohio Association of $10,000.00 Corporate Sponsorship
Rheumatology
Ohio Gastroenterology $5,000.00 Corporate Sponsorship
Society
Oklahoma State Urological $10,000.00 Corporate Sponsorship
Association
Oncology Nursing Society $5,000.00 Educational Grants
One Health Research $50,000.00 Charitable Donation
Oregon Health And Science $3,000.00 Corporate Sponsorship
University
Oregon Health And Science $12,000.00 Educational Grants
University
Oregon Health And Science $5,000.00 Educational Grants
University
Oregon Health And Science $3,000.00 Corporate Sponsorship
University
Oregon State University $7,500.00 Corporate Sponsorship
Foundation
Orthopaedic Research $5,000.00 Educational Grants
Society
Pacific Dermatologic $10,000.00 Corporate Sponsorship
Association
Pacific Dermatologic $20,000.00 Corporate Sponsorship
Association
Pancreas Club The $10,000.00 Educational Grants
Pancreatic Cancer Action $3,000.00 Corporate Sponsorship
Network
Pancreatic Cancer Action $3,000.00 Corporate Sponsorship
Network
Pancreatic Cancer Action $200,000.00 Corporate Sponsorship
Network
Park Nicollet Foundation $1,000.00 Corporate Sponsorship
Parkinson Alliance Inc. $500.00 Corporate Sponsorship
Parkinson Alliance Inc. $1,000.00 Corporate Sponsorship
Parkinson And Movement $4,000.00 Corporate Sponsorship
Disorder Alliance
Parkinson Association of $2,500.00 Corporate Sponsorship
Alabama
Parkinson Association of $1,000.00 Corporate Sponsorship
The Carolinas
Parkinson Association of $8,000.00 Patient Support
The Rockies
Parkinson Council $1,000.00 Corporate Sponsorship
Parkinson Foundation of $500.00 Corporate Sponsorship
Oklahoma
Parkinson Foundation of $1,500.00 Corporate Sponsorship
Oklahoma
Parkinson Foundation of The $5,000.00 Educational Grants
National Capital Area
Parkinson Foundation of The $2,500.00 Corporate Sponsorship
National Capital Area
Parkinson Foundation $5,000.00 Corporate Sponsorship
Western Pennsylvania
Parkinson Institute $25,000.00 Corporate Sponsorship
Parkinson Society of $250.00 Corporate Sponsorship
Greenville Area
Parkinson Support Group of $2,000.00 Educational Grants
Upstate NY
Parkinson Voice Project $2,500.00 Corporate Sponsorship
Parkinsons Action Network $1,000.00 Corporate Sponsorship
Foundation
Parkinsons Action Network $1,000.00 Corporate Sponsorship
Foundation
Parkinsons Action Network $2,500.00 Corporate Sponsorship
Foundation
Parkinsons Action Network $5,000.00 Corporate Sponsorship
Foundation
Parkinsons And Movement $2,000.00 Corporate Sponsorship
Disorder Foundation
Parkinson's Disease $50,000.00 Educational Grants
Foundation
Parkinsons Disease Research $1,000.00 Corporate Sponsorship
Society
Parkinson's Resources of $5,000.00 Patient Support
Oregon
Parkinson's Resources of $2,500.00 Corporate Sponsorship
Oregon
Partnership for A Drug-Free $50,000.00 Charitable Donation
America
Patient Access Network $3,000,000.00 Charitable Donation
Foundation
Patient Access Network $5,000,000.00 Charitable Donation
Foundation
Patient Access Network $5,000,000.00 Charitable Donation
Foundation
Patient Access Network $250,000.00 Charitable Donation
Foundation
Patient Access Network $387,500.00 Charitable Donation
Foundation
Patient Access Network $400,000.00 Charitable Donation
Foundation
Patient Access Network $500,000.00 Charitable Donation
Foundation
Patient Empowerment Network $9,000.00 Educational Grants
Patient Empowerment Network $20,000.00 Patient Support
Patient Empowerment Network $20,000.00 Educational Grants
Patient Empowerment Network $35,000.00 Educational Grants
Pediatric Endocrinology $5,000.00 Corporate Sponsorship
Nursing Society
Pediatric Ibd Foundation $15,000.00 Corporate Sponsorship
Pediatric Specialists of $2,500.00 Corporate Sponsorship
Virginia LLC
Pennsylvania Biotechnology $3,000.00 Corporate Sponsorship
Association
Pennsylvania Prostate $5,000.00 Patient Support
Cancer Coalition
Pennsylvania Society of $15,000.00 Corporate Sponsorship
Gastroenterology
Pennsylvania State Univ $135,000.00 Educational Grants
Pennsylvania State Univ $50,000.00 Educational Grants
Pennsylvania State Univ ($3,067.00) Educational Grants
Pennsylvania State Univ $50,000.00 Educational Grants
Pennsylvania State Univ ($9,660.00) Educational Grants
Pennsylvania State Univ ($32,062.00) Educational Grants
Pennsylvania State Univ $75,000.00 Educational Grants
Pennsylvania State Univ $75,000.00 Educational Grants
Philadelphia Dermatological $75,000.00 Corporate Sponsorship
Society
Philadelphia Fight $5,000.00 Corporate Sponsorship
Philadelphia Fight $2,500.00 Corporate Sponsorship
Phmcy Quality Alliance $10,000.00 Educational Grants
Phrmct Care Mgmt Asoc $75,000.00 Corporate Sponsorship
Phrmct Care Mgmt Asoc $60,000.00 Corporate Sponsorship
Phrmct Care Mgmt Asoc $85,000.00 Corporate Sponsorship
Phrmct Care Mgmt Asoc $70,000.00 Corporate Sponsorship
Physicians' Education $40,000.00 Educational Grants
Resource, LLC
Physicians' Education $85,000.00 Educational Grants
Resource, LLC
Pikes Peak Habitat for $2,500.00 Charitable Donation
Humanity
Premier Cares Foundation $5,000.00 Corporate Sponsorship
Premier Cares Foundation $5,000.00 Corporate Sponsorship
President and Fellows of $3,000.00 Educational Grants
Harvard College
President and Fellows of $5,000.00 Educational Grants
Harvard College
Prevent Cancer Foundation $25,000.00 Corporate Sponsorship
Prevent Cancer Foundation $10,000.00 Corporate Sponsorship
Prevent Cancer Foundation $75,000.00 Corporate Sponsorship
Prime Education, Inc. $198,011.00 Educational Grants
Prime Education, Inc. $400,000.00 Educational Grants
Project Inform Inc. $75,000.00 Patient Support
Project Inform Inc. $75,000.00 Charitable Donation
Prostate Cancer Education $2,500.00 Corporate Sponsorship
Council
Prostate Cancer Foundation $4,000.00 Corporate Sponsorship
Chicago
Prostate Cancer Research $25,000.00 Educational Grants
Institute
Prostate Cancer Research $10,000.00 Corporate Sponsorship
Institute
Prostate Health Education $15,000.00 Educational Grants
Network, Inc.
Prostate Health Education $15,000.00 Educational Grants
Network, Inc.
Prostate Health $5,000.00 Corporate Sponsorship
International
Prostate Health $5,000.00 Corporate Sponsorship
International
Protein Society $1,500.00 Educational Grants
Puerto Rico Academy of $5,000.00 Corporate Sponsorship
Family Physician
Puerto Rico Community $5,000.00 Educational Grants
Network for Clinical
Research On Aids Inc.
Puerto Rico $20,000.00 Educational Grants
Gastroenterology
Association
Puerto Rico $10,000.00 Educational Grants
Gastroenterology
Association
Purdue University $125,000.00 Educational Grants
Purdue University $200,000.00 Educational Grants
Purdue University $300,000.00 Educational Grants
PVI Peerview Institute for $100,000.00 Educational Grants
Medical Education
PVI Peerview Institute for ($207.00) Educational Grants
Medical Education
Quinsigamond Community $500.00 Charitable Donation
College
Rectors And Visitors of The $3,000.00 Educational Grants
University of Virginia
Regents of The University $40,000.00 Fellowships or
of California Scholarships
Regents of The University $25,000.00 Educational Grants
of California
Regents of The University $5,000.00 Educational Grants
of California
Regents of The University $3,500.00 Educational Grants
of California
Regents of The University $5,000.00 Educational Grants
of California
Regents of The University $4,000.00 Educational Grants
of California
Regents of The University $10,000.00 Educational Grants
of California
Regents of The University $2,000.00 Educational Grants
of Michigan
Regents of The University $10,000.00 Educational Grants
of Michigan
Regents of The University $10,000.00 Corporate Sponsorship
of Michigan
Regents University of $40,000.00 Fellowships or
California Los Angeles Scholarships
Regents University of $10,000.00 Educational Grants
California Los Angeles
Regents University of $40,000.00 Fellowships or
California Los Angeles Scholarships
Regents University of $5,000.00 Educational Grants
California Los Angeles
Respiratory Health $3,500.00 Corporate Sponsorship
Association of
Metropolitan Chicago
Respiratory Health $4,050.00 Corporate Sponsorship
Association of
Metropolitan Chicago
Rheumatism Society of The $15,000.00 Corporate Sponsorship
District of Columbia
Rheumatism Society of The $5,000.00 Corporate Sponsorship
District of Columbia
Rheumatology Alliance of $25,000.00 Corporate Sponsorship
Louisiana
Rheumatology Nurses Society $29,700.00 Corporate Sponsorship
Rhode Island Pharmacy $600.00 Corporate Sponsorship
Association
Riverside Medical Clinic $7,500.00 Patient Support
Charitable Foundation
Robert Michael Educational $236,065.00 Educational Grants
Institute LLC
Robert Michael Educational $90,000.00 Educational Grants
Institute LLC
Robert Michael Educational $275,000.00 Educational Grants
Institute LLC
Robert Michael Educational $90,000.00 Educational Grants
Institute LLC
Rock Hlth Inc. $15,000.00 Corporate Sponsorship
Rush University Medical $15,000.00 Educational Grants
Center
Rush University Medical $5,000.00 Educational Grants
Center
Rutgers University $1,250.00 Charitable Donation
Foundation
Rutgers, The State $60,000.00 Educational Grants
University of New Jersey
Rutgers, The State $25,000.00 Educational Grants
University of New Jersey
Rutgers, The State $60,000.00 Educational Grants
University of New Jersey
Rutgers, The State $25,000.00 Educational Grants
University of New Jersey
Safety Pharmacology Society $5,000.00 Educational Grants
Saint Francis Hospital And $15,000.00 Educational Grants
Medical Center
Saint Louis University $50,000.00 Corporate Sponsorship
Hospital
Scientists Center for $2,500.00 Educational Grants
Animal Welfare
Scott And White Healthcare $300.00 Corporate Sponsorship
Foundation
Scripps Health $75,000.00 Educational Grants
Scripps Research Institute $2,000.00 Educational Grants
Scripps Research Institute $2,000.00 Educational Grants
Sexual Medicine Society of $25,000.00 Educational Grants
North America
Sexual Medicine Society of $225,000.00 Corporate Sponsorship
North America
Shanti Project Inc. $20,000.00 Patient Support
Smart Ride The $25,000.00
Corporate
Sponsorship
Sociedad Dermatologica De $20,000.00 Corporate Sponsorship
Puerto Rico
Sociedad Dermatologica De $10,000.00 Corporate Sponsorship
Puerto Rico
Sociedad Endocrinologia $10,000.00 Corporate Sponsorship
Metabolismo Y Diabetes Del
Sur
Sociedad Puertorriquena De $15,000.00 Corporate Sponsorship
Endocronologia Y
Diabetologia
Sociedad Puertorriquena De $10,000.00 Corporate Sponsorship
Endocronologia Y
Diabetologia
Sociedad Puertorriquena De $5,000.00 Corporate Sponsorship
Pediatria
Sociedad Puertorriquena De $5,000.00 Corporate Sponsorship
Pediatria
Sociedad Puertorriquena De $5,000.00 Corporate Sponsorship
Pediatria
Society for Investigative $20,000.00 Educational Grants
Dermatology
Society for Leukocyte $1,500.00 Educational Grants
Biology
Society for Mucosal $16,398.00 Corporate Sponsorship
Immunology
Society for Neuroscience ($2,500.00) Educational Grants
Society for Neuroscience $1,000.00 Educational Grants
Society for Neuroscience $2,000.00 Educational Grants
Society for Translational $15,000.00 Educational Grants
Oncology
Society of Dermatology $20,000.00 Corporate Sponsorship
Physician Assistants
Society of Dermatology $45,000.00 Corporate Sponsorship
Physician Assistants
Society of Dermatology $30,000.00 Corporate Sponsorship
Physician Assistants
Society of Gastroenterology $25,000.00 Educational Grants
Nurses & Associates
Society of Neuro Oncology $16,000.00 Corporate Sponsorship
Society of Nuclear Medicine $4,000.00 Corporate Sponsorship
Society of Toxicologic $15,000.00 Corporate Sponsorship
Pathology
Socty of Toxicology $2,000.00 Fellowships or
Scholarships
Somos El Futuro, Inc. $5,000.00 Corporate Sponsorship
South Carolina Alliance of $5,000.00 Corporate Sponsorship
Health Plans
Southern Illinois ($711.12) Fellowships or
University Scholarships
Spondylitis Association of $40,000.00 Educational Grants
America
Spondylitis Association of $19,000.00 Educational Grants
America
Spondyloarthritis Research $25,000.00 Corporate Sponsorship
And Treatment Network
Spartan
St. Christophers Foundation $5,000.00 Corporate Sponsorship
for Children
St. Lukes Regional Medical $10,000.00 Corporate Sponsorship
Center
St. Luke's-Roosevelt $5,000.00 Educational Grants
Hospital Center
Take A Breather Foundation $10,000.00 Corporate Sponsorship
Tampa Bay Latin American $3,000.00 Corporate Sponsorship
Medical Society
Team Fox North Texas $500.00 Corporate Sponsorship
Tennessee Rheumatology $7,500.00 Corporate Sponsorship
Society
Teratology Society $2,000.00 Educational Grants
Test Positive Awareness $30,000.00 Corporate Sponsorship
Network
Texas Liver Inst The $30,000.00 Corporate Sponsorship
Texas Osteopathic Medical $1,000.00 Corporate Sponsorship
Association
Texas Urological Society $6,000.00 Corporate Sponsorship
Thomas Jefferson University $500,000.00 Educational Grants
Medical College
Thomas Jefferson University $10,000.00 Educational Grants
Medical College
Thomas Jefferson University $2,500.00 Corporate Sponsorship
Medical College
Torrington Area Parkinsons $500.00 Corporate Sponsorship
Support Group
Trustees of The University $40,000.00 Educational Grants
of Pennsylvania
Twine Clinical Consulting $411,950.00 Educational Grants
LLC
Ultimate Med Academy Med ($3,550.00) Educational Grants
Learning Grp LLC
United States Adult Cystic $7,500.00 Educational Grants
Fibrosis Association
Univ Hlth Srvc At Stony $20,000.00 Educational Grants
Point Inc.
Univ of Colorado Denver $2,500.00 Educational Grants
School of Medicine
Universidad Central Del $10,000.00 Educational Grants
Caribe, Inc.
University At Buffalo $1,250.00 Charitable Donation
Foundation Inc.
University of Alabama At $40,000.00 Fellowships or
Birmingham Scholarships
University of California-- $10,000.00 Educational Grants
San Francisco
University of California $30,000.00 Educational Grants
Berkeley
University of California $5,000.00 Educational Grants
Irvine
University of Chicago ($75,000.00) Educational Grants
University of Chicago $65,000.00 Educational Grants
University of Chicago $5,000.00 Educational Grants
University of Chicago $7,000.00 Educational Grants
University of Chicago $157,000.00 Educational Grants
University of Chicago ($4,249.00) Educational Grants
University of Chicago ($3,746.25) Educational Grants
University of Chicago $1,000.00 Corporate Sponsorship
University of Chicago $400,000.00 Educational Grants
University of Chicago $1,500.00 Educational Grants
University of Chicago ($13,195.00) Educational Grants
University of Cincinnati $60,000.00 Educational Grants
University of Cincinnati ($25,000.00) Educational Grants
University of Cincinnati ($50,000.00) Educational Grants
University of Cincinnati ($25,000.00) Educational Grants
University of Cincinnati $2,081,222.00 Educational Grants
University of Cincinnati $5,000.00 Educational Grants
University of Cincinnati $2,000.00 Educational Grants
University of Cincinnati $30,000.00 Educational Grants
University of Cincinnati $8,000.00 Educational Grants
University of Cincinnati $75,000.00 Educational Grants
University of Connecticut $40,000.00 Fellowships or
Scholarships
University of Connecticut $12,000.00 Fellowships or
Scholarships
University of Florida $125,875.00 Educational Grants
University of Florida ($5,709.00) Educational Grants
University of Florida $1,500.00 Educational Grants
Foundation Inc.
University of Florida $40,000.00 Fellowships or
Foundation Inc. Scholarships
University of Illinois $12,000.00 Corporate Sponsorship
University of Illinois $12,000.00 Corporate Sponsorship
University of Louisville $15,000.00 Educational Grants
Research Foundation, Inc.
University of Maryland $5,500.00 Educational Grants
University of Maryland $10,000.00 Educational Grants
Baltimore
University of Maryland $1,250.00 Charitable Donation
Baltimore Foundation
University of Massachusetts $2,500.00 Charitable Donation
Med School
University of Miami $25,000.00 Educational Grants
University of Miami $10,000.00 Educational Grants
University of Miami $50,000.00 Corporate Sponsorship
Department of Dermatology
University of Minnesota $1,250.00 Charitable Donation
University of Minnesota $1,250.00 Charitable Donation
University of Minnesota $1,250.00 Charitable Donation
University of Missouri Dept $500.00 Corporate Sponsorship
of Neurology
University of Nebraska Med $25,000.00 Educational Grants
Ctr
University of Nebraska Med $10,000.00 Educational Grants
Ctr
University of Nebraska Med $50,000.00 Educational Grants
Ctr
University of Nebraska Med $5,000.00 Educational Grants
Ctr
University of North $40,000.00 Fellowships or
Carolina At Chapel Hill Scholarships
University of North $2,500.00 Educational Grants
Carolina At Chapel Hill
University of Pittsburgh $10,000.00 Educational Grants
University of Pittsburgh $10,000.00 Educational Grants
University of Pittsburgh $2,250.00 Educational Grants
University of Pittsburgh $2,000.00 Educational Grants
University of Pittsburgh $20,000.00 Educational Grants
University of Rochester, $40,000.00 Fellowships or
Center for Experiential Scholarships
Learning
University of South Florida $50,000.00 Educational Grants
Hlth Professions
Conferencing Corporation
University of South Florida $10,000.00 Corporate Sponsorship
Hlth Professions
Conferencing Corporation
University of South Florida $10,000.00 Corporate Sponsorship
Hlth Professions
Conferencing Corporation
University of Southern $1,500.00 Educational Grants
California
University of Southern ($17,026.00) Educational Grants
California
University of Southern ($2,974.00) Educational Grants
California
University of Southern $71,800.00 Fellowships or
California Scholarships
University of Texas Hlth $2,500.00 Educational Grants
Scnc Ctr At San Antonio
University of Texas Hlth $135,000.00 Corporate Sponsorship
Scnc Ctr At San Antonio
University of Texas Hlth $50,000.00 Educational Grants
Scnc Ctr At San Antonio
University of Texas ($100,000.00) Educational Grants
Southwestern Med Ctr
University of The $1,500.00 Corporate Sponsorship
Philippines Med Alumni
Socty In America Nevada
University of Toledo $2,000.00 Educational Grants
University of Utah $40,000.00 Fellowships or
Scholarships
Urological Association of $10,000.00 Corporate Sponsorship
Physician Assistants
Urological Association of $25,000.00 Corporate Sponsorship
Physician Assistants
Urology Center of Colorado $7,500.00 Corporate Sponsorship
Foundation
US Pain Foundation, Inc. $25,000.00 Corporate Sponsorship
US Pain Foundation, Inc. $30,000.00 Corporate Sponsorship
US Pain Foundation, Inc. $80,000.00 Corporate Sponsorship
Us Too International Inc. $5,000.00 Corporate Sponsorship
Us Too International Inc. $5,000.00 Corporate Sponsorship
Us Too International Inc. $25,000.00 Corporate Sponsorship
USMD Health System $10,000.00 Corporate Sponsorship
Van Andel Research $5,000.00 Educational Grants
Institute
Vanderbilt University Med $25,000.00 Fellowships or
Ctr Scholarships
Vanderbilt University $2,500.00 Educational Grants
Medical Center
Vindico Medical Education $146,000.00 Educational Grants
LLC
Vindico Medical Education $500,000.00 Educational Grants
LLC
Vindico Medical Education $35,000.00 Educational Grants
LLC
Virginia Commonwealth Univ $1,250.00 Charitable Donation
School of Medicine
Virginia Commonwealth Univ $1,000.00 Corporate Sponsorship
School of Medicine
Wall Las Memorias $25,000.00 Corporate Sponsorship
Washington State Urology $7,500.00 Corporate Sponsorship
Society
Washington University $5,000.00 Educational Grants
Washington University ($1,248.95) Fellowships or
Scholarships
WC Research Inc. $8,500.00 Corporate Sponsorship
Webmd Global LLC $430,600.00 Educational Grants
Webmd Global LLC $1,165,500.00 Educational Grants
Well Project Inc. $20,000.00 Charitable Donation
Western States Phmcy $10,000.00 Corporate Sponsorship
Conference for Phmcy
Residents Fellowships &
Preceptors
Wheaton Franciscan $500.00 Corporate Sponsorship
Healthcare Foundation
Wisconsin Academy of Phys $4,000.00 Corporate Sponsorship
Assistants
Wisconsin Collaborative for $2,500.00 Corporate Sponsorship
Healthcare Quality
Wisconsin Dairyland Chapter $1,910.00 Corporate Sponsorship
of HIMSS
Wisconsin Medical Society $450.00 Corporate Sponsorship
Wisconsin Rheumatology $5,000.00 Corporate Sponsorship
Association
Wishes And Dreams for $2,500.00 Corporate Sponsorship
Cystic Fibrosis
Wj Weiser And Associates $20,000.00 Corporate Sponsorship
Wj Weiser And Associates $10,000.00 Corporate Sponsorship
World Parkinson Coalition $15,000.00 Educational Grants
Inc.
World Parkinson Coalition $207,000.00 Corporate Sponsorship
Inc.
Yale University ($10,000.00) Educational Grants
Yale University $25,000.00 Educational Grants
Yale University $2,500.00 Educational Grants
Young Survival Coalition $30,000.00 Corporate Sponsorship
Zebrafish Disease Models $10,000.00 Educational Grants
Society
Zero The End of Prostate $10,000.00 Corporate Sponsorship
Cancer
Zero The End of Prostate $250,000.00 Corporate Sponsorship
Cancer
Zero The End of Prostate $15,000.00 Corporate Sponsorship
Cancer
Zero The End of Prostate $2,500.00 Corporate Sponsorship
Cancer
------------------------------------------------------------------------
Grants Donations Report--2016
(Parentheses represent refunds of previously disclosed payments)
Report as of 3/31/2017
------------------------------------------------------------------------
Recipient Payment Amount Purpose
------------------------------------------------------------------------
50 Hoops $10,000.00 Educational Grants
A And R Educational Grp LLC $4,000.00 Corporate Sponsorship
A Runners Love $5,000.00 Corporate Sponsorship
AAALAC International $5,000.00 Educational Grants
Academy of Managed Care $25,000.00 Corporate Sponsorship
Phmcy
Academy of Managed Care $25,000.00 Corporate Sponsorship
Phmcy
Academy of Managed Care $18,000.00 Corporate Sponsorship
Phmcy
Academy of Managed Care $40,000.00 Corporate Sponsorship
Phmcy
Academy of Managed Care $50,000.00 Corporate Sponsorship
Phmcy
Advances in Cosmetic And $75,000.00 Corporate Sponsorship
Med Dermatology Inc.
Advances in Cosmetic And $75,000.00 Corporate Sponsorship
Med Dermatology Inc.
Advances in Cosmetic And $100,000.00 Corporate Sponsorship
Med Dermatology Inc.
Adventist Hlth System-- $15,000.00 Corporate Sponsorship
Sunbelt Inc.
Adventist Hlth System-- $15,000.00 Corporate Sponsorship
Sunbelt Inc.
Advocate Hlth And Hospitals $2,000.00 Educational Grants
Corporation
Advocate Hlth And Hospitals $2,500.00 Educational Grants
Corporation
Aesthetic Dermatology $25,000.00 Corporate Sponsorship
Symposia
AIDS Action Committee $5,000.00 Corporate Sponsorship
Aids Drug Assistance $5,000.00 Charitable Donations
Programs Advocacy Asoc
AIDS Foundation of Chicago $7,500.00 Corporate Sponsorship
AIDS Foundation of Chicago $7,500.00 Corporate Sponsorship
AIDS Foundation of Chicago ($7,500.00) Corporate Sponsorship
AIDS Foundation of Chicago $75,000.00 Charitable Donations
AIDS Institute $50,000.00 Corporate Sponsorship
AIDS Institute $50,000.00 Corporate Sponsorship
AIDS Institute $30,000.00 Corporate Sponsorship
AIDS Institute $75,000.00 Corporate Sponsorship
Alabama Asoc of Hlth Plans $3,000.00 Corporate Sponsorship
Alabama Dermatology Socty $35,000.00 Corporate Sponsorship
The
Albany Med Colg $5,000.00 Educational Grants
Albany Med Colg $10,000.00 Corporate Sponsorship
Albert Einstein Colg of $10,000.00 Educational Grants
Medicine Div of
Dermatology Attending Asoc
Albert Einstein College of $20,000.00 Educational Grants
Medicine of Yeshiva
University
Albert Einstein College of $10,000.00 Educational Grants
Medicine of Yeshiva
University
Albert Einstein College of $5,000.00 Educational Grants
Medicine of Yeshiva
University
Albert Einstein College of $5,000.00 Educational Grants
Medicine of Yeshiva
University
Albert Einstein Hlthcr $5,750.00 Corporate Sponsorship
Ntwrk
Alliance for Aging Research $30,000.00 Corporate Sponsorship
Alliance for Aging Research $25,000.00 Corporate Sponsorship
Alzheimers Asoc $15,000.00 Educational Grants
Alzheimers Asoc $2,500.00 Corporate Sponsorship
American Academy of $40,000.00 Charitable Donations
Dermatology
American Academy of $20,000.00 Corporate Sponsorship
Dermatology
American Academy of $13,550.00 Charitable Donations
Dermatology
American Academy of $40,000.00 Educational Grants
Dermatology
American Academy of ($60,000.00) Educational Grants
Dermatology
American Academy of $250,000.00 Corporate Sponsorship
Dermatology
American Academy of $50,000.00 Educational Grants
Dermatology
American Academy of $10,000.00 Charitable Donations
Dermatology
American Academy of Family $15,500.00 Educational Grants
Phys
American Academy of $9,290.00 Educational Grants
Neurology Institute
American Academy of $80,000.00 Corporate Sponsorship
Neurology Institute
American Academy of $20,720.70 Corporate Sponsorship
Neurology Institute
American Academy of $24,700.00 Educational Grants
Neurology Institute
American Academy of $10,010.00 Corporate Sponsorship
Neurology Institute
American Academy of $50,000.00 Fellowships and
Neurology Institute Scholarships
American Academy of $2,700.00 Corporate Sponsorship
Neurology Institute
American Academy of $22,616.70 Corporate Sponsorship
Neurology Institute
American Academy of $6,500.00 Corporate Sponsorship
Ophthalmology AAO
American Academy of $15,000.00 Corporate Sponsorship
Ophthalmology AAO
American Academy of Phys $10,000.00 Educational Grants
Assistants
American Assoc for Cancer $50,000.00 Educational Grants
Research
American Assoc for Cancer $20,000.00 Fellowships and
Research Scholarships
American Assoc for Cancer $10,000.00 Educational Grants
Research
American Assoc for Cancer $50,000.00 Educational Grants
Research
American Assoc for Cancer $10,000.00 Educational Grants
Research
American Assoc for Cancer $25,000.00 Charitable Donations
Research
American Assoc for Cancer $20,000.00 Educational Grants
Research
American Assoc for Cancer $10,000.00 Educational Grants
Research
American Assoc for Cancer $10,000.00 Educational Grants
Research
American Assoc for Cancer $15,000.00 Educational Grants
Research
American Assoc for Cancer $15,000.00 Educational Grants
Research
American Assoc for Cancer $15,000.00 Educational Grants
Research
American Assoc for Cancer $50,000.00 Educational Grants
Research
American Assoc for Cancer $15,000.00 Educational Grants
Research
American Assoc for Cancer $10,000.00 Educational Grants
Research
American Assoc for Lab $20,000.00 Charitable Donations
Animal Scnc Fdtn
American Assoc for The $85,000.00 Corporate Sponsorship
Study of Liver Diseases
American Assoc of Clinical $15,000.00 Educational Grants
Endocrinologists New
Jersey Chapter
American Assoc of Clinical $25,000.00 Educational Grants
Endocrinologists New
Jersey Chapter
American Assoc of Clinical $328,000.00 Corporate Sponsorship
Endocrinologists New
Jersey Chapter
American Assoc of Phys of $10,000.00 Corporate Sponsorship
Indian Origin Arkansas
American Asosc of Phys of $5,000.00 Corporate Sponsorship
Indian Origin Arkansas
American Association for $500,000.00 Charitable Donations
The Study of Liver
Diseases (AASLD
Foundation)
American Association of $50,000.00 Corporate Sponsorship
Pharmaceutical Scientists
American Brain Tumor Asoc $7,500.00 Corporate Sponsorship
American Brain Tumor Asoc $5,000.00 Corporate Sponsorship
American Brain Tumor Asoc $5,000.00 Corporate Sponsorship
American Brain Tumor Asoc $10,000.00 Educational Grants
American Brain Tumor Asoc $7,000.00 Educational Grants
American Cancer Society $5,000.00 Corporate Sponsorship
American Cancer Society $2,500.00 Corporate Sponsorship
Cancer Action Network
American Cancer Society $25,000.00 Corporate Sponsorship
Cancer Action Network
American Cancer Society $2,500.00 Corporate Sponsorship
Cancer Action Network
American Cancer Society $2,500.00 Corporate Sponsorship
Cancer Action Network
American Cancer Society $2,500.00 Corporate Sponsorship
Cancer Action Network
American Cancer Society $5,000.00 Corporate Sponsorship
Cancer Action Network
American Cancer Society $3,500.00 Corporate Sponsorship
Cancer Action Network
American Cancer Society $1,000.00 Corporate Sponsorship
Cancer Action Network
American Cancer Society $7,000.00 Corporate Sponsorship
Cancer Action Network
American Cancer Society $5,000.00 Corporate Sponsorship
Cancer Action Network
American Chem Socty $2,500.00 Educational Grants
American Chem Socty $2,500.00 Educational Grants
American Chem Socty $2,500.00 Educational Grants
American Chem Socty $1,000.00 Educational Grants
American Childhood Cancer $2,500.00 Corporate Sponsorship
Organization
American Colg of Gastro $100,000.00 Corporate Sponsorship
American Colg of Gastro $15,640.00 Corporate Sponsorship
American Colg of Gastro $15,640.00 Corporate Sponsorship
American Colg of Gastro $15,640.00 Corporate Sponsorship
American Colg of Gastro $41,400.00 Corporate Sponsorship
American Colg of Gastro $10,000.00 Educational Grants
American Colg of Gastro $500,000.00 Corporate Sponsorship
American Colg of Gastro $20,000.00 Corporate Sponsorship
American Colg of Lab Animal $30,000.00 Charitable Donations
Medicine
American Colg of $30,000.00 Corporate Sponsorship
Obstetricians And
Gynecologists
American Colg of $32,500.00 Corporate Sponsorship
Obstetricians And
Gynecologists
American Colg of $2,500.00 Corporate Sponsorship
Obstetricians And
Gynecologists District 1
American Colg of Rheumlgy $2,000,000.00 Corporate Sponsorship
Research And Education
Fdtn
American Colg of Rheumlgy $1,500,000.00 Corporate Sponsorship
Research And Education
Fdtn
American Colg of Toxicology $1,000.00 Corporate Sponsorship
American College of $50,000.00 Educational Grants
Rheumatology
American College of $75,000.00 Corporate Sponsorship
Rheumatology
American College of $95,000.00 Fellowships and
Rheumatology Scholarships
American College of $50,000.00 Educational Grants
Rheumatology
American College of $35,000.00 Educational Grants
Rheumatology
American College of $25,000.00 Educational Grants
Rheumatology
American Drug Utilization $20,000.00 Corporate Sponsorship
Review Society Adurs
American Drug Utilization $6,666.67 Corporate Sponsorship
Review Society Adurs
American Drug Utilization $6,666.67 Corporate Sponsorship
Review Society Adurs
American Drug Utilization $6,666.66 Corporate Sponsorship
Review Society Adurs
American Federation for Med $2,000.00 Educational Grants
Research
American Gastro Asoc Inst $50,000.00 Educational Grants
American Gastro Asoc Inst $250,000.00 Educational Grants
American Gastro Asoc Inst $33,300.00 Corporate Sponsorship
American Kdny Fund $3,000.00 Corporate Sponsorship
American Legion National $10,000.00 Corporate Sponsorship
American Legion National $10,000.00 Corporate Sponsorship
Headquarters
American Liver Fdtn $2,500.00 Corporate Sponsorship
American Liver Fdtn $246,500.00 Corporate Sponsorship
American Liver Fdtn $10,000.00 Corporate Sponsorship
American Liver Fdtn $2,500.00 Corporate Sponsorship
American Liver Fdtn $2,500.00 Corporate Sponsorship
American Liver Fdtn $5,000.00 Educational Grants
American Liver Foundation $35,000.00 Corporate Sponsorship
American Med Asoc Fdtn $20,000.00 Corporate Sponsorship
American Med Grp Asoc $6,000.00 Corporate Sponsorship
American Military Partner $5,000.00 Corporate Sponsorship
Association
American Neuro Asoc $5,000.00 Educational Grants
American Neuro Asoc $25,000.00 Educational Grants
American Osteopathic Colg $15,000.00 Corporate Sponsorship
of Dermatology
American Pancreatic Asoc $75,000.00 Educational Grants
American Pancreatic Asoc $15,000.00 Patient Support
American Pancreatic Asoc $50,000.00 Corporate Sponsorship
American Parkinson Disease $5,000.00 Corporate Sponsorship
Association Arizona
Chapter
American Parkinson Disease $500.00 Corporate Sponsorship
Association Arizona
Chapter
American Parkinson Disease $1,000.00 Corporate Sponsorship
Association Arizona
Chapter
American Parkinson Disease $3,500.00 Corporate Sponsorship
Association Arizona
Chapter
American Parkinson Disease $500.00 Corporate Sponsorship
Association Arizona
Chapter
American Parkinson Disease $1,500.00 Corporate Sponsorship
Association Arizona
Chapter
American Parkinson Disease $2,500.00 Corporate Sponsorship
Association Arizona
Chapter
American Parkinson Disease $500.00 Corporate Sponsorship
Association Arizona
Chapter
American Parkinson Disease $5,000.00 Corporate Sponsorship
Association Arizona
Chapter
American Parkinson Disease $3,000.00 Corporate Sponsorship
Association Arizona
Chapter
American Parkinson Disease $1,000.00 Corporate Sponsorship
Association Arizona
Chapter
American Parkinson Disease $55,000.00 Corporate Sponsorship
Association Arizona
Chapter
American Pharmacists Asoc $3,000.00 Corporate Sponsorship
American Pharmacists Asoc $13,500.00 Corporate Sponsorship
American Red Cross of $10,000.00 Charitable Donations
Greater Chicago
American Red Cross of $50,000.00 Charitable Donations
Greater Chicago
American Society for $1,500.00 Educational Grants
Experimental
Neurotherapeutics
American Socty for Matrix $1,000.00 Educational Grants
Biology
American Socty for Mens $10,000.00 Corporate Sponsorship
Hlth The
American Socty for $1,500.00 Educational Grants
Pharmacology and
Experimental Thrpt The
Aspet
American Socty for $5,750.00 Corporate Sponsorship
Reproductive Medicine
American Socty for $25,000.00 Educational Grants
Reproductive Medicine
American Socty for $50,000.00 Corporate Sponsorship
Reproductive Medicine
American Socty of $15,000.00 Corporate Sponsorship
Anesthesiologists
American Socty of Clinical $20,000.00 Educational Grants
Oncology
American Socty of $52,500.00 Corporate Sponsorship
Hematology
American Socty of $10,000.00 Educational Grants
Hematology
American Socty of $40,000.00 Educational Grants
Hematology
American Socty of $60,000.00 Corporate Sponsorship
Hematology
American Socty of $10,000.00 Charitable Donations
Hematology
American Socty of $50,000.00 Educational Grants
Hematology
American Socty of Nphro $40,000.00 Corporate Sponsorship
American Socty of Nphro $8,700.00 Corporate Sponsorship
American Thyroid Asoc Inc. $35,000.00 Educational Grants
American Thyroid Asoc Inc. $10,000.00 Corporate Sponsorship
American Urological Asoc. $50,000.00 Educational Grants
Education and Research
Inc.
American Urological Asoc. $40,000.00 Corporate Sponsorship
Education and Research
Inc.
American Urological Asoc. $25,000.00 Corporate Sponsorship
Education and Research
Inc.
American Urological Asoc. $50,000.00 Charitable Donations
Education and Research
Inc.
American Urological Asoc. $20,000.00 Educational Grants
Education and Research
Inc.
American Urological Asoc. $75,000.00 Educational Grants
Education and Research
Inc.
American Urological Asoc. $5,000.00 Corporate Sponsorship
Fdtn
American Urological Asoc $10,000.00 Charitable Donations
Fdtn
American Urological Asoc $6,000.00 Corporate Sponsorship
Inc. North Ctrl Section
American Urological Asoc $6,000.00 Corporate Sponsorship
Inc. Southeast Section
American Urological Asoc $10,000.00 Corporate Sponsorship
Inc. Western Section
American Urological Asoc $6,000.00 Corporate Sponsorship
South Ctrl Section
Americans for Med Progress $100,000.00 Charitable Donations
Americares Foundation, Inc. $10,000.00 Charitable Donations
Americares Foundation, Inc. $25,000.00 Charitable Donations
Angel Fdtn $5,000.00 Corporate Sponsorship
Annenberg Center for Health $750,000.00 Educational Grants
Sciences at Eisenhower
Annenberg Center for Health $90,000.00 Educational Grants
Sciences at Eisenhower
Annenberg Center for Health $65,000.00 Educational Grants
Sciences at Eisenhower
Annenberg Center for Health $25,000.00 Educational Grants
Sciences at Eisenhower
Annenberg Center for Health $85,000.00 Educational Grants
Sciences at Eisenhower
Annenberg Center for Health $350,000.00 Educational Grants
Sciences at Eisenhower
Annenberg Center for Health $75,000.00 Educational Grants
Sciences at Eisenhower
Annenberg Center for Health $500,000.00 Educational Grants
Sciences at Eisenhower
Annenberg Center for Health $25,000.00 Educational Grants
Sciences at Eisenhower
Annenberg Center for Health $500,000.00 Educational Grants
Sciences at Eisenhower
Annenberg Center for Health $200,000.00 Educational Grants
Sciences at Eisenhower
Annenberg Center for Health $75,000.00 Educational Grants
Sciences at Eisenhower
Arkansas State Rheumlgy $10,000.00 Corporate Sponsorship
Asoc
Arthritis Foundation $1,000.00 Educational Grants
Arthritis Foundation $35,000.00 Corporate Sponsorship
Arthritis Foundation $35,000.00 Educational Grants
Arthritis Foundation $22,500.00 Educational Grants
Arthritis Foundation $30,000.00 Corporate Sponsorship
Arthritis Foundation $20,000.00 Corporate Sponsorship
Arthritis Foundation $30,000.00 Corporate Sponsorship
Arthritis Foundation $10,000.00 Corporate Sponsorship
Arthritis Foundation $15,000.00 Educational Grants
Arthritis Foundation $1,500.00 Corporate Sponsorship
Arthritis Foundation $25,000.00 Corporate Sponsorship
Arthritis Foundation $2,500.00 Corporate Sponsorship
Arthritis Foundation $5,000.00 Corporate Sponsorship
Arthritis Foundation $10,000.00 Corporate Sponsorship
Arthritis Foundation $25,000.00 Corporate Sponsorship
Arthritis Foundation $2,500.00 Corporate Sponsorship
Arthritis Foundation $20,000.00 Corporate Sponsorship
Arthritis Foundation $40,000.00 Corporate Sponsorship
Arthritis Foundation $30,000.00 Corporate Sponsorship
Arthritis Foundation $35,000.00 Corporate Sponsorship
Arthritis Foundation $25,000.00 Corporate Sponsorship
Arthritis Foundation $300,000.00 Corporate Sponsorship
Arthritis Foundation $259,000.00 Corporate Sponsorship
Arthritis Foundation $250,000.00 Corporate Sponsorship
Arthritis Foundation $300,000.00 Corporate Sponsorship
Arthritis Foundation $175,000.00 Corporate Sponsorship
Arthritis Patient Srvc $10,000.00 Charitable Donations
Arthritis Patient Srvc $15,000.00 Educational Grants
Arthritis Patient Srvc $40,000.00 Educational Grants
Asco Cancer Fdtn $100,000.00 Charitable Donations
Asco Cancer Fdtn $60,000.00 Fellowships and
Scholarships
Asco Cancer Fdtn $30,500.00 Corporate Sponsorship
Asco Cancer Fdtn $28,000.00 Educational Grants
Asco Cancer Fdtn $28,000.00 Educational Grants
ASCO Cancer Fdtn $28,000.00 Educational Grants
ASCO Cancer Fdtn $5,000.00 Educational Grants
ASCO Cancer Fdtn $25,000.00 Educational Grants
Asoc De Enfermeria $6,000.00 Corporate Sponsorship
Oncologica Y Hematologica
De Puerto Rico Inc.
Asoc De Reumatologos De $30,000.00 Corporate Sponsorship
Puerto Rico
Asoc Latina De Asistencia Y $1,000.00 Educational Grants
Prevencion Del Cancer De
Mama
Asoc of Univ Tech Managers $5,000.00 Corporate Sponsorship
Asociacion De Salud Publica $5,000.00 Educational Grants
De Puerto Rico
Aspen Cancer Conference $7,500.00 Educational Grants
Inc.
Association of Women in $40,000.00 Corporate Sponsorship
Rheumatology
Association of Women in $40,000.00 Corporate Sponsorship
Rheumatology
Atlanta Dermatological Asoc $10,000.00 Corporate Sponsorship
Autoimmune Advocacy $2,500.00 Corporate Sponsorship
Alliance
Baehr Challenge Ltd $2,500.00 Corporate Sponsorship
Balm In Gilead Inc. $75,000.00 Corporate Sponsorship
Baylor Colg Medicine Inf $100,000.00 Fellowships and
Dis Scholarships
Baylor Colg Medicine Inf $3,500.00 Educational Grants
Dis
Baylor Hlth Care System $50,000.00 Fellowships and
Fdtn Scholarships
Baylor Scott And White $20,000.00 Educational Grants
Health
Baylor Univ Med Ctr $25,000.00 Educational Grants
Baylor Univ Med Ctr $25,000.00 Educational Grants
Baylor Univ Med Ctr $20,000.00 Educational Grants
Beth Israel Deaconess Med $40,000.00 Fellowships and
Ctr Scholarships
Beth Israel Deaconess Med $30,000.00 Fellowships and
Ctr Scholarships
Beth Israel Deaconess Med $27,000.00 Fellowships and
Ctr Scholarships
Beth Israel Deaconess Med $7,500.00 Educational Grants
Ctr
Beth Israel Deaconess Med ($592.19) Fellowships and
Ctr Scholarships
Bexar County Physician $2,500.00 Corporate Sponsorship
Assistant Society
Bioconnections LLC $30,000.00 Corporate Sponsorship
Black Hills Arthritis Asoc $2,200.00 Educational Grants
Boomer Esiason Fdtn $25,000.00 Corporate Sponsorship
Boomer Esiason Fdtn $400,000.00 Corporate Sponsorship
Borland Groover Fdtn $500.00 Corporate Sponsorship
Boston Center for $5,000.00 Corporate Sponsorship
Independent Living
Boston Socty Inc. $4,000.00 Corporate Sponsorship
Boston Socty Inc. $4,000.00 Corporate Sponsorship
Boston Univ Medcn Psychtry $40,000.00 Fellowships and
Scholarships
Boston Univ Medcn Psychtry $45,000.00 Educational Grants
Boston Univ Medcn Psychtry $10,000.00 Educational Grants
Boston Univ Medcn Psychtry $100,000.00 Educational Grants
Boston Univ Medcn Psychtry ($2,482.00) Educational Grants
Boston Univ Medcn Psychtry $40,000.00 Fellowships and
Scholarships
Boston Univ Medcn Psychtry $85,000.00 Educational Grants
Brian Grant Fdtn The $25,000.00 Corporate Sponsorship
Brian Grant Fdtn The $30,000.00 Educational Grants
Brian Grant Fdtn The $10,000.00 Corporate Sponsorship
Brigham And Women's $250,000.00 Educational Grants
Hospital, Inc.
Brigham And Women's $40,000.00 Fellowships and
Hospital, Inc. Scholarships
Bucks Montgomery Counties $1,000.00 Corporate Sponsorship
Oncology Nursing Socty
Business Hlth Coalition $3,300.00 Corporate Sponsorship
Fdtn
California Assn Physcn Grps $20,000.00 Corporate Sponsorship
Fnd
California Assn Physcn Grps $10,000.00 Corporate Sponsorship
Fnd
California Chronic Care $35,000.00 Corporate Sponsorship
Coalition
California Inst of Tech $5,000.00 Fellowships and
Scholarships
California Issues forum $15,000.00 Corporate Sponsorship
California Life Sciences $3,000.00 Corporate Sponsorship
Association
California Life Sciences $5,000.00 Corporate Sponsorship
Association
California Life Sciences $1,500.00 Corporate Sponsorship
Association
California Pacific Med Ctr $2,000.00 Corporate Sponsorship
Fdtn
California Rheumlgy $3,000.00 Corporate Sponsorship
Alliance
California Socty of $10,000.00 Corporate Sponsorship
Dermatology and
Dermatology Surgry
Cancer And Leukemia Grp B $30,000.00 Educational Grants
Fdtn
Cancer Awareness of Nevada $1,000.00 Corporate Sponsorship
Cancer Care $10,000.00 Educational Grants
Cancer Care $25,000.00 Educational Grants
Cancer Care $50,000.00 Charitable Donations
Cancer Care $20,000.00 Educational Grants
Cancer Care $20,000.00 Educational Grants
Cancer Care $10,000.00 Educational Grants
Cancer Care $10,000.00 Educational Grants
Cancer Care $100,000.00 Corporate Sponsorship
Cancer Fdtn for New Mexico $2,500.00 Corporate Sponsorship
Cancer Molecular Thrpt $1,500.00 Educational Grants
Cancer Research Inst $7,500.00 Educational Grants
Cancer Support Community $50,000.00 Corporate Sponsorship
Cancer Wellness Center $2,500.00 Corporate Sponsorship
Carden Jennings Publishing $15,000.00 Corporate Sponsorship
Carden Jennings Publishing $5,000.00 Corporate Sponsorship
Caribe Gyn $5,000.00 Corporate Sponsorship
Caring Ambassadors Program $35,000.00 Corporate Sponsorship
Caring Ambassadors Program $200,000.00 Charitable Donations
Caring Ambassadors Program $2,500.00 Corporate Sponsorship
Cascade AIDS Project $5,000.00 Corporate Sponsorship
CE Outcomes LLC $96,770.00 Educational Grants
Cedars--Sinai Med Ctr $10,000.00 Educational Grants
Cedars--Sinai Med Ctr $40,000.00 Fellowships and
Scholarships
Center for Healthcare $5,000.00 Corporate Sponsorship
Innovation
Central Brain Tumor $20,000.00 Educational Grants
Registry of The United
States
Chesapeake Uro Asoc $5,500.00 Corporate Sponsorship
Chesapeake Uro Asoc $7,500.00 Corporate Sponsorship
Chicago Council On Scnc and $20,000.00 Corporate Sponsorship
Technologies
Chicago Council On Scnc and $5,000.00 Corporate Sponsorship
Technologies
Childrens Digestive Hlth $85,000.00 Educational Grants
and Nutrition Fdtn
Childrens Digestive Hlth $40,000.00 Fellowships and
and Nutrition Fdtn Scholarships
Childrens Hosp Corporation $3,000.00 Corporate Sponsorship
Chimp Haven $25,000.00 Charitable Donations
Chris Elliott Fund $10,000.00 Charitable Donations
Chronic Liver Disease Fdtn $75,000.00 Corporate Sponsorship
Chronic Liver Disease Fdtn $500,000.00 Educational Grants
Chronic Liver Disease Fdtn $25,000.00 Corporate Sponsorship
Chronic Liver Disease Fdtn ($25,824.00) Educational Grants
Chronic Lymphoytic Leukemia $15,000.00 Educational Grants
Society Inc.
Chronic Lymphoytic Leukemia $75,000.00 Educational Grants
Society Inc.
Chronic Lymphoytic Leukemia $50,000.00 Charitable Donations
Society Inc.
Chronic Lymphoytic Leukemia $65,000.00 Educational Grants
Society Inc.
Chronic Lymphoytic Leukemia $10,000.00 Educational Grants
Society Inc.
Cincinnati Childrens Hosp $40,000.00 Fellowships and
Medic Scholarships
Cincinnati Childrens Hosp $22,500.00 Corporate Sponsorship
Medic
Cleveland Clnc $65,000.00 Educational Grants
Cleveland Clnc $57,000.00 Educational Grants
Cleveland Clnc $5,000.00 Educational Grants
Cleveland Clnc $50,000.00 Educational Grants--
Cleveland Clnc $5,000.00 Educational Grants
Cleveland Clnc $4,000.00 Educational Grants
Cleveland Clnc $5,000.00 Corporate Sponsorship
Cleveland Clnc ($6,743.76) Educational Grants
Cleveland Clnc $7,500.00 Educational Grants
Cleveland Clnc ($6,093.50) Educational Grants
Cleveland Clnc $5,000.00 Educational Grants
Cleveland Clnc ($13,210.68) Educational Grants
Cleveland Clnc $5,000.00 Educational Grants
Cleveland Clnc Fdtn $50,000.00 Fellowships and
Scholarships
Cleveland Clnc Fdtn $40,000.00 Fellowships and
Scholarships
Clinical Care Optn LLC $175,000.00 Educational Grants
Clinical Care Optn LLC $85,000.00 Educational Grants
Clinical Care Optn LLC $75,000.00 Educational Grants
Clinical Care Optn LLC $25,000.00 Educational Grants
Clinical Care Optn LLC $173,615.00 Educational Grants
Clinical Care Optn LLC $95,000.00 Educational Grants
Clinical Care Optn LLC $347,520.00 Educational Grants
Clinical Care Optn LLC $126,385.00 Educational Grants
Clinical Care Optn LLC $50,000.00 Educational Grants
Clinical Care Optn LLC $25,000.00 Educational Grants
Clinical Care Optn LLC ($75,000.00) Educational Grants
Clinical Care Optn LLC $75,000.00 Educational Grants
Coalicion Para El Control $12,500.00 Corporate Sponsorship
De Hepatitis En Puerto
Rico
Coalition for Prevention of $10,000.00 Corporate Sponsorship
Colorectal Cancer In
Puerto Rico
Coalition On Positive $20,000.00 Corporate Sponsorship
Health Empowerment
Coalition On Positive $50,000.00 Charitable Donations
Health Empowerment
Coalition On Positive $10,000.00 Corporate Sponsorship
Health Empowerment
Cockerell Educational $15,000.00 Corporate Sponsorship
Foundation
Cold Spring Harbor Lab $5,000.00 Educational Grants
Cold Spring Harbor Lab $1,500.00 Educational Grants
Colegio Medicos--Cirujanos $10,000.00 Educational Grants
Pr
Collegium Internationale $10,000.00 Corporate Sponsorship
Colorado Dietetic Asoc $1,500.00 Corporate Sponsorship
Colorado Gerontological $5,000.00 Corporate Sponsorship
Society
Colorado Retina Asoc $15,000.00 Corporate Sponsorship
Columbia Univ Med Ctr $15,000.00 Educational Grants
Commty Fdtn $5,000.00 Corporate Sponsorship
Commty Fdtn $5,000.00 Corporate Sponsorship
Commty Liver Alliance $75,000.00 Educational Grants
Commty Liver Alliance $5,000.00 Corporate Sponsorship
Community Access National $2,500.00 Corporate Sponsorship
Network
Community Health $10,000.00 Corporate Sponsorship
Community Initiatives $75,000.00 Corporate Sponsorship
Community Initiatives $25,000.00 Corporate Sponsorship
Community Initiatives $30,000.00 Corporate Sponsorship
Community Liver Alliance $9,000.00 Corporate Sponsorship
Community Liver Alliance $25,000.00 Corporate Sponsorship
Community Liver Alliance $19,400.00 Corporate Sponsorship
Complete Conference Mgmt $80,000.00 Educational Grants
Connecticut Advanced Nurse $5,000.00 Corporate Sponsorship
Practitioner Socty
Connecticut Advocates for $500.00 Corporate Sponsorship
Parkinsons Inc.
Connecting To Cure Crohns $20,000.00 Corporate Sponsorship
And Colitis
Consortium of Multiple $150,000.00 Educational Grants
Sclerosis Centers
Consortium of Multiple $40,000.00 Educational Grants
Sclerosis Centers
Consortium of Multiple $85,000.00 Educational Grants
Sclerosis Centers
Consortium of Multiple $60,000.00 Educational Grants
Sclerosis Centers
Consortium of Multiple $25,000.00 Educational Grants
Sclerosis Centers
Consortium of Multiple $150,000.00 Educational Grants
Sclerosis Centers
Continuing Educational ($2,537.67) Educational Grants
Alliance LLC
Continuing Educational ($2,537.67) Educational Grants
Alliance LLC
Continuing Educational $375,000.00 Educational Grants
Alliance LLC
Continuing Educational $200,000.00 Educational Grants
Alliance LLC
Continuing Educational $375,000.00 Educational Grants
Alliance LLC
Continuing Educational $375,000.00 Educational Grants
Alliance LLC
Continuing Educational ($1,250.00) Educational Grants
Alliance LLC
Continuing Educational $75,000.00 Educational Grants
Alliance LLC
Continuing Educational $99,440.00 Educational Grants
Alliance LLC
Cornell Univ Weill Med Colg $1,500.00 Educational Grants
Cornell Univ Weill Med Colg $15,000.00 Educational Grants
Cornell Univ Weill Med Colg $3,000.00 Educational Grants
Cornerstone Hlth Inc. $150,000.00 Educational Grants
Cornerstone Hlth Inc. ($3,750.00) Educational Grants
Cornerstone Hlth Inc. $90,000.00 Educational Grants
Cornerstone Hlth Inc. $40,000.00 Educational Grants
Cornerstone Hlth Inc. $90,000.00 Educational Grants
Cornerstone Hlth Inc. $75,000.00 Educational Grants
Creighton Univ $10,000.00 Educational Grants
Critical Path Inst $25,000.00 Corporate Sponsorship
Crohns And Colitis $165,000.00 Corporate Sponsorship
Foundation
Crohns And Colitis $110,000.00 Educational Grants
Foundation of America
Crohns And Colitis $100,000.00 Educational Grants
Foundation of America
Crohns And Colitis $100,000.00 Educational Grants
Foundation of America
Crohns And Colitis $100,000.00 Educational Grants
Foundation of America
Crohns and Colitis $100,000.00 Educational Grants
Foundation of America
Crohns and Colitis $31,000.00 Educational Grants
Foundation of America
Crohns and Colitis $25,000.00 Charitable Donations
Foundation of America
Crohns and Colitis $25,000.00 Charitable Donations
Foundation of America
Crohns and Colitis $1,500.00 Corporate Sponsorship
Foundation of America
Crohns and Colitis $800.00 Corporate Sponsorship
Foundation of America
Crohns and Colitis $2,500.00 Corporate Sponsorship
Foundation of America
Crohns and Colitis $10,000.00 Corporate Sponsorship
Foundation of America
Crohns and Colitis $10,250.00 Corporate Sponsorship
Foundation of America
Crohns and Colitis $50,000.00 Charitable Donations
Foundation of America
Crohns and Colitis $5,000.00 Corporate Sponsorship
Foundation of America
Crohns and Colitis $2,500.00 Corporate Sponsorship
Foundation of America
Crohns and Colitis $1,500.00 Corporate Sponsorship
Foundation of America
Crohns and Colitis $1,500.00 Corporate Sponsorship
Foundation of America
Crohns and Colitis $47,000.00 Corporate Sponsorship
Foundation of America
Crohns and Colitis $114,000.00 Corporate Sponsorship
Foundation of America
Crohns and Colitis $5,000.00 Corporate Sponsorship
Foundation of America
Crohns and Colitis $2,500.00 Corporate Sponsorship
Foundation of America
Crohns and Colitis $2,000.00 Corporate Sponsorship
Foundation of America
Crohns and Colitis $2,500.00 Corporate Sponsorship
Foundation of America
Crohns and Colitis $15,000.00 Corporate Sponsorship
Foundation of America
Crohns and Colitis $10,000.00 Corporate Sponsorship
Foundation of America
Crohns and Colitis $1,000.00 Corporate Sponsorship
Foundation of America
Crohns and Colitis $15,000.00 Corporate Sponsorship
Foundation of America
Crohns and Colitis $250,000.00 Educational Grants
Foundation of America
Crohns and Colitis $100,000.00 Fellowships and
Foundation of America Scholarships
Crohns and Colitis $400,000.00 Corporate Sponsorship
Foundation of America
Crohns and Colitis $80,000.00 Charitable Donations
Foundation of America
Crohns and Colitis $40,000.00 Corporate Sponsorship
Foundation of America
Crohns and Colitis $40,000.00 Educational Grants
Foundation of America
Ctrl Florida Phmcy Council $15,000.00 Educational Grants
Inc.
Ctrl Savannah River Area $1,000.00 Corporate Sponsorship
Csra Parkinson Support Grp
Curatio Cme Inst ($33,640.17) Educational Grants
Cure CF $1,500.00 Corporate Sponsorship
Curepsp Inc. $15,000.00 Educational Grants
Cystic Fibrosis Fdtn-- $1,000.00 Corporate Sponsorship
Albany
Cystic Fibrosis Fdtn-- $750.00 Corporate Sponsorship
Albany
Cystic Fibrosis Fdtn-- $7,500.00 Corporate Sponsorship
Albany
Cystic Fibrosis Fdtn-- $1,750.00 Corporate Sponsorship
Albany
Cystic Fibrosis Fdtn-- $1,500.00 Corporate Sponsorship
Albany
Cystic Fibrosis Fdtn-- $1,000.00 Corporate Sponsorship
Albany
Cystic Fibrosis Fdtn-- $2,500.00 Corporate Sponsorship
Albany
Cystic Fibrosis Fdtn $4,000.00 Corporate Sponsorship
Maryland Chapter
Cystic Fibrosis Fdtn $5,750.00 Corporate Sponsorship
Maryland Chapter
Cystic Fibrosis Research $5,000.00 Corporate Sponsorship
Fund Emilys Entourage
Cystic Fibrosis Research $18,000.00 Corporate Sponsorship
Inc.
Cystic Fibrosis Research $7,000.00 Corporate Sponsorship
Inc.
Cystic Fibrosis Research $10,000.00 Corporate Sponsorship
Inc.
Cystic Fibrosis Research $10,000.00 Corporate Sponsorship
Inc.
Cystic Fibrosis Research $5,000.00 Corporate Sponsorship
Inc.
Cystic Fibrosis Research $3,000.00 Corporate Sponsorship
Inc.
Cystic Fibrosis Services $500.00 Corporate Sponsorship
Cystic Fibrosis Services $500.00 Corporate Sponsorship
Cystic Fibrosis Services $3,500.00 Corporate Sponsorship
Cystic Fibrosis Services $1,000.00 Corporate Sponsorship
Cystic Fibrosis Services $2,500.00 Corporate Sponsorship
Cystic Fibrosis Services $2,000.00 Corporate Sponsorship
Cystic Fibrosis Services $1,000.00 Corporate Sponsorship
Cystic Fibrosis Services $2,000.00 Corporate Sponsorship
Cystic Fibrosis Services $1,500.00 Corporate Sponsorship
Cystic Fibrosis Services $1,750.00 Corporate Sponsorship
Cystic Fibrosis Services $3,250.00 Corporate Sponsorship
Cystic Fibrosis Services $1,750.00 Corporate Sponsorship
Cystic Fibrosis Services $1,500.00 Corporate Sponsorship
Cystic Fibrosis Services $1,000.00 Corporate Sponsorship
Cystic Fibrosis Services $5,000.00 Corporate Sponsorship
Cystic Fibrosis Services $7,500.00 Corporate Sponsorship
Cystic Fibrosis Services $7,500.00 Corporate Sponsorship
Cystic Fibrosis Services $2,500.00 Corporate Sponsorship
Cystic Fibrosis Services $2,000.00 Corporate Sponsorship
Cystic Fibrosis Services $5,000.00 Corporate Sponsorship
Cystic Fibrosis Services $1,750.00 Corporate Sponsorship
Cystic Fibrosis Services $5,000.00 Corporate Sponsorship
Cystic Fibrosis Services $35,000.00 Corporate Sponsorship
Cystic Fibrosis Services $15,000.00 Corporate Sponsorship
Cystic Fibrosis Services $5,000.00 Corporate Sponsorship
Cystic Fibrosis Services $1,000.00 Corporate Sponsorship
Cystic Fibrosis Services $2,500.00 Corporate Sponsorship
Cystic Fibrosis Services $2,000.00 Corporate Sponsorship
Cystic Fibrosis Services $1,000.00 Corporate Sponsorship
Cystic Fibrosis Services $1,000.00 Corporate Sponsorship
Cystic Fibrosis Services $3,000.00 Corporate Sponsorship
Cystic Fibrosis Services $3,500.00 Corporate Sponsorship
Cystic Fibrosis Services $1,000.00 Corporate Sponsorship
Cystic Fibrosis Services $5,000.00 Corporate Sponsorship
Cystic Fibrosis Services $3,000.00 Corporate Sponsorship
Cystic Fibrosis Services $2,500.00 Corporate Sponsorship
Cystic Fibrosis Services $5,000.00 Corporate Sponsorship
Cystic Fibrosis Services $3,000.00 Corporate Sponsorship
Cystic Fibrosis Services $1,000.00 Corporate Sponsorship
Cystic Fibrosis Services $3,500.00 Corporate Sponsorship
Cystic Fibrosis Services $2,500.00 Corporate Sponsorship
Cystic Fibrosis Services $1,000.00 Corporate Sponsorship
Cystic Fibrosis Services $2,000.00 Corporate Sponsorship
Cystic Fibrosis Services $5,000.00 Corporate Sponsorship
Cystic Fibrosis Services $1,000.00 Corporate Sponsorship
Cystic Fibrosis Services $2,500.00 Corporate Sponsorship
Cystic Fibrosis Services $1,500.00 Corporate Sponsorship
Cystic Fibrosis Services $10,000.00 Corporate Sponsorship
Cystic Fibrosis Services $6,500.00 Corporate Sponsorship
Cystic Fibrosis Services $5,000.00 Corporate Sponsorship
Cystic Fibrosis Services $3,000.00 Corporate Sponsorship
Cystic Fibrosis Services $1,750.00 Corporate Sponsorship
Cystic Fibrosis Services $1,000.00 Corporate Sponsorship
Cystic Fibrosis Services $35,000.00 Corporate Sponsorship
Cystic Fibrosis Services $750,000.00 Corporate Sponsorship
Cystic Fibrosis Services $5,000.00 Corporate Sponsorship
Cystic Fibrosis Services $7,500.00 Corporate Sponsorship
Cystic Fibrosis Services $7,500.00 Corporate Sponsorship
Cystic Fibrosis Services $7,500.00 Corporate Sponsorship
Cystic Fibrosis Services $6,500.00 Corporate Sponsorship
Cystic Fibrosis Services $5,000.00 Corporate Sponsorship
Cystic Fibrosis Services $5,000.00 Corporate Sponsorship
Cystic Fibrosis Services $2,500.00 Corporate Sponsorship
Cystic Fibrosis Services $1,000.00 Corporate Sponsorship
Cystic Fibrosis Services $10,000.00 Corporate Sponsorship
Cystic Fibrosis Services $1,500.00 Corporate Sponsorship
Dallas fort Worth Business $5,000.00 Corporate Sponsorship
Grp On Hlth
Danville D Elegance Fdtn $2,500.00 Corporate Sponsorship
Dava Oncology Lp $50,000.00 Corporate Sponsorship
Dava Oncology Lp $150,000.00 Corporate Sponsorship
David A Winston Health $5,500.00 Corporate Sponsorship
Policy
Davis Phinney Fdtn $30,000.00 Educational Grants
Davis Phinney Fdtn $30,000.00 Educational Grants
Davis Phinney Fdtn $20,000.00 Corporate Sponsorship
Davis Phinney Fdtn $30,000.00 Educational Grants
Davis Phinney Fdtn $60,000.00 Educational Grants
Davis Phinney Fdtn $30,000.00 Educational Grants
Davis Phinney Fdtn $40,000.00 Corporate Sponsorship
Dermatology Education Fdtn $30,000.00 Corporate Sponsorship
Dermatology Fdtn $135,000.00 Charitable Donations
Dermatology Fdtn $50,000.00 Corporate Sponsorship
Dermatology Nurses Asoc $10,000.00 Educational Grants
Dermatology Nurses Asoc $25,850.00 Corporate Sponsorship
Digestive Disease Week $55,000.00 Corporate Sponsorship
Digestive Disease Week $55,000.00 Corporate Sponsorship
Digestive Health Foundation $25,000.00 Corporate Sponsorship
Digestive Health Physicians $100,000.00 Corporate Sponsorship
Association
Direct Relief $50,000.00 Charitable Donations
East Hawaii IPA $8,500.00 Corporate Sponsorship
Elsevier Inc. $40,000.00 Educational Grants
Employers Hlth Colition $4,000.00 Corporate Sponsorship
Inc.
Endocrine Education Inc. $25,000.00 Educational Grants
Endocrine Education Inc. $25,000.00 Educational Grants
Engineering Conferences $1,500.00 Educational Grants
International
Enviormental Mutagen Socty $2,500.00 Corporate Sponsorship
Enzyme Mechanism Conference $1,500.00 Educational Grants
Epilepsy Association of $5,000.00 Corporate Sponsorship
Central Florida
Epilepsy Fnd of North- $20,000.00 Corporate Sponsorship
Central Illinois Iowa and
Nebraska
Epilepsy Foundation of $5,000.00 Corporate Sponsorship
Flordia Inc.
Epilepsy Foundation of $18,000.00 Corporate Sponsorship
Michigan
Epilepsy Foundation of $20,000.00 Corporate Sponsorship
Michigan
Epilepsy Foundation of New $17,000.00 Corporate Sponsorship
Jersey
Escuela De Medicina De $20,000.00 Educational Grants
Ponce
Escuela De Medicina De $10,000.00 Educational Grants
Ponce
Event 360 Inc. $8,330.00 Corporate Sponsorship
Excel Continuing Education $5,000.00 Educational Grants
Excellence in Gastro $100,000.00 Corporate Sponsorship
Education LLC
Excellence in Rheumlgy $100,000.00 Corporate Sponsorship
Education LLC
Family Med Ctr Bolingbrook $13,000.00 Corporate Sponsorship
Family Med Ctr Bolingbrook $5,500.00 Corporate Sponsorship
Fdtn for Biomedical $25,000.00 Charitable Donations
Research
Federation of American $1,500.00 Educational Grants
Socty
Federation of American $1,500.00 Educational Grants
Socty
Federation of American $1,500.00 Educational Grants
Socty
Federation of American $1,500.00 Educational Grants
Socty
Federation of American $1,500.00 Educational Grants
Socty
Federation of American $1,500.00 Educational Grants
Socty
Federation of Clinical $20,000.00 Educational Grants
Immunology Socty
Federation of Clinical $25,000.00 Educational Grants
Immunology Socty
Federation of Clinical $12,500.00 Educational Grants
Immunology Socty
Florida Hlth Care Coalition $5,000.00 Corporate Sponsorship
Florida Socty of $20,000.00 Corporate Sponsorship
Dermatology Phys
Assistants Inc.
Florida Socty of Rheumlgy $25,000.00 Corporate Sponsorship
Focus Med Communications $100,000.00 Corporate Sponsorship
Force--Facing Our Risk of $10,000.00 Corporate Sponsorship
Cancer Emp
Force--Facing Our Risk of $10,000.00 Charitable Donations
Cancer Emp
Foster Ocular Immunology $40,000.00 Corporate Sponsorship
Socty
Foundation for Veterans $20,000.00 Corporate Sponsorship
Health Care
Foundation of Consortium of $12,280.00 Fellowships and
Multiple Sclerosis Centers Scholarships
CMSC
Foundation of Consortium of $25,000.00 Educational Grants
Multiple Sclerosis Centers
CMSC
Foundation of Consortium of $10,000.00 Charitable Donations
Multiple Sclerosis Centers
CMSC
Friends of Cancer Research $50,000.00 Corporate Sponsorship
Friends of Parkinsons $1,000.00 Corporate Sponsorship
Friends of The St Louis $50,000.00 Corporate Sponsorship
Univ Liver Ctr
Fund for Public Hlth In New $200,000.00 Educational Grants
York
Fundacion Alfredo Ruiz $5,000.00 Corporate Sponsorship
Fundacion Daledale Inc. $3,000.00 Corporate Sponsorship
Fundacion De Esclerosis $3,000.00 Corporate Sponsorship
Multiple De Puerto Rico
Fundacion Puertorriquena De $5,000.00 Corporate Sponsorship
Enfermedades Reumaticas
Galien Foundation $22,500.00 Corporate Sponsorship
Galien Foundation $30,000.00 Corporate Sponsorship
Gastro--Intestinal Research $25,000.00 Corporate Sponsorship
Fdtn
Gastro--Intestinal Research $50,000.00 Corporate Sponsorship
Fdtn
Gastrointestinal And Liver $75,000.00 Educational Grants
Association of The
Americas Inc.
Gateway for Cancer Research $10,000.00 Charitable Donations
Georgetown Univ Hosp Phmcy $50,000.00 Fellowships and
Scholarships
Georgia Dermatology Phys $20,000.00 Corporate Sponsorship
Assistants
Georgia Doty Hiv & $10,000.00 Educational Grants
Hepatitis Commty Outreach
Inc.
Georgia Prostate Cancer $2,500.00 Educational Grants
Coalition The
Georgia Society of Clinical $25,000.00 Corporate Sponsorship
Oncology
Georgia Socty of $8,000.00 Corporate Sponsorship
Rhematology
Global Academy for Medical $18,000.00 Corporate Sponsorship
Education
Global Academy for Medical $76,500.00 Corporate Sponsorship
Education
Global Academy for Medical $36,000.00 Corporate Sponsorship
Education
Global Academy for Medical $54,000.00 Corporate Sponsorship
Education
Global Academy for Medical $90,000.00 Corporate Sponsorship
Education
Global Alliance for Medical $10,000.00 Educational Grants
Education
Global Alliance for Patient $30,000.00 Corporate Sponsorship
Access
Global Biological Standards $2,000.00 Educational Grants
Inst
Globalization of $10,000.00 Corporate Sponsorship
Pharmaceutics Education
Ntwrk
Good Grief $500.00 Corporate Sponsorship
Gordon Research Conferences $1,500.00 Educational Grants
Gordon Research Conferences $1,500.00 Educational Grants
Gordon Research Conferences $10,000.00 Corporate Sponsorship
Gordon Research Conferences $1,500.00 Educational Grants
Gordon Research Conferences $1,500.00 Educational Grants
Gordon Research Conferences $1,500.00 Educational Grants
Gordon Research Conferences $1,500.00 Educational Grants
Gordon Research Conferences $1,500.00 Educational Grants
Gordon Research Conferences $1,500.00 Educational Grants
Gordon Research Conferences $1,500.00 Educational Grants
Gordon Research Conferences $1,500.00 Educational Grants
Gordon Research Conferences $1,500.00 Educational Grants
Gordon Research Conferences $1,500.00 Educational Grants
Gordon Research Conferences $1,500.00 Educational Grants
Gordon Research Conferences $1,500.00 Educational Grants
Gordon Research Conferences $2,000.00 Educational Grants
Gordon Research Conferences $1,500.00 Educational Grants
Gordon Research Conferences $2,000.00 Educational Grants
Gordon Research Conferences $2,000.00 Educational Grants
Gordon Research Conferences $2,000.00 Educational Grants
Gordon Research Conferences $2,000.00 Educational Grants
Great Lakes Chapter of The $1,000.00 Corporate Sponsorship
American Society for
Pharmacology And
Experimental Therapeutics
Gynecologic Oncology Grp $35,000.00 Educational Grants
The
Gynecologic Oncology Grp $40,000.00 Educational Grants
The
Gynecologic Oncology Grp $40,000.00 Educational Grants
The
Haymarket Med Education ($2,553.09) Educational Grants
Head for The Cure Fdtn $7,500.00 Corporate Sponsorship
Healthcare Business Women's $7,500.00 Corporate Sponsorship
Association, Inc.
Healthcare Business Women's $7,500.00 Corporate Sponsorship
Association, Inc.
Healthwell Fdtn $507,000.00 Charitable Donations
Healthy Women $30,000.00 Corporate Sponsorship
Heart to Heart $10,000.00 Charitable Donations
International Inc.
Heart to Heart $50,000.00 Charitable Donations
International Inc.
Heb Grocery Company LP $7,000.00 Corporate Sponsorship
Henry ford Hlth System $2,000.00 Corporate Sponsorship
Henry M Jackson Fdtn $5,559.67 Corporate Sponsorship
Henry M Jackson Fdtn $5,559.67 Corporate Sponsorship
Henry M Jackson Fdtn $5,559.66 Corporate Sponsorship
Henry M Jackson Fdtn $10,000.00 Educational Grants
Hep C Connection $5,000.00 Corporate Sponsorship
Hep C Connection $25,000.00 Charitable Donations
Hep C Connection $5,000.00 Corporate Sponsorship
Hepatitis C Asoc $25,000.00 Educational Grants
Hepatitis Education Project $75,000.00 Charitable Donations
Hepatitis Education Project $24,000.00 Corporate Sponsorship
Hepatitis Education Project $25,000.00 Corporate Sponsorship
Hepatitis Foundation $250,000.00 Corporate Sponsorship
International
Hepatitis Foundation $5,000.00 Corporate Sponsorship
International
Herbert Kosten Pancreatic $2,000.00 Corporate Sponsorship
Cancer Charitable Fund
Hidradenitis Suppurativa $13,550.00 Charitable Donations
Fdtn
Hitchcock Fdtn $8,000.00 Educational Grants
Hitchcock Fdtn $20,000.00 Educational Grants
HIV Treaters Med Asoc of $10,000.00 Educational Grants
Puerto Rico
Hlthcr Financial Mgmt Hfma $50,000.00 Corporate Sponsorship
Hmp Communications $31,000.00 Corporate Sponsorship
Hmp Communications $50,000.00 Corporate Sponsorship
Hope Fdtn The $25,000.00 Educational Grants
Hope Healthcare Services $600.00 Corporate Sponsorship
Houston Area Parkinson $1,000.00 Corporate Sponsorship
Society
Houston Business Coalition $6,000.00 Corporate Sponsorship
On Health
Howard Hanna Children's $10,000.00 Charitable Donations
Free Care Fund
Hubbard Street Dance $10,000.00 Educational Grants
Chicago
Human Growth Fdtn $5,000.00 Corporate Sponsorship
Human Growth Fdtn $10,000.00 Charitable Donations
Human Growth Fdtn $4,000.00 Corporate Sponsorship
Humboldt--Del Norte County $1,100.00 Educational Grants
Med Socty
Humboldt--Del Norte County $4,000.00 Educational Grants
Med Socty
Ibd Remedy Inc. $10,000.00 Charitable Donations
Illinois African American $15,000.00 Corporate Sponsorship
Coalition
Illinois Socty of $25,000.00 Corporate Sponsorship
Dermatology Phys
Assistants
Illinois Socty of $15,000.00 Corporate Sponsorship
Dermatology Phys
Assistants
Imedex LLC $50,000.00 Educational Grants
Imedex LLC $75,000.00 Educational Grants
Imedex LLC $75,000.00 Educational Grants
Imedex LLC $9,000.00 Educational Grants
Imedex LLC $25,000.00 Educational Grants
Imedex LLC $50,000.00 Educational Grants
Imedex LLC ($838.00) Educational Grants
Imedex LLC $50,000.00 Educational Grants
Imedex LLC $75,000.00 Educational Grants
Improve Care Now Inc. $15,000.00 Corporate Sponsorship
Indian Medical Association $500.00 Corporate Sponsorship
of New England
Indiana Parkinson Fdtn $1,000.00 Corporate Sponsorship
Indiana Univ ($619.24) Fellowships and
Scholarships
Indiana Univ Fdtn $50,000.00 Charitable Donations
Inflammatory Bowel Disease $75,000.00 Educational Grants
Support Fdtn
Inflammatory Bowel Disease $200,000.00 Educational Grants
Support Fdtn
Inflammatory Bowel Disease $75,000.00 Educational Grants
Support Fdtn
Innovation Development Inst $250,000.00 Corporate Sponsorship
Inc.
Integrated Benefits Inst $25,000.00 Corporate Sponsorship
Inc.
Integrated Med Fdtn $15,000.00 Charitable Donations
Interfaith House $2,000.00 Charitable Donations
Intermountain Dermatology $15,000.00 Educational Grants
Socty
International Aids Socty-- $75,000.00 Educational Grants
USA
International Aids Socty-- $75,000.00 Educational Grants
USA
International Biometric $4,925.00 Corporate Sponsorship
Socty Eastern North
American Region
International Chinese $3,000.00 Corporate Sponsorship
Statistical Asoc
International Dermatology $250,000.00 Educational Grants
Outcome Measures
International League of $20,000.00 Charitable Donations
Asoc for Rheumlgy
International Medical Corps $50,000.00 Charitable Donations
International Organization $145,000.00 Educational Grants
of Multiple Sclerosis
Nurses
International Organization $60,000.00 Educational Grants
of Multiple Sclerosis
Nurses
International Parkinson And $300,000.00 Corporate Sponsorship
Movemen
International Socty for $5,000.00 Educational Grants
Antiviral Research
International Socty for The $3,000.00 Educational Grants
Study of Xenobiotics
International Socty for The $2,500.00 Educational Grants
Study of Xenobiotics
International Socty of $40,000.00 Corporate Sponsorship
Nphro
International Socty of $1,500.00 Educational Grants
Psychiatric Genetics
Iraq and Afghanistan $15,000.00 Corporate Sponsorship
Veterans
ISMPP--International Socty $10,000.00 Corporate Sponsorship
for Med
ISMPP--International Socty $10,000.00 Corporate Sponsorship
for Med
Jefferson Med Colg At $3,000.00 Corporate Sponsorship
Thomas Jefferson Univ
Jefferson Med Colg At $3,000.00 Corporate Sponsorship
Thomas Jefferson Univ
Jefferson Med Colg At $7,500.00 Educational Grants
Thomas Jefferson Univ
John P Mcgovern Museum of $10,000.00 Corporate Sponsorship
Health And Medical Science
Johns Hopkins Univ School $50,000.00 Educational Grants
of Medicine
Johns Hopkins Univ School $20,000.00 Educational Grants
of Medicine
Johns Hopkins Univ School $1,500.00 Corporate Sponsorship
of Medicine
Johns Hopkins Univ School $40,000.00 Fellowships and
of Medicine Scholarships
Johns Hopkins Univ School $99,750.00 Educational Grants
of Medicine
Johns Hopkins Univ School $35,000.00 Educational Grants
of Medicine
Johns Hopkins Univ School $7,000.00 Fellowships and
of Medicine Scholarships
Johns Hopkins Univ School $90,000.00 Educational Grants
of Medicine
Johns Hopkins Univ School $50,000.00 Educational Grants
of Medicine
JWC Covenant Inc. $25,000.00 Educational Grants
Kansas Univ Neuro Fdtn $65,000.00 Educational Grants
Kelsey Research Fdtn $35,000.00 Fellowships and
Scholarships
Kentuckiana Health $2,500.00 Corporate Sponsorship
Collaborative
Kentucky Life Sciences $5,000.00 Corporate Sponsorship
Foundation
Keystone Symposia $25,000.00 Corporate Sponsorship
Laboratorio Clinico Toledo $2,955.00 Patient Support
Laboratorio Clinico Toledo $810.00 Patient Support
Laboratorio Clinico Toledo $720.00 Patient Support
Laboratorio Clinico Toledo $675.00 Patient Support
Laboratorio Clinico Toledo $675.00 Patient Support
Laboratorio Clinico Toledo $630.00 Patient Support
Laboratorio Clinico Toledo $1,440.00 Patient Support
Laboratorio Clinico Toledo $1,485.00 Patient Support
Laboratorio Clinico Toledo $5,250.00 Patient Support
Laboratorio Clinico Toledo $735.00 Patient Support
Laboratorio Clinico Toledo $810.00 Patient Support
Laboratorio Clinico Toledo $660.00 Patient Support
Laboratorio Clinico Toledo $1,875.00 Patient Support
Laboratorio Clinico Toledo $825.00 Patient Support
Laboratorio Clinico Toledo $765.00 Patient Support
Laboratorio Clinico Toledo $750.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $885.00 Patient Support
Laboratorio Clinico Toledo $1,740.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $810.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $372.00 Patient Support
Laboratorio Clinico Toledo $2,550.00 Patient Support
Laboratorio Clinico Toledo $1,470.00 Patient Support
Laboratorio Clinico Toledo $1,350.00 Patient Support
Laboratorio Clinico Toledo $1,215.00 Patient Support
Laboratorio Clinico Toledo $1,080.00 Patient Support
Laboratorio Clinico Toledo $705.00 Patient Support
Laboratorio Clinico Toledo $645.00 Patient Support
Laboratorio Clinico Toledo $204.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $765.00 Patient Support
Laboratorio Clinico Toledo $1,905.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $675.00 Patient Support
Laboratorio Clinico Toledo $585.00 Patient Support
Laboratorio Clinico Toledo $885.00 Patient Support
Laboratorio Clinico Toledo $870.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $975.00 Patient Support
Laboratorio Clinico Toledo $1,080.00 Patient Support
Laboratorio Clinico Toledo $1,035.00 Patient Support
Laboratorio Clinico Toledo $300.00 Patient Support
Laboratorio Clinico Toledo $870.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $1,305.00 Patient Support
Laboratorio Clinico Toledo $1,200.00 Patient Support
Laboratorio Clinico Toledo $645.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $1,290.00 Patient Support
Laboratorio Clinico Toledo $1,005.00 Patient Support
Laboratorio Clinico Toledo $204.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $1,140.00 Patient Support
Laboratorio Clinico Toledo $1,125.00 Patient Support
Laboratorio Clinico Toledo $810.00 Patient Support
Laboratorio Clinico Toledo $240.00 Patient Support
Laboratorio Clinico Toledo $1,395.00 Patient Support
Laboratorio Clinico Toledo $1,275.00 Patient Support
Laboratorio Clinico Toledo $705.00 Patient Support
Laboratorio Clinico Toledo $1,425.00 Patient Support
Laboratorio Clinico Toledo $1,200.00 Patient Support
Laboratorio Clinico Toledo $675.00 Patient Support
Laboratorio Clinico Toledo $405.00 Patient Support
Laboratorio Clinico Toledo $1,095.00 Patient Support
Laboratorio Clinico Toledo $720.00 Patient Support
Laboratorio Clinico Toledo $660.00 Patient Support
Laboratorio Clinico Toledo $495.00 Patient Support
Laboratorio Clinico Toledo $2,355.00 Patient Support
Laboratorio Clinico Toledo $1,200.00 Patient Support
Laboratorio Clinico Toledo $2,295.00 Patient Support
Laboratorio Clinico Toledo $915.00 Patient Support
Lake County Haven $10,000.00 Charitable Donations
Large Uro Grp Prct Asoc $20,000.00 Corporate Sponsorship
Large Uro Grp Prct Asoc $25,000.00 Corporate Sponsorship
Large Uro Grp Prct Asoc $25,000.00 Corporate Sponsorship
Large Uro Grp Prct Asoc $25,000.00 Corporate Sponsorship
Large Uro Grp Prct Asoc $66,400.00 Corporate Sponsorship
Large Uro Grp Prct Asoc $25,000.00 Corporate Sponsorship
Lenox Hill Hosp $10,000.00 Educational Grants
Leukemia and Lymphoma $10,000.00 Educational Grants
Society
Leukemia and Lymphoma $10,000.00 Corporate Sponsorship
Society
Leukemia and Lymphoma $15,000.00 Corporate Sponsorship
Society
Leukemia and Lymphoma $4,000.00 Corporate Sponsorship
Society
Leukemia and Lymphoma $100,000.00 Corporate Sponsorship
Society
Leukemia and Lymphoma $2,500.00 Corporate Sponsorship
Society
Leukemia and Lymphoma $100,000.00 Charitable Donations
Society
Leukemia Research $5,000.00 Educational Grants
Foundation Inc.
Leukemia Research $5,000.00 Corporate Sponsorship
Foundation Inc.
Leukemia Research $5,000.00 Corporate Sponsorship
Foundation Inc.
Leukemia Research $50,000.00 Fellowships and
Foundation Inc. Scholarships
Leukemia Research $5,000.00 Charitable Donations
Foundation Inc.
Leukemia Research $5,000.00 Educational Grants
Foundation Inc.
Leukemia Research $10,000.00 Corporate Sponsorship
Foundation Inc.
Living Beyond Breast Cancer $10,000.00 Corporate Sponsorship
Living Beyond Breast Cancer $10,000.00 Corporate Sponsorship
Loyola Stritch School of $2,000.00 Educational Grants
Medicine Div of
Dermatology
Lung Cancer Alliance $25,000.00 Corporate Sponsorship
Lungevity Foundation $25,000.00 Corporate Sponsorship
Lungevity Foundation $25,000.00 Corporate Sponsorship
Lupus and Allied Diseases $6,000.00 Corporate Sponsorship
Association
Lymphoma Research $2,500.00 Corporate Sponsorship
Foundation
Lymphoma Research $10,000.00 Corporate Sponsorship
Foundation
Lymphoma Research $10,000.00 Corporate Sponsorship
Foundation
Lymphoma Research $2,000.00 Corporate Sponsorship
Foundation
Lymphoma Research $37,500.00 Corporate Sponsorship
Foundation
Magee--Womens Research Inst $10,000.00 Corporate Sponsorship
And Fdtn
Magellan Rx Mgmt Inc. $20,000.00 Corporate Sponsorship
Magic Fdtn $15,000.00 Educational Grants
Magic Fdtn $10,000.00 Charitable Donations
Massachusetts Association $5,000.00 Corporate Sponsorship
for Mental Health
Massachusetts Inst of Tech $1,000.00 Charitable Donations
Massachusetts Prostate $2,500.00 Educational Grants
Cancer Coalition Inc.
Massachusetts Socty for Med $5,000.00 Educational Grants
Research
Massachusetts Socty for Med $5,000.00 Educational Grants
Research
Massachusetts Socty of $5,000.00 Corporate Sponsorship
Clinical Oncologists
Max Foundation $45,000.00 Corporate Sponsorship
Mayo Clnc $10,000.00 Educational Grants
Mayo Clnc $2,500.00 Educational Grants
Mccourt Fdtn Inc. $5,000.00 Educational Grants
Me Strong Inc. $2,500.00 Corporate Sponsorship
Med--LQ LLC $125,000.00 Educational Grants
Med--LQ LLC $185,000.00 Educational Grants
Med--LQ LLC $150,000.00 Educational Grants
Med--LQ LLC $167,933.00 Educational Grants
Med Colg of Wisconsin $7,500.00 Educational Grants
Med Colg of Wisconsin $85,000.00 Educational Grants
Med Colg of Wisconsin $2,000.00 Corporate Sponsorship
Med Colg of Wisconsin $10,000.00 Educational Grants
Med Conference Planners $10,000.00 Corporate Sponsorship
Med Learning Inst $180,000.00 Educational Grants
Med Learning Inst $72,015.00 Educational Grants
Med Learning Inst $100,000.00 Educational Grants
Med Learning Inst $65,000.00 Educational Grants
Med Learning Inst $70,000.00 Educational Grants
Med Learning Inst $40,000.00 Educational Grants
Med Learning Inst $150,000.00 Educational Grants
Med Learning Inst $65,380.00 Educational Grants
Med Learning Inst $125,000.00 Educational Grants
Medicinal And Bioorganic $5,000.00 Educational Grants
Chemistry Fdtn The
Medscape LLC $450,000.00 Educational Grants
Medscape LLC $200,000.00 Educational Grants
Medscape LLC $189,500.00 Educational Grants
Medscape LLC $250,000.00 Educational Grants
Medscape LLC $252,350.00 Educational Grants
Medscape LLC $175,000.00 Educational Grants
Medscape LLC $135,000.00 Educational Grants
Medscape LLC $100,000.00 Educational Grants
Medscape LLC $385,000.00 Educational Grants
Medscape LLC $350,000.00 Educational Grants
Medscape LLC $150,000.00 Educational Grants
Medscape LLC $100,000.00 Educational Grants
Medscape LLC $165,000.00 Educational Grants
Medscape LLC $195,000.00 Educational Grants
Medscape LLC $65,000.00 Educational Grants
Medscape LLC $41,000.00 Educational Grants
Medscape LLC $250,000.00 Educational Grants
Medscape LLC ($2,000.00) Educational Grants
Medscape LLC $300,000.00 Educational Grants
Medscape LLC $112,500.00 Educational Grants
Medstar Washington Hosp Ctr $10,000.00 Educational Grants
Meeting Designs LLC $25,000.00 Corporate Sponsorship
Memorial Sloan Kettering $10,000.00 Educational Grants
Cancer Ctr
Memphis Business Grp On $5,120.00 Corporate Sponsorship
Hlth
Memphis Business Grp On $5,120.00 Corporate Sponsorship
Hlth
Meridian Hospitals $400.00 Corporate Sponsorship
Corporation
Methodist Hosp The $25,000.00 Corporate Sponsorship
Metropolitan Chicago Breast $10,000.00 Charitable Donations
Cancer
Michael J Fox Fdtn $1,000.00 Corporate Sponsorship
Michael J Fox Fdtn $25,000.00 Corporate Sponsorship
Michael J Fox Fdtn $50,000.00 Corporate Sponsorship
Michael J Fox Fdtn $15,000.00 Educational Grants
Michigan Parkinson $2,000.00 Corporate Sponsorship
Foundation
Michigan Parkinson $4,000.00 Corporate Sponsorship
Foundation
Michigan Parkinson $2,500.00 Corporate Sponsorship
Foundation
Michigan Rheumatism Socty $5,000.00 Corporate Sponsorship
Michigan Rheumatism Socty $5,000.00 Corporate Sponsorship
Michigan Rheumatism Socty $5,000.00 Corporate Sponsorship
Michigan State Univ $1,000.00 Charitable Donations
Michigan State Univ $1,000.00 Charitable Donations
Midwest Business Grp On $5,000.00 Corporate Sponsorship
Hlth
Midwest Pediatric Endocrine $6,300.00 Corporate Sponsorship
Socty
Miles for Cystic Fibrosis $20,000.00 Charitable Donations
Miles for Cystic Fibrosis $5,000.00 Corporate Sponsorship
Missouri Hepatitis C $25,000.00 Charitable Donations
Alliance
Montana Asoc of Hlth Care $2,000.00 Corporate Sponsorship
Purchaser
Montefiore Med Ctr $75,000.00 Educational Grants
Montefiore Med Ctr $50,000.00 Educational Grants
Montefiore Med Ctr $50,000.00 Educational Grants
Mount Sinai School of $95,000.00 Educational Grants
Medicine
Mount Sinai School of $40,000.00 Educational Grants
Medicine
Mount Sinai School of $15,000.00 Educational Grants
Medicine
Mount Sinai School of $100,000.00 Educational Grants
Medicine
Mount Sinai School of $2,500.00 Educational Grants
Medicine
Mount Sinai School of $5,000.00 Educational Grants
Medicine
Mount Sinai School of $40,000.00 Educational Grants
Medicine
Mount Sinai School of $1,500.00 Educational Grants
Medicine
Mount Sinai School of $30,000.00 Corporate Sponsorship
Medicine
Mount Sinai School of $15,000.00 Educational Grants
Medicine
Mount Sinai School of $1,500.00 Educational Grants
Medicine
Movement Disorder Socty The $20,000.00 Corporate Sponsorship
Movement Disorder Socty The $25,000.00 Corporate Sponsorship
Movement Disorder Socty The $9,900.00 Corporate Sponsorship
Ms Cure Fund, Inc. $10,000.00 Educational Grants
Ms Cure Fund, Inc. $50,000.00 Educational Grants
Ms Cure Fund, Inc. $15,000.00 Educational Grants
Ms Views And News Inc. $9,000.00 Educational Grants
Multiple Myeloma Research $20,000.00 Educational Grants
Fdtn Inc. The
Multiple Myeloma Research $50,000.00 Educational Grants
Fdtn Inc. The
Multiple Myeloma Research $40,000.00 Corporate Sponsorship
Fdtn Inc. The
Nashville Cares Inc. $8,000.00 Corporate Sponsorship
National Alliance of Mental $5,000.00 Corporate Sponsorship
Illness Flordia
National Alliance of Mental $15,000.00 Corporate Sponsorship
Illness Michigan
National Alliance of Mental $5,000.00 Corporate Sponsorship
Illness Tennessee
National Alliance of Mental $5,000.00 Corporate Sponsorship
Illness Washington
National Alliance of State $30,000.00 Corporate Sponsorship
and Territorial AIDS
Directors
National Association of $6,750.00 Corporate Sponsorship
Hispanic Nurses
National Association of $6,750.00 Corporate Sponsorship
Hispanic Nurses
National Association of $25,000.00 Corporate Sponsorship
Latino Elected & Appointed
officials Educational Fund
National Brain Tumor $15,000.00 Corporate Sponsorship
Society (Nbts)
National Brain Tumor $50,000.00 Charitable Donations
Society (Nbts)
National Brain Tumor $25,000.00 Corporate Sponsorship
Society, Inc
National Coalition for $40,000.00 Corporate Sponsorship
Cancer
National Comprehensive $15,000.00 Corporate Sponsorship
Cancer Network
National Comprehensive $10,000.00 Corporate Sponsorship
Cancer Network
National Comprehensive $15,000.00 Corporate Sponsorship
Cancer Network
National Comprehensive $10,000.00 Corporate Sponsorship
Cancer Network
National Comprehensive $15,000.00 Corporate Sponsorship
Cancer Network
National Hemophlia $5,000.00 Corporate Sponsorship
Foundation
National Minority Quality $10,000.00 Corporate Sponsorship
forum Inc.
National Ms Society Upper $2,500.00 Corporate Sponsorship
Midwest Chapter
National Multiple Sclerosis $250,000.00 Corporate Sponsorship
Society
National Parkinson $2,500.00 Corporate Sponsorship
Foundation Minnesota
National Parkinson $2,500.00 Corporate Sponsorship
Foundation Minnesota
National Parkinson $1,000.00 Corporate Sponsorship
Foundation Minnesota
National Parkinson $2,500.00 Corporate Sponsorship
Foundation Minnesota
Nationwide Childrens Hosp $5,000.00 Corporate Sponsorship
Fdtn
Natl Academy of Dermatology $30,000.00 Corporate Sponsorship
Nurse Practitioners
Natl Aids Treatment $300,000.00 Charitable Donations
Advocacy Project
Natl Alliance of State And $100,000.00 Charitable Donations
Territorial Aids Directors
Natl Asoc of Managed Care $30,000.00 Educational Grants
Phys
Natl Asoc of Managed Care $45,000.00 Educational Grants
Phys
Natl Asoc of Managed Care $40,000.00 Educational Grants
Phys
Natl Asoc of Managed Care $25,000.00 Corporate Sponsorship
Phys
Natl Asoc of Managed Care $35,000.00 Educational Grants
Phys
Natl Breast Cancer $5,000.00 Charitable Donations
Coalition Fund
Natl Business Coalition On $50,000.00 Corporate Sponsorship
Hlth
Natl Commission On $10,000.00 Educational Grants
Correctional Hlth Care
Natl Commission On $7,500.00 Corporate Sponsorship
Correctional Hlth Care
Natl Commission On $7,500.00 Corporate Sponsorship
Correctional Hlth Care
Natl Committee for Quality $100,000.00 Corporate Sponsorship
Assurance
Natl Committee for Quality $95,000.00 Educational Grants
Assurance
Natl Comprehensive Cancer $50,000.00 Charitable Donations
Ntwrk
Natl Comprehensive Cancer $40,000.00 Corporate Sponsorship
Ntwrk
Natl Comprehensive Cancer $50,000.00 Educational Grants
Ntwrk
Natl Comprehensive Cancer $5,000.00 Educational Grants
Ntwrk
Natl Comprehensive Cancer $25,000.00 Educational Grants
Ntwrk
Natl Comprehensive Cancer $25,000.00 Charitable Donations
Ntwrk
Natl Comprehensive Cancer $50,000.00 Educational Grants
Ntwrk
Natl Comprehensive Cancer $50,000.00 Corporate Sponsorship
Ntwrk
Natl Comprehensive Cancer $50,000.00 Educational Grants
Ntwrk
Natl Comprehensive Cancer $40,000.00 Educational Grants
Ntwrk
Natl Comprehensive Cancer $240,000.00 Corporate Sponsorship
Ntwrk
Natl Comprehensive Cancer $75,000.00 Educational Grants
Ntwrk
Natl Multiple Sclerosis $10,000.00 Corporate Sponsorship
Socty
Natl Organization of $5,000.00 Corporate Sponsorship
Rheumlgy Managers
Natl Pancreas Fdtn $200,000.00 Educational Grants
Natl Pancreas Fdtn $85,000.00 Educational Grants
Natl Pancreas Fdtn $85,000.00 Charitable Donations
Natl Pancreas Fdtn $75,000.00 Charitable Donations
Natl Pancreas Fdtn $70,000.00 Educational Grants
Natl Pancreas Fdtn $1,000.00 Corporate Sponsorship
Natl Pancreas Fdtn $75,000.00 Corporate Sponsorship
Natl Pancreas Fdtn $7,500.00 Corporate Sponsorship
Natl Pancreas Fdtn $2,500.00 Corporate Sponsorship
Natl Pancreas Fdtn $200,000.00 Educational Grants
Natl Pancreas Fdtn $25,000.00 Corporate Sponsorship
Natl Pancreas Fdtn $75,000.00 Corporate Sponsorship
Natl Parkinson Fdtn Inc. $75,000.00 Corporate Sponsorship
Natl Parkinson Fdtn Inc. $2,500.00 Corporate Sponsorship
Natl Parkinson Fdtn Inc. $5,000.00 Corporate Sponsorship
Natl Parkinson Fdtn Inc. $2,500.00 Corporate Sponsorship
Natl Parkinson Fdtn Inc. $1,000.00 Corporate Sponsorship
Natl Parkinson Fdtn Inc. $1,500.00 Corporate Sponsorship
Natl Parkinson Fdtn Inc. $10,000.00 Corporate Sponsorship
Natl Parkinson Fdtn Inc. $50,000.00 Educational Grants
Natl Parkinson Fdtn Inc. $10,000.00 Corporate Sponsorship
Natl Parkinson Fdtn Inc. $85,000.00 Corporate Sponsorship
Natl Psoriasis Fdtn $25,000.00 Corporate Sponsorship
Natl Psoriasis Fdtn $75,000.00 Educational Grants
Natl Psoriasis Fdtn $50,000.00 Educational Grants
Natl Psoriasis Fdtn $30,000.00 Educational Grants
Natl Psoriasis Fdtn $26,000.00 Corporate Sponsorship
Natl Psoriasis Fdtn $26,000.00 Corporate Sponsorship
Natl Psoriasis Fdtn $26,000.00 Corporate Sponsorship
Natl Psoriasis Fdtn $26,000.00 Corporate Sponsorship
Natl Psoriasis Fdtn $20,000.00 Corporate Sponsorship
Natl Psoriasis Fdtn $10,000.00 Corporate Sponsorship
Natl Psoriasis Fdtn $13,550.00 Charitable Donations
Natl Psoriasis Fdtn $50,000.00 Educational Grants
Natl Psoriasis Fdtn $20,000.00 Corporate Sponsorship
Natl Psoriasis Fdtn $50,000.00 Corporate Sponsorship
Natl Psoriasis Fdtn $50,000.00 Corporate Sponsorship
Natl Psoriasis Fdtn $40,000.00 Corporate Sponsorship
Natl Psoriasis Fdtn $2,500.00 Corporate Sponsorship
Natl Psoriasis Fdtn $150,000.00 Corporate Sponsorship
Natl Psoriasis Fdtn $20,000.00 Corporate Sponsorship
Natl Psoriasis Fdtn $100,000.00 Corporate Sponsorship
Natl Psoriasis Fdtn $40,000.00 Corporate Sponsorship
Natl Psoriasis Fdtn $30,000.00 Corporate Sponsorship
Natl Psoriasis Fdtn $20,000.00 Corporate Sponsorship
Natl Socty for Cutaneous $50,000.00 Corporate Sponsorship
Medicine
Natl Socty for Cutaneous $75,000.00 Corporate Sponsorship
Medicine
Natl Socty for Cutaneous $135,000.00 Corporate Sponsorship
Medicine
Natl Socty for Cutaneous $135,000.00 Corporate Sponsorship
Medicine
Neuro Challenge Foundation $7,500.00 Educational Grants
Inc.
Neurologic Disease $4,995.00 Educational Grants
Foundation
New Jersey Academy of $105,000.00 Educational Grants
Family Phys
New Mexico Parkinsons $3,500.00 Educational Grants
Disease Coalition
New York Academy of Scnc $1,500.00 Educational Grants
New York Academy of Scnc $1,500.00 Educational Grants
New York Socty for $2,000.00 Corporate Sponsorship
Gastrointestinal Endoscopy
New York State Council of $11,500.00 Corporate Sponsorship
Hlth-System Pharmacists
New York State Rheumlgy $18,000.00 Corporate Sponsorship
Socty
New York Univ School of $20,000.00 Educational Grants
Medicine
New York Univ School of $10,000.00 Educational Grants
Medicine
New York Univ School of $5,000.00 Educational Grants
Medicine
New York Univ School of $5,000.00 Educational Grants
Medicine
New York Univ School of $10,000.00 Educational Grants
Medicine
New York Univ School of $10,000.00 Educational Grants
Medicine
New York Univ School of $20,000.00 Educational Grants
Medicine
Nexus Global Grp Scnc $10,000.00 Corporate Sponsorship
Nicole Jarvis Md Parkinsons $1,000.00 Corporate Sponsorship
Research Fdtn
NL Communications Inc. $50,000.00 Educational Grants
NL Communications Inc. $35,000.00 Educational Grants
NL Communications Inc. $40,000.00 Educational Grants
NL Communications Inc. $50,000.00 Educational Grants
NL Communications Inc. $15,000.00 Educational Grants
NL Communications Inc. $50,000.00 Educational Grants
NL Communications Inc. $50,000.00 Educational Grants
NL Communications Inc. $100,000.00 Educational Grants
NL Communications Inc. $50,000.00 Educational Grants
NL Communications Inc. $10,000.00 Educational Grants
NL Communications Inc. $25,000.00 Educational Grants
NL Communications Inc. $25,000.00 Educational Grants
NL Communications Inc. $40,000.00 Educational Grants
NL Communications Inc. $25,000.00 Educational Grants
NL Communications Inc. ($40,000.00) Educational Grants
NL Communications Inc. $128,000.00 Educational Grants
NL Communications Inc. $125,000.00 Educational Grants
NL Communications Inc. $75,000.00 Educational Grants
NL Communications Inc. $65,000.00 Educational Grants
NL Communications Inc. $50,000.00 Educational Grants
NL Communications Inc. $35,000.00 Educational Grants
NL Communications Inc. $25,000.00 Educational Grants
NL Communications Inc. $20,000.00 Educational Grants
North American Ctr for $390,000.00 Educational Grants
Continuing Med Education
(NACCME, LLC)
North American Ctr for $90,000.00 Educational Grants
Continuing Med Education
(NACCME, LLC)
North American Ctr for $90,000.00 Educational Grants
Continuing Med Education
(NACCME, LLC)
North American Ctr for $100,000.00 Educational Grants
Continuing Med Education
(NACCME, LLC)
North American Socty for $31,000.00 Educational Grants
Pediatric Gastro
Hepatology And Nutrition
North American Socty for $40,000.00 Fellowships and
Pediatric Gastro Scholarships
Hepatology And Nutrition
North Dakota Pharmacists $2,500.00 Corporate Sponsorship
Asoc
North Dakota Society of $1,750.00 Corporate Sponsorship
Health System Pharmacists
North Eastern Section of $3,000.00 Corporate Sponsorship
The American Chemical
Society, Inc.
North Memorial Commty Fdtn $2,500.00 Corporate Sponsorship
Northeast Business Grp On $5,000.00 Corporate Sponsorship
Hlth
Northeast Business Grp On $5,000.00 Corporate Sponsorship
Hlth
Northwest Health Law $1,000.00 Corporate Sponsorship
Advocates
Northwest Kdny Centers $2,500.00 Corporate Sponsorship
Northwest Parkinsons Fdtn $7,000.00 Educational Grants
Northwest Parkinsons Fdtn $5,000.00 Corporate Sponsorship
Northwest Parkinsons Fdtn $5,000.00 Educational Grants
Northwestern Memorial Fdtn $8,000.00 Educational Grants
Northwestern Univ $25,000.00 Corporate Sponsorship
Northwestern Univ $50,000.00 Fellowships and
Scholarships
Northwestern Univ $5,000.00 Educational Grants
Northwestern Univ $5,000.00 Educational Grants
Northwestern Univ $2,000.00 Educational Grants
Norton Hlthcr Inc. $3,000.00 Corporate Sponsorship
Ocular Immunology And $2,500.00 Corporate Sponsorship
Uveitis Fdtn
Ohio Asoc of Rheumlgy $10,000.00 Corporate Sponsorship
Ohio Gastro Socty $5,000.00 Corporate Sponsorship
Omnia Education Inc. $95,000.00 Educational Grants
Oncology Nursing Socty $15,000.00 Educational Grants
Oncology Nursing Socty $38,500.00 Corporate Sponsorship
Open Doors Commty School $2,000.00 Charitable Donations
Oregon Hlth & Scnc Univ $10,000.00 Educational Grants
Oregon Hlth & Scnc Univ $2,000.00 Educational Grants
Oregon Hlth & Scnc Univ $5,000.00 Educational Grants
Oregon Hlth & Scnc Univ $10,000.00 Educational Grants
Oregon State University $7,500.00 Corporate Sponsorship
Foundation
Organic Reactions Catalysis $1,000.00 Educational Grants
Socty
Ostomy Asoc of Greater $1,000.00 Corporate Sponsorship
Chicago
Ounce of Prevention Fund $10,000.00 Charitable Donations
Pacific Dermatologic Asoc $10,000.00 Corporate Sponsorship
Pacific Dermatologic Asoc $20,000.00 Corporate Sponsorship
Pack Hlth LLC $91,375.00 Educational Grants
Pack Hlth LLC $175,000.00 Educational Grants
Pack Hlth LLC $127,800.00 Educational Grants
Pack Hlth LLC $108,875.00 Educational Grants
Pancreas Club The $10,000.00 Educational Grants
Pancreatic Cancer Action $1,250.00 Corporate Sponsorship
Ntwrk Inc.
Pancreatic Cancer Action $1,250.00 Corporate Sponsorship
Ntwrk Inc.
Pancreatic Cancer Action $25,000.00 Corporate Sponsorship
Ntwrk Inc.
Pancreatic Cancer Action $234,000.00 Corporate Sponsorship
Ntwrk Inc.
Park Nicollet $1,000.00 Corporate Sponsorship
Parkinson Alliance Inc. $1,000.00 Corporate Sponsorship
Parkinson And Movement $15,000.00 Educational Grants
Disorder All
Parkinson And Movement $1,250.00 Corporate Sponsorship
Disorder All
Parkinson And Movement $50,000.00 Educational Grants
Disorder All
Parkinson Asoc of The $8,000.00 Educational Grants
Rockies
Parkinson Asoc of The $6,000.00 Educational Grants
Rockies
Parkinson Association of $500.00 Corporate Sponsorship
Alabama
Parkinson Association of $500.00 Corporate Sponsorship
Central Florida Inc.
Parkinson Council $20,000.00 Corporate Sponsorship
Parkinson Fdtn of The Natl $10,000.00 Educational Grants
Capital Area
Parkinson Foundation of $1,000.00 Corporate Sponsorship
Oklahoma
Parkinson Foundation of $1,500.00 Corporate Sponsorship
Oklahoma
Parkinson Institute $5,000.00 Corporate Sponsorship
Parkinson Ntwrk of Arizona $2,500.00 Corporate Sponsorship
Parkinson Society of $500.00 Corporate Sponsorship
Greenville Area
Parkinson Study Group $10,000.00 Educational Grants
Parkinson Support Center of $2,500.00 Corporate Sponsorship
Kentuciana
Parkinson Support Center of $5,000.00 Corporate Sponsorship
Kentuciana
Parkinson Wellness Recovery $1,000.00 Corporate Sponsorship
Parkinsons And Movement $2,500.00 Corporate Sponsorship
Disorder Foundation
Parkinsons Asoc of Western $1,500.00 Corporate Sponsorship
Michigan
Parkinsons Disease Fdtn $25,000.00 Educational Grants
Parkinsons Disease Fdtn $50,000.00 Educational Grants
Parkinsons Disease Fdtn $7,500.00 Corporate Sponsorship
Parkinsons Outreach $1,000.00 Corporate Sponsorship
Association
Parkinsons Resources of $5,000.00 Corporate Sponsorship
Oregon
Parkinsons Resources of $5,000.00 Corporate Sponsorship
Oregon
Parkinsons Unity Walk $50,000.00 Corporate Sponsorship
Parkinsons Unity Walk $64,000.00 Corporate Sponsorship
Partners Hlthcr System ($10,000.00) Educational Grants
Partnership for A Drug Free $50,000.00 Charitable Donations
America
Partnership for Quality Med $2,000.00 Charitable Donations
Donations Pqmd
Partnership for Quality Med $1,000.00 Charitable Donations
Donations Pqmd
Patient Access Ntwrk Fdtn $8,400,000.00 Charitable Donations
Patient Access Ntwrk Fdtn $260,000.00 Charitable Donations
Patient Access Ntwrk Fdtn $557,000.00 Charitable Donations
Patient Empowerment Ntwrk $75,000.00 Educational Grants
Patient Empowerment Ntwrk $40,000.00 Educational Grants
Patient Empowerment Ntwrk $22,500.00 Educational Grants
Patient Empowerment Ntwrk $20,000.00 Educational Grants
Patient Empowerment Ntwrk $22,500.00 Educational Grants
Patient Empowerment Ntwrk $35,000.00 Educational Grants
Patient Empowerment Ntwrk $20,000.00 Educational Grants
Patient Empowerment Ntwrk $35,000.00 Educational Grants
Patient Empowerment Ntwrk $10,000.00 Educational Grants
Patient Power LLC $90,000.00 Corporate Sponsorship
Pediatric Endocrinology $6,000.00 Corporate Sponsorship
Nursing Socty
Pediatric Endocrinology $10,000.00 Charitable Donations
Nursing Socty
Pediatric Splts of Virginia $2,000.00 Corporate Sponsorship
LLC
Pennsylvania Academy of $13,550.00 Corporate Sponsorship
Dermatology And
Dermatologic Surgry
Pennsylvania Socty of $10,000.00 Corporate Sponsorship
Gastro
Pennsylvania State Univ $15,000.00 Educational Grants
Pennsylvania State Univ $15,000.00 Educational Grants
Pennsylvania State Univ ($36,337.33) Educational Grants
Pennsylvania State Univ $20,000.00 Educational Grants
Phmcy Quality Alliance $12,500.00 Educational Grants
Phoenix Childrens Hosp $1,000.00 Corporate Sponsorship
Phys Education Resource $25,000.00 Educational Grants
Phys Education Resource $75,000.00 Educational Grants
Phys Education Resource $25,000.00 Educational Grants
Phys Education Resource $25,000.00 Educational Grants
Phys Education Resource $25,000.00 Educational Grants
Phys Education Resource $50,000.00 Educational Grants
Phys Education Resource $50,000.00 Educational Grants
Phys Education Resource $50,000.00 Educational Grants
Phys Education Resource $75,000.00 Educational Grants
Phys Education Resource $50,000.00 Educational Grants
Pins for Parkinsons $500.00 Corporate Sponsorship
Pittsburgh Business Grp On $3,800.00 Corporate Sponsorship
Hlth
Pittsburgh Business Grp On $3,800.00 Corporate Sponsorship
Hlth
President And Fellows of $6,000.00 Educational Grants
Harvard Colg
Prevent Cancer Fdtn $25,000.00 Charitable Donations
Prime Education Inc. $100,000.00 Educational Grants
Prime Education Inc. $200,000.00 Educational Grants
Prime Education Inc. $218,348.25 Educational Grants
Prime Education Inc. $500,000.00 Educational Grants
Prime Education Inc. $200,000.00 Educational Grants
Prime Oncology Inc. $85,000.00 Educational Grants
Prime Oncology Inc. $142,376.00 Educational Grants
Prime Oncology Inc. $50,000.00 Educational Grants
Prime Oncology Inc. $75,000.00 Educational Grants
Prime Oncology Inc. $85,000.00 Educational Grants
Princeton Univ Trustees $50,000.00 Fellowships and
Scholarships
Proce Inc. $15,000.00 Educational Grants
Project Access Now $3,500.00 Corporate Sponsorship
Project Inform Inc. $75,000.00 Charitable Donations
Project Inform Inc. $30,000.00 Corporate Sponsorship
Projects In Knowledge Inc. $100,000.00 Educational Grants
Promedica International Cme $15,000.00 Educational Grants
Promis Hlth Organization $5,000.00 Educational Grants
Prostate Cancer Foundation $4,000.00 Corporate Sponsorship
Chicago
Prostate Cancer Research $10,000.00 Educational Grants
Inst
Prostate Cancer Research $15,000.00 Corporate Sponsorship
Inst
Prostate Hlth Education $15,000.00 Educational Grants
Ntwrk
Prostate Hlth Education $10,000.00 Educational Grants
Ntwrk
Prostate Net Inc. The $15,000.00 Educational Grants
Prostaware $1,000.00 Corporate Sponsorship
Puerto Rico Academy of $16,000.00 Corporate Sponsorship
Family Phys
Puerto Rico Asoc of Gastro $15,000.00 Educational Grants
Puerto Rico Asoc of Gastro $30,000.00 Corporate Sponsorship
Puerto Rico Asoc of Gastro $6,500.00 Educational Grants
Purdue Univ $200,000.00 Educational Grants
Purdue Univ $250,000.00 Educational Grants
Purdue Univ ($60,000.00) Educational Grants
Regents of The Univ of $10,000.00 Educational Grants
California The
Regents of The Univ of $5,000.00 Educational Grants
California The
Regents of The Univ of $40,000.00 Fellowships and
California The Scholarships
Regents of The Univ of $5,000.00 Educational Grants
California The
Regents of The Univ of $15,000.00 Educational Grants
California The
Regents of The Univ of $50,000.00 Fellowships and
California The Scholarships
Regents of The Univ of $2,500.00 Educational Grants
California The
Regents of The Univ of $10,000.00 Educational Grants
California The
Regents of The Univ of $5,000.00 Educational Grants
Michigan
Regents of The Univ of $10,000.00 Corporate Sponsorship
Michigan
Regents of The Univ of $1,000.00 Educational Grants
Michigan
Regional Osteopathic Med $165,000.00 Educational Grants
Education
Renal Phys Asoc $30,000.00 Corporate Sponsorship
Respiratory Hlth Asoc of $4,050.00 Corporate Sponsorship
Metro Chicago
Rheumatism Socty of The $15,000.00 Corporate Sponsorship
District of Columbia The
Rheumatology Association of $5,000.00 Corporate Sponsorship
Nevada
Rheumlgy Alliance of $25,000.00 Corporate Sponsorship
Louisiana
Rheumlgy Nurses Socty $80,000.00 Educational Grants
Rheumlgy Nurses Socty $31,875.00 Corporate Sponsorship
Rheumlgy Nurses Socty $5,000.00 Corporate Sponsorship
Rheumlgy Nurses Socty $25,000.00 Educational Grants
Rheumlgy Nurses Socty $44,625.00 Corporate Sponsorship
Riverside Medical Clinic $7,500.00 Educational Grants
Charitable Foundation
Robert Michael Educational $123,500.00 Educational Grants
Inst LLC
Robert Michael Educational $80,000.00 Educational Grants
Inst LLC
Rock Steady Boxing $500.00 Corporate Sponsorship
Rocky Mountain Ms Center $5,000.00 Educational Grants
Rush Univ Med Ctr $50,000.00 Educational Grants
Rush Univ Med Ctr $75,000.00 Educational Grants
Rush Univ Med Ctr $35,000.00 Educational Grants
Rutgers The State Univ of $60,000.00 Educational Grants
New Jersey
Rutgers The State Univ of $25,000.00 Educational Grants
New Jersey
Rutgers The State Univ of $50,000.00 Educational Grants
New Jersey
Rutgers University $1,500.00 Educational Grants
Foundation
Safety Pharmacology Socty $2,000.00 Educational Grants
Saint Anthony Hosp Fdtn $1,500.00 Educational Grants
San Francisco Neuro Socty $1,500.00 Educational Grants
San Francisco Retina $5,000.00 Educational Grants
Foundation
San Juan Bautista Med $40,000.00 Fellowships and
Scholarships
Scott And White Healthcare $1,000.00 Corporate Sponsorship
Foundation
Scripps Hlth $5,000.00 Educational Grants
Scripps Hlth $50,000.00 Educational Grants
Scripps Hlth $5,000.00 Educational Grants
Scripps Hlth $5,000.00 Educational Grants
Scripps Hlth $50,000.00 Educational Grants
Scripps Hlth $25,000.00 Educational Grants
Scripps Research Inst. $5,000.00 Fellowships and
Scholarships
Scripps Research Inst. $2,000.00 Educational Grants
Seattle Science Foundation $7,500.00 Educational Grants
Sexual Medicine Socty of ($25,000.00) Educational Grants
North Am
Sexual Medicine Socty of $225,000.00 Corporate Sponsorship
North America Inc.
Share $10,000.00 Patient Support
Sheknows LLC $43,000.00 Corporate Sponsorship
Smith Wholesale Drug $9,000.00 Corporate Sponsorship
Company
Sociedad Dermatologica De $15,000.00 Corporate Sponsorship
Puerto Rico
Sociedad Dermatologica De $35,000.00 Corporate Sponsorship
Puerto Rico
Sociedad Pr Endocrinologia $15,000.00 Corporate Sponsorship
Y Diabetologia
Sociedad Puertorriquena $8,000.00 Corporate Sponsorship
Pediatria
Society for Mucosal $1,500.00 Educational Grants
Immunology
Society for Neuro-Oncology $10,000.00 Educational Grants
Society for Neuro-Oncology $107,400.00 Corporate Sponsorship
Society for Neuro-Oncology $25,000.00 Corporate Sponsorship
Society of Nuclear Medicine $5,000.00 Corporate Sponsorship
and Molecular Imaging
Socty for Immunotherapy of $5,000.00 Educational Grants
Cancer
Socty for Leukocyte Biology $1,500.00 Educational Grants
Socty for Neuroscience $2,500.00 Educational Grants
Socty for Translational $10,000.00 Educational Grants
Oncology
Socty of Dermatology Phys $45,000.00 Corporate Sponsorship
Assistants
Socty of Dermatology Phys $20,000.00 Corporate Sponsorship
Assistants
Socty of Dermatology Phys $40,000.00 Corporate Sponsorship
Assistants
Socty of Investigative $30,000.00 Educational Grants
Dermatology
Socty of Toxicologic $1,000.00 Corporate Sponsorship
Pathology
Socty of Toxicologic $15,000.00 Corporate Sponsorship
Pathology
Socty of Toxicology $450.00 Corporate Sponsorship
Socty of Toxicology $2,500.00 Corporate Sponsorship
South Carolina Alliance of $5,000.00 Corporate Sponsorship
Hlth Plans
South Carolina $5,000.00 Corporate Sponsorship
Dermatological Asoc
South Dakota Parkinson $500.00 Corporate Sponsorship
Foundation
South Texas Asoc of $40,000.00 Corporate Sponsorship
Rheumatologists
Southeastern Consortium for $10,000.00 Corporate Sponsorship
Dermatology
Splty Pharma Education Ctr $49,750.00 Educational Grants
St Louise Regional Hosp ($2,000.00) Educational Grants
State of Maryland $40,000.00 Fellowships and
Scholarships
State of Maryland $5,500.00 Educational Grants
State of Maryland $23,000.00 Educational Grants
Super Jake Fdtn The $25,000.00 Charitable Donations
Susan G Komen Philadelphia $3,500.00 Educational Grants
Take A Breather Foundation $10,000.00 Corporate Sponsorship
Take A Breather Foundation $2,500.00 Corporate Sponsorship
Take A Breather Foundation $15,000.00 Corporate Sponsorship
Tarsus Cardio Inc. Dba $35,000.00 Corporate Sponsorship
South Beach Symposium
Team Fox North Texas $1,000.00 Corporate Sponsorship
Tennessee Dermatology Socty $4,000.00 Corporate Sponsorship
Tennessee Disability $5,000.00 Corporate Sponsorship
Coalition
Tennessee Disability $2,500.00 Corporate Sponsorship
Coalition
Tennessee Nurses $6,000.00 Corporate Sponsorship
Association
Teratology Socty $2,000.00 Corporate Sponsorship
Texas Academy of Family $2,500.00 Corporate Sponsorship
Physicians
Texas Medical Association $3,000.00 Corporate Sponsorship
Texas Medical Association $10,000.00 Corporate Sponsorship
Texas Neuro Socty $5,000.00 Corporate Sponsorship
Texas Osteopathic Medical $3,000.00 Corporate Sponsorship
Association
Texas Urological Socty $4,500.00 Corporate Sponsorship
Texas Urological Socty $4,500.00 Corporate Sponsorship
The Endocrine Socty $25,000.00 Educational Grants
The Endocrine Socty $25,000.00 Educational Grants
The Endocrine Socty $25,000.00 Educational Grants
The International Psoriasis $25,000.00 Educational Grants
Council
Trinity Christian Colg Asoc $1,000.00 Charitable Donations
Trustees of The Univ of $10,000.00 Educational Grants
Pennsylvania
Tufts Med Ctr $2,500.00 Corporate Sponsorship
Tufts Univ ($4,580.00) Educational Grants
Tulane Univ Hlth Scnc Ctr $20,000.00 Corporate Sponsorship
UC Regents Maxillofacial $20,000.00 Educational Grants
Prosthetics Clnc
UC Regents Maxillofacial $10,000.00 Educational Grants
Prosthetics Clnc
UC Regents Maxillofacial $40,000.00 Fellowships and
Prosthetics Clnc Scholarships
UC Regents Maxillofacial $5,000.00 Educational Grants
Prosthetics Clnc
UC Regents Maxillofacial $15,000.00 Educational Grants
Prosthetics Clnc
Ultimate Med Academy Med $150,000.00 Educational Grants
Learning Grp LLC
Ultimate Med Academy Med $198,790.00 Educational Grants
Learning Grp LLC
Ultimate Med Academy Med $98,600.00 Educational Grants
Learning Grp LLC
Ultimate Med Academy Med $389,100.00 Educational Grants
Learning Grp LLC
UMA Education Inc. DBA $90,000.00 Educational Grants
Global Education Grp
Umass Amherst $5,000.00 Corporate Sponsorship
Umass Fdtn $2,500.00 Charitable Donations
United Spinal Association $75,000.00 Corporate Sponsorship
Inc.
United States Adult Cystic $7,500.00 Educational Grants
Fibrosis Asoc Inc.
United Way of Ctrl $1,250.00 Corporate Sponsorship
Massachusetts
United Way of Ctrl $5,000.00 Corporate Sponsorship
Massachusetts
Univ Connecticut Derm $12,000.00 Fellowships and
Scholarships
Univ Connecticut Derm ($130.91) Fellowships and
Scholarships
Univ Hlth Srvc At Stony $20,000.00 Educational Grants
Point Inc.
Univ Hosp Cleveland Med $15,000.00 Fellowships and
Scholarships
Univ Hosp of Brooklyn $16,000.00 Educational Grants
Univ of Alabama At $8,000.00 Educational Grants
Birmingham
Univ of Alabama At $40,000.00 Fellowships and
Birmingham Scholarships
Univ of California--San $50,000.00 Fellowships and
Francisco Scholarships
Univ of California--San $5,000.00 Educational Grants
Francisco
Univ of California--San $10,000.00 Educational Grants
Francisco
Univ of California Berkeley $20,000.00 Educational Grants
Univ of California Berkeley $45,000.00 Corporate Sponsorship
Univ of California Berkeley $50,000.00 Corporate Sponsorship
Univ of California Irvine $5,000.00 Fellowships and
Scholarships
Univ of California Irvine $5,000.00 Educational Grants
Univ of Chicago $10,000.00 Charitable Donations
Univ of Chicago $10,000.00 Educational Grants
Univ of Cincinnati $85,000.00 Educational Grants
Univ of Cincinnati $75,000.00 Educational Grants
Univ of Cincinnati $60,000.00 Educational Grants
Univ of Cincinnati $250,000.00 Educational Grants
Univ of Cincinnati $130,000.00 Educational Grants
Univ of Cincinnati $30,000.00 Educational Grants
Univ of Colorado Denver $3,500.00 Educational Grants
School of Medicine
Univ of Florida $15,898.00 Educational Grants
Univ of Florida $75,000.00 Educational Grants
Univ of Florida Fdtn $500.00 Corporate Sponsorship
Univ of Florida Fdtn $40,000.00 Fellowships and
Scholarships
Univ of Illinios $40,000.00 Fellowships and
Scholarships
Univ of Illinois Fdtn $1,000.00 Charitable Donations
Univ of Illinois Fdtn $1,000.00 Charitable Donations
Univ of Kansas Hosp $50,000.00 Fellowships and
Scholarships
Univ of Kansas Hosp $45,000.00 Educational Grants
Univ of Louisville Research $75,000.00 Educational Grants
Fdtn
Univ of Louisville Research $15,000.00 Educational Grants
Fdtn
Univ of Louisville Research $5,000.00 Educational Grants
Fdtn
Univ of Louisville Research $1,500.00 Educational Grants
Fdtn
Univ of Maryland Baltimore $5,000.00 Fellowships and
Scholarships
Univ of Maryland Baltimore $1,000.00 Charitable Donations
Fdtn
Univ of Massachusetts Med $1,000.00 Charitable Donations
School
Univ of Massachusetts Med $2,500.00 Educational Grants
School
Univ of Minnesota Regents $1,500.00 Educational Grants
Univ of Minnesota Regents $1,000.00 Educational Grants
Univ of Nebraska Med Ctr $20,000.00 Educational Grants
Univ of Nebraska Med Ctr $7,500.00 Educational Grants
------------------------------------------------------------------------
Grants Donations Report--2017
(Parentheses represent refunds of previously disclosed payments)
Report as of 3/31/2018
------------------------------------------------------------------------
Recipient Payment Amount Purpose
------------------------------------------------------------------------
50 Hoops $10,000.00 Educational Grants
A and R Educational Group $4,500.00 Corporate Sponsorships
LLC
A and R Educational Group $20,000.00 Corporate Sponsorships
LLC
Academia Medica Del Sur $8,000.00 Corporate Sponsorships
Academia Puertorriquena DE $3,000.00 Corporate Sponsorships
Neurologia
Academy of Managed Care $25,000.00 Corporate Sponsorships
Pharmacy
Academy of Managed Care $15,000.00 Corporate Sponsorships
Pharmacy
Academy of Physician $2,500.00 Corporate Sponsorships
Assistants, Tennessee
Advanced Urology Institute $10,000.00 Corporate Sponsorships
Education and General Fund
Advances in Cosmetic and $75,000.00 Corporate Sponsorships
Med Dermatology Inc.
Advances in Cosmetic and $100,000.00 Corporate Sponsorships
Med Dermatology Inc.
Advances in Cosmetic and $75,000.00 Corporate Sponsorships
Med Dermatology Inc.
Advocate Bromenn Medical $2,000.00 Educational Grants
Center
Advocate Bromenn Medical $2,500.00 Educational Grants
Center
Aesthetic Dermatology $35,000.00 Corporate Sponsorships
Symposia
Aesthetic Dermatology $25,000.00 Corporate Sponsorships
Symposia
AIDS Connecticut $2,500.00 Corporate Sponsorships
AIDS Connecticut $2,500.00 Corporate Sponsorships
AIDS Foundation of Chicago $25,000.00 Charitable Donations
AIDS Institute $36,000.00 Corporate Sponsorships
Alabama Dermatology Society $50,000.00 Corporate Sponsorships
Alabama Dermatology Society $50,000.00 Corporate Sponsorships
Alaska Rheumatology $5,000.00 Corporate Sponsorships
Alliance
Alliance for Aging Research $5,000.00 Corporate Sponsorships
Alliance for Patient Access $30,000.00 Corporate Sponsorships
Alzheimers Association $10,000.00 Corporate Sponsorships
Greater Illinois Chapter
Alzheimers Association $2,500.00 Corporate Sponsorships
Greater Illinois Chapter
Alzheimers Association $5,000.00 Corporate Sponsorships
Greater Illinois Chapter
Alzheimers Disease and $133,750.00 Corporate Sponsorships
Related Disorders
Association Inc.
American Academy of $50,000.00 Charitable Donations
Dermatology
American Academy of $65,000.00 Corporate Sponsorships
Dermatology
American Academy of $35,000.00 Corporate Sponsorships
Dermatology
American Academy of $25,000.00 Charitable Donations
Dermatology
American Academy of $40,000.00 Educational Grants
Dermatology
American Academy of $25,000.00 Corporate Sponsorships
Dermatology
American Academy of $15,000.00 Charitable Donations
Dermatology
American Academy of $37,500.00 Corporate Sponsorships
Dermatology
American Academy of $50,000.00 Educational Grants
Dermatology
American Academy of $300,000.00 Corporate Sponsorships
Dermatology
American Academy of Family $17,000.00 Educational Grants
Physicians
American Academy of $75,000.00 Corporate Sponsorships
Neurology Institute
American Academy of $30,000.00 Educational Grants
Neurology Institute
American Academy of $53,400.00 Corporate Sponsorships
Neurology Institute
American Academy of $50,000.00 Fellowships and
Neurology Institute Scholarships
American Academy of $30,000.00 Corporate Sponsorships
Neurology Institute
American Academy of $14,000.00 Corporate Sponsorships
Pediatrics
American Academy of $10,000.00 Educational Grants
Physician Assistants
American Academy of $16,000.00 Educational Grants
Physician Assistants
American Association of $20,000.00 Corporate Sponsorships
Clinical Endocrinologists
New Jersey Chapter
American Association of $18,000.00 Educational Grants
Clinical Endocrinologists
New Jersey Chapter
American Association of $10,000.00 Corporate Sponsorships
Physicians of Indian
Origin Arkansas
American Association of $10,000.00 Corporate Sponsorships
Physicians of Indian
Origin Arkansas
American Association for ($2,205.00) Educational Grants
Accreditation of
Laboratory Animal Care
International
American Association for $25,000.00 Fellowships and
Cancer Research Scholarships
American Association for $25,000.00 Educational Grants
Cancer Research
American Association for $25,000.00 Educational Grants
Cancer Research
American Association for $10,000.00 Educational Grants
Cancer Research
American Association for $25,000.00 Charitable Donations
Cancer Research
American Association for $10,000.00 Educational Grants
Cancer Research
American Association for $25,000.00 Educational Grants
Cancer Research
American Association for $25,000.00 Educational Grants
Cancer Research
American Association for $15,000.00 Educational Grants
Cancer Research
American Association for $15,000.00 Educational Grants
Cancer Research
American Association for $15,000.00 Educational Grants
Cancer Research
American Association for $15,000.00 Educational Grants
Cancer Research
American Association for $75,000.00 Educational Grants
Cancer Research
American Association for $20,000.00 Charitable Donations
Laboratory Animal Science
American Association for $5,000.00 Educational Grants
Laboratory Animal Science
New England Branch
American Association for $3,150.00 Corporate Sponsorships
The Study of Liver Disease
American Association of $7,400.00 Corporate Sponsorships
Gynecologic Laparoscopists
Inc
American Association of $59,500.00 Corporate Sponsorships
Gynecologic Laparoscopists
Inc
American Association of $50,000.00 Corporate Sponsorships
Pharmaceutical Scientists
American Autoimmune Related $40,000.00 Corporate Sponsorships
American Brain Tumor $30,000.00 Educational Grants
Association
American Brain Tumor $10,000.00 Educational Grants
Association
American Brain Tumor $15,000.00 Educational Grants
Association
American Brain Tumor $15,000.00 Corporate Sponsorships
Association
American Brain Tumor $7,500.00 Corporate Sponsorships
Association
American Cancer Society $10,000.00 Corporate Sponsorships
American Cancer Society $1,500.00 Corporate Sponsorships
American Cancer Society $3,500.00 Corporate Sponsorships
American Cancer Society $50,000.00 Corporate Sponsorships
American Cancer Society $5,000.00 Corporate Sponsorships
Action Network Connecticut
American Cancer Society $2,500.00 Corporate Sponsorships
Action Network North
Carolina
American Cancer Society $5,000.00 Corporate Sponsorships
Cancer Action Network
American Cancer Society $5,000.00 Corporate Sponsorships
Cancer Action Network
American Cancer Society $10,000.00 Corporate Sponsorships
Cancer Action Network
American Cancer Society $5,000.00 Corporate Sponsorships
Cancer Action Network
American Cancer Society $2,500.00 Corporate Sponsorships
Cancer Action Network
American Cancer Society $10,000.00 Corporate Sponsorships
Cancer Action Network
American Cancer Society $5,000.00 Corporate Sponsorships
Cancer Action Network
American Cancer Society $2,500.00 Corporate Sponsorships
Cancer Action Network
American Cancer Society $3,000.00 Corporate Sponsorships
Cancer Action Network
American Cancer Society $2,500.00 Corporate Sponsorships
Cancer Action Network
American Cancer Society $7,500.00 Corporate Sponsorships
Cancer Action Network
American Cancer Society $2,500.00 Corporate Sponsorships
Cancer Action Network
American Cancer Society $2,500.00 Corporate Sponsorships
Cancer Action Network
American Cancer Society $7,000.00 Corporate Sponsorships
Cancer Action Network
American Cancer Society $10,000.00 Corporate Sponsorships
Cancer Action Network
American Cancer Society $3,000.00 Corporate Sponsorships
Cancer Action Network
American Cancer Society $25,000.00 Corporate Sponsorships
Cancer Action Network
American Cancer Society $2,500.00 Corporate Sponsorships
Cancer Action Network
American Chemist Society $2,500.00 Educational Grants
American Chemist Society $1,000.00 Educational Grants
American Chemist Society $3,000.00 Educational Grants
American College of Chest $35,000.00 Educational Grants
Physicians
American College of $5,000.00 Educational Grants
Clinical Pharmacology
American College of $10,000.00 Patient Support
Endocrinology
American College of $15,000.00 Educational Grants
Gastroenterology
American College of $100,000.00 Corporate Sponsorships
Gastroenterology
American College of $90,000.00 Corporate Sponsorships
Gastroenterology
American College of $30,000.00 Charitable Donations
Laboratory Animal Medicine
American College of $5,000.00 Educational Grants
Obstetricians and
Gynecologists
American College of $15,000.00 Corporate Sponsorships
Osteopathic Obstetricians
and Gynecologists
American College of $15,000.00 Corporate Sponsorships
Osteopathic Obstetricians
and Gynecologists
American College of $57,000.00 Corporate Sponsorships
Physician Foundation
American College of $1,000.00 Corporate Sponsorships
Physicians West Virginia
Chapter
American College of $10,000.00 Corporate Sponsorships
Rheumatology
American College of $80,000.00 Fellowships and
Rheumatology Scholarships
American College of $25,000.00 Educational Grants
Rheumatology
American College of $20,000.00 Educational Grants
Rheumatology
American College of $37,500.00 Educational Grants
Rheumatology
American College of $17,600.00 Educational Grants
Rheumatology
American College of $150,000.00 Corporate Sponsorships
Rheumatology
American College of $2,000,000.00 Corporate Sponsorships
Rheumatology Research and
Education Foundation
American College of $500,000.00 Corporate Sponsorships
Rheumatology Research and
Education Foundation
American Congress of $10,500.00 Corporate Sponsorships
Obstetricians and
Gynecologists
American Congress of $12,500.00 Corporate Sponsorships
Obstetricians and
Gynecologists
American Congress of $12,500.00 Corporate Sponsorships
Obstetricians and
Gynecologists
American Congress of $12,500.00 Corporate Sponsorships
Obstetricians and
Gynecologists
American Congress of $13,250.00 Corporate Sponsorships
Obstetricians and
Gynecologists
American Congress of $50,000.00 Educational Grants
Obstetricians and
Gynecologists
American Congress of $5,000.00 Educational Grants
Obstetricians and
Gynecologists
American $12,500.00 Charitable Donations
Gastroenterological
Association Institute
American $5,000.00 Corporate Sponsorships
Gastroenterological
Association Institute
American $40,000.00 Educational Grants
Gastroenterological
Association Institute
American $75,000.00 Educational Grants
Gastroenterological
Association Institute
American Kidney Fund $5,000.00 Corporate Sponsorships
American Legion National $25,000.00 Corporate Sponsorships
American Liver Foundation $275,000.00 Corporate Sponsorships
American Liver Foundation $25,000.00 Corporate Sponsorships
American Liver Foundation $10,000.00 Corporate Sponsorships
American Liver Foundation $5,000.00 Educational Grants
American Liver Foundation $5,000.00 Educational Grants
American Liver Foundation $2,500.00 Corporate Sponsorships
American Liver Foundation $1,000.00 Corporate Sponsorships
American Liver Foundation $2,500.00 Corporate Sponsorships
American Liver Foundation $2,500.00 Corporate Sponsorships
American Liver Foundation $1,500.00 Corporate Sponsorships
American Lung Association $100,000.00 Corporate Sponsorships
American Lung Association $5,000.00 Corporate Sponsorships
of The Northeast
American Lung Association $5,000.00 Corporate Sponsorships
of The Northeast
American Lung Association $7,500.00 Corporate Sponsorships
of The Northeast
American Med Group $10,000.00 Corporate Sponsorships
Associate
American Med Group $10,000.00 Corporate Sponsorships
Associate
American Med Group $20,000.00 Corporate Sponsorships
Associate
American Med Group $4,940.00 Corporate Sponsorships
Associate
American Med Group $4,940.00 Corporate Sponsorships
Associate
American Med Group $4,940.00 Corporate Sponsorships
Associate
American Med Group $4,940.00 Corporate Sponsorships
Associate
American Med Group $4,940.00 Corporate Sponsorships
Associate
American Med Group $4,940.00 Corporate Sponsorships
Associate
American Med Group $4,940.00 Corporate Sponsorships
Associate
American Med Group $4,940.00 Corporate Sponsorships
Associate
American Med Group $4,940.00 Corporate Sponsorships
Associate
American Med Group $4,940.00 Corporate Sponsorships
Associate
American Neuro Associate $40,000.00 Educational Grants
American Pancreatic $25,000.00 Patient Support
Associate
American Pancreatic $75,000.00 Educational Grants
Associate
American Parkinson Disease $20,000.00 Educational Grants
Association
American Parkinson Disease $3,500.00 Corporate Sponsorships
Association
American Parkinson Disease $62,000.00 Corporate Sponsorships
Association
American Parkinson Disease $5,500.00 Corporate Sponsorships
Association
American Parkinson Disease $3,000.00 Corporate Sponsorships
Association
American Parkinson Disease $2,500.00 Corporate Sponsorships
Association
American Parkinson Disease $5,000.00 Corporate Sponsorships
Association
American Red Cross of $10,000.00 Charitable Donations
Greater Chicago
American Society for $2,000.00 Educational Grants
Pharmacology and
Experimental Therapeutics
American Society for $10,000.00 Corporate Sponsorships
Reproductive Medicine
American Society for $3,000.00 Corporate Sponsorships
Reproductive Medicine
American Society for $15,000.00 Corporate Sponsorships
Reproductive Medicine
American Society of Colon $35,000.00 Educational Grants
and Rectal Surgns
American Society of $50,000.00 Fellowships and
Hematology Scholarships
American Society of $20,000.00 Educational Grants
Hematology
American Society of $60,000.00 Educational Grants
Hematology
American Society of $50,000.00 Educational Grants
Hematology
American Society of Nphro $35,000.00 Corporate Sponsorships
American Society of Nphro $160,000.00 Educational Grants
American Statistical $2,000.00 Educational Grants
Associate
American Statistical $2,500.00 Educational Grants
Associate
American Thyroid Associate $30,000.00 Educational Grants
Inc.
American Urological $50,000.00 Charitable Donations
Associate Education and
Research Inc.
American Urological $20,000.00 Educational Grants
Associate Education and
Research Inc.
American Urological $50,000.00 Educational Grants
Associate Education and
Research Inc.
American Urological $50,000.00 Educational Grants
Associate Education and
Research Inc.
American Urological $13,500.00 Corporate Sponsorships
Associate Inc Western
Section
American Urological $25,000.00 Charitable Donations
Association
American Urological $6,000.00 Corporate Sponsorships
Association
American Urological $2,000.00 Corporate Sponsorships
Association
American Urological $10,000.00 Corporate Sponsorships
Association
American Urological $6,000.00 Corporate Sponsorships
Association
American Urological $10,000.00 Charitable Donations
Association
American Urological $6,000.00 Corporate Sponsorships
Association
American Urological $1,500.00 Corporate Sponsorships
Association
Americans for Med Progress $90,000.00 Charitable Donations
Americares Foundation $12,000.00 Charitable Donations
American Hepato-Pancreato- $30,000.00 Corporate Sponsorships
Biliary Association
Angel Foundation $2,500.00 Corporate Sponsorships
Arizona State Association $3,500.00 Corporate Sponsorships
of Physician Assistants
Arizona United Rheumatology $25,000.00 Corporate Sponsorships
Alliance--Aura
Arkansas State Rheumatology $10,000.00 Corporate Sponsorships
Association Inc.
Arkansas Technology $1,000.00 Charitable Donations
University Foundation
Arthritis Foundation $5,000.00 Charitable Donations
Arthritis Foundation $5,000.00 Educational Grants
Arthritis Foundation $2,000.00 Corporate Sponsorships
Arthritis Foundation $30,000.00 Corporate Sponsorships
Arthritis Foundation $10,000.00 Corporate Sponsorships
Arthritis Foundation $4,000.00 Educational Grants
Arthritis Foundation $5,000.00 Educational Grants
Arthritis Foundation $20,000.00 Educational Grants
Arthritis Foundation $20,000.00 Educational Grants
Arthritis Foundation $3,000.00 Educational Grants
Arthritis Foundation $50,000.00 Corporate Sponsorships
Arthritis Foundation $2,500.00 Educational Grants
Arthritis Foundation $2,500.00 Corporate Sponsorships
Arthritis Foundation $3,000.00 Corporate Sponsorships
Arthritis Foundation $10,000.00 Corporate Sponsorships
Arthritis Foundation $2,500.00 Corporate Sponsorships
Arthritis Foundation $3,000.00 Corporate Sponsorships
Arthritis Foundation $2,000.00 Corporate Sponsorships
Arthritis Foundation $50,000.00 Corporate Sponsorships
Arthritis Foundation $5,000.00 Educational Grants
Arthritis Foundation $250,000.00 Corporate Sponsorships
Arthritis Foundation $300,000.00 Corporate Sponsorships
Arthritis Foundation $300,000.00 Corporate Sponsorships
Arthritis Foundation $259,000.00 Corporate Sponsorships
Arthritis Foundation Inc. $50,000.00 Corporate Sponsorships
Arthritis Patient Services $2,400.00 Educational Grants
Arthritis Patient Services $5,000.00 Educational Grants
Arthritis Patient Services $65,000.00 Educational Grants
ARVO Foundation for Eye $5,000.00 Fellowships and
Research Scholarships
ASCO Cancer Foundation $100,000.00 Patient Support
ASCO Cancer Foundation $20,000.00 Educational Grants
ASCO Cancer Foundation $28,000.00 Educational Grants
ASCO Cancer Foundation $10,000.00 Educational Grants
ASCO Cancer Foundation $10,000.00 Educational Grants
ASCO Cancer Foundation $15,000.00 Educational Grants
ASCO Cancer Foundation $15,000.00 Educational Grants
ASCO Cancer Foundation $15,000.00 Educational Grants
ASCO Cancer Foundation $30,000.00 Educational Grants
ASCO Cancer Foundation $30,000.00 Educational Grants
ASCO Cancer Foundation $30,000.00 Educational Grants
ASCO Cancer Foundation $56,000.00 Educational Grants
ASCO Cancer Foundation $60,000.00 Educational Grants
ASCO Cancer Foundation $75,000.00 Educational Grants
ASCO Cancer Foundation $34,500.00 Corporate Sponsorships
ASCO Cancer Foundation $13,275.00 Educational Grants
ASCO Cancer Foundation $26,000.00 Educational Grants
Asembia $60,000.00 Corporate Sponsorships
ASHP Foundation $75,000.00 Fellowships and
Scholarships
Associate DE $10,000.00 Corporate Sponsorships
Gastroenterologia Y
Hepatologia Pediatrica DE
Puerto Rico Aghppr
Associate DE Reumatologos $7,500.00 Corporate Sponsorships
DE Puerto Rico
Associate DE Reumatologos $15,000.00 Corporate Sponsorships
DE Puerto Rico
Associate of Physician $25,000.00 Corporate Sponsorships
Assistants in Oncology
Inc.
Associate of Physician $7,500.00 Corporate Sponsorships
Assistants in Oncology
Inc.
Associate of Physician $7,500.00 Corporate Sponsorships
Assistants in Oncology
Inc.
Associate of Professors of $50,000.00 Corporate Sponsorships
Gyn and Obstetrician
Associate of Professors of $5,000.00 Corporate Sponsorships
Gyn and Obstetrician
Associate of Professors of $75,000.00 Educational Grants
Gyn and Obstetrician
Associate of Reproductive $50,000.00 Educational Grants
Health Professionals
Associate of Univ $5,000.00 Corporate Sponsorships
Technology Managers
Association of Community $15,000.00 Corporate Sponsorships
Cancer Centers (ACCC)
Association of Community $150,000.00 Corporate Sponsorships
Cancer Centers (ACCC)
Association of Women in $40,000.00 Corporate Sponsorships
Rheumatology
Association of Women in $30,000.00 Corporate Sponsorships
Rheumatology
Association of Women in $75,000.00 Corporate Sponsorships
Rheumatology
Atlanta Dermatology and $10,000.00 Corporate Sponsorships
Pathology Associates, PC
Autoimmune Advocacy $3,000.00 Corporate Sponsorships
Alliance
Auxiliary of Robert Wood $5,000.00 Corporate Sponsorships
Johnson University
Hospital
Baehr Challenge Ltd $1,000.00 Corporate Sponsorships
Ball State University $1,000.00 Charitable Donations
Foundation
Baylor College Medicine $5,000.00 Educational Grants
Infusion Dis
Baylor College Medicine $3,600.00 Fellowships and
Infusion Dis Scholarships
Baylor Health Care System $40,000.00 Fellowships and
Foundation Scholarships
Baylor Scott and White $5,000.00 Educational Grants
Health
Baylor Scott and White $30,000.00 Educational Grants
Health
Bendcare $410,000.00 Corporate Sponsorships
Beth Israel Deaconess ($16,526.70) Educational Grants
Medical Center
Beth Israel Deaconess $40,000.00 Fellowships and
Medical Center Scholarships
Beth Israel Deaconess $30,000.00 Fellowships and
Medical Center Scholarships
Beth Israel Deaconess $35,000.00 Fellowships and
Medical Center Scholarships
Beth Israel Deaconess $40,000.00 Fellowships and
Medical Center Scholarships
Beth Israel Deaconess $3,000.00 Educational Grants
Medical Center
Beth Israel Deaconess ($1,751.70) Educational Grants
Medical Center
Beth Israel Med Center $25,000.00 Fellowships and
Scholarships
Bioconnections LLC $50,000.00 Corporate Sponsorships
Biotechnology Industry $8,000.00 Corporate Sponsorships
Organization
Board of Trustees of The $3,000.00 Corporate Sponsorships
Leland Stanford Junior
Univ
Board of Trustees of The $1,500.00 Educational Grants
Univ of Illinois
Bonnie J Addario Lung $5,000.00 Corporate Sponsorships
Cancer Foundation
Bonnie J Addario Lung $25,000.00 Corporate Sponsorships
Cancer Foundation
Boomer Esiason Foundation $25,000.00 Corporate Sponsorships
Borland Groover Clinic $1,000.00 Corporate Sponsorships
Borland Groover Clinic $750.00 Corporate Sponsorships
Borland Groover Clinic $1,000.00 Corporate Sponsorships
Boston College School of $7,500.00 Corporate Sponsorships
Nursing
Boston Society Inc. $3,000.00 Educational Grants
Boston Taiwanese $2,500.00 Educational Grants
Biotechnology Association
Inc.
Brain Support Network Inc. $5,000.00 Educational Grants
Breast Friends $1,000.00 Corporate Sponsorships
Breastcancer.Org $5,000.00 Educational Grants
Brian Grant Foundation $150,000.00 Educational Grants
Brian Grant Foundation $1,500.00 Corporate Sponsorships
Brigham and Women's $7,000.00 Educational Grants
Hospital, Inc.
Brigham and Women's $40,000.00 Fellowships and
Hospital, Inc. Scholarships
Broad Institute $5,000.00 Corporate Sponsorships
California Associate of $3,500.00 Corporate Sponsorships
Physician Groups
California Associate of $25,000.00 Corporate Sponsorships
Physician Groups
California Chronic Care $25,000.00 Corporate Sponsorships
Coalition
California Chronic Care $10,000.00 Corporate Sponsorships
Coalition
California Life Sciences $5,000.00 Corporate Sponsorships
Association
California Life Sciences $5,500.00 Corporate Sponsorships
Association
California Neurology $5,000.00 Educational Grants
Society
California Neurology $5,000.00 Educational Grants
Society
California Society of $10,000.00 Corporate Sponsorships
Dermatology and
Dermatology Surgry
California Society of $10,000.00 Corporate Sponsorships
Dermatology and
Dermatology Surgry
California Society of $10,000.00 Corporate Sponsorships
Dermatology and
Dermatology Surgry
Cancer and Leukemia Group B $50,000.00 Educational Grants
Foundation
Cancer and Leukemia Group B $30,000.00 Educational Grants
Foundation
Cancer and Leukemia Group B $50,000.00 Educational Grants
Foundation
Cancer Awareness of Nevada $1,000.00 Corporate Sponsorships
Cancer Care $10,000.00 Educational Grants
Cancer Care $50,000.00 Charitable Donations
Cancer Care $15,000.00 Educational Grants
Cancer Care $25,000.00 Educational Grants
Cancer Care $100,000.00 Corporate Sponsorships
Cancer Care $150,000.00 Educational Grants
Cancer Care $150,000.00 Educational Grants
Cancer Care $90,000.00 Educational Grants
Cancer Care $50,000.00 Educational Grants
Cancer Care $100,000.00 Educational Grants
Cancer Care $65,000.00 Corporate Sponsorships
Cancer Molecular Thrpt $5,000.00 Educational Grants
Cancer Support Community $75,000.00 Educational Grants
Cancer Support Community $25,000.00 Educational Grants
Cancer Support Community $50,000.00 Educational Grants
Cancer Wellness Center $5,000.00 Corporate Sponsorships
Cardinal Health $170,000.00 Corporate Sponsorships
Cardinal Health $60,000.00 Corporate Sponsorships
Caribe Gyn $5,000.00 Corporate Sponsorships
Caribe Gyn $17,000.00 Corporate Sponsorships
Caring Ambassadors Program $75,000.00 Charitable Donations
Inc.
Caring Ambassadors Program $15,000.00 Patient Support
Inc.
Carti Foundation $10,000.00 Corporate Sponsorships
Cascade AIDS Project $5,000.00 Corporate Sponsorships
Cedars--Sinai Med Center $40,000.00 Fellowships and
Scholarships
Cedars--Sinai Med Center $10,000.00 Educational Grants
Central Brain Tumor $25,000.00 Educational Grants
Registry of The United
States
Central Brain Tumor $25,000.00 Educational Grants
Registry of The United
States
Central Savannah River Area $1,000.00 Corporate Sponsorships
Csra Parkinson Support
Group
Chicago Urological Soctiey $12,000.00 Corporate Sponsorships
Childrens Hospital Corp $5,000.00 Educational Grants
Childrens Hospital of $10,000.00 Corporate Sponsorships
Philadelphia
Childrens Treehouse $10,000.00 Patient Support
Foundation
Chimp Haven $20,000.00 Charitable Donations
Chinese American Society of $5,000.00 Corporate Sponsorships
Nuclear Medicine and
Molecular Imaging
Chris Elliott Fund $10,000.00 Charitable Donations
Chris Elliott Fund $10,000.00 Charitable Donations
Chris Elliott Fund $10,000.00 Charitable Donations
Chris Elliott Fund $5,000.00 Charitable Donations
Chris Elliott Fund $5,000.00 Charitable Donations
Chronic Liver Disease $50,000.00 Corporate Sponsorships
Foundation
Chronic Liver Disease $300,000.00 Educational Grants
Foundation
Chronic Liver Disease $200,000.00 Educational Grants
Foundation
Chronic Liver Disease $247,350.00 Educational Grants
Foundation
Chronic Liver Disease $226,945.00 Educational Grants
Foundation
Chronic Liver Disease $25,000.00 Corporate Sponsorships
Foundation
Chronic Lymphocytic $75,000.00 Corporate Sponsorships
Leukemia Society Inc.
Chronic Lymphoytic Leukemia $22,825.00 Educational Grants
Society Inc.
Chronic Lymphoytic Leukemia $50,000.00 Charitable Donations
Society Inc.
Chronic Lymphoytic Leukemia $75,000.00 Educational Grants
Society Inc.
Chronic Lymphoytic Leukemia $50,000.00 Educational Grants
Society Inc.
Chronic Lymphoytic Leukemia $50,000.00 Educational Grants
Society Inc.
Cincinnati Childrens $40,000.00 Fellowships and
Hospital Medical Center Scholarships
Cincinnati Childrens $25,000.00 Corporate Sponsorships
Hospital Medical Center
City of Hope National Med $5,000.00 Corporate Sponsorships
Center
Cleveland Clinic $65,000.00 Educational Grants
Cleveland Clinic $65,000.00 Educational Grants
Cleveland Clinic $5,000.00 Educational Grants
Cleveland Clinic $10,000.00 Corporate Sponsorships
Cleveland Clinic $50,000.00 Educational Grants
Cleveland Clinic $20,000.00 Corporate Sponsorships
Cleveland Clinic $5,000.00 Educational Grants
Cleveland Clinic $55,000.00 Fellowships and
Scholarships
Cleveland Clinic $40,000.00 Fellowships and
Scholarships
Cleveland Clinic ($4,853.56) Educational Grants
Educational Foundation
Cleveland Clinic $5,000.00 Educational Grants
Educational Foundation
Cleveland Clinic $15,000.00 Educational Grants
Educational Foundation
Cleveland Clinic $5,000.00 Educational Grants
Educational Foundation
Cleveland Clinic $2,500.00 Educational Grants
Educational Foundation
Cleveland Clinic $5,000.00 Educational Grants
Educational Foundation
Cleveland Clinic $5,000.00 Educational Grants
Educational Foundation
Cleveland Clinic $15,000.00 Educational Grants
Educational Foundation
Cleveland Clinic ($6,652.23) Educational Grants
Educational Foundation
Cleveland Clinic ($5,410.94) Educational Grants
Educational Foundation
Cleveland Clinic $65,000.00 Educational Grants
Educational Foundation
Cleveland Clinic Minority $40,000.00 Fellowships and
Mens Health Center Scholarships
Clinical Care Optn LLC $50,000.00 Educational Grants
Clinical Care Optn LLC $50,000.00 Educational Grants
Clinical Care Optn LLC $60,000.00 Educational Grants
Clinical Care Optn LLC $25,000.00 Educational Grants
Clinical Care Optn LLC $95,560.00 Educational Grants
Clinical Care Optn LLC $25,000.00 Educational Grants
Clinical Care Optn LLC $75,000.00 Educational Grants
Clinical Care Optn LLC $95,000.00 Educational Grants
Clinical Care Optn LLC $150,000.00 Educational Grants
Cll Global Research $35,000.00 Educational Grants
Foundation
Cll Global Research $20,000.00 Educational Grants
Foundation
Cll Global Research $35,000.00 Educational Grants
Foundation
Coalition for Prevention of $10,000.00 Corporate Sponsorships
Colorectal Cancer in
Puerto Rico
Coalition of Positive $40,000.00 Educational Grants
Health Empowerment
Coalition of Texans With $5,000.00 Corporate Sponsorships
Disabilities
Coalition On Positive $5,000.00 Corporate Sponsorships
Health Empower
Cockerell Educational $25,000.00 Corporate Sponsorships
Foundation
Cody Dieruf Benefit $5,000.00 Patient Support
Foundation
Cold Spring Harbor $2,500.00 Educational Grants
Laboratory
Collaborative Alliance for $6,000.00 Fellowships and
Pancreatic Education and Scholarships
Research
Collaborative Alliance for $30,000.00 Educational Grants
Pancreatic Education and
Research
Collaborative Alliance for $1,750.00 Corporate Sponsorships
Pancreatic Education and
Research
Colorado Gerontological $5,000.00 Corporate Sponsorships
Society
Columbia Univ Med Center $5,000.00 Educational Grants
Community Access National $2,500.00 Corporate Sponsorships
Network
Community Center $15,000.00 Corporate Sponsorships
Community Center $10,000.00 Corporate Sponsorships
Community Foundation $5,000.00 Corporate Sponsorships
Community Foundation $5,000.00 Corporate Sponsorships
Community Initiatives $150,000.00 Corporate Sponsorships
Community Initiatives $30,000.00 Corporate Sponsorships
Community Initiatives $25,000.00 Corporate Sponsorships
Community Liver Alliance $20,000.00 Corporate Sponsorships
Community Liver Alliance $5,000.00 Corporate Sponsorships
Community Liver Alliance $9,000.00 Corporate Sponsorships
Community Liver Alliance $3,000.00 Corporate Sponsorships
Community Liver Alliance $5,000.00 Corporate Sponsorships
Complex Mechanisms of $1,500.00 Educational Grants
Disease Aging and Trauma
(Cmdat) Research
Foundation
Connecticut Advanced Nurse $2,000.00 Corporate Sponsorships
Practitioner Society
Connecticut Advocates for $2,500.00 Corporate Sponsorships
Parkinsons
Connecticut Peer Review $3,000.00 Corporate Sponsorships
Organization--Qualidigm
Connecting To Cure Crohns $10,000.00 Corporate Sponsorships
and Colitis
Consortium of Multiple $50,000.00 Educational Grants
Sclerosis Centers
Consortium of Multiple $55,000.00 Educational Grants
Sclerosis Centers
Consortium of Multiple $85,000.00 Educational Grants
Sclerosis Centers
Continuing Educational $95,000.00 Educational Grants
Alliance LLC
Continuing Educational $149,000.00 Educational Grants
Alliance LLC
Continuing Educational $99,550.00 Educational Grants
Alliance LLC
Continuing Educational ($1,050.00) Educational Grants
Alliance LLC
Continuing Educational $200,000.00 Educational Grants
Alliance LLC
Continuing Educational $121,165.00 Educational Grants
Alliance LLC
Continuing Med Education $85,000.00 Educational Grants
Outfitters LLC
Cornell Univ Weill Med $15,000.00 Educational Grants
College
Cornell Univ Weill Med $3,000.00 Educational Grants
College
Cornerstone Health $3,000.00 Corporate Sponsorships
Enablement Strategic
Solutions, LLC
Cornerstone Health Inc. $75,000.00 Educational Grants
Cornerstone Health Inc. $50,000.00 Educational Grants
Cradles To Crayons Inc. $300.00 Charitable Donations
Creighton Univ $15,000.00 Educational Grants
Crohns and Colitis $25,000.00 Charitable Donations
Foundation of America
Crohns and Colitis $25,000.00 Educational Grants
Foundation of America
Crohns and Colitis $60,000.00 Educational Grants
Foundation of America
Crohns and Colitis $80,000.00 Educational Grants
Foundation of America
Crohns and Colitis $200,000.00 Educational Grants
Foundation of America
Crohns and Colitis $3,500.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $5,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $1,500.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $3,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $5,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $12,500.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $14,250.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $10,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $2,500.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $1,500.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $2,500.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $20,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $2,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $2,500.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $5,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $2,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $150,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $10,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $1,500.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $1,500.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $25,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $1,500.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $2,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $100,000.00 Educational Grants
Foundation of America
Crohns and Colitis $15,000.00 Fellowships and
Foundation of America Scholarships
Crohns and Colitis $2,500.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $20,000.00 Charitable Donations
Foundation of America
Crohns and Colitis $2,500.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $10,000.00 Educational Grants
Foundation of America
Crohns and Colitis $150,000.00 Educational Grants
Foundation of America
Crohns and Colitis $25,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $85,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $400,000.00 Corporate Sponsorships
Foundation of America
Cure Cf $1,000.00 Corporate Sponsorships
Curepsp Inc. $30,000.00 Educational Grants
Curepsp Inc. $10,000.00 Educational Grants
Curepsp Inc. $20,000.00 Corporate Sponsorships
Curesearch for Childrens $10,000.00 Charitable Donations
Cancer
Curesearch for Childrens $15,000.00 Corporate Sponsorships
Cancer
Cystic Fibrosis Foundation $2,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $5,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $2,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $3,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $2,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $2,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $2,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $1,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $2,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $1,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $1,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $2,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $2,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $9,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $3,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $1,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $1,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $2,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $5,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $3,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $3,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $3,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $1,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $2,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $2,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $2,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $1,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $1,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $250.00 Corporate Sponsorships
Cystic Fibrosis Foundation $5,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $5,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $1,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $1,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $2,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $2,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $6,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $3,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $5,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $2,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $7,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $750,000.00 Corporate Sponsorships
Cystic Fibrosis Research $5,000.00 Corporate Sponsorships
Fund Emilys Entourage
Cystic Fibrosis Research $10,000.00 Corporate Sponsorships
Inc.
Cystic Fibrosis Research $10,000.00 Corporate Sponsorships
Inc.
Cystic Fibrosis Research $10,000.00 Corporate Sponsorships
Inc.
Cystic Fibrosis Research $3,000.00 Corporate Sponsorships
Inc.
Cystic Fibrosis Research $5,000.00 Corporate Sponsorships
Inc.
Cystic Fibrosis Research $7,000.00 Corporate Sponsorships
Inc.
Cystic Fibrosis Research $18,000.00 Corporate Sponsorships
Inc.
Cystic Fibrosis Research $10,000.00 Corporate Sponsorships
Inc.
Danville D Elegance $5,000.00 Corporate Sponsorships
Foundation
Dava Oncology Lp $25,000.00 Corporate Sponsorships
Dava Oncology Lp $10,000.00 Corporate Sponsorships
Davis Phinney Foundation $5,000.00 Corporate Sponsorships
Davis Phinney Foundation $30,000.00 Educational Grants
Davis Phinney Foundation $10,000.00 Corporate Sponsorships
Davis Phinney Foundation $30,000.00 Educational Grants
Davis Phinney Foundation $2,500.00 Corporate Sponsorships
Davis Phinney Foundation $20,000.00 Educational Grants
Davis Phinney Foundation $30,000.00 Educational Grants
DBC Pri-Med LLC $165,000.00 Corporate Sponsorships
Deep South Cancer $10,000.00 Corporate Sponsorships
Foundation
Deep South Cancer $5,000.00 Corporate Sponsorships
Foundation
Deep South Cancer $5,000.00 Corporate Sponsorships
Foundation
Dermatology Education $75,000.00 Corporate Sponsorships
Foundation
Dermatology Education $75,000.00 Corporate Sponsorships
Foundation
Dermatology Education $50,000.00 Corporate Sponsorships
Foundation
Dermatology Education $50,000.00 Corporate Sponsorships
Foundation
Dermatology Education $50,000.00 Corporate Sponsorships
Foundation
Dermatology Foundation $135,000.00 Charitable Donations
Dermatology Foundation $50,000.00 Corporate Sponsorships
Dermatology Univ LLC $75,000.00 Corporate Sponsorships
Digestive Disease Week $31,500.00 Corporate Sponsorships
Digestive Health Foundation $25,000.00 Corporate Sponsorships
Diversity and Leadership $6,000.00 Corporate Sponsorships
Inc.
Doctor Solomon Carter ($4,919.07) Fellowships and
Fuller Mental Health Scholarships
Center
Donate Life Coalition of $10,000.00 Charitable Donations
Michigan
Duke Univ $5,000.00 Educational Grants
Duke Univ ($16,360.00) Educational Grants
Eastern Virginia Medical $5,000.00 Educational Grants
School
Economic Alliance for $2,500.00 Corporate Sponsorships
Michigan
Eicosanoid Research $2,500.00 Educational Grants
Foundation
Eisenhower Desert $25,000.00 Educational Grants
Orthopedic Center
Eisenhower Desert $250,000.00 Educational Grants
Orthopedic Center
Eisenhower Desert $50,000.00 Educational Grants
Orthopedic Center
Eisenhower Desert $85,000.00 Educational Grants
Orthopedic Center
Eisenhower Desert $25,000.00 Educational Grants
Orthopedic Center
Eisenhower Desert $30,000.00 Educational Grants
Orthopedic Center
Eisenhower Desert $50,000.00 Educational Grants
Orthopedic Center
Eisenhower Desert $500,000.00 Educational Grants
Orthopedic Center
El Centro Regional Medical $6,000.00 Corporate Sponsorships
Center F
Elsevier Inc. $50,000.00 Educational Grants
Employers Health Coalition $7,500.00 Corporate Sponsorships
Endocrine Society $25,000.00 Educational Grants
Endocrine Society $50,000.00 Educational Grants
Endocrine Society $50,000.00 Corporate Sponsorships
Endocrine Society $25,000.00 Educational Grants
Endometriosis Foundation of $10,000.00 Charitable Donations
America
Epilepsy Association of $10,000.00 Corporate Sponsorships
Central Florida
Epilepsy Foundation $5,000.00 Corporate Sponsorships
Escuela DE Medicina DE $10,000.00 Educational Grants
Ponce
Excellence in Rheumatology $100,000.00 Corporate Sponsorships
Education LLC
Family Med Center $7,500.00 Corporate Sponsorships
Bolingbrook
Federation of American $2,000.00 Educational Grants
Society for Experimental
Biology Faseb
Federation of American $5,000.00 Corporate Sponsorships
Society for Experimental
Biology Faseb
Federation of American $2,000.00 Corporate Sponsorships
Society for Experimental
Biology Faseb
Federation of American $5,000.00 Corporate Sponsorships
Society for Experimental
Biology Faseb
Federation of Clinical $20,000.00 Educational Grants
Immunology Society
Federation of Clinical $25,000.00 Educational Grants
Immunology Society
Feinstein Institute for Med $150,000.00 Educational Grants
Research
Florida Cancer Specialists $34,500.00 Corporate Sponsorships
Foundation
Florida Chapter of America $2,500.00 Corporate Sponsorships
Academy of Pediatrics
Florida Chapter, American $5,000.00 Corporate Sponsorships
College of Phyician
Services
Florida Hospital Orlando $10,000.00 Corporate Sponsorships
Florida Society of $22,600.00 Corporate Sponsorships
Dermatology and
Dermatologic Surgry
Florida Society of $25,500.00 Corporate Sponsorships
Dermatology and
Dermatologic Surgery
Florida Society of $60,000.00 Corporate Sponsorships
Dermatology Physician
Assistants Inc.
Florida Society of $65,000.00 Corporate Sponsorships
Dermatology Physician
Assistants Inc.
Florida Society of $35,000.00 Corporate Sponsorships
Rheumatology
Florida Society of $2,500.00 Corporate Sponsorships
Rheumatology Inc.
Florida Society of $3,000.00 Corporate Sponsorships
Rheumatology Inc.
Focus Med Communications $150,000.00 Corporate Sponsorships
Focus Med Communications $5,000.00 Corporate Sponsorships
Foster Ocular Immunology $33,000.00 Corporate Sponsorships
Society
Foundation for Biomedical $50,000.00 Charitable Donations
Research
Foundation of Consortium of $5,450.00 Fellowships and
Multiple Sclerosis Centers Scholarships
Cmsc
Foundation of Consortium of $32,000.00 Fellowships and
Multiple Sclerosis Centers Scholarships
Cmsc
Free To Breathe $25,000.00 Educational Grants
Free To Breathe $50,000.00 Corporate Sponsorships
Free To Breathe $40,000.00 Educational Grants
Friends of Cancer Research $40,000.00 Corporate Sponsorships
Friends of The St Louis $50,000.00 Corporate Sponsorships
Univ Liver Center
Fundacion Alfredo Ruiz $5,000.00 Corporate Sponsorships
Fundacion Daledale Inc. $500.00 Corporate Sponsorships
Fundacion Puertorriquena DE $12,500.00 Educational Grants
Pacientes Consult
Endometriosis
Funk Zitiello Foundation $4,000.00 Corporate Sponsorships
Gastrointestinal Research $50,000.00 Corporate Sponsorships
Foundation
Gateway for Cancer Research $10,000.00 Charitable Donations
Geneva Foundation $10,000.00 Educational Grants
George Washington Univ $5,000.00 Corporate Sponsorships
George Washington Univ $5,000.00 Corporate Sponsorships
Hospital
George Washington Univ $3,000.00 Corporate Sponsorships
Hospital
George Washington Univ $10,000.00 Corporate Sponsorships
Hospital
Georgetown Univ $7,000.00 Educational Grants
Georgetown Univ $50,000.00 Fellowships and
Scholarships
Georgia Society of $50,000.00 Corporate Sponsorships
Dermatology and
Dermatologic Surgery
Gildas Club Chicago $10,000.00 Charitable Donations
Give for A Smile $1,000.00 Corporate Sponsorships
Global Academy for Medical $36,000.00 Corporate Sponsorships
Education
Global Academy for Medical $15,000.00 Corporate Sponsorships
Education
Global Academy for Medical $90,000.00 Corporate Sponsorships
Education
Global Academy for Medical $35,000.00 Corporate Sponsorships
Education
Global Academy for Medical $58,500.00 Corporate Sponsorships
Education
Global Academy for Medical $76,500.00 Corporate Sponsorships
Education
Global Healthy Living $75,000.00 Corporate Sponsorships
Foundation
Global Healthy Living $75,000.00 Corporate Sponsorships
Foundation
Global Healthy Living $150,000.00 Corporate Sponsorships
Foundation
Global Oncology $5,000.00 Corporate Sponsorships
Global Resource for $25,000.00 Educational Grants
Advancing Cancer Education
Global Virus Network Inc. $7,500.00 Educational Grants
Global Virus Network Inc. $8,000.00 Educational Grants
Good Grief $500.00 Corporate Sponsorships
Gordon Research Conferences $2,000.00 Educational Grants
Gordon Research Conferences $2,000.00 Educational Grants
Gordon Research Conferences $2,000.00 Educational Grants
Gordon Research Conferences $2,500.00 Educational Grants
Gordon Research Conferences $2,500.00 Educational Grants
Gordon Research Conferences $2,500.00 Educational Grants
Gordon Research Conferences $3,000.00 Educational Grants
Gordon Research Conferences $2,000.00 Educational Grants
Gordon Research Conferences $2,500.00 Educational Grants
Gordon Research Conferences $2,500.00 Educational Grants
Gordon Research Conferences $2,000.00 Educational Grants
Gordon Research Conferences $2,500.00 Educational Grants
Gordon Research Conferences $2,500.00 Educational Grants
Great Lakes Chapter of The $1,000.00 Corporate Sponsorships
American Society for
Pharmacology and
Experimental Therapeutics
Group for Research and $15,000.00 Corporate Sponsorships
Assessment of Psoriasis
and Psoriatic Arthritis
Grupo de Apoyo de Ninos y $1,000.00 Corporate Sponsorships
Adolescentes Consult
Reumatologia
Grupo de Apoyo de Ninos y $3,000.00 Corporate Sponsorships
Adolescentes Consult
Reumatologia
Gynecologic Oncology Group $40,000.00 Educational Grants
Gynecologic Oncology Group $25,000.00 Educational Grants
H Lee Moffitt Cancer Center $5,000.00 Educational Grants
and Research Institute
H Lee Moffitt Cancer Center $7,500.00 Educational Grants
and Research Institute
Halo House Foundation $5,000.00 Corporate Sponsorships
Harborside Press $38,000.00 Corporate Sponsorships
Harborside Press $20,000.00 Corporate Sponsorships
Healthcare 21 Business $16,000.00 Corporate Sponsorships
Coalition
Healthcare 21 Business $1,000.00 Corporate Sponsorships
Coalition
Healthy Women $30,000.00 Corporate Sponsorships
Healthy Women $45,000.00 Corporate Sponsorships
Heart to Heart $10,000.00 Charitable Donations
International Inc.
Heb Grocery Co Lp $7,000.00 Corporate Sponsorships
Hematology Oncology $5,000.00 Educational Grants
Pharmacy Associate
Hematology Oncology $5,000.00 Educational Grants
Pharmacy Associate
Henry Ford Health System $5,000.00 Educational Grants
Henry M Jackson Foundation $10,000.00 Educational Grants
Hep C Connection $10,000.00 Corporate Sponsorships
Hepatitis C Association $25,000.00 Educational Grants
Hepatitis C Association $20,000.00 Educational Grants
Hepatitis C Mentor and $10,000.00 Educational Grants
Support Group The
Hepatitis Education Project $100,000.00 Charitable Donations
Hidradenitis Suppurativa $27,500.00 Corporate Sponsorships
Foundation
Hitchcock Foundation ($2,685.00) Educational Grants
Hitchcock Foundation $8,000.00 Educational Grants
Hitchcock Foundation $20,000.00 Educational Grants
Hitchcock Foundation $8,000.00 Educational Grants
HMP Communications $10,000.00 Corporate Sponsorships
HMP Communications $60,000.00 Corporate Sponsorships
Hope Foundation $40,000.00 Fellowships and
Scholarships
Hope Foundation $25,000.00 Educational Grants
Hospital of the University $60,000.00 Educational Grants
of Pennsylvania
Hospital of the University $5,000.00 Educational Grants
of Pennsylvania
Hospital of the University $10,000.00 Educational Grants
of Pennsylvania
Houston Area Parkinson $5,000.00 Corporate Sponsorships
Society
Houston Business Coalition $11,000.00 Corporate Sponsorships
On Health
Howard Brown Health Center $2,500.00 Corporate Sponsorships
Howard Hanna Children's $10,000.00 Charitable Donations
Free Care Fund
Hubbard Street Dance $20,000.00 Educational Grants
Chicago
Human Growth Foundation $10,000.00 Corporate Sponsorships
Human Growth Foundation $10,000.00 Corporate Sponsorships
Humboldt--Del Norte County $4,000.00 Educational Grants
Medical Society
IBD Horizons $80,000.00 Educational Grants
IBD Horizons $4,000.00 Corporate Sponsorships
IBD Horizons $25,000.00 Corporate Sponsorships
IBD Horizons $25,000.00 Corporate Sponsorships
IBD Remedy Inc. $5,000.00 Fellowships and
Scholarships
IBD Remedy Inc. $20,000.00 Patient Support
Illinois Cancercare $3,000.00 Corporate Sponsorships
Foundation
Illinois Society of $40,000.00 Corporate Sponsorships
Dermatology Physician
Assistants
Illinois Society of $20,000.00 Corporate Sponsorships
Dermatology Physician
Assistants
Imedex LLC $200,000.00 Educational Grants
Imedex LLC $10,000.00 Educational Grants
Imedex LLC $10,000.00 Educational Grants
Imedex LLC $50,000.00 Educational Grants
Imedex LLC $50,000.00 Educational Grants
Imedex LLC $50,000.00 Educational Grants
Imedex LLC ($3,596.00) Educational Grants
Imedex LLC ($247.00) Educational Grants
Imedex LLC $114,000.00 Corporate Sponsorships
Imedex LLC $45,750.00 Corporate Sponsorships
Impact Education LLC $75,000.00 Educational Grants
Indian Doc Associate of $2,500.00 Corporate Sponsorships
Houston
Indiana Parkinson $2,500.00 Corporate Sponsorships
Foundation
Indiana Parkinson $2,500.00 Corporate Sponsorships
Foundation
Indiana Univ $65,000.00 Educational Grants
Indiana Univ $10,000.00 Charitable Donations
Indiana Urological $5,000.00 Corporate Sponsorships
Association
Infectious Diseases Society $10,000.00 Educational Grants
of America
Inflammatory Bowel Disease $50,000.00 Educational Grants
Support Foundation
Innovation Foundation Inc. $55,000.00 Corporate Sponsorships
Integra Life Science $500,000.00 Educational Grants
Service
Integrated Benefits $25,000.00 Corporate Sponsorships
Institute Inc.
Integrated Med Foundation $15,000.00 Charitable Donations
Integrated Med Foundation $5,000.00 Corporate Sponsorships
Integrated Med Foundation $4,500.00 Corporate Sponsorships
International Aids Society-- $50,000.00 Educational Grants
Usa
International Aids Society-- $75,000.00 Educational Grants
Usa
International Alliance for $5,000.00 Educational Grants
Biological Standardization
International Association $25,000.00 Corporate Sponsorships
for The Study of Lung
Cancer
International Association $95,150.00 Corporate Sponsorships
for The Study of Lung
Cancer
International Association $264,000.00 Corporate Sponsorships
for The Study of Lung
Cancer
International Association $75,000.00 Corporate Sponsorships
for The Study of Lung
Cancer
International Association $75,000.00 Corporate Sponsorships
for The Study of Lung
Cancer
International Cancer $10,000.00 Corporate Sponsorships
Advocacy Netwk
International Chinese $10,000.00 Corporate Sponsorships
Statistical Associate
International Dermatology $70,000.00 Corporate Sponsorships
Outcome Measures
International Dermatology $150,000.00 Corporate Sponsorships
Outcome Measures
International League of $20,000.00 Charitable Donations
Associate for Rheumlgy
International Medical Corps $5,000.00 Charitable Donations
International Pelvic Pain $21,000.00 Corporate Sponsorships
Society
International Physician $90,000.00 Corporate Sponsorships
Ntwrk Dba International
Oncology Ntwrk
International Physician $50,000.00 Corporate Sponsorships
Ntwrk Dba International
Oncology Ntwrk
International Physician $75,000.00 Corporate Sponsorships
Ntwrk Dba International
Oncology Ntwrk
International Society for $5,000.00 Educational Grants
Antiviral Research
International Society for $3,000.00 Educational Grants
The Study of Xenobiotics
International Society of $86,420.00 Corporate Sponsorships
Nephrology
Iraq And Afghanistan $15,000.00 Corporate Sponsorships
Veterans
Jefferson Med College at $10,000.00 Educational Grants
Thomas Jefferson Univ
Jefferson Med College at $3,000.00 Corporate Sponsorships
Thomas Jefferson Univ
Jefferson Med College at $5,000.00 Educational Grants
Thomas Jefferson Univ
Jewish Hospital $7,500.00 Corporate Sponsorships
Johns Hopkins Technology $40,000.00 Fellowships and
Ventures Scholarships
Johns Hopkins Technology $40,000.00 Fellowships and
Ventures Scholarships
Johns Hopkins Technology $40,000.00 Fellowships and
Ventures Scholarships
Johns Hopkins Technology $1,500.00 Corporate Sponsorships
Ventures
Johns Hopkins Technology $6,500.00 Fellowships and
Ventures Scholarships
Johns Hopkins Univ School $25,000.00 Corporate Sponsorships
of Medicine
Johns Hopkins Univ School $20,000.00 Educational Grants
of Medicine
Jonathan Wood and Associate $10,000.00 Corporate Sponsorships
JWC Covenant Inc. $50,000.00 Educational Grants
Kansas Univ Endowment $1,000.00 Charitable Donations
Association
Keystone Symposia $25,000.00 Corporate Sponsorships
Keystone Symposia $25,000.00 Corporate Sponsorships
Kidney Foundation Inc.. $5,000.00 Corporate Sponsorships
Northeast
Laboratorio Clinico Toledo $735.00 Patient Support
Laboratorio Clinico Toledo $1,185.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $450.00 Patient Support
Laboratorio Clinico Toledo $750.00 Patient Support
Laboratorio Clinico Toledo $270.00 Patient Support
Laboratorio Clinico Toledo $1,545.00 Patient Support
Laboratorio Clinico Toledo $552.00 Patient Support
Laboratorio Clinico Toledo $375.00 Patient Support
Laboratorio Clinico Toledo $375.00 Patient Support
Laboratorio Clinico Toledo $675.00 Patient Support
Laboratorio Clinico Toledo $1,095.00 Patient Support
Laboratorio Clinico Toledo $2,085.00 Patient Support
Laboratorio Clinico Toledo $6,000.00 Patient Support
Laboratorio Clinico Toledo $375.00 Patient Support
Laboratorio Clinico Toledo $375.00 Patient Support
Laboratorio Clinico Toledo $705.00 Patient Support
Laboratorio Clinico Toledo $2,250.00 Patient Support
Laboratorio Clinico Toledo $375.00 Patient Support
Laboratorio Clinico Toledo $375.00 Patient Support
Laboratorio Clinico Toledo $390.00 Patient Support
Laboratorio Clinico Toledo $525.00 Patient Support
Laboratorio Clinico Toledo $750.00 Patient Support
Laboratorio Clinico Toledo $1,035.00 Patient Support
Laboratorio Clinico Toledo $1,125.00 Patient Support
Laboratorio Clinico Toledo $1,185.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $1,515.00 Patient Support
Laboratorio Clinico Toledo $750.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $1,950.00 Patient Support
Laboratorio Clinico Toledo $735.00 Patient Support
Laboratorio Clinico Toledo $735.00 Patient Support
Laboratorio Clinico Toledo $555.00 Patient Support
Laboratorio Clinico Toledo $1,125.00 Patient Support
Laboratorio Clinico Toledo $375.00 Patient Support
Laboratorio Clinico Toledo $750.00 Patient Support
Laboratorio Clinico Toledo $855.00 Patient Support
Laboratorio Clinico Toledo $1,020.00 Patient Support
Laboratorio Clinico Toledo $1,125.00 Patient Support
Laboratorio Clinico Toledo $375.00 Patient Support
Laboratorio Clinico Toledo $375.00 Patient Support
Laboratorio Clinico Toledo $990.00 Patient Support
Laboratorio Clinico Toledo $1,125.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $3,000.00 Patient Support
Laboratorio Clinico Toledo $360.00 Patient Support
Laboratorio Clinico Toledo $375.00 Patient Support
Laboratorio Clinico Toledo $510.00 Patient Support
Laboratorio Clinico Toledo $600.00 Patient Support
Laboratorio Clinico Toledo $750.00 Patient Support
Laboratorio Clinico Toledo $2,595.00 Patient Support
Laboratorio Clinico Toledo $750.00 Patient Support
Laboratorio Clinico Toledo $375.00 Patient Support
Laboratorio Clinico Toledo $450.00 Patient Support
Laboratorio Clinico Toledo $825.00 Patient Support
Laboratorio Clinico Toledo $1,035.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $1,860.00 Patient Support
Laboratorio Clinico Toledo $1,080.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $750.00 Patient Support
Laboratorio Clinico Toledo $750.00 Patient Support
Laboratorio Clinico Toledo $1,005.00 Patient Support
Laboratorio Clinico Toledo $1,125.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $750.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $900.00 Patient Support
Laboratorio Clinico Toledo $1,290.00 Patient Support
Laboratorio Clinico Toledo $450.00 Patient Support
Laboratorio Clinico Toledo $525.00 Patient Support
Laboratorio Clinico Toledo $600.00 Patient Support
Laboratorio Clinico Toledo $750.00 Patient Support
Laboratorio Clinico Toledo $1,050.00 Patient Support
Laboratorio Clinico Toledo $1,380.00 Patient Support
Laboratorio Clinico Toledo $750.00 Patient Support
Laboratorio Clinico Toledo $750.00 Patient Support
Laboratorio Clinico Toledo $690.00 Patient Support
Laboratorio Clinico Toledo $720.00 Patient Support
Laboratorio Clinico Toledo $739.00 Patient Support
Laboratorio Clinico Toledo $750.00 Patient Support
Laboratorio Clinico Toledo $885.00 Patient Support
Laboratorio Clinico Toledo $1,035.00 Patient Support
Laboratorio Clinico Toledo $3,000.00 Patient Support
Laboratorio Clinico Toledo $240.00 Patient Support
Laboratorio Clinico Toledo $2,220.00 Patient Support
Lake County Haven $10,000.00 Charitable Donations
Large Urology Group $25,000.00 Corporate Sponsorships
Practice Associate
Large Urology Group $66,400.00 Corporate Sponsorships
Practice Associate
Large Urology Group $20,000.00 Corporate Sponsorships
Practice Associate
Latino Center On Aging $5,000.00 Corporate Sponsorships
Lenox Hill Hospital $10,000.00 Educational Grants
Leukemia and Lymphoma $1,267,000.00 Charitable Donations
Society
Leukemia and Lymphoma $50,000.00 Educational Grants
Society
Leukemia and Lymphoma $5,000.00 Corporate Sponsorships
Society
Leukemia and Lymphoma $25,000.00 Educational Grants
Society
Leukemia and Lymphoma $15,000.00 Corporate Sponsorships
Society
Leukemia and Lymphoma $50,000.00 Educational Grants
Society
Leukemia and Lymphoma $2,500.00 Corporate Sponsorships
Society
Leukemia and Lymphoma $75,000.00 Educational Grants
Society
Leukemia and Lymphoma $32,500.00 Corporate Sponsorships
Society
Leukemia and Lymphoma $50,000.00 Educational Grants
Society
Leukemia and Lymphoma $30,000.00 Corporate Sponsorships
Society
Leukemia and Lymphoma $100,000.00 Corporate Sponsorships
Society
Leukemia and Lymphoma $10,000.00 Corporate Sponsorships
Society
Leukemia Research $50,000.00 Fellowships and
Foundation Scholarships
Leukemia Research $5,000.00 Patient Support
Foundation
Leukemia Research $5,000.00 Educational Grants
Foundation
Leukemia Research $3,000.00 Corporate Sponsorships
Foundation
Liver Health Connection $75,000.00 Fellowships and
Scholarships
Liver Health Connection $5,000.00 Corporate Sponsorships
Livestrong Foundation $10,000.00 Patient Support
Lone Star Parkinson Society $500.00 Corporate Sponsorships
Louisiana Urological $5,000.00 Corporate Sponsorships
Society
Loyola Stritch School of $1,000.00 Charitable Donations
Medicine Division of
Dermatology
Loyola Stritch School of $1,000.00 Charitable Donations
Medicine Division of
Dermatology
Lung Cancer Alliance $25,000.00 Corporate Sponsorships
Lung Cancer Alliance $100,000.00 Corporate Sponsorships
Lung Cancer Alliance $50,000.00 Corporate Sponsorships
Lung Cancer Alliance $50,000.00 Corporate Sponsorships
Lung Cancer Research $50,000.00 Charitable Donations
Foundation
Lung Cancer Research $25,000.00 Charitable Donations
Foundation
Lungevity Foundation $50,000.00 Educational Grants
Lungevity Foundation $5,000.00 Corporate Sponsorships
Lungevity Foundation $2,500.00 Corporate Sponsorships
Lungevity Foundation $25,000.00 Corporate Sponsorships
Lungevity Foundation $75,000.00 Corporate Sponsorships
Lupus and Allied Diseases $6,000.00 Corporate Sponsorships
Association
Lupus and Allied Diseases $25,000.00 Corporate Sponsorships
Association
Lupus and Allied Diseases $35,000.00 Corporate Sponsorships
Association
Lupus Foundation New $5,000.00 Corporate Sponsorships
England, Inc.
Lupus Foundation of Florida $5,000.00 Corporate Sponsorships
Inc.
Lupus Research Alliance, $15,000.00 Corporate Sponsorships
Inc.
Lymphoma Research $5,000.00 Corporate Sponsorships
Foundation
Lymphoma Research $40,000.00 Corporate Sponsorships
Foundation
Lymphoma Research $10,000.00 Corporate Sponsorships
Foundation
Lymphoma Research $10,000.00 Corporate Sponsorships
Foundation
MS Cure Fund Inc. $15,000.00 Educational Grants
Magellan Rx Management Inc. $20,000.00 Corporate Sponsorships
March of Dimes Foundation $5,000.00 Charitable Donations
Massachusetts Association $4,000.00 Corporate Sponsorships
for Mental Health
Massachusetts General $40,000.00 Fellowships and
Hospital Scholarships
Massachusetts General $10,000.00 Corporate Sponsorships
Hospital for Children
Massachusetts General $85,000.00 Corporate Sponsorships
Hospital for Children
Massachusetts Prostate $2,500.00 Educational Grants
Cancer Coalition
Massachusetts Society for $7,500.00 Educational Grants
Med Research
Massachusetts Society of $5,000.00 Corporate Sponsorships
Clinical Oncologists
ME Strong Inc. $2,500.00 Corporate Sponsorships
Med--LQ LLC $50,000.00 Educational Grants
Med College of Wisconsin $2,000.00 Corporate Sponsorships
Med College of Wisconsin $1,000.00 Corporate Sponsorships
Med Univ of South Carolina $5,000.00 Educational Grants
Foundation
Medical Learning Institute $33,790.00 Educational Grants
Medical Learning Institute $75,000.00 Educational Grants
Medical Learning Institute $42,300.00 Educational Grants
Medical Learning Institute $116,850.00 Educational Grants
Medical Univ of South $10,000.00 Educational Grants
Carolina
Medina Community Clinic $1,000.00 Corporate Sponsorships
Medscape LLC $50,000.00 Educational Grants
Medscape LLC $125,000.00 Educational Grants
Medscape LLC $175,000.00 Educational Grants
Medscape LLC $200,000.00 Educational Grants
Medscape LLC $212,000.00 Educational Grants
Medscape LLC $235,500.00 Educational Grants
Medscape LLC $565,100.00 Educational Grants
Medscape LLC $38,000.00 Educational Grants
Medscape LLC $52,500.00 Educational Grants
Medscape LLC $300,000.00 Educational Grants
Medscape LLC $33,500.00 Educational Grants
Memorial Sloan Kettering $25,000.00 Educational Grants
Cancer Center
Memphis Business Group On $5,100.00 Corporate Sponsorships
Health
Mens Health and Wellness $1,500.00 Corporate Sponsorships
Center
Mercy Med Center Inc. $3,250.00 Corporate Sponsorships
Mercy Med Center Inc. $3,250.00 Corporate Sponsorships
Methodist Hospital $25,000.00 Corporate Sponsorships
Methodist Hospital $1,000.00 Corporate Sponsorships
Michael J Fox Foundation $1,000.00 Corporate Sponsorships
Michael J Fox Foundation $50,000.00 Corporate Sponsorships
Michigan Institute of $5,000.00 Corporate Sponsorships
Urology, PC
Michigan Parkinson $10,000.00 Corporate Sponsorships
Foundation
Michigan Parkinson $1,000.00 Corporate Sponsorships
Foundation
Michigan Rheumatism Society $25,000.00 Corporate Sponsorships
Mid America MS Achievement $2,000.00 Corporate Sponsorships
Center
Midwest Business Group on $2,500.00 Corporate Sponsorships
Health
Midwest Business Group on $2,500.00 Corporate Sponsorships
Health
Miles for Cystic Fibrosis $2,500.00 Corporate Sponsorships
Minnesota Urological $5,000.00 Corporate Sponsorships
Society
Missouri Hepatitis C $20,000.00 Educational Grants
Alliance
Mount Sinai School of $10,000.00 Educational Grants
Medicine
Mount Sinai School of $40,000.00 Fellowships and
Medicine Scholarships
Mount Sinai School of $30,000.00 Corporate Sponsorships
Medicine
Mount Sinai School of $40,000.00 Educational Grants
Medicine
Movement Disorder Society $1,000.00 Corporate Sponsorships
Movement Disorder Society $20,000.00 Educational Grants
Movement Disorder Society $321,500.00 Corporate Sponsorships
Movement Disorder Society $12,000.00 Educational Grants
Movement Disorder Society $11,000.00 Corporate Sponsorships
MS Views and News Inc. $5,000.00 Educational Grants
Multiple Myeloma Research $10,000.00 Educational Grants
Foundation Inc.
Multiple Myeloma Research $25,000.00 Educational Grants
Foundation Inc.
Multiple Myeloma Research $15,000.00 Educational Grants
Foundation Inc.
Multiple Myeloma Research $50,000.00 Fellowships and
Foundation Inc. Scholarships
Multiple Sclerosis $5,000.00 Patient Support
Foundation Inc.
Musella Foundation for $25,000.00 Charitable Donations
Brain Tumor Research and
Information Inc.
Nashville Cares Inc. $8,000.00 Corporate Sponsorships
National Academy of $30,000.00 Corporate Sponsorships
Dermatology Nurse
Practitioners
National Aids Treatment $300,000.00 Patient Support
Advocacy Project
National Alliance of Mental $5,000.00 Corporate Sponsorships
Illness Flordia
National Alliance of Mental $7,500.00 Corporate Sponsorships
Illness Tennessee
National Alliance of State $10,000.00 Corporate Sponsorships
and Territorial AIDS
Directors
National Alliance of State $50,000.00 Charitable Donations
and Territorial Aids
Directors
National Animal Interest $20,000.00 Charitable Donations
Alliance
National Associate of $45,000.00 Educational Grants
Managed Care Physician
National Associate of $10,500.00 Corporate Sponsorships
Managed Care Physician
National Associate of $20,000.00 Educational Grants
Managed Care Physician
National Associate of $25,000.00 Educational Grants
Managed Care Physician
National Associate of $45,000.00 Educational Grants
Managed Care Physician
National Associate of $20,000.00 Educational Grants
Managed Care Physician
National Associate of $35,000.00 Educational Grants
Managed Care Physician
National Associate of $10,500.00 Corporate Sponsorships
Managed Care Physician
National Associate of $10,000.00 Charitable Donations
Pediatric Nurse
Practitioners
National Association of $2,500.00 Corporate Sponsorships
Hispanic Nurses
National Association of $25,000.00 Corporate Sponsorships
Latino Elected and
Appointed officials
Education Fund
National Brain Tumor $50,000.00 Patient Support
Society (Nbts)
National Brain Tumor $25,000.00 Corporate Sponsorships
Society, Inc.
National Breast Cancer $5,000.00 Patient Support
Coalition Fund
National Business Coalition $7,500.00 Corporate Sponsorships
On Health
National Business Group On $25,000.00 Corporate Sponsorships
Health
National Coalition for $40,000.00 Corporate Sponsorships
Cancer
National Coalition for $2,500.00 Corporate Sponsorships
Cancer
National Commission On $10,000.00 Educational Grants
Correctional Health Care
National Committee of $125,000.00 Corporate Sponsorships
Quality Assurance
National Community $25,000.00 Corporate Sponsorships
Dispensing Associate NCODA
National Community $30,000.00 Corporate Sponsorships
Dispensing Associate NCODA
National Community $35,000.00 Corporate Sponsorships
Dispensing Associate NCODA
National Comprehensive $90,898.00 Educational Grants
Cancer Network
National Comprehensive $25,000.00 Educational Grants
Cancer Network
National Comprehensive $10,000.00 Educational Grants
Cancer Network
National Comprehensive $25,000.00 Educational Grants
Cancer Network
National Comprehensive $50,000.00 Educational Grants
Cancer Network
National Comprehensive $25,000.00 Educational Grants
Cancer Network
National Comprehensive $50,000.00 Educational Grants
Cancer Network
National Comprehensive $75,000.00 Educational Grants
Cancer Network
National Comprehensive $55,000.00 Educational Grants
Cancer Network
National Comprehensive $50,000.00 Charitable Donations
Cancer Network
National Comprehensive $15,000.00 Educational Grants
Cancer Network
National Comprehensive $75,000.00 Educational Grants
Cancer Network
National Federation of $5,000.00 Corporate Sponsorships
Independent
National Foundation for The ($81,525.67) Educational Grants
Centers for Disease
Control and Prevention
National Hispanic Council $25,000.00 Corporate Sponsorships
On Aging
National Kdny Foundation $292,054.00 Educational Grants
Inc.
National Medical $7,500.00 Educational Grants
Association
National Minority Quality $25,000.00 Corporate Sponsorships
forum
National Multiple Sclerosis $10,000.00 Corporate Sponsorships
Society
National Multiple Sclerosis $2,500.00 Corporate Sponsorships
Society
National Multiple Sclerosis $2,000.00 Corporate Sponsorships
Society
National Multiple Sclerosis $25,000.00 Corporate Sponsorships
Society-Greater Illinois
Chapter
National Organization of $5,000.00 Corporate Sponsorships
Rheumatology Managers
National Pancreas $80,000.00 Charitable Donations
Foundation
National Pancreas $80,000.00 Charitable Donations
Foundation
National Pancreas $85,000.00 Educational Grants
Foundation
National Pancreas $190,000.00 Educational Grants
Foundation
National Pancreas $3,500.00 Corporate Sponsorships
Foundation
National Pancreas $1,000.00 Corporate Sponsorships
Foundation
National Pancreas $85,000.00 Charitable Donations
Foundation
National Pancreas $85,000.00 Educational Grants
Foundation
National Parkinson $2,500.00 Corporate Sponsorships
Foundation Inc.
National Parkinson $1,250.00 Corporate Sponsorships
Foundation Inc.
National Parkinson $85,000.00 Corporate Sponsorships
Foundation Inc.
National Parkinson $45,000.00 Educational Grants
Foundation Inc.
National Parkinson $50,000.00 Educational Grants
Foundation Inc.
National Parkinson $5,000.00 Corporate Sponsorships
Foundation Inc.
National Psoriasis $50,000.00 Corporate Sponsorships
Foundation
National Psoriasis $25,000.00 Corporate Sponsorships
Foundation
National Psoriasis $35,000.00 Corporate Sponsorships
Foundation
National Psoriasis $50,000.00 Corporate Sponsorships
Foundation
National Psoriasis $35,000.00 Corporate Sponsorships
Foundation
National Psoriasis $15,000.00 Corporate Sponsorships
Foundation
National Psoriasis $10,000.00 Educational Grants
Foundation
National Psoriasis $75,000.00 Corporate Sponsorships
Foundation
National Psoriasis $25,000.00 Educational Grants
Foundation
National Psoriasis $15,000.00 Corporate Sponsorships
Foundation
National Psoriasis $10,000.00 Educational Grants
Foundation
National Psoriasis $15,000.00 Educational Grants
Foundation
National Psoriasis $50,000.00 Educational Grants
Foundation
National Psoriasis $35,000.00 Educational Grants
Foundation
National Psoriasis $5,000.00 Corporate Sponsorships
Foundation
National Psoriasis $50,000.00 Educational Grants
Foundation
National Psoriasis $25,000.00 Corporate Sponsorships
Foundation
National Psoriasis $100,000.00 Corporate Sponsorships
Foundation
National Psoriasis $150,000.00 Corporate Sponsorships
Foundation
National Psoriasis $20,000.00 Corporate Sponsorships
Foundation
National Psoriasis $30,000.00 Corporate Sponsorships
Foundation
National Psoriasis $30,000.00 Corporate Sponsorships
Foundation
National Psoriasis $30,000.00 Corporate Sponsorships
Foundation
National Psoriasis $35,000.00 Corporate Sponsorships
Foundation
National Psoriasis $40,000.00 Corporate Sponsorships
Foundation
National Society for $50,000.00 Corporate Sponsorships
Cutaneous Medicine
National Society for $140,000.00 Corporate Sponsorships
Cutaneous Medicine
National Society for $150,000.00 Corporate Sponsorships
Cutaneous Medicine
Neuro Challenge Foundation $25,000.00 Corporate Sponsorships
Inc.
Neurologic Disease $4,995.00 Educational Grants
Foundation
New England Dermatological $75,000.00 Corporate Sponsorships
Society
New England Immunology $2,000.00 Corporate Sponsorships
Conference Inc.
New England Quality Care $5,000.00 Corporate Sponsorships
Alliance
New Venture Fund $10,000.00 Educational Grants
New York Academy of Science $2,500.00 Educational Grants
New York Academy of Science $5,000.00 Corporate Sponsorships
New York Med Colllege $50,000.00 Educational Grants
office of Continuing Med
Education
New York Society for $55,000.00 Corporate Sponsorships
Gastrointestinal Endoscopy
New York State Rheumlgy $18,000.00 Corporate Sponsorships
Society
New York State Rheumlgy $22,500.00 Corporate Sponsorships
Society
Nexus Global Group Science $5,000.00 Corporate Sponsorships
Nicole T. Jarvis, M.D., $2,500.00 Corporate Sponsorships
PLLC
NL Communications Inc. $50,000.00 Educational Grants
NL Communications Inc. $35,000.00 Educational Grants
NL Communications Inc. $35,000.00 Educational Grants
NL Communications Inc. $35,000.00 Educational Grants
NL Communications Inc. $40,000.00 Educational Grants
NL Communications Inc. $20,000.00 Educational Grants
NL Communications Inc. $40,000.00 Educational Grants
NL Communications Inc. $20,000.00 Educational Grants
NL Communications Inc. $65,000.00 Educational Grants
NL Communications Inc. $75,000.00 Educational Grants
NL Communications Inc. $50,000.00 Educational Grants
NL Communications Inc. $30,000.00 Educational Grants
NL Communications Inc. $75,000.00 Educational Grants
North American Center for $375,025.00 Educational Grants
Continuing Med Education
North American Center for $90,000.00 Educational Grants
Continuing Med Education
North American Society for $15,000.00 Educational Grants
Pediatric Gastroenterology
Hepatology and Nutrition
North Carolina Biosciences $2,000.00 Corporate Sponsorships
Organization
North Dakota Pharmacists $2,500.00 Corporate Sponsorships
Association
Northeast Business Group On $15,000.00 Corporate Sponsorships
Health
Northeast Business Group On $15,000.00 Corporate Sponsorships
Health
Northeastern University $1,000.00 Charitable Donations
Northern Illinois $1,000.00 Charitable Donations
University Foundation
Northwest Health Law $1,000.00 Corporate Sponsorships
Advocates
Northwest Indiana $1,000.00 Corporate Sponsorships
Parkinsons
Northwest Kidney Centers $2,500.00 Corporate Sponsorships
Northwest Parkinsons $5,000.00 Educational Grants
Foundation
Northwest Parkinsons $14,900.00 Corporate Sponsorships
Foundation
Northwestern Univ $25,000.00 Corporate Sponsorships
Northwestern Univ $50,000.00 Fellowships and
Scholarships
Norton Healthcare $3,000.00 Corporate Sponsorships
Foundation
Norwich University $1,000.00 Charitable Donations
NYU School of Medicine $5,000.00 Educational Grants
NYU School of Medicine $10,000.00 Educational Grants
NYU School of Medicine $7,500.00 Educational Grants
NYU School of Medicine $10,000.00 Educational Grants
NYU School of Medicine $20,000.00 Educational Grants
Ocular Immunology and $5,000.00 Corporate Sponsorships
Uveitis Foundation
Ocular Immunology and $15,000.00 Corporate Sponsorships
Uveitis Foundation
Ohio Association of $10,000.00 Corporate Sponsorships
Rheumatology
Ohio Gastroenterology $1,250.00 Corporate Sponsorships
Society
Ohio Gastroenterology $1,250.00 Corporate Sponsorships
Society
Ohio Gastroenterology $2,500.00 Corporate Sponsorships
Society
Omnia Education Inc. $98,000.00 Educational Grants
Omnia Education Inc. $350,000.00 Educational Grants
Oncology Nursing Society $20,200.00 Corporate Sponsorships
Oradian Inc. $75,000.00 Corporate Sponsorships
Oregon Health and Science $3,500.00 Corporate Sponsorships
Univ
Oregon Health and Science $20,000.00 Educational Grants
Univ
Oregon Health and Science $5,000.00 Educational Grants
Univ
Oregon Health and Science $3,000.00 Educational Grants
Univ
Oregon Health and Science $20,000.00 Educational Grants
Univ
Osmania Gandhi Kakatiya $2,500.00 Corporate Sponsorships
Medical Alumni Association
of America
Pacific Dermatologic $20,000.00 Corporate Sponsorships
Association
Pacific Dermatologic $20,000.00 Corporate Sponsorships
Association
Pack Center LLC $22,575.00 Educational Grants
Pack Center LLC $175,000.00 Educational Grants
Pack Health LLC $119,750.00 Educational Grants
Pack Health LLC $80,000.00 Educational Grants
Pack Health LLC $79,750.00 Educational Grants
Pack Health LLC $50,000.00 Educational Grants
Pack Health LLC $42,875.00 Educational Grants
Pack Health LLC $42,875.00 Educational Grants
Pack Center LLC $100,000.00 Educational Grants
Pancreas Club $10,000.00 Educational Grants
Pancreatic Cancer Action $50,000.00 Educational Grants
Network
Pancreatic Cancer Action $282,000.00 Corporate Sponsorships
Network
Park Nicollet Foundation $1,000.00 Corporate Sponsorships
Parkinson and Movement $20,000.00 Educational Grants
Disorder Alliance
Parkinson and Movement $4,000.00 Corporate Sponsorships
Disorder Alliance
Parkinson and Movement $2,500.00 Corporate Sponsorships
Disorder Alliance
Parkinson Association $1,000.00 Corporate Sponsorships
Parkinson Association $5,000.00 Corporate Sponsorships
Parkinson Council $25,000.00 Corporate Sponsorships
Parkinson Foundation $2,500.00 Corporate Sponsorships
Parkinson Foundation $5,000.00 Corporate Sponsorships
Parkinson Foundation $10,000.00 Educational Grants
Parkinson Foundation $2,500.00 Corporate Sponsorships
Parkinson Study Group $20,000.00 Educational Grants
Parkinson Study Group $15,000.00 Corporate Sponsorships
Parkinson Study Group $2,716.00 Fellowships and
Scholarships
Parkinson Support Center of $5,000.00 Corporate Sponsorships
Kentuciana
Parkinson Support Center of $5,000.00 Corporate Sponsorships
Kentuciana
Parkinsons and Movement $1,500.00 Corporate Sponsorships
Disorder Foundation
Parkinsons Association $1,000.00 Corporate Sponsorships
Parkinsons Association $8,000.00 Educational Grants
Parkinsons Association $8,000.00 Educational Grants
Parkinson's Awareness $1,500.00 Corporate Sponsorships
Association of Central
Indiana
Parkinsons Disease $5,000.00 Corporate Sponsorships
Foundation
Parkinsons Disease $10,000.00 Corporate Sponsorships
Foundation
Parkinsons Institute $5,000.00 Corporate Sponsorships
Parkinson's Nebraska $1,000.00 Corporate Sponsorships
Parkinsons Outreach $1,000.00 Corporate Sponsorships
Association
Partnership for Quality Med $2,000.00 Charitable Donations
Donations Pqmd
Patient Access Network $287,000.00 Charitable Donations
Foundation
Patient Access Network $2,284,000.00 Charitable Donations
Foundation
Patient Access Network $10,000,000.00 Charitable Donations
Foundation
Patient Access Network $7,577,000.00 Charitable Donations
Foundation
Patient Access Network $15,000,000.00 Charitable Donations
Foundation
Patient Empowerment Ntwrk $40,000.00 Educational Grants
Patient Empowerment Ntwrk $25,000.00 Educational Grants
Patient Empowerment Ntwrk $30,000.00 Educational Grants
Patient Empowerment Ntwrk $30,000.00 Educational Grants
Patient Empowerment Ntwrk $30,000.00 Educational Grants
Patient Empowerment Ntwrk $20,000.00 Educational Grants
Patient Empowerment Ntwrk $15,000.00 Educational Grants
Patient Empowerment Ntwrk $20,000.00 Educational Grants
Patient Empowerment Ntwrk $35,000.00 Educational Grants
Pcec Prostrate Conditions $2,500.00 Corporate Sponsorships
Education Council
Pediatric Endocrine Society $3,750.00 Corporate Sponsorships
Pediatric Endocrine Society $50,000.00 Corporate Sponsorships
Pediatric Endocrinology $2,500.00 Corporate Sponsorships
Nursing Society
Pediatric Endocrinology $17,000.00 Corporate Sponsorships
Nursing Society
Pediatric Ibd Foundation $10,000.00 Corporate Sponsorships
Peerview Institute for ($2,000.00) Educational Grants
Medical Education
Pennsylvania Academy of $10,000.00 Corporate Sponsorships
Dermatology and
Dermatologic Surgry
Pennsylvania Biotechnology $3,000.00 Corporate Sponsorships
Association
Pennsylvania Prostate $5,000.00 Educational Grants
Cancer Coalition
Pennsylvania Society of $5,000.00 Corporate Sponsorships
Gastroenterology
People To People Health $20,000.00 Charitable Donations
Foundation
People To People Health $20,000.00 Charitable Donations
Foundation
Performrx $5,000.00 Corporate Sponsorships
Pharmaceutical Research and $20,000.00 Corporate Sponsorships
Manufacturers of America
Philadelphia Research and $5,500.00 Educational Grants
Education Foundation
Phrmct Care Management $73,000.00 Corporate Sponsorships
Associate
Phrmct Care Management $88,000.00 Corporate Sponsorships
Associate
Phrmct Care Management $73,000.00 Corporate Sponsorships
Associate
Physicians Education $25,000.00 Educational Grants
Resource LLC
Physicians Education $75,000.00 Educational Grants
Resource LLC
Physicians Education $50,000.00 Educational Grants
Resource LLC
Physicians Education $50,000.00 Educational Grants
Resource LLC
Pink Door Nonprofit $2,400.00 Corporate Sponsorships
Organization
Pins for Parkinsons $500.00 Corporate Sponsorships
Pittsburgh Business Group $13,000.00 Corporate Sponsorships
On Health
Pittsburgh Business Group $13,000.00 Corporate Sponsorships
On Health
Postgraduate Institute for $59,725.00 Educational Grants
Medicine
Presbyterian Healthcare $5,000.00 Corporate Sponsorships
Foundation
President and Fellows of $1,500.00 Educational Grants
Harvard College
Prevent Cancer Foundation $25,000.00 Charitable Donations
Prevent Cancer Foundation $100,000.00 Corporate Sponsorships
Prevent Cancer Foundation $5,000.00 Corporate Sponsorships
Prime Education Inc. $150,000.00 Educational Grants
Prime Education Inc. $225,000.00 Educational Grants
Prime Education Inc. $190,000.00 Educational Grants
Prime Education Inc. $244,000.00 Educational Grants
Prime Education Inc. $332,620.00 Educational Grants
Prime Education Inc. $100,000.00 Educational Grants
Prime Education Inc. $200,000.00 Educational Grants
Prime Education Inc. $100,000.00 Educational Grants
Prime Education Inc. $106,400.00 Educational Grants
Prime Education Inc. $128,902.00 Educational Grants
Prime Oncology Inc. $25,000.00 Educational Grants
Prime Oncology Inc. $155,125.00 Educational Grants
Prime Oncology Inc. $75,000.00 Educational Grants
Prime Oncology Inc. $154,150.00 Educational Grants
Primo Education LLC $50,000.00 Educational Grants
Princeton Univ Trustees $50,000.00 Educational Grants
Project Inform $75,000.00 Charitable Donations
Project Inform, Inc. $30,000.00 Corporate Sponsorships
Project Spark Foundation $1,500.00 Corporate Sponsorships
Projects in Knowledge Inc. $125,000.00 Educational Grants
Projects in Knowledge Inc. $80,000.00 Educational Grants
Projects in Knowledge Inc. $150,000.00 Educational Grants
Prostate Cancer Foundation $4,000.00 Corporate Sponsorships
Chicago
Prostate Cancer $5,000.00 Patient Support
International
Prostate Cancer Research $15,000.00 Corporate Sponsorships
Instutute
Prostate Health Education $7,500.00 Educational Grants
Network
Prostate Health Education $5,000.00 Educational Grants
Network
Prostaware $1,500.00 Corporate Sponsorships
Psoriasis and Psoriatic $100,000.00 Corporate Sponsorships
Arthritis Clinics
Multicenter Advancement
Network
Psoriasis and Psoriatic $100,000.00 Corporate Sponsorships
Arthritis Clinics
Multicenter Advancement
Network
Puerto Rico Associate of $20,000.00 Educational Grants
Gastroenterology
Puerto Rico Associate of $40,000.00 Corporate Sponsorships
Gastroenterology
Puerto Rico Associate of $10,000.00 Educational Grants
Gastroenterology
Purdue Univ College of $50,000.00 Educational Grants
Pharmacy
Purdue Univ College of $175,000.00 Educational Grants
Pharmacy
Recovery Idaho $1,000.00 Corporate Sponsorships
Regents of The Univ of $40,000.00 Fellowships and
California Scholarships
Regents of The Univ of $55,000.00 Fellowships and
California Scholarships
Regents of The Univ of ($658.85) Educational Grants
California
Regents of The Univ of $5,000.00 Educational Grants
California
Regents of The Univ of $10,000.00 Educational Grants
California
Regents of The Univ of $5,000.00 Educational Grants
California
Regents of The Univ of $20,000.00 Educational Grants
California
Regents of The Univ of $5,000.00 Educational Grants
Michigan
Regents of The Univ of $20,000.00 Corporate Sponsorships
Michigan
Regents of the University $5,000.00 Educational Grants
of Minnesota
Rehabilitation and $2,500.00 Corporate Sponsorships
Community
Renal Physician Associate $30,000.00 Corporate Sponsorships
Research Institute at $7,500.00 Corporate Sponsorships
Nationwide Childrens
Hospital
Research Institute for Fox $5,000.00 Corporate Sponsorships
Chase Cancer Center
Rheumatology Association of $7,500.00 Corporate Sponsorships
Iowa
Rheumatology Association of $5,000.00 Corporate Sponsorships
Iowa
Rheumatology Association of $7,500.00 Corporate Sponsorships
Iowa
Rheumatology Association of $10,000.00 Corporate Sponsorships
Minnesota and The Dakotas
Rheumatology Nurses Society $75,000.00 Educational Grants
Rheumatology Nurses Society $20,000.00 Educational Grants
Rheumatology Nurses Society $46,325.00 Corporate Sponsorships
Rheumatology Nurses Society $75,000.00 Educational Grants
Rheumatology Nurses Society $75,000.00 Educational Grants
Rheumatology Nurses Society $21,250.00 Corporate Sponsorships
Rheumatology Nurses Society $45,000.00 Corporate Sponsorships
Rheumlgy Alliance of $25,000.00 Corporate Sponsorships
Louisiana
Riverside Family Medicine $2,500.00 Educational Grants
Residency The
Riverside Medical Clinic $10,000.00 Educational Grants
Charitable Foundation
Robert Michael Educational $150,000.00 Educational Grants
Institute LLC
Rock Steady Boxing $500.00 Corporate Sponsorships
Rocky Mountain MS Center $5,000.00 Educational Grants
Rocky Mountain MS Center $10,000.00 Educational Grants
Rocky Mountain MS Center $5,000.00 Educational Grants
Rocky Mountain MS Center $5,000.00 Educational Grants
Rocky Mountain MS Center $10,000.00 Educational Grants
Roger Williams Medical $40,000.00 Fellowships and
Center Scholarships
Roger Williams Medical $5,000.00 Educational Grants
Center
Rotary Club of Downtown $1,000.00 Corporate Sponsorships
Macon
Rush Univ Medical Center $5,000.00 Educational Grants
Rush Univ Medical Center $7,500.00 Educational Grants
Rush Univ Medical Center $75,000.00 Educational Grants
Rush Univ Medical Center $5,000.00 Charitable Donations
Rush Univ Medical Center $75,000.00 Educational Grants
Rush Univ Medical Center $75,000.00 Educational Grants
Rutgers Univ Foundation $1,000.00 Charitable Donations
Sacramento Gastrointestinal $1,500.00 Corporate Sponsorships
Education and Research
Safety Pharmacology Society $5,000.00 Educational Grants
San Francisco Aids $10,000.00 Charitable Donations
Foundation
San Francisco Public Center $75,000.00 Charitable Donations
Foundation
San Francisco Retina $5,000.00 Educational Grants
Foundation
San Francisco Retina $5,000.00 Educational Grants
Foundation
San Juan Bautista Medical $40,000.00 Fellowships and
Center Scholarships
Scott and White Healthcare $1,000.00 Corporate Sponsorships
Foundation
Scripps Health $5,000.00 Educational Grants
Scripps Health $5,000.00 Educational Grants
Scripps Health $50,000.00 Educational Grants
Scripps Research Institute $2,000.00 Educational Grants
Seattle Science Foundation $2,500.00 Educational Grants
Seattle Science Foundation $8,500.00 Educational Grants
Seton Family of Hospitals $40,000.00 Fellowships and
Scholarships
Sexual Medicine Society of $5,000.00 Corporate Sponsorships
North America
Foundation(Smsna)
Sexual Medicine Society of $225,000.00 Corporate Sponsorships
North America
Foundation(Smsna)
Shanti Project Inc. $10,000.00 Patient Support
Share $5,000.00 Educational Grants
Share $10,000.00 Charitable Donations
Sharsheret $10,000.00 Educational Grants
Sheknows LLC $102,500.00 Corporate Sponsorships
Sheknows LLC $57,500.00 Corporate Sponsorships
Sheknows LLC $200,000.00 Corporate Sponsorships
Sinai Health System $10,000.00 Charitable Donations
Sociedad Dermatologica de $35,000.00 Patient Support
Puerto Rico
Sociedad PR Endocrinologia $15,000.00 Corporate Sponsorships
y Diabetologia
Sociedad Puertorriquena $2,000.00 Corporate Sponsorships
Pediatria
Sociedad Puertorriquena $9,500.00 Corporate Sponsorships
Pediatria
Sociedad Puertorriquena $14,000.00 Corporate Sponsorships
Pediatria
Society for Clinical $15,000.00 Corporate Sponsorships
Research Sites Inc.
Society for Clinical Trials $2,000.00 Corporate Sponsorships
Society for Leukocyte $2,500.00 Educational Grants
Biology
Society for Mucosal $2,500.00 Educational Grants
Immunology
Society for Neuro-Oncology $50,000.00 Educational Grants
Society for Neuro-Oncology $55,000.00 Corporate Sponsorships
Society for Neuroscience $2,000.00 Educational Grants
Society for Neuroscience $5,000.00 Educational Grants
Society for Womens Health $15,000.00 Corporate Sponsorships
Research
Society for Womens Health $150,000.00 Corporate Sponsorships
Research
Society of Dermatology $40,000.00 Corporate Sponsorships
Physician Assistants
Society of Dermatology $45,000.00 Corporate Sponsorships
Physician Assistants
Society of Dermatology $40,000.00 Corporate Sponsorships
Physician Assistants
Society of Dermatology $40,000.00 Corporate Sponsorships
Physician Assistants
Society of Investigative $30,000.00 Educational Grants
Dermatology
Society of Nuclear Medicine $5,000.00 Corporate Sponsorships
and Molecular Imaging
Socty for Gynecologic $10,000.00 Corporate Sponsorships
Investigation
Socty for Immunotherapy of $50,000.00 Corporate Sponsorships
Cancer
South Carolina Alliance of $6,000.00 Corporate Sponsorships
Health Plans
South Dakota Parkinson $1,500.00 Corporate Sponsorships
Foundation
South Texas Association of $30,000.00 Corporate Sponsorships
Rheumatologists
South Texas Association of $40,000.00 Corporate Sponsorships
Rheumatologists
Spondylitis Association of $40,000.00 Educational Grants
America
Spondylitis Association of $20,000.00 Educational Grants
America
Spondyloarthritis Research $70,000.00 Corporate Sponsorships
and Treatment Network
Spartan
Stage One Family Theatre $5,000.00 Corporate Sponsorships
State of Maryland $40,000.00 Educational Grants
State of Pennsylvania $25,065.00 Educational Grants
State of Pennsylvania $90,000.00 Educational Grants
State of Pennsylvania $25,000.00 Educational Grants
State of Pennsylvania $25,000.00 Educational Grants
Summit for Stem Cellular $2,500.00 Corporate Sponsorships
Foundation
Surviveit $10,000.00 Educational Grants
Susan G Komen Breast Cancer $10,000.00 Charitable Donations
Foundation Inc.
Swedish Medical Center $5,000.00 Educational Grants
First Hill Campus
Take A Breather Foundation $5,000.00 Corporate Sponsorships
Take A Breather Foundation $20,000.00 Corporate Sponsorships
Talem Health Inc. $150,000.00 Educational Grants
Tarsus Cardiology Inc. Dba $35,000.00 Corporate Sponsorships
South Beach Symposium
Tennessee Disability $7,500.00 Corporate Sponsorships
Coalition
Texas Academy of Family $2,500.00 Corporate Sponsorships
Physicians
Texas Neuro Society $5,000.00 Corporate Sponsorships
Texas Society for $2,000.00 Corporate Sponsorships
Gastroenterology and
Endoscopy
Texas Society for $2,000.00 Corporate Sponsorships
Gastroenterology and
Endoscopy
Texas Society for $2,000.00 Corporate Sponsorships
Gastroenterology and
Endoscopy
Texas Urological Society $6,000.00 Corporate Sponsorships
Texas Urological Society $6,000.00 Corporate Sponsorships
Thomas Jefferson University ($4,242.75) Educational Grants
Thomas Jefferson University $5,000.00 Corporate Sponsorships
Transcelerate Biopharma $1,500,000.00 Corporate Sponsorships
Inc.
Trustees of Boston Univ D/B/ $200,000.00 Educational Grants
A
Trustees of Boston Univ D/B/ $1,500.00 Educational Grants
A
Trustees of Boston Univ D/B/ $10,000.00 Educational Grants
A
Trustees of Dartmouth $1,000.00 Charitable Donations
College--Administration
Trustees of Tufts College $1,000.00 Charitable Donations
Trustees of Tufts College $1,000.00 Charitable Donations
Tufts Medical Center $50,000.00 Fellowships and
Scholarships
Tufts Medical Center $10,000.00 Educational Grants
UC Regents Maxillofacial $10,000.00 Educational Grants
Prosthetics Clinic
UC Regents Maxillofacial $40,000.00 Fellowships and
Prosthetics Clinic Scholarships
UC Regents Maxillofacial $5,000.00 Educational Grants
Prosthetics Clinic
UC Regents Maxillofacial $15,000.00 Educational Grants
Prosthetics Clinic
UCSF Medical Center at $50,000.00 Educational Grants
Parnassus
Ultimate Medical Academy $225,000.00 Educational Grants
LLC
Ultimate Medical Academy $175,000.00 Educational Grants
LLC
Ultimate Medical Academy $225,000.00 Educational Grants
LLC
Ultimate Medical Academy $200,000.00 Educational Grants
LLC
Ultimate Medical Academy $213,500.00 Educational Grants
LLC
Ultimate Medical Academy $249,250.00 Educational Grants
LLC
Ultimate Medical Academy ($5,370.00) Educational Grants
LLC
Ultimate Medical Academy $250,000.00 Educational Grants
LLC
Ultimate Medical Academy $149,000.00 Educational Grants
LLC
Ultimate Medical Academy $250,000.00 Educational Grants
LLC
Ultimate Medical Academy $213,500.00 Educational Grants
LLC
Ultimate Medical Academy $115,000.00 Educational Grants
LLC
Ultimate Medical Academy $289,810.00 Educational Grants
LLC
UMA Education Inc. Dba $375,000.00 Educational Grants
Global Education Group
UMA Education Inc. Dba $200,000.00 Educational Grants
Global Education Group
UMA Education Inc. Dba $38,800.00 Educational Grants
Global Education Group
UMA Education Inc. Dba $80,000.00 Educational Grants
Global Education Group
UMASS Memorial Foundation $2,500.00 Corporate Sponsorships
Inc.
United Rheumatology $36,000.00 Corporate Sponsorships
United Rheumatology $205,000.00 Corporate Sponsorships
United States Adult Cystic $5,000.00 Educational Grants
Fibrosis Association Inc.
Univ Health Service at $1,166.00 Corporate Sponsorships
Stony Point Inc.
Univ Health Service at $1,167.00 Corporate Sponsorships
Stony Point Inc.
Univ Health Service at $1,167.00 Corporate Sponsorships
Stony Point Inc.
Univ Health Service at $5,000.00 Educational Grants
Stony Point Inc.
Univ Health Service at $20,000.00 Educational Grants
Stony Point Inc.
Univ Hospital of Brooklyn ($5,527.00) Educational Grants
Univ of California $30,000.00 Corporate Sponsorships
Berkeley--Administration
Univ of California, $55,000.00 Fellowships and
Riverside Student Health Scholarships
Services
Univ of Chicago $10,000.00 Educational Grants
Univ of Chicago $5,000.00 Educational Grants
Univ of Chicago $5,000.00 Educational Grants
Univ of Chicago $65,000.00 Educational Grants
Univ of Chicago $80,000.00 Educational Grants
Univ of Chicago $140,000.00 Educational Grants
Univ of Chicago $20,000.00 Corporate Sponsorships
Univ of Chicago $15,000.00 Charitable Donations
Univ of Chicago $10,000.00 Educational Grants
Univ of Chicago $30,000.00 Educational Grants
Univ of Cincinnati $60,000.00 Educational Grants
Univ of Cincinnati $75,000.00 Educational Grants
Univ of Cincinnati $195,000.00 Educational Grants
Univ of Cincinnati $80,000.00 Educational Grants
Univ of Cincinnati $250,000.00 Educational Grants
Univ of Cincinnati $454,420.00 Educational Grants
Univ of Cincinnati $25,000.00 Educational Grants
Univ of Cincinnati ($1,212.00) Educational Grants
Univ of Cincinnati $60,000.00 Educational Grants
Univ of Cincinnati $75,000.00 Educational Grants
Univ of Cincinnati $5,000.00 Educational Grants
Foundation--Sunflower Fund
Univ of Colorado Denver $25,000.00 Fellowships and
School of Medicine Scholarships
Univ of Colorado Denver $4,000.00 Educational Grants
School of Medicine
Univ of Florida Foundation $5,000.00 Educational Grants
Univ of Florida Foundation $500.00 Corporate Sponsorships
Univ of Florida Foundation $55,000.00 Fellowships and
Scholarships
Univ of Illinios $2,000.00 Educational Grants
Univ of Illinois $1,000.00 Corporate Sponsorships
Univ of Illinois Foundation $5,000.00 Corporate Sponsorships
Univ of Illinois Foundation $5,000.00 Corporate Sponsorships
Univ of Illinois Foundation $1,000.00 Charitable Donations
Univ of Louisville Research $60,000.00 Educational Grants
Foundation
Univ of Louisville Research $98,000.00 Educational Grants
Foundation
Univ of Louisville Research $47,725.00 Educational Grants
Foundation
Univ of Louisville Research $1,000.00 Educational Grants
Foundation
Univ of Maryland Baltimore $10,000.00 Educational Grants
Foundation Inc.
Univ of Maryland Baltimore $10,000.00 Corporate Sponsorships
Foundation Inc.
Univ of Miami $50,000.00 Fellowships and
Scholarships
Univ of Miami $10,000.00 Educational Grants
Univ of Miami Dept of $10,000.00 Corporate Sponsorships
Dermatology
Univ of Nebraska Med Center $150,000.00 Educational Grants
Univ of Nebraska Med Center $675.00 Corporate Sponsorships
Univ of Nebraska Med Center $68,900.00 Educational Grants
Univ of Nebraska Med Center $25,000.00 Educational Grants
Univ of Nebraska Med Center $25,000.00 Educational Grants
Univ of Nebraska Med Center $5,000.00 Educational Grants
Univ of Nebraska Med Center $7,500.00 Educational Grants
Univ of Nebraska Med Center $5,000.00 Corporate Sponsorships
Univ of New Mexico $5,000.00 Corporate Sponsorships
Foundation
Univ of North Carolina at $40,000.00 Fellowships and
Chapel Hill Scholarships
Univ of North Carolina at ($5,463.46) Educational Grants
Chapel Hill
Univ of North Carolina at ($40,000.00) Fellowships and
Chapel Hill Scholarships
Univ of Pittsburgh $2,200.00 Educational Grants
Univ of Pittsburgh $10,000.00 Educational Grants
Univ of Pittsburgh $15,000.00 Educational Grants
Univ of Pittsburgh $2,500.00 Corporate Sponsorships
Univ of Pittsburgh $15,000.00 Educational Grants
Univ of Rhode Island $2,500.00 Educational Grants
Foundation
Univ of South Alabama $1,500.00 Corporate Sponsorships
College of Medicine
Univ of South Florida $25,000.00 Educational Grants
Health Professions
Conferencing Corp
Univ of Southern California $25,000.00 Educational Grants
Univ of Southern California $50,000.00 Fellowships and
Scholarships
Univ of Southern California $78,500.00 Fellowships and
Scholarships
Univ of Tennessee Obgyn ($1,758.03) Educational Grants
Center
Univ of Tennessee Obgyn $2,000.00 Corporate Sponsorships
Center
Univ of Texas Health $16,032.00 Corporate Sponsorships
Science Center at San
Antonio
Univ of Texas Health $75,000.00 Educational Grants
Science Center at San
Antonio
Univ of Texas Health $3,000.00 Educational Grants
Science Center at San
Antonio
Univ of Texas M D Anderson $10,000.00 Educational Grants
Cancer Center
Univ of Texas Southwestern $55,000.00 Fellowships and
Med Center Scholarships
Univ of Texas Southwestern $2,000.00 Educational Grants
Med Center
Univ of Texas Southwestern $55,000.00 Educational Grants
Med Center
Univ of The State of New $50,000.00 Educational Grants
York Univ at Buffalo
Univ of Toledo $2,000.00 Educational Grants
Universidad Central Del $7,500.00 Educational Grants
Caribe School of Medicine
Universidad Central Del $11,205.00 Educational Grants
Caribe School of Medicine
Universidad Central Del $12,000.00 Educational Grants
Caribe School of Medicine
Universidad Central Del $12,000.00 Educational Grants
Caribe School of Medicine
Universidad Central Del ($308.75) Educational Grants
Caribe School of Medicine
Universidad Central Del $7,500.00 Educational Grants
Caribe School of Medicine
Universidad Central Del $15,000.00 Educational Grants
Caribe School of Medicine
Universidad Central Del $15,000.00 Educational Grants
Caribe School of Medicine
Universidad Central Del $24,939.25 Educational Grants
Caribe School of Medicine
Universidad Central Del $10,000.00 Educational Grants
Caribe School of Medicine
Universidad Central Del $15,000.00 Educational Grants
Caribe School of Medicine
Universidad Central Del ($3,795.00) Educational Grants
Caribe School of Medicine
Universidad Central Del ($3,460.75) Educational Grants
Caribe School of Medicine
University of Alabama at ($186.25) Educational Grants
Birmingham Hospital
University of Alabama at $40,000.00 Fellowships and
Birmingham Hospital Scholarships
University of California $40,000.00 Fellowships and
Irvine Scholarships
University of California $40,000.00 Fellowships and
Irvine Scholarships
University of Colorado $1,000.00 Charitable Donations
Foundation
University of Connecticut $12,000.00 Fellowships and
Health Science Center Scholarships
University of Connecticut $40,000.00 Fellowships and
Health Science Center Scholarships
University of Connecticut ($774.73) Fellowships and
Health Science Center Scholarships
University of Edinburgh Usa $1,000.00 Charitable Donations
Development Trust Inc.
University of Illinois-- $82,092.00 Fellowships and
office of Business and Scholarships
Financial Services
University of Illinois-- $79,559.00 Fellowships and
office of Business and Scholarships
Financial Services
University of Rochester $40,000.00 Fellowships and
Scholarships
University of Sheffield in $1,000.00 Charitable Donations
America Inc.
University of Washington $40,000.00 Fellowships and
Medical Center Scholarships
University of Washington ($255.67) Educational Grants
Medical Center
Upstage Lung Cancer $5,000.00 Charitable Donations
Urology Center of Colorado $10,000.00 Corporate Sponsorships
Foundation
US Too International $25,000.00 Corporate Sponsorships
US Too International $1,500.00 Corporate Sponsorships
Valley Childrens Hospital $4,000.00 Educational Grants
Foundation
Valley Medial Center $5,000.00 Corporate Sponsorships
Foundation
Vanderbilt Univ By and $5,000.00 Corporate Sponsorships
Through Its Medical Center
Vanderbilt Univ By and $12,500.00 Fellowships and
Through Its Medical Center Scholarships
Vanderbilt Univ By and $5,000.00 Educational Grants
Through Its Medical Center
Vanderbilt Univ By and $10,000.00 Educational Grants
Through Its Medical Center
VHA Inc. $35,000.00 Corporate Sponsorships
Vindico Med Education $25,000.00 Educational Grants
Vindico Med Education $50,000.00 Educational Grants
Vindico Med Education $95,000.00 Educational Grants
Vindico Med Education $75,000.00 Educational Grants
Vindico Med Education $50,000.00 Educational Grants
Virginia Association of $2,500.00 Corporate Sponsorships
Health Plans
Virginia Commonwealth Univ $2,500.00 Corporate Sponsorships
School of Medicine
Washington and Lee $1,000.00 Charitable Donations
University
Washington Hospital Center $10,000.00 Educational Grants
Corp
Washington Rheumatology $50,000.00 Corporate Sponsorships
Alliance
Washington Univ in St Louis $5,000.00 Educational Grants
Washington Univ in St Louis $1,600.00 Fellowships and
Scholarships
Washington Univ in St Louis $40,000.00 Fellowships and
Scholarships
Webmd Global LLC ($500.00) Educational Grants
Webmd Global LLC $75,000.00 Educational Grants
Webmd Global LLC $146,500.00 Educational Grants
Webmd Global LLC $340,000.00 Educational Grants
Webmd Global LLC $100,000.00 Educational Grants
Webmd Global LLC $150,000.00 Educational Grants
Webmd Global LLC $105,000.00 Educational Grants
Webmd Global LLC $90,000.00 Educational Grants
Webmd Global LLC $150,000.00 Educational Grants
Webmd Global LLC $300,000.00 Educational Grants
Webmd Global LLC $600,000.00 Educational Grants
Webmd Global LLC $250,000.00 Educational Grants
Western Pennsylvania $5,000.00 Fellowships and
Hospital forbes Regional Scholarships
Campus
Western Pennsylvania ($1,502.07) Fellowships and
Hospital forbes Regional Scholarships
Campus
Western States Pharmacy $3,250.00 Corporate Sponsorships
Conference for Pharmacy
Residents Fellowships and
Preceptors
Wisconsin Chapter of The $5,000.00 Corporate Sponsorships
American College of
Healthcare Executives
Wisconsin Collaborative for $2,650.00 Corporate Sponsorships
Healthcare Quality
Wisconsin Dairyland Chapter $2,000.00 Corporate Sponsorships
of Healthcare Information
and Management Systems
Society (HIMSS)
Wisconsin Rheumatology $10,000.00 Corporate Sponsorships
Association
Wj Weiser Association $5,000.00 Corporate Sponsorships
Management Inc.
World Parkinson Coalition $5,000.00 Charitable Donations
Inc.
Yale Univ $5,000.00 Educational Grants
Young Survival Coalition $25,000.00 Corporate Sponsorships
Zebrafish Disease Models $10,000.00 Educational Grants
Society
Zero The Project To End $270,000.00 Corporate Sponsorships
Prostate Cancer
Zero The Project To End $12,000.00 Corporate Sponsorships
Prostate Cancer
------------------------------------------------------------------------
Grants and Donations Report--2018
(Parentheses represent refunds of previously disclosed payments)
Report as of 3/31/3019
------------------------------------------------------------------------
Recipient Payment Amount Purpose
------------------------------------------------------------------------
50 Hoops $25,000.00 Educational Grants
50 Hoops $10,000.00 Patient Support
A and R Educational Group $80,350.00 Corporate Sponsorships
LLC
A and R Educational Group $4,500.00 Corporate Sponsorships
LLC
AAPS $50,000.00 Corporate Sponsorships
Aasld Foundation (American $500,000.00 Charitable Donations
Association for The Study
of Liver Disease)
Aasld Foundation (American $250,000.00 Charitable Donations
Association for The Study
of Liver Disease)
Academia Puertorriquena DE $4,500.00 Corporate Sponsorships
Neurologia
Academic Cme LLC $45,000.00 Educational Grants
Academy of Managed Care $40,000.00 Corporate Sponsorships
Pharmacy
Academy of Managed Care $27,000.00 Corporate Sponsorships
Pharmacy
Academy of Managed Care $32,000.00 Corporate Sponsorships
Pharmacy
Academy of Managed Care $30,000.00 Corporate Sponsorships
Pharmacy
Advanced Medical Education $2,500.00 Corporate Sponsorships
Consultants, Corp.
Advanced Urology Institute $10,000.00 Corporate Sponsorships
Education and General Fund
Advances in Cosmetic and $75,000.00 Corporate Sponsorships
Med Dermatology Inc.
Advances in Cosmetic and $75,000.00 Corporate Sponsorships
Med Dermatology Inc.
Advances in Cosmetic and $75,000.00 Corporate Sponsorships
Med Dermatology Inc.
Adventist Health System-- $15,000.00 Corporate Sponsorships
Sunbelt Inc.
Aesthetic Dermatology $7,500.00 Corporate Sponsorships
Symposia
AIDS Connecticut $5,000.00 Corporate Sponsorships
AIDS Foundation of Chicago $10,000.00 Corporate Sponsorships
AIDS Foundation of Chicago $10,000.00 Charitable Donations
AIDS Institute $10,000.00 Corporate Sponsorships
AIDS Institute $7,500.00 Corporate Sponsorships
AIDS Support Network $2,000.00 Corporate Sponsorships
Aimed Alliance $20,000.00 Corporate Sponsorships
Alabama Academy of $1,200.00 Corporate Sponsorships
Neurology
Alabama Associate of Center $5,000.00 Corporate Sponsorships
Plans
Alabama Dermatology Society $50,000.00 Corporate Sponsorships
Alabama Society of $750.00 Corporate Sponsorships
Dermatology Professionals
Albert Einstein College of $10,000.00 Educational Grants
Medicine Division of
Dermatology
Albert Einstein College of $50,000.00 Educational Grants
Medicine of Yeshiva Univ
Albert Einstein College of $45,000.00 Educational Grants
Medicine of Yeshiva Univ
Alliance for Aging Research $5,000.00 Corporate Sponsorships
Alsac St Jude Childrens $15,000.00 Charitable Donations
Research Hospital
Alzheimers Association $2,500.00 Corporate Sponsorships
Greater Illinois Chapter
Alzheimers Disease and $100,000.00 Corporate Sponsorships
Related Disorders
Association Inc.
Alzheimers Disease and $10,000.00 Charitable Donations
Related Disorders
Association Inc.
American Academy of $40,000.00 Educational Grants
Dermatology
American Academy of $10,000.00 Charitable Donations
Dermatology
American Academy of $7,500.00 Corporate Sponsorships
Dermatology
American Academy of $300,000.00 Corporate Sponsorships
Dermatology
American Academy of $50,000.00 Charitable Donations
Dermatology
American Academy of $50,000.00 Educational Grants
Dermatology
American Academy of Family $19,000.00 Educational Grants
Physicians
American Academy of $30,000.00 Educational Grants
Neurology Institute
American Academy of $40,050.00 Corporate Sponsorships
Neurology Institute
American Academy of $38,220.00 Corporate Sponsorships
Neurology Institute
American Academy of $100,000.00 Fellowships and
Neurology Institute Scholarships
American Academy of $16,470.00 Corporate Sponsorships
Neurology Institute
American Academy of $24,112.40 Corporate Sponsorships
Ophthalmology Aao
American Academy of $15,000.00 Corporate Sponsorships
Pediatrics
American Academy of $14,000.00 Corporate Sponsorships
Pediatrics
American Academy of $95,000.00 Educational Grants
Physician Assistants
American Association of $5,000.00 Educational Grants
Clinical Endocrinologists
New Jersey Chapter
American Association of $18,000.00 Educational Grants
Clinical Endocrinologists
New Jersey Chapter
American Association for $5,000.00 Educational Grants
Accreditation of
Laboratory Animal Care
International (Aaalac
International
American Association for $40,000.00 Fellowships and
Cancer Research Scholarships
American Association for $25,000.00 Patient Support
Cancer Research
American Association for $25,000.00 Educational Grants
Cancer Research
American Association for $10,000.00 Educational Grants
Cancer Research
American Association for $25,000.00 Charitable Donations
Cancer Research
American Association for $10,000.00 Educational Grants
Cancer Research
American Association for $20,000.00 Educational Grants
Cancer Research
American Association for $5,000.00 Educational Grants
Cancer Research
American Association for $10,000.00 Educational Grants
Cancer Research
American Association for $5,000.00 Educational Grants
Cancer Research
American Association for $5,000.00 Educational Grants
Cancer Research
American Association for $25,000.00 Educational Grants
Cancer Research
American Association for $25,000.00 Educational Grants
Cancer Research
American Association for $75,000.00 Educational Grants
Cancer Research
American Association for $20,000.00 Charitable Donations
Laboratory Animal Science
American Association for $10,000.00 Charitable Donations
The Study of Liver Disease
American Association of $200,000.00 Patient Support
Clinical Endocrinologists
Inc.
American Association of $15,200.00 Corporate Sponsorships
Gynecologic Laparoscopists
Inc.
American Association of $50,000.00 Educational Grants
Nurse Practitioners
American Brain Tumor $50,000.00 Fellowships and
Association Scholarships
American Brain Tumor $2,500.00 Charitable Donations
Association
American Brain Tumor $10,000.00 Patient Support
Association
American Brain Tumor $10,000.00 Corporate Sponsorships
Association
American Brain Tumor $60,000.00 Corporate Sponsorships
Association
American Brain Tumor $3,400.00 Corporate Sponsorships
Association
American Brain Tumor $10,000.00 Patient Support
Association
American Brain Tumor $10,000.00 Patient Support
Association
American Brain Tumor $5,000.00 Corporate Sponsorships
Association
American Brain Tumor $50,000.00 Fellowships and
Association Scholarships
American Brain Tumor $22,500.00 Corporate Sponsorships
Association
American Brain Tumor $25,000.00 Corporate Sponsorships
Association
American Brain Tumor $50,000.00 Corporate Sponsorships
Association
American Cancer Society $5,000.00 Corporate Sponsorships
American Cancer Society $1,500.00 Corporate Sponsorships
American Cancer Society $10,000.00 Corporate Sponsorships
American Cancer Society $10,000.00 Charitable Donations
American Cancer Society $2,500.00 Corporate Sponsorships
American Cancer Society $10,000.00 Corporate Sponsorships
American Cancer Society $5,000.00 Corporate Sponsorships
American Cancer Society $2,500.00 Corporate Sponsorships
American Cancer Society $5,000.00 Corporate Sponsorships
American Cancer Society $10,000.00 Corporate Sponsorships
American Cancer Society $5,000.00 Corporate Sponsorships
American Cancer Society $5,000.00 Corporate Sponsorships
American Cancer Society $2,500.00 Corporate Sponsorships
American Cancer Society $2,500.00 Corporate Sponsorships
American Cancer Society $2,500.00 Corporate Sponsorships
American Cancer Society $2,500.00 Corporate Sponsorships
American Cancer Society $2,500.00 Corporate Sponsorships
American Cancer Society $2,500.00 Corporate Sponsorships
American Cancer Society $5,000.00 Corporate Sponsorships
American Cancer Society $12,000.00 Corporate Sponsorships
American Cancer Society $3,500.00 Corporate Sponsorships
American Cancer Society $10,000.00 Corporate Sponsorships
American Cancer Society $50,000.00 Corporate Sponsorships
American Cancer Society $50,000.00 Corporate Sponsorships
American Chemist Society $3,000.00 Educational Grants
American Chemist Society $2,500.00 Educational Grants
American Chemist Society $1,500.00 Educational Grants
American Chemist Society $3,000.00 Educational Grants
American College of $10,000.00 Corporate Sponsorships
Gastroenterology
American College of $90,000.00 Corporate Sponsorships
Gastroenterology
American College of $90,000.00 Corporate Sponsorships
Gastroenterology
American College of $60,000.00 Corporate Sponsorships
Gastroenterology
American College of $60,000.00 Corporate Sponsorships
Gastroenterology
American College of $450,000.00 Charitable Donations
Gastroenterology
American College of $100,000.00 Corporate Sponsorships
Gastroenterology
American College of $125,000.00 Corporate Sponsorships
Gastroenterology
American College of $30,000.00 Charitable Donations
Laboratory Animal Medicine
American College of $32,500.00 Corporate Sponsorships
Obstetricians and
Gynecologists
American College of $25,000.00 Corporate Sponsorships
Osteopathic Family
Physicians of California
American College of $35,000.00 Corporate Sponsorships
Osteopathic Obstetricians
and Gynecologists
American College of $57,000.00 Corporate Sponsorships
Physician Foundation
American College of $25,000.00 Educational Grants
Rheumatology
American College of $70,000.00 Corporate Sponsorships
Rheumatology
American College of $25,000.00 Educational Grants
Rheumatology
American College of $35,000.00 Educational Grants
Rheumatology
American College of $50,000.00 Educational Grants
Rheumatology
American College of $50,000.00 Corporate Sponsorships
Rheumatology
American College of $2,000,000.00 Corporate Sponsorships
Rheumatology Research and
Education Foundation
American Congress of $3,000.00 Corporate Sponsorships
Obstetricians and
Gynecologists
American Congress of $9,500.00 Corporate Sponsorships
Obstetricians and
Gynecologists
American Congress of $10,000.00 Corporate Sponsorships
Obstetricians and
Gynecologists
American Congress of $2,250.00 Corporate Sponsorships
Obstetricians and
Gynecologists
American Congress of $25,000.00 Educational Grants
Obstetricians and
Gynecologists--Hawaii
Section District Viii
American Congress of $32,500.00 Corporate Sponsorships
Obstetricians and
Gynecologists--Hawaii
Section District Viii
American Congress of $15,000.00 Corporate Sponsorships
Obstetricians and
Gynecologists--Hawaii
Section District Viii
American Congress of $38,400.00 Corporate Sponsorships
Obstetricians and
Gynecologists--Hawaii
Section District Viii
American Congress of $2,500.00 Corporate Sponsorships
Obstetricians and
Gynecologists Montana
Section
American $278,000.00 Educational Grants
Gastroenterological
Association Institute
American $46,325.00 Corporate Sponsorships
Gastroenterological
Association Institute
American $50,000.00 Corporate Sponsorships
Gastroenterological
Association Institute
American $90,000.00 Corporate Sponsorships
Gastroenterological
Association Institute
American $200,000.00 Educational Grants
Gastroenterological
Association Institute
American $40,000.00 Educational Grants
Gastroenterological
Association Institute
American Gastrointestinal ($2,094.95) Educational Grants
Association
American Kdny Fund $5,000.00 Corporate Sponsorships
American Liver Foundation $300,000.00 Corporate Sponsorships
American Liver Foundation $1,000.00 Corporate Sponsorships
American Liver Foundation $7,500.00 Corporate Sponsorships
American Liver Foundation $2,500.00 Corporate Sponsorships
American Liver Foundation $10,000.00 Educational Grants
American Liver Foundation $2,500.00 Corporate Sponsorships
American Liver Foundation $5,000.00 Corporate Sponsorships
American Liver Foundation $50,000.00 Educational Grants
American Liver Foundation $86,000.00 Corporate Sponsorships
American Liver Foundation $25,000.00 Educational Grants
American Med Group $5,022.40 Corporate Sponsorships
Associate
American Med Group $5,022.40 Corporate Sponsorships
Associate
American Med Group $5,022.40 Corporate Sponsorships
Associate
American Med Group $5,022.40 Corporate Sponsorships
Associate
American Med Group $5,022.40 Corporate Sponsorships
Associate
American Military Partner $25,000.00 Corporate Sponsorships
Association
American Military Partner $25,000.00 Corporate Sponsorships
Association
American National Red Cross $1,000.00 Corporate Sponsorships
and Its Constituent
Chapters and Branches
American Neuro Associate $40,000.00 Educational Grants
American Pancreatic $25,000.00 Charitable Donations
Associate
American Pancreatic $75,000.00 Educational Grants
Associate
American Pancreatic $60,000.00 Corporate Sponsorships
Associate
American Pancreatic $70,000.00 Corporate Sponsorships
Associate
American Parkinson Disease $3,000.00 Corporate Sponsorships
Association
American Parkinson Disease $5,000.00 Corporate Sponsorships
Association
American Parkinson Disease $75,000.00 Corporate Sponsorships
Association
American Parkinson Disease $25,000.00 Corporate Sponsorships
Association
American Parkinson Disease $2,000.00 Corporate Sponsorships
Association
American Parkinson Disease $5,000.00 Corporate Sponsorships
Association
American Parkinson Disease $4,000.00 Corporate Sponsorships
Association
American Parkinson Disease $10,000.00 Educational Grants
Association
American Pharmacists $15,000.00 Corporate Sponsorships
Association (Apha)
American Red Cross of $10,000.00 Charitable Donations
Greater Chicago
American Society for $40,000.00 Corporate Sponsorships
Reproductive Medicine
American Society for $10,000.00 Corporate Sponsorships
Reproductive Medicine
American Society for $6,000.00 Corporate Sponsorships
Reproductive Medicine
American Society of $17,500.00 Corporate Sponsorships
Anesthesiologists
American Society of $15,000.00 Educational Grants
Hematology
American Society of $544,550.00 Corporate Sponsorships
Hematology
American Society of $60,000.00 Educational Grants
Hematology
American Society of $50,000.00 Fellowships and
Hematology Scholarships
American Society of $20,000.00 Educational Grants
Hematology
American Society of $50,000.00 Educational Grants
Hematology
American Statistical $26,500.00 Corporate Sponsorships
Associate
American Thyroid Associate $30,000.00 Educational Grants
Inc.
American Uroligical $3,500.00 Corporate Sponsorships
Associate Northeastern
Section
American Urological $25,000.00 Corporate Sponsorships
Associate Education and
Research Inc.
American Urological $50,000.00 Charitable Donations
Associate Education and
Research Inc.
American Urological $20,000.00 Educational Grants
Associate Education and
Research Inc.
American Urological $50,000.00 Educational Grants
Associate Education and
Research Inc.
American Urological $10,000.00 Corporate Sponsorships
Associate Inc. Western
Section
American Urological $35,000.00 Corporate Sponsorships
Associate Inc. Western
Section
American Urological $2,000.00 Corporate Sponsorships
Association--New York
Section
American Urological $25,000.00 Corporate Sponsorships
Association--Southeast
Section
American Urological $5,800.00 Corporate Sponsorships
Association--Southeast
Section
American Urological $10,000.00 Charitable Donations
Association Foundation
Americans for Med Progress $90,000.00 Charitable Donations
Americas Hepato--Pancreato-- $35,750.00 Corporate Sponsorships
Biliary A
Angel Foundation $5,000.00 Corporate Sponsorships
Angel Foundation $10,000.00 Corporate Sponsorships
Angela Hospice Homecare $2,500.00 Charitable Donations
Answer2cancer $3,000.00 Corporate Sponsorships
Arizona State Association $3,500.00 Corporate Sponsorships
of Physician Assistants
Arizona United Rheumatology $10,000.00 Corporate Sponsorships
Alliance--Aura
Arkansas Prostate Cancer $2,000.00 Corporate Sponsorships
Foundation
Arkansas Rheumatology $10,000.00 Corporate Sponsorships
Association
Arkansas Urology Society $1,250.00 Corporate Sponsorships
Arthritis Foundation $100,000.00 Fellowships and
Scholarships
Arthritis Foundation $25,000.00 Corporate Sponsorships
Arthritis Foundation $175,000.00 Corporate Sponsorships
Arthritis Foundation $40,000.00 Corporate Sponsorships
Arthritis Foundation $2,000.00 Corporate Sponsorships
Arthritis Foundation $25,000.00 Corporate Sponsorships
Arthritis Foundation $5,000.00 Charitable Donations
Arthritis Foundation $2,500.00 Patient Support
Arthritis Foundation $5,000.00 Patient Support
Arthritis Foundation $30,000.00 Corporate Sponsorships
Arthritis Foundation $25,000.00 Corporate Sponsorships
Arthritis Foundation $10,500.00 Patient Support
Arthritis Foundation $20,000.00 Patient Support
Arthritis Foundation $10,000.00 Charitable Donations
Arthritis Foundation $7,500.00 Patient Support
Arthritis Foundation $30,000.00 Corporate Sponsorships
Arthritis Foundation $2,500.00 Corporate Sponsorships
Arthritis Foundation $10,000.00 Corporate Sponsorships
Arthritis Foundation $1,595.00 Patient Support
Arthritis Foundation $1,650.00 Corporate Sponsorships
Arthritis Foundation $5,000.00 Corporate Sponsorships
Arthritis Foundation $10,000.00 Corporate Sponsorships
Arthritis Foundation $10,000.00 Corporate Sponsorships
Arthritis Foundation $5,000.00 Corporate Sponsorships
Arthritis Foundation $5,000.00 Corporate Sponsorships
Arthritis Foundation $2,500.00 Corporate Sponsorships
Arthritis Foundation $300.00 Corporate Sponsorships
Arthritis Foundation $2,500.00 Corporate Sponsorships
Arthritis Foundation $3,000.00 Corporate Sponsorships
Arthritis Foundation $5,000.00 Corporate Sponsorships
Arthritis Foundation $250,000.00 Corporate Sponsorships
Arthritis Foundation $400,000.00 Corporate Sponsorships
Arthritis Foundation $5,000.00 Educational Grants
Arthritis Foundation $40,000.00 Corporate Sponsorships
Arthritis Foundation $25,000.00 Corporate Sponsorships
Arthritis Foundation $259,000.00 Corporate Sponsorships
Arthritis Foundation $100,000.00 Fellowships and
Scholarships
Arthritis Foundation $2,000.00 Corporate Sponsorships
Arthritis Foundation $175,000.00 Corporate Sponsorships
Arthritis Foundation $300,000.00 Corporate Sponsorships
Arthritis Patient Services $19,500.00 Charitable Donations
Arts of Healing Foundation $2,500.00 Corporate Sponsorships
ASCO Conquer Cancer $100,000.00 Charitable Donations
Foundation
ASCO Conquer Cancer $40,000.00 Educational Grants
Foundation
ASCO Conquer Cancer $60,000.00 Fellowships and
Foundation Scholarships
ASCO Conquer Cancer $75,000.00 Fellowships and
Foundation Scholarships
ASCO Conquer Cancer $30,000.00 Educational Grants
Foundation
ASCO Conquer Cancer $30,000.00 Fellowships and
Foundation Scholarships
ASCO Conquer Cancer $10,000.00 Educational Grants
Foundation
ASCO Conquer Cancer $30,000.00 Educational Grants
Foundation
ASCO Conquer Cancer $30,000.00 Educational Grants
Foundation
ASCO Conquer Cancer $60,000.00 Educational Grants
Foundation
ASCO Conquer Cancer $50,000.00 Educational Grants
Foundation
ASCO Conquer Cancer $25,000.00 Educational Grants
Foundation
ASCO Conquer Cancer $100,000.00 Charitable Donations
Foundation
ASCO Conquer Cancer $30,000.00 Fellowships and
Foundation Scholarships
ASCO Conquer Cancer $60,000.00 Fellowships and
Foundation Scholarships
ASCO Conquer Cancer $75,000.00 Fellowships and
Foundation Scholarships
ASCO Conquer Cancer $22,000.00 Educational Grants
Foundation
ASHP Foundation $75,000.00 Fellowships and
Scholarships
Aspen Cancer Conference $10,000.00 Educational Grants
Inc.
Associate de Enfermeria $6,700.00 Corporate Sponsorships
Oncologica y Hematologica
de Puerto Rico Inc.
Associate de $10,000.00 Corporate Sponsorships
Gastroenterologia y
Hepatologia Pediatrica de
Puerto Rico Aghppr
Associate de Hematologia y $5,000.00 Corporate Sponsorships
Oncologia Medica de Puerto
Rico
Associate de Hematologia y $12,000.00 Corporate Sponsorships
Oncologia Medica de Puerto
Rico
Associate de Hematologia y $3,000.00 Corporate Sponsorships
Oncologia Medica de Puerto
Rico
Associate de Hematologia y $11,000.00 Corporate Sponsorships
Oncologia Medica de Puerto
Rico
Associate de Reumatologos $15,000.00 Corporate Sponsorships
de Puerto Rico
Associate Medicos Pediatras $6,500.00 Corporate Sponsorships
Region Este Ampre
Associate Medicos Pediatras $6,500.00 Corporate Sponsorships
Region Este Ampre
Associate of Physician $2,950.00 Corporate Sponsorships
Assistants in Oncology
Inc.
Associate of Physician $35,000.00 Corporate Sponsorships
Assistants in Oncology
Inc.
Associate of Professors of $50,000.00 Corporate Sponsorships
Gyn and Obstetrician
Association of Community $30,000.00 Educational Grants
Cancer Centers (Accc)
Association of $5,000.00 Corporate Sponsorships
Frontotemporal
Degeneration
Association of Idaho $1,500.00 Corporate Sponsorships
Rheumatologists Inc.
Association of Physicians $1,500.00 Corporate Sponsorships
of Pakistani Descent of
North America (Appna)--New
York Chapter
Association of VA $15,500.00 Corporate Sponsorships
Hematology Oncology
Association of Women in $40,000.00 Corporate Sponsorships
Rheumatology
Association of Women in $40,000.00 Corporate Sponsorships
Rheumatology
Awesome Enablers LLC $250,000.00 Corporate Sponsorships
Awesome Enablers LLC $250,000.00 Corporate Sponsorships
Baylor College Medicine $100,000.00 Fellowships and
Infusion Dis Scholarships
Baylor Scott and White $5,000.00 Educational Grants
Health
Bellaire Crohns and Colitis $15,000.00 Corporate Sponsorships
Foundation
Bellaire Crohns and Colitis $5,000.00 Corporate Sponsorships
Foundation
Bellaire Crohns and Colitis $400,000.00 Corporate Sponsorships
Foundation
Bendcare $434,000.00 Corporate Sponsorships
Beth Israel Deaconess $40,000.00 Fellowships and
Medical Center Scholarships
Beth Israel Deaconess $40,000.00 Fellowships and
Medical Center Scholarships
Beth Israel Deaconess $3,500.00 Educational Grants
Medical Center
Betty and Milton Katz $1,500.00 Corporate Sponsorships
Jewish Community Center
Bexar County Physician $6,250.00 Corporate Sponsorships
Assistant Society
Big Brothers Big Sisters of $20,000.00 Charitable Donations
Metro Chicago
Bio Ascend LLC $50,000.00 Corporate Sponsorships
Bio Ascend LLC $25,000.00 Corporate Sponsorships
Biomod Foundation $1,500.00 Corporate Sponsorships
Biotechnology Industry $155,000.00 Corporate Sponsorships
Organization
Biotechnology Industry $290,000.00 Corporate Sponsorships
Organization
Biotechnology Industry $25,000.00 Corporate Sponsorships
Organization
Biotechnology Industry $56,000.00 Corporate Sponsorships
Organization
Black Health Matters $5,000.00 Corporate Sponsorships
Board of Trustees of The $1,500.00 Corporate Sponsorships
Univ of Illinois
Bonnie J Addario Lung $50,000.00 Patient Support
Cancer Foundation
Bonnie J Addario Lung $5,000.00 Corporate Sponsorships
Cancer Foundation
Borland Groover Clinic $750.00 Corporate Sponsorships
Boston College School of $10,000.00 Corporate Sponsorships
Nursing
Boston Society Inc. $3,000.00 Educational Grants
Boston Taiwanese $2,500.00 Educational Grants
Biotechnology Association
Inc.
Brian Grant Foundation $85,000.00 Educational Grants
Brian Grant Foundation $15,000.00 Corporate Sponsorships
Brigham and Women's $7,000.00 Educational Grants
Hospital, Inc.
Business Health Coalition $5,000.00 Corporate Sponsorships
Foundation
California Associate of $10,000.00 Corporate Sponsorships
Physician Groups
California Life Sciences $20,000.00 Corporate Sponsorships
Association
California Life Sciences $1,500.00 Corporate Sponsorships
Association
Cancer and Leukemia Group B $30,000.00 Educational Grants
Foundation
Cancer and Leukemia Group B $50,000.00 Fellowships and
Foundation Scholarships
Cancer Care $25,000.00 Charitable Donations
Cancer Care $75,000.00 Charitable Donations
Cancer Care $25,000.00 Educational Grants
Cancer Care $25,000.00 Educational Grants
Cancer Care $100,000.00 Educational Grants
Cancer Care $100,000.00 Educational Grants
Cancer Foundation for New $2,500.00 Corporate Sponsorships
Mexico
Cancer Foundation for New $2,500.00 Corporate Sponsorships
Mexico
Cancer Molecular Thrpt $5,000.00 Educational Grants
Cancer Research Institute $10,000.00 Educational Grants
Cancer Research Institute $40,000.00 Corporate Sponsorships
Cancer Support Community $75,000.00 Educational Grants
Cancer Support Community $75,000.00 Educational Grants
Cancer Wellness Center $5,000.00 Corporate Sponsorships
Cancercare Co-Payment $5,000,000.00 Charitable Donations
Assistance Foundation
Captis Health $3,000.00 Corporate Sponsorships
Cardinal Health $100,000.00 Corporate Sponsorships
Cardinal Health $105,000.00 Corporate Sponsorships
Carevive Systems, Inc. $75,000.00 Educational Grants
Carevive Systems, Inc. $75,000.00 Educational Grants
Carevive Systems, Inc. $75,000.00 Educational Grants
Carevive Systems, Inc. $125,000.00 Educational Grants
Caring Ambassadors Program $5,000.00 Corporate Sponsorships
Inc.
Caring Ambassadors Program $10,000.00 Corporate Sponsorships
Inc.
Caring Ambassadors Program $10,000.00 Corporate Sponsorships
Inc.
Caring Ambassadors Program $50,000.00 Charitable Donations
Inc.
Caring Ambassadors Program $10,000.00 Charitable Donations
Inc.
Carti Foundation $10,000.00 Corporate Sponsorships
Cascade Aids Project $5,000.00 Corporate Sponsorships
Case Western Reserve Univ $20,000.00 Fellowships and
Scholarships
Cedar Rapids Metro $2,000.00 Corporate Sponsorships
Parkinsons Association
Cedars--Sinai Med Center $40,000.00 Fellowships and
Scholarships
Cedars--Sinai Med Center $8,000.00 Educational Grants
Central Brain Tumor $30,000.00 Educational Grants
Registry of The United
States
Central Savannah River Area $1,000.00 Corporate Sponsorships
Csra Parkinson Support
Group
Chicago Gynecological $8,000.00 Corporate Sponsorships
Society
Chicago Urological Soctiey $12,000.00 Corporate Sponsorships
Childrens Digestive Health $42,428.00 Corporate Sponsorships
and Nutrition Foundation
Childrens Hospital of $2,000.00 Corporate Sponsorships
Wisconsin
Children's Skin Disease $600.00 Corporate Sponsorships
Foundation
Childrens Treehouse $10,000.00 Charitable Donations
Foundation
Chimp Haven $15,000.00 Charitable Donations
Chinese American $3,600.00 Corporate Sponsorships
Biopharmaceutical Society
Chris Elliott Fund $10,000.00 Charitable Donations
Chris Elliott Fund $10,000.00 Charitable Donations
Chris Elliott Fund $10,000.00 Charitable Donations
Chris Elliott Fund $25,000.00 Corporate Sponsorships
Chris Elliott Fund $50,000.00 Charitable Donations
Chris Elliott Fund $40,000.00 Educational Grants
Chris Elliott Fund $10,000.00 Corporate Sponsorships
Chris Elliott Fund $10,000.00 Corporate Sponsorships
Chris Elliott Fund $20,000.00 Corporate Sponsorships
Chris Elliott Fund $20,000.00 Corporate Sponsorships
Chris Elliott Fund $25,000.00 Corporate Sponsorships
Chris Elliott Fund $10,000.00 Corporate Sponsorships
Christ Hospital Foundation $5,000.00 Corporate Sponsorships
Chronic Liver Disease $450,000.00 Educational Grants
Foundation
Chronic Liver Disease $75,000.00 Corporate Sponsorships
Foundation
Chronic Liver Disease $75,000.00 Corporate Sponsorships
Foundation
Chronic Liver Disease $90,000.00 Corporate Sponsorships
Foundation
Chronic Lymphoytic Leukemia $50,000.00 Charitable Donations
Society Inc.
Chronic Lymphoytic Leukemia $25,075.00 Patient Support
Society Inc.
Chronic Lymphoytic Leukemia $75,000.00 Patient Support
Society Inc.
Chronic Lymphoytic Leukemia $50,000.00 Patient Support
Society Inc.
Chronic Lymphoytic Leukemia $35,000.00 Patient Support
Society Inc.
Chronic Lymphoytic Leukemia $75,000.00 Patient Support
Society Inc.
Cincinnati Childrens $40,000.00 Fellowships and
Hospital Medical Center Scholarships
City of Hope National Med $50,000.00 Educational Grants
Center
Cleveland Clinic ($3,131.07) Educational Grants
Educational Foundation
Cleveland Clinic $5,000.00 Educational Grants
Educational Foundation
Cleveland Clinic ($13,876.68) Educational Grants
Educational Foundation
Cleveland Clinic $50,000.00 Educational Grants
Educational Foundation
Cleveland Clinic ($7,563.37) Educational Grants
Educational Foundation
Cleveland Clinic $50,000.00 Educational Grants
Educational Foundation
Cleveland Clinic $20,000.00 Educational Grants
Educational Foundation
Cleveland Clinic $5,000.00 Educational Grants
Educational Foundation
Cleveland Clinic $50,000.00 Educational Grants
Educational Foundation
Cleveland Clinic $50,000.00 Educational Grants
Educational Foundation
Cleveland Clinic $25,000.00 Corporate Sponsorships
Educational Foundation
Cleveland Clinic Foundation $55,000.00 Fellowships and
Scholarships
Cleveland Clinic Minority $25,000.00 Corporate Sponsorships
Mens Health Center
Clinical Care Optn LLC $5,000.00 Educational Grants
Clinical Care Optn LLC $35,000.00 Educational Grants
Clinical Care Optn LLC $75,000.00 Educational Grants
Clinical Care Optn LLC $35,000.00 Educational Grants
Clinical Care Optn LLC $50,000.00 Educational Grants
Clinical Care Optn LLC $35,000.00 Educational Grants
Clinical Care Optn LLC ($35,000.00) Educational Grants
Clinical Care Optn LLC $25,000.00 Educational Grants
Clinical Care Optn LLC $75,000.00 Educational Grants
Clinical Care Optn LLC $120,000.00 Educational Grants
Clinical Care Optn LLC $25,000.00 Educational Grants
Clinical Care Optn LLC $25,000.00 Educational Grants
Clinical Care Optn LLC $50,000.00 Educational Grants
Clinical Care Optn LLC $50,000.00 Educational Grants
Clinical Care Optn LLC $75,000.00 Educational Grants
Clinical Care Optn LLC $75,000.00 Educational Grants
Clinical Care Optn LLC $95,000.00 Educational Grants
CLL Global Research $35,000.00 Patient Support
Foundation
CLL Global Research $35,000.00 Educational Grants
Foundation
Club DE oficiales DE LA $495.00 Charitable Donations
Policia DE Puerto Rico
Inc.
Coalition for Prevention of $5,000.00 Corporate Sponsorships
Colorectal Cancer in
Puerto Rico
Coalition of Texans With $5,000.00 Corporate Sponsorships
Disabilities
Coalition of Texans With $5,000.00 Corporate Sponsorships
Disabilities
Cockerell Educational $25,000.00 Corporate Sponsorships
Foundation
Cockerell Educational $30,000.00 Corporate Sponsorships
Foundation
Cody Dieruf Benefit $5,000.00 Charitable Donations
Foundation
Colegio DE Farmaceuticos DE $4,000.00 Corporate Sponsorships
Puerto Rico
Colegio DE Farmaceuticos DE $5,000.00 Corporate Sponsorships
Puerto Rico
Colegio DE Profesionales DE $2,000.00 Corporate Sponsorships
LA Enfermeria DE Puerto
Rico Inc.
Colegio DE Profesionales DE $3,000.00 Corporate Sponsorships
LA Enfermeria DE Puerto
Rico Inc.
Colegio DE Profesionales DE $3,000.00 Corporate Sponsorships
LA Enfermeria DE Puerto
Rico Inc.
Collaborative Alliance for $30,000.00 Educational Grants
Pancreatic Education and
Research (Caper)
Collaborative Alliance for $30,000.00 Fellowships and
Pancreatic Education and Scholarships
Research (Caper)
Collaborative Alliance for $6,000.00 Fellowships and
Pancreatic Education and Scholarships
Research (Caper)
College of American $5,065.00 Corporate Sponsorships
Pathologists
College of Lake County $1,000.00 Charitable Donations
Colorado American Congress $10,000.00 Corporate Sponsorships
of Obstetrician Gyn
Colorado Section
Columbia Univ Med Center $5,000.00 Educational Grants
Columbia Univ Med Center $75,000.00 Fellowships and
Scholarships
Community Center $10,000.00 Corporate Sponsorships
Community Center $10,000.00 Corporate Sponsorships
Community Foundation $5,000.00 Corporate Sponsorships
Community Foundation $1,500.00 Corporate Sponsorships
Community Initiatives $40,000.00 Corporate Sponsorships
Community Initiatives $25,000.00 Patient Support
Community Initiatives $1,500.00 Charitable Donations
Community Liver Alliance $15,000.00 Corporate Sponsorships
Community Liver Alliance $500.00 Corporate Sponsorships
Community Liver Alliance $1,500.00 Corporate Sponsorships
Community Oncology Alliance $20,000.00 Corporate Sponsorships
Connecticut Dermatology $3,722.25 Corporate Sponsorships
Society
Connecticut Dermatology $3,500.00 Corporate Sponsorships
Society
Connecting To Cure Crohns $10,000.00 Corporate Sponsorships
and Colitis
Consortium of Multiple $59,150.00 Educational Grants
Sclerosis Centers
Consortium of Multiple ($452.00) Educational Grants
Sclerosis Centers
Consortium of Multiple ($341.36) Educational Grants
Sclerosis Centers
Continuing Educational $350,000.00 Educational Grants
Alliance LLC
Continuing Educational $375,000.00 Educational Grants
Alliance LLC
Continuing Educational ($623.00) Educational Grants
Alliance LLC
Continuing Educational $200,000.00 Educational Grants
Alliance LLC
Continuing Educational $75,000.00 Educational Grants
Alliance LLC
Continuing Educational $300,000.00 Educational Grants
Alliance LLC
Cornell Univ Weill Med $15,000.00 Educational Grants
College
Cornell Univ Weill Med $3,000.00 Educational Grants
College
Cornerstone Health Inc. $90,000.00 Educational Grants
Cornerstone Health Inc. $50,000.00 Educational Grants
Cradles To Crayons Inc. $300.00 Charitable Donations
Cristo Rey St Martin $7,500.00 Corporate Sponsorships
College Prep
Crohns and Colitis $2,500.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $5,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $1,500.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $2,500.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $5,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $15,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $10,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $20,000.00 Charitable Donations
Foundation of America
Crohns and Colitis $40,000.00 Patient Support
Foundation of America
Crohns and Colitis $150,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $5,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $90,000.00 Patient Support
Foundation of America
Crohns and Colitis $250,000.00 Educational Grants
Foundation of America
Crohns and Colitis $2,500.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $25,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $1,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $1,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $2,500.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $3,500.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $3,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $25,000.00 Educational Grants
Foundation of America
Crohns and Colitis $25,000.00 Educational Grants
Foundation of America
Crohns and Colitis $25,000.00 Educational Grants
Foundation of America
Crohns and Colitis $10,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $2,500.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $5,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $5,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $2,500.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $5,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $7,500.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $5,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $5,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $1,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $25,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $1,500.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $2,500.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $3,500.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $2,500.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $5,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $7,500.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $10,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $10,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $25,000.00 Corporate Sponsorships
Foundation of America
Crohns and Colitis $250,000.00 Educational Grants
Foundation of America
Curators of The Univ of $1,000.00 Charitable Donations
Missouri
Curepsp Inc. $5,000.00 Corporate Sponsorships
Curepsp Inc. $2,500.00 Patient Support
Curepsp Inc. $30,000.00 Corporate Sponsorships
Curepsp Inc. $45,500.00 Corporate Sponsorships
Curepsp Inc. $30,000.00 Charitable Donations
Curesearch for Childrens $15,000.00 Charitable Donations
Cancer
Cystic Fibrosis Foundation $1,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $25,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $2,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $2,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $1,750.00 Corporate Sponsorships
Cystic Fibrosis Foundation $3,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $5,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $2,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $2,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $5,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $1,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $2,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $2,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $2,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $1,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $5,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $2,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $3,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $10,000.00 Charitable Donations
Cystic Fibrosis Foundation $1,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $2,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $2,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $6,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $7,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $7,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $4,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $250.00 Corporate Sponsorships
Cystic Fibrosis Foundation $7,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $2,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $8,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $12,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $161,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $5,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $2,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $2,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $1,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $1,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $3,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $5,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $750.00 Corporate Sponsorships
Cystic Fibrosis Foundation $1,000.00 Corporate Sponsorships
Cystic Fibrosis Foundation $2,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $3,500.00 Corporate Sponsorships
Cystic Fibrosis Foundation $10,000.00 Charitable Donations
Cystic Fibrosis Foundation $750,000.00 Corporate Sponsorships
Cystic Fibrosis Research $5,000.00 Corporate Sponsorships
Fund Emilys Entourage
Cystic Fibrosis Research $20,000.00 Corporate Sponsorships
Inc.
Cystic Fibrosis Research $3,000.00 Corporate Sponsorships
Inc.
Cystic Fibrosis Research $6,000.00 Corporate Sponsorships
Inc.
Cystic Fibrosis Research $7,000.00 Corporate Sponsorships
Inc.
Cystic Fibrosis Research $10,000.00 Corporate Sponsorships
Inc.
Cystic Fibrosis Research $12,000.00 Corporate Sponsorships
Inc.
Cystic Fibrosis Research $12,000.00 Corporate Sponsorships
Inc.
Dade County Medical $5,000.00 Educational Grants
Association
Dahshu $5,000.00 Corporate Sponsorships
Dallas Area Parkinsonism $2,500.00 Corporate Sponsorships
Society
Dana Farber Cancer $25,000.00 Educational Grants
Institute
Dana Farber Cancer $100,000.00 Corporate Sponsorships
Institute, Inc.
Dava Oncology LP $37,500.00 Corporate Sponsorships
Davis Phinney Foundation $30,000.00 Patient Support
Davis Phinney Foundation $80,000.00 Corporate Sponsorships
Davis Phinney Foundation $30,000.00 Patient Support
Davis Phinney Foundation $15,000.00 Patient Support
Davis Phinney Foundation $15,000.00 Educational Grants
Davis Phinney Foundation $15,000.00 Educational Grants
Davis Phinney Foundation $15,000.00 Educational Grants
Dermatologic Society of $100,000.00 Corporate Sponsorships
Greater New York
Dermatology Education $50,000.00 Corporate Sponsorships
Foundation
Dermatology Foundation $135,000.00 Charitable Donations
Dermatology Foundation $50,000.00 Corporate Sponsorships
Dermatology Nurses $18,000.00 Corporate Sponsorships
Associate
Dermatology PA Foundation $2,700.00 Corporate Sponsorships
Digestive Disease Week $32,400.00 Corporate Sponsorships
Digestive Disease Week $80,000.00 Corporate Sponsorships
Digestive Disease Week $255,300.00 Corporate Sponsorships
Digestive Health Foundation $50,000.00 Corporate Sponsorships
Direct Relief $25,000.00 Charitable Donations
Direct Relief $10,000,000.00 Charitable Donations
Direct Relief $25,000,000.00 Charitable Donations
Direct Relief $5,000,000.00 Charitable Donations
Direct Relief $10,000,000.00 Charitable Donations
Doctor Solomon Carter $10,000.00 Educational Grants
Fuller Mental Health
Center
Doctor Solomon Carter $50,000.00 Educational Grants
Fuller Mental Health
Center
Drew University Health $2,500.00 Educational Grants
Services
Drexel Unviersity $55,000.00 Fellowships and
Scholarships
Drugs for Neglected $10,000.00 Charitable Donations
Diseases Initiative North
America Inc.
East Tennessee Foundation $1,500.00 Corporate Sponsorships
Ecog Research and Education $20,000.00 Educational Grants
Foundation Inc.
Ecog Research and Education $20,000.00 Educational Grants
Foundation Inc.
Economic Alliance for $5,000.00 Corporate Sponsorships
Michigan
Eisenhower Desert ($30,000.00) Educational Grants
Orthopedic Center
Eisenhower Desert $75,000.00 Educational Grants
Orthopedic Center
Eisenhower Desert $300,000.00 Educational Grants
Orthopedic Center
Eisenhower Desert $95,000.00 Educational Grants
Orthopedic Center
Eisenhower Desert $90,000.00 Educational Grants
Orthopedic Center
Eisenhower Desert $563,360.00 Educational Grants
Orthopedic Center
Eisenhower Desert $50,000.00 Educational Grants
Orthopedic Center
Eisenhower Desert $35,100.00 Educational Grants
Orthopedic Center
Eisenhower Desert $250,000.00 Educational Grants
Orthopedic Center
Eisenhower Desert $475,000.00 Educational Grants
Orthopedic Center
Eisenhower Desert $50,000.00 Educational Grants
Orthopedic Center
Embarcadero Lions Club of $2,500.00 Corporate Sponsorships
Sacramento
Employers Health Coalition $5,000.00 Corporate Sponsorships
Endocrine Education Inc. $25,000.00 Educational Grants
Endocrine Society $25,000.00 Educational Grants
Endocrine Society $25,000.00 Educational Grants
Endocrine Society ($10,928.00) Educational Grants
Endocrine Society $20,000.00 Educational Grants
Endometriosis Associate $50,000.00 Charitable Donations
Endometriosis Foundation of $30,000.00 Corporate Sponsorships
America
Enzyme Mechanism Conference $2,500.00 Educational Grants
Epilepsy Association of $7,500.00 Corporate Sponsorships
Central Florida
Epilepsy Foundation $15,000.00 Corporate Sponsorships
Epilepsy Foundation of $5,000.00 Corporate Sponsorships
Florida
Epilepsy Foundation of $10,000.00 Corporate Sponsorships
Michigan
Ethiopian Community $2,000.00 Corporate Sponsorships
Association of Greater
Philadelphia
Excellence in $100,000.00 Corporate Sponsorships
Gastroenterology Education
LLC
Excellence in $110,000.00 Corporate Sponsorships
Gastroenterology Education
LLC
Excellence in Rheumatology $100,000.00 Corporate Sponsorships
Education LLC
Family Reach Foundation $5,000,000.00 Charitable Donations
Federation of American $2,000.00 Educational Grants
Society for Experimental
Biology Faseb
Federation of American $2,000.00 Educational Grants
Society for Experimental
Biology Faseb
Federation of American $2,000.00 Educational Grants
Society for Experimental
Biology Faseb
Federation of American $2,000.00 Educational Grants
Society for Experimental
Biology Faseb
Federation of Clinical $20,000.00 Educational Grants
Immunology Society
Federation of Clinical $20,000.00 Educational Grants
Immunology Society
Federation of Clinical $12,500.00 Educational Grants
Immunology Society
Federation of Clinical $20,000.00 Fellowships and
Immunology Society Scholarships
Feed My Starving Children $500.00 Charitable Donations
Feinstein Institute for Med $243,900.00 Educational Grants
Research
Fibroid Foundation $90,000.00 Charitable Donations
Fibroid Foundation $95,000.00 Charitable Donations
Florida Academy of Family $18,000.00 Corporate Sponsorships
Physicians
Florida Atlantic University $1,000.00 Charitable Donations
Foundation Inc.
Florida Coalition $10,000.00 Corporate Sponsorships
Florida Gastroenterological $7,500.00 Corporate Sponsorships
Society
Florida Society of $70,000.00 Corporate Sponsorships
Dermatology Physician
Assistants Inc.
Florida Society of $50,000.00 Corporate Sponsorships
Rheumatology Inc.
Florida Society of $5,000.00 Corporate Sponsorships
Rheumatology Inc.
Focus Med Communications $35,000.00 Corporate Sponsorships
Focus Med Communications $135,000.00 Corporate Sponsorships
Footsteps for Fertility $1,000.00 Corporate Sponsorships
Foundation
Force--Facing Our Risk of $5,000.00 Charitable Donations
Cancer Emp
Forsyth Area Striders Team $500.00 Corporate Sponsorships
Foundation Fighting $2,500.00 Corporate Sponsorships
Blindness
Foundation for Biomedical $50,000.00 Charitable Donations
Research
Foundation for The National $5,000.00 Corporate Sponsorships
Institute of Health
Foundation of Consortium of $17,500.00 Fellowships and
Multiple Sclerosis Centers Scholarships
Cmsc
Foundation of Consortium of $40,000.00 Educational Grants
Multiple Sclerosis Centers
Cmsc
Foundation of Consortium of $32,875.00 Patient Support
Multiple Sclerosis Centers
Cmsc
Franklin and Marshall $1,000.00 Charitable Donations
College
French American Chemical $3,000.00 Educational Grants
Society
Friends of Cancer Research $25,000.00 Charitable Donations
Friends of Cancer Research $25,000.00 Corporate Sponsorships
Friends of Cancer Research $25,000.00 Corporate Sponsorships
Friends of The St Louis $50,000.00 Corporate Sponsorships
Univ Liver Center
Fundacion Puertorriquena DE $17,960.00 Educational Grants
Pacientes Consult
Endometriosis
Gastrointestinal and Liver $150,000.00 Corporate Sponsorships
Association of The
Americas Inc.
Gastrointestinal Health $90,000.00 Corporate Sponsorships
Foundation Inc.
Gateway for Cancer Research $10,000.00 Charitable Donations
Genesis Healthcare $3,000.00 Corporate Sponsorships
Foundation
George Washington Univ $3,000.00 Corporate Sponsorships
Georgia Academy of Family $3,500.00 Corporate Sponsorships
Physicians
Georgia Dermatology $50,000.00 Corporate Sponsorships
Physican Assistants
Georgia Society of $7,500.00 Corporate Sponsorships
Dermatology and
Dermatologic Surgery
Georgia Society of $75,000.00 Corporate Sponsorships
Dermatology and
Dermatologic Surgery
Gildas Club Chicago $10,000.00 Charitable Donations
Global Academy for Medical $20,000.00 Corporate Sponsorships
Education
Global Academy for Medical $43,750.00 Corporate Sponsorships
Education
Global Academy for Medical $40,500.00 Corporate Sponsorships
Education
Global Academy for Medical $76,500.00 Corporate Sponsorships
Education
Global Academy for Medical $58,500.00 Corporate Sponsorships
Education
Global Academy for Medical $76,500.00 Corporate Sponsorships
Education
Global Healthy Living $45,000.00 Corporate Sponsorships
Foundation
Global Healthy Living $75,000.00 Corporate Sponsorships
Foundation
Global Oncology $5,000.00 Corporate Sponsorships
Good Grief $500.00 Corporate Sponsorships
Gordon Research Conferences $2,500.00 Educational Grants
Gordon Research Conferences $3,000.00 Educational Grants
Gordon Research Conferences $1,000.00 Educational Grants
Gordon Research Conferences $2,500.00 Educational Grants
Gordon Research Conferences $3,000.00 Educational Grants
Gordon Research Conferences $1,500.00 Educational Grants
Gordon Research Conferences $2,000.00 Educational Grants
Gordon Research Conferences $2,500.00 Educational Grants
Gordon Research Conferences $2,000.00 Educational Grants
Gordon Research Conferences $2,000.00 Educational Grants
Gordon Research Conferences $2,000.00 Educational Grants
Gordon Research Conferences $2,000.00 Educational Grants
Gordon Research Conferences $1,000.00 Educational Grants
Gordon Research Conferences $2,500.00 Educational Grants
Grand Traverse Area $1,500.00 Corporate Sponsorships
Parkinsons Support Group
Gynecologic Oncology Group $10,000.00 Educational Grants
Gynecologic Oncology Group $25,000.00 Educational Grants
Gynecologic Oncology Group $5,500.00 Educational Grants
Gynecologic Oncology Group $40,000.00 Educational Grants
H Lee Moffitt Cancer Center $7,500.00 Educational Grants
and Research Institute
Halo House Foundation $10,000.00 Corporate Sponsorships
Hamil Kerr Challenge $500.00 Corporate Sponsorships
Harborside Press $30,400.00 Corporate Sponsorships
Harborside Press $80,000.00 Corporate Sponsorships
Hartford Hospital $5,000.00 Corporate Sponsorships
Healthcare 21 Business $1,500.00 Corporate Sponsorships
Coalition
Healthwell Foundation $220,000.00 Charitable Donations
Healthy Women $30,000.00 Corporate Sponsorships
Heart To Heart $15,000.00 Charitable Donations
International Inc.
Heart To Heart $1,000.00 Charitable Donations
International Inc.
Heart To Heart $5,000.00 Charitable Donations
International Inc.
Henry M Jackson Foundation $10,000.00 Educational Grants
Hepatitis C Association $20,000.00 Educational Grants
Hepatitis C Mentor and $20,000.00 Patient Support
Support Group The
Hepatitis Education Project $25,000.00 Corporate Sponsorships
Hermanas Carmelitas Teresas $393.79 Charitable Donations
DE San Jose, Inc.
Hidradenitis Suppurativa $10,000.00 Charitable Donations
Foundation
HIV Treaters Med Associate $7,500.00 Corporate Sponsorships
of Puerto Rico
HMP Communications $15,000.00 Corporate Sponsorships
HMP Communications $70,000.00 Corporate Sponsorships
Hope Foundation $25,000.00 Educational Grants
Hospital of the University $10,000.00 Educational Grants
of Pennsylvania
Hospital of the University $75,000.00 Educational Grants
of Pennsylvania
Hospital of the University $5,000.00 Educational Grants
of Pennsylvania
Hospital of the University $10,000.00 Educational Grants
of Pennsylvania
Howard Hanna Children's $10,000.00 Charitable Donations
Free Care Fund
Hubbard Street Dance $10,000.00 Educational Grants
Chicago
Human Growth Foundation $5,000.00 Corporate Sponsorships
Human Growth Foundation $2,000.00 Corporate Sponsorships
Hunt for A Cure $1,250.00 Corporate Sponsorships
Huntsman Cancer Foundation $500.00 Corporate Sponsorships
Huntsman Cancer Foundation $2,000.00 Corporate Sponsorships
Huntsman Cancer Foundation $2,500.00 Corporate Sponsorships
IASLC Foundation $50,000.00 Fellowships and
Scholarships
IBD Horizons $2,500.00 Corporate Sponsorships
IBD Horizons $2,500.00 Corporate Sponsorships
IBD Horizons $50,000.00 Corporate Sponsorships
Illinois Academy of Family $4,500.00 Educational Grants
Physicians
Illinois Cancercare $2,500.00 Corporate Sponsorships
Foundation
Illinois Society of $65,000.00 Corporate Sponsorships
Dermatology Physician
Assistants
Imedex LLC $75,000.00 Educational Grants
Imedex LLC ($1,119.00) Educational Grants
Imedex LLC $25,000.00 Educational Grants
Imedex LLC $30,000.00 Educational Grants
Imedex LLC ($991.00) Educational Grants
Imedex LLC $40,000.00 Educational Grants
Imedex LLC $75,000.00 Educational Grants
Imedex LLC $40,000.00 Educational Grants
Imedex LLC $114,000.00 Corporate Sponsorships
Imerman Angels $1,500.00 Charitable Donations
Immune Deficiency $9,900.00 Corporate Sponsorships
Foundation
Impact Education LLC $75,000.00 Educational Grants
Impact Education LLC $95,000.00 Educational Grants
Improve Care Now Inc. $12,500.00 Corporate Sponsorships
Improve Care Now Inc. $100,000.00 Patient Support
Improve Care Now Inc. $12,500.00 Corporate Sponsorships
Improve Care Now Inc. $12,500.00 Corporate Sponsorships
Improve Care Now Inc. $12,500.00 Corporate Sponsorships
Indian Doc Associate of $5,000.00 Corporate Sponsorships
Houston
Indiana Parkinson $4,250.00 Corporate Sponsorships
Foundation
Indy Hematology Education $30,000.00 Corporate Sponsorships
Inc.
Indy Hematology Education $19,000.00 Corporate Sponsorships
Inc.
Infectious Disease of $10,000.00 Patient Support
Puerto Rico
Innovation Foundation Inc. $55,000.00 Corporate Sponsorships
Institute for Medical and $15,000.00 Educational Grants
Nursing Education
Integrated Med Foundation $15,000.00 Charitable Donations
Integrated Med Foundation $9,500.00 Corporate Sponsorships
Intellisphere LLC $7,000.00 Corporate Sponsorships
Intellisphere LLC $15,500.00 Corporate Sponsorships
Intellisphere LLC $10,500.00 Corporate Sponsorships
Intellisphere LLC $16,000.00 Corporate Sponsorships
Intellisphere LLC $18,500.00 Corporate Sponsorships
Intellisphere LLC $12,500.00 Corporate Sponsorships
Internaltional Society for $17,500.00 Corporate Sponsorships
Pharmacoeconomics and
Outcomes Research
International Association $311,000.00 Corporate Sponsorships
for The Study of Lung
Cancer
International Association $15,000.00 Corporate Sponsorships
for The Study of Lung
Cancer
International Association $75,000.00 Corporate Sponsorships
for The Study of Lung
Cancer
International Biometric $3,875.00 Corporate Sponsorships
Society Eastern North
American Region
International Dermatology $70,000.00 Corporate Sponsorships
Outcome Measures
International Dermatology $70,000.00 Corporate Sponsorships
Outcome Measures
International Medical Corps $5,000.00 Charitable Donations
International Meyoloma $100,000.00 Corporate Sponsorships
Foundation
International Meyoloma $15,000.00 Corporate Sponsorships
Foundation
International Meyoloma $25,000.00 Charitable Donations
Foundation
International Meyoloma $10,000.00 Educational Grants
Foundation
International Myeloma $50,000.00 Corporate Sponsorships
Society (IMS)
International Organization $50,000.00 Patient Support
of Multiple Sclerosis
Nurses
International Pelvic Pain $23,000.00 Corporate Sponsorships
Society
International Pelvic Pain $5,000.00 Corporate Sponsorships
Society
International Physician $75,000.00 Corporate Sponsorships
Ntwrk Dba International
Oncology Ntwrk
International Physician $95,000.00 Corporate Sponsorships
Ntwrk Dba International
Oncology Ntwrk
International Physician $75,000.00 Corporate Sponsorships
Ntwrk Dba International
Oncology Ntwrk
International Psoriasis $25,000.00 Corporate Sponsorships
Council
International Psoriasis $50,000.00 Corporate Sponsorships
Council
International Society for $5,000.00 Educational Grants
Antiviral Research
It Takes Guts $1,000.00 Corporate Sponsorships
Johns Hopkins Technology $50,000.00 Educational Grants
Ventures
Johns Hopkins Technology $20,000.00 Educational Grants
Ventures
Johns Hopkins Technology $40,000.00 Fellowships and
Ventures Scholarships
Johns Hopkins Technology $2,500.00 Corporate Sponsorships
Ventures
Johns Hopkins Technology $75,000.00 Educational Grants
Ventures
Johns Hopkins Technology $25,000.00 Educational Grants
Ventures
Johns Hopkins Technology $40,000.00 Fellowships and
Ventures Scholarships
Johns Hopkins Technology $40,000.00 Fellowships and
Ventures Scholarships
Johns Hopkins Technology $40,000.00 Fellowships and
Ventures Scholarships
Johns Hopkins Technology $70,000.00 Corporate Sponsorships
Ventures
Johns Hopkins Technology $50,000.00 Fellowships and
Ventures Scholarships
Johns Hopkins Technology $10,000.00 Educational Grants
Ventures
Johns Hopkins University ($3,916.11) Educational Grants
Johns Hopkins University ($2,784.14) Educational Grants
JWC Covenant Inc. $50,000.00 Educational Grants
Kansas Univ Endowment $40,000.00 Educational Grants
Association
Kelsey Research Foundation $40,000.00 Fellowships and
Scholarships
Kentucky Rural Health $35,000.00 Corporate Sponsorships
Association
Kentucky Rural Health $25,000.00 Corporate Sponsorships
Association
Kentucky Rural Health $5,000.00 Corporate Sponsorships
Association
Laboratorio Clinico Toledo $900.00 Patient Support
Laboratorio Clinico Toledo $1,095.00 Patient Support
Laboratorio Clinico Toledo $900.00 Patient Support
Laboratorio Clinico Toledo $2,250.00 Patient Support
Laboratorio Clinico Toledo $5,325.00 Patient Support
Laboratorio Clinico Toledo $465.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $750.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $315.00 Patient Support
Laboratorio Clinico Toledo $705.00 Patient Support
Laboratorio Clinico Toledo $2,295.00 Patient Support
Laboratorio Clinico Toledo $348.00 Patient Support
Laboratorio Clinico Toledo $435.00 Patient Support
Laboratorio Clinico Toledo $750.00 Patient Support
Laboratorio Clinico Toledo $1,050.00 Patient Support
Laboratorio Clinico Toledo $372.00 Patient Support
Laboratorio Clinico Toledo $255.00 Patient Support
Laboratorio Clinico Toledo $600.00 Patient Support
Laboratorio Clinico Toledo $600.00 Patient Support
Laboratorio Clinico Toledo $825.00 Patient Support
Laboratorio Clinico Toledo $345.00 Patient Support
Laboratorio Clinico Toledo $600.00 Patient Support
Laboratorio Clinico Toledo $750.00 Patient Support
Laboratorio Clinico Toledo $1,200.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $1,125.00 Patient Support
Laboratorio Clinico Toledo $255.00 Patient Support
Laboratorio Clinico Toledo $480.00 Patient Support
Laboratorio Clinico Toledo $750.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $705.00 Patient Support
Laboratorio Clinico Toledo $885.00 Patient Support
Laboratorio Clinico Toledo $1,695.00 Patient Support
Laboratorio Clinico Toledo $480.00 Patient Support
Laboratorio Clinico Toledo $525.00 Patient Support
Laboratorio Clinico Toledo $915.00 Patient Support
Laboratorio Clinico Toledo $1,200.00 Patient Support
Laboratorio Clinico Toledo $600.00 Patient Support
Laboratorio Clinico Toledo $675.00 Patient Support
Laboratorio Clinico Toledo $1,200.00 Patient Support
Laboratorio Clinico Toledo $3,000.00 Patient Support
Laboratorio Clinico Toledo $900.00 Patient Support
Laboratorio Clinico Toledo $360.00 Patient Support
Laboratorio Clinico Toledo $1,290.00 Patient Support
Laboratorio Clinico Toledo $900.00 Patient Support
Laboratorio Clinico Toledo $1,200.00 Patient Support
Laboratorio Clinico Toledo $750.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $1,500.00 Patient Support
Laboratorio Clinico Toledo $930.00 Patient Support
Laboratorio Clinico Toledo $1,200.00 Patient Support
Laboratorio Clinico Toledo $675.00 Patient Support
Laboratorio Clinico Toledo $600.00 Patient Support
Laboratorio Clinico Toledo $750.00 Patient Support
Laboratorio Clinico Toledo $525.00 Patient Support
Laboratorio Clinico Toledo $750.00 Patient Support
Laboratorio Clinico Toledo $360.00 Patient Support
Laboratorio Clinico Toledo $1,680.00 Patient Support
Laboratorio Clinico Toledo $525.00 Patient Support
Laboratorio Clinico Toledo $600.00 Patient Support
Laboratorio Clinico Toledo $375.00 Patient Support
Laboratorio Clinico Toledo $990.00 Patient Support
Laboratorio Clinico Toledo $1,830.00 Patient Support
Laboratorio Clinico Toledo $600.00 Patient Support
Laboratorio Clinico Toledo $600.00 Patient Support
Lahey Hospital and Medical $3,000.00 Corporate Sponsorships
Center
Lake County Crisis Center $5,000.00 Charitable Donations
Lake County Haven $10,000.00 Charitable Donations
Large Urology Group $66,400.00 Corporate Sponsorships
Practice Associate
Large Urology Group $20,000.00 Corporate Sponsorships
Practice Associate
Large Urology Group $20,000.00 Corporate Sponsorships
Practice Associate
Large Urology Group $5,000.00 Corporate Sponsorships
Practice Associate
Leukemia and Lymphoma $50,000.00 Patient Support
Society Inc.
Leukemia and Lymphoma $5,000.00 Corporate Sponsorships
Society Inc.
Leukemia and Lymphoma $5,000.00 Corporate Sponsorships
Society Inc.
Leukemia and Lymphoma $100,000.00 Corporate Sponsorships
Society Inc.
Leukemia and Lymphoma $100,000.00 Educational Grants
Society Inc.
Leukemia and Lymphoma $2,000.00 Corporate Sponsorships
Society Inc.
Leukemia and Lymphoma $5,000.00 Corporate Sponsorships
Society Inc.
Leukemia and Lymphoma $95,000.00 Corporate Sponsorships
Society Inc.
Leukemia and Lymphoma $70,000.00 Corporate Sponsorships
Society Inc.
Leukemia and Lymphoma $50,000.00 Educational Grants
Society Inc.
Leukemia and Lymphoma $50,000.00 Educational Grants
Society Inc.
Leukemia and Lymphoma $3,500.00 Corporate Sponsorships
Society Inc.
Leukemia Research $50,000.00 Fellowships and
Foundation Inc. Scholarships
Leukemia Research $10,000.00 Corporate Sponsorships
Foundation Inc.
Leukemia Research $5,000.00 Charitable Donations
Foundation Inc.
Leukemia Research $5,000.00 Educational Grants
Foundation Inc.
Leukemia Research $50,000.00 Fellowships and
Foundation Inc. Scholarships
Linkage To Health Inc. $25,000.00 Educational Grants
Liver Health Connection $40,000.00 Educational Grants
Liver Health Connection $5,000.00 Corporate Sponsorships
Livestrong Foundation $10,000.00 Charitable Donations
Loma Linda University $10,000.00 Educational Grants
School of Medicine
Lung Cancer Alliance $25,000.00 Corporate Sponsorships
Lung Cancer Research $25,000.00 Charitable Donations
Foundation
Lung Cancer Research $20,000.00 Corporate Sponsorships
Foundation
Lungevity Foundation $5,000.00 Corporate Sponsorships
Lungevity Foundation $25,000.00 Charitable Donations
Lungevity Foundation $10,000.00 Corporate Sponsorships
Lungevity Foundation $10,000.00 Educational Grants
Lupus and Allied Diseases $15,000.00 Corporate Sponsorships
Association, Inc.
Lymphoma Research $10,000.00 Corporate Sponsorships
Foundation
Lymphoma Research $25,000.00 Corporate Sponsorships
Foundation
Lymphoma Research $40,000.00 Corporate Sponsorships
Foundation
Lymphoma Research $10,000.00 Corporate Sponsorships
Foundation
Lymphoma Research $15,000.00 Corporate Sponsorships
Foundation
Lymphoma Research $25,000.00 Corporate Sponsorships
Foundation
Lymphoma Research $50,000.00 Corporate Sponsorships
Foundation
Magellan Rx Management Inc. $10,000.00 Corporate Sponsorships
March of Dimes Foundation $5,000.00 Corporate Sponsorships
Massachusetts General $30,000.00 Educational Grants
Hospital
Massachusetts General $40,000.00 Fellowships and
Hospital Scholarships
Massachusetts Society for $10,000.00 Charitable Donations
Med Research
Mayo Clinic $7,500.00 Corporate Sponsorships
Mayo Clinic Scottsdale $8,000.00 Educational Grants
Pharmacy
Mayo Clinic Scottsdale $10,000.00 Educational Grants
Pharmacy
Mckesson Specialty Health $60,000.00 Corporate Sponsorships
Pharmaceuticals and
Biotechnology Solutions
Mckesson Specialty Health $25,000.00 Corporate Sponsorships
Pharmaceuticals and
Biotechnology Solutions
Mckesson Specialty Health $65,000.00 Corporate Sponsorships
Pharmaceuticals and
Biotechnology Solutions
ME Strong Inc. $5,000.00 Corporate Sponsorships
Med--LQ LLC $75,000.00 Educational Grants
Med--LQ LLC $75,000.00 Educational Grants
Med--LQ LLC $75,000.00 Educational Grants
Med Conference Planners $7,500.00 Corporate Sponsorships
Med Educator Consortium $10,000.00 Corporate Sponsorships
Med Univ of South Carolina $2,500.00 Educational Grants
Foundation
Medical Education Resources $20,000.00 Corporate Sponsorships
Medical Learning Institute $148,000.00 Educational Grants
Medical Learning Institute $95,000.00 Educational Grants
Medical Learning Institute $55,495.00 Educational Grants
Medical Learning Institute $50,000.00 Educational Grants
Medical Learning Institute ($715.00) Educational Grants
Medical Oncology $20,000.00 Corporate Sponsorships
Association of Southern
California
Medical Univ of South $1,250.00 Corporate Sponsorships
Carolina
Medical Univ of South $1,250.00 Corporate Sponsorships
Carolina
Medical Univ of South $7,500.00 Corporate Sponsorships
Carolina
Medicinal and Bioorganic $5,000.00 Educational Grants
Chemistry Foundation The
Medina Community Clinic $1,000.00 Corporate Sponsorships
Medscape LLC ($7,703.00) Educational Grants
Medscape LLC ($2,475.00) Educational Grants
Medscape LLC ($205.88) Educational Grants
Medstar Georgetown $800.00 Corporate Sponsorships
Transplant Institute
Fairfax
Medstar Health Inc. $10,000.00 Educational Grants
Meeting Designs LLC $20,000.00 Corporate Sponsorships
Memorial Hermann Foundation $1,500.00 Corporate Sponsorships
Memorial Hermann Foundation $5,000.00 Corporate Sponsorships
Memorial Sloan Kettering $25,000.00 Educational Grants
Cancer Center
Merriam LLC Dba World Class $73,085.00 Educational Grants
Cme
Metavivor Research and $4,000.00 Charitable Donations
Support, Inc.
Methodist Dallas Med Center $5,000.00 Corporate Sponsorships
Irb
Methodist Hospital $25,000.00 Corporate Sponsorships
Metropolitan Chicago Breast $5,000.00 Charitable Donations
Cancer
Michael J Fox Foundation $10,000.00 Corporate Sponsorships
Michael J Fox Foundation $1,000.00 Corporate Sponsorships
Michael J Fox Foundation $600,000.00 Corporate Sponsorships
Michael J Fox Foundation $25,000.00 Corporate Sponsorships
Michael J Fox Foundation $25,000.00 Corporate Sponsorships
Michigan Parkinson $5,000.00 Corporate Sponsorships
Foundation
Michigan Parkinson $3,000.00 Corporate Sponsorships
Foundation
Michigan Rheumatism Society $25,000.00 Corporate Sponsorships
Midwest Business Group On $3,000.00 Corporate Sponsorships
Health
Midwest Parkinsons $1,000.00 Corporate Sponsorships
Initiative
Miles for Cystic Fibrosis $2,500.00 Corporate Sponsorships
Miles for Cystic Fibrosis $15,000.00 Charitable Donations
Minnesota Urological $5,000.00 Corporate Sponsorships
Society
Mississippi Arthritis and $10,000.00 Corporate Sponsorships
Rheumatism Society
Missouri Hepatitis C $25,000.00 Educational Grants
Alliance
MIT Medical Obstetrics and $10,000.00 Charitable Donations
Gynecology
Montana Academy of $1,500.00 Corporate Sponsorships
Ophthalmology
Montefiore Med Center $40,000.00 Fellowships and
Scholarships
Mount Sinai School of $2,500.00 Educational Grants
Medicine
Mount Sinai School of $30,000.00 Corporate Sponsorships
Medicine
Mount Sinai School of $10,000.00 Educational Grants
Medicine
Mount Sinai School of $40,000.00 Educational Grants
Medicine
Mountain Area Center $1,200.00 Corporate Sponsorships
Education Center
Movement Disorder Society $2,500.00 Educational Grants
Movement Disorder Society $10,000.00 Educational Grants
Movement Disorder Society $25,000.00 Corporate Sponsorships
Movement Disorder Society $25,000.00 Corporate Sponsorships
Movement Disorder Society $15,000.00 Corporate Sponsorships
Movement Disorder Society $208,750.00 Corporate Sponsorships
Movement Disorder Society $50,000.00 Corporate Sponsorships
Multiple Myeloma Research $25,000.00 Patient Support
Foundation Inc.
Multiple Myeloma Research $50,000.00 Patient Support
Foundation Inc.
Multiple Myeloma Research $10,000.00 Patient Support
Foundation Inc.
Multiple Myeloma Research $20,000.00 Patient Support
Foundation Inc.
Multiple Myeloma Research $25,000.00 Corporate Sponsorships
Foundation Inc.
Multiple Myeloma Research $55,000.00 Fellowships and
Foundation Inc. Scholarships
Multiple Myeloma Research $20,000.00 Educational Grants
Foundation Inc.
Multiple Myeloma Research $20,000.00 Educational Grants
Foundation Inc.
Multiple Myeloma Research $75,000.00 Educational Grants
Foundation Inc.
Multiple Myeloma Research $50,000.00 Educational Grants
Foundation Inc.
Multiple Myeloma Research $75,000.00 Educational Grants
Foundation Inc.
Musella Foundation for $10,000.00 Corporate Sponsorships
Brain Tumor Research and
Information Inc.
Nami Oregon $2,250.00 Corporate Sponsorships
Nami Oregon $2,250.00 Corporate Sponsorships
Nami Tennessee $2,500.00 Corporate Sponsorships
National Academy of $30,000.00 Corporate Sponsorships
Dermatology Nurse
Practitioners
National Academy of Science $85,000.00 Corporate Sponsorships
National AIDS Treatment $300,000.00 Charitable Donations
Advocacy Project (NATAP)
National Alliance of $20,000.00 Corporate Sponsorships
Healthcare Purchaser
Coalitions
National Alliance of State $100,000.00 Corporate Sponsorships
and Territorial Aids
Directors
National Alliance of State $50,000.00 Charitable Donations
and Territorial Aids
Directors
National Animal Interest $15,000.00 Charitable Donations
Alliance
National Associate of $45,000.00 Educational Grants
Managed Care Physician
National Associate of $20,000.00 Educational Grants
Managed Care Physician
National Associate of $45,000.00 Educational Grants
Managed Care Physician
National Association of $300.00 Charitable Donations
Area Agencies On Aging
(N4a)
National Association of $6,600.00 Corporate Sponsorships
Community Health Centers
Nachc
National Association of $10,000.00 Charitable Donations
School Nurses Inc.
National Brain Tumor $5,700.00 Charitable Donations
Society Inc.
National Brain Tumor $25,000.00 Corporate Sponsorships
Society Inc.
National Brain Tumor $50,000.00 Charitable Donations
Society Inc.
National Brain Tumor $50,000.00 Educational Grants
Society Inc.
National Brain Tumor $50,000.00 Corporate Sponsorships
Society Inc.
National Coalition for $50,000.00 Corporate Sponsorships
Cancer Survivorship
National Coalition for $2,500.00 Corporate Sponsorships
Cancer Survivorship
National Coalition for $2,500.00 Corporate Sponsorships
Cancer Survivorship
National Coalition for $25,000.00 Corporate Sponsorships
Cancer Survivorship
National Coalition for $25,000.00 Corporate Sponsorships
Cancer Survivorship
National Community $80,000.00 Corporate Sponsorships
Dispensing Associate Ncoda
National Comprehensive $15,000.00 Corporate Sponsorships
Cancer Network
National Comprehensive $15,000.00 Corporate Sponsorships
Cancer Network
National Comprehensive $40,000.00 Corporate Sponsorships
Cancer Network
National Comprehensive $30,000.00 Educational Grants
Cancer Network
National Comprehensive $60,000.00 Educational Grants
Cancer Network
National Comprehensive $75,000.00 Educational Grants
Cancer Network
National Comprehensive $5,000.00 Corporate Sponsorships
Cancer Network
National Comprehensive $25,000.00 Educational Grants
Cancer Network
National Comprehensive $50,000.00 Educational Grants
Cancer Network
National Comprehensive $55,000.00 Educational Grants
Cancer Network
National Comprehensive $40,000.00 Patient Support
Cancer Network Foundation
National Comprehensive $100,000.00 Fellowships and
Cancer Network Foundation Scholarships
National Comprehensive $40,000.00 Patient Support
Cancer Network Foundation
National Comprehensive $25,000.00 Patient Support
Cancer Network Foundation
National Comprehensive $40,000.00 Patient Support
Cancer Network Foundation
National Comprehensive $50,000.00 Charitable Donations
Cancer Network Foundation
National Comprehensive $100,000.00 Fellowships and
Cancer Network Foundation Scholarships
National Eczema Association $10,000.00 Corporate Sponsorships
National Health Council $50,000.00 Corporate Sponsorships
National Minority Quality $75,000.00 Corporate Sponsorships
forum Inc.
National Minority Quality $75,000.00 Corporate Sponsorships
forum Inc.
National Multiple Sclerosis $10,000.00 Corporate Sponsorships
Society
National Pancreas $150,000.00 Educational Grants
Foundation
National Pancreas $75,000.00 Corporate Sponsorships
Foundation
National Pancreas $75,000.00 Charitable Donations
Foundation
National Pancreas $70,000.00 Corporate Sponsorships
Foundation
National Partnership for $5,000.00 Corporate Sponsorships
Women and Families Inc.
National Psoriasis $50,000.00 Fellowships and
Foundation Scholarships
National Psoriasis $15,000.00 Corporate Sponsorships
Foundation
National Psoriasis $25,000.00 Corporate Sponsorships
Foundation
National Psoriasis $50,000.00 Corporate Sponsorships
Foundation
National Psoriasis $5,000.00 Corporate Sponsorships
Foundation
National Psoriasis $50,000.00 Educational Grants
Foundation
National Psoriasis $35,000.00 Corporate Sponsorships
Foundation
National Psoriasis $25,000.00 Educational Grants
Foundation
National Psoriasis $150,000.00 Corporate Sponsorships
Foundation
National Psoriasis $30,000.00 Corporate Sponsorships
Foundation
National Psoriasis $15,000.00 Corporate Sponsorships
Foundation
National Psoriasis $50,000.00 Corporate Sponsorships
Foundation
National Psoriasis $75,000.00 Fellowships and
Foundation Scholarships
National Psoriasis $30,000.00 Corporate Sponsorships
Foundation
National Psoriasis $40,000.00 Corporate Sponsorships
Foundation
National Psoriasis $40,000.00 Corporate Sponsorships
Foundation
National Society for $55,000.00 Corporate Sponsorships
Cutaneous Medicine
National Society for $80,000.00 Corporate Sponsorships
Cutaneous Medicine
National Society for $225,000.00 Corporate Sponsorships
Cutaneous Medicine
National Society for $160,000.00 Corporate Sponsorships
Cutaneous Medicine
New England Immunology $2,500.00 Corporate Sponsorships
Conference Inc.
New Jersey Academy of ($7,440.00) Educational Grants
Family Physicians
New York Academy of Science $3,500.00 Educational Grants
New York Academy of Science $5,000.00 Educational Grants
New York Academy of Science $5,000.00 Educational Grants
New York Academy of Science $2,500.00 Educational Grants
New York Cancer Foundation $10,000.00 Corporate Sponsorships
New York University School ($5,000.00) Educational Grants
of Medicine
Nikki Mitchell Foundation $7,500.00 Corporate Sponsorships
NL Communications Inc. $35,000.00 Educational Grants
NL Communications Inc. $75,000.00 Educational Grants
NL Communications Inc. $25,000.00 Educational Grants
NL Communications Inc. $225,000.00 Educational Grants
NL Communications Inc. $25,000.00 Educational Grants
NL Communications Inc. $55,000.00 Educational Grants
NL Communications Inc. $30,000.00 Educational Grants
NL Communications Inc. $85,000.00 Educational Grants
NL Communications Inc. $35,000.00 Educational Grants
NL Communications Inc. $25,000.00 Educational Grants
NL Communications Inc. $75,000.00 Educational Grants
NL Communications Inc. $45,000.00 Educational Grants
NL Communications Inc. $75,000.00 Educational Grants
NL Communications Inc. $20,000.00 Educational Grants
NL Communications Inc. $30,000.00 Educational Grants
NL Communications Inc. $50,000.00 Educational Grants
NL Communications Inc. $25,000.00 Educational Grants
NL Communications Inc. $60,000.00 Educational Grants
NL Communications Inc. $125,000.00 Educational Grants
NL Communications Inc. $145,000.00 Educational Grants
North American Center for $375,000.00 Educational Grants
Continuing Med Education
North American Society for $5,000.00 Corporate Sponsorships
Pediatric and Adolescent
Gynecology
North American Society for $25,000.00 Educational Grants
Pediatric Gastroenterology
Hepatology and Nutrition
North Carolina Academy of $235,500.00 Educational Grants
Family Physcians
North Carolina Academy of $10,000.00 Corporate Sponsorships
Family Physcians
North Carolina Oncology $5,000.00 Corporate Sponsorships
Management Society
North Carolina Society of $5,000.00 Corporate Sponsorships
Eye Physicians and
Surgeons
North Dakota Pharmacists $2,500.00 Corporate Sponsorships
Association
Northeast Business Group On $10,000.00 Corporate Sponsorships
Health
Northeast Business Group On $7,500.00 Corporate Sponsorships
Health
Northeast Kidney Foundation $5,000.00 Corporate Sponsorships
Inc.
Northern California Society $20,000.00 Corporate Sponsorships
for Clinical
Gastroenterology
Northwell Health $10,000.00 Corporate Sponsorships
Northwest Parkinsons $5,000.00 Patient Support
Foundation
Northwest Parkinsons $5,000.00 Patient Support
Foundation
Northwestern Univ $50,000.00 Fellowships and
Scholarships
Northwestern Univ $5,000.00 Corporate Sponsorships
Northwestern Univ $5,000.00 Educational Grants
Northwestern Univ $3,000.00 Educational Grants
Northwestern Univ $3,000.00 Fellowships and
Scholarships
Northwestern Univ $10,000.00 Corporate Sponsorships
Nutrition4kids, LLC $75,000.00 Patient Support
Nutrition4kids, LLC $100,000.00 Patient Support
NYU School of Medicine $7,500.00 Educational Grants
NYU School of Medicine $40,000.00 Fellowships and
Scholarships
NYU School of Medicine $10,000.00 Educational Grants
Cardiothoracic Surgery
NYU School of Medicine $7,500.00 Educational Grants
Cardiothoracic Surgery
Ochsner Clinic Foundation $10,000.00 Corporate Sponsorships
Ocular Immunology and $65,000.00 Corporate Sponsorships
Uveitis Foundation
Ohio Association of $1,300.00 Corporate Sponsorships
Community Health Centers
Ohio Association of $10,000.00 Corporate Sponsorships
Rheumatology
Ohio Gastroenterology $5,000.00 Corporate Sponsorships
Society
Ohio Gastroenterology $3,000.00 Corporate Sponsorships
Society
Ohio State Univ $3,500.00 Educational Grants
Omnia Education Inc. $231,475.00 Educational Grants
Oncology Nursing Society $38,500.00 Corporate Sponsorships
Oncology Nursing Society $9,100.00 Corporate Sponsorships
Oregon Health and Science $3,000.00 Patient Support
Univ
Oregon Health and Science $12,000.00 Corporate Sponsorships
Univ
Oregon Health and Science $10,000.00 Educational Grants
Univ
Our Brain Bank $50,000.00 Corporate Sponsorships
Pacific Business Group On $15,000.00 Corporate Sponsorships
Health
Pacific Business Group On $6,250.00 Corporate Sponsorships
Health
Pacific Business Group On $6,250.00 Corporate Sponsorships
Health
Pacific Business Group On $6,250.00 Corporate Sponsorships
Health
Pacific Business Group On $6,250.00 Corporate Sponsorships
Health
Pacific Dermatologic $20,000.00 Corporate Sponsorships
Association
Pacific Dermatologic $30,000.00 Corporate Sponsorships
Association
Pack Center LLC $242,750.00 Patient Support
Pack Center LLC $200,000.00 Patient Support
Pack Center LLC $13,100.00 Educational Grants
Pack Center LLC $125,500.00 Educational Grants
Pack Center LLC $110,225.00 Educational Grants
Pack Center LLC $151,700.00 Educational Grants
Pancreatic Cancer Action $50,000.00 Educational Grants
Network
Para LA Naturaleza Inc. $500.00 Charitable Donations
Park Nicollet Foundation $1,000.00 Corporate Sponsorships
Park Nicollet Foundation $1,000.00 Corporate Sponsorships
Parkinson Alliance $1,000.00 Corporate Sponsorships
Parkinson and Movement $10,000.00 Patient Support
Disorder Alliance
Parkinson and Movement $15,000.00 Patient Support
Disorder Alliance
Parkinson and Movement $50,000.00 Patient Support
Disorder Alliance
Parkinson and Movement $100,000.00 Corporate Sponsorships
Disorder Alliance
Parkinson and Movement $15,000.00 Patient Support
Disorder Alliance
Parkinson and Movement $10,000.00 Educational Grants
Disorder Alliance
Parkinson Association of $1,000.00 Corporate Sponsorships
Alabama
Parkinson Association of $1,250.00 Corporate Sponsorships
Greater Daytona Beach
Pagdb
Parkinson Association of $1,000.00 Corporate Sponsorships
Northern California
Parkinson Association of $1,000.00 Corporate Sponsorships
The Carolinas
Parkinson Association of $1,000.00 Corporate Sponsorships
The Carolinas
Parkinson Council $25,000.00 Corporate Sponsorships
Parkinson Foundation of $1,000.00 Corporate Sponsorships
Oklahoma
Parkinson Foundation of The $10,000.00 Patient Support
National Capital Area
Parkinson Foundation of The $10,000.00 Patient Support
National Capital Area
Parkinson Foundation of The $2,500.00 Corporate Sponsorships
National Capital Area
Parkinson Foundation $5,000.00 Corporate Sponsorships
Western Pennsylvania
Parkinson Ntwrk of Arizona $500.00 Corporate Sponsorships
Parkinson Support Center of $10,000.00 Corporate Sponsorships
Kentuciana
Parkinson Support Center of $2,500.00 Corporate Sponsorships
Kentuciana
Parkinson's Association of $1,000.00 Corporate Sponsorships
San Diego
Parkinson's Association of $17,000.00 Corporate Sponsorships
San Diego
Parkinsons Association of $7,500.00 Patient Support
The Rockies
Parkinsons Awareness $1,250.00 Corporate Sponsorships
Association of Central
Indiana
Parkinsons Disease $2,500.00 Corporate Sponsorships
Foundation
Parkinsons Disease $5,000.00 Corporate Sponsorships
Foundation
Parkinsons Disease $25,000.00 Corporate Sponsorships
Foundation
Parkinsons Disease $5,000.00 Corporate Sponsorships
Foundation
Parkinsons Disease $135,000.00 Corporate Sponsorships
Foundation
Parkinsons Disease $2,500.00 Corporate Sponsorships
Foundation
Parkinsons Disease $10,000.00 Corporate Sponsorships
Foundation
Parkinsons Disease $4,500.00 Corporate Sponsorships
Foundation
Parkinson's Nebraska $1,000.00 Corporate Sponsorships
Parkinson's Nebraska $1,000.00 Corporate Sponsorships
Parkinsons Unity Walk $54,000.00 Corporate Sponsorships
Partnership for A Drug Free $75,000.00 Charitable Donations
America
Partnership for Cures $60,000.00 Patient Support
Partnership for Quality Med $1,000.00 Charitable Donations
Donations Pqmd
Partnership for Quality Med $5,000.00 Charitable Donations
Donations Pqmd
Patient Access Network $1,200,000.00 Charitable Donations
Foundation
Patient Access Network $12,007,000.00 Charitable Donations
Foundation
Patient Access Network $5,000,000.00 Charitable Donations
Foundation
Patient Access Network $10,000,000.00 Charitable Donations
Foundation
Patient Access Network $11,200,000.00 Charitable Donations
Foundation
Patient Access Network $11,022,000.00 Charitable Donations
Foundation
Patient Access Network $30,000,000.00 Charitable Donations
Foundation
Patient Empowerment Ntwrk $20,000.00 Patient Support
Patient Empowerment Ntwrk $40,000.00 Patient Support
Patient Empowerment Ntwrk $10,000.00 Patient Support
Patient Empowerment Ntwrk $10,000.00 Patient Support
Patient Empowerment Ntwrk $20,000.00 Patient Support
Patient Empowerment Ntwrk $20,000.00 Patient Support
Patient Empowerment Ntwrk $30,000.00 Patient Support
Patient Empowerment Ntwrk $10,000.00 Charitable Donations
Patient Empowerment Ntwrk $20,000.00 Patient Support
PD Gladiators $10,000.00 Corporate Sponsorships
PD Gladiators $10,000.00 Charitable Donations
Pediatric Specialists of $2,500.00 Corporate Sponsorships
Virginia LLC
Peerview Institute for $5,000.00 Educational Grants
Medical Education
Pennsylvania Academy of $10,000.00 Corporate Sponsorships
Dermatology and
Dermatologic Surgry
Pennsylvania Prostate $1,000.00 Corporate Sponsorships
Cancer Coalition
Pennsylvania Society of $10,000.00 Corporate Sponsorships
Gastroenterology
Pennsylvania Society of $5,000.00 Corporate Sponsorships
Gastroenterology
People To People Health $15,000.00 Charitable Donations
Foundation
People To People Health $20,000.00 Charitable Donations
Foundation
Pharmacy Benefit Management $7,500.00 Corporate Sponsorships
Institute
Pharmacy Benefit Management $5,500.00 Corporate Sponsorships
Institute
Phoenix Obgyn Society $2,000.00 Corporate Sponsorships
Phoenix Rheumatology $10,000.00 Corporate Sponsorships
Association
Phrmct Care Management $95,000.00 Corporate Sponsorships
Associate
Physicians Continuing $42,000.00 Corporate Sponsorships
Education
Physicians Education $42,550.00 Educational Grants
Resource LLC
Physicians Education $50,000.00 Educational Grants
Resource LLC
Physicians Education $85,000.00 Educational Grants
Resource LLC
Physicians Education $100,000.00 Educational Grants
Resource LLC
Physicians Education $40,000.00 Educational Grants
Resource LLC
Physicians Education $50,000.00 Educational Grants
Resource LLC
Physicians Education $75,000.00 Educational Grants
Resource LLC
Pinnacle Clinical Research $5,000.00 Corporate Sponsorships
Pins for Parkinsons $500.00 Corporate Sponsorships
Platformq Health Education, $125,000.00 Educational Grants
LLC
Postgraduate Healthcare $25,000.00 Educational Grants
Education LLC
Postgraduate Institute for $50,000.00 Educational Grants
Medicine
Postgraduate Institute for $350,000.00 Educational Grants
Medicine
Presbyterian Healthcare $5,000.00 Corporate Sponsorships
Foundation
President and Fellows of $12,000.00 Educational Grants
Harvard College
President and Fellows of $20,000.00 Corporate Sponsorships
Harvard College
President and Fellows of $30,000.00 Educational Grants
Harvard College
President and Fellows of $11,500.00 Educational Grants
Harvard College
President and Fellows of $3,000.00 Educational Grants
Harvard College
President and Fellows of ($18,400.00) Educational Grants
Harvard College
Prevent Cancer Foundation $25,000.00 Corporate Sponsorships
Prevent Cancer Foundation $100,000.00 Corporate Sponsorships
Prime Education Inc. $120,000.00 Educational Grants
Prime Education Inc. $225,000.00 Educational Grants
Prime Education Inc. $150,000.00 Educational Grants
Prime Education Inc. $199,725.00 Educational Grants
Prime Education Inc. $200,000.00 Educational Grants
Prime Education Inc. $200,000.00 Educational Grants
Prime Education Inc. $295,217.00 Educational Grants
Prime Education Inc. $93,930.00 Educational Grants
Prime Education Inc. $200,000.00 Educational Grants
Prime Education Inc. $274,830.00 Educational Grants
Prime Education Inc. $200,000.00 Educational Grants
Prime Education Inc. $200,000.00 Educational Grants
Prime Oncology Inc. $150,000.00 Educational Grants
Prime Oncology Inc. $85,000.00 Educational Grants
Prime Oncology Inc. $81,260.00 Educational Grants
Prime Oncology Inc. $86,320.00 Educational Grants
Prime Oncology Inc. $222,410.00 Educational Grants
Prime Oncology Inc. $75,000.00 Educational Grants
Prime Oncology Inc. $75,000.00 Educational Grants
Prime Oncology LLC ($21,072.00) Educational Grants
Primo Education LLC $15,000.00 Corporate Sponsorships
Project Inform $50,000.00 Charitable Donations
Project Inform $10,000.00 Corporate Sponsorships
Projects in Knowledge Inc. $125,000.00 Educational Grants
Projects in Knowledge Inc. $78,000.00 Educational Grants
Promis Health Organization $10,000.00 Educational Grants
Prostate Cancer Foundation $1,400.00 Corporate Sponsorships
Chicago
Prostate Cancer $5,000.00 Charitable Donations
International
Prostate Cancer Research $15,000.00 Corporate Sponsorships
Instutute
Prostaware $1,500.00 Corporate Sponsorships
Prostaware $1,500.00 Corporate Sponsorships
Providence Health and $20,000.00 Patient Support
Services Southern
California
Psoriasis and Psoriatic $100,000.00 Corporate Sponsorships
Arthritis Clinics
Multicenter Advancement
Network
Puerto Rico Associate of ($1,088.60) Educational Grants
Gastroenterology
Puerto Rico Associate of $5,000.00 Corporate Sponsorships
Gastroenterology
Puerto Rico Associate of $30,000.00 Corporate Sponsorships
Gastroenterology
Puerto Rico Associate of $20,000.00 Educational Grants
Gastroenterology
Puerto Rico Nephrology $3,500.00 Corporate Sponsorships
Society Inc.
Puerto Rico Obstetrician $1,400.00 Corporate Sponsorships
and Gyn Inc.
Puerto Rico Obstetrician $17,000.00 Corporate Sponsorships
and Gyn Inc.
Puerto Rico Obstetrician $5,000.00 Corporate Sponsorships
and Gyn Inc.
Purdue Univ College of $50,000.00 Educational Grants
Pharmacy
Purdue Univ College of $200,000.00 Educational Grants
Pharmacy
Purdue Univ College of ($18,852.35) Educational Grants
Pharmacy
Purdue Univ College of $150,000.00 Educational Grants
Pharmacy
Randolph College $1,000.00 Charitable Donations
Regents of The Univ of $5,000.00 Educational Grants
California
Regents of The Univ of $40,000.00 Fellowships and
California Scholarships
Regents of The Univ of $40,000.00 Fellowships and
California Scholarships
Regents of The Univ of $17,612.00 Fellowships and
California Scholarships
Regents of The Univ of $2,500.00 Patient Support
California
Regents of The Univ of $55,000.00 Fellowships and
California Scholarships
Regents of The Univ of $40,000.00 Fellowships and
California Scholarships
Regents of The Univ of $10,000.00 Educational Grants
California
Regents of The Univ of $25,000.00 Corporate Sponsorships
California
Regents of The Univ of $10,000.00 Educational Grants
California
Regents of The Univ of $20,000.00 Corporate Sponsorships
Michigan
Regents of The Univ of $1,000.00 Educational Grants
Michigan
Regents of The Univ of $1,000.00 Corporate Sponsorships
Michigan
Respiratory Health $4,050.00 Corporate Sponsorships
Association of
Metropolitan Chicago
Respiratory Health $4,050.00 Corporate Sponsorships
Association of
Metropolitan Chicago
Respiratory Health $4,050.00 Corporate Sponsorships
Association of
Metropolitan Chicago
Revolutionizing Atopic $35,000.00 Corporate Sponsorships
Dermatitis
Rheumatology Association of $10,000.00 Corporate Sponsorships
Minnesota and The Dakotas
Rheumatology Nurses Society $87,500.00 Educational Grants
Rheumlgy Alliance of $25,000.00 Corporate Sponsorships
Louisiana
Rheumnow $105,000.00 Corporate Sponsorships
Rheumnow $60,000.00 Corporate Sponsorships
Richmond County Medical $2,500.00 Corporate Sponsorships
Society
Riverside Medical Clinic $10,000.00 Patient Support
Charitable Foundation
Rocky Mountain MS Center $5,000.00 Patient Support
Ronald Mcdonald House $60,000,000.00 Charitable Donations
Charities, Inc.
Ronald Mcdonald House $20,000,000.00 Charitable Donations
Charities, Inc.
Ronald Mcdonald House $20,000,000.00 Charitable Donations
Charities, Inc.
Roswell Park Alliance $5,000.00 Educational Grants
Foundation
Rotary Club of Downtown $1,000.00 Corporate Sponsorships
Macon
Runx1 Foundation $2,500.00 Educational Grants
Rush University Medical $65,000.00 Educational Grants
Center
Rush University Medical $75,000.00 Educational Grants
Center
Rush University Medical $5,000.00 Charitable Donations
Center
Rush University Medical $300.00 Charitable Donations
Center
Rush University Medical $95,000.00 Educational Grants
Center
Rush University Medical $85,000.00 Educational Grants
Center
Rush University Medical $113,550.00 Educational Grants
Center
Rush University Medical $75,000.00 Educational Grants
Center
Safety Pharmacology Society $5,000.00 Educational Grants
Samaritan Daytop Village $2,500.00 Corporate Sponsorships
San Francisco Aids $10,000.00 Charitable Donations
Foundation
San Francisco Public Center $100,000.00 Charitable Donations
Foundation
San Francisco Retina $5,000.00 Educational Grants
Foundation
San Juan Bautista Medical $40,000.00 Fellowships and
Center Scholarships
Scripps Health $10,000.00 Corporate Sponsorships
Scripps Health $66,500.00 Corporate Sponsorships
Scripps Health $20,000.00 Educational Grants
Seattle Science Foundation $8,500.00 Educational Grants
Shanti $10,000.00 Charitable Donations
Share $7,500.00 Charitable Donations
Sociedad Dermatologica de $20,000.00 Corporate Sponsorships
Puerto Rico
Sociedad Dermatologica de $15,000.00 Corporate Sponsorships
Puerto Rico
Sociedad PR Endocrinologia $15,000.00 Corporate Sponsorships
y Diabetologia
Sociedad Puertorriquena $5,000.00 Corporate Sponsorships
Pediatria
Society for Clinical Trials $2,000.00 Corporate Sponsorships
Society for Leukocyte $2,000.00 Educational Grants
Biology
Society for Neuro-Oncology $50,000.00 Corporate Sponsorships
Society for Neuro-Oncology $20,000.00 Educational Grants
Society for Neuro-Oncology $39,140.00 Educational Grants
Society for Neuro-Oncology $58,000.00 Educational Grants
Society for Neuro-Oncology $50,000.00 Corporate Sponsorships
Society for Physician $10,000.00 Charitable Donations
Assistants in Pediatrics
Society for Womens Health $25,000.00 Corporate Sponsorships
Research
Society of Dermatology $50,000.00 Corporate Sponsorships
Physician Assistants
Society of Dermatology $40,000.00 Corporate Sponsorships
Physician Assistants
Society of Gynecologic $27,500.00 Corporate Sponsorships
Surgeons
Society of Investigative $30,000.00 Educational Grants
Dermatology
Socty for Gynecologic $10,000.00 Corporate Sponsorships
Investigation
Socty for Immunotherapy of $50,000.00 Corporate Sponsorships
Cancer
Socty for Immunotherapy of $5,000.00 Educational Grants
Cancer
Socty for Immunotherapy of $25,000.00 Corporate Sponsorships
Cancer
South Carolina Alliance of $6,000.00 Corporate Sponsorships
Health Plans
South Dakota Parkinson $2,500.00 Corporate Sponsorships
Foundation
South Dakota Parkinson $1,000.00 Corporate Sponsorships
Foundation
South Sound Care Foundation $3,250.00 Corporate Sponsorships
Southern California Society $100,000.00 Corporate Sponsorships
of Gastroenterology
Spondylitis Association of $20,000.00 Patient Support
America
Spondylitis Association of $40,000.00 Patient Support
America
Spondylitis Association of $17,750.00 Educational Grants
America
Spondyloarthritis Research $70,000.00 Corporate Sponsorships
and Treatment Network
Spartan
St. Barnabas Hospital $1,300.00 Fellowships and
Scholarships
St. Jude Childrens Research $30,000,000.00 Charitable Donations
Hospital
St. Jude Childrens Research $20,000,000.00 Charitable Donations
Hospital
St. Lukes Hospital $2,500.00 Corporate Sponsorships
State of West Virginia $2,500.00 Corporate Sponsorships
Rheumatology Society
Super Jake Foundation The $25,000.00 Charitable Donations
Susan G Komen Colorado $5,000.00 Corporate Sponsorships
Susan G Komen Colorado $5,000.00 Corporate Sponsorships
Talem Health Inc. $95,000.00 Educational Grants
Talem Health Inc. $235,820.00 Educational Grants
Tarsus Cardiology Inc. Dba $35,000.00 Corporate Sponsorships
South Beach Symposium
Texas Academy of Family $2,500.00 Corporate Sponsorships
Physicians
Texas Academy of Family $2,500.00 Corporate Sponsorships
Physicians Foundation
Texas Healthcare and $5,000.00 Corporate Sponsorships
Bioscience
Texas Indo-American $5,000.00 Corporate Sponsorships
Physicians Society
Texas Medical Association $5,000.00 Corporate Sponsorships
Texas Osteopathic Medical $3,000.00 Corporate Sponsorships
Association Foundation
Thomas Jefferson University $5,000.00 Educational Grants
Thomas Jefferson University $3,000.00 Corporate Sponsorships
Thomas Jefferson University $3,000.00 Corporate Sponsorships
Thomas Jefferson University $3,000.00 Corporate Sponsorships
Thomas Jefferson University $5,000.00 Corporate Sponsorships
Translational Research in $5,000.00 Educational Grants
Oncology US Inc.
Trinity International $1,000.00 Charitable Donations
College
Tufts Medical Center ($1,190.13) Educational Grants
Tufts Medical Center ($513.14) Educational Grants
UC Regents Maxillofacial $10,000.00 Educational Grants
Prosthetics Clinic
UC Regents Maxillofacial $40,000.00 Fellowships and
Prosthetics Clinic Scholarships
UC Regents Maxillofacial $15,000.00 Educational Grants
Prosthetics Clinic
Ultimate Medical Academy ($4,043.06) Educational Grants
LLC
Ultimate Medical Academy $174,700.00 Educational Grants
LLC
Ultimate Medical Academy $50,000.00 Educational Grants
LLC
Ultimate Medical Academy ($2,344.80) Educational Grants
LLC
Ultimate Medical Academy $150,000.00 Educational Grants
LLC
Ultimate Medical Academy $100,000.00 Educational Grants
LLC
Ultimate Medical Academy $125,000.00 Educational Grants
LLC
Ultimate Medical Academy ($5,138.86) Educational Grants
LLC
Ultimate Medical Academy ($3,284.05) Educational Grants
LLC
Ultimate Medical Academy ($2,134.44) Educational Grants
LLC
Ultimate Medical Academy ($9,000.00) Educational Grants
LLC
Ultimate Medical Academy ($885.32) Educational Grants
LLC
Ultimate Medical Academy $245,000.00 Educational Grants
LLC
Ultimate Medical Academy $95,000.00 Educational Grants
LLC
Ultimate Medical Academy $500,000.00 Educational Grants
LLC
Ultimate Medical Academy $349,450.00 Educational Grants
LLC
UMA Education Inc. Dba $50,000.00 Educational Grants
Global Education Group
UMA Education Inc. Dba $375,000.00 Educational Grants
Global Education Group
UMA Education Inc. Dba $225,000.00 Educational Grants
Global Education Group
UMA Education Inc. Dba $43,358.00 Educational Grants
Global Education Group
UMA Education Inc. Dba $163,000.00 Educational Grants
Global Education Group
UMA Education Inc. Dba $166,000.00 Educational Grants
Global Education Group
UMA Education Inc. Dba $10,000.00 Educational Grants
Global Education Group
UMASS Memorial Foundation $2,500.00 Corporate Sponsorships
Inc.
United Medical Center $2,280.00 Educational Grants
United Rheumatology $225,000.00 Corporate Sponsorships
United Spinal Association $12,500.00 Corporate Sponsorships
Inc.
United Spinal Association $12,500.00 Corporate Sponsorships
Inc.
United States Adult Cystic $5,000.00 Patient Support
Fibrosis Association Inc.
United States and Canadian $30,000.00 Corporate Sponsorships
Academy of Pathology
United States Renal Care $20,000.00 Corporate Sponsorships
Inc.
Unity Health Care, Inc. $7,500.00 Corporate Sponsorships
Univ Connecticut ($2,054.94) Educational Grants
Dermatology
Univ Connecticut $40,000.00 Fellowships and
Dermatology Scholarships
Univ Health Service at $20,000.00 Educational Grants
Stony Point Inc.
Univ Health Service at $120,000.00 Corporate Sponsorships
Stony Point Inc.
Univ Health Service at $120,000.00 Corporate Sponsorships
Stony Point Inc.
Univ of Chicago $8,000.00 Educational Grants
Univ of Chicago $50,000.00 Patient Support
Univ of Chicago $10,000.00 Educational Grants
Univ of Chicago $15,000.00 Educational Grants
Univ of Chicago $25,000.00 Educational Grants
Univ of Chicago ($2,097.00) Educational Grants
Univ of Chicago $125,000.00 Educational Grants
Univ of Chicago $5,000.00 Corporate Sponsorships
Univ of Chicago $10,000.00 Corporate Sponsorships
Univ of Chicago $5,000.00 Educational Grants
Univ of Chicago $5,000.00 Corporate Sponsorships
Univ of Chicago $20,000.00 Corporate Sponsorships
Univ of Chicago $18,000.00 Educational Grants
Univ of Chicago ($7,232.53) Educational Grants
Univ of Chicago $1,000.00 Charitable Donations
Univ of Chicago $10,000.00 Educational Grants
Univ of Chicago $45,000.00 Educational Grants
Univ of Chicago $10,000.00 Educational Grants
Univ of Cincinnati ($68,461.18) Educational Grants
Univ of Cincinnati $25,000.00 Corporate Sponsorships
Univ of Cincinnati $60,000.00 Educational Grants
Univ of Cincinnati $60,000.00 Educational Grants
Univ of Cincinnati $75,000.00 Educational Grants
Univ of Colorado Denver $20,000.00 Fellowships and
School of Medicine Scholarships
Univ of Connecticut Health $12,000.00 Fellowships and
Center, John Dempsey Scholarships
Hospital
Univ of Florida Foundation $60,000.00 Fellowships and
Scholarships
Univ of Illinois Foundation $1,000.00 Charitable Donations
Univ of Louisville $15,000.00 Corporate Sponsorships
Univ of Louisville Research $60,000.00 Educational Grants
Foundation
Univ of Louisville Research $50,000.00 Educational Grants
Foundation
Univ of Louisville Research $60,000.00 Educational Grants
Foundation
Univ of Maryland Baltimore $10,000.00 Patient Support
Foundation Inc.
Univ of Maryland Baltimore $5,000.00 Educational Grants
Foundation Inc.
Univ of Massachusetts Med $2,500.00 Corporate Sponsorships
School
Univ of Miami $20,000.00 Corporate Sponsorships
Univ of Miami $40,000.00 Fellowships and
Scholarships
Univ of Miami $10,000.00 Corporate Sponsorships
Univ of Minnesota Regents $2,000.00 Educational Grants
Univ of Nebraska Med Center $100,000.00 Corporate Sponsorships
Univ of Nebraska Med Center $50,000.00 Educational Grants
Univ of Nebraska Med Center $35,000.00 Educational Grants
Univ of Nebraska Med Center $150,000.00 Educational Grants
Univ of Nebraska Med Center $125,000.00 Educational Grants
Univ of Nebraska Med Center $128,860.00 Educational Grants
Univ of Nebraska Med Center $600.00 Corporate Sponsorships
Univ of Nebraska Med Center $10,000.00 Corporate Sponsorships
Univ of Nebraska Med Center $25,000.00 Corporate Sponsorships
Univ of Nebraska Med Center $30,000.00 Educational Grants
Univ of Nebraska Med Center $7,500.00 Educational Grants
Univ of New Mexico Health $10,000.00 Educational Grants
Science Center Dept of
Pediatrics Neonatology
Division
Univ of Pittsburgh $15,000.00 Educational Grants
Univ of Pittsburgh $2,200.00 Educational Grants
Univ of Pittsburgh $20,000.00 Educational Grants
Univ of South Florida Board $37,500.00 Fellowships and
of Trustees Scholarships
Univ of South Florida $25,000.00 Educational Grants
Health Professions
Conferencing Corp
Univ of Southern California $1,500.00 Educational Grants
Univ of Southern California $25,000.00 Educational Grants
Univ of Southern California $7,097.77 Fellowships and
Scholarships
Univ of Southern California $81,500.00 Fellowships and
Scholarships
Univ of Texas at Austin $5,000.00 Educational Grants
Univ of Texas Health $16,032.00 Corporate Sponsorships
Science Center at San
Antonio
Univ of Texas Health $75,000.00 Educational Grants
Science Center at San
Antonio
Univ of Toledo $2,000.00 Patient Support
Univ of Utah $40,000.00 Fellowships and
Scholarships
Univ of Wisconsin--Madison $1,500.00 Educational Grants
Univeristy of Chicago $15,000.00 Charitable Donations
Cancer Research Foundation
Universidad Central Del ($2,283.00) Educational Grants
Caribe School of Medicine
Universidad DE Puerto Rico $30,000.00 Fellowships and
Scholarships
Universidad DE Puerto Rico $59,783.50 Corporate Sponsorships
Universidad DE Puerto Rico $30,000.00 Fellowships and
Scholarships
University Health Services $75,000.00 Educational Grants
University Health Services $5,000.00 Educational Grants
University Health Services $25,000.00 Educational Grants
University of Alabama at $40,000.00 Fellowships and
Birmingham Hospital Scholarships
University of California $40,000.00 Fellowships and
Irvine Scholarships
University of California $6,000.00 Corporate Sponsorships
San Francisco Foundation
University of Illinois-- $15,821.60 Fellowships and
Office of Business and Scholarships
Financial Services
University of Illinois-- $75,138.40 Fellowships and
Office of Business and Scholarships
Financial Services
University of North $40,000.00 Fellowships and
Carolina at Chapel Hill Scholarships
University of North $1,000.00 Charitable Donations
Carolina at Chapel Hill
University of Rochester $5,000.00 Educational Grants
University of South Florida ($9,615.55) Educational Grants
Foundation
University of Texas $55,000.00 Fellowships and
Southwestern Medical Scholarships
Center
University of Texas $75,000.00 Fellowships and
Southwestern Medical Scholarships
Center
University of Washington $40,000.00 Fellowships and
Medical Center Scholarships
University of Wisconsin LA $1,000.00 Charitable Donations
Crosse Foundation Inc.
Urogpo, LLC $35,000.00 Corporate Sponsorships
Urological Association of $10,000.00 Corporate Sponsorships
Physician Assistants
Urology Center of Colorado $10,000.00 Corporate Sponsorships
Foundation
US Too International $1,500.00 Corporate Sponsorships
US Too International $25,750.00 Corporate Sponsorships
Vanderbilt Univ By and $190,000.00 Educational Grants
Through Its Medical Center
Vanderbilt Univ By and $10,000.00 Educational Grants
Through Its Medical Center
Vanderbilt Univ By and $5,000.00 Educational Grants
Through Its Medical Center
Vanderbilt Urology Society $3,000.00 Corporate Sponsorships
Veritas Meeting Solutions $4,500.00 Corporate Sponsorships
VHA Inc. $35,000.00 Corporate Sponsorships
Vida Global Foundation $1,500.00 Corporate Sponsorships
Vietnamese American $3,000.00 Corporate Sponsorships
Healthcare Professionals
Association of Georgia
Vindico Med Education $50,000.00 Educational Grants
Vindico Med Education $200,000.00 Educational Grants
Vindico Med Education $50,000.00 Educational Grants
Vindico Med Education $75,000.00 Educational Grants
Vindico Med Education $50,000.00 Educational Grants
Vindico Med Education $49,000.00 Educational Grants
Vindico Med Education $50,000.00 Educational Grants
Vindico Med Education $50,000.00 Educational Grants
Virginia Academy of $1,750.00 Corporate Sponsorships
Physician Assistants
Virginia Commonwealth $7,500.00 Corporate Sponsorships
University School of
Medicine
Virginia Council of Nurse $1,493.94 Corporate Sponsorships
Practitioners
Wake Forest Univ $40,000.00 Fellowships and
Scholarships
Wall Las Memorias $10,000.00 Corporate Sponsorships
Wartburg College $1,000.00 Charitable Donations
Washington International $2,500.00 Corporate Sponsorships
Trade Foundation
Washington International $2,500.00 Corporate Sponsorships
Trade Foundation
Washington International $2,500.00 Corporate Sponsorships
Trade Foundation
Washington International $2,500.00 Corporate Sponsorships
Trade Foundation
Washington Univ in St Louis ($263.21) Fellowships and
Scholarships
Washington Univ in St Louis $6,000.00 Educational Grants
Washington Univ in St Louis $1,500.00 Corporate Sponsorships
Washington Univ in St Louis $1,600.00 Fellowships and
Scholarships
Washington Univ in St Louis ($17,777.79) Educational Grants
We Care in Inflammatory $25,000.00 Charitable Donations
Bowel Disease
WebMD Global LLC $90,000.00 Educational Grants
WebMD Global LLC $209,983.00 Educational Grants
WebMD Global LLC $209,983.00 Educational Grants
WebMD Global LLC $209,983.00 Educational Grants
WebMD Global LLC $50,000.00 Educational Grants
WebMD Global LLC $63,500.00 Educational Grants
WebMD Global LLC $81,500.00 Educational Grants
WebMD Global LLC $95,000.00 Educational Grants
WebMD Global LLC $348,000.00 Educational Grants
WebMD Global LLC $151,000.00 Educational Grants
WebMD Global LLC $172,000.00 Educational Grants
WebMD Global LLC $200,000.00 Educational Grants
WebMD Global LLC $75,000.00 Educational Grants
WebMD Global LLC ($1,500.00) Educational Grants
WebMD Global LLC ($1,142.14) Educational Grants
WebMD Global LLC $100,000.00 Educational Grants
WebMD Global LLC $65,000.00 Educational Grants
WebMD Global LLC $182,500.00 Educational Grants
WebMD Global LLC $150,000.00 Educational Grants
WebMD Global LLC $75,000.00 Educational Grants
WebMD Global LLC $350,000.00 Educational Grants
WebMD Global LLC $100,000.00 Educational Grants
WebMD Global LLC $113,500.00 Educational Grants
WebMD Global LLC $200,000.00 Educational Grants
WebMD Global LLC $227,000.00 Educational Grants
WebMD Global LLC $150,000.00 Educational Grants
WebMD Global LLC $350,000.00 Educational Grants
WebMD Global LLC $120,000.00 Educational Grants
WebMD Global LLC $136,150.00 Educational Grants
WebMD Global LLC $215,000.00 Educational Grants
WebMD Global LLC $319,770.00 Educational Grants
West Virginia Community $5,000.00 Corporate Sponsorships
Voices
Wisconsin Collaborative for $3,750.00 Corporate Sponsorships
Healthcare Quality
Wisconsin Rheumatology $10,000.00 Corporate Sponsorships
Association
Wisconsin Rheumatology $10,000.00 Corporate Sponsorships
Association
Wisconsin Section American $2,000.00 Corporate Sponsorships
Congress Obstetrics and
Gynecologist Acog
Women in Government $2,500.00 Corporate Sponsorships
Foundation Ltd
Women in Government $2,500.00 Corporate Sponsorships
Foundation Ltd
Women in Government $5,000.00 Corporate Sponsorships
Foundation Ltd
Women in Government $5,000.00 Corporate Sponsorships
Foundation Ltd
Women in Government $7,500.00 Corporate Sponsorships
Foundation Ltd
Women in Government $7,500.00 Corporate Sponsorships
Foundation Ltd
Women in Government $5,000.00 Corporate Sponsorships
Foundation Ltd
Women in Government $5,000.00 Corporate Sponsorships
Foundation Ltd
Women in Government $5,000.00 Corporate Sponsorships
Foundation Ltd
Women in Government $5,000.00 Corporate Sponsorships
Foundation Ltd
Women in Government $10,000.00 Corporate Sponsorships
Foundation Ltd
Women in Government $10,000.00 Corporate Sponsorships
Foundation Ltd
Women in Government $2,500.00 Corporate Sponsorships
Foundation Ltd
Women in Government $2,500.00 Corporate Sponsorships
Foundation Ltd
Women in Government $2,500.00 Corporate Sponsorships
Foundation Ltd
Women in Government $5,000.00 Corporate Sponsorships
Foundation Ltd
Women in Government $7,000.00 Corporate Sponsorships
Foundation Ltd
Women in Government $2,500.00 Corporate Sponsorships
Foundation Ltd
Women in Government $10,000.00 Corporate Sponsorships
Foundation Ltd
World Parkinson Coalition $50,000.00 Fellowships and
Inc. Scholarships
Worldwide Endomarch $5,000.00 Corporate Sponsorships
Worldwide Endomarch $3,000.00 Corporate Sponsorships
Yale Univ $5,000.00 Educational Grants
Zebrafish Disease Models $5,000.00 Educational Grants
Society
Zero The Project To End $15,000.00 Corporate Sponsorships
Prostate Cancer
Zero The Project To End $270,000.00 Corporate Sponsorships
Prostate Cancer
Zero The Project To End $10,000.00 Corporate Sponsorships
Prostate Cancer
Zero The Project To End $12,000.00 Corporate Sponsorships
Prostate Cancer
Zero The Project To End $270,000.00 Corporate Sponsorships
Prostate Cancer
------------------------------------------------------------------------
Exhibit 2
--------------------------------------------------------------------------------------------------------------------------------------------------------
Organization Legal Name 2014 2015 2016 2017 2018
--------------------------------------------------------------------------------------------------------------------------------------------------------
ALBERT B. SABIN VACCINE INSTITUTE, INC. 203,302.00 835,251.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
ALS THERAPY DEVELOPMENT FOUNDATION INC. 5,159.91
--------------------------------------------------------------------------------------------------------------------------------------------------------
ALZHEIMER'S DISEASE AND RELATED DISORDERS ASSOCIATION, INC. 10,000.00 10,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
AMERICAN CANCER SOCIETY, INC. 1,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
AMERICAN RED CROSS 50,000.00 20,000.00 80,000.00 1,425,000.00 775,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
AMERICARES FOUNDATION, INC. 100,000.00 50,000.00 25,000.00 250,000.00 400,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
APNA GHAR, INC. (OUR HOME) 50,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
ASIAN UNIVERSITY FOR WOMEN SUPPORT FOUNDATION 50,000.00 50,000.00 50,000.00 50,000.00 50,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
ASTRAEA FOUNDATION, INC. 75,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
BAYLOR COLLEGE OF MEDICINE INTERNATIONAL PEDIATRIC AIDS INITIATIVE 2,220,337.00 2,477,111.00 1,660,000.00 1,610,000.00 1,610,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
BEACON PLACE NFP 100,000.00 100,000.00 125,000.00 150,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
BERNARD P. FLORIANI FOUNDATION 50,000.00 75,000.00 110,000.00 420,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
BIG BROTHERS BIG SISTERS OF METROPOLITAN CHICAGO 40,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
BOYS AND GIRLS CLUB OF LAKE COUNTY 10,000.00 10,000.00 10,000.00 25,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
CARING AMBASSADORS PROGRAM, INC. 253,282.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
CASA LAKE COUNTY 25,000.00 25,000.00 25,000.00 25,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
CATALYSIS LLC -
--------------------------------------------------------------------------------------------------------------------------------------------------------
CENTER FOR NEIGHBORHOOD ENTERPRISE 50,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
CENTRAIDE OF GREATER MONTREAL (Matching Grants--Canada) 11,000.00 11,000.00 19,600.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
CHICAGO CARES INC. 314,504.00 18,000.00 15,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
CHICAGO HORTICULTURAL SOCIETY 50,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
CHICAGO HOUSE AND SOCIAL SERVICE AGENCY 25,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
CHICAGO TOOLBANK 5,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
CHINESE AMERICAN SERVICE LEAGUE 50,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
CHOCOLATE CHIPS ASSOCIATION 10,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
CITY OF NORTH CHICAGO 5,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
COMMUNITY ACTION PARTNERSHIP OF LAKE COUNTY 150,400.00 141,875.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
CRADLES TO CRAYONS, INC. 515,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
CRISTO REY ST. MARTIN COLLEGE PREP 50,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
DAVIS PHINNEY FOUNDATION 120.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
IDIRECT RELIEF 1,865,000.00 1,941,111.00 1,325,000.00 2,115,000.00 850,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
DRESS FOR SUCCESS WORLDWIDECENTRAL 90,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
ERIE FAMILY HEALTH CENTER, INC. 100,000.00 55,000.00 50,000.00 50,000.00 50,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
FAMILY REACH FOUNDATION 100,00.00 300,000.00 320,000.00 300,000.00 300,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
FEEDING AMERICA 225,000.00 25,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
FIELD MUSEUM OF NATURAL HISTORY 30,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
FISHER HOUSE FOUNDATION, INC. 750,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
FONDOS UNIDOS DE PUERTO RICO, INC. 136,400.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
FOOD BANK OF EASTERN MICHIGAN 10,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
GILDA'S CLUB CHICAGO 25,000.00 25,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
GLOBAL HEALTH CORPS 50,000.00 100,000.00 100,000.00 100,000.00 100,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
GLOBEMED NFP 50,000.00 75,000.00 75,000.00 75,000.00 75,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
HABITAT FOR HUMANITY INTERNATIONAL 530,200.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
HABITAT FOR HUMANITY, LAKE COUNTY IL, INC. 125,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
HANDS ON ORLANDO, INC 150,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
HEALTHREACH, INC.
--------------------------------------------------------------------------------------------------------------------------------------------------------
HEART TO HEART INTERNATIONAL, INC. 35,000.00 535,000.00 310,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
HISPANIC SCHOLARSHIP FUND 50,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
ILLINOIS SCIENCE AND TECHNOLOGY INSTITUTE 70,000.00 40,000.00 80,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
IMPACTING VETERANS LIVES, INC.--MIDWEST VETERANS CLOSET 50,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
IMSA FUND FOR ADVANCEMENT OF EDUCATION 133,000.00 133,000.00 40,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
INDIANA UNIVERSITY 1,150,000.00 1,100,000.00 1,100,000.00 1,100,000.00 1,100,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
INTERNATIONAL MEDICAL CORPS 100,000.00 350,000.00 25,000.00 450,000.00 550,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
JK GROUP, INC. (Matching Grants)
--------------------------------------------------------------------------------------------------------------------------------------------------------
JUNIOR ACHIEVEMENT OF CHICAGO 33,500.00 50,000.00 50,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
KABOOM! 342,582.00 397,081.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
KIDS RANK 25,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
KOHL CHILDREN'S MUSEUM 495,500.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
KOHL CHILDREN'S MUSEUM OF GREATER CHICAGO 44,615.00 154,000.00 154,300.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
LAKE COUNTY CARES 22,145.00 22,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
LAKE COUNTY CRISIS CENTER FOR THE PREVENTION AND TREATMENT OF 10,000.00 10,000.00 10,000.00 25,000.00
DOMESTIC VIOLENCE, INC.
--------------------------------------------------------------------------------------------------------------------------------------------------------
LAKE COUNTY VETERANS AND FAMILY SERVICES FOUNDATION 50,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
MAP INTERNATIONAL 313,800.00 412,907.00 460,000.00 510,000.00 325,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
MASSACHUSETTS BIOTECHNOLOGY EDUCATION FOUNDATION 40,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
MEMORIAL SLOAN KETTERING CANCER CENTER 100,000.00 100,000.00 100,000.00 100,000.00 100,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
MIDWEST ATHLETES AGAINST CHILDHOOD CANCER, INC 865.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
MOTHERS TRUST FOUNDATION 25,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
NATIONAL AUDUBON SOCIETY, INC. 12 ,500.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
NATIONAL INVENTORS HALL OF FAME, INC. 225,000.00 225,000.00 153,900.00 176,000.00 259,725.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
NATIONAL MULTIPLE SCLEROSIS SOCIETY 350.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
NICASA, NFP
--------------------------------------------------------------------------------------------------------------------------------------------------------
NORTH CHICAGO COMMUNITY PARTNERS 246,833.00 237,889,00 642,500.00 730,000.00 750,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
NORTH CHICAGO COMMUNITY UNIT SCHOOL DISTRICT 187 100,600.00 165,000.00 828,430.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
NORTHERN ILLINOIS FOOD BANK 14,400.00 15,000.00 25,000.00 30,000.00 55,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
PADS LAKE COUNTY, INC. 10,000.00 10,000.00 10,000.00 10,000.00 25,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
PARTNERS IN HEALTH 100,000.00 300,000.00 383,335.00 688,925.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
POINTS OF LIGHT FOUNDATION 545,800.00 708,000.00 954,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
PRAIRIE STATE LEGAL SERVICES, INC. 25,000.00 25,000.00 25,000.00 25,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
PROJECT HOPE--THE PEOPLE-TO-PEOPLE HEALTH FOUNDATION, INC. 250,000.00 100,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
READING POWER, INC. 10,000.00 40,000.00 58,000.00 260,000.00 300,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE 10,000.00 65,120.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
SHEDD AQUARIUM 50,000.00 50,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
SIEMPRE UNIDOS 60,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
SILICON VALLEY COMMUNITY FOUNDATION (Matching Grants) 2,763,823.52 3,059,133.44 504,232.72
--------------------------------------------------------------------------------------------------------------------------------------------------------
STRENGTHEN ORLANDO, INC. 6,515.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
TAPROOT FOUNDATION 200,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
TEAM RUBICON 375,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
TEXAS CHILDREN'S HOSPITAL 50,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
THE ALS ASSOCIATION GREATER CHICAGO CHAPTER 5,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
THE FULLER CENTER FOR HOUSING HERO PROJECT LAKE COUNTY 60,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
THE HEART OF AMERICA FOUNDATION 726,910.00 1,019,652.00 1,327,500.00 2,050,000.00 1,993,300.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
THE SCRIPPS RESEARCH INSTITUTE 290,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
TPA NETWORK INCORPORATED 2,285.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
TRAVIS MANION FOUNDATION 100,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
UNITED WAY OF CENTRAL MASSACHUSETTS 44,000.00 45,000.00 61,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
UNITED WAY OF LAKE COUNTY 80,000.00 80,000.00 70,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
UNIVERSTIY OF CHICAGO 1,000,000.00 1,000,000.00 1,000,000.00 1,000,000.00 1,000.000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
UNIVERSITY OF NOTRE DAME 50,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
WARRIORS AND QUIET WATERS FOUNDATION, INC. 50,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
WILLIAM MARSH RICE UNIVERSITY 94,300.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
WOUNDED WARRIOR PROJECT 750,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
WPS60 110,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
YBLC, INC. 15,000.00 15,000.00 15,000.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
YOUR CAUSE HOLDINGS, LLC (Matching Grants) 2,805,067.87 4,120,115.28 7,012,295.67
--------------------------------------------------------------------------------------------------------------------------------------------------------
12,292,102.52 13,593,332.35 15,187,786.59 19,856.907.28 26,850,256.67
--------------------------------------------------------------------------------------------------------------------------------------------------------
Note: Matching Grants are listed by Organizations that manage the program and not by the ultimate re
Prepared Statement of Hon. Chuck Grassley,
a U.S. Senator From Iowa
I want to welcome the witnesses and thank them for being here.
The information they share will help inform the committee as it
addresses the issue of high prescription drug prices.
America has a problem with the high cost of prescription medicines.
Whether it's about the EpiPen, insulin, or other prescriptions, in
the thousands of letters I've received, Iowans have made clear that
high drug prices are hurting them.
I've heard about people skipping doses of their prescription drugs
to make them last until the next paycheck.
I'm not a doctor, but rationing one's medicine doesn't sound like a
safe prescription for health and wellness.
Others have told me about leaving their prescription on the
pharmacy counter because it cost too much.
There is no question that researchers and doctors have developed
treatments and cures for diseases where there were once none.
And, such innovations take time and money.
But, we're all trying to understand the sticker shock that many
drugs generate. Especially when some of those drugs have been around
for a long time.
There is a balance between incentivizing innovation and keeping
prices affordable for consumers and taxpayers.
Like all systems, things can get out of balance.
The good news is, we are here to discuss solutions.
In fact, we are here today thanks to our system of checks and
balances.
Congress has a constitutional responsibility to be a meaningful
check on the spending of taxpayer money.
That responsibility includes not just holding hearings, but also
holding the private sector and the government accountable through
oversight.
Just like a doctor has to properly diagnose a disease before it can
be treated, Congress needs to understand what's going on in the drug
pricing supply chain in order to respond in a measured and effective
way.
As a part of that fact-finding, as of last Friday, Ranking Member
Wyden and I launched an inquiry into the high cost of insulin.
This hearing is not about scapegoating any one group regarding high
drug costs.
That's why we're holding a series of bipartisan hearings on the
issue.
Without a doubt, drug pricing is a complex issue.
But I think we should all be asking: Should it be so complex?
We cannot allow anyone to hide behind the current complexities to
shield the true cost of a drug.
And, we shouldn't turn a blind eye to industry practices that
thwart the laws and regulations designed to promote competition and
generic drug entry in the market.
Health and Human Services Secretary Alex Azar, FDA Commissioner
Scott Gottlieb and the Federal Trade Commission have identified a
number of tactics that undermine competition--like withholding samples,
pay for delay, product-hopping, and rebate bundling, just to name a
few.
While these agencies are taking enforcement action or looking at
regulatory changes, we here in Congress are exploring legislative
options to deter companies from engaging in these practices that keep
drug prices high for patients.
Today, we expect open, honest answers from the pharmaceutical
industry to figure out how we got here and see what ideas they have to
make things better.
One of the first things we need to talk about is list price.
Secretary Azar has said that pharmaceutical companies believe that
the list price is meaningless.
In fact, some of your testimony today will echo that.
However, for a patient taking a drug that has no competition, the
list price is meaningful.
For seniors on Part D who are paying co-insurance as a percentage
of list price, the list price is meaningful.
For people who have high deductible plans and pay thousands of
dollars towards list price, the list price is meaningful.
For pharmacy benefit managers, providing drugs with a high list
price can be more attractive than providing a less expensive drug.
Therefore, for taxpayers, the list price is meaningful.
We've all seen the finger pointing. Every link in the supply chain
has gotten skilled at that.
But, like most Americans, I'm sick and tired of the blame game.
It's time for solutions.
One way or another, we're going to get some clarity.
The American people deserve straight answers and real solutions.
On that note, I want to remind each of you that it's a crime under
title 18, U.S. Code, section 1001 to provide false testimony to
Congress.
Thank you for coming. I look forward to your testimony.
______
Prepared Statement of Pascal Soriot,
Chief Executive Officer, AstraZeneca
i. overview
AstraZeneca appreciates the opportunity to engage with the
committee on the important topic of drug pricing in the United States.
We would like to emphasize our commitment to addressing these
challenges and the important issues raised by the committee regarding
drug pricing and affordability.
AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialization of
prescription medicines, primarily for the treatment of diseases in
three main therapy areas: Oncology; Cardiovascular; Renal and
Metabolism; and Respiratory. We are also selectively active in the
areas of autoimmunity, neuroscience, and infection. We are proud to
call Wilmington, DE home to our North American headquarters. We are
equally proud that one of our three global Research and Development
(``R&D'') headquarters is located in Gaithersburg, MD.
We are honored to contribute to improving the lives of millions of
patients in the U.S. and across the globe. This statement is focused on
four points explaining AstraZeneca's purpose, core values, and vision
for the future:
First, we are a science-led organization, as reflected in
our continued investment in R&D and our success in introducing
new treatments. Continuing to develop treatments that deliver
long-term benefits to patients and the overall health of the
U.S. population requires society's commitment to supporting
investment in innovation through purchasing our medicines for
the duration of patent protection at a responsible price that
allows for the recoupment of the investment and risk associated
with innovation.
Second, we believe medicines are part of the solution to
controlling health-care costs. They not only improve patient
outcomes and increase quality of life, but also reduce
downstream costs by keeping people healthy and out of the
hospital. This contribution to reducing overall health-care
costs should be considered when discussing drug pricing.
Third, we recognize that we are only able to improve the
lives of patients if they are able to take our medicines as
prescribed. To that end, we are committed to sustaining and
improving patient access and affordability.
Fourth, we recognize that the current state of drug pricing
in the U.S. health-care system is not sustainable and that
patients are facing increasingly high out-of-pocket costs. We
believe that these issues must be addressed urgently, and we
hope to be a constructive partner in finding solutions.
ii. benefits of innovation and r&d funding
Science is at the core of what we do, and we are focused on being
at the forefront of scientific innovation to deliver tomorrow's
treatments and cures. Since 2017, the Food and Drug Administration
(``FDA'') has approved 18 AstraZeneca products or significant
indications, and five of our products have received breakthrough
therapy designation. Breakthrough therapy designation is designed
specifically for the expedited development and review of drugs for
serious or life-threatening conditions, and these designations
highlight how critical our work is to patient health in the U.S. For
example, our oncology medicine CALQUENCE was granted breakthrough
therapy designation for certain patients with mantle cell lymphoma and
tezepelumab received such a designation for certain patients with
severe asthma.
In order to achieve these results, we reinvest a significant
percentage of our revenues in research to identify the next generation
of life-changing medicines. Over the past several years, we have worked
tirelessly to rebuild our R&D pipeline. We now have approximately 8,900
employees in our R&D organization working at sites across the world.
Our financial commitment to R&D has been significant. In 2018 alone, we
spent nearly $6 billion on R&D, or 28 percent of our total product
sales--a commitment to R&D that well exceeds the average spending of
our research-based peers.\1\ Over the past six years, even as our
revenues declined, we continued to make substantial investments in both
R&D and acquiring products for our pipeline. In 2018, these investments
have only just started to contribute to growth of our company.
---------------------------------------------------------------------------
\1\ Pharmaceutical Research and Manufacturers of America (PhRMA).
PhRMA Annual Membership Survey (2018). https://www.phrma.org/report/
2018-phrma-annual-membership-survey.
These results are possible only if society makes a commitment to
support innovation so that treatments can be developed to the benefit
---------------------------------------------------------------------------
of society as a whole for years to come.
The development of new drug therapies requires society to make an
up-front investment through purchasing our medicines during the patent
protection period at a responsible price we charge, and then at a very
substantially reduced price for an indefinite period after patent
expiry when generics are introduced. Thus, long-term improvements in
healthcare derived from new medicines can only be achieved if society
is willing to pay a responsible price for a certain number of years
that allows for the recoupment of the investment and risk involved in
pharmaceutical innovation. Improvements in patient health and reduction
of overall health-care costs over the long term are a direct result of
this commitment to support innovation.
For example, in the U.S., we have seen incredible progress in
reducing cardiovascular disease morbidity and mortality. Between 2000
and 2014, age-adjusted mortality rates for cardiovascular and heart
disease declined by approximately 35 percent; several factors have
contributed to this decline, but the development of new medicines,
including cholesterol-lowering medicines like statins, has played an
important role.\2\ To take an AstraZeneca example, CRESTOR, a statin,
was approved by the FDA in 2003. A study of CRESTOR showed that it
reduced cardiovascular mortality and morbidity over the lifetime of the
patient compared to the standard of care, resulting in economic
value.\3\
---------------------------------------------------------------------------
\2\ Sidney S, Quesenberry CP, Jr, Jaffe MG, Sorel M, et al. Recent
trends in cardiovascular mortality in the United States and public
health goals. JAMA Cardiol. 2016;1(5):594-599. doi: 10.1001/
jamacardio.2016.1326.
\3\ Ohsfeldt RL, Gandhi SK, Smolen LJ, et al. Cost effectiveness of
rosuvastatin in patients at risk of cardiovascular disease based on
findings from the JUPITER trial. J Med Econ. 2010;13(3):428-37. doi:
10.3111/13696998.2010.499758.
It is important to note that there are significant risks involved
in developing new therapies. Only approximately 12 percent of therapies
entering clinical study are approved, and the average cost of
development approaches $2.6 billion.\4\ In 2018, return on R&D
investment among larger biopharmaceutical manufacturers fell to 1.9
percent, its lowest point since 2010.\5\ If we are not successful, we
lose our investment in the therapy. Although we are proud of our
success rate, we know that setbacks are inevitable when pushing the
boundaries of science. For example, in 2018, we announced with our
partner Lilly the discontinuation of Phase III clinical trials of
lanabecestat, an investigational treatment for Alzheimer's disease.
Such results are disappointing, but are an integral part of the nature
of scientific discovery.
---------------------------------------------------------------------------
\4\ DiMasi JA, Grabowski HG, Hansen RA. Innovation in the
pharmaceutical industry: new estimates of R&D costs. J Health Econ.
2016;47:20-33. doi: 10.1016/j.jhealeco.2016.01.012.
\5\ Deloitte Centre for Health Solutions. Unlocking R&D
Productivity: Measuring the return from pharmaceutical innovation 2018.
https://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/
articles/measuring-return-from-pharmaceutical-innovation.html.
Given the risks involved in developing a medicine, strong
intellectual property (``IP'') protections and exclusivity for
innovator products are a key component to ensuring that manufacturers
continue to develop therapies that benefit society as a whole. While
they create incentives to innovate, it is important to note that IP
protections and exclusivity for innovator therapies do not generally
prevent other competitor therapies from entering a given class,
allowing robust competition to exist; for example, there are seven
---------------------------------------------------------------------------
different statin molecules approved in the marketplace.
Once these protections expire, generic and biosimilar competitors
can enter the market, which further increases competition. Again,
taking CRESTOR as example, since 2016 when it lost exclusivity, over 16
generic forms have been approved and are available in the market today,
driving prices down very substantially. We strongly support this
construct and policy efforts to encourage competition. We describe
these proposals in section V of this statement.
Finally, it is also worth noting that a significant portion of our
R&D occurs here in the U.S. We invest more than $2.7 billion annually
in U.S.-based R&D work, employing approximately 2,700 people in our
science units within our R&D centers in Maryland, Massachusetts, and
California. Our approach to R&D is consistent with our broader and
long-standing commitment to U.S. jobs in research and manufacturing.
Our largest footprint is in this country, with 12,800 employees
throughout the U.S. Additionally, we recently completed a $200 million
expansion in our Frederick, MD facility where biologics, including
FASENRA for certain patients with severe asthma, and our immuno-
oncology therapy, IMFINZI, are manufactured. This sustained investment
in R&D leads to the creation of high-quality jobs and generates
economic value in the U.S.
To summarize, because we have put science and research at the
center of our company, we have had more success in our R&D pipeline
than ever before, delivering long-term healthcare benefits. This
success, however, is only possible if society remains committed to
supporting investment in innovation.
iii. value of medicines
The investments we make in researching and developing new therapies
cannot occur in a vacuum. We must also ensure that our medicines bring
value to patients, payers, and the health-care system as a whole.
We are only able to stand behind the value of our medicines if that
value is carefully and appropriately defined. In the health-care
industry and as part of policymaking, there is frequent reflection on
the meaning of ``value.'' We believe value must be assessed
holistically and include all costs related to the treatment of a given
condition. In particular, we must consider improvements in clinical
outcomes and quality of life as well as reduction of hospitalizations
and other medical costs.
Additionally, the future savings that prescription medicines can
bring to the healthcare system by preventing more costly interventions
should not be overlooked as their value is considered. A recent study
in Health Affairs of total Medicare spending per beneficiary from 1999
to 2012 found that the spending growth rate slowed to just 1.1 percent
per year on average since 2005. The study found that half of the total
slowdown was attributable to reduced spending growth on cardiovascular
diseases and events, like heart attacks and related conditions.
Increased medication use for conditions like hypertension, high
cholesterol, and diabetes explained half of that effect. The authors
noted that while large, even this impact of medications is likely to be
understated.\6\
---------------------------------------------------------------------------
\6\ Cutler D, Ghosh K, et al., Explaining the Slowdown in Medical
Spending Growth Among the Elderly, 1999-2012. Health Affairs. February
2019. doi: 10.1377/hlthaff.2018.05372.
One of our own therapies--BRILINTA--is an example of a medicine
used in the cardiovascular setting that brings value to both patients
and the broader health-care system. This oral antiplatelet therapy is
indicated to reduce the rate of cardiovascular death, heart attack, and
stroke in patients with acute coronary syndrome (``ACS'') or a history
of heart attacks. For at least the first 12 months following the
diagnosis of ACS, BRILINTA has been shown to be superior to
clopidogrel, a generic oral antiplatelet. In addition, in patients with
ACS, BRILINTA in combination with aspirin resulted in 21 percent
reduction in cardiovascular mortality compared to clopidogrel in
combination with aspirin.\7\
---------------------------------------------------------------------------
\7\ Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus
clopidogrel in patients with acute coronary syndromes. N Engl J Med.
2009;361(11):1045-57. doi: 10.1056/NEJMoa0904327.
In addition, BRILINTA in combination with aspirin also resulted in
lower medical care costs compared to clopidogrel in combination with
aspirin. The lower medical costs are driven primarily by fewer hospital
readmissions and cardiovascular revascularization interventions--
resulting in medical care cost offsets of approximately $1,000 per
patient per year.\8\ This represents countless hours of patient time
better spent with family and friends than in the hospital.
---------------------------------------------------------------------------
\8\ Data on file. 2134602; AstraZeneca Pharmaceuticals LP.
Another example of the value that medicines can provide relates to
the relationship between diabetes and heart failure. In 2015, an
estimated 30.2 million adults in the U.S. had diabetes, with the vast
majority (90-95 percent) having type 2 diabetes.\9\ Up to 50 percent of
patients with type 2 diabetes may develop heart failure.\10\ The
prevalence of heart failure in the U.S. is expected to increase from
5.8 million in 2012 to 8.5 million in 2030.\11\ The total cost of heart
failure, which includes direct and indirect costs, is projected to
increase from $31 billion in 2012 to $70 billion in 2030, with the
majority of these costs (80 percent) related to hospitalization.\12\
---------------------------------------------------------------------------
\9\ Centers for Disease Control and Prevention (CDC). National
Diabetes Statistics Report, 2017. https://www.cdc.gov/diabetes/pdfs/
data/statistics/national-diabetes-statistics-report.pdf.
\10\ American Diabetes Association. CV Disease and risk management:
standards of medical care in diabetes--2019. Diabetes Care.
2019;42(Suppl 1);S103-S123. doi: 10.2337/dc19-S010.
\11\ Heidenreich P, Albert N, Allen L, et al. Forecasting the
impact of heart failure in the United States: a policy statement from
the American Heart Association. Circ Heart Fail. 2013;6:606-619. doi:
10.1161/HHF.0b013e318291329a.
\12\ Id.
Our oral type 2 diabetes product FARXIGA is a sodium-glucose
cotransporter 2 (SGLT2) inhibitor. This newest class of oral diabetes
medication has consistently demonstrated cardiovascular benefits for
diabetes patients that are absent in older diabetes treatments, further
supporting the importance of biopharmaceutical innovation. A recent
cardiovascular outcomes trial demonstrated that FARXIGA significantly
reduced the risk for hospitalization for heart failure or
cardiovascular death.\13\ With initial hospitalizations and
readmissions for heart failure in the Medicare population exceeding
$10,000 for each event in the U.S., it can be readily observed where
these new therapies can help further reduce total cost of care in the
most at-risk patient populations.\14\
---------------------------------------------------------------------------
\13\ Wiviott SD, Raz I, Bonaca MP, et al. for the DECLARE-TIMI 58
Investigators. Dapagliflozin and cardiovascular outcomes in type 2
diabetes [published online ahead of print November 10, 2018]. N Engl J
Med. 2018. http://dx.doi.org/10.1056/NEJMoa1812389. Accessed November
10, 2018.
\14\ Ziaeian B, Heidenreich PA, Xu H, et al. Medicare expenditures
by race/ethnicity after hospitalization for heart failure with
preserved ejection fraction. JACC Heart Fail. 2018;6:388-97. doi:
10.1016/j.jchf.2017.12.007.
In highly complex conditions, the measure of value and
effectiveness can be more multifaceted. In cancer, for example, there
are several end-points to measure effectiveness, such as progression-
free survival and overall survival. To account for this complexity,
cost-effectiveness studies for cancer therapies can measure the value
in providing the medication earlier in the course of treatment. An
example from our portfolio is IMFINZI--currently the only FDA-approved
immunotherapy for the treatment of patients with unresectable stage III
non-small cell lung cancer whose cancer has not progressed following
platinum-based concurrent chemoradiation therapy. Before IMFINZI,
patients in this setting underwent a period of ``watch and wait'' after
chemoradiation,\15\ and for up to 89 percent of these patients their
cancer was likely to spread further.\16\ Based on the PACIFIC trial,
IMFINZI may reduce the risk of death for these patients by nearly a
third.\17\
---------------------------------------------------------------------------
\15\ Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally
advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Annals of Oncol.
Published online July 1, 2017. doi: 10.1093/annonc/mdx222.
\16\ Albain KS, Swann RS, Rusch VW, et al. Radiotherapy Plus
Chemotherapy With or Without Surgical Resection for Stage III Non-Small
Cell Lung Cancer. Lancet. Published online August 1, 2009. doi: 0.1016/
S0140-6736(09)60737-6.
\17\ Antonia SJ, Villegas A, Daniel D, et al. Overall survival with
durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med.
2018;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25.
In a recent analysis, use of IMFINZI was found to be cost-effective
in comparison to the previous ``watch and wait'' approach to treatment.
This cost-effectiveness analysis, published in the Journal of the
American Medical Association in December 2018, indicates that although
IMFINZI consolidation therapy increased national cancer spending,
treating earlier in the course of cancer progression may provide
significant value.\18\
---------------------------------------------------------------------------
\18\ Criss SD, Mooradian MJ, Sheehan DF, et al. Cost-effectiveness
and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy
vs. No Consolidation Therapy After Chemoradiotherapy in Stage III Non-
Small Cell Lung Cancer in the Context of the U.S. Health Care System.
JAMA Oncol. Published online December 13, 2018. doi: 10.1001/
jamaoncol.2018.5449.
For a drug therapy to bring the most value to patients and the
health-care system, it is imperative that the therapy is reaching the
right patients at the right point in their treatment journeys. At
AstraZeneca, we are focused on improving outcomes for patients on a
personalized level by identifying the most appropriate treatments.
Approximately 90 percent of our pipeline now has a precision medicine
approach and reflects the broad range of cutting-edge technologies,
tissue diagnostics, next-generation sequencing and point of care
diagnostics we have introduced. By more precisely matching patients
with the right medicine, we bring greater value to payers and the
health-care system and help to ensure that patients receive the
---------------------------------------------------------------------------
specific therapy that is most appropriate for their treatment needs.
Finally, the concept of value is a key component in our pricing
determinations. AstraZeneca has always taken a thoughtful approach to
pricing, and we continue to do so, considering many factors. In
addition to our significant R&D investments, we consider clinical
value, size of patient population, government/payer coverage
requirements, patient affordability, competition and other market
conditions. We remain committed to pricing responsibly and making our
medicines available and affordable to patients.
iv. commitment to patient access and affordability
Although we are thoughtful in our approach to pricing, we know that
patients continue to face challenges at the pharmacy counter. We fully
recognize that drug therapies cannot bring value to the health-care
system or to patients unless they can access the medicines they need.
Our commitment to affordable access translates into a number of
resources and programs that have helped make our medicines available to
patients.
A. AstraZeneca Savings and Affordability Programs
To ensure that patients in the U.S. are aware of our affordability
programs, we were the first company to include messages about these
programs in all of our U.S. television advertisements. Since 2005,
every televised advertisement has reminded viewers: ``If you can't
afford your medication, AstraZeneca may be able to help.''
We stand behind this statement. Forty years ago, we were one of the
first manufacturers in our industry to establish a patient assistance
program to help low-
income patients obtain certain medicines free of charge. Through our
``AZ&Me'' program, we have provided prescription drug savings to more
than four million patients in the U.S. and Puerto Rico between 2008 and
2018.
In addition to AZ&Me, we offer extensive copay savings programs to
help eligible, commercially insured patients reduce copay costs at the
pharmacy. These copay savings programs are unfortunately not available
to Part D patients and this has created challenges for this population,
reducing adherence to important lifesaving or life-improving
treatments.
B. Value-Based Agreements
We are also working closely with payers and health systems to
explore innovative solutions to improve access and affordability that
demonstrate the value our medicines bring to patients and the health-
care system. For several years, AstraZeneca has been exploring these
types of solutions through value-based agreements where we are willing
to work with health-care stakeholders to tie payment to patient
outcomes.
To date, we have entered into approximately 40 value-based
agreements across our therapeutic areas with a variety of payers,
making AstraZeneca a leader in the field of value-based agreements. As
an example, AstraZeneca agreed with Express Scripts that for IRESSA, an
oral treatment for certain types of lung cancer, we will fully
reimburse Express Scripts for discontinued use before the third fill,
including if discontinuation occurs because patients did not respond to
treatment.
While most of these agreements have been focused on securing
patient access to our medicines and delivering better patient outcomes,
where payers are willing, we are also looking to more directly address
patient out-of-pocket affordability through these innovative
arrangements.
As an example, last month, we announced the initiation of a value-
based agreement for University of Pittsburgh Medical Center (``UPMC'')
Medicare patients who are prescribed BRILINTA. This value-based
contract, which was effective as of January 1, 2019, is groundbreaking
in two ways. First, the contract lowers the out-of-pocket costs for a
UPMC Medicare Part D patient to approximately $10 for a 30-day supply.
Second, what UPMC pays for BRILINTA will vary based on patient
outcomes, tying the cost of the drug to its real-world clinical
performance.
We are currently exploring another value-based agreement in
Medicare Part D. In addition to having a significant outcomes-based
component, this arrangement would reduce patient out-of-pocket costs.
This type of agreement allows patients to access their medicines at a
lower out-of-pocket cost and payers to control their overall health-
care costs through paying for outcomes.
However, there remain significant operational and regulatory
hurdles to the broader implementation of value-based agreements.
Operational challenges include capturing appropriate data and other
capabilities on the part of payers that are needed to successfully
execute these arrangements. For example, value-based agreements
typically require plans to have systems in place to report measures
like adherence and readmissions. While many payers and health systems
are evolving to meet the needs of the changing health-care environment,
greater investments need to be made in data capabilities. In addition,
policy and regulations must advance to support value-based agreements
in becoming a standard approach to reimbursement.
We believe that there are steps the government can take to address
these challenges to help encourage the timely adoption of value-based
agreements, including in public sector programs like Medicare. These
recommendations are described in more detail in section V of this
statement. Through the partnership of payers and policymakers, we look
forward to a future where implementation of value-based agreements
across public and private payers is widespread.
C. Discounts and Rebates
Finally, we negotiate rebates and discounts with payers and
pharmacy benefit managers (``PBMs'')--including in Medicare Part D--to
help ensure that our therapies have the most robust access possible.
Without providing these discounts and rebates, many life-savings
medicines would not be placed on plan formularies and therefore would
be largely unavailable to the patients who need them most. Our
estimates for 2018 show that across our products, our average rebate is
nearly 50 percent of our gross revenues in the U.S. Taking BRILINTA as
an example, approximately one third of gross revenue is provided back
in rebates. For most of our diabetes therapies, rebates well exceed 50
percent of gross revenues.
Over the past several years, discounts and rebates for our
therapies have increased overall, both in the commercial sector and
Part D. In recent years, in our primary care portfolio, which includes
the majority of our therapies, we have seen flat to declining net
effective prices to AstraZeneca for most of our products. Taking
CRESTOR as an example, in the 5-year period before it lost exclusivity,
even though list price increased, in 2011, CRESTOR's average net
effective price earned by AstraZeneca was $2.52 per day (one pill per
day). In 2016 when CRESTOR lost exclusivity, the average net effective
price was again $2.52.
However, discounts and rebates do not necessarily translate to
lower cost-sharing for patients. There are a series of factors that
impact a patient's out-of-pocket costs, including individual insurance
plan benefit design (copayments, coinsurance, and deductibles),
formulary placement, provider access, and assistance programs or
savings offers. As a science-led, patient-focused company, the fact
that many patients struggle with out-of-pocket costs despite the
discount and rebates we provide stands counter to our mission of
improving patient health.
v. the path forward: evolving the current system
Despite rapidly increasing rebate amounts, affordability of drug
therapies is an increasingly significant public policy and public
health issue. We agree that the current system is not sustainable--for
patients, payers, and society as a whole--and we are committed to
engaging across stakeholders to develop a new paradigm that improves
affordability and access for patients while ensuring that manufacturers
can continue to develop innovative therapies.
To achieve these goals of improving affordability and supporting
innovation, we must progress from a volume-based to a value-based
health-care system. We continue to be forward-leaning in this regard,
and we encourage other stakeholders to join us in the effort to deliver
and pay for health care, including drug therapies, in a more
affordable, efficient, and effective way.
An important step is to evolve the current system of paying for and
delivering drug therapies to one in which patients more directly
benefit from the discounts and rebates we provide. Specifically, we
believe that patient cost-sharing should be more aligned to a product's
net price as opposed to its list price, as is the case today.
However, as we look ahead to the future, even more must be done to
improve patient affordability and to truly build a health-care system
based on the value of therapies provided to patients.
A. Value-Based Agreements Should Be the Future Standard
First, in a future system, the default approach should be that
pricing and reimbursement for drug therapies are tied to patient
outcomes and the value the particular therapy provides. As such, it is
imperative that manufacturers and payers--including Part D plans--
engage in value-based agreements similar to the IRESSA and BRILINTA
examples referenced previously. Policies to encourage these
arrangements and to reduce or eliminate existing challenges will be
essential to their long-term success. To that end, AstraZeneca
appreciates the support of Senators Warner and Cassidy for value-based
agreements, as demonstrated by their requests for input on the Patient
Affordability Value and Efficiency (``PAVE'') Act. This draft
legislation would promote the development of value-based agreements by
offering increased flexibility for manufacturers to enter into such
arrangements, including with Medicare Part D plans.
In addition to the policies outlined in the PAVE Act, there are
other ways that the government could facilitate value-based agreements.
For example, the Department of Health and Human Services (``HHS'')
should consider how its recent proposed rule regarding PBM rebates can
be structured to protect existing and future value-based agreements. We
appreciate that HHS solicited comments on this topic, and we look
forward to sharing our perspective in our written comments to the
proposal. In addition, to encourage utilization of agreements that best
address the government's goals, we recommend that HHS develop a
prioritized list of clinical outcomes measures for manufacturers and
payers to consider when developing outcomes-based agreements.
Over the past several years, we have engaged with HHS, and
specifically the Center for Medicare and Medicaid Innovation
(``CMMI''), to advance specific models involving our therapies in the
Medicare program. To date, we have not been able to execute on a model
with HHS or CMMI and the feedback we have received is that company-
specific models are challenging to implement. We look forward to
continued dialogue on these issues, and we hope to work with HHS, CMMI
and other stakeholders to develop a scalable framework in which
innovative models can be implemented in an appropriate way.
B. All Patients, Including Medicare Patients, Should Benefit From
Reduced Cost-Sharing
Second, a future system should be designed to ensure that all
patients benefit from lower cost-sharing, including those patients
taking drug therapies on the Part D specialty tier. A recent study
found that rates of prescription abandonment and delayed initiation of
oral cancer therapies increase as cost-sharing amounts rise.\19\ Such a
result reflects the need for a restructuring of the current benefit
design for specialty products.
---------------------------------------------------------------------------
\19\ Doshi JA, Li P, Petit AR, et al. Association of Patient Out-
of-Pocket Costs With Prescription Abandonment and Delay in Fills of
Novel Oral Anticancer Agents. J Clin Oncol. 2018; 36(5): 476-482. doi:
10.1200/JCO.2017.74.5091.
Under one potential approach, a portion of manufacturer discounts
could be used to fund a reduction in cost-sharing for patients facing
the highest cost-sharing amounts. This could be accomplished by
establishing a monthly or annual out-of-pocket cap, which would give
patients greater certainty in the total amount of out-of-pocket costs
they could face. The cap would provide a safety-net for patients that
could be funded by a portion of the discounts provided across all Part
D products. Such an approach would help ensure that more patients
benefit from the discounts manufacturers provide.
C. Use of Biosimilars Should Be Supported
Third, we believe that competition is a key component to reducing
costs, and that is why we support expanded use of biosimilars in the
U.S. As a global company, we operate in countries, particularly those
in the European Union, where biosimilar competition is particularly
robust. We support a similarly vigorous biosimilars market in the U.S.
We therefore appreciate the efforts of the FDA to increase the
availability of biosimilars in the U.S., including the FDA's
development of a Biosimilars Action Plan. We support efforts to
streamline and improve the efficiency of the biosimilars approval
pathway for the benefit of patients.
We also support reimbursement policies that facilitate the uptake
of biosimilars. Such policies include Medicare reimbursement rates that
ensure that biosimilars can compete on equal footing with innovator
products.
d. market-based competition should be maintained
Finally, it is imperative to maintain market-based competition
between manufacturers and between plans. Market-based competition plays
an important role in keeping costs down. This is how the lifecycle of
innovator therapies works today when competitors enter the market and
generic medicines become available over time.
The competitive market in the U.S. also provides patients with
access to innovative medicines faster. For example, American patients
have access to cancer medicines about 2 years earlier than patients in
other countries, including Germany, France, and the U.K.\20\ This
timely access to new cancer therapies is correlated with improved
survival rates; from 1997 to 2012, rates of cancer mortality fell by 20
percent in the U.S., compared to a 15 percent reduction in the U.K.\21\
Additionally, nearly 90 percent of newly launched medicines from 2011
to 2017 were available in the U.S., compared to just two-thirds in the
U.K., half in Canada and France, and one-third in Australia; and of 14
new diabetes medicines launched over that period, only one was
available in France.\22\ Given the benefits brought to patients by new
antidiabetic agents such as SGLT2 inhibitors (reduction in heart
failure and hospitalizations for heart failure), U.S. patients and
payers greatly benefit from the earlier introduction of these
innovative medicines.
---------------------------------------------------------------------------
\20\ PhRMA analysis of IMS Consulting Group ``Patient Access to
Innovative Oncology Medicines Across Developed Markets.'' June 2016.
\21\ World Health Organization (WHO). WHO mortality database.
http://www.who.int/healthinfo/mortality_data/en. PhRMA analysis of WHO
mortality database, using age--specific death rates.
\22\ PhRMA analysis of IQVIA Analytics.
While the current system needs reform, some of the benefits to the
current structure are the speed of access and reimbursement of new
medicines and the robust nature of the negotiations between
manufacturers and PBMs, which in turn creates competition between
manufacturers. As the system evolves, it is important that this ability
to compete is maintained. Therefore, there must be flexibility to
continue to negotiate net price by product and indication, among other
---------------------------------------------------------------------------
factors.
This flexibility is necessary not only to maintain competition, but
also to facilitate additional innovations in the way drugs are priced
and reimbursed. For example, variable discounts could be used to reduce
cost-sharing for patients over time as they remain adherent to their
medications. Additionally, we support the concept of indication-based
pricing, which recognizes that the value of a drug therapy with more
than one indication may vary based on indication. Indication-based
pricing would allow greater competition among manufacturers based on
the clinical efficacy of their therapies on an indication-by-indication
basis. Allowing discounts to vary based on the indication for which a
therapy is prescribed will be key to facilitating indication-based
pricing.
Finally, we would like to acknowledge that the coverage and
reimbursement policies in Medicare Part B have been criticized for not
sufficiently encouraging price competition for physician-administered
drug therapies. We are supportive of reforms in the Medicare Part B
program to address these concerns. Such reforms could include an
inflation penalty if a manufacturer's price increase exceeds a certain
threshold, as well as steps to ensure that the government and Medicare
patients more directly benefit from the discounts and rebates provided
in the commercial sector. Similar to the suggestion above on creating a
Part D out-of-pocket cap funded by a portion of manufacturer discounts,
the savings generated from an inflation penalty and increased
competition in Part B could be used to fund an out-of-pocket cap for
Medicare Part B patients.
Competition is a fundamental requirement to reducing costs over
time, both in Medicare Part B and Part D. Flexibility in the future
system will be necessary to maintain competition and to explore
additional innovations in the pricing and reimbursement of drug
therapies. We must also be willing to work together to improve the
efficiency of the Part B program. We look forward to working with
policymakers and other stakeholders to shape the future system to
accomplish these goals.
vi. conclusion
Although there is no single solution to the challenges we face, we
welcome the opportunity to speak with you about ways to evolve our
health-care system. We share your concern that many patients are facing
challenges with out-of-pocket costs, and we are committed to working
towards solutions that support patient access and affordability while
sustaining innovation. AstraZeneca, along with many others in the
pharmaceutical industry, is innovating to discover and develop
tomorrow's cures and treatments, and we know we need to be a
constructive partner to find solutions to ensure that patients benefit
from the therapies we develop.
______
Questions Submitted for the Record to Pascal Soriot
Questions Submitted by Hon. Chuck Grassley
Question. At the hearing, you testified that AstraZeneca does not
withhold samples from generic manufacturers in order to block generic
versions of your drug from entering the market. You also expressed your
support for the ``Creating and Restoring Equal Access to Equivalent
Samples Act,'' also known as the CREATES Act. However, the FDA has a
list on its website which identifies reference listed drug (RLD) access
inquiries where brand manufacturers may have prevented generic
companies from obtaining samples of products necessary to support FDA
approval. AstraZeneca is on this FDA list. This would appear to
contradict your testimony at the hearing that AstraZeneca has not
withheld samples of their products to delay generic competition.
Could you please explain in detail why AstraZeneca is on the FDA
list?
Answer. AstraZeneca appreciates the opportunity to address the
question of one of our medicines, BRILINTA (ticagrelor) appearing on
the Reference Listed Drug Access Inquiries list (RLD List). We would
first like to state that AstraZeneca supports allowing generic
manufacturers access to samples. Withholding or otherwise blocking such
access is inconsistent with that position. Our internal review has not
identified any unanswered, delayed, or outstanding requests for samples
of BRILINTA by any generic manufacturers.
It is our understanding that BRILINTA was included on the RLD List
based on a single inquiry received by the FDA. Unfortunately, the RLD
List does not identify the company that reportedly requested
information (or samples) from AstraZeneca, the date the information was
requested, or any other information that would allow AstraZeneca to
better understand or further investigate the circumstances of this
inquiry. On its website, the FDA does advise that it has ``not
independently investigated or confirmed the access limitations
described in the inquiries received.'' \1\ Given this limitation, the
listing of an inquiry on the RLD List does not mean that the FDA has in
fact determined that access to samples by generic manufacturers was
limited or withheld for the medicines identified. Indeed, based on our
internal review, we have not identified any circumstances that
substantiate the inquiry received by the FDA relating to BRILINTA.
---------------------------------------------------------------------------
\1\ Reference Listed Drug (RLD) Access Inquiries, U.S. Food and
Drug Administration, https://www.fda.gov/Drugs/
DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/
ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/
ucm607738.htm (last updated Feb. 7, 2019).
Question. Could you please explain in detail the discrepancy
---------------------------------------------------------------------------
between your testimony and the FDA list?
Answer. AstraZeneca is not aware of any instances where the company
has withheld or otherwise blocked access to samples by generic
manufacturers. Based on our internal review, AstraZeneca is not aware
of any unanswered, delayed, or outstanding requests for samples of
BRILINTA by any generic manufacturers.
In addition, BRILINTA is and has always been available via normal
commercial distribution channels (i.e., wholesalers) since its U.S.
launch. It has never had a restricted distribution program.
Finally, more than 15 generic manufacturers have applied for
regulatory approval from the FDA for the manufacture of generic
ticagrelor and some, like Watson/Teva, have received tentative
approvals from the FDA. Because conducting bioequivalence studies with
the branded medicine is an FDA pre-approval requirement, it is clear
that these generic manufacturers are not having difficulty accessing
branded ticagrelor for their studies.
In light of the context provided above, it is unclear why any
generic manufacturer would be unable to obtain a sample of BRILINTA for
their purposes or why an inquiry was lodged with the FDA related to
this medicine.
Question. Has AstraZeneca ever blocked access to samples?
Answer. AstraZeneca is not aware of instances where the company has
refused to sell samples or has otherwise blocked access to samples by
generic manufacturers.
Question. The Department of Health and Human Services' proposed
rule, ``Fraud and Abuse; Removal of Safe Harbor Protection for Rebates
Involving Prescription Pharmaceuticals and Creation of New Safe Harbor
Protection for Certain Point-of-Sale Reductions in Price on
Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager
Service Fees,'' envisions that drug manufacturers will offer up-front
discounts rather than the back-end rebates that are now commonly
provided. Some observers argue that a 1996 court case called into
question whether manufacturers could offer up-front discounts,
resulting in today's rebate-based system. I've heard differing opinions
as to whether the issues related to the initial court case are still
relevant.
If the HHS proposed rule is finalized, can you assure the committee
that your company will offer up-front discounts? If not, why?
Answer. If the HHS proposed rule is finalized largely as proposed,
AstraZeneca intends to comply with its requirements and use point-of-
sale discounts.
Question. Please describe how you expect your company to respond to
the HHS proposed rule to eliminate safe harbor protection for back-end
rebates in Medicare Part D that is referenced above if it is finalized.
Assuming you are confident that antitrust laws do not prevent your
company from offering up-front discounts, specifically, do you envision
that your company lowers the list price of a drug to the current after-
rebate net price, offer discounts equal to the current rebate amount,
or a combination of both?
Answer. Assuming the HHS rebate rule is finalized largely as
proposed, AstraZeneca intends to comply with its requirements and use
point-of-sale discounts. Our goal is to maintain net prices broadly in
line with today, recognizing our ability to do so may be dependent on
external factors and market response such as how plans evolve their
benefit design and the total degree of transparency under the new
model.
AstraZeneca would plan to reduce list prices, pending reforms
across all payers, including in the commercial sector in addition to
Part D, as the current construct does not allow for two separate list
prices (i.e., one list price for Part D and a different list price for
the commercial sector). Therefore, we also support efforts to eliminate
rebates in the commercial sector, and recommend that Congress explore
such legislation. While eliminating rebates is an important step,
benefit designs must also be evaluated.
Question. To what extent are the back-end rebates your company
currently offers contingent on the amount of market share realized for
your drugs as a result of Part D plan formulary placement and other
techniques?
Answer. Our arrangements in Part D do not include a market share
component.
Question. Please provide a breakdown of percentage of sales that go
to each payer (including Medicare, Medicaid, private pay, other) and a
similar percentage by volume of the total number of each drug compared
to total volume. Please provide this data for the most recent year
available.
Answer. Below you will find our estimated relative payer split of
Gross Product Sales in the U.S., for the year ending December 31, 2018.
------------------------------------------------------------------------
Total Products
----------------------------- Sales $ Millions Proportion of Total
Payer Business
------------------------------------------------------------------------
Medicaid 1,826,337 11.0%
------------------------------------------------------------------------
Fed Gov't (VA, DOD, CDC, 2,986,585 18.1%
PHS)
------------------------------------------------------------------------
GPO/LTC 1,362,663 8.2%
------------------------------------------------------------------------
Commercial 5,019,907 30.4%
------------------------------------------------------------------------
Medicare Part D 3,514,858 21.3%
------------------------------------------------------------------------
Tricare 70,799 0.4%
------------------------------------------------------------------------
Non-Contracted Sales/Other 1,756,851 10.6%
------------------------------------------------------------------------
Total 16,538,000 100.0%
------------------------------------------------------------------------
Question. Do your companies hire consultants or lobbyists to
promote products at State Medicaid Pharmacy and Therapeutics
Committees? To whom do you disclose advocacy activities surrounding
State Medicaid programs, if at all?
Answer. AstraZeneca does not utilize consultants or lobbyists to
promote medicines at State Pharmacy and Therapeutics (P&T) Committees.
However, AstraZeneca Medical Affairs personnel may engage in peer-to-
peer medical discussions with members of the medical community
including Medicaid P&T committee members.
AstraZeneca has comprehensive internal policies that oversee
interactions between AstraZeneca employees and government officials.
Federal and state laws and regulations also govern lobbying activities,
and AstraZeneca complies with the attendant disclosure requirements.
Question. Please describe how the costs of patient assistance
programs are accounted for within your company's financial statements.
Please also describe the types of market information, such as
prescribing and use patterns, that your company collects from different
types of patient assistance programs and patient hub services.
Answer. AZ&MeTM Prescription Savings Program (Patient
Assistance Program):
In furtherance of its objective of ensuring patient access,
AstraZeneca was one of the first manufacturers in the industry to
establish a patient assistance program to facilitate access to certain
medicines for uninsured and underinsured low-income patients. This
program, known as AZ&Me, provides eligible patients with medicines at
no cost.
We account for the costs of medicines provided through the AZ&Me
program as a component of our Operating Expenses.
In connection with the AZ&Me program, AstraZeneca collects general
program enrollment data such as number of patients in the program and
medicine provided.
Access 360TM (Patient Hub):
AstraZeneca's patient hub, Access 360, is a reimbursement support
program that provides patients and their healthcare providers with
limited access and reimbursement support for AstraZeneca specialty care
medicines. Access 360 collects patient, provider and payer coverage
data in conjunction with appropriate patient opt-ins to administer the
limited reimbursement services offered by the program.
Question. Please provide a list of all contributions since January
1, 2014, that your company has made to any tax exempt organizations
working on issues related to drugs within your product lines, including
but not limited to patient groups, disease awareness groups, medical or
professional societies, universities or hospitals, industry
associations or leagues. For each contribution, please provide the name
of the organization that received the donation, the date the donation
was made, the amount of the donation, and a description of the purpose
of the contribution (i.e., was the contribution for the general fund, a
specific purpose to a specific program, or continuing medical
education). Please also note whether the contribution was unrestricted
or restricted; if it was restricted, please explain all restrictions.
Finally, if your company maintains a foundation or other separate
charitable arm, please provide the name of all such entities, and list
all donations made from that entity or entities.
Answer. Our commitment to improving the lives of patients goes
beyond our innovative medicines. We place significant value on
collaboration and partnerships, including work done by non-profits,
patient advocates, medical professionals, and researchers. To that end,
we provide support for eligible programs through corporate
contributions, research support, fellowships, and medical education
grants. We also support conferences and initiatives for healthcare
professionals and scientists.
AstraZeneca believes in providing information to the public about
our company, our medicines and about how we do business. In 2008, we
began publishing biannual reports of our contributions to nonprofit
organizations. We use contributions as our umbrella term for financial
support to nonprofit organizations contributing to the public good
(e.g., donations, sponsorships, and partnerships).
The below data reflects the total value of contributions made by
AstraZeneca to nonprofit organizations in the U.S. in the years 2014-
2018. A full list of contributions, including the recipient
organization, associated program name, and amount of each contribution,
can be found here: https://www.astrazeneca-us.com/sustainability/
Corporate-transparency/grants-and-contributions-disclosure.html.
2018: $18.3 million
2017: $5.5 million
2016: $10.9 million
2015: $19.8 million
2014: $15.5 million
In addition, in 1993, AstraZeneca founded the AstraZeneca
HealthCare Foundation, a 501(c)(3) entity. The AstraZeneca HealthCare
Foundation aims to promote public awareness surrounding healthcare
issues, further public education and medical knowledge, and support
charitable and qualified exempt organizations whose work aligns with
the Foundation's charitable goals.
In furtherance of AstraZeneca's commitment to improving health, in
2010 the AstraZeneca HealthCare Foundation launched the Connections for
Cardiovascular HealthSM (CCH) program. With the mission of
improving cardiovascular health in the U.S., CCH awards grants to U.S.-
based nonprofit organizations whose work supports CCH's mission. Since
its launch, CCH has awarded nearly $23 million to 52 organizations
working to prevent cardiovascular disease.
The below data reflects the approximate total value of grants made
by CCH per year between 2014 and 2018. A full list of grants, including
the recipient organization, associated program name, and amount of each
contribution, can be found here: https://www.astrazeneca-us.com/
sustainability/healthcare-foundation/connections-for-cardiovascular-
health.html#past-grant-awardees--0.
2018: $1.2 million
2017: $993,880
2016: $1.8 million
2015: $1.9 million
2014: $2.6 million
AstraZeneca also awards medical education grants and scientific
sponsorships. These grants are offered to support independent medical
education, scientific sponsorships, and fellowship or healthcare
professionalin-training. Grants are offered for conduct of programs,
are awarded on the basis of individual applications through our medical
education grants process, and are not conditioned on services. This
process and all grant decisions are managed independently within our
Medical Affairs group and have no connection to our sales and marketing
departments.
The below data reflects the approximate total value of medical
education grants made by AstraZeneca per year, since 2014. A full list
of medical education grants offered to non-profit organizations,
including the recipient organization, associated program name, date,
and amount of each contribution, can be found in Appendix A.
2018: $28.9 million
2017: $17.5 million
2016: $11.6 million
2015: $24.9 million
2014: $14.8 million
Question. Pay-for-delay agreements cost consumers and taxpayers
billions in higher drug costs every year. The FTC has gone after drug
companies that enter into these settlements where the brand pays the
generic company to keep its lower cost alternative off the market. I'm
the lead Republican sponsor of S. 64, the Preserve Access to Affordable
Generics and Biosimilars Act, which would help put an end to these
deals.
Do you agree that these pay-off agreements keep drug costs high for
patients because they delay competition?
Answer. AstraZeneca has confidence in patents that protect our
medicines and, where appropriate, we file lawsuits to protect our
intellectual property.
AstraZeneca does not enter into ``pay-off agreements,'' if those
are understood to include settlements that pay generic competitors to
delay entry into the market. AstraZeneca engages in patent settlements
but we do not believe these resolutions contribute to increased prices.
In the absence of a settlement, a generic would not necessarily prevail
in the patent litigation and therefore would not be able to enter the
market. Indeed, AstraZeneca has entered into many early-entry patent
settlements that allow generic manufacturers to license innovator
patents and thereby permit generic competition before expiration of
AstraZeneca's patent rights.
Settlement agreements that permit entry of generic drugs before
expiration of relevant patent rights do not stifle competition but
instead permit early entry by resolving patent disputes that would
otherwise prevent generic alternatives to branded medication.
All of AstraZeneca's patent settlements fully comply with the law.
These settlements provide increased clarity and stability to both
parties, allowing innovators like AstraZeneca to continue investing
substantially in new medicines for patients and frequently allowing
generic competitors to enter the market before expiration of
AstraZeneca's patent rights.
Question. Has your company ever entered into these kinds of
settlements with a generic company?
Answer. AstraZeneca does not enter into settlements that pay
generic competitors to delay entry into the market.
Question. Do you support the pay for delay bill?
Answer. While AstraZeneca supports efforts to curb patent
settlement abuses, we have concerns about the Preserve Access to
Affordable Generics and Biosimilars Act in its current form. For
example, the proposed legislation would be retroactive to 2013 and
would unfairly subject to potential scrutiny lawful settlements entered
into based on the then existing legal construct. As a general matter,
AstraZeneca believes that patent settlement agreements are pro-
competitive because they can permit entry of generic drugs before
expiration of relevant patent rights.
rebate traps/walls
Question. I'm increasingly concerned about the effect of so-called
``rebate traps'' or ``rebate walls'' on patients' access to quality,
lower cost medicine. I understand there is ongoing litigation
challenging these practices as anti-competitive.
Does your company engage in the bundling of rebates over multiple
products? If so, why? And what benefit does the consumer gain from
that?
Answer. AstraZeneca offers portfolio discount arrangements to
improve patient access and affordability across multiple medicines,
thus ensuring the right medicine can be prescribed for the right
patient. Portfolio discounting allows manufacturers and plans another
mechanism to negotiate for formulary access for the patient, in
addition to single-medicine discounts and rebates. Irrespective of the
approach to discounting, AstraZeneca also ensures discounts are
appropriately reported in government price reporting metrics (e.g.,
Best Price, Average Manufacturer Price, and Average Sales Price).
Question. Does your company view these practices as anticompetitive
or harmful to patients' access to quality, lower cost medicine?
Answer. AstraZeneca does not view these practices as
anticompetitive or harmful to patients' access. In fact, AstraZeneca
offers portfolio discount arrangements to improve patient access and
affordability.
Question. If a policy were adopted to eliminate rebates, or to
require that rebate savings be passed on to the consumer, would that in
and of itself solve the issue of rebate ``traps'' and ``walls''? And
would consumers benefit from such a policy?
Answer. AstraZeneca believes that evolving the current system of
paying for and delivering drug therapies to one in which patients more
directly benefit from the discounts and rebates that AstraZeneca
provides is an important step towards improving affordability and
supporting innovation. This can best be accomplished by eliminating
rebates in Medicare Part D and the commercial sector, which would
create competition between manufacturers on net price instead of rebate
amounts, thereby helping to eliminate rebate ``traps'' and ``walls.''
AstraZeneca also believes that patient cost-sharing should be more
aligned to a medicine's net price, and that eliminating rebates and
moving to a point-of-sale discount model should help accomplish this
goal. Additionally, it is important to note that lowering list prices
in the U.S. without addressing broader challenges, including benefit
design, will not improve affordability for many patients. While
eliminating rebates is an important step, benefit designs must also be
evaluated.
drug pricing
Question. When setting the list price of a drug, does your company
consider regulatory costs or compliance? If so, how specifically do
those factors affect the list price of a drug? Please provide at least
one specific example, if applicable, from your current product
portfolio.
Answer. AstraZeneca does not directly consider regulatory or
compliance costs when setting the list price of a drug. AstraZeneca's
approach to pricing across all medicines is driven by a number of
factors, including clinical value, patient access and affordability,
patient population, government and payer coverage requirements, RandD
expenditures, manufacturing costs, and competitive dynamics.
AstraZeneca is mindful of healthcare costs and is continuously
exploring innovative opportunities and solutions to deliver medicines
while considering cost and value. In setting drug prices, AstraZeneca
takes into account both the budget impact to payers (including Medicare
and pharmacy benefit managers (PBMs)) as well as patient out-of-pocket
costs to maintain patient access to needed medication. AstraZeneca has
also been a leading innovator in developing alternate payment
structures for its medicines. In particular, AstraZeneca has emphasized
value-based agreements, which, broadly speaking, seek to link access,
reimbursement or price, to a demonstrated clinical benefit or outcome.
Question. When setting the list price of a drug, does your company
consider the risk of liability or litigation? If so, how specifically
do those factors affect the list price of a drug? Please provide at
least one specific example, if applicable, from your current product
portfolio.
Answer. AstraZeneca does not consider the risk of liability or
litigation when setting the list price for a particular drug.
______
Questions Submitted by Hon. Pat Roberts
Question. What role do you see value-based arrangements (VBAs)
playing in the effort to reduce prescription drug costs? What potential
do these arrangements have to find the ``sweet spot'' between
controlling costs to patients and encouraging innovation of new drugs?
Answer. We believe medicines are part of the solution to
controlling health-care costs. They not only improve patient outcomes
and increase quality of life, but also reduce downstream costs. Value-
based agreements allow us to reimburse the health-care system if our
medicines do not deliver as intended. This solution demonstrates our
willingness to stand behind the value of our medicines.
AstraZeneca is working closely with payers and health systems to
explore innovative solutions to improve access and affordability that
demonstrate the value our medicines bring to patients and the health-
care system. Our value-based agreements aim to manage the totality of
treatment costs and keep people healthy and out of the hospital. For
several years, AstraZeneca has been exploring these types of solutions
through value-based agreements where we are willing to work with
health-care stakeholders to tie payment to patient outcomes.
To date, we have entered into approximately 40 value-based
agreements across our therapeutic areas with a variety of payers,
making AstraZeneca a leader in the field of value-based agreements.
As an example, and as noted in the written testimony submitted to
the Senate Committee on Finance, AstraZeneca agreed with Express
Scripts that for IRESSA, an oral treatment for certain types of lung
cancer, we will fully reimburse Express Scripts for discontinued use
before the third fill, including if discontinuation occurs because
patients did not respond to treatment.
Question. How can VBAs help lower what patients pay out-of-pocket?
Answer. While most of these agreements have been focused on
securing patient access to our medicines and delivering better patient
outcomes, where payers are willing, we are also looking to more
directly address patient out-of-pocket affordability through these
innovative arrangements.
Our ambition is that these agreements will evolve to enable
reimbursement back to a payer to be shared with the patient when
medicines do not perform as expected.
As an example where a value-based agreement directly reduced out-
of-pocket costs for patients, we recently announced the initiation of a
value-based agreement for University of Pittsburgh Medical Center
(UPMC) Medicare patients who are prescribed BRILINTA. This value-based
contract, which was effective as of January 1, 2019, is groundbreaking
in two ways. First, the contract lowers the out-of-pocket costs for a
UPMC Medicare Part D patient to approximately $10 for a 30-day supply.
Second, what UPMC pays for BRILINTA will vary based on patient
outcomes, tying the cost of the medicine to its real-world clinical
performance.
We are currently exploring another value-based agreement in
Medicare Part D. In addition to having a significant outcomes-based
component, this arrangement would reduce patient out-of-pocket costs.
This type of agreement allows patients to access their medicines at a
lower out-of-pocket cost and payers to control their overall healthcare
costs through paying for outcomes.
Question. Can Congress do more to allow for and encourage the use
of VBAs?
Answer. We believe that there are steps the government can take to
address challenges and help encourage the timely adoption of value-
based agreements, including in public sector programs like Medicare.
For example, at this time, the current Anti-Kickback Safe Harbor
(AKS) regulations do not expressly address value-based agreements.
Accordingly, manufacturers must seek to structure value-based
agreements to meet the requirements of existing safe harbors from the
AKS, such as the discount safe harbor and personal services safe
harbor, that were created for purposes other than value-based
agreements. Although we believe that value-based agreements can
strongly benefit patients and the health-care system overall, the lack
of clarity in application of the safe harbors to value-based agreements
creates regulatory uncertainty that discourages broader implementation
of value-based agreements in public-sector programs.
In addition to the risk of AKS liability, value-based agreements
present other regulatory challenges that manufacturers must navigate.
For example, manufacturers must manage complex government price
reporting calculations that may not account for price fluctuations over
time that may be associated with a value-based agreement.
In a future system, the default approach should be that pricing and
reimbursement for drug therapies are tied to patient outcomes and the
value the particular therapy provides. As such, it is imperative that
manufacturers and payers--including Medicare plans--engage in value-
based agreements similar to the IRESSA and BRILINTA examples referenced
previously.
Policies to encourage these arrangements and to reduce or eliminate
existing challenges will be essential to their long-term success. To
that end, AstraZeneca appreciates the support of Senators Warner and
Cassidy for value-based agreements, as demonstrated by their requests
for input on the Patient Affordability Value and Efficiency (PAVE) Act.
This draft legislation would promote the development of value-based
agreements by offering increased flexibility for manufacturers to enter
into such arrangements, including with Medicare Part D plans by
addressing AKS and government pricing concerns.
This legislation is particularly important given the
administration's proposal to eliminate PBM rebates under the discount
safe harbor. Currently, many value-based agreements are structured
using a rebate agreement, under which the terms of a discount are based
on clinical or cost outcomes measures. Therefore, the elimination of
discount safe harbor protection for rebates without an exception for
value-based agreements could inadvertently reduce incentives for value-
based agreements, which we do not believe is the administration's
intent. We have therefore recommended to HHS that value-based
agreements are exempt from the proposed changes to the discount safe
harbor and we encourage members of Congress to support this exemption.
Through the partnership of payers and policymakers, we look forward
to a future where implementation of value-based agreements across
public and private payers is widespread.
______
Questions Submitted by Hon. John Cornyn
Question. We continue to hear that rebates negotiated off of the
list price of a drug are both good and bad. Pharmacy benefit managers
and plans have argued that rebates are used to lower premiums across
the board and that it is the best way to seek a price concession on
otherwise expensive drugs. Your industry argues that these payers are
insisting on higher rebates that can only be achieved by raising list
prices. But patients often lose under this system, with out of pocket
costs being tied to list price. Insulin patients appear to be routinely
impacted by this perversity in the system.
Please explain to the committee how your company would reduce list
prices if rebates were no longer a part of the equation?
Answer. Assuming the HHS rebate rule is finalized largely as
proposed, AstraZeneca intends to comply with its requirements and use
point-of-sale discounts. Our goal is to maintain net prices broadly in
line with today, recognizing our ability to do so may be dependent on
external factors and market response such as how plans evolve their
benefit design and the total degree of transparency under the new
model.
AstraZeneca would plan to reduce list prices, pending reforms
across all payers, including in the commercial sector in addition to
Part D, as the current construct does not allow for two separate list
prices (i.e., one list price for Part D and a different list price for
the commercial sector). Therefore, we also support efforts to eliminate
rebates in the commercial sector, and recommend that Congress explore
such legislation. While eliminating rebates is an important step,
benefit designs must also be evaluated.
Question. What assurance can you provide that you would in fact
lower your prices?
Answer. Assuming the HHS rebate rule is finalized largely as
proposed, AstraZeneca intends to comply with its requirements and use
point-of-sale discounts. Our goal is to maintain net prices broadly in
line with today, recognizing our ability to do so may be dependent on
external factors and market response such as how plans evolve their
benefit design and the total degree of transparency under the new
model.
AstraZeneca would plan to reduce list prices, pending reforms
across all payers, including in the commercial sector in addition to
Part D, as the current construct does not allow for two separate list
prices (i.e., one list price for Part D and a different list price for
the commercial sector). Therefore, we also support efforts to eliminate
rebates in the commercial sector and recommend that Congress explore
such legislation. While eliminating rebates is an important step,
benefit designs must also be evaluated.
Question. What actions should be taken to ensure that patients are
actually seeing the benefits of lower out-of-pocket costs?
Answer. In the absence of rebates, the market incentives for the
differential between list and net price should be reduced because
manufacturers will be competing on the basis of net price instead of
rebate amounts. Because Part D patient cost-sharing is currently based
on list price and not net price, this change may also result in lower
cost-sharing for patients. Additionally, it is important to note that
lowering list prices in the U.S. without addressing broader challenges,
including benefit design, will not improve affordability for many
patients. While eliminating rebates is an important step, benefit
designs must also be evaluated.
AstraZeneca also supports monthly and annual out-of-pocket caps in
Medicare Part D to further ensure that patients see the benefits of
lower out-of-pocket costs.
Question. If rebates are driving high list prices for drugs as drug
manufacturers' claim, why do you think that Part B drugs, which have no
PBM rebates, are also seeing significant price increases? Whose fault
is that?
Answer. For our Part B products, price increases are modest and
generally in line with inflation. We are supportive of competition,
including policies that support more widespread use of biosimilars.
______
Questions Submitted by Hon. Steve Daines
Question. As an advocate for improving Montanans' access to low-
cost medications, I've been a champion of the Creating and Restoring
Equal Access to Equivalent Samples (CREATES) Act, which would combat
anticompetitive practices used by some brand-name pharmaceutical
companies to block or delay competing generic drugs from entering the
market. During the hearing when I asked if your company had ever
withheld samples from generic manufacturers, you answered emphatically
no. Yet, according to the Food and Drug Administration (FDA), generic
drug makers have made inquiries with the agency claiming they were
unable to access samples provided by Pfizer and AstraZeneca that are
needed to conduct studies to produce low-cost generic drugs.
Do you agree that denying generic drug manufacturers access to
samples keeps drug costs high for patients due to lack of competition?
Answer. AstraZeneca is supportive of allowing generic manufacturers
to have access to samples.
Question. Has your company refused to sell samples or placed any
barriers in the way of generic drug makers acquiring samples?
Answer. AstraZeneca is not aware of instances where the company has
refused to sell samples or has otherwise blocked access to samples by
generic manufacturers.
Question. Are you aware of any outstanding requests for samples?
Answer. AstraZeneca is not aware of any unanswered, delayed, or
outstanding requests for samples of our medicines by generic
manufacturers.
It is our understanding that one of our medicines, BRILINTA, was
included on the Reference Listed Drug Access Inquiries List (RLD List)
based on a single inquiry received by the FDA. However, BRILINTA has
always been available via normal commercial distribution channels
(i.e., wholesalers) and has never had a restricted distribution
program.
Unfortunately, the RLD List does not identify the company that
reportedly requested information (or samples) from AstraZeneca, the
date the information was requested, or any other information that would
allow AstraZeneca to better understand or further investigate the
circumstances of this inquiry. On its website, the FDA does advise that
it has ``not independently investigated or confirmed the access
limitations described in the inquiries received.'' Given this
limitation, the listing of an inquiry on the RLD List does not mean
that the FDA has in fact determined that access to samples by generic
manufacturers was limited or withheld for the medicines identified.
Indeed, based on our internal review, we have not identified any
circumstances that substantiate the inquiry received by the FDA
relating to BRILINTA.
Question. How does your company work to prevent abuses in the
sample system?
Answer. AstraZeneca is supportive of allowing generic manufacturers
to have access to samples and is not aware of instances that would be
considered abuse of the samples system.
______
Questions Submitted by Hon. Todd Young
re-evaluating business strategies in foreign countries
Question. Since taking office, President Trump has made reducing
drug prices one of his highest priorities--and has repeatedly spoken
about his frustration with the U.S. subsidizing the costs of
pharmaceuticals for the rest of the world. He has gone so far as to
issue proposals, like the International Pricing Index (IPI) Model, in
an attempt to bring down prescription drug prices. With the increased
scrutiny of the industry and of the drug supply chain as a whole in the
United States, have any of your companies re-evaluated your business
strategy in foreign countries?
Answer. We continuously evaluate our business approaches in all
markets and adjust our strategies accordingly based on many factors,
including the overall environment.
Question. If not, then why?
Answer. See response above.
Question. If a proposal, like IPI, were implemented, would it force
your companies to potentially ``walk away from the negotiating table
when other countries demand low prices subsidized by America's
seniors,'' as HHS Senior Advisor for Drug Pricing Reform John O'Brien
has said?
Answer. If the IPI model were put into effect as proposed, where an
identified average international price would be derived from 16
countries, this would impact our ability to sell our medicines in some
of the identified markets.
The IPI model was issued as an Advanced Notice of Proposed
Rulemaking (ANPRM). Important details such as the medicines that would
be included in the model, the final list of nations included as
reference countries, and the timing of reimbursement changes are still
unknown. We look forward to engaging with policymakers on this
proposal.
Question. What are some of your ideas on how we can ensure
Americans aren't shouldering the full cost of pharmaceuticals?
Answer. We agree that out-of-pocket costs are unsustainable in the
U.S., but the answer is not to move to a system found in other
countries or to link pricing in the U.S. to the International Pricing
Index.
It is critical to recognize that while price controls are the
default in many other countries, these price controls result in reduced
access to important medicines. In the 16 countries referenced in the
International Pricing Index model proposal, only 55 percent of new
cancer medicines are available, compared to 96 percent in the U.S. In
those countries, it also takes more than a year longer for the
medicines to become available and this can have significant impacts on
patients. For example, in 2018, the Food and Drug Administration (FDA)
and the European Medicines Agency (EMA) approved a new indication for
LYNPARZA for ovarian cancer. However, the U.K.'s National Institute for
Health and Care Excellence (NICE) has not recommended that the U.K.'s
National Health System (NHS) reimburse for LYNPARZA in this indication,
resulting in limited access for patients in the U.K.
Instead of international reference pricing, we should focus on
market-based solutions. We believe that there are several steps that
lawmakers can take to ensure that drug prices are affordable for
Americans, while ensuring that innovation in the biopharmaceutical
sector can continue to flourish in the U.S. Our suggestions fall in
five main categories, described in more detail below:
Rebate Reform: The current pharmacy benefit manager (PBM)
rebate system does not fully benefit patients and has resulted
in a lack of transparency across the supply chain. We support
the current proposed rule to eliminate rebates in Medicare Part
D and Medicaid managed care. We also support efforts to
eliminate rebates in the commercial sector as well, which will
likely require legislation. We therefore recommend that
Congress explore legislation that would eliminate rebates in
the commercial market.
Value-Based Agreements: As described in detail in our
written testimony to the Senate Committee on Finance hearing,
we are also working closely with payers and health systems to
explore innovative solutions to improve access and
affordability that demonstrate the value our medicines bring to
patients and the health-care system. For several years,
AstraZeneca has been exploring these types of solutions through
value-based agreements where we are willing to work with
health-care stakeholders to tie payment to patient outcomes. To
date, we have entered into approximately 40 value-based
agreements across our therapeutic areas with a variety of
payers, making AstraZeneca a leader in the field of value-based
agreements.
We believe that there are steps the government can take to
address certain regulatory challenges to the broader
implementation of value-based agreements and help encourage the
timely adoption of value-based agreements, including in public-
sector programs like Medicare. To that end, AstraZeneca
appreciates the support of Senators Warner and Cassidy for
value-based agreements, as demonstrated by their requests for
input on the Patient Affordability Value and Efficiency (PAVE)
Act. This draft legislation would promote the development of
value-based agreements by offering increased flexibility for
manufacturers to enter into such arrangements, including with
Medicare Part D plans.
Biosimilars: We also encourage Congress to consider policies
to encourage greater use of biosimilars in the U.S. We believe
that competition is a key component to reducing costs, and that
is why we support expanded use of biosimilars in the U.S. As a
global company, we operate in countries, particularly those in
the European Union, where biosimilar competition is
particularly robust. We support a similarly vigorous
biosimilars market in the U.S.
We therefore appreciate the efforts of the FDA to increase
the availability of biosimilars in the U.S., including the
FDA's development of a Biosimilars Action Plan. We support
efforts to streamline and improve the efficiency of the
biosimilars approval pathway for the benefit of patients. Such
efforts could include increased transparency into the patents
applicable to biologic medicines.
We also support cost-sharing and reimbursement policies that
facilitate the uptake of biosimilars. Such policies include
Medicare reimbursement rates that ensure that biosimilars can
compete on equal footing with innovator medicines, and
reductions to cost-sharing amounts for biosimilars.
Out-of-Pocket Caps for Medicare Patients: In the commercial
market, it is common for patients to have a cap on total out-
of-pocket amounts. However, such a construct does not exist in
the Medicare program. Because of the way the Part D benefit is
designed, for example, cost-sharing can be particularly high in
the first months of the plan year and/or in the first months of
therapy. A recent study found that rates of prescription
abandonment and delayed initiation of oral cancer therapies
increase as cost-sharing amounts rise. Such a result reflects
the need for a restructuring of the current benefit design,
which could be accomplished by establishing a monthly or annual
out-of-pocket cap. This would give patients greater certainty
in the total amount of out-of-pocket costs they could face.
Transparency: We support greater transparency across the
biopharmaceutical supply chain, which includes greater
transparency into drug pricing. To that end, we generally
support the policies included in the current versions of the
SPIKE and C-THRU Acts. There are a variety of State-level drug
pricing transparency laws and regulations. We believe that
having a consistent, Federal standard for drug pricing
transparency requirements, like those included in the SPIKE
Act, should pre-empt state transparency laws to reduce
confusion and compliance burden.
We also support transparency efforts to ensure that patients
and prescribers have meaningful information on out-of-pocket
costs at the point of prescribing, so that they can make
informed decisions about the most appropriate and affordable
therapy.
foreign countries' pricing and reimbursement
Question. President Trump and Secretary Azar have both repeatedly
described their frustrations with ``foreign freeloading'' of U.S. drugs
in the last year. ``When foreign governments extort unreasonably low
prices from U.S. drug makers, Americans have to pay more to subsidize
the enormous cost of research and development. . . . It's unfair and
it's ridiculous, and it's not going to happen any longer.''
Do you agree that because of foreign countries' pricing and
reimbursement systems, U.S. patients and innovators are shouldering the
burden for financing edical advances?
Answer. We agree that many foreign countries' pricing and
reimbursement systems do not adequately recognize innovation in the
biopharmaceutical sector. In many other countries, the government
utilizes price controls for drug therapies, and in many cases these
price controls result in reduced or delayed access to therapy for
patients in those countries. The U.S. benefits from an open-market
system that supports competition and innovation and accordingly
Americans place high value on both choice and access to the latest
medicines. For patients in the U.S., it is not a question of when an
important treatment will be available, but rather how they will access
that medicine. It is in this context that AstraZeneca continues to
engage with other stakeholders regarding possible solutions and
specific actions that can be taken to address pricing concerns, which
we describe in greater detail in our written testimony. These
approaches must balance the need to improve access and affordability
while fostering innovation. Pricing controls as well as access and
reimbursement practices in other countries are a challenge.
Question. How do foreign countries' pricing and reimbursement
systems affect our prescription drug costs?
Answer. We do not take into account foreign market pricing in
setting U.S. prices.
Question. Are foreign governments taking note of the concerns being
raised by the Trump administration and have they responded in any way?
Answer. While these matters have been widely reported on globally,
we do not have insights into actions being taken by other health
authorities directly in response to the Trump administration's efforts
in this area.
Question. Has there been any noticeable change in any of our trade
agreements since these concerns have been raised by the Trump
administration?
Answer. AstraZeneca and the biopharmaceutical industry have
consistently advocated for trade agreements that support strong
intellectual property rights and protect market access. We believe our
trade partners should be fair and transparent so that patients around
the world can benefit from U.S. innovation.
medicaid closed formulary proposals
Question. In an attempt to bring down drug costs, various States
have been exploring whether to exclude certain drugs from its Medicaid
program. For example, the State of Massachusetts recently asked CMS for
permission to create a closed formulary where the State Medicaid
program would pick at least one drug per therapeutic class. CMS denied
their waiver request citing violation of Federal law, but this proposal
does bring up important questions on how to contain drug prices in
State Medicaid programs.
If the principles of the Medicare Part D program--including the
necessary patient protections--were applied to State Medicaid programs,
do you think it [would] lower drugs costs while ensuring access to
patients?
Answer. Under the current construct in Medicaid, manufacturers
provide mandatory rebates and in turn, States are required to cover all
of the manufacturer's drugs. This ensures that Medicaid patients have
access to the full range of available therapies. We support increased
flexibility for State Medicaid agencies in managing their Medicaid
programs, but only so long as there are robust protections that ensure
that Medicaid patients can continue to access the medicines they need.
medicaid ``best price''
Question. In the Trump administration's Blueprint, they suggested
that because drug manufactures have to give Medicaid the ``best price''
on drugs, there is no incentive to offer deeper discounts to other
payers--both government and commercial--than what is already offered
under the Medicaid Drug Rebate Program.
Does the Medicaid ``best price'' requirement encourage
manufacturers to increase initial prices?
Answer. We do not believe that the Medicaid Best Price requirement
encourages manufacturers to increase their initial list price. However,
the requirement does impact decisions regarding the size of rebates and
discounts offered in the commercial sector because setting a new Best
Price can result in significantly increased Medicaid rebate and 340B
liability. Additionally, manufacturers may be hesitant to offer very
aggressive value-based agreements due to the risk of setting a new Best
Price.
Question. What, if any, changes would you suggest we make to the
program?
Answer. We recommend an exemption from Best Price for value-based
agreements, which is a policy included in Senator Grassley's and
Senator Warner's draft version of the PAVE Act.
outcomes-based contracts
Question. In almost all of your testimonies, you highlight your
support of outcomes-based contracts and how we need to be shifting our
system toward that approach.
How will these contracts lower drug costs for patients in both the
near term and long-term?
Answer. While most value-based agreements have been focused on
securing patient access to our medicines and delivering better patient
outcomes, where payers are willing, AstraZeneca is also looking to more
directly address patient out-of-
pocket affordability through these innovative arrangements.
As an example, we recently announced the initiation of a value-
based agreement for University of Pittsburgh Medical Center (UPMC)
Medicare patients who are prescribed BRILINTA. This value-based
contract, which was effective as of January 1, 2019, is groundbreaking
in two ways. First, the contract lowers the out-of-pocket costs for a
UPMC Medicare Part D patient to approximately $10 for a 30-day supply.
Second, what UPMC pays for BRILINTA will vary based on patient
outcomes, tying the cost of the medicine to its real-world clinical
performance.
We are currently exploring another value-based agreement in
Medicare Part D. In addition to having a significant outcomes-based
component, this arrangement would reduce patient out-of-pocket costs.
This type of agreement allows patients to access their medicines at a
lower out-of-pocket cost and payers to control their overall healthcare
costs through paying for outcomes.
Question. How will they lower overall health-care costs for our
Federal programs?
Answer. We believe medicines are part of the solution to
controlling health-care costs. They not only improve patient outcomes
and increase quality of life, but also reduce downstream costs. Value-
based agreements have the potential to increase efficiencies in the
health-care system, including government programs, by ensuring that
payment is based on value rather than reimbursement based on volume.
These agreements support patients receiving the most appropriate
treatment, ensure appropriate patient behaviors and, most importantly,
tie reimbursement to improved patient outcomes.
In many cases value-based agreements encourage a focus on important
patient behaviors such as adherence and persistence as well as improved
emphasis on patient education to promote healthier lifestyles and
choices. These agreements broaden payer focus to the total cost of care
and quality outcomes. It is important that we look at all aspects
related to the cost of care to find efficiencies that drive greater
value in the health-care system. These opportunities exist in both the
commercial and government sectors.
We support value-based agreements because they allow us to
reimburse the health-care system if our medicines do not deliver as
intended. This solution demonstrates our willingness to stand behind
the value of our medicines.
Through the partnership of payers and policymakers, we look forward
to a future where implementation of value-based agreements across
public and private payers is widespread.
Question. What have the preliminary results looked like so far?
Answer. We are frequently asked if we have ever had to ``pay out''
on a value-based agreement, and the answer is ``yes.'' For example, we
have entered into an agreement for one of our oncology medicines with a
large payer. We have reimbursed the payer for more than 20 percent of
patients on that medicine. Of course, we also have examples where we
have seen the medicine perform as well or better than our clinical
data. This is good for patients and good for the payer and health
system overall in that, by providing access to that medicine, they have
seen improved patient outcomes.
transparency/point of sale
Question. In almost all of your testimonies, you express your
support for the Trump administration's proposal to allow manufacturers
to provide PBMs up-front discounts that are passed onto patients at the
point of sale.
Do you feel like this proposal will make the transactions within
the drug supply chain more transparent?
Answer. Yes, the Trump administration's rebate proposal should make
transactions more transparent because cost-sharing will reflect point-
of-sale discounts and, therefore, net prices. We encourage the
administration and Congress to closely assess the impact of such
increased transparency on patients and the biopharmaceutical supply
chain more broadly.
Question. If so, would this transparency bring down drug costs--
overall and for specialty drugs?
Answer. In general, we believe that increased transparency due to
point-of-sale discounts will in turn lead to greater competition and
reduced costs overall. However, the impact of transparency on the
prices of specific drugs will vary based on the competitive landscape
for that medicine.
the relationship between wholesalers and manufacturers
Question. When talking about the pharmaceutical supply chain, a lot
of focus has been placed on the pharmacy benefit manager. But there's
another side of the equation that I'd like to ask about. How do
wholesalers negotiate pricing with manufacturers?
Answer. In general, wholesalers do not negotiate pricing with
manufacturers. Wholesalers receive service fees from manufacturers for
bona fide services they provide.
Question. What impact does this have on drug costs?
Answer. In general, wholesalers do not negotiate pricing with
manufacturers.
Question. What incentives or disincentives do they have to contain
price increases?
Answer. Wholesalers receive service fees from manufacturers for
bona fide services they provide. Certain fees across the supply chain--
including with wholesalers--are based on a percentage of the list
price. We support efforts to ``de-link'' such fees from the list price
across the supply chain, as this would align incentives across the
supply chain to lower prices.
______
Questions Submitted by Hon. Ron Wyden
proposed rebate rule
Question. As has been done in many other settings, drug
manufacturers said during the hearing that one reason list prices for
drugs are high is that pharmaceutical benefit managers (PBMs) demand
larger and larger rebates in order for the drug to receive favorable
placement on a formulary. You and your colleagues who testified during
the hearing stated if the administration's proposal on changes to the
anti-kickback safe harbor for pharmaceutical rebates took effect, your
company would likely lower list price. Like many Oregonians, I am
skeptical drug manufacturers would voluntarily lower their prices.
Therefore, would you support legislation that would (1) make
similar changes the administration has put forward related to Part D
and Medicaid managed care, (2) change the rebate system in a similar
way to the proposal for the commercial market, and (3) require drug
makers to lower the list price of their drugs equal to the amount of
rebates provided today?
Answer. Assuming the HHS rebate rule is finalized largely as
proposed, AstraZeneca intends to comply with its requirements and use
point-of-sale discounts. Our goal is to maintain net prices broadly in
line with today, recognizing our ability to do so may be dependent on
external factors and market response such as how plans evolve their
benefit design and the total degree of transparency under the new
model.
AstraZeneca would plan to reduce list prices, pending reforms
across all payers, including in the commercial sector in addition to
Part D, as the current construct does not allow for two separate list
prices (i.e., one list price for Part D and a different list price for
the commercial sector). Therefore, we also support efforts to eliminate
rebates in the commercial sector and recommend that Congress explore
such legislation. While eliminating rebates is an important step,
benefit designs must also be evaluated.
medicaid drug rebate program
Question. The Medicaid Drug Rebate Program (MDRP) requires
manufacturers to provide a basic rebate and an additional inflationary
rebate for both brand and generic drugs. The inflationary rebate is an
increasingly substantial part of total rebates due in large part to
large increases in drug prices that exceed inflation. Under current
law, this inflationary rebate is capped at 100 percent of Average
Manufacturer Price (AMP). This is the case even when manufacturers
continue to raise their prices well above inflation.
Please provide a list of all of your pharmaceutical products that
have reached the Medicaid AMP rebate cap in any of the 20 quarters from
January 1, 2014 through December 31, 2018.
Answer. Please see Appendix B.
Question. For each drug listed in response to question 1, please
also provide a list of which quarters and years each drug hit the cap.
Answer. Please see Appendix B.
medicaid drug rebate program compliance
Question. I am concerned about recent reports and legal settlements
surrounding drug manufacturers' failure to comply fully with the
requirements of the MDRP. For example, an analysis by the U.S.
Department of Health and Human Services Office of Inspector General
found that between 2012 and 2016 taxpayers may have overpaid by as much
as $1.3 billion for 10 potentially misclassified drugs. That is why I
introduced the Right Rebate Act with Chairman Grassley to prevent drug
manufacturers from manipulating Medicaid to increase their profits.
However, I continued to be concerned about oversight and manufacturer
compliance with the requirements of the Medicaid Drug Rebate Program.
Accordingly, please describe the following:
Your company's current compliance plan and procedures used to
ensure compliance with the requirements of the Medicaid Drug Rebate
Program including internal audits or other checks you use to identify
compliance vulnerabilities.
Answer. All aspects of AstraZeneca's compliance with the
requirements of the Medicaid Drug Rebate Program, including Statutory
Pricing (average manufacturer price (AMP) and Best Price) and Medicaid
Rebate payments, are covered by AstraZeneca's compliance framework.
This compliance plan includes a robust review process, including
Sarbanes-Oxley testing, self-auditing, and formal audits by internal
and external audit.
Question. Any past or ongoing issues of non-compliance.
Answer. Since the implementation of AstraZeneca's compliance
framework, we are not aware of any compliance issues that have been
identified via this internal and external audit process.
Question. Any corrective actions taken to address identified
problems or issues of non-compliance with the MDRP and how such steps
were communicated to the Centers for Medicare and Medicaid Services.
Answer. As noted above, to date, no compliance issues have been
identified via this internal and external audit process.
Question. Any steps taken to improve compliance and ensure that all
Medicaid drug rebates owed to the Federal Government and the States are
paid in full.
Answer. AstraZeneca has a comprehensive compliance framework that
includes Sarbanes-Oxley testing, self-auditing, and formal audits by
internal and external audit. Additionally, as it relates to Medicaid
drug rebates owed to the Federal Government and States, AstraZeneca
performs additional reviews of claims-level data, ensuring the
completeness and accuracy of both the payments made by manufacturers as
well as claims submitted to manufacturers. This process has identified
duplicate pharmacy claims submitted to State Medicaid Agencies
resulting in overpayment by both States and manufacturers. Clearly,
these overpayments disadvantage both the States and manufacturers like
AstraZeneca.
bonus payments tied to specific drugs
Question. I am concerned by the potential for employee financial
incentives to encourage high launch prices and price increases for
prescription drugs.
Is your salary, bonus, or other compensation tied to sales or
revenue targets of a single product your company sells? Has it ever
been? If yes, please state the product or products to which your
salary, bonus or other compensation was tied.
Answer. The CEO's compensation as well as the compensation of other
senior leaders is directly based on three areas of performance that are
generally weighted equally: development and delivery of innovative
science, our aggregate sales, and other important financial metrics.
AstraZeneca understands that executive pay is a closely scrutinized
issue. As part of our compensation decisions, we are mindful of the
sensitivity of this issue as we determine how best to incentivize,
reward and retain executives capable of leading a global pharmaceutical
company in a highly competitive market.
Question. Is your salary, bonus, or other compensation tied to
either revenue or net income of the company as a whole? Has it ever
been? If yes, please explain what assumptions about price increases are
used when the compensation committee sets revenue or net income goals.
Does the compensation committee provide any guidance to executives in
regards to the amount of revenue that the company will generate from
price increases versus volume growth?
Answer. The CEO's compensation as well as the compensation of other
senior leaders is directly based on three areas of performance that are
generally weighted equally: development and delivery of innovative
science, our aggregate sales, and other important financial metrics.
AstraZeneca's Remuneration Committee does not provide any guidance on
price increases.
provision of rebates in exchange for formulary placement
Question. In today's system, drug makers receive a limited time
window to sell their drug without competition. After that period has
expired, low-cost generics should become available. However, drug
makers often prevent access to these cheaper generic drugs in Medicare.
Researchers have found that 72 percent of Medicare Part D plans charged
lower cost-sharing for a brand name drug compared to its generic
equivalent. This means seniors were charged less out of pocket for
brand name drugs compared to generics that are on average four times
cheaper than the brand-named drug. This happens because drug makers pay
a rebate to the Part D plans in order to give the more expensive drug
better treatment than a generic. As a result, Medicare spending
increases due to the current structure of the Part D benefit.
Has your company ever paid a rebate to a Part D plan so that a
brand name drug would get preferential treatment (i.e., lower cost-
sharing or less utilization management) compared to a cheaper generic?
Answer. In certain instances, AstraZeneca enters into arrangements
under which a branded agent is discounted at or below the net cost of
the generic(s) in the market, therefore benefiting the plan and the
beneficiary. AstraZeneca typically enters into these types of
arrangements for medicines already existing on formulary. These
arrangements benefit patients by ensuring greater affordability for the
branded medicine and by ensuring continuity of treatment if a patient
has already been prescribed a branded medicine. These arrangements also
support competition because they provide the opportunity for multiple
competitors and medicine options to compete on price and other factors.
We have had several such arrangements in Medicare Part D (see Appendix
C).
Question. If so, please provide:
A list of the drugs for which your company has done this since
January 1, 2014.
Answer. A list providing this information is attached as Appendix
C.
Question. The number of Part D plans in which this type of rebate
was given for each drug in each year.
Answer. A list of the relevant Part D plans is included in Appendix
C.
net prices
Question. During your testimony, you stated, ``The estimates for
2018 show that across our medicines, our average rebate is nearly 50
percent of our gross revenues in the U.S. Despite this, in recent
years, in our primary cap portfolio, we have seen flat to declining net
effective prices for most of our medicines.''
Please describe how the company's year-over-year aggregate net
price is calculated.
Answer. The analysis discussed during the hearing on February 26,
2019 was completed by brand; the change in Net Price was calculated at
the brand level, and then weighted based on Net Sales for each brand as
a percent of Total Net Product Sales for 2018.\2\
---------------------------------------------------------------------------
\2\ Net Product Sales reflect the invoiced amount less movements in
estimated accruals for rebates and chargebacks given to managed-care
and other customers. Cash discounts for prompt payment are also
deducted from sales. Average Net Price per Unit excludes product
returns, and the figures were arrived at using the conventional Net
Price calculation, that is, before deducting cost of goods sold,
royalties, and variable selling expenses.
---------------------------------------------------------------------------
Question. Please also specifically address the following questions:
How many products are included in the calculation of the average
net price change? What was the median net price change?
Answer. The analysis discussed during the hearing on February 26,
2019 included 26 brands that represent 98 percent of annual Net Product
Sales in the United States for the period ending December 31, 2018.
The Median Price Change (prior to weighting) was a Net Price
decrease of 1 percent.
Question. Is net price weighted? If so, how? For example, in
determining the aggregate net price does the company assign different
weights to different products based on volume or other factors? Are
``on patent'' and ``off patent'' drugs weighted identically? Are other
statistical weights used or are all products treated equally?
Answer. The analysis discussed during the hearing on February 26,
2019 was completed by brand; the change in Net Price was calculated at
the brand level, and then weighted based on Net Sales for each brand as
a percent of Total Net Product Sales for 2018 irrespective of whether
the medicines are on or off patent.
Question. Does the figure that you provided during your testimony
account for U.S. prices, international prices, or both? Generally
speaking, when your company reports net price changes, does it
differentiate between U.S. and international prices?
Answer. The analysis discussed during the hearing on February 26,
2019 referred to 26 brands that represent 98 percent of annual Net
Product Sales in the United States for the period ending December 31,
2018.
Question. Please list the five drugs your company sold in the U.S.
that had the greatest year-over-year net price increase in 2018, noting
the increase for each drug by dollar figure and percentage. Please list
the five drugs your company sold in the U.S. that had the lowest year-
over-year net price increase (and/or the greatest decrease) in 2018,
noting the increase (or decrease) for each drug by dollar figure and
percentage.
Answer. In 2018, we experienced a Weighted Average Net price
decline in our hyper-competitive respiratory and diabetes therapeutic
areas, with declines of 2.4 percent and 1.9 percent, respectively. Our
Weighted Average Net prices in oncology remained flat. Brand-specific
pricing information is competitively sensitive information.
Question. For 2018, what was the average net price change in the
U.S. market for (1) drugs with no competition, (2) drugs with only
branded competition, and (3) drugs with generic competition?
Answer. For 2018, the Weighted Average Net price change in the
United States market for:
Medicines with no competition was an increase of 0.6
percent;
Branded ``on patent'' medicines without generic equivalents
was a decrease of 4.7 percent;
``Off patent'' medicines with generic equivalent competition
was an increase of 4.6 percent.
With respect to the last category of medicines described above, we
note by way of context that once generic options enter the market, our
market share rapidly erodes, as many PBMs, insurers, and government
agencies to which AstraZeneca offers rebates and discounts replace our
branded medicines on their formularies with these generic competitors.
Accordingly, the mix of business for medicines with generic competition
shifts towards programs whereby health plans/PBMs chose to list our
branded medicines on their formularies given a lower net cost versus
generics, and to individual patients who chose to pay for branded
agents over generic agents, resulting in a higher average net effective
price across all distribution channels.
Question. You state that ``the estimates for 2018 show that across
our medicines, our average rebate is nearly 50 percent of our gross
revenues in the U.S.'' For each product, please disclose the gross
revenue and the amount of rebates paid.
Answer. The table below reflects our Product Sales in the U.S. for
the period ending December 31, 2018, including the proportion of Gross
Sales allocated to estimated amounts we expect to pay to third-party
managed care organizations, hospitals, long-term care facilities, group
purchasing organizations, and various Federal or State programs. The
percentage of Gross Product Sales column reflects our effective rebate
rate per channel, a combination of mix of business in that channel and
related rebate rate.
------------------------------------------------------------------------
USD (in % of Gross
millions) Product Sales
------------------------------------------------------------------------
Gross Product Sales $16,538,000
------------------------------------------------------------------------
Chargebacks $(2,224,000) -13%
------------------------------------------------------------------------
Regulatory--Medicaid and State $(1,304,000) -8%
programs
------------------------------------------------------------------------
Contractual--Managed-care and $(4,600,000) -28%
Medicare
------------------------------------------------------------------------
Cash and other discounts $(286,000) -2%
------------------------------------------------------------------------
Customer returns $(119,000) -1%
------------------------------------------------------------------------
U.S. Branded Pharmaceutical Fee $(140,000) -1%
------------------------------------------------------------------------
Other $(989,000) -6%
------------------------------------------------------------------------
Net Product Sales $6,876,000
------------------------------------------------------------------------
Brand-specific pricing information is competitively sensitive
information.
______
Questions Submitted by Hon. Robert Menendez
Question. During the hearing, when I asked whether your company
engaged in tactics to delay generic production of your products, you
answered ``no.'' However, AstraZeneca appears on the FDA's list of
companies who have access complaints against them.
Can you explain the discrepancy between your answer and the FDA
list? The FDA list can be found here: https://www.fda.gov/Drugs/
DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/
ApprovalApplications/AbbreviatedNewDrug
ApplicationANDAGenerics/ucm607738.htm.
Answer. AstraZeneca appreciates the opportunity to address the
question of one of our medicines (BRILINTA) appearing on the Reference
Listed Drug Access Inquiries list (RLD List). We would first like to
state that AstraZeneca supports allowing generic manufacturers access
to samples. Withholding or otherwise blocking such access is
inconsistent with that position. Our internal review has not identified
any unanswered, delayed, or outstanding requests for samples of
BRILINTA (ticagrelor) by any generic manufacturers.
It is our understanding that BRILINTA was included on the RLD List
based on a single inquiry received by the FDA. Unfortunately, the RLD
List does not identify the company that reportedly requested
information (or samples) from AstraZeneca, the date the information was
requested, or any other information that would allow AstraZeneca to
better understand or further investigate the circumstances of this
inquiry. On its website, the FDA does advise that it has ``not
independently investigated or confirmed the access limitations
described in the inquiries received.'' Given this limitation, the
listing of an inquiry on the RLD List does not mean that the FDA has in
fact determined that access to samples by generic manufacturers was
limited or withheld for the medicines identified. Indeed, based on our
internal review, we have not identified any circumstances that
substantiate the inquiry received by the FDA relating to BRILINTA.
BRILINTA is and has always been available via normal commercial
distribution channels (i.e., wholesalers) since its U.S. launch. It has
never had a restricted distribution program.
Finally, more than 15 generic manufacturers have applied for
regulatory approval from the FDA for the manufacture of generic
ticagrelor and some, like Watson/Teva, have received tentative
approvals from the FDA. Because conducting bioequivalence studies with
the branded medicine is an FDA preapproval requirement, it is clear
that these generic manufacturers are not having difficulty accessing
branded ticagrelor for their studies.
In light of the context provided above, it is unclear why any
generic manufacturer would be unable to obtain a sample of BRILINTA for
their purposes or why an inquiry was lodged with the FDA related to
this medicine.
Question. When new products enter the market, do drug companies set
high initial rebates and then provide deep rebates in order to gain
access to insurance plan's formularies?
Answer. No, this is not AstraZeneca's general practice. We
negotiate rebates and discounts with payers and pharmacy benefit
managers (PBMs)--including in Medicare Part D--to help ensure that
patients have the most robust access possible to our therapies. Without
these discounts and rebates, many lifesaving medicines would not be
placed on plan formularies and therefore would be largely unavailable
to the patients who need them most.
The current rebate system creates misaligned incentives. This
results in a growing differential between list and net prices. We
support reforms of this system that include the elimination of rebates
in the commercial sector and in Medicare Part D, which will result in
the reduction of the differential between list and net prices and which
would allow manufacturers to ensure that the initial list price of a
drug reflects its net value.
Question. If CMS finalizes the rebate rule, do you anticipate
future products entering the market with significantly lower initial
list prices?
Answer. We believe that eliminating rebates across Medicare Part D
and commercial will generally result in lower initial list prices than
in the absence of reform, although the impact on specific medicines
will vary based on the competitive dynamics for that medicine. Reform
only in Part D and not commercial is unlikely to impact initial list
price setting practices, as the current structure does not allow for
two separate list prices (i.e., one list price for Part D and a
different list price for the commercial sector).
______
Questions Submitted by Hon. Thomas R. Carper
Question. What are your recommendations for lowering prices for the
40 percent of drugs that do not offer rebates in Medicare Part D? In
the health insurance plans that you offer your employees, do you ask
your insurers to pass through the full manufacturer rebates to the
beneficiaries?
Answer. All of our medicines are rebated under the statutory
requirements of Medicaid, Federal Supply Schedule, 340B, and the Part D
coverage gap discount program. For our highly innovative, targeted
therapies, we do not typically provide additional rebates other than
through our value-based agreements, where such discounts are based on
patient outcomes.
In general, medicines with minimal rebates are the newest and most
innovative on the market. Expanded use of value-based agreements is a
key component to lowering costs and improving access to these medicines
that are currently not in highly rebated therapeutic classes. Under
such arrangements, manufacturers may contract to reimburse plans if the
medicine does not work as expected, lowering risks for the payer. This
also results in competition across manufacturers of medicines in these
classes by facilitating competition across clinical results and
outcomes.
As we stated before the Senate Committee on Finance, AstraZeneca
has put forward several proposals in addition to value-based agreements
to address drug pricing:
Moving away from the current rebate system, while continuing
to work with payers and PBMs to ensure robust negotiations;
Using a portion of discounts and rebates to create out-of-
pocket caps for Medicare patients;
Encouraging biosimilars and eliminating policy and
commercial barriers to their greater use.
AstraZeneca also supports increased transparency across the
biopharmaceutical supply chain, including transparency with respect to
drug pricing. To that end, we generally support the policies included
in the current versions of the SPIKE and C-THRU Acts. There are a
variety of state-level drug pricing transparency laws and regulations.
We believe that having a consistent, federal standard for drug pricing
transparency requirements, like those included in the SPIKE Act, should
pre-empt state level laws to reduce confusion and compliance burden.
We also support transparency efforts to ensure that patients and
prescribers have meaningful information on out-of-pocket costs at the
point of prescribing, so that they can make informed decisions about
the most appropriate and affordable therapy.
AstraZeneca wants to be a constructive partner in identifying
solutions that continue to allow manufacturers to innovate while
creating a more efficient and more affordable system.
AstraZeneca provides generous health-care benefits to its
employees. Today, we provide a point-of-sale discount on prescription
medicines in the form of low out-of-pocket costs for our employees. We
cap our employees' out-of-pocket costs on prescription medicines at $50
per fill to ensure they do not forgo their prescriptions due to high
out-of-pocket costs.
Question. The systems for pricing and distributing drugs are opaque
and difficult to understand.
What are your recommendations for increasing transparency in how
your companies set the list prices for drugs, and for improving
transparency in the supply chain for prescription drugs? Would you
support Federal standards for transparency in setting the list prices
for drugs?
Answer. We do believe that greater transparency is needed for
manufacturers as well as other entities in the supply chain. We
therefore would generally support transparency requirements such as
those included in the SPIKE and C-THRU Acts. Any transparency
requirements should consider the need to protect competitively
sensitive information to ensure robust competition in the market.
There are a variety of State-level drug pricing transparency laws
and regulations. We believe that having a consistent, Federal standard
for drug pricing transparency requirements, like those included in the
SPIKE Act, should pre-empt State-level laws to reduce confusion and
compliance burden.
Question. In nearly every sector of the health-care industry,
Medicare, Medicaid, employers, and insurers are moving away from fee-
for-service payments to reimbursements based on value and performance.
Prescription drugs and medical devices were the glaring exceptions to
this trend until recently.
How many of your drugs are included in value-based contracts and
how many patients are benefiting from them? How do these value-based
contracts work to lower drug prices for both patients and taxpayers?
Answer. We believe medicines are part of the solution to
controlling health-care costs. They not only improve patient outcomes
and increase quality of life, but also reduce downstream costs. Value-
based agreements allow us to reimburse the health-care system if our
medicines do not deliver as intended. This solution demonstrates our
willingness to stand behind the value of our medicines.
AstraZeneca is working closely with payers and health systems to
explore innovative solutions to improve access and affordability that
demonstrate the value our medicines bring to patients and the health-
care system. Our value-based agreements aim to manage the totality of
treatment costs and keep people healthy and out of the hospital. For
several years, AstraZeneca has been exploring these types of solutions
through value-based agreements where we are willing to work with
health-care stakeholders to tie payment to patient outcomes.
To date, we have entered into approximately 40 value-based
agreements for 15 medicines across our therapeutic areas with a variety
of payers, making AstraZeneca a leader in the field of value-based
agreements. Tens of thousands of patients have benefited from improved
access as part of these agreements.
As an example, and as noted in our written testimony submitted to
the Senate Committee on Finance, AstraZeneca agreed with Express
Scripts that for IRESSA, an oral treatment for certain types of lung
cancer, we will fully reimburse Express Scripts for discontinued use
before the third fill, including if discontinuation occurs because
patients did not respond to treatment.
While most of these agreements have been focused on securing
patient access to our medicines and delivering better patient outcomes,
where payers are willing, we are also looking to more directly address
patient out-ofpocket affordability through these innovative
arrangements.
As an example, we recently announced the initiation of a value-
based agreement for University of Pittsburgh Medical Center (UPMC)
Medicare patients who are prescribed BRILINTA. This value-based
contract, which was effective as of January 1, 2019, is groundbreaking
in two ways. First, the contract lowers the out-of-pocket costs for a
UPMC Medicare Part D patient to approximately $10 for a 30-day supply.
Second, what UPMC pays for BRILINTA will vary based on patient
outcomes, tying the cost of the medicine to its real-world clinical
performance.
We are currently exploring another value-based agreement in
Medicare Part D. In addition to having a significant outcomes-based
component, this arrangement would reduce patient out-of-pocket costs.
This type of agreement allows patients to access their medicines at a
lower out-of-pocket cost and payers to control their overall health-
care costs through paying for outcomes.
Question. Last year, Senator Portman and I did an investigation on
the pricing of an opioid overdose reversal drug called EVZIO,
manufactured by Kaleo. Kaleo increased the price of EVZIO from $575 in
2014 to $4,100 in 2017. We found that the best price Medicare was able
to get for EVZIO, about $4,000, was much higher than the price other
federal programs and private insurers were able to get. It seemed that
Kaleo was able to get this higher price of $4,000 from Medicare by
helping doctors fill out paperwork showing that the drug was medically
necessary, even though there are cheaper alternatives on the market. As
a result of the investigation, Kaleo announced it will bring a generic
version of the drug to market at only $168 per pack.
Are any of your companies providing medical necessity paperwork to
doctors in order to get your drugs covered by Medicare?
Answer. AstraZeneca policies prohibit completing medical necessity
paperwork for doctors or their staff as described in your inquiry.
Question. In 2017, the Rand Corporation estimated that biosimilar
drugs, which are competitors to complex, biologic drugs, could save the
United States more than $50 billion over the next decade. Some of you
have also argued that increasing the use of biosimilar drugs would help
lower drugs costs for consumers and taxpayers.
What is delaying the uptake of biosimilar drugs in the United
States? What policies do you recommend to increase the development of
biosimilar drugs?
Answer. AstraZeneca believes that competition is a key component to
reducing costs, and that is why we support the expanded use of
biosimilars in the U.S. As a global company, we operate in countries,
particularly those in the European Union, where biosimilar competition
is particularly robust. We support a similarly vigorous biosimilars
market in the U.S.
There are several challenges to biosimilar uptake in the U.S.,
including contracting and rebating dynamics and difficulty in obtaining
interchangeability status. We therefore appreciate the efforts of the
FDA to increase the availability of biosimilars in the U.S., including
the FDA's development of a Biosimilars Action Plan. We support efforts
to streamline and improve the efficiency of the biosimilars approval
pathway for the benefit of patients. Such efforts could include
increased transparency into the patents applicable to biologic
medicines.
We also support reimbursement policies that facilitate the uptake
of biosimilars. Such policies include Medicare reimbursement rates that
ensure that biosimilars can compete on equal footing with innovator
medicines, and reductions to cost-sharing amounts for biosimilars. We
also believe the elimination of rebates will help biosimilars compete
with innovator medicines.
______
Questions Submitted by Hon. Benjamin L. Cardin
Question. The United States is one of the only countries in the
world to allow prescription drug manufacturers to advertise directly to
consumers through magazines, billboards, radio, and television
commercials. While I will not argue that it is beneficial to educate
consumers about an unfamiliar disease and encourage them to seek
medical help, most commercials from all of your companies recommend
asking about a specific brand name drug, not a medical condition.
Furthermore, even if your advertisements follow all FDA rules and list
medication side effects, they also almost always list these while a
smiling, apparently healthy person is walking on a beach. Researchers
say that this type of imagery, combined with viewing hours of drug
commercials each month, leads consumers to underestimate the risks
associated with medications. For the past decade, studies have shown
that aggressive direct-to-consumer advertising is associated with
rising drug prices and an increase in inappropriate drug prescriptions.
Since researchers have concluded that consumers are
misunderstanding the benefits and risks described in your ads, what
further policies could help you and your colleagues ensure that you are
educating patients in a clear manner?
Answer. Our advertising complies with regulatory requirements
governing direct-toconsumer (DTC) advertising and AstraZeneca believes
that DTC advertising is important to raising brand and disease
awareness, fostering patient education, and enhancing the dialogue
between patients and their physicians. Unfortunately, these positive
impacts of health-care communication efforts are often left out of the
DTC debate.
pharmaceutical companies continue to raise prices
Question. As you are well aware, high prescription drug prices are
the number one concern for Americans and their families. According to
the Organization for Economic Cooperation and Development, the average
American spends around $1,208 annually on prescription drugs. There
have been several instances where brand name or even generic drugs that
have been on the market for years continue to increase in price. One of
the most well-known examples is Mylan's increase of the price of EpiPen
from less than $100 in 2007 to more than $600 in 2016. Another example,
is the ever-increasing price of insulin. Sanofi increased the price of
a vial of Lantus from $88.20 in 2007 to $307.20 in 2017. And those are
just a small sample of price increases.
Why don't we see price decreases for drugs that have been on the
market for years without new formulations or added benefit?
Answer. As an initial matter, it is important to note the
distinction between list and net prices. Over the past several years,
discounts and rebates for our therapies have increased overall, both in
the commercial sector and Part D. In recent years, in our primary care
portfolio, which includes the majority of our therapies, we have seen
flat to declining net effective prices to AstraZeneca for most of our
medicines. Flat to declining net prices is a trend across the industry.
However, the current system makes list price decreases challenging.
Therefore, to accomplish meaningful change in terms of lowering
list price, the system must be restructured to eliminate rebates.
Assuming the HHS rebate rule is finalized largely as proposed,
AstraZeneca intends to comply with its requirements and use point-of-
sale discounts. Our goal is to maintain net prices broadly in line with
today, recognizing our ability to do so may be dependent on external
factors and market response such as how plans evolve their benefit
design and the total degree of transparency under the new model.
AstraZeneca would plan to reduce list prices, pending reforms
across all payers, including in the commercial sector in addition to
Part D, as the current construct does not allow for two separate list
prices (i.e., one list price for Part D and a different list price for
the commercial sector). Therefore, we also support efforts to eliminate
rebates in the commercial sector, and recommend that Congress explore
such legislation. While eliminating rebates is an important step,
benefit designs must also be evaluated.
pay for delay
Question. Pay for delay is a tactic that more and more branded drug
manufacturers have been using to stifle competition from lower-cost
generic manufacturers. This allows you to sidestep competition by
offering patent settlements that pay generic companies not to bring
lower-cost alternatives to market. These ``pay-for-delay'' patent
settlements benefit both brand-name pharmaceutical companies by helping
them avoid costly patent litigation and general manufacturers by
rewarding them a hefty sum to delay entering the market with a cheaper
drug alternative. However, these deals do not benefit consumers.
According to an FTC study, these anticompetitive deals cost consumers
and taxpayers $3.5 billion in higher drug costs every year.
Does your company partake in pay-for-delay settlements?
Answer. AstraZeneca does not enter into settlements that pay
generic competitors to delay entry into the market. In the absence of a
settlement, a generic would not necessarily prevail in the patent
litigation and therefore would not be able to enter the market. Indeed,
AstraZeneca has entered into many early-entry patent settlements that
permit generic competitors to enter the market before expiration of
AstraZeneca's patent rights by allowing generic manufacturers to
license innovator patents.
All of AstraZeneca's patent settlements fully comply with the law.
These settlements provide increased clarity and stability to both
parties, allowing innovators like AstraZeneca to continue investing
substantially in new medicines for patients and frequently allowing
generic competitors to enter the market before expiration of
AstraZeneca's patent rights.
Question. Why would a pharmaceutical company enter into a pay-for-
delay agreement?
Answer. AstraZeneca does not enter into agreements that pay generic
competitors to delay entry into the market.
Question. Do you think these agreements stifle competition and
prevent generic alternatives to your branded medications?
Answer. AstraZeneca does not enter into agreements that pay generic
competitors to delay entry into the market. However, AstraZeneca has
entered into many early-entry patent settlements that permit generic
competitors to enter the market before expiration of AstraZeneca's
patent rights by allowing generic manufacturers to license innovator
patents. These do not stifle competition but instead permit early entry
by resolving patent disputes that would otherwise prevent generic
alternatives to branded medication.
value-based pricing
Question. One idea I wanted to get your thoughts on today, is the
idea of value-based pricing. This is an idea where a company could link
the single price it charges for a given drug to an assessment of how
well it works. Some value-based pricing arrangements could allow
insurers and patients to receive rebates from drug manufacturers if a
drug failed to work (outcome-based pricing). Another version would
involve ``indication-based pricing'' in which drug companies charge
different prices for the same drug when it is used to treat different
conditions.
Dr. Soriot, we have heard that AstraZeneca has been participating
in a value-based program in collaboration with the University of
Pittsburgh Medical Center.
Could you talk more about your research in value-based pricing and
how you believe this could be possible solution to some of the high
drug prices?
Answer. We believe medicines are part of the solution to
controlling health-care costs. They not only improve patient outcomes
and increase quality of life, but also reduce downstream costs. Value-
based agreements allow us to reimburse the health-care system if our
medicines do not deliver as intended. This solution demonstrates our
willingness to stand behind the value of our medicines.
AstraZeneca is working closely with payers and health systems to
explore innovative solutions to improve access and affordability that
demonstrate the value our medicines bring to patients and the health-
care system. Our value-based agreements aim to manage the totality of
treatment costs and keep people healthy and out of the hospital. For
several years, AstraZeneca has been exploring these types of solutions
through value-based agreements where we are willing to work with
health-care stakeholders to tie payment to patient outcomes.
To date, we have entered into approximately 40 value-based
agreements across our therapeutic areas with a variety of payers.
Our research in value-based agreements has been focused on
addressing the comprehensive value of a medicine in terms of medical
cost offsets and the economic impact of achieving certain health
benefits with a medicine in a specific population. Our experience in
this area consists of health economics and outcomes research (HEOR) and
real-world evidence (RWE) studies which correlate improved outcomes and
overall better health to a direct, positive economic impact, realized
by both the payer and the patient. We use HEOR and RWE data to
establish the metrics of the value-based agreement. Another important
part of our value-based agreement research is how we measure the impact
of a value-based agreement, so we can learn what works and what does
not work for future iterations of value-based agreements.
In addition, by aligning payments for medicines more directly with
their value in improving health outcomes and/or reducing the need for
other healthcare services (such as hospitalizations), value-based
arrangements make pharmaceutical manufacturers accountable for the
results our medicines achieve and can help improve patients' health and
maximize the benefits of healthcare spending. Over time, proliferation
of value-based agreements can shift utilization toward medicines with
greater clinical value and greater ability to reduce hospitalizations
and other costly services, resulting in better health outcomes and
lower overall healthcare spending.
As manufacturers develop more complex, personalized, and promising
treatments--such as gene therapies, cell therapies, or immuno-
therapies--it will be increasingly important for health plans to enter
into value-based agreements so that they and our healthcare system may
recognize the full value of those treatments and make them available to
patients at affordable out-of-pocket amounts. Value-based agreements
serve an important role in linking the price of a medicine to
beneficiaries' demonstrated real world outcomes using that medicine.
While most of these agreements have been focused on securing
patient access to our medicines, some have also helped payers identify
which patient types are most likely to benefit from our medicines and
deliver improved patient outcomes. Partnering to drive this type of
clarity can reduce overall drug spend in meaningful ways. Where payers
are willing, we are also looking to more directly address patient out-
of-pocket affordability through these innovative arrangements.
As you mention, we recently announced the initiation of a value-
based agreement for University of Pittsburgh Medical Center (UPMC)
Medicare patients who are prescribed BRILINTA. This value-based
contract, which was effective as of January 1, 2019, is groundbreaking
in two ways. First, the contract lowers the out-of-pocket costs for a
UPMC Medicare Part D patient to approximately $10 for a 30-day supply.
Second, what UPMC pays for BRILINTA will vary based on patient
outcomes, tying the cost of the medicine to its real-world clinical
performance.
Through the partnership of payers and policymakers, we look forward
to a future where implementation of value-based agreements across
public and private payers is widespread. Value-based agreements are one
proactive solution; they are not the only solution.
drug rebate rule
Question. In January, the Department of Health and Human Services'
(HHS) Office of Inspector General (OIG) promulgated a new regulation to
remove regulatory safe harbor protections under the Anti-Kickback
Statute (AKS) for rebates on prescription drugs rebates paid by
manufactures to PBMs under Medicare Part D and for Medicaid managed
care organizations (MCOs). The OIG proposal attempts to ban most
rebates by eliminating their regulatory protections. The rule is
predicted to increase net drug costs in its early years. The CMS
actuaries estimate it would cost $196 billion over 10 years. Despite
this high price tag, the beneficiary benefits are limited. The proposed
rule notes that under the CMS Actuary's analysis, the majority of
beneficiaries would see an increase in their total out-of-pocket
payments and premium costs; reductions in total cost sharing will
exceed total premium increases.
I wanted to ask a question about the administration's rebate rule,
which I understand that many of the drug manufacturers, and your main
trade association, strongly support. According to an analysis of the
rule by the Office of Actuaries at CMS, drug manufacturers are likely
to initially retain 15 percent of the current rebates as higher net
drug prices.
Given that estimate, can you provide the committee with any
assurances that prices will not increase under this proposed rule?
Answer. Assuming the HHS rebate rule is finalized largely as
proposed, AstraZeneca intends to comply with its requirements and use
point-of-sale discounts. Our goal is to maintain net prices broadly in
line with today, recognizing our ability to do so may be dependent on
external factors and market response such as how plans evolve their
benefit design and the total degree of transparency under the new
model.
AstraZeneca would plan to reduce list prices, pending reforms
across all payers, including in the commercial sector in addition to
Part D, as the current construct does not allow for two separate list
prices (i.e., one list price for Part D and a different list price for
the commercial sector). Therefore, we also support efforts to eliminate
rebates in the commercial sector, and recommend that Congress explore
such legislation. While eliminating rebates is an important step,
benefit designs must also be evaluated.
______
Questions Submitted by Hon. Sherrod Brown
Question. According to an article recently published in the Journal
of the American Medical Association, medical marketers spent nearly $30
billion dollars in 2016, up from $17 billion in 1997. Direct-to-
Consumer (DTC) advertising had the biggest percentage increase: from
$2.1 billion, or 11.9 percent of all medical marketing, in 1997 to $9.6
billion, or 32 percent of total spending, in 2016.
Can you please provide what your ratio of spending on sales and
marketing to research and development is today?
Answer. In 2018, we spent $5.9 billion on RandD and $6.1 billion on
Sales and Marketing, globally. Our Sales and Marketing figures include
all costs incurred in selling, marketing, promoting, and distributing
our products.
price-gouging
Question. Sanofi, as I understand it, has made a pledge to the
public to limit its price increases to the national health expenditures
growth projection.
Would your company commit to a cap on annual price increases as
part of your PhRMA membership criteria?
Answer. Our decisions around pricing would always need to remain
independent of PhRMA membership criteria.
Question. What policies would you propose to help ensure lower
launch prices for new drugs?
Answer. As we stated at the Senate Committee on Finance hearing,
AstraZeneca has put forward a number of proposals to address drug
pricing, including:
Moving away from the current rebate system, while continuing
to work with payers and PBMs to ensure robust negotiations; and
Encouraging biosimilars and eliminating policy and
commercial barriers to their greater use.
As described below, we also support efforts to increase
transparency in the biopharmaceutical supply chain and drug
pricing specifically.
transparency
Question. In many of your testimonies, you mentioned that the
current system of pharmacy benefit manager (PBM) back-end rebates do
not rarely results in a scenario where the PBM passes on savings to
consumers at the point of sale (POS). The administration recently
proposed a rule to eliminate the anti-kickback statute safe harbor
protections for these drug rebates.
Do you agree that greater transparency should be required to
understand how manufacturers and PBMs are negotiating prices and
rebates to ensure that savings are passed down to beneficiaries?
Answer. Yes, AstraZeneca agrees that greater transparency is
needed. We therefore generally support the policies included in the
current versions of the SPIKE and C-THRU Acts.
There are a variety of State-level drug pricing transparency laws
and regulations. We believe that having a consistent, federal standard
for drug pricing transparency requirements, like those included in the
SPIKE Act, should pre-empt state level laws to reduce confusion and
compliance burden.
pbms
Question. An Axios article from March 7, 2019 highlights the fact
that, while ``pharmaceutical companies put a lot of the blame for high
drug prices on pharmacy benefit managers,'' many large pharmaceutical
companies ``rely on PBMs to manage their own health-care benefits.''
In your role as an employer, does your company contract with a
pharmaceutical benefit manager (PBM) to administer the prescription
drug benefits for your employees and negotiate lower drug costs on your
behalf?
Answer. AstraZeneca prescription drug benefits are managed by
Express Scripts.
Question. For those of you who do use a PBM to help manage the
prescription drug benefit for your employees, how do you utilize the
rebates your PBM negotiates to lower health-care costs or drug costs
for your employee plans and what does your company do with that
savings? Specifically, do the savings go toward lowing premiums?
Answer. AstraZeneca provides generous healthcare benefits to its
employees. Today, we provide a point-of-sale discount on prescription
medicines in the form of low out-of-pocket costs for our employees. We
cap our employees' out-of-pocket costs on prescription medicines at $50
per fill to ensure they do not forgo their prescriptions due to high
out-ofpocket costs.
Question. For those of you who do use a PBM to help manage the
prescription drug benefit for your employees, does your PBM offer
point-of-sale rebates to your employees?
Answer. While AstraZeneca does not currently offer point-of-sale
rebates to employees, we are exploring opportunities to evolve our
benefits in the future.
______
Questions Submitted by Hon. Sheldon Whitehouse
Question. Please describe any policy changes you support that would
result in your company lowering the list prices of its drugs.
Answer. The current rebate construct is the key challenge in
reducing list prices and we would support legislation that would
eliminate rebates in Part D and the commercial sector. Assuming the HHS
rebate rule is finalized largely as proposed, AstraZeneca intends to
comply with its requirements and use point-of-sale discounts. Our goal
is to maintain net prices broadly in line with today, recognizing our
ability to do so may be dependent on external factors and market
response such as how plans evolve their benefit design and the total
degree of transparency under the new model.
AstraZeneca would plan to reduce list prices, pending reforms
across all payers, including in the commercial sector in addition to
Part D, as the current construct does not allow for two separate list
prices (i.e., one list price for Part D and a different list price for
the commercial sector). Therefore, we also support efforts to eliminate
rebates in the commercial sector, and recommend that Congress explore
such legislation. While eliminating rebates is an important step,
benefit designs must also be evaluated.
Question. How much does your company's research and development
portfolio rely on taxpayer-funded research conducted by the National
Institutes of Health (NIH)? How many of your company's products are
based, at least in part, on NIH research, and how many are the result
of research funded solely by your company?
Answer. We collaborate with the National Institutes of Health and
the National Cancer Institute, and these partnerships can lead to
important advances for patients. However, biopharmaceutical companies
conduct the vast majority of R&D needed to bring new medicines to
patients and they bear the associated costs and risks.
Question. In each of the last 5 years, how much has your company
spent on research and development versus the advertising and marketing
of your products?
Answer. Last year alone, we invested nearly $6 billion in R&D,
which represents 28 percent of our total product sales, well above the
industry average.
Our Sales and Marketing figures include all costs incurred in
selling, marketing, promoting, and distributing our products.
------------------------------------------------------------------------
Year R&D Investment Sales and Marketing
------------------------------------------------------------------------
2018 $5.9 billion $6.1 billion
------------------------------------------------------------------------
2017 $5.8 billion $5.6 billion
------------------------------------------------------------------------
2016 $5.9 billion $5.8 billion
------------------------------------------------------------------------
2015 $6.0 billion $6.6 billion
------------------------------------------------------------------------
2014 $5.6 billion $7.1 billion
------------------------------------------------------------------------
Question. During the hearing, you mentioned that your company would
be likely to lower the list prices of its drugs if the recent proposal
by the Trump administration to change the current system of rebates was
extended to the private market.
If the policy was extended to the private market, how large would
the list price reductions be relative to the size of the rebates your
company is currently providing?
Answer. Assuming the HHS rebate rule is finalized largely as
proposed, AstraZeneca intends to comply with its requirements and use
pointof-sale discounts. Our goal is to maintain net prices broadly in
line with today, recognizing our ability to do so may be dependent on
external factors and market response such as how plans evolve their
benefit design and the total degree of transparency under the new
model.
AstraZeneca would plan to reduce list prices, pending reforms
across all payers, including in the commercial sector in addition to
Part D, as the current construct does not allow for two separate list
prices (i.e., one list price for Part D and a different list price for
the commercial sector). Therefore, we also support efforts to eliminate
rebates in the commercial sector, and recommend that Congress explore
such legislation. While eliminating rebates is an important step,
benefit designs must also be evaluated.
Question. How will this proposal affect how your company sets the
list prices for new drug products?
Answer. We believe that eliminating rebates across Medicare Part D
and commercial will generally result in lower initial list prices than
in the absence of reform, although the impact on specific medicines
will vary based on the competitive dynamics for that medicine. Reform
only in Part D and not commercial is unlikely to impact initial list
price setting practices, as the current structure does not allow for
two separate list prices (i.e., one list price for Part D and a
different list price for the commercial sector).
Question. If the proposal is finalized and not extended to the
private market, will your company make any list price reductions? If
so, how large would the reductions be relative to the size of the
rebates your company is currently providing?
Answer. AstraZeneca would plan to reduce list prices, pending
reforms across all payers, including in the commercial sector in
addition to Part D, as the current construct does not allow for two
separate list prices (i.e., one list price for Part D and a different
list price for the commercial sector). Therefore, we also support
efforts to eliminate rebates in the commercial sector, and recommend
that Congress explore such legislation. While eliminating rebates is an
important step, benefit designs must also be evaluated.
______
Question Submitted by Hon. Maggie Hassan
Question. In June of 2018, the Medicaid and CHIP Payment and Access
Commission (MACPAC) unanimously recommended under Recommendation 1.1 in
their annual report to Congress that Congress remove the statutory
requirement that manufacturers blend the average manufacturer price
(AMP) of a brand drug and its authorized generic.\3\ This requirement
created an unintended loophole. Rather than use the price of the
authorized generic, drug companies can sell its authorized generic to a
corporate subsidiary at an artificially lower price, and use that lower
price to bring down the AMP, which in turn lowers the rebate
obligation.
---------------------------------------------------------------------------
\3\ MACPAC, ``Improving Operations of the Medicaid Drug Rebate
Program,'' https://www.macpac.gov/wp-content/uploads/2018/06/Improving-
Operations-of-the-Medicaid-Drug-Rebate-Program.pdf.
Does your company engage in this practice? Has your company ever
---------------------------------------------------------------------------
engaged in this practice in the past?
Answer. No. In limited circumstances, AstraZeneca has made
authorized generics available, but does so through a third-party
distributor, not an AstraZeneca subsidiary.
______
Questions Submitted by Hon. Catherine Cortez Masto
Question. As a portion of your revenue, for what percentage of the
drugs in your portfolio do you offer no rebates? Based on the drugs in
your pipeline, do you foresee that portion growing? For those drugs, is
your list price equal to your net price?
Answer. All of our medicines are rebated under the statutory
requirements of Medicaid, Federal Supply Schedule, 340B, and the Part D
coverage gap discount program. For our highly innovative, targeted
therapies, we do not typically provide additional rebates other than
through our value-based agreements, where such discounts are based on
patient outcomes. Therefore, due to statutory rebates and other fees
and discounts, the net price is lower than list price for all
medicines.
Question. Do you invest more in R&D than you generate in U.S. sales
revenue? Please include specific figures.
Answer. In 2018, AstraZeneca's U.S. revenue was $6.88 billion. We
invested $5.9 billion in R&D, globally.
Question. Do you invest more in R&D than you spend on marketing and
administration? What company functions do you consider to be included
in administration? Please include specific figures.
Answer. In 2018, we spent $5.9 billion on R&D and $10 billion on
Selling, General and Administrative (SG&A) costs globally, which is
inclusive of Sales and Marketing costs of $6.1 billion.
Selling, General and Administrative expenses are defined as fixed
costs of selling products and services and costs of central services
and administration, which are not included in inventory values.
General and administrative costs include costs of central services
and administration, such as: Human Resources, Finance, Facilities,
Purchasing, Strategy and Business Development, Legal, Corporate
Affairs, and other corporate expenses.
Our Sales and Marketing figures include all costs incurred in
selling, marketing, promoting, and distributing our products.
Question. Do you invest more in R&D than you spend on marketing and
sales? What company functions do you consider to be included in sales?
Please include specific figures.
Answer. In 2018, we spent $5.9 billion on R&D and $6.1 billion on
Sales and Marketing, globally.
Our Sales and Marketing figures include all costs incurred in
selling, marketing, promoting, and distributing our products.
Question. Why do you advertise for the drugs you manufacture? What
factors do you consider in choosing which drugs you advertise?
Answer. We consider many factors when making decisions regarding
the advertising of our medicines, including the opportunity to raise
brand and disease awareness, patient education, and the enhancement of
the patient/physician dialogue.
We believe that health-care communications efforts can have a
positive impact on patient health. AstraZeneca made a decision several
years ago to use our direct-to-consumer (DTC) advertisements to share
another important message with patients: We were the first company to
include messages about our affordability programs in all of our DTC TV
advertisements, making clear to patients that if they cannot afford
their medicines, AstraZeneca may be able to help. We continue this
practice today, which we believe is reflective of AstraZeneca's
commitment to patient access and affordability.
______
Appendix A
------------------------------------------------------------------------
Organization Program Title Date Amount
------------------------------------------------------------------------
CARDIOVASCULAR RESEARCH Chronic Total 01/07/2014 $5,000.00
FOUNDATION Occlusion and
Left Main Summit
2014: A Live
Demonstration
Course
------------------------------------------------------------------------
TORRANCE MEMORIAL Cardiology Update 01/08/2014 $2,500.00
MEDICAL CENTER 2014:
Conventional
Wisdom and Beyond
------------------------------------------------------------------------
SCRIPPS HEALTH Grand Rounds in 01/09/2014 $8,027.93
Cardiovascular
Diseases
------------------------------------------------------------------------
UNIVERSITY OF CHICAGO Sixth Annual 01/12/2014 $3,000.00
Morton Arnsdorf
Cardiovascular
Research Day at
the University of
Chicago
------------------------------------------------------------------------
FLORIDA OSTEOPATHIC 15th Annual 01/15/2014 $5,000.00
MEDICAL ASSOCIATION Cardiovascular
DISTRICT SOCIETY 2 and Medicine
Symposium
------------------------------------------------------------------------
AMERICAN COLLEGE OF 25th Annual 01/16/2014 $5,000.00
CARDIOLOGY--PUERTO Meeting ACC
RICO CHAPTER Puerto Rico
Chapter
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF Improving Patient 01/23/2014 $25,000.00
MANAGED CARE Outcomes: Updated
PHYSICIANS Treatment
Strategies in the
Management of
Acute Coronary
Syndrome (ACS)
------------------------------------------------------------------------
UNIVERSITY MEDICAL 6th Annual 01/23/2014 $5,000.00
CENTER OF SOUTHERN Cardiovascular
NEVADA and Stroke
Symposium
------------------------------------------------------------------------
SAINT JOSEPH'S Antithrombotic 01/23/2014 $2,737.62
HOSPITAL--ATLANTA Protocol for
Acute Coronary
Sndrome
------------------------------------------------------------------------
GORDON RESERACH Gordon Research 01/26/2014 $1,700.00
CONFRENCE Seminar--``Lipopr
otein
Metabolism''
------------------------------------------------------------------------
CLEVELAND CLINIC Rheumatology Best 01/26/2014 $9,795.58
EDUCATIONAL FOUNDATION Practices 6th
Annual
Rheumatology
Highlights
Report--``Transla
ting an
International
Meeting into
Clinical
Practice''
------------------------------------------------------------------------
KERN ASPEN LIPID Evolving Concepts 01/26/2014 $7,000.00
CONFERENCE of HDL Function
in
Cardiometabolic
Diseases and
Beyond
------------------------------------------------------------------------
ST. JOSEPH'S REGIONAL Acute Coronary 01/27/2014 $2,225.00
MEDICAL CENTER Syndrome:
Evidence-Based
Management in the
Present Era
------------------------------------------------------------------------
NATIONAL LIPID Lipid Academy 01/28/2014 $20,000.00
ASSOCIATION Series of 2
------------------------------------------------------------------------
NATIONAL LIPID Masters in 01/28/2014 $20,000.00
ASSOCIATION Lipidology Series
of 2
------------------------------------------------------------------------
REGENTS OF THE Rheumatology Grand 01/29/2014 $5,000.00
UNIVERSITY OF Rounds
CALIFORNIA
------------------------------------------------------------------------
DUKE UNIVERSITY Overview of the 01/29/2014 $5,439.84
Duke Health
Systems Acute
Coronary
Syndromes
suggested
algorithm of care
------------------------------------------------------------------------
PENNSYLVANIA ACADEMY OF PAFP/F Smoking 01/29/2014 $13,666.00
FAMILY PHYSICIANS Cessation and
FOUNDATION Asthma Outcomes
CME
------------------------------------------------------------------------
JOHNS HOPKINS Advances in the 01/30/2014 $30,000.00
UNIVERSITY Diagnosis and
Treatment of the
Rheumatic
Diseases
------------------------------------------------------------------------
EMORY UNIVERSITY Emory Symposium on 01/30/2014 $5,000.00
Coronary
Atherosclerosis
Prevention and
Education
(ESCAPE)
------------------------------------------------------------------------
NURSE PRACTITIONER Clinical Pearls 01/30/2014 $5,000.00
ASSOCIATES FOR for COPD
CONTINUING EDUCATION
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF Practical 01/30/2014 $25,000.00
MANAGED CARE Strategies to
PHYSICIANS Improve Patient
Outcomes in the
Prevention and
Treatment of COPD
------------------------------------------------------------------------
ST. JOSEPH'S REGIONAL COPD 02/04/2014 $2,200.00
MEDICAL CENTER
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF AACE 23rd Annual 02/04/2014 $16,130.00
CLINICAL Scientific and
ENDOCRINOLOGISTS Clinical Congress
------------------------------------------------------------------------
NURSE PRACTITIONER Cardiovascular 02/04/2014 $5,000.00
ASSOCIATES FOR Pharmacology:
CONTINUING EDUCATION Latest Updates in
Caring for the
Cardiac Patient
------------------------------------------------------------------------
MIDWEST CARDIOVASCULAR Cardiology at the 02/04/2014 $5,000.00
RESEARCH FOUNDATION Bix
------------------------------------------------------------------------
AMERICAN COLLEGE OF ACCs 63rd Annual 02/05/2014 $100,000.00
CARDIOLOGY FOUNDATION Scientific
Session (ACC.14)
Prevention
Learning Pathway
and Prevention
Pilot Program
------------------------------------------------------------------------
LA BIOMED Cardiology Grand 02/05/2014 $5,000.00
Rounds: Updates
in ACS
------------------------------------------------------------------------
NEBRASKA ACADEMY OF Ten Things You 02/05/2014 $5,500.00
PHYSICIAN ASSISTANTS Didn't Learn
About COPD in
Class (Even If
You Were Paying
Attention
------------------------------------------------------------------------
MINNESOTA SOCIETY OF MSHP Annual 02/05/2014 $2,533.00
HEALTH-SYSTEM Meeting 2014:
PHARMACISTS Evidenced-based
Updates in the
Management of
Dyslipidemia
------------------------------------------------------------------------
CARDIOVASCULAR RESEARCH 20th Annual 02/05/2014 $15,000.00
FOUNDATION Interventional
Cardiology
Fellows Course
------------------------------------------------------------------------
AMERICAN COLLEGE OF Best of ACC.14: 02/05/2014 $50,000.00
CARDIOLOGY FOUNDATION Take Home
Messages for the
Clinicians
------------------------------------------------------------------------
ENDOCRINE SOCIETY ENDO 2014 02/06/2014 $40,000.00
Educational
Sessions
------------------------------------------------------------------------
ALL NYC EMERGENCY All NYC Emergency 02/06/2014 $5,000.00
MEDICINE CONFERENCE, Medicine
INC. Conference; In
the Footsteps of
Giants
------------------------------------------------------------------------
AMERICAN COLLEGE OF Annual Scientific 02/09/2014 $10,000.00
PHYSICIANS; PUERTO Meeting
RICO CHAPTER
------------------------------------------------------------------------
CARDIOVASCULAR RESEARCH Optimizing PCI 02/09/2014 $5,000.00
FOUNDATION Outcomes: A
Vision for 2014
------------------------------------------------------------------------
INTERNATIONAL 14th Annual 02/10/2014 $12,500.00
ASSOCIATION FOR THE Targeted
STUDY OF LUNG CANCER Threapies of Lung
Cancer Meeting
------------------------------------------------------------------------
TENNESSEE ACADEMY OF Breast and Ovarian 02/10/2014 $6,000.00
PHYSICIAN ASSISTANTS Cancer
------------------------------------------------------------------------
PURDUE UNIVERSITY A 2014 National 02/12/2014 $30,000.00
Educational
Initiative on
Therapeutics and
Rheumatology for
Rheumatology
State Societies
------------------------------------------------------------------------
WEST PENN ALLEGHENY Cardiovascular 02/17/2014 $10,000.00
HEALTH SYSTEM, INC. Medicine Update
------------------------------------------------------------------------
MEDSTAR WASHINGTON 12th International 02/18/2014 $25,000.00
HOSPITAL CENTER Congress on
Targeted
Anticancer
Therapies (TAT)
------------------------------------------------------------------------
THE BIBIKHAN FOUNDATION 7th Annual 02/18/2014 $5,000.00
Cardiovascular
Update--``A
Practical
Tutortial''
------------------------------------------------------------------------
SOCIETY OF GYNECOLOGIC SGO 45th Annual 02/19/2014 $25,000.00
ONCOLOGY Meeting on
Women's Cancer
------------------------------------------------------------------------
GORDON RESEARCH Gordon Research 02/19/2014 $5,000.00
CONFERENCES Conferences on
Cardiac
Regulatory
Mechanisms
------------------------------------------------------------------------
BAYLOR UNIVERSITY Emerging 02/20/2014 $17,460.00
MEDICAL CENTER DBA A. Therapeutic
WEBB ROBERTS CENTER Options for
Medullary Thyroid
Cancer and
Differentiated
Thyroid Cancer
------------------------------------------------------------------------
ACADEMIA MEDICA DEL SUR- Cardiometabolic 02/20/2014 $20,000.00
FONDO EDUCACION MEDICA Health Congress
CONTINUADA 2014
------------------------------------------------------------------------
DUKE UNIVERSITY MEDICAL 13th Annual 02/25/2014 $5,498.41
CENTER Southeastern
Fellows Research
Skills Retreat
------------------------------------------------------------------------
THE UNIVERSITY OF 19th Annual 02/25/2014 $5,000.00
CHICAGO University of
Chicago Phase II
Consortium (UC
P2C) Symposium
------------------------------------------------------------------------
INTERNATIONAL SOCIETY 60th Annual 02/25/2014 $25,000.00
ON THROMBOSIS AND Meeting of the
HAEMOSTASIS Scientific and
Standardization
Committee (SSC)
of the
International
Society on
Thrombosis and
Haemostasis
(ISTH)
------------------------------------------------------------------------
THE UNIVERSITY OF Making Sense of 02/25/2014 $5,000.00
CHICAGO the Sequence:
Genomics Primer
for Clinical
Cancer Genetic
Practitioners
------------------------------------------------------------------------
WEST VIRGINIA ACADEMY Dyslipidemia and 02/25/2014 $2,500.00
OF FAMILY PHYSICIANS Atherosclerosis--
Reducing the Risk
------------------------------------------------------------------------
AMERICAN ACADEMY OF PediaLink 02/26/2014 $37,800.00
PEDIATRICS Influenza Course
Series
------------------------------------------------------------------------
PREVENTIVE 20th Annual 02/26/2014 $15,000.00
CARDIOVASCULAR NURSES Symposium
ASSOCIATION
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF 2014 NAFC Annual 02/27/2014 $30,000.00
FREE and CHARITABLE Summit
CLINICS
------------------------------------------------------------------------
VANDERBILT UNIVERSITY Cardiology 2014: 02/27/2014 $5,000.00
Advances in
Science and
Practice
------------------------------------------------------------------------
THE BOARD OF REGENTS OF Cardiovascular 02/27/2014 $5,000.00
THE UNIVERSITY OF Medicine and
WISCONSIN SYSTEM Prevention Update
for Primary Care
------------------------------------------------------------------------
SOCIETY FOR VASCULAR Society for 03/02/2014 $5,000.00
MEDICINE Vascular Medicine
25th Anniversary
and Scientific
Sessions
------------------------------------------------------------------------
AMERICAN ASSOCIATION 94th Annual 03/04/2014 $10,000.00
FOR THORACIC SURGERY Meeting American
Association for
Thoracic Surgery
------------------------------------------------------------------------
CHI ST. LUKE'S HEALTH Cardiology Grand 03/05/2014 $3,857.58
Rounds
------------------------------------------------------------------------
MIDWEST CARDIOVASCULAR Cardiovascular 03/05/2014 $5,000.00
RESEARCH FOUNDATION Interventions and
Practice
Guidelines
------------------------------------------------------------------------
UNIVERSITY OF ROCHESTER 27th Cardiology 03/05/2014 $4,805.00
Spring Update
2014
------------------------------------------------------------------------
UNIVERSITY OF Clinical 03/05/2014 $4,000.00
WASHINGTON Cardiology Pearls
for Primary Care
Providers
------------------------------------------------------------------------
AMERICAN ACADEMY OF Faces and Cases: 03/06/2014 $50,000.00
PAIN MANAGEMENT Assessing and
Managing People
With Complex
Chronic Pain
------------------------------------------------------------------------
PRESIDENT AND FELLOWS Pediatric Asthma 03/06/2014 $5,000.00
OF HARVARD COLLEGE and Allergy
Updates for
Primary Care
Providers
------------------------------------------------------------------------
PRESIDENT AND FELLOWS Boston Bacterial 03/06/2014 $2,500.00
OF HARVARD COLLEGE Meeting 2014
------------------------------------------------------------------------
CARDIOVASCULAR RESEARCH TCTMD 2014 Post 03/09/2014 $100,000.00
FOUNDATION Conference Web
Cast Series
------------------------------------------------------------------------
CARDIOVASCULAR RESEARCH DAPT Dilemmas: A 03/09/2014 $66,913.46
FOUNDATION Case-based
Roundtable
Tutorial
------------------------------------------------------------------------
ASSOCIATION OF BLACK 40th Anniversary 03/11/2014 $20,000.00
CARDIOLOGISTS Annual Scientific
Sessions The
Ecology of
Cardiovascular
Disease in 2014:
Trends,
Challenges and
Targets for 2025
------------------------------------------------------------------------
THE HOPE FOUNDATION Spring 2014 SWOG 03/18/2014 $10,000.00
Group Meeting
------------------------------------------------------------------------
AMERICAN LUNG ALASD Asthma 03/18/2014 $2,500.00
ASSOCIATION OF THE Educator
UPPER MIDWEST Institute
------------------------------------------------------------------------
AMERICAN SOCIETY OF Getting to Goal: 03/19/2014 $5,950.00
CONSULTANT PHARMACISTS The Pharmacist's
FL CHAPTER Role in Managing
Dyslipidemia and
Atherosclerosis
------------------------------------------------------------------------
THE RESEARCH FOUNDATION Cal For Grants CGA 03/19/2014 $2,000.00
CV 1404--Time
Critical
Diagnosis (TCD)
Symposium
------------------------------------------------------------------------
EMORY UNIVERSITY Emory Practical 03/19/2014 $3,000.00
Intervention
Course (EPIC
2014)
------------------------------------------------------------------------
GORDON RESEARCH Gordon Research 03/20/2014 $5,000.00
CONFERENCES Conference and
Seminar on
Hemostasis
------------------------------------------------------------------------
PENNSYLVANIA ALLERGY 2014 Annual 03/20/2014 $5,000.00
AND ASTHMA ASSOCIATION Meeting of the
Pennsylvania
Allergy and
Asthma
Association
------------------------------------------------------------------------
ONCOLOGY NURSING Oncology Nursing 03/20/2014 $25,000.00
SOCIETY Society 39th
Annual Congress
------------------------------------------------------------------------
RICHMOND UNIVERSITY Lipid Management 03/20/2014 $1,400.00
MEDICAL CENTER 2014 Guidelines
and Beyond
------------------------------------------------------------------------
JOHNS HOPKINS 5th Annual Johns 03/23/2014 $2,500.00
UNIVERSITY Hopkins
Cardiovascular
Research Retreat
------------------------------------------------------------------------
AMERICAN ACADEMY OF Fall 2014 03/23/2014 $5,000.00
ALLERGY ASTHMA AND Symposium of the
IMMUNOLOGY Los Angeles
Society of
Allergy, Asthma
and Clinical
Immunology
------------------------------------------------------------------------
UNIVERSITY OF FLORIDA Vascular Biology 03/23/2014 $15,000.00
Working Group US
Chapter Meeting
------------------------------------------------------------------------
THE SOCIETY FOR 2014 SCAI 03/23/2014 $15,000.00
CARDIOVASCULAR Transradial
ANGIOGRAPHY AND Interventional
INTERVENTIONS Program (TRIP)
Series
------------------------------------------------------------------------
ASPEN LUNG CONFERENCE Thomas L. Petty 03/24/2014 $5,000.00
Aspen Lung
Conference:
Rebuilding the
Injured Lung
------------------------------------------------------------------------
INTERNATIONAL SOCIETY ISHIB 2014 Annual 03/24/2014 $10,000.00
ON HYPERTENSION IN Conference-
BLACKS INC. Medical and
Social
Determinants of
Cardiometabolic
Health
------------------------------------------------------------------------
ARKANSAS ACADEMY OF 67th Annual 03/24/2014 $3,000.00
FAMILY PHYSICIANS Scientific
Assembly of the
Arkansas Academy
of Family
Physicians
------------------------------------------------------------------------
TRUSTEES OF THE Current Advances 03/24/2014 $5,000.00
UNIVERSITY OF in Cardiovascular
PENNSYLVANIA Care 2014
------------------------------------------------------------------------
ST. PETER'S HOSPITAL Cardiology 03/25/2014 $3,000.00
Teaching Day
------------------------------------------------------------------------
CHARLES R. DREW 18th Annual 03/26/2014 $25,000.00
UNIVERSITY OF MEDICINE Conference
and SCIENCE
------------------------------------------------------------------------
GORDON RESEARCH 2014 GRC on 03/27/2014 $2,500.00
CONFERENCES Heterocyclic
Compounds
------------------------------------------------------------------------
THE ROCKEFELLER Leptin and 03/30/2014 $25,000.00
UNIVERSITY Metabolic
Disease: A
Special Symposium
on the 20th
Anniversary of
the Discovery of
Leptin
------------------------------------------------------------------------
AMERICAN COLLEGE OF CSAAI's A 03/30/2014 $5,000.00
ALLERGY, ASTHMA AND Midsummer Night's
IMMUNOLOGY Wheeze 2014
------------------------------------------------------------------------
UNIVERSITY OF NEW PeerView Live, 04/01/2014 $353,000.00
MEXICO Using Evidence-
Based Treatment
to Optimize
Control of
Elevated Serum
Triglycerides
(150202699)
------------------------------------------------------------------------
THOMAS JEFFERSON Jefferson Critical 04/01/2014 $5,000.00
UNIVERSITY Care Symposium: A
Multidisciplinary
Review of Current
Evidence and
Controversies
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF 35th Annual 04/01/2014 $3,000.00
ENDOCRINE SURGEONS Meeting of the
American
Association of
Endocrine
Surgeons
------------------------------------------------------------------------
GORDON RESEARCH 2014 Bioorganic 04/02/2014 $1,000.00
CONFERENCES Chemistry Gordon
Research
Conference
------------------------------------------------------------------------
THE NEW YORK Seventh Annual 04/03/2014 $3,050.00
CARDIOLOGICAL SOCIETY, Cardiac Care
INC. Associate
Symposium 2014
------------------------------------------------------------------------
CLEVELAND CLINIC 15th Annual 04/03/2014 $4,706.02
EDUCATIONAL FOUNDATION Intensive Review
of Cardiology
------------------------------------------------------------------------
WASHINGTON UNIVERSITY Cardiology Update 04/06/2014 $4,000.00
------------------------------------------------------------------------
DIGNITY HEALTH ST. 16th Annual 04/06/2014 $6,000.00
BERNARDINE MEDICAL Cardiac Symposium
CENTER
------------------------------------------------------------------------
CONQUER CANCER 2014 Conquer 04/09/2014 $24,000.00
FOUNDATION OF THE Cancer Foundation
AMERICAN SOCIETY OF of ASCO Merit
CLINICAL ONCOLOGY Awards
------------------------------------------------------------------------
MUNSTER MEDICAL New Frontiers in 04/09/2014 $4,200.00
RESEARCH FOUNDATION Cardiovascular
DBA COMMUNITY HOSPITAL Disease 2014
------------------------------------------------------------------------
GORDON RESEARCH 2014 Gordon 04/09/2014 $2,000.00
CONFERENCES Research
Conference:
Enzymes CoEnzymes
and Metabolic
Pathways
------------------------------------------------------------------------
AMERICAN COLLEGE 2014 Mississippi/ 04/09/2014 $5,000.00
PHYSICIANS--MISSISSIPP Louisiana ACP
I CHAPTER Educational and
Scientific
Meeting
------------------------------------------------------------------------
ICHAN SCHOOL OF Live Symposium of 04/10/2014 $10,000.00
MEDICINE AT MOUNT Complex Coronary,
SINAI Valvular and
Vascular Cases
------------------------------------------------------------------------
NATIONAL FOUNDATION FOR Clinical 04/13/2014 $25,000.00
INFECTIOUS DISEASES Vaccinology
Course
------------------------------------------------------------------------
AMERICAN ACADEMY OF The AAPA 2014 04/13/2014 $7,500.00
PHYSICIAN ASSISTANTS Annual
Conference--Cardi
ology Track
------------------------------------------------------------------------
NEW JERSEY ACADEMY OF Cardiovascular 04/13/2014 $5,000.00
FAMILY PHYSICIANS Controversies
JNC8 and
Cholesterol
Treatment
Guidelines (2014
Scientific
Assembly)
------------------------------------------------------------------------
HUMBOLDT-DEL NORTE Asthma Update 04/14/2014 $4,000.00
COUNTY MEDICAL SOCIETY
------------------------------------------------------------------------
DANNEMILLER, INC. Contemporary 04/16/2014 $50,000.00
Perspectives in
COPD: A
Pulmonologist's
Guide to
Individualized
Patient Care
------------------------------------------------------------------------
OKLAHOMA UNIVERSITY 17th Annual 04/16/2014 $3,000.00
HEALTH SCIENCE CENTER-- Primary Care
OUHSC Update
------------------------------------------------------------------------
CONQUER CANCER 2014 Conquer 04/17/2014 $60,000.00
FOUNDATION OF THE Cancer Foundation
AMERICAN SOCIETY OF of ASCO Young
CLINICAL ONCOLOGY Investigator
Award (YIA)
------------------------------------------------------------------------
CLEVELAND CLINIC 6th Annual E- 04/17/2014 $9,352.86
EDUCATIONAL FOUNDATION Journal Club: The
Insights on
Biologics and New
Agents for
Rheumatic
Diseases
------------------------------------------------------------------------
NATIONAL FOUNDATION FOR 17th Annual 04/21/2014 $15,000.00
INFECTIOUS DISEASES Conference on
Vaccine Research
------------------------------------------------------------------------
ECOG RESEARCH AND 2014 ECOG-ACRIN 04/21/2014 $5,000.00
EDUCATION FOUNDATION Spring Group
Meeting
------------------------------------------------------------------------
METABOLIC ENDOCRINE Contemporary T2DM 04/21/2014 $229,200.00
EDUCATION FOUNDATION Management: Focus
on Safety and
Efficacy
------------------------------------------------------------------------
THE CHEST FOUNDATION The CHEST 04/21/2014 $35,000.00
Foundation
Diversity
Research/Women's
Respiratory
Health Awards
Program
------------------------------------------------------------------------
MISSOURI ACADEMY OF Hyperlipidemia 04/21/2014 $5,000.00
PHYSICIAN ASSISTANTS
------------------------------------------------------------------------
REGENTS OF THE Lipidomics Impact 04/22/2014 $2,500.00
UNIVERSITY OF on Cell Biology,
CALIFORNIA, SAN DIEGO Inflammation and
Metabolic Disease
------------------------------------------------------------------------
NATIONAL MINORITY 11th Annual 04/23/2014 $30,000.00
QUALITY FORUM National Summit
on Health
Disparities
------------------------------------------------------------------------
DUKE UNIVERSITY 2014 Carolinas 04/24/2014 $20,000.00
COPD Symposium
------------------------------------------------------------------------
MICHIGAN STATE MEDICAL Rheumatology 04/24/2014 $3,000.00
SOCIETY FOUNDATION Update
------------------------------------------------------------------------
MAIN LINE HEALTH Atherosclerosis: 04/24/2014 $5,000.00
Prevention of
Progression
------------------------------------------------------------------------
CASE MANAGEMENT SOCIETY CMSA 2014 Annual 04/27/2014 $15,000.00
OF AMERICA Conference and
Expo
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE NCCN 2014 Monthly 04/27/2014 $25,000.00
CANCER NETWORK, INC. Oncology Tumor
Boards: A
Multidisciplinary
Approach to
Individualized
Patient Care
------------------------------------------------------------------------
AMERICAN HEART Arteriosclerosis, 04/27/2014 $20,000.00
ASSOCIATION, INC. Thrombosis, and
Vascular Biology
Scientific
Sessions 2014
------------------------------------------------------------------------
SCRIPPS HEALTH 25th Annual 04/27/2014 $5,000.00
Cardiovascular
Interventions
------------------------------------------------------------------------
AMERICAN COLLEGE OF Interventional 04/27/2014 $5,000.00
CARDIOLOGY FOUNDATION Cardiology Board
Preparatory
Educational
Package
------------------------------------------------------------------------
TEXAS ONE VOICE: A Designing 04/28/2014 $1,000.00
COLLABORATIVE FOR Healthcare in
HEALTH AND HUMAN Texas How the
SERVICES Past and Present
will Guide the
Future
------------------------------------------------------------------------
TRUSTEES OF THE Cardiology Update 04/28/2014 $10,000.00
UNIVERSITY OF 2014: A Patient
PENNSYLVANIA Management
Approach
------------------------------------------------------------------------
CONQUER CANCER 2014 ASCO Annual 05/04/2014 $56,000.00
FOUNDATION OF THE Meeting Lung
AMERICAN SOCIETY OF Cancer Track
CLINICAL ONCOLOGY
------------------------------------------------------------------------
FOUNDATION FOR CARE Dyslipidemia and 05/06/2014 $25,000.00
MANAGEMENT New Cholesterol
Guidelines: What
the Primary Care
Provider Needs to
Know
------------------------------------------------------------------------
AMERICAN COLLEGE OF Update in Allergy, 05/06/2014 $10,000.00
ALLERGY, ASTHMA AND Asthma and
IMMUNOLOGY Immunology
------------------------------------------------------------------------
FLORIDA ACADEMY OF Update in the 05/06/2014 $5,000.00
PHYSICIAN ASSISTANTS Management of
Dyslipidemia
------------------------------------------------------------------------
VASSAR BROTHERS MEDICAL 44th Annual 05/06/2014 $5,000.00
CENTER Cardiology
Education Day
------------------------------------------------------------------------
ZOE ROSE MEMORIAL 2014 Preemie 05/06/2014 $10,000.00
FOUNDATION DBA PREEMIE Parent Summit
PARENT ALLIANCE
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF AACE 23rd Annual 05/07/2014 $25,000.00
CLINICAL Scientific and
ENDOCRINOLOGISTS Clinical Congress
------------------------------------------------------------------------
LOUISIANA SOCIETY OF LSAAI 41st Annual 05/07/2014 $5,000.00
ALLERGY, ASTHMA AND Meeting
IMMUNOLOGY
------------------------------------------------------------------------
AMERICAN ACADEMY OF AAFP Assembly 60 05/07/2014 $13,000.00
FAMILY PHYSICIANS Minute Lecture
titled Chronic
Obstructive
Pulmonary
Disorder (COPD)
and Pulmonary
Function Testing
------------------------------------------------------------------------
COLUMBUS COMMUNITY 2014 ASCO REVIEW 05/08/2014 $5,000.00
CLINICAL ONCOLOGY
PROGRAM
------------------------------------------------------------------------
AMERICAN COLLEGE OF Aspen Allergy 05/08/2014 $10,000.00
ALLERGY, ASTHMA AND Conference
IMMUNOLOGY
------------------------------------------------------------------------
AMERICAN DIABETES 29th Annual 05/11/2014 $20,000.00
ASSOCIATION Clinical
Conference on
Diabetes--Reducin
g Risks: Primary
and Secondary
------------------------------------------------------------------------
REGENTS OF THE 20th Annual UCLA 05/11/2014 $5,000.00
UNIVERSITY OF Symposium
CALIFORNIA Pulmonary
Function and
Exercise Testing:
Practical
Approaches for
the Healthcare
Practitioner
------------------------------------------------------------------------
AMERICAN COLLEGE OF The Changing 05/11/2014 $5,000.00
ALLERGY, ASTHMA AND Allergy Practice
IMMUNOLOGY
------------------------------------------------------------------------
AMERICAN COLLEGE OF Caribbean Congress 05/12/2014 $5,000.00
EMERGENCY PHYSICIANS, on Emergency
PUERTO RICO CHAPTER Medicine
------------------------------------------------------------------------
CLEVELAND CLINIC 19th Annual 05/13/2014 $6,613.34
EDUCATIONAL FOUNDATION Diabetes Day:
Diabetes Therapy
------------------------------------------------------------------------
THE REGENTS UNIVERSITY UCLA Family 05/13/2014 $7,500.00
OF CALIFORNIA Medicine
Refresher Course
------------------------------------------------------------------------
CLEVELAND CLINIC ASCO Review 05/13/2014 $4,000.00
EDUCATIONAL FOUNDATION
------------------------------------------------------------------------
SOCIEDAD PUERTORRIQUENA Puerto Rican 05/14/2014 $10,000.00
DE ENDOCRINOLOGIA Y Endocrinology and
DIABETOLOGIA Diabetes Society
Scientific
Meeting
------------------------------------------------------------------------
NATIONAL MEDICAL Asthma as a Model 05/14/2014 $25,000.00
ASSOCIATION Chronic Illness
------------------------------------------------------------------------
GORDON RESEARCH 2014 Lipoprotein 05/14/2014 $2,500.00
CONFERENCES Metabolism Gordon
Research
Conference
------------------------------------------------------------------------
ONCOLOGY NURSING Pharmacology 05/14/2014 $5,000.00
SOCIETY Update:Integratin
g Advances into
Practice
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF 2014 National 05/14/2014 $5,000.00
SERVICE COORDINATORS Service
Coordinator
Conference
------------------------------------------------------------------------
MAYO CLINIC ARIZONA Cardiology Update 05/15/2014 $10,000.00
2014: The Heart
of the Matter
------------------------------------------------------------------------
AMERICAN CHEMICAL 2014 ACS National 05/18/2014 $1,000.00
SOCIETY--DIVISION OF Medicinal
MEDICINAL CHEMISTRY Chemistry
Symposium
------------------------------------------------------------------------
CHICAGO ASTHMA Emergency 05/18/2014 $2,000.00
CONSORTIUM Management of
Asthma
------------------------------------------------------------------------
SUFFOLK ACADEMY OF 31st Update in 05/19/2014 $3,000.00
MEDICINE Allergy and
Immunology
Symposium
------------------------------------------------------------------------
EMORY UNIVERSITY Discussing Cases 05/19/2014 $20,000.00
with Diabetes
Experts
------------------------------------------------------------------------
NATIONAL MEDICAL Evidence-Based 05/19/2014 $23,405.00
ASSOCIATION Diagnosis and
Management of
Asthma and COPD:
Practical Tools
to Improve
Patient Care
------------------------------------------------------------------------
NORTH SHORE LONG ISLAND Post American 05/19/2014 $3,000.00
JEWISH HEALTH SYSTEM Society of
Clinical Oncology
Update 2014
------------------------------------------------------------------------
LAHEY CLINIC HOSPITAL, Cardiovascular 05/19/2014 $6,000.00
INC. Disease: State of
the Art 2014
------------------------------------------------------------------------
AMERICAN COLLEGE OF 2014 05/19/2014 $5,000.00
CARDIOLOGY FOUNDATION Cardiovascular
Board Review for
Certification and
Recertification
Educational
Package
------------------------------------------------------------------------
NEW JERSEY ACADEMY OF The Current 05/21/2014 $2,500.00
FAMILY PHYSICIANS Standards Of Care
and Treatment of
Diabetes (2014
Scientific
Assembly)
------------------------------------------------------------------------
CONQUER CANCER 2014 Conquer 05/21/2014 $250,000.00
FOUNDATION OF THE Cancer Foundation
AMERICAN SOCIETY OF of ASCO Career
CLINICAL ONCOLOGY Development Award
(CDA)
------------------------------------------------------------------------
NORTHWESTERN UNIVERSITY 16th Annual Lynn 05/21/2014 $10,000.00
Sage Breast
Cancer Symposium
------------------------------------------------------------------------
PENNSYLVANIA SOCIETY OF Lipid Management 05/21/2014 $5,000.00
PHYSICIAN ASSISTANTS The Skinny on the
Fat
------------------------------------------------------------------------
DUKE UNIVERSITY 1st Annual Duke 05/29/2014 $10,000.00
Preventive
Cardiology
Symposium
------------------------------------------------------------------------
ALZHEIMER'S ASSOCIATION 2014 Alzheimer's 05/29/2014 $95,000.00
Association
International
Conference
------------------------------------------------------------------------
TRUSTEES OF THE 2014 Updates in 05/29/2014 $5,000.00
UNIVERSITY OF Oncology: With
PENNSYLVANIA Proceedings from
International
Medical Meetings
------------------------------------------------------------------------
SOCIETY FOR Young Investigator 06/01/2014 $25,000.00
NEUROSCIENCE Award
------------------------------------------------------------------------
METABOLIC ENDOCRINE The Role of the 06/03/2014 $149,025.00
EDUCATION FOUNDATION Kidney in Glucose
Homeostasis and
Diabetes
------------------------------------------------------------------------
VIVA PHYSICIANS VIVA 14: Vascular 06/03/2014 $20,000.00
InterVentional
Advances
------------------------------------------------------------------------
SOCIETY OF TOXICOLOGIC Translational 06/04/2014 $3,000.00
PATHOLOGY Pathology:
Relevance of
Toxicologic
Pathology to
Human Health
------------------------------------------------------------------------
UHS PROFESSIONAL Gout and 06/04/2014 $100,825.00
EDUCATION PROGRAMS, Hyperuricemia--Cl
INC. inical Spectrum
and Management
Update
------------------------------------------------------------------------
AMERICAN ACADEMY OF AAFP Assembly 60 06/04/2014 $10,000.00
FAMILY PHYSICIANS Minute Lecture
titled Acute
Coronary Syndrome
and Angina
(Fundamentals)
------------------------------------------------------------------------
AMERICAN ACADEMY OF AAFP Assembly 60 06/04/2014 $10,000.00
FAMILY PHYSICIANS Minute Lecture
titled Acute
Coronary Syndrome
and Angina
(Advanced)
------------------------------------------------------------------------
THE NEPHCURE FOUNDATION 10th International 06/04/2014 $5,000.00
Podocyte
Conference
------------------------------------------------------------------------
ICAHN SCHOOL OF Mount Sinai 06/09/2014 $2,500.00
MEDICINE AT MOUNT Division of
SINAI Occupational
Medicine seminar
series
------------------------------------------------------------------------
SWEDISH MEDICAL CENTER Cardiology Update 06/09/2014 $5,000.00
FOUNDATION for Primary Care
------------------------------------------------------------------------
JOSLIN DIABETES CENTER The Institute of 06/11/2014 $15,000.00
Lifestyle
Medicine 2014
Educational
Activities
------------------------------------------------------------------------
CARDIOVASCULAR RESEARCH ACS/STEMI: Focus 06/11/2014 $60,000.00
FOUNDATION on Acute Care
------------------------------------------------------------------------
PENN STATE COLLEGE OF 20th Annual 06/18/2014 $7,000.00
MEDICINE Pennsylvania
Immunization
------------------------------------------------------------------------
AMERICAN SOCIETY FOR ASPMN 24th 06/18/2014 $10,000.00
PAIN MANAGEMENT National
NURSING Conference
------------------------------------------------------------------------
AMERICAN PHARMACISTS APhA Pharmacy- 06/18/2014 $2,500.00
ASSOCIATION Based
Immunization
Delivery
------------------------------------------------------------------------
WASHINGTON UNIVERSITY Mentors in 06/22/2014 $50,000.00
Medicine
------------------------------------------------------------------------
PONCE MEDICAL SCHOOL Advances in 06/24/2014 $5,000.00
FOUNDATION INC. Dyslipidemia and
Atherosclerosis
Management
------------------------------------------------------------------------
AMERICAN COLLEGE OF Cardiovascular 06/25/2014 $15,000.00
EMERGENCY PHYSICIANS Disease Track at
ACEP 2014
Scientific
Assembly
------------------------------------------------------------------------
THE BRIGHAM AND WOMEN'S BWH Thyroid 06/26/2014 $3,000.00
HOSPITAL INC. Visiting
Professor and
Endocrine Grand
Rounds Speaker
------------------------------------------------------------------------
WASHINGTON UNIVERSITY Clinical Allergy 06/26/2014 $5,000.00
for the
Practicing
Physician
------------------------------------------------------------------------
PREVENTIVE Fall Programs 06/26/2014 $5,000.00
CARDIOVASCULAR NURSES
ASSOCIATION
------------------------------------------------------------------------
GORDON RESEARCH 2014 Gordon 06/26/2014 $500.00
CONFERENCES Research Seminar
on Synaptic
Transmission
------------------------------------------------------------------------
GREENWOOD LEFLORE Call for Grants: 06/29/2014 $2,500.00
HOSPITAL CGA Educating the
Delta on
Asthmatic
Patients
------------------------------------------------------------------------
GORDON RESEARCH Gordon Research 06/29/2014 $2,000.00
CONFERENCE Conference on
Multi-Drug Efflux
Systems
------------------------------------------------------------------------
GORDON RESEARCH Gordon Research 06/29/2014 $2,000.00
CONFERENCES Conference: DNA
Topoisomerases in
Biology and
Medicine
------------------------------------------------------------------------
ALBANY COLLEGE OF Heart to Heart: 06/30/2014 $14,000.00
PHARMACY AND HEALTH Updates on
SCIENCES Cardiovascular
Disease and the
Management of
Cholesterol and
Hypertension
------------------------------------------------------------------------
CANCER MOLECULAR Molecular 06/30/2014 $5,000.00
THERAPEUTICS RESEARCH Therapeutics of
ASSOCIATION Cancer Conference
2014
------------------------------------------------------------------------
VANDERBILT UNIVERSITY Vanderbilt 07/08/2014 $3,000.00
University
Hematology
Oncology
Educational
Symposium
------------------------------------------------------------------------
CHILDREN'S HOSPITAL Translating Neural 07/08/2014 $3,000.00
CORPORATION Circuits and
Pathways into
Treatments
------------------------------------------------------------------------
PENNSYLVANIA SOCIETY OF Breast Cancer- 07/09/2014 $3,000.00
PHYSICIAN ASSISTANTS Fight Like a Girl
------------------------------------------------------------------------
PROMEDICA ACADEMIC After the 07/09/2014 $2,500.00
HEALTH CENTER Diagnosis:
CORPORATION Helping
Cardiopulmonary
Patients Succeed--
Approaches to
Stay Ahead of the
Curve
------------------------------------------------------------------------
CONQUER CANCER 2014 Breast Cancer 07/09/2014 $10,000.00
FOUNDATION OF THE Symposium
AMERICAN SOCIETY OF
CLINICAL ONCOLOGY
------------------------------------------------------------------------
NURSE PRACTITIONER Hyperlipidemia and 07/09/2014 $5,000.00
ASSOC. FOR CONTINUING Hypertension in
EDUCATION 2014: What's New
in Treatment
Guidelines
------------------------------------------------------------------------
DIABLO SOCIETY OF Cost-Effective 07/10/2014 $5,600.00
HEALTH SYSTEM Genotype-Guided
PHARMACISTS Antiplatelet
Therapy with
Ticagrelor
------------------------------------------------------------------------
ALAMO CITY CANCER 12th Annual Breast 07/10/2014 $1,500.00
COUNCIL Cancer Conference
Update
------------------------------------------------------------------------
UNIVERSITY OF TEXAS 37TH Annual San 07/10/2014 $10,000.00
HEALTH SCIENCE CENTER Antonio Breast
SAN ANTONIO SCHOOL OF Cancer Symposium
MEDICINE
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF Best Practices in 07/15/2014 $25,000.00
MANAGED CARE the Prevention
PHYSICIANS and Management of
Chronic
Obstructive
Pulmonary Disease
(COPD)
------------------------------------------------------------------------
CEDARS-SINAI MEDICAL Advances in Care 07/17/2014 $3,000.00
CENTER for the New
Millennium: 20th
Anniversary BRCA
Gene Symposium
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF Current Treatments 07/17/2014 $25,000.00
MANAGED CARE and Novel
PHYSICIANS Strategies in the
Management of
Acute Coronary
Syndrome (ACS)
------------------------------------------------------------------------
MARSHA RIVKIN CENTER 10th Biennial 07/22/2014 $5,000.00
FOR OVARIAN CANCER Ovarian Cancer
RESEARCH Research
Symposium
------------------------------------------------------------------------
FLORIDA ASSOCIATION OF Optimizing Oral 07/22/2014 $9,600.00
CONSULTANT PHARMACISTS Antiplatelet
Therapy in Acute
Coronary Syndrome
------------------------------------------------------------------------
AMERICAN COLLEGE OF Foundations for 07/22/2014 $10,000.00
CARDIOLOGY FOUNDATION Practice
Excellence: Core
Curriculum for
the
Cardiovascular
Clinician 2014
------------------------------------------------------------------------
METABOLIC ENDOCRINE 12th Annual World 07/23/2014 $100,000.00
EDUCATION FOUNDATION Congress on
Insulin
Resistance
Diabetes and
Cardiovascular
Disease--WCIRDC
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF Program Title 07/23/2014 $3,000.00
ENDOCRINE SURGEONS Masters Course in
FOUNDATION Endocrine Surgery
------------------------------------------------------------------------
CARDIOVASCULAR RESEARCH Acute Coronary 07/24/2014 $20,000.00
FOUNDATION Syndromes,
Pharmacotherapy
and Shock/
Hemodynamic
Support
------------------------------------------------------------------------
CARDIOVASCULAR RESEARCH Town Hall and 07/24/2014 $20,000.00
FOUNDATION FDA Clinical Trial
Design and
Interpretation
------------------------------------------------------------------------
MINNESOTA PHARMACISTS MPhA Annual 07/24/2014 $2,150.00
ASSOCIATION Meeting: MTM in
Cardiology Clinic
------------------------------------------------------------------------
AMERICAN ACADEMY OF 6th Annual 07/29/2014 $5,000.00
PHYSICIAN ASSISTANTS Allergy, Asthma
IN ALLERGY, ASTHMA AND and ENT CME
IMMUNOLOGY Conference
------------------------------------------------------------------------
AMERICAN COLLEGE OF Severe Asthma 07/29/2014 $22,000.00
ALLERGY, ASTHMA AND Workshop at the
IMMUNOLOGY 2014 ACAAI Annual
Scientific
Meeting
------------------------------------------------------------------------
INTERNATIONAL 16th World 07/29/2014 $30,000.00
ASSOCIATION FOR THE Conference on
STUDY OF LUNG CANCER Lung Cancer
------------------------------------------------------------------------
AMERICAN COLLEGE OF The Affordable 07/29/2014 $22,000.00
ALLERGY, ASTHMA AND Care Act and
IMMUNOLOGY Asthma Control
------------------------------------------------------------------------
DANA-FARBER CANCER Dana-Farber Cancer 07/31/2014 $2,400.00
INSTITUTE Institute's 10th
Annual
Postdoctoral and
Graduate Student
Retreat
------------------------------------------------------------------------
NATIONAL ASSOCIATION 2014 NAHQ 39th 07/31/2014 $15,000.00
FOR HEALTHCARE QUALITY Annual
Educational
Conference
------------------------------------------------------------------------
ICAHN SCHOOL OF 2014 Top Ten 07/31/2014 $10,000.00
MEDICINE AT MOUNT Advances in
SINAI Clinical
Cardiology
------------------------------------------------------------------------
AMERICAN COLLEGE OF COPD/Asthma Track 07/31/2014 $25,800.00
CHEST PHYSCIANS at CHEST 2014
------------------------------------------------------------------------
DREXEL UNIVERSITY Hypertension 08/03/2014 $5,000.00
HighLights-ASH
2014
------------------------------------------------------------------------
ASSOCIATION OF No Gout About It: 08/03/2014 $9,500.00
REPRODUCTIVE HEALTH Targeted Provider
PROFESSIONALS Education and
Training to
Screen,
Diagnosis, and
Manage Gout among
Female Patients
------------------------------------------------------------------------
AMERICAN ASSOCIATION AACR Tumor 08/03/2014 $10,000.00
FOR CANCER RESEARCH Immunology and
Immunotherapy: A
New Chapter
------------------------------------------------------------------------
THE OHIO STATE Sixth Annual 08/05/2014 $5,000.00
UNIVERSITY Contemporary
Multidisciplinary
Cardiovascular
Conference
------------------------------------------------------------------------
WAYNE STATE UNIVERSITY Update in 08/05/2014 $5,000.00
Rheumatology
------------------------------------------------------------------------
AMERICAN COLLEGE OF COPD Interactive 08/06/2014 $20,000.00
CHEST PHYSICIANS Educational Game
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF Updates in the 08/06/2014 $25,000.00
MANAGED CARE Treatment of
PHYSICIANS, INC. Hypertriglyceride
mia: A Closer
Look at the Role
of Omega-3 Fatty
Acids
------------------------------------------------------------------------
NATIONAL JEWISH HEALTH 19th Annual Allied 08/07/2014 $2,500.00
Health Regional
Conference
------------------------------------------------------------------------
WESTERN SOCIETY OF WSAAI 53rd Annual 08/07/2014 $15,000.00
ALLERGY, ASTHMA AND Scientific
IMMUNOLOGY Session
------------------------------------------------------------------------
DELAWARE ACADEMY OF Acute Coronary 08/07/2014 $3,500.00
PHYSICIAN ASSISTANTS Syndromes: Acute
Myocardial
Infarction and
Unstable Angina
------------------------------------------------------------------------
AMERICAN PHARMACISTS Addressing Racial 08/10/2014 $25,000.00
ASSOCIATION and Ethnic
Healthcare
Disparities in
Diabetes
------------------------------------------------------------------------
THOMAS JEFFERSON Current Issues in 08/10/2014 $10,000.00
UNIVERSITY Coronary and
Structural Heart
Disease: A
Multidisciplinary
Approach
------------------------------------------------------------------------
UNIVERSITY OF University of 08/11/2014 $5,000.00
WASHINGTON CME OFFICE Washington Topics
in Allergy and
Immunology
Teaching Series
2014-2015
------------------------------------------------------------------------
FOUNDATION OF THE The Foundation of 08/11/2014 $50,000.00
NATIONAL LIPID the National
ASSOCIATION Lipid Association
Hunninghake FH
Abstract Award
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF NANN 30th Annual 08/13/2014 $10,000.00
NEONATAL NURSES Educational
Conference
------------------------------------------------------------------------
AMERICAN SOCIETY FOR ASTRO 56th Annual 08/17/2014 $3,000.00
RADIATION ONCOLOGY Meeting
(ASTRO)
------------------------------------------------------------------------
AMERICAN SOCIETY OF SGLT2 Inhibitor 08/17/2014 $170,000.00
NEPHROLOGY Therapy in
Patients with
Mild to Moderate
Diabetic Kidney
Disease
------------------------------------------------------------------------
PRESIDENT AND FELLOWS Multidisciplinary 08/17/2014 $4,500.00
OF HARVARD COLLEGE Breast Rounds
------------------------------------------------------------------------
METABOLIC ENDOCRINE Contemporary T2DM 08/17/2014 $376,125.00
EDUCATION FOUNDATION Management: Focus
on Safety and
Efficacy (Live
Program)
------------------------------------------------------------------------
MISSISSIPPI HEALTHCARE STEMI Protocols 08/17/2014 $1,464.83
ALLIANCE
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF Practical 08/19/2014 $144,399.00
DIABETES EDUCATORS Applications of
Pramlintide in
Type 1 Diabetes
------------------------------------------------------------------------
AMERICAN SOCIETY OF Novel Treatments 08/19/2014 $252,000.00
HEALTH-SYSTEM for the
PHARMACISTS Management of
Type 2 Diabetes:
Focus on SGLT2
Inhibitors
------------------------------------------------------------------------
THE SOCIETY FOR SCAI 2014 08/19/2014 $50,000.00
CARDIOVASCULAR Interventional
ANGIOGRAPHY AND Cardiology
INTERVENTIONS Fellows Courses
------------------------------------------------------------------------
OLIGONUCLEOTIDE 10th Annual 08/19/2014 $10,000.00
THERAPEUTICS SOCIETY Meeting of the
Oligonucleotide
Therapeutics
Society
------------------------------------------------------------------------
SOCIETY FOR THE Advances in Cancer 08/19/2014 $75,000.00
IMMUNOTHERAPY OF Immunotherapy--Se
CANCER ries of 5
Regional Programs
------------------------------------------------------------------------
AMERICAN ACADEMY OF The Sixth Annual 08/19/2014 $7,500.00
PHYSICIAN ASSISTANTS Hospital Medicine
Boot Camp
------------------------------------------------------------------------
UNIVERSITY OF CAll for Grants 08/21/2014 $25,800.00
CINCINNATI Application (CGA)
CV14-1st Annual
Cincinnati
Collaborative
Cardiovascular
Consortium (C4):
Practical and
Contemporary
Cardiology 2014
------------------------------------------------------------------------
WAYNE STATE UNIVERSITY Pulmonary, 08/27/2014 $3,000.00
Critical Care and
Sleep Medicine
Update 2014
------------------------------------------------------------------------
INTERNATIONAL SOCIETY ISAM Textbook of 08/27/2014 $10,000.00
FOR AEROSOLS IN Aerosol Medicine
MEDICINE
------------------------------------------------------------------------
NURSE PRACTITIONER Asthma and COPD 08/27/2014 $5,000.00
ASSOCIATES FOR 2014
CONTINUING EDUCATION
(NPACE)
------------------------------------------------------------------------
AMERICAN COLLEGE OF CHEST 2014 Lung 08/27/2014 $24,150.00
CHEST PHYSCIANS Cancer Track
------------------------------------------------------------------------
THE UNIVERSITY OF TEXAS Medical Oncology 08/28/2014 $3,000.00
MD ANDERSON CANCER and Hematology
CENTER 2014:
Multidisciplinary
Approaches that
Improve
Coordination of
Care
------------------------------------------------------------------------
NATIONAL JEWISH HEALTH 37th Annual 08/28/2014 $5,000.00
Pulmonary and
Allergy Update
------------------------------------------------------------------------
NOT-FOR-PROFIT HOSPITAL Management and 08/28/2014 $2,400.00
CORPORATION Prevention of
Acute
Exacerbation of
COPD (AECOPD)
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF New Jersey--AACE 08/31/2014 $5,000.00
CLINICAL 7th Annual
ENDOCRINOLOGISTS Meeting
------------------------------------------------------------------------
WILLIAM BEAUMONT Practical and 08/31/2014 $2,000.00
HOSPITAL Progressive
Updates in
Primary Care
Medicine
------------------------------------------------------------------------
AMERICAN COLLEGE OF 47th Annual New 08/31/2014 $15,000.00
CARDIOLOGY FOUNDATION York
Cardiovascular
Symposium: Major
Topics in
Cardiology Today
------------------------------------------------------------------------
INTERNATIONAL IASLC Fellowships 09/02/2014 $43,000.00
ASSOCIATION FOR THE
STUDY OF LUNG CANCER
------------------------------------------------------------------------
RUTGERS, THE STATE Update in 09/02/2014 $7,500.00
UNIVERSITY OF NEW Rheumatology 2014
JERSEY
------------------------------------------------------------------------
CHILDREN'S HEALTHCARE Respiratory Update 09/02/2014 $3,000.00
OF ATLANTA 2014
------------------------------------------------------------------------
UNIVERSITY OF MARYLAND, Patient-Focused 09/02/2014 $10,000.00
BALTIMORE FOUNDATION Drug Development
------------------------------------------------------------------------
THE ANGIOGENESIS World Congress on 09/02/2014 $5,000.00
FOUNDATION Angiogenesis
------------------------------------------------------------------------
JOHNS HOPKINS New Therapeutic 09/02/2014 $20,000.00
UNIVERSITY Insights/Advances
in Allergic
Diseases
------------------------------------------------------------------------
GORDON RESEARCH Mammalian DNA 09/02/2014 $5,000.00
CONFERENCES Repair Gordon
Research
Conference and
Seminar 2015
------------------------------------------------------------------------
ILLINOIS ACADEMY OF Health Care Reform 09/04/2014 $2,000.00
FAMILY PHYSICIANS and Care
Coordination
------------------------------------------------------------------------
EXCELLENCE IN Rheumatology 09/04/2014 $25,000.00
RHEUMATOLOGY EDUCATION Winter Clinical
Symposium 2015
------------------------------------------------------------------------
SOCIETY OF INFECTIOUS Society of 09/04/2014 $5,000.00
DISEASES PHARMACISTS Infectious
Diseases
Pharmacists
Research Grant
Program
------------------------------------------------------------------------
CARDIOVASCULAR CVIs 21st Annual 09/09/2014 $10,000.00
INSTITUTE OF Cardiology
PHILADELPHIA Update: Clinical
Management of
Heart Disease
2014
------------------------------------------------------------------------
PROVIDENCE HOLY CROSS Acute Coronary 09/09/2014 $1,900.00
MEDICAL CENTER Syndrome
------------------------------------------------------------------------
DUKE UNIVERSITY 14th Annual 09/14/2014 $10,000.00
Southeastern
Fellows Research
Skills and
Training Workshop
------------------------------------------------------------------------
PHILLIPS GILMORE Atlanta Lung 09/14/2014 $3,000.00
ONCOLOGY Cancer Symposium
COMMUNICATIONS, INC. 2014
------------------------------------------------------------------------
ECOG RESEARCH AND 2014 ECOG-ACRIN 09/14/2014 $5,000.00
EDUCATION FOUNDATION Fall Group
Meeting
------------------------------------------------------------------------
THE NEW YORK ACADEMY OF Pharmacologic 09/14/2014 $10,000.00
SCIENCES Resolution of
Inflammation as a
Novel Therapeutic
Approach
------------------------------------------------------------------------
MEDICAL COLLEGE OF 8th Annual 09/15/2014 $3,000.00
WISCONSIN Translational
Oncology Research
Symposium
------------------------------------------------------------------------
FRIENDS OF CANCER Friends of Cancer 09/15/2014 $100,000.00
RESEARCH Research 2014
programs
------------------------------------------------------------------------
UNIVERSITY OF FLORIDA Vascular Biology 09/15/2014 $15,000.00
Working Group
Global Chapter
Meting
------------------------------------------------------------------------
ORLANDO HEALTH Advancements in 09/15/2014 $3,000.00
the Early
Detection and
Treatment of
Breast and
Gynecologic
Malignancies
------------------------------------------------------------------------
YALE UNIVERSITY Severe Asthma 09/17/2014 $5,000.00
2014: A
Personalized
Approach To
Treatment
------------------------------------------------------------------------
EAST TENNESSEE STATE Asthma and Allergy 09/17/2014 $3,000.00
UNIVERSITY RESEARCH 2014: What's New,
FOUNDATION What's Hot
------------------------------------------------------------------------
AMERICAN COLLEGE OF 2014 ACG 09/17/2014 $25,000.00
GASTROENTEROLOGY Presidential
Poster Award
------------------------------------------------------------------------
PARTNERS HEALTHCARE 2014 Personalized 09/17/2014 $15,000.00
SYSTEM INC. Medicine
Conference
------------------------------------------------------------------------
PERSONALIZED MEDICINE Turning the Tide 09/17/2014 $5,000.00
COALITION Against Cancer
2014 National
Conference
------------------------------------------------------------------------
CEDARS-SINAI MEDICAL Rheumatology Grand 09/21/2014 $5,000.00
CENTER Rounds 2014
------------------------------------------------------------------------
AMERICAN THYROID Early Riser 09/21/2014 $125,900.00
ASSOCIATION Symposium:
Medullary Thyroid
Cancer
------------------------------------------------------------------------
SAFETY PHARMACOLOGY 14th Annual Safety 09/21/2014 $3,000.00
SOCIETY Pharmacology
Society Annual
Meeting
------------------------------------------------------------------------
AMERICAN SOCIETY OF 19th Annual ASHP 09/23/2014 $10,000.00
HEALTH-SYSTEM Conference for
PHARMACISTS Leaders in Health-
System Pharmacy
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF Scenes and 09/23/2014 $35,000.00
CLINICAL Seminars on
ENDOCRINOLOGISTS Hypoglycemia
Management:
Multidisciplinary
Approaches to
Improving Safety
for Patients with
Diabetes
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE 2014 NCCN Congress 09/23/2014 $25,000.00
CANCER NETWORK, INC. Series: Utilizing
Guidelines to
Customize Patient
Care in Non-Small
Cell Lung Cancer
------------------------------------------------------------------------
CITY OF HOPE NATIONAL Multidisciplinary 09/25/2014 $3,000.00
MEDICAL CENTER Approaches to
Cancer Symposium
------------------------------------------------------------------------
THE DEUEL CONFERENCE ON The 2015 Deuel 09/30/2014 $15,000.00
LIPIDS Conference on
Lipids
------------------------------------------------------------------------
AMERICAN COLLEGE OF 2014 ACR/ARHP 09/30/2014 $50,000.00
RHEUMATOLOGY Annual Meeting
Gout Educational
Track
------------------------------------------------------------------------
NORTH AMERICAN SOCIETY NASPGHAN Research 09/30/2014 $4,000.00
FOR PEDIATRIC Skills Workshop
GASTROENTEROLOGY,
HEPATOLOGY AND
NUTRITION
------------------------------------------------------------------------
SOCIETY FOR THE SITC Workshop on 10/03/2014 $100,000.00
IMMUNOTHERAPY OF Combination
CANCER Immunotherapy:
Where Do We Go
From Here?
------------------------------------------------------------------------
LETTERS and SCIENCES PARP Inhibition 10/07/2014 $275,478.44
for BRCA 1/2
Mutation-
Associated
Cancers and
Triple Negative
BC Advances in
Risk Reduction
and Treatment
------------------------------------------------------------------------
CHILDREN'S HOSPITAL Taking on 10/07/2014 $5,000.00
CORPORATION Tomorrow: Global
Pediatric
Innovation Summit
and Awards 2014
------------------------------------------------------------------------
ENZYME MECHANISMS 24th Enzyme 10/07/2014 $3,000.00
CONFERENCE, INC. Mechanisms
Conference
------------------------------------------------------------------------
NAMI MARYLAND 2014 NAMI Maryland 10/07/2014 $5,000.00
Annual Education
Conference
------------------------------------------------------------------------
GORDON RESEARCH Inhibition in the 10/07/2014 $5,000.00
CONFERENCES CNS Gordon
Research
Conference and
Seminar
------------------------------------------------------------------------
AMERICAN COLLEGE OF Cardiometabolic 10/08/2014 $150,000.00
CARDIOLOGY FOUNDATION Clinical
Community on
CardioSource/
ACC.org
------------------------------------------------------------------------
NATIONAL ASSOCIATION Managing Pain in 10/09/2014 $25,000.00
DIRECTORS OF NURSING LTC Residents:
ADMINISTRATION/LTC, Addressing
INC. Opioiod-Induced
Constipation
------------------------------------------------------------------------
AMERICAN HEART Heart Innovation 10/09/2014 $15,000.00
ASSOCIATION Forum
------------------------------------------------------------------------
MEDICAL SOCIETY OF NEW Medical Society of 10/09/2014 $2,500.00
JERSEY New Jersey 2015
Physician
Advocacy
Conference
------------------------------------------------------------------------
PEDIATRIC ENDOCRINE PES Parent, 10/13/2014 $50,000.00
SOCIETY Patient and
Physician WEB
Education Program
for Lipodystrophy
in Children,
Adolescents, and
Adults
------------------------------------------------------------------------
TRUSTEES OF THE 7th Focus on Lung 10/13/2014 $3,000.00
UNIVERSITY OF Cancer Conference
PENNSYLVANIA and 4rd
CANPrevent Lung
Cancer
------------------------------------------------------------------------
SOCIETY FOR Merrill J. Egorin 10/13/2014 $10,000.00
TRANSLATIONAL ONCOLOGY Workshop in
Cancer
Therapeutics and
Drug Development
------------------------------------------------------------------------
SOCIETY FOR The Oncologist CME 10/13/2014 $10,000.00
TRANSLATIONAL ONCOLOGY Online Journal
Curriculum: Lung
Cancer
------------------------------------------------------------------------
PERSONALIZED MEDICINE Integrating 10/15/2014 $5,000.00
COALITION Personalized
Medicine into
Health Care:
Solutions Summit
2015
------------------------------------------------------------------------
BIOMEDICAL SCIENCE Hope Scholarship 10/16/2014 $7,500.00
CAREERS PROGRAM 2015-2016
------------------------------------------------------------------------
AMERICAN COLLEGE OF Fact vs Fact: The 10/21/2014 $25,000.00
CARDIOLOGY FOUNDATION Cholesterol
Guidelines Debate
------------------------------------------------------------------------
A. WEBB ROBERTS CENTER The 41st Annual 10/22/2014 $5,000.00
OF BAYLOR HEALTH CARE Williamsburg
SYSTEM, DALLAS Conference on
Heart Disease
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF COPD: What NPs in 10/22/2014 $20,000.00
NURSE PRACTITIONERS IN Women's Health
WOMEN'S HEALTH Need to Know
------------------------------------------------------------------------
SOCIETY FOR THE SITC 29th Annual 10/22/2014 $10,000.00
IMMUNOTHERAPY OF Meeting
CANCER
------------------------------------------------------------------------
DAIBETES TECHNOLOGY Diabetes 10/22/2014 $10,000.00
SOCIETY Technology
Meeting 2014
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF 2014-2015 AAPS 10/30/2014 $45,000.00
PHARMACEUTICAL Sustaining
SCIENTISTS Sponsorship
------------------------------------------------------------------------
AMERICAN PSYCHIATRIC APNA 28th Annual 10/30/2014 $5,000.00
NURSES ASSOCIATION Conference-
Building
Connections: PMH
Nursing
Perspectives
------------------------------------------------------------------------
PEDIATRIC ENDOCRINE PES Consensus 10/30/2014 $92,200.00
SOCIETY statement on the
Management of
Lipodystrophy in
Children,
Adolescents, and
Adults
------------------------------------------------------------------------
LETTERS AND SCIENCES Ovarian Cancer-- 10/30/2014 $287,365.00
Evolution and
Evidence of
Emerging
Strategies (ISSS)
------------------------------------------------------------------------
THE CVA MEDICAL Cardiovascular 11/02/2014 $5,000.00
EDUCATION FOUNDATION Update 2015
------------------------------------------------------------------------
UNIVERSITY OF MICHIGAN Vaccines: Past, 11/04/2014 $10,000.00
Present, and
Future
------------------------------------------------------------------------
SOCIETY OF TOXICOLOGY Society of 11/04/2014 $2,000.00
Toxicology Annual
Meeting
------------------------------------------------------------------------
NATIONAL COMMISSION FOR CCMEP 11/04/2014 $10,000.00
THE CERTIFICATION OF Certification
CME PROFESSIONALS Exam for
Healthcare CE
Professionals
------------------------------------------------------------------------
MEDSTAR WASHINGTON Cardiovascular 11/05/2014 $50,000.00
HOSPITAL CENTER Research
Technologies CRT
2015
------------------------------------------------------------------------
NATIONAL KIDNEY Primary Care 11/05/2014 $50,000.00
FOUNDATION Practitioner
(PCP) Attitudes
and Practices:
Testing Type-2
Diabetic Patients
for Chronic
Kidney Disease
(CKD) Survey
------------------------------------------------------------------------
AMERICAN DIABETES Pathway To Stop 11/07/2014 $2,500,000.00
ASSOCIATION Diabetes
------------------------------------------------------------------------
AMERICAN PHARMACISTS Optimizing the 11/10/2014 $11,250.00
ASSOCIATION Management of
Acute Coronary
Syndromes through
the Transitions
of Care
------------------------------------------------------------------------
TEMPLE UNIVERSITY 43rd Annual 11/10/2014 $5,000.00
Philadelphia
Workshop on
Hemostasis,
Thrombosis and
Atherosclerosis
------------------------------------------------------------------------
NOT-FOR-PROFIT HOSPITAL Recognizing and 11/11/2014 $3,400.00
CORPORATION Treating Acute
Coronary Syndrome-
Current Guideline
Based Management
------------------------------------------------------------------------
CARDIOVASCULAR RESEARCH Chronic Total 11/11/2014 $10,000.00
FOUNDATION Occlusion Summit
2015: A Live
Demonstration
Course
------------------------------------------------------------------------
INTERNATIONAL IASLC 11/12/2014 $16,000.00
ASSOCIATION FOR THE International
STUDY OF LUNG CANCER Mentorship
Program
------------------------------------------------------------------------
INTERNATIONAL 15th Annual 11/12/2014 $25,000.00
ASSOCIATION FOR THE Targeted
STUDY OF LUNG CANCER Therapies of Lung
(IASLC) Cancer meeting
------------------------------------------------------------------------
AMERICAN HEART Scientific 11/13/2014 $30,000.00
ASSOCIATION, INC. Sessions 2014
Acute Coronary
Syndrome Track
------------------------------------------------------------------------
THE JOHNS HOPKINS The Johns Hopkins 11/13/2014 $138,261.57
UNIVERSITY University
Allergy and
Clinical
Immunology
Fellowship
Program
------------------------------------------------------------------------
REGENTS OF THE The 2nd Annual 11/16/2014 $5,000.00
UNIVERSITY OF UCLA Diabetes
CALIFORNIA Symposium
------------------------------------------------------------------------
AMERICAN ASSOCIATION AACR Annual 11/17/2014 $50,000.00
FOR CANCER RESEARCH Meeting--2015
------------------------------------------------------------------------
AMERICAN SOCIETY OF American Society 11/17/2014 $25,000.00
HEMATOLOGY of Hematolgoy
Scholar Awards
------------------------------------------------------------------------
AMERICAN SOCIETY OF The American 11/17/2014 $25,000.00
HEMATOLOGY Society of
Hematology's
Bridge Award
Program
------------------------------------------------------------------------
AMERICAN ACADEMY OF 2015 AAAAI Annual 11/18/2014 $30,000.00
ALLERGY, ASTHMA AND Meeting Allied
IMMUNOLOGY (AAAAI) Health
Programming
------------------------------------------------------------------------
AMERICAN PSYCHIATRIC Psychiatric 11/21/2014 $60,400.00
NURSES ASSOCIATION Nursing E Series:
Bipolar Disorder
Across the
Lifespan
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF New Paradigms in 12/01/2014 $2,500.00
CLINICAL the Practice of
ENDOCRINOLOGISTS PR Endocrinology
CHAPTER
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF Improving Outcomes 12/01/2014 $25,000.00
MANAGED CARE through Evidence-
PHYSICIANS Based Diagnosis
and Management of
Chronic
Obstructive
Pulmonary Disease
(COPD)
------------------------------------------------------------------------
THE GYNECOLOGIC 3rd Semi Annual 12/02/2014 $10,000.00
ONCOLOGY GROUP Meeting of NRG
ONCOLOGY
(Formerly GOG,
NSABP, RTOG)
------------------------------------------------------------------------
FLORIDA ALLERGY, ASTHMA Florida Allergy, 12/02/2014 $10,825.00
AND IMMUNOLOGY SOCIETY Asthma and
Immunology
Society 2015
Annual CME
Conference
------------------------------------------------------------------------
INTERNATIONAL 16th World 12/02/2014 $200,000.00
ASSOCIATION FOR THE Conference on
STUDY OF LUNG CANCER Lung Cancer--ISS
(IASLC) Association fee
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF Evidence-based 12/02/2014 $23,795.71
SCHOOL NURSES, INC. asthma care in
schools
------------------------------------------------------------------------
THE METHODIST HOSPITAL Cardiovascular 12/03/2014 $15,000.00
Fellows' Bootcamp
Laying the
Foundation
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE NCCN 20th Annual 12/03/2014 $85,000.00
CANCER NETWORK, INC. Conference
General Session:
Advancing the
Standard of
Cancer CareTM
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE Advances in the 12/03/2014 $100,000.00
CANCER NETWORK, INC. Treatment of
Ovarian and
Cervical Cancers:
Expert-
Facilitated Small
Group Discussions
of Challenging
Cases
------------------------------------------------------------------------
THE MOUNT SINAI Complex Coronary 12/03/2014 $10,000.00
HOSPITAL Cases
------------------------------------------------------------------------
JOHNS HOPKINS The Johns Hopkins 12/03/2014 $150,000.00
UNIVERSITY University School
of Medicine
eDiabetes Review
Volume 2
------------------------------------------------------------------------
ROME FOUNDATION Rome IV: The 12/04/2014 $100,000.00
Functional
Gastrointestinal
Disorders
------------------------------------------------------------------------
UNIVERSITY OF KENTUCKY 9th Platelet 12/04/2014 $10,000.00
COLLEGE OF MEDICINE Colloquium
------------------------------------------------------------------------
CONQUER CANCER 2015 Conquer 12/04/2014 $30,000.00
FOUNDATION OF THE Cancer Foundation
AMERICAN SOCIETY OF of ASCO Merit
CLINICAL ONCOLOGY Awards
------------------------------------------------------------------------
CONQUER CANCER 2015 Conquer 12/04/2014 $25,000.00
FOUNDATION OF THE Cancer Foundation
AMERICAN SOCIETY OF of ASCO
CLINICAL ONCOLOGY International
Innovation Grant
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE 2015 Annual 12/04/2014 $10,000.00
CANCER NETWORK NCCN Nursing Program:
Advancing
Oncology Nursing
at the 20th NCCN
Annual Conference
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE 2015 NCCN Oncology 12/04/2014 $10,000.00
CANCER NETWORK, INC. Fellows Program:
New Horizons in
Quality Cancer
Care at the 20th
Annual Conference
------------------------------------------------------------------------
STENO DIABETES CENTER A/ 28th European 12/04/2014 $20,000.00
S Diabetic
Nephropathy Study
Group Annual
Meeting
------------------------------------------------------------------------
AMERICAN SOCIETY OF Improving Patient 12/04/2014 $110,000.00
HEALTH-SYSTEM Outcomes:
PHARMACISTS Maximizing the
Role of the GLP-1
Based Therapies
in Our Patients
with Type 2
Diabetes
------------------------------------------------------------------------
ENDOCRINE SOCIETY ENDO 2015 Thyroid 12/04/2014 $55,000.00
Sessions
------------------------------------------------------------------------
UNIVERSITY OF TEXAS XVI Curso 12/07/2014 $10,000.00
SOUTHWESTERN MEDICAL Intensivo de
CENTER Diabetes,
Endocrinologia y
Enfermedades
Metabolicas
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF Advances in 12/07/2014 $10,000.00
CLINICAL Medical and
ENDOCRINOLOGISTS Surgical
Management of
Thyroid Cancer
------------------------------------------------------------------------
AMERICAN PAIN SOCIETY 2015 Fundamentals 12/07/2014 $35,000.00
of Pain
Management: An
Interdisciplinary
Primer
------------------------------------------------------------------------
HEMATOLOGY/ONCOLOGY 2015 HOPA 11th 12/07/2014 $25,000.00
PHARMACY ASSOCIATION Annual Conference
------------------------------------------------------------------------
LUMEN FOUNDATION Lumen Global 2015 12/08/2014 $75,000.00
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF Mentoring Program 12/08/2014 $10,000.00
NEONATAL NURSES Toolkit for
Novice Nurse
Practitioners
------------------------------------------------------------------------
CONQUER CANCER 2015 Conquer 12/08/2014 $250,000.00
FOUNDATION OF THE Cancer Foundation
AMERICAN SOCIETY OF of ASCO Career
CLINICAL ONOCLOGY Development Award
(CDA)
------------------------------------------------------------------------
CONQUER CANCER 2015 Conquer 12/08/2014 $10,500.00
FOUNDATION OF THE Cancer Foundation
AMERICAN SOCIETY OF of ASCO
CLINICAL ONCOLOGY International
Development and
Education Award
(IDEA)
------------------------------------------------------------------------
THE ENDOCRINE SOCIETY Applying the 12/08/2014 $525,980.00
Evidence for GLP-
1 Receptor
Agonists in Type
2 Diabetes:
Practice
Perspectives
------------------------------------------------------------------------
FORCE--FACING OUR RISK Joining FORCEs 12/08/2014 $50,000.00
OF CANCER EMPOWERED Against
Hereditary Cancer
Conference
------------------------------------------------------------------------
AMERICAN COLLEGE OF Lipid Management 12/08/2014 $50,000.00
CARDIOLOGY FOUNDATION Today: Unanswered
Questions and
Unquestioned
Answers--Live
Clinical Focus
Session at ACC.15
------------------------------------------------------------------------
AMERICAN PHARMACISTS Access to Care: 12/09/2014 $11,250.00
ASSOCIATION Addressing Health
Literacy in
Diabetes
------------------------------------------------------------------------
THE ENDOCRINE SOCIETY Diabetes Diagnosis 12/09/2014 $50,000.00
and Management
2015
------------------------------------------------------------------------
ENDOCRINE SOCIETY Endocrine Fellows 12/09/2014 $70,000.00
Conference: Type
1 Diabetes Care
and Management
------------------------------------------------------------------------
CLINICAL AND PATIENT Clinical Issues in 12/09/2014 $368,966.00
EDUCATORS ASSOCIATION Type 2 Diabetes:
Discussions and
Debates Around
GLP-1 Receptor
Agonists
------------------------------------------------------------------------
AMERICAN COLLEGE OF ACCs 64th Annual 12/09/2014 $100,000.00
CARDIOLOGY FOUNDATION Scientific
Session--ACC.15
Acute Coronary
Syndromes
Clinical Learning
Pathway
------------------------------------------------------------------------
CONQUER CANCER 2015 Conquer 12/10/2014 $60,000.00
FOUNDATION OF THE Cancer Foundation
AMERICAN SOCIETY OF Young
CLINICAL ONCOLOGY Investigator
Award
------------------------------------------------------------------------
ENDOCRINE SOCIETY Diabetes Masters 12/10/2014 $235,867.00
Series 2015 :
Solving the
Puzzle: Putting
the Pieces
Together to
Provide Quality
T2DM Care
------------------------------------------------------------------------
CONQUER CANCER 2015 ASCO Annual 12/10/2014 $112,000.00
FOUNDATION OF THE Meeting Lung
AMERICAN SOCIETY OF Cancer Track
CLINICAL ONCOLOGY
------------------------------------------------------------------------
INSTITUTE FOR MEDICAL Who s on First? 12/10/2014 $316,029.80
AND NURSING EDUCATION What s on Second?
Identifying a
Line-up of Newer
Agents to
Individualize
Care for Your
Patient with T2DM
------------------------------------------------------------------------
PENNSYLVANIA STATE Controlling Severe 12/11/2014 $236,659.94
UNIVERSITY Asthma Today and
Tomorrow
------------------------------------------------------------------------
CHILDREN'S HOSPITAL 2015 Weinstein 12/11/2014 $5,000.00
CORPORATION Cardiovascular
Development
Conference
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE 2015-2016 Monthly 12/11/2014 $35,000.00
CANCER NETWORK, INC Oncology Tumor
Boards: A
Multidisciplinary
Approach to
Individualized
Patient Care
------------------------------------------------------------------------
ENDOCRINE SOCIETY ENDO 2015 Diabetes 12/14/2014 $30,000.00
Sessions
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF Case Challenges in 12/14/2014 $181,705.00
CLINICAL T2D: Applying the
ENDOCRINOLOGISTS AACE Algorithm to
Practice
------------------------------------------------------------------------
THE CHEST FOUNDATION The CHEST 12/15/2014 $180,000.00
Foundation COPD
Research Grant
Program
------------------------------------------------------------------------
JOSLIN DIABETES CENTER, SGLT-2 Inhibitors 12/15/2014 $321,885.00
INC. in Type 2
Diabetes:
Incorporating New
Approaches Into
Practice Through
an
Interdisciplinary
Exploration
------------------------------------------------------------------------
AMERICAN OSTEOPATHIC The Path to Better 12/15/2014 $263,394.54
ASSOCIATION T2DM Outcomes, A
Coordinated
Approach to
Patient-centered
Care
------------------------------------------------------------------------
UNIVERSITY OF Optimizing 12/21/2014 $62,825.00
CINCINNATI Outcomes in Type
2 Diabetes:
Integrating
Longer Acting GLP-
1 Receptor
Agonists
------------------------------------------------------------------------
RICHMOND UNIVERSITY Treatment- 12/22/2014 $1,100.00
MEDICAL CENTER Refractory Gout
------------------------------------------------------------------------
DUKE UNIVERSITY SCHOOL Regional Systems 01/04/2015 $3,500,000.00
OF MEDICINE Accelerator:
Implementation of
The American
Heart
Associations
Mission: Lifeline-
AMI Discharge and
Follow Up
Demonstration
Project
------------------------------------------------------------------------
AMERICAN COLLEGE OF You Say Do, I Say 01/06/2015 $150,000.00
CARDIOLOGY FOUNDATION Don t:
Controversial
Debates in ACS--
Live Clinical
Focus Session at
ACC.15
------------------------------------------------------------------------
AMERICAN COLLEGE OF ACC.15 Prevention 01/07/2015 $75,000.00
CARDIOLOGY FOUNDATION Learning Pathway
------------------------------------------------------------------------
AMERICAN HEART American Heart 01/08/2015 $2,000,000.00
ASSOCIATION, INC. Association
Cardiovascular
Genome Phenome
Study (CV-GPS)
------------------------------------------------------------------------
AMERICAN HEART American Heart 01/11/2015 $6,000,000.00
ASSOCIATION, INC. Association s
Guideline
Transformation
and Optimization
(GTO) Program
------------------------------------------------------------------------
CARDIOVASCULAR RESEARCH Post Conference 01/14/2015 $100,000.00
FOUNDATION CME Webcast
Series 2015
------------------------------------------------------------------------
GASTROINTESTINAL AND The 2015 US GI and 01/14/2015 $35,000.00
LIVER ASSOCIATION OF Liver Association
THE AMERICAS (GALA) of the Americas
(GALA) Conference
Series
------------------------------------------------------------------------
AMERICAN COLLEGE OF ACCs 64th Annual 01/14/2015 $25,000.00
CARDIOLOGY FOUNDATION Scientific
Session (ACC.15)
TCT@ACC-i2
Learning Pathway
------------------------------------------------------------------------
GORDON RESEARCH 2015 Gordon 01/14/2015 $5,000.00
CONFERENCES Research
Conference on the
Molecular and
Cellular Biology
of Lipids
------------------------------------------------------------------------
GEORGIA ASSOCIATION OF Cardiology Track-- 01/14/2015 $5,000.00
PHYSICIAN ASSISTANTS How PAs Can
Impact Patient
Outcomes Across
Cardiovascular
Diseases (Part of
GAPA 2015 Spring
Conference)
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF Endocrine 01/15/2015 $5,000.00
CLINICAL University:
ENDOCRINOLOGISTS Disease
Management and
Technology Skills
for Fellows-in-
Training (Thyroid
Module)
------------------------------------------------------------------------
UNIVERSITY OF TEXAS 16th Annual 01/15/2015 $3,000.00
HEALTH SCIENCE CENTER Practical
SAN ANTONIO SCHOOL OF Applications of
MEDICINE New Agents in
Oncology
------------------------------------------------------------------------
NATIONAL LIPID National Lipid 01/15/2015 $15,000.00
ASSOCIATION Association 2015
Lipid Academy
------------------------------------------------------------------------
NATIONAL LIPID 2015 Masters in 01/15/2015 $15,000.00
ASSOCIATION Lipidology
------------------------------------------------------------------------
EMORY UNIVERSITY Atlanta Clinical 01/18/2015 $15,000.00
Cardiology Update
------------------------------------------------------------------------
SOCIETY FOR SCAI 2015 01/27/2015 $85,000.00
CARDIOVASCULAR Scientific
ANGIOGRAPHY AND Sessions
INTERVENTIONS
------------------------------------------------------------------------
ENDOCRINE SOCIETY Thyroid Endocrine 01/28/2015 $10,000.00
Self-Assessment
Program 2015
------------------------------------------------------------------------
SCRIPPS HEALTH Scripps 35th 01/29/2015 $5,000.00
Annual
Conference:
Clinical
Hematology and
Oncology 2015
------------------------------------------------------------------------
NORTHEASTERN UNIVERSITY Boston Symposium 01/29/2015 $2,500.00
on Organic and
Bioorganic
Chemistry (BSOBC)
------------------------------------------------------------------------
CARDIOVASCULAR RESEARCH ACS/STEMI: Focus 01/29/2015 $60,000.00
FOUNDATION on Acute Care at
SCAI 2015
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF Exploring Optimal 01/29/2015 $25,000.00
MANAGED CARE Antiplatelet
PHYSICIANS Therapies in the
Management of
Acute Coronary
Syndrome (ACS)
------------------------------------------------------------------------
CARDIOVASCULAR RESEARCH 21st Annual 01/29/2015 $25,000.00
FOUNDATION Interventional
Cardiology
Fellows Course
------------------------------------------------------------------------
UNIVERSITY OF FLORIDA Vascular Biology 01/29/2015 $15,000.00
Working Group US
Chapter Meeting
------------------------------------------------------------------------
IOWA PHYSICIAN Update on Lipid 01/29/2015 $6,500.00
ASSISTANT SOCIETY Management
------------------------------------------------------------------------
PREVENTIVE Cardiovascular 02/01/2015 $25,000.00
CARDIOVASCULAR NURSES Risk Reduction:
ASSOCIATION Leading the Way
in Prevention
(21st Annual
Symposium)
------------------------------------------------------------------------
PRIMARY CARE NETWORK, Are Gout Goals 02/02/2015 $619,095.00
INC. Achievable? The
Provider/ Patient
Alliance
------------------------------------------------------------------------
PREVENTIVE PCNA-Triglycerides 02/02/2015 $179,540.00
CARDIOVASCULAR NURSES
ASSOCIATION
------------------------------------------------------------------------
NATIONAL LIPID National Lipid 02/02/2015 $120,000.00
ASSOCIATION Association 2015
Scientific
Meeting Series
------------------------------------------------------------------------
AMERICAN HEART Chest Pain 02/02/2015 $15,000.00
ASSOCIATION Coordinator Boot
Camp
------------------------------------------------------------------------
THE BOARD OF REGENTS OF Cardiovascular 02/08/2015 $5,000.00
THE UNIVERSITY OF Medicine and
WISCONSIN SYSTEM Prevention Update
for Primary Care
------------------------------------------------------------------------
UNIVERSITY OF KANSAS 6th Expert 02/09/2015 $5,000.00
MEDICAL CENTER Strategies in
Endoscopy,
Gastrointestinal
and Liver
Disorders
------------------------------------------------------------------------
TRUSTEES OF THE 2nd Cardiovascular 02/11/2015 $5,000.00
UNIVERSITY OF Symposium
PENNSYLVANIA/CME
------------------------------------------------------------------------
AMERICAN PHARMACISTS APhA2015 Rise in 02/11/2015 $22,500.00
ASSOCIATION Oral Oncologic
Medications
Creates New
Challenges in
Adherence
------------------------------------------------------------------------
EMORY UNIVERSITY EPIC SEC Emory 02/11/2015 $25,000.00
Practical
Intervention
Course Southeast
Consortium
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE Advances in the 02/11/2015 $232,693.00
CANCER NETWORK Treatment of
Ovarian and
Cervical Cancers:
Expert-
Facilitated Small
Group Discussions
of Challenging
Cases
------------------------------------------------------------------------
REGENTS OF THE Moores Cancer 02/12/2015 $3,000.00
UNIVERSITY OF Center 11th
CALIFORNIA Industry/Academia
Translational
Oncology
Symposium
------------------------------------------------------------------------
SCRIPPS HEALTH The Future of 02/12/2015 $10,000.00
Genomic Medicine
VIII
------------------------------------------------------------------------
DELAWARE ACADEMY OF Hyperlipidemia 02/12/2015 $2,780.00
PHYSICIAN ASSISTANTS
------------------------------------------------------------------------
THE MASSACHUSETTS 29th Harvard 02/17/2015 $5,000.00
GENERAL HOSPITAL Critical Issues
in Tumor
Microenvironment:
Angiogenesis
Metastasis and
Immunology Course
------------------------------------------------------------------------
KERN ASPEN LIPID Emerging Therapies 02/17/2015 $10,000.00
CONFERENCE for
Cardiovascular
Diseases: A
Dialogue Between
Academic and
Pharmaceutical
Research
------------------------------------------------------------------------
FLORIDA ASSOCIATION OF Acute Coronary 02/17/2015 $8,325.00
CONSULTANT PHARMACISTS Syndrome;
Strategies to
Optimize
Transitions in
Care and Reduce
Readmissions
------------------------------------------------------------------------
ST. JOSEPH'S REGIONAL COPD 02/18/2015 $1,900.00
MEDICAL CENTER
------------------------------------------------------------------------
CARDIOVASCULAR RESEARCH Issues with DAPT 02/18/2015 $50,000.00
FOUNDATION Series 2015
------------------------------------------------------------------------
NURSE PRACTITIONER The Challenges of 02/19/2015 $5,000.00
ASSOCIATES FOR Asthma and COPD
CONTINUING EDUCATION in Primary Care
(NPACE)
------------------------------------------------------------------------
NORTHWESTERN UNIVERSITY The 8th Annual 02/19/2015 $2,500.00
Womens
Cardiovascular
Health Symposium
------------------------------------------------------------------------
AMERICAN HEART Atlanta Mission: 02/19/2015 $2,500.00
ASSOCIATION Lifeline Meeting
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF How to Talk to 02/22/2015 $231,590.00
NURSE PRACTITIONERS Your Patients
about Opioid-
induced
Constipation: A
Dialogue about
New Advances
------------------------------------------------------------------------
AMERICAN THYROID American Thyroid 02/22/2015 $25,000.00
ASSOCIATION Association
Satellite
Symposium: ATA
Guidelines on
Medullary Thyroid
Cancer and
Pediatric Thyroid
Cancer
Highlights,
Controversies a
------------------------------------------------------------------------
THOMAS JEFFERSON 3rd Annual 02/22/2015 $3,000.00
UNIVERSITY Jefferson Lung
Cancer Symposium
2015
------------------------------------------------------------------------
AMERICAN COLLEGE OF What's New in 02/22/2015 $95,085.00
CHEST PHYSICIANS Asthma/COPD
Syndrome
------------------------------------------------------------------------
WEST PENN ALLEGHENY Cardiovascular 02/22/2015 $10,000.00
HEALTH SYSTEM Medicine Update
2015
------------------------------------------------------------------------
AMERICAN DIABETES 62nd Annual 02/23/2015 $10,000.00
ASSOCIATION Advanced
Postgraduate
Course 2015
------------------------------------------------------------------------
SOCIETY OF GYNECOLOGIC SGO Annual Meeting 02/23/2015 $50,000.00
ONCOLOGY on Women's Cancer
------------------------------------------------------------------------
BAYLOR UNIVERSITY The 18th Annual 02/23/2015 $3,000.00
MEDICAL CENTER DBA A. Tyler Breast
WEBB ROBERTS CENTER Cancer Conferecne
2015
------------------------------------------------------------------------
PENNSYLVANIA ACADEMY OF PAFP/F Live and 02/23/2015 $5,000.00
FAMILY PHYSICIANS Enduring CME
FOUNDATION Primary and
Secondary
Prevention of
ASCVD
------------------------------------------------------------------------
ONCOLOGY NURSING Oncology Nursing 02/23/2015 $25,000.00
SOCIETY Society 40th
Annual Congress
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF 2015-2016 AAPS 02/23/2015 $50,000.00
PHARMACEUTICAL Sustaining
SCIENTISTS Sponsorship
------------------------------------------------------------------------
ASPEN LUNG CONFERENCE Thomas L. Petty 02/24/2015 $15,000.00
Aspen Lung
Conference:Asthma
2015: Mechanisms
to Personalized
Medicine
------------------------------------------------------------------------
ST. FRANCIS HOSPITAL-- Intravascular 02/26/2015 $7,000.00
U.S. CATHOLIC Coronary Imaging
CONFERENCE and Physiology
2015: A Clinical
Workshop
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF NAPNAP Conference 02/26/2015 $7,500.00
PEDIATRIC NURSE Sponsorship
PRACTITIONERS
------------------------------------------------------------------------
AMERICAN ASSOCIATION 95th Annual 02/26/2015 $10,000.00
FOR THORACIC SURGERY Meeting American
Association for
Thoracic Surgery
------------------------------------------------------------------------
NATIONAL KIDNEY Session Support: 02/26/2015 $20,000.00
FOUNDATION INC. CKD MANAGEMENT
ALONG THE
CONTINUUM: FROM
PREDIALYSIS TO
POLICY
------------------------------------------------------------------------
CITY OF HOPE NATIONAL 15th Annual 03/01/2015 $5,000.00
MEDICAL CENTER Rachmiel Levine
Diabetes and
Obesity Symposium
------------------------------------------------------------------------
AMERICAN THORACIC ATS 2015 03/01/2015 $25,000.00
SOCIETY International
Conference,
Fellows Track
Symposium
------------------------------------------------------------------------
AMERICAN THORACIC 2015 International 03/01/2015 $10,000.00
SOCIETY ATS Conference--Selec
ted Topics in
Asthma
------------------------------------------------------------------------
NATIONAL JEWISH HEALTH Improving the 03/01/2015 $10,000.00
Quality of Care
for Patients with
Asthma
------------------------------------------------------------------------
ST. JOSEPH'S REGIONAL Year in Review in 03/01/2015 $3,700.00
MEDICAL CENTER Acute Coronary
Syndromes
------------------------------------------------------------------------
THE BOARD OF REGENTS OF COPD9USA 03/02/2015 $40,000.00
THE UNIVERSITY OF
NEBRASKA DBA THE
UNIVERSITY OF NEBRASKA
MEDICAL CENTER
------------------------------------------------------------------------
AMERICAN THORACIC ATS 2015 03/02/2015 $72,919.82
SOCIETY International
Conference--Selec
ted Topics in
COPD
------------------------------------------------------------------------
NATIONAL JEWISH HEALTH Best Practices in 03/02/2015 $72,161.00
Managing Patients
with COPD:
Emerging
Therapies and
Patient Education
Strategies
------------------------------------------------------------------------
CARDIOVASCULAR RESEARCH DAPT Dilemmas: A 03/02/2015 $69,100.00
FOUNDATION Case-Based
Roundtable
Tutorial
------------------------------------------------------------------------
ALZHEIMER'S ASSOCIATION 2015 Alzheimers 03/02/2015 $50,000.00
Association
Research
Roundtable
------------------------------------------------------------------------
CONQUER CANCER 2015 ASCO Annual 03/02/2015 $56,000.00
FOUNDATION OF THE Meeting
AMERICAN SOCIETY OF Gynecologic
CLINICAL ONCOLOGY Cancer Track:
Scientific and
Educational
Program
------------------------------------------------------------------------
AMERICAN ACADEMY OF AAPA Conference 03/02/2015 $5,000.00
PHYSICIAN ASSISTANTS 2015--CardiologyT
rack
------------------------------------------------------------------------
PREVENTIVE The Post-ACS 03/04/2015 $100,000.00
CARDIOVASCULAR NURSES Patient:
ASSOCIATION Adherence to
Critical
Therapies in the
Short- and Long-
Term
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF 2015 Charitable 03/04/2015 $30,000.00
FREE AND CHARITABLE Health Care
CLINICS Education and
Training
Symposium
------------------------------------------------------------------------
GORDON RESEARCH High Throughput 03/04/2015 $2,500.00
CONFERENCES Chemistry and
Chemical Biology
------------------------------------------------------------------------
NEW YORK ACADEMY OF Non-Motor 03/04/2015 $2,000.00
SCIENCES Symptoms:
Unraveling the
``Invisible''
Face of Parkinson
s Disease
------------------------------------------------------------------------
SOCIETY FOR PHYSICIAN SPAP's 9th Annual 03/08/2015 $1,500.00
ASSISTANTS IN Conference
PEDIATRICS
------------------------------------------------------------------------
JDRF INTERNATIONAL TypeOneNation 03/08/2015 $4,500.00
Research Summit
------------------------------------------------------------------------
GORDON RESEARCH Solving Knowledge 03/08/2015 $3,000.00
CONFERENCE Gaps in Drug
Metabolism and
Pharmacokinetic
Prediction,
Improving
Translational
Medicine
------------------------------------------------------------------------
NURSE PRACTITIONER Clinical Pearls in 03/09/2015 $2,500.00
ASSOCIATES FOR Managing Diabetes
CONTINUING EDUCATION in 2015
(NPACE)
------------------------------------------------------------------------
PRESIDENT AND FELLOWS Cardiovascular 03/09/2015 $11,500.00
OF HARVARD COLLEGE Medicine 2015:
Updates for the
Practitioner
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF Diabetes Sessions 03/10/2015 $25,000.00
CLINICAL at Endocrine
ENDOCRINOLOGISTS University:
Disease
Management and
Technology Skills
for Endocrinology
Fellows in
Training
------------------------------------------------------------------------
NEBRASKA ACADEMY OF Gout 2015 03/10/2015 $1,500.00
PHYSICIAN ASSISTANTS
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE NCCN 2015 Oncology 03/10/2015 $20,000.00
CANCER NETWORK, INC. Case Manager and
Medical Director
Program
------------------------------------------------------------------------
GORDON RESEARCH Preclinical Form 03/11/2015 $500.00
CONFERENCES and Formulation
for Drug
Discovery GRC/GRS
------------------------------------------------------------------------
AMERICAN ASSOCIATION AACR Annual 03/12/2015 $25,000.00
FOR CANCER RESEARCH Meeting--2015
------------------------------------------------------------------------
THE HOPE FOUNDATION 2015 SWOG Group 03/12/2015 $5,000.00
Meetings
------------------------------------------------------------------------
AMERICAN HEAD AND NECK American Head and 03/12/2015 $10,000.00
SOCIETY Neck Society 2015
Annual Meeting
------------------------------------------------------------------------
BOSTON CHILDREN'S Pediatric Asthma 03/16/2015 $3,000.00
HOSPITAL and Allergy
Updates for
Primary Care
Providers
------------------------------------------------------------------------
NURSE PRACTITIONER Managing Asthma 03/16/2015 $1,500.00
ASSOCIATES FOR and COPD in 2015
CONTINUING EDUCATION
(NPACE)
------------------------------------------------------------------------
HEALTHCARE ALLIANCE FOR Essentials in 03/16/2015 $8,400.00
MEDICAL EDUCATION Primary Care
------------------------------------------------------------------------
WEST VIRGINIA ACADEMY Opioid Induced 03/17/2015 $3,000.00
OF FAMILY PHYSICIANS Constipation
------------------------------------------------------------------------
ECOG RESEARCH AND 2015 ECOG-ACRIN 03/18/2015 $5,000.00
EDUCATION FOUNDATION, Spring Group
INC. Meeting
------------------------------------------------------------------------
CONQUER CANCER 2015 ASCO Annual 03/18/2015 $84,000.00
FOUNDATION OF THE Meeting Breast
AMERICAN SOCIETY OF Cancer Track:
CLINICAL ONCOLOGY Scientific and
Educational
Program
------------------------------------------------------------------------
AMERICAN COLLEGE OF Diabetes is 03/19/2015 $15,000.00
OSTEOPATHIC FAMILY Primary
PHYSICIANS Addressing
Primary Care
Clinical Gaps in
Diabetes
Management by
Partnering With
Experts
------------------------------------------------------------------------
MERCY HEALTH SYSTEM Care Transitions 03/19/2015 $5,000.00
SEPA Conference
------------------------------------------------------------------------
THE MEDICAL UNIVERSITY 10th Annual 03/19/2015 $5,000.00
OF SOUTH CAROLINA Symposium
entitled the
Nephrology Update
for Primary Care
and Hospital
Medicine
------------------------------------------------------------------------
ALZHEIMER'S ASSOCIATION 2015 Alzheimer's 03/23/2015 $95,000.00
Association
International
Conference
------------------------------------------------------------------------
SOCIETY FOR 2015 Annual 03/23/2015 $25,000.00
TRANSLATIONAL ONCOLOGY Meeting
------------------------------------------------------------------------
SWEDISH MEDICAL CENTER Thyroid Cancer and 03/24/2015 $3,000.00
FOUNDATION Parathyroid
Disease--A
Practical
Approach
------------------------------------------------------------------------
ASSOCIATION OF WOMEN'S AWHONN Annual 03/24/2015 $7,500.00
HEALTH, OBSTETRIC AND Convention
NEONATAL NURSES
(AWHONN)
------------------------------------------------------------------------
GORDON RESEARCH 2015 Proteins 03/24/2015 $3,000.00
CONFERENCES Gordon Conference
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF AACE 24th Annual 03/25/2015 $30,000.00
CLINICAL Scientifc and
ENDOCRINOLOGISTS Clinical Congress
(Diabetes
portion)
------------------------------------------------------------------------
THE ASSOCIATION FOR AFTD's Annual 03/25/2015 $1,000.00
FRONTOTEMPORAL Education
DEGENERATION (AFTD) Conference
------------------------------------------------------------------------
TRINITAS REGIONAL Lung Cancer 03/25/2015 $1,750.00
MEDICAL CENTER
------------------------------------------------------------------------
INSTITUTE FOR PATIENT 2015 Premature 03/25/2015 $125,000.00
ACCESS Infant Health
Summit
------------------------------------------------------------------------
SOCIETY FOR Young Investigator 03/25/2015 $25,000.00
NEUROSCIENCE Award
------------------------------------------------------------------------
ST. DOMINIC--JACKSON STOP STEMI and 03/25/2015 $25,000.00
MEMORIAL HOSPITAL STOP STROKE
program by
Pulsara
------------------------------------------------------------------------
AMERICAN ASSOCIATION Anti-cancer Drug 03/26/2015 $10,000.00
FOR CANCER RESEARCH Action and Drug
Resistance:
------------------------------------------------------------------------
YALE UNIVERSITY 2015 New England 03/26/2015 $3,000.00
Thyroid Club
Program
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF AACE 24th Annual 03/26/2015 $25,000.00
CLINICAL Scientific and
ENDOCRINOLOGISTS Clinical Congress
(Thyroid
sessions)
------------------------------------------------------------------------
CLEVELAND CLINIC Cleveland Breast 03/26/2015 $5,000.00
EDUCATIONAL FOUNDATION Cancer 2015:
Collaborating For
A Cure
------------------------------------------------------------------------
OKLAHOMA HEART RESEARCH 26th Annual Update 03/26/2015 $2,500.00
AND EDUCATION in Cardiology
FOUNDATION
------------------------------------------------------------------------
CEDARS-SINAI MEDICAL 3rd Annual 03/29/2015 $5,000.00
CENTER Experimental
Therapeutics in
Oncology: The
Road to
Personalized
Medicine
------------------------------------------------------------------------
CASE MANAGEMENT SOCIETY CMSA 2015 03/29/2015 $15,000.00
OF AMERICA Conference and
Expo
------------------------------------------------------------------------
SOCIETY FOR SCAI Complex 03/29/2015 $15,000.00
CARDIOVASCULAR Peripheral
ANGIOGRAPHY AND Vascular
INTERVENTIONS Interventions
FOUNDATION Course
------------------------------------------------------------------------
AMERICAN COLLEGE OF Bringing Science 03/29/2015 $50,000.00
CARDIOLOGY FOUNDATION to Clinical
Practice: Best of
ACC 2015
------------------------------------------------------------------------
ICAHN SCHOOL OF Live Symposium of 03/29/2015 $10,000.00
MEDICINE AT MOUNT Complex Coronary
SINAI Valvular and
Vascular Cases
------------------------------------------------------------------------
ASOCIACION Metabolic Syndrome 03/30/2015 $1,500.00
PUERTORRIQUENA DE Update:
GRADUADOS DE Challenges in
UNIVERSIDADES Preventive
ESPANOLAS-APGUE Medicine
------------------------------------------------------------------------
UNIVERSITY OF Breast Symposium 03/30/2015 $3,250.00
PITTSBURGH 2015: Updates in
the Management of
Breast Cancer/
Breast Disease
------------------------------------------------------------------------
JOHNS HOPKINS 6th Annual Johns 03/30/2015 $2,500.00
UNIVERSITY Hopkins
Cardiovascular
Research Retreat
------------------------------------------------------------------------
SOCIETY FOR VASCULAR Society for 03/30/2015 $5,000.00
MEDICINE Vascular Medicine
26th Annual
Scientific
Sessions
------------------------------------------------------------------------
NURSE PRACTITIONER Updates in COPD 03/30/2015 $3,200.00
ASSOCIATES FOR 2015
CONTINUING EDUCATION
(NPACE)
------------------------------------------------------------------------
THE CHRIST HOSPITAL The FETCH 03/31/2015 $5,000.00
Conference
------------------------------------------------------------------------
THE CHEST FOUNDATION The CHEST 03/31/2015 $30,000.00
Foundation Lung
Cancer Clinical
Research Grant
Program
------------------------------------------------------------------------
NEW YORK MEDICAL Systemic Treatment 03/31/2015 $2,500.00
COLLEGE of Lung Cancer
------------------------------------------------------------------------
THE CENTER OF 8th Annual 03/31/2015 $5,000.00
EXCELLENCE IN Cardiovascular
EDUCATION Update- A
Practical
Tutorial
------------------------------------------------------------------------
ST. JOSEPH'S HOSPITAL 4th Annual Arizona 04/01/2015 $15,000.00
AND MEDICAL CENTER Diabetes Series:
Focus on
Treatment
Advances, Patient-
Centered Care,
Obesity and Other
Comorbidities
------------------------------------------------------------------------
THE UNIVERSITY OF TEXAS Annual Meeting of 04/01/2015 $5,000.00
MD ANDERSON CANCER the Felix
CENTER Rutledge Society
------------------------------------------------------------------------
GOUT AND URIC ACID Gout and Uric Acid 04/01/2015 $70,000.00
EDUCATION SOCIETY Education Society
Roundtable:
Elevating the
Severity of Gout
and Improving
Access to Public
Education and
Treatment
------------------------------------------------------------------------
VIVA PHYSICIANS VIVA 15: Vascular 04/01/2015 $20,000.00
InterVentional
Advances
------------------------------------------------------------------------
UNIVERSITY OF University of 04/02/2015 $20,000.00
WASHINGTON Washington
Allergy and
Immunology
Fellowship
------------------------------------------------------------------------
WASHINGTON ACADEMY OF 26th Annual 04/06/2015 $1,500.00
PHYSICIAN ASSISTANTS Recertification
Review Course and
Spring Conference
------------------------------------------------------------------------
CLEVELAND CLINIC Advances in Lung 04/07/2015 $5,000.00
EDUCATIONAL FOUNDATION Cancer: A
Multidisciplinary
Approach
------------------------------------------------------------------------
FEDERATION OF AMERICAN Molecular, 04/08/2015 $10,000.00
SOCIETIES FOR Structural and
EXPERIMENTAL BIOLOGY Clinical Aspects
of VK and VK-
Dependent
Proteins
------------------------------------------------------------------------
FEDERATION OF AMERICAN FASEB conference 04/08/2015 $5,000.00
SOCIETIES FOR on Genetic
EXPERIMENTAL BIOLOGY Recombination and
Genome
Rearrangements
------------------------------------------------------------------------
SCRIPPS WHITTIER Emerging 04/09/2015 $30,000.00
DIABETES INSTITUTE Therapeutic
Trends to
Optimize Diabetes
Care
------------------------------------------------------------------------
AMERICAN COLLEGE OF 2015 04/09/2015 $5,000.00
CARDIOLOGY FOUNDATION Interventional
Cardiology Board
Preparatory
Course
------------------------------------------------------------------------
AMERICAN FEDERATION FOR 2015 Eastern 04/12/2015 $2,500.00
MEDICAL RESEARCH Regional Meeting
of the American
Federation for
Medical Research
------------------------------------------------------------------------
PONCE MEDICAL SCHOOL Overcoming 04/12/2015 $10,000.00
FOUNDATION INC. Obstacles to
Reduce Acute
Coronary Syndrome
------------------------------------------------------------------------
SOUTH CAROLINA ASTHMA Midlands Regional 04/12/2015 $3,000.00
ALLIANCE Asthma Conference
------------------------------------------------------------------------
PHARMACY QUALITY Measuring What 04/13/2015 $12,500.00
ALLIANCE (PQA, INC.) Matters:
Improving Care
and Driving the
Next Generation
of Performance
Measures
------------------------------------------------------------------------
METABOLIC ENDOCRINE The Comprehensive 04/13/2015 $283,155.00
EDUCATION FOUNDATION Management of DM--
Focus on SGLT2
Inhibitors and
Combination
Therapy--Emerging
Concepts of Renal
Effects
------------------------------------------------------------------------
ASTHMA AND ALLERGY Wheezin', Sneezin' 04/14/2015 $5,000.00
FOUNDATION OF AMERICA, and Itchin' in
ALASKA CHAPTER Alaska
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF Individualizing 04/14/2015 $25,000.00
MANAGED CARE Treatment
PHYSICIANS, INC. Strategies to
Improve Patient
Outcomes in the
Management of
Type 2 Diabetes
(T2DM)
------------------------------------------------------------------------
MIDMICHIGAN MEDICAL Valley Diabetes 04/15/2015 $2,500.00
CENTER--MIDLAND Symposium
------------------------------------------------------------------------
TRUSTEES OF BOSTON Opioid Induced 04/15/2015 $117,200.00
UNIVERSITY DBA BOSTON Constipation: A
UNIVERSITY SCHOOL OF Neglected
MEDICINE Complication
------------------------------------------------------------------------
PARTNERS HEALTHCARE World Medical 04/15/2015 $50,000.00
SYSTEM Innovation Forum
------------------------------------------------------------------------
MASSACHUSETTS INSTITUTE CANCER COMPLEXITY: 04/15/2015 $5,000.00
OF TECHNOLOGY Heterogeneity in
Tumor Progression
and Drug Response
------------------------------------------------------------------------
AMERICAN SOCIETY OF ASN Kidney Week-- 04/16/2015 $55,000.00
NEPHROLOGY CKD Learning
Pathway Support
------------------------------------------------------------------------
NATIONAL ASSOCIATION Leading Care 04/19/2015 $15,000.00
FOR HEALTHCARE QUALITY Transitions:
Improving Quality
in Safety Across
the Healthcare
Continuum
------------------------------------------------------------------------
FEDERATION OF AMERICAN 12th FASEB Summer 04/19/2015 $7,000.00
SOCIETIES FOR Research
EXPERIMENTAL BIOLOGY Conference on
``Proteases in
Hemostasis and
Vascular
Biology''
------------------------------------------------------------------------
AMERICAN SOCIETY FOR ASPMN 25th 04/20/2015 $20,000.00
PAIN MANAGEMENT National
NURSING Conference
------------------------------------------------------------------------
REGENTS OF THE 5th International 04/20/2015 $3,000.00
UNIVERSITY OF Symposium on Lung-
CALIFORNIA Sparing Therapies
for Malignant
Pleural
Mesothelioma
------------------------------------------------------------------------
GORDON RESEARCH 2015 Medicinal 04/20/2015 $3,000.00
CONFERENCES Chemistry Gordon
Research
Conference
------------------------------------------------------------------------
AMERICAN THORACIC ATS 2015 04/21/2015 $50,000.00
SOCIETY International
Conference--Selec
ted Topics in
Lung Cancer
------------------------------------------------------------------------
OKLAHOMA UNIVERSITY 18th Annual 04/21/2015 $1,500.00
HEALTH SCIENCES CENTER Primary Care
Update 2015
Asthma
------------------------------------------------------------------------
OKLAHOMA UNIVERSITY 18th Annual 04/21/2015 $1,500.00
HEALTH SCIENCE CENTER Primary Care
COLLEGE OF MEDICINE Update 2015-
Ovarian Cancer
------------------------------------------------------------------------
REGENTS OF THE LIPID MAPS 04/21/2015 $7,500.00
UNIVERSITY OF Meeting:
CALIFORNIA Lipidomics Impact
on Cancer,
Metabolic and
Inflammatory
Diseases
------------------------------------------------------------------------
CARDIOVASCULAR RESEARCH Knights of the 04/21/2015 $50,000.00
FOUNDATION Roundtable 2015:
Challenging AMI
Therapies
------------------------------------------------------------------------
HOUSTON METHODIST Cardiovascular 04/21/2015 $15,000.00
HOSPITAL Fellows' Bootcamp-
Laying the
Foundation
------------------------------------------------------------------------
UNIVERSITY OF Seventh Annual 04/22/2015 $3,250.00
PITTSBURGH Multidisciplinary
Thyroid Cancer
Symposium:
Integrating the
New ATA
Guidelines into
Clinical Practice
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF 36th Annual 04/22/2015 $3,000.00
ENDOCRINE SURGEONS Meeting of the
American
Association of
Endocrine
Surgeons
------------------------------------------------------------------------
DUKE UNIVERSITY HEALTH Closing the Gap on 04/22/2015 $20,000.00
SYSTEM Medication
Management,
Discharge
Preparedness and
Readmissions
------------------------------------------------------------------------
CLEVELAND CLINIC ASCO Review 04/23/2015 $3,000.00
EDUCATIONAL FOUNDATION
------------------------------------------------------------------------
SWEDISH MEDICAL CENTER Annual Oncology 04/23/2015 $3,000.00
FOUNDATION Symposium:
Personalized
Medicine--Genetic
Testing, Targeted
Molecular Therapy
and WHole Patient
Care
------------------------------------------------------------------------
OKLAHOMA UNIVERSITY 18th Annual 04/23/2015 $1,500.00
HEALTH SCIENCE CENTER Primary Care
COLLEGE OF MEDICINE Update: COPD
------------------------------------------------------------------------
WASHINGTON UNIVERSITY Update on 04/23/2015 $4,000.00
Gynecologic
Cancer
------------------------------------------------------------------------
WASHINGTON UNIVERSITY Cardiology Update 04/23/2015 $4,000.00
SCHOOL OF MEDICINE,
ST. LOUIS
------------------------------------------------------------------------
NEW YORK ACADEMY OF Emerging 04/27/2015 $5,000.00
SCIENCES Approaches to
Cancer
Immunotherapy
------------------------------------------------------------------------
LYMPHOMA RESEARCH Lymphoma Research 04/27/2015 $15,000.00
FOUNDATION Foundation Immune
Checkpoint
Inhibitor
Workshop
------------------------------------------------------------------------
YALE UNIVERSITY Yale Cancer Center 04/28/2015 $5,000.00
Oncology Series--
2015
------------------------------------------------------------------------
MOUNT CARMEL HEALTH 2015 ASCO REVIEW 04/28/2015 $3,000.00
SYSTEM
------------------------------------------------------------------------
COLUMBIA UNIVERSITY Breast Cancer 04/28/2015 $3,000.00
DEPARTMENT OF SURGERY Management 2015
------------------------------------------------------------------------
NORTHWESTERN UNIVERSITY 4th Annual Chicago 04/28/2015 $6,000.00
Cardiovascular
Update
------------------------------------------------------------------------
DIGNITY HEALTH ST. 17th Annual 04/29/2015 $6,000.00
BERNARDINE MEDICAL Cardiac
CENTER Symposium:
Advances in
Cardiovascular
Disease 2015
------------------------------------------------------------------------
GORDON RESEARCH 2015 Gordon 04/29/2015 $2,500.00
CONFERENCES Conference on
Heterocyclic
Compounds
------------------------------------------------------------------------
INTERNATIONAL SOCIETY Regulatory and 04/29/2015 $2,500.00
FOR COMPUTATIONAL Systems Genomics,
BIOLOGY INC. with DREAM
Challenges
Conference
------------------------------------------------------------------------
YALE UNIVERSITY Yale ASCO Review 04/30/2015 $3,000.00
2015
------------------------------------------------------------------------
UNIVERSITY OF VERMONT OBESITY AND 04/30/2015 $5,000.00
AND STATE AGRICULTURAL METABOLISM: An
COLLEGE Emerging Frontier
in Lung Health
and Disease
------------------------------------------------------------------------
SWEDISH MEDICAL CENTER The Transradial 04/30/2015 $5,000.00
FOUNDATION Approach: A Case-
based and Hands-
on Training
Course
------------------------------------------------------------------------
MONTEFIORE MEDICAL Achieving Balance: 05/03/2015 $161,500.00
CENTER Practical
Management
Strategies for
Opioid-Induced
Constipation
------------------------------------------------------------------------
CALIFORNIA SOCIETY OF CSAAI 23rd Annual 05/05/2015 $3,000.00
ALLERGY, ASTHMA, AND Educational
IMMUNOLOGY Meeting
------------------------------------------------------------------------
TRUSTEES OF THE Advanced Thyroid 05/06/2015 $5,000.00
UNIVERSITY OF Master Class
PENNSYLVANIA
------------------------------------------------------------------------
CANCER MOLECULAR Molecular 05/06/2015 $5,000.00
THERAPEUTICS RESEARCH Therapeutics of
ASSOCIATION Cancer
Conference, 2015
------------------------------------------------------------------------
NORTH SHORE LONG ISLAND Post American 05/07/2015 $3,000.00
JEWISH HEALTH SYSTEM Society of
INC. Clinical Oncology
2015
------------------------------------------------------------------------
AMERICAN COLLEGE OF Update in Allergy, 05/12/2015 $5,000.00
ALLERGY, ASTHMA AND Asthma and
IMMUNOLOGY Immunology
------------------------------------------------------------------------
ALBERT EINSTEIN Complex 05/14/2015 $5,000.00
HEALTHCARE NETWORK Angioplasty
Symposium
Exchange
Philadelphia
------------------------------------------------------------------------
SOCIETY FOR The Oncologist CME 05/17/2015 $10,000.00
TRANSLATIONAL ONCOLOGY Online Journal
Curriculum:
Breast Cancer
------------------------------------------------------------------------
ANENBERG CENTER FOR PosterPerspectives 05/18/2015 $25,000.00
HEALTH SCIENCES AT : Research
EISENHOWER Developments in
NSCLC / 2015 ASCO
------------------------------------------------------------------------
WESTERN ASSOCIATION Hitting the 05/18/2015 $12,500.00
GYNECOLOGIOC targets in
ONCOLOGISTS Gynecologic
Cancer
------------------------------------------------------------------------
AMERICAN THYROID ATA Early Riser 05/19/2015 $129,500.00
ASSOCIATION Symposium: New
Modalities to
Treat Medullary
Thyroid Cancer
------------------------------------------------------------------------
CARDIOVASCULAR RESEARCH Issues with DAPT: 05/19/2015 $25,000.00
FOUNDATION A Case-based
Roundtable with
the Experts
------------------------------------------------------------------------
LAHEY CLINIC HOSPITAL, Cardiovascular 05/19/2015 $6,000.00
INC. Disease State of
the Art 2015
------------------------------------------------------------------------
AMERICAN COLLEGE OF ACC Cardiovascular 05/19/2015 $5,000.00
CARDIOLOGY FOUNDATION Board Review for
Certification and
Recertification
------------------------------------------------------------------------
CANCER RESEARCH Immunotherapy for 05/19/2015 $75,000.00
INSTITUTE the Oncology
Nurse
------------------------------------------------------------------------
GORDON RESEARCH Gordon Research 05/20/2015 $5,000.00
CONFERENCES Conference;
Hormone dependent
cancer
------------------------------------------------------------------------
NORTHEASTERN UNIVERSITY Boston Symposium 05/21/2015 $3,500.00
on Organic and
Bioorganic
Chemistry (BSOBC)
------------------------------------------------------------------------
AMERICAN SOCIETY OF Anemia, 05/21/2015 $190,000.00
NEPHROLOGY Erythropoeisis,
and the
Nephrologist
------------------------------------------------------------------------
CANCER RESEARCH 2015 International 05/24/2015 $50,000.00
INSTITUTE Cancer
Immunotherapy
Conference
------------------------------------------------------------------------
ZOE ROSE MEMORIAL 2015 Preemie 05/24/2015 $10,000.00
FOUNDATION Parent Summit
------------------------------------------------------------------------
THE GOG FOUNDATION INC 4th Semi Annual 05/26/2015 $20,000.00
Meeting of NRG
Oncology
(formerly GOG,
NSABP, RTOG)
------------------------------------------------------------------------
CLINICAL CARE OPTIONS Immunotherapy for 05/26/2015 $25,000.00
Cancer Track: CCO
Independent
Conference
Highlights of the
2015 ASCO Annual
Meeting
------------------------------------------------------------------------
ACADEMIA MEDICA DEL SUR Non-Small Cell 05/26/2015 $3,000.00
Lung Cancer:
Current Therapy
and Promising New
Regimens
------------------------------------------------------------------------
AMERICAN ANMS 10th 05/26/2015 $6,400.00
NEUROGASTROENTEROLOGY Postgraduate
AND MOTILITY SOCIETY Course in
Gastroenterology
and
Neurogastroentero
logy in Clinical
Practice
------------------------------------------------------------------------
CEO ROUNDTABLE ON Prostate Cancer 05/27/2015 $30,000.00
CANCER, INC. DREAM Challenge
Winning Teams
Educational Grant
------------------------------------------------------------------------
C-CHANGE Big Data in Cancer 05/27/2015 $25,000.00
Care
------------------------------------------------------------------------
THE GOG FOUNDATION Rational 05/27/2015 $10,000.00
Combination
Targeted
Therapies for
Gynecologic
Cancers
------------------------------------------------------------------------
TRUSTEES OF COLUMBIA Lung Cancer 2015: 05/27/2015 $3,000.00
UNIVERSITY IN THE CITY New Discoveries,
OF NEW YORK New Directions
------------------------------------------------------------------------
NOT-FOR-PROFIT HOSPITAL Lung Cancer 05/27/2015 $1,900.00
CORPORATION Screening in 2015
------------------------------------------------------------------------
OLIGONUCLEOTIDE 11th Annual 05/31/2015 $7,500.00
THERAPEUTICS SOCIETY Meeting of the
Oligonucleotide
Therapeutics
Society
------------------------------------------------------------------------
CONQUER CANCER 2015 Best of ASCO 05/31/2015 $15,000.00
FOUNDATION OF THE Meetings
AMERICAN SOCIETY OF
CLINICAL ONCOLOGY
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF Improving Outcomes 06/02/2015 $101,800.00
DIABETES EDUCATORS for Women With
Type 2 Diabetes
Individualizing
Evidence-Based
Care
------------------------------------------------------------------------
NATIONAL KIDNEY Chronic Kidney 06/02/2015 $75,000.00
FOUNDATION Disease and the
Primary Care
Practitioner:
------------------------------------------------------------------------
UNIVERSITY OF MARYLAND 17th Annual 06/02/2015 $15,000.00
BALTIMORE FOUNDATION, International
INC. Meeting of the
Institute of
Human Virology
------------------------------------------------------------------------
TRUSTEES OF THE 2015 Updates in 06/03/2015 $5,000.00
UNIVERSITY OF Oncology: With
PENNSYLVANIA Proceedings from
International
Medical Meetings
------------------------------------------------------------------------
MELANOMA RESEARCH Melanoma Research 06/03/2015 $112,280.00
FOUNDATION Foundation CURE
OM Junior
Fellowship
------------------------------------------------------------------------
AMERICAN OSTEOPATHIC Optimizing Anti- 06/04/2015 $357,790.00
ASSOCIATION platelet Therapy
and Secondary
Prevention
Strategies in
Acute Coronary
Syndromes The
Role of the
Primary Care
Practice
(150203494)
------------------------------------------------------------------------
INTERNATIONAL SOCIETY Workshop on 06/09/2015 $30,000.00
FOR STEM CELL RESERACH Clinical
Translation
------------------------------------------------------------------------
NURSE PRACTITIONER The Latest in 06/10/2015 $5,000.00
ASSOCIATES FOR Asthma and COPD
CONTINUING EDUCATION
(NPACE)
------------------------------------------------------------------------
AMERICAN PHARMACISTS IMPACT Care 06/10/2015 $74,987.00
ASSOCIATION FOUNDATION Transformation
Institute
------------------------------------------------------------------------
AMERICAN ASSOCIATION Advances in Breast 06/11/2015 $10,000.00
FOR CANCER RESEARCH Cancer Research
------------------------------------------------------------------------
AMERICAN ASSOCIATION Advances in 06/11/2015 $10,000.00
FOR CANCER RESEARCH Ovarian Cancer
Research
------------------------------------------------------------------------
AMERICAN COLLEGE OF Symposium--Asthma, 06/11/2015 $50,000.00
ALLERGY, ASTHMA AND COPD and Asthma-
IMMUNOLOGY COPD Overlap
Syndrome (ACOS)
------------------------------------------------------------------------
CASE MANAGEMENT SOCIETY Improving 06/11/2015 $6,265.00
OF AMERICA Medication
Adherence in the
COPD Patient
through Greater
Patient
Engagement
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF California Chapter 06/16/2015 $20,000.00
CLINICAL of the American
ENDOCRINOLOGISTS Association of
Clinical
Endocrinologists
Presents: Hot
Topics in
Diabetes and
Endocrinology for
Primary Care
------------------------------------------------------------------------
FLORIDA ACADEMY OF Update on COPD and 06/16/2015 $4,300.00
PHYSICIAN ASSISTANTS Asthma Management
INC.
------------------------------------------------------------------------
AMERICAN ACADEMY OF 2015 AAFP FMX 06/16/2015 $13,000.00
FAMILY PHYSICIANS Assembly 60
Minute Lecture
titled Acute
Coronary Syndrome
and Angina
------------------------------------------------------------------------
AMERICAN COLLEGE OF ACEP Pediatric 06/17/2015 $2,500.00
EMERGENCY PHYSICAINS Emergency
Medicine Special
Interest Section
Annual Meeting
------------------------------------------------------------------------
FOUNDATION FOR FGO Genetics 06/18/2015 $35,000.00
GYNECOLOGIC ONCOLOGY Summit
------------------------------------------------------------------------
FRIENDS OF CANCER 2015 Friends of 06/22/2015 $100,000.00
RESEARCH Cancer Research
Programs
------------------------------------------------------------------------
DIVISION OF MEDICINAL Division of 06/23/2015 $2,500.00
CHEMISTRY Medicinal
Chemistry Program
American Chemical
Society 250th
National Meeting
------------------------------------------------------------------------
RECTOR AND VISITORS OF Vasculata 2015 06/24/2015 $10,000.00
THE UNIVERSITY OF
VIRGINIA
------------------------------------------------------------------------
AMERICAN COLLEGE OF Preventing 06/24/2015 $48,000.00
CHEST PHYSICIANS Exacerbations of
COPD
------------------------------------------------------------------------
ASSOCIATION OF ASTHMA The Asthma Team: 06/24/2015 $5,000.00
EDUCATORS Making Wishes
Come True
------------------------------------------------------------------------
THE MASSACHUSETTS 30th Annual 06/24/2015 $5,000.00
GENERAL HOSPITAL Critical Issues
In Tumor
Microenvironment:
Angiogenesis,
Metastasis and
Immunology
------------------------------------------------------------------------
NATIONAL MEDICAL The National 06/24/2015 $3,000.00
ASSOCIATION Medical
Association
Asthma Update:
Evidence-Based
Diagnosis and
management of
Asthma--Practical
Tools to Improve
Patient Care
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF Reducing 06/25/2015 $12,500.00
MANAGED CARE Exacerbations in
PHYSICIANS the Treatment and
Management of
Chronic
Obstructive
Pulmonary Disease
(COPD)
------------------------------------------------------------------------
ONCOLOGY NURSING Pharmacology 06/30/2015 $15,000.00
SOCIETY Updates in
Oncology Practice
Conference
------------------------------------------------------------------------
UC BERKELEY FOUNDATION IGI CRISPR 06/30/2015 $10,000.00
Workshop: Routes
to Designer
Biology
------------------------------------------------------------------------
METABOLIC ENDOCRINE 13th Annual World 07/01/2015 $100,000.00
EDUCATION FOUNDATION Congress on
Insulin
Resistance
Diabetes and
Cardiovascular
Disease--WCIRDC
------------------------------------------------------------------------
PARTNERS HEALTHCARE 2015 Personalized 07/02/2015 $25,000.00
PERSONALIZED MEDICINE Medicine
Conference
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF Improving Patient 07/02/2015 $25,000.00
MANAGED CARE Outcomes with
PHYSICIANS, INC. Novel Treatments
in the Management
of
Hypertriglyceride
mia
------------------------------------------------------------------------
NEW YORK CITY SOCIETY Practical 07/07/2015 $9,500.00
OF HEALTH- SYSTEM considerations
PHARMACISTS for using novel
oral antiplatelet
agents in
patients with
acute coronary
syndromes
------------------------------------------------------------------------
INTERNATIONAL EGFR Diagnostic 07/09/2015 $201,000.00
ASSOCIATION FOR THE Expert Consensus
STUDY OF LUNG CANCER meeting
------------------------------------------------------------------------
UB FOUNDATION Recent Advances in 07/09/2015 $2,500.00
ACTIVITIES, INC. the
pathophysiology
and management of
type 2 diabetes
------------------------------------------------------------------------
AMERICAN PHARMACISTS APhA's Pharmacist 07/14/2015 $25,000.00
ASSOCIATION and Patient
Centered Diabetes
Care Certificate
Training Program
National
Offerings
------------------------------------------------------------------------
AMERICAN ASSOCIATION AACR-NCI-EORTC 07/14/2015 $25,000.00
FOR CANCER RESEARCH Molecular Targets
and Cancer
Therapeutics
------------------------------------------------------------------------
JOHNS HOPKINS Mid-Atlantic 07/14/2015 $49,381.58
UNIVERSITY SCHOOL OF Nephrology Young
MEDICINE Investigators'
Forum
------------------------------------------------------------------------
SOUTH DAKOTA ACADEMY OF COPD: diagnosis 07/14/2015 $3,500.00
PHYSICIAN ASSISTANTS and optimum
treatment
------------------------------------------------------------------------
SOUTHERN SOCIETY FOR 15th Annual SSCI 07/15/2015 $43,940.49
CLINICAL INVESTIGATION Nephrology Young
Investigators'
Forum
------------------------------------------------------------------------
YALE UNIVERSITY 2015 London 07/16/2015 $5,000.00
Cardiovascular
Device Innovation
Summit
------------------------------------------------------------------------
REGENTS OF THE Updates in 07/19/2015 $5,000.00
UNIVERSITY OF Rheumatology 2015
CALIFORNIA
------------------------------------------------------------------------
REGENTS OF THE 13th Annual 07/21/2015 $34,698.53
UNIVERSITY OF Nephrology Young
CALIFORNIA Investigator's
Forum
------------------------------------------------------------------------
SOCIETY FOR 2015 SITC 07/22/2015 $50,000.00
IMMUNOTHERAPY OF International
CANCER Symposium on
Cancer
Immunotherapy
------------------------------------------------------------------------
SOCIETY FOR SITC 2015 Global 07/22/2015 $25,000.00
IMMUNOTHERAPY OF Regulatory Summit
CANCER
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE NCCN/SCCA 2015 07/26/2015 $10,000.00
CANCER NETWORK, INC. Thoracic Oncology
Symposium
------------------------------------------------------------------------
SOCIETY FOR Named Postdoctoral 07/26/2015 $120,000.00
IMMUNOTHERAPY OF Cancer
CANCER Immunotherapy in
NSCLC Clinical
Fellowship Award
------------------------------------------------------------------------
NATIONAL ASSOCIATION Gout: Bridging 07/26/2015 $163,946.00
FOR CONTINUING Knowledge Gaps in
EDUCATION Diagnosis and
Treatment
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE 2015 NCCN Immuno- 07/26/2015 $35,000.00
CANCER NETWORK, INC. Oncology Webinar
Series for
Pharmacists
------------------------------------------------------------------------
AMERICAN COLLEGE OF EPC--Updates in 07/28/2015 $10,000.00
ALLERGY, ASTHMA AND Pulmonary
IMMUNOLOGY Disease: Current,
Relevant and
Interactive
------------------------------------------------------------------------
NATIONAL KIDNEY 11th Annual 07/29/2015 $50,000.00
FOUNDATION National Young
Investigator's
Forum
------------------------------------------------------------------------
JOHNS HOPKINS Immuno-Oncology: A 07/29/2015 $30,000.00
UNIVERSITY SCHOOL OF Revolution in
MEDICINE Cancer Treatment
------------------------------------------------------------------------
GEORGIA CHAPTER OF THE 2015 Scientific 07/30/2015 $5,000.00
AMERICAN COLLEGE OF Meeting
CARDIOLOGY
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF Improving Outcomes 08/02/2015 $25,000.00
MANAGED CARE with
PHYSICIANS, INC. Individualized
Treatment
Strategies in the
Management of
Advanced Non
Small-Cell Lung
Cancer (NSCLC)
------------------------------------------------------------------------
HACKENSACK UNIVERSITY Fifth Annual Heart 08/03/2015 $5,000.00
MEDICAL CENTER and Vascular
Symposium
------------------------------------------------------------------------
METABOLIC ENDOCRINE Early Intervention 08/06/2015 $149,515.00
EDUCATION FOUNDATION in The Continuum
of Hyperglycemia--
The Role of
Initial
Combination
Therapy
------------------------------------------------------------------------
SOCIETY FOR Primer on Tumor 08/10/2015 $15,000.00
IMMUNOTHERAPY OF Immunology and
CANCER Cancer
Immunotherapy
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE NCCN/SCCA 2015 08/11/2015 -$2,005.40
CANCER NETWORK, INC. Thoracic Oncology
Symposium
------------------------------------------------------------------------
CONQUER CANCER 2015 Breast Cancer 08/11/2015 $10,000.00
FOUNDATION OF THE Symposium:
AMERICAN SOCIETY OF Enhancing
CLINICAL ONCOLOGY Clinical Care
through
Collaboration
------------------------------------------------------------------------
AMERICAN ACADEMY OF Management of 08/11/2015 $242,009.00
FAMILY PHYSICIANS Gout:
Individualizing
the Approach
------------------------------------------------------------------------
BREATHE CALIFORNIA OF Advancing the 08/16/2015 $3,000.00
LOS ANGELES COUNTY diagnosis and
management of
COPD with a focus
on COPD
exacerbations
------------------------------------------------------------------------
GLOBAL ACADEMY FOR 8th Annual 08/17/2015 $35,000.00
MEDICAL EDUCATION Perspectives in
Rheumatic
Diseases
presented by
Rheumatology
News, Internal
Medicine News,
Family Practice
News
------------------------------------------------------------------------
NORTHWESTERN UNIVERSITY 17th Annual Lynn 08/17/2015 $10,000.00
Sage Breast
Cancer Symposium
------------------------------------------------------------------------
AMERICAN COLLEGE OF Cardiovascular 08/17/2015 $10,000.00
EMERGENCY PHYSICIANS Disease Track at
ACEP 2015
Scientific
Assembly
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF NANN 31st Annual 08/19/2015 $10,000.00
NEONATAL NURSES Educational
Conference
------------------------------------------------------------------------
UNIVERSITY OF 2nd Annual 08/19/2015 $25,000.00
CINCINNATI Cincinnati
Collaborative
Cardiovascular
Symposium (C4)
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF AACE/ACE 08/20/2015 $99,804.71
CLINICAL Scientific and
ENDOCRINOLOGISTS Clinical Review
of DKA and the
Effects of SGLT2
Inhibitors
------------------------------------------------------------------------
AMERICAN COLLEGE OF TAS: Allergy, 08/23/2015 $1,000.00
ALLERGY, ASTHMA AND Asthma and
IMMUNOLOGY Immunology
Conference
------------------------------------------------------------------------
NAMI MARYLAND NAMI Maryland 2015 08/25/2015 $5,000.00
Annual Education
Conference
------------------------------------------------------------------------
CONNECTICUT PHARMACISTS Insights, Pearls, 08/25/2015 $5,000.00
ASSOCIATION and Perspectives--
An Update in the
Management of
Chronic
Obstructive
Pulmonary Disease
------------------------------------------------------------------------
AMERICAN COLLEGE OF Plenary Session-- 08/25/2015 $50,000.00
ALLERGY, ASTHMA AND Updates in Severe
IMMUNOLOGY Asthma
------------------------------------------------------------------------
UNIVERSITY OF FLORIDA Vascular Biology 08/26/2015 $10,000.00
Working Group
Global Chapter
Meeting
------------------------------------------------------------------------
PENN STATE UNIVERSITY Skin, Bones, 08/26/2015 $5,000.00
Hearts and
Private Parts
------------------------------------------------------------------------
AMERICAS HEALTH Roundtable 08/27/2015 $37,462.15
FOUNDATION Discussion on
Decreasing the
Burden of
Influenza in
Latin America
------------------------------------------------------------------------
DANA-FARBER CANCER 11th Annual 08/27/2015 $2,500.00
INSTITUTE INC. Postdoctoral and
Graduate Student
Retreat
------------------------------------------------------------------------
IOWA PHYSICIAN COPD Board Review 08/27/2015 $2,000.00
ASSISTANT SOCIETY Track
------------------------------------------------------------------------
BAYLOR COLLEGE OF Breast Cancer 08/30/2015 $3,000.00
MEDICINE Research and
Education Program
------------------------------------------------------------------------
BAYLOR COLLEGE OF Metastatic Breast 08/30/2015 $3,500.00
MEDICINE Cancer Conference
------------------------------------------------------------------------
ICAHN SCHOOL OF Top Ten Advances 08/30/2015 $10,000.00
MEDICINE AT MOUNT in Clinical
SINAI Cardiology
------------------------------------------------------------------------
ASSOCIATION OF In the Era of 09/01/2015 $125,000.00
COMMUNITY CANCER Value: The
CENTERS Importance of
Patient
Navigation,
Psychosocial
Distress
Screening, and
Survivorship Care
Planning Programs
in the Community
C
------------------------------------------------------------------------
PENNSYLVANIA STATE Constipation: 09/02/2015 $142,387.00
UNIVERSITY Improving
Outcomes With
Individualized,
Evidence-based
Treatment
------------------------------------------------------------------------
SIDNEY KIMMEL MEDICAL 2nd Annual Current 09/03/2015 $5,000.00
COLLEGE AT THOMAS Issues in
JEFFERSON UNIVERSITY Coronary and
Structural Heart
Disease: A
Multidisciplinary
Approach
------------------------------------------------------------------------
AMERICAN COLLEGE OF 48th Annual New 09/08/2015 $15,000.00
CARDIOLOGY FOUNDATION York
Cardiovascular
Symposium: Major
Topics in
Cardiology Today
------------------------------------------------------------------------
AMERICAN SOCIETY FOR ASTRO's 57th 09/09/2015 $10,000.00
RADIATION ONCOLOGY Annual Meeting
------------------------------------------------------------------------
NATIONAL JEWISH HEALTH 38th Annual 09/14/2015 $5,000.00
Pulmonary and
Allergy Update
------------------------------------------------------------------------
ST. JOSEPH'S REGIONAL Acute Myocardial 09/14/2015 $1,700.00
MEDICAL CENTER Infarction:
Guidelines,
Controversies and
Updates
------------------------------------------------------------------------
TRUSTEES OF BOSTON Head and Neck 09/15/2015 $3,000.00
UNIVERSITY Cancer Symposium:
From Pathways to
Therapies
------------------------------------------------------------------------
UNIVERSITY OF TEXAS Cancer Genetics: 09/15/2015 $3,000.00
SOUTHWESTERN MEDICAL Going Beyond the
CENTER Guidelines
------------------------------------------------------------------------
THE UNIVERSITY OF TEXAS 38TH Annual San 09/15/2015 $25,000.00
HEALTH SCIENCE CENTER Antonio Breast
AT SAN ANTONIO Cancer Symposium
------------------------------------------------------------------------
BAYLOR UNIVERSITY The 42nd Annual 09/15/2015 $8,500.00
MEDICAL CENTER Williamsburg
Conference on
Heart Disease
------------------------------------------------------------------------
UNIVERSITY OF Comprehensive 09/15/2015 $3,500.00
WASHINGTON Hematology and
Oncology Review
------------------------------------------------------------------------
NATIONAL COMMITTEE FOR NCQA Quality Talks 09/15/2015 $25,000.00
QUALITY ASSURANCE and 25th
Anniversary
------------------------------------------------------------------------
ICAHN SCHOOL OF Acute Myocardial 09/15/2015 $1,400.00
MEDICINE AT MOUNT Infarction:
SINAI Guidelines,
Controversies and
Updates
------------------------------------------------------------------------
CONQUER CANCER 2015 Breast Cancer 09/16/2015 $25,000.00
FOUNDATION OF THE Symposium
AMERICAN SOCIETY OF Proceedings
CLINICAL ONCOLOGY
------------------------------------------------------------------------
UT HEALTH SCIENCE 38th Annual San 09/16/2015 $35,000.00
CENTER SAN ANTONIO Antonio Breast
Cancer Symposium--
Basic Science
Forum/Poster
Discussion
Session
------------------------------------------------------------------------
AULTMAN HOSPITAL Aultman Hospital's 09/17/2015 $2,500.00
15th Annual
Cancer Conference
------------------------------------------------------------------------
AMERICAN COLLEGE OF Recognizing 09/20/2015 $209,619.96
EMERGENCY PHYSICIANS Diabetic
Emergencies: Will
You Be Ready?
------------------------------------------------------------------------
INTERNATIONAL Best of the World 09/21/2015 $10,000.00
ASSOCIATION FOR THE Conference on
STUDY OF LUNG CANCER Lung Cancer
------------------------------------------------------------------------
CONQUER CANCER CancerLinQ: Real- 09/21/2015 $400,000.00
FOUNDATION OF THE time Learning
AMERICAN SOCIETY OF Intelligence
CLINICAL ONCOLOGY Network for
Quality
------------------------------------------------------------------------
LUNG CANCER INITIATIVE Advanced 09/22/2015 $3,000.00
OF NC Laboratory
Testing Across
Cancer Types:
Everything you
need to know
------------------------------------------------------------------------
CAROLINAS HEALTHCARE 27th Annual Fall 09/22/2015 $3,000.00
SYSTEM Foliage Cancer
Conference
``Update on Lung
Cancer''
------------------------------------------------------------------------
SCRIPPS HEALTH TRANSFORMING 09/23/2015 $2,000.00
MEDICINE:
Evidence-Driven
mHealth
------------------------------------------------------------------------
WESTERN SOCIETY OF WSAAI 54th Annual 09/23/2015 $10,000.00
ALLERGY, ASTHMA AND Scientific
IMMUNOLOGY Session
------------------------------------------------------------------------
CONQUER CANCER 2016 Conquer 09/23/2015 $120,000.00
FOUNDATION OF THE Cancer Foundation
AMERICAN SOCIETY OF of ASCO Young
CLINICAL ONCOLOGY Investigator
Award (YIA)
------------------------------------------------------------------------
ASSOCIATION OF AMERICAN 2015 AACI/CCAF 09/28/2015 $10,000.00
CANCER INSTITUTES Annual Meeting
------------------------------------------------------------------------
CONQUER CANCER 2016 Conquer 09/29/2015 $40,000.00
FOUNDATION OF THE Cancer Foundation
AMERICAN SOCIETY OF of ASCO Merit
CLINICAL ONCOLOGY Awards
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF 2016 NAHN 09/29/2015 $10,000.00
HISPANIC NURSES Leadership
Meeting
------------------------------------------------------------------------
AMERICAN ACADEMY OF 2015 AAFP FMX 09/30/2015 $5,000.00
FAMILY PHYSICIANS Assembly 60
Minute Lecture
titled Chronic
Obstructive
Pulmonary Disease
(COPD) and
Pulmonary
Function Testing
------------------------------------------------------------------------
NORTHWESTERN UNIVERSITY 2nd Annual Case- 09/30/2015 $5,000.00
Based Coronary
and Structural
Heart
Intervention
Update
------------------------------------------------------------------------
TRUSTEES OF THE 44th Annual 10/04/2015 $5,000.00
UNIVERSITY OF Philadelphia
PENNSYLVANIA Workshop on
Hemostasis,
Thrombosis and
Artherosclerosis
------------------------------------------------------------------------
ECOG RESEARCH AND ECOG-ACRIN Fall 10/05/2015 $5,000.00
EDUCATION FOUNDATION, 2015 Group
INC. Meeting
------------------------------------------------------------------------
PHARMACY QUALITY Getting to the 10/05/2015 $3,500.00
ALLIANCE (PQA, INC) Core: Building
and Implementing
Core Measures
------------------------------------------------------------------------
BAYLOR UNIVERSITY Immune Checkpoint 10/07/2015 $5,000.00
MEDICAL CENTER Inhibitors in the
Treatment of
Selected Tumor
Types: A New
Prospective
------------------------------------------------------------------------
CEDARS SINAI MEDICAL 4th Annual New 10/07/2015 $5,000.00
CENTER Therapeutics in
Oncology: The
Road to
Personalized
Medicine
------------------------------------------------------------------------
PENN STATE UNIVERSITY Skin, Bones, 10/07/2015 $5,000.00
Hearts and
Private Parts
(two conferences)
------------------------------------------------------------------------
INDIANA UNIVERSITY Performance 10/07/2015 $5,000.00
Improvement with
Point of Care
Clinical Decision
Making App in non-
ST segment
elevation
myocardial
infarction
(NSTEMI) patients
------------------------------------------------------------------------
MEDSTAR WASHINGTON Update In 10/08/2015 $15,000.00
HOSPITAL CENTER Rheumatology
2015: New
Diagnostic Tests
and Treatments
for Clinical
Practice
------------------------------------------------------------------------
NEW YORK STATE New York State 10/08/2015 $2,500.00
OSTEOPATHIC MEDICAL Osteopathic
SOCIETY Medical Students
Health Policy
Initiative
------------------------------------------------------------------------
THE UNIVERSITY OF TEXAS 2015 Oncologic 10/11/2015 $5,000.00
MD ANDERSON CANCER Emergency
CENTER Medicine
Conference
------------------------------------------------------------------------
AMERICAN PANCREATIC 46th Annual 10/11/2015 $10,000.00
ASSOCIATION Meeting of the
American
Pancreatic
Association
------------------------------------------------------------------------
WAYNE STATE UNIVERSITY 2nd Annual Update 10/15/2015 $3,000.00
SCHOOL OF MEDICINE in Rheumatology
------------------------------------------------------------------------
WAYNE STATE UNIVERSITY State of the Art 10/15/2015 $3,000.00
Management of
Lung Cancer
Symposium
------------------------------------------------------------------------
MEDICAL UNIVERSITY OF 2nd Annual 10/18/2015 $10,000.00
SOUTH CAROLINA Comprehensive
Stroke and
Cerebrovascular
Update
------------------------------------------------------------------------
AMERICAN COLLEGE OF 2015 10/19/2015 $25,000.00
RHEUMATOLOGY Musculoskeletal
Ultrasound Course
for
Rheumatologists
------------------------------------------------------------------------
LOUISIANA STATE LSUHSC 10/20/2015 $3,500.00
UNIVERSITY HEALTH Cardiovascular
SCIENCES CENTER IN NEW Centers Joint
ORLEANS Retreat
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF Achieving 10/20/2015 $389,000.00
DIABETES EDUCATORS Partnerships and
Improving
Outcomes in Your
Diabetes Patients
------------------------------------------------------------------------
THE ENDOCRINE SOCIETY The Truth of the 10/21/2015 $284,438.73
Matter: An
Evidence-Based
Review of the
Newer
Antihyperglycemic
Agents for T2DM:
a hot seat
Program
------------------------------------------------------------------------
GORDON RESEARCH 2016 Basal Ganglia 10/21/2015 $2,500.00
CONFERENCES Gordon Research
Conference:
Emerging Views of
Cellular and
Circuit Diversity
Within the Basal
Ganglia
------------------------------------------------------------------------
MEDSTAR WASHINGTON Lung Cancer 2015: 10/22/2015 $3,000.00
HOSPITAL CENTER A Shifting
Management
Paradigm with
------------------------------------------------------------------------
NATIONAL QUALITY FORUM NQF Measure 10/22/2015 $100,000.00
Incubator
------------------------------------------------------------------------
GORDON RESEARCH 2016 Gordon 10/26/2015 $2,500.00
CONFERENCES Research
Conference on
Heterocyclic
Compounds
------------------------------------------------------------------------
AMERICAN HEART Scientific 10/26/2015 $30,000.00
ASSOCIATION, INC. Sessions 2015
Dedicated Track
on Acute Coronary
Syndrome: Current
and Emerging
Interventions and
Future Directions
------------------------------------------------------------------------
INOVA HEALTH CARE Inova Heart and 11/03/2015 $15,000.00
SERVICES Vascular
Institute 2016
Interventional
Cardiology
Symposium
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF 17th Annual 11/04/2015 $20,000.00
CLINICAL Intensive Course
ENDOCRINOLOGISTS on Diabetes,
Endocrinology,
and Metabolic
Diseases
------------------------------------------------------------------------
WORLDWIDE INITIATIVE Novel Therapies in 11/05/2015 $77,050.00
FOR DIABETES EDUCATION Type 2 Diabetes
Mellitus
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF AACE/ACE 11/05/2015 $79,500.00
CLINICAL Comprehensive
ENDOCRINOLOGISTS Diabetes
Algorithm 2015
Mobile App
------------------------------------------------------------------------
GORDON RESEARCH GRC Mutagenesis 11/05/2015 $3,500.00
CONFERENCE meeting 2016
------------------------------------------------------------------------
ONCOLOGY NURSING InPractice 11/09/2015 $49,000.00
SOCIETY Oncology Nursing
------------------------------------------------------------------------
PARTNERS HEALTHCARE World Medical 11/22/2015 $50,000.00
SYSTEM INC. Innovation Forum
------------------------------------------------------------------------
AMERICAN ASSOCIATION AACR-IASLC Joint 11/22/2015 $25,000.00
FOR CANCER RESEARCH Conference on the
Molecular Origins
of Lung Cancer
------------------------------------------------------------------------
PREVENTIVE Cardiovascular 11/22/2015 $10,000.00
CARDIOVASCULAR NURSES Risk Reduction:
ASSOCIATION Leading the Way
in Prevention
(22nd Annual
Symposium)
------------------------------------------------------------------------
NATIONAL LIPID National Lipid 11/22/2015 $15,000.00
ASSOCIATION Association 2016
Lipid Academy
Course Series
------------------------------------------------------------------------
NATIONAL LIPID National Lipid 11/22/2015 $15,000.00
ASSOCIATION Association 2016
Masters in
Lipidology Course
Series
------------------------------------------------------------------------
THE DEUEL CONFERENCE ON The 2016 Deuel 11/24/2015 $20,000.00
LIPIDS Conference on
Lipids
------------------------------------------------------------------------
AMERICAN PHARMACISTS APhA2016 11/25/2015 $11,500.00
ASSOCIATION Respiratory
Update:
Guidelines, Novel
Inhalers and More
------------------------------------------------------------------------
REGENTS OF THE 2016 World 12/01/2015 $10,000.00
UNIVERSITY OF Congress on
CALIFORNIA Continuing
Professional
Development:
Advancing
Learning and Care
in the Health
Professions
------------------------------------------------------------------------
NASPGHAN FOUNDATION Appropriate Use of 12/01/2015 $185,000.00
Proton Pump
Inhibitors in the
Treatment of
Pediatric
Patients with
GERD
------------------------------------------------------------------------
TRUSTEES OF BOSTON A COPD Quality 12/01/2015 $139,644.64
UNIVERSITY Improvement
Consortium
------------------------------------------------------------------------
FOUNDATION FOR Evolution and 12/03/2015 $200,000.00
GYNECOLOGIC ONCOLOGY Revolution of
PARP Targeting in
Gynecologic
Malignancies
------------------------------------------------------------------------
AMERICAN FEDERATION FOR 2016 Western 12/03/2015 $5,000.00
MEDICAL RESEARCH Regional Meeting
------------------------------------------------------------------------
UNIVERSITY OF University of 12/06/2015 $19,942.22
WASHINGTON Washington
Allergy and
Immunology
Fellowship
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE NCCN 2016 Congress 12/09/2015 $25,000.00
CANCER NETWORK, INC. Series: Breast
Cancer
------------------------------------------------------------------------
AMERICAN SOCIETY FOR 2016 12/10/2015 $10,000.00
RADIATION ONCOLOGY Multidisciplinary
Head and Neck
Cancer Symposium
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE NCCN 21st Annual 12/10/2015 $75,000.00
CANCER NETWORK, INC. Conference
General Session:
Advancing the
Standard of
Cancer CareTM
------------------------------------------------------------------------
AMERICAN ASSOCIATION AACR Annual 12/10/2015 $125,000.00
FOR CANCER RESEARCH Meeting--2016
------------------------------------------------------------------------
AMERICAN FEDERATION FOR 2016 Southern 12/10/2015 $5,000.00
MEDICAL RESEARCH Regional Meeting
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE NCCN 2016 Nursing 12/13/2015 $25,000.00
CANCER NETWORK, INC. Program:
Advancing
Oncology Nursing
at the NCCN 21st
Annual Conference
------------------------------------------------------------------------
INTERNATIONAL 16th Targeted 12/13/2015 $82,500.00
ASSOCIATION FOR THE Therapy meeting
STUDY OF LUNG CANCER on Lung Cancer
------------------------------------------------------------------------
AMERICAN Opioid-Induced 12/13/2015 $192,601.00
GASTROENTEROLOGICAL Constipation:
ASSOCIATION Recognition and
Optimal
Management
------------------------------------------------------------------------
KANAWHA COUNTY Mobile Integrated 12/14/2015 $50,000.00
EMERGENCY AMBULANCE Health Program:
AUTHORITY Emphasis on
Community
Paramedicine
------------------------------------------------------------------------
INTERNATIONAL PDL1 Atlas 12/14/2015 $120,000.00
ASSOCIATION FOR THE
STUDY OF LUNG CANCER
------------------------------------------------------------------------
CONQUER CANCER 2016 Conquer 12/15/2015 $500,000.00
FOUNDATION OF THE Cancer Foundation
AMERICAN SOCIETY OF of the American
CLINICAL ONCOLOGY Society of
Clinical Oncology
Mission Endowment
------------------------------------------------------------------------
CATAMOUNT MEDICAL PatientGPS : 12/16/2015 $74,841.86
EDUCATION, LLC Clinical Paths in
the Management of
Patients with
COPD
------------------------------------------------------------------------
AMERICAN PHARMACISTS APhA 2016 Hot 12/16/2015 $20,000.00
ASSOCIATION Topics in
Dyslipidemia
------------------------------------------------------------------------
THE SCRIPPS RESEARCH 27th Annual 12/16/2015 $1,500.00
INSTITUTE Frontiers in
Chemistry
Symposium at The
Scripps Research
Institute
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE Behind the 12/17/2015 $10,000.00
CANCER NETWORK, INC. Guidelines:
Insights into the
Standard of Care
in Oncology 2016
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE NCCN 2016 Oncology 12/17/2015 $25,000.00
CANCER NETWORK, INC. Fellows Program:
New Horizons in
Quality Cancer
Care at the NCCN
21st Annual
Conference
------------------------------------------------------------------------
NATIONAL LIPID National Lipid 12/17/2015 $30,000.00
ASSOCIATION Association 2016
Scientific
Meeting Series
------------------------------------------------------------------------
PEDIATRIC INFECTIOUS Pediatric 12/20/2015 $55,000.00
DISEASES SOCIETY Infectious
EDUCATION AND RESEARCH Diseases Society
FOUNDATION (PIDSERF) Fellowship Awards
Program
------------------------------------------------------------------------
THE VANDERBILT Cardiology 2016: 12/20/2015 $5,000.00
UNIVERSITY Advances in
Science and
Practice
------------------------------------------------------------------------
FOUNDATION FOR Quality 12/22/2015 $20,000.00
CONTINUING EDUCATION Improvement
IN THE HEALTH Education (QIE)
PROFESSIONS Initiative
National Training
and Education
------------------------------------------------------------------------
MARYLAND SOCIETY FOR Update on Gout and 01/04/2016 $1,625.00
THE RHEUMATIC DISEASES Pseudogout
------------------------------------------------------------------------
THE GOG FOUNDATION 5th Semi Annual 01/05/2016 $20,000.00
Meeting of NRG
Oncology
(formerly GOG,
NSABP,RTOG)
------------------------------------------------------------------------
CEDARS-SINAI MEDICAL The James R. 01/05/2016 $5,000.00
CENTER Klinenberg, MD
Symposium on
Rheumatic
Diseases: Hot
Topics in
Rheumatology
------------------------------------------------------------------------
LUNGEVITY FOUNDATION LUNGevity 01/06/2016 $25,000.00
Foundation
Scientific and
Clinical Research
Roundtable
------------------------------------------------------------------------
CARDIOVASCULAR RESEARCH Chronic Total 01/07/2016 $10,000.00
FOUNDATION Occlusion Summit
2016
------------------------------------------------------------------------
LUMEN FOUNDATION Lumen Global 2016 01/10/2016 $35,000.00
------------------------------------------------------------------------
CARDIOVASCULAR RESEARCH St. Francis 01/10/2016 $5,000.00
FOUNDATION Imaging Course
2016
------------------------------------------------------------------------
AMERICAN HEART Epidemiology and 01/12/2016 $10,000.00
ASSOCIATION, INC. Prevention--Lifes
tyle and
Cardiometabolic
Health 2016
Scientific
Sessions
------------------------------------------------------------------------
CLEVELAND CLINIC Beyond 01/14/2016 $22,696.65
EDUCATIONAL FOUNDATION Revascularization
for CLI-The Role
of
Pharmacotherapy
Satellite
Symposium
------------------------------------------------------------------------
CARDIOVASCULAR CVIs 4th Annual 01/14/2016 $2,500.00
INSTITUTE OF Interventional
PHILADELPHIA Cardiovascular
Medicine: The
Crossroads of
Interventional
and Clinical
Cardiology
------------------------------------------------------------------------
UNIVERSITY OF TENNESSEE Testing to Target 01/19/2016 $288,885.00
COLLEGE OF PHARMACY in Non-Small Cell
Lung Cancer:
Managed Care
Perspectives
------------------------------------------------------------------------
SOCIETY FOR VASCULAR Society for 01/20/2016 $20,000.00
MEDICINE Vascular Medicine
27th Annual
Scientific
Sessions
------------------------------------------------------------------------
OHIOHEALTH 1st Bi-Annual 01/20/2016 $2,500.00
OhioHealth Acute
Cardiovascular
Care Conference
------------------------------------------------------------------------
SOCIETY FOR Immunotherapy of 01/24/2016 $40,000.00
IMMUNOTHERAPY OF Cancer for the
CANCER Workshop on
Biomarkers
------------------------------------------------------------------------
NORTHEAST GEORGIA 8th Annual 01/25/2016 $2,500.00
MEDICAL CENTER INC. Northeast Georgia
Regional STEMI
Summit
------------------------------------------------------------------------
CALIFORNIA THORACIC COPD: A TEAM 01/26/2016 $5,000.00
SOCIETY APPROACH
------------------------------------------------------------------------
CARDIOVASCULAR RESEARCH Issues with DAPT: 01/28/2016 $50,000.00
FOUNDATION A case-based
guide to optimal
antiplatelet
therapies
------------------------------------------------------------------------
GASTROINTESTINAL AND The 2016 US GI and 01/28/2016 $16,000.00
LIVER ASSOCIATION OF Liver Association
THE AMERICAS INC. of the Americas
(GALA) Conference
Series
------------------------------------------------------------------------
GORDON RESEARCH 2016 Lipoprotein 01/28/2016 $5,000.00
CONFERENCES Metabolism Gordon
Research
Conference and
Gordon Research
Seminar
------------------------------------------------------------------------
AMERICAN ACADEMY OF AAPM 32nd Annual 01/31/2016 $25,000.00
PAIN MEDICINE Meeting 2016
------------------------------------------------------------------------
DUKE UNIVERSITY DCRI Evidence to 02/01/2016 $10,000.00
Practice Series:
Interventional
Cardiology
------------------------------------------------------------------------
AMERICAN COLLEGE OF ACCs 65th Annual 02/01/2016 $50,000.00
CARDIOLOGY FOUNDATION Scientific
Session (ACC.16)
Acute Coronary
Syndromes
Clinical Learning
Pathway
------------------------------------------------------------------------
REGENTS OF THE LIPID MAPS 02/01/2016 $5,000.00
UNIVERSITY OF Meeting:
CALIFORNIA Lipidomics Impact
on Metabolic,
Cancer,
Cardiovascular
and Inflammatory
Diseases
------------------------------------------------------------------------
SCOTTSDALE HEALTHCARE 2016 Scottsdale 02/02/2016 $2,500.00
FOUNDATION Interventional
Forum (SIF 2016)
------------------------------------------------------------------------
UNIVERSITY OF FLORIDA Vascular Biology 02/02/2016 $15,000.00
Working Group
U.S. Chapter
Meeting
------------------------------------------------------------------------
EMORY UNIVERSITY EPIC SEC Emory 02/03/2016 $20,000.00
Practical
Intervention
Course--Southeast
Consortium
------------------------------------------------------------------------
THE ENDOCRINE SOCIETY DMS 2016: 02/07/2016 $235,318.22
Initiating the
Conversation:
Sharing
Perspectives on
Advances in T2DM
Treatment to
Improve Patient-
Centered Care
------------------------------------------------------------------------
CONQUER CANCER 2016 ASCO Annual 02/07/2016 $56,000.00
FOUNDATION OF THE Meeting Lung
AMERICAN SOCIETY OF Cancer Track
CLINICAL ONCOLOGY
------------------------------------------------------------------------
SOCIETY FOR SCAI 2016 02/14/2016 $25,000.00
CARDIOVASCULAR Scientific
ANGIOGRAPHY AND Sessions
INTERVENTIONS
FOUNDATION
------------------------------------------------------------------------
SOCIETY OF HOSPITAL Hospital Medicine 02/14/2016 $15,000.00
MEDICINE 2016
------------------------------------------------------------------------
AMERICAN HEAD AND NECK American Head and 02/17/2016 $50,000.00
SOCIETY Neck Society 9th
International
Conference on
Head and Neck
Cancer
------------------------------------------------------------------------
GLOBAL EDUCATION GROUP Clinical Issues in 02/18/2016 $411,613.00
Type 2 Diabetes:
Consensus and
Controversies
Around
Intensifying
Noninsulin
Therapy.
------------------------------------------------------------------------
NYU POST-GRADUATE Seminar in 03/01/2016 $5,000.00
MEDICAL SCHOOL Advanced
Rheumatology
------------------------------------------------------------------------
NEW MEXICO THORACIC 44th Annual New 03/01/2016 $5,000.00
SOCIETY Mexico Lung
Disease
Symposium--50
Shades of Blue
------------------------------------------------------------------------
MEDSTAR WASHINGTON 14th International 03/01/2016 $10,000.00
HOSPITAL CENTER Congress on
Targeted
Anticancer
Therapies
------------------------------------------------------------------------
FEDERATION OF AMERICAN FASEB Conference 03/01/2016 $6,000.00
SOCIETIES FOR on Genome
EXPERIMENTAL BIOLOGY Engineering
Cutting-Edge
Research and
Application
------------------------------------------------------------------------
DIVISION OF MEDICINAL Division of 03/01/2016 $2,500.00
CHEMISTRY Medicinal
Chemistry Program
251st ACS
National Meeting
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF Personalizing 03/01/2016 $35,000.00
MANAGED CARE Therapy for
PHYSICIANS, INC. Improved Patient
Outcomes in the
Management of
Advanced Non
Small-Cell Lung
Cancer (NSCLC)
------------------------------------------------------------------------
THE AMERICAN THORACIC ATS 2016 03/01/2016 $20,000.00
SOCIETY International
Conference--Selec
ted Topics in
Lung Cancer
------------------------------------------------------------------------
THE ASSOCIATION FOR Building an 03/01/2016 $2,500.00
FRONOTOTEMPORAL Infrastructure to
DEGENERATION Support FTLD
Therapeutic
Development
------------------------------------------------------------------------
WASHINGTON ACADEMY OF 27th Annual 03/01/2016 $1,750.00
PHYSICIAN ASSISTANTS Recertification
Review Course and
Spring Conference
------------------------------------------------------------------------
ONCOLOGY NURSING 41st Annual 03/01/2016 $35,000.00
SOCIETY Oncology Nursing
Society Congress
and Pharmacology
Highlights
regional program
------------------------------------------------------------------------
GORDON RESEARCH Chemical 03/01/2016 $2,500.00
CONFERENCES Approaches for
Unraveling
Biology
------------------------------------------------------------------------
GORDON RESEARCH Medicinal 03/01/2016 $3,000.00
CONFERENCE Chemistry Gordon
Research
Conference
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF 2016 Charitable 03/01/2016 $30,000.00
FREE AND CHARITABLE Health Care
CLINICS Symposium
------------------------------------------------------------------------
THE HOPE FOUNDATION 2016 SWOG Group 03/01/2016 $10,000.00
Meetings
------------------------------------------------------------------------
HEMATOLOGY/ONCOLOGY 2016 Hematology/ 03/01/2016 $25,000.00
PHARMACY ASSOCIATION Oncology PHarmacy
Association
------------------------------------------------------------------------
MEDICAL LEARNING New Developments 03/03/2016 $65,763.00
INSTITUTE INC. in the Treatment
of COPD: Updates
From San
Francisco
(150203884)
------------------------------------------------------------------------
AMERICAN 11th Postgraduate 03/03/2016 $10,000.00
NEUROGASTROENTEROLOGY Course on GI
AND MOTILITY SOCIETY Motility and
Neurogastroentero
logy in Clinical
Practice
------------------------------------------------------------------------
AMERICAN ACADEMY OF AAPA Conference 03/03/2016 $5,000.00
PHYSICIAN ASSISTANT 2016--Allergy/
Immunology and
Pulmonology Track
------------------------------------------------------------------------
GORDON RESEARCH Gordon Research 03/07/2016 $3,000.00
CONFERENCE Conference on
Cyclic Nucleotide
Phosphodiesterase
s: Mechanisms of
PDE Nano-Domain
Control and
Impacts on
Disease
------------------------------------------------------------------------
AMERICAN THORACIC ATS 2016 03/07/2016 $70,000.00
SOCIETY International
Conference--Selec
ted Topics in
COPD
------------------------------------------------------------------------
MASSACHUSETTS GENERAL CoNNCT Workshop 03/07/2016 $2,000.00
HOSPTIAL (Collaborative
Novel-Novel
Cancer Therapies)
------------------------------------------------------------------------
COLLEGIUM 31st Symposium of 03/08/2016 $10,000.00
INTERNATIONALE the Collegium
ALLERGOLOGICUM Internationale
Allergologicum
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF Improving Outcomes 03/08/2016 $25,000.00
MANAGED CARE in the Management
PHYSICIANS and Treatment of
Asthma
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF Identifying New 03/08/2016 $25,000.00
MANAGED CARE Strategies to
PHYSICIANS Optimize the
Management and
Treatment of COPD
------------------------------------------------------------------------
NORTHEASTERN SECTION OF NESACS Advances in 03/08/2016 $1,500.00
THE AMERICAN CHEMICAL Chemical Sciences
SOCIETY, INC. Symposium
------------------------------------------------------------------------
AMERICAN THORACIC ATS 2016 03/08/2016 $30,000.00
SOCIETY INC. International
Conference--Selec
ted Topics in
Asthma
------------------------------------------------------------------------
YALE UNIVERSITY 4th Annual Yale 03/08/2016 $15,000.00
COPD Symposium
------------------------------------------------------------------------
FLORIDA ALLERGY, ASTHMA Florida Allergy, 03/14/2016 $15,000.00
AND IMMUNOLOGY SOCIETY Asthma and
Immunology
Society 2016
Annual CME
Conference
------------------------------------------------------------------------
UNIVERSITY OF Keep your patients 03/14/2016 $25,000.00
CONNECTICUT ``moving''--An
Overview of
Treatment Options
for Constipation
------------------------------------------------------------------------
UHS PROFESSIONAL 32nd Annual 03/14/2016 $10,000.00
EDUCATIONAL PROGRAMS, Congress of
INC. Clinical
Rheumatology
------------------------------------------------------------------------
NATIONAL KIDNEY CKD-Related Anemia 03/17/2016 $100,050.00
FOUNDATION and
Cardiovascular
Risk
------------------------------------------------------------------------
UHS-PROFESSIONAL 1st Annual 03/23/2016 $5,000.00
EDUCATION PROGRAMS Advances in Pain
INC. Care
------------------------------------------------------------------------
GORDON RESEARCH Gordon Research 03/23/2016 $1,000.00
CONFERENCE Conference on
Cyclic Nucleotide
Phosphodiesterase
s: Mechanisms of
PDE Nano-Domain
Control and
Impacts on
Disease
------------------------------------------------------------------------
OUHSC COLLEGE OF 19th Annual 03/24/2016 $1,500.00
MEDICINE OFFICE OF CPD Primary Care
Update
------------------------------------------------------------------------
TENNESSEE ACADEMY OF Spring Fling 2016-- 03/27/2016 $3,000.00
PHYSICIAN ASSISTANTS Asthma and COPD
------------------------------------------------------------------------
AMERICAN THORACIC ATS 2016 03/28/2016 $10,000.00
SOCIETY INC. International
Conference--Fello
w Track Symposium
------------------------------------------------------------------------
COLORADO ALLERGY AND Biologics in the 03/29/2016 $3,000.00
ASTHMA SOCIETY Treatment of
Respiratory
Disease
------------------------------------------------------------------------
BOARD OF REGENTS FOR Updates in 03/29/2016 $10,000.00
UNIVERSITY OF NEBRASKA Rheumatology:
Gout and
Hyperuricemia
------------------------------------------------------------------------
CANCER RESEARCH 2016 International 04/06/2016 $50,000.00
INSTITUTE Cancer
Immunotherapy
Conference
------------------------------------------------------------------------
AMERICAN PAIN SOCIETY 2016 Pain Care for 04/07/2016 $10,000.00
Primary Care
------------------------------------------------------------------------
ALZHEIMER'S ASSOCIATION 2016 Alzheimer's 04/10/2016 $50,000.00
Association
Research
Roundtable
------------------------------------------------------------------------
CANCER MOLECULAR Molecular 04/10/2016 $1,500.00
THERAPEUTICS RESEARCH Therapeutics of
ASSOCIATION Cancer Conference
2016
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF AAPS Sustaining 04/10/2016 $50,000.00
PHARMACEUTICAL Sponsorship
SCIENTISTS
------------------------------------------------------------------------
DINORA INC. Lupus 2016 04/10/2016 $25,000.00
------------------------------------------------------------------------
INTERNATIONAL SOCIETY American 04/10/2016 $3,000.00
OF PHARMACOMETRICS Conference on
Pharmacometrics
------------------------------------------------------------------------
HOWARD 11th Kenneth 04/11/2016 $3,375.00
UNIVERSITYHOSPITAL Austin Annual
Rheumatology
Symposium
------------------------------------------------------------------------
ECOG RESEARCH AND 2016 ECOG-ACRIN 04/11/2016 $5,000.00
EDUCATION FOUNDATION Spring Group
Meeting
------------------------------------------------------------------------
AMERICAN HEART Arteriosclerosis, 04/11/2016 $15,000.00
ASSOCIATION, INC. Thrombosis and
Vascular Biology
Peripheral
Vascular Disease
2016
------------------------------------------------------------------------
AMERICAN UROLOGICAL AUA2016 Highlights 04/11/2016 $25,000.00
ASSOCIATION EDUCATION in Bladder Cancer
and RESEARCH INC.
------------------------------------------------------------------------
NATIONAL KIDNEY National Kidney 04/11/2016 $5,000.00
FOUNDATION Foundation s
Ninth Annual Mid-
Atlantic First
Year Renal
Fellows Symposium
------------------------------------------------------------------------
THOMAS JEFFERSON 5th Annual 04/11/2016 $3,000.00
UNIVERSITY Palliative Care
Spring Symposium
------------------------------------------------------------------------
COLUMBUS NCORP 2016 ASCO REVIEW 04/12/2016 $2,000.00
------------------------------------------------------------------------
ALZHEIMER'S ASSOCIATION 2016 Alzheimer's 04/12/2016 $45,000.00
Association
International
Conference
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE 2016-2017 Monthly 04/12/2016 $49,008.06
CANCER NETWORK Oncology Tumor
Boards: A
Multidisciplinary
Approach to
Individualized
Patient Care
------------------------------------------------------------------------
WASHINGTON UNIVERSITY Advances in Lung 04/13/2016 $3,000.00
Cancer
------------------------------------------------------------------------
TRANSLATIONAL RESEARCH TRIO-US and UCLA 04/14/2016 $3,000.00
IN ONCOLOGY-US, INC. Annual Research
Conference
------------------------------------------------------------------------
YALE UNIVERSITY Yale ASCO Review 04/17/2016 $2,000.00
2016
------------------------------------------------------------------------
SOCIETY FOR SITC 31st Annual 04/17/2016 $300,000.00
IMMUNOTHERAPY OF Meeting
CANCER
------------------------------------------------------------------------
SOCIETY FOR 2016 Primer on 04/17/2016 $50,000.00
IMMUNOTHERAPY OF Tumor Immunology
CANCER and Cancer
Immunotherapy
------------------------------------------------------------------------
INTERNATIONAL IASLC Fellowship/ 04/18/2016 $43,000.00
ASSOCIATION FOR THE Young
STUDY OF LUNG CANCER Investigator
Award
------------------------------------------------------------------------
AMERICAN SOCIETY FOR ASTRO 2016 58th 04/18/2016 $10,000.00
RADIATION ONCOLOGY Annual Meeting
------------------------------------------------------------------------
NORTHWESTERN UNIVERSITY 18th Annual Lynn 04/18/2016 $10,000.00
Sage Breast
Cancer Symposium
------------------------------------------------------------------------
AMERICAN COLLEGE OF GAIN (EnGAiging an 04/19/2016 $500,000.00
CHEST PHYSICIANS Inter-
Disciplinary Team
for NSCLC
Diagnosis,
Personalized
Assessment, and
Treatment)
------------------------------------------------------------------------
AMERICAN ASSOCIATION 11th Biennial 04/21/2016 $10,000.00
FOR CANCER RESEARCH Ovarian Cancer
Research
Symposium
------------------------------------------------------------------------
METABOLIC ENDOCRINE 14th Annual World 04/21/2016 $75,000.00
EDUCATION FOUNDATION Congress on
Insulin
Resistance
Diabetes and
Cardiovascular
Disease--WCIRDC
------------------------------------------------------------------------
C-CHANGE Catalyzing Change 04/24/2016 $50,000.00
in Big Data and
Value in Cancer
Care
------------------------------------------------------------------------
CONQUER CANCER 2016 ASCO Pre- 04/24/2016 $5,000.00
FOUNDATION OF THE Annual Meeting
AMERICAN SOCIETY OF Seminar: How to
CLINICAL ONCOLOGY Integrate Tumor
Immunotherapy
into Your
Clinical Practice
------------------------------------------------------------------------
UNIVERSITY OF FLORIDA Southern Salt, 04/24/2016 $3,000.00
FOUNDATION INC. Water, and Kidney
Club 57th Annual
Scientific
Meeting
------------------------------------------------------------------------
CONQUER CANCER 2016 Best of ASCO 04/24/2016 $30,000.00
FOUNDATION OF THE Meetings
AMERICAN SOCIETY OF
CLINICAL ONCOLOGY
------------------------------------------------------------------------
AMERICAN SOCIETY FOR ASPMN 26th 04/24/2016 $15,000.00
PAIN MANAGEMENT National
NURSING Conference
------------------------------------------------------------------------
UNIVERSITY OF TEXAS American Society 04/24/2016 $2,000.00
HEALTH SCIENCE CENTER of Clinical
AT SAN ANTONIO SOM Oncology (ASCO)
2016 Review
------------------------------------------------------------------------
CLEVELAND CLINIC ASCO Review 04/25/2016 $2,000.00
EDUCATIONAL FOUNDATION
------------------------------------------------------------------------
DUKE UNIVERSITY 15th Annual 04/27/2016 $10,000.00
Southeastern
Fellows Research
Skills and
Training Workshop
------------------------------------------------------------------------
CEDARS-SINAI MEDICAL 2nd Annual Acing 05/02/2016 $5,000.00
CENTER the GI Board
Exam: The
Ultimate High-
Speed Review
Course
------------------------------------------------------------------------
AUGUSTA UNIVERSITY Harnessing the 05/03/2016 $220,000.00
RESEARCH INSTITUTE, Body's Immune
INC. System to Treat
Cancer: the
Promise of
Immunotherapy
------------------------------------------------------------------------
AMERICAN HEART Scientific 05/03/2016 $35,000.00
ASSOCIATION, INC. Sessions 2016
Dedicated Track
on Acute Coronary
Syndromes
------------------------------------------------------------------------
INTERNATIONAL SOCIETY ISN Global Kidney 05/04/2016 $30,000.00
OF NEPHROLOGY Health Summit
------------------------------------------------------------------------
NORTHEASTERN UNIVERSITY Boston Symposium 05/04/2016 $2,500.00
on Organic and
Bioorganic
Chemistry (BSOBC)
------------------------------------------------------------------------
AMERICAN ASSOCIATION 11th Biennial 05/04/2016 $15,000.00
FOR CANCER RESEARCH Ovarian Cancer
Research
Symposium,
------------------------------------------------------------------------
WORLD ALLERGY WAO International 05/09/2016 $30,000.00
ORGANIZATION Scientific
Conference 2016:
Travel Grants
------------------------------------------------------------------------
THE GOG FOUNDATION 6th Semi Annual 05/10/2016 $5,000.00
Meeting of NRG
Oncology
(formerly GOG,
NSABP,RTOG)
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF Cardiovascular 05/10/2016 $5,000.00
PHYSICIANS OF INDIAN Seminar
ORIGIN (AAPI)
------------------------------------------------------------------------
AMERICAN COLLEGE OF Cardiovascular 05/12/2016 $20,000.00
EMERGENCY PHYSICIANS Disease Track at
ACEP 2016
Scientific
Assembly
------------------------------------------------------------------------
AMERICAN SOCIETY OF Expanding the 05/15/2016 $190,000.00
NEPHROLOGY Therapeutic
Armamentarium for
Treatment of
Anemia of Kidney
Disease
------------------------------------------------------------------------
BLADDER CANCER ADVOCACY 2016 Bladder 05/15/2016 $25,000.00
NETWORK Cancer Think Tank
------------------------------------------------------------------------
PREVENTIVE 2016 PCNA Fall 05/16/2016 $5,000.00
CARDIOVASCULAR NURSES Learning Series:
ASSOCIATION Diabetes and CVD:
Managing Patients
with High-Risk
and Co-Morbid
Conditions
------------------------------------------------------------------------
ASSOCIATION OF AMERICAN 2016 AACI/CCAF 05/18/2016 $10,000.00
CANCER INSTITUTES Annual Meeting
------------------------------------------------------------------------
UNIVERSIDAD CENTRAL DEL Role of the 05/19/2016 $2,000.00
CARIBE, INC. Multidisciplinary
Care Team in
Personalizing
Treatment for Non-
Small Cell Lung
Cancer:
Addressing Tissue
Acquisition,
Diagnosis, and
Perso
------------------------------------------------------------------------
THE LEUKEMIA AND 2016 Waldenstrom's 05/24/2016 $3,000.00
LYMPHOMA SOCIETY, INC. Roadmap Symposium
------------------------------------------------------------------------
AMERICAN SOCIETY OF ASH Scholar Award 05/25/2016 $50,000.00
HEMATOLOGY
------------------------------------------------------------------------
AMERICAN ASSOCIATION AACR Conference on 05/25/2016 $35,000.00
FOR CANCER RESEARCH Tumor Immunology
and Immunotherapy
------------------------------------------------------------------------
SCRIPPS HEALTH 13th Annual 05/26/2016 $2,000.00
Oncology Update
------------------------------------------------------------------------
DANA FARBER CANCER International 06/02/2016 $10,000.00
INSTITUTE Workshop on
Waldenstroms
macroglobulinemia
and symposia on
Multiple myeloma
(IWWM9)
------------------------------------------------------------------------
FRIENDS OF CANCER 2016 Friends of 06/05/2016 $100,000.00
RESEARCH Cancer Research
Programs
------------------------------------------------------------------------
PARTNERS HEALTHCARE Massachusetts 06/08/2016 $4,771.88
SYSTEM, INC. General Hospital
Multidisciplinary
Breast Rounds
------------------------------------------------------------------------
VIVA PHYSICIANS, INC. VIVA 16: Vascular 06/12/2016 $25,000.00
InterVentional
Advances
------------------------------------------------------------------------
UNIVERSITY OF COLORADO Sex Differences 06/16/2016 $35,000.00
DENVER, CENTER FOR Across the
WOMEN'S HEALTH HEALTH Lifespan: A Focus
RESEARCH on Metabolism
------------------------------------------------------------------------
THE BOARD OF REGENTS OF Immunotherapy: 06/20/2016 $40,000.00
THE UNIVERSITY OF Transformation of
NEBRASKA Therapies for
Blood Cancer a
satellite
symposium held in
conjunction with
the 2016 ASH
Annual Meeting
------------------------------------------------------------------------
VIVA PHYSICIANS, INC. The Blockbuster at 06/21/2016 $69,100.00
VIVA 16
------------------------------------------------------------------------
AMERICAN COLLEGE OF COPD Learning 06/22/2016 $40,000.00
CHEST PHYSICIANS Track
------------------------------------------------------------------------
ENDOCRINE FELLOWS Third Annual 06/23/2016 $278,000.00
FOUNDATION Endocrine Fellows
Foundation
Research Meeting
------------------------------------------------------------------------
AMERICAN CANCER SOCIETY American Cancer 06/30/2016 $163,500.00
INC. Society Post-
Doctoral Research
Fellowship
Program
------------------------------------------------------------------------
AMERICAN COLLEGE OF Breathing New Air 07/03/2016 $10,000.00
OSTEOPATHIC into the
INTERNISTS, INC. Treatment of COPD
and Asthma
------------------------------------------------------------------------
UNIVERSITY OF TEXAS 39th Annual San 07/03/2016 $75,000.00
HEALTH SCIENCE CENTER Antonio Breast
AT SAN ANTONIO SCHOOL Cancer Symposium
OF MEDICINE--OFFICE OF
CME
------------------------------------------------------------------------
NATIONAL JEWISH HEALTH Evaluation and 07/04/2016 $94,011.50
Treatment of
Severe Asthma:
The Role of
Biologic and
Directed
Therapies
------------------------------------------------------------------------
NATIONAL MEDICAL Chronic 07/04/2016 $150,000.00
ASSOCIATION Obstructive
Pulmonary Disease
Interdisciplinary
Diagnostic and
Treatment
Symposium
------------------------------------------------------------------------
GORDON RESEARCH Gordon Research 07/10/2016 $1,440.00
CONFERENCE Seminar in
Microbial Toxins
and Pathogenesis
------------------------------------------------------------------------
AMERICAN ACADEMY OF 34th Annual Aspen 07/13/2016 $5,200.00
ALLERGY, ASTHMA AND Allergy
IMMUNOLOGY Conference
------------------------------------------------------------------------
GORDON RESEARCH 2016 Protein 07/13/2016 $5,000.00
CONFERENCE Processing
Trafficking and
Secretion
------------------------------------------------------------------------
SOCIETY FOR New Cancer 07/14/2016 $35,000.00
IMMUNOTHERAPY OF Immunotherapy
CANCER Agents in
Development
------------------------------------------------------------------------
AMINISTRATORS OF THE 16th Annual SSCI 07/14/2016 $49,939.06
TULANE EDUCATIONAL Nephrology Young
FUND Investigators'
Forum
------------------------------------------------------------------------
NEW YORK ACADEMY OF Targeting 07/18/2016 $15,000.00
SCIENCES Inflammation and
Podocytopathy in
Chronic Kidney
Disease
------------------------------------------------------------------------
SOCIETY FOR SITC 2016 Workshop 07/19/2016 $150,000.00
IMMUNOTHERAPY OF on Challenges,
CANCER Insights, and
Future Directions
for Mouse and
Humanized Models
in Cancer
Immunology and
Immunotherapy
------------------------------------------------------------------------
MASSACHUSETTS GENERAL 31th Annual 07/21/2016 $10,000.00
HOSPITAL Critical Issues
In Tumor
Microenvironment:
Angiogenesis,
Metastasis and
Immunology
------------------------------------------------------------------------
CARDIOVASCULAR RESEARCH Transcatheter 07/21/2016 $10,000.00
FOUNDATION Cardiovascular
Therapeutics
(TCT) 2016
------------------------------------------------------------------------
PEPTIDE THERAPEUTICS 11th Annual 07/26/2016 $15,000.00
FOUNDATION Peptide
Therapeutics
Symposium
------------------------------------------------------------------------
AMERICAN SOCIETY OF ASN Kidney Week-- 07/27/2016 $20,000.00
NEPHROLOGY CKD Learning
Pathway Support
------------------------------------------------------------------------
AMERICAN ASSOCIATION AACR DNA Repair: 07/31/2016 $25,000.00
FOR CANCER RESEARCH Tumor Development
and Therapeutic
Response
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE NCCN 2016 Congress 08/01/2016 $50,000.00
CANCER NETWORK INC. Series:
Immunotherapies
in Cancer
------------------------------------------------------------------------
CEDARS SINAI MEDICAL Pancreatic Cancer 08/03/2016 $3,000.00
CENTER Conference
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE NCCN 2016 Congress 08/04/2016 $25,000.00
CANCER NETWORK INC. Series: Utilizing
Guidelines to
Customize Patient
Care in Non-Small
Cell Lung Cancer
------------------------------------------------------------------------
AMERICAN COLLEGE OF Managing Severe 08/04/2016 $12,500.00
ALLERGY, ASTHMA AND Asthma in Adults
IMMUNOLOGY and Children
Workshop
------------------------------------------------------------------------
ILLINOIS ACADEMY OF Tenth Annual 08/07/2016 $54,768.91
FAMILY PHYSICIANS Family Medicine
Chief Residents
2016 Summit:
Intensifying
Diabetes
Management
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE Advanced Non-Small 08/10/2016 $100,000.00
CANCER NETWORK, INC. Cell Lung Cancer
Patient
Management
Simulator
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF AACE 2016 Balance 08/11/2016 $233,374.80
CLINICAL of Evidence:
ENDOCRINOLOGISTS Considering the
Clinical Impact
of Newer
Antihyperglycemic
Agents for the
Treatment of Type
2 Diabetes
------------------------------------------------------------------------
HOUSTON METHODIST 4th Annual Houston 08/11/2016 $3,000.00
HOSPITAL Methodist Cancer
Symposium
------------------------------------------------------------------------
THE AMERICAN AASLD/EASL HBV 08/14/2016 $3,000.00
ASSOCIATION FOR THE Treatment
STUDY OF LIVER Endpoints
DISEASES Workshop
------------------------------------------------------------------------
ASTHMA AND ALLERGY Wheezin', Sneezin' 08/15/2016 $5,000.00
FOUNDATION OF AMERICA, and Itchin' in
ALASKA CHAPTER Alaska
------------------------------------------------------------------------
DANA-FARBER CANCER Dana-Farber Cancer 08/15/2016 $2,500.00
INSTITUTE INC. Institute's 12 th
Annual
Postdoctoral and
Graduate Student
Retreat
------------------------------------------------------------------------
GLOBAL VIRUS NETWORK 3rd Annual Short 08/16/2016 $5,000.00
INC. Course for
emerging leaders
in Medical
Virology of the
Global Virus
Network
------------------------------------------------------------------------
AMERICAN COLLEGE OF Eastern Pulmonary 08/21/2016 $8,000.00
ALLERGY, ASTHMA AND Conference 2016
IMMUNOLOGY
------------------------------------------------------------------------
CURATORS OF THE 2017 Midwest 08/25/2016 $35,260.00
UNIVERSITY OF MISSOURI Nephrology
Fellows Research
Day
------------------------------------------------------------------------
GORDON RESEARCH Mammalian DNA 08/25/2016 $2,000.00
CONFERENCES Repair Gordon
Research
Conference and
Seminar
------------------------------------------------------------------------
NATIONAL JEWISH HEALTH The 21st Annual 08/28/2016 $3,000.00
Regional Allied
Health
Conference:
Current
Perspectives in
Asthma, Allergy
and Pulmonary
Practice
------------------------------------------------------------------------
LUNGEVITY FOUNDATION LUNGevity 08/28/2016 $25,000.00
Foundation
Science and
Clinical Research
Roundtable, Part
II
------------------------------------------------------------------------
REGENTS OF THE 14th Annual 08/29/2016 $49,509.01
UNIVERSITY OF Nephrology Young
CALIFORNIA Investigator's
Forum
------------------------------------------------------------------------
UNIVERSITY OF MARYLAND 18th Annual 09/01/2016 $5,000.00
BALTIMORE FOUNDATION, International
INC. Meeting of the
Institute of
Human Virology
------------------------------------------------------------------------
INTERNATIONAL IASLC 17th Wolrd 09/04/2016 $82,500.00
ASSOCIATION FOR THE Conference on
STUDY OF LUNG CANCER Lung Cancer--
International
Mentorship Awards
------------------------------------------------------------------------
USF HEALTH PROFESSIONS Update in Allergy 09/07/2016 $3,000.00
CONFERENCING and Immunology
CORPORATION 2016 Symposium
and
Rhinolarngoscopy
Hands-On Workshop
------------------------------------------------------------------------
UNIVERSITY OF NEW Update and Review 09/07/2016 $2,500.00
MEXICO of Internal
Medicine
------------------------------------------------------------------------
PRESIDENT AND FELLOWS GI Motility and 09/08/2016 $1,500.00
OF HARVARD COLLEGE Functional GI
Disease: Evidence
vs. Consensus
------------------------------------------------------------------------
AMERICAN COLLEGE OF ACT's 37th Annual 09/08/2016 $5,000.00
TOXICOLOGY Meeting
------------------------------------------------------------------------
PERSONALIZED MEDICINE 12th Annual 09/11/2016 $5,000.00
COALITION Personalized
Medicine
Conference
------------------------------------------------------------------------
UNIVERSITY OF SOUTHERN 1st Annual 09/13/2016 $5,000.00
CALIFORNIA Southern
California Kidney
Symposium:
``Slowing the
Progression of
Kidney Disease:
From Bench to
Bedside''
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF Optimizing 09/21/2016 $35,000.00
MANAGED CARE Outcomes in
PHYSICIANS, INC. Advanced Non-
Small Cell Lung
Cancer (NSCLC):
Integrating Novel
Personalized
Therapy into the
Treatment
Paradigm
------------------------------------------------------------------------
ANNENBERG CENTER FOR 2016 JADPRO Live 09/22/2016 $100,000.00
HEALTH SCIENCES AT at APSHO
EISENHOWER
------------------------------------------------------------------------
PARTNERS HEALTHCARE Massachusetts 09/22/2016 $5,000.00
SYSTEM, INC. General Hospital
Multidisciplinary
Breast Rounds
2016-2017
------------------------------------------------------------------------
UNIVERSITY OF FLORIDA Vascular Biology 09/22/2016 $7,800.00
Working Group
Global Chapter
Meeting
------------------------------------------------------------------------
JOHNS HOPKINS Allergy Grand 09/25/2016 $2,846.55
UNIVERSITY Rounds
------------------------------------------------------------------------
AMERICAN ASSOCIATION AACR-AstraZeneca 09/25/2016 $126,500.00
FOR CANCER RESEARCH Fellowship in
Ovarian Cancer
Research
------------------------------------------------------------------------
PHARMACY QUALITY PQA Leadership 09/25/2016 $5,000.00
ALLIANCE (PQA, INC.) Summit 2016 The
I's Have It!
Insights into
Innovations,
Integration and
Implementation
Strategies for
Medication Use
Measurement
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE NCCN 2017 Congress 09/27/2016 $25,000.00
CANCER NETWORK INC. Series : Breast
Cancer with
Updates from the
2016 San Antonio
Breast Cancer
Symposium
------------------------------------------------------------------------
THE SCRIPPS RESEARCH 28th Annual 09/27/2016 $1,500.00
INSTITUTE Frontiers in
Chemistry
Symposium
------------------------------------------------------------------------
THE GOG FOUNDATION INC. 7th Semi Annual 09/28/2016 $20,000.00
Meeting of NRG
Oncology
(formerly; GOG,
NSABP, RTOG)
------------------------------------------------------------------------
INTERNATIONAL Global CME program 09/28/2016 $25,000.00
FEDERATION OF HEAD AND of IFHNOS
NECK ONCOLOGIC
SOCIETIES
------------------------------------------------------------------------
PARKER INSTITUTE FOR PICI Cancer 09/28/2016 $30,000.00
CANCER IMMUNOTHERAPY Immunotherapy
Workshops
------------------------------------------------------------------------
SOCIEDAD PUERTORRIQUE A Endocrinology Now 10/02/2016 $5,000.00
DE ENDOCRINOLOG A Y and Then SPEDs
DIABETOLOGIA 40th Anniversary
------------------------------------------------------------------------
UNIVERSITY OF TEXAS Cancer Genetics: 10/03/2016 $5,000.00
SOUTHWESTERN MEDICAL Finding Meaning
CENTER in Tumor and
Germline Genomes
------------------------------------------------------------------------
NATIONAL KIDNEY 12th Annual 10/03/2016 $50,000.00
FOUNDATION National Young
Investigator's
Forum
------------------------------------------------------------------------
THE UNIVERSITY OF TEXAS The Fourth 10/05/2016 $5,000.00
MD ANDERSON CANCER International
CENTER Conference on
Cancer and the
Heart
------------------------------------------------------------------------
AMERICAN ASSOCIATION AACR Translational 10/05/2016 $25,000.00
FOR CANCER RESEARCH Control of
Cancer: A New
Frontier in
Cancer Biology
and Therapy
------------------------------------------------------------------------
METABOLIC ENDOCRINE 14th Annual World 10/05/2016 $25,000.00
EDUCATION FOUNDATION Congress on
Insulin
Resistance
Diabetes and
Cardiovascular
Disease (WCIRDC)
------------------------------------------------------------------------
CEDARS-SINAI MEDICAL 5th Annual New 10/06/2016 $5,000.00
CENTER Therapeutics in
Oncology: The
Road to
Personalized
Medicine
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE Behind the 10/06/2016 $25,000.00
CANCER NETWORK INC. Guidelines:
Insights into the
Standard of Care
in Oncology 2017
------------------------------------------------------------------------
NATIONAL KIDNEY Chronic Kidney 10/06/2016 $139,980.00
FOUNDATION INC. Disease and
Cardiovascular
Disease: Best
Practices to
Improve Outcomes
------------------------------------------------------------------------
ECOG RESEARCH AND Fall 2016 ECOG- 10/09/2016 $5,000.00
EDUCATION FOUNDATION, ACRIN Group
INC. Meeting
------------------------------------------------------------------------
INTERNATIONAL IASLC 17th World 10/09/2016 $170,000.00
ASSOCIATION FOR THE Conference on
STUDY OF LUNG CANCER Lung Cancer
------------------------------------------------------------------------
CONQUER CANCER 2017 Conquer 10/10/2016 $40,000.00
FOUNDATION OF THE Cancer Foundation
AMERICAN SOCIETY OF of ASCO Merit
CLINICAL ONCOLOGY Awards
------------------------------------------------------------------------
PARTERS HEALTHCARE Massachusetts 10/10/2016 $5,000.00
SYSTEM, INC. General Hospital
Cancer Center
Grand Rounds
------------------------------------------------------------------------
UNIVERSIDAD CENTRAL DEL Redefining Cancer 10/11/2016 $5,000.00
CARIBE, INC. Treatment
Paradigms in Non-
Small Cell Lung
Cancer
------------------------------------------------------------------------
RUSH UNIVERSITY MEDICAL Expert Insights 10/18/2016 $5,000.00
CENTER and Key Nursing
Considerations:
Treating and
Caring for
Patients with
Lung Cancer
------------------------------------------------------------------------
GLOBAL EDUCATION GROUP GOLD COPD: 10/18/2016 $75,000.00
Continuum of Care
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE NCCN 22nd Annual 10/18/2016 $100,000.00
CANCER NETWORK Conference:
Improving the
Quality,
Effectiveness,
and Efficiency of
Cancer CareTM
------------------------------------------------------------------------
SOCIETY FOR 2016 Chabner 10/19/2016 $10,000.00
TRANSLATIONAL ONCOLOGY Colloquium:
Answering the Big
Questions in
Cancer Research
------------------------------------------------------------------------
HEMATOLOGY ONCOLOGY 2017 Hematology 10/26/2016 $27,500.00
PHARMACY ASSOCITATION Oncology Pharmacy
Association q
------------------------------------------------------------------------
INTERNATIONAL 10th Biennial 10/27/2016 $10,000.00
EOSINOPHIL SOCIETY, Symposium
INC.
------------------------------------------------------------------------
CONQUER CANCER 2017 ASCO-SITC 11/03/2016 $13,750.00
FOUNDATION OF THE Clinical Immuno-
AMERICAN SOCIETY OF Oncology
CLINICAL ONCOLOGY Symposium
Proceedings
------------------------------------------------------------------------
MEDSTAR GEORGETOWN LUNG CANCER 2016: 11/03/2016 $5,000.00
UNIVERSITY HOSPITAL Progress and
Future Directions
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF 18th Annual 11/03/2016 $15,000.00
CLINICAL Intensive Course
ENDOCRINOLOGISTS INC. on Diabetes,
Endocrinology,
and Metabolic
Diseases
------------------------------------------------------------------------
GORDON RESEARCH Mammalian DNA 11/03/2016 $3,000.00
CONFERENCES Repair Gordon
Research
Conference and
Seminar
------------------------------------------------------------------------
AMERICAN ASSOCIATION AACR-AstraZeneca 11/08/2016 $73,238.00
FOR CANCER RESEARCH Fellowships in
Lung Cancer
Research
------------------------------------------------------------------------
PENN STATE UNIVERSITY Cases from the 11/08/2016 $30,000.00
Community:
Investigator
Perspectives on
Emerging Research
and Patients with
Advanced Prostate
Cancer: A 2017 GU
Cancers Symposium
ISS
------------------------------------------------------------------------
KEYSTONE SYMPOSIA ON Genomic 11/08/2016 $5,000.00
MOLECULAR AND CELLULAR Instability and
BIOLOGY DNA Repair
------------------------------------------------------------------------
RENAL PHYISICIANS RPA 2017 Annual 11/10/2016 $25,000.00
ASSOCIATION Meeting
------------------------------------------------------------------------
AMERICAN ASSOCIATION AACR-AstraZeneca 11/13/2016 $253,000.00
FOR CANCER RESEARCH Fellowships in
Immuno-oncology
Research
------------------------------------------------------------------------
WINGATE UNIVERSITY AmCare Pharmacy 11/21/2016 $500.00
SCHOOL OF PHARMACY Forum of North
Carolina
------------------------------------------------------------------------
SOCIETY FOR NEURO- 21st Annual 11/28/2016 $26,000.00
ONCOLOGY Meeting of the
Society for Neuro-
Oncology
------------------------------------------------------------------------
LYMPHOMA RESEARCH Lymphoma Research 12/01/2016 $105,000.00
FOUNDATION Foundation
Postdoctoral
Fellowship Grant
Program
------------------------------------------------------------------------
UNIVERSITY OF NEBRASKA PARP Inhibition in 12/01/2016 $45,000.00
MEDICAL CENTER Ovarian Cancer:
Integrating Basic
Science, Clinical
Data, and the
Patient Voice to
Enhance Care
------------------------------------------------------------------------
KEYSTONE SYMPOSIA 2017 Keystone 12/01/2016 $25,000.00
Symposia
Directors' Fund
------------------------------------------------------------------------
BOSTON UNIVERSITY Are You Asking the 12/04/2016 $149,275.00
SCHOOL OF MEDICINE-- Question?
OFFICE OF CME Strategies for
Engaging the
Patient in the
Diagnosis and
Management of
Opioid-Induced
Constipation
------------------------------------------------------------------------
GLOBAL EDUCATION GROUP Comprehensive Pain 12/04/2016 $324,107.00
Management in
Palliative Care:
Relieving the
Burden of Opioid-
Induced
Constipation
------------------------------------------------------------------------
CONQUER CANCER 2017 Conquer 12/04/2016 $500,000.00
FOUNDATION OF THE Cancer Foundation
AMERICAN SOCIETY OF of the American
CLINICAL ONCOLOGY Society of
Clinical Oncology
Mission Endowment
------------------------------------------------------------------------
AMERICAN ASSOCIATION AACR Annual 12/04/2016 $150,000.00
FOR CANCER RESEARCH Meeting- 2017
------------------------------------------------------------------------
SOCIETY OF GYNECOLOGIC Clinical 12/04/2016 $50,000.00
ONCOLOGY Management of New
Biologics and
Immunotherapies
in Gynecologic
Oncology
------------------------------------------------------------------------
SOCIETY OF GYNECOLOGIC Genetic Counseling 12/04/2016 $210,575.00
ONCOLOGY in Gynecologic
Oncology: What
Advanced
Practitioners
Need to Know
------------------------------------------------------------------------
JOHNS HOPKINS DIVISION Mid-Atlantic 12/04/2016 $50,000.00
OF NEPHORLOGY Nephrology Young
Investigators
Forum
------------------------------------------------------------------------
INTERNATIONAL EGFR Atlas 12/04/2016 $380,000.00
ASSOCIATION FOR THE
STUDY OF LUNG CANCER
------------------------------------------------------------------------
INTERNATIONAL 2017 IASLC WCLC 12/04/2016 $150,000.00
ASSOCIATION FOR THE Association-
STUDY OF LUNG CANCER Satellite Fee
------------------------------------------------------------------------
FRIENDS OF CANCER 2017 Friends of 12/04/2016 $100,000.00
RESERACH Cancer Research
Programs
------------------------------------------------------------------------
THE UNIVERSITY OF TEXAS 2017 Oncologic 12/06/2016 $5,000.00
MD ANDERSON CANCER Emergency
CENTER Medicine
Conference
------------------------------------------------------------------------
CONQUER CANCER 2017 Genitourinary 12/08/2016 $50,000.00
FOUNDATION OF THE (GU) Cancers
AMERICAN SOCIETY OF Symposium:
CLINICAL ONCOLOGY Translating
Research to Value-
Based and Patient-
Centric Care
------------------------------------------------------------------------
ALZHEIMER'S ASSOCIATION 2017 Alzheimer's 12/08/2016 $50,000.00
Association
Research
Roundtable
------------------------------------------------------------------------
ALZHEIMER'S ASSOCIATION 2017 Alzheimer's 12/08/2016 $45,000.00
Association
International
Conference
------------------------------------------------------------------------
CANCER RESEARCH Cancer Research 12/11/2016 $50,000.00
INSTITUTE Institute's
Irvington
Postdoctoral
Fellowship
Program
------------------------------------------------------------------------
CONQUER CANCER 2017 ASCO-SITC 12/11/2016 $60,000.00
FOUNDATION OF THE Clinical Immuno-
AMERICAN SOCIETY OF Oncology
CLINICAL ONCOLOGY Symposium
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE NCCN 11th Annual 12/12/2016 $15,000.00
CANCER NETWORK, INC. Congress:
Hematologic
MalignanciesTM
------------------------------------------------------------------------
INTERNATIONAL SOCIETY ISN World Congress 12/12/2016 $130,000.00
OF NEPHROLOGY of Nephrology
2017--WCN 2017
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF AACE 26th Annual 12/12/2016 $50,000.00
CLINICAL Scientific &
ENDOCRINOLOGISTS Clinical
Congress--Diabete
s Session
------------------------------------------------------------------------
NATIONAL KIDNEY National Kidney 12/12/2016 $5,000.00
FOUNDATION INC. Foundation s
Tenth Annual Mid-
Atlantic First
Year Renal
Fellows Symposium
------------------------------------------------------------------------
THE ENDOCRINE SOCIETY Diabetes Masters 12/13/2016 $50,000.00
Series 2017:
Negotiating the
Therapeutic
Terrain: Steps to
Identifying
Individualized
Treatment
Approaches for
Patients With
T2DM
------------------------------------------------------------------------
REGENTS OF THE Making the 12/14/2016 $50,000.00
UNIVERSITY OF Connection
CALIFORNIA between Patients
and Providers: A
Modern Approach
to the Treatment
of Type 1 and
Type 2 Diabetes
------------------------------------------------------------------------
THE NEW YORK ACADEMY OF Cancer 12/14/2016 $20,000.00
SCIENCES Immunotherapy:
Frontiers in
Cancer
Immunotherapy and
Quantitative
Approaches in
Immuno-Oncology
------------------------------------------------------------------------
REGENTS OF THE 44th Annual Family 12/19/2016 $2,792.00
UNIVERSITY OF Medicine
CALIFORNIA LOS ANGELES Reffresher
Course"
------------------------------------------------------------------------
RUTGERS, THE STATE Rutgers 12/19/2016 $61,728.00
UNIVERSITY OF NEW Pharmaceutical
JERSEY Industry
Fellowship
Program
------------------------------------------------------------------------
CONQUER CANCER 2017 Conquer 12/21/2016 $192,000.00
FOUNDATION OF THE Cancer Foundation
AMERICAN SOCIETY OF of ASCO Young
CLINICAL ONCOLOGY Investigator
Award (YIA)
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE NCCN 2017 Oncology 12/21/2016 $35,000.00
CANCER NETWORK, INC. Fellows Program:
New Horizons in
Quality Cancer
Care at the NCCN
22nd Annual
Conference
------------------------------------------------------------------------
METABOLIC ENDOCRINE 1st Annual Heart 12/21/2016 $100,000.00
EDUCATION FOUNDATION in Diabetes
------------------------------------------------------------------------
INTERNATIONAL IASLC 17th World 12/21/2016 $92,500.00
ASSOCIATION FOR THE Conference on
STUDY OF LUNG CANCER Lung Cancer
------------------------------------------------------------------------
PRIMARY CARE EDUCATION 11th Annual Chief 12/21/2016 $50,000.00
CONSORTIUM Residents Summit
on Intensifying
Diabetes
Management
------------------------------------------------------------------------
AMERICAN NEPHROLOGY ANNA 2017 National 12/21/2016 $20,000.00
NURSES ASSOCIATION Symposium
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF 2017 Charitable 12/21/2016 $30,000.00
FREE AND CHARITABLE Health Care
CLINICS Symposium
------------------------------------------------------------------------
AMERICAN SOCIETY OF ASN Kidney Week 12/21/2016 $37,500.00
NEPHROLOGY Educational
Session Support
------------------------------------------------------------------------
AMERICAN SOCIETY OF ASN Kidney Week 12/21/2016 $15,000.00
NEPHROLOGY Early Program
Support
------------------------------------------------------------------------
AMERICAN SOCIETY OF ASN Select 12/21/2016 $20,000.00
NEPHROLOGY Streamed Session
Support
------------------------------------------------------------------------
AMERICAN UROLOGICAL Emerging 12/27/2016 $100,000.00
ASSOCIATION EDUCATION Immunotherapeutic
AND RESEARCH INC. Agents for the
Treatment of
Bladder Cancer
------------------------------------------------------------------------
AMERICAN SOCIETY OF 2016 American 01/04/2017 $150,000.00
HEMATOLOGY Society of
Hematology Annual
Meeting
------------------------------------------------------------------------
RUTGERS, THE STATE Severe Asthma: 01/04/2017 $225,000.00
UNIVERSITY OF NEW Clinical
JERSEY Phenotypes and
the Emerging Age
of Personalized
Therapy
------------------------------------------------------------------------
TRUSTEES OF BOSTON A Better Life for 01/05/2017 $100,000.00
UNIVERSITY Your Severe
Asthma Patients:
Targeted
Therapies for
Fewer
Exacerbations
------------------------------------------------------------------------
NATIONAL JEWISH HEALTH Personalized 01/06/2017 $345,500.00
Medicine in
Severe Asthma:
Applying Emerging
Data and
Treatments to
Everyday Clinical
Practice
------------------------------------------------------------------------
PARKER INSTITUTE FOR Streamlining 01/18/2017 $60,000.00
CANCER IMMUNOTHERAPY Toxicity
Management
Guidelines
------------------------------------------------------------------------
FLORIDA ALLERGY, ASTHMA FAAIS 2017 Annual 01/25/2017 $20,000.00
AND IMMUNOLOGY SOCIETY CME Conference
------------------------------------------------------------------------
NYU POST-GRADUATE Asthma, Airways 01/26/2017 $20,000.00
MEDICAL SCHOOL and Environment
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF Preventing Acute 01/29/2017 $15,000.00
MANAGED CARE Exacerbations
PHYSICIANS, INC. though Novel
Insights in
Treatment
Strategies for
COPD
------------------------------------------------------------------------
NATIONAL JEWISH HEALTH 39th Annual 01/29/2017 $20,000.00
National Jewish
Health Pulmonary
and Allergy
Update
------------------------------------------------------------------------
INTERNATIONAL Best of World 01/29/2017 $20,000.00
ASSOCIATION FOR THE Conference on
STUDY OF LUNG CANCER Lung Cancer
------------------------------------------------------------------------
YALE UNIVERSITY Severe Asthma 02/01/2017 $16,300.00
2016: A
Personalized
Approach To
Treatment
------------------------------------------------------------------------
AMERICAN SOCIETY FOR 2017 02/01/2017 $50,000.00
RADIATION ONCOLOGY Multidisciplinary
Thoracic Cancers
Symposium
------------------------------------------------------------------------
NATIONAL MEDICAL Implementing the 02/01/2017 $75,000.00
ASSOCCIATION New GOLD
Guidelines:
Interdisciplinary
Management of
Chronic
Obstructive
Pulmonary Disease
as a Chronic
Disease
------------------------------------------------------------------------
CARDIOVASCULAR Cardiovascular 02/01/2017 $25,000.00
INNOVATIONS FOUNDATION Innovations 2017
------------------------------------------------------------------------
AMERICAN THORACIC ATS 2017 02/01/2017 $70,000.00
SOCIETY INC. International
Conference--Selec
ted Topics in
COPD
------------------------------------------------------------------------
CARDIOVASCULAR RESEARCH 23rd Annual 02/01/2017 $10,000.00
FOUNDATION Interventional
Cardiology
Fellows Course
------------------------------------------------------------------------
NATIONAL JEWISH HEALTH 13th Annual 02/01/2017 $283,830.79
Respiratory
Disease Young
Investigators
Forum
------------------------------------------------------------------------
WASHINGTON HOSPITAL Cardiovascular 02/02/2017 $30,000.00
CENTER CORPORATION Research
Technologies
------------------------------------------------------------------------
CONNECTICUT PHARMACISTS Breathe Easy: An 02/02/2017 $2,000.00
ASSOCIATION Overview of
Inhalers for the
Management of
Asthma and COPD
------------------------------------------------------------------------
AMERICAN ACADEMY OF AAPA 2017--Allergy/ 02/06/2017 $7,500.00
PHYSICIAN ASSISTANTS, Immunology and
INC. Pulmonology
Tracks
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE Immuno-Oncology 02/07/2017 $75,000.00
CANCER NETWORK Therapeutics for
Renal Cell
Carcinoma and
Bladder Cancer:
Integrating the
Latest
Developments Into
Clinical Practice
------------------------------------------------------------------------
AMERICAN ASSOCIATION AACR Annual 02/09/2017 $100,000.00
FOR CANCER RESEARCH Meeting--2017
------------------------------------------------------------------------
CONQUER CANCER 2017 Conquer 02/12/2017 $253,000.00
FOUNDATION OF THE Cancer Foundation
AMERICAN SOCIETY OF of ASCO Career
CLINICAL ONCOLOGY Development Award
------------------------------------------------------------------------
NYU POST-GRADUATE NYU Seminar in 02/13/2017 $10,000.00
MEDICAL SCHOOL Advanced
Rheumatology
------------------------------------------------------------------------
THE UNIVERSITY OF TEXAS Cardio Renal 02/14/2017 $2,500.00
HEALTH SCIENCE CENTER Connections--2nd
AT SAN ANTONIO Annual Cardio-
Renal Conference
2017
------------------------------------------------------------------------
TRUSTEES OF THE Translational 02/14/2017 $2,500.00
UNIVERSITY OF Research Cancer
PENNSYLVANIA Centers
Consortium
------------------------------------------------------------------------
AMERICAN HEAD AND NECK AHNS 2017 Annual 02/14/2017 $25,000.00
SOCIETY Meeting
------------------------------------------------------------------------
GORDON RESEARCH Gordon Research 02/15/2017 $2,500.00
CONFERENCES Conference on
Drug Metabolism
------------------------------------------------------------------------
NATIONAL JEWISH HEALTH COPD Now: Applying 02/15/2017 $199,618.33
New Guidelines
and Effective
Strategies in
Diagnosis,
Treatment and
Management to
Everyday Practice
------------------------------------------------------------------------
HUMBOLDT-DEL NORTE COPD 02/15/2017 $2,100.00
CONSORTIUM FOR CME
------------------------------------------------------------------------
CONQUER CANCER 2017 ASCO Annual 02/15/2017 $84,000.00
FOUNDATION OF THE Meeting Lung
AMERICAN SOCIETY OF Cancer Track
CLINICAL ONCOLOGY
------------------------------------------------------------------------
GORDON RESEARCH Model Systems, 02/15/2017 $5,000.00
CONFERENCES Emerging
Technologies and
Precision
Medicine in
Arrhythmia
Research and
Therapeutic
Development
------------------------------------------------------------------------
ST. JOSEPH'S REGIONAL Acute Coronary 02/15/2017 $4,200.00
MEDICAL CENTER Syndrome
------------------------------------------------------------------------
AMERICAN CHEMICAL Division of 02/16/2017 $3,000.00
SOCIETY DIVISION OF Medicinal
MEDICINAL CHEMISTRY Chemistry Program
253rd ACS
National Meeting
------------------------------------------------------------------------
SOCIETY FOR 2017 Advances in 02/16/2017 $500,000.00
IMMUNOTHERAPY OF Cancer
CANCER Immunotherapy
Series
------------------------------------------------------------------------
UNIVERSITY OF FLORIDA Vascular Biology 02/16/2017 $5,000.00
Working Group US
Chapter Meeting
------------------------------------------------------------------------
CALIFORNIA ACADEMY OF Addressing the 02/16/2017 $3,000.00
PHYSICIAN ASSISTANTS Needs of the ACS
Patient
------------------------------------------------------------------------
CARDIOVASCULAR RESEARCH DAPT Dilemmas: A 02/19/2017 $10,000.00
FOUNDATION Case-based
Roundtable
Tutorial
------------------------------------------------------------------------
INDIANA ACADEMY OF Managing Severe 02/19/2017 $3,921.00
FAMILY PHYSICIANS Asthma in the
Family
Physician's
Office
------------------------------------------------------------------------
ANNENBERG CENTER FOR The Emerging Role 02/19/2017 $188,600.00
HEALTH SCIENCES AT of Molecular
EISENHOWER Testing in an Era
of Precision
Medicine--NSCLC
------------------------------------------------------------------------
ANNENBERG CENTER FOR The Emerging Role 02/19/2017 $188,600.00
HEALTH SCIENCES AT of Molecular
EISENHOWER Testing in an Era
of Precision
Medicine--Ovarian
Cancer
------------------------------------------------------------------------
SCRIPPS HEALTH Scripps 37th 02/20/2017 $5,000.00
Annual
Conference:
Clinical
Hematology and
Oncology 2017
------------------------------------------------------------------------
AMERICAN COLLEGE OF The Great K Debate 02/21/2017 $100,000.00
CARDIOLOGY FOUNDATION Continues:
Updates and
Controversies in
Heart Failure
Management
------------------------------------------------------------------------
GORDON RESEARCH 2017 Gordon 02/22/2017 $2,500.00
CONFERENCES Conference on
Medicinal
Chemistry
------------------------------------------------------------------------
INTERNATIONAL 17th Annual 02/22/2017 $33,000.00
ASSOCIATION FOR THE Targeted
STUDY OF LUNG CANCER Therapies of lung
Cancer Meeting
------------------------------------------------------------------------
AMERICAN ASSOCIATION AACR-AHNS Head and 02/22/2017 $25,000.00
FOR CANCER RESEARCH Neck Cancer
Conference:
------------------------------------------------------------------------
ASTHMA AND ALLERGY Wheezin', Sneezin' 02/22/2017 $5,000.00
FOUNDATION OF AMERICA, and Itchin' in
ALASKA CHAPTER Alaska
------------------------------------------------------------------------
FASEB SCIENCE RESEARCH FASEB Autoimmunity 02/22/2017 $5,000.00
CONFERENCES
------------------------------------------------------------------------
FEDERATION OF CLINICAL Federation of 02/23/2017 $15,000.00
IMMUNOLOGY SOCIETIES Clinical
INC. Immunology
Societies Annual
Meeting
------------------------------------------------------------------------
THE BOARD OF REGENTS OF Biennial 03/02/2017 $50,000.00
THE UNIVERSITY OF International
NEBRASKA Workshop on
Chronic
Lymphocytic
Leukemia (XVII
iwCLL 2017)
------------------------------------------------------------------------
NATIONAL KIDNEY Change in 03/02/2017 $50,000.00
FOUNDATION, INC. Albuminuria and
GFR as End Points
for Clinical
Trials in Early
Stages of Chronic
Kidney Disease: A
Scientific
Workshop
Sponsored by the
National Kidney
Foundation,
European
Medicines Agency
and the US Food
and Drug
Administration
------------------------------------------------------------------------
AMERICAN RESPIRATORY 56th RESPIRATORY 03/05/2017 $18,000.00
CARE FOUNDATION CARE Journal
Conference
Respiratory
Medications for
COPD and Adult
Asthma:
Pharmacologic
Actions to
Clinical
Applications
------------------------------------------------------------------------
AMERICAN COLLEGE OF ACAAI member 03/05/2017 $40,000.00
ALLERGY, ASTHMA AND publication--Alle
IMMUNOLOGY rgyWatch
------------------------------------------------------------------------
GORDON RESEARCH The Enduring 03/05/2017 $2,500.00
CONFERENCE Potential of
Heterocycles as
Synthetic
Targets, Cellular
Probes, and Drug
Candidates
------------------------------------------------------------------------
THE REGENTS OF THE 35th Carl M. 03/06/2017 $10,000.00
UNIVERSITY OF Pearson Memorial
CALIFORNIA Symposium
Frontiers of
Rheumatology
------------------------------------------------------------------------
GORDON RESEARCH Staphylococcal 03/06/2017 $5,000.00
CONFERENCES--STAPHYLOC Gordon Research
OCCAL DISEASES Conference
------------------------------------------------------------------------
COLD SPRING HARBOR Cell Death 03/07/2017 $2,500.00
LABORATORY
------------------------------------------------------------------------
CEDARS-SINAI MEDICAL Lupus: What's 03/08/2017 $334,625.00
CENTER Next? Examining
Mechanisms,
Monitoring, and
Medication
Updates
------------------------------------------------------------------------
AMERICAN THORACIC ATS 2017 Fellows 03/09/2017 $20,000.00
SOCIETY Track Symposium
------------------------------------------------------------------------
BOSTON UNIVERSITY EFFECTIVE ASTHMA 03/11/2017 $100,000.00
SCHOOL OF MEDICINE, MANAGEMENT IN
CME PRIMARY CARE:
Severity
Assessment,
Guidelines, and
New Therapy
Options
------------------------------------------------------------------------
PENNSYLVANIA STATE Innovations in 03/12/2017 $2,500.00
UNIVERSITY Allergy, Asthma
and Immunology
Management
------------------------------------------------------------------------
INTERNATIONAL IASLC SCLC 03/14/2017 $25,000.00
ASSOCIATION FOR THE workshop
STUDY OF LUNG CANCER
(IASLC)
------------------------------------------------------------------------
TRUSTEES OF BOSTON A Better Life for 03/14/2017 $321,485.44
UNIVERSITY Your Severe
Asthma Patients:
Targeted
Therapies for
Fewer
Exacerbations
------------------------------------------------------------------------
REGENTS OF THE Clostpath 10 03/16/2017 $5,000.00
UNIVERSITY OF MICHIGAN Support
------------------------------------------------------------------------
AMERICAN COLLEGE OF Asthma Fellows 03/20/2017 $5,000.00
CHEST PHYSICIANS Conference
------------------------------------------------------------------------
AMERICAN COLLEGE OF Multidisciplinary 03/20/2017 $24,354.00
CHEST PHYSICIANS Management Of
Severe Asthma: It
Takes A Village
------------------------------------------------------------------------
AMERICAN COLLEGE OF Asthma Learning 03/21/2017 $79,573.00
CHEST PHYSICIANS Track--CHEST 2017
------------------------------------------------------------------------
AMERICAN COLLEGE OF COPD Learning 03/22/2017 $73,765.00
CHEST PHYSICIANS Track
------------------------------------------------------------------------
THOMAS JEFFERSON 10th Annual Young 03/26/2017 $11,000.00
UNIVERSITY Investigators
Forum
------------------------------------------------------------------------
FLORIDA ACADEMY OF Diagnoses and 03/27/2017 $8,000.00
PHYSICIAN ASSISTANTS treatment for
INC. Acute coronary
syndrome
------------------------------------------------------------------------
SOCIETY FOR SITC's Toxicity 03/27/2017 $50,000.00
IMMUNOTHERAPY OF Managment
CANCER Workshop
------------------------------------------------------------------------
HOUSTON METHODIST Cardiology for the 03/27/2017 $8,000.00
HOSPITAL Non-Cardiologist
------------------------------------------------------------------------
WEST PENN ALLEGHENY Cardiovascular 03/28/2017 $3,000.00
HEALTH SYSTEM INC. Medicine Update
------------------------------------------------------------------------
AMERICAN COLLEGE OF 28th Annual 03/29/2017 $5,000.00
CARDIOLOGY PUERTO RICO Meeting of the
CHAPTER ACC Puerto Rico
Chapter
------------------------------------------------------------------------
HOWARD UNIVERSITY The Kenneth Austin 03/30/2017 $2,500.00
12th Annual
Rheumatology
Symposium at
Howard University
Hospital
------------------------------------------------------------------------
AMERICAN RADIUM SOCIETY 99th Annual 04/02/2017 $10,000.00
Meeting of the
American Radium
Society
------------------------------------------------------------------------
TENNESSEE ACADEMY OF Spring Fling 2017: 04/03/2017 $2,000.00
PHYSICIAN ASSISTANTS Optimizing
Outcomes in
Patients with
Opioid Induced
Constipation
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF Navigating a 04/04/2017 $35,000.00
MANAGED CARE Complex Treatment
PHYSICIANS, INC. Landscape in
Advanced Non-
Small Cell Lung
Cancer (NSCLC):
Individualizing
Therapy for
Improved Patient
Outcomes
------------------------------------------------------------------------
MEDICAL LEARNING Improving the 04/06/2017 $149,000.00
INSTITUTE INC. Physical and
Mental Well-Being
of Patients With
COPD: Integrating
Pharmacotherapy
With Pulmonary
Rehabilitation
and Self-
Management
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF UPDATES ABOUND! 04/06/2017 $374,606.00
CLINICAL Latest and
ENDOCRINOLOGISTS INC. Greatest in
Practical
Application of
Cardiovascular
Outcomes for
Diabetes Drugs
------------------------------------------------------------------------
GLOBAL EDUCATION GROUP Overcoming 04/06/2017 $289,267.50
Challenges in
Cancer Pain
Management:
Engaging With
Patients About
Opioid-Induced
Constipation
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF AAPS Sustaining 04/09/2017 $50,000.00
PHARMACEUTICAL Sponsorship
SCIENTISTS
------------------------------------------------------------------------
THE UNIVERSITY OF 14th International 04/10/2017 $10,000.00
CHICAGO CENTER FOR Ultmann Chicago
CONTINUING MEDICAL Lymphoma
EDUCATION Symposium
------------------------------------------------------------------------
AMERICAN ASSOCIATION AACR Hematologic 04/10/2017 $25,000.00
FOR CANCER RESEARCH Malignancies:
------------------------------------------------------------------------
THE HOPE FOUNDATION 2017 SWOG Group 04/11/2017 $10,000.00
Meetings
------------------------------------------------------------------------
PREVENTIVE 2017 PCNA FAll 04/11/2017 $25,000.00
CARDIOVASCULAR NURSES Regional
ASSOCIATION Education
Programs:
Cardiometabolics:
Focus on New
Medications and
Risk Reduction
Benefits and
Protection
------------------------------------------------------------------------
EMORY UNIVERSITY SCHOOL Updates in the 04/12/2017 $5,000.00
OF MEDICINE Management of
Head and Neck
Cancer
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE NCCN 2017 Congress 04/16/2017 $50,000.00
CANCER NETWORK INC. Series : Lung
Cancer
------------------------------------------------------------------------
ONCOLOGY NURSING 42nd Annual ONS 04/16/2017 $50,000.00
SOCIETY Congress and
Oncology Updates
Regional Meetings
------------------------------------------------------------------------
SWEDISH MEDICAL CENTER Annual Oncology 04/16/2017 $5,000.00
FOUNDATION Symposium:
Innovations in
Gynecologic
Cancer Care--
Prevention to
Survivorship
------------------------------------------------------------------------
ANNENBERG CENTER FOR Master Class for 04/18/2017 $10,000.00
HEALTH SCIENCES AT Oncologists--Brea
EISENHOWER st Cancer Track
------------------------------------------------------------------------
ANNENBERG CENTER FOR Master Class for 04/18/2017 $10,000.00
HEALTH SCIENCES AT Oncologist--Genit
EISENHOWER ourinary Cancers
Track
------------------------------------------------------------------------
ANNENBERG CENTER FOR Oral Oncolytics 04/18/2017 $50,000.00
HEALTH SCIENCES AT Adherence
EISENHOWER Resource Center:
An Educational
Platform for
Advanced
Practitioners in
Oncology
------------------------------------------------------------------------
BLADDER CANCER ADVOCACY 2017 Bladder 04/18/2017 $35,000.00
NETWORK Cancer Think Tank
------------------------------------------------------------------------
SOCIETY FOR SCAI 2017 04/23/2017 $50,000.00
CARDIOVASCULAR Scientific
ANGIOGRAPHY AND Sessions
INTERVENTIONS
------------------------------------------------------------------------
TRUSTEES OF THE BRCA1, BRCA2 and 04/23/2017 $20,000.00
UNIVERSITY OF Beyond: An Update
PENNSYLVANIA on Hereditary
Cancer
------------------------------------------------------------------------
CANCER MOLECULAR Molecular 04/24/2017 $2,000.00
THERAPEUTICS RESEARCH Therapeutics of
ASSOCIATION Cancer Research
Conference 2017
------------------------------------------------------------------------
YALE UNIVERSITY 2017 Lung SPORE 04/24/2017 $30,000.00
Workshop
------------------------------------------------------------------------
ECOG RESEARCH AND ECOG-ACRIN Spring 04/24/2017 $5,000.00
EDUCATION FOUNDATION, 2017 Group
INC. Meeting
------------------------------------------------------------------------
CLEVELAND CLINIC Hormone Receptor- 04/25/2017 $20,111.61
EDUCATIONAL FOUNDATION Positive Advanced
Breast Cancer:
Challenges and
New Treatment
Options
------------------------------------------------------------------------
INTERNATIONAL THYROID 2017 ITOG Annual 04/25/2017 $5,000.00
ONCOLOGY GROUP Meeting
------------------------------------------------------------------------
COLUMBIA UNIVERSITY Breast Cancer 04/25/2017 $3,000.00
DEPARTMENT OF SURGERY Management 2017
------------------------------------------------------------------------
CLEVELAND CLINIC 2017 Cleveland 04/26/2017 $5,000.00
EDUCATIONAL FOUNDATION Breast Cancer
Summit:
Collaborating For
A Cure
------------------------------------------------------------------------
DUKE UNIVERSITY 16th Annual 04/27/2017 $10,000.00
Southeastern
Fellows Research
Skills and
Training Workshop
------------------------------------------------------------------------
YALE UNIVERSITY Yale ASCO Review 05/01/2017 $5,000.00
2017
------------------------------------------------------------------------
MEDICAL LEARNING Acute Management 05/02/2017 $573,560.00
INSTITUTE INC. of Immune-Related
Adverse Events in
Cancer Patients
Receiving
Immunotherapies:
Essential
Guidance for
Emergency
Medicine
Specialists
------------------------------------------------------------------------
AMERICAN COLLEGE OF EAC 2017 Update in 05/04/2017 $10,000.00
ALLERGY, ASTHMA AND Allergy, Asthma
IMMUNOLOGY and Immunology
------------------------------------------------------------------------
METABOLIC ENDOCRINE The Real Deal: 05/07/2017 $162,855.00
EDUCATION FOUNDATION Translating
Cardiovascular
Outcomes Data
into Best
Practices in Type
2 Diabetes
Management
------------------------------------------------------------------------
AMERICAN ASSOCIATION EACR-AACR-SIC 05/08/2017 $50,000.00
FOR CANCER RESEARCH Special
Conference 2017:
The Challenges of
Optimizing Immuno-
and Targeted
Therapies
------------------------------------------------------------------------
CONQUER CANCER 2017 Best of ASCO 05/09/2017 $120,000.00
FOUNDATION OF THE Meetings
AMERICAN SOCIETY OF
CLINICAL ONCOLOGY
------------------------------------------------------------------------
REGENTS OF THE Making the 05/10/2017 $200,000.00
UNIVERSITY OF Connection
CALIFORNIA Between Patients
and Providers--A
Modern Approach
to the Treatment
of Type 1 and
Type 2 Diabetes
------------------------------------------------------------------------
GORDON RESEARCH Gordon Research 05/11/2017 $1,500.00
CONFERENCE Conference:
Hormone-Dependent
Cancer:
Functional
Insight and
Clinical
Application
------------------------------------------------------------------------
CARDIOVASCULAR RESEARCH 29th Annual 05/14/2017 $25,000.00
FOUNDATION Transcatheter
Cardiovascular
Therapeutics
------------------------------------------------------------------------
CARDIOVASCULAR RESEARCH DAPT and Triple 05/14/2017 $10,000.00
FOUNDATION Therapy: A Case-
based Guide to
Optimal
Antiplatelet
Therapies
------------------------------------------------------------------------
MINNESOTA PHARMACISTS Treating Acute 05/15/2017 $3,500.00
ASSOCIATION Coronary Syndrome
(ACS)
------------------------------------------------------------------------
ICAHN SCHOOL OF Live Symposium of 05/15/2017 $5,000.00
MEDICINE AT MOUNT Complex Coronary,
SINAI Valvular and
Vascular Cases
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF Acute Coronary 05/17/2017 $5,000.00
CRITICAL CARE NURSES Syndrome New
SEPA CHAPTER Guidelines and
Therapeutic
Options
------------------------------------------------------------------------
ANNENBERG CENTER FOR Integration of 05/18/2017 $50,000.00
HEALTH SCIENCES AT Immunotherapy
EISENHOWER into the
Treatment of
Solid Tumors and
Hematologic
Malignancies:
Considerations
for Advanced
Practitioners in
Oncology
------------------------------------------------------------------------
ST. FRANCIS HOSPITAL Contemporary 05/18/2017 $3,300.00
Dilemmas in Anti
Platelet Therapy
------------------------------------------------------------------------
MEMORIAL SLOAN 2017 MSK Cardio- 05/18/2017 $5,000.00
KETTERING CANCER Oncology
CENTER Symposium:
Cardiovascular
Health and
Disease During
and After Cancer
Therapy--A Case
Based Curriculum
------------------------------------------------------------------------
GORDON RESEARCH Gordon Research 05/18/2017 $8,000.00
CONFERENCE Seminar and
Conference on
Lung Development,
Injury and Repair
------------------------------------------------------------------------
GORDON RESEARCH Next Generation 05/18/2017 $2,000.00
CONFERENCES Computer-Aided
Medicine Design:
Going Beyond
Traditional
Targets,
Pathways,
Modalities,
Agents and
Techniques
------------------------------------------------------------------------
REGENTS OF THE 13th Annual 05/19/2017 $5,000.00
UNIVERSITY OF Biomarkers in
CALIFORNIA Heart Failure and
Acute Coronary
Syndromes:
Diagnosis,
Treatment and
Devices Symposium
------------------------------------------------------------------------
LUNGEVITY FOUNDATION LUNGevity 05/22/2017 $40,000.00
Foundation
Science and
Clinical Research
Roundtable
------------------------------------------------------------------------
PRESIDENT AND FELLOWS Breast Cancer: New 05/22/2017 $20,000.00
OF HARVARD COLLEGE Horizons, Current
Controversies
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE 2017-2018 Monthly 05/25/2017 $50,000.00
CANCER NETWORK Oncology Tumor
Boards: A
Multidisciplinary
Approach to
Individualized
Patient Care
------------------------------------------------------------------------
AMERICAN LUNG LungForce Expo 05/28/2017 $1,000.00
ASSOCIATION IN
MISSOURI
------------------------------------------------------------------------
AMERICAN COLLEGE OF Cardiovascular 06/03/2017 $150,000.00
CARDIOLOGY FOUNDATION Risk in Diabetes
------------------------------------------------------------------------
AMERICAN SOCIETY FOR ASTRO 2017 59th 06/04/2017 $25,000.00
RADIATION ONCOLOGY Annual Meeting
------------------------------------------------------------------------
THE GOG FOUNDATION, 8th Semi Annual 06/04/2017 $20,000.00
INC. Meeting of NRG
Oncology
------------------------------------------------------------------------
AMERICAN ACADEMY OF AAFP FMX 60-minute 06/04/2017 $33,000.00
FAMILY PHYSICIANS Interactive
Lecture and 60-
Minute Problem-
Based Learning
Workshop titled
Acute Coronary
Syndromes
------------------------------------------------------------------------
NORTHWESTERN UNIVERSITY 6th Annual Chicago 06/04/2017 $10,000.00
Cardiovascular
Symposium
------------------------------------------------------------------------
MERCY HOSPITAL Catholic Health 06/04/2017 $5,000.00
FOUNDATION 8th Annual
Cardiovascular
Symposium
------------------------------------------------------------------------
AMERICAN COLLEGE OF Lung Cancer 06/06/2017 $50,000.00
CHEST PHYSICIANS Learning Track
------------------------------------------------------------------------
SOCIETY FOR 2017 Primer on 06/06/2017 $50,000.00
IMMUNOTHERAPY OF Tumor Immunology
CANCER and Cancer
Immunotherapy
------------------------------------------------------------------------
SOCIETY FOR 2017 Workshop on 06/07/2017 $150,000.00
IMMUNOTHERAPY OF Single Cell
CANCER Techniques in
Immunology and
Cancer
Immunotherapy
------------------------------------------------------------------------
SOCIETY FOR 2018 SITC- 06/07/2017 $120,000.00
IMMUNOTHERAPY OF AstraZeneca
CANCER Postdoctoral
Cancer
Immunotherapy in
Combination
Therapies
Clinical
Fellowship Award
------------------------------------------------------------------------
TRANSLATIONAL RESEARCH TRIO-US AND UCLA 06/08/2017 $5,000.00
IN ONCOLOGY-US, INC. Annual Research
Conference
------------------------------------------------------------------------
ACS DIVISION OF Division of 06/08/2017 $2,000.00
MEDICINAL CHEMISTRY Medicinal
Chemistry Program
254th ACS
National Meeting
------------------------------------------------------------------------
SAINT FRANCIS HOSPITAL 53rd Annual Robert 06/11/2017 $3,000.00
AND MEDICAL CENTER M. Jeresaty,
M.D.,
Cardiovascular
Symposium
------------------------------------------------------------------------
NYU POST-GRADUATE Women and Cancer: 06/12/2017 $5,000.00
MEDICAL SCHOOL From Screening to
Survivorship
------------------------------------------------------------------------
PREVENTIVE Antiplatelet 06/12/2017 $10,000.00
CARDIOVASCULAR NURSES Therapy Post-ACS:
ASSOCIATION Choosing the
Right Therapy for
the Right
Duration
------------------------------------------------------------------------
PERSONALIZED MEDICINE Turning the Tide 06/13/2017 $10,000.00
COALITION Against Cancer
Through Sustained
Medical
Innovation 2017
National
Conference
------------------------------------------------------------------------
MEDICAL LEARNING The Present and 06/13/2017 $177,230.00
INSTITUTE the Future of
Cancer
Immunotherapy
Biomarkers:
Assessing
Challenges,
Opportunities,
and Implications
for athologists
(150204581)
------------------------------------------------------------------------
AMERICAN COLLEGE OF ACEP17 06/13/2017 $15,000.00
EMERGENCY PHYSICIANS Cardiovascular
Track
------------------------------------------------------------------------
BINAYTARA FOUNDATION 5th International 06/14/2017 $5,000.00
Conference on
Advances in
Hematology and
Oncology (ICAHO
2017)
------------------------------------------------------------------------
NORTHWESTERN UNIVERSITY 19th Annual Lynn 06/14/2017 $15,000.00
Sage Breast
Cancer Symposium
------------------------------------------------------------------------
AMERICAN ASSOCIATION AACR Special 06/14/2017 $35,000.00
FOR CANCER RESEARCH Conference on
Tumor Immunology
and Immunotherapy
------------------------------------------------------------------------
COPD FOUNDATION INC. COPD10USA 06/14/2017 $6,800.00
------------------------------------------------------------------------
DUKE UNIVERSITY Duke Heart Center 06/15/2017 $5,000.00
General
Cardiology
Update--A Case-
Based Review
------------------------------------------------------------------------
AMERICAN HEART 2017 TN M:L STEMI 06/19/2017 $10,000.00
ASSOCIATION Conference
------------------------------------------------------------------------
THE TRANSVERSE MYELITIS 2017 Rare Neuro- 06/19/2017 $5,000.00
ASSOCIATION immune Disorders
Symposium
------------------------------------------------------------------------
INTERNATIONAL IASLC--Lung Cancer 06/19/2017 $1,605,600.00
ASSOCIATION FOR THE Education
STUDY OF LUNG CANCER
------------------------------------------------------------------------
MEDICAL LEARNING Acute Coronary 06/20/2017 $125,000.00
INSTITUTE INC. Syndrome: Getting
to the Heart of
the Matter for
Pharmacists
------------------------------------------------------------------------
USF HEALTH PROFESSIONS inPractice 06/21/2017 $30,000.00
CONFERENCING Oncology 2017-
CORPORATION 2018: Breast and
Gynecologic
Cancers Tracks
------------------------------------------------------------------------
USF HEALTH PROFESSIONS inPractice 06/21/2017 $20,000.00
CONFERENCING Oncology 2017
CORPORATION 2018: Lung Cancer
Track
------------------------------------------------------------------------
GLOBAL EDUCATION GROUP, The Role of 06/22/2017 $10,000.00
LTD. Antiplatelet
Therapy in the
Short- and Long-
term Management
of Highrisk
Patients with ACS
------------------------------------------------------------------------
FEDERATION OF AMERICAN FASEB Autoimmunity- 06/22/2017 $5,000.00
SOCIETIES FOR Additional
EXPERIMENTAL BIOLOGY Funding for Grant
#73697
------------------------------------------------------------------------
THE LEUKEMIA AND Precision and 06/27/2017 $25,000.00
LYMPHOMA SOCIETY, INC. emerging Medicine
for Hematological
Diseases
------------------------------------------------------------------------
ASSOCIATION OF ASTHMA Unraveling Current 06/27/2017 $10,000.00
EDUCATORS Asthma Challenges
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE NCCN 2017 Oncology 06/27/2017 $40,000.00
CANCER NETWORK Case Manager and
Medical Director
Program
------------------------------------------------------------------------
COPD FOUNDATION PRAXIS and the 06/27/2017 $120,000.00
COPD Readmissions
Institute
------------------------------------------------------------------------
NATIONAL KIDNEY New Paradigms in 06/28/2017 $158,250.00
FOUNDATION, INC. the Treatment of
Hyperkalemia
------------------------------------------------------------------------
AMERICAN ACADEMY OF 9th Allergy, 06/28/2017 $5,000.00
PHYSICIAN ASSISTANTS Asthma and ENT
IN ALLERGY, ASTHMA AND CME
IMMUNOLOGY
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE NCCN 2017 Congress 06/29/2017 $25,000.00
CANCER NETWORK Series :
Biomarkers 101 (4
Live Webinars and
4 Enduring
Webinars)
------------------------------------------------------------------------
ASSOCIATION OF Association of 06/29/2017 $10,000.00
PHYSICIAN ASSISTANTS Physician
IN ONCOLOGY INC. Assistants in
Oncology 20th
Annual Conference
------------------------------------------------------------------------
AMERICAN COLLEGE OF TSAAI 2017 Annual 07/02/2017 $3,000.00
ALLERGY, ASTHMA AND Meeting
IMMUNOLOGY
------------------------------------------------------------------------
FLORIDA ACADEMY OF Rashes, joints and 07/02/2017 $3,000.00
PHYSICIAN ASSISTANTS ANA: 2017 Lupus
update
------------------------------------------------------------------------
WEILL CORNELL MEDICINE Emerging 08/01/2017 $20,000.00
Immunological
Themes in
Oncology,
Metabolism and
Inflammation
------------------------------------------------------------------------
THE DIATRIBE FOUNDATION Glycemic Outcomes 08/01/2017 $25,000.00
Beyond A1c
Consensus
Conference
------------------------------------------------------------------------
THE BOARD OF REGENTS OF PARP Inhibitors: 08/02/2017 $90,000.00
THE UNIVERSITY OF Their Role in the
NEBRASKA MEDICAL Treatment of
CENTER DBA UNMC CENTER Ovarian Cancer
FOR CONTINUING EDU
------------------------------------------------------------------------
LUNGEVITY FOUNDATION HCP Attitudes 08/03/2017 $91,800.00
toward Re-biopsy
of Lung Cancer
Patients Project
------------------------------------------------------------------------
HEART FAILURE SOCIETY Clinical Care 08/03/2017 $150,000.00
OF AMERICA INC. Crossroads:
Navigating the
Intersection of
Heart Failure and
Diabetes
------------------------------------------------------------------------
AMERICAN ACADEMY OF 35th Annual Aspen 08/03/2017 $10,000.00
ALLERGY ASTHMA AND Allergy
IMMUNOLOGY Conference
------------------------------------------------------------------------
BIOCONDUCTOR FOUNDATION Bioconductor 08/03/2017 $2,000.00
OF NA INC. Conference 2017
------------------------------------------------------------------------
MEDICAL LEARNING Orienteering on 08/09/2017 $795,250.00
INSTITUTE, INC. the Complex
Treatment
Landscape for
EGFR-Mutant
NSCLC: Latest
Evidence to Guide
Clinical
Decisions in
Everyday
Community
Practice
------------------------------------------------------------------------
THE ANGIOGENESIS xME: Targeted 08/10/2017 $15,000.00
FOUNDATION Therapy,
Immunotherapy,
and the Chronic
Lymphocytic
Leukemia
Microenvironment
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE NCCN 12th Annual 08/21/2017 $75,000.00
CANCER NETWORK, INC. Congress:
Hematologic
MalignanciesT
------------------------------------------------------------------------
AMERICAN ASSOCIATION AACR-AstraZeneca 08/21/2017 $253,000.00
FOR CANCER RESEARCH Fellowships in
Hematology-
Oncology Research
(Lymphoma)
------------------------------------------------------------------------
MEDICAL LEARNING PeerView Master 08/21/2017 $340,120.00
INSTITUTE, INC. Class and
Practicum Live at
IASLC 2017 CMSTO:
New Options and
Evolving
Strategies for
Hitting the
Target in EGFR-
Mutant NSCLC
------------------------------------------------------------------------
AMERICAN SOCIETY OF ASH Meeting on 08/22/2017 $60,000.00
HEMATOLOGY Hematologic
Malignancies
------------------------------------------------------------------------
MEDICAL LEARNING Addressing Unmet 08/22/2017 $270,630.00
INSTITUTE, INC. Needs in Lung
Cancer With
Rational
Immunotherapy-
Based Approaches:
Evidence and
Practicalities
(150204646)
------------------------------------------------------------------------
MEDICAL LEARNING Integrating 08/22/2017 $304,174.00
INSTITUTE, INC. Immunotherapy
into a Multimodal
Treatment
Approach
(150204726)
------------------------------------------------------------------------
ENDOCRINE FELLOWS Fourth Annual 08/23/2017 $250,000.00
FOUNDATION Endocrine Fellows
Research Forum
------------------------------------------------------------------------
AMERICAN SOCIETY OF 59th ASH Annual 08/24/2017 $250,000.00
HEMATOLOGY Meeting
------------------------------------------------------------------------
MAYO CLINIC ARIZONA Acute and Chronic 08/31/2017 $5,000.00
Leukemias 2017
------------------------------------------------------------------------
COLUMBIA UNIVERSITY Innovations in the 08/31/2017 $1,500.00
DEPARTMENT OF SURGERY Management of
Lung Cancer:
Immunotherapy,
targeted
therapies and
minimally
invasive
techniques
------------------------------------------------------------------------
ANNEBERG CENTER FOR JADPRO Live at 08/31/2017 $25,000.00
HEALTH SCIENCES AT APSHO 2017:
EISENHOWER Managing Side
Effects of Cancer
Patients Treated
With
Immunotherapy
------------------------------------------------------------------------
UNIVERSITY OF MARYLAND, UPDATE: Thoracic 08/31/2017 $5,000.00
SCHOOL OF MEDICINE Oncology 2017
------------------------------------------------------------------------
BAYLOR COLLEGE OF Breast Cancer 09/03/2017 $3,000.00
MEDICINE. BREAST Research and
CENTER Education Program
------------------------------------------------------------------------
SOCIETY FOR Grant Writing 09/03/2017 $10,000.00
IMMUNOTHERAPY OF Workshop
CANCER
------------------------------------------------------------------------
COLUMBIA UNIVERSITY 2017 Gigi Shaw 09/07/2017 $3,500.00
COLLEGE OF PHYSICIANS Arledge
AND SURGEONS, DEPT. OF Conference on
SURGERY Pancreatic
Disease
------------------------------------------------------------------------
LUPUS RESEARCH Lupus Research 09/11/2017 $25,000.00
ALLIANCE, INC. Alliance 2017
Annual Scientific
Conference--Forum
for Discovery
------------------------------------------------------------------------
DANA FARBER CANCER Dana-Farber Cancer 09/13/2017 $2,500.00
INSTITUTE Institute's 13th
Annual
Postdoctoral and
Graduate Student
Retreat
------------------------------------------------------------------------
ASSOCIATION OF The Evolving Role 09/13/2017 $20,000.00
COMMUNITY CANCER of the Oncology
CENTERS Pharmacist in the
Management of Non-
small Cell Lung
Cancer
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE Pharmacy Updates: 09/14/2017 $50,000.00
CANCER NETWORK, INC. A Webinar Series
------------------------------------------------------------------------
CINCINNATI CHILDREN'S 4th CURED EGID 09/18/2017 $5,000.00
Research
Conference and
Patient Education
Program
------------------------------------------------------------------------
JOHNS HOPKINS OncologyConsults.c 09/19/2017 $10,000.00
UNIVERSITY om Integrating
Immunotherapy
into SCCHN Care:
Implications for
the
Multidisciplinary
Oncology Care
Team
------------------------------------------------------------------------
PROSTATE CANCER 24th Annual 09/19/2017 $20,000.00
FOUNDATION Scientific
Retreat
------------------------------------------------------------------------
AMERICAN PANCREATIC 48th Annual 09/19/2017 $25,000.00
ASSOCIATION, INC. Meeting of the
American
Pancreatic
Association
------------------------------------------------------------------------
MAYO CLINIC ARIZONA Mayo Clinic Cancer 09/20/2017 $5,000.00
Center Thoracic
Oncology Update
State of the Art
Evaluation and
Management of
Thoracic Cancers
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE Behind the 09/24/2017 $25,000.00
CANCER NETWORK Guidelines:
FOUNDATION (NCCN) Insights into the
Standard of Care
in Oncology 2018
------------------------------------------------------------------------
FOUNDATION FOR HEART 21st Annual Heart 09/25/2017 $10,000.00
FAILURE INC. Failure 2017-An
Update on Therapy
------------------------------------------------------------------------
UNIVERSITY OF COLORADO/ Sex Differences 10/02/2017 $30,000.00
CENTER FOR WOMEN'S across the
HEALTH RESEARCH Lifespan: A Focus
on Metabolism
------------------------------------------------------------------------
LYMPHOMA RESEARCH Adherence and Oral 10/02/2017 $20,000.00
FOUNDATION Therapies in
Lymphoma and CLL
Workshop
------------------------------------------------------------------------
ECOG RESEARCH AND ECOG-ACRIN 2017 10/02/2017 $15,000.00
EDUCATION FOUNDATION, Fall Group
INC. Meeting
------------------------------------------------------------------------
SOCIETY FOR SCAI 2017 10/02/2017 $35,000.00
CARDIOVASCULAR Interventional
ANGIOGRAPHY AND Cardiology
INTERVENTIONS Fellows Course
FOUNDATION
------------------------------------------------------------------------
THE UNIVERSITY OF TEXAS Emerging Therapies 10/04/2017 $5,000.00
MD ANDERSON CANCER in Oncology From
CENTER Phase I and
Beyond
------------------------------------------------------------------------
INTERNATIONAL Best of 18th World 10/05/2017 $20,000.00
ASSOCIATION FOR THE Conference on
STUDY OF LUNG CANCER Lung Cancer
(WCLC)
------------------------------------------------------------------------
AMERICAN UROLOGICAL Assessing the 10/09/2017 $75,000.00
ASSOCIATION Educational Needs
of Urologic Care
Team in the area
of Bladder Cancer
and Immunotherapy
------------------------------------------------------------------------
COLORADO ALLERGY AND CAAS October 2017 10/09/2017 $3,343.10
ASTHMA SOCIETY ``State of the
Art Approaches to
Asthma Diagnosis
and Treatment''
------------------------------------------------------------------------
ICAHN SCHOOL OF Top Ten Advances 10/12/2017 $5,000.00
MEDICINE AT MOUNT in Clinical
SINAI Cardiology
------------------------------------------------------------------------
THE MASSACHUSETTS Boston 10/12/2017 $4,000.00
GENERAL HOSPITAL Angiogenesis
Meeting
------------------------------------------------------------------------
AMERICAN SOCIETY OF Anemia in Kidney 10/16/2017 $155,550.00
NEPHROLOGY Diseases: Beyond
the Usual
Suspects
------------------------------------------------------------------------
REGENTS OF THE Updates in 10/16/2017 $5,000.00
UNIVERSITY OF Rheumatology
CALIFORNIA, UCSD 2017: Highlights
OFFICE OF CME from the ACR and
EULAR Meetings
------------------------------------------------------------------------
FLORIDA ACADEMY OF Acute Coronary 10/16/2017 $7,500.00
PHYSICIAN ASSISTANTS Syndrome
------------------------------------------------------------------------
NEBRASKA ACADEMY OF Acute Coronary 10/16/2017 $7,500.00
PHYSICIAN ASSISTANTS Syndrome: A
Review of
Diagnostic
Criteria, and
Treatment Options
------------------------------------------------------------------------
PEPTIDE THERAPEUTICS 12th Annual 10/18/2017 $15,000.00
FOUNDATION Peptide
Therapeutics
Symposium
------------------------------------------------------------------------
KEYSTONE SYMPOSIA ON Cancer 10/18/2017 $15,000.00
MOLECULAR AND CELLULAR Immunotherapy:
BIOLOGY Combinations
------------------------------------------------------------------------
THE PENNSYLVANIA STATE Beyond the 10/24/2017 $30,000.00
UNIVERSITY Guidelines:
Investigator
Perspectives on
Current Clinical
Issues and
Ongoing Research
in the Management
of Advanced
Prostate Cancer--
An ISS Held as a
Premium Ancillary
Educational Event
During the 2018
Genitourinary
Cancers Symposium
------------------------------------------------------------------------
TRUSTEES OF TUFTS 2017 Tufts Cancer 10/26/2017 $2,500.00
COLLEGE Symposium,
Transforming
Therapeutic
Outcomes:
Innovations in
Cancer Modeling
------------------------------------------------------------------------
MEDSTAR GEORGETOWN Lung Cancer 2017: 10/26/2017 $7,500.00
MEDICAL CENTER INC. Progress and
Future Directions
------------------------------------------------------------------------
AMERICAN COLLEGE OF American College 10/29/2017 $5,000.00
TOXICOLOGY of Toxicology
38th Annual
Meeting,
Symposium 6:
Early Career
Professionals'
Forum: Current
Topics in
Toxicology
------------------------------------------------------------------------
SOCIETY FOR SITC's connectED 11/01/2017 $500,000.00
IMMUNOTHERAPY OF
CANCER
------------------------------------------------------------------------
THE BOARD OF TRUSTREES Stanford Review of 11/06/2017 $5,000.00
OF THE LELAND STANFORD the 59th Annual
JUNIOR UNIVERSITY American Society
of Hematology
Meeting 2018
------------------------------------------------------------------------
UNIVERSITY OF Rheumatology 11/07/2017 $15,000.00
CINCINNATI Winter Clinical
Symposium 2018
(RWCS 2018)
------------------------------------------------------------------------
UT HEALTH SAN ANTONIO 40TH Annual San 11/07/2017 $75,000.00
(UTHSCSA) Antonio Breast
Cancer Symposium
------------------------------------------------------------------------
THE GOG FOUNDATION INC. 9th Semi Annual 11/08/2017 $20,000.00
Meeting of NRG
Oncology
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE NCCN AACR ASCO 11/08/2017 $710,115.00
CANCER NETWORK, INC. Stage III NSCLC
Practical
Application of
Immune Checkpoint
Inhibition After
Chemoradiotherapy
------------------------------------------------------------------------
CANCER RESEARCH CRI Irvington 11/08/2017 $50,000.00
INSTITUTE Postdoctoral
Fellowship
Program
------------------------------------------------------------------------
MID-ATLANTIC SECTION OF 2017 Society for 11/09/2017 $10,000.00
THE AMERICAN Basic Urologic
UROLOGICAL ASSOCIATION Research (SBUR)
and European
Society for
Urological
Research (ESUR)
joint Fall
Symposium
------------------------------------------------------------------------
WEST PENN ALLEGHENY Twelfth Annual 11/09/2017 $8,000.00
HEALTH SYSTEM DBA Nemacolin
ALLEGHENY GENERAL International
HOSPITAL Asthma Conference
An Interactive
Forum on Patient
Care, Therapy,
and Research
------------------------------------------------------------------------
UNIVERSITY OF Request for 2017 11/14/2017 $5,000.00
CALIFORNIA BERKELEY Funding for the
FOUNDATION Forum for
Collaborative
Research's
Program on HBV
------------------------------------------------------------------------
AMERICAN SOCIETY FOR 2018 11/14/2017 $35,000.00
RADIATION ONCOLOGY Multidisciplinary
(ASTRO) Head and Neck
Cancer Symposium:
Expanding
Treatment
Horizons
------------------------------------------------------------------------
AMERICAN SOCIETY OF Hematology 2017: 11/15/2017 $75,000.00
HEMATOLOGY the ASH Education
Program
------------------------------------------------------------------------
THE UNIVERSITY OF TEXAS Leukemia Research 11/15/2017 $5,000.00
MD ANDERSON CANCER Meeting
CENTER
------------------------------------------------------------------------
AMERICAN SOCIETY OF 2018 Highlights of 11/15/2017 $100,000.00
HEMATOLOGY ASHr in North
America
------------------------------------------------------------------------
CONQUER CANCER 2018 Conquer 11/16/2017 $40,000.00
FOUNDATION OF THE Cancer Foundation
AMERICAN SOCIETY OF of ASCO Merit
CLINICAL ONCOLOGY Awards
------------------------------------------------------------------------
CONQUER CANCER 2018 ASCO-SITC 11/21/2017 $60,000.00
FOUNDATION OF THE Clinical Immuno-
AMERICAN SOCIETY OF Oncology
CLINICAL ONCOLOGY Symposium
------------------------------------------------------------------------
AMERICAN COLLEGE OF New York 11/21/2017 $5,000.00
CARDIOLOGY FOUNDATION Cardiovascular
Symposium
------------------------------------------------------------------------
NATIONAL KIDNEY Scientific 11/22/2017 $160,000.00
FOUNDATION INC. Workshop on
Change in
Albuminuria and
GFR as End Points
for Clinical
Trials in Early
Stages of Chronic
Kidney Disease
------------------------------------------------------------------------
MEDICAL LEARNING PeerView 11/27/2017 $50,000.00
INSTITUTE, INC. MasterClass--Prac
ticum Live at
ASCO GI The Quest
to Win Through
Science in
Pancreatic Cancer
From Sequencing
Current Options
to Testing Novel
Approaches
------------------------------------------------------------------------
THE GUTHY JACKSON ECTRIMS 2017 NMO 11/29/2017 $6,000.00
CHARITABLE FOUNDATION Symposium
------------------------------------------------------------------------
AALAS FOUNDATION Student and 11/30/2017 $5,000.00
Teacher Public
Educational
Outreach
------------------------------------------------------------------------
GORDON RESEARCH Biology of Acute 12/01/2017 $5,000.00
CONFERENCE Respiratory
Infection Gordon
Research
Conference
------------------------------------------------------------------------
LEUKEMIA RESEARCH Hollis Brownstein 12/03/2017 $100,000.00
FOUNDATION Research Grants
Program
------------------------------------------------------------------------
AMERICAN COLLEGE OF 2017 ACR/ARHP 12/03/2017 $75,000.00
RHEUMATOLOGY Annual Meeting
Lupus Educational
Track
------------------------------------------------------------------------
NATIONAL JEWISH HEALTH 40th Annual 12/04/2017 $20,000.00
National Jewish
Health Pulmonary
and Allergy
Update
------------------------------------------------------------------------
KEYSTONE SYMPOSIA ON 2018 Keystone 12/04/2017 $25,000.00
MOLECULAR AND CELLULAR Symposia
BIOLOGY Directors' Fund
------------------------------------------------------------------------
AMERICAN DIABETES Diabetes is 12/04/2017 $40,568.50
ASSOCIATION Primary Digital
Program on
Cardiovascular
Risk
------------------------------------------------------------------------
AMERICAN COLLEGE OF 2017 ACLAM Grants 12/04/2017 $4,000.00
LABORATORY ANIMAL
MEDICINE
------------------------------------------------------------------------
SOUTHERN MEDICAL Medical Dilemmas 12/05/2017 $2,500.00
ASSOCIATION in Patient Care
Conference
------------------------------------------------------------------------
THE NORTH AMERICAN 3RS Virtual Education 12/06/2017 $8,000.00
COLLABORATIVE Community Support
------------------------------------------------------------------------
CONQUER CANCER 2018 Conquer 12/10/2017 $500,000.00
FOUNDATION OF THE Cancer Foundation
AMERICAN SOCIETY OF of ASCO Mission
CLINICAL ONCOLOGY Endowment
------------------------------------------------------------------------
CONQUER CANCER 2018 Genitourinary 12/10/2017 $60,000.00
FOUNDATION OF THE (GU) Cancers
AMERICAN SOCIETY OF Symposium:
CLINICAL ONCOLOGY Translating
Evidence to
Multidisciplinary
Care
------------------------------------------------------------------------
CONQUER CANCER 2018 Conquer 12/10/2017 $256,000.00
FOUNDATION OF THE Cancer Foundation
AMERICAN SOCIETY OF of ASCO Young
CLINICAL ONCOLOGY Investigator
Award (YIA)
------------------------------------------------------------------------
REGENTS OF THE 15th Annual 12/10/2017 $40,000.00
UNIVERSITY OF Nephrology Young
CALIFORNIA Investigators
Forum
------------------------------------------------------------------------
JOHNS HOPKINS Mid Atlantic 12/10/2017 $50,000.00
UNIVERSITY SCHOOL OF Nephrology Young
MEDICINE Investigators
Forum
------------------------------------------------------------------------
ILLINOIS ACADEMY OF The 12th Annual 12/11/2017 $54,771.32
FAMILY PHYSICIANS Chief Residents
Summit on
Intensifying
Diabetes
Management
------------------------------------------------------------------------
AMERICAN COLLEGE OF 2018 ACR 12/11/2017 $50,000.00
RHEUMATOLOGY Rheumatology
Courses
------------------------------------------------------------------------
JOHNS HOPKINS FastForward 12/12/2017 $25,000.00
UNIVERSITY Corporate
Sponsorship
------------------------------------------------------------------------
THE DEUEL CONFERENCE ON The 2018 Deuel 12/13/2017 $5,000.00
LIPIDS Conference on
Lipids
------------------------------------------------------------------------
FEDERATION OF AMERICAN FASEB SRC 12/13/2017 $5,000.00
SOCIETIES FOR Immunoreceptors
EXPERIMENTAL BIOLOGY and Immunotrerapy
(FASEB)
------------------------------------------------------------------------
UNIVERSITY OF Request for 2018 12/13/2017 $10,000.00
CALIFORNIA BERKELEY Funding for the
FOUNDATION Forum for
Collaborative
Research's
------------------------------------------------------------------------
GORDON RESEARCH Gordon Conference 12/14/2017 $5,000.00
CONFERENCE on Drug
Resistance 2018
------------------------------------------------------------------------
ASSOCIATION FOR WOMEN Innovation and 12/17/2017 $25,000.00
IN SCIENCE Inclusion: Women
at the Forefront
of STEM
------------------------------------------------------------------------
VIRGINIA BIOTECHNOLOGY MedImmune 12/17/2017 $25,000.00
ASSOCIATION Chairman's Circle
Membership
------------------------------------------------------------------------
FEDERATION OF AMERICAN The Lung 12/20/2017 $5,000.00
SOCIETIES FOR Epithelium in
EXPERIMENTAL BIOLOGY Health and
SRC Disease
------------------------------------------------------------------------
ENGINEERING CONFERENCES Cell Culture 12/21/2017 $10,000.00
INTERNATIONAL Engineering XVI
Conference
------------------------------------------------------------------------
PENNYSLVANIA SOCIETY 2018 PSBR 12/24/2017 $2,000.00
FOR BIOMEDICAL Membership
RESEARCH
------------------------------------------------------------------------
NATIONAL ACADEMY OF Roundtable in 12/24/2017 $4,000.00
SCIENCES Science and
Welfare of
Laboratory Animal
Use
------------------------------------------------------------------------
CONQUER CANCER 2018 01/02/2018 $30,000.00
FOUNDATION OF THE Gastrointestinal
AMERICAN SOCIETY OF (GI) Cancers
CLINICAL ONCOLOGY Symposium:
Multidisciplinary
Care: Local
Practice, Global
Outcomes
------------------------------------------------------------------------
AMERICAN ASSOCIATION AACR-IASLC Joint 01/02/2018 $25,000.00
FOR CANCER RESEARCH Conference on the
Molecular Origins
of Lung Cancer
------------------------------------------------------------------------
NATIONAL JEWISH HEALTH 14th Annual 01/02/2018 $299,608.49
Respiratory
Disease Young
Investigators'
Forum
------------------------------------------------------------------------
THE CHEST FOUNDATION CHEST Foundation 01/02/2018 $55,000.00
Research Award in
COPD
------------------------------------------------------------------------
INTERNATIONAL Implementation of 01/04/2018 $300,000.00
ASSOCIATION FOR THE diagnostic and
STUDY OF LUNG CANCER molecular
guidelines in low-
middle income
regions for
targeted
therapies in
NSCLC
------------------------------------------------------------------------
UNIVERSITY OF NORTH 9th International 01/09/2018 $2,500.00
CAROLINA AT CHAPEL Symposia for the
HILL CGRP Family
Peptides
Conference
------------------------------------------------------------------------
UNIVERSITY OF The Intersection 01/14/2018 $95,000.00
CINCINNATI Between COPD and
Cardiometabolic
Comorbidities
------------------------------------------------------------------------
NATIONAL KIDNEY 13th Annual 01/14/2018 $50,000.00
FOUNDATION INC. National Young
Investigator
Forum
------------------------------------------------------------------------
AMERICAN COLLEGE OF WSAAI 2018: 56th 01/17/2018 $15,000.00
ALLERGY, ASTHMA AND Annual Scientific
IMMUNOLOGY (ACAAI) Session
------------------------------------------------------------------------
AMERICAN ASSOCIATION AACR-SNMMI Joint 01/18/2018 $10,000.00
FOR CANCER RESEARCH Conference on
State-of-the-Art
Molecular Imaging
in Cancer Biology
and Therapy
------------------------------------------------------------------------
THE UNIVERSITY OF TEXAS 2018 Oncologic 01/23/2018 $10,000.00
MD ANDERSON CANCER Emergency
CENTER Medicine
Conference
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF Exploring the 01/25/2018 $35,000.00
MANAGED CARE Challenges of
PHYSICIANS Severe Asthma:
Understanding
Appropriate
Treatment
Strategies for
Improved Patient
Outcomes
------------------------------------------------------------------------
CANCER RESEARCH Cancer 02/05/2018 $10,000.00
INSTITUTE Immunotherapy
Consortium
Workshop
------------------------------------------------------------------------
ANNENBERG CENTER FOR Advancing 02/11/2018 $200,000.00
HEALTH SCIENCES AT Knowledge to
EISENHOWER Practice
Optimizing Severe
Asthma Care in
the Age of
Biologics
------------------------------------------------------------------------
PENNSYLVANIA STATE PeerView Live at 02/12/2018 $104,507.00
UNIVERSITY the 2018 ASCO
Annual Meeting,
The Arrival of
Novel Agent
Classes in B-Cell
Non-Hodgkin
Lymphoma: A
Personal Guide to
Integrating New
Therapy into
Patient Care
(150204877)
------------------------------------------------------------------------
ANNENBERG CENTER FOR Clinical Advances 02/13/2018 $75,000.00
HEALTH SCIENCES and Case Studies
in Immune
Checkpoint
Inhibitors in
Oncology
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE NCCN 2018 Oncology 02/14/2018 $35,000.00
CANCER NETWORK, INC. Fellows Program:
New Horizons in
Quality Cancer
CareT at the NCCN
23rd Annual
Conference
------------------------------------------------------------------------
INDY HEMATOLOGY 2018 Indy 02/14/2018 $10,000.00
EDUCATION, INC. Hematology Review
------------------------------------------------------------------------
JOHNS HOPKINS 14th International 02/14/2018 $20,000.00
UNIVERSITY Symposium on
Sjogrens Syndrome
------------------------------------------------------------------------
SCRIPPS HEALTH Scripps 38th 02/14/2018 $25,000.00
Annual Clinical
Hematology and
Oncology
Conference
------------------------------------------------------------------------
THE CHEST FOUNDATION CHEST Foundation 02/14/2018 $35,000.00
Research Award in
Severe Asthma
------------------------------------------------------------------------
ANNENBERG CENTER FOR Clinical 02/14/2018 $100,000.00
HEALTH SCIENCES Management of
Novel Therapies
for Hematological
Malignancies (5
Regional lectures
by APSHO/JADPRO)
------------------------------------------------------------------------
MEDICAL LEARNING PeerView inVision, 02/14/2018 $64,125.00
INSTITUTE, INC. ``Targeted
Treatment in
Severe Asthma:
Moving Toward
Precision
Medicine''
------------------------------------------------------------------------
COLLEGIUM 32nd Symposium of 02/14/2018 $10,000.00
INTERNATIONALE the Collegium
ALLERGOLOGICUM Internationale
Allergologicum
------------------------------------------------------------------------
AMERICAN SOCIETY FOR Immuno-Oncology: 02/14/2018 $60,490.00
CLINICAL PATHOLOGY Scientific
Updates
------------------------------------------------------------------------
NATIONAL JEWISH HEALTH COPD Basics: An 02/14/2018 $100,000.00
Integrated
Approach to Best
Practices in Five
Healthcare
Networks
------------------------------------------------------------------------
MAYO CLINIC ARIZONA Clinical 02/14/2018 $15,000.00
Multidisciplinary
Hematology and
Oncology: The
15th Annual
Review
------------------------------------------------------------------------
INTERNATIONAL 18th Targeted 02/14/2018 $55,100.00
ASSOCIATION FOR THE Therapy meeting
STUDY OF LUNG CACEER
------------------------------------------------------------------------
MEDICAL LEARNING PeerView Master 02/14/2018 $299,330.00
INSTITUTE, INC. Class and
Practicum Live at
CHEST 2018, ``New
Avenues in Asthma
Management:
Finding the Right
Patients for
Targeted
Therapies''
(150205033)
------------------------------------------------------------------------
NATIONAL KIDNEY Chronic 02/15/2018 $232,979.00
FOUNDATION INC. Hyperkalemia
Management and
Outcomes in CKD
------------------------------------------------------------------------
ALZHEIMER'S ASSOCIATION Alzheimer's 02/15/2018 $45,000.00
Association
International
Conference, AAIC
2018
------------------------------------------------------------------------
ASTHMA AND ALLERGY Wheezin', Sneezin' 02/16/2018 $10,000.00
FOUNDATION OF AMERICA-- and Itchin' in
ALASKA CHAPTER Alaska
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF New Agents and 02/18/2018 $35,000.00
MANAGED CARE Emerging
PHYSICIANS Strategies in
Advanced Breast
Cancer: Patient-
Centric
Navigation in the
Age of
Personalized Care
------------------------------------------------------------------------
THE PENNSYLVANIA STATE PeerView inPlay, 02/18/2018 $145,730.00
UNIVERSITY ``The Role of the
Eosinophil in
COPD:
Implications for
Personalized Care
and Novel
Treatments''
(150205058)
------------------------------------------------------------------------
DUKE UNIVERSITY 3rd Annual Duke 02/19/2018 $2,500.00
Heart Center/DCRI
Fellows'
Presentation
Skills Course
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF Novel Treatment 02/19/2018 $35,000.00
MANAGED CARE Strategies in the
PHYSICIANS, INC. Management of
Ovarian Cancer: A
Closer Look at
the Role of PARP
Inhibitors
------------------------------------------------------------------------
AMERICAN THORACIC ATS 2018 Fellows 02/19/2018 $10,000.00
SOCIETY INC. Track Symposium
------------------------------------------------------------------------
MEDSTAR WASHINGTON Cardiovascular 02/20/2018 $30,000.00
HOSPITAL CENTER Research
Technologies
(CRT) Annual
Meeting
------------------------------------------------------------------------
DUKE UNIVERSITY The Southeastern 02/21/2018 $2,500.00
Fellows Research
Skills and
Training Workshop
------------------------------------------------------------------------
AMERICAN THORACIC ATS 2018 02/21/2018 $30,000.00
SOCIETY INC. International
Conference--Selec
ted Sessions in
COPD
------------------------------------------------------------------------
SCRIPPS HEALTH 15th Annual 02/22/2018 $25,000.00
Fundamentals of
Diabetes
Management
------------------------------------------------------------------------
AMERICAN ASSOCIATION FDA-AACR-ASTRO: 02/22/2018 $25,000.00
FOR CANCER RESEARCH Clinical
Development of
Drug-Radiotherapy
Combinations
Workshop
------------------------------------------------------------------------
AMERICAN ASSOCIATION Advances in 02/25/2018 $25,000.00
FOR CANCER RESEARCH Malignant
Lymphoma (AACR/
ICML ``off year''
conference in US)
------------------------------------------------------------------------
BLADDER CANCER ADVOCACY 2018 Bladder 02/25/2018 $35,000.00
NETWORK Cancer Think Tank
------------------------------------------------------------------------
GORDON RESEARCH 2018 Gordon 02/27/2018 $5,000.00
CONFERENCE Research Council
on New Antibiotic
Discovery and
Development
------------------------------------------------------------------------
RUTGERS, THE STATE Treat-to-Target 02/28/2018 $124,857.00
UNIVERSITY OF NEW and Targeted
JERSEY Therapy: The
Evolving State of
Systemic Lupus
Erythematosus
Patient Care
------------------------------------------------------------------------
AMERICAN DIABETES Diabetes is 03/01/2018 $300,000.00
ASSOCIATION Primary Core
Programs
------------------------------------------------------------------------
AMERICAN ASSOCIATION AACR Annual 03/01/2018 $225,000.00
FOR CANCER RESEARCH Meeting--2018
------------------------------------------------------------------------
NATIONAL JEWISH HEALTH A Severe Asthma 03/01/2018 $322,170.00
Roadmap for
Improved
Diagnosis and
Personalized
Treatment--A
Guided Workflow
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF California Chapter 03/01/2018 $10,000.00
CLINICAL of the American
ENDOCRINOLOGITS Association of
Clinical
Endocrinologists
Presents Hot
Topics in
Diabetes and
Endocrinology for
Primary Care 2018
Series
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE NCCN 23rd Annual 03/02/2018 $100,000.00
CANCER NETWORK, INC. Conference:
Improving the
Quality,
Effectiveness,
and Efficiency of
Cancer CareTM
------------------------------------------------------------------------
EASTERN VIRGINIA Turning the Tide 03/04/2018 $5,000.00
MEDICAL SCHOOL on Diabetes 2018
------------------------------------------------------------------------
THE UNIVERSITY OF 15th International 03/05/2018 $25,000.00
CHICAGO Ultmann Chicago
Lymphoma
Symposium
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF Innovating 03/05/2018 $300,000.00
CLINICAL Diabetes Care-Use
ENDOCRINOLOGISTS of Real-Time Data
to Transform
Clinical Practice
and Optimize
Patient Glucose
Management
------------------------------------------------------------------------
CARDIOVASCULAR RESEARCH 24th Annual 03/05/2018 $10,000.00
FOUNDATION Interventional
Cardiology
Fellows Course
------------------------------------------------------------------------
AMERICAN PHARMACISTS APhA2018 Your 03/05/2018 $5,000.00
ASSOC Annual Diabetes
Update
------------------------------------------------------------------------
CARDIOVASCULAR RESEARCH DAPT Dilemmas: A 03/05/2018 $20,000.00
FOUNDATION Case-Based
Roundtable at
Fellows 2018
------------------------------------------------------------------------
AMERICAN UROLOGICAL Japanese 03/05/2018 $40,000.00
ASSOCIATION Urological
Association (JUA)
Meeting
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE NCCN Foundation 03/06/2018 $171,801.00
CANCER NETWORK, INC. Young
Investigator
Awards
------------------------------------------------------------------------
PURDUE UNIVERSITY Can You Do It 03/06/2018 $377,342.00
OFFICE OF CONTINUING Better?--A Unique
PROFESSIONAL EDUCATION Approach to
Enabling Improved
Asthma Management
------------------------------------------------------------------------
INTERNATIONAL IASLC Workshop on 03/06/2018 $25,000.00
ASSOCIATION FOR THE Neopadjuvant
STUDY OF LUNG CANCER Therapy in Lung
Cancer
------------------------------------------------------------------------
UNT HEALTH SCIENCE Filling the Gaps 03/07/2018 $4,750.00
CENTER in Asthma Care--
Lessons Learned
from Asthma411
------------------------------------------------------------------------
ANNENBERG CENTER FOR Updates in 03/07/2018 $155,000.00
HEALTH SCIENCES AT Precision
EISENHOWER Medicine
Elevating the
Treatment of
Severe,
Eosinophilic
Asthma
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF 27th Annual 03/07/2018 $63,052.00
CLINICAL Scientific and
ENDOCRINOLOGITS Clinical
Congress--Diabete
s Sessions
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE Support for NCCN 03/08/2018 $60,000.00
CANCER NETWORK Distribution of
the NCCN Clinical
Practice
Guidelines in
Oncology (NCCN
Guidelinesr) for
Management of
Immunotherapy-
Related
Toxicities Pocket
Guides
------------------------------------------------------------------------
BOARD OF REGENTS OF THE 2018 Pan Pacific 03/11/2018 $125,000.00
UNIVERSITY OF NEBRASKA Lymphoma
Conference
------------------------------------------------------------------------
SCRIPPS HEALTH Fifth Annual 03/11/2018 $5,000.00
Clinical Advances
in Heart Failure
and Arrhythmias
------------------------------------------------------------------------
NORTHEAST GEORGIA 10th Annual 03/12/2018 $2,500.00
MEDICAL CENTER Northeast Georgia
STEMI Summit
------------------------------------------------------------------------
HEMATOLOGY/ONCOLOGY HOPA 14th Annual 03/12/2018 $30,000.00
PHARMACY ASSOCIATION Conference
------------------------------------------------------------------------
CONQUER CANCER 2018 ASCO Annual 03/12/2018 $20,000.00
FOUNDATION OF THE Meeting Breast
AMERICAN SOCIETY OF Cancer Track
CLINICAL ONCOLOGY
------------------------------------------------------------------------
CONQUER CANCER 2018 ASCO Annual 03/12/2018 $30,000.00
FOUNDATION OF THE Meeting
AMERICAN SOCIETY OF Genitourinary
CLINICAL ONCOLOGY Cancer Tracks
Bundle: Prostate
and Nonprostate
------------------------------------------------------------------------
THE GUTHY JACKSON The Guthy-Jackson 03/12/2018 $25,000.00
CHARITABLE FOUNDATION Industry Council
------------------------------------------------------------------------
REGENTS OF THE Making the 03/13/2018 $200,000.00
UNIVERSITY OF Connection
CALIFORNIA Between Patients
and Providers: A
Comprehensive
Overview of the
Modern Treatment
Strategies For
People With Type
1 and Type 2
Diabetes
------------------------------------------------------------------------
NATIONAL KIDNEY Cardiovascular 03/13/2018 $232,979.00
FOUNDATION Risk in Patients
with Chronic
Kidney Disease
(CKD): The Impact
of Anemia
------------------------------------------------------------------------
ACADEMY OF MANAGED CARE The Immuno- 03/13/2018 $35,000.00
PHARMACY Oncology Pipeline
and the Managed
Care
Considerations
------------------------------------------------------------------------
INTERNATIONAL IASLC 03/13/2018 $25,000.00
ASSOCIATION FOR THE Immunotherapy
STUDY OF LUNG CANCER Meeting
------------------------------------------------------------------------
ACS DIVISION OF 255th ACS National 03/13/2018 $5,000.00
BIOCHEMICAL TECHNOLOGY Meeting and
Exposition (BIOT
Division)
------------------------------------------------------------------------
AMERICAN ASSOCIATION 12th Biennial 03/14/2018 $15,000.00
FOR CANCER RESEARCH Ovarian Cancer
Research
Symposium
------------------------------------------------------------------------
AMERICAN HEART Arteriosclerosis, 03/18/2018 $2,000.00
ASSOCIATION Thrombosis and
Vascular Biology
| Peripheral
Vascular Disease
2018Scientific
Sessions,
Vascular
Discovery: From
Genes to Medicine
------------------------------------------------------------------------
RILITE FOUNDATION Lupus 21st Century 03/18/2018 $25,000.00
2018 Conference
------------------------------------------------------------------------
RHEUMATOLOGIC 4th International 03/19/2018 $10,000.00
DERMATOLOGY SOCIETY Conference on
INC. Cutaneous Lupus
Erythematosus
------------------------------------------------------------------------
HOWARD UNIVERSITY 13th Annual 03/19/2018 $2,500.00
Kenneth Austin
Rheumatology
Symposium
------------------------------------------------------------------------
SOCIETY OF GYNECOLOGIC SGO Lunch and 03/20/2018 $125,000.00
ONCOLOGY Learn
Contemporary
Ovarian Cancer:
Keys to Therapies
and Integrated
Learning
------------------------------------------------------------------------
LYMPHOMA RESEARCH Mantle Cell 03/20/2018 $20,000.00
FOUNDATION Lymphoma
Scientific
Workshop
------------------------------------------------------------------------
CANCER MOLECULAR Molecular 03/21/2018 $5,000.00
THERAPEUTICS RESEARCH Therapeutics of
ASSOCIATION Cancer Research
Conference 2018
------------------------------------------------------------------------
PREVENTIVE PCNA's 24th Annual 03/22/2018 $10,000.00
CARDIOVASCULAR NURSES Symposium
ASSOCIATION
------------------------------------------------------------------------
ASPEN LUNG CONFERENCE Thomas Petty Aspen 03/22/2018 $25,000.00
Lung Conference/
Translating
Resilience and
Pathogenesis to
Personalized
Therapy for COPD
------------------------------------------------------------------------
ANNENBERG CENTER FOR Master Class for 03/22/2018 $24,246.27
HEALTH SCIENCES Oncologists--Hema
tology Track
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF Clinical Advances 03/25/2018 $15,000.00
MANAGED CARE in the Diagnosis,
PHYSICIANS, INC. Treatment and
Management of
COPD
------------------------------------------------------------------------
FOUNDATION FOR SURGICAL American Head and 03/25/2018 $15,000.00
FELLOWSHIPS Neck Society
Annual Meeting--
Evaluating Head
and Neck Cancer
Care Through
Evidence Based
Medicine
------------------------------------------------------------------------
DUKE UNIVERSITY Duke Debates: 03/25/2018 $15,000.00
Controversies in
the Management of
Patients with
Hematologic
Malignancies
------------------------------------------------------------------------
ICAHN SCHOOL OF Mount Sinai 03/29/2018 $7,500.00
MEDICINE AT MOUNT Division of
SINAI Occupational
Medicine Seminar
Series
------------------------------------------------------------------------
GORDON RESEARCH Gordon Research 04/01/2018 $2,500.00
CONFERENCE Conference:
Mutagenesis--Mech
anisms of
Intrinsic and
Induced Genome
Instability
------------------------------------------------------------------------
THE UNIVERSITY OF Frontiers in 04/02/2018 $25,000.00
CHICAGO Precision
Medicine for
Inherited
Cancers: From
Risk Assessment
to Targeted
Therapies
------------------------------------------------------------------------
THE PENNSYLVANIA STATE PeerView Live: 04/02/2018 $73,575.00
UNIVERSITY ``Unraveling the
Complex Treatment
Landscape for
Prostate Cancer:
Guidance for
Delivering
Evidence-Based,
Patient-Centered
Care''
(150204517)
------------------------------------------------------------------------
GORDON RESEARCH 2018 Gordon 04/03/2018 $2,500.00
CONFERENCES Research
Conference on
Medicinal
Chemistry
------------------------------------------------------------------------
CLEVELAND CLINIC 2018 Cleveland 04/03/2018 $5,000.00
EDUCATION FOUNDATION Breast Cancer
Summit:
Collaborating for
a Cure
------------------------------------------------------------------------
THE PENNSYLVANIA STATE New Directions in 04/04/2018 $124,611.00
UNIVERSITY the Management of
Recurrent Ovarian
Cancer: Focus on
PARP Inhibitors
------------------------------------------------------------------------
ASSOCIATION FOR Advancing Patient 04/04/2018 $416,900.00
MOLECULAR PATHOLOGY Care in NSCLC:
Breaking Down
Barriers
------------------------------------------------------------------------
CLEVELAND CLINIC 2018 Diabetes Day 04/04/2018 $5,000.00
EDUCATIONAL FOUNDATION 23rd Annual
Symposium New
Frontiers in
Diabetes
------------------------------------------------------------------------
MEDICAL LEARNING PeerView Master 04/04/2018 $370,100.00
INSTITUTE, INC. Class and
Practicum Live at
ASH 2018:
``Exploring the
Present and
Future of BTK
Inhibition in B-
cell
malignancies:
Expert Insights
on Practical
Implications for
Patient
Management''
(150205092)
------------------------------------------------------------------------
AMERICAN UROLOGICAL AUA2018 04/04/2018 $150,000.00
ASSOCIATION Highlights:
Immunotherapy in
GU Cancer
------------------------------------------------------------------------
ANNENBERG CENTER FOR Master Class for 04/05/2018 $19,391.02
HEALTH SCIENCES Oncologists--Wome
n's Cancer Track
------------------------------------------------------------------------
FRIENDS OF CANCER Friends of Cancer 04/08/2018 $100,000.00
RESEARCH 2018 Research Programs
------------------------------------------------------------------------
THE HOPE FOUNDATION 2018 SWOG Group 04/08/2018 $10,000.00
Meetings
------------------------------------------------------------------------
CONQUER CANCER 2018 ASCO Annual 04/09/2018 $45,000.00
FOUNDATION OF THE Meeting
AMERICAN SOCIETY OF Gynecologic
CLINICAL ONCOLOGY Cancer Track
------------------------------------------------------------------------
LAHEY CLINIC HOSPITAL, Cardiovascular 04/09/2018 $5,000.00
INC. Disease State of
the Art 2018
------------------------------------------------------------------------
BOARD OF REGENTS FOR Dissecting the 04/11/2018 $75,000.00
UNIVERSITY OF NEBRASKA Decision:
Documenting and
Discussing the
Clinical Practice
Patterns of
Hematologic
Oncology
Investigators in
the Management of
Chronic
Lymphocytic
Leukemia--An ISS
Held in
Conjunction with
the 2018 Pan
Pacific Lymphoma
Conference
------------------------------------------------------------------------
TRUSTEES OF BOSTON CVD AND RENAL 04/11/2018 $109,420.00
UNIVERSITY DISEASE IN T2DM:
Pivotal Role of
Physician
Assistants in
Patient
Management
------------------------------------------------------------------------
CONQUER CANCER 2018 Conquer 04/12/2018 $253,000.00
FOUNDATION OF THE Cancer Foundation
AMERICAN SOCIETY OF of ASCO Career
CLINICAL ONCOLOGY Development Award
(CDA)
------------------------------------------------------------------------
AMERICAN COLLEGE OF CHEST 2018 Post 04/12/2018 $25,000.00
CHEST PHYSICIANS Graduate Program
on Difficult to
Treat Asthma
------------------------------------------------------------------------
ECOG RESEARCH AND ECOG-ACRIN 2018 04/12/2018 $5,000.00
EDUCATION FOUNDATION, Spring Group
INC. Meeting
------------------------------------------------------------------------
LUPUS FOUNDATION OF NEW Lupus Medical and 04/15/2018 $5,000.00
ENGLAND Educational
Symposim
------------------------------------------------------------------------
HEART FAILURE SOCIETY Future Leaders in 04/16/2018 $10,000.00
OF AMERICA INC. Heart Failure
Symposium
------------------------------------------------------------------------
AMERICAN ACADEMY OF CME Applying the 04/17/2018 $313,595.00
INC. Latest Evidence
to Improve Care
for Patients with
HR+/HER2-
Metastatic Breast
Cancer
------------------------------------------------------------------------
PRESIDENT AND FELLOWS Practical 04/17/2018 $5,000.00
OF HARVARD COLLEGE Considerations
ACTING THROUGH THE and Rationale for
DEPARTMENT OF GCE Immunotherapy
2018
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF AACE 27th Annual 04/17/2018 $30,000.00
CLINICAL Scientific &
ENDOCRINOLOGITS Clinical
Congress--Cardiov
ascular Track
------------------------------------------------------------------------
METABOLIC ENDOCRINE 2nd Annual Heart 04/18/2018 $50,000.00
EDUCATION FOUNDATION in Diabetes
------------------------------------------------------------------------
SOCIETY FOR SCAI 2018 04/18/2018 $40,000.00
CARDIOVASCULAR Scientific
ANGIOGRAPHY AND Sessions
INTERVENTIONS featuring
FOUNDATION Controversies in
Interventional
Pharmacology
------------------------------------------------------------------------
AMERICAN HEART STEMI Protocol 04/18/2018 $3,730.00
ASSOCIATION Stakeholder
Education
------------------------------------------------------------------------
ALZHEIMER'S ASSOCIATION 2018 Research 04/19/2018 $50,000.00
Roundtable
------------------------------------------------------------------------
PURDUE UNIVERSITY Critical 04/23/2018 $575,210.00
Conversations on
Bruton's Tyrosine
Kinase Inhibitor
Development and
Use in B-Cell
Malignancies (CCO
GR Pgm)
------------------------------------------------------------------------
AMERICAN COLLEGE OF Severe Asthma 04/23/2018 $60,000.00
ALLERGY, ASTHMA AND Shared Decision
IMMUNOLOGY Making Tool
Instructional
Video
------------------------------------------------------------------------
AMERICAN COLLEGE OF Symposium--A 04/23/2018 $80,375.00
ALLERGY, ASTHMA AND Personalized
IMMUNOLOGY Approach to
Managing Patients
with Uncontrolled
Asthma / Shifting
Paradigms in
Management of
Severe Asthma:
Pathogenesis,
Phenotypes and
Personalized
Medicine
------------------------------------------------------------------------
MEDSTAR HEALTH, INC. 2018 MedStar 04/24/2018 $15,000.00
Health System
Prostate Cancer
Annual Meeting
------------------------------------------------------------------------
UT HEALTH SAN ANTONIO 3rd Annual Cardio 04/24/2018 $5,000.00
Renal Connections
------------------------------------------------------------------------
MEDSTAR HEALTH, INC. Enhancing Health 04/24/2018 $10,000.00
System
Initiatives
Utilizing
Clinical Advances
to Optimize the
Diagnosis and
Treatment of
Prostate Cancer
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF Best Practices in 04/25/2018 $35,000.00
MANAGED CARE the Management of
PHYSICIANS, INC. Advanced Non-
Small Cell Lung
Cancer (NSCLC):
Individualizing
Therapy for
Optimized Patient
Outcomes
------------------------------------------------------------------------
TRUSTEES OF BOSTON CVD AND RENAL 04/25/2018 $49,000.00
UNIVERSITY DISEASE IN T2DM:
Individualizing
Therapeutic
Options to Reduce
Comorbid Risk
------------------------------------------------------------------------
CONQUER CANCER 2018 Best of ASCO 04/25/2018 $120,000.00
FOUNDATION OF THE Meetings
AMERICAN SOCIETY OF
CLINICAL ONCOLOGY
------------------------------------------------------------------------
AMERICAN CHEMICAL Recovery of 04/26/2018 $10,000.00
SOCIETY, DIVISION OF Biological
BIOCHEMICAL Products XVIII
TECHNOLOGY, RECOVERY Conference
OF BIOLOGICAL PRODUCTS
------------------------------------------------------------------------
AMERICAN RADIUM SOCIETY American Radium 04/26/2018 $10,000.00
Society 100th
Annual Meeting
------------------------------------------------------------------------
VANDERBILT UNIVERSITY Midwest Islet Club 04/26/2018 $2,500.00
Meeting
------------------------------------------------------------------------
WEST PENN ALLEGHENY 2018 04/29/2018 $5,000.00
HEALTH SYSTEM, INC. Cardiovascular
DBA ALLEGHENY GENERAL Medicine Update
HOSPITAL Conference
------------------------------------------------------------------------
PRESIDENT AND FELLOWS Diabetes Update 04/30/2018 $5,000.00
OF HARVARD COLLEGE 2018
ACTING THROUGH THE
DEPARTMENT OF GCE
------------------------------------------------------------------------
ASPEN CANCER CONFERENCE 33rd Aspen Cancer 04/30/2018 $10,000.00
Conference
------------------------------------------------------------------------
TRUSTEES OF THE 6th Annual 04/30/2018 $20,000.00
UNIVERSITY OF Scientific
PENNSYLVANIA/PERELMAN Symposium: BRCA1,
SCHOOL OF MEDICINE AT BRCA2 and Beyond:
THE UNIVERSITY OF PA An Update on
Hereditary Cancer
------------------------------------------------------------------------
ASSOCIATION OF AMERICAN 2018 AACI/CCAF 05/01/2018 $15,000.00
CANCER INSTITUTES Annual Meeting
------------------------------------------------------------------------
ONCOLOGY NURSING 2018 ONS Annual 05/01/2018 $50,000.00
SOCIETY Congress and two
Regional
Conferences
------------------------------------------------------------------------
TRUSTEES OF THE 2018 New Advances 05/03/2018 $10,000.00
UNIVERSITY OF in Lung Cancer:
PENNSYLVANIA/PERELMAN Stretching the
SCHOOL OF MEDICINE AT Envelope
THE UNIVERSITY OF PA
------------------------------------------------------------------------
HEMATOLOGY ONCOLOGY Immuno oncology 05/06/2018 $35,000.00
PHARMACY ASSOCIATION Educational
Modules for
Oncology
Pharmacists
------------------------------------------------------------------------
CANCER RESEARCH 2018 05/06/2018 $50,000.00
INSTITUTE International
Cancer
Immunotherapy
Conference
------------------------------------------------------------------------
AMERICAN ASSOCIATION AACR Pancreatic 05/06/2018 $25,000.00
FOR CANCER RESEARCH Cancer: Advances
in Science and
Clinical Care
------------------------------------------------------------------------
ALLIANCE FOR CLINICAL 2018 Group 05/07/2018 $40,000.00
TRIALS IN ONCOLOGY Meetings
FOUNDATION
------------------------------------------------------------------------
AMERICAN THORACIC ATS 2018 05/07/2018 $40,000.00
SOCIETY INC. International
Conference--Selec
ted Sessions in
Lung Cancer
------------------------------------------------------------------------
AMERICAN SOCIETY OF 2018 ASH Meeting 05/08/2018 $50,000.00
HEMATOLOGY on Lymphoma
Biology
------------------------------------------------------------------------
LUNGEVITY FOUNDATION LUNGevity 05/08/2018 $50,000.00
Foundation
Scientific and
Clinical
Roundtable--
Streamlining
Clinical Trials
2018
------------------------------------------------------------------------
HEMATOLOGY/ONCOLOGY HOPA Early Career 05/08/2018 $60,000.00
PHARMACY ASSOCIATION Research Grant
------------------------------------------------------------------------
MEDICAL LEARNING PeerView Live at 05/09/2018 $323,020.00
INSTITUTE, INC. ASTRO 2018--The
Era of
Immunotherapy in
Stage III NSCLC
(150205115)
------------------------------------------------------------------------
TRUSTEES OF THE 2018 Breast Cancer 05/09/2018 $5,000.00
UNIVERSITY OF Clinical Case
PENNSYLVANIA/PERELMAN Series: The Year
SCHOOL OF MEDICINE AT in Review
THE UNIVERSITY OF PA
------------------------------------------------------------------------
HEART FAILURE SOCIETY 2018 HFSA Board 05/09/2018 $15,000.00
OF AMERICA INC. Certification
Review Course in
Advanced Heart
Failure and
Transplant
Cardiology
------------------------------------------------------------------------
SOCIETY FOR Immuno-Oncology 05/10/2018 $25,000.00
IMMUNOTHERAPY OF Biomarkers State
CANCER of the Art
------------------------------------------------------------------------
AMERICAN ACADEMY OF AAPA 2018 Annual 05/10/2018 $10,000.00
PHYSICIAN ASSISTANTS Conference
------------------------------------------------------------------------
HDL WORKSHOP HDL Workshop 2018 05/10/2018 $5,000.00
------------------------------------------------------------------------
LUPUS RESEARCH Lupus Research 05/10/2018 $25,000.00
ALLIANCE, INC. Alliance 2018
Annual Scientific
Conference--Forum
for Discovery
------------------------------------------------------------------------
BOARD OF REGENTS FOR Dissecting the 05/13/2018 $200,000.00
UNIVERSITY OF NEBRASKA Decision:
Documenting and
Discussing the
Clinical Practice
Patterns of
Hematologic
Oncology
------------------------------------------------------------------------
REGENTS OF THE 24th Annual San 05/13/2018 $10,000.00
UNIVERSITY OF Diego Heart
CALIFORNIA Failure Symposium
------------------------------------------------------------------------
CLEVELAND CLINIC Intensive Review 05/15/2018 $10,000.00
EDUCATIONAL FOUNDATION of Cardiology
------------------------------------------------------------------------
GORDON RESEARCH 2018 Heterocyclic 05/15/2018 $2,000.00
CONFERENCE Gordon Research
Conference
------------------------------------------------------------------------
CARDIOVASCULAR RESEARCH 30th Annual 05/16/2018 $40,000.00
FOUNDATION Transcatheter
Cardiovascular
Therapeutics
------------------------------------------------------------------------
AMERICAN ACADEMY OF 2018 Family 05/16/2018 $19,000.00
FAMILY PHYSICIANS Medicine
Experience
Interactive
Lecture titled
Acute Coronary
Syndrome
------------------------------------------------------------------------
HUNTSVILLE HOSPITAL RSS Breast Cancer 05/16/2018 $2,000.00
FOUNDATION Conference
------------------------------------------------------------------------
SOCIETY OF 2018 WCIO 05/20/2018 $15,000.00
INTERVENTIONAL
ONCOLOGY (SIO)
------------------------------------------------------------------------
UNIVERSITY OF University of 05/20/2018 $24,300.00
WASHINGTON SCHOOL OF Washington Topics
MEDICINE in Allergy and
Immunology
Teaching Series
------------------------------------------------------------------------
THE GOG FOUNDATION 10th Semi Annual 05/21/2018 $20,000.00
Meeting of NRG
Oncology
(formerly NCI
cooperatives
groups, GOG,
NSABP, RTOG)
------------------------------------------------------------------------
NORTHWESTERN UNIVERSITY 20th Annual Lynn 05/21/2018 $15,000.00
Sage Breast
Cancer Symposium
------------------------------------------------------------------------
AMERICAN ASSOCIATION Molecular Biology 05/22/2018 $15,000.00
FOR CANCER RESEARCH in Clinical
Oncology Workshop
------------------------------------------------------------------------
UNIVERSITY OF COLORADO Precision Medicine 05/23/2018 $20,000.00
in Autoimmunity
------------------------------------------------------------------------
MEDICAL LEARNING PeerView Live at 05/23/2018 $313,240.00
INSTITUTE, INC. CAP18: Molecular
Testing for EGFR
Mutations in the
Context of a
Changing
Treatment
Landscape,
Evolving Testing
Options, and New
Guidelines
(150205165)
------------------------------------------------------------------------
THE UNIVERSITY OF TEXAS 2018 Lung Cancer 05/23/2018 $15,000.00
SOUTHWESTERN MEDICAL SPORE Workshop
CENTER
------------------------------------------------------------------------
AMERICAN COLLEGE OF ACEP18, ACEP 05/23/2018 $20,000.00
EMERGENCY PHYSICIANS National
Scientific
Assembly--Cardiov
ascular Track
------------------------------------------------------------------------
HOSPITAL QUALITY Advances in the 05/23/2018 $222,127.50
FOUNDATION, LLC Management of
Acute and Chronic
Hyperkalemia: An
Update for
Emergency
Medicine,
Hospitalists and
Healthcare
Providers (MD, PA
and CRNP)
------------------------------------------------------------------------
GORDON RESEARCH 2018 Cardiac 05/23/2018 $5,000.00
CONFERENCE Regulatory
Mechanisms Gordon
Research
Conference
------------------------------------------------------------------------
CONQUER CANCER 2018 ASCO Annual 05/24/2018 $30,000.00
FOUNDATION OF THE Meeting Head and
AMERICAN SOCIETY OF Neck Cancer Track
CLINICAL ONCOLOGY
------------------------------------------------------------------------
CONQUER CANCER 2018 ASCO Pre- 05/24/2018 $10,000.00
FOUNDATION OF THE Annual Meeting
AMERICAN SOCIETY OF Seminar: New
CLINICAL ONCOLOGY Drugs in Oncology
------------------------------------------------------------------------
FEDERATION OF CLINICAL 18th Annual 05/24/2018 $10,000.00
IMMUNOLOGY SOCIETIES Meeting of the
Federation of
Clinical
Immunology
Societies
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE 2018-2019 Monthly 05/24/2018 $75,000.00
CANCER NETWORK Oncology Tumor
Boards: A
Multidisciplinary
Approach to
Individualized
Patient Care
------------------------------------------------------------------------
WINTHROP UNIVERSITY 3rd Annual NYU 05/24/2018 $3,000.00
HOSPITAL Winthrop Breast
Health Symposium
------------------------------------------------------------------------
CONQUER CANCER 2018 ASCO Annual 05/27/2018 $25,000.00
FOUNDATION OF THE Meeting Lung
AMERICAN SOCIETY OF Cancer Track
CLINICAL ONCOLOGY
------------------------------------------------------------------------
MISSOURI ACADEMY OF Updates in 05/30/2018 $3,000.00
PHYSICIANS ASSISTANTS Treating Chronic
Obstructive
Pulmonary
Disorder
------------------------------------------------------------------------
MEDICAL LEARNING Emergency Medicine 06/03/2018 $568,470.00
INSTITUTE, INC. and Immuno-
Oncology
Intersect:
Recognizing and
Managing Immune-
Related Adverse
Effects in the
Emergency
Department
(150205075)
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE NCCN 2018 Oncology 06/03/2018 $40,000.00
CANCER NETWORK, INC. Case Manager and
Medical Director
Program
------------------------------------------------------------------------
AMERICAN SOCIETY FOR ASTRO 2018 60th 06/03/2018 $50,000.00
RADIATION ONCOLOGY Annual Meeting
------------------------------------------------------------------------
UNIVERSITY OF 2018 Pittsburgh 06/04/2018 $10,000.00
PITTSBURGH International
Lung Conference--
Pulmonary
Medicine: Basic
Biology and Novel
Therapies
------------------------------------------------------------------------
AEGEAN CONFERENCES, 2nd International 06/05/2018 $5,000.00
INC. Conference on
Tissue Repair,
Regeneration, and
Fibrosis
------------------------------------------------------------------------
SYNAPTIV, INC. Atlanta Lung 06/05/2018 $20,000.00
Cancer Symposium
2018
------------------------------------------------------------------------
SOCIETY FOR NSCLC Treatment in 06/05/2018 $38,885.00
TRANSLATIONAL ONCOLOGY the Era of
Precision
Medicine: Case-
Based Insights
from ASCO 2018
------------------------------------------------------------------------
MEDICAL LEARNING Traveling Master 06/06/2018 $390,030.00
INSTITUTE, INC. Class for
Emergency
Medicine
Specialists:
Urgent Care of
Patients
Receiving Cancer
Immunotherapy:
Recognition and
Management of
Immune-Mediated
Adverse Reactions
in the ED
------------------------------------------------------------------------
PRESIDENT AND FELLOWS 33rd Annual 06/06/2018 $15,000.00
OF HARVARD COLLEGE Critical Issues
In Tumor
Microenvironment:
Angiogenesis,
Metastasis and
Immunology
------------------------------------------------------------------------
KERN ASPEN LIPID Metabolic 06/06/2018 $10,000.00
CONFERENCE Regulation of
Immunity,
Cardiometabolic
Diseases and
Cancer: New
Theraepeutic
Approaches
------------------------------------------------------------------------
SOCIETY OF TOXICOLOGIC STP 37th Annual 06/06/2018 $3,000.00
PATHOLOGY Symposium:
KEEPING IT RENAL
------------------------------------------------------------------------
WEILL CORNELL MEDICAL 2nd Annual 06/10/2018 $15,000.00
COLLEGE International
Conference
Immunotherapy
Radiotherapy
Combinations
------------------------------------------------------------------------
AMERICAN COLLEGE OF 2018 COPD Learning 06/10/2018 $5,000.00
CHEST PHYSICIANS Track
------------------------------------------------------------------------
AMERICAN COLLEGE OF 2018 06/10/2018 $27,000.00
CHEST PHYSICIANS Interdisciplinary
Program--Lung
Cancer: 2018
Update in Staging
and Management
------------------------------------------------------------------------
AMERICAN COLLEGE OF Breathing New Air 06/10/2018 $20,400.00
OSTEOPATHIC INTERNISTS into the
Treatment of COPD
and Asthma
------------------------------------------------------------------------
THE RECTOR AND VISITORS PREP2018 Symposium 06/10/2018 $5,000.00
OF THE UNIVERSITY OF
VIRGINIA
------------------------------------------------------------------------
SOCIETY FOR NEURO- 3rd CNS Anticancer 06/11/2018 $15,000.00
ONCOLOGY Drug Discovery
and Development
Conference
------------------------------------------------------------------------
ANNENBERG CENTER FOR 2018 JADPRO Live: 06/12/2018 $50,000.00
HEALTH SCIENCES AT The Annual APSHO
EISENHOWER Meeting--Sequenci
ng Therapies in
Indolent
Lymphomas
------------------------------------------------------------------------
AMERICAN COLLEGE OF ACOI 2018 Annual 06/12/2018 $33,782.00
OSTEOPATHIC INTERNISTS Convention and
Scientific
Sessions:
Addressing Unmet
Needs in Type 2
------------------------------------------------------------------------
UNIVERSITY OF Moving Toward A 06/13/2018 $59,912.00
CINCINNATI New Standard of
Care: Checkpoint
Inhibitors in
Advanced
Urothelial Cancer
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF Reducing 06/13/2018 $178,188.13
DIABETES EDUCATORS Cardiovascular
Risk in T2DM with
SGLT2 Inhibitors
and GLP1-Receptor
Antagonists:
Translating
Evidence into
Patient Outcomes
------------------------------------------------------------------------
SOCIETY FOR NEURO- 23rd Annual 06/13/2018 $75,000.00
ONCOLOGY Scientific
Meeting of the
Society for Neuro-
Oncology
------------------------------------------------------------------------
AMERICAN COLLEGE OF 2018 Lung Cancer 06/13/2018 $70,000.00
CHEST PHYSICIANS Learning Track
------------------------------------------------------------------------
UNIVERSITY OF Request for 2018 06/14/2018 $5,000.00
CALIFORNIA BERKELEY Funding for the
FOUNDATION Forum for
Collaborative
Research's
Program on HBV
------------------------------------------------------------------------
JOHNS HOPKINS OncologyConsults.c 06/15/2018 $89,885.00
UNIVERSITY SCHOOL OF om Improving
MEDICINE Outcomes in Stage
III NSCLC The
Emerging Role of
Immunotherapy in
Curbing Disease
Progression
------------------------------------------------------------------------
SOCIETY FOR Advances in Cancer 06/17/2018 $500,000.00
IMMUNOTHERAPY OF ImmunotherapyT
CANCER 2018-19
Educational
Program Series
------------------------------------------------------------------------
METABOLIC ENDOCRINE Medications' Class 06/19/2018 $100,000.00
EDUCATION FOUNDATION Effects in DM and
CVD--All you need
to know- and
never asked.
------------------------------------------------------------------------
MEDICAL LEARNING PeerView Live at 06/21/2018 $262,040.00
INSTITUTE, INC. ASCP 2018:
Navigating the
Complexities of
Molecular Testing
for EGFR
Mutations to
Guide Selection
of EGFR-Targeted
Therapy for
Patients With
Lung Cancer
(150205135)
------------------------------------------------------------------------
NORTHWESTERN UNIVERSITY Lurie Cancer 06/21/2018 $10,000.00
Center
Multidisciplinary
Head and Neck
Symposium
------------------------------------------------------------------------
CHARLOTTE AHEC 30th Annual Fall 06/25/2018 $5,000.00
Foliage Cancer
Conference
------------------------------------------------------------------------
KEYSTONE SYMPOSIA ON Integrated 06/25/2018 $6,000.00
MOLECULAR AND CELLULAR Pathways of
BIOLOGY Disease in NASH
and NAFLD
------------------------------------------------------------------------
AMERICAN SOCIETY OF ASN Kidney Week 06/25/2018 $20,000.00
NEPHROLOGY Educational
Session Support
------------------------------------------------------------------------
GORDON RESEARCH DNA Topoisomerases 06/25/2018 $10,000.00
CONFERENCE in Biology and
Medicine
------------------------------------------------------------------------
INDUSTRY NETWORKING BioHealth Capital 06/25/2018 $10,000.00
GROUP Region Workforce
Community
Engagement
------------------------------------------------------------------------
AMERICAN COLLEGE OF Unraveling the 07/01/2018 $33,782.00
OSTEOPATHIC INTERNISTS Effects of
Antihyperglycemic
Agents on
Cardiovascular
Risk
------------------------------------------------------------------------
MEDICAL LEARNING PeerView Live at 07/02/2018 $262,040.00
INSTITUTE, INC. ASCP 2018:
Advances and
Challenges in
Refining the Use
of Cancer
Immunotherapies
Through Biomarker
Testing
(150205136)
------------------------------------------------------------------------
ENDOCRINE FELLOWS Fifth Annual 07/02/2018 $250,000.00
FOUNDATION Research Forum
------------------------------------------------------------------------
SOCIETY FOR SITC 2018 Workshop 07/02/2018 $100,000.00
IMMUNOTHERAPY OF on Nutrition,
CANCER Metabolism and
the Microbiome in
Cancer Therapy
------------------------------------------------------------------------
AMERICAN SOCIETY OF The Role of 07/02/2018 $167,500.00
NEPHROLOGY Hypoxia-Inducible
Factors and
Inflammation in
the Anemia of
Kidney Disease
------------------------------------------------------------------------
AMERICAN ACADEMY OF Managing 07/04/2018 $160,000.00
PHYSICIAN ASSISTANTS Cardiovascular
Risk Factors in
Patients with
Type 2 Diabetes:
Emerging Concepts
------------------------------------------------------------------------
AMERICAN SOCIETY OF ASH Meeting on 07/04/2018 $60,000.00
HEMATOLOGY Hematologic
Malignancies
------------------------------------------------------------------------
AMERICAN HEART Scientific 07/05/2018 $20,000.00
ASSOCIATION Sessions 2018
Dedicated
Programming on
Acute Coronary
Syndrome
------------------------------------------------------------------------
BREATHE CALIFORNIA OF 2018 BREATHE 07/08/2018 $3,000.00
LOS ANGELES COUNTY California of Los
Angeles County
10th Annual COPD
Conference
------------------------------------------------------------------------
SOCIETY FOR INDUSTRIAL SIMB Annual 07/08/2018 $3,000.00
MICROBIOLOGY AND Meeting
BIOTECHNOLOGY
------------------------------------------------------------------------
JOSLIN DIABETES CENTER, 2018 AANHPI 07/08/2018 $5,000.00
INC. Diabetes
Coalition
Conference The
Future of
Population
Diabetes Research
and Advocacy:
Asian American
Native Hawaiian
Pacific Islanders
------------------------------------------------------------------------
ACS DIVISION OF Division of 07/09/2018 $2,500.00
MEDICINAL CHEMISTRY Medicinal
Chemistry Program
256th ACS
national meeting
------------------------------------------------------------------------
GORDON RESEARCH Gordon Research 07/10/2018 $10,000.00
CONFERENCES, INC. Conference Tissue
Niches and
Resident Stem
Cells in Adult
Epithelia
------------------------------------------------------------------------
NORTH AMERICAN Reducing 07/11/2018 $60,000.00
THROMBOSIS FORUM Cardiovascular
Risk in Patients
with Diabetes: A
Comprehensive Yet
Concise Patient
Focused Action
Plan
------------------------------------------------------------------------
AMERICAN ACADEMY OF 36th Annual Aspen 07/11/2018 $3,000.00
ALLERGY ASTHMA AND Allergy
IMMUNOLOGY Conference
------------------------------------------------------------------------
SOCIETY FOR SITC 33rd Annual 07/16/2018 $400,000.00
IMMUNOTHERAPY OF Meeting
CANCER
------------------------------------------------------------------------
SOCIETY FOR SITC Cancer 07/16/2018 $67,500.00
IMMUNOTHERAPY OF Immunotherapy
CANCER Sparkathon 2018--
Emerging Leaders
Igniting
Innovation
------------------------------------------------------------------------
AMERICAN COLLEGE OF Respiratory 07/16/2018 $35,000.00
CHEST PHYSICIANS Syncytial Virus
(RSV) Education
Program
------------------------------------------------------------------------
BINAYTARA FOUNDATION 6th International 07/16/2018 $5,000.00
Conference on
Advances in
Hematology and
Oncology
------------------------------------------------------------------------
SOCIETY FOR MUCOSAL Mucosal Immunology 07/16/2018 $10,000.00
IMMUNOLOGY Course and
Symposium
------------------------------------------------------------------------
BAYLOR COLLEGE OF Breast Cancer 07/17/2018 $3,000.00
MEDICINE Research and
Education program
------------------------------------------------------------------------
AMERICAN ASSOCIATION AACR Conference on 07/17/2018 $25,000.00
FOR CANCER RESEARCH The Science of
Cancer Health
Disparities
------------------------------------------------------------------------
MEDICAL LEARNING PeerView Live at 07/18/2018 $164,230.00
INSTITUTE, INC. CAP18: The
Central Role of
Biomarker Testing
in Piecing
Together the
Immuno-Oncology
Puzzle in the Era
of Precision
Medicine
(150205123)
------------------------------------------------------------------------
PENNSYLVANIA STATE PeerView inClinic, 07/18/2018 $32,330.00
UNIVERSITY Building
Innovative
Treatment Options
for Patients with
B-cell
Malignancies:
Practical
Insights on
Clinical Evidence
and Integration
Strategies
150205182
------------------------------------------------------------------------
ANNENBERG CENTER FOR 2018 JADPRO Live: 07/19/2018 $50,000.00
HEALTH SCIENCES AT The Annual APSHO
EISENHOWER Meeting--Sequenci
ng of Treatments
for Patients with
Ovarian Cancer
------------------------------------------------------------------------
AMERICAN SOCIETY OF ASH Scholar Awards 07/20/2018 $100,000.00
HEMATOLOGY
------------------------------------------------------------------------
AMERICAN SOCIETY OF 60th ASH Annual 07/20/2018 $150,000.00
HEMATOLOGY Meeting
------------------------------------------------------------------------
AMERICAN ASSOCIATION AACR Cancer Health 07/22/2018 $25,000.00
FOR CANCER RESEARCH Disparities Think
Tank
------------------------------------------------------------------------
ASSOCIATION OF Association of 07/23/2018 $10,000.00
PHYSICIAN ASSISTANTS Physician
IN ONCOLOGY Assistants in
Oncology 21st
Annual Conference
------------------------------------------------------------------------
ANNENBERG CENTER FOR 2018 JADPRO Live: 07/24/2018 $50,000.00
HEALTH SCIENCES AT The Annual APSHO
EISENHOWER Meeting--Manageme
nt of Side
Effects for
Patients with
Multi-Modality
Therapy in
Thoracic Oncology
------------------------------------------------------------------------
AMERICAN SOCIETY OF Kidney Health 07/24/2018 $30,000.00
NEPHROLOGY Initiative
------------------------------------------------------------------------
GORDON RESEARCH 2018 Gordon 07/26/2018 $2,500.00
CONFERENCES Research
Conference and
Seminar on Cell
Death
------------------------------------------------------------------------
JOHNS HOPKINS Fifth Annual 07/29/2018 $10,000.00
UNIVERSITY SCHOOL OF Metastatic Breast
MEDICINE Cancer Conference
------------------------------------------------------------------------
AMERICAN ASSOCIATION AACR Translational 07/31/2018 $25,000.00
FOR CANCER RESEARCH Cancer Research
for Basic
Scientists
Workshop
------------------------------------------------------------------------
BOARD OF REGENTS FOR Virtual 08/01/2018 $75,000.00
UNIVERSITY OF NEBRASKA Challenging Case
Clinic: B-Cell
Lymphomas
------------------------------------------------------------------------
MASSACHUSETTS GENERAL Gene Panel 08/01/2018 $100,000.00
HOSPITAL Testing: Decision
Aid
------------------------------------------------------------------------
LUNG CANCER ALLIANCE Florida and 08/01/2018 $199,200.00
Georgia Lung
Cancer Screening
Demonstration
Project
------------------------------------------------------------------------
YALE SCHOOL OF MEDICINE Severe Asthma 2018 08/01/2018 $15,000.00
Advances in
Pathogenesis and
Treatment
------------------------------------------------------------------------
UTAH CHAPTER OF THE Rockies Chapter 08/02/2018 $3,000.00
AMERICAN COLLEGE OF Meeting
CARDIOLOGY
------------------------------------------------------------------------
SOCIETY FOR Immune Escape: 08/02/2018 $25,000.00
IMMUNOTHERAPY OF Current
CANCER Understanding of
Mechanisms and
Advances in
Therapeutics
Approaches
------------------------------------------------------------------------
LUNG CANCER ALLIANCE Florida and 08/02/2018 $147,972.00
Georgia Lung
Cancer Screening
Demonstration
Project
------------------------------------------------------------------------
NATIONAL JEWISH HEALTH 23rd Annual 08/02/2018 $5,000.00
Regional Allied
Health
Conference:
Current
Perspectives in
Asthma, Allergy,
and Pulmonary
Practice
------------------------------------------------------------------------
AMERICAN ASSOCIATION FDA-AACR Workshop 08/02/2018 $25,000.00
FOR CANCER RESEARCH on Non-clinical
Models for Safety
Assessment of
Immunooncology
Products
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF Novel Treatment 08/06/2018 $35,000.00
MANAGED CARE Advances and
PHYSICIANS, INC. Approaches in the
Management of
Advanced Breast
Cancer: Expert
Strategies for
Individualized
Treatment
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF New Frontiers in 08/06/2018 $45,000.00
MANAGED CARE the Management of
PHYSICIANS, INC. Ovarian Cancer:
Exploring the
Role of PARP
Inhibitors in the
Evolving
Treatment
Paradigm
------------------------------------------------------------------------
SOCIETY FOR 2018 SITC Primer 08/07/2018 $50,000.00
IMMUNOTHERAPY OF on Tumor
CANCER Immunology and
Cancer
ImmunotherapyT
------------------------------------------------------------------------
SOCIETY FOR SITC 2018 Grant 08/07/2018 $10,000.00
IMMUNOTHERAPY OF Writing Workshop:
CANCER Grant Writing:
From Start to
Finish, and Then
Starting Again
------------------------------------------------------------------------
AMERICAS HEALTH The Diagnosis and 08/07/2018 $85,240.00
FOUNDATION Treatment of
Hereditary Breast
and Ovarian
Cancer Syndrome
in Brazil
------------------------------------------------------------------------
ADMINISTRATORS OF THE 18th Annual SSCI 08/10/2018 $55,000.00
TULANE EDUCATION FUND Nephrology Young
Investigators
Forum
------------------------------------------------------------------------
NATIONAL KIDNEY Joint Analyses of 08/10/2018 $105,895.00
FOUNDATION GFR slope and
Change in
Albuminuria by
AstraZeneca and
the CKDEPI
Collaboration
------------------------------------------------------------------------
ANNENBERG CENTER FOR JADPRO Live 2018: 08/12/2018 $25,000.00
HEALTH SCIENCES AT New Drug Updates
EISENHOWER
------------------------------------------------------------------------
UNIVERSITY OF FLORIDA Vascular Biology 08/12/2018 $7,500.00
Working Group
Global Chapter
Meeting
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE Optimizing Small 08/12/2018 $50,000.00
CANCER NETWORK, INC. Molecule
Inhibitor Therapy
for Relapsed/
Refractory B-cell
Lymphomas
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF Improving Clinical 08/12/2018 $35,000.00
MANAGED CARE and Economic
PHYSICIANS, INC. Outcomes with
Emerging
Therapies in the
Management of
Chronic
Lymphocytic
Leukemia (CLL)
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF Optimizing 08/13/2018 $35,000.00
MANAGED CARE Treatment
PHYSICIANS, INC. Strategies in the
Management of
Advanced Non-
Small Cell Lung
Cancer (NSCLC):
Individualized
Therapy for
Improved Patient
Outcomes
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE NCCN 13th Annual 08/13/2018 $75,000.00
CANCER NETWORK, INC. Congress:
Hematologic
MalignanciesTM
------------------------------------------------------------------------
AMERICAN PANCREATIC 49th Annual 08/13/2018 $25,000.00
ASSOCIATION, INC. Meeting of the
American
Pancreatic
Association
------------------------------------------------------------------------
REGENTS OF THE 16th Annual 08/14/2018 $50,000.00
UNIVERSITY OF Nephrology Young
CALIFORNIA Investigators
Forum
------------------------------------------------------------------------
PENNSYLVANIA STATE PeerView 08/15/2018 $115,000.00
UNIVERSITY COLLEGE OF MasterClass:
MEDICINE Innovative
Therapy in B-Cell
Malignancies: An
Expert Tumor
Board on Novel
Agent Classes in
CLL, FL, and MCL
(150205208)
------------------------------------------------------------------------
ASSOCIATION OF Series of AUTM 08/15/2018 $25,287.50
UNIVERSITY TECHNOLOGY 2019 Annual
MANAGERS INC. Meetings
------------------------------------------------------------------------
TRANSLATIONAL RESEARCH TRIO-US & UCLA 08/16/2018 $5,000.00
IN ONCOLOGY-US, INC. Annual Research
Conference
------------------------------------------------------------------------
DANA-FARBER CANCER IWWM10--Internatio 08/17/2018 $100,000.00
INSTITUTE nal Workshop on
Waldenstroms
macroglobulinemia
------------------------------------------------------------------------
MEDICAL LEARNING Integrating BTK 08/20/2018 $245,090.00
INSTITUTE, INC. Inhibitors into
the Management of
B cell
Malignancies: How
is Evidence
Driving Patient
Care
------------------------------------------------------------------------
MEDICAL LEARNING CRI-AACR ISS-- 08/20/2018 $324,460.00
INSTITUTE, INC. Improving Patient
Outcomes With
Cancer
Immunotherapies
and Combinations
Throughout the
Continuum of Lung
Cancer
(150205201)
------------------------------------------------------------------------
AMERICAN NEPHROLOGY ANNA Fall Meeting 08/20/2018 $42,500.00
NURSES ASSOCIATION CE Symposium
(ANNA)
------------------------------------------------------------------------
AMERICAN SOCIETY OF Risk and Treatment 08/20/2018 $125,000.00
NEPHROLOGY of Hyperkalemia
------------------------------------------------------------------------
AMERICAN ASSOCIATION AACR-AstraZeneca 08/20/2018 $276,000.00
FOR CANCER RESEARCH Lymphoma Research
Fellowships
------------------------------------------------------------------------
SOCIETY FOR 2019 SITC- 08/20/2018 $120,000.00
IMMUNOTHERAPY OF AstraZeneca
CANCER Immunotherapy in
Lung Cancer
Clinical
Fellowship
------------------------------------------------------------------------
GBMC HEALTHCARE Advances in 08/21/2018 $2,000.00
Treatment and
Management of
Ovarian Cancer
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE PARP Inhibitors in 08/21/2018 $240,000.00
CANCER NETWORK Breast Cancer:
Expert
Perspectives on
Clinical
Application and
Genetic Testing
------------------------------------------------------------------------
UT HEALTH SCIENCE 41st Annual San 08/21/2018 $75,000.00
CENTER AT SAN ANTONIO Antonio Breast
SCHOOL OF MEDICINE Cancer Symposium
OFFICE OF CME
------------------------------------------------------------------------
MEDICAL LEARNING PeerView Live--The 08/22/2018 $269,660.00
INSTITUTE, INC. Evolving Role of
Immunotherapy as
a Component of
Multi-Modal
Therapy in
Earlier Stages of
Lung Cancer:
Rationale,
Current Evidence,
Key Trials, and
Implications for
Multidisciplinary
Care (150205392)
------------------------------------------------------------------------
TEMPLE UNIVERSITY LUNG Severe 08/26/2018 $65,000.00
CENTER- OF THE Uncontrolled
COMMONWEALTH SYSTEM OF Asthma:
HIGHER EDUCATION Definition,
Management, and
Advance Therapies
------------------------------------------------------------------------
OHIO CHAPTER OF THE 28th Annual 08/26/2018 $4,500.00
AMERICAN COLLEGE OF Meeting of the
CARDIOLOGY Ohio Chapter of
the American
College of
Cardiology
------------------------------------------------------------------------
PROSTATE CANCER 25th Annual 08/27/2018 $20,000.00
FOUNDATION Scientific
Retreat
------------------------------------------------------------------------
AMERICAN UROLOGICAL Advancing the 08/27/2018 $25,000.00
ASSOCIATION EDUCATION Treatment of
AND RESEARCH, INC. Genitourinary
Cancer
------------------------------------------------------------------------
THE ICAHN SCHOOL OF The Lancet Women 08/30/2018 $50,000.00
MEDICINE AT MOUNT and
SINAI Cardiovascular
Disease
Commission
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE Behind the 08/30/2018 $25,000.00
CANCER NETWORK Guidelines:
Insights into the
Standard of Care
in Oncology 2019
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE Behind the 08/30/2018 $25,000.00
CANCER NETWORK Guidelines:
Insights into the
Standard of Care
in Oncology 2019
------------------------------------------------------------------------
THE BOARD OF TRUSTREES Stanford Review of 09/05/2018 $5,000.00
OF THE LELAND STANFORD the 60th Annual
JUNIOR UNIVERSITY ON American Society
BEHALF OF ITS SCHOOL of Hematology
OF MEDICINE Meeting 2019
------------------------------------------------------------------------
INTERNATIONAL CYTOKINE 6th Annual Meeting 09/11/2018 $20,000.00
AND INTERFERON SOCIETY of the
INC. International
Cytokine and
Interferon
Society
------------------------------------------------------------------------
CEDARS-SINAI 7th Annual New 09/11/2018 $10,000.00
Therapeutics in
Oncology: The
Road to
Personalized
Medicine
------------------------------------------------------------------------
MERCY HEALTH FOUNDATION 2019 Tri-State ASH 09/11/2018 $5,000.00
Update
------------------------------------------------------------------------
DUKE UNIVERSITY Duke Stanford CEC 09/18/2018 $20,000.00
Summit:
Scientific,
Regulatory and
Operational Best
Practices
------------------------------------------------------------------------
KENTUCKY ACADEMY OF Breast Cancer-- 09/18/2018 $3,000.00
PHYSICIAN ASSISTANTS Diagnosis and
Patient Treatment
Options
------------------------------------------------------------------------
THE UNIVERSITY OF TEXAS 13th Update on the 09/20/2018 $5,000.00
MD ANDERSON CANCER Management of
CENTER Genitourinary
Malignancies
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE NCCN 2019 Congress 09/20/2018 $50,000.00
CANCER NETWORK, INC. SeriesTM: Breast
Cancer with
Updates from the
2018 San Antonio
Breast Cancer
Symposium
------------------------------------------------------------------------
AMERICAN SOCIETY OF Hematology 2018: 09/21/2018 $100,000.00
HEMATOLOGY the ASH Education
Program Book
------------------------------------------------------------------------
PENN STATE COLLEGE OF Consensus or 09/23/2018 $75,000.00
MEDICINE Controversy?
Clinical
Investigators
Provide
Perspectives on
the Current and
Future Management
of Patients with
Prostate Cancer--
An ISS Held as a
Premium Ancillary
Educational Event
During the 2019
Genitourinary
Cancers Symposium
------------------------------------------------------------------------
HARTFORD HOSPITAL 34th Annual 09/23/2018 $5,000.00
Cardiovascular
Symposium
presented by
Hartford
HealthCare
------------------------------------------------------------------------
JOHN HOPKINS UNIVERSITY Novel Therapeutic 09/24/2018 $5,000.00
Approaches to
Allergic Diseases
------------------------------------------------------------------------
INTERNATIONAL SOCIETY Advances in 09/24/2018 $2,500.00
FOR MAGNETIC RESONANCE Multiscale Cancer
IN MEDICINE Detection: From
Micro to Macro
------------------------------------------------------------------------
PARENTERAL DRUG PDA Universe of 10/01/2018 $24,000.00
ASSOCIATION (PDA) Pre-filled
Syringes and
Injection Devices
------------------------------------------------------------------------
KEYSTONE SYMPOSIA ON 2019 Keystone 10/01/2018 $25,000.00
MOLECULAR AND CELLULAR Symposia
BIOLOGY Directors' Fund
------------------------------------------------------------------------
MEMORIAL SLOAN State-of-the-Art 10/01/2018 $5,000.00
KETTERING CANCER Gynecologic
CENTER Surgery and
Ovarian Cancer
Management
Conference 2018
------------------------------------------------------------------------
UNIVERSITY OF TEXAS Official Best of 10/02/2018 $60,000.00
HEALTH SCIENCE CENTER San Antonio
AT SAN ANTONIO Breast Cancer
Symposium
------------------------------------------------------------------------
AMERICAN ASSOCIATION AACR-AstraZeneca 10/03/2018 $276,000.00
FOR CANCER RESEARCH Immuno-Oncology
Research
Fellowships
------------------------------------------------------------------------
MEDCHI, THE MARYLAND OPTIMAL DURATION 10/8/2018 $387,213.13
STATE MEDICAL SOCIETY OF ANTIPLATELET
THERAPY AFTER
PCI: The Case for
Longerterm Dual
Antiplatelet
Therapy in
Patients with
History of MI
------------------------------------------------------------------------
AMERICAN COLLEGE OF Symposium 4: 10/08/2018 $5,000.00
TOXICOLOGY Update on RNA
Therapies:
Challenges and
Opportunities,
American College
of Toxicology
39th Annual
Meeting
------------------------------------------------------------------------
PEPTIDE THERAPEUTICS 13th Annual 10/08/2018 $15,000.00
FOUNDATION Peptide
Therapeutics
Symposium
------------------------------------------------------------------------
UNIVERSITY OF NEBRASKA 7th International 10/09/2018 $5,000.00
MEDICAL CENTER Conference on
Gram-Positive
Pathogens
------------------------------------------------------------------------
JOHNS HOPKINS 2019 Atlanta 10/09/2018 $10,000.00
UNIVERSITY SCHOOL OF Breast Cancer
MEDICINE OFFICE OF Symposium
CONTINUING MEDICAL
EDUCATION
------------------------------------------------------------------------
LYMPHOMA RESEARCH LRF Postdoctoral 10/10/2018 $105,000.00
FOUNDATION Fellowship
------------------------------------------------------------------------
THE GOG FOUNDATION INC. 11th Semi Annual 10/10/2018 $20,000.00
Meeting of NRG
Oncology
(formerly GOG,
NSABP, RTOG)
cooperative
groups
------------------------------------------------------------------------
THE UNIVERSITY OF Chicago Lung 10/10/2018 $10,000.00
CHICAGO Cancer Updates
2018
------------------------------------------------------------------------
AMERICAN ASSOCIATION OF The Liver Meeting 10/11/2018 $15,000.00
THE STUDY OF LIVER 2018 Park Benches
DISEASES Support
------------------------------------------------------------------------
NATIONAL ANIMAL The Continued 10/14/2018 $2,000.00
INTEREST ALLIANCE Importance of
Animal Research
------------------------------------------------------------------------
AMERICAN ASSOCIATION AACR-AstraZeneca 10/17/2018 $276,000.00
FOR CANCER RESEARCH Lung Cancer
Research
Fellowships
(Driver
Mutations)
------------------------------------------------------------------------
THE COOPER HEALTH Contemporary 10/22/2018 $2,500.00
SYSTEM Practices in
Cardiology
------------------------------------------------------------------------
AMERICAN SOCIETY OF 2019 Highlights of 10/22/2018 $100,000.00
HEMATOLOGY ASH in North
America
------------------------------------------------------------------------
EMORY UNIVERSITY SCHOOL 3rd National 10/24/2018 $5,000.00
OF MEDICINE Congress on the
Prevention of
Diabetes and Its
Complications
------------------------------------------------------------------------
MEMORIAL SLOAN 2018 Annual Cancer 10/24/2018 $5,000.00
KETTERING CANCER Treatment-Related
CENTER Adverse Events
Symposium
------------------------------------------------------------------------
ECOG RESEARCH AND 2018 ECOG-ACRIN 10/24/2018 $5,000.00
EDUCATION FOUNDATION, Fall Group
INC. Meeting
------------------------------------------------------------------------
AMERICAN ASSOCIATION AACR Special 10/28/2018 $25,000.00
FOR CANCER RESEARCH Conference on
Tumor Immunology
and Immunotherapy
------------------------------------------------------------------------
INTERNATIONAL Best of 19th World 10/28/2018 $20,000.00
ASSOCIATION FOR THE Conference on
STUDY OF LUNG CANCER Lung Cancer
(WCLC)
------------------------------------------------------------------------
WASHINGTON UNIVERSITY 45th Annual 10/29/2018 $3,000.00
Washington
University Kilo
Diabetes
Symposium
------------------------------------------------------------------------
VIRGINIA BIOTECHNOLOGY Medimmune 11/01/2018 $25,000.00
ASSOCIATION Chariman's Circle
Membership
------------------------------------------------------------------------
METABOLIC ENDOCRINE 16th Annual World 11/01/2018 $100,000.00
EDUCATION FOUNDATION congress on
Insulin
Resistance
Diabetes and
Cardiovascular
Disease (WCIRDC)
------------------------------------------------------------------------
MEDICAL LEARNING PeerView Live--ISS 11/01/2018 $286,060.00
INSTITUTE, INC. at the Thoracic
Cancers
Symposium, "The
Present and
Future of
Immunotherapy as
a Key Component
of the Treatment
Arsenal for
Locally Advanced
and Earlier
Stages of Lung
Cancer: State of
the Science,
Practicalities,
and Implications
for Mult
------------------------------------------------------------------------
METABOLIC ENDOCRINE CHF, the Next 11/01/2018 $150,705.00
EDUCATION FOUNDATION Frontier in
Diabetes: Do
SGLT2 Inhibitors
Have a Role in
Management and
Prevention?
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE ASCO and NCCN 2019 11/01/2018 $60,000.00
CANCER NETWORK, INC. ISS CCO: PARP
Inhibitors in
Breast Cancer:
Expert
Perspectives on
Clinical
Application and
Genetic Testing
------------------------------------------------------------------------
BOARD OF REGENTS OF THE Grand Rounds 11/01/2018 $250,000.00
UNIVERSITY OF NEBRASKA series Bioascend:
2019 Ovarian
Community Grand
Rounds:
Incorporating
Recently Approved
Targeted Agents,
Emerging
Combinations, and
Genetic Testing
for the Optimal
Management of
Patients with
Ovarian Cancer
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF Webinars: PARP 11/01/2018 $150,000.00
MANAGED CARE Inhibition and
PHYSICIANS, INC. its Evolving Use
in the Treatment
of Cancers: What
Managed Care
Needs to Know for
Improved Clinical
and Economic
Outcomes
------------------------------------------------------------------------
JOHNS HOPKINS FastForward Silver 11/05/2018 $25,000.00
UNIVERSITY Sponsorship
------------------------------------------------------------------------
ASSOCIATION FOR WOMEN Innovation and 11/05/2018 $25,000.00
IN SCIENCE Inclusion Summit
------------------------------------------------------------------------
FOUNDATION FOR THE 2018 Biomarkers 11/05/2018 $10,000.00
NATIONAL INSTITUTES OF Consortium Cancer
HEALTH Steering
Committee Annual
Scientific
Symposium
------------------------------------------------------------------------
MEDICAL LEARNING PeerView Oncology-- 11/06/2018 $324,340.00
INSTITUTE, INC. ISS at ASCO-SITC,
Seminars in
Immuno-Oncology,
``III, II, I:
Addressing Unmet
Needs in Earlier
Stages of NSCLC
With
Immunotherapy''
(150205292)
------------------------------------------------------------------------
MEDICAL LEARNING ISS at 2019 11/06/2018 $286,060.00
INSTITUTE, INC. Multidisciplinary
Thoracic Cancers
Symposium-
Refining Current
Practice and
Exploring New
Frontiers in EGFR-
Mutant NSCLC
(150205322)
------------------------------------------------------------------------
AMERICAN COLLEGE OF Comparative 11/06/2018 $2,000.00
VETERINARY Pathologists in
PATHOLOGISTS Translational
Medicine
reception at the
2018 ACVP/ASVCP
Concurrent Annual
Meeting
------------------------------------------------------------------------
AMERICAN ASSOCATION OF AAPS PharmSci 360 11/06/2018 $50,000.00
PHARMACEUTICAL
SCIENTISTS
------------------------------------------------------------------------
MAYO CLINIC ARIZONA Mayo Clinic Cancer 11/07/2018 $5,000.00
Center Thoracic
Oncology Update
State of the Art
Evaluation and
Management of
Thoracic Cancers
------------------------------------------------------------------------
SOCIETY FOR Case-based Forum: 11/07/2018 $20,000.00
CARDIOVASCULAR Individualizing
ANGIOGRAPHY AND Antithrombotic
INTERVENTIONS Therapies for PCI
FOUNDATION Patients
------------------------------------------------------------------------
UT HEALTH SAN ANTONIO 2019 Practical 11/07/2018 $5,000.00
Application of
New Agents in
Oncology
------------------------------------------------------------------------
AMERICAN SOCIETY FOR 2018 Best of ASTRO 11/07/2018 $10,000.00
RADIATION ONCOLOGY
------------------------------------------------------------------------
PERSONALIZED MEDICINE 14th Annual 11/11/2018 $25,000.00
COALITION Personalized
Medicine
Conference
------------------------------------------------------------------------
ACLAM FOUNDATION 2018 ACLAM Grants 11/11/2018 $4,000.00
------------------------------------------------------------------------
ICAHN SCHOOL OF LIVE Conference: 11/11/2018 $5,000.00
MEDICINE AT MOUNT 3rd International
SINAI Prostate Cancer
and Urologic
Oncology
Symposium
------------------------------------------------------------------------
AMERICAN SOCIETY FOR 2019 11/11/2018 $50,000.00
RADIATION ONCOLOGY Multidisciplinary
Thoracic Cancers
Symposium
------------------------------------------------------------------------
CENTER FOR MEDICAL Core Outcomes in 11/11/2018 $75,000.00
TECHNOLOGY POLICY Non-Alcoholic
Steatohepatitis
------------------------------------------------------------------------
THE UNIVERSITY OF TEXAS Medical Oncology 11/11/2018 $10,000.00
MD ANDERSON CANCER and Hematology
CENTER 2019:
Multidisciplinary
Approaches that
Improve
Coordination of
Care
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE NCCN 2019 Nursing 11/11/2018 $30,000.00
CANCER NETWORK, INC. Program:
Advancing
Oncology NursingT
at the NCCN
Annual Conference
------------------------------------------------------------------------
NORTH AMERICAN 3R'S Virtual Education 11/11/2018 $4,000.00
COLLABORATIVE Community (VEC)
Support
------------------------------------------------------------------------
COLLEGIUM 32nd Biennial 11/12/2018 $40,000.00
INTERNATIONALE Symposium of the
ALLERGOLOGICUM Collegium
Internationale
Allergologicum
------------------------------------------------------------------------
PENN STATE COLLEGE OF ISS at AACR BTK 11/12/2018 $370,330.00
MEDICINE Inhibition as an
Anti-Cancer
Strategy:
Exploring a Model
for Modern
Targeted Therapy
in Hematologic
Malignancies and
Beyond
(150205409)
------------------------------------------------------------------------
CLEVELAND CLINIC Cleveland Clinic 11/12/2018 $5,000.00
EDUCATIONAL FOUNDATION Florida's 2nd
Annual San
Antonio Breast
Cancer Symposium
SABCS Official
Review Course
------------------------------------------------------------------------
MAYO CLINIC Mayo Clinic 11/12/2018 $15,000.00
JACKSONVILLE Advances in
Breast Cancer
Management 2019
------------------------------------------------------------------------
LEUKEMIA RESEARCH Hollis Brownstein 11/13/2018 $100,000.00
FOUNDATION INC. Research Grants
Program
------------------------------------------------------------------------
MEDICAL LEARNING ISS at ONS- Taking 11/13/2018 $317,050.00
INSTITUTE, INC. Aim at B-Cell
Malignancies with
BTK Inhibitors:
Hematology/
Oncology Nurse
Perspectives and
Insights on
Clinical Care
(150205361)
------------------------------------------------------------------------
MEDSTAR HEALTH, INC. Lung Cancer 2018: 11/15/2018 $5,000.00
Progress and
Future Directions
------------------------------------------------------------------------
NATIONAL KIDNEY Research 11/18/2018 $28,800.00
FOUNDATION initiative to
extend the
analytical work
related to
evaluation of
clinical
endpoints
suitable for
early phase
trials in CKD
using the CKD-
Epidemiology
Consortium (CKD-
EPI)
------------------------------------------------------------------------
BOARD OF REGENTS OF THE 2019 Lymphoma 11/20/2018 $7,500.00
UNIVERSITY OF NEBRASKA Study Group
Hematology
Highlights A Post
ASH Review
------------------------------------------------------------------------
SCRIPPS HEALTH 39th Annual 11/20/2018 $25,000.00
Clinical
Hematology and
Oncology
Conference
------------------------------------------------------------------------
AMERICAN ACADEMY OF Pharmacists' Role 11/25/2018 $49,800.00
CME, INC. in the
Comprehensive
Care of Acute
Coronary Syndrome
------------------------------------------------------------------------
PREVENTIVE Connecting Heart 11/26/2018 $40,000.00
CARDIOVASCULAR NURSES Disease and
ASSOCIATION Diabetes-HCP Live
and On-Demand
Education
------------------------------------------------------------------------
UHS PROFESSIONAL Women's Health 11/26/2018 $5,000.00
EDUCATION PROGRAMS 2019
INC. (DBA VCU HEALTH
CONTINUING MEDICAL
EDUCATION)
------------------------------------------------------------------------
CARDIOVASCULAR RESEARCH 25th Annual 11/26/2018 $15,000.00
FOUNDATION Interventional
Cardiology
Fellows Course
------------------------------------------------------------------------
CEDARS-SINAI MEDICAL 13th Annual Women 11/28/2018 $5,000.00
CENTER and Ischemic
Heart Disease
Symposium
------------------------------------------------------------------------
SCRIPPS HEALTH Dr. Richard Schatz 11/28/2018 $5,000.00
Interventional
Cardiology Summit
------------------------------------------------------------------------
KEYSTONE SYMPOSIA ON 2019 DNA 11/29/2018 $10,000.00
MOLECULAR AND CELLULAR Replication and
BIOLOGY Genome
Instability: From
Mechanism to
Disease A1
------------------------------------------------------------------------
THE UNIVERSITY OF TEXAS 11th ANNUAL 11/29/2018 $50,000.00
MD ANDERSON CANCER HEMATOLOGIC
CENTER MALIGNANCIES
DEMYSTIFIED: A
CRITICAL
APPRAISAL OF DATA
FROM 2018
------------------------------------------------------------------------
MEDSTAR WASHINGTON Cardiovascular 11/29/2018 $25,000.00
HOSPITAL CENTER Research
Technologies,
(CRT) 2019
------------------------------------------------------------------------
CONQUER CANCER 2019 Conquer 12/02/2018 $40,000.00
FOUNDATION OF THE Cancer Foundation
AMERICAN SOCIETY OF of ASCO Merit
CLINICAL ONCOLOGY Awards
------------------------------------------------------------------------
NORTHWELL HEALTH New York City-- 12/02/2018 $20,000.00
Debates in
Interventional
Cardiology
------------------------------------------------------------------------
AMERICAN COLLEGE OF New York 12/02/2018 $10,000.00
CARDIOLOGY FOUNDATION Cardiovascular
Symposium
------------------------------------------------------------------------
INTERNATIONAL 11th Biennial 12/02/2018 $25,000.00
EOSINOPHIL SOCIETY, Symposium
INC.
------------------------------------------------------------------------
JOHNS HOPKINS Grand Rounds 12/03/2018 $150,000.00
UNIVERSITY SCHOOL OF series MCM:15
MEDICINE visting faculty
series: Novel
Targeted Agents
in the Management
of Recurrent
Advanced Ovarian
Cancer
------------------------------------------------------------------------
CONQUER CANCER 2019 Conquer 12/03/2018 $500,000.00
FOUNDATION OF THE Cancer Foundation
AMERICAN SOCIETY OF of ASCO Mission
CLINICAL ONCOLOGY Endowment
------------------------------------------------------------------------
AMERICAN ASSOCIATION AACR-AstraZeneca 12/03/2018 $276,000.00
FOR CANCER RESEARCH Breast Cancer
Research
Fellowships
------------------------------------------------------------------------
AMERICAN ASSOCIATION AACR-AstraZeneca 12/03/2018 $276,000.00
FOR CANCER RESEARCH Ovarian Cancer
Research
Fellowships (DNA
Damage Response)
------------------------------------------------------------------------
AMERICAN SOCIETY OF ASH Bridge Grant 12/03/2018 $150,000.00
HEMATOLOGY Program
------------------------------------------------------------------------
GORDON RESEARCH Gordon Research 12/03/2018 $4,000.00
CONFERENCE Conference:
Biotherapeutics
and Vaccines
Development
------------------------------------------------------------------------
INDIANA UNIVERSITY Breast Cancer Year 12/03/2018 $5,000.00
in Review
------------------------------------------------------------------------
AMERICAN ASSOCIATION AACR Annual 12/03/2018 $225,000.00
FOR CANCER RESEARCH Meeting 2019
------------------------------------------------------------------------
TEXAS HEART INSTITUTE 9th Annual Women's 12/03/2018 $3,000.00
Heart and
Vascular
Symposium: A New
Era in
Prevention,
Diagnosis and
Treatment
------------------------------------------------------------------------
AMERICAN COLLEGE OF 2018 Managing 12/03/2018 $150,000.00
CARDIOLOGY FOUNDATION Cardiovascular
Risk in Diabetes
Roundtable
------------------------------------------------------------------------
INTERNATIONAL IASLC 19th 12/03/2018 $100,000.00
ASSOCIATION FOR THE Targeted
STUDY OF LUNG CANCER Therapies for
Lung Cancer
Meeting
------------------------------------------------------------------------
NORTH CAROLINA THORACIC North Carolina 12/04/2018 $14,500.00
SOCIETY Thoracic Society
Annual Meeting
------------------------------------------------------------------------
CONQUER CANCER 2019 Conquer 12/05/2018 $287,500.00
FOUNDATION OF THE Cancer Foundation
AMERICAN SOCIETY OF of ASCO Young
CLINICAL ONCOLOGY Investigator
Award (YIA)
------------------------------------------------------------------------
CONQUER CANCER 2019 Conquer 12/05/2018 $230,000.00
FOUNDATION OF THE Cancer Foundation
AMERICAN SOCIETY OF of ASCO Career
CLINICAL ONCOLOGY Development Award
(CDA)
------------------------------------------------------------------------
FRIENDS OF CANCER 2019 Friends of 12/05/2018 $200,000.00
RESEARCH Cancer Research
Programs
------------------------------------------------------------------------
COLEGIO DE MEDICOS Innovations in 12/06/2018 $10,000.00
CIRUJANOS DE PUERTO Medicine 2018
RICO
------------------------------------------------------------------------
SOCIETY FOR SITC's Cancer 12/06/2018 $150,000.00
IMMUNOTHERAPY OF Immunotherapy
CANCER Winter School
------------------------------------------------------------------------
USF HEALTH PROFESSIONS 15th Annual 12/06/2018 $7,500.00
CONFERENCING Clinical
CORPORATION Breakthroughs and
Challenges in
Hematologic
Malignancies
------------------------------------------------------------------------
SOCIETY FOR SITC's Cancer 12/09/2018 $100,000.00
IMMUNOTHERAPY OF Immunotherapy
CANCER Guidelines
Project
------------------------------------------------------------------------
AMERICAN UROLOGICAL Next Frontiers in 12/09/2018 $10,000.00
ASSOCIATION Urology 2019: a
Biennial AUA/JUA
Symposium
------------------------------------------------------------------------
HOSPITAL QUALITY Update on NSTEMI 12/10/2018 $185,000.00
FOUNDATION Management for
Hospitalists
------------------------------------------------------------------------
CARDIOVASCULAR RESEARCH DAPT Dilemmas: A 12/12/2018 $25,000.00
FOUNDATION Case-Based
Roundtable
Tutorial
------------------------------------------------------------------------
ST. DOMINIC-JACKSON Neuroscience 12/12/2018 $5,000.00
MEMORIAL HOSPITAL Cardiovascular
Symposium
------------------------------------------------------------------------
HEART FAILURE SOCIETY 2019 Future 12/12/2018 $25,000.00
OF AMERICA INC. Leaders in Heart
Failure Symposium
------------------------------------------------------------------------
CONQUER CANCER 2019 12/13/2018 $40,000.00
FOUNDATION OF THE Gastrointestinal
AMERICAN SOCIETY OF (GI) Cancers
CLINICAL ONCOLOGY Symposium:
Multidisciplinary
Treatment,
Personalized
Care, Optimal
Outcomes
------------------------------------------------------------------------
UNIVERSITY OF NEBRASKA ONS 2019 ISS 12/13/2018 $150,000.00
MEDICAL CENTER Bioascend:
Patient and Nurse
Perspectives on
the Use of PARP
Inhibitors for
Ovarian Cancer:
Strategies for
Maximizing
Patient Outcomes
------------------------------------------------------------------------
THE UNIVERSITY OF TEXAS 2019 Oncologic 12/13/2018 $20,000.00
MD ANDERSON CANCER Emergency
CENTER Medicine
Conference
------------------------------------------------------------------------
DUKE UNIVERSITY 4th Annual Duke 12/13/2018 $3,000.00
Heart Center/DCRI
Fellows'
Presentation
Skills Course
------------------------------------------------------------------------
FEDERATION OF AMERICAN Acute Kidney 12/16/2018 $5,000.00
SOCIETIES FOR Injury: from
EXPERIMENTAL BIOLOGY beside to bench
(and back again)
------------------------------------------------------------------------
CONQUER CANCER 2019 ASCO-SITC 12/16/2018 $70,000.00
FOUNDATION OF THE Clinical Immuno-
AMERICAN SOCIETY OF Oncology
CLINICAL ONCOLOGY Symposium
------------------------------------------------------------------------
PENNYSLVANIA SOCIETY 2018 Educational 12/16/2018 $2,000.00
FOR BIOMEDICAL Programming
RESEARCH Support
------------------------------------------------------------------------
AMERICAN DIABETES Pathway to Stop 12/16/2018 $500,000.00
ASSOCIATION Diabetes
------------------------------------------------------------------------
MEDICAL LEARNING ISS at ASCO GI-- 12/17/2018 $37,500.00
INSTITUTE, INC. Breaking the
Paradox:
Expanding Options
and New Questions
in HCC Management
(150205289)
------------------------------------------------------------------------
C DAVIS AND S THOMPSON Corporate 12/17/2018 $2,000.00
DVM FOUNDATION Membership
------------------------------------------------------------------------
MIDWINTER CONFERENCE OF 58th Midwinter 12/18/2018 $5,000.00
IMMUOLOGISTS Conference of
Immunologists
------------------------------------------------------------------------
SOCIETY FOR SITC General 12/19/2018 $3,000.00
IMMUNOTHERAPY OF Society
CANCER
------------------------------------------------------------------------
NATIONAL ACADEMY OF Roundtable in 12/20/2018 $4,000.00
SCIENCES Science and
Welfare of
Laboratory Animal
Use
------------------------------------------------------------------------
MIT Koch Institute 12/23/2018 $5,000.00
2019 Immune
Engineering
Symposium
------------------------------------------------------------------------
NATIONAL KIDNEY The Role of the 01/03/2019 $100,000.00
FOUNDATION Kidney and SGLT2
in Glucose
Homeostasis and
Kidney Disease: A
Scientific
Workshop
Sponsored by the
National Kidney
Foundation
------------------------------------------------------------------------
AMERICAN ACADEMY OF AAAAI Foundation 01/03/2019 $150,000.00
ALLERGY, ASTHMA AND 2019 Lectureship
IMMUNOLOGY FOUNDATION, Series
INC.
------------------------------------------------------------------------
NATIONAL JEWISH HEALTH 15th Annual 01/03/2019 $299,856.00
Respiratory
Disease Young
Investigators'
Forum
------------------------------------------------------------------------
MEDICAL LEARNING ONS 2019 ISS 01/07/2019 $250,000.00
INSTITUTE INC. Peerview:,
``Realizing the
Promise of PARP
Inhibitors in
Solid Tumor
Therapy Guiding
Oncology Nurses
on the Advances
and Challenges''
(150205359)
------------------------------------------------------------------------
AMERICAN SOCIETY OF Kidney Health 01/14/2019 $30,000.00
NEPHROLOGY Initiative
------------------------------------------------------------------------
MELANOMA RESEARCH Melanoma Research 01/14/2019 $10,000.00
ALLIANCE Alliance 11th
Annual Scientific
Retreat
------------------------------------------------------------------------
METABOLIC ENDOCRINE 3rd Annual Heart 01/15/2019 $100,000.00
EDUCATION FOUNDATION in Diabetes (HiD)
------------------------------------------------------------------------
COLD SPRING HARBOR Integrated control 01/16/2019 $10,000.00
LABORATORY of feeding and
energy balance by
hypothalamic and
hindbrain
circuits
------------------------------------------------------------------------
NEW YORK UNIVERSITY XXIV Conference on 01/16/2019 $5,000.00
the Chemistry of
the Organic Solid
State
------------------------------------------------------------------------
NATIONAL JEWISH HEALTH 41st Annual 01/22/2019 $10,000.00
National Jewish
Health Pulmonary
and Allergy
Update
------------------------------------------------------------------------
MEDICAL LEARNING ISS at AATS 2019 01/22/2019 $302,760.00
INSTITUTE INC. Broadening
Horizons:The
Expanding Role of
Immunotherapy in
Locally Advanced
and Earlier
Stages of Lung
Cancer
(150205422)
------------------------------------------------------------------------
MEDICAL LEARNING CAP Chapter 01/24/2019 $414,050.00
INSTITUTE, INC. Meetings:
Molecular Testing
for EGFR
Mutations in the
Context of a
Changing
Treatment
Landscape,
Evolving Testing
Options, and New
Guidelines What
Do Pathologists
Need to Know and
Do? (150205307)
------------------------------------------------------------------------
LUNGEVITY FOUNDATION LUNGevity 02/03/2019 $10,000.00
Foundation
Nursing and Nurse
Navigator
Roundtable
------------------------------------------------------------------------
REGENTS OF UC SAN DIEGO 2nd Annual Multi- 02/04/2019 $25,000.00
Disciplinary Head
and Neck Cancer
Conference-
Maximizing Speech
and Swallowing
Outcomes in
Patients
Undergoing
Radiation
Therapy: We're in
This Together
------------------------------------------------------------------------
UNIVERSITY OF KANSAS 2018 San Antonio 02/06/2019 $5,000.00
MEDICAL CENTER Breast Cancer
Symposium Review
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF Individualizing 02/06/2019 $22,500.00
MANAGED CARE Treatment in the
PHYSICIANS, INC. Management of
Advanced Breast
Cancer: How Novel
Therapies Are
Changing the
Treatment
Paradigm
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF Integrating New 02/06/2019 $22,500.00
MANAGED CARE and Emerging
PHYSICIANS, INC. Targeted
Therapies into
the Treatment
Paradigm in
Ovarian Cancer:
Expert Strategies
for Improved
Patient Outcomes
------------------------------------------------------------------------
FEDERATION OF AMERICAN Mitochondrial 02/07/2019 $10,000.00
SOCIETIES FOR Biogenesis and
EXPERIMENTAL BIOLOGY Dynamics in
Health and
Disease
------------------------------------------------------------------------
NATIONAL JEWISH HEALTH Impact of 02/07/2019 $64,925.00
Educational
Program on the
Career
Development of
Physician
Scientists;
Outcomes from 14
years of the
Annual
Respiratory
Disease Young
Investigators'
Forum--An Article
for Publication
------------------------------------------------------------------------
NYU SCHOOL OF MEDICINE Asthma Airways and 02/10/2019 $20,000.00
the Environment
------------------------------------------------------------------------
MEDSTAR HEALTH Mid-Atlantic 02/10/2019 $50,000.00
Nephrology Young
Investigators
Forum
------------------------------------------------------------------------
SOCIETY OF GYNECOLOGIC SGO 2019 Annual 02/10/2019 $62,500.00
ONCOLOGY Meeting on
Women's Cancer
------------------------------------------------------------------------
COLUMBIA UNIVERSITY Heart Disease and 02/11/2019 $7,500.00
DEPARTMENT OF SURGERY Women
------------------------------------------------------------------------
AMERICAN DIABETES 66th Advanced 02/11/2019 $40,000.00
ASSOCIATION Postgraduate
Course
------------------------------------------------------------------------
NATIONAL KIDNEY Hypoxia-Inducible 02/11/2019 $100,000.00
FOUNDATION Factor
Stabilization as
an Emerging
Therapy for CKD
Related Anemia A
Scientific
Workshop
Sponsored by the
National Kidney
Foundation
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE 2019-2020 Monthly 02/13/2019 $25,000.00
CANCER NETWORK, INC. Oncology Tumor
Boards: A
Multidisciplinary
Approach to
Individualized
Patient Care
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE 2019-2020 Monthly 02/13/2019 $25,000.00
CANCER NETWORK, INC. Oncology Tumor
Boards: A
Multidisciplinary
Approach to
Individualized
Patient Care
------------------------------------------------------------------------
THE SOCIETY OF SURGICAL SSO 2019 Annual 02/14/2019 $5,000.00
ONCOLOGY Cancer Symposium
------------------------------------------------------------------------
ONCOLOGY NURSING ONS Evidence-Based 02/17/2019 $293,500.00
SOCIETY Practice
Improvement
Project:
Constipation
------------------------------------------------------------------------
THE UNIVERSITY OF 16th Annual 02/17/2019 $50,000.00
CHICAGO International
Ultmann Chicago
Lymphoma
Symposium
------------------------------------------------------------------------
HOUSTON METHODIST Heart of a Woman 02/17/2019 $3,000.00
HOSPITAL
------------------------------------------------------------------------
HEMATOLOGY/ONCOLOGY HOPA 15th Annual 02/18/2019 $35,000.00
PHARMACY ASSOCIATION Conference
------------------------------------------------------------------------
BAYLOR SCOTT AND WHITE 8th Annual 02/18/2019 $10,000.00
HEALTH Symposium on
Current
Strategies in the
Treatment of
Multiple Myeloma,
Leukemia,
Hodgkin's
Lymphoma and B-
cell Non-
Hodgkin's
Lymphoma
------------------------------------------------------------------------
USF HEALTH PROFESSIONS CARDIOVASCULAR AND 02/18/2019 $247,330.00
CONFERENCING RENAL
CORPORATION COMPLICATIONS IN
T2DM: Roles of
Physician
Assistants and
Nurse
Practitioners in
Patient
Management
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF New Horizons in 02/18/2019 $35,000.00
MANAGED CARE the Treatment and
PHYSICIANS, INC. Management of B-
Cell Non-Hodgkin
Lymphoma: A
Closer Look at
the Role of
Emerging Targeted
Therapies
------------------------------------------------------------------------
ONCOLOGY NURSING ONS 44th Annual 02/18/2019 $50,000.00
SOCIETY Congress and
Regional
Workshops
------------------------------------------------------------------------
MEDICAL LEARNING PeerView inVision: 02/19/2019 $122,250.00
INSTITUTE INC. ``New Frontiers
in Managing Heart
Failure: Are
SGLT2 Inhibitors
the Next Leap
Forward in
Optimizing
Patient Care?''
(150205455)
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE NCCN 2019 Annual 02/19/2019 $75,000.00
CANCER NETWORK, INC. Conference:
Improving the
Quality,
Effectiveness,
and Efficiency of
Cancer CareTM
------------------------------------------------------------------------
ACS DIVISION OF 257th ACS National 02/19/2019 $2,000.00
MEDICINAL CHEMISTRY Meeting
------------------------------------------------------------------------
ASSOCIATION FOR TARC Targeting DNA 02/19/2019 $125,000.00
MOLECULAR PATHOLOGY Repair Pathways:
Current and
Future
Implications of
PARP Inhibitors
------------------------------------------------------------------------
COLUMBIA UNIVERSITY Pancreas Symposium 02/20/2019 $3,000.00
DEPARTMENT OF SURGERY 2019: Current
Controversies in
Benign and
Malignant
Pancreatic
Disease
------------------------------------------------------------------------
CONQUER CANCER 2019 ASCO Annual 02/20/2019 $30,000.00
FOUNDATION OF THE Meeting Breast
AMERICAN SOCIETY OF Cancer Track
CLINICAL ONCOLOGY
------------------------------------------------------------------------
ST. JOSEPH REGIONAL Annual 02/21/2019 $1,000.00
HEALTH NETWORK Cardiovascular
Symposium
------------------------------------------------------------------------
ANNENBERG CENTER FOR Master Class for 02/21/2019 $25,000.00
HEALTH SCIENCES AT Oncologists 2019--
EISENHOWER Women's Cancer
Track
------------------------------------------------------------------------
ANNENBERG CENTER FOR Master Class for 02/21/2019 $25,000.00
HEALTH SCIENCES AT Oncologists 2019--
EISENHOWER Hematologic
Malignancies
Track
------------------------------------------------------------------------
AMERICAN COLLEGE OF Achieving 02/24/2019 $1,500.00
PHYSICIANS; PUERTO Excellence in
RICO CHAPTER Patient Care
American College
of Physician
Annual Meeting
and Internal
Medicine Update
and Board Review
------------------------------------------------------------------------
MEDICAL LEARNING PeerView Video in 02/25/2019 $95,975.00
INSTITUTE INC. Exchange
Navigating
Clinical
Challenges to
Maximize the
Benefits and
Minimize the
Risks of Cancer
Immunotherapies
(150204478)
------------------------------------------------------------------------
COLUMBIA UNIVERSITY Breast Cancer 02/26/2019 $2,000.00
DEPARTMENT OF SURGERY Management 2019
------------------------------------------------------------------------
HOLY CROSS HOSPITAL Updates in the 02/28/2019 $2,000.00
INC. Treatment of
Common Cancers:
Lung,
Gastrointestinal,
GYN, and Breast
------------------------------------------------------------------------
HOLY CROSS HOSPITAL Updates in the 02/28/2019 $2,000.00
INC. Treatment of
Common Cancers:
Lung,
Gastrointestinal,
GYN, and Breast
------------------------------------------------------------------------
NATIONAL KIDNEY Chronic 03/01/2019 $257,085.00
FOUNDATION Hyperkalemia
Management and
Outcomes in CKD
------------------------------------------------------------------------
AMERICAN ACADEMY OF Crucial 03/03/2019 $99,990.00
CME, INC. Conversations in
Nephrology: PHD
Inhibition as an
Emerging Approach
to Treating CKD
Anemia
------------------------------------------------------------------------
UNIVERSITY OF ROCHESTER 20th Annual 03/03/2019 $6,500.00
Diabetes
Conference:
Current
Treatments for
Diabetes
Complications
------------------------------------------------------------------------
CLEVELAND CLINIC Advanced 03/03/2019 $10,000.00
EDUCATIONAL FOUNDATION Diagnostic
Bronchoscopy
Workshop
------------------------------------------------------------------------
PREVENTIVE Cardiovascular 03/03/2019 $50,000.00
CARDIOVASCULAR NURSES Risk Reduction:
ASSOCIATION 25th
Cardiovascular
Nursing Symposium
Opening Session
------------------------------------------------------------------------
PENN STATE COLLEGE OF An Update on SGLT2 03/03/2019 $142,430.00
MEDICINE Inhibition for
the Prevention
and Treatment of
Kidney Disease in
Patients with
Type 2 Diabetes
(150205286)
------------------------------------------------------------------------
REGENTS OF THE Making the 03/03/2019 $200,000.00
UNIVERSITY OF Connection: A
CALIFORNIA, SAN DIEGO Comprehensive
Strategy on the
Modern Management
of Type 1 and
Type 2 Diabetes
2019
------------------------------------------------------------------------
ANNENBERG CENTER FOR From Inquiry to 03/03/2019 $50,000.00
HEALTH SCIENCES AT Investigation to
EISENHOWER Insight (I3):
Clinical Clarity
in Non-Small Cell
Lung Cancer--The
2019 JADPRO Lung
Cancer Conference
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF Advances in the 03/03/2019 $30,000.00
MANAGED CARE Management of
PHYSICIANS, INC. Acute Coronary
Syndrome (ACS):
Updated Guideline
Recommendations
for Dual
Antiplatelet
Therapy
------------------------------------------------------------------------
EASTERN VIRGINIA Turning the Tide 03/03/2019 $5,000.00
MEDICAL SCHOOL on Diabetes 2019
------------------------------------------------------------------------
AMERICAN ACADEMY OF Foundations of 03/04/2019 $200,000.00
ALLERGY ASTHMA AND Asthma Management
IMMUNOLOGY
------------------------------------------------------------------------
KEYSTONE SYMPOSIA ON 2019 Cancer 03/04/2019 $5,000.00
MOLECULAR AND CELLULAR Immunotherapy:
BIOLOGY Mechanistic
Insights to
Improve Clinical
Benefit
------------------------------------------------------------------------
METABOLIC ENDOCRINE The Primary 03/04/2019 $154,110.00
EDUCATION FOUNDATION Prevention of CHF
and CKD in
Diabetes
Satellite
Symposium
------------------------------------------------------------------------
THE CHEST FOUNDATION 2019 CHEST 03/04/2019 $35,000.00
Foundation
Research Award in
Severe Asthma
------------------------------------------------------------------------
MEDICAL LEARNING PeerView Live at 03/04/2019 $90,000.00
INSTITUTE INC. USCAP 2019,
Clinical Advances
in Cancer
Immunotherapies,
Biomarkers, and
Testing:
Implications for
Pathologists at
the Forefront of
the Emerging
Precision
Oncology Era
(150205529)
------------------------------------------------------------------------
AMERICAN NEPHROLOGY The CKD Patient 03/05/2019 $61,500.00
NURSES ASSOCIATION with
(ANNA) Hyperkalemia:
Nephrology Nurses
Evidence Based
Care
------------------------------------------------------------------------
NATIONAL ASSOCIATION OF Improving Clinical 03/05/2019 $35,000.00
MANAGED CARE and Economic
PHYSICIANS, INC. Outcomes with
Personalized
Treatment in the
Management of
Advanced Non-
Small Cell Lung
Cancer (NSCLC)
------------------------------------------------------------------------
DUKE UNIVERSITY The Southeastern 03/06/2019 $2,500.00
Fellows Research
Skills and
Training Workshop
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE NCCN 2019 Oncology 03/06/2019 $10,000.00
CANCER NETWORK, INC. Fellows Program:
New Horizons in
Quality Cancer
CareT at the NCCN
Annual Conference
------------------------------------------------------------------------
UNIVERSITY OF Allergy Fellowship 03/06/2019 $40,000.00
WASHINGTON SCHOOL OF
MEDICINE
------------------------------------------------------------------------
DREXEL MEDICINE Updates In Women's 03/06/2019 $2,000.00
Health 2109
------------------------------------------------------------------------
MEDICAL LEARNING Addressing Unmet 03/06/2019 $122,250.00
INSTITUTE INC. Needs in Managing
Anemia in Chronic
Kidney Disease: A
Closer Look at
the Clinical
Potential of HIF-
PH Inhibitors
(150205556)
------------------------------------------------------------------------
SIDNEY KIMMEL MEDICAL 7th Annual Lung 03/06/2019 $2,500.00
COLLEGE AT THOMAS Cancer Symposium
JEFFERSON UNIVERSITY
------------------------------------------------------------------------
MEDICAL LEARNING ASCO 2019 peer 03/10/2019 $30,000.00
INSTITUTE INC. view Stories from
the Pancreatic
Cancer CaseBook:
Taking the Road
to Improved
Outcomes with
Modern
Therapeutic
Concepts and
Innovative
Treatments
(150205416)
------------------------------------------------------------------------
AMERICAN COLLEGE OF GKCAS 2019 Annual 03/10/2019 $3,000.00
ALLERGY, ASTHMA AND Meeting
IMMUNOLOGY
------------------------------------------------------------------------
REGENTS OF THE 13th International 03/10/2019 $25,000.00
UNIVERSITY OF Congress on
CALIFORNIA Systemic Lupus
Erythematosus
(LUPUS 2019)
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE Support for NCCN 03/11/2019 $60,000.00
CANCER NETWORK, INC. Distribution of
the NCCN Clinical
Practice
Guidelines in
Oncology (NCCN
Guidelinesr) for
Management of
Immunotherapy-
Related
Toxicities Pocket
Guides
------------------------------------------------------------------------
AMERICAN UROLOGICAL Bladder Cancer in 03/11/2019 $15,000.00
ASSOCIATION Women:
Identifying
Research Needs to
Improve Diagnosis
and Treatment A
Johns Hopkins
Greenberg Bladder
Cancer Institute/
American
Urological
Association
Translational
Research
Collaboration
------------------------------------------------------------------------
GORDON RESEARCH 2019 Multidrug 03/11/2019 $2,500.00
CONFERENCES Efflux Systems
Gordon Research
Conference
------------------------------------------------------------------------
NATIONAL KIDNEY 14th Annual Young 03/12/2019 $50,000.00
FOUNDATION Investigator's
Forum
------------------------------------------------------------------------
AMERICAN COLLEGE OF Lung Cancer 03/12/2019 $25,000.00
CHEST PHYSICIANS Screening
Decision
Counselor and
Navigator
Training
------------------------------------------------------------------------
SOCIETY OF SIR Annual 03/13/2019 $12,500.00
INTERVENTIONAL Scientific
RADIOLOGY Meeting
------------------------------------------------------------------------
ECOG RESEARCH AND ECOG-ACRIN Spring 03/13/2019 $5,000.00
EDUCATION FOUNDATION, 2019 Group
INC. Meeting
------------------------------------------------------------------------
MEDSTAR HEALTH, INC. Kidney and Bladder 03/14/2019 $10,000.00
Cancers 2019
------------------------------------------------------------------------
AMERICAN COLLEGE OF ACC Annual 03/14/2019 $50,000.00
CARDIOLOGY FOUNDATION Scientific
Session
------------------------------------------------------------------------
SAINT FRANCIS HOSPITAL 55th Annual Robert 03/14/2019 $5,000.00
AND MEDICAL CENTER M. Jeresaty, MD
Cardiovascular
Symposium
------------------------------------------------------------------------
CARDIOVASCULAR RESEARCH A New Beat: 03/14/2019 $25,000.00
FOUNDATION Improving
Cardiovascular
Care in Women and
Minorities
------------------------------------------------------------------------
GORDON RESEARCH Therapeutically 03/14/2019 $2,500.00
CONFENCE Targeted Small
Molecules and
Enabling
Technologies in
Drug Discovery
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE Support for NCCN 03/14/2019 $25,000.00
CANCER NETWORK Distribution of
the NCCN Clinical
Practice
Guidelines in
Oncology (NCCN
Guidelinesr) for
Breast Cancer
Pocket Guides
------------------------------------------------------------------------
NORTHWELL HEALTH 1st Annual Heart 03/17/2019 $15,000.00
of Prevention
Symposium:
Updates on
Cardiovascular
Disease
Prevention With a
Focus on Women's
Heart Health
------------------------------------------------------------------------
AMERICAN THORACIC ATS 2019 Fellows 03/17/2019 $10,000.00
SOCIETY INC. Track Symposium
------------------------------------------------------------------------
SOCIETY FOR SITC's PD-L1 03/17/2019 $35,000.00
IMMUNOTHERAPY OF Resistance
CANCER Definition
Project
------------------------------------------------------------------------
CITY OF HOPE 8th Annual 03/17/2019 $10,000.00
Clinical Cancer
Genetics and
Genomics
Conference; From
Exceptionalism to
Exceptional Care:
Mainstreaming
Genomic Medicine
in Clinical
Practice
------------------------------------------------------------------------
FEDERATION OF AMERICAN 2019 FASEB SRC on 03/18/2019 $5,000.00
SOCIETIES FOR Intracellular RNA
EXPERIMENTAL BIOLOGY localization and
local translation
------------------------------------------------------------------------
FOUNDATION FOR HEART 23rd Annual Heart 03/18/2019 $10,000.00
FAILURE EDUCATION, Failure-An Update
INC. on Therapy
------------------------------------------------------------------------
PURDUE UNIVERSITY Type 2 Diabetes 03/19/2019 $75,000.00
Mellitus and
Heart Failure:
Screening,
Diagnosis, and
Management
------------------------------------------------------------------------
ASTHMA AND ALLERGY ``Wheezin, Sneezin 03/19/2019 $10,000.00
FOUNDATION OF AMERICA-- and Itchin in
ALASKA CHAPTER Alaska''
------------------------------------------------------------------------
AMERICAN RADIUM SOCIETY 101st Annual 03/19/2019 $25,000.00
Meeting
------------------------------------------------------------------------
NATIONAL KIDNEY Anemia in Chronic 03/19/2019 $257,085.00
FOUNDATION Kidney Disease:
Arming Clinicians
with Meaningful
Solutions
------------------------------------------------------------------------
AMERICAN UROLOGICAL The Evolving Role 03/19/2019 $25,000.00
ASSOCIATION EDUCATION of the Urologist
AND RESEARCH, INC. in Advanced
Castration
Dependent
Prostate Cancer:
a Guidelines and
Case-based
Discussion
------------------------------------------------------------------------
NATIONAL COMPREHENSIVE Emerging Issues in 03/20/2019 $25,000.00
CANCER NETWORK, INC. Oncology--Ensurin
g Access to, and
Delivery of,
Innovative
Therapies and
Patient Centered
Care in Oncology
------------------------------------------------------------------------
ACS DIVISION OF 257th ACS National 03/20/2019 $5,000.00
BIOCHEMICAL TECHNOLOGY Meeting and
Exposition (BIOT
Division)
------------------------------------------------------------------------
Worksheet: Grants 2014 to Mar 20 2019
Appendix B
--------------------------------------------------------------------------------------------------------------------------------------------------------
Product Q114 Q214 Q314 Q414 Q115 Q215 Q315 Q415 Q116 Q216 Q316 Q416 Q117 Q217 Q317 Q417 Q118 Q218 Q318 Q418
--------------------------------------------------------------------------------------------------------------------------------------------------------
FARXIGA X X X X X X X X
--------------------------------------------------------------------------------------------------------------------------------------------------------
ONGLYZA X X X X X X X X X X X X X X X X
--------------------------------------------------------------------------------------------------------------------------------------------------------
KOMBIGLYZE X X X X X X X X X X X X X
--------------------------------------------------------------------------------------------------------------------------------------------------------
SYMBICORT X X X X X X X X X X X X
--------------------------------------------------------------------------------------------------------------------------------------------------------
PULMICORT X X X X X X X X
FLEXHALER
--------------------------------------------------------------------------------------------------------------------------------------------------------
NEXIUM OS X X X X X X X X X X X X X X X X X X X X
--------------------------------------------------------------------------------------------------------------------------------------------------------
NEXIUM XSULE X X X X X X X X X X X X X X X X X
--------------------------------------------------------------------------------------------------------------------------------------------------------
CRESTOR X X X X X X X X X X X X X X X X X X X X
--------------------------------------------------------------------------------------------------------------------------------------------------------
BYETTA X X X X X X X X X X X X X X X X
--------------------------------------------------------------------------------------------------------------------------------------------------------
BYDUREON X X X X
--------------------------------------------------------------------------------------------------------------------------------------------------------
SYMLIN X X X X X X X X X X X X X X X X X X X X
--------------------------------------------------------------------------------------------------------------------------------------------------------
TUDORZA X X X X
--------------------------------------------------------------------------------------------------------------------------------------------------------
X URA Capped at AMP
Appendix C
------------------------------------------------------------------------
Product MPD Plan Effective Dates
------------------------------------------------------------------------
Abarca 1/1/18-12/31/19
-------------------------------------------------
Envision 1/1/18-12/31/18
-------------------------------------------------
Byetta Express Scripts 4/1/18-12/31/19
-------------------------------------------------
Health Delegates 1/1/18-12/31/18
-------------------------------------------------
MedImpact 1/1/19-12/31/19
-------------------------------------------------
SIS 1/1/18-12/31/19
------------------------------------------------------------------------
Abarca 1/1/16-12/31/16
-------------------------------------------------
Blue Shield of CA 7/1/15-12/31/16; 5/2/16-
12/31/16
-------------------------------------------------
Emblem Health 1/1/15-12/31/15; 1/1/16-
12/31/16
-------------------------------------------------
Envision 1/1/17-12/31/17
-------------------------------------------------
Express Scripts 5/2/16-12/31/19
-------------------------------------------------
Florida Health 1/1/14-12/31/16
-------------------------------------------------
Health Alliance Medical 1/1/15-12/31/16
Plan
-------------------------------------------------
Health Partners Plans 1/1/15-12/31/16
-------------------------------------------------
Healthspring 4/1/15-12/31/15
-------------------------------------------------
Highmark 7/1/14-12/31/16
-------------------------------------------------
Humana 1/1/15-12/31/16; 5/1/16-
7/30/16; 8/1/2016-P12/
31/16
-------------------------------------------------
Crestor IHA 1/1/15-12/31/16
-------------------------------------------------
MedImpact 1/1/15-5/1/16
-------------------------------------------------
Navitus 1/1/15-12/31/16
-------------------------------------------------
OptumRx 7/1/16-12/31/17
-------------------------------------------------
Perform Rx 10/1/15-12/31/16
-------------------------------------------------
Pharm. Tech 1/1/15-12/31/16
-------------------------------------------------
Prime Therapeutics 5/2/16-12/31/16
-------------------------------------------------
SelectHealth 1/1/15-12/31/16
-------------------------------------------------
SilverScript 7/1/14-12/31/16
-------------------------------------------------
SIS 1/1/15-12/31/16
-------------------------------------------------
Ventegra 1/1/15-12/31/16
-------------------------------------------------
WellCare 1/1/15-12/31/16
------------------------------------------------------------------------
Envision 1/1/17-12/31/17; 1/1/18-
12/31/18
-------------------------------------------------
Express Scripts 1/1/16-12/31/19
-------------------------------------------------
Harvard Pilgrim 1/1/14-12/31/14
-------------------------------------------------
Health Alliance Medical 1/1/14-12/31/14
Plan
-------------------------------------------------
Healthspring 4/1/15-12/31/15
-------------------------------------------------
Highmark 7/1/14-12/31/16
-------------------------------------------------
Nexium Humana 1/1/14-12/31/14; 1/1/15-
12/31/16
-------------------------------------------------
Navitus 1/1/14-1/31/14; 1/1/15-
12/31/16
-------------------------------------------------
Optum Rx 1/1/14-12/31/18
-------------------------------------------------
Prime Therapeutics 1/1/14-12/31/14
-------------------------------------------------
Scott & White 1/1/14-12/31/14
-------------------------------------------------
SilverScript 7/1/14-12/31/16
-------------------------------------------------
WellCare 1/1/15-12/31/16
------------------------------------------------------------------------
Abarca 1/1/16-12/31/16
-------------------------------------------------
Blue Shield of CA 1/1/15-12/31/16
-------------------------------------------------
Emblem Health 1/1/15-12/31/15; 1/1/16-
12/31/16
-------------------------------------------------
Envision 1/1/17-12/31/17; 1/1/18-
12/31/18
-------------------------------------------------
Health Partners Plans 1/1/15-12/31/16
-------------------------------------------------
Healthspring 4/1/15-12/31/15
-------------------------------------------------
Seroquel Highmark 7/1/14-12/31/16
-------------------------------------------------
Humana 1/1/15-12/31/16
-------------------------------------------------
IHA 1/1/15-12/31/16
-------------------------------------------------
Navitus 1/1/15-12/31/16; 1/1/17-
12/31/19
-------------------------------------------------
Perform Rx 10/1/15-12/31/16
-------------------------------------------------
Pharm. Tech 1/1/15-12/31/16; 1/1/18-
12/31/18
-------------------------------------------------
SelectHealth 1/1/17-12/31/18
-------------------------------------------------
SIS 1/1/15-12/31/16
------------------------------------------------------------------------
Health Alliance Medical 1/1/15-12/31/16
Plan
-------------------------------------------------
Seroquel XR SilverScript 7/1/14-12/31/16
-------------------------------------------------
Ventegra 1/1/15-12/31/16
-------------------------------------------------
WellCare 1/1/15-12/31/16
------------------------------------------------------------------------
AstraZeneca Pharmaceuticals LP
1800 Concord Pike
P.O. Box 15437
Wilmington DE 19850-5437
Tel 302-886-3000
www.astrazeneca-us.com
March 7, 2019
The Honorable Charles E. Grassley
Chairman
Committee on Finance
U.S. Senate
Washington, DC 20510
The Honorable Ron Wyden
Ranking Member
Committee on Finance
U.S. Senate
Washington, DC 20510
Dear Chairman Grassley and Ranking Member Wyden:
AstraZeneca's CEO Pascal Soriot appeared before your Committee on
February 26, 2019 and answered a question from Senator Cortez Masto
regarding whether AstraZeneca offers authorized generic versions of any
of its products. At that time, Mr. Soriot indicated that AstraZeneca
does not offer any authorized generics, however, following the hearing,
Mr. Soriot was informed by AstraZeneca staff that an authorized generic
is currently available in the U.S. This letter is intended to correct
the record regarding that inadvertent oversight.
AstraZeneca does, in fact, currently have one authorized generic in
the U.S. market, and it was launched more than 3 years after the first
generic of that product was introduced. Authorized generics are not a
primary area of focus for AstraZeneca and are introduced on a selective
basis. In limited circumstances, AstraZeneca has made an authorized
generic available through a third-party distributor. Because patient
prescription access and coverage may vary with respect to branded
versus generic medicines, AstraZeneca believes it is important to keep
branded options available for patients who continue to rely on them.
We appreciate your invitation to discuss important issues of
patient access and affordability with the Committee and the opportunity
to supplement Mr. Soriot's testimony. We look forward to working with
you as a constructive partner in addressing challenges in our health-
care system.
Sincerely,
Christie Bloomquist
Vice President, Corporate Affairs, North America
______
Prepared Statement of Jennifer Taubert, Executive Vice President,
Worldwide Chairman, Janssen Pharmaceuticals, Johnson & Johnson
Chairman Grassley, Ranking Member Wyden, and members of the
committee, thank you for the opportunity to be here to discuss how we
can ensure that Americans have affordable access to the best healthcare
today and to the extraordinary medical breakthroughs of tomorrow.
I am Jennifer Taubert, and I lead the Janssen Pharmaceutical
Companies of Johnson & Johnson. At Janssen, we focus on discovering and
developing transformational medicines that treat and cure some of the
world's most challenging diseases, including blood cancers like
multiple myeloma, chronic lymphocytic leukemia, and mantle cell
lymphoma; prostate cancer; HIV; schizophrenia and other serious mental
illnesses; cardiovascular diseases; rheumatoid arthritis; Crohn's
Disease and other destructive gastrointestinal illnesses; and pulmonary
hypertension, among others.
Like many of you, I know what it's like when a loved one faces a
serious disease. My own mother died of lung cancer in 1988, in her 40s.
At the time, there was very little that could be done for my mom. I've
committed my career to bringing families genuine, meaningful hope--hope
for years of life, hope for the chance to be there for a daughter's
wedding or the birth of a grandchild.
commitment to innovation
Last year Janssen invested $8.4 billion globally in research and
development,\1\ making Janssen one of the world's top research and
development (``R&D'') investors in any industry, anywhere in the
world.\2\ In fact, our investment in R&D last year was 86 percent more
than we spent on sales and marketing. This substantial investment has
enabled us to research and develop more than 100 medicine candidates
last year; and, over the past 5 years, we have introduced six
innovative products in the U.S.\3\ The nine Breakthrough Therapy
Designations we have received from the Food and Drug Administration
(``FDA'') reflect the significance of the advances we are pursuing in
areas of profound unmet medical need.\4\
---------------------------------------------------------------------------
\1\ Johnson & Johnson, FY18-Q4 Form 10-K for the Period Ending
December 31, 2018 (filed February 20, 2019).
\2\ PricewaterHouseCoopers. ``2018 Global Innovation 1000 Study.''
https://www.strategyand.
pwc.com/innovation1000.
\3\ U.S. Food and Drug Administration Center for Drug Evaluation
and Research. ``NDA and BLA Approval Reports--New Molecular Entity
(NME) Drug and New Biologic Approvals.'' https://wayback.archive-
it.org/7993/20170404174205/https://www.fda.gov/Drugs/Develop
mentApprovalProcess/HowDrugsareDevelopedandApproved/
DrugandBiologicApprovalReports/NDAandBLAApprovalReports/ucm373420.htm.
\4\ U.S. Food and Drug Administration Center for Drug Evaluation
and Research. ``CDER Breakthrough Therapy Designation Approvals.''
https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/
HowDrugsareDevelopedandApproved/DrugandBiologicApproval
Reports/NDAandBLAApprovalReports/UCM481542.pdf.
Our investment changes lives. It has helped turn HIV from a death
sentence into a manageable disease. Today, people with HIV can have a
near-normal life expectancy.\5\ And we are working on a vaccine with
the potential to eliminate HIV altogether. Our biologic therapies have
transformed the lives of patients with Inflammatory Bowel Disease by
dramatically improving their quality of life. Our therapies have
reduced major bowel surgeries for patients with Crohn's Disease by 82
percent and cut hospitalizations by 65 percent.\6\ In ulcerative
colitis patients, our therapies have reduced the need for total
colectomy by 41 percent.\7\ One of our earliest pharmaceutical
innovations enabled people with serious mental illness to be treated at
home and in their communities rather than in psychiatric institutions,
and today our innovative first and only 4-time-a-year schizophrenia
treatment is improving adherence and breaking the cycle of
hospitalization so that people with schizophrenia can live their best
lives.\8\ In the area of mental health, we are also investigating a new
medicine for people suffering from treatment-resistant depression,
which profoundly impacts these patients and their families and loved
ones as well. Our first-in-class cancer medicines have helped patients
with some of the most common and deadly types of cancer live longer, in
some cases for many additional years.\9\, \10\ In multiple
myeloma, one of our medicines has more than doubled the length of time
patients live without return of their disease.\11\ We recently launched
a new prostate cancer treatment that delays the spread of the disease
by over an additional two years versus the prior standard of
care.\12\, \13\
---------------------------------------------------------------------------
\5\ Trickey, Adam, Margaret T. May, Jorg-Janne Vehreschild, Niels
Obel, M. John Gill, Heidi M. Crane, Christoph Boesecke et al.
``Survival of HIV-positive patients starting antiretroviral therapy
between 1996 and 2013: a collaborative analysis of cohort studies.''
The Lancet HIV 4, no. 8 (2017): e349-e356. doi: 10.1016/S2352-
3018(17)30066-8.
\6\ Lichtenstein, Gary R., Songkai Yan, Mohan Bala, Marion Blank,
and Bruce E. Sands. ``Infliximab maintenance treatment reduces
hospitalizations, surgeries, and procedures in fistulizing Crohn's
disease.'' Gastroenterology 128, no. 4 (2005): 862-869. doi: 10.1053/
j.gastro.2005.01.048.
\7\ Sandborn, William J., Paul Rutgeerts, Brian G. Feagan, Walter
Reinisch, Allan Olson, Jewel Johanns, Jiandong Lu et al. ``Colectomy
rate comparison after treatment of ulcerative colitis with placebo or
infliximab.'' Gastroenterology 137, no. 4 (2009): 1250-1260.
doi:10.1053/j.gastro.2009.06.061.
\8\ INVEGA TRINZA U.S. Prescribing Information, January 2019.
http://www.janssenlabels.
com/package-insert/product-monograph/prescribing-information/
INVEGA+TRINZA-pi.pdf.
\9\ IMBRUVICA U.S. Prescribing Information, January 2019. https://
www.imbruvica.com/docs/librariesprovider7/default-document-library/
prescribing-information.pdf.
\10\ ZYTIGA U.S. Prescribing Information, April 2019. http://
www.janssenlabels.com/package-insert/product-monograph/prescribing-
information/ZYTIGA-pi.pdf.
\11\ Bahlis, Nizar, Meletios A. Dimopoulos, Darrell J. White, Lotfi
Benboubker, Gordon Cook, Merav Leiba, P. Joy Ho et al. ``Three-Year
Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide
and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd)
Alone in Relapsed or Refractory Multiple Myeloma (RRMM).'' (2018):
1996-1996. doi: 10.1182/blood-2018-99-112697.
\12\ DARZALEX U.S. Prescribing Information, June 2018. http://
www.janssenlabels.com/package-insert/product-monograph/prescribing-
information/DARZALEX-pi.pdf.
\13\ ERLEADA U.S. Prescribing Information, February 2018. http://
www.janssenlabels.com/package-insert/product-monograph/prescribing-
information/ERLEADA-pi.pdf.
This progress against some of the world's most challenging diseases
is heartening but hard-won. Continued advancement will require
perseverance and dedication. For example, we remain very committed to
continuing research exploring new approaches and investigational
medicines to prevent Alzheimer's dementia, which starts many years
before the full onset of disease. In fact, we have invested billions of
dollars in this area, and despite some significant projects that were
halted because of lack of efficacy or a newly identified imbalance in
benefit-risk, we continue to invest with the goal of conquering this
---------------------------------------------------------------------------
major public health challenge in our lifetimes.
Defeating Alzheimer's would not only change the lives of millions
of patients and their families, it would dramatically change the
economic burden of the disease. According to one analysis, if a new
treatment that delays the onset of Alzheimer's by just five years were
approved by 2025, the U.S. would save an estimated $367 billion each
year by 2050.\14\
---------------------------------------------------------------------------
\14\ Alzheimer's Association. ``Changing the Trajectory of
Alzheimer's Disease: How a Treatment by 2025 Saves Lives and Dollars.''
May 2015. https://www.alz.org/media/Documents/changing-the-trajectory-
r.pdf.
In fact, across a wide range of conditions, prescription medicines
play a key role in keeping people well and productive and preventing
the need for costly procedures and hospitalizations. For example, since
the introduction of antiretroviral therapies, we've seen up to a
$402,000 lifetime cost savings for each HIV patient diagnosed at an
early stage.\15\ Cardiovascular medicines have led to a 27 percent
reduction in costs for hospitalizations and procedures.\16\ In fact,
the U.S. health-care system could save $213 billion annually with the
correct use of prescription medications.\17\, \18\
---------------------------------------------------------------------------
\15\ Farnham, Paul G., Chaitra Gopalappa, Stephanie L. Sansom,
Angela B. Hutchinson, John T. Brooks, Paul J. Weidle, Vincent C.
Marconi, and David Rimland. ``Updates of Lifetime Costs of Care and
Quality-of-Life Estimates for HIV-Infected Persons in the United
States: Late Versus Early Diagnosis and Entry Into Care.'' Journal of
Acquired Immune Deficiency Syndromes 64, no. 2 (2013): 183-189. doi:
10.1097/QAI.0b013e3182973966.
\16\ Gotto, Antonio M., Stephen J. Boccuzzi, John R. Cook, Charles
M. Alexander, James B. Roehm, Gregg S. Meyer, Michael Clearfield,
Stephen Weis, and Edwin Whitney. ``Effect of Lovastatin on
Cardiovascular Resource Utilization and Costs in The Air Force/Texas
Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).'' The
American Journal of Cardiology 86, no. 11 (2000): 1176-181.
doi:10.1016/s0002-9149(00)01198-x.
\17\ IMS Institute for Healthcare Informatics, ``Avoidable Costs in
U.S. Healthcare'' (June 2013). http://offers.premierinc.com/rs/381-NBB-
525/images/Avoidable_Costs_in%20_US_Healthcare-
IHII_AvoidableCosts_2013%5B1%5D.pdf.
\18\ Roebuck, M.C., J.N. Liberman, M. Gemmill-Toyama, and T.A.
Brennan. ``Medication Adherence Leads to Lower Health Care Use and
Costs Despite Increased Drug Spending.'' Health Affairs 30, no. 1
(2011): 91-99. doi:10.1377/hlthaff.2009.1087.
But medicines can't make a difference if patients who need them
can't get them. We understand concerns about the cost of health care.
Although prescription medicines represent only 14 percent of overall
health-care spend--a figure that has remained relatively steady for the
past decade and is projected to remain so into the future \19\--and 90
percent of prescriptions are filled with generics,\20\ managing the
cost of medicines, particularly what patients pay at the pharmacy
counter, is important.
---------------------------------------------------------------------------
\19\ Altarum Institute. ``A 10-Year Projection of the Prescription
Drug Share of National Health Expenditures, Including Nonretail.''
Report. August 2015. http://altarum.org/sites/default/files/uploaded-
publication-files/Non-Retail%20Rx%20Forecast%20Data%20Brief%2010-14-14.
pdf.
\20\ IQVIA. ``2017 Medicine Use and Spending in the U.S. a Review
of 2017 and Outlook to 2022.'' April 2018. https://www.iqvia.com/-/
media/iqvia/pdfs/institute-reports/medicine-use-and-spending-in-the-us-
a-review-of-2017-and-outlook-to-2022.pdf.
---------------------------------------------------------------------------
our approach to pricing
At Janssen, we take a responsible approach to pricing that
recognizes our dual responsibility to patients today and patients
tomorrow. Patients today need access to our medicines. Patients
tomorrow count on us to deliver cures and treatments for the most
challenging, intractable diseases. When we set an initial price for our
medicines, we balance:
Value to patients, the health-care system, and society. We
consider how the medicine will improve patient health and
assess its potential to reduce other costs--surgeries, hospital
stays, or long-term care, for example--and the improvement the
medicine represents over the existing standard of care.
Affordable access to medicines for people who need them. We
want to ensure appropriate insurance coverage so that patients
who are prescribed our medicines can get them.
Ability to develop future groundbreaking cures and
treatments. We have an obligation to ensure we have the
resources necessary to invest in future R&D to address serious
unmet medical needs.
The list price of a medicine is a starting point that is ultimately
reduced by the substantial discounts, rebates, and fees we provide to
insurance companies, pharmacy benefit managers (``PBMs''), government
programs, and others. We pay required discounts to government programs,
and we negotiate with private payers so that they will cover our
medicines and make them available to patients with lower out-of-pocket
cost. In 2018, we provided approximately $21 billion in discounts and
rebates on our medicines--an overall reduction from list price of 47
percent. For some of our medicines, and for some of our customers, we
pay discounts, rebates, and fees totaling well over 50 percent of our
list price--so middlemen in the supply chain in those cases realize a
majority of the revenue.
All told, while our 2018 aggregate list price increase was 6.3
percent,\21\ for the second year in a row discounts and rebates
outweighed that increase, and aggregate net price--in other words, the
real price--decreased by 6.8 percent.\22\
---------------------------------------------------------------------------
\21\ Represents the year-over-year change in the average list
price, or wholesale acquisition cost (``WAC'').
\22\ Represents the year-over-year change in the average net price,
which is WAC less rebates, discounts, and returns.
trends in pharmaceutical spending
The fact is that across the industry net prices for branded
medicines have increased well below the rate of medical inflation in
recent years.\23\, \24\, \25\, \26\ In
2017, the total expenditure on pharmaceuticals in the U.S. grew by only
0.4 percent, compared to a 3.9 percent increase in overall health
spending and a 4.6 percent increase in hospital spending.\27\
---------------------------------------------------------------------------
\23\ IQVIA INSTITUTE for Human Data Science. ``The Global Use of
Medicine in 2019 and Outlook to 2023.'' Report. January 2019. https://
www.iqvia.com/-/media/iqvia/pdfs/institute-reports/the-global-use-of-
medicine-in-2019-and-outlook-to-2023.pdf.
\24\ U.S. Department of Labor. Bureau of Labor Statistics.
``Consumer Price Index--December 2016.'' News release, January 18,
2017. https://www.bls.gov/news.release/archives/cpi_01182017.pdf.
\25\ U.S. Department of Labor. Bureau of Labor Statistics.
``Consumer Price Index--December 2017.'' News release, January 12,
2018. https://www.bls.gov/news.release/archives/cpi_01122018.pdf.
\26\ U.S. Department of Labor. Bureau of Labor Statistics.
``Consumer Price Index--December 2018.'' News release, January 11,
2019. https://www.bls.gov/news.release/pdf/cpi.pdf.
\27\ U.S. Centers for Medicare and Medicaid Services. ``NHE Fact
Sheet.'' December 6, 2017. https://www.cms.gov/research-statistics-
data-and-systems/statistics-trends-and-reports/national
healthexpenddata/nhe-fact-sheet.html.
Unfortunately, these trends are not reflected in many patients'
experiences at the doctor's office or pharmacy counter. In fact, total
patient out-of-pocket spending on medicines grew by 54 percent from
2006 to 2016.\28\
---------------------------------------------------------------------------
\28\ Claxton, Gary, Larry Levitt, Matthew Rae, and Bradley Sawyer.
``Increases in Cost-sharing Payments Continue to Outpace Wage Growth.''
Peterson-Kaiser Health System Tracker. June 15, 2018. https://
www.healthsystemtracker.org/brief/increases-in-cost-sharing-payments-
have-far-outpaced-wage-growth/.
One reason patient out-of-pocket spending has grown is due to
changes in how health insurance is designed and, specifically, how
pharmaceutical benefits are managed. As one recent analysis shows,
patients are required to pay 13 percent of overall pharmaceutical costs
versus only 3 percent of hospital costs--even though medicine can help
keep patients out of the hospital.\29\
---------------------------------------------------------------------------
\29\ PhRMA. ``PhRMA Chart Packs: Biopharmaceuticals in
Perspective.'' Report. 2018. https://www.phrma.org/report/chart-pack-
biopharmaceuticals-in-perspective-summer-2018.
The reality is that our health coverage system simply wasn't built
in anticipation of medicines that treat diseases previously only
treated with surgeries, hospitalizations and other complex
interventions. Medicines today can extend and transform life for people
facing very challenging, often relatively rare, diseases. It's critical
that we work together to ensure that today's medicines are more
accessible and affordable for patients while at the same time
preserving the incredible ecosystem of medical innovation that has
delivered so much and promises so much more.
solutions to address the challenges we face
Above all, we need an American solution to this American challenge.
We must maintain the hallmarks that make American health care
remarkable: access to innovative therapies, personal choice, and
doctors and patients making decisions based on what is right for each
individual.
At Janssen, we are committed to being part of the solution.
We believe open dialogue and partnership is essential to addressing
the challenges in our health-care system. That's why in 2016 we began
issuing an annual Janssen U.S. Transparency Report, sharing information
about how we invest our resources, price our medicines, and help people
who need Janssen medicines get access to them. Just recently, we
expanded our commitment to transparency, announcing plans to
voluntarily include list price and potential patient out-of-pocket
costs in our pharmaceutical direct-to-consumer TV advertising, starting
with our most frequently prescribed medicine.
These more recent steps build on a legacy of commitment to
transparency at Janssen. For example, we believe that making clinical
trial data available promotes the understanding of disease, expands the
knowledge needed to develop new treatments, and generates new insights
and more complete evidence that lead to better health-care decisions
for patients. In a first-of-its-kind agreement with the Yale University
School of Medicine, we share clinical trial data through the Yale Open
Data Access (YODA) Project. Since 2014, YODA Project has served as an
independent review panel, evaluating researchers' requests for access
to participant-level trial data and research reports, which provide
extensive details about the methods and results of a clinical trial.
Researchers can use these clinical trial data in their own research to
increase medical knowledge and improve public health.
In the same spirit of open dialogue and partnership, we have
consistently brought forward ideas and perspectives to both Congress
and the administration, with the goal of building on what is working in
our healthcare system while fixing what is not:
part d out-of-pocket cap
While Medicare Part D is working for many seniors and has been
effective in containing costs, we believe an out-of-pocket cap in
Medicare Part D is a needed protection. Without a cap, Medicare
beneficiaries face unlimited out-of-pocket expenses, and, as research
shows, high out-of-pocket costs reduce patient adherence to prescribed
treatments and make them more likely to abandon their prescriptions.
Poor patient outcomes related to lack of adherence or abandonment of
prescribed treatments can lead to an increase in overall health-care
costs.
Individual and group health insurance policies are already required
to have out-of-pocket caps. We believe that Medicare, which serves some
of the sickest and most vulnerable patients and is essential to the
health of American seniors, should also have that protection. We have
been working on policy approaches that would make it possible to
implement an out-of-pocket cap in a fiscally responsible way without
creating new costs or access barriers for patients. As Congress
considers any changes to Part D, we look forward to discussing these
ideas in more depth.
medicare part b reform
We believe policy solutions in Medicare Part B should meet three
objectives: (1) reduce cost and spending; (2) increase competition; and
(3) remove incentives to prescribe higher cost therapies without
causing significant disruption to physicians or patient care.
As changes to Part B are contemplated, it is important to remember
that Medicare currently benefits from aggressive negotiations in the
commercial market through the Average Sales Price (ASP) mechanism. Any
reform should therefore leverage the benefits of the existing system.
In our response to the Health and Human Services advance notice of
proposed rulemaking regarding Part B, we proposed an option that would
allow Medicare to continue to achieve the negotiated cost savings of
the free market, reduce Part B acquisition cost under the ASP-based
model, and reimburse all stakeholders on a fee-based mechanism aligned
with the services that they provide. Our proposal aims to eliminate
incentives for selecting higher list price drugs while maintaining
current Part B patient access to appropriate clinical care.
rebate reform
We support reforms to the rebate system that restructure incentives
to ensure patients benefit from a competitive marketplace and see lower
out-of-pocket costs. In 2017, the pharmaceutical industry paid $150
billion in negotiated rebates and discounts.\30\ As we have noted, too
often these rebates and discounts are not shared with patients, leaving
the sickest patients paying higher out-of-pocket costs. We anticipate
eliminating rebates could result in lower list prices, provided these
rebates and discounts are not replaced with equally high fees or other
payments demanded by middlemen. We also strongly advocate that
beneficiary copays be based on net price.
---------------------------------------------------------------------------
\30\ Adam J. Fein. ``The Gross-to-Net Bubble Topped $150 Billion in
2017.'' Drug Channels (April 24, 2018) (citing IQVIA Institute for
Human Data Science. ``Medicines Use and Spending in the U.S.: A Review
of 2017 and Outlook to 2022.'' Report. April 2018. https://
www.iqvia.com/institute/reports/medicine-use-and-spending-in-the-us-
review-of-2017-outlook-to-2022.
Altering the current rebate structure would be a major change to
the entire pharmaceutical supply chain. It would need to be done
thoughtfully and carefully to avoid disruption for patients. We look
forward to commenting on the administration's proposed rule in this
area.
value-based care
Our current system rewards the quantity or volume of care
delivered, regardless of the results of that care. Consequently,
sometimes we spend money on treatments, diagnostic procedures, and
surgeries that provide limited value or may not even be needed, driving
up health-care costs without actually improving patient health.
At Janssen, we're working with partners throughout the health-care
system to encourage more results-based health-care approaches. While we
have negotiated several value-based contracts, current policy often
limits our ability to implement creative solutions. To address policy
barriers, we support the following measures:
Establish safe harbors in the Federal Anti-Kickback Statute
that better enable manufacturers to partner with payors and
share risk; and,
Clarify Medicaid pricing treatment, including existing
Medicaid best price requirements that inhibit companies from
offering arrangements that may yield lower price in some
circumstances.
promoting competition on a level playing field
Biosimilars--near copies of biologic medicines--have the potential
to increase competition and bring down costs, which is why Janssen has
long supported a
patient-focused, science-based regulatory framework for biosimilars.
Some stakeholders have called for government to drive uptake by
creating further incentives for biosimilars. But policies designed to
increase share for biosimilar manufacturers would distort the
competitive environment and risk limiting the savings biosimilars
deliver to patients and taxpayers. We saw this risk realized most
recently in the 340B Drug Discount Program, where policy designed to
encourage the use of biosimilars had the unfortunate effect of
increasing cost to patients, including low-income patients who can
least afford it, and to taxpayers.\31\
---------------------------------------------------------------------------
\31\ Center for Biosimilars. ``340B Changes: What Biosimilar
Manufacturers Need to Know.'' Feb. 19, 2018. https://
www.centerforbiosimilars.com/contributor/amanda-forys/2018/02/340b-
changes-what-biosimilar-manufacturers-need-to-know.
When it comes to making more biosimilars available for patients and
their physicians, competition, not government intervention, is the best
approach. And that approach is working. Not only is competition driving
prices down for both innovator biologics and biosimilars, the
biosimilars pipeline is strong. Competition on a level playing field
will keep it that way.
340b policy
At Janssen, we recognize that the 340B Drug Discount Program plays
an important role in the healthcare system, helping to ensure that low-
income, needy patients have appropriate access to medicine. However,
congressional oversight, proper implementation, and equitable
application of the program are essential to ensuring the 340B program
is helping those it was designed to help.
Under the 340B Drug Discount Program, we are required to provide
significant discounts on certain medicines purchased by 340B covered
entities (comprised of specific categories of hospitals, clinics, and
health centers that meet Federal eligibility requirements). Growth in
the 340B program has been well documented, and Janssen has experienced
significant growth in this highly discounted channel as well. Although
the program was intended to benefit needy patients, the facilities
themselves receive the discounts. There is no requirement that 340B
covered hospitals pass along those discounts to patients. 340B covered
hospitals can therefore access 340B pricing on outpatient drugs for all
of their patients, including wealthy and well-insured patients.
A more direct and accountable link between the provision of the
discount and patient access is needed. We believe the benefits of the
program should flow more directly and transparently to needy patients.
We support efforts to strengthen the 340B program through greater
transparency and increased clarity and accountability for all
stakeholders. These goals can be achieved through the establishment of
clear, reasonable and auditable rules including a clear definition of
``patient'' as well as hospital eligibility criteria.
conclusion
We are here today at a moment of incredible hope, on the verge of
extraordinary progress that could change our lives and the lives of our
children and grandchildren. We have the opportunity to get this right
for Americans today and for future generations. At Janssen, we are
committed to bringing that promise to life with transformational
medical innovation.
______
Questions Submitted for the Record to Jennifer Taubert
Questions Submitted by Hon. Chuck Grassley
spending on advertising/marketing vs. research and development
Question. The Department of Health and Human Services' proposed
rule, ``Fraud and Abuse; Removal of Safe Harbor Protection for Rebates
Involving Prescription Pharmaceuticals and Creation of New Safe Harbor
Protection for Certain Point-of-Sale Reductions in Price on
Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager
Service Fees,'' envisions that drug manufacturers will offer up-front
discounts rather than the back-end rebates that are now commonly
provided. Some observers argue that a 1996 court case called into
question whether manufacturers could offer up-front discounts,
resulting in today's rebate-based system. I've heard differing opinions
as to whether the issues related to the initial court case are still
relevant. If the HHS proposed rule is finalized, can you assure the
committee that your company will offer up-front discounts? If not, why?
Please describe how you expect your company to respond to the HHS
proposed rule to eliminate safe harbor protection for back-end rebates
in Medicare Part D that is referenced above if it is finalized.
Assuming you are confident that antitrust laws do not prevent your
company from offering up-front discounts, specifically, do you envision
that your company lowers the list price of a drug to the current after-
rebate net price, offer discounts equal to the current rebate amount,
or a combination of both?
Answer. The 1996 antitrust law case cited, in our assessment,
should not limit the ability to move from rebates to other types of
discounts. Depending on whether elimination of rebates applies to the
entire market or only to those related to Federal health plans and
assuming rebates are not replaced by high fees or other costs that
offset the amount saved, we expect to lower list prices or offer
discounts for pass-through at the point of sale. In either case, we
would need to renegotiate our agreements with customers.
The degree to which we can convert current rebates to list price
reductions or point-of-sale discounts will depend upon the details of
the final regulation and the reactions of other stakeholders in the
supply chain. We are concerned that PBMs may seek to replace rebate
revenue with new and increasing fees or may seek to shift costs among
supply chain participants through service fees.
Question. To what extent are the back-end rebates your company
currently offers contingent on the amount of market share realized for
your drugs as a result of Part D plan formulary placement and other
techniques?
Answer. Janssen does not currently offer rebates contingent on the
amount of market share for our drugs as a result of Medicare Part D
formulary placement. In other words, Janssen's current Medicare Part D
rebate agreements do not contain any market share performance
requirement.
Question. Please provide a breakdown of percentage of sales that go
to each payer (including Medicare, Medicaid, private pay, other) and a
similar percentage by volume of the total number of each drug compared
to total volume. Please provide this data for the most recent year
available.
Answer. Potentially responsive information may not be maintained by
the company in the ordinary course of business. As such, an answer to
this question is not readily available.
Question. Do your companies hire consultants or lobbyists to
promote products at State Medicaid Pharmacy and Therapeutics
Committees? To whom do you disclose advocacy activities surrounding
State Medicaid programs, if at all?
Answer. Janssen does not hire external lobbyists or consultants for
the purpose of promoting products at State Medicaid Pharmacy and
Therapeutics Committees. We have internal employees who register as
lobbyists and provide information about Janssen products to State
Medicaid Pharmacy and Therapeutics Committee personnel. We comply with
varied State laws regarding advocacy, including disclosure
requirements.
Question. Please describe how the costs of patient assistance
programs are accounted for within your company's financial statements.
Please also describe the types of market information, such as
prescribing and use patterns, that your company collects from different
types of patient assistance programs and patient hub services.
Answer. Our patient assistance programs include both commercial
copay support programs and charitable donations, which include both
financial contributions and pharmaceutical products.
With respect to Janssen's copay card programs, the value of patient
copayment support is recorded as a reduction in sales revenue. The
administrative costs associated with implementing the copayment
programs are captured in selling, marketing and administrative expenses
on Johnson & Johnson's SEC Form 10K.
With respect to the company's charitable free product programs,
Janssen donates prescription products to the Johnson & Johnson Patient
Assistance Foundation, Inc. (``JJPAF''), a 501(c)(3) organization with
an independent board and decision-making. Janssen also makes financial
contributions to JJPAF and other independent 501(c)(3) organizations.
These product and financial donations are recorded as charitable
deductions.
With respect to our commercial patient assistance programs, we
collect information that is needed to support administering the
program, helping patients get access to the medically appropriate
treatment they have selected, and identifying and addressing barriers
to patient access.
Question. Please provide a list of all contributions since January
1, 2014, that your company has made to any tax-exempt organizations
working on issues related to drugs within your product lines, including
but not limited to patient groups, disease awareness groups, medical or
professional societies, universities or hospitals, industry
associations or leagues. For each contribution, please provide the name
of the organization that received the donation, the date the donation
was made, the amount of the donation, and a description of the purpose
of the contribution (i.e., was the contribution for the general fund, a
specific purpose to a specific program, or continuing medical
education). Please also note whether the contribution was unrestricted
or restricted; if it was restricted, please explain all restrictions.
Finally, if your company maintains a foundation or other separate
charitable arm, please provide the name of all such entities, and list
all donations made from that entity or entities.
Answer. Through our Janssen charitable giving, we're proud to make
a difference for patients and for the communities where we live and
work. Janssen provides charitable donations through an established
application review and approval process designed to ensure that the
recipient of any contribution (i) is a valid 501(c)(3) charitable
organization; (ii) has an established, good reputation; and (iii) is
not on a Federal exclusion list (if the non-profit is a provider or
government contractor). In addition, the charitable contributions
review process is designed to review requests for donations to make
sure that they are not made for the purpose of inducing the use or
recommending the use of any J&J product.
Janssen releases a contributions transparency report
(``Contributions Report'') that details all of the charitable donations
from the company for the prior year. Please see the attached link for
the most recently posted Contributions Report, https://www.janssen.com/
us/transparency/educational-charitable-contribution-disclosures.
With respect to the Contributions Report, please note:
In keeping with our donor agreements and applicable
regulatory guidance, financial donations made to independent
charitable foundations that assist patients who are
underinsured and in need of financial assistance with
treatment-related expenses are disclosed in aggregate on the
Janssen Contributions Report.
Charitable contributions made by recently acquired company
Actelion are not included in our report. In future years, these
donations will be included in the Contributions Report.
Donations in the amount of $270,000 have been made annually
to support the mission of PhRMA Foundation. These donations
were made on April 29, 2014; January 21, 2015; December 21,
2015; September 11, 2017; June 1, 2018; and January 15, 2019.
Contribution Reports for years 2014 through 2017 are attached.
Most donation requests seek support for a specific program or
initiative. If approved, the use of the contributed funds will be
restricted to the purpose set forth in the application request. The
Contribution Report details this purpose in the project title section.
In addition, the company's standard donation agreement used for
most contributions stipulates that funds should not be used to (i)
educate, train or support meals, salary, travel, consulting fees or any
other reimbursement to U.S.-licensed physicians; or (ii) fund services
for which the organization receives government reimbursement under a
fee-for-service model.
Janssen makes financial contributions and prescription product
donations to the Johnson & Johnson Patient Assistance Foundation, Inc.
(``JJPAF''), a 501(c)(3) organization with an independent board and
decision-making. The JJPAF provides free products directly to patients
who meet certain income requirements and who do not have insurance
coverage. In limited circumstances, JJPAF may work with other non-
profit entities to distribute products to patients in need. JJPAF does
not advise Janssen of the specific recipients of its donations.
In 2018, Janssen donated approximately $1 billion in free product
and financial support to the JJPAF, enabling it to provide medicines at
no cost to approximately 76,000 patients.
The Johnson & Johnson Foundation (``JJF'') is a private non-profit
501(c)(3) organization, founded in 1953. Solely funded by the Johnson &
Johnson Family of Companies, the Foundation is responsible for managing
the Corporation's Global Community Impact (``GCI'') programs and
activities across the globe. Donations made by this foundation are
available publicly through the IRS Form 990 it submits each year.
Question. Pay-for-delay agreements cost consumers and taxpayers
billions in higher drug costs every year. The FTC has gone after drug
companies that enter into these settlements where the brand pays the
generic company to keep its lower cost alternative off the market. I'm
the lead Republican sponsor of S. 64, the Preserve Access to Affordable
Generics and Biosimilars Act, which would help put an end to these
deals.
Do you agree that these pay-off agreements keep drug costs high for
patients because they delay competition?
Has your company ever entered into these kinds of settlements with
a generic company?
Do you support the pay for delay bill?
Answer. J&J has not entered into patent settlement agreements that
require payment of money to a generic manufacturer. Since J&J has not
entered into agreements of this type, we do not have direct experience
with their competitive impacts. The current legal framework--FTC
oversight and judicial review on a case-by-case basis--is intended to
identify any patent settlement that is anti-competitive. It is
important to note that not all settlement agreements would result in a
delay in competition; for example, some agreements of this type might
facilitate generic entry prior to patent expiry.
Although we believe that the current legal framework is sufficient
to ensure that patent settlements are not anti-competitive, we would
not oppose pay-for-delay legislation, provided that such legislation
clearly, and in a manner consistent with current case law, defines the
specific features of settlement agreements within its scope, does not
hinder the ability of parties to utilize settlement agreements to
efficiently settle patent disputes, and allows for an assessment of the
competitive impacts of individual settlement agreements on a case-by-
case basis.
rebate traps/walls
Question. I'm increasingly concerned about the effect of so-called
``rebate traps'' or ``rebate walls'' on patients' access to quality,
lower cost medicine. I understand there is ongoing litigation
challenging these practices as anti-competitive.
Does your company engage in the bundling of rebates over multiple
products? If so, why? And what benefit does the consumer gain from
that?
Answer. Like other companies with broad portfolios of medicines
that are highly valued by payers, health-care providers, and patients,
Janssen offers incremental value when customers make a broader range of
our medicines available to patients. Similar programs are common in the
pharmaceutical and other industries. These programs provide an
incentive for the customer to utilize our products and can lower costs.
Those savings may be passed through to patients.
Question. Does your company view these practices as anticompetitive
or harmful to patients' access to quality, lower cost medicine?
Answer. Janssen's contract offerings encourage price competition
among drug manufacturers and ultimately enhance patients' access to
quality medicines at lower prices.
Question. If a policy were adopted to eliminate rebates, or to
require that rebate savings be passed on to the consumer, would that in
and of itself solve the issue of rebate ``traps'' and ``walls''? And
would consumers benefit from such a policy?
Answer. We support reforms to the rebate system that restructure
incentives to ensure patients benefit from a competitive marketplace
and see lower out-of-pocket costs.
It is important to note that in today's health-care marketplace,
payers use their ability to influence utilization to extract rebates,
thereby enhancing competition and lowering overall system costs.
Unfortunately, these savings are not usually shared with patients.
Similarly, if rebates are eliminated, we anticipate that payers
will use their ability to influence utilization to extract discounts
and fees from manufacturers.
drug pricing
Question. When setting the list price of a drug, does your company
consider regulatory costs or compliance? If so, how specifically do
those factors affect the list price of a drug? Please provide at least
one specific example, if applicable, from your current product
portfolio.
When setting the list price of a drug, does your company consider
the risk of liability or litigation? If so, how specifically do those
factors affect the list price of a drug? Please provide at least one
specific example, if applicable, from your current product portfolio.
Answer. At Janssen, we take a responsible approach to pricing that
recognizes our dual responsibility to patients today and patients
tomorrow. Patients today need access to our medicines. Patients
tomorrow count on us to deliver cures and treatments for the most
challenging, intractable diseases. When we set an initial list price
for our medicines, we balance:
Value to patients, the health-care system, and society.
We consider how the medicine will improve
patient health. We also assess the medicine's potential to
reduce other costs--surgeries, hospital stays, or long-term
care, for example--and the improvement the medicine represents
over the existing standard of care.
The importance of maintaining affordable access to medicines
for people who need them.
We work with insurers, pharmacy benefits
managers, governments, hospitals, physicians, and other
providers of care so that patients who are prescribed our
medicines can get access to them.
The importance of preserving our ability to develop future
groundbreaking cures and treatments.
We have an obligation to ensure that the sale
of our medicines provides us with the resources to invest in
R&D to address serious, unmet medical needs.
In addition, the sale of our medicines must enable us to cover the
costs of compliance with all laws and regulations.
Regarding the requests for specific examples from our current
product portfolio, the information requested is confidential and
competitively sensitive. As such, potentially responsive information is
not available for public disclosure.
______
Questions Submitted by Hon. Pat Roberts
Question. What role do you see value-based arrangements (VBAs)
playing in the effort to reduce prescription drug costs? What potential
do these arrangements have to find the ``sweet spot'' between
controlling costs to patients and encouraging innovation of new drugs?
Answer. We believe a value-based health-care system has tremendous
potential to improve patient health, increase access to care, and curb
the growth in health-care spending. Our current health-care system
rewards the quantity or volume of care delivered, regardless of the
results of that care. Consequently, sometimes money is spent on
treatments, diagnostic procedures, and interventions that provide
limited value or may not even be needed, driving up healthcare costs
without actually improving patient health.
Shifting to a value-based system requires innovation in the way
contracts between payers and manufacturers are structured. By creating
common incentives to deliver value for patients, value-based
agreements, including innovative approaches to contracting models, can
provide better outcomes at lower costs. We have established several
innovative, value-based contracts and continue to explore new
opportunities. For example, we have contracts tied to measurable
medical outcomes and contracts tied to offsets of other expenditures.
Fundamentally we believe a value-based health system will drive
down the amount of waste in our current health-care system, so the
money spent actually makes a measurable difference in individual health
and the health of our society overall. Efforts to achieve a more value-
based system have encouraged all stakeholders to more clearly define
and measure the value of health-care services offered, including
medicines. In a health-care system that rewards value over volume, we
believe incentives will be greater to bring to market new drugs that
can reduce the need for other costly health-care intervention and
ultimately produce better health outcomes and lower cost.
Question. How can VBAs help lower what patients pay out-of-pocket?
Answer. Innovative contracting models can align the incentives of
all stakeholders, including pharmaceutical companies, health-care
providers, and payers, to achieve better outcomes for patients at a
lower overall cost of care to the health-care system, including Federal
programs. In most cases, because the pharmaceutical company agrees to
share some of the risk around the economics of the arrangement for a
particular medicine, the health plan or PBM will provide better access
to that medicine, which may entail placing the medicine on a lower
formulary tier. Lower formulary tier placement results in lower out-of-
pocket costs for patients. We know that rising patient copayments are a
barrier to adherence and therefore to optimal outcomes. We believe that
keeping out-of-pocket costs reasonable for patients is an important
element of getting to better outcomes, and innovative contracts can
support this goal.
According to an analysis by PhRMA and Avalere Health, commercially
insured patients in health plans with outcome-based contracts for
diabetes, high cholesterol and HIV medicines between 2015 and 2017 had
copays that were, on average, 28 percent lower for those medicines
compared to patients in other plans.
Question. Can Congress do more to allow for and encourage the use
of VBAs?
Answer. We are enthusiastic about the potential for expanding the
use of innovative value-based agreements. Nevertheless, a number of
technological and policy barriers can make these agreements challenging
to implement. To address technological barriers, we advocate for
modernizing our healthcare data system to make it easier to track
patient outcomes. To address policy barriers, we support the following
approaches: establishing safe harbors to better enable manufacturers to
partner with payers and share risk; clarifying the treatment of value-
based contracts in government price calculations, including in the
complex Medicaid Best Price determination; and making comparative
formulary and cost-sharing information readily available so patients
have the information they need to make better decisions.
______
Questions Submitted by Hon. John Cornyn
Question. We continue to hear that rebates negotiated off of the
list price of a drug are both good and bad.
Pharmacy benefit managers and plans have argued that rebates are
used to lower premiums across the board and that it is the best way to
seek a price concession on otherwise expensive drugs.
Your industry argues that these payers are insisting on higher
rebates that can only be achieved by raising list prices. But patients
often lose under this system, with out of pocket costs being tied to
list price. Insulin patients appear to be routinely impacted by this
perversity in the system.
Please explain to the committee how your company would reduce list
prices if rebates were no longer a part of the equation?
What assurance can you provide that you would in fact lower your
prices?
What actions should be taken to ensure that patients are actually
seeing the benefits of lower out of pocket costs?
Answer. Depending on whether elimination of rebates applies to the
entire market or only to those related to Federal health plans and
assuming rebates are not replaced by high fees or other costs that
offset the amount saved, we expect to lower list prices or offer
discounts for pass-through at the point of sale. In either case, we
would need to renegotiate our agreements with customers.
The degree to which we can convert current rebates to list price
reductions or point-of-sale discounts will depend upon the details of
the final regulation and the reactions of other stakeholders in the
supply chain. We are concerned that PBMs may seek to replace rebate
revenue with new and increasing fees or may seek to shift costs among
supply chain participants through service fees.
We support reforms to the rebate system that restructure incentives
to ensure patients benefit from rebates and discounts that are
provided.
Question. If rebates are driving high list prices for drugs as drug
manufacturers' claim, why do you think that Part B drugs, which have no
PBM rebates, are also seeing significant price increases? Whose fault
is that?
Answer. Part B benefits from competitive commercial rebates and
discounts, while maintaining access to medicines for our nation's
seniors, through the Average Selling Price (``ASP''). ASP, which is the
basis for Part B drug reimbursement, reflects all commercial discounts
and rebates. Since both provider reimbursement and patient out-of-
pocket costs for Part B drugs are based on ASP, changes in a product's
ASP is a more relevant indicator of true cost to the Medicare system
and beneficiaries.
______
Question Submitted by Hon. Michael B. Enzi
Question. The Food and Drug Administration's drug review process is
known to many as the ``gold standard'' for evaluating medical products.
I've long thought that it is critical that we maintain public
confidence in their ability to ensure that drugs are safe and
effective. There is a perception among some, however, that biosimilars
might not be as safe as their reference products. That perception can
undermine patient and provider confidence. Do you believe that when FDA
approves a biosimilar, providers can be confident that it is safe and
effective?
Answer. Biosimilars granted licensure by the FDA are by definition
safe and effective and are highly similar to the reference biologic. We
support the FDA's application of rigorous scientific standards and
appropriate data requirements for the licensure of both biosimilars and
interchangeable biosimilars, and we believe evidence and experience
will drive patient and provider confidence in these products.
______
Questions Submitted by Hon. Todd Young
re-evaluating business strategies in foreign countries
Question. Since taking office, President Trump has made reducing
drug prices one of his highest priorities--and has repeatedly spoken
about his frustration with the U.S. subsidizing the costs of
pharmaceuticals for the rest of the world. He has gone so far as to
issue proposals, like the International Pricing Index (IPI) Model, in
an attempt to bring down prescription drug prices.
With the increased scrutiny of the industry and of the drug supply
chain as a whole in the United States, have any of your companies re-
evaluated your business strategy in foreign countries?
If not, then why?
If a proposal, like IPI, were implemented, would it force your
companies to potentially ``walk away from the negotiating table when
other countries demand low prices subsidized by America's seniors,'' as
HHS Senior Advisor for Drug Pricing Reform John O'Brien has said?
What are some of your ideas on how we can ensure Americans aren't
shouldering the full cost of pharmaceuticals?
Answer. We continuously evaluate our global business strategy and
country-
specific market access approaches in light of current conditions,
including changing policies and circumstances.
We support the use of trade tools to improve the policy environment
for U.S. companies operating overseas and to enhance incentives for
innovation. The U.S. government has already taken steps to advance this
goal with some of our key trading partners. The U.S. Mexico Canada
Agreement (``USMCA'') includes important provisions committing Canada
and Mexico to recognize the value of pharmaceuticals either through the
operation of competitive markets or through procedures that
appropriately value pharmaceuticals. The agreement also contains
procedural safeguards for U.S. companies. These include a requirement
that Canada and Mexico provide opportunities for stakeholder comment on
measures before they are finalized and also offer U.S. companies an
opportunity to appeal administrative actions. These are critical tools
that will help American companies obtain fair value for innovation
outside the U.S.
The U.S. government has announced its intention to negotiate trade
agreements with Japan, the European Union, and the United Kingdom.
These negotiations could address inadequacies in the systems of some
our largest trading partners.
The U.S. government can also effectively leverage existing trade
agreements and tools like Organisation for Economic Cooperation
accession negotiations to induce foreign governments to provide
appropriate value for innovation and offer greater incentives for new
treatments and cures.
foreign countries' pricing and reimbursement
Question. President Trump and Secretary Azar have both repeatedly
described their frustrations with ``foreign freeloading'' of U.S. drugs
in the last year.
``When foreign governments extort unreasonably low prices from U.S.
drug makers, Americans have to pay more to subsidize the enormous cost
of research and development. . . . It's unfair and it's ridiculous, and
it's not going to happen any longer.''
Do you agree that because of foreign countries' pricing and
reimbursement systems, U.S. patients and innovators are shouldering the
burden for financing medical advances?
Answer. According to a report by the U.S. Department of Commerce,
international reference pricing and controls suppress worldwide private
research and development by up to 16 percent annually, leading to fewer
new medicines launched each year. Conversely, recent estimates
demonstrate that removing price controls in other wealthy countries
would increase the number of available new treatments by 9 percent by
2030, equivalent to a range of 8 to 13 new therapeutics that year.
Question. How do foreign countries' pricing and reimbursement
systems affect our prescription drug costs?
Answer. While there is no direct relationship between U.S. drug
prices and foreign prices, according to a report by the U.S. Department
of Commerce, existing foreign price controls suppress worldwide private
research and development and decrease the number of new treatments and
cures, to the detriment of U.S. patients.
It is important to note that most cross-country pricing comparisons
focus solely on the list prices of medicines and do not account for the
significant discounts required for participation in U.S. public
programs, such as Medicaid, the 340B Drug Discount Program, and the
Federal Supply Schedule (for U.S. Department of Veterans Affairs and
the Department of Defense), as well as the discounts and rebates
negotiated by private payers. For this reason, most international
comparisons are not ``apples to apples.'' In addition, in other
countries, medicine prices are achieved through national regulation,
which often restricts or delays access to innovative medicines and
limits patient and physician choice.
Question. Are foreign governments taking note of the concerns being
raised by the Trump administration and have they responded in any way?
Answer. We understand that some foreign government officials have
noted the concerns raised by the Trump administration and appear to be
seeking a better understanding of the proposed policy changes in the
United States and the potential future impacts on their countries.
Question. Has there been any noticeable change in any of our trade
agreements since these concerns have been raised by the Trump
administration?
Answer. The U.S.-Mexico-Canada Agreement (``USMCA'') contains
important provisions on intellectual property that establish a higher
global IP standard than in previous agreements, particularly with
respect to data protection for biologics. The agreement also contains
important provisions committing Canada and Mexico to recognize the
value of pharmaceuticals either through the operation of competitive
markets or through procedures that appropriately value pharmaceuticals.
The agreement includes procedural safeguards for U.S. companies. These
include a requirement that Canada and Mexico provide opportunities for
stakeholder comment on measures before they are finalized and also
offer U.S. companies an opportunity to appeal administrative actions.
These are critical tools that will help American companies obtain fair
value for innovation. The U.S. government has announced its intention
to negotiate trade agreements with Japan, the European Union, and the
United Kingdom. These negotiations could address inadequacies in the
systems of some our largest trading partners. The U.S. government can
also effectively leverage existing trade agreements and tools like
Organisation for Economic Co-operation accession negotiations to induce
foreign governments to provide appropriate value for innovation and
offer greater incentives for new treatments and cures.
medicaid closed formulary proposals
Question. In an attempt to bring down drug costs, various states
have been exploring whether to exclude certain drugs from its Medicaid
program. For example, the state of Massachusetts' recently asked CMS
for permission to create a closed formulary where the state Medicaid
program would pick at least one drug per therapeutic class. CMS denied
their waiver request citing violation of federal law, but this proposal
does bring up important questions on how to contain drug prices in
state Medicaid programs.
If the principles of the Medicare Part D program--including the
necessary patient protections--were applied to State Medicaid programs,
do you think it would lower drug costs while ensuring access to
patients?
Answer. By legislative design, the Medicaid Program already
receives the ``best'' price, in addition to substantial rebates
associated with an inflation penalty and negotiated supplemental
rebates. The rebate is never less than 23.1 percent, the required
statutory minimum, and often requires manufacturers to sell their
products (both older and newer) for as low as 1 cent per pill or unit.
The Medicaid drug rebate statute represents a carefully crafted
legislative approach developed by Congress and designed as a package to
offer Medicaid beneficiaries comprehensive coverage and access to
outpatient drugs at the lowest cost in the marketplace. We support the
significant access protections required under the current Medicaid Drug
Rebate Program that serve a uniquely vulnerable population. We also
question whether reducing access to medically necessary medication for
vulnerable Medicaid beneficiaries will yield true program savings. Any
further restrictions in medication access is likely to increase the
risk of higher costs elsewhere in the health-care continuum. Moreover,
vulnerable Medicaid beneficiaries may be particularly challenged to
navigate the administrative, technical, logistical and other challenges
that inevitably arise when additional restrictions are placed on their
access to care.
medicaid ``best price''
Question. In the Trump administration's Blueprint, they suggested
that because drug manufactures have to give Medicaid the ``best price''
on drugs, there is no incentive to offer deeper discounts to other
payers--both government and commercial--than what is already offered
under the Medicaid Drug Rebate Program.
Does the Medicaid ``best price'' requirement encourage
manufacturers to increase initial prices?
Answer. We take into account the Medicaid ``best price''
requirement at all stages of the drug lifecycle, including launch. We
consider best price when offering large discounts to commercial
customers after a drug is launched and when designing value-based
agreements.
Question. What, if any, changes would you suggest we make to the
program?
Answer. We are supportive of ongoing efforts to promote a value-
driven health-care system, including in Medicaid, and applaud recent
efforts by both the administration and Congress that seek to address
regulatory and legal uncertainty around value-based payment
arrangements. We also support CMS's recent approvals of State proposals
to advance specific Medicaid value-based arrangements with drug makers.
outcomes-based contracts
Question. In almost all of your testimonies, you highlight your
support of outcomes-based contracts and how we need to be shifting our
system toward that approach.
How will these contracts lower drug costs for patients in both the
near term and long-term?
How will they lower overall health-care costs for our Federal
programs?
What have the preliminary results looked like so far?
Answer. Innovative contracting models can align the incentives of
all stakeholders, including pharmaceutical companies, health-care
providers, and payers, to achieve better outcomes for patients at a
lower overall cost of care to the health-care system, including Federal
programs.
In most cases, because the pharmaceutical company agrees to share
some of the risk around the economics of the arrangement for a
particular medicine, the health plan or PBM will provide better access
to that medicine, which often entails placing the medicine on a more
preferable formulary tier. More preferable formulary tier placement
results in lower out-of-pocket costs for patients. We know that rising
patient copayments are a barrier to adherence and therefore to optimal
outcomes. We believe that keeping out-of-pocket costs reasonable for
patients is an important element of getting to better outcomes, and
innovative contracts can support this goal.
According to an analysis by PhRMA and Avalere Health, commercially
insured patients in health plans with outcome-based contracts for
diabetes, high cholesterol and HIV medicines between 2015 and 2017 had
copays that were, on average, 28 percent lower for those medicines
compared to patients in other plans.
Innovative contracting models are still relatively new, and we look
forward to the point at which we will have the long-term data necessary
to evaluate the success of these programs with respect to health-care
cost reduction. We are enthusiastic about the potential of innovative
value-based contracting models to enable us to take full advantage of
medicines' benefits, including their potential to reduce other health-
care costs.
transparency/point of sale
Question. In almost all of your testimonies, you express your
support for the Trump administration's proposal to allow manufacturers
to provide PBMs up-front discounts that are passed onto patients at the
point of sale.
Do you feel like this proposal will make the transactions within
the drug supply chain more transparent?
If so, would this transparency bring down drug costs--overall and
for specialty drugs?
Answer. We do believe that a point-of-sale discount model, wherein
manufacturer discounts could be passed through to a patient at the
point-of-sale, will make price reductions offered by the manufacturer
more transparent because these discounts would be more directly
reflected in patient out-of-pocket cost at the pharmacy. However, we do
not believe that the proposal will improve transparency with respect to
fees or mark-ups to the price of drugs added elsewhere in the supply
chain.
Depending on whether elimination of rebates applies to the entire
market or only with respect to Federal health plans and assuming
rebates are not replaced by high fees or other costs that offset the
amount saved, we expect to lower list prices or offer discounts for
pass-through at the point of sale.
the relationship between wholesalers and manufacturers
Question. When talking about the pharmaceutical supply chain, a lot
of focus has been placed on the pharmacy benefit manager. But there's
another side of the equation that I'd like to ask about: how do
wholesalers negotiate pricing with manufacturers?
Answer. Janssen sells to wholesalers and specialty distributors at
list price, with discounts customarily offered for prompt payment.
Janssen occasionally offers discounts to wholesalers for discrete
periods of time on certain products. These are generally offered to
contracted, authorized wholesalers market-wide. In addition, Janssen
negotiates service agreements with wholesalers and specialty
distributors for bona fide services relating to distribution of Janssen
products.
Question. What impact does this have on drug costs?
Answer. We do not know the details of the wholesalers' arrangements
with downstream stakeholders such as pharmacies, hospitals, providers,
and other sites of care.
Question. What incentives or disincentives do they have to contain
price increases?
Answer. We are not in a position to comment on wholesaler
incentives or disincentives to contain price increases.
______
Questions Submitted by Hon. Ron Wyden
proposed rebate rule
Question. As has been done in many other settings, drug
manufacturers said during the hearing that one reason list prices for
drugs are high is that pharmaceutical benefit managers (PBMs) demand
larger and larger rebates in order for the drug to receive favorable
placement on a formulary. You and your colleagues who testified during
the hearing stated if the administration's proposal on changes to the
anti-kickback safe harbor for pharmaceutical rebates took effect, your
company would likely lower list price.
Like many Oregonians, I am skeptical drug manufacturers would
voluntarily lower their prices. Therefore, would you support
legislation that would (1) make similar changes the administration has
put forward related to Part D and Medicaid managed care, (2) change the
rebate system in a similar way to the proposal for the commercial
market, and (3) require drug makers to lower the list price of their
drugs equal to the amount of rebates provided today?
Answer. We support reforms to the rebate system that restructure
incentives to ensure patients benefit from a competitive marketplace
and see lower out-of-pocket costs.
Depending on whether elimination of rebates applies to the entire
market or only to those related to Federal health plans and assuming
rebates are not replaced by high fees or other costs that offset the
amount saved, we expect to lower list prices or offer discounts for
pass-through at the point of sale. In either case, we would need to
renegotiate our agreements with customers.
The degree to which we can convert current rebates to list price
reductions or point-of-sale discounts will depend upon the details of
the final regulation and the reactions of other stakeholders in the
supply chain. We are concerned that PBMs may seek to replace rebate
revenue with new and increasing fees or may seek to shift costs among
supply chain participants through service fees.
medicaid drug rebate program
Question. The Medicaid Drug Rebate Program (MDRP) requires
manufacturers to provide a basic rebate and an additional inflationary
rebate for both brand and generic drugs. The inflationary rebate is an
increasingly substantial part of total rebates due in large part to
large increases in drug prices that exceed inflation. Under current
law, this inflationary rebate is capped at 100 percent of Average
Manufacturer Price (AMP). This is the case even when manufacturers
continue to raise their prices well above inflation.
Please provide a list of all of your pharmaceutical products that
have reached the Medicaid AMP rebate cap in any of the 20 quarters from
January 1, 2014 through December 31, 2018.
For each drug listed in response to question 1, please also provide
a list of which quarters and years each drug hit the cap.
Answer. Janssen has numerous current products, and products that
have since been sold to third parties, that have reached the Medicaid
AMP rebate cap in at least one of the 20 quarters from 1Q 2014 through
4Q 2018. The fact that these products reaching the 100 percent AMP cap
is based on confidential metrics reported under the Medicaid Drug
Rebate Program. The Medicaid AMP rebate cap is reached when AMP is less
than or equal to the Unit Rebate Amount (URA). URA is calculated based
on AMP and Best Price--which are confidential under the Medicaid Drug
Rebate statute at 42 U.S.C. ' 1396r8(b)(3)(D). There are exceptions in
the statute that permit the Secretary and State Medicaid agencies to
disclose the information only in certain situations, including
disclosure to CBO. Thus, if there was legislation proposing to amend
the 100 percent AMP cap, CBO would be able to access the drugs and
underlying data to estimate the cost/savings to the government of such
a legislative change.
The product-specific information requested is confidential and
competitively sensitive. As such, potentially responsive information is
not available for public disclosure.
medicaid drug rebate program compliance
Question. I am concerned about recent reports and legal settlements
surrounding drug manufacturers' failure to comply fully with the
requirements of the MDRP. For example, an analysis by the U.S.
Department of Health and Human Services Office of Inspector General
found that between 2012 and 2016 taxpayers may have overpaid by as much
as $1.3 billion for 10 potentially misclassified drugs. That is why I
introduced the Right Rebate Act with Chairman Grassley to prevent drug
manufacturers from manipulating Medicaid to increase their profits.
However, I continued to be concerned about oversight and manufacturer
compliance with the requirements of the Medicaid Drug Rebate Program.
Accordingly, please describe the following:
Your company's current compliance plan and procedures used to
ensure compliance with the requirements of the Medicaid Drug Rebate
Program including internal audits or other checks you use to identify
compliance vulnerabilities.
Any past or ongoing issues of non-compliance.
Any corrective actions taken to address identified problems or
issues of non-
compliance with the MDRP and how such steps were communicated to the
Centers for Medicare and Medicaid Services.
Any steps taken to improve compliance and ensure that all Medicaid
drug rebates owed to the Federal Government and the States are paid in
full.
Answer. We comply with the obligations we undertake when
participating in U.S. Federal, State, or local government contracts and
government pricing programs such as the Medicaid Drug Rebate Program.
We have an established compliance framework along with organizational
structure and accountabilities designed to assure compliance. Our
framework includes testing and monitoring and an obligation to correct
any identified discrepancies. As such, any discrepancies have been
timely addressed and corrected.
The other information requested is confidential. As such,
potentially responsive information is not available for public
disclosure.
bonus payments tied to specific drugs
Question. I am concerned by the potential for employee financial
incentives to encourage high launch prices and price increases for
prescription drugs.
Is your salary, bonus or other compensation tied to sales or
revenue targets of a single product your company sells? Has it ever
been? If yes, please state the product or products to which your
salary, bonus or other compensation was tied.
Answer. At no time during her employment with the Johnson & Johnson
Family of Companies has Ms. Taubert's salary, bonus, or other
compensation been tied to sales or revenue targets of a single product.
Question. Is your salary, bonus, or other compensation tied to
either revenue or net income of the company as a whole? Has it ever
been? If yes, please explain what assumptions about price increases are
used when the compensation committee sets revenue or net income goals.
Does the compensation committee provide any guidance to executives in
regards to the amount of revenue that the company will generate from
price increases versus volume growth?
Answer. We structure performance-based compensation to reward an
appropriate balance of short-term and long-term financial and strategic
business results, with an emphasis on managing the business for long-
term results. Our compensation program's emphasis on long-term value
reduces the possibility that our executives make excessively risky
business decisions that could maximize short-term results at the
expense of long-term value.
Ms. Taubert's base salary is tied to performance, market data,
responsibilities, time in position, internal equity, and experience.
Ms. Taubert's bonus and long-term incentive compensation has been and
is awarded based on her individual performance and the company's
performance.
The compensation committee does not provide guidance to executives
regarding the amount of revenue that the company will generate from
price increases versus volume growth.
provision of rebates in exchange for formulary placement
Question. In today's system, drug makers receive a limited time
window to sell their drug without competition. After that period has
expired, low-cost generics should become available. However, drug
makers often prevent access to these cheaper generic drugs in Medicare.
Researchers have found that 72 percent of Medicare Part D plans charged
lower cost-sharing for a brand name drug compared to its generic
equivalent. This means seniors were charged less out of pocket for
brand name drugs compared to generics that are on average four times
cheaper than the brand-named drug. This happens because drug makers pay
a rebate to the Part D plans in order to give the more expensive drug
better treatment than a generic. As a result, Medicare spending
increases due to the current structure of the Part D benefit.
Has your company ever paid a rebate to a Part D plan so that a
brand name drug would get preferential treatment (i.e., lower cost-
sharing or less utilization management) compared to a cheaper generic?
If so, please provide: a list of the drugs for which your company
has done this since January 1, 2014; and the number of Part D plans in
which this type of rebate was given for each drug in each year.
Answer. In negotiations with PBMs and payers, Janssen may offer
multiple different rebate options. The PBM or payer has sole discretion
over how formularies are structured. In some cases, a PBM or payer may
establish a formulary that puts a branded drug in a preferential
position.
The information requested is confidential and competitively
sensitive. As such, potentially responsive information is not available
for public disclosure.
net prices
Question. Your testimony stated that ``while our 2018 aggregate
list price increase was 6.3 percent, for the second year in a row
discounts and rebates outweighed that increase, and aggregate net
price--in other words, the real price--decreased by 6.8 percent.''
According to your testimony, the net price ``represents the year-over-
year change in the average net price, which is WAC less rebates,
discounts, and returns.'' Please describe how the company's year-over-
year aggregate net price is calculated. Please also specifically
address the following questions:
Answer. Average net price change represents the year-over-year
change in the average net price, which is Wholesale Acquisition Cost
less rebates, discounts, and returns.
Question. How many products are included in the calculation of the
average net price change? What was the median net price change?
Answer. We believe weighted average net price change is the
appropriate metric for evaluating list price changes across the
portfolio. There are 99 products (brands) included in the average net
price change calculation. The 2017-2018 weighted average net price
change is -6.8 percent. The non-weighted average 2017-2018 net price
change is -3.7 percent. The 2017-2018 median net price change is -1.9
percent. It is important to note that non-weighted average or median
net price change treats all medicines--whether used by many patients or
by very few--equally, so those figures are not useful or valuable in
understanding the actual change experienced.
Question. Is net price weighted? If so, how? For example, in
determining the aggregate net price does the company assign different
weights to different products based on volume or other factors? Are
``on patent'' and ``off patent'' drugs weighted identically? Are other
statistical weights used or are all products treated equally?
Answer. Annual net price change versus prior year is calculated at
the product level and weighted across the company's U.S. product
portfolio using net trade sales. All products, both ``on patent'' and
``off patent,'' are included.
Question. Does the figure that you provided during your testimony
account for U.S. prices, international prices, or both? Generally
speaking, when your company reports net price changes, does it
differentiate between U.S. and international prices?
Answer. The figure provided, -6.8 percent, accounts for 2018 net
price change for our U.S. pharmaceutical business only. We disclose
this figure in our annual Janssen U.S. Transparency Report.
Question. Please list the five drugs your company sold in the U.S.
that had the greatest year-over-year net price increase in 2018, noting
the increase for each drug by dollar figure and percentage. Please list
the five drugs your company sold in the U.S. that had the lowest year-
over-year net price increase (and/or the greatest decrease) in 2018,
noting the increase (or decrease) for each drug by dollar figure and
percentage.
Answer. The information requested is confidential and competitively
sensitive. As such, potentially responsive information is not available
for public disclosure.
Question. For 2018, what was the average net price change in the
U.S. market for (1) drugs with no competition, (2) drugs with only
branded competition, and (3) drugs with generic competition?
Answer. The information requested is confidential and competitively
sensitive. As such, potentially responsive information is not available
for public disclosure.
Question. Your company noted in its annual financial filing with
the Securities and Exchange Commission that ``Immunology was negatively
impacted by lower sales of REMICADE' (infliximab) due to
increased discounts/rebates and biosimilar competition,'' and ``Strong
sales of long-acting injectables INVEGA TRINZA'/
TREVICTA' (paliperidone palmitate) and INVEGA
SUSTENNA'/XEPLION' were partially offset by
cannibalization of RISPERDAL CONSTA' (risperidone) and
generic competition for CONCERTA'/methylphenidate,'' and
``Lower sales of INVOKANA'/INVOKAMET'
(canagliflozin) in the U.S. was primarily due to an increase in price
discounts, higher rebates and market share decline driven by
competitive pressure. Lower sales of XARELTO' (rivaroxaban)
were driven by an increase in discounts and rebates, partially offset
by an increase in market share.'' What were the year-over-year net
price changes for each of these drugs?
Answer. The information requested is confidential and competitively
sensitive. As such, potentially responsive information is not available
for public disclosure.
Question. Please define the following terms that were used on page
20 of your company's annual report for the year ending December 31,
2018 regarding sales of various pharmaceutical products: strong uptake,
market growth, and share gain. Please also define ``reduction in
sales,'' as used in the sentence ``Biosimilar versions of
REMICADE' have been introduced in certain markets outside
the U.S., resulting in a reduction in sales of REMICADE' in
those markets.''
Answer. ``Strong uptake'' means that we are seeing significant
utilization of a medicine that was recently introduced into the market
or approved for a new indication.
``Market growth'' refers to increase in utilization of medicines
overall for a particular disease state or in a particular class of
medicines.
``Share gain'' means that within a class of medicines or
therapeutic area, a particular medicine is being selected and utilized
more than it had been previously and now represents a greater
percentage of utilization within that class relative to competitor
medicines.
``Reduction in sales'' in the sentence you reference means that
revenues for REMICADE' are lower than they have been in
previous years. Please note that our 2018 Annual Report goes on to
state, ``In the U.S., a biosimilar version of REMICADE' was
introduced in 2016, and additional competitors continue to enter the
market. Continued infliximab biosimilar competition in the U.S. market
will result in a further reduction in U.S. sales of
REMICADE'.''
______
Questions Submitted by Hon. Robert Menendez
Question. During the hearing, when I asked whether your company
engaged in tactics to delay generic production of your products, you
answered ``no.'' However, your Johnson & Johnson's Actelion appears on
the FDA's list of companies who have access complaints against them.
Can you explain the discrepancy between your answer and the FDA list?
The FDA list can be found here: https://www.fda.gov/Drugs/
DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/
ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/
ucm607738.htm.
Answer. Johnson & Johnson acquired Actelion in June 2017. We share
FDA's commitment to policies that promote access to generics when
balanced with the protection of innovation and the safeguarding of
patient safety. It is important to note that the FDA's website on
Reference Listed Drug (``RLD'') Access Inquiries does not differentiate
between inquiries and complaints, and does not clarify whether the RLD
Sponsor made samples available after the FDA issued a Safety
Determination Letter. Following the receipt of a Safety Determination
Letter from the FDA, Actelion has actively entered into a supply
agreement with every generic manufacturer who has requested testing
samples of our products. This is true for each instance cited in the
FDA's RLD Access Inquiry list. Actelion is also actively engaging with
generic manufacturers to develop shared REMS programs that protect
patient safety while enabling patient access to our medicines.
Question. When new products enter the market, do drug companies set
high initial rebates and then provide deep rebates in order to gain
access to insurance plan's formularies?
Answer. At Janssen, we take a responsible approach to pricing that
recognizes our dual responsibility to patients today and patients
tomorrow. Patients today need access to our medicines. Patients
tomorrow count on us to deliver cures and treatments for the most
challenging, intractable diseases. When we set an initial list price
for our medicines, we balance:
Value to patients, the health-care system, and society.
We consider how the medicine will improve
patient health. We also assess the medicine's potential to
reduce other costs--surgeries, hospital stays, or long-term
care, for example--and the improvement the medicine represents
over the existing standard of care.
The importance of maintaining affordable access to medicines
for people who need them.
We work with insurers, pharmacy benefits
managers, governments, hospitals, physicians, and other
providers of care so that patients who are prescribed our
medicines can get access to them.
The importance of preserving our ability to develop future
groundbreaking cures and treatments.
We have an obligation to ensure that the sale
of our medicines provides us with the resources to invest in
R&D to address serious, unmet medical needs.
We go through a lengthy process to gather the information necessary
to assess the medicine according to these factors. We use this
information to determine the value of our medicine compared to what is,
or will be, available to treat the same condition--be it other
medicines, surgery, or other forms of health care.
Question. If CMS finalizes the rebate rule, do you anticipate
future products entering the market with significantly lower initial
list prices?
Answer. Depending on whether elimination of rebates applies to the
entire market or only to those related to Federal health plans and
assuming rebates are not replaced by high fees or other costs that
offset the amount saved, we expect to lower list prices or offer
discounts for pass-through at the point of sale. In either case, we
would need to renegotiate our agreements with customers.
The degree to which we can convert current rebates to list price
reductions or point-of-sale discounts will depend upon the details of
the final regulation and the reactions of other stakeholders in the
supply chain. We are concerned that PBMs may seek to replace rebate
revenue with new and increasing fees or may seek to shift costs among
supply chain participants through service fees.
______
Questions Submitted by Hon. Thomas R. Carper
Question. What are your recommendations for lowering prices for the
40 percent of drugs that do not offer rebates in Medicare Part D? In
the health insurance plans that you offer your employees, do you ask
your insurers to pass through the full manufacturer rebates to the
beneficiaries?
Answer. Drugs that offer lower rebates tend to be drugs that face
less competition in the marketplace. Increased competition can lead to
lower prices of branded and generic drugs. FDA Commissioner Scott
Gottlieb prioritized faster approval of generic drugs. In 2018, FDA set
a record by approving an estimated 971 generic drugs.
Within today's health-care system, we do recover manufacturer
rebates from our PBM. Any savings we receive are used to offset out-of-
pocket costs for employees and total plan costs. In order to help
ensure affordability for our employees, we limit out-of-pocket pharmacy
costs through a monthly per prescription cap.
Question. The systems for pricing and distributing drugs are opaque
and difficult to understand. What are your recommendations for
increasing transparency in how your companies set the list prices for
drugs, and for improving transparency in the supply chain for
prescription drugs? Would you support federal standards for
transparency in setting the list prices for drugs?
Answer. At Janssen, we issue an annual U.S. Transparency Report
that explains what we take into account in setting list prices for our
medicines. When we set an initial list price for our medicines, we
balance:
Value to patients, the health-care system, and society.
We consider how the medicine will improve
patient health. We also assess the medicine's potential to
reduce other costs-- surgeries, hospital stays, or long-term
care, for example--and the improvement the medicine represents
over the existing standard of care.
The importance of maintaining affordable access to medicines
for people who need them.
We work with insurers, pharmacy benefits
managers, governments, hospitals, physicians, and other
providers of care so that patients who are prescribed our
medicines can get access to them.
The importance of preserving our ability to develop future
groundbreaking cures and treatments.
We have an obligation to ensure that the sale
of our medicines provides us with the resources to invest in
R&D to address serious, unmet medical needs.
The list price we set is a publicly available figure that can be--
and is-- compared to other options available. We believe that a point-
of-sale discount model will make price reductions offered by the
manufacturer more transparent because these discounts will be directly
reflected in patient out-ofpocket cost at the pharmacy. However, we do
not believe that the proposal will improve transparency with respect to
fees or mark-ups to the price of drugs added elsewhere in the supply
chain.
Transparency that is meaningful and valuable to patients can help
achieve what we all want: better health care, at more manageable cost,
and, most importantly, longer, healthier lives for all.
We believe an environment that encourages medical innovation and
robust competition to deliver the best health outcomes is essential to
achieving these goals. Our support for legislation that establishes a
federal standard for transparency in setting the list price for drugs
would depend on the extent to which the proposed standards maintained
such an environment.
Question. In nearly every sector of the health-care industry,
Medicare, Medicaid, employers, and insurers are moving away from fee-
for-service payments to reimbursements based on value and performance.
Prescription drugs and medical devices were the glaring exceptions to
this trend until recently. How many of your drugs are included in
value-based contracts and how many patients are benefiting from them?
How do these value-based contracts work to lower drug prices for both
patients and taxpayers?
Answer. We have established several innovative, value-based
contracts with insurers and continue to explore new opportunities. For
example, in immunology, we partnered with payers to create an agreement
in which the price of a medicine for chronic immune conditions varies
based on how well it works for patients. In oncology, we partnered with
public and private payers on novel contracts for patients with prostate
cancer and agreed in one contract to provide additional rebates to the
insurer for plan members who meet eligibility criteria and whose
treatment duration is shorter than a predetermined period of time. We
also partnered with a leading payer on a contract under which we are
paid more if data show our medicine that treats adults with type 2
diabetes contributed to lowering other identified health-care costs,
such as the use of additional medicines.
Question. Last year, Senator Portman and I did an investigation on
the pricing of an opioid overdose reversal drug called EVZIO,
manufactured by Kaleo. Kaleo increased the price of EVZIO from $575 in
2014 to $4,100 in 2017. We found that the best price Medicare was able
to get for EVZIO, about $4,000, was much higher than the price other
Federal programs and private insurers were able to get. It seemed that
Kaleo was able to get this higher price of $4,000 from Medicare by
helping doctors fill out paperwork showing that the drug was medically
necessary, even though there are cheaper alternatives on the market. As
a result of the investigation, Kaleo announced it will bring a generic
version of the drug to market at only $168 per pack. Are any of your
companies providing medical necessity paperwork to doctors in order to
get your drugs covered by Medicare?
Answer. Like other pharmaceutical companies, we offer a sample
letter of medical necessity that offices can complete using their own
clinical judgment regarding the medical and clinical rationale for
submission to the insurance company or PBM. We also research and
provide payer-specific forms required to provide medical necessity
information such as payer-specific prior authorization forms.
Question. In 2017, the Rand Corporation estimated that biosimilar
drugs, which are competitors to complex, biologic drugs, could save the
United States more than $50 billion over the next decade. Some of you
have also argued that increasing the use of biosimilar drugs would help
lower drugs costs for consumers and taxpayers. What is delaying the
uptake of biosimilar drugs in the United States? What policies do you
recommend to increase the development of biosimilar drugs?
Answer. The goal of biosimilar policy should be to lower costs for
the health-care system and patients, and not simply to encourage
biosimilar uptake without regard to price. The current open and
competitive environment supports price competition and biosimilar
uptake as appropriate. For example, the net price of infliximab
products, including the innovator product REMICADE', is
falling. Furthermore, the uptake of infliximab biosimilars in the U.S.
is consistent with branded biologic launches of immunology products,
including those that provide a clinical benefit over the standard of
care.
Biologics are used in patients with serious, chronic conditions,
many of whom have taken years to become stable on a branded product.
Health-care providers and patients may naturally be hesitant to switch
medicines in these circumstances. The approval of an interchangeable
biosimilar may address some of the physician and patient reservations
about switching a stable patient to a non-interchangeable biosimilar.
The biosimilars pipeline is strong and a diverse group of
companies--traditional pharmaceutical manufacturers as well as
manufacturers focused on biosimilars--is investing in the space. For
example, in the immunology therapeutic area alone, at least 18
biosimilars are currently in clinical development or undergoing FDA
review.
We fully support a regulatory framework for FDA review and approval
of biosimilars and interchangeable biosimilars with standards and
policies that are science-based and rooted in patient safety.
Ultimately, the uptake of biosimilars will be reliant on competitive
pricing and on patient and prescriber confidence. Provider and patient
confidence can be strengthened by the application of rigorous review
standards, including the robust approach to interchangeability that FDA
is pursuing and appropriate standards regarding biosimilar to
biosimilar switching.
Biosimilar manufacturers need access to samples of reference
products to perform comparative testing required to demonstrate
biosimilarity or interchangeability. We cooperate with manufacturers of
generic drugs and biosimilars so they have access to samples of our
medicines at reasonable, market-based prices. To facilitate access to
product samples while fostering efficiencies in the delivery and
oversight of healthcare, we believe that manufacturers should identify
for FDA a point of contact to facilitate access to samples for each
approved reference product. When a Risk Evaluation and Mitigation
Strategy (REMS) is in place, the REMS should facilitate the safe use of
medicine and ensure access for appropriate patients; it should not be
used to hinder provision of product samples for use in developing a
generic or biosimilar. We believe FDA should finalize draft guidance,
issued December 2018, describing a process for FDA determination that
protocols pertaining to biosimilarity and interchangeability testing
contain safety protections comparable to an applicable REMS with
limited distribution elements. A letter from FDA stating comparable
protections exist and indicating FDA would not consider it to be a
violation of the REMS to provide samples to the biosimilar manufacturer
provides needed assurances for reference product manufacturers about
both the safe use of our products and regulatory compliance.
The Purple Book is an essential resource for many stakeholders and
should be enhanced to provide timely information to stakeholders, to
clarify practices regarding substitution, and to provide information to
assure the appropriate use of biosimilars and interchangeable products.
In addition, the Purple Book should include detailed information about
approved biosimilars and interchangeable biosimilars, including, for
example, a description or listing of pivotal clinical trials considered
in FDA's approval of the biosimilar.
______
Questions Submitted by Hon. Benjamin L. Cardin
Question. The United States is one of the only countries in the
world to allow prescription drug manufacturers to advertise directly to
consumers through magazines, billboards, radio, and television
commercials. While I will not argue that it is beneficial to educate
consumers about an unfamiliar disease and encourage them to seek
medical help, most commercials from all of your companies recommend
asking about a specific brand name drug, not a medical condition.
Furthermore, even if your advertisements follow all FDA rules and list
medication side effects, they also almost always list these while a
smiling, apparently healthy person is walking on a beach.
Researchers say that this type of imagery, combined with viewing
hours of drug commercials each month, leads consumers to underestimate
the risks associated with medications. For the past decade, studies
have shown that aggressive direct-to-consumer advertising is associated
with rising drug prices and an increase in inappropriate drug
prescriptions.
Since researchers have concluded that consumers are
misunderstanding the benefits and risks described in your ads, what
further policies could help you and your colleagues ensure that you are
educating patients in a clear manner?
Answer. At Janssen, we believe patients can get and stay healthier
when they are well informed about their conditions and treatment
options. We provide accurate, up-to-date educational materials in
language that is clear and understandable for consumers to help
patients facing diseases our medicines treat and to help patients who
take our medicines understand how to use them properly. Our product-
specific communications, including our DTC advertising, are designed to
encourage appropriate dialogue between patients and healthcare
providers about the risks and benefits of treatment.
We believe acting ethically and responsibly is not only the right
thing to do but also the right way to do business. We follow all
relevant laws and regulations regarding the promotion of prescription
drug products and submit promotional materials to the U.S. Food and
Drug Administration at the time of initial publication or
dissemination.
We are always open to ways to improve our communication, including
DTC, to ensure patients better understand the benefits and risks of our
medicines.
pharmaceutical companies continue to raise prices
Question. As you are well aware, high prescription drug prices are
the number one concern for Americans and their families. According to
the Organisation for Economic Co-operation and Development, the average
American spends around $1,208 annually on prescription drugs. There
have been several instances where brand name or even generic drugs that
have been on the market for years continue to increase in price.
One of the most well-known examples is Mylan's increase of the
price of EpiPen from less than $100 in 2007 to more than $600 in 2016.
Another example, is the ever-increasing price of insulin. Sanofi
increased the price of a vial of Lantus from $88.20 in 2007 to $307.20
in 2017. And those are just a small sample of price increases.
Why don't we see price decreases for drugs that have been on the
market for years without new formulations or added benefit?
Answer. In fact, net price does often decrease, sometimes quite
significantly, for medicines that have been on the market for years
because of competition from other, newer medicines for the same
condition. Competition brings down price for payers such as PBMs and
insurers, although unfortunately patients often do not benefit from the
lower net price.
It is also important to note that biopharmaceutical innovation
paves the way for the introduction of generic medicines, which enables
medicine costs to be reduced over time. In the U.S., medicines lose
patent protection, on average, about 12 years after they are
introduced. When that happens, prices generally drop significantly,
giving patients ongoing access to effective therapies at a lower cost.
pay for delay
Question. Pay for delay is a tactic that more and more branded drug
manufacturers have been using to stifle competition from lower-cost
generic manufacturers. This allows you to sidestep competition by
offering patent settlements that pay generic companies not to bring
lower-cost alternatives to market.
These pay-for-delay patent settlements benefit both brand-name
pharmaceutical companies by helping them avoid costly patent litigation
and general manufacturers by rewarding them a hefty sum to delay
entering the market with a cheaper drug alternative. However, these
deals do not benefit consumers. According to an FTC study, these
anticompetitive deals cost consumers and taxpayers $3.5 billion in
higher drug costs every year.
Does your company partake in pay-for-delay settlements?
Answer. We have not entered into patent settlement agreements that
require payment of money to a generic manufacturer.
Question. Why would a pharmaceutical company enter into a pay-for
delay agreement?
Answer. We have not entered into patent settlement agreements that
require payment of money to a generic manufacturer and, therefore, we
cannot speculate as to why other companies might enter into such
agreements in specific cases.
Question. Do you think these agreements stifle competition and
prevent generic alternatives to your branded medications?
Answer. We have not entered into patent settlement agreements that
require payment of money to a generic manufacturer, so we do not have
direct experience with their competitive impacts. However, we believe
that the competitive impact of any individual settlement agreement must
be evaluated on a case-by-case basis. The current legal framework--FTC
oversight and judicial review on a case-by-case basis--is intended to
identify any patent settlement that is anti-competitive.
drug rebate rule
Question. In January, the Department of Health and Human Services'
(HHS) Office of Inspector General (OIG) promulgated a new regulation to
remove regulatory safe harbor protections under the Anti-Kickback
Statute (AKS) for rebates on prescription drugs rebates paid by
manufactures to PBMs under Medicare Part D and for Medicaid managed
care organizations (MCOs). The OIG proposal attempts to ban most
rebates by eliminating their regulatory protections.
The rule is predicted to increase net drug costs in its early
years. The CMS actuaries estimate it would cost $196 billion over 10
years. Despite this high price tag, the beneficiary benefits are
limited. The proposed rule notes that under the CMS Actuary's analysis,
the majority of beneficiaries would see an increase in their total out-
of-pocket payments and premium costs; reductions in total cost sharing
will exceed total premium increases.
I wanted to ask a question about the administration's rebate rule,
which I understand that many of the drug manufacturers, and your main
trade association, strongly support. According to an analysis of the
rule by the Office of Actuaries at CMS, drug manufacturers are likely
to initially retain 15 percent of the current rebates as higher net
drug prices.
Given that estimate, can you provide the committee with any
assurances that prices will not increase under this proposed rule?
Answer. Depending on whether elimination of rebates applies to the
entire market or only to those related to Federal health plans and
assuming rebates are not replaced by high fees or other costs that
offset the amount saved, we expect to lower list prices or offer
discounts for pass-through at the point of sale. In either case, we
would need to renegotiate our agreements with customers.
The degree to which we can convert current rebates to list price
reductions or point-of-sale discounts will depend upon the details of
the final regulation and the reactions of other stakeholders in the
supply chain. We are concerned that PBMs may seek to replace rebate
revenue with new and increasing fees or may seek to shift costs among
supply chain participants through service fees.
______
Questions Submitted by Hon. Sherrod Brown
Question. As I understand it, 2 years ago PhRMA updated its
membership standards to require member companies to meet two new
criteria: (1) each company must meet a 3-year average global research
and development to sales ratio of 10 percent or greater, and (2) each
company must spend at least $200 million on R&D per year over a 3-year
average. As a result of these changes, several companies who continue
to operate under business models that prioritize price gouging over
innovation, left PhRMA.
Given your company's role in setting a higher standard for R&D,
would you support a more even playing field by raising the minimum bar
for R&D across the entire pharmaceutical sector, in particular for
companies that participate in government programs such as Medicare and
Medicaid?
Answer. We are proud to set a high standard for R&D investment. In
2018 Janssen invested $8.4 billion globally in research and
development. This investment in R&D was 86 percent more than we spent
on sales and marketing. However, we would not support a policy that
requires a certain amount of R&D spending for a manufacturer's products
to be covered by Medicare and Medicaid because we would not want to
deny patients access to needed medication based on the investment
decisions of these drug companies.
Question. According to an article recently published in the Journal
of the American Medical Association, medical marketers spend nearly $30
billion dollars in 2016, up from $17 billion in 1997. Direct-to-
Consumer (DTC) advertising had the biggest percentage increase: from
$2.1 billion, or 11.9% of all medical marketing, in 1997 to $9.6
billion, or 32% of total spending, in 2016.
Can you please provide what your ratio of spending on sales and
marketing to research and development is today?
Answer. In 2018, the pharmaceutical segment of Johnson & Johnson
invested 86 percent more in R&D globally ($8.4B) than we spent on
global sales and marketing ($4.5B).
price-gouging
Question. Sanofi, as I understand it, has made a pledge to the
public to limit its price increases to the national health expenditures
growth projection.
Would your company commit to a cap on annual price increases as
part of your PhRMA membership criteria?
Answer. In 1993, the Pharmaceutical Manufacturers Association (PMA,
now the Pharmaceutical Research and Manufacturers of America or PhRMA)
asked the Department of Justice (``DOJ'') Antitrust Division to review
a proposal for a PMA effort to ask member companies to commit
voluntarily to limiting price increases on their entire line of
prescription medicines in any calendar year to an amount not to exceed
the increase in the Consumer Price Index (CPI). In its response, the
DOJ Antitrust Division stated that, ``[T]he Department believes that
the proposed program would violate the antitrust laws. . . . The
Supreme Court has. . . made clear that agreements that set maximum
prices are as equally illegal as agreements that set minimum prices.''
The DOJ noted that it ``intends to bring suit to challenge the program
if PMA and its members go forward with this proposal.'' Therefore, we
are unable to commit to such a cap as part of PhRMA membership
requirements due to likely enforcement action by the DOJ.
Question. What policies would you propose to help ensure lower
launch prices for new drugs?
Answer. We support rebate reforms that ensure patients benefit from
negotiated rebates and discounts--$150 billion in 2017 alone--and, as a
result, have patients see lower out-of-pocket costs at the pharmacy.
Depending on whether elimination of rebates applies to the entire
market or only to those related to Federal health plans and assuming
rebates are not replaced by high fees or other costs that offset the
amount saved, we expect to lower list prices or offer discounts for
pass-through at the point of sale. In either case, we would need to
renegotiate our agreements with customers.
The degree to which we can convert current rebates to list price
reductions or point-of-sale discounts will depend upon the details of
the final regulation and the reactions of other stakeholders in the
supply chain. We are concerned that PBMs may seek to replace rebate
revenue with new and increasing fees or may seek to shift costs among
supply chain participants through service fees.
transparency
Question. In many of your testimonies, you mentioned that the
current system of pharmacy benefit manager (PBM) back-end rebates do
not rarely results in a scenario where the PBM passes on savings to
consumers at the point of sale (POS). The administration recently
proposed a rule to eliminate the anti-kickback statute safe harbor
protections for these drug rebates.
Do you agree that greater transparency should be required to
understand how manufacturers and PBMs are negotiating prices and
rebates to ensure that savings are passed down to beneficiaries?
Answer. We believe that a point-of-sale discount model will make
price reductions offered by the manufacturer more transparent because
these discounts will be directly reflected in patient out-of-pocket
cost at the pharmacy. However, we do not believe that the proposal will
improve transparency with respect to fees or mark-ups to the price of
drugs added elsewhere in the supply chain.
Depending on whether elimination of rebates applies to the entire
market or only to those related to Federal health plans and assuming
rebates are not replaced by high fees or other costs that offset the
amount saved, we expect to lower list prices or offer discounts for
pass-through at the point of sale.
pbms
Question. An Axios article from March 7, 2019 highlights the fact
that, while ``pharmaceutical companies put a lot of the blame for high
drug prices on pharmacy benefit managers,'' many large pharmaceutical
companies ``rely on PBMs to manage their own health-care benefits.''
In your role as an employer, does your company contract with a
pharmaceutical benefit manager (PBM) to administer the prescription
drug benefits for your employees and negotiate lower drug costs on your
behalf?
Answer. As an employer, we design our own pharmacy benefit program
and contract with a PBM for administration and to negotiate on our
behalf.
Question. For those of you who do use a PBM to help manage the
prescription drug benefit for your employees, how do you utilize the
rebates your PBM negotiates to lower health-care costs or drug costs
for your employee plans and what does your company do with that
savings? Specifically, do the savings go toward lowing premiums?
Answer. We use any savings to offset total plan costs, enhance
benefits, and lower premium and out-of-pocket costs for our employees.
In order to ensure our employees have affordable access to medicine, we
have a monthly per prescription out-of-pocket cap.
Question. For those of you who do use a PBM to help manage the
prescription drug benefit for your employees, does your PBM offer
point-of-sale rebates to your employees?
Answer. We are exploring the possibility of offering point-of-sale
rebates with our PBM.
______
Questions Submitted by Hon. Sheldon Whitehouse
Question. Please describe any policy changes you support that would
result in your company lowering the list prices of its drugs.
Answer. We support rebate reforms that ensure patients benefit from
negotiated rebates and discounts-- $150 billion in 2017 alone--and, as
a result, have patients see lower out-of-pocket costs at the pharmacy.
Depending on whether elimination of rebates applies to the entire
market or only to those related to Federal health plans and assuming
rebates are not replaced by high fees or other costs that offset the
amount saved, we expect to lower list prices or offer discounts for
pass-through at the point of sale. In either case, we would need to
renegotiate our agreements with customers.
The degree to which we can convert current rebates to list price
reductions or point-of-sale discounts will depend upon the details of
the final regulation and the reactions of other stakeholders in the
supply chain. We are concerned that PBMs may seek to replace rebate
revenue with new and increasing fees or may seek to shift costs among
supply chain participants through service fees.
Question. How much does your company's research and development
portfolio rely on taxpayer-funded research conducted by the National
Institutes of Health (NIH)? How many of your company's products are
based, at least in part, on NIH research, and how many are the result
of research funded solely by your company?
Answer. The NIH plays an important role in medical research,
primarily funding basic research on medical problems. The
pharmaceutical industry is responsible for developing the solutions--
undertaking the long, financially risky, and costly process to discover
a compound and develop new medicines that meet the stringent safety and
efficacy requirements of the FDA. In those instances where NIH
contributes to a product that is brought to market, NIH would receive
any contracted license fees or royalties.
Question. In each of the last 5 years, how much has your company
spent on research and development versus the advertising and marketing
of your products?
Answer. Below is a chart including global Janssen R&D and Sales and
Marketing expenditures over the last 5 years. Sales and marketing
includes expenses related to: (1) selling, (2) marketing management,
(3) market and consumer research, and (4) advertising and promotion.
------------------------------------------------------------------------
2014 2015 2016 2017 2018
------------------------------------------------------------------------
Janssen R&D $6.2B $6.8B $7B $7.9B $8.4B
------------------------------------------------------------------------
Janssen Sales and Marketing $4.5B $4.6B $4.5B $4.2B $4.5B
------------------------------------------------------------------------
Question. During the hearing, you mentioned that your company would
be likely to lower the list prices of its drugs if the recent proposal
by the Trump administration to change the current system of rebates was
extended to the private market.
If the policy was extended to the private market, how large would
the list price reductions be relative to the size of the rebates your
company is currently providing?
How will this proposal affect how your company sets the list prices
for new drug products?
Answer. Depending on whether elimination of rebates applies to the
entire market or only to those related to Federal health plans and
assuming rebates are not replaced by high fees or other costs that
offset the amount saved, we expect to lower list prices or offer
discounts for pass-through at the point of sale. In either case, we
would need to renegotiate our agreements with customers.
The degree to which we can convert current rebates to list price
reductions or point-ofsale discounts will depend upon the details of
the final regulation and the reactions of other stakeholders in the
supply chain. We are concerned that PBMs may seek to replace rebate
revenue with new and increasing fees or may seek to shift costs among
supply chain participants through service fees.
Question. If the proposal is finalized and not extended to the
private market, will your company make any list price reductions? If
so, how large would the reductions be relative to the size of the
rebates your company is currently providing?
Answer. If elimination of rebates applies only to Medicare and
Medicaid Managed Care and assuming rebates are not replaced by high
fees or other costs that offset the amount saved, we expect to offer
discounts for pass-through at the point of sale. To do so, we would
need to renegotiate our agreements with customers.
The degree to which we can convert current rebates to point-of-sale
discounts will depend upon the details of the final regulation and the
reactions of other stakeholders in the supply chain. We are concerned
that PBMs may replace rebate revenue with new and increasing fees or
may shift costs among supply chain participants through service fees.
______
Question Submitted by Hon. Maggie Hassan
Question. In June of 2018, the Medicaid and CHIP Payment and Access
Commission (MACPAC) unanimously recommended under Recommendation 1.1 in
their annual report to Congress that Congress remove the statutory
requirement that manufacturers blend the average manufacturer price
(AMP) of a brand drug and its authorized generic.\1\
---------------------------------------------------------------------------
\1\ MACPAC, ``Improving Operations of the Medicaid Drug Rebate
Program,'' https://www.macpac.gov/wp-content/uploads/2018/06/Improving-
Operations-of-the-Medicaid-Drug-Rebate-Program.pdf.
This requirement created an unintended loophole. Rather than use
the price of the authorized generic, drug companies can sell its
authorized generic to a corporate subsidiary at an artificially lower
price, and use that lower price to bring down the AMP, which in turn
---------------------------------------------------------------------------
lowers the rebate obligation.
Does your company engage in this practice? Has your company ever
engaged in this practice in the past?
Answer. We do not include authorized generic internal transfer
prices to an affiliate when calculating Average Manufacturer Price for
the branded product. Under previous versions of the statute and CMS
guidance, we have at times in the past included in Average Manufacturer
Price the transfer prices of our authorized generic sold to an
affiliate.
______
Questions Submitted by Hon. Catherine Cortez Masto
Question. As a portion of your revenue, for what percentage of the
drugs in your portfolio do you offer no rebates? Based on the drugs in
your pipeline, do you foresee that portion growing? For those drugs is
your list price equal to your net price?
Answer. The information requested is confidential and competitively
sensitive. As such, potentially responsive information is not available
for public disclosure.
Question. Do you invest more in R&D than you generate in US sales
revenue? Please include specific figures.
Answer. Janssen is one of the world's top R&D investors in any
industry, anywhere in the world. In 2018 we invested $8.4 billion in
pharmaceutical R&D globally. Our pharmaceutical revenue in the U.S. was
$23.3 billion. We invested 86 percent more in pharmaceutical R&D ($8.4
billion) than we spent on pharmaceutical global sales and marketing
($4.5 billion).
Question. Do you invest more in R&D than you spend on marketing and
administration? What company functions do you consider to be included
in administration? Please include specific figures.
Answer. Johnson & Johnson is comprised of three business segments:
pharmaceuticals (Janssen), medical devices, and consumer products. In
its financial statements, Johnson & Johnson reports a global total
figure across all segments for Sales, Marketing and Administration
(``SM&A''). This figure combines marketing, sales, and administrative
expenses such as insurance, legal, finance, and product distribution.
In 2018, that global, cross-sector SM&A expenditure was $22.54 billion.
The total global, cross-sector R&D investment by J&J in 2018 was $10.78
billion.
Johnson & Johnson does not report SM&A by business segment.
Janssen, the pharmaceutical segment of J&J, invested $8.4 billion in
R&D globally in 2018 and spent $4.5 billion on marketing and sales
globally.
Question. Do you invest more in R&D than you spend on marketing and
sales? What company functions do you consider to be included in sales?
Please include specific figures.
Answer. In 2018, we invested 86 percent more in pharmaceutical R&D
($8.4 billion) than we spent on pharmaceutical global sales and
marketing ($4.5 billion). Sales and marketing includes: (1) our
expenses related to selling, (2) marketing management, (3) market and
consumer research, and (4) advertising and promotion.
Question. Why do you advertise for the drugs you manufacture? What
factors do you consider in choosing which drugs you advertise?
Answer. We believe direct-to-consumer communication, including
advertising, can empower patients with information to help them have
appropriate discussions with their healthcare providers, including
dialogue about the risks and benefits of treatment. We provide
accurate, up-to-date educational materials to help patients facing
diseases our medicines treat and to help patients who take our
medicines understand how to use them properly.
We believe acting ethically and responsibly is not only the right
thing to do but also the right way to do business. We follow all
relevant laws and regulations regarding the promotion of prescription
drug products and submit promotional materials to the U.S. Food and
Drug Administration at the time of initial publication or
dissemination.
We work to communicate in ways that will be most valuable in
empowering patients to have appropriate dialogue with their healthcare
providers.
We consider the availability of information and awareness of
treatment options. We build a communication plan that can include a
variety of channels, with direct-to-consumer advertising being one
channel among many we may use.
______
Janssen Biotech, Inc. Monetary and Product Contributions to U.S.-based
Charitable Organizations Full Year 2014
(Payments made from January 1, 2014 to December 31, 2014)--Amended March
19, 2019
------------------------------------------------------------------------
Payment
Donation Payee Payee Amount Payment Project Title/
Type Address (USD) Date Description
------------------------------------------------------------------------
Monetary 100 4631 $1,000 8/29/2014 100 Black Men
Black Delmar of Metro St.
Men (of Boulevard Louis, St.
Metro , St. Louis, MO
St. Louis, MO
Louis) 63108
------------------------------------------------------------------------
Monetary Abington 515 $300 8/29/2014 Abington Art
Art Meetingho Center,
Center use Road Jenkintown,
Jenkintow PA (2014
n, PA Janssen
19046 Cares
Volunteer
Days)
------------------------------------------------------------------------
Monetary Aldie 11 Welden $300 9/10/2014 Aldie
Foundat Drive Foundation,
ion Doylestow Doylestown,
Inc. n, PA PA Janssen
18901 Cares
Volunteer
Days
------------------------------------------------------------------------
Monetary American 2600 US $1,000 4/21/2014 Run for Dad
Cancer Highway 1 Prostate
Society North Cancer event
North in Hamilton,
Brunswick NJ
, NJ
08902
------------------------------------------------------------------------
Monetary Arthriti 115 NE $5,000 8/29/2014 Arthritis
s 100th Foundation,
Foundat Suite Seattle, WA--
ion #350 Great West
Seattle, Region JBRs
WA 98125
------------------------------------------------------------------------
Monetary Arthriti 1876 $6,000 11/10/2014 Jingle Bell
s Minnehaha Run/Walks
Foundat Avenue Upper
ion West St. Midwest
Paul, MN
55104
------------------------------------------------------------------------
Monetary Arthriti 35 East $10,000 8/29/2014 AF, Chicago,
s Wacker IL 2014
Foundat Drive Heartland
ion Suite Region
2260 Jingle Bell
Chicago, Runs and
IL 60601 Walks
------------------------------------------------------------------------
Monetary Arthriti 4300 $7,000 12/22/2014 Arthritis
s McArthur Foundation,
Foundat Suite 245 Dallas, TX--
ion Dallas, JBRs South
TX 75209 Central
Region
------------------------------------------------------------------------
Monetary Arthriti 4530 Park $5,000 8/29/2014 Arthritis
s Road Foundation,
Foundat Charlotte Charlotte,
ion , NC NC--2014
29209 JBRs
------------------------------------------------------------------------
Monetary Arthriti 4630 $7,500 10/3/2014 Arthritis
s Richmond Foundation,
Foundat Road Cleveland,
ion Suite 240 OH JBRs
Cleveland
, OH
44128
------------------------------------------------------------------------
Monetary Arthriti 800 West $12,500 11/13/2014 Jingle Bell
s Sixth Run/Walks,
Foundat Street Los Angeles
ion Suite CA
1250 Los
Angeles,
CA 90017
------------------------------------------------------------------------
Monetary Arthriti 8383 North $1,000 11/13/2014 Arthritis
s Davis Foundation,
Foundat Highway Pensacola,
ion Pensacola FL--Jacksonv
, FL ille JBR
32514
------------------------------------------------------------------------
Monetary Arthriti 8383 North $1,000 11/13/2014 Arthritis
s Davis Foundation,
Foundat Highway Pensacola,
ion Pensacola FL for
, FL Pensacola
32514 JBR/W
------------------------------------------------------------------------
Monetary Arthriti 8383 North $1,500 11/13/2014 Arthritis
s Davis Foundation,
Foundat Highway Pensacola,
ion Pensacola FL--Orlando
, FL Jingle Bell
32514 Run & Walk
------------------------------------------------------------------------
Monetary Arthriti 111 South $2,500 4/18/2014 Walk to Cure
s Independe Arthritis,
Foundat nce Mall Philadelphia
ion, E Suite , PA, May
Inc. 500 17, 2014
Philadelp
hia, PA
19106
------------------------------------------------------------------------
Monetary Arthriti 115 NE $5,000 6/9/2014 Eight Walks
s 100th to Cure
Foundat Suite Arthritis in
ion, #350 the Great
Inc. Seattle, West Region
WA 98125
------------------------------------------------------------------------
Monetary Arthriti 122 East $50,000 4/4/2014 NE Region
s 42nd Jingle Bell
Foundat Street Runs 2014
ion, 18th
Inc. Floor New
York, NY
10168
------------------------------------------------------------------------
Monetary Arthriti 1876 $3,500 4/4/2014 Arthritis
s Minnehaha Foundation's
Foundat Avenue 2014 Walks
ion, West St. in MN, WI
Inc. Paul, MN and ND
55104
------------------------------------------------------------------------
Monetary Arthriti 209 10th $2,000 4/21/2014 Arthritis
s Avenue Foundation
Foundat South Walks to
ion, Suite 228 Cure
Inc. Nashville Arthritis in
, TN TN and AL
37203
------------------------------------------------------------------------
Monetary Arthriti 29 Crafts $3,500 4/21/2014 Walks to Cure
s Street Arthritis in
Foundat Suite 450 CT, RI, NH,
ion, Newton, and MA
Inc. MA 02458
------------------------------------------------------------------------
Monetary Arthriti 35 East $12,000 4/21/2014 Walks to Cure
s Wacker Arthritis in
Foundat Drive IL, IN, IA,
ion, Suite KS, MO, NE
Inc. 2260
Chicago,
IL 60601
------------------------------------------------------------------------
Monetary Arthriti 400 $500 6/9/2014 2014 Walk to
s Hibiscus Cure
Foundat Street Arthritis,
ion, West Palm Lake Worth,
Inc. Beach, FL FL
33401
------------------------------------------------------------------------
Monetary Arthriti 408 12th $500 4/18/2014 Walk to Cure
s Street Arthrits,
Foundat West Sarasota,
ion, Bradenton FL, May 17,
Inc. , FL 2014
34205
------------------------------------------------------------------------
Monetary Arthriti 4300 $4,000 4/21/2014 South Central
s McArthur Region Walks
Foundat Suite 245 to Cure
ion, Dallas, Arthritis
Inc. TX 75209
------------------------------------------------------------------------
Monetary Arthriti 4720 $10,000 4/18/2014 Arthritis
s Montgomer Walks--Mid
Foundat y Lane Atlantic
ion, Suite 300 Region--DE,
Inc. Bethesda, MD, DC, VA,
MD 20814 NC, and SC.
------------------------------------------------------------------------
Monetary Arthriti 800 West $10,000 6/25/2014 Walks to Cure
s 6th Arthritis in
Foundat Street CA, AZ, and
ion, Suite HI
Inc. 1250 Los
Angeles,
CA 90017
------------------------------------------------------------------------
Monetary Arthriti 8383 North $500 3/17/2014 2014 Walk to
s Davis Cure
Foundat Highway Arthritis
ion, Pensacola Pensacola FL
Inc. , FL
32514
------------------------------------------------------------------------
Monetary Big 2875 York $300 6/24/2014 Janssen Cares
Brother Road Volunteers
s Big Jamison, Days--Commun
Sisters PA 18929 ity Service
at Big
Brothers Big
Sisters,
Jamison, PA
------------------------------------------------------------------------
Monetary Bowmans 1635 River $300 8/29/2014 Bowman's Hill
Hill Road New Wild Flower
Wildflo Hope, PA Preserve,
wer 18938 New Hope, PA
Preserv (2014 JCVD)
e
------------------------------------------------------------------------
Monetary Bringing 940 West $2,500 10/28/2014 Bringing Hope
Hope Valley Home Inc.,
Home Road Wayne, PA
Inc. Wayne, PA
19087
------------------------------------------------------------------------
Monetary Cancer 121 Avenue $2,000 4/21/2014 Cancer Care's
Care, of the 6th Annual
Inc. Americas Healing
6th Floor Hearts
New York, Family
NY 10013 Bereavement
Camp,
Milford, PA
------------------------------------------------------------------------
Monetary Cancer 121 Avenue $10,000 4/21/2014 2014-2015
Care, of the Edition of
Inc. Americas ``A Helping
6th Floor Hand: The
New York, Resource
NY 10013 Guide for
People with
Cancer.''
------------------------------------------------------------------------
Monetary Cancer 200 Kirk $600 6/25/2014 Janssen Cares
Support Road Volunteer
Communi Warminste Days--commun
ty r, PA ity service
Gilda's 18974 at Gilda's
Club Club June 24
Warmins and June 26,
ter, PA 2014
------------------------------------------------------------------------
Monetary Cancer 4100 $2,500 10/3/2014 Cancer
Support Chamounix Support
Communi Drive Community of
ty of Philadelp Philadelphia
Philade hia, PA ,
lphia 19131 Warminister,
PA
------------------------------------------------------------------------
Monetary Children 34th and $5,000 10/3/2014 CHOP
s Civic Philadelphia
Hospita Center , PA Child
l of Blvd. Life Program
Philade Philadelp
lphia hia, PA
Foundat 19104-
ion 4399
------------------------------------------------------------------------
Monetary Chrohn's 386 Park $15,000 8/29/2014 Crohn's and
and Avenue Colitis
Colitis South Foundation,
Foundat 17th New York,
ion Floor New NY--Camp
York, NY Oasis
------------------------------------------------------------------------
Monetary Communit 300B $20,000 10/15/2014 Community
y Lawrence Volunteers
Volunte Drive in Medicine,
ers in West West
Medicin Chester, Chester, PA
e Inc. PA 19380
------------------------------------------------------------------------
Monetary Crohns 116 Wilson $5,000 11/13/2014 Buds N Suds
and Pike Benefit
Colitis Circle Concert
Foundat Brentwood Nashville,
ion of , TN TN
America 37027
------------------------------------------------------------------------
Monetary Crohns 116 Wilson $5,000 11/13/2014 Donate A
and Pike Photo
Colitis Circle Awareness
Foundat Brentwood Campaign at
ion of , TN ACG Fall
America 37027 2014
------------------------------------------------------------------------
Monetary Crohns 386 Park $135,000 4/22/2014 Take Steps
and Avenue Walks
Colitis South Nationwide
Foundat 17th
ion of Floor New
America York, NY
------------------------------------------------------------------------
Monetary Crohns 9 Lake $3,000 4/18/2014 CCFA 's Camp
and Bellevue Oasis for
Colitis Drive IBD
Foundat Suite 203 Pediatric
ion of Bellevue, Patients,
America WA 98005 Longbranch,
WA
------------------------------------------------------------------------
Monetary Crohn's 386 Park $5,000 8/29/2014 CCFA, NY, NY
and Avenue (DDW
Colitis South Awareness)
Foundat 17th
ion of Floor New
America York, NY
------------------------------------------------------------------------
Monetary Delaware 215 South $3,000 9/10/2014 Delaware
Valley 16th Valley
Science Street, Science
Council Philadelp Council,
hia PA STEM
19102 Programs
------------------------------------------------------------------------
Monetary Delaware 215 South $21,300 4/4/2014 Delaware
Valley 16th Valley
Science Street, Science
Fairs, Philadelp Fairs Tri-
Inc. hia PA State
19102 Competition,
Oaks, PA
------------------------------------------------------------------------
Monetary Educatio 454 Maple $5,000 10/3/2014 Education-
n-Plus Terrace Plus Inc.,
Inc. Ardmore, Philadelphia
PA , PA Read
Now Program
------------------------------------------------------------------------
Monetary Franklin 222 North $10,000 10/3/2014 Franklin
Institu 20th Institute,
te Street Philadelphia
Philadelp , PA
hia, PA
19103
------------------------------------------------------------------------
Monetary Girl 330 Manor $4,000 10/3/2014 Girl Scouts
Scouts Road of Eastern
of Miquon, PA, Miquon,
Eastern PA 19444 PA
Pennsyl
vania
Inc.
------------------------------------------------------------------------
Monetary Green 1368 $15,000 10/3/2014 Green
Valleys Prizer Valleys,
Assocat Road Pottstown,
ion of Pottstown PA (EITC
Southea , PA participant)
stern 19465
Pennsyl
vania
------------------------------------------------------------------------
Monetary Hatboro 440 South $300 9/4/2014 Hatboro Area
Area York Road YMCA,
YMCA Hatboro, Hatboro, PA
PA 19040 (2014 Jansen
Cares V.D.)
------------------------------------------------------------------------
Monetary Hatboro 229 $300 8/29/2014 Hatboro-
Horsham Meetingho Horsham
Educati use Road Educational
onal Hatboro- Foundation,
Foundat Horsham, Horsham, PA
ion PA 19044
------------------------------------------------------------------------
Monetary Hatboro 229 $25,000 8/29/2014 Hatboro-
Horsham Meetingho Horsham Ed.
Educati use Road Foundation
onal Hatboro- (EITC),
Foundat Horsham, Horsham, PA
ion PA 19044
------------------------------------------------------------------------
Monetary Impact 2979 $300 8/29/2014 JBI Impact
Thrift Bethlehem Thrift
Sortes Pike Sortes,
Inc. Montgomer Inc.,
yville, Montgomeryvi
PA lle, PA
------------------------------------------------------------------------
Monetary Integrat 532 $1,000 4/4/2014 2014 Belmont
ed Broadholl Stakes Blue
Medical ow Road Ribbon Run
Foundat Suite for Prostate
ion, 142A Cancer,
Inc. Melville, Melville, NY
NY 11747
------------------------------------------------------------------------
Monetary Internat 6144 Clark $10,000 12/24/2014 International
ional Center Waldenstroms
Waldens Avenue Macroglobuli
troms Sarasota, nemia
Macrogl FL 34238 Foundation,
obuline Sarasota, FL
mia
Foundat
ion
------------------------------------------------------------------------
Monetary Junior 522 South $5,000 10/3/2014 Junior
Achieve Walnut Achievement,
ment of Street Wayne, PA
Delawar Wilmingto (Horsham
e n, DE Scools)
Valley 19801
------------------------------------------------------------------------
Monetary Leukemia 555 North $175,000 6/16/2014 LLS
and Lane Nationwide
Lympho Suite Light the
Society 5010 Night Walks
, Inc. Conshohoc
ken, PA
19428
------------------------------------------------------------------------
Monetary Metropol 2323 $15,000 10/3/2014 MANNA,
itan Ranstead Philadelphia
Area Street , PA
Neighbo Philadelp
rhood hia, PA
Nurtrit 19103
ion
Allianc
e
------------------------------------------------------------------------
Monetary National PO Box 303 $2,500 8/29/2014 National
Ovarian Holicong, Ovarian
Cancer PA 18928 Cancer
Coaliti Coalition
on Inc. Inc.,
Holicong, PA
------------------------------------------------------------------------
Monetary National 6600 SW $50,000 11/13/2014 National
Psorias 2nd Psoriasis
is Avenue Foundation,
Foundat Suite 300 Portland OR--
ion Portland, Compliments
OR 97223 are
Contagious
------------------------------------------------------------------------
Monetary Open 350 Main $300 8/29/2014 Royersford
Door Street Outreach
Royersfor Open Door
d, PA (Janssen
19468 Cares V.D.),
Royersford,
PA
------------------------------------------------------------------------
Monetary Perkiome 1 West $300 8/29/2014 Perkioment
n Skippack Watershed
Watersh Pike Conservancy,
ed Schwenksv Schwenksvill
Conserv ille, PA e, PA
ancy 19473
------------------------------------------------------------------------
Monetary Philadel 325 $10,000 10/3/2014 Philadelphia
phia Chestnut Reads, Inc.,
Reads, Street Philadelphia
Inc. Philadelp , PA (EITC)
hia, PA
19106
------------------------------------------------------------------------
Monetary Premier PO Box 93 $5,000 10/3/2014 Premier Cares
Cares Pleasant Foundation,
Foundat Valley, Inc.
ion NY 12569
Inc.
------------------------------------------------------------------------
Monetary Prostate 7009 S. $1,000 8/29/2014 Prostate
Cancer Potomac Cancer
Educati Street Education
on Centennia Council,
Council l, CO Centennial,
80112 CO
------------------------------------------------------------------------
Monetary Prostate 500 $10,000 4/21/2014 Prostate
Health Victory Health
Educati Road Education
on Quincy, Network
Network MA 02170 (PHEN) Sixth
, Inc. Annual
Father's Day
Rally
Nationwide
------------------------------------------------------------------------
Monetary Rebuidli PO Box $5,000 6/13/2014 Mantua Block
ng 42752 Build,
Togethe Philadelp Philadelphia
r hia, PA , PA
Philade 19101-
lphia 2752
------------------------------------------------------------------------
Monetary Retired 925 $7,000 10/15/2014 RSVP, Blue
Senior Harvest Bell, PA
Volunte Drive
er Suite 100
Program Blue
of Bell, PA
Montgom 19422
ery
County
------------------------------------------------------------------------
Monetary Riverben 1950 $5,000 6/9/2014 Outreach to
d Spring Children/
Environ Mill Road Access to
mental Gladwyne, Nature
Educati PA 19035 Education
on for local
Center elementary
school in
Norristown,
PA
------------------------------------------------------------------------
Monetary Special 2800 $4,000 12/31/2014 Special
Equestr Street Equestrians,
ians Road Warrington,
Warringto PA
n, PA
18976
------------------------------------------------------------------------
Monetary The 34th $2,000 4/18/2014 5th Annual
Childre Street Walk for
ns Civic Hope,
Hospita Center Veteran's
l of Boulevard Park,
Philade Philadelp Hamilton,
lphia hia, PA NJ,
Foundat 19104 benefitting
ion IBD Research
at CHOP
------------------------------------------------------------------------
Monetary The 4275 $3,000 6/9/2014 Hands-On
Giving County Helping by
Tree Line Road Children
Suite 138
Chalfont,
PA 18914
------------------------------------------------------------------------
Monetary The 2600 $10,000 4/21/2014 Hubert J. P.
Melmark Wayland Schoemaker
Charita Road Classic,
ble Berwyn, October 6,
Foundat PA 19312 2014,
ion Berwyn, PA
------------------------------------------------------------------------
Monetary Trustees University $7,000 10/15/2014 WXPN (Trutees
of the of of the U of
Univers Pennsylva PA),
ity of nia Philadelphia
Pennsyl Philadelp , PA
vania hia, PA
19104
------------------------------------------------------------------------
Monetary United 1709 $223,382 12/22/2014 United Way
Way of Benjamin Campaign
Greater Franklin Match
Philade Parkway
lphia Philadelp
and hia, PA
Souther 19103
n New
Jersey
------------------------------------------------------------------------
Monetary Us Too 5003 $1,000 9/10/2014 Us Too
Interna Fairview Internationa
tional Ave. , Des
Downers Plaines, IL
Grove, IL
60515
------------------------------------------------------------------------
Monetary Wissahic 12 Morris $2,603 6/25/2014 New
kon Road wildflower
Valley Ambler, meadow
Watersh PA 19002 development
ed via Janssen
Associa Cares
tion Volunteer
Days.
------------------------------------------------------------------------
Monetary Wissahic 12 Morris $1,400 4/21/2014 Community
kon Road Service
Valley Ambler, Project for
Watersh PA 19002 JBI's Bridge
ed to
Associa Employment
tion, program;
Inc. mentors and
students
planting
trees and
shrubs for
water
conservation
at
Wissahickon
Valley
Watershed
------------------------------------------------------------------------
Janssen has also made financial donations to independent charitable
foundations that assist patients who are underinsured and in financial
need with treatment-related expenses. In keeping with our donor
agreements and applicable regulatory guidance, we will only disclose
aggregate data on our charitable giving and do not publicize
information on donations to specific foundations and disease states.
In 2014, we contributed approximately $40 million in donations to
independent charitable foundations, enabling them to provide
assistance with medication-related copays to patients with cancer
diseases.
----------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------
Product Johnson & Johnson One Johnson & $84,591,419 3/15/2013 Patient Assistance
Patient Assistance Johnson Plaza, New Product Donation
Foundation Brunswick, NJ 08933
----------------------------------------------------------------------------------------------------------------
Product Johnson & Johnson One Johnson & $86,924,535 6/15/2013 Patient Assistance
Patient Assistance Johnson Plaza, New Product Donation
Foundation Brunswick, NJ 08933
----------------------------------------------------------------------------------------------------------------
Product Johnson & Johnson One Johnson & $78,551,321 9/15/2013 Patient Assistance
Patient Assistance Johnson Plaza, New Product Donation
Foundation Brunswick, NJ 08933
----------------------------------------------------------------------------------------------------------------
Product Johnson & Johnson One Johnson & $86,312,829 12/15/2013 Patient Assistance
Patient Assistance Johnson Plaza, New Product Donation
Foundation Brunswick, NJ 08933
----------------------------------------------------------------------------------------------------------------
Updatd February 24, 2017
Janssen Pharmaceuticals, Inc. Monetary and Product Contributions to U.S.-
based Charitable Organizations Full Year 2014
(Payments made from January 1, 2014 to December 31, 2014)
------------------------------------------------------------------------
Project
Donation Payee Payee Payment Amount Payment Title/
Type Address (USD) Date Description
------------------------------------------------------------------------
Monetary 180 1 $1,000 9/22/2014 Youth
Turnin Bethany Helpline
g Road, Hunterdon,
Lives Buildin Mercer, and
Around g 3 Somerset
, Inc. Suite Operations
42
Hazlet,
NJ
07730
------------------------------------------------------------------------
Monetary A P.O. Box $2,500 12/4/2014 A Woman's
Woman' 299 Place
s Doylest Prevention
Place own, PA Project
18901
------------------------------------------------------------------------
Monetary Adult 872 E $300 8/4/2014 Cost
Day Main associated
Center Street with 2014
of Bridgew Janssen
Somers ater, Cares
et NJ volunteer
County 08807 activity
------------------------------------------------------------------------
Monetary Allies, 1262 $7,500 11/17/2014 Greensleeves
Inc. Whiteho Flemington
rse- Expansion
Hamilto Environment
n al
Square Stewardship
Road Program
Buildin
g A,
Suite
101
Hamilto
n, NJ
08690
------------------------------------------------------------------------
Monetary America 100 West $5,000 5/27/2014 2014 EXPO
n Station Pittsburgh
Diabet Square
es Drive
Associ Suite
ation 1900
Pittsbu
rgh, PA
15219
------------------------------------------------------------------------
Monetary America 1160 $30,000 12/10/2014 Diabetes
n Route Interventio
Diabet 22 East n Project
es Suite ($20,000),
Associ 103 and
ation Bridege Community
water, Outreach
NJ Education
08807 ($10,000)
------------------------------------------------------------------------
Monetary America 1701 $125,000 12/10/2014 American
n North Diabetes
Diabet Beaureg Association
es ard 's Outcomes-
Associ Street based
ation Alexand Community
ria, VA Programs
22311 Targeted to
High Risk
Populations
------------------------------------------------------------------------
Monetary America 1 Union $5,000 10/16/2014 Fundraising
n Street event
Heart Suite support to
Associ 301 benefit
ation Robbins general
ville, mission of
NJ organizatio
08691 n.
------------------------------------------------------------------------
Monetary America 1000 $20,000 12/10/2014 Partnership
n Wilson for
Psychi Bouleva Workplace
atric rd Mental
Founda Suite Health ICU:
tion 1825 Improving
Arlingt Emotional
on, VA Health
22208
------------------------------------------------------------------------
Monetary America 1000 $100,000 12/10/2014 Typical or
n Wilson Troubled?
Psychi Bouleva Student
atric rd Mental
Founda Suite Health
tion 1825 Education
Arlingt Program
on, VA
22208
------------------------------------------------------------------------
Monetary America 1000 $225,000 12/10/2014 Campaign by
n Wilson Psychiatris
Psychi Bouleva ts and
atric rd Judges to
Founda Suite Reduce the
tion 1825 Overreprese
Arlingt ntation of
on, VA Incarserate
22208 d
Individuals
with SMI
------------------------------------------------------------------------
Monetary America 707 $15,000 10/20/2014 Support for
n Red Alexand the
Cross er Road American
Princet Red Cross
on, NJ Disaster
08550 Cycle
Services
Program
------------------------------------------------------------------------
Monetary America Central $20,000 3/14/2014 Support to
n Red New American
Cross Jersey Red Cross
707 Disaster
Alexand Relief
er Road Services
Suite
101
Princet
on, NJ
08540-
6331
------------------------------------------------------------------------
Monetary Anchor 482 $418 1/9/2014 General
House, Centre Operating
Inc. Street Support
Trenton
, NJ
08611
------------------------------------------------------------------------
Monetary Anderso PO Box $17,500 10/22/2014 Integrated
n 134 532 Care
House County Management
Rd. 523
Whiteho
use, NJ
08889
------------------------------------------------------------------------
Monetary Ann 595 West $9,500 12/4/2014 Ann
Silver State Silverman
man Street Community
Commun Doylest Health
ity own, PA Clinic for
Health 18901 Bucks
Clinic County
residents
------------------------------------------------------------------------
Monetary Arc of 141 $5,000 9/22/2014 Fundraising
Somers South event
et Main support to
County Street benefit
Manvill general
e, NJ mission of
08835 organizatio
n
------------------------------------------------------------------------
Monetary Arc of 141 $4,000 10/1/2014 Respite
Somers South Services
et Main for
County Street Families
Manvill with
e, NJ Children
08835 with
Disabilitie
s
------------------------------------------------------------------------
Monetary Arthrit 500 E. $1,500 7/1/2014 The
is Morehea Community
Servic d Arthritis/
es Street Diabetes
Suite Project--ta
320 rgeting
Charlot women with
te, NC Type II
28202 Diabetes
------------------------------------------------------------------------
Monetary Asian 180 W $2,000 8/28/2014 Cardiovascul
Health Washing ar Health
Coalit ton Screenings
ion Street for Low-
Suite Income,
1000 Limited-
Chicago English
, IL Speaking At-
60602 Risk
Diabetic
Asian
Immigrants
and
Refugees in
Chicago
------------------------------------------------------------------------
Monetary Associa 819 $9,000 8/15/2014 Parital Care
tion Alexand Rehabilitat
for er Road ion and
Advanc Princet Support
ement on, NJ Services
of 08540
Mental
Health
------------------------------------------------------------------------
Monetary Associa 2400 N $20,000 11/17/2014 Spirit of
tion Street the Heart:
of NW Community
Black Sutie Inverventio
Cardio 249 n to
logist Washing Improve
s ton, DC Cardiovascu
20037 lar Health
of
Underserved
Patients
with AFIB
------------------------------------------------------------------------
Monetary Athens 7 N. $2,500 6/6/2014 The
Mental Congres Gathering
Health s St Place case
, Inc. Athens, management
OH services
45701 program for
community
drop-in
center for
adults with
mental
illness
------------------------------------------------------------------------
Monetary Autism 1060 $1,000 8/28/2014 Community
Speaks State Partner
Road 15th Annual
2nd Central New
Floor Jersey Walk
Princet Now for
on, NJ Autism
08540 Speaks
------------------------------------------------------------------------
Monetary B More 5 East $5,000 8/15/2014 Support of
Clubho Frankli B'More
use, n Clubhouse
Inc. Street which
Baltimo offers
re, MD members
21202 meaningful
work,
friendship,
and links
to stable
housing,
education
and other
resources
------------------------------------------------------------------------
Monetary Bay 66 Canal $5,000 6/12/2014 Bay Cove
Cove Street Wellness
Human Boston, Center to
Servic MA assist
es, 02114 diverse low-
Inc. income
clients who
are working
towards
recovery
from severe
mental
illness
------------------------------------------------------------------------
Monetary Bear 1162 $500 10/15/2014 Bear Tavern
Tavern Bear Elementary
Parent Tavern School
s Road Science
Associ Titusvi Fair
ation lle, NJ
08560
------------------------------------------------------------------------
Monetary Big 2875 $6,500 10/14/2014 School-Based
Brothe York Mentoring
rs Big Road Program
Sister Jamison
s of , PA
Bucks 18929
County
------------------------------------------------------------------------
Monetary Big 2 West $7,500 10/1/2014 Big Brothers
Brothe Washing Big Sisters
rs Big ton Youth
Sister Avenue Mentoring
s Of Suite Program-
Hunter 210 PO Somerset
don Box 123 County
Somers Washing
et and ton, NJ
Warren 07882
County
------------------------------------------------------------------------
Monetary Big 535 East $8,000 8/26/2014 Big Brothers
Brothe Frankli Big Sisters
rs Big n of Mercer
Sister Street County
s of Trenton Youth
Mercer , NJ Mentoring
County 08610 Program
------------------------------------------------------------------------
Monetary Boys 212 $22,500 10/14/2014 Career
and Centre Launch
Girls Street (Career
Club Trenton Exploration
of , NJ , Work
Trento 08611 Readiness,
n and HS
Mercer Graduation,
County and Career
Pathway
Program)
------------------------------------------------------------------------
Monetary Bridgeh 950 S. $4,000 6/12/2014 Recovery
aven, First Connection
Inc. Street program
Louisvi
lle, KY
40203
------------------------------------------------------------------------
Monetary Bridgew 615 N. $5,000 12/4/2014 Self-
ay Broad Sufficiency
Rehabi Street Fund for
litati Elizabe Somerset,
on th, NJ Mercer and
Servic 07208 Hunterdon
es residents
------------------------------------------------------------------------
Monetary Bristol 120 $7,500 12/10/2014 ArtRageous
Rivers Radclif Summer Camp
ide fe
Theate Street
r Co, P O Box
Inc. 1250
Bristol
, PA
19007
------------------------------------------------------------------------
Monetary Broward 305 $10,000 5/27/2014 Affordable
County Southea Rental
Commun st 18th Housing
ity Court program
Develo Fort
pment Lauderd
Corpor ale, FL
ation 33316
, Inc.
------------------------------------------------------------------------
Monetary Bucks 1069 $5,000 11/17/2014 Bucks County
County Jackson Housing
Housin ville Group's
g Road Veterans
Group Ivyland Housing
, PA Assistance
18974 Program
------------------------------------------------------------------------
Monetary Catholi Diocese $5,000 7/1/2014 On My Own--
c of Supportive
Charit Trenton Housing
ies Delawar Program
e House Services
Mental program
Health
Service
s 25
Ikea
Drive
Westham
pton,
NJ
08060
------------------------------------------------------------------------
Monetary Catholi Diocese $17,500 7/7/2014 Partners In
c of Recovery
Charit Trenton program
ies Delawar
e House
Mental
Health
Service
s 25
Ikea
Drive
Westham
pton,
NJ
08060
------------------------------------------------------------------------
Monetary Catholi 212 $75 1/28/2014 Employee
c Ninth directed
Charit Street donation in
ies Pittsbu lieu of
Dioces rgh, company
e of Pennsyl holiday
Pittsb vania gift
urgh 15222
------------------------------------------------------------------------
Monetary Catholi 212 $75 12/3/2014 Employee
c Ninth directed
Charit Street donation in
ies Pittsbu lieu of
Dioces rgh, company
e of Pennsyl holiday
Pittsb vania gift
urgh 15222
------------------------------------------------------------------------
Monetary Catholi 920 $4,000 10/16/2014 CYO's Broad
c South St. Trenton
Youth Broad Center
Organi Street After
zation Trenton School
of , NJ Program's
Mercer 08611 (ASP)
County Tutoring
Project
------------------------------------------------------------------------
Monetary Center 11 $300 8/4/2014 Cost
for Minneak associated
Educat oning with 2014
ional Road Janssen
Advanc Fleming Cares
ement ton, NJ volunteer
08822 activity
------------------------------------------------------------------------
Monetary Center 11 $15,000 10/20/2014 Employment
for Minneak Training
Educat oning program
ional Road enhancement
Advanc Fleming s
ement ton, NJ
08822
------------------------------------------------------------------------
Monetary Center Harzfeld $10,000 9/16/2014 PAINS:
for Buildin National
Practi g 1111 Pain
cal Main Strategy
Bioeth Street, Roll-Out
ics Suite Meeting
500
Kansas
City,
MO
64105-2
116
------------------------------------------------------------------------
Monetary Chabad PO Box $1,000 5/9/2014 ``We Care''
Lubavi 29 Educational
tch of Princet Series
Mercer on, NJ
County 08542
, Inc.
------------------------------------------------------------------------
Monetary Child 204 N. $2,000 10/1/2014 Adolescent
Home West Prenatal
and Street and
Commun #101 Parenting
ity Doylest Continuum
own, PA
18901
------------------------------------------------------------------------
Monetary Childre 635 $10,000 10/20/2014 CUNA and
n's South Body and
Home Clinton Soul
Societ Avenue Prenatal
y of Trenton Health
New , NJ Education
Jersey 08611 Program
------------------------------------------------------------------------
Monetary Childre Roebling $5,000 5/7/2014 Fundraising
n's Market event
Home Complex support to
Societ 635 benefit
y of South general
New Clinton mission of
Jersey Avenue organizatio
Trenton n
, NJ
08611-
1831
------------------------------------------------------------------------
Monetary Christi PO Box $2,500 12/3/2014 Pajama Bags
nes 190 for Kids in
Hope Hopewel Need in
for l, NJ Mercer
Kids 08525 County
Founda
tion
------------------------------------------------------------------------
Monetary College 2000 $22,500 10/14/2014 Nursing
of New Penning Merit
Jersey ton Scholarship
Road s ($10,000)
P.O. and
Box Educational
7718 Opportunity
Ewing, Fund
NJ Promise
08628 Awards
($12,500)
------------------------------------------------------------------------
Monetary Colorad PO Box $2,500 8/1/2014 Peer
o 6336 Workforce
Mental Denver, Initiative
Wellne CO
ss 80206
Networ
k
------------------------------------------------------------------------
Monetary Communi PO Box $5,000 11/17/2014 Rise Summer
ty 88 116 Healthy
Action North Food
Servic Main Initiative
e Street for low
Center Hightst income
, Inc. own, NJ youth
08520
------------------------------------------------------------------------
Monetary Communi 4059 $5,000 10/23/2014 Arts for
ty Skyron Seniors
Conser Drive ($3,000)
vatory Doylest and Music
of own, PA Therapy
Music 18902 ($2,000)
------------------------------------------------------------------------
Monetary Communi PO Box $150,000 12/12/2014 Johnson &
ty 338 Johnson
Founda Morrist Somerset
tion own, NJ County
of New 07963 Contributio
Jersey ns Fund to
support
healthcare
and basic
needs of
residents
in Somerset
and
Hunterdon
Counties
------------------------------------------------------------------------
Monetary Communi P.O. Box $11,500 10/13/2014 Each One,
ty 15176 Teach One:
Health 407 An Evidence
Coalit Crutchf Based
ion, ield Diabetes
Inc. Street Self-
Durham, Management
NC Workshop
27704 and
Community
Leaders
Training
------------------------------------------------------------------------
Monetary Communi 199 $12,000 5/27/2014 Pathway to
ty Pomeroy Recovery
Hope, Road residential
Inc. Parsipp programs
any, NJ ($10,000)
07054 and The
Mental
Health
Educational
Forum and
Wellness
Fair
($2,000)
------------------------------------------------------------------------
Monetary Communi 199 $13,000 11/5/2014 Hope for
ty Pomeroy Veterans
Hope, Road and Valley
Inc. Parsipp Brook
any, NJ Village for
07054 Veterans
------------------------------------------------------------------------
Monetary Communi 310 W. $7,500 10/20/2014 Social
ty State Security
Justic Street Services
e 3rd and
Center Floor Veterans
, Inc. Trenton Assistance
, NJ Project
08618
------------------------------------------------------------------------
Monetary Communi 507 E. $4,000 7/1/2014 Compeer
ty College Program of
Mental Street Johnson
Health Iowa County
Center City,
For IA
Mid- 52240
Easter
n Iowa
dba
Compee
r
Progra
m,
Inc.
------------------------------------------------------------------------
Monetary Compeer 259 $2,500 7/29/2014 Compeer
Roches Monroe Rochester
ter, Avenue Youth and
Inc. Rochest Family
er, NY Mentoring
14607 Program
------------------------------------------------------------------------
Monetary Compeer 259 $3,000 7/1/2014 Compeer
, Inc. Monroe Senior
Avenue Partners
Suite program
340
Rochest
er, NY
14607
------------------------------------------------------------------------
Monetary Contact 60 S. $8,500 12/4/2014 CRISIS
of Main HOTLINES
Mercer Street and Online
County Penning Emotional
New ton, NJ Support:
Jersey 08534 CRISIS CHAT
, Inc. and
TxtToday
------------------------------------------------------------------------
Monetary Contact 60 South $1,000 3/17/2014 Annual
of Main Senior
Mercer Street Volunteer
County Penning Recognition
New ton, NJ Brunch,
Jersey 08534 ``Volunteer
, Inc. s Are
Heroes!''
------------------------------------------------------------------------
Monetary Court 1450 $12,500 10/14/2014 CASA of
Appoin Parksid Mercer
ted e Child
Specia Avenue Advocacy
l Suite Program for
Advoca 22 Abused and
tes Ewing, Neglected
NJ Children
08638
------------------------------------------------------------------------
Monetary D&R P.O. Box $250 2/3/2014 23rd Annual
Canal 2 Rocky D&R Canal
Watch Hill, Watch 5K
NJ Fun Run
08553
------------------------------------------------------------------------
Monetary Deborah 212 $1,000 8/28/2014 2015 Women's
Hospit Trenton Heart
al Road Health
Founda Browns Symposium
tion Mills,
NJ
08015
------------------------------------------------------------------------
Monetary Delawar 14 $300 8/4/2014 Cost
e Michael associated
River McCorri with 2014
Steamb stin Janssen
oat Road Cares
Floati Hamilto volunteer
ng n, NJ activity
Classr 08690
oom,
Inc.
------------------------------------------------------------------------
Monetary Delawar 14 $4,000 11/3/2014 Environmenta
e Michael l education
River McCorri for
Steamb stin underfunded
oat Road and
Floati Hamilto underserved
ng n, NJ schools and
Classr 08690 youth
oom, groups
Inc.
------------------------------------------------------------------------
Monetary Depress 5 $1,000 3/17/2014 DBSA NJ
ion Village Mutual Aid
and Court Support
Bipola Lawrenc Group
r eville, Facilitator
Suppor NJ Training
t 08648
Allian
ce
------------------------------------------------------------------------
Monetary Detroit 10 $5,000 8/25/2014 Managing
Centra Peterbo SPMI and
l City ro Chronic
Commun Profess Disease
ity ional
Mental Buildin
Health g
, Inc. Detroit
, MI
48201
------------------------------------------------------------------------
Monetary Didi 4760 $3,500 5/7/2014 Healthy
Hirsch South Inglewood
Mental Sepulve Project
Health da
Servic Bouleva
es rd
Culver
City,
CA
90230
------------------------------------------------------------------------
Monetary Dress 3131 $9,000 10/13/2014 Dress for
for Princet Success
Succes on Mercer
s Pike, County--Job
Buildin Readiness
g 4, Program
Suite Expansion
209 Project--To
Lawrenc ols to
eville, Succeed
NJ
08648
------------------------------------------------------------------------
Monetary Eden 2 $5,000 10/14/2014 2015 Eden
Autism Merwick Autism
Servic Road Services
es Princet Princeton
Founda on, NJ Lecture
tion 08540 Series on
Autism
------------------------------------------------------------------------
Monetary Elijah' 211 $850 5/7/2014 General
s Livings Operating
Promis ton Support
e Ave.
New
Brunswi
ck, NJ
08901
------------------------------------------------------------------------
Monetary Emma 670 $3,500 7/1/2014 Mental
Norton North Health
Servic Robert Recovery
es Street Skills
St. Training
Paul, and
MN Medication
55101- Support at
2523 Emma Norton
Residence
------------------------------------------------------------------------
Monetary Enable, 13 $6,000 11/5/2014 Connect with
Inc. Roszel Enable
Road, program
Suite
B110
Princet
on, NJ
08540
------------------------------------------------------------------------
Monetary Every Fred $8,500 11/17/2014 Every Child
Child Vereen, Valued
Valued Jr. After
A NJ Communi School
Nonpro ty Program
fit Center
Corpor 175
ation Johnson
Avenue
Lawrenc
eville,
NJ
08648
------------------------------------------------------------------------
Monetary Everybo PO Box $2,000 11/17/2014 Coming Up
dy 3127 for AIRTM
Loves Princet
Kenny on, NJ
Projec 08543
t,
Inc.
------------------------------------------------------------------------
Monetary Faith 39 $1,000 9/22/2014 Responsible
Christ Somerse Fatherhood
ian t Drive Empowerment
Counse Willing Workshop
ling boro,
Center NJ
08046
------------------------------------------------------------------------
Monetary Family 1931 $8,000 5/27/2014 Behavioral
Guidan Notting Healthcare
ce ham Way Services
Center Hamilto for the
Corpor n, NJ Chronically
ation 08619 Mentally
Ill
------------------------------------------------------------------------
Monetary Family 1 AAA $15,000 11/17/2014 Get FIT
Resour Dr. Youth
ce Suite program
Networ 203
k Trenton
, NJ
08691
------------------------------------------------------------------------
Monetary Family 1 AAA $1,000 5/9/2014 Fundraising
Resour Drive event
ce Suite support to
Networ 203 benefit
k Trenton general
, NJ mission of
08691 organizatio
n
------------------------------------------------------------------------
Monetary Family 4 $7,500 6/6/2014 Emergency
Servic Corners Homeless
e tone Shelter
Associ Drive Community
ation Langhor Nurse
of ne, PA Educator
Bucks 19047
County
------------------------------------------------------------------------
Monetary Family 790 Park $4,000 5/27/2014 STEPS to
Servic Avenue Wellness
e Hunting Program
League ton, NY
, Inc. 11743
------------------------------------------------------------------------
Monetary Federat Administ $1,000 5/9/2014 The Big Nosh
ion of rative Vocational
Organi Offices Services
zation One Program
s Farming
dale
Road
Route
109
West
Babylon
, NY
11704
------------------------------------------------------------------------
Monetary Forsyth 61 $75 12/3/2014 Employee
Humane Miller directed
Societ Street donation in
y Winston- lieu of
Salem, company
NC holiday
21704 gift
------------------------------------------------------------------------
Monetary Foundat 2381 $7,000 11/17/2014 The ``I'm
ion of Lawrenc still
Morris eville here''
Hall/ Road approach to
St. Lawrenc managing
Lawren eville, challenging
ce NJ behaviors
08648 in Grace
Garden.
------------------------------------------------------------------------
Monetary Foundat 2381 $2,500 11/17/2014 Fundraising
ion of Lawrenc event
Morris eville support to
Hall/ Road benefit
St. Lawrenc general
Lawren eville, mission of
ce NJ organizatio
08648 n
------------------------------------------------------------------------
Monetary Gateway 11901 $9,500 7/1/2014 Support for
Homes, Reedy a Nurse
Inc. Branch Practitione
Road r to
Chester provide
field, comprehensi
VA ve
23838 personalize
d health
education
and
counseling
------------------------------------------------------------------------
Monetary Georgia 246 $1,500 6/18/2014 Consumer
Mental Sycamor scholarship
Health e s to attend
Consum STreet the 23rd
er Suite Annual
Networ 160 Statewide
k Decatur Consumer
, GA Conference,
30030 ``Year of
the Peer''
------------------------------------------------------------------------
Monetary Girl 201 $2,000 12/3/2014 Robotics
Scouts Grove Program
Heart Street
of New Westfie
Jersey ld, NJ
, Inc. 07090
------------------------------------------------------------------------
Monetary Good 38 Elm $1,000 12/19/2014 Peer Support
Grief, Street Program--Pr
Inc. Morrist inceton
own, NJ
07960
------------------------------------------------------------------------
Monetary Grand 700 Lawn $100 2/11/2014 Memorial
View Avenue donation
Health Sellers
Founda ville,
tion PA
18960
------------------------------------------------------------------------
Monetary Gulf 13228 N. $100 5/27/2014 Memorial
Ridge Central donation
Counci Avenue
l Boy Tampa,
Scouts FL
of 33612-
Americ 3462
a
------------------------------------------------------------------------
Monetary Habitat 31 Oak $4,000 11/17/2014 Women Build
for Avenue, A Brush
Humani Suite with
ty of 100 Kindness
Greate Chalfon
r t, PA
Bucks 18914
------------------------------------------------------------------------
Monetary Habitat 6860 $800 8/15/2014 Costs
for Cortona associated
Humani Drive, with 2014
ty of Suite A Janssen
Southe Goleta, Cares
rn CA Volunteer
Santa 93117 Activity
Barbar
a
------------------------------------------------------------------------
Monetary Hamilto 1315 $9,500 12/12/2014 A.C.T.
n Area Whiteho (Actively
YMCA rse- Changing
Mercerv Together)
ille Program
Road
Hamilto
n, NJ
08619
------------------------------------------------------------------------
Monetary Heart 78 $2,000 12/19/2014 HealthCare
to Ditmars Portfolio
Hearts Avenue Program
, Inc. Lawrenc
eville,
NJ
08648
------------------------------------------------------------------------
Monetary Heartla 4750 N. $7,500 8/15/2014 Pathways
nd Sherida Home,
Health n Road supportive
Outrea Chicago housing
ch , IL program for
60640 those
living with
mental
health
issues
------------------------------------------------------------------------
Monetary HiTops, 21 $7,000 11/17/2014 HiTOPS'
Inc. Wiggins Dating
Street Violence
Princet Risk-
on, NJ Reduction
08540 and
Prevention
Program
------------------------------------------------------------------------
Monetary HomeFro 1880 $20,000 10/20/2014 24-Hour and
nt Princet Emergency
on Childcare
Avenue Center:
Lawrenc Providing
eville, Care
NJ ``Around
08648 the Time
Clock''
------------------------------------------------------------------------
Monetary HomeFro 1880 $10,000 10/27/2014 Huchet House
nt Princet
on
Avenue
Lawrenc
eville,
NJ
08648
------------------------------------------------------------------------
Monetary Hopewel 35 $1,000 9/16/2014 Hopewell
l Princet Elementary
Elemen on Ave Science
tary Hopewel Fair 2015
School l, NJ
Parent 08525
Teache
r
Organi
zation
, Inc.
------------------------------------------------------------------------
Monetary Hopewel PO Box $3,500 6/12/2014 Scholarship
l 553 for a
Valley Penning Hopewell
Educat ton, NJ Valley
ion 08534 Regional
Founda School
tion District
graduating
student
($1,000), I
Dream a
World: 15
Day Artist
Residency
($2500)
------------------------------------------------------------------------
Monetary Horizon 120 S. $1,000 5/7/2014 Philly Has
House, 30th Talent
Inc. St. outreach
Philade and
lphia, awareness
PA event
19104
------------------------------------------------------------------------
Monetary Hunterd 1410 $2,500 9/22/2014 Fundraising
on Route event
County 22 West support to
YMCA Annanda benefit
le, NJ general
08801 mission of
organizatio
n
------------------------------------------------------------------------
Monetary Institu PO Box $3,500 10/14/2014 IWWWE
te of 7869 Nursing
Wonder West Experiences
ful Trenton hip Program
Women , NJ
Workin 08628
g for
Empowe
rment
------------------------------------------------------------------------
Monetary Interfa 3635 $5,000 8/28/2014 Fundraising
ith Quakerb event
Caregi ridge support to
vers Road benefit
Trento Suite general
n, 16 mission of
Inc. Hamilto organizatio
n, NJ n
08619
------------------------------------------------------------------------
Monetary Interfa 3635 $15,000 10/14/2014 Neighbors
ith Quakerb Helping
Caregi ridge Neighbors
vers Road program to
Trento Suite support
n, 16 elderly and
Inc. Hamilto disabled in
n, NJ Mercer
08619 County
------------------------------------------------------------------------
Monetary Isles, 10 Wood $9,000 11/17/2014 Trenton
Inc. Street ReHEET
Trenton (Residentia
, NJ l, Health,
08618 Energy, and
Environment
al
Treatment)
------------------------------------------------------------------------
Monetary Jewish 707 $7,500 12/4/2014 Mercer
Family Alexand County
and er Road Caregiver
Childr Suite Help Line
en's 102 and
Servic Princet Caregiver
e of on, NJ Services
Greate 08540
r
Mercer
County
------------------------------------------------------------------------
Monetary Junior 4365 $7,800 12/10/2014 2015 J&J
Achiev Route 1 Pharma Day
ement South Program
of New 2nd
Jersey Floor
Princet
on, NJ
08540
------------------------------------------------------------------------
Monetary Karis 1361 $3,500 6/6/2014 Direct
Commun Detroit support of
ity St. the Karis
Denver, Community
CO Continuum
80206 of Care
Programs in
lieu of
event
sponsorship
------------------------------------------------------------------------
Monetary Kidsbri 4556 $4,500 9/22/2014 Kidsbridge
dge, South Anti-
Inc. Broad Bullying
Street Life Skills
2nd Program for
Floor At-Risk
Trenton Children in
, NJ Trenton at
08620 the
Elementary
School
Level
------------------------------------------------------------------------
Monetary Laguna 362 $12,000 5/27/2014 Diabetes
Beach Third Program for
Commun Street Disadvantag
ity Laguna ed
Clinic Beach, Individuals
CA
92651
------------------------------------------------------------------------
Monetary Latin 669 $3,500 12/10/2014 Door to
Americ Chamber Health/
an s Puerta de
Legal Street Salud
Defens Suite B program
e And Trenton
Educat , NJ
ional 08611
Fund,
Inc.
------------------------------------------------------------------------
Monetary Lawrenc PO Box $2,710 10/1/2014 Engaging
e 6531 17 Budding
Townsh Philips Engineers
ip Ave. at
Educat Lawrenc Lawrencevil
ion eville, le
Founda NJ Elementary
tion, 08648 School:
Inc. enhancing
the third
grade STEM
curriculum.
------------------------------------------------------------------------
Monetary Leyden 10001 $5,000 7/18/2014 Health Home
Family Grand and
Servic Avenue Integrated
e and Frankli Care =
Mental n Park, Innovation
Health IL program
Center 60131
------------------------------------------------------------------------
Monetary Liberta 5245 $6,500 12/4/2014 Psychiatric
e, Bensale Services
Inc. m for Women
Bouleva Recovering
rd from
Bensale Substance
m, PA Use
19020 Disorders
------------------------------------------------------------------------
Monetary LifeTie LifeTies $5,150 11/17/2014 The
s, , Inc. Transgender
Inc. 2205 Youth
Penning Health
ton Services
Road Project:
Ewing, Staff
NJ Training
08638 and Mentor
Program
------------------------------------------------------------------------
Monetary Literac 55 $2,500 12/18/2014 Early
y and Primros Childhood:
Life, e Building
Inc. Circle Blocks for
Princet the Future
on, NJ
08540
------------------------------------------------------------------------
Monetary Literac 121 $5,000 12/3/2014 Adult
y New Chestnu Literacy
Jersey t Program in
, Inc. Street Mercer
Suite County
203
Roselle
, NJ
07203
------------------------------------------------------------------------
Monetary Literac 120 $4,000 11/17/2014 Literate
y Findern Moms,
Volunt e Ave-- Stable
eers Box 7 Futures
of Bridgew program
Somers ater,
et NJ
County 08807
------------------------------------------------------------------------
Monetary Main 8 $2,500 7/1/2014 Accessible
Street Marcell Care for
Counse a Schizoaffec
ling Avenue tive
Center West Disorder
Orange,
NJ
07052
------------------------------------------------------------------------
Monetary Mary's 15 $75 3/17/2014 Employee
Place Broadwa directed
By The y Ocean donation in
Sea Grove, lieu of
NJ company
07756 holiday
gift
------------------------------------------------------------------------
Monetary Massach 130 $2,500 6/6/2014 Peer Support
usetts Bowdoin Whole
Associ Street Health
ation Boston, Resiliency
for MA Program
Mental 02108
Health
Inc.
------------------------------------------------------------------------
Monetary McCarte 91 $9,500 11/17/2014 OnStage
r Univers Seniors: A
Theatr ity Community
e Place Project of
Center Princet McCarter
on, NJ Theatre
08450
------------------------------------------------------------------------
Monetary Meals 5 Walter $300 8/4/2014 Cost
On Foran associated
Wheels Bouleva with 2014
in rd Janssen
Hunter Suite Cares
don, 2006 volunteer
Inc. Fleming activity
ton, NJ
08822
------------------------------------------------------------------------
Monetary Meals 180 $15,000 10/22/2014 Meals-on-
on Ewingvi Wheels
Wheels lle Program
of Road
Trento Ewing,
n NJ
Ewing 08638
------------------------------------------------------------------------
Monetary Mental 1431 $1,000 6/6/2014 2014 Mental
Health North Health
Americ Delawar Symposium
a e and Annual
Street Meeting
Indiana
polis,
IN
46202
------------------------------------------------------------------------
Monetary Mental 2000 $90,000 12/10/2014 Building
Health North Skills of
Americ Beaureg Caregivers
a ard to Assist
Street People
6th Living with
Floor Schizophren
Alexand ia through
ria, VA Social Self-
22311 Directed
Care
------------------------------------------------------------------------
Monetary Mental 70 E. $1,500 8/28/2014 Mental
Health Lake Health and
Americ Street Wellness
a Suite Fair/
900 Chicago
Chicago Area
, IL Resource
60601 Guide
------------------------------------------------------------------------
Monetary Mental 2211 $15,000 8/1/2014 School
Health Norfolk Behavioral
Americ Suite Health
a of 810 Initiative
Greate Houston
r , TX
Housto 77098
n
------------------------------------------------------------------------
Monetary Mental 1385 S. $2,500 7/1/2014 Pro Bono
Health Colorad Counseling
Americ o and
a of Bouleva Referral
Colora rd Program
do Suite
610
Denver,
CO
80222
------------------------------------------------------------------------
Monetary Mental 2323 W. $10,000 7/11/2014 Get
Health Fifth Connected
Americ Avenue Wellness
a of Suite program
Frankl 160
in Columbu
County s, OH
43204
------------------------------------------------------------------------
Monetary Mental 100 $5,000 7/1/2014 What is
Health Edgewoo Schizophren
Americ d ia?
a of Avenue Educational
Georgi Suite Forum
a 502
Atlanta
, GA
30303
------------------------------------------------------------------------
Monetary Mental 1210 San $2,500 7/1/2014 Mental
Health Antonio Health
Americ Street Education
a of Suite and
Texas 200 Advocacy
Austin, Campaign
TX
78757
------------------------------------------------------------------------
Monetary Mental 475 $2,500 5/27/2014 Mental
Health Clevela Health
Associ nd Education
ation Avenue for Support
N Suite Systems
222
Saint
Paul,
MN
55104
------------------------------------------------------------------------
Monetary Mental 870 $7,500 8/1/2014 Reducing the
Health Market Stigma and
Associ Street Discriminat
ation Suite ion of
928 San Mental
Francis Illness
co, CA within
94102 Multi-
cultural
Communities
------------------------------------------------------------------------
Monetary Mental 100 West $1,500 7/1/2014 13th Annual
Health 10th Community
Associ Street Mental
ation Suite Health
in 600 Conference-
Delawa Wilming -Back to
re ton, DE Basics:
19801 Mind, Body
and Spirit
------------------------------------------------------------------------
Monetary Mental 100 West $1,000 8/15/2014 Bronze
Health 10th sponsor
Associ Street 2014 E-
ation Suite Racing the
in 600 Blues 5K
Delawa Wilming Run/Walk
re ton, DE 10K Run
19801
------------------------------------------------------------------------
Monetary Mental 330 S. $5,000 8/1/2014 Schizophreni
Health Greene a and
Associ St, Schizo-
ation Suite B- Affective
In 12 Supportive
Greens Greensb Services
boro, oro, NC
Inc. 27401
------------------------------------------------------------------------
Monetary Mental 88 $1,000 8/28/2014 Silver
Health Pompton Sponsor 7th
Associ Ave. Annual Walk
ation Verona, for
in New NJ Wellness
Jersey 07044 and
Recovery
------------------------------------------------------------------------
Monetary Mental 617 $2,500 6/5/2014 Support
Health Garden Mental
Associ Street Wellness
ation Santa Center
in Barbara
Santa , CA
Barbar 93101
a
County
------------------------------------------------------------------------
Monetary Mental 3701 $8,000 8/1/2014 Mental
Health Latrobe Health
Associ Drive, First Aid
ation Suite Training
of 140 for
Centra Charlot Mecklenburg
l te, NC County
Caroli 28211 Sheriff's
nas Office
Inc
------------------------------------------------------------------------
Monetary Mental 1301 $10,000 9/17/2014 Health Care
Health York Reform
Associ Road Parity
ation Suite Initiative
of 505
Maryla Lutherv
nd, ille,
Inc. MD
21093
------------------------------------------------------------------------
Monetary Mental 2335 $1,000 7/1/2014 Open Doors
Health Tamiami Open Minds--
Associ Trail Cultural
ation North Competency
of (Ninth Educational
Southw Street) Program
estern Suite Promoting
Florid 404 Wellness
a Naples, and
FL Recovery
34103 Through
Inclusion
------------------------------------------------------------------------
Monetary Mental 580 $1,000 2/13/2014 Supporting
Health White sponsor
Associ Plains 2014 MHA on
ation Road the Move:
of Tarryto Run/Walk
Westch wn, NY
ester 10591
------------------------------------------------------------------------
Monetary Mental 1870 $1,000 7/24/2014 Copper
Health South sponsor for
Associ Boulder the 20th
ation Avenue Annual
Oklaho Tulsa, Zarrow
ma OK Mental
74119- Health
5234 Symposium,
``All
Things
Prevention'
'
------------------------------------------------------------------------
Monetary Mental 555N. $4,000 8/15/2014 MHA Housing
Health Woodlaw Initiative:
Associ n, Ensuring
ation Suite Housing for
Reside 3105 Our Most
ntial Wichita Vulnerable
Care , KS Populations
Inc. 67208
------------------------------------------------------------------------
Monetary Mental 4141 E. $7,500 7/1/2014 Enhancement
Health Dickens of The
Center on Downstairs
of Place program
Denver Denver,
CO
80222
------------------------------------------------------------------------
Monetary Mental 3809 $10,000 6/24/2014 Outreach and
Illnes Rosewoo Behavioral
s d Dr. Healthcare
Recove P.O. for
ry Box Homeless
Center 4246 Individuals
, Inc. Columbi with Mental
a, SC Illness
29240
------------------------------------------------------------------------
Monetary Mercer 3150 $7,500 12/4/2014 Integrating
Allian Brunswi healthcare
ce to ck Pike access into
End Lawrenc operation
Homele eville, of the
ssness NJ Mercer
08648- County
2420 Service
Access
Center for
Homeless
Individuals
------------------------------------------------------------------------
Monetary Mercer PO Box $3,950 11/17/2014 Z.O.M.B.I.E.
County 17202 : Zooming
Commun Trenton in On
ity , NJ Making
Colleg 08690 Biology
e Interactive
Founda and
tion Engaging--(
Peer Tutor
support)
------------------------------------------------------------------------
Monetary Mercer Growth $7,500 8/11/2014 Data Through
Region Partner Action:
al ship of Education
Econom Central and Tourism
ic Jersey, Initiatives
Develo Inc. 1A Throughout
pment Quakerb Central New
Founda ridge Jersey
tion, Plaza
Inc. Drive,
Suite 2
Mercerv
ile, NJ
08619
------------------------------------------------------------------------
Monetary Mercer 151 $20,000 9/22/2014 Food Bank--
Street Mercer Healthy
Friend Street Choices
s Trenton
, NJ
08611
------------------------------------------------------------------------
Monetary Merrima 60 $800 8/26/2014 Costs
ck Island associated
Valley Street with 2014
Habita 2nd Janssen
t for Floor Cares
Humani East volunteer
ty Lawrenc activity
e, MA
01840
------------------------------------------------------------------------
Monetary Metropo 1 North $1,500 8/4/2014 Adult Mental
litan Dearbor Health
Family n Wellness
Servic Chicago Initiative
es , IL
60602
------------------------------------------------------------------------
Monetary Michael 1115 $100 12/19/2014 Memorial
Stern Broadwa Donation
Parkin y,
son's Suite
Resear 1200
ch New
Founda York,
tion NY
10010
------------------------------------------------------------------------
Monetary Middle P.O. Box $15,000 10/14/2014 Outreach
Earth 8045 Program and
520 Community
North Youth
Bridge Centers
Street
Bridgew
ater,
NJ
08807
------------------------------------------------------------------------
Monetary Midland 60 $7,500 9/22/2014 Midland
Adult Industr Helping
Servic ial Hands
es, Parkway Employment
Inc. PO Box Training
5026 Program
North
Branch,
NJ
08876
------------------------------------------------------------------------
Monetary Millhil 101 $15,000 11/5/2014 Trenton
l Oakland PEERS--Teen
Child Street Education
and Trenton and
Family , NJ Empowerment
08618 Program
------------------------------------------------------------------------
Monetary Millhil 101-A $300 8/4/2014 Cost
l Oakland associated
Founda Street with 2014
tion, Trenton Janssen
Inc. , NJ Cares
08618 volunteer
activity
------------------------------------------------------------------------
Monetary Minding 2083 $5,000 3/17/2014 2014 Minding
our Lawrenc Our
Busine eville Business
ss, Rd Summer
Inc. Lawrenc Program:
eville, Bridge to
NJ the Future
08648 for Mercer
County
Youth
------------------------------------------------------------------------
Monetary Morven 55 $5,000 10/14/2014 Morven
Museum Stockto Museum and
and n Garden
Garden Street Summer
Princet Internship
on, NJ Program for
08540 Isles of
Trenton
Youths
------------------------------------------------------------------------
Monetary Mount 73 North $12,500 9/22/2014 Mount Carmel
Carmel Clinton Guild Home
Guild Avenue Health
Trenton Nursing
, NJ Program
08609
------------------------------------------------------------------------
Monetary NAMI--C 1904 $1,000 5/27/2014 Consumer,
VA Byrd Public, and
Centra Ave Provider
l Richmon Education:
Virgin d, VA Peer to
ias 23230 Peer and In
Voice Our Own
On Voice
Mental Programs
Illnes
s
------------------------------------------------------------------------
Monetary NAMI 1012 $1,000 2/13/2014 Bronze
Arkans Autumn sponsor
as Rd 2014
Suite 1 Arkansas
Little NAMIWalk
Rock,
AR
72211
------------------------------------------------------------------------
Monetary NAMI 2400 $1,000 5/9/2014 Bronze
Delawa West sponsor
re 4th St. 12th Annual
Wilming NAMI
ton, DE Delaware
19805 Walk
------------------------------------------------------------------------
Monetary NAMI P.O. Box $1,000 7/18/2014 Purchase of
Lansin 26101 books for
g, Lansing family
Inc. , MI education,
48909 communicati
on
enhancement
and support
------------------------------------------------------------------------
Monetary NAMI 3371 $2,500 1/14/2014 Silver
Mercer Brunswi sponsor
NJ ck Pike NAMI Mercer
Suite Walk 2014
124
Lawrenc
eville,
NJ
08648
------------------------------------------------------------------------
Monetary NAMI 3371 $9,500 6/6/2014 Education
Mercer Brunswi and Support
NJ ck Pike Programs
Suite
124
Lawrenc
eville,
NJ
08648
------------------------------------------------------------------------
Monetary NAMI 3371 $2,500 12/10/2014 Silver
Mercer Brunswi sponsor
NJ ck Pike 2015 NAMI
Suite Mercer Walk
124
Lawrenc
eville,
NJ
08648
------------------------------------------------------------------------
Monetary NAMI of 2100 $5,000 7/1/2014 Educational
DuPage Manches and
County ter supportive
Illino Road services
is Buildin programs to
g B include
Suite community
925 outreach,
Wheaton school
, IL connections
60187 , hospital
education,
educational
courses,
NAMI
Connection,
MICAP,
Family
Support
Group and
other
resources
------------------------------------------------------------------------
Monetary NAMI of One $500 8/15/2014 Bronze
Lake Victori sponsor
County a Sq., 2014 NAMI
Ste. Lake
260 County's
Painesv Strides for
ille, Awareness
OH Walk
44077
------------------------------------------------------------------------
Monetary NAMI of 100 West $1,000 3/17/2014 Bronze
PA Main sponsor
Montgo Street 2014
mery Suite Greater
County 204 Philadelphi
Lansdal a NAMIWalk
e, PA
19446
------------------------------------------------------------------------
Monetary NAMI 1750 $1,000 5/9/2014 Bronze
St. South sponsor
Louis Brentwo 2014
od NAMIWalks
Blvd.,
Suite
511 St.
Louis,
MO
63144
------------------------------------------------------------------------
Monetary NAMI PO Box $1,000 3/6/2014 Bronze
Summit 462 sponsor
County Cuyahog NAMIWalks
a 2014
Falls,
OH
44321
------------------------------------------------------------------------
Monetary NAMI 5251 $1,000 2/13/2014 Bronze
Ventur Verdugo sponsor
a Road, NAMIWalk
County Suite K Ventura
PO Box County 2014
1613
Camaril
lo, CA
93011
------------------------------------------------------------------------
Monetary NAMI 217 $1,000 5/27/2014 Bronze
Waukes Wiscons sponsor
ha in Ave 2014
Suite NAMIWalks
300 in Waukesha
Waukesh
a, WI
53186
------------------------------------------------------------------------
Monetary Nationa 90 Park $2,500 10/23/2014 26th Annual
l Avenue New York
Allian 16 Mental
ce for Floor Health
Resear New Research
ch on York, Symposium
Schizo NY
phreni 10016
a and
Depres
sion
------------------------------------------------------------------------
Monetary Nationa 1 Bangor $1,000 5/16/2014 Supporter
l Street sponsor
Allian Augusta 2014 NAMI
ce for , ME Maine Walk
the 04330 for Mental
Mental Health
ly Ill Awareness
------------------------------------------------------------------------
Monetary Nationa 10630 $1,000 9/16/2014 Silver
l Little sponsor
Allian Patuxen NAMI
ce for t Maryland
the Parkway 2014 Annual
Mental Columbi Education
ly Ill a, MD Conference
21044
------------------------------------------------------------------------
Monetary Nationa 1225 $10,000 5/9/2014 NAMI Ohio's
l Dublin Medication
Allian Road; Access
ce for Ste. Initiative
the 125
Mental Columbu
ly Ill s, OH
43215
------------------------------------------------------------------------
Monetary Nationa 1536 $7,500 7/1/2014 ``Ending the
l West Silence''
Allian Chicago training
ce for Avenue for
the Chicago students
Mental , IL regarding
ly Ill 60622 mental
illness and
brain
disorders
($6000) and
Special and
Restorative
Programming
for
individuals
living with
Mental
Illness
($1500)
------------------------------------------------------------------------
Monetary Nationa 1562 $1,000 3/17/2014 Bronze
l Route sponsor
Allian 130 2014
ce for North NAMIWalks
the Brunswi New Jersey:
Mental ck, NJ Step
ly Ill 08902 Forward for
Our Heroes
------------------------------------------------------------------------
Monetary Nationa 1562 $2,500 7/1/2014 2014
l Route Conference:
Allian 130 Expanding
ce for North Horizons
the Brunswi
Mental ck, NJ
ly Ill 08902
------------------------------------------------------------------------
Monetary Nationa 237 $1,000 12/3/2014 Bronze
l Fernwoo sponsor
Allian d Blvd 2015
ce for Suite NAMIWALKS,
the 101 Changing
Mental Fern minds one
ly Ill Park, step at a
FL time.
32730
------------------------------------------------------------------------
Monetary Nationa 309 West $1,000 3/17/2014 Bronze
l Millbro sponsor
Allian ok Road 2014
ce for Suite NAMIWalks
the 121
Mental Raleigh
ly Ill , NC
27609
------------------------------------------------------------------------
Monetary Nationa 3250 $1,000 3/6/2014 Bronze
l Wilshir sponsor
Allian e Blvd 2014
ce for Ste NAMIWalks
the 1501 Los Angeles
Mental Los County
ly Ill Angeles
, CA
90010
------------------------------------------------------------------------
Monetary Nationa 3440 $1,000 7/1/2014 Bronze
l Viking sponsor
Allian Drive, Northern
ce for Suite California
the 104A NAMI Walk
Mental Sacrame 2015
ly Ill nto, CA
95827
------------------------------------------------------------------------
Monetary Nationa 3803 N. $50,000 12/10/2014 Crisis
l Fairfax Interventio
Allian Drive n Team
ce for Suite Technical
the 100 Assistance
Mental Arlingt and
ly Ill on, VA Statewide
22203 Expansion
------------------------------------------------------------------------
Monetary Nationa 3803 N. $35,000 12/10/2014 Multicultura
l Fairfax l Action
Allian Drive Center
ce for Suite
the 100
Mental Arlingt
ly Ill on, VA
22203
------------------------------------------------------------------------
Monetary Nationa 3803 N. $40,000 12/10/2014 NAMI Basics
l Fairfax Education
Allian Drive Program
ce for Suite
the 100
Mental Arlingt
ly Ill on, VA
22203
------------------------------------------------------------------------
Monetary Nationa 498 $9,500 8/14/2014 NAMI
l Georget Lexington
Allian own Advocacy,
ce for Street Education,
the Suite Outreach
Mental 201 and Support
ly Ill Lexingt ($8,500),
on, KY bronze
40508 sponsor
2014 Walk
($1,000)
------------------------------------------------------------------------
Monetary Nationa 576 $1,000 1/15/2014 Bronze
l Farming sponsor
Allian ton 2014
ce for Avenue NAMIWalks
the Hartfor
Mental d, CT
ly Ill 06105
------------------------------------------------------------------------
Monetary Nationa 800 $1,000 5/7/2014 Bronze
l Transfe sponsor
Allian r Road NAMIWalks
ce for Suite 2014
the 31
Mental Saint
ly Ill Paul,
MN
55114
------------------------------------------------------------------------
Monetary Nationa 800 $1,000 7/1/2014 NAMI
l Transfe Connections
Allian r Road Training
ce for Suite
the 31
Mental Saint
ly Ill Paul,
MN
55114
------------------------------------------------------------------------
Monetary Nationa 99 Pine $3,000 8/28/2014 2014 NAMI-
l St. NYS
Allian Suite Education
ce for 302 Conference-
the Albany, United We
Mental NY Stand:
ly Ill 12207 Shaping our
Future.
------------------------------------------------------------------------
Monetary Nationa Kentucky $1,000 7/1/2014 Community
l Affilia Sponsor
Allian te c/o 2014 Annual
ce for Somerse Conference,
the t ``Advocatin
Mental Communi g for
ly Ill ty Change
College Together''
808
Montice
llo
Street
Somerse
t, KY
42501
------------------------------------------------------------------------
Monetary Nationa PO Box $1,000 7/24/2014 Family-to-
l 22697 Family and
Allian 2601 Peer-to-
ce for Cold Peer
the Spring Education
Mental Road programs
ly Ill Indiana
polis,
IN
46222-
0697
------------------------------------------------------------------------
Monetary Nationa PO Box $1,000 10/23/2014 Bronze
l 66270 sponsor
Allian Houston 2015
ce for , TX NAMIWalks
the 77274 Greater
Mental Houston
ly Ill
------------------------------------------------------------------------
Monetary Nationa PO Box $1,000 7/1/2014 Bronze
l 8260 sponsor
Allian Richmon 2014
ce for d, VA NAMIWalks
the 23218 Virginia
Mental
ly Ill
------------------------------------------------------------------------
Monetary Nationa Scott $1,000 5/16/2014 Bronze
l County sponsor
Allian 1706 2014
ce for Brady NAMIWalk
the Street Greater
Mental Suite Mississippi
ly Ill 200 Valley
Davenpo
rt, IA
52803
------------------------------------------------------------------------
Monetary Nationa The $1,000 3/17/2014 Bronze
l Schraff sponsor
Allian t's 2014
ce for Center NAMIWalks
the 529 Massachuset
Mental Main ts
ly Ill Street
Suite
1M17
Boston,
MA
02129
------------------------------------------------------------------------
Monetary Nationa 2012 $1,000 7/1/2014 Mental
l West Illness
Allian 25th Peer
ce for Street Support and
the 6th Education
Mental Floor programs
ly Clevela
Ill--G nd, OH
reater 44113
Clevel
and
------------------------------------------------------------------------
Monetary Nationa 2012 $1,000 8/12/2014 Bronze
l West sponsor
Allian 25th 2014
ce for Street NAMIWalks
the 6th for the
Mental Floor Mind of
ly Clevela America
Ill--G nd, OH Greater
reater 44113 Cleveland
Clevel
and
------------------------------------------------------------------------
Monetary Nationa 5911 $1,000 8/12/2014 Bronze
l Meredit sponsor
Allian h Drive 2014 NAMI
ce for Suite E IOWA
the Des NAMIWalk
Mental Moines,
ly IA
Ill--I 50322-
owa 1903
------------------------------------------------------------------------
Monetary Nationa 2753 $1,000 1/15/2014 Bronze
l West sponsor
Allian Central 2014
ce for Avenue NAMIWalk
the Toledo,
Mental OH
ly Ill 43606
of
Greate
r
Toledo
------------------------------------------------------------------------
Monetary Nationa 505 $1,000 2/13/2014 Bronze
l Eighth sponsor
Allian Avenue NAMIWalks
ce for Suite NYC 2014
the 1103 Walk/Run
Mental New
ly Ill York,
of New NY
York 10018
City
------------------------------------------------------------------------
Monetary Nationa 1981 $1,000 11/5/2014 Bronze
l Marcus sponsor
Allian Ave, 2015 Long
ce for C117 Island/
the Lake Queens
Mental Success NAMIWalk
ly Ill , NY for Mental
Queens/ 11042 Health
Nassau
------------------------------------------------------------------------
Monetary Nationa of $1,000 8/12/2014 Bronze
l Butler sponsor
Allian County 2014
ce on 5963 National
Mental Boymel Alliance on
Illnes Drive Mental
s Fairfie Illness of
ld, OH Butler
45014 County
NAMIWalks
------------------------------------------------------------------------
Monetary Nationa 1150 $3,500 5/15/2014 Peer PALS
l South program
Allian Bascom
ce on Ave.,
Mental Ste 24,
Illnes San
s Jose,
Santa CA
Clara 95128
County
------------------------------------------------------------------------
Monetary Nationa P O Box $6,000 5/16/2014 27 Annual
l Art 350891 National
Exhibi Miami Art
tions Fl Exhibition
of the 33135 by the
Mental Mentally
ly Ill
Ill,
Inc
------------------------------------------------------------------------
Monetary Nationa 110 N. $30,000 11/17/2014 STOP THE
l Washing CLOT,
Blood ton SPREAD THE
Clot Street WORD VTE
Allian Suite Awareness
ce 328 and
Rockvil Advocacy
le, MD Initiative
20850 : Patient
Toolkit
($15,000),
and
Specialty
Magazines
($15,000)
------------------------------------------------------------------------
Monetary Nationa 110 $7,500 3/17/2014 Education
l North briefing,
Blood Washing ``So You
Clot ton Think You
Allian Street Can't Get A
ce Suite Blood Clot?
328 B Think
Rockvil Again!''
le, MD
20850
------------------------------------------------------------------------
Monetary Nationa 1701 K $20,000 12/10/2014 Prescription
l Street Drug Abuse
Counci NW, and Pain
l for Suite Management
Behavi 400 Initiative
oral Washing
Health ton, DC
20006
------------------------------------------------------------------------
Monetary Nationa 1701 K $60,000 12/10/2014 Same Day
l Street Access
Counci NW, Initiative
l for Suite
Behavi 400
oral Washing
Health ton, DC
20006
------------------------------------------------------------------------
Monetary Nationa 1701 K $35,000 12/10/2014 Early Onset
l Street Psychosis
Counci NW, Initiative
l for Suite
Behavi 400
oral Washing
Health ton, DC
20006
------------------------------------------------------------------------
Monetary Nationa 1701 K $50,000 12/10/2014 Health
l Street Justice
Counci NW, Learning
l for Suite Initiative
Behavi 400
oral Washing
Health ton, DC
20006
------------------------------------------------------------------------
Monetary Nationa 1701 K $75,000 12/10/2014 2015 Policy
l Street Action
Counci NW, Center
l for Suite
Behavi 400
oral Washing
Health ton, DC
20006
------------------------------------------------------------------------
Monetary Nationa 1701 K $30,000 12/10/2014 Leadership
l Street Development
Counci NW, Initiatives
l for Suite
Behavi 400
oral Washing
Health ton, DC
20006
------------------------------------------------------------------------
Monetary Nationa 949 W. $16,500 12/3/2014 Academic
l State Creative
Junior Street Engagement
Tennis Trenton Program
and , NJ ($6,500.00)
Learni 08618 ,
ng of Benefactor
Trento sponsor
n 2015 Annual
Gala
($10,000.00
)
------------------------------------------------------------------------
Monetary Nationa 9707 E $10,000 11/19/2014 Patient
l Easter Navigator
Stroke Lane, Program /
Associ Suite B Stroke
ation Centenn Recovery
ial, CO Navigator
80112
------------------------------------------------------------------------
Monetary Nationa 9707 E $62,290 11/19/2014 Web-based
l Easter health
Stroke Lane, game,
Associ Suite B ``Stroke
ation Centenn and
ial, CO Nonvalvular
80112 Atrial
Fibrillatio
n: Beating
Your Odds''
------------------------------------------------------------------------
Monetary New 444 W. $6,000 3/17/2014 Support
Founda Frontag Health and
tion e Road Wellness
Center Northfi Program,
eld, IL benefitting
60093-- clients who
3009 are
managing a
co-morbid
diagnosis
------------------------------------------------------------------------
Monetary New 275 Rt. $4,000 3/17/2014 New Jersey
Jersey 10 Parent's
Parent East, Caucus
s Suite Outreach RV
Caucus 220-414 Tour and
Succasu Professiona
nna, NJ l Parent
07876 Advocacy
Training
Program
------------------------------------------------------------------------
Monetary NewBrid PO Box $2,000 7/1/2014 Day
ge 336 (7 Treatment
Servic Industr Program for
es, ial Adults
Inc. Road,
Pequann
ock, NJ
07440)
Pompton
Plains,
NJ
07444
------------------------------------------------------------------------
Monetary NHS 620 E. $5,000 5/27/2014 Hollywood
Human Germant Beauty
Servic own Salon
es Pike Documentary
Founda Lafayet Project--po
tion te st
Inc Hill, production
PA costs
19444
------------------------------------------------------------------------
Monetary Northea 334 $2,500 8/26/2014 Healthy Food
st River for Healthy
Organi Road Communities
c Hillsbo
Farmin rough,
g NJ
Associ 08844
ation
of NJ
------------------------------------------------------------------------
Monetary Notre 1835 $100 8/18/2014 Memorial
Dame Catasau donation
of qua
Bethle Road
hem Bethleh
School em, PA
18018
------------------------------------------------------------------------
Monetary Oldies PO Box $75 3/17/2014 Employee
But 361 directed
Goodie Newingt donation in
s on, VA lieu of
Cocker 22122 company
Rescue holiday
, Inc. gift
------------------------------------------------------------------------
Monetary One 1977 $3,500 11/17/2014 Wish
Simple North Program:
Wish Olden Education
Ave, Fund for
#292 Aging Out
Trenton Youth
, NJ
08618
------------------------------------------------------------------------
Monetary Open 14 Lake $2,000 7/18/2014 Support to
Road Court provide the
Fleming homebound
ton, NJ elderly and
08822 people with
disabilitie
s or mental
illness
with
stimulating
and
enriching
activities
that would
otherwise
be
unavailable
to them
------------------------------------------------------------------------
Monetary Our 2626 E $100 8/4/2014 Memorial
Hospic 17th Donation
e of Street
South Columbu
Centra s, IN
l 47201
Indian
a
------------------------------------------------------------------------
Monetary Passage 211 $5,000 12/15/2014 The State
Theatr Mercer Street
e Street Project
Compan PO Box
y Inc. 967
Trenton
, NJ
08611
------------------------------------------------------------------------
Monetary PEI 231 $300 8/4/2014 Cost
Kids Lawrenc associated
e Road with 2014
Lawrenc Janssen
eville, Cares
NJ volunteer
08648 activity
------------------------------------------------------------------------
Monetary PEI 231 $17,500 10/14/2014 Comprehensiv
Kids Lawrenc e Juvenile
e Road Offenders
Lawrenc Outreach
eville, Services
NJ (CJOOS)
08648 program
------------------------------------------------------------------------
Monetary Penning PO Box $1,000 5/30/2014 Fundrasining
ton 628 event
Day, Penning support to
Inc. ton, NJ benefit
08534 general
mission of
organizatio
n
------------------------------------------------------------------------
Monetary People 140 East $2,500 10/22/2014 People and
And Hanover Stories
Storie Street with Mercer
s--Gen Trenton County
te Y , NJ Seniors
Cuento 08608
s Inc.
------------------------------------------------------------------------
Monetary Planned PO Box $4,000 7/1/2014 Whole-Health
Living 4755 and
Assist Austin, Wellness
ance TX Program
Networ 78765
k of
Centra
l
Texas
------------------------------------------------------------------------
Monetary Planned 13151 $2,500 8/26/2014 Education
Living Emily and Social
Assist Road, Skills
ance Suite Development
Networ 240 Program
k of Dallas,
North TX
Texas, 75240
Inc.
------------------------------------------------------------------------
Monetary Plansma 118 West $3,500 9/16/2014 2014
rt NJ State Corporate
Trenton membership
, NJ renewal
08608 donation to
support
efforts
around
sound land
use
planning
------------------------------------------------------------------------
Monetary Princet 15 $25,000 12/12/2014 Path to
on Princes Impact--Cap
Area s Road acity
Commun Lawrenc Building
ity eville, Program
Founda NJ
tion, 08648
Inc.
------------------------------------------------------------------------
Monetary Princet 123 E. $15,000 11/17/2014 Hunger
on Hanover Prevention
Outrea St. and
ch Trenton Nutrition
Projec , NJ Education
ts / 08608 ($10,000)
Crisis and Housing
Minist Stability
ry of Services
Mercer ($5,000)
County
------------------------------------------------------------------------
Monetary Princet 45 $2,500 10/29/2014 Living
on Stockto Healthy for
Senior n St Older
Resour Princet Adults
ce on, NJ
Center 08540
------------------------------------------------------------------------
Monetary Princet 350 $10,000 9/22/2014 United
on- Alexand Leaders of
Blairs er Road Tomorrow
town Princet (ULOT) at
Center on, NJ Trenton
Inc. 08540 Central
High School-
West Campus
------------------------------------------------------------------------
Monetary Printma 440 $5,000 10/20/2014 Roving Press
king River
Center Road
of New Branchb
Jersey urg, NJ
08876
------------------------------------------------------------------------
Monetary Printma 440 $15,000 10/20/2014 Combat Paper
king River NJ
Center Road
of New Branchb
Jersey urg, NJ
08876
------------------------------------------------------------------------
Monetary Project 1515 $5,000 7/18/2014 Mental
HOME Fairmou Health/
nt Recovery
Avenue Treatment
Philade Services
lphia, for Adults
PA Who Have
19130 Experienced
Homelessnes
s
------------------------------------------------------------------------
Monetary Raritan P.O. Box $8,000 11/17/2014 WaterWays
Headwa 273 Environment
ters Gladsto al
Associ ne, NJ Education
ation 07934 Program
------------------------------------------------------------------------
Monetary Raritan 118 $20,000 11/5/2014 Promoting
Valley Lamingt Access to
Commun on Road STEM and
ity Branchb Nursing
Colleg urg, NJ Education
e 08876 at Raritan
Founda Valley
tion Community
College:
Nursing
Scholarship
s
($10,000),
Galileo
Scholarship
s ($5,000),
Textbooks
($2,500),
STEM
Institute
($2,500)
------------------------------------------------------------------------
Monetary Regions 640 $5,000 5/9/2014 Mental
Hospit Jackson Health Drug
al Street Assistance
Founda St. Program
tion Paul,
MN
55101
------------------------------------------------------------------------
Monetary Regions 640 $12,500 5/9/2014 Make It OK
Hospit Jackson Campaign to
al Street fight
Founda St. stigma
tion Paul,
MN
55101
------------------------------------------------------------------------
Monetary Rescue 98 $25,000 9/22/2014 Emergency
Missio Carroll Services
n of Street, program
Trento PO Box
n 790
Trenton
, NJ
08605
------------------------------------------------------------------------
Monetary Resourc 427 $300 8/4/2014 Cost
e Homeste associated
Center ad Road with 2014
Of Hillsbo Janssen
Somers rough, Cares
et, NJ volunteer
Inc 08844 activity
------------------------------------------------------------------------
Monetary Rider 2083 $20,000 11/5/2014 Urban STEM
Univer Lawrenc ($10,000),
sity eville Janssen
Road Science and
Lawrenc Business
eville, Scholarship
NJ s ($7,500),
08648 Environment
al
Symposium
($2,500)
------------------------------------------------------------------------
Monetary Riverbe PO Box $5,000 7/1/2014 In-SHAPE
nd 2032 Program
Commun Concord
ity , NH
Mental 03302-
Health 2032
Inc
------------------------------------------------------------------------
Monetary Riversi 4 South $7,500 10/20/2014 Riverside
de Union Symphonia
Sympho Street Senior
nia P.O. Outreach
Inc Box 650 Program
Lambert
ville,
NJ
08530
------------------------------------------------------------------------
Monetary San 2789 $5,000 5/27/2014 San
Franci 25th Francisco
sco Street Collaborati
Genera Suite ve Court's
l 2028 PO Behavioral
Hospit Box Health
al 410836 Court--Supp
Founda San orted
tion Francis Employment
co, CA and
94110 Motivationa
l
Incentives
Program
------------------------------------------------------------------------
Monetary Schizop PO Box $2,500 8/15/2014 2014
hrenia 941222 National
And Houston Conference,
Relate , TX ``Call to
d 77094- Action:
Disord 8222 Shattering
ers Stigma''
Allian
ce Of
Americ
a
------------------------------------------------------------------------
Monetary SERV 20 $5,000 5/27/2014 12th Annual
Founda Scotch SERV
tion, Road Recovery NJ
Inc. Ewing, conference
NJ
08628
------------------------------------------------------------------------
Monetary SERV 20 $5,000 5/27/2014 SERV
Founda Scotch Foundation
tion, Road Scholarship
Inc. Ewing, Fund
NJ
08628
------------------------------------------------------------------------
Monetary Shannon PO Box $500 8/28/2014 Donation in
Daley 1271 36 lieu of
Memori Indian event
al Run sponsorship
Fund Whiteho to help
use local area
Station residents
, NJ battling
08889 serious
ailments
and their
families
facing
hardship
------------------------------------------------------------------------
Monetary Sharing 1920 $2,000 7/31/2014 Art program
Place 10th at the 1920
Inc Avenue Club
South
P.O.
Box
55945
Birming
ham, AL
35255
------------------------------------------------------------------------
Monetary Sisters 1201 $1,000 2/3/2014 Blue Ribbon
Networ Hamilto sponsor
k of n 2014 Health
Centra Street Summit and
l New Somerse Breakfast
Jersey t, NJ
08873
------------------------------------------------------------------------
Monetary Sisters 1201 $5,000 8/28/2014 Fundraising
Networ Hamilto event
k of n support to
Centra Street benefit
l New Somerse general
Jersey t, NJ mission of
08873 organizatio
n
------------------------------------------------------------------------
Monetary Somerse PO Box $100 11/12/2014 Memorial
t 3000 donation
County Somervi
Office lle, NJ
on 08876-
Aging 1262
------------------------------------------------------------------------
Monetary Somerse 49 $680 2/3/2014 General
t Home Brahma Operating
for Avenue Support
Tempor Bridgew
arily ater,
Displa NJ
ced 08807
Childr
en
------------------------------------------------------------------------
Monetary Somerse 49 $7,500 10/20/2014 Street
t Home Brahma Smart--HIV
for Avenue Prevention
Tempor Bridgew program
arily ater, within
Displa NJ Somerset
ced 08807 county
Childr
en
------------------------------------------------------------------------
Monetary St. 501 St $100 1/14/2014 Memorial
Jude's Jude Donation
Childr Place
en's Memphis
Resear , TN
ch 38105
Hospit
al
------------------------------------------------------------------------
Monetary St. One $15,000 10/20/2014 Providing
Mary Summit Food for
Medica Square, School-Age
l Suite Children
Center 300 Living in
Founda 1717 Poverty:
tion Langhor The St.
ne- Mary
Newtown Backpacks
Road for Kids
Langhor Program
ne, PA
19047
------------------------------------------------------------------------
Monetary Stony 31 Titus $15,000 11/5/2014 StreamWatch:
Brook Mill Science in
Millst Road the Service
one Penning of
Waters ton, NJ Conservatio
hed 08534 n
Associ
ation
------------------------------------------------------------------------
Monetary SWIM 120 $2,000 9/22/2014 Program
Inc. Findern Development
e Project in
Avenue Somerset
Bridgew and
ater, Hunterdon
NJ Counties--V
08807 olunteer
Training in
aquatic
exercise
for the
disabled,
administrat
ive
training
for
coordinator
s and co-
coordinator
s, and
sensitivity
training
------------------------------------------------------------------------
Monetary TASK, 72\1/2\ $25,000 10/14/2014 TASK Meal
Inc. Escher Service
Street, Program
P.O.
Box 872
Trenton
, NJ
08605
------------------------------------------------------------------------
Monetary The Paul $9,500 10/1/2014 Arts Council
Arts Robeson of
Counci Center Princeton
l of for the Community
Prince Arts Outreach
ton 102 programs
Withers for youth
poon and seniors
Street
Princet
on, NJ
08542
------------------------------------------------------------------------
Monetary The 2020 $2,000 11/17/2014 Art for
Center Burnt Special
for Mills Needs
Contem Road Children
porary Bedmins
Art ter, NJ
07921
------------------------------------------------------------------------
Monetary The 19 $13,500 9/22/2014 Clinically-
Center Dellwoo managed,
For d Lane residential
Great Somerse treatment
Expect t, NJ program for
ations 08873 homeless,
pregnant/
parenting
adult women
in
substance
use
recovery,
and their
children
($10,000),
Annual Gala
($3,500)
------------------------------------------------------------------------
Monetary The 1040 $5,000 7/1/2014 Jail
Edinbu Waltham Diversion
rg Street Program
Center Lexingt
on, MA
02421-
8033
------------------------------------------------------------------------
Monetary The 8150 N. $40,000 11/17/2014 HeartGuide--
Mended Central Patient
Hearts Express Resource
, Inc. way, and
Suite Visiting
M2248 Program
Dallas,
TX
75206
------------------------------------------------------------------------
Monetary The 401 $500 1/14/2014 Flash Lite
Mental Cypress sponsor
Health Street 2014 Lite
Center Manches Up The Nite
Of ter, NH Run/Walk
Greate 03103 for Mental
r Health 5k
Manche
ster
------------------------------------------------------------------------
Monetary The 400 $300 8/26/2014 Costs
Pennsb Pennsbu associated
ury ry with 2014
Societ Memoria Janssen
y l Road Cares
Morrisv volunteer
ille, activity
PA
19067
------------------------------------------------------------------------
Monetary The P.O. Box $5,000 12/3/2014 The
Prince 2063 Princeton
ton Princet Festival
Festiv on, NJ Intergenera
al 08543 tional
Opera
Workshop
for Teens
and their
Families
------------------------------------------------------------------------
Monetary Thomas 101 West $10,000 11/5/2014 Scholarships
Edison State for Nursing
State Street Students
Colleg Trenton Enrolled in
e , NJ Thomas
Founda 08608 Edison
tion State
College's
Accelerated
Second
Degree BSN
Program.
------------------------------------------------------------------------
Monetary Trenton PO Box $1,500 9/22/2014 Financial
Commun 5206 Aid to
ity Trenton subsidize
Music , NJ tuition
School 08638 costs for
families
qualifying
based on
family size
and income--
music
instruction
s for
students
------------------------------------------------------------------------
Monetary Trenton 635 $3,500 11/17/2014 Trenton
Educat South Education
ion Clinton Dance
Dance Avenue Institute
Instit Trenton program for
ute , NJ at-risk
08611 youth in
Trenton
------------------------------------------------------------------------
Monetary Trenton 218 N $10,000 10/23/2014 Inroads for
Health Broad Health:
Team St Taking it
Inc Trenton to the
, NJ Streets
08608
------------------------------------------------------------------------
Monetary Trinity 22 $9,000 11/17/2014 Mental
Counse Stockto Health and
ling n Wellness
Servic Street Programs
es Trinity
Counsel
ing
Service
Princet
on, NJ
08540
------------------------------------------------------------------------
Monetary Truist/ Departme $32,261 12/12/2014 Truist
Fronts nt processing
tream, CH16952 fee for
Inc. Palatin total 2014
e, IL United Way
60055- Campaign
6952 (fee
associated
with NJ
companies)
------------------------------------------------------------------------
Monetary Twiligh P.O. Box $5,000 11/17/2014 Simple Needs
t Wish 1042 11 Wish
Founda Duane Granting
tion Road Program
Doylest Expansion
own, PA
18901
------------------------------------------------------------------------
Monetary UIH 4 North $7,500 10/14/2014 Community of
Family Broad Health for
Partne Street Men
rs 2nd
Floor
Trenton
, NJ
08618-
4408
------------------------------------------------------------------------
Monetary United 9-25 $9,000 8/26/2014 Princeton
Negro Alling Committee
Colleg St. of UNCF
e Fund Second Scholarship
Floor -Scholarshi
Newark, p support
NJ for
07102 deserving
STEM
students in
Mercer or
Somerset
Counties
------------------------------------------------------------------------
Monetary United P.O. Box $607,875 12/12/2014 Company
Way 418607 match to
Worldw Boston, employee
ide MA United Way
02241- campaign
8607 for NJ
based
commercial
companies
of Janssen
Pharmaceuti
cal
Companies
of Johnson
& Johnson
less Truist
processing
fee
------------------------------------------------------------------------
Monetary US Pain 670 $7,500 12/4/2014 INvisible
Founda newfiel Project
tion d
street
suite b
middlet
own, CT
06457
------------------------------------------------------------------------
Monetary Valeo 5401 SW $5,000 7/18/2014 Services for
Behavi 7th Employment
oral Street Success
Health Topeka, Program
Care KS serving
Inc 66606 consumers
with
Schizophren
ia and
other
severe
mental
illness
------------------------------------------------------------------------
Monetary Volunte P.O. Box $8,500 10/1/2014 SkillsConnec
er 615 t skills
Connec Princet based
t on, NJ community
08542 volunteer
program
------------------------------------------------------------------------
Monetary West 120 $2,000 7/1/2014 Young Adults
Bergen Chestnu with
Mental t Schizophren
Health Street ia Young
care Ridgewo Adult Track
od, NJ of the
07450- Partial
2500 Care
Program
------------------------------------------------------------------------
Monetary West 120 $300 8/4/2014 Cost
Bergen Chestnu associated
Mental t with 2014
Health Street Janssen
care Ridgewo Cares
od, NJ Volunteer
07450- Activity
2500
------------------------------------------------------------------------
Monetary West PO Box $5,000 9/22/2014 STEM
Windso 280 Excellence
r West in
Plains Windsor Education
boro , NJ Grant
Educat 08550- Program
ion 0280
Founda
tion
------------------------------------------------------------------------
Monetary Womansp 1530 $2,500 10/20/2014 Emergency
ace Brunswi Domestic
ck Violence
Avenue Shelter
Lawrenc program
eville,
NJ
08648
------------------------------------------------------------------------
Monetary Wounded 4899 $100 5/16/2014 Memorial
Warrio Belfort Donation
r Road
Projec Suite
t 300
Jackson
ville,
FL
32256
------------------------------------------------------------------------
Monetary Wounded 4899 $75 12/3/2014 Employee
Warrio Belfort directed
r Road donation in
Projec Suite lieu of
t 300 company
Jackson holiday
ville, gift
FL
32256
------------------------------------------------------------------------
Monetary YMCA of 431 $7,500 12/10/2014 The YMCA of
Trento Penning Trenton's
n ton Stars of
Avenue Science
Trenton Program
, NJ
08618
------------------------------------------------------------------------
Monetary Young 349 W. $3,500 10/20/2014 College
Schola State Preparatory
rs' St Program
Instit Trenton
ute , NJ
08618
------------------------------------------------------------------------
Monetary YWCA 59 Paul $3,000 11/17/2014 Breast
Prince Robeson Cancer
ton Place Resource
Princet Center--Wom
on, NJ en of
08540 Wisdom
(WOW)
Program
------------------------------------------------------------------------
Product AmeriCa 88 $490,904 3/19/2014 Product
res Hamilto Donation
Founda n for
tion Avenue Humanitaria
Stamfor n Relief in
d, CT the U.S.,
06902 El
Salvador,
Guatemala,
Honduras,
Nicaragua,
Cambodia,
Pakistan,
and Peru.
------------------------------------------------------------------------
Product AmeriCa 88 $834,365 3/19/2014 Product
res Hamilto Donation
Founda n for
tion Avenue Humanitaria
Stamfor n Relief in
d, CT Guatemala,
06902 El
Salvador,
Honduras,
Nicaragua.
------------------------------------------------------------------------
Product AmeriCa 88 $383,214 10/23/2014 Product
res Hamilto Donation in
Founda n Ave support of
tion Stamfor Disaster
d, CT Response
06902
------------------------------------------------------------------------
Product AmeriCa 88 $233,871 12/3/2014 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in Malawi,
Tanzania,
West Bank,
Armenia,
Dominican
Republic,
El
Salvador,
Guatemala,
Nicaragua,
Peru,
Tanzania
------------------------------------------------------------------------
Product AmeriCa 88 $100,985 12/3/2014 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in Malawi,
Tanzania,
Armenia,
Dominican
Republic,
Colombia
------------------------------------------------------------------------
Product AmeriCa 88 $825,981 11/6/2014 Product
res Hamilto Donations
Founda n Ave for
tion Stamfor Humanitaria
d, CT n Aid for
06902 Armenia,
Dominican
Republic,
Gaza,
Pakistan,
West Bank
and
Tanzania.
------------------------------------------------------------------------
Product AmeriCa 88 $2,389,565 8/4/2014 Product
res Hamilto Donation in
Founda n Ave support of
tion Stamfor Humanitan
d, CT Aid for the
06902 U.S.,
Afghanistan
,
Bangladesh,
Pakistan,
and Peru.
------------------------------------------------------------------------
Product Catholi 33-01 $5,279 12/3/2014 Pharmaceutic
c Elevent al Product
Medica h Donation
l Street for
Missio Long Humanitaria
n Island n Aid in
Board City, Haiti
NY
------------------------------------------------------------------------
Product Direct 27 S. La $665,263 3/19/2014 Product
Relief Patera Donation to
Intern Lane support
ationa Santa Humanitaria
l Barbara n Relief in
, CA Haiti,
93117 Dominican
Republic,
Honduras,
Paraguay,
and
Nicaragua.
------------------------------------------------------------------------
Product Direct 27 S. La $614,185 3/19/2014 Product
Relief Patera Donation to
Intern Lane support
ationa Santa Humanitaria
l Barbara n Relief in
, CA Haiti,
93117 Dominican
Republic,
and
Paraguay.
------------------------------------------------------------------------
Product Direct 27 S. La $116,610 2/27/2014 Humanitarian
Relief Patera Aid for
Intern Lane Obstetric
ationa Santa Fistula
l Barbara program.
, CA
93117
------------------------------------------------------------------------
Product Direct 27 S. La $322,359 11/6/2014 Humanitarian
Relief Patera Aid for
Intern Lane Ghana,
ationa Santa Paraguay,
l Barbara and Peru.
, CA
93117
------------------------------------------------------------------------
Product Direct 27 S. La $2,354,643 12/3/2014 Pharmaceutic
Relief Patera al Product
Intern Lane Donation
ationa Santa for
l Barbara Disaster
, CA Response
93117 and/or
Humanitaria
n Aid in
Dominican
Republic,
Guatemala,
Nicaragua,
Peru,
Panama,
Paraguay
and United
States
------------------------------------------------------------------------
Product Direct 27 S. La $30,164 12/3/2014 Pharmaceutic
Relief Patera al Product
Intern Lane Donation
ationa Santa for
l Barbara Humanitaria
, CA n Aid in
93117 Nicaragua,
Peru
------------------------------------------------------------------------
Product Direct 27 S. La $2,093,905 8/5/2014 Humanitarian
Relief Patera Aid for
Intern Lane Haiti,
ationa Santa Paraguay,
l Barbara and U.S.
, CA
93117
------------------------------------------------------------------------
Product Heart 1021 $72,493 3/19/2014 Product
to Pacific Donation
Heart Avenue for
Intern Kansas Humanitaria
ationa City, n Relief in
l KS Papua New
66102 Guinea and
Cameroon.
------------------------------------------------------------------------
Product Heart 1021 $33,156 12/18/2014 Pharmaceutic
to Pacific al Product
Heart Avenue donation
Intern Kansas for Ebola
ationa City, Treatment
l KS Unit in
66102 Liberia
------------------------------------------------------------------------
Product Heart 1021 $46,435 12/3/2014 Pharmaceutic
to Pacific al Product
Heart Avenue donation
Intern Kansas for
ationa City, humanitaria
l KS n relief in
66102 Papua New
Guinea
------------------------------------------------------------------------
Product Johnson One $380,566,479 3/15/2014 Patient
& Johnson Assistance
Johnso & Product
n Johnson Donation
Patien Plaza
t New
Assist Brunswi
ance ck, NJ
Founda 08933
tion
------------------------------------------------------------------------
Product Johnson One $87,387,455 12/15/2014 Patient
& Johnson Assistance
Johnso & Product
n Johnson Donation
Patien Plaza
t New
Assist Brunswi
ance ck, NJ
Founda 08933
tion
------------------------------------------------------------------------
Product Johnson One $74,577,911 9/15/2014 Patient
& Johnson Assistance
Johnso & Product
n Johnson Donation
Patien Plaza
t New
Assist Brunswi
ance ck, NJ
Founda 08933
tion
------------------------------------------------------------------------
Product MAP 4700 $772,428 1/9/2014 Donation for
Intern Glynco Medical
ationa Parkway Mission
l Brunswi Pack Plus
ck, GA Program
31525
------------------------------------------------------------------------
Product MAP 4700 $26,142 1/9/2014 Donation for
Intern Glynco the Medical
ationa Parkway Mission
l Brunswi Pack Plus
ck, GA Program
31525
------------------------------------------------------------------------
Product MAP 4700 $26,394 12/3/2014 Pharmaceutic
Intern Glynco al Product
ationa Parkway Donation to
l Brunswi support the
ck, GA Medical
31525 Mission
Pack Plus
------------------------------------------------------------------------
Product Mercy 15862 $8,397 3/19/2014 Product
Ships State Donation in
Intern Highway support of
ationa 110 Humanitaria
l North n Relief in
Operat Lindale West
ions , TX Africa.
Center 75771
------------------------------------------------------------------------
Product New 1 $13,297 8/4/2014 Product
Jersey Riversi Donation.
Academ de
y of Drive
Aquati Camden,
c NJ
Scienc 08103-
es 1037
------------------------------------------------------------------------
Product Project 255 $149,962 3/19/2014 Product
Hope Carter Donation in
Hall support of
Lane Humanitaria
Millwoo n Relief in
d, VA Kosovo,
22646 Macedonia,
and
Tajikistan.
------------------------------------------------------------------------
Product Project 255 $768,245 3/10/2014 Product
Hope Carter Donation
Hall for
Lane Humanitaria
Millwoo n Relief in
d, VA Tajikistan.
22646
------------------------------------------------------------------------
Product Project 255 $821,994 3/10/2014 Product
Hope Carter Donation
Hall for
Lane Humanitaria
Millwoo n Aid in
d, VA Tajikistan.
22646
------------------------------------------------------------------------
Similar payments to the same organization may appear in this report as
contributions may be distributed in multiple payments.
Janssen Therapeutics, Division of Janssen Products, LP, Monetary and
Product Contributions to U.S.-based Charitable Organizations Full Year
2014
(Payments made from January 1, 2014 to December 31, 2014)--Amended March
19, 2019
------------------------------------------------------------------------
Project
Donation Payee Payee Payment Amount Payment Title/
Type Address (USD) Date Description
------------------------------------------------------------------------
Monetary Aboundi South $1,500 3/24/2014 HEALTHY U! .
ng Bouleva . . HEALTHY
Prospe rd US!
rty Dallas,
TX
75215
------------------------------------------------------------------------
Monetary Acercam 827 $7,000 6/16/2014 ContraSIDA
iento Wildwoo (Against
Hispan d AIDS)
o de Avenue
Caroli Suite
na del 200
Sur Columbi
a, SC
29203
------------------------------------------------------------------------
Monetary Aid for 515 $5,000 11/7/2014 New York
AIDS Greenwi Immigrant
Intern ch AIDS Link
ationa Street Program
l New
York,
NY
10013
------------------------------------------------------------------------
Monetary AIDS 75 Amory $10,000 11/7/2014 Viral
Action Street Hepatitis
Commit Boston, Access
tee MA Project
02119 (VHAP)
------------------------------------------------------------------------
Monetary AIDS 75 Amory $15,000 3/5/2014 Mental
Action Street Health
Commit Boston, Program/
tee MA Charitable
02119 Contributio
n
------------------------------------------------------------------------
Monetary Aids 575 $20,000 7/9/2014 HIV Health
Commun Eighth Literacy
ity Avenue Program
Resear Suite (HHLP)
ch 502 New
Initia York,
tive NY
of 10018
Americ
a
(ACRIA
)
------------------------------------------------------------------------
Monetary AIDS 6260 $4,500 10/27/2014 Wall Talk
Founda Westpar HIV/
tion k Drive Hepatitis C
Housto Houston Co-
n , TX Infection
77057
------------------------------------------------------------------------
Monetary AIDS 411 $30,000 7/10/2014 Road to
Founda South Health:
tion Wells Promoting
of Street Successful
Chicag Suite Implementat
o 300 ion of
Chicago Health Care
, IL Reform for
60607 People
Living with
HIV/AIDS in
Illinois
------------------------------------------------------------------------
Monetary AIDS 7215 $5,000 12/15/2014 Case
Servic Cameron Management
e of Road
Austin Austin,
TX
78752
------------------------------------------------------------------------
Monetary AIDS 17982 $3,000 8/18/2014 HIV Medical
Servic Sky Case
es Park Management
Center Circle
of Irvine,
Orange CA
County 92614
------------------------------------------------------------------------
Monetary AIDS 7215 $5,000 4/4/2014 Case
Servic Cameron Management
es of Road Program
Austin Austin,
TX
78752
------------------------------------------------------------------------
Monetary AIDS 1424 K $250,000 11/10/2014 Access to
United Street, Care (A2C)
NW Initiative
Washing
ton, DC
20005
------------------------------------------------------------------------
Monetary Allianc 825 $5,000 7/8/2014 Group Home
e for Colorad Care for
Housin o Homeless
g and Bouleva Persons
Healin rd with HIV/
g Suite AIDS at
100 Los Soldano
Angeles House and
, CA Casa de
90041 Corazon
------------------------------------------------------------------------
Monetary Bay 701 Oak $2,400 1/17/2014 Youth
Area Street Engagement
Young San Program/
Positi Francis Charitable
ves co, CA contributio
94117 n
------------------------------------------------------------------------
Monetary Bay 701 Oak $5,000 11/7/2014 Patient Peer
Area Street Navigator
Young San
Positi Francis
ves co, CA
94117
------------------------------------------------------------------------
Monetary Bienest 5326 E $15,000 11/5/2014 General
ar Beverly Organizatio
Human Road nal Support
Servic Los
es Inc Angeles
, CA
90022
------------------------------------------------------------------------
Monetary Caring 19591 S. $20,000 8/18/2014 Patients
Ambass Alberta CHOICES--Ch
adors Beaverc anging
reek, Hepatitis
OR through
97004 Outreach,
Information
,
Comprehensi
ve
Education,
and Support
------------------------------------------------------------------------
Monetary Catholi 3009 $5,000 11/7/2014 The Home
c Lake Place
Charit Brook
ies of Bouleva
East rd
Tennes Knoxvil
see le, TN
37909
------------------------------------------------------------------------
Monetary Chicago 1925 $5,000 2/21/2014 Connect2Care
House North (C2C) /
and Clybour Charitable
Social n Suite Contributio
Servic 401 n
e Chicago
Agency , IL
60614
------------------------------------------------------------------------
Monetary Chicago 1925 $10,000 12/15/2014 Connect2Care
House North
and Clybour
Social n Suite
Servic 401
e Chicago
Agency , IL
60614
------------------------------------------------------------------------
Monetary Christi 2440 $15,000 12/15/2014 CHANGE for
e's Third Women
Place Avenue Program
San
Diego,
CA
92101
------------------------------------------------------------------------
Monetary Communi 677 Ala $3,000 3/24/2014 HIV and Hep
ty Moana C
Health Bouleva Prevention
Outrea rd in Drug-
ch Suite Using
Work 226 Community/
to Honolul Charitable
Preven u, HI Contributio
t AIDS 96813 n
------------------------------------------------------------------------
Monetary Desert 1695 N. $5,000 1/17/2014 Case
Aids Sunrise Management/
Projec Way Charitable
t Palm Contributio
Springs n
, CA
92262
------------------------------------------------------------------------
Monetary Fund 121 $25,000 11/5/2014 Get SMART
For Avenue About
The of the Hepatitis C
City America
of New s 6th
York Floor
Inc New
York,
NY
10013
------------------------------------------------------------------------
Monetary Gay 446 West $15,000 11/7/2014 Community
Men's 33rd Education
Health Street and
Crisis New Treatment
York, as
NY Prevention
10001 Program
------------------------------------------------------------------------
Monetary HARM South $50,000 4/18/2014 Hepatitis C
Reduct Bouleva Innovations
ion rd Network/
Coalit Dallas, Charitbale
ion TX Contributio
75215 n
------------------------------------------------------------------------
Monetary Health 1211 $75,000 3/17/2014 ``C Change''
Federa Chestnu Program
tion t
of Street
Philad Suite
elphia 801
Philade
lphia,
PA
19107
------------------------------------------------------------------------
Monetary Hep C 601 $15,000 6/17/2014 HepC
Allian Busines Education
ce s Loop and
70 West Testing--Th
Columbi e Kansas
a, MO Project
65203
------------------------------------------------------------------------
Monetary Hep C 1325 $10,000 3/14/2014 Expanding
Connec South Efforts to
tion Colorad Locate
o Undiagnosed
Bouleva HCV
rd Patients
Suite and Link to
302 Care
Denver,
CO
80222
------------------------------------------------------------------------
Monetary Hepatit 35 East $25,000 7/25/2014 The
is C 38th Hepatitis C
Mentor Street Patient
and New Assistance
Suppor York, Program
t NY
Group, 10016
Inc
------------------------------------------------------------------------
Monetary HIV 100 $5,000 3/12/2014 The
Aids Edgewoo EmpowerLink
Empowe d Program
rment Avenue
Resour NE
ce Suite
Center 1020
for Atlanta
Young , GA
Women, 30303-
Inc. 3065
------------------------------------------------------------------------
Monetary Housing 57 $5,000 11/13/2014 The
Works Willoug Undetectabl
hby es--HIV
Street Viral
Brookly Suppression
n, NY Initiative
11201
------------------------------------------------------------------------
Monetary Howard 4025 N. $10,000 7/25/2014 Hepatitis C
Brown Sherida Medical
Health n Management
Center Street and Support
Chicago for People
, IL who Inject
60613 Drugs
------------------------------------------------------------------------
Monetary Iris 2348 $7,500 2/21/2014 Hepatitis C
House Adam Testing,
Clayton Education
Powell and
Jr Connection
Bouleva to Care
rd New programs/
York, Charitbale
NY Contributio
10030 n
------------------------------------------------------------------------
Monetary J&J One $11,200,000 12/19/2014 Global
Family Johnson Public
of & Health
Compan Johnson programs in
ies Plaza, South
Contri New Africa and
bution Brunswi Uganda (HIV
s Fund ck, NJ and TB)
08933
------------------------------------------------------------------------
Monetary Josephs 1730 $5,000 3/13/2014 Care and
House Lanier Intensive
Place Treatment
NW Adherence
Washing Support for
ton, DC People with
20009 HIV
------------------------------------------------------------------------
Monetary Kansas 3515 $5,000 12/15/2014 Reducing
City Broadwa Risks
Free y through
Health Kansas Health
Clinic City, Education
MO
64111
------------------------------------------------------------------------
Monetary Legacy 4054 $5,000 10/27/2014 Mission
Counse McKinne Support
ling y Legacy
Center Avenue Counseling
Dallas, Center
TX
75204
------------------------------------------------------------------------
Monetary Maine 35 $5,000 6/23/2014 Harm
Genera Medical Reduction
l Center Program:
Health Parkway HIV and HCV
Augusta Prevention
, ME
04330
------------------------------------------------------------------------
Monetary Making 60 Clif $5,000 12/15/2014 Imani Park
It Prescod Transitiona
Possib Lane l Housing
e to Edison, Program
End NJ
Homele 08817
ssness
------------------------------------------------------------------------
Monetary Minorit 5149 $7,500 2/21/2014 ``The Bridge
y AIDS West Program''
Projec Jeffers
t on
Blvd.
Los
Angeles
, CA
90016
------------------------------------------------------------------------
Monetary NAESM, 2140 $5,000 6/16/2014 The D.C.
Inc. Martin Project
Luther
King Jr
Drive
Atlanta
, GA
30310
------------------------------------------------------------------------
Monetary Nashvil 633 $5,000 5/13/2014 Outreach,
le Thompso Testing,
CARES n Lane Linkage to
Nashvil Care, and
le, TN Supportive
37204 Services
for young
AA gay/
bisexual or
other MSM
------------------------------------------------------------------------
Monetary Nationa 2140 $7,000 12/15/2014 Project
l AIDS Martin Impact
Educat Luther
ion King
and Jr. SW
Servic Atlanta
es for , GA
Minori 30310
ties
------------------------------------------------------------------------
Monetary Nationa 580 $175,000 4/18/2014 NATAP HIV,
l AIDS Broadwa HCV/HIV
Treatm y Suite Coinfetion
ent 1010 and Hep C
Advoca New Care and
cy York, Treatment
Projec NY Education/
t 10012 Information
(NATAP and Policy/
) Advocacy
Program
------------------------------------------------------------------------
Monetary Nationa 444 $125,000 3/17/2014 Affordable
l North Care Act
Allian Capitol (ACA),
ce of Street, Viral
State NW Hepatitis,
and Suite and Ryan
Territ 339 White/ADAP
orial Washing Public
AIDS ton, DC Policy and
Direct 20001 Technical
ors Assistance
Projects/
Charitable
Contributio
n
------------------------------------------------------------------------
Monetary Nationa 444 $150,000 12/18/2014 2015
l North Affordable
Allian Capitol Care Act
ce of Street, (ACA),
State NW Viral
and Suite Hepatitis,
Territ 339 and Ryan
orial Washing White/ADAP
AIDS ton, DC
Direct 20001
ors
------------------------------------------------------------------------
Monetary New 44 South $5,000 8/7/2014 Community
Jersey Street, Based
AIDS Morrist Services
Servic own NJ
es 07960
------------------------------------------------------------------------
Monetary North 5 Center $10,000 2/3/2014 Living Well
Shore Street with
Health Glouces Hepatitis C
Projec ter, MA
t, 01930
Inc.
------------------------------------------------------------------------
Monetary Nova 2946 $5,000 6/23/2014 En Direccion
Salud Sleepyh Positiva
ollow Spanish-
Road Speaking
Suite HIV/AIDS
4A Support
Falls Group
Church,
VA
22044
------------------------------------------------------------------------
Monetary OPAT 1192 $2,500 3/12/2014 Infectious
Outcom Smith Disease
es Street Hepatitis C
Regist Honolul Virus (HCV)
ry u, HI Education,
96817 Screening,
Pre/Post
Education
and Linkage
to Care
2014-2015 /
Charitable
Contributio
n
------------------------------------------------------------------------
Monetary Patient 421 $750,000 12/16/2014 Patient
Advoca Butler Advocate
te Farm Foundation'
Founda Road s Co-Pay
tion Hampton Relief
, VA (CPR)
23666 Program
Hepatitis C
Silo
------------------------------------------------------------------------
Monetary Patient 421 $5,000,000 1/14/2014 Patient
Advoca Butler Advocate
te Farm Foundation'
Founda Road s Co-Pay
tion Hampton Relief
, VA (CPR)
23666 Program-
Hepatitis C
Silo
------------------------------------------------------------------------
Monetary Philade 1233 $10,000 7/9/2014 2014 AIDS
lphia Locust Education
FIGHT Street Month
3rd
Floor
Philade
lphia,
PA
19107
------------------------------------------------------------------------
Monetary Project 273 $25,000 6/25/2014 Think Tank
Inform Ninth to Provide
Street Technical
San Assistance
Francis to Ten
co, CA Jurisdictio
94103 ns on the
Use of HIV
Surveillanc
e to
Support
Linkage and
Retention
in Care and
Treatment
------------------------------------------------------------------------
Monetary Project 273 $40,000 7/1/2014 The Support
Inform Ninth Partnership
Street
San
Francis
co, CA
94103
------------------------------------------------------------------------
Monetary Project 273 $40,000 7/4/2014 Mission
Inform Ninth Support for
Street Project
San Inform /
Francis Charitable
co, CA Contributio
94103 n
------------------------------------------------------------------------
Monetary Project 273 $25,000 12/15/2014 Educational
Inform Ninth and Policy
Street Activities
San to Support
Francis Hepatitis C
co, CA Care
94103 Linkage
------------------------------------------------------------------------
Monetary Project 2929 NE $2,000 3/12/2014 Many Men,
Link 6 Many Voices
of Avenue (3MV) and
South Wilton Many Women,
Florid Manors, Many Voices
a, FL (3WV)
Inc. 33334
------------------------------------------------------------------------
Monetary Project 530 W $5,000 11/13/2014 Transitional
Transi Street Housing
tions Road
Warmins
ter, PA
18974
------------------------------------------------------------------------
Monetary Provide 1150 $40,000 7/4/2014 Providence
nce Varnum Hepatitis C
Health St. NE Program
Founda Washing
tion ton, DC
20721
------------------------------------------------------------------------
Monetary Ryan 1775 T $10,000 4/25/2014 HEPATITIS:
White Street Education,
CARE NW Advocacy
Act Washing and
Title ton, DC Leadership
II 20009 (HEAL)
Commun
ity
AIDS
Nation
al
Networ
k (T
II
CANN)
------------------------------------------------------------------------
Monetary San 1035 $30,000 8/25/2014 The
Franci Market Stonewall
sco Street Project
AIDS San
Founda Francis
tion co, CA
94103
------------------------------------------------------------------------
Monetary Southwe 300 $5,000 3/1/2014 HIV Care in
st Southwe a Safety
Boulev st Net Clinic/
ard Bouleva Charitable
Family rd Contributio
Health Kansas n
Care, City,
Inc KS
66103
------------------------------------------------------------------------
Monetary Special 605 W $5,000 1/28/2014 Asian
Servic Olympic Pacific
e for Bouleva AIDS
Groups rd Interventio
, Inc. Suite n Team
600 Los (APAIT)
Angeles Charitable
, CA Contributio
90015 n
------------------------------------------------------------------------
Monetary The 17 Davis $60,000 3/5/2014 Florida
AIDS Bouleva Hepatitis
Instit rd Education
ute Suite and
403 Advocacy
Tampa, Network
FL (FHEAN) and
33606 health web
portal
(www.HepInf
oNow.org) /
Charitable
Contributio
n
------------------------------------------------------------------------
Monetary The 17 Davis $50,000 7/9/2014 Protecting
AIDS Bouleva and
Instit rd enhancing
ute Suite the
403 Hepatitis C
Tampa, and the HIV/
FL AIDS
33606 national
and state
programs
and
policies in
the U.S.
------------------------------------------------------------------------
Monetary The 121 $40,000 4/18/2014 The SHE
Fund Avenue Initiative
for of the
the America
City s 6th
of New Floor
York New
York,
NY
10013
------------------------------------------------------------------------
Monetary The 330 $15,000 7/22/2014 The Well
Well Grace Project's
Projec Glen Online
t Nellysf Resources
ord, VA for Women
22958 and HIV
------------------------------------------------------------------------
Monetary Tides 835 $20,000 11/25/2014 Website:
Center Solano HCVAdvocate
Street
West
Sacrame
nto, CA
95605
------------------------------------------------------------------------
Monetary TPA 5537 N $20,000 7/9/2014 Total Care
Networ Broadwa Portal
k y
Incorp Chicago
orated , IL
-Test 60640
Positi
ve
Aware
Networ
k
------------------------------------------------------------------------
Monetary Treatme 261 5th $40,000 6/17/2014 Case Studies
nt Avenue Project
Action Suite
Group 2110
(TAG) New
York,
NY10016
------------------------------------------------------------------------
Monetary Univers c/o UC $15,000 3/5/2014 ``Linkage To
ity of San Care, After
Califo Diego HIV
rnia, AIDS Testing''/
San Researc Charitable
Diego h Contributio
Institu n
te 9500
Gilman
Drive
#0716
La
Jolla,
CA
92093-
0716
------------------------------------------------------------------------
Monetary Victory 965 $10,000 2/3/2014 Prevention,
Progra Massach Education,
ms, usetts and Health
Inc. Avenue Connections
Boston, Services
MA for People
02118 with HIV/
AIDS.
------------------------------------------------------------------------
Monetary VT 187 $5,000 3/13/2014 HIV Care and
Commit Saint Support
tee Paul Program
For Street Across
AIDS Burling Vermont
Resour ton, VT
ces 05401
Educ
and
Servic
es
------------------------------------------------------------------------
Monetary Wright 8101 $5,000 3/3/2014 Case
House Cameron Management
Wellne Road for HIV/HCV
ss Suite Clients
Center 105
Austin,
TX
78754
------------------------------------------------------------------------
Janssen has also made financial donations to independent charitable
foundations that assist patients who are underinsured and in financial
need with treatment-related expenses. In keeping with our donor
agreements and applicable regulatory guidance, we will only disclose
aggregate data on our charitable giving and do not publicize
information on donations to specific foundations and disease states.
In 2014, we contributed approximately $5.8 million in donations to
independent charitable foundations, enabling them to provide
assistance with medication-related copays to patients with infectious
diseases.
----------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------
Product Johnson & Johnson One Johnson & $5,615,443 3/15/2013 Patient Assistance
Patient Assistance Johnson Plaza, New Product Donation
Foundation Brunswick, NJ 08933
----------------------------------------------------------------------------------------------------------------
Product Johnson & Johnson One Johnson & $9,794,392 6/15/2013 Patient Assistance
Patient Assistance Johnson Plaza, New Product Donation
Foundation Brunswick, NJ 08933
----------------------------------------------------------------------------------------------------------------
Product Johnson & Johnson One Johnson & $26,177,458 9/15/2013 Patient Assistance
Patient Assistance Johnson Plaza, New Product Donation
Foundation Brunswick, NJ 08933
----------------------------------------------------------------------------------------------------------------
Product Johnson & Johnson One Johnson & $58,375,988 12/15/2013 Patient Assistance
Patient Assistance Johnson Plaza, New Product Donation
Foundation Brunswick, NJ 08933
----------------------------------------------------------------------------------------------------------------
Janssen Biotech, Inc. Monetary and Product Contributions to U.S.-based
Charitable Organizations Full Year 2015
(Payments made from January 1, 2015 to December 31, 2015)--Amended on
February 24, 2017
------------------------------------------------------------------------
Project
Donation Payee Payee Payment Amount Payment Title/
Type Address (USD) Date Description
------------------------------------------------------------------------
Monetary 100 4631 $2,000 7/17/2015 The 100
Black Delmar Black Men
Men of St. of
Metrop Louis, Metropolita
olitan Missour n St. Louis
St. i 63108 Community
Louis Health Day
Featuring
Prostate
Cancer Run/
Walk
------------------------------------------------------------------------
Monetary 100 4631 $1,800 12/23/2015 The 100
Black Delmar Black Men
Men of St. of
Metrop Louis, Metropolita
olitan Missour n St. Louis
St. i 63108 Community
Louis Health Day
Featuring
Prostate
Cancer Run/
Walk
------------------------------------------------------------------------
Monetary Achieve 104 $5,625 12/4/2015 Achieve Now:
Now Gladsto Bringing
ne Students Up
Street to Grade
Philade Level
lphia, Reading
PA
19148
------------------------------------------------------------------------
Monetary America Manasqua $10,000 4/8/2015 Road To
n n, NJ Recovery
Cancer 08736 Program
Societ
y,
Inc.
------------------------------------------------------------------------
Monetary America Manasqua $1,000 5/27/2015 2015 Run for
n n, NJ Dad
Cancer 08736
Societ
y,
Inc.
------------------------------------------------------------------------
Monetary America 1626 $1,000 7/8/2015 American
n Locust Cancer
Cancer Street Society,
Societ Philade Relay For
y, lphia, Life of the
Inc. PA Wissahickon
19103 Valley,
Ambler, PA
------------------------------------------------------------------------
Monetary Arthrit National $225,000 6/5/2015 Sponsorship
is Office of 117
Founda 1330 W. Jingle Bell
tion Peachtr Run events,
ee St., reaching
N.W. more than
Atlanta 100,000
, GA participant
30309 s and
volunteers,
across the
country
------------------------------------------------------------------------
Monetary Arthrit 1817 $2,000 6/4/2015 The
is Central Community
Servic Avenue Arthritis
es Suite Project of
211 Charlotte,
Charlot Mecklenburg
te, NC County,
28205 North
Carolina
------------------------------------------------------------------------
Monetary Cancer 275 $2,000 7/3/2015 Seventh
Care, Seventh Annual
Inc. Avenue Healing
New Hearts
York, Family
NY Bereavement
10001 Camp
Milford, PA
------------------------------------------------------------------------
Monetary Cancer 3 $5,000 12/2/2015 Oncology
Suppor Crossro Support
t ads Groups
Commun Drive
ity Bedmins
Centra ter, NJ
l New 07921
Jersey
------------------------------------------------------------------------
Monetary Cancer 200 Kirk $1,000 7/10/2015 Paws 4 Life
Suppor Road PO Dog Walk,
t Box Warminster
Commun 3187 PA
ity of Warmins
Philad ter, PA
elphia 18974
(forme
rly
Gilda'
s Club
Bucks/
Mont
Counti
es)
------------------------------------------------------------------------
Monetary Cancer 200 Kirk $2,500 10/23/2015 Celebration
Suppor Road PO of Hope: A
t Box Free, Full-
Commun 3187 Day,
ity of Warmins Educational
Philad ter, PA and
elphia 18974 Inspiration
(forme al
rly Conference
Gilda' for Greater
s Club Philadelphi
Bucks/ a-Area
Mont Cancer
Counti Patients,
es) Survivors,
and
Caregivers
------------------------------------------------------------------------
Monetary Center 1900 $2,000 7/9/2015 Project for
for Cherry Medically
Child Street Needy
Advoca Philade Children
tes lphia,
PA
19103
------------------------------------------------------------------------
Monetary Childre 6380 $7,500 3/17/2015 Children's
ns Flank Cancer
Cancer Drive, Recovery
Recove Suite Foundation'
ry 400 s Bear-Able
Founda Harrisb Gift
tion urg, PA Program:
17112 administere
d to the
Children's
Hospital of
Philadelphi
a
------------------------------------------------------------------------
Monetary Childre 6380 $7,500 12/22/2015 Bear-Able
ns Flank Gifts
Cancer Drive, program
Recove Suite
ry 400
Founda Harrisb
tion urg, PA
17112
------------------------------------------------------------------------
Monetary Childre The $1,000 12/23/2015 General
n's Childre Operating
Hospit n's Support for
al of Hospita The Center
Philad l of for
elphia Philade Pediatric
Founda lphia Inflammator
tion Foundat y Bowel
ion Disease
Attn:
Staci
Carney,
Associa
te
Directo
r,
Corpora
te and
Foundat
ion
Relatio
ns 100
Penn
Square
East
8th
Floor,
Suite
8050
Philade
lphia,
PA
19107
------------------------------------------------------------------------
Monetary Childre The $12,000 4/8/2016 Family Care
n's Childre Binder
Hospit n's Program at
al of Hospita The
Philad l of Children's
elphia Philade Hospital of
Founda lphia Philadelphi
tion Foundat a
ion Philadelphi
Attn: a, PA
Staci
Carney,
Associa
te
Directo
r,
Corpora
te and
Foundat
ion
Relatio
ns 100
Penn
Square
East
8th
Floor,
Suite
8050
Philade
lphia,
PA
19107
------------------------------------------------------------------------
Monetary Childre The $6,000 4/8/2016 6th Annual
n's Childre Walk for
Hospit n's Hope
al of Hospita benefiting
Philad l of IBD
elphia Philade research at
Founda lphia The
tion Foundat Children's
ion Hospital of
Attn: Philadelphi
Staci a, Veterans
Carney, Park,
Associa Hamilton,
te NJ
Directo
r,
Corpora
te and
Foundat
ion
Relatio
ns 100
Penn
Square
East
8th
Floor,
Suite
8050
Philade
lphia,
PA
19107
------------------------------------------------------------------------
Monetary Communi 300B $20,000 12/8/2015 Free Medical
ty Lawrenc and Dental
Volunt e Drive Care to
eers West Uninsured,
in Chester Low-Income
Medici , PA Individuals
ne 19380 and
Families
Who Live or
Work in
Chester
County.
Community
Volunteers
in Medicine
is located
in West
Chester, PA
------------------------------------------------------------------------
Monetary Crohns 733 $135,000 6/5/2015 CCFA Take
and Third Steps Walk/
Coliti Avenue Run
s Suite
Founda 510 New
tion York,
of NY
Americ 10017
a
------------------------------------------------------------------------
Monetary Crohn's 733 $18,000 7/7/2015 Camp Oasis--
and Third Program is
Coliti Avenue hosted at
s Suite 12 campsite
Founda 510 New locations
tion York, across the
of NY country
Americ 10017
a,
Inc.
------------------------------------------------------------------------
Monetary Delawar 236 $21,500 3/20/2015 Delaware
e Randell Valley
Valley Hall Science
Scienc 3141 Fairs
e Chestnu Philadelphi
Fairs, t a, PA
Inc. Street
Philade
lphia,
PA
19104
------------------------------------------------------------------------
Monetary Family 2001 $250,000 12/21/2015 Family Reach
Reach Route Programmati
Founda 46, c Support
tion Suite
310
Parsipp
any, NJ
07054
------------------------------------------------------------------------
Monetary Family 2001 $20,000 12/21/2015 Family Reach
Reach Route Foundation
Founda 46, General
tion Suite Support
310
Parsipp
any, NJ
07054
------------------------------------------------------------------------
Monetary Friends 113 West $3,000 12/14/2015 Homelessness
Associ Chestnu to
ation t Independenc
For Street e
Care West Initiative
and Chester
Protec , PA
tion 19380
Of
Childr
en
------------------------------------------------------------------------
Monetary Friends 815 West $825 9/23/2015 Employee
of the 7th directed
Queen Street donation in
City Plainfi Lieu of
Academ eld, NJ holiday
y 07063 gift
Charte
r
School
------------------------------------------------------------------------
Monetary Georgia Alpharet $1,500 8/12/2015 Georgia
Prosta ta, GA Prostate
te 30022 Cancer Free
Cancer Screening
Coalit Event
ion,
Inc.
------------------------------------------------------------------------
Monetary Georgia Alpharet $1,700 12/23/2015 Georgia
Prosta ta, GA Prostate
te 30022 Cancer Free
Cancer Screening
Coalit Event
ion,
Inc.
------------------------------------------------------------------------
Monetary Girl 330 $3,000 12/14/2015 GSEP STEM
Scouts Manor Programming
of Road
Southe Miquon,
astern PA
Pennsy 19444
lvania
------------------------------------------------------------------------
Monetary Girl 501 S. $1,250 5/27/2015 16th Annual
Scouts College Women of
of the Avenue Distinction
Chesap Newark, Program and
eake DE Celebration
Bay 19713
Counci
l,
Inc.
------------------------------------------------------------------------
Monetary Great PO Box $5,000 12/14/2015 GVNC
Valley 82 4251 Environment
Nature State al
Center Road Education
Devault Programs
, PA with
19432 Schools-
Water
Quality,
Pond,
Stream and
Habitat
Study
------------------------------------------------------------------------
Monetary Green 1368 $15,000 12/8/2015 Watershed
Valley Prizer Education
s Road Programs
Associ Pottsto
ation wn, PA
19465
------------------------------------------------------------------------
Monetary Habitat P.O. Box $1,000 10/27/2015 Habitat for
for 1452 Humanity of
Humani 621 Chester
ty of Lumber County
Cheste Street
r Coatesv
County ille,
, Inc. PA
19320
------------------------------------------------------------------------
Monetary Habitat 1829 N. $5,000 12/14/2015 Habitat for
For 19th Humanity
Humani Street Philadelphi
ty Philade a
Philad lphia, Homeownersh
elphia PA ip Program
, Inc. 19121
------------------------------------------------------------------------
Monetary Hatboro- 229 $25,000 12/2/2015 STEM
Horsha Meeting Programs
m house for Hatboro-
Educat Road Horsham
ional Horsham Students
Founda , PA
tion 19044
------------------------------------------------------------------------
Monetary Hope 129 $300 9/21/2015 Costs
for Yerger associated
Kids, Road with 2015
Inc. Schwenk Janssen
sville, Cares
PA Volunteer
19473 Activity
------------------------------------------------------------------------
Monetary Kids 26071 $3,000 9/4/2015 Support
Connec Merit Groups for
ted Circle, Children of
#103 Cancer
Laguna Patients
Hills, Costa Mesa,
CA Ca Brea, Ca
92653- Santa Ana,
7016 Ca Laguna
Hills, Ca
La Jolla,
Ca
Temecula,
Ca
------------------------------------------------------------------------
Monetary Metropo 2323 $20,000 12/7/2015 Medically
litan Ranstea Appropriate
Area d Meals for
Neighb Street People with
orhood Philade Critical
Nutrit lphia, Illnesses
ion PA
Allian 19103
ce
(MANNA
)
------------------------------------------------------------------------
Monetary Montgom 340 $10,000 12/15/2015 Bridge to
ery DeKalb Employment
County Pike Program
Commun Blue Enhancement
ity Bell, through
Colleg PA Strategies
e 19422 for Success
Founda
tion
------------------------------------------------------------------------
Monetary Movembe Culver $5,000 5/22/2015 Movember is
r City, a national
Founda CA US campaign
tion 90232 where we
ask men to
grow
moustaches
to raise
awareness
and funds
for men's
health
------------------------------------------------------------------------
Monetary Multipl 51 Locus $5,000 7/10/2015 2015 MMRF
e Avenue Team for
Myelom Suite Cures: New
a 201 York City
Resear Norwalk 5K Walk/Run
ch , CT
Founda 06851
tion
------------------------------------------------------------------------
Monetary Multipl 51 Locus $5,000 7/10/2015 2015 MMRF
e Avenue Team for
Myelom Suite Cures:
a 201 Philadelphi
Resear Norwalk a 5K Walk/
ch , CT Run
Founda 06851
tion
------------------------------------------------------------------------
Monetary Multipl 383 Main $10,000 7/13/2015 MMRF Team
e Avenue for Cures
Myelom 5th Sponsor--NY
a Floor C Marathon,
Resear Norwalk (NY, NY)
ch , CT and Fenway
Founda 06851 Spartan
tion Race
(Boston, MA
)
------------------------------------------------------------------------
Monetary Nationa 4719 $2,500 4/8/2015 17th Annual
l Reed Break the
Ovaria Road Silence on
n #150 Ovarian
Cancer Holicon Cancer
Coalit g, PA Philadelphi
ion--C 18928 a, PA
entral
Ohio
Chapte
r
------------------------------------------------------------------------
Monetary Nationa 6600 SW $75,000 4/14/2015 2015 Team
l 02nd NPF Walk--
Psoria Avenue, National
sis Ste. (19 U.S.
Founda 300 cities)
tion Portlan
d, OR
97223
------------------------------------------------------------------------
Monetary Pennypa 7005 $300 9/21/2015 Costs
ck Sheaff associated
Farm Lane with 2015
and Fort Janssen
Educat Washing Cares
ion ton, PA Volunteer
Center 19034 Activity
------------------------------------------------------------------------
Monetary Project 1515 $1,000 12/2/2015 Mental
HOME Fairmou Health and
nt Recovery
Avenue Services
Philade for
lphia, Individuals
PA Who Have
19130 Experienced
Homelessnes
s
------------------------------------------------------------------------
Monetary Prostat 7009 S. $30,000 7/13/2015 Prostate
e Potomac Cancer
Cancer Street Disparities
Educat Suite Outreach
ion 125 Program--A
Counci Centenn national,
l ial, CO ten city
80112 event
------------------------------------------------------------------------
Monetary Prostat 7009 S. $20,000 12/23/2015 Prostate
e Potomac Cancer
Cancer Street Disparities
Educat Suite Outreach
ion 125 Program--A
Counci Centenn national,
l ial, CO ten city
80112 event
------------------------------------------------------------------------
Monetary Rebuild P.O. Box $6,000 3/17/2015 House Build
ing 42752
Togeth Philade
er lphia,
Philad PA
elphia 19101-
2752
------------------------------------------------------------------------
Monetary Retired 925 $10,000 3/20/2015 RSVP's My
and Harvest Free Tutor
Senior Drive, (MFT) and
Volunt Suite Family
eer 100 Literacy
Progra Blue Volunteer
m of Bell, Program
Montgo PA (FLVP)
mery 19422
County
------------------------------------------------------------------------
Monetary Retired 925 $5,000 7/9/2015 RSVP's
and Harvest Protege and
Senior Drive, America
Volunt Suite Reads/
eer 100 Writes
Progra Blue Programs
m of Bell,
Montgo PA
mery 19422
County
------------------------------------------------------------------------
Monetary Retired 925 $10,000 12/7/2015 RSVP's
and Harvest Family
Senior Drive, Literacy
Volunt Suite Volunteer
eer 100 Program
Progra Blue (FLVP) and
m of Bell, My Free
Montgo PA Tutor (MFT)
mery 19422 virtual
County STEM
tutoring
and career
awareness
program.
------------------------------------------------------------------------
Monetary Riverbe 1950 $6,000 7/3/2015 Outreach to
nd Spring Children/
Enviro Mill Access to
nmenta Road Nature
l Gladwyn (Norristown
Educat e, PA , PA)
ion 19035
Center
------------------------------------------------------------------------
Monetary Sandy 2010 $2,000 5/15/2015 11th Annual
Rollma West Sandy
n Chester Sprint 5K/
Ovaria Pike 10K Run/
n Suite Walk
Cancer 300
Founda Haverto
tion, wn, PA
Inc. 19083
------------------------------------------------------------------------
Monetary Senior 536 $500 8/12/2015 2015 Meals
Adult George On Wheels
Activi St. Outrunning
ties Norrist Senior
Center own, PA Hunger 5k/
of 19401 3k. Mont Co
Montgo Comm
mery College,
County Blue Bell,
PA. Meals
On Wheels
of the
Senior
Adult
Activities
Center of
Montgomery
County
impacts
homebound
seniors in
Central,
North Penn
and the
Eastern
Montgomery
Co areas.
------------------------------------------------------------------------
Monetary Senior 536 $300 8/20/2015 Costs
Adult George associated
Activi St. with 2015
ties Norrist Janssen
Center own, PA Cares
of 19401 Volunteer
Montgo Activity
mery
County
------------------------------------------------------------------------
Monetary Special 2800 $300 8/20/2015 Costs
Equest Street associated
rians Road with 2015
P.O. Janssen
Box Cares
1001 Volunteer
Warring Activity
ton, PA
18976
------------------------------------------------------------------------
Monetary Special 2800 $4,000 9/23/2015 Special
Equest Street Equestrians
rians Road Equine
P.O. Assisted
Box Learning
1001 and
Warring Therapeutic
ton, PA Riding
18976 Program
Warrington,
PA
------------------------------------------------------------------------
Monetary Starfin 4015 $10,000 3/20/2015 Youth
der Main Development
Founda Street through
tion Philade Soccer and
lphia, Education
PA Philadelphi
19127 a, PA
------------------------------------------------------------------------
Monetary Stop 2501 $40,700 5/22/2015 Janssen
Hunger Clark Biotech and
Now Street, Stop Hunger
Suite Now Engage
301 Employee
Raleigh Volunteers
, NC in Dallas,
27607 Texas
------------------------------------------------------------------------
Monetary The 222 $10,000 11/26/2015 Corporate
Frankl North Membership
in 20th
Instit Street
ute Philade
lphia,
PA
19103
------------------------------------------------------------------------
Monetary The Gwynedd $3,000 7/3/2015 General
Giving Valley, Operating
Tree PA Support
19437
------------------------------------------------------------------------
Monetary The 2600 $10,000 4/8/2015 Hubert J.P.
Melmar Wayland Schoemaker
k Road Classic
Charit Berwyn,
able PA
Founda 19312
tion
------------------------------------------------------------------------
Monetary The 2600 $300 8/21/2015 Costs
Melmar Wayland associated
k Road with 2015
Charit Berwyn, Janssen
able PA Cares
Founda 19312 Volunteer
tion Activity
------------------------------------------------------------------------
Monetary The 400 $300 8/20/2015 Costs
Pennsb Pennsbu associated
ury ry with 2015
Societ Memoria Janssen
y l Road Cares
Morrisv Volunteer
ille, Activity
PA
19067
------------------------------------------------------------------------
Monetary Trustee 3025 $5,000 12/23/2015 WXPN
s Of Walnut Musicians
The Street On Call
Univer Philade
sity lphia,
Of PA
Pennsy 19104
lvania
------------------------------------------------------------------------
Monetary United 1709 $260,045 12/23/2015 United Way
Way of Benjami Campaign
Southe n Match
astern Frankli
Pennsy n
lvania Parkway
Philade
lphia,
PA
19103
------------------------------------------------------------------------
Monetary Us Too 5003 $1,000 4/8/2015 11th Annual
Intern Fairvie SEA Blue
ationa w Ave. Prostate
l, Downers Cancer 5K
Inc. Grove, Run and
IL Celebration
60515 Walk in
Chicago, IL
------------------------------------------------------------------------
Monetary Zero 515 King $75,000 4/8/2015 ZERO
The Street, Prostate
Projec Suite Cancer Run/
t To 420 Walk Series
End Alexand 40-plus
Prosta ria, VA cities
te 22314 nationwide
Cancer running
from March
to November
2015
------------------------------------------------------------------------
Monetary Zero 515 King $8,000 10/23/2015 ZERO
The Street, Baltimore
Projec Suite Free
t To 420 Prostate
End Alexand Cancer
Prosta ria, VA Screening
te 22314 Program
Cancer
------------------------------------------------------------------------
Janssen has also made financial donations to independent charitable
foundations that assist patients who are underinsured and in financial
need with treatment-related expenses. In keeping with our donor
agreements and applicable regulatory guidance, we will only disclose
aggregate data on our charitable giving and do not publicize
information on donations to specific foundations and disease states.
In 2015, we contributed $29.5 million in donations to independent
charitable foundations, enabling them to provide assistance with
medication-related copays to patients with cancer and autoimmune
diseases.
----------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------
Product Johnson & Johnson One Johnson & $87,940,000 3/15/2015 Patient Assistance
Patient Assistance Johnson Plaza, New Product Donation
Foundation Brunswick, NJ 08933
----------------------------------------------------------------------------------------------------------------
Product Johnson & Johnson One Johnson & $69,856,000 6/15/2015 Patient Assistance
Patient Assistance Johnson Plaza, New Product Donation
Foundation Brunswick, NJ 08933
----------------------------------------------------------------------------------------------------------------
Product Johnson & Johnson One Johnson & $60,259,000 9/15/2015 Patient Assistance
Patient Assistance Johnson Plaza, New Product Donation
Foundation Brunswick, NJ 08933
----------------------------------------------------------------------------------------------------------------
Product Johnson & Johnson One Johnson & $70,842,000 12/15/2015 Patient Assistance
Patient Assistance Johnson Plaza, New Product Donation
Foundation Brunswick, NJ 08933
----------------------------------------------------------------------------------------------------------------
Updated February 24, 2017
Janssen Pharmaceuticals, Inc. Monetary and Product Contributions to U.S.-
based Charitable Organizations Full Year 2015
(Payments made from January 1, 2015 to December 31, 2015)
------------------------------------------------------------------------
Project
Donation Payee Payee Payment Amount Payment Title/
Type Address (USD) Date Description
------------------------------------------------------------------------
Monetary 180 1 $1,000 11/3/2015 Youth
Turnin Bethany Helpline
g Road,
Lives Buildin
Around g 3,
, Inc. Suite
42
Hazlet,
NJ
07730
------------------------------------------------------------------------
Monetary Adult 872. E. $600 8/20/2015 Costs
Day Main associated
Center Street with 2015
of Bridgew Janssen
Somers ater, Cares
et NJ Volunteer
County 08807 Activity
------------------------------------------------------------------------
Monetary Advanci 1005 $2,500 10/23/2015 College
ng Whitehe Aspire and
Opport ad Road Inquire
unitie Extensi Program
s, on,
Inc. Suite 1
Ewing,
NJ
08520
------------------------------------------------------------------------
Monetary Allies, 1262 $7,500 11/16/2015 Project Grow-
Inc. Whiteho Allies Farm
rse- Program
Hamilto located on
n the Grounds
Square of Mercer
Road County
Buildin Community
g A, College,
Suite West
101 Windsor, NJ
Hamilto
n, NJ
08690
------------------------------------------------------------------------
Monetary America 6500 $600 1/22/2015 Employee
n Sugarlo directed
Cancer af donation in
Societ Parkway lieu of
y , Suite company
260 holiday
Duluth, gift
GA
30097
------------------------------------------------------------------------
Monetary America Buffalo $100 3/12/2015 Memorial
n Hope donation
Cancer Lodge
Societ 197
y Summer
Street
Buffalo
, NY
14222
------------------------------------------------------------------------
Monetary America 1160 $30,000 10/29/2015 Diabetes
n Route Interventio
Diabet 22 East n Project
es Suite ($30K) and
Associ 103 the General
ation Bridege Education
water, Outreach
NJ ($10K)
08807
------------------------------------------------------------------------
Monetary America 1701 $125,000 12/8/2015 American
n North Diabetes
Diabet Beaureg Association
es ard 's What Can
Associ Street I Eat?
ation, Alexand Choices for
Inc. ria, VA People with
22311 Type 2
Diabetes
------------------------------------------------------------------------
Monetary America 1392 CR $30,000 12/23/2015 Atrial
n 2740, Fibrillatio
Founda Decatur n Patient
tion , TX Education
For 76234- and Support
Womens 7401
Health
------------------------------------------------------------------------
Monetary America 7272 $10,000 12/8/2015 Garden State
n Greenvi Go Red For
Heart lle Women
Avenue Luncheon
Dallas,
TX
75231
------------------------------------------------------------------------
Monetary America 1000 $210,000 12/17/2015 Judges'
n Wilson Leadership
Psychi Blvd, Initiative-
atric Suite Psychiatric
Founda 1825 Leadership
tion Arlingt for
on, VA Criminal
22209 Justice
(JLI/PLCJ)
------------------------------------------------------------------------
Monetary America 1000 $35,000 12/17/2015 Partnership
n Wilson for
Psychi Blvd, Workplace
atric Suite Mental
Founda 1825 Health
tion Arlingt
on, VA
22209
------------------------------------------------------------------------
Monetary America 1000 $100,000 12/17/2015 Typical or
n Wilson Troubled?
Psychi Blvd, Student
atric Suite Mental
Founda 1825 Health
tion Arlingt Education
on, VA Program
22209
------------------------------------------------------------------------
Monetary America 707 $94,250 12/17/2015 Effort to
n Red Alexand support
Cross er Road disaster
Princet relief
on, NJ american
08550 military
families,
health and
safety
services,
internation
al aid, and
blood
donation
services
within
central New
Jersey and
across the
US
------------------------------------------------------------------------
Monetary AmeriCa 88 $4,600 12/8/2015 General
res Hamilto mission
Founda n Ave support
tion Stamfor
d, CT
06902
------------------------------------------------------------------------
Monetary Anchor 482 $812 4/16/2015 General
House, Centre Operating
Inc. Street Support
Trenton
, NJ
08611
------------------------------------------------------------------------
Monetary Anderso PO Box $300 8/19/2015 Costs
n 134 532 associated
House Route with 2015
523 Janssen
Whiteho Cares
use Volunteer
Station Activity
, NJ
08889
------------------------------------------------------------------------
Monetary Anderso 532 $19,000 12/3/2015 Integrated
n County Care
House Road Management
523
P.O.
Box 134
Whiteho
use
Station
, NJ
08889
------------------------------------------------------------------------
Monetary Ann 595 West $9,500 11/12/2015 Ann
Silver State Silverman
man Street Community
Commun Doylest Health
ity own, PA Clinic for
Health 18901 Bucks
Clinic County
residents
------------------------------------------------------------------------
Monetary Arc 141 $3,500 11/2/2015 Fundraising
Founda South event
tion Main support to
Of Street benefit
Somers Manvill general
et e, NJ mission of
County 08835 organizatio
, Inc. n
------------------------------------------------------------------------
Monetary Associa 819 $9,000 11/16/2015 Partial Care
tion Alexand Day
for er Road Treatment,
Advanc Princet Physical
ement on, NJ Health
of 08540 Expansion
Mental
Health
------------------------------------------------------------------------
Monetary Athens 7 N. $1,000 7/1/2015 Mental
Mental Congres Health
Health s St. Awarenss
, Inc. Athens, Event: 2nd
OH Annual
45701 Community
Illuminatio
n
------------------------------------------------------------------------
Monetary Autism 1060 $1,000 11/16/2015 Autism
Speaks State Resource
Road Fair
2nd Sponsor
Floor 2016
Princet Central NJ
on, NJ Walk Now
08540 for Autism
Speaks
------------------------------------------------------------------------
Monetary Bay 66 Canal $5,000 6/22/2015 Bay Cove
Cove St Wellness
Human Boston, Center to
Servic MA assist
es, 02114 diverse low-
Inc. income
clients who
are working
towards
recovery
from severe
mental
illness
------------------------------------------------------------------------
Monetary Bentley PO Box $300 8/11/2015 Costs
Commun 1093 associated
ity Belle with 2015
Servic Mead, Janssen
es, NJ Cares
Inc. 08502 Volunteer
Activity
------------------------------------------------------------------------
Monetary Big 2875 $6,500 11/16/2015 The STEM
Brothe York School
rs Big Road Mentoring
Sister Jamison program
s of , PA (Centennial
Bucks 18966 , Bensalem,
County Bristol
Township,
and
Pennsbury
school
districts
in Bucks
County, PA)
------------------------------------------------------------------------
Monetary Big 2 West $7,500 10/13/2015 Big Brothers
Brothe Washing Big Sisters
rs Big ton of
Sister Avenue, Hunterdon
s of Suite Somerset
Hunter 210 PO and Warren
don Box 123
Somers Washing
et and ton, NJ
Warren 07882
Counti
es
------------------------------------------------------------------------
Monetary Big 535 East $6,500 9/28/2015 Youth
Brothe Frankli Mentoring
rs Big n Program
Sister Street Support
s of Trenton
Mercer , NJ
County 08610
------------------------------------------------------------------------
Monetary Boys 212 $22,500 12/8/2015 Career
and Centre Launch
Girls Street
Club Trenton
of , NJ
Trento 08611
n and
Mercer
County
------------------------------------------------------------------------
Monetary Bristol 120 $7,500 11/12/2015 ArtRageous
Rivers Radclif Theatre
ide fe Arts
Theate Street Education
r Co, Bristol Program
Inc. , PA
19007
------------------------------------------------------------------------
Monetary Broward 305 SE $12,500 7/21/2015 Affordable
County 18th Rental
Commun Court Housing
ity Fort program
Develo Lauderd
pment ale, FL
Corpor 33316
ation,
Inc.
------------------------------------------------------------------------
Monetary Bucks 1069 $5,000 11/16/2015 Bucks County
County Jackson Veterans
Housin ville Housing
g Road Assistance
Group Ivyland Program
, PA
18974
------------------------------------------------------------------------
Monetary Caminar 2600 S. $2,500 4/9/2015 First Annual
El Mental
Camino Health
Real, Symposium:
Suite New
200 San Research in
Mateo, Mental
CA Health and
94403 its Impact
on
Treatment
------------------------------------------------------------------------
Monetary Camp P.O. Box $10,000 12/11/2015 Camp Odayin--
Odayin 2068 a camp with
Stillwa heart
ter, MN
55082
------------------------------------------------------------------------
Monetary Carrier PO Box $300 8/19/2015 Costs
Clinic 147 252 associated
Route with 2015
601 Janssen
Belle Cares
Mead, Volunteer
NJ Activity
08502
------------------------------------------------------------------------
Monetary Catholi 25 Ikea $4,000 10/2/2015 Catholic
c Drive Charities,
Charit Westham Diocese of
ies pton, Trenton On
NJ My Own--
08060 Supportive
Housing
Program
Services
------------------------------------------------------------------------
Monetary Catholi 25 Ikea $15,000 10/6/2015 Partners In
c Drive Recovery
Charit Westham
ies pton,
NJ
08060
------------------------------------------------------------------------
Monetary Catholi 920 $4,000 11/16/2015 CYO's Broad
c South St. Center
Youth Broad After
Organi Street School
zation Trenton Program
of , NJ Tutoring
Mercer 08611 Project
County
------------------------------------------------------------------------
Monetary Center 11 $600 8/19/2015 Costs
for Minneak associated
Educat oning with 2015
ional Road Janssen
Advanc Fleming Cares
ement ton, NJ Volunteer
08822 activity
------------------------------------------------------------------------
Monetary Center 11 $12,000 11/25/2015 CORE Values
for Minneak job
Educat oning readiness
ional Road program
Advanc Fleming
ement ton, NJ
08822
------------------------------------------------------------------------
Monetary Child 204 N. $3,000 9/28/2015 Teen
Home West Prenatal
and Street and
Commun #101 Parenting
ity Doylest Continuum
own, PA
18901
------------------------------------------------------------------------
Monetary Childre 635 $5,000 3/30/2015 Fundraising
n's South event
Home Clinton support to
Societ Avenue benefit
y of Trenton general
New , NJ mission of
Jersey 08611 organizatio
n
------------------------------------------------------------------------
Monetary Childre 635 $5,000 12/22/2015 Fundraising
n's South event
Home Clinton support to
Societ Avenue benefit
y of Trenton general
New , NJ mission of
Jersey 08611 organizatio
n
------------------------------------------------------------------------
Monetary Childre 635 $10,000 12/22/2015 CUNA and
n's South Body and
Home Clinton Soul
Societ Avenue Prenatal
y of Trenton Health
New , NJ Education
Jersey 08611 Program
------------------------------------------------------------------------
Monetary Cit 111 S. $3,000 10/13/2015 Silver level
Intern Highlan sponsor of
ationa d St. the 2016
l, Box 71 Internation
Inc. Memphis al
, TN Conference
38111
------------------------------------------------------------------------
Monetary College 50 Milk $20,000 12/8/2015 Assessing
Diabet St 16th the unmet
es Floor needs of
Networ Boston, young
k, MA adults with
Inc. 02109 diabetes on
college
campuses
------------------------------------------------------------------------
Monetary College 2000 $22,500 12/17/2015 Nursing
of New Penning Merit
Jersey ton Scholarship
Road s ($10,000)
P.O. and
Box Educational
7718 Opportunity
Ewing, Fund
NJ Promise
08628 Awards
($12,500)
------------------------------------------------------------------------
Monetary Colorad 1031 $2,500 7/28/2015 Peer Support
o 33rd Coach
Mental Street, Training
Wellne Suite
ss 237
Networ Denver,
k CO
80205
------------------------------------------------------------------------
Monetary Communi PO Box $5,000 8/18/2015 Rise Summer
ty 88 116 Healthy
Action North Food
Servic Main Initiative
e Street for low
Center Hightst income
, Inc. own, NJ youth.
08520
------------------------------------------------------------------------
Monetary Communi PO Box $200,000 11/25/2015 Johnson &
ty 338 Johnson
Founda Morrist Somerset
tion own, NJ County
of New 07963 Companies
Jersey Contributio
n Fund at
the
Community
Foundation
of NJ
------------------------------------------------------------------------
Monetary Communi 15 $7,000 12/25/2015 Donation to
ty Highlan be split
Health d evenly
Charit Avenue across
ies Matawan charitable
, NJ organizatio
07747 ns which
serve
patients in
their
therapeutic
areas
------------------------------------------------------------------------
Monetary Communi P.O. Box $16,000 11/24/2015 Each One,
ty 15176 Teach One:
Health 407 An Evidence
Coalit Crutchf Based
ion, ield Diabetes
Inc. Street Self-
Durham, Management
NC Workshop
27704 and
Community
Leaders
Training
------------------------------------------------------------------------
Monetary Communi 959 $12,000 5/15/2015 Pathway to
ty Route Recovery
Hope, 46 Residential
Inc. East, Programs
Suite ($10,000)
402 The Annual
Parsipp Learning
any, NJ Forum on
07054 Mental
Health and
Wellness
Fair
($2,000)
------------------------------------------------------------------------
Monetary Communi 959 $12,000 10/6/2015 Hope for
ty Route Veterans
Hope, 46 and Valley
Inc. East, Brook
Suite Village for
402 Veterans
Parsipp
any, NJ
07054
------------------------------------------------------------------------
Monetary Communi 310 W. $5,000 9/28/2015 Making the
ty State Invisible
Justic Street, Visible--Le
e 3rd gal
Center Floor Services
, Inc. Trenton for the
, NJ Underserved
08618
------------------------------------------------------------------------
Monetary Communi 507 E. $4,000 7/1/2015 Compeer
ty College Program of
Mental Street Johnson
Health Iowa County,
Center City, Iowa
For IA
Mid- 52245
Easter
n Iowa
dba
Compee
r
Progra
m,
Inc.
------------------------------------------------------------------------
Monetary Compeer 259 $2,500 7/16/2015 Youth and
Roches Monroe Family
ter, Avenue Mentoring
Inc. Rochest Program--Fa
er, NY mily
14607 Support
------------------------------------------------------------------------
Monetary Contact 60 S. $5,000 8/18/2015 Fundraising
Of Main event
Mercer Street support to
County Penning benefit
New ton, NJ general
Jersey 08534 mission of
, Inc. organizatio
n
------------------------------------------------------------------------
Monetary Contact 60 S. $8,500 12/1/2015 CRISIS
Of Main HOTLINE,
Mercer Street CRISIS
County Penning CHAT, and
New ton, NJ TxtToday
Jersey 08534 Programs
, Inc.
------------------------------------------------------------------------
Monetary CONTACT P.O. Box $3,500 5/14/2015 Crisis
We 2376 Interventio
Care, Westfie n for
Inc. ld, NJ Nonprofessi
07091 onals for
People
Experiencin
g Psychosis
------------------------------------------------------------------------
Monetary Court 1450 $15,000 11/13/2015 CASA of
Appoin Parksid Mercer
ted e County
Specia Avenue, Child
l Suite Advocacy
Advoca 22 Program for
tes Suite Abused and
22 Neglected
Ewing, Children
NJ
08638
------------------------------------------------------------------------
Monetary Daytop 362 $2,500 12/10/2015 Daytop of NJ
Villag Sunset at Crawford
e Of Rd House--work
New Skillma readiness
Jersey n, NJ initiative
, Inc. 08558
------------------------------------------------------------------------
Monetary Deborah 212 $2,000 11/3/2015 Women's
Hospit Trenton Heart
al Road Health
Founda Browns Symposium
tion Mills,
NJ
08015
------------------------------------------------------------------------
Monetary Delawar 14 $300 8/19/2015 Costs
e Michael associated
River McCorri with 2015
Steamb stin Janssen
oat Road Cares
Floati Hamilto Volunteer
ng n, NJ Activity
Classr 08690
oom,
Inc.
------------------------------------------------------------------------
Monetary Delawar 14 $4,900 11/16/2015 Environmenta
e Michael l education
River McCorri for
Steamb stin underfunded
oat Road and
Floati Hamilto underserved
ng n, NJ schools and
Classr 08690 youth
oom, groups
Inc.
------------------------------------------------------------------------
Monetary Denver 3501 E $75 2/6/2015 Employee
Rescue 46th directed
Missio Avenue donation in
n Denver, lieu of
CO company
80216 holiday
gift
------------------------------------------------------------------------
Monetary Depress C/O $1,000 6/4/2015 DBSA NJ
ion David Annual
and Mizenko Conference
Bipola 5 for Support
r Village Group
Suppor Ct Participant
t Lawrenc s
Allian eville,
ce NJ
08648
------------------------------------------------------------------------
Monetary Depress C/O $1,000 6/4/2015 DBSA NJ
ion David Mutual Aid
and Mizenko Support
Bipola 5 Group
r Village Facilitator
Suppor Ct Training
t Lawrenc
Allian eville,
ce NJ
08648
------------------------------------------------------------------------
Monetary Desert 1695 N. $3,500 7/28/2015 Quality of
Aids Sunrise life
Projec Way services
t Palm for
Springs patients
, CA with
92262 schizophren
ia and
schizo-
affective
disorders
------------------------------------------------------------------------
Monetary Detroit 10 $5,000 7/16/2015 InSHAPE
Centra Peterbo Program
l City ro (Individual
Commun Detroit ized Self
ity , MI Health
Mental 48201 Action Plan
Health for
, Inc. Empowerment
)
------------------------------------------------------------------------
Monetary Detroit 645 $750 2/9/2015 Employee
Metrop Griswol directed
olitan d, donation in
Bar Suite lieu of
Associ 1356 company
ation Detroit holiday
Founda , MI gift
tion 48226
------------------------------------------------------------------------
Monetary Diabete 13 $15,000 10/21/2015 Medical
s Sunflow Assistance
Founda er and Patient
tion Avenue, Support
Suite Services
1010
Paramus
, NJ
07652
------------------------------------------------------------------------
Monetary Diabete 13 $5,000 12/11/2015 Medical
s Sunflow Assistance
Founda er and Patient
tion Avenue, Support
Suite Services
1010
Paramus
, NJ
07652
------------------------------------------------------------------------
Monetary Diabete 319 N. $20,000 12/1/2015 DiabetesSist
s Weber ers'
Sister Road, Minority
s pmb Initiative
#163
Bolingb
rook,
IL
60490
------------------------------------------------------------------------
Monetary Dress 3131 $9,000 11/16/2015 Roads to
for Princet Success:
Succes on The Latina
s Pike, Literacy
Buildin Mobile
g 4, Program.
Suite
209
Lawrenc
eville,
NJ
08648
------------------------------------------------------------------------
Monetary Emory Rollins $10,000 12/23/2015 Emory Latino
Univer School Diabetes
sity of Education
Public Program
Health (ELDEP)
1518
Clifton
Rd, NE
Room
606
Atlanta
, GA
30322
------------------------------------------------------------------------
Monetary Emory Rollins $12,500 12/23/2015 Emory Latino
Univer School Diabetes
sity of Education
Public Program
Health (ELDEP)
1518
Clifton
Rd, NE
Room
606
Atlanta
, GA
30322
------------------------------------------------------------------------
Monetary Enable, 13 $7,500 11/12/2015 Connect with
Inc. Roszel Enable
Road,
Suite
B110
Princet
on, NJ
08540
------------------------------------------------------------------------
Monetary Every Fred $9,000 11/16/2015 Every Child
Child Vereen, Valued
Valued Jr. After
A NJ Communi School
Nonpro ty Program
fit Center
Corpor 175
ation Johnson
Avenue
Lawrenc
eville,
NJ
08648
------------------------------------------------------------------------
Monetary Everybo PO Box $4,000 11/16/2015 Coming Up
dy 3127 for AIRTM
Loves Princet
Kenny on, NJ
Projec 08543
t,
Inc.
------------------------------------------------------------------------
Monetary Family 1931 $9,000 6/4/2015 Outpatient
Guidan Notting Mental
ce ham Way Health
Center Hamilto Treatment
Corpor n, NJ for the
ation 08619 Chronically
Mentally
Ill
------------------------------------------------------------------------
Monetary Family 1931 $300 6/26/2015 Costs
Guidan Notting associated
ce ham Way with 2015
Center Hamilto Janssen
Corpor n, NJ Cares
ation 08619 Volunteer
Activity
------------------------------------------------------------------------
Monetary Family 1931 $300 9/24/2015 Costs
Guidan Notting associated
ce ham Way with 2015
Center Hamilto Janssen
Corpor n, NJ Cares
ation 08619 Volunteer
Activity
September
------------------------------------------------------------------------
Monetary Family 1 AAA $10,000 10/2/2015 Get FIT @
Resour Dr. YMCA
ce Suite
Networ 203
k Trenton
, NJ
08691
------------------------------------------------------------------------
Monetary Family 4 $9,500 11/16/2015 Nursing
Servic Corners services at
e tone the
Associ Drive emergency
ation Langhor homelss
of ne, PA shelter
Bucks 19047
County
------------------------------------------------------------------------
Monetary Family 790 Park $4,000 4/16/2015 STEPS to
Servic Avenue Wellness
e Hunting program
League ton, NY
, Inc. 11743
------------------------------------------------------------------------
Monetary Federat One $1,000 4/16/2015 Big Nosh
ion of Farming Vocational
Organi dale Services
zation Road
s West
Babylon
, NY
11704
------------------------------------------------------------------------
Monetary Feed Central $75 1/14/2015 Employee
More, Virgini directed
Inc. a Food donation in
Bank lieu of
1415 company
Rhoadmi holiday
ller gift
Street
Richmon
d, VA
23220
------------------------------------------------------------------------
Monetary Feed 333 N. $75 2/25/2015 Employee
the Meridia directed
Childr n donation in
en, Avenue lieu of
Inc. Oklahom company
a City, holiday
OK gift
73107
------------------------------------------------------------------------
Monetary Forsyth 61 $75 11/19/2015 Employee
Humane Miller directed
Societ Street donation in
y Winston- lieu of
Salem, Company
NC Holiday
21704 gift
------------------------------------------------------------------------
Monetary Foundat 2381 $2,000 11/16/2015 Fundraising
ion of Lawrenc event
Morris eville support to
Hall/ Road benefit
St. Lawrenc general
Lawren eville, mission of
ce NJ organizatio
08648 n
------------------------------------------------------------------------
Monetary Foundat 2381 $7,500 11/16/2015 Communicatin
ion of Lawrenc g for
Morris eville Success
Hall/ Road
St. Lawrenc
Lawren eville,
ce NJ
08648
------------------------------------------------------------------------
Monetary Fountai 425 West $1,000 3/30/2015 Silver
n 47th sponsor
House Street Fountain
New House
York, Wellness
NY Campaign
10036 and One in
Four 5K
------------------------------------------------------------------------
Monetary Fountai 425 West $5,000 10/13/2015 Fundraising
n 47th event
House Street support to
New benefit
York, general
NY mission of
10036 organizatio
n
------------------------------------------------------------------------
Monetary Gateway 11901 $7,500 7/16/2015 Support for
Homes, Reedy an
Inc. Branch Occupationa
Road l Therapist
Chester
field,
VA
23238
------------------------------------------------------------------------
Monetary Georgia 246 $1,500 7/1/2015 Consumer
Mental Sycamor scholarship
Health e St. s to attend
Consum Suite the 24th
er 260 Annual
Networ Decatur Statewide
k , GA Consumer
30030 Conference
------------------------------------------------------------------------
Monetary Girl 1171 $2,000 12/3/2015 GSHNJ
Scouts Route Robotics
Heart 28 Program
of New North Expansion--
Jersey Branch, Make It and
, Inc. NJ Take It
08876
------------------------------------------------------------------------
Monetary Greater 16 W. $100,000 12/22/2015 Greater
Trento Lafayet Trenton
n te St. Initiative
Trenton operating
, NJ activities
08608 in support
of its
strategic
plan for
2015 and
2016
------------------------------------------------------------------------
Monetary Grounds 80 $7,200 12/15/2015 Supporting
for Sculpto Wellness
Sculpt rs Way Walks for
ure Hamilto Low Income
n, NJ Seniors
08619
------------------------------------------------------------------------
Monetary Habitat 601 N $7,500 11/16/2015 Community
for Clinton Development
Humani Ave Grant for 7-
ty--Tr Trenton Plex Build
enton , NJ
Area 08638-
3446
------------------------------------------------------------------------
Monetary Habitat 31 Oak $4,000 11/16/2015 Women Build
for Ave Homes and
Humani Chalfon Strong
ty of t, PA Families
Greate 18914
r
Bucks
------------------------------------------------------------------------
Monetary Habitat 212 Yost $300 8/24/2015 Costs
for Bouleva associated
Humani rd with 2015
ty of Suite A Janssen
Greate Pittsbu Cares
r rgh, PA Volunteer
Pittsb 15221 Activity
urgh
------------------------------------------------------------------------
Monetary Hamilto 1315 $15,000 12/15/2015 Healthy
n Area Whiteho Living
YMCA rse- Programs:
Mercerv Diabetes
ille Prevention
Road Program
Hamilto ($7,500.00)
n, NJ , ACT
08619 ($7,500.00)
------------------------------------------------------------------------
Monetary Heart 1325 G $20,000 1/19/2015 Improving
Rhythm Street Health
Societ NW, Literacy
y, Suite and Health
Inc. 400 Information
Washing in Atrial
ton, DC Fibrillatio
20005 n and
Stroke
Patients
------------------------------------------------------------------------
Monetary Heartla 4750 N. $7,500 7/16/2015 Pathways
nd Sherida Home,
Health n Road supportive
Outrea Chicago housing
ch , IL program for
60640 those
living with
mental
health
conditions
------------------------------------------------------------------------
Monetary Henders 4740 $5,800 8/5/2015 Mental
on North Health
Behavi State First Aid:
oral Road 7 Helping
Health Lauderd Persons in
ale Need
Lakes,
FL
33319
------------------------------------------------------------------------
Monetary HiTops, 21 $6,000 11/12/2015 HiTops'
Inc. Wiggins Adolescent
Street Women and
Princet Girls'
on, NJ Sexual
08540 Health
Programming
------------------------------------------------------------------------
Monetary Homecar 240 $100 8/5/2015 Memorial
e and North donation
Hospic Radnor-
e -Cheste
Founda r Road,
tion Suite
100
Radnor,
PA
19087-
5174
------------------------------------------------------------------------
Monetary HomeFro 1880 $365 7/10/2015 Costs
nt Princet associated
on Ave. with 2015
Lawrenc Janssen
eville, Cares
NJ Volunteer
08648 Activity
------------------------------------------------------------------------
Monetary HomeFro 1880 $9,000 10/13/2015 Huchet House
nt Princet
on Ave.
Lawrenc
eville,
NJ
08648
------------------------------------------------------------------------
Monetary Hopewel 35 $750 11/16/2015 Hopewell
l Princet Elementary
Elemen on Science
tary Avenue Fair 2016
School Hopewel
Parent l, NJ
Teache 08525
r
Organi
zation
, Inc.
------------------------------------------------------------------------
Monetary Hopewel P.O. Box $750 12/21/2015 ``aMAZing
l 145 Pumpkin
Valley Hopewel Carve''
Arts l, NJ Exhibition
Counci 08525
l,
Inc.
------------------------------------------------------------------------
Monetary Hopewel PO Box $5,400 7/27/2015 Scholarship
l 553 for a
Valley Penning Hopewell
Educat ton, NJ Valley
ion 08534 Regional
Founda School
tion District
graduating
student
($1,000),
district-
wide
workshops
on
childhood
mental
health
($4,400)
------------------------------------------------------------------------
Monetary Hopewel 48 $2,500 2/12/2015 Hopewell
l Orchard Valley
Valley Avenue Rides
Senior Penning
Founda ton, NJ
tion 08534
------------------------------------------------------------------------
Monetary Humane 1201 $75 2/3/2015 Employee
Societ Macklin directed
y of d donation in
Missou Avenue lieu of
ri St. company
Louis, holiday
MO gift
63110
------------------------------------------------------------------------
Monetary Hunterd 1410 $300 8/19/2015 Costs
on Route associated
County 22 West with 2015
YMCA Annanda Janssen
le, NJ Cares
08801 Volunteer
Activity
------------------------------------------------------------------------
Monetary Hunterd 1410 $2,500 10/13/2015 Fundraising
on Route event
County 22 West support to
YMCA Annanda benefit
le, NJ general
08801 mission of
organizatio
n
------------------------------------------------------------------------
Monetary Hunterd 8 Main $10,000 4/20/2015 Prescription
on Street Drug Abuse
Drug Fleming Education
Awaren ton, NJ and
ess 08822 Evaluation
Progra Project.
m,
Inc.
------------------------------------------------------------------------
Monetary Hunterd 111 Mine $1,000 12/8/2015 Stewardship
on Street of the
Land Fleming Hunterdon
Trust ton, NJ Land
08822 Trust's
Dvoor Farm
Preserve
------------------------------------------------------------------------
Monetary Institu P.O. Box $3,500 10/2/2015 Nursing
te of 7869 Experiences
Wonder West hip Program
ful Trenton
Women , NJ
Workin 08628
g For
Empowe
rment
------------------------------------------------------------------------
Monetary Interfa 3635 $15,000 11/13/2015 Neighbors
ith Quakerb Helping
Caregi ridge Neighbors
vers Rd. Program
Trento Suite
n, 16
Inc. Hamilto
n, NJ
08619
------------------------------------------------------------------------
Monetary Isles, 10 Wood $7,500 11/16/2015 Healthy
Inc. Street Homes
Trenton Training to
, NJ Reduce
08618 Asthma and
Lead
------------------------------------------------------------------------
Monetary Jewish 707 $300 7/14/2015 Costs
Family Alexand associated
and er with 2015
Childr Road, Janssen
en's Suite Cares
Servic 102 Volunteer
e of Princet Activity
Greate on, NJ
r 08540
Mercer
County
------------------------------------------------------------------------
Monetary Jewish 707 $7,500 12/15/2015 Mercer
Family Alexand County
and er Caregiver
Childr Road, Help Line
en's Suite and
Servic 102 Caregiver
e of Princet Services
Greate on, NJ 2016
r 08540
Mercer
County
------------------------------------------------------------------------
Monetary Jewish 707 $10,000 12/15/2015 Fundraising
Family Alexand event
and er support to
Childr Road, benefit
en's Suite general
Servic 102 mission of
e of Princet organizatio
Greate on, NJ n
r 08540
Mercer
County
------------------------------------------------------------------------
Monetary Johnson One $6,000,000 6/29/2015 Funding to
& Johnson support the
Johnso & Johnson &
n Johnson Johnson
Patien Plaza Patient
t New Assistance
Assist Brunswi Foundation
ance ck, NJ (JJPAF) to
Founda 08933 help fund
tion their
mission to
provide
pharmaceuti
cal product
to needy
patients on
a
nondiscrimi
natory
basis
without
charge
------------------------------------------------------------------------
Monetary Junior 4365 $5,850 9/25/2015 2016 J&J
Achiev Route 1 Pharma Day
ement South, Program
of New 2nd
Jersey flr.
Princet
on, NJ
08540
------------------------------------------------------------------------
Monetary Kansas 1919 $450 1/10/2015 Employee
Foodba East directed
nk Douglas donation in
Wareho Wichita lieu of
use , KS company
67211 holiday
gift
------------------------------------------------------------------------
Monetary Kidsbri 4556 $7,500 9/28/2015 Kidsbridge
dge, South Anti-
Inc. Broad Bullying
St, 2nd Life Skills
Floor Program for
Trenton At-Risk
, NJ Children in
08620 Trenton at
the
Elementary
School
Level
------------------------------------------------------------------------
Monetary Lawrenc PO Box $2,500 11/16/2015 WaterBotics:
e 6531 17 An
Townsh Philips underwater
ip Ave. robotics
Educat Lawrenc program for
ion eville, 6th grade
Founda NJ students in
tion, 08648 Lawrence
Inc. Township
Public
Schools
------------------------------------------------------------------------
Monetary Leyden 10001 W $5,000 6/23/2015 Peer Support
Family Grand Center
Servic Ave
e and Frankli
Mental n Park,
Health IL
Center 60131
------------------------------------------------------------------------
Monetary Literac 55 $2,500 11/12/2015 Early
y And Primros Childhood--
Life, e Building
Inc. Circle Blocks for
Princet the Future
on, NJ Program
08540
------------------------------------------------------------------------
Monetary Literac 121 $5,000 9/28/2015 Adult
y New Chestnu Literacy
Jersey t Program
, Inc. Street
Suite
203
Roselle
, NJ
07203
------------------------------------------------------------------------
Monetary Literac 120 $4,000 12/1/2015 Let's Talk
y Findern About
Volunt e Ave-- Health
eers Box 7 Literacy
of Bridgew
Somers ater,
et NJ
County 08807
------------------------------------------------------------------------
Monetary Main 8 $2,500 4/16/2015 Serious
Street Marcell Mental
Counse a Disorders:
ling Avenue Improving
Center West Access to
Orange, Treatment
NJ Without
07052 Insurance
As an
Obstacle
------------------------------------------------------------------------
Monetary Massach 15 $4,000 2/25/2015 Changing
usetts Vernon Minds and
Clubho Street Improving
use Waltham Lives of
Coalit , MA People with
ion 02453 Mental
Illness
Project
------------------------------------------------------------------------
Monetary McCarte 91 $12,000 12/15/2015 OnStage
r Univers Seniors: A
Theatr ity Community
e Place Project of
Compan Princet McCarter
y on, NJ Theatre
08450
------------------------------------------------------------------------
Monetary Meals 5 Walter $300 8/20/2015 Costs
On Foran associated
Wheels Blvd with 2015
In Suite Janssen
Hunter 2006 Cares
don, Fleming Volunteer
Inc. ton, NJ Activity
08822
------------------------------------------------------------------------
Monetary Meals 320 $15,000 10/2/2015 Meals on
on Hollowb Wheels
Wheels rook Program
of Drive
Trento Ewing,
n NJ
Ewing 08638
------------------------------------------------------------------------
Monetary Mental 2000 N. $90,000 12/17/2015 It's My
Health Beaureg Life:
Americ ard St. Social Self
a 6th Directed
Floor Care
Alexand
ria, VA
22311
------------------------------------------------------------------------
Monetary Mental 2221 $15,000 7/27/2015 School
Health Norfolk Behavioral
Americ , Suite Health
a of 810 Initiative
Greate Houston
r , TX
Housto 77098
n
------------------------------------------------------------------------
Monetary Mental 2323 W $10,000 8/6/2015 Get
Health 5th Connected
Americ Ave. program
a of Suite
Frankl 160
in Columbu
County s, OH
43204
------------------------------------------------------------------------
Monetary Mental 205 $1,500 9/4/2015 2015 Montana
Health Haggert Mental
Americ y Lane, Health
a of Suite Policy
Montan 170 Summit
a Bozeman
, MT
59715
------------------------------------------------------------------------
Monetary Mental 1210 San $2,500 8/10/2015 Mental
Health Antonio Health
Americ , Suite Education
a of 200 and
Texas Austin, Advocacy
TX Campaign
78701
------------------------------------------------------------------------
Monetary Mental 100 W. $1,000 4/16/2015 Bronze
Health 10th sponsor
Associ St. 2015 E-
ation Ste. Racing the
in 600 Blues for
Delawa Wilming Mental
re ton, DE Health
19801
------------------------------------------------------------------------
Monetary Mental 100 W. $1,500 9/25/2015 Annual
Health 10th Community
Associ St. Mental
ation Ste. Health
in 600 Conference-
Delawa Wilming -Understand
re ton, DE ing Mental
19801 Wellness
------------------------------------------------------------------------
Monetary Mental 617 $2,500 5/22/2015 Support of
Health Garden the Mental
Associ Street Wellness
ation Santa Center
in Barbara
Santa , CA
Barbar 93101
a
County
------------------------------------------------------------------------
Monetary Mental 3701 $7,500 6/4/2015 ParentVOICE:
Health Latrobe Bringing
Associ Drive, Hope to
ation Suite Families in
of 140 Need
Centra Charlot
l te, NC
Caroli 28211
nas,
Inc.
------------------------------------------------------------------------
Monetary Mental 1301 $10,000 7/27/2015 Equitable
Health York Access to
Associ Road, Effective
ation Suite Care
of 505 Project--(p
Maryla Lutherv rint, web,
nd, ille, media,
Inc. MD salaries)
21093
------------------------------------------------------------------------
Monetary Mental 580 $1,000 2/25/2015 Supporting
Health White sponsor
Associ Plains 2015 MHA on
ation Road the Move:
of Suite Run/Walk
Westch 510
ester Tarryto
wn, NY
10591
------------------------------------------------------------------------
Monetary Mental 1870 $2,000 4/16/2015 Costs
Health South associated
Associ Boulder with Peer
ation Avenue Outreach
Oklaho Tulsa, Services
ma OK program
74119
------------------------------------------------------------------------
Monetary Mental 555 N $4,000 6/22/2015 MHA Housing
Health Woodlaw Initiative:
Associ n, Ste. Ensuring
ation 3105 Housing for
Reside Wichita Our Most
ntial , KS Vulnerable
Care, 67208 Populations
Inc.
------------------------------------------------------------------------
Monetary Mental 3809 $10,000 7/28/2015 Outreach and
Illnes Rosewoo Behavioral
s d Drive Healthcare
Recove PO Box for
ry 4246 Homeless
Center Columbi Individuals
, Inc. a, SC with Mental
29240 Illness
------------------------------------------------------------------------
Monetary Mercer 3150 $8,000 11/16/2015 Integrating
Allian Brunswi housing and
ce to ck Pike healthcare
End Lawrenc access for
Homele eville, veteran and
ssness NJ senior
08648- homeless
2420 populations
in the
Trenton/
Mercer
CEASE
HOMELESSNES
S System
------------------------------------------------------------------------
Monetary Mercer PO Box $19,500 12/15/2015 Supporting
County 17202 STEM
Commun Trenton Education:
ity , NJ Making
Colleg 08690 Physics
e Available
Founda to Students
tion at the
James
Kerney
Campus at
Trenton
------------------------------------------------------------------------
Monetary Mercer 151 $300 7/10/2015 Costs
Street Mercer associated
Friend Street with 2015
s Trenton Janssen
, NJ Cares
08611 Volunteer
Activity
------------------------------------------------------------------------
Monetary Mercer 151 $20,000 10/23/2015 Food Bank-
Street Mercer Food
Friend Street Distributio
s Trenton n Programs
, NJ
08611
------------------------------------------------------------------------
Monetary Middle P.O. Box $15,000 11/24/2015 Outreach
Earth 8045 Program and
520 Community
North Youth
Bridge Centers
Street
Bridgew
ater,
NJ
08807
------------------------------------------------------------------------
Monetary MIDJers 1A $1,500 11/23/2015 Urban Youth
ey Quakerb Employment
Center ridge Initiative
for Plaza
Econom Drive,
ic Suite 2
Develo Hamilto
pment n, NJ
08619
------------------------------------------------------------------------
Monetary Midland 60 $7,500 10/6/2015 Midland
Adult Industr Meals on
Servic ial Wheels
es, Parkway Employment
Inc. PO Box Training
5026 Program
North
Branch,
NJ
08876
------------------------------------------------------------------------
Monetary Mighty 10th and $100 5/14/2015 Memorial
Rivers Poplar Donation
Region Cairo,
al IL
Worshi 62914
p
Center
------------------------------------------------------------------------
Monetary Millhil 101 $15,000 10/2/2015 Millhill
l Oakland Trenton
Child Street PEERS
and Trenton
Family , NJ
08618
------------------------------------------------------------------------
Monetary Millhil 101 $5,000 10/2/2015 Trenton Area
l Oakland Stakeholder
Child Street s
and Trenton
Family , NJ
08618
------------------------------------------------------------------------
Monetary Minding 2083 $5,000 6/4/2015 Minding Our
Our Lawrenc Business
Busine eville Summer
ss, Road Program: A
Inc. Lawrenc Bridge to
eville, the Future
NJ for Mercer
08648 County Low-
Income
Youth
------------------------------------------------------------------------
Monetary Morven 55 $5,000 9/28/2015 Morven
Museum Stockto Museum and
and n Garden
Garden Street Summer
Princet Internship
on, NJ Program for
08540 Isles of
Trenton
Youths
------------------------------------------------------------------------
Monetary Mount 73 North $15,000 11/2/2015 Mount Carmel
Carmel Clinton Guild Home
Guild Avenue Health
Trenton Nursing
, NJ Program
08609
------------------------------------------------------------------------
Monetary NAMI--C 1904 $2,000 4/10/2015 Community
VA Byrd Mental
Centra Avenue, Health
l Suite Education
Virgin 207 and Social
ia's (POB Inclusion
Voice 18086)
on Richmon
Mental d, VA
Illnes 23230
s
------------------------------------------------------------------------
Monetary Nami 1401 I- $1,000 7/1/2015 Bronze
Alabam 85 sponsor
a Parkway 2015 NAMI
, Suite Alabama
A Walk
Montgom
ery, AL
36106
------------------------------------------------------------------------
Monetary NAMI 2400 W. $1,000 2/12/2015 Bronze
Delawa 4th St. sponsor
re Wilming 2015
ton, DE NAMIWalks
19805 Delaware
------------------------------------------------------------------------
Monetary NAMI 3371 $9,500 8/18/2015 Education
Mercer Brunswi and Support
NJ ck Programs
Pike,
Suite
124
Lawrenc
eville,
NJ
08648
------------------------------------------------------------------------
Monetary NAMI 85 N. $1,000 8/6/2015 Bronze
New State sponsor
Hampsh Street 2015
ire Concord NAMIWalks
, NH New
03301 Hampshire
------------------------------------------------------------------------
Monetary NAMI of 2100 $7,500 7/28/2015 Living Room-
DuPage Manches Peer to
County ter Rd, Peer
Illino Bldg B, program
is Suite
925
Wheaton
, IL
60187
------------------------------------------------------------------------
Monetary NAMI of One $1,500 7/1/2015 Start to
Lake Victori Finish
County a Sq., sponsor
Ste. 2015
260 Strides for
Painesv Awareness
ille, Walk
OH
44077
------------------------------------------------------------------------
Monetary NAMI of One $2,000 7/1/2015 Supporting
Lake Victori Families
County a Sq., and
Ste. Individuals
260 Impacted by
Painesv Schizophren
ille, ia: NAMI
OH Family-to-
44077 Family
Education
------------------------------------------------------------------------
Monetary NAMI of 100 W. $1,000 2/13/2015 Bronze
PA Main sponsor
Montgo Street 2015
mery Suite Greater
County 204 Philadelphi
Lansdal a NAMIWalk
e, PA
19446
------------------------------------------------------------------------
Monetary NAMI of 6122 E $1,000 12/15/2015 Bronze
Southe 22nd St sponsor
rn Tucson, 2016
Arizon AZ Southern
a 85711 Arizona
NAMIWalks
------------------------------------------------------------------------
Monetary NAMI 1750 S. $1,000 2/27/2015 Bronze
St. Brentwo sponsor
Louis od 2015 St.
Blvd. Louis
Suite NAMIWalks
511 St.
Louis,
MO
63144
------------------------------------------------------------------------
Monetary NAMI 150 $1,000 5/14/2015 Bronze
Summit Cross sponsor
County Street, 2015
Akron NAMIWalks
Ohio
44311
PO Box
462,
Cuyahog
a
Falls,
Ohio
44222
Akron,
OH
44311
------------------------------------------------------------------------
Monetary NAMI 5251 $1,000 3/13/2015 Bronze
Ventur Verdugo sponsor
a Way, #K 2015
County (PO Box NAMIWalk
1613) Ventura
Camaril County
lo, CA
93011
------------------------------------------------------------------------
Monetary NAMI 217 $1,000 6/10/2015 Bronze
Waukes Wiscons sponsor
ha in Ave 2015
Suite NAMIWalks
300 in Waukesha
Waukesh
a, WI
53186
------------------------------------------------------------------------
Monetary Nationa 90 Park $2,500 8/10/2015 27th Annual
l Avenue New York
Allian 16 Mental
ce for Floor Health
Resear New Research
ch on York, Symposium
Schizo NY
phreni 10016
a and
Depres
sion
------------------------------------------------------------------------
Monetary Nationa 90 Park $2,500 9/13/2015 Meet the
l Avenue Scientist:
Allian 16 A Virtual
ce for Floor Q&A Webinar
Resear New Series
ch on York,
Schizo NY
phreni 10016
a and
Depres
sion
------------------------------------------------------------------------
Monetary Nationa 100 $1,000 1/20/2015 Bronze
l Clearbr sponsor
Allian ook 2015 NAMI
ce for Drive Walks
the Elmsfor Westchester
Mental d, NY
ly Ill 10523
------------------------------------------------------------------------
Monetary Nationa 576 $1,000 1/20/2015 Bronze
l Farming sponsor
Allian ton 2015 NAMI
ce for Avenue Connecticut
the Hartfor Walk
Mental d, CT
ly Ill 06105
------------------------------------------------------------------------
Monetary Nationa 3250 $1,000 2/13/2015 Bronze
l Wilshir sponsor
Allian e 2015
ce for Blvd., NAMIWalk
the Suite Los Angeles
Mental 1501 County
ly Ill Los
Angeles
, CA
90010
------------------------------------------------------------------------
Monetary Nationa 309 W. $1,000 2/25/2015 Bronze
l Millbro sponsor
Allian ok 2015
ce for Road, NAMIWalks
the Suite
Mental 121
ly Ill Raleigh
, NC
27609
------------------------------------------------------------------------
Monetary Nationa 1706 $1,000 3/12/2015 Bronze
l Brady sponsor
Allian Street 2015
ce for Suite NAMIWalk
the 101 Greater
Mental Davenpo Mississippi
ly Ill rt, IA Valley
52803
------------------------------------------------------------------------
Monetary Nationa 5095 $1,000 3/12/2015 Bronze
l Murphy sponsor
Allian Canyon 2015 San
ce for Road, Diego
the Suite County NAMI
Mental 320 San Walk
ly Ill Diego,
CA
92123
------------------------------------------------------------------------
Monetary Nationa The $1,000 3/30/2015 Bronze
l Schraff sponsor
Allian t's 2015
ce for Center, NAMIWalks
the 529 Massachuset
Mental Main ts
ly Ill Street
Suite
1M17
Boston,
MA
02129
------------------------------------------------------------------------
Monetary Nationa 800 $5,000 4/17/2015 Understandin
l Transfe g
Allian r Road Psychosis:
ce for #31 St. Resources
the Paul, and
Mental MN Recovery
ly Ill 55114
------------------------------------------------------------------------
Monetary Nationa 3250 $5,000 5/14/2015 Crisis
l Wilshir Interventio
Allian e n Team
ce for Blvd., training
the Suite for Custody
Mental 1501 Program for
ly Ill Los Los Angeles
Angeles County
, CA Sheriff's
90010 Department
------------------------------------------------------------------------
Monetary Nationa 1225 $10,000 5/14/2015 2015 State
l Dublin Conference
Allian Road,
ce for Suite
the 125
Mental Columbu
ly Ill s, OH
43215
------------------------------------------------------------------------
Monetary Nationa 1 Bangor $1,000 6/10/2015 Supporter
l Street sponsor
Allian Augusta 2015 NAMI
ce for , ME Maine
the 04330 Annual
Mental Awareness
ly Ill Walk Walk
the Walk to
Start the
Talk
------------------------------------------------------------------------
Monetary Nationa 3440 $1,000 6/10/2015 Bronze
l Viking sponsor
Allian Drive 2016
ce for Suite Northern
the 104 California
Mental Sacrame NAMI Walk
ly Ill nto, CA
95827
------------------------------------------------------------------------
Monetary Nationa PO Box $1,000 7/15/2015 Platinum
l 550039 level
Allian Birming sponsor
ce for ham, AL NAMI
the 35255- Birmingham
Mental 0039 2015 Walk
ly Ill for Mental
Health
------------------------------------------------------------------------
Monetary Nationa 808 $1,000 7/15/2015 2015 Annual
l Montice Conference,
Allian llo ``Shatterin
ce for Street g the
the Somerse Stigma--Fac
Mental t, KY ts vs.
ly Ill 42501 Fiction--Ho
w Much Do
You Know?''
------------------------------------------------------------------------
Monetary Nationa 1536 W $6,000 7/16/2015 Coming out
l Chicago Proud
Allian Chicago Program
ce for , IL
the 60642
Mental
ly Ill
------------------------------------------------------------------------
Monetary Nationa PO Box $1,000 7/20/2015 2015 Mental
l 4096 Health
Allian 2206 N. Awareness
ce for Gordon Conference
the Street (MHAC)
Mental Alvin,
ly Ill TX
77512
------------------------------------------------------------------------
Monetary Nationa 2059 $1,000 7/28/2015 Bronze
l Atwood sponsor
Allian Avenue 2015 Dane
ce for Madison County
the , WI NAMIWalk
Mental 53704
ly Ill
------------------------------------------------------------------------
Monetary Nationa P.O Box $1,500 8/25/2015 Silver
l 8260 sponsor
Allian Richmon 2015
ce for d, VA NAMIWalks
the 23226 Virginia
Mental
ly Ill
------------------------------------------------------------------------
Monetary Nationa 99 Pine $4,000 8/28/2015 2015 NAMI-
l St. NYS
Allian Suite Education
ce for 302 Conference-
the Albany, Redefining
Mental NY Recovery:
ly Ill 12207 New
Challenges,
New
Opportuniti
es, New
Hopes
------------------------------------------------------------------------
Monetary Nationa 2601 $2,000 8/28/2015 Support of
l Cold the 2015
Allian Spring NAMI
ce for Road Indiana
the P.O. State
Mental Box Conference
ly Ill 22697
Indiana
polis,
IN
46222
------------------------------------------------------------------------
Monetary Nationa 1562 $2,500 9/25/2015 Healing
l Route Ourselves,
Allian 130 Healing
ce for North Others:
the Brunswi NAMI NJ
Mental ck, NJ 2015 Annual
ly Ill 08902 Conference
------------------------------------------------------------------------
Monetary Nationa 3803 N. $75,000 12/17/2015 NAMI
l Fairfax Helpline
Allian Drive
ce for Suite
the 100
Mental Arlingt
ly Ill on, VA
22203
------------------------------------------------------------------------
Monetary Nationa 3803 N. $50,000 12/17/2015 NAMI
l Fairfax Multicultur
Allian Drive al Action
ce for Suite Center
the 100
Mental Arlingt
ly Ill on, VA
22203
------------------------------------------------------------------------
Monetary Nationa 2012 $1,000 6/10/2015 Bronze
l West sponsor
Allian 25th NAMIWalks
ce for Street, 2015
the #600
Mental Clevela
ly nd, OH
Ill--G 44113
reater
Clevel
and
------------------------------------------------------------------------
Monetary Nationa 2012 $2,000 6/23/2015 Mental
l West Illness
Allian 25th Peer
ce for Street, Support and
the #600 Education
Mental Clevela programs
ly nd, OH
Ill--G 44113
reater
Clevel
and
------------------------------------------------------------------------
Monetary Nationa 2753 $1,000 2/13/2015 Bronze
l West sponsor
Allian Central 2015 NAMI
ce for Avenue Walk
the Toledo,
Mental OH
ly Ill 43606
of
Greate
r
Toledo
------------------------------------------------------------------------
Monetary Nationa 505 8th $1,000 2/25/2015 Bronze
l Avenue, sponsor
Allian Ste 2015
ce for 1103 NAMIWalks
the New NYC
Mental York,
ly Ill NY
of New 10018
York
City
------------------------------------------------------------------------
Monetary Nationa 1981 $1,000 11/17/2015 Bronze
l Marcus sponsor
Allian Ave, 2016 Long
ce for C117 Island/
the Lake Queens/
Mental Success NAMIWalks
ly Ill , NY
Queens/ 11042
Nassau
------------------------------------------------------------------------
Monetary Nationa 5963 $1,000 7/27/2015 Bronze
l Boymel sponsor
Allian Dr. 2015
ce on Fairfie National
Mental ld, OH Alliance on
Illnes 45014 Mental
s Illness of
Butler
County
NAMIWAlk
------------------------------------------------------------------------
Monetary Nationa 324A $1,000 1/9/2015 Gold sponsor
l Springf of the 2015
Allian ield NAMI-WM
ce on Street Annual
Mental Agawam, Walkathon:
Illnes MA A Journey
s 01001 of Hope and
Wester Recovery
n
Mass.,
Inc.
------------------------------------------------------------------------
Monetary Nationa PO Box $6,000 4/16/2015 28 Annual
l Art 350891 National
Exhibi Miami, Art
tions FL Exhibition
of the 33135 by the
Mental Mentally
ly Ill
Ill,
Inc.
------------------------------------------------------------------------
Monetary Nationa 110 N $30,000 12/1/2015 MY BLOOD
l Washing CLOT--An
Blood ton St. Online
Clot Suite Resource
Allian 328 for
ce Rockvil Patients
le, MD and
20850 Caregivers
Managing
Life with
VTE
------------------------------------------------------------------------
Monetary Nationa 1400 K $75,000 12/17/2015 2016 Policy
l Street Action
Counci NW, Center
l for Suite
Behavi 400
oral Washing
Health ton, DC
20005
------------------------------------------------------------------------
Monetary Nationa 1400 K $75,000 12/17/2015 Early Onset
l Street Psychosis
Counci NW, Project
l for Suite
Behavi 400
oral Washing
Health ton, DC
20005
------------------------------------------------------------------------
Monetary Nationa 1400 K $75,000 12/17/2015 Health
l Street Justice
Counci NW, Learning
l for Suite Initiative
Behavi 400
oral Washing
Health ton, DC
20005
------------------------------------------------------------------------
Monetary Nationa 949 W. $7,500 11/16/2015 Academic
l State Creative
Junior Street Engagement
Tennis Trenton (ACE) and
and , NJ STEM Pilot
Learni 08618 Program
ng of
Trento
n
------------------------------------------------------------------------
Monetary Nationa 9707 E $100 11/3/2015 Memorial
l Easter Donation
Stroke Lane,
Associ Suite B
ation Centenn
ial, CO
80112
------------------------------------------------------------------------
Monetary Nationa 9707 E $15,000 12/3/2015 Navigator
l Easter training,
Stroke Lane, program
Associ Suite B development
ation Centenn , services
ial, CO delivered,
80112 participant
materials
and
resources,
and
outcomes
measurement
.
------------------------------------------------------------------------
Monetary Nationa 9707 E $35,000 12/4/2015 Develop a
l Easter multi-
Stroke Lane, channel
Associ Suite B marketing
ation Centenn plan
ial, CO
80112
------------------------------------------------------------------------
Monetary New P.O. Box $1,500 12/8/2015 Fundraising
Jersey 7683 event
Capita Trenton support to
l , NJ benefit
Philha 08628 general
rmonic mission of
Orches organizatio
tra, n
Inc.
------------------------------------------------------------------------
Monetary New 275 Rt. $4,000 7/1/2015 NJPC
Jersey 10 East Strengtheni
Parent Suite ng Family
s 220-414 and Youth
Caucus Succasu Involvement
nna, NJ Conference
07876 and
Professiona
l Parent
Advocacy
Training
------------------------------------------------------------------------
Monetary NewBrid 7 $2,000 6/10/2015 NewBridge
ge Industr Day
Servic ial Treatment
es, Road Program for
Inc. Pequann Adults
ock, NJ
07440
------------------------------------------------------------------------
Monetary Ohio 433 $75 2/6/2015 Employee
Great Canal directed
Dane Ct donation in
Rescue Watervi lieu of
lle, OH company
43566 holiday
gift
------------------------------------------------------------------------
Monetary Paralyz 2235 $75 2/6/2015 Employee
ed Enterpr directed
Vetera ise donation in
ns of Drive, lieu of
Americ Suite company
a 3501 holiday
Westche gift
ster,
IL
60154
------------------------------------------------------------------------
Monetary Parent P.O. Box $2,000 12/8/2015 Steinert
Booste 3352 High
r USA Mercerv Robotics
dba ille, FIRST FRC
Steine NJ Team 2180
rt 08690 Parents
High Association
Roboti
cs
Parent
s
Associ
ation
------------------------------------------------------------------------
Monetary Partner 888 $10,700 12/15/2015 General
s in Commonw mission
Health ealth support of
Ave, organizatio
3rd n
Floor
Boston,
MA
02215
------------------------------------------------------------------------
Monetary Passage PO Box $5,000 12/8/2015 The State
Theatr 967 Street
e Trenton Project
Compan , NJ
y, 08608
Inc.
------------------------------------------------------------------------
Monetary PEI 231 $300 8/27/2015 Costs
Kids Lawrenc associated
e Road with 2015
Lawrenc Janssen
eville, Cares event
NJ
08648
------------------------------------------------------------------------
Monetary PEI 231 $17,500 10/27/2015 Comprehensiv
Kids Lawrenc e Juvenile
e Road Offenders
Lawrenc Outreach
eville, Services
NJ
08648
------------------------------------------------------------------------
Monetary People 140 E $2,500 11/16/2015 People and
And Hanover Stories
Storie Street with Mercer
s--Gen Trenton County
te Y , NJ Seniors
Cuento 08608
s,
Inc.
------------------------------------------------------------------------
Monetary Plansma 118 West $3,500 6/4/2015 2015
rt NJ State Corporate
PlanSma membership
rt NJ renewal
Trenton donation to
, NJ support
08608 efforts
around
sound land
use
planning
------------------------------------------------------------------------
Monetary Princet P.O. Box $1,500 10/30/2015 Giving Voice
on 145 190 To
Girl Nassau Communities
Choir Street, : PGC's
Lower Music
Level Afterschool
Princet Program
on, NJ
08542
------------------------------------------------------------------------
Monetary Princet 78 LEIGH $5,000 11/16/2015 PNS Role
on AVE Models for
Nurser PRINCET Health
y ON, NJ
School 08542
, Inc.
------------------------------------------------------------------------
Monetary Princet 123 E. $12,500 12/15/2015 Hunger
on Hanover Prevention
Outrea St. and
ch Trenton Nutrition
Projec , NJ Education
ts / 08608 ($7,500.00)
Crisis Healthy
Minist Living and
ry of Housing
Mercer Stability
County Services
($5,000.00)
------------------------------------------------------------------------
Monetary Princet P.O. Box $2,500 12/8/2015 Princeton
on 250 Symphony
Sympho Princet Orchestra @
ny on, NJ Isles Youth
Orches 08542 Institute--
tra a series of
interactive
music
appreciatio
n programs
------------------------------------------------------------------------
Monetary Princet 13 $7,500 11/16/2015 Princeton-
on- Roszel Blairstown
Blairs Road, Center's
town Suite 2015-16
Center C204A Summer
, Inc. Princet Bridge
on, NJ Program for
08540- Mercer
7137 County At-
Risk Youth
------------------------------------------------------------------------
Monetary Printma 440 $5,000 11/3/2015 Roving Press
king River
Center Road
of New Branchb
Jersey urg, NJ
08876
------------------------------------------------------------------------
Monetary Printma 440 $15,000 11/24/2015 Combat paper
king River of NJ
Center Road
of New Branchb
Jersey urg, NJ
08876
------------------------------------------------------------------------
Monetary PTA New 171 Old $3,000 8/5/2015 Fundraising
Jersey Turnpik event
Congre e Road support to
ss Of Califon benefit
Parent , NJ general
s and 07830 mission of
Teache organizatio
rs n
------------------------------------------------------------------------
Monetary Raritan P.O. Box $8,000 12/1/2015 WaterWays
Headwa 273 Environment
ters Gladsto al
Associ ne, NJ Education
ation 07934 Program
------------------------------------------------------------------------
Monetary Raritan 118 $20,000 11/24/2015 Promoting
Valley Lamingt Access to
Commun on Road STEM,
ity Branchb Nursing and
Colleg urg, NJ Community
e 08844 Health
Education
at Raritan
Valley
Community
College
------------------------------------------------------------------------
Monetary ReDisco 901 NE $7,500 6/23/2015 Same-Day
ver Indepen Access to
dence Care
Avenue program
Lees
Summit,
MO
64086
------------------------------------------------------------------------
Monetary Regions 640 $15,000 7/21/2015 Make It OK
Hospit Jackson Stigma
al Street, Campaign
Founda MS
tion 11202C
St.
Paul,
MN
55101
------------------------------------------------------------------------
Monetary Rescue 98 $5,000 1/14/2015 Fundraising
Missio Carroll event
n of Street, support to
Trento PO Box benefit
n 790 general
Trenton mission of
, NJ organizatio
08605 n
------------------------------------------------------------------------
Monetary Rescue 98 $25,000 10/2/2015 Emergency
Missio Carroll services
n of Street, program
Trento PO Box
n 790
Trenton
, NJ
08605
------------------------------------------------------------------------
Monetary Rider 2083 $20,000 11/24/2015 STEM
Univer Lawrenc Program;
sity eville Janssen
Road Science and
Lawrenc Business
eville, Scholarship
NJ s;
08648 Shakesperia
n at Rider
------------------------------------------------------------------------
Monetary Riverbe 3 N. $5,000 5/22/2015 InSHAPE
nd State Program
Commun Street,
ity PO Box
Mental 2032
Health Concord
, Inc. , NH
03301
------------------------------------------------------------------------
Monetary Riversi 4 South $9,300 11/16/2015 Riverside
de Union Symphonia
Sympho Street Senior
nia, P.O. Outreach
Inc. Box 650 Program
Lambert
ville,
NJ
08530
------------------------------------------------------------------------
Monetary San 445 $5,000 5/14/2015 Culinary,
Antoni Recolet Education
o a Rd. and
Clubho San Nutrition
use, Antonio Program--Nu
Inc. , TX tritious
78216 meals,
culinary
training,
pre-
vocational
education,
employment
placement
------------------------------------------------------------------------
Monetary San 2789- $5,000 4/16/2015 MHRC Client
Franci 25th Wellness
sco Street, Enhancement
Genera #2028 Project
l PO Box
Hospit 410836
al San
Founda Francis
tion co, CA
94110
------------------------------------------------------------------------
Monetary SAVE A 900 $300 10/13/2015 Costs
Friend Herront associated
to own with 2015
Homele Road Janssen
ss Princet Cares
Animal on, NJ Volunteer
s 08540 Event
------------------------------------------------------------------------
Monetary Save 501 $66,700 12/22/2015 Support
The Kings efforts to
Childr Highway give
en East, children a
U.S. Suite healthy
Headqu 400 start, the
arters Fairfie opportunity
ld, CT to learn
06825 and
protection
from harm
(child
protection,
education,
emergency
response,
health and
nutrition,
hunger and
livelihoods
, HIV and
AIDS)
------------------------------------------------------------------------
Monetary Schizop 602 Pink $2,500 7/16/2015 2015
hrenia Azalea Conference,
And Trl PO ``Schizophr
Relate Box enia: It's
d 941222 Global''
Disord Houston
ers , TX
Allian 77094-
ce Of 8222
Americ Houston
a , TX
77079-
1123
------------------------------------------------------------------------
Monetary Scripps 10140 $30,000 12/23/2015 Dulce
Founda Campus Prevention:
tion Point A Diabetes
for Drive Early
Medici Suite Prevention
ne and 200 San Program
Scienc Diego,
e CA
92121
------------------------------------------------------------------------
Monetary Scripps 10140 $25,000 12/23/2015 Project
Founda Campus Dulce
tion Point
for Drive
Medici Suite
ne and 200 San
Scienc Diego,
e CA
92121
------------------------------------------------------------------------
Monetary SERV 20 $7,500 9/22/2015 The SERV
Founda Scotch Foundation
tion, Road, Scholarship
Inc. 3rd Fund
Floor
Ewing,
NJ
08628
------------------------------------------------------------------------
Monetary SERV 20 $5,000 9/22/2015 13th Annual
Founda Scotch Recovery NJ
tion, Road, Conference
Inc. 3rd
Floor
Ewing,
NJ
08628
------------------------------------------------------------------------
Monetary SERV 20 $300 9/24/2015 Costs
Founda Scotch associated
tion, Road, with 2015
Inc. 3rd Janssen
Floor Cares
Ewing, Volunteer
NJ event
08628
------------------------------------------------------------------------
Monetary Shannon PO Box $500 12/1/2015 Shannon
Daley 1271 36 Daley
Memori Indian Memorial
al Run Fund
Fund Whiteho Charity
use Events
Station
, NJ
08889
------------------------------------------------------------------------
Monetary Sharing 1920 $2,000 5/22/2015 Art and
Place, 10th Music
Inc. Avenue Program at
South the 1920
PO Box Club
55945
Birming
ham, AL
35255-
5945
------------------------------------------------------------------------
Monetary Sister 1201 $6,500 10/6/2015 Fundraising
Networ Hamilto event
k of n support to
Centra Street benefit
l New Somerse general
Jersey t, NJ mission of
, Inc. 08873 organizatio
n
------------------------------------------------------------------------
Monetary Sisters 1201 $1,000 2/6/2015 2015 Health
Networ Hamilto Summit and
k of n Breakfast
Centra Street
l New Somerse
Jersey t, NJ
08873
------------------------------------------------------------------------
Monetary Somerse 1810 $8,292 12/1/2015 Teaching
t Burnt Social
Hills Mills Skills
Learni Road
ng Bedmins
Instit ter, NJ
ute 07921
------------------------------------------------------------------------
Monetary Somerse 49 $1,250 1/20/2015 2014 Steps
t Home Brahma for Giving
for Avenue, Program
Tempor P.O.
arily Box
Displa 6871
ced Bridgew
Childr ater,
en NJ
08807-
0871
------------------------------------------------------------------------
Monetary Somerse 49 $7,500 5/22/2015 Fundraising
t Home Brahma event
for Avenue, support to
Tempor P.O. benefit
arily Box general
Displa 6871 mission of
ced Bridgew organizatio
Childr ater, n
en NJ
08807-
0871
------------------------------------------------------------------------
Monetary Somerse 49 $7,500 11/25/2015 Street
t Home Brahma Smart--HIV/
for Avenue, AIDS and
Tempor P.O. STD
arily Box Prevention
Displa 6871
ced Bridgew
Childr ater,
en NJ
08807-
0871
------------------------------------------------------------------------
Monetary St. 208 $100 2/13/2015 Memorial
France Bound donation
s Brook
Cabrin Avenue
i Piscata
Church way, NJ
08854
------------------------------------------------------------------------
Monetary St. One $15,000 12/8/2015 Providing
Mary Summit Food for
Medica Square, School-Age
l Suite Children
Center 300 Living in
Founda 1717 Poverty in
tion Langhor Bucks
ne- County: The
Newtown St. Mary
Road Backpacks
Langhor for Kids
ne, PA Program
19047
------------------------------------------------------------------------
Monetary Stony 31 Titus $15,000 11/13/2015 StreamWatch
Brook Mill Volunteer
Millst Road Water
one Penning Quality
Waters ton, NJ Monitoring
hed 08534 Program
Associ
ation
------------------------------------------------------------------------
Monetary T-1 8216 $35,000 11/25/2015 Type 2
Today, Princet Education
Inc. on- for Type 1
Glendal Families
e Road,
PMB 200
West
Chester
, OH
45069
------------------------------------------------------------------------
Monetary TASK, 72\1/2\ $300 6/23/2015 Costs
Inc. Escher associated
Street, with 2015
P.O. Janssen
Box 872 Cares
Trenton Volunteer
, NJ Activity
08605
------------------------------------------------------------------------
Monetary TASK, 72\1/2\ $25,000 10/8/2015 Trenton Area
Inc. Escher Soup
Street, Kitchen
P.O. Meal
Box 872 Service
Trenton Program
, NJ
08605
------------------------------------------------------------------------
Monetary TASK, 72\1/2\ $20,700 12/15/2015 Support
Inc. Escher hunger
Street, program in
P.O. the Trenton
Box 872 area,
Trenton programs to
, NJ encourage
08605 self-
sufficiency
and improve
the quality
of life of
their
patrons
------------------------------------------------------------------------
Monetary The Paul $5,000 11/13/2015 Communiversi
Arts Robeson ty ArtsFest
Counci Center 2016
l of for the
Prince Arts
ton 102
Withers
poon
Street
Princet
on, NJ
08542
------------------------------------------------------------------------
Monetary The Paul $10,000 11/16/2015 Community
Arts Robeson outreach
Counci Center programs
l of for the for youth
Prince Arts and seniors
ton 102
Withers
poon
Street
Princet
on, NJ
08542
------------------------------------------------------------------------
Monetary The 2020 $2,000 12/1/2015 ``Art for
Center Burnt Children
for Mills with Autism
Contem Road Spectrum
porary Bedmins Disorder
Art ter, NJ and Special
07921 Needs''
------------------------------------------------------------------------
Monetary The 19 $300 8/19/2015 Costs
Center Dellwoo associated
For d Lane with 2015
Great Somerse Janssen
Expect t, NJ Cares
ations 08873 Volunteer
Activity
------------------------------------------------------------------------
Monetary The 19 $13,500 10/21/2015 Trauma-
Center Dellwoo informed,
For d Lane residential
Great Somerse treatment
Expect t, NJ for
ations 08873 homeless,
pregnant/
parenting
adult women
in
substance
use
recovery,
and their
children.
------------------------------------------------------------------------
Monetary The 1040 $5,000 6/23/2015 Jail
Edinbu Waltham Diversion
rg Street Program
Center Lexingt
on, MA
02421
------------------------------------------------------------------------
Monetary The 8150 N. $40,000 12/4/2015 VTE
Mended Central Education
Hearts Express and
, Inc. way, Outreach
Suite Program
M2248
Dallas,
TX
75206
------------------------------------------------------------------------
Monetary The 401 $500 3/2/2015 Flash Lite
Mental Cypress sponsor
Health Street 2015 Lite
Center Manches up the Nite
Of ter, NH for Mental
Greate 03103 Health Run/
r Walk
Manche
ster
------------------------------------------------------------------------
Monetary The P.O. Box $7,500 11/16/2015 Arts
Prince 2063 education
ton Princet and
Festiv on, NJ community
al 08543 engagement
programs
------------------------------------------------------------------------
Monetary Thomas 101 West $12,000 11/13/2015 Scholarships
Edison State for
State Street Students
Colleg Trenton Enrolled in
e , NJ the
Founda 08608 Accelerated
tion Second
Degree BSN
Program at
Thomas
Edison
State
College's
W. Cary
Edwards
School of
Nursing
------------------------------------------------------------------------
Monetary TPTO 51 South $1,000 11/16/2015 2016
Inc--T Timberl Timberlane
imberl ane Science and
ane Drive, Engineering
Parent Penning Fair
Teache ton NJ
r 08534
Organi Penning
zation ton, NJ
08534
------------------------------------------------------------------------
Monetary Trenton P.O. Box $5,000 11/12/2015 Trenton
Commun 5206 Community
ity (physic Music
Music al School
School address Community-
: 439 Based Music
S. Education
Broad
Street,
Ste.
90,
Trenton
NJ
08611
Trenton
, NJ
08638
------------------------------------------------------------------------
Monetary Trenton 635 $3,500 11/16/2015 Trenton
Educat South Education
ion Clinton Dance
Dance Avenue Institute
Instit Trenton program for
ute , NJ at-risk
08611 youth in
Trenton
------------------------------------------------------------------------
Monetary Trenton 218 N $15,000 10/23/2015 Further
Health Broad Inroads for
Team, St Health
Inc. Trenton
, NJ
08608
------------------------------------------------------------------------
Monetary Trinity 22 $7,500 11/12/2015 Mental
Counse Stockto Health and
ling n Wellness
Servic Street Programs
es Trinity
Counsel
ing
Service
Princet
on, NJ
08540
------------------------------------------------------------------------
Monetary Twiligh P.O. Box $7,500 11/16/2015 Simple Needs
t Wish 1042 11 Wish
Founda Duane Granting
tion Road Program
Doylest
own, PA
18901
------------------------------------------------------------------------
Monetary UIH 4 North $7,500 9/28/2015 Community of
Family Broad Health for
Partne Street Men Program
rs 2nd (Year 2)
Floor
Trenton
, NJ
08618-
4408
------------------------------------------------------------------------
Monetary United 9-25 $7,500 9/25/2015 Princeton
Negro Alling Committee
Colleg Street of UNCF
e Fund 2nd Scholarship
Floor
Newark,
NJ
07102
------------------------------------------------------------------------
Monetary United Attn: $595,877 12/21/2015 Company
Way Finance match to
Worldw Operati employee
ide on P.O. United Way
Box campaign
418607 for NJ
Boston, based
MA commercial
02241- companies
8607 of Janssen
Pharmaceuti
cal
Companies
of Johnson
& Johnson
------------------------------------------------------------------------
Monetary Valeo 5401 SW $3,500 5/22/2015 Creations of
Behavi 7th Hope: A
oral Street gallery by
Health Topeka, artists
Care, KS experiencin
Inc. 66606 g mental
illness
------------------------------------------------------------------------
Monetary Volunte 12 $7,500 11/12/2015 SkillsConnec
er Stockto t program
Connec n
t Street
Princet
on, NJ
08540
------------------------------------------------------------------------
Monetary Washing P.O. Box $500 2/27/2015 Educational
ton 83 program
Crossi Titusvi focused on
ng lle, NJ New Jersey
Park 08560 in the
Associ American
ation, Revolutiona
Inc. ry War
------------------------------------------------------------------------
Monetary We Care 3035 $1,500 6/22/2015 Support
Arts Wilming Artowork
ton program,
Pike which aims
Ketteri to use art
ng, OH to help
45429 enrich
lives of
the
mentally
ill
------------------------------------------------------------------------
Monetary West 120 $300 8/20/2015 Costs
Bergen Chestnu associated
Mental t with 2015
Health Street Janssen
care Ridgewo Cares
od, NJ Volunteer
07450- Activity
2500
------------------------------------------------------------------------
Monetary West PO Box $5,000 11/12/2015 Excellence
Windso 280 in
r West Education
Plains Windsor Grant
boro , NJ Program
Educat 08550-
ion 0280
Founda
tion
------------------------------------------------------------------------
Monetary Womansp 1530 $300 6/26/2015 Costs
ace Brunswi associated
ck Ave. with 2015
Lawrenc Janssen
eville, Cares
NJ Volunteer
08648 Activity
------------------------------------------------------------------------
Monetary Women's 3200 $75 1/14/2015 Employee
Commun Hilltop directed
ity, Avenue donation in
Inc. Wausau, lieu of
WI company
54401 holiday
gift
------------------------------------------------------------------------
Monetary Woods 40 $4,000 11/20/2015 Improving
Servic Martin the Health
es Gross of People
Founda Drive with
tion PO box Disabilitie
36 s at Woods
Langhor Services
ne, PA through
19047 Enhanced
Recreationa
l
Activities
------------------------------------------------------------------------
Monetary YMCA of 431 $5,000 11/16/2015 Science in
Trento Penning the City--
n ton Minorities
Avenue in M.I.N.T.
Trenton Mentoring
, NJ Program
08618
------------------------------------------------------------------------
Monetary Young 349 W. $300 7/14/2015 Costs
Schola State associated
rs' St with 2015
Instit Trenton Janssen
ute , NJ Cares
08618 Volunteer
Activity
------------------------------------------------------------------------
Monetary Zufall 18 West $300 8/3/2015 Costs
Health Blackwe associated
Center ll with 2015
, Inc. Street Janssen
Dover, Cares
NJ Volunteer
07801 Activity
------------------------------------------------------------------------
Product AmeriCa 88 $6,802,406 3/10/2015 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Afghanistan
, Armenia,
Dominican
Republic,
Gaza,
Ghana,
Honduras,
Nicaragua,
Peru, US,
West Bank
------------------------------------------------------------------------
Product AmeriCa 88 $413,439 3/10/2015 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Dominican
Republic,
Nicaragua,
Peru, US,
West Bank
------------------------------------------------------------------------
Product AmeriCa 88 $292,148 4/2/2015 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in Armenia,
Columbia,
Dominican
Republic,
Gaza,
Lebanon,
Nicaragua,
West Bank
------------------------------------------------------------------------
Product AmeriCa 88 $219,598 4/30/2015 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in Nepal
(2015
earthquake
relief)
------------------------------------------------------------------------
Product AmeriCa 88 $673,887 5/5/2015 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n relief in
06902 Lebanon
(ANERA
program)
------------------------------------------------------------------------
Product AmeriCa 88 $279,339 5/20/2015 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n relief in
06902 Romania,
Senegal,
United
States
------------------------------------------------------------------------
Product AmeriCa 88 $1,454,074 6/4/2015 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in Lebanon,
West Bank,
US,
Tanzania,
Peru,
Afghanistan
, Colombia,
Malawi,
Armenia
------------------------------------------------------------------------
Product AmeriCa 88 $6,800,452 6/29/2015 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in Gaza,
West Bank,
US
------------------------------------------------------------------------
Product AmeriCa 88 $13,984 8/3/2015 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Nicaragua
------------------------------------------------------------------------
Product AmeriCa 88 $54,149,760 8/6/2015 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in Armenia,
Uzbekistan,
US
------------------------------------------------------------------------
Product AmeriCa 88 $84,124 9/9/2015 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance:
disaster
relief
preparednes
s
------------------------------------------------------------------------
Product AmeriCa 88 $2,921,081 10/5/2015 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Honduras,
Peru,
Armenia,
Tanzania,
Senegal,
Afghanistan
and for
disaster
preparednes
s modules
------------------------------------------------------------------------
Product AmeriCa 88 $1,544,676 10/5/2015 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Afghanistan
, Armenia,
Gaza, Peru,
Senegal,
Tanzania,
West Bank,
US
------------------------------------------------------------------------
Product AmeriCa 88 $456,654 11/4/2015 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in Armenia,
Gaza, Peru,
Romania,
Senegal,
Uzbekistan,
West Bank
------------------------------------------------------------------------
Product AmeriCa 88 $1,070,880 11/18/2015 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Guatemala
------------------------------------------------------------------------
Product AmeriCa 88 $897,021 12/8/2015 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in Armenia,
Nicaragua,
Peru, US
------------------------------------------------------------------------
Product AmeriCa 88 $48,945 12/21/2015 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in USA
------------------------------------------------------------------------
Product AmeriCa 88 $2,005,526 12/21/2015 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in USA
------------------------------------------------------------------------
Product Catholi 100 Wall $812,025 3/10/2015 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in Haiti,
10005 Honduras,
Jamaica,
Nicaragua
------------------------------------------------------------------------
Product Catholi 100 Wall $105,683 3/10/2015 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in Haiti,
10005 Jamaica
------------------------------------------------------------------------
Product Catholi 33-01 $275,375 6/4/2015 Product
c Elevent donation
Medica h for
l Street humanitaria
Missio Long n
n Island assistance
Board City, in Jamaica,
NY Armenia,
Guatemala
------------------------------------------------------------------------
Product Catholi 33-01 $313,574 6/29/2015 Product
c Elevent donation
Medica h for
l Street humanitaria
Missio Long n
n Island assistance
Board City, in El
NY Salvador
------------------------------------------------------------------------
Product Catholi 100 Wall $1,612,989 10/9/2015 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in
10005 Guatemala,
Honduras,
Haiti
------------------------------------------------------------------------
Product Catholi 100 Wall $563,598 10/9/2015 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in
10005 Guatemala,
Honduras,
Haiti
------------------------------------------------------------------------
Product Catholi 33-01 $8,754 11/4/2015 Product
c Elevent donation
Medica h for
l Street humanitaria
Missio Long n
n Island assistance
Board City, in
NY Dominican
Republic,
El
Salvador,
Guyana,
Nicaragua
------------------------------------------------------------------------
Product Catholi 33-01 $343,347 12/18/2015 Product
c Elevent donation
Medica h for
l Street humanitaria
Missio Long n
n Island assistance
Board City, in El
NY Salvador,
Dominican
Republic,
Sierra
Leone,
Uganda,
Guatemala,
Guyana,
Philippines
------------------------------------------------------------------------
Product Direct 27 S. La $2,014,130 3/10/2015 Pharmaceutic
Relief Patera al Product
Lane Donation
Goleta, for
CA Humanitaria
93117 n Aid in
Dominican
Republic,
El
Salvador,
Guatemala,
Haiti, US
------------------------------------------------------------------------
Product Direct 27 S. La $274,761 3/10/2015 Product
Relief Patera donation
Lane for
Goleta, humanitaria
CA n
93117 assistance
in
Dominican
Republic,
Ghana,
Guatemala,
Nicaragua,
US
------------------------------------------------------------------------
Product Direct 27 S. La $17,185 4/2/2015 Pharmaceutic
Relief Patera al Product
Lane Donation
Goleta, for
CA Humanitaria
93117 n Aid in
Paraguay
------------------------------------------------------------------------
Product Direct 27 S. La $13,131 5/4/2015 Product
Relief Patera donation
Lane for
Goleta, humanitaria
CA n
93117 assistance
in Nepal
(2015
earthquake
relief)
------------------------------------------------------------------------
Product Direct 27 S. La $10,680 5/5/2015 Product
Relief Patera donation
Lane for
Goleta, humanitaria
CA n
93117 assistance
in Congo,
Malawi,
Mali,
Somalia,
Tanzania,
Zambia
(obstetric
fistula
program)
------------------------------------------------------------------------
Product Direct 27 S. La $187,713 5/20/2015 Product
Relief Patera donation
Lane for
Goleta, humanitaria
CA n relief in
93117 El
Salvador,
Guatemala,
Dominican
Republic,
United
States
------------------------------------------------------------------------
Product Direct 27 S. La $852,327 6/4/2015 Product
Relief Patera donation
Lane for
Goleta, humanitaria
CA n
93117 assistance
in
Paraguay,
El
Salvador,
Nicaragua
------------------------------------------------------------------------
Product Direct 27 S. La $9,636,065 6/29/2015 Product
Relief Patera donation
Lane for
Goleta, humanitaria
CA n
93117 assistance
in Haiti,
India,
Jamaica,
Paraguay,
Armenia,
Dominican
Republic,
Ghana,
Guatemala,
Hondorus,
US
------------------------------------------------------------------------
Product Direct 27 S. La $20,976 8/4/2015 Product
Relief Patera donation
Lane for
Goleta, humanitaria
CA n
93117 assistance
in Paraguay
------------------------------------------------------------------------
Product Direct 27 S. La $13,878 8/5/2015 Product
Relief Patera donation
Lane for
Goleta, humanitaria
CA n
93117 assistance
in Africa
------------------------------------------------------------------------
Product Direct 27 S. La $198,318 9/11/2015 Product
Relief Patera donation
Lane for
Goleta, humanitaria
CA n
93117 assistance:
disaster
relief
preparednes
s
------------------------------------------------------------------------
Product Direct 27 S. La $5,543,118 10/12/2015 Product
Relief Patera donation
Lane for
Goleta, humanitaria
CA n
93117 assistance
in
Nicaragua,
Sierra
Leone,
Ghana, US
and for
disaster
preparednes
s modules
------------------------------------------------------------------------
Product Direct 27 S. La $918,456 10/12/2015 Product
Relief Patera donation
Lane for
Goleta, humanitaria
CA n
93117 assistance
in Ghana,
Sierra
Leone,
Nicaragua,
US
------------------------------------------------------------------------
Product Direct 27 S. La $81,702 11/4/2015 Product
Relief Patera donation
Lane for
Goleta, humanitaria
CA n
93117 assistance
in
Cambodia,
Guatemala,
Haiti,
Honduras,
India,
Paraguay
------------------------------------------------------------------------
Product Direct 27 S. La $27,755 11/25/2015 Product
Relief Patera donation
Lane for
Goleta, humanitaria
CA n
93117 assistance
in Africa
(obstetric
fistula
program)
------------------------------------------------------------------------
Product Direct 27 S. La $186,387 12/7/2015 Product
Relief Patera donation
Lane for
Goleta, humanitaria
CA n
93117 assistance
in Ecuador,
Ghana,
Mexico,
Jamaica
------------------------------------------------------------------------
Product Heart 13250 W $4,874,474 10/6/2015 Product
To 98th donation
Heart Street for
Intern Lenexa, humanitaria
ationa KS n
l 66215 assistance
in
Dominican
Republic,
Papua New
Guinea
------------------------------------------------------------------------
Product Heart 13250 W $1,148,070 10/6/2015 Product
To 98th donation
Heart Street for
Intern Lenexa, humanitaria
ationa KS n
l 66215 assistance
in
Dominican
Republic
------------------------------------------------------------------------
Product Johnson One $299,754,483 12/31/2015 Patient
& Johnson Assistance
Johnso & Product
n Johnson Donation
Patien Plaza
t New
Assist Brunswi
ance ck, NJ
Founda 08933
tion
------------------------------------------------------------------------
Product MAP 4700 $2,230,112 2/20/2015 Pharmaceutic
Intern Glynco al Product
ationa Parkway Donation to
l Brunswi support the
ck, GA Medical
31525 Mission
Pack+
Program
------------------------------------------------------------------------
Product MAP 4700 $1,312,483 7/20/2015 Global
Intern Glynco Public
ationa Parkway Health
l Brunswi programs in
ck, GA Sub Saharan
31525 Africa
(HIV)
------------------------------------------------------------------------
Product MAP 4700 $46,453 9/11/2015 Product
Intern Glynco donations
ationa Parkway for
l Brunswi humanitaria
ck, GA n
31525 assistance:
Medical
Mission
Pack Plus
replenishme
nt
------------------------------------------------------------------------
Product MAP 4700 $35,015 11/25/2015 Product
Intern Glynco donation
ationa Parkway for
l Brunswi humanitaria
ck, GA n
31525 assistance
and medical
mission
pack +
program
------------------------------------------------------------------------
Product MAP 4700 $951,077 12/15/2015 Product
Intern Glynco donation
ationa Parkway for
l Brunswi humanitaria
ck, GA n
31525 assistance
(medical
mission
pack +
program)
------------------------------------------------------------------------
Product US 1300 PA $29,310,000 12/17/2015 Global
Agency Avenue. Public
for , NW, Health
Intern SA-44 programs--B
ationa Rm 475- edaquiline
l J Donation
Develo Washing Program
pment ton, DC
20523
------------------------------------------------------------------------
Updated March 24, 2016
Janssen Therapeutics, Division of Janssen Products, LP, Monetary and
Product Contributions to U.S.-based Charitable Organizations Full Year
2015
(Payments made from January 1, 2015 to December 31, 2015)
------------------------------------------------------------------------
Project
Donation Payee Payee Payment Amount Payment Title/
Type Address (USD) Date Description
------------------------------------------------------------------------
Monetary Aboundi 2311 $5,000 5/8/2015 Project
ng Martin CONNECT
Prospe Luther
rty, King
Inc. Blvd
Dallas,
TX
75215
------------------------------------------------------------------------
Monetary Aboundi 2311 $15,000 11/13/2015 Confidential
ng Martin and Mature
Prospe Luther Explanation
rty, King s (C-ME):
Inc. Blvd HCV
Dallas, Awareness
TX for At-Risk
75215 Adults in
South
Dallas
------------------------------------------------------------------------
Monetary Aboundi 2311 $30,000 12/22/2015 Project TEST
ng Martin
Prospe Luther
rty, King
Inc. Blvd
Dallas,
TX
75215
------------------------------------------------------------------------
Monetary Acercam 827 $7,000 5/8/2015 ContraSIDA
iento Wildwoo (Againsts
Hispan d Ave, AIDS)
o de Suite
Caroli 200
na del Columbi
Sur a, SC
29203
------------------------------------------------------------------------
Monetary ADAP PO Box $5,000 3/16/2015 ADAP
Advoca 15275 Directory
cy Physica
l:312
11th
Avenue,
#21g,
New
York,
NY
10001
Washing
ton, DC
20003
------------------------------------------------------------------------
Monetary Aid For 515 $10,000 7/13/2015 Case
AIDS Greenwi Management
Intern ch St Program
ationa New
l, York,
Inc. NY
10013
------------------------------------------------------------------------
Monetary AID 811 $18,259 12/22/2015 Project
Upstat Pendlet Healthy
e on Pink Parts
Street
Bldg.
#10
Greenvi
lle, SC
29601
------------------------------------------------------------------------
Monetary AIDS 75 Amory $15,000 11/13/2015 Viral
Action Street Hepatitis
Commit Boston, Access to
tee of MA Care
Massac 02119 Project:
husett Access to
s treatment
------------------------------------------------------------------------
Monetary AIDS 995 $5,000 7/27/2015 Bridges
Care Northwe Project
Servic st
e, Bouleva
Inc. rd
Winston
Salem,
NC
27101
------------------------------------------------------------------------
Monetary AIDS 575 8th $20,000 7/13/2015 HIV Health
Commun Ave, Literacy
ity Suite Education
Resear 502 New and
ch York, Training
Initia NY for Service
tive 10018 Providers
of Working
Americ with
a Vulnerable
ACRIA Populations
------------------------------------------------------------------------
Monetary AIDS 6260 $3,000 5/27/2015 Supportive
Founda Westpar Services
tion k Drive
Housto Suite
n, 100
Inc. Houston
, TX
77057
------------------------------------------------------------------------
Monetary AIDS 200 W. $40,000 5/20/2015 Road to
Founda Jackson Health:
tion Blvd., Promoting
of Suite Successful
Chicag 2100 Implementat
o Chicago ion of
, IL Health Care
60606 Reform for
People
Living with
HIV/AIDS in
Illinois
------------------------------------------------------------------------
Monetary AIDS 400 N $5,000 3/12/2015 Case
Outrea Beach Management
ch Street, Program for
Center Suite People
100 Ft. Living with
Worth, HIV
TX
76111
------------------------------------------------------------------------
Monetary AIDS 1320 $28,020 12/22/2015 Transcend
Projec Webster
t of Street
the oakland
East , CA
Bay 96612
------------------------------------------------------------------------
Monetary AIDS 1424 K $150,000 11/17/2015 Disseminatio
United Street, n of Access
NW, to Care and
Ste. Retention
200 in Care
Washing Best
ton, DC Practices
20005
------------------------------------------------------------------------
Monetary AIDS Box 3068 $5,000 3/13/2015 Latino
Walk San Services
San Diego,
Diego CA
92163
------------------------------------------------------------------------
Monetary Alexian 825 W. $5,000 7/15/2015 Transitional
Brothe Welling Living
rs ton Program for
Bonave Chicago Homeless
nture , IL Adults with
House 60657 HIV/AIDS
Case
Management
Services
------------------------------------------------------------------------
Monetary Alivene 3808 $5,000 5/27/2015 Health and
ss Nicolle Wellness
Projec t Ave Program:
t, Minneap Aging with
Inc. olis, HIV/AIDS
MN
55409
------------------------------------------------------------------------
Monetary Allianc 825 $3,000 5/27/2015 Nurse Case
e For Colorad Management
Housin o for
g And Blvd., Residential
Healin Suite Care
g 100 Los Facility
Angeles Serving
, CA Homeless
90041 Persons
with HIV/
AIDS
------------------------------------------------------------------------
Monetary Atlanta P.O. Box $32,000 4/16/2015 Comprehensiv
Harm 92670 e HIV and
Reduct Atlanta HCV
ion , GA treatment
Coalit 30314 for IDUs
ion
------------------------------------------------------------------------
Monetary BASIC 432 $5,000 5/15/2015 Fully
NWFL, Magnoli Committed
INC. a
Avenue
Panama
City,
FL
32401
------------------------------------------------------------------------
Monetary BASIC 432 $29,250 12/22/2015 FULLY
NWFL, Magnoli COMMITTED:
INC. a Improving
Avenue Linkage to
Panama Care and
City, Retention
FL among Young
32401 MSM of
Color
Living with
HIV
------------------------------------------------------------------------
Monetary Bay 701 Oak $5,000 12/21/2015 Patient Peer
Area Street Navigation
Young San
Positi Francis
ves co, CA
94117
------------------------------------------------------------------------
Monetary Brockto 500 $5,000 3/24/2015 HIV/AIDS
n Area Belmont Case
Multi- Street Management
Servic Ste 300 Initiative
es, Brockto and
Inc. n, MA Hepatitis C
02301 Support
Group.
------------------------------------------------------------------------
Monetary Bronx 540 East $40,000 3/10/2015 Improving
AIDS Fordham Care and
Servic Rd Treatment
es, Bronx, for People
Inc. NY who Inject
10458 Drugs
(PWID) who
are Living
with HIV
and/or
Hepatitis C
------------------------------------------------------------------------
Monetary Caring PO Box $40,000 5/20/2015 Hepatitis C
Ambass 1748 Program
adors Oregon Support
Progra City,
m, OR
Inc. 97045
------------------------------------------------------------------------
Monetary Center 900 $25,000 3/10/2015 Hepatitis
for Avila and HIV
Health Street, Navigation
Justic Suite Project--RF
e 301, A
Los
Angeles
, CA
90012
------------------------------------------------------------------------
Monetary Central 1785 $5,000 10/12/2015 Increasing
Louisi Jackson Timely
ana Street Access to
Aids Alexand HIV Care,
Suppor ria, LA Testing and
t 71301 Prevention
Servic Services
es,
Inc.
(CLASS
)
------------------------------------------------------------------------
Monetary Coaliti 127 W $50,000 12/21/2015 Hepatitis C
on On 127th Education
Positi street and
ve Suite Services
Health 208 New Project
Empowe York,
rment, NY
Inc. 10027
------------------------------------------------------------------------
Monetary Coastal 400 Mann $40,000 3/24/2015 Hepatitis
Bend Street, Education
AIDS Suite Program
Founda 800 (HEP)
tion Corpus
Christi
, TX
78401
------------------------------------------------------------------------
Monetary Communi 677 Ala $7,500 10/3/2015 Integrating
ty Moana Hepatitis
Health #226 Care
Outrea Honolul Coordinatio
ch u, HI n into
Work 96813 Hawaii AIDS
To Service
Preven Organizatio
t Aids ns
------------------------------------------------------------------------
Monetary Desert 1695 N. $5,000 3/16/2015 Get Tested
Aids Sunrise Coachella
Projec Way Valley
t Palm
Springs
, CA
92262
------------------------------------------------------------------------
Monetary Exponen 2 $5,000 11/16/2015 HEPAware
ts, Washing Project
Inc. ton
Street,
Fourth
Floor
New
York,
NY
10004
------------------------------------------------------------------------
Monetary Gay 446 W $15,000 10/3/2015 HIV
Men's 33rd St Community
Health New Education
Crisis York, and
NY Treatment
10001 Adherence
Support
------------------------------------------------------------------------
Monetary Gay 446 W $30,000 12/22/2015 Peer
Men's 33rd St Navigation
Health New Services
Crisis York, for HIV-
NY positive
10001 Transgender
and Gender
Non-
Conforming
Individuals
------------------------------------------------------------------------
Monetary Harm 22 West $30,000 6/5/2015 Hepatitis C
Reduct 27th and
ion Street Injection
Coalit 5th Drug Use
ion Floor Initiative
New
York,
NY
10001
------------------------------------------------------------------------
Monetary Hips HIPS $30,000 12/22/2015 Treatment
Center Plus: Peer
for Based
Health Community
and Health
Achieve Worker
ment Support to
906 H Improve
St., NE Health
Washing Outcomes
ton, DC for Highly
20002 Marginalize
d
Transgender
Women
------------------------------------------------------------------------
Monetary Housing 301 West $7,500 12/8/2015 Hepatitis C
Works, 37th Peer
Inc. Street, Navigator
#3 New Program
York,
NY
10018
------------------------------------------------------------------------
Monetary Jackson P.O. Box $5,000 8/27/2015 JASMYN
ville 380103 Safety Net
Area 923 Program
Sexual Peninsu Expansion
Minori lar
ty Place
Youth Jackson
Networ ville,
k, FL
Inc. 32205
(JASMY
N)
------------------------------------------------------------------------
Monetary Legacy 4054 $5,000 12/21/2015 Counseling
Counse McKinne services to
ling y individuals
Center Avenue, living with
Suite HIV/AIDS
102
Dallas,
TX
75204
------------------------------------------------------------------------
Monetary Long 2740 $30,000 12/22/2015 Pride for
Island Martin Youth POZ
Crisis Ave Night
Center Bellmor
, Inc. e, NY
11710
------------------------------------------------------------------------
Monetary Macedon 1835 $5,000 3/24/2015 Peer
ia Centre Navigator
Family Avenue, for
And Suite Prevention/
Commun 285 Case
ity Pittsbu Management
Enrich rgh, PA Services
ment 15219
Center
------------------------------------------------------------------------
Monetary Macedon 1835 $5,000 10/23/2015 Peer
ia Centre Navigator
Family Avenue, for
And Suite Prevention/
Commun 285 Case
ity Pittsbu Management
Enrich rgh, PA Services
ment 15219 Implementat
Center ion
------------------------------------------------------------------------
Monetary MCCNY 446 West $30,000 12/23/2015 Trans in
Charit 36th Action
ies Street
New
York,
NY
10018
------------------------------------------------------------------------
Monetary Mendoci 148 $39,870 3/30/2015 Linkage and
no Clara Support
County Ave. Services
AIDS Ukiah, for PWID's
Volunt CA
eer 95482
Networ
k adba
Mendoc
ino
County
AIDS/
Viral
Hepati
tis
Networ
k
------------------------------------------------------------------------
Monetary Metropo 3251 3rd $30,000 12/23/2015 TransHealth
litan Avenue Care
Charit North Coordinatio
ies, Suite#1 n
Inc. 25 St
Petersb
urg, FL
33713
------------------------------------------------------------------------
Monetary Minorit 5149 W. $7,500 4/30/2015 ``G.L.A.M.O.
y AIDS Jeffers R.''
Projec on Blvd Getting
t Los Linked And
Angeles Managing
, CA Our
90016 Regimen. It
is The
Missing
Link.
------------------------------------------------------------------------
Monetary Missour 601 $18,000 3/24/2015 General
i Busines Charitable
Hepati s Loop Contributio
tis C 70 n
Allian West,
ce Suite
134K,
Columbi
a, MO
65203-
2585
------------------------------------------------------------------------
Monetary Montgom 820 W. $18,000 3/13/2015 Alabama
ery Wouth eHealth
AIDS Blvd., Access to
Outrea Montgom Rural care
ch ery, AL for HIV/
36105 AIDS and
Hepatitis C
------------------------------------------------------------------------
Monetary Nashvil 633 $18,000 12/22/2015 Brothers
le Thompso United
CARES, n Lane Network of
Inc. Nashvil Tennessee:
le, TN Mobilizatio
37204 n of Young
African
American
MSM in
Rural
Middle and
East
Tennessee
------------------------------------------------------------------------
Monetary Nationa 2140 $5,000 7/15/2015 Brothers
l AIDS Martin Like Us
Educat Luther (B.L.U.)
ion King Project
and Jr.
Servic Drive
es for Atlanta
Minori , GA
ties 30310
------------------------------------------------------------------------
Monetary Nationa 2140 $30,000 12/22/2015 Be Connected
l AIDS Martin Mentoring
Educat Luther Program
ion King
and Jr.
Servic Drive
es for Atlanta
Minori , GA
ties 30310
------------------------------------------------------------------------
Monetary Nationa 580 $200,000 2/25/2015 Hepatitis C
l AIDS Broadwa Project,
Treatm y Suite HIV Too
ent 1010
Advoca New
cy York,
Projec NY
t 10012
------------------------------------------------------------------------
Monetary Nationa National $150,000 11/17/2015 Affordable
l Latino Care Act
Allian AIDS (ACA),
ce of Action Viral
State Network Hepatitis,
and and and Ryan
Territ Nationa White/ADAP
orial l Public
AIDS Allianc Policy and
Direct e of Technical
ors State Assistance
and Programs
Territo
rial
AIDS
Directo
rs 444
N
Capitol
St
Suite
339
Washing
ton, DC
20001
------------------------------------------------------------------------
Monetary Nationa Post $7,500 7/27/2015 Black LGBT
l Office Health and
Black Box Wellness
Justic 71395 Initiative
e Washing
Coalit ton, DC
ion, 20024
Inc.
------------------------------------------------------------------------
Monetary Nationa 1825 $35,000 3/10/2015 Strong
l Connect Communities
Minori icut :
ty Avenue, Strengtheni
AIDS NW ng
Counci Washing connections
l ton, DC between
20009- communities
5721 of color
and the
healthcare
providers
that serve
them.
------------------------------------------------------------------------
Monetary New 44 South $5,000 8/27/2015 Support of
Jersey Street case
AIDS Morrist management
Servic own, NJ
es 07960
------------------------------------------------------------------------
Monetary Next 99 $5,000 7/27/2015 Next Step
Step Bishop Transitiona
Fund, Allen l Support
Inc. Drive for HIV+
Cambrid Teens and
ge, MA Young
02139 Adults
------------------------------------------------------------------------
Monetary Our 2727 SE $5,000 3/13/2015 NHCP:
House Alder Independent
Of St. Living
Portla Portlan Support for
nd d, OR Individuals
Incorp 97214 with HIV/
orated AIDS
------------------------------------------------------------------------
Monetary Philade 1233 $10,000 6/25/2015 End AIDS
lphia Locust Summit/AIDS
Fight St. Education
Philade Month 2015
lphia,
PA
19107
------------------------------------------------------------------------
Monetary Project 273 $40,000 3/13/2015 The Support
Inform Ninth Partnership
Street
San
Francis
co, CA
94103
------------------------------------------------------------------------
Monetary Project 273 $65,000 6/12/2015 Mission
Inform Ninth Support for
Street Project
San Inform
Francis
co, CA
94103
------------------------------------------------------------------------
Monetary Project P.O. Box $5,000 10/3/2015 Transitional
Transi 4826 Supportive
tions, Austin, Housing
Inc. TX Programs
78765
------------------------------------------------------------------------
Monetary Resourc 2701 $3,000 5/27/2015 Valor
e Reagan Latino--HIV
Center Street Prevention
of Dallas, Program
Dallas TX
, Inc. 75219
------------------------------------------------------------------------
Monetary San 2508 $20,000 8/3/2015 Creating
Diego Histori Circles of
Human c Care
Dignit Decatur
y Road
Founda Suite
tion 160 San
Diego,
CA
92106
------------------------------------------------------------------------
Monetary Set 8035 E. $5,000 10/3/2015 Phenomenal
Apart R.L. Woman
Aiming Thornto Program
Victor n Frwy. (PWP)
iously Suite
To 424
Elimat Dallas,
e TX
Diseas 75228
es
------------------------------------------------------------------------
Monetary Sexual 410 7th $30,000 12/22/2015 Peer
Minori st SE Education:
ty Washing Empowering
Youth ton, DC young MSM
Assist 20003 of color to
ance end HIV.
League
(SMYAL
) DBA:
Suppor
ting
and
Mentor
ing
Youth
Advoca
tes
and
Leader
s
------------------------------------------------------------------------
Monetary Shanti 730 Polk $15,000 7/14/2015 Shanti's Hep
Projec Street C Pilot
t, 3rd Expansion
Inc. Floor of our HIV
San Services
Francis Program
co, CA
94109
------------------------------------------------------------------------
Monetary Someone 1950 $30,000 12/22/2015 Improving
Cares Spectru Linkage to
Inc Of m Care and
Atlant Circle Retention
a Ste. among
A145 Transgender
Mariett Women and
a, GA Gender
30067 Nonconformi
ng People
Living with
HIV Project
title:
Transformin
g, Renewing
and
Unifying
Transgender
Health
Project
(TRUTH)
------------------------------------------------------------------------
Monetary Southwe 300 $5,000 9/3/2015 HIV Care in
st Southwe a Safety
Boulev st Net Clinic
ard Bouleva Setting
Family rd
Health Kansas
Care, City,
Inc. KS
66103
------------------------------------------------------------------------
Monetary Southwe 1101 N. $4,500 5/15/2015 Hepatitis C
st Central Education
Center Avenue, and Support
For Suite for High-
HIV/ 200 risk
AIDS, phoenix Populations
Inc. , AZ
85004
------------------------------------------------------------------------
Monetary St 808 W. $40,000 3/10/2015 South L.A.
Johns 58th Mobile
Well Street Health--Pee
Child Los r Navigator
And Angeles Program for
Family , CA PWID Living
Center 90037 with HIV
, Inc. and/or
Hepatitis C
------------------------------------------------------------------------
Monetary St. 1111 $75,000 12/22/2015 FINISH THE
Luke's Amsterd JOB:
Roosev am Ave Providing
elt New HCV care to
Hospit York, current or
al NY former IV
Center 10025 drug users
previously
diagnosed
through
governmenta
l testing
programs.
------------------------------------------------------------------------
Monetary The 17 Davis $65,000 7/14/2015 Ensuring
AIDS Blvd. Adequate
Instit Suite Funding for
ute 403 Domestic
Tampa, HIV/AIDS
FL and
33606 Hepatitis
Programs
------------------------------------------------------------------------
Monetary The Hep 1325 S. $25,000 5/20/2015 Hepatitis C
C Colorad Testing and
Connec o Linkage to
tion Blvd., Care
B-302
Denver,
CO
80222
------------------------------------------------------------------------
Monetary The PO Box $39,000 3/13/2015 The Open
Open 99243 Door: Peer
Door, Pittsbu Support for
Inc. rgh, PA HIV
15233 Engagement
and
Retention
in Care
------------------------------------------------------------------------
Monetary The 85 $15,000 5/15/2015 Women's HIV
Well Norman Treatment
Projec Avenue, Advocacy
t Suite 1 Development
Brookly Program
n, NY
11222
------------------------------------------------------------------------
Monetary The 85 $15,000 7/21/2015 Charitable
Well Norman Donation
Projec Avenue, for Online
t Suite 1 Resources
Brookly and Program
n, NY Evaluation/
11222 Outcome
Measurement
------------------------------------------------------------------------
Monetary The 8101 $5,000 7/15/2015 Personal
Wright Cameron Disease
House Rd., Management
Wellne Suite for HIV/
ss 105 AIDS and
Center Austin, HepC
, Inc. TX Clients
78754
------------------------------------------------------------------------
Monetary TPA 5050 N. $20,000 10/8/2015 Peer Health
Networ Broadwa Navigation
k y Suite Services
Incorp 300
orated Chicago
Test , IL
Positi 60640
ve
Aware
Networ
k
------------------------------------------------------------------------
Monetary TPA 5050 N. $26,056 12/22/2015 Youth
Networ Broadwa Investment
k y Suite
Incorp 300
orated Chicago
Test , IL
Positi 60640
ve
Aware
Networ
k
------------------------------------------------------------------------
Monetary Treatme 261 $40,000 5/21/2015 Case Studies
nt Fifth
Action Ave
Group, Suite
Inc. 2110
New
York,
NY
10016
------------------------------------------------------------------------
Monetary Univers UCSF $7,500 8/27/2015 Mission-
ity of Allianc Based
Califo e Support of
rnia Health UCSF
San Project Alliance
Franci 1855 Health
sco Folsom Project
Street, Services
Ste. for People
670 Box Living With
0884 or at Risk
San of HIV/AIDS
Francis
co, CA
94143
------------------------------------------------------------------------
Monetary Univers 51 $7,500 10/23/2015 The
ity of Goodman Cincinnati
Cincin Drive Exchange
nati Suite Project: A
100, Public
P.O. Health
Box Initiative
19970
Cincinn
ati, OH
45219-
0970
------------------------------------------------------------------------
Monetary US 1300 PA $1,000,000 10/23/2015 Sirturo
Agency Avenue. Donation
for , NW, Program--US
Intern SA-44 AID
ationa Rm 475- Agreement
l J
Develo Washing
pment ton, DC
20523
------------------------------------------------------------------------
Monetary Vermont P. O. $40,000 3/10/2015 Expansion of
Commit Box Vermont's
tee 5248 Services to
For Burling Improve
Aids ton, VT Care for
Resour 05402 PWID Living
ces with HCV
Educat
ion
and
Servic
es
------------------------------------------------------------------------
Monetary Warren- 511 Ruin $28,800 12/22/2015 Online
Vance Creek Linkage and
Commun Rd STE Retention
ity 105 Project for
Health Henders YMSM
Center on, NC
, Inc. 27536
------------------------------------------------------------------------
Monetary Washing 566 West $40,000 3/13/2015 Engaging
ton 181st High Risk
Height Street, Active
s Floor 2 Injection
CORNER New Drug Users
Projec York, in
t NY Hepatitis C
10033 testing and
Treatment
in Northern
Manhattan
------------------------------------------------------------------------
Monetary Wellnes 2921 NE $5,000 7/15/2015 Sister-to-
s 6th Ave Sister
Center Wilton
of Manors,
South FL
Florid 33334
a,
Inc.
------------------------------------------------------------------------
Monetary WORLD 449 15th $15,000 12/17/2015 2nd CHANCE
Women St., (Creating a
Organi Suite Healthy and
zed to 303 Nurturing
Respon Oakland Community
d to , CA Environment
Life- 94612 )
threat
ening
Diseas
es
------------------------------------------------------------------------
Product Johnson One $13,174,000 3/15/2013 Patient
& Johnson Assistance
Johnso & Product
n Johnson Donation
Patien Plaza,
t New
Assist Brunswi
ance ck, NJ
Founda 08933
tion
------------------------------------------------------------------------
Product Johnson One $6,019,000 6/15/2013 Patient
& Johnson Assistance
Johnso & Product
n Johnson Donation
Patien Plaza,
t New
Assist Brunswi
ance ck, NJ
Founda 08933
tion
------------------------------------------------------------------------
Product Johnson One $59,199,000 9/15/2013 Patient
& Johnson Assistance
Johnso & Product
n Johnson Donation
Patien Plaza,
t New
Assist Brunswi
ance ck, NJ
Founda 08933
tion
------------------------------------------------------------------------
Product Johnson One $4,718,000 12/15/2013 Patient
& Johnson Assistance
Johnso & Product
n Johnson Donation
Patien Plaza,
t New
Assist Brunswi
ance ck, NJ
Founda 08933
tion
------------------------------------------------------------------------
Updated March 24, 2016
Janssen Biotech, Inc. Monetary and Product Contribution to U.S.-based
Charitable Organizations Full Year 2016
(Payments made from January 1, 2016 to December 31, 2016)
------------------------------------------------------------------------
Project
Donation Payee Payee Payment Amount Payment Title/
Type Address (USD) Date Description
------------------------------------------------------------------------
Monetary Aid For 12271 $300 9/19/2016 Costs
Friend Townsen associated
s d Rd with 2016
Philade Janssen
lphia, Cares
PA Volunteer
19154 Activity
------------------------------------------------------------------------
Monetary America 2310 $1,500 4/11/2016 2016 Run for
n Route Dad,
Cancer 34, Awareness
Societ Suite Sponsor
y Inc. 1D
Manasqu
an, NJ
08736
------------------------------------------------------------------------
Monetary America 1626 $1,000 4/15/2016 Relay For
n Locust Life of the
Cancer Street Wissahickon
Societ Philade Valley
y Inc. lphia,
PA
19103
------------------------------------------------------------------------
Monetary Arthrit 1355 $200,000 6/3/2016 Renewal
is Peachtr support of
Founda ee Arthritis
tion Street, Foundation
Suite Run / Walk
600 series -
Atlanta Walk to
, GA Cure
30309 Arthritis
and Jingle
Bell Run
------------------------------------------------------------------------
Monetary Arthrit 1355 $100,000 4/11/2016 General
is Peachtr Operating
Founda ee Support
tion Street,
Suite
600
Atlanta
, GA
30309
------------------------------------------------------------------------
Monetary Arthrit 2280 $75 3/7/2016 Employee
is South directed
Founda Albion donation in
tion, Street lieu of
Great Denver, company
West CO holiday
Region 80222- gift
, Inc. 4906
------------------------------------------------------------------------
Monetary Bicol 21019 $1,425 3/8/2016 Employee
Founda 47th directed
tion Ave W donation in
Lynnwoo lieu of
d, WA company
98036 holiday
gift
------------------------------------------------------------------------
Monetary Cancer 200 Kirk $2,000 8/17/2016 Paws 4 Life
Suppor Road PO Dog Walk
t Box
Commun 3187
ity of Warmins
Philad ter, PA
elphia 18974
------------------------------------------------------------------------
Monetary Cancer 200 Kirk $2,500 8/30/2016 Celebration
Suppor Road PO of Hope
t Box
Commun 3187
ity of Warmins
Philad ter, PA
elphia 18974
------------------------------------------------------------------------
Monetary Cancer 200 Kirk $900 9/13/2016 Costs
Suppor Road PO associated
t Box with 2016
Commun 3187 Janssen
ity of Warmins Cares
Philad ter, PA Volunteer
elphia 18974 Activity
------------------------------------------------------------------------
Monetary Cancer 944 $3,500 8/5/2016 Cancer
Suppor Marcon Support and
t Blvd., Education
Commun #110 Allentown,
ity of Allento PA
the wn, PA
Greate 18109
r
Lehigh
Valley
------------------------------------------------------------------------
Monetary Canine PO Box $300 9/14/2016 Costs
Partne 170 associated
rs for Cochran with 2016
Life ville, Janssen
PA Cares
19330 Volunteer
Activity
------------------------------------------------------------------------
Monetary Center 1900 $5,000 5/27/2016 Project for
for Cherry Medically
Child Street Needy
Advoca Philade Children
tes lphia,
PA
19103
------------------------------------------------------------------------
Monetary Childre CHOP $5,000 4/12/2016 7th Annual
n's Foundat Walk for
Hospit ion Hope
al of ATTN: benefiting
Philad Holly pediatric
elphia Hubbard/ Inflammator
Founda Walk y Bowel
tion for Disease
Hope Research
2016 PO
Box
40930
34th
and
Civic
Center
Blvd.
Philade
lphia,
NJ
19107
------------------------------------------------------------------------
Monetary Communi 300B $20,000 12/14/2016 Free medical
ty Lawrenc and dental
Volunt e Drive care
eers West services
in Chester for
Medici , PA uninsured
ne 19380 families in
Chester
County
------------------------------------------------------------------------
Monetary Crohn's 733 $135,000 2/26/2016 Take Steps
and Third 2016 Walk
Coliti Avenue Program
s Suite
Founda 510 New
tion York,
of NY
Americ 10017
a,
Inc.
------------------------------------------------------------------------
Monetary Crohn's 733 $5,000 6/13/2016 Disease
and Third State
Coliti Ave, Awareness
s Suite (DSA) Word
Founda 510 New Cloud
tion York, Activity
of NY
Americ 10017
a,
Inc.
------------------------------------------------------------------------
Monetary Crohn's 733 $18,000 6/13/2016 Camp Oasis
and Third
Coliti Ave,
s Suite
Founda 510 New
tion York,
of NY
Americ 10017
a,
Inc.-
NY
Chapte
r
------------------------------------------------------------------------
Monetary Delawar 236 $5,000 3/21/2016 Teacher
e Randell Development
Valley Hall Program
Scienc 3141
e Chestnu
Fairs, t
Inc. Street
Philade
lphia,
PA
19104
------------------------------------------------------------------------
Monetary Doernbe 1121 SW $75 3/21/2016 Employee
cher Salmon directed
Childr St #100 donation in
en's Portlan lieu of
Hospit d, OR company
al 97205 holiday
Founda gift
tion
------------------------------------------------------------------------
Monetary Family 142 $25,000 9/30/2016 Family Reach
Reach Berkele Foundation
Founda y General
tion Street, Support
4th
Floor
Boston,
MA
02116
------------------------------------------------------------------------
Monetary Family 142 $250,000 12/22/2016 Family Reach
Reach Berkele Programmati
Founda y c Support
tion Street;
4th
Floor
Boston,
MA
02116
------------------------------------------------------------------------
Monetary Food 1501 $5,000 12/15/2016 Year Round
Bank John Youth
of Tipton Feeding
South Blvd Programs
Jersey Pennsau
ken
Townshi
p, NJ
08110
------------------------------------------------------------------------
Monetary Friends 113 West $3,000 12/26/2016 Outreach to
Associ Chestnu Homeless
ation t Families
For Street
Care West
and Chester
Protec , PA
tion 19380
Of
Childr
en
------------------------------------------------------------------------
Monetary Georgia 560 $1,700 4/12/2016 Free
Prosta Barnesl Prostate
te ey Lane Cancer
Cancer Alphare Screening
Coalit tta, GA
ion 30022
Inc.
------------------------------------------------------------------------
Monetary Girl 330 $4,000 10/10/2016 Girl Scouts
Scouts Manor of Eastern
of Road Pennsylvani
Southe Miquon, a Science,
astern PA Technology,
Pennsy 19444 Engineering
lvania , and Math
(STEM)
programming
.
------------------------------------------------------------------------
Monetary Green 1368 $15,000 12/15/2016 Watershed
Valley Prizer Science
s Road Education
Associ Pottsto Program
ation wn, PA
19465
------------------------------------------------------------------------
Monetary Habitat 1847 E $2,000 5/30/2016 Building
for Lincoln communities
Humani Hwy and
ty of Coatesv changing
Cheste ille, lives
r PA
County 19320
, Inc.
------------------------------------------------------------------------
Monetary Habitat 1829 N. $300 11/3/2016 Costs
For 19th associated
Humani Street with 2016
ty Philade Janssen
Philad lphia, Cares
elphia PA Volunteer
Inc. 19121 Activity
------------------------------------------------------------------------
Monetary Habitat 1829 N. $5,000 12/26/2016 Diamond Park
For 19th Phase 2--
Humani Street affordable
ty Philade housing
Philad lphia,
elphia PA
Inc. 19121
------------------------------------------------------------------------
Monetary Hatboro- 229 $25,000 12/14/2016 STEM
Horsha Meeting Programs
m house for Hatboro-
Educat Road Horsham
ional Horsham Students
Founda , PA
tion 19044
------------------------------------------------------------------------
Monetary Horsham PO Box $1,000 8/5/2016 K9 Program
Neighb 621 Fit Out and
ors Horsham National
Associ , PA Night Out
ation 19044 Celebration
------------------------------------------------------------------------
Monetary Junior 994 Old $7,500 8/18/2016 Junior
Achiev Eagle Achievement
ement School Whole
Of Rd School
Delawa Suite Initiative
re 1014
Valley Wayne,
PA
19087
------------------------------------------------------------------------
Monetary Kids 26071 $3,000 8/30/2016 Support
Connec Merit Groups for
ted Circle, the
#103 Children of
Laguna Cancer
Hills, Patients
CA
92653-
7016
------------------------------------------------------------------------
Monetary Melanom 250 $100 9/30/2016 Memorial
a Maplefl Donation
Intern ower
ationa Road
l Glenmoo
Founda re, PA
tion 19343
------------------------------------------------------------------------
Monetary Metropo 2323 $25,000 12/16/2016 Medically
litan Ranstea Appropriate
Area d Meals for
Neighb Street People with
orhood Philade Critical
Nutrit lphia, Illnesses
ion PA
Allian 19103
ce
(MANNA
)
------------------------------------------------------------------------
Monetary Mitzvah 1561 $300 9/22/2016 Costs
Circle Gehman associated
Founda Road with 2016
tion Harleys Janssen
ville, Cares
PA Volunteer
19438 Activity
------------------------------------------------------------------------
Monetary Mitzvah 1561 $5,000 8/5/2016 Critical
Circle Gehman Needs
Founda Road Support for
tion Harleys Individuals
ville, and
PA Families
19438
------------------------------------------------------------------------
Monetary Montgom 340 $10,000 12/9/2016 The Study of
ery DeKalb Psychology
County Pike as a Guide
Commun Blue to Peer
ity Bell, Mentorship
Colleg PA for BTE--
e 19422 Wissahickon
Founda
tion
------------------------------------------------------------------------
Monetary Montgom 340 $23,811 12/9/2016 Bridge to
ery DeKalb Employment-
County Pike -Wissahicko
Commun Blue n
ity Bell,
Colleg PA
e 19422
Founda
tion
------------------------------------------------------------------------
Monetary Mt. One $50,000 10/18/2016 Overcoming
Sinai Gustave the
Medica L. Levy Barriers to
l Place Clinical
Center Box Care for
1049 Underserved
New Multiple
York, Myeloma
NY Patients
10029
------------------------------------------------------------------------
Monetary Multipl 383 Main $50,000 12/22/2016 MMRF
e Avenue Endurance
Myelom 5th Events
a Floor
Resear Norwalk
ch , CT
Founda 06851
tion
------------------------------------------------------------------------
Monetary Multipl 383 Main $100,000 12/22/2016 2017 MMRF
e Avenue Team for
Myelom 5th Cures 5K
a Floor Walk/Run
Resear Norwalk Program
ch , CT
Founda 06851
tion
------------------------------------------------------------------------
Monetary Multipl 383 Main $275,000 12/22/2016 MMy Ride for
e Avenue a Cure
Myelom 5th
a Floor
Resear Norwalk
ch , CT
Founda 06851
tion
------------------------------------------------------------------------
Monetary Multipl 383 Main $40,000 12/23/2016 MMRF Patient
e Avenue Support
Myelom 5th Center
a Floor
Resear Norwalk
ch , CT
Founda 06851
tion
------------------------------------------------------------------------
Monetary Multipl 51 Locus $100,000 2/23/2016 2016 MMRF
e Avenue Team for
Myelom Suite Cures 5K
a 201 Walk/Run
Resear Norwalk Program
ch , CT
Founda 06851
tion
------------------------------------------------------------------------
Monetary Multipl 383 Main $50,000 3/7/2016 2016 MMRF
e Avenue Team for
Myelom 5th Cures
a Floor Endurance
Resear Norwalk Events
ch , CT Program
Founda 06851
tion
------------------------------------------------------------------------
Monetary Nationa 4950 $2,500 4/15/2016 Run/Walk to
l York Break the
Ovaria Rd, Silence on
n Unit Ovarian
Cancer 631 Cancer
Coalit Holicon
ion g, PA
Inc. 18928
------------------------------------------------------------------------
Monetary Nationa 6600 SW $50,000 5/3/2016 2016 Team
l 92nd NPF Walk
Psoria Ave.,
sis #300
Founda Portlan
tion d, OR
97223
------------------------------------------------------------------------
Monetary NET 499 N. $1,125 3/4/2016 Employee
Treatm 5th directed
ent St., donation in
Servic Suite A lieu of
es Philade company
lphia, holiday
PA gift
19123
------------------------------------------------------------------------
Monetary Philade 1729 $75,000 12/27/2016 STEAM Mural
lphia Mount Initiative
Mural Vernon
Arts Street
Progra Philade
m lphia,
PA
19130
------------------------------------------------------------------------
Monetary Project 1515 $1,000 12/16/2016 Mental
HOME Fairmou Health and
nt Recovery
Avenue Services
Philade
lphia,
PA
19130
------------------------------------------------------------------------
Monetary Prostat 7009 S. $30,000 5/20/2016 Prostate
e Potomac Cancer
Cancer Street Disparities
Educat Suite Outreach
ion 125 Program
Counci Centenn
l ial, CO
80112
------------------------------------------------------------------------
Monetary Prostat 500 $50,000 2/8/2016 Partnerships
e Victory for
Health Road Education,
Educat Quincy, Support and
ion MA Outreach
Networ 02170
k Inc.
------------------------------------------------------------------------
Monetary Reach 89 South $5,000 12/21/2016 Preparing
Out Street, Families
and Suite for School
Read 201 Success
Boston,
MA
02111
------------------------------------------------------------------------
Monetary Rebuild 4355 $5,000 4/12/2016 Mantua Block
ing Orchard Build 2016
Togeth Street
er Suite
Philad 2R
elphia Philade
lphia,
PA
19124
------------------------------------------------------------------------
Monetary Regiona 30 $100 6/10/2016 Memorial
l Milesto Donation
Hospic ne Road
e and Danbury
Home , CT
Care 06810
Center
------------------------------------------------------------------------
Monetary Retired 901 East $7,000 5/23/2016 RSVP's
and 8th America
Senior Street Reads/
Volunt Suite Writes and
eer 200 Protege One-
Progra King of on-One
m of Prussia Mentoring
Montgo , PA Programs.
mery 19406
County
------------------------------------------------------------------------
Monetary Retired 901 East $10,000 12/15/2016 RSVP's
and 8th Family
Senior Street Literacy
Volunt Suite Volunteer
eer 200 Program
Progra King of (FLVP) and
m of Prussia My Free
Montgo , PA Tutor (MFT)
mery 19406 virtual
County STEM
tutoring
and career
awareness
Program.
------------------------------------------------------------------------
Monetary Riverbe 1950 $6,000 8/5/2016 Outreach to
nd Spring Children/
Enviro Mill Access to
nmenta Road Nature/
l Gladwyn Norristown
Educat e, PA Area School
ion 19035 District
Center
------------------------------------------------------------------------
Monetary Sandy 2010 $2,000 12/14/2016 Sandy Sprint
Rollma West Superhero
n Chester 5K or 10K
Ovaria Pike, Run/Walk
n Suite
Cancer 410
Founda Haverto
tion, wn, PA
Inc. 19083
------------------------------------------------------------------------
Monetary SARC 24 Frank $9,500 9/22/2016 General
Lloyd Operating
Wright Support--We
Drive A/ bsite
3100 PO
Box 406
Ann
Arbor,
MI
48105
------------------------------------------------------------------------
Monetary Special 2800 $300 9/22/2016 Costs
Equest Street associated
rians Road with 2016
P.O. Janssen
Box Cares
1001 Volunteer
Warring Activity
ton, PA
18976
------------------------------------------------------------------------
Monetary Special 2800 $4,000 10/10/2016 Special
Equest Street Equestrians
rians Road Equine-
P.O. Assisted
Box Learning
1001 and
Warring Therapeutic
ton, PA Riding
18976 Program
------------------------------------------------------------------------
Monetary Starfin 4015 $10,000 4/19/2016 Starfinder's
der Main Soccer,
Founda Street Education,
tion Philade and
lphia, Leadership
PA Development
19127 Programs
for Youth
------------------------------------------------------------------------
Monetary The The $12,000 4/19/2016 Family Care
Childr Childre Binder
en's n's Program
Hospit Hospita
al of l of
Philad Philade
elphia lphia
Founda Foundat
tion ion
Attn:
Staci
Carney,
Associa
te
Directo
r,
Corpora
te and
Foundat
ion
Relatio
ns 100
Penn
Square
East
8th
Floor,
Suite
8050
Philade
lphia,
PA
19107
------------------------------------------------------------------------
Monetary The The $5,000 4/12/2016 Child Life,
Childr Childre Education,
en's n's and
Hospit Hospita Creative
al of l of Arts
Philad Philade Therapy
elphia lphia Program
Founda Foundat
tion ion
Attn:
Staci
Carney,
Associa
te
Directo
r,
Corpora
te and
Foundat
ion
Relatio
ns 100
Penn
Square
East
8th
Floor,
Suite
8050
Philade
lphia,
PA
19107
------------------------------------------------------------------------
Monetary The 222 $10,000 12/26/2016 Corporate
Frankl North Membership
in 20th
Instit St.
ute Philade
lphia,
PA
19103
------------------------------------------------------------------------
Monetary The 622 $2,000 8/18/2016 General
Giving Evans Operating
Tree Road PO Support
Box 823 with an
Gwynedd emphasis on
Valley, the Public
PA Educational
19437 Giving
Events
------------------------------------------------------------------------
Monetary The 2600 $10,000 3/24/2016 Hubert J.P.
Melmar Wayland Schoemaker
k Road Classic
Charit Berwyn,
able PA
Founda 19312
tion
------------------------------------------------------------------------
Monetary The 400 $600 9/19/2016 Costs
Pennsb Pennsbu associated
ury ry with 2016
Societ Memoria Janssen
y l Road Cares
Morrisv Volunteer
ille, Activity
PA
19067
------------------------------------------------------------------------
Monetary The 775 E $9,500 8/5/2016 Sarcoma
Sarcom Blithed Alliance
a ale General
Allian #334 Support
ce Mill
Valley,
CA
94941
------------------------------------------------------------------------
Monetary Trustee 3025 $5,000 12/26/2016 WXPN
s Of Walnut Musicians
The Street On Call
Univer Philade
sity lphia,
Of PA
Pennsy 19104
lvania
------------------------------------------------------------------------
Monetary Turning 415 $5,000 4/12/2016 Families and
Points South Schools
For 15th Together
Childr Street (FAST)
en Philade Program
lphia,
PA
19146
------------------------------------------------------------------------
Monetary United 1709 $245,879 12/19/2016 Impact Fund
Way of Benjami Greater
Southe n Philadelphi
astern Frankli a, PA and
Pennsy n Southern,
lvania Parkway NJ
Philade
lphia,
PA
19103
------------------------------------------------------------------------
Monetary Youth 949 $5,000 12/9/2016 The Youth
Rally Chestnu Rally--a
Commit t Oak camp for
tee Dr St. kids/teens
Inc. Charles living with
, MO conditions
63303 affecting
the bowel
(Crohn's
Disease and
UC) and
bladder
systems.
------------------------------------------------------------------------
Monetary Zero 2000 $50,000 4/21/2016 ZERO
The Joseph Prostate
Projec E Cancer Run/
t To Sanker Walk
End BLVD National
Prosta Norwood Series--Nat
te , OH ionwide
Cancer 45212
------------------------------------------------------------------------
Janssen has also made financial donations to independent charitable
foundations that assist patients who are underinsured and in financial
need with treatment-related expenses. In keeping with our donor
agreements and applicable regulatory guidance, we will only disclose
aggregate data on our charitable giving and do not publicize
information on donations to specific foundations and disease states.
In 2016, we contributed $47 million in donations to independent
charitable foundations, enabling them to provide assistance with
medication-related copays to patients with cancer and autoimmune
diseases.
----------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------
Product Johnson & Johnson One Johnson & $71,016,839 3/31/2016 Patient Assistance
Patient Assistance Johnson Plaza New Product Donation
Foundation Brunswick, NJ 08933
----------------------------------------------------------------------------------------------------------------
Product Johnson & Johnson One Johnson & $58,963,086 6/30/2016 Patient Assistance
Patient Assistance Johnson Plaza New Product Donation
Foundation Brunswick, NJ 08934
----------------------------------------------------------------------------------------------------------------
Product Johnson & Johnson One Johnson & $60,107,176 9/30/2016 Patient Assistance
Patient Assistance Johnson Plaza New Product Donation
Foundation Brunswick, NJ 08935
----------------------------------------------------------------------------------------------------------------
Product Johnson & Johnson One Johnson & 99,129,337 $12/31/2016 Patient Assistance
Patient Assistance Johnson Plaza New Product Donation
Foundation Brunswick, NJ 08936
----------------------------------------------------------------------------------------------------------------
Updated March 30, 2017
Janssen Pharmaceuticals, Inc. Monetary and Product Contribution to U.S.-
based Charitable Organizations Full Year 2016
(Payments made from January 1, 2016 to December 31, 2016)
------------------------------------------------------------------------
Project
Donation Payee Payee Payment Amount Payment Title/
Type Address (USD) Date Description
------------------------------------------------------------------------
Monetary 180 1 $1,000 12/15/2016 2NDFLOOR
Turnin Bethany Youth
g Road, Helpline
Lives Buildin Hunterdon,
Around g 3 Mercer, and
Inc. Suite Somerset
42 Operations
Hazlet,
NJ
07730
------------------------------------------------------------------------
Monetary Alzheim 225 N. $5,000 12/15/2016 Comfort Zone
er's Michiga Program
Associ n Support
ation Avenue
Chicago
, IL
60601
------------------------------------------------------------------------
Monetary America 4100 $20,000 12/7/2016 General
n Alpha mission
Diabet Road, support
es Suite
Associ 100
ation Dallas,
TX
75244
------------------------------------------------------------------------
Monetary America 1160 $10,000 7/11/2016 What Can I
n Route Eat?
Diabet 22
es East,
Associ Suite
ation 103
Bridgew
ater,
NJ
08807
------------------------------------------------------------------------
Monetary America PO Box $30,000 12/23/2016 Atrial
n 541 Fibrillatio
Founda Greenwo n Patient
tion od, TX Education
For 76246 and Support
Womens
Health
------------------------------------------------------------------------
Monetary America 1 Union $5,000 12/23/2016 Garden State
n Street Go Red For
Heart Suite Women
Associ 301 Luncheon
ation- Robbins
-New ville,
Jersey NJ
08691
------------------------------------------------------------------------
Monetary America 1000 $100,000 12/15/2016 Typical or
n Wilson Troubled?
Psychi Blvd, School-
atric Suite Based
Founda 1825 Mental
tion Arlingt Health
on, VA Education
22209 Program
------------------------------------------------------------------------
Monetary America 1000 $200,000 12/15/2016 Judges' and
n Wilson Psychiatris
Psychi Blvd, ts'
atric Suite Leadership
Founda 1825 Initiative
tion Arlingt previously
on, VA known as
22209 Judges'
Leadership
Initiative
(JLI)
------------------------------------------------------------------------
Monetary America 1000 $35,000 12/15/2016 Partnership
n Wilson for
Psychi Blvd, Workplace
atric Suite Mental
Founda 1825 Health
tion Arlingt
on, VA
22209
------------------------------------------------------------------------
Monetary America 150 $300 9/27/2016 Costs
's Pittsto associated
Grow-A- wn Road with 2016
Row, Pittsto Janssen
Inc. wn, NJ Cares
08867 Volunteer
Activity
------------------------------------------------------------------------
Monetary Anchor 482 $743 1/19/2016 General
House, Centre Operating
Inc. Street Support
Trenton
, NJ
08611
------------------------------------------------------------------------
Monetary Anderso PO Box $20,000 12/7/2016 Integrated
n 134 532 Care
House Route Management
523
Whiteho
use
Station
, NJ
08889
------------------------------------------------------------------------
Monetary Ann 595 W. $9,500 12/15/2016 Improving
Silver State Patient
man Street Self-Care
Commun Doylest and
ity own, PA Management
Health 18901 of Chronic
Clinic Illnesses
at a Free
Clinic for
the
Uninsured.
------------------------------------------------------------------------
Monetary Arbor 211 $75 5/17/2016 Employee
Day North directed
Founda 12th St donation in
tion Lincoln lieu of
, NE company
68508 holiday
gift
------------------------------------------------------------------------
Monetary Arc of 141 $3,000 9/28/2016 Day Care
Somers South subsidies
et Main for at risk
County Street children
Manvill and
e, NJ children
08835 with
disabilitie
s
------------------------------------------------------------------------
Monetary Asian 180 W $2,000 4/6/2016 Cardiovascul
Health Washing ar Health
Coalit ton St Screenings
ion Suite for Low-
1000 Income at-
Chicago risk Asians
, IL Immigrants
60602 and
Refugees in
Chicago
------------------------------------------------------------------------
Monetary Bay 66 Canal $5,000 6/24/2016 Bay Cove
Cove Street Wellness
Human Boston, Center
Servic MA
es, 02114
Inc.
------------------------------------------------------------------------
Monetary Bear 1162 $750 12/15/2016 The Bear
Tavern Bear Tavern
Parent Tavern Science
s Road Fair
Associ Titusvi
ation lle, NJ
08560
------------------------------------------------------------------------
Monetary Bear 1162 $750 3/1/2016 Bear Tavern
Tavern Bear Elementary
Parent Tavern School
s Road Science
Associ Titusvi Fair
ation lle, NJ
08560
------------------------------------------------------------------------
Monetary Big 2875 $6,500 11/18/2016 STEM School
Brothe York Mentoring
rs Big Road Initiative
Sister Jamison
s of , PA
Bucks 18929
County
------------------------------------------------------------------------
Monetary Big 535 East $7,500 11/18/2016 Youth
Brothe Frankli Mentoring
rs Big n Programs
Sister Street
s of Trenton
Mercer , NJ
County 08610
------------------------------------------------------------------------
Monetary Boys 212 $20,000 12/15/2016 Extended Day
and Centre Learning
Girls Street
Club Trenton
of , NJ
Trento 08611
n and
Mercer
County
------------------------------------------------------------------------
Monetary Bristol 120 $7,500 12/15/2016 ArtRageous
Rivers Radclif Theatre
ide fe Arts
Theate Street Education
r Co Bristol Program
Inc. , PA
19007
------------------------------------------------------------------------
Monetary Broward 305 SE $15,000 8/4/2016 Affordable
County 18th Housing
Commun Court program
ity Fort
Develo Lauderd
pment ale, FL
Corpor 33316
ation
, Inc.
------------------------------------------------------------------------
Monetary Bucks 1069 $5,000 12/15/2016 Veterans
County Jackson Housing
Housin ville Assistance
g Road Program
Group Ivyland
, PA
18974
------------------------------------------------------------------------
Monetary Califor 2015 $25,000 4/11/2016 Using
nia Steiner Community
Pacifi Street Health
c San Workers to
Medica Francis increase
l co, CA underserved
Center 94115 patients'
Founda ability to
tion manage type
2 diabetes.
------------------------------------------------------------------------
Monetary Caminar 2600 S. $7,500 4/12/2016 Bridges to
El Wellness
Camino
Real,
Suite
200 San
Mateo,
CA
94403
------------------------------------------------------------------------
Monetary Cardiov PO Box $5,000 3/31/2016 25th Annual
ascula 54632 Lansdale
r Philade Internation
Instit lphia, al Spring
ute of PA Festival
Philad 19148
elphia
------------------------------------------------------------------------
Monetary Catholi 25 Ikea $4,000 12/22/2016 Catholic
c Drive Charities,
Charit Westham Diocese of
ies pton, Trenton On
NJ My Own--
08060 Supportive
Housing
Program
Services
------------------------------------------------------------------------
Monetary Catholi 25 Ikea $15,000 12/22/2016 Partners in
c Drive Recovery
Charit Westham program
ies pton,
NJ
08060
------------------------------------------------------------------------
Monetary Catholi 212 $75 1/19/2016 Employee
c Ninth directed
Charit Street donation in
ies Pittsbu lieu of
Dioces rgh, company
e of Pennsyl holiday
Pittsb vania gift
urgh 15222
------------------------------------------------------------------------
Monetary Catholi 920 $4,000 11/18/2016 CYO's Broad
c South St. Trenton
Youth Broad Center
Organi Street After
zation Trenton School
of , NJ Program
Mercer 08611 (ASP)
County Tutoring
Project
------------------------------------------------------------------------
Monetary Catholi 920 $600 10/19/2016 Costs
c South associated
Youth Broad with 2016
Organi Street Janssen
zation Trenton Cares
of , NJ Volunteer
Mercer 08611 Activity--(
County 2
Activities)
------------------------------------------------------------------------
Monetary Center 11 $10,000 10/24/2016 Community
for Minneak Based Work
Educat oning Assessments
ional Road
Advanc Fleming
ement ton, NJ
08822
------------------------------------------------------------------------
Monetary Center 11 $300 11/3/2016 Costs
for Minneak associated
Educat oning with 2016
ional Road Janssen
Advanc Fleming Cares
ement ton, NJ Volunteer
08822 Activity
------------------------------------------------------------------------
Monetary Childre 635 $300 11/19/2016 Costs
n's South associated
Home Clinton with 2016
Societ Avenue Janssen
y of Trenton Cares
New , NJ Volunteer
Jersey 08611 Activity
------------------------------------------------------------------------
Monetary Childre 635 $10,000 11/22/2016 CUNA and
n's South Body and
Home Clinton Soul
Societ Avenue Prenatal
y of Trenton Health
New , NJ Education
Jersey 08611 Program
------------------------------------------------------------------------
Monetary Clevela 9500 $25,000 8/19/2016 Diabetes
nd Euclid Center
Clinic Ave. Educational
Educat Clevela Initiatives
ional nd, OH at
Founda 44195 Cleveland
tion Clinic
South
Pointe
Hospital
------------------------------------------------------------------------
Monetary College 50 Milk $20,000 12/21/2016 Establishing
Diabet St 16th Best
es Floor Practices,
Networ Boston, Policies,
k Inc. MA and
02109 Interventio
ns
------------------------------------------------------------------------
Monetary College 2000 $20,000 11/22/2016 Nursing
of New Penning Merit
Jersey ton Scholarship
Road s ($7,500)
P.O. and
Box Educational
7718 Opportunity
Ewing, Fund
NJ Promise
08628 Awards
($12,500)
------------------------------------------------------------------------
Monetary College 2000 $5,000 11/22/2016 TCNJ Stress
of New Penning Management
Jersey ton and Mental
Road Health Days
P.O.
Box
7718
Ewing,
NJ
08628
------------------------------------------------------------------------
Monetary Colorad 915 E. $3,000 8/9/2016 Wellness
o 9th Recovery
Mental Avenue Action
Wellne Denver, Planning
ss CO Program
Networ 80218
k
------------------------------------------------------------------------
Monetary Communi PO Box $5,000 12/15/2016 Rise Summer
ty 88 116 Healthy
Action North Food
Servic Main Initiative
e Street for low
Center Hightst income
, Inc. own, NJ youth.
08520
------------------------------------------------------------------------
Monetary Communi 4059 $5,000 3/1/2016 Arts for
ty Skyron Seniors
Conser Drive ($3,000)
vatory Doylest and Music
of own, PA Therapy
Music 18902 ($2,000)
------------------------------------------------------------------------
Monetary Communi PO Box $250,000 12/21/2016 Janssen
ty 338 Pharmaceuti
Founda Morrist cal
tion own, NJ Companies
of New 07963 Contributio
Jersey n Fund
------------------------------------------------------------------------
Monetary Communi PO Box $60,000 12/21/2016 HealtheVoice
ty 338 s Impact
Founda Morrist Fund
tion own, NJ
of New 07963
Jersey
------------------------------------------------------------------------
Monetary Communi PO Box $125,000 12/7/2016 Healthcare
ty 338 and Basic
Founda Morrist Needs Fund
tion own, NJ
of New 07963
Jersey
------------------------------------------------------------------------
Monetary Communi 315 $75 5/27/2016 Employee
ty Losher directed
Founda Street donation in
tion Suite lieu of
of 100 Company
Northw Hernand Holiday
est o, MS gift
Missis 38632
sippi
------------------------------------------------------------------------
Monetary Communi 959 $2,000 3/10/2016 General
ty Route Operating
Hope, 46 Support
Inc. East,
Suite
402
Parsipp
any, NJ
07054
------------------------------------------------------------------------
Monetary Communi 959 $15,000 11/15/2016 Hope for
ty Route Veterans
Hope, 46 and Valley
Inc. East, Brook
Suite Village for
402 Veterans
Parsipp
any, NJ
07054
------------------------------------------------------------------------
Monetary Communi 959 $11,000 5/16/2016 Pathway to
ty Route Recovery
Hope, 46 Residential
Inc. East, Programs
Suite ($10,000)
402 The Annual
Parsipp Forum and
any, NJ Wellness
07054 Fair
($1,000)
------------------------------------------------------------------------
Monetary Compeer 259 $2,500 5/30/2016 Youth and
Roches Monroe Family
ter, Avenue Mentoring--
Inc. Rochest Family Peer
er, NY Advocate
14607 Services
------------------------------------------------------------------------
Monetary Contact 60 South $1,000 10/20/2016 Fundraising
of Main event
Mercer Street support to
County Penning benefit
New ton, NJ general
Jersey 08534 mission of
Inc. organizatio
n
------------------------------------------------------------------------
Monetary Contact 60 South $8,500 12/15/2016 Crisis and
Of Main Suicide
Mercer Street Prevention
County Penning HOTLINES,
New ton, NJ Telephone
Jersey 08534 and Online:
Inc. Crisis Chat
and
TxtToday
------------------------------------------------------------------------
Monetary CONTACT P.O. Box $3,500 4/12/2016 Training
We 2376 Nonprofessi
Care, Westfie onals in
Inc. ld, NJ Crisis
07091 Interventio
n for
People
Experiencin
g Psychosis
------------------------------------------------------------------------
Monetary Court 1450 $15,000 12/15/2016 CASA of
Appoin Parksid Mercer
ted e County
Specia Avenue, Child
l Suite Advocacy
Advoca 22 Program for
tes Ewing, Abused and
NJ Neglected
08638- Children
2946
------------------------------------------------------------------------
Monetary Curtain 1483 $5,000 12/19/2016 Deaf and
Up Rte. Hard of
Produc 179 Hearing
tions Lambert Access for
Inc. ville, Curtain Up
NJ Productions
08530
------------------------------------------------------------------------
Monetary Daytop 80 West $2,000 11/15/2016 Work
Villag Main St Readiness
e Of Mendham
New , NJ
Jersey 07945
Inc.
------------------------------------------------------------------------
Monetary Deborah 212 $2,000 11/14/2016 2017 Women's
Hospit Trenton Heart
al Road Health
Founda Browns Symposium
tion Mills,
NJ
08015
------------------------------------------------------------------------
Monetary Delawar 14 $300 10/19/2016 Costs
e Michael associated
River McCorri with 2016
Steamb stin Janssen
oat Road Cares
Floati Hamilto Volunteer
ng n, NJ Activity
Classr 08690
oom,
Inc.
------------------------------------------------------------------------
Monetary Depress C/O $750 3/1/2016 DBSA NJ
ion David Annual
and Mizenko Conference
Bipola 5 for Support
r Village Group
Suppor Ct Participant
t Lawrenc s--July,
Allian eville, 2016
ce NJ
08648
------------------------------------------------------------------------
Monetary Depress C/O $750 3/1/2016 DBSA NJ
ion David Mutual Aid
and Mizenko Support
Bipola 5 Group
r Village Facilitator
Suppor Ct Training--M
t Lawrenc arch, 2016
Allian eville,
ce NJ
08648
------------------------------------------------------------------------
Monetary Desert 1695 N. $3,500 5/16/2016 Quality of
Aids Sunrise Life and
Projec Way Wellness
t Palm Interventio
Springs ns for
, CA Desert AIDS
92262 Project
Clients
Living with
Schizophren
ia or
Schizoaffec
tive
Disorder
------------------------------------------------------------------------
Monetary Diabete 319 N. $24,000 12/22/2016 Diabetes
s Weber Sisters'
Sister Road, Minority
s pmb Initiative
#163 Program
Bolingb
rook,
IL
60490
------------------------------------------------------------------------
Monetary Direct 27 S. La $4,600 2/18/2016 Support to
Relief Patera improve the
Lane lives of
Santa people
Barbara affected by
, CA poverty or
93117 emergency
situations
by
mobilizing
and
providing
essential
medical
resources
needed for
their care
------------------------------------------------------------------------
Monetary Dress 3131 $9,000 10/11/2016 Women's
for Princet Empowerment
Succes on Pike Programs
s Bldg 4;
Suite
209
Lawrenc
eville,
NJ
08648
------------------------------------------------------------------------
Monetary Eden 2 $9,500 12/15/2016 Adult
Autism Merwick Employment
Servic Road Program
es Princet
Founda on, NJ
tion 08540
------------------------------------------------------------------------
Monetary Emory 49 Jesse $25,000 10/24/2016 Emory Latino
Univer Hill Diabetes
sity Jr. Dr Education
Atlanta Program
, GA (ELDEP)
30303
------------------------------------------------------------------------
Monetary Enable, 13 $3,000 9/12/2016 Fundraising
Inc. Roszel event
Road, support to
Suite benefit
B110 general
Princet mission of
on, NJ organizatio
08540 n
------------------------------------------------------------------------
Monetary Enable, 13 $7,500 12/15/2016 Enable
Inc. Roszel Connect--Ca
Road, mpus
Suite Volunteer
B110 Program
Princet
on, NJ
08540
------------------------------------------------------------------------
Monetary Every Fred $9,000 12/15/2016 Every Child
Child Vereen, Valued
Valued Jr. (ECV) After
A NJ Communi School
Nonpro ty Program
fit Center
Corpor 175
ation Johnson
Avenue
Lawrenc
eville,
NJ
08648
------------------------------------------------------------------------
Monetary Everybo 707 $7,500 12/15/2016 Coming Up
dy Alexand for AIRTM
Loves er
Kenny Road,
Projec Suite
t Inc. 208 PO
Box
3127
Princet
on, NJ
08543
------------------------------------------------------------------------
Monetary Family 1931 $10,000 12/21/2016 Family
Guidan Notting Campus
ce ham Way Project--Ho
Center Hamilto meFront
Corpor n, NJ Collaborati
ation 08619 on
------------------------------------------------------------------------
Monetary Family 1931 $600 10/19/2016 Costs
Guidan Notting associated
ce ham Way with 2016
Center Hamilto Janssen
Corpor n, NJ Cares
ation 08619 Volunteer
Activities
------------------------------------------------------------------------
Monetary Family 1 AAA $14,790 12/13/2016 Center on
Resour Dr. Nutrition
ce Suite and
Networ 203 Disability-
k Trenton -Diabetes
, NJ Prevention
08691 and Self
Management
Program
------------------------------------------------------------------------
Monetary Family 4 $10,000 12/15/2016 Nurse
Servic Corners Educator
e tone for
Associ Drive Homeless
ation Langhor Shelter
of ne, PA
Bucks 19047
County
------------------------------------------------------------------------
Monetary Federat One $2,000 4/11/2016 Big Nosh
ion of Farming Vocational
Organi dale Services
zation Road Program
s West
Babylon
, NY
11704
------------------------------------------------------------------------
Monetary Feed Central $75 1/19/2016 Employee
More, Virgini directed
Inc. a Food donation in
Bank lieu of
1415 company
Rhoadmi holiday
ller gift
Street
Richmon
d, VA
23220
------------------------------------------------------------------------
Monetary Feeding National $32,200 2/18/2016 Domestic
Americ Office hunger
a 35 East relief
Wacker efforts--me
Drive al program
Suite
2000
Chicago
, IL
6618
------------------------------------------------------------------------
Monetary Fleming 110 $300 9/15/2016 Costs
ton Broad associated
Area Street with 2016
Food Box 783 Janssen
Pantry Fleming Cares
ton, NJ Volunteer
08822 Activity
------------------------------------------------------------------------
Monetary Foundat 2381 $2,500 12/15/2016 Funding
ion of Lawrenc support for
Morris eville the 2017
Hall/ Road Philly Pops
St. Lawrenc Benefit
Lawren eville, Concert
ce NJ
08648
------------------------------------------------------------------------
Monetary Foundat 2381 $7,000 12/15/2016 Music and
ion of Lawrenc Memory
Morris eville
Hall/ Road
St. Lawrenc
Lawren eville,
ce NJ
08648
------------------------------------------------------------------------
Monetary Fountai 425 West $6,000 9/13/2016 2016 Mad
n 47th About Art
House Street Auction and
New Benefit
York,
NY
10036
------------------------------------------------------------------------
Monetary Fountai 425 West $1,000 3/11/2016 Silver
n 47th sponsor
House Street Fountain
New House One-
York, in-Four 5K--
NY April 9,
10036 2016
------------------------------------------------------------------------
Monetary From 1455 $12,500 8/4/2016 N.O.S. Film
The Mandala Project
Heart y Beach
Produc Road
tions Oxnard
Inc. Shores,
CA
93035
------------------------------------------------------------------------
Monetary Gateway 11901 $10,000 5/19/2016 Community
Homes, Reedy Reintegrati
Inc. Branch on:
Road PO Maximizing
Box 460 Work
Chester Readiness
field, and
VA Independenc
23838 e for Those
with
Schizophren
ia and
Schizoaffec
tive
Disorder
------------------------------------------------------------------------
Monetary Georgia 246 $1,500 8/4/2016 Consumer
Mental Sycamor Scholarship
Health e St. s to attend
Consum Suite the 25th
er 260 Annual
Networ Decatur Statewide
k , GA Consumer
30030 Conference
------------------------------------------------------------------------
Monetary Girl 1171 $2,000 12/23/2016 Science,
Scouts Route Technology,
Heart 28 Engineering
of New North and Math
Jersey Branch, (STEM)
, Inc. NJ Program
08876
------------------------------------------------------------------------
Monetary Grounds 80 $7,500 12/15/2016 Wellness
for Sculpto Walks/
Sculpt rs Way Wellness
ure Hamilto Talks for
n, NJ Fixed
08619 Income
Seniors
------------------------------------------------------------------------
Monetary Habitat 31 Oak $5,000 12/15/2016 Women Build
for Ave and Repair
Humani Chalfon Homes that
ty of t, PA Strengthen
Greate 18914 Families
r
Bucks
------------------------------------------------------------------------
Monetary Habitat 212 Yost $500 11/3/2016 Costs
for Bouleva associated
Humani rd with 2016
ty of Suite A Janssen
Greate Pittsbu Cares
r rgh, PA Volunteer
Pittsb 15221 Activity
urgh
------------------------------------------------------------------------
Monetary HARK, 5 $2,000 12/15/2016 Scholarships
Inc. Pirozzi for low-
Lane income
Hillsbo participant
rough, s in Girls
NJ on the Run
08844 of Central
New Jersey
------------------------------------------------------------------------
Monetary Heartla 4750 N. $7,500 5/30/2016 Pathways
nd Sherida Home
Health n Road
Outrea Chicago
ch , IL
60640
------------------------------------------------------------------------
Monetary Henders 4740 $7,500 4/12/2016 Helping
on North Individuals
Behavi State Live Longer
oral Road 7 (HILL)
Health Lauderd
ale
Lakes,
FL
33319
------------------------------------------------------------------------
Monetary Henry 321 $7,500 12/21/2016 Decreasing
J. North Opioid Use
Austin Warren through
Health Street Patient
Center Trenton Empowerment
, Inc. , NJ and
08618 Chiropracto
r Services
------------------------------------------------------------------------
Monetary His 20000 NW $600 1/18/2016 Employee
House 47th directed
Childr Avenue donation in
en's Hector lieu of
Home Buildin company
g No. 2 holiday
Develop gift
ment
Departm
ent
Miami
Gardens
, FL
33055
------------------------------------------------------------------------
Monetary HiTops, 21 $7,500 9/12/2016 HiTOPS'
Inc. Wiggins Sexual
Street Health
Princet Interventio
on, NJ ns for
08540 Youth-at-
Risk
------------------------------------------------------------------------
Monetary Holiday 968 $4,000 9/29/2016 Holiday
Expres Shrewsb Express
s Inc. ury Central
Avenue Jersey
Tinton Charity
Falls, Concert
NJ Series
07724
------------------------------------------------------------------------
Monetary HomeFro 1880 $2,500 9/12/2016 Fundraising
nt Princet event
on support to
Avenue benefit
Lawrenc general
eville, mission of
NJ organizatio
08648 n
------------------------------------------------------------------------
Monetary HomeFro 1880 $10,000 10/26/2016 Breaking the
nt Princet Cycle of
on Poverty for
Avenue Homeless
Lawrenc Families
eville,
NJ
08648
------------------------------------------------------------------------
Monetary HomeFro 1880 $300 10/20/2016 Costs
nt Princet associated
on with 2016
Avenue Janssen
Lawrenc Cares event
eville,
NJ
08648
------------------------------------------------------------------------
Monetary Hopewel 35 $750 12/15/2016 Hopewell
l Princet Elementary
Elemen on School
tary Avenue Science
School Hopewel Fair
Parent l, NJ
Teache 08525
r
Organi
zation
Inc.
------------------------------------------------------------------------
Monetary Hopewel PO Box $6,500 12/15/2016 (1) College
l 553 Scholarship
Valley Penning ($1,000)
Educat ton, NJ (2)
ion 08534 Hopewell
Founda Valley HOSA
tion ($500) (3)
Teaching
the Stars--
Using
Starlab to
enhance
curricula
in the
HVRSD
($5,000)
------------------------------------------------------------------------
Monetary Hopewel PO Box $1,000 5/2/2016 Scholarship
l 553 support
Valley Penning
Educat ton, NJ
ion 08534
Founda
tion
------------------------------------------------------------------------
Monetary Hopewel 48 $2,000 12/21/2016 Hopewell
l Orchard Valley
Valley Ave PO Rides
Senior Box 567
Founda Penning
tion ton, NJ
08534
------------------------------------------------------------------------
Monetary Hunterd 7 Lower $7,500 12/21/2016 Artistic
on Art Center Expressions
Center Street Program
Clinton
, NJ
08809
------------------------------------------------------------------------
Monetary Hunterd 1410 $2,500 11/9/2016 YMCA Comedy
on Route Night
County 22 West
YMCA Annanda
le, NJ
08801
------------------------------------------------------------------------
Monetary Hunterd 9100 $100 1/19/2016 Memorial
on Wescott Donation
Health Drive
care Suite
Founda 202
tion Fleming
ton, NJ
08822
------------------------------------------------------------------------
Monetary Hunterd 111 Mine $2,000 12/15/2016 Dvoor Farm
on Street Public
Land Fleming Access
Trust ton, NJ Enhancement
08822
------------------------------------------------------------------------
Monetary HVRSD C/O $5,000 12/22/2016 Playground
Specia Pupil resurfacing
l Service project
Educat s 425 Stonybrook
ion South Elementary
PtO Main
Street
Penning
ton, NJ
08534
------------------------------------------------------------------------
Monetary Interfa 3635 $15,000 10/26/2016 Neighbors
ith Quakerb Helping
Caregi ridege Neighbors
vers Road, Program
Trento Suite (NHN)
n, 16
Inc. Hamilto
n, NJ
08619
------------------------------------------------------------------------
Monetary Isles, 10 Wood $9,000 12/15/2016 Trenton
Inc. Street Healthy
Trenton Homes
, NJ
08618
------------------------------------------------------------------------
Monetary Jewish 707 $7,500 11/22/2016 Mercer
Family Alexand County
and er Caregiver
Childr Road, Support
en's Suite Initiative
Servic 102
e of Princet
Greate on, NJ
r 08540
Mercer
County
------------------------------------------------------------------------
Monetary Jewish 707 $7,500 11/22/2016 Senior
Family Alexand Outreach
and er Service
Childr Road,
en's Suite
Servic 102
e of Princet
Greate on, NJ
r 08540
Mercer
County
------------------------------------------------------------------------
Monetary Jewish 707 $600 10/19/2016 Costs
Family Alexand associated
and er with 2016
Childr Road, Janssen
en's Suite Cares
Servic 102 Volunteer
e of Princet Activities
Greate on, NJ
r 08540
Mercer
County
------------------------------------------------------------------------
Monetary Junior 360 Pear $7,150 12/21/2016 Junior
Achiev Blossom Achievement
ement Drive program in
of New Edison, Trenton
Jersey NJ Schools
08837
------------------------------------------------------------------------
Monetary Lafayet 1214 $30,000 1/6/2016 The Healthy
te Coolidg Heart
Genera e Fairs: EKG
l Street to
Medica Lafayet Survivorshi
l te, LA p Program
70503
------------------------------------------------------------------------
Monetary Latin 669 $5,000 12/16/2016 Welcome
Americ Chamber House
an s St Community
Legal Suite B Center
Defens Trenton
e And , NJ
Educat 08611
ional
Fund
Inc.
------------------------------------------------------------------------
Monetary Lawrenc PO Box $3,900 12/15/2016 Mobile
e 6531 17 Makerspaces
Townsh Philips to create,
ip Ave. build,
Educat Lawrenc tinker,
ion eville, fail and
Founda NJ think
tion 08648 critically
Inc. from
elementary
classrooms
in Lawrence
Township,
NJ.
------------------------------------------------------------------------
Monetary Leyden 10001 W $8,500 5/16/2016 Affordable
Family Grand Supportive
Servic Ave Housing for
e and Frankli Individuals
Mental n Park, with
Health IL Serious
Center 60131 Mental
Illness
------------------------------------------------------------------------
Monetary Literac PO Box $5,000 12/21/2016 Early
y And 55636 Childhood:
Life Trenton Building
Inc. , NJ Blocks for
08638 the Future
------------------------------------------------------------------------
Monetary Literac 100 $5,000 12/22/2016 Women
y New Menlo Empowered
Jersey Park
Inc. Dr.
#314
Edison,
NJ
08837
------------------------------------------------------------------------
Monetary Literac 120 $4,000 12/15/2016 Let's Talk
y Findern About
Volunt e Ave-- Health
eers Box 7
of Bridgew
Somers ater,
et NJ
County 08807
------------------------------------------------------------------------
Monetary Main 8 $4,000 4/12/2016 Accessible
Street Marcell Mental
Counse a Health Care
ling Avenue for
Center West Schizoaffec
Orange, tive
NJ Disorder
07052
------------------------------------------------------------------------
Monetary Massach 15 $3,500 2/9/2016 Changing
usetts Vernon Minds and
Clubho Street Expanding
use Waltham Employment
Coalit , MA Campaign
ion 02453
------------------------------------------------------------------------
Monetary McCarte 91 $10,000 11/22/2016 OnStage
r Univers Seniors: A
Theatr ity Community
e Place Project of
Center Princet McCarter
on, NJ Theatre
08540
------------------------------------------------------------------------
Monetary Meals 5 Walter $300 11/3/2016 Costs
On Foran associated
Wheels Blvd with 2016
In Suite Janssen
Hunter 2006 Cares
don Fleming Volunteer
Inc. ton, NJ Activity
08822
------------------------------------------------------------------------
Monetary Meals 1501 $75 5/23/2016 Employee
On Sunset directed
Wheels Ave donation in
of Rocky lieu of
Rocky Mount, company
Mount NC holiday
Inc. 27804 gift
------------------------------------------------------------------------
Monetary Meals 320 $15,000 10/26/2016 Meals on
on Hollowb Wheels
Wheels rook Program
of Drive
Trento Ewing,
n NJ
Ewing 08638
------------------------------------------------------------------------
Monetary Mental 500 $90,000 12/15/2016 Social Self-
Health Montgom Directed
Americ ery St. Care (SSDC)
a Suite
820
Alexand
ria, VA
22314
------------------------------------------------------------------------
Monetary Mental 2211 $7,500 6/21/2016 Mental
Health Norfolk Health
Americ , Suite Community
a of 810 and
Greate Houston Legislative
r , TX Advocacy
Housto 77098
n
------------------------------------------------------------------------
Monetary Mental 2323 W $10,000 5/27/2016 Get
Health 5th Connected
Americ Ave. program
a of Suite
Frankl 160
in Columbu
County s, OH
43204
------------------------------------------------------------------------
Monetary Mental 8280 $2,500 8/24/2016 2016 Florida
Health Princet Mental
Americ on Health
a Of Square Summit
Northe Blvd.
ast W.
Florid Suite 8
a Inc. Jackson
ville,
FL
32256
------------------------------------------------------------------------
Monetary Mental 1210 San $2,500 5/16/2016 Mental
Health Antonio Health
Americ , Suite Education
a of 200 and
Texas Austin, Advocacy
TX Campaign
78701
------------------------------------------------------------------------
Monetary Mental 100 W. $1,000 8/9/2016 Bronze
Health 10th sponsor
Associ St. 2016 E-
ation Ste. Racing the
in 600 Blues for
Delawa Wilming Mental
re ton, DE Health--Oct
19801 ober 30,
2016
------------------------------------------------------------------------
Monetary Mental 100 W. $2,000 10/18/2016 Community
Health 10th Mental
Associ St. Health
ation Ste. Conference
in 600 2016:
Delawa Wilming Bridging
re ton, DE the Gaps--
19801 Through
Resources
and
Networking
------------------------------------------------------------------------
Monetary Mental 673 $10,000 8/4/2016 MHANJ Access
Health Morris to Mental
Associ Avenue, Health Care
ation Suite
in New 100
Jersey Springf
ield,
NJ
07081
------------------------------------------------------------------------
Monetary Mental 617 $2,500 4/21/2016 Operating
Health Garden Support for
Associ Street the Mental
ation Santa Wellness
in Barbara Center's
Santa , CA Fellowship
Barbar 93101 Club
a
County
------------------------------------------------------------------------
Monetary Mental 3701 $7,500 5/16/2016 ParentVOICE
Health Latrobe
Associ Drive,
ation Suite
Of 140
Centra Charlot
l te, NC
Caroli 28211
nas
Inc.
------------------------------------------------------------------------
Monetary Mental 1301 $10,000 8/4/2016 Citizens
Health York Action
Associ Road, Team:
ation Suite Engaging
of 505 Consumers
Maryla Lutherv of
nd, ille, Behavioral
Inc. MD Health in
21093 Healthcare
Reform
Initiatives
------------------------------------------------------------------------
Monetary Mental 580 $1,000 3/15/2016 Bronze
Health White sponsor MHA
Associ Plains on the
ation Road Move: Run/
of Suite Walk--May
Westch 510 1, 2016
ester Tarryto
wn, NY
10591
------------------------------------------------------------------------
Monetary Mental 555 N $3,500 6/24/2016 Access to
Health Woodlaw Care Fund
Associ n, Ste.
ation 3105
Reside Wichita
ntial , KS
Care 67208
Inc.
------------------------------------------------------------------------
Monetary Mental 3809 $12,500 8/4/2016 Outreach and
Illnes Rosewoo Behavioral
s d Drive Healthcare
Recove PO Box for
ry 4246 Homeless
Center Columbi Individuals
, Inc. a, SC with Mental
29240 Illness
------------------------------------------------------------------------
Monetary Mercer 1001 $9,500 12/15/2016 Implementing
Allian Spruce a Plan to
ce to Street, End Chronic
End Suite Homelessnes
Homele 205 s in the
ssness Trenton Trenton/
, NJ Mercer
08638 Community:
Utilizing
assertive
engagement,
permanent
housing and
healthcare
access to
achieve
this goal
------------------------------------------------------------------------
Monetary Mercer P.O. Box $16,680 12/15/2016 Mercer
County 17202 Student
Commun Trenton Competency
ity , NJ in Optical
Colleg 08690 Examination
e (M-SCOPE)
Founda
tion
------------------------------------------------------------------------
Monetary Mercer 151 $20,000 10/26/2016 Mercer
Street Mercer Street
Friend Street Friends
s Trenton Food Bank
, NJ
08611
------------------------------------------------------------------------
Monetary Mercer 151 $300 10/19/2016 Costs
Street Mercer associated
Friend Street with 2016
s Trenton Janssen
, NJ Cares
08611 Volunteer
Activity
------------------------------------------------------------------------
Monetary Metropo 945 $5,000 7/20/2016 Supported
litan Fawcett Employment
Develo Ave.
pment Tacoma,
Counci WA
l 98402
------------------------------------------------------------------------
Monetary Middle P.O. Box $15,000 11/15/2016 Outreach
Earth 8045 Program and
520 Community
North Youth
Bridge Centers
Street
Bridgew
ater,
NJ
08807
------------------------------------------------------------------------
Monetary MIDJers 423 $5,000 10/26/2016 Urban Youth
ey Rivervi Employment
Center ew Program
for Plaza
Econom Trenton
ic , NJ
Develo 08611
pment
------------------------------------------------------------------------
Monetary Midland 60 $6,500 9/28/2016 Midland
Adult Industr Helping
Servic ial Hands
es Parkway Employment
Inc. PO Box Training
5026 Program.
North
Branch,
NJ
08876
------------------------------------------------------------------------
Monetary Millhil 101 $5,000 10/26/2016 Trenton Area
l Oakland Stakeholder
Child Street s
and Trenton
Family , NJ
08618
------------------------------------------------------------------------
Monetary Millhil 101 $15,000 10/26/2016 Millhill
l Oakland Trenton
Child Street PEERS
and Trenton
Family , NJ
08618
------------------------------------------------------------------------
Monetary Minding 2083 $6,000 12/15/2016 Minding Our
Our Lawrenc Business
Busine eville Summer
ss Road Program: A
Inc. Lawrenc Bridge to
eville, the Future
NJ for Mercer
08648 County Low-
Income
Youth
------------------------------------------------------------------------
Monetary Minding 2083 $6,000 5/2/2016 Minding Our
Our Lawrenc Business
Busine eville Summer
ss Road Program: A
Inc. Lawrenc Bridge to
eville, the Future
NJ for Mercer
08648 County Low-
Income
Youth
------------------------------------------------------------------------
Monetary Morven 55 $5,000 12/15/2016 Internship
Museum Stockto for At-Risk
and n Youth
Garden Street
Princet
on, NJ
08540
------------------------------------------------------------------------
Monetary Mount 73 North $15,000 9/15/2016 In Home
Carmel Clinton Health
Guild Avenue Nursing
Trenton Program
, NJ
08609
------------------------------------------------------------------------
Monetary NAMI 4161 NW $1,000 4/18/2016 Bronze
Browar 5 St, sponsor
d Suite NAMIWalks
County 203 Broward
, Inc. Plantat County--Nov
ion, FL ember 12,
33317 2016
------------------------------------------------------------------------
Monetary NAMI 8324 $1,000 3/21/2016 Bronze
Cook Skokie sponsor
County Blvd NAMI CCNS
North 420 Walk--Septe
Suburb Frontag mber 18,
an e Road 2016
Northfi
eld
Skokie,
IL
60077
------------------------------------------------------------------------
Monetary NAMI 2400 W. $1,000 3/15/2016 Bronze
Delawa 4th St. sponsor
re Wilming NAMIWalks
ton, DE Delaware--M
19805 ay 7, 2016
------------------------------------------------------------------------
Monetary NAMI 3371 $2,500 3/1/2016 Silver
Mercer Brunswi sponsor
NJ ck 2016 NAMI
Pike, Mercer
Suite Walk--May
124 7, 2016
Lawrenc
eville,
NJ
08648
------------------------------------------------------------------------
Monetary NAMI 3371 $10,000 9/15/2016 NAMI Mercer
Mercer Brunswi Education
NJ ck and Support
Pike, Programs
Suite
124
Lawrenc
eville,
NJ
08648
------------------------------------------------------------------------
Monetary NAMI 85 N. $1,000 9/7/2016 Bronze
New State sponsor
Hampsh Street 2016
ire Concord NAMIWalks
, NH New
03301 Hampshire--
October 2,
2016
------------------------------------------------------------------------
Monetary NAMI of 115 $8,000 8/9/2016 Peer Support
DuPage North Specialist
County County Program
Illino Farm
is Road
Wheaton
, IL
60187
------------------------------------------------------------------------
Monetary NAMI of 2701 $4,000 8/24/2016 General
Johnso Rochest Program
n er Support/
County Avenue Finds
dba Iowa Friends/
Compee City, Volunteer
r of IA Recruitment
Johnso 52245
n
County
------------------------------------------------------------------------
Monetary NAMI of One $1,500 8/4/2016 Start to
Lake Victori Finish
County a Sq., sponsor
Ste. NAMI Lake
260 County
Painesv Strides for
ille, Awareness
OH NAMI Walk--
44077 August 20,
2016
------------------------------------------------------------------------
Monetary NAMI of 100 W, $1,000 3/15/2016 Bronze
PA Main sponsor
Montgo St. Greater
mery Suite Philadelphi
County 204 a
Lansdal NAMIWalks--
e, PA May 14,
19446 2016
------------------------------------------------------------------------
Monetary NAMI of 4055 $2,500 5/4/2016 Hope for
Southw Executi Recovery
est ve Park Pilot
Ohio Drive,
Suite
450
Cincinn
ati, OH
45241
------------------------------------------------------------------------
Monetary NAMI 1750 S. $1,000 3/15/2016 Kilometer
St. Brentwo sponsor
Louis od NAMIWalks
Blvd. St. Louis--
Suite May 28,
511 St. 2016
Louis,
MO
63144
------------------------------------------------------------------------
Monetary NAMI PO Box $1,000 4/19/2016 Bronze
Summit 462 sponsor
County Cuyahog 2016
a NAMIWalks
Falls, Summit
OH County--Oct
44222 ober 22,
2016
------------------------------------------------------------------------
Monetary NAMI 217 $1,000 5/27/2016 Bronze
Waukes Wiscons sponsor
ha in Ave 2016
Suite NAMIWalks
300 Waukesha--P
Waukesh 9/17/16
a, WI
53186
------------------------------------------------------------------------
Monetary Nationa 90 Park $2,500 5/16/2016 Meet the
l Avenue Scientist
Allian 16th Monthly
ce for Floor Webinar
Resear New Series
ch on York,
Schizo NY
phreni 10016
a and
Depres
sion
------------------------------------------------------------------------
Monetary Nationa 90 Park $2,500 5/16/2016 28th New
l Avenue York Mental
Allian 16th Health
ce for Floor Research
Resear New Symposium
ch on York,
Schizo NY
phreni 10016
a and
Depres
sion
------------------------------------------------------------------------
Monetary Nationa 1851 $2,500 2/9/2016 Bronze
l Heritag sponsor
Allian e Lane, 2016 NAMI
ce for Suite California
the 150 Annual
Mental Sacrame Conference
ly Ill nto, CA
95815
------------------------------------------------------------------------
Monetary Nationa The $1,000 3/15/2016 Bronze
l Schraff sponsor
Allian t's NAMIWalks
ce for Center Mass--May
the 529 14, 2016
Mental Main
ly Ill Street,
Suite
1M17
Boston,
MA
02129
------------------------------------------------------------------------
Monetary Nationa 3250 $1,000 3/15/2016 Bronze
l Wilshir sponsor
Allian e NAMIWalks
ce for Blvd., Los Angeles
the Suite County--Oct
Mental 1501 ober 1,
ly Ill Los 2016
Angeles
, CA
90010
------------------------------------------------------------------------
Monetary Nationa 2812 $1,000 5/16/2016 Bronze
l Swiss sponsor
Allian Avenue Dallas
ce for Dallas, NAMIWalk--M
the TX ay 14, 2016
Mental 75204
ly Ill
------------------------------------------------------------------------
Monetary Nationa 1706 $1,000 3/15/2016 Bronze
l Brady sponsor
Allian Street NAMIWalks
ce for Suite Greater
the 101 Mississippi
Mental Davenpo Valley--Sep
ly Ill rt, IA tember 24,
52803 2016
------------------------------------------------------------------------
Monetary Nationa PO Box $1,000 8/4/2016 NAMIFest
l 4096 2016--2 Day
Allian Alvin, Educational
ce for TX Conference
the 77512
Mental
ly Ill
------------------------------------------------------------------------
Monetary Nationa 1225 $7,500 2/9/2016 The Year of
l Dublin the
Allian Road, Affiliate:
ce for Suite Strengtheni
the 125 ng NAMI's
Mental Columbu Voice in
ly Ill s, OH Ohio's
43215 Local
Communities
------------------------------------------------------------------------
Monetary Nationa 1562 $1,000 2/2/2016 Bronze
l Route sponsor
Allian 130 2016 NAMI
ce for North Walks New
the Brunswi Jersey,
Mental ck, NJ ``Step
ly Ill 08902 Forward for
Our
Heroes''
------------------------------------------------------------------------
Monetary Nationa 5095 $1,000 2/2/2016 Bronze
l Murphy sponsor
Allian Canyon 2016 NAMI
ce for Road Walk
the Suite
Mental 320 San
ly Ill Diego,
CA
92123
------------------------------------------------------------------------
Monetary Nationa 3200 S. $1,000 2/9/2016 Bronze
l 3rd sponsor
Allian Street, 2016
ce for Unit 6 NAMIWalks
the Milwauk Greater
Mental ee, WI Milwaukee
ly Ill 53207
------------------------------------------------------------------------
Monetary Nationa 2601 $2,500 2/9/2016 Supporting
l Cold sponsor
Allian Spring NAMI
ce for Road Indiana's
the P.O. 13th Annual
Mental Box Mental
ly Ill 22697 Health and
Indiana Criminal
polis, Justice
IN Summit
46222
------------------------------------------------------------------------
Monetary Nationa 576 $1,500 2/9/2016 Bronze
l Farming sponsor
Allian ton 2016 NAMI
ce for Avenue Walk
the Hartfor
Mental d, CT
ly Ill 06105
------------------------------------------------------------------------
Monetary Nationa PO Box $1,000 5/27/2016 Platinum
l 550039 sponsor
Allian Birming 2016 NAMI
ce for ham, AL Birmingham
the 35255- Walk for
Mental 0039 Mental
ly Ill Health--9/
17/16
------------------------------------------------------------------------
Monetary Nationa 1536 $8,000 6/24/2016 Honest,
l West Open, Proud
Allian Chicago to erase
ce for Ave the stigma
the Chicago of mental
Mental , IL illness
ly Ill 60642
------------------------------------------------------------------------
Monetary Nationa 1562 $2,500 11/18/2016 2016 NAMI NJ
l Route Conference:
Allian 130 ``Building
ce for North Better
the Brunswi Lives''
Mental ck, NJ
ly Ill 08902
------------------------------------------------------------------------
Monetary Nationa 3333 $1,000 12/14/2016 Pink Ribbon
l West Sponsor--20
Allian Pensaco 17
ce for la Blueberry
the Street Horseshoe
Mental Suite 5k--Februar
ly Ill 250 y 19, 2017
Tallaha
ssee,
FL
32302-0
961
------------------------------------------------------------------------
Monetary Nationa 99 Pine $4,000 12/1/2016 2016 NAMI-
l St. NYS
Allian Suite Education
ce for 302 Conference
the Albany,
Mental NY
ly Ill 12207
------------------------------------------------------------------------
Monetary Nationa 3803 N. $75,000 12/15/2016 Strengthenin
l Fairfax g CIT
Allian Drive
ce for Suite
the 100
Mental Arlingt
ly Ill on, VA
22203
------------------------------------------------------------------------
Monetary Nationa 3803 N. $50,000 12/15/2016 NAMI
l Fairfax Helpline
Allian Drive
ce for Suite
the 100
Mental Arlingt
ly Ill on, VA
22203
------------------------------------------------------------------------
Monetary Nationa 2012 $5,000 6/24/2016 Mental
l West Illness
Allian 25th Education
ce for Street,
the #600
Mental Clevela
ly nd, OH
Ill--G 44113
reater
Clevel
and
------------------------------------------------------------------------
Monetary Nationa 2012 $1,000 3/15/2016 Bronze
l West sponsor
Allian 25th NAMIWalks--
ce for Street, August 27,
the #600 2016
Mental Clevela
ly nd, OH
Ill--G 44113
reater
Clevel
and
------------------------------------------------------------------------
Monetary Nationa 3839 $1,000 3/15/2016 Bronze
l Merle sponsor
Allian Hay NAMIWalks
ce for Road, Iowa--Septe
the Suite mber 24,
Mental 226 Des 2016
ly Moines,
Ill--I IA
owa 50310
------------------------------------------------------------------------
Monetary Nationa 505 8th $1,000 3/15/2016 Bronze
l Avenue, sponsor
Allian Ste NAMIWalks
ce for 1103 NYC--May 7,
the New 2016
Mental York,
ly Ill NY
of New 10018
York
City
------------------------------------------------------------------------
Monetary Nationa 1981 $1,000 11/11/2016 Bronze
l Marcus sponsor
Allian Ave NAMIWalks
ce for Suite Long Island/
the C117 Queens May
Mental Lake 6, 2017
ly Ill Success
Queens/ , NY
Nassau 11042
------------------------------------------------------------------------
Monetary Nationa 5963 $1,000 7/20/2016 Bronze
l Boymel sponsor
Allian Dr. NAMIWalks
ce on Fairfie Butler
Mental ld, OH County--Oct
Illnes 45014 ober 8,
s 2016
------------------------------------------------------------------------
Monetary Nationa 324A $1,000 3/15/2016 NAMI Walk--
l Springf May 15,
Allian ield 2016
ce on Street
Mental Agawam,
Illnes MA
s 01001
Wester
n
Mass.,
Inc.
------------------------------------------------------------------------
Monetary Nationa P O Box $6,000 5/3/2016 29th Annual
l Art 350891 NAEMI Art
Exhibi Miami, Exhibition
tions FL
of the 33135
Mental
ly
Ill,
Inc.
------------------------------------------------------------------------
Monetary Nationa 1400 K $75,000 12/15/2016 Policy
l St NW, Action
Counci #400 Center
l for Washing
Behavi ton, DC
oral 20005
Health
------------------------------------------------------------------------
Monetary Nationa 1400 K $75,000 12/15/2016 Early Onset
l St NW, Psychosis
Counci #400 Community
l for Washing of Practice
Behavi ton, DC
oral 20005
Health
------------------------------------------------------------------------
Monetary Nationa 1400 K $75,000 12/15/2016 Health
l St NW, Justice
Counci #400 Learning
l for Washing Collaborati
Behavi ton, DC ve
oral 20005
Health
------------------------------------------------------------------------
Monetary Nationa 949 W. $7,500 12/15/2016 Academic
l State Creative
Junior Street Engagement
Tennis Trenton (ACE)
and , NJ Program and
Learni 08618 Science
ng of Technology
Trento Engineering
n Arts Math
(STEAM)
Pilot
Program
------------------------------------------------------------------------
Monetary Nationa 9707 E $20,000 12/22/2016 Stroke
l Easter Recovery
Stroke Lane, Navigator
Associ Suite B
ation Centenn
ial, CO
80112
------------------------------------------------------------------------
Monetary Nationa 9707 E $30,000 12/22/2016 National
l Easter Stroke
Stroke Lane, Awareness
Associ Suite B Month
ation Centenn
ial, CO
80112
------------------------------------------------------------------------
Monetary New 275 Rt. $4,000 4/12/2016 NJPC NJ
Jersey 10 East Youth
Parent Suite Caucus
s 220-414 (Formerly
Caucus Succasu known as NJ
nna, NJ Youth
07876 Coalition)
------------------------------------------------------------------------
Monetary NewBrid 7 $2,000 6/24/2016 NewBridge
ge Industr Day
Servic ial Treatment
es, Road Progam for
Inc. P.O. Adults
Box 336
Pequann
ock, NJ
07440
------------------------------------------------------------------------
Monetary Northea 2900 $2,500 7/12/2016 Day of
st Conner Restoration
Guidan Avenue, -assistance
ce Buildin for
Center g A Detroit's
Detroit Homeless
, MI with Mental
48215 Illness
------------------------------------------------------------------------
Monetary NorthSh 1033 $10,000 12/22/2016 Clot Aware
ore Univers Support
Univer ity Group
sity Place
Health Suite
system 450
Evansto
n, IL
60201
------------------------------------------------------------------------
Monetary Ohio 33 N. $2,500 3/21/2016 Ohio's 2016
Associ High Recovery
ation Street, Conference:
of Ste. Recovery Is
County 500 Beautiful
Behavi Columbu
oral s, OH
Health 43215
Author
ities
------------------------------------------------------------------------
Monetary Pancrea 1500 $100 2/15/2016 Memorial
tic Rosecra Donation
Cancer ns Ave,
Action Suite
Networ 200
k Manhatt
an
Beach,
CA
90266
------------------------------------------------------------------------
Monetary Passage PO Box $7,500 12/15/2016 Support for
Theatr 967 the State
e Trenton Street
Compan , NJ Project
y Inc. 08605
------------------------------------------------------------------------
Monetary PEI 231 $17,500 10/26/2016 Comprehensiv
Kids Lawrenc e Juvenile
e Road Offenders
Lawrenc Outreach
eville, Services
NJ
08648
------------------------------------------------------------------------
Monetary PEI 231 $300 10/20/2016 Costs
Kids Lawrenc associated
e Road with 2016
Lawrenc Janssen
eville, Cares event
NJ
08648
------------------------------------------------------------------------
Monetary People 295 $2,500 11/18/2016 Reading
And Eggerts Deeply in
Storie Crossin Community:
s--Gen g Road A
te Y Lawrenc Literature
Cuento eville, Project for
s Inc. NJ Mercer
08648 County
Youth and
Seniors
------------------------------------------------------------------------
Monetary Places 4130 $100 3/3/2016 Memorial
for Lindell Donation
People Blvd.
, Inc. St.
Louis,
MO
63108
------------------------------------------------------------------------
Monetary Planned P.O. Box $5,000 4/12/2016 Life
Living 4755 Planning
Assist Austin, Program
ance TX
Networ 78765
k of
Centra
l
Texas
------------------------------------------------------------------------
Monetary Positiv 1411 N. $75 3/1/2016 Donation in
e Westsho lieu of
Coachi re company
ng Blvd. holiday
Allian Suite gift
ce 205
Tampa
Bay, FL
33607
------------------------------------------------------------------------
Monetary Princet 15 $50,000 12/21/2016 Bridge to
on Princes Employment
Area s Road program
Commun Lawrenc
ity eville,
Founda NJ
tion, 08648
Inc.
------------------------------------------------------------------------
Monetary Princet P.O. Box $2,500 12/15/2016 PGC
on 145 190 Afterschool
Girl Nassau Music
Choir Street, Outreach
Lower Program
Level
Princet
on, NJ
08542
------------------------------------------------------------------------
Monetary Princet 123 E. $10,000 12/15/2016 Hunger
on Hanover Prevention
Outrea St. and
ch Trenton Nutrition
Projec , NJ Education
ts / 08608 ($7,500.00)
Crisis Healthy
Minist Living and
ry of Housing
Mercer Stability
County Services
($2,500.00)
------------------------------------------------------------------------
Monetary Princet 45 $4,000 12/15/2016 Family
on Stockto Caregiver
Senior n St Conference:
Resour Princet Family
ce on, NJ Caregiving:
Center 08540 Compassion
for Self
and Others
------------------------------------------------------------------------
Monetary Princet 575 $3,500 12/15/2016 BRAVO!
on Ewing Trenton
Sympho Street Initiative
ny Princet
Orches on, NJ
tra 08540
------------------------------------------------------------------------
Monetary Princet 13 $7,500 12/15/2016 Summer
on- Roszel Bridge
Blairs Road, 2017--Trent
town Suite on
Center C204A
Inc. Princet
on, NJ
08540
------------------------------------------------------------------------
Monetary Printma 440 $5,000 12/22/2016 Roving Press
king River
Center Road
of New Branchb
Jersey urg, NJ
08876
------------------------------------------------------------------------
Monetary Printma 440 $15,000 12/8/2016 Combat Paper
king River NJ
Center Road
of New Branchb
Jersey urg, NJ
08876
------------------------------------------------------------------------
Monetary Raritan P. O. $7,000 12/15/2016 WaterWays
Headwa Box 273 Environment
ters Gladsto al
Associ ne, NJ Education
ation 07934 Program
------------------------------------------------------------------------
Monetary Raritan 118 $20,000 10/24/2016 Promoting
Valley Lamingt Access to
Commun on Rd STEM and
ity Branchb Nursing
Colleg urg, NJ Education
e 08844 at Raritan
Valley
Community
College
------------------------------------------------------------------------
Monetary Recover 3423 $15,000 5/16/2016 Healthy
y Covingt Start Pilot
Consul on Program--(M
tants Drive, ental
Of Suite B Health
Atlant Decatur Portion of
a , GA Program)
Incorp 30032
orated
------------------------------------------------------------------------
Monetary Regions 640 $15,000 5/16/2016 Make It OK,
Hospit Jackson the
al Street, campaign to
Founda MS fight
tion 11202C stigma
St.
Paul,
MN
55101
------------------------------------------------------------------------
Monetary Rescue 98 $25,000 12/16/2016 Emergency
Missio Carroll Services
n of St. PO program
Trento Box 790
n Trenton
, NJ
08605
------------------------------------------------------------------------
Monetary Rider 2083 $19,500 12/6/2016 Summer STEM
Univer Lawrenc ($12,000);
sity eville Scholarship
Road Support
Lawrenc ($5,000);
eville, Shakesperia
NJ n at Rider
08648 ($2,500)
------------------------------------------------------------------------
Monetary Riverbe PO Box $5,000 4/12/2016 InSHAPE
nd 2032 Program
Commun Concord
ity , NH
Mental 03302-
Health 2032
Inc.
------------------------------------------------------------------------
Monetary Riversi 4 South $10,000 12/7/2016 Riverside
de Union Symphonia
Sympho Street Senior
nia P.O. Outreach
Inc. Box 650 Program
Lambert
ville,
NJ
08530
------------------------------------------------------------------------
Monetary Rutgers 4 $124,863 9/19/2016 Corporate
Univer Hunting Social
sity ton Responsibil
School Street ity
of New Fellowship
Commun Brunswi
icatio ck, NJ
n, 08901-
Inform 1071
ation
and
Librar
y
Studie
s
------------------------------------------------------------------------
Monetary SAFE in 47 East $600 9/22/2016 Costs
Hunter Main associated
don Street with 2016
Fleming Janssen
ton, NJ Cares
08822 Volunteer
Activity
------------------------------------------------------------------------
Monetary Saint 436 Port $100 3/28/2016 Memorial
Anthon Reading Donation
y of Avenue
Padua Port
Roman Reading
Cathol , NJ
ic 07064
Church
------------------------------------------------------------------------
Monetary San 2789- $5,000 5/16/2016 MHRC Client
Franci 25th Wellness
sco Street, Enhancement
Genera #2028 Project
l San
Hospit Francis
al co, CA
Founda 94110
tion
------------------------------------------------------------------------
Monetary SAVE A 1010 $600 9/19/2016 Costs
Friend Route associated
to 601 with 2016
Homele Cedar Janssen
ss Lodge Cares
Animal Road Volunteer
s Skillma Activity
n, NJ
08558
------------------------------------------------------------------------
Monetary Schizop 602 Pink $5,000 5/23/2016 Platinum
hrenia Azalea sponsor
and Trl PO 2016
Relate Box symposium
d 941222 and
Disord Houston workshop,
ers , TX ``You are
Allian 77094- NOT Alone''
ce Of 8222 Self-help/
Americ peer
a support
Symposium
and
workshop
------------------------------------------------------------------------
Monetary Scripps 10140 $25,000 12/14/2016 Scripps
Founda Campus Community
tion Point Diabetes
for Drive Programs:
Medici Suite Dulce
ne and 200 San Transitions
Scienc Diego,
e CA
92121
------------------------------------------------------------------------
Monetary Scripps 10140 $30,000 12/14/2016 Scripps
Founda Campus Community
tion Point Diabetes
for Drive and
Medici Suite Prevention
ne and 200 San Programs:
Scienc Diego, Project
e CA Dulce
92121
------------------------------------------------------------------------
Monetary SERV 20 $5,000 9/15/2016 14th Annual
Founda Scotch SERV
tion, Road, Wellness
Inc. 3rd and
Floor Development
Ewing, Conference
NJ
08628
------------------------------------------------------------------------
Monetary SERV 20 $7,500 9/15/2016 SERV
Founda Scotch Foundation
tion, Road, Scholarship
Inc. 3rd Fund
Floor
Ewing,
NJ
08628
------------------------------------------------------------------------
Monetary Shannon PO Box $500 12/14/2016 Shannon
Daley 1271 36 Daley
Memori Indian Memorial
al Run Fund
Fund Whiteho Charity
use Events
Station
, NJ
08889
------------------------------------------------------------------------
Monetary Sharing 1920 $2,000 5/30/2016 1920 Club
Place 10th Art Program
Inc. Avenue
South
PO Box
59455
Birming
ham, AL
35255
------------------------------------------------------------------------
Monetary Shiloh PO Box $5,000 2/18/2016 Family
Commun 398 Wellness
ity Trenton Club--Diabe
Develo , NJ tes and
pment 08603 Chronic
Corpor Disease
ation Self
Management
------------------------------------------------------------------------
Monetary Shiloh PO Box $5,000 12/15/2016 Family
Commun 398 Wellness
ity Trenton Club--Diabe
Develo , NJ tes and
pment 08603 Chronic
Corpor Disease
ation Self
Management
------------------------------------------------------------------------
Monetary Sister 1201 $5,000 9/14/2016 Pearl Grace
Networ Hamilto Breast
k of n Cancer
Centra Street Assistant
l New Somerse Tournament
Jersey t, NJ
, Inc. 08873
------------------------------------------------------------------------
Monetary Somerse 49 $7,500 12/23/2016 Street
t Home Brahma Smart--HIV/
for Avenue AIDS
Tempor P.O. Program
arily Box
Displa 6871
ced Bridgew
Childr ater,
en NJ
08807
------------------------------------------------------------------------
Monetary Somerse 49 $900 12/5/2016 Costs
t Home Brahma associated
for Avenue with 2016
Tempor P.O. Janssen
arily Box Cares
Displa 6871 Volunteer
ced Bridgew Activity
Childr ater,
en NJ
08807
------------------------------------------------------------------------
Monetary Somerse One $20,000 12/13/2016 El Poder
t Rehill Sobre La
Medica Avenue Diabetes--N
l Somervi J Neighbor
Center lle, NJ of Choice
Founda 08876 Program
tion
------------------------------------------------------------------------
Monetary Somervi 51 West $2,000 10/19/2016 A Maker
lle Cliff Space for
Educat Street Every Child
ional P.O.
Founda Box
tion, 8721
Inc. Somervi
lle, NJ
08876
------------------------------------------------------------------------
Monetary St. 1025 $100 3/3/2016 Memorial
Mark Radclif Donation
Church fe
and Street
School Bristol
, PA
19007
------------------------------------------------------------------------
Monetary St. One $15,000 12/21/2016 Providing
Mary Summit Food for
Medica Square, Underserved
l Suite School-Age
Center 300 Children in
Founda 1717 Bucks
tion Langhor County: The
ne- St. Mary
Newtown Backpacks
Road for Kids
Langhor Program
ne, PA
19047
------------------------------------------------------------------------
Monetary Stony 31 Titus $15,000 10/26/2016 StreamWatch
Brook Mill Volunteer
Millst Road Water
one Penning Quality
Waters ton, NJ Monitoring
hed 08534 Program
Associ
ation
------------------------------------------------------------------------
Monetary T-1 8216 $35,000 10/25/2016 Friends for
Today Princet Life
Inc. on- Orlando
Glendal 2017
e Road,
PMB 200
West
Chester
, OH
45069
------------------------------------------------------------------------
Monetary Taking 1110 $35,000 10/25/2016 Taking
Contro Camino Control Of
l of Del Mar Your
Your Suite C Diabetes
Diabet Del (TCOYD)
es Mar, CA Conference
92014 and Health
Fair
------------------------------------------------------------------------
Monetary TASK, 72\1/2\ $25,000 10/26/2016 Trenton Area
Inc. Escher Soup
Street, Kitchen
P.O. Meal
Box 872 Service
Trenton Program
, NJ
08605
------------------------------------------------------------------------
Monetary The Paul $5,000 9/15/2016 Communiversi
Arts Robeson ty ArtsFest
Counci Center 2017
l of for the
Prince Arts
ton 102
Withers
poon
Street
Princet
on, NJ
08542
------------------------------------------------------------------------
Monetary The Paul $10,000 9/15/2016 Arts Council
Arts Robeson of
Counci Center Princeton
l of for the Community
Prince Arts Outreach
ton 102 Programs
Withers
poon
Street
Princet
on, NJ
08542
------------------------------------------------------------------------
Monetary The 2020 $2,000 12/23/2016 Art Classes
Center Burnt for
for Mills Children
Contem Road with Autism
porary Bedmins Spectrum
Art ter, NJ Disorder
07921 and Other
Special
Needs
------------------------------------------------------------------------
Monetary The 19 $12,000 9/14/2016 Support of
Center Dellwoo Adult
For d Lane Women's
Great Somerse Program
Expect t, NJ through a
ations 08873 Program
Grant and
2016 Gift
of Hope
Gala
Sponsorship
------------------------------------------------------------------------
Monetary The 1040 $7,500 8/4/2016 Jail
Edinbu Waltham Diversion
rg Street Program
Center Lexingt
on, MA
02421
------------------------------------------------------------------------
Monetary The 222 $75,000 12/22/2016 Terracotta
Frankl North Warriors:
in 20th Guards for
Instit St. Eternity
ute Philade
lphia,
PA
19103
------------------------------------------------------------------------
Monetary The 1289 $300 9/22/2016 Costs
Legacy Route associated
Treatm 38 West with 2016
ent Suite Janssen
Servic 203 Cares
es Hainesp Volunteer
Founda ort, NJ Activity
tion 08036
------------------------------------------------------------------------
Monetary The 8150 N. $40,000 12/14/2016 HeartGuide--
Mended Central Patient
Hearts Express Resource
, Inc. way and
Suite Visiting
M2248 Program: An
Dallas, Educational
TX and Support
75206 Program for
Patients,
Caregivers
and
Families
Affected by
Heart
Disease
------------------------------------------------------------------------
Monetary The 401 $1,000 4/11/2016 Head Lite
Mental Cypress sponsor 7th
Health Street Annual Lite
Center Manches up the Nite
Of ter, NH Run/Walk
Greate 03103 for Mental
r Health--Jun
Manche e 23, 2016
ster
------------------------------------------------------------------------
Monetary The P.O. Box $7,500 11/18/2016 Opera for
Prince 2063 All
ton Princet
Festiv on, NJ
al 08543
------------------------------------------------------------------------
Monetary The 4101 $20,000 8/23/2016 MindStrong
Thresh North program
olds Ravensw
ood
Avenue
Chicago
, IL
60613
------------------------------------------------------------------------
Monetary The 100 $10,000 8/4/2016 Farm Based
Willia Gould Psychiatric
m J. Road PO Rehabilitat
Gould Box 157 ion and
Associ Montere Recovery
ates, y, MA
Inc. 01245
------------------------------------------------------------------------
Monetary Thomas 111 West $12,000 12/15/2016 Scholarship
Edison State Support for
State Street Nursing
Colleg Trenton Students
e , NJ Enrolled in
Founda 08608 the W. Cary
tion Edwards
School of
Nursing's
Accelerated
Second
Degree BSN
Program at
Thomas
Edison
State
University
------------------------------------------------------------------------
Monetary Tpto 51 South $1,000 9/12/2016 2017
Inc.-- Timberl Timberlane
Timber ane Science and
lane Drive, Engineering
Parent Penning Fair
Teache ton, NJ
r 08534
Organi
zation
------------------------------------------------------------------------
Monetary Trenton 439 S. $7,000 9/12/2016 Second
Commun Broad Semester,
ity Street, Trenton
Music Ste. 90 Community
School Trenton Music
, NJ School
08638
------------------------------------------------------------------------
Monetary Trenton 635 $5,000 12/15/2016 Trenton
Educat South Education
ion Clinton Dance
Dance Avenue Institute
Instit Trenton (TEDI)
ute , NJ
08611
------------------------------------------------------------------------
Monetary Trenton 218 N $15,000 11/22/2016 Navigating
Health Broad for Health
Team St
Inc. Trenton
, NJ
08608
------------------------------------------------------------------------
Monetary Trinity 22 $7,500 12/15/2016 TCS Mental
Counse Stockto Health and
ling n Wellness
Servic Street Program
es Trinity
Counsel
ing
Service
Princet
on, NJ
08540
------------------------------------------------------------------------
Monetary Tuscalo PO Box $1,000 3/30/2016 Supporting
osa 2322 sponsorship
Mental Tuscalo -Hot
Health osa, AL Hundred
Allian 35403 Bicycle
ce Ride--July,
30, 2016
------------------------------------------------------------------------
Monetary Twiligh P.O. Box $7,500 11/9/2016 Simple Needs
t Wish 1042 11 Wish
Founda Duane Granting
tion Road Program
Doylest
own, PA
18901
------------------------------------------------------------------------
Monetary UIH 4 North $9,000 12/15/2016 Community of
Family Broad Health for
Partne Street Men, Year 3
rs 2nd
Floor
Trenton
, NJ
08618-
4408
------------------------------------------------------------------------
Monetary United 9-25 $7,500 11/18/2016 Janssen
Negro Alling Pharmaceuti
Colleg Street cals-
e Fund 2nd Princeton
Floor Committee
Newark, of UNCF
NJ Scholarship
07102
------------------------------------------------------------------------
Monetary United Crossroa $530,664 12/19/2016 Company
Way of ds match to
Greate Corpora employee
r te United Way
Mercer Center campaign
County 3150 for
Brunswi Titusville
ck based
Pike, companies
Suite
230
Lawrenc
eville,
NJ
08648-
2420
------------------------------------------------------------------------
Monetary United 4 Walter $600 11/29/2016 Costs
Way of Foran associated
Hunter Blvd. with 2016
don Fleming Janssen
County ton, NJ Cares
08822 Volunteer
Activity
------------------------------------------------------------------------
Monetary United PO Box $42,219 12/21/2016 Company
Way of 6835 match to
Northe 1011 employee
rn New Route United Way
Jersey 22 campaign
West, less Truist
2nd processing
Floor fee for
Bridgew Raritan
ater, campus
NJ
08807
------------------------------------------------------------------------
Monetary Urbanpr 801 West $3,500 10/26/2016 StreetLeader
omise State Program
Intern Street
ationa Trenton
l Inc. , NJ
08618
------------------------------------------------------------------------
Monetary Valeo 5401 SW $3,500 4/12/2016 Creations of
Behavi 7th Hope: A
oral Street gallery by
Health Topeka, artists
Care KS experiencin
Inc. 66606 g mental
illness
focused on
advocacy
through
art.
------------------------------------------------------------------------
Monetary Volunte 12 $7,500 12/15/2016 SkillsConnec
er Stockto t
Connec n
t Street
Princet
on, NJ
08540
------------------------------------------------------------------------
Monetary Washing P. O. $750 9/12/2016 Educational
ton Box 83 program
Crossi Titusvi support:
ng lle, NJ ``Digging
Park 08560 New Jersey:
Associ Colonial
ation and
Inc. Revolutiona
ry War
Archeology'
' and ``The
Occupation
of Trenton:
December 1-
21, 1776''
------------------------------------------------------------------------
Monetary West PO Box $5,000 11/9/2016 Excellence
Windso 280 in
r West Education
Plains Windsor Grant
boro , NJ Program
Educat 08550-
ion 0280
Founda
tion
------------------------------------------------------------------------
Monetary Womansp 1530 $5,000 11/18/2016 Domestic
ace Brunswi Violence
ck Ave. Shelter
Lawrenc (Safe
eville, House) and
NJ Transitiona
08648 l Housing
(Barbara's
House)
------------------------------------------------------------------------
Monetary Women's 3200 $75 1/19/2016 Employee
Commun Hilltop directed
ity, Avenue donation in
Inc. Wausau, lieu of
WI company
54401 holiday
gift
------------------------------------------------------------------------
Monetary Woods 40 $600 10/24/2016 2016 Janssen
Servic Martin Cares
es Gross Volunteer
Founda Drive Events
tion PO box
36
Langhor
ne, PA
19047
------------------------------------------------------------------------
Monetary Woods 40 $4,000 12/15/2016 Yoga at
Servic Martin Maplewood:
es Gross A Program
Founda Drive for People
tion PO box with Prader-
36 Willi
Langhor Syndrome
ne, PA
19047
------------------------------------------------------------------------
Product AmeriCa 88 $ 1,489,699 4/27/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in Gaza,
Tanzania,
West Bank,
Afghanistan
, USA,
Jamaica,
Nicaragua
------------------------------------------------------------------------
Product AmeriCa 88 $ 1,865,102 4/27/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Afghanistan
, Jamaica,
Nicaragua,
USA
------------------------------------------------------------------------
Product AmeriCa 88 $ 2,283,779 4/27/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Afghanistan
, Armenia,
Nicaragua,
Peru, St.
Lucia, West
Bank
------------------------------------------------------------------------
Product AmeriCa 88 $ 189,778 4/27/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in USA
------------------------------------------------------------------------
Product AmeriCa 88 $ 871,464 5/10/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in USA
------------------------------------------------------------------------
Product AmeriCa 88 $ 3,176,645 5/10/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Afghanistan
, USA,
Armenia,
Nicaragua,
Peru, St.
Lucia, West
Bank
------------------------------------------------------------------------
Product AmeriCa 88 $ 1,347,810 5/10/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Afghanistan
, Armenia,
Nicaragua,
Peru, St.
Lucia, West
Bank
------------------------------------------------------------------------
Product AmeriCa 88 $ 1,482,447 5/10/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Tanzania,
Armenia,
St. Lucia,
Jamaica
------------------------------------------------------------------------
Product AmeriCa 88 $ 133,034 5/10/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in St.
Lucia,
Tanzania,
Afghanistan
------------------------------------------------------------------------
Product AmeriCa 88 $ 15,673 6/8/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Tanzania.
------------------------------------------------------------------------
Product AmeriCa 88 $ 518,523 6/9/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Nicaragua,
Tanzania,
West Bank,
and the US
------------------------------------------------------------------------
Product AmeriCa 88 $ 1,087,540 6/9/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in Gaza,
Sierra
Leone,
Tanzania,
West Bank,
Afghanistan
, and US
------------------------------------------------------------------------
Product AmeriCa 88 $672,076 8/1/2016 Product
res Hamilto Donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in:
Dominican
Republic,
Lebanon,
Palestine
Territory,
Senegal,
St. Lucia,
Guatemala,
Nicaragua
and US
------------------------------------------------------------------------
Product AmeriCa 88 $15,291 8/1/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Guatemala,
Nicaragua,
Dominican
Republic.
------------------------------------------------------------------------
Product AmeriCa 88 $536,094 8/1/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in:
Dominican
Republic,
Lebanon,
Palestine
Territory,
Senegal,
Guatemala,
Nicaragua
------------------------------------------------------------------------
Product AmeriCa 88 $2,923,869 8/1/2016 Product
res Hamilto Donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in:
Dominican
Republic,
Lebanon,
Palestine
Territory,
Senegal,
St. Lucia,
Guatemala,
Nicaragua,
US
------------------------------------------------------------------------
Product AmeriCa 88 $83,360 8/1/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in: Haiti,
Palestine
Territory,
St. Lucia,
Lebanon,
Senegal,
Jamaica
------------------------------------------------------------------------
Product AmeriCa 88 $481,959 8/1/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in:
Guatemala,
Nicaragua,
Palestine
Territory,
Senegal, US
------------------------------------------------------------------------
Product AmeriCa 88 $354,276 9/13/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Colombia,
Lebanon,
Tanzania
and West
Bank.
------------------------------------------------------------------------
Product AmeriCa 88 $589,968 9/13/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor Americares
d, CT US Clinics
06902 Network.
------------------------------------------------------------------------
Product AmeriCa 88 $34,315 9/13/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in Tanzania
and West
Bank.
------------------------------------------------------------------------
Product AmeriCa 88 $114,481 9/13/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Afghanistan
, Colombia,
Tanzania,
and West
Bank
------------------------------------------------------------------------
Product AmeriCa 88 $613,250 9/21/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in US
Clinics.
------------------------------------------------------------------------
Product AmeriCa 88 $6,343,517 9/21/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in Lebanon,
St. Lucia,
West Bank,
Gaza,
Afghanistan
and the US
------------------------------------------------------------------------
Product AmeriCa 88 $807,284 9/21/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Colombia,
West Bank,
Afghanistan
.
------------------------------------------------------------------------
Product AmeriCa 88 $61,169 9/21/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in St.
Lucia.
------------------------------------------------------------------------
Product AmeriCa 88 $1,516,094 9/21/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in West
Bank and
the US
------------------------------------------------------------------------
Product AmeriCa 88 $252,240 9/21/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in US
------------------------------------------------------------------------
Product AmeriCa 88 $292,992 9/21/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in US
Clinics.
------------------------------------------------------------------------
Product AmeriCa 88 $1,270,212 9/21/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in US
Clinics
------------------------------------------------------------------------
Product AmeriCa 88 $641,091 9/21/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in West
Bank and
the US
------------------------------------------------------------------------
Product AmeriCa 88 $113,318 9/13/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Afghanistan
, Colombia,
Tanzania,
West Bank.
------------------------------------------------------------------------
Product AmeriCa 88 $622,686 10/24/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Dominican
Republic.
------------------------------------------------------------------------
Product AmeriCa 88 $42,437 10/24/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in Haiti,
Sierra
Leone,
Ghana.
------------------------------------------------------------------------
Product AmeriCa 88 $555,202 10/24/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in West
Bank, Gaza,
US
------------------------------------------------------------------------
Product AmeriCa 88 $1,321,288 11/17/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in Puerto
Rico
------------------------------------------------------------------------
Product AmeriCa 88 $99,595 11/22/2016 Product
res Hamilto Donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in St.
Lucia and
Colombia
------------------------------------------------------------------------
Product AmeriCa 88 $25,655 11/29/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in West
Bank, Gaza,
Dominican
Republic,
St. Lucia,
Colombia
------------------------------------------------------------------------
Product AmeriCa 88 $151,578 11/29/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Colombia.
------------------------------------------------------------------------
Product AmeriCa 88 $38,160 11/29/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Colombia.
------------------------------------------------------------------------
Product AmeriCa 88 $119,132 11/29/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in West
Bank and
St. Lucia.
------------------------------------------------------------------------
Product AmeriCa 88 $238,579 11/29/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Colombia.
------------------------------------------------------------------------
Product AmeriCa 88 $381,064 11/30/2016 Produce
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Nicaragua.
------------------------------------------------------------------------
Product AmeriCa 88 $86,941 12/22/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Nicaragua
and West
Bank.
------------------------------------------------------------------------
Product AmeriCa 88 $239,612 12/22/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Nicaragua,
St. Lucia.
------------------------------------------------------------------------
Product AmeriCa 88 $46,647 12/22/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Nicaragua.
------------------------------------------------------------------------
Product AmeriCa 88 $10,987 12/22/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in St.
Lucia.
------------------------------------------------------------------------
Product AmeriCa 88 $145,709 12/22/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Dominican
Republic,
Nicaragua,
West Bank
and US
------------------------------------------------------------------------
Product AmeriCa 88 $23,053 12/22/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Dominican
Republic.
------------------------------------------------------------------------
Product AmeriCa 88 $282,912 12/22/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in US
------------------------------------------------------------------------
Product AmeriCa 88 $142,865 12/22/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Afghanistan
,
Nicaragua,
St. Lucia,
and West
Bank.
------------------------------------------------------------------------
Product AmeriCa 88 $212,731 12/22/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Afghanistan
and
Nicaragua.
------------------------------------------------------------------------
Product AmeriCa 88 $54,332 12/22/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Nicaragua
and
Liberia.
------------------------------------------------------------------------
Product AmeriCa 88 $25,485 12/22/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in US
------------------------------------------------------------------------
Product AmeriCa 88 $183,120 12/22/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in the US
------------------------------------------------------------------------
Product AmeriCa 88 $179,712 12/19/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in Romania.
------------------------------------------------------------------------
Product AmeriCa 88 $428,182 12/21/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in St.
Lucia.
------------------------------------------------------------------------
Product AmeriCa 88 $270,923 12/22/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Afghanistan
and
Tanzania.
------------------------------------------------------------------------
Product AmeriCa 88 $30,737 12/22/2016 Product
res Hamilto donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in US
------------------------------------------------------------------------
Product AmeriCa 88 $291,417 12/30/2016 Product
res Hamilto Donation
Founda n Ave for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Dominican
Republic,
Nicaragua,
West Bank,
and US
------------------------------------------------------------------------
Product Catholi 100 Wall $1,167,782 12/22/2016 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in D.R., El
10005 Salvador,
Guatemala,
Haiti,
Honduras.
------------------------------------------------------------------------
Product Catholi 100 Wall $30,737 12/22/2016 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in El
10005 Salvador.
------------------------------------------------------------------------
Product Catholi 100 Wall $30,737 12/22/2016 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in El
10005 Salvador.
------------------------------------------------------------------------
Product Catholi 100 Wall $12,212,928 12/21/2016 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in Haiti,
10005 Honduras,
Jamaica,
Dominican
Republic,
El
Salvador,
Guatemala
------------------------------------------------------------------------
Product Catholi 100 Wall $135,843 12/19/2016 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance.
Board NY
10005
------------------------------------------------------------------------
Product Catholi 100 Wall $43,471 12/22/2016 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in Jamaica.
10005
------------------------------------------------------------------------
Product Catholi 100 Wall $374,394 12/22/2016 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in
10005 Dominican
Republic,
El
Salvador,
Guatemala.
------------------------------------------------------------------------
Product Catholi 100 Wall $42,860 12/22/2016 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in El
10005 Salvador.
------------------------------------------------------------------------
Product Catholi 100 Wall $106,365 12/22/2016 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in El
10005 Salvador.
------------------------------------------------------------------------
Product Catholi 100 Wall $27,166 12/22/2016 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in Jamaica.
10005
------------------------------------------------------------------------
Product Catholi 100 Wall $101,942 12/22/2016 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in El
10005 Salvador.
------------------------------------------------------------------------
Product Catholi 100 Wall $2,140,908 12/22/2016 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in
10005 Dominican
Republic,
El
Salvador,
Guatemala,
Haiti,
Honduras.
------------------------------------------------------------------------
Product Catholi 100 Wall $336,398 12/22/2016 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in
10005 Dominican
Republic,
El
Salvador,
Guatemala.
------------------------------------------------------------------------
Product Catholi 100 Wall $582,322 12/22/2016 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in
10005 Dominican
Republic,
El
Salvador,
Guatemala,
Haiti,
Honduras.
------------------------------------------------------------------------
Product Catholi 100 Wall $2,723,631 12/22/2016 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in
10005 Dominican
Republic,
El
Salvador,
Guatemala,
Haiti,
Honduras.
------------------------------------------------------------------------
Product Catholi 100 Wall $89,706 12/22/2016 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in El
10005 Salvador.
------------------------------------------------------------------------
Product Catholi 100 Wall $43,293 12/1/2016 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in Haiti,
10005 Jamaica and
El
Salvador.
------------------------------------------------------------------------
Product Catholi 100 Wall $223,922 12/1/2016 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in
10005 Guatemala,
Haiti,
Dominican
Republic.
------------------------------------------------------------------------
Product Catholi 100 Wall $218,883 12/1/2016 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in
10005 Guatemala,
Haiti,
Dominican
Republic.
------------------------------------------------------------------------
Product Catholi 100 Wall $41,696 12/1/2016 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in Haiti.
10005
------------------------------------------------------------------------
Product Catholi 100 Wall $26,039,346 12/1/2016 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in
10005 Guatemala,
Haiti,
Dominican
Republic,
El
Salvador.
------------------------------------------------------------------------
Product Catholi 100 Wall $248,988 12/1/2016 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in Haiti.
10005
------------------------------------------------------------------------
Product Catholi 100 Wall $381,604 12/1/2016 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in Haiti
10005 and
Dominican
Republic.
------------------------------------------------------------------------
Product Catholi 100 Wall $361,008 12/1/2016 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in
10005 Guatemala
and Haiti.
------------------------------------------------------------------------
Product Catholi 33-01 $76,321 9/13/2016 Product
c Elevent donation
Medica h for
l Street humanitaria
Missio Long n
n Island assistance
Board City, in Haiti.
NY
------------------------------------------------------------------------
Product Catholi 100 Wall $622,686 10/25/2016 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in El
10005 Salvador,
Guatemala
------------------------------------------------------------------------
Product Catholi 100 Wall $482,784 10/25/2016 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in El
10005 Salvador
and
Guatemala.
------------------------------------------------------------------------
Product Catholi 100 Wall $16,848,000 10/25/2016 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in
10005 Guatemala.
------------------------------------------------------------------------
Product Catholi 33-01 $822,943 9/22/2016 Product
c Elevent donation
Medica h for
l Street humanitaria
Missio Long n relief in
n Island Honduras.
Board City,
NY
------------------------------------------------------------------------
Product Catholi 33-01 $139,387 9/22/2016 Product
c Elevent donation
Medica h for
l Street humanitaria
Missio Long n
n Island assistance
Board City, in
NY Honduras.
------------------------------------------------------------------------
Product Catholi 33-01 $732,675 9/22/2016 Product
c Elevent donation
Medica h for
l Street humanitaria
Missio Long n
n Island assistance
Board City, in
NY Honduras.
------------------------------------------------------------------------
Product Catholi 33-01 $76,696 9/13/2016 Product
c Elevent donation
Medica h for
l Street humanitaria
Missio Long n
n Island assistance
Board City, in Haiti.
NY
------------------------------------------------------------------------
Product Catholi 33-01 $30,737 9/13/2016 Product
c Elevent Donation
Medica h for
l Street humanitaria
Missio Long n
n Island assistance
Board City, in Haiti.
NY
------------------------------------------------------------------------
Product Catholi 33-01 $75,546 9/13/2016 Product
c Elevent donation
Medica h for
l Street humanitaria
Missio Long n
n Island assistance
Board City, in Haiti.
NY
------------------------------------------------------------------------
Product Catholi 33-01 $270,923 9/13/2016 Product
c Elevent donation
Medica h for
l Street humanitaria
Missio Long n
n Island assistance
Board City, in Haiti.
NY
------------------------------------------------------------------------
Product Catholi 33-01 $151,003 9/13/2016 Product
c Elevent donation
Medica h for
l Street humanitaria
Missio Long n
n Island assistance
Board City, in Haiti.
NY
------------------------------------------------------------------------
Product Catholi 100 Wall $275,235 8/1/2016 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in
10005 Guatemala
and
Nicaragua.
------------------------------------------------------------------------
Product Catholi 100 Wall $48,005 8/1/2016 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in
10005 Guatemala
and
Nicaragua.
------------------------------------------------------------------------
Product Catholi 100 Wall $208,481 8/1/2016 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in
10005 Guatemala
and
Nicaragua.
------------------------------------------------------------------------
Product Catholi 100 Wall $1,162,207 8/1/2016 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in
10005 Guatemala
and
Nicaragua.
------------------------------------------------------------------------
Product Catholi 100 Wall $4,168 8/1/2016 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in Jamaica.
10005
------------------------------------------------------------------------
Product Catholi 100 Wall $952,711 8/1/2016 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in
10005 Guatemala
and
Nicaragua.
------------------------------------------------------------------------
Product Catholi 33-01 $15,673 6/8/2016 Product
c Elevent donation
Medica h for
l Street humanitaria
Missio Long n
n Island assistance
Board City, in
NY Nicaragua
------------------------------------------------------------------------
Product Catholi 33-01 $884,080 6/9/2016 Product
c Elevent donation
Medica h for
l Street humanitaria
Missio Long n
n Island assistance
Board City, in
NY Nicaragua
------------------------------------------------------------------------
Product Catholi 33-01 $294,990 6/9/2016 Product
c Elevent donation
Medica h for
l Street humanitaria
Missio Long n
n Island assistance
Board City, in
NY Nicaragua.
------------------------------------------------------------------------
Product Catholi 33-01 $97,026 5/10/2016 Product
c Elevent donation
Medica h for
l Street humanitaria
Missio Long n
n Island assistance
Board City, in
NY Nicaragua
------------------------------------------------------------------------
Product Catholi 33-01 $137,045 5/10/2016 Product
c Elevent donation
Medica h for
l Street humanitaria
Missio Long n
n Island assistance
Board City, in
NY Nicaragua
------------------------------------------------------------------------
Product Catholi 33-01 $561,881 5/10/2016 Product
c Elevent donation
Medica h for
l Street humanitaria
Missio Long n
n Island assistance
Board City, in Armenia,
NY Guatemala,
Honduras,
El Salvador
------------------------------------------------------------------------
Product Catholi 33-01 $3,165,318 5/10/2016 Product
c Elevent donation
Medica h for
l Street humanitaria
Missio Long n
n Island assistance
Board City, in
NY Dominican
Republic,
El
Salvador,
Haiti,
Jamaica
------------------------------------------------------------------------
Product Catholi 33-01 $439,527 4/27/2016 Product
c Elevent donation
Medica h for
l Street humanitaria
Missio Long n
n Island assistance
Board City, in
NY Dominican
Republic,
Haiti,
Jamaica,
Honduras
------------------------------------------------------------------------
Product Catholi 33-01 $864,289 4/27/2016 Product
c Elevent donation
Medica h for
l Street humanitaria
Missio Long n
n Island assistance
Board City, in
NY Dominican
Republic,
Armenia,
Haiti,
Jamaica, El
Salvador
------------------------------------------------------------------------
Product Direct 27 S. La $1,970,703 4/27/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Ecuador,
Guatemala,
Honduras,
Liberia,
Paraguay,
Peru,
Dominican
Republic,
Ghana,
Haiti
------------------------------------------------------------------------
Product Direct 27 S. La $2,216,643 4/27/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Ghana,
Honduras,
Jordan,
Liberia,
Malawi,
Paraguay,
Peru,
Sierra
Leone,
Guatemala,
Haiti
------------------------------------------------------------------------
Product Direct 27 S. La $68,096 4/4/2016 Product
Relief Patera donation
Lane for
Santa disaster
Barbara preparednes
, CA s module
93117
------------------------------------------------------------------------
Product Direct 27 S. La $571,913 4/27/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in
Nicaragua,
Malawi,
Ghana, US
------------------------------------------------------------------------
Product Direct 27 S. La $1,270,853 4/27/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in
Colombia,
Ghana,
Guatemala,
Honduras,.
Jordan,
Paraguay
------------------------------------------------------------------------
Product Direct 27 S. La $172,405 6/8/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in
Dominican
Republic,
Ghana,
Pakistan,
Paraguay.
------------------------------------------------------------------------
Product Direct 27 S. La $3,702,692 5/10/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Guyana,
Armenia
------------------------------------------------------------------------
Product Direct 27 S. La $114,204 5/10/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Guyana
------------------------------------------------------------------------
Product Direct 27 S. La $4,350,366 6/9/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in
Dominican
Republic,
Ghana,
Jamaica,
Pakistan,
Paraguay,
Liberia,
and
Honduras
------------------------------------------------------------------------
Product Direct 27 S. La $2,620,434 6/9/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Ghana,
Haiti,
Paraguay,
Somaliland,
Dominican
Republic,
Honduras,
Jamaica,
Malawi,
Pakistan,
Rwanda.
------------------------------------------------------------------------
Product Direct 27 S. La $20,006 8/2/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Haiti.
------------------------------------------------------------------------
Product Direct 27 S. La $91,508 9/7/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in the
Dominican
Republic.
------------------------------------------------------------------------
Product Direct 27 S. La $1,368,726 9/7/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in
Dominican
Republic,
Guyana,
Fiji.
------------------------------------------------------------------------
Product Direct 27 S. La $30,737 9/7/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in
Nicaragua.
------------------------------------------------------------------------
Product Direct 27 S. La $812,768 9/7/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in
Dominican
Republic.
------------------------------------------------------------------------
Product Direct 27 S. La $300,317 9/7/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in
Dominican
Republic
and Guyana.
------------------------------------------------------------------------
Product Direct 27 S. La $572,406 9/7/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in
Dominican
Republic
and Guyana.
------------------------------------------------------------------------
Product Direct 27 S. La $423,969 9/7/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in
Dominican
Republic
and
Honduras.
------------------------------------------------------------------------
Product Direct 27 S. La $996,184 11/16/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Ghana
------------------------------------------------------------------------
Product Direct 27 S. La $159,065 11/16/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Ghana
------------------------------------------------------------------------
Product Direct 27 S. La $296,198 11/16/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Ghana
------------------------------------------------------------------------
Product Direct 27 S. La $113,778 11/16/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Ghana
------------------------------------------------------------------------
Product Direct 27 S. La $70,614 11/16/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Ghana
------------------------------------------------------------------------
Product Direct 27 S. La $56,506 11/16/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Ghana
------------------------------------------------------------------------
Product Direct 27 S. La $801,421 11/16/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Ghana
------------------------------------------------------------------------
Product Direct 27 S. La $720,416 11/16/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Ghana
------------------------------------------------------------------------
Product Direct 27 S. La $848,095 11/16/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Ghana
------------------------------------------------------------------------
Product Direct 27 S. La $22,144 5/10/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in USA
------------------------------------------------------------------------
Product Direct 27 S. La $1,151,659 10/24/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Haiti,
Ghana,
Sierra
Leone.
------------------------------------------------------------------------
Product Direct 27 S. La $1,781,473 10/24/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Honduras
------------------------------------------------------------------------
Product Direct 27 S. La $49,798 11/22/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Jamaica.
------------------------------------------------------------------------
Product Direct 27 S. La $18,947 11/22/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Peru and
Nicaragua.
------------------------------------------------------------------------
Product Direct 27 S. La $21,529 11/22/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Peru.
------------------------------------------------------------------------
Product Direct 27 S. La $152,642 11/22/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Jamaica
and
Nicaragua.
------------------------------------------------------------------------
Product Direct 27 S. La $244,221 11/22/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Jamaica,
Guatemala,
Colombia,
Nicaragua
------------------------------------------------------------------------
Product Direct 27 S. La $54,936 11/22/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Peru,
Nicaragua
and
Colombia.
------------------------------------------------------------------------
Product Direct 27 S. La $86,941 12/22/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Honduras
and
Afghanistan
.
------------------------------------------------------------------------
Product Direct 27 S. La $381,882 12/22/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Haiti,
Afghanistan
, Honduras.
------------------------------------------------------------------------
Product Direct 27 S. La $64,354 12/22/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in US
------------------------------------------------------------------------
Product Direct 27 S. La $145,709 12/22/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in US
------------------------------------------------------------------------
Product Direct 27 S. La $57,146 12/22/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Lebanon
and
Honduras.
------------------------------------------------------------------------
Product Direct 27 S. La $53,183 12/22/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in
Afghanistan
.
------------------------------------------------------------------------
Product Direct 27 S. La $45,277 12/22/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in
Afghanistan
and
Honduras.
------------------------------------------------------------------------
Product Direct 27 S. La $203,883 12/22/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n relief in
, CA Honduras
93117 and US.
------------------------------------------------------------------------
Product Direct 27 S. La $241,908 12/22/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Haiti
and US
------------------------------------------------------------------------
Product Direct 27 S. La $102,180 12/22/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in the US
------------------------------------------------------------------------
Product Direct 27 S. La $126,300 12/22/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Haiti.
------------------------------------------------------------------------
Product Direct 27 S. La $8,017 11/28/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Peru.
------------------------------------------------------------------------
Product Direct 27 S. La $179,712 12/19/2016 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Malawi.
------------------------------------------------------------------------
Product Heart 13250 W $8,017 11/28/2016 Product
To 98th donation
Heart Street for
Intern Lenexa, humanitaria
ationa KS n
l 66215 assistance
in
Honduras.
------------------------------------------------------------------------
Product Heart 13250 W $199,190 11/28/2016 Product
To 98th donation
Heart Street for
Intern Lenexa, humanitaria
ationa KS n
l 66215 assistance
in Haiti.
------------------------------------------------------------------------
Product Heart 13250 W $190,802 11/28/2016 Product
To 98th donation
Heart Street for
Intern Lenexa, humanitaria
ationa KS n
l 66215 assistance
in Honduras
------------------------------------------------------------------------
Product Heart 13250 W $83,392 11/28/2016 Product
To 98th donation
Heart Street for
Intern Lenexa, humanitaria
ationa KS n
l 66215 assistance
in
Dominican
Republic,
Honduras.
------------------------------------------------------------------------
Product Heart 13250 W $635,226 9/26/2016 Product
To 98th donation
Heart Street for
Intern Lenexa, humanitaria
ationa KS n
l 66215 assistance
in Haiti.
------------------------------------------------------------------------
Product Heart 13250 W $194,454 9/16/2016 Product
To 98th donation
Heart Street for
Intern Lenexa, humanitaria
ationa KS n
l 66215 assistance
in Haiti
and
Guatemala
------------------------------------------------------------------------
Product Heart 13250 W $1,327,428 9/16/2016 Product
To 98th donation
Heart Street for
Intern Lenexa, humanitaria
ationa KS n
l 66215 assistance
in Haiti,
Guatemala
and
Honduras.
------------------------------------------------------------------------
Product Heart 13250 W $114,481 9/16/2016 Product
To 98th donation
Heart Street for
Intern Lenexa, humanitaria
ationa KS n
l 66215 assistance
in Haiti.
------------------------------------------------------------------------
Product Heart 13250 W $61,475 9/16/2016 Product
To 98th donation
Heart Street for
Intern Lenexa, humanitaria
ationa KS n
l 66215 assistance
in
Guatemala
and El
Salvador.
------------------------------------------------------------------------
Product Heart 13250 W $128,184 9/16/2016 Product
To 98th donation
Heart Street for
Intern Lenexa, humanitaria
ationa KS n
l 66215 assistance
in Haiti
and
Guatemala.
------------------------------------------------------------------------
Product Heart 1021 $148,499 6/9/2016 Product
to Pacific donation
Heart Avenue for
Intern Kansas humanitaria
ationa City, n
l KS assistance
66102 in
Dominican
Republic,
Guatemala,
Jamaica
------------------------------------------------------------------------
Product Heart 1021 $31,346 6/8/2016 Product
to Pacific donation
Heart Avenue for
Intern Kansas humanitaria
ationa City, n
l KS assistance
66102 in
Guatemala,
Jamaica.
------------------------------------------------------------------------
Product Heart 13250 W $963,188 5/10/2016 Product
To 98th donation
Heart Street for
Intern Lenexa, humanitaria
ationa KS n
l 66215 assistance
in
Dominican
Republic
------------------------------------------------------------------------
Product Heart 13250 W $808,425 5/10/2016 Product
To 98th donation
Heart Street for
Intern Lenexa, humanitaria
ationa KS n
l 66215 assistance
in
Swaziland
------------------------------------------------------------------------
Product Johnson One $84,928,778 3/31/2016 Patient
and Johnson Assistance
Johnso & Product
n Johnson Donation
Patien Plaza
t New
Assist Brunswi
ance ck, NJ
Founda 08933
tion
------------------------------------------------------------------------
Product Johnson One $86,415,842 6/31/2016 Patient
& Johnson Assistance
Johnso & Product
n Johnson Donation
Patien Plaza
t New
Assist Brunswi
ance ck, NJ
Founda 08934
tion
------------------------------------------------------------------------
Product Johnson One $68,286,613 9/30/2016 Patient
& Johnson Assistance
Johnso & Product
n Johnson Donation
Patien Plaza
t New
Assist Brunswi
ance ck, NJ
Founda 08935
tion
------------------------------------------------------------------------
Product Johnson One $77,655,085 12/31/2016 Patient
& Johnson Assistance
Johnso & Product
n Johnson Donation
Patien Plaza
t New
Assist Brunswi
ance ck, NJ
Founda 08936
tion
------------------------------------------------------------------------
Product MAP 4700 $168,361 10/21/2016 Product
Intern Glynco donation
ationa Parkway for
l Brunswi disaster
ck, GA response in
31525 Haiti.
------------------------------------------------------------------------
Product MAP 4700 $35,275 11/28/2016 Product
Intern Glynco donation
ationa Parkway for
l Brunswi humanitaria
ck, GA n
31525 assistance
in Central
America.
------------------------------------------------------------------------
Product MAP 4700 $1,600,598 12/14/2016 Product
Intern Glynco donation
ationa Parkway for
l Brunswi Humanitaria
ck, GA n
31525 assistance
in
Dominican
Republic.
------------------------------------------------------------------------
Product MAP 4700 $1,816 12/14/2016 Product
Intern Glynco donation
ationa Parkway for
l Brunswi humanitaria
ck, GA n
31525 assistance
in
Dominican
Republic
------------------------------------------------------------------------
Product MAP 50 Hurt $1,471,357 12/16/2016 Product
Intern Plaza donation
ationa Atlanta for
l , GA humanitaria
30303 n
assistance
in
Dominican
Republic
------------------------------------------------------------------------
Updated March 30, 2017
Janssen Therapeutics, Division of Janssen Products, LP, Monetary and
Product Contribution to U.S.-based Charitable Organizations Full Year
2016
(Payments made from January 1, 2016 to December 31, 2016)
------------------------------------------------------------------------
Project
Donation Payee Payee Payment Amount Payment Title/
Type Address (USD) Date Description
------------------------------------------------------------------------
Monetary Acercam 827 $7,500 4/25/2016 ContraSIDA
iento Wildwoo (Against
Hispan d Ave, HIV/AIDS)
o de Suite
Caroli 200
na del Columbi
Sur a, SC
29203
------------------------------------------------------------------------
Monetary ADAP 312 11th $5,000 6/1/2016 Improving
Advoca Avenue, Access to
cy #21g Care Among
New Transgender
York, Men and
NY Women
10001 Living with
HIV/AIDS
under the
AIDS Drug
Assistance
Program
(ADAP)
------------------------------------------------------------------------
Monetary ADAP 312 11th $5,000 2/29/2016 ADAP
Advoca Avenue, Directory
cy #21g
New
York,
NY
10001
------------------------------------------------------------------------
Monetary African- 1833 W. $200,000 12/6/2016 Certificatio
Americ 8th n of the
an St., U.S. HIV
Aids Suite Workforce:
Policy 200 Los A Project
And Angeles to Increase
Traini , CA HIV
ng 90057 Literacy
Instit and
ute Competency
------------------------------------------------------------------------
Monetary AIDS 600 St. $26,700 8/24/2016 (RFA)--Healt
Action Clair hy Start
Coalit Avenue
ion of P.O.
Huntsv Box
ille 2409
Huntsvi
lle, AL
35801
------------------------------------------------------------------------
Monetary AIDS 75 Amory $30,000 12/6/2016 Getting to
Action Street Zero MA
Commit Boston,
tee of MA
Massac 02119
husett
s
------------------------------------------------------------------------
Monetary Aids 575 8th $15,000 7/13/2016 HIV Health
Commun Ave, Literacy
ity Suite Education
Resear 502 New and
ch York, Training
Initia NY for Service
tive 10018 Providers
of Working
Americ with
a Vulnerable
ACRIA Populations
------------------------------------------------------------------------
Monetary AIDS 200 W. $48,000 6/21/2016 Ensuring
Founda Jackson Access to
tion Blvd HIV
of Suite Prevention
Chicag 2100 and Care in
o Chicago Illinois
, IL through
60606 Policy
Monitoring
and
Advocacy
------------------------------------------------------------------------
Monetary AIDS 400 N $5,000 2/29/2016 HIV Case
Outrea Beach Management
ch Street at AIDS
Center Fort Outreach
Worth, Center
TX
76111
------------------------------------------------------------------------
Monetary AIDS The $7,500 12/14/2016 HIV Access
Projec David and Care
t Los Geffen Coordinatio
Angele Center n Program
s 611 S.
Kingsle
y Dr.
Los
Angeles
, CA
90005
------------------------------------------------------------------------
Monetary AIDS 64 West $20,000 6/21/2016 Peer
Servic 35th Education,
e Street, Health
Center 3rd Coaching,
NYC Floor and Access
New to Care
York, programs
NY
10001
------------------------------------------------------------------------
Monetary AIDS P.O. Box $30,000 8/24/2016 (RFA)--Posit
Servic 169 121 ive Living
es College
Coalit Street
ion Hatties
burg,
MS
39401
------------------------------------------------------------------------
Monetary AIDS 17982 $5,000 12/16/2016 HIV and
Servic Sky Hepatitis C
es Park Testing
Founda Circle, Program
tion Suite J
Orange Irvine,
County CA
92614
------------------------------------------------------------------------
Monetary AIDS 17982 $5,000 2/29/2016 HIV and
Servic Sky Hepatitis C
es Park Testing
Founda Circle, Program
tion Suite J
Orange Irvine,
County CA
92614
------------------------------------------------------------------------
Monetary AIDS 7215 $5,000 1/18/2016 HIV Case
Servic Cameron Management
es of Road
Austin Austin,
Inc. TX
78752
------------------------------------------------------------------------
Monetary AIDS 7215 $2,500 12/14/2016 Palateria
Servic Cameron Cart
es of Road
Austin Austin,
Inc. TX
78752
------------------------------------------------------------------------
Monetary AIDS 7215 $30,000 8/8/2016 (RFA)--Risin
Servic Cameron g Star
es of Road University
Austin Austin,
Inc. TX
78752
------------------------------------------------------------------------
Monetary AIDS 1424 K $300,000 12/19/2016 Transgender
United Street, Leadership
NW Demonstrati
Suite on Project
200
Washing
ton, DC
20005-2
411
------------------------------------------------------------------------
Monetary Alexian 825 W. $5,000 6/20/2016 Transitional
Brothe Welling Living
rs ton Program for
Bonave Chicago Homeless
nture , IL Adults with
House 60657 HIV/AIDS
------------------------------------------------------------------------
Monetary Allianc 825 $3,000 12/14/2016 Continuum-of-
e For Colorad Care
Housin o Services
g And Blvd., for Multi-
Healin Suite Diagnosed
g 100 Los Persons
Angeles with HIV/
, CA AIDS
90041
------------------------------------------------------------------------
Monetary America Greater $3,000 8/25/2016 Ask the
n New Experts:
Liver York Hepatitis C/
Founda Divisio HIV Co-
tion n 39 infection
Broadwa Seminar
y Suite
2700
New
York,
NY
10006
------------------------------------------------------------------------
Monetary Atlanta P.O. Box $15,000 2/16/2016 Hepatitis C
Harm 92670 Prevention
Reduct Atlanta Program
ion , GA
Coalit 30314
ion
------------------------------------------------------------------------
Monetary Bienest 5326 E $25,000 12/6/2016 Bienestar
ar Beverly HIV
Blvd Programs
Los and
Angeles Services
, CA
90022
------------------------------------------------------------------------
Monetary Brother 2714 $28,500 8/24/2016 (RFA)--EMPOW
hood, Canal ER NOLA
Inc. Street
Suite
503A
New
Orleans
, LA
70119
------------------------------------------------------------------------
Monetary Caring PO Box $40,000 3/24/2016 Hepatitis C
Ambass 1748 Program
adors Oregon Support--SH
Progra City, APE and
m Inc. OR CHOICES
97045
------------------------------------------------------------------------
Monetary Catholi 119 $5,000 3/14/2016 The Home
c Dameron Place
Charit Avenue
ies of Knoxvil
East le, TN
Tennes 37917
see
Inc.
------------------------------------------------------------------------
Monetary Central 1785 $5,000 2/29/2016 Free On-Site
Louisi Jackson Neighborhoo
ana Street d Testing,
Aids Alexand Counseling,
Suppor ria, LA and
t 71301 Prevention
Servic Program
es
Inc.
(CLASS
)
------------------------------------------------------------------------
Monetary Christi 2440 $10,000 7/13/2016 Integrated
e's Third Services
Place Ave San for Women,
Inc. Diego, Children
CA and
92101 Families
------------------------------------------------------------------------
Monetary Christi 2440 $20,000 2/18/2016 CHANGE for
e's Third Women
Place Ave San
Inc. Diego,
CA
92101
------------------------------------------------------------------------
Monetary Coaliti 127 W $50,000 12/6/2016 Strengthenin
on On 127th g Patient
Positi Street Education
ve Suite through
Health 208 New Technology
Empowe York, and Social
rment NY Media
Inc. 10027
------------------------------------------------------------------------
Monetary Coastal 5633 $15,000 10/7/2016 HEP:
Bend South Hepatitis
Wellne Staples Education
ss , Suite Program
Founda 700
tion Corpus
Christi
, TX
78411
------------------------------------------------------------------------
Monetary Communi 714 East $5,000 6/24/2016 Patient
ty Sahara Wellness
Counse Ave. Education
ling Suite
Center 103 Las
Vegas,
NV
89104
------------------------------------------------------------------------
Monetary Communi 2409 $29,633 8/24/2016 (RFA)--Safe
ty Murchis Spaces
Health on Rd Ambassador
Interv Fayette Program
ention ville,
s and NC
Sickle 28301
Cell
Agency
Incorp
orated
------------------------------------------------------------------------
Monetary Communi 60 $30,000 2/29/2016 Transgender
ty Madison Linkage to
Health Avenue, Care
care 5th
Networ floor
k New
York,
NY
10010
------------------------------------------------------------------------
Monetary Compreh 142 S. $25,000 8/24/2016 (RFA)--Proje
ensive Brunswi ct IRIS
Aids ck (Improving
Resour Street Retention
ce Suite B In the
Encoun P.O. South)
ter Box 552
Inc. Jesup,
GA
31545
------------------------------------------------------------------------
Monetary Crisis 1218 $75 7/12/2016 Employee
Shelte West directed
r of State donation in
Lawren Street lieu of
ce New company
County Castle, holiday
PA gift
16101-
2021
------------------------------------------------------------------------
Monetary Desert 1695 N. $5,000 6/1/2016 Get Tested
AIDS Sunrise Coachella
Projec Way Valley
t Palm Linkage to
Springs Care for
, CA Newly
92262 Diagnosed
HIV-
Positive
Persons
------------------------------------------------------------------------
Monetary Frannie 30 $5,000 9/13/2016 Integrated
Peabod Danfort Access to
y h St. Care for
Center Suite People
Inc. 311 Living with
Portlan HIV/AIDS
d, ME
04101
------------------------------------------------------------------------
Monetary Harm 22 West $25,000 7/13/2016 Hepatitis C
Reduct 27th Project
ion Street
Coalit 5th
ion Floor
New
York,
NY
10001
------------------------------------------------------------------------
Monetary Health 1211 $5,000 12/14/2016 Pennsylvania
Federa Chestnu Ryan White
tion t Part C/D
Of Street, Collaborati
Philad Suite ve
elphia 801
Philade
lphia,
PA
19107
------------------------------------------------------------------------
Monetary HealthH 2000 S $30,000 2/18/2016 Do You Know
IV Street Me?:
NW Engaging
Washing and
ton, DC Retaining
20009 Young MSM
of Color in
HIV Care
------------------------------------------------------------------------
Monetary Heart 3600 $5,000 3/16/2016 BROTHA--Brot
Health Broadwa hers
and y West Responding
Healin Palm Openly to
g Beach, HIV/AIDS
Minist FL (Ujima
ries 33407 Men's
Inc. Collective)
------------------------------------------------------------------------
Monetary Hepatit 35 East $22,000 2/18/2016 The
is C 38th Hepatitis C
Mentor Street, Education
And Suite and Support
Suppor #4G New Group
t York, Assistance
Group NY Program
Inc. 10016
------------------------------------------------------------------------
Monetary Hepatit 1261 S. $35,000 3/14/2016 Case
is Jackson management
Educat St. ($25,000);
ion Suite King County
Projec 201 Jail
t Seattle Hepatitis
, WA Education
98144 ($10,000)
------------------------------------------------------------------------
Monetary Hepatit 8121 $5,000 5/6/2016 Call To
is Georgia Action: A
Founda Avenue National
tion Suite Response
Intern 350 for
ationa Silver Hepatitis C
l Inc. Spring, Treatment
MD among the
20910 Hard to
Reach, Hard
to Treat.
Proposal
------------------------------------------------------------------------
Monetary Jackson P.O. Box $30,000 8/8/2016 (RFA)--#AIDS
ville 380103 FreeJax
Area Jackson Linkage to
Sexual ville, Care (L2C)
Minori FL Program--a
ty 32205 Comprehensi
Youth ve HIV/AIDS
Networ Linkage to
k, Care
Inc. Program for
(JASMY African
N) American
YMSM, ages
13-23
------------------------------------------------------------------------
Monetary Legacy 4054 $5,000 12/14/2016 Legacy
Counse McKinne Counseling
ling y Center
Center Avenue Counseling
Suite and Walk-In
102 Crisis
Dallas, Clinic
TX Program for
75204 People
Living with
HIV/AIDS
------------------------------------------------------------------------
Monetary Make-A- 2880 $450 2/8/2016 Employee
Wish Slater directed
Founda Road, donation in
tion Suite lieu of
of 108 company
Easter Morrisv holiday
n ille, gift
North NC
Caroli 27560
na
------------------------------------------------------------------------
Monetary MCCNY 446 West $10,000 12/6/2016 Linkage to
Charit 36th Care for
ies Street LGBTQI
New Homeless
York, Youth
NY
10018
------------------------------------------------------------------------
Monetary Minorit 5149 W. $7,500 4/12/2016 The Missing
y AIDS Jeffers Link
Projec on Blvd ``G.L.A.M.O
t Los .R.''
Angeles (Getting
, CA Linked And
90016 Managing
Our
Regimen)
------------------------------------------------------------------------
Monetary Missour 601 $9,650 8/9/2016 Hep C
i Busines Education
Hepati s Loop and
tis C 70 West Testing--Th
Allian Suite e Texas
ce 138 Project
Columbi
a, MO
65203
------------------------------------------------------------------------
Monetary Nationa 580 $175,000 3/7/2016 NATAP HIV
l AIDS Broadwa and HCV
Treatm y Suite Information
ent 1010 and
Advoca New Education
cy York, Project
Projec NY
t 10012
------------------------------------------------------------------------
Monetary Nationa 444 N. $150,000 12/19/2016 Health
l Capitol Systems
Allian St., NW Integration
ce of Suite , Ryan
State 339 White/ADAP,
and Washing and Viral
Territ ton, DC Hepatitis
orial 20001 Public
AIDS Policy and
Direct Technical
ors Assistance
Programs
------------------------------------------------------------------------
Monetary Nationa 1000 $50,000 12/15/2016 Strong
l Vermont Communities
Minori Avenue : Social
ty NW Drivers of
AIDS Suite HIV
Counci 200
l Washing
ton, DC
20005
------------------------------------------------------------------------
Monetary Nationa 1000 $30,000 2/16/2016 Strong
l Vermont Communities
Minori Avenue :
ty NW Strengtheni
AIDS Suite ng
Counci 200 connections
l Washing between
ton, DC LGBT
20005 communities
of color
and the
providers
that serve
them
------------------------------------------------------------------------
Monetary New 44 South $5,000 2/29/2016 Community
Jersey Street Based
AIDS Morrist Services
Servic own, NJ
es 07960
------------------------------------------------------------------------
Monetary Next 99 $5,000 6/20/2016 Expansion of
Step Bishop Next Step's
Fund Allen Year-round
Inc. Drive Programming
Cambrid for teens
ge, MA and young
02139 adults
living with
HIV.
------------------------------------------------------------------------
Monetary Our 2727 SE $5,000 8/23/2016 Neighborhood
House Alder Housing and
of St. Care
Portla Portlan Program
nd d, OR (NHCP)
Incorp 97214
orated
------------------------------------------------------------------------
Monetary Palmett 2638 Two $7,500 5/6/2016 HIV Care
o AIDS Notch Coordinatio
Life Road, n Program
Suppor Suite
t 108
Servic Columbi
es a, SC
29204
------------------------------------------------------------------------
Monetary Positiv 785 $2,500 12/16/2016 Employment
e Market and
Resour Street, Benefits
ce 10th Education
Center Floor
San
Francis
co, CA
94103
------------------------------------------------------------------------
Monetary Project 273 $60,000 10/6/2016 Policy
Inform Ninth Initiatives
Street to Improve
San Access to
Francis Care and
co, CA Treatment
94103
------------------------------------------------------------------------
Monetary Project 273 $20,000 7/15/2016 Hepatitis C
Inform Ninth Education
Street and Linkage
San to Care
Francis
co, CA
94103
------------------------------------------------------------------------
Monetary Project 273 $30,000 12/19/2016 The Support
Inform Ninth Partnership
Street
San
Francis
co, CA
94103
------------------------------------------------------------------------
Monetary Project 273 $70,000 5/19/2016 Mission
Inform Ninth Support for
Street Project
San Inform
Francis
co, CA
94103
------------------------------------------------------------------------
Monetary Project 273 $40,000 2/18/2016 The Support
Inform Ninth Partnership
Street
San
Francis
co, CA
94103
------------------------------------------------------------------------
Monetary RAIN, 601 E. $30,000 8/8/2016 (RFA)--Impro
Inc. 5th ving
Street, Retention
Suite in Care and
470 Access to
Charlot Treatment
te, NC for African
28202 Americans
Living with
HIV in
Charlotte
Metropolita
n area
------------------------------------------------------------------------
Monetary RAIN, 601 E. $5,000 4/25/2016 Medical Case
Inc. 5th Management
Street, for Youth,
Suite Adults and
470 Seniors
Charlot with HIV/
te, NC AIDS
28202
------------------------------------------------------------------------
Monetary Recover 3423 $75,000 4/15/2016 The Healthy
y Covingt Start
Consul on Program
tants Drive,
Of Suite B
Atlant Decatur
a , GA
Incorp 30032
orated
------------------------------------------------------------------------
Monetary Resourc 5750 $3,000 12/14/2016 Valor Latino
e Cedar Project
Center Springs
of Road
Dallas Dallas,
, Inc. TX
75235-6
805
------------------------------------------------------------------------
Monetary Sero PO Box $15,000 2/29/2016 HIV is Not a
Projec 1233 Crime
t Inc. Milford regional
, PA and
18337 national
conferences
and webinar
trainings
------------------------------------------------------------------------
Monetary Shanti 730 Polk $10,000 7/13/2016 Shanti HIV
Projec Street, Services
t Inc. 3rd Program/HCV
Floor Services
San
Francis
co, CA
94109
------------------------------------------------------------------------
Monetary South 601 $7,500 6/27/2016 West
Centra Bland Virginia
l Street Infection
Educat P.O. Disease
ional Box Coalition
Develo 4322
pment Bluefie
ld, WV
24701
------------------------------------------------------------------------
Monetary Southwe 1101 N. $5,000 12/14/2016 General
st Central mission
Center Avenue support
For Suite
HIV/ 200
AIDS Phoenix
Inc. , AZ
85004
------------------------------------------------------------------------
Monetary Step-Up 850 N. $5,000 12/16/2016 Indianapolis
Incorp Meridia Men
orated n Advancing
Street Prevention
First (IMAP)
Floor
Indiana
polis,
IN
46204
------------------------------------------------------------------------
Monetary The 17 Davis $65,000 12/6/2016 Ensuring
Aids Blvd. Adequate
Instit Suite Funding for
ute 403 Domestic
Tampa, HIV/AIDS
FL and
33606 Hepatitis
Programs
------------------------------------------------------------------------
Monetary The 429 E. $75 2/8/2016 Employee
Health Vermont directed
Founda Street, donation in
tion Suite lieu of
of 400 company
Greate Indiana holiday
r polis, gift
Indian IN
apolis 46202
------------------------------------------------------------------------
Monetary The Hep 1325 S. $15,000 7/12/2016 HCV Patient
C Colorad Linkage to
Connec o Care and
tion Blvd., Navigation
B-302
Denver,
CO
80222
------------------------------------------------------------------------
Monetary The PO Box $30,000 8/24/2016 (RFA)--``Rep
Open 99243 ''
Door, Pittsbu presenting
Inc. rgh, PA the
15233 solution
for optimal
health
outcomes
and housing
stability
for African
American
``payees''
living with
HIV/AIDS
------------------------------------------------------------------------
Monetary The San 3909 $5,000 3/7/2016 Latin@
Diego Centre Services
LGBT St San program
Commun Diego,
ity CA
Center 92103
------------------------------------------------------------------------
Monetary The 85 $30,000 3/24/2016 Support
Well Norman Information
Projec Avenue, ,
t Suite 1 Community,
P.O. Advocacy
Box and
220410 Evaluation
Brookly
n, NY
11222
------------------------------------------------------------------------
Monetary The 1331 $30,000 8/24/2016 (RFA)--Enhan
Women' Rhode cements of
s Island Community
Collec Avenue Health
tive NE Worker
Washing Program
ton, DC
20018
------------------------------------------------------------------------
Monetary Tourett 4240 $75 5/4/2016 Donation in
e Bell lieu of
Associ Blvd., company
ation Suite holiday
of 205 gift
Americ Bayside
a , NY
11361
------------------------------------------------------------------------
Monetary TPA 5050 N. $5,000 6/1/2016 Healthy
Networ Broadwa Aging with
k y Suite HIV
Incorp 300
orated Chicago
Test , IL
Positi 60640
ve
Aware
Networ
k
------------------------------------------------------------------------
Monetary TPA 5050 N. $25,000 10/6/2016 Total Care
Networ Broadwa Portal
k y Suite
Incorp 300
orated Chicago
Test , IL
Positi 60640
ve
Aware
Networ
k
------------------------------------------------------------------------
Monetary Treatme 261 $25,000 5/19/2016 Case Studies
nt Fifth
Action Ave
Group, Suite
Inc. 2110
New
York,
NY
10016
------------------------------------------------------------------------
Monetary Univers UCSF $7,500 6/20/2016 Mission-
ity of Allianc Based
Califo e Support of
rnia Health UCSF
San Project Alliance
Franci 1855 Health
sco Folsom Project
Street, Services
Ste. for People
670 Box Living With
0884 or at Risk
San of HIV/AIDS
Francis
co, CA
94143
------------------------------------------------------------------------
Monetary Univers 5801 S. $20,741 3/7/2016 4 Her by Her
ity of Ellis
Chicag Avenue
o Chicago
, IL
60637
------------------------------------------------------------------------
Monetary US 1300 PA $500,000 8/5/2016 Bedaquiline
Agency Avenue. Donation
for , NW SA- Program in
Intern 44 Rm support of
ationa 475-J World
l Washing Health
Develo ton, DC Organizatio
pment 20523 n's END TB
Strategy
for 2016-
2035
------------------------------------------------------------------------
Monetary Venice 604 Rose $5,000 12/16/2016 Venice
Family Ave. Family
Clinic Venice, Clinic's
CA Common
90291 Ground
------------------------------------------------------------------------
Monetary Vermont 187 $5,000 6/1/2016 Vermont HIV
Commit Saint Transportat
tee Paul ion Support
For Street
Aids Burling
Resour ton, VT
ces 05401
Educat
ion
and
Servic
es
------------------------------------------------------------------------
Monetary Washing 566 West $30,000 3/24/2016 Engaging
ton 181st High Risk
Height Street, Active
s Floor 2 Injection
CORNER New Drug Users
Projec York, in
t NY Hepatitis C
10033 Testing and
Treatment
in Northern
Manhattan
------------------------------------------------------------------------
Monetary Women 417 $7,500 4/25/2016 SafetyPIN
On Welshwo
Mainta od
ining Drive,
Educat Suite
ion 303
And Nashvil
Nutrit le, TN
ion 37211-
4248
------------------------------------------------------------------------
Monetary Womens 4615 $2,500 3/23/2016 She's Still
Challe Harrier Got It
nge Way educational
Inc. Belcamp initiative
, MD
21017
------------------------------------------------------------------------
Monetary WORLD 389 30th $15,000 12/14/2016 Community
Women St Researchers
Organi Oakland Engaging
zed to , CA Women
Respon 94609 (CREW) III
d to
Life-
threat
ening
Diseas
es
------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------
Product Johnson & Johnson One Johnson & $ 3,700,026 3/31/2016 Patient Assistance
Patient Assistance Johnson Plaza New Product Donation
Foundation Brunswick, NJ 08933
----------------------------------------------------------------------------------------------------------------
Product Johnson & Johnson One Johnson & $ 3,459,402 6/30/2016 Patient Assistance
Patient Assistance Johnson Plaza New Product Donation
Foundation Brunswick, NJ 08934
----------------------------------------------------------------------------------------------------------------
Product Johnson & Johnson One Johnson & $ 2,280,117 9/30/2016 Patient Assistance
Patient Assistance Johnson Plaza New Product Donation
Foundation Brunswick, NJ 08935
----------------------------------------------------------------------------------------------------------------
Product Johnson & Johnson One Johnson & $ 3,874,808 12/31/2016 Patient Assistance
Patient Assistance Johnson Plaza New Product Donation
Foundation Brunswick, NJ 08936
----------------------------------------------------------------------------------------------------------------
Product Partnership for 1616 Fort Myer $ 6,123,407 10/3/2016 Product donation
Supply Chain Drive, 12th Floor for humanitarian
Management Arlington, VA 22209- assistance.
3100
----------------------------------------------------------------------------------------------------------------
Product US Agency for 1300 PA Avenue., NW, $ 44,580,000 12/1/2016 Bedaquiline product
International SA-44 Rm 475-J donation
Development Washington, DC
20523
----------------------------------------------------------------------------------------------------------------
Updated March 30, 2018
Janssen Biotech, Inc. Monetary and Product Contribution to U.S.-based
Charitable Organizations Full Year 2017
(Payments made from January 1, 2017 to December 31, 2017)
------------------------------------------------------------------------
Project
Donation Payee Payee Payment Amount Payment Title/
Type Address (USD) Date Description
------------------------------------------------------------------------
Monetary AAUW 7511 $1,000 12/14/2017 Annual
Makefi Germant Girl's
eld own Recognition
Area Avenue Reception
Branch Philade and
PA lphia, Scholarship
Inc. PA Awards
19119 American
Association
of
University
Women--Make
field
Branch
------------------------------------------------------------------------
Monetary Aid For 12271 $300 11/16/2017 Costs
Friend Townsen associated
s d Rd. with
Philade Janssen
lphia, Cares
PA Volunteer
19154 Activity--S
eptember
27, 2017
------------------------------------------------------------------------
Monetary Aid For 12271 $300 11/16/2017 Costs
Friend Townsen associated
s d Rd. with
Philade Janssen
lphia, Cares
PA Volunteer
19154 Activity--O
ctober 6,
2017
------------------------------------------------------------------------
Monetary America 250 $9,500 2/2/2017 General
n William Operating
Cancer s Support
Societ Street
y NW
(HDQTS Atlanta
) , GA
30303
------------------------------------------------------------------------
Monetary America Atlanta $300 10/25/2017 Costs
n Hope associated
Cancer Lodge with
Societ 1552 Janssen
y Inc. Shoup Cares
Ct Volunteer
Decatur Activity
, GA
30033
------------------------------------------------------------------------
Monetary America 1626 $1,000 4/21/2017 Relay For
n Locust Life of the
Cancer Street Wissahickon
Societ Philade Valley
y Inc, lphia,
Philad PA
elphia 19103
, PA
------------------------------------------------------------------------
Monetary Arthrit 1355 $200,000 5/24/2017 Walk To Cure
is Peachtr Arthritis
Founda ee and Jingle
tion Street, Bell Run
Suite
600
Atlanta
, GA
30309
------------------------------------------------------------------------
Monetary Arthrit 1355 $200,000 12/21/2017 Walk To Cure
is Peachtr Arthritis
Founda ee and Jingle
tion Street, Bell Run
Suite
600
Atlanta
, GA
30309
------------------------------------------------------------------------
Monetary Artz 1229 $7,500 11/30/2017 ``ARTZ in
Philad Chestnu the
elphia t Neighborhoo
Street, d: A
#188 Community-
Philade Based
lphia, Program''
PA
19107
------------------------------------------------------------------------
Monetary Breathi 600 West $5,000 12/25/2017 Program and
ng Avenue, Family
Room P.O. Services--B
Founda Box 287 reathing
tion Jenkint Room
own, PA Foundation
19046-2
729
------------------------------------------------------------------------
Monetary Cancer 3 $5,000 3/30/2017 Oncology
Suppor Crossro Support
t ads Groups
Commun Drive
ity Bedmins
Centra ter, NJ
l New 07921
Jersey
------------------------------------------------------------------------
Monetary Cancer 1200 Old $5,000 5/19/2017 Voice of the
Suppor Henders Patient:
t on Distress
Commun Columbu Screening
ity s, OH and Support
Centra 43220 for Cancer
l Ohio Patients
and
Survivors
------------------------------------------------------------------------
Monetary Cancer 200 Kirk $2,000 7/31/2017 Paws 4 Life
Suppor Road Dog Walk
t Warmins
Commun ter, PA
ity of 18974
Philad
elphia
------------------------------------------------------------------------
Monetary Cancer 200 Kirk $300 11/30/2017 Costs
Suppor Road associated
t Warmins with
Commun ter, PA Janssen
ity of 18974 Cares
Philad Volunteer
elphia Activity--S
eptember 28
2017
------------------------------------------------------------------------
Monetary Cancer 200 Kirk $300 11/30/2017 Costs
Suppor Road associated
t Warmins with
Commun ter, PA Janssen
ity of 18974 Cares
Philad Volunteer
elphia Activity--S
eptember 28
2017
------------------------------------------------------------------------
Monetary Center 1617 $5,000 9/4/2017 Project for
for John F. Medically
Child Kennedy Needy
Advoca Bouleva Children
tes rd
Philade
lphia,
PA
19103
------------------------------------------------------------------------
Monetary Central 2500 $300 11/30/2017 Costs
Bucks Lower associated
Family State with
YMCA Road Janssen
Doylest Cares
own, PA Volunteer
18901 Activity--O
ctober 3
2017
------------------------------------------------------------------------
Monetary Chester 100 $5,000 12/1/2017 Outreach
County North Programs
Art Bradfor
Associ d
ation Avenue
West
Chester
, PA
19382
------------------------------------------------------------------------
Monetary Chester 790 East $6,000 12/22/2017 Certified
County Market Nurse
Opport Street, Assistant
unitie Suite (CNA)
s 100 Program
Indust West
rializ Chester
ation , PA
Center 19382
------------------------------------------------------------------------
Monetary Chestnu 1710 $2,500 11/30/2017 General
t Hill Bethleh Operating
Meals em Pike Support
on Flourto
Wheels wn, PA
19031
------------------------------------------------------------------------
Monetary Childre 100 Penn $12,000 6/28/2017 Family Care
n's Square Binder
Hospit East Program
al of 8th
Philad Floor,
elphia Suite
Founda 8050
tion Philade
lphia,
PA
19107
------------------------------------------------------------------------
Monetary Childre 100 Penn $6,000 4/13/2017 Walk for
n's Square Hope
Hospit East Benefiting
al of 8th Pediatric
Philad Floor, Inflammator
elphia Suite y Bowel
Founda 8050 Disease
tion Philade Research at
lphia, CHOP
PA
19107
------------------------------------------------------------------------
Monetary Communi 300B $25,000 12/21/2017 Provision of
ty Lawrenc free
Volunt e Drive medical and
eers West dental
in Chester healthcare
Medici , PA to the
ne 19380 uninsured
in Chester
County
------------------------------------------------------------------------
Monetary Crohn's 733 3rd $18,000 6/13/2017 Camp Oasis
and Avenue
Coliti Suite
s 510 New
Founda York,
tion-- NY
NY 10017
Chapte
r
------------------------------------------------------------------------
Monetary Crohn's 733 3rd $100,000 10/30/2017 Take Steps
and Avenue for Crohn's
Coliti Suite and Colitis
s 510 New Walks
Founda York,
tion-- NY
NY 10017
Chapte
r
------------------------------------------------------------------------
Monetary Delawar 236 $5,000 5/22/2017 Teacher
e Randell Development
Valley Hall Program
Scienc 3141
e Chestnu
Fairs, t
Inc. Street
Philade
lphia,
PA
19104
------------------------------------------------------------------------
Monetary Emmanue 67 $3,500 12/21/2017 Pediatric
l Walnut Cancer
Cancer Ave. Family
Founda Suite Financial
tion 107 Assistance
Clark, Fund
NJ
07040
------------------------------------------------------------------------
Monetary Family 142 $250,000 12/15/2017 Family Reach
Reach Berkele Financial
Founda y Assistance
tion Street; and
4th Resource
Floor Navigation
Boston, Programs
MA
02116
------------------------------------------------------------------------
Monetary For 620 West $1,000 5/15/2017 7th Annual
Pete's Germant For Pete's
Sake own Sake, Walk!
Cancer Pike at Citizens
Respit Suite Bank Park
e 250
Founda Plymout
tion h
Meeting
, PA
19462
------------------------------------------------------------------------
Monetary Friends 113 West $5,000 12/14/2017 Outreach to
Associ Chestnu Homeless
ation t Families
For Street
Care West
and Chester
Protec , PA
tion 19380
Of
Childr
en
------------------------------------------------------------------------
Monetary Georgia 560 $2,500 5/11/2017 Free
Prosta Barnesl Prostate
te ey Lane Cancer
Cancer Alphare Screening
Coalit tta, GA
ion 30022
Inc.
------------------------------------------------------------------------
Monetary Girl 330 $4,000 11/21/2017 Science,
Scouts Manor Technology,
of Road Engineering
Southe Miquon, , and Math
astern PA Outreach
Pennsy 19444-1 Programming
lvania 741
------------------------------------------------------------------------
Monetary Global 515 N. $25,000 12/21/2017 Puerto Rico
Health Midland Rheumatolog
y Ave y Relief
Living Upper
Founda Nyack,
tion, NY
Inc. 10960
------------------------------------------------------------------------
Monetary Habitat 1847 E $2,500 12/18/2017 Cambria
for Lincoln Housing
Humani Hwy Development
ty of Coatesv -providing
Cheste ille, decent
r PA affordable
County 19320 housing
, Inc. options in
Chester
County Pa.
------------------------------------------------------------------------
Monetary Habitat 1829 N. $5,000 12/13/2017 Diamond Park
For 19th
Humani Street
ty Philade
Philad lphia,
elphia PA
Inc. 19121
------------------------------------------------------------------------
Monetary Hatboro- 229 $25,000 12/1/2017 STEM
Horsha Meeting Programs
m house for Hatboro-
Educat Road Horsham
ional Horsham Students
Founda , PA
tion 19044
------------------------------------------------------------------------
Monetary Jack 3282 $25,000 5/31/2017 WOW!
And Northsi Experience
Jill de
Late Parkway
Stage , NW
Cancer Suite
Founda 100
tion Atlanta
Inc. , GA
33327
------------------------------------------------------------------------
Monetary Joy of 580 $525 4/11/2017 Employee
Sox Lindsey directed
Dr., donation in
Ste 150 lieu of
Radnor, company
PA holiday
19087 gift
------------------------------------------------------------------------
Monetary Kids 26071 $3,000 11/21/2017 Support
Connec Merit Groups for
ted Circle, the
#103 Children of
Laguna Cancer
Hills, Patients
CA
92653-7
016
------------------------------------------------------------------------
Monetary Lenape 500 N. $ 300 11/30/2017 Costs
Valley West associated
Founda Street with
tion Doylest Janssen
own, PA Cares
18901 Volunteer
Activity--S
eptember 29
2017
------------------------------------------------------------------------
Monetary Metropo 420 N $30,000 12/1/2017 Medical
litan 20th Nutrition
Area Street for People
Neighb Philade with Severe
orhood lphia, Illnesses
Nutrit PA
ion 19103
Allian
ce
(MANNA
)
------------------------------------------------------------------------
Monetary Mitzvah 1561 $5,000 11/28/2017 Critical
Circle Gehman Needs for
Founda Rd. Families
tion Harleys and
ville, Individuals
PA
19438
------------------------------------------------------------------------
Monetary Montgom 340 $33,660 10/27/2017 Bridge to
ery Dekalb Employment
County Pike Extension--
Commun Blue Wissahickon
ity Bell, High School
Colleg PA
e 19422
Founda
tion
------------------------------------------------------------------------
Monetary NAMI of 100 W, $2,500 10/4/2017 Mental
PA Main health
Montgo St. education,
mery Suite support and
County 204 advocacy
Lansdal programs as
e, PA well as
19446 support of
Ending the
Silence
program
------------------------------------------------------------------------
Monetary NAMI of 100 W, $1,000 12/25/2017 NAMIWalks
PA Main Greater
Montgo St. Philadelphi
mery Suite a
County 204
Lansdal
e, PA
19446
------------------------------------------------------------------------
Monetary Nationa 1107 $2,500 5/31/2017 National
l Lakevie Cancer
Cancer w Dr, Survivors
Surviv Suite Day 2017
ors C1
Day Frankli
Founda n, TN
tion 37067
------------------------------------------------------------------------
Monetary Nationa 4950 $2,500 7/31/2017 19th Annual
l York Break the
Ovaria Rd, Silence on
n Unit Ovarian
Cancer 631 Cancer Run/
Coalit Holicon Walk
ion g, PA
Inc. 18928
------------------------------------------------------------------------
Monetary Nationa 6600 SW $50,000 3/16/2017 2017 Team
l 92nd NPF Walk
Psoria Ave.,
sis #300
Founda Portlan
tion d, OR
97223
------------------------------------------------------------------------
Monetary Nationa 6600 SW $20,000 12/5/2017 Patient
l 92nd 2017 Education
Psoria Ave., Initiative:
sis #300 Phase Three
Founda Portlan
tion d, OR
97223
------------------------------------------------------------------------
Monetary North P.O. Box $5,000 12/4/2017 Project
Penn 103 16 Learn
Valley Susqueh Homework
Boys anna Program
and Avenue
Girls Lansdal
Club e, PA
Inc. 19446
------------------------------------------------------------------------
Monetary One P.O. Box $75 4/11/2017 Employee
Days 18071 directed
Wages Seattle donation in
, WA lieu of
98118 company
holiday
gift
------------------------------------------------------------------------
Monetary Patient 700 12TH $5,000 3/31/2017 Patients
s ST NW Rising
Rising Ste. University:
Inc. 700 Spotlight
Washing Rheumatoid
ton, DC Arthritis
20005
------------------------------------------------------------------------
Monetary Philade 325 $5,000 1/24/2017 Summer READS
lphia Chestnu
Reads t
Street-
-Suite
903
Philade
lphia,
PA
19106
------------------------------------------------------------------------
Monetary Project 1515 $2,000 11/30/2017 Ending
Home Fairmou Homelessnes
nt s in
Avenue Philadelphi
Philade a Through
lphia, Supportive
PA Housing
19130
------------------------------------------------------------------------
Monetary Prostat 7009 S. $30,000 6/2/2017 Prostate
e Potomac Cancer
Cancer Street Disparities
Educat Suite Outreach
ion 125 Program
Counci Centenn
l ial, CO
80112
------------------------------------------------------------------------
Monetary Quest 461 Cann $4,000 5/25/2017 Hippotherapy
Therap Rd. (Equine-
eutic West PAssisted
Servic Chester Therapy)
es , PA Program
Inc. 19382 Support to
Serve
Children
with
Special
Needs
------------------------------------------------------------------------
Monetary Rebuild 4355 $5,000 3/22/2017 Belmont
ing Orchard Block Build
Togeth Street 2017
er Suite
Philad 2R
elphia Philade
lphia,
PA
19124
------------------------------------------------------------------------
Monetary Retired 901 East $7,000 5/31/2017 RSVP's
and 8th America
Senior Street Reads/
Volunt Suite Writes and
eer 200 Protege
Progra King of Programs
m of Prussia
Montgo , PA
mery 19406
County
------------------------------------------------------------------------
Monetary Retired 901 East $10,000 12/13/2017 RSVP's My
and 8th Free Tutor
Senior Street (MFT)
Volunt Suite Program and
eer 200 Family
Progra King of Literacy
m of Prussia Volunteer
Montgo , PA Program
mery 19406 (FLVP)
County
------------------------------------------------------------------------
Monetary Riverbe 1950 $6,000 7/31/2017 Philadelphia
nd Spring Children
Enviro Mill Access
nmenta Road Nature
l Gladwyn Program
Educat e, PA
ion 19035
Center
------------------------------------------------------------------------
Monetary Sandy 2010 $2,000 11/21/2017 Sandy Sprint
Rollma West Superhero
n Chester 5K or 10K
Ovaria Pike, Run/Walk
n Suite and Canine
Cancer 410 Sprint
Founda Haverto
tion, wn, PA
Inc. 19083
------------------------------------------------------------------------
Monetary Sarcoma 9899 $2,500 11/16/2017 Race to Cure
Founda Main SarcomaT 5K
tion Street, Walk/Run
of #204 Series
Americ Damascu
a s, MD
20872
------------------------------------------------------------------------
Monetary Special 2800 $4,000 11/21/2017 Special
Equest Street Equestrians
rians Road Equine-
P.O. Assisted
Box Learning
1001 and
Warring Therapeutic
ton, PA Riding
18976 Program
------------------------------------------------------------------------
Monetary Starfin 4015 $10,000 5/24/2017 Starfinder's
der Main Senior
Founda Street Leaders
tion Philade Program
lphia,
PA
19127
------------------------------------------------------------------------
Monetary The 222 $10,000 12/22/2017 Corporate
Frankl North Membership
in 20th
Instit Street
ute Philade
lphia,
PA
19103
------------------------------------------------------------------------
Monetary The PO Box $2,000 7/31/2017 General
Giving 823 Operating
Tree, Gwynedd Support
Gwyned Valley,
d PA
Valley 19437
, PA
------------------------------------------------------------------------
Monetary The 3 $250,000 4/12/2017 FY 2018
Leukem Interna Light the
ia and tional Night
Lympho Drive National
ma Suite Sponsor
Societ 200 Rye
y Brook,
NY
10573
------------------------------------------------------------------------
Monetary The 123 $7,500 12/14/2017 Master Class
Mann South Artist
Center Broad Residency
for Street
the Suite
Perfor 815
ming Philade
Arts lphia,
PA
19109
------------------------------------------------------------------------
Monetary The 2600 $10,000 4/25/2017 Hubert J.P.
Melmar Wayland Schoemaker
k Road Classic
Charit Berwyn,
able PA
Founda 19312
tion
Berwyn
, PA
------------------------------------------------------------------------
Monetary Travis 164 E $5,000 12/13/2017 Character
Manion State Does Matter
Founda Street
tion Doylest
own, PA
18901
------------------------------------------------------------------------
Monetary Trustee 3025 $6,000 12/14/2017 WXPN
s of Walnut Musicians
the Street On Call
Univer Philade
sity lphia,
of PA
Pennsy 19104
lvania
------------------------------------------------------------------------
Monetary Turning 415 $5,000 4/20/2017 Families and
Points South Schools
For 15th Together
Childr Street (FAST)
en Philade
lphia,
PA
19146
------------------------------------------------------------------------
Monetary United 8085 $2,017 8/8/2017 General
Mitoch Saltsbu mission
ondria rg Road support
l Suite
Diseas 201
e Pittsbu
Founda rgh, PA
tion 15239
------------------------------------------------------------------------
Monetary Us Too 2720 $1,000 5/25/2017 13th Annual
Intern South SEA Blue
ationa River Prostate
l Inc. Road Cancer Walk
#112 & Run
Des
Plaines
, IL
60018
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk
te ria, VA Austin, TX
Cancer 22314
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk
te ria, VA Columbus,
Cancer 22314 OH
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk
te ria, VA Charleston,
Cancer 22314 SC
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk
te ria, VA Boston, MA
Cancer 22314
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk
te ria, VA Cleveland,
Cancer 22314 OH
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk
te ria, VA Birmingham,
Cancer 22314 AL
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk San
te ria, VA Diego, CA
Cancer 22314
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk San
te ria, VA Antonio, TX
Cancer 22314
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk
te ria, VA Sacramento,
Cancer 22314 CA
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk
te ria, VA Oklahoma
Cancer 22314 City, OK
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk East
te ria, VA Lansing, MI
Cancer 22314
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk Kansas
te ria, VA City, KS
Cancer 22314
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk
te ria, VA Jacksonvill
Cancer 22314 e, FL
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk
te ria, VA Harrisburg,
Cancer 22314 PA
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk
te ria, VA Greensboro,
Cancer 22314 NC
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk Des
te ria, VA Moines, IA
Cancer 22314
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk
te ria, VA Dayton, OH
Cancer 22314
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk Dallas/
te ria, VA Fort Worth,
Cancer 22314 TX
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk Corpus
te ria, VA Christi, TX
Cancer 22314
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk
te ria, VA Virginia
Cancer 22314 Beach, VA
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk Tyler,
te ria, VA TX
Cancer 22314
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk St.
te ria, VA Louis, MO
Cancer 22314
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk Puget
te ria, VA Sound, WA
Cancer 22314
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk San
te ria, VA Francisco,
Cancer 22314 CA
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,000 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk Napa
te ria, VA Valley, CA
Cancer 22314
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk
te ria, VA Minneapolis
Cancer 22314 , MN
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk
te ria, VA Hollywood,
Cancer 22314 FL
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk
te ria, VA Asheville,
Cancer 22314 NC
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk
te ria, VA Augusta, SC
Cancer 22314
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk Towson/
te ria, VA Baltimore,
Cancer 22314 MD
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk El
te ria, VA Paso, TX
Cancer 22314
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk
te ria, VA Hartford,
Cancer 22314 CT
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk
te ria, VA Wichita, KS
Cancer 22314
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk
te ria, VA Capital
Cancer 22314 Area/
Arlington,
VA
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk
te ria, VA Syracuse,
Cancer 22314 NY
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk Salt
te ria, VA Lake City,
Cancer 22314 UT
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk
te ria, VA Raleigh, NC
Cancer 22314
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk
te ria, VA Portland,
Cancer 22314 OR
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk Los
te ria, VA Angeles, CA
Cancer 22314
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk
te ria, VA Lincoln, NE
Cancer 22314
------------------------------------------------------------------------
Monetary ZERO--T 515 King $1,250 8/1/2017 ZERO
he End Street, Prostate
of Ste 420 Cancer Run/
Prosta Alexand Walk Lehigh
te ria, VA Valley, PA
Cancer 22314
------------------------------------------------------------------------
Monetary ZERO--T 515 King $20,000 6/16/2017 Printed News
he End Street, Resource
of Ste 420 for Men
Prosta Alexand Living with
te ria, VA Advanced
Cancer 22314 Disease
------------------------------------------------------------------------
Product Johnson One $497,856,557 12/31/2017 Patient
& Johnson Assistance
Johnso & Product
n Johnson Donation
Patien Plaza
t Kilmer
Assist Square,
ance Suite
Founda 130 New
tion Brunswi
ck, NJ
08933
------------------------------------------------------------------------
Janssen has also made financial donations to independent charitable
foundations that assist patients who are underinsured and in financial
need with treatment-related expenses. In keeping with our donor
agreements and applicable regulatory guidance, we will only disclose
aggregate data on our charitable giving and do not publicize
information on donations to specific foundations and disease states.
In 2017, we contributed approximately $61 million in donations to
independent charitable foundations, enabling them to provide
assistance with medication-related copays to patients with cancer and
autoimmune diseases.Updated
Updated March 30, 2018
Janssen Pharmaceuticals, Inc. Monetary and Product Contribution to U.S.-
based Charitable Organizations Full Year 2017
(Payments made from January 1, 2017 to December 31, 2017)
------------------------------------------------------------------------
Project
Donation Payee Payee Payment Amount Payment Title/
Type Address (USD) Date Description
------------------------------------------------------------------------
Monetary 180 1 $2,500 12/5/2017 2NDFLOOR
Turnin Bethany Youth
g Road, Helpline--H
Lives Buildin unterdon,
Around g 3 Mercer,
, Inc. Suite Somerset
42 Operations
Hazlet,
NJ
07730
------------------------------------------------------------------------
Monetary Adult 872 E. $300 11/6/2017 Costs
Day Main associated
Center Street with
of Bridgew Janssen
Somers ater, Cares
et NJ Volunteer
County 08807 Activity--O
ctober 4,
2017
------------------------------------------------------------------------
Monetary Allianc 2021 K $20,000 12/28/2017 ``Living
e For Street with Atrial
Aging N.W. Fibrillatio
Resear Suite n'' Stroke
ch 305 Prevention
Washing PSA
ton, DC Campaign
20006
------------------------------------------------------------------------
Monetary Allies, 1262 $7,500 11/6/2017 Project Grow
Inc. Whiteho
rse
Hamilto
n
Square
Rd.
Hamilto
n, NJ
08690
------------------------------------------------------------------------
Monetary Alterna 600 $300 9/29/2017 Costs
tives First associated
Ave. with
Raritan Janssen
, NJ Cares
08869 Volunteer
Activity
#2--Septemb
er 12, 2017
------------------------------------------------------------------------
Monetary Alterna 600 $300 9/29/2017 Costs
tives First associated
Ave. with
Raritan Janssen
, NJ Cares
08869 Volunteer
Activity
#1--Septemb
er 12, 2017
------------------------------------------------------------------------
Monetary Alterna 600 $7,500 12/13/2017 Fundraising
tives First event
Ave. support to
Raritan benefit
, NJ general
08869 mission of
organizatio
n
------------------------------------------------------------------------
Monetary America 900 Fort $10,000 5/2/2017 Stop
n Street Diabetes @
Diabet Mall, Work
es Suite
Associ 940
ation Honolul
u, HI
96813
------------------------------------------------------------------------
Monetary America PO Box $30,000 12/22/2017 Atrial
n 541 Fibrillatio
Founda Greenwo n Patient
tion od, TX Education
For 76246 Conference,
Women' AF Patient
s Treatment
Health and Stroke
Prevention
Decision-
Making
Tool, and
AF
Community
Screening
Pilot
------------------------------------------------------------------------
Monetary America 7272 $30,000 12/28/2017 Raising
n Greenvi Awareness
Heart lle Ave on the
Dallas, Effects and
TX Consequence
75231 s of
Untreated
Type 2
Diabetes
------------------------------------------------------------------------
Monetary America 7272 $30,000 12/28/2017 Increasing
n Greenvi Awareness
Heart lle Ave of Deep
Dallas, Vein
TX Thrombosis/
75231 Venous
Thromboembo
lism in
General
Population
and At-Risk
Patients
------------------------------------------------------------------------
Monetary America One $300 9/29/2017 Costs
n Union associated
Heart Street with
Associ Suite Janssen
ation- 301 Cares
-New Robbins Volunteer
Jersey ville, Activity--O
NJ ctober 7,
08691 2017
------------------------------------------------------------------------
Monetary America One $5,000 12/4/2017 16th Annual
n Union Garden
Heart Street State Go
Associ Suite Red For
ation- 301 Women
-New Robbins Luncheon
Jersey ville,
NJ
08691
------------------------------------------------------------------------
Monetary America 1000 $200,000 12/12/2017 Judges and
n Wilson Psychiatris
Psychi Blvd, ts
atric Suite Leadership
Founda 1825 Initiative
tion Arlingt (JPLI)
on, VA
22209
------------------------------------------------------------------------
Monetary America 1000 $100,000 12/12/2017 Typical or
n Wilson Troubled?
Psychi Blvd, School
atric Suite Mental
Founda 1825 Health
tion Arlingt Education
on, VA Program
22209
------------------------------------------------------------------------
Monetary America 1000 $35,000 12/12/2017 Center for
n Wilson Workplace
Psychi Blvd, Mental
atric Suite Health
Founda 1825 (formerly
tion Arlingt the
on, VA Partnership
22209 for
Workplace
Mental
Health)
------------------------------------------------------------------------
Monetary America 88 $600 11/28/2017 Donation In
res Hamilto Lieu of
Founda n Ave. Gift
tion Stamfor
d, CT
06902
------------------------------------------------------------------------
Monetary America 150 $300 9/29/2017 Costs
's Pittsto associated
Grow-A- wn Road with
Row, Pittsto Janssen
Inc. wn, NJ Cares
08867 Volunteer
Activity--S
eptember
27, 2017
------------------------------------------------------------------------
Monetary America 150 $300 9/29/2017 Costs
's Pittsto associated
Grow-A- wn Road with
Row, Pittsto Janssen
Inc. wn, NJ Cares
08867 Volunteer
Activity--O
ctober 6,
2017
------------------------------------------------------------------------
Monetary Anchor 482 $300 9/29/2017 Costs
House, Centre associated
Inc. Street with
Trenton Janssen
, NJ Cares
08611 Volunteer
Activity--S
eptember
28, 2017
------------------------------------------------------------------------
Monetary Anchor 482 $8,000 12/12/2017 Anchor House
House, Centre Shelter
Inc. Street
Trenton
, NJ
08611
------------------------------------------------------------------------
Monetary Ann 595 W. $9,500 12/12/2017 Increasing
Silver State Access to
man Street Comprehensi
Commun Doylest ve
ity own, PA Healthcare
Health 18901 for Low-
Clinic Income,
Uninsured
Bucks
County
residents
------------------------------------------------------------------------
Monetary Arm In 123 E. $15,000 10/30/2017 Improving
Arm, Hanover Food
Inc. St. Security
Trenton and Housing
, NJ Stability
08608
------------------------------------------------------------------------
Monetary Bear 1162 $750 12/12/2017 2018 Bear
Tavern Bear Tavern
Parent Tavern Elementary
s Road Science
Associ Titusvi Fair
ation lle, NJ
08560
------------------------------------------------------------------------
Monetary Big 2875 $6,500 10/30/2017 STEM School
Brothe York Mentoring
rs Big Road Initiative
Sister Jamison
s of , PA
Bucks 18929
County
------------------------------------------------------------------------
Monetary Big 535 East $10,000 8/23/2017 Fundraising
Brothe Frankli event
rs Big n support to
Sister Street benefit
s of Trenton general
Mercer , NJ mission of
County 08610 organizatio
n
------------------------------------------------------------------------
Monetary Big 535 East $7,500 10/16/2017 Youth
Brothe Frankli Mentoring
rs Big n Programs
Sister Street
s of Trenton
Mercer , NJ
County 08610
------------------------------------------------------------------------
Monetary Boys 212 $20,000 10/30/2017 Extended Day
and Centre Learning
Girls Trenton
Club , NJ
of 08611
Trento
n and
Mercer
County
------------------------------------------------------------------------
Monetary Bristol 120 $7,500 11/6/2017 ArtRageous
Rivers Radclif Theatre
ide fe Arts
Theate Street Education
r Co P.O. Program
Inc. Box
1250
Bristol
, PA
19007
------------------------------------------------------------------------
Monetary Britesi 16 Sand $300 11/15/2017 Costs
de Hill associated
Adult Road with
Day Fleming Janssen
Center ton, NJ Cares
s, 08822 Volunteer
Inc. Activity--S
eptember
22, 2017
------------------------------------------------------------------------
Monetary Broward 305 SE $15,000 6/28/2017 Affordable
County 18th Housing
Commun Court
ity Fort
Develo Lauderd
pment ale, FL
Corpor 33316
ation,
Inc.
------------------------------------------------------------------------
Monetary Bucks 400 $300 9/20/2017 Costs
County Freedom associated
Associ Drive with
ation Newtown Janssen
For , PA Cares
The 18940 Volunteer
Blind Activity--S
And eptember
Visual 26, 2017
ly
Impair
ed
------------------------------------------------------------------------
Monetary Bucks 626 $5,000 12/18/2017 Veterans
County Jackson Housing
Housin ville Assistance
g Road Program
Group Suite
140
Warmins
ter, PA
18974
------------------------------------------------------------------------
Monetary Bucks 100 $10,000 12/21/2017 Economic
County Doyle Self-
Opport Street Sufficiency
unity Doylest Program
Counci own, PA
l, 18901
Inc.
------------------------------------------------------------------------
Monetary Caminar 2600 S. $7,500 8/11/2017 Bridges to
El Wellness
Camino Program
Real,
Suite
200 San
Mateo,
CA
94403
------------------------------------------------------------------------
Monetary Capital PO Box $8,000 2/1/2017 ``I Am
City 1743 Trenton!'':
Commun Trenton Positive
ity , NJ Images
Founda 08607-1 Campaign
tion 743
------------------------------------------------------------------------
Monetary Catholi 920 $5,000 12/5/2017 CYO's Broad
c South St. Trenton
Youth Broad Center's
Organi St. After
zation Trenton School
of , NJ Program
Mercer 08611 Tutoring
County Project
------------------------------------------------------------------------
Monetary Center 151 $10,000 10/13/2017 Community-
for Lawrenc Based
Altern e Health
ative Street Services
Senten 3rd for Justice-
cing Floor Involved
and Brookly Adults with
Employ n, NY Schizophren
ment 11201 ia
Servic
es
(CASES
)
------------------------------------------------------------------------
Monetary Central 2500 $5,000 10/3/2017 Diabetes
Bucks Lower Prevention
Family State Program
YMCA Road
Doylest
own, PA
18901
------------------------------------------------------------------------
Monetary Child 204 N. $3,000 3/8/2017 Upper Bucks
Home West Area Young
and Street Parent
Commun #101 Initiative
ity Doylest
own, PA
18901
------------------------------------------------------------------------
Monetary Childre 635 $10,000 11/20/2017 CUNA and
n's South Body and
Home Clinton Soul
Societ Avenue Prenatal
y of Trenton Health
New , NJ Education
Jersey 08611 for Low-
Income
Women
------------------------------------------------------------------------
Monetary CIT 111 S. $5,000 8/15/2017 CIT
Intern Highlan Internation
ationa d St. al
l, Box 71 Conference
Inc. Memphis 2017
, TN
38111
------------------------------------------------------------------------
Monetary Clevela 9500 $20,000 10/25/2017 Diabetes
nd Euclid Center
Clinic Ave., Educational
Founda DV4 Initiatives
tion Clevela at
nd, OH Cleveland
44195 Clinic
South
Pointe
Hospital
------------------------------------------------------------------------
Monetary College 50 Milk $20,000 12/28/2017 Campus
Diabet St 16th Quality
es Floor Improvement
Networ Boston, : Diabetes
k MA and Higher
(CDN) 02109 Education
------------------------------------------------------------------------
Monetary College 2000 $20,000 11/20/2017 Nursing
of New Penning Merit
Jersey ton Scholarship
Road s $7,500;
P.O. and
Box Educational
7718 Opportunity
Ewing, Fund (EOF)
NJ Promise
08628 Awards
$12,500
------------------------------------------------------------------------
Monetary Communi P.O. Box $5,000 12/5/2017 Rise Summer
ty 88 116 Healthy
Action North Food
Servic Main Initiative
e Street for Low-
Center Hightst Income
, Inc. own, NJ Youth
08520-
9804
------------------------------------------------------------------------
Monetary Communi 4059 $5,000 3/8/2017 Arts for
ty Skyron Seniors
Conser Drive ($3,000)
vatory Doylest and Music
of own, PA Therapy
Music 18902 ($2,000)
------------------------------------------------------------------------
Monetary Communi 4059 $4,500 11/6/2017 Making the
ty Skyron Arts
Conser Drive Accessible
vatory Doylest for Seniors
of own, PA and Persons
Music 18902 with
Disabilitie
s: Music
Therapy and
Arts for
Seniors
------------------------------------------------------------------------
Monetary Communi P.O. Box $60,000 12/18/2017 HealtheVoice
ty 338 sTM Impact
Founda Morrist Fund
tion own, NJ
of New 07963-
Jersey 0338
------------------------------------------------------------------------
Monetary Communi P.O. Box $75,000 12/18/2017 Healthcare
ty 338 and Basic
Founda Morrist Needs Fund
tion own, NJ
of New 07963-
Jersey 0338
------------------------------------------------------------------------
Monetary Communi P.O. Box $14,000 7/17/2017 ``Each One,
ty 15176 Teach
Health 407 One'':
Coalit Crutchf Community
ion, ield Empowerment
Inc. Street Diabetes
Durham, Self-
NC Management
27704 Education
Program
------------------------------------------------------------------------
Monetary Communi 959 $11,000 6/14/2017 Pathway to
ty Route Recovery
Hope, 46 East Residential
Inc. Suite Programs/
402 The Annual
Parsipp Forum and
any, NJ Wellness
07054 Fair
------------------------------------------------------------------------
Monetary Communi 959 $15,000 10/16/2017 Hope for
ty Route Veterans
Hope, 46 East and Valley
Inc. Suite Brook
402 Village for
Parsipp Veterans
any, NJ
07054
------------------------------------------------------------------------
Monetary Communi 310 W. $5,000 12/18/2017 Basic Needs:
ty State Legal
Justic Street, Services
e 3rd
Center Floor
, Inc. Trenton
, NJ
08618
------------------------------------------------------------------------
Monetary Compeer 259 $2,500 5/31/2017 Caregiver
Roches Monroe Support
ter, Avenue
Inc. Rochest
er, NY
14607
------------------------------------------------------------------------
Monetary Contact 60 S. $8,500 12/4/2017 Emotional
Of Main Support and
Mercer St. Crisis
County Penning Services:
New ton, NJ HOTLINE,
Jersey 08628 Crisis Chat
Inc. and
TxtToday
------------------------------------------------------------------------
Monetary CONTACT P.O. Box $4,000 10/4/2017 Training
We 2376 Nonprofessi
Care, Westfie onals in
Inc. ld, NJ Crisis
07091 Interventio
n for
People
Experiencin
g Psychosis
------------------------------------------------------------------------
Monetary Court 1450 $300 8/29/2017 Costs
Appoin Parksid associated
ted e with
Specia Avenue, Janssen
l Suite Cares
Advoca 22 Volunteer
tes Ewing, Activity--S
NJ eptember
08638- 12, 2017
2946
------------------------------------------------------------------------
Monetary Court 1450 $15,000 11/20/2017 General
Appoin Parksid mission
ted e support
Specia Avenue,
l Suite
Advoca 22
tes Ewing,
NJ
08638-
2946
------------------------------------------------------------------------
Monetary Deborah 212 $5,000 12/22/2017 2018 Women's
Hospit Trenton Heart
al Road Health
Founda Browns Educational
tion Mills, Expo
NJ
08015
------------------------------------------------------------------------
Monetary Delawar 14 $4,500 11/6/2017 Environmenta
e Michael l education
River McCorri for
Steamb stin underfunded
oat Road and
Floati Hamilto underserved
ng n, NJ schools and
Classr 08690 youth
oom, groups
Inc.
------------------------------------------------------------------------
Monetary Depress 5 $1,000 3/8/2017 DBSA NJ
ion Village Mutual Aid
and Ct. Support
Bipola Lawrenc Group
r eville, Facilitator
Suppor NJ Training
t 08648
Allian
ce
------------------------------------------------------------------------
Monetary Diabete 14652 $5,000 3/23/2017 The Diabetes
s Corkwoo UnConferenc
Collec d Drive e
tive, Tampa,
Inc. FL
33626
------------------------------------------------------------------------
Monetary Dress 3131 $10,000 10/16/2017 Women's
for Princet Empowerment
Succes on Pike Programs
s Buildin
g 4,
Suite
209
Lawrenc
eville,
NJ
08648
------------------------------------------------------------------------
Monetary Eden 2 $10,000 10/16/2017 Adult
Autism Merwick Employment
Servic Road Program
es Princet
Founda on, NJ
tion 08540
------------------------------------------------------------------------
Monetary Eden 2 $10,000 12/18/2017 Eden Dreams
Autism Merwick Sponsorship
Servic Road
es Princet
Founda on, NJ
tion 08540
------------------------------------------------------------------------
Monetary Emory 550 $3,500 7/3/2017 Atrial
Univer Peachtr Fibrillatio
sity ee n Support
Street Group
6th Fl, Meeting
Suite
4300
Atlanta
, GA
30308
------------------------------------------------------------------------
Monetary Enable, 13 $7,500 12/12/2017 Connect with
Inc. Roszel Enable--Div
Road, ersity
Suite Drive
B110
Princet
on, NJ
08540
------------------------------------------------------------------------
Monetary Every Fred $9,000 12/4/2017 Every Child
Child Vereen, Valued
Valued Jr. (ECV) After
A NJ Communi School
Nonpro ty Program
fit Center
Corpor 175
ation Johnson
Avenue
Lawrenc
eville,
NJ
08648
------------------------------------------------------------------------
Monetary Everybo 707 $7,500 12/4/2017 Coming Up
dy Alexand for AIRTM
Loves er
Kenny Road,
Projec Suite
t Inc. 208
Princet
on, NJ
08540
------------------------------------------------------------------------
Monetary Familie 320 N. $3,500 8/29/2017 DBT-Based
s and Goodman Coping
Friend St., Skills for
s of Suite Families
the 102
Mental Rochest
ly Ill er, NY
and 14607
Emotio
nally
Distur
bed,
Inc,
dba
NAMI-
Roches
ter
------------------------------------------------------------------------
Monetary Family 1931 $300 8/24/2017 Costs
Guidan Notting associated
ce ham Way with
Center Hamilto Janssen
Corpor n, NJ Cares
ation 08619 Volunteer
Activity--S
eptember
28, 2017
------------------------------------------------------------------------
Monetary Family 1931 $10,000 10/27/2017 Outpatient
Guidan Notting mental
ce ham Way health
Center Hamilto treatment
Corpor n, NJ for
ation 08619 homeless
women and
children.
------------------------------------------------------------------------
Monetary Family 1 AAA Dr $12,500 11/20/2017 Caregiver
Resour Suite Wellness
ce 203 Series
Networ Trenton
k , NJ
08691
------------------------------------------------------------------------
Monetary Family 4 $14,000 12/4/2017 Nurse
Servic Corners Educator at
e tone Bucks
Associ Drive County
ation Langhor Emergency
of ne, PA Homeless
Bucks 19047 Shelter
County
------------------------------------------------------------------------
Monetary Federat One $2,500 5/31/2017 Big Nosh
ion of Farming Vocational
Organi dale Services
zation Road Program
s West
Babylon
, NY
11704
------------------------------------------------------------------------
Monetary Feed Central $75 2/24/2017 Employee
More, Virgini directed
Inc. a Food donation in
Bank lieu of
1415 company
Rhoadmi holiday
ller gift
Street
Richmon
d, VA
23220
------------------------------------------------------------------------
Monetary Florida 2525 $1,500 10/13/2017 2017 Florida
Coalit Saint Institute
ion Lucie on
for Avenue Homelessnes
the Vero s and
Homele Beach, Supportive
ss, FL Housing
Inc. 32960
------------------------------------------------------------------------
Monetary Forsyth 4881 $75 4/11/2017 Employee
Humane Country directed
Societ Club donation in
y Rd. lieu of
Winston company
Salem, holiday
NC gift
27104
------------------------------------------------------------------------
Monetary Foundat 2381 $2,500 12/5/2017 Funding
ion of Lawrenc support for
Morris eville the 2018
Hall/ Road Philly Pops
St. Lawrenc Benefit
Lawren eville, Concert
ce NJ
08648
------------------------------------------------------------------------
Monetary Foundat 2381 $7,000 12/5/2017 It's Never 2
ion of Lawrenc Late
Morris eville
Hall/ Road
St. Lawrenc
Lawren eville,
ce NJ
08648
------------------------------------------------------------------------
Monetary Fountai 425 West $2,500 10/16/2017 Danny Zorn
n 47th Scholarship
House Street Fund
New
York,
NY
10036
------------------------------------------------------------------------
Monetary Fountai 425 West $6,000 10/16/2017 Mad About
n 47th Art Auction
House Street and Benefit
New
York,
NY
10036
------------------------------------------------------------------------
Monetary Fountai 425 West $1,000 3/23/2017 Fountain
n 47th House One-
House Street in-Four 5K
New
York,
NY
10036
------------------------------------------------------------------------
Monetary Friends P.O. Box $10,125 11/20/2017 Project
Of 395 Hopewell
Hopewe Penning Healthy
ll ton, NJ Habitats
Valley 08534
Open
Space
------------------------------------------------------------------------
Monetary Friends P.O. Box $2,500 10/27/2017 Fundraising
Of 395 event
Hopewe Penning support to
ll ton, NJ benefit
Valley 08534 general
Open mission of
Space organizatio
n
------------------------------------------------------------------------
Monetary Friends 6 Lilly $3,600 12/18/2017 Giving Voice
of Street Through
Lamber Lambert Film
tville ville,
Librar NJ
y, 08530
Inc.
------------------------------------------------------------------------
Monetary Friends 57 $300 10/16/2017 Costs
Of Mountai associated
Prince n with
ton Avenue Janssen
Open Princet Cares
Space on, NJ Volunteer
08540 Activity--S
eptember
13, 2017
------------------------------------------------------------------------
Monetary Gateway 4901 $10,000 8/29/2017 Outpatient
Homes, Libbie Clinical
Inc. Mill Services to
East Support
Bouleva Individuals
rd with
Suite Schizophren
210 ia and
Richmon Schizoaffec
d, VA tive
23230 Disorder
------------------------------------------------------------------------
Monetary Georgia 246 $2,000 8/21/2017 26th Annual
Mental Sycamor Statewide
Health e St. Consumer
Consum Suite Conference
er 260
Networ Decatur
k , GA
30030
------------------------------------------------------------------------
Monetary Globalg 1110 $825 11/30/2017 Donation In
iving Vermont Lieu of
Founda Ave. NW Gift
tion, Suite
Inc. 550
Washing
ton, DC
20005
------------------------------------------------------------------------
Monetary Good 38 Elm $5,000 12/18/2017 Nights of
Grief, Street Support--Pr
Inc. Morrist inceton
own, NJ Center
07960
------------------------------------------------------------------------
Monetary Greater 102 $150,000 2/2/2017 Greater
Trento Barrack Trenton
n Street Initiative
Trenton
, NJ
08608
------------------------------------------------------------------------
Monetary Grounds 80 $7,500 12/4/2017 Wellness
for Sculpto Walks
Sculpt rs Way
ure Hamilto
n, NJ
08534
------------------------------------------------------------------------
Monetary Habitat 530 $300 12/18/2017 Costs
for Route associated
Humani 38 E with
ty of Maple Janssen
Burlin Shade, Cares
gton NJ Volunteer
County 08052 Activity--O
and ctober 6,
Greate 2017
r
Trento
n-
Prince
ton
------------------------------------------------------------------------
Monetary Habitat 530 $300 12/18/2017 Costs
for Route associated
Humani 38 E with
ty of Maple Janssen
Burlin Shade, Cares
gton NJ Volunteer
County 08052 Activity--O
and ctober 4,
Greate 2017
r
Trento
n-
Prince
ton
------------------------------------------------------------------------
Monetary Habitat 530 $300 12/18/2017 Costs
for Route associated
Humani 38 E with
ty of Maple Janssen
Burlin Shade, Cares
gton NJ Volunteer
County 08052 Activity--S
and eptember
Greate 29, 2017
r
Trento
n-
Prince
ton
------------------------------------------------------------------------
Monetary Habitat 530 $300 12/18/2017 Costs
for Route associated
Humani 38 E with
ty of Maple Janssen
Burlin Shade, Cares
gton NJ Volunteer
County 08052 Activity--S
and eptember 8,
Greate 2017
r
Trento
n-
Prince
ton
------------------------------------------------------------------------
Monetary Habitat 530 $5,000 12/18/2017 Affordable
for Route Homeownersh
Humani 38 E ip Program
ty of Maple
Burlin Shade,
gton NJ
County 08052
and
Greate
r
Trento
n-
Prince
ton
------------------------------------------------------------------------
Monetary Habitat 31 Oak $7,500 11/6/2017 Women Build
for Avenue, and Safe at
Humani Suite Home Repair
ty of 100 Clinics
Greate Chalfon
r t, PA
Bucks 18914
------------------------------------------------------------------------
Monetary Heart 1325 G $30,000 12/22/2017 HRS-WebMD:
Rhythm Street Atrial
Societ NW, Fibrillatio
y, Suite n and How
Inc. 400 to Reduce
Washing Your Risk
ton, DC of Stroke
20005
------------------------------------------------------------------------
Monetary Heartla 4750 N. $7,500 8/11/2017 Pathways
nd Sherida Home
Health n Road
Outrea Chicago
ch , IL
60640
------------------------------------------------------------------------
Monetary Henders 4740 $7,500 5/31/2017 Helping
on North Individuals
Behavi State Live Longer
oral Road 7 (HILL)
Health Lauderd
ale
Lakes,
FL
33319
------------------------------------------------------------------------
Monetary HiTOPS, 21 $9,000 12/12/2017 HiTOPS
Inc. Wiggins Comprehensi
Street ve
Princet Sexuality
on, NJ Interventio
08540 ns for
Youth-at-
Risk
------------------------------------------------------------------------
Monetary HomeFro 1880 $300 10/30/2017 Costs
nt Princet associated
on with
Avenue Janssen
Lawrenc Cares
eville, Volunteer
NJ Activity--O
08648 ctober 20,
2017
------------------------------------------------------------------------
Monetary HomeFro 1880 $300 10/30/2017 Costs
nt Princet associated
on with
Avenue Janssen
Lawrenc Cares
eville, Volunteer
NJ Activity--S
08648 eptember
27, 2017
------------------------------------------------------------------------
Monetary HomeFro 1880 $300 10/30/2017 Costs
nt Princet associated
on with
Avenue Janssen
Lawrenc Cares
eville, Volunteer
NJ Activity--S
08648 eptember
20, 2017
------------------------------------------------------------------------
Monetary HomeFro 1880 $10,000 11/20/2017 Helping
nt Princet Homeless
on Families
Avenue Break the
Lawrenc Cycle of
eville, Poverty
NJ
08648
------------------------------------------------------------------------
Monetary Hopewel 35 $750 12/12/2017 2018
l Princet Hopewell
Elemen on Elementary
tary Avenue School
School Hopewel Science
Parent l, NJ Fair
Teache 08525
r
Organi
zation
Inc.
------------------------------------------------------------------------
Monetary Hopewel PO Box $6,446 12/4/2017 Scholarship
l 553 Support:
Valley Penning $1,000;
Educat ton, NJ STEM
ion 08534 Education
Founda and
tion Sustainabil
ity
Education
at Hopewell
Elementary
and Stony
Brook
Elementary
Schools :
$5446
------------------------------------------------------------------------
Monetary Hopewel 48 $1,500 12/4/2017 Mobility for
l Orchard Homebound
Valley Ave PO Residents
Senior Box 567 of the
Founda Penning Hopewell
tion ton, NJ Valley
08534
------------------------------------------------------------------------
Monetary Hopewel P.O. Box $2,525 12/18/2017 Scholarship
l 159 16 Fund
Valley Seminar
Youth y
Choral Avenue,
e, Suite C
Inc. Hopewel
l, NJ
08525
------------------------------------------------------------------------
Monetary Hunterd 7 Lower $7,500 12/4/2017 Open Studio/
on Art Center Open
Center Street Hearts:
Clinton Artistic
, NJ Expressions
08809 and Art
with Heart
------------------------------------------------------------------------
Monetary Hunterd 1410 $2,500 11/6/2017 Fundraising
on Route event
County 22 West sponsorship
YMCA Annanda to benefit
le, NJ general
08801 mission of
organizatio
n
------------------------------------------------------------------------
Monetary Hunterd 111 Mine $300 9/29/2017 Costs
on Street associated
Land Fleming with
Trust ton, NJ Janssen
08822 Cares
Volunteer
Activity--S
eptember
14, 2017
------------------------------------------------------------------------
Monetary Hunterd 111 Mine $2,500 12/4/2017 Promotion
on Street and
Land Fleming Protection
Trust ton, NJ of
08822 Preserves
------------------------------------------------------------------------
Monetary Interfa 3635 $15,000 10/30/2017 Neighbors
ith Quakerb Helping
Caregi ridge Neighbors
vers Road,
Trento Suite
n, #16
Inc. Hamilto
n, NJ
08619
------------------------------------------------------------------------
Monetary Isles, 10 Wood $300 9/29/2017 Costs
Inc. Street associated
Trenton with
, NJ Janssen
08618 Cares
Volunteer
Activity--S
eptember
20, 2017
------------------------------------------------------------------------
Monetary Isles, 10 Wood $9,000 12/12/2017 Trenton
Inc. Street Healthy
Trenton Homes
, NJ
08618
------------------------------------------------------------------------
Monetary Jewish 707 $300 9/29/2017 Costs
Family Alexand associated
and er Road with
Childr Suite Janssen
en's 102 Cares
Servic Princet Volunteer
e of on, NJ Activity--S
Greate 08540 eptember
r 28, 2017
Mercer
County
------------------------------------------------------------------------
Monetary Jewish 707 $15,000 12/18/2017 Senior
Family Alexand Outreach
and er Road Service
Childr Suite (SOS) PLUS
en's 102 ($12,000);
Servic Princet Caregiver
e of on, NJ Program
Greate 08540 ($3,000)
r
Mercer
County
------------------------------------------------------------------------
Monetary Jewish 150-A $5,000 10/30/2017 Expanding
Family West Horizons
Servic High
e of St.
Somers Somervi
et lle, NJ
Hunter 08876
don
and
Warren
Counti
es
Inc.
------------------------------------------------------------------------
Monetary Johnson One $5,500,000 7/3/2017 General
& Johnson mission
Johnso & support
n Johnson
Patien Plaza
t Kilmer
Assist Square
ance Suite
Founda 130 New
tion Brunswi
Inc. ck, NJ
08933
------------------------------------------------------------------------
Monetary Johnson One $15,500,000 9/28/2017 General
& Johnson mission
Johnso & support
n Johnson
Patien Plaza
t Kilmer
Assist Square
ance Suite
Founda 130 New
tion Brunswi
Inc. ck, NJ
08933
------------------------------------------------------------------------
Monetary Johnson One $2,400,000 12/18/2017 General
& Johnson mission
Johnso & support
n Johnson
Patien Plaza
t Kilmer
Assist Square
ance Suite
Founda 130 New
tion Brunswi
Inc. ck, NJ
08933
------------------------------------------------------------------------
Monetary Junior 360 Pear $7,150 10/30/2017 STEMCivics
Achiev Blossom High School
ement Drive Heroes JA
of New Edison, Day
Jersey NJ
08837
------------------------------------------------------------------------
Monetary Kidsbri 999 $10,000 10/16/2017 Bullying
dge, Lower Prevention
Inc. Ferry and
Rd Diversity
Ewing, Appreciatio
NJ n Life
08628 Skills
Program for
At-Risk
Middle
School
Students in
Trenton
------------------------------------------------------------------------
Monetary Kidsbri 999 $9,500 2/1/2017 Bullying
dge, Lower Prevention
Inc. Ferry and
Rd Diversity
Ewing, Appreciatio
NJ n Life
08628 Skills
Program for
At-Risk
Elementary/
Middle
School
Students in
Trenton
------------------------------------------------------------------------
Monetary Latin 669 $5,000 12/12/2017 FUTURO
Americ Chamber
an s
Legal Street,
Defens Suite B
e and Trenton
Educat , NJ
ional 08611
Fund
Inc.
------------------------------------------------------------------------
Monetary Leyden 10001 W $25,000 12/12/2017 Transitional
Family Grand Living
Servic Ave Program
e and Frankli Expansion
Mental n Park,
Health IL
Center 60131
------------------------------------------------------------------------
Monetary LifeTie 2205 $8,000 12/18/2017 Programs to
s, Penning Serve
Inc. ton Chronically
Road Ill and
Ewing, Abused and
NJ Neglected
08638 Older Youth
Transitioni
ng Into
Adulthood.
------------------------------------------------------------------------
Monetary Literac 100 $5,000 12/12/2017 Women
y New Menlo Empowered
Jersey Park (WE)
, Inc. Drive,
Suite
314
Edison,
NJ
08837
------------------------------------------------------------------------
Monetary Literac 120 $4,000 12/12/2017 Health
y Findern Literacy
Volunt e for All
eers Avenue
of Box 7
Somers Bridgew
et ater,
County NJ
08807
------------------------------------------------------------------------
Monetary Main 8 $1,000 5/31/2017 Crisis
Street Marcell Interventio
Counse a n Team
ling Avenue Training
Center West for Essex
Orange, County Law
NJ Enforcement
07052
------------------------------------------------------------------------
Monetary Main 8 $5,000 6/12/2017 Accessible
Street Marcell Mental
Counse a Health Care
ling Avenue for
Center West Individuals
Orange, Suffering
NJ From
07052 Schizoaffec
tive
Disorder
------------------------------------------------------------------------
Monetary Massach 15 $3,500 2/6/2017 Changing
usetts Vernon Minds and
Clubho Street Expanding
use Waltham Employment
Coalit , MA Campaign
ion 02453
------------------------------------------------------------------------
Monetary McCarte 91 $10,000 11/20/2017 OnStage
r Univers Seniors: A
Theatr ity Community
e Place Project of
Center Princet McCarter
on, NJ Theatre
08540
------------------------------------------------------------------------
Monetary Meals 320 $300 9/29/2017 Costs
on Hollowb associated
Wheels rook with
of Drive Janssen
Trento Ewing, Cares
n NJ Volunteer
Ewing 08638 Activity--O
ctober 4,
2017
------------------------------------------------------------------------
Monetary Meals 320 $15,000 11/6/2017 Subsidized
on Hollowb Meal
Wheels rook Program
of Drive (SMP)
Trento Ewing,
n NJ
Ewing 08638
------------------------------------------------------------------------
Monetary Mental 500 $50,000 9/21/2017 General
Health Montgom mission
Americ ery St. support
a Suite
820
Alexand
ria, VA
22314
------------------------------------------------------------------------
Monetary Mental 500 $100,000 12/12/2017 Social Self-
Health Montgom Directed
Americ ery St. Care (SSDC)
a Suite
820
Alexand
ria, VA
22314
------------------------------------------------------------------------
Monetary Mental 2211 $7,500 10/20/2017 Mental
Health Norfolk Health
Americ , Suite Advocacy
a of 810
Greate Houston
r , TX
Housto 77098
n
------------------------------------------------------------------------
Monetary Mental 2323 W $10,000 5/24/2017 Get
Health 5th Connected
Americ Ave.
a of Suite
Frankl 160
in Columbu
County s, OH
43204
------------------------------------------------------------------------
Monetary Mental 1210 San $2,500 4/24/2017 Mental
Health Antonio Health
Americ , Suite Education
a of 200 and
Texas Austin, Advocacy
TX Campaign
78701
------------------------------------------------------------------------
Monetary Mental 100 W. $2,000 10/13/2017 Community
Health 10th Mental
Associ St. Health
ation Ste. Conference
in 600 2017
Delawa Wilming
re ton, DE
19801
------------------------------------------------------------------------
Monetary Mental 100 W. $1,000 10/3/2017 E-Racing the
Health 10th Blues for
Associ St. Mental
ation Ste. Health Run/
in 600 Walk
Delawa Wilming
re ton, DE
19801
------------------------------------------------------------------------
Monetary Mental 617 $2,500 5/31/2017 Operating
Health Garden Support for
Associ Street the
ation Santa Fellowship
in Barbara Club
Santa , CA
Barbar 93101
a
County
------------------------------------------------------------------------
Monetary Mental 3701 $7,500 5/31/2017 ParentVOICE
Health Latrobe
Associ Drive,
ation Suite
of 140
Centra Charlot
l te, NC
Caroli 28211
nas,
Inc.
------------------------------------------------------------------------
Monetary Mental 580 $1,000 5/31/2017 Get On Your
Health White Mat For
Associ Plains Mental
ation Road Health
of Suite
Westch 510
ester Tarryto
wn, NY
10591
------------------------------------------------------------------------
Monetary Mental 3809 $12,500 8/30/2017 Outreach and
Illnes Rosewoo Behavioral
s d Drive Healthcare
Recove P.O. for
ry Box Homeless
Center 4246 Individuals
, Inc. Columbi with Mental
a, SC Illness
29240
------------------------------------------------------------------------
Monetary Mercer 1001 $15,000 12/19/2017 Addressing
Allian Spruce Young Adult
ce to Street Homelessnes
End Suite s, through
Homele 205 planning,
ssness Trenton assertive
, NJ engagement,
08638 housing,
and
healthcare
access
------------------------------------------------------------------------
Monetary Mercer P.O. Box $6,500 11/6/2017 Miscellaneou
County 17202 s medical
Commun Trenton equipment
ity , NJ ($1,000),
Colleg 08690 and work
e study
Founda student
tion mentors
($3,500) to
provide
academic
enrichment
for health
profession
students
success
------------------------------------------------------------------------
Monetary Mercer 3 Creek $1,000 11/20/2017 Mercer
Scienc Rim Science
e And Drive Fair 2018
Engine Titusvi
ering lle, NJ
Club 08560
------------------------------------------------------------------------
Monetary Mercer 151 $300 8/24/2017 Costs
Street Mercer associated
Friend Street with
s Trenton Janssen
, NJ Cares
08611 Volunteer
Activity--O
ctober 4,
2017
------------------------------------------------------------------------
Monetary Mercer 151 $300 8/24/2017 Costs
Street Mercer associated
Friend Street with
s Trenton Janssen
, NJ Cares
08611 Volunteer
Activity--S
eptember
14, 2017
------------------------------------------------------------------------
Monetary Mercer 151 $25,000 10/30/2017 Mercer
Street Mercer Street
Friend Street Friends
s Trenton Food Bank
, NJ
08611
------------------------------------------------------------------------
Monetary Middle P.O. Bos $15,000 10/16/2017 Outreach
Earth 8045 Program and
520 Community
North Youth
Bridge Center
Street
Bridgew
ater,
NJ
08807
------------------------------------------------------------------------
Monetary MIDJers 423 $5,000 8/16/2017 City of
ey Rivervi Trenton--Su
Center ew mmer Youth
for Plaza Employment
Econom Trenton Program
ic , NJ
Develo 08611
pment
------------------------------------------------------------------------
Monetary Midland 60 $6,500 8/16/2017 Midland
Adult Industr Meals on
Servic ial Wheels
es, Parkway Employment
Inc. P.O. Training
Box Program
5026
North
Branch,
NJ
08876
------------------------------------------------------------------------
Monetary Midland 94 $300 9/13/2017 Costs
Founda Reading associated
tion ton with
Road Janssen
P.O. Cares
Box Volunteer
5026 Activity--O
North ctober 3,
Branch, 2017
NJ
08876
------------------------------------------------------------------------
Monetary Millhil 101 $5,000 10/30/2017 Trenton Area
l Oakland Stakeholder
Child Street s
and Trenton
Family , NJ
Develo 08618
pment
------------------------------------------------------------------------
Monetary Millhil 101 $15,000 10/30/2017 Millhill
l Oakland Trenton
Child Street PEERS
and Trenton
Family , NJ
Develo 08618
pment
------------------------------------------------------------------------
Monetary Morven 55 $5,000 11/6/2017 Internships
Museum Stockto for At-Risk
and n Youth
Garden Street
Princet
on, NJ
08540
------------------------------------------------------------------------
Monetary Mount 73 North $15,000 10/27/2017 In Home
Carmel Clinton Nursing
Guild Avenue Services
Trenton
, NJ
08609
------------------------------------------------------------------------
Monetary NAMI 7500 $3,000 10/4/2017 Educational
Greenwo and
od Ave Training
N Programs
Seattle
, WA
98103
------------------------------------------------------------------------
Monetary NAMI--C 1904 $2,500 8/14/2017 Education
VA Byrd and support
Centra Avenue programs
l Suite and
Virgin 207 HelpLine
ias (POB
Voice 18086)
On Richmon
Mental d, VA
Illnes 23230
s
------------------------------------------------------------------------
Monetary NAMI 107 $5,000 8/29/2017 NAMI Ending
Geauga South the Silence
County Street;
# 5
Chardon
, OH
44024
------------------------------------------------------------------------
Monetary NAMI 107 $2,000 8/29/2017 NAMI
Geauga South Connection
County Street; and Peer-to-
# 5 Peer
Chardon Collaborati
, OH on A Peer-
44024 led Support
and
Education
Program
------------------------------------------------------------------------
Monetary NAMI 4161 NW $1,000 5/31/2017 NAMIWalks
Browar 5 St. Broward
d Suite County
County 203
, Inc. Plantat
ion, FL
33317
------------------------------------------------------------------------
Monetary NAMI 8324 $1,000 3/20/2017 NAMI CCNS 5k
Cook Skokie Run/Walk
County Blvd 2017
North Skokie,
Suburb IL
an 60077
------------------------------------------------------------------------
Monetary NAMI 2400 W. $1,000 3/20/2017 2017
Delawa 4th NAMIWalks
re Street Delaware
Wilming
ton, DE
19805
------------------------------------------------------------------------
Monetary NAMI P.O. Box $2,500 10/4/2017 Support
Hernan 5613 Services
do Spring and CARE
Hill, Line
FL
34609
------------------------------------------------------------------------
Monetary NAMI 1235 $10,000 10/16/2017 Education
Mercer Whiteho and Support
NJ rse Programs
Mercerv for Mental
ille Health
Road Consumers
Bldg. and Family
C, Members
Suite
303
Hamilto
n, NJ
08619
------------------------------------------------------------------------
Monetary NAMI 1235 $2,500 3/8/2017 Silver
Mercer Whiteho sponsor
NJ rse 2017
Mercerv NAMIWalks
ille Mercer
Road County, NJ
Bldg. May 6, 2017
C,
Suite
303
Hamilto
n, NJ
08619
------------------------------------------------------------------------
Monetary NAMI 85 N. $1,000 10/5/2017 NAMIWalks NH
New State 2017
Hampsh Street
ire Concord
, NH
03301
------------------------------------------------------------------------
Monetary NAMI 1538 $7,500 8/29/2017 1-on-1
New Louisia Education
Orlean na Ave. for People
s New Living with
Orleans Schizoaffec
, LA tive
70115 Disorder/
Schizophren
ia and
Their Loved
Ones/
Caregivers
------------------------------------------------------------------------
Monetary NAMI of 115 $8,000 10/3/2017 Living Room
DuPage North Program
County County
Illino Farm
is Road
Wheaton
, IL
60187
------------------------------------------------------------------------
Monetary NAMI of 2701 $3,000 10/13/2017 Compeer
Johnso Rochest connects
n er Ave. with Local
County Iowa Businesses
dba City, to Increase
Compee IA Volunteeris
r of 52245 m and
Johnso Visibility
n
County
------------------------------------------------------------------------
Monetary NAMI of One $3,000 9/29/2017 NAMI Peer-to-
Lake Victori Peer
County a Sq., Recovery
Ste. Education
260 Program
Painesv
ille,
OH
44077
------------------------------------------------------------------------
Monetary NAMI of One $1,500 8/11/2017 NAMI Lake
Lake Victori County
County a Sq., Strides for
Ste. Awareness
260 NAMI Walk
Painesv
ille,
OH
44077
------------------------------------------------------------------------
Monetary NAMI of 100 W, $1,000 1/31/2017 Bronze
PA Main sponsor
Montgo St. NAMIWalks
mery Suite Greater
County 204 Philadelphi
Lansdal a May 6,
e, PA 2017
19446
------------------------------------------------------------------------
Monetary NAMI of 4055 $3,500 9/29/2017 Hope for
Southw Executi Recovery
est ve Park
Ohio Drive,
Suite
450
Cincinn
ati, OH
45241
------------------------------------------------------------------------
Monetary NAMI 3037 NW $1,000 5/9/2017 NAMI Walks
Oklaho 63RD, Oklahoma
ma SUITE
104W
Oklahom
a City,
OK
73116
------------------------------------------------------------------------
Monetary NAMI 1750 S. $1,000 5/4/2017 2017
St. Brentwo NAMIWALKS
Louis od St. Louis
Blvd.
Suite
511 St.
Louis,
MO
63144
------------------------------------------------------------------------
Monetary NAMI P.O. Box $1,000 9/7/2017 13th Annual
Summit 462, NAMIWalks
County Cuyahog Summit
a Falls County 2017
OH
44222
Akron,
OH
44311
------------------------------------------------------------------------
Monetary NAMI 5251 $1,000 5/31/2017 NAMIWalks
Ventur Verdugo event in
a Way, #K Ventura
County P.O. County, CA
Box
1613
Camaril
lo, CA
93011
------------------------------------------------------------------------
Monetary NAMI 217 $1,000 8/30/2017 NAMIWalks
Waukes Wiscons Waukesha
ha in Ave
Suite
300
Waukesh
a, WI
53186
------------------------------------------------------------------------
Monetary NAMI 217 $1,000 8/11/2017 Crisis
Waukes Wiscons Interventio
ha in Ave n Training
Suite for Law
300 Enforcement
Waukesh
a, WI
53186
------------------------------------------------------------------------
Monetary Nationa 1851 $2,500 5/31/2017 2017 NAMI
l Heritag California
Allian e Way, Annual
ce for Suite Conference
the 150
Mental Sacrame
ly Ill nto, CA
95815
------------------------------------------------------------------------
Monetary Nationa 576 $1,500 3/20/2017 2017 NAMI
l Farming Connecticut
Allian ton Walk
ce for Avenue
the Hartfor
Mental d, CT
ly Ill 06105
------------------------------------------------------------------------
Monetary Nationa 5095 $1,000 3/20/2017 NAMIWalks/
l Murphy Run San
Allian Canyon Diego
ce for Road, County
the Suite
Mental 320 San
ly Ill Diego,
CA
92123
------------------------------------------------------------------------
Monetary Nationa 1562 $1,000 1/31/2017 Bronze
l Route sponsor
Allian 130 2017
ce for North NAMIWalks
the Brunswi New Jersey
Mental ck, NJ ``Building
ly Ill 08902 Better
Lives''--Ma
y 13, 2017
------------------------------------------------------------------------
Monetary Nationa 800 $3,500 8/29/2017 Project ADD
l Transfe Advocating
Allian r Road for Dual
ce for #31 St. Diagnosis
the Paul,
Mental MN
ly Ill 55114
------------------------------------------------------------------------
Monetary Nationa 3440 $1,000 4/21/2017 NAMIWalks
l Viking Northern
Allian Drive, California
ce for Suite
the 104A
Mental Sacrame
ly Ill nto, CA
95827
------------------------------------------------------------------------
Monetary Nationa PO Box $1,000 8/29/2017 NAMI
l 550039 Birmingham
Allian Birming 2017 Walk
ce for ham, AL for Mental
the 35255- Health
Mental 0039
ly Ill
------------------------------------------------------------------------
Monetary Nationa 3803 N. $50,000 10/3/2017 General
l Fairfax mission
Allian Drive support
ce for Suite
the 100
Mental Arlingt
ly Ill on, VA
22203
------------------------------------------------------------------------
Monetary Nationa 1801 W $8,000 11/16/2017 Honest,
l Warner Open,
Allian Ave, Proud:
ce for Suite Addressing
the 202 Stigma
Mental Chicago Among the
ly Ill , IL Incarcerate
60613 d
Population
------------------------------------------------------------------------
Monetary Nationa 1562, $2,500 10/13/2017 Annual
l Route Conference-
Allian 130 -Honoring
ce for North The Past,
the Brunswi Embracing
Mental ck, NJ The
ly Ill 08902 Present,
Looking To
The Future
------------------------------------------------------------------------
Monetary Nationa 3200 S. $1,000 1/31/2017 Bronze
l 3rd sponsor
Allian Street, 2017 NAMI
ce for Unit 6 Walk of
the Milwauk Greater
Mental ee, WI Milwaukee--
ly Ill 53207 May 20,
2017
------------------------------------------------------------------------
Monetary Nationa 218 West $5,000 10/19/2017 NAMI
l Lawrenc Illinois--G
Allian e rassroots
ce for Springf Advocacy
the ield, Capacity
Mental IL Project
ly Ill 62704
------------------------------------------------------------------------
Monetary Nationa P.O. Box $1,000 10/11/2017 Mental
l 4096 Health
Allian Alvin, Education
ce for TX Conference-
the 77512 -May 2018
Mental
ly Ill
------------------------------------------------------------------------
Monetary Nationa 3803 N. $75,000 12/18/2017 NAMI 2018
l Fairfax CIT/
Allian Drive Criminal
ce for Suite Justice
the 100 Enhancement
Mental Arlingt Initiative
ly Ill on, VA
22203
------------------------------------------------------------------------
Monetary Nationa 3803 N. $50,000 12/18/2017 NAMI
l Fairfax HelpLine
Allian Drive 2018
ce for Suite
the 100
Mental Arlingt
ly Ill on, VA
22203
------------------------------------------------------------------------
Monetary Nationa 99 Pine $5,000 10/27/2017 Intervention
l St. ,
Allian Suite Engagement,
ce for 105 Implementat
the Albany, ion: Three
Mental NY Pronged
ly Ill 12207 Approach to
Sustainable
Mental
Health
Recovery
------------------------------------------------------------------------
Monetary Nationa P.O. Box $1,000 10/19/2017 12th Annual
l 24128 NAMI
Allian 117 Lowcountry
ce for William Walk
the Hilton
Mental Parkway
ly Ill , Suite
K
Hilton
Head
Island,
SC
29925
------------------------------------------------------------------------
Monetary Nationa 4701 SE $2,500 8/23/2017 NAMI Oregon
l 24th Mental
Allian Ave., Health
ce for Suite E Education
the Portlan and Support
Mental d, OR Programs
ly Ill 97202 for
Recovery
and
Wellness
------------------------------------------------------------------------
Monetary Nationa 10630 $1,000 5/9/2017 2017 NAMI
l Little Walks
Allian Patuxen Maryland
ce for t
the Parkway
Mental Columbi
ly Ill a, MD
21044
------------------------------------------------------------------------
Monetary Nationa 2059 $2,000 5/31/2017 Dane County
l Atwood Crisis
Allian Ave, Interventio
ce for Floor 4 n Team
the Madison (CIT)
Mental , WI Program
ly Ill 53704
------------------------------------------------------------------------
Monetary Nationa 2059 $1,000 5/31/2017 NAMIWalks
l Atwood Dane County
Allian Ave, 2017
ce for Floor 4
the Madison
Mental , WI
ly Ill 53704
------------------------------------------------------------------------
Monetary Nationa 309 West $1,000 5/5/2017 NAMI Walks
l Millbro North
Allian ok Rd, Carolina
ce for Suite
the 121
Mental Raleigh
ly Ill , NC
27609
------------------------------------------------------------------------
Monetary Nationa 2012 $5,000 8/29/2017 Mental
l West Illness
Allian 25th Peer
ce for Street, Support and
the #600 Education
Mental Clevela
ly nd, OH
Ill--G 44113
reater
Clevel
and
------------------------------------------------------------------------
Monetary Nationa 2012 $1,000 8/29/2017 NAMIWalks
l West 2017
Allian 25th
ce for Street,
the #600
Mental Clevela
ly nd, OH
Ill--G 44113
reater
Clevel
and
------------------------------------------------------------------------
Monetary Nationa 505 8th $1,000 5/4/2017 NAMIWalks
l Avenue, NYC 2017
Allian Ste. Walk/Run
ce for 1103 for Mental
the New Health
Mental York,
ly Ill NY
of New 10018
York
City
------------------------------------------------------------------------
Monetary Nationa 154 $1,000 10/2/2017 NAMIWalks
l Waterma Rhode
Allian n St., Island 2017
ce of Suite
Mental 5B
Illnes Provide
s nce, RI
02906
------------------------------------------------------------------------
Monetary Nationa 5963 $1,000 8/11/2017 NAMIWalks
l Boymel Butler
Allian Dr. County
ce on Fairfie
Mental ld, OH
Illnes 45014
s
------------------------------------------------------------------------
Monetary Nationa P.O. Box $6,000 4/21/2017 General
l Art 350891 mission
Exhibi Miami, support
tions FL
of the 33135
Mental
ly
Ill,
Inc.
------------------------------------------------------------------------
Monetary Nationa 8321 Old $30,000 12/28/2017 TakeIt2Heart
l Courtho TM--An e-
Blood use Rd. Health
Clot Suite Anticoagula
Allian 255 110 tion
ce N. Management
Washing Education
ton Program
St., Focused on
Suite AFib
255 Awareness
Rockvil and
le, MD Lifestyle
20850 Issues
Vienna, Encountered
VA by AFib
22182 Patients
and their
Non-Medical
Caregivers
------------------------------------------------------------------------
Monetary Nationa 1100 $10,000 10/25/2017 2017 Science
l 17th and
Coalit Street, Leadership
ion NW Symposium
for Suite
Women 500
with Washing
Heart ton, DC
Diseas 20036
e,
Inc.
------------------------------------------------------------------------
Monetary Nationa 1400 K $85,000 12/18/2017 Medication
l Street Adherence
Counci NW Learning
l for Washing Community
Behavi ton, DC
oral 20005
Health
------------------------------------------------------------------------
Monetary Nationa 1400 K $85,000 12/18/2017 Policy
l Street Action
Counci NW Center
l for Washing
Behavi ton, DC
oral 20005
Health
------------------------------------------------------------------------
Monetary Nationa 949 West $7,500 12/4/2017 ACE and STEM
l State Program,
Junior St. plus tennis
Tennis Trenton
and , NJ
Learni 08618
ng of
Trento
n
------------------------------------------------------------------------
Monetary Nationa 9707 E $25,000 12/22/2017 National
l Easter Stroke
Stroke Lane, Awareness
Associ Suite B Month
ation Centenn
ial, CO
80112
------------------------------------------------------------------------
Monetary New 275 Rt. $4,000 5/24/2017 NJPC
Jersey 10 East Professiona
Parent Suite l Parent
s 220-414 Advocacy
Caucus Succasu Training
nna, NJ
07876
------------------------------------------------------------------------
Monetary North 368 $10,000 12/22/2017 NATF Spring
Americ Boylsto Patient
an n St. Program
Thromb Brookli
osis ne, MA
Forum 02445
------------------------------------------------------------------------
Monetary North 368 $20,000 12/22/2017 VTE Support
Americ Boylsto Group
an n St. Project
Thromb Brookli
osis ne, MA
Forum 02445
------------------------------------------------------------------------
Monetary Northea 2900 $2,500 4/4/2017 Day of
st Conner Restoration
Guidan Avenue,
ce Buildin
Center g A
Detroit
, MI
48215
------------------------------------------------------------------------
Monetary Passage P.O. Box $7,500 12/4/2017 Support for
Theatr 967 Passage
e Trenton Theatre's
Compan , NJ Education
y, 08605 programming
Inc. the State
Street
Project
------------------------------------------------------------------------
Monetary Peggie 93 $75 3/9/2017 Employee
and Patrici directed
Paul a Place donation in
Shevli Media, lieu of
n PA company
Family 19063 holiday
Founda gift
tion
------------------------------------------------------------------------
Monetary PEI 231 $17,500 10/16/2017 Comprehensiv
Kids Lawrenc e Juvenile
e Road Offenders
Lawrenc Outreach
eville, Services
NJ (CJOOS)
08648 Program
------------------------------------------------------------------------
Monetary PEI 231 $300 9/29/2017 Costs
Kids Lawrenc associated
e Road with
Lawrenc Janssen
eville, Cares
NJ Volunteer
08648 Activity--O
ctober 13,
2017
------------------------------------------------------------------------
Monetary People 295 $2,500 12/5/2017 Reading
And Eggerts Deeply in
Storie Crossin Community:
s--Gen g Road A
te Y Lawrenc Literature
Cuento eville, Project for
s, NJ Mercer
Inc. 08648 County
Youth and
Seniors
------------------------------------------------------------------------
Monetary PlanSma 118 West $3,500 3/8/2017 2017
rt NJ State Corporate
PlanSma membership
rt NJ renewal
Trenton donation to
, NJ support
08608 efforts
around
sound land
use
planning
------------------------------------------------------------------------
Monetary Princet P.O. Box $2,500 12/4/2017 Afterschool
on 134 190 Music
Girl Nassau Outreach
Choir Street Program
Princet
on, NJ
08542
------------------------------------------------------------------------
Monetary Princet 45 $4,000 12/12/2017 Supporting
on Stockto Family
Senior n St Caregivers
Resour Princet
ce on, NJ
Center 08540
------------------------------------------------------------------------
Monetary Princet P.O. Box $4,000 12/12/2017 PSO BRAVO!
on 250, TRENTON
Sympho 575 Youth
ny Ewing Education
Orches Street Initiative
tra Princet
on, NJ
08540
------------------------------------------------------------------------
Monetary Princet 13 $7,500 12/5/2017 Summer
on- Roszel Bridge
Blairs Road 2018--Trent
town Suite on
Center C204A
, Inc. Princet
on, NJ
08540
------------------------------------------------------------------------
Monetary Printma 440 $15,000 12/18/2017 Combat Paper
king River NJ
Center Road
of New Branchb
Jersey urg, NJ
08876
------------------------------------------------------------------------
Monetary Public 825 $7,500 7/25/2017 NJTV's In
Media Eighth Your
NJ, Avenue Neighborhoo
Inc. New d Trenton
York,
NY
10019
------------------------------------------------------------------------
Monetary Rainier 12020 $750 4/20/2017 Employee
Therap 123rd directed
eutic Ave. SE donation in
Riding Rainier lieu of
Rainier company
, WA holiday
98576 gift
------------------------------------------------------------------------
Monetary Raritan P.O. Box $7,000 12/5/2017 WaterWays
Headwa 273 Environment
ters Gladsto al
Associ ne, NJ Education
ation 07934 Program
------------------------------------------------------------------------
Monetary Raritan 118 $20,000 10/30/2017 Nursing
Valley Lamingt Scholarship
Commun on Rd. s
ity Branchb ($12,500);
Colleg urg, NJ Galileo
e 08876 Scholars
Program
($5,000);
Textbook
Scholarship
s ($2,500)
------------------------------------------------------------------------
Monetary Regions 640 $15,000 5/24/2017 Make It OK
Hospit Jackson
al Street,
Founda MS
tion 11202C
St.
Paul,
MN
55101
------------------------------------------------------------------------
Monetary Rescue 98 $25,000 10/16/2017 Emergency
Missio Carroll Services
n of Street Program
Trento P.O.
n Box 790
Trenton
, NJ
08605-
0790
------------------------------------------------------------------------
Monetary Rider 2083 $19,500 10/30/2017 Summer STEM
Univer Lawrenc ($12,000);
sity eville Scholarship
Rd. Support
Lawrenc ($5,000);
eville, Shakespeari
NJ an at Rider
08648 ($2,500)
------------------------------------------------------------------------
Monetary Riverbe P.O. Box $5,000 8/14/2017 InSHAPE
nd 2032 Program
Commun Concord
ity , NH
Mental 03302-
Health 2032
, Inc.
------------------------------------------------------------------------
Monetary Riversi P.O. Box $10,000 12/4/2017 Riverside
de 650 Symphonia
Sympho Lambert Senior
nia, ville, Outreach
Inc. NJ Program
08530
------------------------------------------------------------------------
Monetary Robert One $8,500 12/18/2017 Girls to
Wood Hamilto Women: Myth
Johnso n vs. Reality
n Health
Hamilt Place
on Hamilto
Founda n, NJ
tion 08690
------------------------------------------------------------------------
Monetary Rush 2000 $2,500 10/16/2017 Fox Valley
Copley Ogden Heart Fund
Founda Ave.
tion Aurora,
IL
60504
------------------------------------------------------------------------
Monetary Rutgers 7 $300 9/29/2017 Costs
Univer College associated
sity Avenue with
Founda Winants Janssen
tion Hall Cares
New Volunteer
Brunswi Activity--S
ck, NJ eptember
08901 20, 2017
------------------------------------------------------------------------
Monetary Rutgers 4 $8,546 12/18/2017 Corporate
Univer Hunting Social
sity ton Responsibil
School Street ity
of New Fellowship
Commun Brunswi
icatio ck, NJ
n, 08901-1
Inform 071
ation
and
Librar
y
Studie
s
------------------------------------------------------------------------
Monetary SAFE in 46 East $300 9/29/2017 Costs
Hunter Main associated
don Street with
Fleming Janssen
ton, NJ Cares
08822 Volunteer
Activity--S
eptember
19, 2017
------------------------------------------------------------------------
Monetary SAFE in 46 East $300 9/29/2017 Costs
Hunter Main associated
don Street with
Fleming Janssen
ton, NJ Cares
08822 Volunteer
Activity--S
eptember
18, 2017
------------------------------------------------------------------------
Monetary San P.O. Box $5,000 8/15/2017 Behavioral
Franci 410836 Health
sco San Court's
Genera Francis Motivationa
l co, CA l
Hospit 94110 Incentives
al Program
Founda
tion
------------------------------------------------------------------------
Monetary SAVE A 900 $300 9/29/2017 Costs
Friend Herront associated
to own with
Homele Road Janssen
ss Princet Cares
Animal on NJ Volunteer
s 08540 Activity--S
eptember
22, 2017
------------------------------------------------------------------------
Monetary Schizop P.O. Box $15,000 12/12/2017 HVoS
hrenia 94122 (Hearing
And Houston Voices of
Relate , TX Support)
d 77094 Perception
Disord Changing
ers Experientia
Allian l
ce Of Installatio
Americ n and
a Scientific
Briefing
------------------------------------------------------------------------
Monetary SERV 20 $5,000 10/16/2017 SERV 15th
Founda Scotch Annual
tion, Road Wellness
Inc. Ewing, and
NJ Development
08628 Conference
------------------------------------------------------------------------
Monetary SERV 20 $7,500 10/16/2017 SERV
Founda Scotch Foundation
tion, Road Scholarship
Inc. Ewing, Fund
NJ
08628
------------------------------------------------------------------------
Monetary SERV 20 $300 8/24/2017 Costs
Founda Scotch associated
tion, Road with
Inc. Ewing, Janssen
NJ Cares
08628 Volunteer
Activity--A
ugust 20,
2017
------------------------------------------------------------------------
Monetary Shannon 36 $500 12/5/2017 Shannon
Daley Indian Daley
Memori Run Memorial
al P.O. Fund
Fund Box Charity
1271 Events
Whiteho
use
Station
, NJ
08889
------------------------------------------------------------------------
Monetary The 1920 $2,500 8/14/2017 1920 Club
Sharin 10th Art Program
g Avenue
Place, South
Inc. P.O.
Box
59455
Birming
ham, AL
35255
------------------------------------------------------------------------
Monetary Sisters 1201 $5,000 10/30/2017 Pearl Grace
Networ Hamilto Memorial
k of n Golf
Centra Street Tournament
l New Somerse
Jersey t, NJ
08873
------------------------------------------------------------------------
Monetary Somerse 190 Lord $300 8/24/2017 Costs
t Stirlin associated
County g Road with
Park Basking Janssen
Founda Ridge, Cares
tion NJ Volunteer
07920 Activity--S
eptember
15, 2017
------------------------------------------------------------------------
Monetary Special 1 Eunice $7,500 12/12/2017 Special
Olympi Kennedy Olympics
cs New Shriver New Jersey--
Jersey Way Camp
Lawrenc Shriver
e
Townshi
p, NJ
08648
------------------------------------------------------------------------
Monetary St. One $20,000 12/4/2017 Providing
Mary Summit Food for
Medica Square, Underserved
l Suite Children in
Center 300 Bucks
Founda 1717 County: The
tion Langhor St. Mary
ne- Backpacks
Newtown for Kids
Rd. Program
Langhor
ne, PA
19047
------------------------------------------------------------------------
Monetary Stony 31 Titus $15,000 12/18/2017 StreamWatch:
Brook Mill Citizen
Millst Road Scientists
one Penning Monitoring
Waters ton, NJ Water
hed 08534 Quality in
Associ Central New
ation Jersey
------------------------------------------------------------------------
Monetary TASK, 72\1/2\ $25,000 10/30/2017 Meal Service
Inc. Escher Program
Street
Trenton
, NJ
08609
------------------------------------------------------------------------
Monetary The Arc 180 $5,000 12/18/2017 The Arc
Mercer Ewingvi Mercer and
lle Medina
Road Community
Ewing, Clinic
NJ
08683
------------------------------------------------------------------------
Monetary The Paul $5,000 10/27/2017 Communiversi
Arts Robeson ty ArtsFest
Counci Center 2018
l of for the
Prince Arts
ton 102
Withers
poon
Street
Princet
on, NJ
08542
------------------------------------------------------------------------
Monetary The Paul $10,000 10/27/2017 Arts Council
Arts Robeson of
Counci Center Princeton
l of for the Community
Prince Arts Outreach
ton 102 Programs
Withers
poon
Street
Princet
on, NJ
08542
------------------------------------------------------------------------
Monetary The Paul $300 9/29/2017 Costs
Arts Robeson associated
Counci Center with
l of for the Janssen
Prince Arts Cares
ton 102 Volunteer
Withers Activity--S
poon eptember
Street 11, 2017
Princet
on, NJ
08542
------------------------------------------------------------------------
Monetary The 2020 $2,000 11/6/2017 Art Classes
Center Burnt for
for Mills Children
Contem Road with Autism
porary Bedmins Spectrum
Art ter, NJ Disorder
07882 and Other
Special
Needs
------------------------------------------------------------------------
Monetary The 19B $300 8/24/2017 Costs
Center Dellwoo associated
For d Lane with
Great Somerse Janssen
Expect t, NJ Cares
ations 08873 Volunteer
Activity--S
eptember
19, 2017
------------------------------------------------------------------------
Monetary The 19B $12,000 9/15/2017 Adult
Center Dellwoo Women's
For d Lane Program
Great Somerse
Expect t, NJ
ations 08873
------------------------------------------------------------------------
Monetary The 205 $7,500 10/30/2017 The Edinburg
Edinbu Burling Center Jail
rg ton Diversion
Center Road Program
Lexingt
on, MA
01730
------------------------------------------------------------------------
Monetary The 401 $1,000 5/4/2017 8th Annual
Mental Cypress Run/Walk
Health Street for Mental
Center Manches Health
Of ter, NH
Greate 03103
r
Manche
ster
------------------------------------------------------------------------
Monetary The 400 $300 9/29/2017 Costs
Pennsb Pennsbu associated
ury ry with
Societ Memoria Janssen
y l Rd. Cares
Morrisv Volunteer
ille, Activity--S
PA eptember
19067 25, 2017
------------------------------------------------------------------------
Monetary The P.O. Box $9,000 12/5/2017 Opera for
Prince 2063 All
ton Princet
Festiv on, NJ
al 08543
------------------------------------------------------------------------
Monetary The 243 $5,000 12/14/2017 Sensory
Roxey North Friendly
Ballet Union Performance
Compan Street s at
y, Lambert Trenton
Inc. ville, Psychiatric
NJ Hospital
08530 and The
College of
New Jersey
------------------------------------------------------------------------
Monetary The 4101 $20,000 9/26/2017 MindStrong
Thresh North
olds Ravensw
ood
Avenue
Chicago
, IL
60613
------------------------------------------------------------------------
Monetary The 100 $10,000 8/30/2017 Farm Based
Willia Gould Psychiatric
m J. Road Rehabilitat
Gould P.O. ion and
Associ Box 157 Recovery
ates, Montere
Inc. y, MA
01245
------------------------------------------------------------------------
Monetary Thomas 111 West $15,000 12/18/2017 Scholarships
Edison State for Nursing
State Street Students
Colleg Trenton Enrolled in
e , NJ the
Founda 08608 Accelerated
tion Second
Degree BSN
Program at
the W. Cary
Edwards
School of
Nursing at
Thomas
Edison
State
University.
------------------------------------------------------------------------
Monetary TPTO 51 South $1,500 10/30/2017 2018
Inc--T Timberl Timberlane
imberl ane Science and
ane Drive Engineering
Parent Penning Fair
Teache ton, NJ
r 08534
Organi
zation
------------------------------------------------------------------------
Monetary Trenton 471 $7,500 12/18/2017 Trenton
Childr Parkway Children's
en's Avenue Chorus
Chorus Trenton
, Inc. , NJ
08618
------------------------------------------------------------------------
Monetary Trenton P.O. Box $8,500 11/6/2017 Second
Commun 5206 Semester
ity Trenton Programs,
Music , NJ Trenton
School 08638 Music
Makers
------------------------------------------------------------------------
Monetary Trenton 635 $5,000 12/4/2017 Trenton
Educat South Education
ion Clinton Dance
Dance Avenue Institute
Instit Trenton (TEDI)
ute , NJ
08611
------------------------------------------------------------------------
Monetary Trenton 218 $19,000 10/27/2017 Wheels to
Health North Wellness
Team Broad
Inc. Street
Trenton
, NJ
08608
------------------------------------------------------------------------
Monetary Trinity 22 $7,500 10/30/2017 TCS General
Counse Stockto Counseling
ling n and
Servic Street Prevention
es Princet Programming
on, NJ
08540
------------------------------------------------------------------------
Monetary Tuscalo P.O. Box $1,000 5/4/2017 Hot Hundred
osa 2322 2017
Mental Tuscalo
Health osa, AL
Allian 35403
ce
------------------------------------------------------------------------
Monetary Twiligh P.O. Box $7,500 10/30/2017 Simple Needs
t Wish 1042 Wish
Founda Doylest Granting
tion own, PA Program
18901
------------------------------------------------------------------------
Monetary UIH 4 North $10,000 12/18/2017 Healthy
Family Broad Relationshi
Partne Street ps, Healthy
rs Suite Choices
2R
Trenton
, NJ
08608
------------------------------------------------------------------------
Monetary UIH 4 North $20,000 12/18/2017 Community of
Family Broad Health for
Partne Street Men, Year 4
rs Suite
2R
Trenton
, NJ
08608
------------------------------------------------------------------------
Monetary United 60 Park $7,500 10/30/2017 UNCF
Negro Place Scholarship
Colleg Suite
e Fund 406
Newark,
NJ
07102
------------------------------------------------------------------------
Monetary United 413 Hood $85,000 9/29/2017 Fresh
Way of Blvd Connect
Bucks Fairles program
County s
Hills,
PA
19030
------------------------------------------------------------------------
Monetary United 413 Hood $42,500 9/29/2017 Emergency
Way of Blvd Needs
Bucks Fairles program
County s
Hills,
PA
19030
------------------------------------------------------------------------
Monetary United 3150 $85,000 10/30/2017 United Way
Way of Brunswi of Greater
Greate ck Pike Mercer
r Suite County
Mercer 230 Minority
County Lawrenc and
eville, Multicultur
NJ al Health
08648 Initiative
------------------------------------------------------------------------
Monetary United 3150 $920 12/4/2017 Costs
Way of Brunswi associated
Greate ck Pike with
r Suite Janssen
Mercer 230 Cares
County Lawrenc Volunteer
eville, Activity--S
NJ eptember
08648 26, 2017
------------------------------------------------------------------------
Monetary UrbanPr 801 West $2,770 12/12/2017 Mindfulness
omise State Pilot
Intern Street Program
ationa Trenton
l, , NJ
Inc. 08618
------------------------------------------------------------------------
Monetary Valeo 5401 SW $3,500 9/19/2017 Vocational
Behavi 7th Empowerment
oral Street Photovoice
Health Topeka,
Care, KS
Inc. 66606
------------------------------------------------------------------------
Monetary Visions 49 $7,500 12/12/2017 Street-Smart
and Brahma HIV/AIDS
Pathwa Ave.
ys Bridgew
ater,
NJ
08807
------------------------------------------------------------------------
Monetary Visions 49 $300 11/6/2017 Costs
and Brahma associated
Pathwa Ave. with
ys Bridgew Janssen
ater, Cares
NJ Volunteer
08807 Activity
------------------------------------------------------------------------
Monetary Volunte 12 $9,000 12/1/2017 SkillsConnec
er Stockto t
Connec n
t Street
Princet
on, NJ
08540
------------------------------------------------------------------------
Monetary Washing P.O. Box $750 10/16/2017 Revolutionar
ton 83 y War
Crossi Titusvi Weekend
ng lle, NJ
Park 08560
Associ
ation,
Inc.
------------------------------------------------------------------------
Monetary We Care 3035 $1,500 5/31/2017 ArtWORK
Arts Wilming
ton
Pike
Ketteri
ng, OH
45429
------------------------------------------------------------------------
Monetary West P.O. Box $5,000 12/5/2017 Excellence
Windso 280 in
r West Education,
Plains Windsor and
boro , NJ Innovation
Educat 08550 Fair 2018
ion
Founda
tion
------------------------------------------------------------------------
Monetary Westmor 100 $75 3/22/2017 Employee
eland Devonsh directed
County ire donation in
Food Drive lieu of
Bank, Delmont company
Inc. , PA holiday
15626- gift
1607
------------------------------------------------------------------------
Monetary Womansp 1530 $7,500 12/5/2017 Safe House
ace Brunswi (Emergency
ck Ave. Shelter)
Lawrenc and
eville, Barbara's
NJ House
08648 (Transition
al
Housing):
Supporting
Women and
Children
Impacted by
Domestic
Violence
------------------------------------------------------------------------
Monetary Womansp 1530 $300 9/29/2017 Costs
ace Brunswi associated
ck Ave. with
Lawrenc Janssen
eville, Cares
NJ Volunteer
08648 Activity--O
ctober 2,
2017
------------------------------------------------------------------------
Monetary Womansp 1530 $300 9/29/2017 Costs
ace Brunswi associated
ck Ave. with
Lawrenc Janssen
eville, Cares
NJ Volunteer
08648 Activity--O
ctober 5,
2017
------------------------------------------------------------------------
Monetary Woods 40 $4,000 12/12/2017 Yoga at
Servic Martin Woods
es Gross Services: A
Founda Drive, Recreationa
tion P.O. l Program
Box 36 for People
Langhor with
ne, PA Special
19047 Needs
------------------------------------------------------------------------
Monetary Young 349 W. $3,500 12/18/2017 Early
Schola State Literacy
rs' St Engagement
Instit Trenton and
ute , NJ Development
08618
------------------------------------------------------------------------
Product AmeriCa 88 $493,168 1/3/2017 Product
res Hamilto donation
Founda n Ave. for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Dominican
Republic,
Nicaragua,
West Bank,
and U.S.
------------------------------------------------------------------------
Product AmeriCa 88 $145,709 1/6/2017 Product
res Hamilto donation
Founda n Ave. for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Nicaragua,
Dominican
Republic,
West Bank,
and U.S.
------------------------------------------------------------------------
Product AmeriCa 88 $257,792 1/9/2017 Product
res Hamilto donation
Founda n Ave. for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Nicaragua,
Dominican
Republic,
West Bank,
and U.S.
------------------------------------------------------------------------
Product AmeriCa 88 $100,065 2/16/2017 Product
res Hamilto donation
Founda n Ave. for
tion Stamfor humanitaria
d, CT n
06902 assistance
in St.
Lucia,
Nicaragua,
Republic,
and Lebanon
------------------------------------------------------------------------
Product AmeriCa 88 $1,185,644 2/16/2017 Product
res Hamilto donation
Founda n Ave. for
tion Stamfor humanitaria
d, CT n
06902 assistance
in U.S.
clinics
------------------------------------------------------------------------
Product AmeriCa 88 $4,640 3/13/2017 Product
res Hamilto donation
Founda n Ave. for
tion Stamfor humanitaria
d, CT n
06902 assistance
in Puerto
Rico
------------------------------------------------------------------------
Product AmeriCa 88 $1,281,296 3/20/2017 Product
res Hamilto donation
Founda n Ave. for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Tanzania,
West Bank,
Gaza, St.
Lucia,
Lebanon,
Dominican
Republic,
Colombia,
Nicaragua,
and U.S.
------------------------------------------------------------------------
Product AmeriCa 88 $91,239 3/20/2017 Product
res Hamilto donation
Founda n Ave. for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Nicaragua
and
Colombia
------------------------------------------------------------------------
Product AmeriCa 88 $1,077,988 4/11/2017 Product
res Hamilto donation
Founda n Ave. for
tion Stamfor humanitaria
d, CT n
06902 assistance
in Gaza,
West Bank,
Colombia,
and U.S.
------------------------------------------------------------------------
Product AmeriCa 88 $181,140 4/11/2017 Product
res Hamilto donation
Founda n Ave. for
tion Stamfor humanitaria
d, CT n
06902 assistance
in St.
Lucia,
Afghanistan
, and
Colombia
------------------------------------------------------------------------
Product AmeriCa 88 $191,031 5/23/2017 Product
res Hamilto donation
Founda n Ave. for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Nicaragua,
Dominican
Republic,
and St.
Lucia
------------------------------------------------------------------------
Product AmeriCa 88 $72,844 5/23/2017 Product
res Hamilto donation
Founda n Ave. for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Nicaragua.
------------------------------------------------------------------------
Product AmeriCa 88 $871,110 6/22/2017 Product
res Hamilto donation
Founda n Ave. for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Dominican
Republic,
St. Lucia,
and West
Bank
------------------------------------------------------------------------
Product AmeriCa 88 $185,347 6/22/2017 Product
res Hamilto donation
Founda n Ave. for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Dominican
Republic,
and West
Bank
------------------------------------------------------------------------
Product AmeriCa 88 $9,583,716 7/17/2017 Product
res Hamilto donation
Founda n Ave. for
tion Stamfor humanitaria
d, CT n
06902 assistance
in
Kyrgyzstan
------------------------------------------------------------------------
Product AmeriCa 88 $149,758 7/19/2017 Product
res Hamilto donation
Founda n Ave. for
tion Stamfor humanitaria
d, CT n
06902 assistance
in St.
Lucia
------------------------------------------------------------------------
Product AmeriCa 88 $91,601 8/21/2017 Product
res Hamilto donation
Founda n Ave. for
tion Stamfor humanitaria
d, CT n
06902 assistance
in United
States
------------------------------------------------------------------------
Product AmeriCa 88 $259,213 8/21/2017 Product
res Hamilto donation
Founda n Ave. for
tion Stamfor humanitaria
d, CT n
06902 assistance
in United
States
------------------------------------------------------------------------
Product AmeriCa 88 $383,085 9/27/2017 Pharmaceutic
res Hamilto al product
Founda n Ave. Donation
tion Stamfor for
d, CT humanitaria
06902 n aid in
Gaza, St.
Lucia, and
Peru
------------------------------------------------------------------------
Product AmeriCa 88 $134,651 9/27/2017 Product
res Hamilto donation
Founda n Ave. for
tion Stamfor humanitaria
d, CT n aid for
06902 El
Salvador,
Peru and
St. Lucia
------------------------------------------------------------------------
Product AmeriCa 88 $2,013,098 10/10/2017 Product for
res Hamilto humanitaria
Founda n Ave. n and
tion Stamfor disaster
d, CT response in
06902 Houston,
Florida and
Puerto Rico
------------------------------------------------------------------------
Product AmeriCa 88 $65,375 10/10/2017 Product
res Hamilto donation
Founda n Ave. for
tion Stamfor humanitaria
d, CT n and
06902 disaster
relief in
Houston,
Florida,
and Puerto
Rico
------------------------------------------------------------------------
Product AmeriCa 88 $75,473 10/20/2017 Product
res Hamilto donation
Founda n Ave. for
tion Stamfor humanitaria
d, CT n aid in
06902 Nicaragua
and US
Clinics
------------------------------------------------------------------------
Product AmeriCa 88 $82,469 11/15/2017 Product
res Hamilto donation
Founda n Ave. for
tion Stamfor humanitaria
d, CT n aid in US
06902 Clinic
Network
------------------------------------------------------------------------
Product AmeriCa 88 $442,409 11/15/2017 Product
res Hamilto donation
Founda n Ave. for
tion Stamfor humanitaria
d, CT n aid in
06902 Sierra
Leone
------------------------------------------------------------------------
Product AmeriCa 88 $816,348 8/31/2017 Product
res Hamilto Donation
Founda n Ave. for
tion Stamfor Disaster
d, CT Response--H
06902 urricane
Harvey
------------------------------------------------------------------------
Product AmeriCa 88 $1,320,624 11/17/2017 Product
res Hamilto donation
Founda n Ave. for
tion Stamfor humanitaria
d, CT n
06902 assistance
in U.S
------------------------------------------------------------------------
Product AmeriCa 88 $504,595 12/5/2017 Product
res Hamilto donation
Founda n Ave. for
tion Stamfor humanitaria
d, CT n
06902 assistance
in the
Dominican
Republic
------------------------------------------------------------------------
Product AmeriCa 88 $971,862 12/5/2017 Product for
res Hamilto humanitaria
Founda n Ave. n
tion Stamfor assistance
d, CT in the
06902 Dominican
Republic
------------------------------------------------------------------------
Product AmeriCa 88 $4,298,976 12/5/2017 Product
res Hamilto donation
Founda n Ave. for
tion Stamfor humanitaria
d, CT n
06902 assistance
in US
Clinic
Networks
------------------------------------------------------------------------
Product Catholi 100 Wall $432,510 11/16/2017 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in:
10005 Dominican
Republic,
Haiti and
Guatemala
------------------------------------------------------------------------
Product Catholi 100 Wall $566,919 11/16/2017 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in:
10005 Dominican
Republic,
Haiti, and
Guatemala
------------------------------------------------------------------------
Product Catholi 100 Wall $68,662 10/20/2017 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in the
10005 Dominican
Republic,
Guatemala
and Haiti
------------------------------------------------------------------------
Product Catholi 100 Wall $47,020 9/27/2017 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n aid in
n York, the
Board NY Dominican
10005 Republic
------------------------------------------------------------------------
Product Catholi 33-01 $1,626,679 7/19/2017 Product
c Elevent donation
Medica h for
l Street humanitaria
Missio Long n
n Island assistance
Board City, in
NY Guatemala,
Haiti,
Dominican
Republic,
and
Nicaragua
------------------------------------------------------------------------
Product Catholi 33-01 $2,839,769 7/19/2017 Product
c Elevent donation
Medica h for
l Street humanitaria
Missio Long n
n Island assistance
Board City, in
NY Guatemala,
Haiti,
Dominican
Republic,
and
Nicaragua
------------------------------------------------------------------------
Product Catholi 100 Wall $129,896 8/21/2017 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in
10005 Dominican
Republic,
and
Nicaragua
------------------------------------------------------------------------
Product Catholi 100 Wall $2,091,213 8/21/2017 Product
c Street, donation
Medica 9th for
l Floor humanitaria
Missio New n
n York, assistance
Board NY in
10005 Dominican
Republic,
Haiti, and
Nicaragua
------------------------------------------------------------------------
Product Catholi 33-01 $698,911 6/22/2017 Product
c Elevent donation
Medica h for
l Street humanitaria
Missio Long n
n Island assistance
Board City, in
NY Guatemala,
El
Salvador,
Nicaragua,
Haiti, and
Jamaica
------------------------------------------------------------------------
Product Catholi 33-01 $537,473 6/22/2017 Product
c Elevent donation
Medica h for
l Street humanitaria
Missio Long n
n Island assistance
Board City, in
NY Dominican
Republic,
Haiti,
Guatemala,
Jamaica,
and El
Salvador
------------------------------------------------------------------------
Product Catholi 33-01 $597,003 4/10/2017 Product
c Elevent donation
Medica h for
l Street humanitaria
Missio Long n
n Island assistance
Board City, in El
NY Salvador,
Haiti, and
Nicaragua
------------------------------------------------------------------------
Product Catholi 33-01 $565,051 4/10/2017 Product
c Elevent donation
Medica h for
l Street humanitaria
Missio Long n
n Island assistance
Board City, in El
NY Salvador,
Haiti,
Honduras,
Nicaragua,
and
Guatemala
------------------------------------------------------------------------
Product Catholi 33-01 $610,715 5/23/2017 Product
c Elevent donation
Medica h for
l Street humanitaria
Missio Long n
n Island assistance
Board City, in
NY Tanzania,
Guatemala,
Jamaica,
and
Dominican
Republic
------------------------------------------------------------------------
Product Catholi 33-01 $716,298 5/23/2017 Product
c Elevent donation
Medica h for
l Street humanitaria
Missio Long n
n Island assistance
Board City, in
NY Dominican
Republic,
Tanzania,
and
Guatemala
------------------------------------------------------------------------
Product Catholi 33-01 $1,336,614 3/20/2017 Product
c Elevent donation
Medica h for
l Street humanitaria
Missio Long n
n Island assistance
Board City, in
NY Guatemala,
El
Salvador,
and Haiti
------------------------------------------------------------------------
Product Catholi 33-01 $102,932 3/20/2017 Product
c Elevent donation
Medica h for
l Street humanitaria
Missio Long n
n Island assistance
Board City, in
NY Guatemala
and Haiti
------------------------------------------------------------------------
Product Catholi 33-01 $117,953 2/15/2017 Product
c Elevent donation
Medica h for
l Street humanitaria
Missio Long n
n Island assistance
Board City, in Haiti,
NY El Salvador
and
Honduras
------------------------------------------------------------------------
Product Direct 27 S. La $1,051,504 3/20/2017 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in
Honduras,
Liberia,
Haiti and
El
Salvador.
------------------------------------------------------------------------
Product Direct 27 S. La $91,239 3/20/2017 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Haiti
and
Liberia.
------------------------------------------------------------------------
Product Direct 27 S. La $23,107 2/16/2017 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in
Honduras.
------------------------------------------------------------------------
Product Direct 27 S. La $378,636 2/16/2017 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in
Honduras.
------------------------------------------------------------------------
Product Direct 27 S. La $2,390,729 4/11/2017 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in
Colombia,
Sierra
Leone,
Vanuatu,
Ghana,
Malawi,
Haiti,
Nicaragua
and U.S.
------------------------------------------------------------------------
Product Direct 27 S. La $249,548 4/11/2017 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Ghana,
Malawi,
Sierra
Leone,
Liberia,
Pakistan
and U.S.
------------------------------------------------------------------------
Product Direct 27 S. La $804,308 5/23/2017 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Malawi
and Sierra
Leone
------------------------------------------------------------------------
Product Direct 27 S. La $209,508 5/23/2017 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in
Colombia,
Pakistan,
Ghana,
Malawi,
Sierra
Leone and
Liberia.
------------------------------------------------------------------------
Product Direct 27 S. La $500,169 6/22/2017 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Jamaica,
Nicaragua,
Pakistan,
and Liberia
------------------------------------------------------------------------
Product Direct 27 S. La $710,949 6/22/2017 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Jamaica
------------------------------------------------------------------------
Product Direct 27 S. La $1,405,277 7/19/2017 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in
Honduras,
Colombia,
and
Pakistan
------------------------------------------------------------------------
Product Direct 27 S. La $1,152,189 7/19/2017 Product
Relief Patera Donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in
Honduras,
Colombia,
Pakistan,
and USA.
------------------------------------------------------------------------
Product Direct 27 S. La $271,063 9/27/2017 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Ghana
------------------------------------------------------------------------
Product Direct 27 S. La $61,205 9/27/2017 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Ghana
------------------------------------------------------------------------
Product Direct 27 S. La $373,326 8/21/2017 Product
Relief Patera donation
Lane for
Santa Humanitaria
Barbara n
, CA assistance
93117 in the
United
States
------------------------------------------------------------------------
Product Direct 27 S. La $259,561 8/21/2017 Product
Relief Patera donation
Lane for
Santa Humanitaria
Barbara n
, CA assistance
93117 in the
United
States
------------------------------------------------------------------------
Product Direct 27 S. La $239,304 10/23/2017 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in US
Clinics
------------------------------------------------------------------------
Product Direct 27 S. La $571,784 12/5/2017 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Syria
------------------------------------------------------------------------
Product Direct 27 S. La $62,628 10/2/2017 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Houston,
Florida,
and Puerto
Rico
------------------------------------------------------------------------
Product Direct 27 S. La $3,961,872 11/17/2017 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Syria
------------------------------------------------------------------------
Product Direct 27 S. La $3,482,171 12/1/2017 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Syria
------------------------------------------------------------------------
Product Direct 27 S. La $82,127 9/7/2017 Product
Relief Patera Donation
Lane for
Santa Disaster
Barbara response--H
, CA urricane
93117 Harvey
------------------------------------------------------------------------
Product Direct 27 S. La $494,813 11/16/2017 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Syria
------------------------------------------------------------------------
Product Direct 27 S. La $224,506 11/16/2017 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Syria
------------------------------------------------------------------------
Product Direct 27 S. La $161,977 11/16/2017 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in Syria
------------------------------------------------------------------------
Product Direct 27 S. La $31,448 11/16/2017 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in US
------------------------------------------------------------------------
Product Direct 27 S. La $505,634 11/16/2017 Product
Relief Patera donation
Lane for
Santa humanitaria
Barbara n
, CA assistance
93117 in US
Clinics
------------------------------------------------------------------------
Product Heart 1021 $61,205 9/27/2017 Product
to Pacific donation
Heart Avenue for
Intern Kansas humanitaria
ationa City, n
l KS assistance
66102 in the
Dominican
Republic
------------------------------------------------------------------------
Product Heart 1021 $224,044 9/27/2017 Product
to Pacific donation
Heart Avenue for
Intern Kansas humanitaria
ationa City, n
l KS assistance
66102 in the
Dominican
Republic
------------------------------------------------------------------------
Product Heart 1021 $979,095 6/22/2017 Product
to Pacific donation
Heart Avenue for
Intern Kansas humanitaria
ationa City, n
l KS assistance
66102 in
Honduras.
------------------------------------------------------------------------
Product Heart 1021 $126,867 6/22/2017 Product
to Pacific Donation
Heart Avenue for
Intern Kansas humanitaria
ationa City, n
l KS assistance
66102 in
Honduras.
------------------------------------------------------------------------
Product Heart 1021 $436,536 4/10/2017 Product
to Pacific donation
Heart Avenue for
Intern Kansas humanitaria
ationa City, n
l KS assistance
66102 in
Dominican
Republic,
Honduras
and Papua
New Guinea.
------------------------------------------------------------------------
Product Heart 1021 $62,476 4/10/2017 Product
to Pacific donation
Heart Avenue for
Intern Kansas humanitaria
ationa City, n
l KS assistance
66102 in Honduras
and
Dominican
Republic.
------------------------------------------------------------------------
Product Johnson One $338,315,809 12/31/2017 Patient
& Johnson Assistance
Johnso & Product
n Johnson Donation
Patien Plaza
t Kilmer
Assist Square,
ance Suite
Founda 130 New
tion Brunswi
ck, NJ
08933
------------------------------------------------------------------------
Product MAP 4700 $13,197 2/15/2017 Product
Intern Glynco donation
ationa Parkway for
l Brunswi humanitaria
ck, GA n
31525 assistance
(Medical
Mission
Packs).
------------------------------------------------------------------------
Product MAP 4700 $125,592 2/14/2017 Product
Intern Glynco donation
ationa Parkway for
l Brunswi humanitaria
ck, GA n
31525 assistance
in Sierra
Leone
------------------------------------------------------------------------
Product MAP 4700 $108,127 11/16/2017 Product
Intern Glynco donation
ationa Parkway for
l Brunswi humanitaria
ck, GA n
31525 assistance
in the
Eastern
Caribbean
------------------------------------------------------------------------
Product MAP 4700 $19,241 7/31/2017 Product
Intern Glynco donation
ationa Parkway for medical
l Brunswi mission
ck, GA program
31525
------------------------------------------------------------------------
Product MAP 4700 $868,191 6/22/2017 Product
Intern Glynco donation
ationa Parkway for
l Brunswi humanitaria
ck, GA n
31525 assistance
in Haiti,
Dominican
Republic,
and
Guatemala.
------------------------------------------------------------------------
Monetary Acercam P.O. Box $5,000 4/26/2017 ContraSIDA
iento 3820
Hispan Columbi
o de a, SC
Caroli 29230
na del
Sur
------------------------------------------------------------------------
Monetary ADAP P.O. Box $5,000 4/4/2017 ADAP
Advoca 15275 Directory
cy Washing
ton, DC
20003
------------------------------------------------------------------------
Monetary ADAP P.O. Box $5,000 10/16/2017 Improving
Advoca 15275 Access to
cy Washing Care Among
ton, DC Formerly
20003 Incarcerate
d
Populations
with HIV/
AIDS under
the AIDS
Drug
Assistance
Program
(ADAP)
------------------------------------------------------------------------
Monetary African- 1833 $75,000 7/20/2017 Black
Americ West Treatment
an 8th Advocates
Aids Street Network
Policy Suite (BTAN)
And 200 Los Advanced
Traini Angeles Development
ng , CA Program
Instit 90057
ute
------------------------------------------------------------------------
Monetary AIDS 6260 $3,000 4/4/2017 Linkage to
Founda Westpar Care
tion k Drive
Housto Suite
n, 100
Inc. Houston
, TX
77057
------------------------------------------------------------------------
Monetary AIDS 200 W. $50,000 3/1/2017 Ensuring
Founda Jackson Access to
tion Blvd., HIV
of Suite Prevention
Chicag 2100 and Care in
o Chicago Illinois
, IL through
60606 Policy
Monitoring
and
Advocacy
------------------------------------------------------------------------
Monetary AIDS 400 $5,000 4/4/2017 HIV Case
Outrea North Management
ch Beach at AIDS
Center Street Outreach
Fort Center
Worth,
TX
76111
------------------------------------------------------------------------
Monetary AIDS 820 N. $5,000 8/17/2017 Driving
Resour Plankin Innovation
ce ton in HIV
Center Ave. Healthcare
of Milwauk Via ARCW
Wiscon ee, WI HIV Medical
sin 53203 Centers
------------------------------------------------------------------------
Monetary AIDS 17982 $2,000 5/8/2017 HIV and
Servic Sky Hepatitis C
es Park Testing
Founda Circle, Program
tion Suite J
Orange Irvine,
County CA
92614
------------------------------------------------------------------------
Monetary AIDS 1101 $200,000 12/19/2017 Transgender
United 14th Leadership
Street, Initiative
NW
Suite
300
Washing
ton, DC
20005
------------------------------------------------------------------------
Monetary Alexian 825 W. $5,000 8/17/2017 Transitional
Brothe Welling Living
rs ton Program for
Bonave Chicago Homeless
nture , IL Adults with
House 60657 HIV/AIDS
------------------------------------------------------------------------
Monetary Alivene 3808 $1,000 7/31/2017 Integrative
ss Nicolle Therapies
Projec t Ave for People
t, Minneap Living with
Inc. olis, HIV
MN
55409
------------------------------------------------------------------------
Monetary Aunt 1101 N. $2,500 7/11/2017 Project
Rita's Central HIVAZ
Founda Ave.
tion Suite
212
Phoenix
, AZ
85004
------------------------------------------------------------------------
Monetary Caring PO Box $40,000 3/20/2017 General
Ambass 1748 Hepatitis C
adors Oregon Program
Progra City, Support
m, Inc OR
97045
------------------------------------------------------------------------
Monetary Catholi 119 $5,000 4/4/2017 The Home
c Dameron Place
Charit Avenue
ies of Knoxvil
East le, TN
Tennes 37917
see,
Inc.
------------------------------------------------------------------------
Monetary Center 1115 E. $3,500 10/23/2017 HIV
For 12th Prevention
Health St. Access and
Empowe Austin, Linkage to
rment TX Care
(CHE) 78702
------------------------------------------------------------------------
Monetary Central 1785 $5,000 11/13/2017 HIV Testing,
Louisi Jackson Counseling,
ana Street and
Aids Alexand Prevention
Suppor ria, LA for African
t 71301 American
Servic Teens and
es Inc Young
(CLASS Adults
)
------------------------------------------------------------------------
Monetary Communi 1930 $20,000 12/18/2017 Equal Access
ty Martin
Educat Luther
ion King Jr
Group Avenue
SE
Washing
ton, DC
20020
------------------------------------------------------------------------
Monetary Communi 1930 $20,000 3/13/2017 Access Tools
ty Martin Linking All
Educat Luther to Services
ion King Jr (ATLAS).
Group Avenue
SE
Washing
ton, DC
20020
------------------------------------------------------------------------
Monetary Communi 575 8th $15,000 7/20/2017 HIV Health
ty Avenue, Literacy
Resear Suite Education
ch 502 New and
Initia York, Training
tive NY for Service
on 10018 Providers
AIDS, Working
Inc. with
Vulnerable
Populations
------------------------------------------------------------------------
Monetary Frannie 30 $5,000 11/13/2017 Supportive
Peabod Danfort Pathways
y h St. Along the
Center Suite Care
Inc. 311 Continuum
Portlan (SPACC)
d, ME
04101
------------------------------------------------------------------------
Monetary Gay 446 W. $30,000 12/19/2017 Peer
Men's 33rd Navigation
Health Street for high-
Crisis New risk and
York, HIV-
NY positive
10001 transgender
people
------------------------------------------------------------------------
Monetary Gay 446 W. $30,000 3/1/2017 Peer
Men's 33rd Navigation
Health Street for high-
Crisis New risk and
York, HIV-
NY positive
10001 transgender
people
------------------------------------------------------------------------
Monetary Hepatit 35 East $20,000 2/7/2017 The
is C 38th Hepatitis C
Mentor Street, Education
and Suite and Support
Suppor #4G New Group
t York, Assistance
Group NY Program
Inc. 10016
------------------------------------------------------------------------
Monetary Hepatit 1261 S. $35,000 2/8/2017 General
is Jackson Program
Educat St., Support
ion Suite
Projec 201
t Seattle
, WA
98144
------------------------------------------------------------------------
Monetary Howard 4025 N. $25,000 9/29/2017 Patient
Brown Sherida Assistance
Health n Clinic
Center Chicago (PAC):
, IL Medication
60613 Therapy
Management
for
Underserved
Patients
------------------------------------------------------------------------
Monetary Interna 2200 $75,000 3/1/2017 Conversation
tional Pennsyl Maps:
Associ vania Patient
ation Avenue, Empowerment
of NW 4th through HIV
Physic Floor Peer
ians East Dialogue in
in Washing Five U.S.
AIDS ton, DC Fast-Track
Care 20037 Cities
Inc.
------------------------------------------------------------------------
Monetary Legacy 4054 $5,000 4/26/2017 Grace
Counse McKinne Project
ling y Ave., Program for
Center Suite Women
102 Living with
Dallas, HIV/AIDS
TX
75204
------------------------------------------------------------------------
Monetary Legal 17 N. $5,000 8/23/2017 Communities
Counci State of Color
l for Street, Outreach
Health Suite Program
Justic 900
e Chicago
, IL
60602
------------------------------------------------------------------------
Monetary Lifelon P.O. Box $3,000 3/20/2017 Living
g Aids 80547 Positively
Allian Seattle
ce , WA
98108
------------------------------------------------------------------------
Monetary Minorit 5149 W. $7,500 4/4/2017 S.T.E.P.
y AIDS Jeffers Program
Projec on Blvd Strengtheni
t Los ng
Angeles Treatment
, CA Education
90016 for People
Living with
HIV/AIDS
------------------------------------------------------------------------
Monetary Nationa 580 $175,000 3/16/2017 NATAP HIV
l AIDS Broadwa and HCV
Treatm y Suite Information
ent 1010 and
Advoca New Education
cy York, Project
Projec NY
t 10012
------------------------------------------------------------------------
Monetary Nationa 580 $175,000 12/18/2017 NATAP HIV
l AIDS Broadwa and
Treatm y Suite Hepatitis
ent 1010 Information
Advoca New and
cy York, Education
Projec NY Project
t 10012
------------------------------------------------------------------------
Monetary Nationa 444 $150,000 12/19/2017 Affordable
l North Care Act
Allian Capitol (ACA), Ryan
ce of Street White/ADAP,
State NW #339 Public
and Washing Policy and
Territ ton, DC Technical
orial 20001 Assistance,
AIDS and the
Direct Minority
ors Leadership
Programs
------------------------------------------------------------------------
Monetary NovaSal 2946 $2,500 11/15/2017 ``Increasing
ud, Sleepy Testing and
Inc. Hollow Improving
Rd. Retention
Falls in Care and
Church, Access to
VA Treatment
22044 for People
at Risk or
Currently
Living with
HIV''
------------------------------------------------------------------------
Monetary Palmett 2638 Two $7,500 7/11/2017 HIV Care
o AIDS Notch Coordinatio
Life Road, n Program
Suppor Suite
t 108
Servic Columbi
es a, SC
29204
------------------------------------------------------------------------
Monetary Positiv 785 $2,500 11/13/2017 Integrated
e Market Support
Resour Street, Services
ce 10th
Center Floor
San
Francis
co, CA
94103
------------------------------------------------------------------------
Monetary PowerSo P.O. Box $2,500 10/23/2017 Bridging the
urce 12354 Gap
Tucson Tucson,
, Inc. AZ
85732
------------------------------------------------------------------------
Monetary Project 273 $10,000 12/18/2017 Mission
Inform Ninth Support
Street
San
Francis
co, CA
94103
------------------------------------------------------------------------
Monetary Project 273 $10,000 6/26/2017 Mission
Inform Ninth Support for
Street Project
San Inform
Francis
co, CA
94103
------------------------------------------------------------------------
Monetary Project 273 $25,000 6/26/2017 HIV Care
Inform Ninth Linkage,
Street Retention
San and Re-
Francis engagement
co, CA
94103
------------------------------------------------------------------------
Monetary Project 273 $25,000 6/26/2017 Policy
Inform Ninth Advocacy to
Street Protect HIV
San Treatment
Francis and Care
co, CA
94103
------------------------------------------------------------------------
Monetary Project 2929 NE $5,000 10/16/2017 ``Surviving
Link 6TH and
of Avenue Thriving;
South Wilton Long-term
Florid Manors, Survivors
a, FL workshops,
Inc. 33334 for Gay Men
50 and Over
Living with
HIV,'' and
for our
``Long-term
Survivor''
support
group.
------------------------------------------------------------------------
Monetary RAIN, 601 E. $20,000 9/29/2017 Free On-Site
Inc. 5th Mental
Street, Health
Suite Services
470 PO for People
Box Living with
37190 HIV
Charlot
te, NC
28202
------------------------------------------------------------------------
Monetary San 1035 $25,000 6/27/2017 TransLife
Franci Market HIV Care
sco Street, and Support
AIDS Suite
Founda 400 San
tion Francis
co, CA
94103
------------------------------------------------------------------------
Monetary Service 305 7th $5,000 4/21/2017 SAGEPositive
s and Avenue,
Advoca 15th
cy For Floor
Gay New
Lesbia York,
n NY
Bisexu 10001
al and
Transg
ender
Elders
Inc.
------------------------------------------------------------------------
Monetary The 17 Davis $65,000 7/20/2017 Ensuring
AIDS Bouleva Adequate
Instit rd, Funding for
ute Suite Domestic
403 HIV/AIDS
Suite Programs
403
Tampa,
FL
33606
------------------------------------------------------------------------
Monetary The 17 Davis $65,000 12/19/2017 2018 Federal
AIDS Bouleva and State
Instit rd, HIV/AIDS
ute Suite Policy
403 Issues
Suite
403
Tampa,
FL
33606
------------------------------------------------------------------------
Monetary The 64 West $4,000 9/18/2017 ID Inspired
Allian 35th Challenge
ce for Street,
Positi 3rd
ve Floor
Change New
York,
NY
10001
------------------------------------------------------------------------
Monetary The 99 $5,000 7/11/2017 Expansion of
Next Bishop Next Step's
Step Allen Year-round
Fund, Drive Programming
Inc. Cambrid for teens
ge, MA and young
02138 adults
living with
HIV.
------------------------------------------------------------------------
Monetary The San P.O. Box $2,500 8/18/2017 Youth
Diego 3357 Services
LGBT San
Commun Diego,
ity CA
Center 92163
------------------------------------------------------------------------
Monetary The San P.O. Box $5,000 7/19/2017 HIV services
Diego 3357
LGBT San
Commun Diego,
ity CA
Center 92163
------------------------------------------------------------------------
Monetary The 85 $30,000 12/18/2017 Building
Well Norman H.O.P.E.
Projec Avenue (Hopeful
t P.O. Outreach
Box and
220410 Positive
Brookly Engagement
n, NY for Women
11222 Living with
HIV)
------------------------------------------------------------------------
Monetary The 85 $30,000 3/1/2017 HIV Disease
Well Norman Awareness/
Projec Avenue Information
t P.O. , Community
Box Support,
220410 Advocacy
Brookly and
n, NY Capacity
11222 Building
------------------------------------------------------------------------
Monetary Treatme 90 Broad $15,000 6/26/2017 Ending the
nt Street, Epidemic
Action Suite
Group, 2503
Inc. New
York,
NY
10004
------------------------------------------------------------------------
Monetary Univers UCSF $15,000 9/29/2017 UCSF
ity Of Allianc Alliance
Califo e Health
rnia Health Project
San Project Mission-
Franci 1855 Based
sco Folsom Support--Co
Street, mmunity
Ste. Based
670 Box Intensive
0884 Case
San Management
Francis for People
co, CA Living With
94143 HIV/AIDS
------------------------------------------------------------------------
Monetary Univers 620 W. $2,500 11/13/2017 JACQUES
ity Of Lexingt Initiative
Maryla on St. Community
nd 2nd Outreach
Baltim floor Program
ore Baltimo
Founda re, MD
tion, 21201
Inc.
------------------------------------------------------------------------
Monetary US 1300 PA $725,000 12/19/2017 Global
Agency Avenue. Public
for , NW SA- Health
Intern 44 Rm Programs:
ationa 475-J Infection
l Washing Control
Develo ton, DC ($250,000),
pment 20523 Anti-
Microbial
Resistance
($300,000),
Pharmacovig
ilance
($175,000)
------------------------------------------------------------------------
Monetary Wellnes 2929 NE $2,000 10/16/2017 Prevention
s 6 for HIV
Center Avenue, Positive
of Suite B Heterosexua
South Wilton l/Minority
Florid Manors, Outreach
a, FL Program
Inc. 33334
------------------------------------------------------------------------
Monetary Young 4164 $5,000 7/19/2017 TruEvolution
Schola Brockto Community
rs For n Ave Wellness
Academ Riversi Center
ic de, CA
Empowe 92501
rment
------------------------------------------------------------------------
Product Johnson One $14,933,212 12/31/2017 Patient
& Johnson Assistance
Johnso & Product
n Johnson Donation
Patien Plaza
t Kilmer
Assist Square,
ance Suite
Founda 130 New
tion Brunswi
ck, NJ
08933
------------------------------------------------------------------------
Product Partner 1616 $1,018,932 3/31/2017 Product
ship Fort Donation
for Myer for New
Supply Drive, Horizons
Chain 12th global
Manage Floor public
ment Arlingt health
on, VA program
22209-
3100
------------------------------------------------------------------------
Product Partner 1616 $124,669 9/8/2017 Product
ship Fort donation
for Myer for New
Supply Drive, Horizons
Chain 12th Global
Manage Floor Public
ment Arlingt Health
on, VA Program
22209-
3100
------------------------------------------------------------------------
Product US 1300 $302,250,000 12/18/2017 Product
Agency Pennsyl donation
for vania for global
Intern Avenue, public
ationa N.W. health
l Washing programs
Develo ton, DC
pment 20523
------------------------------------------------------------------------
Actelion Pharmaceuticals US, Inc. Contribution Payments Made in 2018
------------------------------------------------------------------------
Organization Information Project Title Paid Amount Paid
------------------------------------------------------------------------
Westchester Medical Girls' Night Out $2,000.00 20180326
Center Foundation
------------------------------------------------------------------------
Scleroderma Research CONQUER Registry $500,000.00 20180125
Foundation Project
------------------------------------------------------------------------
Multiple Sclerosis The Latest MS $12,000.00 20180424
Association of America Research Updates
------------------------------------------------------------------------
Have a Ball Foundation 14th Annual ``Have a $5,000.00 20180309
Ball'' Golf
Tournament
------------------------------------------------------------------------
CMDAT Research Foundation Free seminars on $1,400.00 20180411
pulmonary arterial
hypertension and
Gaucher disease in
the Greater Denver
area
------------------------------------------------------------------------
Echo Hill Outdoor School Echo Hill Outdoor $5,000.00 20180410
Heart Camp 2018 School Heart Camp
2018
------------------------------------------------------------------------
Pulmonary Hypertension Chicago Area Trivia $3,200.00 20180510
Association Night
------------------------------------------------------------------------
American Lung Association St. Louis Lung Force $1,500.00 20180524
in Missouri Expo
------------------------------------------------------------------------
Pulmonary Hypertension Thirsting for a Cure $6,000.00 20180725
Association
------------------------------------------------------------------------
UPHill Journeys 11th Annual Northern $2,000.00 20180710
New England PH Forum
------------------------------------------------------------------------
Pulmonary Hypertension Steps for Stripes Fun $1,500.00 20180925
Association Walk
------------------------------------------------------------------------
American Heart Ann Arbor-Jackson $5,000.00 20181025
Association Heart Ball
------------------------------------------------------------------------
phaware global PHAWARE CHARITY $2,500.00 20181116
association POKER TOURNAMENT
------------------------------------------------------------------------
Pulmonary Hypertension Georgia Fun Walk $2,500.00 20181010
Association
------------------------------------------------------------------------
American Lung Association St. Louis Lung Force $1,500.00 20181010
in Missouri Expo
------------------------------------------------------------------------
Actelion has also made financial donations to independent charitable
foundations that assist patients who are underinsured and in financial
need with treatment-related expenses. In keeping with our donor
agreements and applicable regulatory guidance, we will only disclose
aggregate data on our charitable giving and do not publicize
information on donations to specific foundations and disease states.
In 2018, we contributed approximately $50.2 million in donations to
independent charitable foundations, enabling them to provide
assistance with medication-related copays to patients with pulmonary
hypertension.
______
Submitted by Hon. John Thune, a U.S. Senator From South Dakota
340B Health
1101 15th Street NW, Suite 910
Washington, DC 20005
Phone: 202-552-5850
FAX: 202-552-5868
www.340bhealth.org
340B is a Small Share of the Drug Market
and Does Not Increase Drug Prices
New data show drug manufacturers provided $6.1 billion in total drug
discounts in 2015 under the 340B Program. The 340B discount is less
than 2 percent of the total U.S. drug market and is dwarfed by other
segments of the drug industry.
340B does not increase drug prices. 340B reduces costs for safety net
providers, allowing them to provide affordable drugs and services to
low-income patients.
[GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT]
Compared to other segments of the market, the total 340B discount is:
Less than 2 percent of total U.S. drug spending.
3.6 percent of all discounts and rebates offered by
manufacturers.
4 percent of the specialty drug spending.
89 percent less than the rebates manufacturers provide to health
plans and PBMs.
78 percent less than what manufacturers spend on advertising.
57 percent less than what brand-name manufacturers have lost
from patent expirations.
Nearly one third of the total 340B discount is due a penalty enforced
against drug manufacturers for raising the price of drugs higher than
the rate of inflation or voluntarily providing a discount lower than
the 340B price. Manufacturers could avoid this penalty by not
increasing their drug prices at such high rates.
Total 340B Discount, $6.1 Billion
------------------------------------------------------------------------
------------------------------------------------------------------------
Required by 340B Statute, $4.2 Billion Inflationary Penalty,
$1.9 Billion
------------------------------------------------------------------------
The full analysis by Dobson Davanzo is available here: http://
www.340bhealth.org/files/340B_Financial_Impact_7_17.pdf.
______
Prepared Statement of Hon. Ron Wyden,
a U.S. Senator From Oregon
Prescription drugs did not become outrageously expensive by
accident. It's not the result of a system too complicated for Americans
to comprehend. Drug prices are astronomically high because that's where
pharmaceutical companies and their investors want them. The brakes have
come off pharmaceutical pricing, and American families are hurtling
along in the passenger seat terrified of what comes next.
Today the committee will hear uplifting stories about miracle
cures, but it is morally repugnant when patients can't afford them. It
is morally repugnant when ailing patients are forced to choose between
filling that next prescription or putting food on the table, because
they can't afford both. It is morally repugnant when patients are
forced to skip doses.
You Pharma executives are here because the way you do business is
unacceptable and unsustainable. Ten companies accounted for half of all
profts in the health-care sector last fall. Nine of those ten were drug
manufacturers. All but one of today's witnesses represent companies on
that list. Drug makers behave as if patients and taxpayers are unlocked
ATMs full of cash to be extracted, and their shareholders are the
customers they value above all else.
Let's look at concrete examples, starting with AbbVie. AbbVie
manufactures the top-selling prescription drug in America, the
arthritis medication Humira. Over 6 years, the company doubled the
price of a 12-month supply from $19,000 to $38,000. Can patients opt
for a less-expensive alternative? No they cannot, because AbbVie
protects the exclusivity of Humira like Gollum with his ring: thick
cobwebs of patents, legal tricks, and shadowy deals with other drug
makers, all to keep the cash flowing.
I also want to address troubling information the committee recently
uncovered. I'm holding AbbVie's proxy statement, a document every
publicly traded company must file with the SEC. Page 37 shows that in
2017, a portion of CEO Richard Gonzalez's multi-million-dollar bonus
was directly tied to sales of Humira. It appears the same incentive was
in place in 2015 and 2016.
In fact, the committee's review shows that all of AbbVie's top
executives had the same arrangement. Mr. Gonzalez is welcome to
respond, but the implication of that incentive ought to be clear. From
top down, AbbVie's leadership had reason to keep pushing prices and
sales upward.
Now on to Pfizer. Pfizer gets first prize for emptiest gesture on
pricing in 2018. After stern Trump tweets last year, Pfizer said it
would temporarily freeze prices. But once the President got his splashy
headlines, his gaze turned elsewhere, and Pfizer's former CEO told
investors it was back to ``business as normal.'' Another round of price
hikes in 2019, including on its pain medication Lyrica. Lyrica's price
has increased 163 percent since 2012. With this one drug, Pfizer raked
in $4.5 billion in 2017.
Merck: Merck gets second prize for emptiest gesture on pricing in
2018. It made sweet-sounding promises after coming under criticism, but
it cut prices for drugs that provide essentially no revenue to the
company. Left untouched were the cash cows Keytruda and Januvia, which
account for more than a quarter of Merck's revenue. It's like promising
car shoppers a great deal, except the only discounted model on the lot
is an Edsel.
Sanofi: A company wringing more and more cash out of people with an
incurable disease. In 2010, a vial of Sanofi insulin cost less than
$100. In 2018 it cost nearly $300, and the company raised prices again
in 2019. Considering that the landmark breakthrough on insulin came
early in the roaring twenties, nothing could justify that sudden price
increase nearly a century later. Diabetics who can't afford the costs
are self-rationing and endangering their lives, but at least the
investors are happy.
AstraZeneca: A lesson in saying the quiet part out loud. In an
interview earlier this year, CEO Pascal Soriot complained that his $12-
million salary made him ``the lowest-paid CEO in the whole industry.''
He said it was ``annoying to some extent.'' His company, meanwhile,
continues to raise the price of Symbicort, its $3-billion asthma drug.
For some asthmatics, being able to breathe costs hundreds of dollars a
month.
Johnson & Johnson: A record-setting flip-flop. This January 7th, at
the JP Morgan Healthcare Conference, CEO Alex Gorsky said that the
pharmaceutical industry needed to self-police on pricing. Sounds good,
but it didn't last long. Three days later, his company hiked the prices
of hundreds of its drugs, including drugs that account for billions in
Medicare spending.
Bristol-Myers-Squibb: In 2017, the company spent roughly $11.5
billion on dividends, stock buybacks, marketing, sales, and
administrative costs. That's roughly triple the amount it spent on R&D.
This is all a stark illustration of drug makers' profiteering and
two-faced scheming. The central argument that the committee will hear
in response is that the fault is everybody else's. The health plans are
at fault. The PBMs are at fault. Regulators are at fault. They always
point the finger elsewhere.
We'll also hear that list prices don't matter; that the true costs
are complicated. But companies don't set and raise list prices for fun.
Those prices are directly tied to the amount patients pay out-of-pocket
at the pharmacy window. They are directly tied to what taxpayers spend
on health-care programs.
Next, drug makers point fingers at the middlemen, pharmacy benefit
managers. I've said for years that PBMs are wasteful and secretive,
taking their cut without proving their worth to anybody. They will have
their day before this committee. But PBMs don't set list prices;
manufacturers do. Furthermore, manufacturers don't offer rebates for
nearly 40 percent of Part D brand-name drugs. Those prices continue to
rise. That's on the drug companies, not on PBMs.
Next, drug makers say changes in the status quo will hurt R&D. A
quick look at these companies' finances, on both sides of the balance
sheet, shows that isn't the case. Revenue generated from American
patients alone dwarfs what they spend on R&D worldwide. Drug makers
also spend as much, if not more, on flashy TV ads and office-to-office
salesmen as they spend on R&D. And if lower prices would diminish R&D,
why don't costly dividends? Why don't stock buybacks? Is the stock
price more important than inventing the next miracle cure?
Even if you buy the specious argument that a drug's list price at
launch is driven by the cost of R&D, what could justify arbitrary price
increases year after year, long after the R&D spending is done?
Finally, companies say they help patients afford drugs with
``coupons`` or patient assistance programs. But if these programs are
so widely generous, why can't drug makers instead simply lower prices
across the board? Because it's just more slick branding--ploys that
allow companies to maintain the status quo.
One final point. I was there when seven Big Tobacco CEOs testifed
in a committee room like this one, and they lied. The chairman and I
expect better this morning. Your profits are outsized compared to
others in the industry, you receive a massive portion of your revenue
from American taxpayers, and you bear none of the consequences of high
drug prices. It's past time to get beyond the excuses and make
prescription drugs affordable.
______
Communications
----------
AARP
601 E Street, NW
Washington, DC 20049
202-434--2277 | 1-888-OUR-AARP | 1-888-687-2277 | TTY: 1-877-434-7598
www.aarp.org | twitter: @aarp | facebook.com/aarp | youtube.com/aarp
February 26, 2019
The Honorable Chuck Grassley The Honorable Ron Wyden
Chairman Ranking Member
Committee on Finance Committee on Finance
U.S. Senate U.S. Senate
219 Dirksen Senate Office Building 219 Dirksen Senate Office Building
Washington, DC 20510 Washington, DC 20510
Dear Chairman Grassley and Ranking Member Wyden:
AARP appreciates your focus on prescription drug prices and the
challenges that increasing drug costs pose for seniors, and we thank
you for holding the hearing on February 26, 2019, to highlight rising
prescription drug prices. AARP, with its nearly 38 million members in
all 50 states, the District of Columbia, and the U.S. territories is a
nonpartisan, nonprofit, nationwide organization that helps people turn
their goals and dreams into real possibilities, strengthens communities
and fights for the issues that matter most to families such as
healthcare, employment and income security, retirement planning,
affordable utilities and protection from financial abuse.
Prescription drug prices are a high priority for AARP and all older
Americans, as older adults are particularly vulnerable to high
prescription drug prices. Medicare Part D enrollees take an average of
4.5 prescriptions per month, and over two-thirds have two or more
concurrent chronic illnesses. When older Americans talk about the
impact of high prescription drug prices, they are often talking about
costs that they will face every year for the rest of their lives.
Most Medicare beneficiaries live on modest incomes, with an annual
median of just over $26,000. One-quarter have incomes of just over
$15,000. One-quarter have less than $15,000 in savings. This is not a
population that has the resources to absorb rapidly escalating
prescription drug prices, and many are simply unable to afford the
medications they need.
Unfortunately, older Americans have seen their prescription drug prices
skyrocket in recent years. About 30 years ago, the public was outraged
over a drug that cost less than $10,000 per year. We now have drugs
with prices approaching $1 million per year.
In 2015, the average annual cost for a single specialty drug used on a
chronic basis was $52,486--which is only slightly less than the median
household income in the United States.\1\ We strongly support efforts
to bring new treatments to market, but innovation is meaningless if
patients cannot afford to use the treatment.
---------------------------------------------------------------------------
\1\ https://www.aarp.org/content/dam/aarp/ppi/2017/11/full-report-
trends-in-retail-prices-of-specialty-prescription-druqs-widely-used-by-
older-americans.pdf.
AARP has been tracking the prices of widely-used prescription drugs
since 2004. Our most recent Rx Price Watch Report focused on brand-name
drugs and found that their retail prices increased by an average of
8.4% in 2017--four times the rate of inflation. AARP's report also
examined how drug companies' relentless price increases add up over
time and found that the average annual cost of one brand-name drug--now
around $6,800--would have been just under $2,200 in 2017 if retail
price changes had been limited to general inflation between 2006 and
2017.\2\
---------------------------------------------------------------------------
\2\ https://www.aarp.org/content/dam/aarp/ppi/2018/09/trends-in-
retail-prices-of-brand-name-prescription-druqs-year-end-update.pdf
The average annual price increases for brand name drugs have exceeded
the corresponding rate of inflation every year since at least 2006.
More importantly, this problem goes beyond a few bad actors: virtually
---------------------------------------------------------------------------
all of the manufacturers we track raise their prices every single year.
As a result, it is hardly surprising that our members consistently tell
us they cannot afford the medications they need and are forced to make
difficult choices as a result. Even less surprising is that they want
this situation to change. Last year, in AARP's 2018 Mid-Term Voter
Issues Survey, 92 percent of voters age 50 and older told us that
candidates' positions on lowering drug costs was important to them,
with 74 percent saying ``very important.''
Moreover, in a Kaiser 2018 Health Tracking Poll, prescription drug
prices topped the list of the public's priorities, with 90 percent
calling it an important priority, and 52 percent listing it as a ``top
priority.'' In that poll, a large majority (80 percent) of the public
reported perceiving prescription drug costs as ``unreasonable,'' a
share that has increased since 2015.
Today it seems that prescription prices are in a never-ending race to
the top. High priced specialty drug approvals have exceeded traditional
drug approvals since 2010, and the number of people using such drugs is
growing. Meanwhile, the research pipeline is full of products like
orphan drugs, biologics, and personalized medicines that face little
competition and will undoubtedly command even higher prices.
We have also seen massive increases in Medicare spending on
prescription drugs. Between 2005 and 2016, Medicare Part B drug
spending more than doubled from $12 billion to $29 billion. Total
Medicare Part D spending is approaching $150 billion. These escalating
costs will eventually result in higher taxes, cuts to vitally important
public programs, or both.
Current prescription drug price trends are simply not sustainable. High
and growing drug prices are affecting all Americans in some way. Their
cost is passed along to everyone with health coverage through increased
health care premiums, deductibles, and other forms of cost-sharing.
They are also driving larger cost increases for a variety of taxpayer-
funded programs. Meanwhile, drug companies are working very hard to try
to shift the blame to others in the health care system, leaving them
free to set incredibly high prices and increase them with little
restraint.
It is long past time for Congress to take action to rein in high drug
prices. Thoughtful bipartisan efforts to help reduce prescription drug
prices could save tens of billions of dollars for patients, taxpayers
and the U.S. health care system. More importantly, they will help
ensure that all Americans have affordable access to the drugs that they
need to get and stay healthy.
We look forward to working with this Committee to find solutions that
will lower prescription drug prices and costs for older Americans. If
you have any additional questions, feel free to contact me or have your
staff contact Amy Kelbick on our Government Affairs staff at
[email protected] or 202-434-2648.
Sincerely,
Joyce A. Rogers
Senior Vice President
Government Affairs
______
American Society of Health-System Pharmacists (ASHP)
4500 East West Highway, Suite 900
Bethesda, MD 20814
Email: [email protected]
Phone: 301-664-8692
ASHP (American Society of Health-System Pharmacists) respectfully
submits the following statement for the record to the Senate Committee
on Finance hearing on ``Drug Pricing in America: A Prescription for
Change, Part II.''
ASHP represents pharmacists who serve as patient care providers in
acute and ambulatory settings. The organization's nearly 50,000 members
include pharmacists, student pharmacists, and pharmacy technicians. For
more than 75 years, ASHP has been at the forefront of efforts to
improve medication use and enhance patient safety.
ASHP's vision is that medication use will be optimal, safe, and
effective for all people all of the time. A primary tenet of that
vision includes access to affordable medications needed to save or
sustain lives. Addressing the issue of skyrocketing drug prices,
including excessive price increases on commonly used generic
medications, is one of ASHP's highest and longstanding public policy
priorities. According to a Kaiser Health Tracking Poll, 1 in 4
Americans cannot afford their medications.\1\ Poor access to
medications can lead to increased morbidity and mortality, and can
cause healthcare costs to increase.
---------------------------------------------------------------------------
\1\ DiJulio, Bianca, et al. ``Kaiser Health Tracking Poll: August
2015.'' The Henry J. Kaiser Family Foundation, 20 Aug. 2015,
www.kff.org/health-costs/poll-finding/kaiser-health-tracking-poll-
august-2015/. Accessed February 10, 2019.
ASHP has been proactively addressing challenges related to the rapid
increase of prescription drug pricing on several fronts, including
working with like-minded stakeholders and educating members of Congress
about the unsustainable burdens faced by patients, healthcare
---------------------------------------------------------------------------
providers, and the entire healthcare system.
ASHP is a lead member of the Steering Committee of the Campaign for
Sustainable Rx Pricing (CSRxP), a coalition of prominent national
organizations representing physicians, consumers, payers, hospitals,
health systems, and patient advocacy groups. CSRxP has developed a
policy platform promoting market based solutions supported by three
pillars: competition, value, and transparency.
The goal of the campaign is to identify policy options that have
bipartisan support and, therefore, a greater likelihood of passage. To
that end, CSRxP focuses on policies to incentivize a more competitive
marketplace to help stimulate lower drug prices. The campaign has also
expressed support for efforts to loosen restrictions that prevent
generic drug companies from obtaining the samples necessary to
manufacture a competing product.
The price increases have placed enormous budgetary pressure on
healthcare organizations, including hospitals and health systems. ASHP,
along with the American Hospital Association (AHA) and the Federation
of American Hospitals (FAH), recently released a report on the impact
that the cost of and access to prescription drugs are having on
hospital budgets and operations.
Specifically, the report showed that:
Average total drug spending per hospital admission increased by
18.5% between fiscal years (FY) 2015 and FY2017.
Outpatient drug spending per admission increased by 28.7%, while
inpatient drug spending per admission increased by 9.6%, between FY2015
and FY2017.
Hospitals experienced price increases of over 80% across
different classes of drugs, including those for anesthetics, parenteral
solutions, and chemotherapy.
Over 90% of surveyed hospitals reported having to identify
alternative therapies to manage spending.
One in 4 hospitals had to cut staff to mitigate budget
pressures.\2\
---------------------------------------------------------------------------
\2\ NORC at the University of Chicago. ``Recent Trends in Hospital
Drug Spending and Manufacturer Shortages'' (2019), https://www.aha.org/
system/files/2019-01/aha-drug-pricing-study-report-01152019_1.pdf.
Accessed 25 Feb. 2019.
ASHP does not collect, store, or report drug pricing information.
However, we continually hear from pharmacy leaders in hospitals and
health systems that sudden, inexplicable, and unpredictable price
increases in connection with some of the most commonly used, long
standing generic medications are becoming more prevalent--and are
---------------------------------------------------------------------------
occurring on a nationwide basis.
As there is no single solution to spikes in the prices of certain
drugs, there is no single cause either. In this statement, we address
four additional issues as they relate to drug pricing: competition,
Risk Evaluation and Mitigation Strategies (REMS), Direct and Indirect
Remuneration (DIR Fees), and the 340B Drug Pricing Program.
COMPETITION
In particular, ASHP would like to learn more about the marketplace
dynamics that could contribute to this issue, as we have worked
diligently to address the issue of drug shortages for nearly 15 years.
Although drug shortages are caused by a number of factors, we have
observed that drugs in short supply made by only one or two
manufacturers often result in higher-than-normal prices. If, for
example, there is a lack of competition in the generic market place, we
urge the committee to look at ways to stimulate more marketplace
presence. ASHP supports bills such as S. 64, the ``Preserve Access to
Affordable Generics and Biosimilars Act.'' This bipartisan bill would
potentially increase competition by prohibiting companies from engaging
in ``pay-to-delay'' tactics to stifle generic and biosimilar entry into
the market.
RISK EVALUATION AND MITIGATION STRATEGY (REMS)
ASHP recognizes that there may be limited circumstances in which
constraints on the traditional drug supply system may be appropriate
for reasons of patient safety, including through the use of
manufacturer-driven REMS. However, we believe that REMS should never be
used to artificially inflate drug prices, nor should REMS interfere
with the professional practice of pharmacists, physicians, nurses, and
other providers. We believe that there may be current cases in which a
manufacturer-
driven REMS using restricted distribution is causing higher prices for
those drugs, having adverse effects on patient access, and delaying
treatment. In some cases, there may be evidence to suggest that the use
of restricted or limited distribution channels has resulted in the
inability of a potential competitor to acquire enough of a drug to
conduct the required testing to bring a generic competitor to market.
For this reason, ASHP thanks Chairman Grassley for introducing S. 340,
the ``Creating and Restoring Equal Access to Equivalent Samples
(CREATES) Act of 2019.'' The CREATES Act will help ensure that brand-
name pharmaceutical companies cannot manipulate regulatory rules to
prevent competition, which is essential for patient access to
affordable medications. Additionally, we recommend that Congress
require the Food and Drug Administration (FDA) to investigate
restricted distribution under a REMS as a means to artificially
increase drug prices and limit access to critical medications.
Restricting distribution of medications is often a means to push
patients to a specific purchasing channel, which in some cases
increases not only their out-of-pocket costs, but also systemic costs.
Further, restricted distribution networks can complicate patient access
to critical medications, potentially disrupting care.
DIRECT AND INDIRECT REMUNERATION FEES (DIR FEES)
Many factors contribute to high drug product costs; addressing the
problem is made difficult by lack of transparency about the marketplace
for those products. For example, DIR fees and other rebates negotiated
by pharmacy benefit managers (PBMs) make it difficult to determine the
actual cost of a drug. DIR fees are a growing nationwide concern among
pharmacies that dispense medications in a community pharmacy or
outpatient clinic setting. Created under the Medicare Part D Program,
DIR fees were originally intended as a way for CMS to account for the
true cost of the drug dispensed, including any manufacturer rebates.
Often these rebates were unknown until the drug was dispensed and the
claim adjudicated. Moreover, the fees themselves, which are often
arbitrary in nature, have mushroomed over the past decade, to the point
that pharmacies regularly see annual DIR totals in the tens of
thousands of dollars.
Recently, a concerning trend has emerged in which pharmacy benefit
managers (PBMs) have begun to charge DIR fees to their pharmacy
providers. Under this scenario, PBMs are inappropriately applying their
own plan performance measures as a way to assess fees on pharmacies.
This is problematic for the following reasons:
It is an arbitrary and unintended application of quality
measures meant for total plan performance as opposed to pharmacy-level
metrics.
The quality measures applied tend to be based on maintenance
medications such as blood pressure medications or medications used to
treat diabetes. These measures were never intended to be applied to
specialty medications or to other specialized disease states such as
oncology, yet PBMs assess DIR fees against the gross reimbursement for
all prescriptions received by pharmacy providers, not just maintenance
medication s.
Pharmacy providers are essentially being penalized with backdoor
fees without any requirement that PBMs define, justify, or explain
these charges to providers and to CMS.
DIR fees assessed on pharmacies providing specialty medications have
been especially hard-hit, due to the fee structure. Fees could be a
flat rate of per dollar per claim or a percentage (typically 3-9%) of
the total reimbursement per claim. Using the percentage-based
structure, the fees would increase markedly for specialty drugs, which
are typically much more expensive than maintenance medications,
sometimes resulting in thousands of dollars. A 9% fee on a drug costing
$100,000 is $9,000. Additionally, these fees are assessed
retroactively, sometimes months after the claim has been adjudicated,
providing no recourse for the pharmacy impacted by the assessment.
The result of imposing DIR fees has led to higher cost-sharing
responsibilities for Medicare beneficiaries, which have, in turn,
caused more of these beneficiaries to enter the Part D donut hole,
where the patient is solely responsible for the cost of the drug. Along
with the higher costs absorbed by patients, adherence rates tend to be
lower among Medicare beneficiaries who are in the donut hole and may
not have the financial resources to pay for their medications. This is
in stark contrast to the very reason DIR fees targeting manufacturer
rebates were created--so that savings could be passed on to patients.
Pharmacies are not alone in their concern. In January 2017, CMS
published a fact sheet expressing concern over DIR fees and cited those
fees as contributing to increased drug costs, which, in turn, increased
patients' out-of-pocket spending and Medicare spending overall.\3\
Additionally, questions remain as to whether Part D plan sponsors have
the authority to assess these fees on pharmacies. There are no
references to DIR fees collected on pharmacies in either the Part D
statute or corresponding CMS regulations.
---------------------------------------------------------------------------
\3\ Fact sheet, ``Medicare Part D--Direct and Indirect Remuneration
(DIR).'' Centers for Medicare and Medicaid Services, 19 January. 2017,
https://www.cms.gov/newsroom/fact-sheets/medicare-part-d-direct-and-
indirect-remuneration-dir. Accessed February 10, 2019
---------------------------------------------------------------------------
ASHP's professional policy on DIR fees is as follows:
To advocate that payers and pharmacy benefit managers be
prohibited from recovering direct and indirect remuneration
fees from pharmacies on adjudicated dispensing claims; further,
To oppose the application of plan-level quality measures on
specific providers, such as participating pharmacies.\4\
---------------------------------------------------------------------------
\4\ ASHP Policy 1814, ``Direct and Indirect Remuneration Fees.''
---------------------------------------------------------------------------
THE 340B DRUG PRICING PROGRAM
For 25 years, the federal 340B program has allowed safety-net hospitals
``to stretch scarce Federal resources as far as possible, reaching more
eligible patients and providing more comprehensive services.'' This
program has been essential to expanding access to lifesaving
prescription drugs and comprehensive healthcare services to low-income
and uninsured individuals, at no cost to the federal government. The
federal 340B program is not causing high drug prices. The program
accounts for less than 5% of annual drug purchases in the United
States, while safety-net providers give 30% of the care. There are many
contributing factors to higher drug costs, but there is no objective
evidence that the program has increased overall drug pricing. In fact,
the 340B program is revenue-neutral, benefiting patients without
increasing costs for federal payors.
The federal 340B program enables these hospitals to serve their
communities by providing vital care such as:
Free or lower-cost medications to patients.
Programs to increase medication adherence, including clinical
pharmacy services to high-risk patients who are on multiple and/or
complex medications.
Increased access to primary care.
Screenings and preventive care services to detect health
problems early and decrease morbidity and mortality, as well as to
decrease healthcare costs and hospital admissions.
The federal 340B program is at risk because of a recent change in
Medicare payment policy that reduces payment from average sales price
plus 6 percent to average sales price minus 22.5 percent. Cuts of this
magnitude undermine the intent of the program, reducing resources that
hospitals use to expand access to care and services to vulnerable
communities. Given the increasingly high cost of pharmaceuticals, the
federal 340B program provides critical support to the entities eligible
to participate in the program.
CONCLUSION
ASHP thanks the Committee on Finance for holding this important
hearing. ASHP remains committed to working with Congress and industry
stakeholders to ensure that patients have affordable access to
lifesaving and life-sustaining medications.
______
Coalition for Affordable Prescription Drugs
U.S. Senate
Committee on Finance
Dirksen Senate Office Bldg.
Washington, DC 20510-6200
Tuesday, February 26, 2019
The Coalition for Affordable Prescription Drugs (CAPD) appreciates the
opportunity to submit the following statement for the record.
Overview
CAPD is a diverse group of employers, unions, public sector employees
and retirees and the pharmacy benefit managers (PBMs) they partner with
to provide more affordable prescription drug coverage for millions of
Americans.
Today, too many patients and families are struggling to pay for the
medications they need. It's no surprise that a recent Politico/Harvard
Chan School of Public Health poll showed that 80 percent of Americans
see high prescription drug prices as a top priority for the new
Congress and the Administration.
The Role of PBMs in Lowering Costs
In the face of rising drug prices, PBMs partner with employers, unions,
public sector retirees and other organizations who purchase health care
to help manage prescription drug coverage for millions of Americans. By
negotiating with drug companies and providing patient-centered tools to
improve care and help lower out-of-pocket costs, PBMs save over $900
per person each year.
In addition, PBMs are expanding visibility into drug prices by enabling
doctors and patients to see the price of various medicines at the point
of prescribing, based on the individual's specific drug benefits. With
this information, physicians switch to a more affordable medicine
nearly 20 percent of the time when clinically equivalent alternatives
are offered through UnitedHealth Group's RTBT, PreCheck MyScript. In
another example, CVS Health's Real Time Benefits tool has saved
patients an average of $120 to $130 per fill.
Drug Company Prices Are the Problem
Although there have been many ideas proffered about how to address the
rising prices of medicines, CAPD believes that we first need to address
the root problem: prices set by drug makers. Drug companies alone set
their prices and they are rising at an unsustainable rate. In fact,
drug companies have raised prices already in 2019 on hundreds of
medicines. And, what's worse is that this is repeat behavior. Drug
companies often raise those prices multiple times a year for the exact
same product. Over the last five years, prices increased on the top 20
most prescribed brand-name drugs for seniors by an average of 12
percent each year, which is significantly above the annual rate of
inflation. The truth is simple: Drug companies hike their prices
because they can. When they do so, millions of patients pay more at the
counter.
Drug companies, hoping to avoid scrutiny and sustain high profits, are
pointing the finger at every other industry except themselves.
According to drug companies, the reason why drug prices are so high
isn't because they keep raising prices, or abuse the patent system, or
make by far the highest profits in health care--it's everyone else's
problem, not theirs.
In today's testimony, we will likely hear a common refrain from drug
companies: part of the reason that drug prices are so high are because
of the rebates that they are forced to give to PBMs. But the problem
with this argument is that, according to a recent study, there is
little correlation between prices drug companies set for their drugs
and the rebates negotiated by PBMs across 23 major drug categories.
What's more, in Medicare Part D, even after accounting for rebates, the
costs of brand name drugs still increased 62% from 2011 to 2015.
All parties need to come to the table to make prescriptions more
affordable and accessible to the patients who need them--but nothing
will be done if pharma refuses to even pull up a chair and address the
problem where it starts: their high prices. We hope Congress will use
this hearing as an opportunity to ask the pharmaceutical industry to
answer for these increases.
Pharma's Gamesmanship Reducing Competition to Keep Prices High
One way to meaningfully lower drug prices for patients is to stop the
gamesmanship of the patent and regulatory systems that drug companies
use to maintain their monopoly pricing power and keep lower-cost
generic alternatives from entering the market.
Brand drug manufacturers exploit the FDA Risk Evaluation and Mitigation
Strategies (REMS) program to prevent generic drug makers from accessing
needed samples, costing the U.S. health care system $5.4B each year.
The CREATES Act, which passed out of the Senate Judiciary Committee
last year, is a targeted, market-based, bipartisan solution to the
longstanding problem of brand name pharmaceutical companies denying
generic manufacturers access to the samples they require to conduct
necessary equivalence testing to bring their product to market.
Another way brand drug manufacturers game the patent and regulatory
system is through ``pay-for-delay'' deals, in which drug makers engage
in anticompetitive patent settlements with potential generic
competitors, resulting in $3.58 in higher drug costs each year. In the
most high-profile example of these abuses, drug maker AbbVie last year
reached agreements with Amgen, Samsung Bioepis and Mylan to delay entry
of a lower-cost biosimilar version of the drug to 2023 in the United
States.
A third example of gamesmanship by brand drug manufacturers is
evergreening, in which generic competition is delayed by additional
patents on minor variations of the original drug for the clear purpose
of extending monopoly protection. While these tweaks often do not
convey enhanced clinical benefits to the patient, they do extend the
time period during which drug manufacturers can continue to control
pricing by preventing competition. For example, best selling drug
Humira to treat rheumatoid arthritis and psoriasis is protected by over
100 patents and the product may not face any competition until as late
as 2034.
We encourage Congress to explore proposals that target patent and
regulatory abuses by drug companies in order to lower drug prices for
patients.
Conclusion
Simply put, a patient cannot be helped by a drug they cannot afford. We
ask today that Congress once and for all refuse to accept drug
manufacturers' excuses for high prices and take steps to put an end to
the patent and regulatory abuses that keep prices artificially high.
We believe the time to act is now. CAPD is committed to working with
Congress and other stakeholders on this and other solutions to
meaningfully lower prescription drug prices for all Americans. We look
forward to supporting this critical effort.
Debra Barrett
Executive Director, Coalition for Affordable Prescription Drugs
Contact:
Meghan Scott
Spokesperson, Coalition for Affordable Prescription Drugs
[email protected]
(202) 341-2060
What They're Saying: Don't Let Pharma Off the Hook
On January 29, the Senate Finance Committee held a hearing, ``Drug
Pricing in America: A Prescription for Change.'' During the hearing,
both Senators and witnesses discussed drug companies' high prices and
their anti-competitive actions.
DRUG COMPANIES' HIGH PRICES
Chairman Chuck Grassley (R-Iowa): ``I've also heard from seniors
who have seen their prescriptions increase month after month for no
apparent reason. And I've heard stories about people reducing their
life-saving medicines...to save money. This is unacceptable. . . . But
other drugs are creating problems as well, that is why tackling high
prescription drug costs is one of Senator Wyden's and my first priority
on this committee.''
Ranking Member Ron Wyden (D-Oregon): ``So there's no shortage of
evidence about what the problems are. The companies have unchecked
powers to set prices on their own, and often it's to meet Wall Street's
expectations rather than meet demand in the market.''
Mark Miller, The Arnold Foundation: ``The revenues that come out
of the United States exceed R&D by something like 70, 75 percent. . . .
So the first point is when people say R&D is driving these prices,
there is a big disconnect in there. . . . We found many companies in
which they're spending much more on advertising, marketing and other
administrative expenses than they are on R&D.''
Peter Bach, Memorial Sloan Kettering: ``Prices for monopoly
goods such as these are determined by the market in which they are
sold, not the other way around. . . . Please realize that these drugs
do not inherently cost $1 million any more than they inherently cost
$1.''
Kathy Sego, mother of a child with diabetes: ``As a mother, I
would probably say to them--I hope you know that there are people who
are going without their medication, and because they're going without
their medication they're at risk of dying. And how can you be OK with
that? . . . That should never be a decision that a person needs to
make. And unfortunately, it is.''
GAMESMANSHIP AND ANTICOMPETITIVE PRACTICES
Douglas Holtz-Eakin, American Action Forum: ``We have some very
isolated instances of cost associated with off-patent sole-source
drugs. And in those circumstances, it appears that firms are able to
take advantage of their market power and raise the prices of drugs
sharply. This strikes me as a fundamental anti-competitive act that
ought to be investigated.''
Senator Robert Menendez (D-New Jersey): ``Manufacturer coupons,
many suggest, distort spending. . . . Who's winning with these
coupons?'' Peter Bach: ``I can assure you we know who's winning and
it's the people who are printing the coupons . . . the reality is
they're artificial price supports.''
Senator Maggie Hassan (D-New Hampshire): ``We've seen a lot of
bad actors gaming the system over the years, really to pad their
pockets. There are countless ways drug companies take advantage of
loopholes and taxpayers end up footing the bill.''
Mark Miller: ``We need to curb the anticompetitive behaviors of
manufacturers and inject competition back into the marketplace.
Manufacturers benefit from taxpayer-funded NIH research and from
government granted monopolies. And naturally, they devote resources to
protecting those monopolies.''
AffordablePrescriptionDrugs.org
______
Letter Submitted by Linda George
March 4, 2019
U.S. Senate
Committee on Finance
Dirksen Senate Office Bldg.
Washington, DC 20510-6200
RE: ``Drug Pricing in America,'' Senate hearing held on February 26,
2019
Dear Finance Committee:
On Wednesday January 23, 2019, I gave myself my last weekly
injection of Humira, which had helped my mobility due to psoriatic
arthritis. I have done very well for the past two years with this
drug--one typically requiring a biweekly 40mg syringe injection. But I
just started a new medication, an infusion administered in my doctor's
office by an outsourced nurse who's not part of the practice.
I needed to switch to the infused medication because on March 1st--
when I became eligible for Medicare--Humira would increase from $5/
monthly under our previous private insurer, Anthem Blue Cross, to a
prohibitive $800+ per injection with Medicare Part D coverage. Bottom
line: Medicare does not cover self-injections. Because an infusion
would be administered in my rheumatologist's office, it is 100% covered
as a medical procedure through Part B via Medicare. Now, I understand
why Humira's advertisements, invading my television screen no matter
what time or what channel I watch, always feature younger people
engaged in various physical activities.
When I needed information about how to navigate this insurance
morass, I called my Humira ambassador, an AbbVie employee who serves as
a liaison between the consumer and the company. She assured me that I
may be covered if I submitted my tax returns to the company's
foundation. Evidently if I make less than $65,000, through the
company's assistance program, the parent company's foundation pays a
portion of the thousands needed to offset consumers' exorbitant cost of
this drug; however, regardless of my income, I have a huge problem
submitting my tax statements to anyone--except to my trusted accountant
and the IRS.
It seems AbbVie puts some big money into tiers of bureaucracy
through advertising, marketing, and supporting a foundation based on
employees forced to donate a percentage of their income. In addition,
whenever a consumer needs to have the simplest question answered by the
company, instead of AbbVie offering an 800 phone number, that consumer
must first enroll in the ``Ambassador Program,'' then wait for their
designated ambassador to return the call. I've had two ambassadors so
far, and each seems more than willing to keep me on the phone for an
extended time, asking all kinds of questions, as if padding their own
positions by calling consumers on a monthly basis. I'd much prefer that
these ambassadors work to figure out ways to reduce the drug's cost, so
consumers like me can afford it.
Switching to new medication certainly had caused me some angst. I
had no sense of how I will respond to the new infusion. Based on
history, I've had my share of side effects during the 38 years I've
been dealing with arthritis. I have trouble with drugs that are
ingested through the GI tract. I also have had two different cancers, a
risk accompanying many of the biologic arthritis medications. In
addition, I've had some serious adverse reactions to medications,
requiring hospitalization. Lucky for me, the new infusion, 100% covered
by Medicare Part B, seems to be working well.
Despite having this ailment, I consider myself to be healthy, doing
whatever possible to maintain whatever I can do to stay well to
overcome arthritis' swelling, fatigue, and pain that has challenged me
physically and mentally. I probably have had more knee aspirations and
steroid injections than some Olympic athletes. My Fitbit gets a daily
workout. Even after trying many alternative treatments in search of a
solution, Humira seemed to help me resume a normal life. And for that,
I was grateful.
AbbVie Chairman and CEO Richard A Gonzalez stated at the U.S.
Senate Finance Committee on February 26, 2019, ``We believe it is
important that discussions about access and affordability include a
focus on how to alleviate Medicare Part D out-of-pocket burdens above
and beyond just lowering list prices.'' I must raise the question to
AbbVie: What is the company doing internally to cut costs for
consumers?
I am hoping that you will help address the mounting bureaucratic
issues surrounding health care in America that make it challenging for
consumers to afford and navigate. Please feel free to reach out to me
if you need more information or assistance in any way.
Yours,
Linda George
cc: Senator Patrick Toomey
Senator Bob Casey
Attorney General Josh Shapiro
______
Statement of Robin K. Huszagh
February 26, 2019
After listening to the hearing today on C-SPAN, I wanted to share my
situation with you as a patient being forced to pay the full
``negotiated'' price for Humira and Enbrel. My husband and I are self-
employed and self-insured. We must purchase health insurance through
the independent ``retail'' market. I specifically renewed a
grandfathered ``retail'' PPO health insurance policy we've had since
2010 for our family of 3, now priced at $2,166.00/month, so that could
get the specialty formulary I needed to treat my Rheumatoid Arthritis
at an affordable price and continue to see my doctors. To my distress,
the Insurer (BCBS) and Pharmacy Benefit Manager (Prime Therapeutics)
altered the PPO plan's pharmacy benefits (cost sharing details) after
the plan commenced, leaving me with an expensive policy that no longer
covers my expensive specialty formulary at an affordable price. Unlike
typical commercial employer-based group policies, once I needed the
expensive specialty formulary, my independent retail PPO policy was
switched into a restricted pharmacy network with only one mail-order
supplier and an ``Accumulator Adjustment Program.'' The Insurer/PBM
also blocked the use of drug manufacturer's discount coupons and
programs completely (worth $12,000 to $16,000 per year in my case) so
that a drug that used to cost me $5.00 to $10.00 per month with a
manufacturer's coupon now costs between $5356 to $6652 per month, the
negotiated contract rate between the insurer and the drug manufacturer.
My deductible was raised from $2600 to $5200 for a 20% coinsurance
responsibility and $11,200 out-of-pocket max for full benefits. The
insurer added a second review process in 2019 for any drug with a
contract rate of $5000/month or higher, in addition to the one put in
place in 2018 as part of a ``step therapy'' restriction/review. In 2019
the price for both Humira and Enbrel jumped to over $5000 per month and
the insurer has stated their ``secondary review'' would allow them to
deny benefits for these drugs even though the policy states they are
approved formularies.
At the current premium rate, paying for insurance and an expensive
formulary has been financially challenging to say the least and has
caused us to take an early withdrawal from our IRA. I contacted the
Illinois Department of Insurance and asked why insurers can change
pharmacy benefits mid-year and weren't required to document the
specific cost-sharing and pharmacy details on all insurance policy
documents, so benefits are locked in for the year. I was told those
details are NOT a requirement for retail plans, and pharmacy benefit
changes are allowed to occur throughout the life of the contract which
also includes medication price changes. So, if a consumer buys a policy
based on access and pricing for a particular drug, there is no
guarantee the terms will remain in effect for the full contract year. I
was never notified of the changes even after contacting the insurer. I
hadn't realized any changes until I went to the pharmacy to pick up a
prescription and hit the payment ``brick wall''!
The Network Transparency Act of 2019 was passed in Illinois, however
that only set policy guidelines for ``notification requirements'' to
the policy holder if a particular provider pulls out of a network but
doesn't address the insurer's ability to change a policy's pharmacy
benefits mid-year, leaving the policy holder with a shocking bill. The
contract price for Humira went up 9% in January, the cost of my PPO
policy went up 9% in 2019, and now I'm required to pay a higher
premium, higher out-of-pocket max, and the full price for Humira
without the use of manufacturer's discount programs. Patients with
employer-based group plans who are already benefiting from employer
cost-sharing perks are allowed the use of discount programs and coupons
at the point of sale (the pharmacy) because the insurer and the
employer never know the coupon is being used as a form of payment at
the retail pharmacy location. The coupon value pays for the drug and
that hidden payment is applied to the user's deductible. Those who
benefit from these programs do not care what the list price or the
negotiated price is for a high-priced drug because they never have to
actually pay it, the insurer pays for it because deductibles and out-
of-pocket limits are met early in the year. Those with commercial group
plans obtain specialty formularies for $5 to $10 per month. I have to
pay the full price. The change in my PPO policy was intentionally made
by the insurer to ensure I personally pay the full cost of the drug for
as long as possible. They do not want me to get assistance from Pharma
to reach my deductible or maximum. There is no relief in sight for the
independently insured who have no employer or government subsidies and
actually pay the full high price for each medication and monthly
insurance premiums. With the majority of Americans getting health
insurance perks from their employer and using drug coupons, there is no
incentive for drug manufacturers to ever lower list prices.
______
Interfaith Center on Corporate Responsibility (ICCR)
475 Riverside Drive, Suite 1842
New York, NY 10115
(212) 870-2295
www.iccr.org
March 12, 2019
Mr. Chairman, Ranking Member and Members of the Committee:
ICCR is a coalition of over 300 global institutional investors
representing more than $400 billion in managed assets. Leveraging our
equity ownership in some of the world's largest and most powerful
companies, ICCR members regularly engage management to identify and
mitigate social and environmental risks resulting from corporate
operations and policies. While ICCR members never shy away from making
the moral case for action, our fundamental proposition as investors is
that responsible and sustainable business practices--and a strong
corporate culture of ethics--are in the long-term interest of
companies, investors and communities.
ICCR members have a long-standing history of engagement with
pharmaceutical companies on issues of price restraint, equitable
pricing strategies, anti-competitive practices, marketing policies and
practice, as well as disclosure of R&D expenditures (e.g., report on
the number of products in the R&D pipeline that are new versus enhanced
versions of existing products) and lobbying/political activities with
agendas that may restrict the access and affordability of medicines.
For decades, ICCR members have pressed drug companies for greater
disclosures on pricing structures as a way to promote greater access to
medicines. A lack of transparency around how drug prices are determined
has led to an industry-wide ethos of ``whatever the market will bear,''
which can lead to predatory pricing. We have asked companies to
disclose the rates of price increases year-to-year of their top selling
branded prescriptions drugs and to disclose the rationale and criteria
used for these price increases. We have also asked the companies to
assess the legislative, reputational and financial risks these
increases represent for the companies. However, that lack of
transparency still prevails.
Most recently, we have become increasingly concerned about
pharmaceutical companies' governance structures and their Boards'
ability to proactively mitigate risk related to high drug prices. A
2017 Credit Suisse analyst report stated that ``US drug price rises
contributed 100% of industry EPS growth in 2016'' and characterized
that fact as ``the most important issue for a Pharma investor today.''
In response to this, in 2018 ICCR members filed resolutions at the
companies highlighted in the 2017 Credit Suisse report asking ``the
Compensation Committee (the `Committee') to report annually to
shareholders on the extent to which risks related to public concern
over drug pricing strategies are integrated into [company's] incentive
compensation policies, plans and programs (`arrangements') for senior
executives. The report should include, but need not be limited to,
discussion of whether (i) incentive compensation arrangements reward,
or not penalize, senior executives for adopting pricing strategies, or
making and honoring commitments about pricing, that incorporate public
concern regarding prescription drug prices; and (ii) such concern is
taken into account when setting financial targets for incentive
compensation arrangements.'' In other words, are executives
incentivized to simply increase the price of drugs with no added
benefit in clinical efficacy simply to meet short-term revenue targets?
In particular, we are seeking better articulation of the goal-setting
process and the translation of those goals into incentive pay targets.
We would strongly encourage you, as members of the Senate Finance
Committee, to also seek written answers to the following questions:
How assumptions about price changes are incorporated when
revenue goals are set;
Whether any policy or guideline exists regarding the preferred
proportion of revenue growth derived from price increases;
Whether any policy exists regarding unplanned price increases
that would enable revenue goals or compensation revenue targets to be
met and whether the board has to approve such increases; and
How the compensation committee uses revenue goals or estimates
to produce the various target levels (e.g., minimum, target and
maximum) used to determine incentive payouts.
Mirroring Senator Wyden's concern that AbbVie's CEO's bonus is directly
tied to the sales of Humira, we have also been asking why Humira sales
are an appropriate measure for AbbVie's short-term incentive plan
(STIP), and whether the company considers pricing increases when
awarding STIP? AbbVie uses net revenue, income before taxes and Humira
sales as metrics for the annual bonus and earnings per share (EPS) as a
metric for certain long-term incentive awards to senior executives. For
Pfizer, it is concerning to investors that the company publicly states
that ``innovation in medicine has been and continues to be the
cornerstone of the company,'' yet no pipeline metrics are included in
the executive incentive agreements.
In addition to increased disclosure on incentive structures, we have
also asked companies to formalize board oversight of prescription drug
pricing risk. For example, what is Pfizer's board oversight of drug
pricing, or lack thereof, which may have led to the settlement of the
co-pay kickback investigation and drug shortages due to manufacturing
or market issues. A 2018 Credit Suisse report highlighted AbbVie as
among the companies most at risk from specialty pricing pressures in
commercial insurance. Humira, which accounted for 65% of AbbVie's
revenues in 2017 now faces competition in Europe from biosimilars,
which are expected to cost less. Therefore, robust board oversight of
risks related to drug pricing would provide a valuable outside
perspective and help ensure that those risks are being managed for the
long term.
Lastly, we also recognize that the strategy to expand monopolies
without any meaningful new science is an unsustainable business model
that exacts a heavy cost on patients and on the systems in which they
seek care, and therefore, encourage companies to refrain from engaging
in anti-competitive practices.
As investors, we want the companies in which we invest to be successful
in the long term, with sustainable business models that deliver value
to customers and stakeholders. Because pharmaceutical companies derive
their social license to operate from their contribution to public
health, it is critical that their businesses--including their executive
incentives structures--reinforce, not undermine, that social contract.
After many years of investor engagement in an effort to promote greater
access and affordability of medicines, today we seriously question the
value pharmaceutical companies are delivering to their shareholders and
to the greater public.
If you have any questions, please contact, Meg Jones-Monteiro, Program
Director--Health Equity, at [email protected] or (212) 870-2984.
APPENDIX: 2019 ICCR EXECUTIVE INCENTIVES AND
DRUG PRICING RISK RESOLUTIONS
2018 Companies: AbbVie, Amgen, Biogen, Bristol-Meyers Squibb, Eli Lilly
2019 Companies: AbbVie, Biogen, Bristol-Meyers Squibb, Celgene, Johnson
& Johnson, Merck & Co, Pfizer, Vertex
Example 2019 Resolutions:
AbbVie (ABBV)
_______________________________________________________________________
RESOLVED, that shareholders of AbbVie Inc. (``AbbVie'') urge the
Compensation Committee (the ``Committee'') to report annually to
shareholders on the extent to which risks related to public concern
over drug pricing strategies are integrated into AbbVie's incentive
compensation policies, plans and programs (together, ``arrangements'')
for senior executives. The report should include, but need not be
limited to, discussion of whether (i) incentive compensation
arrangements reward, or not penalize, senior executives for adopting
pricing strategies, or making and honoring commitments about pricing,
that incorporate public concern regarding the level or rate of increase
in prescription drug prices; and (ii) such concern is considered when
setting financial targets for incentive compensation arrangements.
Supporting Statement: As long-term investors, we believe that senior
executive incentive compensation arrangements should reward the
creation of sustainable long-term value. To that end, it is important
that those arrangements align with company strategy and encourage
responsible risk management.
A key risk facing pharmaceutical companies is potential backlash
against high drug prices. Societal anger over exorbitant prices and
pressure over limited patients' access due to unaffordability may force
price rollbacks and harm corporate reputation.
We applaud AbbVie for committing not to increase prices by more than
10% for 2018, yet we are unaware of a like commitment for 2019 or
beyond. Moreover, we are concerned that the incentive compensation
arrangements applicable to AbbVie's senior executives may undermine any
such commitment.
AbbVie uses net revenue, income before taxes and Humira sales as
metrics for the annual bonus and earnings per share (EPS) as a metric
for certain long-term incentive awards to senior executives (2018 Proxy
Statement, at 31). A 2017 Credit Suisse analyst report stated that ``US
drug price rises contributed 100% of industry EPS growth in 2016'' and
characterized that fact as ``the most important issue for a Pharma
investor today.'' The report identified AbbVie as a company where price
increases accounted for at least 100% of EPS growth in 2016 (Global
Pharma and Biotech Sector Review: Exploring Future US Pricing Pressure,
Apr. 18, 2017, at 1). It has been noted that the company's 2018 9.7%
price increase for Humira could add $1.2 billion to the U.S. healthcare
system (https://www.fiercepharma.com/pharma/drug-price-hikes-a-few-bad-
actors-or-widespread-pharma?mkt_tok=eyJpljoiWWpZeFlt
RTBOMIZoTkRJNSlslnQiOiJhckk2UONqNXBxNOx2UCtvdVdldzZVZXRIUHIrSOx
ZOVRBNXdTV1FOeVNBSDMxb3NWUGJsRWtNcFROZmlPYmM5d2hXd3VuVOkld
GICelBTYmk2).
In our view, excessive dependence on drug price increases is a risky
and unsustainable strategy, especially when price hikes drive large
senior executive payouts. We believe that the company's strategy to use
``nursing support,'' which the California Department of Insurance
claims in its suit against the company to be largely a kickback scheme
to boost Humira sales, may have been better managed by leadership if
Humira sales were not an explicit part of the payment incentive plan
(https://www.law360.com/articles/1084008).
The disclosure we request would allow shareholders to better assess the
extent to which compensation arrangements encourage senior executives
to responsibly manage risks relating to drug pricing and contribute to
long-term value creation. We urge shareholders to vote for this
Proposal.
Merck & Co. (MRK)
_______________________________________________________________________
RESOLVED, that shareholders of Merck & Co., Inc. (``Merck'') urge the
Compensation and Benefits Committee to report annually to shareholders
on the extent to which risks related to public concern over drug
pricing strategies are integrated into Merck's incentive compensation
policies, plans and programs (``arrangements'') for senior executives.
The report should include, but need not be limited to, discussion of
whether (i) incentive compensation arrangements reward, or not
penalize, senior executives for adopting pricing strategies, or making
and honoring commitments about pricing, that incorporate public concern
regarding prescription drug prices; and (ii) such concern is considered
when setting financial targets for incentive compensation arrangements.
Supporting Statement: As long-term investors, we believe that senior
executive incentive compensation arrangements should reward the
creation of sustainable value. To that end, it is important that those
arrangements align with company strategy and encourage responsible risk
management.
We are concerned that the incentive compensation arrangements
applicable to Merck's senior executives may discourage them from taking
actions that result in lower short-term financial performance even when
those actions may be in Merck's best long-term interests. Merck has
committed to limit average price increases of its drugs to no more than
the rate of inflation (https://www.marketwatch.com/story/merck-to-
lower-price-of-hep-c-treatment-zepatier-by-60-commits-to-responsible-
pricing-2018-07-19), but incentive compensation arrangements may be
inconsistent with that commitment.
Merck uses revenue and pre-tax income as metrics for the annual bonus,
and earnings per share (EPS) is a metric for performance share units
granted after January 1, 2017 (2018 Proxy Statement, at 51, 61). A 2017
Credit Suisse analyst report identified Merck as a company where U.S.
net price increases accounted for at least 100% of 2016 net income
growth (Global Pharma and Biotech Sector Review: Exploring Future US
Pricing Pressure, Apr. 18, 2017, at 22).
In our view, risks to long-term value arise when large senior executive
payouts can be driven by price hikes. Attention may focus on both high
senior executive payouts and drug pricing, fueling public outrage. Ovid
Therapeutics CEO Jeremy Levin has argued that incentives to boost
short-term performance, such as EPS, lead executives to raise prices
(and rebates to middlemen), starve research and development and buy
back shares (https://www.biocentury.com/biocentury/strategy/2016-09-19/
why-jeremy-levin-says-executive-compensation-and-drug-pricing-must-).
Incentives may have societal implications, as one critic of high pay
for healthcare executives has noted: ``[I]f the most influential
executives of these companies are being paid to keep that [cost]
trajectory up, that's money that's being taken away from education or
infrastructure or other parts of the economy that may not be growing as
quickly, and maybe that we'd want to grow more quickly'' (https://
www.npr.org/sections/health-shots/2017/07/26/539518682/as-cost-of-u-s-
heaIth-care-skyrockets-so-does-pay-of-heaIth-care-ceos).
The disclosure we request would allow shareholders to better assess the
extent to which compensation arrangements encourage senior executives
to responsibly manage risks relating to drug pricing and contribute to
long-term value creation. For example, it would be useful for investors
to know whether incentive compensation target amounts reflect
consideration of pricing pressures. We urge shareholders to vote for
this Proposal.
Pfizer (PFE)
_______________________________________________________________________
RESOLVED, that shareholders of Pfizer Inc. (``Pfizer'') urge the
Compensation Committee (the ``Committee'') to report annually to
shareholders on the extent to which risks related to public concern
over drug pricing strategies are integrated into Pfizer's incentive
compensation policies, plans and programs (``arrangements'') for senior
executives. The report should include, but need not be limited to,
discussion of whether (i) incentive compensation arrangements reward,
or not penalize, senior executives for adopting pricing strategies, or
making and honoring commitments about pricing, that incorporate public
concern regarding prescription drug prices; and (ii) such concern is
considered when setting financial targets for incentive compensation
arrangements.
Supporting Statement: As long-term investors, we believe that senior
executive incentive compensation arrangements should reward the
creation of sustainable value. To that end, it is important that those
arrangements align with company strategy and encourage responsible risk
management.
A key risk facing pharmaceutical companies is potential backlash
against high drug prices. Pfizer has been criticized for repeated price
increases, and in July 2018 President Trump called out ``Pfizer and
others'' in a tweet, saying they ``should be ashamed that they have
raised drug prices for no reason''; Pfizer then postponed planned
increases.
We are concerned that the incentive compensation arrangements
applicable to Pfizer's senior executives may discourage them from
taking actions, like foregoing price increases that result in lower
short-term financial performance even when those actions may be in
Pfizer's best long-term interests.
Pfizer uses revenue and earnings per share (EPS) as metrics for the
annual bonus and operating income as a metric for performance share
awards (2018 Proxy Statement, at 66, 68). A 2017 Credit Suisse analyst
report identified Pfizer as a company where U.S. net price increases
accounted for at least 100% of 2016 net income growth (Global Pharma
and Biotech Sector Review: Exploring Future US Pricing Pressure, Apr.
18, 2017, at 22). In its 2018 report, Credit Suisse characterized
Pfizer's 2017 10% net price increase as above average for the industry
and noted that its list price increases were the second highest (Global
Pharmaceuticals: Scoring Sensitivity to Trump's Reforms, May 25, 2018,
at 15, 20).
In our view, excessive dependence on drug price increases is a risky
and unsustainable strategy, especially when price hikes appear to drive
large senior executive payouts. Highlighting this connection, a March
2018 article carried the headline, ``Pfizer CEO Gets 61% Pay Raise--to
$27.9 Million--As Drug Prices Continue to Climb'' (https://
arstechnica.com/science/2018/03/amid-drug-price-increases-pfizer-ceo-
gets-61-pay-raise-to-27-9-million/; see also https://www.usnews.com/
opinion/articles/2017-08-30/bernie-sanders-take-on-big-pharma-and-
lower-prescription-drug-prices). We are concerned that large payouts
based on financial metrics that can be affected by pricing create risks
for Pfizer.
The disclosure we request would allow shareholders to better assess the
extent to which compensation arrangements encourage senior executives
to responsibly manage risks relating to drug pricing and contribute to
long-term value creation. For example, it would be useful for investors
to know whether incentive compensation target amounts reflect
consideration of pricing pressures. We urge shareholders to vote for
this Proposal.
______
National Association of Free and Charitable Clinics
1800 Diagonal Road, Suite 600
Alexandria, VA 22314
Nicole Lamoureux, President and Chief Executive Officer
Chairman Grassley, Ranking Member Wyden and Members of the Committee,
my name is Nicole Lamoureux and I am the President and Chief Executive
Officer of the National Association of Free and Charitable Clinics.
Last month, I was sitting in the hearing room as the pharma executives
testified. While I applaud Congress for finally getting these
executives to speak, I noticed some important gaps in the conversation.
During the hearing, both Congress and the pharmaceutical executives
focused on a specific group of Americans: those with health insurance.
Senate Finance Committee Chairman Grassley opened the hearing by
describing how high list prices hurt ``those with high deductibles''
and ``taxpayers,'' but did not mention the uninsured. While we
understand that the committee's focus remains largely on health
programs within your jurisdiction that require significant federal
investments, we believe that by not addressing the high cost of
medication for the uninsured as well as the insured, the overall cost
of health care will continue to increase.
When medication costs are too high, uninsured individuals must forgo
their medication or split doses, and often end up needing the emergency
department for both the repercussions of missed prescriptions and for
primary care. Research shows that 75 percent of all emergency
department visits not resulting in admission are for non-emergencies
that should be treated outside of the emergency room (Hwang et al.
2012). Patients who lack insurance and access to primary care are often
forced to use the emergency room for routine medical needs. These
emergency room visits are expensive, contribute to overcrowding, and
drive up healthcare costs for everyone.
Currently, there are 27 million Americans without insurance--about 1 in
12 people--and that number is growing. I know this group well. These
are the people who receive access to health care and medication from
the 1,400 free and charitable clinics in our country. Free and
Charitable Clinics are safety-net health care organizations that
utilize a volunteer/staff model to provide a range of medical, dental,
pharmacy, vision and/or behavioral health services to economically
disadvantaged individuals. Such clinics are 501(c)(3) tax-exempt
organizations or operate as a program component or affiliate of a
501(c)(3) organization. Free or Charitable Clinics restrict eligibility
for their services to individuals who are uninsured, underinsured and/
or have limited or no access to primary, specialty or prescription
health care. Additionally, Free and Charitable Clinics receive little
to no state funding and no federal funding, do not receive HRSA 330
funds, and are not Federally Qualified Health Centers or Rural Health
Centers. Therefore, these clinics rely heavily on the generosity of
individual donors, foundations and grants as funding sources.
Even though our organizations do not receive federal funding, we are
impacted by every decision that is made at the federal level,
especially when it comes to medication affordability. In 2018, the
1,400 free and charitable clinics served 2 million Americans, with a
total of 6.3 million patient visits. In the most recent data reported
by our members, the number one concern for both our patient population
and their providers is the high cost of medication.
I understand why Medicaid and Medicare patients were the main focus of
the testimony, but the needs of millions of uninsured Americans are
also critical to the conversation about solving the pricing issues and
inequities of the current healthcare system. When Congress asked the
seven executives, ``Who pays list price?'' Merck CEO Ken Frazier
responded by saying, ``There's a small percentage of people who have no
insurance who could actually be charged the list price.'' He also said
that in our current system, ``The poorest and the sickest are
subsidizing others.'' Senator Daines summarized the issue this way: "So
the people who can afford it the least, arguably, are paying the list
price?''
Those who are paying the list price are our patients, the uninsured and
underinsured in this country. The current minimum price of $150 for a
vial of insulin is not affordable for a mother making the choice
between putting food on her table or paying for her prescription. Our
patients have no choice but to ration medications, taking lower doses
of them or stopping them altogether. We have no shortage of these
stories, from young adults eating less than they should to reduce the
amount of insulin they need to parents starving themselves to afford
insulin for their children. In our network of clinics, this is a lived
reality.
In a time when few issues are truly bipartisan, and health care
continues to become ever more divisive, the exponential growth of drug
prices is a rare issue that crosses the aisle. Needing insulin isn't
red or blue, nor is using an EpiPen or depending on an inhaler to
breathe. We need to harness this rare moment of unity and push for true
progress.
I know that Congress realizes how important it is to have the
conversation to make medication more affordable once and for all, so we
can fix this broken system. I want to make sure we get it right this
time around. America's free and charitable clinics try to catch the
people who slip through the cracks. If we don't stop this unchecked
rise in the cost of medications, these cracks will widen until they
threaten the foundation of our health care system.
I appreciate the opportunity to submit my comments to the hearing
record on behalf of the 2 million Americans who receive care at free
and charitable clinics and look forward to answering any questions that
the committee might have.
Works Cited:
Hwang, Liao, Griffin, and Foley. ``Do Free Clinics Reduce Unnecessary
Emergency Department Visits?'' The Virginian Experience Journal of
Health Care for the Poor and Underserved 23 (2012): 1189-1204.
______
National Business Group on Health
20 F Street, NW, Suite 200
Washington, DC 20001
202-558-3000 Fax 202-628-9244
www.businessgrouphealth.org
Chairman Grassley, Ranking Member Wyden and members of the Senate
Committee on Finance, thank you for the opportunity to submit a
statement for the record on the large employers' perspective on drug
pricing.
The National Business Group on Health (NBGH or the ``Business Group''),
whose members include 437 of the nation's largest employers, commend
the Committee's effort to take a holistic look at the root causes of
high and escalating drug prices. In addition to these, we anticipate
submitting comments on subsequent hearings within the Committee's
series on drug pricing.
Along with the government, taxpayers and families, employers have a
vested interest in improving the efficiency and effectiveness of health
care delivery, which includes the delivery of pharmaceuticals.
According to NBGH's 2019 Large Employers' Health Care Strategy and Plan
Design Survey, almost half, 49% of respondents are taking an activist
role in driving delivery system change.\1\ As part of this, more
employers are scrutinizing the role of the pharmaceutical supply chain,
as specialty pharmacy costs remain one of the top drivers of overall
health care trend. Particularly as the growth of high-deductible plans
over the past decade has put a spotlight on drug prices, employers have
become increasingly frustrated by complexity within the supply chain,
which could be described as a ``rebate-driven'' contracting model.
---------------------------------------------------------------------------
\1\ 2019 Large Employers' Health Care Strategy and Plan Design
Survey, National Business Group on Health.
Nearly all employers believe the pharmaceutical supply chain model
needs to change:
14% believe it needs to be more transparent.
35% believe rebates need to be reduced.
49% believe the model needs to be overhauled and simplified.
Regarding the use of rebates as a mechanism to control drug costs:
75% do not believe drug manufacturer rebates are an effective
tool for helping to drive down pharmaceutical costs.
91% would welcome an alternative to the rebate-driven approach
to managing drug costs.
The rapid pace at which reforms are being considered within the
marketplace and by both legislative and regulatory bodies at the
federal and state levels is encouraging. A focus of the hearing, the
Administration's proposals to implement changes to how pharmaceutical
reimbursement and contracting is administered within Medicare Part Band
Part D illuminates the need and possibility that there are likely to be
multiple solutions that improve upon the current model within the
private and public sector. NBGH supports a model marked by
transparency, and one that removes incentives to consistently increase
prescription drug prices. However, we also urge cautious, thoughtful,
and analytical approaches that comprehensively evaluate the impact to
market dynamics for all supply chain stakeholders.
Below, we highlight NBGH's perspectives on two of the widely discussed
proposals. Our full comments on the International Pricing Index (IPI)
model can be found online. Additionally, we intend to provide full
comments on the rebate proposal by the April 8th deadline.
International Pricing Index (IPI) Model \2\
---------------------------------------------------------------------------
\2\ ``International Pricing Index (IPI) Model,'' Center for
Medicare and Medicaid Innovation, accessed March 11, 2019.
---------------------------------------------------------------------------
We must take a broad perspective to assure that public policy
decisions contribute to overall cost control and quality improvement
for all Americans. We commend the Administration's commitment to
lowering the cost of prescription drugs and encourage it to seek
solutions. However, we strongly recommend that whatever CMS adopts,
part of the consideration and criteria for evaluating the results must
be the impact on the private market and the 170 plus million people
covered by employers and insurers and not limited to the impact on
Medicare alone. If we as a nation are to succeed in controlling health
care costs, we must ensure that public policy decisions do not merely
``squeeze the cost balloon'' in one area only for it to expand and
exacerbate the problem in another area.
Our chief concern centers on the ANPRM's proposal to link
reimbursement rates to other nations' prices. Apart from the fact that
these nations determine prices differently, have different patent and
exclusivity models, and often vastly different incentives for
biosimilar utilization, we are concerned that the impact on prices for
the same pharmaceuticals in the US may rise in the private sector and
the market for biosimilars may be adversely impacted if Medicare adopts
this approach.
Rebate Reform Proposal \3\
---------------------------------------------------------------------------
\3\ ``Fraud and Abuse; Removal of Safe Harbor Protection for
Rebates Involving Prescription Pharmaceuticals and Creation of New Safe
Harbor Protection for Certain Point-of-Sale Reductions in Price on
Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager
Service Fees'' (Federal Register, February 6, 2019).
---------------------------------------------------------------------------
Many large employers have already begun evaluating the utility of
point-of-sale rebates as part of their benefit design and a subset (29
percent) have them in place today. Thus, HHS's proposal picks up on the
momentum from large employers and, more importantly, underscores the
inefficiency of the pharmaceutical supply chain. Given the market
momentum on this issue, to both lower out-of-pocket costs for patients
and evaluate ways to simplify a complex system, the Business Group is
in favor of market-based solutions relative to point-of-sale rebates.
NBGH has the following serious concerns about proposals around rebates.
While the stated goal of these proposals is to lower prescription drug
prices and out-of-pocket costs for consumers by encouraging PBMs to
pass discounts from drug manufacturers directly on to consumers and
bring transparency to prescription drug market, we have various
concerns with the proposals including but not limited to the following:
The proposals focus on out-of-pocket costs only. The intent of
the proposed rule and companion legislation is to lower out-of-pocket
costs at the pharmacy counter and add needed pricing transparency to
the market. While we support the proposed increased transparency and
pricing relief for patients, we urge policy makers to avoid ``quick
fixes'' that focus only on out-of-pocket costs, as opposed to total
cost to the system. Focusing on out-of-pocket costs only has the
potential to mask root causes of price increases, potentially lead to
even higher increases over time, and drive the escalating trend on drug
expenditures.
Any changes in supply-chain contracting should not result in a
net increase in drug costs to any payor, nor windfall to any supply
chain stakeholder. Medicaid and CHIP Payment and Access, the
Congressional Budget Office Commission (MACPAC) staff have noted that
the CMS Office of the Actuary (OACT) estimated a net increase in
Medicaid drug spending of $200 million over 10 years if the proposed
rebate rule is finalized. A large chunk, if not the largest chunk, of
this expected increase would come from the decline in inflation-based
rebates.\4\ Further, manufacturer claim liabilities through the
coverage gap discount program (CGDP) would be lower, which would
produce an overall substantial savings for
manufacturers.\5\, \6\ While savings is expected, that
savings should be realized comprehensively across both the supply and
demand sides of the pharmaceutical supply chain.
---------------------------------------------------------------------------
\4\ ``Proposed Safe Harbor Regulation Impact'' (Office of the
Actuary, August 30, 2018).
\5\ Manufacturer payments through the CGDP are expected to be about
$2 billion per year lower on average. When POS costs are lower, it
takes longer for he costs to accumulate toward the initial coverage
limit (ICL) and the TrOOP threshold. CGDP payments would be lower as
fewer members would be calculated as a percentage of a lower POS cost,
but the impact would vary by manufacturer and by plan sponsor.
\6\ ``Impact of Potential Changes to the Treatment of Manufacturer
Rebates'' (Milliman, Inc., January 31, 2019).
The proposals do nothing to address list prices. The proposed
rule ``intends'' and speculates that manufacturers might lower list
prices, but there is little assurance that manufacturers will offset
rebates with price reductions. In fact, at the hearing, not all CEOs in
attendance would affirmatively state this would be the case at all, due
to antitrust case law.\7\
---------------------------------------------------------------------------
\7\ ``Foley Hoag LLP white paper, ``Antitrust Implications of a
Proposed HHS Rule to Limit Manufacturer Rebates,'' accessed March 11,
2019.
The proposed timeline within the HHS proposal is arguably too
aggressive. PBMs have largely already concluded negotiations on price
concessions for plan year 2020 and are in the middle of actuarial
analysis to prepare bids. There is no way to renegotiate in time to
know the associated costs in order to bid properly, and it would be
---------------------------------------------------------------------------
impossible to retool the supply chain in such a short period of time.
Premiums will increase. The proposals are projected to increase
the cost of healthcare for those who don't use drugs having rebates,
through premium increases, while disproportionately decreasing costs
for those who do use drugs with discounts.
Thus, while we agree that the rebate-driven model is ripe for reform
and ineffective at controlling drug prices, we are concerned about the
unintended consequences associated with the proposals as written.
In addition to contracting concerns within the rebate-driven model,
there remains substantial opportunity for policy change relative to
prescription drug prices, most of which would encourage a more
competitive and dynamic market with correspondingly more affordable
prices.
Advance Policies to Promote More Affordable, Financially Sustainable
Prescription Drug Pricing
While many of the recommendations below are directed toward various
agencies in the Administration, several of them require Congressional
action. All of these policy recommendations are highlighted in the
National Business Group on Health's Issue Brief on Policy
Recommendations to Promote Sustainable, Affordable Pricing for
Specialty Pharmaceuticals.
Remove Uncertainties Surrounding Risk-based and Value-Oriented
Contracting and Implement Indication Specific Pricing and Reference
Pricing in Public Programs:
- Consider exemptions for value-based contracts from Medicaid
best price requirements and clarify how drug makers and payers can
conceive of value-based contracts without triggering broader Medicaid
best price program implications.
- Allow for variable pricing, where the price better reflects
the evidence for benefit.
- Evaluate the usefulness and application of the existing
developed value frameworks and their potential to impact drug pricing
in public programs, as well as their overall utility to the health care
system.
- Directly link reimbursement and improved patient outcomes.
- Consider how drug makers and payers can enter into other
types of innovative VBP arrangements, such as indication-specific
pricing.
- Implement reference pricing policies supported by clinical
evidence consistently across public programs, where possible.
Limit Reach of Medicare Part D Protected Classes:
- Following the MedPAC's recommendations, the Congress and CMS
should limit legislative and regulatory restrictions on formulary
design within protected classes by modifying the Medicare Part D rules
to remove those protected classes where enough generic competition
exists, a change that would give private plans more freedom to control
their formularies and negotiate for expanded manufacturer rebates.
- Specifically, CMS should resubmit its proposal to remove
antidepressants, antipsychotics, and immunosuppressants for transplant
rejection from the list of protected classes because, in these classes,
price reductions have been more closely linked with the availability of
generics than to their status as ``protected'' and stand firm against
industry-funded campaigns that seek to undermine the agency's data-
driven proposal to increase competitive pricing.
- At a minimum, policy makers should evaluate the potential
anticompetitive influence of protected classes on the commercial
market, and specifically, evaluate the limitations imposed on private
payers' ability to negotiate competitive prices for drugs in the
protected classes due to market spillover.
Eliminate Perverse Payment Incentives Under Medicare Part B:
- Eliminate financial incentives for prescribing more
expensive medicines, in more expensive settings.
- Establish direct links between reimbursement and improved
patient outcomes.
- Encourage manufacturers to assume some financial risk for
use of high-priced drugs.
Encourage the Uptake of Biosimilars:
- Consider the utility of having an ``interchangeability''
distinction and potential alignment with the European biosimilars
model, which has no such distinction.
- Work with stakeholders to disseminate provider and patient
education to firmly establish the safety and efficacy of biosimilar
drugs to their reference products, recognizing that key successes to
the uptake of biosimilar medicines in other countries was predicated on
the creation of trust and confidence among all the stakeholders
involved, such as prescribers, pharmacists, and patients.
- Maintain payer autonomy to implement utilization management
tools for specialty pharmaceuticals, including tools that pertain to
biosimilar products.
Reform Permissive Patent and Exclusivity Protocols:
- Reduce the market exclusivity period for biologics from 12
years to 7 years.
- Eliminate or limit additive patent extensions and
exclusivity periods that serve only to extend monopoly power,
especially where there is limited, or no additional company investment
or patient value produced.
- Develop sound policy that would discourage patent abuses
such as ``evergreening'' and ``product hopping.'' These policies may
include financial penalties, loss of exclusivity periods and/or reduced
patent terms for other products.
- Refine the biosimilars patent dance to effectively
incentivize the use of the section 351(1) patent dispute resolution
provisions.
Reject anticompetitive ``quick fixes'':
- As consumers find themselves paying more of their drug
costs, it's tempting to be lured into new policies which may only
further contribute to an anticompetitive climate. These policies may
include specialty drug price caps, out-of-pocket payment caps,
limitations on utilization management tools and mandated disclosure of
propriety information.
- Additionally, a federal law permitting importation
nationwide could lead to some price reductions for both payors and
patients in the short-term but, as markets adapt, it is unclear what
the long-term effect on prices would be. It would also likely require a
significant boost in resources for the Food and Drug Administration
(FDA) to monitor imports and assure safety.
The National Business Group on Health, representing 437, primarily
large, employers (including 70 of the Fortune 100) who voluntarily
provide valued health benefits and other health programs to over 55
million American employees, retirees, and their families, looks forward
to working with you on our shared goals for health care: lower costs,
improved access, and higher quality--umbrella goals we consider
inclusive of prescription drugs. Please contact Steven Wojcik, the
National Business Group on Health's Vice President of Public Policy, at
(202) 558-3012, if you would like to discuss our comments in more
detail or if we can provide additional information as the Committee
continues its evaluation of drug pricing.
Sincerely,
Brian J. Marcotte
President and CEO
______
National Coordinating Committee for Multiemployer Plans
815 16th Street, NW
Washington, DC 20006
Telephone: (202) 737-5315
Michael Scott, Executive Director
The National Coordinating Committee for Multiemployer Plans (the
``NCCMP'') appreciates the opportunity to provide comments to the
Committee on the issue of prescription drug pricing and the challenges
that multiemployer group health plans face in today's environment. We
also appreciate the efforts of the Committee to promote discussion of
solutions to America's problem of the high cost of prescription
medications.
Background on the Multiemployer Plans and the NCCMP
Multiemployer plans are a product of the collective bargaining process,
where at least one labor organization and two or more employers provide
health, pension and a variety of other employee benefits through
negotiated contributions to trust funds that are required by law to be
maintained for the ``sole and exclusive benefit'' of plan participants.
Multiemployer plans are jointly trusted by both labor and management
and are subject to applicable provisions of the Taft-Hartley Act,
ERISA, and the Internal Revenue Code. The NCCMP is the only national
organization devoted exclusively to protecting the interests of the
over 20 million active and retired American workers and their families
who rely on multiemployer plans for retirement, health, and other
benefits. The NCCMP is a nonprofit, non-partisan organization with
members, plans, and contributing employers in a broad range of
industries, including agriculture, building and construction, bakery
and confectionary, entertainment, health care, hospitality, longshore,
maritime, mining, retail food, service, steel, and trucking. The
NCCMP's purpose is to assure an environment in which multiemployer
plans continue their vital role in providing benefits to working men
and women.
Multiemployer health plans are often self-insured and plan sponsors
contract with both medical and pharmacy benefit managers to provide
administrative services. These plans provide benefits to both active
workers and their families, and to retirees. Consequently,
multiemployer plans will often contract with a Medicare Part D
Prescription Drug Plan or Medicare Advantage plan to provide
prescription drug and other benefits to retired participants.
Prescription Drug Prices Continue to Rise
Most multiemployer health plans provide prescription drug coverage to
active employees, dependents, and retirees. Prescription drug costs are
a significant part of health plan expenses. Multiemployer plan sponsors
have looked to a variety of means to lower drug prices. Strategies
include increased use of step therapy, prior authorization, quantity
limits, formularies (which exclude certain drugs) and other utilization
management techniques. However, prescription drug cost increases are
primarily driven by price increases, not increased utilization.\1\ Drug
price inflation is a significantly greater component of projected
prescription drug price trend than utilization. In addition, specialty
drug price increases are projected to be in the double digits for 2019,
a significant and concerning pattern because specialty drugs now
account for as much as 35 percent of total pharmacy spending.\2\ New
specialty brand drugs to treat serious illnesses contribute to the cost
increase, and there are limited opportunities to substitute generic
drugs in therapeutic classes dominated by single-source specialty brand
drugs. Consequently, plan sponsors cannot effectively control prices
through utilization controls alone.
---------------------------------------------------------------------------
\1\ 2019 Segal Health Plan Cost Trend Survey, available at http://
www2.segalco.com/me-trend-survey-20l9.pdf.
\2\ Id.
---------------------------------------------------------------------------
Areas for Congressional and/or Regulatory Inquiry and Action
The NCCMP recommends that the Committee take action to promote
transparency in the rebate system while ensuring that action taken on
the rebate side of the pricing equation results in lower--not higher--
drug prices paid by plan sponsors and consumers. In addition, we
emphasize the NCCMP's commitment to eliminating the tax that penalizes
plan sponsors and workers for the high costs of health care (including
drug costs) beyond their control.
Rebates and Transparency
Rebates account for a substantial portion of the drug pricing equation.
Rebate offsets that are passed through to multiemployer plan sponsors
from pharmacy benefit managers (PBMs) help to lower net plan cost
trends. However, multiemployer plans must aggressively monitor PBMs to
assure that rebates are actually passed through to the plan, and in
many cases, the rebate structure is opaque and impenetrable. Pricing
structures also change frequently, as can be seen by some of the PBMs
``market pricing'' strategies, which adjust prices, rebates, and
participant cost sharing based on market price variations for certain
drugs.
State legislators are increasingly attempting to rein in drug costs by
passing laws requiring greater transparency. However, those laws may
not be effective, either because the states cannot tackle the problem
alone, or the laws will be subject to multiple challenges by
pharmaceutical manufacturers and PBMs.
As a core principle of ERISA, employee benefit plan fiduciaries need
information concerning all compensation to be received by a service
provider and any conflicts of interest that may adversely affect the
service provider's performance under the contract or arrangement. In
2014, the NCCMP provided supporting testimony to the ERISA Advisory
Council, which was studying PBM Compensation and Fee Disclosure.\3\ At
that time, we suggested that plan fiduciaries would be well served if
PBMs were required to disclose all instances in which they receive
financial remuneration from drug manufacturers, retail pharmacy
providers, and data managers. The disclosures need to be sufficient to
allow trustees to assess whether, and to what extent, the services
offered by the PBMs are in the best interest of plan participants,
rather than simply furthering the financial interests of the PBM.
Transparency continues to be a concern to plan sponsors and efforts of
the Committee to increase transparency for rebates and financial
arrangements between PBMs and pharmaceutical manufacturers would assist
multiemployer plans in efforts to control prescription drug prices.
---------------------------------------------------------------------------
\3\ https://www.dol.gov/sites/default/files/ebsa/about-ebsa/about-
us/erisa-advisory-council/2014-pbm-compensation-and-fee-disclosure.pdf.
More attention is being paid of late to the rebate system and the
important role that it plays in determining the prices that plan
sponsors and consumers pay for prescription drugs. But rebates are only
part of the equation. The list price that drug manufacturers set for
their prescription drugs is the starting point for the negotiation
between manufacturers and PBMs over rebates. More transparency in the
setting of list prices could help to put some downward pressure on
those prices. But if list prices continue to go up while rebates go
down, plan sponsors and consumers will end up paying more. As a result,
it is essential that any action taken to address the rebate structure
not have the unintended consequence of actually increasing what plan
sponsors and consumers pay for prescription drugs.
Eliminating the Unfair Tax on Health Plan Coverage
For decades before the enactment of the Patient Protection and
Affordable Care Act (ACA), the majority of Americans with health
coverage received their coverage through employment. This has remained
the case well after the ACA first went into effect. Today, over 181
million Americans have employment-based health coverage, which includes
coverage under multiemployer plans. The 40 percent excise tax under
Internal Revenue Code section 49801, enacted as part of the ACA,
threatens these hard-working Americans with a steep and unfair tax on
their health coverage. Sometimes popularly (although inappropriately)
referred to as the ``Cadillac plan'' tax, the original intent of the
tax was to impact plans with ``gold-plated coverage.'' In actuality,
however, the tax will have a much broader impact on even modest plans
as a result of underlying medical inflation.
Employers understand that quality health care is an investment in
employees and not simply a monetary benefit. At the same time, both
employers and employees recognize that the cost of health care cannot
become so great that it makes employers non-competitive. This
marketplace reality is the reason that the vast majority of private
plan sponsors have utilized cost containment strategies for decades to
manage and stretch finite compensation dollars as much as possible.
Unfortunately, the high and ever-increasing health care costs faced by
the private sector are directly amplified by the U.S. Government
through its own health care programs, statutes, and regulatory
requirements. As the largest provider and purchaser of health care in
the U.S. through Medicare and Medicaid, programs that collectively
spend more than $1.2 trillion annually,\4\ the U.S. Government's
longstanding policy of significantly under-compensating health care
providers results in these providers charging more to their private
sector clients in order to recoup their uncompensated federal expenses.
In this way, the private sector subsidizes Medicare, Medicaid, and the
U.S. Government by absorbing these uncompensated expenses through
higher costs and premiums.
---------------------------------------------------------------------------
\4\ In 2017, Medicare spending grew 4.2% to $705.9 billion in 2017
and Medicaid spending grew 2.9% to $581.9; https://www.cms.gov/
research-statistics-data-and-systems/statistics-trends-and-reports/
nationalhealthexpenddata/nhe-fact-sheet.html.
The simple fact is that the high costs of employment-based health plans
and medical inflation are not driven by employment based health plans
themselves, but by other factors, including the actions (and inactions)
of the U.S. Government. Congress should continue to work to address
medical care inflation, including rising drug costs, while maintaining
good health care outcomes and quality of care. Congress should not
penalize employers, health plans, or employees and their families
through unfair taxes. If the excise tax is imposed, the end result will
not be an overall reduction in health care costs, lower medical
inflation or higher federal tax revenue; rather it will be borne by
hardworking Americans through cost-shifting and foregoing needed care.
Additionally, as employment based healthcare is penalized, it will
become increasingly unavailable to those currently covered, which will
increase federal spending on subsidies and Medicare as a significant
portion of the currently covered workforce is eligible for these
---------------------------------------------------------------------------
programs.
NCCMP appreciates the actions Congress has taken in the past to help
prevent the imposition of the 40 percent excise tax by delaying it
twice, so that the effective date is now pushed back to 2022. Delays,
however, are not sufficient to prevent the harmful impact of this tax.
In calling for repeal, NCCMP joins the voices of a large, diverse
group, as evidenced by a recent letter to Congress signed by over 550
organizations representing such interests as public and private sector
employers across a wide range of industries, non-profit organizations,
chambers of commerce, unions, and patient groups. We support the bi-
partisan Middle Class Health Benefits Tax Repeal Act of 2019, recently
introduced in the Senate by Senators Heinrich (D-NM) and Rounds (R-SD)
and co-sponsored by many others, including members of this Committee.
We also support the House version of the bill, which was introduced in
January and which as of this writing has 229 co-sponsors, with growing
numbers.
The NCCMP recommends fully and immediately repealing the 40% excise tax
on employer sponsored health coverage and also opposes any efforts to
tax employees on their health care benefits.
______
Oxfam America
1101 17th Street, NW, Suite 1300
Washington, DC 20036
Tel +1 (202) 496-1180 | Fax +1 (202) 496-1190 | www.oxfamamerica.org
February 26, 2019
Mr. Chairman, Ranking Member and Members of the Committee,
Oxfam appreciates the Committee's sincere intention to ensure
affordable and accessible medicines for all who need them. We would
like to take this opportunity to bring the Committee's attention to our
recent investigation, Prescription for Poverty,\1\ illustrating how
four major pharmaceutical firms (three of whom are testifying before
the Committee at this hearing) may well be underpaying their US taxes
to the tune of $2.3 billion annually by systematically stashing their
profits in overseas tax havens. On top of these tax losses from
offshore tax avoidance, these companies likely benefitted significantly
from the Tax Cuts and Jobs Act (TCJA).\2\
---------------------------------------------------------------------------
\1\ Oxfam, ``Prescription for Poverty: Drug companies as tax
dodgers, price gougers, and influence peddlers,'' Sept. 2018 at https:/
/www.oxfamamerica.org/explore/research-publications/prescription-for-
poverty/.
\2\ Report of the Senate Finance Committee Democratic Staff,
``Trump Tax Law and the Health Care Industry: A $100 Billion Bonanza,''
April 17, 2018.
Here in the US and around the world, in rich and poor countries alike,
high drug prices are causing too many people to sacrifice their savings
or worse--their lives--to enrich executives at highly profitable and
---------------------------------------------------------------------------
influential drug companies.
As is well known, these drug companies' very business model depends to
a large degree on American taxpayer dollars: to pay for essential
front-end drug research, to protect patents and intellectual property,
and to purchase their drugs through Medicare, and the Veteran's
Administration.
Yet, these same companies are undermining public trust (and their very
own business model) by steadily under-paying their taxes, in the US and
around the world. Scouring the companies' financials, we've found that
four major pharmaceutical firms--Abbott, Johnson & Johnson (JNJ), Merck
(MRK), and Pfizer (PFE)--alone appear to have deprived rich and poor
countries alike of around $3.7 billion of vital revenue that could have
been spent on vaccines, midwives, or health clinics. Because the
companies reveal little financial information about their subsidiaries,
Oxfam's investigation barely scratches the surface. Yet even a small
sampling reveals a striking degree of tax avoidance through profit-
shifting.
As the largest market for the four pharmaceutical companies, the United
States is the biggest loser from tax avoidance by these companies, to
the tune of an estimated $2.3 billion a year: $1 billion by JNJ, $589
million by Pfizer, $533 million by Merck, and $143 million by Abbott.
Together, this is enough to pay for health insurance for nearly a
million low-income children in the US.
How are companies avoiding their tax responsibilities?
Oxfam examined publicly available data on subsidiaries of four of the
largest US drug companies and found a striking pattern. In the
countries analyzed with standard corporate tax rates, the companies
reported low pre-tax profits--7 percent profits on average in high-
income countries, and 5 percent on average in seven low- and middle-
income countries. In contrast, these corporations reported annual
global profits of up to 30 percent. So, where were these companies
reporting such sky-high profits? Tax havens. In four countries which
charge very low or no corporate tax rates, these companies posted 31
percent profit margins--suggesting that the companies are artificially
shifting their profits to avoid paying taxes in countries with higher
tax rates.
In the case of the pharmaceutical giants, the ploy may involve
``domiciling'' their patent, not in the corporation's home country
where the drug was actually developed, but in a tax haven-where a
company's presence may be as little as a mailbox. That subsidiary then
charges hefty licensing fees to subsidiaries in other countries. The
fees are a tax deductible expense in the normal jurisdictions, meaning
that they can be used to offset any earnings and thereby lower the
reported profits. At the same time, the fee income accrues to the
subsidiary in the tax haven, where it is taxed lightly or not at all.
The company's overall tax payment then is lowered, sometimes
significantly.
Another technique many companies have used is to sell their production
or services not directly to the countries where they will be consumed,
but to ``pivot'' companies in low tax jurisdictions that then resell
them at a profit to affiliated distributors. This practice creates an
artificial profit that remains in the tax haven. Most of the time,
these are only paper transactions--the goods are shipped straight from
the factory in the production country to the warehouse in the
consumption country--but the transactions allow profits to move from
one country to another almost tax-free.
Because companies refuse to release their full country-by-country
financial reports to the public, and many governments have yet to make
these reports public, the information on tax dodging is far from
complete. Yet, the pattern of Big Pharma's tax practices is consistent:
this is either an astounding coincidence or the result of using
accounting tricks to deliberately shift profits from where they are
actually earned to tax havens. Pfizer, Merck, and Abbott are among the
20 US corporations with the greatest number of subsidiaries in tax
havens; Johnson & Johnson is not far behind. While profits can vary
from country to country for any number of legitimate reasons, it is
highly unlikely that these explanations can fully account for the
consistent pattern of much higher profits being posted in countries
with very low tax rates where these corporations do not sell the
majority of their medicines.
Tax injustice and price gouging are two sides of the same coin
Tax avoidance and price gouging are not, in fact, completely
independent phenomena. Today's hearing provides a timely opportunity to
connect the dots between high drug prices and unjust tax avoidance
practices which deprive the US Treasury of precious public revenue
needed to fund essential public health programs in the US. Every tax
dollar avoided means a tax dollar less for new drug research at the
National Institutes of Health, and for essential health insurance
programs like Medicaid, Medicare and the Child's Health Insurance
Program.
What's more, as we detail in our report cited above, a cornerstone of
these companies' business model--the intellectual property rules
protecting many of these pharmaceutical companies' most profitable
products--is a central factor in allowing these companies to drive up
drug prices, while driving down their tax payments. And conversely, our
tax system at present incentivizes price hikes in a variety of ways.
While the specific solutions to drug pricing and tax avoidance are
distinct, there are some essential common approaches in our view.
Global companies should be transparent about where they earn and spend
their money, they should pay tax in alignment with actual economic
activity rather than abuse our tax system in a variety of ways, and
they should use their political influence responsibly, rather than
undermining governments' efforts to provide essential medicines and
healthcare for us all.
------------------------------------------------------------------------
-------------------------------------------------------------------------
In this context, we would encourage the Senate Committee to raise the
following questions to JNJ, PFE and MRK during the February 26th
hearing:
1. According to evidence received, your companies systematically report
low pre-tax profits in high-tax countries, and high pre-tax profits in
low-tax countries: reportedly resulting in billions of dollars of lost
revenue in the US which could have been spent on new drug research or
to fund essential healthcare. Can you explain why these aggressive tax
planning practices serve the public interest?
2. Is your company involved in offshore tax avoidance? If so, please
explain why you believe this is acceptable practice. Can you commit to
publicly releasing your company's country-by-country financial reports
to show and prove your tax practices meet social expectations?
3. How has your company invested the fresh cash resulting from the
passage of the TCJA? Very concretely, can you explain how these
expenditures are working to drive down drug prices? If they are not
doing so, why not?
------------------------------------------------------------------------
For any questions, please contact Nicholas J. Lusiani, Senior Advisor
at [email protected], or (202) 777-2912.
______
Patients for Affordable Drugs Now
Statement by David Mitchell, Founder
Chairman Grassley, Ranking Member Wyden, and members of the Senate
Finance Committee,
Thank you for your leadership to address the problem of high drug
prices in America. U.S. patients and taxpayers spend more than $450
billion \1\ each year on prescription drugs. By some estimates, nearly
one-fifth \2\ of all health care costs go toward prescription drugs.
The main driver of prescription drug spending is patent-protected
brand-name drugs, which make up only about 10 percent \3\ of
prescriptions but account for three-quarters of drug spending.\4\
---------------------------------------------------------------------------
\1\ https://www.finance.senate.gov/imo/media/doc/
29JAN2019MILLERSTMNT.pdf
\2\ https://www.ncbi.nlm.nih.gov/pubmed/27552619.
\3\ https://docs.house.gov/meetings/GO/G000/20190129/108817/HHRG-
116-GOOO-Wstate-KesselheimA-20190129.pdf.
\4\ https://docs.house.gov/meetings/GO/G000/20190129/108817/HHRG-
116-GOOO-Wstate-KesselheimA-20190129.pdf.
That's why today's hearing is so important. You have called CEOs of
seven major drug corporations before the Senate Finance Committee to
explain their pricing practices, patent thickets and the fact that
American patients and taxpayers pay anywhere from two to six times \5\
more than the rest of the world for brand name prescription drugs.
---------------------------------------------------------------------------
\5\ https://www.cnn.com/2015/09/28/health/us-pays-more-for-drugs/
index.html.
We hear every day from patients suffering under the high cost of
prescription drugs--cutting pills in half, choosing between groceries
---------------------------------------------------------------------------
and medication, and simply going without.
Patients have questions for the CEOs in front of you today, and we hope
Congress will ask them.
AbbVie Inc,
About AbbVie: AbbVie's anti-inflammatory drug Humira is the top-selling
\6\ drug in the world. The drug company doubled the price \7\ from
about $19,000 per year in 2012 to $38,000 per year in 2018. AbbVie
secured over 100 patents \8\ on Humira, ensuring that patent thickets
will keep competition off the U.S. market, while the company cut the
price in Europe by 80 percent \9\ for the exact same drug.
---------------------------------------------------------------------------
\6\ https://www.nytimes.com/2018/01/06/business/humira-drug-
prices.html.
\7\ https://www.nytimes.com/2018/01/06/business/humira-drug-
prices.html.
\8\ https://www.bloomberg.com/news/articles/2017-09-07/this-shield-
of-patents-protects-the-world-s-best-selling-drug.
\9\ https://www.axios.com/abbvie-cuts-humira-price-europe-
biosimilars-cc2d3d61-5782-4042-8c24-b322ea8285b4.html.
Questions:
Is it fair that Europeans have access to a less expensive
biosimilar competitor for Humira, but your company bragged \10\ about
blocking that competition in the U.S.?
---------------------------------------------------------------------------
\10\ https://www.nbcnews.com/nightly-news/video/world-s-best-
selling-drug-costs-five-times-more-in-u-s-than-europe-1445064259924.
---------------------------------------------------------------------------
Do you partake in pay for delay or deals for delay? Do you
support the Preserve Access to Affordable Generics and Biosimilars Act
(S. 64)?
Since Humira has already been very successful with more sales
than the revenue of eBay,\11\ will you commit to holding the price of
Humira steady until a biosimilar comes to market?
---------------------------------------------------------------------------
\11\ https://www.axios.com/humira-2018-revenues-drug-prices-
eb637e1f-09ae-479a-91ca-870edf7f5b4a.htm.
Patient Stories:
James Baer from Aurora, CO: ``I have seropositive degenerative
rheumatoid arthritis, and am on a regimen of high cost drugs. Humira is
the most expensive, at $4,500-$6,500 a month. My insurance, Humana, is
refusing to pay for it starting next month. My doctor says I need it to
win my fight against this genetic defect.''
Jacquie from Iowa: ``Since my Crohn's diagnosis, I've taken
Lialda and Humira. Both drugs would have been astronomical if I hadn't
been for my good insurance and eligibility for the pharmacy savings
programs for each. I have been lucky. But I am always constantly
worried about no longer being able to work due to my health, or losing
my health insurance, making these essential drugs unaffordable.''
Sherry from North Carolina: ``I am unable to afford the biologic
Humira even on Medicare. My monthly copay went from $5/month to $1,200/
month.''
Pfizer
About Pfizer: Pfizer's history of price hikes is as staggering as it is
long. Here's a look at the last three years: In 2017,\12\ Pfizer raised
the price of 91 drugs by 20 percent--that was nearly 10 times the rate
of inflation. In mid-2018,\13\ Pfizer announced price hikes on about
100 prescription drugs. After temporary freezes, Pfizer raised the
raised the price of 40 drugs in January 2019.\14\
---------------------------------------------------------------------------
\12\ https://www.ft.com/contenUb2eOdd80-47ab-11e7-8519-
9f94ee97d996.
\13\ https://medcitynews.com/2018/07/pfizer-increases-prices-on-
100-drugs/.
\14\ https://www.cnn.com/2018/11/16/business/pfizer-drug-prices/
index.html.
---------------------------------------------------------------------------
Questions:
Will you commit to limiting the increase in list price of your
drugs to the rate of inflation?
Will you commit to submitting to this committee at the end of
this year (2019) a report of the ways you have utilized the $10 billion
stock buyback \15\ to serve patients?
---------------------------------------------------------------------------
\15\ https://www.axios.com/pharma-share-buyback-tax-reform-
40a30b93-6149-4c67-bd6cd50-5ee814215.htm.
---------------------------------------------------------------------------
Patient Stories:
Helen Sgarlat from Kingston, PA: ``Because of the $600 price
tag, I had to switch medications. I switched from Spiriva to one that's
not working as well, Singulair. This is outrageous.''
Sharon from Iowa: ``I can't eat any more! My Keppra costs $460,
Pradaxa $400, Lyrica $360. If drug prices came down, I would be able to
eat again.''
Susan from Nevada: ``My sister has metastatic breast cancer
taking Ibrance. Her co-pay is $2,290/month! Without this [drug] her
cancer will spread! She received a short term grant to help but has to
reapply to keep receiving. This is a lifesaving drug . . . must be more
affordable!''
Sanofi
About Sanofi: Almost 30 million\16\ Americans live with diabetes and 6
million need insulin to survive. From 2010 to 2015, Sanofi raised the
price of the lifesaving diabetes drug Lantus by 168 percent.\17\
---------------------------------------------------------------------------
\16\ https://www.cbsnews.com/news/insulin-prices-rise-yet-again-
causing-diabetics-to-cry-foul/.
\17\ https://www.nytimes.com/2016/02/21/opinion/sunday/break-up-
the-insulin-racket.html.
---------------------------------------------------------------------------
Questions:
If PBM rebates were eliminated, would you lower your list
prices?
Will you commit to undoing the dozens of times you've raised the
price of Lantus and lower the list price this year?
As the Chairman of the lobbying group, PhRMA, your organization
spent $27.5 million on lobbying in 2018.\18\ Next year, will you agree
to take half that money and use it to lower drug prices across the
board for patients?
---------------------------------------------------------------------------
\18\ https://www.statnews.com/2019/01/22/phrma-spent-a-record-
breaking-27-5-million-on-lobbying-in-2018-new-filings-show/.
---------------------------------------------------------------------------
Patient Stories:
Jerraline Krawetzki from Berlin Heights, OH: ``Because of
diabetes type 2, Lantus and Humalog are required. Because of the
increased costs of these medications, after filling the first
prescriptions, already IN the donut hole. This means a one month
prescription of these 2 drugs, will cost over $600 per month. Senior
citizens on a fixed income cannot afford this.''
David from Nevada: ``I have to take Lantus and Januvia for my
Diabetes and Xeralto for my AFIB and many other medications for my
heart, blood pressure, cholesterol, and BPH. These medications are very
expensive and I can't afford them after I reach the Medicare Part D
donut hole. Medicare prohibits free medications or discounts so living
on social security means I will eventually die from lack of medicine.''
Jeannie from Kansas: ``I am a type 2 diabetic. I take Lantus
insulin. One month supply is $128 with insurance. I am single and on
Social Security of $942 a month. How am I to pay for the insulin that
keeps me alive?''
Merck & Co. Inc.
About Merck: Merck is no stranger to drug price increases. From January
2017 to mid-2018, Merck raised the price of Januvia by nearly 20
percent.\19\ In November 2018, the corporation raised the price on five
drugs,\20\ including top-selling Gardasil and Keytruda.
---------------------------------------------------------------------------
\19\ https://www.latimes.com/business/hiltzik/la-fi-hiltzik-drug-
prices-20181206-story.html.
\20\ https://www.reuters.com/article/us-merck-co-drugprices/merck-
raised-prices-five-drugs-including-keytruda-in-november-idUSKCN1NX2ZN.
---------------------------------------------------------------------------
Questions:
Will you submit, for the record, the cost of research and
development for the drug Keytruda, which reaped \21\ a total of $1.89
billion the third quarter of 2018 alone--an increase of 80% since 2017?
---------------------------------------------------------------------------
\21\ https://www.bloomberg.com/news/articles/2018-10-25/merck-
plans-10-billion-buyback-as-cancer-drug-tops-estimates.
---------------------------------------------------------------------------
Your company recently spent $10 billion on stock buybacks.\22\
This year, will you commit to decreasing drug prices by that same
amount?
---------------------------------------------------------------------------
\22\ https://www.bloomberg.com/news/articles/2018-10-25/merck-
plans-10-billion-buyback-as-cancer-drug-tops-estimates.
---------------------------------------------------------------------------
Patient Stories:
Stephen Hadfield from Charlotte, NC: ``I am on very expensive
insulin for my diabetes. My Januvia is $400 a month and my Lantus is
$350 every three weeks. If it was not for insurance, I would not be
able to afford these drugs.''
Yvonne from Georgia: ``I can't afford the medicines I need to
treat my diabetes. Januvia costs over $200, and with my other
medications too I am in the donut hole, making it hard to manage my
disease.''
Mark from Louisiana: ``I have extremely high cholesterol and I
am allergic to statins. The only medication that I can take would be
Zetia which costs $800 for 3 month supply after insurance coverage. The
same drug is available in Canada for $150 for a 3 month supply and no
insurance coverage!''
Johnson & Johnson
About Johnson & Johnson: Since 2012, Johnson & Johnson has raised the
price of its blockbuster drug Xarelto by 87 percent.\23\ In January of
2019, the company raised the price on about two dozen drugs.\24\
---------------------------------------------------------------------------
\23\ https://www.i-mak.org/wp-content/uploads/2018/08/I-MAK-
Overpatented-Overpriced-Report.pdf.
\24\ https://www.reuters.com/article/us-johnson-johnson-
drugpricing/jj-raises-u-s-prices-on-around-two-dozen drugs-
idUSKCN1P42VY.
---------------------------------------------------------------------------
Questions:
Will you commit to holding your price increases to inflation
each year?
Will you commit to striking a deal with the New York Drug
Utilization Review Board if they deem it necessary to decrease the cost
of Remicade for state taxpayers?
Patient Stories:
Sarah Pekarske from Texas: ``I have Lupus and I have had 3 blood
clot episodes. I take Xarelto. In August of last year it was suddenly
$100/month. It has cost $150/month since September! This is too
expensive for me.''
Diane from Georgia: ``I have been on Remicade since 2013, but
when I retire I won't be able to take it anymore because of change in
insurance and higher co-pays. I don't know what I'll do.''
Patricia from Texas: ``I am on fixed income because I am
disabled with rheumatoid arthritis. I need infusions for Simponi Aria I
cannot afford. Even with help to pay for the infusion, my part is going
to be over $500 per month. That is half of my income every month.''
Bristol-Myers Squibb Co.
About Bristol-Myers Squibb: Over the last eight years, Bristol-Myers
Squibb has spent over $25 million \25\ in lobbying expenditures and
$1.75 million \26\ in campaign contributions, according to Open
Secrets. The company raised the price of its blockbuster drug Eliquis
by 6 percent \27\ in January 2019. Last year alone, U.S. Patients' paid
Bristol-Myers Squibb $3.8 billion \28\ for Eliquis, a 30 percent \29\
year-over-year increase.
---------------------------------------------------------------------------
\25\ https://www.opensecrets.org/orgs/
summary.php?id=D000000149&cycle=2018.
\26\ https://www.opensecrets.org/orgs/
summary.php?id=D000000149&cycle=2018.
\27\ https://www.foxbusiness.com/healthcare/meet-the-big-pharma-
ceos-who-will-testify-in-the-senate.
\28\ https://www.foxbusiness.com/healthcare/meet-the-big-pharma-
ceos-who-will-testify-in-the-senate.
\29\ https://www.foxbusiness.com/healthcare/meet-the-big-pharma-
ceos-who-will-testify-in-the-senate.
---------------------------------------------------------------------------
Questions:
Will you commit to donating 50% less to candidates for public
office in 2020 and investing that money toward research and development
or decreasing price for patients?
With your recent acquisition of Celgene, will you commit to
ending Celgene's use of the REMS program to prevent a generic from
coming to market for its blockbuster drug, Revlimid?
Do you support the CREATES Act?
Patient Stories:
Elizabeth from New Jersey: ``The greed of Bristol-Myers-Squibb
is horrible. Now I have to decide if I should just take asprin each day
and hope I don't have a stroke or pay the high cost each month for
Eliquis for $145 per month.''
Gail from Michigan: ``I didn't have coverage for a year and the
Eliquis I need costs $400 per month. It's a crying shame that these
drugs are so expensive. I had to stretch the script out by taking them
every other day.''
Tara from Kansas: ``Drug prices are killing me faster than the
disease. When I first started taking my blood thinner a few years ago,
I thought $400 a month was terrible. Now, I wonder how I can possibly
afford the next dose of Opdivo. I can't. Without it I die. With it I go
broke. What kind of choice is that? No one should ever be put in this
position. No one should make this choice ever.''
AstraZeneca
About AstraZeneca: AstraZeneca has a history of charging cancer
patients high prices. Here are three examples: Imfinzi costs $180,000
per year \30\ for lung cancer, Lynparza costs around $15,000 for 112
pills \31\ for ovarian cancer, and Iressa costs $8,000for 30 pills \32\
lung cancer. And before AstraZeneca faced a generic competitor for its
high cholesterol drug, Crestor, the company raised prices multiple
times, including by about 15 percent \33\ right before a generic
competitor came to market.
---------------------------------------------------------------------------
\30\ https://professionals.optumrx.com/content/dam/optum3/
professional-optumrx/news/rxnews/drug-approvals/
drugapprovals_imfinzi_2017-0502.pdf.
\31\ https://www.goodrx.com/lynparza/medicare-coverage.
\32\ https://www.goodrx.com/iressa.
\33\ https://www.marketwatch.com/story/big-pharma-games-the-system-
to-make-generic-drugs-more-expensive-2018-07-27.
---------------------------------------------------------------------------
Question:
Will you submit for the record the following information: the
amount you have spent on research and development vs. AstraZeneca's
yearly budget for marketing and advertising?
Patient Stories:
Teresa Bianco from Elyria, OH said: ``We have a family history
of dangerously high cholesterol levels. My sister and I have been on
every medicine out there. The only one that lowers us into the high
200's is Crestor. It is not covered by our insurances and thus is out
of our reach. Sadly, we are both RNs and see others also go through
this. We are college educated, helping people, always gainfully
employed full time, but we are apparently disposable.''
Linda Schoene from Pikesville, MD said: ``I have GERD and am
prescribed Nexium. On Medicare Part D, my copay is a little over $100
per month. I can't afford that. So I go without which causes me sharp
pains in my stomach when I have a flair. I sometimes buy the over the
counter version, but it is half the strength of what I am prescribed
and doesn't treat my symptoms.''
Silvio from Pennsylvania: ``I was taking Crestor but the prices
kept rising and because I am on Medicare I was not eligible for a
discount. So I had to stop taking it. Next time I got a blood test my
bad cholesterol skyrocketed.''
______
Pharmaceutical Care Management Association
325 7th Street, NW, Suite 900
Washington, DC, 20004
Introduction
The Pharmaceutical Care Management Association (PCMA) is the national
association representing America's pharmacy benefit managers (PBMs),
which administer prescription drug plans for more than 266 million
Americans with health coverage provided through Fortune 500 employers,
health insurers, labor unions, Medicare, Medicaid, and the Federal
Employees Health Benefits Program (FEHBP).
PBMs are the primary advocate for consumers and health plans in the
fight to keep prescription drugs accessible and affordable. PBMs
negotiate on behalf of consumers, and work to keep a lid on overall
costs for prescription drugs with market-based tools that encourage
competition among drug manufacturers and pharmacies, and incentivize
consumers to take the most cost effective and clinically appropriate
medication.
By leveraging competition among manufacturers, PBMs save patients and
health plans $123 per prescription, and will negotiate prescription
drug costs down $654 billion over the ten years ending 2025.\1\
---------------------------------------------------------------------------
\1\ Visante, ``Pharmacy Benefit Managers (PBMs): Generating Savings
for Plan Sponsors and Consumers,'' February 2016, https://
www.pcmanet.org/wp-content/uploads/2016/08/visante-pbm-savings-feb-
2016.pdf.
PBMs manage Medicare Part D drug benefits through insurers, either as
contractual service providers to stand-alone Prescription Drug Plans
(PDPs) or Medicare Advantage plans that offer prescription drug
---------------------------------------------------------------------------
coverage (MA-PDs).
PBMs are proud of their performance in Part D. PBMs and Part D sponsors
have kept overall program costs 30 percent below original government
projections, offered beneficiaries lower-than-expected premiums, and
generated high levels of generic utilization while providing broad
choice of drugs and access to over 60,000 pharmacies, all while
attaining a continually high rate of beneficiary satisfaction.
PBMs Negotiate to Keep Drug Spending Manageable
The most recent available data, which is for years 2016 and 2017, show
that the overall growth in spending for all prescription drugs has been
low.\2\ tallying 1.4% and -0.3% for 2016 and 2017, respectively. Drug
industry stakeholders rightly trumpet such figures to show the success
of private-sector negotiation in bringing spending discipline to the
prescription drug market.
---------------------------------------------------------------------------
\2\ KFF, ``What Are the Recent and Forecasted Trends in
Prescription Drug Spending?'', February 20, 2019, https://
www.healthsystemtracker.org/chart-collection/recent-forecasted-trends-
prescription-drug-spending/#item-start.
However, the totals mask the dynamics at work in different sectors of
the prescription drug market. Spending on generic drugs has actually
been declining, while spending on brands has been increasing. According
to a November 2018 analysis, for the previous year, spending on brands
increased 4% while spending on generics decreased 3%.\3\
---------------------------------------------------------------------------
\3\ Blue Cross Blue Shield Association, ``Prescription Drug Cost
Trend Update,'' November 14, 2018, https://www.bcbs.com/the-health-of-
america/reports/prescription-drug-costs-trend-update.
Further, the report indicates that while brand drugs made up only 17%
of total prescriptions, they accounted for 79% of overall drug spending
in the previous year.\4\
---------------------------------------------------------------------------
\4\ BCBSA, Op. Cit.
Data underlying the overall spending figures shows that manufacturers
have been increasing the prices they set for their drugs rapidly.
According to IQVIA data, for the 5-year period ending 2017, brand
invoice price grew at an average annual rate of 10.5%, while overall
inflation in the economy, as measured by CPI-U, grew at an average
annual rate of 1.3%.\5\ These trends are mirrored in a study conducted
on drugs most used by the elderly. A 2018 AARP analysis found retail
prices for 113 chronic-use brand name drugs on the market since at
least 2006 increased cumulatively over 12 years by an average of 214
percent, compared with the cumulative general inflation rate of 25
percent from 2006 to 2017.\6\
---------------------------------------------------------------------------
\5\ https://www.iqvia.com/institute/reports/medicine-use-and-
spending-in-the-us-review-of-2017-outlook-to-2022.
\6\ AARP, ``No End in Sight for Skyrocketing Prescription Drug
Prices,'' September 26, 2018.
The near-flat overall trend for spending on all drugs, despite rising
prices and spending for brands, illustrates the work that PBMs do as
advocates for patients and their client health plans to hold the line
on prescription drug costs.
Drug Manufacturers Alone Set and Raise Prescription Drug Prices
As the Committee continues its work with respect to prescription drug
costs, one thing is clear: only manufacturers have the power to set or
change prices. In recent years, brand manufacturers and their allies
have attempted to deflect blame for the prices they set by blaming
other parties in the drug supply chain,\7\ including pharmacies, PBMs,
and wholesalers. While much has been said and written, research studies
show that there is no correlation between the prices manufacturers set
and the rebates PBMs negotiate with manufacturers.
---------------------------------------------------------------------------
\7\ See, e.g., https://www.phrma.org/press-release/new-report-
shows-how-supply-chain-shapes-brand-name-medicine-prices.
A 2018 study found no correlation between the prices that brand drug
manufacturers set for individual drugs and the rebates that they
negotiate with PBMs on those products (see chart below).\8\ The data in
the scatter plot below show that increasing list prices over a 5-year
period were not correlated with changes in rebates (R\2\=0.016), as
shown with the horizontal blue line. Additionally, there are prominent
cases of higher-than-average price increases on brand drugs where
rebates stayed the same or declined (e.g., Humulin).
---------------------------------------------------------------------------
\8\ Visante, ``Increasing Prices Set by Drugmakers Not Correlated
With Rebates: An Analysis Prepared by Visante on Behalf of PCMA,'' June
2017.
[GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT]
At the same time, separate research confirmed that negotiated rebates
are correlated with competition-that the size of drug rebates is
positively correlated with the extent to which a given brand drug faces
competition in the market.\9\
---------------------------------------------------------------------------
\9\ Credit Suisse Equity Research, ``Global Pharma and Biotech,''
April 18, 2017.
Other research sponsored in part by a multinational brand drug
manufacturing firm reports that, for every $100 spent in the drug
supply chain on branded drugs, manufacturers capture $58. This
contrasts sharply with the amounts captured by pharmacies ($3), PBMs
($2), and wholesalers ($1).\10\ These results show that it is the
manufacturers who benefit far more than any other party in the drug
supply chain, and any rhetoric to the contrary is a smokescreen.
---------------------------------------------------------------------------
\10\ Sood, N. et al. ``The Flow of Money Through the Pharmaceutical
Distribution System,'' University of Southern California, Leonard D.
Schaeffer Center for Health Policy and Economics, June 2017, https://
healthpolicy.usc.edu/wp-content/uploads/2017/06/USC_Flow-of-Money
WhitePaper_Final_Spreads.pdf.
Further illustrating the lack of any connection of manufacturer list
prices to negotiated rebates is the chart below containing Part B
pricing data. Drugs under Medicare Part B typically carry no rebates.
The chart shows that several unrebated branded drugs have posted price
increases vastly outpacing the rate of inflation, as well as the rate
of price increases among most drugs. Moreover, unrebated drugs in
Medicare are not unique to Part B--HHS's Office of the Inspector
General finds a full 39% of branded drugs in Part D carry no
rebatex.\11\
---------------------------------------------------------------------------
\11\ HHS Office of the Inspector General, ``Increases in
Reimbursement for Brand-Name Drugs in Part D,'' June 2018.
Selected Part B Drugs With High Price Increases From 2017 to 2018
----------------------------------------------------------------------------------------------------------------
Estimated Estimatied
2012 Price 2017 Price % Price 2018 Price % Price
Brand Name per Part B per Part B Increase per Part B Increase
Prescription Prescription* 2012-17 Prescription 2012-17
----------------------------------------------------------------------------------------------------------------
Miacalcin $461 $16,375 3,449% $19,266 18%
Krystexxa $2,717 $19,163 605% $21,127 10%
Teflaro $110 $399 263% $439 10%
Bicillin $41 $106 159% $120 13%
Rituxan $5,125 $6,890 34% $7,416 8%
Orencia $1,636 $2,849 74% $3,020 6%
----------------------------------------------------------------------------------------------------------------
* Estimated inflation adjusted price = 2012 price * weighted average manufacturer increase in list price per
unit. Not affected by changes in numbers of units per claim, or mix of doses/dosage forms. Estimated 2018
price through Q3 2018. During study years PBMs were not involved in Medicare Part B program, so no PBM rebates
were involved. Analysis included drugs with Part B spending data for full period 2012-16.
Source: Visante and PCMA analysis of data from CMS and SSR Health, 2019.
In sum, the research record is clear: drug manufacturers alone are
responsible for the prices they set and neither PBM-negotiated rebates,
nor any other party nor factor in the supply chain affects the list
price of a brand drug.
Managing Drug Cost Growth Is Challenging, but Policy Changes Could
Improve Competition
PBMs have an established record of negotiating with manufacturers and
pharmacies to reduce costs for patients, either in the form of lower
premiums for all participants in a plan, or through lower costs at the
pharmacy, and usually both.
The key to reducing prescription drug costs is increasing and
encouraging competition. PBMs are best able to negotiate when
competition exists, and PCMA's member companies support a number of
ideas for increasing competition and building upon market-based tools
to improve the Part D program. These include:
Remove Part D's protected classes. Designating ``classes of
clinical concern'' where all or substantially all drugs in a class must
be covered allows drug manufacturers to virtually name their price.
Indeed, a recent Milliman analysis showed that the average brand rebate
(for drugs that had any rebate) in Part D was 30%, while the average
rebate for brand drugs in protected classes was 14%.\12\ CMS already
applies careful plan formulary coverage checks to assure proper
coverage. A pending CMS plan only to lessen the effect of protected
classes-not eliminate them-would save $2 billion over 10 years.
---------------------------------------------------------------------------
\12\ Milliman, ``Prescription Drug Rebates and Part D Drug Costs:
Analysis of Historical Medicare Part D Drug Prices and Manufacturer
Rebates,'' July 16, 2018, https://www.ahip.org/wp-content/uploads/2018/
07/AHIP-Part-D-Rebates-20180716.pdf.
Encourage greater use of generics for Part D LIS enrollees.
MedPAC recommended allowing the Secretary to lower cost-sharing on
generics and raise it for brands that have generic competition.
Allowing plans to lower generic cost-sharing for these beneficiaries
would save money for beneficiaries, taxpayers, and the Medicare
---------------------------------------------------------------------------
program.
Modify the requirement for two drugs per class. The requirement
that Part D plans cover two drugs per class is outmoded. It has
encouraged manufacturers to argue for ever more granular classes and
reduced competition, increasing Part D costs. Modifying the requirement
by requiring plans to ensure access to therapies based on conditions or
disease states instead would reduce costs without reducing access to
needed drugs.
Build on existing efforts to apply Part D management tools to
Part B drugs. PBM tools such as value-based formularies, manufacturer
negotiation, and prior authorization have proven indispensable for
improving patient safety and lowering costs in outpatient prescription
drug plans like Part D. Adding Part D management tools to the Medicare
fee-for-service program and building on efforts in Medicare Advantage
for Part B drugs would make drugs more affordable on Medicare's medical
side.
Encourage use of mail-order pharmacy in Part D. Mail-order
pharmacy: vastly reduces errors in dispensing; increases convenience
for beneficiaries on maintenance medications; improves adherence; and
offers a lower cost-sharing option to beneficiaries in most cases. With
much of the public using home-
delivery for a wide range of goods and with many Medicare beneficiaries
home-bound, CMS should take further steps to encourage home delivery of
maintenance medications.
Repeal any willing pharmacy provisions. Requirements that all
pharmacies be included in Part D networks drives up costs and are
unnecessary, given the network adequacy requirements. Congress should
repeal the provision. One study showed that greater use of limited
network pharmacies in Part D could generate $35 billion in savings over
10 years.\13\
---------------------------------------------------------------------------
\13\ Visante, ``How Pharmacy Networks Could Save Medicare,
Medicaid, and Commercial Payers $115 Billion,'' January 2013, https://
www.pcmanet.org/wp-content/uploads/2016/10/visante-pcma-pharmacy-
networks-study-1-13.pdf.
Give Part D plans meaningful access to Part A and B claims data.
To coordinate care and make the best coverage decisions for
beneficiaries, plans need to be able to use medical data as well as Rx
data. Existing prohibitions on using A and B data to inform coverage
design and decisions are misguided and keep plans from using claims
data to improve care coordination and coverage. Researchers suggest
combined data sets of Parts A, B, and D claims can be a ``rich
---------------------------------------------------------------------------
resource'' for comparative effectiveness data.
The following list of additional solutions would further increase
competition in the marketplace. While these proposals are outside the
Finance Committee's jurisdiction, they should help to bring balance
back to the drug marketplace and enhance competition.
Eliminate use of Risk Evaluation and Mitigation Strategies
(REMS) to delay competition. Some manufacturers have used REMS to
prevent generic or biosimilar developers from getting sufficient
quantities of a drug or biologic to develop a competitor to the
innovator product. REMS were never intended for this purpose; this
practice should be prohibited. S. 340, ``Creating and Restoring Equal
Access to Equivalent Samples Act of 2019'' or the ``CREATES Act of
2019'' would address these abuses.
Stop anticompetitive product adjustments, i.e.,
``evergreening.'' Drug manufacturers sometimes use tactics such as
``product hopping'' or ``evergreening,'' submitting applications to the
FDA for approval of a ``new'' product that is essentially the same as
the original product. These product lifecycle management tactics
artificially extend drug exclusivity periods and delay the take-up of
lower-cost generics.
End orphan drug exclusivity abuses. Orphan drug exclusivities
are meant to encourage research on rare diseases, but manufacturers
have gamed the policy to apply it to blockbuster drugs with script
volume in the tens of millions. Orphan exclusivity periods should only
apply to those drugs originally approved by FDA under an orphan
indication and only for the orphan indication itself.
Eliminate ``pay-for-delay'' agreements. Patent settlements, or
``pay-for- delay'' agreements, allow drug patent holders to pay off
potential competitors who would otherwise produce a competing generic
or biosimilar drug. These anticompetitive agreements should be
eliminated. S. 64, The Preserve Access to Affordable Generics and
Biosimilars Act, would greatly ameliorate these concerns.
Allow for FDA accelerated approval of brand drugs based on
increasing competition. Accelerated review is granted to new drug
applications that address ``unmet need.'' The economic need for
competition to lower prices, or what some call ``financial toxicity,''
should be a criterion of unmet need.
Revisit and improve biosimilar labeling and naming.
Substitutable biosimilars should bear identical names and labels to
their innovator analogs. Use of different names will confuse patients
and providers and inhibit prescribing of biosimilars.
Reduce innovator biologic exclusivity to 7 years. Seven years of
data exclusivity would still provide a sufficient return to
manufacturers, while also speeding more affordable biosimilars to
market.
These policies and some of the specific bills that contain them can
help lower costs in Part D and the wider prescription drug market.
Part D Should Work for All Enrollees, but the Administration's Proposed
Rule Ending Drug Rebates Is Counterproductive
In addition to the suggested policy changes above, specific
interventions to help Part D beneficiaries who have high out-of-pocket
spending are needed. Fourteen years into the program, it remains a
great success with high enrollee satisfaction, however, policymakers
should consider how best to balance the needs of all Part D enrollees.
With respect to the Administration's recently proposed rule to end the
drug rebate safe harbor, there is grave concern that this proposed rule
would increase premiums for Medicare beneficiaries and costs for
taxpayers.
While the Administration's goals are well intentioned, the proposed
rule does nothing to reduce the prices drug manufacturers set. To the
contrary, it would cause substantial increases in seniors' Part D
premiums, as well as the cost to taxpayers.
The Administration's proposal also includes an unprecedented six
different cost impact estimates by three different actuarial groups,
including the independent HHS Office of the Actuary (OACT). The range
of impact for cost to the federal government across the six estimates
is an immense $300 billion. The great uncertainty surrounding the
proposal should give the Committee pause. Americans deserve clarity on
how such a proposal will affect those who rely on Medicare and
Medicaid, and commercial coverage. Given OACT's skill and institutional
independence from the agency, it is likely they have the most accurate
estimates.
Under the Administration's proposal, according to OACT, Part D premiums
could rise by as much as 25 percent for 2020 to reach $47.66, marking
the largest average premium increase in the program's history. Such a
large increase could cause many seniors and disabled Americans to drop
the prescription drug coverage they need to protect their health and
financial security, or never sign up in the first place. Healthier
beneficiaries (i.e., those who need fewer drugs) would drop coverage
first, causing premiums to increase further and potentially
destabilizing the Part D program, as increasingly those eligible for
enrollment would find Part D coverage unaffordable.
Additionally, OACT estimates that the proposal would cost the federal
government an extra $196 billion over the next 10 years. If finalized,
this could make the proposed rule among the costliest in U.S.
history.\14\
---------------------------------------------------------------------------
\14\ American Action Forum, ``Mandating Talking Cars: Costliest and
Most Beneficial?'', December 16, 2016. This article describes what were
at the time, the two costliest proposed regulations in U.S. history.
The OACT cost estimate for the Administration's proposal is in excess
of these two, https://www.americanactionforum.org/regulation-review/
mandating-talking-cars-costliest-beneficial/.
PCMA urges the Committee to encourage the Administration to withdraw,
or at the very least significantly delay the implementation of, the
proposed rule until its impact on beneficiaries and on Part D can be
better understood and managed.
Conclusion
In the search for solutions to address high drug costs, the Committee
and Congress would be best served in pursuing policies that foster and
encourage competition to keep prescription drug costs and pharmacy
benefits more affordable for employers, enrollees, taxpayers, and
government programs. Unfortunately, the rule recently proposed by the
Administration will not accomplish this goal, since it does nothing to
encourage manufacturers to bring down the drug prices they alone set.
PCMA member companies welcome continuing discussion among all
stakeholders to create a robust, sustainable market that will continue
to deliver needed cures and treatments for patients who suffer through
disease and chronic illness.
______
Letter Submitted by Debra L. Raffle
February 27, 2019
U.S. Senate
Committee on Finance
Dirksen Senate Office Bldg.
Washington, DC 20510-6200
RE: The Escalating and Unsustainable Rising Cost of Insulin for
Insulin-Dependent Diabetics
Chairman Grassley and the Committee:
I hope I am not too late and will be read at least. I only received
this notification a few days ago from the American Diabetes
Association, but I see you continue to have hearings, so I am revising
and resending my letter.
I have type 1 diabetes. I am an insulin-dependent diabetic, which means
there's not one hour of every single day of my life that I MUST have
insulin, or I will die. It's that simple. I was diagnosed around 9-11,
sadly that it makes it easy to remember. I was an adult diagnosed with
a mostly childhood disease and had a lot to learn! The cost of insulin
that I need to stay alive 24 hours a day has escalated from $70 per
1000 ml vial to nearly $300 a bottle. The same bottle of Novolog sells
for $47.99 in Canada. I just had to pay $2300 out of pocket for 3
months of insulin (and that was with a supposed discount)! The
insurance I have through my employer has an extremely high deductible
and high copays and some items are not covered at all. If my insulin
pump supplies are not covered, I simply cannot afford them. If I can't
afford to manage my diabetes the way my doctor and I have been doing
successfully through pump therapy all these years, I will likely get
sick, get a complication or two and then die. And no one seems to care!
Certainly not the insurance companies or the pharmacies. People need to
care. It will cost far more with the complications that will arise if I
don't get my insulin and if I can't afford to pay it, other tax payers
will ultimately bear those costs when all of this can be avoided.
Again, I feel that most insurance companies and certainly the
pharmacies prefer their profits over actual health care and effective
management and if we can't afford the astronomical prices they are
putting on once affordable drugs and supplies, then they would prefer
we die and let someone else pay. This is insane to me! I should be able
to afford my insulin and pump supplies, as in the past, but due to
escalating prices of medications, insulin and insurance costs (so they
can all make their profits) it is becoming unsustainable. I can't
afford it and am very healthy and have a good paying job.
I would like to join in the battle to fight insurance companies who
seem to think we can do without these drugs--insulin is not even a
drug, it's something my body quit making almost 20 years ago and that
most of you all take for granted, but without it, I will, in fact, die
within a few days/possibly lingering a few weeks in a coma. I didn't
ask for this, however, if I am able to get what I need, what my doctor
prescribes for me and have that covered by my insurance, I remain
healthy. I am a working, productive, tax paying citizen and if you
allow me to get insulin and medical supplies at a sustainable price, I
can continue to be a productive tax paying citizen. If you don't I
become unable to work, pay taxes and get sicker and die. Diabetes is a
completely manageable disease and it's disheartening that the insurance
companies, the pharmacies and the United States Government seem to have
such low regard for those of us who were unfortunate to contract a
disease where we have NO OPTION but to buy insulin at escalating
prices. They keep raising the price of insulin higher and higher and
higher, because they have a captive audience they are holding hostage.
I really wish someone would take a stand on this and I would be willing
to help, testify, or whatever it takes to help this situation.
In addition, I also take a medication called Symlin that allows me to
utilize my insulin more efficiently. It decreases my insulin intake
about 30%. This helps me maintain a healthy weight. More insulin means
more weight and more weight means taking more insulin. It's a vicious
circle. I am a type 1 so I have never been over weight and I struggle
to maintain my weight for the reasons I have listed above. If I can
maintain my weight, not only will I be healthier, but I can take
slightly less insulin to help combat the astronomical cost of something
that I MUST HAVE EVERY SINGLE DAY OF MY LIFE. By reducing my intake by
10 units a day, I may get another day or two out each vial and that's a
lot! It certainly will NOT help my overall health to put on extra
pounds! Anyhow, my new insurance will not cover Symlin at all and they
tell me it will cost $5800 for a 3 month's supply that I used to pay
$70 co-pay when I had Premera. I have been on this drug about 10 years.
This is ridiculous and clearly, I cannot afford this, so I get to go
off it cold turkey, increase my insulin intake and pay more than I ever
have for the same insulin!
I don't think they understand how this all works nor do insurance
companies and administrators care, but if you give us the tools
(medications and supplies) to manage our diseases with, we will not
have as many costly complications. So, it is cost-effective to give us
what we need now to avoid higher costs of complications later! To date,
since I was diagnosed as a type 1 in 2001 and having been on an insulin
pump for 17-18 years, I have never had any complications due to my
diabetes and would like to keep it that way.
I am so disgusted with insurance companies and I want to know what we
can do to get things changed. Can I go up to Canada and purchase my
insulin? Can I testify and be a witness? I am willing to do whatever I
can to help! What can I do to lower my medication and durable medical
equipment costs? The insurance company cannot even tell me what things
cost until I purchase them, which is ridiculous since I don't want to
pay for things I clearly cannot afford. I'm lost and feeling desperate.
I look to your committee to make this manageable disease financially
manageable. It is manageable if we can afford what we need to survive
and there's NO reason for the price to quadruple in the last 10 years,
NONE except for greed and profits.
I spent over $6.5K last year on out pocket medical costs, mostly
insulin and pump supplies. I had no surgeries, I had no illnesses, I
had no procedures. This is becoming very difficult to afford.
I don't think I should have to struggle to afford groceries and lose my
home or just make simple choices because I can't afford my insulin and
supplies. Please do something about the escalating cost of health care,
specifically common insulin, Novolog in my case, and do what you have
promised for many years! This is unsustainable as it currently is!
Thank you for listening.
Debra L. Raffle
______
Letter Submitted by Laura T. Ricci
March 4, 2019
U.S. Senate
Committee on Finance
Dirksen Senate Office Building
Washington, DC 20510-6200
RE: February 26, 2019, ``Drug Pricing in America: A Prescription for
Change, Part II''
To the Senate Committee on Finance,
Thank you for beginning to tackle the outrageous prices of prescription
drugs in America. I've watched many of the meetings and also the
Congressional Oversight meeting with Congressman Cummings. I watched
this meeting again and took notes. What I find interesting is several
of the ``Magnificent Seven'' are foreigners. These are CEOs that have
come to America to use Americans and the American healthcare system as
pawns for their profits. I do think that it is a multi-layered problem
and the American healthcare system is to blame for a lot of it. The
first thing that the senate and congress need to do is regulate this
industry so these people have to abide by stricter laws. All of the
levels need to abide by stricter laws.
I come to you as a mother of a type 1 diabetic, 20 years old, who will
soon be on his own. What will happen to him if he has to enter a high
deductible healthcare plan one day? Will he be the next Alec Smith or
Antavia Worsham? I would like to see this system fixed before he has to
cross that road. I am lucky enough to live in the Commonwealth of
Massachusetts, where he is eligible for Masshealth benefits so I am not
taxed in my wallet for his insulin. But one day, under the current
system, he may be. What if he ever wants to move out of Massachusetts?
What kind of healthcare plan will he be forced into? The current system
is designed for failure for a T1 diabetic. The only way T1s can get
their insulin for free or cheap is to make less than $16,000 or just
work a part-time job so you will qualify financially. What kind of
contribution to society is that? Will he ever be able to use the
college degree he will earn? He might end up living at home for the
rest of his life to be able to afford insulin because he will never be
able to afford $324.00 for a bottle of insulin or the ridiculous copays
assessed and high deductibles. High deductible healthcare plans need to
be abolished. High deductible healthcare plans are only for the really
healthy, they're not for anyone who needs to use the system, the only
system in place. T1s are forced to use the system because insulin is
not available over the counter like a loaf of bread is. My son can't
buy and eat the bread if he doesn't have the insulin to go with it.
Why does America not allow insulin to be purchased over the counter
without a prescription? Why does America not trust Americans to use
insulin correctly? I want insulin to be able to be purchased over the
counter, maybe with a prescription, but no insurance attached to it.
When you look at the supply chain of food, there's a manufacturer, a
warehouse and distributor, the supermarket and then the consumer. When
you look at the supply chain of medicine, there's the manufacturer, the
warehouse and distributor, the pharmacy (supermarket), the consumer and
then the PBMS and insurance companies. If the PBMS and insurance
companies were eliminated from this chain, then the prices would come
down because there would be no clawbacks and rebates involved. Is there
a rebate for bread? No.
My son was diagnosed with T1 diabetes in 2007. I was looking at some of
my old receipts. I looked at one from 2010. The price that Blue Cross
paid was $390.13 for 6 bottles of humalog. I had a $60 copay. That was
$75.00 a bottle, but I only paid $10.00 a bottle with the copay. The
lantus insulin was $152.48 that the insurance paid, and I paid $60.00.
I got 3 bottles. So that was $212.48 divided by 3 is $70.82. I paid
$20.00 for each bottle with the $60.00 copay. Today, I see the receipt
from Walgreen's, and the cash price is $974.89 for 3 bottles of
humalog. That's $324.96 each. That is what the Commonwealth of
Massachusetts must pay because he is covered under Masshealth. Does
Massachusetts pay that much? I have a feeling they do because Medicaid
is not allowed to negotiate prices with drug companies. The budget for
Massachusetts is 40% healthcare. Former Gov. Mitt Romney put this
mandatory healthcare in place. This should have been used as the
template for the ACA. Did the ACA cause these high deductible
healthcare plans? Some people think it did. That's a question I have
for you. Did the ACA cause high deductible plans? High deductible plans
are bankrupting Americans. They're causing people to have to pay
upwards to $25,000.00 sometimes for drug coverage before insurance will
pay anything. It's unaffordable. People are selling their houses,
taking out second and third mortgages, moving back home with mom and
dad, and even living on the streets.
You've heard the stories about people rationing insulin and dying. I
don't want that to happen to my son. T1 diabetes will never go away.
There is no cure. The pharmaceutical companies know there is no cure
and know we are at their mercy. The American lawmakers allow them to
carry on. You need to regulate this industry and put the brakes on
their practices. Utilities, food, tobacco, guns, are all regulated.
It's time for pharmaceutical companies to be held accountable so they
will stop using Americans as pawns for profit. As said in the hearing,
they make money on their drugs in Germany. If they didn't, they would
say goodbye to Germany.
When people can go to Mexico and buy the insulin for $30.00 a bottle,
Canada for $35-45.00 a bottle, then that tells you that the price to
produce it is low. I read an article that showed a study that said it
only costs $3-6.00 to produce a bottle of insulin. It's just like the
EpiPen. Heather Bresch, the CEO of Mylan, she told the Senate that it
costs Mylan $1.00 to make it, they sell it for $60.00 and it retailed
for $300.00! That's nuts. A lot of EpiPens never even get used. They're
there for an emergency. Insulin is used anywhere from 4-10 times a day
because you need to take it every time you eat. You don't need an
EpiPen every time you eat. The equivalent to an EpiPen for a diabetic
is a device called a glucagon injection. It is also very expensive and
is often never used. It's an injection that will revive you from a low
blood sugar if you pass out and may have a seizure. According to GoodRX
website, the glucagon retails for $292.81 which is 19% off the retail
price of $364.50. This is another device that often goes unused, but
people pay for it because they want it in case of emergency. There are
no coupons available to get it for free. I would like to know how much
it really costs to manufacture a glucagon kit.
The other thing that people are doing to get insulin is they're taking
out gofundme accounts. They try to raise money to pay for the copays.
They don't always succeed in raising the money and still end up dead,
which is the case with a man named Shane Patrick Boyle. People then
have to take out gofundme accounts to bury their loved ones because
once you are diagnosed with T1 diabetes, you have a lot of difficulty
in getting life insurance. You're a threat to insurance companies. They
only want to bring money in, they don't want to pay it out. But they
pay it out to CEOs in the form of huge salaries.
All of the CEOs at every level of the supply chain make a lot of money.
David Ricks, CEO of Eli Lilly, he makes $40,000.00 a day in salary.
$5,000.00 an hour. Some people don't make $40K in two years. The CEOs
of CVS, Walgreen's, Rite Aid, Kroger and all the insurance companies,
like United Healthcare and Blue Cross, they also make millions. Why?
Why is that allowed? They've all created monopolies. I've watched their
stocks and they've all skyrocketed and I see a new CVS store in many
towns around where I live. They've closed the old stores and built
these fancy new buildings that are full of expensive products. I only
get my son's insulin at Walgreen's because I am forced to get it
locally, Medicaid will not allow you to use a 90 day pharmacy service.
And insulin isn't the only thing that diabetics need to use for daily
management of diabetes. They need test strips, meters, pump supplies,
Dexcom supplies, glucose tablet s, ketone test strips, alcohol wipes,
and sometimes they have to eat special food if they also end up with
Celiac Disease.
There are at least 80 autoimmune diseases. There is no cure for any of
them. Do you think the pharmaceutical companies think there is a cure
on the horizon, a vaccine? Is that why they're raping American's to get
their profits before people don't need insulin anymore?
Nicole Smith-Holt, the mother from Minnesota that lost her son Alec to
rationing insulin said this in a Minnesota Roundtable: ``Before insulin
was invented, diabetes was a death sentence. Now diabetes is a death
sentence again because insulin is no longer affordable.'' Let that sit
with you.
I have a change.org petition going around asking Congress to subpoena
the CEOs of the insulin companies. One of the signers of the petition
posted that this is the new AMERICAN GENOCIDE. Let that sit with you.
I like what Senator Wyden said about these CEOs using patients and
taxpayers as ``unlocked ATMS.'' It's the truth. I also like what he
said when he said ``drug prices are astronomically high because that's
where pharmaceutical companies and investors want them, and diabetics
who can't afford the costs self-ration and endanger their lives but the
investor s are happy.'' It's the truth.
The CEOs were asked `'What keeps you up at night?'' None of them
answered that they were concerned about anyone dying because they can't
afford their medicines. They all answered that they were more concerned
about their drugs being put on formularies. That brings me to another
problem. The formularies. The PBMS play games all the time with the
switching in and out of the type of insulin that the insurance company
will pay for. This means that people often end up getting a physician's
override to be able to continue using the insulin of their choice. The
formulary dictates to the diabetic what they can and cannot use. They
limit your choices or make you fight for the kind of insulin you want
to use. Do you have the choice to buy Pepperidge Farm bread or store
brand bread? Yes. So why doesn't the diabetic or person in need of
medication, have the ability to choose the one that works right for
them and not have to argue and fight for it? If the industry was
regulated, we may have the ability to choose what is right for us, the
patient and consumer.
Another problem I see and have stated this before, is that Congress has
to pass legislation stopping these pharmaceutical companies from
advertising on TV. They did it with tobacco. The last advertisement for
tobacco was for a Virginia Slims ad on December 31, 1970 on the Johnny
Carson show. Congress did that. So they need to do it again for
pharmaceutical. American and New Zealand are the only countries that
allow them to spend their profits on advertising. If they want to
advertise, they should only be able to advertise for medicines that
don't require a prescription. And I'm also tired of seeing
advertisements on TV for erectile dysfunction.
Doctors: Doctors need to inform patients of alternatives to getting
insulin and not having to use insurance. People are already buying
insulin from Canadian Pharmacies and going to Mexico if they can. The
State of Utah will actually pay their state employees $500.00 to cross
the Mexican border and get their medicines there instead of having to
put the burden on the state's budget to pay for expensive medicines in
the U.S. Isn't that crazy? Why should that happen? If medicines were
affordable, the drug companies wouldn't have to give so much away for
free. The burden would be shared equally and the money would stay in
America. And I don't buy the insulin companies' stories about the fact
that the insulin supply chain is not protected in Mexico like it is in
the U.S. If the insulin in Mexico were tainted, people would be dying
from it and it would be in the news that people are dying from it
there, and dying in foreign countries from it. So that is just a scare
tactic to get you to continue to pay high prices to support the high
CEO salaries.
Soriot--He said he was annoyed that he was the lowest paid CEO. Give me
a break. That is all part of the GREED before NEED and PROFITS before
PATIENTS.
The FDA--Mr. Gottlieb, the commissioner, he is a part of the problem
behind insulin as well. Insulin was classified as a DRUG. He went and
changed the classification to a BIOLOGIC. That's just a term for a
liquid medicine. So then that created the new biosimilar insulins.
After thinking about this, I figured out that the biosimilars didn't
make insulin a generic, all it did was allow these insulin companies to
take out new patents, patents that will have maybe a 20 year life span
under the Hatch-Waxman Act. So what does that do? It creates even more
of a monopoly. Why, after almost 100 years, is there no generic insulin
available? No one has an answer to that. The patent for humalog is long
since expired. All these insulin companies have to do is tweak an amino
acid in the insulin and they get a new patent. That's ridiculous to me.
Today, March 4, 2019, there was a news article issued about Eli Lilly:
https://investor.lilly.com/news-releases/news-release-details/lilly-
introduce-lower-priced-insulin. In this article, Eli Lilly said they
were going to make a ``generic'' humalog and the list price of it would
be $137.35 for a vial and $265.20 for a box of 5 pens. That is
ridiculous to me. First, how do we know that Eli Lilly won't just use
the humalog as it is now and just put it in a new bottle with a
different color and change the name on it? Are they only doing this to
appease the senate and Ms. DeGette's investigation into these high
prices? Plus, they already have their BLINK HEALTH system, which is
like a GoodRX, that allows you to get a vial of insulin at $178.90 and
if you don't have insurance, you can get insulin from GoodRX for
$177.87. These prices are lower than the $324.00, but they still aren't
the $30.00 or $45.00 that Mexicans and Canadians reap the benefits
from. Canada would never allow insulin to be price gouged because it
was invented there by Sir Frederick Banting who has probably rolled
over in his grave a million times by now. I told my congressman, James
McGovern, that insulin wasn't supposed to be a FOR-PROFIT business. He
turned around to me, looked me in the eyes, and said: ``Well, it is''!
The other thing about the financial aid that Eli Lilly offers, is you
have to be really poor to be able to qualify for it. So only the poor,
nonworking people in America can get it for free. They wouldn't have to
give it out for free if it was affordable and accessible over the
counter at the pharmacy. They also give a lot of insulin way to camps.
Another thing that doctors don't tell people about is the 340B program.
That's like a big secret, just like the other secrets that revolve
around this industry. Many state attorney general's already have their
own investigations going on to find out what is going on behind closed
doors.
What I heard from some of these CEOs, especially Caforio, was that they
``need America's help and support'' to fix this problem. I heard that
from several of them. So they are asking YOU, the congress and the
senate, those that write the laws, to help them figure it out because
they know the system is unsustainable as it is and they will only
continue to do what they are doing because there are no laws saying
they can't do it. That's where my new hashtag comes into play--
#thepowerofthepen. Lawmakers are voted in with the power of the pen and
lawmakers can pick up the pen and write laws to protect Americans from
the greed of this industry.
I write to my congressman, James McGovern, and my senator, Elizabeth
Warren, and share with them what I am sharing with you. I share that
they need to take action and write better laws and regulate this
industry. They also have to stop taking money from the pharmaceutical
companies and lobbyists and don't fall for their antics. These people
are crooked and have the thief mentality.
Mr. Frazier stated that he couldn't walk away from the U.K. even though
they give lower prices because he believes it is immoral. But it's
okay. that he price gouges Americans and that's not immoral?
I read in a recent article about Mr. Brandicourt, that he fought to
keep any generic insulins out of the market and actually took out more
patents to prevent it. So why is that allowed? That's crookedness. That
is another case of Greed before Need. Companies like his, Sanofi, they
give out coupons for their lantus insulin. They wouldn't have to give
out coupons for people to get it for cheap or free if they just lowered
the prices and made them affordable.
NovoNordisk also gives out coupons and the same applies to them. Why
can they let you have insulin for $25.00 with the coupon, but you can't
go to the pharmacy and get the insulin for $25.00 without the coupon?
So you know the price to make insulin is cheap if they are able to give
out coupons for you to get it for free or cheap.
Senator Isakson, he had quite the story. He has Parkinson's disease and
takes 8 medicines. His story about all the ways he could get his
medicines for cheaper were right on target. The options: Don't use
insurance, use coupons, get rebates or just pay CASH. People could just
pay cash if they didn't have to pay and arm and a leg for medicines
that are supposed to keep you alive, not kill you because you can't
afford them. And his story about his staff member's 2nd child being
diagnosed with T1 diabetes was heartbreaking. T1 diabetes is an
epidemic. There is never anything shared on TV about the signs and
symptoms of T1 diabetes. Kids die from it after being misdiagnosed with
strep throat or the flu. T1 diabetes mimics the flu. My son had strep
throat when he was diagnosed. And it's not caused by vaccines. T1
diabetes has been around for over 4500 years and no vaccines were
invented then. People just died from it before insulin was invented in
1921.
My personal story is this: I have epilepsy. I take 3 medications for
it. One of them was invented in 1914. It's older than insulin. When my
husband had a great job with great insurance, I paid $3.96 for a 90 day
supply. When my husband lost his job, I was eligible to get on Medicare
because I am on disability. When I went to get my medicine at the
pharmacy, I was hit with a $114.41 bill. YIKES! This stuff is cheaper
than aspirin and here I am paying $114.41. The Medicare system, the
Part D, they put the medicine on the most expensive tier. So what am I
supposed to do? I have to pay it or my head goes nuts. Another medicine
I take, the patent doesn't expire until 2022, so there is no generic
for it. I just had to pay $1,200.00 for this medicine at the beginning
of the year. Ouch! My disability benefits are $1,600.00 a month. Do the
math. I wish I had never started to take it. The next time I get the
prescription filled, it will be $800.00 for it. I will never meet the
deductible set on my Part D plan because it is set so high that I never
reach it. So I pay over $300/year for my Part D plan, over 1,200.00/
year for my Part B, and even though the deductibles are lower than a
high deductible plan like a Blue Cross plan, it still hurts the wallet
every time I need to refill these prescriptions.
I'd like to share with you some stories of people that have children
with T1 diabetes.
1. This lady had a child die from T1 diabetes after the girl was kicked
off of BCMH at the age of 21. The girl rationed her insulin and was
found dead at home. The lady also has a second daughter that has T1
diabetes. She started a foundation and is on the warpath to make sure
people don't die from insulin rationing and get kicked off of health
plans. She just shared a story about her daughter being denied the
Dexcom continuous glucose monitor. People like her are always fighting
with insurance and distributors, especially Edgepark Medical Supply, to
get their supplies. This is a problem created by insurance companies
that ``don't want to pay.'' They will do everything in their power to
deny you and now people are turning to Costco to get this Dexcom device
and get out of the insurance loop to get it, and get it cheaper than it
costs to use their insurance. Yet, these people are still paying their
premiums and they can't use the insurance.
2. This lady and her son, they live in Tennessee. Tennessee, as I found
out, is one of the states that did not adopt the Medicaid expansion.
The son is 24 years old. He is a T1 diabetic as well. He was working at
a Hardee's burger place. He lost his job after getting sick with
diabeticketoacidosis (OKA). He was in the hospital and couldn't work so
they fired him. He had no access to insulin and started taking the
``WALMART'' insulin. This isn't the right kind of insulin for a T1
diabetic to take. He ended up with a big sore on his arm from injecting
the insulin in the same spot all the time. He ended up with a bad MRSA
infection. He went to the hospital and was not taken care of very well
and he checked himself out. He wanted something to drink and was denied
water. The mother didn't know how to navigate the politics to get help
in the state. She tried to get a social worker to get her son on
Medicaid. She was told NO, that he didn't qualify because he wasn't
pregnant, wasn't a single parent, and was over the age of 21.
So the message from the state of Tennessee is ``JUST GO DIE'' if you
can't work and get private insurance and you're over the age of 21.
``We don't want to take care of you anymore even though you have a life
threatening disease.'' So I contacted the governor there and got his
office to contact TennCare, the Medicaid office, and was able to at
least get him set up to get insulin, but he still has no doctor to
report to because he was denied care at a medical center there because
he missed three appointments and they won't take him because of a long
wait list. The option of moving out of the state is out of the question
I was told. So here is a man that will end up living with his mother
the rest of his life because he can't hold a job due to his diabetes.
3. A family from Texas. The father has a decent job but they live
paycheck to paycheck. They also have a T1 diabetic child. The father
was offered a TWENTY CENT raise. That means he would make $416.00 more
per year. Guess what? The twenty cent raise put his family over the
income qualifications to be able to continue to get CHIP benefits so
they can afford the insulin for the diabetic. The family would be
forced to take the insurance from the place of work. The insurance
would cost them $400.00 per month out of their paycheck. That means
they would lose $2.50 an hour if they took the twenty cent raise. Does
that make sense to you? The father ended up signing a waiver and not
accept the raise so he won't lose the CHIP benefits so he can keep his
child alive and not have to go get another job or try to come up with
the money for insulin one way or another? If insulin was affordable and
accessible over the counter, the $416.00 a year raise might pay for it.
But that's not the case. So much for a raise. I told the mother to tell
the company to give him a gift card for $400.00 that she can use on
groceries.
4. A United States citizen moved to the U.K. so she could get her
insulin to stay alive. What in the world? Are you kidding me? Cases
like this are what take money out of the U.S. economy.
5. A mother was on vacation, she only took one bottle of insulin with
her. The insulin got dropped on the floor. She came running to Facebook
to see if anyone could supply her with insulin because she couldn't get
a hold of her doctor to see if she could get her prescription filled
where she was. She couldn't just walk into any pharmacy and say she
wanted to buy the insulin her child used. She could do that if she
needed a bottle of water, but she can't do that with insulin. She was
frantic, thinking, how am I going to keep my child alive? The
pharmacist was not allowed to give her insulin without a prescription.
There was no emergency system in place. The pharmacist had no
authorization to give an emergency supply of insulin to this desperate
mother. In the end, she was finally able to get her doctor to call her
back and call in a prescription to the pharmacy to get a bottle of
insulin. That should never happen in America.
So I see people pay for premiums out of their paychecks, they pay for
copays at the doctor's office, they pay outrageous amounts of money in
high deductibles, and what do they end up with? They end up in debt,
end up with their own health problems because they are going crazy
wondering where in the world they are going to get this money from and
not have to lose everything they have.
Senator Stabenow was in a hearing that I watched and she actually said
she took people over the border to Canada herself to get cheaper
medicines. What does that tell you? That tells you that she's a great
person that will do whatever she has to do to make sure people don't
die at the hands of the current system. Our system is broken, it's old,
it out of date, and I am not 100% sure if this is all because of the
Affordable (Unaffordable) Care Act. I find that the people that make
these laws are not the people that actually have children with life-
threatening diseases and they have no idea what the cost of managing
the diseases consists of. If America is going to allow the
pharmaceutical industry to dictate to them how the system should be
run, then that is the wrong way of doing business.
I do think that the Senate Finance Committee and congress have to
subpoena these other pharmaceutical CEOs and get them to answer and be
transparent about how much it costs them to make their products. I have
a change.org petition going around getting signatures to ask congress
to subpoena them. You can't just invite them. An invitation can be
ignored and turned down, but not a subpoena. Heather Bresch had to come
to Washington to be transparent, so don't let the rest of them off the
hook.
Another thing about Eli Lilly: I read in the news that they were going
to buy an $8Billion oncology company. If they have $8B to buy an
oncology company, then why are they killing people with the high costs
of insulin, literally killing people because they just can't afford
their outrageous prices? They should not be able to buy a company like
that until insulin is affordable and accessible to everyone, not just
in America, but even in Africa. Why isn't insulin available in Africa?
People die from having no access to insulin there as well. Diabetes is
a global disease. You can't eradicate it. There is a genetic component
to it. People are living longer now with the invention of insulin so
they are passing the genes along to their offspring who ultimately pass
it on to the next generation.
March 5, 2019: This morning, as I continue to write and finish this, I
see a news article about Senator Durbin's response to Eli Lilly's
announcement yesterday. He acknowledges in there that insulin is as low
as $38.00 in Canada, but charging Americans four times the amount of
what Canadians pay it not an outpouring of gratitude. Canadians pay
less because their government negotiates the prices with these insulin
companies (http://www.kfvs12.com/2019/03/05/lawmaker-weighs-
annoucement-by-drug-maker-sell-lower-cost-insulin/). When will the
United States do the same thing? Why do you have to have a National
Health Care system to do it? Just regulate the industry, like gas and
electric, and start setting limits on the prices they can charge. And
the article says that Senator Durbin is urging the FDA to approve lower
cost drugs. There is no generic insulin. Why, after almost 100 years,
is there no generic insulin? Generic insulin is not the solution to
this dilemma. Just lower the cost. They've made their money over the
years, the patent for humalog is long since expired.
Like I said, Eli Lilly can just take humalog, stick it in a different
bottle, relabel it, and tell you it's a generic. The FDA can't regulate
prices. Let them be in charge of making sure drugs are safe, but don't
leave them in charge of this. Mr. Gottlieb went and changed the
category from a drug to a biologic--that didn't lower the price, it
only created new patent s. If there was a regulated industry, the price
would still be controlled on new patents.
Recap:
The drug industry needs to be regulated. These companies need to
be saved from themselves. They don't know how to do it on their own.
Insulin needs to be available over the counter without a
prescription. (Kevin's Law has been passed in many states to authorize
pharmacies to give an emergency, up to 30 day, supply of insulin and
the pharmacy and insurance can catch up with paperwork afterwards.)
The United States needs to trust citizens to use insulin
correctly. It's available over the counter in Mexico.
The United States needs to find out exactly how much it costs to
make insulin. The U.S. found out how much it costs to make an epipen.
PBMs need to be abolished.
High deductible healthcare plans need to be abolished.
If insulin is not accessible over the counter without a
prescription, then it should be exempt from any and all deductibles on
healthcare plans, as should any prescription medications.
No diabetic in America should be denied healthcare
(#medicare4all).
People shouldn't have to take out gofundme accounts to raise
money for their medicines.
People shouldn't have to take out home equity loans and second
mortgages to pay for their medicines.
People shouldn't have to turn to the black market and Facebook
to find insulin.
People shouldn't have to go out of the country to get affordable
insulin (#insulin4all).
People shouldn't have to share insulin with family members.
People shouldn't have to revert to using the ``WALMART'' insulin
which is going to kill them if not used correctly.
People shouldn't have to rely on coupons and scrounge around for
ways to get discounts on insulin and other drugs.
People shouldn't have to feel they are a burden to their family
and ration insulin.
Companies that price gouge should be held accountable, fined and
sued so they will stop being so greedy.
CEOs shouldn't be making so much money while people are dying.
Insurance companies shouldn't be able to dictate which medicines
and insulin they want us to use. We should be able to choose the one
that works for us. That's how the PBMs work. They tell us which insulin
they will pay for. If insulin was available over the counter, the PBMs
wouldn't be able to dictate which kind of insulin I want to use, just
like they can't decide what kind of bread I want to eat or if I want to
buy Mobil or Shell gasoline for my car.
The Hatch-Waxman Act is being abused.
The V.A. can negotiate prices for drugs and medical care, but
only Medicare Parts A and B can negotiate prices. Medicare part D needs
to be able to negotiate prices in an unregulated industry. You have the
power, use it.
Insulin doesn't need new R&D. Using that as a reason for high
prices is a bad excuse for high prices.
Television ads for prescription drugs has to stop, just as
tobacco ads stopped.
Politicians have to stop taking money from big pharmaceuticals.
The pharmaceutical companies are like the mafia.
If financial aid is going to remain available, the income
requirements need to be adjusted to keep up with inflation and keep up
with the times. People that make a decent, living wage, should be able
to get some relief if these high deductible plans continue to exist. If
you just got rid of high deductibles and the prices got lowered, we
wouldn't be talking about this.
Be proactive, not reactive. Right now we are in a reactive
position.
A sick person will always use the system since most want to
live. Those that don't want to live will commit suicide.
More teaching needs to take place in our country on what Type 1
Diabetes really is. It is often mixed up with Type 2 diabetes. They are
not the same disease.
The PBMs need to be hired by the U.S. government to do the
negotiating for lower prices, not be employees of the insurance
companies. That creates a racket and secrets.
Listen to more REAL stories of the burdens placed on Americans.
Let the Americans tell you what they need and want, not allow the
pharmaceutical companies to run their own agenda. Without sick people,
they wouldn't even be in business.
Put the brakes on big pharma.
List prices work against the patient. Either set lower list
prices or pass on the discounts to the patient.
Patients don't care about pharmaceutical's position on the
formularies, they care about being well.
Stop the ``Happy Talk''; get down to business and pick up the
pen (#thepowerofthepen).
Lawmakers work for the citizens of the United States and get
paid by our tax dollars. It's time for lawmakers to listen to citizens
and not big pharma.
Soriot's wise words: VBP--It used to be a system that was fit
for purpose. Now it's no longer fit for purpose. No one in the system
can fix it for themselves. The government has to step up and change the
rules.
#painpassionpurpose: Three words uttered to Nette Worsham by
Congressman Cummings on January 29, 2019.
CEOs from the two other insulin manufacturers, Eli Lilly and
NovoNordisk need to be subpoenaed. They have been invited too many
times and never accept the invite.
Don't send letters asking for CEOs to tell you how much it costs
them to make their drugs, make them come to Washington to tell you so
the public can hear their lame excuses as well.
Thank you, and I look forward to the next showdown with the PBMs and
insurance companies. They are part of the problem, not part of the
solution. The United States government is the entity that is part of
the solution.
Sincerely,
Laura T. Ricci
Statement of Rhonda Rowland
R2 Communications, LLC
Atlanta, GA
March 5, 2019
U.S. Senate
Committee on Finance
Dirksen Senate Office Bldg.
Washington, DC 20510-6200
To whom it may concern:
This is in reference to the ``Drug Pricing in America: A Prescription
for Change, Part II'' hearing held on February 26, 2019.
As a person living with a rare disease and an advocate, I'm submitting
the attached articles that provide background on the discovery/
development of two old, cheap drugs that pharma has raised prices on,
and the impact on patients.
Best regards,
Rhonda Rowland
R2 Communications, LLC
[email protected]
RhondaRowland.com
404-680-9053
High drug costs: the tale of 4 women
In 2016, Berna Heyman testified before a U.S. Senate committee about
her personal experience with sudden and dramatic increases in drug
prices. She was forced to switch drugs to treat her chronic genetic
disease, which was not the ideal option for her.
``The only reason I changed was the cost,'' Berna testified. Her health
had been stable while taking the drug Syprine, which removes excess
copper in people with Wilson disease (WD) to prevent potentially fatal
poisoning. ``My doctor and I made the change only under duress.''
Valeant Pharmaceuticals (now Bausch Health) acquired the rights to
Syprine in 2010 and began increasing the price. It's an old drug that
was developed in the 1960s by British physician Dr. John Walshe, who
made it in his laboratory and distributed it for free for many years.
``It was cheap to make,'' he told me. The generic name for it is
trientine.
As a librarian at the College of William and Mary in Virginia for 34
years, Berna had good health insurance and drug coverage. Her WD went
undiagnosed for 60 years, making her one of the oldest patients to be
diagnosed. The first sign of her disease was cirrhosis of the liver
that was picked up incidentally by a radiologist.
Upon retirement, she was insured through Medicare and supplementary
insurance.
``By 2014 my projected co-pay exceeded $10,000 per year with my
insurance paying over $260,000,'' Berna testified. ``That is untenable.
Something has to be done.''
At the hearing, Valeant executives expressed regret and admitted to
being too aggressive with their pricing strategies. When questioned by
Senators, they said they'd lower their prices.
For 3 years, Berna has waited. But Bausch Health has yet to lower
prices.
``I left the hearing feeling hopeful, and anticipated changes by
Valeant,'' Berna told me. ``It's very disappointing. It's the same old,
same old.''
Therapist kept patients out of the system, but drug company put her in
it
Rose was completing her college degree in mechanical engineering when
she noticed that she drooled while reading. Then she began forgetting
math formulas, so she'd write them on her arm. As a straight-A student,
she was bewildered that she had to re-read book chapters because she
forgot what she'd read. She was on the crew team, but her fatigue got
so bad that she couldn't keep up.
``I left college and went home,'' said Rose, who asked that her name be
changed for privacy. After seeing more than a dozen doctors in New York
and not getting a diagnosis, she went to an ophthalmologist who told
her that some diseases can be diagnosed through the eye. He was right;
an exam revealed Rose had rust-colored rings in her eyes, known as
Kayser-Fleischer rings which are commonly seen in WD patients.
Once diagnosed, Rose began taking the de-coppering drug, penicillamine.
Her condition improved and she returned to college. But her WD left her
with some memory loss and she couldn't remember her calculus formulas.
She switched majors and got a degree in occupational therapy.
Rose moved to Arizona and worked full-time as an occupational therapist
for 20 years.
``Then one day I went to the pharmacy to pick up my WD drugs and was
told my co-pay was $12,000! I was a single mom raising two kids and I
couldn't afford it,'' said Rose. ``I felt totally screwed.''
She had been prescribed Cuprimine, the brand name version of
penicillamine--also made by Bausch Health. Penicillamine was discovered
in 1955, also by Dr. John Walshe. ``It's easy to make if you're a good
chemist,'' Dr. Walshe told me.
Rose tried zinc supplements, an inexpensive, alternate treatment for
WD, but they made her violently ill. Without her daily dose of
Cuprimine, her fatigue returned and depression set in. She could only
work part-time, so she lost her health insurance. Her WD symptoms
worsened, so she could no longer work and applied for disability
benefits.
``As an occupational therapist I was contributing to the system, and
keeping others out of the system,'' said Rose. ``Then the drug company
put me into the system.''
Importing drugs from Canada and overseas
After going without medication for months, Rose's uncle found a way for
her to get affordable penicillamine through a Canadian pharmaceutical
broker. At first, her supply came from England. ``The medicine looked
and smelled like what I had taken for years, although the brands were
different,'' said Rose. ``But then a shipment came from India that
didn't smell right.''
She looked for another option and found Duane, a prescription drug
broker in the Midwest who could get her drugs shipped directly from
Australia. She needed a doctor's prescription and paid about $200 for a
3-month supply.
``We operate in a loophole,'' Duane said. ``Individuals are allowed to
bring in a three-month supply of prescription drugs from other
countries.''
What Duane told me is partly true: It's illegal for individuals to
import prescription drugs in most circumstances, because the FDA can't
ensure the drugs' safety. And anyone who facilitates the importation is
also liable. But in reality, the FDA looks the other way.
So, it's tempting to take the risk. Duane imports an AIDS medication
for a client who had a $25,000 co-pay. ``I can get it for him for
$1,200 a month.''
With exorbitant drug prices and patients' growing inability to pay
them, there's momentum to make such drug imports legal. Five bills are
before Congress that would allow prescription drug imports, primarily
from Canada.
Staying at poverty level to get prescription drugs
Ashley Williams was about to start classes at Kansas State when she was
diagnosed with WD and had to quit school to go to work instead. She was
grateful to have a diagnosis for the hospitalizations and unnecessary
surgeries she experienced the previous 2 years.
``I needed health insurance, so I took a full-time job with a
technology company,'' said Ashley. ``I worked my way up from `coffee
girl' to project manager and was working 70-80 hours a week.'' Even
though she was taking Syprine, her health deteriorated. She thinks it
was due to working too hard, to prove she wasn't sick.
For medical reasons she got laid off and applied for disability
benefits. Now with Medicare and supplemental insurance to cover her
health care, she can't afford her Syprine co-pays.
``This year, I was told that the funds for Wilson disease were already
gone!'' said Ashley. ``The $1,200 co-pay for my 30 days of trientine
took my entire Social Security check.''
``A health insurance broker advised me to look into the PAN
Foundation,'' said Ashley. ``I qualified and get $10,000 a year to
cover the cost of my co-pay.'' The Patient Access Network Foundation
relies on donations to help people who are underinsured with medication
costs.
Patients have to reapply every January for the PAN Foundation's drug
benefit. ``But this year, I was told that the funds for Wilson disease
were already gone!'' said Ashley. ``The $1,200 co-pay for my 30 days of
trientine took my entire Social Security check.''
Teva Pharmaceuticals introduced the first generic trientine in 2018 to
compete with Bausch's Syprine.
Generic competition hasn't lowered the drug cost . . . yet
Dawn, who was diagnosed with WD at age 37 after her liver failed, was
shocked when she picked up her prescription for trientine in January.
The list price was $38,365.09. Her insurance co-pay was only $15.
Still, she's not taking her good fortune for granted, and is
stockpiling her drugs.
``I'm scared to take them all,'' said Dawn, who asked that her real
name not be used. ``I went without my drugs for 3 years because we
couldn't pay for them when the costs spiked.''
Ultimately, the drug saved her life. But they went bankrupt in the
process.
Her husband had taken a new job just before she was diagnosed with WD.
And then, just as their new insurance was coming through, ``the suckers
fired him,'' Dawn says. ``They knew I needed a liver transplant and was
really sick.''
She had no choice but to take Syprine, and ultimately, the drug saved
her life. But they went bankrupt in the process.
Bausch currently offers patient assistance programs to insured and
uninsured WD patients in the US who need Syprine or Cuprimine. ``Our
first priority is that every patient has access to the medicines they
need,'' a Bausch Health spokesperson said in a statement.
Dawn tried to get help from the drug company previously, but couldn't.
The inexpensive alternative, zinc therapy, made her sick.
Her husband eventually found a job that provided health insurance--700
miles from their home, in another state. ``He works 70 hours a week
hauling chemicals in extreme weather on treacherous roads. It aged him
so much.''
Dawn's liver healed enough so she could be taken off the transplant
list. Still, she's furious with the drug company for making the drug's
cost out of reach for 3 years. And, she's fearful it could happen
again.
How does the tale end for the 4 women?
Berna Heyman is encouraged that the problem of high drugs costs is
still a major discussion. ``That's the bright side,'' she said.
However, since she was forced to switch her WD medication, tests show
copper has reaccumulated in her liver. Her doctor advised a low-copper
diet for several months, but that didn't help. ``I may have to start
taking trientine again.''
Rose credits Duane for saving her life with the drug imports. But fear
of her supply line drying up led her to enroll in a clinical trial
testing a new drug for Wilson disease so she can get her life-saving
medication at no cost for the next five years. ``I hope the new drug
works,'' she said.
Fear over the uncertainty of being able to pay for her drugs also led
Ashley Williams to enroll in the new WD drug trial. By chance, she was
put in the ``standard of care'' arm of the trial. That means she
continued on trientine for a year and paid the drug's cost. ``Starting
in April, I will be taking the new study drug,'' she said. That means
she pays the $1,200 co-pay for her trientine for another month.
``It's scary to think that I have to stay in a drug trial to get my
medication paid for,'' Ashley said.
Even though Syprine saved Dawn's life, she's fearful that the drug's
cost could make it out of reach for her again. Her solution: Rationing
her drugs.
Perhaps this will be the year that the Wilson disease drugs Dr. John
Walshe discovered and developed more than 50 years ago will be
affordable again. But, the human toll and cost to society that the
drugs' price spikes caused, remains.
______
98-year-old drug inventor chastises pharma for ``behaving badly''
I've spent my career reporting medical news. It's an important topic to
me because I live with my own health challenge: A rare, genetic
condition called Wilson disease that allows copper--an essential
dietary mineral--to build up in the liver and brain, leading to copper
poisoning that can be fatal. It caused my liver to fail when I was a
college student. But I was lucky--I was diagnosed, there was a
treatment, and it worked.
Before 1955, my disease was fatal. Then, through a series of chance
events and serendipities, an English physician, Dr. John Walshe,
discovered a drug that turned Wilson disease (WD) into one that could
be treated and managed. The drug is known by its generic name,
penicillamine, and the brand names, Cuprimine and Depen.
While doing research for a book I'm writing on WD, I discovered that
Dr. Walshe is still very much alive and well at age 98. So I traveled
to Cambridge, England to thank him for saving my life and talk to him
about his drug discovery.
He invited me to his home, which is a William and Mary style house
built in the late 1600s, in the riverside village of Hemingford Grey,
near Cambridge. Talking in Dr. Walshe's quintessential English garden,
it didn't take him long to attack the pharmaceutical industry that now
sells the drug that he discovered and tested.
``The way they're charging for it now is absolutely immoral. There is
no other word for it,'' Dr. Walshe told me. ``It is totally immoral. It
is business at its worst!''
For more than 20 years I took Cuprimine and never paid more than $60 a
month for it. Today, it costs $31,426 a month making it the 13th most
expensive prescription drug in 2018.
Discovering the first treatment for Wilson disease
Listening to the story of Dr. Walshe's drug discovery, it's easy to
understand why he's incredulous about its cost.
The story began in 1954, when Dr. Walshe traveled to the United States
for a Fulbright Fellowship in Boston. ``I was working with Charlie
Davidson who was a liver doctor, and we were asked to see a Wilson
disease patient who had gone into liver failure,'' said Dr. Walshe.
They couldn't do anything to help the patient then, but crossing the
``bridge'' from what was then Boston City Hospital where the patient
was being cared for, back to Thorndike Laboratory where he worked, Dr.
Walshe had what he calls as inspiration: ``I said to Charlie Davidson,
`You know what this chap really needs is penicillamine.' And Charlie
Davidson said `What's that?' I told him I discovered this new amino
acid that had never been seen in human urine before,'' said Dr. Walshe.
Previously, while working in London during the early 1950s, Dr. Walshe
had studied laboratory samples from people who were given the
antibiotic penicillin. He observed that penicillamine--a derivative of
penicillin--binds with copper. It's a process called chelation. His
theory was that penicillamine could search out the excess copper in
people with Wilson disease, bind with it, and then remove it from the
body through urination.
Proving his idea
To test his theory, Dr. Walshe obtained some penicillamine from a
chemist at MIT. Then, he did what would be unheard of today--he tried
it on himself first. ``It didn't do me any harm and the next day I was
alive and well,'' he said. ``I decided if it was safe for me, it was
safe for the patient.''
Dr. Walshe gave penicillamine to the WD patient--who was in liver
failure at Boston City Hospital--and as he predicted, it got copper
out. When his fellowship in Boston ended, he returned to London with a
small supply of penicillamine to continue his experiments there.
``My father was England's leading neurologist at the time, and I asked
him to find some Wilson disease patients for me to try it out on,''
said Dr. Walshe. His father came through with a handful of patients,
and in 1956 Dr. Walshe reported in the American Journal of Medicine
that his drug discovery worked.
After that, Dr. Walshe searched for chemical companies willing to make
penicillamine so the new treatment could be made available to WD
patients as soon as possible. This was years before the start of the
current FDA drug approval process that requires costly and extensive
testing before a drug can be considered for marketing.
Developing an alternative
As word spread that there was a treatment for Wilson disease, doctors
started prescribing penicillamine for their patients. However, as more
patients took it, they found that some developed severe side effects.
So, Dr. Walshe looked for a second option.
``We had run into trouble with penicillamine, and I wanted an
alternative treatment,'' said Dr. Walshe.
By this time he was working at the University of Cambridge, and one
morning he ran into a biochemist named Dr. Hal Dixon. Dr. Walshe
explained his predicament, and Dr. Dixon pulled a chemical called
triethylene tetramine off his laboratory shelf.
``He said it was non-toxic and known to bind with copper,'' said Dr.
Walshe. ``He told me to try it, and that's how we got the drug
trientine. It was Hal Dixon's idea, and my work proving that it worked
and it was safe.''
Walshe made the drug himself
For years, Dr. Walshe and his assistant made trientine in their
laboratory until they could no longer keep up with demand.Dr. Dixon had
explained how to purify the chemical so it would be safe to use in
people. So, as he had done with penicillamine, Dr. Walshe searched for
a chemical company to make and distribute trientine. In 1985, trientine
became the fifth drug approved through the Orphan Drug Act.
``The trouble now is the people who make trientine behave so badly
about pricing,'' said Dr. Walshe. ``No doubt about it, they have
behaved appallingly badly about pricing.''
Univar Europe charges the UK's National Health Service the equivalent
of $96,000 to treat a patient for a year. Because of the high cost, the
NHS debated whether or not it could continue paying for the drug in
2019. The North American company Valeant Pharmaceuticals--now Bausch
Health--charges even more for its brand-name version, Syprine.
Investigating high drug costs
In 2016, Senator Susan Collins (R-Maine) launched a bipartisan
investigation into the extreme spikes that were being seen in drugs
that were off-patent. ``For example, the price of a Valeant drug that
is used to treat Wilson disease,'' said Collins, ``increased from $652
per month to more than $21,000 per month. That's more than a 3,000
percent increase in price with no justification.''
``It's monstrous, it's iniquitous what they're charging for it,'' said
Dr. Walshe. For several years he made trientine in his laboratory. ``I
sent it out for free on my basic laboratory expense allowance without
upsetting it. It was cheap!''
In the United States, Bausch Health now markets Syprine (the brand-name
version of trientine) as well as Cuprimine.The company acquired both
drugs in 2010 and, soon after, boosted the prices astronomically.
Despite extensive adverse publicity, a Congressional hearing, and the
addition of generic equivalents the company has yet to lower the drugs'
unjustified cost.
Walshe never profited from his drug discoveries
It's been almost 65 years since Dr. John Walshe had his ``inspiration''
while walking across the bridge at Harvard. I asked him where the idea
came from. He simply pointed to the sky and posed the rhetorical
question: ``Where do ideas come from?''
Dr. Walshe's discovery of penicillamine and the development of
trientine turned Wilson disease from a death sentence into a treatable
disease. Today, the challenge for patients is not finding treatment,
but being able to pay for it. Dr. Walshe says he never made any money
from the two drugs, instead devoting his medical career to helping
people with WD.
His idea saved my life. Now with the prices being charged for his
discoveries, will others be so lucky?